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The 1993 publication of the now classic book, Disease Control
Priorities in Developing Countries, by Oxford University Press
and of its companion document, the World Development Report
1993: Investing in Health, published by the World Bank that
same year, constitute a landmark in the public health literature.
For the first time, decision makers and public health practi-
tioners had a comprehensive review of the cost-effectiveness of
available interventions to address the most common health
problems in the developing world. They were also provided
with the useful metric known as disability-adjusted life years
to calculate the burden of disease and the cost-effectiveness of
interventions more accurately than in the past.
As was the case with the first edition, this second edition of
Disease Control Priorities in Developing Countries will serve an
array of audiences. One primary audience consists of people
working in the health sector, ranging from those who are
responsible for making evidence-based decisions to those who
practice medicine and public health under often suboptimal
field conditions. A second audience consists of people working
in finance and planning ministries, who will benefit from the
solid recommendations for improving the health of popula-
tions through sound resource reallocation and cost-effective
practices.
PURPOSE
The purpose of this book is to provide information about what
works—specifically, the cost-effectiveness of health interven-
tions in a variety of settings. Such information should influence
the redesign of programs and the reallocation of resources,
thereby helping to achieve the ultimate goal of reducing mor-
bidity and mortality.
FUNDAMENTAL POLICY CONSIDERATIONS
Although economic and budgetary constraints are clearly
important considerations, money is not the only limitation.
Additional factors fundamental to improving outcomes are the
particular circumstances in each country, as well as the indi-
vidual institutional capacities to deliver goods and services and
to implement policies and processes.
Context-specific strategies and responses are essential,
because application of the Disease Control Priorities Project’s
findings will vary according to each country’s circumstances:
one size does not fit all. Understanding that most health inter-
ventions require a minimum level of institutional capacity to
deliver goods and services is equally important, and such capac-
ity may have to be built up before money or physical inputs can
yield any benefits. Accordingly, goals and priorities should be
established and tailored to each country’s context.
TRANSITION IN HEALTH
Every developing region is facing a transition in its epidemio-
logical profile from an environment with high fertility rates
and high mortality from preventable causes to one in which a
combination of lower fertility rates and changing lifestyles has
led to aging populations and epidemics of tobacco addiction,
obesity, cardiovascular disease, cancers, diabetes, and other
chronic ailments. The 20th century will be remembered
for, among other things, witnessing the largest universal
increase in life expectancy in history. While life expectancy is
highest in the richest countries, the upward trend is apparent in
almost every society. Moreover, in the past 50 years, variations
in this health indicator across and within countries have
decreased. This convergence of improved life expectancy and
reduced variations, which has occurred even in the presence of
widening income gaps in many regions, can be explained solely
by the impact of knowledge expansion and direct public health
interventions.
The increase in life expectancy worldwide will, however,
soon reach a plateau, and a retraction has occurred in many
countries. HIV/AIDS and civil unrest in Africa, vaccine-
preventable diseases and alcoholism in Eastern Europe, and
obesity in the United States have reduced—or will soon do
so—the years of life their populations can expect.
Foreword 
SCALING UP EFFECTIVE INTERVENTIONS
The late Jim Grant, former executive director of the United
Nations Children’s Fund, was one of the first leaders with a
vision for setting specific health goals and priorities within a
time frame and on a global scale. He recognized the need to
raise awareness of the dramatic disparities in children’s health
and to mobilize political will accordingly. His missionary zeal
for universal child immunization and for organizing the first
summit of world leaders for children’s health and rights in 1990
permitted the scaling up of interventions of proven efficacy.
The Millennium Development Goals are a natural consequence
of that vision and an extremely useful instrument for main-
taining both focus and social pressure. Achieving these ambi-
tious goals will require not only the universal implementation
of effective interventions that are currently available, but also
the development of new interventions.
NEED FOR ONGOING RESEARCH
Today, most vaccines, medical devices, diagnostic tools, and
drugs have been subjected to careful investigation in the labo-
ratory, at the bedside, and in the field. However, not enough
investment has gone into research to increase well-being and
development globally. We need more epidemiological and
health systems research to improve the efficiency of available
interventions, technological research to reduce their costs, and
biomedical research to develop new tools for dealing with as yet
unsolved and emerging health problems.
OPPORTUNITIES AND CHALLENGES
OF GLOBALIZATION
One of the greatest opportunities and challenges for interna-
tional public health is globalization. We live in an era when the
explosion of trade, travel, and communications is spreading
new cultural influences and lifestyles faster than ever before,
and the division between domestic and international health
problems is becoming increasingly obsolete. At the same time,
globalization also permits the spread of risks, pathogens, and
other threats. The ever-increasing movement of people every-
where increases the potential for epidemics. Travelers, refugees,
and displaced people are more vulnerable to infectious dis-
eases, and their movement contributes to spreading pathogens
into new areas. Overall, however, the positive consequences
outweigh the negative ones, and cautious optimism about this
irreversible trend is justified. Certainly, one of the most valu-
able contributions of globalization is the rapid accrual and
spread of knowledge about useful tools for controlling disease
and ways to implement those tools on a large scale.
In recent years, the huge advances in information techno-
logy have greatly boosted the globalization of knowledge.
Ideally, this should become a tide that lifts all boats to yield
global benefits. The challenge is to harness the information
technology revolution to foster the growth of economies. One
step in the right direction is the open access movement, which
promotes and permits free and immediate access to research
results and other components of knowledge transfer.
SPENDING MORE AND SPENDING BETTER
It is indeed a paradox to observe that even though the money
spent on health worldwide has reached 10 percent of overall
global income, that amount is both insufficient and poorly
allocated. The World Health Organization’s Commission on
Macroeconomics and Health and several other global initia-
tives make a persuasive plea for a larger investment in health. At
the same time, this book is dedicated to making the case for
better spending—that is, deriving more health benefits from
every dollar spent. The aim should be to reduce inequalities in
health investment between and within countries: a 100-fold
difference between the rich and the poor in money spent on
health services still persists in many places. Despite a lack of
clarity about what constitutes the optimum balance of health
spending, a larger share should go to prevention. This book
looks at several prevention options and clinical interventions
that are not being fully implemented.
SELECTING INTERVENTIONS
This book persuasively makes the case that both clinical and
public health interventions depend on the capacity of a given
country’s health system to deliver, noting that some interven-
tions are more demanding than others in terms of infrastruc-
ture and human resources. Therefore, both the costs and the
likelihood of success of the more complex interventions are a
function of the health capacity in place. In addition, decisions
about which interventions should be given priority will
depend on assessments of the local burden of disease, local
health infrastructure, and other social factors as well as on
cost-effectiveness analyses. The following chapters identify the
health system capacity needed for scaling up a given interven-
tion. Even middle-income countries with relatively better
health infrastructure often pursue sophisticated approaches to
medical care that result in fewer health gains per amount of
money invested. Every country, regardless of level of develop-
ment, could benefit from the recommendations presented
here.
DIAGONAL APPROACH
The medical literature has long debated which approach to
delivering health interventions is more effective: vertical pro-
grams or horizontal programs. Vertical programs refer to
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focused, proactive, disease-specific interventions on a massive
scale, whereas horizontal programs refer to more integrated,
demand-driven, resource-sharing health services. This is a false
dilemma, because both need to coexist in what could be called
a diagonal approach—that is, the proactive, supply-driven pro-
vision of a set of highly cost-effective interventions on a large
scale that bridges health clinics and homes. This approach
often starts vertically (polio vaccination, for instance) but
moves toward an increasing number of interventions (for
example, oral rehydration, other vaccines, residual spraying
and bednets for malaria control, micronutrient supplementa-
tion, and supervised tuberculosis treatment), making full use
of field health workers and existing infrastructure. This could
well be the equivalent of a public health polypill.
MULTIDISCIPLINARY ORIENTATION
What makes this book unique, in addition to its comprehensive
scope, is its truly multidisciplinary approach to disease control,
which merges the best of the medical and economic sciences.
Every recommendation has been carefully researched and doc-
umented. Evidence-based approaches must be the foundation
for allocating scarce resources. The poor cannot afford
anything but the most efficient methods for organizing and
implementing health care. This book is a fundamental compo-
nent for fostering equitable outcomes in health and develop-
ment. It will inspire all those who seek the highly complex but
attainable goal of universal good health for all members of the
global community.
FACILITATING PROGRESS
We all share global responsibility: governments and interna-
tional agencies, public and private sectors, and society and
individuals all have specific tasks. We must all strive toward
more equitable distribution of the benefits of new knowledge
to reduce health and development gaps between rich and poor,
between countries, and within countries. The second edition of
Disease Control Priorities in Developing Countries is a new step
in precisely the right direction. If we succeed in conveying the
main lessons and messages of this book, public health in devel-
oping countries will progress farther and faster.
Jaime Sepúlveda, Director, National Institutes of Health of
Mexico, Mexico City, Mexico
Chair, Advisory Committee to the Editors
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In the late 1980s, the World Bank initiated a review of priorities
for the control of specific diseases and used this information as
input for comparative cost-effectiveness estimates of interven-
tions addressing most conditions important in developing
countries. The purpose of the comparative cost-effectiveness
work was to inform decision making within the health sectors
of highly resource-constrained low- and middle-income coun-
tries. This process resulted in the 1993 publication of the first
edition of Disease Control Priorities in Developing Countries
(DCP1) (Jamison and others 1993). That volume’s preface
stated its purpose as follows:
Between 1950 and 1990, life expectancy in developing
countries increased from forty to sixty-three years with a
concomitant rise in the incidence of the noncommuni-
cable diseases of adults and the elderly. Yet there remains
a huge unfinished agenda for dealing with undernutri-
tion and the communicable childhood diseases. These
trends lead to increasingly diverse and complicated epi-
demiological profiles in developing countries. At the
same time, new epidemic diseases like AIDS are emerg-
ing; and the health of the poor during economic crisis is
a source of growing concern. These developments have
intensified the need for better information on the effec-
tiveness and cost of health interventions. To assist coun-
tries to define essential health service packages, this book
provides information on disease control interventions
for the commonest diseases and injuries in developing
countries.
To this end, DCP1 aimed to provide systematic guidance on the
selection of interventions to achieve rapid health improve-
ments in an environment of highly constrained public sector
budgets through the use of cost-effectiveness analysis.
DCP1 provided limited discussion of investments in health
system development. Other major efforts undertaken at the
World Bank at about the same time, including the World
Development Report 1993: Investing in Health, used the findings
of DCP1 and dealt more explicitly with the financial and health
systems aspects of implementation (Feachem and others 1992;
World Bank 1993). Closely related efforts in collaboration with
the World Health Organization led to the first global and
regional estimates of numbers of deaths by age, sex, and cause
and of the burden (including the disability burden) from more
than 100 specific diseases and conditions (Murray, Lopez, and
Jamison 1994; World Bank 1993).
This second edition of Disease Control Priorities in
Developing Countries (DCP2) seeks to update and improve
guidance on the “what to do” questions in DCP1 and to address
the institutional, organizational, financial, and research capac-
ities essential for health systems to deliver the right interven-
tions. DCP2 is the principal product of the Disease Control
Priorities Project, an alliance of organizations designed to
review, generate, and disseminate information on how to
improve population health in developing countries. In addition
to DCP2, the project produced numerous background papers,
an extensive range of interactive consultations held around the
world, and several additional major publications. The other
major publications are as follows:
• Global Burden of Disease and Risk Factors (Lopez and others
2006), undertaken in collaboration with the World Health
Organization
• Millions Saved: Proven Successes in Global Health (Levine
and the What Works Working Group 2004), undertaken in
collaboration with the Center for Global Development
• “The Intolerable Burden of Malaria: II. What’s New, What’s
Needed” (Breman, Alilio, and Mills 2004), undertaken in
collaboration with the Multilateral Initiative on Malaria
• Priorities in Health (Jamison and others 2006), a brief and
nontechnical companion to this volume.
Each product of the Disease Control Priorities Project marries
economic approaches with those of epidemiology, public
health, and clinical medicine.
While general lessons emerge from the Disease Control
Priorities Project, they result from careful consideration of
individual cases. The diversity of health conditions necessitates
specificity of analysis. Arrow clearly stated the need for
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technical analyses to underpin health economics: “Another
lesson of medical economics is the importance of recognizing
the specific character of the disease under consideration. The
policy challenges that arise in treating malaria are simply very
different from those attached to other major infectious
scourges (Arrow,Panosian,and Gelband 2004, xi–xii).” Chapters
in this volume address this need for specificity, yet use cost-
effectiveness analysis in a way that makes findings on the
relative attractiveness of interventions comparable.
DCP2 goes beyond DCP1 in a number of important ways as
follows:
• While virtually all chapters of DCP1 were structured around
clusters of conditions, DCP2 provides integrative
chapters—for example, on school health systems, surgery,
and  integrated management of childhood illness—that
draw together the implementation-related responses to a
number of conditions. These and other chapters reflect
DCP2’s inclusion of implementation and system issues.
• DCP2 includes explicit discussions of research and product
development opportunities.
• Although DCP1 dealt with policy mechanisms to change
behavior (or the environment), DCP2 attempts to do so in a
more systematic way. In particular, a number of chapters
assess in depth the public sector instruments for influencing
behavior change that were described briefly in DCP1: infor-
mation, education, and communication; laws and regula-
tions; taxes and subsidies; engineering design, such as speed
bumps; and facility location and characteristics.
• Different interventions place different levels of demand on a
country’s health system capacity. DCP2 builds on earlier
work (Gericke and others 2005) in attempting, in some
chapters, to identify which interventions require relatively
less system capacity for scaling up and which require more.
• Although DCP1 briefly discussed the nonhealth outcomes
of interventions, DCP2 does so in a more systematic way,
including looking at the consequences of interventions (and
intervention financing) for reducing financial risks at the
household level. Other important nonhealth outcomes
include, for example, the time-saving value of having piped
water close to the home, the increased labor productivity of
healthy workers, and the amenity value of clean air.
• An important element of DCP1 was its assumption that to
inform broad policy, major changes from the status quo
need to be considered, not just marginal ones. For cost-
effectiveness analysis, any major change needs to be
informed by burden of disease assessments in a way not
required for judging the attractiveness of marginal change,
because the size of the burden affects total costs and the fea-
sibility of extending the intervention to all who would ben-
efit. This is particularly true when considering research and
development priorities, but also applies to control priorities.
In this regard, DCP2 continues in the spirit of DCP1 in
assessing cost-effectiveness analyses of major changes, but it
does so more systematically for each of the six regional
groupings of low- and middle-income countries used
throughout this volume (see map 1, inside the front cover).
What was becoming clear in 1990 is clearer today: focusing
health system attention on delivering efficacious and often rel-
atively inexpensive health interventions can lead to dramatic
reductions in mortality and disability at modest cost. A valu-
able dimension of globalization has been the diffusion of
knowledge about what these interventions are and how to
deliver them. The pace of this diffusion into a country deter-
mines the pace of health improvement in that country much
more than its level of income. Our purpose is to help speed this
diffusion of life-saving knowledge.
The Editors
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eradication. In 1976, in the Democratic Republic of Congo
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Center in 1995 and has been director of the International
Training and Research Program in Emerging Infectious
Diseases and senior scientific adviser. He has been a member
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ASD autism spectrum disorder
ATLS advanced trauma life support
AUD alcohol-use disorder
AZT Zidovudine 
BCC behavior-change communication
BCG Bacillus Calmette-Guérin
BEmOC basic emergency obstetric care
BINP Bangladesh Integrated Nutrition Program
BMI body mass index
BMT buprenorphine maintenance treatment
BOD burden of disease
BRAC Bangladesh Rural Advancement Committee
BRFSS behavioral risk factor surveillance system
BZA benzimidazole anthelmintic 
CABG coronary artery bypass graft
CAD coronary artery disease
CAM complementary and alternative medicine
CAPP Country/Area Profile Programme 
CBA cost-benefit analysis
CBE clinical breast examination
CBHI community-based health insurance
CBR cost-benefit ratio
CDC U.S. Centers for Disease Control and Prevention
CDD control of diarrheal diseases
CEA cost-effectiveness analysis
CEmOC comprehensive emergency obstetric care
CER cost-effectiveness ratio
CFR case-fatality rate
CHA community health aide
CHD coronary heart disease
CHF congestive heart failure
CHNP community-based health and nutrition program
CHNW community health and nutrition worker
CHOICE choosing interventions that are cost-effective
CI confidence interval
CKD chronic kidney disease
CL cutaneous leishmaniasis
CL/P cleft lip and palate
CM cerebral malaria
CMH Commission on Macroeconomics and Health
CML chronic myeloid leukemia
CO carbon monoxide
COBRA combination therapy for rheumatoid arthritis 
COHRED Council on Health Research for Development
COM chronic otitis media
COPCORD Community-Oriented Program for Control of
Rheumatic Disease
COPD chronic obstructive pulmonary disease
CoV coronavirus
COX cyclo-oxygenase
CRA comparative risk analysis
CT computed tomography
CVD cardiovascular disease
CVS chorionic villus sampling
CYP couple-year of protection
DAH development assistance for health
DALY disability-adjusted life year
dBHL decibel hearing level
DCP1 Disease Control Priorities in Developing
Countries, first edition
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DCP2 Disease Control Priorities in Developing
Countries, second edition
DCPP Disease Control Priorities Project
DDT dichlorodiphenyltrichloroethane 
DEET N,N-diethyl-meta-toluamide
DF dengue fever
DHF dengue hemorrhagic fever
DHS demographic and health survey
DMARD disease-modifying antirheumatic drug
DMFT decayed, missing, and filled teeth
DNA deoxyribose nucleic acid
DOT directly observed therapy
DOTS directly observed therapy short course 
DRC Democratic Republic of Congo
DSM-IVTR Diagnostic and Statistical Manual of Mental
Disorders
DSS dengue shock syndrome
DTP diphtheria-tetanus-pertussis
EAP economically active population
EBM evidence-based medicine
ED emergency department
EFA education for all
EFM electronic fetal monitoring
EHCAP Effective Health Care Alliance Programme
EIR entomological inoculation rate
ELISA enzyme-linked immunosorbent assay
EMR electronic medical record
EMS emergency medical services
EPI Expanded Program on Immunization
ESRD end-stage renal disease
EUROSTAT European Statistical Office
FA folic acid
FBD food-borne disease 
FCTC Framework Convention on Tobacco Control
FDA U.S. Food and Drug Administration
FDC fixed-dose combinations
FEFO first expiry, first out
FETP Field Epidemiology Training Program
FEV1 forced expiratory volume in one second
FGM female genital mutilation
FHP family health program
FIC fully immunized child
FRESH focusing resources on effective school health
FTE full-time equivalent
G6PD glucose-6-phosphate dehydrogenase
G-7 Group of Seven
GATB Global Alliance for TB Drug Development
GAVI Global Alliance for Vaccines and Immunization 
GDP gross domestic product
GET 2020 World Health Organization Alliance for the
Global Elimination of Trachoma
GFHR Global Forum on Health Research
GIS geographic information system
GM genetic modification
GMP good manufacturing practice
GNI gross national income
GNP gross national product
GSE glutathione S-transferase
GUSTO global use of strategies to open occluded
coronary arteries
HAART highly active antiretroviral therapy for the
treatment of HIV/AIDS
Hb hemoglobin
HBV hepatitis B virus
HDL high-density lipoprotein
HepB hepatitis B
HHV human herpes virus
Hib Haemophilus influenzae type B
HIC high-income country
HIS health information system
HIV human immunodeficiency virus
HMN Health Metrics Network
HPLC high-performance liquid chromatography
HPS health promoting school
HPV human papillomavirus
HR human resource
HRT hormone replacement therapy
HSV-1 herpes simplex virus type 1
HSV-2 herpes simplex virus type 2
IAEA International Atomic Energy Agency
IAP indoor air pollution
IAVI International AIDS Vaccine Initiative 
ICD-10 International Statistical Classification of Diseases
and Related Health Problems, 10th revision 
ICDS integrated child development services
ICER incremental cost-effectiveness ratio
ICPD international conference on population and
development
ICT information and communication 
technologies
IDA International Development Association
IDD iodine deficiency disorders
IDSR integrated disease surveillance and response
IEC information, education, and communication
IFF International Finance Facility
IHD ischemic heart disease
ILO International Labour Organisation
IMCI integrated management of infant and childhood
illness
IMF International Monetary Fund
IMR infant mortality rate
INCB International Narcotics Control Board
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INDEPTH International Network of Field Sites with
Continuous Demographic Evaluation of
Populations and Their Health in Developing
Countries
INFECTOM information, feedback, contracting with
providers to adhere to practice guidelines, and
ongoing monitoring
IPT intermittent preventive treatment
IPTi intermittent preventive treatment in 
infancy
IPV inactivated polio vaccine
IRB institutional review board
IRR internal rate of return 
IRS indoor residual spraying
ISDR international strategy for disaster reduction
ISIC international standard industrial classification of
all economic activities
ITN insecticide-treated net
IUATLD International Union against Tuberculosis and
Lung Disease
IUD intrauterine device
IUGR intrauterine growth retardation
JE Japanese encephalitis
LAAM levo-alpha-acetyl-methadol
LBW low birthweight
LDD learning and developmental disability
LDL low-density lipoprotein
LE 20 life expectancy at age 20
LF lymphatic filariasis
LIC low-income country
LMICs low- and middle-income countries
LPG liquid petroleum gas
LRI lower respiratory tract infection
LSD lysergic acid diethylamide
MBB marginal budgeting for bottlenecks
MCE multi-country evaluation of IMCI effectiveness,
cost, and impact
MCH maternal child and health
MDA mass drug administration
MDG Millennium Development Goal
MDMA methylenedioxymethamphetamine
MDR-TB multidrug-resistant tuberculosis
MDT multidrug therapy
MEASURE monitoring and evaluation to assess and use
results
MIC middle-income country
MMR measles-mumps-rubella
MMT methadone maintenance treatment
MMV Medicines for Malaria Venture
MNCH maternal, neonatal, and child health
MOH ministry of health
MR mental retardation
MRI magnetic resonance imaging
MSF Médecins Sans Frontières (Doctors Without
Borders)
MTCT mother-to-child transmission
MVA modified vaccinia virus Ankara
NAFTA North American Free Trade Agreement
NAP nonaffective psychosis
NCCAM National Center for Complementary and
Alternative Medicine
NCE new chemical entity
NDP national drug policy
NGO nongovernmental organization
NHA national health account
NHS national health service
NIH National Institutes of Health
NIOSH National Institute for Occupational Safety
and Health
NIPA national income and product accounts
NMR neonatal mortality rate
NO2 nitrogen dioxide
NORA national occupational research agenda
NOx nitrogen oxide and nitrogen dioxide
NRA national regulatory authority
NRT nicotine replacement therapies 
NSAID nonsteroidal anti-inflammatory drug
NSO national statistics office
NTD neural tube defect
OA osteoarthritis
OCP Onchocerciasis Control Program
ODA official development assistance
OECD Organisation for Economic Co-operation
and Development
OEPA Onchocerciasis Elimination Program 
for the Americas
OP osteoporosis
OPV oral polio vaccine
ORS oral rehydration solution
ORT oral rehydration therapy
PAHO Pan American Health Organization
PAL practical approach to lung health
PARIS21 Partnership in Statistics for Development in the
21st Century
PCBs polychlorinated biphenyls
PCD Partnership for Child Development
PCP Pneumocystis carinii pneumonia
PCR polymerase chain reaction
PCV protein-conjugated polysaccharide vaccine
PD Parkinson’s disease
PDOH Philippine Department of Health
PDSA plan-do-study-act
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PFGE pulsed-field-gel-electrophoresis
PHC primary health care
PHSWOW public health school without walls
PLACE Priorities for Local AIDS Control Effort 
PM particulate matter
PMTCT prevention of mother-to-child transmission
PopEd population and family life education
ppm parts per million
PPPs public-private partnerships
PRSC poverty reduction support credit
PRSP Poverty Reduction Strategy Paper
PSV polysaccharide vaccine
PTA parent-teacher association
PTCA percutaneous transluminal coronary angioplasty
PTSD posttraumatic stress disorder
PZQ Praziquantel 
QALY quality-adjusted life year
RA rheumatoid arthritis
R&D research and development
RCT randomized clinical trial
RDI recommended dietary intake
RESU regional epidemiology and surveillance unit
RHD rheumatic heart disease
RNA ribonucleic acid
ROP retinopathy of prematurity
RRT renal replacement therapy
RSV respiratory syncytial virus
RTI road traffic injury
rt-PA recombinant tissue plasminogen activator
SAFE surgery, antibiotics to control the infection,
facial cleanliness, and environmental
improvements
SAR search and rescue
SARS severe acute respiratory syndrome
SBP systolic blood pressure
SCC short-course chemotherapy
SD standard deviation
SiC significant caries (index) 
SMA severe malarial anemia
SO2 sulfur dioxide
SP sulfadoxine-pyrimethamine
SSO social security organization
SSRI selective serotonin reuptake inhibitor
STATCAP statistical capacity building
STH soil-transmitted helminth
STI sexually transmitted infection
SWAp sectorwide approach
TB tuberculosis
TCA tricyclic antidepressant
TDR Special Programme for Research and Training in
Tropical Diseases
TEHIP Tanzania Essential Health Interventions
Program
THC tetrahydrocannabinol
TINP Tamil Nadu Integrated Nutrition Program
TLTI treatment for latent tuberculosis infection
TLV threshold limit value
TM traditional medicine
TRIPS Agreement on Trade-Related Aspects of
Intellectual Property Rights
UN United Nations
UNAIDS Joint United Nations Programme on HIV/AIDS
UNEP United Nations Environment Programme
UNESCO United Nations Education, Scientific, and
Cultural Organization
UNFPA United Nations Population Fund
UNICEF United Nations Children’s Fund
UNIDO United Nations Industrial Development
Organization
URI upper respiratory tract infection
USAID U.S. Agency for International Development
VAD vitamin A deficiency
VC vital capacity
VCT voluntary counseling and testing
VERC village education resource center 
VF ventilation factor
VIA visual inspection after application of an acetic
acid solution
VL visceral leishmaniasis
VOI value-of-information (techniques)
VSL value of a statistical life
WFP World Food Programme
WHA World Health Assembly
WHO World Health Organization
WHO/TDR WHO Special Programme for Research and
Training in Tropical Diseases
WHOCC WHO Collaborating Center
WISE work improvement in small enterprises
WTO World Trade Organization
YF yellow fever
YLD year of life lived with disability 
YLL year of life lost 
YLS year of life saved
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Part One
Summary and Cross-Cutting Themes
• Summary
• Cross-Cutting Themes

3A girl born in Chile in 1910 could expect to live only to age 33.
Since then, her life expectancy has more than doubled to its
current level of 78 years. What has this increase meant for her?
The probability that she will die before her fifth birthday has
declined from 36 percent to less than 2 percent. Throughout
middle age the likelihood that she will die is also far lower:
death in childbearing or from tuberculosis (TB) as a young
adult are no longer threats, and she is less likely to die in mid-
dle age from cancer. Mirroring this mortality reduction—but
less easily quantified—are marked improvements in health-
related quality of life. She will be able to choose to have fewer
children and thus spend less time in pregnancy and child rear-
ing. From an average of about 5.3 children at midcentury,
Chilean women’s fertility rate has dropped to its current level
of 2.3. She will have fewer infections, less anemia, greater
strength and stature, and a quicker mind. Her life is not only
much longer; it is much healthier as well.
Chile’s history of health improvements is unusually well
documented but typifies changes that have occurred in much of
the world. These dramatic improvements in health have, more-
over, been possible without major increases in income. In the
early 1900s, income levels in the United States were roughly
the same as they are in Chile today, yet U.S. life expectancy then
was 25 years shorter. New knowledge, new vaccines, and new
drugs have inexpensively enabled major gains in health that
were not possible before, even for those whose incomes were
high. Although those gains are now possible, they do not occur
unless health systems and policies effectively realize the avail-
able potential.
Although the magnitude of possible gains in health was
clear by the early 1990s, it is even clearer today: focused atten-
tion by health systems on delivering powerful but often inex-
pensive interventions can lead to dramatic improvements in
health at modest cost. Globalization has helped diffuse knowl-
edge about what those interventions are and how health sys-
tems can deliver them. The pace of diffusion of such knowledge
into a country—much more than its level of income—
determines the pace of health improvement in that country.
Our purpose in Disease Control Priorities in Developing
Countries, 2nd edition (DCP2), is to help speed the diffusion of
policy-relevant knowledge.
This introductory chapter to DCP2 serves two purposes:
• First, it provides the context for the rest of the book by dis-
cussing broad trends in health conditions, by summarizing
health conditions of the world at the dawn of the 21st cen-
tury, and by pointing to recent research suggesting that the
economic benefits from successful investments in health are
likely to be exceptionally high.
• Second, it highlights some of the main messages for policy
that emerge from the 37 chapters that deal with conditions
and risk factors and the 21 chapters that deal with strength-
ening health systems. These highlights are deliberately brief
because chapters 2 and 3 summarize the remainder of the
book: chapter 2 summarizes findings about intervention
cost-effectiveness from across the book, and chapter 3 syn-
thesizes findings on strengthening health systems.
Box 1.1 summarizes the main messages of this chapter.
Chapter 1
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Box 1.1
Chapters in this volume convey compact distillations of
current knowledge concerning interventions to improve
health and the related delivery systems. Chapter 2 sum-
marizes main messages of the chapters dealing with
interventions, and chapter 3 summarizes the main mes-
sages concerning health systems. Chapter 1 provides
context and conveys examples of the range of findings
from across the volume. Here, in brief, are the main
messages of chapter 1:
1. Average life expectancy in low- and middle-income
countries increased dramatically in the past half-
century, while cross-country health inequalities
decreased. In the countries with the best health indi-
cators, life expectancy increased a substantial two and
one-half years per decade since 1960; low- and
middle-income countries on average, with life
expectancy gains of about five years per decade,
have been converging toward the countries with
the longest life expectancy. Improvement in average
income and education levels contributed to these
worldwide gains in health. Of much greater quantita-
tive significance, however, have been the generation
and diffusion of new knowledge and of low-cost,
appropriate technologies. Increased access to knowl-
edge and technology has accounted for perhaps as
much as two-thirds of the impressive 2 percent per
year rate of decline in under-five mortality rates.
2. Improved health has contributed significantly to eco-
nomic welfare. Per capita GNP rose rapidly in devel-
oping countries in the decades following 1960, and
economic research suggests that health improvements
led to perhaps 10 percent to 15 percent of that GNP
growth. Although GNP includes the costs of provid-
ing medical care and reflects changes in health-related
consumption, such as the quantity and quality of
food, it omits altogether the value that mortality
reduction represents for countries. Recent economic
research has extended measurement to a broader
indicator, known as full income, that reflects reason-
able valuation of changes in mortality. For many
countries, recent mortality changes exceed in value
the growth of GNP. More widespread use of full-
income measures to calculate the rate of return to
investments in health—and health research—will
almost certainly conclude that, today, most countries
substantially undervalue those investments.
3. Although health improvements constituted an enor-
mous success for human welfare in the 20th century,
four critical challenges face developing countries (and
the world) at the beginning of the 21st century:
• high levels and rapid growth (for mostly demo-
graphic reasons) of noncommunicable conditions
in the disease profiles of developing countries
• the still unchecked HIV/AIDS pandemic
• the possibility of a successor to the influenza pan-
demic of 1918
• the persistence in many countries and many popu-
lation subgroups of high but preventable levels
of mortality and disability from diseases such as
malaria, TB, diarrhea, and pneumonia; from
micronutrient malnutrition; and, for both mothers
and infants, from childbirth.
The main purpose of this volume is to facilitate diffu-
sion of appropriate approaches for addressing those
problems.
4. The volume’s conclusions concerning interventions
include the following:
• Although 50 percent of deaths (including still-
births) of children under age five occur at ages
younger than 28 days, relatively little attention has
been paid to this age group. Cost-effective interven-
tions exist.
• Treatment of HIV-positive mothers, treatment of
sexually transmitted infections, free distribution
of condoms, and other interventions can cost-
effectively interrupt HIV transmission. These
preventive interventions continue to receive inade-
quate attention from health systems and workers.
• Controlling tobacco use, particularly through taxa-
tion, is feasible in developing countries and is the
single most important intervention for reducing
noncommunicable disease.
• Lifelong medical management of risk factors in
individuals at high risk for heart attacks or strokes,
using aspirin and other drugs, is cost-effective and
would benefit tens of millions of individuals.
5. This volume’s findings concerning health services and
systems include the following:
• Provider incentives matter. Financial or other
recognition for timely, responsive service increases
the likelihood of such services. Conversely, financial
incentives for excessive or inappropriate use of
THE 20TH CENTURY TAKEOFF IN HUMAN HEALTH 
The 20th century differed markedly from previous history in
two critical domains:
• First, the rapid economic growth that had begun in the 19th
century in countries of the North Atlantic diffused widely
around the globe while continuing in the countries where it
originated (DeLong 2000; Maddison 1999).
• Second, human mortality rates plummeted, and other
dimensions of health improved dramatically. These changes
also began in the North Atlantic countries in the 19th cen-
tury but remained modest until the 20th century, during
which the rate of improvement increased and spread to
most of the rest of the world (Easterlin 1996, 1999; Oeppen
and Vaupel 2002).
Improvements in Health
This section briefly documents the magnitude of health
improvements and then points to the challenges that remain.
For the past 160 years, life expectancy in the healthiest countries
has increased steadily. At the same time, differences in life
expectancy between those countries and much of the rest of the
world have narrowed. Figure 1.1 depicts trends in female life
expectancy in the country with the highest estimated level of
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drugs or diagnostic tests is an all-too-common
cause of high costs and poor health outcomes.
• Provider experience matters. Having providers do a
few things frequently, rather than attempting to
provide diverse services, facilitates quality improve-
ment with potentially major improvements in
health outcomes.
• Strengthening surgical capacity at district hospitals
is likely to be cost-effective and would address
broad needs.
• In low-income countries, targeting the very limited
public sector resources for health to control of
diseases—such as TB—that particularly affect the
poor would be efficient.
• In middle-income countries, public finance—or
publicly mandated finance—of a substantial pack-
age of clinical care for all would be not only equi-
table but also efficient in terms of meeting health
needs, controlling costs, and providing financial
protection to populations.
6. The generation and diffusion of new knowledge and
products underpinned the enormous improvements in
health in the 20th century. Every reason exists to
believe that continued progress—meeting the chal-
lenges of noncommunicable disease, HIV/AIDS,
potential pandemics, and neglected populations—
will also rely heavily on new knowledge. The rapidly
growing commitment of high-income countries to
providing development assistance for health would be
more effectively used if a larger share were devoted to
research and development. Public-private partner-
ships provide a promising institutional mechanism
for new product development. A particularly
important—and much neglected—type of knowl-
edge results from tight evaluations of interventions
and systems.
This volume represents an attempt to learn systematically
from the enormous successes of the past half-century in
improving human health. Knowledge that has been
gained—and that this volume pulls together—creates a
platform for addressing the problems that remain.
1550 1600 1650
Source: Oeppen 1999.
1700 1750 1800 1850 1900 1950 2000 2050
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
Life expectancy in years Percent
Estimates for
United Kingdom
Norway
Nordic countries
New Zealand
Japan
Sierra Leone
World
population
interquartile
range
75%
25%
50%
Lower viability limit
Figure 1.1 Trends in Maximum Female Life Expectancy, 1600–2000
Source: Author.
life expectancy. From about 1600 to about 1840, there is fluctu-
ation but no clear trend; after 1840, the graph turns upward at
a surprisingly uniform rate of improvement: maximum life
expectancy increased by about two and one-half years per
decade for 160 years.
Table 1.1 shows progress in life expectancy by World Bank
region between 1960 and 2002. (Map 1 on the inside front
cover depicts the World Bank regions.) For the first three
decades of this period, progress was remarkably fast—a gain of
6.3 years in life expectancy per decade on average, albeit with
substantial regional variation. Progress continued between
1990 and 2002 in the low- and middle-income countries but at
a much slower pace. This slower pace is due, in great part, to
mortality increases from HIV/AIDS. Sub-Saharan Africa actu-
ally lost more than four years of life expectancy.
Since 1950, life expectancy in the median country has
steadily converged toward the maximum and cross-country
differences have decreased markedly. This reduction in inequal-
ity in health contrasts with long-term increases in income
inequality between and within countries. Despite the magni-
tude of global improvements, many countries and populations
have failed to share in the overall gains or have even fallen
behind. Some countries—for example, Sierra Leone—remain
far behind (figure 1.1). China’s interior provinces lag behind
the more advantaged coastal regions. Indigenous people every-
where probably lead far less healthy lives than do others in their
respective countries, although confirmatory data are scant.
Reasons for remaining health inequalities lie only partially in
income inequality: the experiences of China, Costa Rica, Cuba,
Sri Lanka, and Kerala state in India, among many others, con-
clusively show that dramatic improvements in health can occur
without high or rapidly growing incomes. The experiences of
countries in Europe in the late 19th and early 20th centuries sim-
ilarly show that health conditions can improve without prior or
concomitant increases in income (Easterlin 1996). A recent
review, undertaken in part as background for this volume,
identified many specific examples of low-cost interventions
leading to large and carefully documented health improvements
(Levine and others 2004). The public sector initiated and
financed virtually all of these interventions. The goal of this
book is to assist decision makers—particularly those in the pub-
lic sector—to realize the potential for low-cost intervention to
rapidly improve the health and welfare of their populations.
Remaining Challenges
Four central challenges for health policy ensue from the pace
and unevenness of the progress just documented and from the
evolving nature of microbial threats to human health.
Epidemiological Transition. First, the next two decades will
see continuation of trends resulting from the dramatic mortal-
ity declines of recent decades. The key phenomenon is that
the major noncommunicable diseases—circulatory system
diseases, cancers, and major psychiatric disorders—are fast
replacing (or adding to) the traditional scourges—particularly
infectious diseases and undernutrition in children. This phe-
nomenon results in substantial part from rapid relative
population growth at the older ages, when noncommunicable
diseases become manifest. Additionally, injuries resulting from
road traffic are replacing more traditional forms of injury.
Using data from Chile, figure 1.2 illustrates the huge increase in
the relative importance of injuries, cancers, and cardiovascular
disease between 1909 and 1999. Responding to this epidemio-
logical transition with sharply constrained resources is a key
challenge. Tables 1.A1 and 1.A2 (see annex 1.A) provide cause-
specific summaries of death and disease burden, measured in
DALYs, in 2001 for the world as a whole and for low- and
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Table 1.1 Levels and Changes in Life Expectancy, 1960–2002, by World Bank Region
Life expectancy (years) Rate of change (years per decade)
Region 1960 1990 2002 1960–90 1990–2002
Low- and middle-income countries 44 63 65 6.3 1.7
East Asia and the Pacific 39 67 70 9.3 2.5
(China) (36) (69) (71) (11) (1.7)
Europe and Central Asia — 69 69 — 0.0
Latin America and the Caribbean 56 68 71 4.0 2.5
Middle East and North Africa 47 64 69 5.7 4.2
South Asia 44 58 63 4.7 4.2
(India) (44) (59) (64) (5) (4.6)
Sub-Saharan Africa 40 50 46 3.3 3.3
High-income countries 69 76 78 2.3 1.7
World 50 65 67 5.0 1.7
Source: World Bank 2004 (CD-ROM version).
—  not available.
Note: Entries are the average of male and female life expectancies. 
middle-income countries as a group as well as for high-income
countries. Those summaries indicate that noncommunicable
disease already accounts for over half of all deaths in the low-
and middle-income countries, although nearly 40 percent of
deaths continue to be from infection, undernutrition, and
maternal conditions, creating a “dual burden” that Julio Frenk
and colleagues have pointed to (Bobadilla and others 1993).
HIV/AIDS Epidemic. A second key challenge is the HIV/AIDS
epidemic. Control efforts and successes have been very real but,
with only a few exceptions, limited to upper-middle-income
and high-income countries. Poorer countries remain in the
epidemic’s deadly path.
New Pandemics. The global influenza pandemic of 1918
resulted in more than 40 million human deaths, exceeding the
20th-century toll of HIV/AIDS or of World Wars I and II.
Continued evolution of the influenza virus leaves the world at
risk of another such pandemic—as has been much discussed in
the press as this book goes to print. If the H5N1 strain of avian
influenza, for example, evolved so that (like the human flu) it
could be efficiently transmitted from human to human, a
major pandemic would be likely. Preparing for such an eventu-
ality is the third great challenge to global health.
Unequal Progress. A fourth key challenge results from con-
tinued high levels of inequality in health conditions across
and within countries. Bourguignon and Morrisson (2002) have
stressed that global inequalities are declining if one properly
accounts for convergence across countries in health conditions,
which more than compensates for income divergence.
However, in far too many countries health conditions remain
unacceptably—and unnecessarily—poor. This factor is a
source of grief and misery, and it is a sharp brake on economic
growth and poverty reduction. From 1990 to 2001, for exam-
ple, the under-five mortality rate remained stagnant or
increased in 23 countries. In another 53 countries (including
China), the rate of decline in under-five mortality in this
period was less than half of the 4.3 percent per year required to
reach the fourth Millennium Development Goal (MDG-4) (see
map 2 on the inside back cover of this book). Meeting the
MDG for under-five mortality reduction by 2015 is not
remotely possible for these countries. Yet the examples of many
other countries, often quite poor, show that with the right poli-
cies dramatic reductions in mortality are possible. A major goal
of this volume is to identify strategies for implementing inter-
ventions that are known to be highly cost-effective for dealing
with the health problems of countries remaining behind—for
example, treatment for diarrhea, pneumonia, TB, and malaria;
immunization; and other preventive measures against a large
proportion of those diseases.
THE ECONOMIC BENEFITS OF BETTER HEALTH 
The dramatic health improvements globally during the 20th
century arguably contributed as much or more to improve-
ments in overall well-being as did the equally dramatic innova-
tion in and expansion of the availability of material goods and
services. To the substantial extent that appropriate investments
in health can contribute to continued reductions in morbidity
and mortality, the economic welfare returns to health invest-
ments are likely to be exceptional and positive—with pre-
viously unrecognized implications for public sector resource
allocation. These returns go far beyond the contribution better
health makes to per capita income, which itself appears
substantial (see Bloom, Canning, and Jamison 2004; Lopez-
Casasnovas, Rivera, and Currais 2005). This section first sum-
marizes the evidence concerning health’s effect on per capita
income and then turns to more recent literature concerning the
effect of health changes on a broader measure of economic
well-being than per capita gross domestic product (GDP).
Health and Income
How does health influence GDP per person? Healthy workers
are more productive than workers who are similar but not
healthy. Supporting evidence for this plausible observation
comes from studies that link investments in health and nutrition
of the young to adult wages (Strauss and Thomas 1998). Better
Investing in Health | 7
Source: WHO 1999, 13.
Note: For 1909, 35.1 percent of deaths were categorized as “other,” and for 1999, the
corresponding percentage was 17.5. The cause-specific percentages shown in the
figure are the number from the indicated cause as a percentage of the total number
classified into a specific cause for that year. 
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Figure 1.2 Distribution of Deaths by Cause in Chile, 1909 and 1999
health also raises per capita income through a number of other
channels. One involves altering decisions about expenditures
and savings over the life cycle. The idea of planning for retire-
ment occurs only when mortality rates become low enough for
retirement to be a realistic prospect. Rising longevity in devel-
oping countries has opened a new incentive for the current
generation to save—an incentive that can dramatically affect
national saving rates. Although this saving boom lasts for only
one generation and is offset by the needs of the elderly after
population aging occurs, it can substantially boost investment
and economic growth rates while it lasts.
Encouraging foreign direct investment is another channel:
investors shun environments in which the labor force suffers a
heavy disease burden. Endemic diseases can also deny humans
access to land or other natural resources, as occurred in much
of West Africa before the successful control of river blindness.
Boosting education is yet another channel. Healthier chil-
dren attend school and learn more while they are there. A
longer life span increases the returns on investment in
education.
Demographic channels also play an important role. Lower
infant mortality initially creates a “baby-boom” cohort and
leads to a subsequent reduction in the birth rates as families
choose to have fewer children in the new low-mortality regime.
A baby-boom cohort thereby affects the economy profoundly
as its members enter the educational system, find employment,
save for retirement, and finally leave the labor market. The
cohorts before and after a baby boom are much smaller; hence,
for a substantial transition period, this cohort creates a large
labor force relative to overall population size and the potential
for accelerated economic growth (Bloom, Canning, and
Malaney 2000).
If better health improves the productive potential of
individuals, good health should accompany higher levels of
national income in the long run. Countries that have high levels
of health but low levels of income tend to experience relatively
faster economic growth as their income adjusts. How big an
overall contribution does better health make to economic
growth? Evidence from cross-country growth regressions sug-
gests the contribution is consistently substantial. Indeed, the
initial health of a population has been identified as one of the
most robust and potent drivers of economic growth—among
such well-established influences as the initial level of income
per capita, geographic location, institutional environment,
economic policy, initial level of education, and investments in
education. Bloom, Canning, and Sevilla (2004) found that one
extra year of life expectancy raises GDP per person by about
4 percent in the long run. Jamison, Lau, and Wang (2005)
estimated that reductions in adult mortality explain 10 to
15 percent of the economic growth that occurred from 1960 to
1990. Not all countries benefit equally from this link. Bhargava
and others (2001) found that better health matters more for
income growth in low-income countries than in high-income
ones. Although attribution of causality is never unequivocal
in analyses like these, different types of evidence point consis-
tently to a likely causal effect of health on growth.
Health declines can precipitate downward spirals, setting off
impoverishment and further ill health. For example, the effect
of HIV/AIDS on per capita GDP could prove devastating in the
long run. An enormous waste of human capital occurs as
prime-age workers die. A high-mortality environment deters
the next generation from investing in education and creating
human capital. The creation of a generation of orphans means
that children may be forced to work to survive and may not get
the education they need. High rates of mortality may reduce
investment. Saving rates are likely to fall, and retirement
becomes less likely. A foreign company is less likely to invest in
a country with a high HIV prevalence rate because of the threat
to the firm’s own workers, the prospect of high labor turnover,
and the loss of workers who have gained specific skills by work-
ing for the firm. The International Monetary Fund recently
published a collection of important studies of the multiple
mechanisms through which a major AIDS epidemic can be
expected to affect national economies (Haacker 2004).
Health and Economic Welfare
Judging countries’ economic performance by GDP per person
fails to differentiate between situations in which health condi-
tions differ: a country whose citizens enjoy long and healthy
lives clearly outperforms another with the same GDP per per-
son but whose citizens suffer much illness and die sooner.
Individual willingness to forgo income to work in safer envi-
ronments and social willingness to pay for health-enhancing
safety and environmental regulations provide measures, albeit
approximate, of the value of differences in mortality rates.
Many such willingness-to-pay studies have been undertaken
in recent decades, and their results are typically summarized
as the value of a statistical life (VSL). Chapter 7 discusses these
issues in the context of assessing the economic returns to
investments in health research and development.
Although the national income and product accounts
include the value of inputs into health care (such as drugs and
physician time), standard procedures do not incorporate infor-
mation on the value of changes in longevity. In a seminal paper,
Usher (1973) first brought the value of mortality reduction
into national income accounting. He did this by generating
estimates of the growth in what Becker, Philipson, and Soares
(2003) have called full income—a concept that captures the
value of changes in life expectancy by including them in an
assessment of economic welfare. Estimates of changes in full
income are typically generated by adding the value of changes
in annual mortality rates (calculated using VSL figures) to
changes in annual GDP per person. These estimates of change
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in full income are conservative in that they incorporate only the
value of mortality changes and do not account for the total
value of changes in health status. Valuation of changes in mor-
tality, it should be noted, is only one element—albeit a quanti-
tatively important one—of potentially feasible additions to
national account to deal with nonmarket outcomes. The U.S.
National Academy of Sciences has recently proposed broad
changes for the United States that would include but go beyond
valuation of mortality change (Abraham and Mackie 2005).
For many years, little further work was done on the effects of
mortality change on full income although, as Viscusi and Aldy
(2003) document, the number of carefully constructed esti-
mates of VSLs increased enormously. Bourguignon and
Morrisson (2002) address the long-term evolution of inequality
among world citizens, starting from the premise that a “com-
prehensive definition of economic well-being would consider
individuals over their lifetime.” Their conclusion is that rapid
increases in life expectancy in poorer countries had resulted in
declines in inequality (broadly defined) beginning sometime
after 1950, even though income inequality had continued to
rise. In another important paper, Nordhaus (2003) assessed the
growth of full income per capita in the United States in the 20th
century. He concludes that more than half of the growth in full
income in the first half of the century—and less than half in the
second half of the century—had resulted from mortality
decline. In this period, real income in the United States increased
sixfold and life expectancy increased by more than 25 years.
Three lines of more recent work extend those methods to
the interpretation of the economic performance of developing
countries. All reach conclusions that differ substantially from
analyses based on GDP alone. Two of those studies—one
undertaken for the Commission on Macroeconomics and
Health (CMH) of the World Health Organization (WHO)
(Jamison, Sachs, and Wang 2001) and the other at the
International Monetary Fund (Crafts and Haacker 2004)—
assessed the impact of the AIDS epidemic on full income. Both
studies conclude that the AIDS epidemic in the 1990s had far
more adverse economic consequences than previous estimates
of effects on per person GDP growth would suggest.
Accounting for mortality decline in Africa before the 1990s, on
the other hand leads to estimates of much more favorable over-
all economic performance than does the trend in GDP per per-
son. Figure 1.3 shows that in Kenya, for example, full income
grew more rapidly in GDP per person before 1990 (and far
more rapidly in the 1960s). After 1990 the mounting death toll
from AIDS appears to have only a modest effect on GDP per
person but a dramatically adverse impact on changes in full
income. Becker, Philipson, and Soares (2003) extended the ear-
lier work of Bourguignon and Morrisson (2002) in finding
strong absolute convergence in full income across countries
over time, in contrast to the standard finding of continued
divergence (increased inequality) of GDP per person. Finally,
Jamison, Jamison, and Sachs (2003) have adapted standard
cross-country growth regressions to model determinants of full
income (rather than GDP per person). Like Becker, Philipson,
and Soares (2003), they conclude that inequalities have been
decreasing.
The dramatic mortality declines of the past 150 years—and
their reversal in Africa by AIDS subsequent to 1990—have had
major economic consequences. The effect of health on GDP
is substantial. The intrinsic value of mortality changes—
measured in terms of VSL—is even more substantial. What are
the implications of these findings for development strategy and
for benefit-cost analyses of public sector investment options?
Using full income in benefit-cost analyses of investments in
health (and in health-related sectors such as education, water
supply and sanitation, and targeted food transfers) would
markedly increase estimates of net benefits or rates of return.
A careful, quantitative reassessment of competing policies for
improving a country’s living standards would probably con-
clude that development assistance and budgetary allocations to
health deserve greater relative priority.
WHY HAS MORTALITY DECLINED AT SUCH
DIFFERENT RATES IN DIFFERENT COUNTRIES?
This section explores some of the reasons mortality has declined
so rapidly and at such different rates in different countries. It
considers the question of whether income levels or growth rates
play an important role in achieving better health or whether
good policies can potentially lead to good health for low-income
populations. The section concludes with a snapshot of health
conditions in the world at the dawn of the 21st century.
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Source: Jamison, Sachs, and Wang 2001.
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Figure 1.3 Changes in GDP and Full Income in Kenya, 1960–2000
The 20th century witnessed huge and unprecedented
declines in mortality rates at all ages and in most parts of the
world. Easterlin (1996) and Crafts (2000) place an emphasis on
mortality transformation that is comparable to their emphasis
on economic growth in their retrospectives on the unprece-
dented changes in the human condition during the 20th
century. Understanding the sources of mortality changes is
important for understanding one of the defining events of
world history and also for devising policies to address the needs
of the perhaps 25 percent of the world’s population whose mor-
tality rates remain far higher than those of the rest of humanity.
Several approaches shed light on the sources of mortality
decline. Epidemiologists and demographers have carefully
tracked specific communities for many years to assess levels of
mortality and causes of death. In rural Senegal, rapid mortality
decline followed introduction of interventions addressing spe-
cific conditions (Pison and others 1993).
Another approach is historical. Easterlin (1996, 1999) exam-
ined the interplay of economic growth, urbanization, and
mortality in 19th- and 20th-century Europe. He concluded that
although income growth in the 19th century probably did play
a role in reducing mortality (through its influence on food
availability and environmental conditions), the magnitude of
the effect was small. Fogel (1997) stressed the importance of
increases in food availability during this period. Positive effects
of income growth were partially offset by increased infectious
disease transmission resulting from urbanization. Easterlin
(1999) concludes that 20th-century mortality decline, which
was much more rapid than that of the 19th century, had its ori-
gin in technical progress, and Powles (2001) has pointed to the
importance and nature of the institutional changes required to
translate technical change and economic improvements into
mortality reduction. Mosk and Johansson’s (1986) assessment
of the interplay between income and mortality in Japan illus-
trates the role that adoption of public health knowledge and
institutional development played in mortality decline in the
country that now has the world’s lowest mortality rates.
Most analysts agree that advances in science and technology
have underpinned the 20th-century transformations both of
income and of mortality levels. Models of economic growth
rely heavily on technological progress to account for economic
change (Boskin and Lau 2000; Easterly and Levine 1997; Solow
1957). Preston (1975, 1980) and Fuchs (1974) provided early
quantitative assessments of the central importance of technical
progress in accounting for 20th-century increases in life
expectancy. [Economists use the term technical progress to
denote advances in knowledge that lead to new products, like
vaccines, or that can inform behavior change, like knowledge of
the germ theory of disease (Preston and Haines 1998).] Davis
(1956) had already concluded that the unprecedented reduc-
tion in mortality in underdeveloped areas since 1940 is the
result primarily of the discovery and dissemination of new
methods of disease treatment that can be applied at reasonable
cost. The reduction was rapid because it did not depend on
general economic development or social modernization (Davis
1956, 306–7, 314). Some strands of the literature, however,
attribute the high correlation of income and life expectancy at
any given time to a significant causal effect of income on health
(see, for example, Pritchett and Summers 1996).
Background work for this volume (Jamison, Sandbu, and
Wang 2004) attempted to provide a better sense of the impor-
tance of income as a determinant of mortality by exploring the
relationships among income, technical progress (or diffusion),
and mortality decline. Previous econometric research either
has given little emphasis to technical progress—in part simply
because much of the research is cross-sectional and therefore
fails to address developments over time—or has assumed the
rate of technical progress or technology adoption to be con-
stant across countries. The background work for this volume
relaxed the assumption that the rate of technology adoption is
constant across countries. Allowing for cross-country variation
in the rate of adapting new methods resulted in weaker esti-
mated effects of income on infant mortality rates than previ-
ously found, although education’s estimated effect was robust
with respect to this change.
Much of the variation in country outcomes results from the
very substantial cross-country variation in the rate of technical
progress—from essentially no decline in infant mortality rate
caused by technical progress to reductions of up to 5 percent
per year from that source. Deaton (2004) provides a comple-
mentary and extended discussion of the importance of techno-
logical diffusion for improvements in health. Many factors
from outside the health sector also affect the pace of health
improvement; the education levels of populations are most
important. Box 1.2 briefly discusses the multisectoral nature of
health’s determinants. The importance of technical progress
and diffusion should be viewed in this larger context.
However technical progress or diffusion may be manifested,
the large differences in its magnitude across countries suggest
important effects of a country’s health-related policies (Fuchs
1980; Oeppen 1999). This point bears reiterating in a slightly dif-
ferent way: income growth is neither necessary nor sufficient for
sustained improvements in health. Today’s tools for improving
health are so powerful and inexpensive that health conditions can
be reasonably good even in countries with low incomes.
CHILD HEALTH 
A small number of conditions accounts for most of the (large)
differences in health between the poor and the not so poor.
Less than 1 percent of all deaths from AIDS, TB, and malaria,
for example, occur in the high-income countries. Available
technical options—exemplified by but going well beyond
immunization—can address most of the conditions that affect
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children, and can do so with great efficacy and at modest cost.
That short list of conditions, including undernutrition, relates
directly to achieving the MDGs for health. Public expenditures
to address those conditions have, in the past, benefited the rel-
atively well off, albeit within poor countries (although global
inequities have decreased because many poor countries have
made much progress).
Under-Five Health Problems and Intervention Priorities
MDG-4 for under-five mortality (reducing its level in 2015
by two-thirds relative to what it was in 1990) is highly
ambitious. Yet its implication of an average 4.3 percent per
year decline is well within recent experience. In the first
half of the MDG period (1990–2002), 46 countries achieved
rates of decline in under-five mortality greater than 4.3 per-
cent per year. Figure 1.4 displays trends in the rate
of decline in under-five mortality relative to the requisite
4.3 percent per year for China, India, Latin America and
the Caribbean, and Sub-Saharan Africa. Africa’s slowed
progress probably stems mostly from HIV/AIDS and the
spread of resistance to previously effective and widely used
antimalarial drugs. Map 2 (on the inside back cover of this
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The Multisectoral Determinants of Health
Box 1.2
Malnourished children easily acquire diseases, and they
easily die from the diseases that they acquire. Dwellings
and neighborhoods without sanitation provide fertile
environments for transmission of intestinal infections.
Cooking with wood and coal results in air dense with
particulates and gases, which destroy lungs and lives.
Hopeless life circumstances thrust young girls (and boys)
into commercial sex work with its attendant risks of vio-
lence and sexually transmitted infections, including
HIV/AIDS. Manufacturers of tobacco and alcohol profit
enormously from advertising and promotion that spread
addiction. Rapid growth in vehicular traffic—often with
untrained drivers on unsafe roads—generates a rising toll
of injury. Poorly designed irrigation creates breeding
grounds for vectors of disease. The point is clear: determi-
nants of health are truly multisectoral.
WHO coordinated a group of more than 100 individu-
als to generate estimates of the percentage of deaths, by
region and globally, associated with a range of 26 risk fac-
tors (Ezzati and others 2004). Those estimates were
revised and updated for the Disease Control Priorities
Project. The results give a sense of the extent to which
multisectoral factors contributed to mortality and disease
burden in low- and middle-income countries in 2001. The
following, for example, are estimates of the percentage of
disease burden (and, in parentheses, of deaths) in those
countries attributable to the indicated risk factors:
• tobacco smoking—4.7 percent (8.5 percent)
• indoor air pollution—2.7 percent (3.2 percent)
• inadequate water and sanitation—3.4 percent (2.8 per-
cent)
• risky sexual activity—5.3 percent (5.1 percent)
• alcohol use—3.6 percent (3.4 percent).
Underlying most proximal risks are more general
determinants of health, such as  education and, to a lesser
extent, income. The effects of income and education oper-
ate for the most part through influencing risk (and per-
mitting effective use of health services). If an important
fraction of ill health results from poverty and low educa-
tional levels—or from their consequences in inadequate
food or sanitation or other specific risks—then ought the
task of the health professional lie principally in addressing
these underlying problems? In one sense, the answer is
surely yes: the health community should measure the
effects on health of actions outside the health sector. It
should ensure that these findings are communicated and
are considered by those making policy choices. The mag-
nitude of the demonstrated effect of girls’ education on
health and fertility outcomes, for example, provides one
powerful argument for investing in expansion of educa-
tional access to girls. Millions of premature deaths, to take
another example, could be averted in Africa alone in the
next quarter century with appropriate policies toward
supply of energy for household use (Bailis, Ezzati, and
Kammen 2005). It is essential that the health sector docu-
ment and advocate opportunities such as these.
The health community has limited capacity for direct
action outside the health sector, however. It will make more
of a difference if it focuses its energy, expertise, and re-
sources on ensuring that health systems efficiently deliver
the powerful interventions provided by modern science.
Source: Author.
Note: The estimates reported here of DALYs and deaths that are attributable to various risk factors come from Ezzati and others (2006).
book) shows country-specific progress in reducing under-five
mortality:
• Countries colored in green experienced annual rates of
decline greater than 4.3 percent in the first half of the MDG
period (1990–2002).
• Countries colored in red saw no decrease (or an increase) in
their under-five mortality.
• Countries colored in yellow and orange depict countries in
between—with yellow indicating performance in the top half
of the range between 0 and 4.3 percent, and orange indicat-
ing poorer performance in the bottom half of the range.
Basic knowledge about the cost-effectiveness of interven-
tions to address maternal and child health has been available
from the 1980s. DCP2’s work provides a reassessment with few
surprises but some additions. It makes two important relatively
new points. The first results from noting that half of under-five
deaths occur at ages less than 28 days, when the substantial
but usually neglected problem of stillbirth is considered. DCP2
identifies some highly cost-effective approaches to interven-
tion against stillbirth and neonatal death (chapter 27). The
second new point results from the rapid spread of resistance
of the malaria parasite to chloroquine and sulfadoxine-
pyrimethamine (SP). These inexpensive, highly effective,
widely available drugs provided an important partial check on
the high levels of malaria mortality in Africa. Their loss is
leading to an even greater rise in malaria mortality and mor-
bidity that could be substantial. Figure 1.5 illustrates increases
in malaria death rates in under-five children in Sub-Saharan
Africa in the period from 1990 to 2001. The design of instru-
ments for financing a rapid transition to effective new
treatments—artemisinin combination therapies (ACTs)—is a
high priority (chapter 21; Arrow, Gelband, and Jamison 2005).
The other intervention priorities for addressing under-five
mortality are for the most part familiar:
• Expand immunization coverage.
• Expand the use of the simple and low cost but highly effec-
tive treatments for diarrhea and child pneumonia through
integrated management of childhood illness or other
mechanisms.
• Prevent transmission of and mortality from malaria by
expanding coverage of insecticide-treated bednets, by
expanding use of intermittent preventive treatment for
pregnant women, and, particularly, by financing the adop-
tion of ACTs to replace the now widely ineffective drugs
chloroquine and SP.
• Ensure widespread distribution of key micronutrients.
• Expand the use of a package of measures to prevent mother-
to-child transmission of HIV (further discussed in the next
section on HIV/AIDS).
In addition to interventions to reduce under-five mortality,
one other priority is clear. The world’s most prevalent infec-
tions are intestinal helminth (worm) infections, and children of
all ages are among the most heavily affected. Chapter 24
discusses these infections, which a low-cost drug (albendazole),
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Source: Calculations based on data in World Bank 2004 (CD-ROM version).
Note: The black bar in the center shows the 4.3 percent per year rate of decline
required for the period 1990–2015 to meet MDG-4 of reducing under-five mortality
by two-thirds.
0
1
2
3
4
5
6
7
Rate of decline of under-five mortality rates (percent)
China India MDG
requirement
Sub-Saharan
Africa
Latin America
and the
Caribbean
1960s 1980s1970s 1990s
Figure 1.4 Rate of Progress in Reducing Under-Five Mortality,
1960–2000: China, India, Latin America and the Caribbean, and 
Sub-Saharan Africa
Source: Lopez, Begg, and Bos 2006, table 2.4.
0
20
40
AIDS Malaria Other causes
60
80
100
140
160
Under-five deaths per 1,000 births
120
1990 2001
3
12
26
38
151
122
Figure 1.5 Under-Five Deaths from AIDS, Malaria, and Other
Causes, per Thousand Births, 1990 and 2001, Sub-Saharan Africa
Investing in Health | 13
taken every six months to a year, can control effectively.
Chapter 58 on school health services points to both the impor-
tance to children’s school progress of taking albendazole where
needed and the potential efficacy of school health programs as
a vehicle for delivery. In the long run, improved sanitation and
water supplies will prevent transmission. Use of albendazole is
only an interim solution, but it is one that may be required for
decades if the experience of the currently high-income coun-
tries is relevant.
Delivering Child Health Interventions
The list of potential interventions is far from exhaustive, and
different regions, countries, and communities will face
different mixes of the problems these interventions address.
However, there can be little dispute that any short list of
intervention priorities for under-five mortality in low- and
middle-income countries would include many on the list in the
preceding section. Why not, then, simply put money into scal-
ing up these known interventions to a satisfactory level? 
To greatly oversimplify—and these issues are discussed
more substantially in chapter 3—two schools of thought exist.
One line of thinking—often ascribed to macroeconomist
Jeffrey Sachs and his work as chair of the WHO CMH—
concludes that more money and focused effort are the solu-
tions. Although acknowledging dual constraints—of money
and of health system capacity—Sachs and his colleagues
(WHO CMH 2001; Sachs 2005) contend that money can buy
(or develop, or both) relevant system capacity even over a peri-
od as short as five years. Major gains are affordable and health
system capacity constraints can be overcome. Immunization
provides an example of where, even in the short term, money
can substitute for system capacity. Adding antigens for
Haemophilus influenzae type B (Hib) and hepatitis B (HepB) to
the immunization schedule is costly (although still cost-
effective). In some environments, however, it proves less
demanding of system capacity than expanding coverage does.
Money can be effectively spent by adding antigens at the same
time as investing in the capacity to extend coverage.
A second school of thought acknowledges the need for more
money but asserts that health system capacity is often a bind-
ing short- to medium-term constraint on substantial scaling
up of interventions. Critical priorities are, therefore, system
reform and strengthening while ensuring that such reforms
focus clearly on achieving improved health outcomes and
financial protection.
Chapter 3, as indicated, discusses these issues further in the
context of all the problems facing a health system, and
chapter 9 provides a thoughtful assessment of how to overcome
the constraints facing achievement of the MDGs for health.
From an individual country’s perspective, however, if financial
resources are available, the question is very much an empirical
one: to what extent can those resources be effectively deployed
in buying interventions, in buying out of prevailing system
constraints, and in investing in relevant system capacity for the
future? What needs to be constantly borne in mind throughout
this continued controversy is that something works: under-five
mortality rates have plunged by more than half since 1960 in
the low- and middle-income countries.
HIV/AIDS
For dozens of countries around the world—including several
of the most populous—the AIDS epidemic threatens every
aspect of development. No other threat comes close, with the
possible exceptions of use of nuclear weapons in densely pop-
ulated areas or a devastating global pandemic similar to the
1917–18 influenza episode. Most governments of affected low-
and middle-income countries and most providers of develop-
ment assistance have only recently begun to respond more
than minimally. Creation of the Global Fund to Fight AIDS,
Tuberculosis, and Malaria can be viewed as an attempt of the
world’s top political leaders to improve on the records of exist-
ing institutions. The Global Fund’s initial years have seen
substantial success, but that success is potentially undermined
by sharp constraints on resource availability (Bezanson 2005).
Tools to Control the Epidemic
In contrast to the initially slow programmatic movement of
most national leaders and international institutions, the
research and development community—public and private—
has made rapid progress in developing tools to control the
HIV/AIDS epidemic, although both a vaccine and a curative
drug remain distant objectives. Sensitive, specific, and inexpen-
sive diagnostics are available; means of prevention have been
developed and tested; modes of transmission are well under-
stood; and increasingly powerful drugs for controlling viral
load allow radical slowing of disease progression. Tools for
dealing with HIV/AIDS are thus available: As emphasized in
chapter 18, a number of countries show by example that those
tools can be put to effective use. Most of the high-income
countries have done so, and Brazil and Mexico provide exam-
ples of upper-middle-income countries that have forestalled
potentially serious epidemics. Mexico succeeded, for example,
with a policy of responding both early and forcefully to the
epidemic (del Rio and Sepúlveda 2002). The major successes of
Thailand and Uganda demonstrate that countries with fewer
financial resources can also succeed—and succeed against
more established epidemics that had already penetrated deeply
into their populations.
Prevention and Management
Prevention underpins success. At the time the World Bank’s
World Development Report: Investing in Health (World Bank
1993) was being written in 1992 and 1993, the only tool for
dealing with the epidemic was prevention. In collaboration
with the then–Global Programme against AIDS at WHO, the
World Development Report commissioned very approximate
estimates of the consequence for the new infection rate of
fully implementing available preventive measures (its opti-
mistic case scenario) or of doing very little (worst case).
Actual incidence numbers for 2000, unfortunately, fall very
close to the worst-case projection, and chapter 18 points out
that even by 2003 fewer than one in five people at high risk of
infection had access to the most basic preventive services. In
much of the world, little has been spent on prevention, and
little has been achieved. In addition, the current U.S. admin-
istration may be partially responsible for discouraging con-
dom use in some countries and in stigmatizing and alienating
commercial sex workers who are particular priorities for pre-
vention programs. Despite those problems, the potential for
prevention is very real, and a number of successful countries
have shown the possibility of using that potential well.
Chapter 17 on sexually transmitted infections (STIs) and
chapter 18 on AIDS discuss a broad menu of preventive mea-
sures and experiences with their implementation. Among
them, treatment of STIs may be of particular salience both
because the diseases are well worth treating in their own right
and because the absence of STIs greatly reduces transmission
of HIV.
In addition to prevention, better management of patients
with AIDS could avert much misery, both by treating oppor-
tunistic infections and by ameliorating the often excruciating
pain associated with many AIDS deaths. Medically inappropri-
ate restrictions on the use of inexpensive but powerful opiates
for pain control continue to deny dignity and comfort to mil-
lions of patients with AIDS and cancer in their final days
(chapter 52).
Antiretroviral Treatment
Intensive research and development efforts have led in the past
decade to the availability of well over a dozen antiretroviral
drugs that can greatly reduce the quantity of HIV in an infected
person. This reduction in viral load slows or halts progression
of AIDS and can return individuals from serious illness to rea-
sonable health. Available drugs leave a residual population of
HIV in the body, however, and this population grows if the
drugs are stopped. At present the drugs must be taken for life.
Widespread use of these drugs in high-income (and some
middle-income) countries has transformed the life prospects of
HIV-infected individuals.
Early generation antiretroviral drugs suffered notable short-
comings: they were enormously costly; regimens for their use
were complicated, making adherence difficult; their use gener-
ated unpleasant side effects; and rapid evolution of HIV led to
resistant mutants that undermined the efficacy of therapy. In a
remarkably short time, scientific advances have substantially
attenuated those problems, making feasible, at least in princi-
ple, antiretroviral therapy in low-income settings. WHO’s “3 by
5” program had as its objective, for example, to reach 3 million
people in low- and middle-income countries with antiretrovi-
ral therapy by 2005. Although that goal was far from being met,
the global effort to make treatment widely available is well
under way.
Despite the indicated progress against the problems
with antiretroviral drugs, challenges to their effective use in
low-income environments remain formidable. The complexity
of patient management is very real. Management requires
high levels of human resources and other capacities in many
of the countries where those capacities need to be most
carefully rationed. Perhaps in consequence, achieving effective
implementation has been difficult on even a limited scale.
Chapter 18 reviews those problems and how they might be
addressed.
Three points concerning widespread antiretroviral drug use
are particularly noteworthy:
• Poor implementation (low adherence, development of
resistance, interruptions in drug supplies) is likely to lead to
very limited health gains, even for individuals on therapy.
(This outcome is unlike that of a weak immunization pro-
gram in which health gains still exist in the fraction of the
population that is immunized.) Poorly implemented anti-
retroviral drug delivery programs could divert substantial
resources from prevention or from other high-payoff activ-
ities in the health sector. Even worse, they could lead to a
false sense of complacency in affected populations: evidence
from some countries suggests that treatment availability has
led to riskier sexual behavior and increased HIV transmis-
sion. The injunction to “do no harm” holds particular
salience.
• Unless systematic efforts are made to acquire hard knowl-
edge about which approaches work and which do not, the
likelihood exists that unsuccessful implementation efforts
will be continued without the appropriate reallocation of
resources to successful approaches. Learning what works
will require major variations in approach and careful evalu-
ation of effects. Failing to learn will lead to large numbers of
needless deaths. Most efforts to scale up antiretroviral ther-
apy unconscionably fail to commit the substantial resources
required for evaluation of effects. Such evaluations are
essential if ineffective programs are to be halted or effective
ones are to receive more resources.
• Many programs rely exclusively on the cheapest possible
drugs, thereby risking problems with toxicity, adherence,
and drug resistance. From the outset a broader range of
drug regimens needs to be tested.
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NONCOMMUNICABLE DISEASE AND INJURY 
At the same time that most low- and middle-income countries
need to address health problems that are now effectively con-
trolled in high-income countries, they are increasingly sharing
the high-income countries’ heavy burdens of cardiovascular
system disease (chapters 33, 44, and 45); cancers (chapter 29);
psychiatric disorders (chapter 31); and automobile-related
injuries (chapter 39). The public health research and policy
community has been surprisingly silent about these epidemics
even though, for example, cardiovascular disease (CVD) in
low- and middle-income countries killed over twice as many
people in 2001 as did AIDS, malaria, and TB combined
(table 1.A1). An important early exception is Feachem and oth-
ers (1992), who indicated approaches to treatment and preven-
tion of these conditions that can be adapted to the tighter
budget constraints of developing countries. The World Health
Organization provides a valuable and more up-to-date discus-
sion that emphasizes prevention (WHO 2005). In addition,
low-cost but effective approaches to long-term management of
chronic conditions need to be developed and implemented.
The remainder of this section briefly discusses, as examples,
the prevention and management of cardiovascular diseases,
psychiatric disorders, and injuries.
Cardiovascular Disease
Cardiovascular diseases in low- and middle-income countries
result in about 13 million deaths each year, over a quarter of all
deaths in those countries. Most cardiovascular deaths result
from ischemic heart disease (5.7 million) or cerebrovascular
disease (4.6 million). Because such deaths occur at older ages,
they account for a substantially smaller fraction of total disease
burden in disability-adjusted life years (DALYs)—12.9 per-
cent—than they do of deaths (table 1.A2).
Growing tobacco use accounts for a substantial and avoid-
able fraction of CVD and of cancers. Reasonable projections
show the number of tobacco-related deaths to be not only large
but also growing, particularly in developing countries. In 2000,
the number of tobacco-related deaths in developing countries
about equaled the number in high-income countries; projec-
tions suggest that by 2030 developing countries will have more
than twice as many. For those reasons, controlling smoking is
a key element of any national strategy for preventing CVD or
for promoting health more generally. Preventing the initiation
of smoking is important because addiction to tobacco makes
smoking cessation very difficult, even for the numerous
individuals who would like to do so. However, helping people
quit smoking is at least as important as preventing initiation.
Figure 1.6 portrays estimates showing that far more lives could
be saved between now and 2050 with successful efforts to help
people stop smoking than with efforts to keep them from
starting. Reducing smoking levels is well demonstrated to be
within the control of public policy. The principal instrument
is through taxation: Complementary measures discussed in
chapter 46 are important as well.
The main risk factors for CVD account for very large frac-
tions of the deaths (and even more of the burden) from those
diseases. For ischemic heart disease, they collectively account
for 78 percent of deaths in low- and middle-income countries;
for stroke, they account for 61 percent (Ezzati and others 2006).
Measures to reduce the levels of those risk factors—high blood
pressure, high cholesterol, smoking, obesity, excessive alcohol
use, physical inactivity, and low fruit and vegetable
consumption—are the goals for prevention. Unlike the favor-
able experience with controlling tobacco use, attempts to
change the behaviors leading to obesity, hypertension, high
cholesterol, or physical activity appear to have had little success
at a population level. However, as chapter 44 documents, many
promising approaches remain to be tried. Common sense sug-
gests that they should be initiated even while more systematic
efforts to develop and evaluate behavior-change packages are
ramped up.
Pharmaceutical interventions to manage two major compo-
nents of cardiovascular risk—hypertension and high choles-
terol levels—are well established and are highly cost-effective
for individuals at high risk of a stroke or heart attack. From at
least the time of publication of Disease Control Priorities in
Developing Countries, 1st edition (DCP1), researchers have rec-
ognized that the low cost and high effectiveness of drugs to
prevent the reoccurrence of a cardiovascular event made their
long-term use potentially cost-effective in low-income
Source:  Chapter 46, figure 46.2. Adapted from Jha and Chaloupka 2000; Peto and
Lopez 2001.
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environments (Pearson, Jamison, and Trejo-Gutierrez 1993).
Even if sustained behavior change proves difficult to achieve,
medications have the potential to reduce CVD risks by 50 per-
cent or more. Chapters 33 and 45 develop the current
evidence on that point. A key problem, however, concerns the
health care personnel and systems requirements associated
with the need for lifelong medication use, a problem also faced
with antiretroviral therapy for AIDS and the use of medica-
tions to target several major psychiatric disorders. How to
achieve effective long-term management of lifesaving drugs
is a key delivery and research challenge for health system
reformers.
In contrast to the lifelong requirement for drug use associ-
ated with CVD risk reduction in high-risk individuals, treat-
ment of acute heart attacks with inexpensive drugs is both less
demanding of system resources and highly cost-effective (chap-
ter 45). Given the high incidence of these problems, systemwide
efforts to achieve high rates of appropriate drug use in response
to acute heart disease are a high priority.
Psychiatric Disorders
Although neurological and psychiatric disorders lead to only
about 1.4 percent of deaths in low- and middle-income coun-
tries (1.8 percent in high-income countries), they cause suffer-
ing and disability far beyond what the mortality numbers sug-
gest. About 10 percent of disease burden in DALYs in low- and
middle-income countries results from these conditions; three
major psychiatric diseases—unipolar major depression (3.1
percent of DALYs), bipolar disorder (0.6 percent), and schizo-
phrenia (0.8 percent)—account for much of it (table 1.A2).
Chapter 31 provides a concise overview of advances made in
recent years in treating these conditions (as well as panic disor-
der), summarizes information on their burden, and develops
estimates of the cost-effectiveness of drug-based and cognitive
behavioral therapies in different settings (hospital based and
community based). Although the cost-effectiveness estimates
reported in chapter 31 suggest interventions are only moder-
ately cost-effective, the authors suggest that a fuller analysis of
benefits than is captured by a health metric such as the DALY
would justify substantial investments. They analyze a basic
package of mental health services that could provide a practical
vehicle for providing these interventions in environments with
tightly constrained financial and implementation resources. A
continuing theme in this volume—and one of particular rele-
vance here—is that without careful evaluations of the effects of
alternative approaches to large-scale intervention against psy-
chiatric disorders, the world will fail to develop hard knowledge
of what does—and does not—work. Without that knowledge,
far less health and financial security will be gained than is
potentially possible from the inevitably limited resources
available.
Injuries
Injuries constitute an additional major and neglected compo-
nent of disease burden in developing countries. This volume’s
chapters on injury (chapters 39 and 40) emphasize prevention.
Timely treatment is also important, and chapters 67 (on sur-
gery) and 68 (on emergency medical services) point to the
potential, at low cost, for much better treatment of injury vic-
tims than is typical today.
The great diversity of both causes and consequences of
injury precludes an attempt in this chapter to do more than
highlight their importance. Chapter 2 and the injury-related
chapters just mentioned provide a rich menu of practical
options. It is worth pointing out here the central importance of
two specific categories of injury—road-traffic injuries (1.07 mil-
lion deaths in 2001 in low- and middle-income countries) and
suicides (0.75 million deaths). Safer roads, safer driving, safer
vehicles, and better emergency care have sharply reduced the
toll from road-traffic injuries in high-income countries, but
unless dramatic action is taken in developing countries, the toll
will surely rise. Although there has been less success in reduc-
ing suicide rates, the improved treatments now available for
psychiatric disorders are proving to be one important approach
in suicide prevention.
This discussion of noncommunicable diseases and injury
highlights the huge and growing burden from those conditions
and conveys a consistent message that constructive action is
feasible at relatively modest cost. No attempt has been made to
be comprehensive (chapters 29 through 38 all deal with non-
communicable diseases); rather the discussion points to the
need for health systems to systematically incorporate effective
responses to noncommunicable diseases and injuries as their
capacities grow.
HEALTH SYSTEM DEVELOPMENT AND FINANCE 
DCP1 focused principally on intervention priority. What mix
of public health and clinical interventions would best respond
to important disease conditions in highly resource constrained
environments? Given the results of those assessments, where
were the most important overall best buys? Where were
resource commitments likely to be of low value? DCP2 returns
to those questions but goes beyond them in assessing the steps
required for strengthening of health services and systems in
ways that will allow the appropriate mix of interventions to be
delivered equitably and well. De Savigny and others (2004)
describe a specific example from Tanzania that links system
reform to intervention selection.
Part 3 of the volume addresses strengthening of health sys-
tems. For valuable discussions of the goals of health systems,
see WHO’s World Health Reports for 1999 and 2000 (WHO
1999, 32–33; 2000, 23–25) and Roberts and others (2003).
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Part 3 first reviews options for public health services with
chapters on surveillance and information (chapters 53 and 54),
drug resistance (chapter 55), community health and nutrition
programs (chapter 56), contraception (chapter 57), school-
based health (chapter 58), adolescent health (chapter 59),
occupational health (chapter 60), natural disaster relief (chap-
ter 61), and disease elimination and eradication (chapter 62).
A major point implied by the simple number of chapters
devoted to public health is that health system strengthening and
reform efforts need to commit substantial financial resources
and political and managerial attention to public health.
A second cluster of chapters in part 3 deals with strengthen-
ing personal health services. The first of those chapters deals
with an important facet of community-level health services, the
integrated management of the sick child (chapter 63). Chapters
64 to 66 deal with levels of care: general primary care, the dis-
trict hospital, and the referral hospital, respectively. Three chap-
ters address services offered at multiple levels of the system: sur-
gery (chapter 67), emergency medical services (chapter 68), and
complementary and alternative medicine (chapter 69). The
final cluster of four chapters addresses capacity strengthening
and management reform: quality of care (chapter 70), the
health workforce (chapter 71), supplies of drugs and vaccines
(chapter 72), and management of clinical services (chapter 73).
This overview of the topics on health systems provides a
sense of the breadth of the issues considered. Chapter 3 pro-
vides a concise and integrated statement of the main findings.
The remainder of this section deals briefly with assessing
the performance of health systems and with the key issue of
finance. Before we turn to those topics, however, it is worth
highlighting several particular points.
First, in low-income countries, limited health system capac-
ity has sometimes led governments (and development assis-
tance agencies) to focus their capacity on a few high-priority
items—such as immunization or control of HIV/AIDS. The
objective may be a reasonable one: a greater reduction in dis-
ease burden in the population and more financial protection
for it are likely to be achieved by doing a few important things
well than by doing many things poorly. Yet if this focused effort
is undertaken by establishing vertical structures outside the
health system, then important opportunities for increasing
capacity may be missed. Chapter 3 stresses a critical point: a
focused program should be designed so that it contributes to,
rather than detracts from, long-term system strengthening.
Second, quality of care is important; it can be measured, and
it can be improved (box 1.3). Third, providing basic surgical
services, particularly at the district hospital level appears to
offer major but neglected opportunities for addressing
Tangible Approaches to Improving Quality of Care
Box 1.3
A 2001 report from the Institute of Medicine of the U.S.
National Academy of Sciences (Institute of Medicine
2001b) highlights great variation in the quality of clinical
care in the United States. Its publication catalyzed reform
efforts. In a recent evaluation, Leape and Berwick (2005)
found that those reform efforts had a major effect on pro-
fessional attitudes and organizational culture, although
less effect, so far, on mortality. Chapter 70 on quality of
care documents the similarly large variation in quality in
low- and middle-income countries and the associated cost
in lives and money. Improving quality of care amplifies
the effect of investments in health. Promising approaches
in improving the quality of care include the following:
• Invest in measuring quality and feeding that informa-
tion back into the system. This approach has been
shown to be possible (for example, clinical vignettes)
and effective.
• Use evidence-based criteria to link quality of care to out-
comes. This approach can be implemented by training
and creating incentives for adapting clinical guidelines or
by using the collaborative improvement model.
• Improve system-level and provider incentives.
Minimally, do no harm with the structure of financial
incentives facing providers, for example, by establishing
a legal and ethical environment where care providers
do not profit personally from sale of drugs, diagnostic
procedures, or referrals to expensive specialized care.
• Emphasize high-volume care for selected surgical pro-
cedures and prevalent medical conditions. Such an
approach can lead to higher quality and lower cost even
while, in some cases (for example, cataract removal),
allowing lower-level workers to substitute for more
expensive and scarcer physicians.
Source: This box was prepared with input from John Peabody.
significant sources of disease burden. An important substantive
component of health sector reforms should often involve
strengthening surgical capacity.
Health System Performance
Since about 1940, the publication of economic performance
indicators in national income and product accounts has
made it possible to hold political leaders accountable for eco-
nomic management. Additionally, measures of economic
performance—such as GDP growth rates and unemployment
rates—have allowed economists to move toward evidence-
based assessments of which policies facilitate good economic
performance and which do not.
In many ways, unfortunately, the assessment of health sys-
tem performance remains where economic performance mea-
sures were before the development of national income and
product accounts in the United Kingdom in the late 1930s.
Chapter 3 observes, for example, that “The body of knowledge
[on health systems] represents a largely ad hoc and disjointed
collection of facts, figures, and points of view. Making confi-
dent recommendations relevant to strengthening health system
capacity is thus difficult.” In its 2000 World Health Report,
WHO made an ambitious effort to provide the performance
measures for health systems that would enable progress toward
more systematic knowledge of the policies to improve health
systems (WHO 2000). Such knowledge could replace what is
now frequently simply ideology and opinion. The 2000 World
Health Report proved to be highly controversial, and its ranking
of health system performance may in the end be judged as
more of a first attempt than an initial approximation (Jamison
and Sandbu 2001). WHO set an agenda that will certainly con-
tinue to be advanced.
Despite current inability to judge health system perform-
ance and the consequently ad hoc character of knowledge,
much is in fact known that bears on health policy. Chapters 2
and 3 of this volume summarize very specific knowledge about
intervention characteristics and system design that can inform
policy. Although broad prescriptions may still elude us, partic-
ular knowledge is still important. Additionally, the perform-
ance of countries is better understood even though relating
country performance to performance of its health systems may
remain only judgmental for the moment. For example, Brazil
and China had under-five mortality rates that were quite close
in 2002: 37 per 1,000 for Brazil and 38 per 1,000 for China. In
1990, however, Brazil’s rate was 60 per 1,000 and China’s was 49
per 1,000: the rate of improvement in Brazil was far more rapid
than in China. This measure is only one dimension of out-
come, and many explanations are possible. Yet hard numbers
on country perform do exist to initiate discussions of policy.
Financing Health Services
Chapters 12 and 13 in this volume discuss domestic and exter-
nal financing of health systems. Different issues arise in low-
income countries than in middle-income ones, and the discus-
sion that follows is so divided. Table 1.2 provides context by
conveying the level of health expenditures in 2001 in different
income groupings of countries, the fraction of GDP spent on
health, and the extent to which those expenditures are publicly
financed. Almost 10 percent of the total product of the world
pays for health services. In the low-income countries, about
three-quarters of expenditures are from private, out-of-pocket
payment. In the high-income European countries, only about
one-quarter of expenditures is private. Middle-income coun-
tries spend about 5 times as much per capita on health services
as do low-income ones and over 10 times as much through the
public sector. Although available data sets (for example, from
the World Bank or WHO) provide no direct evidence on trends
over time in health expenditures (for more than very short
periods), current levels of expenditure are likely to substantially
exceed those of several decades ago, even as a percentage
of growing incomes. The availability of physicians provides
one indicator: in a large sample of countries the number of
physicians per 100,000 population increased from 54 in the
mid 1960s to 116 in the early 1990s, an annual rate of increase
of 2.8 percent.
Before we turn to questions of financing health services (or
insurance), briefly discussing related issues concerning the
public sector’s financial role is worthwhile. Those issues address
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Table 1.2 Health Expenditures by Country Income Level, Public and Total, 2001
Health expenditure Health expenditure Public sector expenditures
Country group per capita (2001 US$) (percentage of GDP) (percentage of total health expenditures)
Low income 23 4.4 26.3
Middle income 118 6.0 51.1
High income 2,841 10.8 62.1
(Countries in the European Monetary Union) (1,856) (9.3) (73.5)
World 500 9.8 59.2
Source: World Bank 2004, table 2.14.
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what chapter 11 calls “healthy fiscal policy and fiscal policy for
health.” An example of unhealthy fiscal policy was the Polish
government’s subsidy of fatty animal products. Elimination of
that subsidy was a gain for the treasury and resulted in
improved diets and health. Minimally, a healthy fiscal policy
identifies and corrects such inappropriate subsidies. Fiscal pol-
icy for health is exemplified by tobacco taxation, which chapter
46 deals with at length and chapter 11 deals with more briefly.
Fiscal policy for health involves taxes whose principal purposes
lie more in changing health-related behaviors than in generat-
ing revenue (although the latter can be important as well).
Financing Health in Middle-Income Countries. A major
cause of poverty (and economic insecurity more generally)
results from highly uneven and unpredictable needs to finance
health expenditures. In consequence, most societies have
moved toward prepaid care as income rises. The current high-
income countries, with only two exceptions, have decided in
favor of universal public financing (rather than private volun-
tary insurance) as the principal means of meeting the demand
for prepaid care. Taiwan (China) and the Republic of Korea,
several years ago, and Mexico and Thailand more recently, have
also taken the path toward universal public, financing. The
health sector is exceptional: no one in the mature capitalist
democracies would contemplate substantial public financing
for food or housing, and public subsidies and protection for
agriculture result from unusually powerful interest groups.
Public financing for health, including for clinical services for
well-off individuals, has been the result of the democratic
process in all the major capitalist countries except Switzerland
and the United States. (Public financing is, of course, consistent
with private provision of services, and the countries of the
Organisation for Economic Co-operation and Development
(OECD) display substantial diversity in this regard.) Efficiency
as well as equity concerns underlie this pattern. Barr (2001)
examines in detail the efficiency rationales that have under-
pinned major public sector financial involvement in health,
education, and social protection in the high-income countries.
Why do market economies choose public sector financing
(either public spending or publicly mandated social insurance)
for many of their personal clinical services? The case for
publicly financing interventions that are shared by all (for
example, antitobacco advertising or water fluoridation) or
where significant externalities exist (such as interruption of
transmission of TB by treatment of infections) is widely
accepted. Providing personal clinical services, like hernia
repair, has none of those attributes. Nonetheless, as Arrow
(1963) articulated in a now-classic article, the pervasiveness
of incomplete information for decision makers (patients,
providers, insurers) dominates private health insurance and
delivery of clinical services. These personal clinical services
account for the bulk of health expenditure. The evidence is
increasingly clear that a strong government presence in finance
is the least bad way of dealing with these problems. Such a
presence is necessary to achieve universal access to health care
and makes it easier to impose the hard budget constraints that
impose discipline in resource allocation. Additional evidence
indicates that introducing universal mandatory health coverage
favorably affects both wages and employment levels. Gruber
and Hanratty (1995) provide thorough documentation of these
effects in Canada. Some combination of these factors likely
underpins the choices of the high-income democracies to fund
a large fraction of private clinical services with public resources.
Public financing of services for all does not imply that all
services can be provided. Indeed, given their resource con-
straints, countries face hard choices about what to include (and
exclude) in the universal benefits package—choices that this
volume seeks to inform.
Middle-income countries vary substantially in the extent to
which health care providers are financed on a fee-for-service
basis—that is, by direct payment for specific services. Although
that is traditionally the chief way to pay for private care, it is
worth clarifying that government providers can also be financed
(legally or illegally) on a fee-for-service basis—as is increas-
ingly the case in China, for example. Similarly, providers are
sometimes compensated through other means, such as capita-
tion, and individual physicians in the private sector are some-
times on salary or a combination of salary plus capitation. Out-
of-pocket payments to a public sector provider are usually
called user fees, but they differ little from fee-for-service com-
pensation of private providers.
What is the OECD experience with user fees? Basically, it is
that both providers and patients respond strongly to the incen-
tive environment. Indeed, a problem exists of providers being
too responsive: much low-value or useless surgery, diagnosis,
and drug use is, in some systems, highly profitable to the
provider, and often the provider must, as agent for the patient,
decide what to do. This conflict of interest has led to cost esca-
lation and to inappropriate care. A case may be made for
divorcing provider compensation from the delivery of individ-
ual services, drugs, or diagnostic tests unless a need exists to
accelerate coverage of critical services by giving bonuses to
providers for providing them, as the United Kingdom’s
National Health Service has done with immunization.
If fee-for-service financing can generate a perverse incentive
environment, does that imply that a system must forgo charg-
ing beneficiaries for services they receive? Not at all: other ways
exist to ensure that funds are adequate for costs—ways that
may be more effective. Earmarking payroll taxes to finance
health care for workers and their dependents (usually called
social insurance) is one approach for recovering costs that is
consistent with provider compensation mechanisms relying
principally on salaries or capitation rather than fee-for-service.
It has been argued that cost recovery through payroll taxes
will generate more economic distortions than do income,
consumption, or sin taxes—although recent evidence suggests
that may not be true (Blanchard and Katz 1997). Nonetheless,
when general revenue mechanisms are incapable of financing
the nationally defined basic package of services for all, the
option of cost recovery through payroll taxes for the privileged
workers in the formal sector is clearly desirable on equity
grounds. This form of taxation also links contributions to a
specific service, which increases its acceptability.
Financing Health in Low-Income Countries. Approximately
2.5 billion people live in countries the World Bank classifies as
low-income—that is, with a per capita gross national income in
2002 of less than US$735 per year. These countries include
India but not China. Table 1.2 reflects that the estimated aver-
age per capita health expenditure for these 2.5 billion people is
about US$23 per year, of which US$5 or US$6 comes from
public sources. Chapter 12, on financing health systems, points
to the severe challenges in setting priorities that these resource
limitations imply. Not only are expenditure levels currently
very low, but also the fiscal space needed to increase them is,
in most low-income countries, sharply constrained. Fiscal
space results from an excess of potential government revenues,
including reasonable projections of official development assis-
tance (ODA), over public expenditures. The concept of fiscal
space combines both short-term fiscal balance and long-term
debt sustainability. Grant ODA can help with short-term bal-
ance, and soft loans (such as International Development
Association credits from the World Bank) can reduce the repay-
ment burden from a given level of incurred debt. Health financ-
ing policy for low-income countries must focus heavily on
mobilizing public sector resources and concentrating resources
on true priorities (although the broader range of issues just dis-
cussed that middle-income countries must address is relevant
to low-income countries with large formal sectors).
The chapters in this volume make clear that incremental
resources for health, well spent, could have an enormous effect:
resource mobilization is important. Increasing public sector
expenditures in health by 0.5 percent or more of GDP will be
possible in some countries, but not in all, and even where it is
possible other investment priorities will also be pressing.
However, increases of as much as 1 percent of GDP may possi-
ble where the political will exists, as is now being attempted in
India. Cost estimates for meeting just the health-related MDGs,
as reported in chapter 9, can exceed that amount, and other
estimates have run higher. Development assistance for health,
discussed in chapter 13 and here, can expand the available
resource envelope, but even multiples of current levels of devel-
opment assistance would likely prove insufficient to finance
attainment of the MDGs in some countries.
Achieving gains for health (and frequently concomitant
gains in financial protection) requires that critical decisions be
made on how to allocate highly limited public sector resources.
Much of this volume deals with resource allocation across
interventions. Public finance must address an additional set of
decisions. Do interventions with substantial positive externali-
ties have a particular claim on public resources—beyond the
amount of health and financial protection they buy per million
dollars spent? Should public resources be spent only on indi-
viduals with low income? Or should health systems provide
universal public finance for the very limited range of interven-
tions that can be afforded? Should public finance emphasize
providing interventions that maximize financial protection
or improvements in health? What patterns of public sector
resource allocation are likely to prove politically sustainable?
Fewer tradeoffs may exist among these criteria than at first
seems to be the case.
A starting point for thinking about these criteria is the avail-
ability of an increasing number of good benefit incidence
studies—that is, studies of how the benefits of a public inter-
vention distribute across income (or asset) quintiles of the
population. Those studies find that in a great majority of coun-
tries wealthier people are more likely to benefit from public
programs than are the poor, at least where benefits are meas-
ured in expenditures. The World Bank’s 1993 World
Development Report pointed to that pattern some time ago
(although noting a number of important exceptions), and
more recent studies add support to that conclusion. The caveat
“measured in expenditures” is important and insufficiently
noted. The value or welfare benefit to the poor of a given level
of transfer may well exceed the value received by the well off
from the same level of transfer. A landmark benefit incidence
study of the U.S. Medicare program, a mandatory health insur-
ance for the elderly, found it to be regressive in dollar terms but
pro-poor in welfare outcomes (McClellan and Skinner 1997).
Public programs that are not universal appear to systemati-
cally benefit the better off, and that pattern is understandable
from a political perspective. It follows that if an immunization
program, for example, is differentially benefiting the well off,
then making immunization universal would be pro-poor in
terms of incremental public expenditures. Figure 1.7 uses data
from a careful benefit incidence assessment in the Philippines
(Gwatkin and others 2000) to illustrate this point for immu-
nization and for attended deliveries.
Making coverage universal for cost-effective interventions
for conditions important to the poor is thus likely to prove to
be an efficient way of both improving health outcomes and
enhancing equity. Many of these interventions address infec-
tious disease where control has significant externalities, and
implementing universal coverage is likely to prove more politi-
cally sustainable than targeting population subgroups. Lindert
(2004) extensively discusses the experience in high-income
countries with universalization of public financing of educa-
tion, health, and old-age pensions and concludes not only that
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it is politically sustainable but also that no evidence indicates
that the resulting higher taxes have harmed economic growth.
Two final points are worth stating about making coverage
universal:
• First, early adoption of universalization of coverage for pub-
licly financed interventions—even if only a few can be
financed—sets the stage for expansion, in a middle-income
environment, to universal public financing of health care,
the overwhelming choice of the democratic process in high-
income countries.
• Second, the implementation capacity of health systems in
low-income countries will often be highly constrained.
Capacity is likely to grow most rapidly by building on a base
of doing a few things well rather than many things poorly.
Universal coverage implies tight focus in highly resource-
constrained environments.
RESEARCH AND DEVELOPMENT
Why has health improved so dramatically after controlling for
income and, hence, the availability of commodities that, like
food, are essential for health? Although no unambiguous
answer to this question exists, an important factor has been
advance in scientific knowledge and its application both in
creating powerful interventions and in guiding behavior.
Acquisition and use of health research and development or its
products becomes, then, an essential function of a country’s
health system. Moreover, it is important that research extend
beyond development of new products to encompass knowl-
edge generation on health system financing and performance.
Much knowledge is embodied in global public goods:
once a vaccine against hepatits B has been developed any-
where, it becomes, in some sense, available everywhere.
Although monopoly pricing made possible by patents may
slow the diffusion of some innovations, the temporary nature
of patent-induced monopoly pricing limits that effect.
However, an innovation’s being cheap, powerful, and globally
available in no way assures its global use. The implication is
clear: globally available knowledge and products offer enor-
mous opportunities to countries, but national policies and
national health systems determine whether that knowledge is
put to local use. Additionally, although some information for
improving outcomes is principally local and must be locally
produced, making the results available contributes to a grow-
ing evidence base. Chapter 4 on health research stresses the
value of contributing to a global evidence base and summa-
rizes with the observation that “all health care is national” and
“all health research is global.”
What are the implications for policy? One is that if knowl-
edge gains prove even partially as important for future health
improvements as they have in the past century—and chapters
in this volume point to a number of reasons for expecting this
to be so—then investments in health research and develop-
ment will continue to have high payoffs in health status and
economic productivity. Chapter 7 points to the potential for
enormous economic returns. Ensuring an adequate level of
research and development investment, therefore, holds strong
claim on health budgets—a claim for more than the approxi-
mately 3 percent now committed. Equally important—or more
important—is that the investments be efficient in generating
useful new knowledge and products. Fauci (2005) discusses the
need for greater efficiency in conducting research and develop-
ment in an environment of tightening budgets in U.S. agencies,
and he points to a number of specific directions for doing so.
In some cases, additional resources (probably from growth
within national health budgets or health aid budgets) will be
required to meet these research and development needs ade-
quately. In many cases, institutional change will be necessary to
create the information and incentives required for efficient
resource allocation. At the international level, resource alloca-
tion has often lacked focus, failing to bring results to the point
of application, and has neglected important conditions and
issues while providing, often generously, for less important
ones. Reform is needed. Successful models of competitively
Source: Calculations based on data reprinted in Gwatkin and others (2000).
Notes: Universal immunization coverage means complete coverage with the standard
immunization schedule. The Philippines achieved 75 percent coverage overall in 1998,
and Gwatkin and others (2000) show the coverage level by quintile. The black bar shows
what the percentage distribution of benefits by population quintile would be of moving
from the 1998 status quo to universal coverage. Universal delivery attendance means
that all births would be attended by a doctor, nurse, or nurse-midwife. The Philippines
achieved 63 percent coverage overall, and the white bar shows what the percentage
distribution of benefits by population quintile would be of moving from the current
pattern of coverage to universal coverage. 
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Figure 1.7 Equity Implications of Providing Universal Coverage for
Immunization and Attended Delivery in the Philippines, 1998
driven international funding and experience-sharing networks
should be applied to currently neglected clusters of conditions.
Just as the quality and productivity of research efforts vary
dramatically from one institution to another within the high-
income countries, they vary in the low- and middle-income
countries. Exemplary work is done in a number of institutions
and countries; but in general, the obstacles to high quality are
greater when countries’ incomes are lower. Inadequate train-
ing, insufficient staff motivation, and lack of competition
prevent many institutions from attaining their potential. The
instability of short-term funding, isolation from peers, and
poor access to the research literature all compound the prob-
lem and prevent researchers from responding rapidly to ever-
changing demands. Given the shortage of good researchers, an
argument exists for the talent to move to countries (including
low- and middle-income countries) whose policies are likely to
facilitate productive research (WHO 1996). Donor funding
should reflect this possibility.
Institutions are more likely to succeed not only if they
receive stable core funding but also if a proportion of their
work is funded competitively. Some institutions, such as the
Oswaldo Cruz Foundation in Brazil, have already moved in
these directions with great success—for example, by freeing up
intramural resources for competitive allocation between
groups and within the institution, with assessments being
made by an external review group. Notable successes have
occurred in assisting with capacity strengthening, such as the
Special Programme for Research and Training in Tropical
Diseases collaboratively supported by WHO, the World Bank,
and the United Nations Development Programme.
The failure of current incentive structures, essentially the
patent system, to produce health products for the lowest
income groups demands remedial action (chapter 5). In
essence, either the public sector must harness the skills, energy,
and capacity of the private sector to develop and bring promptly
to market products for the lowest income groups, or it must
take responsibility for doing so itself. In reality, a combination
of the two is likely, as is exemplified in successful public-private
partnerships such as the Medicines for Malaria Venture or the
International AIDS Vaccine Initiative. Recently proposed pre-
commitments by the public sector to purchase specific new
products are an additional potential instrument to generate
incentives for private sector investment (Kremer and
Glennerster 2004). Developing countries that participate in
private sector innovation will be positioned to more quickly
learn of and have access to the technical progress that is critical
in driving health improvements.
Global challenges demand, in some sense, a global response.
All nations share the fruits of research and development. Even
though each country may invest a relatively modest sum
toward collective goals, the aggregate effort potentially benefits
all substantially. Collective action is the economically rational
approach to public goods such as research and development;
here, responsibility for catalyzing collective action lies princi-
pally in the hands of the global community. Far from over-
shadowing action at the national level, global efforts help both
to make national research and development efforts more pro-
ductive and to lead to a global result that exceeds the sum of
national ones. Thus, among the many competing demands on
the funds allocated to international assistance for health, those
contributing to generation of new knowledge, products, and
interventions that can be shared by all have special merit.
DEVELOPMENT ASSISTANCE FOR HEALTH
Development assistance, wisely focused, has the potential for
unusual effect. First, because health gains for the poor can be
relatively inexpensive (compared to the cost of achieving sig-
nificant effect in other sectors), development assistance itself
can achieve much, particularly if it serves as a channel for dif-
fusion of new technologies and best practices. Second, evidence
suggests that development assistance in health can be more
effective than other development assistance in poor policy and
weak institutional environments. Third, the economic benefits
of investing in health can be exceptionally high. Finally, because
research and development have had high impact (chapter 7)
and are an international public good, development assistance
has a particular comparative advantage in ensuring their
finance.
Those conclusions point to a proactive strategy within
development assistance agencies and governments for achiev-
ing major shifts in staffing and budgetary allocations toward
specific high-payoff investments in health. They also point to
the need, in order to achieve the potential benefits, for a
focused concentration of health system development on a
limited set of priority health goals—for example, controlling
AIDS, controlling smoking, meeting the health-related MDGs,
and—for middle-income countries—implementing finance
reforms that lead toward universal public financing. The sec-
tion argues that although financial fungibility—the capacity to
redirect government resources away from areas supported by
external financing—can dilute the effect of development assis-
tance in health, as in other sectors, designing development
assistance for health that minimizes the fungibility problem is
possible. Performance-based budget support will be one
instrument.
In 2003, the world committed to ODA of almost US$100
billion, and news reports in May 2005 suggested the possibility
of substantial increases by European donors. Approximately
10 percent of ODA is spent for health, a percentage that has
grown rapidly. Table 13.1 in chapter 13 shows recent trends in
external financing for health, of which ODA (that is, grant or
highly concessionary loans) is only a part: these numbers are
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for commitments, not actual disbursements, which are smaller
and lag behind commitments. (The Global Fund to Fight
AIDS, Tuberculosis, and Malaria is one of the few providers of
developmental finance that reports disbursements as well as
commitments.) External financing for health has grown from
about US$6.7 billion in 1998 to US$9.3 billion in 2002
(Michaud 2003). For some countries, development assistance
constitutes a significant and growing fraction of health expen-
ditures. Economists have recently returned to the question of
the returns to expenditures on development assistance, and
several recent trends have important potential implications for
health.
Aid Effectiveness
Recent work has been reassessing aid effectiveness and has
focused on the following questions: Is there any evidence that
infusions of development assistance have affected economic
growth rates? Is there any evidence that infusions of economic
assistance have affected mortality rates or levels of poverty?
These questions are clearly not easy to answer. Nonetheless,
some data provide insights. Burnside and Dollar (2000) con-
clude, for example, that development assistance does seem to
work in countries where a good policy environment and a good
institutional environment exist, but not in countries lacking
those elements. Recent work focuses on aid directed to eco-
nomic development and greatly strengthens the inclusiveness
of the conclusion that aid boosts growth (Clemens, Radelet,
and Bhavnani 2004). The effect of development assistance on
growth is quantitatively important even in countries with poor
policies and institutions, although the effect is stronger in
countries with better policies. Interestingly, aid’s effect appears
larger in countries with higher life expectancy. That develop-
ment assistance contributes broadly to growth does not, of
course, imply that development assistance for health will accel-
erate health improvements. However, it is certainly suggestive
of the potential in health to know that development assistance
works for growth.
Even if development assistance is viewed as working better
in strong institutional and policy environments, a dilemma
exists in that the countries that most need aid are often ones
that have weak policies and weak institutions (Radelet 2003,
194). Experiences with ODA in health complement the recent
research on aid for growth in suggesting that ODA can pay off
despite limited institutional or absorptive capacity. Polio has
certainly been eliminated in countries with good health sys-
tems, but it has also been eliminated from most countries with
weak ones. No smallpox exists today in countries with bad
policies and bad institutions. A number of those countries have
immunization rates of 60 or 70 percent, or as high as in the
United States. An important question concerns the extent to
which other development assistance for health, particularly
highly targeted development assistance, can be as successfully
implemented as immunization programs where health systems
are weak.
Project Support versus Budget Support
Development assistance is tending to move away from project
support—for example, of an immunization program, an AIDS
control program, or an extension of a road network—and
toward general budgetary support, often to be provided
through pooling of donor assistance. There are many reasons
for this tendency, some of which are good (Kanbur and Sandler
1999, 106). The usefulness (and even propriety) of budget sup-
port is contingent, however, on adequacy of the policy and
institutional environments. Chapter 3 points to arguments that
as health systems evolve, development assistance should move
from project assistance toward program assistance. The Global
Alliance for Vaccines and Immunization (GAVI) is pointing
to ways that support for immunization programs can be
advanced within the context of this tendency to move toward
general budget support. GAVI’s innovation is to support
immunization programs based on performance—US$20 for a
fully immunized child. The country gets the US$20 for immu-
nizing the child in whatever way it decides; thus, GAVI provides
general budget support that is conditioned on performance.
GAVI’s concern has been with transitional financing (rather
than with sustained assistance), but its approach points the way
for designing long-term budget support conditioned on meas-
urable performance with respect to specific health goals.
Jamison (2004) outlined design of long-term development
assistance for health that could meet this objective, maintaining
incentives for countries to increase coverage (or performance)
while scaling back the volume of aid as a country’s income
increased. Adequate measurement underpins assessment of
performance and can be difficult even for immunization cov-
erage. Measurement requires resources that must be planned
for and budgeted.
Macroeconomic Consequences of Aid 
Another concern in the aid community—particularly in the
International Monetary Fund—is that development assistance
could have adverse domestic macroeconomic consequences—
essentially inflationary consequences (see WHO 2002,
chapter 8). This argument needs to be taken seriously. It is in
essence an argument about the generation of domestic infla-
tionary pressures—of projects chasing after those few good
engineers or doctors with an increasing amount of foreign
money and creating an inflationary spiral in that way. However,
if the principal proposed use for the money is for drugs or
vaccines—for example, the US$10 increment for adding Hib
and HepB vaccines to the Expanded Program on Immunization
schedule—that money is almost all foreign exchange, and the
macroeconomic arguments about inflationary consequences
simply would not apply. Careful project design can respond
to what on the whole are serious concerns from the macro-
economic part of the development assistance community.
Economic analysis can provide information—such as this vol-
ume attempts to provide—on getting the maximum health and
financial protection outcomes from the development assistance
available and for designing interventions (tradable and com-
modity intensive) that will minimize potentially adverse
macroeconomic consequences.
The Millennium Development Goals 
An additional and significant direction in thinking about ODA
concerns achievement of the MDGs (chapter 9). The MDGs are
very specific targets for improvement in education, health, and
income-related poverty. Interestingly, focusing development
assistance on achieving the MDGs stands in at least partial
opposition to the move toward budget support.
These considerations point to several directions for the
design of development assistance for health. Radelet (2003,
194) provides detailed quantitative examples to show that, even
under very favorable circumstances, in a lower-middle-income
country development assistance is likely to be needed for
decades. Some conclusions follow that are drawn from the pre-
ceding discussion and from the need for predictability and long
time horizons in donor behavior. ODA should move toward
the following:
• providing aid over long-term perspectives (10 or more
years) 
• ensuring predictability in assistance commitments
• emphasizing demand-side support (with concomitant
country control of resources)
• providing incentives for countries to maintain high cover-
age for cost-effective programs
• avoiding perverse incentives
• including a transparent exit strategy (for example, reduced
grant support with per capita GDP growth).
There is a strong analogy to within-country programs like
Mexico’s Progresa, which provides cash transfers to poor
households contingent on getting children immunized or into
school. Gertler (2004) has reported evaluation results indicat-
ing a high degree of effectiveness. The effectiveness of coverage
incentives is well exemplified by the Bill & Melinda Gates
Foundation in its work on polio with both GAVI and the World
Bank in providing a financial incentive for enhanced coverage
(chapter 13). Although donors increasingly state a commit-
ment to providing aid predictably and over long periods, the
reality for many countries is that aid flows will be volatile and
of uncertain duration. Jamison and Radelet (2005) point to
ways of using such aid that can be minimally disruptive.
CONCLUSIONS
A volume as large as this one can provide only a sampling of
opportunities and potential pitfalls for investments in health.
Indeed, the International Statistical Classification of Diseases
(WHO 2003a) takes more than 1,500 pages simply to list the
conditions that a health system must address. Yet the diseases
accounting for most of the burden can be listed in perhaps half
a dozen pages, and the diseases that account for most of the
differences in outcome between high- and low-mortality coun-
tries can be listed on a page. Chapters in this volume assess 115
population interventions and 204 personal interventions that
address most conditions of importance. The conclusions listed
in this final section of the chapter simply highlight important
conclusions for policy without attempting to summarize the
volume as a whole. Chapters 2 and 3 complement this one with
a fuller summary.
Table 1.3 provides a sense of the nature of the findings in
much of the book,and box 1.4 provides a brief description of the
methods.The table shows the number of DALYs that we estimate
could be averted (or years of healthy life that could be bought) by
spending a million dollars on a few of the interventions address-
ing major sources of disease burden. If we think of these num-
bers as the prices for buying health by different means, the price
variation is enormous, ranging from one or two DALYs per mil-
lion dollars up to well over 100,000. All the standard caveats
more than apply to these numbers. Nonetheless, they do convey
information relevant for policy. Expanding coverage of the cur-
rently used mix of vaccines, for example,appears more attractive
than does adding new vaccines (except when the lower demands
on system capacity of adding new vaccines are considered).
Bypass surgery used even in the most appropriate circumstances
is an expensive way to buy a year of healthy life, but for many
common indications it is inordinately expensive. Findings from
table 1.3 exemplify findings of the cost-effectiveness analyses
from throughout the book that are summarized in chapter 2.
A general conclusion follows from the preceding discussion.
There are many inexpensive ways to reduce mortality rates and
improve health. A country that focuses on those interventions
can expect to achieve major improvements—even with very
limited resources. There are also ways to spend money on
health that can dissipate even a substantial budget with almost
no return—either for better health or for the financial protec-
tion of populations. Intervention selection matters. Many of
the good and bad buys are now well known. Some are not, and
our main purpose in this volume has been to assemble the evi-
dence based on what is known.
We now turn to more specific conclusions. Different items
on the list are relevant in different countries. (Chapter 2
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suggests, for example, major differences between the priorities
for South Asia and those for Sub-Saharan Africa.) Many inter-
ventions or policy changes that are important are not on this
list, but they are included in the more extensive discussions in
chapters 2 and 3, which synthesize messages from the rest of
the book on setting intervention priorities and strengthening
health system capacity. Given often quite limited availability of
money or political leadership or health system capacity, it will
often be necessary to focus the available resources on a few key
priorities. Chapter 12 makes it disappointingly clear that, for
the low-income countries, not only are financial resources
sharply limited now, but prospects for more than modest
increases seem unlikely for many years. (Financial constraints
in the middle-income countries, although real, are less
Table 1.3 How Much Health Will a Million Dollars Buy?
Estimated DALYs averted  
Service or intervention Cost per DALY (US$) per million US$ spent
Reducing under-five mortality
Improving care of children under 28 days old 10–400 2,500–100,000
(including resuscitation of newborns)
Expanding immunization coverage with standard child vaccines 2–20 50,000–500,000
Adding vaccines against additional diseases to the standard 40–250 4,000–24,000
child immunization program (particularly Hib and HepB)
Switching to the use of combination drugs (ACTs) against 8–20 50,000–125,000
malaria where resistance exists to current inexpensive and 
previously highly effective drugs (Sub-Saharan Africa)
Preventing and treating HIV/AIDS
Preventing mother-to-child transmission (antiretroviral-nevirapine 50–200 5,000–20,000
prophylaxis of the mother; breastfeeding substitutes)
Treating STIs to interrupt HIV transmission 10–100 10,000–100,000
Using antiretroviral therapy that achieves high adherence for a large 350–500 2,000–3,000
percentage of patients
Using antiretroviral therapy that achieves high adherence for only a Because of very limited gains by individual
small percentage of patients patients and the potential for adverse
changes in population behavior, it is possi-
ble that more life years would be lost than
saved.
Preventing and treating noncommunicable disease
Taxing tobacco products 3–50 24,000–330,000
Treating AMI (heart attacks) with 10–25 40,000–100,000
an inexpensive set of drugs
Treating AMI with inexpensive drugs plus streptokinase (costs and 600–750 1,300–1,600
DALYs for this intervention are in addition to what would have
occurred with inexpensive drugs only)
Treating heart attack and stroke survivors for life with a daily polypill 700–1,000 1,000–1,400
combining four or five off-patent preventive medications
Performing coronary artery bypass grafting (bypass surgery) in specific 25,000 40
identifiable high-risk cases—for example, disease of the left main
coronary artery (incremental to treatment with polypill)
Using bypass surgery for less severe coronary artery disease Very high Very small
(incremental to treatment with polypill)
Other
Detecting and treating cervical cancer 15–50 20,000–60,000
Operating a basic surgical ward at the district hospital level that focuses 70–250 4,000–15,000
on trauma, high-risk pregnancy, and other common surgically treatable
conditions
Source: Authors.
AMI  acute myocardial infarction.
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binding.) Selecting priorities will be hard. This section provides
a starting point for discussing which activities should be high
priorities. The conclusions are grouped under four headings:
interventions; health services, systems, and financing; research
and development; and development assistance.
Interventions 
1. Standard interventions for reducing under-five mortality
have long been known to be highly cost-effective. The chal-
lenge is to scale up while conserving and strengthening
scarce health system capacity. These interventions include
immunization; micronutrient supplement delivery;
treatment for diarrhea, malaria, and acute respiratory
infections; and improved prenatal and delivery care. In
cases of sharply limited resources—financial or health
system capacity—often the single highest priority will
be expansion of immunization coverage with the basic
antigens: poliomyelitis, measles, diphtheria, tetanus,
pertussis, and perhaps BCG.
2. Cost-effective interventions exist to address the 50 percent
of under-five deaths that occur under 28 days of age,
including stillbirths. These are underused relative to inter-
ventions for older children, and correcting this neglect is a
priority.
Cost-Effectiveness Analysis in This Volume
Box 1.4
A starting point for cost-effectiveness analysis is to observe
that health systems have two objectives: (a) to improve the
level and distribution of health outcomes in the popula-
tion and (b) to protect individuals from financial risks
that are often very substantial and that are frequent causes
of poverty. Financial risk results from illness-related loss of
income as well as expenditures on care; the loss can be
ameliorated by preventing illness or its progression and by
using appropriate financial architecture for the system.
For the purposes of this book, we consider two classes
of resources to be available: financial resources and health
system capacity. To implement an intervention in a popu-
lation, the system uses some of each resource. Just as
some interventions have higher dollar costs than others,
some interventions are more demanding of system capac-
ity than others. In countries with limited health system
capacity, it is clearly important to select interventions that
require relatively little of such capacity. Human resource
capacity constitutes a particularly important aspect of sys-
tem capacity, discussed in chapter 71 and in a recent
report of the Joint Learning Initiative (2004).
Although in the very short run little tradeoff may exist
between dollars and human resources or system capacity
more generally, investing in the development of such
capacity can help make more of that resource available in
the future. Chapter 3 discusses different types of health
system capacity and intervention complexity, and it points
to the importance of and potential for responding to low
capacity by selecting interventions that are less demanding
of capacity and by simplifying interventions. Chapter 3
also explores the extent to which financial resources can
substitute for different aspects of system capacity (see also
Gericke and others 2003). An important mechanism for
strengthening capacity, inherent in highly outcome-
oriented programs, may simply be to use it successfully—
learning by doing. Several chapters discuss capacity
strengthening at different levels of the clinical system, in
public health, and in health research and development.
The literature on economic evaluation of health proj-
ects typically reports the cost per unit of achieving some
measure of health outcome—quality-adjusted life years
(QALYs) or DALYs or deaths averted—and at times
addresses how that cost varies with the level of intervention
and other factors. Pritchard (2004) provides a valuable
introduction to this literature. DCP1 reported such cost-
effectiveness findings for a broad range of interventions;
DCP2 does so as well. DCP2 authors were asked to use
methods described in Jamison (2003); chapter 15 discusses
actual implementation. Cost-effectiveness calculations
provide important insights into the economic attractive-
ness of an intervention, but other considerations—such as
consequences for financial protection and demands on
health system capacity—are also relevant.
DCP2 also makes a preliminary attempt to accumulate
information about the extent to which interventions place
demands on health system capacity; this information is
qualitative. DCP2 provides only an initial effort, but quali-
tative information does provide helpful input to policy.
Kim (2005) develops a more quantitative approach in an
analysis dealing with cervical cancer. Much less has been
done on the extent to which specific interventions provide
financial protection for patients and their families.
Source: Author.
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3. Standard interventions to treat TB are also known to be
highly cost-effective, although probably more demanding
of health system capacity than are some of the child health
interventions. Scaling up by using already developed mod-
els for strengthening relevant health system capacity is a
priority.
4. Many well-tested preventive interventions for AIDS are
effective and cost-effective. Such interventions include
treating STIs, promoting condom use, providing voluntary
counseling and testing, promoting peer intervention, using
antiretroviral therapies to prevent mother-to-child trans-
mission, ensuring safe blood supplies, and encouraging the
use of breast milk alternatives by HIV-positive mothers.
Scaling up treatment for STIs may prove particularly
important. Much more rapid implementation of these
interventions is of highest priority and needs to be accom-
panied by effective mechanisms of surveillance and evalu-
ation. The appropriate mix and distribution of interven-
tions depends on the stage of the epidemic. In particular,
limited financial and institutional resources imply focus-
ing effort on populations at high risk early in an epidemic.
5. Antiretroviral drugs have been successful on a wide scale
in high-income countries (and in some upper-middle-
income countries—notably Brazil and Mexico) in sharply
reducing viral load and extending the life expectancy of
patients who are HIV positive. Health system capacity for
achieving durable benefits from antiretroviral drug use at
scale in resource-constrained environments, however,
remains to be demonstrated. Failure to achieve good
adherence in such an environment would provide minimal
benefits to the patient, increase risks of drug resistance,
and incur substantial costs: the financial and human losses
could be enormous. Multiple approaches to successful
maintenance on antiretroviral drugs should be tried and
evaluated in large-scale pilots or as part of implementation
scale-up. Given the magnitude of the AIDS problem,
undertaking and evaluating variations in implementation
(including possible variation in the choice of first-line
drugs) in parallel rather than serially is important. This
approach is not now being used. Similarly important is
being rigorous in dropping unsuccessful implementation
models before they consume substantial resources that
could otherwise have greatly affected AIDS prevention or
other priorities in the health sector.
6. Control of tobacco use is the cornerstone of proven
approaches to primary prevention of heart disease, stroke,
chronic pulmonary disease, and many types of cancer.
Instruments for control of tobacco use centering on
taxation and improved public information are well
established.
7. A range of potential approaches to changing dietary and
exercise patterns of populations would, if successful,
reduce problems of obesity, hypertension, and dyslipi-
demia and their consequences for vascular disease.
Successes are rare but suggestive that large-scale efforts
could be worthwhile. Careful impact evaluation will be
essential to ascertain whether these investments deliver
value for money.
8. Lifetime medical management—eventually using variants
of the polypill—of individuals at high risk for stroke or
ischemic heart disease is cost-effective and important for
tens of millions of individuals. The clearest indications of
high risk are a previous vascular event or diabetes.
Health Services, Systems, and Financing
9. Focused funding for particular diseases or programs—for
example,TB or immunization—is a fact of life in many low-
income countries. Using such funding to build health sys-
tem capacity is feasible as well as desirable, but it is far from
automatic. As capacity grows, the potential advantages of
categorical programs are likely to fade while a more inte-
grated (but still outcome-oriented) health system assumes
responsibility for dealing with the relevant conditions.
10. Quality of clinical care makes an enormous difference,
both to the cost of care and to health outcomes. Tangible
actions can be taken to improve quality: important among
them is having each provider do a few things well rather
than many things poorly.
11. Strengthening capacity for surgery at the district hospital
level is a frequently neglected priority. Major important
uses of this capacity will be to deal with injuries and
obstetrical emergencies.
12. In low-income countries public funding for health will
remain highly constrained as a percentage of GDP for the
foreseeable future. Targeting these funds to provide uni-
versal access to a limited number of interventions that are
high priority for poor people is both efficient and equity
enhancing, but it will require clear setting of priorities,
particularly for incremental resources as they become
available.
13. Middle-income countries can learn from the OECD expe-
rience that universal public financing of a substantial pack-
age of clinical care is both efficient and equity enhancing.
Research and Development 
14. Impact evaluation of interventions in many domains is an
essential priority and should be done around planned vari-
ations in implementation. One specific area of importance
is evaluation of effective ways to manage lifelong drug
use—for example, for AIDS, secondary prevention of
vascular disease, diabetes, and major psychiatric disorders.
15. Public-private partnerships such as the Medicines for
Malaria Venture and the International AIDS Vaccine
Initiative provide promising models for developing impor-
tant new drugs, vaccines, and diagnostic products to deal
with the major diseases of poverty as well as the problem
of drug resistance and microbial evolution more generally.
Development Assistance
16. Development assistance for health has begun to become
performance based, and this trend should accelerate, along
with making development assistance more stable and long
term (contingent on performance). This change may
involve at least a partial shift away from the sectorwide
approaches to development assistance that recent evidence
suggests may lead to neglect of focus on outcomes. It will
require renewed attention to outcome measurement.
17. Resistance of the malaria parasite that is responsible for
most deaths to chloroquine and SP is now widespread and
rapidly increasing. A particular challenge is overcoming
financial and institutional barriers to virtually complete
replacement of those drugs with ACTs, which minimize
resistance and can decrease transmission. Absent such an
effort, malaria mortality is likely to continue rising. A
centralized procurement mechanism receiving subsidies
from development assistance agencies and making low-
cost ACTs available to public and private supply chains
globally would address this problem.
18. Investing in global capacity to respond effectively to a new
influenza pandemic, particularly within the resource con-
straints of low-income countries, is a priority for the inter-
national system. Such capacity would include effective
surveillance, surge manufacturing capacity for drugs and
vaccines, stockpiles of drugs that could be used to attempt
to contain epidemics, and mass media messages and pub-
lic policies prepared in advance to be deployed if needed.
19. Because research and development is so important for
health and because it is a classic international public good,
a substantial fraction of incremental development assis-
tance for health should go to research and development.
The content of these specific recommendations, and of rec-
ommendations throughout this volume, point to the enormous
potential we now have to reduce further the human and finan-
cial burden of ill health. Scientific advance created this potential.
Its more widespread realization requires the focused attention of
health systems to finance and deliver priority interventions.
ANNEX 1.A: THE BURDEN OF DISEASE IN 2001
This annex provides estimates of the burden of different dis-
eases and injuries in 2001. Alan Lopez, Colin Mathers,
Christopher Murray, and their colleagues at WHO generated
the estimates, aggregated them by World Bank regions, and
provided final updates. A companion volume (Lopez and
others 2006) will provide more comprehensive tables of results
for a much finer disaggregation of conditions, a full exposition
of methods and data sources, and sensitivity analyses (includ-
ing assessments of the sensitivity of results to including still-
birth). All numbers in this annex are consistent with those in
the companion volume.
This annex first provides a brief background on assess-
ments of deaths by cause and disease burden and then an
overview of the uses of such measures for health policy. It
concludes with aggregated tables on deaths and on disability-
adjusted life years (DALYs) by selected causes or groups of
causes. The tables present estimates both with and without
stillbirths, which constituted approximately 5.5 percent of
deaths globally in 2001. Estimates are provided separately for
high-income countries and for the low- and middle-income
countries as a group.
Background
Many countries, including all high-income ones, maintain vital
registration systems that provide data (usually annual) on the
number of deaths by cause, age, sex, and sometimes race. Some
countries additionally compute years of life lost (or YLL) by
cause, which assigns a number of years of life lost attributable
to each cause that depends on the age of death and some rele-
vant measure of life expectancy. As of the early 1990s, no simi-
lar estimates existed for many developing countries or for
regional groupings of them. Experts on individual conditions
or the relevant disease program at WHO generated estimates
for the diseases of interest to them. When added up across dis-
eases, however, such estimates exceeded, often by a factor of 2
or more, any plausible estimate of the total number of deaths
occurring in each age group. DCP1 and the World Development
Report 1993 (Lopez 1993 and World Bank 1993) generated esti-
mates of the number of deaths by cause that were consistent
with demographically determined death totals for eight
regional groupings of countries. WHO collaborated closely on
this work. The number of deaths from a disease is one measure
of the magnitude of its burden, and YLL constitutes for many
purposes a better measure. Neither takes account of the dis-
ability or suffering associated with a nonfatal disease.
The 1993 World Development Report also developed a vari-
ant of the quality-adjusted life year (QALY) from the health
economics literature to add a disability dimension to YLLs in
order to generate a more comprehensive measure of burden.
The result, called a disability-adjusted life year, measures bur-
den from a specific cause as the sum of years of life lost from
that cause and the equivalent years of life lost (in a sense that is
made quite specific) from the disability caused by the condi-
tion. Original publications on disease burden included esti-
mates that discounted future events at 0 percent or at 3 percent
per year. They also included estimates that weighted the value
of a year of life uniformly across all age groups and estimates
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that placed greater value on middle-aged groups. These are
labeled DALYs (r,k) with the first number indicating the dis-
count rate in percent per year and the second indicating
whether uniform or nonuniform age weights were used. The
most widely reported variant on the DALY is the DALY (3,1)—
that is, one that uses a 3 percent discount rate and nonuniform
age weighting. This chapter and the companion volume report
DALYs (3,0)—that is, with discounting but uniform age
weighting.
Estimates of DALYs by cause for 1990 first appeared as
appendix B of the 1993 World Development Report and, in
expanded form, in Murray, Lopez, and Jamison (1994).
Christopher Murray, Alan Lopez, and colleagues later produced
updated estimates for 1990 and a fuller account of the methods
used (Murray and Lopez 1996a, 1996b). The relative burden of
different conditions as measured by numbers of deaths corre-
lates highly with DALYs, but important exceptions exist. The
massive burden of major psychiatric conditions, for example, is
captured by DALYs but missed in estimates of deaths by cause
or YLLs. Table 1.A1 summarizes the current estimates of deaths
by cause in 2001 from Mathers, Murray, and Lopez (2006).
Table 1.A2 shows disease burden in DALYs. Additional
columns in these tables show the effect of including stillbirths
on the percentage distribution of burden across conditions
while leaving unchanged the other numbers (see Jamison and
others 2006).
Disease burden can be assessed by risk factor as well as by
disease or condition. An initial assessment of risk factor burden
appeared in the 1993 World Development Report and later in
Murray and Lopez (1997) and WHO (1996). WHO published
a much fuller set of estimates in its 2003 World Health Report
(WHO 2003b). Ezzati and others (2006) provided a substantial
update adjusted to the same methodological assumptions as for
deaths and DALYs, including use of DALYs (3,0).
Uses of Disease Burden Measures
DALYs are useful for informing health policy in at least six
ways. Estimates of deaths by cause or YLL serve these same
purposes, but for some uses less well.
1. Assessing performance. A country-specific (or regional)
assessment of the burden of disease provides an outcome
indicator that can be used over time to judge progress or
across countries or regions to judge relative performance.
The most natural comparison is to the development of
national income and product accounts (NIPAs) by Simon
Kuznets and others in the 1930s, which culminated in 1939
with a complete NIPA for the United Kingdom prepared by
James Meade and Richard Stone at the request of the U.K.
Treasury. NIPAs have, in the subsequent decades, trans-
formed the empirical underpinnings of economic policy
analysis. One leading scholar has put it this way:
The national income and product accounts for the
United States (NIPAs), and kindred accounts in other
nations, have been among the major contributions to
economic knowledge over the past half century. . . .
Several generations of economists and practitioners
have now been able to tie theoretical constructs of
income, output, investment, consumption, and sav-
ings to the actual numbers of these remarkable
accounts with all their fine detail and soundly meshed
interrelations. (Eisner 1989, 1)
Disease burden measures have the potential of serving a
similar purpose for health policy.
2. Generating a forum for informed debate of values and priori-
ties. The assessment of disease burden in a country in prac-
tice involves participation of a broad range of national
disease specialists, epidemiologists, and, often, policy mak-
ers. Debating the appropriate values, say, for disability
weights or for years of life lost at different ages helps clarify
values and objectives for national health policy. Discussing
the interrelations among diseases and their risk factors in the
light of local conditions sharpens consideration of priorities.
3. Identifying national control priorities. Many countries
now identify a relatively short list of interventions, the full
implementation of which becomes an explicit priority for
national political and administrative attention. Examples
include interventions to control TB, poliomyelitis, HIV
infection, smoking, and specific micronutrient deficiencies.
Because political attention and high-level administrative
capacity are in relatively fixed and short supply, the benefits
from using those resources will be maximized if they are
directed to interventions that are both cost-effective and
aimed at problems associated with a high burden. Thus,
national assessments of disease burden are one input in
establishing a potential short list of control priorities. In the
summary of the cost-effectiveness analyses reported in this
volume, chapter 2 pays particular attention to identifying
cost-effective interventions capable of averting a large dis-
ease burden.
4. Allocating training time for clinical and public health practi-
tioners. Medical schools offer a fixed number of instruc-
tional hours; training programs for other levels and types of
practitioners are likewise limited. A major instrument for
implementing policy priorities is allocating this fixed-time
resource well. Again that means allocation of time to train-
ing in cost-effective interventions in which disease burden is
high.
5. Allocating research and development resources. Whenever a
fixed effort will have a benefit proportional not only to the
size of the effort but also to the size of the problem being
addressed, estimates of disease burden become essential for
formulating policy. Developing a vaccine for a broad range
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Table 1.A1 Causes of Deaths in Low- and Middle-Income and High-Income Countries and the World, 2001 
(percent)
Low- and Middle-Income High-Income World
Stillbirths Stillbirths Stillbirths Stillbirths Stillbirths Stillbirths
excluded included excluded included excluded included
Population (thousands) 5,221,572 928,660 6,150,233 
Births (thousands) 118,505 121,733 11,371 11,416 129,878 133,150
Total deaths (thousands) 48,377 51,605 7,936 7,981 56,268 59,542
Causes of death (percent)
I. COMMUNICABLE DISEASES, 36.4 34.1 7.0 6.9 32.3 30.5
PREGNANCY OUTCOMES, AND
NUTRITIONAL DEFICIENCIES
A Infectious and parasitic diseases 22.1 20.7 1.9 1.9 19.3 18.2
1 Tuberculosis 3.3 3.1 0.2 0.2 2.9 2.7
2 STIs excluding HIV 0.4 0.3 0.0 0.0 0.3 0.3
3 HIV/AIDS 5.3 4.9 0.3 0.3 4.6 4.3
4 Diarrheal diseases 3.7 3.4 0.1 0.1 3.2 3.0
5 Childhood diseases 2.8 2.6 0.0 0.0 2.4 2.3
a Pertussis 0.6 0.6 0.0 0.0 0.5 0.5
b Poliomyelitis 0.0 0.0 0.0 0.0 0.0 0.0
c Diphtheria 0.0 0.0 0.0 0.0 0.0 0.0
d Measles 1.6 1.5 0.0 0.0 1.4 1.3
e Tetanus 0.6 0.6 0.0 0.0 0.5 0.5
6 Meningitis 0.3 0.3 0.1 0.1 0.3 0.3
8 Malaria 2.5 2.3 0.0 0.0 2.1 2.0
Other I.A. (7, 9–15) 3.8 3.6 1.3 1.3 3.5 3.3
B Respiratory infections 7.2 6.7 4.4 4.4 6.8 6.4
C Maternal conditions 1.0 1.0 0.0 0.0 0.9 0.9
D Perinatal conditions 5.1 4.8 0.4 0.4 4.5 4.2
1 Low birth weight 2.7 2.5 0.1 0.1 2.3 2.2
2 Birth asphyxia and birth trauma 1.5 1.4 0.1 0.1 1.3 1.2
3 Other perinatal conditions 1.0 0.9 0.1 0.1 0.9 0.8
E Nutritional deficiencies 0.9 0.9 0.2 0.2 0.8 0.8
II. NONCOMMUNICABLE CONDITIONS 53.8 50.5 86.5 86.0 58.5 55.3 
A Malignant neoplasms 10.2 9.6 26.0 25.9 12.5 11.8
C Diabetes mellitus 1.6 1.5 2.6 2.5 1.7 1.6
E Neuropsychiatric disorders 1.4 1.4 4.8 4.7 1.9 1.8
1 Unipolar major depression 0.0 0.0 0.0 0.0 0.0 0.0
2 Bipolar disorder 0.0 0.0 0.0 0.0 0.0 0.0
3 Schizophrenia 0.0 0.0 0.0 0.0 0.0 0.0
Other II.E. (4–16) 1.4 1.3 4.7 4.7 1.9 1.8
G Cardiovascular disease 27.6 25.9 38.3 38.1 29.1 27.5
3 Ischaemic heart disease 11.8 11.0 17.2 17.1 12.6 11.9
4 Cerebrovascular disease 9.5 8.9 9.8 9.8 9.6 9.1
Other II.G. (1, 2, 5, 6) 6.3 5.9 11.3 11.2 7.0 6.6
H Respiratory diseases 6.5 6.1 6.0 6.0 6.4 6.1
I Digestive diseases 3.3 3.1 4.2 4.2 3.4 3.3
M Congenital anomalies 1.0 0.9 0.4 0.4 0.9 0.9
Other II. (B, D, F, J–L, N) 2.2 2.0 4.3 4.3 2.5 2.3
III. INJURIES 9.8 9.1 5.9 5.9 9.2 8.7
A Unintentional 6.6 6.2 4.0 4.0 6.3 5.9
1 Road traffic accidents 2.2 2.1 1.5 1.5 2.1 2.0
Other III. A. (2–6) 4.4 4.2 2.5 2.5 4.2 3.9
B Intentional 3.1 2.9 1.9 1.9 2.9 2.8
1 Self-inflicted 1.5 1.5 1.6 1.6 1.6 1.5
Other III.B. (2–4) 1.6 1.5 0.3 0.3 1.4 1.3
Sources: Estimates in the columns excluding stillbirths come from Mathers, Lopez, and Murray (2006). Estimates in the columns including stillbirths come from Jamison and others (2006), which uses the
estimates from Mathers, Lopez, and Murray (2006) while adding in stillbirths.
Investing in Health | 31
Table 1.A2 The Burden of Disease in Low- and Middle-Income and High-Income Countries and the World, 2001 
(percent)
Low- and Middle-Income High-Income World
DALYsa DALYsSB
b DALYsa DALYsSB
b DALYsa DALYsSB
b
Total DALYs (thousands) 1,387,426 1,260,643 149,161 148,316 1,536,587 1,412,600
Causes of death (percent)
I. COMMUNICABLE DISEASES, 39.8 33.6 5.7 5.4 36.5 30.5
PREGNANCY OUTCOMES, AND 
NUTRITIONAL DEFICIENCIES
A Infectious and parasitic diseases 23.1 21.0 2.3 2.2 21.1 18.9
1 Tuberculosis 2.6 2.8 0.1 0.1 2.3 2.5
2 STIs excluding HIV 0.7 0.7 0.1 0.1 0.6 0.6
3 HIV/AIDS 5.1 5.3 0.4 0.4 4.7 4.8
4 Diarrheal diseases 4.2 2.6 0.3 0.3 3.9 2.6
5 Childhood diseases 3.1 2.4 0.1 0.1 2.8 2.4
a Pertussis 0.8 0.7 0.1 0.1 0.8 0.6
b Poliomyelitis 0.0 0.0 0.0 0.0 0.0 0.0
c Diphtheria 0.0 0.0 0.0 0.0 0.0 0.0
d Measles 1.7 1.5 0.0 0.0 1.5 1.4
e Tetanus 0.6 0.5 0.0 0.0 0.5 0.4
6 Meningitis 0.4 0.4 0.1 0.1 0.4 0.3
8 Malaria 2.9 2.1 0.0 0.0 2.6 1.8
Other I.A. (7, 9–15) 4.1 4.2 1.1 1.1 3.8 4.2
B Respiratory infections 6.3 4.6 1.7 1.7 5.8 4.3
C Maternal conditions 1.9 2.1 0.3 0.3 1.7 1.9
D Perinatal conditions 6.4 3.7 0.9 0.6 5.9 3.4
1 Low birth weight 3.1 1.4 0.3 0.2 2.8 1.5
2 Birth asphyxia and birth trauma 2.3 1.5 0.4 0.4 2.1 1.4
3 Other perinatal conditions 1.1 0.6 0.3 0.3 1.0 0.5
E Nutritional deficiencies 2.1 2.2 0.6 0.6 2.0 2.0
II. NONCOMMUNICABLE CONDITIONS 48.9 52.4 86.7 87.2 52.6 56.4
A Malignant neoplasms 5.4 5.9 17.4 17.4 6.6 7.1
C Diabetes mellitus 1.1 1.3 2.8 2.8 1.3 1.4
E Neuropsychiatric disorders 9.9 10.8 20.9 21.0 11.0 11.9
1 Unipolar major depression 3.1 3.4 5.6 5.7 3.4 3.7
2 Bipolar disorder 0.6 0.7 0.7 0.7 0.6 0.7
3 Schizophrenia 0.8 0.8 0.7 0.8 0.8 0.8
Other II.E. (4–16) 5.4 5.9 13.8 13.9 6.2 6.7
G Cardiovascular disease 12.9 14.2 20.0 20.1 13.6 14.7
3 Ischaemic heart disease 5.2 5.7 8.3 8.4 5.5 6.0
4 Cerebrovascular disease 4.5 5.0 6.3 6.3 4.7 5.1
Other II.G. (1, 2, 5, 6) 3.2 3.5 5.4 5.5 3.4 3.7
H Respiratory diseases 4.2 4.5 6.6 6.6 4.4 4.7
I Digestive diseases 3.8 4.0 4.4 4.4 3.8 4.1
M Congenital anomalies 1.7 1.3 1.0 0.8 1.6 1.3
Other II. (B, D, F, J–L, N) 9.9 10.9 13.7 13.8 10.3 11.2
III. INJURIES 11.2 12.1 7.5 7.5 10.9 11.6
A Unintentional 8.2 8.8 5.3 5.3 7.9 8.4
1 Road traffic accidents 2.3 2.5 2.0 2.0 2.3 2.5
Other III. A. (2–6) 5.9 6.3 3.2 3.3 5.6 6.1
B Intentional 3.1 3.4 2.3 2.3 3.0 3.2
1 Self-inflicted 1.3 1.4 1.7 1.7 1.3 1.4
Other III.B. (2–4) 1.8 2.0 0.5 0.5 1.7 1.8
Sources: Mathers, Lopez, and Murray (2006) provide the reported estimates of DALYs. Jamison and others (2006) provide the estimates for DALYsSB.
a. The burden of disease is measured in DALYs. DALYs form a class of measures that aggregate years of life lost from premature mortality with years of life lost due to disability. The DALYs reported
here are calculated at a 3 percent per year discount rate with no age-weights, i.e. a year of life at any age is valued the same. These are referred to as DALYs (3,0) in the accompaning volume on burden
of disease and risk factors (Lopez and others, 2006).
b. The DALYsSB is analagous to the DALY except that it includes stillbirths in the estimates of burden and assumes a gradual “acquisition of life potential” that allows the burden associated
with a death near the time of birth to grow gradually with age rather than instantaneously increasing from 0 to a high value at birth or some earlier time. Jamison and others (2006) provide the estimates
used here, which they label DALYsSB (3,0,0.54).
of viral pneumonias, for example, would have perhaps hun-
dreds of times the effect of a vaccine against Hanta virus
infection. Thus, information on disease or risk factor burden
is one vital input (of several) to inform research and devel-
opment resource allocation, as discussed in chapters 4 and 5.
6. Allocating resources across health interventions. Here disease
burden assessment often plays a minor role; the task is to
shift resources to interventions, which, at the margin, will
generate the greatest reduction in DALY loss. When there
are major fixed costs in mounting an intervention, as is the
case with political and managerial attention for national
control priorities, burden estimates are required to improve
resource allocation. Likewise, major fixed costs may be asso-
ciated with making the use of an intervention universal (or
expanding it to cover a major percentage of the population),
and if so, the cost-effectiveness of the expansion will depend
in part on the size of the burden.
Results
Tables 1.A1 and 1.A2 convey summaries of deaths by cause and
burden of disease in 2001, respectively.
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In the early 1990s, the World Bank initiated efforts to
understand and disseminate policies to address the remaining
large burden of disease affecting the world’s poor. The World
Bank’s (1993) World Development Report: Investing in Health
reported the results of that assessment, which drew on a
second publication, Disease Control Priorities in Developing
Countries, 1st edition (DCP1) (Jamison and others 1993).
Enormous changes both in the world and in our knowledge
base occurred during the subsequent decade, leading to the
conclusion that a major revision, update, and expansion of
DCP1 would be of value. In a collaborative undertaking, the
World Bank, the World Health Organization, and the Fogarty
International Center of the U.S. National Institutes of Health
sponsored this new effort (DCP2) with substantial financial
support from the Bill & Melinda Gates Foundation. This book
results from that collaboration.
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Deeper understanding of the role of human health as a critical
component of economic development has stimulated interest
in improving the efficiency with which the modest health
resources available in low- and middle-income countries
(LMICs) are spent. In recent years, exponential growth in the
number of economic evaluations of health interventions,
spurred in part by the first edition of this volume (Jamison and
others 1993), has created a wider knowledge base for evaluating
the costs and benefits of interventions to enable better targeting
of financial resources in the health sector (box 2.1). Although
efficient spending on health has always been a desirable goal, it
is particularly critical in the face of recent threats, such as
HIV/AIDS and drug-resistant bacteria, as well as the problems
presented by increasing prevalence of chronic diseases, such
as diabetes and cardiovascular disease (CVD), that threaten to
roll back the significant health gains achieved in the past two
decades. This book is an opportunity to assess anew the costs
associated with and the health gains attainable from specific
interventions and thereby better inform the allocation of new
health funding.
Drawing from the collective knowledge and analytical work
of the many experts who have contributed to this volume,
this chapter provides a broader perspective on the relative effi-
ciency and effect on health of a number of interventions than
is possible in a single, condition-specific chapter.1 The objective
is to provide information on the cost-effectiveness estimates
for 319 interventions covering nearly every disease condition
considered in the volume, and the resulting avertable burden
of disease.2 This chapter provides broad conclusions on the
economic efficiency of using these interventions to improve
health.
PRIORITY SETTING
Information on the costs of purchasing health in conjunction
with regional or national realities regarding disease priorities,
private willingness to pay for health, and public budget con-
straints can be used to identify widely prevalent investments
that are not cost-effective (shaded in figure 2.1) and highly
cost-effective opportunities to improve health that policy mak-
ers are currently neglecting. Throughout the chapter, “not cost-
effective” describes an intervention that has a relatively high
ratio of costs to effectiveness. The information provided also
may be helpful in identifying interventions that are not cost-
effective and are rarely used and cost-effective interventions
that are justifiably widely used (unshaded in figure 2.1). The
broad objective of this exercise is to help improve global popu-
lation health by improving understanding of the implications
of investing in different interventions. Some of the interven-
tions considered are widely prevalent, whereas others are less
well known. Although some interventions are personal, others
are population-based (see annex 2.A for definitions). They
encompass the spectrum of disease conditions covered in this
book but are by no means exhaustive of the universe of possi-
ble interventions.
Chapter 2
Intervention Cost-Effectiveness:
Overview of Main Messages
Ramanan Laxminarayan, Jeffrey Chow, and Sonbol A. Shahid-Salles
Cost-Effectiveness
The specific measure of cost-benefit analysis adopted in this
volume is cost-effectiveness. Effectiveness is measured in
natural units (deaths averted and years of life saved) and in
disability-adjusted life years (DALYs), a composite measure
that combines years lived with disability and years lost to pre-
mature death in a single metric (see chapter 15 for an explana-
tion of how DALYs are calculated). Nevertheless, dollars per
DALY averted can at best be only one consideration in the allo-
cation of resources to different diseases and interventions. This
chapter also focuses on the total burden of disease avertable by
expanding population coverage of an intervention. The deliv-
ery of many interventions, including those that are relatively
cost-effective, may require a certain degree of institutional and
organizational capacity on the part of a health system, and
countries will have to pay attention to this important consider-
ation.3 These factors, in combination with other considerations
such as equity, social justice, medical suitability, and epidemio-
logical appropriateness, should guide where money may be
spent most effectively (Cookson and Dolan 1999, 2000).
Cost-effectiveness ratios can be used to set health priorities
in two ways. One approach is to use a cutoff level of cost-
effectiveness beyond which interventions are no longer used.
This cutoff can vary from place to place depending on the
availability of health resources, the disease burden, and the
local preferences for health spending. The World Bank has
described health interventions that cost less than US$100 per
year of life saved as highly cost-effective for poor countries, but
this benchmark is arbitrary, as chapter 15 makes clear by not-
ing the interaction with income, budget levels, and the disease
burden (Jamison and others 1993).
An alternative approach to using cost-effectiveness data to
set intervention priorities is to interpret the cost-effectiveness
ratio as the “price” of equivalent units of health using different
interventions (box 2.2 explains this approach). Reinterpreted
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Use of Cost-Effectiveness to Set Policy: The Directly Observed Treatment Strategy 
Box 2.1
Nearly 2 million people die from tuberculosis (TB) each
year, 98 percent of whom live in developing countries and
most of whom are 15 to 49 years old. Meanwhile, anti-TB
medicines are 95 percent effective in curing TB, even in
low-income countries, and cost as little as US$10 for a 
six-month course of treatment or directly observed ther-
apy short course (DOTS). The TB chapter of the first edi-
tion of this book (Murray, Styblo, and Rouillon 1993) and
studies by Joesoef, Remington, and Jiptoherijanto (1989)
and Kamolratanakul and others (1993) describe treatment
of smear-positive TB with short-course chemotherapy as
an extremely cost-effective intervention for TB.
Since 1980, the World Health Organization (WHO) has
collaborated closely with many countries in East Asia and
the Pacific to introduce short-course chemotherapy and
then the DOTS strategy to achieve global targets, with a
cure rate of 85 percent and a case-detection rate of 70 per-
cent. In 1990, 10 countries were using short-course
chemotherapy. In 1993, as a result of growing TB preva-
lence rates, WHO’s declaration of a global emergency,
and studies showing DOTS’ cost-effectiveness, the DOTS
strategy was established worldwide as the most effective
response to TB. By 1995, DOTS had expanded to 73 coun-
tries, and by 2003, it had reached more than 180 countries
worldwide (WHO 2004).
As of 1999, DOTS has been implemented with the col-
laboration of WHO in 13 provinces of China and has
achieved a cure rate of 90 percent. The population in East
Asia and the Pacific with access to DOTS increased from
44 percent in 1995 to 57 percent in 1997, with the propor-
tion of registered TB patients who are enrolled in a DOTS
program also increasing, from 30 percent in 1995 to
46 percent in 1997 (WHO 1999). The progress is mainly
attributable to high-prevalence countries in the region,
which include Cambodia, China, and the Philippines.
By 2002, national TB programs reported that 69 per-
cent of the world’s population lived in countries or parts
of countries with DOTS coverage. DOTS programs
treated a total of 13.3 million TB patients and 6.8 million
smear-positive patients between 1995 and 2002.
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A Framework for Using Cost-Effectiveness Information to Set Health Priorities
Box 2.2
A frequent, often justified, criticism of cost-effectiveness
analyses is that they address only one of many criteria
that could be used to evaluate health interventions.
Epidemiological, medical, political, ethical, and cultural
factors often also play important roles in the decision to
allocate resources to a specific health condition or inter-
vention; however, determining how one might weigh cost-
effectiveness ratios alongside these other considerations
when setting priorities for spending is difficult. Musgrove
(1999) shows how to take some of these connections
into account, including circumstances in which cost-
effectiveness is an adequate criterion by itself. One
approach is for the policy maker to think of cost-
effectiveness ratios as the relative “price” of purchasing a
unit of health (a DALY, for instance) using different inter-
ventions. These costs, along with the budget constraint, can
help determine the optimal allocation of resources among
a given set of interventions.
Consider, for instance, a policy maker in a country in
Sub-Saharan Africa facing the choice between treating
Parkinson’s disease and expanding malaria treatment pro-
grams while constrained by a fixed budget allocated by the
ministry of finance. The cost per DALY averted of treating
Parkinson’s disease using carbidopa is vastly greater than
that for the malaria control program. A simplistic interpre-
tation of the cost-effectiveness information would be to
expand the malaria treatment program to the maximum
extent possible before turning to the treatment of
Parkinson’s disease. This solution could be desirable in
some situations, particularly if the budget is large enough to
deal fully with the malaria problem and still allow for some
treatment of Parkinson’s. Emphasizing as complete cover-
age as possible of a particular problem may be especially
appropriate in an epidemic situation, in which turning to
another disease first can mean the epidemic will be worse in
the future. Devoting some resources to each problem
instead of concentrating on either may be more sensible
when neither presents the threat of a growing epidemic.
Asking policy makers to make a binary choice between
two sets of interventions on the basis of cost-effectiveness
ratios alone may be unrealistic and misleading. Rather, pol-
icy makers should first determine their willingness to trade
off health improvements in children (malaria) versus the
elderly (Parkinson’s). Policy makers may want to avert at
least some burden from Parkinson’s even if these cases are
relatively expensive to treat for each unit of health gained
because of such considerations as the target age group, the
socioeconomic status of target populations (including the
extent to which they can obtain treatment from their own
resources), and the ministry of health’s ability to deliver
the program effectively. After the tradeoffs have been made
and can be represented by an indifference curve (see the
figure and explanation), the cost-effectiveness information
is useful in determining how much of the policy makers’
fixed budget should be allocated to each intervention—
that is, at what coverage of one problem should they start
devoting resources to the other? The indifference curve
represents health planners’ willingness to trade off between
investment in antimalarial drugs and treatment for
Parkinson’s based on all the relevant factors and independ-
ent of the budget constraint.
DALYs gained
from treating
Parkinson’s
disease 
X
Y
DALYs gained from
treating malaria 
The solid line represents the budget, and its slope is the
ratio of the cost-effectiveness ratios of the two interven-
tions. The dashed line represents an alternative scenario in
which the cost-effectiveness of treating Parkinson’s is bet-
ter (more DALYs can be gained) than the ratio represented
by the solid line. The axes show how many DALYs can be
gained from each treatment, so a large number of DALYs
corresponds to a low “price” of health or cost per DALY.
The figure shows the simple case, in which these prices are
constant for either budget line—that is, expanding either
program does not raise the unit cost—although this case is
unlikely when part of the population is difficult to reach, is
harder to treat, or has more severe disease, in which case
the rise in unit cost means that an intervention becomes
relatively less cost-effective, giving a further reason to start
devoting resources to an alternative intervention.
When the price of buying a unit of health to treat
Parkinson’s is relatively high in terms of cost per DALY
averted, the relatively flat (solid) budget line applies, and the
optimal balance of investment in the two interventions is at
this way, there is no one-dimensional economic criterion that
interventions must attain to be declared economically fit, and
cost-effectiveness plays the more useful function of informing
tradeoffs that policy makers are forced to make when investing
in a portfolio of health interventions.
Target Audiences
The general notion of efficiency in how resources, both public
and private, are spent on improving health is of interest not
only to severely resource-constrained countries that each year
spend only a few public dollars on health for each individual,
but also to relatively wealthier nations with many competing
priorities for public and private resources. The primary audi-
ences for cost-effectiveness information are ministries of health
and finance and policy makers in other branches of govern-
ment in LMICs, both to help reallocate existing outlays in the
health sector and to allocate new monies efficiently. Other
audiences include aid agencies, international development
lending institutions, nongovernmental organizations, and pri-
vate health care providers.
Priority Setting in the Private Sector
The use of the efficiency criterion in priority setting should not
be limited to public resources. A large proportion of health care
in developing countries is paid for out of pocket, and greater
clarity on interventions that are efficient from an economic
perspective is no less urgent when the payer is private: ineffi-
cient private spending on health care in developing countries is
wasteful as well. Much of this inefficiency may be attributed to
significant differences in knowledge—termed information
asymmetries—between profit-making providers and patients.
Private providers may encourage unnecessary procedures and
excessively invasive procedures that, in some instances, can be
more dangerous than no treatment at all. Governments have a
role to play in lowering these information asymmetries, partly
by providing information to populations, for instance, on the
importance of childhood vaccinations. Moreover, even if gov-
ernment expenditures are not directly influenced by the lack of
efficiency in privately delivered health care, they are affected by
the inefficiency of private health systems if private patients seek
public emergency care or require other state assistance. In their
role as large purchasers of health care, governments—even in
largely privately financed health care systems, such as in the
United States—exercise enormous influence over the choices of
drugs used and interventions provided and can play an impor-
tant role in promoting policies to facilitate greater efficiency in
health care systems.
The costs and efficacy of interventions may vary greatly,
even within a single geographical region, depending on local
health system capacity, cultural context, disease epidemiology,
and a host of other factors. Greater efficiency in how countries
spend their health care resources can have a tremendous effect
on the health of their populations. Box 2.3 discusses gains from
improved priority setting found in the lifesaving study by
Harvard University (Tengs 1997; Tengs and others 1995).
METHODOLOGY
This chapter compares the cost-effectiveness of interventions
that cover a broad spectrum of health conditions prevalent in
developing countries. All results are presented in U.S. dollars
discounted to the year 2001 using a 3 percent annual discount
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point X. If the cost of buying a unit of health to treat
Parkinson’s is relatively low, then the steeper (dashed)
budget line applies and the relative allocation of resources is
represented by point Y. Therefore, policy makers would
allocate relatively more resources to treating Parkinson’s
when the price of buying a unit of health through this inter-
vention is relatively low, and they would allocate fewer
resources when the price of health obtained through this
intervention is relatively high. The figure shows the general
likely shape of an indifference curve, but one possibility is
that policy makers’ willingness to trade off between buying
health from the two approaches is just a straight line, in
which case they would want to invest the maximum amount
possible in the lower-cost intervention (malaria) before
turning to the higher-cost intervention (Parkinson’s). The
role of the cost-effectiveness information is to make policy
makers aware of differences in the price of improving health
using different interventions. Interventions with a high
price should, all else being equal, be used less, whereas those
with a low price should be used to a greater extent.
Continued
Box 2.2
rate. Chapter 15 summarizes the general guidelines governing
the analysis leading to the results reported for all LMICs.
Regional Variations
Where possible and appropriate, intervention cost-effectiveness
ratios and other information have been disaggregated by World
Bank region. In discussing the estimates, this chapter focuses
on differences in the costs of interventions rather than on
differences in their effectiveness in specific regional settings,
although both contribute to differences in cost-effectiveness
estimates across regions. Cost-effectiveness estimates also differ
among regions because of variations in underlying mortality,
age structure, disease prevalence, and efficiency with which
interventions are implemented. The analyses take all but the
last of these considerations into account.
Interregional cost differences are attributable to differences
in the local costs of goods and services that are not easily trad-
able. For components that are tradable, such as patented drugs
and specialized medical equipment typically imported from
industrial nations, the analyses assume uniform international
costs for all LMICs, usually adjusted for local transportation
and distribution costs. By using a single composite set of
resource costs for each region, the analyses mask intraregional
differences in the costs of nontradable goods, such as physician
time or hospitals, but this methodology is appropriate because
results are presented only at the level of the region.4
Interventions may differ in cost-effectiveness because they are
targeted more appropriately to some age groups rather than
others, and important gender differences may also exist in cost-
effectiveness for some conditions, but data to estimate such
differences are lacking.
Caveats
The findings in this chapter are subject to a number of caveats.
First, despite efforts to ensure the consistency of cost-
effectiveness numbers across chapters, the approaches taken in
arriving at these numbers vary significantly. Although some
chapters rely on cost-effectiveness numbers drawn from the
literature, other chapters have analyzed these numbers afresh
using the standardized resource costs described elsewhere.
Table 2.1 contains definitions of indicators used to assess the
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The Harvard Lifesaving Study 
Box 2.3
A study by Harvard University in the United States
showed potential gains of life years saved by choosing
interventions on the basis of their cost-effectiveness. The
study’s authors assessed more than 500 types of lifesaving
interventions, defined as any behavioral or technological
strategy that reduces the probability of premature death
among a specified target population. The study focused on
185 interventions and the extent to which each interven-
tion was currently being implemented, without taking its
cost-effectiveness into account.
The authors estimated that the selected 185 interven-
tions would cost US$21.4 billion per year and would save
592,000 life years. The same amount of money could have
saved another 636,000 life years had funds been redirected
from less to more cost-effective interventions. Following
an assessment of varying factors regarding interventions—
those that affect the most people and are the most effective,
least cost, and most cost-effective—the study reports that
if the goal is to save the most life years, cost-effectiveness is
a useful approach that will result in the most efficient allo-
cation of resources. The study indicates that choosing the
most cost-effective interventions could double the life
years saved.
Sources: Tengs 1997; Tengs and others 1995.
Table 2.1 Quality of Cost-Effectiveness Evidence for
Interventions
Level Source of cost-effectiveness evidence 
1 Literature review of one cost-effectiveness study in one country
2 Literature review of several cost-effectiveness studies for multiple
countries
3 Literature review of several cost-effectiveness studies for a single
intervention in a single region
4 Original economic analysis by authors following the volume editors’
guidelines in one country
5 Original economic analysis by authors following the volume editors’
guidelines in one region 
Source: Authors.
Note: Standard region-specific age structures and underlying mortality rates were used to calcu-
late DALYs. Nontradable inputs were converted into U.S. dollars at the market exchange rate. The
costs of tradable inputs were assumed to be internationally consistent, as were the costs associ-
ated with surgical treatments.
quality of evidence on which the cost-effectiveness estimates
are based. The tables in annex 2.B and annex 2.C indicate the
quality of evidence associated with each intervention.
Second, almost without exception, the cost-effectiveness
numbers do not vary with the scale at which the intervention
is undertaken, and this is probably not the case in reality
(Birch and Donaldson 1987; Johns and Torres 2005). Some
interventions, such as vaccination programs, have large setup
costs but marginal costs of extending coverage that decline at
least initially. Other interventions, such as educational cam-
paigns for condom use, may be easy to target to urban popula-
tions, but the marginal costs of expanding such interventions
to relatively inaccessible populations increase with coverage.
Therefore, many of the cost-effectiveness ratios presented here
are useful only for modest increments in coverage, and separate
analyses may have to be conducted to determine their applica-
bility to program start-ups and larger-scale intervention
changes.
Third, the cost-effectiveness numbers presented apply to
countries whose institutional and technical capacity in relation
to health is close to the average for the region. This evaluation
is restricted to what countries could do more (or less) of,
and clearly a more ambitious analysis would also cover what
countries could do better. This issue is discussed in detail in
chapters 3 and 70.
Finally, the estimates are based on the best available data,
which in many cases are somewhat weak. Statistically derived
confidence bounds for the cost-effectiveness estimates are not
provided, and in most cases, uncertainty analysis has not been
carried out. Readers are encouraged to pay attention to the
order of magnitude of each estimate rather than to the specific
number presented.
ASSESSING THE EVIDENCE ON THE 
COST-EFFECTIVENESS OF INTERVENTIONS 
Figures 2.2 and 2.3 display results gathered from other chapters
on cost-effectiveness ratios. In some cases, interventions are
grouped on the basis of their similarity and whether they were
personal interventions or population-based interventions. For
instance, all population-based programs to prevent HIV trans-
mission via contaminated blood and needles were grouped as
a single intervention. Note that the cost-effectiveness ranges
should not be interpreted as statistical confidence intervals but
rather as a range of “best estimates” of cost-effectiveness incor-
porating variation across interventions included in the cluster.
Ranges for the cost-effectiveness ratios are also attributable to
variations in the epidemiological settings in which these inter-
ventions were evaluated. For example, a population-based pri-
mary intervention in an area of low prevalence is likely to be
less cost-effective than the same intervention in a region of
high prevalence. Figure 2.2 reflects sets of interventions dealing
with high-burden diseases, and figure 2.3 deals with relatively
low-burden diseases.
Within each figure, intervention clusters are displayed in the
order of increasing cost-effectiveness. Additional information
on the setting, objective, and target population of each interven-
tion cluster for which cost-effectiveness has been calculated is
provided in annex 2.B. The tables in annex 2.B also provide
information on the quality of the evidence on which the data
presented are based. Furthermore, the annex tables present
information on potentially avertable deaths and DALYs if the
coverage of these interventions were expanded by a further
20 percentage points of the relevant population (scaling up from
62 percent means reaching 82 percent,not 74 percent,of the per-
tinent population). Care should be taken not to confuse this
information with the current burden of the underlying disease,
on which basis interventions were divided into high-burden
and low-burden diseases (figures 2.2 and 2.3, respectively).5 For
example, a cost-effective treatment for CVD has only limited
scope for increased scale of intervention in countries with a low
burden of this disease. At the same time, in many parts of Asia
and Sub-Saharan Africa, even though HIV treatment is not a
highly cost-effective intervention, it deserves attention because
of its sizable potential for lowering the disease burden.
The tables in annex 2.C summarize information on inter-
vention clusters for which cost-effectiveness was evaluated with
a metric other than DALYs. For these interventions too, details
of setting, objective, target population, and quality of the evi-
dence have been provided. Given the difficulty in comparing
these intervention clusters with those evaluated using DALYs,
they are excluded from figures 2.2–2.5.
Observations about specific interventions follow. Ranges of
cost-effectiveness estimates shown reflect geographical varia-
tions across regions.
Prevention and Control of Tuberculosis 
The treatment of all forms of active tuberculosis (TB) using the
directly observed treatment strategy based on short-course
chemotherapy is among the most cost-effective of all interven-
tions available to improve health in LMICs (US$5 to US$35 per
DALY averted except in Europe and Central Asia) (box 2.1).
The bacillus Calmette-Guérin (BCG) vaccination for children
is also cost-effective (US$40 to US$170 per DALY averted), but
its main effect is to reduce the burden of severe TB in children
(TB meningitis and miliary TB). Because BCG has relatively
little effect on the huge burden of pulmonary TB in adults—
which constitutes the major cause of ill health resulting from
Mycobacterium tuberculosis—development of a new vaccine
that targets adults is highly desirable. The treatment of latent
TB in patients uninfected with HIV is relatively cost-ineffective
(US$4,000 to US$25,000 per DALY averted), but it is more
cost-effective for groups of patients who are coinfected with TB
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Note: Diseases were considered high burden for LMICs if their total avertable burden was greater than 35 million DALYs. Bars represent the range in point estimates of cost-effectiveness ratios for specific interventions included in each
intervention cluster and do not represent variation across regions or statistical confidence intervals. Point estimates for LMICs were obtained directly from the relevant chapters, calculated as the midpoint of range estimates reported in
the chapters, or calculated from a population-weighted average of the region-specific estimates reported in the chapters. For details of these intervention clusters, including the specific interventions covered in each, see annex tables 2.B.1
and 2.B.2. Only interventions with cost-effectiveness reported in terms of DALYs are included in this figure. For interventions with cost-effectiveness reported in other units, see annex tables 2.C.1 and 2.C.2.
a.  Nonprice interventions for tobacco addiction include advertising bans, smoking restrictions, supply reduction, and information dissemination.
b.  EPI = Expanded Program on Immunization.
c.  Chloroquine as first-line drug, artemisinin combination therapy as second-line drug and sulfadoxine-pyrimethamine as first- or second-line drug.
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Diarrheal disease:  hygiene promotion
Emergency medical care: training volunteer paramedics with lay first responders
Malaria: intermittent preventive treatment in pregnancy with drugs other than sulfadoxine-pyrimethaminec
Tuberculosis, diphtheria-pertussis-tetanus, polio, measles: traditional EPIb
Malaria: insecticide-treated bed nets
Myocardial infarction: acute management with aspirin and beta-blocker
Malaria: residual household spraying
Malaria: intermittent preventive treatment in pregnancy with sulfadoxine-pyrimethamine
Tobacco addiction: taxation causing 33% price increase
HIV/AIDS: peer and education programs for high-risk groups
Childhood illness: integrated management of childhood illness
Underweight child (0-4 years): child survival program with nutrition
Diarrheal disease: water sector regulation with advocacy where clean water supply is limited
HIV/AIDS: voluntary counseling and testing
Coronary artery disease: legislation substituting 2% of trans fat with polyunsaturated fat at US$0.50 per adult
HIV/AIDS: sexually transmitted infections diagnosis with treatment
Tuberculosis (endemic): BCG vaccine
HIV/AIDS: condom promotion and distribution
HIV/AIDS: blood and needle safety
Tuberculosis (epidemic, infectious): directly observed short-course chemotherapy
Emergency medical care: staffed community ambulance
HIV/AIDS: tuberculosis co-infection prevention and treatment
Problems requiring surgery: surgical ward or services in district hospital or community clinic
Diarrheal disease: construction and promotion of basic sanitation where facilities are limited
Stroke (ischemic): acute management with aspirin
Congestive heart failure: angiotensin-converting enzyme inhibitor and beta-blocker, with diuretics
HIV/AIDS: opportunistic infection treatment
Diarrheal disease: hand pump, standpost, or house connection where clean water supply is limited
HIV/AIDS: mother-to-child transmission prevention
Tuberculosis (epidemic, latent): isoniazid treatment
Tuberculosis (epidemic): management of drug resistance
Haemophilus influenzae type B, hepatitis B, diphtheria, pertussis, and tetanus: pentavalent vaccine
Tuberculosis (endemic, infectious or noninfectious): directly observed short-course chemotherapy
Tuberculosis (endemic): management of drug resistance
Tobacco addiction: nonprice interventionsa
Tobacco addiction: nicotine replacement therapy
Lower acute respiratory infection (0-4 years): case management package at community, facility, and hospital levels
Alcohol abuse: advertising ban and reduced access to beverage retail
Myocardial infarction and stroke: secondary prevention with polypill
Alcohol abuse: excise tax, advertising ban, with brief advice
Alcohol abuse: brief advice by primary health care doctor
Myocardial infarction: acute management with streptokinase, with aspirin and beta-blocker
HIV/AIDS: home care
Ischemic heart disease: aspirin, beta-blocker, with optional angiotensin-converting enzyme inhibitor
Coronary artery disease: legislation substituting 2% of trans fat with polyunsaturated fat at US$6 per adult
HIV/AIDS: antiretroviral therapy
Diarrheal disease: breastfeeding promotion
Diarrheal disease: oral rehydration therapy for package costing US$5.50 per episode
Alcohol abuse: 25-50% increase in excise tax rate
Depression: drugs with optional episodic or maintenance psychosocial treatment
Diabetes, ischemic heart disease, and stroke: legislation with public education to reduce salt content
Stroke (ischemic): acute management with heparin and recombinant tissue plasminogen activator
Ischemic heart disease: statin, with aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor
Stroke and ischemic and hypertensive heart disease: polypill by absolute risk approach
Diabetes, ischemic heart disease, and stroke: media campaign to reduce saturated fat
Diarrheal disease: cholera or rotavirus immunization
Diarrheal disease: improved water and sanitation at current coverage of amenities and other interventions
Tuberculosis (endemic, latent): isoniazid treatment
Myocardial infarction: acute management with tissue plasminogen activator, with aspirin and beta-blocker
Ischemic heart disease: coronary artery bypass graft
HIV/AIDS: treatment of Kaposi’s sarcoma
Cost-effectiveness ratio (US$ per DALY averted)
Figure 2.2 Cost-Effectiveness of Interventions Related to High-Burden Diseases in LMICs
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Note: Diseases were considered low burden for LMICs if their total avertable burden was less than 35 million DALYs. Bars represent the range in point estimates of cost-effectiveness ratios for specific interventions included in each
intervention cluster and do not represent variation across regions or statistical confidence intervals. Point estimates for LMICs were obtained directly from the relevant chapters, calculated as the midpoint of range estimates reported
in the chapters, or calculated from a population-weighted average of the region-specific estimates reported in the chapters. For details of these intervention clusters, including the specific interventions covered in each, see annex
tables 2.B.1 and 2.B.2. Only interventions with cost-effectiveness reported in terms of DALYs are included in this figure. For interventions with cost-effectiveness reported in other units, see annex tables 2.C.1 and 2.C.2. 
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Soil-transmitted helminths: albendazole
Measles: second opportunity vaccination in a fixed facility
Leishmaniasis: case finding with treatment
Down syndrome: prenatal screening with option of pregnancy termination
Traffic accidents: increased speeding penalties, enforcement, media campaigns, and speed bumps
Onchocerciasis: treatment with ivermectin
Adolescent health and nutrition: school health and nutrition programs
Trachoma: trichiasis surgery
Zinc deficiency (0-4 years): supplements with oral rehydration salts
Stroke: secondary prevention with aspirin and dipyridamole
Epilepsy: first-line treatment with phenobarbital
Unwanted pregnancies: family-planning programs
Lower acute respiratory infection (0-4 years): case management of non-severe cases at community or facility level
Cataract: extracapsular surgery
Undernutrition and malnutrition (0-4 years): sustained child health and nutrition package
Dengue: improved case management
Haemophilus influenzae type B: H. influenzae type B-containing vaccine
Panic disorder: drugs with optional psychosocial treatment
Parkinson's disease: ayurvedic treatment and levodopa or carbidopa
Tetanus: tetanus toxoid vaccination, mix of strategies
Dengue: immunization
Stroke: secondary prevention with carotid endarterectomy
Traffic accidents: enforcement of seatbelt laws, promotion of child restraints, and random driver breath testing
Dengue: vector control
Epilepsy: second-line treatment of phenobarbital with lamotrigine or surgery
Bipolar disorder: lithium, valproate, with optional psychosocial treatment, community-based
Bipolar disorder: lithium, valproate, with optional psychosocial treatment, hospital-based
Lower acute respiratory infection (0-4 years): case management of severe and very severe cases at hospital level
Trachoma: tetracycline or azithromycin treatments
Schizophrenia: antipsychotic drugs with optional psychosocial treatment, community-based
Schizophrenia: antipsychotic drugs with optional psychosocial treatment, hospital-based
Hepatitis B: vaccination
Parkinson's disease: levodopa or carbidopa with deep brain stimulation
Figure 2.3 Cost-Effectiveness of Interventions Related to Low-Burden Diseases in LMICs
and HIV. In the context of TB control, antiretroviral therapy
for HIV/AIDS is likely to be useful in extending the lives of
patients successfully treated for TB.
Multidrug-resistant TB is much more expensive to treat than
drug-susceptible TB—2 to 10 times the cost of standard first-
line regimens for drug-susceptible TB—and this is one reason
why priority should be given to preventing its emergence and
spread. The management of drug resistance through the use of
a standardized regimen that includes second-line drugs costs
roughly US$70 to US$450 per DALY averted. Individualized
treatment regimens for multidrug-resistant TB—that is, with
drug combinations adjusted to the resistance pattern of each
patient—are more costly but usually yield higher cure rates.
Individualized treatment is harder to implement on a large scale
but may not be less cost-effective than standardized treatment
with regimens that include second-line drugs. The set of
interventions needed to manage drug-resistant TB and TB
associated with HIV requires higher levels of investment than
the basic directly observed treatment strategy, but its cost is still
typically less than US$1 for each day of healthy life gained.
Thus, a strong economic argument exists for integrating such
interventions into an enhanced strategy for TB control.
Prevention and Treatment of HIV/AIDS 
Despite the scale and relentless progression of the HIV/AIDS
epidemic, important strides have been made in developing
cost-effective interventions for both prevention and treatment.
Prevention. Although remarkably little rigorous evaluation
has been conducted, population-based programs to prevent
HIV/AIDS appear to be highly cost-effective approaches in
countries with high HIV/AIDS prevalence where the epidemic
is generalized. These programs include voluntary testing and
counseling (US$14 to US$261 per DALY averted); peer-based
programs to educate high-risk groups, including sex workers
and injecting drug users (US$1 to US$74 per DALY averted);
and social marketing, promotion, and distribution of condoms
(US$19 to US$205 per DALY averted). Programs to improve
blood and needle safety, while highly cost-effective (US$4 to
US$51 per DALY averted), are limited in terms of the burden of
disease they can avert.
Prevention of mother-to-child transmission using a single
dose of nevirapine in generalized epidemic settings (US$6 to
US$12 per DALY averted) stands out for its combination of well-
documented high cost-effectiveness and significant avertable
infections and deaths. Treatment of sexually transmitted
infections to lower the risk of HIV transmission, although less
well proven, also appears to be highly cost-effective (US$16 to
US$105 per DALY averted).
Treatment. For care of people living with HIV/AIDS,
treatment of most infectious opportunistic infections is cost-
effective (US$10 to US$500 per DALY averted), with treatment
becoming significantly more cost-effective for patients who
also have access to antiretroviral treatment. Few studies evalu-
ate the cost-effectiveness of providing antiretroviral treatment,
and even these are limited to clinical trial settings and are not
directly applicable to the resource-poor settings in which anti-
retroviral treatment is being expanded. Economic evaluation of
the cost-effectiveness of antiretroviral treatments based only on
health outcomes for the treated patient is incomplete because
of the large nonhealth impacts of HIV/AIDS and the effect of
treatment on prevention of HIV transmission.
The cost-effectiveness of antiretroviral treatments is highly
variable across settings as a function of drug prices and adher-
ence rates. In low-cost settings with high adherence rates, anti-
retroviral treatment is moderately cost-effective (US$350 to
US$500 per DALY averted); however, it can be a significantly
poor value for resources spent in low-adherence settings if drug
resistance is allowed to emerge and proliferate. Little is known
about how to achieve necessary adherence levels (80 to 90 per-
cent) at large scale at an affordable cost in low-income settings.
To this end, research on effective, low-cost interventions to
achieve long-term adherence to antiretroviral treatments
(using support groups and other complementary interven-
tions) in resource-poor settings is an urgent priority.
Childhood Illnesses and Mortality among 
Children under Five
Neonatal mortality rates and mortality rates for children under
five can be reduced by large margins, at an affordable cost, by
using interventions proven effective in low-income settings.
Improvements are likely to come from increasing the coverage
of preventive measures, such as breastfeeding, and from
expanding the scope of existing childhood vaccines beyond the
traditional six antigens in areas where existing coverage is rela-
tively high and where new antigens address diseases of signifi-
cant burden, particularly pneumococcal vaccines. Curative
interventions—including case management of acute respira-
tory infections, malaria, and diarrhea—hold promise for lower-
ing the 6 million preventable deaths each year in this age
group.
Neonatal Mortality. An estimated 4 million deaths occur dur-
ing the first 28 days of life, accounting for 38 percent of all
deaths of children under five. Causes include infections (36 per-
cent, including neonatal sepsis, pneumonia, diarrhea, and
tetanus), preterm birth (27 percent), and asphyxia (23 percent).
Intensive care is not required to save most of these babies.
Developed countries and some low-income countries—for
instance, Sri Lanka—have achieved neonatal mortality rates of
15 per 1,000 without intensive care, which is less than a third of
current neonatal mortality rates in Sub-Saharan Africa.
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Adding a set of community-based interventions—including
promoting healthy behaviors, such as breastfeeding, and
providing extra care of moderately small babies at home
through cleanliness, warmth, and exclusive breastfeeding, plus
community-based management of acute respiratory infec-
tions—to the standard maternal and child health package is
likely to be highly effective. The cost of a year of life saved using
this approach could be as low as US$100 to US$257 in India
(US$221 to US$568 per DALY averted) and US$100 to US$270
in Sub-Saharan Africa (US$183 to US$493 per DALY averted).
Use of these approaches is feasible now in most countries.
Adding a clinical package that includes essential newborn care
(warmth, cleanliness, and immediate breastfeeding); neonatal
resuscitation; facility-based care of small newborns; and emer-
gency care of ill newborns to the maternal and child health
package has been shown to be highly cost-effective in India
(US$11 to US$265 per year of life saved, or US$24 to US$585
per DALY averted) and Sub-Saharan Africa (US$25 to US$360
per year of life saved, or US$46 to US$657 per DALY averted);
however, clinical care will require significant initial investment
to raise coverage.
Basic resuscitation of newborns using a self-inflating bag
that is available for as little as US$5 in LMICs can save lives at
low cost in areas where a midwife is available. Providing two
tetanus toxoid immunizations costing less than US$0.20 each
to all pregnant women would avert more than 250,000 deaths
at low cost and is eminently achievable. Improving maternal
and child health services delivered through a combination of
family- and community-level care, outreach, and clinical care
will improve the survival of newborns and children and reduce
stillbirths and maternal deaths.
Vaccinations. Childhood vaccinations, long recognized as
among the most cost-effective uses of limited health resources
in low-income countries, prevented more than 3 million
deaths in 2001. National immunization programs traditionally
have included vaccines against TB, diphtheria, tetanus, pertus-
sis, poliomyelitis, and measles at a cost per fully immunized
child of US$13 to US$24, depending on coverage levels and
type of delivery strategy. The total cost in developing countries
for national programs in 2001 ranged from US$717 million to
US$1.4 billion, with an estimated cost per death averted rang-
ing by region from under US$275 (under US$10 per DALY
averted) in Sub-Saharan Africa and South Asia to US$1,754
(US$20 per DALY averted) in Europe and Central Asia.
The cost-effectiveness of scaling up immunization coverage
with the traditional Expanded Program on Immunization
(EPI) vaccines is highly dependent on the underlying preva-
lence of illness, starting coverage levels and trajectories, and
mix of delivery strategies (whether facility-based strategies,
campaigns, or mobile and outreach modalities). The cost per
death averted varies by region, from US$162 in Africa to more
than US$1,600 in Eastern Europe. Cost-effectiveness ratios are
less than US$20 per DALY averted in all regions other than
Europe and Central Asia. The cost-effectiveness of the tetanus
toxoid vaccine also varies widely by region from under US$400
per death averted and under US$14 per DALY averted in Sub-
Saharan Africa and South Asia to more than US$190,000 per
death averted and more than US$15,000 per DALY averted in
Europe and Central Asia.
Adding additional antigens to national programs has been
successfully accomplished in many countries. Expanding the
vaccination schedule to include a second opportunity for
measles through either routine or campaign-based approaches
costs between US$23 and US$228 per death averted and under
US$4 per DALY averted in regions other than Europe and
Central Asia. Other new vaccines are less cost-effective because
of their high unit costs per dose, but they may be worthwhile,
especially in regions of high disease prevalence. For instance,
the pentavalent vaccine (diphtheria, pertussis, tetanus,
hepatitis B, and Haemophilus influenzae type B) was estimated
to have a cost per death averted ranging from US$1,433 to
greater than US$40,000 and cost-effectiveness of US$42 per
DALY averted in Sub-Saharan Africa and greater than US$245
per DALY averted in other regions. The cost of adding a yellow
fever vaccine ranges from US$834 per death averted and US$26
per DALY averted in Sub-Saharan Africa to US$2,810 per death
averted and US$39 per DALY averted in Latin America and the
Caribbean.
Because certain regions and countries contain the largest
burden of disease, such as measles in India and Nigeria, target-
ing scarce public health resources to those geographic areas
could potentially yield high returns to investment. Although
immunization may have relatively low incremental cost-
effective ratios, the total budget requirements for maintaining
or increasing coverage rates, as well as for introducing new
vaccines, can account for a large share of government health
budgets.
The cost-effectiveness ratios of vaccination interventions
presented here are based on estimates of their current costs
and effectiveness; but they could change substantially with
changing costs and the development of new interventions. For
instance, multivalent pneumococcal conjugate vaccines have
shown the potential to reduce the incidence of invasive pneu-
mococcal disease while lowering the need for antibiotic use and
the likelihood of drug resistance. The current price of these
vaccines makes them expensive to most people in the develop-
ing world. However, with future price decreases, these vaccines
could be adopted widely and could markedly lower the impact
of the most common causes of morbidity and mortality in
children under five (excluding the neonatal period). Moreover,
new vaccines being developed could be included in the EPI
schedule, including vaccines that protect against rotavirus,
malaria, human papilloma virus associated with cervical
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cancer, HIV/AIDS, and dengue. With future demonstrations of
reasonable cost-effectiveness, these vaccines could become a
component of the set of attractive interventions.
Acute Respiratory Infections. Even though vaccination
strategies can be cost-effective in lowering the disease burden
related to acute respiratory infections, case management may
also be an efficient use of financial resources, although more
demanding of health system capacity. Moreover, community
case management and case management at a health care facil-
ity may be of comparable cost-effectiveness. In fact, treating
nonsevere pneumonia at health care facilities using a combina-
tion of oral antimicrobials and acetaminophen (US$24 to
US$424 per DALY averted) is more cost-effective than a similar
treatment administered at home by a health care worker
(US$139 to US$733 per DALY averted). Treating severe pneu-
monia in a hospital facility is more expensive (US$1,486 to
US$14,719 per DALY averted).
Diarrheal Disease. Among interventions against diarrheal
disease during the first year of life, breastfeeding promotion
programs (US$527 to US$2,001 per DALY averted), measles
immunization (US$257 to US$4,565 per DALY averted), and
oral rehydration therapy (US$132 to US$2,570 per DALY
averted) are relatively cost-effective compared with rotavirus
immunizations (US$1,402 to US$8,357 per DALY averted) and
cholera immunizations (US$1,658 to US$8,274 per DALY
averted). The cost-effectiveness of oral rehydration therapy
is extremely sensitive to the cost of the package. The cost-
effectiveness of this intervention can be as low as US$132 per
DALY averted for an assumed cost per child of US$0.70. An
important reason for the relatively unfavorable cost-
effectiveness ratios for diarrheal disease is that significant
reductions in mortality from this condition have already been
achieved and further gains are likely to be more expensive.
Further improvements in water and sanitation (US$1,118 to
US$14,901 per DALY averted from diarrheal disease) are
generally less cost-effective in regions where access to these
amenities is adequate and other interventions against diarrheal
disease exist. However, in areas with little access to water and
sanitation facilities, improving access can be highly cost-
effective (US$94 per DALY averted for installation of hand
pumps and US$270 per DALY averted for provision and pro-
motion of basic sanitation facilities).
Inherited Disorders of Hemoglobin. Inherited hemoglobin
disorders, including sickle cell anemia and the thalassemias,
affect roughly 500,000 babies born each year and cause early
death for many of them. Prenatal screening for sickle cell dis-
ease, which is expensive, can be replaced by much cheaper
newborn screening. Antibiotic prophylaxis is moderately cost-
effective at preventing death in the first few years (US$8,000 to
US$12,000 per death averted, or US$300 to US$400 per DALY
averted). Expensive interventions, such as bone marrow
transplantation or repeated transfusions, are seldom needed.
At US$10,000 or more per DALY averted, treatment for
transfusion-dependent thalassemias is expensive and probably
unaffordable to all but the rich in LMICs. A feasible strategy to
deal with the thalassemias is to screen couples to determine
their risk of having an affected child, followed by prenatal test-
ing—a relatively expensive proposition—of couples at high
risk. Information is then available to parents to help them
determine whether to terminate the pregnancy. Such strategies
appear to have worked in Cyprus, Greece, and Italy, all coun-
tries that formerly had a high incidence of thalassemias.
Ongoing Challenges: Malaria and Other 
Tropical Diseases
Despite health researchers’ relative neglect of diseases predom-
inantly found in the tropics, interventions to control—and in
some cases even eliminate—these diseases rank among the
most cost-effective of all available options.
Malaria. In countries where malaria is prevalent, both preven-
tion and effective treatment of this disease are highly cost-
effective and can result in large health gains. Prevention tools
include insecticide-treated bednets (US$5 to US$17 per DALY
averted) and indoor residual spraying where DDT, malathion,
deltamethrin, or lambda-cyhalothrin is applied to surfaces
inside homes as a spray or deposit for prolonged action (US$9
to US$24 per DALY averted for Sub-Saharan Africa).
Intermittent preventive treatment of malaria during preg-
nancy using sulfadoxine-pyrimethamine is a highly cost-
effective intervention (US$13 to US$24 per DALY averted) to
decrease neonatal mortality and reduce severe maternal ane-
mia. Changing first-line treatment for malaria from chloro-
quine, a drug that is ineffective in many parts of the world, to
artemisinin-based combinations offers the advantage of faster
cures and potential reductions in transmission, with cost-
effectiveness ratios of less than US$150 per DALY averted.
Changing to sulfadoxine-pyrimethamine may be slightly more
cost-effective initially because of the lower cost of this drug
relative to artemisinin-based combinations; however, this
advantage is likely to be eroded quickly because of the rapid
expected growth of parasite resistance.
Lymphatic Filariasis, Onchocerciasis, and Chagas Disease.
Annual mass drug administration to treat the entire population
at risk for a period long enough to interrupt transmission is a
cost-effective approach for eliminating lymphatic filariasis in
areas of high prevalence (US$4 to US$8 per DALY averted). An
alternative approach is to fortify salt with diethylcarbamazine
(US$1 to US$3 per DALY averted) and to use ivermectin in
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countries where onchocerciasis is coendemic. Onchocerciasis
control programs have been highly successful in West Africa:
investigators have estimated the cost-effectiveness of
community-directed ivermectin treatment programs at
roughly US$6 per DALY averted when the drug has been pro-
vided free of charge. The cost of vector control to prevent—and
perhaps eliminate—Chagas disease has been estimated at
US$260 per DALY averted.
Leishmaniasis and African Trypanosomiasis. Feasible inter-
vention opportunities exist even for tropical diseases for which
control measures are relatively less effective. Improved case
management and immunization (currently undergoing clinical
trials) for dengue (US$587 to US$1,440 per DALY averted)
are relatively cost-effective compared with environmental
vector control (more than US$2,000 per DALY averted).
Leishmaniasis treatment is also extremely cost-effective
(US$315 per death averted and US$9 per DALY averted), as is
treating African trypanosomiasis patients in the second stage of
the disease using melarsoprol or eflornithine (US$10 to US$20
per DALY averted).
Helminthic Infections. Helminthic infections, although not a
major contributor to deaths in tropical regions, have a signifi-
cant effect on health, growth and physical fitness, school
attendance, worker productivity, and earning potential. Mass
school-based treatment of soil-transmitted helminths (Ascaris,
Trichuris, and hookworm) using albendazole costs US$2 to
US$9 per DALY averted. Although the cost of treating
schistosomiasis with praziquantel is significantly greater
(US$336 to US$692 per DALY averted), a combination of
albendazole and praziquantel is extremely cost-effective (US$8
to US$19 per DALY averted).
Maternal and Neonatal Health
Given the hugely disproportionate burden of maternal and
neonatal deaths in LMICs, identifying affordable, easy-to-
implement interventions to prevent these deaths is a priority.
Evidence from South Asia and Sub-Saharan Africa suggests
that improved primary-level coverage with a package of inter-
ventions is extremely cost-effective (US$3,337 to US$6,129 per
death averted and US$92 to US$148 per DALY averted).
Improvements in the quality of prenatal and delivery care are
of similar cost-effectiveness (US$2,729 to US$5,107 per
death averted and US$82 to US$142 per DALY averted). An
important finding is that improving the quality of care and
expanding coverage are of comparable cost-effectiveness.
Improving Nutrition
The direct and indirect effects of undernutrition and
micronutrient deficiencies account for a significant propor-
tion of the overall burden of disease in LMICs. For the most
part, interventions to provide micronutrient supplementation
can prevent malnutrition in children at a fairly low cost. They
include breastfeeding support programs (US$3 to US$11 per
DALY averted and US$100 to US$300 per death averted) and
growth monitoring and counseling (US$8 to US$11 per
DALY averted). Specific micronutrient supplementation pro-
grams can be implemented either by distributing capsules or
by fortifying sugar, salt, water, or other essentials. In address-
ing vitamin A deficiencies, capsule distribution (US$6 to
US$12 per DALY averted) is more cost-effective than sugar
fortification (US$33 to US$35 per DALY averted), especially
in countries where the prevalence of vitamin A deficiency is
low. However, fortification of salt, sugar, and cereal in the case
of iron deficiency and fortification of water and salt in the
case of iodine deficiency is less expensive than distributing
supplements for mild deficiency, though pregnant women
and severely anemic or iodine-deficient people may still
require supplementation. Overall cost-effectiveness is US$66
to US$70 per DALY averted for iron fortification programs
and US$34 to US$36 per DALY averted for iodine fortifica-
tion programs.
Cancer Prevention and Treatment 
Screening for breast cancer using clinical breast examination
(CBE) is estimated to be cost-effective at US$552 per life year
saved for biennial screening of women from age 40 to 60. This
efficacy of CBE is related to the large percentage of tumors with
a poor prognosis observed in developing countries. In this set-
ting, CBE is estimated to be more cost-effective than mam-
mography: mammograms every two years result in 10 percent
more life years saved than annual CBE, but the cost is more
than 100 percent greater. As with any screening program, cost-
effectiveness is greater with higher underlying prevalence of
disease.
In general, cancer prevention, when feasible, is far more
cost-effective than treatment. The cost-effectiveness of initial
treatment is between US$1,300 and US$6,200 per year of life
saved for the more treatable cancers of the cervix, breast, oral
cavity, colon, and rectum and between US$53,000 and
US$163,000 per year of life saved for the less treatable cancers
of the liver, lung, stomach, and esophagus. Postmastectomy
radiation might be more cost-effective in developing coun-
tries, where the cost of radiation treatment can be relatively
low compared to developed countries. Palliative care for ter-
minally ill cancer patients can be a challenge in resource-
constrained settings, where opioid drugs, a cost-effective
option, may be in short supply. Studies from developed coun-
tries indicate that more advanced treatments to relieve pain
and side effects of chemotherapy may be cost-effective under
certain conditions.
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Mental and Neurological Disorders 
Mental disorders are a heterogeneous group of conditions with
considerable variation in both the cost of the interventions and
the burden reduction associated with such interventions.
Interventions to treat depression, bipolar disorder, and schizo-
phrenia rank among the least cost-effective of interventions
considered in this volume. However, the potentially significant
benefits to family members and to society as a whole are not
captured by the DALY methodology and should be balanced
against the relatively high cost of improving health of people
with these disorders. For many disorders, drug treatment has
been shown to be effective, especially when combined with
psychosocial treatment that includes cognitive-behavioral
approaches to managing symptoms and improving adherence
to medications, group therapy, and family interventions.
Schizophrenia and Bipolar Disorder. Drug treatment
accompanied by psychosocial treatment delivered through a
community-based service was found to be the most cost-
effective approach for severe mental disorders such as
schizophrenia and bipolar disorder. Newer antipsychotic and
mood-stabilizing drugs have recently become less expensive;
even so, they are less cost-effective than drugs that have been
available for many years. For example, family psychoeducation
was much more cost-effective with haloperidol (US$1,743 to
US$4,847 per DALY averted) compared with a newer anti-
psychotic drug (risperidone) in treating schizophrenia
(US$10,232 to US$14,481 per DALY averted). For bipolar
affective disorder, the combination of family psychoeducation
with the older medication lithium (US$1,587 to US$4,928 per
DALY averted) is more cost-effective than the combination of
family psychoeducation with the newer sodium valproate
(US$2,765 to US$5,908 per DALY averted).
Depression and Panic Disorder. Treating the more common
depressive and anxiety disorders was more cost-effective than
treating the more severe disorders; the interventions were less
expensive, and the reduction in disability was greater. For
depression, drug therapy with tricyclic antidepressants
(imipramine or amitriptyline) costs US$478 to US$1,288 per
DALY averted. Managing depression as a chronic illness with
case management to reduce relapses did not greatly decrease
the cost-effectiveness (US$749 to US$1,760 per DALY
averted). Using newer medications with fewer side effects and
potentially greater compliance (an advantage if medications
need to be taken long term)—for example, a generic selective
serotonin reuptake inhibitor (SSRI) such as fluoxetine—
increased the cost somewhat (US$1,229 to US$2,459 per
DALY averted). Finally, the treatment of panic disorder using
tricyclic antidepressants (US$305 to US$619 per DALY
averted) and SSRIs (US$567 to US$865 per DALY averted) was
more cost-effective than when combined with psychosocial
treatment. Psychosocial treatment without drug treatment
was of comparable cost-effectiveness (US$338 to US$927 per
DALY averted).
The use of tricyclic antidepressants was more cost-effective
than benzodiazepines, which are still commonly prescribed for
anxiety disorders and produce dependence in many patients.
Overall, the cost-effectiveness of a package of mental health
interventions that addressed all four sets of disorders is
between US$1,429 and US$2,902 per DALY averted, depending
on the region.
Parkinson’s Disease and Epilepsy. Ayurvedic treatment, a
form of traditional medicine used in India, is relatively cost-
effective in treating Parkinson’s disease (US$750 per DALY
averted). Less cost-effective interventions include a combina-
tion of levodopa and carbidopa (US$1,500 per DALY averted),
which are used to treat the debilitating symptoms and delay the
progress of the disease, and deep-brain stimulation (US$31,000
per DALY averted).
Cost-effective options for treating epilepsy are available,
especially the use of phenobarbital to help control seizures
(US$89 per DALY averted), but few eligible patients receive
treatment. More expensive options, such as lamotrigine or sur-
gery, are significantly less cost-effective than phenobarbital for
first-line treatment; however, they are cost-effective for the
small proportion of epilepsy patients who do not respond to
phenobarbital.
Multipronged Strategy to Prevent and Treat CVD
CVD, including ischemic heart disease, congestive heart failure,
and stroke, is the single most important cause of death world-
wide; interventions to treat CVD are likely to account for
increasingly greater proportions of health care expenditures in
developing countries.
Population-Based Primary Prevention. Interventions to
modify lifestyles can effectively lower the risk of coronary
artery disease and stroke without expensive health infrastruc-
ture. They include lowering the fat composition of the diet,
limiting sodium intake, avoiding tobacco use, and engaging in
regular physical activity. The costs and the effectiveness of these
approaches vary widely with the socioeconomic and cultural
context in which they are contemplated.
Replacing dietary trans fat from partial hydrogenation with
polyunsaturated fat is likely to be extremely effective in popu-
lations in South Asia, where the intake of trans fat is high. If
such replacement is done during manufacture at a relatively
low cost rather than through changes in individual behavior, a
cost-effectiveness ratio of US$25 to US$73 per DALY averted
can be attained. Replacing saturated fat with monounsaturated
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fat in manufactured foods accompanied by a public education
campaign is relatively expensive in the base case (US$1,865 to
US$4,012 per DALY averted), although the cost per DALY
averted is highly sensitive to both the relative risk reduction in
CVD events as well as the cost per individual. Reducing salt in
manufactured foods through a combination of legislation and
education campaigns is also relatively expensive in the base
case (US$1,325 to US$3,056 per DALY averted), but could be
much more cost-effective in high-density populations with a
high salt intake. Little evidence is available on the cost-
effectiveness of programs to encourage exercise and other
behavior changes by individuals.
Personal Interventions. Prevention strategies targeted at indi-
viduals at high risk for CVD—measured as a combination of
nonoptimal blood pressure and cholesterol, lifestyle, and
genetic risk factors—can be effective, especially when imple-
mented in tandem with population-based measures. A previ-
ous cardiovascular event is a reliable predictor of a second
event. The cost-effectiveness of primary prevention of CVD
may vary greatly depending on the underlying risk factors, the
age of the patient, and the cost of medications.
Single-pill combinations of blood pressure–lowering med-
ications, statins, and aspirin offer the potential dual benefit of
being highly effective at lowering the risk of CVD and facilitat-
ing patient compliance with the ongoing drug regimen. A
hypothetical multidrug regimen that includes generic aspirin,
a beta-blocker, a thiazide diuretic, an angiotensin-converting
enzyme (ACE) inhibitor, and a statin may be implemented at a
cost-effectiveness ratio of US$721 to US$1,065 per DALY
averted compared with a baseline of no treatment in a popula-
tion with an underlying 10-year CVD risk of 35 percent. The
use of the multidrug regimen for prevention in patients with a
lower underlying CVD risk improves health benefits, but costs
increase more than proportionately.
Acute Management of CVD. The cost of treating acute
myocardial infarction using aspirin and beta-blockers is less
than US$25 per DALY averted in all regions. Relatively more
expensive interventions that offer marginally greater effective-
ness include the use of thrombolytics such as streptokinase
(US$630 to US$730 per DALY averted) and tissue plasminogen
activator (US$16,000 per DALY averted).
The combination of aspirin and the beta-blocker atenolol
has been shown to be highly cost-effective in preventing the
recurrence of a vascular event. The incremental cost-
effectiveness ratio of sequentially adding an ACE inhibitor such
as enalapril (US$660 to US$866 per DALY averted), a statin
such as lovastatin (US$1,700 to US$2,000 per DALY averted),
and coronary artery bypass graft (more than US$24,000 per
DALY averted) to the baseline therapy is greater when hospital
facilities are available. In regions with poor access to hospitals,
the combination of aspirin and a beta-blocker is highly cost-
effective (US$386 to US$545 per DALY averted). In all regions,
treating congestive heart failure using enalapril and the beta-
blocker metoprolol is also highly cost-effective (approximately
US$200 per DALY averted).
Acute Management and Secondary Prevention of Stroke.
The cost of treating acute ischemic stroke using aspirin is
US$150 per DALY averted. Relatively cost-ineffective interven-
tions involve the use of a tissue plasminogen activator
(US$1,300 per DALY averted) and anticoagulants such as
heparin or warfarin (US$2,700 per DALY averted). Aspirin is
the lowest-cost option for secondary prevention of stroke
(US$3.80 per single percentage point decrease in the risk of a
second stroke within two years or US$70 per DALY averted).
The combination of the antiplatelet medication dipyridamole
and aspirin is equally cost-effective (US$93 per DALY averted).
In contrast, carotid endarterectomy is expensive for secondary
prevention (US$1,500 per DALY averted).
Strategies for Injury Prevention
Increasing economic development and use of motor vehicles
has resulted in increases in traffic-related deaths and injuries;
these events account for roughly a third of the burden from all
unintentional injuries in LMICs.
Speed bumps appear to be the most cost-effective and cost
less than US$5 per DALY averted in all regions if installed at the
most dangerous junctions that account for 10 percent of junc-
tion deaths. Increased speeding penalties, media coverage, and
enforcement of traffic laws are only slightly less cost-effective.
Motorcycle helmet legislation (US$467 per DALY averted
in Thailand), bicycle helmet legislation (US$107 per DALY
averted in China), and improved enforcement of traffic codes
through a combination of enforcement and information cam-
paigns (US$5 to US$169 per DALY averted) are relatively more
expensive but deserve greater attention, given the growing
health burden associated with rising levels of vehicle owner-
ship. Research has demonstrated that seat belts and child
restraints are effective in the developed world, and lowering
their costs and encouraging their routine use may improve
their cost-effectiveness in LMICs.
Key interventions to reduce intentional violence, both self-
inflicted (suicides) and interpersonal (homicides and war-
related deaths), include changing cultural norms, reducing
access to guns, and improving criminal justice and social wel-
fare systems, but these interventions are difficult to evaluate
using a cost-effectiveness framework, and a cost-benefit analy-
sis is more appropriate. Studies of interventions targeting inter-
personal violence in developed countries show that behavioral,
legal, and regulatory interventions cost less than the money
they save, in some cases by an order of magnitude. Providing
shelters for victims of domestic violence in the United States
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has a benefit-cost ratio of 6.8 to 18.4. Implementing a gun reg-
istration law in Canada involved a one-time cost of US$70 mil-
lion, compared with annual health-related costs of US$50 mil-
lion for firearm-related injuries in that country. Interventions
for troubled youths to reduce criminal activity include mentor-
ing (with net benefits ranging from US$231 to US$4,651 per
participant), family therapy (US$14,545 to US$60,721), and
aggression replacement therapy (US$8,519 to US$34,071).
Policy Interventions to Lower Alcohol and Tobacco Use
The growing prevalence of smoking, especially among women
in LMICs, is a serious threat to health. Interventions to reduce
tobacco use are noteworthy not just because they are highly
cost-effective but also because the burden of deaths and dis-
ability that they can avert is large. Tobacco control through tax
increases often has dual benefits of increasing tax revenues as
well as discouraging smoking initiation and encouraging
smokers to quit. The cost-effectiveness of a policy to increase
cigarette prices by 33 percent ranges from US$13 to US$195
per DALY averted globally, with a better cost-effectiveness ratio
(US$3 to US$42 per DALY averted) in low-income countries.
In comparison, nicotine replacement therapy (US$55 to
US$751 per DALY averted) and nonprice interventions, includ-
ing banning advertising, providing health education informa-
tion, and forbidding smoking in public places, are relatively
less cost-effective (US$54 to US$674 per DALY averted) in low-
income countries but are still important components of any
tobacco control program.
In regions with a relatively high prevalence of high-risk
alcohol use—that is, Europe and Central Asia, Latin America
and the Caribbean, and Sub-Saharan Africa—tax increases to
lower alcohol use are extremely cost-effective (US$105 to
US$225 per DALY averted). However, in regions with a lower
prevalence of high-risk use—namely, East Asia and the Pacific
and South Asia—tax-based policies can be among the least
cost-effective interventions (more than US$2,500 per DALY
averted). Advertising bans are among the most cost-effective
(but least studied) of all interventions to reduce high-risk
drinking in all regions (US$134 to US$280 per DALY averted).
In East Asia and the Pacific, a comprehensive ban on advertis-
ing and reduced access to retail outlets are highly cost-effective
interventions (US$123 to US$146 per DALY averted). Random
breath testing is one of the least cost-effective interventions
to reduce the alcohol-related disease burden (US$973 to
US$1,856 per DALY averted). In Sub-Saharan Africa, however,
averting the burden of disease associated with drunk driving is
an important priority and is addressed effectively through such
policies as random breath testing and stricter enforcement of
drunk-driving laws (US$531 per DALY averted). Providing
high-risk drinkers with brief advice from a physician in pri-
mary care settings is of intermediate cost-effectiveness
(US$480 to US$819 per DALY averted) in all regions, but
combining this intervention with a tax on alcohol increases
cost-effectiveness (US$260 to US$533 per DALY averted) in all
regions except Sub-Saharan Africa.
Packaging of Interventions and Services 
This section examines the overall cost-effectiveness of a service
level, including all conditions addressed as part of a package
of services, rather than evaluating individual interventions
separately.
Emergency and Hospital Care. The cost per death averted of
training lay first responders and volunteer paramedics is
between US$130 and US$283 (or US$5 to US$11 per DALY
averted) depending on the region. Ambulances outfitted with
trained paramedics can avert deaths at a cost of US$1,148 to
US$3,479 (US$46 to US$137 per DALY averted) in urban set-
tings and US$3,457 to US$10,449 (US$140 to US$410 per
DALY averted) in rural settings. Although the evidence for the
cost-effectiveness of district and referral hospitals is very
limited, it does indicate that basic hospital care at the district
level could be highly cost-effective (US$13 to US$104 per
DALY averted).
Surgery. Some types of surgery are highly cost-effective as part
of a country’s health strategy. These include providing surgical
care to injury victims, including those suffering from head
trauma and burns; handling obstetric complications, such as
obstructed labor or hemorrhage; and undertaking elective sur-
gery to address conditions such as cataracts and otitis media
that have a significant impact on the quality of life. In areas
of high prevalence, cataract surgery can be extremely cost-
effective at roughly US$100 per DALY averted.
Many of these surgical interventions—including improved
resuscitation and airway management using relatively simple
procedures such as chest tubes and tracheostomy, improved
fracture management, and improved management of burns
covering less than 30 percent of the body—require only the
basic facilities offered by district hospitals. The quality of sur-
gery and the risk of complications vary widely, and adequate
health system capacity is an important consideration. For the
typical surgical facility located in a district hospital in an LMIC,
the average cost per DALY averted for a representative set of
surgical procedures is between US$70 and US$230. General
surgery at the district hospital is cost-effective relative to other
interventions in South Asia and Sub-Saharan Africa because of
the relatively low input costs related to infrastructure and the
high level of the avertable disease burden. Examples of surgical
interventions with poor cost-effectiveness include first-line
treatment of epilepsy with surgery, which is useful only
to patients who do not respond to drug treatment, and
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percutaneous transluminal coronary angioplasty for cardiovas-
cular events.
Integrated Management of Childhood Illnesses. An inter-
vention package consisting of exclusive breast feeding; vitamin
A and zinc supplementation; screening for immunization; and
case management of pneumonia, malaria, and diarrhea,
including oral rehydration therapy, costs approximately
US$4.10 per child in Sub-Saharan Africa and is a cost-effective
approach (US$38 per DALY averted) to improving the health
of children under five when program coverage is 50 percent.
Value of Doing Things Better
Intervention quality is an important determinant of cost-
effectiveness, and improving quality can be an efficient way to
use resources. Community health status tends to be correlated
with the quality of health service facilities, which can be
enhanced even in resource-constrained settings. Indeed,
resource-poor settings have the greatest potential for improving
quality at low cost. In the case of acute respiratory infections,
for example, the cost-effectiveness of improving the quality of
care by implementing an educational activity for providers
ranges from US$132 to US$800 per life saved (US$4 to US$28
per DALY averted) when initial intervention quality is poor
and infections are widespread. Quality improvements can cost
between US$2,000 and US$5,000 per life saved (US$70 to
US$176 per DALY averted) with improved baseline quality, low
disease prevalence, or both. Educational interventions to
improve the quality of diarrhea treatment can be extremely
cost-effective (less than US$18 per DALY averted) depending
on these two factors.
Regional Analyses for South Asia and Sub-Saharan Africa
Given the significant health burden borne by countries in
South Asia and Sub-Saharan Africa, cost-effectiveness informa-
tion for interventions related to high-burden health conditions
is presented for these two regions. In South Asia (figure 2.4),
CVD-related interventions, including tobacco taxes, treatment
of acute myocardial infarction with aspirin and beta-blockers,
and increasing coverage of the EPI program, rank among the
most cost-effective interventions. Treatment of latent TB, coro-
nary artery bypass graft for ischemic heart disease, treatment of
depression, and cholera immunization to prevent diarrheal dis-
ease rank among the least cost-effective. Vitamin A deficiency,
leprosy, and epilepsy are important conditions that impose a
relatively lower burden of DALYs on this region, but a number
of highly cost-effective interventions to deal with each of these
conditions could be scaled up.
In Sub-Saharan Africa (figure 2.5), HIV/AIDS and malaria
rank among the highest-burden conditions. Of the 16 most
cost-effective interventions addressing high-burden diseases, 8
are associated with these two sources of ill health alone. Other
interventions that are both cost-effective and address high-
burden diseases include nutritional support (including breast-
feeding advice for mothers) for children under the age of four,
and increasing coverage of the EPI. Oral rehydration therapy
for diarrheal disease can be cost-effective if the cost of the
package is relatively low (that is, less than US$1 per child per
treatment).
Table 2.2 identifies interventions relevant to South Asia and
Sub-Saharan Africa that have been evaluated in this volume
and have the greatest potential to reduce the burden of disease
in those regions at an affordable price.6 The table also high-
lights interventions that address conditions that account for a
moderate to high burden of disease but at a relatively high cost.
Personal versus Population-based Interventions
Figure 2.6 displays a histogram of intervention clusters catego-
rized as either population based or personal (see annex 2.A for
definitions). A greater number of personal intervention clusters
than population-based intervention clusters are categorized as
being highly cost-effective. Although this result may be partly
an artifact of the way in which we have grouped interventions
into clusters, it lends some support to the observation first
made in the first edition of Disease Control Priorities in
Developing Countries (Jamison and others 1993) that personal
interventions are not necessarily less cost-effective than
population-based interventions. Population-based interven-
tions are cost-effective when effectively targeted to populations
in which disease prevalence (or the potential prevalence and
subsequent mortality if the interventions are not imple-
mented) is high. For example, primary prevention of acute
myocardial infarction using aspirin is not nearly as cost-
effective as secondary prevention in patients who have already
suffered a stroke or myocardial infarction, because this latter
category has, by virtue of the first event, identified itself as
being at higher risk than the general population. Similarly,
malaria prevention programs will be highly cost-effective in
areas where malaria is a serious problem but less so in countries
where the burden of this disease is less and people are better
served by treatment with an effective antimalarial.
DISCUSSION 
Since the publication of the previous edition of this book, the
epidemiological and demographic profiles of many LMICs and
the range of available health interventions have changed signif-
icantly. This edition has the benefit of hindsight in looking
back at the variety and affordability of interventions that were
evaluated in the previous edition, both to see how the optimal
mix of strategies may have changed in the intervening period
and to ascertain trends.
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Note: Diseases were considered high burden for South Asia if their total avertable burden was greater than 10 million DALYs. Bars represent the range in point estimates of cost-effectiveness ratios for specific interventions included in
each intervention cluster and do not represent variation across regions or statistical confidence intervals. Point estimates for LMICs were obtained directly from the relevant chapters, calculated as the midpoint of range estimates
reported in the chapters, or calculated from a population-weighted average of the region-specific estimates reported in the chapters. For details of these intervention clusters, including the specific interventions covered in each, see
annex tables 2.B.1 and 2.B.2. Only interventions with cost-effectiveness reported in terms of DALYs are included in this figure. For interventions with cost-effectiveness reported in other units, see annex tables 2.C.1 and 2.C.2.
a. Cost-effectiveness range of aspirin, beta-blockers, and statin to prevent stroke and ischemic and hypertensive heart disease is incremental to salt reduction legislation and health education. 
b. Nonprice interventions for tobacco addiction include advertising bans, smoking restrictions, supply reduction, and information dissemination.
c. EPI = Expanded Program on Immunization. 
Emergency medical care: training volunteer paramedics with lay first responders
Tuberculosis, diphtheria-pertussis-tetanus, polio, measles: traditional EPIc
Myocardial infarction: acute management with aspirin and beta-blocker
Tobacco addiction: taxation causing 33% price increase
Coronary artery disease: legislation substituting 2% of trans fat with polyunsaturated fat at US$0.50 per adult
Tuberculosis (endemic): BCG vaccine
Tuberculosis (endemic, infectious or noninfectious): directly observed short-course chemotherapy
Tuberculosis (epidemic, infectious): directly observed short-course chemotherapy
Lower acute respiratory infection (0–4 years): case management of non-severe cases at community or facility level
Emergency medical care: staffed community ambulance
Tuberculosis (epidemic): management of drug resistance
Tuberculosis (epidemic, latent): isoniazid treatment
Problems requiring surgery: surgical ward or services in district hospital or community clinic
Maternal conditions: improved quality of comprehensive emergency obstetric care
Maternal conditions: increased primary care coverage
Maternal conditions: improved overall quality of care
Congestive heart failure: angiotensin-converting enzyme inhibitor and beta-blocker, with diuretics
Maternal conditions: improved quality of care and coverage
Tuberculosis (endemic): management of drug resistance
Tobacco addiction: nonprice interventionsb
Lower acute respiratory infection (0–4 years): case management package at community, facility, and hospital levels
Myocardial infarction and stroke: secondary prevention with polypill
Neonatal mortality: family, community, or clinical neonatal package
Tobacco addiction: nicotine replacement therapy
Haemophilus influenzae type B, hepatitis B, diphtheria, pertussis, and tetanus: pentavalent vaccine
Coronary artery disease: legislation substituting 2% of trans fat with polyunsaturated fat at US$6 per adult
Ischemic heart disease: aspirin, beta-blocker, with optional angiotensin-converting enzyme inhibitor
Myocardial infarction: acute management with streptokinase, with aspirin and beta-blocker
Diarrheal disease: oral rehydration therapy for package costing US$2.91 per episode
Neonatal mortality: combined maternal and child health and neonatal packages
Neonatal mortality: maternal and child health package, with no neonatal care after birth
Stroke and ischemic and hypertensive heart disease: aspirin, beta-blocker, statin by absolute risk approacha
Diarrheal disease: breastfeeding promotion
Diabetes, ischemic heart disease, and stroke: legislation with public education to reduce salt content
Depression: drugs with optional episodic or maintenance psychosocial treatment
Stroke and ischemic and hypertensive heart disease: polypill with absolute risk approach
Diabetes, ischemic heart disease, and stroke:  media campaign to reduce saturated fat
Ischemic heart disease: statin, with aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor
Diarrheal disease: improved water and sanitation at current coverage of amenities and other interventions
Diarrheal disease: rotavirus or cholera immunization
Tuberculosis (endemic, latent): isoniazid treatment
Myocardial infarction: acute management with tissue plasminogen activator, with aspirin and beta-blocker
Ischemic heart disease: coronary artery bypass graft
Figure 2.4 Cost-Effectiveness of Interventions Related to High-Burden Diseases in South Asia
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Note: Diseases were considered high burden for Sub-Saharan Africa if their total avertable burden was greater than 10 million DALYs. Bars represent the range in point estimates of cost-effectiveness ratios for specific interventions
included in each intervention cluster and do not represent variation across regions or statistical confidence intervals. Point estimates for LMICs were obtained directly from the relevant chapters, calculated as the midpoint of range
estimates reported in the chapters, or calculated from a population-weighted average  of the region-specific estimates reported in the chapters. For details of these intervention clusters, including the specific interventions covered in
each, see annex tables 2.B.1 and 2.B.2. Only interventions with cost-effectiveness reported in terms of DALYs are included in this figure. For interventions with cost-effectiveness reported in other units, see annex tables 2.C.1 and 2.C.2.
a.  Cost-effectiveness range of aspirin, beta-blockers, and statin to prevent stroke and ischemic and hypertensive heart disease is incremental to salt reduction legislation and health education.
b.  Chloroquine as first-line drug, artemisinin combination therapy as second-line drug and sulfadoxine-pyrimethamine as first- or second-line drug. 
Measles: second opportunity vaccination in a fixed facility
Tuberculosis, diphtheria-pertussis-tetanus, polio, measles: traditional Expanded Program on Immunization
Malaria: intermittent preventive treatment in pregnancy with drugs other than sulfadoxine-pyrimethamineb
Emergency medical care: training volunteer paramedics with lay first responders
Underweight child (0–4 years): breastfeeding promotion and support
HIV/AIDS: peer programs for high-risk groups
Malaria: insecticide-treated bed nets
Malaria: residual household spraying
Malaria: intermittent preventive treatment in pregnancy with sulfadoxine-pyrimethamine
Childhood illness: integrated management of childhood illness
Haemophilus influenzae type B, hepatitis B, diphtheria, pertussis, and tetanus: pentavalent vaccine
HIV/AIDS: voluntary counseling and testing
HIV/AIDS: sexually transmitted infections diagnosis with treatment
HIV/AIDS: condom promotion and distribution
Lower acute respiratory infection (0–4 years): case management of non-severe cases at community or facility level
Maternal conditions: improved overall quality of care
HIV/AIDS: blood and needle safety
Maternal conditions: improved quality of care and coverage
Maternal conditions: improved quality of comprehensive emergency obstetric care
Maternal conditions: increased primary care coverage
HIV/AIDS: tuberculosis coinfection prevention and treatment
Problems requiring surgery: surgical ward or services in district hospital or community clinic
Emergency medical care: staffed community ambulance
HIV/AIDS: mother-to-child transmission prevention
Lower acute respiratory infection (0–4 years): case management package at community, facility, and hospital levels
Stroke and ischemic and hypertensive heart disease: aspirin, beta-blocker, statin by absolute risk approacha
Neonatal mortality: family, community, or clinical neonatal package
Diarrheal disease: breastfeeding promotion
HIV/AIDS: home care
Neonatal mortality: combined maternal and child health and neonatal packages
HIV/AIDS: antiretroviral therapy
Neonatal mortality: maternal and child health package, with no neonatal care after birth
Diarrheal disease: oral rehydration therapy for package costing US$5.51 per episode
Diarrheal disease: rotavirus or cholera immunization
Stroke and ischemic and hypertensive heart disease: polypill with absolute risk approach
Diarrheal disease: improved water and sanitation at current coverage of amenities and other interventions
Figure 2.5 Cost-Effectiveness of Interventions Related to High-Burden Diseases in Sub-Saharan Africa
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Lessons
Three lessons are broadly applicable. They relate to communi-
cable diseases, noncommunicable diseases, and technological
progress.
Communicable Diseases. Interventions to treat communica-
ble diseases have been highly cost-effective in the past and
remain so despite new challenges, such as drug-resistant
pathogens and vectors. Although much progress has been
made in lowering the burden of disease associated with
vaccine-preventable illnesses, diarrhea, and to a lesser extent
with acute respiratory infections, progress made on other dis-
eases, such as malaria and TB, has been rolled back by such
challenges as parasite resistance in the case of malaria and the
HIV epidemic in the case of TB. An important exception may
be diseases for which vaccines have been available, where sig-
nificant gains in health have been achieved. In general, discern-
ing a link between the availability of effective, affordable inter-
ventions in 1993 and a significant effect on the disease burden
since that time is difficult because of the problem in defining
the appropriate counterfactual of what would have happened
in the absence of interventions that were implemented.
Noncommunicable Diseases. Compared with 13 years ago,
many more cost-effective interventions have been evaluated
and are being used for noncommunicable diseases, which con-
tinue to grow in importance as populations undergo the epi-
demiological transition. Many of these interventions have been
available for more than a decade; however, their costs have
dropped as key drugs have gone off patent. Acute management
of stroke and myocardial infarction using aspirin, beta-
blockers, and nitroglycerin costs as little as US$15 to US$30 per
DALY averted and ranks among the most cost-effective inter-
ventions available in LMICs. Even though many of the
interventions were first developed in the industrial world, their
benefits are now largely available in the developing world.
Thus, the challenge lies in the ability of health care systems in
LMICs to adopt these interventions on a large scale.
Technological Progress. Much progress has been made in sci-
entific understanding and in the availability of affordable,
population-based and personal interventions for preventing
and treating HIV/AIDS; however, adequate scaling up of these
interventions remains a challenge, with a few notable excep-
tions. The international health system has shown remarkable
technological agility in responding to this epidemic, demon-
strating that the world’s scientific-industrial machinery is capa-
ble of rising to the challenge of emerging diseases when there is
sufficient economic motivation for doing so. For instance, com-
bination antiretroviral treatments are currently available for as
little as US$150 for a year’s supply in some countries. In con-
trast, monotherapy with zidovudine, or AZT, which was the
standard of care 10 years ago, was less effective, more expensive,
and much more prone to drug resistance. As before, the chal-
lenge does not appear to be in the availability of interventions
either to prevent infection in adults or to effectively ensure
against transmission from infected mothers to newborns.
Rather, the challenge lies in the willingness and ability to fund
and deploy the interventions effectively. Clearly, much more
remains to be done to develop affordable treatments. However,
without a vaccine, the only feasible solution appears to be to
aggressively prevent further transmission while treating
patients under well-implemented programs that can achieve
the high rates of treatment adherence required to maintain the
continued effectiveness of drug therapy.7 More generally, the
challenge of motivating technological advances for diseases that
do not threaten the developed world remains to be addressed.
Importance of Health Systems
In describing efficient means of producing health, this chap-
ter has said little about how such efficiency may be translated
into practice. The overall cost-effectiveness of a service level
or package of interventions, rather than the cost-effectiveness
of individual interventions, is the appropriate indicator to
determine which interventions should be used. From a plan-
ning point of view, taking the infrastructure as fixed, at least
in the immediate future, and then asking how it can best be
used to deliver the most cost-effective interventions might be
sensible. Where infrastructure is limited, expanding access will
have to take priority. Other factors related to health system
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Table 2.2 Neglected Low-Cost Opportunities and High-Cost Interventions in South Asia and Sub-Saharan Africa
Neglected low-cost opportunities in South Asia Cost Thousands of DALYs Burden of target 
per DALY averteda,b per 20% diseasesa (millions 
averteda (US$) increase in coverage of DALYs)
CHILDHOOD IMMUNIZATION
Additional coverage of traditional Expanded Program on Immunization 8 n.e. 28.4
(tuberculosis, diphtheria-pertussis-tetanus, polio, measles)
HIV AND AIDS
Voluntary counseling and testing
Peer-based programs targeting at-risk groups (e.g., commercial 
sex workers) to disseminate information and teach specific skills 9–126 n.e. 7.4
School-based interventions that disseminate information to students
Prevention of mother-to-child-transmission with antiretroviral therapy
SURGICAL SERVICES AND EMERGENCY CARE
Surgical ward in a district hospital, primarily for obstetrics, trauma 
and injury 6–212 at least 1.8 48.0–146.3
Staffed community ambulance
Training of lay first responders and volunteer paramedics
TUBERCULOSIS 
Childhood vaccination against endemic TB
Directly observed short-course chemotherapy 8–263 n.e. 13.9
Isoniazid treatment of epidemic TB
Management of drug resistance
LOWER ACUTE RESPIRATORY ILLNESSES OF CHILDREN UNDER FIVE
Community- or facility-based case management of non-severe cases
Case management package including community- and facility-based 28–264 0.7–1.8 9.7–26.4
care for non-severe cases and hospital-based care for severe cases
CARDIOVASCULAR DISEASE
Management of acute myocardial infarction with aspirin and 
beta-blocker
Primary prevention of coronary artery disease with legislation 
substituting 2% of trans fat with polyunsaturated fat, at 
$0.50 per adult
Secondary prevention of congestive heart failure with 9–304 at least 0.1 25.9–39.1
angiotensin-converting enzyme inhibitors and beta-blockers 
incremental to diuretics
Secondary prevention of myocardial infarction and stroke with 
polypill containing aspirin, beta-blocker, thiazide diuretic, 
angiotensin-converting enzyme inhibitor, and statin
TOBACCO USE AND ADDICTION
Tax policy to increase price of cigarettes by 33 percent 
Non-price interventions such as advertising bans, health information 14–374 at least 2.5 15.7
dissemination, tobacco supply reductions, and smoking restrictions
Nicotine replacement therapy
MATERNAL AND NEONATAL CARE
Increased primary care coverage
Improved quality of comprehensive emergency obstetric care 127–394 at least 1.3 37.7–47.8
Improved overall quality and coverage of care
Neonatal packages targeted to families, communities, and clinics
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Neglected low-cost opportunities in Sub-Saharan Africa Cost Thousands of DALYs Burden of target 
per DALY averteda,b per 20% diseasesa (millions 
averteda (US$) increase in coverage of DALYs)
CHILDHOOD IMMUNIZATION
Second opportunity measles vaccinationc
Additional coverage of traditional Expanded Program on Immunization 1–5 n.e. 13.5–31.3
(tuberculosis, diphtheria-pertussis-tetanus, polio, measles)
TRAFFIC ACCIDENTS
Increased speeding penalties, media, and law enforcement 2–12 n.e. 6.4
Speed bumps at the most dangerous traffic intersections
MALARIA
Insecticide-treated bed netsc
Residual household sprayingc 2–24 20.8–37.6 35.4
Intermittent preventive treatment during pregnancyc
SURGICAL SERVICES AND EMERGENCY CARE
Surgical ward in a district hospital, primarily for obstetrics, trauma 
and injury 7–215 1.6–21.2 25–134.2
Staffed community ambulance
Training of lay first responders and volunteer paramedics
CHILDHOOD ILLNESSES
Integrated management of childhood illnessesc
Case management of non-severe lower acute respiratory illnesses 
at the community or facility level
Case management package including community- or facility-based 9–218 at least 1.2 9.6–45.1
care for non-severe cases and hospital-based care for severe 
lower acute respiratory illnesses
Breastfeeding support to prevent underweight childrenc
CARDIOVASCULAR DISEASE
Management of acute myocardial infarction with aspirin and beta-blocker
Primary prevention of coronary artery disease with legislation 
substituting 2% of trans fat with polyunsaturated fat, at $0.50 per adult
Secondary prevention of congestive heart failure with angiotensin- 9–273 at least 0.04 4.6
converting enzyme inhibitors and beta-blockers incremental to diuretics
Secondary prevention of myocardial infarction and stroke with 
polypill containing aspirin, beta-blocker, thiazide diuretic, 
angiotensin-converting enzyme inhibitor, and statin
HIV AND AIDS
Peer-based programs targeting at-risk groups (e.g., commercial 
sex workers) to disseminate information and teach specific skills
Voluntary counseling and testing
Diagnosis and treatment of sexually-transmitted diseasesc 6–377 n.e. 56.8
Condom promotion and distributionc
Prevention and treatment of tuberculosis co-infectionc
Blood and needle safety programsc
Prevention of mother-to-child transmission with antiretroviral therapy
MATERNAL AND NEONATAL CARE
Increased primary care coverage
Improved quality of comprehensive emergency obstetric care 82–409 at least 2.8 29.8–37.7
Improved overall quality and coverage of care
Neonatal packages targeted to families, communities, and clinics
Table 2.2 (Continued)
(Continues on the following page.)
56 | Disease Control Priorities in Developing Countries | Ramanan Laxminarayan, Jeffrey Chow, and Sonbol A. Shahid-Salles
High-cost interventions in South Asia Cost Thousands of DALYs Burden of target 
per DALY averteda,b per 20% diseasesa (millions 
averteda (US$) increase in coverage of DALYs)
DEPRESSION
Episodic treatment with newer antidepressant drug (selective 
serotonin reuptake inhibitors) 1,003–1,449 0.4–0.8 14.6
Episodic or maintenance psychosocial treatment plus treatment with
newer antidepressant drug (selective serotonin reuptake inhibitors)
HIGH BLOOD PRESSURE AND CHOLESTEROL
Primary prevention of stroke and ischemic and hypertensive heart 
disease with aspirin, beta-blocker, and statin, incremental to 
policy-induced behavior change, at 15 percent risk of CVD event 
over 10 years 1,120–1,932 at least 6.7 48.6
Primary prevention of stroke and ischemic and hypertensive heart 
disease with a polypill, containing aspirin, beta-blocker, thiazide 
diuretic, angiotensin-converting enzyme inhibitor, and statin, at 
15 percent risk of CVD event over 10 years 
LIFESTYLE DISEASES
Primary prevention of diabetes, ischemic heart disease, and stroke 
through policy that replaces saturated fat with monounsaturated fat 
in manufactured foods, accompanied by a public education campaign 1,325–1,865 1.3–1.8 39.5
Primary prevention of diabetes, ischemic heart disease, and stroke 
through legislation that reduces salt content plus public education
STROKE (ISCHEMIC)
Acute management with recombinant tissue plasminogen 
activator with 48 hours of onset
Acute management with heparin within 48 hours of onset 1,630–2,967 0.03–0.4 2.2–9.2
Secondary prevention with carotid endarterectomy
DIARRHEAL DISEASES
Oral rehydration therapy if the package cost is greater than 
US$2.30 per child per episode 500–6,390 0.02–2.5 22.3
Rotavirus or cholera immunization
TUBERCULOSIS
Isoniazid treatment for latent endemic TB in patients uninfected with HIV 5,588–9,189 n.e. 13.9
SCHIZOPHRENIA AND BIOPOLAR DISORDER
Antipsychotic medication and psychosocial treatment for schizophrenia 1,743–17,702 0.02–0.12 2.2–2.9
Valproate and psychosocial treatment for bipolar disorder
CARDIOVASCULAR DISEASE
Management of acute myocardial infarction with streptokinase or 
tissue plasminogen activator, incremental to aspirin and beta-blocker
Secondary prevention of ischemic heart disease with statin, 638–24,040 0.04–0.3 25.9
incremental to aspirin, beta-blocker, and angiotensin-converting 
enzyme inhibitor
Secondary prevention of ischemic heart disease with coronary 
artery bypass graft
Table 2.2 (Continued)
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Table 2.2 (Continued)
High-cost interventions in Sub-Saharan Africa Cost Thousands of DALYs Burden of target 
per DALY averteda,b per 20% diseasesa (millions 
averteda (US$) increase in coverage of DALYs)
DIARRHEAL DISEASES
Oral rehydration therapy if the cost per episode is greater 500–1,658 0.1–4.6 22
than US$2.80 per child
Rotavirus or cholera immunization
HIV AND AIDS
Home care treatmentc 673–1,494 n.e. 56.8
Antiretroviral therapy in populations with low adherencec
TRAFFIC ACCIDENTS
Random driver breath tests
Enforcement of seatbelt laws 973–2,146 at least 0.05 6.2–6.4
Child restraint promotion
HIGH BLOOD PRESSURE AND CHOLESTEROL
Primary prevention of stroke and ischemic and hypertensive heart disease 1,920 n.e. 10.6
with aspirin, beta-blocker, and statin, incremental to policy-induced 
behavior change, at 15 percent risk of CVD event over 10 years
LIFESTYLE DISEASES
Primary prevention of diabetes, ischemic heart disease, and stroke 
through policy that replaces saturated fat with monounsaturated fat 
in manufactured foods, accompanied by a public education campaign 1,766–2,356 1.4–1.8 9.6
Primary prevention of diabetes, ischemic heart disease, and stroke 
through legislation that reduces salt content plus public education
STROKE (ISCHEMIC)
Acute management with recombinant tissue plasminogen activator 
within 48 hours of onset 1,284–2,940 0.02–0.3 0.9–3.6
Acute management with heparin within 48 hours of onset
Secondary prevention with carotid endarterectomy
TUBERCULOSIS
Isoniazid treatment for latent endemic TB in patients uninfected 4,129–5,506 n.e. 8.1
with HIV
CARDIOVASCULAR DISEASE
Management of acute myocardial infarction with streptokinase or
tissue plasminogen activator, incremental to aspirin and beta-blocker
Secondary prevention of ischemic heart disease with statin, incremental 634–26,813 0.03–0.2 4.6
to aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor
Secondary prevention of ischemic heart disease with coronary artery 
bypass graft
Source: Authors.
n.e.  not evaluated.
a. Ranges represent variation in point estimates of cost-effectiveness, DALYs averted, or burden of disease among the different interventions listed in each group. Point estimates of cost-effectiveness
and DALYs averted were obtained directly from the relevant chapters or calculated as the midpoint of range estimates reported in the chapters. Burden of disease were obtained from the relevant
chapters and from Mathers and others 2006.
b. Avertable DALYs per 20% increase in treatment coverage in a hypothetical sample population of one million people.
c. Only evaluated for Sub-Saharan Africa.
capacity and infrastructure may play a key role in determin-
ing the adoption of interventions. The current evidence on
the cost-effectiveness of service levels such as district or refer-
ral hospitals is weak. Even though part of the problem lies
with the difficulty of valuing the health benefits these facilities
produce, more could be done. Chapter 3 presents a more
detailed discussion of issues pertaining to health systems, but
the broader questions of why some cost-effective interven-
tions are used while others are not is a subject for future
inquiry.
Even though much of the technology to significantly reduce
the burden of disease already exists, few cost-effective interven-
tions are available for some diseases. Shaping research priorities
in a manner that is responsive to the treatment needs of the
millions of HIV/AIDS patients and of people suffering from
mental disorders across the range of LMICs is a challenge.
Setting intervention priorities efficiently can make a dollar
go farther in improving health and can substantively increase
available resources. Moreover, without demonstrably improved
efficiency in health spending, aid agencies and development
partners are unlikely to be persuaded to dig deeper into their
pockets to pay for further expansions of health programs.
Improving efficiency should not, however, detract from the
importance of increasing resources that are available for
implementing these interventions and of meeting broader
internationally agreed-upon development goals such as the
Millennium Development Goals. These objectives are comple-
mentary.
The lack of reliable data on costs and effectiveness is an
important obstacle to efficient priority setting. Despite the rel-
atively good data on the efficacy of interventions in clinical trial
settings, reliable effectiveness data are generally lacking.
Furthermore, not enough is known about the costs, extent of
coverage, and institutional capacity requirements of interven-
tions in developing countries. The messages presented in this
chapter represent the best available information about the
relative costs of purchasing health through a wide range of
interventions. The challenge that lies ahead is for these mes-
sages to move beyond the academic realm: ultimately, it is the
extent to which policy makers make the commitment to act on
them that will save lives.
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ANNEX 2.A: INTERVENTION CATEGORIES AND
PERTINENT POLICY INSTRUMENTS
The term intervention is used to denote actions taken by or for
individuals to reduce the risk, duration, or severity of an
adverse health condition. Policy instruments encourage, dis-
courage, or undertake interventions. Stopping smoking, for
example, is an intervention that an individual can take to
reduce his or her risk of a range of diseases, and taxing tobacco
products is a potential instrument of government policy to
encourage this intervention. Interventions are divided into
those that are population based and those that are personal as
follows:
• Population-based primary prevention is directed toward
entire populations or population subgroups. These inter-
ventions fall into three broad categories: personal behavior
change, control of environmental hazards, and population-
oriented medical interventions (for example, immuniza-
tion, mass chemoprophylaxis, and screening and referral).
• Personal interventions are directed toward individuals and
can be provided at home; at clinics (community, private,
work-based, or school-based); at district hospitals; or at
referral hospitals.
Primary prevention aims at reducing the level of one or
more identified risk factors to reduce the probability of the ini-
tial occurrence of a disease (for instance, providing medication
for established hypertension to prevent stroke or myocardial
infarction).
Cure of a condition aims at removing the cause and restor-
ing function to what it was before.
Acute management consists of time-limited interventions
that decrease the severity of acute events or the level of
established risk factors to minimize their long-term effect (for
instance, providing thrombolytics for acute myocardial
infarction or angioplasty to reduce stenosis in coronary
arteries).
Secondary prevention (or chronic care) consists of ongoing
interventions aimed at decreasing the severity and frequency of
recurrent events of chronic or episodic diseases (for instance,
providing selective serotonin reuptake inhibitors for severe
unipolar depression).
Rehabilitation aims at restoring or partially restoring physi-
cal, psychological, or social function resulting from a previous
condition.
Palliation aims at reducing pain and suffering from a condi-
tion for which no cure or means of rehabilitation is currently
available. It may range from the use of aspirin for headaches to
the use of opiates to control terminal cancer pain.
Policy instruments are activities that governments or other
entities that wish to encourage or discourage interventions or
to expand the potential interventions could undertake. The fol-
lowing are five major instruments of policy:
• Information, education, and communication seek to
improve the knowledge of individuals and service providers
about the consequences of their choices.
• Taxes and subsidies on commodities, services, and pollu-
tants seek to effect appropriate behavioral responses.
• Regulation and legislation seek to limit the availability of
certain commodities, to curtail certain practices, and to
define the rules governing the financing and provision of
health services.
• Direct expenditures seek to provide or to finance the provi-
sion of selected interventions (such as immunizations); to
provide infrastructure (for instance, medical schools) that
facilitates the provision of a range of interventions; or to
alter infrastructure so as to influence behavior (for example,
by installing speed bumps).
• Research and development, either undertaken directly or
encouraged through subsidies, are central to the goal of
expanding the range of interventions available and reducing
their costs.
Source: This annex was prepared by Thomas Gaziano, Dean
Jamison, and Sonbol Shahid-Salles.
ANNEX 2.B: SUMMARY OF INTERVENTIONS
Table 2.B.1 summarizes personal interventions. A summary of
population-based interventions is shown in table 2.B.2.
ANNEX 2.C: SUMMARY OF OTHER
INTERVENTIONS
Table 2.C.1 summarizes personal interventions for which cost-
effectiveness is evaluated using a measure other than
US$/DALY averted. A summary of population-based interven-
tions evaluated using measures other than DALYs is shown in
table 2.C.2.
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Table 2.B.1 Summary of Personal Interventions
Quality 
Cost- Number of cost-
Cost- effectiveness of DALYs Number effectiveness 
Intervention Target effectiveness rangeb avertedb of deaths analysis 
Condition Intervention Intervention description setting Objective populationa (US$/DALY) (US$/DALY) (hundreds) avertedb evidencec
African 
trypanosomiasis
African
trypanosomiasis 
African 
trypanosomiasis
Alcohol abuse
Bipolar disorder
Bipolar disorder
Cataract
Congestive heart
failure
Case finding and
treatment
Melarsoprol 
Eflornithine
Brief advice to
heavy drinkers by
primary health
care providers
Lithium, valproate,
with optional
psychosocial
treatment,
hospital-based
Lithium, valproate,
with optional psy-
chosocial treat-
ment, 
community-based
Extracapsular
surgery
ACE inhibitor and
beta-blocker, with
diuretics
Identification and treatment of
Trypanosoma brucei gambiense
using the card agglutination try-
panosomiasis test with parasito-
logical confirmation, allowing for
rapid diagnosis and treatment
Used in the second stage of the
disease
Used in the second stage of the
disease
During primary health care visits,
provision of advice by physicians
through education sessions and
psychosocial counseling
Episodic treatment in a hospital
setting with lithium or valproate
with or without maintenance or
episodic psychosocial treatment
Episodic treatment of bipolar
disorder in a community setting
using lithium or valproate with
or without maintenance or
episodic psychosocial treatment
Extracapsular cataract extraction
with implantation of a posterior
chamber intraocular lens;
removal of the lens and the front
portion of the capsule, which are
then replaced with an artificial
lens
Use of ACE inhibitor and an
optional beta-blocker (metopro-
lol), incremental to diuretics
Clinic
Clinic
Clinic
Clinic
District or
referral
hospital
District or
referral 
hospital
District or
referral
hospital
District
hospital
Primary
prevention,
cure
Secondary
prevention
Secondary
prevention
Primary
prevention
Secondary
prevention
Secondary
prevention
Cure 
Secondary
prevention
All ages
All ages
All ages
Adolescents
and adults
Adults over
15
Adults over
15
Adults over
40
Adults
15 (Sub-Saharan
Africa) 
10 (Sub-Saharan
Africa) 
20 (Sub-Saharan
Africa) 
642 
4,417
3,113 
183
150
—
—
—
1.75 
1.00 
1.35 
— 
11.59 
—
— 
—
—
— 
—
—
—
2 (Sub-Saharan
Africa)
2 (Sub-Saharan
Africa)
2 (Sub-Saharan
Africa)
5
5
5
3
5
—
—
—
—
3,590–5,244 
2,498–3,728
—
27–274 
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Dengue
Depression
Diarrheal disease
Epilepsy
Epilepsy
(refractory)
HIV/AIDS
HIV/AIDS
Improved case
management
Drugs with
optional episodic
or maintenance
psychosocial
treatment
Oral rehydration
therapy for pack-
age costing
US$5.50 per
episode
First-line
treatment with
phenobarbital
Second-line
treatment with
phenobarbital
and lamotrigine
or surgery 
Mother-to-child
transmission
prevention
Sexually trans-
mitted infection
diagnosis and
treatment
No specific treatment: early
recognition of symptoms such as
intense continuous abdominal
pain, persistent vomiting, rest-
lessness or lethargy; supportive
treatment includes fluid replace-
ment and electrolytic therapy
Antidepressant drugs (tricyclic
antidepressant or selective sero-
tonin reuptake inhibitor) used
alone or in combination with
psychosocial treatment for
episodic depression or mainte-
nance treatment
Case management of acute diar-
rheal infection with oral rehydra-
tion salt solutions, for package
costing US$5.50 per child per
episode
First line treatment with pheno-
barbital to treat epilepsy
patients
Antiepileptic drugs, phenobarbi-
tal and lamotrigine, or a combi-
nation of phenobarbital and sur-
gery to treat epilepsy patients
unresponsive to phenobarbital
All pregnant women offered
screening to prevent mother-to-
child transmission; administra-
tion of a short-course of AZT,
lamivudine, or nevirapine to
mothers prepartum and intra-
partum and to newborns postpar-
tum to reduce the risk of mother-
to-child transmission; also
includes breastfeeding advice
Sexually transmitted infection
screening and treatment promo-
tion to prevent future infection
and to identify and treat high-
risk populations
Clinic or 
district 
hospital
District or
referral
hospital
Clinic
District
hospital
Referral
hospital
Clinic
Clinic
Acute man-
agement
Secondary
prevention
Acute
management
Secondary
prevention
Secondary
prevention
Primary
prevention
Primary pre-
vention, cure
All ages
Adults over
15
Children
All ages
All ages
Mothers
and infants
Adolescents
and adults
587
1,699
1,062
89 
3,027
192
57 (Sub-
Saharan Africa)
—
3.96 
16.57 
2.99 
0.29 
—
—
—
—
58.20 
3.32 
0.32 
—
—
2
5
5
5
5
2
2 (Sub-Saharan
Africa)
—
657–2,741
—
—
2,994–3,060
7–377 
9–105 (Sub-
Saharan Africa)
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Table 2.B.1 (Continued)
Quality 
Cost- Number of cost-
Cost- effectiveness of DALYs Number effectiveness 
Intervention Target effectiveness rangeb avertedb of deaths analysis 
Condition Intervention Intervention description setting Objective populationa (US$/DALY) (US$/DALY) (hundreds) avertedb evidencec
HIV/AIDS
HIV/AIDS
HIV/AIDS
HIV/AIDS
HIV/AIDS
Treatment of
Kaposi’s sarcoma
Treatment of
opportunistic
infections
Tuberculosis
coinfection pre-
vention and
treatment
Home care
Antiretroviral
therapy
Treatment before or after anti-
retroviral treatment, including
failed antiretroviral treatment;
local or systemic treatment of
lesions to provide largely cos-
metic benefit
Opportunistic infection prophy-
laxis; necessary for patients
without access to antiretroviral
treatment, for immunosup-
pressed patients waiting for
antiretroviral treatment to take
effect, for patients who refuse
or cannot take antiretroviral
treatment, for patients for whom
antiretroviral treatment fails,
and for groups of patients who
are unable to recover sufficient
CD4 cells despite good inhibition
of viral replication
Preventive therapy, short-course
chemotherapy, or co-trimoxazole
prophylaxis
Home visits providing basic care
to sick AIDS patients or compre-
hensive schemes that provide
palliative care, nutrition, psy-
chosocial support and counsel-
ing, and links to primary and
secondary health care
Combination therapy with
multiple antiretroviral drugs
associated with prolonged
survival in treated patients
Clinic or 
district 
hospital 
Clinic or 
district 
hospital
Clinic
Household
Clinic
Primary
prevention,
palliation
Primary
prevention,
cure
Primary 
prevention,
cure
Secondary
prevention,
palliation
Primary
prevention
All ages
All ages
All ages
All ages
All ages
52,449
156
121 (Sub-
Saharan Africa)
673 (Sub-
Saharan Africa)
922 (Sub-
Saharan Africa) 
—
—
—
— 
—
—
—
—
—
—
3
3
2 (Sub-Saharan
Africa) 
2 (Sub-Saharan
Africa)
3 (Sub-Saharan
Africa)
34,968–69,930
3–310
6–235 (Sub-
Saharan Africa)
—
350–1,494 (Sub-
Saharan Africa)
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Integrated 
management of
childhood illness
Ischemic heart
disease
Ischemic heart
disease
Ischemic heart
disease
Leishmaniasis
Lower acute 
respiratory infec-
tions (nonsevere)
Lower acute 
respiratory infec-
tions (severe and
very severe)
Integrated 
management of
childhood illness
Aspirin, beta-
blocker, and
optional ACE
inhibitor 
Statin, with
aspirin, beta-
blocker and ACE
inhibitor
Coronary artery
bypass graft
Case finding and
treatment
Case 
management at
community or
facility level
Case 
management at
hospital level
Integration of effective interven-
tions to improve child health and
nutrition into a coordinated
strategy by improving health
worker performance, child health
service delivery, and family and
community practices
Aspirin plus beta-blocker
(atenolol) with optional ACE
inhibitor (enalapril), with or with-
out hospital availability
Statin (lovastatin), incremental
to aspirin, beta-blocker
(atenolol), and ACE inhibitor
(enalapril), with or without hos-
pital availability
Placement of grafts (usually
saphenous vein or internal mam-
mary artery) to bypass stenosed
coronary arteries, while main-
taining cerebral and peripheral
circulation by cardiopulmonary
bypass
Combination of identification
and treatment, vector control
where feasible, and (in zoonotic
foci) control of animal reservoirs
Nonsevere infection diagnosed
by breath rate and treated by a
community health worker or at a
health facility, with amoxicillin,
acetaminophen, and possibly
salbutamol
Severe or very severe infection
diagnosed by breath rate and
with x-ray tests and treated at a
hospital with antibiotics and
possibly salbutamol, oxygen, and
prednisolone
Clinic
District or
referral
hospital
District or
referral
hospital
Referral
hospital
Clinic or
district
hospital
Clinic,
community
District
hospital
Primary 
prevention,
secondary
prevention,
cure
Secondary
prevention
Secondary
prevention
Secondary
prevention
Primary
prevention
Cure
Cure
Children
Adults
Adults
Adults
All ages
Children
under 5
Children
under 5
39 (Sub-
Saharan Africa)
688
2,028
36,793
9
129
4,530
—
8.40 
3.54 
0.76 
—
5.15 
0.48 
—
—
—
—
—
17.36 
1.57 
3 (Sub-Saharan
Africa)
5
5
5
2
5
5
—
451–926
1,864–2,193
—
—
50–208 
2,916–6,144
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Lower acute
respiratory
infections
Malaria
Malaria
Maternal
mortality
Maternal
mortality
Case-
management
package at com-
munity, facility,
and hospital levels
Intermittent pre-
ventive treatment
in pregnancy with
sulfadoxine-
pyrimethamine
Intermittent pre-
ventive treatment
in pregnancy with
drug other than
sulfadoxine-
pyrimethamine
Increased primary
care coverage
Improved quality
of comprehensive
emergency
obstetric care
Comprehensive case-manage-
ment strategy covering nonse-
vere infection being treated by a
community health worker or at a
health facility, severe infection
treated at a hospital, and very
severe infection treated at a
hospital
Intermittent preventive
treatment in areas with high
and stable transmission of
Plasmodium falciparum malaria;
two curative doses of
sulfadoxine-pyrimethamine given
during the second and third
trimesters of pregnancy during
prenatal care visits
Intermittent preventive treat-
ment in areas with high and sta-
ble transmission of Plasmodium
falciparum malaria; two curative
doses of antimalarial treatment
given with a possible change
in first-line therapies from
chloroquine to sulfadoxine-
pyrimethamine, chloroquine to
artemisinin combination therapy,
or sulfadoxine-pyrimethamine to
artemisinin combination therapy
Increased percentage of women
accessing routine prenatal,
intranatal, and postnatal care
Increased percentage of women
with severe complications
receiving comprehensive
emergency obstetric care
Clinic or
district
hospital
Clinic
Clinic
Clinic or 
district 
hospital
Clinic or 
district 
hospital
Cure 
Primary
prevention
Primary
prevention
Primary
prevention
Acute
management
Children
under 5
Pregnant
women
Pregnant
women
Pregnant
women
Pregnant
women
398
19 (Sub-Saharan
Africa) 
7 (Sub-Saharan
Africa) 
132 (South
Asia), 88 (Sub-
Saharan Africa) 
127 (South
Asia), 87 (Sub-
Saharan Africa) 
11.26 
208.00 (Sub-
Saharan
Africa) 
—
13.09 (South
Asia), 27.88
(Sub-Saharan
Africa) 
13.28 (South
Asia), 28.28
(Sub-Saharan
Africa) 
37.86 
827.80 (Sub-
Saharan Africa) 
77,500.00 (Sub-
Saharan Africa) 
32.00 (South
Asia), 77.00
(Sub-Saharan
Africa) 
32.00 (South
Asia), 78.00
(Sub-Saharan
Africa) 
5
5 (Sub-Saharan
Africa)
5 (Sub-Saharan
Africa)
5 (South Asia),
5 (Sub-Saharan
Africa) 
5 (South Asia),
5 (Sub-Saharan
Africa) 
—
13–24 (Sub-
Saharan Africa) 
2–11 (Sub-
Saharan Africa) 
—
—
Table 2.B.1 (Continued)
Quality 
Cost- Number of cost-
Cost- effectiveness of DALYs Number effectiveness 
Intervention Target effectiveness rangeb avertedb of deaths analysis 
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Maternal
mortality
Maternal
mortality
Myocardial
infarction 
Myocardial
infarction 
Myocardial
infarction 
Myocardial
infarction and
stroke
Improved overall
quality of care 
Improved quality
of care and
coverage 
Aspirin and 
beta-blocker
Streptokinase,
with aspirin and
beta-blocker
Tissue plasmino-
gen activator,
with aspirin and
beta-blocker 
Polypill
Improvements to quality of
prenatal and delivery care;
enhanced package including
availability of doctor and full
range of basic and comprehen-
sive emergency obstetric care
(all six essential obstetric func-
tions: administering antibiotics
intravenously or intramuscularly,
administering oxytocics intra-
venously or intramuscularly,
manually removing the placenta,
administering anticonvulsants
intravenously or intramuscularly,
carrying out instrumental deliv-
ery, and removing retained prod-
ucts of conception; optional
nutritional supplementation
Improvements to quality of pre-
natal and delivery care and
increase in the proportion of
women receiving needed care;
enhanced package including
availability of doctor and full
range of basic and comprehen-
sive emergency obstetric care
(all six essential obstetric func-
tions noted above); optional
nutritional supplementation
Aspirin with or without beta-
blocker (atenolol) 
Incremental use of streptoki-
nase, in addition to aspirin and
beta-blocker (atenolol) 
Incremental use of tissue plas-
minogen activator in addition to
aspirin and beta-blocker
(atenolol)
Combination treatment with
aspirin, beta-blocker, thiazide
diuretic, ACE inhibitor and statin,
based on 10-year risk of cardio-
vascular disease
Clinic
Clinic
District or
referral
hospital
District or
referral
hospital
District
hospital
District
hospital
Primary
prevention,
acute
management
Primary
prevention,
acute
management
Acute
management
Acute
management
Acute
management
Secondary
prevention
Pregnant
women
Pregnant
women
Adults
Adults
Adults
Adults
147 (South
Asia), 83 (Sub-
Saharan Africa) 
152 (South
Asia), 86 (Sub-
Saharan Africa) 
14
671
15,869 
409
21.90 (South
Asia), 53.05
(Sub-Saharan
Africa) 
23.51 (South
Asia), 56.93
(Sub-Saharan
Africa) 
1.04 
1.04
0.42 
—
56.20 (South
Asia), 153.20
(Sub-Saharan
Africa) 
60.29 (South
Asia), 164.14
(Sub-Saharan
Africa) 
—
—
—
—
5 (South Asia),
5 (Sub-Saharan
Africa) 
5 (South Asia),
5 (Sub-Saharan
Africa) 
5
5
5
5
133–160 (South
Asia), 82–85 (Sub-
Saharan Africa) 
138–167 (South
Asia), 85–86 (Sub-
Saharan Africa) 
13–15 
—
—
—
(Continues on the following page.)
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Neonatal
mortality
Neonatal
mortality
Neonatal
mortality
Panic disorder
Parkinson’s
disease
Parkinson’s
disease
Maternal and
child health pack-
age with no
neonatal care
after birth
Family, communi-
ty, or clinical
neonatal package
Combined mater-
nal and child
health with
neonatal
packages
Drugs with
optional
psychosocial
treatment 
Ayurvedic
treatment and
levodopa or
carbidopa
Levodopa or car-
bidopa and deep
brain stimulation
Mother and child health package
that includes family planning,
prenatal care, and comprehen-
sive obstetric care 
Healthy home care practices,
including exclusive breastfeed-
ing, warmth protection, clean
cord care, care seeking for
emergencies; if birth outside a
facility, then clean delivery kit
Family planning, prenatal care,
and comprehensive obstetric
care packages, as well as
healthy home care practices,
including exclusive breastfeed-
ing, warmth protection, clean
cord care, care seeking for
emergencies; if birth outside a
facility, then clean delivery kit
Anxiolytic drugs (benzodi-
azepine), tricyclic antidepres-
sants or selective serotonin
reuptake inhibitor used with or
without psychosocial treatment
Levodopa (l-dopa), carbidopa, or
ayurvedic therapy for partial
relief of symptoms
Levodopa or carbidopa and deep
brain stimulation
Clinic or
district
hospital
Clinic, com-
munity or
household 
Clinic, com-
munity or
household 
District or
referral
hospital
District
hospital or
referral
hospital
District
hospital or
referral
hospital
Primary
prevention
Primary
prevention
Primary
prevention
Secondary
prevention
Secondary
prevention
Secondary
prevention
Mothers
and
infants
Mothers
and
infants
Mothers
and
infants
Adults
over 15
Adults
over 45
Adults
over 45
1,060 (South
Asia), 924  (Sub-
Saharan Africa) 
349 (South
Asia), 345 (Sub-
Saharan Africa) 
839 (South
Asia), 789 (Sub-
Saharan Africa) 
734 
1,132 
31,114 
—
—
—
0.83 
0.13 
0.15 
—
—
—
—
—
—
4 (South Asia),
5 (Sub-Saharan
Africa) 
4 (South Asia),
5 (Sub-Saharan
Africa) 
4 (South Asia),
5 (Sub-Saharan
Africa) 
5
5
5
—
305–394 (South
Asia), 338–351
(Sub-Saharan
Africa) 
—
384–1,084
752–1,512
—
Table 2.B.1 (Continued)
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Schizophrenia
Schizophrenia
Stroke (ischemic)
Stroke (ischemic)
Stroke (recurrent)
Stroke (recurrent)
Stroke and
ischemic and
hypertensive
heart disease
Tobacco
addiction
Trachoma
Antipsychotic
drugs with
optional psy-
chosocial treat-
ment, hospital-
based 
Antipsychotic
drugs with
optional psy-
chosocial treat-
ment, community-
based 
Aspirin
Heparin and
recombinant
tissue plasmino-
gen activator
Aspirin and
dipyridamole
Carotid
endarterectomy
Polypill by
absolute risk
approach
Nicotine replace-
ment therapy
Trichiasis surgery
Maintenance treatment in a hos-
pital setting with antipsychotic
drugs, neuroleptic antipsychotic
drug, or an atypical antipsychotic
drug, with or without psychoso-
cial treatment
Maintenance treatment in a
community-based setting with
antipsychotic drugs, neuroleptic
antipsychotic drug, or an atypical
antipsychotic drug, with or with-
out psychosocial treatment
Aspirin dose within 48 hours of
onset of acute stroke
Heparin within 48 hours of onset
of stroke or thrombolytic therapy
using recombinant tissue plas-
minogen activator within 3 hours
of onset
Daily aspirin dose or combina-
tion of aspirin and extended
release dipyridamole
Carotid endarterectomy surgery
to remove harmful plaque from
the carotid arteries
Combination treatment with
aspirin, beta-blocker, thiazide
diuretic, ACE inhibitor, and statin
based on 10-year risk of cardio-
vascular disease
Smoking cessation treatments in
the form of nicotine replacement
therapy
Trichiasis surgery (eyelid correc-
tion) to prevent blindness and
reduce likelihood of other condi-
tions
District
hospital or
referral
hospital
Community 
Clinic or dis-
trict hospital
District
hospital
Clinic or dis-
trict hospital
Referral
hospital
District or
referral
hospital
Clinic
District
hospital or
referral
hospital
Secondary
prevention
Secondary
prevention
Acute man-
agement
Acute man-
agement
Secondary
prevention
Secondary
prevention
Primary
prevention
Primary
prevention
Secondary
prevention
Adults
over 15
Adults
over 15
Adults
over 15
Adults
over 15
Adults
over 15
Adults
over 15
Adults
Adults
Adults
over 40
11,920
9,834
149
1,977 
81
1,458
2,128
396
39
0.60 
0.70 
1.62
1.22 
1.77 
4.93 
61.65 
37.14 
—
—
—
0.12
1.70 
14.29 
39.82 
—
452.05 
—
5
5
5
5
5
5
5
5
3
4,105–19,736
2,472–17,197
—
1,278–2,675
70–93
—
773–3,483
—
—
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Table 2.B.1 (Continued)
Quality 
Cost- Number of cost-
Cost- effectiveness of DALYs Number effectiveness 
Intervention Target effectiveness rangeb avertedb of deaths analysis 
Condition Intervention Intervention description setting Objective populationa (US$/DALY) (US$/DALY) (hundreds) avertedb evidencec
Trachoma
Tuberculosis
(endemic)
Tuberculosis
(endemic, infec-
tious or nonin-
fectious)
Tuberculosis
(endemic, latent)
Tuberculosis
(epidemic)
Tuberculosis
(epidemic,
infectious)
Tetracycline or
azithromycin
Management of
drug resistance
Directly observed
short-course
chemotherapy
Isoniazid
treatment
Management of
drug resistance
Directly observed
short-course
chemotherapy
Tetracycline or azithromycin to
treat the initial trachoma infec-
tion through either mass treat-
ment of all children younger
than 10 or through targeted
treatment of infected children
and household members
Introduction of resistance test-
ing, second-line drugs, longer
treatment regimen (12–18
months), and rigorous bacterio-
logical and clinical monitoring;
standardized or individualized
regimen 
Short-course chemotherapy of
infectious or noninfectious
tuberculosis (with or without
transmission, non-HIV-positive),
diagnosed via directly observed
treatment strategy
Isoniazid treatment of latent
infection (with or without x-ray
exclusion of active cases; non-
HIV-infected population)
Management of drug resistance
(standard regimen) for epidemic
TB conducted via introduction of
resistance testing, second-line
drugs, longer treatment regimen
(12–18 months), and rigorous
bacteriological and clinical moni-
toring
Short-course chemotherapy of
infectious TB (allowing for trans-
mission, non-HIV positive) car-
ried out for epidemic TB
Clinic
District
hospital
Clinic
District
hospital
District
hospital
Clinic 
Primary
prevention
Secondary
prevention,
cure
Primary 
prevention,
cure
Secondary
prevention
Secondary
prevention,
cure
Primary 
prevention,
cure
Children
and adults
Adults
over 15
Adults
over 15
Adults
over 15
Adults
over 15
Adults
over 15
6,269
318
301
13,158
207
102
—
—
—
—
—
—
—
—
—
—
—
—
3
5
5
5
5
5
3,752–8,785
208–429
84–551
9,450–16,867
201–212
15–189
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Tuberculosis (epi-
demic, latent)
Unwanted 
pregnancy
Zinc deficiency 
Isoniazid
treatment
Family-planning
programs
Supplements
with oral rehy-
dration salts
Isoniazid treatment of latent
infection (x-ray exclusion of
active cases; non-HIV-positive
population) is conducted for
epidemic tuberculosis
Intrauterine devices, voluntary
sterilization, condoms and other
barrier methods, implants, and
oral contraceptives
Provision of zinc as an adjunct to
oral rehydration salts in treating
diarrhea in young children
District
hospital 
Clinic
Clinic or
district
hospital
Secondary
prevention
Primary
prevention
Primary
prevention
Adults
over 15
Women of
childbear-
ing age
Children
under 5
197
117
73
—
—
—
—
—
—
5
3
3
45–348
—
—
Source: Authors.
ACE  angiotensin  converting enzyme
Note: —  not available.
a. Refers to the age group to whom the intervention is targeted and not necessarily the one that is benefiting.
b. Ranges in cost-effectiveness reflect the variation in point estimates for specific interventions included in each intervention cluster and do not represent either variation across regions or statistical confidence intervals. Point estimates were obtained directly from the
relevant chapters, calculated as the midpoint of range estimates reported in the chapters, or calculated from a population-weighted average of the region-specific estimates reported in the chapters.  DALYs and deaths potentially avertable are for a 20 percentage point
increase in intervention coverage in a hypothetical sample population of 1 million.
c. See table 2.1.
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Adolescent
health and
nutrition
Alcohol abuse
Alcohol abuse
Alcohol abuse
Chagas disease
School health
and nutrition
programs
Excise tax 
Advertising ban
and reduced
access to
beverage retail
Excise tax, adver-
tising ban, with
brief advice
Vector control
Inclusion of deworming of intes-
tinal worms and schistosomia-
sis; prompt recognition and
treatment of malaria;
insecticide-treated bednets;
micronutrient supplements;
breakfast, snacks, other meals;
first-aid kits; referral to youth-
friendly clinics; and counseling
and psychosocial support
25 to 50 percent increase in the
current excise tax rate on
alcoholic beverages
Reduced access to alcoholic
beverage retail outlets by reduc-
ing the hours of sale or advertis-
ing bans on television, radio,
and billboards
50 percent increase in the cur-
rent excise tax rate on alcoholic
beverages, combined with
advice, education sessions, and
psychosocial counseling; possi-
ble inclusion of random driver
breath testing and advertising
bans
Vector control activities includ-
ing spraying combined with
housing improvement,
community involvement in sur-
veillance, and strong programs
of health education
Community,
school
Policy level
Policy level
Policy level
Community
Population-
oriented
medical
intervention
Instrument
of policy
Instrument
of policy
Instrument
of policy
Control of
environmen-
tal hazard
School-age
children
Adolescents
and adults
Adolescents
and adults
Adolescents
and adults
All ages
37
1,377
404
631
284 (Latin
America and the
Caribbean)
—
0.62 
0.44 
2.85
—
—
—
—
—
—
3 
5
5
5
1 (Latin
America and
the Caribbean)
—
1,249–1,504
367–441
601–661
—
Table 2.B.2 Summary of Population-Based Interventions
Quality 
Cost- Number of cost-
Target Cost- effectiveness of DALYs Number effectiveness 
Intervention popula- effectiveness rangeb avertedb of deaths analysis 
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Coronary 
artery disease
Coronary 
artery disease
Dengue
Dengue
Diabetes,
ischemic heart
disease, and
stroke
Diabetes,
ischemic heart
disease, and
stroke
Diarrheal disease
Legislation sub-
stituting 2% of
trans fat with
polyunsaturated
fat at US$0.50
per adult
Legislation sub-
stituting 2% of
trans fat with
polyunsaturated
fat at US$6 per
adult
Vector control
Immunization
Legislation with
public education
to reduce salt
content
Media campaign
to reduce
saturated fat
Breastfeeding
promotion
Legislation replacing 2% of
dietary trans fat from partial
hydrogenation in manufactured
foods with polyunsaturated fat,
at a cost of US$0.50 per adult,
and assuming a 7% reduction in
coronary artery disease
Legislation replacing 2% of
dietary trans fat from partial
hydrogenation in manufactured
foods with polyunsaturated fat,
at a cost of US$6 per adult, and
assuming a 7–40% reduction in
coronary artery disease
Chemical vector control using
larvicides and insecticide space
sprays (including emephos, per-
methrin, methoprene, pyriprox-
yfen, and Bacillus thuringiensis
israelensis) to protect drinking
water, or environmental vector
control, such as removal of
standing water
Dengue immunization (a vaccine
is currently undergoing clinical
trials in Southeast Asia)
Legislated reduction in salt con-
tent of manufactured foods and
an accompanying public educa-
tion campaign
Media campaign to reduce satu-
rated fat content in manufac-
tured foods and replace part of
the saturated fat with
polyunsaturated fat
Promotion of exclusive breast-
feeding (recommended for six
months) to new mothers, in
which no other food or drink,
including water, is permitted,
except for supplements of
vitamins and minerals and
necessary medicines
Policy level
Policy level
Community
or district
hospital
Community
clinic or
district
hospital
Policy level
2,617
Community,
clinic, or
district
hospital
Instrument
of policy
Instrument
of policy
Control of
environmen-
tal hazard
Population-
oriented
medical
intervention
Instrument
of policy
Instrument
of policy
Personal
behavior
change
Adults
Adults
All ages
Children
All ages
All ages
Adult
women
48
838
2,566
1,440
1,937
2,617
930
—
—
—
—
18.73
13.86
0.43
—
—
—
—
—
—
1.33
5
5
2
2
5
5
5
—
199–1,478
1,992–3,139 
—
—
—
—
(Continues on the following page.)
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Table 2.B.2 (Continued)
Quality 
Cost- Number of cost-
Target Cost- effectiveness of DALYs Number effectiveness 
Intervention popula- effectiveness rangeb avertedb of deaths analysis 
Condition Intervention Intervention description setting Objective tiona (US$/DALY) (US$/DALY) (hundreds) avertedb evidencec
Diarrheal disease
Diarrheal disease
Diarrheal disease
Diarrheal disease
Diarrheal disease
Cholera or
rotavirus
immunization
Improved water
and sanitation at
current coverage
of amenities
and other
interventions
Hand pump,
standpost, or
house connection
where clean
water supply is
limited
Water sector
regulation with
advocacy where
clean water
supply is limited
Construction and
promotion of
basic sanitation
where facilities
are limited
Immunization for endemic
cholera with live oral vaccine or
rotavirus immunization with
rhesus-human rotavirus
reassortant-tetravalent vaccine
(currently under development) in
populations at risk of an
outbreak 
Improved water supply and
excreta disposal where estab-
lished infrastructure currently
exists, in urban or rural settings
for at least five years
Installation of hand water pump,
standpost, or house connection
where clean water supply is
limited and associated infra-
structure currently do not exist
Surveillance of drinking water
quality and quality of service by
the water supply utility in terms
of coverage, quantity, continuity,
control of sanitary hazards, and
cost, as well as advocacy of
lower connection charges
Construction of low-cost excreta
disposal facilities such as house-
hold pit latrines, ventilation-
improved latrines, or pour-flush
toilets, combined with public
promotion of sanitation and
hygiene
Clinic
Community
Community
Policy level,
community
Policy level,
community
Population-
oriented
medical
intervention
Control of
environmen-
tal hazards
Control of
environmen-
tal hazards
Instrument
of policy,
control of
environmen-
tal hazards
Instrument
of policy,
control of
environmen-
tal hazards
Children
All ages
All ages
All ages
All ages
2,712
4,185
159
47
141
0.62 
3.52 
—
—
—
1.98 
315.30
—
—
—
5
5
1
1
1
2,478–2,945
1,974–6,396
—
—
11–270
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Down syndrome
Emergency
medical care
Emergency
medical care
Haemophilus
influenzae type B
(Hib)
Hib, and
hepatitis B,
diphtheria,
pertussis, and
tetanus
Hepatitis B
Prenatal screen-
ing with option of
pregnancy 
termination
Training volun-
teer paramedics
with lay first
responders 
Staffed 
community 
ambulance
Vaccine 
containing Hib
Pentavalent
vaccine
Hepatitis B
vaccination
Prenatal genetic screening pro-
gram, incorporating maternal
serum triple screening of all
pregnant women, for trisomy of
chromosome 21, to allow par-
ents to determine whether to
continue with an affected
pregnancy
Identification and training of
community member first respon-
ders and paramedics to act in
health emergencies, recognize
life- or limb-threatening situa-
tions, transport patients, and
provide basic first aid
Introduction or promotion of
training programs for emergency
responders and ambulance driv-
ers in urban or rural settings for
countries that lack ambulances
and training programs
Hib vaccination (three or four
doses), given concurrently with
diphtheria-pertussis-tetanus 
Hib vaccination (three or four
doses) and hepatitis B (three or
four doses) given concurrently
with diphtheria-pertussis-
tetanus vaccine
Hepatitis B (three or four doses)
given through intramuscular
injection
Clinic,
district
hospital
Policy level
Policy level
Clinic
Clinic
Clinic
Population-
oriented
medical
intervention
Instrument
of policy
Instrument
of policy
Population-
oriented
medical
intervention
Population-
oriented
medical
intervention
Population-
oriented
medical
intervention
Pregnant
women
All ages
All ages
Infants and
children
Infants and
children
Infants and
children
15
6
120
733d
296d
23,520d
—
18.42
34.84 
29.25
—
—
—
74.00 
140.00 
113.83
— 
—
5
5
5
5
5
5
—
—
60–179 
—
—
—
(Continues on the following page.)
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Table 2.B.2 (Continued)
Quality 
Cost- Number of cost-
Target Cost- effectiveness of DALYs Number effectiveness 
Intervention popula- effectiveness rangeb avertedb of deaths analysis 
Condition Intervention Intervention description setting Objective tiona (US$/DALY) (US$/DALY) (hundreds) avertedb evidencec
HIV/AIDS
HIV/AIDS
HIV/AIDS
HIV/AIDS
Lymphatic
filariasis
Condom promo-
tion and
distribution
Blood and
needle safety
Voluntary
counseling
and testing
Peer and educa-
tion programs for
high-risk groups
Annual mass
drug
administration
Targeted distribution and place-
ment of condoms in locations
such as bars or brothels; distri-
bution linked to voluntary coun-
seling and testing and sexually
transmitted infection care to
ensure universal access; infor-
mation, education, and commu-
nication, including education
through literature, classroom,
and clinical settings and radio,
newspapers, and television
Screening of all blood for trans-
fusions; sterilization for all injec-
tions; harm reduction for inject-
ing drug users, including needle
exchange and drug substitution
programs
Routine and voluntary confiden-
tial HIV counseling and testing
Targeting community members
(for example, students or com-
mercial sex workers) to dissemi-
nate information and teach
specific skills
Two annual, single-dose, two-
drug regimens are recommend-
ed: ivermectin plus albendazole
in African countries that are
coendemic for onchocerciasis,
and diethylcarbamazine plus
albendazole for all other
endemic countries
Community
or
Community,
clinic
All levels,
including
community
clinics to
referral
hospitals
Clinic
Community
Clinic,
community
Personal
behavior
change
Population-
oriented
medical
intervention
Population-
oriented
medical
intervention
Personal
behavior
change
Population-
oriented
medical
intervention
Adolescents
and adults
All ages
Adults
Adolescents
and adults
All ages
82 (Sub-Saharan
Africa) 
84 (Sub-Saharan
Africa)
47
37
15 (South Asia)
—
—
—
—
—
—
—
—
—
—
1 (Sub-
Saharan
Africa)
2 (Sub-
Saharan
Africa)
2
2
4 (South Asia)
52–112 (Sub-
Saharan Africa) 
7–161 (Sub-
Saharan Africa) 
10–85 
6–68
4–27 (South Asia)
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Lymphatic
filiariasis
Lymphatic
filariasis
Malaria
Malaria
Measles
Meningitis
Problems
requiring surgery
Onchocerciasis
Soil-transmitted
helminthic
infections
Diethyl carba-
mazine salt
Vector control
Insecticide-
treated bednets
Residual house-
hold spraying
Second opportu-
nity vaccination
in a fixed facility
Neisseria menin-
gitidis vaccine
Surgical ward or
services in dis-
trict hospital or
community clinic
Ivermectin
Albendazole
Fortification of salt with diethyl
carbamazine
Integrated vector control to
reduce overall prevalence of
microfilaria parasites, such as
polystyrene beads in vector
(mosquito) breeding habitats
Impregnation of bednets with
deltamethrin, one treatment of
permethrin, or two treatments of
permethrin, with the bednets
either purchased or subsidized
One or two doses of malathion,
DDT, deltamethrin, or lambda-
cyhalothrin applied to household
surfaces
Second opportunity to receive a
dose of measles vaccine (either
through routine or supplemental
immunization activities) at a
fixed facility
Neisseria meningitidis vaccine for
serogroups A, C, Y, Wi35 only;
unconjugated polysaccharides
given subcutaneously; one dose
with repeat three to five years
later for those at high risk 
Surgical ward in a district
hospital or community clinic to
provide care for a wide range of
conditions, such as trauma,
childbirth, and abdominal
conditions
Annual dose of ivermectin
Annual albendazole anti-
helminthic drug treatment to
reduce morbidity through the
deworming of Ascaris, Trichuris,
and hookworm in school-age
children
Policy level
Policy level
Household 
Household 
Clinic
Clinic
District
hospital,
clinic
Clinic,
community
Community,
school
Instrument
of policy
Instrument
of policy
Control of
environmen-
tal hazards
Control of
environmen-
tal hazards
Population-
oriented
medical
intervention
Population-
oriented
medical
intervention
Instrument
of policy
Population-
oriented
medical
intervention
Population-
oriented
medical
intervention
All ages
All ages
All ages
All ages
Infants
and
children
Children
All ages
Adults
over 40
School-age
children
22 (South Asia)
160 (South Asia)
11 (Sub-Saharan
Africa) 
17 (Sub-Saharan
Africa) 
4
12,632 (Sub-
Saharan Africa) 
136
37
3
—
—
376.00 (Sub-
Saharan
Africa) 
376.00 (Sub-
Saharan
Africa) 
—
—
—
—
127.76 
—
—
1,429.60 (Sub-
Saharan Africa) 
1,429.60 (Sub-
Saharan Africa) 
—
—
—
—
1.98 
4 (South Asia)
4 (South Asia)
5 (Sub-
Saharan
Africa)
5 (Sub-
Saharan
Africa)
5
5 (Sub-
Saharan
Africa)
5
3
5
1–43 (South Asia)
43–277 (South
Asia)
5–17 (Sub-
Saharan Africa) 
9–24 (Sub-
Saharan Africa) 
—
—
54–217
—
—
(Continues on the following page.)
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Tetanus
Tobacco
addiction
Tobacco
addiction
Traffic accidents
Traffic accidents
Tetanus toxoid
vaccination, mix
of strategies
Taxation causing
33% price
increase
Nonprice
interventions
Increased speed-
ing penalties,
enforcement,
media cam-
paigns, and
speed bumps
Enforcement of
seatbelt laws,
promotion of child
restraints and
random driver
breath testing
Tetanus toxoid vaccination via a
mix of strategies depending on
local needs, including fixed facil-
ities, immunization campaigns,
mobile delivery, and community
outreach
A 33 percent price increase due
to tobacco taxes to discourage
tobacco use, prevent initiation
(and subsequent addiction)
among youths, increase the
likelihood of cessation among
current users, reduce relapse
among former users, and reduce
consumption among continuing
users
Advertising bans on television,
radio, and billboards; health
information and advertising in
the form of health warning
labels on tobacco products;
interventions to reduce tobacco
supply, such as smuggling con-
trol; restrictions on smoking
Minimizing exposure to high-risk
scenarios by installation of
speed bumps at hazardous junc-
tions, increased penalties for
speeding, and other effective
road-safety regulations com-
bined with media coverage and
better enforcement of legislation
Mandatory seat belt and child-
restraint laws, enforcement of
drunk-driving laws, and random
breath testing of drivers 
Clinic,
community
Policy level
Policy level
Policy level
Policy level
Population-
oriented
medical
intervention
Instrument
of policy
Instrument
of policy
Instrument
of policy
Instrument
of policy
Infants and
children
Adolescents
and adults
Adolescents
and adults
Adults
Adults
1,411 
22
353
21
2,449
—
37.27 
—
0.67 
0.32 
—
1,905.99 
—
197.16 
93.87 
5
5
5
5
5
—
—
—
3–38
999–3,899
Table 2.B.2 (Continued)
Quality 
Cost- Number of cost-
Target Cost- effectiveness of DALYs Number effectiveness 
Intervention popula- effectiveness rangeb avertedb of deaths analysis 
Condition Intervention Intervention description setting Objective tiona (US$/DALY) (US$/DALY) (hundreds) avertedb evidencec
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Tuberculosis
(endemic)
Tuberculosis,
diphtheria, per-
tussis, tetanus,
polio, measles
Undernutrition
and malnutrition
Underweight
children 
BCG vaccine
Traditional
Expanded
Program on
Immunization
(EPI)
Sustained child
health and nutri-
tion program
Child survival
program with
nutrition
component
Live attenuated vaccine, BCG;
recommended at birth or at first
contact with health services in
areas of high incidence
Scaling up of EPI; a fixed incre-
ment of coverage added for each
year 2002–11 to reach 90 per-
cent; coverage increases
assumed to result from switch-
ing to more effective and inten-
sive implementation strategies
rather than additional infrastruc-
ture investments
Possible inclusion of prenatal
care, women’s health and nutri-
tion, breastfeeding promotion
and counseling, complementary
feeding, growth monitoring and
promotion, micronutrient supple-
mentation, micronutrient fortifi-
cation, supplementary feeding
using local supplies, oral rehy-
dration, and immunization and
deworming; actual mix depends
on local capabilities and
conditions
Community-based nutrition pro-
grams to prevent growth falter-
ing, control morbidity, and
improve survival by promoting
breastfeeding, providing educa-
tion and counseling on optimal
child feeding, preventing diar-
rheal disease, and monitoring
growth
Clinic or
district
hospital
Community
Community,
clinic
Community
Primary
prevention
Population-
oriented
medical
intervention
Population-
oriented
medical
intervention
Population-
oriented
medical
intervention
Population-
oriented
medical
intervention
Children
Infants
and
children
Children
under five
Children
under five
68
7
225
42
—
—
—
—
—
—
—
—
5
5
3
2
55–82
—
—
—
Source: Authors.
BCG  bacillus Calmette  Guérin; DDT  dichlorodiphenyl trichloroethane; EPI  Expanded Program on Immunizations
Note: —  not available.
a. Refers to the age group to whom the intervention is targeted and not necessarily the one that is benefiting.
b. Ranges in cost-effectiveness reflect the variation in point estimates for specific interventions included in each intervention cluster and do not represent either variation across regions or statistical confidence intervals. Point estimates were obtained directly from the
relevant chapters, calculated as the midpoint of range estimates reported in the chapters, or calculated from a population-weighted average of the region-specific estimates reported in the chapters. DALYs and deaths potentially avertable are for a 20 percentage point
increase in intervention coverage in a hypothetical sample population of 1 million.
c. See table 2.1. 
d. Cost-effectiveness ratio calculated from deaths averted only. 
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Breast cancer
Breast cancer
Breast cancer
Breast cancer
Cervical cancer
Cervical cancer
Cervical cancer
Cervical cancer
Cervical cancer
Clinical breast exam
Screening mammography
Chemotherapy and/or
tamoxifen
Radiation therapy
Nationwide Pap screening
program based on five-
year intervals 
Conventional or liquid-
based cytology testing
Two-visit HPV testing
One-visit VIA
Three-visit cytology
Examination of the breast performed by
doctors or other trained health care pro-
fessionals; annually, biennially, or every
five years; for women ages 40–60
Examination of the breasts performed by
compressing the breast firmly between a
plastic plate and an X-ray cassette that
contains special X-ray film; one lifetime or
biennially
Tamoxifen and/or chemotherapy for 
45-year-old premenopausal women with
early-stage breast cancer; for node-
positive, node-negative, estrogen-
receptor-positive, and estrogen-
receptor-negative patients
Radiation therapy following mastectomy
and chemotherapy for node-positive breast
cancer in premenopausal women 
Nationwide Pap screening program based
on five-year intervals 
Conventional cytology using the
Papanicolaou (Pap) smear and HPV testing
every 1 to 10 years; or Liquid-based cytol-
ogy using the Papanicolaou (Pap) smear
and HPV testing every 1 to 5 years
HPV DNA testing during the first visit fol-
lowed by treatment of screen-positive
women during the second visit
Cervix is viewed after the application of
an acetic acid solution; screening and
treatment conducted during the same visit
Cytology sample obtained during the first
visit, colposcopy for screen-positive women
conducted during the second visit, and
treatment provided during the third visit
Clinic
Clinic
District hospital
District hospital
District hospital
District hospital
District hospital
District hospital
District hospital
Secondary prevention
Secondary prevention
Secondary prevention
Secondary prevention
Secondary prevention
Secondary prevention
Secondary prevention
Secondary prevention
Secondary prevention
Women ages
40–60
Women ages
40–70
Women age 45
Premenopausal
women
Adult women
Adult women
Adult women
Women age
35–42
Women age
35–48
7,125–9,907 per death
prevented (India);
522–722 per LYS (India) 
12,262–24,493 per death
prevented (India);
902–1846 per LYS (India);
2,450–14,790a per YLS
(Europe); 28,600–47,900
(USA) 
12,820–171,700 (USA) 
23,300–44,000 per QALY
(USA) 
769 per YLS (Vietnam) 
126,500 (USA); 162,400
(Thailand) 
122 per YLS (Brazil);
167 per YLS
(Madagascar); 41 per YLS
(South Africa); 117
per YLS (Zimbabwe) 
56 per YLS (Brazil); 54 per
YLS (Madagascar); 43 per
YLS (Zimbabwe) 
589 per YLS (Brazil); 379
per YLS (Madagascar);
331 per YLS (Zimbabwe) 
4
2 (USA, Europe);
4 (India)
3
2
2
2
1
1
1
Table 2.C.1 Cost Effectiveness of Other Personal Interventions
Cost- Quality 
Intervention Target effectiveness of CEA 
Condition Intervention Intervention description setting Objective population estimate (US$)a evidenceb
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Cervical cancer
Chronic obstruc-
tive pulmonary
disease
Chronic obstruc-
tive pulmonary
disease
Chronic obstruc-
tive pulmonary
disease, asthma,
and cardiovascu-
lar disease
Colorectal cancer
Colorectal cancer
Colorectal cancer
Colorectal cancer
Colorectal cancer
Chemoradiation therapy
Inhaled medication
A-1 antitrypsin augmenta-
tion therapy
Mechanical ventilation or
oxygen therapy
Flexible sigmoidoscopy
every 5 years with or
without fecal occult blood
test
Double-contrast barium
enema every 5 years
Colonoscopy every
10 years
Chemotherapy
Radiation therapy
Cisplatin-based chemoradiation regimens
on the basis of published and estimated
survival
Inhaled ipratroprium bromide or cortico-
steroid such as fluticasone propionate
Intravenous treatment of chronic obstruc-
tive pulmonary disease related to severe
deficiency; ranges with age and efficacy
Mechanical ventilation with inspiratory
support, invasive respiration in intensive
care unit, or long-term home oxygen
therapy
Flexible sigmoidoscopy enables the physi-
cian to look at the inside of the large
intestine from the rectum through the last
part of the colon, called the sigmoid or
descending colon; fecal occult blood test
checks stool samples for traces of blood.
A series of x-rays of the colon and rectum
taken after the patient is given an enema,
followed by an injection of air. The barium
outlines the intestines on the x-rays,
allowing many abnormal growths to be
visible. This is conducted every 5 years.
Colonoscopy allows the physician to look
inside the entire large intestine, from the
lowest part, the rectum, all the way up
through the colon to the lower end of the
small intestine. The procedure is used to
look for early signs of cancer in the colon
and rectum.
Adjuvant chemotherapy for stage three
colon cancer 
Preoperative radiation therapy for rectal
cancer patients; with varying rates of
recurrence and survival advantage with
and without radiation treatment
District hospital
Clinic/district
hospital
Clinic/district
hospital
Clinic/district
hospital
District hospital
District hospital
District hospital
District hospital
District hospital
Secondary prevention
Palliation
Palliation
Palliation
Secondary prevention
Secondary prevention
Secondary prevention
Secondary prevention
Secondary prevention
Adult women
Adults
Adults
Adults
Adults
Adults
Adults
Adults
Adults
337–31,400 per LYS
(USA) 
7,800–13,400 per QALY
(High-income countries)
14,400–215,000 per
QALY (High-income
countries) 
15,000–19,000 per YLS
(High-income countries);
32,350–47,850 per QALY
(High-income countries) 
18,700–25,954 (USA) 
11,503–26,393 per YLS
(USA) 
9,309–22,672 per YLS
(USA) 
3,000–7,000 per YLS
(High-income countries) 
908–15,228 per YLS
(Sweden) 
1
1
1
1
2
2
2
1
1
(Continues on the following page.)
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Table 2.C.1 (Continued)
Cost- Quality 
Intervention Target effectiveness of CEA 
Condition Intervention Intervention description setting Objective population estimate (US$) evidence
Diabetes
Diabetes
Diabetes
Diabetes
Diabetes
Diabetes
Kidney disease
Smoking cessation
Annual eye examination 
ACE inhibitor 
Metformin intervention for
preventing type 2 diabetes
Cholesterol control
Intensive glycemic control
Hemodialysis
Counseling and medication such as the
nicotine patch 
Dilated eye examination to detect prolifer-
ative diabetic retinopathy and macular
edema followed by appropriate photoco-
agulation therapy to prevent blindness 
ACE inhibitors for blood pressure control
Metformin therapy for preventing type 2
diabetes among people at high risk, such
as those with prediabetes
Cholesterol control for people with total
cholesterol higher than 200
milligrams/deciliter
Intensive glucose control to lower the
level of glucose in the person with dia-
betes to a level close to that of a person
without diabetes, for people with HbA1c
higher than 8 percent, in order to prevent
or delay long-term diabetes complications
Most common method used to treat
advanced and permanent kidney failure;
conducted in a treatment center or home.
Clinic
Clinic
Clinic
Clinic
Clinic
Clinic
Clinic, home
Primary prevention
Secondary prevention
Secondary prevention
Primary prevention
Secondary prevention
Secondary prevention
Secondary prevention
Adolescents and
adults
Adults
Adults
Adults
Adults
Adults
Adults
870 per QALY (EAP);
1,170 per QALY (ECA);
1,450 per QALY (LAC);
1,230 per QALY (MNA);
730 per QALY (SAR); 660
per QALY (SSA)
420 per QALY (EAP); 560
per QALY (ECA); 700 per
QALY (LAC); 590 per
QALY (MNA); 350 per
QALY (SAR); 320 per
QALY (SSA)
620 per QALY (EAP); 830
per QALY (ECA); 1,020
per QALY (LAC); 870 per
QALY (MNA); 510 per
QALY (SAR); 460 per
QALY (SSA)
2,180 per QALY (EAP);
2,930 per QALY (ECA);
3,630 per QALY (LAC);
3,080 per QALY (MNA);
1,820 per QALY (SAR);
1,640 per QALY (SSA)
4,420 per QALY (EAP);
5,940 per QALY (ECA);
7,350 per QALY (LAC);
6,240 per QALY (MNA);
3,680 per QALY (SAR);
3,330 per QALY (SSA)
2,410 per QALY (EAP);
3,230 per QALY (ECA);
4,000 per QALY (LAC);
3,400 per QALY (MNA);
2,000 per QALY (SAR);
1,810 per QALY (SSA)
42,700–70,000 per YLS
(USA); 61,000–99,400 per
QALY (USA) 
5
5
5
5
5
5
1
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Kidney disease
Kidney disease
Mild to moderate
asthma
Opioid abuse
Opioid abuse
Opioid abuse
Opioid abuse
Opioid abuse
Osteoarthritis
Osteoarthritis
Osteoporosis
Kidney transplant
ACE inhibitors 
Quick-releavers in addition
to inhaled corticosteriods 
Naltrexone induced rapid
opioid detoxification under
sedation (RODS)
Conventional outpatient
detoxification 
Drug-free treatments
Methadone maintenance
substitution
Buprenorphine mainte-
nance substitution
Lifestyle change
Replacement surgery
Hormone replacement
therapy
Kidney transplant surgery
ACE inhibitors for all type-1 diabetics 
with macroproteinuria and all type-2
diabetics
Rapid-acting bronchodilators that act to
relieve bronchoconstriction and accompa-
nying acute symptoms of wheeze, chest
tightness, and cough, e.g., salbutamol;
incremental to inhaled corticosteroid
treatment
Patient is given naltrexone under general
anesthetic.
Conventional outpatient detoxification is
supervised withdrawal from a drug of
dependence that attempts to minimize
withdrawal symptoms.
Residential or outpatient drug-free
treatments as well as self-help group
attendance
Substitution of short-acting heroin with
long-acting orally administered opioid
Methodone; includes heroin users living in
communities with high HIV prevalence
Buprenorphine substitution maintenance
treatment for non-methadone patients.
Exercise (aquatic) and calcium
supplements
Synovial fluid replacement (hylan G-F 20)
for patients with osteoarthritis of the
knee; or complete hip joint or knee
replacement with implant
Estrogen replacement from age 50, 60, or
menopause for healthy women; 5-year to
lifetime treatment
District or referral
hospital
Clinic
Clinic or district
hospital
District hospital
Clinic
Clinic
Clinic
Clinic
Clinic
Clinic, district
hospital
Clinic
Cure
Secondary prevention
Palliation
Rehabilitation
Rehabilitation
Rehabilitation
Rehabilitation
Rehabilitation
Primary/secondary
prevention
Secondary preven-
tion; tertiary inter-
vention
Primary/secondary
prevention
Adults
Adults
Adults
Adults
Adults
Adults
Adults
Adults
Adults age 
55–75; post-
menopausal
women
Elderly men and
women
Postmenopausal
women and
women age 50
and up
10,000 per LYS (USA);
11,000 per QALY (USA) 
1,100–7,700 per QALY
(USA) 
10,600-13,900 per QALY
(High-income countries) 
2,498 per week of absti-
nence (Australia) 
12,764 per abstinent
patient (Australia) 
7,000–13,000a (USA) 
6,800 per LYS (High-
income countries); 9,000
per QALY (High-income
countries, high-HIV
prevalence) 
49,000 per QALY (High-
income countries) 
96,119–498,700 per
QALY (High-income
countries) 
5,233–6893 per QALY
(High income countries) 
5,088–23,734 per QALY 
2
4
1
1
1
1
1
1
1
1
1
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Source: Authors.
a. Currency units in US$, but not necessarily 2001.
b. See table 2.1.
Osteoporosis
Osteoporosis
Osteoporosis
Pain
Primary care
ailments
Respiratory
disease (end
stage)
Calcium supplements with
or without vitamin D
Nonestrogen drug
treatments
Fluoride
Morphine
Limited care
Lung transplant
Calcium with or withouth vitamin D
supplements, based on evidence that it
reduces appendicular fractures; assumes a
compliance rate of 70%
Raloxifene or calcitonin to reduce bone
fractures; with or without 5 years of
therapy
Fluoride appears to decrease the risk of
vertebral fracture for women with estab-
lished osteoporosis; assumes neutral
effect on hip fractures
Providing oral morphine and necessary
associated drugs 
Includes treatment of infection and minor
trauma; for more complicated condition,
includes diagnosis, advice and pain relief,
and treatment as resources permit
Surgical replacement with donor lung
Clinic
Clinic
Clinic
Clinic
Clinic
District hospital
Primary prevention
Secondary prevention
Secondary prevention
Palliation
Cure
Cure
Women age 50
to 80
Postmenopausal
women age 50
to 80
Postmenopausal
women
All ages
All ages
Adults
37,633–149,705 per
QALY 
34,166–835,622 per
QALY (High income
Countries) 
46,684 per QALY (UK) 
210–408 per year of pain
free life added (Chile,
Romania, Uganda) 
253–380 per DALY (Low
income countries);
507–760 per DALY
(Middle income countries)
238,200–464,000 per
QALY (High-income
countries)
1
1
1
4
1
1
Table 2.C.1 (Continued)
Cost- Quality 
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Condition Intervention Intervention description setting Objective population estimate (US$)a evidenceb
Intervention Cost-Effectiveness: Overview
 of M
ain M
essages
|
83
Table 2.C.2 Cost-Effectiveness of Other Population-Based Interventions
Cost- Quality 
Intervention Target effectiveness of CEA 
Condition Intervention Intervention description setting Objective population estimate (US$)a evidenceb
Asthma
Colorectal cancer
Diarrhea
Diabetes
Diabetes
Diabetes
Diabetes
Indoor air
pollution-related
illness
Education
Fecal occult blood test
Improved quality of care
Lifestyle intervention
(type 2 prevention) 
Influenza and pneumococ-
cal vaccinations 
Screening 
Annual screening for
microalbuminuria
Liquefied petroleum gas 
Education in addition to exercise program
Fecal occult blood test to check stool
samples for traces of blood; conducted
annually or biennially
Educational interventions to improve
quality of care and encourage oral rehy-
dration therapy in hospitals; varies with
marginal improvement; low to average
prevalence
Behavioral change for weight reduction by
means of a combination of a low-calorie
diet and moderate physical activity 
Influenza and pneumococcal vaccinations
for elderly individuals with type 2 diabetes 
Screening of individuals at increased risk
for undiagnosed diabetes 
Screening for microalbuminuria and treat-
ing those who test positive
Substitution of wood, dung, and crop
residues with liquefied petroleum gas for
cooking and heating
Clinic
District hospital
Clinic/district
hospital
Clinic
Clinic
Clinic, district
hospital
Clinic, district
hospital
Policy level
Personal behavior
change
Secondary prevention
Instrument of policy
Personal behavior
change
Population-oriented
medical intervention
Population-oriented
medical intervention
Population-oriented
medical intervention
Instrument of policy
Adults
Adults
All ages
Adults
Elderly
Adults over 25
Adults
All ages
71,500/QALY (High-income
countries) 
3,200–12,100 per YLS (High-
income countries) 
14–6000a per death averted 
80 per QALY (EAP); 100 per
QALY (ECA); 130 per QALY
(LAC); 110 per QALY (MNA);
60 per QALY (SAR); 60 per
QALY (SSA)
220 per QALY (EAP); 290 per
QALY (ECA); 360 per QALY
(LAC); 310 per QALY (MNA);
180 per QALY (SAR); 160 per
QALY (SSA)
5,140 per QALY (EAP); 6,910
per QALY (ECA); 8,550 per
QALY (LAC); 7,260 per QALY
(MNA); 4,280 per QALY
(SAR); 3,870 per QALY (SSA)
3,310 per QALY (EAP); 4,450
per QALY (ECA); 5,510 per
QALY (LAC); 4,680 per QALY
(MNA); 2,760 per QALY
(SAR); 2,500 per QALY (SSA)
103–1,746 per healthy year
(EAP); 1,258–1,361 per
healthy year (ECA);
806–1,447 per healthy year
(LAC); 779–785 per healthy
year (MNA); 321–558 per
healthy year (SA); 534–736
per healthy year (SSA)
1
2
4
5
5
5
5
5
(Continues on the following page.)
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Indoor air
pollution-related
illness
Indoor air
pollution-related
illness
Indoor air
pollution-related
illness
Lung cancer
Pneumonia
Pollution-related
illness
Pollution-related
illness
Pollution-related
illness
Kerosene
Improved stove
Improved stove with
kerosene or LPG
Early detection screening
Improved quality of care
Control of toxins related
to energy industry
Control of toxins related
to agriculture and forestry
Control of toxins related
to residential sector
Substitution of wood, dung, and crop
residues with kerosene for cooking and
heating
Replacement of traditional open stoves
with enclosed stoves that are more effi-
cient and/or have flues for ventilation
Replacement of traditional open stoves
with enclosed stoves that use kerosene or
liquified petroleum gas (LPG)
Screening of high-risk individuals, such as
current and former smokers, for lung can-
cer using helical computed tomography 
Improved quality of care, including educa-
tion for health providers and treatment of
non-severe and severe pneumonia; varies
with marginal improvement; low to aver-
age prevalence
Interventions include coal-fired power
plant emissions controls, gasoline lead
reduction, and desulphuring of residual
fuel oil
Interventions include targeted pesticide
bans and emissions standards at process-
ing facilities
Interventions include radon remediation
and sedimentation, filtration, and chlorina-
tion of drinking water
Policy level
Policy level
Policy level
District hospital
Clinic/district
hospital
Policy level
Policy level
Policy level
Instrument of policy
Instrument of policy
Instrument of policy
Population-oriented
medical intervention
Instrument of policy
Instrument of policy
Instrument of policy
Instrument of policy
All ages
All ages
All ages
Adults
Children
All ages
All ages
All ages
12–232 per healthy year
(EAP); 172–188 per healthy
year (ECA); 109–650 per
healthy year (LAC); 98 per
healthy year (MNA): 37–65
per healthy year (SAR);
62–87 per healthy year (SSA)
306–605 per healthy year
(EAP); 975–1,134 per healthy
year (LAC); 379–471 per
healthy year (MNA): 13–15
per healthy year (SAR);
21–26 per healthy year (SSA)
26–85 per healthy year (EAP);
522–1,416 per healthy year
(ECA); 305–784 per healthy
year (LAC); 227–624 per
healthy year (MNA): 27–182
per healthy year (SAR);
46–304 per healthy year
(SSA)
20,000–100,000 per YLS
(USA) 
132–5,000a per death
averted 
less than 0 per LYS (USA) 
less than 0 per LYS (USA) 
5320–7730 per LYS (USA) 
5
5
5
3
4
1
1
1
Table 2.C.2 (Continued)
Cost- Quality 
Intervention Target effectiveness of CEA 
Condition Intervention Intervention description setting Objective population estimate (US$)a evidenceb
Intervention Cost-Effectiveness: Overview
 of M
ain M
essages
|
85
Pollution-related
illness
Silicosis
Silicosis
Silicosis
Control of toxins related
to industrial sector
Engineering control
Comfort or dust mask
Respirator
Interventions include arsenic emissions
standards at copper smelters and
asbestos ban for brake linings
Wet method e.g. spraying a surface or
wetting a blade to reduce dust; local
exhaust ventilation; total plant ventilation
Comfort or dust mask with associated
training
Half-face or full-face respirator and asso-
ciated training
Policy level
Policy level
Policy level
Policy level
Instrument of policy
Control of environ-
mental hazards
Instrument of policy
Instrument of policy
All ages
Working adults
Working adults
Working adults
less than 45,600 per LYS
(USA) 
105a per DALY (USA and
Canada); 109a per DALY
(Western Pacific) 
111–191a per DALY (USA
and Canada); 117–174a
(Western Pacific) 
300–305a per DALY (USA
and Canada); 266–274a per
DALY (Western Pacific) 
3
3
3
Source: Authors.
a. Currency units in US$, but not necessarily 2001.
b. See table 2.1.
NOTES
1. Few other cost-effectiveness studies have covered a similarly exten-
sive set of health interventions (Dixon and Welch 1991; Jamison and oth-
ers 1993; Tengs and others 1995), and only one of those studies makes these
comparisons on a global scale (Jamison and others 1993). The current
World Health Organization project CHOICE (Choosing Interventions
That Are Cost-Effective) is a parallel effort to make such global compar-
isons (Murray and others 2000; http://www.who.int/evidence/cea).
2. Of these 319 cost-effectiveness estimates, 257 were in terms of
U.S. dollars per DALY and therefore comparable. Interventions with cost-
effectiveness in terms of dollars per DALY were grouped into 121 inter-
vention clusters to facilitate analyses and presentation.
3. Health system capacity is often used to describe both the level of care
(primary, secondary, and tertiary) and the institutional and organizational
capacities. We use the term to refer to the latter.
4. Chapter 15 presents a fuller discussion of these methods. Note that
not all chapters have used these standardized costs. Furthermore, the
analyses have used U.S. dollars rather than purchasing-power parity dol-
lars (which provide a better measure of input resource intensity and are
less susceptible to exchange rate fluctuations) in order to provide a mone-
tary estimate that may be more useful to policy makers and donors.
5. Noneconomic reasons for maintaining certain interventions can
include retaining key technical skills that may be required in the future
and may lead to the development of new methods that may be more 
cost-effective (see chapter 66 on referral hospitals for a more in-depth
discussion).
6. Some interventions with high potential to reduce the burden of dis-
ease may have been excluded due to the way their cost-effectiveness ratios
were calculated. For example, nutrition-related interventions are excluded
from the table because those evaluated in the volume address either vita-
min A deficiency or iodine deficiency both of which are associated with
low avertable burden. Also, only the burden of children age 0 to 4 was con-
sidered, further lowering the avertable burden. Another example is of
the integrated management of infant and childhood illness, which is eval-
uated for Sub-Saharan Africa but not for the South Asia Region.
7. The second and third observations speak more generally to the
global public goods nature of health research (see chapter 4 for an in-
depth discussion). In relation to both HIV/AIDS and noncommunicable
diseases, the responsiveness of the medical research system to threats to
populations in developed countries has the potential to bring great bene-
fits to people living in LMICs.
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Interventions are not generally provided as freestanding activi-
ties but are delivered in a variety of packages and through dif-
ferent levels of a health system.1 For this reason, this book—in
addition to including the disease- and program-specific
chapters—addresses not only the cost-effectiveness of levels of
care, packages of care, and services but also the strengthening
of the management of health systems as a whole.
Cost-effectiveness data reflect largely what can be achieved
in a reasonably well-functioning health system. In that
sense, they can be considered to represent potential cost-
effectiveness and need to be supplemented with evidence and
guidance on how health systems can be strengthened to pro-
vide interventions effectively, efficiently, and equitably. This
argument is given added weight by evidence on inadequacies
in the performance of health institutions in countries at all lev-
els of development (Hensher 2001; Preker and Harding 2003).
Hensher (2001) documents the extensive inefficiencies in low-
and middle-income countries, including the following:
• failure to minimize the physical inputs used—for example,
prescribing excessive quantities of drugs 
• failure to use the mix of inputs that costs the least—for
instance, allocating a high proportion of expenditure to
staff salaries and only a small share to operating costs and
maintenance 
• failure to operate at the appropriate scale—for example,
running extremely large hospitals that suffer from scale
inefficiencies
• failure to pay staff enough to encourage good performance.
Hensher estimates that hospital inefficiencies could easily
account for up to 10 percent of total health spending.
Such inefficiencies have two main causes. First, they may
occur because decision makers lack incentives to behave effi-
ciently; for example, their promotion chances may not depend
on how well they perform in managing a hospital. Second,
decision makers may be constrained in their ability to make
efficient choices; for instance, they may lack knowledge or
experience of what to do or political factors may affect whether
they can dismiss underperforming staff members or determine
which company they must buy drugs from. Evidence on the
quality of care (chapter 70) demonstrates that health systems
may not merely be inefficient in failing to minimize costs but
may also fail to deliver effective care.
The extent of inequities is also a major concern. Recent
analyses show that even when interventions are provided, the
poorest members of society usually have the least access to
them (Gwatkin and others 2000). In many countries, gaps in
child mortality between the poor and the better off widened
during the 1990s (World Bank 2004). Thus, health systems
need to have the capacity not only to deliver interventions effi-
ciently but also to sustain high levels of coverage, especially of
the poorest and most vulnerable.
Awareness has grown that international targets, such as the
Millennium Development Goals (MDGs) and the provision of
antiretroviral treatment for HIV/AIDS patients cannot be
achieved without the key elements of a functioning health
system. The example of the reduction of maternal mortality
in Sri Lanka (chapter 8) demonstrates the improvements in
health outcomes that are possible once a basic platform of
functioning health services is available on which targeted ini-
tiatives can build (Levine 2004).
Thus, the aim of this chapter is to review how health systems
can be strengthened in differing country contexts to deliver
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interventions effectively, efficiently, and equitably. The chapter
is mainly concerned with strengthening health services: issues
in managing core public health functions are reviewed else-
where (Khaleghian and Das Gupta 2004). Although the chap-
ter seeks to draw valuable lessons from all parts of the world, it
focuses on countries with the least capacity, especially the
poorer countries in Sub-Saharan Africa and Asia.
HISTORY AND CURRENT THEMES 
Efforts to improve health in low- and middle-income countries
over the past 50 years can be divided into a number of periods,
with pendulum swings between focused, disease-specific sup-
port and broader health service or health system support. The
1950s, 1960s, and 1970s witnessed a number of successful dis-
ease control efforts, often termed mass campaigns—notably
smallpox eradication, but also, for example, malaria and yaws
control (Walt 2001). These mass campaigns built on earlier
efforts, including those of the Rockefeller Foundation from the
1920s in controlling hookworm, yellow fever, and malaria.
Despite regional differences in the degree of progress—for
example, malaria control was not attempted in most of Sub-
Saharan Africa—successes in regional and global control of
diseases such as Chagas disease and measles in Latin America
and the Caribbean and, more recently, polio worldwide have
continued since the 1960s.
From early in the history of mass campaigns, the terminol-
ogy used was of vertical and horizontal approaches (Gonzalez
1965), referring essentially to two key dimensions in program
organization (Mills 2005): the extent to which program man-
agement was integrated into general health systems manage-
ment, especially at lower management levels, as opposed to
kept strictly separate, and the extent to which health workers
had one function as opposed to many functions. Vertical pro-
grams (also known as categorical programs) had their own
financing, management structures, and staff, even down to the
service delivery level, instead of relying on existing systems. In
contrast, horizontal programs delivered a number of services
through the general health service structure.
In malaria control, for example, the World Health
Organization defined a process whereby an initial vertical
approach would evolve into a horizontal approach as the inci-
dence of malaria fell. Initially, the effort required to detect and
treat cases demanded dedicated and mobile workers. As trans-
mission was reduced, these workers would detect fewer and
fewer cases, so on efficiency grounds, detection and treatment
activities needed to be handed over to the general health serv-
ice infrastructure. However, this approach faced the dilemma
that such services were often not strong enough to carry the
control efforts forward.
The Alma Ata Declaration of 1978 was a turning point. The
increasing emphasis on building networks of peripheral health
services in a number of postindependence Sub-Saharan
African countries and the health successes of countries such as
China and Cuba influenced a new international emphasis on a
broadly based definition of primary health care. Quickly, how-
ever, the advocates of more focused disease-specific efforts
responded with the notion of selective primary health care
(Walsh and Warren 1980), focused on a limited number of pre-
sumed cost-effective interventions.
Since 1980, this tension in international health policy has
persisted, with four main strands, namely:
1. The health care reform movement of the 1990s, which
has continued into the new millennium in a somewhat
attenuated form, has focused almost exclusively on financ-
ing and organizational changes, largely neglecting the ques-
tion of whether improved health outcomes have been
achieved.
2. The definition and development of cost-effective packages
of care has progressed, as reviewed in chapter 64, with some
attention given to their implications for services and
systems.
3. The emphasis on specific disease-focused international
programs, as reflected in the Global Fund for AIDS,
Tuberculosis, and Malaria, has been increasing, and
resources for such programs have been expanding.
4. The effort to encourage investment in integrated health
services has continued.
Recent events indicate that these tensions remain unre-
solved. For example, Molyneux and Nantulya (2004) call for
combining community-driven, global health initiatives
(including drug distribution for schistosomiasis, filariasis, and
onchocerciasis; trachoma control; bednet distribution for
malaria control; and immunization), with little mention of
how community-based efforts might link with the general
health infrastructure. In contrast, Unger, de Paepe, and Green
(2003) examine how best to implement disease control pro-
grams so as to strengthen existing health systems and propose
a code of best practice for such programs.
This debate is being given a new urgency by the introduc-
tion of treatment for HIV/AIDS. Immunization can be deliv-
ered using either a vertical or a horizontal approach.
HIV/AIDS treatment, which requires continuing care, calls for
strong health service backup. Nonetheless, such treatment
services could be organized so that they isolate themselves
from the broader health system—say, through separate clinics
with their own workers and separate laboratories—or they
could contribute to a greater degree of integration by sharing
resources.
The implications of these different approaches for health
system change are not purely academic. Table 3.1 compares
the responses to health system constraints that derive from a
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disease-specific focus as opposed to a health systems focus. A
disease-specific focus leads to solutions for the specific pro-
gram, whereas a health systems focus identifies a somewhat dif-
ferent set of reform priorities that relate to system-level
changes and affect disease management across multiple
diseases and conditions. The disease-focused responses can
generally be implemented relatively quickly, whereas the
systems-focused actions take longer. However, numerous,
separate disease-specific responses can rapidly overwhelm
frontline workers and managers.
HEALTH SYSTEM CONSTRAINTS ON THE
DELIVERY OF PUBLIC AND PERSONAL
HEALTH SERVICES 
The challenge of scaling up services to meet the health-related
MDGs and concerns that the multiple international efforts may
overwhelm countries’ fragile infrastructures have encouraged
efforts to think systematically about health system constraints
on achieving the MDGs, and the extent to which additional
funding can readily and quickly improve services (Ranson,
Hanson, and Mills 2003; Travis and others 2004). Weaknesses in
service delivery—for example, at the health center level—may
stem from problems at that level, such as staff shortages, or may
be affected by factors higher up the system, such as a poor drug
distribution system. Ranson and others (2003) therefore ana-
lyze constraints by five different levels: community and house-
hold, health services delivery, health sector policy and strategic
management, public policies cutting across sectors, and envi-
ronmental and contextual characteristics (see table 3.2).
At the community and household level, lack of demand can
limit coverage. This lack may stem from cultural factors, such
as low acceptability of immunization or prenatal care, but it
may also result from financial and physical barriers to access.
For example, estimates indicate that, in Niger, children under
five average only 0.5 visits to a health provider per year, and in
Bangladesh, only 8 percent of ill children were taken to a qual-
ified provider (see chapter 63). Many barriers can be reduced
by increasing accessibility, for example, by expanding the serv-
ice infrastructure closer to communities. In Cameroon, Litvack
and Bodart’s (1993) study finds that a combination of user fees
and improved quality, including a better drug supply and
improved geographic access, led to increased use despite the
user fees.
Low use may stem less from inaccessibility than from low
quality at the level of health care delivery. Low quality can
result from human resource shortages, limited incentives for
the staff to provide good quality care, training inappropriate to
local needs, poor drug supply systems, and lack of simple
equipment such as that needed to measure blood pressure
(Southern Africa Stroke Prevention Initiative Project Team
2004). In Tanzania, an analysis of the treatment-seeking deci-
sions of those who later died from malaria showed that the
great majority had preferred modern medicine, even for cere-
bral malaria, which according to a substantial body of evidence
mothers view as a condition best treated by traditional healers
(de Savigny and others 2004). Yet despite high rates of seeking
modern medicine, malaria mortality remained high, whether
because of delay in seeking treatment, poor quality care, or
poor patient adherence. Treatment quality can be improved
by increasing resources, although it may also demand change
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Table 3.1 Typical Health System Constraints and Possible Disease-Specific and Health System Responses
Constraint Disease-specific response Health system response
Financial inaccessibility: inability
to pay, informal fees
Physical inaccessibility: distance
to facility
Inappropriately skilled staff
Poorly motivated staff
Weak planning and management
Lack of intersectoral action and
partnership
Poor-quality care among private
sector providers
Allowing exemptions or reducing prices for
focal diseases
Providing outreach for focal diseases
Organizing in-service training workshops
to develop skills in focal diseases
Offering financial incentives for the delivery
of particular priority services
Providing ongoing education and training
workshops to develop planning and
management skills
Creating disease-focused, cross-sectoral
committees and task forces at the
national level
Offering training for private sector providers
Developing risk-pooling strategies
Reconsidering long-term plans for capital investment and siting
of facilities
Reviewing basic medical and nursing curricula to ensure that
basic training includes appropriate skills 
Instituting performance review systems, creating greater clarity
about roles and expectations, reviewing salary structures and
promotion procedures 
Restructuring ministries of health, recruiting developing a cadre
of dedicated managers
Building systems of local government that incorporate represen-
tatives from health, education, and agriculture, promoting the
accountability of local governance structures to the people
Developing accreditation and regulation systems
Source: Travis and others 2004. 
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higher up the system; for example, better health worker
performance may not be possible without reforming human
resource management systems.
Performance at the third level, health sector policy and
strategic management, can have a pervasive influence on per-
formance at lower levels and is less easy to address through
additional funding alone. Some improvements, such as orient-
ing management more toward good performance and reduced
corruption, may require a change in organizational culture or a
change in structures—for instance, decentralizing authority or
creating autonomous agencies. Such changes can be difficult
and may take time to implement (Preker and Harding 2003).
Other improvements require action outside the country—for
example, a change in aid agency practices so that weak country
management structures are not overloaded by multiple
demands and reporting structures.
Finally, at the highest levels, broad multisectoral public poli-
cies and environmental and contextual characteristics set limits
on what the health sector can change without help. For exam-
ple, wage policies for the public sector health staff are usually
set centrally and linked to overall levels of pay for the public
sector. Even if funds are available, increasing the wages of only
health staff members may not be possible.
At this highest level, constraints also reflect much broader
institutional influences, as was demonstrated by recent analyses
of the results of efforts to build state capacity in Africa. Levy’s
(2004) review points out that the results are mixed at best. For
example, of all World Bank civil service reform projects com-
pleted by 1997, only 29 percent were rated as satisfactory by the
operations evaluation department. Levy argues that a key rea-
son for the limited success was an implicit presumption that
the weakness of public administration was managerial and
could be remedied through organizational change and finan-
cial support for technical advice, hardware, and training.
However, public administrations are part of political institu-
tions and of social, economic, and political interests more
broadly, and they do not change readily or quickly. Never-
theless, windows of opportunity may open that drastically
Table 3.2 Constraints on Improving Access to Essential Health Interventions, by Level
Level of constraint Types of constraints
Community and household Lack of demand for effective interventions 
Barriers to the use of effective interventions (physical, financial, social) 
Health services delivery Shortages and inadequate distribution of appropriately qualified staff
Weak technical guidance, program management, and supervision
Inadequate drugs and medical supplies
Lack of equipment and infrastructure, including poor accessibility of health services
Health sector policy and strategic management Weak and overly centralized planning and management systems
Weak drug policies and drug supply system
Inadequate regulation of pharmaceutical and private sectors and improper industry practices
Lack of intersectoral action and partnership for health between government and civil society
Weak incentives to use inputs efficiently and to respond to users’ needs and preferences
Reliance on aid agency funding, which reduces flexibility and ownership
Aid agency practices that overload country management capacity
Public policies cutting across sectors Government bureaucracy (civil service rules and remuneration, centralized management system)
Poor availability of communications and transportation infrastructure
Environmental and contextual characteristics Governance and overall policy framework:
• Corruption, weak government, weak rule of law, weak enforceability of contracts
• Political instability and insecurity
• Low priority attached to social sectors
• Weak structures for public accountability 
• Lack of a free press
Physical environment:
• Climatic and geographic predisposition to disease
• Physical environment unfavorable to service delivery
Source: Hanson and others 2003. 
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affect the chances of change within a few years. Consider the
cases of Mozambique, Rwanda, and Uganda, all countries that
experienced many years of conflict and economic collapse but
that have since made significant progress in reforming govern-
ment institutions and performance. Apart from those excep-
tional cases, Levy argues that the way forward for administra-
tive reform is likely to be an incremental one.
In general, straightforward shortages of buildings, equip-
ment, and drugs and a lack of specific skills on the part of health
workers and managers can be addressed fairly rapidly with addi-
tional funding. Remedying staff shortages takes somewhat
longer, especially if the education system is producing insuffi-
cient numbers of people with the qualifications needed to enter
health training programs. The constraints most impervious to
additional funding are likely to relate to broader systems and
institutional deficiencies, such as a bureaucratic culture that
does not reward good performance and political systems that
ignore the voices of the poor. Long-term and carefully phased
capacity building in the broadest sense, including political
development and strengthened governance structures, is likely
to be required to relax these constraints (Mills and others 2001).
ASSESSMENT OF APPROACHES TO
STRENGTHEN HEALTH SYSTEM CAPACITY 
Strengthening health system capacity to improve performance
is a wide-ranging subject, likely to require action—often simul-
taneously or appropriately sequenced—on many fronts. In
particular, it requires attention to the various functions of the
health system, especially to the various dimensions of manage-
ment, as well as to the relationships between the health system,
its patients (clients), and their communities. Evidence on
which approaches work best is limited. The coverage of this
section is therefore selective, drawing on chapters in part III
and focusing on stewardship and regulation, organizational
structures and their financing, and general management
functions—namely, human resources and quality assurance.
When possible, we identify general lessons and note
instances of relevant country experiences. In interpreting them,
readers will need to keep in mind the strengths and weaknesses
of their own country’s health system. For example, in South
Africa, where basic hospital supplies are good, improved train-
ing of health staff members reduced case-fatality rates for
severe malnutrition, whereas in settings that experience short-
ages of antibiotics, potassium, and milk powder and that lack a
doctor, training alone is highly unlikely to reduce high case-
fatality rates (Ashworth and others 2004).
Stewardship and Regulation 
Saltman and Ferroussier-Davis (2000, 735) explain stewardship
as a “function of governments responsible for the welfare of
populations and concerned about the trust and legitimacy with
which its activities are viewed by the general public.” The
importance of the stewardship role is indicated by analyses that
suggest that, in countries with good governance, a relationship
is apparent between increased health spending and reduced
child mortality (chapter 9), but that such a relationship is not
apparent in countries that scored less well on indicators of
good governance.
Strengthening structures of accountability to communities
and introducing mechanisms to ensure that users have a voice
in the local health system and can influence priorities are likely
to be important in encouraging good performance. Methods to
increase the transparency of resource allocation to peripheral
services are also needed. In Burkina Faso, participation by com-
munity representatives in public primary health care clinics has
increased the coverage of immunization, the availability of
essential drugs, and the percentage of women who get two or
more prenatal visits. In Ceara, Brazil, strengthened community
accountability mechanisms helped improve service delivery
(chapter 9). Factors identified as important to the success of
community-based health and nutrition programs in chapter 56
include the existence of an effective, respected, and socially
inclusive organization at the community level that builds on
established community procedures.
Because of the substantial role that private sources of care
play in almost all low- and middle-income countries, regulat-
ing and developing creative ways to work with the private sec-
tor are important. This effort needs to be seen as part of the
stewardship role. Even though most countries have a network
of regulations controlling private providers and products such
as drugs, the regulations are often outdated and poorly
enforced and can even be counterproductive (box 3.1).
Evidence is growing that using a mix of measures to influ-
ence both consumers and providers can improve the quality of
care obtained through private providers. Chapter 70 provides
several examples, including introducing total quality manage-
ment practices and training with peer review feedback.
Providers in the informal sector are some of the hardest to
reach because of their wide distribution, small scale, and mini-
mal education; however, some evidence indicates that their dis-
pensing practices can be improved (box 3.2).
Regulation can be used as an intervention in its own right,
as well as a way to improve health service delivery. The list
of interventions identified as success stories (chapter 8)
includes these in which a change in regulation was at the root
of success:
• regulations requiring all sex workers in brothels to use con-
doms in Thailand
• tobacco control legislation in Poland and South Africa
• provision of a legal and regulatory framework for adding
fluoride to salt in Jamaica
• legislation banning the sale of noniodized salt in China.
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Bringing de Jure and de Facto Regulations in Line
Box 3.1
In Tanzania, local drug shops are important sources of
drugs. They are required to obtain a permit each year and
to meet certain conditions related to premises, qualifica-
tions of the seller, and products (nonprescription medi-
cines only). A study in three districts found that, despite
regular inspections of drug shops, infringement of the reg-
ulations was widespread—including the sale of prohibited
or inappropriately packaged drugs, which inspectors must
have known about. Illegal drug sales may have contributed
to poor-quality treatment and encouraged the develop-
ment of drug resistance, but they had important benefits in
terms of accessibility, because drug supplies in drug shops
were more reliable than those in government facilities.
Revising the regulations to permit drug shops to stock a
small set of oral antibiotics, for example, would allow more
constructive engagement between sales staff members and
regulators, including the provision of information on
essential drugs, registered brands, appropriate dosing, and
consumer advice. The Strategies for Enhancing Access to
Medicines Project is experimenting with allowing a wider
range of drugs to be provided in one region using accred-
ited outlets for dispensing drugs (drug shops that meet
specified quality criteria and whose staff members have
been trained by the project).
Source: Goodman 2004.
Improving the Quality of Drug Dispensing by Private Sector Shops 
Box 3.2
In Kilifi district, Kenya, an education program piloted by
the Kenya Medical Research Institute–Wellcome Trust
Collaborative Research Programme worked with district
health managers to train and inform rural drug retailers
and communities. Its effect was evaluated by means of
annual household surveys of drug use and shop surveys in
an early and a late implementation area. The program
showed major improvements in drug-selling practices.
Between 1998 and 1999, the proportion of antimalarial
drug users obtaining an adequate dose rose from 8 to 33
percent, and by 2001, with a national change to sulfadox-
ine pyrimethamine, to 64 percent. The proportion of those
with malarial fevers who received an adequate dose of a
recommended antimalarial drug within 24 hours rose
from 1 to 28 percent by 2001.
Source: Marsh and others 2004.
Given that enforcement is the Achilles heel of regulation, a
noteworthy point is that these countries are all middle-income
countries with a reasonable level of enforcement capacity. In
other countries, approaches such as that outlined in box 3.2,
where the authorities work with the private sector rather
than seeking to control it, may have a better chance of
succeeding.
Organizational Structures and Financing 
The appropriate configuration of health system structures can
ensure a clear delineation of responsibilities and accountabili-
ties inside organizations, linking performance with rewards.
Governance and organizational structures can also help ensure
organizations’ accountability to the public.
In recent years, the approach known as new public manage-
ment, explained further in chapter 73, has encouraged a
rejection of traditional, hierarchical forms of public sector
management, whereby a single organization both finances and
provides health services. For example, the U.K. health service
has introduced a clear separation between the entities purchas-
ing services (deciding what services are required for a given
population and allocating funds for them) and those providing
services. One aim of such arrangements is to ensure that
providers’ interests—as opposed to users’ interests—do not
dominate decisions on what services are funded. In addition,
separating purchasers and providers allows competition to be
introduced in service provision. Although introducing compe-
tition is widely considered desirable to encourage efficiency,
debate continues on the magnitude of potential adverse effects.
Examples of new organizational structures include remov-
ing national health services from civil service control, intro-
ducing executive agencies to manage health services, and using
contracts to govern relationships, both within the public sector
(between public purchasers and public providers) and between
the public and private sectors (Preker and Harding 2003).
Colombian reforms introducing competition in both insur-
ance and provider markets are among the most comprehensive.
Another reform example is Ghana’s creation of the Ghana
Health Service, which is separate from the Ministry of Health.
The high transaction costs involved in creating and manag-
ing these types of arrangements and the lack of evidence that
competition improves the quality of care have moderated
initial enthusiasm for new forms of public management. In
addition, critics argue that such arrangements are more
demanding on management capacity than is direct service pro-
vision (Mills and others 2001). Moreover, implementation has
proved challenging. For example, in Trinidad and Tobago and
in Zambia, reforms to create new health service agencies have
run into major opposition from public sector workers, who
oppose changes in their terms and conditions of service.
Some of the more successful elements of new public
management reforms are those that involve contracting out
services, especially to nongovernmental organizations
(NGOs). Early evaluation of contracting experiences indicated
that, even though contracting had been perceived as a way to
avoid the inefficiencies inherent in public sector provision, it
nonetheless required public sector capacity to manage the
contracting process (Mills 1998). This situation was particu-
larly a problem if the contractor was a commercial firm or
individual provider with incentives to maximize profits
(box 3.3). Contracting with individuals and firms that are
strongly influenced by a profit motive requires a certain level
of state capacity to ensure that the arrangements work in the
interests of the state and the general public. In some countries,
therefore, NGOs may be more appropriate service providers
(Palmer and Mills 2003). A number of quite positive results
from contracting with NGOs are now available (World Bank
Strengthening Health Systems | 93
The Importance of Government Capacity: Contracting Out Health Services in South Africa
Box 3.3
Successive studies have evaluated experiences in contract-
ing out hospital care and primary care services in South
Africa. The hospital study compared three district hospi-
tals whose management had been contracted out to the
same private company with three nearby, comparable,
publicly managed district hospitals. Overall, the contrac-
tor hospitals were able to provide care of more or
less equivalent quality at significantly lower cost to
themselves—in major part because their productivity was
more than double that of the public hospitals as a result of
their effective human resource policies. However, the con-
tractor captured all the efficiency gains as profit, leading to
a situation where contracting out was actually more costly
for the government than direct provision. The contractor’s
capacity to profit from the arrangement was due mainly to
its ability to secure highly favorable contract terms and
prices and to ensure a high total number of days of care.
Interview data confirmed a substantial imbalance between
the government and the contractor in relation to the
skills, capacities, and information required to negotiate
contracts. In addition, government officials underesti-
mated the extent of potential competition for contracts
and therefore overestimated their dependence on the one
contractor.
A similar study evaluated the performance of contracts
with general practitioners for primary care in two
provinces and compared their performance with that of
public clinics. General practitioners’ costs were similar to
those of small public clinics, but the service was generally
of poorer quality. Exploration of the relationship between
purchasers and providers found that the contract was
incomplete and open to interpretation and that monitor-
ing was constrained both by a lack of capacity and
resources and by the difficulty of monitoring a complex
service delivered in remote locations. Sanctions were
vaguely specified and rarely used because of a sense of
mutual dependence between parties to the contract that
lessened their willingness to enter into disputes. In addi-
tion, the two provinces varied in terms of their capacity to
monitor performance. The province with lesser capacity
had little information about general practitioners’ per-
formance and little contact with them, which seemed to
increase suspicions of what general practitioners were
doing. In contrast, the province with greater capacity had
a better information system and a decentralized manage-
ment system that led to greater contacts between man-
agers and general practitioners and an apparently greater
degree of understanding between the parties.
Sources: Broomberg, Masobe, and Mills 1997; Mills and others 2004; Palmer and Mills 2003.
2004), and the example of Cambodia is one of the most fre-
quently quoted (chapter 13). Nevertheless, most evidence
comes from programs with substantial external financial and
technical resources, and long-term experience of sustainability
is lacking.
Management decentralization has been another continuing
theme in recent years. One variant is its application to hospi-
tal management, which involves giving hospitals autonomous
or corporate status along with much greater responsibilities
for raising income and managing their own affairs. A second
variant is the creation of autonomous government agencies,
and a third is decentralization to general management
structures at lower levels, such as a health authority or local
government.
Some pushing down of the locus of control over decision
making is a prerequisite for effective management at the local
and facility levels. However, without the necessary resources
and management expertise at these levels and the right incen-
tives, adverse consequences may arise for both efficiency and
equity. For example, experience with hospital autonomy in
low-capacity settings suggests that making the hospital partially
dependent on fees for its income will restrict access by the poor
to the hospital and also worsen the care they receive when
admitted (Castaño, Bitrán, and Giedion 2004). However, for
nonpatient care services, whose functions are easier to specify
and monitor, autonomous agencies may have some advantages.
For example, the Tamil Nadu Medical Supply Corporation has
greatly improved the efficiency and effectiveness of drug pur-
chasing and distribution (Mills and others 2001).
For decentralization of general health service management
to succeed, attention must be paid to the entire management
system, including management skills, information, analytical
tools, and accountability mechanisms both to the community
and to higher levels of management. Because decentralization
is a complex process, takes a variety of forms, and is affected by
the local context, research on its merits and demerits has been
inconclusive (Alliance for Health Policy and Systems Research
2004). Some evidence indicates that decentralization to local
governments can lead to neglect of broader public health func-
tions and disease control, because these types of care are less
visible to the public than curative care, as Khaleghian and Das
Gupta (2004) indicate occurred in the Philippines.
Reviews of the merits of integrating services and of the
effect of vertical programs on health systems have also been
inconclusive. Some positive examples are available, such as the
strengthening of health infrastructure and surveillance systems
by the polio elimination campaign in Latin America and the
Caribbean (Levine 2004). Nonetheless Briggs, Capdegelle, and
Garner’s (2001) review of the effects of strategies for integrat-
ing primary health care services on performance, costs, and
patient outcomes finds too few studies of good enough quality
to draw firm conclusions.
Human Resources 
Achieving health policy goals depends on being able to train,
recruit, and retain a staff with the necessary bundles of skills. In
planning for human resource needs, countries must relate
the numbers and levels of each category of staff members to
health policy goals and the priorities that are set, given the
overall availability of resources and local labor market
constraints.
In recent years, concerns about the international brain drain
have increased greatly, with evidence indicating that migration
by doctors and nurses is severely affecting health services in some
Sub-Saharan African countries (Physicians for Human Rights
2004). Actions by developing countries to improve recruitment
and retention should either raise the rewards, both financial and
nonfinancial, of local employment or reduce the attractiveness
of alternative employment—for example, by making qualifica-
tions less portable across countries (chapter 71). Raising the
remuneration of health workers may be difficult because it is
likely to lead to demands for increased pay from other public sec-
tor employees. There is a long history of making use of local
cadres, which can also allow training that is more specific to the
needs of the local health system and its priorities.
Examples include nurses with extended training and roles
and people working at subnurse levels with training of a few
weeks to three years. For example, Bangladesh employs family
welfare visitors, health assistants, and medical assistants;
Uganda provides three years of training to clinical officers, who
function as subdoctors, and three months of training to nurs-
ing aides; and Malawi trains clinical officers, who carry out
surgical procedures and administer anesthetics in addition to
providing medical care. Despite widespread use of such work-
ers, evidence on how they perform relative to more qualified
staff members is limited, though a study of clinical officers in
Malawi suggests that well-trained clinical officers can safely
substitute for doctors in performing cesarean deliveries
(Fenton, Whitty, and Reynolds 2003).
The salaries necessary to recruit and retain staff members
will depend on the opportunities they have for other employ-
ment both within the country and in other countries. Salary
levels will also depend on health workers’ preferences between
financial and nonfinancial incentives. Evidence suggests that
influences on motivation, though reflecting universal princi-
ples, will vary considerably from place to place (Brown 2002).
Therefore, compensation and incentive structures need to be
adapted to countries’ circumstances; however, evidence is
scanty on how countries have attempted to adapt such struc-
tures and whether they have been successful in improving
recruitment and retention.
One approach to improving health workers’ performance is
to link performance and remuneration. The Chinese national
tuberculosis (TB) program, identified as a success story (chap-
ter 8), provided village doctors with incentives to treat TB
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patients. However, performance-related pay requires a good
regulatory framework, skilled managerial resources, and care-
ful monitoring to counter adverse effects—all features that are
unlikely to be available in countries with limited capacity. Even
in China, other experiences are much less positive because
managers were not required to take likely adverse health conse-
quences into account (box 3.4). Similar comments apply to the
widespread practice of allowing doctors to work in both the
public and the private sectors to increase their incomes.
Doctors may exploit their private practice rights by encourag-
ing patients to attend privately if they want better quality
care—or even by diverting government resources, such as
drugs, to private patients. Thus, the effects of private practice
on incentives in public practice tend to be negative unless care-
fully monitored and controlled.
Nonmonetary rewards to encourage staff retention can be
useful in such settings, as well as easier to manage. They include
the availability of facilities and materials; of opportunities for
learning and career progression; of subsidized housing and
education for dependents; and of a culture that values the con-
tribution of health workers to the achievement of organiza-
tional and system goals. In addition, the methods and levels of
funding, the extent of organizational autonomy, the nature of
support and supervisory systems, the role of the organization
and of providers in the health system, and the regulation and
accountability structures all influence how organizations and
individuals function. Thailand provides an example in which
the provision of both monetary and nonmonetary rewards has
improved the recruitment, retention, and status of rural doc-
tors (box 3.5).
The introduction of well-funded disease control programs
runs the risk of attracting the most able staff members away
from other positions. Past programs have successfully used
combinations of financial and other incentives to encourage
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Incentive Payments in China
Box 3.4
China has made wide use of incentive payments in
hospitals—and even in public health programs. Research
suggests that such payments have deleterious effects when
their ability to skew behavior is not controlled. In
Shandong province, studies found that a change in the
bonus system for hospital doctors from one that was tied
to the quantity of services provided to one that was tied to
revenue generated was associated with a significant
increase in hospital revenue. About 20 percent of hospital
revenue was generated by the provision of unnecessary
care. Although data did not permit linking bonus type to
quality of care, the bonus system was clearly designed to
achieve financial goals rather than quality goals.
Furthermore, during the 1980s and 1990s, the government
provided a decreasing share of the income of public health
institutions, and the share of service charges greatly
increased. As a result, public health institutions became
heavily dependent on generating their own income.
Negative effects included duplicate inspections of factory
premises by different public health units, excessively fre-
quent inspections, and neglect of less profitable factories
that were less able to pay inspection charges.
Source: Liu and Mills 2002, 2003.
The Role of Financial and Nonfinancial Incentives in Thailand
Box 3.5
Thailand has experienced periods of severe medical brain
drain from the public to the private sector and has had
great difficulties in staffing hospitals in rural areas. Since
the late 1970s, policies have been directed at making serv-
ice in rural areas more attractive. Measures include sub-
stantial salary increases, good working conditions in
district hospitals, and provision of housing. Professional
self-esteem has been increased by providing career oppor-
tunities up to the post of deputy director general, an
annual award for rural doctors, and membership in the
rural doctor society. Substantial experience as a rural doc-
tor is explicitly valued by leading public health specialists,
who themselves have spent substantial periods working as
rural doctors.
Source: Wibulpolprasert and Pengpaiboon 2003.
good worker productivity and program performance (chap-
ter 71). Incentives have included better salaries; field and trans-
portation allowances; and nonfinancial incentives such as
streamlined management, specialized training, availability of
facilities and material resources, and results-oriented manage-
ment that provides effective administrative and technical sup-
port. Governments need to find ways of benefiting and learning
from these experiences. For example, governments might allow
periods of secondment to externally funded programs, after
which staff members return to the government with enhanced
skills. The success of such an approach will depend on remuner-
ation not differing too greatly and on government bureaucracies
providing the scope for staff members to use their new skills.
However, the history of civil service reform is not encourag-
ing (Nunberg 1999). Reforms have sought to reduce the size of
the civil service and to improve productivity using incentive
schemes such as performance-based pay and promotion struc-
tures. Such reforms have been largely unsuccessful because of
the political difficulties of reducing the size of the civil service.
Structural and organizational changes are typically unpopular
with labor unions, especially if they perceive such changes as
threatening workers’ well-being. Experience demonstrates the
difficulties of aligning system and organizational objectives
with individual workers’ objectives (Martineau and Buchan
2000) and suggests that solutions need to be sought that do not
involve radical reform of employment patterns unless the
country setting is particularly propitious.
Where contracting with NGOs or other private providers is
an option, doing so may permit changed employment patterns
and improved performance without the widespread disruption
that can result from attempting to change government workers’
terms and conditions of service. In Cambodia, a project con-
tracted to an NGO (HealthNet) obtained some improvements
in staff performance by establishing clear agreements with staff
members concerning issues such as the working hours that
would be expected and the informal charges that staff members
were not to demand from patients. In return, staff members
received substantial incentive payments (box 3.6).
Quality Assessment and Assurance 
The quality of health services has a number of important impli-
cations. It affects the outcomes that a health system can
achieve—both directly, through patient treatment, and indi-
rectly, by encouraging or discouraging use of the services. It also
affects staff morale, because working in an environment where
employees know the treatment quality is poor is not motivating.
Substantial evidence, reviewed in chapter 70, indicates that
the quality of care is often suboptimal and varies widely with-
in countries. In part this suboptimal quality is attributable to
resource constraints, but providing good-quality care is possi-
ble even in resource-poor settings.
Evidence on how providers’ practices can be improved can
be grouped into two categories: policies that indirectly affect
providers’ practices by changing structural conditions, includ-
ing the practice environment, and policies that directly affect
individual and group practices.
In the first category, legal mandates and administrative reg-
ulations can be used to bar unqualified workers from practic-
ing; professional oversight and clinical guidelines can encour-
age good practices; contracts can specify and monitor quality
standards, such as immunization coverage targets; and accred-
itation can stimulate quality improvements. Among policies
that directly affect providers’ behavior, training with peer
review feedback has been shown to improve quality, as have
total quality management approaches; remuneration can be
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Improving Staff Performance in Cambodia
Box 3.6
An NGO contracted to manage a district in Cambodia
introduced contracts between the NGO’s managers and
facility staff members involving a monthly incentive pay-
ment, a punctuality incentive, and a performance bonus.
The contracts were initially introduced in three facilities,
which subsequently experienced significantly higher use
levels than those that did not have the incentive payments.
Because individual contracts were too demanding to man-
age and excluded health center and hospital directors from
staff management, the system was changed to one of sub-
contracting with facility managers. Output improved even
more. Subcontracts were made competitive: if a health
center’s management or output was poor, other health
workers or managers were asked to apply to take over the
contract. During 2001, four contracts were replaced.
Monitoring activities, especially spot checks at the
household level to verify that recorded visits had taken
place, were considered vital to ensuring quality and trans-
parency. Soeters and Griffiths (2003) argue that out-
siders—in this case the NGO—are better able to introduce
new management procedures than a ministry of health,
which tends to be risk averse.
Source: Soeters and Griffiths 2003.
made dependent on performance subject to the caveats raised
earlier. Measures that improve quality can increase use,
strengthen the public sector’s capabilities, and be highly cost-
effective—even cost saving.
TARGETING RESOURCES 
An important dimension of health system capacity that has not
been considered explicitly so far, is the ability to ensure that
resources are used in ways that meet health system objectives.
As noted earlier, many health systems fail to perform as well as
they might on effectiveness, efficiency, and equity criteria. This
section addresses what policy instruments might be available to
ensure that additional resources are used to the greatest effect,
first at the systems level and then at the level of service delivery.
Systems-Level Mechanisms
At the systems level, tools available to decision makers include
regulation and legislation, resource allocation formulas, and
financial incentives.
Decision makers can use regulation and legislation to set
minimum standards of care that insurance packages must
cover, for instance. They can influence the availability of drugs
by, for example, liberalizing prescribing and introducing
accompanying measures to educate providers and users so as to
increase the use of certain drugs that are safe to distribute on a
large scale. One approach that has worked in Uganda is a
social-marketing program making subsidized and clearly pack-
aged drugs for sexually transmitted diseases available through
the retail sector (Mills and others 2002).
In some settings, explicit rationing of the provision of care
in the public and private sectors can be used to prioritize the
most cost-effective interventions and limit the provision of less
cost-effective ones. However, regulatory controls are unlikely to
be effective in low-capacity settings and will simply encourage
illicit activities. Moreover, explicit rationing requires a high
degree of public acceptance and public involvement in the pri-
oritization process. A more acceptable strategy in most settings
is to constrain the overall public sector resource envelope in
terms of staff, buildings, equipment, and drugs and to leave
rationing decisions within the envelope to clinical discretion
(Segall 2003). However, clinicians may implicitly ration
services in inequitable ways—for example, on the basis of age
or social status—and supplementary measures are likely to be
needed to ensure that health workers do not discriminate
against poorer and marginalized members of society.
Resource allocation formulas have an important role to play
in the public sector in directing resources to underserved geo-
graphic areas and population groups and to underfunded pro-
grams (Musgrove 2004). Given the typical shortages of health
workers in more remote areas, such formulas should include
remote area allowances or allow for the higher costs of deliver-
ing services in such areas. A formula in Zambia, for example,
used distance from the railway line as a proxy for remoteness.
A similar approach to ensuring that resources go where they
are most needed is the “marginal budgeting for bottlenecks”
approach of the World Bank (see chapter 9). This country-
based planning and budgeting approach assesses health sector
impediments to faster progress toward the MDGs, identifies
ways to remove them, and estimates both the costs and the
likely effects of their removal on MDG outcomes.
In targeting resources to specific programs, expansion of
one area of health provision should not occur at the expense of
another priority area. For example, where staff capacity and
facilities are limited, targeting additional funding to TB case
detection and treatment may simply take staff time away from
child health. This problem of the systemwide effects of disease-
specific programs was discussed earlier. Addressing this prob-
lem requires empowering a central body, such as a ministry of
health or a regional or district health authority, to take an over-
all view of priorities so that resource conflicts can be resolved.
Even though financial incentives need to be used cautiously,
they can be powerful tools for influencing providers’ behavior, as
indicated earlier. They can also be an important influence on
users’behavior.Experience in South Africa and Uganda (box 3.7)
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Removal of Fees at the Primary Care Level in Uganda
Box 3.7
In February 2001, the government of Uganda abolished
cost sharing in public facilities at the community level.
This move was followed by a marked increase in the use of
health services by all population groups. For villages near
public health centers, the increase was greatest among the
poorest groups. The frequency with which centers ran out
of drugs worsened during the first year of implementation
but gradually improved during the second year. A study
concluded that before the policy change user fees were
probably a major deterrent to the use of public health
services and that their removal was especially beneficial to
the poor.
Source: Nabyonga and others 2005.
suggests that, in some settings, removing or reducing user fees at
the primary care level may be an important element in encour-
aging greater take-up of primary care. Further studies of the
effects of fee removal are needed.
Service-Level Mechanisms
At the service level, evidence suggests the value of providing a
framework of resources and guidance within which managers
and health workers can prioritize their efforts. The experience
of the Tanzania Essential Health Interventions Program (chap-
ter 54) highlights the health gains that a decentralized manage-
ment structure can achieve when district managers are pro-
vided with the information, tools, and training to enable them
to match services and additional resources with the local bur-
den of disease. Berwick (2004) draws similar lessons from the
experience of several highly successful projects in resource-
poor settings: set clear aims and targets, use a team approach,
build an infrastructure of human resources and data systems,
engage with the policy environment, and develop simple
approaches to rapid scaling up.
Patient education on major causes of ill health is also impor-
tant to ensure that people know when to seek care (for example,
in the case of childhood illness); understand their rights to var-
ious services and the official level of charges; and can make
appropriate decisions about drug purchases. Patient charters
may play a role in making explicit what patients have the right
to expect from their health services and what level of service
providers should achieve. Local policies on service provision
need to relate to community preferences: if they do not, clients’
confidence in the public health system will be undermined. One
simple example is the pervasive view in some South African
communities that public clinics water down medicines, thereby
rendering them ineffective (Schneider and Palmer 2002).
Indeed, generic medicines used by the public sector are often
perceived as less effective than name brand drugs. Accurate
public information is needed to counter that perception.
SOLUTIONS IN LOW-CAPACITY ENVIRONMENTS 
Developing countries possess a range of capacities to improve
the functioning of their health systems, but one group of coun-
tries faces the greatest constraints to doing so. Analyses under-
taken for the Commission on Macroeconomics and Health
used the framework presented in table 3.2 to understand the
dimensions of the constraints problem in 79 low-income
countries. Using proxies for the various types and levels of
constraints—gross domestic product per capita, female literacy
rate, number of nurses per population ratio, diphtheria-
pertussis-tetanus immunization coverage, access to health serv-
ices, control of corruption, and government effectiveness—
countries can be classified as more or less constrained. Table 3.3
shows key indicators for the most constrained and other
countries.
The most constrained group has significantly worse health
indicators and much worse access to health resources. For
example, countries in this group have almost twice the infant
mortality rate and more than twice the maternal mortality rate
of other countries but only one-sixth as many nurses. In
absolute terms, the most constrained group represents a rela-
tively small share of the total population of countries analyzed
and consists, for the most part, of small countries (more than
half have populations of less than 10 million) in Sub-Saharan
Africa.
The key question in relation to improving health outcomes is
what financing and delivery strategy might work best in these
settings. Should it take the form of a limited number of pro-
grams, each addressing one or a few diseases? Or should efforts
be devoted to building up the basic health service infrastructure
on which targeted efforts to address specific health problems can
then be built? Given the lack of evidence, providing guidance is
difficult, and the chapters in this book present different views.
Chapter 63 firmly dismisses the option of bypassing organized
health services altogether in the poorest countries and promot-
ing the delivery of child health interventions directly to house-
holds through, for example, community-based projects dis-
pensing antimalarials or antibiotics. It argues that, though this
approach may be a short-term solution, successes using it largely
occur in small-scale pilots with strong managerial backup.
Chapter 56 suggests that in the poorest societies basic preventive
services should be introduced first—especially immunization,
access to basic drugs,and management of the most severe threats
to health such as emergency care for traffic injuries. At slightly
higher levels of development, the introduction of community-
based activities may be cost-effective if coverage by the formal
health service is poor. Both chapters imply that the issue is not
which approach to use but how to phase approaches and use a
mix that depends on the intervention and the local context.
Accomplishing this requires not only service delivery capacity
but also management capacity to plan and evaluate the mix of
approaches and make adjustments over time.
Molyneux (2004) suggests that disease control programs
can be used to build capacity for the long term and that, with
time, such programs can become more advisory and less man-
agerial. For example, in Pakistan, primary health care was built
on the experience of TB and leprosy clinics. In China, the ver-
tical programs for disease control purchased time from health
service operational staff members, thereby ensuring that funds
flowed into the health service infrastructure (Dean Jamison,
personal communication, 2004). In seven countries in
southern Africa, a successful combined strategy for measles
immunization started with a single, nationwide catch-up cam-
paign in which mobile teams vaccinated all children in a par-
ticular age group (Levine 2004), an action that can sharply
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reduce the spread of the virus. Routine services were used to
continue measles immunization but with a follow-up cam-
paign three to four years later to prevent the number of sus-
ceptible cases from rising to the level required for transmission.
Over five years, measles virtually disappeared from southern
Africa. However, maintaining this achievement requires that
routine services be able to reach more than 80 percent cover-
age, a level many countries find hard to sustain. Moreover, in
low-capacity environments, campaigns can divert attention
and resources from routine primary health care services.
Schreuder and Kostermans (2001) indicate that this problem
occurred in southern Africa, particularly with respect to divert-
ing scarce management capacity, implying that reducing deaths
from one cause may risk worsening services for other diseases
and conditions.
Victora and others (2004) suggest that the most appropriate
mix of vertical and horizontal approaches depends on the
human and financial resources available, the urgency with
which results need to be achieved, the existing organization of
health services, and the natural development of programs over
time. Within a horizontal approach, the weaker the health
system setting is, the more important the provision of good
technical and management backup will be to service delivery.
The authors ascribe some of the difficulties that integrated
management of infant and childhood illness (IMCI) faced in
several countries to the absence of full-time IMCI coordina-
tors, operational plans, and specific budget lines. They suggest
that, when health systems are extremely weak, vertical pro-
grams may be required; however, as health systems strengthen,
financing and delivery strategies can become less vertical and
more horizontal and less selective and more integrated.
RESEARCH PRIORITIES
A notable paucity of evidence is apparent in relation to most
key areas discussed in this chapter. This lack of evidence is illus-
trated by a recent review of the evidence on the equity of uti-
lization and financing strategies (box 3.8). This and other
reviews of the available evidence have led the Lancet to call for
a new health systems research specialty (“Mexico 2004: Global
Health Needs a New Research Agenda” 2004).
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Table 3.3 Health Indicators by Country Level of Constraint
Most constrained
Indicator Unit countriesa Other countries
Total population (in 2000) Millions 401 3,525
Population living on less than US$1/day Millions 123 (9 countries) 886 (29 countries)
Population living on less than US$1/day Percentb 30 25
Population living on less than US$2/day Millions 192 (9 countries) 2,128 (30 countries)
Population living on less than US$2/day Percentb 48 60
Physicians Per 100,000 population 8.9 101.7
Nurses Per 100,000 population 39.6 208.7
Hospital beds Per 1,000 population 0.78 3.00
Maternal mortality Per 100,000 births 1,134 565
Births with skilled attendant Percent 30.6 59.8
Low birthweight infants Percent 16.4 13.9
Infant mortality (in 1998) Per 1,000 live births 105.3 61.2
Mortality among children under five Per 1,000 live births 171.2 91.9
Measles immunization coverage Percent 48.4 75.3
Diphtheria-pertussis-tetanus Percent 40.3 76.3
immunization coverage
TB Directly observed therapy short Percent 31.15 42.10
course (DOTS) detection 
TB DOTS treatment success Percent 68.4 77.1
Number of countries included  n.a. 20 59
Source: Ranson, Hanson, and Mills 2003.
n.a.  not applicable.
Note: Calculations were performed for a constraints index with up to three missing variables. Values for missing variables were imputed using a method described in the source.
a. These are the bottom quartile of countries, according to the constraints indicators, compiled into an index. The constraints index was calculated by normalizing each of the variables (subtracting the
mean and dividing by the standard deviation) and then summing the normalized values. This calculation gives each variable equal weight in the index.
b. These averages are population weighted, whereas all other means in the table are unweighted.
Areas where evidence is especially limited that are identified
in this chapter—where research is a high priority—include the
following:
• Evidence on most health system reforms—for example,
hospital autonomy reforms and decentralization—is inade-
quate to draw conclusions about the circumstances under
which reforms are likely to improve the efficiency and
equity of service delivery.
• Few studies relate a reform to health outcomes, and even
evidence on intermediate outcome measures, such as costs
and quality of service provision, is often lacking.
• Virtually no information is available about the costs of
strengthening capacity or the effectiveness of different
approaches to capacity strengthening, even though the lack
of system capacity is widely noted.
• Evidence is largely lacking on the characteristics of delivery
strategies capable of achieving and maintaining high cover-
age for specific interventions in various epidemiological,
health system, and cultural contexts.
• Evidence is lacking on what types of governance and
institutional arrangements will support the achievement of
widespread health improvements, especially for the poorest
members of society.
Addressing the deficiencies in the evidence base requires
developing better study designs and analytical methods and
building expertise in and understanding of health systems
research. Capacity for research and analysis in health policy and
health systems is currently limited. A recent survey (Alliance for
Health Policy and Systems Research 2004) estimated that proj-
ect funding for health systems research accounted for less than
0.02 percent of the total annual health expenditure of develop-
ing countries. More than half of research projects had budgets
of less than US$25,000. Of institutions identified as engaged in
health systems research, a third had no staff qualified at the
doctoral level, and researchers with doctoral degrees made up
only a quarter of the research workforce. An analysis of studies
cited in Medline showed that only 5 percent of the health sys-
tems research literature concerned developing countries.
Given the importance of influencing policy and practice, the
approach to research needs to encompass solving operational
problems in real-life settings. Ethical issues arise in using limited
supplies of talent to study problems unrelated to the local con-
text when the human resources and systems required to
improve operational programs are lacking. Moreover, the qual-
ity and effect of investigations are much improved when they
are based on dialogue with the primary users and set in real-life
contexts. The concept of the cycle from research to policy and
practice needs to be emphasized more strongly. It encompasses
not only generating knowledge but also managing the research
agenda, including setting priorities, and promoting the use of
evidence through means such as advocacy channels and spe-
cific mechanisms designed to link producers and users of
research (Alliance for Health Policy and Systems Research
2004). Given the importance of context in translating research
evidence into service and system practice, operational research
and program evaluation capacity must be built among coun-
try-based scientists and practitioners.
CONCLUSIONS
This chapter has sought to address the question of how health
systems can be strengthened to deliver cost-effective and equi-
table interventions and services. Recent cross-country analysis
on the association between health expenditure by government
and health outcomes has suggested that the effectiveness of
increased health expenditure depends heavily on governments
adopting the right policies (World Bank 2004). What are the
right policies, and what are effective implementation processes?
The review in this chapter suggests that in many areas not
enough is known to recommend particular approaches and
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Gaps in the Evidence on Equity of Health Financing and Utilization in Low-Income Settings
Box 3.8
A recent review evaluated evidence on the effect of various
financing strategies on use of health care. It found that
most research was small scale and had findings of limited
applicability. Well-designed, large-scale evaluations of the
effect of alternative financing interventions were lacking,
and a multitude of case studies described specific experi-
ences but with little methodological rigor. The review
recommended larger-scale, more systematic studies in a
range of settings, including nonrandomized designs when
randomization is impossible or inappropriate and multi-
center case studies that examine why arrangements do or
do not work in different settings. The study proposed
developing and applying quality criteria for quantitative
and case study research along the lines of guidelines
recently developed for randomized group trials.
Source: Palmer and others 2004.
also that recommendations need to be adapted to local con-
texts. Nonetheless, six key points can be identified in relation to
improving health systems:
• Health systems face numerous constraints in low-income
countries, but they are the basis for the long-term future of
sustained health improvements. The health of the system
must, therefore, be carefully considered whenever major
new programs are put in place.
• If capacity constraints are such that a focused disease- or
program-specific effort is desirable to address an urgent
problem, the effort should be designed to contribute to the
long-term system strengthening, rather than detracting
from it. Countries must avoid having multiple vertical pro-
grams competing for limited human resources and manage-
rial capacity. Over time, as horizontally organized services
strengthen, the need for more vertical financing and deliv-
ery strategies will lessen.
• Reforms affecting organizational structures and human
resource management are likely to play an important role in
improved performance. However, emerging evidence sug-
gests in most settings that changes are most likely to be suc-
cessfully implemented if they are incremental and gradual
rather than “big bang” reforms. Stability of policies and con-
sistent implementation are also required.
• Linking financial incentives to performance, whether
through contracts with health care providers or through
performance-related pay, may bring rewards if careful mon-
itoring is possible; however, evidence on the sustainability of
such arrangements is lacking, and effective monitoring may
require long-term external involvement. Evidence is needed
on alternative approaches to improving performance.
• Organizational reforms must keep the goal of improved
health outcomes, equity, and responsiveness in sight. Doing
so requires paying special attention to users’ demands, to
primary care and first-level hospitals, to quality of care, and
to technical backup for disease control programs.
• Capacity-strengthening efforts in most settings must
encompass action at all levels, from increasing leadership of
the ministry of health at the national level through strength-
ening support for peripheral levels.
The current body of knowledge represents a largely ad hoc
and disjointed collection of facts, figures, and points of view.
Making confident recommendations relevant to strengthening
health system capacity is thus difficult. Although international
financing is vital, countries need flexibility to develop solutions
based on local assessments and experience and to progress at a
pace commensurate with their situations. Sustained investment
in analytical and operational research capacity is needed as part
of program and systems support, to serve national priority set-
ting and policy formulation.
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NOTE
1. The health system is understood to encompass all activities whose
prime intent is to improve health.
REFERENCES 
Alliance for Health Policy and Systems Research. 2004. Strengthening
Health Systems: The Role and Potential of Policy and Systems Research.
Geneva: Alliance for Health Policy and Systems Research.
Ashworth, A., M. Chopra, D. McCoy, D. Sanders, D. Jackson, N. Karaolis,
and others. 2004. “WHO Guidelines for Management of Severe
Malnutrition in Rural South African Hospitals: Effect on Case Facility
and the Influence of Operational Factors.” Lancet 363: 1110–15.
Berwick, D. M. 2004. “Lessons from Developing Nations on Improving
Health Care.” British Medical Journal 328: 1124–29.
Briggs, C. J., P. Capdegelle, and P. Garner. 2001. “Strategies for Integrating
Primary Health Services in Middle- and Low-Income Countries:
Effects on Performance, Costs, and Patient Outcomes. Cochrane
Database of Systematic Reviews (4) CD003318.
Broomberg, J., P. Masobe, and A. Mills. 1997. “To Purchase or to Provide?
The Relative Efficiency of Contracting Out versus Direct Public
Provision of Hospital Services in South Africa.” In Private Health
Providers in Developing Countries: Serving the Public Interest?, ed. S.
Bennett, B. McPake, and A. Mills, 214–36. London: Zed Press.
Brown, K. 2002. “Improving Organisational and Individual Performance
for Service Delivery: How Can Officials Become More Responsive to
the Needs of the Poor?” Paper presented at the Department for
International Development workshop on Improving Service Delivery
in Developing Countries, Eynsham Hall, Oxfordshire, U.K., November
24–30.
Castaño, R., R. Bitrán, and U. Giedion. 2004. Monitoring and
Evaluating Hospital Autonomization and Its Effects on Priority Services.
Bethesda, MD: Partners for Health Reform Plus Project, Abt
Associates.
de Savigny, D., E. Mwageni, C. Mayombana, H. Masanja, A. Minhaj, D.
Momburi, and others. 2004. “Care-Seeking Patterns in Fatal Malaria.”
Background paper prepared for the Institute of Medicine study on the
Economics of Antimalarial Drugs, Washington, DC.
Fenton, P. M., C. J. Whitty, and F. Reynolds. 2003. “Caesarean Section in
Malawi: Prospective Study of Early Maternal and Perinatal Mortality.”
British Medical Journal 327 (7415): 587–91.
Goodman, C. 2004. “An Economic Analysis of the Retail Market for Fever
and Malaria Treatment in Rural Tanzania.” Ph.D. thesis, University of
London.
Gonzalez, C. L. 1965. “Mass Campaigns and General Health Services.”
Public Health Paper 29. Geneva: World Health Organization.
Gwatkin, D., S. Rutstein, K. Johnson, R. Pande, and A. Wagstaff. 2000.
Socioeconomic Differences in Health, Nutrition, and Population: 45
Countries. Washington, DC: World Bank.
Hanson, K., K. Ranson, V. Oliveira-Cruz, and A. Mills. 2003. “Expanding
Access to Health Interventions: A Framework for Understanding the
Constraints to Scaling Up.” Journal of International Development 15
(1): 1–14.
Strengthening Health Systems | 101
Hensher, M. 2001. “Financing the Health System through Efficiency
Gains.” Background paper prepared for Working Group 2 of the
Commission on Macroeconomics and Health, World Health
Organization, Geneva. http://www.cmhealth. org/docs/wg3_paper2.pdf.
Khaleghian, P., and M. Das Gupta. 2004. “Public Management and the
Essential Public Health Functions.” Working Paper 25, Disease Control
Priorities Project, Bethesda, MD.
Levine, R. 2004. What’s Worked? Accounting for Success in Global Health.
Washington, DC: Center for Global Development.
Levy, B. 2004. “Governance and Economic Development in Africa:
Meeting the Challenge of Capacity Building.” In Building State
Capacity in Africa: New Approaches, Emerging Lessons, ed. B. Levy and
S. Kpundeh, 1–42. Washington, DC: World Bank Institute.
Litvack, J., and C. Bodart. 1993. “User Fees plus Quality Equals Improved
Access to Health Care: Results of a Field Experiment in Cameroon.”
Social Science and Medicine 37 (3): 369–83.
Liu, X., and A. Mills. 2002. “Financing Reforms of Public Health Services
in China: Lessons for Other Nations.” Social Science and Medicine 54
(11): 1691–98.
———. 2003. “The Influence of Bonus Payments to Doctors on Hospital
Revenue: Results of a Quasi-Experimental Study.” Applied Health
Economics and Health Policy 2 (2): 91–98.
Marsh, V. M., W. M. Mutemi, A. Willetts, K. Bayah, S. Were, A. Ross, and
K. Marsh. 2004. “Improving Malaria Home Treatment by Training
Drug Retailers in Rural Kenya.” Tropical Medicine and International
Health 9 (4): 451–60.
Martineau, T., and J. Buchan. 2000. “Human Resources and the Success of
Health Sector Reform.” Human Resources Development Journal 4 (3):
174–83.
“Mexico 2004: Global Health Needs a New Research Agenda.” 2004. Lancet
364: 1555–56.
Mills, A. 1998. “To Contract or Not to Contract? Issues for Low- and
Middle-Income Countries.” Health Policy and Planning 13 (1): 32–40.
———. 2005. “Mass Campaigns versus General Health Services: What
Have We Learnt in 40 Years about Vertical versus Horizontal
Approaches.” Bulletin of the World Health Organization 83 (4): 315–16.
Mills, A., S. Bennett, S. Russell, with N. Attanayake, C. Hongoro, V. E.
Muraleedharan, and P. Smithson. 2001. The Challenge of Health Sector
Reform: What Must Governments Do? Oxford, U.K.: Macmillan Press.
Mills, A., R. Brugha, K. Hanson, and B. McPake. 2002.“What Can Be Done
about the Private Health Sector in Low-Income Countries?” Bulletin of
the World Health Organization 80 (4): 325–30.
Mills, A., N. Palmer, L. Gilson, D. McIntyre, H. Schneider, E. Sinanovic, and
H. Wadee. 2004. “The Performance of Different Models of Primary
Care Provision in Southern Africa.” Social Science and Medicine 59 (5):
931–43.
Molyneux, D. 2004. “‘Neglected’ Disease but Unrecognised Successes:
Challenges and Opportunities for Infectious Disease Control.” Lancet
364: 380–83.
Molyneux, D., and V. Nantulya. 2004. “Linking Disease Control
Programmes in Rural Africa: A Pro-Poor Strategy to Reach Abuja
Targets and Millennium Development Goals.” British Medical Journal
328 (7448): 1129–32.
Musgrove, P. 2004. “Compensatory Finance in Health: Geographic Equity
in a Federal System.” In Health Economics in Development, ed. P.
Musgrove, 133–42. Health, Nutrition, and Population Series.
Washington, DC: World Bank.
Nabyonga, J., M. Desmet, H. Karamagi, P. Y. Kadama, F. G. Omaswa, and
O. Walker. 2005. “Abolition of Cost-Sharing Is Pro-Poor: Evidence
from Uganda.” Health Policy and Planning 20 (2): 100–8.
Nunberg, B. 1999. “Rethinking Civil Service Reform.” Poverty Reduction
and Economic Management Notes 31, World Bank, Washington, DC.
http://www1.worldbank.org/ prem/PREMNotes/premnote31.pdf.
Palmer, N., and A. Mills. 2003. “Classical versus Relational Approaches to
Understanding Controls on a Contract with GPs in South Africa.”
Health Economics 12: 1005–20.
Palmer, N., D. Mueller, L. Gilson, A. Mills, and A. Haines. 2004. “Health
Financing and Equity of Utilisation in Low-Income Settings: Is There
an Evidence Base?” Lancet 364 (9442): 1365–70.
Physicians for Human Rights. 2004. An Action to Prevent Brain Drain:
Building Equitable Health Systems in Africa. Boston: Physicians for
Human Rights.
Preker, A. S., and A. Harding. 2003. Innovations in Health Service Delivery.
Washington, DC: World Bank.
Ranson, K., K. Hanson, and A. Mills. 2003. “Constraints to Expanding
Access to Health Interventions: An Empirical Analysis and Country
Typology.” Journal of International Development 15 (1): 15–40.
Saltman, R. B., and O. Ferroussier-Davis. 2000. “On the Concept of
Stewardship in Health Policy.” Bulletin of the World Health
Organization 78 (6): 732–39.
Schneider, H., and N. Palmer. 2002. “Getting to the Truth? Researching
User Views of Primary Health Care.” Health Policy and Planning 17:
32–41.
Schreuder, B., and C. Kostermans. 2001. “Global Health Strategies versus
Local Primary Health Care Priorities: A Case Study of National
Immunization Days in Southern Africa.” South African Medical Journal
91 (3): 249–54.
Segall, M. 2003. “District Health Systems in a Neoliberal World: A Review
of Five Key Policy Areas.” International Journal of Health Planning and
Management 18 (S1): S5–26.
Soeters, R., and F. Griffiths. 2003.“Improving Government Health Services
through Contract Management: A Case from Cambodia.” Health Policy
and Planning 18 (1): 74–83.
Southern Africa Stroke Prevention Initiative Project Team. 2004.
“Secondary Prevention of Stroke: Results from the Southern Africa
Stroke Prevention Initiative (SASPI) Study.” Bulletin of the World
Health Organization 82 (7): 503–8.
Travis, P., S. Bennett, A. Haines, T. Pang, Z. Bhutta, A. Hyder, and others.
2004. “Overcoming Health Systems Constraints to Achieve the
Millennium Development Goals.” Lancet 364: 900–6.
Unger, J.-P., P. de Paepe, and A. Green. 2003. “A Code of Best Practice to
Avoid Damaging Health Care Services in Developing Countries.”
International Journal of Health Planning and Management 18 (S1):
S27–40.
Victora, C., K. Hanson, J. Bryce, and J. P. Vaughan. 2004. “Achieving
Universal Coverage with Health Interventions.” Lancet 364: 1541–48.
Walsh, J., and K. Warren. 1980.“Selective Primary Health Care: An Interim
Strategy for Disease Control in Developing Countries.” New England
Journal of Medicine 301: 967–74.
Walt, G. 2001. “Global Cooperation in Global Public Health.” In
International Public Health, ed. M. Merson, R. Black, and A. Mills,
667–99. Gaithersburg, MD: Aspen Publishers.
Wibulpolprasert, S., and P. Pengpaiboon. 2003. “Integrated Strategies to
Tackle the Inequitable Distribution of Doctors in Thailand: Four
Decades of Experience.” Human Resources for Health 1: 12.
World Bank. 2004. The Millennium Development Goals for Health: Rising to
the Challenges. Washington, DC: World Bank.
102 | Disease Control Priorities in Developing Countries | Anne Mills, Fawzia Rasheed, and Stephen Tollman
103
NEEDS, CONTEXT, OPPORTUNITIES, 
AND MAJOR CHALLENGES
Half of the entire increase in human life expectancy—a crude
but easily defined measure of the health of populations—
realized over recorded history occurred in the 20th century.
From 1900 to 2000, life expectancy at birth increased from
48.0 to 77.1 years in the United States and from 48.0 to 77.7
years in the United Kingdom, gains of almost 30 years.
However, improvements in life expectancy were not limited to
the industrial nations. For example, between 1900 and 1990,
life expectancy in India increased from 27 to 59 years, a gain of
32 years (Fogel 2004). These increases are largely attributable
to a better understanding of biology, medicine, and public
health—that is, to the benefits of research.
Research is traditionally defined as the generation of new
knowledge and the development of new and enabling tech-
nologies to identify or respond to major gaps in current
knowledge. Research includes the development of new
tools, methodologies, and strategies. The World Health
Organization (WHO) and its Advisory Committee on
Health Research have suggested two other defining aspects
of health research—namely, the verification of knowledge in
different contexts and the creation and dissemination of prod-
ucts of knowledge. The Institute of Medicine (1997, page 1) in
the United States has defined the realm of global health
research as “problems, issues, and concerns that transcend
national boundaries and may best be addressed by sharing
knowledge and cooperative action.”
An important corollary of this definition is that global
health research is derived from individuals and institutions
rather than from nation states. Thus, global health knowledge
should be available to everyone, not just to the country in
which it is done or that sponsored it. As a result, knowledge
derived from health research is a true public good, which by
definition possesses the following two special properties
(Commission on Macroeconomics and Health 2001):
• Nonexclusivity. Thus, when supplied it does not require pay-
ment to benefit individuals or groups (for example, the ben-
efit to the world community of eliminating smallpox).
• Nonrivalry. Hence, the use of the benefits by an individual,
group, or country will not diminish others’ ability to bene-
fit from the same good or service.1
Investments in research have produced remarkable improve-
ments in global health, especially over the past 20 years.
Immunization programs have led to unprecedented progress in
the fight against common childhood diseases (such as measles,
Chapter 4
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It is a profound and necessary truth that the deep things in science are not found because they are useful; 
they are found because it was possible to find them.
—J. Robert Oppenheimer
In R. Rhodes, The Making of the Atomic Bomb
pertussis, poliomyelitis, and tetanus) and in the eradication of
smallpox. At the same time, vaccination programs have cat-
alyzed the construction of a global infrastructure for epidemio-
logical monitoring and research, especially in the Americas and
in Asia. Moreover, researchers are rapidly developing many pre-
ventive, diagnostic, and therapeutic tools, and the growing
power of genomics and proteomics will accelerate the pace.
The 21st century will see a continuation of the inexorable
trend toward the globalization of travel, trade, and communi-
cations. At one level, economic globalization has increased dis-
parities between countries in terms of gross domestic product
per capita. On a population basis, however, economic gains by
China, India, and other developing countries have made vast
numbers of people substantially wealthier than ever before
(Fischer 2003). Cell phones and radios are ubiquitous, even in
the most remote parts of Africa and Asia, and the Internet has
permitted the transmission of data across long distances rapidly,
accurately, reliably, and cheaply. With these technologies, global
research relationships that once would have been impossible
are now commonplace. For example, in a matter of weeks,
researchers in China could sequence the gene for the surface
protein of the coronavirus associated with severe acute respira-
tory syndrome (SARS) and then produce the surface protein
as diagnostic antigen. Such speedy reaction would have been
inconceivable just a decade ago.
Daunting challenges remain, however, that health research
alone is unlikely to solve. The context for health is very complex
and varies in different countries of the world (box 4.1). The
predictable outcome of current trends is an increase in the
health and technology gaps between the rich and poor coun-
tries. Tip O’Neill, the colorful speaker of the U.S. House of
Representatives for 10 years, often said that “all politics is
local.” A provocative thesis we present here is that (a) all health
care is national, and (b) all health research is global.
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Context of Global Health
Box 4.1
Advances include the following:
• the globalization of knowledge and the increased
mobility of the world’s population
• the expansion of knowledge about disease problems in
most of the developing world
• the remarkable progress achieved in the control of
infectious diseases in most parts of the world
• the worldwide penetration of new forms of
communication
• the promise of new technologies in biomedical research
(for example, in the fields of genomics, transgenic
organisms, informatics, robotics, and nanotechnology)
• the increasing flow of private resources devoted to
understanding health problems related to development.
The following concerns are pertinent:
• The world’s population continues to grow, numbering
6.3 billion people in 2004, with 200,000 added each
day. In at least 68 countries, more than 40 percent of
the population is younger than 15, whereas in wealthy
countries, the proportion of elderly people in the
population is expanding quickly.
• Despite falling global poverty rates, progress is uneven:
1.2 billion people still live on less than US$1 a day, and
2.8 billion live on less than US$2 a day. One in six
children is chronically hungry.
• Disparities have increased. The richest 20 percent of
the world’s population now accounts for 150 times the
income of the poorest 20 percent. The ratio of the
income of the top 20 percent to that of the poorest
20 percent rose from 30 to 1 in 1960 to 61 to 1 in 1991
and to 78 to 1 in 1994. Evidence of global environmen-
tal degradation is apparent, especially in the developing
world. For example, 45 percent of tropical rain forest
has already been lost, at least 20 percent of current
species will be extinct by 2030 and 50 percent by the
end of the century, and half of China’s and many other
countries’ cities already face water shortages.
• With global warming, temperatures will likely rise
1.0°C to 4.5°C this century, threatening coastal areas
and changing patterns of vectorborne and epidemic
disease.
• The pace of migration from rural to urban environ-
ments is speeding up, giving rise to more megacities.
• The period 1955–98 witnessed 31 civil and foreign
wars, 35 million displaced people and refugees, and
127 instances of state failures—ethnic wars, revolution-
ary wars, and disruptive regime changes—in 96 states.
• Terrorism has become a global threat.
• Gender discrimination persists.
Sources: King and Zeng 2001, 2002; Wilson 2003; World Bank 2004; World Revolution
(http://www.worldrevolution.org).
Global Burden of Disease
Tables 4.1 and 4.2 summarize some of the key findings that are
most relevant to a discussion of global health research priori-
ties. The magnitude and distribution of the burden of disease
across different regions in 2001 reveals a great deal about
unmet research needs (Mathers and others 2003), in particular:
• Communicable diseases and maternal, perinatal, and nutri-
tional conditions remain the major contributors to the bur-
den of disease in Sub-Saharan Africa and in parts of East
Asia and the Pacific. These regions differ significantly from
all the other low- and middle-income regions and call for a
unique set of priorities in relation to global health research.
• Noncommunicable diseases are already the leading
contributors to the disease burden in all other low- and
middle-income regions, which are undergoing rapid demo-
graphic, economic, and epidemiological transitions. Not
only does the world face an epidemic of cardiovascular
disease and major unipolar depressive disorders, for exam-
ple, but also these two chronic conditions already account
for an increasing burden of disease and death in developing
countries. Demographic changes in many low- and middle-
income countries are driving the observed transition toward
patterns of disease previously seen only in the industrial
countries. The incidence of both ischemic heart disease and
cerebrovascular disease increases rapidly with age; thus,
countries in which the proportion of elderly people in the
population increases will also experience increases in the
relative importance of noncommunicable illness. Unlike
communicable illnesses among younger people, chronic ill-
ness associated with aging cannot be entirely prevented,
only delayed. These factors must be considered when setting
priorities for global health research.
Children under five still account for an unnecessarily large
share of the disease burden in many low- and middle-income
Priorities for Global Research and Development of Interventions | 105
Table 4.1 Broad Patterns of the Disease Burden, by World Bank Region, 2001
East Asia Europe and Latin America Middle Sub- High-
and the Central and the East and South Saharan income 
Category Pacific Asia Caribbean North Africa Asia Africa countries World
Population (millions) 1,851 477 526 310 1,388 668 929 6,150
Communicable, maternal, 22.2 9.4 21.8 27.1 44.3 70.4 5.7 36.7
perinatal, and nutritional 
conditions (prevalence, percent)
Noncommunicable diseases 65.8 76.4 65.0 59.3 44.4 21.2 86.7 52.6
(prevalence, percent)
Injuries (prevalence, percent) 12.0 14.3 13.2 13.7 11.4 8.4 7.5 10.7
Source: Mathers and others 2003.
Table 4.2 Leading Causes of the Disease Burden, by World Bank Region, 2001
East Asia Europe and Latin America Middle East Sub-Saharan High-income 
Rank and the Pacific Central Asia and the Caribbean and North Africa South Asia Africa countries
1
2
3
4
5
Cerebrovascular
diseases
Perinatal
conditionsa
Chronic obstruc-
tive pulmonary
disease
Ischemic heart
disease
Unipolar 
depressive 
disorders
Ischemic heart
disease
Cerebrovascular
diseases
Unipolar depressive
disorders
Self-inflicted injuries
Chronic obstructive
pulmonary disease 
Perinatal conditionsa
Unipolar depressive
disorders
Homicide and 
violence
Ischemic heart
disease
Cerebrovascular
diseases
Ischemic heart 
disease
Perinatal conditionsa
Traffic accidents
Lower respiratory
infections
Diarrheal diseases
Perinatal 
conditionsa
Lower respiratory
infections
Ischemic heart
disease
Diarrheal diseases
Unipolar depressive
disorders
HIV/AIDS
Malaria
Lower 
respiratory
infections
Diarrheal
diseases
Perinatal
conditionsa
Ischemic heart
disease 
Cerebrovascular
diseases
Unipolar 
depressive
disorders
Alzheimer’s
disease and
other dementias
Tracheal and
lung cancer
Source: Mathers and others 2003. 
a. Perinatal conditions include low birthweight, birth asphyxia, and birth trauma.
regions where lower respiratory infections, diarrheal diseases,
and perinatal conditions persist. Because these diseases can
largely be prevented through relatively low-cost interventions,
research into how best to implement these interventions and
reduce the infectious disease burden in lower-income countries
remains a priority.
The 10:90 Issue
Efforts over the past two decades by the Commission on Health
Research in Development, the WHO human reproduction
and tropical disease research programs, the WHO Ad Hoc
Committee on Research Relating to Future Intervention
Options, and—more recently—the Global Forum for Health
Research have been largely responsible for the increasing focus
on the role of health research in economic and social develop-
ment. At a time when few health research resources were being
devoted to the specific health problems of developing coun-
tries, these entities played a critical role in making the case
that more should be done. The Global Forum for Health
Research took the most effective advocacy position, arguing
that 90 percent of the US$70 billion per year devoted to health
research and development (R&D) was spent on diseases of the
rich countries and only 10 percent was spent on the diseases
uniquely afflicting poor countries. This advocacy has been
effective and has galvanized global recognition that more
research funding should be devoted to improving the health of
the 85 percent of the world’s population who live in developing
or transition countries.
An absolute divergence in gross domestic product persists
between industrial and developing countries and, thus, what
they can reasonably devote to research. Infectious diseases con-
tinue to exact their highest tolls in the poorest countries, and
new tools to prevent and treat HIV/AIDS, tuberculosis (TB),
malaria, respiratory and diarrheal disease, SARS, influenza, and
more exotic infections such as Ebola are urgently needed.
A longer-term view of global health problems recognizes the
increasing convergence of health problems, particularly chronic
diseases and injuries. It is no longer true that research on car-
diovascular disease, diabetes, or depression, for example, is not
relevant to developing countries. Vast knowledge is available on
how to prevent a major portion of heart disease, lung cancer,
type 2 diabetes, sexually transmitted infections, and injuries in
the elderly, yet most countries do not implement that knowl-
edge effectively. Thus, more research is needed to successfully
transfer that knowledge from industrial to developing
countries. For example, if monitored carefully, cost-effective,
community-based antihypertensive, antiretroviral, and antide-
pressive treatments could have an enormous effect in most
developing countries.
Increased surveillance and diagnostic capacity for emerging
infectious diseases in developing countries will prevent
enormous new disease burdens in those countries, while at the
same time providing early warning to industrial countries to
stimulate new research on vaccines and drugs. Even though
industry in developing countries may currently be devoting
more effort to creating look-alike drugs, which are unlikely to
add a great deal to the duration or quality of life, than to creat-
ing drugs for major global killers, and even though market
incentives for interventions in resource-poor countries are
lacking for most diseases, the solution is not to balkanize
research and science, but to stimulate scientific capacity in all
countries. Local researchers and industries in developing coun-
tries might be able to create interventions that can find a niche
in markets in developing countries or that public sector or
public-private partnerships are prepared to support.
Global Health Agendas 
Some major global health problems cannot be addressed with
the available knowledge and existing tools. Major challenges for
R&D remain to reduce the unfinished burden of infectious dis-
eases; address the rapidly increasing burden of chronic diseases
in aging populations; and reduce the unnecessary burden caused
by injuries, casualties of war, and humanitarian emergencies.
The Unfinished Agenda of Infectious Diseases. In 1969, the
U.S. surgeon general issued a now famous, if less than pre-
scient, pronouncement: “The time has come to close the book
on infectious diseases” (WHO 2000). In 2001, infectious dis-
eases still accounted for 32 percent of the global burden of
mortality and 37 percent of the global burden of disease. In
Sub-Saharan Africa, they are responsible for 68 percent of
deaths. The HIV/AIDS epidemic continues to spread, affecting
large proportions of populations in Sub-Saharan Africa, but it
is at only an early stage in Asia, when effective prevention
efforts could make a difference, as they did in Thailand. AIDS
is responsible for the decline in life expectancy to less than
40 years of age in five Sub-Saharan African countries. Yet recent
promising results of public health efforts in Brazil, Senegal,
Thailand, and Uganda demonstrate that HIV/AIDS can be pre-
vented and controlled on a nationwide scale.
Even though the public in industrial countries often seems
surprised by each new outbreak of infectious disease, the pat-
tern of emerging infectious diseases worldwide is continuing
and, at the same time, is constantly changing. Since 1970, peo-
ple have been afflicted by 32 new diseases that had never
previously been reported in humans, such as hepatitis C,
Legionnaire’s disease, Ebola, Vibrio cholerae 0139 epidemic,
Nipah virus encephalitis, SARS, and the highly pathogenic avian
influenza. The 1918 influenza epidemic killed 20 million to
40 million people worldwide. Precisely when human-to-human
transmission of the avian influenza viruses will occur is impos-
sible to predict, but it is likely to happen eventually. This
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eventuality underscores the importance of encouraging system-
atic collaboration on emerging and reemerging infections and
strengthening global surveillance and laboratory capability. A
syndromic approach to diagnosis and surveillance, as for the
identification of flaccid paralysis, which accelerated the elimi-
nation of poliomyelitis in the Western hemisphere, may be cru-
cial when laboratory diagnosis is not readily available.
Finally, the deliberate dissemination of anthrax spores in
September and October 2001 in the United States has raised the
specter of biological terrorism, either with pathogens natural to
the environment that took years to eradicate, like smallpox, or
genetically engineered pathogens of unknown capability.
Thus, the global infectious disease agenda remains unfin-
ished. Given the continuing emergence of new infectious dis-
eases and the increasing resistance of microbial pathogens to
existing drugs and of insect vectors to pesticides, as well as low
compliance with treatments, it is likely to remain so.
The Coming Epidemic: Chronic Diseases and Aging
Populations. In 1998, for the first time, chronic diseases con-
tributed more to the global burden of disease than infectious
diseases, indicating the emergence of a convergence between
the principal diseases of the developing countries and the
industrial countries. Worldwide, cardiovascular disease is the
major cause of mortality and morbidity (13.6 percent of total
disability-adjusted life years) followed by cancer (6.6 percent of
total disability-adjusted life years). Diabetes type 2 is increasing
in most countries of the world at an alarming rate. An unan-
ticipated finding from the global burden of disease analysis was
that psychiatric illness, particularly depression, is a major cause
of disability everywhere (Murray and Lopez 1996a, 1996b).
Depression is now the most important disability among
women in the United States, and globally it is projected to be
the second largest contributor to the burden of disease by 2020.
The success of public health and childhood immunization
in reducing the number of childhood deaths from infectious
disease is partially responsible for the increasing burden of
chronic diseases. However, part of the increase is caused by
poor eating habits, lack of exercise, smoking, and other
unhealthy lifestyle choices that tend to increase with a nation’s
income. Even though noncommunicable diseases associated
with aging are increasingly contributing to the global burden
of disease, the emergence of a highly virulent infectious disease
pandemic could allow communicable illnesses to reassert their
primacy.
The Unnecessary Epidemic: Injuries, Casualties of War, and
Humanitarian Emergencies. Before the analysis of the global
burden of disease, the contribution of injuries to the burden of
disease and disability was unclear. The most rapidly rising cat-
egory of injuries is that resulting from motor vehicle crashes. If
present trends continue, by 2020 motor vehicle crashes will be
the third largest contributor to the global burden of disease.
Clearly public health sectors have a great deal to contribute in
terms of reducing injuries from motor vehicle crashes, falls,
and workplace injuries. Less amenable to intervention by pub-
lic health systems will be wars and humanitarian emergencies.
Obtaining accurate figures is difficult, but as Murray and others
(2002) note, available statistics have greatly underestimated the
burden of war and civil strife on health systems.
The Crisis in Health Systems
Unprecedented advances in the development of health care
technologies, drugs, vaccines, and new diagnostics, which hold
the promise of healthier and longer lives for many, have pro-
found influences on health systems worldwide; in rich and
poor countries alike, they raise expectations and demand for
health services along with difficult issues relating to access to
information, costs, quality of care, equity, organization, and
accountability. All systems are challenged by the need for
quality improvement and self-learning.
The overall cost of health care has increased so much that
fewer individuals can afford to pay for the best available care;
thus, the financing of health systems has become central to
national policy debates worldwide. Access and equity consider-
ations pose particularly daunting challenges in poor countries,
where access to treatment may be a matter of life and death
for entire populations. This situation now prevails in the Sub-
Saharan African countries, where the continuing spread of the
HIV/AIDS epidemic has resulted in a sharp drop in life
expectancy.
Comparative analysis of health systems worldwide seeks to
understand the determinants of their performance—for
instance, financing, human resources, health information,
and quality of care—and to find ways to correct failures.
Strengthening such research is one obvious way to tackle the
current crisis in health systems.Another less obvious but impor-
tant implication of the current situation is the need to pursue
the best possible science to develop new and better tools and the
concomitant need to ensure the availability and affordability of
drugs and technologies where they are needed to address major
health problems.
New Frontiers for R&D
The extraordinary advances in science provide unprecedented
opportunities for both industrial and developing regions. The
following sections highlight promises as well as potential pit-
falls of frontier research.
Genomics, Molecular Epidemiology, and Preventive
Medicine. Probably the most exciting area of biomedical
research for at least the next decade derives from the Human
Genome Project and other efforts to sequence entire genomes
of mammals, birds, insects, and microbial pathogens.
Examination of these genome sequences will allow investiga-
tors to define and understand intrinsic risks for disease as well
as interactions between genes and environmental threats. The
sequencing of the major microbial pathogens has given rise to
molecular targets for new drugs against specific pathogens that
are distinct from their host counterparts and unique antigenic
fragments that may become effective components of new vac-
cines. Researchers have sequenced the genomes of virtually all
major viral, bacterial, and parasitic infectious disease agents
and placed the results in databases available to everyone, a
true public good (see The Institute of Genomic Research at
http://www.tigr.org).
The availability of these genome sequences has catalyzed
ambitious research efforts. For example, a project is under way
to genetically engineer the Anopheles mosquito to render it
unable to transmit malaria. Even if this effort fails, knowledge
of the mosquito’s genome has given new life to medical ento-
mology and will likely help reduce vectorborne diseases in
other ways. In a second example, the growing number of avail-
able influenza virus sequences will greatly aid understanding of
the epidemiology and evolution of pandemic and interpan-
demic influenza viruses and will be a powerful tool for guiding
vaccine strain selection.
The genome project has already changed the understanding
of health and disease (box 4.2). Until now, epidemiology has
dealt largely with external and environmental risks for disease.
What the Human Genome Project offers is knowledge of the
other side of the health equation—that is, the intrinsic risks for
disease. Previously undreamed of molecular and cellular tools
to explore gene expression and function are becoming available
to provide such knowledge on a scale that was inconceivable
even five years ago.
The hope is that genomics and related biomedical research
on stem cells will give rise to new therapies for repairing and
remodeling tissue damaged by chronic disease, from heart dis-
ease to diabetes and chronic neurological diseases. The possi-
bility of preventive treatment has now also arisen—that is, the
identification of risks for chronic disease early in life and the
implementation of preventive strategies—behavioral, nutri-
tional, or medical—to avert or overcome intrinsic risks and
thereby prevent disease.
Despite the optimism and enthusiasm, a darker side of the
Human Genome Project is emerging. Because individuals
face different risks, the focus on “boutique medicine” will
increase—that is, the focus on risks for individuals and the
development of niche interventions targeting those risks,
rather than the focus on populations. Identification of those
intrinsic risks at birth, for example, will for some time be a lux-
ury available to better-off children in rich countries but not to
babies in poor countries or to poor populations of rich coun-
tries. Ultimately the Human Genome Project and the rapid
advances in biomedical research in the industrial world have
the unintended potential to increase the gap between rich and
poor. If, however, most complex diseases have multigenic sus-
ceptibilities, the magic bullet approach of boutique medicine
may not fulfill current expectations of rich or poor countries.
New therapies, whether they arise from genomics or from
more traditional pharmacology, must be tested carefully to
ensure that people in developing countries are not unfairly
treated in clinical trials. Contract research organizations now
carry out 60 percent of clinical trials. Many of these organiza-
tions already test products in developing countries that will
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Uncovering Individual Risks for Specific Diseases
Box 4.2
Genomic information makes possible predicting individ-
ual risks for certain diseases and to certain components of
the environment. One level relates to polymorphisms in
individual genes that represent intrinsic risks for certain
conditions (for example, breast cancer). A second level
relates to differences in the expression patterns of multiple
genes on DNA chips that make it possible, for example,
to distinguish melanomas from lymphomas from colon
cancers or stages within these cancers that no pathologist
could duplicate for accuracy. Within patterns for breast
cancer or certain types of leukemia, experts can now dis-
tinguish those likely to survive five years from those with
a poor prognosis and are creating the first generation
of drugs effective against mutated genes causing specific
cancers.
The promise of the genome is first and foremost a
greater knowledge about disease, risks for disease, and
mechanisms of pathogenesis. The exploitation of knowl-
edge from the genome is just beginning, and practical
ramifications and many effective products have yet to be
realized. Despite the hyperbole about its promise, the
genome does represent a new frontier, beyond random
testing of compounds, for rational and evidence-based
design of effective interventions.
Source: Authors.
have anticipated markets in rich countries but are unlikely,
should they be licensed, to be available or affordable to popu-
lations in developing countries. This practice is both an ethical
and a practical health problem.
Finally, in countries where testing for genetic risks becomes
available, the likelihood of risk adjustment—that is, the exclu-
sion of people with some risks from insurance and discrimina-
tion in relation to jobs, marriage, and housing—can be antici-
pated. In this information age, personal genetic information
will certainly present an unprecedented challenge to privacy
and confidentiality.
A Faint Hope: Population-Based Research. The focus of
future research in the rich countries will likely be on individual
risks and on interventions tailored to those risks. Yet from the
point of view of the world as a whole, the most effective inter-
ventions are population-based interventions, such as vaccines,
insecticide-impregnated bednets, environmental modifica-
tions, antismoking campaigns, clean water, and safe sex. With
knowledge derived from biomedical science and the Human
Genome Project, it is hoped that some interventions will
emerge that do not require knowing any individuals’ intrinsic
genetic risks and that may apply to entire populations at risk.
The hope is that they could be comparable to existing
population-based interventions—for example, vaccines rec-
ommended for all children to prevent major infectious dis-
eases, treatment of schoolchildren once a year with ivermectin
to prevent onchocerciasis, and antismoking campaigns.
In the rich countries, research has shown that aspirin and
a combination of inexpensive antihypertensive drugs reduce
deaths from heart attacks by 30 percent and from strokes by
50 percent. Even though they are off patent, these interventions
are currently not widely used in developing countries. These
findings are the products of basic research, but their effective
use will depend on operational research.
The Next Frontier: Human Behavior and Social
Determinants of Disease. Another revolution in research is
emerging: understanding the functioning of the human brain
and, ultimately, human behavior. Biomarkers for neuropsychi-
atric disease and environmental stresses are being sought, and
with MRI and positron emission tomography technology,
researchers can see areas of the brain that are thinking, remem-
bering, or enjoying music. Within the next 50 years, science will
have the technical ability to begin to untangle the processes of
thinking in molecular terms, with exciting or frightening pos-
sibilities to alter or affect them. Anticipating quantifiable bio-
markers for stresses and psychopathology as well as objective
tools for measuring the effectiveness of new psychotropic inter-
ventions in changing behavior is not unreasonable.
Thefactors that lead people to engage in unhealthy or destruc-
tive behaviors are more complex than simple individual choices.
Many of the lessons of social epidemiology—and the flourishing
world of advertising—indicate that most behaviors, including
risky or unhealthy behaviors, are socially patterned. Science has
unfortunately not done a good job of learning how to change
social patterns. For example, merely targeting individuals at high
risk for HIV/AIDS without changing the social context that
might reinforce stigmatization is not the best way to prevent dis-
ease. Indeed, in many developing countries that now provide free
counseling, testing, and antiretroviral drugs for people with
HIV/AIDS, the biggest barrier remains the social stigma of being
HIV positive.Health systems must widen their view beyond indi-
vidual patients to target entire communities and the media to
change unhealthy socially patterned behavior. In the United
States, epidemiological estimates indicate that 50 percent of the
2.3 million annual deaths are preventable or postponable.
McGinnis and Foege (2004) find that in 2000, 19 percent of
deaths were caused by tobacco, about 14 percent were attributa-
ble to poor diet and lack of exercise, and about 12 percent to
injuries. One of the great challenges is to learn how to communi-
cate what is known about the prevention of such conditions as
heart disease, obesity, and diabetes more effectively.
Reliable and comparative analysis of health risks is key for
preventing disease and injury. A recently published study
(Ezzati and others 2003) reports estimates of the disease bur-
den caused by the joint effect of 20 selected leading risk factors
in 14 subepidemiological regions of the world. In regions
where high mortality persists, four risk factors—underweight
in childhood, micronutrient deficiency, indoor smoke from
solid fuels, and tobacco—caused 35 to 42 percent of lower res-
piratory infections in 2000. In the same regions, the combined
risks of high blood pressure, high cholesterol, high body mass
index, low fruit and vegetable intake, and physical inactivity
caused 82 to 89 percent of the burden of ischemic heart disease.
Important gaps in scientific evidence about the effects of mul-
tiple risk factors and risk factor interactions persist and require
further exploration (Ezzati and others 2003). In this context,
investigators should not underestimate social and behavioral
determinants of disease, including poverty, environment,
culture, and so on.
”Appropriate Science” for the Developing World
Although much discussion about “appropriate technology” for
developing countries has taken place in recent decades, curi-
ously little discussion has occurred about appropriate science.
Much of the past debate assessed the imbalance of research
relevant to developing countries’ health problems largely as a
function of the projected affordability of the products of the
research—drugs, diagnostics, and new technologies developed
in the industrial countries—rather than considering the poten-
tial contributions that scientists from developing countries
could make both to advancing science and to addressing their
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countries’ health problems. Although some technologies are
more or less appropriate to contexts in developing countries for
reasons of cost, maintenance, or skill requirements, no limita-
tion exists on what science or knowledge is appropriate in
developing countries.
Some might argue that people in developing countries
should restrict their research focus to diseases that principally
affect their countries. If that were generalized to all countries,
rich countries would not carry out research on tropical diseases,
and the developing countries would do little research on chronic
diseases. This strategy would violate two fundamental princi-
ples of science. First, connectivity in science is unpredictable:
research on one disease or problem often brings conceptual or
technological advances that are vital to progress in others;
therefore, to the extent possible, every country should support
a relatively broad spectrum of research. Second, creative science
requires the freedom to pursue ideas. Progress in science is not
fostered by restricting freedom of inquiry. There is every reason
to believe that scientists in developing countries will create
knowledge of value to diseases that primarily afflict people in
industrial countries, both because of the convergence of health
problems and because scientific knowledge is a public good.
Epistemology is the formal study of knowledge, and theories
of how knowledge is generated abound. One such theory par-
ticularly relevant in the context of health research holds that
three basic kinds of knowledge exist:2
• Public knowledge. This knowledge is generally published in
the scientific literature, available in principle to all (with the
glaring exception of those who cannot afford the major sci-
entific journals). Because this knowledge is available to the
entire global scientific community, it is a true public good.
Indeed, publication in such journals is the basis for most
judgments of academic and scientific achievement and is a
precondition for scientific support and advancement.
• Contextual knowledge. This kind of knowledge is absolutely
essential to bringing the fruits of public knowledge to a par-
ticular country or people. It requires learning and experi-
ence and involves cultural, social, and economic knowledge
of a place, without which effectively implementing public
knowledge or scientific discoveries in that context or evalu-
ating the success of programs within national contexts is
often impossible. In this case, research may have to be car-
ried out in relation to how to implement interventions, as
WHO’s Special Programme for Research and Training in
Tropical Diseases programs in leprosy and malaria have
done in the absence of full scientific evidence. As essential as
it may be, the global scientific and academic communities
do not widely recognize or value contextual knowledge.
• Tacit knowledge. In contrast to public knowledge and con-
textual knowledge, tacit or intrinsic knowledge is impossible
to write down or teach because it depends on a special kind
of communication between individuals that makes trans-
mission of knowledge possible. One thinks of a few great
clinical teachers who simply “know” the diagnosis without
laboratory tests, or health care professionals who can put
their colleagues in developing countries at ease and bring
out the best in everyone being taught rather than being
condescending or patronizing. Tacit knowledge is intuitive,
breaks down barriers of culture or training, is highly moti-
vating, and is often transformational in people’s lives.
A few examples illustrate the importance of contextual
knowledge. Many ideas and interventions are available, but
knowledge on their effectiveness in different populations and
on how to increase their usefulness is limited. The need to
define best practices in different circumstances is urgent in
relation to health. For example, data from the industrial coun-
tries indicate that providing a three-drug package containing
aspirin to people with hypertension as preventive treatment
might be possible on a population-based model as well as by
individual physicians or medical personnel. However, Asians
are more predisposed to hemorrhagic strokes than Europeans;
therefore, treatment with such a regimen in Asia might have a
significantly increased risk of adverse effects.
In another example, antiretroviral drugs are responsible
for the 50 percent decline in mortality from HIV/AIDS in
the United States, and the Global Fund to Fight AIDS,
Tuberculosis, and Malaria; bilateral agencies; and the pharma-
ceutical industry are engaging in major efforts to make them
available to resource-poor endemic countries. Despite encour-
aging examples in Brazil and Haiti, it is unclear whether—as in
DOTS (directly observed treatment short course), a supervised
method of administering drugs used for treating TB in
resource-poor countries—these drugs can be given safely and
effectively by community-based treatment programs, be
appropriately monitored, and prevent the emergence of drug
resistance or toxicity and thus provide cures for a high percent-
age of the patients in poor countries. However, if this method
can be used, it will strengthen the fight against HIV/AIDS.
Research on community-based programs for treating chil-
dren with epilepsy or adults with depression provides another
example. The provision of ivermectin (Mectizan) to prevent
and treat onchocerciasis revealed that even making a drug to be
taken only once a year available and providing it free of charge
had an almost negligible effect initially, because in some areas
of Sub-Saharan Africa an effective health delivery system was
simply not available. It is to Merck’s credit that the Mectizan
program invested considerable resources to create a delivery
and monitoring system that has moved onchocerciasis to the
category of diseases targeted for elimination as public health
problems by WHO.
The flow of knowledge is not unidirectional. Reciprocity
between research in different fields and different countries is
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vital for the expansion of knowledge, and the unique contribu-
tions of developing countries to global health research are often
overlooked and not always appreciated. For example, DOTS
was initially developed in Tanzania, where researchers found
that the best drug combination given with supervision, even
though more costly, was both more effective in preventing
relapse and emerging drug resistance and more cost-effective
than the cheapest combinations. Similarly, artemisinin, the
most rapidly acting drug for treating cerebral malaria, derives
from an ancient Chinese medicine, qinghaosu, and is now a
major tool in the armamentarium of malaria treatments.
Research on isolated populations in developing countries can
further the understanding of some of the genetic determinants
of a variety of diseases, and transnational research on almost
any disease has the potential to provide important insights into
differences in risk factors in different contexts.
Such reciprocity depends critically on the development of
scientific capacity. In terms of resource allocation, research
funders often appear to have overlooked the necessary connec-
tion between research and training the next generations of
researchers. Scientific and health capacity building and training
are inseparable from research, yet funders seldom recognize the
training aspect, and it is difficult to ensure that funding for
training will be recognized as integral to research.
”Appropriate Technology” for the Developing World
The development community has long debated the nature
of appropriate technology for resource-poor countries.
Innumerable instances exist of high-tech biomedical equip-
ment standing unused in laboratories and hospitals through-
out the developing world, serving as status symbols but not as
tools to further knowledge or alleviate illness. However, the best
tools appropriate for learning from the research should be
made available when the primary purpose of research is to
acquire knowledge, particularly if human subjects are engaged
as volunteers in clinical studies to help develop that new knowl-
edge. For example, researchers studying the effectiveness of
antiretroviral drugs in resource-poor countries should have
access to technology that can measure CD4 cells, viral loads,
and antiviral drug resistance, which are critical for analyzing
the drugs’ effectiveness. Sophisticated technology may be vital
to establish the scientific principle of effectiveness, thereby
enabling implementation of the most cost-effective treatment
program in settings where the high-tech methodology may no
longer be necessary on a large scale but may remain useful for
validating the effectiveness of lower-tech surrogate markers.
Strengthening Capacity and Institutions
A 1996 WHO report (Ad Hoc Committee on Health Research
Relating to Future Intervention Options 1996) emphasizes
three research needs that had not previously been articulated as
essential to development.
• The first is a need for new knowledge through research to
develop new tools for addressing continually emerging
global health problems. Some of this knowledge will be gen-
eralizable, but much will be context specific and perhaps
country specific.
• The second is the recognition that in many developing
countries research capacity—that is, people with the train-
ing to carry out surveillance and laboratory and operational
research—is limited, indicating an enormous need for
training. Career structures and incentives to retain trained
professionals in public health, medical sciences, and health
systems in developing countries are also needed. An enor-
mous brain drain is under way for nursing and other health
professionals. The inducements to leave developing coun-
tries for higher salaries and better working conditions in the
industrial world are compelling, even though many in the
health field would prefer to help alleviate their own coun-
tries’ health problems if it were feasible for them to do so.
• The third is that all the key priorities depend on the
strengthening of institutions: universities, schools of public
health and medicine, centers for disease control, and
research institutions for health policy and economics. As the
report indicates, remarkably few high-level institutions for
research and training in public health have been created in
developing countries during the past 25 years. Little
progress has been made since the mid 1990s. Thus, their
large needs for human capacity as well as laboratory and
research infrastructure for public health are not surprising.
For this situation to improve in a timely way, a new basis for
cooperation in support of people and institutions must be
forged between the developing and industrial countries.
Clearly governments should make greater commitments to
health training and institutions. Whereas the international
community has focused primarily on access to drugs in
resource-poor countries, new partnerships in research are clear-
ly needed. It is gratifying that programs that encourage and sup-
port cross-national, North-South, and South-South scientific
collaborations and institutional links have been increasing, and
the tremendous effect of the Bill & Melinda Gates Foundation
in supporting research has emphasized the value of public and
private commitments and partnerships in research. Regrettably,
concomitant commitment has been lacking on the part of
governments and many foundations to support training in
research; career path opportunities; and institutions such as
university science departments, medical schools, and schools of
public health, all of which are critical for reducing the research
and capacity gap between rich and poor countries.
No simple answer is available regarding the best ways to
ensure effective collaboration in relation to global heath. Global
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collaborations can be difficult, they are not inexpensive,and their
successes are limited in number, but they can potentially have a
major effect (box 4.3). Questions arise about how to develop
economies of scale in R&D and institutional capabilities;
how many research centers are optimal in a developing country;
how much should be done by country partners and how much
in the developing countries; and what the roles of basic scientific
versus epidemiological, clinical, and operational research should
be. The experience of working together in true partnerships
appears to be generally rewarding for scientists in both industrial
and developing countries and seems to be an effective way of
increasing research capacity. One set of lessons still to be learned
is what the best forms of collaboration are: individual scientist,
institutional, transnational, or multinational.
PRIORITY SETTING
Setting priorities for R&D of interventions is both complex and
critical in the context of severely constrained resources. A sys-
tematic approach that takes into account the disease burden as
well as scientific opportunities has been proposed to guide
decisions.
Approaches
The challenge is to ensure that available resources are targeted
at major health problems.
Inherent Difficulties in Setting Priorities. The first part of
this chapter underscored the immense scope of health prob-
lems and the potential of global health research to make a
difference. Given the complexity of the task and the multiple
participants involved in the process, defining priorities for the
global health research agenda is daunting.
Scientists tend to argue that more research is urgently need-
ed on the diseases they are studying. Their research may cer-
tainly include worthwhile issues, but they may not be priorities
in the wider context of global health R&D.
Some hold the view that the choice of priorities should
begin with a statement defining topics that should not be
priorities—for example, the development of vaccines (such as
a leprosy or hookworm vaccine) when cost-effective treatments
are available. Others strongly disagree, given the interconnect-
edness and unpredictability of science.
The failure of the U.S. “war on cancer” offers a useful cau-
tion on the limitations of rational planning of science. In the
1960s, a group of distinguished scientists developed a set of
future research priorities for the National Cancer Program.
Despite the importance of the problem, the requisite scientific
knowledge was not then available to develop the modern tools
that have recently been successful in treating and preventing
cancer. Planning for where the new innovations and discover-
ies will come from is hard, and planners have to be open to
changing their priorities and incorporating new approaches.
SARS and Influenza: A Paradigm Shift for Global Research Collaboration
Box 4.3
Outbreaks of emerging infectious diseases are by their
nature unpredictable. They can be contained when they
are detected early and the number of cases is small. When
they are not contained, they can have enormous human
and economic consequences. Economic losses attributed
to SARS, which infected 8,000 people and killed 774, have
been estimated at US$30 million per day in Canada and a
total of US$16 billion to US$30 billion in Asia.
The global response to the SARS epidemic demon-
strated the power of international collaboration under
leadership of WHO among public health professionals,
researchers, and institutions in several countries to halt
the progression of a new disease (La Montagne and others
2004). Another example is influenza: an existing interna-
tional network of influenza research sites, which is criti-
cal for defining the strains to be used each year for
immunization, was instrumental in developing an
unprecedented rapid response to the potentially devastat-
ing bird H5N1 influenza A.
These examples represent an important paradigm shift
in global research collaboration in that they required
national surveillance at the epidemiological and laboratory
levels; unprecedented sharing of information at all levels of
the health system; and close cooperation among clinicians,
epidemiologists, and bench scientists, as well as those
involved in veterinary surveillance, for the rapid develop-
ment of effective intervention strategies. Integrated global
responses raise difficult issues pertaining to information
sharing and ownership of specimens and reagents, which
have profound implications for future global health R&D.
They also underscore that, despite the political temptations
of denial and the economic threats of epidemic disease,
honest and accurate information is essential for early warn-
ing and for making effective health policy.
Source: Authors.
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A key challenge is the problematic nature of anticipating sci-
entific connections in advance. For example, the sequencing of
a mouse leukemia virus genome as part of the National Cancer
Program is what enabled scientists years later to classify HIV as
a related member of the retrovirus family. Indeed, who would
have predicted that research on the once arcane coronavirus
would become essential to control the spread of SARS? Or that
the esoteric question of whether tumor cells extinguished dif-
ferentiated functions of normal body cells would lead to the
discovery of monoclonal antibodies? Or that the study of sex in
bacteria would give rise to the entire genetic revolution of the
past half century? The need to recognize the unpredictability of
science and the limitations of scientists at any time is best
illustrated by Oppenheimer’s statement at the beginning of this
chapter.
Systematic and Evidence-Based Approach to Priority Setting.
The process of setting priorities for the global health research
agenda is complex and includes accurate or perceived assess-
ments of the burden of disease; developed countries’ threat
assessments, for example, in relation to bioterrorism and epi-
demic potential; scientific or technical opportunities; advocacy;
political commitment; ethical considerations; and funding
availability.
Using a systematic and evidence-based approach to priority
setting, the WHO Ad Hoc Committee for Health Research
Relating to Future Intervention Options (1996) undertook the
first broadly based, systematic effort to formulate “best buys”
for health R&D (table 4.3). The steps included assessments of
the following:
• size of the disease burden
• reasons the disease burden persisted
• adequacy of the current scientific knowledge base
• cost-effectiveness of potential interventions and the prob-
ability of successful development of new tools 
• adequacy of the current level of ongoing research and
funding.
Table 4.3 R&D Best Buys
Category Key R&D investments
Maternal and child health
Strategic research Understand the relative importance, in different environments, of increased nutrient intake and of control of infectious disease
as a way to reduce malnutrition
Package development Evaluate and refine the package for the integrated management of the sick child 
and evaluation Develop, evaluate, and refine the mother-baby package for pregnancy, delivery, and neonatal care
Evaluate the implementation of a range of family planning packages offering a wide choice of methods 
New tools to improve Evaluate the efficacy and optimal dosage of candidate rotavirus vaccines in low-income countries
package content Evaluate the efficacy of optimal dosage of candidate conjugate pneumococcal vaccines and the effectiveness of existing vaccine
against influenza B in low-income countries
Develop and evaluate ways to increase efficiency in the Expanded Program on Immunizations by simplifying delivery and
maximizing use of opportunities for immunization
Evaluate the promotion of insecticide-impregnated bednets for inclusion in a future healthy household package
Develop new contraceptive methods, particularly to widen the choice of long-term but reversible methods, postcoital methods
for regular and emergency use, and methods for men
Microbial threats
Strategic research Screen drugs on molecular targets predicted by the genome sequence of major pathogens
Investigate influences on the spread of antimicrobial resistance and approaches to monitoring resistant strains with the aim of
identifying ways of slowing their emergence
Intervention development Develop an effective prophylaxis for TB—for example, depot (or long-acting), or a vaccine chemoprophylaxis
Develop a malaria vaccine
Develop an HIV vaccine
Develop improved methods for the diagnosis, prevention, and treatment of sexually transmitted diseases, including vaginal
microbicides
Noncommunicable Establish a special program for research and training on noncommunicable diseases and healthy aging
diseases and injuries Establish a special program or initiative for research, training, and capacity building on injuries
Health policy Establish a special program for research and training on health systems and policy
Source: Ad Hoc Committee on Health Research Relating to Future Intervention Options 1996.
Infectious Diseases of the U.S. National Institutes of Health and
was conducted in May 2004 were leading scientists from low-
and middle-income developing countries and worked in the
same region in which they held their citizenship. The survey
highlighted their views about key factors influencing research
priority setting as well as major barriers that hampered
stronger participation by scientists from developing countries
in global health research. According to the survey, the most
important factors determining research priorities were the
magnitude of disease burdens and the needs of the industrial
countries. Major barriers to the success of research collabora-
tion in global health were the lack of sustained funding; the dif-
ficulty of linking research, programs, and policy; the weak
research leadership; and the absence of a science culture
(Harley, Simonsen, and Breman 2004).
A more balanced participation of scientists from industrial
and developing countries, a better gender mix, and the inclu-
sion of major stakeholders are essential to the successful devel-
opment of a truly global health research agenda. The challenge
is to develop creative mechanisms for addressing current
shortcomings.
The process for selecting the best research projects and pro-
grams within each priority area is well established and is
grounded in scientific merit, based primarily on trust in peer
review and expert judgment. Keeping this process independent
from political pressures is extremely important. However, the
peer review process has limitations, including a natural conser-
vatism and risk aversion by scientists, given the responsibility
for the allocation of public funding, their often narrow base of
expertise in one discipline, and their specific cultural perspec-
tive. Alternative models of project selection from industry and
other scientific, mission-oriented entities might offer interest-
ing alternatives—for example, managerial systems or strategic
planning processes, particularly for translating knowledge into
successful interventions, an area that research is currently
emphasizing.
Ethical considerations and pressures exerted by advocacy
groups—such as public-private partnerships for targeted drug
or vaccine development, fresh looks at “orphan drug” legisla-
tion, patent rules ensuring financial returns to industry as well
as the affordability of new products in developing countries,
and commitment before their development by the public and
private sectors to subsidize their development or ensure mar-
kets for the products—are likely to counterbalance to some
extent the lack of incentives for the pharmaceutical industry to
develop drugs, diagnostics, and vaccines for which markets do
not exist or are not profitable. In addition, one might hope that
the growing pharmaceutical and vaccine industry in develop-
ing countries might place a higher priority on addressing
nationally and regionally important health problems than do
multinational companies.
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This five-step approach has been influential. The Global
Forum for Health Research and the Special Programme for
Research and Training in Tropical Diseases have endorsed it
and further developed it. The Global Forum’s combined
approach matrix links the five steps with four actors or factors
determining the health status (Global Forum for Health
Research 2002):
• individual, family, and community
• health ministry, health research institutions, and health
systems and services
• sectors other than health
• central government macroeconomic policies.
The five steps also provide the basis for the strategic
emphases matrix for tropical diseases research (Remme and
others 2002).
The individual disease chapters in this volume used a
slightly modified version of the framework developed by the
WHO Ad Hoc Committee to identify gaps and guide the for-
mulation of research priorities on the basis of the following
premise: even though the current mix of available cost-
effective interventions averts a proportion of the burden of
any particular disease and the remaining burden could be fur-
ther reduced with improved application of existing technolo-
gies to affected populations, a fraction of disease remains that
cannot be averted. Two reasons account for this fact. First, the
cost for extending the existing technology to the remainder of
the population would be prohibitive. Second, the existing
interventions may simply not be sufficiently effective. These
two categories define the magnitude of the need for new or
better tools and, in essence, serve as a rationale and indicate
priorities for research.
A clear example is the case of HIV/AIDS. Neither behavioral
interventions, such as exhortations for abstinence and fidelity
and the provision of condoms, nor antiretroviral therapy has
stopped the global spread of HIV, which challenges the scien-
tific community to undertake more research on preventive vac-
cines. The availability of highly active antiretroviral therapy
challenges the research community to find ways of providing
effective and life-saving treatment for HIV/AIDS patients in a
manner that ensures proper use and compliance, averts the
development of drug resistance, and thereby becomes a finan-
cially sustainable policy.
Participants and Decision Makers. Two main concerns lie at
the core of most discussions of the priority-setting processes:
the predominance of the industrial countries and the predom-
inance of the scientific community in formulating research
agendas. Two-thirds of respondents in a survey of researchers
that was funded by the National Institute of Allergy and
The share of total R&D funds allocated to major causes
of the disease burden in developing countries remains
insufficient. As a result, the availability of funding to support
global health R&D is ultimately the defining factor regarding
the implementation of selected R&D priorities. Thus, the Bill &
Melinda Gates Foundation has become a major driving force in
defining priorities for global health R&D through its support
of promising public-private partnerships. The new US$200 mil-
lion it provided to finance the Grand Challenges in Global
Health represents the newest large influx of funds in support of
global health research (see Foundation of National Institutes of
Health at http://www.grandchallengesgh.org).
Findings
Research agendas proposed in the various chapters fall into
three broad categories:
• priorities that are already on the global health agenda 
• important topics that are not yet on the global agenda, but
should be pursued
• promising research topics that are not yet priorities, but
should be pursued.
Michaud and others (2005) provide a more exhaustive
account of the research priorities summarized here and recom-
mended in the volume.
Priorities Already Part of the Global Health Agenda.
Priorities that are already the most prominent part of the
global health agenda relate almost exclusively to the unfinished
agenda of infectious diseases and to the continuous threats
of emerging infectious diseases, including bioterrorism. The
largest investments pertain to the development of new drugs
and vaccines that are needed to reduce the burden of
HIV/AIDS, malaria, and TB; to the early detection and control
of new highly pathogenic viral agents (for example, SARS);
and to the prevention and treatment of infectious diseases
resulting from microbial terrorism (for instance, anthrax and
smallpox).
In 2001, the National Institute of Allergy and Infectious
Diseases developed a global research plan for HIV/AIDS,
malaria, and TB. The plan outlines a comprehensive approach
for fighting infectious diseases that involves building a sustain-
able research capability domestically and internationally and
enhancing global partnerships. It comprises short-, medium-,
and long-term goals for research that “will lead to prevention
and treatment strategies that are effective, feasible, and realistic
for individual countries struggling with the burden of numer-
ous infectious diseases” (National Institute of Allergy and
Infectious Diseases 2001).
Since the mid 1970s, the WHO Special Programme for
Research and Training in Tropical Diseases and a few other
institutions have been key players in strengthening research
and research capacity for tropical diseases that are endemic in
specific developing regions—African trypanosomiasis, Chagas
disease, dengue, leishmaniasis, leprosy, lymphatic filariasis,
malaria, onchocerciasis, and schistosomiasis. As a result, effec-
tive control measures are now available for Chagas disease, lep-
rosy, lymphatic filariasis, and onchocerciasis—but questions
remain regarding effective implementation strategies. The
other diseases still lack effective control measures and, thus,
require further research to develop better tools and effective
control strategies (http://www.who.int/tdr/grants/strategic-
emphases/default.htm).
The process that led to the formulation of the Grand
Challenges in Global Health represents two important depar-
tures from earlier approaches to priority setting. First, the
announcement of the call for ideas in May 2003 had an
unprecedented dissemination worldwide and resulted in over
1,000 submissions from scientists and institutions in 75 coun-
tries. Second, the formulation of a grand challenge, described
as “a call for specific scientific or technological innovation that
would remove a critical barrier to solving an important health
problem in the developing world with a high likelihood of
global impact and feasibility” (Varmus and others 2003) was
broad and had a clear goal.
The research agendas proposed in chapters 16, 18, and 21
are extensive and encompass research on basic epidemiology
and risk factors and the development of new or better drugs,
vaccines, diagnostics, and intervention methods. The fact that
these priorities do not represent a marked departure from
previous research priorities for these conditions attests to the
complexity of these diseases and their importance in the
poorest countries. They will require a broadly based and sus-
tained global research effort to overcome the rapid spread of
antibiotic and insecticide resistance, limited human resources,
and poorly developed health systems that severely constrain
the health community’s ability to reduce the burden of
disease.
Important Topics That Are Not Yet on the Global Research
Agenda but Should Be Pursued. Cardiovascular diseases,
neuropsychiatric disorders, obesity, diabetes, and cancers are
causing a rapidly increasing share of the disease burden in all
developing regions, with the exception of Sub-Saharan Africa;
however, they do not yet figure prominently on the global
health research agenda. The research priorities recommended
independently by the authors of various chapters pertaining to
major causes of noncommunicable diseases converge. Indeed,
diet, lifestyle, obesity, tobacco, and alcohol are common
risk factors for cardiovascular diseases, certain cancers, and
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diabetes. These diseases and risk factors represent a cluster of
conditions that pose similar research challenges.
The first important cross-cutting theme emerging from this
cluster of chapters is the issue of portability, or how to bring
knowledge and programs from one location and define how
they can become best practices elsewhere. Cost-effective pre-
ventive strategies and therapeutic approaches to reduce the
burden of cardiovascular diseases, cancer, diabetes, and mental
disorders have been developed and tested in industrial coun-
tries. Much of the extensive knowledge base accumulated in
industrial countries to prevent the development of cardiovas-
cular diseases, diabetes, and cancers is likely to be relevant to
developing countries, yet few epidemiological studies have
quantified the impact of major risk factors for chronic diseases
in developing regions, and few trials have been conducted to
assess the effectiveness of different intervention strategies.
Research to explore the transferability of cost-effective inter-
ventions from industrial to developing countries therefore
figures prominently in several chapters.
The primary prevention for noncommunicable diseases
in industrial countries rests on the reduction of major risk
factors—namely, diet, lifestyles, and tobacco and alcohol con-
sumption. Research priorities include the development of epi-
demiological databases and of intervention studies to identify
cost-effective strategies to reduce the prevalence of major risk
factors in different contexts in developing countries. The trans-
fer of personal and population-based interventions to reduce
the risk of cardiovascular disease, which are based on decades of
research in the industrial countries, is particularly promising.
Research priorities include evaluating a range of intervention
strategies, from simple dietary interventions to reduce the risk of
cardiovascular disease (for example, food supplementation with
folic acid and linoleic acid and reduction in the salt, saturated
fat, and trans fat content of processed foods), to the hypotheti-
cal “polypill,” which would combine drugs to lower cholesterol,
clotting, and blood pressure. Reducing the risk of cardiovascu-
lar disease is particularly important for diabetes, which is itself
an important risk factor for cardiovascular disease.
The second theme pertains to lifelong medical management
of chronic conditions that cannot be cured but could be im-
proved through the development and testing of public health
prevention and treatment algorithms. This issue has been little
considered in past discussions of priorities for global health
research but now appears to be reasonably cost-effective.
Examples include unipolar depression, bipolar disorders, schiz-
ophrenia, epilepsy, diabetes, and secondary prevention of
ischemic heart disease and stroke.
The third theme pertains to crucial implementation
research that combines operations research and health services
and systems research. Such research is becoming central to
ensuring the success of the rapid scaling-up of cost-effective
interventions that is required to meet the health targets of the
Millennium Development Goals, particularly in resource-poor
countries with weak health systems. In this context, further
research is critical to elucidate neglected areas of health system
reforms, including the following (Mills 2004):
• improving public service provision
• enhancing human resources 
• ensuring accountability for health outcomes, funds, and
medicines 
• ensuring a functioning central government 
• providing evidence for policy.
Promising Research Topics Not Yet Global Priorities. Other
important research topics emerge from the various chapters
that are not yet global priorities but that are nevertheless
worthwhile pursuing. Major themes pertain to the following:
• epidemiology of injuries and cost-effective interventions to
reduce the burden resulting from both intentional and
unintentional injuries, particularly motor vehicle crashes
and road and vehicle safety
• major risk factors for disease in different contexts (for
example, tobacco, obesity, physical activity)
• medical and surgical errors
• occupational and environmental health
• risk analysis and risk communication
• delivery of care at different levels of the health system
• performance of health systems 
• management of health research
• reproductive and sexual health
• health effects of global warming.
The importance of strengthening the research agenda in
those and other areas and the resultant opportunities to make a
real difference have not been sufficiently recognized in the past.
KEY RECOMMENDATIONS
The priority-setting process should focus initially on defining a
small number of key priorities that have a reasonable chance of
succeeding and yielding cost-effective outcomes in resource-
constrained environments and that are, thus, least likely to divert
limited resources from being more effectively directed else-
where. Five broad recommendations emerge from this chapter.
Invest More Wisely in Health R&D
The focus should be on how best to invest limited resources for
health R&D. This approach raises hard questions about select-
ing priorities and the extent to which the burden of disease and
scientific opportunity to play a role. A telling example of the
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dilemma may be a vaccine against bird flu. Because bird flu,
A (H5N1) or other strains, is not yet a major human disease,
the setting of priorities by the disease burden criterion would
not accord a bird flu vaccine high priority. But knowing that
between 20 to 40 million people died in the 1918 influenza epi-
demic, and that with a transmission time of 1.5 days, there
would be few public health measures other than a vaccine that
would make a difference in preventing a pandemic, developing
and testing multiple candidate vaccines should be an urgent
research priority.
Despite the paucity of past analysis of the relationship
between the cost of research in an area and its success in im-
proving the level of health, the amount invested is unlikely to
have been the most important determinant of success. The
What Works Working Group has developed 17 case studies of
success stories, all of which were supported by public finance
mostly in resource-constrained settings (Levine and What
Works Working Group 2004). A review of lessons learned from
the 20 biggest research successes in improving health in low- and
middle-income countries would be a worthwhile undertaking.
Shift the Paradigm for Priority Setting 
The paradigm shift from dividing the world’s health problems
into those of the industrial countries and those of the devel-
oping countries toward creating a better understanding of the
commonality of health problems between the industrial and
most developing countries lies at the core of priority setting
for global health research. Implicit in this shift is the recogni-
tion that the health problems of Sub-Saharan Africa are
urgent and require special emphasis on the devastating bur-
den of infectious diseases, particularly HIV/AIDS, and on the
need to develop effective infrastructure for health. In time,
the expectation is that the health needs of most Sub-Saharan
African countries will similarly converge with those of other
regions of the world and that knowledge developed in these
regions will be transferable and helpful to accelerating devel-
opment there.
As sociologists have long recognized, scientific and medical
technology diffuses from the industrial to the developing
countries, and it will, in the short term at least, increase the
disparities between rich and poor countries—and perhaps to
a comparable extent between the rich and the poor within
countries—because more affluent and better-educated popu-
lations tend to have greater access to new technologies.
However, even though disparities in health between affluent
urban dwellers and poor rural populations in China and India
have increased over the past decade, the overall quality of
health of the entire population has increased during the same
period. The hope is that information derived from research
will be a great leveler over time and will contribute to reduc-
ing global inequities.
The shift in thinking in relation to the convergence of health
burdens and research opportunities in both industrial and
developing countries has far-reaching implications for the for-
mulation of research priorities. In addition to emphasizing the
commonality of health problems, it also emphasizes the impor-
tance of stronger global research collaboration in tackling
major health problems and underscores the need for much
stronger public-private partnerships to ensure that affordable
drugs and vaccines will be developed and made available in
resource-constrained environments.
Maximize the Potential of Information Technology
No advances in science have more potential for improving
health globally than the information and communication sci-
ences. At the scientific level, the ability to handle increasingly
massive amounts of data, whether from genetics, epidemiolo-
gy, or clinical trials, offers the opportunity to mine the world of
knowledge in ways that could not be contemplated a decade
ago. Knowledge can be transferred instantaneously through the
Internet; through access to open databases; and through the
new public libraries of science and medicine, such as the U.S.
National Library of Medicine PubMed Central. With informa-
tion technology, procedures can be put in place to minimize
medical and pharmaceutical errors and to provide greater
accounting for medical costs and outcomes. Finally, research
with partners in many parts of the world can now be carried
out in real or in lag time, as in the case of clinical research on
malaria (Royall and others 2004). The tools, hardware, and
software for this informatics revolution must be made available
as widely as possible to universities and health systems in devel-
oping countries.
Increase Global Research Capacity
Research capacity continues to limit the successful implemen-
tation of those interventions most needed to improve health in
resource-constrained environments. The number of people
trained to carry out the surveillance and the laboratory and
operational research that are so essential to the succes-
sful implementation of cost-effective interventions remains
woefully inadequate. Redressing this limitation is a daunting
task that will require substantial financial investment and
creative approaches to create conditions that will reverse the
brain drain and strengthen academic and research institutions
in developing countries.
Create a Global Health Architecture
Health is not the sole provenance of the health sector, and yet
there is no forum or architecture for coordinating the increas-
ingly important multisectoral interactions to improve health.
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Cardiovascular and pulmonary disease in Europe and the
United States are increasingly determined by China’s energy
sector, and global warming is impacted by the policy of the U.S.
President. Health is critically affected by education, energy,
transport, finance, trade, immigration, communication, and the
environment. Major health problems will be most successfully
addressed if partnerships can be developed between sectors,
governments, NGOs, business and industry, and academe.
Support Freedom of Scientific Inquiry
No country has a monopoly on ideas, and every country has
something important to contribute to knowledge about health.
The universality of science requires that scientists everywhere
strive for the highest level of rigor and quality and that every
country have some sustainable level of scientific research and
problem-solving capacity. Encouraging and supporting scien-
tists with the ability and passion to contribute to knowledge
about health, globally or locally, must become one of the key
aims of the global health and development agendas.
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NOTES
1. Obviously, nonrivalry does not pertain to knowledge that is propri-
etary, as in the pharmaceutical industry, although the system of patents
was created to make such enabling knowledge available to all by providing
a limited monopoly for its exploitation by discoverers or inventors.
2. For this formulation, we are indebted to Suwit Wibulpolprasert,
deputy permanent secretary of the Ministry of Health, Thailand.
REFERENCES
Ad Hoc Committee on Health Research Relating to Future Intervention
Options. 1996. Investing in Health Research and Development. Geneva:
World Health Organization.
Commission on Macroeconomics and Health. 2001. Macroeconomics and
Health. Geneva: World Health Organization.
Ezzati, M., S. V. Hoorn, A. Rodgers, A. D. Lopez, C. D. Mathers, and 
C. J. Murray. 2003. “Estimates of Global and Regional Potential Health
Gains from Reducing Multiple Major Risk Factors.” Lancet 362 (9380):
271–80.
Fischer, S. 2003. “Socialist Economy Reform: Lessons of the First Three
Years.” American Economic Review 93 (May): 390–95.
Fogel, R. W. 2004. The Escape from Hunger and Premature Death,
1700–2100. Cambridge, U.K.: Cambridge University Press.
Global Forum for Health Research. 2002. The 10/90 Report on Health
Research 2001–2002. Geneva: Global Forum for Health Research.
Harley, L., L. Simonsen, and J. Breman. 2004. “Perceptions of Health
Research Priority Setting and Barriers: A Survey of International
Health Researchers.” Unpublished paper, National Institute of Allergy
and Infectious Diseases, U.S. National Institutes of Health, U.S.
Department of Health and Human Services, Bethesda, MD.
Institute of Medicine. 1997. America’s Vital Interest in Global Health:
Protecting Our People, Enhancing Our Economy, and Advancing Our
International Interests. Washington DC: National Academy Press.
King, G., and L. Zeng. 2001. “Improving Forecasts of State Failure.” World
Politics 53 (July): 623–58.
———. 2002. Consolidated State Failure Events, 1955–2001. College Park,
MD: University of Maryland.
La Montagne, J. R., L. Simonsen, R. J. Taylor, and J. Turnbull. 2004. “SARS
Research Working Group Co-Chairs—Severe Acute Respiratory
Syndrome: Developing a Research Response.” Journal of Infectious
Diseases 189 (4): 634–41.
Levine, R., and What Works Working Group with Molly Kinder. 2004.
Millions Saved: Proven Successes in Global Health. Washington, DC:
Center for Global Development.
Mathers, C., A. Lopez, C. Stein, D. Ma Fat, R. Chalapati, M. Inoue, and
others. 2005. “Death and Disease Burden by Cause: Global Burden of
Disease Estimates for 2001 by World Bank Country Groups.” Disease
Control Priorities Project Working Paper No. 18. Fogarty International
Center and National Institutes of Health, Washington, DC.
McGinnis, J. M., and W. H. Foege. 2004. “The Immediate versus the
Important.” Journal of the American Medical Association 291 (10):
1263–64.
Michaud, C. M., P. Maslen, S. Sahid-Salles, and J. Breman. 2005. “Synthesis
of Priorities for Global Research and Development.” Disease Control
Priorities Project Working Paper, Fogarty International Center and
National Institutes of Health, Washington, DC.
Mills, A. 2004. “Missing Areas in Health Sector Reform.” Unpublished
paper, London School of Hygiene and Tropical Medicine.
Murray, C. J., G. King, A. D. Lopez, N. Tomijima, and E. G. Krug. 2002.
“Armed Conflict as a Public Health Problem.” British Medical Journal
324 (7333): 346–49.
Murray, C. J., and A. D. Lopez, eds. 1996a. The Global Burden of Disease: A
Comprehensive Assessment of Mortality and Disability from Diseases,
Injuries, and Risk Factors in 1990 and Projected to 2020. Vol. 1 of Global
Burden of Disease and Injury. Cambridge, MA: Harvard School of
Public Health for the World Health Organization and the World Bank.
———. 1996b. Global Health Statistics: A Compendium of Incidence,
Prevalence, and Mortality for over 200 Conditions. Vol. 2 of Global
Burden of Disease and Injury. Cambridge, MA: Harvard School of
Public Health for the World Health Organization and the World Bank.
National Institute of Allergy and Infectious Diseases. 2001. “NIAID Global
Health Research Plan for HIV/AIDS, Malaria, and Tuberculosis.”
National Institute of Allergy and Infectious Diseases, National
Institutes of Health, U.S. Department of Health and Human Services,
Bethesda, MD.
Remme, J. H., E. Blas, L. Chitsulo, P. M. Desjeux, H. D. Engers, T. P. Kanyok,
and others. 2002. “Strategic Emphases for Tropical Diseases Research:
A TDR Perspective.” Trends in Parasitology 18 (10): 421–26.
Royall, J., M. Bennett, I. van Schayk, and M. Alilio. 2004. “Tying up Lions:
Multilateral Initiative on Malaria Communications: The First Chapter
of a Malaria Research Network in Africa.” American Journal of Tropical
Medicine and Hygiene 71 (2 Suppl.): 259–67.
Varmus,H.,R.Klausner,E.Zerhouni,T.Acharya,A.S.Daar,and P.A.Singer.
2003.“Grand Challenges in Global Health.” Science 302 (5644): 398–99.
Wilson, E. O. 2003. The Future of Life. New York: Vintage Books.
WHO (World Health Organization). 2000. Report on Global Surveillance
of Epidemic-Prone Infectious Diseases. WHO/CDS/CSR/ISR/2000.1.
Geneva: WHO.
World Bank. 2004. World Development Indicators. Washington, DC: World
Bank.
118 | Disease Control Priorities in Developing Countries | Barry R. Bloom, Catherine M. Michaud, John R. La Montagne, and others
119
As we move into the new millennium it is becoming increas-
ingly clear that the biomedical sciences are entering the most
exciting phase of their development. Paradoxically, medical
practice is also passing through a phase of increasing uncer-
tainty, in both industrial and developing countries. Industrial
countries have not been able to solve the problem of the spiral-
ing costs of health care resulting from technological develop-
ment, public expectations, and—in particular—the rapidly
increasing size of their elderly populations. The people of many
developing countries are still living in dire poverty with dys-
functional health care systems and extremely limited access to
basic medical care.
Against this complex background, this chapter examines the
role of science and technology for disease control in the past
and present and assesses the potential of the remarkable devel-
opments in the basic biomedical sciences for global health care.
MEDICINE BEFORE THE 20TH CENTURY
From the earliest documentary evidence surviving from the
ancient civilizations of Babylonia, China, Egypt, and India, it is
clear that longevity, disease, and death are among humanity’s
oldest preoccupations. From ancient times to the Renaissance,
knowledge of the living world changed little, the distinction
between animate and inanimate objects was blurred, and spec-
ulations about living things were based on prevailing ideas
about the nature of matter.
Advances in science and philosophy throughout the 16th
and 17th centuries led to equally momentous changes in
medical sciences. The elegant anatomical dissections of Andreas
Vesalius swept away centuries of misconceptions about the rela-
tionship between structure and function of the human body;
the work of Isaac Newton, Robert Boyle, and Robert Hooke
disposed of the basic Aristotelian elements of earth, air, fire, and
water; and Hooke, through his development of the microscope,
showed a hitherto invisible world to explore. In 1628, William
Harvey described the circulation of the blood, a discovery that,
because it was based on careful experiments and measurement,
signaled the beginnings of modern scientific medicine.
After steady progress during the 18th century, the biological
and medical sciences began to advance at a remarkable rate
during the 19th century, which saw the genuine beginnings
of modern scientific medicine. Charles Darwin changed the
whole course of biological thinking, and Gregor Mendel laid
the ground for the new science of genetics, which was used
later to describe how Darwinian evolution came about. Louis
Pasteur and Robert Koch founded modern microbiology, and
Claude Bernard and his followers enunciated the seminal prin-
ciple of the constancy of the internal environment of the body,
a notion that profoundly influenced the development of phys-
iology and biochemistry. With the birth of cell theory, modern
pathology was established. These advances in the biological
sciences were accompanied by practical developments at the
bedside, including the invention of the stethoscope and an
instrument for measuring blood pressure, the first use of x-rays,
the development of anesthesia, and early attempts at the
classification of psychiatric disease as well as a more humane
approach to its management. The early development of the use
of statistics for analyzing data obtained in medical practice also
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occurred in the 19th century, and the slow evolution of public
health and preventive medicine began.
Significant advances in public health occurred on both sides
of the Atlantic. After the cholera epidemics of the mid 19th
century, public health boards were established in many
European and American cities. The Public Health Act, passed
in the United Kingdom in 1848, provided for the improvement
of streets, construction of drains and sewers, collection of
refuse, and procurement of clean domestic water supplies.
Equally important, the first attempts were made to record basic
health statistics. For example, the first recorded figures for the
United States showed that life expectancy at birth for those who
lived in Massachusetts in 1870 was 43 years; the number of
deaths per 1,000 live births in the same population was 188. At
the same time, because it was becoming increasingly clear that
communicable diseases were greatly depleting the workforce
required to generate the potential rewards of colonization, con-
siderable efforts were channeled into controlling infectious dis-
eases, particularly hookworm and malaria, in many countries
under colonial domination.
However, until the 19th century, curative medical tech-
nology had little effect on the health of society, and many of the
improvements over the centuries resulted from higher stan-
dards of living, improved nutrition, better hygiene, and other
environmental modifications. The groundwork was laid for a
dramatic change during the second half of the 20th century,
although considerable controversy remains over how much we
owe to the effect of scientific medicine and how much to con-
tinued improvements in our environment (Porter 1997).
This balance between the potential of the basic biological
sciences and simpler public health measures for affecting the
health of our societies in both industrial and developing coun-
tries remains controversial and is one of the major issues to be
faced by those who plan the development of health care ser-
vices for the future.
SCIENCE, TECHNOLOGY, AND MEDICINE 
IN THE 20TH CENTURY 
Although rapid gains in life expectancy followed social change
and public health measures, progress in the other medical sci-
ences was slow during the first half of the 20th century, possi-
bly because of the debilitating effect of two major world wars.
The position changed dramatically after World War II, a time
that many still believe was the period of major achievement in
the biomedical sciences for improving the health of society.
This section outlines some of these developments and the effect
they have had on medical practice in both industrial and devel-
oping countries. More extensive treatments of this topic are
available in several monographs (Cooter and Pickstone 2000;
Porter 1997; Weatherall 1995).
Epidemiology and Public Health
Modern epidemiology came into its own after World War II,
when increasingly sophisticated statistical methods were first
applied to the study of noninfectious disease to analyze the pat-
terns and associations of diseases in large populations. The
emergence of clinical epidemiology marked one of the most
important successes of the medical sciences in the 20th century.
Up to the 1950s, conditions such as heart attacks, stroke,
cancer, and diabetes were bundled together as degenerative dis-
orders, implying that they might be the natural result of wear
and tear and the inevitable consequence of aging. However,
information about their frequency and distribution, plus, in
particular, the speed with which their frequency increased in
association with environmental change, provided excellent evi-
dence that many of them have a major environmental compo-
nent. For example, death certificate rates for cancers of the
stomach and lung rose so sharply between 1950 and 1973 that
major environmental factors must have been at work generat-
ing these diseases in different populations.
The first major success of clinical epidemiology was the
demonstration of the relationship between cigarette smoking
and lung cancer by Austin Bradford Hill and Richard Doll in
the United Kingdom. This work was later replicated in many
studies, currently, tobacco is estimated to cause about 8.8 per-
cent of deaths (4.9 million) and 4.1 percent of disability-
adjusted life years (59.1 million) (WHO 2002c). Despite this
information, the tobacco epidemic continues,with at least 1 mil-
lion more deaths attributable to tobacco in 2000 than in 1990,
mainly in developing countries.
The application of epidemiological approaches to the study
of large populations over a long period has provided further
invaluable information about environmental factors and dis-
ease. One of the most thorough—involving the follow-up of
more than 50,000 males in Framingham, Massachusetts—
showed unequivocally that a number of factors seem to be
linked with the likelihood of developing heart disease (Castelli
and Anderson 1986). Such work led to the concept of risk
factors, among them smoking, diet (especially the intake of ani-
mal fats), blood cholesterol levels, obesity, lack of exercise, and
elevated blood pressure. The appreciation by epidemiologists
that focusing attention on interventions against low risk factors
that involve large numbers of people, as opposed to focusing
on the small number of people at high risk, was an important
advance. Later, it led to the definition of how important envi-
ronmental agents may interact with one another—the
increased risk of death from tuberculosis in smokers in India,
for example.
A substantial amount of work has gone into identifying risk
factors for other diseases, such as hypertension, obesity and
its accompaniments, and other forms of cancer. Risk factors
defined in this way, and from similar analyses of the pathological
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role of environmental agents such as unsafe water, poor sanita-
tion and hygiene, pollution, and others, form the basis of The
World Health Report 2002 (WHO 2002c), which sets out a pro-
gram for controlling disease globally by reducing 10 conditions:
underweight status; unsafe sex; high blood pressure; tobacco
consumption; alcohol consumption; unsafe water, sanitation,
and hygiene; iron deficiency; indoor smoke from solid fuels;
high cholesterol; and obesity. These conditions are calculated to
account for more than one-third of all deaths worldwide.
The epidemiological approach has its limitations, however.
Where risk factors seem likely to be heterogeneous or of only
limited importance, even studies involving large populations
continue to give equivocal or contradictory results.
Furthermore, a major lack of understanding, on the part not
just of the general public but also of those who administer
health services, still exists about the precise meaning and inter-
pretation of risk. The confusing messages have led to a certain
amount of public cynicism about risk factors, thus diminishing
the effect of information about those risk factors that have been
established on a solid basis. Why so many people in both indus-
trial and developing countries ignore risk factors that are based
on solid data is still not clear; much remains to be learned
about social, cultural, psychological, and ethnic differences
with respect to education about important risk factors for dis-
ease. Finally, little work has been done regarding the perception
of risk factors in the developing countries (WHO 2002c).
A more recent development in the field of clinical
epidemiology—one that may have major implications for
developing countries—stems from the work of Barker (2001)
and his colleagues, who obtained evidence suggesting that
death rates from cardiovascular disease fell progressively with
increasing birthweight, head circumference, and other meas-
ures of increased development at birth. Further work has
suggested that the development of obesity and type 2 diabetes,
which constitute part of the metabolic syndrome, is also
associated with low birthweight. The notion that early fetal
development may have important consequences for disease in
later life is still under evaluation, but its implications, particu-
larly for developing countries, may be far reaching.
The other major development that arose from the applica-
tion of statistics to medical research was the development of
the randomized controlled trial. The principles of numerically
based experimental design were set out in the 1920s by the
geneticist Ronald Fisher and applied with increasing success
after World War II, starting with the work of Hill, Doll, and
Cochrane (see Chalmers 1993; Doll 1985). Variations on this
theme have become central to every aspect of clinical research
involving the assessment of different forms of treatment. More
recently, this approach has been extended to provide broad-
scale research syntheses to help inform health care and
research. Increasing the numbers of patients involved in trials
and applying meta-analysis and electronic technology for
updating results have made it possible to provide broad-scale
analyses combining the results of many different trials.
Although meta-analysis has its problems—notably the lack of
publication of negative trial data—and although many poten-
tial sources of bias exist in the reporting of clinical trials, these
difficulties are gradually being addressed (Egger, Davey-Smith,
and Altman 2001).
More recent developments in this field come under the gen-
eral heading of evidence-based medicine (EBM) (Sackett and
others 1996). Although it is self-evident that the medical pro-
fession should base its work on the best available evidence, the
rise of EBM as a way of thinking has been a valuable addition
to the development of good clinical practice over the years.
It covers certain skills that are not always self-evident,
including finding and appraising evidence and, particularly,
implementation—that is, actually getting research into
practice. Its principles are equally germane to industrial and
developing countries, and the skills required, particularly
numerical, will have to become part of the education of physi-
cians of the future. To this end, the EBM Toolbox was estab-
lished (Web site: http://www.ish.ox.ac.uk/ebh.html). However,
evidence for best practice obtained from large clinical trials
may not always apply to particular patients; obtaining a balance
between better EBM and the kind of individualized patient care
that forms the basis for good clinical practice will be a major
challenge for medical education.
Partial Control of Infectious Disease. The control of commu-
nicable disease has been the major advance of the 20th century
in scientific medicine. It reflects the combination of improved
environmental conditions and public health together with the
development of immunization, antimicrobial chemotherapy,
and the increasing ability to identify new pathogenic organ-
isms. Currently, live or killed viral or bacterial vaccines—or
those based on bacterial polysaccharides or bacterial toxoids—
are licensed for the control of 29 common communicable dis-
eases worldwide. The highlight of the field was the eradication
of smallpox by 1977. The next target of the World Health
Organization (WHO) is the global eradication of poliomyelitis.
In 1998, the disease was endemic in more than 125 countries.
After a resurgence in 2002, when the number of cases rose to
1,918, the numbers dropped again in 2003 to 748; by March
2004, only 32 cases had been confirmed (Roberts 2004).
The Expanded Program on Immunization (EPI), launched
in 1974, which has been taken up by many countries with slight
modification, includes Bacillus Calmette-Guérin (BCG) and
oral polio vaccine at birth; diphtheria, tetanus, and pertussis at
6, 10, and 14 weeks; measles; and, where relevant, yellow fever
at 9 months. Hepatitis B is added at different times in different
communities. By 1998, hepatitis B vaccine had been incorpo-
rated into the national programs of 90 countries, but an esti-
mated 70 percent of the world’s hepatitis B carriers still live in
countries without programs (Nossal 1999). Indeed, among
12 million childhood deaths analyzed in 1998, almost 4 million
were the result of diseases for which adequate vaccines are
available (WHO 2002a).
The development of sulfonamides and penicillin in the
period preceding World War II was followed by a remarkable
period of progress in the discovery of antimicrobial agents
effective against bacteria, fungi, viruses, protozoa, and
helminths. Overall, knowledge of the pharmacological mode of
action of these agents is best established for antibacterial and
antiviral drugs. Antibacterial agents may affect cell wall or pro-
tein synthesis, nucleic acid formation, or critical metabolic
pathways. Because viruses live and replicate in host cells, antivi-
ral chemotherapy has presented a much greater challenge.
However, particularly with the challenge posed by HIV/AIDS,
a wide range of antiviral agents has been developed, most of
which are nucleoside analogues, nucleoside or nonnucleoside
reverse-transcriptase inhibitors, or protease inhibitors.
Essentially, those agents interfere with critical self-copying or
assembly functions of viruses or retroviruses. Knowledge of
the modes of action of antifungal and antiparasitic agents is
increasing as well.
Resistance to antimicrobial agents has been recognized since
the introduction of effective antibiotics; within a few years,
penicillin-resistant strains of Staphylococcus aureus became
widespread and penicillin-susceptible strains are now very
uncommon (Finch and Williams 1999). At least in part caused
by the indiscriminate use of antibiotics in medical practice,
animal husbandry, and agriculture, multiple-antibiotic-
resistant bacteria are now widespread. Resistance to antiviral
agents is also occurring with increasing frequency (Perrin and
Telenti 1998), and drug resistance to malaria has gradually
increased in frequency and distribution across continents
(Noedl, Wongsrichanalai, and Wernsdorfer 2003). The critical
issue of drug resistance to infectious agents is covered in detail
in chapter 55.
In summary, although the 20th century witnessed remark-
able advances in the control of communicable disease, the cur-
rent position is uncertain. The emergence of new infectious
agents, as evidenced by the severe acute respiratory syndrome
(SARS) epidemic in 2002, is a reminder of the constant danger
posed by the appearance of novel organisms; more than 30 new
infective agents have been identified since 1970. Effective vac-
cines have not yet been developed for some of the most com-
mon infections—notably tuberculosis, malaria, and HIV—and
rapidly increasing populations of organisms are resistant to
antibacterial and antiviral agents. Furthermore, development
of new antibiotics and effective antiviral agents with which to
control such agents has declined. The indiscriminate use of
antibiotics, both in the community and in the hospital popula-
tions of the industrial countries, has encouraged the emergence
of resistance, a phenomenon exacerbated in some of the
developing countries by the use of single antimicrobial agents
when combinations would have been less likely to produce
resistant strains. Finally, public health measures have been
hampered by the rapid movement of populations and by war,
famine, and similar social disruptions in developing countries.
In short, the war against communicable disease is far from
over.
Pathogenesis, Control, and Management of Non-
communicable Disease. The second half of the 20th century
also yielded major advances in understanding pathophysiology
and in managing many common noncommunicable diseases.
This phase of development of the medical sciences has been
characterized by a remarkable increase in the acquisition of
knowledge about the biochemical and physiological basis of
disease, information that, combined with some remarkable
developments in the pharmaceutical industry, has led to a situ-
ation in which few noncommunicable diseases exist for which
there is no treatment and many, although not curable, can be
controlled over long periods of time.
Many of these advances have stemmed from medical
research rather than improved environmental conditions. In
1980, Beeson published an analysis of the changes that
occurred in the management of important diseases between
the years 1927 and 1975, based on a comparison of methods for
treating these conditions in the 1st and 14th editions of a lead-
ing American medical textbook. He found that of 181 condi-
tions for which little effective prevention or treatment had
existed in 1927, at least 50 had been managed satisfactorily by
1975. Furthermore, most of these advances seem to have
stemmed from the fruits of basic and clinical research directed
at the understanding of disease mechanisms (Beeson 1980;
Comroe and Dripps 1976).
Modern cardiology is a good example of the evolution of
scientific medicine. The major technical advances leading to a
better appreciation of the physiology and pathology of the
heart and circulation included studies of its electrical activity
by electrocardiography; the ability to catheterize both sides of
the heart; the development of echocardiography; and, more
recently, the development of sophisticated ways of visualizing
the heart by computerized axial tomography, nuclear magnetic
resonance, and isotope scanning. These valuable tools and the
development of specialized units to use them have led to a
much better understanding of the physiology of the failing
heart and of the effects of coronary artery disease and have rev-
olutionized the management of congenital heart disease. Those
advances have been backed by the development of effective
drugs for the management of heart disease, including diuretics,
beta-blockers, a wide variety of antihypertensive agents,
calcium-channel blockers, and anticoagulants.
By the late 1960s, surgical techniques were developed to
relieve obstruction of the coronary arteries. Coronary bypass
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surgery and, later, balloon angioplasty became major tools.
Progress also occurred in treatment of abnormalities of cardiac
rhythm, both pharmacologically and by the implantation of
artificial pacemakers. More recently, the development of
microelectronic circuits has made it possible to construct
implantable pacemakers. Following the success of renal trans-
plantation, cardiac transplantation and, later, heart and lung
transplantation also became feasible.
Much of this work has been backed up by large-scale con-
trolled clinical trials. These studies, for example, showed that
the early use of clot-dissolving drugs together with aspirin had
a major effect on reducing the likelihood of recurrences after
an episode of myocardial infarction (figure 5.1). The large
number of trials and observational studies of the effects of
coronary bypass surgery and dilatation of the coronary arteries
with balloons have given somewhat mixed results, although
overall little doubt exists that, at least in some forms of coro-
nary artery disease, surgery is able to reduce pain from angina
and probably prolong life. Similar positive results have been
obtained in trials that set out to evaluate the effect of the con-
trol of hypertension (Warrell and others 2003).
The management of other chronic diseases, notably those of
the gastrointestinal tract, lung, and blood has followed along
similar lines. Advances in the understanding of their patho-
physiology, combined with advances in analysis at the struc-
tural and biochemical levels, have enabled many of these
diseases to be managed much more effectively. The pharma-
ceutical industry has helped enormously by developing agents
such as the H2-receptor antagonists and a wide range of drugs
directed at bronchospasm. There have been some surprises—
the discovery that peptic ulceration is almost certainly caused
by a bacterial agent has transformed the management of this
disease, dramatically reducing the frequency of surgical inter-
vention. Neurology has benefited greatly from modern diag-
nostic tools, while psychiatry, though little has been learned
about the cause of the major psychoses, has also benefited
enormously from the development of drugs for the control of
both schizophrenia and the depressive disorders and from
the emergence of cognitive-behavior therapy and dynamic
psychotherapy.
The second half of the 20th century has witnessed major
progress in the diagnosis and management of cancer (reviewed
by Souhami and others 2001). Again, this progress has followed
from more sophisticated diagnostic technology combined with
improvements in radiotherapy and the development of power-
ful anticancer drugs. This approach has led to remarkable
improvements in the outlook for particular cancers, including
childhood leukemia, some forms of lymphoma, testicular
tumors, and—more recently—tumors of the breast. Progress
in managing other cancers has been slower and reflects the
results of more accurate staging and assessment of the extent
and spread of the tumor; the management of many common
cancers still remains unsatisfactory, however. Similarly,
although much progress has been made toward the prevention
of common cancers—cervix and breast, for example—by pop-
ulation screening programs, the cost-effectiveness of screening
for other common cancers—prostate, for example—remains
controversial.
Many aspects of maternal and child health have improved
significantly. A better understanding of the physiology and dis-
orders of pregnancy together with improved prenatal care and
obstetric skills has led to a steady reduction in maternal mor-
tality. In an industrial country, few children now die of child-
hood infection; the major pediatric problems are genetic and
congenital disorders, which account for about 40 percent of
admissions in pediatric wards, and behavioral problems
(Scriver and others 1973). Until the advent of the molecular
era, little progress was made toward an understanding of the
cause of these conditions. It is now known that a considerable
proportion of cases of mental retardation result from definable
chromosomal abnormalities or monogenic diseases, although
at least 30 percent of cases remain unexplained. Major
improvements have occurred in the surgical management of
congenital malformation, but only limited progress has been
made toward the treatment of genetic disease. Although a few
factors, such as parental age and folate deficiency, have been
incriminated, little is known about the reasons for the occur-
rence of congenital abnormalities.
In summary, the development of scientific medical prac-
tice in the 20th century led to a much greater understanding
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Figure 5.1 Effects of a One-hour Streptokinase Infusion Together
with Aspirin for One Month on the 35-Day Mortality in the Second
International Study of Infarct Survival Trial among 17,187 Patients
with Acute Myocardial Infarction Who Would Not Normally Have
Received Streptokinase or Aspirin, Divided at Random into Four
Groups to Receive Aspirin Only, Streptokinase Only, Both, or Neither
of deranged physiology and has enabled many of the com-
mon killers in Western society to be controlled, though few
to be cured. However, although epidemiological studies of
these conditions have defined a number of risk factors and
although a great deal is understood about the pathophysiol-
ogy of established disease, a major gap remains in our
knowledge about how environmental factors actually cause
these diseases at the cellular and molecular levels (Weatherall
1995).
Consequences of the Demographic and Epidemiological
Transitions of the 20th Century. The period of development
of modern scientific medicine has been accompanied by major
demographic change (Chen 1996; Feachem and others 1992).
The results of increasing urbanization, war and political unrest,
famine, massive population movements, and similar issues
must have had a major effect on the health of communities
during the 20th century, but there has been a steady fall in
childhood mortality throughout the New World, Europe, the
Middle East, the Indian subcontinent, and many parts of Asia
during this period, although unfortunately there has been
much less progress in many parts of Sub-Saharan Africa.
Although much of the improvement can be ascribed to
improving public health and social conditions, the advent of
scientific medicine—particularly the control of many infec-
tious diseases of childhood—seems likely to be playing an
increasingly important part in this epidemiological transition.
Although surveys of the health of adults in the developing
world carried out in the 1980s suggested that many people
between the ages of 20 and 50 were still suffering mainly from
diseases of poverty, many countries have now gone through an
epidemiological transition such that the global pattern of dis-
ease will change dramatically by 2020, with cardiorespiratory
disease, depression, and the results of accidents replacing com-
municable disease as their major health problems.
Countries undergoing the epidemiological transition are
increasingly caught between the two worlds of malnutrition
and infectious disease on the one hand and the diseases of
industrial countries, particularly cardiac disease, obesity, and
diabetes, on the other. The increasing epidemic of tobacco-
related diseases in developing countries exacerbates this prob-
lem. The global epidemic of obesity and type 2 diabetes is a
prime example of this problem (Alberti 2001). An estimated
150 million people are affected with diabetes worldwide, and
that number is expected to double by 2025. Furthermore,
diabetes is associated with greatly increased risk of cardiovas-
cular disease and hypertension; in some developing countries
the rate of stroke is already four to five times that in industrial
countries. These frightening figures raise the questions
whether, when developing countries have gone through the
epidemiological transition, they may face the same pattern of
diseases that are affecting industrial countries and whether
such diseases may occur much more frequently and be more
difficult to control.
Partly because of advances in scientific medicine, industrial
countries have to face another large drain on health resources
in the new millennium (Olshansky, Carnes, and Cassel 1990).
In the United Kingdom, for example, between 1981 and 1989,
the number of people ages 75 to 84 rose by 16 percent, and that
of people age 85 and over by 39 percent; the current population
of males age 85 or over is expected to reach nearly 0.5 million
by 2026, at which time close to 1 million females will be in this
age group. Those figures reflect the situation for many indus-
trial countries, and a similar trend will occur in every country
that passes through the epidemiological transition. Although
data about the quality of life of the aged are limited, studies
such as the 1986 General Household Survey in the United
States indicate that restricted activity per year among people
over the age of 65 was 43 days in men and 53 days in women;
those data say little about the loneliness and isolation of old
age. It is estimated that 20 percent of all people over age 80 will
suffer from some degree of dementia, a loss of intellectual
function sufficient to render it impossible for them to care for
themselves. Scientific medicine in the 20th century has pro-
vided highly effective technology for partially correcting the
diseases of aging while, at the same time, making little progress
toward understanding the biological basis of the aging process.
Furthermore, the problems of aging and its effect on health
care have received little attention from the international public
health community; these problems are not restricted to indus-
trial countries but are becoming increasingly important in
middle-income and, to a lesser extent, some low-income
countries.
Although dire poverty is self-evident as one of the major
causes of ill health in developing countries, this phenomenon is
emphatically not confined to those populations. For example,
in the United Kingdom, where health care is available to all
through a government health service, a major discrepancy in
morbidity and mortality exists between different social classes
(Black 1980). Clearly this phenomenon is not related to the
accessibility of care, and more detailed analyses indicate that it
cannot be ascribed wholly to different exposure to risk factors.
Undoubtedly social strain, isolation, mild depression, and lack
of social support play a role. However, the reasons for these
important discrepancies, which occur in every industrial coun-
try, remain unclear.
Economic Consequences of High-Technology Medicine
The current high-technology medical practice based on mod-
ern scientific medicine must steadily increase health expendi-
tures. Regardless of the mechanisms for the provision of health
care, its spiraling costs caused by ever more sophisticated
technology and the ability to control most chronic illnesses,
combined with greater public awareness and demand for
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medical care, are resulting in a situation in which most indus-
trial countries are finding it impossible to control the costs of
providing health care services.
The U.K. National Health Service (NHS) offers an interest-
ing example of the steady switch to high-technology hospital
practice since its inception 50 years ago (Webster 1998). Over
that period, the NHS’s overall expenditure on health has
increased fivefold, even though health expenditure in the
United Kingdom absorbs a smaller proportion of gross domes-
tic product than in many neighboring European countries. At
the start of the NHS, 48,000 doctors were practicing in the
United Kingdom; by 1995 there were 106,845, of whom 61,050
were in hospital practice and 34,594 in general (primary care)
practice. Although the number of hospital beds halved over the
first 50 years of the NHS, the throughput of the hospital service
increased from 3 million to 10 million inpatients per year, over
a time when the general population growth was only 19 per-
cent. Similarly, outpatient activity doubled, and total outpatient
visits grew from 26 million to 40 million. Because many indus-
trial countries do not have the kind of primary care referral pro-
gram that is traditional in the United Kingdom, this large skew
toward hospital medicine seems likely to be even greater.
The same trends are clearly shown in countries such as
Malaysia, which have been rapidly passing through the epi-
demiological transition and in which health care is provided on
a mixed public-private basis. In Malaysia, hospitalization rates
have steadily increased since the 1970s, reflecting that use is
slowly outstripping population growth. The number of private
hospitals and institutions rose phenomenally—more than
300 percent—in the same period. In 1996, the second National
Health and Morbidity Survey in Malaysia showed that the
median charge per day in private hospitals was 100 times
higher than that in Ministry of Health hospitals. Those figures
reflect, at least in part, the acquisition of expensive medical
technology that in some cases has led to inefficient use of soci-
etal resources. As in many countries, the Malaysian government
has now established a Health Technology Assessment Unit to
provide a mechanism for evaluating the cost-effectiveness of
new technology.
Those brief examples of the effect of high-technology prac-
tice against completely different backgrounds of the provision
of health care reflect the emerging pattern of medical practice
in the 20th century. In particular, they emphasize how the rapid
developments in high-technology medical practice and the
huge costs that have accrued may have dwarfed expenditure on
preventive medicine, certainly in some industrial countries and
others that have gone through the epidemiological transition.
A central question for medical research and health care
planning is whether the reduction in exposure to risk factors
that is the current top priority for the control of common dis-
eases in both industrial and developing countries will have a
major effect on this continuing rise of high-technology hospi-
tal medical practice. The potential of this approach has been
discussed in detail recently (WHO 2002c). Although the claims
for the benefits of reducing either single or multiple risk factors
are impressive, no way exists of knowing to what extent they
are attainable. Furthermore, if, as seems likely, they will reduce
morbidity and mortality in middle life, what of later? The
WHO report admits that it has ignored the problem of com-
peting risks—that is, somebody saved from a stroke in 2001 is
then “available” to die from other diseases in ensuing years.
Solid information about the role of risk factors exists only for a
limited number of noncommunicable diseases; little is known
about musculoskeletal disease, the major psychoses, dementia,
and many other major causes of morbidity and mortality.
The problems of health care systems and improving per-
formance in health care delivery have been reviewed in World
Health Report 2000—Health Systems: Improving Performance
(WHO 2000). Relating different systems of health care to out-
comes is extremely complex, but this report emphasizes the
critical nature of research directed at health care delivery. As a
response to the spiraling costs of health care, many govern-
ments are introducing repeated reforms of their health care
programs without pilot studies or any other scientific indica-
tion for their likely success. This vital area of medical research
has tended to be neglected in many countries over the later
years of the 20th century.
Summary of Scientific Medicine in the 20th Century
The two major achievements of scientific medicine in the 20th
century—the development of clinical epidemiology and the
partial control of infectious disease—have made only a limited
contribution to the health of developing countries. Although in
part this limited effect is simply a reflection of poverty and dys-
functional health care systems, it is not the whole story. As
exemplified by the fact that of 1,233 new drugs that were mar-
keted between 1975 and 1999, only 13 were approved specifi-
cally for tropical diseases, the problem goes much deeper,
reflecting neglect by industrial countries of the specific medical
problems of developing countries.
For those countries that have gone through the epidemio-
logical transition and for industrial countries, the central prob-
lem is quite different. Although the application of public health
measures for the control of risk factors appears to have made a
major effect on the frequency of some major killers, those gains
have been balanced by an increase in the frequency of other
common chronic diseases and the problems of an increasingly
elderly population. At the same time, remarkable developments
in scientific medicine have allowed industrial countries to
develop an increasingly effective high-technology, patch-up
form of medical practice. None of these countries has worked
out a way to control the spiraling costs of health care, and
because of their increasing aged populations, little sign exists
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that things will improve. Although some of the diseases that
produce this enormous burden may be at least partially pre-
ventable by the more effective control of risk factors, to what
extent such control will be achievable is unclear, and for many
diseases these factors have not been identified. In short, scien-
tific medicine in the 20th century, for all its successes, has left a
major gap in the understanding of the pathogenesis of disease
between the action of environmental risk factors and the basic
disease processes that follow from exposure to them and that
produce the now well-defined deranged physiology that char-
acterizes them.
These problems are reflected, at least in some countries, by
increasing public disillusion with conventional medical prac-
tice that is rooted in the belief that if modern medicine could
control infectious diseases, then it would be equally effective
in managing the more chronic diseases that took their place.
When this improvement did not happen—and when a mood
of increasing frustration about what medicine could achieve
had developed—a natural move occurred toward trying to find
an alternative answer to these problems. Hence, many countries
have seen a major migration toward complementary medicine.
It is against this rather uncertain background that the role of
science and technology for medical care in the future has to be
examined.
SCIENCE, TECHNOLOGY, AND MEDICINE 
IN THE FUTURE 
Before considering the remarkable potential of recent develop-
ments in basic biological research for improvements in health
care, we must define priorities for their application.
Priorities for Biomedical Research in the Future
In the setting of priorities for biomedical research in the future,
the central objective is to restore the balance of research
between industrial and developing countries so that a far
greater proportion is directed at the needs of the latter. In the
1990s, it was estimated that even though 85 percent of the
global burden of disability and premature mortality occurs in
the developing world, less than 4 percent of global research
funding was devoted to communicable, maternal, perinatal,
and nutritional disorders that constitute the major burden of
disease in developing countries (WHO 2002b).
The second priority is to analyze in much more detail meth-
ods of delivery of those aspects of health care that have already
been shown to be both clinically effective and cost-effective.
It is vital that the delivery of health care be based on well-
designed, evidence-based pilot studies rather than on current
fashion or political guesswork. It is essential to understand why
there are such wide discrepancies in morbidity and mortality
between different socioeconomic groups in many industrial
countries and to define the most effective approaches to edu-
cating the public about the whole concept of risk and what is
meant by risk factors. In addition, a great deal more work is
required on mechanisms for assessing overall performance of
health care systems.
The third priority must be to focus research on the impor-
tant diseases that the biomedical sciences have yet to control,
including common communicable diseases such as malaria,
AIDS, and tuberculosis; cardiovascular disease; many forms of
cancer; all varieties of diabetes; musculoskeletal disease; the
major psychoses; and the dementias. Of equal importance is
gaining a better understanding of both the biology and patho-
physiology of aging, together with trying to define its social and
cultural aspects.
In the fields of child and maternal health, the requirements
for research differ widely in industrial and developing coun-
tries. Industrial countries need more research into the mecha-
nisms of congenital malformation and the better control and
treatment of monogenic disease and behavioral disorders of
childhood. In developing countries, both child and maternal
health pose different problems, mainly relating to health edu-
cation and the control of communicable disease and nutrition.
In many developing countries, some of the common mono-
genic diseases, notably the hemoglobin disorders, also require
urgent attention.
In short, our priorities for health care research come under
two main heads: first, apply knowledge that we already have
more effectively; second, apply a multidisciplinary attack on
diseases about which we have little or no understanding. These
issues are developed further in chapter 4.
New Technologies
The sections that follow briefly outline some examples of the
new technologies that should help achieve these aims.
Genomics, Proteomics, and Cell Biology. Without question
the fields of molecular and cell biology were the major devel-
opments in the biological sciences in the second half of the
20th century. The announcement of the partial completion of
the human genome project in 2001 was accompanied by claims
that knowledge gained from this field would revolutionize
medical practice over the next 20 years. After further reflection,
some doubts have been raised about this claim, not in the least
the time involved; nevertheless, considerable reason for opti-
mism still exists. Although the majority of common diseases
clearly do not result from the dysfunction of a single gene, most
diseases can ultimately be defined at the biochemical level;
because genes regulate an organism’s biochemical pathways,
their study must ultimately tell us a great deal about pathologi-
cal mechanisms.
126 | Disease Control Priorities in Developing Countries | David Weatherall, Brian Greenwood, Heng Leng Chee, and others
The genome project is not restricted to the human genome
but encompasses many infectious agents, animals that are
extremely valuable models of human disease, disease vectors,
and a wide variety of plants. However, obtaining a complete
nucleotide sequence is one thing; working out the regulation
and function of all the genes that it contains and how they
interact with each other at the level of cells and complete
organisms presents a much greater challenge. The human
genome, for example, will require the identification and deter-
mination of the function of the protein products of 25,000
genes (proteomics) and the mechanisms whereby genes are
maintained in active or inactive states during development
(methylomics). It will also involve the exploration of the roles of
the family of regulatory ribonucleic acid (RNA) molecules that
have been discovered recently (Mattick 2003). All this informa-
tion will have to be integrated by developments in information
technology and systems biology. These tasks may take the rest
of this century to carry out. In the process, however, valuable
fallout from this field is likely to occur for a wide variety of
medical applications. Many of these are outlined in a recent
WHO report, Genomics and World Health 2002 (WHO 2002a).
The first applications of DNA technology in clinical practice
were for isolating the genes for monogenic diseases. Either by
using the candidate gene approach or by using DNA markers
for linkage studies, researchers have defined the genes for many
monogenic diseases. This information is being used in clinical
practice for carrier detection, for prenatal diagnosis, and for
defining of the mechanisms of phenotypic variability. It has
been particularly successful in the case of the commonest
monogenic diseases, the inherited disorders of hemoglobin,
which affect hundreds of thousands of children in develop-
ing countries (Weatherall and Clegg 2001a, 2001b). Through
North-South collaborations, it has been possible to set up
screening and prenatal diagnosis programs for these conditions
in many countries, resulting in a marked decline in their fre-
quency, particularly in Mediterranean populations (figure 5.2).
Gene therapy, that is, the specific correction of monogenic dis-
eases, has been fraught with difficulties, but these are slowly
being overcome and this approach seems likely to be successful
for at least some genetic diseases in the future.
From the global perspective, one of the most exciting
prospects for the medical applications of DNA technology is in
the field of communicable disease. Remarkable progress has
been made in sequencing the genomes of bacteria, viruses, and
other infective agents, and it will not be long before the genome
sequence of most of the major infectious agents is available.
Information obtained in this way should provide opportunities
for the development of new forms of chemotherapy (Joët and
others 2003) and will be a major aid to vaccine development
(Letvin, Bloom, and Hoffman 2001). In the latter case, DNA
technology will be combined with studies of the basic immune
mechanisms involved in individual infections in an attempt to
find the most effective and economic approach. Recombinant
DNA technology was used years ago to produce pure antigens
of hepatitis B in other organisms for the development of safe
vaccines. More recently, and with knowledge obtained from the
various genome projects, interest has centered on the utility of
DNA itself as a vaccine antigen. This interest is based on the
chance observation that the direct injection of DNA into mam-
malian cells could induce them to manufacture—that is, to
express—the protein encoded by a particular gene that had
been injected. Early experiences have been disappointing, but
a variety of techniques are being developed to improve the
antigens of potential DNA-based vaccines.
The clinical applications of genomics for the control of
communicable disease are not restricted to infective agents.
Recently, the mosquito genome was sequenced, leading to the
notion that it may be possible to genetically engineer disease
vectors to make them unable to transmit particular organisms
(Land 2003). A great deal is also being learned about genetic
resistance to particular infections in human beings (Weatherall
and Clegg 2002), information that will become increasingly
important when potential vaccines go to trial in populations
with a high frequency of genetically resistant individuals.
The other extremely important application of DNA tech-
nology for the control of communicable disease—one of par-
ticular importance to developing countries—is its increasing
place in diagnostics. Rapid diagnostic methods are being devel-
oped that are based on the polymerase chain reaction (PCR)
technique to identify pathogen sequences in blood or tissues.
These approaches are being further refined for identifying
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Figure 5.2 Decline in Serious Forms of Thalassemia in Different
Populations after the Initiation of Prenatal Diagnosis in 1972
Following the Development of North-South Partnerships.
organisms that exhibit drug resistance and also for subtyping
many classes of bacteria and viruses. Although much remains
to be learned about the cost-effectiveness of these approaches
compared with more conventional diagnostic procedures,
some promising results have already been obtained, particu-
larly for identification of organisms that are difficult to grow or
in cases that require a very early diagnosis (Harris and Tanner
2000). This type of technology is being widely applied for
the identification of new organisms and is gaining a place
in monitoring vaccine trials (Felger and others 2003). The
remarkable speed with which a new corona virus and its differ-
ent subtypes were identified as the causative agent of SARS and
the way this information could be applied to tracing the puta-
tive origins of the infection are an example of the power of this
technology (Ruan and others 2003).
Genomics is likely to play an increasingly important role
in the control and management of cancer (Livingston and
Shivdasani 2001). It is now well established that malignant
transformation of cell populations usually results from
acquired mutations in two main classes of genes:
• First are oncogenes—genes that are involved in the major
regulatory processes whereby cells interact with one
another, respond to environmental signals, regulate how
and when they will divide, and control the other intricate
processes of cell biology (box 5.1).
• Second are tumor suppressor genes; loss of function by muta-
tion may lead to a neoplastic phenotype.
In the rare familial cancers, individuals are born with one
defective gene of this type, but in the vast majority of cases,
cancer seems to result from the acquisition during a person’s
lifetime of one or more mutations of oncogenes. For example,
in the case of the common colon cancers, perhaps up to six
different mutations are required to produce a metastasizing
tumor. The likelihood of the occurrence of these mutations
is increased by the action of environmental or endogenous
carcinogens.
Array technology, which examines the pattern of expression
of many different genes at the same time, is already providing
valuable prognostic data for cancers of the breast, blood, and
lymphatic system. This technology will become an integral part
of diagnostic pathology in the future, and genomic approaches
to the early diagnosis of cancer and to the identification of
high-risk individuals will become part of clinical practice. It is
also becoming possible to interfere with the function or
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Chronic Myeloid Leukemia: The Path from Basic Science to the Clinic
Box 5.1
1960 An abnormal chromosome, named the Philadelphia
chromosome, was found in the white cells of most patients
with chronic myeloid leukemia (CML).
1973 By the use of specific dyes to label chromosomes,
notably quinocrine fluorescence and Giemsa staining,
the Philadelphia chromosome was found to be the result
of a translocation between chromosomes 9 and 22:
t(9:22)(q34:q11).
1983 It was found that the translocation that causes the
Philadelphia chromosome juxtaposes the c-abl oncogene
from chromosome 9 with a breakpoint cluster (bcr) region
on chromosome 22, resulting in an abnormal bcr/abl
gene. The product of this gene,an abnormal tyrosine kinase,
has increased tyrosine kinase activity compared with the
product of the normal c-abl gene, a major fact in causing the
uncontrolled white cell proliferation characteristic of CML.
1996 A selective inhibitor of the abnormal tyrosine kinase
produced by the bcr/abl gene product was developed that
results in a high remission rate in patients with CML and
other tumors.
A major advance in the understanding of the mecha-
nisms of malignant transformation followed the discov-
ery that many forms of cancer result from the acquisition
of mutations in cellular oncogenes—that is, normal
housekeeping genes of cells that are involved in a variety
of regulatory functions. In some cases, we may be born
with a mutation of this kind, but the vast majority of
cancers seem to be attributable to acquired mutations
involving one or more oncogenes. The discovery of a
drug that was able to interfere specifically with the activ-
ity of the product of an abnormal oncogene was a major
advance in oncology, offering the hope that future
research will make it possible to tailor-make agents
directed at abnormal oncogene activity for the treatment
of cancer.
Source: Bartram and others 1983; Druker and others 1996; Klein and others 1982; Nowell
and Hungerford 1960; Rowley 1973.
products of oncogenes as a more direct approach to the treat-
ment of cancer (box 5.1), although early experience indicates
that drug resistance may be caused by mutation, as it is in more
conventional forms of cancer therapy.
The genomic approach to the study of common diseases of
middle life—coronary artery disease, hypertension, diabetes,
and the major psychoses, for example—has been widely publi-
cized (Collins and McKusick 2001). Except in rare cases, none
of them is caused by a defective single gene; rather, they appear
to be the result of multiple environmental factors combined
with variation in individual susceptibility attributable to the
action of several different genes. The hope is that if these sus-
ceptibility genes can be identified, an analysis of their products
will lead to a better understanding of the pathology of these
diseases and will offer the possibility of producing more defin-
itive therapeutic agents. Better still, this research could provide
the opportunity to focus public health measures for prevention
on genetically defined subsets of populations.
Pharmacogenomics is another potential development
from the genomics revolution (Bumol and Watanabe 2001)
(table 5.1). Considerable individual variability exists in the
metabolism of drugs; hence, clinical medicine could reach a
stage at which every person’s genetic profile for the metabolism
of common drugs will be worked out and become part of their
physicians’ toolkit. This information will also be of consider-
able value to the pharmaceutical industry for designing more
effective and safer therapeutic agents.
A word of caution is necessary: Although well-defined
genetic variation is responsible for unwanted side effects of
drugs, this information is still rarely used in clinical practice;
a possible exception is screening for glucose-6-phosphate
dehydrogenase (G6PD) deficiency for primaquine sensitivity,
though the costs preclude its application in many developing
countries. Furthermore, plasma levels after the administration
of most common drugs follow a normal distribution, indicat-
ing that if genetic variation exists, a number of different genes
must be involved. Hence, although the idea of all people having
their genetic profile for handling drugs as part of their standard
medical care will take a long time to achieve, if it ever happens,
no doubt exists that this field will gradually impinge on med-
ical research and clinical practice.
Many other potential applications of genomic research for
medical practice wait to be developed. The role of DNA array
technology for the analysis of gene expression in tumors has
already been mentioned. Advances in bioengineering, with the
development of biomicroelectromechanical systems, micro-
level pumping, and reaction circuit systems, will revolutionize
chip technology and enable routine analysis of thousands of
molecules simultaneously from a single sample (Griffith and
Grodzinsky 2001), with application in many other fields of
research. Although somatic cell gene therapy—that is, the
correction of genetic diseases by direct attack on the defective
gene—has gone through long periods of slow progress and
many setbacks, the signs are that it will be successful for at least
a limited number of monogenic diseases in the long term (Kaji
and Leiden 2001). It is also likely to play a role for shorter-term
objectives—in the management of coronary artery disease
and some forms of cancer, for example. DNA technology has
already revolutionized forensic medicine and will play an
increasingly important role in this field. Although it is too
early to assess to what extent the application of DNA technol-
ogy to the studies of the biology of aging will produce infor-
mation of clinical value, considering the massive problem of
our aging populations and the contribution of the aging
process to their illnesses, expanding work in this field is vital.
Current work in the field of evolution using DNA technology
seems a long way from clinical practice; however, it has con-
siderable possibilities for helping us understand the lack of
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Table 5.1 Pharmacogenomics
Gene Drug Clinical consequence
Drug metabolism
NAT-2 Isoniazid, hydralazine, Neuropathy, lupus 
procainamide, erythematosus
sulfonamides
CYP2D6 Beta-blockers, Arrhythmias, dyskinesia 
antidepressants, with antipsychotics, 
codeine, debrisoquine, narcotic effects, changes 
antipsychotics, many in efficacy, many others
others
CYP2C9 Tolbutamide, phenytoin, Anticoagulant effects of
nonsteroidal anti- warfarin modified
inflammatories
RYR-1 Halothane and other Malignant hyperthermia
anesthetics
Protection against oxidants
G6PD Primaquine, sulfonamides, Hemolytic anemia
acetanilide, others
Drug targets
ACE Captopril, enalapril Modified response to treat-
ment of cardiac failure,
hypertension, renal disease 
HERG Quinidine Cardiac arrhythmia (long
Q–T syndrome)
HKCNE2 Clarithromycin Drug-induced arrhythmia
Source: Modified from Evans and Relling (Science 286: 487 [2001], as quoted in WHO 2002a).
Note: Table shows examples of genetic polymorphisms that cause unwanted effects of drugs or
modification of response. Currently, arrays are being developed for the rapid identification of
families of polymorphisms related to infection-defense genotypes, drug-metabolism genotypes,
and many others. Although many polymorphisms associated with variations to drug response or
toxicity have been defined, the bulk of variation of response to drugs follows a multifactorial
pattern of inheritance.
The examples shown are as follows: NAT-2  N-acetyltransferase; CYP  cytochrome P450;
RYR-1  ryanidine receptor; G6PD  Glucose-6-phosphate dehydrogenase; and 
ACE  angiotensin-converting enzyme. HERG and HKCNE2 are potassium channels.
adaptation of present day communities to the new environ-
ments that they have created.
Stem Cell and Organ Therapy. Stem cell therapy, or, to use its
more popular if entirely inappropriate title, therapeutic
cloning, is an area of research in cellular biology that is raising
great expectations and bitter controversies. Transplant surgery
has its limitations, and the possibility of a ready supply of cells
to replace diseased tissues, even parts of the brain, is particu-
larly exciting. Stem cells can be obtained from early embryos,
from some adult and fetal tissues, and (at least theoretically)
from other adult cells.
Embryonic stem cells, which retain the greatest plasticity,
are present at an early stage of the developing embryo, from
about the fourth to seventh day after fertilization. Although
some progress has been made in persuading them to produce
specific cell types, much of the potential for this field so far has
come from similar studies of mouse embryonic stem cells. For
example, mouse stem cells have been transplanted into mice
with a similar condition to human Parkinson’s disease with
some therapeutic success, and they have also been used to try
to restore neural function after spinal cord injuries.
Many adult tissues retain stem cell populations. Bone mar-
row transplantation has been applied to the treatment of a wide
range of blood diseases, and human marrow clearly contains
stem cells capable of differentiating into the full complement of
cell types found in the blood. Preliminary evidence indicates
that they can also differentiate into other cell types if given the
appropriate environment; they may, for example, be a source of
heart muscle or blood vessel cell populations. Although stem
cells have also been found in brain, muscle, skin, and other
organs in the mouse, research into characterizing similar cell
populations from humans is still at a very early stage.
One of the major obstacles to stem cell therapy with cells
derived from embryos or adult sources is that, unless they come
from a compatible donor, they may be treated as “foreign” and
rejected by a patient’s immune system. Thus, much research is
directed at trying to transfer cell nuclei from adult sources into
an egg from which the nucleus has been removed, after which
the newly created “embryo” would be used as a source of
embryonic stem cells for regenerative therapy for the particular
donor of the adult cells. Because this technique, called somatic
cell nuclear transfer, follows similar lines to those that would be
required for human reproductive cloning, this field has raised a
number of controversies. Major ethical issues have also been
raised because, to learn more about the regulation of differen-
tiation of cells of this type, a great deal of work needs to be
carried out on human embryonic stem cells.
If some of the formidable technical problems of this field
can be overcome and, even more important, if society is able to
come to terms with the ethical issues involved, this field holds
considerable promise for correction of a number of different
intractable human diseases, particularly those involving the
nervous system (Institute of Medicine 2002).
Information Technology. The explosion in information tech-
nology has important implications for all forms of biomedical
research, clinical practice, and teaching. The admirable desire
on the part of publicly funded groups in the genomics field to
make their data available to the scientific community at large
is of enormous value for the medical application of genomic
research. This goal has been achieved by the trio of public
databases established in Europe, the United States, and Japan
(European Bioinformatics Institute, GenBank, and DNA Data
Bank of Japan, respectively). The entire data set is securely held
in triplicate on three continents. The continued development
and expansion of accessible databases will be of inestimable
value to scientists, in both industrial and developing countries.
Electronic publishing of high-quality journals and related
projects and the further development of telepathology will
help link scientists in industrial and developing countries. The
increasing availability of telemedicine education packages
will help disseminate good practices. Realizing even these few
examples of the huge potential of this field will require a major
drive to train and recruit young information technology scien-
tists, particularly in developing countries, and the financial
support to obtain the basic equipment required.
Minimally Invasive Diagnostics and Surgery: Changes in
Hospital Practice. Given the spiraling costs of hospital care in
industrial countries and the likelihood of similar problems for
developing countries in the future, reviewing aspects of diag-
nostics and treatment that may help reduce these costs in the
future is important. Changes in clinical practice in the latter
half of the 20th century have already made some headway on
this problem. In the U.K. NHS, the number of hospital beds
occupied daily halved between 1950 and 1990 even though the
throughput of the service, after allowance for change of defini-
tion, increased from 3 million to 10 million inpatients per
year. Remarkably, by 1996, of 11.3 million finished consultant
episodes, 22 percent were single-day cases. How can this
efficient trend be continued? A major development with this
potential is the application of minimally invasive and robotic
surgery (Mack 2001). Advances in imaging, endoscopic tech-
nology, and instrumentation have made it possible to convert
many surgical procedures from an open to an endoscopic
route. These procedures are now used routinely for gall bladder
surgery, treatment of adhesions, removal of fibroids, nephrec-
tomy, and many minor pediatric urological procedures. The
recent announcement of successful hip replacement surgery
using an endoscopic approach offers an outstanding example
of its future potential. Although progress has been slower, a
number of promising approaches exist for the use of these
techniques in cardiac surgery and for their augmentation by
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the introduction of robotics into surgical practice. Transplant
surgery will also become more efficient by advances in the
development of selective immune tolerance (Niklason and
Langer 2001).
These trends, and those in many other branches of medi-
cine, will be greatly augmented by advances in biomedical
imaging (Tempany and McNeil 2001). Major progress has
already been made in the development of noninvasive diagnos-
tic methods by the use of MRI, computer tomography, positron
imaging tomography, and improved ultrasonography. Image-
guided therapy and related noninvasive treatment methods are
also showing considerable promise.
Human Development and Child and Maternal Health.
Among the future developments in molecular and cell biology,
a better understanding of the mechanisms of human develop-
ment and the evolution of functions of the nervous system
offer some of the most exciting, if distant, prospects
(Goldenberg and Jobe 2001). In the long term, this field may
well have important implications for reproductive health and
birth outcomes. The role of a better understanding of the
monogenic causes of congenital malformation and mental
retardation was mentioned earlier in this chapter. Already
thoughts are turning to the possibility of the isolation and clin-
ical use of factors that promote plasticity of brain development,
and specific modulators of lung and gut development are pre-
dicted to start to play an increasing role in obstetric practice. A
better understanding of the mechanisms leading to vasocon-
striction and vascular damage as a cause of preeclampsia has
the potential for reducing its frequency and thus for allowing
better management of this common condition. Similarly, an
increasing appreciation of the different genetic and metabolic
pathways that are involved in spontaneous preterm births
should lead to effective prevention and treatment, targeting
specific components of these pathways and leading to reduc-
tion in the frequency of premature births. An increasing
knowledge of the mode of action of different growth factors
and promoters of gut function will enhance growth and devel-
opment of preterm infants.
Neuropsychiatry. Particularly because depression and related
psychiatric conditions are predicted to be a major cause of ill
health by 2020 and because of the increasing problem of
dementia in the elderly, neuropsychiatry will be of increas-
ing importance in the future (Cowan and Kandel 2001).
Developments in the basic biomedical sciences will play a major
role in the better diagnosis and management of these disorders.
Furthermore, the application of new technologies promises to
lead to increasing cooperation between neurology and psychia-
try, especially for the treatment of illnesses such as mental retar-
dation and cognitive disorders associated with Alzheimer’s and
Parkinson’s diseases that overlap the two disciplines.
The increasing application of functional imaging, together
with a better understanding of biochemical function in the
brain, is likely to lead to major advances in our understanding
of many neuropsychiatric disorders and, hence, provide op-
portunities for their better management. Early experience
with fetally derived dopaminergic neurons to treat parkinson-
ism has already proved to be successful in some patients and
has raised the possibility that genetically manipulated stem
cell treatment for this and other chronic neurological disor-
ders may become a reality. Promising methods are being
developed for limiting brain damage after stroke, and there is
increasing optimism in the field of neuronal repair based on
the identification of brain-derived neuronotrophic growth
factors. Similarly, a combination of molecular genetic and
immunological approaches is aiding progress toward an
understanding of common demyelinating diseases—notably
multiple sclerosis.
Strong evidence exists for a major genetic component to the
common psychotic illnesses—notably bipolar depression and
schizophrenia. Total genome searches should identify some of
the genes involved. Although progress has been slow, there are
reasonable expectations for success. If some of these genes can
be identified, they should provide targets for completely new
approaches to the management of these diseases by the phar-
maceutical industry. Recent successes in discovering the genes
involved in such critical functions as speech indicate the
extraordinary potential of this field. Similarly, lessons learned
from the identification of the several genes involved in familial
forms of early-onset Alzheimer’s disease have provided invalu-
able information about some of the pathophysiological mech-
anisms involved, work that is having a major effect on studies
directed at the pathophysiology and management of the much
commoner forms of the disease that occur with increasing
frequency in aged populations.
Nutrition and Genetically Modified Crops. By 2030, the
world’s population is likely to increase by approximately 2.5 bil-
lion people, with much of this projected growth occurring in
developing countries. As a consequence, food requirements
are expected to double by 2025. However, the annual rate of
increase in cereal production has declined; the present yield is
well below the rate of population increase. About 40 percent of
potential productivity in parts of Africa and Asia and about
20 percent in the industrial world are estimated to be lost to
pathogens.
Given these considerations, the genetic modification (GM)
of plants has considerable potential for improving the world’s
food supplies and, hence, the health of its communities. The
main aims of GM plant technologies are to enhance the
nutritional value of crop species and to confer resistance to
pathogens. GM technology has already recorded several suc-
cesses in both these objectives.
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Controversy surrounds the relative effectiveness of GM
crops as compared with those produced by conventional
means, particularly with respect to economic issues of farming
in the developing world. Concerns are also expressed about the
safety of GM crops, and a great deal more research is required
in this field. The results of biosafety trials in Europe raise some
issues about the effects of GM on biodiversity (Giles 2003).
Plant genetics also has more direct potential for the control
of disease in humans. By genetically modifying plants,
researchers hope it will be possible to produce molecules toxic
to disease-carrying insects and to produce edible vaccines that
are cheaper than conventional vaccines and that can be grown
or freeze dried and shipped anywhere in the world. A promis-
ing example is the production of hepatitis B surface antigen
in transgenic plants for oral immunization. Work is also well
advanced for the production of other vaccines by this approach
(WHO 2002a).
Social and Behavioral Sciences, Health Systems, and Health
Economics. As well as the mainstream biomedical sciences,
research into providing health care for the future will require
a major input from the social and behavioral sciences and
health economics. These issues are discussed in more detail in
chapter 4.
The World Health Report 2002 (WHO 2002c) emphasizes
the major gaps in public perception of what is meant by health
and, in particular, risk factors, in both industrial and develop-
ing countries. Epidemiological studies have indicated that
morbidity and mortality may be delayed among populations
that are socially integrated. Increasing evidence of this kind
underlines the importance of psychosocial factors in the devel-
opment of a more positive approach to human health, clearly a
valuable new direction for research on the part of the social
sciences.
Neither developing nor industrial countries have come to
grips with the problems of the organization and delivery of
health care. Learning more about how to build effective health
delivery strategies for developing countries is vital. Similarly,
the continuous reorganization of the U.K. NHS, based on
short-term political motivation and rarely on carefully
designed pilot studies, is a good example of the requirement for
research into the optimal approaches to the provision of health
care in industrial countries. Indeed, across the entire field of
health provision and the education of health care professionals,
an urgent requirement exists for research into both methodol-
ogy and, in particular, development of more robust endpoints
for its assessment.
Similar problems exist with respect to research in health
economics. Many of the parameters for assessing the burden of
disease and the cost-effectiveness of different parameters for
the provision of health care are still extremely crude and con-
troversial, and they require a great deal more research and
development. These problems are particularly relevant to the
health problems of the developing countries.
One of the main barriers to progress in these fields is the rel-
ative isolation of the social sciences and health care economics
from the mainstreams of medical research and practice. Better
integration of these fields will be a major challenge for univer-
sities and national and international health care agencies.
Integration of the Medical Sciences: Organizational
Priorities for the Future
From these brief examples of the likely direction of biomedical
research in the future, some tentative conclusions can be drawn
about its effects on the pattern of global health care.
The control of communicable disease will remain the top
priority. Although this goal can be achieved in part by improv-
ing nutrition and sanitation and applying related public health
measures in developing countries, the search for vaccines
or better chemotherapeutic agents must also remain a high
priority. However, although optimism that new vaccines will
become available is well founded, many uncertainties still exist,
particularly in the case of biologically complex diseases like
malaria. It is vital that a balance be struck between the basic
biomedical science approach and the continued application of
methods to control these diseases by more conventional and
well-tried methods.
For the bulk of common noncommunicable diseases, the
situation is even less clear. Although much more humane, cost-
effective, and clinically effective approaches to their manage-
ment seem certain to be developed, mainly by high-technology
and expensive procedures, the position regarding prevention
and a definitive cure is much less certain. Hence, the program
for reducing risk factors, as outlined in the World Health Report
2002 (WHO 2002c), clearly should be followed. However, a
strong case exists for a partnership of the public health, epi-
demiological, and genomic sciences to develop pilot studies to
define whether focusing these programs on high-risk subsets of
populations will be both cost-effective and more efficient. For
those many chronic diseases for which no risk factors have been
defined, strategies of the same type should be established to
define potential environmental factors that may be involved.
Although surprises may arise along the way, such as the discov-
ery of the infective basis for peptic ulceration, the multilayered
environmental and genetic complexity of these diseases, com-
bined with the ill-understood effects of aging, suggests that no
quick or easy answers to these problems will present them-
selves; future planning for global health services must take this
factor into consideration.
Given these uncertainties, an important place exists for the
involvement and integration of the social sciences and health
economics into future planning for biomedical research.
Major gaps in knowledge about public perceptions and
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understanding of risk factors, a lack of information about the
social and medical problems of aging populations, and wide-
spread uncertainty about the most cost-effective and efficient
ways of administering health care—both in developing coun-
tries and in those that have gone through the epidemiological
transition and already have advanced health care systems—still
exist.
In short, the emerging picture shows reasonable grounds for
optimism that better and more definitive ways of preventing or
curing communicable diseases will gradually become available;
only the time frame is uncertain. Although there will be major
improvements in management based on extensive and increas-
ingly high-technology practice, the outlook for the prevention
and definitive cure of the bulk of noncommunicable diseases
is much less certain. Hence, it is vital that research in the basic
biomedical sciences be directed at both the cause and the
prevention of noncommunicable diseases, and that work in
the fields of public health and epidemiology continues to be
directed toward better use of what is known already about their
prevention and management in a more cost-effective and
efficient manner.
New Technologies and Developing Countries
The role of genomics and related high-technology research and
practice in developing countries is discussed in detail in
Genomics and World Health 2002 (WHO 2002a). The central
question addressed by the report was, given the current eco-
nomic, social, and health care problems of developing coun-
tries, is it too early to be applying the rather limited clinical
applications of genomic and related technology to their health
care programs? The report concluded that it is not too early,
and subsequent discussion has suggested that this decision
was right. Where DNA technology has already proven cost-
effective, it should be introduced as soon as possible
(Weatherall 2003). Important examples include the common
inherited disorders of hemoglobin (see chapter 34) and, in par-
ticular, the use of DNA diagnostics for communicable disease.
The advantage of this approach is that it offers a technical base
on which further applications can be built as they become
available. It also provides the impetus to develop the training
required, to initiate discussions on the many ethical issues that
work of this type may involve, and to establish the appropriate
regulatory bodies. The way this type of program should be
organized—through North-South collaboration, local net-
working, and related structures, monitored by WHO—was
clearly defined in the report.
For the full benefits of genomics to be made available to
developing countries—and for these advances not to widen
the gap in health care provision between North and South—
the most pressing and potentially exciting developments
from the new technologies of science and medicine will have to
be exploited by current scientific research in the industrial
countries.
This need is particularly pressing in the case of the major
communicable killers: malaria, tuberculosis, and AIDS.
Similarly—and equally important—if developing countries are
to make the best use of this new technology for their own
particular disease problems, partnerships will have to be
established between both academia and the pharmaceutical
industries of the North and South.
Although this approach should be followed as a matter of
urgency, that developing countries build up their own research
capacity is equally important. Genomics and World Health 2002
(WHO 2002a) includes some encouraging accounts of how
this capacity is being achieved in Brazil, China, and India. The
establishment of the Asian-Pacific International Molecular
Biology Network is a good example.
It is important that work start now to apply the advances
stemming from the basic biological sciences for the health of
the developing world. This beginning will form a platform for
the integration of future advances into health care programs
for these countries. However, because of uncertainties of the
time involved, more conventional public health approaches to
medical care must not be neglected, and a balance should be
struck between research in this area and research in the emerg-
ing biomedical sciences.
Economic Issues for Future Medical Research
The central economic issues regarding medical research in the
future are how it is to be financed and how its benefits are to be
used in the most cost-effective way in both industrial and devel-
oping countries. Currently, research is carried out in both
private and public sectors (table 5.2). Work in the private sector
is based mainly in the pharmaceutical industry and, increas-
ingly, in the many large biotechnology companies that evolved
rapidly following the genomic revolution. In the public sector,
the major sites of research are universities, government research
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Table 5.2 Estimated Global Health Research and
Development Funding for 1998 
Type of funding Total (US$ billions) Percentage
Public funding: high-income and 34.5 47
transition countries
Private funding: pharmaceutical 30.5 42
industry
Private not-for-profit funding 6.0 8
Public funding: low- and middle- 2.5 3
income countries
Total 73.5 100
Source: WHO 2002b.
institutes, and centers—either within the universities or
freestanding—that are funded through a variety of philan-
thropic sources. The input of philanthropic sources varies
greatly between countries. In the United Kingdom, the
Wellcome Trust provides a portion of funding for clinical and
basic biomedical research that approaches that of the govern-
ment, and in the United States, the Howard Hughes organiza-
tion also plays a major, though proportionally less important,
role in supporting medical research. Similarly, the Bill &
Melinda Gates Foundation and other large international philan-
thropic foundations are contributing a significant amount of
funding for medical research. In developing countries, such
research funding as is available comes from government sources.
For example, Thailand and Malaysia spend US$15.7 million and
US$6.9 million each year, representing 0.9 percent and 0.6 per-
cent of their health budgets, respectively (WHO 2002b).
As examined in the report of the WHO Commission on
Macroeconomics and Health (WHO 2001), considerable dis-
cussion is taking place about how to mobilize skills and
resources of the industrial countries for the benefit of the
health of the developing world. However, how this interna-
tional effort should be organized or, even more important,
funded is still far from clear. A number of models have been
proposed, including the creation of a new global institute for
health research and a global fund for health research with an
independent, streamlined secretariat analogous to the Global
Fund to Fight AIDS, Tuberculosis, and Malaria. Recently, a
number of large donations have been given—either by govern-
ments or by philanthropic bodies—to tackle some of the major
health problems of the developing world. Although many of
these approaches are admirable, those that involve single dona-
tions raise the critical problem of sustainability. People with
experience in developing interactions between the North and
South will have no doubts about the long period of sustained
work that is often required for a successful outcome.
Because of the uncertainties about sustainability and the
efficiency of large international bodies, it has been suggested
that a virtual global network for health research be established
in which the leading research agencies of the North and South
take part, together with a coordinating council (Keusch and
Medlin 2003). In this scheme or in a modified form (Pang
2003), both government funding agencies and philanthropic
bodies would retain their autonomy and mechanisms of fund-
ing while at the same time their individual programs would be
better integrated and directed toward the problems of global
health.
A central problem of both private and public patterns of
funding for medical research is that industrial countries have
tended to focus their research on their own diseases and have,
with a few exceptions, tended to ignore the broader problems
of developing countries, a trend that has resulted in the well-
known 10/90 gap in which more than 90 percent of the world’s
expenditure on health research is directed at diseases that,
numerically, affect a relatively small proportion of the world’s
population. If the enormous potential of modern biomedical
research is not to result in a widening of the gap in health care
between North and South, this situation must be corrected.
The governments of industrial countries may be able to
encourage a more global view of research activity on the part of
their pharmaceutical and biotechnology industries by various
tax advantages and other mutually beneficial approaches.
Progress in this direction seems likely to be slow, however. For
this reason, moving quickly toward a virtual global network for
research that would bring together the research agencies of the
North and South holds many attractions. Although those of the
North that rely on government and charitable funding may
find it equally difficult to convince their governments that
more of their budget should be spent on work in the develop-
ing world, they vitally need to move in this direction, possibly
by turning at least some proportion of their overseas aid to
this highly effective approach to developing North-South
partnerships.
In short, to produce the funding required for medical
research in the future and to ensure that it takes on a much
more global view of its objectives, a complete change in atti-
tude is called for on the part of the industrial countries. This
transformation, in turn, will require a similar change of out-
look on the part of those who educate doctors and medical
scientists. The introduction of considerable sums of research
monies into the international scene by governments or philan-
thropic bodies as single, large donations, while welcome, will
not form the basis for the kind of sustainable research program
that is required. Rather, the attitudes of both government
funding agencies and charitable bodies in industrial countries
will have to change, with a greater proportion of their funding
being directed at diseases of the developing world in the future.
Achieving this end will require a major program of education
on the global problems of disease at every level, including
governments, industry, universities, charitable organizations,
and every other body that is involved in the medical research
endeavor.
Issues requiring the assessment of the economic value of
medical research are discussed in chapter 4.
Education
The central theme of the previous sections is that the potential
fruits of the exciting developments in the biomedical sciences
will be achieved only if a complete change in attitude occurs on
the part of industrial countries, with the evolution of a much
more global attitude to the problems of medical research and
health care. Change will have to start in the universities of the
industrial countries, which will need to incorporate a more
global perspective in medical education so that the next gener-
ation of young people is more motivated to develop research
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careers that take a more international view of the problems of
medical research. A major change of emphasis in education will
be required and will be difficult to achieve unless those who
control the university education and research programs can be
convinced that funding is available for further development in
these new directions (Weatherall 2003). Excellent examples of
the value of the development of North-South partnerships
between universities and other academic institutions do
already exist.
An effective approach to increasing global funding for inter-
nationally based research is through virtual global networks
involving the leading research agencies in the North and South.
Hence, a similar effort will be required to educate these agen-
cies and their governments that this approach to improving
the level of health globally is cost-effective. In particular, it will
be vital to persuade them that this approach may constitute an
effective use of their programs of aid for developing countries.
Carrying out a number of pilot studies showing the economic
value of North-South partnerships in specific areas of medical
research may be necessary. Indeed, a number of these partner-
ships have already been formed in several countries and infor-
mation of this type almost certainly exists (WHO 2002a).
Of course, much broader issues involving education need to
be resolved for the better exploitation of medical research. The
problems of educating the public so that developing countries
can partake in the advancements of the genome revolution
were set out in detail in Genomics and World Health 2002
(WHO 2002a), but a great deal of work along these lines is also
required for industrial countries. People are increasingly suspi-
cious of modern biological science and of modern high-
technology medicine, a factor that, together with concerns over
the pastoral skills of today’s doctors, is probably playing a role
in driving many communities in industrial countries toward
complementary medicine (see Horton 2003). These trends
undoubtedly are attributable to inadequacies of medical edu-
cation and the way that science is taught in schools—reflected
by the lack of scientific literacy both in the general public and
in governments. If trust is to be restored between the biomed-
ical sciences and the public, significant efforts will have to be
made to improve the level of scientific literacy, and a much
more open dialogue will need to be developed between scien-
tists and the community. This requirement will be increasingly
important as work on basic biomedical sciences impinges on
areas such as gene therapy, stem cell research, and the collection
of large DNA databases to be used for both research and ther-
apeutic purposes in the future.
The difficulties in achieving a more global view of medical
research and health care on the part of industrial countries for
the future should not be underestimated. Without a major
attempt to solve these difficulties, the potential of modern
biomedical sciences seems certain to simply widen the gap in
health care between North and South.
Ethical Issues
Few advances in scientific medicine have not raised new ethical
issues for society. The genomics era has encountered many
problems in this respect, and although many of the initial fears
and concerns have been put to rest by sensible debate and the
development of effective control bodies, new problems con-
tinue to appear (WHO 2002a). The ill-named field of thera-
peutic cloning is still full of unresolved issues regarding human
embryo research, the creation of embryos for research pur-
poses, and other uncertainties, but these questions should not
be overemphasized at a time when most societies face even
more onerous ethical issues. For example, as the size of our
aging population increases, many societies may have to face the
extremely difficult problem of rationing medical care. The
theme recurring throughout both industrial and developing
countries is how to provide an adequate level of health care
equally to every income group.
Many developing countries still lack the basic structure for
the application of ethical practices in research and clinical care,
including the development of institutional ethics committees,
governmental regulatory bodies, and independent bioethical
research bodies. Every country requires a completely inde-
pendent bioethics council that can debate the issues uninhib-
ited by pressures from government, commerce, or pressure
groups of any kind. Our approaches to developing a more ade-
quate ethical framework for much of medical decision making,
whether it involves preventive medicine, clinical practice, or
research, constitute another neglected area that requires
research input from many different disciplines.
The important question of the ethical conduct of research
in the developing countries by outside agencies has been
reviewed in detail recently (Nuffield Council on Bioethics
2002).
Why Do We Need Research?
It is important to appreciate that considerable public suspicion
exists about both the activities and the value of biomedical
research. Suspicion has been generated in part by the field’s
exaggerated claims over recent years, an uneasy feeling that
research is venturing into areas that would best be avoided, and
a lack of understanding about the complexity of many of the
problems that it is attempting to solve. At the same time, many
government departments that run national health care pro-
grams, the private sector (with the exception of the pharma-
ceutical industry), and many nongovernmental organizations
set aside extremely small fractions of their overall expenditure
for research. For many of those organizations, research seems
irrelevant as they deal with the stresses of daily provision of
programs of health care and with crisis-management scenarios
that have to follow rapid change or major failures in providing
health care.
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One of the major challenges for the biomedical research
community will be to better educate the public about its activ-
ities and to restore their faith in and support for the medical
research endeavor. Educating many governments and non-
governmental organizations about the critical importance of
decision making based on scientifically derived evidence will be
vital. Medical care will only get more complex and expensive in
the future; its problems will not be solved by short-term, polit-
ically driven activity. The need for good science, ranging from
studies of molecules to communities, has never been greater.
SUMMARY
Clearly, the most important priorities for medical research are
development of more effective health delivery strategies for
developing countries and control of the common and
intractable communicable diseases. In this context, the argu-
ment has been that much of the medical research that has been
carried out in industrial countries, with its focus on noncom-
municable disease and its outcomes in high-technology prac-
tice, is completely irrelevant to the needs of developing
countries. This view of the medical scene, however, is short
term. Although some redistribution of effort is required, every
country that passes through the epidemiological transition is
now encountering the major killers of industrial countries.
Learning more about those killers’ basic causes, prevention,
and management is crucial. Although the initial costs of pro-
viding the benefits of this research are often extremely high,
they tend to fall as particular forms of treatment become more
widely applied. Hence, because we cannot completely rely on
our current preventive measures to control these diseases, med-
ical research must continue.
Research in basic human biology and the biomedical sci-
ences is entering the most exciting phase of its development.
However, it is difficult to anticipate when the gains of this
explosion in scientific knowledge will become available for
the prevention and treatment of the major killers of mankind.
Thus, medical research must strike a balance between the well-
tried approaches of epidemiology, public health, and clinical
investigation at the bedside with the application of discoveries
in the completely new fields of science that have arisen from the
genome revolution.
If this balanced approach toward the future provision of
health care is not to continue to worsen the gap between North
and South, however, a complete change of attitude is necessary
toward health care research and practice on the part of the
industrial countries. A major effort will be required to educate
all parties—international nongovernmental organizations,
governments, universities, and the private sector—in global
health problems (Weatherall 2003). Equally important will be a
major change of emphasis in the universities of industrial
countries toward education programs in science and medicine
to provide medical scientists of the future with a more global
perspective of health and disease. If this transformation can be
achieved—if it can form the basis for the establishment of net-
works for sustainable research programs between universities
and related bodies in the North and South—much progress
will be made toward distributing the benefits of biomedical
research and good practice among the populations of the
world. However, the great potential of advances in the biomed-
ical sciences for global health will not come to full fruition
without much closer interaction between the fields of basic and
clinical research and the fields of public health, health econom-
ics, and the social sciences.
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The overall goal of this chapter is to introduce the multistep
process that leads to new product development and use and to
outline the economic and institutional context for products
developed specifically for major global diseases. In addition, it
attempts to define the major financial efforts under way to help
stimulate the process. Because product development is inte-
grally related to intellectual property issues and to regulatory
and liability concerns, these topics are also included. Data on
product development for the developing countries are not
systematically available. We have, therefore, used information
based on analyses for developed countries and, when possible,
made comparisons.
INTRODUCTION
In recent decades, scientific advances in many disciplines,
particularly molecular biology, genomics, and medicinal
chemistry, opened the way for developing new therapeutic
agents, several vaccines, and enhanced diagnostic capabilities.
The central questions for the purpose of this chapter are what
drives research, discovery, and development and what institu-
tional and financing arrangements are necessary to promote
research and development (R&D) for global diseases? Medical
needs and public health imperatives constitute the logical
answer to the first question; however, our armamentarium for
combating major global diseases suffers from certain funda-
mental gaps. Innovation or discovery in the health fields is the
process whereby the findings of many sciences are translated
from basic findings into approaches to protect health (vac-
cines) or reverse disease (therapeutic and diagnostic products).
Even though investigators have explored the conceptual
framework for understanding how knowledge may be trans-
lated into products over the years, consensus is lacking on the
specific drivers of the process or on the effects of alternative
institutional arrangements.
Several features of the innovation process and its environ-
ment are essential for product development (Hilleman 2000;
Nederbragt 2000; Schmid and Smith 2002). Innovation
advances through a sequence of steps from discovery, through
process development, to animal and human testing—a se-
quence with many overlapping features. Discovery may come in
two ways: in a nonlinear, quantum-leap fashion that results in
findings of an unexpected or unpredictable nature or in a linear
fashion that builds on existing knowledge. Nonlinear processes
are characteristically random despite many efforts to inject
varying degrees of predictability or goal definitions (Webber
and Kremer 2001). By contrast, the goal of linear innovation is
defined improvement of a known process or mechanism.
Discovery
Product development is fundamentally anchored to the discov-
ery process. In modern societies, discovery represents a societal
capability that involves multiple institutions and constituents.
The concept of networks of innovation has been introduced
to describe one of the processes of discovery that leads to
the development of pharmaceutical products or vaccines
(Galambos and Sewell 1995, 272). Original scientific observa-
tions are made in organizations widely distributed across soci-
ety, such as academic environments, government laboratories,
biotechnology companies, or the large organizations dedicated
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to R&D. Because of the multiplicity of these settings and the
traditions of open scientific communications, combined with
the high costs of research and the importance of incentives,
intellectual property issues must be taken into account.
The outcome is appreciably complex. Therefore, prescribing
in a systematic way how to develop products along a planned
pathway—particularly those intended for use in developing
countries—is challenging. Recent decades have witnessed many
attempts to develop specific drugs or vaccines to meet develop-
ing countries’needs,and the process has been difficult.Examples
include pharmaceuticals to treat major global killers such as
malaria and African trypanosomiasis and vaccines for most of
the diarrheal diseases and respiratory infections (Nossal 2000).
Development Cycles
Discovery may set in motion a series of steps that eventually
leads to the deployment of a product suitable for human use.
The next step following discovery is process definition to map
the steps of manufacturing and scalability to optimize the size of
manufacturing. This process involves translating an idea discov-
ered anywhere in the multiplicity of settings defined earlier,
including mobilizing the energies of many sciences, to come up
with a product. For instance, for a discovery in the therapeutic
field to be translated into a drug, the sciences of medicinal
chemistry, structural biology, and structure-function relation-
ships are fundamental to the process. More recently, the product
development process has begun using genomics and proteomics
to bring about a more focused approach to defining clinical can-
didate products. Only then are pharmacology, toxicology, and
bioavailability used in the next phase of therapeutic evaluation.
The capabilities for process definition and scalability have
traditionally been concentrated in the research-based pharma-
ceutical industry, but several recent successful efforts in public-
private partnerships (PPPs) have expanded these capabilities,
such as the Medicines for Malaria Venture (MMV) and Global
Alliance for TB Drug Development (GATB). Developing coun-
tries such as Brazil, India, and the Republic of Korea are now
undertaking major efforts to achieve similar capabilities
(Biehl 2002; Lohray 2003).
Therapeutic evaluation may begin at an in vitro or molecu-
lar level before proceeding to animal testing and the usual three
phases of human assessment (Hilts 2003). The scientific disci-
plines of clinical research, epidemiology, and biostatistics have
progressed at a significant pace in recent decades. In parallel,
ethical and societal concerns about research involving human
subjects and its standards, particularly across countries, cul-
tures, and capabilities, are being extensively debated (Agre and
Rapkin 2003; Barrett and Parker 2003; Emanuel and others
2004; McMillan and Conlon 2004).
The engineering aspects of product development are the
next major step. Optimizing manufacturability and assessing
market needs to determine the level of investment required for
plant construction and operation are the two fundamental
components of this phase.
One important feature of discovery and development is the
length of time it takes. Estimates indicate that the average time
for a new chemical entity (NCE) or vaccine to proceed from dis-
covery through preclinical testing,human clinical trials,and reg-
ulatory approval is longer than a decade (Garber, Silvestri, and
Feinberg 2004; Hilleman 1996; Rappuoli, Miller, and Falkow
2002), including the time spent on unsuccessful attempts. This
timeline imposes certain pressures on how decisions are made,
on the investment needed, and on competing priorities.
Development Institutions
As indicated previously, innovation and discovery occur in a
multiplicity of settings. Although these settings have been con-
centrated in developed counties and have served the process of
product development well, the challenges of developing new
products for the developing world are considerable. Many coun-
tries, such as Brazil, India, and Singapore, are initiating a new
wave of fundamental research institutions (Ahmad 2001;
Jayaramann 2003). Their involvement in the discovery of prod-
ucts necessary for the health needs of developing countries is a
fundamental paradigm shift. Along with the developing world’s
emerging biotechnology industry, a movement toward product
discovery and development is under way. In addition, multiple
PPPs—for example, the MMV (2002) and the GATB (2001)—
are adding to the total global effort (Lyles 2003; Widdus 2001).
The major feature of these new settings is their ability to focus
on the immediate needs of developing countries. The challenge,
however, lies in sustaining their funding and ensuring their abil-
ity to proceed from discovery to development and manufactur-
ing, possibly with appropriate partners.
Finally, the evaluation of a product’s pharmacological, bio-
logical, and toxicological properties may be carried out in
developed or developing countries. Indeed, the evaluation of
the safety and efficacy of products intended for developing
countries should occur in those settings. Although quality
control standards should be applied globally (Milstien and
Belgharbi 2004), specific efforts must be directed at protecting
the rights of human subjects (Agre and Rapkin 2003; Barrett
and Parker 2003; Emanuel and others 2004; McMillan and
Conlon 2004). In general, clinical development is heavily regu-
lated in developed countries, and additional mechanisms exist
for monitoring other aspects of product development, such as
animal experimentation, use of controlled substances, and so
on, but the global situation varies considerably. The time is ripe
to consider the development of a global coordinated effort that
involves uniform standards and reciprocity.
The analysis in the following sections focuses on the costs of
developing drugs, vaccines, and diagnostics. The emphasis on
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drugs and vaccines reflects both the available evidence and the
fact that regulatory requirements and costs are much greater
for drugs and vaccines than for devices and diagnostics.
PHARMACEUTICAL PRODUCTS
The costs of developing new medicines and diagnostics reflect
both the technical complexities of product development and
costs related to regulatory approval, which requires clinical tri-
als to establish product safety and efficacy. Although the rela-
tive contributions of these two components are difficult to
distinguish empirically—and even conceptually—there is gen-
eral consensus that increasing regulatory requirements have
contributed to the rising costs of new product development
in the United States. In considering the costs of new product
development for diseases prevalent in low-income countries
(LICs), we attempt to identify those costs that might be influ-
enced by regulatory policy as opposed to the unavoidable costs
resulting from the hard science of new product development.
R&D Costs for Drugs for Industrial Countries
The most detailed evidence on the cost of developing new drugs
is from DiMasi, Hansen, and Grabowski (2003), who estimate
the cost of bringing a compound to market at US$802 million
in 2000 dollars. Their estimate is based on U.S. data from
10 major companies for a randomly selected sample of 68 com-
pounds that entered human testing between 1983 and 1994 and
reached approval between 1990 and 2001. The 68 compounds
include 61 small molecule chemical entities, 4 recombinant
proteins, 2 monoclonal antibodies, and 1 vaccine. Together, the
10 companies accounted for 42 percent of R&D by U.S. compa-
nies. The cost estimates are based on project-level data obtained
from the companies for the period 1980–99. The sample was
restricted to compounds that originated within these compa-
nies to avoid omitted costs of in-licensed products.
Earlier studies using similar data and methods found signif-
icantly lower R&D costs for drugs launched in the 1970s and
1980s (DiMasi and others 1991; Hansen, 1979). For the 1980s
drug cohort, the estimate was US$359 million per NCE (U.S.
Congress, Office of Technology Assessment 1993). Thus, the
estimate for the 1990s drug cohort of US$802 million repre-
sents a significant increase over and above inflation.
Three main factors contribute to this high and rising cost of
R&D. Understanding the contribution of each of these factors
is important to understanding whether drug R&D costs might
be lower in developing countries.
First, the inputs into pharmaceutical R&D are costly, includ-
ing highly trained scientists, highly specialized capital equip-
ment, expensive animal studies, and clinical trials involving
thousands of human subjects that are often coordinated across
multiple countries. Clinical trial out-of-pocket costs reflect
expenditures on patients’ medical treatment and monitoring,
data collection, and analysis. In the study by DiMasi, Hansen,
and Grobowski (2003), the average expected clinical cost,
adjusted for the probability of entering each clinical phase, was
US$60.6 million per compound entering human trials. In addi-
tion, the authors estimated that the out-of-pocket costs of drug
discovery and preclinical development account for 30 percent
of overall R&D costs, raising the total expected out-of-pocket
cost to US$86.8 million per compound entering clinical trials.
The average number of clinical trial patients per compound was
5,303, and the average cost per patient was US$23,500 before
adjusting for the probability of entering each clinical phase.
Second, in the United States, the Food and Drug
Administration (FDA) approves only roughly one in five com-
pounds that enter human clinical trials.1 The costs incurred for
the four out of five compounds that failed must be included as
costs of bringing one new compound to market. Failures occur
because of safety concerns, lack of significant efficacy, and poor
economic prospects. Even though the new technologies of drug
discovery should eventually improve predictive accuracy for
both safety and efficacy, success rates were no better in the 1990s
than in the 1980s (DiMasi,Hansen,and Grabowski 2003;DiMasi
and others 1991). Adjusting for failure rates raises the total out-
of-pocket cost from US$86.8 million to US$403 million per
approved compound.
Third, the US$802 million total cost estimate includes the
opportunity cost of capital over the roughly 12-year investment
period. Using an 11 percent real (net of inflation) cost of capi-
tal, DiMasi, Hansen, and Grabowski (2003) estimate the total
cost of capital at US$399 million. This figure represents the
return that shareholders would have received had they invested
in activities that yielded immediate returns rather than in the
lengthy drug discovery process. If pharmaceutical R&D is
financed by—and hence must compete for—private equity
capital, shareholders must be compensated for this opportu-
nity cost. Thus, the cost of capital is appropriately included as
a cost of R&D if the R&D is undertaken in commercial firms
and financed by equity capital. As discussed later, if not-for-
profit organizations finance R&D, the opportunity cost of
capital may be lower. If we assume financing by private equity,
adding the US$399 million cost of capital to the US$403 mil-
lion out-of-pocket cost yields US$802 million as the capitalized
cost at launch, before taxes, per approved compound. The
after-tax estimate is considerably lower because, like any busi-
ness expense, R&D expenses are tax deductible, plus R&D tax
credits may be available in certain circumstances. However, for
purposes of comparing the costs of R&D to the revenues a
commercial firm would require to cover these costs, if costs are
measured net of tax, then revenues must also be measured net
of tax, in which case adjusting for tax makes little difference.
Hereafter we use the before-tax R&D cost estimates to facilitate
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comparison with other estimates of R&D costs. The before-tax
estimates are also most relevant to not-for-profit firms and
PPPs that are not subject to taxes.
If commercial firms facing a commercial cost of capital and
with no in-kind contributions (see the next section) undertake
R&D, they might be able to save roughly 10 to 20 percent of
their costs by conducting trials in developing countries and
possibly more if they adhere to the countries’ regulatory
requirements, which may permit fewer and shorter trials than
are normal for the FDA. Whether firms could realize those
potential savings may be a matter of judgment depending on
perceived liability risks. If commercial firms conduct R&D for
LIC diseases in not-for-profit spinoffs, they may realize tax
advantages and a lower cost of capital, which would further
reduce their cost below the US$802 million estimate.
R&D Costs for Drugs for Developing Countries
Recent studies by two PPPs that focus on new product devel-
opment for diseases in developing countries yield much lower
cost estimates for drugs in their portfolios than those in the
previous section. The GATB and the MMV estimate the costs
of R&D at US$150 million (MMV 2002) and US$178 million
(midpoint of the range of US$115 million to US$240 million)
(GATB 2001, 101) or less than a quarter of DiMasi, Hansen,
and Grabowski’s (2003) estimate of US$802 million. The rea-
sons for these large differences are instructive.
First, the GATB and MMV estimates reflect only out-of-
pocket costs,with no allowance made for the opportunity cost of
capital. Nevertheless, the estimates of out-of-pocket cost are less
than half of the US$403 million out-of-pocket cost estimated by
DiMasi, Hansen, and Grabowski (2003). This difference in out-
of-pocket costs primarily reflects two factors: (a) fewer clinical
trials and, hence, fewer patients in trials—namely, 1,368 patients
per drug for the GATB compared with 5,303 in the DiMasi,
Hansen, and Grabowski (2003) study—and (b) lower costs per
patient of US$1,000 to US$3,000 for the GATB for trials run in
developing countries compared with US$23,500 per patient in
the DiMasi, Hansen, and Grabowski (2003) study.
Some drugs for LICs may require fewer trials, fewer patients,
or both per trial because of differences in drug types and trial
objectives and different regulatory requirements. For example,
some of the drugs in the two PPPs’ portfolios are modifications
of existing drugs for which some data have been established.
R&D costs for LIC drugs may also be lower to the extent that
these drugs are tested for fewer indications, with less within-
sample stratification by patient subgroup and less need to test
for drug interactions. Clinical effects for infectious and parasitic
diseases may also be greater than for chronic diseases, which
permit smaller trial sizes.2 The lower trial cost per patient for
LIC drugs partly reflects the lower costs of conducting trials in
developing countries,with much lower costs of medical care and
personnel than in the United States. The trial duration may also
be shorter because the target diseases are acute rather than
chronic. To the extent that the lower out-of-pocket clinical costs
in the GATB and MMV studies reflect fewer patients in trials and
lower cost per patient, such savings could, in principle, apply to
LIC drugs regardless of whether these drugs are developed by
not-for-profit or commercial enterprises.3
Another factor contributing to the lower out-of-pocket
costs reported by the MMV and the GATB is that these PPPs
benefit from in-kind contributions of personnel, technologies,
and other resources supplied by their industry and academic
partners. The MMV estimates these in-kind contributions as
equivalent to its own incurred costs. Thus, if these in-kind con-
tributions are included, the full social cost for developing LIC
drugs increases to US$250 million to US$300 million per com-
pound, or only 25 to 35 percent less than the DiMasi, Hansen,
and Grabowski (2003) estimate of US$403 million. However,
as long as such in-kind contributions are available without
charge to PPPs, the actual budget cost to PPP funders is only
US$150 million to US$178 million, or less than half DiMasi,
Hansen, and Grabowski’s (2003) estimate.4
The second major determinant of R&D costs is failure rates.
The GATB and MMV estimates show overall drug failure rates
similar to those in DiMasi, Hansen, and Grabowski’s (2003)
study. Indeed, there is no obvious reason to expect significant
differences in failure rates if LIC drugs face similar scientific
challenges and are reviewed by the FDA or the European
Medicines Evaluation Agency applying the same safety, efficacy,
and risk-benefit tradeoff standards as are applied to drugs for
the industrial countries. However, if the regulatory review of
LIC drugs uses risk-benefit tradeoffs that reflect conditions in
developing countries, then success rates might be higher, imply-
ing a lower budget cost per approved compound for LIC drugs.
Finally, the third major contributor to R&D costs is the
opportunity cost of capital, which accounts for US$399 million,
or almost half of DiMasi, Hansen, and Grabowski’s (2003)
US$802 million cost per compound. The GATB and MMV esti-
mates do not include the cost of capital. Whether the cost of
capital should be included in estimating the cost of R&D for
LIC drugs depends on the circumstances and the perspective. If
LIC drugs are to be developed by commercial firms that must
generate a competitive return for their shareholders, then the
cost estimates appropriately include a cost of capital at roughly
11 percent, as in the DiMasi, Hansen, and Grabowski (2003)
study. However, if LIC drugs are developed by PPPs or other
not-for-profit institutions with financing from philanthropic or
governmental agencies, the opportunity cost of capital may be
lower if these funders typically do not require a rate of return on
their investment to compensate them for the forgone alternative
uses of the funds during the investment period. For example,
government investments sometimes assume a social opportu-
nity cost of capital of about 5 percent. Using a 5 percent cost of
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capital for financing from philanthropic or governmental agen-
cies implies a roughly 50 percent markup over out-of-pocket
R&D costs to reflect the cost of capital rather than the roughly
100 percent estimated by DiMasi, Hansen, and Grabowski
(2003), assuming the same time flow of investments.
Applying this markup to the US$150 million to US$178 mil-
lion estimated out-of-pocket R&D cost for the MMV and
the GATB yields a total capitalized R&D cost of roughly
US$250 million for LIC drugs if they are developed by PPPs
with foundation or government funding, assuming that in-
kind contributions are at current levels and that trials are con-
ducted in developing countries. Alternatively, these funders
might choose to use a zero cost of capital, reflecting the impor-
tance that they attach to developing new medicines to treat cur-
rently untreatable diseases and to replace existing drugs that are
increasingly ineffective because of resistance. In that case, the
appropriate capitalization cost is zero, and the out-of-pocket
costs of US$150 million to US$178 million are the full R&D
costs per new compound for LIC diseases.
Economics of Vaccine Discovery and Development
In discussions of the economics of vaccine development, com-
paring the findings with those obtained for pharmaceuticals
is useful. Note, however, that the two product categories are
different in many fundamental and practical aspects.
Pharmaceuticals are used to treat an existing clinical condition
with the ultimate aim of reversing the course of disease. By
contrast, vaccines are used to prevent a future threat. In addi-
tion, pharmaceuticals may be administered over a prolonged
time frame and, in many chronic conditions, may be taken
from the time of diagnosis for the rest of the patient’s life,
whereas most vaccines are administered once or a few times.
The costs of vaccine production consist of the traditional
components of discovery, process development, scale-up, and
manufacturing, as well as the costs pertaining to regulatory
requirements, liability, and postlicensing studies (Andre 2002;
Grabowski 1997). Furthermore, the economic framework for
disease prevention (Kou 2002) raises many questions that are
less clear than calculating the cost of treatment of a specific
pathological condition in an individual or setting priorities for
government budgets. Finally, the financing of vaccine purchas-
ing and immunization programs has traditionally been sepa-
rated from the totality of health care financing. Although this
practice may have appeared to be advantageous at some point
globally or in individual countries, the current outcome is less
than satisfying in that the financing of vaccines is fragmented
(Institute of Medicine 2004) and competes at a less favorable
level with other budgetary priorities.
Costs of Vaccine R&D
The decision to develop a new vaccine is usually based on med-
ical need, scientific feasibility, and market conditions. Because
most currently available vaccines have been developed over
relatively long periods and multiple organizations have been
involved in their discovery, our cost estimates are based on his-
torical data and on many assumptions that are probably chang-
ing rapidly (Agre and Rapkin 2003; Barrett and Parker 2003;
Emanuel and others 2004; McMillan and Conlon 2004). The
cost elements are similar to those for pharmaceutical R&D
except for the specific regulatory procedures for vaccines, such
as the completion of plant construction before phase 3 trials.
As noted earlier, estimates indicate that an NCE costs
US$403 million to US$802 million in 2000 dollars (DiMasi,
Hansen, and Grabowski 2003). Clarke (2002) estimates that a
vaccine costs approximately US$700 million by the time the
product is marketed, including not only the actual costs of
products, but also such items as the cost of failures and the cost
of funds (Grabowski 1997). In addition, the size of phase three
clinical trials has recently escalated along with costs.
The Institute of Medicine (2004) estimates that total expen-
diture on vaccine R&D in 1995 was US$1.4 billion. The large
pharmaceutical companies accounted for approximately 50
percent of the total (Mercer Management Consulting 1995).
However, the current situation is more complex for vaccine
research than for drug R&D. In 2004, only five major multina-
tional companies were investing in vaccine R&D and produc-
tion (Institute of Medicine 2004). In addition, a multitude of
smaller, new biotechnology organizations in both developed
and developing countries are pursuing multiple vaccine targets
that are of considerable value (Nossal 2004). Since September
11, 2001, U.S. government funding for microbial threats that
can be used as agents of terror has increased: Project Bioshield
is devoting more than US$5 billion during the next 10 years to
discovering and producing vaccines and other therapeutics
(Herrera 2004). These initiatives may have spillover benefits for
vaccines and therapeutics for developing countries.
Another barrier, in addition to complexity and costs that
may directly or indirectly affect investment in vaccine R&D, is
the condition of the vaccine market. Even though experts
anticipate healthy growth in the total global vaccine market
from approximately US$6 billion in 2004 to US$20 billion in
2009, the number of large private pharmaceutical compa-
nies involved in vaccine research is down to five (Mercer
Management Consulting 2002). As a recent Institute of
Medicine report (2004) demonstrates, other significant barri-
ers also stand in the way of a well-functioning vaccine research
and production system. These barriers include the difficulties
of entering the field and of financing research, plus in the
United States they include the government’s role in determin-
ing pricing in relation to the government’s purchase of a signif-
icant proportion of vaccines. Similar situations arise in other
countries. All lead to an underappreciation of the value of vac-
cines and reduce the incentives for investment in future vaccine
products.
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As noted earlier, whether the cost of R&D for drugs or vac-
cines intended for use in developing countries is less than for
products targeted to high-income markets is questionable.
Certainly, developing vaccines for LICs requires investment
from both industrial and developing countries and participa-
tion by scientists from both industrial and developing coun-
tries. In the case of vaccines, discovery similar to pharmaceuti-
cals is a costly process. Therefore, a research infrastructure has
to be supported in academic institutions and private sector and
government laboratories for new ideas to emerge and to be
tested. The capabilities needed to discover a new HIV or malaria
vaccine are different and far more complex than those used to
manufacture traditional vaccines such as whole-cell pertussis.
Indeed, the technological know-how needed to discover new
vaccines is embedded in the advancing edge of science.
Alternative mechanisms of financing and managing the
development of new vaccines for the developing world must
be identified and may require governmental, international,
and philanthropic funding. Appropriate new institutions or
alliances could evolve from the multiple PPPs now being pur-
sued. The case has repeatedly been made for a massive infusion
of funds and global coordination if vaccines against great killer
diseases such as HIV/AIDS are to be developed (Klausner and
others 2003).
Effect and Cost of Vaccination Programs
The major societal and health effect of vaccines are realized
mainly when immunization programs reach a significant
proportion of individuals in a society (Mahmoud 2004). The
effect of vaccines in interrupting or preventing the transmission
of infectious agents depends on two concepts: inducing resist-
ance in healthy individuals before exposure and extending the
umbrella of prevention to the majority of the target population
to achieve herd immunity (Anderson and May 1990). When
deciding to mount a vaccination program, health professionals
face scientific, public health, and financial considerations. The
ultimate outcome is a cost structure that has to compete against
well-established budgetary constraints and comparisons. The
subject of the cost-effectiveness of vaccination programs has
been examined at multiple levels and in many settings (Miller
and Hinman 1999). The overall conclusion derived from most
quantitative techniques—for example, cost-benefit analysis,
cost-effectiveness analysis, and cost utility and decision
analysis—indicates that vaccination was one of the most effec-
tive health measures of the 20th century (CDC 1999).
DIAGNOSTICS
Evidence-based disease control strategies are now in place for
most of the major infectious diseases affecting developing
countries. Implementing these strategies depends on accurate
diagnostic methods. Progress has been made in securing ade-
quate drug supplies to treat or prevent diseases such as tubercu-
losis (TB), and in many instances, the most pressing need is for
improved diagnostics to ensure wider and wiser use of effective
therapies. Thus, an urgent need exists to develop diagnostic tests
that are simple, cost-effective, and robust enough to be used in
resource-constrained settings with endemic diseases.
Diagnostics Development Priorities 
for Developing Countries
The top priorities for developing new diagnostic methods per-
tain to HIV, TB, and malaria. In the field of HIV/AIDS, where
the goal is to simplify the diagnosis of HIV, the need is for a
noninvasive, inexpensive, and simple but highly sensitive and
specific HIV test for saliva, sputum, urine, or other body secre-
tions, as well as tests for monitoring highly active antiretroviral
therapy.
In diagnosis of mycobacterium TB, the limited sensitivity
of microscopy and the diagnostic challenges posed by smear-
negative, extrapulmonary, and pediatric TB emphasize the
need to find an alternative approach. In this context, the Gen-
Probe Amplified Mycobacterium Tuberculosis Direct Test (Coll
and others 2003; O’Sullivan and others 2002) and nucleic acid
amplifications assays, as well as serological tests (Perkins 2000),
have great potential. Diagnosing latent mycobacterium TB
infection using tuberculin skin testing has major limitations,
including the inability to differentiate latent TB from active
TB. The QuantiFERON-TB test (Mazurek and Villarino 2003),
which was approved by the FDA for detecting latent mycobac-
terium TB infection, and the MPB64 patch test (Perkins
2000), a mycobacterial antigen test (Nakamura and others
1998) specific to the mycobacterium TB complex, are promis-
ing and should undergo further evaluation.
For specific diagnosis of malaria, the most useful approach
would be a rapid test to determine whether patients who pres-
ent with fever have malaria. If this rapid test has the capability
of estimating parasite density, it may help predict those at
higher risk of progression to severe disease or treatment failure.
For the major noncommunicable diseases—for instance,
cardiovascular diseases—portable imaging devices, such as radi-
ographic or ultrasound machines, are becoming the new stan-
dard for diagnosis. Adaptation of these technologies to settings
in developing countries is urgently needed.
Economics of Diagnostics R&D
R&D for new drugs and vaccines poses major challenges in
developing countries because of financial constraints and lack
of infrastructure. By contrast, both the timelines and the costs of
developing diagnostics are significantly lower even though the
process of developing diagnostics is in many respects similar to
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the development of drugs or vaccines. Whereas the costs related
to clinical trials and the opportunity cost of funds are lower, the
process does have additional engineering requirements. For
diseases with relatively large at-risk populations, large and small
biotechnology companies have been sufficiently attracted to
invest in diagnostic R&D and stand to generate adequate com-
mercial returns even for inexpensive products. For less com-
mon diseases or diagnostic indications, industry investment
has been minimal, and direct R&D investment by the Special
Programme for Research and Training in Tropical Diseases
(TDR) (http://www.who.int/tdr) and other public sector agen-
cies or PPPs will be needed if products are to be developed.
Diagnostics activity in the TDR’s Product Research and
Development Unit currently focuses on two disease areas
through work carried out by the TB Diagnostics Initiative
(http://www.who.int/tdr/diseases/tb/tbdi.htm) and the Sexually
Transmitted Diseases Diagnostic Initiative. This work is done
in partnership with academic researchers, disease control
experts, public health officials from disease-endemic countries,
and industry. The TDR has recently invested substantially in its
capacity to support the clinical development and registration
of new diagnostics and will work closely with industry, regula-
tory agencies, and ministries of health in industrial countries
and disease-endemic countries to improve the quality and
standardization of diagnostic trials and to facilitate the imple-
mentation and appropriate use of proven technologies. As an
example, the mission of the TB Diagnostics Initiative is to work
closely with interested parties to stimulate interest; identify
obstacles; and facilitate the development, evaluation, approval,
and appropriate use of new diagnostics for TB in LICs
(http://www.who.int./tdr/about/resources/contributions.htm).
Current activities include research on new diagnostic targets
and methodologies, product development programs to facili-
tate commercial and noncommercial R&D, and formal
laboratory and field product evaluation trials. The Sexually
Transmitted Diseases Diagnostic Initiative is a 10-year-old col-
laborative project established in recognition of the critical need
for improved diagnostic tools for common sexually transmit-
ted diseases. Its mission is to promote the development, evalu-
ation, and application of diagnostic tests appropriate for use in
primary health care settings in developing countries, with a
focus on syphilis, chlamydia, and gonorrhea.
Cost Estimates of Diagnostics R&D
No systematic estimates of the costs of developing diagnostics
are available that are comparable to the studies for pharmaceu-
ticals. The costs of developing new diagnostics depend on the
type of tool; the duration from discovery to approval; and the
technicalities involved in technology acquisition, patent fees,
market research, laboratory and field trials, marketing and
product launch, and support costs. Table 6.1 summarizes costs
related to the development of selected diagnostics for TB. Note
that these are out-of-pocket costs and do not include the
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Table 6.1 Costs of Developing Selected TB Diagnostics 
(US$)
Type of test
Nucleic Drug susceptibility 
Item acid amplification Screening test testing 
Location of company Rest of world United States and United States and United States and United States and 
European Union European Union European Union European Union
Market research costs 10,000 100,000 50,000 500,000 500,000
Technology acquisition and patent fees 275,000 250,000 50,000 200,000
Development of prototype 3,775,000 4,000,000 4,662,000 2,825,000
Consumables used during development 1,575,000 75,000 150,000
Scale-up and validation 600,000 200,000 200,000
Total product development costs 575,000 5,625,000 4,850,000 4,987,000 3,375,000
Total costs of clinical trials 180,000 1,450,000 2,000,000 294,000
(location of study sites) (disease-endemic (United States and (United States and (disease-endemic 
countries) European Union) European Union) countries)
Regulatory approval costs (agencies) 100,000 800,000 454,000
(FDA, European (United States)
Union)
Marketing and launch support costs 80,000 1,500,000 200,000
Product support costs for one year 50,000 1,125,000 20,000
Total 995,000 10,600,000 7,574,000 5,781,000 3,875,000
Source: http://www.who.int.tdr/about/resources/default.htm.
opportunity cost of capital (http://www.who.int./tdr/about/
resources/contributions.htm).
FINANCING AND INSTITUTIONAL
ARRANGEMENTS FOR NEW PRODUCT
DEVELOPMENT
Research that contributes to the discovery and development of
drugs, vaccines, and diagnostics occurs in public, private, and
mixed settings, each with different funding mechanisms.
Public Sector
In most high-income countries (HICs), government funding
from tax revenues is generally targeted to basic research—that is,
research that advances understanding of underlying disease
processes but is unlikely to yield commercially viable products
in the near term. The research may be done in government insti-
tutions or in academic and other not-for-profit research institu-
tions. Governments also stimulate private sector R&D through
tax credits.
Private For-Profit Sector
Applied research that targets specific products is generally
undertaken by the private sector using equity financing. Firms
that rely on equity financing must provide a return to their
investors comparable to returns on other potential invest-
ments, hereafter referred to as a competitive return. This
requirement applies for multinational pharmaceutical compa-
nies, for biotechnology firms, and for firms in developing
countries, unless they receive public subsidies. Start-up firms in
HICs generally rely on equity capital from venture capitalists
and other private investors, whereas established firms issue
shares in the broadly based public equity markets but finance
most of their R&D from retained earnings on existing prod-
ucts. The need to provide a competitive return to shareholders
means that commercial firms can invest only in products that
they expect will generate sufficient revenues to cover all costs,
including the costs of R&D. In practice, commercial firms have
focused on products with a potential market in industrial
countries because of their residents’ ability to pay prices suffi-
cient to cover costs.
Differential, or “Tiered,” Pricing. For global products—that
is, products targeting diseases that occur in all countries, such as
cardiovascular diseases—revenues generated in HICs and in the
more affluent sectors of middle-income countries are sufficient
to recoup the investment in R&D to the extent that, ideally,
prices in LICs need to cover only the incremental or marginal
costs of production for these countries.
Even with pricing at marginal cost, medicines may still be
unaffordable for the poorest populations, particularly for drugs
with high manufacturing costs, in which case additional subsi-
dies may be necessary. However, the important conclusion is
that for drugs for global diseases, the existence of a market in
industrial countries attracts private sector investment in R&D;
thus, differential (tiered) pricing provides a finance mechanism
for developing new drugs that can achieve both dynamic effi-
ciency (appropriate incentives for R&D) and static efficiency
(appropriate incentives for use of existing products) (Danzon
and Towse 2005).
By contrast, for drugs and vaccines that target diseases that
occur predominantly in LICs, no HIC market exists in which to
recoup the costs of R&D, and patents and differential pricing
will not suffice to attract R&D for products that cannot expect
to generate sufficient revenue to cover their development costs.
In 2002, annual per capita spending on drugs alone in member
states of the Organisation for Economic Co-operation and
Development was US$279, while developing countries typically
spent less than US$20 per capita for all health services (Sachs
2001; Troullier and others 2002). Per capita health spending on
drugs by the poorest individuals, who may be the majority of
patients for communicable diseases, is even lower. Thus, for
products that target LIC-only diseases, even if millions of
patients are in need, expected revenues are insufficient to attract
private sector investment for developing new products without
additional public subsidies.
For HIV/AIDS, even though the majority of the disease
burden is in LICs, the markets in HICs have been sufficient to
attract private sector companies to develop several drugs and
to undertake considerable investment in an AIDS vaccine,
albeit with little success to date. In 2001, the GATB increased
the estimated size of the TB market from US$150 million
to US$450 million per year, with the potential to grow to
US$700 million per year (GATB 2001). This amount is within
the range normally considered necessary to attract private
investment. However, estimated potential revenues for anti-
malarials and treatments for other LIC diseases are still well
below this threshold. In addition to the limited ability to pay,
some developing countries still lack the health care infrastruc-
ture necessary for conducting clinical trials and for delivering
medicines and vaccines effectively, which further reduces
incentives for R&D investment.
Given the low potential revenues and lack of necessary
infrastructure, R&D for tropical diseases and TB for the past
25 years has been far less, relative to need, than for global dis-
eases. The number of NCEs per million disability-adjusted life
years lost (a proxy for research relative to need) was 0.55 for
infectious and parasitic diseases but roughly 1.25 to 1.44 for
cardiovascular system diseases (Troullier and others 2002).
Between 1975 and 1999, just 16 of the 1,393 NCEs registered
were for tropical diseases or TB (Troullier and others 2002).5
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Several of these products were fortuitous by-products of com-
mercial research efforts initially intended for the oncology or
veterinary market (Ridley 2003).
Multinational companies appear to be showing some signs
of increasing their investment in tropical disease R&D. For
example, GlaxoSmithKline, AstraZeneca, and Novartis have
recently announced or established research centers devoted to
tropical disease. AstraZeneca’s facility in Bangalore, India, will
focus on TB treatments and receive a commitment of person-
nel and US$40 million in investment during 2003–8. The non-
profit Novartis Institute for Tropical Diseases in Singapore is a
US$122 million joint venture between Singapore and Novartis
that will focus on dengue fever and TB. GlaxoSmithKline has
established a research institute for TB and malaria in Spain
(“Drugs for the Poor” 2003).
Orphan Drug Acts. Orphan drug acts provide additional
stimulus for private sector R&D for diseases that afflict only
small populations in HICs. The U.S. Orphan Drug Act grants
orphan status to drugs to treat diseases that affect 200,000 or
fewer patients per year in the United States. Orphan drug status
provides additional R&D tax credits and seven years of market
exclusivity, during which the FDA cannot approve another
drug to treat the same condition unless it uses a novel mecha-
nism of action. Such market exclusivity enhances the orphan
drug’s market power, enabling the developer to charge high
prices that to some extent offset the low sales volumes, thereby
covering the costs of R&D. The U.S. act has stimulated a sharp
increase in the number of drugs developed to treat orphan con-
ditions since its passage. The European Union recently adopted
similar legislation.
The potential for orphan status in the United States and the
European Union may provide some additional stimulus for
commercial firms to develop drugs and vaccines for LIC dis-
eases, but the effects are likely to be minor for several reasons.
First, after one product has acquired market exclusivity, firms
have few incentives to develop other products to treat the
same disease. Second, the value of orphan drug status in terms
of annual revenue per patient is greatest for drugs to treat
chronic diseases that require daily or weekly treatment.
Potential revenues for treatments for acute diseases, for which
each patient needs only a short course of treatment, are likely
to be smaller. Thus, though orphan drug acts may create some
additional stimulus for R&D for LIC diseases, other institu-
tional and financing mechanisms are essential. Of these, PPPs
are the most promising.
“Pull” Financing Mechanisms. Since the late 1990s, organiza-
tions such as the Bill & Melinda Gates Foundation and the
Rockefeller Foundation have increased their funding commit-
ments to fight diseases in developing countries. This new fund-
ing, including funding coordinated through the Global Fund to
Fight AIDS, Tuberculosis, and Malaria, is allocated primarily to
paying for vaccinations and treatment. By paying for vaccines
and drugs, such financing could provide additional revenues
to suppliers of these products and, hence, stimulate R&D.
However, for the financing of vaccines and therapeutics to
serve as an effective pull mechanism for future R&D, such
financing must be sustained and must pay originators enough
that they can recoup the costs of R&D. Thus, purchasers such
as the United Nations Children’s Fund or the Global Fund face
a tradeoff between paying the lowest possible prices so as to
maximize their ability to supply existing medicines to current
patients and paying somewhat higher prices so as to create
incentives for future R&D.
Creating effective pull financing incentives for R&D is prob-
ably best done by means of explicit purchasing commitments
for specific products. Some progress has been made in identify-
ing the contractual and legal requirements of such commit-
ments to enter into future contracts. The most promising
candidates for initial implementation would be products or vac-
cines that are already in late stages of development or have been
approved for industrial countries but for which additional pur-
chasing commitments are needed to induce the investment nec-
essary to undertake clinical trials and build the manufacturing
capacity required to extend these products to LICs. Possible can-
didates are the pneumococcal vaccine and the rotavirus vaccine.
For both these products, accelerated development and intro-
duction plans have been created in the Global Alliance for
Vaccines and Immunization to address the many practical issues
surrounding the implementation of an advance purchase
contract. When advance purchasing commitments have been
successfully demonstrated on products in the late stages of
development, extending this promising approach to products at
earlier stages of development may be possible.
Public-Private Partnerships
In recent years, a growing number of initiatives involving part-
nerships between industry and government, nonprofit, and
philanthropic organizations have been set up to stimulate trop-
ical disease R&D. One of the oldest is the World Health
Organization, World Bank, and United Nations Development
Programme TDR, which has worked with industry, academia,
and research institutions to spur R&D and has contributed to
half the new drugs developed for neglected tropical diseases
during the past 25 years (Ridley 2003; Troullier and others
2002) (see table 6.2 for examples of the program’s initiatives).
The TDR is a relatively small program, with contributions of
US$30 million in 2002.
Since the late 1990s, increased government and foundation
funding, particularly from the Rockefeller Foundation and the
Bill & Melinda Gates Foundation, has stimulated the growth of
product development PPPs, giving a “push” stimulus to R&D
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(Varmus and others 2004). According to the Initiative on
Public-Private Partnerships for Health, about 20 PPPs were
involved in product development as of 2004. Although a few
focus on a specific project, most adopt a portfolio approach
with multiple candidates. The latter include five targeting
HIV/AIDS vaccines or microbicides; three working with
malaria therapeutics or vaccines; three investigating TB thera-
peutics, vaccines, or diagnostics; and at least six targeting drugs
for other neglected diseases (Widdus 2004).
The PPPs are heterogeneous in terms of their objectives,
structure, and financing. In general, their goal is to develop
products for use in developing countries with a public health
rather than a commercial goal. Their sources for promising
compounds include modifications of existing compounds;
continued development of compounds previously abandoned
because of a lack of commercial potential; and totally new ini-
tiatives coming out of academia, industry, or government lab-
oratories. If a PPP acquires a product from another firm, the
other firm typically retains patent rights in HICs and middle-
income countries, and the PPP commits to noncommercial
pricing in developing countries.
PPPs draw on financing from foundations and, to a lesser
extent, from governments. They work closely with private
industry, including large pharmaceutical and biotechnology
firms, obtaining a range of in-kind contributions, including
promising compounds; useful technologies; patent rights; and
expertise and advice on discovery, clinical trials, manufactur-
ing, market estimation, regulatory requirements, and so on.
They operate largely as “virtual” firms, usually contracting out
actual operations to other firms or to contract research or serv-
ice organizations. As compounds move into human trials, PPPs
must also liaise closely with disease-endemic countries regard-
ing clinical trials, regulatory requirements, and product deliv-
ery. Thus, they face significant scientific, managerial, financing,
and operational challenges.
Table 6.3 lists the leading product development PPPs and
their committed funding as of early 2004. Several have received
grants of US$50 million or less, with significantly larger
amounts for the International AIDS Vaccine Initiative and
the Malaria Vaccine Initiative. Several of the organizations rely
heavily on the Bill & Melinda Gates Foundation and the
Rockefeller Foundation for both their initial and continued
funding (Widdus 2004). Note that the dollar funding amounts
shown exclude in-kind contributions from industry and other
sources, whose worth is difficult to calculate because the value
to the PPPs is presumably greater than the cost to the donor.
Table 6.4 shows the product development PPPs’ portfolios
of products as of early 2004. The percentage of products still in
preclinical development is higher for vaccines than for drugs,
which may reflect the scientific challenges of developing vac-
cines for LIC diseases. In general, comparing funding amounts
with the number of products in development across PPPs is
inappropriate as an indicator of performance because the dif-
ferent PPPs target different problems and have received varying
in-kind contributions. Also, some products are modest exten-
sions of existing therapies, whereas others are more innovative
and, hence, more risky approaches.
As table 6.3 shows, aggregate committed funding for the
product development PPPs as of early 2004 was US$1.2 billion,
excluding in-kind contributions. A comparison of these fund-
ing amounts to the costs per NCE suggests that current rates
of investment will produce some progress, but not rapid
advances. Assuming optimistically that future funding for PPPs
will be US$300 million per year, that private industry will
invests similar amount, and that other sources will provide
US$100 million a year (all of which are probably generous esti-
mates) would imply total investment of US$700 million per
year. If this level of investment were sustained over time, it
might result in two or three NCEs per year, using the conserva-
tive cost estimates of US$200 million to US$300 million per
NCE. This development level would be significant progress,
although it still leaves a large shortfall, given the number of dis-
eases for which no good treatment or vaccine is available and
the threat of resistance developing to existing treatments. It is
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Table 6.2 Selected Initiatives of the TDR
Disease Product Partner Status
Uncomplicated malaria Lapdap GlaxoSmithKline Dossier submitted (2002)
Lapdap, artesunate GlaxoSmithKline Phase 1
Pyronaridine, artesunate Shin Poong Preclinical trials 
Severe malaria Intramuscular artemether Artecef Registered (2000)
Rectal artesunate Under discussion FDA approval letter received
Visceral leishmaniasis Miltefosine Zentaris Registered (2002)
Paromomycin Institute for OneWorld Health Phase 3 studies
Sleeping sickness Intravenous eflornithine Aventis Registered (2001)
River blindness Ivermectin Merck Registered (1989)
Source: Ridley 2003.
Product Development Priorities | 149
Table 6.3 Selected Endeavors by Product Development PPPs, 2004
Number of
people killed Number of Committed funds
annually by new cases raised to date
Disease the disease per year PPP Focus (US$ millions)
HIV/AIDS 2,800,000 5,500,000 International AIDS Vaccine Initiative Vaccines 350
South African AIDS Vaccine Initiative Vaccines 45
International Partnership for Microbicides Microbicides 95
Microbicides Development Programme Microbicides 27
Global Microbicide Project Microbicides 64
TB 1,600,000 8,000,000 Global Alliance for TB Drugs 42
Aeras Vaccines 108
Foundation for Innovative New Diagnostics Diagnostics 30
Malaria 1,200,000 300,000,000– Malaria Vaccine Initiative Vaccines 150
500,000,000 European Malaria Vaccine Initiative Vaccines 18
MMV Drugs 107
Dengue fever 19,000 20,000,000 Pediatric Dengue Vaccine Initiative Vaccines 56
Hookworm 3,000 — Human Hookworm Vaccine Initiative Vaccines 20
Leishmaniasis 51,000 1,000,000– Drugs for Neglected Diseases Initiative Drugs 11 (Institute for 
1,500,000 and Institute for OneWorld Health OneWorld Health)
Chagas disease 14,000 16,000,000– Drugs for Neglected Diseases Initiative Drugs 30 (Drugs for 
18,000,000 and Institute for OneWorld Health Neglected Diseases
Initiative)
Total 5,700,000 351,000,000– n.a. n.a. 1,200
353,000,000
Source: Sander 2004.
n.a.  not applicable; —  not available.
Table 6.4 Product Development PPPs’ Portfolios, 2004 
Number of products in
PPP Preclinical trials Phase 1 Phase 2 Phase 3
Aeras 2
Drugs for Neglected Diseases Initiativea 3
European Malaria Vaccine Initiative
Foundation for Innovative New Diagnostics 1 1 1
GATBb 10 0 1 0
Human Hookworm Vaccine Initiative 2
International AIDS Vaccine Initiative 2 2 1
Institute for OneWorld Health 3 1 1
International Partnership for Microbicides
Microbicides Development Programme 1 1
MMV 14 in discovery 4 2 2
Malaria Vaccine Initiative 8 6 1
Pediatric Dengue Vaccine Initiative
South African AIDS Vaccine Initiativec 6 0
Total 47 16 7 8
Of which drugs 26 8 5 8
Of which vaccines 19 8 2 0
Sources: Initiative on Public-Private Partnerships for Health survey, PPPs’ Web sites, interviews.
a. The Drugs for Neglected Diseases Initiative has two malaria drugs in phase 3 that are partly financed by the European Union. 
b. The GATB anticipates a portfolio of three phase 1 trials and expects its current phase 2 trial will enter phase 3 before 2007. Its portfolio also includes platform-related investments. 
c. The South African AIDS Vaccine Initiative does not yet have any of its own products at phase 1 but is collaborating on two projects that are at this stage.
also far short of the Commission on Macroeconomics and
Health’s target for 2006 of US$3 billion in R&D spending for
diseases in developing countries (Sachs 2001).
Industry in Developing Countries
Pharmaceutical firms in developing countries have tradition-
ally focused on the generic sector, making use of their expertise
in engineering and other skills needed for efficient drug manu-
facturing. More recently, the adoption of product patents has
created incentives for LIC firms to invest in R&D. For example,
India adopted product patents as of 2005, and several leading
generic firms are already developing new products. However,
assuming that these firms will focus their efforts on developing
drugs for tropical diseases would be a mistake. As for-profit
firms, they face similar incentives to those of commercial firms
in any country, which means focusing on the global diseases
that offer the greatest expected net revenues rather than dis-
eases specific to LICs. Nonetheless, several policies might help
target R&D efforts in these countries toward tropical diseases.
These policies include collaboration with the product develop-
ment PPPs, provision of special government funding or tax
credits for products that target LIC diseases, and provision of
subsidies targeting the development and scientific testing of
products derived from local products and other traditional
medicines.
Other Proposed Mechanisms for Increasing Affordability
In evaluating other proposals for making drugs or vaccines
available in developing countries, distinguishing proposals to
stimulate new product development from proposals to increase
the affordability of existing drugs is critical. One proposal
pertaining to affordability is that multinational companies
should voluntarily license production rights to LIC producers.
Experience with generic markets across countries indicates that
necessary conditions for such out-licensing to reduce prices to
consumers are (a) the existence of competition between multi-
ple licensees, (b) the licensees having lower production costs
than the originator firms, and (c) a mechanism that prevents
middlemen and retailers from capturing any potential savings.
In practice, these conditions may not be met. The more proba-
ble scenario of licensing to only one local generic manufacturer
is unlikely to reduce prices to consumers.
Another proposal is that governments should purchase
patent rights, paying the originator firm the estimated value of
the drug (net of production costs) and then selling the product
to consumers at the marginal cost of production. This proposal
has several disadvantages. First, because the government would
presumably have to raise taxes to pay for the patents, the tax-
induced efficiency loss could offset any efficiency gain in the
pharmaceutical market, so the net effect on efficiency is
unclear. Second, the presumption that patents result in subop-
timal drug consumption because of monopoly pricing ignores
the widespread prevalence of insurance in HICs and middle-
income countries, so that, in practice, consumers face out-of-
pocket prices that are already close to marginal cost. Third, and
most important, is the difficulty of estimating the value of a
product before its use in the market, because both positive fea-
tures (additional uses) and negative features (side effects) may
be discovered. In addition, distortions in the amounts paid for
patent rights would distort incentives for R&D. Moreover, the
proposal would reduce originator firms’ incentives to invest in
postlaunch improvements.
INTELLECTUAL PROPERTY
The issue of intellectual property is involved in the debate
about the perceived conflict between patents and access.
The Role of Patents in Drug Development
Under a patent system, an inventor is entitled to a limited
monopoly for a period of time, typically 20 years. This exclusiv-
ity may permit high prices and, consequently, an increased
economic return that serves as an incentive to develop new
products. The system has worked quite effectively in the phar-
maceutical area, where the incentives deriving from exclusivity
have resulted in important new drugs. The first generation of
patients pays a higher price than subsequent generations, which
provides compensation for the large research costs involved in
developing a new drug. When the patent expires, the price nor-
mally falls as generic competitors enter the market.
Even though this approach has been extremely successful in
the developed world, it does not generally work for products
for which the main market is limited to the developing world.
The total magnitude of the market in the developing world for
products for HIV, malaria, TB, or less widespread diseases is
likely to be too small to provide an adequate incentive for the
private sector. This fact, together with the fact that patents are
likely to result in higher prices, has raised important concerns
in the developing world.
The Drug Access Debate
The Agreement on Trade-Related Aspects of Intellectual
Property Rights (TRIPS) entered into force on January 1,
1995.6 This agreement requires the members of the World
Trade Organization (WTO), which include nearly all major
trading nations, to live up to defined standards of intellectual
property protection. TRIPS was part of a much broader inter-
national trade package negotiated during the Uruguay Round,
one of a series of international trade negotiations that have
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taken place since World War II. The United States and
European nations, which were the strong proponents of TRIPS,
were responding to pressure from their pharmaceutical, copy-
right content, and trademark-based industries.
The pharmaceutical industry’s concern was that a number
of developing nations had made deliberate decisions to deny
patent protection to pharmaceutical products and to grant pro-
tection only to processes for producing pharmaceuticals. These
nations believed that inexpensive access to pharmaceutical
products was so important that these products should not be
patented. In its 1970 patent law, for example, India excluded
pharmaceuticals from product patent protection, effectively
choosing to provide low-cost pharmaceuticals for its people at
the expense of eliminating incentives to create new products.
This law was one of the reasons the Indian generic pharmaceu-
tical industry was able to evolve to make and market copies of
drugs that were still on patent in wealthier nations. Another
concern for the pharmaceutical industry arose from the com-
pulsory license process, a legal process available in some
nations to authorize the use of a patented technology under
some circumstances even over the patent holder’s objection. In
practice, compulsory licenses are rarely granted but are instead
used as a threat to negotiate lower prices for the technology or
pharmaceutical involved.
The United States was determined to change these laws
and in TRIPS achieved important requirements for expanding
patent protection. The most important TRIPS provision
relevant to pharmaceuticals is article 27, which includes a
requirement that “patents shall be available for any inventions,
whether products or processes, in all fields of technology.”
(U.K. Commission on Intellectual Property Rights 2002). The
clear intent of this language was to prohibit exclusions of phar-
maceutical products as in the Indian law. Article 31 established
careful procedural limitations on when a nation could grant a
compulsory license. As part of the political compromise, tran-
sitional provisions gave developing nations extra time to com-
ply with the treaty’s requirements and also set up arrangements
for the remaining parts of patent terms to be made available for
products developed during the transition period. Because of
these transitional provisions, developing nations were not gen-
erally required to provide product patents on pharmaceuticals
until January 1, 2005 (a date that has since been extended to
2016 for the least developed countries).
During the years following the entry into force of TRIPS,
a substantial and bitter debate over access to pharmaceutical
products in developing countries focused largely on access to
antiretroviral agents for HIV patients in Sub-Saharan Africa. A
group of nongovernmental organizations argued that patents
on these drugs in the developing world raise the prices of the
products necessary to help such patients survive. The research-
based pharmaceutical industry countered that many of the
relevant products are not covered by patents in the nations
involved and that the problem is not patents but the inade-
quacy of the countries’ medical infrastructure.
An area of convergence has begun to emerge in relation to
differential pricing: prices should be lower in developing
nations than in developed nations, permitting pharmaceutical
firms to recover their research expenditures in the developed
world while making products available at near marginal pro-
duction cost to the poor in the developing world. This differ-
ential pricing is justified because potential sales in poor nations
are so small that the market provides only a minimal incentive:
total sales in the poorest nations account for only about 1 per-
cent of global pharmaceutical sales. The research-based phar-
maceutical industry would prefer to achieve this differential
pricing by means of a donation program or simply by charging
different prices. Critics would prefer that the patent monopoly
not be available to raise prices in the developing world, thereby
opening up markets to local generic producers.
Movement toward agreement on differential pricing was
reflected in the Doha Declaration on TRIPS agreement and
public health, reached at a November 2001 WTO meeting of
trade ministers. This declaration affirmed that TRIPS “should
be interpreted and implemented in a manner supportive of
WTO members’ right to protect public health and, in particu-
lar, to promote access to medicines for all” (TRIPS, paragraph
4, 2001). It affirmed the right of nations to use the exceptions
to TRIPS to address public health concerns, specifically stating
that “public health crises, including those related to HIV/AIDS,
tuberculosis, malaria and other epidemics, can represent a
national emergency” and, thus, facilitate the right to use com-
pulsory licensing (WTO 2003).
The Doha Declaration left an issue unresolved: the manu-
facture of drugs under compulsory license for nations that do
not have the capability to manufacture the drugs themselves.
The problem arises from the compulsory licensing article of
TRIPS, which contains a provision, article 31(f), requiring that
the manufacture of products under compulsory license be pre-
dominantly for the domestic market. Thus, a small Sub-Sahara
African nation clearly has the right to grant a compulsory
license but may have no local industry able to manufacture the
product. If it asks a foreign firm to manufacture the product,
that firm would be manufacturing the product primarily for
export, a violation of TRIPS.
The Doha negotiators did not find a way to resolve this
problem, and article 6 of the Doha Declaration called for mem-
bers of the TRIPS Council (a group of national representatives)
to find a solution by the end of 2002. By that time, all member
countries except the United States had agreed to a procedure
for waiving article 31(f). The new agreement covered products
needed to address public health problems recognized in the
Doha Declaration, but the United States feared that it would be
expanded to a variety of other products and was unwilling to
accept it. Finally, a compromise was reached in August 2003.
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The United States accepted the 2002 document, provided that
the General Council chairperson of the WTO made an appro-
priate parallel statement. The chair made the statement, which
included language that the agreement would be used “in good
faith to protect public health” and not be “an instrument to
pursue industrial or commercial policy objectives,” and recog-
nized the need to respond to the industry’s concern that
products produced under this agreement would not be
exported to major developed world markets (WTO 2003; see
also UNAIDS 2003).
This agreement represents a step forward for access and will
certainly place pressure on the research-based pharmaceutical
industry to provide products in the developing world at low
prices. It leaves several important problems only partly
resolved, however. One is the need to prevent importation of
the low-priced products into the developed world. Such
imports would cut into the patent-protected market and affect
incentives to develop new products. A second is political back-
lash. When the general public becomes aware that a product is
available to the poor in a developing nation at a price far below
that which patients in developed nations must pay, the political
backlash for the pharmaceutical industry in the developed
world may be severe.
Most important, resolving the legal problem of article 31(f)
does not resolve the economic problem. It confirms that there
will be no patent incentive for the development of drugs for
diseases endemic to the developing nations and that public
funds will be needed for this purpose. Such funds are currently
inadequate.
The Research Tool Issue
Another important problem arises from the changing nature of
medical research and of patenting practice. This is the research
tool problem: many of the basic tools used in medical research
are now themselves patented. For example, the research use of
certain genetically modified mice is patented in the United
States, as are the uses of many gene sequences and protein crys-
tal coordinates. In the case of the malaria antigen merozoite
surface protein 1, some 39 patent families cover various aspects
of the protein (U.K. Commission on Intellectual Property
Rights 2002).
Such patents can significantly complicate research and
make it more expensive. Each one that might affect a particular
research program requires legal analysis to determine whether
it is valid and actually applies to the planned research program.
If relevant, a license must be sought or the research program
must be redesigned. The more patents are involved, the greater
the likelihood that a patent holder will refuse to grant a license
or will demand an exorbitant sum. Even though Walsh, Arora,
and Cohen’s (2003) study finds no cases of research programs
being canceled midstream because of this problem, it finds
many cases of efforts to avoid the problem by, for example,
modifying the research; conducting the research offshore in
locations where the relevant patents are not in force; or, in
some cases, simply ignoring the patent.
REGULATORY AND LIABILITY ISSUES
Developing and registering new products are generally lengthy
and complicated processes (Abraham and Reed 2002; Baylor
and McVittie 2003; FDA 2004) that are regulated both at the
national level and, in some circumstances, at the international
level. The role of the regulatory system extends beyond the
launch of a new product to manufacturing and compliance
standards and to postmarketing surveillance for clinical effects
and potential untoward outcomes. For products that are
intended to be deployed in global markets, manufacturers have
to comply with regulatory requirements in the country of ori-
gin as well as the requirements of each country where the prod-
uct may be marketed. One exception is the mutual recognition
systems used currently by European Union countries (Pignatti,
Boone, and Moulon 2004). The situation may be different for
products intended for use only in developing countries; how-
ever, for legal and liability reasons, manufacturers in developed
countries have refrained from working with two different sets
of regulatory requirements.
The best example for illustrating this process is the FDA
(2004). Over the years, FDA regulations have developed into a
clear pathway. The process is initiated through an application
by the manufacturer and a step-by-step approach toward
licensing. The agency gets involved in every phase of the devel-
opment process and approves in advance the experimental
design, assays, and endpoints for clinical trials. After it has col-
lected all the information, the agency examines the materials
submitted and reaches a decision. The FDA process extends
through regulating and approving marketing materials and
postlicensing collection of efficacy data and information about
possible side effects.
The FDA approval process differs somewhat for pharma-
ceutical products and vaccines. One of the main differences is
the obligation of vaccine manufacturers to prepare materials
for use in phase 3 trials in the final and approved production
facility. This requirement means that the firm must invest in
completing the manufacturing plant well ahead of launching a
specific product, a process that can take three to six years. The
regulatory process for vaccines also dictates batch release for
every batch ready for deployment in the marketplace. This part
of the regulatory process, although it ensures quality control,
adds to costs and to the timeline.
In 1996, the European Union adopted a centralized
procedure for applications and approvals through the
European Medicines Evaluation Agency and through a mutual
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recognition process (Pignatti, Boone, and Moulon 2004). In
many ways, the procedure parallels the FDA process, with sev-
eral differences reflecting the fact that the European Union
consists of many countries, each with a country-based process
that remains as an alternative or an addition to the com-
munitywide process. The International Conference on
Harmonization of Technical Requirements for Regulation of
Pharmaceuticals for Human Use was established to achieve
coordination of the process of drug development between
industry, Japan, the United States, and the European Union
(Abraham and Reed 2002; Ohno 2002). The conference’s activ-
ities have improved understanding of the regulatory process
and reduced duplication.
In contrast, the absence of a unified or harmonized
approach to product registration and approval at the global
level adds multiple layers of complexity. National systems
consist of complex processes with differing thresholds and
interpretations and with changing requirements in addition
to differing Global Manufacturing Program standards and
enforcement. A number of recent attempts have been made
to resolve the issue. First among these is the World Health
Organization’s effort to expand its prequalification system, to
develop technical standards earlier in the approval process, and
to expand the availability of reference reagents for international
calibration (Milstien and Belgharbi 2004). These efforts aim at
injecting a higher level of quality control and transparency into
the global regulatory system. The effort may have the potential
to provide a global process that transcends national borders.
Such a process should provide a simplified, systematic, and dis-
ciplined system that would reduce costs and speed up market
access for new products.
The issue of liability in relation to harm to individuals
receiving pharmaceutical products has been extremely signifi-
cant in U.S. product development. It is entirely appropriate for
those developing new products to be sued if they are negligent
in their research or product development, but in some cases
pharmaceutical firms have been sued for side effects of drugs
that may have been unforeseeable or may not even have been
the result of the product. This type of liability can be a barrier
to product development. Although perhaps a less serious con-
cern since the 1993 Daubert v. Merrell Dow Pharmaceuticals
lawsuit in the United States, a case that has been interpreted to
restrict the presentation to juries of evidence determined not to
be “scientific,” the issue is still significant. It may also be part of
the reason the U.S. vaccine industry has shrunk significantly,
and it has certainly affected the direction of investment, push-
ing it away, for example, from products such as vaccines that
are used in one or a few doses in healthy people toward prod-
ucts used repetitively by those who already have a chronic dis-
ease (Institute of Medicine 2004). It, thus, provides pressure
directly contrary to public health priorities, which emphasize
prevention and, therefore, the use of vaccines.
Whether or how this trend in the United States will affect
the developing world is unclear. Europe has moved toward a
liability system somewhat similar to that of the United States,
but many developing nations may not have such a tort liability
system. Even if they do not have such a system, groups partici-
pating in pharmaceutical development might be sued in the
United States for harm occurring in the developing world.
Doctrines exist that restrict such suits, but firms may fear that
these doctrines are insufficiently effective. Hence, recognizing
the potential costs of protecting against liability and, at the
same time, ensuring that products are designed and manufac-
tured to the highest standards will be important.
NOTES
1. The phase transition probabilities in DiMasi, Hansen, and
Grabowski (2003) and the overall success probability of 0.215, conditional
on entering human trials, are estimated from a larger sample of 538 inves-
tigational compounds first tested in humans between 1983 and 1994.
2. The size of trial required to estimate statistical significance depends
on the magnitude of the drug effect; the extent of stratification within the
total sample by patient age, condition, and so on; the required statistical
confidence; and other factors.
3. DiMasi, Hansen, and Grabowski’s (2003) data for average cost and
average number of patients are based on actual, retrospective cost data,
whereas the GATB estimates are prospective estimates (best guesses) based
on prior clinical trials for tuberculosis drugs in the United States and a sur-
vey of clinical trial experts to determine administrative and data manage-
ment costs.
4. The MMV estimate of in-kind contributions does not include the
value of basic research conducted by universities and foundations from
which it obtains its lead compounds. Similarly, commercial firms also ben-
efit from such basic research and it is omitted from the DiMasi, Hansen,
and Grabowski (2003) estimates, so comparisons are not necessarily
biased by this exclusion.
5. Tropical diseases include parasitic diseases (malaria, African try-
panosomiasis, Chagas disease, schistosomiasis, leishmaniasis, lymphatic
filariasis, onchocerciasis, and intestinal nematode infections); leprosy;
dengue fever; Japanese encephalitis; trachoma; and infectious diarrheal
diseases.
6. This section is based in part on Barton (2004).
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Health research has contributed tremendously to advancing
health and welfare throughout the world. Gains in health have
already been attained, and health research continues to have
great potential to contribute to the well-being of persons in
both low-income and high-income countries. The “10/90”
reports of the Global Forum on Health Research (GFHR) have
helped highlight that, although the burden of disease attributa-
ble to morbidity and mortality is greatest in developing coun-
tries, most health research has focused on the needs of devel-
oped countries and relatively little on the needs of lower-income
countries (GFHR 2003). Despite the relative dearth of health
research focused specifically on their most important health
problems, lower-income countries have also benefited from
health research, often as much from research originally moti-
vated to serve high-income countries as from research specifi-
cally designed to address the needs of low-income countries.
In the future, health research aimed primarily at addressing
the needs of affluent countries is likely to continue to produce
benefits for lower-income countries, even in the absence of
efforts to manage scientific research in the interest of lower-
income nations. Indeed, as lower-income countries increase in
income, their health problems will likely come to resemble
more closely the health problems of higher-income countries.
However, “trickle-down” approaches are not an efficient way of
producing knowledge to advance the health and well-being of
the populations of lower-income nations. Instead, a rational
approach is needed that appreciates both the value of health in
lower-income nations and the potential for rational scientific
management to efficiently allocate resources for scientific
research. The work of the GFHR and other organizations in
this regard is an important step in this direction. Moreover,
recent advances in understanding about the value of improve-
ments in health and in approaches to the value and priorities of
health research provide powerful theoretical tools to address
these issues.
Although the application of these principles is still in its
infancy, these tools provide a valuable framework for determin-
ing the value of health research relevant to low-income coun-
tries and for maximizing the value of research that aims to pro-
mote health in those countries. In the following section, recent
innovations in determining the value of health research at an
aggregate level are reviewed. The conclusion is that the value of
health research has been immense and is likely to increase dra-
matically in coming years, especially in lower-income countries.
In deriving these conclusions, not only health-oriented meas-
ures of improved health, such as life years, disability-adjusted
life years (DALYs), or quality-adjusted life years (QALYs), were
considered, but also how increases in income may increase the
value of such improvements. In a later section, recent methods
that can be used to estimate the value of specific research proj-
ects are reviewed. The application of such methods promises to
better identify the value of health research in specific instances,
which can enhance the case for research spending to improve
health in developing countries and can increase the efficiency
with which available research funds are spent.
THE VALUE OF HEALTH RESEARCH
Health research can be valuable for a variety of reasons. The
most obvious reason is simply the value that people place on
improvements in health. Those health improvements may be
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reflected in increased length of life or quality of life. Other rea-
sons that health research can be valuable include the improve-
ments in productivity, decreases in medical care costs, and
greater ability to plan for and invest in the future when health
improves. Health research can also sometimes decrease costs
independent of any effects on health—for example, when a
lower-cost treatment can replace a higher-cost treatment of
similar efficacy.
A large body of work has attempted to assess and quantify
the economic value of health from these perspectives. The goal
of some of this literature is a comprehensive assessment of the
cost of illness (for example, Rice 1994). Such comprehensive
assessments are often attempted in order to assess the cost-
effectiveness of medical or public health interventions, which
are frequently measured in terms of quality-adjusted life
expectancy (Gold and others 1996) or DALYs (WHO 1994;
World Bank 1993). Other aspects of this literature focus on
single dimensions of the economic value of health. For exam-
ple, Ram and Schultz (1979) performed an early analysis show-
ing the effects of malaria eradication on productivity. Similarly,
Meltzer (1992) attempted to identify the effects of mortality
on investment in education, the demographic transition, and
the onset of sustained economic growth. In that work, it was
suggested that health can increase income because increasing
life expectancy raises returns to investment in education, in
turn encouraging decreases in family size and further increases
in investment in the education of children and a transition to
sustained human capital–based economic growth. These and
other mechanisms, including shifts in the ratio of productive
adults to dependents and changes in savings rates with increas-
ing life expectancy, have been suggested to produce positive
effects of health on per capita income in both the short and the
long run (Bloom, Canning, and Jamison 2004).
Although some evidence suggests the importance of all
these effects, recent work on the value of health in developed
countries has focused primarily on the value that people place
on improvements in their health. Such studies for the United
States have suggested that increases in longevity over the past
several decades are valued in the tens of trillions of dollars,
indeed, contributing about as much to increasing welfare over
the period as increases in per capita income. Subsequently, sim-
ilar findings have been reported for other countries, and cross-
national studies have found that the value of growth in life
expectancy compared with the value of income growth has
been even greater for low-income countries (Becker, Philipson,
and Soares 2003). These studies have been influential in devel-
oping a broad consensus that the returns to health research are
large and in producing dramatic increases in the budget for the
National Institutes of Health (NIH) in the United States. The
conclusions of these studies in the United States have been
based on assessments of both the high value of health and the
role that health research has played in improvements in health.
Although both the connection of health research to health and
the valuation of health differ in important ways between lower-
income and higher-income countries, these studies provide a
useful framework for understanding the past and likely future
value of health research in lower-income countries.
The Value of Improved Health
Several authors have contributed to the literature on the value
of improvements in health: Becker, Philipson, and Soares
(2003); Cutler and others (1997); Murphy and Topel (2003);
and Nordhaus (2003). Although these studies differ somewhat
in the analytic framework they use, the basic form of their
analyses is quite similar. In essence, they all use estimates of the
value of longevity on the basis of revealed preference tech-
niques and multiply these values by the increases in longevity
that have been observed to determine the value of improve-
ments in health. Revealed preference estimates of the value of
life are most commonly derived by assessing the wage premium
required by workers to accept riskier jobs. This idea dates back
at least to the work of Adam Smith, but the modern treatment
of this issue stems primarily from the work of Thaler and
Rosen (1975). For example, if the lifetime earnings of a risky
mining job that has a 11,000 increased risk of death compared
with another mining job is US$1,000, then the statistical value
of a life would be said to be US$1,000,000, since paying 1,000
workers would result in one extra death on average and require
that the employer pay wages equal to 1,000 workers 
US$1,000/worker  US$1,000,000.
A simple example considering the value of increases in life
expectancy in the United States from 1970 to 2000 illustrates
well how these sorts of estimates have been used to estimate the
value of increased longevity. From 1970 to 2000, life expectancy
at birth for Americans grew by a little more than 5 years, from
about 75 years to about 80 years. With about 300 million
Americans living during this period, this increase constitutes
about 1.5 billion life years. Using a conservative revealed pref-
erence estimate of about US$4 million as the statistical value of
a life (Viscusi and Aldy 2003), assuming a life expectancy of 75
to 80 years, and assuming discounting is somewhere between 0
and 3 percent annually, one gets a value of about US$50,000 to
US$100,000 per life year saved. Multiplying this gain in life
years and the estimate of the value of a life year, one gets a value
of increased longevity over this period of about US$75 trillion
to US$150 trillion, or about US$2 trillion to US$4 trillion per
year. The average of these numbers translates into almost
US$10,000 per person per year, which is about as large as the
increase in per capita income in the United States during this
period. In essence, this analysis is a simplified form of that per-
formed by Murphy and Topel (2003).
An alternative approach to obtaining a similar number may
help some readers better understand the intuition behind these
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effects. Over this 30-year period, the 5-year increase in life
expectancy that occurred raised life expectancy by about two
months (or one-sixth year) per year. With each life year valued
at about US$75,000, these gains in life years are readily seen to
be worth about US$10,000 per person per year.
Understanding the value of improvements in health in
lower-income countries requires data both on increase in
longevity and on how such increases in longevity might be val-
ued. Data on increases in longevity are relatively easy to obtain
for most countries and vary substantially across countries over
time. For example, many countries that had low income in
1950, including the Arab Republic of Egypt, Mexico, and
Thailand, have had an increase in life expectancy since 1950 of
more than 20 years, or about three months per year, which is
about 50 percent greater than the rate of growth in life
expectancy in the United States. Although some countries that
had low incomes in 1950 and did not experience much eco-
nomic growth during this period did not increase in life
expectancy over this period, the vast majority of countries with
low incomes in 1950 experienced increases in life expectancy
far exceeding the rate of increase in the United States and other
developed countries. This fact suggests that the potential for
increases in life expectancy is greater for lower-income coun-
tries than for higher-income ones, so the increase in life
expectancy for lower-income countries might be expected to
slow in coming years. If the rate of change in the value of health
gains were determined primarily by the rate of increase in life
expectancy, growth in the value of health in lower-income
countries would be expected to slow in the future.
Assessing the importance of changes in life expectancy
relative to changes in the value of increased life expectancy in
influencing the value of health requires data on the value of
increased longevity. Such data on the value of mortality reduc-
tions are limited but do exist. Viscusi and Aldy (2003) reviewed
the literature on the statistical value of life across countries that
vary in income. One key finding is that the statistical value of
life increases with income, with an elasticity of approximately
0.5 to 0.6, so that a 100 percent increase in income leads to a
50 to 60 percent increase in the statistical value of life.
One implication of this finding is that economic growth is
likely to result in increases in welfare through improved health,
both because economic growth improves health and because
the value of those health improvements increases as income
increases. This statement can be assessed formally by analyzing
change over time in the value of life (VL)  VLY  LY, where
VLY is the value of a life year, and LY is life expectancy. Such
numbers easily show the value of health gains that have been
achieved. For example, India is the poorest country for which
calculations of revealed preference estimates of the statistical
value of life have been done (Viscusi and Aldy 2003). This
study suggests a statistical value of life of US$0.6 million, or
about US$10,000 to US$20,000 per life year saved. With
gains in life expectancy of about 25 years since 1950 and a
population in 2000 of about 1 billion persons, the gains in life
expectancy in India alone over the period are worth about
US$400 trillion, or US$8 trillion per year, equivalent to about
US$800 per person per year.
Thus, as large as the US$75 trillion to US$150 trillion esti-
mate for the health gains for the United States is, such gains are
only about one-fourth as large as the gains for India. The value
of the gains for India is larger for several reasons. One is just the
longer period considered—30 years for the United States com-
pared with 50 for India—although, in fact, gains in the United
States were small enough between 1950 and 1970 that the
longer period explains relatively little of the difference. Much
larger factors are the fivefold greater increase in life expectancy
in India than in the United States over the period (25 years
compared with 5 years) and a population about five times as
large. Thus, if health gains are valued in U.S. dollars, the value
of such gains for India over this period far exceeds that for the
United States. Given the 5:1 size of India and the gains in life
expectancy, the ratio of those gains would be more like 25:1
than 4:1 (US$400 trillion as opposed to US$75 trillion to
US$150 trillion) were it not that the statistical value of life in
the United States is greater than that in India. Even if one does
not feel comfortable assigning differential valuation to lives
across countries, the fact that the valuation of gains in India is
so much larger than the valuation of the gains in the United
States using this method provides a powerful reminder of cer-
tain basics of the value of improving health in lower-income
versus higher-income countries: many more people live in low-
income than in high-income countries, and the potential for
large increases in life expectancy is thus far greater.
Such statistics provide some insights into the value of his-
torical improvements in health, but in terms of considering
future investments, considering what can be said about the
growth of the value of health in lower- versus higher-income
countries in the future is useful. To do so, one finds it useful to
decompose growth in the value of health into growth in life
expectancy and growth in the value of longevity (growth in
the value of life years). We begin with VL  VLY  LY and dif-
ferentiate to obtain the finding that growth rates can be
decomposed to find that gVL  gVLY  gLY , so that the growth in
the value of life is the sum of the growth in the value of a life
year and growth in life expectancy.
To understand the meaning of this relationship, one finds
it useful to consider the Viscusi and Aldy (2003) estimate of
the elasticity of the value of life with respect to income.
Substituting this elasticity income in the above equation,
gVL  0.5 gY  gLY, where gY is the growth rate in per capita
income. The relative magnitude of these two components is
instructive. In developed countries such as the United States,
where growth in life expectancy has been on the order of two
months per year from a base of 75 or so years, the growth in
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life expectancy is (212)75  0.2 percent per year. This rate is
substantially smaller than the component of increased value of
life related to growth in the valuation of gains in life, even with
long-run real growth rates of only 2 to 3 percent, so the com-
ponent attributable to growth in the value of life is 0.5  (2 to
3 percent)  1 to 2 percent per year. In lower-income countries
in which growth in life expectancy is greater and baseline life
expectancy is lower, life expectancy growth may be more
important but is still not likely to exceed the effects of growth
in per capita income. For example, Mali experienced dramatic
growth in life expectancy of 1 percent per year (from 30 to 45
years from 1950 to 1990), but growth in per capita income in
Mali from 1980 to 2000 was about 3 percent annually, translat-
ing into effects on the value of life of 1.5 percent annually.
More striking perhaps is China, where growth in life expec-
tancy from 40 to 70 years from 1950 to 1990 represented an
increase of about 2 percent per year, whereas growth in per
capita income (from 1980 to 2000) was about 8 percent per
year (translating into effects on the value of life of about 4 per-
cent per year). Two implications are immediately obvious:
• First, the growth in the overall value of health over the
period has been large—about 2 to 6 percent annually for
these initially low-income countries.
• Second, the major driver of the value of health over time has
not been an increase in health per se but, instead, increases
in income that produce increases in how health is valued.
This finding is likely to be even more true as life expectancy
increases so that continuing large increases in life expectancy
become more difficult to achieve.
As noted previously, estimates such as these of the statistical
value of life can understandably be criticized on the basis of
associating a greater value with saving lives of wealthier persons
than saving lives of poorer persons. Nevertheless, it is striking
to note that in India—the only relatively low-income country
for which data on the statistical value of life are available—the
total value of recent health gains far exceeds even the immense
gains in the United States. Data on the value of life for other
low-income countries would help reinforce this finding, but
the combination of the greater potential for large increases in
life expectancy and for greater growth in per capita income in
low-income countries in the future suggests that the total value
of health gains for such countries may far exceed those of
higher-income countries. Indeed, it bears emphasis that, in
attempting to value health in monetary terms rather than
merely health terms, such as life years or QALYs or DALYs, an
important new avenue is opened by which the value of health
research can increase over time even as gains in life expectancy
slow with increasing life expectancy, as they have in developed
countries. Despite the concern that economic approaches
undervalue the health of persons with lower incomes, such
valuations clearly suggest that the potential value of health
research for these countries is immense. That this discussion
has focused only on the value of mortality reductions and neg-
lected those of reductions in morbidity even further reinforces
the potential gains from health research.
Not only is the magnitude of the value of these improve-
ments in health immense in regard to how people value being
healthier, but the total value of health also includes increased
productivity, decreased medical care costs, and increased ability
to plan for and invest in the future when health improves.
Although these effects are often not easy to quantify, they may
prove to be important components of the total economic value
of improvements in health.
The Connection between Gains in Health 
and Health Research 
To move from the finding that gains in health are highly valued
to the finding that health research is highly valued, gains in
health must be connected to health research. Making such asso-
ciations is difficult even in high-income countries, but it has
been done with some success. For example, Cutler and Kadiyala
(2003) argue that the major recent gains in life expectancy in the
United States have come from reductions in cardiovascular dis-
ease, about two-thirds of which can be tied to advances that have
resulted from medical research as opposed to secular trends in
nonmedical factors that promote health, such as per capita
income and education. Similar calculations for lower-income
countries have not been done. Nevertheless, although growth in
income and education seem more likely to be important in pro-
ducing increases in life expectancy for such countries, the major
role of reductions in childhood infectious disease in recent gains
in life expectancy suggests the great value of the research that has
produced such innovations as childhood immunizations,
improved sanitation, and oral rehydration therapy. Similarly,
the high burden of cardiovascular disease in lower-income
countries will be expected to decline in the coming years if the
benefits of research can be applied in those settings.
Such conclusions speak to the value of health research as a
whole for lower-income countries, and they reflect the gains
that come both from research done initially to benefit higher-
income countries and from research done to benefit lower-
income countries. Although both of these classes of research
may produce benefits for lower-income countries, discussion
of their differences is in order. In the case of research done ini-
tially with the needs of high-income countries in mind, clearly
some types of research benefit low-income countries more
than others. For example, research that has demonstrated the
power of relatively inexpensive medications to reduce mortal-
ity from cardiovascular disease (for example, aspirin in acute
myocardial infarction) has much greater potential to produce
large benefits for lower-income countries in the foreseeable
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future than does research that advances techniques for expen-
sive acute treatments, such as cardiac catheterization. In this
particular case of cardiovascular disease, estimates summarized
by Cutler and Kadiyala (2003) suggest that higher-income
countries have also benefited more from research that
advanced such low-technology treatments than from research
on high-technology treatments.
Such patterns may not be maintained across other health
conditions, but they do hold out the tantalizing thought that
health research initiated by high-income countries in their own
interest may sometimes be directed toward work of greater
value if issues of cost and generalizability to lower-income set-
tings are reflected more greatly in decisions about research pri-
orities. When research directed toward the needs of lower-
income countries is considered, cost and feasibility must, of
course, receive great attention. However, the immense reduc-
tions in mortality that have come from advances in knowledge
about public health efforts—such as efficient and effective san-
itation, immunization, and oral rehydration programs, all of
which were developed primarily with the needs of low-income
countries in mind—suggest the value of research targeted
toward the needs of lower-income countries. Rigorous studies
of the value of these innovations akin to those studies done to
assess the value of health research for the United States are
sorely needed to inform potential funders of the potential
returns to such research.
METHODS OF ASSESSING THE VALUE OF HEALTH
RESEARCH PROJECTS
Although the aggregate value of health research has unques-
tionably been large, not all health research projects are suffi-
ciently valuable to justify their costs. Some of these latter
projects are inevitable because the outcome of research is intrin-
sically unpredictable. However, even if one abstracts from such
uncertainty by considering the expected returns from a project
before one embarks on it, research projects clearly vary in their
likely value relative to their cost. Such assessments are obvious-
ly difficult to make, yet they are routinely done as part of
the process of deciding the allocation of research funds. These
assessments have traditionally been done rather informally,
even in the most closely structured settings in which research
funding is sought, such as the NIH study sections in the United
States that review research proposals for NIH funding.
An active discussion over the past decade has helped to iden-
tify valuable strategies for priority setting in global health
research and determine their implications for research priori-
ties in the field. The 2004 report on health research of the GFHR
summarized the major contributions to this discussion (GFHR
2003). The approaches that are described date back to as early
as 1990 with the work of the Commission on Health Research
for Development. They include the essential national research
approach developed by the Council on Health Research for
Development and approaches developed by the Ad Hoc
Committee on Health Research, the Advisory Committee on
Health Research, and the GFHR’s own Global Forum combined
matrix approach. The 2004 report compares these approaches
along several dimensions that include the following:
1. Objective of priority setting
2. Focus at global or national level
3. Strategies or principles (especially relating to the process for
participation by stakeholders)
4. Criteria for priority setting:
• Burden of disease
• Analysis of determinants of disease burden
• Cost-effectiveness of interventions (resulting from
proposed research)
• Effect on equity and social justice
• Ethical, political, social, and cultural acceptability
• Probability of finding a solution
• Scientific quality of research proposed
• Feasibility (availability of human resources, funding,
facilities)
5. Contribution to capacity strengthening.
In addition to describing the dimensions considered in
these approaches to priority setting, the 2004 report also sum-
marizes several efforts to apply these approaches in individual
countries or for individual diseases or disease areas (see, for
example, Remme and others 2002). The priorities identified
include many of those identified in chapter 4 in this volume.
Examining these dimensions of priority setting, one finds
that some are intrinsically qualitative in nature but quantitative
analysis also sometimes plays an important role. For example,
several approaches, including the GFHR’s combined matrix
approach, use DALYs to quantify the number of healthy years
of life lost to the disease toward which the research is directed.
Looking forward, one may find additional quantitative
approaches helpful in assessing the value of research. For exam-
ple, new methods based on value-of-information (VOI) tech-
niques have begun to be proposed to better inform such assess-
ments. In essence, VOI techniques model the uncertainty in the
outcomes of research and the value of research contingent on
that uncertainty in order to assess the expected value of the
research. For example, a research project that has a 5 percent
chance of success that it would produce health gains worth
US$100 million and a 95 percent chance of failure, would have
an expected value of (0.05  US$100 million)  (0.95 
US$0)  US$5 million. Although these techniques have rich
roots in statistical and economic theory, they are often difficult
to apply well because of the difficulty in valuing health out-
comes and modeling the uncertain outcomes of research. As a
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result, these methods often can provide only loose bounds on
the value of a research project (Meltzer 2001). Indeed, in the
worst-case scenarios, in which the available information about
the likely outcomes of research is essentially uninformative,
VOI techniques only reproduce information on the burden and
costs of illness. Nevertheless, in settings where more structure
can be put into the problem, these techniques have begun to be
applied successfully to specific research questions, such as the
prioritization of research in Alzheimer’s disease (Claxton and
others 2001). In general, the more remote the connection of the
research to health outcomes, the harder it is to gain meaningful
information from a VOI approach. Thus VOI approaches are
far better at providing information on the value of applied
research than they are at providing information on the value of
basic research.
For lower-income countries, this ability to illustrate the
value of applied work may be especially valuable because often
a technology has already been developed and the question is
how best to apply it in a given setting. With the limited funds
that have traditionally been available for research in lower-
income countries and the high value that appears to be placed
on improvements in health in these countries, VOI studies, as
discussed previously, seem likely to frequently show that the
benefits of research in lower-income countries far exceed
the costs. It is hoped that such findings may be used to increase
the pool of funds available for research in these settings.
However, even if VOI techniques do not lead to increases in the
total funding available for research in low-income countries,
they may be helpful in informing resource allocation decisions,
given available resources. In the context of a fixed research
budget in which some research projects whose expected benefit
exceeds their costs could still not be funded, rigorous data on
the high rates of return on projects that did not make the fund-
ing line would then serve to highlight the returns to greater
research in these settings. Because VOI calculations need not be
complex (see box 7.1), the most important barriers to their
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Box 7.1
Although VOI calculations can be quite complex (for
example, Claxton and others 2001), they need not be. For
a researcher seeking funding, much simpler calculations
may be sufficient to build a compelling case for funding.
For example, quantifying the burden of illness in life years,
QALYs, or DALYs lost and converting this into a burden or
cost-of-illness measure in economic terms using an esti-
mate of the statistical value of life may even be sufficient.
To take a simple example, imagine a research program in
a country with a statistical value of life of US$0.6 million
(for example, the estimate for India) for a disease that cur-
rently kills 1,000 people per year. If one abstracts from
issues such as the age of death and how one might differ-
entially value deaths at different ages, this would have a
potential value of US$0.6 billion per year. If the research
study were viewed as having a 10 percent chance of pre-
venting 50 percent of those deaths, its expected value
would be P(success)  percent efficacy  statistical value
of life  0.1  0.5  US$0.6 billion  US$30 million per
year. Potential annual productivity gains produced by a
successful treatment and annual costs of the treatment
could be added to, or subtracted from, these US$0.6
billion annual benefits as well. One could go further, argu-
ing that the research would be valuable into the future,
and discount an infinite stream of those annual returns. At
a discount rate (R) of 10 percent, this stream would have
a value of US$20 million/R  US$200 million. This result
suggests that a research program costing up to this
amount would be worthwhile if it could be expected to
have this likelihood of success and percent efficacy. Even if
those probabilities could not be reliably estimated, mini-
mum values could be calculated at which the research pro-
gram would continue to be worthwhile.
As in their use in affluent countries, such calculations are
likely to suggest that health research is of great value, often
being predicted to return value many times its cost even
accounting for uncertainty. In the preceding example, for
instance, even an immense US$100 million research pro-
gram would have an expected return 20 times as large. Such
results would reflect the immense value in health research
but would also suggest caution: with limited research funds,
not all programs whose benefits exceed their costs should
be funded if more valuable projects remain unfunded. In
this area, funding agencies can be helpful to the research
community by highlighting how they have used calcula-
tions such as these and publicizing the ratio of research
costs to returns for those projects they have been able to
fund. Even when a project is not funded despite a favorable
ratio of expected returns to research costs, reporting the
missed opportunity will serve as a reminder to the world
community of the potential of health research for lower-
income countries that remains unrealized and thereby,
perhaps, promote greater investment in health research to
benefit the people of these countries.
useful application to research in developing countries are the
lack of awareness and acceptance of these methods on the part
of researchers and funders focused on these settings.
Organizations concerned with international health can exercise
valuable international leadership by exposing these researchers
and funders to these methods and encouraging their use.
CONCLUSIONS
Improvements in health in recent decades have been of great
value in both high- and low-income countries. Furthermore,
future improvements in health are likely to be highly valued as
the value of health increases with continuing growth in
income. Health research has played a major role in the
advances in health that have occurred, and the great potential
value of future gains in health suggests that health research
continues to merit increasing investment. New tools to
prospectively assess the value of research offer the promise of
even greater returns from health investment, especially for
more applied research that can be closely connected to meas-
urable benefits at the population level. Because low-income
countries may often particularly benefit from applied research,
these techniques to assess the value of research may be espe-
cially helpful in ensuring that the value of applied research in
these settings is recognized. Providing researchers and policy
makers in low- and high-income countries with the analytic
tools needed to better identify and advocate for valuable
opportunities for health research may be an important avenue
to increasing the level and effectiveness of spending for health
research.
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In the past 50 years, the world has experienced enormous and
unprecedented gains in the health of human populations.
Progress has been especially apparent in developing countries.
Average life expectancy has risen by more than 60 percent, from
40 years in 1950 to 65 years today. In 1950, roughly 28 percent
of children died before their fifth birthday, but by 1990, this
number had fallen to 10 percent. Furthermore, many of the
world’s most deadly and debilitating diseases, including lep-
rosy, measles, poliomyelitis (polio), and many childhood ill-
nesses, have been effectively contained in most areas and virtu-
ally eliminated in others. Smallpox, a highly contagious and
deadly disease that affected more than 50 million people a year
prior to 1950, has been completely eradicated.
Researchers have identified economic growth, rising
incomes, and better living conditions brought about by rapid
social and political transformations in many societies as major
contributors to these impressive health gains. However, in
recent years, the role of scientific and technological progress
has emerged as a crucial, but little understood, factor underly-
ing these gains. As Davis (1956, 306–7) observes,“It seems clear
that the great reduction of mortality in underdeveloped areas
since 1940 has been brought about mainly by the discovery of
new methods of disease treatment applicable at reasonable cost
[and] by the diffusion of these new methods.”
New research has sought to validate, and indeed quantify,
this basic intuition. For example, Jamison, Lau, and Wang
(2005) show that technological progress (which is broadly
defined as the generation or adoption of new technologies),
together with education, has been a far more important
contributor to declining infant mortality rates in developing
countries than income growth. Furthermore, improvements in
health brought about by investments in technological progress
generate an important and positive feedback loop favoring
economic growth and development in these countries.
An important question that follows is what can be done to
further consolidate these gains and ensure that the fruits of
scientific and technology progress are placed in the hands of
the people in developing countries who stand to benefit most?
Because the work of the Disease Control Priorities Project
(DCPP) focuses primarily on identifying the most cost-
effective interventions for diseases and conditions affecting the
health of populations in developing countries, this work pro-
vides the starting point for analysis. The goal is to isolate the
critical factors—in particular those “actionable” through spe-
cific public policies—that have contributed to the effective
deployment and scaling up of proven cost-effective technolo-
gies and services in low-income settings.
To address this question, the DCPP joined forces with the
What Works Working Group of the Global Health Policy
Research Network, an initiative led by the Center for Global
Development in Washington, D.C., and funded by the Bill &
Melinda Gates Foundation. DCPP authors were asked to iden-
tify outstanding examples of successful implementation of pro-
grams and projects geared toward the deployment of proven
cost-effective interventions in their respective fields of interna-
tional health and to speculate on what kinds of programmatic
aspects and broader public policy decisions might have con-
tributed to their success.
From an initial set of nominations, the What Works Working
Group selected a subset of cases that conformed to strict
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selection criteria, researched them thoroughly, and produced a
report to be widely disseminated to policy makers and leading
health experts in both developed and developing countries. In
parallel, the DCPP initiated a systematic review of the case mate-
rials to identify commonalities or factors that may have con-
tributed to the deployment and scaling up of those interven-
tions. The objective was to identify a set of specific policy levers
and programmatic decisions that could facilitate the transplan-
tation of those and other cost-effective interventions to new and
different settings. This chapter presents the results of that study.
RESEARCH METHODS
The study consisted of a qualitative analysis of a set of case
studies selected to help illustrate how proven, cost-effective
interventions have been successfully deployed and brought to
scale with dramatic results in low- and middle-income coun-
tries in Africa, Asia, and Latin America and the Caribbean. We
examined evidence culled from interviews, peer-reviewed arti-
cles published in journals, and official project evaluations and
attempted to organize this information in a way that would
allow us to reach tentative conclusions about the most signifi-
cant elements associated with the interventions’ success.
The study thus followed one of Mill’s (1843) five methods of
experimental reasoning: the method of agreement. Such a
method postulates that “if two or more instances of the phe-
nomenon (A) . . . have only one circumstance (B) in common,
the circumstance (B) in which alone all the instances agree is the
cause (or effect) of the given phenomenon (A).” For this study,
the phenomenon (A) is represented by success. Cases that qual-
ified as successes had to conform to the following five criteria:
• Scale. All cases selected for study involved a national,
regional, or global scale. Pilot projects or interventions
implemented on a subnational scale were not considered.
• Importance. Selected cases addressed a problem of major
public health significance that could be expressed, at the
program’s inception, in terms of disability-adjusted life
years, a composite measure of mortality and morbidity
caused by the disease.
• Health impact. Selected cases had documented evidence of
a clear and measurable effect on the health of the popula-
tion targeted by the intervention. Process indicators, includ-
ing immunization coverage rates, were not considered an
acceptable substitute for health impact data.
• Duration. All cases selected for study had a life span of at
least five consecutive years.
• Cost-effectiveness. Selected cases relied on interventions
that had been proven to be cost-effective at a threshold
of approximately US$100 per disability-adjusted life year
saved.
The unabashed focus on success meant that the study
ignored potentially important information about factors that
may be associated with programmatic failures or not-so-
successful cases that did not meet the strict criteria described
above. However, the inclusion of less-than-successful cases was
not an option in light of time, resource constraints, and paucity
of available documentation. Thus, a significant limitation of
our study results from the lack of variance in the outcome
observed. This type of selection bias is a common problem that
may result from the nonrandom selection of cases in qualita-
tive research.
Although bias cannot be eliminated without expanding the
study to include unsuccessful examples, working skillfully with
the presumption of bias to increase the level of confidence in
the findings is possible. First, counterfactual examples, even if
purely speculative (what would have happened if . . . ?), can be
used to further substantiate the hypothesis that circumstance
(B) has directly contributed to the observed phenomenon (A).
Second, theorizing in a constructive way about what the direc-
tion of the bias might be and, therefore, minimizing its impact
on the results of the study are also possible. For example, any
potential bias more than likely results from overdetermining
causality rather than overlooking or ignoring key factors
related to success. In a related point, the study design makes
discerning the relative contributions of the various factors dif-
ficult, because weights cannot be assigned easily.
Remarkably few rigorous studies of this sort attempt to
track the implementation of proven, cost-effective interven-
tions in the field. Although we have a good understanding of
the efficacy of the available arsenal of interventions for treating
and preventing diseases specific to low-income countries, we
often know little about the range of programmatic and policy
options that are needed to support these interventions in the
real world. This study represents the first major contribution
toward the development of a body of knowledge in that area,
and the preliminary conclusions reached should be understood
in that context (Collier and Brady 2004).
CASES
From an initial set of nominations received from DCPP
authors as well as from other international health researchers,
we selected a subset of 17 cases for study. We could not consider
many cases that were nominated because of the absence 
of reliable data. Thus, the 17 cases selected are merely a subset
of the many successes in international health that have been
achieved during the past 50 years, not the full universe.
Nonetheless, the cases draw from all three continents of the
developing world—Africa, Asia, and Latin America and the
Caribbean—and involve both communicable and noncommu-
nicable diseases as well as curative and preventive care. Most
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cases are national-level programs, but a few involve regional
initiatives, and one is global.
Many near misses did not make the cut. The reasons for
this exclusion varied. For example, a program in Costa Rica,
El Salvador, and Guatemala to promote hand washing appears
to have resulted in a dramatic decline in child morbidity
and mortality but did not meet the duration criterion because
it was fully operational for only three years (1996–99). In
another example, the evidence of a health impact was mixed:
a successful schistosomiasis control program in the Arab
Republic of Egypt that included treatment of blood flukes in
infected individuals was later linked to high prevalence rates of
hepatitis C caused by the use of improperly sterilized syringes
(Frank and others 2000). Nonetheless, the most common
rationale for excluding a case from this study had to do with a
lack of consistent documentation and of analysis of the health
impact of the program in question. Thus, a reasonable conclu-
sion is that the true universe of cases is much larger than the
subset of cases we examined.
Each case reviewed here illustrates how a discrete health
intervention or combination of interventions was successfully
brought to scale in a specific context. To gain insight into this
process, we can distinguish between the intervention—for
example, the tool or technology that has been proven to be cost-
effective for the treatment or prevention of a given disease—
and the programmatic characteristics and policies that
contributed to the successful delivery or deployment of the
intervention through specially designed programs or projects.
The following list of cases selected for review describes the
programs or projects that were scaled up, identifies the specific
intervention or interventions deployed, and summarizes the
existing evidence about health outcomes and impact:1
• Chagas disease control. In 1991, seven countries—
Argentina, Bolivia, Brazil, Chile, Paraguay, Uruguay, and
later Peru—joined forces as part of an initiative for the
Southern Cone countries led by the Pan American Health
Organization to combat Chagas disease through a combina-
tion of surveillance activities, house-to-house spraying, and
other vector control methods. Health impact—Disease inci-
dence had fallen by 94 percent by 2000. By 2001, disease
transmission had been halted in Chile, Uruguay, and large
parts of Brazil and Paraguay. The project is ongoing.
• Diarrheal treatment. In Egypt, the government launched a
national program in the early 1980s to promote the use by
mothers of locally manufactured oral rehydration salts in a
four-part strategy that included tailoring product design
and branding to accommodate local preferences and cus-
toms; strengthening production and distribution channels,
both public and private; training health workers; and using
social marketing and a mass media campaign. Health
impact—Between 1982 and 1987, infant and child mortality
dropped by 36 and 43 percent, respectively. Mortality attrib-
uted to diarrhea fell 82 percent among infants and 62 per-
cent among children. The project closed in 1991.
• Guinea worm eradication. Twenty countries in Asia and
Sub-Saharan Africa began a global campaign to eradicate
guinea worm in the mid 1980s. Led by the Carter Center,
the United Nations Children’s Fund, the U.S. Centers for
Disease Control and Prevention, and the World Health
Organization, the campaign promoted improved water
safety through deep-well digging, environmental control,
and the use of cloth filters for drinking water; health educa-
tion programs; and case management, containment, and
surveillance. Health impact—By 1998, 9 million to 13 mil-
lion cases of guinea worm had been prevented and global
prevalence had dropped by 99 percent. The project is ongo-
ing in three countries.
• Family planning. In Bangladesh, family planning has been
promoted since the 1970s through a door-to-door outreach
program conducted by young, married women who provide
information about limiting family size or spacing pregnan-
cies along with products. An extensive media campaign
accompanied the outreach program. Health impact—
Contraceptive use among married women in Bangladesh is
approximately 50 percent today, compared with only 8 per-
cent in the mid 1970s, and the average number of children
per family is 3.3, down from 7 in the mid 1970s. The project
is ongoing.
• Hib vaccination. Chile began to include the Hib vaccine as
part of its national immunization program in 1996. In The
Gambia, a similar initiative was introduced in 1997. Health
impact—In Chile, the prevalence of Hib disease fell by
90 percent, and the incidence of pneumonia and other
Hib-related illnesses fell by 80 percent. In The Gambia, the
number of children developing Hib meningitis fell from
200 per 100,000 to 21 per 100,000 only 12 months following
the introduction of the vaccine. The projects are ongoing in
both countries.
• HIV/AIDS prevention. Thailand launched the 100 Percent
Condom Program in 1991 to address the rising incidence
of HIV/AIDS in the country. The program provided boxes
of condoms to brothels free of charge, mandated the use of
condoms by sex workers, and threatened brothels with
penalties and closure for noncompliance. Health impact—
By 1992, condom use in brothels had risen to more than
90 percent, up from 14 percent in 1989. The number of cases
of new sexually transmitted infections fell from 200,000 in
1989 to 15,000 in 2001, and an estimated 200,000 new infec-
tions were averted between 1993 and 2000. The project is
ongoing.
• Health improvement of the poor using financial incen-
tives. In 1997, the Mexican government launched a new
social welfare program designed to help lift rural families
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out of poverty by providing cash payments in exchange for
their participation in nutrition and supplementation pro-
grams, their use of prevention and basic health care servic-
es, and their children’s school attendance. Health impact—
After five years, the children of participating families were
12 percent less likely to experience illness than those of non-
participating families, and their nutritional status had
improved. Adult health indicators also improved. The proj-
ect is ongoing.
• Maternal health. The Sri Lankan government relied on pro-
fessional midwives and sustained investments in the coun-
try’s health care system, including in rural areas, to improve
maternal health. Health impact—The maternal mortality
ratio fell from approximately 500 per 100,000 live births in
1950 to 60 per 100,000 in 2003. The project is ongoing.
• Measles elimination. In 1996, the seven southern African
countries agreed to a coordinated immunization strategy,
supported by improved surveillance and laboratory capacity,
to eliminate measles by including the vaccine as part of rou-
tine immunization for all nine-month-old babies and
organizing nationwide catch-up and follow-up campaigns
for children age nine months to 14 years. Health impact—
The number of measles cases reported annually in the
region fell from 60,000 in 1996 to 117 in 2000. The number
of deaths attributed to measles fell from 166 to 0 during the
same period. The project is ongoing.
• Onchocerciasis control. The discovery of ivermectin
(Mectizan) in 1978 and Merck’s decision to provide it free of
charge to anyone who needed it allowed early successes
based on weekly aerial spraying in 11 West African countries
to be further consolidated and later expanded to the other
19 endemic countries in Central and East Africa. Health
impact—In West Africa, disease transmission has been vir-
tually halted, and 1.5 million previously infected people are
now symptom free. In Central and East Africa, the program
has helped prevent an estimated 40,000 cases of blindness
each year. The Onchocerciasis Control Program (OCP)
ended in 2002. The African Programme for Onchocerciasis
Control is ongoing.
• Polio elimination. In 1985, the Pan American Health
Organization launched a campaign to eradicate polio from
the Americas. National vaccine days were held twice a year
and were targeted at children under the age of five, regard-
less of their immunization status, to increase coverage in
countries with weak routine immunization programs. An
extensive surveillance system and mop-up campaigns to
address outbreaks were crucial during the campaign’s final
stages. Health impact—The last case of polio in the
Americas was reported in 1991.
• Salt fluoridation. In Jamaica, a formal agreement between
the Ministry of Health and the country’s only salt producer
introduced fluoridation to salt in 1987 to prevent caries.
Health impact—By 1995, the severity of caries in children
between the ages of 6 and 12 had fallen by more than 80 per-
cent. The project is ongoing.
• Salt iodination. China launched the National Iodine
Deficiency Disorders Elimination Program in 1993. The gov-
ernment requires producers to iodize salt and has stepped
up its monitoring and enforcement capacity to ensure com-
pliance. Health impact—Total goiter rates among children
between the ages of 8 and 10 years fell from 20.4 percent in
1995 to 8.8 percent in 1999. The project is ongoing.
• Smallpox eradication. The campaign to eradicate small-
pox, led by the World Health Organization and heavily
financed by the United States, was launched in the mid 1960s.
Strong leadership, dedication, and commitment on the part
of the international community and the timely discovery of
simple, new technologies—for example, the bifurcated nee-
dle and the “ring” strategy of surveillance and contain-
ment—characterized the effort. Health impact—The World
Health Assembly declared smallpox eradicated in May 1980.
• Tobacco control. Poland passed groundbreaking legisla-
tion in 1995 imposing strong warning labels on cigarette
packages, banning smoking from enclosed workplaces, and
prohibiting tobacco sales to minors. South Africa passed
similar legislation in 1999 to strengthen a previously
imposed tax of 50 percent on the retail price of cigarettes.
Health impact—Cigarette consumption dropped 10 percent
between 1990 and 1998, resulting in a 30 percent decline in
lung cancer among men age 20 to 44, a nearly 7 percent
decline in cardiovascular disease, and a decline in the num-
ber of babies with low birthweight. South Africa witnessed a
30 percent decline in cigarette consumption in the 1990s,
especially among youths and the poor. The projects are
ongoing in both countries.
• Trachoma control. The Moroccan National Blindness
Control Program, launched in 1991, promoted the use of
“SAFE” interventions (surgery, antibiotics to control the
infection, facial cleanliness, and environmental improve-
ments), with the goal of eliminating trachoma by 2005.
Health impact—Overall prevalence rates have fallen by
75 percent since 1999, and the prevalence of active disease in
children under the age of 10 has seen a 90 percent reduction
since 1997. The project is ongoing.
• Tuberculosis control. In 1991, China launched a 10-year
program in 13 of its 31 mainland provinces to apply the
directly observed therapy short course (DOTS) strategy to
turberculosis (TB) control. Peru, previously one of 23 high-
burden countries that collectively account for 80 percent of
the world’s new TB cases each year, launched a similar effort
the same year. Health impact—Within two years, China had
achieved a 95 percent cure rate for new cases and a cure rate
of 90 percent for those patients who had previously com-
pleted treatment unsuccessfully. The number of people with
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TB declined by more than 37 percent between 1999 and
2000. The project ended in 2001, but important elements
have been incorporated in the 10-year National Plan for the
Prevention and Control of TB (2001–10). In Peru, disease
incidence declined each year by 6 percent. The program
achieved a case detection rate of 70 percent and an 85 per-
cent cure rate. The project is ongoing.
GENERAL FINDINGS
Taken as a whole, the cases support four general findings. The
first two have special relevance because they serve to discon-
firm aspects of the prevailing wisdom about aid effectiveness—
or at least present a serious challenge to such wisdom.
First, these cases demonstrate that a wide range of proven,
cost-effective interventions exists that can and have been
brought to scale in developing countries, even in extremely
low-income settings with limited health infrastructure and in
challenging macropolicy environments. In West Africa, aerial
spraying of the blackflies’ breeding sites, part of the strategy
promoted by the OCP throughout the 1980s, “continued
unabated through wars between member countries and coups
that grounded all other aircraft” (Eckholm 1989, 20). In Sudan,
despite the difficulties created by the more than 20-year civil
war, and in other areas of Sub-Saharan Africa, the campaign
to eradicate the guinea worm has made progress. The finding
is significant in that it challenges a central tenet of the aid-
effectiveness literature: that only countries with a “good” policy
environment can benefit from external financial assistance
(Devarajan, Dollar, and Holmgren 2001).
The aid-effectiveness literature has tended to focus on a
different set of outcomes—for example, macroeconomic and
structural reform—rather than on health outcomes, and this
focus may partly explain the contradictory conclusions; how-
ever, an examination of whether such a conclusion is true goes
well beyond the scope of this study. In any event, the cases
reviewed for this study displayed a striking degree of variation
in the political and economic contexts in which interventions
were applied and brought to scale, and no clear pattern of
association was apparent between this variation and successful
outcomes in relation to health.
Second, the cases provided new evidence of the importance
of the public sector to achieving successful health outcomes.
This finding was a surprise, especially considering the strength
of recent evidence documenting “weak links in the chain
between government spending for services to improve health
and actual improvements in health status” (Filmer, Hammer,
and Pritchett 2000, 199). The specific roles that the public sec-
tor played in achieving these outcomes varied tremendously.
In some instances, such as promoting maternal health in Sri
Lanka and controlling TB in China and Peru, governments
were involved in direct service provision. In other instances, the
public sector’s regulatory or legislative authority was critical.
Governments in Poland and South Africa passed strict laws,
despite strong opposition from the tobacco industry, requiring
explicit health warnings on cigarette packs, banning smoking
in enclosed public places, and prohibiting tobacco media
advertisements, among other things. Governments also used
their authority creatively to encourage health-promoting
behaviors and to discourage risky ones. In Mexico, the govern-
ment provided direct cash payments to poor families in
exchange for visits to health care clinics and school attendance.
In Thailand, local police worked in collaboration with health
officials to lend credibility to the government’s threat to shut
down brothels that failed to comply with the no condom, no
sex policy, giving teeth to the national campaign.
Third, the cases reviewed for this study share a number of
common features or attributes that appear to have contributed
to the successful outcomes. Without exception, they enjoyed
and managed to reap the benefits of strong leadership, effective
management, realistic financing arrangements, country owner-
ship, and openness and receptivity to learning by doing, con-
stantly improving on strategies and processes by incorporating
new research findings and technical innovation into program
improvements.
For example, successful projects appeared to benefit from a
strong champion who could provide the necessary leadership
to bring relevant stakeholders together, encourage them to
focus and coordinate their activities, and instill in them a sense
of purpose and enthusiasm for their work. However, we did
find that leadership came packaged in many different shapes
and sizes. In Jamaica, the curiosity and persistence of a Ministry
of Health dentist led to the identification of the island’s only
salt producer as the vehicle for fluoridation. In Mexico,
President Ernesto Zedillo Ponce de León seized on the innova-
tive proposal of a close adviser, Santiago Levy, then director-
general of social security, and launched a program linking
education, health, and nutrition as part of an integrated strategy
to lift rural families out of poverty, and the program was not
abandoned when Zedillo left office. The new Vicente Fox
administration, motivated by undeniable evidence of the pro-
gram’s effectiveness, instead sought to expand the program into
urban areas and added an educational component. In a less vis-
ible but nonetheless critical display of leadership and forward
thinking, the sustained investments of the Sri Lankan govern-
ment over a nearly 50-year period to build a rural health net-
work emphasizing critical elements of maternal health have led
to gains in the health of women unparalleled by countries at
similar, and higher, income levels.
Strong program management was needed to ensure that
plans, once conceived, were implemented effectively. Successful
cases had well-delineated goals that were clearly linked to
inputs, activities, outputs, and outcomes. This factor was espe-
cially evident in the case of global or regional immunization
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campaigns, given the many logistical challenges and the need
for fluid and effective coordination of many countries and
stakeholder groups, often within a highly constrained time
frame. However, similar management skills are needed for
health service delivery systems, especially when patient referral,
tracking, and follow-up are essential components of the inter-
vention. In China, incentive schemes to motivate physicians,
extensive training and supervision of health care staff, and
substantial investments in local TB dispensaries were all crucial
elements in improving management capacity for large-scale
rollout of the country’s DOTS program, which covered a pop-
ulation of 573 million in 1,208 counties in 13 provinces.
A closely related requirement was having a realistic financ-
ing strategy that was compatible with a project’s goals. Even
when large sums of money were involved, deployment of the
intervention yielded tremendous returns at a relatively low cost
per disability-adjusted life year. In the case of onchocerciasis
control, for which donors have invested US$560 million over a
period of 28 years, transmission has been virtually halted in 20
West African countries, and nearly 600,000 cases of blindness
have been averted at an annual cost of only US$1 per person.
In the case of guinea worm control, in which donors have
invested approximately US$88 million over a 12-year period,
disease prevalence has fallen by 99 percent, and only 35,000
people remain affected, down from 3.5 million, at a cost of
US$5 to US$8 per person.
Country ownership was another distinguishing feature of
successful programs. A government’s willingness to commit
scarce funding to scaling up an intervention can be an impor-
tant indication of this ownership, although not the sole predic-
tor. Despite the extremely constrained budgets of the seven
participating countries, the campaign to eliminate measles
in southern Africa was almost entirely funded by their min-
istries of health. The Thai government covered approximately
96 percent of the cost of the 100 Percent Condom Program. In
Morocco, the government bore the bulk of the costs for imple-
menting the SAFE strategy to address blindness caused by tra-
choma, with contributions from the United Nations Children’s
Fund and the International Trachoma Initiative, an interna-
tional public-private partnership.
Most of the cases we reviewed benefited from new research
findings and technical innovation. Successful cases appear to
display the openness and receptivity needed to make good use
of new knowledge and to support ongoing research when
appropriate or when gaps in knowledge prove to be a hin-
drance to progress. In Bangladesh, a program to treat child-
hood diarrhea trained mothers to make their own salt solution
when the authorities determined that mass production and
distribution of prepackaged oral rehydration salts was unreal-
istic. Control of Chagas disease in the Southern Cone of Latin
America required public health officials in each country to
devise and deploy environmental control strategies appropri-
ate to local conditions and vector behavior. Finally, adoption of
the ring vaccination strategy marked a crucial turning point
in the global campaign to eradicate smallpox, enabling rapid
containment of the disease in remote parts of the world with-
out vaccination of every child.
In sum, a small number of features appear to be common to
all the successful cases. A reasonable hypothesis suggested by
the evidence is that these five attributes represent the known set
of necessary, but not sufficient, conditions for successfully
implementing cost-effective health interventions in the devel-
oping world.
Fourth, despite the obvious limitations of case study meth-
ods in hypothesis testing and confirmation, the evidence from
the cases sheds important light on two important debates in
international health policy. First, the cases suggest that much
more is involved than what is currently understood about
whether weak policy environments can make good use of care-
fully selected, strategic investments in health. As the next sec-
tion indicates, different types of programmatic characteristics
and policies are needed for the deployment of different types
of interventions. How these characteristics interact with dif-
ferent policy environments—whether strong, weak, or in
between—deserves further scrutiny and exploration. Second,
evidence from the cases of successful government action
should call into question any premature and overly general
conclusions about public sector ineffectiveness in developing
countries. Even though such a small sample of cases is surely
insufficient to close the book on these important policy
debates, it should at least encourage further study and refine-
ment of the arguments.
INTERVENTION TYPE, PROGRAMMATIC
CHARACTERISTICS, AND POLICIES
Programmatic characteristics and policies associated with
successful outcomes appear to vary by intervention type.
The starting point for this discussion is the intervention, tech-
nology, or tool in question. What allows for the widespread
deployment of a proven, cost-effective intervention? What are
the steps for converting a proven, cost-effective intervention
into a fully fledged health program that has been successfully
brought to scale, preferably at the national level? Is it possible
to distinguish between the specific health intervention and the
programmatic characteristics and public policies associated
with its successful deployment?
The cases under review were grouped according to the
primary type of intervention deployed by the program or proj-
ect in question. The types of interventions varied in terms of
their emphasis on the delivery of standardized products to a
population (product-intensive interventions), the delivery of
clinical services (service-intensive interventions), a personal
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behavior change (behavioral change interventions), the control
of environmental hazards (environmental control interven-
tions), or some combination thereof.
Further scrutiny of subgroupings of cases revealed that
certain programmatic characteristics, delivery modalities, and
public policy instruments also appeared to vary by interven-
tion type. This finding appeared to substantiate the claim of
the first edition of this volume (Jamison 1993, 11) that “com-
monalities of logistics, policy instruments, and approach”
vary by intervention type and play a role in determining
whether the intervention or interventions will be deployed
successfully.
The typology presented here differs from the one elaborated
by World Development Report 2004: Making Services Work
for Poor People (World Bank 2004), in that the classification
depends on characteristics inherent to the intervention in
question. By contrast, World Development Report 2004 identi-
fies three classes of service delivery arrangements: individual-
oriented clinical services, population-oriented outreach
services, and community- and family-oriented services that
support self-care. The focus is on differences in the relationship
between provider and client and how these differences interact
with market and public sector dynamics.2 However, our focus
was on how characteristics of the interventions themselves give
rise to certain programmatic or policy imperatives that may
contribute, ultimately, to successful health outcomes.
This section presents the five intervention types and
explores the clusters of programmatic characteristics and poli-
cies that appear to support the successful deployment of each
intervention type, based on case study analysis.
Product-Intensive Interventions
These types of interventions (box 8.1) involve the simple trans-
fer of a standardized technology to an individual or to an entire
population. They can be targeted at either prevention or cure,
but the distinguishing feature is standardization. Unlike
service-intensive interventions, product-intensive interven-
tions need not be tailored to the unique health care needs of the
individual receiving treatment.
To the degree that product-intensive interventions place rel-
atively low technical demands on health care staff at the point
of delivery, they may be more easily deployed in low-resource
settings than other types of interventions. Compared with
service-intensive interventions, they are less transaction inten-
sive, requiring fewer interactions between providers and clients.
Also, compared with behavioral-change interventions, they are
less dependent on individual compliance, requiring simply that
individuals make themselves available for treatment. Product-
intensive interventions include mass drug administration
(chemotherapy), childhood immunizations, mineral fortifica-
tion, and nutritional supplementation. (These specific inter-
ventions are addressed in detail in chapters 20, 22, and 28.)
Product-intensive interventions are often, though not nec-
essarily, linked to vertical rather than horizontal delivery
modalities. According to Gonzalez (cited in Mills 1983, 1972),
the vertical approach “calls for the solution of a given health
problem through the application of specific measures through
single-purpose machinery.” By contrast, the horizontal
approach “seeks to tackle . . . health problems on a wide front
and on a long-term basis through the creation of a system of
permanent institutions commonly known as ‘general health
services.’” Where health systems are weak and poorly function-
ing, vertical programs—in particular, mass campaigns—can be
an effective means of rapidly providing coverage to a large pop-
ulation. However, the same approach could result in an unfor-
tunate duplication of effort in countries where the health care
system is already strong and functioning properly.
Mass Drug Administration. Of the product-intensive inter-
ventions, those that can be delivered in pill or capsule form in
standardized doses, often through what is referred to as mass
drug administration, are perhaps the least complex to deliver
and, as a result, may be the least costly. Onchocerciasis, also
known as river blindness, can be treated by a single dose of
ivermectin administered annually to infected individuals.
Lymphatic filariasis can be treated in much the same way using
a two-drug combination therapy of albendazole plus either
diethylcarbamazine or ivermectin administered annually in
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Oral polio vaccine
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single doses for four to six years (the estimated productive life
span of the adult-stage parasite).
The importance of product-intensive therapies can easily be
illustrated by reference to the case of onchocerciasis control in
most parts of Africa. Although aerial spraying, an environmen-
tal control intervention, had been used successfully to slow dis-
ease transmission in 11 West African countries, it was not a
viable option for 19 countries of East and Central Africa because
of geographical differences. However, Merck scientists’ discov-
ery of ivermectin in 1978 and the company’s generous commit-
ment to provide the drug free of charge to anyone who needed it
changed the parameters of what was possible. Seizing the oppor-
tunity, the African Programme for Onchocerciasis Control, an
international partnership led by the World Bank, the World
Health Organization, the United Nations Development
Programme, and the Food and Agriculture Organization of the
United Nations, was created in 1995 with the goal of eliminating
onchocerciasis as a disease of public health and socioeconomic
importance in East and Central Africa.
It quickly became apparent that the weak and sometimes
nonfunctioning health systems of many African countries were
not up to the task; thus, a new approach was tried that took
advantage of the fact that the success of the intervention no
longer depended on a clinic-based delivery system. Under the
supervision of national public health ministries and non-
governmental organizations, community volunteers received
training on organizing and managing the local ivermectin
campaigns. The community-directed approach of treatment
with ivermectin has been so successful that it has been consid-
ered as a possible model for delivering other types of treat-
ments to remote areas.
Immunizations. Product-intensive interventions may vary in
complexity, which has implications for their delivery or deploy-
ment. For vaccines, the need to maintain an effective cold chain
adds an additional layer of complexity to the delivery system.
Other pertinent factors are whether the intervention can be
delivered as a single shot or iteratively, whether it can be bun-
dled together with other products or must be delivered sepa-
rately, and whether the number of distribution points is few or
many. In many cases, the characteristics of the disease or con-
dition being addressed may affect the level of complexity.
For example, the overwhelming success of the global effort
to eradicate smallpox has been attributed, at least in part, to spe-
cific characteristics of the variola virus. Unlike other infectious
diseases, such as malaria or yellow fever, smallpox depends
solely on the human host and does not have an animal or insect
carrier. Unlike polio, smallpox does not produce silent or
asymptomatic infection, thereby facilitating diagnosis and sur-
veillance of the disease (Tucker 2001). Other notable differences
from other diseases have more to do with the vaccine than the
virus. Tucker (2001, 64) explains that “a freeze-dried smallpox
vaccine was available that was easy to manufacture, cost only
about a penny a dose, protected for several years with a single
inoculation, and was relatively stable in warm climates, reduc-
ing the need for refrigeration. Whereas most vaccines took
months to induce immunity, the smallpox vaccine acted with
remarkable speed, providing nearly total protection within ten
to twelve days.” This unique set of characteristics together
meant that a “surveillance-containment” approach could
replace mass vaccination entirely, in effect reducing the number
of distribution points required by the intervention, thereby
permitting major strides in the global eradication campaign.
The more complex the intervention, the more challenging—
and probably costly—it will likely be to implement.
Interventions that can be delivered in a single shot or that can
be easily incorporated into routine immunization (bundled)
are clearly the easiest to implement. As the case of Hib vaccina-
tion in Chile illustrates, delivering the intervention was rela-
tively straightforward after the government got past the hurdle
of evaluating its cost-effectiveness relative to other inter-
ventions. The government determined that the creation of a
combined diphtheria-tetanus-pertussis and Hib vaccine was
worthwhile and that the vaccine could be administered as part of
an already well-functioning system of routine immunization.
Some of the common complexities associated specifically
with immunizations range from the need for multiple inocula-
tions administered at regular intervals, to the need to maintain
a reliable cold chain, or to the need for the large population
coverage required to achieve “herd immunity”—whereby the
likelihood of person-to-person transmission is drastically
reduced, even among the unimmunized population. In view of
these potential complexities, polio elimination in the Americas
represents a remarkable achievement. The oral polio vaccine
must be administered in three properly spaced doses, and cov-
erage must be high to prevent “silent” epidemics. In the 1970s,
before the campaign was launched, polio caused an estimated
15,000 cases of paralysis and 1,750 deaths each year (Musgrove
1988). However, a carefully orchestrated campaign organized
around achieving and maintaining high coverage through
routine immunization and national vaccination days, the
prompt identification of new cases, and the aggressive control
of outbreaks led to the elimination of polio from the Americas
in 1991. The creation of the Inter-Agency Coordinating
Committee, made up of representatives from the Pan American
Health Organization, the United Nations Children’s Fund,
the U.S. Agency for International Development, the Inter-
American Development Bank, Rotary International, and the
Canadian Public Health Association, played a key role not only
in generating political and financial support, but also in help-
ing address the logistical and managerial challenges inherent
to the campaign. The Inter-Agency Coordinating Committee
model was so effective that it was quickly duplicated at the
country level.
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The technical and logistical challenges associated with
measles elimination in southern Africa were no less complex.
Measles is one of the most contagious of all human diseases. The
measles vaccine requires 90 percent coverage to achieve herd
immunity and to stop the spread of the virus. Furthermore, it
often requires two doses to be effective and must be adminis-
tered to infants no earlier than nine months of age, or about six
months later than other recommended vaccines. If given earlier,
the vaccine will fail to trigger an active immune response,
because infants are passively protected by their mothers’ anti-
bodies until that age. Thus, the vaccination interval falls outside
of what most routine immunizations require.
To overcome this challenge, the southern African countries
adopted a strategy known as catch up, keep up, and follow up.
In each country, beginning with the program’s launch in 1996,
the strategy involved organizing a national catch-up campaign
in which mobile teams vaccinated all children, regardless
of their vaccination status, between the approximate ages of
9 months and 14 years; sustained routine coverage; and ran at
least one follow-up campaign several years later. The countries
also strengthened their surveillance and laboratory capabilities
to investigate all suspected measles cases.
Mineral Fortification. A different type of product-intensive
intervention, mineral fortification, requires fewer points of
delivery and is far less labor intensive. However, potential chal-
lenges include the need for a different set of technical capacities
than is typical for health sector solutions; the possibility of a
need for significant initial investments to modify production
processes or manufacturing capabilities; and the involvement
of non–health sector entities, such as private industry.
Jamaica’s salt fluoridation program beautifully illustrates
the simplicity of a single delivery point for an intervention.
With the agreement of the island’s only salt producer, Alkali
Limited, in place, universal coverage was easy to achieve. All
that was needed was a complementary legal and regulatory
framework to oversee the process. In this case, the start-up
costs were small: only US$3,000 worth or so of new equipment
was needed, which the company was easily able to recoup with
a slight increase in the price of salt.
In China, salt fortification with iodine was more difficult,
involving a larger investment in the production process and a
greater number of potential delivery points. Because salt
production is licensed at the provincial level in China, imple-
menting the change involved working with several layers of
government bureaucracy; however, perhaps ironically, the sys-
tem of central control eased the challenge. During a four-year
period, 55 salt factories were upgraded and 112 iodination cen-
ters were established throughout the country to support the
initiative. The government also introduced changes in bulk and
retail packaging to help consumers more easily recognize
iodized salt. The basic plan achieved nearly 90 percent cover-
age, but the remaining challenge is to address the numerous
delivery points that function outside the national system, for
instance, in areas where people live near the sea and produce
their own salt.
Summary. In sum, product-intensive interventions can be
extraordinarily complex even though they involve fewer trans-
actions between providers and clients and lower technical
requirements at the point of delivery than other types of inter-
ventions, particularly service-intensive interventions. However,
the relative simplicity of deployment when the scientific and
technical issues of development and production have been
addressed may help explain why product-intensive interven-
tions are perceived to be easier to implement than other types
of interventions and why countries experiencing political and
economic instability might prefer them.
Service-Intensive Interventions
Service-intensive interventions (box 8.2) include the full range
of diagnostic and therapeutic health services usually provided
not only in the clinic setting, but also in the home or at school.
Unlike product-intensive interventions, service-intensive inter-
ventions cannot easily be standardized and may require
careful—and time-consuming—monitoring and reporting on
patients’ progress. Thus service-intensive interventions are
highly transaction intensive and typically place high technical
demands on the health staff at the point of delivery. Examples
range from primary care services, including essential obstetri-
cal care, to surgical procedures, to treatment of communicable
and noncommunicable diseases.
The complexity of service-intensive interventions may vary,
just as in the case of product-intensive interventions. The more
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standardized the treatment protocol, the easier it will be to
administer on a large scale. However, standardized or not, the
transaction-intensive character of this type of intervention
means that its successful deployment depends on the program’s
or project’s ability to overcome potential (and likely) con-
straints on human resources. A related concern is the overall
health system’s capacity to effectively manage competing
demands on these resources. In contrast to product-intensive
interventions, human capacity constraints for service-intensive
interventions are harder, but not impossible, to address
through community mobilization or the use of volunteers,
because of the need for specialized training. Chapter 71 inves-
tigates developing countries’ experiences with new types of
professionals in service delivery settings that have traditionally
relied on physicians.
Single-Shot Surgical Services. If the intervention is relatively
standardized, it can sometimes be deployed using a vertical
modality in a manner similar to the more standardized, single-
shot, product-intensive interventions. This was the case of the
surgical procedure used in Morocco as part of the broader
SAFE strategy to address trachoma. A relatively simple surgical
procedure, the bilamellar tarsal rotation procedure, can be used
to halt corneal damage to prevent the onset of blindness caused
by repeated trachoma infections. Morocco’s Ministry of Health
organized mobile surgical teams of doctors and nurses to carry
out the corrective surgery in small towns and communities
throughout the country. In just eight years, the teams carried
out more than 26,000 surgeries. The effort required the
involvement of 43 physicians and 119 nurses working in
34 clinics. However, despite the relatively standardized nature
of this kind of service-intensive intervention, human capacity
constraints may slow progress. Compared with product-
intensive interventions for which community volunteers can be
recruited to assist with distribution, service-intensive interven-
tions require a more specialized workforce. Even when nurses
and other health workers with lower-level skills can substitute
for more highly trained physicians, constraints on human
resource capacity may persist. Morocco faces a backlog of
about 15,000 cases, many of which are urgent.
Strengthened Outreach and Referral Systems. If the inter-
vention is not easily standardized, or if it is highly transaction
intensive, its successful deployment will also depend on well-
developed outreach and referral systems. Outreach systems are
needed to ensure that those requiring care will have access to
care, and referral systems are needed to route patients requir-
ing additional care toward specialized care and treatment facil-
ities. However, ensuring that such systems are in place for spe-
cific programs and projects is a major challenge in countries
where the health care system is already weak and under consid-
erable strain.
The cases we reviewed relied on a variety of strategies to
address this problem. Although the specific interventions var-
ied, the strategies ranged from traditional investments in pub-
lic sector provision to improve access, to supply-side incentives
to address quality concerns, to demand-side incentives to
strengthen the effective demand for health care services. For
example, in an effort to improve maternal health even in
remote areas, Sri Lanka adopted the traditional model of pub-
lic sector provision, but with a twist. Instead of a physician-
based solution, which would have been extremely costly,
Sri Lanka relied instead on professional midwives to provide
widespread access to maternal health care, building on a strong
health care system that provides free health care. Midwives
serve a population of 3,000 to 5,000 each and live locally. They
visit pregnant women in their homes, register them for care,
and encourage them to attend prenatal clinics (run by doctors).
Midwives receive 18 months of training and are backed up
by supervision and a well-functioning referral network.
Established procedures for service delivery and supervision,
along with frequent in-service training, help keep midwives
current and delivering high-quality services. Health clinics are
supported by a network of cottage hospitals (clinics having
doctors as well as nurses assigned to them), rural hospitals, and
maternity homes at the secondary level; tertiary provincial
hospitals with specialist services; teaching hospitals; and spe-
cialist maternity hospitals.
China faced a similar dilemma with regard to establishing
an effective system of outreach and referral to address a grow-
ing TB problem by scaling up DOTS. Although DOTS is
relatively standardized as far as service interventions go (see
chapter 16), the treatment protocol is highly transaction
intensive, and complicated cases may require specialized treat-
ment. DOTS is thus also highly dependent on well-developed
systems of outreach and referral for its success. However,
China faced a challenging situation because most village doc-
tors who were needed to conduct patient diagnosis, treatment,
and surveillance in rural areas were in private practice and
had little incentive to treat patients for whom drugs were now
provided free of charge. In response, the government created
a financial scheme to provide incentives for these doctors to
participate. For each patient enrolled in the treatment pro-
gram, village doctors received US$1. They received an
additional US$2 for each smear examination carried out in
the county TB dispensary during a two-month period and
another US$4 for each patient who completed treatment.
Simultaneously, the government made significant administra-
tive, managerial, and institutional investments. Tens of
thousands of staff from TB dispensaries were trained, and
supervisory systems were put into place. Furthermore, the
government set up a national TB project office and a TB con-
trol center to oversee and coordinate the various levels of
government involvement.
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Demand-Side Incentives. Demand-side incentives can be
designed to complement supply-side investments. Indeed, both
skeptics and supporters of governments’ ability to translate
public spending into effective service provision and positive
health outcomes encourage the use of demand-side incentives
as a means of quality control to improve routine care (Filmer,
Hammer, and Pritchett 2000). Economists consider demand-
side incentives to be valuable tools for stimulating weak
demand for services or for overcoming barriers to use that can
artificially dampen demand. This was how at least two of the
cases included in this study constructively used demand-side
incentives. However, in neither case was this use an either-or
proposition; that is, both demand-side and supply-side invest-
ments were relied on to generate the successful outcomes that
qualified the cases for this study.
In Peru, the newly revised National Tuberculosis Control
Program offered food packages, employment training, and
stipends to patients to improve compliance with the drug treat-
ment regime. Simultaneously, the program was dramatically
scaled up and the number of participating health centers rose
from 977 to 6,539 over the next decade. In the clinics, nurses
were the medical personnel responsible for administering
DOTS. In isolated rural areas, the program recruited local
leaders to serve under the direction of the nursing staff to
administer the treatment and follow up with patients.
Mexico’s Education, Health, and Nutrition Program (origi-
nally known as PROGRESA, but now called “Oportunidades”)
also provides a compelling example of how a program can use
demand-side incentives to stimulate demand for basic health
care services. The program offers cash transfers to families in
exchange for the attendance of mothers and children age five
and under at nutrition monitoring clinics and to pregnant
women if they agree to prenatal care visits and nutritional sup-
plementation. The program also includes cash transfers to pro-
mote school attendance and performance. A rigorous evalua-
tion provided evidence of the program’s effect on the use of
health services: after just one year of implementation, atten-
dance at health care clinics was significantly higher in partici-
pating localities. However, the increased demand for services
was also met with significant improvements in the quality of
services available through public providers. Health care
providers in participating localities were paid more and
received more on-the-job training, and clinics benefited from a
steadier flow of pharmaceutical and other supplies.
Summary. In sum, service-intensive interventions are highly
transaction intensive, especially compared with product-
intensive interventions. The more standardized the interven-
tion, the more likely that it can be delivered by means of
military-like campaigns in the same manner as product-
intensive interventions, although the skill level of the health
workers involved will need to be higher. If complications of
treatment are possible—or if the intervention cannot easily be
standardized—its deployment will likely require fairly elabo-
rate systems of outreach and referral. Although recent
scholarship has strongly encouraged the use of demand-side
mechanisms, particularly in an effort to address quality con-
cerns in public sector service provision, evidence from the cases
highlighted in this chapter suggests that a variety of modalities
are possible and that a mix of supply- and demand-side
incentives may even be desirable.
Behavioral Change Interventions
Behavioral change interventions (box 8.3) are designed to
induce or encourage an individual behavior change or habit
modification to achieve specific health goals. The focus is
usually on prevention, but need not be exclusively so—for
example, the use of oral rehydration therapy to treat childhood
diarrhea. Behavioral change interventions are often linked to
the uptake of a specific product, as in the case of condoms and
insecticide-treated bednets. However, unlike product-intensive
interventions, behavioral change interventions require active
participation by the individual and cannot be passively
received in the form of an injection or supplement. Also, unlike
service-intensive interventions, behavioral change interven-
tions do not depend on the involvement of a health care pro-
fessional on an ongoing basis. Illustrative examples include the
uptake of oral rehydration therapy for use by mothers in the
home, not the clinic; face washing to prevent trachoma; and
condoms to prevent HIV infection or other sexually transmit-
ted infections.
As Jamison (2002) notes, some changes in behavioral prac-
tices associated with improved health, such as improved
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hygiene and better nutrition, are linked to rising incomes, but
the pathway for this link is not entirely clear, especially at the
individual level, which makes it difficult to predict which mix
of programs and policies can be used to change behavior at the
population level. Information plays an important role, but the
evidence suggests that its effect may be limited if it is not com-
bined with other mechanisms to induce behavioral change.
The cases under review typically used a mix of strategies to
induce behavioral change, including information, education,
and communication (IEC) campaigns; regulatory policies;
taxation or subsidies; and financial incentives or disincentives.
The evidence is suggestive, but hardly conclusive, that a relative
hierarchy exists among the available strategies and policy
instruments and that some are more effective than others at
altering how individuals perceive risk and weigh the costs and
benefits of behavioral change. Chapter 11, for example, pro-
vides an in-depth discussion of how and when fiscal instru-
ments may be used effectively to alter producers’ and con-
sumers’ decisions in ways that encourage healthy behaviors.
Information, Education, and Communication. Recent stud-
ies have challenged the effectiveness of mass IEC campaigns
(Kremer and Miguel 2003), and evidence from the cases
appears to support a degree of healthy skepticism. However,
IEC campaigns did appear to have an effect in the cases under
review when they were accompanied by the promotion of a
new technology or a product. Also, acceptability appeared to
increase if the product was adapted to fit the local circum-
stances or cultural context. In Sub-Saharan Africa, educational
campaigns to stop transmission of the guinea worm to humans
have encouraged the construction and maintenance of safe
water sources (through deep-well digging and the application
of larvicide to contaminated ponds) and the use of cloth or
nylon filters to purify drinking water, in addition to case iden-
tification and containment. The primary IEC tool was so-called
worm weeks—that is, weeks of intensive health education and
community mobilization.
In Egypt, in addition to nurses and physicians, mothers were
a primary target of the campaign to promote the use of oral
rehydration salts for the treatment of diarrhea in children,
especially those under three years of age. Television was the
primary educational medium and proved to be an effective
strategy for reaching a broad population base, including rural,
illiterate households. Appropriate product design and branding
were essential. Oral rehydration salt packets were supplied in
a 200-milliliter size, not the standard 1-liter packs, because
mothers did not have appropriate containers at home and
felt that a full liter was too much to give to a child to drink.
By contrast, in Bangladesh, where few households had access
to a radio, much less a television, health workers went door
to door to teach mothers how to make the solution in their
homes.
In these cases, the targeted population not only was aware of
the health care problem, but also was eager to adopt solutions
to address it. Clearly this situation does not always prevail, but
a reasonable conclusion is that a relatively simple technology
that addresses a recognizable, but as yet unmet, need will find a
receptive audience. In Bangladesh, a mass media campaign to
encourage families to have fewer children was backed up by a
large cadre of female outreach workers, who went door to door
in rural areas to provide information to young married women
and to make family-planning commodities available to them.
Market research indicates that almost all Bangladeshi women
were in favor of family planning but were unable to go against
their husbands’ objections if they were opposed to the use of
contraceptives. The fact that the campaign and the provision of
contraceptive commodities addressed an unmet need among
Bangladeshi women may provide a partial explanation for the
rapid acceptance of the program when it was launched on a
large scale.
Regulatory Policies. By contrast, other behavioral changes,
such as using condoms to prevent HIV infection and other
sexually transmitted infections and stopping smoking, have
clearly been harder to induce, although the precise reasons for
this difficulty remain elusive (see, in particular, chapters 18 and
46). Nevertheless, evidence from the cases suggests that gov-
ernments can put the right mix of policies in place to either
discourage high-risk behaviors or encourage health-promoting
behaviors. For example, they may use regulatory policies to
ensure compliance through nonfinancial means and may com-
plement these by using fines and sanctions as an enforcement
mechanism.
The Thai government’s 100 Percent Condom Program is an
excellent example of such a strategy. In 1991, the National AIDS
Committee launched a national program to be implemented at
the provincial level requiring all workers in brothels and other
commercial sex establishments to refuse to have sex with any
client not using a condom. The program had several compo-
nents, including free distribution of condoms to health workers
during regular health checks and a media campaign to raise
awareness of the risks of HIV and the dangers associated with
unprotected sex. What gave the program its unique character
was its regulatory and enforcement component. Local govern-
ments, health authorities, and police officers were responsible
for monitoring and enforcing condom use in the brothels.
Those brothels that failed to comply with the strict policy
would be fined or forced to shut down. The results were impres-
sive. Condom use in brothels exceeded 90 percent in just the
first year of the program, up from 14 percent in 1989. The num-
ber of new HIV infections fell by more than 80 percent, from
142,819 cases in 1991 to 25,790 cases in 2001. Furthermore, the
program appears to have generated important spillover effects,
or externalities, in unexpected places. For example, studies
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indicate that indirect sex workers—a group that cannot be
reached through similar enforcement strategies—have also
begun to insist that their clients use condoms.
Taxation and Subsidies. Another option for discouraging
high-risk behaviors is the adoption of taxation policies. A 1997
study by the World Bank in partnership with the World Health
Organization found that a price increase of 10 percent on cig-
arettes would lower smoking rates by about 4 percent in high-
income countries and about 8 percent in low-income countries
(Jha and Chaloupka 2000, 358). In South Africa, a 50 percent
tax on the retail price of cigarettes contributed to a 30 percent
decrease in consumption. In Poland, an increase in taxes on
cigarettes from 30 to 47 percent of the retail price, in conjunc-
tion with other policies—including a ban on smoking in health
care establishments, schools, enclosed spaces in the workplace,
and elsewhere—contributed to a dramatic decline in smoking
rates. Before the fall of communism, Poland had the highest
cigarette consumption in the world, but by the end of the
1990s, there were 4 million fewer smokers compared with
the previous decade, and cigarette consumption had fallen by
10 percent. These successes led to a 30 percent decrease in lung
cancer among men age 20 to 44 and a 19 percent decrease
among men age 45 to 64 over the same period.
The section on service-intensive investments has already
discussed the remarkable power of explicit subsidies to encour-
age health-promoting behaviors. The Mexican case of PRO-
GRESA offers a by now familiar example of such a strategy.
Although none of the cases included in this study dealt with
subsidies explicitly directed at behavioral change interventions,
evidence suggests that they have a significant effect. However,
as Nugent and Knaul discuss in chapter 11, poorly targeted
subsidies can be costly, particularly relative to the result
achieved. Much more research is needed in this area to under-
stand the specific contexts in which subsidies can achieve their
desired effects and their cost-effectiveness relative to other
types of interventions.
Summary. In sum, behavioral change interventions differ
from both product-intensive and environmental control
interventions in that they require active participation by the
individual for the intervention to be fully effective. In some
cases, this requirement is also true for service-intensive inter-
ventions, but it is not as exclusively true as for behavioral
change interventions. The degree to which incentives (or disin-
centives) are needed to induce (or discourage) behavior
depends on the interaction between the usage characteristics of
the intervention, the perceived risk of not using the interven-
tion, and the perceived effectiveness of the intervention. To
have an effect, policy incentives (and disincentives) must either
succeed in changing the individual’s risk-benefit assessment or
make ignoring the policy extremely costly.
Environmental Control Interventions
As with behavioral change interventions, environmental con-
trol interventions are geared toward prevention and are used in
conjunction with other treatments or alone when effective vac-
cines or other prophylaxes are unavailable. However, rather
than focus on risk factors associated with individual behavior,
environmental control interventions target risks associated
with the physical environment that are largely beyond the
individual’s control. The physical environment refers to media
in the natural (water, air, or soil) or man-made (housing, roads)
environment. Examples of environmental control interventions
include many vector control strategies, such as aerial and
household spraying, water and sanitation projects, and air qual-
ity control measures. (See, in particular, chapters 41 and 43.)
Few of the cases reviewed for this study involved “pure”
environmental control interventions; although in several cases
environmental control measures were coupled with other types
of interventions. Whenever activities involved in executing
the intervention fall outside the realm of typical health care
services, nonhealth government agencies will be involved, and
strong political and technical leadership will be required of the
ministry of health to ensure that proper attention is given to
health care concerns during implementation.
Successful interventions in this category also appeared to be
associated with strong multicountry partnerships, particularly
in relation to vector control activities. This factor raises an
interesting question concerning governments’ capacity to
engage in these types of partnerships. Technical capacity,
although essential, is just the first hurdle, because what is ulti-
mately required is a political and financial commitment at the
highest levels in participating countries.
In the case of Chagas disease control, the Southern Cone
Initiative brought together the seven countries in the endemic
region under a coordinated, comprehensive, Chagas disease
control strategy. This multicountry approach was led by the
Pan American Health Organization, following the recognition
that disease transmission from neighboring countries was
threatening the health gains achieved under Brazil’s national
eradication plan. A central aim of the Southern Cone Initiative
was to eliminate the protozoan parasite, Trypanosoma cruzi, in
the region by coordinating technical efforts to detect and elim-
inate it. This coordination ensured consistent use of highly
effective control measures across the region and limited any
possibility of reinvasion. Infested homes throughout the region
were treated with long-lasting pyrethroid insecticides and
structurally improved to eliminate hiding places for the blood-
sucking insects that spread the parasite. These coordinated
environmental control efforts, combined with blood screening,
proved to be highly successful at interrupting Chagas disease
transmission in the region.
Environmental control interventions also appear to be char-
acterized by many consecutive years of sustained activity. In
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some cases, this activity may take the form of ongoing mainte-
nance of filters and distribution systems to prevent recontami-
nation. In other cases, as in the case of vectorborne disease con-
trol in which elimination or eradication is within reach, the
intervention must be sustained at least until transmission has
been interrupted in humans. (The intervention may need to be
sustained for much longer, or indefinitely, if the disease has an
animal host.) In the case of onchocerciasis, the lifetime of the
filarial load is 14 years, and vector spraying would need to be
sustained for at least 14 years to cut transmission. If reinvasions
or native vector population growth are allowed to take hold
before the human loads die off, transmission will occur and the
disease will not be effectively controlled. The OCP in West
Africa has demonstrated the effectiveness of a long-term com-
mitment to vector control in reducing the burden of onchocer-
ciasis. Since its inception in 1974, the OCP has used aerial
spraying of blackfly breeding sites to control vector popula-
tions and interrupt transmission. The original OCP area
remains free of onchocerciasis transmission following the
withdrawal of regular spraying after 14 years. This sustained
attention proved to be highly successful in eliminating
onchocerciasis transmission and infection. Even after the intro-
duction of ivermectin drug therapy to the program, vector con-
trol has remained a key strategy for maintaining health benefits
in the expansion area of the OCP.
In sum, environmental control interventions are associated
with intersectoral collaboration, multicountry partnerships,
sustained activity, and attentiveness to context (for example,
epidemiological conditions, patterns of disease transmission,
and vector behavior). These factors place special capacity
requirements on governments that may differ markedly from
nonenvironmental interventions. Thus, to be effective,
ministries of health must be capable of advocacy and influence
within the broader structures of government.
Combination or Bundled Interventions
A two-front battle involving both prevention and treatment
must be waged against most diseases and conditions to achieve
the desired effect on morbidity and mortality. Under such cir-
cumstances, a combination or bundling of interventions is
needed, adding an additional layer of complexity to the deploy-
ment of any particular intervention. An effective malaria con-
trol strategy, for example, demands effective distribution and
uptake of insecticide-treated bednets (a behavioral change
intervention) and rapid treatment of malaria symptoms
through strong outreach and referral systems (a service-
intensive intervention). Similarly, countries have adopted a
dual approach to controlling the spread of HIV/AIDS: promot-
ing safe sex practices (a behavioral control intervention) and
supporting the scale-up of antiretroviral therapy (a service-
intensive intervention). In this context, global partnerships
have a critical role to play in providing technical assistance to
countries in formulating policies and developing strategic plans
that are tailored toward their specific needs and capabilities.
Perhaps the most successful example of bundling interven-
tions included in our study is the Moroccan National Blindness
Control Program, launched in 1991. The program was based
on the development in the mid 1980s of SAFE, a comprehen-
sive strategy to treat and prevent trachoma. The philosophy of
the new strategy, which was heavily researched and promoted
under the support and guidance of the Edna McConnell Clark
Foundation, was to augment the traditional medical approach
to the treatment of trachoma with behavioral and environ-
mental changes. The four main interventions the strategy rec-
ommended were surgery (service-intensive intervention);
antibiotics (product-intensive intervention); face washing
(behavioral change intervention); and environmental activities,
including water and sanitation programs (environmental con-
trol intervention).
The program consisted of a wide-ranging partnership that
included five government divisions: the Ministry of Health, the
Ministry of National Education, the Ministry of Employment,
the Ministry of Equipment, and the National Office for Potable
Water. Targets were set—Morocco’s political leaders were com-
mitted to eliminating trachoma by 2005—and the institutional
and policy artillery to support the initiative was quickly put in
place. Mobile surgical teams were deployed to small towns and
villages to perform a simple, quick, and inexpensive procedure
of the eyelid to halt corneal damage in infected patients; treat-
ment campaigns were organized to distribute the newly discov-
ered antibiotic, azithromycin, that could be administered in a
single dose; IEC campaigns were launched at the community
level with the participation of the Ministry of Education to
educate the population about the causes of the disease and how
to prevent it; and the National Office for Potable Water has
expanded water and sanitation projects in many areas of the
country. By 1999, prevalence levels had dropped 75 percent,
from 28 to 6.5 percent, and acute infections in children had
been reduced significantly.
CONCLUSION
The accumulation of evidence presented in this study should
help allay any remaining doubts about whether existing tech-
nologies and interventions, proven to be cost-effective in
randomized controlled trials, can be successfully deployed to
improve the lives and health of people throughout the devel-
oping world. The evidence suggests not only that it is possible,
but also that it has been achieved in many parts of the world, in
many different socioeconomic and political settings.
The study also found important commonalities among
programs and projects that appear to have contributed to the
successful deployment and rapid scale-up of cost-effective
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interventions. Strong leadership, effective management, realis-
tic financing, country ownership, and application of new
research findings and technical innovation all played a role in
implementation and appeared to have made major contribu-
tions to the positive achievements of the cases under review.
In some respects, the study also presents a sobering view of
the difficulties inherent in moving from a cost-effective inter-
vention to a successful program or project. No single formula
is available, and identification of unique characteristics and
attributes that will permit the large-scale, effective deployment
of many known interventions is difficult.
In addition, evidence from the case studies suggests that the
programmatic characteristics and policies associated with suc-
cessful outcomes vary depending on the type of intervention.
Although no single formula exists, the implementation of the
programs and projects structured around various types of inter-
ventions appears to depend on certain types of organizational,
managerial, and financial capacities that can be anticipated and
specifically targeted for strengthening before the full-scale
launch of a program or project. Thus, the findings of this study
may serve as pointers for future research seeking to understand
the range of government capacities that are needed to support
the successful deployment and scaling up of interventions in
various contexts and in different parts of the world.
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NOTES
1. Unless otherwise indicated, the background information and health
impact data presented about the 17 cases reviewed for this study are drawn
from Levine and What Works Working Group (2004). All materials are
available at www.cgdev.org/publication/millionssaved.
2. According to World Development Report 2004 (World Bank 2004),
because the relationship between provider and client differs, each of the
three types of service arrangements will experience a different con-
stellation of market, government, and accountability failures. The report
proposes that if these failures are properly addressed and client power
increases, the quality of service delivery will improve, especially among
poorer groups.
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The scale of the diseases and conditions that the Millennium
Development Goals (MDGs) address is staggering:
• Almost 11 million children died before their fifth birthday
in 2000 (UNICEF 2001). Less than 1 percent of these 11 mil-
lion deaths (79,000) occurred in high-income countries,
compared with 42 percent in Sub-Saharan Africa, 35 percent
in South Asia, and 13 percent in East Asia.
• In 1998, an estimated 843 million people were considered
undernourished on the basis of their food intake (FAO
2000). Of the estimated 140 million children under the age
of five who were underweight, almost half (65 million) were
in South Asia.
• Of the 3.1 million people who died from HIV/AIDS in
2003, almost all (99 percent) were in the developing
world—74 percent in Sub-Saharan Africa alone (UNAIDS
2004). Tuberculosis and malaria together killed an equal
number; most of these deaths were among the poor.
• In 1995, 515,000 women died during pregnancy or child-
birth: 1,000 in the industrial world, contrasted with 252,000
in Sub-Saharan Africa (UNICEF 2001).
This burden of death and suffering is heavily concentrated in
the world’s poorest countries (Wagstaff and Claeson 2004).
Death and disease matter in their own right, but they also act as a
brake on poverty reduction. Nobel laureate Amartya Sen (2002)
has described health as one of “the most important conditions
of human life and a critically significant constituent of human
capabilities which we have reason to value.” Health also matters
because it influences the living standards of both households
and countries. Health expenses can easily become burdensome
for households. In Vietnam, they are estimated to have pushed
3 million people into poverty in 1993 (Wagstaff and van
Doorslaer 2003).
Beyond the direct impact of ill health on households’ living
standards through out-of-pocket expenditures, it indirectly
affects labor income through productivity and the number of
hours that people can work. The effects of illness on income,
which may take time to appear, are often long lasting. Mal-
nourished children are less likely to attend school and less likely
to learn when they do attend, reducing their productivity in
later life. The devastating economic consequences of illness and
death are evident at the macroeconomic level as well. The AIDS
epidemic alone has been estimated to reduce rates of eco-
nomic growth by 0.3 to 1.5 percentage points annually (Bell,
Devarajan, and Gersbach 2003).
In the 1990s, the international community recognized the
importance of health in development. In a period when overall
official development assistance declined, development assis-
tance to health rose in real terms. World Bank lending for
health increased, with a doubling of the share of International
Development Association disbursements going to health
(OECD Development Assistance Committee 2000). The 1990s
saw an increased global concern over the debt in the develop-
ing world, fueled in part by a perception that interest payments
were constraining government health expenditures in
developing countries. The enhanced Highly Indebted Poor
Country Initiative, spearheaded by the International Monetary
Fund and World Bank in response to the unsustainable debt
burden of the poorest countries, was explicitly geared to chan-
nel freed resources into the health and other social sectors. The
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Poverty Reduction Strategy Papers submitted by governments
of developing countries seek debt relief or concessional 
(low-interest) International Development Association loans to
set out their plans for fighting poverty on all fronts, including
health.
The 1990s also saw the development of major new global
health initiatives and partnerships, including the Joint United
Nations Programme on HIV/AIDS (UNAIDS); the Global
Alliance for Vaccines and Immunization; the Stop TB
Partnership; the Roll Back Malaria Partnership; the Global
Fund to Fight AIDS, Tuberculosis, and Malaria; and the Global
Alliance for Improved Nutrition. A range of new not-for-profit
organizations were set up to spur the accelerated discovery and
uptake in developing countries of low-cost health technologies
to address the diseases of the poor; these organizations
included the International AIDS Vaccine Initiative, the
Medicines for Malaria Venture, the Global Alliance for
Tuberculosis, and the International Trachoma Initiative. In
addition, the scale of philanthropic involvement in interna-
tional health increased, with the launch of the Bill & Melinda
Gates Foundation and the Packard Foundation and the contin-
ued attention to global health issues by such established entities
as the Rockefeller Foundation. These initiatives brought not
only new resources—funds, ideas, energy, and mechanisms—
but also new challenges to harmonization in the attempt to coor-
dinate and link global goals with local actions in the fight against
disease, death, and malnutrition in the developing world.
As the 1990s closed, the international community decided
that even more needed to be done. At the United Nations
Millennium Summit in September 2001, heads of 147 states
endorsed the MDGs, nearly half of which concern different
aspects of health—directly or indirectly (box 9.1). Several other
goals are indirectly related to health—for example, the goals on
education and gender. Gender equality is considered important
to promoting good health among children. Other health out-
comes than those included in the MDGs measure progress on
health—for example, targets related to noncommunicable
diseases. These targets are referred to as the MDG plus and
are included in national priority setting, especially in many
middle-income countries.
THE MILLENNIUM DEVELOPMENT GOALS
FOR HEALTH: PROGRESS AND PROSPECTS
Of the MDGs for which trend data are available or estimated,
the fastest progress has been on malnutrition, whereas overall
progress on under-five mortality and maternal mortality has
been slower.
A Mixed Score at Halftime
In-depth analysis of the health-related MDGs shows a mixed
score at halftime (Wagstaff and Claeson 2004):
• The number of people living in on-track countries (coun-
tries that will reach the MDGs if they maintain the rate of
progress they have already achieved during the period from
1990 to the present) matters. For the malnutrition target,
77 percent of the developing world’s people live in an on-
track country, but in Sub-Saharan Africa only 15 percent of
the people live in an on-track country.
• Different indicators show different levels of improvement.
For under-five mortality, the developing world was reduced
by an average of only a 2.5 percent in the 1990s, well short
of the target of 4.3 percent.
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The Health-Related Millennium Development Goals
Box 9.1
Goal 1—eradicating extreme poverty and hunger. This goal
includes as a target the halving between 1990 and 2015 of
the proportion of people who suffer from hunger, with
progress to be measured in terms of the prevalence of
underweight children under five years of age. The target
implies an average annual rate of reduction of 2.7 percent.
Goal 4—reducing child mortality. The target is to reduce by
two-thirds between 1990 and 2015 the under-five mortality
rate, equivalent to an annual rate of reduction of 4.3 percent.
Goal 5—improving maternal health. The target is to reduce
by three-quarters between 1990 and 2015 the maternal
mortality ratio, equivalent to an annual rate of reduction of
5.4 percent.
Goal 6—combating HIV/AIDS, malaria, and other diseases.
The target is to halt and begin to reverse the spread of these
diseases by 2015.
Goal 7—ensuring environmental sustainability. This goal
includes as a target the halving by 2015 of the proportion
of people without sustainable access to safe drinking water.
Goal 8—developing a global partnership for development.
This goal includes as a target the provision of access to
affordable essential drugs in developing countries.
Source: United Nations Millennium Declaration, the United Nations Millennium Summit 2000.
• Regional differences are also pronounced, with Sub-Saharan
Africa faring worse than other regions. In Africa, trends in
reducing under-five mortality and underweight in children
were barely above zero during the 1990s, and maternal mor-
tality fell on average by just 1.6 percent a year compared
with the annual target rate of 5.4 percent.
• Evidence on how the poor are faring within countries is
mixed. For malnutrition, the poorest 20 percent of the pop-
ulation within countries appears, on average, to have been
experiencing broadly similar rates of reduction to the pop-
ulation as a whole. However, for under-five mortality, the
rate has been falling more slowly among the poor, while
better-off families are seeing faster rates of progress.
Will the Second Half Go Better?
As a comparison of the child mortality experiences in the 1980s
and 1990s demonstrates, past performance is not necessarily a
good predictor of future performance. The fact that a country
is on track on the basis of its performance in the 1990s does not
guarantee that it will maintain the required annual rate of
reduction of malnutrition or mortality during the second half
of the MDG “window” from 2000 to 2015. Countries currently
off track may possibly get on track in the second half if they can
combine good policies with expanded funding for programs
that address both the direct and the underlying determinants
of the health-related goals.
Stimuli External to the Health Sector. The World Bank esti-
mates that economic growth will fall somewhat in East Asia
and the Pacific in 2000–15, turn from negative to positive in
Europe and Central Asia as well as Sub-Saharan Africa, and
increase somewhat in Latin America and the Caribbean, the
Middle East and North Africa, and South Asia (Jones and oth-
ers 2003). Primary education completion rates will probably
grow faster in the new millennium as a result of the global edu-
cation initiatives and partnerships on Education for All and
the Fast-Track Initiative. However, higher rates of educational
attainment among women of childbearing age will not be
achieved until 2005 or so, and even then the first full round of
effects on under-five mortality will not be felt until 2010.
More relevant is the fact that gender gaps in secondary edu-
cation may well narrow faster in the new millennium than in
the 1990s as a result of the gender MDG (Goal 3: Eliminate
gender disparity in primary and secondary education by 2005
and in all levels of education no later than 2015). To achieve
parity with boys by 2015 in the proportion of the population
who are age 15 and have completed secondary education, girls
will have to achieve a faster growth in completion rates in the
new millennium than in the 1990s in most regions, especially
in South Asia and in East Asia and the Pacific. If the water
MDG (ensuring that households have access to safe drinking
water) is to be reached, access rates will need to grow much
faster in 2000–15, especially in Sub-Saharan Africa (Wagstaff
and Claeson 2004). Gender equality in school and access to
clean water will have a positive effect on progress toward the
health MDGs. Even with economic growth and faster progress
on these nonhealth goals, however, many regions will still miss
many of the health targets. The picture is bleakest for under-
five mortality—and for Sub-Saharan Africa.
The Goals Matter for All Countries. These goals need to be
taken seriously for three main reasons:
• Faster progress is important even if targets are missed. A key
message of this chapter is that progress can be accelerated
in all countries through a judicious mix of spending and pol-
icy and institutional reform.
• The goals facilitate benchmarking and monitoring of results.
Because the goals focus on a limited set of outcomes, moni-
toring and evaluating progress toward the MDGs can show
what is achievable and where faster progress can be made.
• Focusing attention on national progress, as measured by
distributional analysis of the MDGs, forces countries to con-
sider how the benefits of progress are distributed among the
rich and poor within each country—the poor risk being left
behind even in countries making progress overall. One limi-
tation of the MDGs and targets is that they are national aver-
ages. However, distributional analysis of MDG trends
(Wagstaff and Claeson 2004) reminds us that progress needs
to be for everyone, not just the better off. Progress has been
uneven, with the poorer countries lagging behind the rest,
and for under-five mortality, the poor within countries are
lagging behind the rest of the population.
SCALING UP: DEFINING INTERVENTIONS
AND REMOVING CONSTRAINTS
A lack of interventions is not the primary obstacle to faster
progress toward the goals, although new interventions that can
be delivered by weak health systems could greatly improve
progress—for example, malaria or HIV vaccines and effective
vaginal microbicides to block the spread of HIV and other
sexually transmitted infections. The main obstacle is the low
levels of use—especially among the poor—of existing effective
interventions. For example, if use of all the proven effective
preventive and treatment interventions for childhood illness
were to rise from current levels to reach all, the number of
under-five deaths worldwide could fall by as much as 63 per-
cent (World Bank 2003b).
Array of Interventions, Programs, and Service Modalities
The available interventions constitute a powerful arsenal for
preventing and treating the main causes of malnutrition and
death (table 9.1).1 The major diseases and conditions that the
MDGs aim to prevent and control are discussed in several
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chapters (for example, see chapters 15, 19, 21–24, 28–31, 44,
and 45). The most cost-effective interventions and programs
are also discussed in several chapters (see chapters 59–62 and
65). The chapters dealing with health systems and service
delivery issues and other constraints related to the health
MDGs are found in the latter part of the book (see chapters
66–68, and 73).
In the case of child mortality, for example, diarrheal dis-
eases, pneumonia, and malaria account for 52 percent of deaths
worldwide (World Bank 2003b). For each of these major causes
of childhood mortality, at least one proven effective preventive
intervention and at least one proven effective treatment inter-
vention exist, capable of being delivered in a low-income set-
ting. In most cases, several proven effective interventions exist.
For diarrhea—the second-leading cause of child deaths—no
fewer than five proven preventive interventions and three
proven treatment interventions are available.
Effective Interventions Reaching Too Few People
The high rates of malnutrition and death in the developing
world have several causes. First, people do not receive the effec-
tive interventions that could save their lives or make them well
nourished. In middle- and high-income countries, 90 percent of
children are fully immunized, more than 90 percent of deliver-
ies are assisted by a medically trained provider (that is, a doctor,
nurse, or trained midwife, excluding traditional birth atten-
dants), and more than 90 percent of pregnant women have at
least one prenatal visit (UNICEF 2001). In South Asia, fewer
than 50 percent of pregnant women receive a prenatal checkup,
and only 20 percent of deliveries are assisted by a trained
provider.
The story is similar for other childhood interventions—
and for interventions for other goals. Condom use to prevent
transmission of HIV is low in much of Sub-Saharan Africa
and South Asia, and inexpensive one-time treatment with
antiretroviral medicine to prevent transmission from mother
to child covers only a small fraction of at-risk pregnant
women in most of the developing world. In Asia, where
more than 7 million people are living with HIV/AIDS, no
country has yet exceeded 5 percent antiretroviral therapy
coverage among those who could benefit from it (World Bank
2003c).
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Table 9.1 Effective Interventions to Reduce Illness, Deaths, and Malnutrition
MDG Preventive interventions Treatment interventions
Child mortality
Maternal mortality
Nutrition
HIV/AIDS
Tuberculosis
Malaria
Breastfeeding; hand washing; safe disposal of stool; latrine use; safe prepara-
tion of weaning foods; use of insecticide-treated bednets; complementary feed-
ing; immunization; micronutrient supplementation (zinc and vitamin A); prenatal
care, including steroids and tetanus toxoid; antimalarial intermittent preventive
treatment in pregnancy; newborn temperature management; nevirapine and
replacement feeding; antibiotics for premature rupture of membranes; clean
delivery 
Family planning (lifetime risk); intermittent malaria prophylaxis; use of
insecticide-treated bednets; micronutrient supplementation (iron, folic acid,
calcium for those who are deficient) 
Exclusive breastfeeding for 6 months, appropriate complementary child feeding
for next 6–24 months, iron and folic acid supplementation for children, improved
hygiene and sanitation, improved dietary intake of pregnant and lactating
women, micronutrient supplementation for prevention of anemia and vitamin A
deficiency for mothers and children, anthelmintic treatment in school-age
children
Safe sex, including condom use; unused needles for drug users; treatment of
sexually transmitted infections; safe, screened blood supplies; antiretrovirals
in pregnancy to prevent maternal to child transmission and after occupational
exposure 
Directly observed treatment of infectious cases to prevent transmission and
emergence of drug-resistant strains and treatment of contacts, Bacillus
Calmette-Guérin immunization
Use of insecticide-treated bednets, indoor residual spraying (in epidemic-prone
areas), intermittent presumptive treatment of pregnant women
Case management with oral rehydration therapy
for diarrhea; antibiotics for dysentery, pneumo-
nia, and sepsis; antimalarials for malaria;
newborn resuscitation; breastfeeding; comple-
mentary feeding during illness; micronutrient
supplementation (zinc and vitamin A) 
Antibiotics for preterm rupture of membranes,
skilled attendants (especially active management
of third stage of labor), basic and emergency
obstetric care
Appropriate feeding of sick child and oral rehy-
dration therapy, control and timely treatment of
infectious and parasitic diseases, treatment and
monitoring of severely malnourished children,
high-dose treatment of clinical signs of vitamin A
deficiency
Treatment of opportunistic infections, 
co-trimoxazole prophylaxis, highly active
antiretroviral therapy, palliative care 
Directly observed treatment to cure, including
early identification of tuberculosis symptomatic
cases
Rapid detection and early treatment of uncompli-
cated cases, treatment of complicated cases
(such as cerebral malaria and severe anemia)
Source: Authors.
Just as shortfalls in coverage vary across countries, so do
they vary within countries, with the poor and other deprived
groups consistently lagging. These groups are less likely to
receive full basic immunization coverage, to have their deliver-
ies attended by a trained provider, and to have at least one pre-
natal care visit to a medically trained provider. On the positive
side, the poor are often making fastest progress in coverage,
reflecting in part that the better off already have high coverage
rates for many interventions.
Underuse of Effective Interventions Costs Lives
The low use of effective interventions—in the developing
world in general and among the poor in particular—translates
into rates of mortality, morbidity, and malnutrition that are far
higher than necessary. If use of all the proven effective child-
hood preventive and treatment interventions, for example,
were to rise from their current levels to 99 percent—95 percent
for breastfeeding—the number of under-five deaths worldwide
could fall by as much as 63 percent (Jones and others 2003).
Deaths from malaria and measles could be all but eliminated,
and deaths from diarrhea, pneumonia, and HIV/AIDS could be
reduced dramatically. If coverage rates of the key maternal
mortality interventions were increased from current levels to
99 percent, an estimated 391,000 maternal deaths worldwide
(74 percent of current maternal deaths) might be averted
(Ramana 2003). One intervention stands out as especially
important: access to essential obstetric care, which accounts for
more than half the maternal deaths averted.
WHAT DO COUNTRIES NEED TO DO?
If the lack of interventions is not holding countries back from
achieving the goals, what is? What do countries need to do to
make progress toward the MDGs?
In countries with good governance, additional government
health spending does reduce child mortality (Rajkumar and
Swaroop 2002). Development assistance has a stronger effect in
countries with strong policies and institutions than in coun-
tries with only average-quality policies and institutions—and
an insignificant effect in countries where policies and institu-
tions are weak. This assertion is also consistent with the find-
ings of a study undertaken by the World Bank for the MDG
report, The Millennium Development Goals for Health: Rising to
the Challenges (Wagstaff and Claeson 2004). The study includes
other outcomes with child mortality and uses the World Bank’s
Country Policy and Institutional Assessment index to measure
the quality of policies and institutions.
In principle, well-governed countries with good policies and
institutions could achieve the goals simply by scaling up their
expenditures on existing programs in proportion to current
allocations. In practice, however, the amount of extra spending
required would be difficult to attain on present trends and
would even be prohibitively expensive. In the case of East Asia
and the Pacific, for example, if economic growth proceeds as
expected and the other relevant Millennium Development
Targets are attained, the region would achieve the required
rates of reduction of underweight and maternal mortality—
assuming that economic growth is accompanied by the devel-
opment of appropriate human resources for health—even if
government health spending continues to grow at its current
rate. However, the region would miss the under-five mortality
target. To reach that target, a minimum of 5 percentage points
would need to be added to the annual rate of growth of the
government health share of gross domestic product (GDP).
That would take the projected share of GDP spent on govern-
ment health programs to 3.7 percent in 2015—more than twice
what it would be if the 1990s pattern of growth continued
(Wagstaff and Claeson 2004).
In Sub-Saharan Africa, the situation is even starker. Even if
faster economic growth materializes and the other targets are
achieved, the share of government health spending in GDP
would need to grow nearly sixfold over the coming decade, tak-
ing the share to 12.2 percent of GDP in 2015. This percentage
compares with a 2000 figure of 1.8 percent and a 2015 forecast
of 2.2 percent based on the 1990s annual growth in govern-
ment spending for health. In conclusion, African countries will
not be able to reach the MDGs simply by multiplying their
health spending along the lines of historical expenditure pat-
terns, because the multiples required are beyond any realistic
expectation of what these governments will be able to do dur-
ing the next 10 years.
What Are the Implications?
Poorly governed countries cannot expect to make much
progress toward the MDGs simply by scaling up their expendi-
tures on existing programs in proportion to current alloca-
tions. Although well-governed countries could, in principle,
simply scale up existing spending to reach the targets, this
option is unlikely to be affordable for them or their donors.
This situation has two implications:
• First, targeting additional government spending to activities
that will have the largest effect on the MDGs is important
for both sets of countries.
• Second, building good policies and institutions is important
for all countries: doing so increases the productivity not just
of additional spending but also of existing spending com-
mitments. What do better policies and institutions entail in
the health sector? Health systems are very broad, and weak
policies and institutions can arise at several points along
the pathway, from government health spending to health
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outcomes (Claeson and others 2001). Countries can do a
number of things, with help from donors, to build stronger
policies and institutions.
Improving Expenditure Allocations and Targeting
In most countries, government spending gets stuck in the cities
and disproportionately accrues—in a financial sense—to
people who are better off.
Geographic Targeting. Resource allocation formulas can be
used to reduce government spending gaps across regions and
ideally to favor geographic zones that are furthest behind.
These formulas have been used, for example, as part of Bolivia’s
decentralization efforts since 1994 and have been associated
with some large—and pro-poor—improvements in maternal
and child health indicators. Targeting resources to poor regions
and provinces may be most effectively implemented through
nontraditional mechanisms for priority setting and implemen-
tation, such as social investment funds. In Bolivia, a recent
impact evaluation concluded that such funds were responsible
for a decline in under-five mortality from 88.5 to 65.6 per 1,000
live births over a five-year period (Newman and others 2002).
Changing the Allocation of Spending across Care Levels.
Spending on health in developing countries is characterized by
a high concentration of spending on secondary and tertiary
infrastructure and personnel. Some governments have tried to
scale back the share of hospital spending. Tanzania, for exam-
ple, reduced the share of hospital spending from 60 percent in
2000 to 43 percent in 2002. Chapter 3 deals with the issue of
how to couple expenditure reallocations across levels of care
with measures to improve performance at each level of the
health care system.
Targeting Specific Programs. Programs such as those deliver-
ing directly observed treatment short course (DOTS) for tuber-
culosis or integrated management of infant and childhood
illness (IMCI) for child health are good examples of programs
that may yield high returns to government spending at the
margin. A recent World Bank study in India provides further
support for the idea that the way government spending is allo-
cated across programs makes a difference to its effect on the
Millennium Development Indicators (World Bank 2003a).
Successful public health programs—large-scale programs with
a measurable health effect over at least a five-year period—are
further discussed in chapter 8. All successful programs have
several factors in common: technical innovation and stake-
holder consensus, strong political leadership, coordination
across agencies and management, effective use of information
and financial resources, and participation of the beneficiary
community.
Targeting Specific Population Groups. Many countries subsi-
dize all government health services for everyone. These blanket
subsidy schemes not only fail to target interventions that give
rise to externalities but also fail to disproportionately benefit
the poor—despite the stronger equity case for subsidizing their
care and the fact that they tend to bear a disproportionate
burden of malnutrition as well as child and maternal mortality.
There are many proven ways to target the poor—for example,
by delivering essential services in clinics or health posts that
only poor families attend or by promoting and delivering serv-
ices in a way that segments the market and appeals to those in
low-income households.
Targeting Spending to Remove Bottlenecks. A planning and
budgeting approach is to assess—for a country—the health
sector impediments to faster progress, to identify ways of
removing them, and to estimate both the costs of removing
them and the likely effects of their removal on MDG outcomes
(Soucat and others 2002). MDG analysis along these lines—
referred to sometimes as marginal budgeting for bottlenecks
(MBB)—has begun in several African countries and in some
states of India (UNICEF and World Bank 2003). In Mali, key
bottlenecks were identified for supporting home-based prac-
tices and delivering periodic and continual professional care.
They included low access to affordable commodities and the
need for community-based support for home-based care; low
geographical access to preventive professional care (immuniza-
tion, vitamin A supplementation, and prenatal care); shortages
of qualified nurses and midwives; and an absence of effective
third-party payment mechanisms for the poor for professional
continuous care. Important health systems bottlenecks, such as
human resources, drug availability, and health care manage-
ment, are discussed in chapters 71–73.
Improving Policies toward Households as Producers
and Demanders of Care
Households are at the center of any efforts to scale up; they not
only demand and consume care, but they are also important
producers of prevention and care. Policies to increase coverage
of cost-effective interventions to reach the health MDGs, there-
fore, need to identify and influence the key constraints to both
the production and the demand for those services at the
household and community levels.
Lowering Financial Barriers. Low income is a barrier to the
use of most health interventions, and economic growth is an
important weapon in the war against malnutrition and mor-
tality. However, social protection programs are also important.
Successful schemes aimed at households and communities are
discussed in chapter 56.
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One part of the affordability equation is price. User charges
for MDG interventions are to be discouraged. Why? Many of
those interventions involve benefits that spill over to people
who do not receive the intervention; high coverage of immu-
nization is a classic example. However, an equity case also can
be made for reducing prices facing the poor and near poor,
even where no spillovers occur. Subsidies should be targeted to
services with spillovers and to the poor. In practice, subsidies
are often badly targeted in at least one respect if not both.
Exceptions exist. In Ifakara, Tanzania, a voucher program for
mosquito nets was launched successfully for pregnant women
and children under five (Schellenberg and others 2001).
Some recent programs, especially in Latin America, have not
only made health care affordable for the poor but have also
made it profitable. Rather than simply reducing the cost of
using specific interventions, these programs provide users with
cash payments, which are linked to specific interventions and
restricted to certain groups—often poor mothers and their
children. The experience with these programs in targeting and
achieving results is encouraging (Mesoamerica Nutrition
Program Targeting Study Group 2002; Morris and others 2003;
Palmer and others 2004).
Risk aversion coupled with the unpredictability of illness
provides a motivation for pooling risks through an insurance
scheme. The Arab Republic of Egypt, for example, introduced
a school health insurance program for all children attending
school. The program resulted in larger increases in coverage
among the poor and achieved considerable effect on use and
out-of-pocket expenditures (Yip and Berman 2001). However,
insurance in the developing world is very limited, and those
who are least able to smooth consumption without insurance
are the least likely to have insurance coverage (Musgrove,
Zeramdini, and Carrin 2002). Another problem is that many of
the schemes are small scale, and evaluations of these schemes
do not generally measure health effect or effect on equity, thus
resulting in limited evidence (Palmer and others 2004).
Providing Information—Enhancing Knowledge. Lack of
knowledge is a major factor behind poor health. It results in
people not seeking care when needed, despite the absence of
price barriers, and it also results in people—especially poor
people—wasting limited resources on inappropriate care.
Ignorance may also result in people not getting the maximum
health gain out of inputs they have available to them and use.
Many people do not know that hand washing confers much of
the health benefit of piped water (see chapter 41). Not surpris-
ingly, piped water has a much greater effect on the prevalence
of diarrhea among the children of the better off and better
educated. Better-educated women—especially those with a
secondary education—achieve better health outcomes for
themselves and their children not by using health-specific
knowledge that they acquire at school, but by using general
numeracy and literacy skills learned at school to acquire health-
specific knowledge later in life. Although better-educated girls
will mean healthier women and healthier children in years to
come, a shorter and more direct route to increasing health-
specific knowledge and skills is through information dissemi-
nation, health promotion, and counseling in the health sector.
Several success stories exist. In Brazil, after health workers
trained by IMCI provided information and counseling at
health facilities and in the community, health knowledge
among mothers improved, as did feeding practices (Santos and
others 2001). After only 18 months, the nutritional status of
children in the area improved as well. Social marketing and
media campaigns—for example, malaria and social marketing
of insecticide-treated nets (see chapter 21)—have also proved
effective in some circumstances.
Reducing Time Costs Transportation systems, road infrastruc-
ture, and geography influence the demand for care delivered by
formal providers through their effect on time costs, which can
be substantial. In rural communities, where the roads are poor
and the transportation unreliable, the time spent waiting for
the transportation is also a major cost. Time costs tend to be a
major issue for maternal mortality: health centers are unable to
provide essential obstetric care for a complicated delivery, and
women would have to travel to distant hospitals to get
such services. Road rehabilitation and other transportation
projects are important here, but so are subsidies linked to
the use of health services. Malaysia and Sri Lanka provide free
or subsidized transportation to hospitals in emergencies
(Pathmanathan and others 2003). Other options for tackling
inaccessibility include using outreach and establishing partner-
ships between government and nongovernmental organiza-
tions (NGOs), private providers, or community organizations.
Providing Access to Water and Sanitation The availability of
adequate supplies of water and improved sanitation is associ-
ated with better maternal and child health outcomes, at least
among the better educated, even after controlling for other
influences. This result is not altogether surprising. Hand wash-
ing is easier if the household has piped water that provides
readily available quantities of safe water. The safe disposal of
feces is easier if the household has an improved form of sanita-
tion. The developing world lags well behind the industrial
world in both; the poorer people fare especially badly. They are
less likely to be connected to a network, and the sources they
rely on tend to be more costly per liter than the networked serv-
ices used by the better off.
The challenge from a health perspective is to get maximum
health benefits from investments in access to water and sanita-
tion infrastructure. Efforts to work across sectors on water and
health, in order to influence the health MDGs, are under way in
Ethiopia, Peru, and Rwanda.
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Improving Health Service Delivery
Health providers—in the public and private sectors, as well as
in both formal and informal sectors—should deliver interven-
tions of relevance to the MDGs. Many are efficient, deliver high
quality services, and are responsive to their patients. Many,
however, are not; many are not even there to deliver any serv-
ices at all. As a result, resources—public and private—are often
nonexistent, underused, or wasted.
Two things can make a difference. One is the quality of
management. Better management means a clearer delineation
of responsibilities and accountabilities inside organizations,
a clearer link between performance and reward, and so on.
Management means getting accountabilities right within an
organization. The other thing that can make a difference is get-
ting accountabilities right between the organization and the
public (World Bank 2003d).
Improving Management—Increasing Accountability within
Provider Organizations. Management styles in government-
funded and government-implemented health schemes have
recently begun to change, focusing on performance—that is,
on outputs and outcomes—rather than on inputs and pro-
cesses. Good performance is rewarded, financially or in some
other way. The focus is on clients and on the belief that an
organization is ultimately accountable to its clients. A client-
oriented strategy emphasizes customer choice and satisfaction.
Business techniques enhance performance and are a standard
part of strategic planning.
This new approach is evident in several countries, and ele-
ments of the approach are visible in successful nutrition and
child health programs (see chapter 56). For example, in Tamil
Nadu’s Integrated Nutrition Program, community nutrition
workers were given clearly defined duties. Information on out-
puts not only enabled the community to keep the workers
accountable but also enabled the nutrition workers to see how
their program was working. In Ceara’s Programa de Agentes de
Saude, which is credited with a substantial reduction in child
mortality (Victora and others 2000), health agents and nurse-
supervisors were assigned clear tasks and given clear responsi-
bilities. The intended outcomes of the program were empha-
sized to health workers and members of the public, and the
health agents were held accountable through community-
based monitoring and rewarded for good performance.
Governance. The accountability of provider organizations to
the public can be improved through enhanced governance or
contracting. Having community representatives participate in
the governance and oversight of providers can improve the
productivity and quality of public sector providers. In Burkina
Faso, participation of community representatives in public
primary health care clinics increased immunization coverage,
the availability of essential drugs, and the percentage of
women with two or more prenatal visits. In Peru, comparisons
of primary health care clinics with and without community
participation in governance suggested decreases in staff absen-
teeism and waiting times and suggested increases in perceived
quality by patients (Cotlear 1999). The approach probably
works best for primary care and in situations in which strong
technical and advisory support is provided to community rep-
resentatives who are close to the service being delivered.
Contracting. Evidence on the effect of contracting within the
public sector is mixed, and the experiences are mainly based
on lessons learned from middle-income countries. In several
countries in Europe and Central Asia, evidence shows a positive
effect from performance-based payment, but that is not neces-
sarily the same as contracting, which can occur without
performance-related pay. The best evidence relates to the use
of target payments for the attainment of a given level of
coverage—for example, for immunization or cervical cytology
at the primary care level (Langenbrunner 2003). In Argentina
and Nicaragua, social security institutes have increased pro-
ductivity by establishing capitation-based payments for an
integrated package of inpatient and ambulatory services
(Bitran 2001). Key influences on the success of contracts with-
in the public sector include whether the provider has the abil-
ity to respond, whether service commitments are congruent
with funding levels, whether output and key components of
performance expectations are easily measurable, and how far
capacity strengthening of the payer or funder is addressed.
Contracting with nonprofit organizations is most common
in low-income countries (see chapter 12, which contains a
longer discussion of contracting with NGOs). Most cases have
had positive effects on target outcome or output variables.
In Bangladesh, contracts with nonprofit organizations for
planning and implementing an expanded program on immu-
nization project were credited with a dramatic increase in
immunization. In Haiti, contracting for a primary health care
package also significantly increased immunization coverage
(Eichler, Auxilia, and Pollock 2001). In Bangladesh,
Madagascar, and Senegal, significant reductions in nutrition
rates were attributed to contracting initiatives (Marek and oth-
ers 1999). Only a few cases assess efficiency. Contracting with
nonprofits works best when the contractors have well-
functioning accountability arrangements and strong intrinsic
motivation and when the government makes timely payments
to the NGOs. The government needs to be capable of assessing,
selecting, and managing the ongoing relationship with con-
tractors. The methodological quality of evaluating contracting
is often poor and needs to be improved. An exception is the
Cambodian contracting trial that used a rigorous cluster ran-
domized design, but the intervention groups had greater input
of resources than the control communities, which may have
been partly responsible for the difference in performance.
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Results on contracting with for-profit private service
providers are also mixed. Experience from the hospital sector
warns that weak government contracting capacity often allows
the provider to capture efficiency gains or to expand volume—
not necessarily of cost-effective services—to generate more
income. In Zimbabwe, the cost per service decreased, but the
lack of volume control led to an increase in total cost (McPake
and Hongoro 1995). Other adverse outcomes are possible. In
Brazil, contracting with for-profit hospitals led to increases
in access, but also increases in fraud (false billing) and cream-
skimming to avoid costly patients (Slack and Savedoff 2001).
These problems seem less pronounced in primary health care.
In Peru and El Salvador, contracting with private primary
health care providers increased access, choice, and consumer
satisfaction (Fiedler 1996). Contracting with for-profit
providers seems to work best when the government invests in
the development of capacity to manage the contracting process
(Mills, Bennett, and Russell 2001); when quality is at least as
high in the private sector as in the public sector; and when the
services involve primary care or other relatively observable
services, such as diagnostic services.
Strengthening Core Public Health Functions
Vulnerable populations need to be protected from risks and
damages, informed, and educated. Public health regulations
need to be established and enforced. Infrastructure needs to be
in place to reduce the impact of emergencies and disasters
on health. All this action needs to be implemented through a
public health system that is transparent and accountable.
Governments in developing countries generally recognize that
these public health functions are important, but they often lack
the capacity and financial resources to implement them.
Indeed, few low-income countries invest in these public health
functions.
By employing public health professionals with core public
health competencies, the government can develop and enforce
standards; can monitor the health of communities and popula-
tions; and can emphasize health education, public information,
health promotion, and disease prevention. Public action can
help improve consumer knowledge and change attitudes so
that private markets can operate effectively to meet the needs of
the poor, for example, through social marketing of insecticide-
treated bednets to reduce malaria transmission or of condoms
for protection against HIV/AIDS.
Government-Led Monitoring and Evaluation. Integrated
disease surveillance, program assessment, and collection and
analysis of demographic and vital registration data are essen-
tial if governments and donors are to ascertain whether poli-
cies and programs are positively affecting health goals.
Governments can use a list of intermediate indicators and
proxies for the goals that can help monitor progress, test the
impact of policies, and adjust programs going forward (World
Bank 2001). Such indicators should be simple, easily measura-
ble, representative, easy to understand, scientifically robust, and
ethical. They need to be assessed regularly because the MDGs
themselves are difficult to collect, thus entail delays, and are
therefore not useful for regular monitoring of progress. Greater
investments are needed in systems to monitor these intermedi-
ate indicators and to track expenditures on public health.
Although some good practices in surveillance are being
developed—for example, in Brazil, China, and India—few low-
income developing countries can afford to invest in the infra-
structure required for strong surveillance systems. Most rely on
alternative short- to medium-term solutions for data gather-
ing, such as intermittent household surveys, health facility
surveys, and simplified facility-based routine reporting. A few
countries have made special efforts to improve the surveillance
of a specific intervention, such as AIDS and tuberculosis treat-
ment or childhood immunization, whereas others have
attempted to monitor progress toward a specific MDG.
INDEPTH (International Network of Field Sites with
Continuous Demographic Evaluation of Populations and
Their Health in Developing Countries), which is supported by
the Rockefeller Foundation with help from other donors, coor-
dinates a range of surveillance sites, many of them in Africa,
and the Health Metrics network aims at improving the quality
of surveillance data. Some governments are explicitly develop-
ing or modifying their monitoring and evaluation framework
to focus on the MDGs.
Intersectoral Actions—Going Beyond the Ministry of
Health. A review of the evidence base for the key determinants
of the health and nutrition MDGs identifies significant poten-
tial for intersectoral synergies (Wagstaff and Claeson 2004).
Transportation Although roads and transport are vital for
health services, especially for reducing maternal mortality, it is
not just the physical infrastructure that matters. Also impor-
tant are the availability of transportation and the affordability
of its use, as shown in a study in Nigeria (Eissen, Efenne, and
Sabitu 1997). Transportation and roads complement health
services. A 10-year study in Rajasthan, India, found that better
roads and transportation helped women reach referral
facilities, but many women still died because no corresponding
improvements took place at household and facility levels.
Working with the transportation sector is also important for
reducing HIV transmission in many settings and making
progress on the HIV/AIDS-related MDG.
Hygiene Improved hygiene (use of hand washing) and sanita-
tion (use of latrines and safe disposal of children’s stools) are at
least as important as drinking water quality in shaping health
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outcomes, specifically in reducing diarrhea and associated child
mortality (Esrey and others 1991). Constructing water supply
and sanitation facilities is not enough to improve health out-
comes; sustained human behavior change must accompany the
infrastructure investment. By collaborating with other sectors,
the health sector can develop public health promotion and
education strategies and implement them in partnership with
agencies that plan, develop, and manage water resources. The
health sector can also work with the private sector to manufac-
ture, distribute, and promote affordable in-home water purifi-
cation solutions and safe storage vessels—and advocate for
water, sanitation, and hygiene interventions in strategies to
reduce poverty.
Indoor Air Quality Indoor air pollution is caused by use of
low-cost, traditional energy sources, such as coal and biomass
for cooking and heating, the main source of energy for 3.5 bil-
lion people. Indoor air pollution is a major risk factor for pneu-
monia and associated deaths in children and for lung cancer in
women who risk exposure during cooking (see chapter 42).
Studies in China, Guatemala, and India are under way to
improve access to efficient and affordable energy sources
through local design, manufacturing, and dissemination of
low-cost technologies, modern fuel alternatives, and renewable
energy solutions. The community-based project in China was
initiated by the Ministry of Health, which was troubled by the
leveling off of child mortality reductions among the rural poor
and was seeking ways to influence major environmental deter-
minants of child mortality. The program combines appropri-
ately improved stoves and ventilation with behavior-change
modification; it is in an early stage of implementation, and
results on outcomes are not yet available. Agricultural policies
and practices influence food prices, farm incomes, diet diver-
sity and quality, and household food security. Policies that
focus on women’s access to land, training, and agricultural
inputs; on their roles in production; and on their income from
agriculture are more likely to have a positive effect on nutrition
than interventions without a focus on women, particularly if
combined with other strategies, such as women’s education and
behavior change (Johnson-Welch 1999; Quisumbing 1995).
The MDG agenda highlights the need not only to prioritize
within health to achieve better health outcomes, but also to
better inform priority setting in resource allocations between
sectors, identifying intersectoral synergies and finding ways to
maximize benefits for health.
COSTING AND FINANCING ADDITIONAL
SPENDING FOR THE MDGS
Additional health spending will be required in many countries
to accelerate progress toward the health goals (see chapter 12).
What will it cost, and how will extra spending be financed? 
Cost of Achieving the MDGs Globally 
The global estimates of what it would cost to achieve the MDGs
range from an additional US$20 billion to US$70 billion a year.
A World Bank study (http://www.worldbank.org/html/extdr/
mdgassessment.pdf) estimates that the additional official
development assistance required to meet the health goals is in
the range of US$20 billion to US$25 billion per year, which is
roughly four times the current amount of official development
assistance spending for health in 2002 (US$6.5 billion) and
three times all external financing, including that of foundations
and loans from multilateral sources (see chapter 13). The dra-
matic shortfalls in resources required to achieve the MDGs
were emphasized during the 2002 Monterrey Conference on
Financing for Development, which brought significant atten-
tion to issues concerning the estimation of the cost of achiev-
ing the health MDGs.
Another analysis conducted by the Commission on
Macroeconomics and Health (2001) of the World Health
Organization estimated that an additional US$40 billion to
US$52 billion annually would be required until 2015 to scale up
the coverage for malaria, tuberculosis, HIV/AIDS, childhood
mortality, and maternal mortality (Kumaranayake, Kurowski,
and Conteh 2001). A third study using the production frontiers
approach estimated that between US$25 billion and US$70 bil-
lion of additional spending was needed to bring poorly per-
forming countries up to the level of high performers (Preker and
others 2003). A fourth study prepared by the World Bank for the
Development Committee estimated at least US$30 billion annu-
ally in additional aid was needed to accelerate all the MDGs,
including health (Development Committee 2003).Whatever the
method of analysis, all global estimates show that reaching the
MDGs will require significant additional resources compared
with the current levels of funding for health.
Cost of Achieving the MDGs in Countries
Global estimates of what it costs to achieve the health MDGs
are not very useful for countries wanting to plan and budget in
order to reach the MDGs. The substantial range of estimates
between US$20 billion and US$75 billion per year to achieve
the MDGs at a global level has led to debates over the most
appropriate costing method for country-specific analysis and
to the development of new costing methodologies for obtain-
ing consistent and reliable estimates to use for policy dialogue
and decision making at the country levels. Some of the meth-
ods are summarized in box 9.2.
Preliminary Country Cost Estimates. Table 9.2 provides a
set of preliminary country-level estimates for the cost of
removing bottlenecks and accelerating progress toward the
health MDGs (MBB method) and for the cost of achieving
the health MDGs (Millennium Project tools) in selected
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countries. The estimates are presented for illustration of
orders of magnitude and should not be used for intercountry
comparison.
Financing Extra Health Spending
The additional resources needed to reach the MDGs are large
at both country and global levels, as discussed in the previous
section. The key question is how to finance the extra spending
that is needed.
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Estimating the Cost of Scaling Up to Achieve the MDGs
Box 9.2
The following are the country-specific models for MDG
cost analysis:
• The MDG Needs Assessments Model developed by the
United Nations Millennium Project, (Millennium
Project 2004). The Millennium Project model yields
total cost estimates for full coverage of the needs of a
defined population with a comprehensive set of health
interventions in a given year. It uses unit cost of cover-
ing one person multiplied by the total population in
need in a given year to yield the direct health cost.
Additional resource requirements are added (on the
basis of assumptions rather than actual inputs) for,
among other items, health system improvement, salary
increases for human resources, administration and
management, promotion of community demand, and
research and development.
• The Marginal Budgeting for Bottlenecks Model devel-
oped by the United Nations Children’s Fund, the World
Bank, and the World Health Organization (Soucat and
others 2002, 2004; UNICEF and World Bank 2003). The
MBB model yields additional resources required for
removing a set of health system bottlenecks that are
considered to hinder the delivery of health services to
the population through three delivery modes: family-
community, outreach, and clinical levels. The MBB
method also estimates the effect on outcomes (for
instance, child and maternal mortality) of increased
coverage and use of the health services provided. First, a
set of high-impact services are selected on the basis of a
country’s epidemiological needs. These services are the
same as those cost-effective priority interventions iden-
tified in the relevant disease control priorities chapters.
Second, health system bottlenecks hindering delivery of
these services are identified. Then, strategies for
removal of bottlenecks are discussed, and the inputs are
identified for improving coverage, for example, in a vil-
lage. Cost estimates are based on these inputs by scaling
up the cost to cover the district, province, or nation.
• Elasticity estimates through econometric modeling devel-
oped by the World Bank staff (Wagstaff and Claeson
2004). A few studies have used econometric techniques
to analyze the effect on MDG outcomes of certain cross-
sector determinants (such as economic growth, water
and sanitation, education, and road infrastructure) as
well as government expenditures on health. Eco-
nometric analysis has been used mostly to analyze the
effect of changes in government health expenditures on
outcomes using cross-sectional or panel data at a global
scale. But in one particular study in India, the method-
ology was used to estimate the marginal costs of avert-
ing a child’s death at the state level. The estimates could
vary from as low as US$2.40 per child death in a low-
income state to US$160 in a middle-income state in
India.
• The Maquette for Multisectoral Analysis of MDGs is
under development by the World Bank (Bourguignon
and others 2004). The thesis for this new approach is
that development aid is a key ingredient of a country’s
development process, but its effectiveness has to be
assessed at the country level within each country’s local
implementation and macroeconomic constraints. The
objective of the model is to calculate the financial needs
to attain a targeted path to 2015 and determine an opti-
mal allocation of additional funding toward different
social sectors for the MDGs. This modeling framework
is still at an early stage of development and will be
applied later to countries. This model is anticipated to
draw extensively from results of other models, such as
the elasticity analysis and MBB models.
Source: Millennium Project 2003, 2004; Soucat and others 2004; Bourguignon and others 2004.
Encouraging Risk Pooling Rather Than Out-of-Pocket
Spending. Health spending can be broken down into three
categories:
• private (out-of-pocket expenditures and private insurance)
• public (financing from general revenues and social insur-
ance contributions)
• external sources (development assistance).
Private spending absorbs a larger share of income in poorer
countries. In low-income countries, it absorbs a larger share of
GDP, on average, than domestically financed public spending.
In low-income and lower-middle-income countries, it invari-
ably means out-of-pocket expenditures rather than private
insurance (Musgrove, Zeramdini, and Carrin 2002). This situ-
ation leaves many near-poor households heavily exposed to the
risk of impoverishing health expenses. The risk is clearly
greater the poorer the country, because poorer countries tend,
on average, to have larger shares of poor people (World Bank
2000). Governments thus have a major role to play in helping
shape effective risk-pooling mechanisms, in addition to
increasing their own spending and targeting it to services for
the poor that will have a large positive effect on the MDGs.
Getting Governments to Spend What They Can Afford
Government spending is an important part of the picture, and
the issue is how much they can afford. Unlike private spending,
government spending as a share of GDP is higher in richer
countries. However, at any given per capita income, a surpris-
ing amount of variation occurs across countries in the share of
GDP allocated to government health programs. Countries that
appear able to spend similar shares of GDP on government
health programs end up spending quite different amounts.
How can extra domestic resources be mobilized if countries
are spending less than they can afford? Domestically financed
government health spending comes from general revenues,
social insurance contributions, or both. The amount of general
revenues flowing into the health sector is the product of the
amount of general (tax and nontax) revenues collected by
the government (the general revenue share) and the share of
general revenues allocated to the health sector (the health share
of government spending) (Hay 2003). Low government health
spending could be attributable to either share or both shares
being low. In poorer countries, both shares are typically lower
than they are in richer countries. However, differences exist
across countries that cannot be explained by per capita income
alone.
Countries need to ascertain whether their low spending
is caused by unduly low general revenues or by unduly low allo-
cations to health and explore ways of making appropriate
adjustments. Bolivia managed to raise its general revenue share
consistently in the 1990s as the result of a sustained reform
process begun in 1983. The health sector there has been one of
the beneficiaries of this growth of tax revenues: government
health spending as a share of GDP grew at an annual rate of
nearly 10 percent in the 1990s.
Although raising domestic resources takes time, countries
that can apparently afford to spend more out of their own
resources should be encouraged to start the process.
Development agencies have a role here—in providing technical
support of tax reform, in helping develop government com-
mitment to health in public expenditure allocations, and in
giving financial assistance, both to ease the adjustment costs
and to provide support while the gap is being closed between
current and affordable spending.
Recognizing the Limits of Development Assistance. Official
development assistance tends to account for a larger share of
government health spending in poorer countries. Development
assistance for health is especially important in Sub-Saharan
Africa. Twelve countries in Sub-Saharan Africa had external
funding exceeding 35 percent of total health expenditures in
2000 (World Bank 1998).
Increased development assistance is needed to achieve the
MDGs. Development assistance, however, is not without its
drawbacks. Many donors require that assistance be kept in
parallel budgets outside the ministry of finance, which risks
undermining government efforts to appropriately plan and
target expenditures. Such off-budget expenditures make it
difficult in some countries to properly target resources to
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Table 9.2 Alternative Cost Estimates Using Millennium Project and Marginal Budgeting for Bottlenecks Models
Country Model used Cost estimate (US$ per capita per year)
Ethiopia MBB 3.56
Madagascar (Toamasina) MBB 2.38
Mali (one region) MBB 3.97
Ethiopia Millennium Project 32.00
Bangladesh Millennium Project 20.60
Cambodia Millennium Project 22.50
Ghana Millennium Project 24.70
Tanzania Millennium Project 34.70
Uganda Millennium Project 32.10
Source: Authors.
particular interventions, geographic locations, or population
groups, even though such targeting may be essential for
improving the effect of expenditures on outcomes and the
probability of reaching the health goals. Donors often require
recipient governments to maintain separate accounts and to
provide separate progress reports, thereby increasing the
administrative burden on weak health ministries. Most impor-
tant, donor commitments of expenditures in health are short
term, whereas the needs are permanent. Thus, any external
financing must at some point be substituted with additional
domestic revenues or expenditure reallocations. This substitu-
tion or transition to domestic sources of funding has typically
been difficult to achieve, leading to a dropoff in effort in
important health programs, such as immunizations and repro-
ductive health services.
Consensus on how to improve aid effectiveness is grow-
ing among development partners, and partners at the High
Level Forum on Health MDGs (http://www.hlfhealthmdgs.
org). This agenda includes supporting countries in developing
more MDG-responsive Poverty Reduction Strategy Papers,
tracking resource flows, strengthening monitoring and evalua-
tion, and more effectively dealing with the human resources
crisis in health. Effective monitoring can help ensure that
increased external funds do not simply lead to reduced domes-
tic financing (the fungibility problem) but actually boost overall
spending for health. In concert with moves affecting all devel-
opment assistance, donors and governments are trying to see
that in the health area external funds are pooled and that min-
istries can use a common management and reporting format.
In addition, a research agenda to support acceleration toward
the health MDGs is being proposed; it needs to focus on how
to translate knowledge into action and on how to remove
health systems constraints to scaling up coverage of cost-
effective interventions that are available but do not reach those
who need them (Claeson and others 2004; Task Force on
Health Systems Research 2004).
NOTE
1. Intervention in this chapter refers to the direct action that leads to
prevention or cure.
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In health, more than in other social sectors, sex (biological) and
gender (behavioral and social) variables are acknowledged use-
ful parameters for research and action because biological differ-
ences between the sexes determine male-specific and female-
specific diseases and because behavioral differences between the
genders assign a critical role to women in relation to family
health. Until recently, however, the importance of sex and gen-
der informed work on female-specific diseases but did not carry
over to diseases shared by men and women. As a result, the
literature contained comparatively little about which diseases
affect men and women differently, why that difference might be
the case, and how to structure prevention and treatment in
response to these differences. This situation has changed, how-
ever, and interest in measuring, understanding, and responding
to sex and gender differentials in disease has surged, nurtured by
breakthroughs in science and advances in advocacy.1
In line with this interest and using global burden-of-disease
data for 2001, this chapter reviews worldwide gender differen-
tials in mortality and morbidity that result in excess disease
burdens for women and examines cost-effective interventions
drawn from chapters 17 (on sexually transmitted infections),
26 (on maternal and perinatal conditions), 29 (on health serv-
ice interventions for cancer control in developing countries),
31 (on mental disorders), 32 (on neurological disorders), 51
(on musculoskeletal disability and rehabilitation), and 57 (on
contraception) to address them.
The focus on women’s excess disease burden is justified to
fill gaps in knowledge regarding women’s health that are in part
a product of male bias and male norms in clinical studies. In
the past, medical research often wrongly assumed that women
were biologically weaker (male bias) and extrapolated findings
from trials with male subjects only (male norm) to both sexes,
whereas female biology can affect the onset and progression of
disease, and women’s lower position in society can affect their
health-seeking behaviors (Pinn 2003; Sen, George, and Ostlin
2002).
As A. K. Sen (1990) and others have indicated, gender bias
results in the neglect of female children and in selective abor-
tion and excess female mortality in China, India, and other
South Asian countries, explaining the “missing” women in pop-
ulation counts. In addition, such bias can have intergenera-
tional health effects, starting with maternal undernutrition
and leading to fetal growth retardation, low birthweight, child
undernutrition, and ailments in adult children of disadvan-
taged mothers (Osmania and Sen 2003).
This chapter only partially addresses women’s health needs.
It omits important disease conditions for women, such as lung
cancer and HIV/AIDS, where men and women currently have
similar disease burdens. (In the case of HIV/AIDS this balance
is changing, and women’s disease burden is rising over men’s,
especially for the 18–25 age group and for specific world
regions.) It also does not cover important sources of the disease
burden for women that are not measured in disability-adjusted
life years (DALYs), such as burden from female genital mutila-
tion (FGM). Last, the emphasis on disease underplays women’s
reproductive and other health needs.
ANTECEDENTS
The chapter’s emphasis on gender differentials and inequalities
in health rather than on women’s absolute health conditions
reflects the evolution of thinking on women and health issues.
Chapter 10
Gender Differentials in Health
Mayra Buvinic´, André Médici, Elisa Fernández, 
and Ana Cristina Torres
(Annex 10.A charts these advances in the past two decades,
highlighting milestones and influential publications.) In the
1960s and 1970s, the field of international women’s health issues
emerged from and was influenced by an interest in women’s fer-
tility behavior as a means of curbing population growth and by
an interest in maternal and child health to improve child wel-
fare, with little or no attention paid to mothers (McNamara
1981; Rosenfield and Maine 1985). Much of the work in the
1980s sought to bring a woman-centered perspective into pop-
ulation and maternal and child health programs. This focus
included awareness of how women’s lower status in society
affected health delivery and health-seeking behaviors and how
women’s time burdens in poor households affected child health.
The issues raised included the quality of care in health and
family-planning programs and the nature of women’s work and
its impact on child survival and health (Bruce 1990; Leslie
1988). Reducing maternal mortality became a major develop-
ment objective (Herz and Measham 1987).
The 1994 United Nations International Conference on
Population and Development in Cairo placed women’s repro-
ductive health and rights at the center of the population and
development debate, and the United Nations Women’s
Conference in Beijing the following year reinforced the impor-
tance of women’s empowerment and of a gender perspective
in health. Along with the global burden-of-disease effort,
researchers estimated the loss of women’s healthy years of life
caused by gender violence (Heise, Pitanguy, and Germain
1994), and gender was identified as central to women’s risk of
and treatment for HIV/AIDS (Gupta 2000; Mann 1993). The
World Health Organization analyzed how differences between
women and men in access to and control over resources deter-
mine differential exposure to risk and access to the benefits of
health technology and care (WHO 1998). After more than two
decades almost solely devoted to maternal and reproductive
health issues, attention expanded to cover a range of women’s
health issues unrelated to reproduction and to identify and cor-
rect gender differentials and inequities in health (Sen, George,
and Ostlin 2002). These new emphases complemented renewed
interest in health inequities and their reduction in the field of
international health (see, for instance, Evans and others 2001).
Framework
Both sex and gender matter in health. We use the term sex to
describe differences between men and women that are primar-
ily biological in origin and that may be genetic or phenotypic.
By contrast, we use the term gender to describe differences that
are primarily caused by social conditions or cultural and reli-
gious beliefs and norms regarding the sexes. Structural gender
inequalities that place women in a subordinate position to men
underlie and contribute to gender differentials in disease (Sen,
George, and Ostlin 2002). A gender perspective addresses dif-
ferences between men’s health and women’s health that arise
from this lower position and the consequent unequal power
relationship between the sexes. Sex and gender can act alone,
independently, or interactively in determining differentials in
the burden of disease (Krieger 2003). Some women’s excess
health burdens, such as uterine cancer, are based almost solely
on biology. At the other end of the continuum, some women’s
excess health burdens, such as injuries from domestic fires or
domestic abuse, are solely gender based.
However, in most cases sex and gender interact to determine
women’s disease burdens. Two salient examples are depressive
disorders and HIV/AIDS. Women are twice as likely as men to
become depressed, and genetics and hormones influence the
risk of depression. However, genes and sex hormones cannot
entirely explain women’s excess burdens, and gender factors
play an important role (WHO 2000). HIV infection rates
among teenage girls are 5 to 16 times higher than among
teenage boys in Sub-Saharan Africa. This earlier age of HIV
exposure for girls is partly explained by the greater biological
efficiency of male-to-female transmission and partly by girls’
lack of knowledge, opportunities, and bargaining power in sex-
ual relations that make them prime victims of the rapid spread
of the disease.
Existing knowledge about the interplay between sex and
gender in determining disease is imperfect and evolving
(Krieger 2003; Pinn 2003). This chapter groups women’s excess
health burdens from diseases into the following four broad
categories:
• diseases specific to women (that is, where biology plays a
major role in the disease) 
• diseases related to women’s average greater longevity (where
both sex and gender tend to play important roles) 
• diseases that result from the interaction of sex and gender
• diseases that are predominantly gender based (that is, that
result from specific behavioral, social, and cultural factors
associated with women’s condition).
Sex and gender have a much wider influence on disease than
is usually acknowledged. They influence the etiology, diagnosis,
progression, prevention, treatment, and health outcomes of
disease as well as health-seeking behaviors and exposure to risk.
Whereas sex plays a bigger role in the etiology, onset, and pro-
gression of disease, gender and its consequences influence dif-
ferential risks, symptom recognition, severity of disease, access
to and quality of care, and compliance with care. In addition,
poverty and social exclusion because of race and ethnicity
interact with sex and gender and contribute to women’s excess
disease burdens in ways that are largely unexplored to date
(Breen 2002).
Factors that influence gender differentials in relation to the
risk of disease include (a) biological (genetic, physiological, and
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hormonal) differences between the sexes; (b) women’s longer
life expectancy; (c) nature and rate of change of women’s
labor force participation compared with men’s participation;
(d) women’s differential access to social protection mecha-
nisms (health and social insurance); (e) cultural norms,
religious beliefs, and family arrangements and behaviors
determining gender roles and gender hierarchy in society;
(f) gender differences in educational attainment; (g) income
differences between the genders resulting from the interaction
of all the previous factors; and (h) interactions between race,
ethnicity, income, and gender.
Women’s overall underutilization of health services has been
well documented. For instance, even though women in India
report more illness than men, hospital records show that men
receive more treatment (World Bank 1996); in Thailand, men
are six times more likely than women to seek clinical treatment
for malaria, a disease that affects women and men similarly
(Hanson 2002); and in Brazil, the Dominican Republic,
Jamaica, Paraguay, and Peru, low-income women underuse
health services (Levine, Glassman, and Schneidman 2001).
Three groups of factors influence this underuse of health
services. The first group is service factors, such as accessibility;
affordability (money and time costs); and appropriateness or
adequacy, including friendliness, of the health and social infra-
structure for meeting women’s needs. The second group is user
factors, which include social constraints, such as restrictions on
women’s mobility and women’s average lower incomes and
greater time burdens than men’s; asymmetric information
about health needs and rights and the availability of services,
which disproportionately affects poor women; and marital sta-
tus, family roles, and work conditions affecting access and use.
The third group is institutional factors, including men’s
decision-making power and control over health budgets and
facilities, which affect local perceptions of illness and norms
concerning treatment, and stigmatization and discrimination
in health settings, which affect women among the poor and
women of minority ethnic and racial groups.
Context
The global demographic dynamic, a product of the interplay of
nature and nurture, biology and society, helps determine gen-
der differentials in health. In 2001, the world’s population, an
estimated 6.2 billion, was 50.3 percent male and 49.7 percent
female. The surplus male population was concentrated in the
developing countries, whereas the developed countries had a
higher proportion of women, primarily in the older age groups
(WHO 2001).
In the developed countries, the number of women age 80
and older was more than double the number of men in the
same age group. This female advantage in longevity helps shape
a gender paradox in health outcomes worldwide: on average,
males live shorter but healthier lives than females. Even though
more boys are born than girls, gender differences in mortality
eventually change the sex balance in populations so that by age
30 or so women start outliving men, and the absolute female
advantage in survivability increases with age (Kinsella and Gist
1998). Therefore, differences in life expectancy at birth by gen-
der, using 2000 data, vary in favor of females, ranging from one
year in the low-income countries of South Asia and Sub-
Saharan Africa to seven years in Europe and Central Asia and
nine years in the middle-income countries of Latin America
and the Caribbean.
Overall, however, women have higher morbidity than men.
Murray and Evans (2003) find that in relation to expected lost
healthy years at birth, whereas men lose 7.8 years over their
lifetimes as a result of poor health, women lose 10.2 years. In
other words, women spend about 15 percent of their lives in
unhealthy conditions and men spend just 12 percent. Therefore,
living longer lives should not be taken to indicate better health
for women. Women live less healthy lives and are saddled with
higher morbidity in part because they outlive men (Verbrugge
1989). Supporting the less healthy lives assertion, women up to
age 65 reported worse health status in virtually all 64 household
surveys from 46 countries (Sadana and others 2000). Because of
these differences in morbidity, the concept of healthy adjusted
life expectancy at birth describes differences in health conditions
between males and females better than the concept of life
expectancy at birth.
GENDER DIFFERENTIALS IN DISEASE BURDENS
The global burden of disease for 2001 proportionally affects
males slightly more than females. About 52 percent of DALY
losses are attributed to males, but this proportion varies
between 54.8 percent in Europe and Central Asia and 49.9 per-
cent in South Asia. The only region where the global burden of
disease affects females more than males is South Asia.
Table 10.1 shows the burden of disease by region, gender, and
age group. The burden of disease during early childhood (age 0
through 4) is somewhat smaller for girls than boys; however,
from age 5 through 29, females lose more DALYs than males,
but only in developing countries. Larger differences favoring
women appear starting at age 30 and continue until after the age
of 70, when women, because of their greater longevity, lose
more DALYs than men. However, when DALYs are estimated
per 1,000 males and females as in table 10.1, women in the
older age groups lose fewer DALYs than men both in low- and
middle-income countries (LMICs) and in high-income
countries (HICs).
Communicable diseases and maternal conditions con-
tribute significantly to females’ burden of disease in develop-
ing countries and add little to their burden in HICs, where
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noncommunicable diseases prevail in both women’s and men’s
disease burden. Injuries weigh more heavily in males’ than in
females’ burden of disease across regions. In summary, in both
developed and developing countries, the overall burden of dis-
ease is higher for males than for females; however, this situation
reverses in developing countries for young girls and women in
their prime childbearing years. In addition, in LMICs, females
are more affected than males by highly preventable communi-
cable diseases.
WOMEN’S EXCESS DISEASE BURDENS
The 2001 global burden-of-disease data underestimate both
women’s and men’s disease burdens because of the incomplete-
ness of health statistics, especially in the developing world. This
underestimation is probably more pronounced for women
because they experience more disability—which is less well
recorded than mortality—than men. This underestimation is
aggravated by underreporting resulting from the stigma associ-
ated with certain diseases in women, such as sexual infections;
the prevalence of asymptomatic illness, such as sexually
transmitted infections among women; the differences in
health-seeking behaviors that favor males accessing formal
health care, which is the main source for health statistics; and
the exclusion of some conditions that affect only women,
such as FGM, from global burden-of-disease estimations
(Hanson 2002). Thus, the findings in the preceding section
may be affected by a quality problem, and the estimates in this
section are probably conservative.
Table 10.2 breaks down 11 conditions specific to women
by region. In 2001, conditions specific to women accounted
for 5.3 percent of women’s total DALY losses, compared with
0.7 percent for two conditions (prostate cancer and benign
prostate hypertrophy) specific to men.2 Most causes of mortal-
ity or morbidity specific to women are related to maternal
conditions and malignant neoplasms. The DALY losses associ-
ated with conditions specific to women are around 6 percent in
both HICs and LMICs, but maternal conditions are more
prevalent in LMICs, whereas neoplasms cause more DALY
losses in HICs.
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Table 10.1 DALYs by Region, Gender, and Age Group, 2001
(DALYs per 1,000 population)
Age (years)
Region 0–4 5–14 15–29 30–44 45–59 60–69 70–79 80+ Total
Males
Low- and middle-income countries 754.6 75.4 137.4 194.5 349.3 600.1 799.4 950.8 271.5
East Asia and the Pacific 408.0 46.5 99.6 124.2 276.4 522.8 735.3 965.1 192.6
Europe and Central Asia 345.4 50.1 137.9 220.8 412.8 695.6 855.3 952.5 278.3
Latin America and the Caribbean 449.1 56.7 155.0 173.2 290.4 493.2 682.6 870.8 217.8
Middle East and North Africa 585.6 67.5 109.3 151.4 337.8 608.5 825.8 1,019.8 219.8
South Asia 805.2 83.0 131.9 196.0 383.0 661.7 861.7 899.6 285.1
Sub-Saharan Africa 1,480.7 142.2 248.2 532.2 609.0 778.6 1,002.5 1,194.3 528.6
High-income countries 128.2 28.6 84.4 97.0 189.6 355.7 541.5 721.5 168.2
World 698.5 70.9 131.1 178.5 315.4 540.4 721.0 856.7 256.3
Females
Low- and middle-income countries 753.4 78.5 142.5 162.1 275.3 501.3 745.4 946.7 259.8
East Asia and the Pacific 434.9 47.1 86.2 103.4 225.7 442.9 699.5 966.8 182.1
Europe and Central Asia 303.6 39.1 87.0 117.7 223.6 423.7 663.2 909.6 212.5
Latin America and the Caribbean 395.8 51.1 101.8 120.5 222.3 423.8 604.9 827.6 179.0
Middle East and North Africa 538.0 62.7 103.6 140.6 278.3 509.2 767.6 1,069.1 203.3
South Asia 865.5 98.3 168.7 188.5 334.0 616.6 901.0 938.3 304.4
Sub-Saharan Africa 1,367.4 138.7 317.3 448.9 478.8 701.4 1,009.8 1,196.5 504.3
High-income countries 117.5 28.9 72.5 77.7 144.8 258.4 414.6 625.9 153.3
World 696.5 73.7 134.2 148.1 247.2 441.6 641.0 800.0 243.4
Source: WHO 2001.
Table 10.3 shows the gender ratio and burden of disease of
eight conditions, by region, that are more prevalent among
women than among men. The selection of diseases was done
using as the threshold the mean plus one standard deviation
(SD) of the distribution of gender ratio scores for each disease.
The diseases selected were then screened for their importance
in women’s disease burden, using the same criterion of the
mean plus one SD in the distribution of DALY scores for
women. Although some diseases, such as unipolar depressive
disorders and osteoarthritis, are priorities for both HICs and
LMICs, others, such as Alzheimer’s disease, are more relevant
in HICs, reflecting women’s longer life expectancy. Conditions
such as age-related vision disorders, migraine, fires, and cere-
brovascular diseases have particular relevance in specific
regions.
Combining gender-specific conditions and shared condi-
tions that disproportionately affect women gives a total of 19
priority conditions for women. Taken together, these condi-
tions represent about one-fifth of women’s total DALY losses
and indicate priorities for research and the search for cost-
effective methods of promotion, prevention, and treatment.
Note that some important contributors to females’ health
burdens, such as malaria and HIV/AIDS, have been omitted
because females do not currently suffer disproportionately
from these diseases. However, the growing feminization of the
HIV/AIDS epidemic in developing countries should result in
excess disease burdens for women in the near future.
We determined priority conditions affecting females in dif-
ferent age groups using a method that took into account both
the gender ratio and the weight of specific conditions in
females’ total DALYs lost. The results indicate that women are
affected by communicable diseases and maternal conditions
until age 29 and by noncommunicable diseases after age 30,
with chronic diseases having a heavy weight during the last
stages of the life cycle. Conditions for which females’ burden of
disease is more or less double that of males at a specific stage in
the life cycle are migraine at age 5 to 14, fires and panic disor-
der at age 15 to 29, and unipolar depressive disorders at age 60
to 69.
PRIORITY DISEASE GROUPS FOR WOMEN
Table 10.4 presents conditions with excess burdens for women
divided into the four groups defined earlier.
Conditions Specific to Women
In developed countries, advances in medical technology have
almost eliminated the burden of disease resulting from mater-
nal conditions. Three types of cost-effective intervention pack-
ages for maternal conditions are the prevention of pregnancy by
means of effective family-planning methods; the prevention of
complications (for example, hemorrhage); and the prevention
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Table 10.2 Percentage of DALYs Resulting from Conditions Specific to Women by Region, 2001
East Asia Europe and Latin America Middle East
and the Central and the and Sub-Saharan
Condition HICs LMICs Pacific Asia Caribbean North Africa South Asia Africa World
Maternal 0.5 4.0 2.0 0.8 2.5 4.1 4.9 5.7 2.8
Maternal hemorrhage 0.0 0.6 0.2 0.0 0.2 0.4 0.8 1.0 0.5
Maternal sepsis 0.1 0.8 0.5 0.2 0.7 0.7 0.9 1.1 0.7
Hypertensive disordersa 0.0 0.3 0.1 0.0 0.2 0.2 0.4 0.5 0.3
Obstructed labor 0.0 0.4 0.1 0.0 0.1 0.3 0.6 0.5 0.3
Abortion 0.0 0.5 0.1 0.0 0.2 0.5 0.7 0.9 0.5
Other 0.4 1.4 1.0 0.6 1.3 2.0 1.5 1.7 0.5
Neoplasms 5.5 1.7 1.8 4.1 3.1 1.4 1.5 0.8 2.2
Breast cancerb 3.4 0.8 1.0 2.0 1.3 0.9 0.6 0.3 1.1
Cervix uteri cancer 0.4 0.6 0.5 0.7 1.0 0.3 0.7 0.4 0.6
Corpus uteri cancer 0.8 0.1 0.1 0.7 0.5 0.1 0.0 0.0 0.2
Ovarian cancer 0.9 0.2 0.3 0.7 0.3 0.1 0.2 0.1 0.3
Chlamydiab 0.1 0.3 0.2 0.2 0.4 0.5 0.4 0.3 0.3
Total 6.1 6.0 4.0 5.1 6.0 6.0 6.8 6.8 5.3
Source: WHO 2001.
a. Related to maternal conditions only.
b. Even though these conditions are not specific to women, women account for more than 90 percent of the DALY losses associated with these conditions.
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Table 10.3 Gender Ratio and Women’s Excess Burden of Disease for Top Priority Conditions by Region, 2001
Latin American Middle East 
East Asia and Europe and and the and North Sub-Saharan
World LMICs HICs the Pacific Central Asia Caribbean Africa South Asia Africa
BOD BOD BOD BOD BOD BOD BOD BOD BOD
Condition GR (percent) GR (percent) GR (percent) GR (percent) GR (percent) GR (percent) GR (percent) GR (percent) GR (percent)
Alzheimer’s disease 1.81 1.48 n.a. n.a. 2.13 7.02 1.55 1.51 2.40 2.16 1.63 1.58 n.a. n.a. n.a. n.a. n.a. n.a.
and other dementias
Osteoarthritis 1.64 1.46 1.63 1.26 1.71 3.30 1.64 2.15 1.76 2.76 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Unipolar depressive disorders 1.53 4.22 1.51 3.89 1.69 7.30 n.a. n.a. 1.73 5.15 1.72 6.94 1.44 3.86 1.56 4.33 1.54 1.17
Age-related vision disorders n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 1.63 2.10 n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Migraine n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 2.81 1.14 n.a. n.a. n.a. n.a. n.a. n.a.
Other cardiovascular diseases n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 1.45 3.20 n.a. n.a. n.a. n.a.
Fires n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 2.43 2.04 n.a. n.a.
Cerebrovascular diseases n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 1.47 1.80
Source: WHO 2001.
n.a.  not applicable; BOD  burden of disease; GR  gender ratio.
Note: The gender ratio is the ratio of female to male DALYs. 
For each world region or classification, data are shown only for those diseases that are classified as “priority” given that they meet the selection criteria according to the methodology used in this study (that is, the gender ratio was equal to or higher than the mean
plus one SD of the distribution of gender ratio scores, and in a second screening, the BOD was equal to or higher than the mean plus one SD of the distribution of female DALY scores). 
of death or disability resulting from complications through
emergency obstetric care. Proven technologies also exist for
screening and early detection of some neoplasms, although
their implementation has been uneven. Problems pertaining to
conditions in this category are not simply related to the avail-
ability of medical technologies, but also to the behavioral and
social factors that influence women’s exposure to risks and
underuse of services as well as the economic and institutional
factors that influence the availability and quality of services,
especially in developing countries.
Even though the international women’s health movement
has promoted significant advances in the quality of care
for reproductive health and maternal conditions in the past
25 years, the main challenges in relation to conditions specific
to women include reaching poor and socially excluded women
with basic maternal and reproductive health services;
strengthening the adoption of preventive health behaviors in
developing countries; extending the quality of care to other
conditions specific to women, including neoplasms; and edu-
cating and empowering women to promote their own healthy
behaviors.
Conditions Associated with Women’s Greater Longevity 
The main group of diseases with excess burdens for women
associated with women’s greater longevity are Alzheimer’s
disease; musculoskeletal disorders, such as osteoarthritis,
rheumatoid arthritis, and osteoporosis; and cardiovascular dis-
eases,3 which together account for 12 percent of total DALY
losses for women worldwide. LMICs account for about 80 per-
cent of the DALYs resulting from these conditions, likely
because of the lack of medical care during the early stages of
these diseases.
Alzheimer’s disease and other dementias account for 1.5 per-
cent of total female DALYs, and this burden is almost twice as
high as that for men. About 46 percent of this burden is
concentrated in HICs and 54 percent in LMICs, but DALYs lost
per capita are much greater in the HICs than in more densely
populated LMICs. Because of population aging, during the
next 50 years the number of people with Alzheimer’s disease is
expected to more than double, with more women affected than
men (McCann and others 1997). Studies of the effects of estro-
gen therapy on Alzheimer’s disease have been inconsistent:
estrogen may increase the risk of both dementia and other dis-
eases such as stroke in postmenopausal women (Shumaker and
others 2003).
As concerns musculoskeletal disorders, osteoarthritis affects
9.6 percent of men and 18.0 percent of women age 60 or older
worldwide and accounts for 1.5 percent of total female DALYs.
Osteoarthritis is related to aging and is most common in over-
weight women over the age of 45. Demographic changes in
developing countries, especially middle-income countries,
indicate that osteoarthritis prevention and treatment needs will
increase during the next decade. Most prevention and treat-
ment are linked to regular exercise, healthy weight manage-
ment, physical and occupational therapy, and pain manage-
ment with over-the-counter medications.
Because cardiovascular diseases are generally thought of
by society as “men’s diseases,” women tend to delay seeking
treatment for cardiac-related events (Seils, Friedman, and
Schulman 2001). However, cardiovascular and cerebrovascular
diseases account for about 8.2 percent of total female DALYs,
more than half of which is caused by cerebrovascular
diseases.
In addition to age, smoking, and obesity, another risk factor
that exposes women to a greater burden of cardiovascular
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Table 10.4 Priority Conditions by Category, 2001
Region where
Gender gender ratio is
Category and condition ratio apparent
Conditions specific to women
Maternal hemorrhage n.a. n.a.
Maternal sepsis n.a. n.a.
Hypertensive disorders related n.a. n.a.
to maternal conditions
Obstructed labor n.a. n.a.
Abortion n.a. n.a.
Other maternal conditions n.a. n.a.
Breast cancer 244.62 World
Cervix uteri cancer n.a. n.a.
Corpus uteri cancer n.a. n.a.
Ovarian cancer n.a. n.a.
Chlamydia 9.76 World
Conditions associated with women’s greater longevity
Alzheimer’s disease and 1.81 World
other dementias
Osteoarthritis 1.64 World
Cerebrovascular diseases 1.47 Sub-Saharan Africa
Other cardiovascular diseases 1.45 Middle East and 
North Africa
Age-related vision disorders 1.63 Europe and
Central Asia
Conditions arising from the interaction of sex and gender
Unipolar depressive disorders 1.53 World
Migraine 2.81 Latin America and
the Caribbean
Gender-based conditions
Fires 2.43 South Asia
Source: WHO 2001.
n.a.  not applicable.
diseases is depression, which is associated with increased
morbidity and mortality from heart diseases and is highly
prevalent in women (Linfante and others 2003). Also, women’s
symptoms of heart disease tend to be different from men’s,
increasing the difficulties of diagnosis (Seils, Friedman, and
Schulman 2001). Finally, evidence suggests that physical 
activity significantly reduces the risk of cardiovascular events;
however, women tend to exercise less than men (Manson and
others 2002). Whether this observation can be generalized to all
age groups and whether it occurs because of biological factors
or social norms deserve further attention.
Conditions Arising from the Interaction of Sex and Gender 
In the group of conditions resulting from the interaction of
biological and social factors, unipolar depressive disorders have
the most significant gender ratio and most unequal burden
of disease in every region except East Asia and the Pacific.
Unipolar depressive disorders account for 4.2 percent of
women’s global burden of disease. Even though the DALYs lost
per capita are similar in LMICs and HICs, these disorders
represent a higher share of women’s total burden of disease
in HICs (7.3 percent) than in LMICs (3.9 percent). Another
important consideration is the high comorbidity between
depression and other psychiatric disorders (for example,
anxiety disorders). Neuropsychiatric disorders account for
11.8 percent of women’s total global burden of disease and
23.5 percent in HICs.
The exact contributions of biology and society in the etiol-
ogy of depression are unknown. Some believe that genetic
causes account for about half of the risk for mood disorders
(Zubenko and others 2002), whereas others suggest that gender
roles, stressors, social relationships, and personality traits
may play a larger role than hormones and neurotransmitters
(Bromberger 2004). As concerns biology, aside from genetic
predisposition, the fluctuation of sex hormones, especially
estrogen, during women’s reproductive life is believed to be an
important risk factor for depression (Bromberger 2004). As
concerns social factors, poverty; lack of proper nutrition and
education; stressful and insecure life circumstances; and
domestic and sexual violence and the concomitant feelings of
loss, entrapment, and lack of control are likely at the root of
depression (Bromberger 2004; WHO 2000).
Treatment for depression includes medication and psy-
chotherapy or counseling, and instruments are available to
assess the severity of depression, including prenatal and post-
partum depression. In developing countries, severe depression
and anxiety disorders go mostly untreated (76 to 85 percent of
serious cases receive no treatment), partly because of igno-
rance, social barriers, and stigmatization, which may affect
women’s access to treatment (WHO 2004). A main challenge,
therefore, is increasing women’s access to treatment for
depression in developing countries by creating systems that
help them overcome social stigma and economic and social
barriers.
In addition to treatment, prevention of depression and
other mental illness needs to address women’s role in society
and the control they have over their lives and circumstances.
According to the World Health Organization, pertinent factors
are related to having sufficient autonomy to exercise some
control in response to severe events, access to adequate
resources to be able to make choices, and social supports
(WHO 2000). The promotion of healthy behaviors, including
exercise, is also crucial for prevention.
Gender-Based Conditions 
The main characteristic of gender-based conditions is that they
have no biological referent and can, therefore, be prevented by
means of behavioral change. The role of social components in
this category explains excessive health burdens for women in
particular world regions. For example, women are dispropor-
tionately affected by fires in South Asia, an outcome of the vio-
lence caused by dowries. Too often women die in what are
called “cooking fire accidents,” whereas in reality they are mur-
dered so that their husbands may remarry and obtain another
dowry.
Another characteristic of the diseases and injuries in this
category is that they are often underreported because of
stigma and social pressures. As a result, the data probably
underreport the true extent of the problem. FGM and domes-
tic violence are two examples. In 2000, estimates indicated
that 100 million to 140 million girls and women had under-
gone FGM and that more than 2 million girls were at risk. At
least 28 African and Middle Eastern countries practice FGM
for social, cultural, or religious reasons (WHO 2000).
Unfortunately, global burden-of-disease data do not report
the resulting DALYs lost. Regarding violence against women,
10 to 50 percent of women report having been physically
abused by an intimate partner, and 12 to 25 percent report
attempted or completed forced sex. Although men experience
more absolute DALY losses from violence, women are also
seriously affected. In 1998, interpersonal violence was the
10th-leading cause of death for women age 15 to 44
worldwide.
Given the complexity of these health problems, comprehen-
sive interventions are necessary. Changes are needed in the
following areas:
• legislation and law enforcement
• public policies and programs in areas such as health, educa-
tion, and police and legal services
• training of service providers and creation of gender-
sensitive services, especially at the community level 
202 | Disease Control Priorities in Developing Countries | Mayra Buvinic´, André Médici, Elisa Fernández, and others
• education of the general public to create awareness, behav-
ioral change, and promotion of advocacy groups 
• better data collection, research, and understanding of
the individual and social mechanisms sustaining these
problems.
COST-EFFECTIVENESS OF INTERVENTIONS
This section summarizes the costs and health benefits of strate-
gies to address conditions that are specific to women and
conditions that affect women disproportionately. Table 10.5
presents cost-effectiveness estimates for recognized effective
interventions.
Conditions Specific to Women
Conditions specific to women include the cluster of diseases
related to women’s maternal function plus chlamydia (which is
predominantly but not exclusively a female disease) and
female-specific cancers.
Maternal Conditions. The analysis developed in chapter 26
uses a model for maternal and perinatal conditions that gener-
ates 128 potential scenarios. According to the findings of this
theoretical exercise, the cost per DALY averted of mother and
baby packages could vary from US$77 to US$151 in Sub-
Saharan Africa and from US$143 to US$278 in South Asia,
depending on the complexity of the intervention.
Prenatal care prevents almost a quarter of maternal deaths,
especially when backed by essential and emergency obstetric
care to deal with conditions detected during the course of
pregnancy care. Good prenatal care includes information, edu-
cation, and communication activities and behavior-change
communication to increase women’s skills in relation to the
identification of danger signs and potential complications and
where to seek care in these cases (Dayaratna and others 2000).
In Uganda, for example, integral prenatal care ranged from
US$2.26 (public services) to US$6.43 (religious mission
services) per pregnant woman per year (Levin and others 1999).
Another important service is supplementation with iron
and folic acid. Iron deficiency accounts for 1.8 percent of
women’s deaths and 2.6 percent of female DALY losses. Iron
and folic acid supplements administered to highly anemic
pregnant women can save lives at a cost of US$13 per DALY
averted (Berman and others 1991), demonstrating that this
intervention is very cost-effective.
Good maternal health services can strengthen the entire
health system. A health facility that is equipped to provide
essential obstetric care can also treat accidents, trauma, and
other medical emergencies. The costs of emergency obstetric
care vary depending on the country. In Uganda, costs per
episode vary from US$73 (public hospital) to US$86 (mission
hospital) (Levin and others 1999). In Bolivia, the cost of a
cesarean section ranges from US$56 to US$104 (Rosenthal and
Percy 1991), and the cost of a normal delivery varies from
US$11 to US$16 (Dmytraczenko and others 1998).
In developing countries, 61 percent of maternal deaths
occur 23 to 48 hours after delivery because of such problems as
postpartum hemorrhage and hypertensive disorders or after
48 hours because of sepsis. Complications from unsafe abor-
tions account for 13 percent of maternal deaths, though this
figure is probably an underestimate because of the scarcity of
data. Little information is available on costs related to postna-
tal care given the different kind of interventions and the sever-
ity of cases, but the literature generally agrees that emergency
obstetric care can reduce costs. As concerns postabortion care,
costs per case in LMICs could vary from US$4.40 to US$17.19
(Dayaratna and others 2000).
Millions of premature deaths, illnesses, and injuries could be
avoided by helping women prevent unwanted pregnancies and
obtain prompt treatment for reproductive health problems. The
contraception costs per couple-year of protection could vary,
depending on the method used, from US$6 (intrauterine
device) to US$20 (condoms or injections) (Dayaratna and
others 2000). A 1999 experiment by the Planned Parenthood
Association of South Africa considered total health planning
costs per couple-year of protection, including travel expenses to
health clinics. Comparing these costs with total health planning
costs in services provided by community-based doctors, the
study found that the former cost US$44 per couple-year of pro-
tection and the latter cost US$42.
Chlamydia. Although not specific to women, chlamydia is
nine times more prevalent among women than among men,
and its consequences and treatment are much more compli-
cated and severe for women, affecting women’s and infants’
health during pregnancy and the postnatal period. Chlamydia
is widespread in low-income countries. Chlamydia, as well as
other sexually transmitted diseases, could be prevented by
using condoms, with an average cost per DALY averted in
developing countries estimated at US$3.40 in noncore target
groups and US$12.60 in core target groups (Mumford and
others 1998). Detecting chlamydia in pregnant women could
cost $4.38 per case, with treatment, at $3.82 per case, being less
expensive than detection (Shultz, Schulte and Berman 1992).
Chlamydia’s adverse effects are trachoma (chronic conjunctivi-
tis, endemic in Africa and Asia), reproductive tract infections,
genital ulcer disease in tropical countries, and infertility. The
cost of each adverse outcome averted varies from about US$85
to US$308 (Shultz, Schulte, and Berman 1992).
Neoplasms. Cancers specific to women are responsible for
high levels of female morbidity and mortality, with cervical
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Maternal conditions
Mother and baby package
Mother and baby package
Mother and baby package
Mother and baby package
Integral prenatal care 
Iron and folic acid nutritional
supplementation
Emergency obstetric care
Cesarean delivery
Normal delivery
Postabortion care (dilation
and curettage) 
Total health-planning costs 
Chlamydia
Prevention
Prevention (use of condoms) 
Detection
Treatment
Detection and treatment
Neoplasms
Detection of cervical cancer
Cervical cytology screening
Cervical cytology screening
Treatment of cervical cancer
Treatment of cervical cancer
Treatment of cervical cancer
Treatment of ovarian cancer
Management of breast
cancer
LMICs
LMICs
Sub-Saharan Africa
South Asia
Uganda
Low-income countries
Uganda
Bolivia
Bolivia
LMICs
South Africa
Developing countries,
1990
Developing countries, 
Various sites, 1992
Various sites, 1992
Various sites, 1992
Ecuador, 1996
Honduras, 1991
Zimbabwe, 1995
Vietnam, 2000
South Africa, 2000
Zimbabwe, 1994
Mexico, 1994
Developed countries
Developed countries
Thailand, 1995
Brazil, 1995
US$2 per capita
US$18 per DALY averted
US$77 per DALY averted
US$143 per DALY averted
US$2.26 per pregnant woman
US$13 per DALY averted in highly
anemic pregnant women
US$73 per episode
US$56 per case 
US$11 per case
US$4.40 per case
US$42 per couple-year of
protection
US$47.98 per DALY averted
(noncore target groups)
US$3.40 per DALY averted
(noncore target groups)
US$4.38 per pregnant woman
US$3.82 per pregnant woman
US$84.92 per adverse outcome
averted in low-prevalence context
(5 percent)
US$2.95 per visit
US$5.60 per visit
US$2.99 per visit
US$725 per discounted DALY
averted 
US$39 per DALY averted
US$12.35 per visit 
US$52.51 per visit
US$2,384 to US$28,770 per DALY
averted based on actual survival
US$308 to US$3,712 per DALY
averted based on estimated
survival
US$234.25 per case 
US$1,667.88 per case
US$4 per capita
US$58 per DALY averted
US$151 per DALY averted
US$278 per DALY averted
US$6.43 per pregnant woman
n.a.
US$86 per episode
US$104 per case
US$16 per case
US$17.19 per case
US$44 per couple-year of
protection
US$651.82 per DALY averted
(core target groups)
US$12.60 per DALY averted
(core target groups)
n.a.
n.a.
US$307.88 per adverse
outcome averted in high-
prevalence context 
(20 percent)
US$3.51 per visit
(laboratory costs)
US$12.89 per visit 
US$3.89 per visit
n.a.
US$81 per DALY averted
US$95.82 per visit
US$432.42 per visit
n.a.
n.a.
US$472.27 per case
n.a.
WHO 1997
Raviez, Griffin, and Follmer
1995; World Bank 1993
Chapter 26 of this publication
Chapter 26 of this publication
Levin and others 1999
Berman and others 1991
Levin and others 1999 
Rosenthal and Percy 1991 
Dmytraczenko and others 1998
Dayaratna and others 2000
Dayaratna and others 2000
Over and Piot 1993 
Mumford and others 1998
Shultz, Schulte, and Berman
1992
Shultz, Schulte, and Berman
1992
Shultz, Schulte, and Berman
1992 
Mumford and others 1998
Mumford and others 1998
Mumford and others 1998
Suba and others 2001
Goldie and others 2001 
Mitchell, Littlefield, and
Gutter 1997
Rose and Lappas 2000 
Rose and Lappas 2000
Tintara and Leetanapon 1995
Arredondo, Lockett, and Icaza
1995 
Table 10.5 Cost-Effectiveness of Selected Interventions Aimed at Conditions Specific to Women or That Affect
Women Disproportionately
Intervention Region or country Lower end of range Upper end of range Source
cancer being one of the most important. Recommended strate-
gies involve early detection and treatment. The following are
the main strategies to prevent cervical cancer:
• screening and treatment performed during the same visit 
• screening and treatment performed at two separate visits 
• traditional three-visit intervention, in which a cytology sam-
ple is obtained during the first visit, a diagnostic colposcopy
is performed for those who screened positive during the sec-
ond visit, and treatment is provided at the third visit.
The data on costs associated with cervical cancer detection
and treatment in developing countries are limited. In
Honduras in 1991, costs per visit for cervical cancer detection
varied from US$5.60 (small clinics) to US$12.90 (larger clinics)
(Mumford and others 1998). Lower detection costs were found
in Ecuador in 1996 (US$2.95 to US$3.51 per visit) and in
Zimbabwe in 1995 (US$3.00 to US$3.90 per visit). Recent stud-
ies on cervical cancer screening in South Africa show that the
two-visit method is more cost-effective than the traditional
three-visit method, US$39 per DALY averted compared with
US$81 (Goldie and others 2001). Studies in Vietnam found
costs equivalent to US$725 per DALY averted with cytology
screening (Suba and others 2001).
Regarding treatment of cervical cancer, Rose and Lappas’s
(2000) studies in developed countries find costs varying from
US$2,384 to US$28,770 per DALY averted. Costs are lower in
developing countries, ranging from US$52.51 to US$432.42
per visit in Mexico and from US$12.35 to US$95.82 per visit
in Zimbabwe. Differences in treatment costs are associated
with the kinds of procedures used. How the results of cost-
effectiveness studies for cervical cancer prevention and screen-
ing interventions in developed countries might translate to
health care delivery settings in developing countries is not clear,
but prevention could clearly play an important role.
Many studies of breast cancer prevention view diet as an
important condition explaining the predisposition for breast
cancer. Ministries of health in many developing countries invest
in promotion and prevention, issuing communications and
guidelines for early detection using self-testing as a cost-effective
way to provide information.Few studies of the cost-effectiveness
of different breast cancer treatments are available, especially in
developing countries. One on the management of breast cancer
in Brazil in 1995 showed extremely high costs of US$1,678 per
death averted (Arredondo, Lockett, and Icaza 1995).
Conditions That Affect Women Disproportionately
Few studies on shared diseases that affect women dispropor-
tionately include gender-related considerations, especially in
developing countries. Most literature on Alzheimer’s disease,
unipolar depressive disorders, and osteoarthritis presented in
this section is based on studies in developed countries with
no specific analysis of gender differences in relation to cost-
effectiveness.
Alzheimer’s Disease and Other Dementias. Alzheimer’s dis-
ease is linked to genetic and other risk factors, including
Gender Differentials in Health | 205
Acetylcholinesterase
inhibitors
Osteoarthritis
Celecoxib monotherapy
Rofecoxib monotherapy
Different packages of drugs,
including acetaminophen,
naproxen, misoprostol,
celecoxib, and rofecoxib
Total hip arthroplasty 
Knee replacement
Developed countries
Developing countries
Sweden
United Kingdom
United States
United States
Australia
US$13 per hour of caregiver time
saved
US$10 per hour of caregiver time
saved
US$1,394 per QALY
US$2,184 per life year saved (result
was sensitive to the use of gas-
trointestinal protective agents)
US$2,001 to US$2,140 per QALY,
depending on the drug
combination
US$6,893 per QALY for 
85-year-old men
US$6,000 per QALY
n.a.
n.a.
n.a.
n.a.
n.a.
n.a.
Marin and others 2003
Marin and others 2003
Haglund and Svarvar 2000 
Moore and others 2001 
Sigal 2002 
Chang, Pellissier, and Hazen
1996 
Sigal and others 2004 
Alzheimer’s disease and other dementias
Source: Authors. 
QALY  quality-adjusted life year.
Note: Costs are based in current U.S. dollars as presented in each study. Many studies do not present well-documented data regarding reference period of costs. To avoid mistakes on interpretation, we
kept the costs in the currency informed by the authors. n.a. indicates that information is not available.
Table 10.5 Continued
Intervention Region or country Lower end of range Upper end of range Source
increasing age, positive family history of dementia, and lower
levels of education. Treatment is based mostly on drugs, and
the practical benefits of treatment translate mainly into
reduced caregiver hours.
Some studies have found that interventions aimed at reduc-
ing caregiver stress, even providing low-dose antipsychotic
medication, can be effective. However, the costs of undertaking
such interventions have not been quantified; thus, their cost-
effectiveness cannot be calculated. Institutional care for
patients with any form of dementia is extremely limited in
LMICs. The costs of setting up institutions for those with
Alzheimer’s disease and the costs of care are prohibitive. In this
context, inexpensive, home-based care appears to be the only
viable option for Alzheimer’s disease patients in developing
countries. These countries will therefore have to face the chal-
lenges of addressing families’ needs in relation to financial and
social support and caregiver training. Another issue is the
tradeoff between women’s income-earning opportunities and
their traditional primary role as family caregivers.
Unipolar Depressive Disorders. Depression is among the
most disabling and costly illnesses in the world, especially for
women. Despite good short-term treatment outcomes, long-
term outcomes remain disappointing. Costs associated with
depression affect not just the sufferers themselves, but also their
families and friends (time dedicated to caregiving); employers
(payment for treatment and care, as well as for reduced pro-
ductivity); and society (provision of mental health care
financed by taxpayers). Most of these costs are difficult to
obtain, but the consensus is that the indirect costs of depression
are larger than the direct costs.
The treatment setting for depression is usually primary
health care, with many kinds of episodic treatments combining
old and new generations of antidepressants and psychosocial
procedures. Averting depressive episodes results in average
gains of up to 50 disability days per treated case per year. Studies
of the factors influencing women’s access to screening, preven-
tion, and treatment for depression and the cost-effectiveness of
treatment options should be a priority in developing countries.
Osteoarthritis. Despite clear evidence of a reduction in symp-
toms and delayed progression of osteoarthritis with weight
reduction, no formal studies of cost-effectiveness are available.
Education and exercise programs for osteoarthritis are avail-
able in developed countries, but such programs are unknown
in developing countries. Studies of the effect of diet and physi-
cal exercise in preventing osteoarthritis in women are a priority
not just in developed countries, but especially in developing
countries with fiscally strapped health systems and growing
elderly populations.
Acetaminophen is thought to be the most cost-effective ini-
tial treatment with drugs. In addition, some cost-effectiveness
measures of using several kinds of medicines (acetaminophen,
naproxen, misoprostol, celecoxib, and rofecoxib) under differ-
ent conditions are available. Sigal (2002) shows that by using
different combinations of medicines, treatment costs can vary
from US$2,001 to US$2,140 per quality-adjusted life year, but
these costs are prohibitive for developing countries.
Another treatment for osteoarthritis is synovial fluid replace-
ment, but given the costs of this intervention, it is not currently
recommended for developing regions. Surgical interventions
for osteoarthritis, such as joint replacement,are most commonly
performed in developed countries. Sigal and others (2004)
review a number of interventions for osteoarthritis and suggest
a cost per quality-adjusted life year of US$6,000 for knee
replacements. In developing countries, however, the availability
of surgical interventions is constrained by its costs and by the
availability of surgeons qualified to perform the operation.
RESEARCH AGENDA
Health research and practice should give priority attention to
the 19 conditions with excess burdens for women that this
chapter has identified and clustered into four main groups,
according to the interplay of sex and gender in their etiology, to
improve women’s health status worldwide. A number of cost-
effective health technologies are available, but women are dying
because these technologies are not available and accessible to
all. Thus, a priority need is to deploy them more widely in
developing countries. The research challenge is also urgent,
given the unacceptably high disease burdens for women in
developing countries and the rising numbers of older women
worldwide. Research on sex and gender factors affecting
women’s disease burdens should give physicians new informa-
tion that will increase their options in relation to diagnostic
practices and drug approaches, not only for women, but
also for men, thereby improving the provision of gender-
appropriate health care for all.
Key general items in a research agenda to reduce women’s
excess disease burdens include the following:
• Expand and sharpen analyses of sex and gender and their
interaction in the etiology, onset, progression, prevention,
and treatment of diseases that women and men share, but
where women face an excess health burden, and in the
assessment of cost-effective interventions.
• Increase research to identify the determinants of women’s
underuse of health services, paying special attention to the
accessibility, affordability, and appropriateness of services.
Identify and analyze best practices in health service delivery
that incorporate gender variables to inform training and
human resource development programs for health sector
providers in developing countries for both services specific
to women and general services.
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• Investigate how interactions between sex and gender, race,
ethnicity, and poverty affect the etiology, onset, and pro-
gression of disease as well as access to and compliance with
prevention and treatment. Investigate the effects of stigma-
tization and discrimination on service quality and use.
• Use demographic accounting methods to project and plan
for the demands that women’s overall greater longevity
imposes on health systems and investigate cost-effective
treatment options, effect of gender variables on prevention
and treatment, and viable options for increasing older
women’s access to health and to social insurance and pro-
tection mechanisms. Investigate affordable options for fam-
ily care of elderly patients that take into account the time
and the physical and emotional burdens on women, the
traditional family caretakers.
• Improve the methodology used for disease classification, and
expand data collection efforts to address the largely unre-
ported causes of women’s disease burdens, emphasizing con-
ditions specific to women, including FGM and other domes-
tic-, social-, and religious-based violence against women.
• Promote research, health promotion activities, health
services, and advocacy efforts that will help women adopt
desirable nutrition and physical exercise practices for opti-
mal health. Exercise is a preventive measure that can help
reduce women’s excess disease burdens throughout the life
cycle and has numerous indirect psychological and social
benefits, but it will often require changing deeply rooted cul-
tural mores.
• Support research on the costs and effectiveness of treat-
ments for diseases that affect both men and women but
affect women disproportionately, especially in developing
countries.
Research needs pertaining to specific conditions include the
following:
• Carry out further testing of innovative technologies for
diagnosing neoplasms specific to women and explore new
options for preventing their growth and proliferation.
Regarding treatment, the literature describes few best prac-
tices and cost-effective measures, especially for breast and
ovarian cancer.
• Evaluate the viability of applying the results of cost-
effectiveness analysis carried out in developed countries
on the prevention and treatment of cancers specific to
women in developing countries to help adapt viable
procedures.
• Promote and study the cost-effectiveness of approaches to
preventing Alzheimer’s disease, osteoarthritis, and other
chronic conditions related to aging.
• Compare the prevalence of Alzheimer’s disease in
different populations, including carrying out genetic epi-
demiology studies to assess the importance of different
genetic risks.
• Expand research on the biological and behavioral determi-
nants of depression in women, on screening alternatives,
and on cost-effective prevention and treatment options
adapted to specific contexts in developing countries.
Explore ways to reduce the stigmatization and discrimina-
tion associated with depression in developing countries.
• Continue research to document the risks and benefits of
common, but unproven, approaches of preventing and
treating diseases specific to women, such as the finding that
long-term hormone replacement therapy does not reduce
cardiovascular disease in postmenopausal women as had
long been thought but instead increases risks for cardiovas-
cular disease and breast cancer.
• Establish a research program to document the prevalence
and disease burdens associated with FGM, and seek preven-
tion and treatment alternatives.
CONCLUSIONS
The purpose of this chapter has been to move beyond the
traditional international health focus on women’s diseases
related to their reproductive and maternal functions and to
highlight those conditions for which sex and gender consider-
ations, if adequately incorporated into prevention and treat-
ment, could reduce women’s excess health burdens and, as a
result, increase health equity. Because of the approach taken,
the chapter has excluded a set of important conditions for
which the gender ratio is similar or is unfavorable for men,
including HIV/AIDS, injuries resulting from domestic vio-
lence, and malaria. Therefore, this chapter should not be
viewed as covering all diseases and conditions important to
women or all conditions that result from the interaction of sex
and gender.
The chapter has two other main limitations. First, the dataset
(the global burden of disease) understates certain disease
burdens, especially for women, because it does not estimate
disability weights for some gender-based conditions, such as
FGM. Second, the information available for cost-effectiveness
analysis is inadequate. Following this chapter’s emphasis on the
importance of sex and gender in explaining women’s excess
disease burdens, assuming that sex and gender considerations in
prevention and treatment would affect the analysis of cost-
effectiveness seemed reasonable; however, general information
for assessing cost-effectiveness was deficient, and gender-related
information was entirely lacking. This limitation was additional
to the common limitation of cost-effectiveness analysis in terms
of underestimating the value of prevention for conditions spe-
cific to women and non–health sector interventions important
to women.
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Annex 10.A Milestones and Influential Works in International Women’s Health (1980–2003)
Year Milestones and Influential Work
1980 • Maternal and child health
• Infant feeding practices
• Women’s reproductive and fertility behaviors
1984 • Child survival research (Mosley and Chen 1984)
• Women’s issues for child survival
1985 UN Women’s Conference in Nairobi • Gender perspective/framework (DAWN)
1987 Safe Motherhood Initiative (World Bank) • Barber Conable speech (Conable 1986)
• Herz and Measham 1987
Reproductive Health and Dignity: Choices by • Germain 1987
Third World Women (International Women’s 
Health Coalition)
1988 Women’s Work and Child Nutrition (Leslie 1988) • Debunks myth of incompatibility between breastfeeding and work
1989 Quality of Care for Women in Family Planning • Quality of care (Bruce 1990)
(Population Council)
1990 1990–1994: 10 Working Papers (World Bank)
1992 Women’s Health: Across Age and Frontier (WHO)
1993 Disease Control Priorities in Developing 
Countries (World Bank)
1994 New Agenda for Women’s Health and • Lifecycle approach to account for specific and cumulative effects of nutrition
Nutrition (World Bank) • Cost-effective intervention packages advocated
• Women and AIDS (Mann 1993)
• Stigma and lack of empowerment as risk factors
International Conference on Population and • Agenda setting, policy making, and programming for reproductive health since
Development, Cairo the 1994 Cairo conference
1995 UN Beijing Women’s Conference • Reproductive health and rights
1996 In Her Lifetime: Female Morbidity and Mortality • Burdens exclusive to, greater for, and of particular significance to women 
in Sub-Saharan Africa (Institute of Medicine) reviewed
• Burdens tracked across life span
1998 Women, Aging and Health (WHO) • Social, cultural, political, economic determinants of major health issues facing
aging and postmenopausal women
• Life-cycle approach
Gender and Health: A Technical Paper (WHO) • Role of social and cultural factors and power relations between men and 
women in promoting and protecting health
1999 Safe Motherhood and the World Bank • Effect of safe motherhood on labor supply, productive capacity, community 
economic well-being
Gender and HIV/AIDS (Joint United Nations • Gender-specific personal and societal vulnerability to HIV/AIDS
Program on HIV, International Center for 
Research on Women)
2000 Women of South East Asia: Health Profile (WHO) • Life-cycle approach to review gender-specific and disproportionate burdens
Improving Women’s Health: Issues and • Role of biological and social factors in women’s exposure risk and disease 
Interventions (World Bank) progression
• Life cycle approach
• Life-stage focus: adolescents, postreproductive age, and so on
• Burden focus: cervical cancer, abortion, HIV/AIDS, reproductive tract infections,
violence, and so on
• Socioeconomic, cultural, and legal factors affecting women’s health
• Policy directions for women’s nutrition
• Access and empowerment
• Cost-effectiveness issues in women’s health 
• Missing women in India (A. K. Sen 1990)
• Sector study of women’s health in India (1992)
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NOTES
1. See, for instance, the documentation of efforts to understand gender
differentials in infectious diseases (Altman 2004) and in unipolar depres-
sive disorders (Gilbert 2004).
2. Males suffer the weight of some external causes in the burden of dis-
eases more than females. For example, in 2001, mortality and morbidity
caused by war and violence worldwide accounted for about 2.7 percent of
males’ total DALY losses and 0.6 percent of females’ losses.
3. Cardiovascular diseases include cerebrovascular diseases but do not
include ischemic heart disease, which affects men more than women, or
coronary artery disease.
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Governments use fiscal policy to encourage healthy behavior.
The instruments of government for this purpose are taxes and
subsidies, and direct provision of certain health services for free
or at subsidized rates. Examples of fiscal policies for health are
taxes on tobacco and alcohol, subsidies on certain foods, and
tax incentives for health care purchases.
Government intervention through fiscal policy works best
when public institutions and credibility are strong, the design
and application of the fiscal instruments are appropriate, and
consumers’ and producers’ responsiveness to a price signal is
high. When these conditions are not present, direct provision,
information and education campaigns, or legislation may be
preferable in conjunction with fiscal policy.
The purpose of this chapter is to review country experiences
with promoting health through fiscal policies and to examine
the usefulness and success of these policies. The chapter consid-
ers both the role of fiscal policies in the production of health and
the effect of these policies on the well-being of the economy—
fiscal policy for health and healthy fiscal policy.1 Little exists in
the literature linking fiscal policy and health promotion except
in relation to tobacco. This work contributes to filling that gap.
The chapter deals specifically with experiences at the coun-
try level with tax policies affecting some goods related to
health, such as food, tobacco, alcohol, and condoms; subsidized
provision of workplace promotion of healthy behavior and
caregiving; and direct subsidies affecting food provision and
fortification, cooking fuels, water purification and soap, con-
doms, bednets, vaccines, and medical research. The chapter
only touches on health care provision and does not discuss its
financing, either directly by governments or through insur-
ance, because other chapters deal with those topics.
The chapter is divided into five sections:
• The first section provides a general framework through
which fiscal policy options can be considered in terms of
their impact on health and the health sector.
• The next section examines the experiences in developing
countries of using subsidies to achieve health-related objec-
tives (columns 1 and 2 in table 11.1).
• The third section presents examples of how taxes are used
in a number of countries to promote health (column 3 in 
table 11.1).
• The next section discusses nonhealth goods where fiscal
policies are often used and have important indirect health
benefits (lower part of column 2 in table 11.1).
• The final section presents conclusions and suggestions for
further research and policy development.
USE OF FISCAL POLICY FOR HEALTH 
IN DEVELOPING COUNTRIES
Fiscal policies come in a wide range of designs, but the main
effect is either to alter the price of health-related goods or to
alter the quantity available. Table 11.2 summarizes the health
interventions subject to fiscal policies. The behaviors that
require these interventions are divided into the following
categories:
• unhealthy consumption (foods, tobacco, and alcohol), for
which the most salient fiscal policies are taxes on consumers
and producers, and fines
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• health promotion and disease and accident prevention
(hygiene, pollution, safety, public health, maternal and child
and reproductive health, infectious disease, and healthy
lifestyles), for which the most important fiscal instruments
are subsidies, but which may also be affected by tax policy
• health care goods and inputs, including insurance and
human resources, that may be exempted from taxation,
subsidized, or guaranteed as a constitutional right
• other goods that indirectly promote health (education,
housing, agriculture, energy, charitable giving, charities that
provide targeted subsidies, and so on), which are often sub-
ject to their own particular tax regime or sets of subsidies
that affect their production or consumption and, therefore,
also affect health behavior 
• research and development initiatives that can be applied to
health and health care goods and are sensitive to tax exemp-
tions and subsidies.
Fiscal interventions can have various rationales, such as
macroeconomic benefits, equity, or efficiency—and promoting
health may or may not be the primary goal. A fiscal policy may
be designed to affect some other sphere of behavior or a good
other than health—for instance, education—and the effects on
health or the use of health care may be indirect. The shaded
boxes in table 11.3 indicate the possible rationale behind each
type of fiscal policy.
A fiscal policy should be effective, efficient, and cost-
effective and should promote or maintain equity goals. An
effective tax or subsidy reaches the intended target and alters
health-related behavior in the desired manner. An efficient
policy minimizes resource distortions and involves minimal
administrative costs. A cost-effective policy has the lowest cost
relative to the desired health goal.
SUBSIDIES FOR HEALTH AND
HEALTH-RELATED PRODUCTS
Using examples primarily from developing countries, this sec-
tion of the chapter analyzes the range of subsidies that are
available to promote healthy behavior and the consumption of
health-related goods. The first sections deal with consumer
subsidies both to promote the consumption of health-
producing goods and of health care. The second section dis-
cusses producer subsidies.
Consumer Subsidies
Governments use consumer subsidies to encourage the use of a
beneficial product by lowering the price consumers pay—
usually in situations where the consumers are too poor, the
market prices of the good are too high, or both situations
apply—to otherwise achieve a socially optimal consumption
level. Examples include subsidies for staple foods, condoms,
soap, insecticide-treated bednets, cooking fuels, and medicines.
Staple Foods. Ample evidence indicates that food subsidies
are effective in improving nutrition; however, appropriate tar-
geting is often a problem (Alderman 2002). Subsidies may be
targeted to specific foods, specific delivery locales or geo-
graphic areas, or specific populations. Often targeting includes
all three.
Food-specific subsidies, whether in the form of general
subsidies, ration cards, quotas, or food stamps, increase food
consumption. They will have a positive effect on health if this
consumption occurs in undernourished populations that
require increased caloric or nutrient intake. In some cases, food
subsidy programs have had unintended macroeconomic and
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Table 11.1 Fiscal Policies for Health Promotion Covered in Chapter 11
Subsidy Health-related Subsidized Health-related Government
for or tax products receiving provision products directly financing of
imposed on direct subsidies of health taxed health care
Consumer Medicine Caregiving (partially covered) Tobacco Not covered
Food Alcohol
Cooking fuel Food
Water purification Imported medicine and supplies
Soap
Condoms
Bednets
Producer Vaccinations Workplace promotion of healthy Fuel usage (partially covered)
Food additives behavior (partially covered)
Medical research
Source: Authors.
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Table 11.2 Use of Taxes and Subsidies to Promote Health by Type of Intervention
Tax 
Taxes preferences Subsidies
Consumer
(sales and Director- Targeted
value Credits and subsidized Subcontract consumer
Intervention Payroll added tax) Excise Production Input Fines exemptions provision provision subsidies Producers Rights
Unhealthy consumption
Foods
Alcohol
Tobacco
Health promotion and disease and accident prevention
Hygiene (soap)
Pollution (for example, fuels)
Safety (for example, 
seat belts)
Public health (vaccines,
clean water, 
supplementation,
education, and information)
Child, maternal, and
reproductive health
(information and
education,
supplementation, and
medical attention)
Infectious disease
(condoms and healthy
workplaces)
Healthy lifestyles
(food, exercise, and
healthy workplaces)
(Continues on the following page.)
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Table 11.2 Continued
Tax 
Taxes preferences Subsidies
Consumer
(sales and Director- Targeted
value Credits and subsidized Subcontract consumer
Intervention Payroll added tax) Excise Production Input Fines exemptions provision provision subsidies Producers Rights
Health care goods
Insurance
Medical attention
Medicines
Human resources for
health
Other goods that indirectly promote health
Personal leave
Caregiving and family leave 
(maternity, paternity, and 
chronic illness)
Education (for mothers or 
women, early childhood, or 
special needs)
Housing (provision, flooring, 
and roofing)
Agriculture (type of products 
produced or imported)
Energy (types of fuels, 
heating, cars, and gasoline)
Charitable giving
Research and development
Source: Authors.
Note: Shaded boxes indicate possible fiscal policies for each type of intervention.
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Table 11.3 Taxes and Subsidies by Policy Rationale
Rationale
Macroeconomic or Promotion of another
Policy Healthy behavior fiscal benefits Equity Efficiency good or type of behavior
Taxes
Payroll
Consumer (value added tax/sales)
Levy
Excise
Producer
Input
Fines
Subsidies
Tax credits
Direct provision
Subsidized provision
Subcontracted provision
Targeted subsidies
Subsidies to producers
Rights
Tax exemptions
Source: Authors.
Note: The shaded boxes indicate the possible rationale behind each type of fiscal policy.
microeconomic consequences (Adams 2000; del Ninno and
Dorosh 2002; Pinstrup-Anderson 1988; Siamwalla 1988). They
become expensive if they are too widely available, can create
incentives for black market activities, and can affect prices and
volumes in agricultural and trade markets.
Indonesia switched from a general rice support system to a
limited subsidy during the 1997 macroeconomic crisis. The
earlier system had successfully reduced food insecurity to low
levels, but higher prices increased the cost of maintaining the
subsidy and led to food being smuggled out of the country
(Tabor and Sawit 2001). The government targeted the new rice
subsidy to the poor and issued ration cards. Within roughly a
year of implementation, the subsidy was reaching an estimated
85 percent of the poor. Only about 10 percent of the subsidy
appeared to be reaching nontarget population groups.
India has subsidized essential consumer goods for decades,
including health-related goods such as food grains, edible oils,
sugar, and fuels (S. Jha 1992). The government rationed certain
goods in the belief that only the truly needy would endure
waiting in lines and purchasing the poorer quality products
that were involved in the subsidy schemes. This is called self-
targeting. However, Jha shows that 40 percent of the population
purchased subsidized rice in 1990, only half of whom were
poor. The government recently modified the program to better
target the subsidy to the poor and removed such barriers as
bulk purchasing (Rao 2000).
The Arab Republic of Egypt’s generalized program also illus-
trates the problems that beset broad food subsidy programs.
The program reached its zenith in 1980, when it subsidized 20
food products and accounted for 15 percent of government
expenditures (Adams 2000). The program has been scaled back
to cover four staple foods and now accounts for 6 percent of
government expenditures. Nevertheless, about 75 percent of
the population holds ration cards entitling them to purchase
the subsidized foods. The program is intended to achieve self-
targeting, but the nonpoor purchase many of the subsidized
foods. The program accounts for 44 percent of the total calorie
supply of the poorest quintile group, but in rural areas, the rich
obtain more calories from subsidized food than the poor do.
Musgrove (1993) reviews 104 supplementary feeding pro-
grams in 19 countries in Latin America and the Caribbean. The
review covers a range of program sizes, from those serving
1,000 individuals to those supplying 28 million people; of types
of subsidies (namely, food distribution, direct feeding, and
direct payments); of levels of coverage of the targeted popula-
tion, ranging from 1.9 to 100.0 percent; and of extent of
coverage of the poor, varying from 5.8 to 88.0 percent. The per
capita costs of reaching beneficiaries differed widely. The most
common reasons for program ineffectiveness were spreading
resources too thinly across beneficiaries, targeting foods with
minor health benefits, choosing inappropriate beneficiaries,
and encountering excessive costs in distributing resources.
These kinds of issues underscore the importance of design
considerations and country conditions in creating effective and
efficient food subsidy programs.
In sum, many food subsidy programs avoid the political and
administrative challenges of explicit targeting by allowing uni-
versal access to the subsidies on the assumption that the needy
will self-select into the programs. However, Adams (2000)
shows that countries with targeted food programs—for exam-
ple, Chile, Jamaica, and Peru—provide much higher income
transfers to the poor than do self-targeted programs of the kind
used in Egypt, Morocco, and Tunisia.
Condoms. Preliminary investigation indicates that subsidies
on condoms can be effective in increasing their use in both
general and high-risk populations, but whether price reduc-
tion, increased access, or education leads to greater use is not
clear (Price 2001) because information campaigns about the
health benefits of condoms usually accompany price subsidies.
Recent surges in social-marketing schemes to distribute con-
doms as part of the fight against HIV/AIDS, especially in
Africa, have increased condom use.2
Few researchers have compared HIV infection rates—or
even condom use rates—before and after the introduction of a
subsidy on condoms. Cohen and others (1999) conclude that in
a particular jurisdiction in Louisiana, free distribution through
public clinics and 1,000 small businesses in areas with high lev-
els of HIV and other sexually transmitted diseases achieved
significantly higher condom distribution than a fee-based sys-
tem (77 percent use during the last sexual encounter compared
with 64 percent) and that the revenues from cost recovery were
insufficient to justify imposition of the fee. The dropoff in
condom use during the cost-recovery period persuaded the
jurisdiction to reinstate the free distribution program.
Another example suggests that promotion and information
are also effective. A social-marketing effort in Turkey in the
early 1990s offered condoms at a commercial price but
included intensive advertising and other promotional efforts. It
achieved sales well beyond original expectations and gained
41 percent of the market share (Yaser 1993).
Water Purification. The U.S. Centers for Disease Control and
Prevention and the Pan American Health Organization
designed the Safe Water System Initiative to improve the qual-
ity of drinking water for households that draw their water from
sources outside the home. The principle underlying the initia-
tive is to subsidize storage containers, disinfectant, and educa-
tion on proper handling to avoid contamination (Quick and
others 1999). Numerous countries have implemented similar
initiatives, including Bangladesh, Bolivia, Burkina Faso, Kenya,
and Zambia. The government provides containers and chemi-
cals at subsidized prices, but the costs are still higher than the
cost of boiling water (Quick and others 2002).
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Soap. Another proven method for reducing the incidence of
diarrhea and other hygiene-related diseases is hand washing,
with or without soap. Whether the key factor is education or
the subsidized provision of soap is unclear. Some investigators
claim that small-scale programs that subsidize soap and edu-
cate households about the benefits of hand washing are self-
financing because of the consequent reduction in disease
(Borghi and others 2002).
Luby and others’ (2001) results from Pakistan suggest that
education alone may be just as effective as education accompa-
nied by soap provision in reducing diarrheal disease. By con-
trast, Hoque (2003) and other researchers suggest that the cost
of soap is a barrier to its widespread use among extremely poor
populations and that behavioral change may be difficult to
achieve without a subsidy.
Insecticide-Treated Bednets. The degree of subsidization of
bednets has become a controversial issue, with some arguing
for full subsidization and others for partial subsidization. Most
long-term studies indicate that consumers resist purchasing
bednets even at subsidized prices after they have had access to
free bednets (Snow and others 1999).
A number of researchers have undertaken studies in various
locations in Africa to assess the effect of selling bednets rather
than providing them free to vulnerable populations
(Armstrong-Schellenberg and others 2001; Kolaczinski and
others 2004; Snow and others 1999). The key issue is con-
sumers’ responsiveness to changes in the prices of bednets,
through either subsidies or a reduction in taxes and tariffs.
Many households do not own a bednet because they cannot
afford it, while other reasons are lack of information, poor
access to markets, and cultural preferences (Hanson and
Worrall 2002; Simon and others 2002). The evidence suggests
that responsiveness to price changes alone may be modest, but
in combination with removing some of the other barriers,
demand for bednets could increase substantially in malaria-
affected regions (Simon and others 2002).
Nigeria removed tariffs and taxes on bednet insecticide in
2001, and the 18 percent price drop resulted in an estimated 9
to 27 percent increase in purchases (Simon and others 2002).
Another study that reviewed a public sector subsidy for bednets
combined with private sector marketing and distribution by
means of a social-marketing scheme concluded that the pro-
gram was successful because 18 percent of children slept under
bednets as a result; however, the low insecticide retreatment
rate led the authors to conclude that subsidies were needed on
both bednets and insecticide (Armstrong-Schellenberg and
others 2001).
Clean Cooking Fuels. High rates of respiratory illness occur as
a result of exposure to smoke and particle emissions from bio-
mass burning in many developing countries. Fuel subsidy pro-
grams have been designed to promote the use of liquid petro-
leum gas, natural gas, or kerosene, which burn more cleanly
and emit a low amount of smoke and particulates, but none has
been efficacious or efficient (UNDP 2003).
Liquid petroleum gas subsidies have been shown to benefit
middle- and higher-income families in urban areas rather than
the poor (UNDP 2003). In attempting to target the poor more
accurately, Côte d’Ivoire and Senegal focused subsidies on
smaller liquid petroleum gas cylinders but found that poor
consumers still preferred charcoal (UNDP 2003). Electricity
subsidies in low-income countries are also often skewed toward
the well off, who are more likely than the poor to be connected
to the electricity grid (Alderman 2002).
Medicines and Medical Supplies. In relation to the direct pro-
vision of health-related goods, including drugs, supplies, and
services of medical personnel, governments may subsidize and
regulate drug prices, make bulk purchases from manufacturers
for distribution at reduced prices, and distribute certain drugs
with complete or partial subsidies to target populations.
Specific interventions—for instance, antiretrovirals, vaccines,
or reproductive health care—are often more heavily subsidized
or may be targeted by population group or disease—for exam-
ple, child and maternal health, tuberculosis, and malaria. With
the exception of antiretroviral drugs, the health benefits and
low costs of these medicinal interventions make them good
targets for subsidization.
General Health Care. In developing countries, where informal
sectors tend to be large, providing subsidized health care is an
important tool for health promotion. Some countries have
chosen direct provision of health goods, whereas others com-
bine the public provision of services with subsidized health
insurance for families below a certain income cutoff. Both
models require identifying the families that are unable to afford
health care and the types of services that are considered public
goods.
One example of subsidizing the production and provision
of health care is the Mexican program originally called
PROGRESA and now known as Oportunidades. This program
is also an example of how income transfers for other goods
can affect health and how cross-subsidies can be used to
strengthen the incentive effects of a fiscal policy to promote
healthy behavior. The government launched the program in
1997 to provide subsidized health, nutrition, and education to
poor families. By mid 2004, it was serving the majority of
those living below the poverty line. Oportunidades combines
a cash transfer equivalent to 20 to 30 percent of families’
incomes that includes incentives for positive behaviors in rela-
tion to health, nutrition, and schooling with subsidized basic
health interventions. The program is largely financed from
federal budgets.
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Oportunidades is successful both in terms of targeting the
poorest households and in terms of achieving measurable gains
in health, health care use, nutritional status and growth, school
attendance, and school achievement. Gertler (2004), for exam-
ple, finds significant and cumulative reduction in illness rates
among children, lower prevalence of anemia, and an addition-
al centimeter of growth in the first year of the program.
The program’s success is attributable to many factors,
including a rigorous longitudinal evaluation process; an inte-
grated package of services; and the presence of financial stimuli
tied to school attendance, visits to health clinics, and participa-
tion in health education initiatives. Furthermore, the program
incorporates several targeting methods.
Producer Subsidies 
Governments use producer subsidies to encourage production
that improves health by lowering manufacturers’ costs in situa-
tions in which the private market supply is inadequate to meet
social needs. Examples include medical supplies, vaccines, food
additives, and medical research.
Food Fortification. Governments sometimes subsidize the
fortification of staple foods through the addition of selected
micronutrients as a way of achieving broadly based nutrition
improvements. Challenges involve maintaining a relationship
between the public sector, which initiates and funds the pro-
gram, and the private sector, which implements the fortifica-
tion. Incentives for private providers are often needed in the
form of tax exemptions, import preferences, subsidies for start-
up costs, quality control, and training. Illegal markets selling
nonfortified products at a lower price often arise in response
(Alderman 2002; Dorosh, del Ninno, and Sahn 1996; Rao
2000).
Health Research. Government support for health research
consists of the provision of direct subsidies for private sector
investment, the granting of tax benefits for private research and
development (R&D) investment, the establishment of property
rights and a system to protect them, and the promotion of pri-
vate goods by other means (OECD 2003). Despite the strong
evidence from developed countries that the private sector will
underinvest in R&D and that tax incentives increase R&D
investment, developing countries should be cautious in apply-
ing those results to their own situations. Empirical investiga-
tions tend to conclude that producer subsidies for R&D in
developing countries are not effective (Shah 1995; Zee, Stotsky,
and Ley 2002). Many conditions need to be in place to realize
high social returns and to minimize rent seeking and profiteer-
ing, including a strong private sector research effort that is
stimulated by the public investment, the presence of appropri-
ate targeting, a transparent and fair set of public laws and insti-
tutions to grant and monitor the tax benefits, and the ability to
forgo alternative public investments.
TAXES AND TAX EXPENDITURES: 
DESIGN AND OUTCOMES
The following section describes various examples of the use of
taxation directed at both consumers and producers. This sec-
tion of the chapter also analyzes the design issues that are
important in order to guarantee that these instruments con-
tribute to achieving healthy fiscal policy.
Taxes on Consumers
Sales taxes—including excise taxes and value added taxes—
and exemptions from those taxes are the most common fiscal
policy tools used to influence consumers’ health purchases.
Examples are exempting medicines and foods from sales tax
and imposing an excise tax on cigarettes and alcohol.
Developed countries often use income tax incentives to provide
deductions and credits for specific health care purchases.
Box 11.1 discusses issues surrounding use of taxes for health.
“Sin” Taxes on Tobacco and Alcohol. A wide range of coun-
tries and local jurisdictions have taxed tobacco, with acknowl-
edged success in reducing consumption (P. Jha 1999). The
health benefits of curbing the demand for cigarettes may go
beyond eliminating the health consequences of smoking and
secondhand smoke if consumer expenditures are diverted from
cigarettes to healthier alternatives (for example, food).
Taxes on alcohol are widespread and are used primarily to
raise revenue. Governments typically impose taxes at the pro-
ducer, wholesale, and retail levels that are levied as a percentage
of the sale price or are based on a flat amount per unit.
Harmful alcohol consumption is controlled through prohibi-
tion, government monopolization of sales, “dry” days, restric-
tions on hours when sales are legal, restrictions on age and
locations for sales and consumption, laws against drinking and
driving, limits to alcohol content, laws against the sale of cer-
tain types of alcohol, and licensing.
Alcohol taxes do contribute revenue to government coffers
in developing countries, generally in higher proportions than
in developed countries (WHO 2002a), but smuggling and tax
evasion are common. For example, Zimbabwe raised taxes on
certain beers in 1995 but repealed the increase within months
when tax revenues dropped significantly (WHO 2002a). Some
developing countries have lowered alcohol taxes with conse-
quent negative results. Mauritius experienced a dramatic
increase in drunk-driving arrests, alcohol-related fatalities,
and hospital admissions after it reduced taxes on alcohol
(WHO 2002a). In sum, alcohol taxes do reduce drinking, but
the evidence that such taxes are well targeted to those most at
risk of problem drinking is not strong.
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Food Taxes. The issue of taxing unhealthy foods has received
increasing attention in the wake of the Global Strategy on Diet,
Physical Activity, and Health, which was approved by member
countries of the World Health Organization (WHO 2004). The
global strategy points to the rising prevalence of obesity and
overweight in developing countries, along with that of nutri-
tion-related noncommunicable diseases, and recommends that
countries consider fiscal policies and other measures to reduce
those problems.
Governments can use excise taxes to reduce the consump-
tion of unhealthy foods only if tax rates are sufficient to
change consumption in a way that improves health outcomes,
if they tax enough harmful foods or food ingredients, and if
they levy the taxes in an effective manner. Guo and others’
(1999) study in China demonstrates significant potential for
price changes to affect consumption. The researchers studied
dietary intake in a sample of urban and rural Chinese house-
holds and show that a 10 percent increase in the price of pork
potentially reduces fat consumption by 8 percent. Energy and
protein intake would both drop by 2 percent. The overall
effect may be different for the poor and the rich. The poten-
tially harmful effects on the poor of increasing the price of
pork would be buffered by substitutions from other food
groups, such as oil, wheat flour, and coarse grains, but con-
cerns remain that overall nutrition would worsen. These
results suggest that using price changes to alter dietary intake
in a setting where overnutrition and undernutrition coexist
may have mixed outcomes.
A natural experiment in Poland during the economic down-
turn of the 1990s suggests a beneficial role for price policy in a
consumer switch from animal fats to vegetable fats with lower
amounts of trans fatty acids (Zatonski, McMichael, and Powles
1998). A dramatic decline in ischemic heart disease and related
circulatory system diseases during the first half of the 1990s is
most easily explained by the removal of consumer subsidies
from foods of animal origin, the aggressive marketing of mar-
garines, and a general decline in food purchasing power. The
major change in the food supply appeared to be a reduction in
foods containing animal fats; however, no direct relationship
can be conclusively attributed without further study of the
Polish experience and the experiences of other countries
undergoing similar transitions.
Governments may choose to address food-related health
problems by taxing imports of high-fat or high-sugar food;
however, such efforts conflict with rules governing interna-
tional trade. Fiji, for example, tried to ban the import of mut-
ton flaps, an extremely fatty food that was contributing to the
country’s obesity problem. To comply with its World Trade
Organization obligations, Fiji had to ban the sale of all mutton
flaps, not just imports (Evans and others 2001). One analysis
suggests that the same kind of broad treatment would be nec-
essary to grant subsidies to healthy foods, but taxing unhealthy
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Using Taxes to Influence Consumption and Production Behavior
Box 11.1
Taxes as a tool for health policy face significant imple-
mentation obstacles. First, targeting can be difficult. A
close link must exist between the consumption of the
product or behavior to be taxed and a specific population
with a health risk. For instance, all consumers would pay a
tax on “junk” food, even though it would only present a
health threat to a small percentage of them. The taxed
good must also be appropriately defined in relation to
close substitutes; for example, taxing only certain forms of
tobacco such as cigarettes, but not chewing tobacco, may
increase consumption of the latter. Governments may also
distinguish between locally produced goods and imported
goods, often because of lobby groups. If governments
place a higher tax on the good that is less harmful, this
action will encourage greater consumption of the more
harmful good.
Key weaknesses in using taxes for health policy include
the feasibility of smuggling and the existence of large
informal or illegal markets. Smuggled or contraband
products that cannot be regulated or certified for quality
and safety, such as alcohol or tobacco in particular, may
be more harmful to health than goods that are legally
produced and sold.
Any tax should be efficient in terms of both its admin-
istration and its effect on resource allocation. Tax author-
ities need a well-functioning system for imposing, collect-
ing, and monitoring taxes and taxed products, and the
public should perceive the system as fair and credible in
order to achieve a high degree of compliance.
Finally, a tax should be cost-effective in achieving its
stated goal of improving health outcomes. The net costs of
imposing the tax should compare favorably with the net
costs of using another policy instrument, such as regula-
tion or direct government provision. Depending on the
characteristics of the tax base, the health goal and the
revenue goal may even be at odds.
Source: Authors.
domestic foods alone would probably not pose a problem
under World Trade Organization rules (WHO 2003). Further-
more, avenues for using other regulatory and economic
policies to improve the consumption of healthy foods may be
acceptable under the World Trade Organization Agreement on
Technical Barriers to Trade and the Agreement on Agriculture
if countries can justify them as contributing to legitimate
national health objectives.
Agricultural policies affect food prices, food choices, and
farm incomes in addition to the food security of both rural and
urban populations. Each country must assess the potential for
reorienting its agricultural policies so as to produce a healthier
food supply. Developing countries are generally more likely to
directly subsidize food consumption than food production;
however, they frequently make indirect subsidies available
through the provision of cheap fuel, chemical inputs, water,
and loans to the agriculture sector. These policies may be envi-
ronmentally and fiscally costly and rarely contribute to
improved population health.
Research is needed on individual countries’ agricultural
policies and food supply needs to make them more compatible
(Nugent 2004). At the same time, the dynamics of food choice
and the effects of price manipulation need to be better under-
stood before tax and subsidy systems can be designed to effec-
tively promote healthy food choices.
Sales Tax Exemptions on Healthy and Staple Foods and
Medicines and Other Health Care Goods. Governments may
set tax policies to ensure that certain expenditures on health-
related behaviors and health goods are tax deductible or tax
exempt for firms, employers, or individuals. Exemptions
should apply to a limited number of goods that are easily dif-
ferentiated from goods that are not exempted. Note that in
countries with large informal sectors, income tax systems are
weak, and fiscal policies for the deductibility of credits are
unlikely to be effective.
South Africa provided value added tax exemptions for a
short list of essential foods and found a varied consumption
pattern by commodity, with the poor receiving most of the
benefits of the maize exemption, but few of the benefits of the
milk exemption (Alderman and del Ninno 1999).
Mexico imposes a 15 percent value added tax on almost all
goods. Exemptions include medicines, physician’s services, and
some foods. Recently, a government proposal to make drug and
food purchases eligible for value added tax and to channel the
resulting revenues into financing programs targeted to the
poor has given rise to extensive debate. Those in favor have
argued that the existing subsidy is regressive because most drug
and food purchases are by the wealthy (Fundación Mexicana
para la Salud 2001).
Many developing countries concerned about the spread of
HIV/AIDS have dropped import taxes on condoms, but others
continue to impose tariffs on imports. For example, Malaysia is
a major producer and imposes a 25 percent tax on imports.
Brazil used to impose both an import tax and a distribution tax
that amounted to a total of 45 percent of the original condom
price, but it granted a permanent sales tax exemption when
condom sales increased following a temporary tax holiday.
Taxes on Producers
Producer taxes are usually aimed at discouraging socially
harmful products or processes. They can be imposed either on
the use of certain inputs, such as more heavily polluting fuels,
or on their outputs, such as emissions of air pollutants.
Theoretical and simulation models have examined the use
of taxes on fuels and emissions taxes to control air pollution
(World Bank 1994a, 1994b), but empirical data are lacking.
Models of taxes suggest potential to induce substitution by
cleaner fuels and reductions in overall energy use, but actual
results will depend on the availability of fuel substitutes within
countries. Data on Chilean manufacturing support the possi-
bility of clean fuels substitution but indicate the likelihood of
uneven sectoral incidence of the emissions tax. For example,
bakeries were responsive to changes in relative prices, whereas
metal products plants were unresponsive, and meat packers
were unable to adjust their electricity demand but could reduce
energy from other sources (World Bank 1994b). If this poten-
tial were realized on a global or regional basis—for example,
through agreements to the Kyoto Protocol—a double benefit of
reducing harmful externalities and raising significant revenues
might be achieved.
FISCAL POLICY TO PROMOTE HEALTH
The fiscal policies discussed in this chapter in relation to health
and health care goods can be applied to other goods and mar-
kets, such as housing and education, some of which may have
important effects on health. This chapter does not provide an
exhaustive discussion of the goods that indirectly promote
health, but it does briefly consider some of these policies in
relation to workplaces, employment leave policies, and day
care. Note that policies focused on formal labor markets will
not be effective in reaching large segments of the population in
many countries. Policies that provide health-related services,
such as day care, that are not based on formal labor market
participation may have a broader effect.
Workplace Health 
Governments can use tax relief and financial support to pro-
ducers to encourage firm-specific actions to promote health.
Many countries mandate safeguards in the workplace and
levy penalties against occupational health violations. Most
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government actions are mandates rather than fiscal policies,
but a combination of approaches may also be used.
A growing area for workplace health promotion is
HIV/AIDS. Bloom and others (2004) suggest that the failure on
the part of most firms to act—even if they correctly perceive
the business, human, and social challenges HIV/AIDS poses—
is attributable to a lack of incentives. Significant externalities
(benefits to society and firms) are likely to result from promot-
ing greater action by firms. Some private firms have begun
providing HIV/AIDS prevention and treatment services to
employees, families, and their communities (“Face Value: AIDS
and Business” 2004). Sometimes government support is
involved, but little information is available to evaluate the
potential of fiscal policy.
Maternity Leave, Sick Leave, and Family Care Leave
Government policy can alter choices regarding different types
of worker leave. Many countries have financial or legislative
support for caregiving, although most focus on children.
Rhum (1998) cites evidence that more than 100 countries—
and almost all the industrial countries—have some legislation
about parental leave, although in several countries it is unpaid.
Caregiving policies that allow people to take time off work
to care for aged and chronically ill family members are
less common than policies for child care, particularly in devel-
oping countries, but tax benefits and allowances for these types
of caregiving are becoming increasingly available in the indus-
trial countries (Brodsky, Habib, and Mizrahi 2000; Pijl 2003;
Wiener 2003). Although the provision of services in kind by the
government is still an important mechanism, the trend is
toward empowering consumers by offering subsidies or tax
deductions that allow them to choose among caregiving
options. Countries tend to use a combined approach to financ-
ing that relies on payroll taxes imposed on employees and
employers, general taxation, and copayments. Important issues
that developing countries need to address in this respect
include targeting compared with universal provision, the
mechanisms to pay for or to insure care, and the extent to
which long-term care should be integrated into the health care
and social service systems (Brodsky, Habib, and Mizrahi 2000;
WHO 2003).
Day Care and Early Childhood Education
Some countries use targeted fiscal policies, such as income tax
deductions or direct provision, to increase the use and quality
of early childhood education and child care services. Important
health, labor market efficiency, growth, and equity arguments
support subsidizing these services, particularly for low-income
families, because without subsidies women may be forced to
limit their work or to leave the labor market, and families
may have to use low-quality care or leave children unattended.
Van der Gaag and Tan (1997) argue for public subsidies based
on cost-benefit analysis of early childhood development pro-
grams. They conclude that the greatest payoff comes from tar-
geting the most deprived families and that the private benefits
are sufficient to expect better-off parents to pay.
Two large-scale, home-based day care programs targeted to
poor families are Community Well-Being Homes (Hogares
Comunitarios de Bienestar) run by the Colombian Institute for
Family Well-Being (Instituto Colombiano de Bienestar
Familiar) in Colombia (Myers 1995) and the Integrated Child
Development Program in Bolivia. The former is an interesting
case of a targeted cross-subsidy because the financing comes
from the wealthier formal sector by means of a payroll tax,
whereas the services are targeted to the poorest families. The
program was 85 percent subsidized in the early 1990s. Parents
paid a proportion of the caregivers’ wages on a sliding-scale
user fee (Young 1996). The Bolivian program includes nutri-
tion, health, and cognitive development interventions and is
one of the few early childhood programs in developing coun-
tries that has been formally evaluated (Behrman, Cheng, and
Todd 2000). The evaluation shows that the program signifi-
cantly increases cognitive achievement, although the results
depend on age and the duration of exposure to the program.
CONCLUSIONS
A broad range of experiences cited in this chapter demonstrates
that fiscal and health policies interact in a number of areas.
Although substantial research has focused on tobacco and alco-
hol, other links—for example the promotion of health in the
workplace—have been much less recognized or studied, partic-
ularly in developing countries.
The research presented in this chapter suggests that fiscal
policy can be a useful tool for influencing health in developing
countries. Nevertheless, budgetary limitations to withstand
pressure for program expansion, leakages to unintended bene-
ficiaries, public compliance with the tax system, and corruption
among both government officials and the public are important
factors to take into account in design and implementation.
Table 11.4 summarizes some lessons learned on the use of fis-
cal policy to promote health.
Governments may find it worthwhile to examine their use
of fiscal policies to identify the entire range of effects and have
health ministries participate in this exercise. More generally, the
chapter indicates an area for increased interaction between
ministries of health and finance. Healthy fiscal policy and fiscal
policy for health should be topics that are debated, agreed on,
and formalized between the two areas of policy making to
guarantee that those developing fiscal policy take both its eco-
nomic and its health implications into account.
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Rigorous evaluation studies are needed of most of the fiscal
policy interventions discussed in this chapter. Such studies
should address the health, fiscal, macroeconomic, and distrib-
utional effects of using fiscal policy to achieve health goals and
should be performed in a range of countries with mixed pub-
lic and private sector capacity to deliver health services. The
studies should also examine the differing effects of policies in
urban and rural settings and across income quintiles. Of par-
ticularly high priority are further studies of the results of sub-
sidizing drugs, medical supplies, and hygiene interventions
with or without education campaigns. Those areas may reveal
new fiscal approaches for addressing the disease burden in
developing countries.
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NOTES
1. The idea of healthy fiscal policy is discussed in Cook and
Vlaisavljevich (1994), Joffe and Mindell (2004), and Secretaría de Salud
(2001).
2. Social marketing is defined as the use of marketing principles to
influence behavior for a socially desirable outcome. It provides a desirable
product at an affordable price with adequate promotion and placement
(that is, access).
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This chapter assesses health financing policy in low- and
middle-income countries (LMICs). It discusses the basic func-
tions of health financing systems and the various mechanisms
for effective revenue collection, pooling of resources, and pur-
chase of interventions (WHO 2000). It analyzes the basic
financing challenges facing LMICs as a result of revenue gener-
ation and collection constraints, increasing flows of develop-
ment assistance for health (DAH) coupled with donors’
concerns about aid effectiveness, and the difficult economic
situation facing many LMICs as a result of globalization and
poor economic management.
In 2001, about US$3.059 trillion—approximately 9 percent
of global gross domestic product (GDP)—was spent on health
care worldwide (WHO 2004b; World Bank 2004e); however,
only 12 percent of this amount was spent in LMICs, which
account for 84 percent of the global population and 92 percent
of the global disease burden (Mathers and others 2002).
Ongoing epidemiological, demographic, and nutrition transi-
tions will pose significant challenges for health financing sys-
tems in LMICs in the near future as the communicable disease
burden lessens and the noncommunicable disease and injury
burdens expand. At the same time, the current communicable
disease burden in low-income countries (LICs) and in many
middle-income countries (MICs), especially that caused by
malaria, tuberculosis, and HIV/AIDS, poses a serious threat to
public health, health systems, and economic growth.
As a result of the international focus on poverty reduction,
the HIV/AIDS pandemic, and the Millennium Development
Goals (MDGs), international health financing policy has
evolved over the past decade from defining a basic package of
cost-effective health services to figuring out how to finance and
deliver those services equitably and efficiently, to recognizing
the need to scale up health systems to meet basic service needs
and achieve the MDGs, which will require large amounts of
DAH for poor countries (see, for example, WHO 2000, 2001;
World Bank 1993, 2004b).
This chapter updates and reviews the global evidence on
health spending, health needs, revenue-raising capacity, organi-
zation of health financing, and trends in DAH. It discusses
the key challenges that country policy makers face in ensuring
access to services and financial protection while dealing with a
new health policy world defined by new instruments such as sec-
torwide approaches (SWAps) and Poverty Reduction Strategy
Papers (PRSPs). The chapter also discusses the scope and poten-
tial effects of new and relatively large global funding sources,
such as the Bill & Melinda Gates Foundation; the Global Fund to
Fight AIDS, Tuberculosis, and Malaria; and the Global Alliance
for Vaccines and Immunization (GAVI) Vaccine Fund.
HEALTH FINANCING SYSTEMS
Health financing provides the resources and economic incen-
tives for the operation of health systems and is a key deter-
minant of health system performance in terms of equity,
efficiency, and health outcomes.
Health Financing Functions
Health financing involves the basic functions of revenue collec-
tion, pooling of resources, and purchase of interventions.
Chapter 12
Financing Health Systems 
in the 21st Century
George Schieber, Cristian Baeza, Daniel Kress, and Margaret Maier
• Revenue collection is how health systems raise money from
households, businesses, and external sources.
• Pooling deals with the accumulation and management of
revenues so that members of the pool share collective health
risks, thereby protecting individual pool members from
large, unpredictable health expenditures. Prepayment allows
pool members to pay for average expected costs in advance,
relieves them of uncertainty, and ensures compensation
should a loss occur. Pooling coupled with prepayment
enables the establishment of insurance and the redistribu-
tion of health spending between high- and low-risk individ-
uals and high- and low-income individuals.
• Purchasing refers to the mechanisms used to purchase serv-
ices from public and private providers. Figure 12.1 illus-
trates these functions and their interactions.
In terms of health policy at the country level, these three
financing functions translate into the following:
• raising sufficient and sustainable revenues in an efficient
and equitable manner to provide individuals with both a
basic package of essential services and financial protection
against unpredictable catastrophic financial losses caused by
illness or injury.
• managing these revenues to equitably and efficiently pool
health risks; and,
• ensuring the purchase of health services in an allocatively
and technically efficient manner.
These financing functions are generally embodied in the fol-
lowing three stylized health financing models:
• national health service (NHS): compulsory universal cover-
age, national general revenue financing, and national own-
ership of health sector inputs
• social insurance: compulsory universal coverage under a
social security (publicly mandated) system financed by
employee and employer contributions to nonprofit insurance
funds with public and private ownership of sector inputs
• private insurance: employer-based or individual purchase of
private health insurance and private ownership of health
sector inputs.
Although these models provide a general framework for
classifying health systems and financing functions, they are not
useful from a micropolicy perspective because all health sys-
tems embody features of the different models. The key health
policy issues are not whether a government uses general
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revenues or payroll taxes, but the amounts of revenues raised
and the extent to which they are raised in an efficient, equitable,
and sustainable manner. Similarly, nothing is intrinsically good
or bad about public versus private ownership and provision.
The important issue is whether the systems in place ensure
access, equity, and efficiency.
Revenue Collection
Governments use a variety of financial and nonfinancial mech-
anisms to carry out their functions, including directly providing
services; financing, regulating, and mandating service provi-
sion; and providing information (Musgrove 1996). A substan-
tial literature is devoted to the various sources for financing
health services and the economic and institutional effects of
using these sources in terms of efficiency, equity, revenue-
raising potential, revenue administration, and sustainability
(Schieber 1997; Tait 2001; Tanzi and Zee 2000; WHO 2004b;
World Bank 1993). An additional source of revenue receiving
increasing attention is efficiency gains (Hensher 2001). LICs
rarely use tax credits as a financing source (Tanzi and Zee 2000).
The key fiscal issue for LMICs is for their financing systems,
both public and private, to mobilize enough resources to
finance expenditures for basic public and personal health serv-
ices without resorting to excessive public sector borrowing
(and creation of excessive external debt); to raise revenues
equitably and efficiently; and to conform with international
standards (Tanzi and Zee 2000). Institutional constraints are
particularly important, including a country’s economic
structure—for example, large rural populations and limited
formal sector employment; ineffective tax administration; and
lack of data, all of which tend to preclude LMICs from using
the most efficient and equitable revenue-raising instruments
(Schieber and Maeda 1997; Tait 2001). The high level of
inequality in most LMICs means that governments face the dif-
ficult situation of needing to tax the politically powerful and
wealthy elites to raise significant revenues in an equitable
manner but of being unable to do so easily. As Tanzi and Zee
(2000, 4) point out, “tax policy is often the art of the possible
rather than the pursuit of the optimal.”
Another area of health financing that continues to generate
heated debate is user fees (that is, charges to individuals for
publicly provided services). The need to significantly scale up
resources to meet the MDGs in LICs has pushed the user fee
issue to the forefront of this debate. Arhin-Tenkorang (2000)
and Palmer and others (2004) suggest that the overall effect is
negative: use decreases, particularly among the poor, and fre-
quently, administrative costs of collecting the fees are higher
than the revenue generated. Further, Kivumbi and Kintu
(2002) suggest that granting waivers and exemptions for the
poor is difficult, if not impossible. Given those findings, many
have called for the abolition of user fees, including the United
Nations Millennium Project (2005) and the Commission for
Africa (2005).
Others have argued, however, that absent resources to fund
drug purchases, provide facilities with some discretionary
funding, and motivate providers, use of primary health care by
the poor will remain low because of both poor quality and lack
of drugs, and the poor will purchase these essential services on
the private market. The Bamako Initiative shows that user fees
may be an important revenue source where institutions are
weak, resources are limited, and the choice is between having
drugs or not having them (World Bank 2003, 76–77).
Furthermore, studies indicate that user fees can improve bene-
fit incidence if user fee and waiver policies have been well
designed and implemented and if providers are compensated
for forgone revenues. Indeed, proponents of user fees argue
that as long as the fees are set below private market levels, this
“savings” may result in a net reduction in overall out-of-pocket
spending for the poor (Bitrán and Giedion 2003). These diverse
experiences demonstrate the difficultly involved in making
blanket statements regarding user fees. As the World Bank
(2003, 71) points out, “user fees, as with other public policy
decisions, must balance protection of the poor, efficiency in
allocation, and the ability to guarantee that services can be
implemented and sustained.”
Risk Pooling and Financial Protection
Preventing individuals from falling into poverty because of cat-
astrophic medical expenses and protecting and improving the
health status of individuals and populations by ensuring finan-
cial access to essential public and personal health services pro-
vide a strong basis for public intervention in financing health
systems. Public intervention may be needed because of market
failures in private financing and provision (for instance, infor-
mation asymmetries) and instabilities in insurance markets
(such as favorable risk selection by insurers and moral hazard).
Indeed, in virtually all Organisation for Economic Co-
operation and Development (OECD) countries except the
United States, governments have decided to publicly finance or
require private financing of the bulk of health services.
However, given both low income levels and limits on possibili-
ties for domestic resource mobilization in LICs and some
MICs, these countries face severe challenges in publicly financ-
ing essential public and personal health services. They also
often confront difficult tradeoffs with respect to financing
these basic essential services and providing financial protection
against the costs of catastrophic illness.
Ensuring Financial Protection. Ensuring financial protection
means that no household spends so much on health that it falls
into and cannot overcome poverty (ILO and STEP 2002b).
Achieving adequate levels of financial protection requires max-
imizing prepayment for insurable health risks; achieving the
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largest possible pooling of health risks within a population,
thereby facilitating redistribution among high- and low-risk
individuals; ensuring equity through prepayment mechanisms
that redistribute costs from low- to high-income individuals;
and developing purchasing arrangements that promote effi-
cient delivery of good-quality services.
Meeting those requirements depends on how health systems
arrange the three key health financing functions of revenue col-
lection, risk pooling, and purchasing. Although all health
financing functions play an important role in ensuring finan-
cial protection, risk pooling and prepayment—whether
through taxes or individual premiums—play the central and
often the most poorly understood roles.
Risk pooling refers to the collection and management of
financial resources so that large individual and unpredictable
financial risks become predictable and are distributed among all
members of the pool. The pooling of financial risks is at the core
of traditional insurance mechanisms. Whereas pooling ensures
predictability and the potential for redistribution across individ-
ual health risk categories, prepayment provides various options
for financing those risks equitably and efficiently across high-
and low-income pool members. The health financing models
described earlier embody different means for creating risk pools
and financing such pools through prepaid contributions.
In most LMICs, multiple public and limited private
arrangements coexist, making system fragmentation the norm
rather than the exception. This situation increases administra-
tive costs; creates potential equity and risk selection problems,
for example, when the wealthy are all in one pool; and limits
pool sizes. Moreover, health care risks change over the life cycle
of an individual or household, but because generally little cor-
relation exists between life cycle needs and capacity to pay, sub-
sidies are often necessary and are facilitated by risk pooling.
Risk pooling and prepayment functions are central to the
creation of cross-subsidies between high-risk and low-risk
(that is, a risk subsidy) and rich and poor (that is, an equity sub-
sidy) individuals. The larger the pool, the greater the potential
for spreading risks and the greater the accuracy in predicting
average and total pool costs. Placing all participants in a single
pool and requiring contributions according to capacity to pay
rather than individual or average pool risk facilitates cross-
subsidization and, depending on the level of pooled resources,
can significantly increase financial protection.
However, spreading risks through insurance schemes is not
enough to ensure financial protection, because it can result in
low-risk, low-income individuals subsidizing high-income,
high-risk individuals. Furthermore, significant portions of the
population may not be able to afford insurance. For this reason,
most health care systems aim not only at spreading risk, but
also at ensuring equity in financing of health care services
through subsidies from high- to low-income individuals.
Equity subsidies are the result of such redistribution policies.
At least four alternative organizational arrangements exist
for risk pooling and prepayment: ministries of health (MOHs)
or NHSs, social security organizations (SSOs), voluntary pri-
vate health insurance, and community-based health insurance
(CBHI). Each of these is linked to distinctive instruments for
revenue collection (for example, general revenues, payroll
taxes, risk-rated premiums, and voluntary contributions) and
for purchase of health services.
Within these organizational structures, three alternatives
often coexist for generating revenues and financing equity sub-
sidies: subsidies within a risk pool, subsidies across different
risk pools, and direct public subsidies through transfers from
the government. Although medical savings accounts (with or
without public subsidization) are also sometimes referred to as
a risk pooling mechanism, they do not pool risks over groups
and, therefore, are far more limited in terms of predictability
and equity subsidization. They are simply intertemporal mech-
anisms for smoothing health risks over an individual’s or
household’s life cycle.
Subsidies within a risk pool, whether financed through gen-
eral revenues or payroll taxes, are prerequisites for pooling risks
in traditional NHSs and SSOs. The goal of collecting revenues
through an income-related or general revenue–based contribu-
tion (in contrast to a risk-related contribution, as is generally
the case with private insurance) is to generate subsidies from
high- to low-income individuals. These systems are effective
when payroll contributions are feasible, when the general rev-
enue base is sufficient and a large proportion of the population
participates in the same risk pool, or when both conditions
exist. Moreover, in a system with multiple, competing, public
and private insurers and a fragmented risk pool, payroll contri-
butions may increase incentives for risk selection. In the case of
a NHS or SSO, financial resources might be insufficient or
inappropriate for spreading the financial risks or for creating
an equity subsidy, particularly if the general revenue or payroll
contribution base is regressive.
Subsidies across different risk pools involve the creation of
funds, often called solidarity or equalization funds, financed by
a portion of contributions to each risk pool. This mechanism
is found in systems with multiple insurers in, for example,
Argentina, Colombia, Germany, and the Netherlands. A key
element of this mechanism’s success is the implementation of
adequate systems of compensation among different risk and
income groups.
Finally, in many OECD countries, direct public transfers
funded through general taxation are made to insurers for sub-
sidizing health care for certain groups or for the entire popula-
tion. They are also used in some LMICs, although at a limited
level because of low revenue collection capacity.
In most LMICs, risk pool fragmentation significantly
impedes effective risk pooling, while limited revenue-raising
capacity precludes the use of broad public subsidies as the main
228 | Disease Control Priorities in Developing Countries | George Schieber, Cristian Baeza, Daniel Kress, and others
Financing Health Systems in the 21st Century | 229
source of finance. Therefore, targeting scarce public subsidies
across different risk pooling schemes is probably the most
feasible way to finance equity subsidies for the poor and those
outside formal pooling arrangements. However, this method
has important transaction costs. Because a significant portion
of the population is excluded from the formal sector, using this
mechanism for ensuring universal financial protection is
limited, particularly in LICs. Even if significant subsidies are
available from general taxation, the lack of insurance portabil-
ity restricts its usefulness as a subsidization mechanism among
risk pools because individuals may lose their coverage when
they change jobs. LICs and certain MICs will be challenged
both to publicly finance essential public and personal health
services and to ensure financial protection through equity sub-
sidies. Thus, LMICs should strive to achieve the best value for
publicly financed health services in terms of health outcomes
and equity and should try to facilitate effective risk pooling for
privately financed services. Providing public financing for cost-
effective interventions is one critical aspect of determining
which services to finance publicly.
Distributing and Sourcing Health Expenditures. As table 12.1
shows, health spending is derived from three broad sources:
public sector (expenditures financed out of general revenues
and social insurance contributions), private sector (expendi-
tures financed out of pocket and by private insurance), and
external sources (grants or loans from international funding
agencies). In 2001, high-income countries spent an average of
7.7 percent of their GDP on health (country weighted), MICs
spent 5.8 percent, and LICs spent 4.7 percent.
Even though a clear upward trend between a country’s
income level and the level of public and total health spending is
apparent in terms of both absolute spending and share of GDP,
spending for any given income level varies a great deal, particu-
larly at lower income levels (Musgrove, Zeramdini, and Carrin
2002). The composition of health spending also exhibits major
differences.As incomes increase, both private and out-of-pocket
shares of total health spending decrease. In LICs, private and
out-of-pocket spending and external assistance account for the
bulk of all health spending. As countries move up the income
scale, public spending predominates and both out-of-pocket
spending and external assistance decrease drastically.
LMICs with high levels of out-of-pocket spending have
limited opportunities for risk pooling, which hinders alloca-
tive efficiency and financial protection efforts.1 Moreover, low
overall spending levels in many LICs and some MICs result in
limited access to essential services and limited financial pro-
tection, particularly for the poor. As Musgrove (personal com-
munication with G. Schieber, April 2004) indicates, if GDP is
adjusted for basic subsistence needs, poor households in LICs
appear to be spending a substantial share of their postsubsis-
tence income on health, reinforcing much of the discussion
that follows on the need for additional funds from external
financing sources.
As also discussed by Hecht and Shah in this book 
(chapter 13), external funds—development assistance for
health—have become an increasingly importance source of
health financing in LICs, supporting some 20 percent of LIC
spending. Specifically, DAH from governments, multilateral
and bilateral agencies, and private foundations increased from
an average of US$6.7 billion between 1997 and 1999 to US$9.3
billion in 2002. Sub-Saharan Africa received 36 percent of DAH
funds in 2002, and in 13 extremely poor countries, DAH
accounted for more than 30 percent of health spending (WHO
2004b).
The relationship between health expenditures and health
outcomes is not always clear. Higher spending does not neces-
sarily translate to better health outcomes. Although the evi-
dence tenuously demonstrates a positive relationship between
public spending on health and selected health indicators, it falls
far short of a definitive statement (Bidani and Ravallion 1997;
Filmer and Pritchett 1999; Gupta, Verhoeven, and Tiongson
2001; World Bank 1993, 2003). Health outcomes also vary
across income groups, with the poor generally receiving fewer
services and having worse health outcomes. As in the case of
health services and health outcomes, health spending is often
not pro-poor (Gwatkin and others 2003). The quality of a
country’s institutions also plays a key role in determining the
effectiveness of health spending (Devarajan, Swaroop, and
Heng-Fu 1996; Rajkumar and Swaroop 2002; Wagstaff and
Claeson 2004; World Bank 1993).
Mobilizing Government Revenues. Governments of LICs
have recognized the need for greater domestic investments
in health. In the 2001 Abuja Declaration on HIV/AIDS,
Tuberculosis, and Other Related Infectious Diseases, African
leaders pledged to increase health spending to 15 percent of
their government’s budgets (Haines and Cassels 2004; UNECA
2001). Yet LICs’ ability to raise enough revenue to meet needs
and demands for publicly financed health services is highly
constrained (Gupta and others 2004; Schieber and Maeda
1997). Even though revenue mobilization is directly correlated
with income, wide cross-country variation in revenue mobi-
lization within income groups is apparent. For example,
Myanmar’s tax revenues amounted to only 4 percent of its
GDP, whereas Lesotho’s were 36 percent (WHO 2002).
As table 12.2 shows, during the early 2000s, LICs collected
the equivalent of about 18 percent of their GDP as revenues,
whereas high-income countries collected almost 32 percent.
Given projected future economic growth on the order of 4 per-
cent for LMICs during 2006–15, they will face difficulties in
mobilizing additional domestic revenues (World Bank 2004b).
In other words, even though economic growth is a necessary
condition for progress, it is unlikely to provide the financing
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Table 12.1 Composition of Health Financing by Region and Country Income Level, 2001 
(Averages)
Public Social security Private Out-of-pocket External 
expenditures expenditures expenditures expenditures Private prepaid provision for 
Per capita Total health on health as on health as on health as on health as a plans as a health as a
health expenditures a percentage a percentage of a percentage percentage of total percentage of percentage of
Region and country Per capita expenditures as a percentage of total health total public health of total health private health private health total health
income level GDP (US$) (US$)a of GDP expenditures expenditures expenditures expenditures expenditures expenditures
East Asia and the Pacific 1,387 84 (46) 5.6 59.3 11.1 40.7 83.4 3.5 11.9
Eastern Europe and Central Asia 2,053 132 (131) 5.5 67.1 42.1 32.9 94.9 3.5 2.6
Latin America and the Caribbean 3,705 237 (264) 6.4 56.2 28.5 43.8 81.5 13.7 4.0
Middle East and North Africa 2,834 102 (82) 5.6 52.7 15.6 47.3 79.1 8.1 3.1
South Asia 737 38 (21) 4.6 49.0 6.2 51.0 97.7 0.2 9.9
Sub-Saharan Africa 868 42 (29) 4.5 54.0 1.0 46.0 83.3 6.9 21.7
High-income countries 21,198 1,527 (2,860) 7.7 70.1 33.1 29.9 74.0 16.2 0.1
MICs 3,026 176 (106) 5.8 61.7 28.5 38.3 86.4 8.9 3.4
LICs 576 25 (19) 4.7 51.7 2.2 48.3 84.4 4.0 20.0
Sources: WHO 2004b; World Bank 2004e.
Note: All figures are weighted by country. 
a. Per capita health expenditures include population-weighted averages (in parentheses).
base needed to deal with the HIV/AIDS pandemic or to achieve
the health MDGs.
Trends in Health System Financing
As countries move to different stages of the income spectrum,
their health financing profiles transition as well. The following
discussion compares countries at different stages of the income
spectrum. Given health systems’ variability across time periods,
countries, and income levels, the analysis provides only a snap-
shot. Figure 12.2 illustrates transitions in general health systems
as countries move from low- to middle- to high-income status.
In LICs, almost half of health spending is private, virtually
all out of pocket, and usually in the form of payments for
privately provided health services and pharmaceuticals. The
government, through the MOH, generally operates like a NHS.
It provides basic public health and other services, including
some tertiary-level hospital care, generally in major urban
areas, to the entire population within an extremely limited
budget. In general, because of the small size of formal sector
employment, social insurance is limited, except perhaps for
government employees. Community-based health insurance
may be available to varying degrees but is unlikely to play a
major role. Private health insurance, if any, is extremely limited
because of people’s inability to pay and institutional constraints
to the industry’s development, including the lack of well-
developed financial markets and regulatory environments.
As countries’ economies improve, government revenues
tend to increase because of the expansion of the more readily
taxable formal sector. Other institutions, such as financial
markets, legal systems, and regulatory capabilities, are able to
develop. Although private spending still accounts for some
40 percent of all health spending in MICs, the out-of-pocket
share declines as private health insurance markets develop.
The MOH generally continues to provide basic public health
services and to serve as the insurer of last resort for the poor or
for the entire population for specific chronic conditions as
social health insurance mechanisms develop.
Countries move into the high-income group with improved
institutions, more efficient governments, and greater revenue-
raising capacity and spend a relatively small share on basic pub-
lic health. With few exceptions, publicly financed universal
coverage—or, in some cases, publicly mandated private
coverage—becomes the goal. MOHs maintain responsibility
for public health and surveillance and for the general regulato-
ry environment but generally do not directly provide services.
Risks are pooled either through a NHS, as in Italy and the
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Table 12.2 Average Central Government Revenues, Early 2000s
Total revenue as a Tax revenue as a Social security taxes as
Region and country income level percentage of GDP percentage of GDP a percentage of GDP
Americas 20.0 16.3 2.3
Asia and the Pacific 16.6 13.2 0.5
Central Europe, Baltic states, Russian Fed., 26.7 23.4 8.1
and other former Soviet republics
Middle East and North Africa 26.2 17.1 0.8
Sub-Saharan Africa 19.7 15.9 0.3
Small islands (population less than 1 million) 32.0 24.5 2.8
LICs 17.7 14.5 0.7
Lower-middle-income countries 21.4 16.3 1.4
Upper-middle-income countries 26.9 21.9 4.3
High-income countries 31.9 26.5 7.2
Source: IMF 2004b.
High-income
countries
Patient out of
pocket
National health
insurance model
Private health
insurance model
Source: Maeda 1998.
Middle-income
countries
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countries
Government
budget
National health 
service model
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Patient out of
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Figure 12.2 Health Care Financing System Trends by Country
Income Level
United Kingdom, or through single or multiple insurance
mechanisms, as in France and Germany. The Netherlands
requires wealthier individuals to be insured through a private
system. Private spending declines to 30 percent, and out-of-
pocket spending represents about 20 percent of total health
spending. Although health financing systems are highly coun-
try specific, available information on sources of health spend-
ing and government revenues supports these stylized models.
ABSORPTION, EFFECTIVENESS, AND
SUSTAINABILITY OF DONOR FUNDS
In recent years, several new dimensions have emerged in the
debate on international health financing, namely the effective-
ness of large increases in DAH and the enormous costs of scal-
ing up health and other social systems to meet the MDGs. Both
the donor community and recipient countries have raised con-
cerns pertaining to countries’ absorptive capacity, aid effective-
ness, and sustainability.
Countries’ Absorptive Capacity
Large increases in DAH channeled to LICs have raised ques-
tions about whether countries can make effective use of these
new aid flows. As table 12.3 shows, absorptive capacity has
macroeconomic, budgetary management, and service delivery
dimensions.
Increased aid has important macroeconomic implications
given its potential effect on exchange rates, inflation, balance
of trade, overall competitiveness, aid dependency, domestic
revenue mobilization efforts, and future recurrent costs. Most
studies indicate that the macroeconomic saturation point for
aid lies somewhere between 15 and 45 percent of GDP, depend-
ing on the country’s policy environment (Clemens, Radelet,
and Bhavnani 2004; Collier and Dollar 1999; Collier and
Hoeffler 2002; Foster 2003).
Aid can have a number of negative effects. If aid flows are
not included in the recipient country’s budget, they can result
in corruption. Aid may substitute donors’ priorities for
countries’ priorities. A country may have insufficient human
resources, physical infrastructure, or managerial capacity to
use funds effectively. Resources that may already be in short
supply and that are critical for effective service delivery may
be diverted from other important activities. New resources
may overwhelm the system, and the donors’ reporting and
administrative requirements may impose additional burdens
on countries.
Absorptive capacity problems may also result from
demand-side constraints at the individual, household, or com-
munity levels, including lack of education, limited informa-
tion, travel costs, and income loss (Ensor and Cooper 2004).
Conditional cash transfers are among the demand-side innova-
tions developed to improve the use of essential public health
services by the poor that have been receiving increased atten-
tion. Such programs were initially developed in Latin America
as part of social safety-net programs and provide direct cash
payments to poor households contingent on certain behavior,
such as completing a full set of prenatal visits or attending
health education classes (Rawlings 2004). Conditional cash
transfers are in effect negative user fees. Even though investiga-
tors have found that such programs are quite successful in
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Table 12.3 Major Constraints to Countries’ Absorption of Additional External Resources
Macroeconomic Institutional Physical and human Social, cultural, and political
National government
Fiscal instruments and
allocative mechanisms
Service delivery and
local governments
Debt sustainability
Competitiveness
Dutch disease
n.a.
n.a.
Monetary and fiscal policy
instruments
Exchange rate management
Public expenditure management:
Budget preparation and execution
Accounting and auditing
Local government institutions
Private sector capacity
Administrative, management, and
planning skills
Training technicians and
sector specialists
Sector management skills
Connectivity and communications
networks
Accessibility
Sanitation and water
Roads
Geography
Local government skills and
capacity
Stable national political institutions
Power-sharing mechanisms
Social stability
Cultural norms
Weak institutions
Power-sharing mechanisms 
Cultural norms
Ethnic, caste, and class relations
Source: World Bank 2004a.
n.a.  not applicable.
MICs and have the potential to improve human capital and
health outcomes and reduce poverty with relatively modest
administrative costs, their applicability in LICs is still
unresolved.
Health sector supply and demand constraints can also hin-
der countries’ effective employment of large increases in health
resources. As Mills, Rasheed, and Tollman point out in this
book (chapter 3) and elsewhere, these constraints can occur at
all levels of service delivery and governances (Oliviera-Cruz,
Hanson, and Mills 2003). Additional funding alone does not
create sufficient conditions for overcoming structural weak-
nesses, particularly in the short run. If aid is targeted to specif-
ic diseases or interventions, effective use of such aid may
“consume” different amounts of a country’s administrative
capacity. Increased public funds may supplant private spending
not only by the poor, but also by the nonpoor, resulting in lim-
ited marginal effects on the poor (Filmer and Pritchett 1999).
Aid Effectiveness
Given calls for increases in aid of anywhere between US$25 bil-
lion and US$75 billion a year, the question of aid effectiveness
has taken on increased importance.2 A protracted debate has
generated the following findings concerning aid (Burnside and
Dollar 1997; Clemens and Radelet 2003; Clemens, Radelet, and
Bhavnani 2004; Collier and Dollar 1999; Collier and Hoeffler
2002; Foster 2003; United Nations Millennium Project 2005;
WHO 2001; World Bank 2004a):
• Aid has diminishing returns.
• Countries’ absorptive capacity is limited.
• Aid is fungible overall and among sectors.
• Aid achieves better results in good policy environments.3
• Aid requires ownership by countries; for example, donor-
imposed conditions rarely work.
• Aid is related to increased investment and growth.
• Debt repayments have a negative effect on economic
growth.
• Aid has high transaction costs for countries.
• Aid makes governments accountable to donors as opposed
to their citizens.
Serious overall and health sector–specific questions pertain
to the levels, predictability, variability, fungibility, and sustain-
ability of aid flows, and debate continues between those argu-
ing for vertical disease–specific program assistance and those
supporting broader health system reform changes (WHO
2001). As Mills, Rasheed, and Tollman show in this book (chap-
ter 3), evidence on the effectiveness of both approaches is
mixed. Aid unpredictability and uncertainty need to be
addressed by aligning donors’ disbursement and commitment
cycles with those of recipient countries, strengthening
countries’ budgetary and financial management capacity, and
fostering a more transparent and predictable implementation
structure (World Bank 2004a).
The effect of the composition of aid on countries’ efforts to
mobilize domestic resources is also critical given the strong
push by heavily indebted countries, several Group of Seven 
(G-7) countries, and the United Nations Millennium Project
for grant assistance. Gupta and others (2004) find that
increases in overall aid (net loans plus grants) result in a decline
in total domestic revenues; however, the effects of loans were
quite different from those of grants. Each 10.0 percent increase
in loans was associated with a 2.3 percent increase in domestic
revenues, whereas a 10.0 percent increase in grants was associ-
ated with a 2.8 percent decrease in domestic revenues. The
same study also finds higher levels of corruption result in
reduced domestic revenue-raising efforts.
Fiscal Sustainability
Fiscal sustainability is an often used but rarely defined term,
though it has generally been defined in terms of self-
sufficiency. In its broadest context, achieving sustainability
means that, over a specific period, the managing entity will
generate sufficient resources to fund the full costs of a particu-
lar program, sector, or economy, including the incremental
service costs associated with new investments and the servicing
and repayment of external debt.
Knowles, Leighton, and Stinson (1997, 39) define health
system sustainability as the “capacity of the health system to
replace withdrawn donor funds with funds from other, usually
domestic, sources” and sustainability of an individual program
as the “capacity of the grantee to mobilize the resources to
fund the recurrent costs of a project once it has terminated.”
However, given the enormous unmet needs in the poorest
countries, coupled with stagnant economic performance, some
donors are now defining sustainability on the basis of the man-
aging entity’s commitment of a stable and fixed share of pro-
gram costs (Brenzel and Rajkotia 2004; Kaddar, Lydon, and
Levine 2003).
In light of criticisms leveled at the International Monetary
Fund (IMF) regarding its structural adjustment programs and
fiscal ceilings, IMF has recently paid increased attention to fiscal
sustainability. However, evaluating a country’s fiscal situation
and defining sustainability are not easy matters (Croce and
Juan-Ramon 2003; Dunaway and N’Diaye 2004; Hemming,
Kell, and Schimmelpfennig 2003; Tanzi and Zee 2000). Work
is under way to develop operational indicators of debt and fiscal
sustainability and to define the concept of fiscal space (Dunaway
and N’Diaye 2004; Heller 2005). Understanding the details of
IMF fiscal programs and ensuring stable and predictable long-
term DAH are important conditions for avoiding the macroeco-
nomic distortions discussed earlier.
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HEALTH FINANCING ISSUES IN LICs
This section discusses the severe challenges LICs face in mobi-
lizing sufficient revenues, both domestically and externally, to
meet even the basic health needs of their populations.
The Needs Gap
Since the release of the 1993 World Bank World Development
Report: Investing in Health, researchers have undertaken
numerous efforts to estimate the costs of a basic package of
essential health services. The Commission on Macroeconomics
and Health (WHO 2001) estimated that, in 1997, the 48 poorest
developing countries were spending on average US$11 per
capita (US$6 per year in public funds) and that the level of
spending would have to rise to US$34 per capita to ensure
delivery of an essential package.4 On the basis of these data, the
Commission on Macroeconomics and Health estimated that
total DAH should rise to US$27 billion in 2007 and to US$38
billion by 2015 to scale up coverage (WHO 2001).
Within the framework of the MDGs, a number of other
studies have been undertaken to determine the financial
resources needed to meet the goals. In this book, Wagstaff and
others (chapter 9) review the estimates and methodologies
from these various studies, finding that the annual cost of scal-
ing up to meet the MDGs is between US$25 billion and US$75
billion. The United Nations Millennium Project (2005)
estimates that the additional overall development assistance
needed for scaling up to meet all the MDGs will be US$74 bil-
lion by 2015. All the studies indicate that most LICs will face
enormous constraints in raising additional resources through
domestic resource-mobilization efforts and that the interna-
tional community must essentially finance most of the gap.
New Global Alliances and Funds
Recent years have witnessed a marked increase in the number
of global alliances and institutions aimed at alleviating specific
health sector deficiencies, a number of which owe their exis-
tence to resources made available by philanthropic organiza-
tions.5 The GAVI Vaccine Fund and the Global Fund to Fight
AIDS, Tuberculosis, and Malaria are perhaps the largest and
most well known. While the GAVI Vaccine Fund is both a fun-
der and an implementer, Roll Back Malaria is an example of an
alliance that is a global partnership without a funding mecha-
nism. Some entities like the Global Fund are purely financial
vehicles with little alliance structure. The effect of these new
alliances and funds is significant. Since its inception in 2000,
the GAVI Vaccine Fund has raised and spent more than US$1
billion for immunization, and the Global Fund has commit-
ments of more than US$5 billion and has signed grant
agreements with more than 70 countries worth in excess of
US$3 billion.
Although assessments of global initiatives and alliances are
generally positive, some observers have concerns about their
effects on health systems and prioritization (Travis and others
2004). Increasing concerns are being expressed about the
“verticalization” of DAH and the development of separate
health system “silos,” each dedicated to specific diseases and
activities. This strategy is especially problematic in light of the
scarce human resources available for health in many LICs
(Global Health Trust 2004; Joint Learning Initiative 2004).
As a result of these concerns, the G-7 countries are currently
discussing a number of new, broad-based, global financing
mechanisms to mobilize and facilitate the transfer of resources
from developed countries to LICs, and significant progress
has been made in relation to the International Finance Facility
(IFF), a proposal advanced by the U.K. government. The IFF
will frontload development assistance by issuing bonds on
international markets that would be secured based on legally
binding, long-term donor commitments. The IFF would repay
bondholders using future donor payments. Depending on the
number of donors involved, the IFF could raise an additional
US$50 billion a year in development assistance between now
and 2015. One of the many advantages of this kind of mecha-
nism is that a portion of funding for international develop-
ment is effectively taken out of the annual budgetary process in
participating countries. In this way, the hope is that the revenue
streams available to fund development can be rationalized,
both in terms of the total volume of assistance and in terms of
the stability of annual flows.
These global funds have added a major new dynamic to
global health policy and a new level of influence over LICs.
Large grants are approaching the World Bank’s financing levels
for the health sector. Moreover, such funding is often targeted
to specific diseases or interventions, frequently outside the
basic broadly based financing instruments required by the
World Bank and the IMF. This factor raises important issues of
donor coordination and harmonization of procedures and has
implications for IMF fiscal ceilings.
Financing Instruments
During the past decade, a new reform instrument known as the
SWAp has heavily influenced health financing, particularly for
LICs. Concomitantly, the World Bank and the IMF have
imposed a series of requirements and instruments to ensure
that external assistance is targeted to the poor through PRSPs.
These new policy blueprints and requirements are radically dif-
ferent from previous DAH mechanisms, which were largely
funded on a bilateral basis through projects.
SWAps. Starting in the mid-1990s, donors and recipient coun-
tries established the SWAp to address the limitations of project-
based forms of donor assistance, to ensure that overall health
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reform goals were met, to reduce large transaction costs for
countries,and to establish genuine partnerships between donors
and countries in which both had rights and responsibilities. The
core elements of a SWAp follow (McLaughlin 2003, 2004):
• The government is “in the driver’s seat.”
• The partnership results in a shared vision and agreed-upon
priorities for the sector.
• A comprehensive sector development strategy that reflects
all development activities to identify gaps, overlaps, or
inconsistencies.
• An expenditure framework that clarifies sectoral priorities
and guides all sectoral financing and investment.
• A partnership across development assistance agencies that
reduces governments’ transaction costs.
SWAps explicitly recognize the need to tie health sector
changes to new aid instruments, to macroeconomic and public
sector management, to poverty reduction, and to achievement
of the MDGs (Cassels 1997). A key aspect of this approach is to
improve countries’ policy-making processes, including budget
and public expenditure management, by capturing all funding
sources and expenditures and by putting resource allocation
decisions into a medium-term budget and expenditure frame-
work that is based on national priorities (Foster 1999). To date,
SWAps are in various stages of development and implementa-
tion, and few conform fully to the specifications listed above
(Institute for Health Sector Development 2003). At this point
in their evolution, SWAps should be viewed as a way of coordi-
nating development assistance and creating country owner-
ship. They should be judged on how well they do these things
compared with the previous environment characterized by
multiple, stand-alone projects.
PRSPs. Starting in the mid 1990s, the World Bank and the IMF
began to radically change both the focus and the tools for pro-
viding development assistance to poor countries. In response
to criticisms about the ineffectiveness of previous development
assistance efforts and the high level of indebtedness in some of
the world’s poorest countries, the two organizations focused on
debt forgiveness for heavily indebted poor counties, poverty
reduction, and improved economic growth. Debt forgiveness
required countries to reprogram the bulk of the savings from
forgiven debt into social sectors such as health and education.
In 1999, the World Bank and the IMF stipulated that all of
their concessionary assistance to 81 eligible poor countries
would need to be based on a Poverty Reduction Strategy Paper
(IMF and World Bank 2002, 2003). This new approach was
intended to the following:
• strengthen country ownership 
• enhance the poverty focus of country programs 
• provide a comprehensive coordination framework for the
World Bank, the IMF, and other development partners 
• improve public governance and accountability 
• improve priority setting.
The PRSP process is country driven, involves broadly based
participation, is results oriented and focused on outcomes that
benefit the poor, is comprehensive in recognizing the multidi-
mensional nature of poverty, is partnership oriented,and is based
on a long-term perspective (IMF 2004a; World Bank 2004d).
The PRSP process has made poverty reduction the priority
issue for development (SHC Development Consulting 2001).
Because macroeconomic and sectoral strategies need to be for-
mulated around the PRSP, health reform strategies must be
included and focus on the poor. As of September 2004, about
42 LICs had developed PRSPs that are serving as the basis for
World Bank and IMF financing in those countries. Extensive
evaluations of PRSPs by the World Bank and the IMF, by bilat-
eral donors, and by other development partners have painted
the following mixed picture of their success (IMF 2004a; IMF
and World Bank 2002, 2003; World Bank 2004d):
• PRSPs have the potential to encourage the development of
country-owned, long-term strategies for poverty reduction
and growth, but tensions concerning ownership among
countries, the World Bank and the IMF, and other donors
remain. External partners have not adapted their assistance
programs to PRSP processes in a coordinated manner, and
better frameworks for accountability of both countries and
partners are needed.
• Country participation has improved; however, greater
inclusiveness is still needed. Moreover, the process has not
strengthened domestic institutional policy-making pro-
cesses or accountability.
• PRSPs are an improvement over previous processes in terms
of results orientation, poverty reduction focus, and long-
term perspective. They have fallen short in terms of being a
strategic reform road map, especially in relation to under-
taking structural reforms, boosting economic growth, link-
ing with medium-term expenditure frameworks and budg-
ets, integrating sectoral strategies into the macroeconomic
framework, assessing the social effects of macroeconomic
strategies, understanding links between macroeconomics
and microeconomics, integrating strategy components, and
linking medium- and long-term operational targets.
• Capacity constraints have been serious impediments to
effective implementation, but little attention has focused on
capacity building.
• Monitoring and evaluation is still a significant weakness.
Evaluations of the health sector components of PRSPs raise
many of these issues (DFID Health Systems Resource Centre
2003; WHO 2004a). As more and more partners buy into this
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process and as increased amounts of development assistance
are funneled through PRSPs, their effectiveness will ultimately
depend on country commitment, capacity, and processes; part-
ner flexibility; and funding availability. At this stage, PRSPs
still seem to be a work in progress.
Community-Based Health Insurance 
As noted earlier, private and out-of-pocket spending accounts
for almost half of total health spending in LICs. Given LIC gov-
ernments’ limited abilities to mobilize revenues, country and
donor attention has turned to informal sector insurance mech-
anisms as a way to improve financial protection, mobilize rev-
enues, and improve the efficiency of out-of-pocket spending.
Community-based health insurance is an umbrella term for the
various types of community financing arrangements that have
emerged because of high out-of-pocket spending, uncertainty
surrounding anticipated financial flows from donors, and large
and unregulated private sectors. Here, CBHI refers to prepay-
ment plans that attempt to pool risks to reduce the financial
risk an individual faces because of illness (Atim and others
1998; Bennett, Creese, and Monash 1998; Bennett, Kelley, and
Silvers 2004).
CBHI is found throughout the world but is particularly
prevalent in Sub-Saharan Africa (Bennett, Kelley, and Silvers
2004). CBHI plans are relatively heterogeneous in terms of
populations covered, services offered, regulation, management
function, and objectives. The Commission on Macroeconomics
and Health found that CBHI plans provided significant finan-
cial protection and extended access to a large number of rural
and low-income populations (WHO 2001), but that affordabil-
ity impeded access for the very poor. As a result, the commis-
sion called for increased support for CBHI and for the estab-
lishment of a cofinancing scheme that would match dollar for
dollar the premiums individuals paid toward their health insur-
ance with a government or donor dollar (WHO 2001).
One recent review of the CBHI experience found less positive
results, noting “no evidence from the documents reviewed that
[CBHI schemes] positively impact health status or at least the
utilization of services and financial protection for their mem-
bers and/or for society at large, particularly the poor” (ILO and
STEP 2002a, 54). The review finds that most CBHI schemes
“tend to be small organizations (70 percent covering less than
200 members) with community participation in key decisions at
one point or another in their history but with limited legal or de
facto ownership by the community and with significant depend-
ence from other health subsystems or subsidies as reflected by
their low market exposure” (ILO and STEP 2002a, 54).
In his assessment of CBHI, Ekman (2004, 249) notes the
following:
Overall, the evidence base is limited in scope and
questionable in quality. There is strong evidence that
community-based health insurance provides some
financial protection by reducing out-of-pocket spending.
There is evidence of moderate strength that such
schemes improve cost-recovery. There is weak or no evi-
dence that schemes have an effect on the quality of care
or the efficiency with which care is produced. In absolute
terms, the effects are small and schemes serve only a lim-
ited section of the population. The main policy implica-
tion of this review is that these types of community
financing arrangements are, at best, complementary to
other more effective systems of health financing.
The evidence from these reviews suggests that, even though
CBHI provides financial protection for those enrolled and some
degree of resource mobilization, the overall effect is relatively
small and schemes are less effective in reaching the very poor.
Thus, CBHI is unlikely to be a panacea for substantially improv-
ing risk pooling and mobilizing resources in LICs, and for MICs,
CBHI is less relevant given higher incomes and levels of formal
sector employment. This finding does not suggest that CBHI
should not be part of an overall solution to financing health
care, but it indicates that CBHI is unlikely to play a major role.
The most critical challenge facing LICs is raising sufficient
revenues to meet their basic health needs and the health MDGs.
Although increased grant funding is badly needed, the large
amounts of funds often targeted to a few countries and for spe-
cific diseases and interventions raise questions of country
absorptive capacity, potential distortions of health systems’ pri-
orities, and interactions with IMF fiscal ceilings. Concomitantly,
LICs must improve their institutions in order to increase
absorptive capacity and increase the effectiveness of all official
development assistance. It is also critical for the international
community to reassess the entire official development assistance
and DAH structure; to develop country-compatible mecha-
nisms to reinforce promised international redistribution; and to
improve the targeting, levels, predictability, and timeliness of
external assistance.
HEALTH FINANCING ISSUES IN MICs
MICs benefit from higher levels of domestic funding, higher
initial levels of risk pooling and prepayment, and stronger
health systems than LICs. Many MICs are now focused on
ensuring access and financial protection through universal
health coverage. Chile, Colombia, the Republic of Korea,
Mexico, Poland, and Thailand are implementing universal cov-
erage reforms or have already done so. However, they and many
other MICs still face challenges similar to those facing LICs.
Alternative Risk Pooling Arrangements
Country experience shows that the critical factors for increas-
ing coverage—that is, the number of individuals covered and
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the extensiveness of the benefit package—are increased risk
pooling and prepayment and better access to equity subsidies.
As discussed earlier, most MICs face fragmented risk pools
(ILO and STEP 2002b). Table 12.4 presents MIC approaches to
reforming risk pooling arrangements for achieving universal
coverage.
Most MICs face an additional strategic decision: whether to
pursue aggregation of all pools in a single organization (a sin-
gle pool) or whether to allow for the existence of multiple risk
pooling organizations, which would explicitly or implicitly
compete for members and would be subject to the same rules
regarding benefit packages, revenue collection mechanisms,
and portability of benefits (that is, a virtual single pool).
Colombia and Turkey have opted for the virtual single pool
reform, whereas Costa Rica has chosen a single risk pool. In the
OECD context, Germany and the Netherlands have virtual sin-
gle pool arrangements, whereas New Zealand and the United
Kingdom have single pool arrangements.
Reforms of Social Security. Because SSOs traditionally cover
salaried formal sector workers from whom payroll contribu-
tions can be collected, requiring informal sector workers or
self-employed workers to join is difficult. The reforms for con-
fronting this issue range from voluntary enrollment to various
types of subsidization, as detailed in table 12.4.
Country experiences are also illuminating. For instance,
Chile and Mexico have opened SSOs to the informal sector and
the self-employed through voluntary affiliation, yet they still
face risks of adverse selection because of the voluntary nature
of enrollment and the exclusion of the poorest (Bitrán and
others 2000; Instituto Mexicano de Seguro Social 2003). Chile,
Colombia, Costa Rica, and the Philippines have addressed
exclusion either by subsidizing the SSO directly or by subsidiz-
ing premiums for the poor and informal and self-employed
workers who join. The Republic of Korea and Taiwan, China,
have implemented mandatory universal participation, includ-
ing gradual expansion to the whole population, whereas
Panama has expanded coverage to dependents of contributing
members.
Some of the most important advantages underlying SSO
innovations include the existence of organizational capacity
and of pools of funds (or sometimes a single large fund) that
allow newly enrolled individuals and groups to take advantage
of the risk and income cross-subsidization mechanisms and
purchasing arrangements that are already in place. This
approach results in an immediate enlargement of the risk pool
in contrast to creating other pooling organizations as interme-
diate steps for the future merging of schemes. However, SSOs
usually cover only a relatively small portion of the total popu-
lation, and their focus on formal sector workers and use of pay-
roll contributions as their main revenue collection mechanisms
might be an insurmountable obstacle for reaching the informal
sector and the poor, particularly those in rural areas.
In countries where a SSO is well established and covers a
large population, it might face problems in including informal
sector workers in the absence or even the presence of public
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Table 12.4 MIC Reforms and Innovations for Achieving Universal Coverage
Organizational arrangement Reforms or innovations
Social security Opening affiliation to self-employed and informal sector workers
Mandating universal participation
Providing direct public subsidies to the organization for including the poor
Subsidizing premiums for the poor, self-employed, and workers in the informal sector
MOHs and NHSs Separating the purchase and provision of care 
Using public and private purchasing
Reforming provider payments
Private health insurance Regulating voluntary health insurance
Making private insurers eligible for mandatory social security for health
Providing demand-side subsidies for health insurance
Integration reforms (reforms that allow synergic Using public and private purchasing
interaction of multiple organizational Providing demand-side subsidies for health
arrangements) insurance for the poor and for high-risk groups
Setting up risk equalization and solidarity funds
Providing health education to stimulate demand
Having a virtual single pool 
Source: Authors.
subsidies if the incentive structure is not well designed. For
instance, in the case of Mexico, the SSO operates a scheme that
is partially subsidized by the central government, yet the
scheme still has experienced severe adverse selection and has
few participants, which has also discouraged actively promot-
ing enrollment (World Bank 2004c).
Reforms of MOHs and NHSs. MIC reform approaches for
MOHs and NHSs include introducing internal markets,
including separating the purchasing function from the provi-
sion of health services; using public-private purchasing;
reforming provider payment systems; and decentralizing. In
theory, efficiency gains in the system could be used to provide
access to new enrollees, to increase the number and quality of
services to all participants in the system, or to do both. Success
in these areas has been limited (Baeza and Packard 2005).
Effective modernization of public sector management and civil
services statutes has to date been missing from most provider
payment and health sector reform efforts.
Private Health Insurance Reforms in MICs. Since the 1980s,
MICs have seen two main reforms related to private insurance:
(a) the facilitation and promotion of voluntary health insurance,
including formal recognition of competing private health insur-
ance, and (b) the integration of regulated private insurance as
one component of mandatory social security schemes for formal
workers. Many MICs, such as Indonesia, Mexico, and the
Philippines,now recognize and regulate voluntary private health
insurance. In Chile and Colombia,private insurers participate in
the provision of mandatory risk pooling for social security.
The literature provides some evidence of the potential ben-
efits and problems resulting from the introduction of private
health insurance and competition in the insurance market
(Londoño and Frenk Mora 1997; Sheshinski and López-Calva
1998). However, an ample literature also deals with the equity
and efficiency problems of private health insurance competi-
tion, including risk selection (insurers seeking to enroll low-
risk individuals) and underservice (insurers setting barriers
to the use of services, for instance, by not contracting with
providers of expensive interventions or in low-income areas)
(Arrow 1963; Hsiao 1994, 1995; Laffont 1990; Milgrom and
Roberts 1992).
As to whether harnessing private health insurance con-
tributes to or damages MICs’ chances for achieving universal
coverage, the question is whether MICs can take advantage of
the benefits of introducing health insurance competition and
avoid the related efficiency and equity problems. MICs must
confront the feasibility of introducing specific financial, regula-
tory, and organizational reforms at a level of transaction costs
that would not offset the benefits of competition and privati-
zation (Baeza and Cabezas 1998; Coase 1937; Newhouse 1998;
Williamson 1985).
Single Pool versus Virtual Single Pool. Most MICs must also
decide whether to aggregate all pools into a single organization
or to aim for a virtual single pool (Baeza and Packard 2005).
The implementation of more effective and efficient cross-
subsidies between groups with different income and health
risks is facilitated by merging smaller pools into large pools—
in some cases, national pools. Indeed, the main preliminary les-
sons emerging from Costa Rica, the Republic of Korea, and
Taiwan (China), all of which have achieved universal coverage,
suggest that the combination of a clearly defined benefit pack-
age and reforms for enlarging risk pools plays a paramount role
in achieving greater inclusion through solidarity in financing
and increasing access.
Yet for most MICs, the reality is that multiple pooling
arrangements exist, leading to a fragmented, inefficient, and
inequitable health financing situation overall. Given that devel-
oping proper regulations and incentive systems for counterbal-
ancing such problems is complicated, both institutionally and
cost-wise, fostering a virtual single pool is likely the most feasi-
ble option for these countries.
Sources of Health System Financing in MICs
As discussed earlier in this chapter, health systems use different
sources of financing and revenue collection, including general
taxation, payroll contributions, risk-rated premiums, and user
fees. However, concern is increasing about the use of payroll
contributions as a mechanism for collecting revenue. In a
recent study on financial protection in Latin America, Baeza
and Packard (2005) argue that to extend effective risk pooling
to the informal and nonsalaried sectors and to achieve univer-
sal participation in risk pooling arrangements, policy makers
need to delink health insurance financing and eligibility from
labor market status or employment sector, by gradually reduc-
ing and eventually eliminating payroll contribution financing.
In addition to extending protection against health shocks, this
delinking might also have a positive effect on labor market
mobility and formalization. This delinking can be achieved
through shifting health financing toward general taxation,
which is likely preferred on equity and efficiency grounds, or
through risk-rating premiums as a transition if fiscal con-
straints do not permit full fiscal financing.
Donor Disengagement from MICs
As demonstrated both by the composition and recipients of
DAH and by new health financing and policy agendas, global
health financing policy is currently focused on LICs, leaving
most MICs under the radar. The MDG agenda is predomi-
nantly a LIC agenda, or at least most MICs perceive it as such.
Thus, the question is what to do with the MIC policy dialogue.
Is the status quo tantamount to disengagement? If so, the
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international community is in danger of losing important
financing lessons that would most likely be of great use for
LICs. In addition, a more concerted effort is needed to analyze
what the MDGs mean for MICs—particularly in light of their
increased noncommunicable disease and injury burdens, areas
that the MDGs do not address—and to invest more in the
evidence base for MIC-relevant reforms. It is important to
maintain broad goals, but also important to develop new MIC-
specific indicators, especially for financial protection, which is
at the core of poverty alleviation in MICs as well as LICs but is
not explicitly reflected in the MDGs.
The PRSP process also sends a clear signal to the interna-
tional community to focus on the LICs. Unfortunately, few
PRSPs consider the role of the health system in ensuring finan-
cial protection and reforms of risk pooling arrangements,
which are at the core of most LIC and MIC health sector
financing strategies. A new approach is needed to support
MICs’ efforts to improve public subsidy management and
health system performance to ensure financial protection. Such
approaches are also critical in assisting LICs with their poverty
reduction and health financing reform efforts in the future.
CONCLUSIONS
Global health financing policy is in transition. Infusions of large
amounts of grant money from new financing entities have
changed the players involved in shaping global health policy.
Decisions made by the World Bank and the IMF in 1999 requir-
ing PRSPs as the basis for concessionary financing have pushed
LICs to develop their health policies in the context of an overall
strategy framework for poverty reduction that considers intra-
sectoral, intersectoral, and macroeconomic tradeoffs.
Clearly, neither increased domestic resource mobilization
nor future economic growth will provide the resources neces-
sary for LICs to finance their health needs, whether defined in
terms of a basic package of essential health services or whether
identified within the framework of the MDGs. Increasing offi-
cial development assistance is thus critical for LICs to make
progress in either respect. However, the projected magnitude
and speed of scaling up raises serious questions about coun-
tries’ absorptive capacity, aid effectiveness, predictability, and
stability and about new investments’ financial sustainability at
the country and donor levels. Even though empirical evidence
is still lacking, concerns have arisen that new sources and
increased levels of funding for disease-specific programs will
lead to verticalization and could distort health systems. The
donor community and countries urgently need to reform the
current system of DAH, to improve institutions in developing
countries, and to develop mechanisms to ensure that donors
meet their DAH commitments. Finally, MIC issues need to
receive greater attention.
Global health financing policy makers face the following
challenges:
• The architecture for formulating, coordinating, and imple-
menting global health financing policy at the international
and country levels needs to be improved.
• The donor community needs to harmonize procedures,
ensure aid predictability, and guarantee longer-term assis-
tance.
• Donors need to meet their development assistance obliga-
tions as well as provide more assistance to help countries
improve their domestic resource mobilization efforts.
• The IMF needs to improve understanding of its fiscal pro-
grams and be more flexible in reconciling fiscal constraints
with increased official development assistance and DAH.
• The global community needs to improve the knowledge
base in terms of good (and bad) international practice with
respect to health financing. In this context, absorptive
capacity constraints on both the demand and the supply
sides must be removed. Better use of existing tools, includ-
ing cost-effectiveness analysis, and development of new
tools are needed to help poor countries realistically priori-
tize their financing and spending options and deal with the
tradeoffs between financing essential services and providing
financial protection.
• The potential for verticalization as a result of increased lev-
els of DAH needs to be assessed rigorously and empirically,
taking into account the benefits of such assistance as well as
its potential distortionary effects on other programs and on
health systems as a whole. By focusing limited resources on
a few targeted areas, countries can achieve impressive results
in terms of disease control efforts; however, many disease
eradication efforts have succeeded because such efforts
enhanced overall system capacity.
• The existing assistance instruments need to be objectively
and fully analyzed. Examples of potential inconsistencies,
such as disease-specific program grants versus PRSPs, need
to be highlighted and addressed.
• The issue of financial sustainability needs to be assessed
objectively and apolitically. The international donor com-
munity needs to face up to the realities of those poor coun-
tries whose economies are not sustainable in the medium
term and to consider redistributional policies to assist
them.
• The donor community needs to put MICs on the agenda
both in terms of their economic and social development and
in terms of their use as good practice examples for LICs as
they transition to MIC status.
Because of the different accountabilities of the various mul-
tilateral and bilateral organizations, global funds and alliances,
and private foundations, coordinating global health financing
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policy has become increasingly complex. Given that interna-
tional redistribution of wealth is central to meeting basic needs
in poor countries, the lack of an effective international mecha-
nism to enforce agreed-on transfers of wealth is problematic.
Under these circumstances, the global community must help
countries prioritize on the basis of realistic expectations of
promised donor assistance and harmonization.
Providing countries with advice on good practice and assist-
ing both LICs and MICs to develop equitable and efficient
institutional structures, revenue-raising mechanisms, and
spending prioritizations are important areas worthy of more
international focus and collaboration. Assessments of the costs
and constraints in reaching the health MDGs, taking into
account the large increases in marginal costs to cover the most
difficult-to-reach 5 or 10 percent of the population, are impor-
tant knowledge products in a resource-constrained world.
Making better use of cost-effectiveness information and devel-
oping better-costing tools are necessary for assisting countries,
and donors could help by providing better information on
where to focus policies to remove bottlenecks to the absorption
of additional resources, particularly in terms of achieving the
MDGs. A needed step for assisting LIC and MIC governments
is developing and disseminating evidence about effective health
financing polices, both in severely resource-constrained LICs
that have achieved good health outcomes and in MICs that
have achieved universal coverage with good health outcomes at
reasonable spending levels. Last, the donor community must
harmonize its procedures, simplify aid instruments, ensure the
predictability of assistance, and create a more effective global
policy environment.
DISCLAIMER
The findings, interpretations, and conclusions expressed in this
paper are entirely those of the authors and should not be
attributed in any manner to the Bill & Melinda Gates
Foundation, the RAND corporation, or to the World Bank, its
affiliated organizations, the members of its Board of Directors,
or the countries it represents.
NOTES
1. For a detailed analysis of country-specific and global health expen-
diture trends, see Musgrove, Zeramdini, and Carrin (2002).
2. In addition to aid, countries receive significant financial inflows
through foreign direct investment, expatriate workers’ remittances, special
targeted assistance, South-South support, and so on, and these inflows
must also be taken into account (World Bank 2004b).
3. Clemens, Radelet, and Bhavani’s (2004) study shows that aid can be
somewhat effective in countries with weaker policy environments.
4. More recent data for all LICs indicate per capita spending of US$19
if the data are population weighted and US$25 if they are country
weighted. The public share is 52 percent (country weighted).
5. One of the main funding organizations is the Bill & Melinda Gates
Foundation, which is investing approximately US$1.35 billion per year,
with a considerable portion of that allocated to global health issues.
REFERENCES
Arhin-Tenkorang, D. 2000.“Mobilizing Resources for Health: The Case for
User Fees Revisited.” Working Paper 81, Center for International
Development, Cambridge, MA.
Arrow, K. J. 1963. “Uncertainty and the Welfare Economics of Medical
Care.” American Economic Review 53 (5): 851–83.
Atim, C., F. Diop, J. Etté, D. Evrard, P. Marcadent, and N. Massiot. 1998.
The Contribution of Mutual Organizations to Financing, Delivery, and
Access to Health Care: Synthesis and Research in Nine West and Central
African Countries. Bethesda, MD: Abt Associates, Partnerships for
Health Reform Project.
Baeza, C., and M. Cabezas. 1998. “Is There a Need for Risk Adjustment in
Health Insurance Competition in Latin America?” Discussion paper
prepared for the World Bank, Latin America and the Caribbean Region,
Human and Social Development Department, Washington, DC.
Baeza, C., and T. G. Packard. 2005. Beyond Survival: Protecting Households
from the Impoverishing Effects of Health Shocks in Latin America.
Washington, DC: World Bank.
Bennett, S., A. Creese, and R. Monash. 1998. “Health Insurance Schemes
for People outside Formal Sector Employment.” Discussion of
Analysis, Research, and Assessment Paper 16, World Health
Organization, Geneva.
Bennett, S., A. G. Kelley, and B. Silvers. 2004. 21 Questions on CBHF: An
Overview of Community-Based Health Financing. Bethesda, MD: Abt
Associates, Partnerships for Health Reform Project.
Bidani, B., and M. Ravallion. 1997. “Decomposing Social Indicators Using
Distributional Data.” Journal of Econometrics 77 (1): 125–39.
Bitrán, R., and U. Giedion. 2003. “Waivers and Exemptions for Health
Services in Developing Countries.” Social Protection Discussion Paper
308, World Bank, Washington, DC.
Bitrán, R., J. Muñoz, P. Aguad, M. Navarrete, and G. Ubilla. 2000. “Equity
in the Financing of Social Security for Health in Chile.” Health Policy
50 (3): 171–96.
Brenzel, L., and Y. Rajkotia. 2004. “Vaccine Financing Report.” Paper pre-
pared for the World Bank Human Development Network, Health
Nutrition and Population Unit, Washington, DC.
Burnside, C., and D. Dollar. 1997. “Aid, Policies, and Growth.” Policy
Research Working Paper 1777, World Bank, Policy Research
Department, Macroeconomics and Growth Division, Washington, DC.
Cassels, A. 1997. A Guide to Sectorwide Approaches for Health Development:
Concepts, Issues, and Working Arrangements. Geneva: World Health
Organization.
Clemens, M. A., and S. Radelet. 2003. “The Millennium Challenge
Account: How Much Is Too Much, How Long Is Long Enough?”
Working Paper 23, Center for Global Development, Washington, DC.
Clemens, M. A., S. Radelet, and R. Bhavnani. 2004. “Counting Chickens
When They Hatch: The Short-Term Effect of Aid on Growth.”Working
Paper 44, Center for Global Development, Washington, DC.
Coase, R. H. 1937. “The Nature of the Firm.” Economica 4 (16): 386–405.
Collier, P., and D. Dollar. 1999. “Aid Allocation and Poverty Reduction.”
Unpublished manuscript, World Bank, Development Research Group,
Washington, DC.
Collier, P., and A. Hoeffler. 2002. “Aid, Policy, and Growth in Post-Conflict
Societies.” Policy Research Working Paper 2902, World Bank,
Washington, DC.
240 | Disease Control Priorities in Developing Countries | George Schieber, Cristian Baeza, Daniel Kress, and others
Commission for Africa. 2005. Our Common Interest: Report of the Com-
mission for Africa. London: Commission for Africa. http://www.
commissionforafrica.org/english/report/thereport/cfafullreport_1.
pdf.
Croce, E., and V. H. Juan-Ramon. 2003. “Assessing Fiscal Sustainability:
A Cross-Country Comparison.” Working Paper 03/145, International
Monetary Fund, Washington, DC.
Devarajan, S., V. Swaroop, and Z. Heng-Fu. 1996. “The Composition of
Public Expenditures and Economic Growth.” Journal of Monetary
Economics 37 (2–3): 313–44.
DFID (Department for International Development) Health Systems
Resource Centre.2003.A Review of Human Resource Content of PRSP and
HIPC Documentation in 6 Selected African Countries. London: DFID.
Dunaway, S., and P. N’Diaye. 2004. “An Approach to Long-Term Fiscal
Policy Analysis.” Working Paper 04/113, International Monetary Fund,
Washington, DC.
Ekman, B. 2004. “Community-Based Health Insurance in Low-Income
Countries: A Systematic Review of the Evidence.” Health Policy and
Planning 19 (5): 249–70.
Ensor, T., and S. Cooper. 2004. “Overcoming Barriers to Health Service
Access: Influencing the Demand Side.” Health Policy and Planning
19 (2): 69–79.
Filmer, D., and L. Pritchett. 1999. “The Impact of Public Spending on
Health: Does Money Matter?” Social Science and Medicine 49 (10):
1309–23.
Foster, M. 1999. “Lessons of Experience from Sectorwide Approaches in
Health.” Paper prepared for the World Health Organization and the
Inter-Agency Working Group on Sector-wide Approaches and
Development Cooperation, Geneva.
———. 2003. The Case for Increased Aid: Final Report to the Department for
International Development. Chelmsford, U.K: Mick Foster Economics.
Global Health Trust. 2004. Specific Programs and Human Resources:
Addressing a Key Implementation Constraint. Cambridge, MA: Harvard
University.
Gupta, S., B. J. Clements, A. Pivovarsky, and E. R. Tiongson. 2004. “Foreign
Aid and Revenue Response: Does the Composition of Aid Matter?” In
Helping Countries Develop: The Role of Fiscal Policy, ed. S. Gupta, B. J.
Clements, and G. Inchauste, 385–406. Washington, DC: International
Monetary Fund.
Gupta, S., M. Verhoeven, and E. R. Tiongson. 2001. “Public Spending
on Health Care and the Poor.” Working Paper 01/127, International
Monetary Fund, Washington, DC.
Gwatkin, D., S. Rutstein, K. Johnson, E. A. Suliman, and A. Wagstaff. 2003.
Initial Country-Level Information about Socioeconomic Differences in
Health, Nutrition, and Population. Vols. I and II. Washington, DC:
World Bank.
Haines, A., and A. Cassels. 2004. “Can the Millennium Development Goals
Be Attained?” British Medical Journal 329: 394–97.
Heller, P. 2005. “Fiscal Space-What It Is and How To Get It.” Finance and
Development 42 (2).
Hemming, R., M. Kell, and A. Schimmelpfennig. 2003. “Fiscal
Vulnerability and Financial Crisis in Emerging Market Economies.”
Occasional Paper 218, International Monetary Fund, Washington,
DC.
Hensher, M. 2001. “Financing Health Systems through Efficiency Gains.”
Commission on Macroeconomics and Health Working Paper Series
WG3:2, World Health Organization, Geneva.
Hsiao, W. C. 1994. “‘Marketization’: The Illusory Magic Pill.” Health
Economics 3 (6): 351–57.
———. 1995. “Abnormal Economics in the Health Sector.” Health Policy
32: 125–39.
ILO and STEP (International Labour Organization and Strategies and
Tools against Exclusion and Poverty). 2002a. “Extending Social
Protection in Health through Community Based Health Or-
ganizations.” Discussion paper, ILO and STEP, Geneva.
———. 2002b. “Toward Decent Work: Social Protection for Health for All
Workers and Their Families.” Working paper, ILO and STEP, Geneva.
IMF (International Monetary Fund). 2004a. Evaluation of the IMF’s Role
in Poverty Reduction Strategy Papers and Poverty Reduction and
Growth Facility. Washington, DC: IMF, Independent Evaluation 
Office.
———. 2004b. 2004 Government Finance Statistics. Washington, DC: IMF.
IMF and World Bank. 2002. “Review of the Poverty Reduction Strategy
Paper (PRSP) Approach: Early Experience with Interim PRSPs and
Full PRSPs.” Paper prepared for the International Development
Association and the IMF, Washington, DC.
———. 2003. “Poverty Reduction Strategy Papers: Detailed Analysis and
Progress to Date.” Paper prepared for the International Development
Association and the IMF, Washington, DC.
Institute for Health Sector Development. 2003. “Mapping of Sector-Wide
Approaches in Health.” Report prepared for the Swedish International
Development Cooperation Authority Sectorwide Approach Seminar,
San Francisco, CA, June 19.
Instituto Mexicano de Seguro Social. 2003. Informe al Ejecutivo Federal y al
Congreso de la Unión sobre la situación financiera y los riesgos del
Instituto Mexicano del Seguro Social. Mexico City: Instituto Mexicano
de Seguro Social.
Joint Learning Initiative. 2004. “Human Resources for Health:
Overcoming the Crisis.” Harvard University Press Global Equity
Initiative, Cambridge, Mass.
Kaddar, M., P. Lydon, and R. Levine. 2003. “A Critical Review of Financial
Sustainability: The GAVI Experience.” Discussion paper prepared for
London School of Hygiene and Tropical Medicine, Workshop on the
Economics of Immunization, London, October 29–30.
Kivumbi, G. W., and F. Kintu. 2002. “Exemption and Waivers from Cost
Sharing: Ineffective Safety Nets in Decentralized Districts in Uganda.”
Health Policy and Planning 17 (Suppl. 1): 64–71.
Knowles, J. C., C. Leighton, and W. Stinson. 1997. Measuring Results of
Health Sector Reform for System Performance: A Handbook of Indicators.
Special Initiatives Report 1. Bethesda, MD: Abt Associates,
Partnerships for Health Reform Project.
Laffont, J-J. 1990. The Economics of Uncertainty and Information.
Cambridge, MA: Massachusetts Institute of Technology Press.
Londoño, J-L., and J. Frenk Mora. 1997. “Structured Pluralism: Toward an
Innovative Model for Health System Reform in Latin America.” Health
Policy 41 (1): 1–36.
Maeda, A. 1998. “A Model for the Evolution of Health Systems.”
Presentation prepared for the World Bank, Washington, DC.
Mathers, C. D., C. Stein, D. M. Fat, C. Rao, M. Inoue, N. Tomijima, and
others. 2002. “Global Burden of Disease 2000: Version 2 Methods and
Results.” Global Programme on Evidence for Health Policy Discussion
Paper 50, World Health Organization, Geneva.
McLaughlin, J. 2003. “Accelerating Progress toward the Health MDGs:
Important Lessons Learned from Development Assistance.” Paper
prepared for the World Bank, Washington, DC.
———. 2004. “The Evolution of the Sectorwide Approach (SWAp) and
Explaining the Correlation between SWAps and Reform Initiatives.”
Paper prepared for the World Bank, Washington, D.C.
Milgrom, P., and J. Roberts. 1992. Economics, Organization, and Manage-
ment. Englewood Cliffs, NJ: Prentice-Hall.
Musgrove, P. 1996. “Public and Private Roles in Health: Theory and
Financing Patterns.” Health, Nutrition, and Population Discussion
Paper, World Bank, Washington, DC.
Financing Health Systems in the 21st Century | 241
Musgrove, P., R. Zeramdini, and G. Carrin. 2002. “Basic Patterns in
National Health Expenditures.” Bulletin of the World Health
Organization 80 (2): 134–46.
Newhouse, J. 1998.“Risk Adjustment: Where Are We Now?” Inquiry 35 (2):
122–31.
Oliviera-Cruz, V., K. Hanson, and A. Mills. 2003. “Approaches to
Overcoming Constraints to Effective Health Service Delivery: A
Review of the Evidence.” Journal of International Development 15 (1):
41–65.
Palmer, N., D. H. Mueller, L. Gilson, A. Mills, and A. Haines. 2004. “Health
Financing to Promote Access in Low Income Settings—How Much
Do We Know?” Lancet 364 (9442): 1365–70.
Rajkumar, A. S., and V. Swaroop. 2002. “Public Spending and Outcomes:
Does Governance Matter?” Policy Research Working Paper 2840,
World Bank, Washington, DC.
Rawlings, L. 2004. “A New Approach to Social Assistance: Latin America’s
Experience with Conditional Cash Transfer Programs.” Social
Protection Discussion Paper 0146, World Bank, Washington, DC.
Schieber, G., ed. 1997. Innovations in Health Care Financing. Washington,
DC: World Bank.
Schieber, G., and A. Maeda. 1997. “A Curmudgeon’s Guide to Financing
Health in Developing Countries.” In Innovations in Health Care
Financing, ed. G. Schieber, 1–40. Washington, DC: World Bank.
SHC Development Consulting. 2001. Sector Programmes and PRSP
Implementation: Chances and Challenges. Kassel, Germany: SHC
Development Consulting.
Sheshinski, E., and L. F. López-Calva. 1998. “Privatization and Its Benefits:
Theory and Evidence.” Consulting Assistance on Economic Reform II
Discussion Paper 35, Harvard University, Cambridge, MA.
Tait, A. 2001. “Mobilization of Domestic Resources for Health through
Taxation: A Summary Survey.” Commission on Macroeconomics and
Health Working Paper WG3:14, World Health Organization, Geneva.
Tanzi, V., and H. H. Zee. 2000. “Tax Policy for Emerging Markets:
Developing Countries.” Working Paper 00/35, International Monetary
Fund, Washington, DC.
Travis, P., S. Bennet, A. Haines, T. Pang, Z. Q. Bhutta, A. A. Hyder, and
others. 2004. “Overcoming Health Systems Constraints to Achieve
the Millennium Development Goals.” Lancet 364: 900–6.
UNECA (United Nations Economic Commission for Africa). 2001. “Abuja
Declaration on HIV/AIDS, Tuberculosis, and Other Related Infectious
Diseases.” Paper presented at UNECA Special Summit on HIV/AIDS,
Tuberculosis, and Other Related Infectious Diseases, Abuja, Nigeria,
April 27. http://www.uneca.org/adf2000/Abuja%20Declaration.htm.
United Nations Millennium Project. 2005. UN Millennium Project 2005:
Investing in Development—A Practical Plan to Achieve the Millennium
Development Goals. New York: United Nations.
Wagstaff, A., and M. Claeson. 2004. The Millennium Development Goals for
Health: Rising to the Challenges. Washington, DC: World Bank.
WHO (World Health Organization). 2000. The World Health Report 2000:
Health Systems—Improving Performance. Geneva: WHO.
———. 2001. Report of the Commission on Macroeconomics and Health:
Investing in Health for Economic Development. Geneva: WHO.
———. 2002. The Report of Working Group 3 of the Commission on
Macroeconomics and Health. Geneva: WHO.
———. 2004a. Poverty Reduction Strategy Papers: Their Significance for
Health—Second Synthesis Report. Geneva: WHO.
———. 2004b. World Health Report 2004: Changing History. Geneva:
WHO.
Williamson, O. E. 1985. The Economic Institutions of Capitalism. New York:
Free Press.
World Bank. 1993. World Development Report 1993: Investing in Health.
New York: Oxford University Press.
———. 2003. World Development Report 2004: Making Services Work for
Poor People. New York: Oxford University Press.
———. 2004a. “Aid Effectiveness and Innovative Financing Mechanisms.”
Report prepared for the 2004 Annual Meetings of the International
Monetary Fund and the World Bank, Washington, DC, October 2–3.
———. 2004b. Global Development Finance: Harnessing Cyclical Gains for
Development. Washington, DC: World Bank.
———. 2004c. Poverty in Mexico: An Assessment of Conditions, Trends, and
Government Strategy. Washington, DC: World Bank.
———. 2004d. The Poverty Reduction Strategy Initiative: An Independent
Evaluation of the World Bank’s Support through 2003. Washington, DC:
World Bank, Operations Evaluation Department.
———. 2004e. 2004 World Development Indicators. Washington, DC:
World Bank.
242 | Disease Control Priorities in Developing Countries | George Schieber, Cristian Baeza, Daniel Kress, and others
243
After nearly a decade during which levels of external develop-
ment assistance for health (DAH) stagnated, an encouraging
rise has occurred in the volume of such assistance. Donors and
developing countries are testing and implementing innovative
approaches to the use of DAH, while simultaneously seeking
ways to raise the effectiveness of existing streams of aid and
more traditional financing mechanisms. In short, DAH has
entered a dynamic phase that holds considerable promise.
Nevertheless, it continues to suffer from a broad range of
disappointments: misuse and inefficiency in the deployment of
funds, gaps in essential areas that require financing support,
and weaknesses in institutional and management arrange-
ments. Substantial room for improvement exists.
This chapter documents those recent trends, analyzes the
effects and assesses the performance of DAH, and points to
areas that require priority attention. In the first part, we present
statistics on DAH, updating the World Development Report
1993 (World Bank 1993) and the report of the Commission on
Macroeconomics and Health (CMH 2001). In the second part,
we assess the performance of DAH. In the third part, we present
recent innovations to underscore the current dynamic nature
of such assistance. The chapter concludes with some sugges-
tions on future directions.
TRENDS AND GAPS IN DEVELOPMENT
ASSISTANCE FOR HEALTH
Despite a decline in overall official development assistance in
the 1990s, DAH rose in real terms and as a proportion of offi-
cial development assistance (table 13.1). New funding sources
became available in 2000–2, including the Global Fund to
Fight AIDS, Tuberculosis, and Malaria and special U.S. financ-
ing for HIV/AIDS, plus rapid growth in grant awards from the
Bill & Melinda Gates Foundation and in World Bank
International Development Association (IDA) grants. Com-
mitments from all external sources, including foundations, rose
from an annual average of US$6.7 billion in 1997–99 to about
US$9.3 billion in 2002.
Total DAH is the sum of external financing for health from
several different sources: bilateral agencies as reported through
the creditor reporting system of the Organisation for Economic
Co-operation and Development (OECD); multilateral agen-
cies, including the United Nations (UN) system—especially the
World Health Organization (WHO), the United Nations
Children’s Fund, the United Nations Population Fund, and the
global and regional development banks; the European Union;
philanthropic organizations; and the Global Fund to Fight
AIDS, Tuberculosis, and Malaria. Because no central repository
of data on all the sources of DAH is currently available and
comprehensive information is not published on any regular
basis, painstaking and time-consuming efforts are required to
assemble accurate, comparable data about all these sources.
After a long period of decline in official development assis-
tance (grants from bilateral government channels and UN
agencies plus net flows from development banks) during the
1990s, the OECD reported a real increase of 7 percent from
2001 to 2002 and a further increase of 4 percent from 2002 to
2003. Those increases took official development assistance to an
all-time high, in both nominal and real terms, of US$68.5 bil-
lion. As a percentage of gross national income, this represents
an increase from the all-time low of 0.22 percent recorded
during most years from 1997 to 2001 to about 0.25 percent in
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2003, still well below the target of 0.7 percent set by the OECD’s
member states in 1970. Only five countries—Denmark,
Luxembourg, the Netherlands, Norway, and Sweden—currently
achieve this target, and six others have now set prospective dates
for its achievement—namely, Belgium (2010), Finland (2010),
France (2012), Ireland (2007), Spain (2012), and the United
Kingdom (2013).
Bilateral assistance for health rose from an annual average of
US$2.2 billion (3.8 percent of the total) during 1997–99 to
US$2.9 billion (6.8 percent) in 2002. Among the bilateral
arrangements, the United States accounted for about 40 per-
cent of the total, even though as a percentage of gross domestic
product (GDP), its allocation to international development
was among the lowest of all the high-income countries.
Within the UN system, DAH rose from an average of
US$1.6 billion per year during 1997–99 to US$2 billion in
2002. Commitments from the development banks remained
stationary at about US$1.4 billion. However, changes in
accounting by the World Bank to include financing for health
activities contained in projects managed by other sectors (such
as urban, water and sanitation, transportation, and social
development), suggest that its new commitments for health
actually rose from about US$1 billion in 2001 to US$1.3 billion
in 2002 and US$1.7 billion in 2003.
In the future, consensus will need to be reached on whether
allocations by the multilateral development banks to projects in
other sectors or to projects that are classified as multisectoral—
especially broad budget support to governments, which may be
specifically tied to domestic spending and policy reforms in
health—should be counted as DAH. Another issue in DAH
accounting involves distinguishing between allocations for
health from the multilateral banks that take different forms—
namely, outright grants (a recent innovation for the World
Bank and the regional banks); subsidized loans for the poorest
countries, which at the World Bank are IDA credits; and loans
for the middle-income developing countries that reflect the
actual costs of borrowing by the development banks. For exam-
ple, of the US$1.7 billion in World Bank commitments for
health in 2003, about US$1 billion took the form of IDA cred-
its, and most of the rest was in the form of loans that reflected
the costs of borrowing. Because the face value of the financial
commitment can be considered to be reduced by repayments in
the case of subsidized and market rate loans, some argue that
the net financial value of such loans, rather than their face
value, should be used in calculating DAH. This calculation fur-
ther complicates the task of monitoring DAH.
Despite these various cautions and qualifications, it is clear
that DAH has grown in recent years. This upward trend has
been driven by several factors, including (a) donors’ increasing
attention to the challenges presented by the Millennium
Development Goals (MDGs), which are heavily centered on
maternal and child health and control of communicable dis-
eases; (b) strong global mobilization to confront the AIDS pan-
demic in developing countries since 1998–99, especially in
Africa; and (c) donors’ expanding interest in research and
development (R&D) in relation to new health technologies to
address the major diseases prevalent in poor countries. In con-
trast, external funding for health system development, human
resources, and noncommunicable diseases has increased more
slowly.
In terms of the areas that have benefited from the growing
volume of DAH, three stand out: HIV/AIDS, immunization,
and new health product development. According to Michaud
(2003), in 2002 about US$900 million in DAH was for
HIV/AIDS, followed by US$210 million for tuberculosis (TB),
and US$160 million for malaria control. The Joint United
Nations Programme on HIV/AIDS (UNAIDS) also reports a
substantial rise in external financing for AIDS prevention, treat-
ment, and social mitigation activities over the past four years
(UNAIDS 2004). Most of the increase in assistance for immu-
nization has taken place through the Global Alliance for
Vaccines and Immunization (GAVI), which has amassed com-
mitments of about US$1.3 billion to finance the expansion of
existing childhood immunization programs and the accelerated
introduction of hepatitis B and Haemophilus influenzae type B
vaccines. Assistance for health technologies directed at diseases
that are prevalent in the developing world has been channeled
through new public-private partnerships. Examples include the
International AIDS Vaccine Initiative (IAVI), the Medicines for
Malaria Venture, and the International Partnership for
Microbicides. Estimates indicate that the 10 largest public-
private partnerships have raised more than US$1 billion over
the past five years (IPPPH 2004).
In terms of the sources of the expanded volume of DAH, a
small number of institutions account for much of the recent
increase. Among the traditional donors, these institutions
include the World Bank and the governments of Canada and
the United Kingdom. At the same time, as a share of GDP,
contributions from Ireland, the Netherlands, Norway, and
Sweden remain high. Among nontraditional sources, the Bill &
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Table 13.1 Development Assistance for Health, Selected Years
(US$ millions)
Annual average,
Source 1997–99 2002
Bilateral agencies 2,560 2,875
Multilateral agencies 3,402 4,649
European Commission 304 244
Global Fund to Fight AIDS, 0 962
Tuberculosis, and Malaria
Bill & Melinda Gates Foundation 458 600
Total 6,724 9,330
Sources: Michaud 2003; OECD 2004a. 
Melinda Gates Foundation stands out as a major new player as
of the late 1990s. With a focus on the development of new
drugs, vaccines, and diagnostics for the developing world, the
Gates Foundation’s commitments for health started in 1998
and rose rapidly to some US$600 million in 2002, with annual
commitments expected to approach US$1 billion in 2004 and
beyond.
Development assistance for health is channeled to a large
number of low- and middle-income developing countries, but
the largest recipient region is Africa. In 2002, about 35 percent of
all such assistance went to Africa, followed by Latin America and
the Caribbean with around 14 percent, East Asia and South Asia
with 11 percent each, and the Middle East with 7 percent. The
remaining 22 percent was for global programs (Michaud 2003).
This growth in funding for the control of communicable
diseases and new health technologies to address them is impor-
tant, given the high burden of illness and premature death
these diseases cause. Nevertheless, the focus on AIDS, TB, and
malaria should be matched by similar increases in investments
in broader health system improvements. Relatively little DAH is
being channeled to address the serious problems of shortages
in health workforces in poor countries and their low produc-
tivity or to deal with weaknesses in health management
information systems, in supply chain logistics for drugs and
commodities, and so on. Even though focused spending on
AIDS, TB, and malaria will clearly touch on these weaknesses,
it will not on its own go to the core of the problem or lead to
sustainable solutions. For example, GAVI allocates resources to
strengthen immunization infrastructure such as cold chains
and to train health workers to deliver vaccinations more
effectively. The Global Fund to Fight AIDS, Tuberculosis, and
Malaria provides funds to prepare health workers to deliver and
monitor compliance with antiretroviral treatments. Useful as
those activities are, they will not address the underlying weak-
nesses in human resources for health in poor countries, such
as low levels of pay, unattractive conditions of service, and
uncertain prospects for career advancement.
The recent rise in DAH is encouraging, but it is still far short
of the volume of external financing for health that is needed,
according to recent estimates and political pronouncements.
On a global level, estimates of what donors need to provide to
help countries reach the MDGs for health have typically ranged
from US$15 billion to US$35 billion per year. The Commission
on Macroeconomics and Health suggested a figure of about
US$30 billion a year. While preparing for the Monterrey
Summit on Finance for Development, the World Bank calcu-
lated a funding gap of US$15 billion to US$25 billion a year
(Devarajan, Miller, and Swanson 2002). For the United Nations
General Assembly special session on AIDS in June 2001,
UNAIDS suggested that spending on HIV/AIDS alone in the
developing countries needed to rise to about US$9 billion
annually by 2005, with about two-thirds of this amount to
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come from external sources (UNAIDS 2001). At the 2004
International AIDS Conference in Bangkok, UNAIDS raised its
estimate of resources needed to more than US$15 billion a year
by 2010 (UNAIDS 2004).
These global calculations have been followed by more
detailed costing exercises at the country level, which hold the
promise of yielding more accurate and meaningful figures than
the global estimates. Donors working with government special-
ists in developing countries have tested a variety of methods.
The UN Millennium Project has used a bottom-up approach,
which is based on expanded coverage of key interventions and
fixed unit costs, assuming no shared costs or benefits among
different interventions, omitting the possibility of private
financing, and adding a rough amount for system improve-
ments (UN Millennium Project 2004). The World Bank has
followed two other approaches. One, in India, is based on
observed elasticities of change in children’s health and nutri-
tion outcomes in relation to public expenditures on health,
primary education, water, and so on (World Bank 2003a).
Another, in Ethiopia, Mali, and other countries, is based on
detailed modeling of the costs of removing bottlenecks in health
service delivery to enhance the coverage, utilization, and quali-
ty of key health interventions proven to have a positive effect on
maternal and child health outcomes (Soucat and others 2003;
World Bank and Ministry of Health, Ethiopia 2005).
A comparison of the Millennium Project’s and the World
Bank’s results for East Africa is interesting. The Millennium
Project calculates that nearly US$30 per capita are needed in
additional spending for health, whereas the World Bank calcu-
lates that about US$4 per capita are needed for Ethiopia to
reduce child and maternal death rates by 30 to 40 percent by
2015. The large difference between the two sets of results sug-
gests that more work needs to be done to move toward con-
sensus on the best methodology for countries to use.
Part of the difference is due to technical factors. The
Millennium Project approach covers all the health MDGs,
whereas the bottlenecks method has focused on the MDGs
pertaining to child and maternal health only. The Millennium
Project also calculates costs to achieve the MDGs in their
entirety, whereas the bottlenecks method addresses incremental
improvements. For example, in relation to the child mortality
goal, the bottlenecks analysis for Ethiopia considers a substantial
decline to be from 176 to 107 deaths per 1,000 live births, but the
MDG is 59 deaths per 1,000 births. In addition, the Millennium
Project multiplies additional units of service by a standard cost
per unit, whereas the bottlenecks method estimates the cost of
system improvements and then divides this amount by the addi-
tional services rendered to derive incremental unit costs.
The two approaches also have important differences in polit-
ical philosophy. The Millennium Project approach sets high
targets for DAH and health spending, which are based on full
achievement of the MDGs, regardless of the starting points and
gaps and without addressing the feasibility of reaching the tar-
gets. The World Bank’s approach is less ambitious but may be
seen as more realistic and as pointing the way to implementation
based on gradual improvements—improvements that countries
can pursue as additional financial resources and capacity to
manage them effectively are combined on the ground.
MAKING DEVELOPMENT ASSISTANCE FOR
HEALTH MORE EFFECTIVE: LESSONS LEARNED
More assistance is part of the answer to helping developing
countries achieve more rapidly the improved health outcomes
they seek and that are enshrined in the MDGs. To this end, we
need to know how effective DAH has been and what can be
done to make it more effective.
Despite valid criticisms of DAH, some health programs—
inspired and supported by donors—have worked at scale and
contributed to more than four decades of steady improvements
in health, as measured by under-five mortality and overall life
expectancy. The record of public health successes in developing
countries is becoming increasingly clear, as noted in a recent
review of four decades of experience (Levine and What Works
Working Group 2004). The success stories cover a broad spec-
trum of circumstances. They are found in all regions and cover
both communicable and noncommunicable diseases. They
have been driven by new technologies, including vaccines,
drugs, and diagnostics; community- and clinic-based care; and
knowledge for behavior change.
Significant gains have occurred even in the poorest coun-
tries and in those with weak institutional environments.
Consider, for example, the high levels of TB case detection in
the Democratic Republic of Congo and in Myanmar (Stop TB
Partnership 2003), the successes in polio eradication in African
countries experiencing civil wars, and the growing availability
of antiretroviral therapy in Haiti.
Some of this progress can be attributed to the general effects
of economic growth and improvements in education, water,
and sanitation. However, specific, compelling examples of the
success of DAH-backed initiatives are available. For example,
programs to immunize against measles, to control river
blindness and guinea worm, and to fortify salt with iodine have
had sustained and widespread effects (Levine and What Works
Working Group 2004). These programs have been successful at
scale, have generated sustainable health improvements at the
population level, and have succeeded in a broad range of insti-
tutional environments.
Recent analyses and reviews of donor-supported successes
in international health have noted a set of factors that tend to
contribute to positive outcomes:
• strong internal (governments) and external (donors) politi-
cal leadership 
• collaboration across governments, donors, and nongovern-
mental organizations (NGOs) in program design and
implementation
• consistent, predictable funding support, even after success
has been achieved
• simple and flexible technologies that can be adapted to local
conditions and do not require complex skills to operate and
maintain
• programmatic approaches that recognize and address the
need to help build health system infrastructure, especially in
human resources
• household or community participation in the design, exe-
cution, and monitoring of program activities.
Policy Environment
Development assistance for health supports a vast array of
activities and services, some focused on specific diseases (polio,
TB, HIV/AIDS), some on strengthening health systems (disease
surveillance, nurse and midwife training), and some on partic-
ular services (reproductive and child health services). But has
DAH actually changed health outcomes? Recent work from the
World Bank, the Commission on Macroeconomics and Health,
and others suggests that it has (Rajkumar and Swaroop 2002).
However, DAH does not work as effectively in countries where
the policy environment is poor, even though some carefully
targeted disease control activities can confer limited benefits.
With good policies and institutions (strong property rights,
reduced corruption, an efficient bureaucracy), an extra 1 per-
cent of GDP in aid is estimated to reduce infant mortality by
0.9 percent. By contrast, where policies are average, the decline
is estimated at only 0.4 percent, and where policies are poor, aid
is estimated to have no significant effect on infant mortality
(World Bank 2004b).
The issue is not black and white: there are gradations of
good policy, and as policies improve, the productivity of aid
increases. For example, Bangladesh has made large strides in
reducing under-five mortality in recent years, relying on NGOs
to deliver many services. If Bangladesh were able to raise the
quality of its governance from below average to above average,
even at its same public spending levels, it would realize more
rapid gains. An additional dollar of government health spend-
ing would reduce under-five mortality by 14 percent, compared
with 9 percent without such improvements (World Bank
2003c).
Tradeoffs may be necessary between targeting assistance
toward the neediest countries and achieving the greatest effect
from DAH, but even in needy countries with weak policies,
some kinds of carefully targeted assistance for health (for
example, immunizations delivered by reputable NGOs) can
have a positive effect. In addition, in countries with weak
policies, a focus by donors on policy dialogue and technical
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assistance to improve the environment for DAH can set the
stage for a larger infusion of financial support down the road.
Conditionality
Conditionality is making the availability of funding dependent
on a government completing an agreed task, such as enacting a
new health law or spending a certain share of its budget on
health activities. It can work, but only if the government is
committed to making such a change. Tying aid to policy
changes is a common practice, but recent studies have cast
doubt on the ability of such conditionality to bring about
reform (World Bank 1998, 2003a). If governments are not
committed to reform, conditionality will not make them
reform. Donors themselves often undermine the rigor and
credibility of conditions because they usually face strong inter-
nal pressures to continue disbursement of the funds anyway,
even when governments do not adhere to the agreed-on condi-
tions. On the other hand, if governments are committed to
reform, conditions can help by enabling governments to com-
mit publicly to certain reforms and persuade private investors
of their seriousness. For example, the government of Uganda’s
commitment to decentralizing the management of basic health
services and to making local authorities accountable to com-
munities was reinforced by conditions in the Uganda poverty
reduction support credit, which several donors financed.
Similarly, the Chinese government’s commitment to reaching
the poor with TB control services was reinforced by stipula-
tions in donor-funded TB projects that they target the coun-
try’s poorest provinces and reach out to deprived households
(World Bank 2003c).
Donors cannot force policies on governments, but they can
help with policy design. Donors can alert governments to the
reasons for reform and help nurture commitment, but at the
end of the day, it is governments that have to sustain any
reforms (box 13.1). Undertaking analytical work, providing
training and technical assistance, disseminating ideas about
policy reform and development, and stimulating debate in civil
society can all be valuable activities for donors to support while
a government’s commitment to reform is growing.
Vietnam in the late 1980s and early 1990s is a good example.
At a landmark meeting in 1986, the ruling Communist Party
decided to break with the past and introduce sweeping eco-
nomic reforms. In the health sector, the reforms included
introducing user fees at public facilities, legalizing private med-
icine, deregulating the pharmaceutical industry, and opening
the pharmaceuticals and medical equipment subsectors to
international trade. Initially, Vietnam saw no increase in aid,
but such agencies as the United Nations Development
Programme and the World Bank helped facilitate the reform
process by organizing international workshops for the
Vietnamese to exchange ideas on policy with their neighbors.
This effort set the stage for a large inflow of donor financing,
starting around 1995 and continuing to the present.
Fungibility of Development Assistance for Health
Much aid is earmarked, both across sectors and within them.
One part of a development agency gives a grant to the ministry
of health for a health sector reform, while another does the
same for a primary education project. An agency makes a loan
to the ministry of health for a TB project, while another makes
a loan for a malaria control project. The donors’ intent is that
these activities remain tightly sealed: the funds for health sector
reform are to be kept separate from the funds for the primary
education project; the TB project funds are to be kept separate
from the malaria control project funds. The idea is to ensure
that the government makes a certain spending choice. It is
based on the assumption that the choice would not be made if
the government had been handed a blank check for the same
amount.
The implied view of such aid is that what you see is what
you get; that is, a government receives US$1 million for a water
project and the net effect is US$1 million worth of extra
spending on the water sector. This view has recently been chal-
lenged, with the alternative view being that aid is at least part-
ly fungible (Burnside and Dollar 2000; World Bank 1998).
Hence, as a result of the inflow of development assistance for a
specific health activity, the government changes the way in
which it spends the rest of its resources, both in the health sec-
tor and in terms of allocations between health and other sec-
tors. As a result, for each dollar earmarked for a specific health
project, spending on health rises by less than a dollar but by
more than would have been the case had the government
received an extra dollar in its overall budget. Similarly, spend-
ing for the specified purpose in the health sector rises by less
than a dollar, but by more than would have been the case had
the government allocated an extra dollar of its own resources
to health generally.
Assessing whether aid is indeed fungible is not straightfor-
ward. The difficulty is knowing how the government would
have responded had its own resources increased by the amount
of the aid or had it received a blank check for the same amount.
Recent research suggests that, despite considerable variation
across countries, on average only 29 cents of each additional
dollar of aid goes into government development programs,
with the rest leaking out into nondevelopment programs such
as military spending (World Bank 2004b).
One important implication of those findings is that donors
should spend less time and effort trying to channel their exter-
nal funding to specific programs for priority diseases and
populations. Instead, a more useful exercise would be to engage
in a dialogue with the government on basic changes in the
overall patterns of public spending for health—that is, the total
Recent Trends and Innovations in Development Assistance for Health | 247
allocation and the amounts for, say, providing child health and
communicable disease control services and for improving
community and primary-level health delivery systems. If the
government followed through on those basic changes, then
donors would transfer their financial assistance to the health
sector as a whole.
The finding that aid is indeed fungible has encouraged some
donors to search for broader development assistance mecha-
nisms that recognize the importance of the entire expenditure
program and explicitly avoid earmarking. Such mechanisms
include the Multi-Country AIDS Program in Africa, which
supports national HIV/AIDS strategies; sectorwide approaches
in health; and poverty reduction support credits (PRSCs) that
back a broad public spending agenda.
An opposing viewpoint is that although, in general, good
policies matter and the fungibility of aid tends to undermine
donors’ ability to earmark their funding effectively, many high-
impact health services can be delivered to the population on a
targeted basis even when national policies and institutions are
weak—and this aid would not occur in the absence of DAH.
This argument applies especially to services with simple
technologies—for instance, basic childhood vaccinations that
can be delivered on a single occasion through annual cam-
paigns or disease treatment programs (such as short-course
drug therapy for TB) that can be provided through tightly
managed top-down efforts (Jamison 2004). The high coverage
and treatment success using the directly observed short-course
therapy approach for TB in the Democratic Republic of
Congo in recent years, even during the civil war, can be cited as
an example of how a well-protected enclave project with
strong donor backing can be successful (Stop TB Partnership
2003).
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Donors and Commitment: Nutrition in Bangladesh and Thailand 
Box 13.1
In most countries, nutrition has not become a visible issue
on the national political agenda, because nutrition advo-
cates have not succeeded in linking improved nutrition with
political and economic goals or in creating popular demand
to eliminate malnutrition. In Bangladesh in the early 1990s,
the United Nations Children’s Fund and the World Bank
joined forces to present a case to the government showing
how the country could not achieve its economic goals
unless it reduced malnutrition. This effort persuaded the
government’s financial planners that funding a national
nutrition program was a good investment, and the govern-
ment approved a new nutrition project in 1995.
However, the issue is not just how to build initial com-
mitment, often the main focus of organizations such as the
World Bank. Commitment can be fragile, and the issue is
how to broaden and maintain commitment and comple-
ment it with systematic investments in institutional capac-
ity development. The first nutrition investment in
Bangladesh was completed in 2001. Children’s nutritional
status and households’ health-seeking behaviors improved
substantially in project areas, and malnutrition rates
declined. A follow-on nutrition investment was approved,
but because of weak government commitment, it is strug-
gling in the challenging policy environment in which the
social sectors operate. The Ministry of Health has not
assigned high priority to the program, and conflicts
between the government and the NGOs involved in
community activities have complicated the situation.
Contradictory messages from donors and frequent changes
in leadership within the government have added to the
challenge.
More recently, donors and advocates for nutrition
within the government have proposed that nutrition
activities that build on earlier successes be included in the
Health, Nutrition, and Population Sector Program, which
is scheduled to be finalized and approved in early 2005.
In contrast, in Thailand, building commitment for
nutrition was achieved during the 1980s and nurtured
with little external support. Government-sponsored
efforts through studies, workshops, and media outreach
generated commitment for nutrition by building broad
consensus (in the government, NGOs, and the private
sector) on the benefits of nutrition—not as a welfare issue,
but as a human development issue. This initial commit-
ment was sustained by ensuring that policy statements
were closely linked to national investment plans, by build-
ing strong technical and managerial capacity for nutrition
in the country (often by means of external aid), and by
linking those actions with a strong buy-in and demand
from communities. Malnutrition rates in Thailand
declined from 51 percent in the early 1980s to 18 percent
in 1990 and continue to fall.
Source: Heaver 2002. 
Another argument against broad budget support of health
sector funding or in favor of the more traditional earmarking
of DAH is that it helps maintain governments’ and donors’
focus on implementing and monitoring specific health serv-
ice interventions and on the necessary technical and mana-
gerial improvements to ensure the achievement of targets in
those areas. On the basis of experience in countries such as
Bangladesh, Ghana, Mozambique, and Zambia, donors are
increasingly of the view that broad support to a national health
sector program leads to superficial oversight of bureaucratic
processes and a corresponding loss of technical focus and
depth (Foster, Brown, and Conway 2000). Although a sector-
wide approach is theoretically fully compatible with careful
monitoring of key outputs and health outcomes and with in-
depth technical improvements, in practice, achieving this mix
of objectives may prove difficult.
In summary, the debate on earmarked versus broad DAH
support for national health programs continues. More analysis
is needed to produce clearer conclusions on the advantages and
disadvantages of the two approaches.
Transaction Costs of Aid
In a single low-income country, more than 20 donors—
including bilaterals, multilaterals, global programs, founda-
tions, and large NGOs—may be involved in the health sector.
The demands placed on recipient countries can be huge, and
donors are starting to acknowledge this burden. They are rec-
ognizing that their individual procedures for reporting,
accounting, and managing funds—which often encompass dif-
ferent budget structures; different ways of measuring progress
toward objectives; different regulations for the procurement of
goods, services, and works; and different approaches toward
and cycles for disbursing funds—place heavy and unreasonable
demands on recipient countries. Demands are particularly
heavy in poor countries that are forced to allocate limited
human resources away from service delivery to manage donor
funding.
The donor community is working to harmonize and
simplify its procedures to reduce these transaction costs. In the
health sector, experiments are taking place in several develop-
ing countries, including Bangladesh, the Kyrgyz Republic,
Mozambique, and Zambia, to determine how best to lower the
costs (OECD 2004b). Some of the principles of improved
donor action include the following:
• ensuring that countries, not donors, drive the coordination
• fostering strategic coherence through a poverty reduction
strategy and the health, nutrition, and population analyses
that feed into it
• promoting financial coherence through a medium-term
expenditure framework and an agreement that all donor
funding will respect the government’s overall spending
plans and limits 
• pooling donor funds in a single account and untying aid so
that the government can procure goods and services from
the lowest-cost source and not just from the donor
countries
• limiting the number of country coordination bodies that
can bring together national and international actors
involved in health.
At the same time, some of the experiments in country-level
coordination of DAH reveal the difficulties of implementing
the principles of better donor harmonization. In some
instances, persuading donors to pool their funds and sever the
links between funding and procurement has proven difficult.
Some donors face pressure from their legislatures to maintain
separate accounting for the use of their DAH allocations so
they can claim credit for achieving progress and thus “plant
flags” on individual health projects. In addition, monitoring
and evaluation systems have frequently not been strong enough
to yield timely and meaningful data on progress, a critical fail-
ure if disbursements are linked to performance rather than to
spending on specific inputs. Multiple national coordination
bodies for government, donors, and NGOs for different dis-
eases (AIDS, TB) and services (immunization, polio eradica-
tion) also persist in many settings. In short, a number of polit-
ical and technical changes are needed to ensure the successful
implementation of a harmonized donor agenda at the country
level in the poorest developing nations.
Unpredictability of Development Assistance for Health
Some donors have taken steps to put in place instruments for
DAH that extend the length of their financial commitments.
The development of multiphase funding “slices” of 3 to 5 years
embedded in a 10- or 15-year program of support is one way
to lengthen commitments. Nevertheless, donor financing for
health is not yet as reliable or sustained as is often claimed or
hoped for, even under these new, long-term arrangements. In
some developing countries, cuts in DAH have been sharp.
Donors’ budgets are subject to the usual business and political
cycles and may go up or down during their annual budgetary
processes. For such countries as the Comoros and Eritrea,
where the year-to-year changes in external funding can amount
to as much as a fifth of all public spending for health, the
fluctuations are so great that they make planning and imple-
menting coherent national health programs nearly impossible
(figure 13.1).
Further work is needed to design mechanisms for DAH
that provide greater assurance of sustained financial support.
The challenges are to overcome the factors that result in inter-
ruptions to long-term DAH. Those factors include changes in
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political leadership and aid agency management that lead to
modifications of earlier agreements and end up reducing
external funding levels or reallocating those funds to other
activities.
One example of an innovative approach is the recently pro-
posed establishment of an international finance facility. This
facility would use financial commitments from governments of
developed countries to tap funds in capital markets and would
use those funds to frontload development assistance so as to
accelerate progress toward the MDGs. The International
Finance Facility for Immunization, which the United Kingdom
formally announced at the World Economic Forum in January
2005 and is aiming to launch later in the year, will expand
external financing for childhood vaccinations. The pilot project
could be used to pledge funding against multiyear advance-
purchase contracts for new vaccines (such as rotavirus vaccine)
that may not reach the market for several years. Such an effort
could help create a more assured market and reduce the risks
for vaccine companies, thereby speeding up the introduction of
these new health commodities to low-income countries (GAVI
2004b).
RECENT INNOVATIONS TO IMPROVE THE
EFFECTIVENESS OF DEVELOPMENT ASSISTANCE
FOR HEALTH 
In recent years, donor agencies working with developing coun-
tries have been testing—and in some cases rolling out on a
large scale—a series of innovative approaches and instruments
to improve the effectiveness of DAH. Those innovations
include the use of broad budgetary support to countries with
strong governance and institutions, the implementation of sec-
torwide approaches in health, the use of performance-based
financing mechanisms, a shift to direct engagement with the
private sector, and the implementation of programs designed
to move resources expeditiously to the frontlines of the battle
for improved health (that is, to communities). Evidence on the
effectiveness of those innovative approaches and the conditions
under which they tend to work is starting to accumulate.
Budget Support in Strong Policy Environments
In low-income settings where policies, governance, and institu-
tions are sound, donors have increasingly sought to provide
broad, untied, and flexible budget support to governments to
help support a full public expenditure program aimed at rais-
ing the level of spending and the effectiveness of resource use
for health. Frequently, this support has taken the form of PRSC
operations, including grants and credits. The PRSC is typically
built on the foundations of a national poverty reduction strat-
egy that analyzes the links between poor health outcomes and
income poverty and identifies policies that can improve the
health of the general population, especially that of poor house-
holds. The policies are then used to design a medium-term
public expenditure program or framework that, in turn, is
backed by external funding from donors in the form of a PRSC.
This approach draws on three of the key lessons from
decades of experience with DAH:
• A good policy environment improves the use of external
financing.
• The fungibility of DAH makes it logical to allocate external
funds to a general budget that prioritizes health rather than
to narrow projects in the health sector.
• An integrated system for managing public finance for health
improves national ownership of policies and programs to
improve the health of the poor and raises the chances that
such funding will be sustained over a long period and
eventually will use domestic resources.
Plenty of examples are now available of the use of DAH for
PRSCs that focus on improvements in health. The earliest
health-oriented PRSCs were in Mozambique and Uganda, fol-
lowed since by similar operations in Benin, Mauritania, and
other low-income African countries. In Mauritania, for exam-
ple, the country received a transfer of US$25 million in exter-
nal financing to back a public spending plan that doubled
health spending from about US$8 per capita in 2000 to US$16
per capita in 2004. The plan also emphasized increasing health
investments that are designed to lower maternal and child
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deaths and combat communicable diseases by expanding rural
health facilities, by providing higher pay and other incentives
for health personnel working in rural areas, and by improving
the availability of drug supplies at lower-level facilities. External
financing was not earmarked for these actions in the health sec-
tor. Instead, the government committed itself to spending for
these purposes from a consolidated national budget that was
closely monitored by civil society, government officials, and
donor representatives (World Bank 2004a). The early results
from Mauritania are encouraging. Spending for health has
risen, with most of the increase going to those parts of the
country and for those kinds of services likely to have the largest
effect on the health of the poorest households.
In middle-income countries, an analogous shift of DAH
in strong policy environments has been the increasing use of
single-tranche, programmatic, sector adjustment loans. These
loans have emerged as a favored instrument for DAH in certain
Latin American countries with sound management of public
finances and internationally accepted procurement practices.
Unlike the PRSCs, the programmatic sector loans have tended
to target a single sector (such as health) or, occasionally, two
sectors (such as health and education in the case of Brazil or
health insurance and pensions in the case of Ecuador).
Whereas the PRSCs have their analytical roots in poverty stud-
ies, the programmatic sector loans tend to be based on sector
assessments. After the government has taken key legal, institu-
tional, and spending actions to improve the efficiency of health
spending or to target services for poor households, donor
funds are transferred in a block or tranche to the government.
In 2003, the World Bank approved four programmatic sector
loans—for Brazil, Colombia, Ecuador, and Peru—totaling
US$900 million (D. Cotlear, personal communication,
December 12, 2003).
Another recent example is the World Bank’s US$750 million
Maternal and Child Insurance Program sector adjustment loan
to Argentina, which followed decisions made by that govern-
ment in 2003 to create a mother and child health insurance
scheme for poor provinces, to increase spending for communi-
cable diseases, and to establish a national health council to set
policies on the sharing of revenues to be used for health
between the central government and the provinces. The central
pillar of this project, as well as the follow-on operation in 2004,
is the implementation of the Maternal and Child Insurance
Program. It delivers a publicly financed package of essential
services to uninsured mothers and children at the provincial
level. The donor funding is used in an innovative way to provide
matching grants from the national to the provincial level, on the
basis of a capitated payment per mother and child enrolled plus
additional transfers to the province for performance. That per-
formance is measured in terms of key health service goals (for
example, coverage of vaccine programs, incidence of low birth-
weight, and number of prenatal consultations). In the first four
months of program execution, more than 100,000 eligible
women and children joined the insurance scheme.
Pooling and Donor Harmonization
As mentioned earlier, another innovation in recent years has
been the use of sectorwide approaches as a way for multiple
donors to pool their funds for a commonly agreed-on program
and to use similar, streamlined procedures for procurement,
monitoring and evaluation, and reporting. Sectorwide
approaches grew out of sector investment programs for health
that were launched in the early 1990s as a way to bring donors
together to support broader government objectives in health.
The main features of sectorwide approaches are as follows:
a. a partnership among a broad coalition of donors, with the
government taking the lead;
b. a comprehensive sector policy framework to achieve goals
over the short and medium terms;
c. an agreed-on expenditure program;
d. the improvement of management systems and capacity
building (Swedish International Development Cooperation
Agency 2003).
The main difference between sectorwide approaches and
PRSCs is that, in the former, pooled donor funding is disbursed
against specific expenditure items—for example, construction
of health facilities or purchase of drugs—whereas in PRSCs,
donor funds are transferred to the general budget, with dis-
bursements triggered by policy actions.
A prime example of a sectorwide approach is the Ghana
health sector support program, in which 17 donor organiza-
tions have committed US$442 million over a five-year period to
improve the health status of the population while focusing
efforts on reducing inequalities in health. The program includes
the following main spheres of action aimed at strengthening
priority health interventions: developing human resources for
health services, enhancing infrastructure and support services,
fostering partnerships for health, improving regulation,
reforming organizational arrangements, improving health
sector financing, enhancing financial management systems,
strengthening management information systems and perform-
ance monitoring, and linking with traditional medicine.
Performance-Based Financing
Developing countries and their international partners are
increasingly adopting methods for financing health care
activities that link the availability of funding to concrete,
measurable results on the ground. Such performance-based
financing was advocated a decade ago in the 1993 World
Development Report (World Bank 1993) and in other policy
documents in the early 1990s, although relatively little practical
knowledge of this type of financing was available at the time.
Since then, much more experimentation has taken place,
and the important potential—as well as the challenges—of
performance-based financing for achieving national and global
health goals is becoming apparent.
Performance-based financing is now being widely and
actively tested at several levels of the health care system. These
tests include situations in which the following occurs:
• Governments of developing countries pay health care
providers in NGOs and the private sector to deliver essential
health services to poor households.
• Central governments determine the transfer of funds to
local governments on the basis of their performance in
strengthening health services.
• Donors release funding to recipients in developing
countries as and when they achieve certain key health
targets.
Performance-Based Contracts with Nongovernmental
Organizations. A number of governments in low-income
countries are funding NGOs to deliver basic health services on
a performance basis (Hecht 2004). Many of the earliest experi-
ments are from Latin America and the Caribbean. In Haiti, for
example, the government contracted NGOs to provide child
health and family planning services. The government gave the
NGOs an advance each year and then a quarterly sum based on
a negotiated budget. At the end of the year, performance was
measured against various indicators, including the extent of
immunization coverage, the percentage of families using oral
rehydration to treat acute diarrhea, the share of pregnant
women attending prenatal care, and the average waiting times
in clinics. The NGOs’ performance determined the bonus they
received, which could be up to 10 percent of the original nego-
tiated budget. As a result, the Haitian NGOs made changes in
their service delivery schemes and improved their performance
in immunization and oral rehydration in particular (Eichler,
Auxilia, and Pollack 2001). In Guatemala, the government is
implementing a large performance-based program with NGOs
that currently covers nearly 4 million people, mostly among the
country’s indigenous population (box 13.2). Similar schemes
have been implemented in Argentina, El Salvador, and
Nicaragua.
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Large-Scale Performance Contracting with Nongovernmental Organizations in Guatemala
Box 13.2
Guatemala has successfully implemented contracting on a
large scale with NGOs to deliver health services. The gov-
ernment started the Program to Extend Coverage of Basic
Health Services in 1997, soon after the end of a long civil
war. The program has continued under successive admin-
istrations. By 2000, a total of 89 NGOs were involved in
providing health care to about 3.7 million people under
137 contracts.
The contracts specify a range of maternal and child
health services, as well as the prevention and treatment of
a number of diseases, including malaria. The NGOs are
paid about US$8 per person served, mostly in cash, but
also in kind in the form of such items as vaccines and
medicines. Payments are released quarterly after the
NGOs’ performance has been checked and verified.
Performance is measured according to a series of indi-
cators, including coverage of immunization and prenatal
care, distribution of iron sulfate tablets to pregnant
women and to children, and frequency of home visits by
NGO outreach staff. The government has hired private
firms to develop the monitoring system, which also looks
at the NGOs’ accounting practices.
The contracting system under the program appears to
have resulted in important gains in health service delivery.
Immunization rates rose from 69 percent in 1997 to 87 per-
cent in 2001. Household surveys currently under way will
be able to assess the program’s effect on mothers’ and chil-
dren’s health outcomes.
During the program’s early years, the government had
to overcome a number of obstacles. Government health
workers resisted the scheme because they feared that con-
tracting with NGOs was a hidden form of privatization of
government health services. The NGOs were initially
reluctant to get involved, because they thought that the
government was demanding too much in the way of
improved performance and also doubted that the govern-
ment would pay them in a timely manner. Given the
financial fragility of many local NGOs in Guatemala, the
government had to make advance payments to the NGOs
and release quarterly payments without delay to build
confidence in the relationship between the public and pri-
vate sectors.
Source: Hecht 2004; World Bank 2000.
More recently, countries in South Asia have begun to enter
into performance-based health programs with NGOs. In
Afghanistan, under a recently approved World Bank–financed
project for health service rehabilitation, the government is con-
tracting with NGOs to run health centers. NGOs that achieve
specified targets will be eligible to receive additional payments of
up to 10 percent of their baseline subsidies from the government.
In a similar vein, the central and state governments in India
have started to reimburse NGOs and private providers on the
basis of performance. The national TB program reimburses
private laboratories for testing sputum samples to detect TB; it
also pays NGOs and private doctors a fixed sum per infected
patient who is cured using the directly observed short-course
therapy approach. In one district of Kerala state where this
scheme is well advanced, NGOs and private providers have
helped boost coverage from some 55 percent of those infected
with TB to 78 percent.
In Cambodia, government agreements and funding to
NGOs to operate district health services showed impressive
results compared with the standard approach, whereby the
government ran district services. The NGOs operated in one of
two ways: (a) on a fully contracted-out basis, with complete
responsibility for service delivery, including hiring and firing
staff members and setting wages and procuring and distribut-
ing essential drugs and supplies, or (b) through a pure man-
agement contract, in which the NGOs worked within the
Ministry of Health system and had to strengthen the existing
district structure. The NGOs that were fully contracted out
raised immunization rates by 40 percentage points between
1997 and 2001, twice the rate of improvement produced by the
government-run districts. The rate of growth in prenatal care
in the contracted-out districts was more than triple that in the
government-run districts, and the use of modern contracep-
tion methods expanded 50 percent more in the contracted-out
districts (Bhushan, Keller, and Schwartz 2002).
Central Government Transfers to Local Authorities. In
Brazil’s Family Health Project, the central government is mak-
ing per capita transfers to local municipalities on the basis of
planned increases in certain services, such as safe deliveries for
low-income women and poor children treated for various ill-
nesses and monitored for their nutritional status and growth.
For example, at least 40 percent of babies are to be delivered in
maternity facilities managed under the government’s family
health program. Participating outreach workers are to provide
an average of at least nine home visits to targeted low-income
families each year. All doctors enrolled in the program are to
undergo special training. If the municipalities reach those tar-
gets and several others, they will continue to be eligible for
future financial transfers; otherwise, the level of central gov-
ernment support will be reduced, and remedial measures will
be put in place to try to improve the targeting and effectiveness
of the activities run by the underperforming municipalities
(G. M. LaForgia, personal communication, October 21, 2003).
Donor Disbursements to National Governments and Other
Recipients. A number of innovative approaches are in place
that make donor financing of health programs conditional on
successful performance on the ground. One example is the
World Bank’s credit buy-down program for polio eradication
(box 13.3).
GAVI has also been a pioneer in the performance-based
approach to grant assistance. Through its sister organization,
the Vaccine Fund, which raises and disburses funds for the
alliance, GAVI provides commodity assistance to countries in
the form of new and underused vaccines (hepatitis B,
Haemophilus influenzae type B, and yellow fever, with new
products for rotavirus and pneumococcus to follow); safe
injection supplies; and support for strengthening national
immunization systems. In addition, GAVI allocates grant funds
to countries on the basis of their performance in increasing
coverage rates for diptheria-pertussis-tetanus immunizations.
Countries’ applications to GAVI specify current coverage levels.
On the basis of these data, their performance is assessed
annually, and US$20 per child is given to the country
for each additional child immunized with the diphtheria-
pertussis-tetanus vaccine.
In 2004, GAVI made its first payment for performance veri-
fied by means of externally audited health data. Eight countries
received US$15 million in performance-based payments for
their achievements in increasing immunization rates to reach
an additional 750,000 children. Sierra Leone, for example, qual-
ified for these payments on the basis of its performance in rais-
ing coverage from 44 percent of children in 2000 to 62 percent
in 2002, as the country emerged from civil war (GAVI 2004a).
Stronger Engagement with the Private Sector
As donors have increasingly become aware of the extent of pri-
vate sector involvement in the health sector in developing
countries—that is, both the share of health services delivered
by private providers and the share of total health spending
coming from private sources, including out-of-pocket
payments—they have sought to use DAH to engage the private
sector in pursuit of basic health goals.
Innovative approaches include both the transfer of develop-
ment assistance to the private sector through government
channels in developing countries and the provision of direct
financial support to private institutions (World Bank 2003b).
In the former category, social investment funds have been
established in many regions as a way to channel DAH to com-
munity groups and NGOs involved in running health centers
and disease control programs (Jorgensen and Domelen 2001),
especially in Africa and Latin America. In a similar vein, donors
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have been prime movers behind schemes to encourage govern-
ments to contract with NGOs and private hospitals and labo-
ratories for basic services targeted to the poor, such as cataract
surgery and TB case detection and treatment in India (Central
TB Division 2002; World Bank 2002).
In terms of direct DAH financing to the private sector in
developing countries, the most common and longstanding
examples are in the social marketing of health-related personal
products, such as contraceptives, kits for treating sexually
transmitted infections, insecticide-impregnated bednets to
prevent malaria, and point-of-use water purification kits.
Donors are currently providing millions of dollars each year to
subsidize the purchase of these items by poor families in devel-
oping countries. More recently, other donor engagements with
the private sector have included the Global Alliance for
Improved Nutrition, in which a consortium of donors that
includes the Bill & Melinda Gates Foundation and the govern-
ments of Canada, the Netherlands, and the United States have
pooled funds that can be used to expand the fortification of
basic foods with micronutrients by private manufacturers. The
Global Alliance for Improved Nutrition is helping to fortify
wheat with iron in western China and in Morocco and fish
sauce with vitamin A in Vietnam.
Another recent example of DAH going directly to the pri-
vate sector is Avahan, the innovative AIDS prevention program
that the Bill & Melinda Gates Foundation is financing in six
Indian states. The program uses external financing to leverage
financial and in-kind support from major Indian companies
that can then be used to support a range of HIV prevention
programs, such as condom promotion, peer education, and
voluntary counseling and testing targeted at truck drivers,
commercial sex workers, and others at high risk (Sengupta and
Sinha 2004).
The other area in which donor funds are increasingly being
used to stimulate private sector action and leverage private
funding is through public-private partnerships for new health
technologies, including vaccines, drugs, and diagnostics.
Private financing, technical input, and management make
sense in this area, because typically it is the private sector that
has the technical knowledge and the manufacturing and distri-
bution capacity to create and market new health products, but
major scientific risks and the lack of an attractive market in
poor countries are barriers to investment. The public-private
partnerships aim to overcome those barriers through a combi-
nation of up-front financing for R&D (so-called push funding)
and market guarantees for effective products (so-called pull
financing). The 20 largest partnerships for new products have
raised more than US$1.5 billion over the past decade and are
beginning to see results, such as the development of new drugs
for malaria and TB, promising vaccines for malaria and AIDS,
and microbicides to protect against HIV infection (IPPPH
2004; Rockefeller Foundation 2004). The largest partnership,
the IAVI, illustrates the innovative nature of these partnerships
and the effective use of DAH (box 13.4).
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IDA Credit Buy-Downs for Polio Eradication
Box 13.3
To ensure financing for the MDGs, governments, founda-
tions, agencies, and development banks are all exploring
new financing approaches that have the potential to
increase resource flows, adjust the concessionality of fund-
ing (that is, reduce interest rates and thus increase the
grant element) where appropriate, and help focus more
attention on effects.
The IDA credit buy-down mechanism was recently
piloted in several projects supporting polio eradication,
clearly a global public good. The mechanism enhances the
concessionality of IDA’s assistance in priority areas, mobi-
lizes additional resources from external partners, and
focuses the attention of governments, partners, and World
Bank staff on clearly defined performance objectives.
Working in partnership with the Bill & Melinda Gates
Foundation, Rotary International, and the United
Nations Foundation, the World Bank implemented two
projects in fiscal 2003, one in Pakistan and the other in
Nigeria. The partnerships will buy down a country’s IDA
loans on successful completion of the country’s polio
eradication program. Because of the generous loan terms,
each grant dollar unlocks roughly US$2.50 for countries
to fight polio. To fund the buy-downs, the partnership has
established a trust fund with US$25 million from the Bill
& Melinda Gates Foundation and US$25 million from
Rotary International and the United Nations Foundation.
This US$50 million investment has the potential to buy
down roughly US$125 million in IDA loans. In this way,
developing countries can mobilize what ultimately
becomes grant funding to eradicate polio and to con-
tribute to the global campaign to eliminate the transmis-
sion of polio.
Source: World Bank 2004d.
Getting Funds to the Front Line
Central government funds can easily leak as they move through
the pipeline from the center to local levels. In addition, in the
absence of local initiative and the right incentives, service pro-
vision can fail to reflect the views of local people. Effective DAH
needs to address those impediments. It needs to channel tech-
nologies, ideas, finance, and technical assistance closer to
households, health providers, and supervisory officials in ways
that are consistent with national policies and are amenable to
monitoring and reporting.
Development assistance for health is more likely to reach
communities if they have the following:
• a decentralized system of fiduciary and technical manage-
ment in the public sector 
• a strong financial capacity in NGOs and private providers in
cases in which the government’s strategy for local develop-
ment is to rely on private institutions 
• a government body that is appropriately equipped and
responsible for regulating the quality of public and private
providers 
• a balanced approach to community-driven development in
health to ensure that financing for community health initia-
tives of the social fund type is sustainable.
Examples of DAH reaching frontline workers in an expedi-
tious and sustainable way include block grants for districts in
Uganda; social development funds in Central America; con-
tracts with urban and rural NGOs under India’s Reproductive
and Child Health Program; and support to community-led
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The International AIDS Vaccine Initiative
Box 13.4
The International AIDS Vaccine Initiative was established
in 1996 with support from the Rockefeller Foundation as
an innovative way to give a boost to AIDS vaccine R&D.
Optimism about AIDS vaccines in the late 1980s had given
way to a series of failures and to discouragement by the
end of the decade. R&D efforts were spending less than
US$100 million a year. Neither governments nor private
vaccine companies were investing much in research into
AIDS vaccines.
IAVI’s mission was defined as ensuring the develop-
ment of a safe, effective, and accessible vaccine for use
throughout the world. IAVI’s activities were to include a
combination of global advocacy, policy analysis and
reform, and investments in carefully chosen R&D projects
focusing on the most promising vaccine candidates.
IAVI’s collaboration with the private sector has
occurred at several levels. Funding for IAVI has come from
six governments (Canada, Denmark, the Netherlands,
Norway, the United Kingdom, and the United States); the
European Union; and the World Bank, as well as from pri-
vate foundations and companies. IAVI’s vaccine develop-
ment partnerships take many forms. They typically
include an academic developer and a biotechnology com-
pany, plus researchers, laboratories, and clinical trial sites
in developing countries such as India, Kenya, and Uganda.
Private companies generally manufacture test lots of the
AIDS vaccines and undertake bioengineering studies and
enhancements to the vaccine. IAVI generally shares the
risks and costs of the partnerships with the private code-
velopers, while ensuring that developing countries will
have access to the vaccine at an affordable price if it turns
out to be effective.
Since IAVI embarked on these vaccine development
partnerships in 1999, it has spent a total of about 
US$200 million in this area. Five vaccine candidates are
undergoing clinical trials in eight countries in Africa, Asia,
Europe, and North America. IAVI is poised to spend
another US$300 million in R&D during 2005–7 in an
effort to accelerate the discovery, development, and licens-
ing of a vaccine to prevent HIV infection. IAVI is also try-
ing to stimulate expanded use of donor funding for R&D
in the field of AIDS vaccines and is calling for govern-
ments to increase public financing from the current
amount of around US$600 million a year to US$1.2 bil-
lion annually. At the same time, IAVI has proposed that
donors create a purchase fund of several billion dollars to
serve as a promise to buy large numbers of doses of an
efficacious vaccine from qualified manufacturers. The
U.K. government has committed itself to joining such an
advance purchase fund and is urging others to join it
(“Gordon Brown to Earmark” 2004).
The health and economic stakes are enormous.
Without improved HIV prevention tools, an additional
100 million HIV infections are likely over the next two
decades, resulting in huge economic losses. IAVI estimates
that an efficacious vaccine could prevent 2 million AIDS
deaths a year and generate billons of dollars in lives saved
and antiretroviral treatment costs averted.
Source: IAVI 2004.
initiatives under the Multi-Country AIDS Program, which
financed an average of 10,000 local initiatives in each of its first
four years in several African countries (World Bank 2004c).
CONCLUSIONS 
Despite the promising trends in DAH over the past five to seven
years, the outlook for the next few years is uncertain. What
happens will depend on overall trends and innovations in
development assistance, which in turn are driven by such fac-
tors as political changes and the rate of economic growth in
OECD countries, and the willingness of high-income countries
to honor their pledges to increase the share of GDP they devote
to development.
Under most scenarios, the share of overall assistance going to
health will likely continue its recent rise, given the current polit-
ical focus on the global AIDS pandemic and the growing aware-
ness of the challenges and opportunities associated with the
MDGs for maternal and child health and communicable
diseases.
Under a more conservative scenario, a number of factors
could have a negative impact on DAH. Those factors could
include an overall slowing in the rate of growth of development
financing and the donor fatigue that could set in if the larger allo-
cations for HIV/AIDS, TB, and malaria are not fully disbursed,
are misused, or yield disappointing results on the ground.
Under a more optimistic scenario, DAH will continue to
grow as developing countries and donors find new ways to dis-
burse a higher volume of funds and use them effectively—for
example, through subcontracts with NGOs and private health
service delivery organizations. Sectorwide approaches and
budget support through national poverty reduction programs
may also result in expanded flows of DAH. New generations of
technologies adapted to the developing world, such as more
effective antimalarials, better TB diagnostics, and a vaccine to
prevent HIV infection, would almost certainly attract increas-
ing amounts of DAH.
Even under the more optimistic scenario, DAH will still face
major challenges. The expected volume of financial assistance
is unlikely to match the large needs of the developing world
and the requirements to attain the MDGs. Countries and
donors will therefore face difficult decisions in relation to pri-
ority setting and require better tools to make such allocation
decisions. Cost-effectiveness analysis offers one such tool.
Effective absorption of DAH will also continue to pose diffi-
culties for countries with weak capacity. In such cases,
increased use of NGOs and the private sector in general to
complement public sector action may help make the informa-
tion and services that poor households need to improve their
health status more accessible.
Another issue is that the current architecture of develop-
ment assistance does not contain a mechanism to ensure that
adequate funds flow to the upstream stages of R&D on new
health technologies, where the private sector lacks the market
incentives to invest and where national research bodies have so
far not been up to the task. The multilateral banks do not have
the instruments to channel major funding to global, as opposed
to national, health technology programs, and the bilateral agen-
cies alone are not equal to this task. Even with the modest exter-
nal funds allocated to the recently established public-private
partnerships (such as the IAVI, the Medicines for Malaria
Venture, the Global TB Drug Alliance, and the International
Partnership for Microbicides), new technologies are emerging.
However, they need to be reinforced with additional funding.
One option would be to design a new funding facility within
the multilateral banks that would allow them to allocate signif-
icant resources to global health research and product develop-
ment. Another would be to use the nascent international
finance facility to provide funds for global research.
To address those challenges, strong political will is the essen-
tial baseline ingredient, as recent experience with HIV/AIDS
has clearly demonstrated. The United Nations and the multi-
lateral agencies must remain firmly behind more robust DAH,
as they are currently doing by means of the Millennium Project
and the High-Level Forum on the Health-Related MDGs.
Individual bilateral donors and foundations must continue to
demonstrate their leadership. Finally, and perhaps most impor-
tant, leaders and civil society organizations in poor countries
need to continue to speak out for more and more effective
DAH, indicating that health is their priority and that they are
prepared to commit domestic resources to match the larger
external flows provided through DAH.
REFERENCES
Bhushan, I., S. Keller, and B. Schwartz. 2002. Achieving the Twin Objectives
of Efficiency and Equity: Contracting for Health Services in Cambodia.
Policy Brief Series 6. Manila: Asian Development Bank.
Burnside, C., and D. Dollar. 2000. “Aid, Growth, the Incentive Regime, and
Poverty Reduction.” In The World Bank: Structure and Policies, ed. C. L.
Gilbert and D. Vines, 210–27. Cambridge, U.K.: Cambridge University
Press.
Central TB Division, Directorate General of Health Services, Ministry of
Health and Family Welfare. 2002. TB India 2002: RNTCP Status Report.
New Delhi: Directorate General of Health Services.
CMH (Commission on Macroeconomics and Health). 2001.
Macroeconomics and Health: Investing in Health for Economic
Development—Report of the Commission on Macroeconomics and
Health. Geneva: World Health Organization.
Devarajan, S., M. J. Miller, and E. V. Swanson. 2002. “Goals for
Development: History, Prospects and Costs.” Discussion Paper 2819,
World Bank, Washington, DC.
Eichler, R., P. Auxilia, and J. Pollock. 2001. Output-Based Health Care:
Paying for Performance in Haiti. Washington, DC: Abt Associates.
Foster, M., A. Brown, and T. Conway. 2000. Sector-Wide Approaches for
Health Development: A Review of Experience. Geneva: World Health
Organization.
256 | Disease Control Priorities in Developing Countries | Robert Hecht and Raj Shah
GAVI (Global Alliance for Vaccines and Immunization). 2004a. GAVI
Awards for Top Performing Countries. Geneva: GAVI.
———. 2004b. Programmatic Aspects of the IFF Immunization Pilot.
Geneva: GAVI.
“Gordon Brown to Earmark 200 Million Pounds a Year to Fund AIDS
Vaccine.” 2004. Independent (London), December 1, p. 18.
Heaver, R. 2002. Thailand’s National Nutrition Program: Lessons in
Management and Capacity Development. Washington, DC: World
Bank.
Hecht, R. 2004. “Making Health Care Accountable: The New Focus on
Performance-Based Funding of Health Services.” Finance and
Development 41 (March): 16–19.
IAVI (International AIDS Vaccine Initiative). 2004. The IAVI Strategic Plan
2005–07. New York: IAVI.
IPPPH (Initiative for Public-Private Partnerships for Health). 2004.
Combating Diseases Associated with Poverty: Financing Strategies for
Product Development and the Potential Role of Public-Private
Partnerships. Geneva: IPPPH.
Jamison, D. T. 2004. “External Finance of Immunization Programs: Time
for a Change of Paradigm?” In Vaccines: Preventing Disease and
Protecting Health, ed. C. de Quadros, 325–32. Washington, DC: Pan-
American Health Organization.
Jorgensen, S., and J. V. Domelen. 2001. Helping the Poor Manage Risks
Better: The Role of Social Funds. Washington, DC: Brookings
Institution.
Levine, R., and What Works Working Group. 2004. Millions Saved.
Washington, DC: Center for Global Development.
Michaud, C. 2003. Development Assistance for Health: Recent Trends and
Resource Allocation. Boston: Harvard Center for Population
Development.
OECD (Organisation for Economic Co-Operation and Development).
2004a. CRS Online Database on Aid Activities. http://www.oecd.org/
dac/stats/idsonline.
———. 2004b. Survey on Harmonisation and Alignment: Preliminary
Edition. Paris: OECD.
Rajkumar, A., and V. Swaroop. 2002. “Public Spending and Outcomes:
Does Governance Matter?” Policy Research Working Paper 2840,
World Bank, Washington, DC.
Rockefeller Foundation. 2004. Partnering to Develop New Products for
Diseases of Poverty. New York: Rockefeller Foundation.
Sengupta, J., and J. Sinha. 2004. “Battling AIDS in India.” McKinsey
Quarterly 3. New Delhi: McKinsey.
Soucat, A., W. Van Lerberghe, F. Diop, S. Nguyen, and R. Knipperberg.
2003. Marginal Budgeting for Bottlenecks: A New Costing and
Resource Allocation Practice to Buy Health Results. Washington, DC:
World Bank.
Stop TB Partnership. 2003. Report of the DOTS Working Group for the 22
High-Burden Countries. Geneva: World Health Organization.
Swedish International Development Cooperation Agency. 2003. Mapping
of Sector-Wide Approaches in Health. London: Institute for Health
Sector Development.
UN (United Nations) Millennium Project. 2004. “Millennium
Development Goals Needs Assessment: Case Studies of Bangladesh,
Cambodia, Ghana, Tanzania, and Uganda.” Working Paper, United
Nations, New York.
UNAIDS (Joint United Nations Programme on HIV/AIDS). 2001. Report
on the Global HIV/AIDS Epidemic. Geneva: UNAIDS.
———. 2004. Global Expenditures and Requirements to Address the
HIV/AIDS Pandemic. Geneva: UNAIDS.
World Bank. 1993. World Development Report 1993: Investing in Health.
New York: Oxford University Press.
———. 1998. Assessing Aid: What Works, What Doesn’t, and Why. Oxford,
U.K.: Oxford University Press.
———. 2000. “Large-Scale Government Contracting of NGOs to Extend
Basic Health Services to Poor Populations in Guatemala.” Paper pre-
pared for the Challenge of Health Reform: Reaching the Poor, Europe
and Americas Forum, San José, Costa Rica, May 24–28.
———. 2002. “India—Cataract Blindness Control Project.” Imple-
mentation Completion Report 25232, World Bank, Washington, DC.
———. 2003a. Attaining the Millennium Development Goals in India: How
Likely and What Will It Take? Washington, DC: World Bank.
———. 2003b. “Private Health: Policy and Regulatory Options for Private
Participation.” Private Sector and Infrastructure Network Note 264,
World Bank, Washington, DC.
———. 2003c. Progress Report and Critical Next Steps in Scaling up
Education for All, Health, HIV/AIDS, and Water and Sanitation.
Washington, DC: World Bank and International Monetary Fund
Development Committee.
———. 2004a. “The Mauritania Health System and Implementation of
the Poverty Reduction Strategy.” Africa Human Development Working
Paper 39, World Bank, Washington, DC.
———. 2004b. The Millennium Development Goals for Health: Rising to
the Challenges. Washington, DC: World Bank.
———. 2004c. Experience in Scaling Up Support to Local Response in
Multi-Country AIDS Programs (MAP) in Africa. Washington, DC:
World Bank.
———. 2004d. “Financing Modalities toward the Millennium
Development Goals: Progress Note.” World Bank, Washington, DC.
World Bank and Ministry of Health, Ethiopia. 2005. Ethiopia: A Country
Status Report on Health and Poverty. Volumes I and II. Washington,
DC: World Bank.
Recent Trends and Innovations in Development Assistance for Health | 257

259
The ethical justification for developing and providing the
means to reduce the burden of disease in developing countries
is self-evident. Nevertheless, those who pursue these laudable
ends encounter ethical dilemmas at every turn. The develop-
ment of new interventions requires testing with human
subjects, an activity fraught with controversy since the dawn of
scientific medicine and especially problematic with poor and
vulnerable participants in developing countries. Ethical dilem-
mas arising in setting priorities among interventions and
among individuals in need of care are most acute when needs
are great and resources few.
We address some of these concerns in this chapter, identify-
ing some of the principal ethical issues that arise in the devel-
opment and allocation of effective interventions for developing
countries and discussing some alternative resolutions. We omit
discussion of two other aspects of these ethical decisions:
ensuring that the process of decision making is fair and
involves the subject population (Daniels 2000; Holm 1998),
and respecting legal obligations under international human
rights treaties (Gruskin and Tarantola 2001).
HEALTH RESOURCE ALLOCATION
Resource allocation in health and elsewhere should satisfy two
main ethical criteria. First, it should be cost-effective—limited
resources for health should be allocated to maximize the health
benefits for the population served. A cost-effectiveness analysis
(CEA) of alternative health interventions measures their respec-
tive costs and benefits to determine their relative efficiency in
the production of health. Costs are measured in monetary
terms; benefits are measured in health improvements. By divid-
ing costs by benefits, one can obtain a cost-to-effectiveness ratio
for each health intervention, and interventions can be ranked
by these ratios. Although a CEA is typically an economic analy-
sis performed by health economists, it is also a measure of
one ethical criterion for the evaluation of health programs.
Cost-effectiveness is not merely an economic concern, because
improving people’s health and well-being is a moral concern,
and an allocation of resources that is not cost-effective pro-
duces fewer benefits than would have been possible with a dif-
ferent allocation. Producing more rather than fewer benefits for
people is one important ethical consideration in evaluating
actions and social policies.
Second, the allocation should be equitable or just; equity is
concerned with the distribution of benefits and costs to distinct
individuals or groups. The maximization of benefits, which is
associated with the general philosophical moral theory of util-
itarianism or consequentialism, however, is routinely criticized
for ignoring those considerations (Rawls 1971). Equity in
health care distribution is complex and embodies several dis-
tinct moral concerns or issues that this chapter delineates
(Brock 2003a). There is no generally accepted methodology
comparable to CEA for determining how equitable a distribu-
tion is; nevertheless, allocations are unsatisfactory if equity
considerations are ignored.
Efficiency and equity can sometimes coincide. In some of
the world’s poorest countries, for example, health budgets
support tertiary care and travel to clinics abroad for the elite
and the well connected, even as the poor are denied effective,
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low-cost prevention or treatment for life-threatening diseases
(Birdsall and Hecht 1995). Moreover, because equity concerns
the relative treatment of different individuals, CEA is largely
unobjectionable when it is used only for evaluating alternative
health interventions that would serve the same patients.
However, considerations of equity may conflict with cost-
effectiveness and so may provide moral reasons for an alloca-
tion that is not cost-effective. The discussion in this chapter
accepts that CEA identifies one important ethical criterion in
evaluating health care interventions—producing the most ben-
efits possible for individuals served by those interventions—
and then focuses on the other ethical criterion of ensuring
equitable distribution of those benefits.
This chapter considers two types of equity issues: first, those
that arise in the general construction of a CEA—that is, in
determining the form of a CEA; second, those that arise in the
use of the results of a CEA for resource allocation in the health
sector. It is worth noting that, when applied appropriately and
broadly to all social conditions and programs that significantly
influence health, CEA may often support using resources to
affect the so-called social determinants of health—which
largely affect the incidence of disease, disability, and premature
mortality—rather than using those resources on health care to
treat disease. However, we shall focus largely on CEA in the
evaluation of health care and public health programs.
Issues in the Construction of a Cost-Effectiveness Analysis
Cost-effectiveness analyses require decisions about which costs
to include, which if any financial gains should be counted as off-
setting costs, whether to include benefits beyond the effects of
the intervention on health, and whether all health gains should
be valued alike. None of those decisions, in our view, is exclu-
sively a technical issue, and CEA results reflect the analysts’
ethical judgments on those issues.
Evaluation of Benefits. Evaluating health benefits within a
CEA involves several issues. This chapter assumes that some
version of a quality-adjusted life year (QALY) is used to com-
bine the two main benefits of health care—(a) protecting or
improving health or health-related quality of life and (b) pre-
serving life. Disability-adjusted life years (DALYs) are a variant
of QALYs in that they measure the losses from disability or pre-
mature death; a CEA will determine which interventions will
maximize QALYs or minimize DALYs. Calculating QALYs
requires a metric evaluating the effect of different states of lim-
itations in function on health-related quality of life, such as the
Health Utilities Index (Horsman and others 2003). The Disease
Control Priorities Project uses the health state valuations or
disability weights of the World Health Organization (WHO).
The relative value of any particular health state, typically on a
scale in which “0” represents death and “1” represents full,
undiminished function (or health) is generally determined by
soliciting a group of individuals’ preferences for life in that state
using standard gambles, time tradeoffs, visual analog scales, or
person tradeoffs. In all these methods, a common issue is
whose preferences to use for valuing health states. The main
debate has been whether to use a randomly selected group of
citizens or to use people who have the particular disability or
limitation in function being evaluated.
This issue matters because a number of studies have shown
that persons without disabilities generally evaluate the quality
of life with a particular disability as significantly worse than do
persons who have that same disability (Menzel and others
2002). If the preferences of persons without disabilities are
used, their lower evaluation of quality of life with various dis-
abilities will mean that fewer QALYs will be produced by life-
saving interventions for persons with disabilities than if the
preferences of persons with disabilities had been used.
However, if we use the preferences of persons with disabilities,
then both prevention and rehabilitation will receive less value
than if the preferences of persons without disabilities had been
used.
This difference in evaluations in part results from igno-
rance, prejudice, and stereotypes on the part of persons
without disabilities about what it is like to live with various
disabilities. The difference results as well from the process of
adaptation to disability in which disabled persons adjust by
learning new skills, cope by adjusting their expectations to their
new circumstances, and accommodate by substituting new
aims and activities for ones made difficult or impossible by
their disabilities (Solomon and Murray 2002). They thus adopt
a new valuational perspective for making health and quality-
of-life evaluations. Because the adoption of this new perspec-
tive resulted from a disability, it will represent a set of values for
making choices that reflects a restricted set of abilities.
Nevertheless, neither the nondisabled perspective nor the
adapted disabled perspective is mistaken; they are only different
(Brock 1995). These differences create controversy in the litera-
ture over which perspective is correct for cost-effectiveness
evaluations in health care.
A second issue is whether, in evaluating interventions that
preserve or extend life, we should use life years saved (as QALYs
do) or lives saved. Certainly individuals offered two interven-
tions that would preserve their lives for different lengths of time
would prefer, all other things being equal, the alternative with
the longer period of survival. Moreover, when the differences
are extreme—for example, extending group A’s lives by a week
or extending an equally numerous group B’s lives by 10 years—
virtually everyone would judge this difference to support giving
priority to group B. This fact suggests that even the proponent
of counting lives saved should require that the lives saved for a
shorter period of time must still be saved for a significant
period of time; what is significant will depend in part on the
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duration of lives saved by the alternative with which it is being
compared. Some empirical studies indicate that ordinary peo-
ple tend not to give much weight to differences in the duration
of health benefits to different groups of persons when priori-
tizing between them, as long as the lesser duration benefits are
viewed as significant; this attitude suggests that they favor lives
saved over life years saved (Nord and others 1996). The life
years saved versus lives saved controversy remains unsettled.
Should Life Years Be Age Weighted? The standard assumption
in most CEAs using QALYs is that one QALY has the same
social value, regardless of the age of the recipient (Gold and
others 1996). Thus, equality is adopted as the weighting for
QALYs achieved by recipients at different ages, and that is the
approach adopted in this volume. The use of any age weighting
that gives less value to benefits for the elderly than for younger
persons is often charged as unjust age discrimination. Even the
use of equally weighted QALYs is often charged as unjust age
discrimination because, other things being equal, saving the
lives of younger persons will produce more QALYs than saving
the lives of older persons. The goal of lives saved, as opposed to
life years saved, removes this disadvantage to the elderly from
CEAs that use QALYs. However, if the relevant benefit is adding
years to life, then standard CEA is neutral or impartial regard-
ing age, in the sense that it gives the same value to a year of life
extension whatever the age of its recipient.
WHO, in its burden-of-disease and resource prioritization
studies that use DALYs, rejected the equal age weighting that is
standard with QALYs. Instead, it gave less value to DALYs
prevented for infants, young children, and the elderly, in com-
parison with persons in their productive adult years. WHO jus-
tified this weighting by the fact that the very young and the eld-
erly both tend to be economically, socially, and psychologically
dependent on adults during those adults’ productive working
and child-rearing years (Murray 1994). This justification is eth-
ically problematic, however, because it assigns different value to
meeting people’s health needs on the basis of differences in the
instrumental value to others of meeting their needs. This
approach differentiates people solely on whether they are a
means to benefiting others. The same reasoning would justify
giving priority to rich over poor patients with the same med-
ical needs because the rich are more socially productive than
the poor, a practice that would be widely regarded as unjust.
Writers in this field have provided different reasons for giv-
ing greater value to QALYs for younger patients, however, that
are not subject to this moral objection and that are specifically
grounded in fairness. For example, Alan Williams has devel-
oped an argument to the effect that fairness requires that indi-
viduals should each receive “fair innings” of QALYs in their
lives (Williams 1997). In this view, the earlier a preventable
death could occur and the worse a person’s past health is, the
greater is the unfairness the person suffers—so the greater is
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the moral urgency, grounded in fairness, of preventing the
death. The younger a person is, the greater is the moral value of
providing a QALY to him or her. This view leaves open to what
extent the moral value of QALYs should decline with the age of
the recipient. This age weighting to favor the young has been
attacked by some as unjust age discrimination, but because an
explicit moral justification in terms of fairness is offered for it,
critics must show why that justification is unsound.
What Costs Should Count in Health Cost-Effectiveness
Analyses? No controversy surrounds the inclusion in a CEA of
direct costs of a health intervention program or direct health
benefits to the intervention’s recipients. Ethical issues do, how-
ever, arise in other aspects of the cost calculation (Brock
2003b). A full CEA of alternative health programs should take
account of all the economic effects on public or private expen-
ditures of the alternative health interventions or programs
under analysis. An example is provided in the consideration of
treatment for two alternative health conditions judged to have
equally detrimental effects on patients’ health: the first condi-
tion permits patients to continue working, and the second
interferes with regular work and so has large economic costs to
the patients’ employers. Should the costs of treating the second
be reduced by the cost savings to the employers from returning
the patients to work on a regular basis? If so, the second treat-
ment program will have a more favorable cost-effectiveness
ratio than the first, even if it may be no better or worse without
consideration of those economic effects. The same issue arises
in many other contexts.
From the moral perspectives of both a consequentialist and
a standard CEA, these indirect economic effects for others are
real benefits or cost reductions and should be part of the CEA.
The fundamental moral objection to giving higher priority to
treating those who can be treated at lower net cost because of
the economic savings to their employers is the same as that
with WHO’s instrumental rationale for its age weighting. One
condition or group of patients gets higher priority solely
because treating it or them is a means to producing economic
benefits to others, thereby reducing the net social costs of their
treatment. This approach violates the Kantian injunction
against treating people solely as means—the first group has
lower priority for treatment solely because treating that group
is not a means to the economic savings to employers. It fails to
give equal moral concern to the health needs of each group of
patients because it discriminates against the less socially valu-
able patients. Conversely, at the macro level of the allocation of
resources to health instead of other social goods, the WHO
Commission on Macroeconomics and Health has supported
increasing health investments in developing countries because
such investments often more than pay for themselves in their
economic and development benefits (CMH 2001). Using a
“separate spheres” view, only the health benefits and health
costs of alternative health interventions should determine
their priority for obtaining resources, but this view remains
controversial.
Another aspect of cost calculation concerns whether future
health care and other costs, such as old-age payments, that will
be incurred as a result of a person’s life being saved should be
added to the costs of treating that person now. Persons who do
not die now because of a life-saving intervention will typically
go on to incur future health costs that would not have been
incurred had they died now. The U.S. Public Health Service
Panel on cost-effectiveness recommended that inclusion of
these costs be optional in CEAs (Gold and others 1996). Others
have argued that, if CEA is designed to maximize lifetime util-
ity, the future costs should be included (Meltzer 1997). These
are costs that would not be incurred if the patient was not
saved, but virtually no one would argue that, because of those
costs, we should judge a life-saving intervention as not cost-
effective and thus deserving of lower priority than interven-
tions that do not have those effects. What does this thinking
show? That we are not prepared to allocate health resources on
the basis of a full CEA that accounts for all the costs incurred
and saved by those interventions—that is, that some should be
disregarded on ethical grounds.
Should Health Benefits and Costs Be Discounted in 
Cost-Effectiveness Analyses? As standard practice in CEAs,
both health care costs and benefits are discounted at the same
rate, for example, 3 percent or 5 percent, and the Disease
Control Priorities Project applies a 3 percent discount rate to
costs and benefits (Gold and others 1996). Little controversy
surrounds the idea that future monetary costs and benefits
should be discounted to their present value in a CEA. The same
amount of money is worth more if received today than in
10 years because it can be invested at the market rate of inter-
est if received today. For the same reason, costs that can be
deferred require fewer present dollars to meet them.
The controversial issue is whether health benefits should be
discounted—that is, whether the same magnitude of health
benefit has progressively less social value the farther into the
future it occurs. This issue is complex and has engendered an
extensive literature that cannot be reviewed here, but we can at
least try to focus the issue. It is appropriate to discount for the
uncertainty about whether potential beneficiaries will survive
to receive a future health benefit and to discount for any
increased uncertainty about whether a benefit will occur
because it is more distant. However, these uncertainties are
reflected in the calculation of expected future benefits and do
not require that future benefits be discounted. Likewise, if indi-
viduals receive a health benefit (such as regaining mobility)
sooner rather than later, their total lifetime benefit may be
greater, but this fact, too, is reflected in the estimation of the
total benefit without discounting.
The ethical issue about discounting is whether, after taking
account of such considerations, a health benefit of the same
size has progressively less social value the farther into the future
that it occurs. To make the issue more concrete, suppose we
must decide between two programs: one will save 100 lives
now, and the other, say a hepatitis vaccination program, will
save 200 lives in 30 years. The vaccination program will save
twice as many lives, but if we apply even a 3 percent discount
rate to the future lives saved, they are equivalent to only 78 lives
saved now, and we should prefer the first program. This exam-
ple illustrates not only the theoretical issue, but its practical
import, too, because discounting future health benefits will sys-
tematically tend to disadvantage prevention programs that
must be undertaken now but whose benefits occur only at
some point in the future. This reasoning applies not only to
many vaccination programs, but also to most programs to
change unhealthy behaviors in which the benefits generally
occur at some later time.
Arguments for discounting health benefits at the same rate
as costs have included consistency arguments (Weinstein and
Stason 1997), avoidance of paradoxes in allocation concerning
research and deferral of spending (Keeler and Cretin 1983),
individual or social rates of time preference, and so forth.
Those arguments cannot be reviewed here, but whether to dis-
count health benefits is squarely an ethical question about the
valuing of health benefits over time and should be explicitly
addressed as such in allocating resources.
Issues in the Use of Cost-Effectiveness Analysis
for Resource Allocation
It is now widely recognized that CEA alone is not a satisfactory
guide to resource allocation in all cases. CEA, as customarily
formulated, measures the sum of costs and benefits and largely
ignores the pattern of their distribution across the affected
population. In some cases, the resulting allocation will strike
most observers as unfair. Health resource allocators need to
take distributional issues into account along with cost-
effectiveness.
Priority to the Worst Off. Justice requires a special concern for
the worst off, as is reflected in aphorisms such as “you can tell
the justice of a society by how it treats its least well-off mem-
bers,” in the well-known Difference Principle in John Rawls’s
theory of justice, and by the special concern for the poor with-
in many religious traditions (Brock 2002; Rawls 1971). This
concern is often understood to reflect a concern for equality—
in particular, equality in outcomes or welfare between people.
In the health context, it takes the form of a concern for reduc-
ing inequalities in health between persons or groups. A variety
of ethical bases underpin a concern for equality in general and
for equality in health in particular, and they cannot be explored
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here. It is important, however, to understand that concern
for the worst off is different from a concern for equality,
because the two can be and often are confused. Raising the
position of the worst off will typically reduce inequality, but it
need not always do so. Sometimes improving the position of
the worst off may unavoidably improve the position of those
who are better off even more and thereby increase inequality.
Moreover, the concern for equality in outcomes is subject to the
“leveling down” objection, in which equality is achieved by
making the better-off members worse off, even when doing so
in no way benefits those who are worst off. In the face of that
objection, many have rejected equality in outcomes in favor of
a prioritarian view, according to which benefiting people has
greater moral value the worse off those people are (Parfit 1991).
A number of possible lines of reasoning support prioritari-
anism. For example, the worse off that people are, the greater is
the relative improvement that a given size of benefit will pro-
vide them, so the more the benefit may matter to them.
Alternatively, the greater the undeserved health deprivation or
need that an individual suffers, the greater is the moral claim to
have it alleviated or met.
However priority to the worst off is justified, an important
issue is who the worst off are. In the context of resource alloca-
tion in health care, the worst off might be those who are glob-
ally worst off, those with the worst overall well-being (such as
the poor), or those with the worst health (that is, the sickest).
General theories of justice usually focus on people’s overall
well-being, often allowing a lower level in one domain of well-
being to be compensated for by a higher level in another
domain. However, there are both moral and pragmatic reasons
for what has been called a separate spheres view, according to
which the worst off for the purpose of health resource alloca-
tion should be considered to be those with worse health.
Morally, for example, Scanlon has argued that “for differences
in level to affect the relative strength of people’s claims to help,
these differences have to be in an aspect of welfare that the
help in question will contribute to” (Scanlon 1997, 227).
Pragmatically, it may generally be too difficult, costly, intrusive,
and controversial, as well as too subject to mistake and abuse,
to have to inquire into all aspects of people’s overall levels of
well-being.
Even if health allocation to the worst off should be based on
levels of health, other issues remain. For example, are those
with worse health those who are sickest now, at the time a
health intervention would be provided for them, or those with
worse health over time, taking into account past and perhaps
expected future health? The latter would give special weight to
meeting the health needs of those with long-term chronic dis-
eases and disabilities. Separate spheres would still include past
and future health. Should special priority also be given to those
whose health is not worse now but is especially vulnerable to
becoming worse? 
Finally, how much priority should the worst off receive?
Giving absolute priority to the worst off is implausible because
it faces the bottomless pit problem—using very great amounts
of resources to produce very limited or marginal gains in the
health-related quality of life of the severely ill or disabled.
However, there is no apparent principled basis for determining
how much priority the worst off should receive.
Aggregation and Cost Differences. The aggregation problem
occurs when determining at what point small benefits to a large
number of persons should take priority over very large benefits
to a few, because the former result in greater aggregate or total
benefits (Daniels 1993; Kamm 1993). The issue can be illus-
trated by the initial effort to prioritize different treatment-
condition pairs in the Medicaid program in the U.S. state of
Oregon by what was essentially a cost-effectiveness standard.
As was widely reported, capping teeth for exposed pulp was
ranked just above performing appendectomies for acute
appendicitis, even though appendicitis is a life-threatening
condition. A variety of methodological problems affected
Oregon’s analysis, but this kind of result is to be expected from
CEA. The Oregon Health Services Commission estimated that
it was possible to provide a tooth capping for more than
100 patients for the cost of one appendectomy, so the aggregate
benefits of the many tooth cappings were estimated to exceed
the benefit of one appendectomy. As a consequence of results
of this sort, the commission fundamentally changed its priori-
tization methodology to largely ignore cost differences, except
in the case of roughly equally beneficial interventions. The
commission essentially adopted what might be called a relative
effectiveness or benefit standard (Hadorn 1991).
What Oregon’s experience shows is that most people’s sense
of priorities is determined by a one-to-one comparison of the
benefits of different interventions, in which case appendec-
tomies are clearly a higher priority than tooth capping. That
ignores the great differences in costs between different health
interventions that a CEA will reflect. Is it then simply a mistake
to ignore those cost differences in allocating health resources?
At least two moral considerations suggest not. First, empirical
studies have shown that many people ignore the cost differ-
ences because they believe that patients should not be at a
disadvantage in priority for treatment simply because their
condition happens to be more expensive to treat than are other
patients’ conditions (Nord and others 1995). Second, according
to many moral theories, individuals should confront other
competitors for scarce resources as individuals, and their prior-
ity for treatment should be determined by the urgency of their
individual claims to treatment (Scanlon 1997).
Then again, most people and most moral theories do not
reject all aggregation of different sizes and costs of health ben-
efits in setting priorities and allocation, although there is no
consensus either on when aggregation should be permitted or
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for what reasons. However, at a minimum, we suggest that indi-
viduals should not be denied very great health benefits—in the
extreme case, life-saving interventions—merely to provide
small health benefits to a large number of other persons.
Fair Chances and Best Outcomes. The thesis that resources
should be targeted to interventions in which they will do the
most good ascribes a higher priority to those who can be helped
more easily or cheaply. This thinking, in turn, implies that some
patients will lose out simply because their needs are more diffi-
cult or expensive to meet. Consider, for example, a ward with
100 patients,50of whomrequireonepill and50of whomrequire
two pills to recover. The patients are otherwise similar. The clinic
has 50 pills and must decide how to distribute them. To achieve
the best outcome, all 50 pills should be given to the patients who
need only one to recover. However, to give each patient an equal
chance to recover, entitlement to treatment should be awarded
randomly. Seventeen fewer cures would result.
Limited surveys indicate a sharp difference between health
professionals and the general public in their responses to this
conflict. Most health professionals favor distribution to one-
pill patients only, and most members of the general public
insist that people should not be penalized for needing two pills
(Nord 1999). This division of opinion goes to the heart of CEA,
which is precisely a guide to identifying the route to the best
outcomes that can be hoped for with existing resources. It also
creates a dilemma for those health professionals who maintain
that health policy should be based on values most frequently
endorsed by the population affected.
The conflict between fair chances and best outcomes arises
not only from differences in the costs of treating otherwise sim-
ilar groups of patients, but also when one group of patients will
receive somewhat greater benefits than another at the same
cost. The appeal of a fair-chances solution is greater when the
difference in cost-effectiveness between the two programs is
relatively small compared with the potential gain or loss to
individual patients. Suppose that health program A will pro-
duce 5,000 QALYs while program B will produce 4,500 QALYs
and that the effect on the health or life of each patient served is
large—in the extreme, life saving. Patients who would be served
by program B could complain that it is not fair that all the
resources go to program A and none to B when they have
nearly as pressing health needs and would be benefited by
treatment nearly as much as the patients served by program A.
If all cannot be treated, they might go on to argue, they deserve
a fair chance to have their needs met rather than having no
chance for treatment only because treating them would pro-
duce slightly less benefit than treating the patients served by
program A. The small difference in benefits produced for the
two groups—for example, a slightly greater life expectancy or
more serious disability averted in program A—they argue, is
too small to justify the tremendous difference in how the two
groups are treated. In the extreme case, some live and others
die. The better outcome is produced by funding program A
rather than program B, but that additional good is insufficient
to justify morally the huge difference in the way the two groups
of patients are treated. The conflict between fair chances and
best outcomes can arise in a variety of contexts (Kamm 1993).
Preferring the most cost-effective program can also seem
unfair because it compounds existing unfair inequalities. For
example, screening slum-dwelling black men for hypertension
targets the group with the highest incidence and greatest risk of
premature death. However, it is more cost-effective to
target well-to-do suburban white men, because they have more
ordered lives, comply better, have personal doctors and
the means to obtain medical services, are more educated,
and are more likely to modify their lifestyles wisely. However, if
the poor black men are not screened for this reason, it only
compounds their existing unjust deprivation and, of course, is
also in conflict with giving priority to the worst off.
If those who need a less cost-effective program deserve a fair
chance to have their needs met, what would be a fair chance?
Some argue that a fair chance is an equal chance, so some ran-
dom method of selecting which program to fund should be
used (Broome 1991). Others suggest proportional chances or a
weighted lottery, in which the chance of each program being
selected is proportional to the amount of health benefit each
would produce, as a way of balancing fair chances against best
outcomes (Brock 1988). Alternatively, some resources might go
to each program (which is usually possible at the macro level),
thereby benefiting some patients in each group—at least if
their relative benefits are not strikingly dissimilar—instead of
all going to the most cost-effective programs.
Another consideration supports spreading some resources
to less cost-effective programs instead of devoting them all to
the most cost-effective: to give all—or at least more—patients
a reason to hope that their health needs will be met. This con-
sideration may be especially important in developing countries
where resource scarcity is more severe and adhering strictly to
cost-effectiveness criteria could result in large numbers of
patients with serious—or even life-threatening—health needs
having no hope that their needs will be met.
Discrimination against Persons with Disabilities. The use of
CEA in resource allocation to maximize the QALYs produced
by available resources will often discriminate against persons
with disabilities. Many persons with disabilities such as cystic
fibrosis, HIV/AIDS, and chronic pulmonary or heart disease
have reduced life expectancies or health-related quality of life
as a result of their disabilities. Life-extending health care for
those people will produce fewer QALYs than for people with-
out them, all else being equal.
When health interventions are aimed at improving quality
of life rather than extending life, similar discrimination can
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arise. The presence of disabilities can act as comorbidities,
making treatment less effective or more expensive (or both)
than it would otherwise be, thereby worsening its cost-
effectiveness ratio relative to comparable treatment for persons
without disabilities. These effects of treatment can result from
a disability that exists before treatment and is unrelated to the
treatment provided. So it seems that a cost-effectiveness stan-
dard for resource allocation discriminates against such persons
specifically because of their disabilities. Moreover, this effect
will arise not only in the case of preexisting disabilities, but also
in the case of patients who become disabled as a result of treat-
ment that is only partially effective.
Several strategies to avoid this discrimination in resource
allocation have been suggested. Perhaps the most plausible, at
least for the case of life-sustaining treatment, is to ignore dif-
ferences in patients’ posttreatment quality of life as long as each
patient accepts and values that quality of life and to ignore dif-
ferences in life expectancy after treatment as long as each will
receive a significant gain in life extension; obviously, what
counts as significant is vague and needs finer definition.
Ignoring differences in life expectancy posttreatment fits with
empirical evidence that individuals give little weight to dura-
tion of benefits in prioritizing between health interventions
that serve different individuals.
Cutoffs for Cost per Quality-Adjusted Life Year. It is not
uncommon in health care allocation to suggest the use of cut-
offs tied to cost per QALY, although the cutoffs suggested vary
substantially depending on the overall wealth of the country
and on the amount that it spends on health care. The cutoffs
can be of some value in identifying health interventions that
are either good or poor buys, given the society’s overall wealth
and overall level of health spending. However, it is important to
be clear that such cutoffs should never function as anything
more than a rough initial guide in health resource allocation.
The various equity considerations discussed briefly above can
serve as justification for departing from or violating any cutoffs
related to cost per QALY.
Responsibility for Health Needs. Some have suggested that
health needs for which individuals are morally responsible
should have lower priority than health needs for which indi-
viduals are not responsible (Moss and Siegler 1991). If individ-
uals are responsible for their health needs and could have taken
steps to avoid them, they have weaker claims on social
resources to meet those needs than do individuals whose health
needs are no fault of their own and could not have been pre-
vented. Smoking and substance abuse are two of the most
prominent examples of behaviors often cited. However, differ-
entiating patients by whether they deserve care on the basis of
whether they are responsible for their health needs does not fit
the practice or norms of medicine, which have the goal of
meeting patients’ medical needs.
There are strong moral reasons for considerable caution in
letting health resource allocation depend on individuals’
responsibility for their health needs (Wikler 2002). For that
practice to be fair to those whose needs receive lower priority
because of behavior, (a) the needs must have been caused by the
behavior, (b) the behavior must have been voluntary, and (c)
the persons must have known that the behavior would cause the
health needs and that if they engaged in it their health needs
resulting from it would receive lower priority. Smoking shows
that these conditions are not easily satisfied. Smoking is one
causal factor in much cancer and heart disease, but many smok-
ers do not get those diseases, indicating that other factors, no
doubt in part genetic differences for which individuals are not
responsible, also play an important causal role. Smoking is typ-
ically begun when individuals are young adolescents, and as dis-
cussed in chapter 46, it is highly addictive, which undermines
the voluntariness of continuing to smoke. Individuals in indus-
trial countries are now generally familiar with the health risks of
smoking, but this is less true among less educated populations
in developing countries, where smoking is an increasing prob-
lem. No one anywhere has been informed before they smoke
that, if they do, their health needs from smoking will receive
lower priority for treatment than will other health needs.
Thus, it would generally be unfair to give smokers lower pri-
ority for treatment of smoking-related diseases on the grounds
that they were morally responsible for those health needs,
although there may be other behaviors for which individuals
could more justifiably be held responsible. Moreover, attempt-
ing to make those judgments in individual cases would be
extremely difficult and controversial. Given the difficulty of
instituting a fair practice that allocates health resources accord-
ing to people’s moral responsibility for their health needs, we
generally have good moral reason to preserve the egalitarian
feature of the practice of medicine that looks to patients’ needs
for care rather than to whether they deserve care.
ETHICS IN RESEARCH AND NEW
PRODUCT DEVELOPMENT
All new drugs and other medical products must be tested on
human subjects before they are sold. Although participation
in health research is often a valuable opportunity for partici-
pants, what happens to them is determined not only by their
clinicians’ therapeutic intent (if any) but also by the need to
ensure that the research yields useful information. Managing
the potential conflict between those motivations is often an
ethically challenging task, and the issues become particularly
contentious when research is conducted in developing
countries.
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Developing Consensus on Ethics and Human
Subjects Research
The central ethical question in health research that involves
human subjects is what may be asked of some individuals so
that others may benefit. The question arises in any research in
which human subjects are asked to participate, but is most
pressing if the care that is offered to subjects provides no ther-
apeutic benefit or if that care is compromised by the require-
ments of the study design. Informed consent, while in most
cases a requirement for ethical justification of research involv-
ing risk, does not relieve the scientist of responsibility. The eth-
ical question is what potential subjects may be recruited for,
even if they do consent.
A rough consensus exists worldwide on the elements of
research ethics and, increasingly, on the central role of the eth-
ical review committee, or institutional review board (IRB).
This consensus can be traced back to the post–World War II
international determination to ensure that the kind of barbaric
research practiced by Nazi scientists would not again stain the
good name of medical science.1 Three advisory documents
have been particularly influential. The Nuremberg Tribunal
that conducted the postwar Doctors’ Trial promulgated a code
of conduct for medical research that stressed the requirement
of informed consent. The World Medical Association issued the
first version of its Declaration of Helsinki in 1964 and has
revised it several times. A further set of guidelines, issued in
1993 and revised a decade later, was published by the Geneva-
based Council for International Organizations of Medical
Sciences. Although they lack the force of law, these documents
are widely acknowledged as international standards. Indeed,
the World Medical Association’s periodic revisions of the
Declaration of Helsinki have become focal points for interna-
tional debates over outstanding issues in research ethics.
The most elaborate codification of research ethics is the so-
called Common Rule of Conduct of the U.S. Code of Federal
Regulations (title 45, section 46), which derived from the work
of the National Commission for the Protection of Human
Subjects of Biomedical and Behavior Research of the mid
1970s. In addition to proposing rules governing many aspects
of research with human subjects, the commission proposed
that the IRB be given the central role in research ethics and be
responsible for prior review of research proposals.2 The IRB
was a compromise, granting a measure of self-regulation to sci-
entists and an assurance of ethical conduct to the government
and the public for publicly funded investigations.
The basic elements of research ethics engender little dis-
agreement. The research must never be brutal or inhumane,
and all unnecessary risks should be eliminated. Any net risks to
subjects must be justified by the prospect of potential benefits
to others. Prospective participants must be told that they are in
a study and must be informed of its nature and its risks and
benefits. In the case of research that offers therapeutic benefit,
scientists must explore the range of reasonable therapeutic
alternatives with the patient. Potential subjects must under-
stand that their participation is completely voluntary and that
they may withdraw at any time and for any reason. Because
they cannot voluntarily shoulder risks, further protection must
be provided to those who cannot give consent. Such people
include, among others, mentally incompetent or immature
participants and those involved in research (chiefly in social
psychology) that requires initial deception. Consent, however,
is not sufficient to ensure fairness; there should be additional
safeguards against unfair distribution of the burdens and ben-
efits of research. Finally, all research that involves potential risks
should be reviewed by an IRB acting on the basis of interna-
tionally recognized ethical principles.
The global acceptance of these principles and the rapid
development of capacity for ethical review attest to the per-
ceived validity of this system of rules and procedures of ethi-
cal review. However, there has been relatively little research on
how IRBs actually perform. Many IRBs in smaller institutions
lack the necessary expertise to review novel or complex pro-
posals, and their institutional setting creates a potential con-
flict of interest. Government investigations of the adequacy of
IRBs for the tasks that are now assigned to them have often
been critical (for example, Office of the Inspector General
1998, 2000). IRBs are often overworked and understaffed,
resulting in ever-lengthening delays between initial submis-
sion of protocols and final approval. Regardless of the value of
IRBs, predicting what will pass through them and what might
provoke delay or rejection has become a significant concern
for medical researchers. The system thus has costs as well as
benefits, a fact that lends additional gravity to the controversies
that it must resolve.
Goals of Ethical Review of Research
Although the overall purpose of ethical review is to ensure that
research with human subjects is ethically defensible, the inter-
national consensus specifies several distinct goals that are
sometimes in tension with each other:
• Protection. Ethical review committees can protect subjects
by alerting investigators to unforeseen hazards and by sug-
gesting research designs that can avoid unnecessary risk or
reduce the number of subjects exposed to risk. By insisting
that a clear explanation of risks and benefits be provided to
potential participants, ethical review committees also help
potential participants to protect themselves. Ethical review
committees often take the name “Committee for the
Protection of Human Subjects,” reflecting a central preoccu-
pation of research ethics today.
• Assurance that participation is voluntary. Some research can-
not be conducted without asking some participants to
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endure discomfort or pain, to delay relief from symptoms of
their disease, or to risk other harm so that future patients
may benefit. Permitting investigators to approach potential
subjects in these cases requires an ethical judgment. In
approving such a proposal, the function of the ethical
review committee is not, strictly speaking, only to protect
the subjects (the goal of protection would often be served
more effectively by declining to do the research), but also to
permit them to be enlisted in the effort to improve health
care for others. Thus, a second function of ethical review is
to ensure that those who agree to participate do so volun-
tarily and freely and that they understand what is being
asked of them.
• Equality and fairness. Although research ethics committees
have little authority to address persistent social injustices, a
third concern of research ethics is that the benefits and bur-
dens of health research be distributed fairly. This function
receives relatively little attention in the literature of research
ethics, despite its prominence in such well-known docu-
ments as the Belmont Report of the National Commission
for the Protection of Human Subjects (1979). Many of the
most notorious abuses of research subjects, including the
Nazi investigations in the concentration camps, the Japanese
biowarfare experiments on Chinese and other civilians,
and the Tuskegee research on African Americans suffer-
ing from syphilis, were committed on subjects chosen
exclusively from disadvantaged groups.
Those three goals of ethical review—protecting subjects;
ensuring voluntary, informed participation; and reviewing the
fairness of recruitment—are promulgated in the international
guidelines and in the Common Rule (and in the regulations of
other countries), but they do not always point in the same
direction. For example, a research project that asks participants
to endure a burden or risk—thus failing to offer full
protection—can still meet the requirement of equality if the
burden is equally shared.
Ethical review, thus, is not a matter of applying a checklist,
but it imposes an obligation of substantial ethical judgment. A
key challenge for IRBs is to earn and retain the trust of partic-
ipants and of the public, a task made more difficult by the
unavoidable absence of explicit criteria for approval. This prob-
lem is exacerbated by the institutional conflict of interest
inherent in the placement of the IRB within the research
institution, which prompts concern that the committees will
downplay risks to subjects for projects that profit or benefit the
institution or its influential staff members. Conversely, IRBs
that are fearful of institutional embarrassment or legal sanction
in the event of any harm befalling research participants might
lean too far in the direction of overprotection of subjects, at the
expense of important scientific research initiatives. Both con-
cerns have been raised about the IRB system.
Current Controversies in Research Ethics
Some of the most sharply disputed issues have arisen in inter-
national collaborative research involving scientists and spon-
sors from wealthy countries conducting experiments in devel-
oping countries. Some of the problems are procedural. For
example, U.S. agencies have insisted on the same kind of
recordkeeping for IRBs in developing countries that is required
of IRBs in U.S. research institutions. IRBs in developing coun-
tries may accept the same principles of accountability, but they
do not have the elaborate staffs and budgets that leading IRBs
rely on.
The most difficult disputes involving the ethics of research
in developing countries are, however, substantive rather than
procedural.
Standard of Care. The international guidelines used in navi-
gating the ethical dilemmas of research in developing countries
were created for the very different purpose of ensuring that
what happened at Dachau and Auschwitz would not recur. It is
not clear whether those rules usefully resolve the kinds of
dilemmas that arise in, say, Uganda or Peru.
The Declaration of Helsinki, following the Nuremberg
Tribunal, requires informed consent of all competent research
subjects, and in section 29 states that “the benefits, risks, bur-
dens, and effectiveness of a new method should be tested
against those of the best current prophylactic, diagnostic, and
therapeutic methods.”
To its supporters, any departure from the letter of the
Declaration of Helsinki that would permit an experiment in a
poor country that would be forbidden in a rich one would
constitute a double ethical standard. In their view, this clause of
the Declaration of Helsinki affirms the equal importance of
human lives, regardless of wealth or nationality, and stands as a
safeguard against exploitation of those made vulnerable by
poverty, sickness, and absence of governmental protection.
Opponents, however, argue that this position seems to rule
out the possibility of testing cheap new products that may be
effective, although perhaps not as effective as other products
that the population could not afford. If so, it would be difficult
to understand whom the single-standard-of-care position
would be protecting, for surely it is better for a seriously ill per-
son to receive a good drug, even if it is not the best, than to
receive no drug at all.3
Both points of view deserve respect. The single-standard
approach is consistent with the postwar consensus on princi-
ples of research ethics, and it offers a bright line between
research that amply respects human subjects and that which
might result if sponsors and scientists were tempted to roam the
globe in search of human subjects who could be used as exper-
imental material with a minimum of expense or trouble.
Opponents of the universal-standard view, however, chal-
lenge its premise. It made sense to insist on a single, universal
standard when the problem was Nazi barbarity, because the
prevailing standard was high and the medical criminals in the
death camps denied it to the imprisoned minority—people
unjustly stripped of their entitlements. In Uganda or Nepal,
however, care at the highest world standard is available, if at all,
to only a small elite.
A full reconciliation of those points of view may not be pos-
sible. The authors suggest that a relativized standard should be
considered only when the beneficiaries will include the impov-
erished, sick population. Even in those cases, however, the local
standard of care could be adopted in the experiment only if it
met or exceeded the standard provided by other countries at
similar levels of development.
Placebo Controls and Other Issues Involving Research
Design. For certain purposes, scientists use a placebo control
even though a proven treatment exists. Patients in these control
groups thus receive care that is inferior to what they would expe-
rience in good clinical care. Until very recently, the Declaration
of Helsinki flatly condemned this practice (its current language
is somewhat less restrictive), but the U.S. Food and Drug
Administration (FDA) accepted results of these trials in applica-
tions for approval of new drugs. The FDA’s justification for this
acceptance rests on two claims, one scientific and one ethical.
The first is that in certain contexts (for example, for conditions
such as depression, in which eligibility criteria and outcomes are
subjective, to an appreciable extent, and in which symptoms
fluctuate in both treated and untreated patients), active controls
may produce misleading indications of equivalency, yielding
seemingly positive results that may be spurious. The second is
that when only placebo controls can be informative, it is some-
times justifiable to ask participants to be randomized with
placebo and thereby to risk discomfort and distress (but not any
appreciable risk of death or long-term impairment).
Debates over placebo controls are often joined in the con-
text of disputes over the appropriate standard of care that arise
in the case of research in developing countries, but placebo
controls are controversial in trials in high-income countries,
too. Placebo controls are one instance of a large category of
ethical issues in research that require weighing the importance
of a scientifically ideal research design against the well-being of
participants. For example, a study of long-term chemotherapy
to prevent the recurrence of breast cancer was halted before the
designated endpoints had been reached after the study’s Data
Safety and Monitoring Board decided that continuing the
study after a strong trend had been established favoring the
chemotherapy would be unfair to the control group. It is
notable that in this instance severe criticism of this decision
was voiced by an organization representing women at risk for
breast cancer, as well as by the editorial board of the New York
Times. Critics of the early termination of the trial were,
in effect, aligning themselves with the interests of future
beneficiaries of the research and possibly against the immedi-
ate interests of the women in the control group.
Rights of Host Communities. Ideally, research involving
human subjects would be a cooperative endeavor for mutual
advantage among free citizens who understand and endorse
the need for research and who expect to share both in the bur-
den of serving as research subjects and in the eventual benefit
of improved health care. Societies that recruit subjects prima-
rily from lower socioeconomic strata fall short of this ideal;
those that do not offer new advances in care to all of their citi-
zens fall even further short, raising serious questions about
fairness. Furthest of all from this ideal are some instances of the
increasingly common practice of recruiting research subjects
among the poorest people in the poorest countries. The means
for protecting human subjects in these countries are often non-
existent. Most of their citizens will be unable to afford new
drugs developed by firms in industrial countries. It is not clear
that these subjects participate voluntarily. Their lack of scien-
tific education or even literacy limits their ability to understand
the terms of the proposed agreement with the scientists and
sponsors (particularly when consent forms, on legal advice, run
to 20 dense pages), and poverty often deprives them of any
alternative means of recovering their health.
Despite these potential ethical shortcomings, international
collaborative research is assured of continued growth. Some of
this research targets diseases affecting mainly poor people, who
as a group suffer more from too little research on their popula-
tions than from too much. Even research intended to develop
therapies that will be affordable only to much wealthier
patients can be defended. Individual participants may receive
better care than they would otherwise, and visiting scientists
offer employment and technical training.
To right the perceived imbalance in what is asked of research
subjects in poor countries and the value that is obtained by sci-
entists who experiment on them, some have proposed that
sponsors of research in the poorest countries compensate their
hosts by offering a supplementary benefit (Glantz and others
1998). One much discussed option is access following the end
of the study to any drugs or other therapies whose effectiveness
is confirmed in the research. The most limited proposals would
restrict this entitlement to individuals who were enrolled in the
study (those who received placebo as members of a control
group, for instance), and time limits (such as three years) have
been proposed in the case of chronic diseases such as
HIV/AIDS. More expansive community benefit proposals have
called for lifetime access to the treatments by all participants,
their families, other members of the local community, or even
all citizens of the country. Other proposed benefits include a
specified amount of technology transfer, including scientific
training and the construction of clinics and laboratories, and
cash payments earmarked for health care. A moderate proposal
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is to encourage these benefits but to require only that they be
discussed and agreed on before investigations are initiated
(National Bioethics Advisory Commission 2001).
These proposals are intended to restore fairness to the rela-
tionship between participants and those who benefit from
research, including scientists and their sponsors and also future
beneficiaries of advances in medical science. Among the poten-
tial drawbacks are the inability to specify, even roughly, how
much is owed to host communities; the inability to determine
whether community benefit should be required even of
research funded by governments or philanthropists for the
benefit of people living in the host communities; and the risk
that placing these demands on proposed research projects will
drive them away from these very needy sites. Some of these
uncertainties may be resolved over time as a variety of
approaches are attempted, particularly if they are studied and
reported to officials in potential research sites.
These international collaborations would draw less scrutiny
if it were clear that all subjects knew what they were getting into
and participated of their own free will. Although evidence on
this point is mixed, special circumstances in some countries
introduce problems that will have to be addressed over the long
run. Cultural differences between host populations and scien-
tists may lead to conflicts over who has the authority to speak
for the individuals invited to participate in a given study.
Regulatory authorities in high-income countries have been
reluctant to accept permission by a woman’s husband or by a
village chief on behalf of his people in lieu of individual con-
sent. It is often unclear—particularly from the vantage point of
an IRB in Europe or the United States—whether the cultural
norms of the host population designate the husband or village
chief as decision makers in these transactions and whether
insistence on concurrent individual consent would be viewed
as intrusive or insulting.
Another recurring issue is whether people enrolled in a trial
of a promising therapy who are ill and very poor can rightly be
viewed as volunteers. The prospect of a cure for a person who
would otherwise die would seem to be irresistible, even if the
treatment is not up to the standards that even less well-to-do
citizens of richer countries would expect. Financial incentives,
too, would predictably have a powerful effect on an individual
who may always be looking for a day’s wage to feed hungry
children. Some IRBs limit payments to compensation for lost
wages and travel expenses, but even at this level researchers are
asked to change the amounts offered to avoid forcing a choice
on the potential participant. As with alleged cultural differences
regarding individual informed consent, IRBs operate with
scant evidence on this point. It is difficult from a long distance
to decide what amount of compensation undermines freedom
of choice. It is also unclear whether the moral categories used
in these disputes have been adequately thought through. The
fact that a poor person finds an attractive offer irresistible will
be viewed as evidence of coercion by some observers but noth-
ing more than common sense by others.
Most of these controversies can be traced back to underde-
velopment and the inequalities of wealth and education that
prevail among and within nations today, but progress in resolv-
ing the ethical controversies that have become obstacles to
badly needed health research must be made even as these dis-
parities persist. Viewing health research in the context of devel-
opment and emphasizing research that is targeted to the needs
of the poor majorities in poor countries can provide a context
in which trust rather than fear or suspicion is the default
response in host countries. Efforts to build capacity for ethical
review within the host countries, such as financial support for
ethical review committees, can place the locus of decision mak-
ing closer to the people who serve as subjects. Research on the
effectiveness of current ethical and regulatory requirements
and mechanisms might enhance the process of ethical review
while reducing its bureaucratic burden. Meanwhile, the quality
and appropriateness of ethical review of this research that takes
place in the sponsors’ countries would be enhanced by eliciting
the views of officials in developing countries, clinicians, scien-
tists, and community leaders.
NOTES
1. Because our current system of ethical review and regulation of
research with human subjects derives from our resolve to prevent the
recurrence of earlier abuses, it deserves mention that the standard histor-
ical account of research ethics has been seriously incomplete. While the
Allies sat in judgment of the Nazi scientists at Nuremberg, abuses of sim-
ilar scope and savagery practiced by Japanese biowarfare researchers on
Chinese and other civilians and prisoners of war were kept secret (and
their perpetrators were unpunished) following a pact with the criminal
scientists to exchange data for war crimes immunity. Moreover, the Allied
governments did not always honor the Nuremberg principles. In the
Soviet Union, scientists attempting to develop for clandestine operations
poisons that would not be identified on autopsy practiced their craft, with
predictably lethal results, on hapless prisoners (Birstein 2001). Abuses in
the United States, such as the Tuskegee syphilis study (Brandt 2000), have
been more widely publicized, but ethical lapses in large-scale Cold
War–related studies, ranging from radiation studies on urban populations
(Advisory Committee on Human Radiation Experiments 1995) to surrep-
titious administration of mind-altering drugs such as LSD (Rockefeller
Commission 1975), were state secrets.
2. In the United States, the Office of Human Research Protections, an
agency of the Department of Health and Human Services, has overall
responsibility for oversight of IRBs administering research using U.S.
government funds. Its Web site is http://ohrp.osophs.dhhs.gov/.
3. Supporters of the single-standard view might point out that, in its
current version, the Declaration of Helsinki does not require that everyone
in an experiment receive the best available care, but rather that new treat-
ments be tested against the best available care. But this defense faces further
objections. In some cases, testing against the best available care (rather than
against the care currently provided to the population or against placebo)
will fail to provide the evidence needed to convince the ministry of health
or potential donors that funds should be provided. There is a potential con-
tradiction in any view that claims both that all patients in experiments
deserve the best care and that it is ethically acceptable to test a new treat-
ment that is not expected to be quite as good as the best currently available.
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The economic analyses in this volume focus on activities whose
main objective is to improve health. Although the chapters vary
considerably, all possess, nonetheless, a common core of defi-
nitions, assumptions, and methods of analysis. These are
drawn primarily from concepts and applications in the Oxford
Textbook of Public Health (Jamison 2002), drawing partly on
the 1993 World Development Report (World Bank 1993). In this
chapter, we summarize and explain the common features and
some of the variations of economic analysis and point the
reader to examples throughout the book.
First is a general discussion of cost-effectiveness analysis
(CEA), which is the principal analytic tool used here. Here we
explain what such analysis does and does not provide, how it is
related to the concept of burden of disease, and how it can be
used, along with other criteria, in setting priorities.
Because CEA is applied to specific interventions, the next
section describes the several meanings of that term and the way
that interventions are classified and evaluated. It is essential to
understand what is being analyzed before considering in detail
how the analysis is conducted.
Estimating the effectiveness of an intervention requires
specifying the units in which that concept is measured. This
action in turn requires choices of several parameter values,
including, in the analyses reported here, the discount rate
applied to future years; the disability weights that describe the
severity of diseases and conditions, corresponding to the health
losses that they cause; and the life expectancy at different ages,
which determines how many years of healthy life can be saved
by averting a death or preventing or treating a long-term health
problem. We also consider briefly the nonhealth benefits that
may result from a health intervention.
The subsequent section deals with the costs of interventions:
first with the question of which costs to include in the analysis,
and then with the conversion of costs in national currencies to
equivalents in U.S. dollars for international comparisons.
Despite the common assumptions and parameter values,
the economic analyses differ from chapter to chapter in how
comprehensive and how exact they are, including how they
deal with a variety of approximations and how the results vary
from place to place or according to differences in the assump-
tions. This section also contains a brief description of the dif-
ferences in the quality of the basic evidence and in how widely
conclusions are applicable.
Estimates of the cost-effectiveness of interventions often
describe what happens at the level of the individual patient or
beneficiary. In the next section, we suggest two ways to consider
costs and outcomes at the population level, allowing for large
differences among countries in the size of population; the inci-
dence or prevalence of a disease, condition, or risk factor; and
the amount spent or available to spend on an intervention.
In the final section, we indicate how the type of analysis pre-
sented in this volume might be improved and how it can be
applied to help set priorities among the large number of inter-
ventions to which limited resources can be applied.
COST-EFFECTIVENESS AND PRIORITY SETTING
The principal analytic tool throughout this volume is
CEA, which compares the cost of an activity, called an inter-
vention, with the known or expected health gain. The result is
summarized in a cost-effectiveness ratio (CER), as explained
more fully below. This ratio corresponds to the concept of
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(health) value for money. Favoring activities that are more
cost-effective over those that are less so is consistent with the
ethical view that “limited resources for health should be allo-
cated to maximize the health benefits for the population
served” (chapter 14).
Cost-effectiveness provides the clearest simple way to pro-
mote value for money in health: hence, the emphasis on it here.
CEA allows comparisons throughout the health sector and not
only for the same health outcome. It does not allow comparison
to nonhealth outcomes unless these outcomes can be incorpo-
rated into costs, and the calculation of the CER by itself makes
no pretense of monetizing the intrinsic value of health. To use
CERs for choosing what to buy and what not to, decision mak-
ers must determine a maximum willingness to pay for units of
health gain, unless other criteria are considered to justify buy-
ing something with relatively poor cost-effectiveness.
For risk factors, CEA requires estimating the gain in health
consequent on introducing an intervention to reduce the risk of
acquiring or transmitting a condition. For packages of inter-
ventions or elements of the health system, such as hospitals,
effectiveness is estimated by judging how much mortality and
morbidity would be reduced by providing the whole package or
set of services or by operating the facility. With some excep-
tions, the analyses may describe but do not quantify the non-
health benefits of an intervention. Apart from the difficulty of
obtaining enough data, such quantification requires attaching
values to nonhealth outcomes, which is problematic when com-
parisons are made over large cultural and income differences.
All comparisons are relative, with no absolute distinction
between being and not being cost-effective. In assigning priori-
ties among interventions for public funding or for other policy
actions, one must also consider the magnitude of health prob-
lems to which interventions apply because that affects what is
affordable. Calculations of the effect of spending US$1 million
or the total cost and health gain in a population of 1 million
people offer ways of looking at such choices. Equity, poverty,
and risk of impoverishment from ill health may also influence
priorities; so do the budgets available—and the decisions of
how much to make available—for buying interventions. Finally,
the effectiveness of an intervention and, therefore, the degree to
which it deserves priority depend on how far it is culturally
appropriate or acceptable for the population it is intended to
benefit. The identical intervention, technically speaking, may
lead to different degrees of use or compliance in different pop-
ulation groups, and information and incentives may be needed
to achieve the full potential outcomes.
Cost-effectiveness is only one of at least nine criteria rele-
vant for priority setting in health if the object is to decide how
to spend public funds (Musgrove 1999). Cost matters by itself,
as do the capacities of potential beneficiaries to pay for an
intervention. The other criteria that may affect priorities
include horizontal equity (equal treatment for people in equal
circumstances); vertical equity (priority for people with worse
problems); adequacy of demand; and public attitudes and
wants. Two criteria—whether an intervention is a public good
and whether it yields substantial externalities—are classic justi-
fications for public intervention, because private markets could
not supply them efficiently, just as in other sectors. As noted in
chapter 1, the interventions analyzed in this volume are not
limited to public or semipublic goods. The emphasis is on value
for money—that is, whether an intervention is worth buying,
not who pays for it. Nonetheless, when one is choosing which
public goods to buy, several criteria become irrelevant, and
cost-effectiveness can be used as the chief or even the only con-
sideration. Cost-effectiveness can similarly determine what to
include in a mandatory universal public package of health care
alongside competitive voluntary insurance (Smith 2005).
Cost-effectiveness can conflict with both kinds of equity—
that is, the more cost-effective of two interventions may also
lead to a less equitable distribution of health benefits. Equity
and cost-effectiveness are compatible when a cost-effective
intervention is provided to only part of the population that
would benefit from it because everyone in the group suffers
from the same problem. Then expanding coverage will gener-
ally also promote horizontal equity. These equity effects are
reinforced when those who are better off already benefit while
the poorer and sicker population does not. Choices about ver-
tical equity—doing more for those in greatest need—are more
complicated. Doing very little for people with severe health
problems—because the available interventions for those prob-
lems are not very effective at reducing their suffering—is not
necessarily preferable to doing more for people with less severe
problems that are more amenable to intervention. When an
intervention is reaching only part of a potential beneficiary
population and those not benefiting tend to have more severe
illness, then expanding coverage can improve both horizontal
and vertical equity. Where possible, chapters consider the equity
effects of expanding or changing interventions.
Cost-Effectiveness and Disease Burden
Cost-effectiveness and disease burden are related because
effectiveness is the reduction in burden caused by an interven-
tion. This relationship holds true at the individual level. The
magnitude of a health problem—the total burden in the
population—is irrelevant for marginal changes in resource
allocation. However, it matters for large changes from the sta-
tus quo. Health interventions demand managerial capacity as
well as financial and physical resources, and managerial ability
may be stretched thin if it has to deal with a large number of
interventions. In consequence, it may be efficient to concen-
trate on relatively few and somewhat less cost-effective inter-
ventions, provided they attack substantial burdens, rather than
many other interventions that are more cost-effective but
affect only small burdens. Moreover, even for a cost-effective
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intervention, high prevalence or incidence may make the cost
of covering the whole potential beneficiary population prohib-
itive. The authors of chapter 21 indicate how expensive it
would be to protect all at-risk African children from malaria
with bednets, even though bednets are highly cost-effective.
Conversely, an intervention that costs more per health gain
may be affordable and given priority if it treats a manageable
burden of disease and corresponds to a small beneficiary
group. Priority turns on the available budget relative to the cost
of a program; on how divisible a program is (that is, how easily
it can be operated at different scales, as a technical or political
matter); and on whether interventions are mutually exclusive
(Karlsson and Johannesson 1996).
Because of the interaction between cost-effectiveness,
disease burden, and available funds, no single threshold of
maximum cost per health gain exists below which an interven-
tion is “cost-effective.” A rule of thumb, such as that any inter-
vention is worthwhile if it costs less than two or three times
income per capita, ignores this interaction and is an inadequate
guide to priority setting. However, even an intervention that is
considered justified by cost-effectiveness may be infeasible to
deliver, for example, if the costs are monetary and come from
the public budget but the benefits are nonmonetary and dif-
fused over the population. Economic theory would suggest
removing the current budget constraint by raising more rev-
enue until the marginal social cost of the interventions plus the
cost of obtaining the revenue equals the marginal social bene-
fit. Although theoretically attractive, this escape from resource
limitation may not be possible because of political reasons or
because the economic cost of raising extra taxes is prohibitive.
Because so many criteria can affect priority setting and
because evidence on cost-effectiveness in low- and middle-
income countries is so scarce, health system policies and
budgets seldom derive purely from considerations of cost ver-
sus outcomes. Even in high-income countries, where more such
analyses are available, their effect has been limited, although it is
growing (Gabbay and le May 2004; Glick, Polsky, and Schulman
2001; Hoffmann and others 2002; McDaid, Cookson, and
ASTEC Group 2003; Sheldon and others 2004; Taylor and NICE
2002). Cost-effectiveness studies are now required by, for
example, the U.S. Food and Drug Administration for labeling
claims, the National Institute for Clinical Excellence before
advising national policy on treatments and care in England,
and the Ministry of Health in the Netherlands for new drugs
(iMTA 2005).
DEFINITION AND CHARACTERISTICS
OF INTERVENTIONS
The object of a CEA—the thing to which it is applied, the costs
and outcomes of which are to be analyzed—is an intervention.
An intervention is an activity using human, physical, and finan-
cial resources in a deliberate attempt to improve health by
reducing the risk, duration, or severity of a health problem
(Jamison 2002, table 2). The term usually refers to an activity
undertaken by a health system rather than by an individual.
The emphasis on a deliberate, systemic effort means that an
intervention is not simply anything that improves health; for
example, if more rainfall leads to higher crop yields and better
nutritional status, the rain does not count as an intervention.
Similarly, although breastfeeding protects infants’ health, it is
not itself an intervention as the word is used in this volume. In
contrast, a program to encourage new mothers to breastfeed is
an intervention (as described in chapter 27). How effective
such a program is, of course, depends on how many mothers it
persuades to adopt the practice when they are neither currently
breastfeeding nor planning to do so.
Interventions can be directed against an injury or disease
(such as trachoma), a condition associated with or deriving
from a disease (such as blindness), or a risk factor that makes
the disease or condition more likely (such as the lack of hygiene
that leads to trachoma). An intervention may pursue primary
prevention at the population level—promoting personal
behavior change, controlling environmental hazards, or deliv-
ering a medical intervention such as immunization to a large
population—or individual action for primary prevention,
cure, acute management, chronic management, secondary pre-
vention, rehabilitation, or palliation. Box 15.1 defines these
terms, and the figure in the box illustrates how interventions
may prevent ill health events or deal with their consequences.
Characterizing an intervention fully also means distinguishing
the level at which it is delivered (home, primary care facility,
district hospital, or referral hospital); indicating whether it
involves drugs, immune enhancement, surgery, or physical or
psychological therapy; and determining whether it requires a
physician or uses diagnostic, laboratory, or imaging proce-
dures. Such procedures are most often evaluated relative to the
interventions they screen for or lead to, because they produce
no health gain by themselves (although the information they
provide can be valuable for reassurance or for promoting
behavioral changes).
An intervention in the everyday sense includes such activi-
ties as immunizing a child, performing a surgical procedure, or
treating an infection with antibiotics. The authors of some
chapters use the term only in this sense—for example, in dis-
cussing interventions that contribute to meeting the
Millennium Development Goals (chapter 9). Authors of other
chapters use the term in several other senses as well. It can
mean modifying an existing intervention—for example,
adding Haemophilus influenzae type B (Hib) antigen to the
Expanded Program on Immunizations (EPI). Immunization
against Hib is itself an intervention, but instead of analyzing it
separately, one can use CEA to evaluate the additional cost of
incorporating that antigen and the additional health gain that
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Intervention Categories, with Examples
Box 15.1
The following figure illustrates how interventions are
related to a health event; the definitions of these categories
are given below.
• Primary prevention—to reduce the level of one or more
risk factors, to reduce the probability of initial occur-
rence of disease (medication for hypertension to pre-
vent stroke or heart attack), or to reduce the likelihood
of disease when the risk factor is already present (pro-
phylaxis for sickle cell anemia).
• Secondary prevention following the occurrence of
disease—either to prevent another event of the same
kind or to reduce the risk of a different but related event
(medication to reduce the likelihood of a second coro-
nary event or a first heart attack after stroke).
• Cure—to remove the cause of a condition and restore
function to the status quo ante (surgery for appendicitis)
• Acute management—short-term activity to decrease
the severity of acute events or the level of established
risk factors, to minimize their long-term impacts
(thrombolytic medication following heart attack,
angioplasty to reduce stenosis in coronary arteries).
• Chronic management—continued activity to decrease
the severity of chronic conditions or prevent deteriora-
tion (medication for unipolar depression, insulin for
diabetes). Chronic management can include some sec-
ondary prevention.
• Rehabilitation—full or partial restoration of physical,
psychological, or social function that has been damaged
by a previous disease or condition (therapy following
musculoskeletal injury, counseling for psychological
problems).
• Palliation—to reduce pain and suffering from a condi-
tion for which no cure or rehabilitation is currently
available (analgesics for headache, opiates for terminal
cancer).
Before After
Primary prevention
of the occurrence of a risk
factor or
of an existing risk
factor developing into an
adverse health event
Secondary prevention
of another event of the
same kind (for example,
a second stroke) or
of a related event of a
different kind (for
example, heart attack
after stroke)
Case management
Cure
Acute care
Chronic care
Rehabilitation
Palliation  
Event
Interventions Related to the Occurrence of an Adverse Health
Event
Population-based interventions all aim at primary preven-
tion (as defined later), are directed to entire populations
or large subgroups, and fall into three categories:
• Promoting personal behavior change (diet, exercise,
smoking, sexual activity)
• Control of environmental hazards (air and water pollu-
tion, disease vectors)
• Medical interventions (immunization, mass chemopro-
phylaxis, large-scale screening, referral).
Personal interventions are directed to individuals and can
be intended for the following:
is expected to result (see chapter 20). The intervention studied
is then not Hib immunization as such but the change in the full
vaccination procedure. A change in the scale of an existing
activity can also be considered an intervention, even if the
activity itself is unchanged: that is, one can analyze the change
in costs and in outcomes associated with expanding or
contracting the coverage of the activity—for example, extend-
ing antiretroviral treatment for HIV and AIDS to a larger pop-
ulation (chapter 18) or screening more newborns for sickle cell
anemia (chapter 34). In most chapters, the authors assume that
expansion affects costs and outcomes linearly, so that the CER
does not change. The chapters on vaccine-preventable diseases
(chapter 20) and malaria (chapter 21) provide explicit esti-
mates of the differential costs of expanding coverage.
Adding one intervention to another to deal with the same
disease or condition is also an intervention, and combinations
of interventions can be analyzed to determine which is most
cost-effective or how the cost-effectiveness of one intervention
depends on the other activities with which it is combined.
Examples include successively adding drugs for treatment of
epilepsy (chapter 32) or secondary prevention of cardiovascular
disease (chapter 33) or combining several quite different inter-
ventions to control tobacco addiction or alcohol (chapters 46
and 47, respectively). The analyses of community health and
Source: Authors.
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nutrition programs (chapter 56) and integrated management of
infant and childhood illness (IMCI; chapter 63) define “the
intervention” as a whole program incorporating several differ-
ent activities. Generally, even less empirical evidence exists con-
cerning combinations of interventions than for individual
activities, but IMCI is an exception; it has been evaluated more
thoroughly than most single interventions.
Box 15.2 includes a more detailed discussion, using a hypo-
thetical example of three different ways to deliver immuniza-
tion, of how CEA can be applied to four of the meanings of
intervention used here: an existing intervention at its current
coverage, changes in the scale of that intervention, the addition
of one intervention to another when expanding coverage, and
the complete shift from one intervention to a different (and
more cost-effective) one.
Depending on the comparison undertaken, the result may
be an average cost-effectiveness ratio (ACER) or an incremen-
tal cost-effectiveness ratio (ICER). The former compares total
costs and total results, starting from zero, whereas the latter
compares additional costs and additional results, starting from
the current or some other level of coverage of an intervention.
Either shifting completely from one intervention to another
or partially replacing one with another may reduce costs while
producing more health gain. For example, if spending is high
on hospitalization for acute myocardial infarction, a program
using a “polypill” (several medications in a single pill) would
reduce expenditures by lowering incidence (chapter 33) and
would be cost saving, because less hospitalization would be
needed. If the status quo is no hospitalization (as is typical at
low incomes), a polypill program increases costs but may more
than correspondingly increase health gains and therefore be
more cost-effective. If the polypill both reduces costs and
improves outcomes compared with hospitalization, it is said
to dominate a hospital-only strategy. The second figure in
box 15.2 illustrates the concept of dominance; table 45.4 and
box 45.1 of chapter 45 provide examples of interventions that
are dominated by others.
Unfortunately, reliable information on current intervention
coverage, costs, and results is not always available even in high-
income countries (iMTA 2005) and is extremely scarce in low-
and middle-income countries. Studies showing whether an
intervention is effective or cost-effective seldom cover the
entire potential beneficiary population, and service provision
in the private sector is often not recorded. Many chapter
authors describe only the ACER of an existing or potential
intervention, whereas others explicitly compare alternatives to
current practice (for an example, see chapter 16).
Many of the activities analyzed here aim at promoting
changes in personal behavior, by informing and persuading
individuals to eat differently, to avoid smoking and excessive
alcohol, to reduce the risks of sexually transmitted infections,
or to practice better hygiene. Such efforts can be considered
interventions in themselves, and as such are crucial for
controlling HIV and AIDS (chapter 18), promoting better
infant and child care (chapters 20 and 27), preventing inherit-
ed disorders (chapter 34), encouraging healthful diets and
exercise (chapters 44 and 45), and avoiding addiction (chap-
ters 46–48). But they can also be used to improve the effec-
tiveness of other interventions by increasing awareness and
demand, combating mistaken beliefs about diseases and risks,
or reducing anxiety and stigma. In that sense, information,
education, and communication delivered to consumers or
providers or both are examples of policy instruments. They
can facilitate or promote the use of such interventions as con-
dom distribution, screening for diseases or congenital disor-
ders, prenatal care, or immunization.
Other activities that can be classified either as interventions
or as policy instruments include the following:
• Measures to increase the quality of care, such as some kinds of
staff training or the introduction of better recordkeeping.
These activities may simultaneously affect a large number of
specific interventions in a health facility (chapter 70).
• Legislation and regulation to impose an intervention (for
example, limiting the salt content of foods, chapter 45,
or requiring that salt be iodized, chapter 28); to limit or
prohibit an intervention that is ineffective or dangerous or
to reduce unhealthful behavior such as smoking and exces-
sive drinking (chapters 46–47); or to codify how an inter-
vention should be delivered and determine who may pro-
vide it, as by licensing doctors, nurses, and health facilities
(chapter 71).
• Economic incentives, which can take the form of subsidies or
taxes (chapter 11) for particular items of consumption other
than health goods or services, such as tobacco and alcohol
(chapters 46–47) or condoms to reduce HIV transmission
(chapter 18), or can be provided through protection of
property rights, as for patented drugs (chapter 72).
These activities of informing, mandating, legislating, regu-
lating, and taxing or subsidizing, which are at one remove or
more from medical interventions, are also often called func-
tions of the health system (WHO 2000, chapter 2; see also
chapter 9 in this volume). Several of these instruments may be
used together, such as increased taxes on tobacco or alcohol
along with measures to educate consumers and to restrict the
times, places, or quantities of consumption. Sometimes the
instrument is needed before introducing or expanding an
intervention to overcome barriers to its use or to make it cost-
effective enough to be worth pursuing. Educating the affected
population, for example, is crucial to screening and treatment
of cancers and hemoglobin disorders. The need for a particular
instrument may vary from country to country even if the
276 | Disease Control Priorities in Developing Countries | Philip Musgrove and Julia Fox-Rushby
Average and Incremental Cost-Effectiveness and Intervention Choices
Box 15.2
In the figure below, which compares three ways of deliver-
ing immunization, point X describes the status quo of a
current intervention, delivering immunization by means
of fixed facilities. At point X, the intervention achieves a
total effect E2 (measured as coverage or as disease reduc-
tion) at a total cost C2. The ratio C2 to E2 is the average
cost-effectiveness ratio (ACER), shown by the slope of the
line O–X. Beyond point X, expanding coverage becomes
very costly, perhaps because the population not yet immu-
nized is dispersed and hard to reach. (Chapter 20 includes
estimates of how costs increase as immunization coverage
expands but without introducing a sharp increase in
costs.) Expansion to point X1, which increases the cost
from C2 to C3, yields only a small increment E3–E2 in
effect. The slope of the line X–X1 represents the incre-
mental cost-effectiveness ratio (ICER) of that expansion,
which would raise the ACER to line O–X1. The line X–X2
shows the alternative of reducing coverage, which would
improve the average cost-effectiveness (to C1/E1) because
marginal costs are rising steeply near point X. The ICER
of the reduction in coverage is the ratio of C2–C1 to
E2–E1.
Raising immunization coverage at an affordable cost
may require adopting the alternative of mobile vaccina-
tion teams, intervention Y. The hypothetical combination
of fixed facilities and such teams allows increasing the
effect to E4 (complete or nearly complete immunization)
at a total cost of C4. The ICER of the mobile teams is
shown by the slope of the line X–Y and the resulting over-
all or combined ACER by the slope O–Y. Adopting inter-
vention Y would be clearly preferable to trying to expand
coverage through intervention X by building and staffing
more fixed facilities.
An alternative even better than Y might subsequently
be developed, represented by point Z—for example, com-
munity-based immunization teams that could operate
either near or far from fixed facilities because they use heat-
stable vaccines that do not require a cold chain. The ICER
of turning to that choice, represented by the line X–Z, is not
only more favorable than intervention Y, but it is even bet-
ter than the current ACER, and preferable to intervention X
at any coverage level beyond X2. The cost-effective choice,
therefore, is not to retain intervention X at its current level
and add Z beyond that point but to switch entirely from X
(or from X plus Y, if Y has already been adopted) to Z.
Because it costs less but provides a better outcome, Z is said
to dominate both X and Y. The following figure illustrates
dominance of one intervention by another, as well as cases
in which neither of two interventions is dominant.
Total cost 
C4
Y
X1C3 
C2 X
C1 X2
Z 2
Z
O E1
 Total effect (coverage or health gain) 
Through mobile teams
Through fixed facilities
E2 E3 E2* E4
Through community
teams using heat-stable
vaccines (no cold chain)
Average and Incremental Cost-Effectiveness and Intervention
Choices: Comparison of Three Ways to Deliver Immunization 
Maximum acceptable
incremental cost per
disability life year
averted 
Old intervention X
dominates
New intervention Z
dominates 
New
intervention
more effective 
New
intervention
more costly 
New
intervention
less effective  
New
intervention
less costly
X
New intervention
V less effective
but less costly
New intervention W
more effective but
more costly 
Comparison of Cost and of Effectiveness between Interventions:
Conditions for Dominance
intervention that it facilitates is identical, because the legal,
regulatory, or financial environment differs.
ESTIMATING EFFECTIVENESS IN HEALTH
Using cost-effectiveness for resource allocation requires health
effects to be represented in common units in order to facilitate
comparison across interventions, diseases, or conditions. All
analyses start with some natural unit: cases of disease or injury,
deaths, or numbers of people who quit smoking or adopt some
other health-improving behavior. All interventions that avert
death are alike in that regard. Preventing a child’s death at a par-
ticular age, independent of the cause, means that the averted
death alone is an adequate measure of outcome. However, when
lives are saved at different ages—averting death from malaria at
age 2 versus death from beta thalassemia at age 10–15—the out-
come is no longer identical, and some measure must account
for the difference in years of life saved. These cases provide
another natural unit, subject to estimating how much longer a
person spared death might live. The choice of life expectancy to
assume for such calculations is discussed later.
The unit of time becomes a less natural and more synthetic
measure if the future is discounted, as in all these analyses.
Discounting means reducing the value of each variable in each
future year by an amount that increases the further in the
future that year is. The discounting procedure reflects inherent
uncertainty about the future and preferences for timing of con-
sumption, and it avoids two problems. First, outcomes that
potentially generate benefits forever, such as smallpox eradica-
tion, appear to have infinite benefits if the future is not
discounted and therefore seem to justify any finite cost at all.
Second, it makes little sense to postpone interventions forever
simply because funds to finance them could be invested today
and be worth more tomorrow. Even discounting the future at
the low rate of 3 percent annually has a substantial effect—that
is, dividing the values for future years by successive powers of
1.03. That means dividing values for year 1 by 1.03; those for
year 2 by 1.03 squared, or 1.0609; and so on. At that rate, avert-
ing an infant death saves not all the 80 calendar years of life
expectancy at birth (or fewer in low-income countries) but at
most 30 discounted years.
For interventions that avert mortality, analysis starts by
estimating the deaths prevented, uses age at death to yield
numbers of life years saved, and then discounts those years as
described above. When interventions improve health by avert-
ing or reducing nonfatal disability, different disabilities must be
compared in severity. As with mortality, age at the time of
intervention matters for long-lasting conditions, and so does
discounting. In contrast, age is irrelevant for episodes of illness
or injury that are self-limited or quickly resolved by interven-
tion, because the duration of ill health does not depend on age,
and all ages are treated alike in this analysis. Discounting also
makes little difference over short intervals.
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If intervention Z is divisible (meaning that it can be
operated at any desired scale, such as Z2), then it is prefer-
able to X at a cost of C2 because of the additional effect
E2*–E2. It can be extended all the way to E4, just as with
intervention Y, provided only that the ICER represented by
the slope X–Z is still acceptable to decision makers choosing
how far to expand the intervention. That is, the cost must
still appear to be justified by the increased coverage. Under
either of these conditions, an obstacle to switching, or to
doing so quickly, would exist only if substantial fixed costs
accompanied the transition from one intervention to the
other, such as recruiting or retraining staff, building health
posts in communities, or setting up the system for dis-
tributing the new heat-stable vaccines.
Compared with intervention X, intervention Z is better
in both dimensions (lower cost and greater effectiveness),
so it is to be preferred, and is said to dominate X. However,
intervention X would dominate any other treatment that
is both more costly and less effective and, therefore, falls in
the upper left quadrant. An intervention such as V or W
may or may not be considered preferable to X (V is cheap-
er but also less effective, and W is more effective but also
more costly). Whether either such intervention would be
selected over X depends on the relation of the increased
(or decreased) cost to the increased (or decreased) effec-
tiveness. That ratio corresponds to an ICER. If a maxi-
mum acceptable, or threshold, value for the ICER is deter-
mined, as shown by the dashed diagonal line, then any
intervention that falls below the dashed line would be
acceptable (preferable to X), and those that fall above the
dashed line would not be. Uncertainty about the estimates
of cost and effectiveness means that, instead of a sharp line
as in the figure, the division of preferable from nonprefer-
able interventions corresponds to a zone of some width
that depends on the confidence intervals around the esti-
mates. This kind of comparison can start from an existing
intervention such as X in the first figure or, when there is
currently no intervention, from point O in the first figure.
Source: Authors.
Unit of Measurement of Health
The common unit of health loss or gain used here takes into
account duration and severity, as well as discounting the future.
The disability-adjusted life year (DALY) is a unit introduced by
the World Health Organization (WHO) and the World Bank
(Jamison and others 1993; Murray 1996; World Bank 1993). As
previously discussed, the DALY incorporates assumptions and
measurements about severity of nonfatal conditions, age at
incidence or intervention, duration with and without interven-
tion, and remaining life expectancy at that age. For interven-
tions directed to risk factors rather than diseases, the analysis
incorporates estimates of reductions in diseases that result
from changes in the level of risks. Smoking cessation, for
example, reduces deaths from both cardiovascular disease and
cancer (chapter 46).
Published analyses, particularly in high-income countries,
often use not DALYs but quality-adjusted life years (QALYs), an
alternative measure of how much a year of life is worth if a per-
son suffers one or more limitations of various kinds and
degrees. QALYs can be estimated directly using a valuation
method such as the time tradeoff (comparing and varying the
time spent in one health state with time spent in another state
until the quality of life is judged the same in both).
Alternatively, a prescored questionnaire such as the EQ5D (a
European quality of life measure) could be used. The EQ5D
distinguishes three grades—no problem, an extreme problem,
and total disability—on each of five dimensions of life
quality—mobility, self-care, performance of usual activities,
pain or discomfort, and anxiety or depression (Brooks, Rabin,
and de Charro 2003). Discounting of QALYs occurs as an addi-
tional step, although some concern exists that discounting
values derived from the time tradeoff approach is double
discounting (Dolan and Jones-Lee 1997).
QALYs allow comparison among interventions and can eas-
ily account for comorbidity. Although the concept of DALYs
averted by an intervention is similar to that of QALYs gained,
no systematic formula exists for converting between DALYs
and QALYs except in broad approximations (Fox-Rushby
2002). This gap is partly because DALY disability weights are
specific to diseases whereas the QALY system of evaluation is
not (it is based on overall health status). Authors sometimes
report effectiveness results in QALYs, because they cite studies
in high-income countries that often use QALYs. When some
interventions are evaluated in DALYs and others in QALYs,
ranking interventions according to cost-effectiveness may still
be possible (see chapter 29 for examples of the use of both
units).
Priority setters sometimes stop exercises in priority setting
after concluding that something is or is not cost saving, without
asking whether an intervention yielding a different outcome
(against a different disease, for example) would be still more
cost-effective. In this volume, the intent is to estimate both
costs and effects, permitting all such comparisons. Knowing
that one intervention achieves the same results as another at
lower cost, which would be relevant if they were the only two
possible interventions against a common problem, is not
enough. Comparing both with another intervention with dif-
ferent effects may also be necessary. For example, a coronary
artery bypass graft for myocardial infarction costs, on average
across regions, US$37,000 per DALY gained, compared with an
average of only US$409 for the polypill discussed earlier.
However, both are much more expensive than saving life years
for a middle-aged person by treating active tuberculosis (and
thereby preventing transmission), an intervention that costs
only US$15 per DALY in the absence of HIV infection, or
US$102 on average where coinfection makes treatment more
difficult. (In only a few cases do chapters deal explicitly with
comorbidity, in part because the DALY approach considers
conditions only individually.)
Parameter values for effectiveness are required in order to
conduct CEA: how to value disability, compared with mortality;
how to treat the future; and whether to distinguish people
according to age, sex, or other characteristics. Because effec-
tiveness is related to reduction in disease burden, nearly all
these parameter choices coincide with those adopted to esti-
mate the existing burden (see Mathers and others 2005 for a
full explanation).
Because disease burden estimates discount the future at
3 percent annually, CEA in this volume does the same, for both
effects and costs. This method follows the recommendations of
the U.S. Public Health Service Panel on Cost-Effectiveness in
Health and Medicine (Gold and others 1996) and appears
appropriate whenever the benefits of an intervention begin
immediately. Constant discounting (using the same percentage
rate each year) undervalues interventions for which the bene-
fits appear long after the costs have been paid. Immunization
against hepatitis B can prevent liver cancer decades later (chap-
ter 20) but, compared with the costs incurred at the moment of
vaccination, appears less cost-effective if the health gain is
heavily discounted during that interval. Slow discounting, with
the rate falling close to zero for the more distant future, would
yield a higher present value of benefits (Jamison and Jamison
2003), but given the absence of consensus on the correct form,
the analyses here use constant discounting.
The limitations from a disease or condition in the absence of
intervention are measured by disability weights (Mathers and
others 2005), despite some controversy as to whether they ade-
quately capture all the disability (see chapter 24 on helminthic
infections). These weights range from zero for perfect health to
1.0 for death. Authors have made their own estimates whenever
WHO did not provide any disability weight because the
corresponding condition was not explicitly included in the
burden of disease. For example, weights for anemia caused by
hemoglobin disorders (chapter 34) were taken from other
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causes of anemia. Note that years lost to early death also are
DALYs, since they include the disability weight of 1.0.
When an intervention prevents or completely cures a condi-
tion, the postintervention disability is zero. For partially suc-
cessful interventions leaving residual disability, the disability
weight is reduced but not eliminated. WHO has sometimes
estimated weights for “treated” as opposed to “untreated” con-
ditions (Murray and Lopez 1996, annex table 3) without spec-
ifying the intervention. This distinction is introduced for some
consequences of chronic conditions: cancers not yet in the ter-
minal stage, diabetic conditions, major psychological disorders,
cataracts, various cardiovascular conditions, chronic respira-
tory conditions, ulcers, arthritis, cleft lip and palate, edentulism
(total loss of teeth), and some burns. Chapters 31 and 33 use
these values to describe intervention outcomes.
WHO burden-of-disease estimates used in the first edition
of Disease Control Priorities in Developing Countries (Jamison
and others 1993) incorporated age weights—that is, numbers
attempting to describe the relative value of life at different ages.
These numbers were calculated to keep the discounted integral
from age 0 to 80 the same, as if no age distinction were made.
The weights are zero at birth, ignoring health losses from still-
birth prior to live birth; reach a maximum at age 25; and
decline almost to zero at advanced age. They are a particularly
controversial element in the burden estimates (Musgrove 2000)
because they value some years of life more than others, and lit-
tle evidence suggests what an appropriate weight should be. In
consequence, only constant age weighting (treating all years
alike) is used in these analyses. Removing age weights makes no
difference to an intervention that averts an infant death, but it
changes the relative importance of interventions at later ages.
Because life is more highly valued at advanced ages, death and
disability after age 38 become more important compared with
events before that age, and interventions later in life become
more cost-effective. Some estimates used here therefore differ
from those published previously by WHO even when all the
other parameters are unchanged.
The only parameters for CEA that differ from those in the
burden of disease concern life expectancy. In estimating bur-
den, people at any age and in all regions are assumed, on the
ethical criterion of valuing all lives equally, to have the same life
expectancy. The only exception is that at birth males appear to
have a biologically determined (not behavior-related) life
expectancy of 80 years, which is shorter than the life expectancy
of females by 2.5 years. However, applying these expectancies to
CEA will overstate the effects of interventions when life
expectancy in a population is low. Averting a death at age 5 in
Sub-Saharan Africa or South Asia does not confer a high prob-
ability of living to age 80 or longer. Competing causes of death
reduce the effectiveness of any single intervention, unless it
affects so large a population that it actually increases life
expectancy. An intervention that completely interrupted the
transmission of HIV and AIDS or prevented all deaths from
malaria would do that. Given the absence of evidence that any
intervention actually has such a substantial effect, it is assumed
in this volume that individuals face the same probability of
death at each subsequent age as the existing population does.
This assumption makes interventions appear less effective
when overall mortality is high than when mortality is low. For
example, averting an infant death in Sub-Saharan Africa will
save, on average, only 44 to 49 undiscounted life years
and should not be credited with saving 80 or more. Cost-
effectiveness calculations and estimates of burden of disease are
inconsistent in that fully effective interventions appear able to
deal with only part of the burden they aim to control. Regional
rather than standard life expectancy also makes interventions
in a high-mortality region appear more effective relative to
outcomes where mortality is lower, when they avert deaths later
in life.
Nonhealth benefits of health interventions sometimes
should be taken into account, because many health interven-
tions also yield other kinds of benefits. They often make bene-
ficiaries mentally or physically more productive, better able to
continue in and learn from school or to work and earn more.
This benefit occurs particularly with interventions against non-
fatal consequences, as indicated in the chapters on malnutri-
tion (chapter 28), malaria (chapter 21), helminthic infections
(chapter 24), tropical diseases (chapters 22–23), psychiatric dis-
orders (chapter 31), and learning and developmental disorders
(chapter 49). Interventions that prevent injury or restore work
capacity also have such effects (chapters 39–40 and 60), as
do interventions against diseases that kill in the prime of
life, notably tuberculosis and AIDS (chapters 16 and 18).
Nonhealth benefits also occur as time is saved when piped
water is made available, as less cleaning is needed when air
pollution is reduced (chapter 42), or as property damage is
reduced by improved traffic safety (chapter 39).
Several chapters include discussions of the nature and,
where possible, the magnitude of nonhealth benefits from
health interventions. This factor is important when the health
benefits, although substantial, are so costly that interventions
do not appear cost-effective on health grounds alone but may
be justified by large nonhealth returns. Safe water and sanita-
tion services are the classic example (chapter 41). Because dif-
ferent types of benefits—health gains, increased income, time
saved—cannot be compared directly, the only way of combin-
ing them into a single expression is usually to evaluate all out-
comes in monetary terms. (An exception occurs when some
monetary gains can be measured directly—for example,
increased worker productivity from better health. Those gains
can be subtracted from costs and incorporated into CEA with-
out attributing a monetary value to the health gains.) Most
chapters that account for any nonhealth benefits simply offer
descriptions of them rather than incorporating them into
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monetary outcome indicators. Chapter 7 is an exception; it
compares gains in welfare from living longer or in better health
with those from higher income.
Estimating the monetary value of all benefits and adding
them together for comparison with cost is what cost-benefit
analysis does. Interventions are considered justified in absolute
terms if the benefits exceed the costs. However, when faced with
constrained budgets that cannot finance all interventions
whose benefits are greater than costs, policy makers need to
establish some minimum acceptable rate of return. This choice
is parallel to the need to set a maximum on cost per unit of
health gain when choosing according to cost-effectiveness.
Published analyses of health interventions sometimes use
cost-benefit analysis, so results following that method are
incorporated in some chapters here. The decision to emphasize
CEA instead derives from two chief considerations. One is that,
for most interventions, the health consequences seem more rel-
evant or more important than any nonhealth outcomes. The
other is that, conceptually, it is unclear what dollar value to
assign to improved health, as would have to be done in most
cases. Two approaches to valuing health, particularly for judging
how much a life is worth, are known respectively as (a) the value
of a statistical life, or the human capital approach, and (b) the
willingness-to-pay valuation, or contingent valuation. The for-
mer depends on estimating earnings lost from premature death
or retirement, and the latter on what people pay or indicate they
would pay for care to protect or restore their health.
Both approaches reflect a society’s level of income. Although
they may be appropriate within a homogeneous society, if
applied globally they imply that better health is worth less
among poor populations than among those who are better off.
Both methods are arguably more appropriate for marginal
improvements (like saving travel time for commuters) than for
valuing life-or-death differences, although willingness to pay is
sometimes used in analyses of policies to reduce mortality.
Avoiding monetary evaluation of health benefits sidesteps most
of the ethical problems of valuing individual lives and requires
fewer assumptions about what benefits are worth. The cost of
this simplification is that occasionally substantial nonhealth
benefits are not explicitly valued, so interventions may look less
justified than they would be if all benefits were analyzed.
DETERMINING COSTS FOR INTERVENTIONS
Whatever outcome measures are used to evaluate an interven-
tion, its costs must be estimated. This need raises several ques-
tions about which costs to attribute to the intervention and
how some of them should be valued.
Direct and indirect costs should be distinguished, and
choices should be made about which, if any, of the latter to
include. In addition to the direct costs to the health system of
producing an intervention, the U.S. Public Health Service
guidelines (Gold and others 1996) recommend including the
indirect costs to patients and their families of consuming it.
This recommendation means, in particular, the value of time
needed for travel, waiting, and undergoing medical tests and
procedures, or the value of time used in caregiving, as well as
any income forgone during treatment. Externalities, or costs
imposed on third parties, such as on the school system or the
environment, should also be included. The analyses in this vol-
ume generally exclude such costs and report only the direct
costs of delivering interventions, partly because published
analyses seldom include the various indirect costs, and they are
harder to estimate. Walker and Fox-Rushby (2000) found that
only 20 of 101 studies included some element of indirect cost-
ing. Valuing time according to local wages or income, for exam-
ple, may underestimate how valuable time actually is to poor
people. Estimating such costs, even if time is not valued in
money, may show whether time or monetary costs or both
account for a relatively low level of use and therefore impede
expanding coverage. Applying one or more of the policy
instruments discussed earlier, along with the intervention, may
then be important in order for it to be cost-effective.
Including such costs also raises a question of interpretation.
If an intervention appears low in cost-effectiveness because it
requires much travel or waiting time, the fault may lie not with
the intervention itself but with health facilities that are located
too far from the beneficiary population, are understaffed, or
are inefficiently managed. For this reason, cost-effectiveness is
estimated assuming a functional health system that does not
impose prohibitive time costs on users.
Not only the characteristics of the interventions themselves,
but also the capacity to deliver interventions greatly affect cost-
effectiveness across many activities. In a complete analysis, each
intervention is characterized by how demanding it is of mana-
gerial or institutional capacity. This element is difficult to
measure directly, but authors often provide at least an intuitive
description of how easy or hard delivery of an intervention is
or what factors facilitate or impede its implementation. Where
capacity to deliver several interventions together is important,
authors deal explicitly with the issue, as in the chapters on
health facilities (chapters 64–66), resources (chapters 71–72),
service management (chapter 73), and whole packages of inter-
ventions (chapters 56 and 63).
Dollar values of unit costs need to be calculated for interna-
tional comparisons. The inputs used to produce an
intervention—the time (and training) of human resources;
drugs and supplies; and depreciation or rental value of equip-
ment, vehicles, and buildings—are either produced in the
country or imported. If the latter, they already have prices in U.S.
dollars; if the former, prices in local currency must be converted
to U.S. dollars for comparison with other interventions
and other countries. The usual distinction between tradable
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and nontradable goods is that tradables move from producing
to importing countries at relatively constant “world” prices. In
fact, the same good may be imported at different prices to dif-
ferent countries or may be imported to one country but locally
produced in another, so that it has both an international and a
local price. This situation is increasingly true of drugs and sup-
plies, which middle-income countries (Brazil, for example) and
some low-income countries (India) now produce and some-
times export.
Prices in local currency can be converted to U.S. dollars by
exchange rates or by purchasing-power parity rates (as esti-
mated in World Bank 2003). The former may reflect under- or
overvaluation of the local currency, making goods systemati-
cally cheaper or more expensive than at world prices, and they
may change quickly and substantially in response to changes
in a country’s trade balance, indebtedness, or capital flows.
Nonetheless, they represent what is actually paid for locally
produced inputs at any given moment. Purchasing-power par-
ity rates, in contrast, attempt to say what local currency is
worth in purchasing power, correcting for systematic price dif-
ferences. Such rates can be calculated for the country as a
whole, for the health sector, or for specific inputs or combina-
tions thereof (Wordsworth and Ludbrook 2004). This calcula-
tion means valuing local inputs at external prices, assuming
they are equally productive or of equal quality in the particular
country as in the countries from which purchasing-power par-
ity rates are derived. A doctor in South Asia or Sub-Saharan
Africa is treated as costing just as much as a physician in high-
income countries. This approach approximates measuring the
real resource cost of intervention by comparing quantities
of inputs among countries, eliminating price differences as a
source of cost variation. Estimates of real national income are
derived this way, making poor countries usually look less poor
in dollar terms than if income in local currency were valued at
exchange rates.
Granted that purchasing-power parity rates are reasonable
for comparing large aggregates such as income across coun-
tries, but they bear little relation to the allocation of resources
and budgetary choices within a country. The cost calculations
in this volume are, therefore, all based on exchange rates.
Exchange rates more accurately reflect what a domestic
buyer—or a foreign donor or investor—has to pay for
imported versus domestic inputs and, therefore, are more rele-
vant for choices between interventions with high or low
imported content. (If exchange rates are artificially fixed, the
country pays a cost for that distortion that affects all interven-
tions to the extent that they require foreign exchange.) In gen-
eral, the more an intervention is produced with local inputs, the
more cost-effective it will appear when priced using exchange
rates, compared with its cost at purchasing-power parity rates.
For decision makers and purchasers in the country, efficiency
means choosing interventions according to what they actually
cost, not according to what they would cost if prices were more
nearly uniform among countries. If, in local currency, physi-
cians are paid little more than nurses are, it may make sense to
employ more doctors per nurse—even if at international prices
doctors would cost much more and should be replaced by
nurses when possible. Of course, the staffing decision turns
on the competencies of the two groups as well as on their costs;
for certain health problems, more nurses might be the better
choice even if they cost more.
Two other reasons besides that of efficiency in buying inter-
ventions support basing cost-effectiveness on exchange rate
prices. First, authors who have used published costs (which
usually involve exchange rates) rather than building up esti-
mates from individual prices and quantities seldom break
down costs into imported and domestic components. Local
inputs cannot be repriced at purchasing-power parity rates or
can only be repriced very approximately. Second, for readers
accustomed to dealing with prices converted using exchange
rates, real resource estimates may simply appear to penalize the
use of local inputs by valuing them at unrealistic prices. The
problem with exchange rate prices, in contrast, is that when
rates change, so may the relative cost-effectiveness of interven-
tions, as imported inputs become relatively more or less expen-
sive. Cost-effectiveness is not static or intrinsic but depends
on prices as well as on quantities and on the results of an
intervention—and prices can change individually or generally,
through exchange movements. Priorities sometimes need to
shift because of such price changes, as well as because of tech-
nological changes that make interventions more effective, and
so analyses should be kept up to date.
MORE AND LESS COMPREHENSIVE DATA
AND ANALYSIS
Several authors (Drummond and others 1997; Gold and others
1996; Sloan 1995) provide similar guidance and recommenda-
tions for relatively comprehensive economic evaluation in
general or for specific medical procedures. This volume aims at
estimating cost-effectiveness for interventions against many
different problems in all low- and middle-income regions, for
which varying amounts and quality of information are avail-
able. It has therefore not always been possible to conduct as
complete an analysis as would be desirable. Some degree of
modeling is usually inescapable (Buxton and others 1997).
More complete analysis starts by characterizing, in each
regional setting where an intervention is relevant (where the
health problem causes some measurable burden and the inter-
vention appears feasible), estimates of the quantities of inputs
required (Q), the unit costs of those inputs (P), and the effec-
tiveness or health gain (E). Authors were provided regional esti-
mates of unit costs for the major inputs—salaries, facility costs,
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fuel and vehicle operation, drugs, representative equipment,
diagnostic tests, and buildings (Mulligan and others 2003). The
total cost of delivery is the sum of the input costs PQ, which is
compared with effectiveness E and the CER calculated from the
total costs and total effects of the proposed intervention or
from the changes in those costs and outcomes compared with
current practice.
The data on unit costs, quantities, and outcomes may all
derive from published literature; what is original is how that
information is combined to calculate cost-effectiveness rather
than taking the ratios from existing studies. Estimates are built
up using prices and physical inputs in the chapters on tubercu-
losis (chapter 16), vaccine-preventable diseases (chapter 20),
malaria (chapter 21), cancers (chapter 29), psychiatric
disorders (chapter 31), neurological disorders (chapter 32),
cardiovascular disease (chapter 33), hemoglobin disorders
(chapter 34), water and sanitation (chapter 41), indoor air pol-
lution (chapter 42), tobacco (chapter 46), alcohol (chapter 47),
community programs (chapter 56), family planning (chapter
57), surgery (chapter 67), emergency care (chapter 68), and
complementary medicine (chapter 69). Several chapters ana-
lyze some interventions more fully and others less fully,
depending on the available information.
As indicated in box 15.2, expanding or contracting the scale
of an intervention may change the CER because of difficulty
in reaching more of the population. The ratio may also vary
because of the cost of identifying who would benefit most from
the intervention—for example, whether to screen all newborns
for sickle cell disease or only those of African origin (chap-
ter 34). And expansion may change the cost-effectiveness
because it would require considerable fixed investment. The
costs of expanding capacity to deliver an intervention, includ-
ing physical capital and training of human resources, should be
amortized over a reasonable interval (10 years is the standard
in this volume) and included in the total costs. Ideally, one
would know the complete production function of the inter-
vention, including the possibilities of substituting one input for
another to minimize costs in response to differences in prices.
However, analysis of this level of complexity is difficult to
achieve, so most chapters assume fixed input proportions. Q,
then, does not depend on P, and the CER varies (at most) only
with coverage, prices, and outcomes. This result could be an
underestimate of the true cost-effectiveness if much substitu-
tion is possible (see chapter 16 on tuberculosis).
Approximations are required when the average and incre-
mental CERs have to be taken directly from the literature and
when key parameter values are not easily available. Existing
estimates of total cost or effectiveness may or may not
incorporate the standard assumptions about discounting, dis-
ability weights, and life expectancy. Authors then need to
judge how to adjust the available estimates for a more consis-
tent analysis.
Local cost and outcome estimates that have not been con-
structed transparently from inputs and prices provide a less
complete basis for secondary analysis. Where such estimates are
used, information about how costs are constructed or how
results vary with the scale of the intervention is usually not
available, but the data may explicitly show regional differences
in one or both elements, thereby permitting regionally differ-
entiated recommendations (or may show differences so small
that recommendations need not differ regionally). If costs and
results refer to only one moment or are specified year by year,
they can be discounted at 3 percent. Published analyses often
use higher constant rates of 5, 6, or even 10 percent and may
specify only total costs and outcomes rather than the respective
streams through time. In that case, both costs and health gains
occurring in the future are valued less, but conversion to a CER
based on 3 percent discounting may be impossible and is at
best only approximate. Some published analyses discount costs
but not health outcomes, which makes interventions look more
cost-effective when costs are spread over long intervals (for
examples, see chapter 29). Imported estimates of cost and
effect—that is, estimates from other regions, commonly from
high-income countries—are often all that is available.
Sometimes data on costs and outcomes derive from the same
source; in other cases, they come from different sources and
even different regions and are difficult to compare directly.
More appropriate adjustments to total costs are possible with
information on quantities of inputs. In the absence of data on
quantities of resources used, differences in average cost can
sometimes be calculated using estimates of input proportions.
Such an approximation characterizes the analysis for diabetes
(chapter 30), in which proportions were known in one region
and assumed to be the same elsewhere and costs were estimated
from regional cost ratios.
Variation of Results and Uncertainty of Estimates
Variation and uncertainty are two different aspects of cost-
effectiveness estimates that also need to be accounted for in set-
ting priorities. Because costs of inputs differ among regions,
intervention costs vary even if effectiveness does not—and there
are often reasons why the same intervention is more effective in
one place than another. Such variation means that a single
estimate of incremental or average cost-effectiveness of an inter-
vention is not universally applicable.All estimates should ideally
be local, and regional values capture only part of the real varia-
tion. For example, the average cost per DALY of chemotherapy
for active or contagious tuberculosis, in the absence of HIV and
AIDS, is US$15, but that figure varies from US$6 to US$31
across regions, and such wide variation is common in many
chapters. Whenever the estimates of cost-effectiveness in differ-
ent chapters use the same input prices, their results are compa-
rable within a given region. Analyses that draw on published
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estimates for price or unit cost information are necessarily less
comparable across interventions and introduce another ele-
ment of variation, even in the same locale. Still more variation
arises when costs or outcomes are extrapolated from one coun-
try or region to another.
Because the CER depends on many parameters and vari-
ables, of which only the discount rate and the disability weights
are uniform, good analytic practice calls for sensitivity analysis
to see how the ACERs and ICERs change with plausible varia-
tion in one or more parameters. Many chapters (such as chapter
26) provide such analyses, varying one value at a time, to sketch
the likely range of estimates. This method is one way of dealing
with uncertainty (which differs from real, known variation)
about the true values of the data and seeing whether the ranking
of interventions changes when those values change. Such analy-
ses do not indicate the probability that the true CER falls in a
particular interval, only under what input values it would do
so. Estimating such probabilities requires knowing or assuming
the statistical distributions of the parameters in question
and using that information to derive confidence intervals
around the point estimates. Guides to CEA recommend these
approaches (Gold and others 1996), and the National Institute
for Clinical Excellence requires probabilistic sensitivity analysis
before approving medical treatments in the United Kingdom
(NICE 2004).
Data for estimating probability distributions around mean
parameter estimates are seldom available in low- and middle-
income countries. Simply having available several different
estimates of a parameter is inadequate for deriving a distribu-
tion, because the differences may be caused by variation in
regional costs or expected life years rather than uncertainty.
However, assumptions about the shape of distributions can
be applied within modeling exercises to give an indication of
the likely distribution of ICERs. Only a few chapters, therefore,
include confidence intervals. The analyses for tuberculosis
(chapter 16) and malaria (chapter 21) do, but ranges associated
with most cost-effectiveness estimates (see chapter 2) reflect
other causes of variation, not statistical accuracy.
Although calculations are often reported to several signifi-
cant digits, such precision is not really feasible given the
uncertainties in the original data: “economics is a one- or at
most a two-digit science” (Morgenstern 1963). However, even
crude findings can be valuable, either as guides to value for
money if inaccuracies do not affect the relative order of
magnitude of the results or for understanding and exploring
the sources of variation and their effect on priorities as well as
indicating future research needs (Claxton, Sculpher, and
Drummond 2002). These issues arise, for example, when con-
sidering whether to expand the EPI or to add new antigens
(chapter 20), how far to extend screening procedures (chapters
29 and 34), and when to change drugs in response to vector or
parasite resistance (see chapters 21 and 23).
The quality and relevance of evidence can vary considerably,
depending on whether information comes from randomized
controlled trials or systematic overviews, nonrandomized stud-
ies with multivariate analyses and well-defined endpoints, or
case studies or expert opinion. For these analyses, the quality of
evidence also depends on geographic coverage, as distinguished
in chapter 2:
• literature review of one cost-effectiveness study, in one
country
• literature review of several studies in different countries in
different regions
• literature review of several studies in different countries in
the same region
• original analyses starting with price and quantity data in
one country
• original analyses starting with price and quantity in one or
more regions.
The first three categories differ in how representative published
findings are; the latter two categories differ according to the
data used in constructing total effects and total costs.
Besides the quality of the evidence at its source, how the
results will apply to other settings matters, particularly when
the data are limited to high-income countries. The more that
outcomes depend on underlying biology, the more the find-
ings will apply to low- and middle-income countries. Outcomes
depending more on cultural or environmental factors are less
readily transferred and require judgment and evidence as to
their applicability elsewhere. Sometimes the only detailed stud-
ies refer to high-income countries, as for abuse of substances
other than alcohol and tobacco (chapter 48). At the other
extreme, in a few cases all or nearly all the information comes
from low- and middle-income countries, and there is no need
to extrapolate, as for nutritional interventions (chapter 28) and
community health and nutrition programs (chapter 56).
COST-EFFECTIVENESS AND POPULATION IMPACT
An intervention CER, whether average or incremental, is based
on assumptions about introduction, expansion, contraction, or
modification of the activity compared with current (or some-
times “best”) practice. Comparison of ratios indicates whether
one intervention offers better or worse value for money than
another at the individual level but says nothing about how
either one affects the whole population. The analysis, therefore,
includes, wherever possible, two ways of describing the latter
effect. One is to consider a population of 1 million, with a typ-
ical regional age and sex structure, and to suppose that the
intervention were delivered to all the potential beneficiaries.
That number of people is just the prevalence or incidence of
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the condition times 1 million. The total cost would then be the
unit cost times that number (or the cost of reaching that many
people if the unit cost varies with coverage). The total health
gain would be the individual effectiveness times that same
number (or the overall outcome if that depends on externali-
ties, such as the transmission of communicable disease, that are
sensitive to coverage). Standardizing on a population of 1 mil-
lion allows comparisons among regions and interventions in
which the incidence or prevalence may vary greatly.
A second approach standardizes not on population but on
expenditure: if an additional US$1 million were devoted to the
resources needed for an intervention, how many people could
benefit from it and how large would the health gain be? The
coverage of the intervention would be US$1 million divided by
the average cost, and the total gain in DALYs would be that
number of people times the average effectiveness. This
approach is applied in relatively few chapters because of the
information requirements; its advantage is to facilitate judg-
ments as to where increased spending would be most
justified—where it would yield the largest improvement in
health, reach the most people, or account for the largest share
of burden from a condition. Table 1.3 in chapter 1 provides
examples for some interventions to reduce child mortality, pre-
vent or treat HIV and AIDS, reduce smoking prevalence, treat
heart attack and stroke, detect and treat cervical cancer, and
operate a basic surgical ward. The estimates of DALYs gained
per US$1 million vary from less than 100 to more than
100,000—a thousandfold difference in value for money. Annex
26.A of chapter 26 provides both kinds of calculations, per mil-
lion population, to compare the cost-effectiveness of interven-
tions for improved maternal health in South Asia and Sub-
Saharan Africa.
IMPROVEMENTS AND FURTHER APPLICATIONS
What would improve the kind of estimates and conclusions
reported in this volume? Most crucially,more and better data are
needed in low- and middle-income countries to reduce reliance
on extrapolation from high-income countries and on expert
judgments. The need for information starts, in some cases, with
better estimates of incidence and prevalence, but even where the
epidemiology is well known, data on coverage and outcomes of
existing interventions are scarce. Evidence of what it would cost
to change coverage of existing interventions or add new inter-
ventions, and with what results, is particularly scarce and
depends heavily on assumptions. This situation is sometimes
true even for activities that have been conducted widely for
many years and have been extensively analyzed, notably the EPI
(chapter 20). Analyses should when possible be conducted at
the level of a country or even smaller units, to take full account
of all the reasons cost-effectiveness varies from place to place
and to develop priorities on the basis of analyses appropriate to
local circumstances.The methods used here are intended to help
guide such efforts, and they can and should be refined through
research to provide more robust help to policy.
Finally, a more concerted approach is needed for clarifying
the options facing different decision makers and incorporating
the results from systematic literature reviews into analytic
models that compare the costs and effects of alternative inter-
ventions (Buxton and others 1997; Kuntz and Weinstein 2001).
Modeling encourages explicit decision making and can deal
comprehensively with the inputs and outcomes of decision
options, which allows a range of uncertainties to be reflected.
Thus, hypotheses about interventions can be formulated and
tested statistically. Specifying models explicitly (as in chapter
16, for example) can also help identify gaps in current evidence
and can capture details specific to particular populations and
settings.
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• Consequences of Disease and Injury
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Despite the availability of drugs to cure tuberculosis (TB) since
the 1940s, TB remains an important cause of death from an
infectious agent, second only to the human immunodeficiency
virus, or HIV (WHO 2004f). TB control is high on the inter-
national public health agenda, not only because of the enor-
mous burden of disease, but also because short-course
chemotherapy (SCC) is recognized as one of the most cost-
effective of all health interventions (Jamison and others 1993).
That recognition is partly attributable to an influential series of
studies done in three of the poorest countries of southeastern
Africa (Malawi, Mozambique, and Tanzania), which suggested
that a year of healthy life could be gained for less than about
US$5 (de Jonghe and others 1994; Murray and others 1991).
This evidence has been central to the global promotion of the
DOTS strategy, the package of measures combining best
practices in the diagnosis and treatment of patients with active
TB, in which direct observation of treatment during SCC is a
key element (WHO 2002a, 2004c).
Although the World Health Organization (WHO) has fos-
tered the implementation of DOTS over the past decade, four
recent developments have drawn attention to a wider range of
options for TB control:
• First, many more studies have investigated the costs, efficacy,
and cost-effectiveness of different approaches to TB control.
They are mostly studies of ways to improve the delivery
of first-line drug treatment for active disease, but they
include some investigations of preventive therapy (treat-
ment of latent infection), treatment of multidrug-resistant
TB (MDR-TB) using both first- and second-line drugs, and
different approaches to diagnosis. They have been carried
out in a variety of settings, in richer as well as poorer coun-
tries. The results have not been fully synthesized but may
suggest ways to enhance DOTS.
• Second, striking increases in TB have been associated with
the spread of HIV infection and drug resistance, suggesting
that DOTS alone may not be enough to bring TB under
control, especially in Africa and in the countries of the
former Soviet Union.
• Third, there is now substantially more investment in new
tools for TB control, including multimillion-dollar initia-
tives to develop better diagnostics, drugs, and vaccines,
many of which operate under the umbrella of the Stop TB
Partnership (see http://www.stoptb.org). Some of the possi-
ble products of this new research would stimulate reevalua-
tions of the current reliance on chemotherapy, especially the
development of a new high-efficacy vaccine.
• Fourth, interest in TB is renascent, not simply as the out-
come of mycobacterial infection, but also as the conse-
quence of exposure to exacerbating risks, such as tobacco
smoke, air pollution, malnutrition, overcrowding, and poor
access to health services. Research directed at quantifying
these risks will also suggest ways to minimize them.
These developments set a big agenda for analysis. To make
some inroads, this chapter presents an overview of the value
for money and potential effect of the principal modes of
TB control around the world. The starting point is a review
of the natural history and clinical characteristics of TB and
the geographical distribution of and trends in TB cases and
deaths. This introduction sets the context for a discussion of
the interventions that are now available to control TB and of
how they have been used. We use a new method for evaluating
the cost-effectiveness of infectious disease control and apply
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this method systematically to four groups of TB interventions
as they could be implemented in six regions of the world.
The internationally agreed-on targets for TB control,
embraced by the United Nations Millennium Development
Goals (MDGs), are to detect 70 percent of sputum-smear-
positive cases and successfully treat 85 percent of such cases by
the end of 2005. The expectation is that, if these targets can be
reached and maintained, incidence rates will be falling by 2015,
and the TB prevalence and death rates of 1990 will be halved by
2015. Meeting these targets requires a set of interventions that
are not only cost-effective but also affordable and capable of
having an effect on a large scale. The final sections of the chap-
ter discuss the absolute costs and benefits of global TB control
and the potential for achieving the effect defined within the
MDG framework. The main themes of the text that follows
are elaborated in a series of annexes available online at http://
www.fic.nih.gov/dcpp as well as at http://www.who.int/tb/
publications/en/.
TUBERCULOSIS INFECTION, DISEASE, AND DEATH
Human TB is caused by infection with mycobacteria, princi-
pally Mycobacterium tuberculosis. Individuals with pulmonary
or laryngeal TB produce airborne droplets while coughing,
sneezing, or simply talking. Inhaled infectious droplets lodge in
the alveoli, and bacilli are taken up there by macrophages,
beginning a series of events that results in either the contain-
ment of infection or the progression to active disease (Frieden
and others 2003). Following uptake by macrophages, M. tuber-
culosis replicates slowly but continuously and spreads through
the lymphatic system to hilar lymph nodes. In most infected
people, cell-mediated immunity, associated with a positive
tuberculin test, develops two to eight weeks after infection.
Activated T lymphocytes and macrophages form granulomas,
which limit the further replication and spread of bacilli. Unless
a later defect occurs in cell-mediated immunity, the infection
remains contained within the granulomas.
The immune mechanisms are, in their details, far more
complex. For example, following antigenic challenge, a suite of
different T cells is responsible for the induction and suppres-
sion of protective immunity, delayed hypersensitivity, cytolysis,
and the production of antibodies and memory cells. Helper T
cells mature into two functionally different populations: in M.
tuberculosis infection, the TH1 response is associated with gran-
uloma formation and protection, whereas the TH2 response
results in tissue-necrotizing hypersensitivity and the progres-
sion of disease. The processes that determine the balance of the
two responses affect, for example, the interaction between
M. tuberculosis and other infectious agents (Grange 2003).
When the immune response cannot suppress replication,
primary infection leads to active TB (progressive primary TB).
The most common clinical manifestation is pulmonary
disease, typically in the parenchyma of the middle and lower
lung. In the most infectious patients, bacilli can be seen micro-
scopically on stained sputum smears (60 to 70 percent of
pulmonary cases; Marais and others 2004; Styblo 1991).
Smear-negative patients may also be infectious but, per patient,
contribute relatively little to transmission (Behr and others
1999; Hernandez-Garduno and others 2004). Extrapulmonary
tuberculosis accounts for 10 to 30 percent of the disease but is
more common among women and children (particularly lym-
phatic TB) and in people infected with HIV (Aaron and others
2004; Rieder 1999; Rieder, Snider, and Cauthen 1990; Shafer
and Edlin 1996).
In the absence of other predisposing conditions, only
about 5 percent of infected people develop progressive pri-
mary disease within five years of infection (Comstock,
Livesay, and Woolpert 1974; Sutherland 1968, 1976). After
five years, the annual risk of developing TB by the reactivation
of latent infection is much lower(?104 per capita per year).
The risk of progressing to active disease is relatively high in
infancy and lower in older children; it increases quickly dur-
ing adolescence (earlier in girls) and then more slowly
throughout adulthood (Comstock, Livesay, and Woolpert
1974; Nelson and Wells 2004; Sutherland, Svandova, and
Radhakrishna 1982; Vynnycky and Fine 1997). Whether latent
bacilli remain viable for the full life span of all infected peo-
ple is unknown, but the risk of reactivation certainly persists
into old age. The lifetime risk of developing TB following
infection clearly depends on the prevailing transmission rate;
the rule of thumb is 10 percent, but it has been calculated at
12 percent for all forms of pulmonary disease in England and
Wales during the second half of the 20th century (Vynnycky
and Fine 2000).
Besides the strong innate resistance to developing disease,
infection is associated with an acquired immune response. This
response is only partially protective (Dye and others 1998;
Sutherland, Svandova, and Radhakrishna 1982; Vynnycky and
Fine 1997), which helps explain why developing an effective
vaccine has been difficult (few manufactured vaccines are
more protective than natural immunity; Andersen 2001;
Fordham von Reyn and Vuola 2002; Young and Stewart 2002).
Consequently, individuals who carry a latent infection and who
continue to be exposed are at risk of TB following reinfection.
The importance of reinfection remains controversial, but
mathematical modeling shows that the decline of TB in Europe
cannot easily be explained without reinfection (Dye and others
1998; Vynnycky and Fine 1997). In addition, molecular finger-
printing has produced direct evidence that TB commonly
arises from infection and reinfection in endemic areas (de
Viedma and others 2002; Richardson and others 2002; van Rie
and others 1999; Verver and others 2004), especially where sub-
jects are infected with HIV (Glynn and others 2004).
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The low incidence of infection and the low probability of
breakdown to disease explain why TB is relatively rare. Its
importance among infectious diseases is attributable not so
much to the number of cases as to the high case-fatality rate
among untreated or improperly treated patients. About two-
thirds of untreated smear-positive patients will die within five
to eight years, the majority within the first 18 months (Styblo
1991). Most of those who are still alive after eight years will
have quiescent TB (self-cures, susceptible to relapse), and a few
will become chronic excretors of bacilli. The case-fatality rate
for untreated smear-negative cases is lower, but still of the
order of 10 to 15 percent (Krebs 1930; Rieder 1999). Even
among smear-positive patients receiving antituberculosis
drugs, the case-fatality rate can exceed 10 percent if adherence
to treatment is low or if rates of HIV infection and drug resist-
ance are high (WHO 2004c).
Online annex 1 contains more information about factors
that affect the risk to individuals of contracting infection and
developing disease and the distribution of TB in populations.
EPIDEMIOLOGICAL BURDEN AND TRENDS
Surveys of the prevalence of infection and disease, assessments
of the performance of surveillance systems, and death registra-
tions yield an estimated 8.8 million new cases of TB in 2003,
fewer than half of which were reported to public health author-
ities and WHO (online annex 2). Approximately 3.9 million
cases were sputum-smear positive, the most infectious form of
the disease (Corbett and others 2003; Dye and others 1999;
WHO 2005). The African region has the highest estimated inci-
dence rate (345 per 100,000 population annually), but the most
populous countries of Asia harbor the largest number of cases:
Bangladesh, China, India, Indonesia, and Pakistan together
account for half the new cases arising each year. In terms of
the total estimated number of new TB cases arising annually,
about 80 percent of new cases occur in the top-ranking
22 countries.
In most countries (but not all), more cases of TB are
reported among men than women. This differential is partly
because women have less access to diagnostic facilities in some
settings (Hudelson 1996), but the broader pattern also reflects
real epidemiological differences between men and women,
both in exposure to infection and in susceptibility to disease
(Borgdorff and others 2000; Hamid Salim and others 2004;
Radhakrishna, Frieden, and Subramani 2003). Where the
transmission of M. tuberculosis has been stable or increasing
for many years, the incidence rate is highest among young
adults, and most cases are caused by recent infection or rein-
fection. As transmission falls, the caseload shifts to older age
groups, and a higher proportion of cases comes from the reac-
tivation of latent infection.
Globally, the TB incidence rate per capita appears to be
growing slowly (online annex 2). Case numbers have been
declining more or less steadily for at least two decades in
Western and Central Europe, the Americas, and the Middle
East. Striking increases have occurred in countries of Eastern
Europe (mainly the former Soviet republics) since 1990 and
in Sub-Saharan Africa since the mid 1980s, although trends
in case notifications suggest that the rate of increase in both
regions has slowed significantly since the mid 1990s (WHO
2005).
TB has increased in Eastern European countries because of
economic decline and the general failure of TB control and
other health services since 1991 (Shilova and Dye 2001).
Periodic surveys indicate that more than 10 percent of new TB
cases in Estonia, Latvia, and some parts of the Russian
Federation are multidrug-resistant—that is, resistant to at least
isoniazid and rifampicin, the two most effective anti-TB drugs
(Espinal and others 2001; WHO 2004a). Drug resistance is
likely to be a by-product of the events that led to TB resurgence
in these countries, not the primary cause of it, for three rea-
sons. First, resistance is generated initially by inadequate treat-
ment caused, for example, by interruption of the treatment
schedule or use of low-quality drugs. Second, resistance tends
to build up over many years, and yet TB incidence increased
suddenly in Eastern European countries after 1991. Third,
although formal calculations have not been done, resistance
rates are probably too low to attribute all of the increase in
caseload to excess transmission from treatment failures.
Globally, 12 percent of new adult TB cases were infected
with HIV in 2003, but there was marked variation among
regions—from an estimated 33 percent in Sub-Saharan Africa
to 2 percent in East Asia and the Pacific (online annex 2). HIV
infection rates in TB patients have so far remained below 1 per-
cent in Bangladesh, China, and Indonesia. The increase in TB
incidence in Africa is strongly associated with the prevalence of
HIV infection (Corbett and others 2002), and in populations
with higher rates of HIV infection, women 15–24 years old
constitute a higher proportion of TB patients (Corbett and
others 2002). The rise in the number of TB cases in Africa is
slowing, almost certainly because HIV infection rates are also
beginning to stabilize or fall (Asamoah-Odei, Garcia Calleja,
and Boerma 2004). HIV has probably had a smaller effect on
TB prevalence than on incidence because HIV significantly
reduces the life expectancy of TB patients (Corbett and others
2004). Where HIV infection rates are high in the general pop-
ulation, they are also high among TB patients; estimates
for 2003 suggested that more than 50 percent of TB patients
infected with HIV in Botswana, South Africa, Zambia, and
Zimbabwe, among other countries.
Approximately 1.7 million people died of TB in 2003
(Corbett and others 2003), including 229,000 patients who
were also infected with HIV (online annex 2). Although these
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are usually reported as AIDS deaths under the International
Statistical Classification of Diseases and Related Health
Problems, 10th revision (ICD-10), and by WHO, TB control
programs need to know the total number of TB deaths, what-
ever the underlying cause.
INTERVENTIONS AGAINST TUBERCULOSIS
TB can be controlled by preventing infection, by stopping pro-
gression from infection to active disease, and by treating active
disease. The principal intervention is the DOTS strategy and its
variations, centered on the diagnosis and treatment of the most
severe and most infectious (smear-positive) forms of TB but
including treatment for smear-negative and extrapulmonary
cases as well. Anti-TB drugs can also be used to treat latent
M. tuberculosis infection and active TB in patients with HIV
coinfection, and the widely used bacillus Calmette-Guérin
(BCG) vaccine prevents (mainly) severe forms of TB in child-
hood. These biomedical interventions directed specifically
against TB can be implemented in a variety of ways through
medical services and public action and can be supported by other
efforts to reduce environmental risk factors (online annex 1).
Vaccination
Currently, the only means of immunizing against TB is with the
live attenuated vaccine BCG, although other vaccines are under
development (Fruth and Young 2004; Goonetilleke and others
2003; Horwitz and others 2000; Letvin, Bloom, and Hoffman
2001; Reed and others 2003; Young and Stewart 2002).
Randomized controlled trials and case-control studies have
shown consistently high protective efficacy of BCG against seri-
ous forms of disease in children (73 percent [95 percent
confidence limits 67–79 percent] for meningitis and 77 percent
[95 percent confidence limits 58–87 percent] for miliary TB)
but highly variable—and often very low—efficacy against
pulmonary TB in adults (Bourdin Trunz, Fine, and Dye, forth-
coming; Fine 2001; Rieder 2003). Thus, even with the high cov-
erage now achieved, BCG is unlikely to have any substantial
effect on transmission. In parts of Europe and North America
that did and did not use BCG, TB declined at rates that were
not measurably different (Styblo 1991). In areas of high inci-
dence, BCG vaccination is recommended for children at birth
or at first contact with health services. Vaccination is being dis-
continued in many low-incidence countries because the risk of
infection is low and because the response to BCG confounds
the interpretation of tuberculin skin tests used to track persons
infected during occasional outbreaks. BCG may have substan-
tial nonspecific effects on child mortality—that is, in reducing
deaths from causes other than TB—but this possibility is still
controversial (Kristensen, Aaby, and Jensen 2000).
Reported BCG vaccination coverage has increased through-
out the world during the past 25 years, reaching about 100 mil-
lion infants, or 86 percent of all infants, in 2002. An estimated
92 percent of children were vaccinated in Europe and 62 per-
cent in Africa in 2002 (WHO 2001). During the past 15 years,
coverage has generally been most variable among African
countries and least variable in Europe and the Americas. The
most complete analysis of the effect of BCG vaccination sug-
gests that BCG given to children born in 2002 prevents about
29,700 cases of childhood meningitis and 11,500 cases of mil-
iary TB during the first five years of life, or one case for every
3,400 and 9,300 vaccinations, respectively (Bourdin Trunz,
Fine, and Dye, forthcoming).
Treatment of Latent Infection
Individuals at high risk of TB who have a positive tuberculin
skin test but not active disease (for example, associates of active
cases, especially children and immigrants to low-incidence
countries) can be offered treatment for latent TB infection
(TLTI), most commonly with the relatively safe and inexpensive
drug isoniazid. Studies among those who have contacts with
active cases have demonstrated that 12 months of daily isoni-
azid gives 30 to 100 percent protection against the development
of active TB (Cohn and El-Sadr 2000; Comstock 2000). For
patients who may be carrying a strain resistant to isoniazid,
rifampicin daily for 4 months is an acceptable alternative (or
rifabutin, if used with protease inhibitors for HIV-infected peo-
ple; Cohn 2003; Menzies and others 2004). Nevertheless, TLTI is
not widely used. The main reason is that compliance with long-
term daily treatment tends to be poor among healthy people—
a relatively high risk of TB among those who are latently
infected is usually still a low risk in absolute terms. An addi-
tional reason is that the tuberculin skin test tends to be less spe-
cific when applied to individuals who have been vaccinated with
BCG. Although it is sometimes possible to make separate esti-
mates of the number of individuals in a population who have
been infected and who have received BCG (Neuenschwander
and others 2002), distinguishing the responses to BCG and
infection is harder in any given individual.
The exceptionally high risk of TB among persons coinfected
with M. tuberculosis and HIV is a reason for encouraging wider
use of TLTI, especially in Africa. However, there are significant
barriers to making TLTI effective for coinfected individuals liv-
ing in areas of high transmission (in addition to those listed ear-
lier). Although trials of TLTI with individuals infected with HIV
whose tuberculin skin test was positive have averaged about
60 percent protection for up to three years (with a good deal of
variability), the effects have been lost soon afterward, and little
or no effect has been seen on mortality (Bucher and others
1999; Johnson and others 2001; Mwinga and others 1998;
Quigley and others 2001; Whalen and others 1997; Wilkinson,
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Squire,and Garner 1998). In addition, identifying M. tuberculosis
infection is more difficult in HIV-positive individuals than in
those who are HIV-negative because the former are often aner-
gic and are, therefore, unresponsive to tuberculin. Early studies
have also experienced problems with uptake and compliance. In
a pilot project in Zambia, for example, only 35 percent of HIV-
infected individuals identified through HIV testing and coun-
seling services actually started TLTI, and, of those who started,
only 23 percent completed at least six months of treatment
(Terris-Prestholt and Kumaranayake 2003).
TLTI has been used as a component of intensive, local con-
trol campaigns, such as those carried out for North American
and Greenland Eskimos, but probably had effects secondary to
the prompt treatment of active disease (Comstock, Baum, and
Snider 1979; Styblo 1991). At present, TLTI plays no more than
an accessory role in TB control in any setting, although the
number of recipients around the world has been neither
directly quantified nor indirectly estimated.
Treatment of Active Disease: The DOTS Strategy
The cornerstone of TB control is the prompt treatment of active
cases with SCC using first-line drugs, administered through
the DOTS strategy (WHO 2002a) within targets framed by the
MDGs. The DOTS strategy has five elements:
• political commitment
• diagnosis primarily by sputum-smear microscopy among
patients attending health facilities
• SCC with effective case management (including direct
observation of treatment)
• a regular drug supply 
• systematic monitoring to evaluate the outcomes of every
patient started on treatment.
Standard SCC can cure more than 90 percent of new, drug-
susceptible TB cases, and high cure rates are a prerequisite for
expanding case finding. Although the DOTS strategy aims pri-
marily to provide free treatment for smear-positive patients,
most DOTS programs also treat smear-negative patients, usu-
ally without a fee. DOTS can be used as the basis for more com-
plex TB control strategies where rates of drug resistance or HIV
infection are high.
Mathematical modeling and practical experience suggest
that the incidence of TB will decline at 5 to 10 percent per year
when 70 percent of infectious cases are detected through pas-
sive case finding and 85 percent of these cases are cured, even
though that level represents a treatment success rate among all
infectious cases of only 60 percent (Dye 2000; Dye and others
1998). In principle, TB incidence could be forced down more
quickly, by as much as 30 percent per year, if new cases could be
found soon enough to eliminate transmission. In general, the
decline will be faster where a larger fraction of cases arises from
recent infection (that is, in areas where transmission rates have
recently been high) and slower where there is a large backlog of
asymptomatic infection. As TB transmission and incidence go
down, a higher proportion of cases comes from the reactivation
of latent infection and the rate of decline in incidence slows.
These facts explain why it should be easier to control epidemic
than endemic disease: during an outbreak in an area that pre-
viously had little TB, the reservoir of latent infection will be
small, and most new cases will come from recent infection.
In the control of endemic TB, largely by chemotherapy, the
best results have been achieved in communities of Alaskan,
Canadian, and Greenland Eskimos, where incidence was
reduced at 13 to 18 percent per year from the early 1950s
(Styblo 1991). Over a much wider area in Western Europe, TB
declined at 7 to 10 percent per year after drugs became widely
available during the 1950s, although incidence was already
falling at 4 to 5 percent per year before chemotherapy (Styblo
1991). More recently, between 1994 and 2000, the incidence of
pulmonary TB among Moroccan children 0 to 4 years of age
fell at more than 10 percent per year, suggesting that the risk of
infection was falling at least as quickly (S. Ottmani, personal
communication 2005). The overall reduction in pulmonary TB
was only 4 percent per year, in part because of the large reser-
voir of infection in adults. DOTS was launched in Peru in 1991,
and high rates of case detection and cure appear to have pushed
down the incidence rate of pulmonary TB by 6 percent per
year (Suarez and others 2001). For epidemic TB, as a result of
aggressive intervention following an outbreak in New York
City, the number of MDR-TB cases fell at a rate of more than
40 percent per year (Frieden and others 1995).
Although the long-term aim of TB control is to eliminate
all new cases, cutting prevalence and death rates is arguably
more important. About 86 percent of the burden of TB, as
measured in terms of disability-adjusted life years (DALYs) lost,
is attributable to premature death rather than illness, and preva-
lence and mortality can be reduced faster than incidence in
chemotherapy programs. Thus, the TB death rate among
Alaskan Eskimos dropped at an average of 30 percent per year
in the period 1950–70 and at an average of 12 percent per year
throughout the Netherlands from 1950 to 1990. Indirect assess-
ments of the effect of DOTS suggest that 70 percent of the TB
deaths expected in the absence of DOTS were averted in Peru
between 1991 and 2000, and more than half the TB deaths
expected in the absence of DOTS are prevented each year in
DOTS provinces of China (Dye and others 2000; Suarez and
others 2001). There have been few direct measures of the reduc-
tion in TB prevalence over time, but surveys done in China in
1990 and 2000 showed a 32 percent (95 percent confidence
limits 9–51 percent) reduction in the prevalence rate of all
forms of TB in DOTS areas, as compared with the change in the
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prevalence rate in other parts of the country (China
Tuberculosis Control Collaboration 2004; PRC Ministry of
Health 2000). These findings imply that the targets of halving
prevalence and death rates between 1990 and 2015 are techni-
cally feasible, at least in countries that are not burdened by high
rates of HIV infection or drug resistance.
Many of the 182 national DOTS programs in existence by
the end of 2003 have shown that they can achieve high cure
rates: the average treatment success rate was 82 percent (that is,
the percentage that were sputum-smear negative at the end of
treatment plus the percentage that had completed treatment
but for whom cure was not confirmed by sputum smear), not
far below the 85 percent international target (WHO 2005).
The outstanding deviations below that average were in Africa
(73 percent) and some former Soviet republics (for example,
67 percent in Russia). Although the completion of treatment
was almost a guarantee of cure before the spread of HIV and
drug resistance, “completed” is an unsatisfactory way to report
the outcome of treatment if cure is in doubt.
Although most TB patients probably receive some form of
treatment, only 45 percent of all estimated new smear-positive
cases were reported by DOTS programs to WHO in 2003. The
case-detection rate in DOTS programs has been accelerating
globally since 2000, but the annual increment must be still
greater if the 70 percent target is to be reached by the end of
2005. Observations on the way DOTS is presently implemented
suggest that a ceiling on case detection might be reached
at about 50 to 60 percent (Dye and others 2003; WHO 2005).
This fraction is about the same as the percentage of all cases
reported annually to WHO from all sources (that is, from
DOTS and non-DOTS programs). The problem is that, as
DOTS programs have expanded geographically, they have not
yet reached far beyond existing public health reporting systems.
ALTERNATIVE AND COMPLEMENTARY
APPROACHES TO THE DIAGNOSIS 
AND TREATMENT OF ACTIVE DISEASE
The limitations of the DOTS strategy have stimulated numerous
initiatives to improve program performance (including treat-
ment protocols for patients carrying drug-resistant bacilli or
who are infected with HIV), active case finding, collaborations
within and between public and private sector health services,
schemes for outpatient and community-based treatment, and
integration of the management of TB and other illnesses.
Management of Drug-Resistant Disease
The higher the proportion of patients carrying drug-resistant
bacilli is, the greater the need for accurate resistance testing and
for the provision of alternative regimens that include at least
three drugs to which bacilli are fully susceptible. Of greatest
importance is resistance to the two principal first-line drugs,
isoniazid and rifampicin (that is, MDR-TB). The introduction of
resistance testing, second-line drugs, longer treatment regimens
(12 to 18 months), and rigorous bacteriological and clinical
monitoring all increase program costs without necessarily ensur-
ing high cure rates (equal to or greater than 85 percent). Indeed,
achieving the same cure rates for MDR-TB patients as for
patients carrying fully susceptible strains may not be possible.
The cost-effectiveness of this component of a TB control pro-
gram is therefore lower by an amount that depends on the nature
of the resistance, the methods of testing and monitoring, and the
choice of regimen. The higher costs and lower cure rates associ-
ated with treating drug-resistant TB are part of the argument for
preventing the spread of resistance in the first place, as can be
investigated with models of selection and transmission (Dye and
Espinal 2001; Dye and others 2002; Dye and Williams 2000).
Suarez and others (2002) have investigated the cost-effectiveness
of managing drug-resistant TB in Peru, but because studies in
other settings have yet to be published, an empirical overview is
not yet possible. Further data will be available from studies in
Estonia, the Philippines, and Russia in 2005.
Treatment of HIV Coinfection
Antiretroviral therapy for HIV-positive individuals is unlikely to
prevent a large fraction of TB cases unless treatment can be
given shortly after HIV infection is acquired (Sonnenberg and
others 2005; Williams and Dye 2003). In general, antiretroviral
therapy is likely to be most effective, not in reducing TB inci-
dence, but in extending the life expectancy of HIV-positive
patients successfully treated for TB (Friedland and others 2004).
Antiretroviral therapy and DOTS are formally synergistic,
because without undergoing both together, HIV-infected TB
patients have a short life expectancy, typically less than five years.
Where the prevalence of HIV infection has been rising
quickly, as in eastern and southern Africa, even the most ener-
getic programs of TB chemotherapy may not be able to reverse
the rise in TB incidence. However, mathematical modeling indi-
cates that, even in the midst of a major HIV epidemic, early
detection and cure are the most cost-effective ways of minimiz-
ing TB cases and deaths (Currie and others, 2005). One reason
is that DOTS programs treat all TB cases, not just those linked
with HIV. The alternatives—the prevention of HIV infection,
TLTI, and antiretroviral therapy—are less promising strategies
to control TB, at least for the coming decade, although they
could be used in combination with DOTS.
Active Case Finding
The DOTS strategy is based on passive case detection for three
reasons: (a) the majority of incipient TB cases develop active
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smear-positive, infectious disease more quickly than any rea-
sonable interval between successive rounds of mass screening
for TB symptoms or x-ray abnormalities; (b) the majority of
patients severely ill with a life-threatening disease are likely to
seek help quickly (Toman 1979); and (c) countries that have
not yet implemented effective systems for passive case detec-
tion are not in a position to pursue cases more actively. The
drawback of passive case finding is that the delays to diagnosis
among symptomatic patients are often long, and health ser-
vices never see some patients. To shorten delays and increase
the proportion of cases detected, studies of risk can identify
subpopulations in which TB tends to be relatively common.
Systematic surveys of these subpopulations for active TB may
be logistically feasible and affordable. The target populations
include individuals infected with HIV, refugees (Marks and
others 2001), contacts of active cases (Claessens and oth-
ers 2002; Noertjojo and others 2002), health workers
(Cuhadaroglu and others 2002), and drug users and prisoners
(Nyangulu and others 1997). Despite the practical possibili-
ties and the potential effect on transmission (Murray and
Salomon 1998), active case finding is rarely done in high-
burden countries, where the emphasis is still on implementing
the basic DOTS strategy.
Case Finding and Treatment in the Private Sector
It is well known that many TB patients first seek treatment from
private practitioners and that diagnosis and treatment in the
private sector often do not meet internationally accepted stan-
dards (Uplekar, Pathania, and Raviglione 2001). A new scheme
to deliver DOTS through the private sector (Public-Private Mix
DOTS) operates through the provision of free drugs, by infor-
mation exchange and patient referral, and with some financial
support from participating governments. Two pilot projects in
Hyderabad and Delhi, India, improved case-detection rates by
26 percent and 47 percent, respectively, and maintained treat-
ment success close to the target of 85 percent (WHO 2004b).
Other such projects are under way elsewhere in India as well as
in Bangladesh, Indonesia, Nepal, the Philippines, and Vietnam
(WHO 2004d).
Outpatient and Community-Based Treatment
Early studies of the cost-effectiveness of TB control found that
full ambulatory treatment, eliminating hospitalization during
the first two months (intensive phase), was cheaper and did not
compromise cure rates (de Jonghe and others 1994; Murray
and others 1991). Partly as a result, ambulatory treatment has
become the standard of care in many high-burden countries.
The natural extension, to home- and community-based treat-
ment, has proved to be just as effective in several African set-
tings, and even lower in cost (Adatu and others 2003; Dudley
and others 2003; Floyd and others 2003; Floyd, Wilkinson, and
Gilks 1997; Moalosi and others 2003; Okello and others 2003;
Sinanovic and others 2003; Vassall and others 2002; Wilkinson,
Floyd, and Gilks 1997). Various schemes have been used to
provide TB care in the community, in which nongovernmental
organizations, volunteers (Okello and others 2003), or
appointed “guardians” (Floyd and others 2003) supervise
treatment, sometimes with financial incentives (Sinanovic and
others 2003). Consequently, community-based care is being
adopted in some countries (for example, Uganda) as standard
procedure.
Integrated Management of Tuberculosis and Other 
Respiratory Illnesses
Surveys in nine countries found that up to one-third of patients
over five years of age attending primary health centers had res-
piratory symptoms, of whom 5 to 10 percent were TB suspects,
but only 1 to 2 percent had TB (WHO 2004e). Because TB
is rare among respiratory diseases, comanaging TB with other
conditions has clear advantages. The purpose of the WHO’s
Practical Approach to Lung Health (PAL) project is to encour-
age a syndromic approach to management of patients, to stan-
dardize health service delivery through the development and
implementation of clinical guidelines, and to promote the nec-
essary coordination within national health services. Preliminary
investigations in the Kyrgyz Republic and Morocco suggest that
PAL projects can improve the accuracy of diagnosis, encourage
better practice in prescribing drugs, and strengthen primary
care. However, a full analysis of costs and effects in the nine-
country study remains to be done.
COST-EFFECTIVENESS OF INTERVENTIONS
AGAINST TUBERCULOSIS
Some questions about investing in TB control are broad and
strategic (for example, should money be spent on the control
of TB rather than on the control of some other condition?);
others are specific and technical (for example, which laboratory
diagnostic procedures should be used?). On whatever level the
question is posed, cost-effectiveness analysis (CEA) has become
a prominent method for evaluating and choosing among dif-
ferent health interventions.
Background
Between 1980 and 2004, 32 studies of the cost-effectiveness of
TB control were published from the low- and middle-income
countries considered by the Disease Control Priorities Project
(table 16.1; online annex 3 summarizes the 32 studies that have
been published according to the country and year of publica-
tion, the question being addressed, the strategies compared, the
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subjects and costs considered, the effectiveness of measures
used, whether or not transmission is considered, and the main
results and conclusions). Almost all of these studies (28, or
88 percent) have concerned ways of finding, diagnosing, and
treating patients with active TB, and most (18, or 56 percent)
have been done in eight countries in Sub-Saharan Africa (Floyd
2003). Three studies (all in Sub-Saharan Africa) have investi-
gated TLTI, and one study in Indonesia has examined BCG
vaccination. The principal findings are that short-course
chemotherapy for active TB is a comparatively cost-effective
intervention and one of the most cost-effective of all health
interventions. TB patients can be treated more cheaply and
conveniently outside hospitals on an ambulatory basis, by
health staff or with the help of family and community
members, without compromising the success of treatment.
Supplementary methods, such as standardized second-line
drug treatment for MDR-TB, appear to be affordable and cost-
effective in some settings.
What does not emerge from this compilation of data is a
comprehensive overview of the value for money provided by
current and potential interventions against TB in all major
regions of the world, expressed using a common measure of
effectiveness and based on a consistent approach to the evalua-
tion of transmission. (The returns on investment in infectious
disease control include the immediate benefits to individuals
treated—for example, those vaccinated or given drug therapy—
plus the longer-term benefits gained by preventing secondary
cases through reduced transmission.) Little work has been done
in China, India, and other large countries in Asia, even though
Asia carries the largest burden of TB, and only limited informa-
tion is available for Europe and Central Asia, Latin America and
the Caribbean, and the Middle East and North Africa. Of the
32 studies, only 10 used a measure of effectiveness that allows
comparison with other diseases (table 16.2), and only 9
attempted to include an estimate of the benefits gained from
reduced transmission (table 16.1). The benefits from reduced
transmission are usually assessed through mathematical model-
ing (using computer simulations) for a given epidemiological
situation, an approach that produces specific solutions for each
setting rather than results that are generally applicable. In addi-
tion, although the benefits from prevented transmission are
lower when TB is endemic, existing studies do not make a clear
distinction between the cost-effectiveness of interventions in
epidemic (outbreak) and endemic situations.
Methods
In this study, a general analytical framework was used to eval-
uate the total costs and total effects (defined as cases prevent-
ed, deaths averted, and DALYs gained) of the principal
interventions against TB across six regions of the world (see
online annexes 4–7 for further details). A dynamic infectious
disease model (online annex 4) was used to derive general
formulas for calculating the cost-effectiveness of interventions
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Table 16.1 Number of Studies on the Cost-Effectiveness of TB Control by Topic and Region, 1980–2004
East Asia Europe and Latin America Middle East Number that
and the Central and the and Sub-Saharan consider
Intervention Pacific Asia Caribbean North Africa South Asia Africa World Total transmission
BCG vaccination 1 0 0 0 0 0 0 1 0
TLTI 0 0 0 0 0 3 0 3 3
Treatment of 4 2 0 1 0 2 0 9 4
active disease: 
the DOTS strategy
Variations on DOTS:
Management of drug- 0 0 1 0 0 1 0 2 1
resistant disease
Treatment of HIV 0 0 0 0 0 1 0 1 0
coinfection
Active case finding 0 1 1 0 0 4 1 7 1
and diagnosis
Outpatient and 0 0 0 0 2 7 0 9 0
community-based
treatment
All interventions 5 3 2 1 2 18 1 32 9
Source: Authors.
to control endemic (online annex 5) and epidemic (online
annex 6) TB in a wide variety of settings. The formulas are
approximate, but they are simple and able to provide insights
into the strategies that give value for money under a wide
variety of epidemiological circumstances. The model was then
supplied with cost and efficacy data (online annex 7) for
each of the six World Bank regions for four main groups of
interventions:
• immunization with BCG (proportion of infants, m,
assumed to be protected against severe, noninfectious child-
hood TB only), or a new vaccine that prevents infection and
progression to pulmonary and extrapulmonary TB in chil-
dren and adults
• isoniazid treatment of latent TB infection (TLTI, given at
per capita rate ), for people infected with M. tuberculosis,
with or without HIV coinfection and with or without the
use of radiography to exclude patients with active disease 
• short-course chemotherapy, delivered as a component of
the DOTS strategy, for smear-positive or smear-negative
pulmonary disease and extrapulmonary disease (with a
combination of drugs given at per capita rate ), and for
patients infected with HIV, with or without supporting anti-
retroviral therapy
• treatment for MDR-TB using a standardized regimen
including first- and second-line drugs or using individual-
ized regimens of first- and second-line drugs that are tai-
lored to each patient’s drug susceptibility pattern.
Costs were considered from a health system or provider per-
spective. They were calculated by combining estimates of the
quantities of resources required for each intervention (per
patient or per person treated) with the unit prices of those
resources (in 2001 U.S. dollars) using the cost categories and
unit prices defined in the Disease Control Priorities costing
guidelines.
COST-EFFECTIVENESS OF MANAGING 
ENDEMIC TUBERCULOSIS
The primary problem in global TB control is the management
of disease in countries where incidence has been roughly stable
for many years (that is, where TB is endemic).
Cost per Case Prevented
In monetary terms, the cost-effectiveness (C/E) of a new pro-
gram of treatment for active infectious disease (here defined as
sputum-smear positive), per case prevented, can be calculated
from C/E ? P/kT, where P is the cost of treatment,  is the effi-
cacy of treatment, k is a constant determined by the mode of
action of the intervention, and T is the duration of the inter-
vention in years (online annex 5). The cost per case prevented
is mostly in the range of US$1,000 to US$10,000, depending on
the region of the world (figure 16.1). The exception is Europe
and Central Asia, where costs are high because patients are cur-
rently treated for long periods in hospitals rather than on an
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Table 16.2 Number of Studies on the Cost-Effectiveness of TB Control by Effectiveness Measure and Intervention, 1980–2004
Cases detected Cure or
or cases Cases successful Deaths Years of QALYs DALYs 
Intervention diagnosed prevented treatment rate prevented life saved gained gained
BCG vaccination 0 1 0 1 0 0 0
TLTI 0 3 0 0 0 1 0
Treatment of active disease: 0 1 6 1 3 0 1
the DOTS strategy
Variations on DOTS: 
Management of drug- 0 0 2 2 0 0 1
resistant disease
Treatment of HIV 0 0 0 1 0 0 0
coinfection
Active case finding and 5 0 0 0 1 0 2
diagnosis
Outpatient and community- 0 0 10 0 0 1 0
based treatment
All interventions 5 5 18 5 4 2 4
Source: Authors.
QALY  quality-adjusted life year.
Note: The total for all interventions is greater than the number of studies because some studies use more than one measure of effectiveness.
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Figure 16.1 Cost-Effectiveness of Different Interventions against Endemic TB
ambulatory basis. These cost-effectiveness ratios (CERs) are
computed from the total costs and total effects of treatment.
Costs are therefore the same as the incremental costs for new
programs. If costs and effects are compared with those of a pre-
vious treatment program, CERs for the treatment of active dis-
ease are often negative; that is, the program sooner or later
saves money, as well as preventing TB cases. The positive CERs
reported here for new treatment programs are, in this sense,
upper estimates.
The cost of TLTI per active case prevented also depends on
the initial incidence rate (I) and is calculated from C/E ? P/kIT
(online annex 5). The cost is substantially higher than that for
the treatment of active TB: US$20,000 to US$40,000 when
radiography is used to exclude patients with active disease,
but it is less (US$13,000 to US$20,000) if active TB can be
ruled out on the basis of symptoms and clinical examination
(figure 16.1). TLTI is less cost effective than the treatment of
active TB because preventive treatment would be given to
latently infected individuals, most of whom were not recently
infected and who are at small risk of developing active disease.
In an endemic setting, there is no feasible method of identify-
ing individuals who have recently acquired infection and who
will proceed rapidly to active TB.
A new vaccine that prevents infection and, hence, the
progression to pulmonary TB among people who were previ-
ously uninfected would be extremely competitive (US$90 to
US$200) per case prevented if the costs were the same as
those for BCG. BCG is cheap to manufacture and administer
(US$1 to US$3 per dose) but less cost-effective (US$2,000 to
US$8,500 per case prevented) than the treatment of active dis-
ease because it is assumed to protect against severe forms of
childhood TB only and because it does not affect transmission
(figure 16.1).
Cost per Death Prevented and DALY Gained
The wider benefits of treating active TB are revealed when
allowing for the additional reduction in case fatality. For a
10-year program of treatment for infectious TB, the cost per
death prevented is typically US$150 to US$750, and the cost
per DALY gained is US$5 to US$50 for all regions except
Europe and Central Asia (figure 16.1). When TB is close to the
endemic equilibrium, the extra benefits gained from reducing
transmission under DOTS are small: the cost per DALY gained
is only 60 percent higher when transmission benefits are
excluded. The treatment of noninfectious TB is less cost-
effective (US$60 to US$200 per DALY gained), not primarily
because transmission is unaffected, but because the case fatality
of untreated smear-negative and extrapulmonary disease is
relatively low. Treating infectious MDR-TB is between two and
ten times more costly than treating drug-susceptible TB per
death prevented (greater than US$2,000), or per DALY gained
(greater than US$90), assuming resistant bacilli are as trans-
missible and pathogenic as susceptible bacilli.
BCG vaccination is not much less cost-effective than the
treatment of active disease (US$40 to US$170 per DALY
gained; higher where the risk of infection is lower). If a new
vaccine with 75 percent efficacy against pulmonary disease and
other forms of TB costs the same as BCG, it would be almost
as cost-effective (US$20 to US$100 per DALY gained) as the
ambulatory treatment of active TB. As expected from the pre-
ceding analysis, TLTI is much more expensive than all other
options (US$5,500 to US$26,000 per DALY gained) and most
costly where the death rate from TB among adults is already
relatively low—for example, because an effective DOTS
program already exists. Although the cost-effectiveness of
each intervention varies among regions, the variation among
strategies is much greater, whatever the outcome measure
(figure 16.1).
COST-EFFECTIVENESS OF MANAGING 
TUBERCULOSIS OUTBREAKS
The basic case reproduction number, R0, is a ready-made epi-
demiological tool for relating effort and reward in the manage-
ment of outbreaks. R0 is the average number of secondary cases
generated by a primary case introduced into a previously unin-
fected population (Anderson and May 1991). No country is
presently free of TB, but some countries have recently suffered
“epidemic” increases in incidence from previously low levels.
The algebraic expression of R0 for TB reveals how the various
components of a disease’s natural history and the different
kinds of intervention interact with each other to influence
transmission and the generation of new cases (online annex 4).
For example, the cost-effectiveness of chemotherapy per M.
tuberculosis generation is C/E  P/R0, where  is the number
of TB patients treated per prevalent case per unit time, and  is
the proportion of new cases that is infectious.
The biggest resurgences of TB in recent history have been
driven by the spread of HIV in Africa and are linked to the rise
of drug resistance in former Soviet republics; this analysis is
confined to interventions associated with these two phenomena
(figure 16.2; online annex 6). Indeed, in this study, interventions
related to TB with HIV are considered only in the epidemic
context.
If multidrug-resistant strains of M. tuberculosis are assumed
to have the same intrinsic transmissibility and pathogenicity as
drug-susceptible strains, and given the spread of MDR-TB as
an independent epidemic (Dye and Williams 2000), then treat-
ment of MDR-TB with a standard regimen including second-
line drugs is more costly per DALY gained than treatment
of fully susceptible disease in Sub-Saharan Africa, but it is
marginally less costly than TLTI (with an x-ray screen) over
most rates of case detection and treatment (online annex 6).
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Note: Five interventions used in the management of TB epidemics that are linked with HIV and MDR-TB (TLTI for people coinfected with TB and HIV, treatment of infectious MDR-TB
with a standard or individual regimen, treatment of HIV-infected TB patients with TB drugs, treatment of HIV-infected TB patients with TB and antiretroviral drugs) are compared with
two standard methods (TLTI, with active disease excluded by x-ray screen, and treatment of active infectious disease, allowing for transmission). Cost-effectiveness ratios (plotted
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gray line in the third figure marks a cost-effectiveness of US$1 per day of healthy life gained. Error bars are 90 percent confidence limits.
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Figure 16.2 Cost-Effectiveness of Managing Epidemic TB
For example, at the fixed rate of treatment used to generate
figure 16.2, treatment of MDR-TB with a standard regimen
costs US$91 to US$846 per DALY gained, depending on the
region, as compared with US$6 to US$31 for the treatment of
drug-susceptible TB. The treatment of MDR-TB with regimens
tailored to the resistance patterns of individual patients is more
costly but also more efficacious than standardized treatment
for MDR-TB and, therefore, almost equally cost-effective under
this set of assumptions.
TB patients infected with HIV are more costly to treat per
DALY gained than HIV-negative patients, either without anti-
retroviral therapy (low cost, short life expectancy) or with such
therapy (high cost, long life expectancy). TLTI is a more attrac-
tive option for the management of epidemic TB than for
endemic TB (compare figures 16.1 and 16.2), because during
an outbreak, TLTI is directed at recent rather than remote
infection. TLTI is even more cost-effective in the control of TB
and HIV coinfection, because it prevents the rapid breakdown
to active disease caused by immunodeficiency.
These results are indicative rather than definitive, because
the calculations assume, among other things, that HIV-infected
populations exist in isolation; in reality, HIV-infected people
also acquire TB infection from TB patients who are not infected
with HIV. Neither does this analysis address all the important
questions about managing outbreaks of drug-resistant or HIV-
related TB. Fuller investigations should assess, for example, the
benefits to whole populations of giving antiretroviral therapy
to HIV-infected individuals before they develop TB and of
investing in DOTS to prevent multidrug-resistant epidemics
from arising in the first place.
SUMMARY OF COST-EFFECTIVENESS ANALYSES
Box 16.1 summarizes the results of these calculations of the
cost-effectiveness of managing epidemic and endemic TB. The
findings are one justification for maintaining and expanding
DOTS programs, on the basis of SCC for patients with active
disease, as the dominant mode of TB control around the world.
BCG vaccination and the treatment of MDR-TB (standard or
individualized regimens) or HIV-infected TB patients (with or
without supporting antiretroviral therapy) are more costly in
absolute terms, but they typically cost less than US$1 per day of
healthy life gained, which is less than the average economic
productivity of workers in the least developed countries. TLTI
appears to be relatively poor value for money, even though this
analysis assumes that one course of treatment prevents active
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Cost-Effectiveness of TB Interventions: Main Findings
Box 16.1
• The cost effectiveness of TB control depends not only
on local costs but also on the local characteristics of TB
epidemiology (for example, epidemic or endemic, low
or high rates of HIV infection and drug resistance) and
on the rate of application of any chosen intervention.
• Short-course chemotherapy for the treatment of infec-
tious and noninfectious TB patients through the DOTS
strategy is highly cost-effective for the control of either
epidemic or endemic TB (US$5 to US$50 per DALY
gained, for regions excluding Eastern and Central
Europe). When a new treatment program is compared
with a previous program, DOTS often saves money as
well as preventing cases and deaths.
• Some variations on DOTS are less cost-effective but
still good value for money, including the treatment of
patients with MDR-TB (standard or individualized
drug regimens) and with HIV infection (with or with-
out supporting antiretroviral therapy). For these addi-
tional interventions, the cost per DALY gained is less
than the annual average economic productivity per
capita in the least developed countries.
• Even with relatively favorable assumptions, the treat-
ment of latent TB infection where TB is endemic and
populations are unaffected by HIV is the least cost-
effective of the interventions examined here (US$5,500
to US$26,000 per DALY gained). TLTI is more cost-
effective during outbreaks (US$150 to US$500 per
DALY gained) and for people who are coinfected with
TB and HIV (US$15 to US$300 per DALY gained).
• BCG vaccination to prevent severe forms of childhood
TB is much less effective than SCC but nearly as cost-
effective (US$40 to US$170 per DALY gained).
• A new vaccine that prevents pulmonary TB with high
efficacy (equal to or greater than 75 percent) would be
more cost-effective than BCG if the cost of immuniza-
tion were the same as BCG (US$20 to US$100 per
DALY gained).
• For any intervention with the potential to cut trans-
mission (that is, excluding BCG vaccination), control
of epidemic disease produces more favorable cost-
effectiveness ratios than control of endemic disease,
because the benefits gained from reduced transmission
are greater during outbreaks.
Source: Authors.
TB for life. TLTI is more cost-effective in epidemic than in
endemic settings, and it is more cost-effective when it is used
to treat individuals coinfected with TB and HIV. A new, high-
efficacy vaccine that prevents infection and the progression
to pulmonary TB in adults, to be directed at the control of
endemic TB, would be more cost-effective than BCG at the
same price and almost as cost-effective as SCC.
Averted and Avertable Burden of Tuberculosis
Trends in case notifications can be used, judiciously, to assess
regional and global trends in TB incidence, but no satisfactory
large-scale analysis has been done of the number of cases
prevented by chemotherapy (as distinct from the reductions
in transmission and susceptibility associated with improved
living standards). One approach to evaluating the averted and
avertable burden of TB begins with the observation that
86 percent of the years of healthy life lost that are attributable
to TB are from premature death, and only 14 percent are from
illness. Because DALYs lost are dominated by premature death,
a conservative estimate of the burden of TB alleviated can be
obtained in terms of the number of deaths and associated
DALYs gained, regionally and globally, since the introduction
of the DOTS strategy in 1991.
Figure 16.3 is derived from recent estimates of cases and
deaths and their trends by region, including those attributable
to HIV coinfection (Corbett and others 2003; WHO 2004c).
In the MDG baseline year, 1990, approximately 1.5 million TB
deaths (28 per 100,000) occurred. BCG vaccination saved
roughly 650,000 deaths from extrapulmonary TB among
children between 1990 and 2003. If chemotherapy is assumed to
reduce only the case-fatality rate and to have no effect on trans-
mission and incidence, 23 million deaths (44 percent) would
have been saved in non-DOTS treatment programs. The expan-
sion to 45 percent case-detection rate under DOTS during the
same period saved an estimated 2.3 million (?5 percent) addi-
tional deaths, the largest numbers in Sub-Saharan Africa
(1.1 million), East Asia and the Pacific (558,000), and South Asia
(408,000). Further analysis shows that, if 70 percent of TB cases
(smear positive and smear negative) can be treated under DOTS
before MDG target year 2015, an estimated 1.9 million TB
deaths (26 per 100,000) will occur in that year, a greater num-
ber than in 1990, but a 7 percent lower death rate per capita
(Dye and others 2005).
The calculations for Africa assume that treatment cures TB
in the majority of HIV-infected patients even though, without
antiretroviral therapy, many of these patients will die anyway.
Despite these favorable assumptions, the number of TB deaths
was evidently still rising in Africa in 2003, whereas it was falling
in Asia, aided by the large programs of DOTS expansion in
China (1991–97) and India (from 1998).
Reducing the TB death rate sufficiently to meet the MDG
target requires a significant cut in incidence, as well as in case
fatality. An extension of this assessment suggests that case detec-
tion must reach at least 70 percent and the TB incidence rate
must fall by 5 to 6 percent annually between 2003 and 2015
(Dye and others 2005). For the world, excluding Sub-Saharan
Africa and former Soviet republics, the incidence rate would
have to fall at a more modest 2 percent per year.
New diagnostics, drugs, and vaccines would also help reduce
the global TB burden more quickly. The most desirable of these
is a vaccine that prevents pulmonary disease, whether or not
vaccination subjects are already infected (a pre- or postexposure
vaccine), and that confers lifetime immunity (Andersen 2001;
Fordham von Reyn and Vuola 2002; McMurray 2003; Young
and Stewart 2002). A new vaccine with high efficacy against
pulmonary TB would almost certainly change immunization
practice: mass vaccination campaigns among adults (rather
than infants) would have dramatic effects, going far beyond the
expectations of DOTS programs (figure 16.4; Dye 2000). A
postexposure vaccine that stops progression to disease among
those already infected, as well as preventing infection in others,
would have greater effect than a preexposure vaccine that only
prevents infection (Lietman and Blower 2000). However, such
calculations are at present highly speculative, because the mode
of action and efficacy of any new vaccine is unknown.
Economic Benefits of Tuberculosis Control
Preventing TB deaths brings no savings in the costs of TB con-
trol unless it is accompanied by a reduction in incidence so that
fewer patients require treatment. The prompt and effective
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Figure 16.3 Estimated Number of TB Deaths Worldwide under
Various Hypothetical Scenarios and the Estimated Effect of DOTS
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treatment of active disease is almost certainly reducing trans-
mission around the world, but because the effect on incidence
is necessarily slow, it has been hard to quantify in all but a few
countries, notably Peru (Suarez and others 2001).
The monetary savings implied by a reduction in incidence
of one-quarter (26 percent) between 2000 and 2015—which
may be enough to achieve the MDG targets—could be magni-
fied or diminished by adjustments to the DOTS strategy. On
the one hand, without compromising cure rates, chemotherapy
can be delivered more cheaply to outpatients than inpatients
and with less reliance on x-ray diagnosis and surgical proce-
dures. On the other hand, various additions to DOTS—contact
tracing, active case finding, antiretroviral therapy for HIV-
infected patients, second-line drugs for patients carrying resist-
ant bacilli, or joint public-private schemes for the management
of TB—might be desirable but more costly per year of healthy
life gained. Whether the savings made by reducing incidence
and improving efficiency offset the costs of DOTS add-ons will,
therefore, depend on the setting.
Besides the possibility of reducing diagnostic and treatment
costs, improved health and longevity yield other economic
benefits, but the quantification of those benefits is always con-
troversial. This difficulty is reflected in the limited number of
cost-benefit analyses of TB control; among the few examples,
one detailed study in India estimated the potential societal ben-
efits of DOTS to be worth US$8.3 billion in 1993–94, or 4 per-
cent of the gross domestic product (Dholakia 1996). Without
attempting to extend such analyses here, we note that the
preceding results also imply that large-scale treatment programs
for TB are likely to give net returns on investment or at least to
appear to be good value for money in ways that go beyond the
arguments from cost-effectiveness (Jack 2001).
The analysis earlier in this chapter showed that SCC typi-
cally costs up to US$30 per DALY gained for the treatment of
infectious TB and up to US$200 per DALY gained for the treat-
ment of noninfectious TB (excluding Europe and Central
Asia). These figures can be compared with a recent estimate of
US$1.5 billion as the annual global cost of treating 70 percent
of cases with 85 percent cure (WHO 2004c). Reaching these
targets would prevent approximately 2.1 million of all the TB
deaths expected if no treatment were available in 2003, includ-
ing 391,000 deaths prevented by DOTS (figure 16.3). Because
each TB death prevented gains approximately 20 DALYs
(WHO 2002b), the total cost per DALY gained would be about
US$36. This rough calculation excludes any benefits in reduced
transmission but includes the costs of treating smear-negative
and extrapulmonary TB and is of the same order of magnitude
as the results from CEA.
However the calculation is done, the cost of gaining a year
of healthy life under DOTS is substantially less than the annual
average productivity per capita in the low-income (gross
national income [GNI] less than or equal to US$735) or least
developed (GNI average US$290, http://www.worldbank.org)
countries, and it is probably less than the marginal productiv-
ity of labor in the poorest communities. It is also less than
twice the average annual income per capita, which has also
been proposed as a benchmark for assessing whether an inter-
vention is cost-effective (Garber and Phelps 1997). Moreover,
it is less than the World Bank’s definition of absolute poverty
(living on US$1 per day or less, close to average GNI per capita
for the least developed countries) and is certainly less than the
monetary values that are typically placed on the value of a
human life year (for example, a life was valued at US$100,000
by the 2004 Copenhagen Consensus panel, http://www.
copenhagenconsensus.com). All these comparisons suggest
not only that the basic DOTS strategy, and perhaps even an
enhanced DOTS strategy, are cost-effective but that they also
have very favorable cost-benefit ratios.
RESEARCH AND DEVELOPMENT
The preceding review and analysis suggest at least six areas for
economic and epidemiological research and development:
1. DOTS expansion. Refinement of existing cost estimates of
scaling up DOTS programs to reach and move beyond
targets for case detection (70 percent) and cure (85 percent)
in the poorest countries—notably in Africa—through more
comprehensive planning and budgeting exercises. The
analyses should include the costs of developing fully staffed
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health services, with expanded and renovated infrastructure
and improved management capacity where necessary, and
the costs of the new initiatives that will be required to
improve case detection and cure rates.
2. Service delivery. Assessment of the potential for health
service restructuring to detect, diagnose, and treat TB
patients more efficiently through syndromic management of
respiratory diseases at primary health centers and through
collaborations between public and private health services,
between different parts of the public sector health service,
and between TB and HIV/AIDS control programs.
3. Complementary strategies. Further investigation of the costs
and effectiveness of strategies that are potentially comple-
mentary to DOTS, including active case finding and TLTI in
high-risk populations, and the management of drug resist-
ance and of patients infected with HIV.
4. Impact and targets. Evaluation of the actual and potential
effects of the tools (mostly drugs) now being used for TB
control. This research requires a better understanding of the
ways human population density, age structure, migration,
HIV coinfection, and drug resistance affect TB epidemi-
ology. The analyses should check the internal consistency
of international targets for the implementation and effect of
chemotherapy programs, as defined by the MDGs. The
analyses should also make better use of the rich body of
routine surveillance data collected by all national TB control
programs around the world.
5. Risk factors. Assessment of the reductions in TB cases and
deaths that could be made by reducing exposure to environ-
mental risk factors, notably indoor and outdoor air pollu-
tion, tobacco smoking, and malnutrition. These risk factors
affect the establishment of infection, the progression to
active disease, and the outcome of treatment.
6. New diagnostics, drugs, and vaccines. A sensitive and specific
test for active TB that is cheap and simple to use at the first
point of contact between patients and health services would
be a major advance in diagnosis. Mycobacterial culture,
which detects a higher proportion of active TB patients than
sputum-smear microscopy, is a prerequisite for screening
for drug resistance. However, present culture methods are
slow, taking four to six weeks to obtain a result. Technology
based on phage amplification and nucleic acid amplification
can establish whether cultures are positive in days or hours,
but this technology needs to be packaged for use in devel-
oping countries (Albert and others 2002, 2004; Johansen
and others 2003; Woods 2001). The tuberculin skin test
is being superseded in many developed countries by more
specific methods for detecting infection (Doherty and
others 2002; Pai, Riley, and Colford 2004). A test that can
predict who will progress from latent to active disease, as yet
hypothetical, would greatly increase the feasibility of treat-
ing latent infection.
Among a growing list of new vaccine antigens (Fruth and
Young 2004), three of the most promising are now undergo-
ing phase 1 safety trials in humans. One trial has evaluated
mycobacterial antigen 85, delivered as a recombinant smallpox
vaccine (Goonetilleke and others 2003). Another is testing a
live attenuated BCG bacterium (rBCG30) that overexpresses
antigen 85B protein and that provides guinea pigs with greater
protection than BCG alone (Horwitz and others 2000). A third
trial is assessing a fusion protein of two different antigens in
adjuvant, referred to as Mtb72f, that is likely to be used as a
booster to either BCG or rBCG30 (Reed and others 2003).
Compounds that could form the basis of new drugs and
new drug regimens include the nitroimidazopyran PA-824.
Experiments with a mouse model of TB have shown that
PA-824 has bactericidal activity similar to that of isoniazid and
sterilizing activity that may rival that of rifampicin and that it
is particularly active against dormant bacilli.
Among the most important recent discoveries is a
diarylquinoline with a novel mode of action on the ATP syn-
thase of M. tuberculosis that powerfully inhibits both drug-
sensitive and drug-resistant strains of bacilli (Andries and
others 2004). Alongside these laboratory studies, analytical
and operational research are needed to find out what kinds of
new tools will give the best returns on investment. Investigations
of this kind will contribute to the introduction of new vac-
cines, drugs, and diagnostics and will inform the work of the
Foundation for Innovative New Diagnostics (http://www.
finddiagnostics.org), the Global Alliance for TB Drug
Development (http://www.tballiance.org), and the AerasGlobal
TB Vaccine Foundation (http://www.aeras.org).
CONCLUSIONS
After more than a decade of climbing incidence rates in Africa
and former Soviet republics, the global TB epidemic appears
once again to be on the threshold of decline. The spread of HIV
and drug resistance, respectively, in those two regions has exac-
erbated the problems of TB control, but at the same time it
has helped keep TB on the international public health agenda.
The global incidence rate was still rising in 2003, but more
slowly each year. This slowdown is not only (or even mainly)
because of direct intervention through DOTS programs but
because HIV epidemics are approaching peak levels in Africa
and because incidence is now starting to fall again in some
former Soviet republics, including Russia. Where TB incidence
is already falling, prevalence and death rates should be drop-
ping more quickly, although little evidence demonstrates this
decrease yet.
The prompt diagnosis and treatment of active TB has been
the mainstay of TB control and will continue to be so for the
foreseeable future. Short-course chemotherapy, delivered
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through the DOTS strategy, is, at typically US$5 to US$350 per
DALY gained, the most cost-effective among current methods
for the management of TB, and in most high-burden countries,
the cost is toward the lower end of this range. A comparison of
the costs of treating active TB with the costs of running a pre-
vious program suggests that DOTS could actually save money
in the long run. In addition, DOTS provides an operational
framework for the introduction of more specialized methods
in certain risk groups. The extensions to DOTS investigated
here include the treatment of MDR-TB with second-line drugs,
preventive therapy (TLTI) during outbreaks and for people
coinfected with M. tuberculosis and HIV, and antiretroviral
therapy for HIV-infected TB patients. Those interventions cost
more than the basic DOTS strategy but are still less than a
dollar for each day of healthy life gained, which provides an
economic argument for their integration into enhanced DOTS
programs.
Although the analyses in this chapter show that DOTS and
its extensions are good value for money, they conceal various
features of health systems, as yet poorly defined, that may facil-
itate the implementation of treatment programs. For example,
if broader investment in the health sector is needed before TB
control programs can work in some parts of some countries,
then the full cost of DOTS could be greater. By contrast, a more
integrated approach to the management of TB and other respi-
ratory diseases in primary health facilities could lead to cost
savings. Those possibilities have not yet been investigated.
The only development that could radically alter the current
approach to TB control—shifting the emphasis from cure to
prevention—is the discovery of a new vaccine that protects
adults against infectious pulmonary disease. Whether such a
vaccine would be more or less cost-effective than BCG (US$40
to US$1,600 per DALY gained) depends on price and efficacy,
but the potential epidemiological effect would be far greater
than that of BCG, perhaps justifying mass adult vaccination. If
research and development proceed according to plan, a new
vaccine of some kind could be licensed between 2010 and 2015.
New drugs and diagnostics should be available earlier, shorten-
ing the delay to, and duration of, treatment.
Although cost-effectiveness studies show that DOTS is a
good investment, they do not formally show that the strategy is
affordable. The analytical difficulty is that CEA does not solve
the practical problem of how to allocate money to TB control
in combination with other interventions, or even how to com-
bine different approaches to TB control (Tan-Torres Edejer and
others 2004). Interpreted literally, CEA says that the best return
on total investment is obtained by ranking interventions
according to CER and then fully implementing each interven-
tion, from smallest to largest CER, allowing for diminishing
returns, until the total budget is spent. This method is unlikely
to lead to a balanced health care portfolio in the poorest
countries. Besides, the evidence is rarely available to carry out
such a complete analysis. The results of CEA are therefore
typically used more informally, along with other evidence and
constraints, when a mix of health interventions is chosen.
Although this problem will recur in discussions about allo-
cating health budgets, the case for large-scale programs of TB
treatment has now been accepted in many parts of the world.
That is the fruit of more than 10 years’ work on burden, cost,
efficacy, effectiveness, and cost-effectiveness. The governments
of the less poor members of the group of 22 high-burden coun-
tries have demonstrated that they can budget for, and provide,
most of the funds needed to reach target levels of case detection
and cure (WHO 2004c, 2005). Some of the poorer countries
among the 22 are now receiving sufficient external assistance
to fill the gaps in their budgets for TB control, principally
from the Global Fund to Fight AIDS, Tuberculosis, and
Malaria. Consequently, the total reported budget deficit for the
high-burden countries in 2005 was remarkably small—just
US$119 million—and concentrated in the poorest countries
(WHO 2005).
From those findings and observations arise two key ques-
tions for global TB control: If the estimated budget gap is filled,
would the money be enough to ensure that enhanced DOTS
programs reach 70 percent case detection and 85 percent
cure—and by when? And if those targets are reached, will the
effort be sufficient to achieve the MDG objectives of halving
prevalence and death rates by 2015?
As yet, there are only partial answers. On the costs, it is clear
that, by moving treatment out of hospitals and into the com-
munity, DOTS can often be made cheaper and more conven-
ient for patients and health services without compromising
treatment outcome. However, planning for TB control in the
poorest countries is still inadequate, and budgets commonly
understate the real costs of scaling up national TB control pro-
grams (WHO 2004c, 2005). Despite those weaknesses in the
budgeting and funding process, the overall expenditure on TB
control in high-burden countries has increased since 2000, and
the injection of extra effort and money has led to a small accel-
eration in case finding globally. As a result, case detection under
DOTS could reach 50 to 60 percent by 2005, and treatment
success should be close to the target level of 85 percent.
A case-detection rate of 50 to 60 percent may not be
enough. The analysis in this chapter suggests that the MDG
objective of halving the death rate can be reached with 70 per-
cent case detection globally, provided this case detection also
generates a 5 to 6 percent annual reduction in the incidence
rate between 2003 and 2015. The DOTS program in Peru gen-
erated a 6 to 7 percent annual reduction in the incidence rate of
pulmonary TB, but that result has not yet been repeated in
other high-burden countries with good control programs (for
example, India, Morocco, and Vietnam). It is unlikely to be
achieved in African countries that currently have high rates of
HIV infection.
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Although others have emphasized that the costs of infec-
tious disease control can be related to the benefits in complex
ways (Brandeau, Zaric, and Richter 2003), we advocate the use
of a powerful new method of carrying out CEA, which is based
on the observation that mathematical models can be used to
generate simple (albeit approximate) and general formulas that
relate reward to effort in the management of both epidemic
(based on R0) and endemic (based on dynamics in the vicinity
of equilibrium) TB. The results are similar to those obtained by
using more complex simulations in specific settings, and they
are accurate enough to offer a choice between interventions
(Currie and others, 2005). The generality of the method expos-
es more clearly the reasons some interventions are compara-
tively cost-effective and indicates the range of conditions under
which specific cost-effectiveness results apply. The scope for
using this approach for other infectious diseases remains to be
explored, but it should be readily applicable in the evaluation
of new approaches to TB control, whether through vaccina-
tion, drug treatment, the reduction of environmental risks, or
improved service delivery.
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Sexually transmitted infections (STIs) are responsible for an
enormous burden of morbidity and mortality in many devel-
oping countries because of their effects on reproductive and
child health (Wasserheit 1989) and their role in facilitating the
transmission of HIV infection (Laga, Diallo, and Buvé 1994).
INTRODUCTION
Largely because of the HIV epidemic, interest in STIs has
increased over the past two decades. During that time, the epi-
demiology of STIs has changed in developing countries, partly
as a result of modifications in STI case management approaches
and partly because of behavioral changes in response to the
HIV epidemic. At the same time, advances in STI prevention
have enhanced understanding of the intricacies of STI trans-
mission dynamics and the role of interventions in the control
of STIs. However, what has not changed is as significant as what
has changed: the epidemiology of STIs still differs substantially
in the industrial countries and the developing world. The
sociocultural and economic contexts in developing countries
influence the epidemiology of STIs and help make them an
important public health priority.
Incidence and prevalence rates of STIs are generally high in
both urban and rural populations and vary considerably across
areas. Because diagnosis and treatment of STIs are often
delayed, inadequate, or both, rates of STI complications are
also high in developing countries. Those complications include
pelvic inflammatory disease, ectopic pregnancy, and chronic
abdominal pain in women; adverse pregnancy outcomes,
including abortion, intrauterine death, and premature delivery;
neonatal and infant infections and blindness in infants; infer-
tility in both men and women; urethral strictures in men; gen-
ital malignancies, such as cancer of the cervix uteri, vulva,
vagina, penis, and anus; arthritis secondary to gonorrhea and
chlamydia; liver failure and liver cancer secondary to hepatitis
B or human T cell lymphotropic virus type I; and central nerv-
ous system disease secondary to syphilis (Holmes and Aral
1991; Meheus, Schulz, and Cates 1990; van Dam, Dallabetta,
and Piot 1999). Thus, STI sequelae affect mostly women and
children.
In developing countries, high levels of STIs and high rates of
complications and sequelae result largely from inadequacies in
health service provision and health care seeking (Aral and
Wasserheit 1999). STI care is provided by a large variety of
health care providers, many of whom are poorly trained in STI
case management, and the quality of care they provide is often
less than desirable (Moses and others 1994; WHO 1991).
Health care seeking for STIs is frequently inadequate, particu-
larly among women (van Dam 1995), because of the low levels
of awareness regarding sexual health, the stigmatization associ-
ated with genital symptoms, and the asymptomatic nature of
many STIs. A study in Nairobi, Kenya, found that 42 percent of
patients had been symptomatic for more than a week before
coming to a clinic and that 23 percent had been symptomatic
for more than two weeks (Moses and others 1994).
Setting up good-quality STI services is considerably more
difficult in resource-poor settings than elsewhere. Variables
that affect the duration of infectiousness include adequacy of
health workers’ training, attitudes of health workers toward
such marginalized groups as sex workers, patient loads at
health centers, availability of drugs and clinic supplies, and
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costs of care (Moses and others 2002). Thus, improvements
pertaining to all these factors would greatly improve STI-
related services, help reduce the duration of infectiousness, and
decrease the incidence of STIs (Aral 2002a). However, in many
countries in the developing world, worsened economic condi-
tions and the increasing burden of HIV/AIDS have negatively
affected these variables. For example, in South Africa, the ratio
of hospital beds to population declined from 6.5 per 1,000 in
1976 to 2.3 in 1996; during 1999, approximately 300 profes-
sionally trained nurses left the country each month; and stu-
dent enrollments in nursing school declined from 12,282 in
1996 to 10,398 in 1999 (Aral 2002a).
Sexual behaviors also contribute to the STI burden in devel-
oping countries. These behaviors are heavily influenced by the
sociocultural, economic, and political contexts, which in the
past two decades have deteriorated at an accelerated rate in
many areas. Societal change has included rising levels of
inequality within countries, growing inequality between coun-
tries, increased levels of globalization, increased proportions of
people who live in cultures they were not born in, and a larger
proportion of the world’s population living in postconflict
societies (Aral 2002a). One effect of these changes is an increase
in multipartner sexual activity, which in turn increases the rate
at which infected and susceptible individuals are sexually
exposed to each other and consequently the rate at which STIs
spread.
Changes in STI Epidemiology, Management, and Prevention
since 1993
Since 1993, STI epidemiology and management have evolved
interactively, particularly in developing countries. Techno-
logical advances in diagnosis, screening, and treatment; evalua-
tion and widespread implementation of new case-management
algorithms; and changes in risk behaviors in response to the
AIDS epidemic have all influenced the dynamic typology of
STIs (Wasserheit and Aral 1996).
The introduction of nucleic acid amplification tests, which
have improved the sensitivity and expanded the repertoire of
usable specimens, has heralded a new era in STI diagnosis.
The use of urine and vaginal swabs in diagnosis has enabled
providers to supply diagnostic and screening services outside
traditional clinical facilities and has greatly enhanced the cov-
erage of outreach activities (Schachter 2001). Unfortunately,
many of these tests are currently too expensive for routine use
in developing countries. Single-dose oral azithromycin has
improved the treatment of several bacterial STIs (Lau and
Qureshi 2002), but quinolones are apparently becoming inef-
fective for gonorrhea in some locations (Donovan 2004).
A major recent advance in STI prevention is the early suc-
cess of a prophylactic, monovalent human papillomavirus
(HPV) type 16 vaccine (Koutsky and others 2002); HPV
vaccines may be able to help prevent genital and anal cancers in
the foreseeable future. Researchers are evaluating multivalent
vaccines for preventing moderate to severe cervical dysplasia as
well. Other advances include easier episodic treatment of geni-
tal herpes (Strand and others 2002) and the use of suppressive
therapy to reduce the transmission of genital herpes to regular
partners (Corey and others 2004). In a related development,
a prophylactic vaccine against herpes simplex virus type 2 
(HSV-2) has shown limited efficacy in that it has proved partly
effective for HSV-seronegative women, but not for men or
herpes simplex virus type 1 (HSV-1) seropositive women
(Stanberry and others 2002). Prevention successes of the recent
past include STI sequelae, such as pelvic inflammatory disease
and cervical cancer. A randomized controlled trial showed that
selective screening of women for Chlamydia trachomatis signif-
icantly reduced the incidence of pelvic inflammatory disease
(Scholes and others 1996).
Widespread implementation of syndromic management as
an approach to STI case management has apparently had a
considerable effect on the epidemiology of STIs, particularly in
resource-poor settings (King Holmes and Michael Alary, per-
sonal communication, May 15, 2003).
In some developing countries, including Cambodia, the
Dominican Republic, and Thailand, sexual risk behaviors have
been changing over the past decade. In Uganda, for example,
the age of sexual debut has increased, the frequency of sex with
casual partners has decreased, and the use of condoms has
increased (Stoneburner and Low-Beer 2004). During the
1990s, demographic and health surveys in 29 developing coun-
tries asked individuals if they had done anything to avoid AIDS
(Low-Beer and Stoneburner 2003): almost 80 percent of men
and 50 percent of women surveyed reported that they had.
Specific behavior changes reported included increased mono-
gamy, reduced number of partners, avoidance of sex workers,
and increased condom use.
By contrast, in developed countries, recent years have seen
behavior changes in the opposite direction; for example, in
many European countries and in the United States, risk behav-
iors among men who have sex with men have increased signif-
icantly (CDC 2004; L. Doherty and others 2002). In addition,
Grémy and Beltzer (2004) report declines in condom use
among heterosexual adult populations in Europe. Investigators
attribute increases in risk behaviors to the introduction and
availability of antiretroviral therapy for HIV infection and the
difficulties in sustaining preventive behaviors in the long term,
referred to as prevention fatigue. Some researchers speculate
that the widespread introduction of antiretroviral therapy in
developing countries may have a similar disinhibitory effect on
sexual behaviors and that changes in sexual behavior may off-
set the beneficial effect of antiretroviral therapy (Blower and
others 2001; Blower and Farmer 2003; Blower and Volberding
2002; Over and others 2004).
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Advances in STI prevention in recent decades have
enhanced understanding of transmission dynamics and the
role of interventions. Investigators have articulated the follow-
ing five emergent insights about STI epidemiology and preven-
tion over the past two decades:
• Populations consist of many diverse subpopulations, and
each population-level epidemic trajectory consists of many
distinct subpopulation epidemic trajectories (Pisani and
others 2003). The epidemic trajectories of specific STIs
differ depending on when and where the infection was
introduced; the natural history and transmissibility of the
infection; the structure of sexual networks; the demographic,
economic, social, and epidemiological context; and the state
of the health system (Aral and others 2005).
• Temporal dimensions are important in relation to STI epi-
demiology (Aral and Blanchard 2002). At the individual
level, concurrency of partnerships and gaps between part-
nerships are risk factors for the acquisition and transmission
of STIs (Adimora and others 2002; Agrawal, Gillespie, and
Foxman 2001; Kraut and Aral 2001). At the population level,
investigators have described the evolution of STI epidemics
through sometimes predictable phases, characterized by
changing patterns in the distribution and transmission
of STI pathogens within and between subpopulations
(UNAIDS and WHO 2000; Wasserheit and Aral 1996).
• Sexual networks are important in the transmission dynam-
ics of STIs at the population level, and position in a sexual
network is important in the transmission and acquisition of
STIs at the individual level (Morris 2004).
• Trajectories whereby STI epidemics evolve differ for
different types of population-pathogen interactions (Aral
2002a; Blanchard 2002; Garnett 2002). Whereas highly
infectious, short-duration bacterial STIs—for instance,
gonorrhea—depend on the presence of core groups marked
by multiple sex partnerships of short duration for their
spread, less infectious, long-duration viral STIs—for exam-
ple, HSV—depend on the presence of multiple partnerships
of longer duration.
• Interactions among sexually transmitted pathogens affect
STI epidemic trajectories at the population level (Wasserheit
1991). The inconsistent findings of three landmark random-
ized community trials evaluating the effect of STI treatment
on HIV transmission (Grosskurth and others 1995; Kamali
and others 2003; Wawer and others 1999) can be accounted
for by the complex, multifactorial, multilevel, and phase-
specific nature of STI epidemics (Orroth 2003).
Epidemiology and Control 
The epidemiology of STI pathogens, the local prevention and
care infrastructure, and the cultural and sociopolitical context
vary considerably within and across developing countries. At
the same time, health care delivery for STIs varies by type of
institution and location, although inadequate resources are
universal in the developing world, as are recordkeeping, data
management, and data analysis. The limited data that are avail-
able suggest that STIs are a major public health burden in the
developing world. Although the prevalence and incidence of
bacterial STIs have apparently declined because of expanded
syndromic management, changes in sexual behavior, and death
of high-risk populations, the prevalence and incidence of viral
STIs seem to have increased over the past decade.
Syndromic Management. Health systems can use three differ-
ent approaches to manage patients presenting with symptoms
suggestive of an STI. First, etiology-based management relies
on identifying causative micro-organisms or detecting specific
antibodies. It requires costly and often technically complex lab-
oratory diagnosis, trained personnel, quality assurance pro-
grams, and infrastructure. Second, clinical diagnosis–based
management is rapid, inexpensive, and requires less infrastruc-
ture than etiology-based management; however, clinical diag-
nosis is often inaccurate, may miss multiple infections, and
may result in undertreatment or overtreatment. Third, syn-
dromic management, which is based on the recognition of a
constellation of clinical signs and symptoms, is inexpensive,
can be standardized, and can be used by both physicians and
paramedical personnel, though it often results in some
overtreatment. Nevertheless, syndromic management has
been recommended as a realistic approach for managing
symptomatic patients in developing countries (Over and Piot
1993). Implementation issues associated with the syndromic
management approach involve inadequate local evaluation of
treatment algorithms because of a lack of local data, inconsis-
tencies in implementation, and inadequate monitoring
(Dallabetta, Gerbase, and Holmes 1998; Hawkes and Santhya
2002; WHO 2001b).
Limitations of the syndromic management approach
include the inability to directly target the subclinical STI pool,
the variability of STI symptoms and signs, the potential for
wasting antibiotics, the risk of promoting drug resistance, and
the unintended consequence of decreasing the skill levels of
health care providers (Dallabetta Gerbase, and Holmes 1998;
Donovan 2004). Moreover, syndromic management tends to
undermine STI surveillance efforts because cases are managed
and treated in the absence of a specific clinical or laboratory
diagnosis (O’Farrell 2002).
Role of Core Groups and Bridge Populations. Core groups—
that is, groups of individuals who have large numbers of sex
partners who themselves have large numbers of sex partners—
play an important role in the spread and persistence of STIs
and are characterized by a high prevalence of STIs. Examples of
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core groups include sex workers, drug users, truck drivers, and
bar girls. Because a case treated or prevented in a core group
member tends to prevent that person from infecting several
others, interventions that target core groups tend to be more
effective and more cost-effective than interventions that target
the general population (Ainsworth and Over 1997; Over 1999;
Over and Piot 1993). In situations in which a high prevalence
of STIs is concentrated in core groups, so-called bridge popu-
lations (individuals who have sexual links with members of
both high- and low-prevalence subpopulations) may play an
important role in disseminating infection from core groups to
the general population (Aral 2000; Aral and others 1999;
Gorbach and others 2000; Morris and others 1996).
Several variables influence the relative importance of core
groups in the spread of STIs, including the characteristics of
the specific pathogen, such as its transmissibility and duration
of infectiousness; the phase of a particular epidemic; and the
duration of sexual partnerships among those involved in mul-
tipartner sexual activity (Aral 2002a, 2002b; Blanchard 2002;
Garnett 2002; Wasserheit and Aral 1996). The role of core
groups in STI dissemination tends to be greater during the ini-
tial and later phases of epidemics, when infection is highly con-
centrated in small, high-risk subpopulations, than during the
middle phases of epidemics, when infection tends to be widely
spread across subpopulations. The importance of core groups
appears to be greater in populations in which most people are
involved in sexual activity with a single partner and only a
small minority of people engage in short-term sexual partner-
ships with a large number of sex partners (Laumann and Youm
1999).
Antibiotic Use and Drug Resistance. Antibiotic use is unreg-
ulated in many developing countries, and antibiotics are fre-
quently misused and overused, which results in drug resistance.
Resistance to antimicrobial drugs is increasing mortality and
morbidity from infectious diseases (Hart and Kariuki 1998).
STIs are among the most frequently occurring infections
worldwide, with more than 76 percent estimated to occur in
the developing world (WHO 2001a). Neisseria gonorrhoeae has
shown great versatility in developing resistance to antimicro-
bial drugs, including sulfonamides, penicillins, and tetracy-
cline. Fluoroquinolones such as ciprofloxacin and ofloxacin
have proved highly effective in treating gonorrhea, but after
widespread and often inappropriate use of fluoroquinolones,
resistant N. gonorrhoeae has emerged. In some areas, such
resistance leaves third-generation cephalosporins as the only
predictably effective antibiotic treatment for gonorrhea.
STIs and HIV/AIDS. Because HIV is a sexually transmitted
infection, people who are infected with another STI also tend
to be at increased risk of HIV infection and vice versa.
However, beyond this correlation resulting from common risk
behaviors, STIs and HIV may facilitate each other’s
transmission.
BACTERIAL AND VIRAL STIs AND THEIR
SEQUELAE
Both bacterial and viral STIs are widespread in developing
countries; recently, incidence of bacterial STIs has declined
while that of viral STIs has been increasing.
Natural History of Bacterial STIs and Their Sequelae
Chancroid is a genital ulcer disease caused by Haemophilus
ducreyi. Its incidence has declined greatly in both developed
and developing countries. This decline has been associated
with the provision of STI diagnostic and therapeutic services to
sex workers (Steen 2001) and with improved syndromic man-
agement of genital ulcers. Like other genital ulcer diseases,
chancroid is associated with increased acquisition and trans-
mission of HIV (Donovan 2004).
Syphilis is a genital ulcer disease caused by Treponema pal-
lidum. In 1999, the World Health Organization (WHO) esti-
mated the global prevalence of syphilis at 12 million (WHO
2001a), with high prevalence rates in South and Southeast Asia
and Sub-Saharan Africa. Those most likely to be affected are
populations in developing countries and disadvantaged sub-
populations in developed countries. Since 1999, syphilis out-
breaks have reemerged in many developed countries among
men who have sex with men (CDC 2004; L. Doherty and oth-
ers 2002). Among heterosexuals, sexual contact with sex
workers is an important risk factor. If untreated, syphilis dur-
ing pregnancy may lead to stillbirth and congenital syphilis
(Genc and Ledger 2000).
Gonorrhea is a discharge disease caused by N. gonorrhoeae.
In 1999, WHO estimated its global prevalence at 62.4 million
(WHO 2001a). Like syphilis, its prevalence is high in South
and Southeast Asia and Sub-Saharan Africa, in many develop-
ing countries elsewhere, and among high-risk groups and
disadvantaged subpopulations in developed countries.
Community surveys reveal a substantial pool of asymptomatic
gonococcal infections (Chandeying and others 2000; Turner
and others 2002). Following the emergence of AIDS, gonor-
rhea cases declined among men having sex with men, sex
workers, and the general population in the developed world
and among sex workers in many developing countries
(Donovan 2004).
In most populations tested, infection with Chlamydia tra-
chomatis is the most common bacterial STI. In 1999, WHO
estimated the global prevalence of chlamydial infection to be
92 million (WHO 2001a). Chlamydial infection is common
in most countries, especially among young people. Key risk
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factors are being younger than 25 and having a new sex part-
ner. Many women with uncomplicated infection are asympto-
matic or have mild symptoms. Like untreated gonococcal
infection, untreated chlamydial infection can cause pelvic
inflammatory disease, chronic pelvic pain, and ectopic preg-
nancy. Chlamydial infection is an important acquired cause of
infertility in women (Simms and Stephenson 2000). Roughly
half of men with urethral chlamydial infection develop symp-
tomatic urethritis, chlamydial infection is the most common
cause of epididymitis in young men, and both men and women
may develop chlamydial conjunctivitis or reactive arthritis
(Stamm 1999). Research also suggests that chlamydial infection
in men may be associated with reduced fecundity among cou-
ples (Idahl and others 2004). In addition, chlamydial infection
can affect neonates: many delivered vaginally become infected,
developing conjunctivitis or, less often, chlamydia pneumonia
(Donovan 2004). The role of C. trachomatis in preterm births
and in cervical cancer awaits further clarification through
research (Samoff and others 2004; Wallin and others 2002).
In the absence of control programs, the prevalence of
Trichomonas vaginalis varies greatly across countries, ranging
from less than 1 percent among urban women to more than
20 percent in underserved populations in the same country
(Brown and Brown 2000), and may increase with age. WHO
estimated the global prevalence of T. vaginalis at 174 million in
1999. The introduction of nucleic acid amplification tests high-
lighted the poor sensitivity of microscopy in the detection of
T. vaginalis. Even though most infected people are asympto-
matic, T. vaginalis can cause vaginitis with vaginal discharge in
women and urethritis in men. T. vaginalis has been associated
with preterm birth and may promote the sexual transmission
of HIV (Laga and others 1993). However, a randomized con-
trolled trial did not show that screening and treatment for
T. vaginalis to prevent preterm birth were effective (Klebanoff
and others 2001).
Like T. vaginalis, bacterial vaginosis and vulvovaginal can-
didiasis cause vaginal symptoms in women, are extremely
prevalent in developing countries, and in one or more studies
have been associated with HIV acquisition or HIV genital shed-
ding by women (Donovan 2004). Although often referred to as
reproductive tract infections rather than STIs, they are man-
aged in conjunction with STIs, and bacterial vaginosis is asso-
ciated with some of the same risk factors as other STIs.
Viral STIs and Their Sequelae
Both HSV-1 and HSV-2 infect the genital and anal areas, but
HSV-2 causes the most clinical recurrences in the genital tract.
Symptoms are mild in most of those infected and tend to go
unrecognized and undiagnosed (Corey 2000; Scoular 2002).
Genital herpes establishes a lifelong infection that in some peo-
ple is associated with significant morbidity. Complications of
HSV-2 include severe primary disease, meningitis, hepatitis,
erythema multiforme, and neonatal herpes (Donovan 2004).
Infected neonates may die or develop severe neurological
sequelae despite antiviral therapy. In contrast to bacterial STIs,
HSV-2 may be transmitted to sex partners many years after ini-
tial infection and during periods when the infected individual
may be asymptomatic. Infection with HSV-2 is now one of the
most common STIs worldwide and is the most frequent cause
of genital ulcers in almost all areas; however, this observation
may be related to better diagnostic technologies rather than a
genuine alteration in the spectrum of genital ulcer disease
(Corey and Handsfield 2000). Improved control of chancroid
and syphilis as well as actual increases in the sexual transmis-
sion of HSV-2 in areas with advanced HIV epidemics, where
HIV-related immunosuppression causes more frequent and
more severe HSV-2 disease, may also play a role. Estimates indi-
cate that 10 to 30 percent of adults worldwide are infected with
HSV-2 (Brugha and others 1997). Prevalence increases with age
and is higher in women and high-risk populations.
HPV types are grouped into low-risk (nononcogenic) and
high-risk (oncogenic) types. Low-risk types, including types 6
and 11, cause benign anogenital warts, whereas high-risk
types, including HPV 16, 18, 31, and 45, occasionally lead to
genital and anal squamous cell cancers. The introduction of
nucleic acid amplification tests revealed that genital and anal
HPV infection is common even among relatively sexually
inexperienced individuals (Giuliano and others 2002; Stone
and others 2002). Investigators believe that most adults
become infected with HPV but that only a few develop warts
or genital or anal cancer. Infection with a high-risk HPV type
is implicated in nearly all cases of invasive cervical cancer
(Walboomers and others 1999) and with vaginal, vulvar, and
anal cancers.
In developed countries, hepatitis B virus is spread predomi-
nantly by sexual and injecting drug-use transmission. Indeed,
the first three trials of hepatitis B vaccine successfully demon-
strated prevention of sexual transmission of hepatitis B virus in
men who have sex with men (Manhart and Holmes 2005). In
developing countries, hepatitis B is more often acquired peri-
natally or during childhood, but a rise in seroincidence in ado-
lescence and young adulthood in some countries probably
reflects sexual or injecting drug-use transmission. Hepatitis B
virus causes acute hepatitis and in some people causes chronic
hepatitis that can lead to cirrhosis and liver cancer.
Human T cell lymphotropic virus type I (and perhaps in
more cases type II) is, like hepatitis B virus, transmitted
perinatally and sexually. In some high-risk populations, for
example, female sex workers in Latin America, human T cell
lymphotropic virus type I infection is substantially more com-
mon than HIV infection. This infection causes a serious form
of spastic paralysis or human T cell lymphotropic-associated
myelopathy, as well as T cell lymphoma or leukemia.
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Coinfection with Sexually Transmitted Pathogens
The epidemiology and natural history of coinfection with
more than one sexually transmitted pathogen may have impor-
tant intervention and economic implications. Coverage by
clinical services, outreach, access, partner management, and
treatment may be different with coinfection than with inde-
pendent infections. Although coinfections with HIV and other
STIs have received a great deal of attention in recent years,
researchers have not focused on overlaps among non-HIV STIs
in a similar systematic manner. A number of biological mech-
anisms may lead to coinfection with STIs: infection with one
pathogen may increase the probability of acquiring or trans-
mitting another pathogen; infection with one pathogen may
increase or decrease the frequency, the severity, or both of
symptoms associated with another sexually transmitted
pathogen; and presence of one STI may affect the natural his-
tory of another STI. High-risk behaviors and networks often
lead to coinfection.
Empirical data on coinfection are limited. Most studies have
been conducted in developed countries and have focused on
co-occurrences of chlamydial and gonococcal infection. Earlier
studies of coinfection assessed the proportion of gonorrhea
cases with concurrent chlamydial infection in a variety of clin-
ical settings. Reported levels of coinfection were 4 to 64 percent
among attendees at STI clinics, 46 percent among prenatal
clinic attendees, and 4 to 25 percent at primary health care
facilities (Creighton and others 2003). The proportion of those
with chlamydia who also have gonorrhea has been assessed less
well, and estimates have ranged between 3 and 4 percent
(Creighton and others 2003).
Sexual Behavior and Sexual Health Care
Unprotected sex with an infected partner is the most important
risk factor for acquiring an STI. This risk is influenced by the
behaviors of the individual and the probability that the partner
is infected, which is determined by the prevalence and distri-
bution of infection in the population as well as the partner’s
behaviors. Current approaches to STI epidemiology recognize
at least three distinct components of transmission dynamics at
the population level: likelihood of sexual exposure between
infected and uninfected individuals, transmissibility of infec-
tion upon exposure between an infected and an uninfected
person, and duration of infection among those infected (Aral
and Holmes 1999; Over and Piot 1993). The first of these com-
ponents is entirely behavioral, and behavior plays an important
role in the last two—for example, condom use, sexual practices,
and health care–seeking behaviors.
Demographic and Social Risk Markers. The prevalence and
incidence of STIs vary across societies and subpopulations
defined by age, gender, race and ethnicity, and socioeconomic
status (Fenton, Johnson, and Nicoll 1997). In all societies, ado-
lescents and young people are at greater risk for acquiring most
STIs. Women tend to have a higher prevalence and incidence of
all STIs (except for men who have sex with men) and suffer
more of the serious complications, such as pelvic inflammatory
disease, ectopic pregnancy, infertility, and chronic abdominal
pain. For many STIs, the probability of transmission from an
infected man to a susceptible woman is higher than from an
infected woman to a susceptible man. Social and behavioral
patterns also increase women’s vulnerability to STIs; for
instance, many men have concurrent sex partnerships, which
increase their risk for transmitting infection to their female sex
partners. In addition, many young women have sex with older
male partners, who expose them to the higher STI prevalence
rates in older age groups.
In most societies, minority racial ethnic groups have higher
STI rates than other groups. Both in the United Kingdom
(Fenton, Johnson, and Nicoll 1997) and in the United States
(Laumann and Youm 1999), assortative sexual mixing and
higher rates of sexual mixing with members of core groups
emerge as determinants of ethnicity differentials in STI rates.
The prevalence of concurrent partnerships is also higher among
racial ethnic minorities (Kraut-Becher and Aral 2003). The
relative inadequacy of STI health services and of health
care–seeking behaviors among minority racial ethnic groups
may also contribute to their higher prevalence of STIs (Aral and
Wasserheit 1999).
Socioeconomic status differentials in STI prevalence and
incidence are similar to ethnicity differentials. However, the
multicollinearity between the two factors makes delineating the
independent contributions of either variable to differentials in
STI prevalence and incidence difficult.
Behavioral Risk Factors for Exposure to Infected Sex
Partners. Most sexual behaviors of individuals are associated
with exposure to sex partners infected with sexually trans-
mitted pathogens and, consequently, with acquisition of STI.
These behavioral factors include number of sex partners
over the individual’s lifetime, over the past year, and over a
short term (Fenton and others 2001; Laumann and Youm
1999); frequency or number of sexual encounters (Garnett and
Rottingen 2001); having sex with members of groups with
high STI prevalence, such as core groups and sex workers
(Fenton and others 2001; Laumann and Youm 1999) or older
age groups (Service and Blower 1996); and position in a sexual
network (I. A. Doherty and others 2005). Some sexual behav-
iors of individuals are associated with transmission of STIs,
and for those infected the behaviors increase the probability
that people will transmit their infections to susceptible sex
partners. These behaviors include having concurrent
partnerships (Koumans and others 2001; Kraut-Becher and
Aral 2003; Morris and Kretzchmar 1995) and having short
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gaps between sex partners in serial monogamous partnerships
(Kraut-Becher and Aral 2003).
Sex partners’ behaviors are also critical determinants of
exposure to infection. Investigators use many behavioral and
epidemiological indicators to assess partners’ risk of having
infection, including existence and number of new sex partners;
presence of concurrent partnerships; gap between sex part-
ners; partners’ number of partners; and risk status of partners’
partners—for example, if they have sex with sex workers or
men who have sex with men (Aral 2002b).
Behavioral Risk Factors Associated with STI Acquisition and
Transmission on Exposure to Infected Partners. Certain
behaviors influence the likelihood of an infected person’s trans-
mitting infection to a susceptible partner, including condom
use, sexual practices such as anal intercourse, vaginal douching,
and use of drying agents in the vagina (Bailey, Plummer, and
Moses 2001; Donovan 2000a, 2000b). The probability of trans-
mission varies depending on the pathogen and is much higher
for bacterial STIs, such as gonorrhea, syphilis, and chlamydia,
than for other STIs, such as HIV infection. Thus, preventive
behaviors such as condom use may be more effective in pre-
venting the latter than the former (National Institute for
Allergy and Infectious Diseases 2001). In addition, the proba-
bility of both acquisition and transmission is significantly
affected by such nonbehavioral cofactors as circumcision status
(Aral and Holmes 1999).
Overall, oral sex and anal sex tend to be practiced less often
in the developing world than in the developed world (Vos
1994). Insertion of herbs to tighten or dry the vagina and
other practices of vaginal clearing and wiping are widespread
(Brown and Brown 2000). Condom use is increasing in some
countries—for example, India, Thailand, and Uganda—
especially during high-risk encounters.
Behaviors Associated with the Duration of Infectiousness.
The duration of infectiousness is an important component of
transmission dynamics. Because effective treatment curtails the
duration of curable STIs, the speed with which infected
individuals seek treatment and the speed and effectiveness with
which health care providers supply effective treatment together
determine duration. To the extent that suppressive therapies
truncate the period of infectiousness of viral STIs, as they do
for HSV-2 and HIV infection, duration is also important in the
transmission dynamics of incurable viral STIs.
Behaviors that can reduce the average duration of infec-
tiousness include timely and appropriate health care seeking,
effective participation in risk assessment, and compliance with
therapy and prevention recommendations on the part of those
infected and at risk (Aral and Wasserheit 1999). Health care
seeking depends on perceived seriousness and causality of
symptoms, availability and accessibility of health care, costs
(including opportunity costs) of treatment, perceived and
actual quality of care, and beliefs about the appropriate provider
to consult. The proportion of those infected seeking care is
highly variable, and delays in seeking treatment can be substan-
tial. In many places, the proportion of people seeking timely
care from appropriately trained providers is limited (Hawkes
and Santhya 2002; Moses and others 2002; Rekart 2002).
Behaviors on the part of health care providers that ensure
timely and accurate diagnosis, appropriate treatment, and non-
judgmental attitudes toward those infected would also help
reduce the duration of infectiousness of STIs. However, estab-
lishing effective, accessible, affordable, and decentralized
services is difficult (Over 2004; World Bank 2003). The major
barriers Moses and others (2002) identified in Nairobi reflect
the situation in many developing countries. Those barriers
include inadequate basic training and inefficient deployment
of health workers; attitudes of health workers toward margin-
alized groups (for instance, female sex workers); high patient
loads at health centers; lack of supportive supervision; inade-
quate referral systems; chronic shortages of supplies and drugs;
and inadequate recording of health information. User fees can
be a substantial additional barrier, though they may contribute
to the sustainability of the treatment program and improve the
provider’s incentives.
Behavioral Interactions. Both at the individual and the pop-
ulation levels, people’s risk behaviors respond to changing
circumstances. In many developing countries where HIV
incidence has been high, people have adopted compensatory
behavior changes, such as delayed age of sexual debut, reduced
number of sex partners, and increased use of condoms
(Shelton and others 2004; Stoneburner and Low-Beer 2004),
especially with high-risk partners (Peterman and others 2000).
Some people now seek health care when they suspect they have
been exposed to an STI.
At the same time, risk behaviors can overlap: people who
initiate sexual activity early in life tend to have many partners,
and people who engage in risky sex tend to also use drugs and
alcohol. A history of sexual abuse or of being an abuser is also
positively associated with high-risk sexual behaviors and drug
use (Aral 2004). The adoption of preventive behaviors raises
the possibility that people will compensate by changing other
behaviors in response; for example, many believe that the
widespread adoption of antiviral therapy or condom use may
lead to increases in the numbers of sex partners (Blower and
others 2001; Blower and Farmer 2003; Over and others 2004).
Although constructing mathematical models to explore the
effects of such changes in behavior is helpful, empirical
research in varied contexts is urgently needed to identify the
variables that determine patterns of interaction among risky
and preventive behaviors. Two such variables may be individ-
ual autonomy and awareness of the epidemiological context.
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Societal Determinants of STIs. Sexual networks and patterns
of sexual partnership formation and dissolution constitute a
major mechanism through which the political economy and
the sociolegal system influence the rate of spread of STIs in a
population. Sexual networks that are highly critical to the rate
of spread of STIs include those involving sex work; exchange of
sex for drugs, gifts, or material needs; and anonymous sex. The
frequency of sex in exchange for money or other goods appears
to be highly sensitive to changes in the political economy and
the sociolegal system. Internal conflicts, war, economic crises,
and social collapse are accompanied by the establishment of
major sex markets or the expansion of existing ones. For exam-
ple, following the collapse of the former Soviet Union, the
number and size of commercial sex and sex-drug networks
expanded significantly (Aral and St. Lawrence 2002; Aral and
others 2005). The availability and use of condoms also influ-
ence the rate of spread of STIs.
Many developing countries continuously face political con-
flict, war, economic deterioration, mass migration, and increas-
ing inequality plus the effect of globalization. In addition, in
most developing societies, gender power relationships are
marked by great inequality. Those contextual factors lead to
sexual networks and sexual mixing patterns that are highly
conducive to the spread of STIs. Sexual partnerships are often
not stable, and in the long-term absence of a spouse, both men
and women (but especially men) have other partners.
In addition, as economic needs rise, the number of women
who exchange sex for material needs increases. Wilson and
others (1989) estimate that approximately 10 percent of the
female population in Bulawayo, Zimbabwe, had engaged in
full- or part-time sex work at some time in their lives, whereas
Aral and St. Lawrence’s (2002) estimates for Saratov, Russian
Federation, are closer to 25 percent. As the supply of sex work-
ers increases, the demand for their services often increases in
parallel. Economic need also affects sexual mixing patterns. In
most developing countries, young girls commonly have “sugar
daddies”—that is, older, often married men who provide them
with material goods in return for sex while also exposing them
to chronic STIs typical of relatively older cohorts (Gregson and
others 2002).
Gender inequalities put women in a highly vulnerable posi-
tion in many ways. For example, Decosas and Padian (2002)
find that, among women attending family-planning and pri-
mary health care clinics in Zimbabwe, 17 percent had at some
time received a gift in exchange for sex, 22 percent had been
forced to have sex with a steady partner, 5 percent had been
forced to have sex with a nonsteady partner, 35 percent were
certain their steady partner had other partners, 27 percent said
their partners had STI symptoms, 24 percent said their partner
was intoxicated during sexual intercourse more than half the
time, and only 10 percent had used a condom in the previous
three months.
Income and Inequality. A cross-country database (George
Schmid, personal communication, September 15, 2004)
enables us to analyze the association between national STI
prevalence rates and two important economic variables: gross
national income per capita and the degree of income inequal-
ity as measured by the Gini coefficient.1 As table 17.1 shows,
these two variables explain 45 percent of the variation in STI
prevalence in low-risk groups and 16 percent of STI prevalence
in high-risk groups. Figure 17.1 illustrates the relationship
between each of these two economic variables and STI
prevalence.
Poor countries’ higher prevalence rates of STIs are unsur-
prising and could be explained by the fact that people in richer
countries are likely to seek and find care for STIs more quickly.
More notable is that income inequality is such a strong predic-
tor of STI prevalence even after controlling for gross national
income per capita. Furthermore, income inequality is a strong
predictor of STI prevalence among high-risk groups, where
income per capita performs less well. A possible explanation for
this finding is that greater inequality creates more active mar-
kets for commercial and casual sex as higher-income men
negotiate for the sexual services of lower-income sex workers
(Aral 2002b; Over 1998).
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Table 17.1 Cross-Country Regressions of Average STI
Prevalence on Per Capita Income and the Gini Coefficient
of Inequality for Low- and High-Risk Groups, Selected
Countries 
Average prevalence Average prevalence 
of STIs in of STIs in 
Category low-risk groups high-risk groups
Gross national income 0.862** 0.194
purchasing power parity 
per capita, log, 19~2001
Gini index, 1990s 7.731** 2.73*
Dummy for syphilis 0.093 0.051
Dummy for chlamydia 1.992** 0.308
Dummy for herpes 3.611** 1.507**
Constant 0.515 1.751
R 2 0.45 0.16
Number of countries 204 147
Source: Authors’ calculations from Schmid and others 2004. 
Note: *  probability of less than 0.05 percent; **  probability of less than 0.01 percent.
Positive numbers indicate a probability of 0.1 to 0.2 percent. Both regressions pool data across
these STIs: syphilis, chlamydia, and herpes. The coefficients of the dummies show that the esti-
mated prevalence rates are significantly higher for herpes than for the other diseases. Among
low-risk groups, the prevalence of chlamydia is higher than that of syphilis. Standard errors (not
shown) are estimated using the White correction for heteroskedasticity under the assumption
that the observations for a single country are comparable to a cluster of data. Other explanatory
variables that were unsuccessful in explaining a significant proportion of the variance included
percentage of the population foreign born, percentage of the population that is Muslim, male-to-
female literacy gap, urban male-to-female population ratio, and military personnel per 1,000
urban population.
BURDEN OF STIs AND BENEFITS OF CONTROL
On the basis of an independent analysis of cross-country data
on STI prevalence, we believe that WHO may have underesti-
mated the burden of STIs relative to that of HIV and other dis-
eases (www.fic.nih.gov/dcpp/gbd.html). Adjusting the WHO
estimates on the basis of our calculations increases the estimate
of years of life lost burden by about 18.1 percent and the over-
all estimate of disability-adjusted life years (DALYs) lost by
about 8.2 percent.
DALYs Gained from Effectively Preventing or Treating STIs
In the first edition of this volume, chapter 20 presented esti-
mates of the so-called static and dynamic burdens of prevent-
ing or curing a single case of an STI and of HIV (Over and Piot
1993). We reproduce those estimates in table 17.2 for four of
the STIs.2 The static benefit column estimates the average
number of DALYs saved for a single person by curing or pre-
venting his or her own case of each disease. These estimates
are based on specific assumptions regarding the distribution of
incidence, case-fatality rates, and severity across age ranges.
Although updating these estimates to 2004 and varying them
by region would ideally be possible, we have not found any
more recent data. If the person who is cured of an STI ceases to
be sexually active, the static benefit would be the only benefit of
curing or preventing his or her case; however, most individuals
who have contracted an STI remain sexually active and are
therefore likely to communicate that STI to others. An STI
prevented or cured in a sexually active person will prevent
additional cases in that person’s sex partners, in the sex part-
ners’ partners, and so on. Thus, the dynamic benefit columns
indicate the magnitude of those additional benefits.
The key finding is that preventing or curing a case of any
of the STIs in a core group member generates approximately
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Figure 17.1 Association between Per Capita Income and Income
Inequality with STI Prevalence for Low-Risk Groups, Selected
Countries
Table 17.2 Discounted DALYs Saved Per Case Prevented or Cured
Dynamic benefits Total benefits
Static Member of Member of Member of Member of 
STI benefits noncore group core group noncore group core group
Chancroid 0.2 0.2 1.6 0.4 1.8
Chlamydia 1.1 4.4 43.0 5.5 44.1
Gonorrhea 0.9 3.6 36.4 4.5 37.3
Syphilis 3.8 16.0 157.0 19.8 160.8
For comparison
HIV without ulcers 19.5 35.1 340.1 54.6 359.6
HIV with ulcers 19.5 39.2 410.7 58.7 430.2
Source: Over and Piot 1993, table 20-16, appendix 20B.
10 times the dynamic benefits of the same intervention in a per-
son in a noncore group. This result is driven by the assumption
that a member of a noncore group has a new sexual contact
every 50 days, or about seven new contacts per year, whereas a
member of a core group has 10 times as many contacts. Within
this model, the results are proportional to the frequency of
partner change, so that the dynamic benefits of curing or pre-
venting a case in a sex worker who has two partners a day would
be approximately 10 times as great as for a member of the core
group in table 17.2. The implication is that preventing or cur-
ing a case of syphilis in a sex worker can result in up to 1,600
DALYs of benefit, a health effect that is likely to be competitive
with any discussed in the other chapters in this volume.
Impact of STIs on HIV
The preceding discussion does not address the possibility that
STI infections increase HIV transmission. On this point the
evidence is mixed, with a study in Mwanza, Tanzania
(Grosskurth and others 1995), demonstrating a statistically sig-
nificant 40 percent reduction in HIV incidence attributable to
an STI intervention, while two studies (Kamali and others
2003; Wawer and others 1999) in Uganda failed to show any
such effect. Recent reanalyses (Orroth 2003) of the data from
these studies suggest that the effect of an STI intervention on
an HIV epidemic will vary depending on the sexual activity and
resulting prevalence of STIs among those being treated.
None of the randomized controlled trials of the effect of STI
treatment on HIV prevention exclusively targeted the most sex-
ually active people in the community. In Mwanza, Tanzania,
and Masaka, Uganda, treatment was provided to those who
sought it at health care clinics. In Rakai, Uganda, treatment was
given to all adults in all households, regardless of whether the
individual complained of STI symptoms. Data on the preva-
lence of HIV infection in the three communities suggest that
the HIV and STI epidemics were both at an earlier stage in
Mwanza and were therefore more concentrated among those
more sexually active. Thus, the people who became sympto-
matic and sought treatment were among the most sexually
active people in Mwanza, and treating them would therefore
have had a greater effect on HIV incidence than would treating
an average person in the two Ugandan sites. Conversely, in the
more generalized epidemics in Uganda, a larger proportion of
new infections occurred within stable HIV-1 serodiscordant
couples.
An alternative, less rigorous way to test for the effect of STI
prevalence on HIV infection is to study the cross-sectional cor-
relation in ecological data. In a replication of an earlier study
(Over 1998), we have attempted to explain urban HIV preva-
lence in a cross-country sample by the prevalence of syphilis and
gonorrhea seven years earlier after controlling for six other
potentially confounding variables. The results of these cross-
country regressions are presented in table 17.3.3 Columns (1)
and (2) of table 17.3 present the results of regressions estimated
on the subsets of countries for which data are available on all
eight explanatory variables and on the dependent variable (2002
urban HIV prevalence). Their specifications differ only by the
replacement of the prevalence of syphilis as an explanatory vari-
able in column (1) with the prevalence of gonorrhea in column
(2). Columns (3) and (4) repeat the same two regressions by
replacing missing values of the two prevalence rates with esti-
mates that are based on a regression of these rates on the other
variables in the regression. This procedure expands the samples
dramatically from 56 and 38 to 181 and 180, respectively.4
In interpreting these regressions, note first that all four spec-
ifications explain more than half of the variance in 2002 urban
HIV prevalence, a remarkably good fit for cross-sectional
regressions. In all these specifications, the lagged value of an
STI prevalence is a statistically significant predictor of HIV
prevalence approximately seven years later. The coefficient for
gonorrhea is larger than the coefficient for syphilis and is more
statistically significant in the augmented sample, though less so
in the basic sample.
After the age of the epidemic is controlled for, several other
variables contribute to explaining the variation in HIV preva-
lence. These variables include national income per capita
(richer countries have lower infection rates), the percentage of
the population that is Muslim (a higher percentage is associ-
ated with lower infection rates), and the ratio of males to
females in the sexually active age range (higher ratios are asso-
ciated with higher infection rates).
The major difference between the regressions using the aug-
mented sample and those using the basic sample is in the sta-
tistical significance of the estimated coefficient of income
inequality as measured by the Gini coefficient. When the sam-
ple is expanded to take advantage of the available data, the coef-
ficient stabilizes at about 5.3 and is statistically significant at the
0.01 probability value, suggesting that an increased degree of
income inequality is associated with increased HIV infection
even after controlling for STI prevalence. This result lends sup-
port to the idea that income inequality is just as important as
poverty in setting the stage for HIV transmission.
As with the results of any ecological or cross-sectional analy-
sis, questions of attribution and interpretation arise. Is the sta-
tistically significant coefficient of syphilis or gonorrhea captur-
ing a biological effect of an STI on increasing the transmission
probability during sexual intercourse? Or is the coefficient
instead simply reflecting the fact that greater sexual activity
spreads all STIs, including gonorrhea, syphilis, and HIV? Is the
coefficient of the percentage of the population that is Muslim
capturing differential sexual activity or the prevalence of male
circumcision, which is increasingly recognized as biologically
protective? A biological interpretation of both the STI and the
Muslim coefficients is suggested by the fact that the variable
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urban male-to-female ratio is probably already capturing much
of the variation in the most risky sexual behavior: the practice
of prostitution.
Increasing the availability of treatment for STIs and for HIV
infection reduces the prevalence of the former and increases
the prevalence of the latter. Thus, this statistical relationship
between STI prevalence and HIV prevalence, even if once valid,
will no longer obtain. Under current conditions, estimating the
effect of a change in the prevalence rate of an STI on the inci-
dence rate of HIV would be more relevant.
If we assume that in 2002 the HIV epidemic was approach-
ing equilibrium in many urban settings and that prior to anti-
retroviral treatment the median duration of the illness was
about 10 years, the prevalence of HIV infection is approxi-
mately equal to 10 times the incidence rate. Thus, a 10 percent-
age point increase in the prevalence of syphilis or gonorrhea is
estimated to increase the incidence of HIV by 0.27 percentage
points for syphilis and 0.57 for gonorrhea. For comparisons,
the Mwanza trial found that a reduction in the prevalence of
male urethritis of 0.6 percent was associated with a decrease of
0.7 percent in the incidence of HIV (Grosskurth and others
1995). Thus, the present study suggests an effect about one-
fourth as strong as that of the Mwanza study.
EFFECTIVENESS OF THE PRINCIPAL
INTERVENTIONS
Unlike HIV interventions, STI interventions benefit from a
large body of rigorous evaluations. STI interventions that have
been rigorously evaluated for effectiveness can be organized
by intervention level (that is, individual, group, or commu-
nity); by the outcomes measured; and by the intervention
modality used (for example, behavior change, vaccination,
topical microbicide use, screening, or treatment). Prevention
outcomes may measure the prevention of acquisition, of
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Table 17.3 Multiple Regression of circa 2002 Urban HIV Prevalence on circa 1995 STI Prevalence and Other
Socioeconomic Variables
(1) (2) (3) (4)
Augmented Augmented
Basic sample Basic sample sample with sample with
Category with syphilis with gonorrhea syphilis gonorrhea
Age of epidemic (urban low) in 2002a 0.177 0.131 0.12 0.08
(4.07)*** (2.00)* (2.90)*** (1.70)*
Per capita national income, median 1996–2001 1.344 1.177 0.929 0.949
(2.82)*** (2.30)** (3.63)*** (4.45)***
Income equality, Gini index, 1990s 0.125 3.186 5.349 5.258
(0.04) (0.83) (2.77)*** (2.79)***
Percentage of the population that is Muslim, 1999 0.026 0.031 0.015 0.02
(4.05)*** (3.50)*** (3.45)*** (4.10)***
Urban male-to-female ratio for those age 20–39, 1999 6.178 6.199 3.27 3.038
(2.03)** (1.40) (1.29) (1.19)
Urban high-risk population dummy 1.17 0.564 0.894 0.37
(1 if yes, 0 is no) (2.83)*** (0.85) (2.64)*** (0.71)
Logit syphilis in low-risk group, 1995b 0.31 0.233
(2.46)** (1.78)*
Logit gonorrhea in low-risk group, 1995b 0.502 0.479
(1.92)* (1.86)*
Constant 0.297 0.791 2.117 0.054
(0.05) (0.11) (0.63) (0.02)
Number of observations 56 38 181 180
Number of countries 40 29 101 100
R 2 0.57 0.56 0.5 0.51
Source: Authors’ calculations. Syphilis and gonorrhea prevalence in 1995 (George Schmid, personal communication, April 5, 2004). HIV prevalence circa 2002 is from the urban low-risk tables in the U.S.
Bureau of Census database on HIV prevalence. Other variables are from World Bank data.
*  significant at 10 percent; **  significant at 5 percent; ***  significant at 1 percent. 
Note: The figures in parentheses are robust t-statistics.
a. Age of epidemic is defined as the number of years since the first case of HIV/AIDS was reported.
b. The logarithm of the ratio of the prevalence to 1 minus the prevalence of the given STI for the low risk population in 1995.
transmission, and of complications of STIs (Manhart and
Holmes 2005). This section reviews the interventions for which
the strongest evidence exists.
Individual-Level Interventions
A large number of STI interventions that have been rigorously
evaluated are individual-level interventions.
Preventing Acquisition. The following have been the main
means of preventing STI acquisition:
• Behavior change. Counseling on risk reduction was the most
frequently used behavior-change approach. Most studies
showed a reduction in risk behaviors as a result of counsel-
ing, and some showed decreases in STI outcomes (Kamb
and others 1998).
• Antimicrobial prophylaxis. Two studies (Harrison and others
1979; Kaul and others 2004) showed reductions in the inci-
dence of gonococcal, chlamydial, or trichomonal infections
following antimicrobial prophylaxis.
• Vaccines and passive immunization. A yeast-derived HPV
type 16 vaccine was 100 percent efficacious in preventing
persistent HPV-16 infection in young college women
(Koutsky and others 2002), and a bivalent HPV type 16 and
type 18 vaccine was also highly efficacious in preventing
those infections. An HSV-2 glycoprotein D-adjuvant vac-
cine among those with no serological evidence of prior
HSV-1 infection partially protected women, but not men,
from experiencing genital herpes disease, with 73 percent
efficacy for such women in one trial and 74 percent in
another (Stanberry and others 2002).
• Microbicides. To date, studies have not identified any effica-
cious topical microbicides.
• Male circumcision. Even though cross-sectional evidence
suggesting that male circumcision decreases the risk of
acquiring chancroid and HIV is strong, outcome data are
not yet available from ongoing randomized trials in Kenya,
South Africa, and Uganda.
Preventing Transmission. All individual-level interventions
aimed at preventing transmission have involved curative or
suppressive therapy. Giving tinidazole to male partners of
females treated for vaginal trichomoniasis infections signifi-
cantly reduced recurrences in the females; administering vala-
cyclovir to positive members of HSV-2 serodiscordant couples
reduced the incidence of symptomatic genital herpes and 
HSV-2 seroconversion in the uninfected partners; patient-
delivered therapy to partners of women with chlamydial infec-
tion demonstrated a nonsignificant trend toward reduced risk
of reinfection with C. trachomatis; and expedited partner ther-
apy (usually patient delivered) significantly reduced persistent
or recurrent gonococcal or chlamydial infection in the index
patient (Golden and others 2005).
Preventing Complications. Risk-based screening for C. tra-
chomatis infection resulted in a 56 percent reduction in the
subsequent risk of incident pelvic inflammatory disease
(Scholes and others 1996). Several trials have shown that
antiviral suppression decreases clinical and virological recur-
rences of genital herpes (Corey and Handsfield 2000).
Group-Level Interventions
Studies of behavior-change methods in small-group settings to
reduce the acquisition of STIs had mixed outcomes. Behavior-
change approaches resulted in significant reduction in incident
STIs; antimicrobial prophylaxis and provision of female con-
doms did not.
Community-Level Interventions
Four community-level randomized trials have sought to reduce
the prevalence and transmission of STIs by shortening the
duration of infectiousness within the general population
(Manhart and Holmes 2005).
The “Mema Kwa Vigara” study in Mwanza, Tanzania, ran-
domized 20 communities to intervention and control commu-
nities. The intervention consisted of school-based sexual and
reproductive health education, enhanced reproductive health
services for youths, condom distribution, and community
activities. Knowledge and reported behaviors improved; how-
ever, no differences were apparent between the intervention
and control communities in relation to HIV or HSV-2 seroin-
cidence, incidence of other STIs, or pregnancy outcomes
(Hayes and others 2003).
A second study in Mwanza, Tanzania, randomized commu-
nities to intervention and control conditions. The intervention
consisted of syndromic treatment of STIs. The results showed
a 40 percent reduction in HIV incidence and reductions in
symptomatic urethritis in men and prevalence of syphilis
seroreactivity; the prevalence of gonorrheal or chlamydial
infection in prenatal women did not change (Grosskurth and
others 1995; Mayaud and others 1997).
In a community randomized trial in Masaka, Uganda, one
community received information, education, and communica-
tion; a second community received information, education, and
communication plus syndromic management of STIs; and the
control received community development assistance. The
results showed no differences in HIV-1 incidence. The incidence
of HSV-2 seroconversion declined in the community receiving
information, education, and communication only; the inci-
dence of syphilis and of gonorrhea decreased in the community
receiving information, education, and communication plus
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STI syndromic management; and condom use increased in all
three communities (Kamali and others 2003).
In Rakai, Uganda, a community randomized trial evaluated
the efficacy of repeated mass treatment of STIs. Relative to con-
trol communities, in intervention communities the prevalence
of T. vaginalis in women was reduced significantly, but no sig-
nificant reduction was apparent in prevalence of gonorrhea,
chlamydial infection, new syphilis seroreactivity, and bacterial
vaginosis; in HIV incidence; or in history of urethral or vaginal
discharge or genital ulcer disease (Wawer and others 1999). A
subanalysis of pregnant participants showed a reduction in the
prevalence of several STIs in women tested near delivery and
in potentially STI-related pregnancy, puerperal, and neonatal
morbidity (Gray and others 2001).
Conclusions on Interventions
The review of STI intervention research suggests several, per-
haps counterintuitive, insights:
• First, most evidence is on individual-level interventions
aimed at reducing STI acquisition, even though individual-
level interventions may be costly and difficult to sustain.
• Second, behavior change is the most commonly evaluated
modality, followed by treatment.
• Third, theory-based behavioral interventions failed to show
an effect as often as behavioral interventions not based on
theory.
• Fourth, behavioral interventions delivered in small group
settings were as effective as those delivered to individuals
(Manhart and Holmes 2005).
• Fifth, the effect of a particular behavior change on STI risk
depended on the type of STI; however, the number of part-
ners may be more predictive of risk for highly infectious
STIs than for HIV, and unprotected sex acts may be more
predictive of risk for HIV than for highly infectious STIs
(Semaan and others 2002). Thus, behavioral interven-
tions may have different effects on STIs of differing
infectiousness.
• Finally, the number of intervention trials that demonstrate
declines in risk behaviors combined with either no effect on
STIs or increases in STIs is increasing. This observation calls
into question the use of behavioral outcome measures as
indicators of biomedical outcomes (Aral and Peterman
2002).
INTERVENTION COSTS AND 
COST-EFFECTIVENESS
Widespread implementation of effective interventions depends
on cost and cost-effectiveness considerations.
Organization of STI Control Activities in Poor Countries
In poor countries, patients can typically obtain treatment for an
STI in a public sector health care facility. Many countries have
publicly funded, stand-alone STI clinics, but the typical pattern
is for health care personnel to provide care for STIs as part of
their regular practice in general outpatient clinics. Despite the
availability of such publicly funded care, or perhaps because of
concerns about anonymity, many STI patients in poor coun-
tries avoid public facilities in favor of traditional healers and
private pharmacies. A recent study of the cost-effectiveness of
delivering STI treatment through trained pharmacists in
Peruvian cities included reports of the popularity of self-
treatment in Brazil, Cameroon, Ghana, Nepal, South Africa,
Thailand, Vietnam, and Zambia (Adams and others 2003).
After reviewing this literature, Adams and others selected the
point estimate of 0.4 as their best guess for the proportion of
STI patients seeking treatment from a pharmacy in Lima.
Determinants of the Costs of Interventions
We adopt a government perspective in analyzing the costs and
cost-effectiveness of interventions. Thus, we define the costs of
an activity as the total budgetary expenditure attributable to
that activity—that is, the total budget for buildings, equipment,
personnel, and supplies, with adjustments made when build-
ings are used for multiple purposes.
We define the unit costs of an activity as the total budgetary
expenditure during a stated time period divided by the number
of units of output during that same period. Because the same
activity can have several outputs, this definition necessarily
entails some ambiguity. For example, an intermediate output of
the delivery of STI treatment services is the patient treated,
whereas a more final output is the patient cured. An even more
complete measure of output would include the secondary
infections averted as a result of the cure.
One of the reasons that many economists prefer cost-benefit
analysis to cost-effectiveness analysis is that the former attaches
a dollar value to each of the outputs of an activity and then
aggregates across the outputs to construct a summary measure
of the total benefit of the activity. However, this simple result
hides many arbitrary assumptions that are required to value
the separate outputs. One of the most arbitrary of these
assumptions is the assignment of a dollar value to a healthy life
year. So instead we present costs and cost-effectiveness denom-
inated in the outputs for which we have data. We then go as
far as we can toward aggregation by adopting the conventions
of the healthy life year and the disability-adjusted healthy
life year.
Kumaranayake and others’ (2004) background study for this
chapter reviews the literature on the unit costs of STI treat-
ment. They identify 35 studies on this topic that provide a total
of 77 unit cost estimates. These are grouped in table 17.4 by the
disease or syndrome being treated and by the output that was
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costed. Of the 46 estimates of the unit cost of treatment, only
33 could be interpreted as, or converted to, 2001 U.S. dollars,
and the same applied to 9 of the 10 estimates of the unit cost of
a cure. Table 17.4 summarizes the results of these studies by the
disease or syndrome that occasioned the treatment.
The most notable thing about the summary statistics is their
variability: the cost per unit of output can vary by a factor of
100 or more. Even though the mean dollar cost per cure could
plausibly be almost four times that of treatment alone, the
standard errors are so large as to make the difference statisti-
cally insignificant.
The same point—that is, that unit costs vary enormously
from one site to another—is made by the preliminary results of
a study by Dandona and others (2005). The cost per case
treated in the study varies by a factor of 10 across the 14 sites.
Furthermore, the two sites that treat the fewest and the most
cases per year also display the highest costs, a finding that sug-
gests the existence of both economies and diseconomies of
scale.
The variables that determine the costs—and therefore the
cost-effectiveness—of STI treatment include the following:
• delivery by the public or private sector 
• economies of scale
• economies of scope
• prevalence and incidence
• epidemic phase
• transmission efficiency
• health system characteristics
• population composition and concentration
• resource combinations and input prices
• incentives to providers for high quality and quantity of serv-
ice delivery
• willingness to pay for treatment as a function of price,
income, and distance
• stigmatization
• disutility of condom use.
SCALING UP CONTROL STRATEGIES
Throughout the history of STI control, tension has been appar-
ent between those who support prioritizing resources for the
small proportion of people with the most sexual contacts and
those who advocate spreading prevention, screening, and treat-
ment resources more thinly over the entire population.
Opponents of prioritization argue that most of the people who
practice the riskiest behavior are hard to find and that attempts
to find them would expose those individuals to stigmatization
and repressive measures.
A group of researchers at the University of North Carolina
has developed and applied a novel approach to STI interven-
tions that has demonstrated in several countries that finding
the people who practice the riskiest sexual behavior without
targeting them as individuals is possible (Weir and others
2003). As an example of this approach, consider its application
to Madagascar, a country where risky sexual behavior had pre-
viously been thought to be too common to be identified or to
be distinguished from less risky behavior.
In May 2003, the Malagasy Steering Committee, which con-
sisted of representatives of the Ministry of Health, local gov-
ernment officials, and other knowledgeable experts, selected
five towns judged to be at high risk for STIs for a pilot study.
The Priorities for Local AIDS Control Effort (PLACE) method
applied in these towns was, first, to interview adults at random
on the streets of the city to find out where people go to meet
and socialize and, second, to visit and collect data on these loca-
tions and the people who frequent them.
In each of the five cities, the informants tended to agree on
the most frequented sites. They identified between 70 and
267 unique socialization sites of various types, ranging from
bars and restaurants to beaches and brothels. Interviews with
people frequenting the sites revealed them to be much more
sexually active than the average Malagasy adult. According to
the 1997 demographic and health survey, 13 percent of women
outside the capital city, Antananarivo, had two or more sexual
partners in the previous year. In contrast, the percentage of
women at the socialization sites who had had more than two
partners ranged from 46 to 68 percent. According to the
demographic and health survey, only about 3 percent of
women outside Antananarivo had four or more partners in the
previous year, but the percentage of women at the study sites
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Table 17.4 Average Estimated Costs per Unit of Output, by
Disease or Syndrome and Type of Output
(2001 US$)
Disease or syndrome Treatment Cure Average
Syphilis 36.04 n.a. 36.04
(5.91) n.a. (5.91)
Urethral discharge 14.29 89.07 29.25
(20.68) (0) (37.94)
Genital ulcer 23.16 100.60 48.97
(21.73) (83.74) (59.56)
Venereal disease 25.47 82.65 31.83
(18.56) (111.55) (37.12)
Pelvic inflammatory disease 7.12 n.a. 7.12
(3.09) n.a. (3.09)
Vaginal discharge 48.23 102.92 81.04
(0) (89.63) (70.10)
Total 24.05 96.10 39.49
(19.04) (73.44) (47.23)
Source: Authors’ calculations based on a literature review done as a background study for this
chapter by Kumaranayake and others 2004. 
n.a.  not applicable.
Note: The figures in parentheses are standard deviations. The 42 observations in the table are
individual unit cost estimates distributed across separate studies.
having this many partners was 10 times larger. The men inter-
viewed at these sites were even more sexually active than the
women.
The pilot study also investigated whether information on or
products for prevention of STIs, HIV, or both were available at
the socialization sites. In the five towns, the proportion of sites
where condoms were available on the day of the visit varied
from 27 to 54 percent. These percentages are not negligible
and are undoubtedly much higher than they were 10 years ago,
and the availability of condoms at so many of these sites is a
tribute to the success of the condom social-marketing cam-
paign. However, the statistics also indicate substantial room for
improvement, for example, by distributing condoms in 100 per-
cent of identified socialization sites. The feasibility of such a
program is enhanced by information from the PLACE study
that more than 80 percent of the owners or managers of these
sites expressed their willingness to host STI and HIV preven-
tion programs, and more than half were willing to sell
condoms.
Researchers have carried out similar PLACE studies in
Burkina Faso, Ghana, South Africa, and elsewhere. Un-
fortunately, in none of these countries has this extensive risk
mapping been followed by the implementation of prevention
programs at all the identified locations. Until such programs
are implemented and evaluated, no African country will be able
to claim that it has scaled up the most effective type of STI pre-
vention to population levels.
RESEARCH AND DEVELOPMENT AGENDA
Priorities for global STI research include the following:
• The development and evaluation of therapeutic (drug treat-
ment or vaccines), behavioral, and structural interventions
to prevent or reduce STIs and their sequelae. Given the
spread of drug-resistant strains of gonorrhea and other
STIs, new pharmaceutical products and new combination
therapies are needed to prevent and treat STIs.
• The development and evaluation of mechanisms to accu-
rately quantify the disease burden in order to prioritize
activities.
• The development and evaluation of inexpensive and practi-
cal rapid diagnostic tests to permit early detection and treat-
ment of STIs.
• The conducting of studies to evaluate effective prevention
modalities for persons at highest risk for STIs.
• The undertaking of health services research to gain an
understanding of practical and cost-effective STI prevention
strategies or systems that ideally can be integrated into exist-
ing public health infrastructure. When an individual is
treated for an STI, this treatment has both positive and neg-
ative spillover effects (externalities). The right combination
of patient and provider incentives needs to be found that
will maximize the beneficial spillovers while minimizing the
harmful ones.
• The implementation of studies in support of global elimi-
nation programs.
Because of the clandestine nature of most sexual behavior,
STIs are probably massively underreported, which in turn leads
to an underestimation of their importance. New survey and
measurement tools have been developed. They now need to be
applied to populations in poor countries to improve these
estimates.
In addition, randomized controlled trials need to be con-
ducted in different settings to test the hypothesis that treating
or preventing STIs in high-risk individuals has beneficial
spillover effects by preventing infections among low-risk indi-
viduals. An improved understanding of the determinants of
high-risk sexual behavior and the role that such behavior can
sometimes play in helping women to escape from poverty and
helping men to cope with it is also needed, as is a better under-
standing of the full range of benefits of effective STI interven-
tions for high-risk individuals and their dependents.
As concerns disease modeling and surveillance, further
improvements are needed in understanding the implications
for interventions of different kinds of local, regional, and inter-
national sex networks.
Tools
Because of the difficulty of persuading patients to adhere to a
course of medication for the prescribed period, single-dose
therapy would be valuable. Rapid, point-of-care diagnostics
are also a high priority, so that drugs can be targeted at
pathogens more accurately. New approaches for treating
chronic STIs should be incorporated into prevention strategies,
and blister packs of antibiotics that can be sold over the counter
for syndromic management of STIs should be available.
Vaccines would be particularly valuable, both for preventing
and for potentially treating chronic viral STIs and chlamydial
infection, which is often asymptomatic but is responsible for
considerable morbidity.
Diagnostics tests that could be used at home or at social
meeting spots may help people decide whether to engage in
risky sex. Packages of diagnostic tests that change color when
the contents expire would also be useful.
Intervention Methods
Syndromic management algorithms have now existed for more
than a decade. However, treatment algorithms are sensitive to
changes in the relative prices of pharmaceuticals and diagnostic
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reagents, in the prevalence of the various STIs, in pathogens’
resistance, and so on. Thus, every country needs some ability to
respond to local changes by developing or modifying algo-
rithms as needed.
As concerns intervention packaging, many policy makers
continue to believe that the most sexually active people are
hard to find. This belief hampers efforts to target these people
with STI prevention programs. The PLACE methods devel-
oped at the University of North Carolina offer an opportunity
to correct that impression and should be packaged with other
urban public health functions. Packaging sex education into
school curricula is a challenge in most of the world. As enroll-
ment rates for poor children, especially girls, rise, the presence
of a strong, culturally appropriate, sex education curriculum
will lay the foundation for strong STI prevention and treatment
campaigns.
As this chapter has argued, the determinants of the unit
costs of STI treatment and prevention are largely unknown. We
recommend health services and operations research to study
the determinants of the unit costs of STI prevention and treat-
ment services. The purpose of this research would be to learn
not only how to deliver care in the most cost-effective ways, but
also how to build systems that achieve that technological fron-
tier in a high percentage of public and private facilities and pass
those cost savings on to the government and to patients. Given
the beneficial spillover effects from effective STI prevention
and treatment among those who are most sexually active,
research is needed to learn how the PLACE approach to target-
ing can be implemented most cost-effectively in different cul-
tural contexts.
Finally, improved understanding of the best way to design
an STI treatment system, including the rewards and penalties
that best motivate providers (to be polite, discrete, prompt, effi-
cient, and accurate in following best practice, evidence-based
treatment protocols) and patients (to seek and then to adhere
to treatment) is a priority. Improved data on the costs of each
STI intervention at the pilot stage and after scaling up to the
national level are also necessary.
CONCLUSIONS
Regarding the cost-effectiveness of STI control, the position
this chapter takes is “it depends.” The health benefit in terms of
numbers of disability-adjusted, discounted, healthy life years
saved by curing or preventing a case of syphilis varies from
3 years in a person who has ceased all sexual activity to as many
as 161 years in a sex worker with two partners a day. The cost
of treating that prostitute for syphilis varies from US$5 to
US$100. Thus, the cost per DALY of syphilis treatment can
range from 100/3 or US$33 per DALY to 5/161 or less than
US$0.05 per DALY.
As we learn more about the complexities of delivering STI
treatment services and take into account the diversity of risk
behavior, the ease with which STI interventions can be ascribed
a simple cost-effectiveness ratio has declined. If no easy way to
summarize experience to date with a simple cost-effectiveness
ratio is available, how should we analyze economic investments
in STI treatment? We believe that the way forward is a better
understanding of why STI treatment and other health services
vary so much in terms of their efficiency and effectiveness from
one setting to another. By studying the determinants of this
variation, we should gain an improved understanding of the
full costs of high-quality STI service delivery and its place in the
health sector investment picture.
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NOTES
1. The Gini coefficient is a measure of inequality that here we apply to
income. If income is distributed equally in the population, the coefficient
is equal to 0, and if a few individuals hold almost all the wealth, the coef-
ficient is close to 1.
2. Given that WHO has expended enormous efforts to estimate dis-
counted years of life lost, disability years lost, and DALYs lost as a result of
STIs, the simplest and most direct approach for computing the DALY ben-
efits of preventing or curing an STI in a single patient would be to use
WHO’s years of life lost, disability years lost, or DALY per case assump-
tions. Alternatively, one could simply divide WHO’s aggregate values of
these indicators by the incidence rate of each disease in each region to
obtain the estimated burden per incident case. Unfortunately, neither the
case-specific burden numbers nor the incidence rates that correspond to
the DALY aggregates are available from WHO.
3. In contemporaneous data, STIs can either affect or be affected by
HIV prevalence. To focus on the effects of an STI on HIV infection, we lag
infection by an STI by seven years. Though partially correcting for simul-
taneity bias, this strategy does not allow us to identify whether lagged STI
prevalence is directly affecting HIV infection or only serving as a proxy for
the risky sexual behavior that drives both epidemics.
4. The samples include two measures of HIV prevalence (low- and
high-risk groups) for some countries. These measures enable us to expand
the sample used in the column (1) regression from 40 countries to 56 sep-
arate observations. Equations are estimated with Stata’s cluster option to
correct the standard errors of the coefficients for the correlation between
the errors on separate observations from the same country. The variable
urban high-risk dummy is used to shift the intercept coefficient for the
high-risk sample in comparison with the low-risk one.
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Although global commitment to control the HIV/AIDS pan-
demic has increased significantly in recent years, the virus con-
tinues to spread with alarming and increasing speed. By the end
of 2005, an estimated 40 million people worldwide were living
with HIV infection or disease, a notable rise from the 35 mil-
lion infected with HIV in 2001 (UNAIDS 2005). In 2005, close
to 5 million new HIV infections and 3 million AIDS deaths
occurred, more of both than in any previous year. Sub-Saharan
Africa remains the region most affected by HIV/AIDS; how-
ever, the virus is now spreading rapidly in Asia and parts of
Eastern Europe.
Despite the rapid spread of HIV, several countries have
achieved important success in curbing its transmission. The
extraordinary potential of HIV prevention is exemplified by
such diverse efforts as Thailand’s 100 percent condom pro-
gram, Uganda’s remarkable decrease in HIV prevalence, and
the community-based syndromic management of sexually
transmitted infections (STIs) in Mwanza, Tanzania. Box 18.1
describes characteristics common to these programs.
Successes also include the development and effective use of
highly sensitive and specific HIV screening tests, which have
virtually eliminated infection from the blood supply in the
developed world and in most parts of the developing world
(WHO 2002a). In addition, the administration of a short course
of nevirapine to mothers during labor and to newborns post-
partum reduces the risk of mother-to-child transmission
(MTCT) by as much as 47 percent (Guay and others 1999).
However, recent data suggest that such short-term successes
may be at the expense of resistance and viral failure once treat-
ment is introduced after delivery (Eshleman and others 2001).
Enormous advances in HIV/AIDS treatment regimens have
fundamentally altered the natural history of the disease and
sharply reduced HIV-related morbidity and mortality in coun-
tries where such treatments are accessible. The advent of anti-
retroviral drugs in the late 1980s began a revolution in the
management of HIV, which can be seen as analogous to the
use of penicillin for treating bacterial infections in the 1940s. The
most notable advance on the treatment front is the use of com-
bination antiretroviral therapy, which is far more effective than
monotherapy (zidovudine or AZT), the standard of care when
the first edition of this volume was published. Recent declines
in the price of combination antiretroviral therapy in develop-
ing countries from US$15,000 per year to less than US$150 in
some countries have prompted numerous developing countries
to introduce antiretroviral therapy through the public sector.
These declines also pose difficult questions regarding the optimal
allocation of limited resources for HIV/AIDS, as well as the
potential impact on already strained health care infrastructures.
OBSTACLES TO HIV CONTROL
Obstacles to effective HIV control include lack of prevention
and care coverage and lack of rigorous evaluations. Both are
discussed below.
Lack of Coverage and Access to Prevention Services
Notwithstanding these treatment strides, global efforts have
not proved sufficient to control the spread of the pandemic or
to extend the lives of the majority of those infected. The desired
level of success has not yet been achieved for several reasons.
Chapter 18
HIV/AIDS Prevention and Treatment
Stefano Bertozzi, Nancy S. Padian, Jeny Wegbreit, Lisa M.
DeMaria, Becca Feldman, Helene Gayle, Julian Gold, Robert Grant,
and Michael T. Isbell
Most people who could benefit from available control strate-
gies, including treatment, do not have access to them. Modelers
commissioned by the World Health Organization (WHO) and
the Joint United Nations Programme on HIV/AIDS (UNAIDS)
determined that existing interventions could prevent 63 per-
cent of all infections projected to occur between 2002 and 2010
(Stover and others 2002). Nonetheless, a 2003 survey of cover-
age revealed that fewer than one in five people at high risk of
infection had access to the most basic prevention services,
including condoms, AIDS education, MTCT prevention, vol-
untary counseling and testing (VCT), and harm reduction pro-
grams (Global HIV Prevention Working Group 2003). WHO
and UNAIDS estimate that only about 7 percent of the nearly
6 million people in need of treatment receive it and that the
number of people who require antiretroviral therapy increases
by 8,000 each day (UNAIDS 2004).
Current coverage shortfalls, combined with the relentless
expansion of the epidemic, underscore the acute need for rapid
scale-up of prevention and treatment interventions—an imper-
ative that the international community has acknowledged but
that remains to be realized after more than 15 years. However,
the activities of the Global Fund to Fight AIDS, Tuberculosis, and
Malaria and the U.S. President’s Emergency Plan for AIDS
Relief (a five-year, US$15 billion initiative) suggest a growing
commitment to tackle these issues. The latter aims to provide
antiretroviral drugs for 2 million HIV-infected people, to pre-
vent 7 million new infections, to provide care for 10 million indi-
viduals, and to develop health system capacity in Vietnam and
in Africa and the Caribbean. Even though 15 countries are cur-
rently slated to receive support from the President’s Emergency
Plan, many of the countries most affected by HIV/AIDS—
including Lesotho, Malawi, Swaziland, and Zimbabwe—are not
included in the list of beneficiary countries.
Because antiretroviral therapy has historically been unavail-
able in most developing countries, national programs have
lacked the means to undertake a comprehensive approach to
HIV/AIDS (notable exceptions are Argentina, Brazil, and
Mexico, which provide universal coverage for antiretroviral
therapy). As discussed in chapter 8, control of the pandemic
demands a two-front battle that emphasizes both prevention
and care. Even though the prospect of greater access to treat-
ment increases the feasibility of integrating prevention and care
in resource-limited settings, it also raises new questions regard-
ing the selection of optimal prevention programs to pair with
treatment programs.
Lack of Rigorous Evaluations
In addition to poor coverage of key interventions, perhaps the
greatest challenge to effective global control is the lack of
reliable evidence to guide the selection of interventions for spe-
cific areas or populations. In the same way that global policy
makers are increasingly recognizing the need for rigorous eval-
uation of development programs to ensure their success and
eliminate waste, the need for reliable scientific evaluations of
AIDS control programs is equally paramount for the same rea-
sons. There are simply not enough resources to do everything
everywhere; choices must be made and priorities set. In the
HIV/AIDS field, this information deficit is especially pro-
nounced with respect to HIV prevention in general and preven-
tion implemented on a population level in particular. Currently,
the allocation of resources for HIV/AIDS prevention is seldom
evidence based, primarily because of a lack of data on both the
effectiveness and the cost of interventions (Feachem 2004).
Few evaluations have collected data specifically on HIV
infection as an outcome (Fleming and DeMets 1996). In the
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Successful HIV Prevention Strategies
Box 18.1
The HIV prevention success stories highlighted in this
chapter stem in part from each country’s unique cultural,
historical, and infrastructural elements. Nevertheless,
these successes share several common features, thereby
offering potential guidance for the development and
implementation of prevention strategies in other settings.
These features include:
• high-level political leadership
• active engagement of civil society and religious leaders
in a multisectoral approach
• population-based programs designed to change social
norms
• increased open communication about sexual activities
and HIV/AIDS
• programs to combat stigma and discrimination
• condom promotion
• STI surveillance and control
• interventions targeting key “bridge” populations—
populations that transmit the virus from high-risk to
low-risk groups.
Source: Authors.
case of care and treatment, success and failure are more readily
and rapidly apparent, leading to a substantial degree of auto-
correction of ineffective policies. In contrast, with respect to
HIV prevention, it is unlikely that those infections that might
have occurred in the absence of a prevention program would
be monitored, thus reducing the meaningfulness of the auto-
feedback cycle for prevention. This underscores the importance
of proactive, rigorous evaluation to differentiate success from
failure in a timely manner. Sound evidence on the effectiveness
of HIV prevention measures is especially important in light of
the tendency of many governments and international aid agen-
cies to avoid programs that address sexual behaviors, drug use,
and highly stigmatized and vulnerable populations.
In addition, prevention studies have rarely incorporated
the well-defined control or comparison groups necessary to
identify contextual factors that are essential for appropriately
tailoring interventions to the diverse regional settings and the
myriad of microenvironments in which HIV transmission
occurs (Grassly and others 2001). Contextual data are similarly
critical for developing strategies to combat HIV/AIDS-related
stigma and restrictive social and gender norms, which often
frustrate attempts to address sexual and addictive behaviors
associated with HIV transmission. Even where national efforts
have succeeded in curbing the spread of the epidemic, as in
Senegal and Uganda, evidence often does not clearly indicate
the specific, well-defined, contextual features that account for
success.
The lack of both contextual data and sound evidence
regarding the effectiveness of HIV interventions hinders policy
makers’ ability to tailor HIV interventions to the nature and
stage of national epidemics, something that the authors argue
is necessary to address HIV/AIDS effectively. In the absence of
such data, HIV/AIDS expenditures undoubtedly incorporate
an unacceptable degree of waste, people are unnecessarily
becoming infected with HIV, and HIV-infected individuals are
dying prematurely.
Why has this type of research not been more forthcoming?
In part it is because, by definition, such research is less innova-
tive scientifically and also typically less experimental than
research to develop new interventions. It is handicapped both
in competing for traditional research funding and in receiving
academic recognition. The only way to redress the imbalance is
through specific earmarking of significant research funds.
ACTION UNDER UNCERTAINTY
Even though the current deficit in evaluation research is glar-
ing, the magnitude and seriousness of the global pandemic
means that action is nevertheless required. Moreover, despite
such gaps in knowledge, we can still improve control strategies
by tailoring interventions to the nature and scope of the epi-
demic. Summarized below is what is known with regard to the
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burden of disease, the determinants of transmission, and the
effectiveness and cost-effectiveness of existing prevention
interventions.
Burden of Disease 
As a result of large-scale implementation of data collection
methods for surveillance worldwide and enhanced methods for
validating and interpreting HIV-related data, the HIV/AIDS
epidemic is probably one of the best documented epidemics
in history. An increasing number of data sources contribute
to reasonably accurate estimates and a more nuanced under-
standing of the epidemic’s trends. Unfortunately, this relatively
accurate picture of where the epidemic is and has been is not
matched by similarly convincing maps of the factors that
explain its spread.
Although no single country has been spared the virus, the
epidemic has affected certain regions of the world dispropor-
tionately, and Sub-Saharan Africa remains by far the hardest hit
region (table 18.1). With only 10 percent of the world’s popu-
lation, it accounts for more than 75 percent of all HIV infec-
tions worldwide and more than 75 percent of AIDS-related
deaths estimated for 2003. Asia and the Pacific, with several
large and populous countries, account for 7.4 million infec-
tions, or 19.5 percent of the current burden of disease.
Prevention and treatment efforts in Sub-Saharan Africa and
Asia—regions that together represent 85 percent of all current
infections—have dictated, and will continue to dictate, global
trends in the burden of HIV- and AIDS-related mortality.
Between 1997 and 2001, the percentage of women living
with HIV/AIDS increased from 41 to 50 percent. This trend is
most apparent in Sub-Saharan Africa, where women represent
57 percent of adults living with HIV and 75 percent of HIV-
infected young people. Even though women account for a
smaller share of infections in Asia (28 percent), the disease bur-
den among women and girls is likely to rise as the epidemic
becomes generalized. More detailed information about the
global burden of HIV/AIDS, regional differences, and trends
over time is available in the UNAIDS (2005) report on the
global AIDS epidemic.
Determinants of Infection
HIV transmission predominantly occurs through three mech-
anisms: sexual transmission, exposure to infected blood or
blood products, or perinatal transmission (including breast-
feeding). The likelihood of transmission is heavily affected by
social, cultural, and environmental factors that often differ
markedly between and within regions and countries. There is
also some indication that molecular, viral, immunological, or
other host factors might influence the likelihood of HIV trans-
mission. For a more detailed discussion of sexual behaviors and
the contextual determinants of infection, see chapter 17.
Sexual Transmission. Worldwide, sexual intercourse is the
predominant mode of transmission, accounting for approxi-
mately 80 percent of infections (Askew and Berer 2003). Sexual
intercourse accounts for more than 90 percent of infections in
Sub-Saharan Africa. Although many people who know they
are infected reduce their risk behaviors, studies in developed
countries suggest that a substantial percentage nevertheless
continue to engage in unprotected sex (Marks, Burris, and
Peterman 1999). The risk of sexual transmission is determined
by behaviors that influence the likelihood of exposure to an
infected individual and by infectivity in the event of exposure.
This also includes factors related to the infectiousness of the
infected partner and the susceptibility of the uninfected partner.
Infectivity The per contact infectivity of HIV from sexual trans-
mission varies depending on sexual activity (Royce and others
1997).Anal intercourse carries a higher transmission probability
than penile-vaginal intercourse, and male-to-female transmis-
sion is more likely than female-to-male transmission. Data on
infectivity by transmission mode are shown in table 18.2.
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Table 18.1 Deaths and Disability-Adjusted Life Years Attributed to AIDS by Region, Age, and Gender, 2001
Number (thousands)
Region Total Both sexes, age 0–14 Both sexes, age 15 Percentage female
Deaths
World 2,576 439 2,133 46
High-income countries 22 0 21 23
Low- and middle-income countries 2,554 439 2,111 46
Sub-Saharan Africa 2,058 408 1,651 51
East Asia and the Pacific 107 5 100 25
Europe and Central Asia 28 0 27 14
Latin America and the Caribbean 83 8 73 36
Middle East and North Africa 4 0 2 25
Southeast Asia 272 18 255 23
Disability-adjusted life years
World 71,460 13,586 57,875 47
High-income countries 665 7 660 23
Low- and middle-income countries 70,795 13,579 57,215 47
Sub-Saharan Africa 56,820 12,526 44,294 52
East Asia and the Pacific 3,121 195 2,927 25
Europe and Central Asia 982 25 957 18
Latin America and the Caribbean 2,354 260 2,092 36
Middle East and North Africa 105 20 84 39
Southeast Asia 7,413 553 6,861 25
Source: Mathers and others 2006.
Table 18.2 Estimated HIV Transmission Risk per Exposure
Type of exposure Estimated risk HIV transmission per exposure
Receptive anal intercourse  3.0 percent (1/125 to 1/31) (DeGruttola and others 1989) 
Receptive vaginal intercourse  0.1 percent (1/2,000 to 1/667) (Mastro and others 1994; Wiley, Herschkorn, and Padian 1989)
Insertive vaginal or anal intercourse  0.1 percent (1/3,333 to 1/1,111) (Nagachinta and others 1997; Peterman and others 1988) 
Needlestick injury  0.3 percent (1/313) (Henderson and others 1990) 
Use of contaminated injecting drug equipment  0.6 percent (1/149) (Kaplan and Heimer 1992) 
Mucous membrane  0.1 percent (1/1,111) (Ippolito, Puro, and De Carli 1993) 
Source: Authors.
Biological Mediators of Infectivity Untreated STIs increase
the risk of sexual HIV transmission several-fold (Institute of
Medicine 1997). Numerous epidemiological studies have sup-
ported the association of genital ulcers in general and of geni-
tal herpes (herpes simplex virus 2, or HSV-2) in particular with
HIV infection (Hook and others 1992). Not only does the bio-
logical interaction between HSV-2 and HIV enhance the trans-
mission and acquisition of HIV, but HIV infection is also asso-
ciated with more frequent reactivation of HSV-2. The presence
of herpetic ulcers and lesions allows an entry point for HIV in
the uninfected individual, and the presence of high copy num-
bers of HIV ribonucleic acid (RNA) in HSV-2 lesions in HIV-
infected individuals underscores the importance for HIV pre-
vention of controlling HSV-2 infections (Mbopi Keou and
others 1999).
Vaginal infections are also emerging as important risk
factors for HIV. For example, infection with trichomonas
increases the risk for HIV seroconversion (Buve 2002). In addi-
tion, higher trichomonas rates have been detected in regions of
Sub-Saharan Africa that have higher HIV rates, and investiga-
tors working throughout Sub-Saharan Africa report similar
results, with odds ratios from 1.5 to 56.8 (Gregson and others
2001). In addition, studies have shown an increased risk of HIV
acquisition in patients who have bacterial vaginosis (Martin
and others 1999).
Circumcision also affects HIV transmission. In a meta-
analysis of 27 studies (Weiss, Quigley, and Hayes 2000), uncir-
cumcised men were almost twice as likely to be infected with
HIV as those who were circumcised. Studies that controlled
adequately for other risks and studies that separately assessed
risk in high-risk populations, such as STI clinic attendees or
truck drivers, found an even stronger protective effect of cir-
cumcision. Similarly, an ecological study comparing two high-
prevalence Sub-Saharan African cities with two low-prevalence
cities found that circumcised individuals were substantially less
likely to be infected with HIV (Auvert and others 2001). Two
recent studies conducted in Kenya and India (Donnelly 2004;
Reynolds and others 2004) found that uncircumcised men had
an HIV rate 7 to 11 times greater than circumcised men. More
recently, results from a randomized controlled trial conducted
in South Africa indicated that the risk of HIV acquisition was
reduced by more than 60 percent of men randomized for
circumcision (controlling for sexual behavior, including con-
dom use and health seeking behavior) in a community where
more than 30 percent of the women were infected (Auvert and
others 2005).
Before circumcision among adult males becomes a wide-
spread policy recommendation, results are still pending in two
similar trials. Obviously one issue is the acceptability of such a
procedure as well as the fact that some increase in high risk sex-
ual activity was noted among the men who were circumcised,
although this did not offset the results of the intervention.
The risk of sexual transmission is also strongly correlated
with the plasma level of virus in the infected individual (Quinn
and others 2000); thus, infectivity varies over the natural
progression of the disease. Individuals are most infectious sub-
sequent to infection and again during the late stage of the
disease. Antiretroviral therapy significantly reduces the level of
virus, often to the point that standard tests cannot detect HIV
in the patient’s blood (Palella and others 1998). Available data
suggest that viral load reductions induced by antiretroviral
therapy will lower infectiousness. Studies have shown a close
relationship between the amount of viral suppression and the
risk of vertical transmission (Garcia and others 1999). Quinn
and others (2002) show that the risk of sexual transmission
between couples in Africa was strongly related to the level of
viral load in the infected partner.
Exposure to Infected Blood or Blood Products. Injection
drug use and blood transfusion are two mechanisms of HIV
exposure to infected blood. Determinants of each are discussed
below.
Injection Because of the efficiency of HIV transmission
through needle sharing, the introduction of HIV into an urban
network of injecting drugs users can quickly lead to extraordi-
narily high HIV prevalence in this population. Sharing of injec-
tion equipment and frequency of injection are both important
correlates of HIV infection (Chaisson and others 1989).
Attendance at shooting galleries, where sharing with anony-
mous injecting partners is likely to occur, is also an independent
risk factor across many studies (Vlahov and others 1990).
Injecting cocaine (associated with “booting” or “kicking,” where
blood is drawn into the syringe and then injected) and having a
number of needle-sharing partners are also associated with HIV
infection (Anthony and others 1991).
Blood Transfusion The probability of becoming infected
through an HIV-contaminated transfusion is estimated at
more than 90 percent (UNAIDS 1997), and the amount of HIV
in a single contaminated blood transfusion is so large that indi-
viduals infected in this manner may rapidly develop AIDS.
Currently, between 5 and 10 percent of HIV infections world-
wide are transmitted through the transfusion of contaminated
blood products (WHO 2002a). Setting up and maintaining a
safe blood supply will virtually eliminate HIV transmission
through transfusions.
Perinatal Transmission. Perinatal HIV transmission includes
both vertical transmission and transmission during breastfeed-
ing. Determinants of each are discussed below.
Vertical Transmission Perhaps the most compelling evidence
of the significance of viral load and transmission risk has been
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documented with respect to MTCT. Maternal viral load, as
quantified by RNA polymerase chain reaction, is associated
with increased risk in each mode of vertical transmission. A
recent randomized clinical trial in Kenya found that maternal
plasma HIV RNA levels higher than 43,000 copies per milliliter
were associated with a fourfold increase in vertical transmis-
sion (John and others 2001).
Independent of HIV RNA levels in maternal plasma, addi-
tional risk factors include cervical HIV deoxyribonucleic acid
(DNA), vaginal HIV DNA, and cervical or vaginal ulcers.
Chorioamnionitis has also been documented as a risk factor for
MTCT among African mothers (Ladner and others 1998), as
has exposure to maternal blood during labor and delivery.
Newell (2003) estimates that for every hour an infant is
exposed to ruptured membranes, the risk of transmission
increases by 2 percent.
Breastfeeding Transmission through breastfeeding is likely
associated with an elevated viral load in the breast milk, which
in turn is associated with maternal plasma viral load and CD4
T cell levels. Mastitis has also been associated with increased
risk of vertical transmission. Meta-analyses suggest that the
cumulative probability of HIV infection increases from 0.6 per-
cent at age 6 months to 9.2 percent at age 3 (Read 2003). A
study in Malawi, however, indicates that most transmission
occurs in the early breastfeeding months, with an incidence per
month of 0.7 percent at age 1 to 5 months, 0.6 percent at age 6
to 11 months, and 0.3 percent at age 12 to 17 months (Miotti
and others 1999). In one study, infants who were breastfed in
combination with receiving other supplementary foods were
twice as likely to be infected at age 6 months than infants fed
exclusively on breast milk or on formula (Coutsoudis and oth-
ers 2001). The hypothesis is that antigens and bacterial con-
taminants present in supplemental fluids and foods consumed
by infants who are not exclusively breastfed may cause inflam-
mation and microtrauma to the infant’s intestinal gut, thereby
facilitating viral transmission. Another hypothesis is that mixed
feeding increases the risk of subclinical or clinical mastitis in
the mother, which could increase milk viral load (Semba and
others 1999).
Decisions about breastfeeding are further complicated by
recent data indicating possible increased mortality among
breastfeeding mothers (Nduati and others 2001) and by the
stigma associated with not breastfeeding in countries where
abstaining from breastfeeding is tantamount to disclosing a
woman’s HIV status.
Effectiveness and Cost-Effectiveness 
of Prevention Interventions
Below we discuss the need for ongoing surveillance and con-
textual data to determine the effectiveness of HIV interventions
and how best to implement those interventions. We then dis-
cuss the existing effectiveness and cost-effectiveness data.
Essential Background Data for Any Intervention. Because
the prioritization of prevention strategies for any epidemic
requires accurately identifying the epidemiological profile (dis-
cussed below), maintaining a sound and reliable public health
surveillance system is a prerequisite for an effective prevention
response. An understanding of HIV and STI prevalence and
trends, as well as the prevalence and distribution of behaviors
that contribute to the epidemic’s spread, should be supple-
mented by national monitoring systems that track sources and
uses of funding to promote greater accountability. In addition,
data are needed to identify and characterize key contextual
issues that affect the selection of interventions.
Although surveillance is essential for an optimally strategic
public health response, its utility depends on the degree to
which the information it yields is effectively deployed. As noted
below, countries with concentrated epidemics should prioritize
interventions that are targeted to the populations at highest
risk. In Latin America, however, where information on national
AIDS funding is strongest, the proportion of limited preven-
tion resources that is not targeted to the populations at highest
risk of infection varies from less than 5 percent to more than
50 percent (Saavedra 2000). This range strongly suggests that
resource allocation is frequently not based on available epi-
demiological and effectiveness data.
Table 18.3 summarizes information about the effectiveness
of the interventions discussed below.
Cost-Effectiveness Estimates for Prevention Interventions.
How countries spend funds and which interventions they
prioritize should be guided by estimates of the relative cost-
effectiveness of such interventions. Unfortunately, reliable
estimates of cost-effectiveness are largely lacking, for a number
of reasons. The main reason is that HIV prevention interven-
tions are difficult to force into a typology that clearly distin-
guishes one intervention from another. For example, the
counseling component of VCT has a strong information-
sharing element that overlaps with (a) information, education,
and communication (IEC) through the media; (b) peer
interventions; and (c) the counseling component of STI treat-
ment. Similarly, the psychological support offered through
counseling is comparable to support provided through support
groups or to interventions designed to increase social support.
Such overlap and duplication among components of different
interventions complicate efforts to estimate both the effective-
ness and the cost-effectiveness of different interventions.
Several authors have recently reviewed estimates of cost-
effectiveness for the prevention interventions described here
(Creese and others 2002; Jha and others 2001; Marseille and
others 2002; Walker 2003). These reviews address a number of
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Table 18.3 Effectiveness of HIV Interventions
Intervention Outcome Effect Citations
School-based education
Abstinence education
VCTa
Peer-based programs
Condom promotion and
distribution and IECa
Sexual debut
Multiple sex partners
Condom use
HIV incidence
STI prevalence and incidence
Condom use
Early sexual debut
Condom use
Unprotected intercourse
HIV incidence
STI prevalence and incidence
Condom use
Unprotected intercourse
Communication about condoms
with partner
HIV incidence
STI prevalence and incidence
Condom use
The number of students reporting early
sexual debut was significantly lower in the
intervention group in both studies. 
The number of students reporting multiple sex
partners was significantly lower in the
intervention group in both studies. 
Condom use was significantly higher in the
intervention group in three of the four studies
and nonsignificantly higher in one study.
The study found no significant differences 
in HIV incidence.
The study found no significant differences 
in STI prevalence and incidence.
The study found no significant differences 
in condom use. 
The study found no significant differences 
in early sexual debut. 
Condom use was significantly higher in the
intervention group in six of the seven studies
and unchanged in one study. 
Unprotected intercourse was significantly
lower in the intervention group in both
studies.
HIV incidence was significantly lower in the
intervention group in one of the studies and
nonsignificantly lower in the other study.
STI prevalence and incidence were
significantly lower in the intervention group
in all three studies.
Condom use was significantly higher in the
intervention group in all four studies. 
Unprotected intercourse was significantly
lower in the intervention group in all four
studies.
Communication was significantly higher in
the intervention group. 
HIV incidence was significantly lower in the
intervention group in both studies. 
STI prevalence and incidence were
significantly lower in the intervention group. 
Condom use was significantly higher in the
intervention group in 10 of the 11 studies
and unchanged in 1 study.
Hayes and others 2003; Stanton and
others 1998
Fawole and others 1999; Hayes and others
2003
Fawole and others 1999; Harvey, Stuart,
and Swan 2000; Hayes and others 2003;
Stanton and others 1998
Hayes and others 2003
Hayes and others 2003
Jemmott, Jemmott, and Fong 1998
Meekers 2000
Bentley and others 1998; Bhave and others
1995; Deschamps and others 1996;
Jackson and others 1997; Kamenga and
others 1991; Levine and others 1998;
Voluntary HIV-1 Counseling and Testing
Efficacy Study Group 2000
Deschamps and others 1996; 
Voluntary HIV-1 Counseling and Testing
Efficacy Study Group 2000 
Bhave and others 1995; Celentano and
others 2000
Celentano and others 2000; Jackson and
others 1997; Levine and others 1998
Kelly and others 1997; Norr and others
2004; Sikkema and others 2000; Stanton
and others 1996
Basu and others 2004; Kegeles, Hays, and
Coates 1996; Kelly and others 1997;
Sikkema and others 2000
Lauby and others 2000
Ghys and others 2002; Katzenstein and
others 1998
Ghys and others 2002 
Bentley and others 1998; Bhave and
others 1995; Egger and others 2000; Ford
and others 1996; Jackson and others 1997;
Jemmott, Jemmott, and Fong 1998;
Kagimu and others 1998; Laga and
others 1994; Levine and others 1998;
Ngugi and others 1988; Pauw 
and others 1996
(Continues on the following page.)
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Table 18.3. Continued
Intervention Outcome Effect Citations
Condom social marketing
STI treatmenta
Antiretroviral therapy to
reduce MTCT
MTCT feeding
substitutions
Harm reduction in injecting
drug users 
Drug substitution for
injecting drug users
Blood safety
Universal precautions
Antiretroviral therapy for
prevention, postexposure
prophylaxis
Behavior change for those
HIV positive
HIV incidence
STI prevalence and incidence
Condom use
Early sexual debut
HIV incidence
STI prevalence and incidence
Mother-to-infant transmissionb
Mother-to-infant transmission
HIV incidence
Reuse or sharing of syringes
Drug use
HIV infections averted
Units of HIV-positive blood
averted
Blood volume transferred in
needlestick injury
HIV seroconversion
Condom use
Unprotected intercourse
HIV incidence was significantly lower in the
intervention group in two out of three studies
and nonsignificantly lower in one study.
STI prevalence and incidence were
significantly lower in the intervention group
in all four studies.
Condom use was significantly higher in 
the intervention group in one study; no
significant differences were found in the
other study.
The study found no significant differences in
early sexual debut. 
HIV incidence was significantly lower in the
intervention group in two of the studies, but
the other two studies found no significant
differences. 
The prevalence and incidence of STIs were
significantly lower in the intervention group
in all six studies.
Significant reduction in mother-to-infant HIV
transmission in the intervention group was
found in all eight studies, with a range of 
33 to 67 percent reduction in transmission.
Use of breast milk substitutes prevented 
44 percent of infant infections and was
associated with significantly improved 
HIV-1-free survival.
Significant reduction in HIV incidence in the
intervention group was found in both studies.
Significant reduction in needle sharing in the
intervention group was found in all three
studies; correlation between needle
exchange program attendance and lower
needle sharing was found in one study.
This meta-analysis found significantly lower
rates of drug use. 
HIV screening was associated with a
reduction in HIV infections by both studies. 
HIV screening was associated with a
reduction in units of HIV-positive blood. 
Glove material reduced the transferred blood
volume by 46 to 86 percent. 
The study found a significant relationship
between seroconversion and not having
received antiretroviral therapy.
Condom use was significantly higher in the
intervention group. 
Unprotected intercourse was significantly
lower in the intervention group.
Bhave and others 1995; Celentano and
others 2000; Laga and others 1994 
Bhave and others 1995; Celentano and
others 2000; Jackson and others 1997;
Laga and others 1994; Levine and others
1998 
Agha, Karlyn, and Meekers 2001; 
Meekers 2000
Meekers 2000 
Grosskurth and others 1995; Kamali and
others 2003; Laga and others 1994;
Wawer and others 1999
Jackson and others 1997; Kamali and oth-
ers 2003; Laga and others 1994; Mayaud
and others 1997; Wawer and others 1999
Ayouba and others 2003; Connor and others
1994; Dabis and others 1999; Guay and
others 1999; Jackson and others 2003;
PETRA Study Team 2002; Shaffer and
others 1999; Wiktor and others 1999
Nduati and others 2000
Des Jarlais and Friedman 1996; Hurley,
Jolley, and Kaldor 1997
Jenkins and others 2001; Ksobiech 2003;
Peak and others 1995; Vlahov and others
1997
Metzger, Navaline, and Woody 1998
Foster and Buve 1995; Laleman and 
others 1992
Jacobs and Mercer 1999
Mast, Woolwine, and Gerberding 1993
Cardo and others 1997
Kalichman and others 2001
Kalichman and others 2001 
Source: Authors.
a. Studies examined may have included educational components, condom promotion and distribution components, HIV testing and counseling, or STI treatment.
b. The types of MTCT antiretroviral therapy varied in theses studies.
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Table 18.4 Cost-Effectiveness of Interventions by Epidemic Profile
Intervention
Surveillance
IEC
School-based
education
Abstinence
education
VCT
Low-level epidemic
(Middle East and 
North Africa)
No CE studies found
No CE studies found
No CE studies found
No CE studies found
No CE studies found
Concentrated epidemic
(East Asia and the Pacific,
Europe and Central Asia,
Latin America and the 
Caribbean, South Asia)
No CE studies found
No CE studies found
India (E/D/no STIs) 
US$1,350 per HIV infection
US$68 per DALY
(World Bank 1999)
No CE studies found
India 
US$196 per HIV infection
US$10 per DALY
(World Bank 1999) 
Generalized low-
level epidemic 
(Sub-Saharan Africa)
No CE studies found
No CE studies found
No CE studies found
No CE studies found
Chad (M/S/no STIs)
US$891 to US$5,213 per HIV
infection
US$45 to US$261 per DALY
(Hutton, Wyss, and N’Diekhor
2003)
Kenya and Tanzania (M/S/STI)
US$270 to US$376 per HIV
infection
US$14 to US$19 per DALY
(Sweat and others 2000)
Generalized high-
level epidemic 
(Sub-Saharan Africa)
No CE studies found
No CE studies found
No CE studies found
No CE studies found
No CE studies found
2003 US$ millions 
—
129
100
—
2,175
Percentage
of all
prevention
needs
—
1
1
—
22
UNAIDS estimate of need for 2007Epidemic profile (2001 US$) 
(Continues on the following page.)
340
|
Disease Control Priorities in Developing Countries
|
Stefano Bertozzi, N
ancy S. Padian, Jeny W
egbreit, and others
Table 18.4 Continued
Intervention
Peer-based
programs
Condom promotion
and distribution 
and IEC
Low-level epidemic
(Middle East and 
North Africa)
No CE studies found
No CE studies found 
Concentrated epidemic
(East Asia and the Pacific,
Europe and Central Asia,
Latin America and the 
Caribbean, South Asia)
United States (E/S/no STIs) 
US$71,113 per HIV infection, 
US$3,556 per DALY
(Pinkerton and others 1998)
United States (E/D/no STIs)
US$14,934 to US$18,719 per
HIV infection
US$747 to US$936 per DALY
(Kahn and others 2001)
India (sex workers)
US$52 per HIV infection
US$3 per DALY
(World Bank 1999)
India (high-risk men) 
US$303 per HIV infection 
US$15 per DALY
(World Bank 1999)
No CE studies found 
Generalized low-
level epidemic 
(Sub-Saharan Africa)
Chad (sex workers)
US$6 to US$30 per HIV
infection
US$0 to US$2 per DALY
(Hutton, Wyss, and
N’Diekhor 2003)
Chad (high-risk men)
US$24 to US$1,476 per HIV
infection
US$1 to US$74 per DALY
(Hutton, Wyss, and
N’Diekhor 2003)
Chad (youths) 
US$129 to infinity per HIV
infection
US$6 to infinity per DALY
(Hutton, Wyss, and
N’Diekhor 2003)
Cameroon (E/D/STIs) 
US$67 to US$137 per HIV
infection
US$3 to US$7 per DALY
(Kumaranayake and others
1998)
No CE studies found
Generalized high-
level epidemic 
(Sub-Saharan Africa)
No CE studies found
South Africa (female condom)
(M/D/STI)
US$378 to US$4,094 per HIV
infection
US$19 to US$205 per DALY
(Marseille and others 2001)
2003 US$ millions 
3,696
1,093
Percentage
of all
prevention 
needs
37 
11
UNAIDS estimate of need for 2007Epidemic profile (2001 US$) 
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Condom social
marketing
STI treatment
Antiretroviral
therapy to reduce
MTCT
No CE studies found
No CE studies found
No CE studies found
No CE studies found
No CE studies found
Mexico (M)
US$39,230 to US$42,528 per
HIV infection
US$2,124 to US$2,303 per
DALY
(Rely and others 2003)
India
$2,527 per HIV infection 
$126 per DALY
(World Bank 1999)
Chad
US$77 per HIV infection
US$4 per DALY
(Hutton, Wyss, and
N’Diekhor 2003)
Chad
US$1,675 per HIV infection
US$84 per DALY
(Hutton, Wyss, and
N’Diekhor 2003)
Tanzania (E/S/STI)
US$326 per HIV infection 
US$16 per DALY
(Gilson and others 1997)
Kenya (E/D/STI)
US$11 to US$16 per HIV
infection
US$1 per DALY
(Moses and others 1991)
Zambia (E)
US$848 per HIV infection
US$34 per DALY
(Stringer and others 2003)
Chad (AZT) 
US$924 to US$4,044 per HIV
infection
US$37 to US$162 per DALY
(Hutton, Wyss, and
N’Diekhor 2003)
Chad (breastfeeding advice) 
US$1,241 to US$4,382 per
HIV infection
US$50 to US$175 per DALY
(Hutton, Wyss, and
N’Diekhor 2003)
No CE studies found
South Africa (E/STI)
US$2,093 per HIV infection
US$105 per DALY
(Vickerman and others
forthcoming) 
South Africa (M) 
US$1,650 to US$3,844 per
HIV infection
US$66 to US$154 per DALY
(Wilkinson, Floyd, and Gilks
1998)
Sub-Saharan Africa (M)
US$5,279 to US$11,444 per
HIV infection 
US$211 to US$458 per DALY
(Marseille, Kahn, and Saba
1998)
Sub-Saharan Africa (nevira-
pine) (M) 
US$142 to US$306 per HIV
infection
US$6 to US$12 per DALY
(Marseille and others 1999)
198
783
320 
2
8 
3 
(Continues on the following page.)
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Table 18.4 Continued
Intervention
MTCT, feeding
substitution
Harm reduction for
injecting drug users 
Drug substitution for
injecting drug users
Blood safety
Low-level epidemic
(Middle East and 
North Africa)
No CE studies found 
No CE studies found
No CE studies found
Concentrated epidemic
(East Asia and the Pacific,
Europe and Central Asia,
Latin America and the 
Caribbean, South Asia)
No CE studies found
Belarus (E)
US$353 per HIV infection
US$18 per DALY
(Kumaranayake and others
2004)
Russia (E)
US$564 per HIV infection
US$28 per DALY
(Bobrik 2004)
No CE studies found
Generalized low-
level epidemic 
(Sub-Saharan Africa)
No CE studies found
No CE studies found
No CE studies found
Chad 
US$75 to US$151 per HIV
infection
US$4 to US$8 per DALY
(Hutton, Wyss, and
N’Diekhor 2003)
Zambia (E/D/STI)
US$215 to US$262 per HIV
infection
US$11 to US$13 per DALY
(Watts, Goodman, and
Kumaranayake 2000)
Zambia (E)
US$41 per HIV infection
US$2 per DALY
(Foster and Buve 1995)
Generalized high-
level epidemic 
(Sub-Saharan Africa)
No CE studies found
No CE studies found
No CE studies found
Zimbabwe (E) 
US$166 to US$1,010 per HIV
infection
US$8 to US$51 per DALY
(McFarland and others 1995)
2003 US$ millions 
—
241 
—
230
Percentage
of all
prevention 
needs
—
2 
—
2 
UNAIDS estimate of need for 2007Epidemic profile (2001 US$) 
1–40 percent HIV prevalence
US$9 to US$1,806 per HIV infection
US$0.45 to $90 per DALY 
(Over and Piot 1996)
0.01–1 percent HIV prevalence
(M/D/STIs)
US$374 to US$45,173 per 
HIV infection
US$19 to US$2,259 per DALY
(Over and Piot 1996)
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Sterile injection
Universal
precautions
Antiretroviral
therapy for
prevention and
postexposure
prophylaxis 
Vaccines
Behavior change for
those who are
HIV
Middle East (M)
US$393 per DALY
(Dziekan and others 2003) 
No CE studies found
No CE studies found
No CE studies found
No CE studies found
Southeast Asia 
US$143 to US$593 per DALY 
Americas 
US$1,851 to US$56,642 
per DALY 
Western Pacific
US$953 per DALY 
(Dziekan and others 2003)
No CE studies found
United States (E/S/no STIs)
US$76,584 per HIV infection
US$3,829 per DALY
(Pinkerton, Holtgrave, and
Bloom 1998)
No CE studies found
No CE studies found
Africa
US$91 to US$230 per DALY
(Dziekan and others 2003)
No CE studies found
No CE studies found
No CE studies found
No CE studies found
No CE studies found
No CE studies found
No CE studies found
No CE studies found
94
663
1
—
112
1
7
1
—
1
Source: Authors.
—  not available.
CE  cost-effectiveness.
Note: The authors have categorized each of the studies. The first time each study is mentioned, it is identified by whether it was modeled (M) or empirical (E); whether it calculated primary HIV infections averted (S, for static) or if it also showed secondary infections
averted (D, for dynamic); and where appropriate, we indicate if the study also looked at the impact on STIs. The cost-effectiveness of these interventions will differ depending on the population to which they are targeted, (that is, mass interventions versus targeted
interventions). In addition, the cost-effectiveness of each intervention may vary greatly by study, because each cost-effectiveness study is not uniform. No cost-effectiveness studies of male condom promotion were found, because condom promotion, distribution, and
IEC are generally part of a larger program with many components and studies did not distinguish between the costs of individual components of such programs.
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methodological issues that will not be repeated here. The
reviews agree that the availability of cost and cost-effectiveness
analyses for HIV/AIDS prevention strategies is limited and that
the need for such knowledge for planning and decision-making
purposes is urgent.
Table 18.4 summarizes available cost-effectiveness estimates
for the four UNAIDS epidemic profiles that are described later
in table 18.5. The estimates of cost per disability-adjusted life
year (DALY) saved assume a uniform 20 DALYs lost per infected
adult (Murray and Lopez 1996) and 25 DALYs lost per infected
child (Marseille and others 1999) and do not account for the
increasing proportion of people living with HIV/AIDS in
developing countries who will have access to antiretroviral
therapy over the coming years.
General Interventions Relevant for All Modes of Transmission
The following are general interventions not specifically target-
ing the mode of transmission:
• Information, education, and communication. This interven-
tion includes education on HIV/AIDS and condom use
through pamphlets, brochures, and other promotional
materials in classroom or clinic settings or through the
radio, television, or press. In general, discerning the effec-
tiveness of IEC alone is difficult, because IEC is often
included in condom promotion and distribution interven-
tions. Here we consider the effectiveness of IEC in concert
with condom promotion and distribution. Of all available
prevention interventions, providing information and edu-
cation about HIV/AIDS is perhaps the most difficult to
assess for cost-effectiveness. Numerous studies have shown
that information alone is typically insufficient to change risk
behavior. Accurate information, however, is indisputably the
basis for informed policy discourse—a vital ingredient in
the fight against fear-based stigma and discrimination. In
the absence of studies to guide the level of investment in
IEC, the only reasonable alternative seems to be to imple-
ment IEC on the basis of data derived from relative levels of
knowledge and understanding in the population. For exam-
ple, if only 25 percent of the sexually active population were
able to describe how HIV is transmitted and prevented,
clearly more IEC would be needed, but if 75 percent of the
population understood the basic facts about HIV/AIDS, the
need for additional funding would be diminished.
• School-based sex education. School-based sex education pro-
grams, an aspect of IEC, provide information to young peo-
ple and reinforce healthy norms in a school setting
(Peersman and Levy 1998). Limited data have shown differ-
ences in students who have been exposed to school-based
sex education (summarized in table 18.3). Box 18.2 reviews
the effectiveness of abstinence-only education and compre-
hensive sex education, subsets of school-based sex educa-
tion. In light of more recent controlled studies that have not
shown an effect on condom use, STIs, or HIV infection, any
cost-effectiveness estimate is extremely speculative.
• Voluntary counseling and testing. This intervention enables
people to know their HIV status and provides counseling
support to help them cope with the outcome. Knowledge of
serostatus may lead individuals to avoid engaging in risky
behaviors (Sweat and others 2000). Cost-effectiveness esti-
mates of VCT vary widely,and as with many other prevention
interventions, these estimates are extremely sensitive to the
prevalence of HIV in the population that is seeking testing.
• Peer-based programs. Peer interventions use influential
members of a targeted community to disseminate informa-
tion or teach specific skills. Such interventions have gener-
ally been found to be effective in reducing unsafe behaviors.
Work on the cost-effectiveness of peer-based interventions
in developing countries has been minimal. In Chad, Hutton,
Wyss, and N’Diekhor (2003) reviewed data on 12 prevention
Comprehensive Sex Education Versus Abstinence-Only Education
Box 18.2
The available data on sex education suggest the following:
• Sex education, including condom promotion, does not
encourage or increase sexual activity (Kirby 2001).
• Sex education reduces risk and positively affects sexu-
al behaviors. In general, sex education programs
increase knowledge about AIDS and related issues,
increase intention to use condoms, and increase con-
dom use among sexually active youths (Kim and
others 1997).
• Abstinence-only education is not effective in promoting
healthy sexual behaviors. Programs that promote both
postponement of intercourse and contraceptive use
were more effective in changing behaviors than those
that stressed abstinence alone. None of the abstinence-
only programs that have been evaluated demonstrated
an overall positive effect on sexual behavior, nor did
they affect contraceptive use among sexually active
participants (Kirby 1997).
Source: Authors.
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interventions and integrated them into a comparative analy-
sis. Their findings suggest that peer education for sex work-
ers is likely to be highly cost-effective and to entail one-fifth
the cost of the next most favorable intervention, blood safe-
ty. However, the estimated cost-effectiveness for the same
intervention directed toward young people and high-risk
men is 33- to 36-fold lower.
Interventions to Prevent Sexual Transmission Below we dis-
cuss the effectiveness and cost-effectiveness of interventions
that target sexual transmission of HIV:
• Condom promotion, distribution, and social marketing.
Condom promotion, distribution, and social marketing vary
by epidemic profile.The evidence on condom promotion and
distribution programs indicates that such programs result in
significantly higher condom use and significantly lower STI
incidence (see table 18.3). Given the central role that condom
promotion, distribution, and social marketing has played in
HIV prevention programs, the lack of data on the relative
cost-effectiveness of such programs 20 years into their imple-
mentation is striking. It is beyond dispute that the use of a
condom by sexual partners who are HIV-discordant is
extraordinarily cost-effective, given the low cost and high
effectiveness of the condom in preventing HIV transmission.
Information on the relative costs and effectiveness of differ-
ent approaches to increasing condom use by serodiscordant
sexual partners is not available, with the shortage of informa-
tion being far more acute for effectiveness than for costs. In
the absence of empirical evidence, decision makers are
reduced to formulating policy on the basis of theory and
common sense. Even inefficient use of condoms by serocon-
cordant couples is likely to be highly cost-effective because of
the reduction in other STIs, cervical cancer, and unwanted
pregnancies. However, more reliable information on
strategies to optimize the effectiveness and cost-effectiveness
of condom programs is urgently needed.
• STI screening and treatment. The latest analyses suggest that
STI control may be most effective as an HIV prevention
strategy when initiated earlier in the course of national epi-
demics and when sexual risk behaviors are high (Orroth and
others 2003). In most developing countries, the greatest
benefits from treating STIs almost certainly accrue from
averting the morbidity and mortality caused directly by STIs
rather than indirectly because of reduced HIV transmission.
Estimates of the cost-effectiveness of STI treatment purely
as a way to reduce HIV transmission vary widely.
Prevention of Mother-to-Child Transmission The existing
data on the effectiveness and cost-effectiveness of HIV inter-
ventions target MTCT in order of decreasing cost-effectiveness
as follows:
• Avoidance of unwanted pregnancies among infected mothers.
One of the most effective strategies to reduce HIV among
infants is to provide better contraception services.See box 18.3
for details.
• Use of antiretroviral therapy. Evidence indicates that the pro-
vision of antiretroviral drugs to infected mothers signifi-
cantly reduces vertical transmission (see table 18.4). The
provision of antiretroviral therapy to prevent MTCT is
highly cost-effective, to the point of being cost-saving for
women who already know that they are infected. When
screening of women is involved, cost-effectiveness declines
as HIV prevalence falls, because of the larger number of
women who must be screened to identify an HIV-positive
woman (Rely and others 2003).
• Feeding substitution. Whereas in high-income countries the
health community recommends complete avoidance of
breastfeeding for HIV-infected mothers to prevent postnatal
Preventing Mother-to-Child Transmission: Antiretroviral Therapy or Contraception?
Box 18.3
The differential effect of contraceptive delivery versus
antiretroviral therapy in preventing HIV can be shown by
comparing the provision of effective contraception and of
nevirapine to a population of 1,000 HIV-infected
women. In the absence of an intervention, approximately
150 infants would be infected with HIV during delivery
(Cates 2004). If nevirapine were available, the number of
infected infants would be reduced to 82 (the expected
47 percent decline). If effective contraceptive services were
available, this number would be reduced to 49. If both
strategies were adopted, the number of infected infants
would be further reduced to 25.
The greatest difference between providing antiretrovi-
ral therapy and providing contraception is the number of
infants orphaned in the future because their mothers die
of HIV infection. Three models all come to this conclu-
sion (Reynolds and others 2004; Stover and others
forthcoming; Sweat and others 2004).
Source: Authors.
HIV transmission, in developing countries the feasibility of
this approach is often limited by such factors as cost, sus-
tainability, lack of safe water, health, and child spacing and
by sociocultural factors (Coutsoudis 2002). Prolonged
breastfeeding more than doubles the likelihood of MTCT
(Nduati and others 2000). Because evidence indicates that
mixed feeding (breast milk and formula or other sub-
stance) has a higher risk of transmission than exclusive
breastfeeding (Coutsoudis and others 1999), mothers
should be counseled on the superiority of early weaning
over mixed feeding. Even fewer data are available on the
cost-effectiveness of feeding substitution.
Prevention of Bloodborne Transmission Below we discuss the
effectiveness and cost-effectiveness of harm reduction for
injecting drug users, implementation of blood safety practices,
and provision of sterile injections:
• Harm reduction for injecting drug users. Harm reduction
involves a combination of health promotion strategies for
users, including needle and syringe exchange programs,
ready access to effective drug treatment and substitution,
and provision of counseling and condoms. Brazil, which
has reduced the incidence of HIV and kept HIV prevalence
from reaching projected levels, has relied on strong official
support for harm reduction as a cornerstone of its national
prevention program (Mesquita and others 2003). A limited
number of studies have shown significant reductions in
HIV incidence among those exposed to needle exchange
programs, and several studies have shown significant
reductions in needle sharing (see table 18.3). Methadone
maintenance is both safe and effective as a treatment for
drug addiction (National Consensus Development Panel
on Effective Medical Treatment of Opiate Addiction 1998)
and may help reduce the risk of HIV transmission by
enabling individuals to avoid the drug-using behaviors that
can lead to HIV infection (Metzger, Navaline, and Woody
1998; Needle and others 1998). However, the effect of drug
treatment modalities on the rate of HIV transmission is
currently limited by laws in many countries that prohibit or
restrict the use of methadone maintenance or other drug
substitution strategies. The evidence supporting the cost-
effectiveness of needle exchange programs in high-income
countries is strong. However, little has been published in
relation to developing countries, partly because these pro-
grams have not been as widely implemented as hoped.
Given the low cost of syringes, the extremely high efficiency
of HIV transmission by this route, and the demonstrated
effectiveness of harm reduction programs in changing
syringe-sharing behavior, needle exchange programs
should be one of the most cost-effective interventions.
• Implementation of blood safety practices. Transmission of
HIV can be virtually eliminated in health care settings
through a blood safety program that ensures (a) a national
blood transfusion service; (b) the recruitment of voluntary,
low-risk donors; (c) the screening of all donated blood for
HIV; and (d) the reduction of unnecessary and inappropri-
ate transfusions (UNAIDS 1997). Available evidence indi-
cates that HIV screening is effective in reducing HIV infec-
tions (see table 18.4). Blood screening for HIV is costly but
has been shown to be cost-effective in numerous studies in
developing countries (see table 18.3) (Foster and Buve 1995;
Hutton, Wyss, and N’Diekhor 2003; Watts, Goodman, and
Kumaranayake 2000). The evidence appears to support the
WHO and UNAIDS recommendations that all countries,
regardless of the nature of the epidemic in the country,
should implement a comprehensive blood safety program.
• Universal precautions. A critical component of standard
infection control in health care settings is a prohibition on
reusing needles and syringes. A controversy has recently
arisen among researchers who contend that HIV infections
have been significantly misclassified because of the under-
counting of cases that result from unsafe injection practices
by misattributing such cases to heterosexual transmission
(Gisselquist and others 2003). However, after much investi-
gation, WHO and the U.S. Department of Health and
Human Services concluded that even though transmission
caused by unsafe injections may have been underreported, it
nevertheless does not account for an appreciable amount of
HIV transmission (WHO and UNAIDS 2003). Cost-
effectiveness analyses indicate that a combined policy strat-
egy of single-use syringes and interventions to minimize
injection use could reduce injection-related infections by
as much as 96.5 percent, or 8.86 million DALYs between 2000
and 2030, at an average cost of US$102 per DALY. Additional
cost-effectiveness studies are needed to guide decisions
regarding the optimal choice of technology in this area.
To prevent bloodborne transmission of HIV and other
diseases, health care workers, emergency personnel, and
others who might experience occupational exposure to
blood or body fluids are advised to take universal precau-
tions. This approach, which treats all bodily fluids as poten-
tially infectious, includes the use of gloves, gowns, and gog-
gles; the proper disposal of waste; and the use of sterile
injection and other infection control practices (CDC 1989).
Studies have demonstrated that the use of protective gear,
such as gloves, reduces the likelihood of blood exposure in
health care settings.
Although the cost-effectiveness of implementing universal
precautions increases as HIV prevalence increases, universal
precautions are unlikely to be cost-effective in resource-
limited settings especially where HIV prevalence is low.
Postexposure prophylaxis with antiretroviral agents is
considered the standard of care after occupational needle-
stick exposure to blood from an HIV-infected person.
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Cost-effectiveness analyses of postexposure prophylaxis have
been conducted only in high-income countries and have con-
cluded that this intervention is not cost-effective (Low-Beer
and others 2000; Pinkerton, Holtgrave, and Bloom 1998).
PREVENTION IN THEORY AND PRACTICE: USING
EPIDEMIC PROFILES AND CONTEXTUAL FACTORS
TO INFORM PREVENTION GUIDELINES
Prevention studies and national experiences over the past
20 years strongly suggest that prevention strategies are likely to
be most effective when they are carefully tailored to the nature
and stage of the epidemic in a specific country or community.
UNAIDS has developed epidemiological categories for charac-
terizing individual epidemics on the basis of prevalence of
infection in particular subpopulations and in the general pop-
ulation (table 18.5).
As a complement to the guidance provided by the epidemic
profile, Grassly and others (2001) recommend assessing the
prevalence of other STIs; estimating the extent of mixing
between high- and low-risk groups (for example, men who
have sex with men who have sexual contact with female
partners); and estimating the prevalence of high-risk sexual
behaviors in the population (such as lack of condom use with
casual partners). They also cite two other critical contextual
factors: the capacity of the health service and the social, eco-
nomic, and legislative context, including social norms and atti-
tudes about sexual and drug use behaviors and the acceptance
of breastfeeding. Contextual factors that may play a role in
the success of interventions include the status of women, the
stigmatization of high-risk groups, and the presence of armed
conflict and social upheaval. Together, the epidemic profile and
the context in which the epidemic occurs suggest various pre-
vention strategies.
General Prevention Guidelines by Type of Epidemic
Generally, it is more important to change the behavior of people
who have high levels of risk behavior than it is to change that of
people with lower levels of risk behavior. However, the difference
in the effectiveness between the two falls as epidemics become
more generalized, and as the average and maximum size of the
connected components (number of people linked to each other
directly or through others by their sexual or injecting risk
behavior). Thus, in heavily affected countries, or those where
the virus has the potential to spread rapidly, prevention inter-
ventions are likely to become extremely cost-effective even when
targeted at individuals with relatively low levels of risk behavior.
Consequently, countries with low-level and concentrated epi-
demics should emphasize interventions that target individuals
at especially high risk of becoming infected or of transmitting
the virus, whereas countries with generalized epidemics should
also invest heavily in interventions that target entire populations
or population subgroups. Thus, any determination of the likely
effectiveness and cost-effectiveness of specific interventions in
particular circumstances requires an accurate understanding of
the stage and nature of the national epidemic.
The countrywide successes discussed in boxes 18.4 and 18.5
highlight population-level interventions that modify social
norms as well as highlighting legislative and economic factors.
Other examples include instituting government regulation of
brothels and interventions to change social norms among sex
workers in Thailand, implementing national sex education and
blood safety programs in Senegal in concert with creating a
national registry of sex workers, and mandating involvement
by women in politics in Uganda.
Low-Level Epidemic. Providing widespread VCT, screening
for STIs, universal precautions, and postexposure prophylaxis
may not be cost-effective in a low-level epidemic. In this set-
ting, such as in the Middle East and North Africa, HIV/AIDS
control strategies should emphasize the following:
• surveillance and individual-level interventions that target
key populations
• IEC, including limited education through the mass media
and sex education in schools 
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Table 18.5 Epidemic Profiles
Highest prevalence in a key Prevalence in the general 
Extent of HIV infection populationa (percent) population (percent) WHO region
Low level  5  1 Middle East and North Africa
Concentratedb  5  1 East Asia and the Pacific, Europe and 
Central Asia, Latin America and the 
Caribbean, South Asia
Generalized low level 	 5 1–10 Sub-Saharan Africa
Generalized high level 	 5 	 10 Sub-Saharan Africa
Source: Adapted from UNAIDS 2004. 
a. Key populations include sex workers, men who have sex with men, and drug injecting users.
b. We consider three types of concentrated epidemics depending on the key population most affected: sex workers, men who have sex with men, or drug injecting users.
• prevention programs for people living with HIV/AIDS and
harm reduction for injecting drug users 
• VCT that is available to key populations with the highest
levels of risk behavior and infection rates 
• MTCT prevention to mothers known to be infected
with HIV 
• screening all blood for transfusions and providing sterile
injections 
• addressing market inefficiencies in condom procurement
and distribution—including strategies such as bulk pur-
chases and incentives 
• responding to community attitudes toward sexual activity, as
they may dictate people’s response to sex education materials.
Concentrated Epidemic. In a concentrated epidemic, as in
countries in East Asia and the Pacific, Europe and Central Asia,
Latin America and the Caribbean, and South Asia, prevention
priorities should include the following:
• ongoing surveillance
• subsidized VCT and promotion of VCT among key
populations
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Thailand’s 100 Percent Condom Program
Box 18.4
Thailand’s HIV prevalence, fueled primarily by high rates
of commercial sex work and low levels of condom
use, began to rise rapidly in the late 1980s. Beginning in
1989, the Thai government initiated a nationwide condom
distribution and education campaign focusing on com-
mercial sex workers and their clients to ensure 100 percent
condom use in all commercial sex encounters. Elements
thought to contribute to the program’s success include
• government-mandated 100 percent condom use in
commercial sex establishments
• mass condom promotion advertising campaign
• education in commercial sex workplaces
• government-distributed condoms
• STI testing and treatment
• surveillance and tracking of infections to points of
origin
• strong political and financial commitment
• active involvement of provincial and local governments.
Despite this unprecedented success, evidence indicates
that enforcement of the 100 Percent Condom Program is
not as strong today as when it was initially implemented.
A recent study in Bangkok found that 89 percent of sex
workers used condoms, a decline from 96 percent in 2000
(UNDP 2004).
Uganda HIV/AIDS Prevention Program 
Box 18.5
Like many countries in Sub-Saharan Africa, Uganda expe-
rienced a rapid increase in HIV incidence and a general-
ization of the epidemic in the late 1980s and early 1990s.
By 1991, overall HIV prevalence was 21 percent (Low-Beer
and Stoneburner 2003); however, the trajectory of
Uganda’s epidemic has differed markedly from that of its
neighbors. By 2001, overall HIV prevalence had fallen to
5 percent, with dramatic decreases in incidence among key
populations, such as soldiers, pregnant women, and young
women (USAID 2002). Critical components of Uganda’s
HIV prevention program include 
• having strong political support, especially from
President Yoweri Museveni
• implementing interventions to empower women and
girls
• having a strong focus on youths
• engaging in active efforts to fight stigma and discrimi-
nation
• emphasizing open communication about HIV/AIDS
• engaging the religious leadership and faith-based
organizations
• creating Africa’s first confidential VCT interventions
• emphasizing STI control and prevention.
Source: Authors.
Source: Authors.
• HIV screening of pregnant women, guided by individuals’
risk profiles
• peer-based programs for key populations to educate
individuals at risk, promote safer behaviors, and distribute
condoms
• harm reduction for injecting drug users, including needle
exchange and drug substitution programs 
• STI screening and treatment for key risk groups
• targeted distribution and promotion of condoms to key
populations with condom distribution linked to VCT and
STI care.
In addition, contextual factors, such as government accept-
ance of needle exchange programs, incarceration of drug users,
and harassment of sex workers, will likely have a major impact
on the effectiveness of prevention efforts. Because HIV/AIDS is
typically concentrated in socially or economically marginalized
populations in countries with concentrated epidemics, atten-
tion to socioeconomic factors and to the stigmatization of key
populations will also be vital to an effective response.
Generalized Low-Level Epidemic. In a generalized low-level
epidemic, such as in some countries in Sub-Saharan Africa (for
example, Tanzania), the emphasis on targeted interventions
must be maintained or even strengthened. Interventions for
broader populations must also be aggressively implemented.
These prevention priorities should include the following:
• maintaining surveillance of STIs, risk behaviors, and HIV
infections in the entire population, with a particular focus
on young people 
• extending mass media IEC beyond basic education 
• providing routine voluntary and confidential HIV testing
and STI screening and promoting treatment beyond key
populations
• providing subsidized and social marketing of condoms and
strengthened distribution to ensure universal access 
• offering HIV screening to all pregnant women
• broadening peer approaches and targeted IEC to include all
populations with higher rates of STIs and risk behavior.
Contextual factors remain critical to the success of preven-
tion efforts in generalized low-level epidemics, but population-
level factors now have greater priority. The most important is
likely to be the status of women, especially with regard to their
ability to control their sexual interactions, to negotiate VCT, to
be protected from abuse, and to have property rights following
the death of a spouse.
Generalized High-Level Epidemic. In a generalized high-level
epidemic, such as in some countries in Sub-Saharan Africa (for
instance, Botswana and Zimbabwe), an attack on all fronts is
required. Prevention efforts should focus on broadly based,
population-level interventions that can mobilize an entire soci-
ety so as to address prevention and care at all levels. Prevention
should include the following:
• mapping and maintaining surveillance of risk behaviors,
STIs, and HIV infection 
• offering routine, universal HIV testing and STI screening
and universal promotion of treatment 
• promoting condom use and distributing condoms free in all
possible venues
• providing VCT for couples seeking to have children 
• counseling pregnant women and new mothers to make
informed and appropriate choices for breastfeeding.
• implementing individual-level approaches to innovative
mass strategies with accompanying evaluations of
effectiveness
• using the mass media as a tool for mobilizing society and
changing social norms
• using other venues to reach large numbers of people effi-
ciently for a range of interventions—workplaces, transit
venues, political rallies, schools and universities, and mili-
tary camps
• establishing official institutional policies to provide for
harm reduction among injecting drug users.
In a generalized high-level epidemic, contextual factors—
such as poverty and the fragility of the health care infrastruc-
ture—will dramatically affect service provision at every level.
The status of women, an important factor in all epidemics,
becomes an overriding concern in this setting, requiring priority
action to radically alter gender norms and reduce the economic,
social, legal, and physical vulnerability of girls and women.
PREVENTION-CARE SYNERGY
In addition to the benefits antiretroviral therapy has for the indi-
vidual being treated (Komanduri and others 1998; Ledergerber
and others 2001), it almost certainly has other effects on popu-
lations where therapy is widely available. Effective antiretroviral
therapy appears to decrease the infectiousness of treated indi-
viduals. Chemoprophylaxis in exposed, uninfected people may
reduce transmission. In addition, availability of treatment may
destigmatize the disease and make prevention programs more
effective (Castro and Farmer 2005).
However, these benefits in relation to reduced transmission
may be offset by a “disinhibition” of risk behavior that is asso-
ciated with greater availability of antiretroviral therapy, by the
spread of drug-resistant HIV, or by increases in the incidence of
exposure to partners with HIV infection because of increased
survival. These sometimes opposing effects of offering therapy
may differ to such a degree that the net effects of widespread
therapy on transmission rates may vary among risk groups and
across geographic regions.
HIV/AIDS Prevention and Treatment | 349
Table 18.6 reviews the information available on the popula-
tion effects of antiretroviral therapy and makes suppositions
about potential effects for those areas for which data and
research are lacking. The information in the table suggests that
widespread therapy using currently available combination reg-
imens will provide a net benefit in relation to the transmission
of HIV. However, because confidence in this prediction is not
high, the population consequences of therapy programs must
be evaluated and monitored with active surveillance of pre-
scribing patterns, sexual risk behavior, STI prevalence, HIV
incidence and prevalence, and prevalence of primary drug
resistance and sexual networks of risk behavior.
CARE AND TREATMENT
This section reviews evidence of the cost-effectiveness of
HIV/AIDS care and treatment interventions in resource-
limited settings. Until relatively recently, the majority of HIV
clinical care in resource-limited countries was confined to
managing the terminal stage of infection, including extremely
late diagnosis of opportunistic infections and cancers, use of
basic palliative symptom management, and short-term hospi-
talization just before death. Few people were aware of their HIV
status until the onset of severe HIV-associated illness, and most
did not seek help from the health care system until they were
already terminally ill.
The advent of primary prophylaxis and treatment for
opportunistic infections, including tuberculosis, prolonged
survival to a limited extent but did nothing to restore immune
function. Such restoration was not possible until the advent
of antiretroviral therapy. Because clinical intervention in HIV
is so recent in resource-limited settings, few cost-effectiveness
studies are available. Those that are available on the treatment
of and prophylaxis for opportunistic infections were largely
conducted before the availability of antiretroviral therapy and
therefore need to be reestimated to be relevant for decision
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Table 18.6 Effect of Antiretroviral Therapy on Transmission Dynamics 
Area or behavior affected
Viral load
Prophylaxis
Drug resistance
Risk behavior
Sexual networks
Epidemiological
Treatment effects expected to decrease transmission
Decreased infectiousness of the treated partner is substantial even 
with monotherapy (Musicco and others 1994). Transmission after 
exposure to individuals with a viral load of less than 1,500 copies 
per milliliter is extremely rare (Quinn and others 2000). No cases 
of sexual transmission from a partner with undetectable viremia 
have been reported.
Decreased susceptibility may occur during postexposure prophylaxis 
(Cardo and others 1997). 
Impaired fitness and decreased viral load during drug-resistant 
viremia (Deeks and others 2000) appear to allow persistent 
decreases in infectiousness even after drug resistance has 
occurred (Leigh Brown and others 2003). 
Treatment may provide incentives for HIV testing and counseling,
which has been associated with decreased risk behavior and HIV
incidence. The availability of treatment may reduce stigma directly,
and also indirectly by increasing the visibility of people living with
HIV/AIDS.
Risk reduction counseling during treatment programs may reduce 
risk behavior. 
Decreased fear of HIV may foster more informed risk behavior, 
including increased use of testing and more thoughtful partner 
selection, including serosorting and sorting by risk level 
(McConnell and Grant 2003). 
The effective prevalence of infectious people will decrease because
of treatment effects on infectiousness or increased serosorting.
Treatment effects expected to increase transmission
As survival increases, the incidence of exposure to 
partners with HIV infection may increase (Hammer 
and others 1997).
None.
Impaired virological responses to therapy in the person 
who is infected by a resistant virus may partially offset 
the beneficial effect on infectiousness (Little and others 
2002; Grant, Kahn, and others 2002). However, primary 
infection with a resistant virus may also be associated 
with slower progression of the disease (Grant, Hecht, 
and others 2002). 
Decreased fear of HIV and disinhibition of risk behavior 
are possibilities (Katz and others 2002). Risk behavior by 
people who are sick and who recover their health status 
may increase (Stolte and others 2001).
Decreased fear of HIV may disinhibit risk behavior, reduce 
serosorting, and increase mixing between higher- and 
lower-risk groups in the population.
Treatment-induced reduction in mortality may increase the 
prevalence of infection, although many being treated will 
be less infectious or better informed regarding risk 
reduction strategies. A rebound of viral load with 
treatment failure may mean that treatment postpones 
transmission rather than reducing it.
Source: Authors.
making today. Fortunately, because the determinants of biolog-
ical responses are better conserved across countries and cul-
tural settings than the determinants of behavior, effectiveness
data from high-income countries can help inform decisions
about treatment in resource-limited settings.
Unlike drugs for many other high-burden health conditions
in developing countries, antiretroviral therapy for HIV and
drugs for some of its associated opportunistic infections depend
on medications that are still under patent protection.
Nevertheless, generic drug makers in India and Thailand have
produced a range of effective antiretroviral therapies that com-
bine multiple drugs into single tablets and reduce the pill burden
to one tablet twice daily. These companies have made it possible
for prices to drop dramatically for some antiretroviral therapy
combinations—to less than US$250 per year, compared with
more than US$4,000 for the same combinations (from the orig-
inal manufacturers) in high-income countries. In response to
this threat, some multinational pharmaceutical companies have
introduced a system of price differentiation among countries
depending on their per capita income and HIV/AIDS burden.
In addition, the World Trade Organization’s Agreement on
Trade-Related Aspects of Intellectual Property Rights (TRIPS)
includes a provision that permits compulsory licensing of
pharmaceutical products in cases of national emergency and
other circumstances of extreme emergency, which is clearly the
case for HIV/AIDS in much of the developing world. A 2003
World Trade Organization decision also made it easier for 
low- and middle-income countries (LMICs) to import cheaper
generics made under compulsory licensing if the countries are
unable to manufacture the medicines themselves (WTO 2003).
As a result, some countries, including Brazil, India, and
Thailand, have begun to produce generic versions of antiretro-
viral drugs to be sold at greatly reduced prices. The TRIPS pro-
vision has also improved developing countries’ bargaining
power with large pharmaceutical companies, to the point that
some countries have been able to secure drugs from the origi-
nal manufacturers at substantially reduced prices. As a result,
the relative cost-effectiveness of different drug combinations
has been in rapid flux, increasing the importance of updating
recommendations frequently.
Diagnostic HIV Testing 
A positive HIV test can be confirmed within one month of
infection. Infection is diagnosed in two ways: by a biological
test that detects the presence of HIV antibodies or by diagnosis
of an opportunistic infection that is a clear sign of HIV disease.
The most widely used biological test in high-income countries,
conducted in a laboratory on a blood sample, is called an
ELISA (enzyme-linked immunosorbent assay). Obtaining a
result may take several days. Rapid tests that can provide results
in 20 minutes are being used more widely as their costs fall.
When the prior probability of infection is low and resources are
abundant, following up an initially positive ELISA with a sec-
ond ELISA—and even a Western blot test if the second ELISA
is positive—may be appropriate (this is typically done in high-
income countries).
However, in a high-prevalence environment where the prior
probability is high and resources are scarce, such an approach
is almost certainly not cost-effective. Each additional confirma-
tory test decreases the number of false positive results, thereby
averting the costs associated with such a result. The costs of
averting a false positive result range from US$425 with a single
confirmatory rapid test or ELISA to more than US$500,000 for
a confirmatory Western blot test following two positive ELISAs
as the prevalence of HIV in patients who are clinically suspected
of being infected is varied from 5 to 50 percent (these calcula-
tions are based on assumptions in John Snow, Inc. 2003 and
WHO 2004). These results suggest that LMICs should not use
a second confirmatory test unless the prevalence among
patients is extremely low.
Palliative Care
Palliative care has traditionally focused on patients in the ter-
minal stages of disease. More recent definitions of palliative
care, including WHO’s definition, have been broadened to
encompass quality-of-life issues of patients and their families
throughout the course of a life-threatening illness (WHO
2002b). The control of pain and other symptoms is the crux of
any palliative care model, but the WHO model also addresses
patients’ and their families’ psychological, social, and spiritual
problems. Under this definition, in many developing countries,
most people living with HIV/AIDS are not receiving the mini-
mum standard of palliative care. Of the 5 million people living
with HIV/AIDS in South Africa, one of the wealthiest countries
in Sub-Saharan Africa, Carlisle (2003) estimates that only
250,000 have access to palliative care services. In the face of a
growing epidemic of historic dimensions, the provision of
comprehensive palliative care represents a critical, but neg-
lected, global priority.
Health care professionals have promoted community
home-based care as an affordable way to expand the coverage
of palliative care (Hansen and others 1998), but the great het-
erogeneity among home-based care programs complicates
comparisons. Most programs for which data are available
are community-based outreach programs administered by
local clinics or hospitals. These programs can consist of simple
home visits to provide basic care for AIDS patients or may be
comprehensive schemes that provide care, palliative medica-
tions, meals, psychosocial support and counseling, and links to
primary and secondary health care.
Studies indicate that home-based care has considerable
potential to deal cost-effectively with the palliative care needs
of HIV/AIDS patients (Ramsay 2003; UNAIDS 2001; Uys and
Hensher 2002; Wenk, Bertolino, and Pussetto 2000). Although
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a Zimbabwe study found that home visits were associated with
extensive travel time and costs (Hansen and others 1998), little
research has examined the extent to which home-based care
can be used to substitute for hospitalization, nor is evidence
available to determine the most cost-effective combination of
palliative care strategies. Most people living with HIV/AIDS do
incur some end-of-life costs in the formal health care sector. In
one South African study, primary care clinic and hospital costs
accounted for 39 and 18 percent, respectively, of the costs of
care in the last year of life, whereas community home-based
care accounted for 42 percent (Uys and Hensher 2002).
Higginson and others’ (2003) meta-analysis concludes that
overall evidence demonstrates a positive effect of home-based
palliative care, especially its effect on pain management and
symptom control. Available data do not permit estimating a
cost per DALY of community-based palliative care programs,
but a review of available studies suggests that palliative care
provided by health professionals in the home is unlikely to be
cost-effective in low-income countries. However, low-cost,
community-based models have been developed that require
minimal external resources and function almost like care coop-
eratives among affected households. These models are likely to
be highly cost-effective.
Symptom-Based Care. Pain management is extremely
important in HIV and is addressed in chapter 52. Diarrhea, nau-
sea, vomiting, and skin problems are all symptoms that are tar-
geted for treatment in palliative care. Oral rehydration for diar-
rheal treatment costs pennies per episode. Nausea and vomiting
are prevalent in people with AIDS and can lead to anorexia and
weight loss (UNAIDS 2000). Treating nausea costs an estimated
US$1.75 per episode (Willbond and others 2001), and contin-
uous treatment of nausea and vomiting in end-stage patients
costs about US$2 per day (World Bank 1997).
Approximately 90 percent of people with HIV suffer from
some form of skin condition. These conditions include infec-
tions, drug reactions, scabies, pressure sores, and cancers. Skin
often becomes dry in the middle and late stages of AIDS
because of dehydration caused by persistent diarrhea, vomit-
ing, and malabsorption. The cost of treating an episode of skin
rash is estimated to be US$2 (UNAIDS 2000). No estimates are
available on the benefits of providing such care in terms of
DALYs, especially to terminally ill patients.
Psychosocial Support. Psychosocial support is an integral
component of the multidisciplinary management strategies
that care providers regard as essential for people with HIV
(Murphy and others 2004). Support for patients and families
can have a positive effect on adherence to therapies and can
contribute to the critical aim of integrating prevention with
treatment and care.
Psychosocial support and counseling has a positive effect on
the quality of life of people living with HIV/AIDS. Cook’s
(2004) study of U.S. women demonstrated that the use of men-
tal health services was associated with reduced mortality and
that AIDS-related deaths were more likely among women who
had symptoms of chronic depression. While results have not
been replicated in resource-constrained countries, an assess-
ment of clinic-based psychosocial support and counseling serv-
ices in northern Thailand showed that 50% of PLWHA became
more positive about their lives and 40% stated that they learned
how to live with the disease (Tsunekawa and others 2004).
Although few data are available on the costs of various strate-
gies, interventions for psychosocial support appear to be cost-
effective—especially where innovative solutions, such as group
counseling sessions, are implemented. Although studies indi-
cate an improved quality of life for these patients, little infor-
mation is available on the cost of the interventions. Additional
evaluation research is needed to guide decisions about how
much to invest in psychosocial support.
Nutrition Programs and Food Security. Strong evidence
indicates that malnutrition and AIDS work in tandem at both
the individual and the societal levels. Infection with HIV
increases the risk of malnutrition in the individual, while mal-
nutrition worsens the impact of HIV and AIDS. Similarly,
HIV/AIDS can both cause and be worsened by food insecurity.
This reciprocity must be considered when planning specific
program responses.
Protein deficiency is a well-known cause of cell-mediated
immunodeficiency (Vanek 1953). HIV-infected individuals
need to consume more energy than uninfected individuals: as
much as 10 percent greater consumption for asymptomatic
individuals and 20 to 30 percent more for symptomatic indi-
viduals. Malnutrition alters the susceptibility of individuals to
HIV infection and their vulnerability to its various sequelae,
increases the risk of HIV transmission from mothers to babies,
and accelerates the progression of HIV infection (Gillespie,
Haddad, and Jackson 2001).
Small studies of adults with AIDS, including those on anti-
retroviral therapy, have shown that daily micronutrient supple-
mentation increases bodyweight, reduces HIV RNA levels,
improves CD4 counts, and reduces the incidence of
opportunistic infections. Fawzi and others’ (2004) large trial
among pregnant women infected with HIV in Tanzania
demonstrates that multivitamin supplements (a) decrease the
risk of progression to WHO stage 4 (progression from HIV to
AIDS, the most advanced level of HIV infection) or death from
AIDS-related causes and (b) reduce many HIV-related symp-
toms. The multivitamins used in the trial cost US$15 per
person per year (Fawzi and others 2004).
The World Food Program guidelines prioritize three nutri-
tion interventions for people living with HIV/AIDS: counseling
on specific behaviors, prescribed or targeted nutrition
supplements, and links with food-based interventions and
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programs. The guidelines cite three types of nutrition supple-
ments: food rations to manage mild weight loss and nutrition-
related side effects of antiretroviral therapy and to address
nutritional needs in food-secure areas; micronutrient supple-
ments for specific HIV-positive risk groups; and therapeutic
foods for addressing moderate and severe malnutrition in HIV-
positive adults and children. Cost-effectiveness data in support
of these recommendations are not available, but the low costs
of supplementation, coupled with the likely benefits to other
malnourished household members, suggest that such interven-
tions will be highly cost-effective.
Infection with HIV/AIDS can severely undermine an indi-
vidual’s food security, affecting the availability, stability, access
to, and use of essential foods. The epidemic is stunting progress
in rural development and causing significant increases in rural
poverty and destitution in the countries most affected by the
epidemic (Bonnard 2002). Thus, interventions must consider
the epidemic’s impact on the broader community and not
solely on people living with the disease. Care-related household
and community-level interventions include school feeding
with special take-home rations for families caring for orphans,
food for training programs that promote income-generating
activities, and food for work to support homestead production
activities (Van Liere 2002). Chapter 56 estimates that sustained
community nutrition programs would save US$200 to US$250
per DALY. Such programs targeted at communities at especially
high risk are likely to be even more cost-effective (World Food
Programme 2001).
Treatment of Opportunistic Infections 
and Secondary Prophylaxis
Even as the availability of antiretroviral therapy increases in
many developing countries, appropriate diagnosis and man-
agement of life-threatening opportunistic infections, including
HIV-associated cancers, remain the most important aspects of
the care of patients with HIV disease. Opportunistic infections
usually begin five to seven years after infection (Munoz, Sabin,
and Phillips 1997) and occur progressively as uncontrolled
HIV replication destroys the immune system (Colebunders
and Latif 1991). Figure 18.1 describes the cascade of infections
that occur as the immune system is depleted. Opportunistic
infections are typically caused by organisms that exist in the
environment of the body (on the skin, in the lungs and gas-
trointestinal system) and remain latent until HIV has impaired
the immune system.
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Figure 18.1 Cascade of Infections and Cancers That Develop as Immune Function Is Depleted
The epidemiology of opportunistic infections is complex; it
is related to the severity of individual immune depletion and
shows considerable intercountry variation. Each infection has
its unique clinical expression, requiring specific diagnostic
techniques and treatment. Many opportunistic infections can
be prevented by judicious use of chemoprophylaxis, ranging
from the low-cost (cotrimoxazole to prevent Pneumocystis
jiroveci pneumonia [PCP] at less than US$20 per year) to the
extremely expensive (ganciclovir to prevent cytomegalovirus at
more than US$10,000 per year) (Schneider and others 1995;
Spector and others 1996). In high-income countries, antiretro-
viral therapy has so effectively controlled viral replication that
the process of HIV-related immune destruction has been
slowed or halted, leading to marked declines in the incidence
of opportunistic infections and a dramatic reduction in their
resultant high death toll (McNaghten and others 1999).
Unfortunately, the emerging problem of poor adherence to
drug regimes is now making HIV resistance to antiretroviral
therapy more prevalent in high-income countries, triggering a
resurgence of opportunistic infections.
More than 20 infections and cancers have been associated
with severe immune depletion. The most common pathogens
and cancers include bacteria such as Mycobacteria tuberculo-
sis and avium; protozoa such as Cryptosporidium, Strongyloides,
and Toxoplasma; fungi such as Candida, PCP, Cryptococcus,
Aspergillis, and Penicillium (the latter largely restricted to South
and Southeast Asia); viruses such as cytomegalovirus, herpes
simplex, and herpes zoster; and cancers such as Kaposi sarcoma
and non-Hodgkin lymphoma.
The range of complications arising from continued HIV
infection varies from country to country, reflecting the differ-
ences in infectious agents that populations have encountered
earlier in life or are exposed to when immunosuppressed. In
high-income countries, the most common opportunistic
infections are PCP, esophageal candidiasis, cytomegalovirus
retinitis, cryptococcal meningitis, toxoplasma encephalopathy,
cryptosporidium diarrhea, and human herpes virus–8 and
Kaposi sarcoma (Bacellar and others 1994; Hoover and others
1993; Lanjewar and others 1996; Selik, Starcher, and Curran
1987). In resource-limited countries, because of the higher
background prevalence of infectious agents, it is more com-
mon to encounter tuberculosis, cryptococcal meningitis, toxo-
plasma encephalopathy, infectious diarrhea, and nonspecific
wasting (slim disease) (Hira and others 1998; Hira, Dore, and
Sirisanthana 1998a; Sengupta, Lal, and Srinivas 1994).
The time from HIV infection to manifestation of the first
AIDS-defining illness varies within populations. In high-
income countries, reports on the natural history of untreated
HIV infection suggest that AIDS occurs between 7 and 10 years
after infection (Alcabes and others 1993; Lui and others 1988).
The time can be as short as 24 months (Anzala and others
1995) in some individuals, whereas some long-term survivors
remain disease free for longer than 15 years (Easterbrook
1994). In developing countries, disease progression, though not
as well studied, appears to be more rapid (Morgan and others
1997). Once an AIDS-defining illness occurs, the average time
to death seems to be similar across countries, reported at
approximately 12 to 18 months in Uganda and the United
States (Carre and others 1994).
The time from presentation with an AIDS-defining oppor-
tunistic infection to death depends on the type of infection, the
availability of care, and the patient’s adherence to prescribed
prophylaxis and treatment. Even as access to antiretroviral
therapy increases, prophylaxis for opportunistic infections
remains one of the most important ongoing and successful care
strategies for patients with advanced HIV disease. In high-
income countries, the widespread use of such simple inter-
ventions as cotrimoxazole for PCP prophylaxis has had a
significant effect in delaying the onset of PCP, the most com-
mon initial AIDS-defining event, thus positively influencing
survival (Hoover and others 1993). However, prophylaxis for
opportunistic infections appears to be underused in LMICs.
Prevention of PCP or any other opportunistic infection
does not halt the relentless erosion of the immune system and
provides only a short-term prolongation of life (Morgan and
others 1997). The only way to halt or delay the progression of
HIV disease is to interrupt viral replication.
Role of Antiretroviral Therapy in Relation to Opportunistic
Infections. Antiretroviral therapy is effective in reducing viral
load and partially enabling immune restoration, thereby pre-
venting the onset and recurrence of opportunistic infections.
If taken strictly according to directions, antiretroviral therapy
can induce a sustained recovery of CD4 cell reactivity against
opportunistic pathogens in severely immunosuppressed
patients (Li and others 1998). The effectiveness of antiretroviral
therapy is determined by its ability to rapidly reduce viral load
and to sustain low levels of viral activity. This viral activity is
what has an independent effect on increasing or decreasing sus-
ceptibility to opportunistic infections (Kaplan and others 2001).
Initiating antiretroviral therapy can also have detrimental
effects by causing complications from latent or undiagnosed
opportunistic infections, especially in resource-poor settings.
One of the challenges in initiating antiretroviral therapy in
resource-limited settings is that patients tend to present late
in their illness, usually when they have an opportunistic infec-
tion that prompts them to seek medical care, or in the case of
countries with lax pharmaceutical policy, when they buy anti-
retroviral therapy from a private pharmacy. It is well docu-
mented that initiating antiretroviral therapy in severely
immunosuppressed patients can result in illnesses associated
with reconstitution of the immune system (Shelburne and
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others 2005). These illnesses can occur with all presenting
opportunistic infections and may be more serious than the
infection itself. The major problem with care of patients in this
situation is that they may believe the illness is a side effect of
their antiretroviral therapy and refrain from medicating.
Training clinicians to recognize and treat immune reconstitu-
tion disease is therefore essential.
Management of Opportunistic Infections. The three compo-
nents of effective management of oppportunistic infections are
diagnosis, treatment, and secondary prophylaxis. As immune
function continues to deteriorate, secondary prophylaxis is
required to prevent recurrence of the treated infection. Some of
the most common infections, such as PCP, can be diagnosed
with a reasonable degree of confidence by clinical history and
treated empirically (Kaplan, Masur, and Holmes 2002). Less fre-
quently occurring infections often require sophisticated diag-
nostic equipment and skilled clinicians to confirm a diagnosis
from a wide range of pathogenic possibilities before starting
complex and expensive treatment. For example, toxoplasmosis
can be accurately diagnosed only by a lumbar puncture and CT
brain scan (and in some cases an MRI), and cryptosporidium
diagnosis requires specialized laboratory techniques.
The full spectrum of options for treating opportunistic
infections in developing countries has not been systematically
evaluated for cost-effectiveness. Because of the effect of anti-
retroviral therapy on both the efficacy of treatment of individ-
ual infections and on life expectancy (and therefore on potential
DALYs gained from treating a life-threatening infection), the
limited economic evaluations conducted are already out of date.
In particular, chronic infections such as Mycobacterium avium
complex and cytomegalovirus may be more effectively treated
over the medium term by reversing immunosuppression with
antiretroviral therapy than by directly treating the infectious
agent. Other treatment regimens for opportunistic infections
that were marginally cost-effective before antiretroviral therapy
may now become substantially more cost-effective if the patient
can begin the therapy following treatment of the infection,
thereby extending life expectancy. Table 18.7 shows the cost-
effectiveness of care and treatment options for opportunistic
infections and antiretroviral therapy.
In most resource-limited settings, few specialized diagnostic
facilities are available for opportunistic infections. Clinicians
have little training in the diagnosis and management of com-
plex opportunistic infections, and laboratory backup is either
nonexistent or so expensive that end users cannot afford it. The
spectrum of opportunistic infections in LMICs is such that
most require highly technical facilities for confirmation of
diagnosis. Consider M. tuberculosis, the most prevalent such
infection in Thailand. The rate of latent tuberculosis becoming
clinically active in the presence of HIV increases from a lifetime
risk of 10 percent in the general population to an annual risk of
10 percent for those coinfected with HIV (Pape and others
1993). Hence, after five years, about 40 percent of HIV-infected
people with latent tuberculosis will have developed active
disease.
Primary Prophylaxis for Opportunistic Infections 
Before the advent of antiretroviral therapy, the use of prophy-
laxis to decrease the risk of acquiring opportunistic infections
was the only intervention available to delay the onset of life-
threatening infections (Kitahata and others 1996). With the
development of antiretroviral therapy in the 1990s, the preva-
lence of many opportunistic infections has been greatly
reduced, and the use of prophylaxis has decreased correspond-
ingly (Palella and others 2003). Nevertheless, prophylaxis for
opportunistic infections remains necessary in patients who
lack access to antiretroviral therapy, in extremely immunosup-
pressed patients until the therapy takes effect, in patients who
do not wish to or who cannot take antiretroviral therapy, in
patients for whom such therapy fails, and in the small group
of patients who are unable to recover sufficient CD4 cells
despite good inhibition of viral replication (Berenguer and
others 2004). Note that extensive clinical research is still being
carried out in relation to the withdrawal of secondary prophy-
laxis following immune restoration with antiretroviral therapy.
Treatment of HIV Infection with Antiretroviral Therapy 
Combination therapy with multiple antiretroviral drugs is
associated with prolonged survival. Whereas monotherapies
are associated with one year or less of additional survival, the
survival benefit conferred by combination therapy appears to
be sustainable for extended periods (Palella and others 2003).
Long-term toxicities related to treatment may include athero-
sclerosis, lipodystrophy, hepatic failure, and cardiac failure.
Researchers are still evaluating the effects of these toxicities on
HIV/AIDS mortality.
Cost-Effectiveness Considerations in the Choice and Initiation
of Antiretroviral Therapy. WHO has issued global guidelines
for scaling up antiretroviral therapy access; the guidelines pro-
mote a combination of stavudine, lamivudine, and nevirapine
(as a fixed-dose formulation) as initial therapy. A number of
clinical trials have produced results outlining differential efficacy
for a number of antiretroviral therapy combinations, which pro-
vide guidance in the selection of appropriate drugs for treating
HIV (Yeni and others 2004). The preferred first-line medications
in developing countries are dictated by these considerations, in
addition to pricing and patent concerns.
Table 18.7 Cost-Effectiveness of Care and Treatment for HIV/AIDS
Intervention
HIV testing and diagnosis
Confirmatory ELISA, Western blot
Palliative care
Pain alleviation
Symptom-based care
Nutrition interventions
End-of-life care
Oral candidias 
Esophageal candidiasis
Histoplasmosis
Kaposi’s sarcoma
Cryptococcal meningitis
Penicilliosis
Mycobacterium avium complex 
Cytomegalovirus
PCP
Toxoplasmosis
Herpes simplex virus 
Tuberculosis 
Opportunistic infection prophylaxis
PCP
Toxoplasmosis
Mycobacterium avium complex 
Cytomegalovirus
Tuberculosis preventive therapy
HPV screening and treatment
Antiretroviral therapy
First-line antiretroviral therapy
Second-line (and subsequent)
antiretroviral therapy
Adherence interventions 
Monitoring response to
antiretroviral therapy
Source
No cost-effectiveness studies found
in developing countries
Chapter 52
No cost-effectiveness studies found
in developing countries
Chapter 56
No cost-effectiveness studies found
in developing countries
Modeling estimates based on
efficacy trials reported from
HIVInsite (CHI, 2005) and drug costs
(UNICEF and others 2004) 
Chapter 16
South Africa (Floyd, Wilkinson, and
Gilks 1997); Malawi, Mozambique,
Tanzania (Murray and others 1991);
Uganda (Saunderson 1995) 
Modeling estimates based on
efficacy trials reported from
HIVInsite (CHI, 2005) and drug costs:
(UNICEF and others 2004) 
Uganda (Bell, Rose, and Sacks 1999);
Chapter 16 
South Africa (Goldie and others
2001)
Sub-Saharan Africa (Marseille,
Hofmann, and Kahn 2002) 
India (Over and others 2004) 
No cost-effectiveness studies found
in developing countries
No cost-effectiveness studies found
in developing countries
No cost-effectiveness studies found
in developing countries
Before or when initiating
antiretroviral therapy
—
420/year of pain-free life added
—
200–250 for HIV-negative individuals
—
0.5–157
0.4–55
12–77
6,236–63,700
3–86
11–72
31–51
586–995
0.4–5
5–44 
3–32
200–370
Short-course ambulatory: 2–16 
Short-course hospital: 3–8
Community-based directly observed
therapy: 14–22
29–1487
14–412
786–3,604
151,855–972,955
15–300 (Isoniazid, Rifampicin plus
pyrazinamide, Isoniazid plus rifampicin)
Direct visual inspection using acetic
acid:  4/years of life saved 
350
492/patient yeara
—
—
—
Failed or no antiretroviral therapy
—
420/year of pain-free life added
—
200–250 for HIV-negative individuals
—
1–394
1–165
81–539
12,460–127,400 
21–546 
76–483 
87–320
4,875–5,120
3–35
31–291
7–80 
50–450
Short-course ambulatory: 2–16 
Short-course hospital: 3–8
Community-based directly observed
therapy: 14–22
590–29,817
252–8,265
2,247–18,020
976,209–4.5 million
15–300 (Isoniazid, Rifampicin plus
pyrazinamide, Isoniazid plus rifampicin)
Direct visual inspection using acetic
acid:  4/years of life saved
350
492/patient yeara
—
—
—
Cost-effectiveness (2001 US$/DALY)
Early detection and screening for opportunistic infections 
Treatment of opportunistic infections, per episode
Source: Authors.
—  not available. 
a. Antiretroviral therapy for the poorest HIV positive adults. The estimates include the cost of drugs, clinic visits, and laboratory tests for physician monitoring of treatment and assumes 50 percent
condom use in the general population. 
In recent years, the most volatile parameter in cost-
effectiveness analyses for HIV/AIDS has been the prices of anti-
retroviral drugs, which have dropped by about two orders of
magnitude for some LMICs. Price reductions have not been
consistent across countries, nor have they necessarily been
larger for the poorest countries. This variability in pricing
greatly complicates the establishment of national guidelines
regarding which regimens to prescribe under which circum-
stances, because the ranking of regimens varies among and
within countries as relative prices change. Box 18.6 discusses
the three classes of drugs used in antiretroviral therapy.
Because of their higher manufacturing costs and their
more recent introduction into the market, protease inhibitors
are more expensive than either nucleoside reverse transcrip-
tase inhibitors or nonnucleoside reverse transcriptase
inhibitors. They are also more difficult to manufacture, mak-
ing them less attractive to generic manufacturers. Although
the difference is less marked, nucleoside reverse transcriptase
inhibitors tend to cost less than nonnucleoside reverse tran-
scriptase inhibitors.
Ranking different antiretroviral therapy regimens by their
cost-effectiveness is more complex than doing so for most ther-
apeutic situations, because a high proportion of patients will
develop resistance to or intolerance of initial therapy and will
need to stop their initial regimen and then initiate a second
(and perhaps a subsequent) regimen, if available. One U.S.
cohort study suggests that for 50 percent of patients the
prescribed protease inhibitor–based regimen fails within a year
(Deeks and others 1999). As a result, the cost-effectiveness of a
regimen is a function not only of its effectiveness in isolation,
but also of its impact on the effectiveness of future regimens.
Thus, the comparative cost-effectiveness of different sequences
of regimens needs to be considered.
The effectiveness of antiretrovirals depends on not only the
benefits conferred but also the associated side effects, the toxic-
ity level of the drugs, and patients’ adherence to the drug regi-
men. The ability of care providers to detect incipient toxicity at
an early stage also influences the magnitude of side effects and
toxicities. In low-income settings with limited laboratory
capacity, a greater proportion of side effects will not be detect-
ed until they become severe. As a result, the relative cost-
effectiveness profiles will change depending on the availability
of toxicity monitoring.
Initiating antiretroviral therapy has a proven benefit for
patients with a CD4 count of fewer than 350 cells per cubic
millimeter (Palella and others 2003). In patients with a
higher CD4 count, the benefits of antiretroviral therapy are
believed to be outweighed by the toxicities that may accrue
from continued drug exposure (Mallal and others 2000).
Concerted research efforts are needed to gauge both the aver-
age costs of care and the survival benefits of identifying
patients and initiating antiretroviral therapy while their
immune function is still competent, compared with the costs
and survival benefits associated with starting care late, on
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Antiretroviral Drugs
Box 18.6
Current antiretroviral drugs can be divided into three
classes:
• Nucleoside analogue reverse transcriptase inhibitors
(NRTIs) were the first type of drug available to treat
HIV infection in 1987. When HIV infects a cell, it
copies its own genetic code into the cell’s DNA, and the
cell is then programmed to create new copies of HIV.
To reproduce, HIV must first convert its RNA into
DNA using the enzyme reverse transcriptase.
Nucleoside analogue reverse transcriptase inhibitors
act like false building blocks and compete with the cell’s
nucleosides, thereby preventing DNA synthesis. This
inhibits reverse transcriptase, which prevents HIV
from infecting cells and duplicating itself.
• Nonnucleoside reverse transcriptase inhibitors (NNRTIs)
started to be approved in 1997. Like nucleoside analogue
reverse transcriptase inhibitors, nonnucleosides also
interfere with HIV’s ability to infect cells by targeting
reverse transcriptase. In contrast to nucleoside analogue
reverse transcriptase inhibitors, nonnucleosides bind
directly to the enzyme. This blocks the binding site of
the reverse transcriptase and inhibits the binding of
nucleotides.
• Protease inhibitors (PIs) were first approved in 1995.
PIs interfere with viral replication by binding to the
viral protease enzyme and preventing it from process-
ing viral proteins into their functional forms and
thereby rendering the resulting viral particles non-
infectious (Peiperl, Coffey, and Volberding 2005).
Source: Authors.
presentation of an opportunistic infection—as is currently the
norm in LMICs.
Drug Resistance. Drug resistance occurs as the virus evolves
to escape the inhibitory effects of antiretroviral drugs. The
capacity of HIV to mutate is extraordinary, as the wide
diversity of HIV variants that occurs worldwide demonstrates.
Viral diversification is driven by low-fidelity enzymes (which
have a high rate of mutation) that carry out replication of the
viral genome.
Drug resistance resulting from being infected by a drug-
resistant HIV strain is known as primary drug resistance.
Secondary drug resistance develops as a consequence of treat-
ment. Primary HIV drug resistance to nucleoside reverse tran-
scriptase inhibitors, nonnucleoside reverse transcriptase
inhibitors, and protease inhibitors has been reported
(Salomon and others 2000; Wegner and others 2000). The first
reports of transmission of drug resistance have typically
occurred within a few years of a drug’s introduction into clin-
ical practice. The proportion of newly infected people who
acquire drug-resistant HIV has implications for the choice of
first-line regimen. Primary resistance in recently infected indi-
viduals in high-income countries is stable or has been in
decline since 2000, following a rise between 1996 and 1999.
Almost nothing is known regarding primary drug resistance
among those recently infected in low-income countries,
although this question will become more important with the
increased availability of antiretroviral therapy in resource-lim-
ited settings.
Drug resistance is associated with increases in plasma viral
RNA levels and attenuation of the responses of CD4 counts to
therapy. Nonetheless, clinical and epidemiological observations
suggest that drug resistance does not completely offset the ben-
efits of therapy (Deeks and others 1999; Ledergerber and oth-
ers 1999). Individuals with drug-resistant HIV typically have
plasma viral RNA levels that remain 3- to 10-fold lower than
pretreatment levels. Furthermore, patients with drug resistance
experience more rapid immunological decline and disease pro-
gression if they discontinue their drugs (Nijhuis, Deeks, and
Boucher 2001).
Importance of Adherence to Prescribed Therapy. With cer-
tain drugs, resistance can develop in as little as two weeks if
therapy is suboptimal (which can be less than 90 percent
adherence). Conversely, patients who adhere to therapy can
obtain continued viral suppression for many years without
the need for second- or third-line options. Research has
shown that drug adherence is one of the most important pre-
dictors of continued treatment response (Mannheimer and
others 2002). Patients in resource-limited countries are likely
to be subjected to a number of influences that challenge their
ability to adhere to the prescribed therapy, including limited
education and the consequent poorer understanding of their
disease state, unstable housing and financial circumstances, a
limited number of treatment options, and clinicians with lim-
ited antiretroviral therapy treatment experience (Kitahata and
others 1996). Those factors, in addition to the toxicity of the
therapy, influence adherence and future disease progression
rates (Duran and others 2001) and lead to an increase in drug
resistance. Thus, poorly coordinated scale-up of antiretroviral
therapy in some developing countries has the potential to
jeopardize both the duration of clinical benefit for the first
wave of patients who receive substandard care and future
response rates as the prevalence of drug resistance increases
(Harries and others 2001).
Studies in India, Mexico, Senegal, and Uganda point to poor
adherence (which for some classes of drugs can be adherence
of less than 95 percent), inadequate doses and regimes, and
poor monitoring as factors that contribute to more rapid
development of antiretroviral therapy resistance (Oyugi and
Bangsberg 2004, Laniece and others 2004, Bautista and others
2003, Liechty and Bangsberg 2003). By contrast, experiences in
Haiti and Uganda suggest that it is possible to achieve adher-
ence rates in developing countries equal to or better than those
observed in high-income countries (Farmer and others 2001;
Mitty and others 2002).
Second-Line and Subsequent Therapies. Studies from high-
income countries have unequivocally demonstrated that the
probability that an antiretroviral therapy regimen will achieve
viral suppression diminishes with each subsequent regimen
(Deeks and others 1999). Similarly, the mean duration of viral
suppression for those who achieve suppression is also lower for
subsequent regimens (Deeks and others 1999). This finding is
entirely expected because failing a previous regimen is associ-
ated with lower adherence, higher toxicity, or side effects and
increased resistance, all of which increase the probability of
similar problems occurring with subsequent regimens. Thus,
the expected survival benefit per month of antiretroviral ther-
apy declines with each change of regimen. In contrast, the
monthly cost of therapy rises as a patient moves from first-line
to more expensive protease inhibitor–based second-line and
subsequent therapies. Given this steadily declining cost-
effectiveness, wealthier countries are likely to offer a greater
number of regimen changes than poorer countries.
Laboratory Monitoring of Immune Function 
to Guide Therapy
Laboratory monitoring determines when antiretroviral therapy
should be initiated and when it should be changed because of
toxicity, lack of efficacy, or resistance. The optimal frequency
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and precision of monitoring depends on numerous factors,
principally the following:
• the expected rate of change of variables of interest
• the expected frequency of events, such as development of
resistance, adherence failure, and side effects
• the relative cost of monitoring versus the cost of providing
ineffective treatment
• the magnitude of the secondary effects of monitoring
(motivating prevention, motivating adherence).
WHO has suggested a pragmatic approach to monitoring,
with inexpensive, easy-to-measure parameters (bodyweight or
body mass index, body temperature, hemoglobin, liver
enzymes, and clinical symptoms) for monitoring in low-
income countries. More specialized markers—namely, CD4
count, viral load, and resistance genotyping—would be
restricted to sentinel sites and tertiary care services (Gutierrez
and others 2004), at least initially.
The large price reductions for antiretroviral drugs are only
now starting to be mirrored in the costs of monitoring tests as
new technologies are introduced, collective bargaining is under-
taken, and international pressure mounts on diagnostic manu-
facturers to provide more favorable pricing for LMICs.
Commercial cytometric CD4 measurements are now available
to some developing countries at less than US$5 per test
(R. Göhde, personal communication, 2004).Viral load testing is
still significantly more expensive, but even those prices have
dropped to US$20 following negotiations on behalf of low-
income countries by the William Jefferson Clinton Foundation.
Even when the potential savings become an operational reality
in developing countries, the costs of laboratory monitoring will
still represent an important proportion of the costs of providing
antiretroviral therapy.
Monitoring to Guide Initiation of Antiretroviral Therapy. If
laboratory monitoring is performed, its optimal frequency
must be determined. The closer patients get to an antiretrovi-
ral therapy threshold, the more often they must be tested to
detect a CD4 decline that falls within a specific CD4 range. As
use of antiretroviral therapy expands in LMICs and as the costs
of drugs fall relative to the costs of laboratory monitoring, col-
lecting empirical data and constructing models to compare dif-
ferent monitoring strategies is becoming increasingly urgent.
In the absence of capacity to perform CD4 counts, several
studies suggest that total lymphocyte count can be used as a
proxy because of the correlation between the two counts (Badri
and Wood 2003).Research has also shown that falling body mass
index is highly predictive of disease progression (Pistone and
others 2002). In light of those findings, the cost-effectiveness of
CD4 monitoring in developing countries must be considered
in terms of its incremental improvement over total lymphocyte
monitoring or body mass index monitoring rather than being
compared with no monitoring at all.
Testing for Primary Resistance. Testing for resistance in indi-
vidual patients is still costly, because of both the cost of the
diagnostic kit and the sophisticated laboratory capacity
required to perform the tests. Because primary resistance is far
less prevalent in LMICs than in high-income countries, no
serious consideration is being given at this time to initiating
individual resistance testing in the developing world. However,
the choice of optimal first-line and subsequent treatment
strategies should be guided by information about the preva-
lence of primary resistance to different antiretroviral drugs
in a particular country, which indicates that population-
level monitoring of the prevalence of resistance among
antiretroviral-naive people living with HIV/AIDS is important.
Monitoring Response to Therapy. Ideally, therapeutic failure
should be detected as soon as possible to permit the imple-
mentation of clinical strategies to address toxicity, drug resist-
ance, or poor adherence. Therapeutic failure leads to rising
viral load and falling immune competence and to the subse-
quent development of opportunistic infections. Unfortunately,
earlier detection comes at a price: testing for increases in viral
load, which can be detected soonest, is more expensive than
CD4 testing, which in turn is more expensive than the less sen-
sitive monitoring of total lymphocyte count, which is more
expensive than monitoring body mass index or waiting until
clinical signs of failure appear. Where facilities for detecting
early failure are absent, first-line therapy should be replaced by
a completely new combination at failure, usually a protease
inhibitor–based combination.
Monitoring Toxicity. Available antiretroviral drugs have sig-
nificant toxicity. Such toxicity is often insidious, progressing
unnoticed until the patient’s health has been seriously
impaired. Examples include zidovudine-associated anemia,
nevirapine-associated impaired liver function, and didanosine-
associated pancreatitis. Fortunately, the most commonly
encountered serious toxicities can be detected either on clinical
examination or with inexpensive laboratory tests. Data on the
relative cost-effectiveness of different toxicity monitoring
regimens are unavailable. Current guidelines identify what
monitoring should be conducted in conjunction with specific
antiretroviral drugs, depending on whether laboratory capacity
is available (WHO 2004).
Unfortunately, in the absence of a quantitative analysis of
the costs of monitoring and the benefits associated with early
detection of toxicity, it is difficult to provide guidance on the
minimum laboratory capacity that should accompany the
delivery of specific treatment combinations. Clearly, extremely
low-cost monitoring tests are warranted for toxicities that
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occur frequently. The preeminent example is anemia monitor-
ing for patients receiving zidovudine. Hemoglobin levels can
be monitored for less than US$0.02 per test, which is almost
certainly cost-effective given that the incidence of anemia
with zidovudine therapy is approximately 10 percent in
advanced-stage patients and that anemia frequently progresses
to life-threatening levels if not detected.
RESEARCH AGENDA 
As in many other areas of public health in developing coun-
tries, a profound tension exists between (a) the need for
research to discover new technologies and interventions for
both prevention and care and (b) the need for research to learn
how to effectively apply the technologies that are currently
available. The most important barrier to control is lack of
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Interventions in the Pipeline or in Trial
Box 18.7
The following interventions are currently being developed
or evaluated:
• Microbicides. Most microbicide products are currently
in preclinical development; however, 18 products are
being evaluated in clinical research studies, most in
small phase 1 safety and acceptability trials. Three
phase 3 effectiveness trials are currently under way.
• Diaphragms. The safety and effectiveness of the
diaphragm and Replens gel in preventing HIV and STIs
among women are being tested in an ongoing phase 3
randomized controlled trial in South Africa and
Zimbabwe. Two trials, in the Dominican Republic and
Madagascar, are planned to test the diaphragm’s effec-
tiveness against bacterial STIs. Several other trials in
Sub-Saharan Africa are planned to test the acceptability
and safety of the diaphragms plus microbicides.
• Circumcision. Two randomized controlled trials are
under way in Kenya and Uganda to examine whether
circumcision confers protection among adult men.
• Community-based VCT. Project Accept is a community-
based VCT trial in 32 communities in South Africa,
Tanzania, and Zimbabwe and 14 communities in
Thailand. Communities are randomized to receive either
a community-based VCT intervention or a standard
clinic-based VCT. The community-based VCT interven-
tion has three major strategies: to make VCT more avail-
able in community settings, to engage the community
through outreach, and to provide posttest support.
• HSV-2 treatment. One study in six countries will deter-
mine the efficacy of twice-daily acyclovir in reducing
susceptibility to HIV infection among high-risk, HIV-
negative, HSV-2 seropositive women and men who
have sex with men. A companion study will also be
conducted to assess whether acyclovir reduces HIV
infectiousness in individuals infected with both HSV-2
and HIV.
• Tenofovir for preexposure use. Studies are now enrolling
participants at three West African sites and will soon
begin in Botswana, Malawi, Thailand, and the United
States.
• Antiretroviral therapy to prevent sexual transmission.
A phase 3, randomized, controlled, multisite trial to
assess whether antiretroviral therapy can prevent
sexual transmission of HIV in serodiscordant couples
will begin in Brazil, India, Malawi, Thailand, and
Zimbabwe.
• Vaccines. Although preliminary results from a phase 3
clinical trial in Thailand found that AIDSVAX failed
to protect against infection, several other vaccines are
being developed. Merck and GlaxoSmithKline have
unveiled sizable vaccine programs and moved products
into human testing. An International AIDS Vaccine
Initiative U.K.-Kenya team is in the midst of interme-
diate human trials of DNA/MVA (modified vaccinia
virus Ankara), and Aventis Pasteur is taking ALVAC-
AIDSVAX into the final phase of trials. The South
African AIDS Vaccine Initiative is preparing for the
country’s first trials, India’s prime minister has pledged
national resources for vaccines, and the European
Union is broadening its vaccine research for HIV.
• Behavior change programs for people with HIV. In recent
years, a growing number of public health experts have
proposed implementing prevention interventions that
target people with HIV (De Cock, Marum, and Mbori-
Ngacha 2003; Janssen and others 2001), although evi-
dence on the most effective strategies to encourage
safer behavior among people with HIV is lacking.
Source: Authors.
knowledge about how best to implement packages of existing
interventions at the appropriate scale to maximize the effect of
prevention and care interventions and to protect the human
rights of those affected by the epidemic. Accurate surveillance
data are needed on risk behaviors, and effectiveness research is
needed to discern what interventions work where and how they
do so. Unfortunately, few rigorous evaluations of new or exist-
ing interventions have been conducted using large prospective
cohorts, with the result that, for many interventions, convinc-
ing data on effectiveness are not available. Finally, research on
policy or structural interventions, which by definition must be
conducted on a population level, is also insufficient. These
interventions include the development and testing of such pol-
icy tools as changing the tax structure, regulating the sex indus-
try, and guaranteeing property rights and access to credit for
women.
Box 18.7 lists new prevention interventions in the pipeline.
Although numerous promising interventions are listed, results
for most of these strategies are at best years away. Centuries
hence, when future generations study the history of our time
and the epidemic that killed 50 million or perhaps many more,
the most difficult question to answer may well be “why did they
invest so little for so long in developing a vaccine?” Creating
such knowledge is about as close as one can get to a pure inter-
national public good, and the lack of global cooperation in ade-
quately funding such research is an indictment of global com-
mitment to multilateral cooperation. However, given both the
uncertainty about whether developing an effective vaccine is
possible and the long delay until a new vaccine can be widely
applied, vaccine development efforts must be accompanied by
the development of other new biomedical and behavioral pre-
vention technologies.
In contrast, research on care and treatment has been far
more successful than research on prevention, and innovation in
new therapies continues apace. The ability of HIV to rapidly
evolve resistance to antiretroviral drugs, combined with the
existence of an important market in high- and middle-income
countries, appears to ensure continued investment in new
drug development. In addition, because treatment generally
has important commercial returns, HIV therapies, unlike
behavioral interventions, have benefited the most from private
sector investment. The paradox is that research on the behav-
ioral aspects of adherence to drug regimens would improve the
effectiveness of antiretroviral therapy, and thereby benefit both
commercial and public interests.
The greatest research challenges in relation to care and treat-
ment in developing countries do not revolve around new drug
development. They revolve around how to adapt care and
treatment strategies to low-income, low-technology, low–
human resource capacity settings in ways that maximize adher-
ence; minimize toxicity, monitoring, and costs; and maximize
the prolongation of high-quality life from antiretroviral
therapy—all without damaging existing and often fragile
health care infrastructure that must also address other health
concerns. Although simplified regimens, such as delivering
multiple drugs in a single tablet and fewer doses per day, are
desirable everywhere, they are especially important in low-
resource settings. Similarly, low-technology, low-cost monitor-
ing tests for antiretroviral therapy toxicity and for immunolog-
ical and virological responses to treatment are especially
needed in low-income countries, which otherwise must cen-
tralize testing—an especially difficult prospect when transport
and communications systems are poorly developed.
CONCLUSION 
Despite the glaring deficits in AIDS research, the magnitude
and seriousness of the global pandemic calls for action in the
absence of definitive data. The appropriate mix and distribu-
tion of prevention and treatment interventions depends on
the stage of the epidemic in a given country and the context in
which it occurs. In the absence of firm data to guide program
objectives, national strategies may not accurately reflect the
priorities dictated by the particular epidemic profile, resulting
in highly inefficient investments in HIV/AIDS prevention and
care. This waste undoubtedly exacerbates funding shortfalls
and results in unnecessary HIV infections and premature
deaths. The lack of good data—and thus the ability to tailor
responses to epidemics—may be somewhat understandable
when the burden of disease is minimal and the resources ded-
icated to it are similarly small. Neither is the case for
HIV/AIDS.
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NOTE
1. See http://www.hivinsite.org/global?page=cr-00-04 for a compila-
tion of international guidelines.
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Diarrheal diseases remain a leading cause of preventable death,
especially among children under five in developing countries.
This chapter reviews and prioritizes a number of available
interventions.
The normal intestinal tract regulates the absorption and
secretion of electrolytes and water to meet the body’s physio-
logical needs. More than 98 percent of the 10 liters per day of
fluid entering the adult intestines are reabsorbed (Keusch
2001). The remaining stool water, related primarily to the indi-
gestible fiber content, determines the consistency of normal
feces from dry, hard pellets to mushy, bulky stools, varying
from person to person, day to day, and stool to stool. This vari-
ation complicates the definition of diarrhea, which by conven-
tion is present when three or more stools are passed in 24 hours
that are sufficiently liquid to take the shape of the container in
which they are placed. The frequent passage of formed stool is
not diarrhea (Black and Lanata 2002). Although young nursing
infants tend to have five or more motions per day, mothers
know when the stooling pattern changes and their children
have diarrhea (Ronsmans, Bennish, and Wierzba 1988). The
interval between two episodes is also arbitrarily defined as at
least 48 hours of normal stools. These definitions enable epi-
demiologists to count incidence, relapses, and new infections.
TRANSMISSION
Diarrhea is caused by infectious organisms, including viruses,
bacteria, protozoa, and helminths, that are transmitted from
the stool of one individual to the mouth of another, termed
fecal-oral transmission. Some are well known, others are recently
discovered or emerging new agents, and presumably many
remain to be identified. They differ in the route from the stool
to the mouth and in the number of organisms needed to cause
infection and illness. Among bacteria, the ability to survive
stomach acid is an important determinant of the inoculum
size required to cause illness. For example, Shigella bacteria are
resistant to low pH, and a few thousand organisms suffice,
which are readily transferred by direct person-to-person con-
tact or through contamination of inanimate objects, such as a
cup. In contrast, bacteria readily killed by acid, such as Vibrio
cholerae, require millions of organisms to cause illness, and
therefore must first multiply in food or water to an infectious
dose. Some pathogens, such as rotavirus, display a sharp host
species preference, and others have a broad host range. Among
Salmonella bacteria, certain bio-serotypes are adapted to infect
animals and pose no threat to humans, and others are adapted
to humans and do not infect animals. The majority, however,
are not adapted to a specific host and can infect either humans
or domestic animals, thus facilitating transmission of these
organisms to humans. Less than a dozen of the more than 2,500
individual Salmonella cause the majority of human infections,
reflecting the requirement for genes that encode essential
virulence factors.
The ability to identify virulence genes and their products
has led to new molecular approaches to epidemiology and
diagnosis, and undoubtedly will lead to new measures to pre-
vent and treat diarrhea. Molecular methods also allow the
separation of organisms that otherwise appear to be identical.
Nonpathogenic Escherichia coli in normal stool cannot be
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separated from diarrhea-causing E. coli by standard methods;
however, identification of virulence genes or factors distin-
guishes five groups of E. coli that cause illnesses ranging from
cholera-like watery diarrhea to neonatal diarrhea, persistent
diarrhea, and bloody diarrhea (Nataro and Kaper 1998).
LABORATORY DIAGNOSIS 
Etiologic diagnosis of diarrhea is valuable for public health
interventions and case management. Microbiological culture
and microscopy remain the standard, despite their limited sen-
sitivity. Their effectiveness is further reduced by antibiotic use,
and patients with severe illness are more likely both to be cul-
tured and to have taken antibiotics. Even when cultures are
positive, the delay in laboratory identification limits their cost-
effectiveness for managing individual patients. The informa-
tion is always epidemiologically and clinically important; how-
ever, during epidemics, culturing every patient is unnecessary
when the causative organism is known. Antimicrobial resist-
ance data are essential to guide initial antibiotic choices.
New rapid tests to detect inflammatory mediators or white
or red blood cells in stool offer the promise of distinguishing
between secretory and inflammatory disease and optimizing
case management (Huicho and others 1996). High background
levels, probably from frequent infections, limits the use of such
tests in developing countries, where they would be most useful
(Gill and others 2003).
Simple microscopy for protozoa or helminths can be quick
and effective when the proper sample is obtained and a well-
trained technician is available to examine a fresh specimen, but
these prerequisites are often not available in developing coun-
tries. Newer immunological and nucleic acid–based tests to
detect pathogen-specific factors hold great promise for all diar-
rhea agents, but they are too expensive or require specialized
instrumentation and trained technicians. For the foreseeable
future, then, syndromic diagnosis will be the norm.
SYNDROMIC DIAGNOSIS
Three major diarrhea syndromes exist. They are acute watery
diarrhea, which results in varying degrees of dehydration; per-
sistent diarrhea, which lasts 14 days or longer, manifested by
malabsorption, nutrient losses, and wasting; and bloody diar-
rhea, which is a sign of the intestinal damage caused by inflam-
mation. The three are physiologically different and require spe-
cific management. Syndromic diagnosis provides important
clues to optimal management and is both programmatically
and epidemiologically relevant.
Acute watery diarrhea can be rapidly dehydrating, with
stool losses of 250 milliliters per kilogram per day or more, a
quantity that quickly exceeds total plasma and interstitial fluid
volumes and is incompatible with life unless fluid therapy can
keep up with losses. Such dramatic dehydration is usually due
to rotavirus, enterotoxigenic E. coli, or V. cholerae (the cause of
cholera), and it is most dangerous in the very young.
Persistent diarrhea is typically associated with malnutrition,
either preceding or resulting from the illness itself (Ochoa,
Salazar-Lindo, and Cleary 2004). Even though persistent diar-
rhea accounts for a small percentage of the total number of
diarrhea episodes, it is associated with a disproportionately
increased risk of death. In India, persistent diarrhea accounted
for 5 percent of episodes but 14 percent of deaths, and a mor-
tality rate three times higher than briefer episodes (Bhan and
others 1989). In Pakistan, persistent diarrhea accounted for 8 to
18 percent of episodes but 54 percent of deaths (Khan and oth-
ers 1993). In Bangladesh, persistent diarrhea associated with
malnutrition was responsible for nearly half of diarrhea deaths,
and the relative risk for death among infants with persistent
diarrhea and severe malnutrition was 17 times greater than for
those with mild malnutrition (Fauveau and others 1992).
Persistent diarrhea occurs more often during an episode of
bloody diarrhea than an episode of watery diarrhea, and the
mortality rate when bloody diarrhea progresses to persistent
diarrhea is 10 times greater than for bloody diarrhea without
persistent diarrhea. HIV infection is another risk factor for per-
sistent diarrhea in both adults and children (Keusch and others
1992). Management focuses on overcoming the nutritional
alterations initiated by persistent diarrhea.
Bloody diarrhea, defined as diarrhea with visible or micro-
scopic blood in the stool, is associated with intestinal damage
and nutritional deterioration,often with secondary sepsis.Some
dehydration—rarely severe—is common, as is fever. Clinicians
often use the term bloody diarrhea interchangeably with dysen-
tery; however,dysentery is a syndrome consisting of the frequent
passage of characteristic, small-volume, bloody mucoid stools;
abdominal cramps; and tenesmus, a severe pain that accompa-
nies straining to pass stool. Those features show the severity of
the inflammation. Agents that cause bloody diarrhea or dysen-
tery can also provoke a form of diarrhea that clinically is not
bloody diarrhea, although mucosal damage and inflammation
are present, and fecal blood and white blood cells are usually
detectable by microscopy. The release of host-derived cytokines
causes fever, altering host metabolism and leading to the break-
down of body stores of protein, carbohydrate, and fat and the
loss of nitrogen and other nutrients. Those losses must be
replenished during convalescence, which takes much longer
than the illness does to develop. For these reasons, bloody diar-
rhea calls for management strategies that are markedly different
than those for watery or persistent diarrhea. New bouts of infec-
tion that occur before complete restoration of nutrient stores
can initiate a downward spiral of nutritional status terminating
in fatal protein-energy malnutrition (Keusch 2003).
372 | Disease Control Priorities in Developing Countries | Gerald T. Keusch, Olivier Fontaine, Alok Bhargava, and others
DIARRHEA, ENVIRONMENT, AND POVERTY
Diarrheal disease affects rich and poor, old and young, and
those in developed and developing countries alike, yet a strong
relationship exists between poverty, an unhygienic environ-
ment, and the number and severity of diarrheal episodes—
especially for children under five.
Poverty is associated with poor housing, crowding, dirt
floors, lack of access to sufficient clean water or to sanitary dis-
posal of fecal waste, cohabitation with domestic animals that
may carry human pathogens, and a lack of refrigerated storage
for food—all of which increase the frequency of diarrhea.
Poverty also restricts the ability to provide age-appropriate,
nutritionally balanced diets or to modify diets when diarrhea
develops so as to mitigate and repair nutrient losses. The
impact is exacerbated by the lack of adequate, available, and
affordable medical care. Thus, the young suffer from an appar-
ently never-ending sequence of infections, rarely receive appro-
priate preventive care, and too often encounter the health care
system when they are already severely ill.
Although the presence of blood in the stool is a recognized
danger signal, prompting more urgent care seeking, even these
patients either are not treated early or receive poor medical
care. Ironically, the poor spend considerable amounts on inap-
propriate care and useless drugs purchased from local shops
and untrained practitioners. If antibiotics are properly pre-
scribed, poverty often limits the purchase of a full course of
treatment or leads to cessation of treatment as soon as symp-
toms improve, even though the infection has not been cured.
PUBLIC HEALTH SIGNIFICANCE OF
DIARRHEAL ILLNESSES
Continuing surveillance and longitudinal studies allow track-
ing of current levels and trends in diarrhea incidence and
mortality and provide the basis for future projections and for
evaluations of different control strategies.
Morbidity 
Comparisons over time of the global burden of diarrheal dis-
eases have revealed secular trends and demonstrated the
impact of public health interventions (Bern and others 1992;
Kosek, Bern, and Guerrant 2003; Snyder and Merson 1982).
The long-term consequences of diarrhea are only now being
systematically assessed and are not reflected in earlier studies.
Reviews in 1992 (Bern and others) and 2003 (Kosek, Bern,
and Guerrant) are similar in many ways—for example,
assessing morbidity at least twice weekly—but differ signifi-
cantly in the use of different sources for data on children under
five and in the inclusion of studies differing in design and data
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collection protocols (and only the later study includes data
from China). Remarkably, the estimated median incidence of
diarrheal disease in children under five in developing countries
has not changed much since the early 1990s (figure 19.1): 3.2
episodes per child per year in 2003 (Parashar and others 2003)
compared with 3.5 episodes per child per year in 1993 (Jamison
and others 1993). However, many fewer surveys were available
for the most recent review (31 in 20 countries) compared with
the 1993 consensus (276 in 60 countries), reflecting diminished
support for the systematic collection of incidence data.
Incidence rates in Sub-Saharan Africa and Latin America are
clearly greater than in Asia or the Western Pacific, while subject
to greater data limitations from individual countries. Incidence
continues to show a peak in infants age 6 to 11 months, drop-
ping steadily thereafter.
The seemingly lower estimates of diarrheal incidence before
1980 (Snyder and Merson 1982) are likely due to methodolog-
ical differences. These estimates are not precise or directly com-
parable; the trends are most relevant. The persistently high
rates of diarrhea throughout the 1990s despite intensive efforts
at control, particularly among children age 6 to 24 months, is of
particular concern. Early childhood diarrhea during periods
of critical postnatal development may have long-term effects
on linear growth and on physical and cognitive functions.
Data on the incidence of shigellosis, the principal cause of
bloody diarrhea in developing countries, are even more lim-
ited. Kotloff and others’ (1999) review of studies on Shigella
infection estimates that more than 113 million episodes occur
every year in children under five in developing countries, or 0.2
episodes of bloody diarrhea per year caused by Shigella species.
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Mortality 
Bern and others (1992); Kosek, Bern, and Guerrant (2003); and
Snyder and Merson (1982) also estimate diarrheal mortality
using data from longitudinal studies with active surveillance in
place (figure 19.2). The estimate before 1980 was 4.6 million
deaths per year. This estimate dropped to 3.3 million per year
between 1980 and 1990 and to 2.6 million per year between
1990 and 2000. Two other studies (Parashar and others 2003;
Boschi-Pinto and Tomaskovic forthcoming) report even lower
figures for 1990–2000: 2.1 million and 1.6 million deaths per
year, respectively. Methodological variations (inclusion of stud-
ies with different designs and data collection methods and
inclusion of data from China, different sources for estimating
the number of children under five, and different strategies for
calculating mortality for this age group) may account for some
of the striking differences. However, the end of the 20th cen-
tury witnessed significant reductions in diarrheal deaths in
children under five.
This steady decline in diarrheal mortality, despite the lack of
significant changes in incidence, is most likely due to modern
case management (introduced since the 1980s) and to the
improved nutrition of infants and children. Major recommen-
dations include the following:
• counseling mothers to begin suitable home-prepared rehy-
dration fluids immediately on the onset of diarrhea
• treating mild to moderate dehydration early with oral rehy-
dration solution (ORS), reserving intravenous electrolytes
for severe dehydration
• continuing breastfeeding and complementary foods during
diarrhea and increasing intake afterward
• limiting antibiotic use to cases of bloody diarrhea or dysen-
tery and avoiding antidiarrheal and antimotility drugs
• advising mothers to increase fluids and continue feeding
during future episodes.
Victora and others’ (2000) review provides evidence that this
strategy, and especially oral rehydration therapy (ORT), has
influenced the outcome of dehydrating diarrhea. Data from 99
national surveys carried out in the mid 1990s and compiled by
the United Nations Children’s Fund (UNICEF) increasingly
show that diarrhea patients are appropriately managed in most
parts of the world,with overall use rates of ORS or recommended
home fluids reaching 49 percent. Country case studies in Brazil,
the Arab Republic of Egypt, Mexico, and the Philippines showed
a dramatic reduction of diarrhea mortality as ORT use rates
increased from close to zero in the early 1980s to 35 percent in
Brazil, 50 percent in Egypt, 81 percent in Mexico, and 33 percent
in the Philippines in the early 1990s. Hospital admissions for
diarrhea also plummeted (Victora and others 2000). As mor-
tality attributable to acute dehydration decreased, the propor-
tionate mortality associated with persistent diarrhea increased.
Data from Brazil and Egypt suggest that even relatively low ORT
use rates can positively affect mortality,because ORT use tends to
be much higher for severe illness (Victora and others 2000).
Worldwide mortality caused by Shigella infection is esti-
mated to be 600,000 deaths per year among children under five,
or a quarter to a third of all diarrhea-related mortality in this
age group (Kotloff and others 1999). Because mortality caused
by bloody diarrhea is not tracked separately, it is difficult to
assess the impact of standard case management recommenda-
tions, and disease-specific trends cannot be tracked. In the past
few years, however, data from the International Centre for
Diarrheal Disease Research, in Bangladesh, have shown a
marked decrease in the rate of hospitalization caused by
Shigella, especially S. dysenteriae type 1, the most severe form of
shigellosis. Some investigators have suggested that this decrease
may be because Shigella infections are now in the low part of a
10-year cycle (Legros 2004). The observed change could also be
explained by better case management with more efficacious
antimicrobials. More comprehensive, syndrome-specific sur-
veillance data will be required if rational control priorities are
to be set, because the options for dehydrating and bloody diar-
rheal diseases differ substantially.
Despite national data that indicate a significant decline in
mortality (Baltazar, Nadera, and Victora 2002; Miller and
Hirschhorn 1995), diarrheal diseases remain among the five
top preventable killers of children under five in developing
countries and among the top two in many.
Long-Term Consequences
The long-term consequences of diarrheal diseases remain
poorly studied, and analyses of global trends have not consid-
ered them. Niehaus and others (2002) recently evaluated the
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long-term consequences of acute diarrheal disease on psy-
chomotor and cognitive development in young children.
Following a cohort of 47 children in a poor urban community
in northeastern Brazil, they correlated the number of diarrheal
episodes in the first two years of life with measures of cognitive
function obtained four to seven years later. They found a sig-
nificant inverse correlation (average decrease of 5.6 percent)
between episodes of early diarrheal disease and overall intellec-
tual capacity and concentration, even when controlling for
maternal education or helminth infection, which are known
to be independent predictors of malnutrition and cognitive
defects. Test scores were also 25 to 65 percent lower in children
with an earlier history of persistent diarrhea.
Recent evidence suggests that genetic factors may also be
involved in the developmental response to repeated diarrhea
(Oria and others 2005). Better and more sensitive assessment
tools are needed to define the relationships between diarrheal
diseases and developmental disorders and to calculate individ-
ual and societal costs and the cost-effectiveness of interven-
tions. In addition, early childhood malnutrition resulting from
any cause reduces physical fitness and work productivity in
adults (Dobbing 1990).
PREVENTIVE STRATEGIES
Strategies for controlling diarrheal diseases have remained
substantially unchanged since the 1993 edition of this volume
(Martinez, Phillips, and Feachem 1993). The World Health
Organization (WHO 2004) recently reevaluated these inter-
ventions to determine the extent to which they have been effec-
tively implemented and their effect.
Promotion of Exclusive Breastfeeding
Exclusive breastfeeding means no other food or drink, not
even water, is permitted, except for supplements of vitamins
and minerals or necessary medicines. The optimal duration
of exclusive breastfeeding is six months (WHO 2001). A
meta-analysis of three observational studies in developing
countries shows that breastfed children under age 6 months
are 6.1 times less likely to die of diarrhea than infants who are
not breastfed (WHO Collaborative Study Team 2000).
Exclusive breastfeeding protects very young infants from diar-
rheal disease in two ways: first, breast milk contains both
immune (specific) and nonimmune (nonspecific) antimicro-
bial factors; second, exclusive breastfeeding eliminates the
intake of potentially contaminated food and water. Breast
milk also provides all the nutrients most infants need up to
age 6 months. When exclusive breastfeeding is continued dur-
ing diarrhea, it also diminishes the adverse impact on nutri-
tional status.
Those data underpin the global campaign to promote exclu-
sive breastfeeding for the first six months of life by increasing
both the initiation and the duration of exclusive breastfeeding.
The strategies include the following:
• hospital policies and actions to encourage breastfeeding and
discourage bottle feeding
• counseling and education provided by peers or health
workers 
• mass media and community education
• mothers’ support groups.
Interventions focused on hospital practices apply where
most women deliver in such facilities. Such interventions have
shown up to a 43 percent increase in exclusive breastfeeding
with good institutional policies and retraining of health staff
(Westphal and others 1995). Interventions focused on educa-
tion and counseling increase exclusive breastfeeding by 4 to
64 percent (Sikorski and others 2002). Peer-counseled women
are less likely to stop exclusive breastfeeding than are those who
receive either professional support or no support, and their
infants are 1.9 to 2.9 times less likely to have diarrhea (Barros
and others 1995; Haider and others 1996). No large-scale peer
counseling programs exist; therefore, feasibility is unknown.
Community-based mother’s support groups are sustainable,
but they have low coverage and are biased toward women who
are already motivated to breastfeed (Bhandari and others
2003). Mass media can be effective where media coverage is
high, where production skills are good, and where it addresses
barriers to breastfeeding instead of just proclaiming its bene-
fits. We found no studies that examined the relationship
between breastfeeding promotion and diarrheal disease mor-
tality; however, estimates suggest such promotion could
decrease all-cause mortality in children under five by 13 per-
cent (Jones and others 2003).
Maternal HIV infection has put a new wrinkle in the “breast
is best” dogma because of the risk of transmission of infection
to the infant (De Cock and others 2000). There is a trade-off,
however, between the risk of mortality associated with replace-
ment feeding and the risk of HIV infection, especially where
safe replacement feeding is difficult. For women who are HIV-
negative or whose status is unknown, WHO currently recom-
mends exclusive breastfeeding for at least six months (WHO
2000). The best option for HIV-positive women is acceptable,
affordable, sustainable, and safe replacement feeding. If this
option is not possible, there are four alternatives: (a) heat-
treated breast milk, (b) HIV-negative wet nurses, (c) unconta-
minated donor milk, or (d) exclusive breastfeeding for six
months and rapid discontinuation thereafter (WHO 2003).
A danger of promoting replacement feeding is that unin-
fected women or women with unknown HIV status will adopt
the practice. Even in high-prevalence communities, the best
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option for women with unknown status for the overall health
of their children appears to be exclusive breastfeeding for six
months. In Coutsoudis and others’ (1999) cohort study in
South Africa, the risk of mother-to-infant transmission of HIV
after three months of exclusive breastfeeding was similar to that
with no breastfeeding and significantly lower than that with
mixed feeding. Providing antiretroviral therapy to the mother
should significantly extend the period of safe breastfeeding for
the initially HIV-negative infants of HIV-positive mothers.
Improved Complementary Feeding Practices 
Ideally, complementary foods should be introduced at age
6 months, and breastfeeding should continue for up to two
years or even longer to increase birth intervals (WHO 2003).
There is a strong inverse association between appropriate, safe
complementary feeding and mortality in children age 6 to 11
months. Malnutrition is an independent risk predictor for the
frequency and severity of diarrheal illness. There is a vicious
cycle in which sequential diarrheal disease leads to increasing
nutritional deterioration, impaired immune function, and
greater susceptibility to infection. The cycle may be broken by
interventions to decrease infection incidence to reduce malnu-
trition (Keusch and Scrimshaw 1986) or improving nutritional
status to reduce the burden of infection (Victora and others
1999).
Improved feeding practices to prevent or treat malnutrition
could save as many as 800,000 lives per year (Jones and others
2003). Pediatricians have long been aware of an increase in
diarrhea incidence during weaning from exclusive breast milk
feeding. Microbial contamination of complementary foods
(Mondal and others 1996) and nutritionally inadequate diets
during and after diarrhea episodes (Badruddin and others
1991) increase the risk. Contamination of complementary
foods can potentially be reduced by educating caregivers on
hygienic practices (Guptill and others 1993), improving home
food storage (English and others 1997), fermenting foods to
reduce pathogen multiplication (Kimmons and others 1999),
or ingesting nonpathogenic probiotic microorganisms that col-
onize the gut and help resist pathogens (Allen and others
2004). These interventions have not been evaluated at scale in
communities, and effectiveness trials are lacking.
We could not find any reports on the effects of complemen-
tary feeding interventions on mortality. Five efficacy trials to
improve the intake of complementary foods noted a net
increase in energy intake of between 65 and 300 kilocalories a
day and improvements of 0.25 to 0.46 standard deviations in
weight-for-age and 0.04 to 0.35 standard deviations in height-
for-age (Caulfield, Huffman, and Piwoz 1999). By extrapola-
tion, this increment in growth should translate into a 2 to 13
percent reduction in deaths associated with malnutrition
(Black and others 1995).
Brown, Dewey, and Allen (1998) reviewed experiences with
large-scale complementary feeding interventions in 14 coun-
tries. They demonstrate that it is possible to provide nutrition-
ally improved complementary foods in diverse cultural settings
and that poor mothers are willing to prepare new foods their
children will eat. However, caregivers face considerable time
and resource constraints in providing such foods, especially
during episodes of illness. A pilot study in Brazil that imple-
mented nutritional counseling through the Integrated
Management of Childhood Illness Program reported signifi-
cant weight gain in children age one year or more, but not in
younger children (Santos and others 2001).
Unfortified complementary foods do not meet all essential
micronutrient requirements. Although improvements in vita-
min A status do not significantly reduce the incidence of diar-
rhea and other common childhood illnesses, vitamin A supple-
mentation can reduce the frequency of severe diarrhea (Barreto
and others 1994) and mortality (Ross and others 1995).
Chapter 28 describes interventions to promote vitamin A
intake. Zinc supplementation also reduces the incidence of
diarrhea.
Rotavirus Immunization 
Almost all infants acquire rotavirus diarrhea early in life, and
rotavirus accounts for at least one-third of severe and poten-
tially fatal watery diarrhea episodes—primarily in developing
countries, where an estimated 440,000 vaccine-preventable
rotavirus deaths per year occur (Parashar and others 2003),
compared with about a dozen in a developed country such as
France (Fourquet and others 2003). An effective rotavirus vac-
cine would have a major effect on diarrhea mortality in devel-
oping countries.
In 1998, a quadrivalent Rhesus rotavirus–derived vaccine
that reduced the frequency of severely dehydrating rotavirus—
but not the overall incidence of rotavirus infections—was
licensed in the United States (Glass and others 1999). It was
cost-effective, even at US$100 for a full course of immuniza-
tion, when direct economic losses resulting from health care
expenses and indirect costs of lost productivity and wages for
the caretakers were considered (Tucker and others 1998). The
strategy was clear: use the high-priced vaccine routinely in
industrial countries to subsidize its use in developing countries.
However, postmarketing surveillance detected an apparent
increase in a relatively rare event, intussusception, a condition
in which the intestine telescopes on itself, causing a potentially
serious obstruction (CDC 1999a). The relationship was
strongest with the first dose of vaccine given with the first or
second dose of diphtheria-pertussis-tetanus vaccine (Peter and
others 2002), although this was counterbalanced by a decrease
in the incidence of intussusception in older children (Murphy
and others 2003).
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The overall reduced incidence in immunized infants com-
pared with nonimmunized infants in these studies suggested
that the vaccine may actually protect against later adverse
events. Nonetheless, the ensuing controversy led to a reversal of
the recommendation for universal immunization in the United
States and withdrawal of the vaccine from the market, preclud-
ing the possibility of its deployment in developing countries
(CDC 1999b). Because very young infants are less prone to
develop intussusception, initial immunization at birth might
have been entirely safe.
Despite this setback, efforts to produce an effective and safe
rotavirus vaccine continue. The Rhesus vaccine has been reli-
censed to another manufacturer, and new vaccines derived
from human or bovine rotavirus are undergoing field trials in
developing countries (Dennehy 2005). A monovalent human
rotavirus vaccine was introduced in Mexico in 2005. The entry
of both China and India into rotavirus vaccine development
and their potential for manufacturing quality vaccines at low
cost will make it easier to deploy an effective vaccine where it is
really needed.
Cholera Immunization 
Endemic cholera is primarily a pediatric disease, although
adult morbidity and mortality are significant, especially dur-
ing epidemics. The lethality of cholera is due to the physio-
logical consequences of rapid and profound dehydration.
Oral rehydration therapy has dramatically improved survival
and reduced the cost of treatment. Wherever parenteral and
oral rehydration is readily available, even in epidemic situa-
tions, a cholera mortality rate above 1 percent indicates fail-
ure of the public health system to provide appropriate case
management.
A vaccine would further reduce the morbidity and mortal-
ity associated with cholera in endemic areas; however, devel-
oping an effective, safe vaccine has proven difficult. The most
immunogenic and protective vaccines tested thus far are
administered orally. Two such vaccines have been licensed: an
attenuated live vaccine and a heat-killed vaccine combined
with recombinant cholera toxin B subunit, which functions
as an immunoadjuvant (Graves and others 2000; Ryan and
Calderwood 2000). Many developing countries can produce
the killed vaccine, especially without cholera toxin B. Current
oral cholera vaccines appear to be safe and offer reasonable
protection for a limited period; however, the main users have
been individual travelers from industrial countries who may
be exposed to the risk of cholera while traveling in endemic
areas.
The use of oral cholera vaccine in mass vaccination cam-
paigns as an adjunct to good case management, disposal of
fecal waste, and access to safe water during humanitarian dis-
asters has recently been reviewed (WHO 1999). Analysis of an
outbreak in Micronesia suggested that a single dose was useful
in limiting the spread of cholera (Calain and others 2004). But
because ORT is so inexpensive and useful in preventing death,
immunization is not a high priority. Only Vietnam routinely
deploys cholera vaccine.
Operational information on the costs, logistics, and avail-
ability of vaccines for use by global programs and on the vul-
nerable populations in high-risk settings who would benefit
from cholera vaccine remains limited. Although scientific
interest in a cholera vaccine remains high, its public health pri-
ority is less than that of a vaccine for rotavirus or Shigella.
Measles Immunization
Measles is known to predispose to diarrheal disease secondary
to measles-induced immunodeficiency. Feachem and Koblinsky
(1983) estimate that measles vaccine given to 45 to 90 percent
of infants would prevent 44 to 64 percent of measles cases, 0.6
to 3.8 percent of diarrheal episodes, and 6 to 26 percent of diar-
rheal deaths among children under five. Global measles immu-
nization coverage is now approaching 80 percent, and the dis-
ease has been eliminated from the Americas, raising hopes for
global elimination in the near future (GAVI 2005), with a pre-
dictable reduction in diarrhea as well.
Improved Water and Sanitary Facilities and Promotion
of Personal and Domestic Hygiene
Human feces are the primary source of diarrheal pathogens.
Poor sanitation, lack of access to clean water, and inadequate
personal hygiene are responsible for an estimated 90 percent of
childhood diarrhea (WHO 1997). Promotion of hand washing
reduces diarrhea incidence by an average of 33 percent (Huttly,
Morris, and Pisani 1997); it works best when it is part of a
package of behavior change interventions. Effects on mortality
have not been demonstrated. However, the required behavior
change is complex, and significant resources are needed.
Antiseptic soaps are more costly than plain hand soap and con-
fer little advantage. Washing hands after defecating or handling
children’s feces and before handling food is recommended, but
it entails an average of 32 hand washes a day and consumes
20 liters of water (Graef, Elder, and Booth 1993). If soap is too
costly, ash or mud can be used, but access to water remains
essential (Esrey 1996).
Six rigorous observational studies demonstrated a median
reduction of 55 percent in all-cause child mortality associated
with improved access to sanitation facilities (Esrey, Feachem,
and Hughes 1985). The greatest effect of improving sanitation
systems will be in areas of high population density and wher-
ever the entire community, rather than single households,
adopts the intervention. Current technology can be costly and
difficult to maintain, and in some settings it is simply not
feasible.
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CASE MANAGEMENT
Two recent advances in managing diarrheal disease—(a) newly
formulated ORS containing lower concentrations of glucose
and salts and (b) zinc supplementation—used in combination
with promotion of exclusive breastfeeding, general nutritional
support, and selective and appropriate use of antibiotics, can
further reduce the number of diarrheal deaths among children.
Families and communities are key to achieving case manage-
ment goals by making these recommendations routine practice
in homes and health facilities.
New Oral Rehydration Solutions 
For more than 25 years, UNICEF and WHO have recom-
mended a single formulation of glucose-based ORS considered
optimal for cholera, irrespective of cause or age group affected.
This formulation has proven effective and without significant
adverse effects (Ruxin 1994), but because watery stools persist
and duration of diarrhea is not reduced, mothers’ and health
workers’ acceptance of current ORSs has been suboptimal.
During the past 20 years, efforts to improve ORS to treat
dehydration from all types of diarrhea and reduce stool output
or duration have continued—for example, by reducing the
sodium content in line with sodium losses for noncholera diar-
rhea. Compared with standard ORS, lower sodium and glucose
ORS reduces stool output, vomiting, and the need for intra-
venous fluids (Hanh, Kim, and Garner 2001). If household use
increases, new ORS can reduce childhood deaths from non-
cholera diarrhea (Duggan and others 2004), and it appears to
be as effective as standard ORS for children or adults with
cholera. A WHO expert group now recommends that ORS
containing 75 milliequivalents of sodium and 75 millimoles of
glucose per liter (total osmolarity, 245 milliosmoles per liter) be
used everywhere (WHO and UNICEF 2004).
Zinc Supplementation
A review of all relevant clinical trials indicates that zinc supple-
ments given during an episode of acute diarrhea reduce both
duration and severity and could prevent 300,000 deaths in chil-
dren each year (Black 2003). WHO and UNICEF now recom-
mend that all children with acute diarrhea be given zinc in
some form for 10 to 14 days during and after diarrhea (10 mil-
ligrams per day for infants younger than 6 months and 20 mil-
ligrams per day for those older than 6 months) (WHO and
UNICEF 2004).
Pilot studies in Brazil, Egypt, Ethiopia, India, Mali, Pakistan,
and the Philippines that include zinc routinely in the manage-
ment of acute diarrhea not only show an improvement over
ORS alone but also suggest two important new effects: (a) use
rates of ORS increase, and (b) use rates of antidiarrheals and
antimicrobials decrease significantly (Baqui and others 2004).
Large community-based studies are being implemented to cor-
roborate these potentially important findings.
Management of Bloody Diarrhea
The primary treatment for shigellosis, the most common and
severe cause of bloody diarrhea, is antimicrobials. The choice of
effective, safe, and inexpensive oral drugs for use in developing
countries has, however, become problematic because of the
increasing prevalence of antimicrobial drug resistance (Salam
1998). Tetracycline, ampicillin, and the fixed-ratio combina-
tion of trimethoprim and sulfmethoxazole, once used as first-
line treatment, are no longer reliably effective. When epidemic
dysentery caused by multidrug-resistant S. dysenteriae type 1
appeared in Africa and Asia in the 1980s and 1990s, nalidixic
acid was pressed into use (Salam and Bennish 1988). Nalidixic
acid is a drug used primarily for urinary tract infections, but it
is also effective against Shigella. Clinical responses were initially
excellent, but with continued use, resistance to nalidixic acid
has been increasing in many parts of the world (Dutta and
others 2003).
A number of other drugs have been tested and shown
effective, including ceftriaxone, azithromycin, pivmecillinam,
and some new generation 5-fluoroquinolones, such as
ciprofloxacin (Salam 1998). Because of its effectiveness, safety,
ease of administration by the oral route, short course, and low
cost (US$0.10 for a three-day course for a 15-kilogram child),
ciprofloxacin is the current drug of choice for shigellosis
(Zimbasa Dysentery Study Group 2002). However,
ciprofloxacin-resistant strains are already appearing (Pazhani
and others 2004), and it is only a matter of time before resist-
ance becomes widespread, especially if the drug is readily avail-
able and indiscriminately used. Because of these concerns,
development of a vaccine for Shigella is critical. The Diseases of
the Most Impoverished initiative, supported by the Bill &
Melinda Gates Foundation (Nossal 2003), which promotes vac-
cine development for Shigella, cholera, and typhoid, is a signif-
icant advance since the previous edition of this volume.
COST-EFFECTIVENESS OF INTERVENTIONS 
Cost-effectiveness ratios of diarrheal disease interventions were
calculated by World Bank region in terms of disability-adjusted
life years (DALYs) averted for a model population of 1 million,
following the standardized guidelines of the Disease Control
Priorities Project for economic analyses (see chapter 15).
Europe and Central Asia were excluded because data were lack-
ing owing to the low prevalence of disease. Input variables
included (a) region-specific diarrhea morbidity rates adapted
from Kosek, Bern, and Guerrant (2003); (b) region-specific
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underlying mortality rates and age structures provided by the
Disease Control Priorities Project; (c) median intervention
effectiveness rates (that is, percentage of diarrheal morbidity
reduction and percentage of diarrheal mortality reduction);
and (d) median per capita intervention costs gathered from the
literature and from personal communications (table 19.1).
Because approximately 90 percent of all cases in the devel-
oping world occur in children under five, the analysis focused
on this age group alone. Uniform intervention effectiveness
rates were assumed for all regions because region-specific
information was not available. Regional variations in cost-
effectiveness were due to regional variations in the prevalence
of diarrheal disease, in the diarrhea-attributable morbidity and
mortality, and in the intervention cost, where region-specific
information was available.
Disability-adjusted life years are averted through the avoid-
ance of cotemporaneous disability and mortality attributable
to diarrhea. We did not consider long-term developmental and
cognitive effects of childhood diarrhea or the external benefits
of interventions unrelated to diarrhea (for instance, benefits of
measles immunization unrelated to diarrhea or other health
benefits of improved public water and sanitation). Therefore,
our estimates err on the conservative side.
We explored two general categories of interventions: early
interventions that take place within the first year of life—
breastfeeding promotion and immunizations for rotavirus
(with the prototype Rhesus reassortant tetravalent vaccine),
cholera (with live oral vaccine), and measles—and other inter-
ventions that treat an entire cohort of children under five simul-
taneously (improved water and sanitation). For early interven-
tions, cost-effectiveness ratios were calculated by considering
the cost of treating all newborns in a single year and the bene-
fits (DALYs averted) from those treatments that occur over the
first five years of life. These benefits include avoided mortality
that allows individuals to live to the expected life expectancy for
the region. Other interventions included ORT and improved
water and sanitation infrastructure. Because a single year of
these interventions yields only cotemporaneous benefits—
because effectively treated individuals do not necessarily live to
life expectancy given that they are likely to be reinfected the next
year—we calculated cost-effectiveness of a five-year interven-
tion. Analysis of a five-year intervention enabled us to consider
the case in which an entire cohort of children age zero to four
avoids early childhood diarrheal mortality because of the inter-
vention and receives the benefit of living to life expectancy.
Disability and deaths averted for those benefiting from
improved water and sanitation were calculated from only the
fraction of the model populations currently without access. For
each region, the proportion of rural and urban children age
zero to four currently without access to improved water and
sanitation was calculated using region-specific information
from World Bank Development Indicators (World Bank 2002)
for 2000. Infrastructure improvements for rural and urban
populations were considered separately because of differences
in infrastructure type and cost, although the same effectiveness
rates were used for both.
The per child treatment costs and effectiveness rates used
are presented in table 19.1. Cost per treatment of ORT varied
widely depending on the type and method of ORT imple-
mented. Oral rehydration therapy can be as inexpensive as
US$0.02 per child treated—the cost of a home remedy with
sugar and salt. However, treatment can become substantially
more expensive if commercially manufactured ORS is used or
if there are substantial personnel or infrastructure costs
(Martinez, Phillips, and Feachem 1993). Finally, our analysis
considered only long-run marginal costs (which vary with the
number of individuals treated) and did not include fixed costs
of initiating a program where none currently exists.
Figure 19.3 shows the cost-effectiveness of all interventions
over the first five years of life. Two interventions administered
during the first year of life—breastfeeding promotion (US$930
per DALY) and measles immunization (US$981 per DALY)—
were the most cost-effective. ORT (US$1,062 per DALY) and
water and sanitation in rural areas (US$1,974 per DALY) were
the next most cost-effective, but only if they were implemented
continuously for five years, thereby allowing an entire cohort of
effectively treated children age zero to four to survive past the
age at which they are most at risk for diarrheal infection, dis-
ability, and mortality. Rotavirus immunization (US$2,478 per
DALY), cholera immunization (US$2,945 per DALY), and
water and sanitation in urban areas (US$6,396 per DALY) were
the least cost-effective.
Among the early interventions, breastfeeding promotion was
less effective than other interventions but also less expensive
than rotavirus and measles vaccination (table 19.1). Cholera
vaccination was less expensive than breastfeeding promotion,
but it was also many times less effective because of the signifi-
cantly higher prevalence of diarrhea that is not related to
cholera—making cholera vaccination the least cost-effective of
the early interventions considered. Oral rehydration therapy
and water and sanitation interventions were more effective than
breastfeeding and vaccination interventions in reducing mor-
bidity and mortality caused by diarrhea, but they were also more
expensive. However, our analysis for water and sanitation did
not consider the benefits of this intervention other than those
related to health, and the high cost-effectiveness ratio is more a
limitation of our methodology than of the intervention itself.
The high cost-effectiveness ratio for ORT is attributable to
the high variation in reported treatment costs, which may
inflate the median cost used in this analysis (table 19.2). Given
the range of reported treatment costs (table 19.1), the cost-
effectiveness ratio of ORT could be as low as US$4 per DALY or
as high as US$2,124 per DALY in low- and middle-income
countries. High variation in reported treatment costs results in
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Table 19.1 Cost and Effectiveness Values Used to Calculate Cost-Effectiveness Ratios for Select Interventions for Diarrhea for Children under Age Five
Median Median diarrhea Morbidity Median diarrhea Mortality 
Source regions cost/child Cost/child range morbidity reduction reduction range mortality reduction reduction range 
Model regions Sources or countries (2001 US$) (2001 US$) (percent) (percent) (percent) (percent)
Breastfeeding promotion
Costs
LMICs, EAP, MENA, Horton and others 1996; LMICs, Brazil, 8.98 0.46–17.50
SA, SSA Martinez, Phillips, and Honduras, Mexico
Feachem 1993
LAC Horton and others 1996 Brazil, Honduras, 1.86 0.46–3.26
Mexico
Effectiveness (age 0 to 5)
All Feachem and Koblinsky LMICs 4.5 1–8 10.5 4–17
1984
Rotavirus immunization with RRV-TV
Costs
LMICs, EAP, LAC, Martinez, Phillips, and LMICs, India 53.80 3.33–104.30
MENA, SSA Feachem 1993; Narula, 
Tiwari, and Puliyeh 2004
SA Narula, Tiwari, and India 104.30 —
Puliyeh 2004
Effectiveness (age 0 to 5)
All Parashar and others Brazil, Peru, R. B. 8.54 — 24.1 —
1998a de Venezuela
Cholera immunization with live oral vaccine
Costs
LMICs, EAP, MENA, Cookson and others 1997; LMICs, Argentina 3.65 1.70–5.60
SA, SSA Martinez, Phillips, and 
Feachem 1993
LAC Cookson and others 1997 Argentina 1.70 —
Effectiveness (age 0 to 5)
All de Zoysa and Feachem Bangladesh 0.095 0.06–0.13 1.5 1–2
1985
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Measles immunization
Costs
LMICs, LAC, Duke 1999; Feachem and LMICs, Côte d’Ivoire, 13.26 0.52–26.00
MENA, SA Koblinsky 1983; Phillips, Ghana, Indonesia, 
Feachem, and Mills 1987; Papua New Guinea, 
Martinez, Phillips, and Zambia
Feachem 1993; 
Shann 2000
EAP Duke 1999; Phillips, Indonesia, 1.62 0.52–1.10
Feachem, and Mills 1987; Papua New Guinea
Shann 2000
SSA Feachem and Koblinsky Côte d’Ivoire, 15.00 4.00–26.00
1983; Phillips, Feachem, Ghana, Zambia
and Mills 1987
Effectiveness (age 0 to 5)
All Feachem and LMICs 2.2 0.6–3.8 16 6.4–25.6
Koblinsky 1983
Water supply and sanitation improvement
Costs (rural)
All Esrey, Feachem, and LMICs 25.00 —
Hughes 1985
Costs (urban)
All Esrey, Feachem, and LMICs 81.00 —
Hughes 1985
Effectiveness (age 0 to 5)
All Esrey, Feachem, and LMICs 24 22–26 65 —
Hughes 1985; Esrey and 
others 1991
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Table 19.1 Continued
Median Median diarrhea Morbidity Median diarrhea Mortality 
Source regions cost/child Cost/child range morbidity reduction reduction range mortality reduction reduction range 
Model regions Sources or countries (2001 US$) (2001 US$) (percent) (percent) (percent) (percent)
Oral rehydration therapy
Costs
LMICs Horton and Claquin 1983; Bangladesh, Arab 5.50 0.02–11.00
Islam, Mahalanabis, and Rep. of Egypt, The 
Majid 1994; Qualls and Gambia, Honduras, 
Robertson 1989; Indonesia, Malawi, 
Shepard, Brenzel, and Swaziland, Turkey
Nemeth 1986; WHO and 
UNICEF 2001
EAP Shepard, Brenzel, and Indonesia 0.71 0.02–1.40
Nemeth 1986
LAC Shepard, Brenzel, and Honduras 2.59 0.02–5.16
Nemeth 1986
MENA Shepard, Brenzel, and Arab Rep. of Egypt 4.89 0.02–9.75
Nemeth 1986
SA Horton and Claquin 1983; Bangladesh 2.91 0.02–5.80
Islam, Mahalanabis, and 
Majid 1994
SSA Shepard, Brenzel, and The Gambia, 5.51 0.02–11.00
Nemeth 1986; Qualls and Malawi, Swaziland
Robertson 1989
Effectiveness (age 0 to 5)
All Boschi-Pinto and LMICs 0 — 95 —
Tomaskovic forthcoming
Source: Authors.
LMICs  low- and middle-income countries; EAP  East Asia and the Pacific; LAC  Latin America and the Caribbean; MENA  Middle East and North Africa; SA  South Asia; SSA  Sub-Saharan Africa; —  not available.
a. Effectiveness calculated based on vaccine efficacy reported in Parashar and others (1998) and under the assumption that rotavirus infection is responsible for 20 percent of all diarrheal morbidity and severe infection is responsible for 33.3 percent of all diarrheal
mortality.
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high variation in cost-effectiveness for the other regions as well.
There remains little doubt, however, about the effect of wide-
spread use of ORT on diarrhea morbidity and mortality and
about the associated direct and indirect cost savings for treat-
ment and hospitalization.
RESEARCH AGENDA 
Good evidence now supports the view that promoting ORT in
conjunction with other key interventions, preventive as well as
curative, has had a large role in the marked reduction in deaths
of children caused by diarrhea (Victora and others 2000).
Preventive strategies—such as breastfeeding, improving com-
plementary feeding and using micronutrient supplementation
or fortification, and increasing coverage with the full set of
Expanded Programme on Immunization vaccines (especially
measles vaccine)—are all useful and effective (GAVI 2005).
Failure to separately track the full impact of bloody diarrhea—
especially Shigella infection—on morbidity and mortality or
to effectively implement good clinical management (including
guidelines for and control over the use of antibiotics) has con-
tributed to the continuing burden of bloody diarrhea and
dysentery worldwide and the alarming increase in antibiotic
resistance. The challenges for the next decade will be to
increase or ensure universal appropriate implementation of
these interventions in developing countries and to avoid a sit-
uation in which they compete for funding and staff time.
Delivery of good-quality services is essential, and much
remains to be learned through research before this require-
ment can be met.
Other interventions, such as vaccines against rotavirus,
Shigella, or cholera, are either not yet available or not ready for
universal administration. Progress toward the development of
these vaccines, with the highest priority for the first two, is
encouraging, but further investments in research and develop-
ment will be required before large-scale implementation of
these interventions can be considered. The cost of these vac-
cines will remain a major constraint for poor people, who can-
not pay for the costs of development and ensure reasonable
profits for industry. However, increased public investment in
16,000
Low- and middle-
income countries
Latin America 
and the Caribbean
East Asia and
the Pacific
Middle East and
North Africa
Cost-effectiveness ratio (2001US$/DALY)
Source: Authors.
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Figure 19.3 Cost-Effectiveness: Intervention at Birth through Age 5 with Benefits that Occur over Five Years
(age 0–4)
Table 19.2 Cost-Effectiveness Ratios of Oral Rehydration
Therapy Interventions Based on Minimum, Median, and
Maximum per Capita Costs (2001 US$/DALY)
Region Minimum cost Median cost Maximum cost
Low- and middle-income 
countries 4 1,062 2,124
East Asia and the Pacific 4 132 260
Latin America and the 
Caribbean 20 2,570 5,120
Middle East and 
North Africa 10 2,564 5,113
South Asia 4 642 1,279
Sub-Saharan Africa 4 988 1,972
Source: Authors.
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fundamental and applied research, vaccine purchase schemes,
and development of low-cost, high-quality manufacturing
capacity in developing countries may change the prevailing
dynamics. By creating public-private partnerships for vaccine
development, organized as targeted product development pro-
grams, the public sector, private foundations, and industry are
taking steps toward these goals.
Because of the fecal-oral transmission of enteric pathogens,
improving the supply of safe water and the ability to safely dis-
pose of fecal waste are the best ways to reduce the burden of
morbidity and mortality. However, major investments and crit-
ical improvements in water and sanitary waste disposal on the
necessary scale are unlikely to occur in the next decade or two.
Local low-tech solutions can be useful, and enhanced efforts to
find ways to improve water cleanliness at the point of use and
to build simple latrines that will be used consistently are needed
(chapter 41). However, in the face of HIV and the attention
being given to tuberculosis and malaria, coordinated efforts to
build safe water and sanitation capacity at the local level, one
village at a time, that are sufficient to significantly influence the
burden of illness are unlikely—even though many more infants
and children die each year of preventable and treatable diar-
rhea than of HIV/AIDS.
The cycle of research, followed by implementation, followed
by research has enabled the development of improved tools to
manage diarrheal diseases—tools that have the potential to fur-
ther drive down diarrhea mortality. The challenge is to achieve
high coverage and good practice with ORT and correct diar-
rhea case management, including antimicrobial and nutrition
interventions. Interventions to integrate health care through
programmatic initiatives such as the Integrated Management
of Childhood Illness program, critically evaluated elsewhere in
this book (chapter 63), could be essential to ensure this high
coverage. Some concern remains that in low-resource settings
such targeted vertical programs may be abandoned, to the
detriment of the goals for disease burden reduction that they
were established to achieve.
The challenge posed by the case management of bloody
diarrhea is a different matter. Until a vaccine is available, the
keystone for managing bloody diarrhea will continue to be the
early use of effective antimicrobial agents. That is made diffi-
cult by increasing drug resistance, aided by the widespread
indiscriminate and inappropriate use of antimicrobials, and
the increasingly difficult task of finding a safe, inexpensive, and
effective oral agent and then ensuring that the drug is given in
a clinically optimal manner. From a technical perspective, the
development of a vaccine against Shigella infections is still in its
infancy and in need of greater investment. For both watery and
bloody diarrhea, the challenge of developing drugs to normal-
ize the pathophysiology caused by the infection remains a sci-
entific challenge and a distant hope.
CONCLUSIONS
Existing interventions to prevent or treat diarrheal diseases
have proven their efficacy in reducing mortality, but a major
challenge for the next 10 years will be to scale up these inter-
ventions to achieve universal utilization coverage. The United
Nations Millennium Development Goal to reduce the mortality
rate among children under five by two-thirds by 2015 will be
easier to attain if the scale-up goals are reached. New products
and tools could significantly improve the efficacy of these inter-
ventions—for example, rapid specific diagnostics, new treat-
ment strategies based on reversing the pathophysiology of the
infection, simple and effective ways to produce clean water and
control human waste, and vaccines to prevent illness. However,
these products and tools will not become widely available in
time to influence the achievement of the Millennium
Development Goals. Continued investment in diarrheal disease
research across the spectrum of basic, social and behavioral,
and applied investigations is, therefore, essential, including
expanded behavioral research to understand how parents assess
risk and how actionable health messages can be presented in
different cultures and settings.
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Vaccination against childhood communicable diseases through
the Expanded Program on Immunization (EPI) is one of the
most cost-effective public health interventions available
(UNICEF 2002; World Bank 1993). By reducing mortality and
morbidity, vaccination can contribute substantially to achiev-
ing the Millennium Development Goal of reducing the mortal-
ity rate among children under five by two-thirds between 1990
and 2015. Accelerated research into the development of new
vaccines has been made possible in part by innovative public-
private partnerships, such as the Global Alliance for Vaccines
and Immunization (GAVI). GAVI focuses on expanding access
by immunization programs in developing countries to new
and underused vaccines, such as those for hepatitis B and
Haemophilus influenzae type B (Hib). These newer, more
expensive vaccines are challenging previous notions of the
cost-effectiveness of immunization. Analyses of their costs and
cost-effectiveness are particularly important because of the
need to determine the level of resources required in the future
to improve immunization programs, to cover the costs of new
vaccines, and to allocate scarce public and external resources
available for immunization in the most optimal manner.
This chapter analyzes the costs and cost-effectiveness of
scaling up the EPI and introducing selected new vaccines into
the program. It also summarizes the epidemiology of diseases
preventable through immunization and estimates the disease
burden with and without immunization programs. In addi-
tion, the chapter discusses the organization, delivery, and
financing of immunization programs and highlights future
prospects and areas for further study.
Several areas overlap with other chapters. For example,
the vaccines that prevent measles, tuberculosis, diphtheria,
pertussis, Hib, and Neisseria meningitis prevent respiratory dis-
eases. Some vaccines, such as those against measles and pertus-
sis, prevent diseases that cause or contribute to malnutrition.
Chapter 16 provides an in-depth review of tuberculosis and a
discussion of the potential impact of bacillus Calmette-Guérin
(BCG) vaccines. This chapter also does not discuss some new
vaccines, including conjugate Streptococcus pneumoniae,
influenza, typhoid fever, and rotavirus, because other chapters
deal with those diseases and vaccines. Vaccines to prevent
mumps and varicella that are routinely used in some developed
countries are not included in most vaccination programs in
developing countries. Other interventions that can reduce the
burden of vaccine-preventable diseases and are not covered in
this chapter include clean umbilical cord care to reduce the
incidence of neonatal tetanus, vitamin A therapy to reduce the
case-fatality rate (CFR) from measles, and intensive clinical
care that can reduce the mortality associated with most of the
vaccine-preventable diseases.
CAUSES AND EPIDEMIOLOGY OF DISEASES
PREVENTED BY VACCINES USED IN NATIONAL
IMMUNIZATION PROGRAMS
The epidemiology and burden of vaccine-preventable diseases
vary by country and region partly because of differences in
vaccine uptake. Numerous other factors that contribute to the
disease burden include geography, seasonal patterns, crowding,
nutritional status, travel to and from other countries, and pos-
sibly genetic differences in populations that affect disease
severity. Table 20.1 summarizes the features of selected vaccines
Chapter 20
Vaccine-Preventable Diseases
Logan Brenzel, Lara J. Wolfson, Julia Fox-Rushby, Mark Miller,
and Neal A. Halsey
390
|
Disease Control Priorities in Developing Countries
|
Logan Brenzel, Lara J. W
olfson, Julia Fox-Rushby, and others
Table 20.1 Selected Vaccine-Preventable Diseases and Vaccines
Meningococcal Japanese 
Category Tuberculosis Diphtheria Tetanus Pertussis Poliomyelitis Measlesa Rubella Hib Hepatitis B Yellow fever disease encephalitis
Causative
agent
Reservoir
Spread
Trans-
mission
period
Subclinical
infection
Duration of
natural
immunity
Mycobacterium
tuberculosis
Humans (some
bovine)
Airborne droplet
nuclei from
sputum-positive
persons
As long as spu-
tum acid-fast
bacilli are
positive
Common but
not important in
transmission
Not known;
reactivation of
old infection
commonly
causes disease
Toxin-producing
bacterium
(Corynebacterium
diphtheriae)
Humans
Close respiratory
or cutaneous
contact 
Usually under two
weeks; some
chronic carriers
Common
Lasting protective
immunity not pro-
duced by infec-
tion; second
attack possible 
Toxin-producing
bacterium
(Clostridium
tetani)
Animal intes-
tines; soil
Spores enter
the body
through wounds
or the umbilical
cord stump 
No person-to-
person trans-
mission 
No
Lasting protec-
tive immunity
not produced
by infection;
second attack
possible 
Bacterium
(Bordetella 
pertussis)
Humans
Close 
respiratory 
contact
Usually under
three weeks
(starts before
cough is
apparent)
Mild illness
common: may
not be diag-
nosed
Incomplete
and waning
protection 
Virus (serotypes
1, 2, and 3)
Humans
Fecal-oral;
close respira-
tory contact
A few days
before and
after acute
symptoms
More than 100
subclinical
infections for
each paralytic
case
Lifelong type-
specific
immunity
Virus
Humans
Close respiratory
contact and
aerosolized
droplets
Four days before
rash until two
days afterward 
May occur in
children under
one, but relative
importance is
minimal 
Lifelong
Virus
Humans
Close respira-
tory contact and
aerosolized
droplets
A few days
before to seven
days after rash;
up to one year
of age in
congenitally
infected
Common
Lifelong
Bacterium
(Haemophilus
influenzae
type B)
Humans
Close respira-
tory contact
Chronic carriage
for months
Common
Uncertain; no
protection
against carriage
and those previ-
ously infected
may develop
some disease
(epiglottitis)
Virus
Humans
Blood, perina-
tal, household,
occupational,
or sexual
transmission
Up to lifelong
chronic carriage
and transmis-
sion 
Common, espe-
cially in infants
If develops,
lifelong
Virus
Monkeys and
humans
Bites by
infected
mosquitoes
Infected individ-
uals can trans-
mit the disease
when bitten by
a mosquito vec-
tor during the
viremic phase
(the first three
or four days of
illness) 
Common
Lifelong
Neisseria menin-
gitis groups A, B,
C, Y, W135
Humans
Close respiratory
contact
Chronic carriage
for months
Common
Uncertain; no pro-
tection against
carriage
Virus
Birds and
mammals
Bites by
infected
mosquitoes
Unknown, rare
cases for sev-
eral months
Common
Lifelong
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Risk factors
for infection
(for unvacci-
nated indi-
viduals)
Case-
fatality rateb
Vaccine
(number of
doses);
route
Vaccine
efficacy
High population
densities in
regions with
historically poor
control; low
socioeconomic
status; poor
access to care;
immunodefi-
ciency; malnu-
trition; alco-
holism; diabetes
See chapter 16
BCG attenuated
Mycobacterium
bovis (1);
intradermal
0 to 80 percent
for pulmonary
tuberculosis; 75
to 86 percent
for meningitis
and miliary
tuberculosis
Crowding; low
socioeconomic
status
2 to 20 percent
Diphtheria toxoid
(three to five pri-
mary including
booster doses in
most countries);
intramuscular
More than 
87 percent 
Wound contam-
inated by soil;
umbilical cord;
agricultural
work 
25 to 90 per-
cent
Tetanus toxoid
(three to five in
children, includ-
ing booster
doses in many
countries; five
for women of
childbearing
age; adult
boosters
for injury
prevention);
intramuscular
More than
95 percent
(more than
80 percent after
two doses) in
infants
Young age;
crowding
Up to 10 per-
cent in infants
and children
Killed whole-
cell or acellular
pertussis (three
to five, includ-
ing booster
doses in most
countries);
intramuscular
70 to 90 per-
cent
Poor environ-
mental hygiene
and sanitation
2 to 10 percent
Live (OPV)
(three to four
primary plus
campaigns);c
killed (IPV)
(three to four)
OPV: more than
95 percent in
industrial coun-
tries; 72 to 98
percent in
developing
countries;
lower protec-
tion against
type 3 than 1
and 2; IPV:
more than
95 percent
Highly transmis-
sible agent with
nearly 100 per-
cent infectivity
except for iso-
lated popula-
tions; crowding,
low socioeco-
nomic status
0.05 to 10.0 per-
cent
Measles (two);
subcutaneous
95 percent at 12
months of age;
85 percent at
9 months of age
from one dose,
more than 98
percent from
two doses
Highly transmis-
sible; crowding;
low socioeco-
nomic status
Less than
0.1 percent
Rubella (one
or two); 
subcutaneous 
95 percent (at
12 months
and up)
Failure to
breastfeed;
crowding; low
socioeconomic
status; immune
deficiency,
including HIV
Meningitis, 5 to
90 percent;
pneumonia 5 to
25 percent
Capsular poly-
saccharide
linked to protein
Hib (three to
five); intramus-
cular
More than
95 percent for
invasive 
disease
Carrier mother,
sibling, or sex
partner; multi-
ple sex part-
ners; intra-
venous drug
use; unsafe
injection
practices
Acute, more
than 1 percent;
chronic; 25 per-
cent (delayed)
Hepatitis B sur-
face antigen
(three to four);
intramuscular
75 to 95 per-
cent; efficacy
against chronic
infection in
infants born to
carrier mothers;
more than
95 percent for
exposure at
older ages 
Young age; for-
est workers;
season (late
rainy season,
early dry
season)
10 to 40 percent
Yellow fever
attenuated live
virus (1 plus
boosters); sub-
cutaneous
90 to 98 percent
Crowding; respi-
ratory viral infec-
tions, especially
influenza
Untreated 90 to
100 percent;
treated 5 to
20 percent
Vaccines for A, C,
Y, W135 only;
unconjugated
polysaccharides
given subcuta-
neously or intra-
muscularly: one
dose with repeat
three to five
years later for
high-risk persons;
conjugated: for
C only or A, C, 
Y, + W135, one
dose given
intramuscularly
Unconjugated
polysaccharides:
poor efficacy
under two years
of age; conju-
gated polysac-
charides: approxi-
mately 95 percent
and up serogroup
specific
Young age;
forest workers;
season
5 to 30 per-
cent
Live attenu-
ated (two,
China only);
killed (two);
booster com-
monly used
but of uncer-
tain value
Live attenu-
ated: 90 per-
cent (after one
dose at one
year); 94 to
100 percent
(after two
doses one to
two months
apart); inacti-
vated: 80 per-
cent (declining
to 55 percent
after one year;
no decrease in
another study)
(Continues on the following page.)
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Table 20.1 Continued
Meningococcal Japanese 
Category Tuberculosis Diphtheria Tetanus Pertussis Poliomyelitis Measlesa Rubella Hib Hepatitis B Yellow fever disease encephalitis
Duration of
immunity
after pri-
mary series
Schedule
Unknown; some
evidence that
immunity
wanes with
time
Given at or near
birth in popula-
tions at high
risk
Variable: probably
around five years;
longer in pres-
ence of natural
boosting or
booster doses
Three-dose sched-
ule recommended
at 6, 10, and 14
weeks in develop-
ing countries for
DTP vaccine;
other schedules
in common use;
booster doses at
18 months and
four to six years
also suggested
10 years or
more
Normally given
as DTP vaccine
to children;
unimmunized
pregnant
women should
be given two
doses of
tetanus toxoid
or tetanus-
reduced diph-
theria toxoid,
and a total of
five doses is
required to pro-
vide protection
through all
childbearing
years
Unknown;
wanes with
time
Usually given
in childhood as
combination
vaccine (DTP) 
Presumed life-
long for both
OPV and IPV,
but unknown
OPV: four doses
(birth, 6, 10,
and 14 weeks)
in polio-
endemic coun-
tries; birth dose
may be omitted
elsewhere with
fourth dose
given later;
supplemental
doses (up to 10)
given in
national cam-
paigns for
eradication; IPV:
three to four
doses: 2, 4, 6 to
18 months, and
four to six years
Lifelong in most;
rare cases of
waning immu-
nity after one
dose, not two
First dose at
9 or 12 to 15
months); a sec-
ond opportunity
to receive a
dose of measles
vaccine (either
through routine
[18 months or
four to six years]
or supplemental
immunization
activities) should
be provided for
all children
Lifelong in
most; presumed
rare cases of
waning immu-
nity after one
dose, not two
First dose at 12
to 15 months;
when given, a
second dose
with measles
vaccine
Unknown, but
lasts for at least
three years
beyond period
of greatest
exposure
Three or four
doses; usually
given during the
same visit as for
DTP
More than 15
years; further
follow-up is
continuing
Several sched-
ules: at birth, 6,
and 14 weeks;
with first three
doses of DTP;
birth dose
needed if
mother is a car-
rier and recom-
mended if peri-
natal transmis-
sion of
hepatitis B is
frequent; four
doses total can
be given
although only
three are
required
For at least 10
years and possi-
bly for life
One dose at 9
to 12 months
with measles in
countries where
yellow fever
poses a risk 
Unconjugated
wanes rapidly for
children under
five, more than
three to five
years for older
children; conju-
gated uncertain
Unconjugated:
one dose at two
years or older and
second dose
three to five
years later for
high risk; conju-
gate C: three
doses at two,
three, and four or
two, four, and six
months for
infants; one dose
for older children
and adults; conju-
gate A, C, Y,
W135 currently
only approved for
one dose at 11
years or older
Unknown, may
be lifelong
Live: one year
and two years;
killed: days 0,
7, and 30 fol-
lowed by
booster two
years later and
then every
three years 
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Status as of
the end of
2001
Comments 
158 countries
using BCG;
85 percent
coverage
Reasons for
varying efficacy
are multifacto-
rial, including
differences in
vaccines
All countries;
78 percent
coverage
Recent trends to
lower antibody
levels in adults
without booster
doses because of
waning immunity
and less natural
boosting
Childhood: all
countries;
78 percent
coverage 
Five doses in
adults provide
protection for
more than
20 years 
All countries;
78 percent
coverage
Variability in
whole cell vac-
cines; acellular
vaccines used
in some devel-
oped countries 
All countries;
79 percent rou-
tine, plus sup-
plemental
coverage
Primary series
gives incom-
plete protection
in developing
countries
Routine first
dose all coun-
tries, 77 percent
coverage; sec-
ond opportunity,
164 out of 192
countries
Lower efficacy
when maternal
antibody present
110 countries in
2003
Lower efficacy
when maternal
antibody
present
89 countries;
global coverage
less than
18 percent
None 
147 countries;
global coverage
42 percent
Efficacy lower
if injected into
fat
29 of 43 coun-
tries at risk
using vaccine;
30 percent cov-
erage in target
population
None
European coun-
tries, Canada
(and United
States in 2005)
None
Southeast
Asia
None
Sources: WHO 2002, 2004.
DTP  diphtheria-tetanus-pertussis; IPV  inactivated polio vaccine; OPV  oral polio vaccine.
a. Measles vaccine is given as measles, measles-rubella, or measles-mumps-rubella vaccine. The latter two vaccines are routinely used in industrial countries and are increasingly being adopted in other countries. The World Health Organization recommends that the
combination measles-rubella or measles-mumps-rubella vaccines be introduced only after careful evaluation of public health priorities within each country and following the establishment of an adequate program for measles control as demonstrated by high coverage
rates as part of a well-functioning childhood immunization program. 
b. Note that variations in case-fatality rates are related to access to care, type of care administered, setting, age at onset of disease, and other factors. The ranges presented in this table reflect both uncertainty as to actual case-fatality rates and the variability 
of populations. 
c. As of 2003, an injected IPV is given alone or in combination with OPV in 31 countries. IPV is currently not recommended for routine use in developing countries because of its relatively high cost and uncertain efficacy when given at 6, 10, and 14 weeks. The usual
recommended IPV schedule is 2, 4, and 6 to 18 months. Routine use of OPV is expected to cease following polio eradication. Stockpiles of monovalent OPV for each of the three virus types are under development to protect against vaccine-associated paralytic
poliomyelitis and outbreaks of circulating vaccine-derived polioviruses. 
in use in childhood immunization programs throughout the
world.
Burden of Vaccine-Preventable Diseases
A number of vaccine-preventable diseases are not reportable
events in many countries. The estimates of the burden of dis-
ease by the World Health Organization (WHO) are based on a
combination of often incomplete vital registration data, mor-
tality survey data, and mathematical models using numerous
assumptions. Most models of vaccine-preventable diseases are
derived from the susceptible fraction of the population (calcu-
lated from natural immunity from presumed historical infec-
tions in regions without previous vaccination and historical
immunization coverage rates), infectivity rates of disease,
sequelae of diseases, and estimates of local CFRs. The degree of
accuracy of these models is only as good as the data supporting
the assumptions. The disease burden is most appropriately rep-
resented by a range of values reflecting uncertainty. In this
chapter, we estimate the burden of disease as the number of
deaths and DALYs per World Bank region in 2001. The follow-
ing description draws in part on discussion of methods for
burden of disease calculations reflected in the Global
Immunization and Vision Strategy of WHO and the United
Nations Children’s Fund (UNICEF) (Wolfson and Lydon 2005).
Diphtheria
Diphtheria is caused by a toxin-producing strain of the bacte-
rium Corynebacterium diphtheriae, which is transmitted by
means of respiratory droplets. The 2001 WHO estimates of
diphtheria mortality are extrapolations from reported deaths in
countries with full or partial vital registration systems.
Before the widespread use of immunization,more than 5 per-
cent of people living in temperate climates suffered from clinical
diphtheria at some point during their lifetimes (Griffith 1979).
Rates exceeding 100 cases per 100,000 population were seen
in Europe during World War II (Galazka, Robertson, and
Oblapenko 1995). The CFRs from respiratory tract diphtheria
have been 2 to 20 percent, with an average of 10 percent for
patients receiving good medical care (Feigin, Stechenberg, and
Hertel 2004).To estimate diphtheria deaths in the absence of vac-
cination and to project future deaths with and without vaccina-
tion, we assumed an average incidence rate of 15 per 100,000 and
CFRs of 2.5 percent in developed countries,5.0 percent in Europe
and Central Asia, and 10.0 percent elsewhere (Birmingham and
Stein 2003; Galazka and Robertson forthcoming).
Tetanus
Clostridium tetani is maintained in nature and is found in all
countries. Spores remain viable for many years in soil and dust,
especially in areas contaminated by animal feces (Cherry and
Harrison 2004). The organism is usually transmitted through
burns, cuts, and other penetrating injuries. Neonatal tetanus is
the most common presentation in developing countries. The
portal of entry is usually the umbilical stump but has been
associated with circumcision and other surgical procedures
(Birmingham and others 2004; Stanfield and Galazka 1984).
Children born to women who do not have protective levels of
tetanus antibody are susceptible to neonatal tetanus.
The estimated burden of neonatal tetanus assumes that in
areas with low rates of skilled delivery, all births not protected
by the immunization of pregnant women are subject to a preim-
munization era neonatal tetanus mortality rate expressed as
deaths per 1,000 live births (Birmingham and others 2004;
Griffiths and others 2004). In other areas, we assume that births
not protected through immunization or skilled delivery are
subject to an incidence and CFR equal to 25 percent of the
preimmunization era neonatal tetanus mortality rate.1
CFRs are directly associated with the quality of medical care
available. With the availability of secondary and tertiary care,
CFRs have declined to 25 percent or less (Cherry and Harrison
2004; Wassilak and others 2004). The CFRs used to derive cases
from estimated deaths range from 40 percent in developed
countries to 80 percent in the poorest developing countries. We
estimate the tetanus burden other than for neonates by apply-
ing an estimated age distribution of total tetanus to the esti-
mated neonatal tetanus deaths (Galazka and others forthcom-
ing) and region-specific CFRs, which indicate a range of from
27 percent among children age one to four in developed coun-
tries to 65 percent among those age 80 or older in developing
countries.
Pertussis
Bordetella pertussis is transmitted through respiratory excre-
tions and occurs throughout the world. Most pertussis in
developing countries occurs in school-age children. In devel-
oped countries, mild or asymptomatic infections in adults are
believed to be common sources of transmission to very young
infants (Edwards and Decker 2004). Clinical manifestations
include an initial 7 to 10 days of rhinorrhea progressing to a
cough that becomes paroxysmal or spasmodic, usually associ-
ated with profuse rhinorrhea (Cherry and Heininger 2004).
Clinical pneumonia is seen in approximately 10 percent of
infants.
Our estimates for the burden of pertussis followed the
model described in Crowcroft and others (2003). We estimated
that the proportion of susceptible children becoming infected
in countries with vaccination coverage of less than 70 percent
over the previous five years was 30 percent by age 1, 80 percent
by age 5, and 100 percent by age 15. For countries with cover-
age of more than 70 percent in the past five years, we assumed
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that 10 percent of susceptible children were infected by age 1,
60 percent by age 5, and 100 percent by age 15. A vaccine effi-
cacy of 80 percent was assumed for preventing infection and
95 percent for preventing deaths. The CFR was 0.20 percent in
infants, 0.04 percent in children age one to four, and 0 percent
in those older than five in low-mortality countries; and 3.7 per-
cent among infants, 1 percent among children age one to four,
and 0 percent in those older than five in high-mortality
countries.
Poliomyelitis
Before the availability of polio vaccines, as many as 90 percent
of children in the developing world were infected with all three
types of the polio virus in the first two or three years of life
(Sutter and Kew 2004). In developed countries, transmission
occurred primarily in school-age children and more than 90 per-
cent of infections were asymptomatic; 4 to 8 percent of chil-
dren had nonspecific febrile illness and less than 1 percent
developed acute flaccid paralysis (Sutter and Kew 2004).
Children with residual paralysis require rehabilitation.
Surgical intervention is necessary if contractures develop
because of the lack of rehabilitative services following the acute
illness. These children are at increased risk of premature death
because of late onset postpolio muscle atrophy (postpolio syn-
drome), which occurs 20 to 40 or more years after acute illness.
Disease burden estimates are based on actual active surveil-
lance. The estimated 1,000 deaths a year caused by polio reflect
past infections and current deaths. Following Robertson
(1993), we obtained the number of cases and deaths in the
absence of immunization by applying an incidence rate of 1 per
1,000 population under age five and CFRs of from 2.5 percent
in developed countries to 10.0 percent in Sub-Saharan Africa.
To determine current cases, we applied an estimate of notifica-
tion efficiency to reported cases.
Measles
Measles is an acute respiratory viral infection. Children born to
immune mothers are protected against clinical measles from
passively acquired maternal antibodies until they are five to
nine months of age. More than 90 percent of infections are
associated with clinical disease (Krugman 1963). Compli-
cations include pneumonia, diarrhea, encephalitis, and blind-
ness, especially in children with vitamin A deficiency. In recent
years, CFRs have been estimated at 3 percent in many develop-
ing countries, but historically they have been as high as 30 per-
cent in some community-based studies (Aaby 1988; Aaby and
Clements 1989; Moss, Clements, and Halsey 2003; Perry and
Halsey 2004).
For a disease such as measles in which infection is almost
universal in the absence of immunity, small changes in the CFR
result in large changes in estimates of total mortality. Increased
complication and mortality rates occur in children who are
younger than five, vitamin A deficient, or infected with HIV or
who have acquired measles from a household contact (Perry
and Halsey 2004). Declines in CFRs in the past two decades are
associated with the tendency of the disease to infect older chil-
dren, decreased crowding, and improved nutritional status in
many developing countries (Perry and Halsey 2004). At the
same time, recent studies indicate CFRs of 0.4 to 9.7 percent in
Sub-Saharan African countries with low immunization cover-
age (Perry forthcoming).
Considerable controversy is associated with the number of
deaths resulting from measles, because of difficulty in accu-
rately specifying the cause of death in children afflicted with
measles and in separating complications of measles from those
of other conditions. In addition, CFRs, which have decreased
rapidly in many countries, vary significantly. The natural his-
tory model used in this chapter is based on Stein and others
(2003), modified to account for the effect of supplementary
immunization activities.
We derived estimates of the burden of disease in countries
with high-quality surveillance data and high sustained cover-
age of measles vaccine by adjusting the number of reported
cases by a reporting efficiency factor ranging from 5 to 40 per-
cent. In estimating the future burden of disease, the averted
burden of disease, and the burden in countries without both
adequate surveillance and sustained high coverage, we assumed
that the average number of cases per year is equal to the num-
ber of children in the current birth cohort who are not pro-
tected by either routine or supplemental vaccination. WHO
(2005a) estimates that in 2001, 611,000 deaths (approximately
5 percent of all childhood mortality) were attributable to
measles.
An alternative proportional mortality approach, which is
based on retrospective verbal autopsy studies in 18 countries
to derive the proportional causes of child deaths in 42 high-
mortality countries, also has appeared in the literature (Morris,
Black, and Tomaskovic 2003). This model suggests that measles
may have accounted for approximately 3 percent of all child-
hood deaths in 2000.
In countries with a high disease burden, the true number of
measles deaths may be somewhere between the proportional
mortality and natural history estimates. WHO (2005b) uses a
hybrid method that estimates that measles was responsible for
an average of 4 percent of mortality among children under five
between 2000 and 2003, or approximately 400,000 deaths per
year. If the actual number of deaths in 2001 was 400,000, then
the cost per death averted will be lower than what has been esti-
mated for this chapter, and the effect of increasing coverage will
be overestimated because fewer deaths could be prevented.
Both of the approaches described have strengths and limita-
tions. We adopt the natural history approach for this analysis
because the chapter includes deaths at all ages and the model
can adapt to recent changes in CFRs and coverage rates.
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However, the natural history method is sensitive to the accu-
racy of parameter inputs such as CFRs and may underestimate
the effect of herd immunity. Further modeling efforts would
need to incorporate sensitivity testing around a range of param-
eter estimates.
In the absence of vaccination, the measles virus would infect
almost 100 percent of the population, including most of the
688 million children under five in the developing world. Using
the methods described here, approximately 125 million
cases and 1.8 million to 2.0 million deaths per year would be
expected in the absence of vaccination.
Haemophilus influenzae Type b (Hib)
Hib is transmitted through the respiratory tract and causes
meningitis, pneumonia, septic arthritis, skin infections,
epiglottitis, osteomyelitis, and sepsis. Deaths caused by Hib
occur primarily from meningitis and pneumonia. In developed
countries, approximately half of diagnosed invasive infections
are meningitis (Wenger and Ward 2004). In developing coun-
tries, a larger proportion of identified cases is meningitis result-
ing from underdiagnosis of other clinical syndromes (Martin
and others 2004; Peltola 2000). Intervention studies have
demonstrated significant reductions in pneumonia in vacci-
nated compared with unvaccinated children (Levine and oth-
ers 1998; Mulholland and others 1997). Although infections
occur throughout the world, the incidence of Hib disease may
be lower in some Asian countries than in Africa and the
Americas (Gessner and others 2005).
We derived estimates of Hib disease burden from incidence
rates and CFRs for meningitis and pneumonia. We derived
country-specific estimates of the incidence of Hib meningitis
from the literature on incidence in the prevaccine era (Bennett
and others 2002). For countries without meningitis incidence
data, we used the average incidence in countries with similar
epidemiological profiles. Regional averages ranged from 219
cases per 100,000 to 3 per 100,000 population in children
under one, and 1 to 15 per 100,000 population in children age
one to four. The CFR for meningitis is nearly 100 percent in the
absence of intensive antibiotic therapy, but it can be reduced to
5 to 8 percent when appropriate therapy is available (Swartz
2004). We derived CFRs in a manner similar to that used for
incidence rates and adjusted them on the basis of country-
specific data on access to care. Regional means ranged from 3 to
32 percent.
Estimating the burden of Hib pneumonia is much more
complex. A rapid assessment method assumes five pneumonia
cases for every meningitis case (WHO 2001). An alternative
approach assumes that Hib is responsible for a fixed propor-
tion (about 20 percent) of acute lower respiratory infection
deaths in the absence of immunization (Peltola 2000). We
derived pneumonia CFRs from a literature review of lower res-
piratory infections in children (Bennett and others 2002), with
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average CFRs ranging from 1 percent among infants in devel-
oped countries to 12 percent in Sub-Saharan Africa.
Hepatitis B 
In many developed countries, most transmission of hepatitis B
occurs during or after adolescence, coinciding with the onset of
sexual activity and of drug abuse involving unsafe reuse of nee-
dles and syringes (McQuillan and others 1999). In many
African countries, transmission occurs primarily in early child-
hood through mucosal contact with infectious body fluids and
unsafe injection practices (Margolis, Alter, and Hadler 1997).
Some Asian countries have a high rate of chronic carrier states,
and the primary mode of transmission is mothers to infants
(Beasley 1988; Mast and others 2004). The rate of symptomatic
disease is only about 1 percent in infancy and 10 percent in
early childhood, but it increases to 30 to 40 percent in adults.
Serosurveys for carrier states of hepatitis B are available for
almost all nations (WHO 1996).
Models of hepatitis B disease burden are based on estimated
ratios between infected and carriage states at various ages or
estimates of the percentage of carriers that progress to
hepatoma, fulminant hepatitis, or cirrhosis at later stages of life
(Miller and McCann 2000). The model we used for estimating
hepatitis B mortality estimates the age- and sex-specific pro-
gression of hepatitis B surface antigen infection to disease
incorporating competing mortality, particularly because indi-
viduals infected with HIV are more likely to perish from HIV
before the full mortality impact from hepatitis B infection
(Gay and others 2001; Griffiths, Hutton, and Pascoal 2005).
Whereas most vaccine-preventable diseases that result in
death occur at an early age shortly after the age of vaccination,
deaths from hepatitis B occur many years into the future.
Countries that introduce hepatitis B vaccines today will not
reap most of the benefits for many years. In the absence of
vaccination, we estimated approximately 1.4 million future
deaths attributable to hepatitis B for the 2001 birth cohort
after accounting for competing mortality. Global vaccination
of 35 percent would prevent more than 500,000 of those
future deaths. Discounting the value of future hepatitis B
deaths to their equivalent value in the present to make the
burden of disease prevented equivalent to that of other
vaccine-preventable diseases results in approximately 87,000
deaths averted.
Yellow Fever 
Yellow fever virus is transmitted by mosquitoes, primarily Aedes
eqypti, with a three- to six-day incubation period. Patients pre-
sent with intense headache, fever, chills, and myalgia, among
other symptoms. Although once much more widespread,
yellow fever is now limited to West and Central Africa, the
northern half of South America, and Panama. In approximately
15 to 20 percent of yellow fever patients, severe disease occurs,
with liver and kidney failure and cardiovascular collapse. The
CFR varies, with increased severity in older adults (Monath
2004). The average CFR in patients in Africa with jaundice is
20 percent (Monath and others 1980; Nasidi and others 1989).
On the basis of surveillance data adjusted for underreport-
ing, WHO (1992) estimates the global burden of yellow fever at
200,000 cases and 30,000 deaths in 1990. Most cases and deaths
occur in 33 African countries, where 1 in 80 cases is assumed
to be reported. In South American countries, 1 in 10 cases is
assumed to be reported. We use the implied incidence rate and
a CFR of 15 percent to project future mortality. Between 1990
and 2001, some improvement in routine coverage of yellow
fever vaccine occurred, but the overall burden of yellow fever is
unlikely to have declined.
ESTIMATES OF THE CURRENT BURDEN OF
VACCINE-PREVENTABLE DISEASES AND OF
THE BURDEN AVERTED BY VACCINATION 
Table 20.2 provides WHO estimates of deaths from selected
vaccine-preventable diseases for 2001, taking immunization
coverage rates into account. The greatest burden of disease is in
Sub-Saharan Africa, which accounts for 58 percent of pertussis
deaths, 41 percent of tetanus deaths, 59 percent of measles
deaths, and 80 percent of yellow fever deaths. East Asia and the
Pacific has the greatest burden from hepatitis B, with 62 per-
cent of deaths worldwide. South Asia also experienced a high
disease burden, particularly for tetanus and measles.
Table 20.2 also shows the extent of mortality in the absence
of immunization and the estimated number of deaths averted
by vaccination. In 2001, vaccination averted up to 52 percent of
yellow fever deaths, 61 percent of measles deaths, 69 percent
of tetanus deaths, 78 percent of pertussis deaths, 94 percent of
diphtheria deaths, and 98 percent of polio deaths that would
have occurred in the absence of vaccination. These results
demonstrate the significant effect that vaccination programs
have had on worldwide disease burden. The figures also show
that vaccination programs have been less successful in reducing
the disease burden in Sub-Saharan Africa, where coverage rates
are lower.
Table 20.3 reports WHO estimates of disability-adjusted life
years (DALYs) lost from vaccine-preventable diseases by region
for 2001, demonstrating the high burden of disease worldwide
from disability associated with sequelae of hepatitis B (liver
cancer and cirrhosis), pertussis, and tetanus.2
EXPANDED PROGRAM ON IMMUNIZATION 
WHO initiated the EPI in 1974 to provide countries with guid-
ance and support to improve vaccine delivery and to help make
vaccines available for all children (Hadler and others 2004;
Turk 1982; WHO 1974). A standard immunization schedule
was established in 1984 on the basis of a review of immuno-
logical data for the original EPI vaccines: BCG, diphtheria-
tetanus-pertussis (DTP), oral polio, and measles vaccines
(Halsey and Galazka 1985).
Today, national immunization programs in developing
countries are responsible for improving access to the tradi-
tional EPI antigens and introducing new vaccines. In 2002, the
EPI introduced the Reaching Every District strategy, which
focused on achieving an 80 percent coverage rate of DTP3 in
80 percent of districts and using immunization contacts to
deliver other high-priority child health interventions. In addi-
tion to delivering vaccinations, national immunization
programs are concerned with the quality and safety of immu-
nization through the adoption of safe injection technologies
(autodisabled syringes, storage boxes, and incinerators) and
proper cold chain and vaccine stock maintenance.
In most developing countries, immunizations are provided
through a system of fixed facilities at different levels of the
health system. Immunization campaigns are discrete, time-
limited efforts at national or subnational levels that usually
focus on specific antigens (for example, polio). Mobile strate-
gies rely on the use of specialized vehicles to transport health
professionals and vaccines to deliver services to remote or
migrating populations. Outreach is a strategy by which staff
members from a health facility travel to villages and surround-
ing areas to administer vaccines. Extended outreach refers to
more targeted and intensive efforts.
In 1999, the major international development partners
involved in immunization (for example, WHO, UNICEF, the
World Bank, and bilateral donors) joined the Bill & Melinda
Gates and Rockefeller Foundations, the vaccine industry, and
nongovernmental organizations to create GAVI (http://www.
vaccinealliance.org) to increase access to new and underused
vaccines in the world’s poorest countries, improve access to
basic immunization services, and accelerate research and
development pertaining to new vaccines and delivery technol-
ogy. Through the Vaccine Fund, GAVI raised more than
US$1.3 billion to strengthen immunization systems, introduce
new vaccines, and support safe injection practices. More than
US$3 billion has been pledged for the next 10 years. Between
2000 and 2003, an additional 4 million children were vacci-
nated with DTP3, 42 million with hepatitis B, nearly 5 million
with Hib, and more than 3 million with yellow fever vaccine.
COSTS AND COST-EFFECTIVENESS OF EXISTING
VACCINATION PROGRAMS
Brenzel and Claquin (1994) and GAVI (2004) estimate the cost
per fully immunized child (FIC) for the traditional six EPI
antigens as approximately US$20.3 We evaluated the cost per
Vaccine-Preventable Diseases | 397
398 | Disease Control Priorities in Developing Countries | Logan Brenzel, Lara J. Wolfson, Julia Fox-Rushby, and others
Table 20.2 Estimated Number of Deaths in the Absence of Vaccination, Deaths from Vaccine-Preventable Diseases,
and Deaths Averted by Vaccination, All Ages, by Region and Vaccine, 2001
(thousands)
East Europe Latin Middle 
Asia and and America East and Sub-
High the Central and the North South Saharan 
Disease Total income Pacific Asia Caribbean Africa Asia Africa
Diphtheria
If no vaccination 78 3 28 4 8 5 21 10
Estimated deaths 5 1 1 1 1 1 3 1
Deaths averted 73 3 27 4 8 5 18 9
Pertussis
If no vaccination 1,343 7 377 4 138 93 428 296
Estimated deaths 301 1 3 1 6 8 108 176
Deaths averted 1,042 7 374 4 132 85 320 120
Tetanus
If no vaccination 936 1 110 1 20 23 543 239
Estimated deaths 293 1 27 1 1 4 140 121
Deaths averted 643 1 83 1 19 19 403 118
Poliomyelitis
If no vaccination 52 1 15 1 3 4 17 11
Estimated deathsa 1 1 1 0 0 0 0 0
Deaths averted 51 n.a. 15 1 3 4 17 11
Measles
If no vaccination 2,000 6 301 36 6 55 567 1,025
Estimated deathsb 676 1 77 4 1 7 239 348
Deaths averted 1,237 5 229 28 6 40 351 578
Hib
If no vaccination 468 1 28 2 9 14 199 216
Estimated deaths 463 1 28 2 5 14 199 215
Deaths averted 5 1 1 1 4 1 1 1
Hepatitis B 
If no vaccination 600 34 370 36 11 17 75 58
Estimated deaths 600 34 370 36 11 17 75 58
Deaths avertedc 1 1 1 1 1 1 1 1
Yellow fever
If no vaccination 63 n.a. n.a. n.a. 8 n.a. n.a. 54
Estimated deaths 30 n.a. n.a. n.a. 6 n.a. n.a. 24
Deaths averted 33 n.a. n.a. n.a. 2 n.a. n.a. 30
Source: Mathers and others 2006 and authors’ calculations.
n.a.  not available.
Note: Totals may not add due to rounding. 
a. Primarily deaths at older ages caused by delayed effect of poliomyelitis in childhood. 
b. See text for discussion of uncertainty regarding measles estimates. The values shown here are an updated version of the 2001 estimates.
c. Deaths averted to date from the use of the hepatitis B vaccine in infant immunization programs are minimal, largely because of the long time period (20 to 40 years) to see mortality effects.
FIC for the childhood EPI cluster antigens by World Bank
region on the basis of published and unpublished data. These
studies used a standard costing approach that estimated the
costs of labor, vaccines, supplies, transportation, communica-
tion, training, maintenance, and overhead and included the
annualized value of equipment, vehicles, and building space
(Khaleghian 2001; USAID, Asia–Near East Region 1988; WHO
1988). The number of FICs in these studies was measured
using community-based sample surveys (Henderson and
Sundaresen 1982).
Our literature review found 102 estimates of total and unit
immunization program costs from 27 countries between 1979
and 2003 for different immunization delivery strategies
(Berman and others 1991;1 Beutels 1998, 2001; Brenzel 2005;
Brenzel and Claquin 1994; Brinsmead, Hill, and Walker 2004;
Creese 1986; Creese and Domínguez-Ugá 1987; Domínguez-
Ugá 1988; Edmunds and others 2000; Griffiths and others
2004; Levin and others 2001; Pegurri, Fox-Rushby, and Walker
2005; Robertson and others 1992; Soucat and others 1997;
Steinglass, Brenzel, and Percy 1993). All costs were converted
to 2001 U.S. dollar equivalents. Because total and unit costs are
related to population size, table 20.4 reports population-
weighted results only. National immunization program refers
to total national costs for all strategies.
The population-weighted mean cost per FIC for all regions
and all strategies is approximately US$17, with a range of US$3
to US$31. The lowest mean population-weighted cost per FIC
was for extended outreach services (US$5.81), perhaps because
the strategy is a more targeted approach. Routine facility-based
strategies had lower average costs (US$13.65 per FIC) than
campaigns (US$26.82 per FIC) or mobile strategies (US$25.84
per FIC). Higher unit costs associated with these strategies are
possibly attributable to a different mix of inputs as well as
greater expenses for per diems, fuel, and social mobilization.
The results also vary by World Bank region, with East Asia
and the Pacific (US$13.25) and Sub-Saharan Africa (US$14.21)
having lower estimates of cost per FIC than Europe and
Central Asia (US$24.12) and the Middle East and North Africa
(US$22.15).
The findings of our analysis are generally supported by the
literature (Creese 1986; Brenzel and Claquin 1994; Khaleghian
2001), which has shown that variation in the cost per FIC is
related to the mix of delivery strategies, the prices of key inputs
such as vaccines, and the overall scale of programs. In addition,
an analysis of 13 national financial sustainability plans for
immunization reveals a wide range in the cost per FIC by
region and strategy.4
Recurrent costs are the lion’s share of total immunization
costs (80 percent for fixed facility strategy and 92 percent for
campaigns), which has implications for the need for continu-
ous and predictable program financing. Labor costs account
for the largest share (roughly 30 to 46 percent of total cost) for
all strategies except extended outreach. Vaccine costs range
from 8 percent for mobile strategies to 29 percent for extended
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Table 20.3 DALYs Lost from Vaccine-Preventable Diseases, All Ages By Region, 2001 
(thousands)
Europe Latin Middle 
East Asia and America East and Sub-
High and the Central and the North South Saharan
Disease Total income Pacific Asia Caribbean Africa Asia Africa
Diphtheria 164 1 18 2 8 1 90 45
Tetanus 8,342 5 762 2 17 110 3,965 3,481
Pertussis 11,542 139 584 81 366 326 3,930 6,116
Poliomyelitis 145 8 49 2 6 8 55 17
Measles 23,129 23 2,318 236 13 470 6,527 13,539
Hepatitis Ba
Acute hepatitis B 2,169 86 675 79 95 111 585 536
Liver cancer 9,168 1,223 5,925 379 277 138 464 762
Cirrhosis of the liver 15,780 2,146 3,890 2,084 1,513 686 4,249 1,212
Meningitisb 5,607 131 1,071 403 591 328 2,142 941
Lower respiratory infectionsc 85,920 2,314 10,827 2,111 3,043 2,974 34,196 30,455
Source: Mathers and others 2006 and Authors’ calculations.
Note: Totals may not add due to rounding. 
a. Includes all DALYs attributable to the three conditions. Hepatitis B is the underlying cause of only a portion of the liver cancer and cirrhosis of the liver DALYs.
b. Includes all DALYs attributable to meningitis, including Hib, S. pneumococcus, and N. meningitides.
c. Includes all DALYs attributable to lower respiratory infections, including Hib and S. pneumococcus. 
outreach strategies. Transportation costs account for the
second-largest share of EPI costs for mobile strategies, while
building costs account for a greater share of fixed facility
strategies.
Using data from table 20.4 on costs per FIC and multiplying
by the size of the population covered, we estimate US$1.17 bil-
lion for the total cost of immunization programs in develop-
ing countries in 2001, with a range of US$717 million to
US$1.48 billion. At US$20 per FIC, the cost of the six tradi-
tional vaccines in developing countries would have amounted
to US$1.57 billion in 2001. Table 20.5 shows that the estimated
cost per death averted ranges from US$205 in South Asia and
Sub-Saharan Africa to US$3,540 in Europe and Central Asia.
These results suggest that the cost per death averted rises with
coverage rates. Europe and Central Asia, Latin America and the
Caribbean, and the Middle East and North Africa had higher
coverage rates in 2001, resulting in fewer deaths that could be
averted. The table also shows that the cost per DALY from the
traditional EPI vaccines ranges from US$7 to US$438, depend-
ing on region, mix of strategy, and levels of scale.
Our analysis highlights the variation in cost per FIC by
region and strategy and demonstrates the value of more disag-
gregated results for making policy decisions. However, given
the limited sample of estimates available for the regions and
strategies, the results should be used as an indicative guide for
policy making and not as a substitute for country-specific cost-
effectiveness evaluations of strategies. In addition, our esti-
mates do not take into account household costs, such as time
spent seeking services, and other social costs. Our estimates
also do not consider the direct and indirect costs of acute ill-
nesses prevented by vaccination or the costs of long-term com-
plications from disease and of adverse events associated with
vaccination (though the latter are unlikely to have a significant
impact on costs because rates of serious complications are
extremely low). Furthermore, the analysis focuses on FICs and
underemphasizes the benefits of partial immunization. Future
economic evaluations of immunization program alternatives
could consider these factors as a critical step in determining
the allocation of scarce resources among high-priority health
interventions.
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Table 20.4 Estimates of the Population-Weighted Annual Cost for the Traditional Vaccines per FIC, by Immunization Strategy and
Region, 2001
(2001 US$)
Europe Latin Middle 
East Asia and America East and Sub-
and the Central and the North South Saharan All 
Pacific Asia Caribbean Africa Asia Africa regions
Strategy (n 4) (n 1) (n 1) (n 1) (n 10) (n 15) (n 32)
National immunization — — 18.10 22.15 24.82 21.05 23.52 
program (23–27) (17–26) (17–27) 
n  2 n  2 n  6
Fixed facility 20.00 24.12 — — 13.79 6.31 13.65 
(18–22) (6–24) (3–31) (3–31)
n  2 n  7 n  6 n  16
Campaign — — — — — 26.82 26.82 
(13–28) (13–28)
n  3 n  3
Mobile — — — — — 25.84 25.84
n  1 n  1
Outreach 6.50 — — — 7.11 — 7.10
(4–9) n  1 (4–9)
n  2 n  3
Extended outreach — — — — — 5.81 5.81
(5.8–13) (5.8–13)
n  3 n  3
Mean for all strategies 13.25 24.12 18.10 22.15 17.11 14.21 16.91
(4–22) (6–27) (3–31) (3–31)
Source: Authors’ calculations for the traditional vaccines based on the literature. 
—  not available.
Note: Mean values are used in the analysis. Ranges for estimates are reported in parentheses. Europe and Central Asia, Latin America and the Caribbean, and the Middle East and North Africa are
limited to one observation for each region, which may not be indicative of the cost per FIC in each region. However, in lieu of using region-specific estimates, the overall average (US$13.65) would be
applied, which may underestimate the cost per FIC in these more developed regions, where higher unit costs for delivery of health services would be expected.
COST-EFFECTIVENESS OF INCREASING
IMMUNIZATION COVERAGE FOR THE
TRADITIONAL EPI 
WHO (2004) estimates that in 2001, 30 million children were
inadequately immunized with DTP. Achieving higher coverage
rates by improving access for remote populations, accelerating
immunization delivery strategies, and introducing new vac-
cines will mean increasing the level of investment (Batt, Fox-
Rushby, and Castillo-Riquelme 2004).
We estimated the costs of scaling up EPI coverage for a hypo-
thetical population of 1 million in each region between 2002 and
2011. Costs were reported in 2001 dollars, and a 3 percent dis-
count rate was applied. Brenzel (2005) provides details on the
methods. The costs of scaling up coverage are based on vaccine
and delivery costs per dose. We derived vaccine costs from the
unit price of each vaccine (provided by WHO, UNICEF, and the
Vaccine Fund); wastage rates for vaccines and injection supplies
by strategy; the required injection supplies; and the number of
doses per FIC. A 2 percent adjustment was made for inflation.
We used data on the cost per FIC generated earlier to derive
delivery costs per dose by strategy and region by subtracting the
costs of vaccines, injection supplies, and fixed costs.
Fixed costs were excluded from the scaling-up exercise
because they were assumed to remain constant during the pro-
jection period.
• First, the largest projected coverage increase of 9 percentage
points (figure 20.1) may not require additional infrastruc-
ture investments.
• Second, how and to what extent fixed costs would change by
region is uncertain, and a conservative approach would be
to exclude them.
• Third, because most immunization costs are recurrent costs,
the analysis focuses on these.
• Finally, because the scale factor is derived from the unit costs
of a health center visit, the assumption of constant fixed
costs in the short run appears reasonable.
Previous studies have found that the main cost drivers of
immunization costs are the mix of strategies and the scale
of immunization programs (Brenzel and Claquin 1994;
Domínguez-Ugá 1988; Robertson and others 1992; Soucat and
others 1997). Countries are unlikely to achieve 90 percent or
more coverage relying on fixed facilities alone because of
limited population access. We estimate the proportion of FICs
obtained for each strategy by region.5 The best mix of strategies
for increasing coverage will vary by country depending on the
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Table 20.5 Average Cost per FIC, Total Immunization Cost, Cost per Death Averted and Cost per DALY for the Traditional
Immunization Program by Region
Latin Middle 
East Asia Europe America East and Sub-
and the and and the North South Saharan 
Strategy Pacific Central Asia Caribbean Africa Asia Africa
Cost/FIC (2001 US$) (from table 20.4) 13.25 24.12 18.10 22.15 17.11 14.21
Percentage of FIC 78.22 93.72 86.36 90.90 58.86 50.20
Estimated total immunization cost (2001 US$ millions) 316 131 174 152 227 172
Estimated deaths averted (thousands, from table 20.2) 728 37 174 153 1,109 867
Estimated cost/death averted (2001 US$) 434 3,540 1,030 993 205 205
Estimated cost/DALY (2001 US$) 85 395 438 166 16 7
Source: Authors’ calculations.
Note: DALY estimates are the sum total for diphtheria, pertussis, tetanus, polio, and measles from table 20.3. 
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Figure 20.1 Coverage of FICs Projected to 2011
dispersion of the population, the access to health facilities, the
vaccines being delivered, and the effectiveness of various strate-
gies in reaching target populations. Estimates are also adjusted
for the level of scale by a factor derived from the unit cost per
health center contact by coverage level (Mulligan and others
2003), and details are provided in Brenzel (2005).
The total additional cost of reaching higher coverage levels
was divided by the number of deaths averted. Coverage projec-
tions for 2002–11 were based on statistical modeling of official
WHO and UNICEF estimates for the period between 1995 and
2002 for all developing countries. The model relates coverage in
future years to that in the previous year, with the relationship
between past and future coverage differing for each region and
economic status combination.
Figure 20.1 shows historical and projected coverage rates
by region. The figure shows that coverage increased in all the
regions during the late 1980s under universal childhood immu-
nization. After 1990, when funding for universal childhood
immunization waned, the figure indicates the subsequent stag-
nation and, in some cases, the declines in coverage rates. For the
scaling-up period, we project that the coverage of FICs will
increase from 78 to 79 percent in East Asia and the Pacific, from
92 to 95 percent in Europe and Central Asia, from 88 to 90 per-
cent in Latin America and the Caribbean, from 91 to 95 percent
in the Middle East and North Africa, from 70 to 79 percent in
South Asia, and from 52 to 61 percent in Sub-Saharan Africa.
The projections show that three of the six regions are expected
to achieve 90 percent FIC by 2011. East Asia and the Pacific,
South Asia, and Sub-Saharan Africa will require additional
intensive efforts to achieve higher coverage rates.
Table 20.6 reports the results of the scaling-up analysis for
the traditional EPI vaccines, for tetanus toxoid vaccination for
women of reproductive age, and for selected new vaccines. The
discounted incremental cost per child vaccinated with the tra-
ditional EPI vaccines ranges from US$10.89 in Latin America
and the Caribbean to US$12.84 in the Middle East and North
Africa. The number of discounted deaths averted because of
full immunization depends on incremental coverage rates and
varies from 747 in Europe and Central Asia to 14,584 in Sub-
Saharan Africa, resulting in regional variations in the dis-
counted incremental cost per death averted from US$169 in
Sub-Saharan Africa to US$1,754 in Europe and Central Asia.6
DALYs were estimated indirectly based on the ratio of deaths
to DALYs for each disease in 2001. This ratio is applied to the
hypothetical population in each World Bank region over the
projection period. Calculated this way, the number of DALYs
averted will not account for changes in the average age of infec-
tion that ordinarily results from expanding immunization cov-
erage. This method over-estimates the number of DALYs and
thus under-estimates the cost/DALY. Cost-effectiveness ratios
should be treated as indicative only. The cost/DALY ranges from
$2 to $20 for scaling up traditional immunizations.
For tetanus toxoid immunization, the additional discounted
cost per person vaccinated ranges from US$3.28 to US$4.06.
The cost per death averted varies from US$271 to more than
US$190,000. The results of this analysis fall within the range of
estimates reported in the literature (Berman and others 1991;
Steinglass, Brenzel, and Percy 1993). Differences in coverage
levels and in protection against neonatal tetanus through
skilled delivery contribute to the variation in results across
regions.
The analysis shows both an increase in costs and potential
benefits from scaling up immunization programs. In practice,
the costs and benefits related to scaling up in any one region
will be highly dependent on a few countries or subnational
areas within countries. Aggregate country- or region-level data
do not reveal the efficiency that could best be obtained by
targeting immunization efforts on specific countries or geo-
graphic areas rather than making diffuse investments across
regions. For instance, Miller and others (1998) show that India
and Nigeria contribute the most to estimates of global measles
deaths; therefore, reducing transmission in those countries
would contribute the most to reducing the global disease bur-
den caused by measles.
Despite its importance for policy, empirical and country-
specific evidence on how immunization program costs change
as coverage increases is lacking. Because scaling up im-
munization coverage will require more intensive efforts to find
unvaccinated children, an extra cost for vaccinating each addi-
tional child is generally expected. Nevertheless, most cost-
effectiveness studies assume constant returns to scale (Elbasha
and Messonnier 2004; Karlsson and Johannesson 1998) even
when emerging evidence suggests that the cost of vaccinating
each additional child may rise with the size of delivery unit
(Valdmanis, Walker, and Fox-Rushby 2003). Box 20.1, which
focuses on scaling up traditional immunization coverage, and
box 20.2, which focuses on new antigens, summarize the results
of two studies that shed more light on this subject.
COSTS AND COST-EFFECTIVENESS OF ADDING
NEW ANTIGENS TO THE CURRENT
IMMUNIZATION SCHEDULE
We also estimated the additional costs per person vaccinated
and cost per death averted of introducing new and underused
vaccines into the traditional EPI in a hypothetical population of
1 million in each region between 2002 and 2011. The new vac-
cines considered protect against hepatitis B, yellow fever, Hib,
measles, rubella, Japanese encephalitis, and meningococcal A,
as well as inactivated polio vaccine (IPV). For comparison pur-
poses, we assumed that new vaccines were introduced in 2002.
The additional cost of combination vaccines is net of the
original cost of DTP vaccination to avoid duplication. The
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delivery cost per FIC was apportioned to individual antigens
on the basis of the share of number of doses per FIC for that
antigen (Brenzel 2005). Cost estimates are based on the num-
ber of doses required for full immunity (that is, hepatitis B, Hib,
and IPV vaccines require three doses for full immunity, and
meningococcal A requires two doses for full immunity). Results
are reported in table 20.6.
The analysis also assumes that an additional visit to a health
facility is required for new doses (depending on timing in the
EPI schedule).Combination vaccines may be more cost-efficient
because of potential savings in supplies, syringes, and health
workers’ time, in addition to the overall health benefits of reduc-
ing the number of required injections. However, if the combina-
tion vaccine does not reduce the number of visits a child would
ordinarily need to make to a health facility, any cost savings may
be subsumed by the higher costs of increasing coverage.
The discounted incremental cost per person ranges from
less than US$1 to US$16.23, depending on the unit price of
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Table 20.6 Average Cost per Person Vaccinated and per Death Averted for Scaling Up Immunization Coverage and Adding
in Selected New Vaccines in a Hypothetical Population of 1 million for 2002–11 
(2001 US$, current vaccine prices)
Europe Latin Middle 
East Asia and America East and Sub-
and the Central and the North South Saharan 
Pacific Asia Caribbean Africa Asia Africa
Traditional EPI (mix of strategies)
Incremental discounted cost/person vaccinated 12.03 11.54 10.89 12.84 11.58 11.16
Incremental discounted deaths averted 3,165 747 2,552 4,576 7,584 14,584
Incremental discounted cost/death averted 478 1,754 791 698 274 169
Tetanus toxoid (mix of strategies)
Incremental discounted cost/person vaccinated 4.06 3.34 3.28 3.34 3.98 3.88
Incremental discounted deaths averted 343 2 200 465 2,815 2,412
Incremental discounted cost/death averted 1,541 190,000 3,117 1,880 271 394
Second opportunity for measles (fixed facility)
Incremental discounted cost/person vaccinated 1.08 1.05 0.98 1.19 1.04 1.00
Incremental discounted deaths averted 1,138 599 95 1,304 2,509 9,646
Incremental discounted cost/death averted 119 199 1,906 228 74 23
DTP-hepatitis B and Hib (pentavalent) vaccine (mix of strategies)
Incremental discounted cost/person vaccinated 15.14 14.61 15.69 16.23 15.24 11.68
Incremental discounted deaths averted 47 19 116 274 192 1,796
Incremental discounted cost/death averted 40,000 85,000 25,000 14,000 14,000 1,433
Yellow fever (campaigns)
Incremental discounted cost/person vaccinated n.a. n.a. 1.43 n.a. n.a. 1.42
Incremental discounted deaths averted n.a. n.a. 94 n.a. n.a. 376
Incremental discounted cost/death averted n.a. n.a. 2,810 n.a. n.a. 834
Incremental discounted cost/person vaccinated (mix of strategies)
Hepatitis B monovalent (birth dose) 2.26 2.15 2.36 2.37 2.24 2.02
DTP-hepatitis B (tetravalent) 7.85 7.57 7.34 8.03 7.55 7.26
Rubella (campaigns) 1.20 1.19 1.20 1.07 1.19 1.19
Meningococcal A (fixed facilities) n.a. n.a. n.a. 2.73 n.a. 2.33
Japanese encephalitis (fixed facilities) 4.56 n.a. n.a. n.a. 4.37 n.a.
Injectable polio vaccine (monovalent) 7.12 6.72 6.42 7.32 6.85 6.60
Injectable polio vaccine (combination with DTP) 13.88 14.84 14.62 15.28 14.77 14.19
Source: Authors’ calculations. 
Note: n.a. refers to not applicable when a specific disease is not prevalent in a specific region.
vaccine, the type of vaccine, the delivery strategy, and the cov-
erage levels. The results lead to several conclusions:
• First, the additional incremental cost per person vaccinated
is relatively small for some new vaccines.
• Second, because fixed costs are excluded, the results repre-
sent conservative estimates of additional costs.
• Third, because of price uncertainty, cost variations are great-
est for newer vaccines, such as the DTP-IPV combination.
The second opportunity for measles has the lowest cost
per death averted, ranging from US$23 to US$1,906 for fixed
facility strategies, and from US$65 to US$1,363 for campaigns
These results are consistent with the literature. Foster,
McFarland, and John (1993) find an incremental cost per death
averted ranging from US$335 to US$552 in urban areas and
from US$327 to US$706 in rural areas. The Africa Measles
Partnership (2004) estimates a cost per death averted of
US$131 to US$393 in the African context, but these figures
include the costs of infrastructure.
In the hypothetical populations, the incremental cost per
death averted for the pentavalent vaccine ranged from
US$1,433 to more than US$85,000, depending mostly on the
number of potential deaths that could be averted. Although a
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Marginal Costs of Immunization Services in India
Box 20.1
A study in Tamil Nadu evaluated immunization costs and
coverage using a longitudinal panel dataset of immuniza-
tion program costs (Brenzel 1995). Data were collected
from a stratified, random sample of facilities between 1989
and 1991 for the North Arcot District Polio Control
Program.a The sample included 120 observations of 59 dif-
ferent health centers: 17 followed for three years (29 per-
cent), 27 followed for two years (46 percent), and 15 with
a single observation (25 percent). Total immunization
costs included the cost of labor, vaccines, injection sup-
plies, transportation, and overhead and the value of equip-
ment, vehicles, and buildings.
During this period, coverage rates for FICs increased
from 5 to 77 percent. The table shows that the cost per
dose and the cost per FIC increased during this period.b
Changes in the cost per dose were highly statistically sig-
nificant, whereas no statistical differences were apparent
in the cost per FIC during the study period.
The study used data from the health facility sample to
explain the determinants of immunization costs, which
were modeled as a function of outputs, input prices, and
other production-related variables that influence the cost
function with respect to outputs. A random effects estima-
tion was performed on the analysis sample relating the nat-
ural logarithm of health facility costs to the type of polio
vaccine in use, estimated target population, and size of
geographical area serviced by the health facility and natu-
ral logarithms of the number of FICs per facility, the num-
ber of hours spent by a village health nurse on immuniza-
tion services per facility, and the number of small pieces of
equipment used for immunization service delivery.
The analysis revealed a significant association between
facility cost and the number of FICs, the hours worked
by village health nurses, the area served, and the type of
polio vaccine. When calculated using mean values, the
marginal cost per FIC was Rs 24.43 (US$1.30) lower than
the associated average cost per FIC of Rs 183 (US$9.80),
implying that the average cost curve lies above the mar-
ginal cost curve for the sample of health facilities in India.
A declining relationship is apparent between costs and
coverage for this sample of facilities, calling into question
assumptions of constant returns to scale. The results sug-
gest that, in India, average cost-effectiveness ratios would
overestimate total resource needs. Using a single-point
estimate of average unit costs to determine the use of
scarce public health resources will result in suboptimal
resource allocations.
a. The program was a joint effort by the Indian Council for Medical Research, the Centre for Advanced Research in Virology at the Christian Medical Centre and Hospital in Vellore, and the
governments of Tamil Nadu and India. 
b. Higher costs in the second year reflect a change in the organization of the primary health care system in 1990 to improve access to basic services.
Comparison of Total Facility Immunization Costs,
Immunization Activity, and Unit Costs by Year, North
Arcot District Polio Control Program, 1989–91 
(2001 US$)
Indicator Year 1 Year 2 Year 3 Overall
Total costs 996 1,337 980 1,104
Variable costs 697 1,260 917 958
Cost/dose 1.09 1.98 1.33 1.47
Cost/FIC 13.11 27.92 17.07 19.37
Source: Brenzel (1995).
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An Immunization Costing Study of Adding New Vaccines to the EPI in Peru 
Box 20.2
Data were collected from 19 government health facilities in
three districts in Peru, including five hospitals and 14 health
centers (Walker and others 2004). Total annual costs per
center included vaccines, supplies, personnel, cold chain,
overhead, and shared inputs. The average cost per dose for
traditional EPI antigens plus yellow fever varied from
US$1.50 to US$3.20 per dose as shown in the table, with
vaccines and personnel accounting for the bulk of costs.
At 2,000 doses, the marginal cost of delivering one
more dose is US$1.08, increasing to US$5.33 for 12,000
doses. Average and marginal costs are equal (US$1.18)
when 5,000 doses are provided per site. When an outlier
delivering many vaccines at a high cost was removed, cost-
minimizing output rose to 6,000 doses at US$1.11.
Although each vaccination facility is likely to be associa-
ted with different average and marginal costs, considering
vaccine provision across a range of providers is relevant,
because targets for vaccination can be set by site.
Information about marginal costs can help determine
what the most efficient size for vaccination facilities is in
the long run and how to minimize costs across different
size units in the short run, given targets (see figure).
When hepatitis B, Hib, and the pentavalent vaccine
(DTP-hepatitis B-Hib) are added to the delivery schedule,
the total annual additional cost increases to US$4,121,
US$11,886, and US$25,261, respectively, with an average
incremental cost per dose of vaccine of US$0.20, US$4.14,
and US$4.24, respectively. Adding these new vaccines
increased the total cost of providing 5,100 doses from
US$5,840 to US$9,415 and changed the minimum average
cost from US$1.18 per dose to US$1.68. Therefore, the
addition of new vaccines shifts both average and marginal
costs upward.
US$ per year
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Marginal and Average Vaccination in Sample Facilities in Peru
(2001 US$) 
Mean Cost per Dose by Type of Facility, Selected Districts in Peru 
(2001 US$)
Department 
Health Rural Provincial hospital National 
Cost items Health post center hospital hospital (Ayacucho) hospital
Recurrent items
Vaccines 0.59 0.87 1.39 1.03 0.60 0.31
Syringes 0.04 0.05 0.07 0.04 0.05 0.03
Personnel 0.46 0.28 1.17 0.33 0.76 0.29
Other 0.05 0.03 0.03 0.04 0.03 0.13
Capital items 0.01 0.02 0.09 0.01 0.03 0.02
Direct costs 1.15 1.25 2.75 1.45 1.47 0.78
Indirect costs 0.33 0.26 0.41 0.30 0.45 1.19
Average cost 1.48 1.51 3.17 1.79 1.92 1.98
Source: Walker and others (2004).
Note: Totals may not sum exactly because of rounding.
wide range of results was found, these estimates are supported
by the literature. Miller (1998) estimated between US$3,127
and US$3.2 million per life saved for Hib vaccine. Brinsmead,
Hill, and Walker’s (2004) systematic review of the literature on
the cost-effectiveness of Hib vaccine finds wide variations in
results because of methodological differences and epidemio-
logical and health system characteristics. The discounted
incremental cost of introducing the pentavalent (DTP–
hepatitis B–Hib) vaccine is roughly equal to the total mean cost
of the traditional vaccine package estimated earlier. This find-
ing implies that introducing this combination vaccine may
double the financial requirements, an implication that is sup-
ported by data from national financial sustainability plans for
immunization (Lydon 2004).
The incremental discounted cost per person vaccinated with
a birth dose of hepatitis B is approximately US$2, and that for
the tetravalent vaccine was between US$7 and US$8. The 10-
year time period for our analysis is too short to accumulate
deaths averted resulting from hepatitis B vaccination because
deaths from liver cancer occur at older ages. Beutels’s (1998,
2001) reviews of studies of the cost-effectiveness of introducing
hepatitis B vaccine indicate that results vary depending on
assumptions of endemicity and the methodology used, with a
cost per death averted ranging from US$3,500 to US$271,800.
Rubella vaccination had a low additional cost per person vac-
cinated, at slightly more than US$1. Golden and Shapiro (1984)
found that vaccinating all prepubertal children with rubella vac-
cine had the highest benefit-cost ratio (ranging from US$1.70 to
US$1.96). Most benefits were future cost savings from long-
term institutional care. When rubella was delivered in combina-
tion with measles and mumps, the benefit-cost ratios varied
from US$4.70 to US$38.80 (Hinman and others 2002).
The additional cost per person vaccinated with one dose
of Japanese encephalitis vaccine was between US$4.37 and
US$4.56. A study in Thailand using two doses showed a cost per
child ranging from US$2.31 to US$4.20, depending on the
mode of delivery (Siraprapasiri, Sawaddiwudhipong, and
Rojanasuphot 1997). Ding and others (2003) estimate a cost per
case averted of US$258 and a cost per DALY averted of US$16.80
for a five-dose inactivated Japanese encephalitis vaccine.
Our analysis suggests an additional discounted cost per per-
son vaccinated for injectable polio vaccine of between US$6.60
and US$7.32, depending on coverage levels and mix of delivery
strategy. The additional discounted unit cost of the combina-
tion DTP-IPV vaccine was higher, ranging from US$13.88 to
US$15.28. These results are also sensitive to the current prices
of the vaccine, which will probably decline in coming years.
Brenzel (1995) finds that in India the cost per case prevented
for the combination DTP-polio vaccine was much lower than
for oral polio vaccine (OPV), primarily because the combina-
tion vaccine was associated with a greater reduction in the
number of polio cases. Miller and others (1996) suggest that
introducing IPV into routine vaccination in the United States
would cost an additional US$15 million to US$28 million de-
pending on the type of schedule adopted, resulting in a cost per
vaccine-associated paralytic poliomyelitis case prevented of
approximately US$3 million. Sangrugee, Caceres, and Cochi
(2004) found that the least costly option would be for pro-
grams to stop providing OPV after postpolio eradication and
certification and that optionally introducing IPV with univer-
sal IPV had the highest costs and the lowest expected number
of vaccine-associated paralytic poliomyelitis cases. If the unit
price of IPV fell to US$0.47, switching to IPV from OPV would
be economically worthwhile.
FINANCIAL SUSTAINABILITY OF IMMUNIZATION
PROGRAMS 
Even though research has demonstrated that vaccination
against childhood diseases is one of the most cost-effective
health interventions, governments in many developing coun-
tries are considering how to meet the financing requirements
of immunization programs, particularly as new vaccines are
introduced and programs are scaled up. GAVI is working with
countries to prepare for the transition from grant funding and
to secure the overall financial sustainability of national pro-
grams. Approximately 55 countries have prepared national
financial sustainability plans for immunization. These plans
help countries evaluate the current and future costs and financ-
ing of national immunization programs and identify strategies
to address future funding gaps (GAVI 2004; http://www.who.
int/immunization_financing/en).
According to a recent analysis of financial sustainability
plans, specific costs for immunization programs represent an
average of 2 percent of total health spending and 6 percent of
government health spending and are equivalent to less than
0.2 percent of gross domestic product on average. However,
this profile changes after new and more expensive vaccines are
introduced. In some countries, program-specific costs for
immunization can reach as high as 20 percent of government
health spending with introduction of combination vaccines
(Lydon 2004). This share is related to the current unit price of
the vaccine, which is expected to decline.
Governments and their development partners are chal-
lenged to find ways to finance and sustain immunization
programs. In countries that are implementing reforms to
achieve greater transparency and fiscal discipline through sec-
torwide approaches and medium-term expenditure frame-
works, the additional financing requirements are compounded
by the need to operate within a fixed budget for the health sec-
tor, so that increased funding needs for one program may
necessitate budget cuts for others. This example illustrates the
potential tradeoffs that exist at the country level, which create
both opportunities for more open policy dialogue in relation to
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priority setting for the use of scarce public funds and risks that
the cost of new vaccines may not be readily integrated into
national plans and budgets. Because of the financial implica-
tions of reaching higher coverage levels and simultaneously
introducing new vaccines, policy makers will not only have to
weigh the cost-worthiness of alternative investments but also
have to understand their long-term budgetary implications.
IMPROVING THE COSTS AND COST-
EFFECTIVENESS OF IMMUNIZATION PROGRAMS 
The cost-effectiveness of immunization programs could be im-
proved by either reducing costs or improving programs’ health
benefits. Programs could reduce costs by using a more efficient
mix of delivery strategies, reducing vaccine wastage, and using
lower-cost inputs while maintaining the same quality of serv-
ice. Reductions in the price of vaccines in the near future will
also reduce costs. Innovations in vaccine technology may result
in more widespread use of vaccine vial monitors, and increased
use of heat-stable vaccines could potentially reduce the cost of
the cold chain, although these innovations may themselves add
to costs. The number of children and adults immunized can
be increased by creating additional demand for vaccination;
reducing missed opportunities; and reducing the dropout rate
between the first and third doses of DTP, hepatitis B, and other
vaccines. Finally, changes in the EPI schedule could affect total
costs by reducing the number of doses required to achieve
immunity and thereby reducing the number of visits, resulting
in savings in the costs of labor, supplies, transport, and perhaps
overhead.
The EPI schedule was established in 1984 based on a review
of immune responses to diphtheria, tetanus, pertussis, polio,
and measles vaccines starting at different ages and with varying
intervals between doses (Halsey and Galazka 1985). The EPI
schedule administers three doses of DTP at the shortest possi-
ble intervals to complete the immunization series as early in life
as possible. However, if the primary series could be reduced to
two doses with a booster dose at 12 to 15 months of age, the
cost savings from reduced visits and one fewer dose of DTP in
countries that administer a fourth dose of DTP would be con-
siderable. Additional serological studies would be needed to
compare the existing EPI schedule with the theoretical sched-
ule before a new schedule could be adopted. Also, other vac-
cines to be introduced into immunization programs would
need to be revaluated in this schedule. Two doses of IPV
administered beginning at two months of age induce protective
levels of antibodies between 95 and 100 percent for each of the
three polio types (Halsey and others 1997; Plotkin and Vidor
2004).
Some countries with a low incidence of tuberculosis (such
as those of Eastern Europe) are considering the discontinua-
tion of routine BCG vaccination, given the low risk of
acquiring tuberculosis in early childhood. If the BCG were not
administered during the first month of life, program costs
would be reduced by the value of one visit and by the costs
associated with vaccine purchase, shipping, storage, and
administration.
RESEARCH AGENDA
Private and public sector investment in research and develop-
ment pertaining to new vaccines and improved use of existing
vaccines is considerable. Most research and development is
focusing on vaccines likely to have the greatest effect in the
developed world and the best financial return; however, by
means of public-private partnerships for product develop-
ment, foundations have stepped in to support vaccine research
and development for diseases for which the greatest burden
occurs in developing countries.
New vaccines are being developed that could be incorpo-
rated into EPI schedules, including vaccines that protect against
rotavirus, S. pneumoniae, malaria, cervical cancer associated
with human papilloma virus, HIV/AIDS, and dengue. New and
improved vaccines are also being developed to protect against
meningococcal infections in infancy and Japanese encephalitis
(NIH 2000). WHO recently created the Initiative for Vaccine
Research Department to facilitate global coordination of re-
search and development efforts for these and other vaccines.
In compiling data for this chapter, we noted a number of key
gaps in knowledge that could usefully drive a research agenda
and contribute to more evidence-based policy making in the
future (Fox-Rushby and others 2004). First, little is currently
known about how and why delivery costs change with increas-
ing numbers of vaccinations and at higher coverage rates and
whether economies of scale can be achieved. Little is known
about the relative cost-effectiveness of different strategies to
increase coverage given different baseline coverage rates. This
issue relates to other questions of the optimal timing for intro-
ducing new vaccines and of how decisions should vary given
different epidemiological and economic settings. Future
research should therefore consider the extent to which cost-
effectiveness analyses need to be repeated for every country or
context or whether (and how) estimating and validating rela-
tionships across countries and accounting for uncertainty in
estimates of costs and effects are possible.
Second, more attention needs to be given to measuring
effect. For example, even though the coverage of single antigens
required to reach particular levels of FICs should be accounted
for, economic evaluations need to move beyond such indica-
tors of output to measuring effect on the quantity and qual-
ity of life. In evaluating different schedules, methodological
research needs to focus on how to incorporate the combined
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effects of multiple vaccinations in this respect. Remarkably few
studies have considered the effect on nonhealth benefits, such
as economic growth and welfare. The larger the package of
vaccinations considered, the more important this question
becomes.
CONCLUSIONS 
This chapter confirms that vaccination of children and women
with the traditional EPI vaccines is a highly cost-effective pub-
lic health intervention, although cost-effectiveness ratios vary
by region, delivery strategy, and level of scale. Overall, vaccina-
tion has had a significant effect on reducing mortality and
morbidity from childhood diseases and will be a priority
intervention for achieving the child health Millennium
Development Goals. Improving and sustaining measles control
are among the most cost-effective interventions in high-
mortality regions.
Establishing and maintaining high immunization coverage
rates in many of the poorest developing countries have proven
challenging for those with high population growth rates,
limited infrastructure and resources, and fluctuating demand
for services. According to historical coverage rate trends,
Europe and Central Asia, Latin America and the Caribbean,
and the Middle East and North Africa are expected to achieve
90 percent coverage of FIC by 2011, with East Asia and the
Pacific, South Asia, and Sub-Saharan Africa lagging behind.
Increasing and sustaining higher immunization coverage
rates will require further efforts so that disease control can be
maintained, particularly when a perception exists at the com-
munity level that vaccine-preventable diseases are no longer a
major public health issue. At higher coverage rates, further
disease burden reductions will be smaller, which will affect rel-
ative cost-effectiveness. Targeted approaches in countries or at
subnational levels could potentially yield high returns, espe-
cially in those areas with poor control of vaccine-preventable
diseases.
Our analysis shows that the cost per FIC will increase as
countries scale up immunization coverage and introduce new
vaccines. Adding more antigens to traditional EPIs has been
successfully accomplished in many countries, especially for Hib
and hepatitis B vaccines. Although many of the new vaccines
under consideration are more expensive than those for the
original six targeted EPI diseases, they may still be relatively
cost-effective compared with other interventions and with
treatment costs. Our analysis shows a wide range of cost-
effectiveness estimates depending on the type of vaccine,
vaccine prices, coverage levels, and delivery strategy, with the
additional incremental cost per person being relatively small
for some new vaccines. Declines in unit prices of new vaccines
also will affect cost-effectiveness results.
Financing and sustaining immunization programs are chal-
lenges that governments in developing countries and their
development partners will face. The financial implications of
reaching higher coverage levels and the simultaneous desire to
introduce new vaccines will require policy makers to consider
both the relative cost-effectiveness of interventions and the
long-term budgetary implications.
Although global and regional estimates of cost-effectiveness
of interventions are useful guides, further analytical work will
be needed to evaluate the relative benefits (deaths and cases
averted and DALYs) and costs (delivery and treatment) of vac-
cines for different delivery strategies and higher coverage rates,
particularly at the country level.
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NOTES
1. For our analysis, the preimmunization era neonatal tetanus mortal-
ity rate per 1,000 live births is used: developed countries, 0.1; East Asia and
the Pacific, 4.7; Europe and Central Asia, 0.4; Latin America and the
Caribbean, 4.4; Middle East and North Africa, 4.7; South Asia, 15.3; and
Sub-Saharan Africa, 10.2.
2. Because disease classification does not have a one-to-one correspon-
dence with those prevented by vaccine, according to table 20.3 is based on
estimates of the proportion of these illnesses that may be preventable by
specific vaccines. For example, some meningitis and acute lower respira-
tory infections are caused by Hib or S. pneumoniae, and some cirrhosis is
caused by hepatitis B.
3. A fully immunized child is a standard term that refers to a child who
has received one dose of BCG vaccine, three doses each of oral polio vac-
cine and DTP vaccines, and one dose of measles vaccine. The number of
FICs does not include children who have been partially immunized, so this
measure underestimates the total effect on the disease burden. However,
the number of FICs is representative of the effectiveness of the delivery
system in providing access to immunization services to children. The
authors are aware that fully vaccinating a child does not correspond to full
immunity.
4. The mean population-weighted cost per FIC for the financial sustain-
ability plans for immunization was US$21.06. The plans use DTP3 coverage
as a proxy for FICs rather than coverage measured through population-
based surveys (http://www.who.int/immunization_financing/en).
5. Assumptions about the relative distribution of FICs by strategy and
region were based loosely on such factors as the proportion of the popu-
lation with access to health services for fixed facilities and the likelihood of
active mobile strategies.
6. A proxy for the total number of deaths averted is the sum of the indi-
vidual deaths averted for each antigen in the traditional EPI. This figure
may overestimate the actual number of deaths averted by fully immuniz-
ing children and therefore underestimate the cost per death averted.
However, the values estimated by region appear to support previously
reported estimates, and direct estimation of deaths averted was impossible
given data and model limitations.
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Malaria is the most important of the parasitic diseases of
humans, with 107 countries and territories having areas at risk
of transmission containing close to 50 percent of the world’s
population (Hay and others 2004; WHO 2005). More than
3 billion people live in malarious areas and the disease causes
between 1 million and 3 million deaths each year (Breman,
Alilio, and Mills 2004; Snow and others 2003). Recent esti-
mates of the global falciparum malaria morbidity burden have
increased the number to 515 million cases, with Africa suffer-
ing the vast majority of this toll (Snow and others 2005). In
addition, almost 5 billion clinical episodes resembling malaria
occur in endemic areas annually, with more than 90 percent of
this burden occurring in Africa (Breman 2001; Breman, Alilio,
and Mills 2004; Carter and Mendis 2002; Snow and others
1999, 2003; Snow, Trape, and Marsh 2001).
The disease has resurged in many parts of the tropics, and
nonmalarious countries face continual danger from importa-
tion. Contributing to this resurgence are the increasing prob-
lems of Plasmodium falciparum resistance to drugs and of the
Anopheles vectors’ resistance to insecticides. The recent findings
that insecticide-treated nets (ITNs) are extremely cost-effective
in preventing malaria and overall deaths and that intermittent
preventive therapy (IPT) (treatment doses given during
periods of vulnerability) is effective for protecting pregnant
women and their fetuses, along with the discovery of new drugs
(artemisinins) and their use in combination with other
antimalarials and promising vaccine trials, have given great
impetus to the battle against this scourge (Alonso and others
2004; Armstrong-Schellenberg and others 2001; Lengeler 2004;
Newman and others 2003; Yeung and others 2004).
CAUSES, EPIDEMIOLOGY, MANIFESTATIONS,
AND DIAGNOSIS
Four species of the genus Plasmodium cause malarial infections
in humans: P. falciparum, P. vivax, P. ovale, and P. malariae.
Virtually all deaths are caused by falciparum malaria. Human
infection begins when the malaria vector, a female anopheline
mosquito, inoculates plasmodial sporozoites from its salivary
gland into humans during a blood meal. The sporozoites
mature in the liver and are released into the bloodstream as
merozoites. These invade red blood cells, causing malaria
fevers. Some forms of the parasites (gametocytes) are ingested
by anopheline mosquitoes during feeding and develop into
sporozoites, restarting the cycle.
P. falciparum predominates in Haiti, Papua New Guinea, and
Sub-Saharan Africa, while P. vivax is more common in Central
America and the Indian subcontinent and causes more than
80 million clinical episodes of illness yearly (Mendis and others
2001). The prevalence of these two species is approximately
equal in the Indian subcontinent, eastern Asia, Oceania, and
South America. P. malariae is found in most endemic areas,
especially throughout Sub-SaharanAfrica,but is much less com-
mon than the other species. P. ovale is unusual outside Africa,
and where it is found accounts for less than 1 percent of isolates.
While more than 40 anophelines can transmit malaria, the
most effective are those such as Anopheles gambiae, which are
long-lived, occur in high densities in tropical climates, breed
readily, and bite humans in preference to other animals. The
entomological inoculation rate (EIR)—that is, the number of
sporozoite-positive mosquito bites per person per year—is the
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most useful measure of malarial transmission and varies from
less than 1 in some parts of Latin America and Southeast Asia
to more than 300 in parts of tropical Africa.
The epidemiology of malaria may vary considerably within
relatively small geographic areas. In tropical Africa or coastal
Papua New Guinea, with P. falciparum transmission, more than
one human bite per infected mosquito can occur per day and
people are infected repeatedly throughout their lives. In such
areas, morbidity and mortality during early childhood are con-
siderable. For survivors, some immunity against disease devel-
ops in these areas, and by adulthood, most malarial infections
are asymptomatic. This situation, with frequent, intense, year-
round transmission, is termed stable malaria. In areas where
transmission is low, erratic, or focal, full protective immunity
is not acquired and symptomatic disease may occur at all
ages. This situation is termed unstable malaria. An epidemic or
complex emergency can develop when changes in environmen-
tal, economic, or social conditions occur, such as heavy rains
following drought or migrations of refugees or workers from a
nonmalarious to an endemic region. A breakdown in malaria
control and prevention services intensifies epidemic condi-
tions. Epidemics occur most often in areas with unstable
malaria, such as Ethiopia, northern India, Madagascar, Sri
Lanka, and southern Africa. Many other African countries sit-
uated in the Sahelian and Sub-Saharan areas are susceptible to
epidemics (Djimdé and others 2004; Worrall, Rietveld, and
Delacollette 2004). Public health specialists have only recently
begun to appreciate the considerable contribution of urban
malaria, with up to 28 percent of the burden in Africa occur-
ring in rapidly growing urban centers (Keiser and others 2004).
The determinants of malaria and of risk factors for patients
and communities relate to intrinsic (human, parasite, and
vector) and extrinsic (environmental, control, and socioeco-
nomic) factors (figure 21.1)(Breman 2001). Both humoral and
cellular immunity are necessary for protection.
Anemia may be quite common among young children living
in areas with stable transmission, particularly where the para-
site is resistant to chloroquine, sulfadoxine-pyrimethamine
(SP), or other drugs. Correctly and promptly treated, uncom-
plicated falciparum malaria has a mortality rate of approxi-
mately 0.1 percent (Sudre and others 1992). Once vital organ
dysfunction occurs or the proportion of erythrocytes infected
increases to more than 3 percent, mortality rises steeply. Coma
is a characteristic and ominous feature of falciparum malaria,
and despite treatment it is associated with death rates of some
20 percent among adults and 15 percent among children.
Convulsions, usually generalized and often repeated, occur in
up to 50 percent of children with cerebral malaria (CM)
(Mung’Ala-Odera, Snow, and Newton 2004). Whereas less than
3 percent of adults suffer neurological sequelae, roughly 10 to
15 percent of children surviving CM—especially those with
hypoglycemia, severe malarial anemia (SMA), repeated
seizures, and deep coma—have some residual neurological
deficit when they regain consciousness. Protein-calorie under-
nutrition and micronutrient deficiencies, particularly zinc and
vitamin A, contribute substantially to the malaria burden
(Caulfield, Richard, and Black 2004).
In areas with intense and stable transmission, falciparum
malaria in primigravid and secundigravid women is associated
with low birthweight (average reduction of about 170 grams)
and consequently with increased infant and childhood mor-
tality (Steketee and others 2001). HIV infection predisposes all
pregnant women to more frequent and severe malaria, and the
reverse may also be true (Ter Kuile and others 2004). P. vivax
malaria in pregnancy is also associated with a reduction in
birthweight (average reduction of some 100 grams), and this
effect is greater in multigravid than in primigravid women
(Nosten and others 1999).
The confirmatory diagnosis of clinical malaria rests on the
microscopic demonstration of asexual forms of the parasite in
stained peripheral blood smears. Newer diagnostic tests using
antigen and nucleic acid detection methods are being evalu-
ated. These tests are promising, but their limitations in relation
to species sensitivity (except for P. falciparum), parasite quanti-
tation, field feasibility, and costs necessitate further develop-
ment and evaluation (Warhurst and Williams 2004).
BURDEN OF DISEASE
In 2001, the World Health Organization (WHO) ranked malaria
as the eighth-highest contributor to the global disease burden
as reflected in disability-adjusted life years (DALYs), and the
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Figure 21.1 Determinants of the Malaria Burden: Intrinsic and
Extrinsic Factors
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Control
and prevention
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Source:  Breman 2001.
second highest in Africa (WHO 2002a). The DALYs attributa-
ble to malaria were estimated largely from the effects of P. falci-
parum infection as a direct cause of death and the much smaller
contributions of short-duration, self-limiting, or treated mild
febrile events, including malaria-specific mild anemia and neu-
rological disability following CM (Murray and Lopez 1996,
1997). The estimate assumes that each illness event or death
can be attributed only to a single cause that can be measured
reliably. Table 21.1 shows deaths and DALYs from deaths attrib-
utable to malaria and to all causes by WHO region (WHO
2002a). It does not include the considerable toll caused by the
burden of malaria-related moderate and severe anemia, low
birthweight, and comorbid events (Snow and others 2003).
Sub-Saharan African children under four represent 82 percent
of all malaria-related deaths and DALYs. Malaria accounts for
2.0 percent of global deaths and 2.9 percent of global DALYs. In
the African region of WHO, 9.0 percent of deaths and 10.1 per-
cent of DALYs are attributable to malaria.
Recent analysis of falciparum malaria morbidity concludes
that 515 (interquartile range 298 to 659) million cases occur
yearly (table 21.2). This figure is 92 percent higher than the
278 million malaria cases estimated by WHO for 1998, which
also includes those attributable to P. vivax, and 200 percent
higher than previous estimates for areas outside of Africa
(Snow and others 2005). While the malaria incidence globally
is 236 episodes per 1,000 persons per year in all endemic areas,
it ranges from about 400 to 2,000 (median 830) episodes per
1,000 persons per year in areas with intense, stable (hyperen-
demic and holoendemic) transmission; these areas represent
38 percent of all falciparum-endemic areas.
Background
Recent estimates of malaria deaths have varied from 0.5 million
to 3.0 million per year (Breman 2001; Breman, Alilio, and
Mills 2004; Snow and others 2003). Of the 10.6 million yearly
deaths in children younger than 5 years 8 percent are ascribed
to malaria (Bryce and others 2005). In 1998, an empirical
analysis of malaria mortality undertaken on behalf of WHO
used malaria risk maps to capture measures of disability, mor-
bidity, and mortality associated with P. falciparum prevalence
rates among African populations and yielded an estimate of
about 1 million (Korenromp and others 2003; Snow and Marsh
2002; Snow and others 2003; Snow, Trape, and Marsh 2001).
Each malarious country must now measure its own burden and
progress toward decreasing that burden (WHO 2005).
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Table 21.1 Deaths and DALYs from Deaths Attributable to All Causes and to Malaria by WHO Region, 2000
Deaths, 2000 DALYs from deaths, 2000
All causes Malaria All causes Malaria
Region Population Thousands Percent Thousands Percent deaths Thousands Percent Thousands Percent DALYs
World 6,122,211 56,554 100.0 1,124 100.0 2.00 1,467,257 100.0 42,279 100.0 2.90
Africa 655,476 10,681 18.9 963 85.7 9.00 357,884 24.4 36,012 85.2 10.10
Americas 837,967 5,911 10.5 1 0.1 0.02 145,217 9.9 108 0.2 0.07
Eastern 493,091 4,156 7.3 55 4.9 1.30 136,221 9.3 2,050 4.8 1.50
Mediterranean
Europe 874,178 9,703 17.2 1 0.1 0.010 151,223 10.3 20 0.04 0.01
Southeast Asia 1,559,810 14,467 25.6 95 8.5 0.70 418,844 28.5 3,680 8.7 0.90
Western Pacific 1,701,689 11,636 20.6 10 0.9 0.09 257,868 17.6 409 1.0 0.20
Source: Breman, Alilio, and Mills 2004; WHO 2002b.
Percentages may not add up to 100 percent because of rounding.
Malaria
deaths 
as a 
percent-
age of all
Malaria
DALYs 
as a per-
centage 
of all 
Table 21.2 Population at Risk for Falciparum Malaria, Cases
and  Attack Rates by World Health Organization Region,
2002*
Population Cases in Falciparum attack 
at risk in millions rate (1,000 persons 
Region millions (percent) (IQR) (percent) at risk per year)
World 2,211 (100) 515 (100) 236
[298–659]
Africa 521 (24) 365 (71) 701
[216–374]
Americas 55 (3) 4 (1) 73
[2–8]
Eastern 176 (8) 12 (2) 68
Mediterranean [5–25]
Europe 4 (1) 1(1) 157
[1–1]
Southeast Asia 1,314 (59) 119 (23) 91
[66–224]
Western Pacific 142 (6) 15 (3) 106
[9–26]
Source: Modified from Snow and others 2005.
IQR  interquartile range, urban-adjusted.
Geographic and climate-driven (mainly rainfall) models of
suitability for malaria transmission characterize the diversity of
malaria transmission across the African continent (Craig,
Snow, and le Sueur 1999; Snow and others 1999). Four distinct
areas can be identified:
• class 1, no transmission (northern and parts of southern
Africa)
• class 2, marginal risk (mainly in some areas of southern
Africa and in high-altitude [1500 meters] settings)
• class 3, seasonal transmission with epidemic potential
(along the Sahara fringe and in highlands) 
• class 4, stable and unstable malarious areas (most areas
south of the Sahara to southern Africa and below an altitude
of around 1,500 meters).
Direct Consequences of P. falciparum Infection
Two major syndromes, CM and moderate (hemoglobin less
than 11 grams per deciliter) and severe (hemoglobin less than
8 grams per deciliter) malarial anemia, contribute directly and
significantly to malaria mortality (tables 21.3 and 21.4). The
differences in numbers derive from the different methods of cal-
culating the burden. Children presenting with an acute febrile
disease, peripheral parasitemia, and low hemoglobin concen-
trations account for the majority of inpatient admissions in
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Table 21.4 Deaths from Malaria in Children Under Five,
Africa, 2001
Cause of malaria-related death Number of malaria deaths
Cerebral malaria 110,000
Severe malarial anemia 190,000–974,000
Respiratory distress 110,000
Hypoglycemia 153,000–267,000
Low birthweight 62,000–363,000
Total deaths from malaria 625,000–1,824,000
All-cause deathsa 962,000–2,806,000
Sources: Breman, Alilio, and Mills 2004; Murphy and Breman 2001.
a. Children under five represent 65 percent of all deaths in Africa as per Snow and others (2003).
Table 21.3 Malaria-Related Mortality and Morbidity, Africa, 2000
Percentage affected by age in years
Condition Number (range) 0–4 5–14 15
Mortality and Morbidity
Malaria-specific mortality 1,144,572a 65 19 16
(702,957–1,605,448)
Maternal mortality (anemia) 5,300 n.a. n.a. 100
Infant mortality (pregnancy related) 71,000–190,000 100 n.a. n.a.
Fatal adverse events from malaria drugs 2,300 100 Unknown Unknown
HIV from blood transfusion necessitated by malaria 5,300–8,500 100 —
Epilepsy-related mortality after cerebral malaria Unknown Unknown Unknown Unknown
Malaria-related anemia, undernutrition, and HIV mortality Unknown Unknown Unknown Unknown
Episodes of malaria (thousands) 213,549 51 35 14
(134,322–324,617)
Illness days from malaria (thousands) 803,699 69 21 10
(494,416–1,298,872)
Neurocognitive sequelae after CM
Hemiparesis 360–400 100 Unknown
Quadriparesis 770–860 100 Unknown
Hearing impairment 650–730 100 Unknown
Visual impairment 300–330 100 Unknown
Behavioral difficulties 1,540–1,720 100 Unknown
Language deficits 7,000–7,800 100 Unknown
Epilepsy 2,700–3,000 100 Unknown
Effects on cognition Unknown Unknown Unknown Unknown
Source: Breman, Alilio, and Mills 2004; Snow and others 2003.
n.a.  not applicable.
—  not available.
Note: Figures in parentheses are interquartile ranges.
a. WHO (2002b) reports 1,124,000 deaths from malaria.
areas with stable transmission. The arbitrary definition of
5 grams of hemoglobin per deciliter is prognostic for a fatal out-
come and proves useful clinically as a criterion for transfusion.
Lactic acidosis commonly coexists with hypoglycemia and is
(with coma, repeated convulsions, shock, and hyperpara-
sitemia) an important predictor of death from severe malaria
(White and Breman 2005; WHO 2000b).
The vast majority of deaths in developing countries occur
outside the formal health service, and in Africa, most govern-
ment civil registration systems are incomplete (Breman 2001;
Greenberg and others 1989). Newer demographic and disease-
tracking systems are being used globally and should help rectify
the woefully inadequate vital statistics available for malaria and
other diseases (INDEPTH 2002).
Health personnel usually attribute causes of death during
demographic surveillance system surveys through a verbal
autopsy interview with relatives of the deceased about the
symptoms and signs associated with the terminal illness. Both
the specificity and the sensitivity of verbal autopsy vary
considerably depending on the background spectrum of other
common diseases, such as acute respiratory infection, gas-
troenteritis, and meningitis, which share common clinical
features with malaria (Korenromp and others 2003).
In malarious Africa, some 30 to 60 percent of outpatients
with fever may have parasitemia. Monthly surveillance of
households will detect a quarter of the medical events that are
detected through weekly surveillance, and weekly contacts with
cohorts identify approximately 75 percent of events detected
through daily surveillance (Snow, Menon, and Greenwood
1989). Given the predominance of fevers, malaria case man-
agement in Africa and other endemic areas usually centers on
presumptive diagnosis.
Estimates of the frequency of fever among children suggest
one episode every 40 days. If we assume that the perceived
frequency of fever in Africa is similar across all transmission
areas (and possibly all ages), African countries would witness
approximately 4.9 billion febrile events each year. Estimates
indicate that in areas of stable malaria risk, a minimum of
2.7 billion exposures to antimalarial treatment will occur each
year for parasitemic persons, or 4.93 per person per year (Snow
and others 2003). While these diagnostic, patient management,
and drug delivery assumptions are debatable, they indicate the
magnitude of the challenges malaria presents.
The case-fatality rates of CM are high, even with optimal
management. Murphy and Breman (2001) report a mean case-
fatality rate of 19.2 percent and Snow and others (2003) cite a
figure of 17.5 percent. Those who succumb at home without
optimal treatment will have higher case-fatality rates.
Studies of neurological sequelae after severe malaria indicated
that 3 to 28 percent of survivors suffered from such sequelae,
including prolonged coma and seizures (Mung’ Ala-Odera,
Snow, and Newton 2004). CM is associated with hemipare-
sis, quadriparesis, hearing and visual impairments, speech and
language difficulties, behavioral problems, epilepsy, and other
problems (table 21.3). The incidence of neurocognitive sequelae
following severe malaria is only a fraction of the true residual
burden, and the impact of milder illness is unknown.
Studies of children presenting to hospital with malaria and
hemoglobin of less than or equal to 5 grams per deciliter indi-
cate a median transfusion rate of 80.1 percent. Thus, 275,400 to
442,290 surviving SMA admissions, newborn through 14 years,
will be exposed to blood transfusion each year in Sub-Saharan
Africa. As a result, each year 5,300 to 8,500 children, age birth
through 14 years, living in stable endemic areas of Africa are
likely to acquire HIV infection because of exposure to blood
transfusion to manage SMA (Colebunders and others 1991;
Savarit and others 1992).
Indirect and Comorbid Risks
The DALY model of malaria does not sufficiently take it into
account as an indirect cause of broader morbid risks. Some
consider anemia to be caused indirectly unless linked to acute,
high-density parasitemia. Similarly, low birthweight may also
be indirectly attributable to malaria, and a child’s later under-
nutrition and growth retardation linked to malaria infection
enhances the severity of other concomitant or comorbid
infectious diseases through immune suppression. Thus,
malaria infection contributes to broad causes of mortality
beyond the direct fatal consequences of infection and is prob-
ably underestimated (Breman, Alilio, and Mills 2004; Snow
and others 2003).
In Africa, pregnant women experience few malaria-specific
fever episodes but have an increased risk of anemia and
placental sequestration of the parasite. Maternal clinical mani-
festations are more apparent in areas with less intense
transmission, particularly in Asia. Estimates indicate that in
Sub-Saharan Africa, malaria-associated anemia is responsible
for 3.7 percent of maternal mortality, or approximately 5,300
maternal deaths annually.
Prematurity and intrauterine growth retardation resulting
in low birthweight associated with maternal malaria account
for 3 to 8 percent of infant mortality in Africa (Steketee and
others 1996, 2001). Assuming an infant mortality rate of 105
per 1,000 live births, Snow and others (2003) calculate that in
2000, 71,000 to 190,000 infant deaths were attributable to
malaria in pregnancy (table 21.3). Other studies indicate that
malaria-associated low birthweight accounted for 62,000 to
363,000 infant deaths (Murphy and Breman 2001).
Anemia among African children is caused by a combination
of nutritional deficiencies and iron loss through helminth
infection, red cell destruction, decreased red cell production
as a result of infectious diseases, and genetically determined
hemoglobinopathies. Chronic or repeated infections, often
associated with parasite resistance to drugs, are more likely to
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involve bone marrow suppression (Menendez, Fleming, and
Alonso 2000).
Murphy and Breman (2001) estimate that 190,000 to
974,000 deaths per year in Sub-Saharan Africa are attributable
to SMA. Children residing in areas where the prevalence of
P. falciparum was more than 25 percent had a 75 percent preva-
lence of anemia. By modeling the relationship between anemia
and parasite prevalence, Snow and others (2004) found that
mild anemia rose 6 percent for every 10 percent increase in the
prevalence of infection. Reducing the incidence of new infec-
tions through ITNs or the prevalence of blood-stage infections
through chemoprophylaxis or IPT for children halved the risk
of anemia.
Caulfield, Richard, and Black (2004) report that iron, zinc,
and protein-calorie deficits are responsible for a considerable
amount of malaria-related mortality and morbidity and indi-
cate that 57.3 percent of deaths of underweight children under
five are attributable to nutritional deficiencies. One striking
feature of the global distribution of anthropometric markers of
undernutrition is its congruence with the distribution of
endemic malaria. Improved growth among young children has
more recently been demonstrated in The Gambia and Kenya in
a comparison of those protected and unprotected by ITNs
(Ter Kuile and others 2003).
Early during the HIV epidemic, Greenberg and others
(1988) and Greenberg (1992) demonstrated that malaria-
associated anemia treated with unscreened blood transfusions
contributed to HIV transmission. At the same time, two longi-
tudinal cohort studies in Kenya and Uganda and one hospital-
based case-control study in Uganda demonstrated that HIV
infection approximately doubles the risk of malaria parasitemia
and clinical malaria in nonpregnant adults and that increased
HIV immunosuppression is associated with higher-density
parasitemias (French and others 2001; Whitworth and others
2000). In pregnant women, the presence of HIV increases the
rate and intensity of parasitemia and frequency of anemia
(Ter Kuile and others 2004). The increasing incidence of HIV-
associated febrile illnesses may lead to increased use of
antimalarials. Some believe that the recommended use of
trimethoprim-sulfamethoxazole for prophylaxis of bacterial
pneumonia and other infections in HIV/AIDS patients may
contribute to SP resistance and that monitoring is required. Yet,
evaluation of trimethoprim-sulfamethoxazole for malaria pro-
phylaxis in Mali did not show any increases in parasite resistance
mutations specific for these drugs (Thera and others 2005).
Malaria accounts for 13 to 15 percent of medical reasons for
absenteeism from school, but little information is available on
the performance of parasitized schoolchildren (Holding and
Kitsao-Wekulo 2004). A randomized placebo control study of
chloroquine prophylaxis in Sri Lankan schoolchildren demon-
strated an improvement in mathematics and language scores
by those who received chloroquine but found no difference in
absenteeism (Fernando and others 2003) As noted earlier,
malaria may result in low birthweight, and low birthweight can
lead to a range of persistent impaired outcomes, predomi-
nantly behavioral difficulties, cerebral palsy, mental retarda-
tion, blindness, and deafness. The recently launched studies of
intermittent preventive treatments during infancy (IPTi)
should provide a more precise means of examining the benefits
of IPTi and consequences on learning and performance of
infection early in life (Holding and Kitsao-Wekulo 2004; Rosen
and Breman 2004; Schellenberg and others 2005).
INTERVENTIONS AND THEIR EFFECTIVENESS
Malaria will be conquered only by full coverage, access to, and
use of antimalarial services by priority groups; rapid, accurate
diagnosis; prompt and effective patient management (diagno-
sis, treatment, counseling and education, referral); judicious
use of insecticides to kill and repel the mosquito vector, includ-
ing the use of ITNs; and control of epidemics. Eliminating
malaria from most endemic areas remains a distant, huge, but
surmountable challenge because of the widespread Anopheles
breeding sites; the large number of infected people; the use of
ineffective antimalarial drugs; and the inadequacies of
resources, infrastructure, and control programs. The Roll Back
Malaria Partnership, which began in 1998, aims to halve the
burden of malaria by 2010 and has developed strategies and
targets for 2005 (box 21.1). While ambitious, the initiative is
making substantial progress by means of effective and efficient
deployment of currently available interventions (WHO 2003,
2005). Indeed, Brazil, Eritrea, India, and Vietnam are reporting
recent successes in reducing the malaria burden (Barat 2005).
Despite the enormous investment in developing a malaria vac-
cine administered by means of a simple schedule and recent
promising results in the laboratory and in field trials in Africa,
no effective, long-lasting vaccine is likely to be available for
general use in the near future (Alonso and others 2004; Ballou
and others 2004).
Drug Use
Proper use of drugs is essential. Early diagnosis and effective
treatment of patients lends credibility to the malaria program,
strengthens confidence in the health care system by families
and communities, and raises the esprit of clinicians and public
health workers.
Early Diagnosis and Treatment. Early diagnosis and effective
treatment can cure infection, prevent further morbidity
and progression to severe disease and death, and arrest
transmission. This intervention requires timely and accurate
diagnosis; use of efficacious drugs; education of patients and
their families about the disease, home management, and
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prevention; and referral to higher levels of the health system.
The following are critical to the effectiveness of this
intervention:
• Timeliness. A febrile malaria attack warrants early treat-
ment. If left untreated, a proportion of P. falciparum malaria
infections, perhaps 1 in 250 (and to a far lesser extent infec-
tions with other malaria species) will progress to severe
disease within a few hours to a few days (Greenwood and
others 2005). The globally agreed goal is that diagnosis
and effective treatment should be provided within 24 hours
of the onset of symptoms and signs.
• Diagnosis and effective drug treatment. An accurate diagno-
sis of malaria is based on detection of the parasite and, if
laboratory diagnosis is not feasible, on clinical grounds.
Health workers must monitor the therapeutic efficacy of
drugs closely and change treatment policies when parasite
resistance to chloroquine (figure 21.2), SP, and other drugs
emerges (Baird 2005; Laxminarayan and others 2006; WHO
2002a). Concerns include unreliable and inaccurate
microscopy and the disadvantages of alternative tests plus
the widespread distribution and use of substandard and
counterfeit drugs. The recommended treatments for malaria
in areas with resistance to single drugs are combination
treatments, preferably artemisinin combination therapy
(ACT) (WHO 2001a, 2001b, 2003a, 2005). While ACT is a
welcome, life-saving approach, more information on the
cost-effectiveness of this new strategy is needed (Arrow,
Panosian, and Gellband 2004; Yeung and others 2004).
Baird (2005) reports that ACT costs range from US$2.00
(artesunate-amodiaquine, three doses in 48 hours) to
US$9.12 (artemether-lumefantrine, six doses in 48 hours)
per adult treatment; WHO has obtained the latter drug for
US$2.40 per adult treatment for qualified purchasers, mean-
ing those from low-income malarious countries.
• Location of clinical management. Effective management of
patients requires skilled and well-equipped personnel at all
levels of the health system. The two strategies for delivering
antimalarials effectively are through health facilities and in
or near the home when access to health facilities is limited.
Given the pervasiveness of malaria infections, more infor-
mation on the most effective and efficient ways to promote
home treatment is urgently needed.
Evidence for the effectiveness of early diagnosis and treat-
ment is available from two different epidemiological conditions
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Roll Back Malaria’s Strategy and Goals for 2005
Box 21.1
Strategy
• Prompt access to effective treatment
• Provision of ITNs
• Prevention and control of malaria in pregnant women
• Epidemic and emergency response
Abuja target (by 2005)
• 60 percent of those suffering with malaria should have
access to and be able to use correct, affordable, and
appropriate treatment within 24 hours of the onset of
symptoms.
• 60 percent of those at risk for malaria, particularly chil-
dren under five and pregnant women, will benefit from
a suitable combination of personal and community pro-
tective measures, such as ITNs.
• 60 percent of pregnant women at risk of malaria will
have access to IPTa.
• 60 percent of epidemics are detected within two weeks of
onset.
• 60 percent of epidemics are responded to within two
weeks of detection.
Source: WHO 2003b, 2005.
a. The original Abuja declaration included the recommendation for chemoprophylaxis as well, but current WHO and Roll Back Malaria policy strongly recommends IPT and not chemopro-
phylaxis for preventing malaria during pregnancy.
The goal of Roll Back Malaria Partnership is to halve the burden of malaria by 2010. The following targets for specific
intervention strategies were established at the Abuja Malaria Summit in April 2000.
and health systems. In areas of low to moderate transmission,
for example, southern Africa, the Americas, and Southeast Asia,
where health care systems are relatively effective, the two major
consequences of prompt and effective intervention are
reduction of the period of infectivity of infected persons,
and thus reduced transmission and incidence, and a lowered
case-fatality rate and overall mortality. In Vietnam and the
KwaZulu-Natal province of South Africa, P. falciparum malaria
incidence and mortality rates fell when effective treatment
policies (artesunate and ACT) replaced failing monotherapies
(Hung and others 2002). The effective drug policies were
implemented in conjunction with enhanced vector control;
thus, effective treatment alone does not account for the fall in
malaria incidence and mortality.
In areas with stable, high transmission of P. falciparum
malaria—for instance, Papua New Guinea and Sub-Saharan
Africa—where access to treatment is poor, little is known about
the impact of early and effective treatment on malaria trans-
mission. With a high EIR (10 to 1,000), a reduction in trans-
mission intensity is unlikely to affect the incidence of disease
until low EIRs (less than 10) are reached.
IPT in Pregnancy and Infancy. IPT is recommended in
pregnancy in areas with high and stable transmission of P. falci-
parum malaria; IPT usually consists of two curative doses of
antimalarial treatment. The recommended drug is SP given dur-
ing the second and third trimesters of pregnancy during prena-
tal care visits. IPT in infancy involves giving infants treatment
doses during vaccination or well-baby visits to health clinics.
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In primigravid and secundigravid women, the incidence of
severe maternal anemia, the incidence and density of placental
parasitemia, and the incidence of low birthweight were 25 to
95 percent lower when mothers were given IPT than when they
were not (Kayentao and others 2005; Steketee and others 2001).
While initial studies indicate that IPT in infancy reduces ane-
mia and febrile episodes, more research is needed. SP is becom-
ing ineffective for IPT, and health experts are suggesting ACT as
a replacement (White 2005).
Chemoprophylaxis. Chemoprophylaxis is advised by travel
medicine specialists for nonresidents of endemic areas who are
exposed to malaria for short periods. WHO does not recom-
mend chemoprophylaxis for permanent residents of endemic
areas because of low feasibility and compliance and high costs
relative to the public health benefits (WHO 1996, 2000a,
2000b). The choice of chemoprophylaxis will depend on the
drug-sensitivity profile, tolerance, side effects, costs, regimen,
and compliance by patients (Baird 2005; Kain, Shanks, and
Keystone 2001; White and Breman 2005). The effectiveness of
chemoprophylaxis will depend mainly on patient compliance
and parasite susceptibility.
Supervision and Policy Change. In relation to drug use, all
control activities must be supervised and evaluated rigorously
to ensure high-quality care for patients and program effective-
ness and efficiency (Bryce and others 1994; Jha, Bangoura, and
Ranson 1998). Studies in 37 countries indicate the need for a
treatment policy change to ACT (WHO 2002a). Several
Figure 21.2 Chloroquine Treatment Failure in Africa, 1997–2002
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Note:  WHO has established 126 sentinel sites in 36 African countries that monitor the efficacy of locally used antimalarial drugs by following patients in clinics.
The box indicates the 25th–75th percentile, the vertical line the lower and upper values, and where the lines cross the median.
countries in Africa, Asia, and South America are now imple-
menting ACT as the first-line treatment for uncomplicated
malaria (WHO 2005). Many countries are also trying to
improve the time lag before treatment. More than 83 percent of
the population in the three malarious provinces in South Africa
is within 10 kilometers of a health facility (Sharp and le Sueur
1996). In Burkina Faso, Ethiopia, and Uganda, where access to
clinics was poor and difficult, mothers and community health
workers were empowered to dispense treatment, which result-
ed in major reductions in mortality and morbidity in children
(Kidane and Morrow 2000; Pagnoni and others 1997; Sirima
and others 2003).
Insecticide-Treated Nets
The use of ITNs (bednets, curtains, and other materials) to
provide personal protection by killing or repelling mosquitoes
is one of the major strategies of malaria control (RBM 2002).
Pyrethroids are recommended for the periodic treatment or re-
treatment of the protective materials.
The effectiveness of ITNs depends on their acceptability by
the population at risk and their affordability. It is contingent
on the habits, biology, and susceptibility of the mosquito
vector; the compliance of the human population; and the con-
centration of insecticide on or in the fiber, which has to be
maintained by regular re-treatment or by incorporating the
insecticide in the fiber for long duration.
Over 20 studies in Africa and Asia have demonstrated more
than 50 percent protective efficacy for individual users of ITNs
in reducing malaria episodes, 29 percent protection against
severe malarial disease, and substantial protection against
anemia (Lengeler 2004). Most importantly, the use of ITNs
reduced child mortality by 18 percent in five sites in Sub-
Saharan Africa (Lengeler 2004).
Lengeler’s (2004) review demonstrates the efficacy of ITNs
in both stable and unstable transmission areas. Widespread
use of ITNs resulted in an overall reduction in mortality of
19 percent, protected against anemia, and had a substantial
impact on mild disease episodes. One large-scale rural study
in Tanzania found that ITNs and untreated nets reduced mor-
tality of children one month to four years, with protective
efficacies of 27 and 19 percent, respectively (Armstrong-
Schellenberg and others 2001). Re-treating ITNs semiannually
or just before the annual peak in transmission is essential for
effective vector control and is proving a major logistical and
financial challenge. Fortunately, new types of nets with a long-
lasting insecticidal property are now available, and re-
treatment will soon cease to be an issue. The salutary impact
of large-scale ITN programs has been demonstrated in China
(Tang 2000), Tanzania (Abdulla and others 2001; Armstrong-
Schellenberg and others 2001; WHO 2005), and Vietnam
(Hung and others 2002). More operational experience is
required to inform national initiatives to scale up ITN use
(Lengeler and Sharp 2003); yet, recent encouraging reports
show that Eritrea, Malawi, Togo, Zambia, and other countries
in Africa are already scaling up nationally with high coverage.
Vector Control
The reduction of Anopheles breeding and biting of humans
involves different methods of insecticide and repellent applica-
tion, environmental management, and behavioral change of
populations at risk.
Indoor Residual Spraying of Dwellings with Insecticide.
Indoor residual spraying (IRS) is the application of long-lasting
insecticides (up to six months) on the walls of dwellings.
Insecticides repel mosquitoes from entering houses or impart
a lethal dose of the insecticide on the female mosquito when it
rests on a sprayed surface, thereby preventing subsequent
transmission. IRS is most effective against indoor-biting
(endophilic) mosquito vectors. Vector susceptibility and post-
feeding behavior are the main criteria to be considered when
choosing an insecticide: organophosphates, carbamates, and
pyrethroids are the main compounds used although some
countris still rely on organochlorines (dichlorodiphenyl-
trichloroethane, or DDT).
The effectiveness of this intervention depends on cost, toxi-
city, acceptability of the insecticide, its residual effects, and local
political and international partnership commitment. Malaria
incidence decreased sharply following the use of IRS in large-
scale programs in many parts of Africa, the Americas, Asia, and
Europe (Lengeler and Sharp 2003).
In southern Africa, more than 13 million people in six coun-
tries are protected from malaria (WHO 2002c). Control was
initiated through the use of IRS and supported by engineering
approaches, larviciding, prompt diagnosis, and effective treat-
ment. Examples of successful and sustained malaria elimina-
tion using IRS with effective drug treatment are available from
Cyprus, Greece, Portugal, Spain, and the former Yugoslavia and
its successor states (Curtis and Mnzava 2000). The most suc-
cessful malaria control efforts were linked closely to research
and took place in many parts of Asia, where the notable exam-
ple is the near eradication of malaria from Sri Lanka in the
early 1960s, and in Central and South America from the late
1950s to early 1970s (Alilio, Bygbjerg, and Breman 2004; Carter
and Mendis 2002; Gilles 2002).
Larviciding and Fogging. Larviciding is the application of
chemical insecticides, including those of biological origin and
insect growth regulators, to breeding sites. These may be
applied to all mosquito breeding sites or targeted to the breed-
ing sites of specific vectors. Recommended compounds, for-
mulations, and dosages for larviciding are available through the
WHO Pesticides Evaluation Scheme. Fogging or space spraying
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with insecticides requires specialized equipment, because the
particle size of the insecticide determines its suspension quali-
ties in the air, the number of droplets, and the penetration of
space. The insecticide is not effective for as long as with IRS
or ITNs, and application must occur during periods of peak
target mosquito activity, generally at night.
Larviciding is not generally indicated for large-scale vector
control in rural endemic areas because of the difficulty of locat-
ing all breeding sites, their often temporary nature, and the
required frequency of application. Thus, larviciding is usually
limited to urban areas, refugee camps, and industrial and
development projects. Despite its impact on mosquito density
and its contribution to reducing transmission, larviciding is not
as effective as IRS and ITNs in reducing mosquito longevity
(Najera and Zaim 2002).
Civil Engineering. Draining and filling larval breeding sites is
one of the oldest methods of mosquito control and must be
targeted to the breeding sites of locally important malaria
vectors. Civil engineering strategies can require costly heavy
equipment and materials and are useful for eliminating perma-
nent breeding sites in urban areas, which are increasing
globally, and at development project sites where earth removal
has occurred.
Home Repellents and Insecticide Use
Commercially available mosquito repellents are applied directly
on the skin or clothing as aerosols, lotions, or creams and
contain active ingredients that protect the individual from mos-
quito bites. Commercially available mosquito coils containing
pyrethroids can be burnt to repel mosquitoes, and electrically
heated dispensers serve a similar function. Some communities
in endemic regions use smoke, burning herbs, or plants to deter
mosquitoes from entering the home.
N,N-diethyl-meta-toluamide (DEET) is the most widely
used and effective ingredient in commercially available repel-
lents (Curtis and others 1991). While several studies have shown
that mosquito coils are effective at repelling mosquitoes, they are
not as effective as ITNs (Charlwood and Jolly 1984).
Health Education and Counseling
Health education is the provision of information via news-
papers, radio, or television, and health counseling is interactive,
is individual, and involves the transfer of skills. The provision
of information to households on ways to prevent malaria is
needed in all endemic communities. It should cover the impor-
tance of early treatment and where to access it, the use of
referral services, and the significance of full compliance with
treatment and other interventions. The necessary information
can be provided by community and voluntary health workers.
These persons are an extension of the health system and work
under the direct supervision of health facility staff or non-
governmental organizations and in conformity with standards
and norms established by the national government (Gilles
2002). Such information can help to increase the standard of
patient care and prevention programs by promoting citizen
and community advocacy and demand for control.
ECONOMICS OF MALARIA CONTROL
INTERVENTIONS
Goodman, Coleman, and Mills’s (2000) study represents the
most thorough attempt to compare the cost-effectiveness of a
wide range of malaria control interventions. They find that in
a very low-income country, the cost-effectiveness range
per DALY averted was US$19 to US$85 for ITNs (nets plus
insecticide), US$32 to US$58 for residual spraying (two rounds
per year), US$3 to US$12 for chemoprophylaxis for children
(assuming an existing delivery system), US$4 to US$29 for IPT
for pregnant women, and US$1 to US$8 for case-management
improvements. Goodman, Coleman, and Mills (2000) find that
even though some interventions are relatively cheap, achieving
high coverage may require a level of expenditure currently out
of reach for many African countries and that overcoming oper-
ational barriers to achieving widespread coverage is likely to
require substantial assistance from external donors.
Analysis
The following analysis incorporates new knowledge on the
effects of interventions and on their costs for a low-income,
Sub-Saharan African population living in an area of high,
stable transmission. The modeling draws on a wide range of
sources on the costs and effects of each intervention, extrapo-
lated across settings and operational conditions. The approach
allows for changing cost-effectiveness over time, for example, as
resistance to antimalarial drugs or insecticides increases. To
address problems of uncertainty in relation to many of the
parameters, we used probabilistic sensitivity analysis, which
allows for multivariate uncertainty by assigning ranges rather
than point estimates to input variables. We assumed that cost
and effectiveness input variables follow uniform triangular or
normal continuous probability distributions (Mulligan, Morel,
and Mills 2005).
We consider the cost-effectiveness of a limited subset of
interventions: ITNs, IRS, IPT during pregnancy, and patient
management with a change of the first-line drug. We include
costs to the provider and the community and incremental out-
of-pocket expenses for households, but because of major
valuation and measurement problems, we do not include the
indirect costs of patients’ time to seek care and of the lost
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productivity resulting from morbidity. We consider only gross
costs for all interventions except patient management, given
the uncertainty inherent in estimating savings.
Insecticide-Treated Nets. We based our analysis of ITNs on
the delivery mechanism used in the WHO Special Programme
for Research and Training in Tropical Diseases (WHO/TDR)
trials, where householders, community health workers, and
program staff worked together to treat the nets. In relation to
insecticide, we considered permethrin and deltamethrin.
Deltamethrin is effective for a year; thus, re-treatment is
annual. Permethrin lasts for six months; thus, we assumed two
treatments per year if the transmission season is longer than
six months. The activities undertaken were the training of
staff and community health workers, a campaign to inform the
community about the intervention, the procurement and
transport of the insecticide and nets, and the initial treatment
and the re-treatment of the nets. We calculated cost-
effectiveness for each intervention for two scenarios: one
whereby nets were distributed to households and the second
whereby treatment was arranged for existing nets. We drew
estimates of the effectiveness of ITNS from a recent meta-
analysis of WHO/TDR-sponsored trials conducted in Sub-
Saharan Africa (Lengeler 2004). We adjusted the key parameter
and effectiveness estimates to account for the proportion of
children sleeping and not sleeping under a recently treated net.
With one treatment per year using deltamethrin, the mean
cost per DALY averted was US$11 (90 percent range of US$5 to
US$21). With one treatment of permethrin per year the cost-
effectiveness ratio (CER) increased slightly to a mean of
US$12 (90 percent range of US$6 to US$20). Two treatments of
permethrin per year increased the mean CER to US$17 (90 per-
cent range of US$9 to US$31). Even if net coverage is low and
nets have to be distributed and treated, the intervention
remains an extremely attractive use of resources. Moreover, the
model includes health benefits only for children under five. If
we included benefits for other household members, the CERs
would be lower.
Insecticide Residual Spraying. We considered four insecti-
cides for our analysis of the cost-effectiveness of IRS: DDT;
malathion; and two pyrethroids, deltamethrin and lambda-
cyhalothrin. We used the results of the Cochrane Review 
meta-analysis of ITN trials conducted in Africa to approxi-
mate the results of spraying on morbidity and mortality and
adjusted effectiveness estimates to account for noncompliance
(Lengeler 2004).
We found little difference between the CERs for the four
insecticides when one round of spraying was done per year:
they ranged from US$5 to US$18. With two rounds per year,
costs increased, but we assumed that effectiveness remained the
same, so all the CERs approximately doubled to US$11 to
US$34. These results should be interpreted with caution
because of uncertainty in relation to the estimates of effective-
ness in children under five. The model was based on one round
of spraying per year in areas of seasonal transmission and two
rounds per year in areas of high, intense (perennial) transmis-
sion. Effectiveness will depend on the length of the transmis-
sion seasons and on the insecticide. DDT lasts for six months
or more, lambda-cyhalothrin for three to six months, and
malathion and deltamethrin for only two to three months
(Lengeler 2004; Lengeler and Sharp 2003).
IPT during Pregnancy. We analyzed the cost-effectiveness of
IPT assuming that primigravid women are given two or three
doses of SP at a prenatal clinic. We analyzed benefits to the child
by decreased mortality and benefits to the mother resulting
from changes in the incidence of severe anemia. We estimated
the effect of IPT on the neonatal mortality rate as a function of
increased birthweight based on the Cochrane meta-analysis
of malaria prevention in pregnancy (Gülmezoglu and Garner
1998). The model allowed for level of drug resistance, prob-
ability of initial attendance at a prenatal clinic, probability of
returning for a second visit, probability of returning for a third
visit, and compliance with the drug regimen. We estimated both
incremental and average costs.
The incremental CER for IPT in pregnancy using SP had a
90 percent range from US$9 to US$21 with a mean of US$13.
Average total cost-effectiveness had a mean of US$24 (90 per-
cent range of US$16 to US$35).
Change in First-Line Drug. We analyzed the cost-effectiveness
of changing first-line therapies to SP and to ACT using a
patient-management model with a decision-tree framework in
which a patient presents with uncomplicated malaria at an out-
patient facility and progresses to full recovery, recovery with
neurological sequelae, or death. Three potential drug policy
changes were considered (see table 21.5). For current drug poli-
cies we assumed either chloroquine or SP as the first-line drug,
with SP or amodiaquine as a second-line drug and quinine as
the third-line drug. We then examined the cost-effectiveness of
policy switches to either SP or ACT as first-line drug (with
amodiaquine as second line and quinine as third line).
Amodiaquine was chosen as the second-line drug in the new
drug policy because, like chloroquine and SP, it is relatively
cheap. Low compliance, adverse effects, and potential cross-
resistance between amodiaquine and chloroquine excluded it
from first-line selection. We omitted other potential drugs to
limit the scope of analysis.
We used commonly found levels of drug resistance to create
likely ranges. When used as second-line treatment, we assumed
that a drug faced half the level of resistance than when it was
used as a first-line drug. We estimated the growth rate of resist-
ance to each drug based on its expected current location along
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a sigmoid growth curve. We assessed compliance with each
drug based on the length and complexity of each regimen. We
gave the widest range (20 to 70 percent) to compliance with
ACT, which usually requires a three-day treatment, to account
for the different lengths of regimen and variety of formulations.
Figure 21.3 shows that a switch from chloroquine to SP is
cost-effective (less than $150 per DALY averted) when chloro-
quine resistance is above 35 percent. Switching from chloro-
quine to ACT becomes cost-effective as chloroquine resistance
reaches around 37 percent. Switching from SP to ACT becomes
cost-effective as SP resistance reaches 12 percent. This low
threshold is due to the high growth rate of resistance to SP
when it is used as a first-line therapy.
Results and Interpretation. Table 21.6 presents the average
CERs for the interventions reviewed. All interventions can be
considered attractive using a cutoff of US$150 per DALY
averted. For the childhood preventive interventions, the level
of existing infrastructure is a key factor in influencing 
cost-effectiveness. ITNs are an even better use of resources if
net coverage is already high, and IPT is even more cost-effective
if prenatal care coverage is good. However, even if levels of
infrastructure are poor, these interventions are still attractive
based on cost-effectiveness criteria.
Curtis and Mnzava’s (2000) review comparing worldwide
trials of ITNs and IRS for malaria control suggests that they
were of equivalent effectiveness. Lengeler and Sharp (2003 21,)
also conclude that choosing between IRS and ITNs is “large-
ly a matter of operational feasibility and availability
of local resources, rather than one of malaria epidemiology or
cost-effectiveness.” DDT is the cheapest insecticide but is
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Table 21.5 Change in First-Line Drug
Current drug policy New drug policy
Scenario First-line drug Second-line drug Third-line drug First-line drug Second-line drug Third-line drug
A Chloroquine SP Quinine SP Amodiaquine Quinine
B Chloroquine SP Quinine ACT Amodiaquine Quinine
C SP Amodiaquine Quinine ACT Amodiaquine Quinine
Source: Authors.
Figure 21.3 Cost-Effectiveness of Switching the First-Line Drug
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Table 21.6 CERs for ITNs, IRS, and IPT 
(2001 US$)
Mean cost per 90 per-
Intervention DALY averted cent range
ITNs (net  insecticide treatment)
Deltamethrin 11 5–21
Permethrin (1 treatment) 12 6–20
Permethrin (2 treatments) 17 9–31
ITNs (without provision of nets)
Deltamethrin 5 2–7
Permethrin (1 treatment) 6 3–9
Permethrin (2 treatments) 11 6–17
IRS (1 round)
Melathion 12 8–18
DDT 9 5–13
Deltamethrin 10 6–14
Lambda-cyhalothrin 10 6–14
IRS (2 rounds)
Malathion 24 15–34
DDT 17 11–24
Deltamethrin 18 12–27
Lambda-cyhalothrin 19 12–28
IPT
Incremental costs 13 9–21
Average costs 24 16–35
Source: Authors’ calculations.
seldom used because of concerns about its environmental
impact. An updated systematic review of the health effects of
IRS as well as a full economic comparison between spraying
with DDT and other insecticides and ITNs is urgently required.
Such reviews should include the environmental benefits of
reducing DDT levels and the costs of alternative interventions.
As effective patient management, IPT, and other approaches
toward drug use become more widespread, drug resistance will
increase, which will affect cost-effectiveness. In terms of first-
line treatment, while a switch from chloroquine to SP is unlikely
to be costly, cost-effectiveness depends on the initial level of
severe resistance to each drug. A switch from chloroquine to
ACT is likely to be costly but more effective, given that resist-
ance to ACT is essentially nonexistent and the growth rate of
resistance to ACT is likely to be low (Yeung and others 2004).
Given the high growth rate of resistance to SP, switching to ACT
becomes cost-effective when SP resistance surpasses 12 percent,
a relatively low threshold. A switch from chloroquine to ACT
appears to be highly cost-effective at all initial levels of chloro-
quine resistance above 37 percent. Recent studies indicate the
remarkable effectiveness of the ACT artemether-lumefantrine
in East African areas of chloroquine, amodiaquine, and SP
resistance (Mutabingwa and others 2005; Piola and others
2005); it is expected that the availability of ACTs will increase
and the costs will decrease in the near future.
Affordability and Scaling Up
Cost-effectiveness analyses can identify which interventions
are the most efficient to implement, but information is also
needed on affordability. Some interventions are cheap, such as
prevention in pregnancy. Achievement of high coverage with an
intervention to prevent childhood malaria (for example, ITNs)
has a high total cost, which needs to be borne in part by exter-
nal funding. For example, full coverage of children (assuming
22 percent of the population is under five years of age) would
cost US$2.81 million per 1 million persons of the general pop-
ulation covered (assuming the provision of nets plus two
rounds of permethrin). The same coverage with IRS would cost
about US$4.01 million using deltamethrin (two rounds).
In addition to the difficulties of financial feasibility, the
implementation of ITN interventions poses operational and
logistical challenges. A number of strategic approaches are
available for national ITN upscaling (RBM 2002). The main
ones are social marketing (for example, in Malawi and Kenya),
assisted commercial sector development (Senegal, Mali,
Tanzania), and totally free distribution (Togo). An important
feature of all the approaches is that their cost per net distrib-
uted decreases significantly as the scale of the undertaking
increases, so it is hard to use available estimates to project cost
in national programs.
Independent of the main ITN distribution strategy, a num-
ber of countries are implementing additional actions targeted
at the main high-risk groups. For example, a national voucher
scheme is currently being implemented in Tanzania to provide
every pregnant woman in the country with a free ITN, and a
net is being distributed to children at the time of measles vac-
cination in Togo.
Re-treatment of ITNs on a large-scale remains a formidable
operational issue, and free distribution of insecticide in the
way it is done in Vietnam and China is probably the best way
forward. This should occur while waiting the availability of
long-lasting insecticidal nets that do not require retreatment.
Curtis and Maxwell (2002) point to the successful experi-
ence of Vietnam, where ITNs now protect 10 million people
and the public health service provides free insecticide. This
approach in Africa would require a substantial commitment by
donors and governments given that most African governments
spend only around US$4 per capita per year on health (World
Bank 2003). Eritrea, with 65 percent ITN coverage, and other
African countries are beginning to make great strides in getting
ITNs to their populations (Barat 2006; WHO 2005; World
Bank 2005).
The move toward ACT poses the most difficult questions in
relation to the long-term affordability of malaria control inter-
ventions. After scale-up, estimates indicate that the additional
annual costs of ACT versus current failing drugs range from
US$300 million to US$500 million globally (Arrow, Panosian,
and Gellband 2004), with the precise amount depending on the
extent to which all fevers are treated. This figure does not
include drugs for nonmalarial fevers in endemic areas and the
costs for the substantial health system strengthening required
to make the most effective use of ACT. These include the costs
of improved drug regulation, pharmacovigilance, diagnostics,
and implementation of different drug policies for different
population groups. The introduction of ACT has permanently
changed the economic landscape of malaria control. Innovative
funding solutions at the global level are required to ensure that
effective drugs are made available to the most vulnerable
groups. The Global Fund to Fight AIDS, Tuberculosis, and
Malaria is providing the major leadership and resources for
securing ACTs and other commodities, and many other agen-
cies and organizations are joining coalitions to combat malaria
through control, research, training, funding, and advocacy
activities (Breman, Alilio, and Mills 2004; Feacham 2004:
http://www. theglobalfund.org/en).
Economic Benefits of Malaria Control
Given the substantial total costs of several malaria control inter-
ventions, the case for introducing them can be strengthened by
evidence on non-health-related benefits, especially evidence of
income gains or prevention of income losses. Three different
approaches to measuring such benefits are assessing the direct
and indirect costs of malaria, studying the relationship between
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malaria and the output of agricultural or industrial activities,
and exploring the macroeconomic impact of malaria. Only the
third approach sheds much light on the benefits of control as
opposed to the burden of the disease in the absence of control.
This point is important, because in places facing the most
severe malaria problems, direct information on the economic
benefits of control is largely unavailable.
Direct and Indirect Costs of Malaria. The standard approach
has been to view the two key determinants of the economic
costs of malaria as the direct costs of expenditure on preven-
tion and treatment and the indirect costs of productive labor
time lost because of malaria morbidity and mortality, and to
estimate the total economic impact by adding the direct and
indirect costs (Mills 1992). Households use a range of preven-
tive measures (mosquito coils, aerosol sprays, bednets, and
mosquito repellents) to differing degrees. A review of evidence
for Sub-Saharan Africa found that monthly per capita house-
hold expenditures ranged from US$0.05 per person in rural
Malawi to US$2.10 in urban Cameroon, equivalent to US$0.24
and US$15 per household in 1999 U.S. dollars (Chima,
Goodman, and Mills 2003). The costs of treatment for malaria
include out-of-pocket expenditures for consultation fees,
drugs, transport, and subsistence at a distant health facility. For
Sub-Saharan Africa, these costs ranged between US$0.41 and
US$3.88 per person, equivalent to between US$1.88 and US$26
per household per year. Household expenditure on treatment is
usually highly regressive, consuming a much larger proportion
of income in the poorest households.
Computations of public expenditures on malaria preven-
tion and treatment are imprecise because most fall within
general health service expenditures. About 20 to 40 percent of
outpatient visits in malarious Africa are for fever, and suspect-
ed malaria among inpatients ranges from 0.5 to 50.0 percent of
admissions. Kirigia and others (1998) found that inpatient
treatment for pediatric malaria absorbed 15 percent of the
annual recurrent costs of inpatient care in one Kenyan hospital
and 9 percent in another. Ettling and Shepard (1991) estimated
that Rwanda’s Ministry of Health spent 19 percent of its oper-
ating budget on malaria treatment. Because of the dominance
of out-of-pocket spending by households, public expenditures
on malaria generally account for a minority of total malaria
expenditure.
The methods used to measure and value time lost and a
day’s work vary considerably between studies; the average time
lost per episode for a sick adult and for an adult caring for sick
children ranged from one to five days. The average indirect
cost per episode ranged from US$0.68 for children under
10 years of age in Malawi to US$23 per adult episode in
Ethiopia. Authors have concluded that aggregate productivity
losses can be significant for households and for the economy
as a whole. In Malawi, the indirect costs of malaria were equiv-
alent to 2.6 percent of annual household income (Ettling and
others 1994), and Russell (2004) reports that malaria generally
consumes less than 10 percent of family income. Leighton and
Foster (1993) estimate that the total annual value of malaria-
related production losses was 2 to 6 percent of gross domestic
product in Kenya and 1 to 5 percent in Nigeria. The productiv-
ity consequences of mortality have received relatively little
attention.
The direct and indirect cost approach involves two method-
ological problems. First, calculations are based mainly on days
of illness and neglect mortality, debility (usually from anemia),
and neurological and other long-term sequelae. Second, house-
holds’ coping strategies are likely to reduce the immediate
impact of illness, although in the long term they may impose
costs through the sale of assets such as livestock, which jeop-
ardizes a household’s asset base.
Relationship between Malaria and Output. With the excep-
tion of a study of cotton production in Côte d’Ivoire, where the
prevalence of parasitemia above a cutoff density had a major
impact on labor efficiency (Audibert, Mathonnat, and Henry
2003), studies have not succeeded in identifying impacts on
output. One possibility is that the risk of malaria may discour-
age the planting of crops that require intensive cultivation, the
settlement and cultivation of fertile land, or the development of
tourism and industry in suitable locations, but good evidence
is lacking.
Macroeconomic Impact of Malaria. Recent empirical cross-
country comparisons of economic growth indicate that
eliminating malaria would have a strong positive impact on
economic development. Gallup and Sachs (2001) use cross-
country regression analysis to relate the growth in gross domes-
tic product per capita between 1965 and 1990 to initial income
levels, initial human capital stock, policy variables, geographi-
cal variables, and a malaria index calculated as the product of
the fraction of land area with endemic malaria in 1965 and the
fraction of malaria cases that were due to P. falciparum in 1990.
Their results suggest that countries with a substantial amount
of malaria grew 1.3 percent per year less than countries with
little or no malaria between 1965 and 1990 (controlling for
other influences on growth) and that a 10 percent reduction in
malaria was associated with 0.3 percent higher growth per year.
McCarthy, Wolf, and Wu (2000) employ a similar approach to
explore the impact of malaria on average per capita growth
rates during three five-year periods. They find a significant
negative association between malaria and economic growth,
although the estimated impact differed sharply across coun-
tries. The impact was smaller than that found by Gallup and
Sachs (2001), exceeding 0.25 percent per year in only a quarter
of the sample countries and averaging 0.55 percent for those in
Sub-Saharan Africa.
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Benefit-Cost Ratios
Mills and Shillcutt 2004 related the evidence on the macroeco-
nomic benefits of malaria control to information on the costs
of reducing malaria to calculate a benefit-cost ratio (Mills and
Shillcutt 2004). Depending on the assumptions, the benefit-
cost ratio ranged between 1.9 and 4.7 (using a 3 percent dis-
count rate). In terms of economic growth alone malaria control
is extremely cost beneficial.
RESEARCH PRIORITIES
Current interventions to combat malaria remain inadequate for
achieving the increased levels of successful patient management
and prevention to which all malarious countries aspire and
for which ambitious targets have been set (box 21.1). Greatly
increased support for malaria research and for developing insti-
tutional capacity must occur to make advances and to bring them
to populations in need. The WHO Scientific Working Group on
Malaria and others have identified four major areas of research as
follows (Remme and others 2002; WHO 1996, 2003c).
Patient Management
Patient management, including treatment, should address the
following:
• evaluation of treatment effectiveness and of access to treat-
ment for uncomplicated malaria in children and during
pregnancy, with an emphasis on home management and
evaluation of alternative delivery systems
• investigation of the pathogenesis of malaria, in particular
anemia and immune response mechanisms
• evaluation of new approaches, for example, rectal drug
administration, for managing severe illness
• evaluation of ACT, including delivery approaches via the
public and private sectors
• development of new drugs with novel targets; the Medicines
for Malaria Ventura (MMV) is spearheading this activity.
Prevention Research
Prevention research should focus on the following:
• new approaches to drug-based malaria prevention, includ-
ing IPT in children and during pregnancy
• strategies for scaling up the use of ITNs.
Innovative Approaches
Innovative approaches should use new technologies, including
recent advances in sequencing the DNA of P. falciparum and
A. gambiae, to achieve the following:
• discover and develop drugs, diagnostics, vaccines, insecti-
cides, and antiparasite effector molecules using genomics
• carry out strategic and basic research on vector-parasite-
host interactions
• assess mechanisms for addressing drug and insecticide
resistance
• develop and carry out field evaluations of transgenic meth-
ods for interrupting malaria transmission.
Policy Research
Social, economic, and policy research should focus on the
following:
• developing and applying a common methodology for meas-
uring socioeconomic status
• carrying out policy and operational research on the impact,
viability, sustainability, and optimal balance of public-
private partnerships
• investigating ethical, legal, and social issues pertaining to
new malaria-related tools.
Capacity strengthening for research and operations (includ-
ing clinical trials) is urgently needed. This strengthening will
result in the ability to better evaluate new drugs and vaccines
and existing malaria control tools (ITNs, IPT) and to tackle the
scaling up of malaria strategies.
A classification of research priorities by time frame includes
the three-year, five-year, and ten-year targeting.
Three-year completion targeting includes the following:
• apply to the U.S. Food and Drug Administration (FDA)
with evidence for two separate fixed-dose artemisinin com-
binations at a target adult treatment price of US$1.00, or
US$0.60 or less for children; two combinations are neces-
sary, as one may fail in testing or have other unforeseen
problems
• evaluate the two best candidate ACT drugs for IPT in preg-
nant women and in infancy and early childhood (IPTi)
• launch studies to reach an evidence-based conclusion on the
costs and benefits of long-lasting ITNs versus IRS in Sub-
Saharan Africa and other endemic areas
• carry out operational studies to determine the best methods
of deploying ACT through the public and private sectors so
that first-level patient management can occur at the home
and at the village levels; this involves studying packaging
and distribution networks, assessing adherence, and ad-
dressing how to deploy and supervise use of artesunate rec-
tal suppositories
• conduct economic reviews and predictive modeling to make
an economic case for increased international investment in
malaria control, including collecting detailed data from sev-
eral scaled-up, national, fully supported control programs
employing the best available strategies and interventions
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• conduct in Africa and other endemic continents a maxi-
mum number of FDA-compliant phase I and phase II
malaria vaccine trials to select candidates for clinical trials.
The five-year completion target is as follows:
• develop and deploy more sensitive, specific, and predictive
diagnostic tests that are inexpensive and practical
• carry out operational studies on how to deploy diagnostics
in areas of low, intermediate, and high transmission.
The ten-year completion target has these focuses:
• develop an inexpensive, safe, and synthetic trioxane anti-
malarial drug
• develop another new drug with a target and resistance
mechanism that is unrelated to existing drugs
• carry out basic insecticide research to develop new
approaches to both personal protection and residual house
spraying
• launch successful phase III and phase IV field testing of
malaria vaccines to prevent clinical illness and transmission
with licensure by regulatory bodies
• use genomic, proteomic, and bioinformatic tools to better
understand the pathogenesis of malaria, to design new
drugs and vaccine candidates for training scientists, and to
transfer technologies
• train a critical mass of leaders in science and operations to
carry out the required research in support of control.
CONCLUSION
Given the heavy burden of malaria, the need to use existing
strategies and interventions in scaled-up programs more
effectively and to deploy them more widely is urgent and mer-
its the highest priority, especially in Africa. While existing tools
can be improved, newer tools are required. The history of
malaria research and control shows that they are synergistic.
Integrating research and control activities has resulted in suc-
cess in several areas of the world, and will result in vanquishing
malaria early in the 21st century.
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Tropical diseases are infectious diseases that are found pre-
dominantly in the tropics, where ecological and socioeconomic
conditions facilitate their propagation. Climatic, social, and
economic factors create environmental conditions that facili-
tate transmission, and the lack of resources prevents affected
populations from obtaining effective prevention and adequate
care. Tropical diseases are diseases of the poor, and investments
in control and research to develop more effective intervention
tools and strategies have been minimal (Gwatkin, Guillot, and
Heuveline 1999; Remme and others 2002). For some, however,
effective intervention methods have been developed, and suc-
cessful control has been achieved.
This chapter focuses on four tropical diseases—Chagas dis-
ease, lymphatic filariasis (LF), onchocerciasis, and leprosy—for
which effective means of control are available. All four diseases
are targeted for elimination as a public health problem. Control
strategies are being implemented at scale and have already
achieved a major reduction in the burden of disease, and the
causative agent has even been eliminated in some previously
endemic areas. Those successes have not come easily, and much
remains to be done to ensure complete and sustained control of
the diseases.
DISEASE CHARACTERISTICS AND TRANSMISSION
Chagas disease, LF, onchocerciasis, and leprosy are all parasitic
infections, but their causative agents, modes of transmission,
and geographic distribution differ. Chagas disease is caused by
infection with a protozoan, leprosy by a mycobacterium, and
LF and onchocerciasis by filarial nematodes. Three are vector-
borne diseases, but leprosy is transmitted directly from person
to person. Chagas disease occurs only in the Americas,
onchocerciasis is found predominantly in Africa, and LF and
leprosy occur in all tropical regions.
Chagas Disease 
Chagas disease—also known as American trypanosomiasis—
is a zoonotic disease caused by the protozoan hemoflagellate
Trypanosoma cruzi that is mainly transmitted by large, blood-
sucking, reduviid bugs of the subfamily Triatominae (known as
kissing bugs). Infection with this blood parasite has been
recorded in more than 150 species of 24 families of domestic
and wild mammals as well as in humans. In the vertebrate host,
T. cruzi usually infects macrophage, muscle, and nerve cells.
Human infection with T. cruzi most commonly originates
through contact of broken skin or mucosa with the excretion of
infected insect vectors. The incubation period ranges from 7 to
15 days, leading to the acute phase of infection—characterized
by patent parasitemia—which may last up to four weeks. The
acute phase may be without obvious symptoms. Romaña’s
sign—that is, uniocular, bipalpebral edema with regional
lymphadenopathy—is diagnostic of the acute infection but
occurs in less than 5 percent of infections.
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If a recent infection is untreated, the individual will remain
infected for life. After an asymptomatic period of 10 years or
more, some 10 to 40 percent of those infected will develop
cardiac or digestive complications that are characteristic of
the chronic stage of the disease. In chagasic myocardiopathy
the most common symptoms are dyspnea and arrhythmias.
Electrocardiographic alterations can occur, such as right bun-
dle branch block, left anterior hemiblock, or both, which may
require a pacemaker implant. Apical aneurisms are also typical
of advanced chagasic cardiopathy, which may rupture on exces-
sive exercise, leading to sudden death. Chagas disease can also
involve intestinal complications characterized by severe dilata-
tions of parts of the digestive tract known as megasyndromes.
Megaesophagus and megacolon are the most common.
Symptoms of megaesophagus are dysphagia and odinophagia
and subsequent malnutrition. Chagasic megacolon is charac-
terized by constipation and meteorism. As a result of colon
distension and contractions, abdominal pain is frequent, and
fecalomas are a complication.
More than 120 species of Triatominae and three transmis-
sion cycles are recognized. The domestic cycle, responsible for
maintaining infection in humans, occurs mostly in rural or
periurban areas where houses have adobe walls and thatched
roofs. Humans, dogs, cats, and in some countries guinea pigs
are the main parasite reservoirs in this cycle. The vector lives
and multiplies in cracks in the walls, holes in the roof, under
and behind furniture and pictures, and so on. The sylvatic cycle
involves sylvatic triatomine bugs that become infected and in
turn infect rodents, marsupials, and other wild animals. The
third is the peridomestic cycle in which mammals participate
(domestic rodents, marsupials, livestock, cats, dogs) by moving
freely in and out of human dwellings, and sylvatic bugs are
attracted to lights in houses and to food. This peridomestic
cycle acts as a link between the domestic and sylvatic cycles.
Occasionally, infected sylvatic species of Triatominae fly into
houses and contribute to transmission either by feeding and
defecating on the people or their domestic animals or (indi-
rectly) by contaminating food and drink in which the parasites
can survive. In the Amazon region, cases of acute Chagas dis-
ease have been associated with sylvatic Triatominae contami-
nating sugarcane or fruit juice.
Transmission by blood transfusion is the second-most com-
mon way of acquiring T. cruzi infection. The true incidence of
infection through blood transfusion is unknown, because most
cases are not recognized. In transfusionally acquired T. cruzi
infection, the incubation period is 30 or more days, and the
most common symptoms are fever, general lymph node
enlargement, and splenomegaly (Schmunis and others 2001).
Transplacental transmission of T. cruzi can occur, and esti-
mates indicate that 5 percent of newborns born to chagasic
mothers will become infected. Less common routes of trans-
mission are by transplantation with an infected organ or,
more rarely, through contaminated food or infection in the 
laboratory (WHO 2002a).
Lymphatic Filariasis 
LF is caused by species of nematode parasites—Wuchereria
bancrofti, Brugia malayi, and Brugia timori—and is transmitted
by mosquitoes (WHO 2002c). The adult filarial parasites live
in the lymphatics of humans. After mating, each female worm
produces several thousand offspring, microfilariae, during its
lifetime. The microfilariae are found in humans’ internal organs
and appear in peripheral blood at times that coincide with the
vector’s biting activity. The biting mosquito ingests the micro-
filariae along with the blood meal, and they develop into
infective-stage larvae in 10 to 12 days. When an infective mos-
quito bites a human, the infective-stage larvae are transmitted
to the human host and develop into the adult stage in about
one year. The adult parasites live 5 to 10 years, of which the
fecund life span is 4 to 6 years. Several hundreds to thousands
of infective mosquito bites are necessary to establish infection.
Of the three parasite species, W. bancrofti accounts for nearly
90 percent of LF infections worldwide. B. malayi is prevalent
only in some parts of South and Southeast Asia, and B. timori is
found only in Indonesia. Several species of Culex, Anopheles,
Aedes, and Mansonia mosquitoes are involved in the transmis-
sion of LF. C. quinquefasciatus is the major vector in Africa,
Asia, and South America and transmits nocturnally periodic
W. bancrofti. Among anophelines, An. gambiae and An. funestus
play a significant role in Africa. Several Aedes species, particu-
larly Ae. polynesiensis, are the major vectors in the South Pacific
islands, where diurnally subperiodic W. bancrofti is common. B.
malayi is primarily transmitted by Mansonia and Anopheles
species.
Infected people can harbor microfilaremia without overt
clinical manifestations. The disease process is determined pri-
marily by living adult worms, inflammatory responses caused
by the death of adult worms, and secondary bacterial infec-
tions. The inflammatory response begins with the death of or
damage to adult worms, which leads to host reaction and acute
filarial lymphangitis. A heavy worm burden and the presence
of worms in the scrotal area precipitate the development of
hydrocele, chyluria, chylocele, and lymph scrotum. Lymphatic
dysfunction caused by dilatation of the lymphatic vessels
makes the patient more prone to repeated secondary bacterial
infection, which precipitates lymphedema and elephantiasis.
Microfilariae play an important role in the pathogenesis of
tropical pulmonary eosinophilia (Dreyer and others 2000).
Onchocerciasis 
Onchocerciasis is an infection with the filarial parasite
Onchocerca volvulus. The main complications are severe eye dis-
ease that can lead to blindness and severe skin disease with
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unsightly lesions and intense itching (WHO 1995a). O. volvulus
is transmitted by vector blackflies of the genus Simulium, whose
larvae and pupae develop in rapidly flowing, well-oxygenated
streams and rivers. As a result, onchocerciasis is often known as
river blindness. The most important vectors are members of the
S.damnosum complex inAfrica and the Middle East and S.neavei
in parts of East Africa. Of the many vectors in the Americas, the
most important are S. ochraceum, S. metallicum, S. oyapockense,
S. guianense, and S. exiguum.
When taking a blood meal, infected Simulium vectors deposit
one or more infective (third-stage) O. volvulus larvae, which
reach adulthood in the human host after about a year but may
live as long as 14 years. The adult worms typically entwine in
nodules where they mate, producing microfilariae that migrate
into the skin, eyes, and other organs. These microfilariae are
unable to develop into adult worms without first being ingested
in the blood meal of a blackfly vector. The microfilariae trans-
form in the vector over a period of 6 to 12 days to produce the
third-stage larvae that are infective to humans.
The thousands of microfilariae that do not succeed in reach-
ing a blackfly vector die in the human body, provoking inflam-
matory reactions in tissues. Inflammation in the eyes leads to
irreversible ocular lesions, resulting first in impaired vision and
finally in total blindness (WHO 1995a). The death of microfi-
lariae in the skin gives rise to intense itching, dermatitis, depig-
mentation, and atrophy of the skin (Murdoch and others
2002). A less common complication is lymphadenitis, which
may lead to hanging groin and elephantiasis of the genitals, and
increasing evidence indicates that onchocerciasis is a risk factor
for epilepsy and hyposexual dwarfism in certain areas
(Boussinesq and others 2002). The greater is the body load of
adult worms and microfilariae, the greater is the risk of devel-
oping skin and eye disease.
The disease pattern of onchocerciasis—in particular the
severity of ocular disease—varies considerably between geo-
graphic zones. Onchocercal blindness can be extensive in hyper-
endemic communities of the West African savannas, whereas in
forest villages with a comparable intensity of infection, the skin
manifestations tend to be the main complications of the disease
(Dadzie and others 1989; Murdoch and others 2002). These dif-
ferences may reflect the existence of different vector-parasite
complexes, with strains of O. volvulus that differ in pathogenic-
ity (Zimmerman and others 1992). The vector-parasite com-
plex in the West African savanna is responsible for the most
severe form of ocular onchocerciasis in the world: in the most
affected villages, more than 10 percent of the population may be
blind because of onchocerciasis.
Leprosy
Leprosy is caused by Mycobacterium leprae, a gram-positive,
strongly acid-fast bacterium. M. leprae is an obligate,
intracellular parasite that resides predominantly in
macrophages. It is the only bacterium that infects peripheral
nerves, showing a preference for Schwann cells, particularly of
unmyelinated fibers.
The disease spectrum of leprosy ranges from a single self-
healing, hypopigmented macule to a generalized illness causing
widespread peripheral nerve damage and affecting even bones
and internal organs. Skin lesions may be well- or ill-defined
hypopigmented macules, plaques, or nodules that are localized
or distributed over the whole skin. They may be hypaesthetic,
anesthetic, hyperaesthetic, or have normal sensibility. Nerve
lesions occur in dermal nerves as well as in superficial sensory
nerves and mixed nerve trunks. One or more nerves may be
enlarged on palpation. Signs such as clawing of fingers and
toes, “absorption” of digits caused by repeated injury, and dry
skin are secondary to impairment of motor, sensory, and auto-
nomic nerve function.
A diagnosis of leprosy is based on finding at least one of
three so-called cardinal signs (ILA 2002):
• diminished sensibility in a typical macule or plaque in the
skin 
• palpable enlargement of one or more peripheral nerve
trunks at specific sites 
• demonstration of acid-fast mycobacteria in a slit skin smear.
Currently, patients are classified based on clinical signs only,
but skin smear results are taken into account when available.
Patients who have more than five skin lesions or who have a
positive skin smear are classified as multibacillary; others are
classified as paucibacillary.
The skin signs of leprosy are relatively harmless, but com-
plications of the disease may lead to severe consequences, such
as blindness, infertility, disfigurement, and severe sensory and
motor disability. Reactions—that is, episodes of acute inflam-
mation caused by hypersensitivity to bacterial antigens—can
be particularly severe. Patients can develop nerve damage with-
out any obvious sign of these reactions, but after neuropathy
has become irreversible, it may lead to secondary impairments,
such as wounds, contractures, and shortening of digits. As a
result of visible impairments or activity limitations—or simply
because of the diagnosis of leprosy—many people experience
psychosocial problems (van Brakel 2000).
The exact mode of transmission of M. leprae is still not fully
understood, but the respiratory tract seems to play an impor-
tant role. The primary reservoir of infection is the human host.
Untreated multibacillary leprosy patients are able to shed large
amounts of M. leprae from the nose, and household and social
contacts of such patients are at a higher risk of developing
leprosy than the general population (van Beers, Hatta, and
Klatser 1999). M. leprae–specific DNA sequences have been iso-
lated from the noses of apparently healthy individuals, and
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widespread seropositivity against M. leprae–specific antigens
has been demonstrated in endemic areas, although the role of
these individuals in transmitting leprosy is not fully under-
stood. Effective antileprosy treatment usually renders a patient
noninfectious within a few days.
DISEASE BURDEN
Information on the number of people infected is often difficult
to obtain for tropical diseases. Many infected people may be
without obvious symptoms, those with symptoms may not
seek care at public health facilities, and those who do may not
be reported. Routine health information systems provide little
information on the number of people infected in the popula-
tion. Surveys are more informative but are rarely done. A bet-
ter picture emerges only when control programs need to map
the distribution of the disease as a basis for targeting large-scale
interventions. Hence, the apparent paradox is that intensifica-
tion of disease control may result in a significant initial increase
in estimates of the burden of disease through better epidemio-
logical data.
Chagas Disease
Chagas disease is an important public health problem in 17
countries in Latin America. Estimates from the 1980s indi-
cated that some 16 million to 18 million individuals were infect-
ed (WHO 1991), and in the 1990s, a series of multinational
control initiatives was launched that was designed to interrupt
transmission by eliminating domestic insect vectors
and improving the serological screening of blood donors. As a
result, estimates of the number of infected people were revised
to 9.8 million in 2001 (Schmunis 2000). The estimated burden
of disease in terms of disability-adjusted life years (DALYs)
declined from 2.7 million in 1990 (World Bank 1993) to 586,000
in 2001 (Mathers, Murray, and Lopez 2006). Because of
migration, T. cruzi–infected individuals can be found outside
Latin America (for example, in Spain or the United States).
Estimates from the 1980s suggested that 5 million people in
the Americas had symptoms of Chagas disease (WHO 1991).
These estimates decreased to 1.2 million to 2.8 million in the
1990s. The World Health Organization (WHO) attributed
45,000 yearly deaths to Chagas disease (WHO 1991). WHO
decreased its mortality estimates to 13,000 in 2001 (WHO
2002d).
In all affected countries, Chagas disease has been responsi-
ble for a high burden of disease and significant direct and indi-
rect costs. Reports from Brazil in the late 1980s suggested that
the aggregate costs for pacemakers and intestinal surgeries
for Chagas disease were US$250 million per year, excluding
the costs of consultations, care, and supportive treatment for
chronic chagasic patients, which amounted to US$1,000 per
year per patient, and disability awards, which in one state
accounted for US$399,600 (Dias 1987; Schofield and Dias
1991). In Bolivia, in 1992, aggregate treatment costs were esti-
mated at US$21 million. In Chile, in 1997, aggregate treatment
costs for Chagas disease were estimated at US$14 million to
US$19 million (Schenone 1998), and in Uruguay, in 1996, costs
were estimated at US$15 million (Salvatella and Vignolo 1996).
Lymphatic Filariasis
LF is endemic in 83 countries, with 1.1 billion people living in
known endemic areas. In 1992, the WHO Expert Committee
estimated that 78 million people were infected (WHO 2002c).
This estimate was later revised to 119 million, and current esti-
mates indicate that LF is responsible for the loss of 4.6 million
DALYs per year. Many endemic areas lack reliable data on the
prevalence of LF, and estimates of the number infected may
increase when more precise data become available from epi-
demiological mapping. Nationwide mapping in four neighbor-
ing countries in West Africa showed that LF was endemic in a
much wider area than expected, and the findings resulted in a
dramatic increase in the estimated number infected (Gyapong
and others 2002).
Epidemiological trends have varied widely among different
regions in recent decades. LF was controlled or eliminated from
several islands in the Pacific, and China has seen a dramatic re-
duction in infection levels. Unfortunately, in India and Africa,
the most endemic areas of the world, recent decades have
witnessed little change (WHO 2002c).
The acute form of the disease is common and causes severe
hardship in endemic communities. Infected individuals suffer
from one to eight acute episodes per year, and during each
episode, affected patients are bedridden for three to five days.
Morbidity caused by chronic LF is mostly lifelong, and the
disease is considered the second leading cause of disability in
the world (WHO 1995b). Patients affected by elephantiasis or
hydrocele are often victims of societal discrimination, and the
disease impairs their educational and employment opportuni-
ties, marriage prospects, and sexual life. Case-control studies in
India revealed that affected individuals are 27 percent less pro-
ductive than their uninfected counterparts (Ramu and others
1996). The patients work less and often switch to lighter jobs,
leading to a loss of more than 1 billion person-days per year in
India alone (Ramaiah and others 2000), which translates into
an annual economic loss equivalent to 0.63 percent of gross
national product.
Onchocerciasis
More than 99 percent of those infected with O. volvulus reside
in 30 endemic countries in Africa, with the remainder living
in the Republic of Yemen and six countries of the Americas.
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In 1995, the WHO Expert Committee on Onchocerciasis
estimated that 17.7 million people were infected, of whom
about 270,000 were blind and another 500,000 were severely
visually impaired (WHO 1995a). However, more recent
information from rapid epidemiological mapping of
onchocerciasis (Noma and others 2002) by the African
Programme for Onchocerciasis Control (APOC) indicates
that the number of those infected is twice as high and that
some 37 million people were infected in 1995. This revised
estimate corresponds to an estimated 1.99 million DALYs lost
because of onchocerciasis in 1995.
Using the most recent rapid epidemiological mapping data
and the latest APOC data on treatment coverage and assum-
ing that four rounds of ivermectin treatment will reduce the
prevalence of troublesome itching by 85 percent and the bur-
den of visual impairment and blindness by 35 percent give a
DALY estimate of 1.49 million DALYS lost for 2003 (see
table 22.1).
In addition to the burden of blindness and severe itching,
onchocerciasis has important socioeconomic consequences. In
the West African savanna, fear of blindness has resulted in the
depopulation of fertile river valleys, severely affecting agricul-
tural production. It was this socioeconomic impact, and not
just the health impact, that led to the creation of the
Onchocerciasis Control Program (OCP) in West Africa in 1975
(Remme 2004b).
Even though the importance of onchocercal blindness has
long been recognized, only in 1995 did research demonstrate
that the public health importance of onchocercal skin disease
was even greater. Troublesome itching associated with dermal
onchocerciasis makes working, studying, or interacting socially
difficult (Murdoch and others 2002; Vlassoff and others 2000).
Onchocercal itching now accounts for 60 percent of DALYs lost
(Remme 2004a). Other skin manifestations, such as reactive
skin lesions, are not included in the DALY estimates, even
though they are highly prevalent and have major psychosocial
and economic impacts. Onchocercal skin disease also dimin-
ishes people’s income-generating capacity, and the school
dropout rate is twice as high among children from households
in which the head of household is affected by onchocercal skin
disease (Benton 1998).
Leprosy
In May 2001, 10 years after the World Health Assembly had
adopted a resolution to eliminate leprosy by the end of the
millennium, the target—a prevalence rate of less than 1 per
10,000—had been achieved at the global level. The number of
cases registered for treatment worldwide fell from 5.4 million
in 1985 to 460,000 by the end of 2003 (WHO 2004a); however,
this trend should not be taken at face value because the reduc-
tion is attributable mainly to such factors as the shortening of
treatment duration for multibacillary patients and the cleaning
up of patient registers.
Leprosy is reported from all regions of the world, but the
burden of disease, which is estimated at 192,000 DALYs, is con-
centrated in a few countries. During 2003, 513,798 new cases
were detected, of which more than 80 percent were in Brazil,
India, Madagascar, Mozambique, Nepal, and Tanzania (WHO
2004a). India alone accounted for about 75 percent of the new
cases. Case detection has remained remarkably stable over the
past decade. Trends in case detection rates should be analyzed
in conjunction with the proportion of new patients with grade
2 impairment (an indicator of the delay between onset of the
disease and diagnosis) and the proportion of children among
new cases (an indicator of recent transmission).
Virtually all published data on leprosy-related disability
concern impairments. In 1997, WHO estimated the global
prevalence of patients with visible impairments (disability
grade 2) as 2 million. A similar number may have sensory
impairment without deformity. Sensory and motor impair-
ment that are already present at diagnosis are important risk
factors for developing additional impairment and disability.
Evidence indicates that sensory impairment itself causes signif-
icant functional disability.
The prevalence of activity limitations among people
affected by leprosy is unknown. Van Brakel and Anderson’s
(1998) survey in Nepal finds that among those with any
impairment, about 20 percent had limitations in relation to
one or more indoor activities and up to 34 percent had signifi-
cant limitations in relation to common outdoor activities. Even
less is known about the prevalence of restrictions on social and
economic participation. Surveys are urgently needed to assess
the extent of patients with leprosy-related disabilities who
require intervention.
Two difficulties affect the validity of DALY estimates for lep-
rosy. The first is the lack of data, particularly on the burden of
functional and psychosocial disability caused by leprosy. The
second is that the effect of leprosy often goes well beyond the
affected individual; the psychosocial consequences may affect
the whole family. People without any visible signs of leprosy
may be stigmatized simply because they are known to be a lep-
rosy patient. Even after completing treatment, people may
remain stigmatized.
Summary of DALY Estimates 
Table 22.1 summarizes the DALY estimates for each of the four
diseases by World Bank region. The high estimate for LF
reflects not only its wider distribution and the larger number
of people affected, but also the reduction in the burden for the
other three diseases as a result of control efforts. For those dis-
eases for which there has been significant progress toward
elimination, public health officials should remain aware of the
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burden of disease that is currently averted but that might
return if control were not to be sustained before transmission
has been completely eliminated.
INTERVENTIONS AND THEIR EFFECTIVENESS
For each of the four diseases in this chapter, effective interven-
tions are available.
Chagas Disease
The primary approaches to control of Chagas disease are halt-
ing transmission and providing adequate treatment for those
infected. The two most important routes of transmission are
insect vectors and blood transfusion from infected donors;
thus, control programs focus on eliminating domestic vector
populations and improving the serological screening of blood
donors.
Vector Control. Triatoma infestans lives only inside houses
and in the peridomestic area. Work during the late 1940s sug-
gested that spraying houses with residual insecticides could
eliminate vectors’ domestic populations. The effect and sus-
tainability of such vector control programs can be enhanced
when they are combined with improved housing and when
communities are well informed and closely involved in vector
surveillance activities.
Argentina and Brazil initiated programs for nationwide
vector control in the 1960s, and Chile and Uruguay did so in
the 1970s. These programs were strengthened in 1991 by the
Southern Cone Initiative, a multinational effort to eliminate
infestation by T. infestans launched by the ministries of health
of Argentina, Bolivia, Brazil, Chile, Paraguay, and Uruguay and
coordinated by the WHO Regional Office for the Americas.
Similar regional initiatives for Central America and the Andean
Pact regions, targeted primarily against Rhodnius prolixus, fol-
lowed in 1997.
The results in the Southern Cone region have been impres-
sive, with vast areas now free of domestic infestation with
T. infestans and other vector species. In Argentina, seropreva-
lence rates among men age 18 to 20 drafted for military service
decreased from 5.8 percent in 1981 to 1.2 percent in 1993. The
number of cases of Chagasic cardiomyopathy, when compared
with the number expected in the absence of control, indicates a
decrease of 81 percent in the population up to 18 years of age.
In 2001, a WHO commission certified that 4 of the 18 endemic
provinces were free of vectorial transmission. In Brazil,
domestic infestation rates decreased by 98.3 percent between
1991 and 2000. Of the 11 Brazilian states that were originally
endemic for T. infestans, 9 have been certified as free of vecto-
rial transmission. In Chile, house infestation rates decreased
from 28.80 percent in 1982 to less than 0.01 percent in 1999,
when the country was certified free of vectorial transmis-
sion. Uruguay also achieved a dramatic reduction in house
infestation rates, from 5.7 percent in 1983 to 0.3 percent in
1997, when it too was certified as free of vectorial transmission.
Bolivia and Paraguay have not yet eliminated transmission, but
thousands of houses have been sprayed since 1991.
Blood Transfusion Control. The purpose of screening for
T. cruzi in blood banks is to eliminate all units of potentially
infected blood. Argentina and Brazil require screening to be
done using two serological tests to reduce the risk of false neg-
atives; however, the cost-benefit ratio of the two-test approach
may be questionable in countries where prevalence is low and
the reagents used for diagnosis are highly sensitive.
In 1993, the national coverage of blood donor screening
was analyzed in four Central American and six South American
countries (Schmunis and others 1998). At that time, only
Honduras, Uruguay, and República Bolivariana de Venezuela
screened 100 percent of donors, and even in those countries
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Table 22.1 DALYs Lost, by Disease and World Bank Region 
(thousands)
Disease (date  East Asia and Europe and Latin America Middle East and Sub-Saharan High-income
of information) the Pacific Central Asia and the Caribbean North Africa South Asia Africa countries Total
Chagas disease 0 1 583 0 0 0 1 585
(2001)
LF (2001) 373 1 9 4 2,412 1,656 212 4,667
Onchocerciasis 0 0 2 0.4 0 481 0 484
(2003)
Onchocerciasis 0 0 2 0.4 0 1,487 0 1,490
(latest APOC data)
Leprosy (2001) 34 0 18 2 113 24 1 192
Source: Mathers, Lopez, and Murray 2006; WHO 2004b; authors’ calculations. 
infected transfusions were possible because of the lack of
sensitivity of the reagents used. Since then, the sensitivity and
specificity of serological tests have improved, and more coun-
tries have passed legislation requiring the screening of all blood
donors. By 2001, seven endemic countries were screening
100 percent of blood donors for T. cruzi, four were screening
more than 99 percent of donors, and two were screening about
90 percent; but four countries were still screening fewer than
25 percent of donors. In countries with a high number of
immigrants from Latin America, such as Spain and the United
States, thousands of individuals are potentially infected, and
screening of blood donors for T. cruzi infection may be indi-
cated in these countries.
Treatment. If untreated, most individuals infected with T.
cruzi will remain infected for life. Spontaneous cure is rare.
Only two drugs, nifurtimox and benznidazole, are effective for
treating T. cruzi. Both are highly effective for acute infections
and can be used in cases of congenital Chagas disease. Their
effectiveness for treating chronic cases remains unclear, but
increasing evidence indicates that they are effective in clearing
parasitemia when administered to young cases, which may
impede the development of chronic lesions. Both drugs may
cause serious side effects and should be administered under
medical supervision.
Lymphatic Filariasis
In recent years, new control tools and strategies have become
available for LF (Ottesen and others 1997), and the World
Health Assembly has adopted a resolution on the global elimi-
nation of LF. The Global Programme for the Elimination of
Lymphatic Filariasis was launched in 2000 with the primary
goals of interrupting transmission and preventing suffering
and disability caused by the disease (Ottesen 2000).
The core strategy for interrupting transmission is annual
mass drug administration (MDA) to treat the entire at-risk
population for a period long enough to ensure that levels of
blood microfilariae remain below those necessary to sustain
transmission. Two annual, single-dose, two-drug regimens are
recommended for MDA: ivermectin plus albendazole in
African countries that are coendemic for onchocerciasis, and
diethylcarbamazine plus albendazole for all other endemic
countries. Where feasible, diethylcarbamazine-fortified salt as
the only source of domestic salt for a period of at least six
months would be an alternative strategy to MDA.
The principal strategy for alleviating suffering and decreas-
ing the disability caused by LF focuses on decreasing secondary
bacterial and fungal infection of limbs or genitals whose lym-
phatic function has already been compromised by filarial infec-
tion. Operationally, a regimen of meticulous local hygiene of
affected areas and the creation of hope and understanding
among patients and their communities are the principal strate-
gic approaches (Dreyer, Dreyer, and Noroes 2002).
Mass Treatment. It is not yet known how many years of MDA
are needed to eliminate LF transmission, but empirical evi-
dence on the effect of MDA on transmission is progressively
becoming available. In Anopheles-transmitted W. bancrofti in
Papua New Guinea, four rounds of MDA with diethylcarba-
mazine or diethylcarbamazine plus ivermectin that reached
about 88 percent of the target population reduced the annual
transmission potential (the estimated number of infective-
stage larvae inoculated per person per year) by 97 percent and
84 percent in low- and high-transmission areas, respectively. In
India, where W. bancrofti is transmitted by C. quinquefasciatus,
six rounds of MDA that reached 54 to 75 percent of the target
population reduced the annual transmission potential by 95
and 80 percent in diethylcarbamazine- and ivermectin-treated
villages, respectively (Ramaiah and others 2003). Modeling
studies indicate that the required duration of treatment will
depend largely on the treatment coverage achieved and the
extent of systematic noncompliance to treatment—that is,
noncompliance by the same individuals during successive
treatment rounds (Stolk and others 2003). The physiology of
the vectors also plays a role, because with Culex-transmitted LF,
the critical microfilariae density required to interrupt trans-
mission is thought to be lower than in areas where Anopheles is
the vector.
The addition of albendazole to the two established anti-
filarial drugs—diethylcarbamazine and ivermectin—is based
on clinical trials indicating that the combination therapy is as
good as or better than single-drug therapy and that albendazole
may enhance the macrofilaricidal action of diethylcarbamazine.
Albendazole is also effective and safe against intestinal helminth
infections, and its inclusion may enhance compliance with
MDA. However, clinical trials have not yet been conclusive, and
more robust evidence on the advantages of combination thera-
py is needed (Addiss and others 2004; Gyapong and others
2005). Community trials are ongoing in India and Africa, and
preliminary results of a trial in south India suggest that the
combination of diethylcarbamazine and albendazole may
indeed achieve greater reduction in the prevalence of antigene-
mia than diethylcarbamazine alone (Rajendran and others
2002). A study in Nigeria showed that the addition of albenda-
zole to ivermectin had an additive effect on reducing LF mos-
quito infection rates. (Richards and others 2005).
Vector Control. Vector control has sometimes been extremely
effective against LF. In the Solomon Islands, 9 to 10 years of
vector control virtually eliminated LF. In India, five years of
integrated vector control in an urban area reduced the overall
prevalence of microfilariae by 28 percent and the prevalence in
children by 92 percent. Studies suggest that 11 to 12 years of
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effective vector control may eliminate LF (Ramaiah, Das, and
Dhanda 1994). Vector control combined with chemotherapy
produced the best results. The introduction of polystyrene
beads in vector breeding habitats and treatment with diethyl-
carbamazine reduced the annual infective biting rate in
Tanzania by 99.7 percent (Maxwell and others 1990). In India,
vector control combined with single-dose treatment with
diethylcarbamazine plus ivermectin reduced the annual trans-
mission potential by 96 percent, compared with 60 percent
using chemotherapy alone (Reuben and others 2001).
Such results, along with the limitations of MDA for
completely eliminating microfilariae in some situations, have
reactivated the debate on the role of vector control in LF elim-
ination (Burkot and Ichimori 2002). However, few endemic
countries have an adequate vector control infrastructure.
In some African countries, the same vector species transmit
both LF and malaria. In such situations, the effect of malaria
control measures, particularly insecticide-treated bednets, on
LF vector densities and transmission needs further evaluation.
A review of the role and feasibility of community-based vector
control strategies and large-scale application of biological con-
trol agents is also needed.
Morbidity Management. The second objective of the Global
Programme for the Elimination of Lymphatic Filariasis is to
decrease the disability caused by LF. Simple and cheap methods
have been developed for managing lymphedema, using water
and soap occasionally supplemented with antibiotics. Studies
in India, Africa, and the Americas have shown that such
methods can significantly improve the quality of life of those
affected, but implementation of this strategy has greatly lagged
behind the MDA campaigns.
Onchocerciasis
Onchocerciasis control is based on vector control and large-
scale ivermectin treatment.
Vector Control. Vector control used to be the only feasible
intervention when available drugs were too toxic for large-
scale use. Following success with vector control in Kenya, where
the application of larvicides resulted in local elimination of
the vector S. neavei, and in selected locations in West Africa,
where the application of larvicides effectively stopped local vec-
tor breeding but could not prevent reinvasion of infective
vectors from elsewhere, vector control was considered feasible
in the West African savanna if carried out on a large scale. In
1975, the OCP started large-scale vector control operations
using helicopters for weekly spraying of larvicides over the vec-
tor breeding sites in river rapids (Molyneux 1995). The opera-
tion ultimately covered some 50,000 kilometers of rivers over a
geographic area of 1,235,000 square kilometers. The OCP’s
strategy was to maintain vector control for at least 14 years to
interrupt transmission and eliminate the parasite reservoir.
Despite initial problems with reinvasion by infective flies, the
strategy proved effective, eliminating onchocerciasis as a public
health problem throughout the OCP area. The OCP was suc-
cessfully concluded in 2002, but concerns remain about the
possible recrudescence of onchocerciasis through reinvasion by
infected blackflies or migration of infected persons into OCP
areas. The OCP countries, therefore, need to maintain effective
surveillance to identify any recurrences of infection (Richards
and others 2001).
Treatment with Ivermectin. In 1987, Merck & Co., the
manufacturer of ivermectin, agreed to donate the drug for
onchocerciasis control for as long as needed (Peters and
Phillips 2004). Clinical and community trials involving more
than 70,000 people showed that annual ivermectin treatment
was safe, prevented ocular and dermal morbidity, and signifi-
cantly reduced transmission; however, ivermectin is a microfi-
laricide and does not kill the adult worms, and long-term
treatment is needed to sustain suppression of the microfilarial
load (Remme 2004b). Additional research is needed to deter-
mine the extent to which repeated treatments reduce the
reproductive capacity of the adult worm population over time.
The introduction of ivermectin allowed the OCP to achieve
its objective in 12 years instead of 14 by combining vector con-
trol with ivermectin treatment, but most important, it also pro-
vided an opportunity to control onchocerciasis in endemic
areas outside the OCP where vector control was not feasible.
This ability led to the creation of two other regional programs
for controlling onchocerciasis in endemic areas of Africa and
the Americas: APOC (Remme 1995) and the Onchocerciasis
Elimination Program for the Americas (OEPA) (Richards and
others 2001).
The World Bank and WHO launched APOC in 1995 to
serve 19 onchocerciasis-endemic countries outside the OCP.
APOC’s principal strategy is to establish annual ivermectin
distribution in highly endemic areas to prevent eye and skin
morbidity. In partnership with ministries of health and non-
governmental organizations, APOC currently provides more
than 35 million ivermectin treatments per year and aims to
reach 65 million treatments per year before its scheduled
termination in 2010. APOC uses an approach referred to as
community-directed treatment with ivermectin, whereby local
communities rather than health services direct the treatment
process (Amazigo and others 2002). A community decides col-
lectively whether it wants ivermectin treatment, how it will col-
lect ivermectin tablets from the medical supply entity, when
and how the tablets will be distributed, who will be responsible
for distribution and recordkeeping, and how the community
will monitor the process. Health workers provide only the nec-
essary training and supervision. To date, communities have
responded enthusiastically to this approach (Seketeli and
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others 2002), and interest is now growing in exploring this
strategy for interventions against other diseases (Homeida and
others 2002).
In the Americas, O. volvulus transmission occurs only in a
few small areas in six endemic countries. Accordingly, OEPA’s
strategy is based on intense ivermectin treatment twice a year
that should allow eventual cessation of ivermectin delivery
without the risk of recrudescence (Richards and others 2001).
OEPA was launched in 1992 and is currently reaching more
than 85 percent of its intended target population.
Leprosy
The objectives of leprosy control are to interrupt transmission,
to cure patients, to prevent the development of associated
deformities, and to rehabilitate those patients already afflicted
with deformities. The strategy involves early case detection
and the provision of adequate chemotherapy and comprehen-
sive patient care (ILA 2002).
Multidrug Therapy. Dapsone therapy for leprosy was intro-
duced in the late 1940s and successfully used as monotherapy
for two decades. In the 1970s, resistance to dapsone emerged,
and WHO introduced multidrug therapy (MDT) in 1982.
Paucibacillary patients were to be given a six-month regimen
of daily dapsone and supervised monthly rifampicin.
Multibacillary patients were to be treated with a three-drug
regimen for two years or, where feasible, until the skin smear
had become negative. This regimen followed the paucibacillary
regimen, adding a smaller daily dose of clofazimine and a larger
supervised dose once a month.
These regimens have had good results, with a relapse
incidence of less than 0.1 percent per year (ILA 2002). No
multidrug-resistant leprosy has been reported so far, and
reports of rifampicin-resistant M. leprae have been few. In
1998, the standard multibacillary MDT regimen was shortened
to 12 months. Long-term relapse rates for the 12-month regi-
men are not yet available.
Public health specialists expected that wide application of
MDT together with earlier diagnosis resulting from the up-
grading of leprosy services would have a considerable effect on
transmission; however, by 2002, clear evidence of a reduction
in transmission had not been seen.
Immunoprophylaxis and Chemoprophylaxis. Several ran-
domized trials have shown that vaccination with the bacillus
Calmette-Guérin (BCG) vaccine reduces the risk of develop-
ing leprosy (Fine and Smith 1996), with the level of protection
varying from 20 to 80 percent. Chemoprophylaxis based on
dapsone or intramuscular acedapsone conferred overall pro-
tection against leprosy of about 60 percent (Smith and Smith
2000). Two large trials are currently under way in Bangladesh
and Indonesia to investigate the efficacy of one or two doses
of rifampicin in preventing leprosy, with preliminary results
from the Indonesian trial indicating a significant protective
effect.
Prevention of Disabilities. As concerns primary prevention,
leprosy-related disability is preventable, but when peripheral
neuropathy has become established, it is irreversible and leads
to lifelong morbidity and disability (Bekri and others 1998;
Meima and others 1999). Early case detection and treatment
are therefore likely to be the most effective interventions in
relation to preventing disability. When detected and treated
in time with corticosteroids, primary impairments may be
reversible, but because many patients present late, some 11 to
51 percent do not recover or get worse.
In relation to secondary prevention, the main strategy is
self-care to prevent worsening of impairments in people who
already have irreversible neural impairment or secondary
impairments such as wounds and contractures. The role of
health care workers is to educate patients so that they can be
responsible for the daily management of the effects of nerve
function impairment. An essential part of secondary preven-
tion is the use of protective footwear by people with anesthetic
feet. Several studies have shown that the use of locally
acceptable, appropriate footwear is a cost-effective interven-
tion for those with a loss of plantar sensation (ILA 2002).
Reconstructive surgery, protective footwear for people with
insensitive feet, and assistive devices to correct or prevent activ-
ity limitations are also used in secondary prevention.
As concerns tertiary prevention, the stigma attached to
leprosy often prevents patients from participating in normal
community activities. Strategies include counseling of those
affected and their families, neighbors, and communities; voca-
tional training; and advocacy work.
Rehabilitation. Impairments often lead to activity limitations
and restrictions on social participation, which can be prevented
by correcting the underlying impairment if it is not yet irre-
versible. After impairment is established, activity limitations
can still be minimized with the help of reconstructive surgery
or appropriate assistive devices, such as orthoses, grip aids,
calipers, or prostheses. A large but unknown percentage of peo-
ple succeed in overcoming activity limitations by themselves.
Some require rehabilitation interventions, such as physical or
occupational therapy, reconstructive surgery, or temporary
socioeconomic assistance.
Intervention Effectiveness
For all four diseases covered in this chapter, interventions are
available that are effective under routine control conditions.
The feasibility of eliminating these diseases as public health
problems from most endemic areas is therefore not in doubt;
however, questions remain about the effectiveness and
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sustainability of control under specific conditions and about
the feasibility of eliminating the parasites and transmission.
The vector control strategy for Chagas disease worked well in
the Southern Cone countries, but the sylvatic reservoir of T.
cruzi remains unaffected, and continued surveillance will be
essential. Vector control is more challenging in the Andean and
Central American countries, where some of the vectors are not
domiciliated. For LF, the number of years of MDA and the
treatment coverage required to interrupt transmission remain
unknown, just as the epidemiological conditions and the num-
ber of rounds of ivermectin treatment required to achieve the
same for onchocerciasis are not yet known. For leprosy, the key
questions remain how much effect MDT has on transmission
and when the incidence of new cases can be expected to decline
significantly. Hence, the sustainability of control remains a
critical issue.
The control programs for three of the diseases depend on
drug donations. To date, the pharmaceutical companies donat-
ing the drugs and the donors supporting drug distribution
have shown impressive commitment to the programs, but if
their commitment were to lapse, the control programs would
collapse and the diseases would return as public health prob-
lems. Another risk is drug resistance. The control programs rely
on just a few drugs, and even though drug resistance is not cur-
rently apparent, if it were to emerge, the essential tools for con-
trol would be lost. Hence, although elimination is in sight, the
battle has not yet been won, and research to develop new and
improved interventions and strategies for these tropical dis-
eases remains important.
COSTS AND COST-EFFECTIVENESS
OF INTERVENTIONS
The published information on cost-effectiveness of interven-
tions for the four diseases is incomplete, and this section pro-
vides some new data on the cost per DALY averted that is not
available in the literature.
Chagas Disease
For the Southern Cone countries, investment in the control of
Chagas disease since 1991 has been about US$320 million, well
within the original estimates of US$190 million to US$350 mil-
lion (Schofield and Dias 1991). Initial predictions of cost-
effectiveness suggested an internal rate of return (IRR) for the
initiative of about 14 percent, but point studies during the
course of the interventions suggest actual IRRs of about 30 per-
cent for Brazil (Akhavan 1998) and more than 60 percent for
the province of Salta, Argentina (Basombrio and others 1998).
Brazil had an estimated 2 million infected individuals in
1995. Annual follow-up of the 1.6 million asymptomatic cases
would have cost US$98 million. Diagnosis of megasyndromes
for 6 percent of infected individuals at an average cost of
US$141 each would add US$16.9 million, and corrective sur-
gery for 3 percent of the latter would add US$60 million.
Cardiac pacemakers for 5 percent of infected individuals at
US$3,000 each would add another US$30 million, so that the
partial direct costs for medical attention in Brazil in 1995–96
would have been US$205 million.
In Argentina, the costs for medical attention in 1992 were
US$435 for acute cases, US$122 per patient for asymptomatic
cases, US$336 for moderate cardiopathy, and US$1,135 for
severe cardiopathy. Given that Argentina had 2 million infected
individuals, and assuming that 85 percent of them would have
been asymptomatic,9 percent would have had mild cardiopathy,
4 percent would have had moderate cardiopathy, and 2 percent
would have had severe cardiopathy, then total expenditures for
medical attention would have amounted to US$457 million.
In Chile, aggregate treatment costs were estimated at US$37
million in 1991. New estimates in 1997 using the government
payment schedule and an estimate of 142,000 people infected,
including 26,545 with myocardiopathy of which 9,652 were
severe cases, resulted in an estimated cost of US$14 million to
US$19 million. In Uruguay, annual costs for treatment were
estimated at US$15 million for 1996.
These treatment costs are significantly higher than the costs
of vector control, which for 1996 were US$13 million in
Argentina, US$28 million in Brazil, US$650,000 in Chile, and
US$4,000 in Uruguay. Akhavan’s (1998) study in Brazil esti-
mates a cost of US$260 per DALY prevented, and Robles’s
(1997) study in Bolivia indicated a cost of US$362 to prevent
one year of life lost.
Data on the cost-effectiveness of treating those infected are
sparse; however, Robles’s (1997) study in Bolivia estimates the
costs of treating infected children under the age of five, coming
up with a cost of US$3,009 per death averted or about US$100
per DALY averted.
Lymphatic Filariasis 
The most widely used interventions for LF control are MDA,
vector control, and administration of diethylcarbamazine-
fortified salt. We estimate the cost-effectiveness of those strate-
gies in terms of DALYs averted from studies in India on the
costs and effectiveness of control and for different scenarios for
the minimum duration of control required to achieve sus-
tained interruption of transmission. These scenarios assume
that all three strategies are implemented in areas with similar
levels of endemicity of Culex-transmitted Bancroftian filariasis
and that the available cost data for India apply.
We consider three scenarios (table 22.2). Elim1 is an opti-
mistic elimination scenario under which sustained interrup-
tion of transmission is achieved after a relatively short period
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of intervention (six annual rounds of MDA, 10 years of vector
control, and 2 years of diethylcarbamazine-fortified salt). Elim2
is a conservative elimination scenario under which sustained
interruption is achieved only after a longer period of interven-
tion (10 years of MDA, 15 years of vector control, and 4 years
of diethylcarbamazine-fortified salt). Control is a scenario
under which transmission is brought to low levels but not
interrupted and where control efforts will have to continue.
Because of the slow dynamics of filariasis transmission and
disease, the prevalence of the chronic disease manifestations
(lymphedema and hydrocele) on which the DALY estimates are
based will not fully reflect the effect of control for many years.
We have therefore tried to predict the trend in chronic disease
over a 30-year period. Recent findings from a longitudinal
study (Ramaiah and others 2003) of the effect of MDA in
Pondicherry, India, showed that the prevalence of hydrocele
and lymphedema had declined by 58 percent after seven annual
treatment rounds with diethylcarbamazine. We assumed that
from the seventh year of intervention, any further reduction in
disease prevalence was attributable exclusively to reduced inci-
dence as a result of reduced transmission, and that 30 years
after the initiation of the intervention, the prevalence of disease
would have fallen by 90 percent. We assumed that the effect of
diethylcarbamazine-fortified salt was similar to that of MDA,
whereas for vector control we assumed that prevalence would
decline with a delay of seven years.
The predicted costs per DALY averted (table 22.3) indicate
that MDA and diethylcarbamazine-fortified salt are extremely
cost-effective. Elimination with MDA costs about US$4 to
US$8 per DALY averted, and even if transmission were not
interrupted and MDA would have to be continued for 30 years
(control scenario), the cost would be still only be around
US$29 per DALY averted. Diethylcarbamazine-fortified salt
would be the cheapest intervention, but governments rarely
favor it, and compliance can be difficult to ensure. Vector
control is at least 10 times more expensive in terms of DALYs
averted, but it offers additional benefits in terms of malaria and
dengue control and significant relief from mosquito nuisance.
The effect of MDA on hydrocele and lymphedema is not yet
well established and the results of the Indian trial on which
the previous calculations are based may be too optimistic.
However, even under much less favorable assumptions that the
prevalence of hydrocele and lymphedema declines by 20 per-
cent after 7 years of MDA and by 75 percent after 30 years, the
estimated cost per DALY averted would be only 50 percent
higher than those given in table 22.3, and the interventions
would still be very cost-effective.
The prevention of chronic disease also has direct economic
benefits (Ramaiah and Das 2004). The cost of preventing one
case of chronic disease through six rounds of MDA in India has
been estimated at US$8.41. The economic benefits include sav-
ings of 58.24 working days per year per case, yielding wages of
US$39.39 and treatment costs of US$1.44. On average, chronic
patients lose 11 years of productive life; thus, the average eco-
nomic benefits total US$449.13 per chronic case averted. This
figure gives a benefit-cost ratio of 52.6, perhaps one of the
highest for any disease control program.
Onchocerciasis 
Investment in onchocerciasis control has included about
US$570 million provided by donors to the OCP during
1975–2002, US$140 million provided and earmarked for
APOC for 1996–2010, and US$10 million for OEPA for
1991–2003. The African onchocerciasis control programs are
considered highly cost-effective. No cost-benefit analysis has
yet been published for OEPA.
The OCP has been highly successful. More than 40 million
people in the program’s 11 countries are now considered free
from infection and eye lesions, more than 1.5 million people
are no longer infected, and more than 200,000 cases of blind-
ness have been prevented. Sixteen million children born since
the program began are free of onchocerciasis. The socioeco-
nomic effect has also been dramatic: 25 million hectares of fer-
tile land in the river valleys were made available for resettle-
ment and agriculture. A cost-benefit analysis of the OCP has
estimated the net present value for the OCP over a 39-year
project horizon from 1974 to 2002 as US$485 million (Kim and
Benton 1995). This figure corresponds to an IRR of 20 percent,
resulting mainly from increased labor because of prevention
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Table 22.2 Costs per DALY Averted for LF
Mass drug Diethylcarbamazine-
administration Vector control fortified salt
Scenario Elim1 Elim2 Control Elim1 Elim2 Control Elim1 Elim2 Control
Duration (years) 6 10 30 10 5 30 2 4 30
Costs of control operations 0.35 0.65 2.22 2.92 6.64 22.74 0.09 0.29 3.56
per capita (US$) 
Cost per DALY averted (US$) 4.40 8.10 29.00 47.50 84.30 302.50 1.10 3.62 46.48
Source: Authors’ calculations. 
of blindness (25 percent of benefits) and increased land use
(75 percent of benefits).
A similar cost-benefit analysis for APOC also considered
benefits in terms of additional labor resulting from blindness
prevention (Benton 1998). It did not consider land use because
depopulation of river valleys is rarely seen in APOC countries,
where the forest type of onchocerciasis predominates.
Nevertheless, the estimated IRR for APOC remained almost as
high as that for the OCP (17 percent), because the cost is lower
but the number of people served is far greater.
The estimated rates of return for the OCP and APOC did
not include the effects of control on onchocercal skin disease.
Hence, these rates underestimate the benefits, because trouble-
some itching accounts for more than 50 percent of the DALYs
attributable to onchocerciasis. The cost of ivermectin, which is
donated by Merck, was not included in our analyses.
To estimate the approximate cost per DALY averted, we con-
sidered the burden of disease and treatment with ivermectin
in APOC countries. Using the latest epidemiological mapping
data, we estimate that, in 1995, 34.6 million people were
infected in APOC countries and that 1.86 million DALYs were
lost. Currently more than 44 percent of those infected are cov-
ered by community-directed treatment with ivermectin, and
expectations are that treatment will be expanded to cover most
of the remainder before the end of APOC in 2010. Information
from areas where ivermectin treatment has been in effect for
more than 15 years shows that the prevalence and intensity of
onchocerciasis infection have fallen to low levels (Borsboom
and others 2003), and computer simulations predict that the
disease could not become a public health problem again for at
least another 10 to 20 years if treatment were halted (Remme,
Alley, and Plaisier 1995). We therefore estimate that 15 years of
ivermectin treatment at 65 percent coverage will prevent at least
25 years of onchocercal disease. If we assume that 70 percent
of endemic communities will ultimately be covered by
community-directed treatment with ivermectin and that
80 percent of those communities will maintain annual treat-
ment at 65 percent coverage for at least 15 years, at least 26 mil-
lion DALYs would be prevented over a 25-year period.
The predicted cost of community-directed treatment with
ivermectin in APOC countries is US$145 million by the inter-
national donor community plus US$64 million by ministries of
health and collaborating nongovernmental organizations,
giving a total of US$209  million. Therefore we estimate that
the cost of community-directed treatment is approximately
US$7 per DALY averted.
The ultimate cost-benefit of onchocerciasis control will
depend on how long effective control programs will need to be
maintained to keep the disease under control. National govern-
ments and ministries of health should plan to invest in
ivermectin distribution and in surveillance activities for the
foreseeable future. Thus, a case must continually be made with
national decision makers that if investments do not continue,
recrudescence of infection is likely. One strategy for sustaining
national investment is to show that ivermectin distribution sys-
tems can be made polyfunctional. Treatment programs based
on MDA for intestinal parasites, schistosomiasis, and LF and on
vitamin A distribution can be integrated with ivermectin dis-
tribution programs and thereby further improve cost-benefit
ratios. The use of community-directed treatment with iver-
mectin is also envisaged as a way of strengthening peripheral
and district health systems (Homeida and others 2002).
Leprosy
Costs associated with leprosy control include case detection,
treatment, prevention of disability, and rehabilitation. We cal-
culate the incremental health service cost to arrive at the aver-
age cost of curing a patient with leprosy. Our estimates are
based on the limited published cost data available, program
expenditure data, and expert opinion, although costs are likely
to differ substantially by country.
As case-detection rates decrease, the average cost of detect-
ing one case increases. The previous edition of this volume
estimated a cost of US$2 per case detected based on a 
case-detection rate of about 300 per 100,000; however, case-
detection rates are now considerably lower in most countries
(Dharmshaktu and others 1999; Ganapati and others 2001;
Smith 1999). Many leprosy control programs now rely on vol-
untary case finding supported by information, education, and
communication activities to raise or maintain people’s aware-
ness of the early signs and symptoms of leprosy. We estimate
the cost of this approach to be about US$1 per case detected.
Nevertheless, if active methods are still used in areas where
case-detection rates are low, the cost of case detection may be
as high as US$108.
The costs of diagnosing and treating leprosy have fallen in
the past decade, and diagnosis by clinical examination only is
now recommended. We therefore exclude the cost of skin
smears. In addition, a shortening of the treatment regimen has
lowered drug costs to about US$12 for a multibacillary case
and US$1 for a paucibacillary case. Globally, almost 40 percent
of leprosy cases are classified as multibacillary cases, with the
remaining 60 percent being paucibacillary cases. Thus, we esti-
mate the average drug cost as US$5.40 per case.
The cost of treatment, however, is more than the cost of
drugs alone. WHO guidelines recommend that a multibacillary
case receive supervised treatment for 12 months and that a
paucibacillary patient receive treatment for 6 months. Using
cost data from Ethiopia and Pakistan, we estimate these
treatment costs at US$20 to US$30 in low-income countries.
Data from studies of tuberculosis interventions show that
community-supervised treatment may reduce costs by up to
50 percent (Khan and others 2002), and this approach is being
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advocated as part of “flexible MDT delivery” (ILA 2002) and
“accompanied MDT” (WHO 2002b). Reducing the nondrug
costs of treating leprosy to about US$10 to US$20 per patient
may, therefore, be possible. We thus estimate the costs of treat-
ing a case of leprosy with MDT to be between US$15.40 and
US$35.40 per case, depending on the strategy used.
About 10 to 20 percent of new leprosy cases are likely to suf-
fer a reaction during or after MDT. We estimate treatment of
those reactions to cost US$25 per patient. Of these patients,
1 percent may develop severe complications requiring hospital-
ization, at an estimated cost of US$480 per patient. In addition,
10 percent of new cases will develop neural or secondary
impairments and may require footwear and education about
wound management. We estimate the lifetime cost of protec-
tive footwear at US$300 per patient (Seboka, Saunderson, and
Currie 1998) and education at US$10 per patient. In 1 percent
of cases, reconstructive surgery may be required at about
US$455 per patient. We therefore estimate the average incre-
mental cost of interventions for prevention of disability to be
US$44.15 per new case of disability. Because about 3 percent of
new patients will need rehabilitation, we estimate the average
cost at under US$1 for each new case of leprosy detected
(Jagannathan and others 1993). However, a backlog of old cases
exists. Although data in this area are weak, up to a third of the
4 million people living with leprosy globally (2 million with
grade 1 disability and 2 million with grade 2 disability) could
require rehabilitation.
Few data are available on the program costs associated with
leprosy. A review of expenditure in Asia found that up to
40 percent of the total costs could be classified as programmatic
costs, although this amount may now be less because leprosy
programs have increasingly been integrated into general health
services. Data from Indonesia demonstrate that program costs
can be reduced by up to 35 percent by integrating them with
tuberculosis programs (Plag 1995). We therefore estimate the
average cost of finding, treating, and preventing disabilities and
rehabilitating a new case of leprosy at US$76 to US$264.
In practice, many leprosy programs will also be providing
disability prevention and rehabilitation interventions to a large
backlog of patients, so the average cost per new case will be
higher than here. Programs that face a high proportion of
multibacillary cases and cases presenting with high levels of
disability are also likely to have higher costs.
Assuming a cure rate of around 85 percent, we estimate the
costs of curing one patient of leprosy to be about US$93 per
new case. Using data from India (25 percent of those with lep-
rosy will self-cure, an average age of onset of 27, a disability
weighting of 0.152, and a life expectancy at age 25 to 29 of
44.75), we estimate the cost per DALY of detecting and treating
a new case of leprosy to be US$38.
In addition, assuming a 90 percent success rate, we calculate
a cost per DALY of US$7 for patients needing treatment for
reactions and ulcers, US$75 for those needing footwear and
self-care education, and US$110 for those needing reconstruc-
tive surgery. These estimates provide only a broad indication
because data on the effectiveness of these interventions are
scarce, and the application of the disability weight of 0.152 to
all interventions may overestimate their benefits.
Data on the economic effect of leprosy at the national level
are not available. However, leprosy affects those who are eco-
nomically active, with a peak in incidence at 10 to 20 years of
age and again at 30 to 50 years of age. Studies of the impact of
leprosy on productivity show that deformity from leprosy can
reduce the probability of obtaining employment and can
reduce household income and expenditure on food (Diffey and
others 2000; Kopparty 1995). In addition, leprosy can have a
significant social impact because participation in the commu-
nity may be restricted. This impact continues well beyond the
actual treatment period because leprosy-related impairments
have a tendency to get worse over time even after the infection
has been arrested.
Summary
Available information indicates that interventions for the four
diseases are highly cost-effective and that the benefit-cost ratio
of control is high (table 22.3).
RESEARCH NEEDS AND PRIORITIES 
Because the diseases in this chapter are targeted for elimination
as public health problems, it is sometimes assumed that
research for these diseases is no longer necessary and that all
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Table 22.3 Cost-Effectiveness Estimates for the Main
Interventions for Each Disease 
Cost per DALY Internal rate of 
Intervention averted (US$) return (percent)
Chagas disease
Vector control 260 30–60 
Treatment (children under five) 100 —
LF
MDA 4–29 —
Diethylcarbamazine-fortified salt 1–46 —
Vector control 48–303 —
Onchocerciasis
MDA 7 17 (APOC)
Vector control — 20 (OCP)
Leprosy
Case detection and treatment 38 —
Prevention of disability 1–110 —
Source: Authors’ calculations. 
MDA  mass drug administration, —  not available.
available resources should be allocated to elimination efforts.
However, research remains critical to address questions per-
taining to how to achieve elimination with currently available
tools and especially to how to optimize implementation in dif-
ferent epidemiological, sociocultural, and health system set-
tings. Epidemiological questions on the required intervention
coverage, frequency, and duration need to be answered to guide
elimination strategies, and research on the risk, prevention, and
control of recrudescence is crucial to ensure sustained success.
The Special Programme for Research and Training in
Tropical Diseases, a joint project of the United Nations
Children’s Fund, United Nations Development Programme,
World Bank, and WHO, recently undertook a systematic analy-
sis of research needs for each of the 10 tropical diseases in its
portfolio (Remme and others 2002). This analysis involved
assessing the burden of disease and recent epidemiological
trends, reviewing current control strategies, and identifying the
major problems and challenges for disease control and the
research needed to address these challenges. Table 22.4 summa-
rizes the results of this analysis for the four diseases discussed
in this chapter.
Chagas disease has two main research priorities. The first is
the development of new vector control strategies that will allow
the successful elimination campaign used in the Southern
Cone countries to be extended to the Central American and
Andean countries, where the vectors are often not domiciliated.
The second is the development of effective and affordable treat-
ment for the millions of people already infected and the pre-
vention of chronic complications.
For onchocerciasis and LF, the main research priorities are
similar: implementation research to improve MDA; epidemio-
logical research to determine if, when, and with what treatment
coverage the parasite reservoir can be locally eliminated for dif-
ferent vector-parasite complexes; and research to develop a
macrofilaricide and improved diagnostics that would facilitate
elimination.
For leprosy, the research needs were further reviewed during
a Scientific Working Group (Special Programme for Research
and Training in Tropical Diseases 2003). The meeting arrived at
a clear consensus of three top priorities for leprosy research:
implementation research on sustainable and integrated resid-
ual leprosy control activities, improved diagnosis of infection,
and improved approaches for preventing and managing nerve
damage.
These are the current main priorities for research in support
of elimination. Eradication is not currently anticipated for any
of the diseases; thus, research on better tools and strategies that
will allow a permanent solution for these infectious diseases is
also needed. Furthermore, currently available control tools may
be lost because of factors such as resistance, and research to
develop replacement tools is essential now.
CONCLUSION
Tropical diseases are often viewed as neglected, because the
investments made to fight them appear negligible compared
with the massive amounts expended globally on the health
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Table 22.4 Control Strategies, Major Challenges, and Research Needs for Each Disease
Disease Principal control strategy Major problems and challenges Major research needs
Chagas disease
LF
Onchocerciasis
Leprosy
Interruption of transmission through domestic
vector control and improved blood transfusion
Interruption of transmission through periodic
mass treatment 
Disability alleviation by local hygiene measures
Periodic mass treatment to eliminate the
disease as a public health problem
Case finding and multidrug treatment 
Rehabilitation and prevention of disability
Control of nondomiciliated vectors
Sustained vector control
Millions of those infected still at risk of
disease
Need for high treatment coverage
Unknowns in elimination strategy
Limited effect of current drugs
Need to sustain high coverage for decades
Risk of ivermectin resistance
Eradication not possible with current tools
Incomplete MDT coverage
Need to integrate and sustain control
Impact on transmission not known
Strategies for surveillance of nondomicil-
iated vectors
Better drugs and diagnostics
Strategies for high treatment coverage 
Evidence base for elimination strategies
Drug that kills or sterilizes adult worms
Strategies for sustained high treatment
coverage 
Feasibility of elimination with ivermectin
Drug that kills or sterilizes adult worms
Integration and sustainability of control
Improved diagnosis of infection
Prevention and management of nerve
damage
Source: Remme and others 2002.
problems of developed countries. Tropical diseases are truly
diseases of the poor, but despite the limited resources available
for research and control, simple and effective interventions
have been developed and delivered to populations in need for
the four tropical diseases discussed in this chapter. Thus, expe-
rience with these four diseases sends a powerful message: suc-
cess is possible, even for neglected tropical diseases of poor
populations in developing countries. Elimination of these dis-
eases as public health problems can be achieved, and invest-
ments in tropical disease research and control can make a sig-
nificant contribution to poverty reduction.
An important reason for the success was that the interven-
tions were extremely cost-effective. The available cost-
effectiveness data, though limited, show convincingly that
intervention against these diseases is a good investment, and
the argument for investment gets better when other economic
benefits, not reflected in DALYs, are taken into account, such as
increased food production when fertile land along river valleys
became available for agriculture after the control of onchocer-
ciasis in West Africa and increased labor productivity after
effective filariasis control in India.
The pharmaceutical industry also played a major role
through large drug donations, and the creation of intercountry
control programs provided effective mechanisms for imple-
menting interventions, technical support, and coordination.
Another reason for the success was a focused research program
that ensured the development of interventions based on simple
and sustainable approaches that use cheap and “appropriate”
technology and that are potentially multifunctional.
Chagas disease, LF, onchocerciasis, and leprosy are now on
target for elimination as public health problems from large
parts of the world. However, these diseases cannot be eradi-
cated using current tools, and much remains to be done to
expand and sustain the control efforts and undertake the nec-
essary research to improve the control efforts as well as to
develop more definite solutions. It will be essential, therefore,
that donors and ministries of health not abandon these pro-
grams because of their success.
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Dengue, leishmaniasis, and African trypanosomiasis (sleeping
sickness) are serious diseases that the World Health
Organization (WHO) characterizes as lacking effective control
measures. They are transmitted by insect vectors and can result
in epidemic outbreaks. Specific treatment is unavailable for
dengue, although good supportive treatment can drastically
reduce mortality. For the leishmaniases and for sleeping sick-
ness, treatment relies largely on antiquated drugs based on
antimony and arsenic, respectively. Sustained control of the
insect vectors is difficult for dengue and leishmaniasis because
their high reproductive potential allows the vector populations
to recover quickly after intervention wherever adequate breed-
ing conditions exist. By contrast, tsetse flies, the vectors for
sleeping sickness, have a much lower reproductive potential
and could be eliminated over large areas, given adequate organ-
ization and surveillance. Through the African Union, African
nations are developing a large-scale initiative for areawide
elimination of tsetse flies, partly because of sleeping sickness,
but also because of their importance as vectors of animal try-
panosomiasis, which poses a serious constraint to livestock
development and agriculture.
DISEASE CHARACTERISTICS
AND TRANSMISSION
Dengue
Dengue is a mosquitoborne viral disease with a high capacity
for epidemic outbreaks. Infection can be asymptomatic or can
present with symptoms ranging from mild, self-limiting,
febrile illness to severe, life-threatening disease. Two clinical
pictures are recognized: (a) dengue fever (DF) and (b) dengue
hemorrhagic fever (DHF) or dengue shock syndrome (DSS).
The four dengue serotypes, known as dengue 1, 2, 3, and 4,
constitute a complex of the flaviviridae transmitted by Aedes
mosquitoes, particularly Ae. aegypti. Infection by any of the
four serotypes induces lifelong immunity against reinfection by
the same serotype, but only partial and transient protection
against the others. Sequential infection by different serotypes
seems to be the main trigger for DHF/DSS.
Disease Manifestations. The incubation period is four to six
days. Infants and young children usually develop fever, some-
times accompanied by a rash. Older children and adults may
develop either a mild febrile syndrome or classic DF with fever,
headache, myalgias, arthralgia, nausea, vomiting, and rash. Skin
bleeding, petechiae, or ecchymosis are observed in some
patients. Bleeding from the nose, gums, and gastrointestinal
tract; hematuria; or hypermenorrhea can accompany the clini-
cal picture. Leukopenia is common and thrombocytopenia is
sometimes observed. DF can be incapacitating, but the prog-
nosis is favorable and the case-fatality rate is low.
By contrast, DHF/DSS can be life threatening. It is character-
ized by high fever, bleeding, thrombocytopenia, and hemocon-
centration (Nimmanitya 1993; PAHO 1994). Plasma leakage
differentiates DHF/DSS from classic DF. Severity is classified as
mild (grades I and II) or severe (grades III and IV), with the
Chapter 23
Tropical Diseases Lacking Adequate
Control Measures: Dengue, Leishmaniasis,
and African Trypanosomiasis 
Pierre Cattand, Phillippe Desjeux, M. G. Guzmán, Jean Jannin,
A. Kroeger, André Médici, Philip Musgrove, Mike B. Nathan,
Alexandra Shaw, and C. J. Schofield 
main difference being shock in the latter. In some epidemics,
hepatomegaly has been prominent. As with DF, DHF generally
begins with a sudden temperature rise accompanied by facial
flush and other nonspecific manifestations, such as anorexia,
vomiting, headache, and muscle or joint pains. The most
common hemorrhagic manifestation is a positive tourniquet
test, although petechiae, ecchymosis, epistaxis, and gingival or
gastrointestinal bleeding may also be observed. After three or
four days, when the temperature returns to normal or below, the
patient’s condition can suddenly deteriorate with signs of circu-
latory disturbance. The patient may sweat, be restless, have cool
extremities, and show changes in pulse rate and blood pressure.
Many recover spontaneously or after brief fluid therapy, but
some proceed to shock with typical signs of circulatory failure.
Initially patients may be lethargic but become restless and rap-
idly enter a critical stage of shock. Some patients evolve to severe
circulatory failure (DSS), presenting a rapid and weak pulse, a
narrow pulse pressure or hypotension, cold and clammy skin,
and an altered mental state. DSS is fatal in 5 to 10 percent of
cases if fluid management is inadequate or delayed.
Transmission and Epidemiological Trends. The dengue virus
is transmitted from humans to humans by Aedes mosquitoes,
of which the most important is Ae. aegypti (Bennett and others
2002; Gubler 1979; Tardieux and others 1990). Female mosqui-
toes ingest the virus while feeding on viremic individuals, and
after an 8- to 12-day incubation period they can transmit the
virus to other humans during blood feeding (Watts and others
1987). Thereafter, the female mosquito remains infective for
life. Transmission of the virus from infected females to their
progeny has been documented, but its epidemiological signifi-
cance is not well understood (Hull and others 1984; Rosen and
others 1983).
Although believed to be of African origin, Ae. aegypti is now
established throughout the tropics and subtropics, exploiting
almost any water-filled container as larval habitat. Ae. aegypti is
also the urban vector of yellow fever. Ae. albopictus also trans-
mits dengue and is an important secondary vector in parts of
Southeast Asia and the Pacific. This species is of Asian origin
but has spread to parts of Africa, the Americas, and Europe by
depositing egg masses in used car tires, which are traded
around the world.
Major epidemics of denguelike illness were documented in
the 18th and 19th centuries in Africa, the Americas, and Asia,
and clinical descriptions of illness compatible with dengue in
China date from about 265. During 1900–50, dengue epi-
demics occurred in Australia, China, Greece, India, Japan,
Malaysia, Thailand, and Vietnam and in the Caribbean (Gubler
and Kuno 1997). DHF was first recognized in the 1950s,
although a similar hemorrhagic fever was reported in
Philadelphia in 1780, in Australia in 1897, and in Greece in
1928. Dengue is now endemic in Africa, the Americas, the
Eastern Mediterranean, Southeast Asia, and the Western
Pacific. According to WHO, it occurs in more than 100 coun-
tries and an estimated 2.5 billion people are at risk.
The increase in dengue epidemics can be attributed to rising
levels of urbanization, which promote contact between humans
and Ae. aegypti; inadequate domestic water supplies; and
increasing international travel, migration, and trade, which help
disseminate vectors and the virus. Epidemiological changes in
the Americas since the 1970s illustrate this process. During the
1940s through the 1960s, the Ae. aegypti control program was
successful in most of the region, with several countries declaring
complete eradication. However, after some years, reinfestation
with Ae. aegypti was apparent, and by 1995 it had returned to
most of the previously infested countries. Reinvasion by the vec-
tor was followed by increased circulation of the virus, and the
region evolved from nonendemic to hypoendemic (sporadic
epidemics caused by a single serotype) to hyperendemic (simul-
taneous circulation of multiple serotypes resulting in frequent
epidemics). DHF became a major public health problem. Before
1981, 5 countries in the region reported only a few cases of DHF,
but by 2002, 21 countries reported more than 14,000 cases and
250 deaths (Gubler 2002; Guzmán and Kouri 2002, 2003;
Guzmán and others 2002).
Leishmaniasis
Leishmaniasis (or the leishmaniases) refers to infections caused
by protozoan parasites of the genus Leishmania transmitted by
female sandflies (Phlebotominae). More than 20 Leishmania
species are pathogenic to humans, and more than 30 species of
sandflies are proven vectors. The disease tends to be focal in dis-
tribution. In anthroponotic foci, sandflies transmit parasites
from human to human, and in zoonotic foci, sandflies transmit
the parasites between mammal hosts and from them to humans.
Disease Manifestations. The different species of Leishmania
cause illness of differing severity. Visceral leishmaniasis (VL),
caused by species of the L. donovani complex, is usually fatal
if untreated. Mucocutaneous leishmaniasis, caused by the
L. braziliensis complex, is highly disfiguring and mutilating, and
it can be fatal because of secondary complications. Cutaneous
leishmaniasis (CL), caused by the L. major, L. donovani, and
L. braziliensis complexes, may be a simple, self-limiting skin
ulcer, but it can be disabling when numerous lesions occur.
Diffuse cutaneous leishmaniasis, caused by the L. mexicana and
L. aethiopica complexes, is longer lasting because of deficient
immune responses.
Epidemiological Trends. Leishmaniasis is found in 88 coun-
tries worldwide. VL occurs in 62 of those countries, with most
of the estimated 500,000 annual cases occurring in poorer rural
and suburban areas of Bangladesh, Brazil, India, Nepal, and
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Sudan. Mucocutaneous leishmaniasis is mainly limited to
South and Central America, whereas most of the estimated
1 million to 1.5 million annual CL cases occur in the Middle
East (Afghanistan, Algeria, the Islamic Republic of Iran, Saudi
Arabia, and the Syrian Arab Republic) and in Brazil and Peru
(Desjeux 1996). Reliable data on incidence and prevalence are
scarce because only 33 endemic countries provide official noti-
fication of infection.
Leishmaniasis transmission is increasing in several areas.
For example, the number of cases of CL in Kabul, Afghanistan,
increased from 14,200 in 1994 to 65,000 in 2002, and the num-
ber of cases of VL in northeastern Brazil increased from 1,840
in 1998 to 6,000 in 2002. Such increases reflect the following
environmental, land-use, and behavioral changes that increase
exposure to the sandflies:
• Rural-urban migration seems to have contributed to urban-
izing VL in Brazil, whereas in East Africa, VL seems to be
more closely associated with migrations of seasonal workers
and refugees. Transborder migrations between Bangladesh,
India, and Nepal are also a risk factor for VL.
• New settlements in high-risk endemic areas, such as those
established by people migrating from high plateaus to trop-
ical plains in some Andean countries, increase their expo-
sure to vectors.
• Development in areas of zoonotic transmission, such as
road building, mining, oil prospecting, forestry, and eco-
tourism, and military activity increase risks for those
involved (Desjeux 2001).
• Deteriorating social and economic conditions in the poorer
suburbs of some cities may contribute to increasing trans-
mission, especially of VL.
Leishmaniasis can be an opportunistic infection in people
with HIV/AIDS, and coinfections have been reported in
34 countries (Desjeux and Alvar 2003). Malnutrition or
HIV/AIDS coinfection can also increase disease severity by
impairing the immune response.
African Trypanosomiasis
African trypanosomiasis is caused by parasites transmitted by
tsetse flies (Glossinidae). The most important are forms of
Trypanosoma brucei that infect humans and livestock, and
T. congolense and T. vivax that infect only livestock. Human
infection causes severe disease known as sleeping sickness,
which is acute in the case of infection with T. brucei rhodesiense
but more chronic with T.b. gambiense. Both forms lead to cen-
tral nervous involvement and are fatal without appropriate
treatment.
Disease Manifestations. Parasites are transmitted by the bite of
infected tsetse flies. They multiply locally in extracellular spaces,
producing a characteristic lesion or chancre. The parasites cir-
culate in blood and lymph, resulting in waves of parasitemia
with episodes of fever, often accompanied by chills, rigor,
malaise, prostration, and weight loss. These symptoms may
occur within days of development of the chancre and constitute
the hemolymphatic early stage. Febrile episodes become less
severe as the disease progresses, and after a variable period the
parasites invade the central nervous system and cerebrospinal
fluid, leading to the late stage, with meningoencephalitis typi-
cally accompanied by severe and protracted headache, apathy,
sleep disorders, irritability, and antisocial behavior.
The clinical features of late-stage sleeping sickness can
resemble AIDS. With T.b. rhodesiense, meningoencephalitis
typically occurs within weeks of initial infection, whereas with
T.b. gambiense, this syndrome occurs later, sometimes after sev-
eral years. Untreated disease causes relentless deterioration in
cerebral function, with patients becoming increasingly difficult
to rouse and passing into coma and death. Infection does
not seem to confer immunity, so reinfection can occur after
treatment.
Transmission and Vectors. Male and female tsetse flies are
obligate bloodsuckers and can transmit trypanosomes, which
undergo cyclical development in the infected flies. With T.b.
gambiense, the main reservoir host is people, so tsetse flies
mainly transmit from person to person, although increasing
evidence suggests that pigs and some other animals are also
important reservoirs. With T.b. rhodesiense, the main reservoir
hosts are cattle and related animals, so transmission occurs
mainly from animals to humans, although transmission from
human to human also occurs (Okoth 1986). Mechanical (Frézil
1983), sexual (Rochas and others 2004), and transplacental (De
Raadt 1985; Libala, Wery, and Ruppol 1978; Traub and others
1978) transmission have been described but are believed to be
insignificant.
Thirty-one species and subspecies of Glossina are recog-
nized. All probably can transmit trypanosomes, but only eight
are known vectors for human infection. Animal trypanosomi-
asis can be found wherever wild tsetse flies occur, but human
trypanosomiasis is usually associated with historic foci with
strong epidemic potential. Most T.b. gambiense transmission is
attributed to G. palpalis species occupying riverine and forest
habitats in West and Central Africa, whereas T.b. rhodesiense
transmission is mainly attributed to G. morsitans species in East
African savannas. G. fusca species, although important vectors
of animal trypanosomiasis, are considered insignificant for
human forms.
Tsetse flies have an unusual life cycle. An inseminated female
nurtures the egg and larva in her uterus, depositing the mature
larva on the ground, where it burrows and pupates. Thus, each
female produces only one offspring at a time. She produces up
to 12 during her two- to three-month adult life span. The
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intrinsic population growth rate is low. Even small increases in
average daily mortality rates can cause population decline, even
to extinction.
Epidemiological Trends. Tsetse flies occur in parts of 37 coun-
tries in Sub-Saharan Africa. Animal trypanosomiasis is wide-
spread throughout this region, but human disease is focused in
areas of 20 countries. Over the entire tsetse-fly belt, WHO esti-
mates that 60 million people are at risk of infection, with a
standing prevalence of about 300,000 infections. Of these, prob-
ably fewer than 15 percent are diagnosed and treated (Cattand,
Jannin, and Lucas 2001). For T.b. rhodesiense, epidemiological
work in Uganda estimated that for every individual correctly
diagnosed and treated, a further 12 cases are undiagnosed and
unreported (Odiit 2003). The incidence of sleeping sickness has
been increasing steadily since the 1970s, with epidemics in sev-
eral areas, particularly the Democratic Republic of Congo
(DRC) and northern Angola. In 1998–99, some 45,000 new
cases were reported each year, representing a 10-fold increase
since the 1960s. Most current epidemics are due to T.b. gambi-
ense, although major epidemics of T.b. rhodesiense occurred in
Uganda in 1978, 1980, and 1988.
The apparent increase is largely attributable to a decline in
tsetse and trypanosomiasis control operations, which are influ-
enced both by changing political priorities and by civil unrest
and war. In the DRC, some 10,000 cases were diagnosed annu-
ally during the 1980s, but after four years with little or no con-
trol, the number of reported cases rose to 30,000 per year. In
Angola, cases rose sixfold following the interruption of control
operations because of war. Transmission is also occurring in
new locations. In 1999, urban and periurban transmission was
reported in Kinshasa, DRC, and in Luanda, Angola, and a new
focus was reported in Soroti, Uganda, where an epidemic of
T.b. rhodesiense disease followed the introduction of infected
cattle (Fèvre and others 2001).
DISEASE BURDEN
All three diseases affect substantial populations. Globally, WHO
estimates that 500,000 cases of DHF occur annually. Assuming
that DHF cases constitute 6 percent of all clinical dengue cases
(that is, all other cases are classical DF) implies a total of almost
8 million new infections per year. For leishmaniasis, current
estimates suggest an overall prevalence of 12 million people
infected in an at-risk population of 350 million, suggesting
more than 2 million new infections each year. The prevalence of
sleeping sickness is estimated at 300,000 people, with 60 million
people considered to be at risk. Uncertainty about the true
number of cases makes all these estimates approximate, partic-
ularly because incidence is increasing. In terms of disability-
adjusted life years (DALYs) lost to these diseases (table 23.1), a
dengue or trypanosomiasis death accounts for 27 to 28 DALYs
lost. Leishmaniasis kills less often than trypanosomiasis, but
each death is responsible for a loss of 34 DALYs.
Dengue
In hyperendemic areas of Southeast Asia, where multiple virus
serotypes are circulating, DF and DHF are mainly childhood
diseases and in some countries are leading causes of pediatric
hospitalization and death, particularly in Cambodia, Myanmar,
and Vietnam. Worldwide, 80 to 90 percent of deaths occur
before age 15. In recent years in the Americas, DHF in adults in
endemic form has been reported frequently (Diaz and others
1988; Guzmán and others 1999; Harris and others 2000; Zagne
and others 1994). In some countries, the disease is more fre-
quent among females, and in Cuba, significantly more severe
cases occur among Caucasians than among those of African
descent (Kouri, Guzmán, and Bravo 1987). Dengue causes rel-
atively few deaths, estimated at 19,000 in 2001, corresponding
to a case-fatality rate of 3.8 percent for DHF. Nonetheless, it can
cause a substantial burden: in Puerto Rico during 1984–94, the
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Table 23.1 Number of Deaths and DALYS Caused by Dengue, Leishmaniasis, and African Trypanosomiasis, by World Bank
Region, 2001
(thousands)
African
Dengue Leishmaniasis trypanosomiasis Total
Region Deaths DALYs Deaths DALYs Deaths DALYs Deaths DALYs
East Asia and the Pacific 8 217 2 48 0 0 10 265
Europe and Central Asia 0 0 0 6 0 0 0 6
Latin America and the Caribbean 2 59 0 37 0 0 2 96
Middle East and North Africa 0 8 1 48 1 22 2 78
South Asia 9 240 40 1,306 0 0 49 1,546
Sub-Saharan Africa 0 4 8 312 48 1,310 56 1,626
Total 19 528 51 1,757 49 1,332 119 3,617
DALY loss per million population was similar to that for the
entire Latin America and Caribbean region from malaria,
tuberculosis, intestinal helminths, and the childhood disease
cluster (Meltzer and others 1998).
Economic Impact. Studies in Thailand estimated the eco-
nomic impact of dengue as equivalent to US$12.6 million in
1994, of which patients and their families incurred 45 percent
(Okanurak, Sornmani, and Indaratna 1997). Kouri and others
(1989) estimate the cost of the 1981 DHF epidemic in Cuba at
US$103 million, constituting US$41 million in medical care,
US$5 million in social security disability payments, US$14
million in lost production, and US$43 million for vector
control. For Southeast Asia, Shepard and others (2004)
estimate individual treatment costs of US$139 for DHF and
US$4.29 for DF (including health clinic visits, hospitalization,
medications, travel expenses, and parents’ time seeking treat-
ment for their children). This estimate implies annual costs in
the region of US$105 million—US$69.5 million for DHF and
US$35.5 million for DF. Extrapolating from current trends (on
the basis of cases reported to WHO since 1960), this figure will
increase to an average of US$118 million each year through the
first decade of the 21st century. Using the Thailand study to
add the value of productive work lost doubles this figure to
US$236 million. Thus, during the next decade, Southeast Asian
economies could lose a total of US$2.36 billion because of DF
and DHF. Additional economic losses are expected because of
the impact of dengue outbreaks on tourism.
Social Impact. During the transmission season, parents famil-
iar with DHF are anxious about their children’s survival and
the financial consequences of emergency medical care. In
Cambodia, even relatively modest out-of-pocket health expen-
ditures can lead to debt and poverty (Van Damme and others
2004). The psychological burden is poorly understood and
warrants further study.
Even though dengue affects all strata of society, it may
selectively affect the poorest. Most larval habitats in dengue-
endemic communities are artificial: water storage containers,
flower vases, discarded food containers, used tires, and habitats
created by poor design of roof gutters and drains. Local vector
ecology is largely determined by community social and cultural
practices and infrastructure, and increasing urbanization typi-
cally attracts the poor to periurban settlements with deficient
water supplies. Studies in the República Bolivariana de
Venezuela (Barrera, Avila, and Gonzalez-Teller 1993; Barrera
and others 1995) and in Thailand (Nagao and others 2003)
have shown higher Ae. aegypti infestations where water distri-
bution systems are deficient or unreliable. Along the border
between Mexico and the United States, Reiter and others
(2003) attribute the low dengue seroprevalence reported in
Laredo, Texas, to factors such as air conditioning that limited
human-vector contact, whereas in contiguous Nuevo Laredo
on the Mexican side, where per capita income was one-seventh
of that in Laredo, seroprevalence was much higher despite
lower vector densities.
In countries with weak or unprepared health services,
epidemics of dengue can be extremely disruptive and health
services can be rapidly overwhelmed. Frequently, governments
declare states of emergency to mobilize additional resources
against dengue outbreaks, sometimes deploying the army to
eliminate or apply larvicides to larval habitats. These responses
are often launched at or after the peak of the epidemic, and the
decline in transmission is unjustifiably attributed to the inter-
vention rather than to the natural epidemic decline.
Leishmaniasis
In 2001, leishmaniasis killed an estimated 51,000 people,
including 40,000 in South Asia and 8,000 in Sub-Saharan
Africa, representing 0.3 percent and less than 0.1 percent,
respectively, of all deaths (table 23.1). Nearly all deaths occurred
at ages 5 to 29. Males were more affected than females, espe-
cially in Sub-Saharan Africa, where the ratio was three to one.
Economic Impact. Treatment for leishmaniasis is expensive,
especially for VL. For many countries, the cost of treating all
leishmaniasis patients would far exceed their total health
budgets. For a WHO-recommended course of pentavalent anti-
monials, current drug costs per patient are US$150 for sodium
stibogluconate, US$120 for meglumine antimoniate, and
US$30 for generic sodium stibogluconate. Cases not responding
to antimonials may require second-line, more toxic drugs, such
as amphotericin B at a cost of US$60 or pentamidine at a cost of
US$70. Less toxic amphotericin in liposomes is effective, but
costs US$1,500 per patient. The first oral drug for VL, miltefos-
ine, currently costs US$120 per patient.
In addition to drug costs, the additional costs of drug deliv-
ery can be high, especially for patients in remote areas. Patients
often live far from a treatment center, and the expense of hos-
pitalization may lead to interrupted treatment, facilitating
resistance and requiring additional therapy. Without treatment,
severe leishmaniasis can become chronic and debilitating, inca-
pacitating patients and making them unable to work and vul-
nerable to poverty, malnutrition, and secondary infections.
Social Impact. Even self-limiting CL can leave disfiguring
scars, which have associated stigma and may affect marriage
prospects. CL can be disabling when lesions are numerous, and
the most severe form, recidivans leishmaniasis, is difficult to
treat, long-lasting, and disfiguring. In individuals with a defec-
tive cell-mediated immune response, the disseminated lesions
of diffuse cutaneous leishmaniasis resemble those of leprosy.
They do not heal spontaneously and frequently recur after
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treatment. Diffuse cutaneous leishmaniasis is recognized as a
special public health problem, both clinically and because of its
severe emotional consequences.
The lesions of mucocutaneous leishmaniasis can cause
extensive destruction and distortion of oronasal and pharyn-
geal cavities, leading to mutilation of the face. Patients may be
shunned and, in severe cases, even incarcerated. Although
mainly associated with L. braziliensis and L. guyanensis in the
Americas, mucocutaneous leishmaniasis has been reported in
Africa, Asia, and Europe as a complication of L. donovani and
L. major infections and, in immunosuppressed patients, of
L. infantum.
Untreated VL is usually fatal. Even after recovery, patients
may develop a chronic form of CL that usually requires pro-
longed and expensive therapy.
African Trypanosomiasis
WHO estimates the number of deaths caused by sleeping sick-
ness as 48,000 in 2001 (table 23.1), although current estimates
are in the range of 50,000 to 100,000 per year. Men are affected
at nearly twice the rate of women. In relation to mortality, of all
parasitic diseases in Sub-Saharan Africa, trypanosomiasis ranks
behind only malaria. As concerns DALYs, the health burden is
similar to that of schistosomiasis. In Sudan, 33 DALYs on aver-
age are lost because of each premature death from sleeping
sickness (McFarland 2003). In Uganda, 23 DALYs were lost per
death, but only 0.21 DALYs per successfully treated individual
(Odiit and others 2004). Underreporting makes deriving esti-
mates for the whole continent difficult: 100,000 deaths per year
would imply more than 2 million DALYs lost, compared with
the WHO estimate of 1.31 million (830,000 for males and
480,000 for females) (table 23.1).
Economic Impact. Information on age at death indicates that
sleeping sickness mainly affects economically active adults.
Data from Uganda show nearly 25 percent of cases occurring in
those age 20 to 29 and more than 60 percent in those age 10 to
39 (Odiit 2003). Thus, when people become ill, their families
not only become burdened with the care of seriously ill indi-
viduals but also often lose their breadwinners. Poor diagnostic
support in many areas means that families often invest in a
number of treatments that have no effect on the disease. In a
T.b. rhodesiense area of Uganda, Odiit and others (2004) find
that some patients made up to seven visits to health facilities
before being correctly diagnosed, with just under three-
quarters initially being diagnosed with malaria. For the 11 of 12
who were never diagnosed or were told that they had a differ-
ent fatal disease, the costs to and burdens on their families can
only be imagined.
In addition to the economic losses caused by interruption
of their work, sleeping sickness patients face direct financial
costs. Even though WHO now provides specific first-line
drugs at no cost in excess of delivery and administration,
hospitalization and treatment are expensive. In the DRC,
Gouteux and others (1987) estimate that total costs are
equivalent to at least 25 percent of a year’s income from
agriculture.
Social Impact. The importance of sleeping sickness lies not
only in the number of new cases reported, but also in its
potential for epidemic outbreaks causing thousands of deaths:
during recent epidemics in the DRC, in some villages up to
70 percent of the population became infected. Because of the
severity of the disease, one case can affect all family members,
placing a burden on the whole community, reducing the labor
force, interrupting agricultural activities, and jeopardizing
food security. Although untreated trypanosomiasis is lethal,
treated patients often remain incapacitated, perpetuating the
cycle of poverty, malnutrition, and disease. DALYs do not take
into account the psychosocial impact and the “minor” disabil-
ities. In adults, loss of memory and ability to concentrate is
common. Such disabilities are often accompanied by reading
and writing difficulties and occasionally by extreme incoher-
ence. These disabilities greatly affect everyday life, particularly
for those school-age children who, even after successful treat-
ment, do not recover fully and cannot pursue their studies
(Frézil 1983).
Burden of Animal Trypanosomiasis. Animal trypanosomi-
asis constrains agricultural production—in particular, the use
of draft power. Cattle infected with T.b. brucei, T. vivax, or T.
congolense quickly succumb to a wasting form of anemia. In
many areas with a high tsetse challenge, such as Central Africa,
cattle are few or not present at all. Elsewhere, countries invest
an estimated total of US$30 million to US$50 million per year
in some 35 million doses of veterinary trypanocides to prevent
the disease in livestock (Geerts and Holmes 1998). About
60 percent of the cattle at risk are not treated, and the disease is
thought to kill about 1 million a year. Current drugs are more
than 40 years old, and drug resistance is increasing, as are
problems of drug availability and accessibility, counterfeit
drugs, and drug mismanagement (Geerts and Holmes 1998).
Constraints on draft power mean that farmers can till only
small plots, making subsistence farmers extremely vulnerable
to food shortages. Milk yields are lower in infected cows, and
animal trypanosomiasis lowers fertility and increases mortality,
thereby constraining the overall growth rate of the number of
livestock (Swallow 2000). Kristjanson and others (1999) esti-
mate annual direct losses of US$1.3 billion per year as a result
of lowered production of milk and meat, with aggregate agri-
cultural losses attributable to trypanosomiasis estimated at
US$4.5 billion per year.
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MANAGEMENT AND CONTROL STRATEGIES
Dengue
Patient Management and Treatment. Classic dengue fever is
generally self-limiting. No specific treatment is available, but
supportive treatment must be given, including fluid replace-
ment when necessary. Early recognition of DHF cases—
indicated by intense, continuous abdominal pain; persistent
vomiting; and restlessness or lethargy—and early supportive
treatment are of utmost importance to reduce case-fatality
rates (Martinez 1992). For differential diagnosis, a wide spec-
trum of viral and bacterial infections should be considered,
especially leptospirosis, malaria, yellow fever, chikungunya
virus, rubella, and influenza.
Vector Control. Although good patient management can be
effective for individual cases, currently no alternative to vector
control is available for the prevention of dengue. Most endemic
countries have a vector control component in their programs;
however, the application of vector control measures is fre-
quently insufficient, ineffective, or both and is currently failing
to reduce the public health burden to an acceptable level.
Most Aedes control programs rely on the application of lar-
vicides and adulticidal insecticide space sprays (Zaim and
Jambulingham 2004). Because Ae. aegypti characteristically
breeds in water that does not contain high levels of organic
pollutants, control measures typically must be applied to water
stored for household purposes, including drinking water.
WHO currently approves five insecticides for application to
potable water (FAO 1999; WHO 1991). Since the early 1970s,
the organophosphate temephos has been the most widely
used, but increasing levels of resistance to this insecticide are
reducing the duration of effectiveness of treatments in some
countries (Brengues and others 2003; Lima and others 2003;
Rodriguez and others 2001). An additional challenge is the
growing objection among householders, particularly in Latin
America, to the application of chemicals to drinking water.
Biological control agents, including larvivorous fish and
copepods, have had a demonstrable role in integrated control
of Ae. aegypti, but operational difficulties—particularly a lack
of facilities and of expertise in mass rearing and the need for
repeated introduction of these agents into some container
habitats—have largely precluded their widespread use. One
encouraging exception is Vietnam, where indigenous species of
predatory copepods are increasingly used to control semiper-
manent larval habitats of Ae. aegypti (Kay and others 2002;
Nam and others 2000). However, some communities have
strong cultural objections to the introduction of live animals
into household water storage containers—for example, in
Thailand, where bathing with water that contains small fish or
other creatures is widely regarded as unacceptable.
Environmental management is generally considered the
core component of dengue prevention and control, including
cleanup campaigns, regular emptying and cleaning of contain-
ers, installation of water supply systems, solid waste manage-
ment, and urban planning. However, huge investments in
infrastructure are needed to increase access to safe and reliable
water supplies, to provide solid waste management services,
and to dispose of liquid waste. In addition to overall health
gains, such provision would have a major effect on vector ecol-
ogy, although the relationship is not invariably an inverse one.
Cost-recovery mechanisms, such as the introduction of
metered water, may encourage household collection and stor-
age of roof catchment rainwater that can be harvested at no
cost. Although unproven, the installation of community water
services in rural townships and villages may be contributing to
the rural spread of dengue in Southeast Asia and elsewhere.
At the household and community levels, where most vector
control efforts are centered, increasing attention is given to
such activities as covering or frequently cleaning water storage
vessels, removing discarded food and beverage containers, and
storing or disposing of used tires in such a way that they do not
collect rainwater. Such tasks would seem to be simple and well
suited to engagement by communities, but with a few excep-
tions, achievements to date have been unspectacular.
Nevertheless, such community-based interventions are widely
seen as the most promising way of achieving sustainable con-
trol through behavior change (Parks and Lloyd 2004).
Leishmaniasis
Leishmaniasis control is based primarily on finding and treat-
ing cases, combined where feasible with vector control and, in
some zoonotic foci, control of animal reservoirs.
Diagnosis and Treatment. For VL, serological diagnosis is
usually based on the enzyme-linked immunosorbent assay
(ELISA), indirect fluorescent antibody tests, and direct aggluti-
nation tests, including a new direct agglutination test kit using
lyophilized antigen, which avoids the need for refrigeration
(Schallig and others 2001). A dipstick test based on a highly
specific recombinant antigen is also available, together with a
latex agglutination test that can be used to detect antigens in
urine (Attar and others 2001; Sundar and others 1998).
Parasitological diagnosis relies on microscopy of aspirates of
the spleen, bone marrow, and lymph nodes.
Specific treatment includes the first-line drugs, which are
pentavalent antimonials (sodium stibogluconate and meglu-
mine antimoniate), and the second-line drugs, which are
amphotericin B and AmBisome (amphotericin B in lipo-
somes). Miltefosine for VL was registered in India in 2002, and
aminosidine (paromomycin) has just completed phase 3 clin-
ical trials and follow-up. For CL, parasitological diagnosis is
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made from skin smears followed by treatment with pentava-
lent antimonials. Treatment is given locally if lesions are few
and relatively small, or systemically if lesions are more numer-
ous. For mucocutaneous leishmaniasis, diagnosis relies on
serology because patients generally develop a strong humoral
response.
Vector and Reservoir Control. In foci of peridomestic or
intradomestic transmission, vector control can be carried out
by indoor residual spraying using pyrethroid insecticides.
Individual protection using pyrethroid-impregnated bednets is
also used in some areas. In zoonotic foci of VL, control has
also included culling stray dogs—and pet dogs if found to be
infected—although this practice is often poorly accepted by
communities and is probably of limited effectiveness. Trials
with insecticide-treated dog collars are showing some promise
as an alternative way to reduce the peridomestic reservoir of
infection (Mazloumi Gavgani and others 2002). For zoonotic
CL, rodent reservoirs can be controlled using poisoned bait and
environmental management, including physical destruction of
rodents’ burrows.
African Trypanosomiasis
For human trypanosomiasis, control consists primarily of
active and passive case finding and treatment, occasionally
associated with vector control operations. Dissemination of
sleeping sickness can be prevented by regular surveillance of
the population at risk, including diagnosis and treatment; con-
trol of the tsetse-fly population can affect the transmission of
sleeping sickness as well as of animal trypanosomiasis. In T.b.
rhodesiense foci, where cattle are reservoirs of the disease, treat-
ing cattle with trypanocides is being investigated as an addi-
tional approach to controlling outbreaks.
Case Finding and Treatment. No single clinical sign is regarded
as pathognomonic for sleeping sickness. Tests have been devel-
oped to detect antibodies, circulating antigens, or trypanoso-
mal DNA, but all require parasitological confirmation. For
mass screening, infection can be confirmed by the card agglu-
tination trypanosomiasis test, which is easy to perform and rel-
atively inexpensive. Parasitological confirmation is by
microscopy of lymph node aspirates and of thin or thick blood
films. Concentration methods increase sensitivity. The most
sensitive is the miniature anion exchange centrifugation tech-
nique. The capillary tube centrifugation technique is less sensi-
tive but is commonly used in the field because of its ease and
rapidity of use and its low cost.
Determining the stage of disease is essential, because early-
and late-stage infections require different treatments. The cri-
teria for late-stage infection are based on cerebrospinal fluid
analysis.
Sleeping sickness is fatal if untreated. No vaccination
exists. Specific drugs are currently available free through
WHO. Pentamidine is used to treat early-stage T.b. gambiense
infection, and suramine is used for early-stage T.b.
rhodesiense. The organoarsenical compound melarsoprol
(Arsobal) is used for the late stages of both. Eflornithine has
been introduced to treat late-stage T.b. gambiense but is
difficult to administer. Nifurtimox, although not yet regis-
tered for the treatment of sleeping sickness, has been used on
compassionate grounds to treat patients unresponsive to
melarsoprol.
Vector Control. A wide range of techniques for tsetse control
is available (Maudlin, Holmes, and Miles 2004). Most current
approaches exploit the acute susceptibility of tsetse flies to
biodegradable pyrethroid insecticides. Spraying can be applied
from the ground to known fly resting sites or at ultra-low
volume from the air. Spraying is carried out sequentially to
kill all flies initially present and thereafter to kill each
generation of newly emerging flies. The sequential aerosol
technique uses extremely low levels of insecticide and has been
effective in Botswana, Somalia, South Africa, and Zambia. It is
also useful against epidemic outbreaks of sleeping sickness,
where a rapid cessation in contact between humans and tsetse
flies is needed.
Tsetse flies can also be controlled using traps and targets.
Targets are combinations of cloth and netting baited with an
odor attractant and impregnated with a pyrethroid insecticide.
Traps work on the same principle, but the fly is encouraged to
enter a net or plastic chamber where it remains trapped. Live
bait techniques are also used. Cattle are treated with a veteri-
nary formulation of pyrethroid insecticides applied as sprays or
pour-ons, which kill both tsetse flies and ticks. This technique
has been successfully used in Burkina Faso, Ethiopia, Kenya,
Tanzania, Zambia, and Zimbabwe (Kuzoe and Schofield 2005).
The sterile insect technique involves mass release of steril-
ized male tsetse flies, which compete with local males to mate
with females. Because female tsetse flies generally mate only
once, the result is infertile offspring and a decline of the wild
tsetse population. This technique is expensive, because it
requires large-scale rearing of flies, and it is only recommended
for use once the wild tsetse population has been suppressed to
low levels using other techniques. A combination of insecticide
spraying and trap deployment followed by the sterile insect
technique has been successfully used to eliminate G. austeni
from Zanzibar (Vreysen and others 2000).
Degrees of resistance to trypanosome infection are found in
the N’dama, Dwarf, and Savannah Shorthorn breeds in West
Africa and, to a lesser extent, in some Orma Boran breeds
in East Africa. However, even though these cattle show toler-
ance, can control parasitemia, and resist development of ane-
mia, they can ultimately succumb to the disease.
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COSTS AND COST-EFFECTIVENESS
OF INTERVENTIONS 
Dengue
Few studies are available on the cost-effectiveness of vector
control for reducing dengue transmission. One of the difficul-
ties is that the level of vector population control needed to
reduce transmission is influenced by the human population’s
past exposure to the circulating virus serotype. A direct rela-
tionship is apparent between seroprevalence rates and levels
of vector abundance needed for epidemic transmission. Thus,
the paradox is that, as herd immunity declines over time in
response to effective vector control, progressively lower vector
densities can maintain the same level of transmission.
Modeling of the dynamics of dengue transmission is help-
ing to improve understanding of the interrelationships
between virus, vector, and host (Ferguson, Donnelly, and
Anderson 1999; Focks and others 1995; Newton and Reiter
1992; Shepard 2001), but the absence of epidemiologically
defined target levels for vector control has hindered calcula-
tions of cost-effectiveness. According to Shepard and others
(2004), average annual costs for dengue vector control per
1,000 population were US$15 in 1998 in Indonesia, US$81 in
1994 and US$188 in 1998 in Thailand, US$240 in 2002 in
Malaysia, and US$2,400 in 2000 in Singapore. In 1997, spend-
ing on dengue control in 14 Latin American countries ranged
from US$20 to US$3,560 per 1,000 population, with a median
of US$260. For 17 Caribbean islands in 1990, the correspon-
ding expenditures ranged from US$140 to US$8,490, with a
median of US$1,340 (Nathan 1993). By contrast, McConnell
and Gubler’s (2003) study in Puerto Rico concludes that larval
control programs that achieve a 50 percent reduction in dengue
transmission and cost less than US$2.50 per person would be
cost-effective in that setting. From research based on analytical
models (Shepard 2001) and primary data from Singapore, we
estimate the cost of using environmental management for con-
trol at US$3,139 per DALY averted and the cost of using insec-
ticides at US$1,992 per DALY averted.
Dengue case management depends on the severity of the ill-
ness. Despite the lack of information about cost-effective inter-
ventions to treat dengue cases, Shepard (2001) estimates an
average cost of US$587 per DALY averted by appropriate case
management. Were a dengue vaccine to become available, the
Shepard model estimates that immunization would cost
US$3,040 per DALY averted.
Leishmaniasis
Case Finding and Treatment. For leishmaniasis, diagnosis
represents a small proportion of the cost of case finding
and treatment, with diagnostic tests becoming available at
approximately US$1.50 for the dipstick, US$3.00 for the direct
agglutination test using freeze-dried antigen, and US$1.50 for
the urine latex agglutination text. These tests can be used in the
field. A study in Nepal (Pokhrel 1999) comparing outreach case
detection using serology (the dipstick) with parasitological
diagnosis at health centers (bone marrow aspirate) concluded
that the median cost per VL case detected was US$25 in the
outreach program, compared with US$145 at health centers (of
which more than 50 percent was due to absence from work).
Treatment costs increased these figures to US$131 and US$200
per patient, respectively.
In India, an examination of the costs of drugs and hospital-
ization and of the evolution of the disease under treatment
(cure, relapse, failure, intolerance) indicated that the final cost
of successful treatment depends largely on the basic drug cost,
which averaged US$86 per patient successfully treated with
miltefosine (using reduced pricing because of the large number
of patients), US$467 for treatment with amphotericin B, and
US$1,613 for treatment with AmBisome. Given current esti-
mates of about 100,000 cases of VL each year in the state of
Bihar, India, the estimated total cost of treatment using miltefo-
sine as a first-line drug and amphotericin B as a second-line
drug would be about US$11 million, or approximately US$110
per patient (personal communication with P. Olliaro and
S. Sundar on treatment options for kalaazar [visceral leishman-
iasis], 2003). By contrast, analysis of humanitarian relief inter-
ventions by Médecins sans Frontières–Holland that combined
case finding with treatment after a VL epidemic in southern
Sudan indicated total costs of US$394 per patient, or an average
cost of US$595 per life saved (Griekspoor, Sondorp, and Vos
1999). Thus, the average cost per DALY averted was US$18.40.
Vector Control. Vector control is rarely carried out as a spe-
cific approach to leishmaniasis control, and cost-effectiveness
estimates are not available. In general, domestic and perido-
mestic sandfly vectors are more susceptible to indoor residual
spraying than are other domestic vectors, such as anopheline
mosquitoes or triatomine bugs, so that transient suppression of
sandfly populations is seen as an additional benefit of malaria
or Chagas disease vector control in areas where these vectors
coincide. However, insecticide-treated bednets, which are
becoming widely deployed against malaria transmission, may
also become cost-effective for reducing leishmaniasis in areas
of domestic transmission. In Yenice, Turkey, the use of impreg-
nated bednets reduced the incidence of CL from 1.90 percent
to 0.04 percent between 2000 and 2001 (Alten and others
2003).
African Trypanosomiasis
Case Finding and Treatment. WHO (1986, 1998) has ana-
lyzed the costs of T.b. gambiense control by means of case
finding and treatment based on practice in Côte d’Ivoire and
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Uganda. This work and other studies indicate that, at current
prices, the cost of active detection using the card agglutination
trypanosomiasis test with parasitological confirmation varies
around US$1 per person screened or slightly more for mobile
teams. However, mobile teams are more effective in screening a
high proportion of the population and are also more successful
in ensuring that a high proportion of patients receive treat-
ment. Unit costs are currently US$0.33 per person for the card
agglutination trypanosomiasis test and US$2.20 for the minia-
ture anion exchange centrifugation technique. Less sensitive
parasitological techniques, such as examination of lymph node
aspirate or blood smears, cost only a few cents but may miss a
third to half of patients.
By contrast, treatment is expensive despite the availability of
free drugs. Treatment of early-stage disease incurs costs of
more than US$100 per person, rising to more than US$250 for
late-stage treatment with melarsoprol and about US$700 with
eflornithine (WHO 1998). The long hospitalization period is a
major component of costs during the second stage, although
work undertaken by Burri and others (2000) on a shorter
melarsoprol regimen offers opportunities for reducing these
costs.
Despite the costs and the risk of complications, treating
sleeping sickness patients in the second stage of the disease is
cost-effective. In Uganda, costs were less than US$10 per
DALY averted for melarsoprol treatment and less than US$20
per person for eflornithine (Politi and others 1995). Similarly,
in southern Sudan, the cost per DALY averted ranged from
US$4 to US$22 (Trowbridge and others 2001). Shaw and
Cattand (2001) considered the costs of case finding and treat-
ment for T.b. gambiense infection for three delivery options
and a wide range of prevalences. Given the limited informa-
tion available on DALYs gained or on the effect on transmis-
sion of reducing the size of the human reservoir, they estimate
that under different scenarios the costs per DALY averted tend
to converge. For most assumptions, the cost per DALY averted
fell below a US$25 threshold at prevalences of 0.5 to 1.0 per-
cent but rose sharply at low prevalences, which explains the
reluctance of control programs to invest in screening opera-
tions when prevalence is less than 0.2 percent. With better
quantitative understanding of the effects of screening and
removing patients from the reservoir in preventing future
epidemics, investigators could demonstrate that even at low
prevalences screening for sleeping sickness is highly cost-
effective.
Vector Control. Several countries have undertaken
community-based programs to trap tsetse flies, notably Côte
d’Ivoire, where costs came to US$2.30 per person protected
per year (Laveissière and others 1994), and Uganda, which
achieved a cost of US$0.50 per person protected per year
(Lancien and Obayi 1993). Vector control costs have been
studied in more detail in the context of livestock disease
(Maudlin, Holmes, and Miles 2004). These costs vary accord-
ing to the technique used and the environmental context, often
ignoring overheads for organizing and planning. With that
caveat in mind, the figures per square kilometer cited for local
tsetse-fly eradication range from about US$250 to US$550 at
current prices for aerial spraying (based on experience in
Somalia, South Africa, Zambia, and Zimbabwe); US$250 to
US$400 per square kilometer for ground spraying; and US$200
to US$400 per square kilometer for targets. However, the cost
of traps and targets falls to US$25 to US$60 per square kilome-
ter for control or suppression operations alone. Projects
treating cattle with insecticides have been implemented at costs
of US$50 to US$60 per square kilometer. Use of the sterile
insect technique is much more expensive because it relies on
prior suppression of fly populations using another technique.
The overall costs of the experimental eradication of G. austeni
from Zanzibar using the sterile insect and other techniques
were about US$3,000 per square kilometer, although the
International Atomic Energy Agency (IAEA) envisages that
the cost of the sterile insect technique component could
be reduced to less than US$800 per square kilometer as the
technology is developed and applied on a sufficiently
large scale (Dr. Udo Feldmann, IAEA, Vienna, personal 
communication).
PROBLEMS AND CHALLENGES 
FOR DISEASE CONTROL
Dengue
Potential for Vaccine Development. The occurrence of DHF
in children and adults with previous dengue antibodies,
acquired passively or actively, has been the most important
challenge for the development of a dengue vaccine. Lack of a
suitable animal model, insufficient knowledge of disease
pathogenesis, and limited research funding have also had a neg-
ative influence. Researchers generally agree that a dengue vac-
cine must confer long-lasting protection against the four
dengue serotypes. Currently, they are following different strate-
gies in the development of several vaccine candidates. Some
vaccines are currently undergoing human clinical trials—for
example, live attenuated dengue and yellow fever chimeric vac-
cines. The conventional live attenuated vaccines are entering
phase 3 trials, while the chimeric vaccines are presently in phase
1 and phase 2 trials. Others are in the preclinical phase of devel-
opment. To accelerate the development of a dengue vaccine, a
new initiative—the pediatric dengue vaccine initiative—has
been launched, with the major objective of mobilizing
resources to accelerate the development of a safe and effective
pediatric dengue vaccine (Almond and others 2002; Halstead
and Deen 2002; Pang 2003).
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Vector Control. Without a vaccine, vector control remains the
only available strategy against dengue. Selective, integrated vec-
tor control with community and intersectoral participation,
active disease surveillance based on a strong health information
system, emergency preparedness, capacity building and train-
ing, and vector control research constitute the major elements
of WHO’s global strategy for dengue prevention and control.
Since the eradication era, few examples of successful dengue
prevention and control on a national scale are available.
Exceptions include Cuba and Singapore, both island states.
Cuba, with approximately 11 million inhabitants, has been able
to interrupt dengue transmission. Despite being in an endemic
area, the country has maintained low vector densities and has
successfully controlled epidemics in recent years (Arias 2002).
Critical factors contributing to this achievement are the strong
dengue surveillance system, which integrates environmental,
entomological, epidemiological, clinical, and virological
surveillance in conjunction with the public health infrastruc-
ture, and a strong vector control program, along with good
intersectoral coordination, active community involvement, and
strong political commitment.
A limited array of tools is available for vector control inter-
ventions, any one of which can control at least part of the vec-
tor population or provide personal protection. However,
approaches are converging, at least at the policy level, toward
application of vector control tools through social or commu-
nity mobilization. Consensus is growing that community-
based approaches are desirable and necessary, and many believe
that only through such approaches can a degree of sustainabil-
ity be accomplished in relation to dengue vector control. Even
though few such interventions have expanded beyond the pilot
stage, the decentralization of budgetary and operational
responsibilities for program delivery appears to offer opportu-
nities for strengthening and expanding this integrated vector
management approach.
Increasing levels of resistance of Ae. aegypti to temephos
imply shorter intervals between treatments. This situation is
already a reality in some countries, including Brazil and several
Caribbean islands (Carvalho and da Silva 1999; Rawlins 1998).
Resistance of adult mosquitoes to malathion and to pyrethroids
has been reported in the Americas and in Asia (WHO 1992) and
is likely to reduce the efficacy of space spraying. Given the
peridomestic ecology of Ae. aegypti in most regions and the
widespread use of pyrethroids for public health purposes and in
household insecticide products, the rate of development of
pyrethroid resistance is likely to accelerate.At the same time, few
new insecticide products are becoming available in the public
health market because of the costs involved in development
and registration compared with the returns on investment
from the relatively small commercial market. The high cost of
re-registration of existing products is also contributing to the
withdrawal of some insecticides from the market.
New Risk Factors. Environmental changes, particularly those
related to climate, directly affect the incidence and prevalence
of vectorborne diseases. However, social factors, such as
lifestyles and population density, particularly in the case of
dengue, are also important. Using an empirical model of the
effect of population and climate change on the global distribu-
tion of dengue fever, Hales and others (2002) conclude that
predicted changes in humidity will increase the areas with a cli-
mate suitable for dengue transmission.
The world is also becoming increasingly urbanized: during
2000–25, Asia’s urban population is expected to double, and
that of Latin America and the Caribbean is expected to
increase by almost 50 percent. The resulting high human pop-
ulation densities, coupled with lifestyles that increasingly
contribute to the proliferation of larval habitats and infra-
structural deficiencies in relation to water supply and sanita-
tion, are such that effective delivery of vector control on the
scale needed is beyond the reach of many governments.
The increasing global trend in international travel also facili-
tates the dissemination of virus serotypes and strains between
vulnerable populations.
Genetic variability is another element to be considered. The
genetic diversity of the viruses is increasing, with some geno-
types associated with severe disease (Cologna and Rico-Hesse
2003; Leitmeyer and others 1999; Rico-Hesse and others 1997).
Recombination has been demonstrated in all four serotypes,
but the implications in terms of pathogenesis are unknown. In
addition to recombination, mutations, gene flow, and other
factors could further influence the genetic diversity and selec-
tion of virulent strains (Holmes and Burch 2000). At the same
time, in addition to initial observations of the higher risk of
DHF in Caucasian than in those of African descent, a few
reports associate some human leukocyte antigen alleles with
disease severity (Bravo, Guzmán, and Kouri 1987; LaFleur and
others 2002; Loke and others 2001; Paradoa, Trujillo, and
Basanta 1987; Stephens and others 2002). The sequence of
infecting viruses and, more recently, the longer interval
between primary and secondary infection as a risk factor for
DHF, add a new perspective to the problem (Guzmán and
others 2002; Nisalak and others 2003).
Leishmaniasis
Because the primary control strategy against leishmaniasis is
based on case finding and treatment, the priority for control is
developing and implementing improved diagnostic methods
and better treatments that are more amenable to field use.A par-
allel requirement is for the development of more cost-effective
drug delivery systems, especially ones that take advantage of
new oral drugs, such as miltefosine, and the planned registration
and local production of aminosidine in India.
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Improved Diagnostics and Treatment. Even though the
new serological tests, such as the dipstick, lyophilized direct
agglutination test kit, and latex agglutination urine test, repre-
sent major improvements, they are not yet widely used in
endemic countries. Moreover, they are indirect tests that can-
not provide direct parasitological confirmation of infection or
of cure immediately following treatment. Current parasitolog-
ical tests tend to be highly invasive and can be costly to per-
form; therefore, simple molecular-based tests would be an
advantage.
For leishmaniasis treatment, development of the oral VL
drug, miltefosine, represents a substantial improvement, but it
remains expensive and with a long treatment regimen and can-
not be administered to pregnant women because of the risk of
teratogenicity. Further clinical evaluation is required to estab-
lish the possibility of shorter treatment regimes and the poten-
tial of combination therapy to inhibit the development and
spread of drug resistance. Another oral drug, sitamaquine, is
currently under development and will require similar clinical
and implementation studies. Clinical trials of aminosidine
(paromomycin) are proceeding, and use of this drug against VL
may become widespread. An improved understanding of dis-
ease pathogenesis would be helpful in refining the criteria for
cure and in improving patients’ prognosis.
Vaccine Development. The leishmaniases offer substantial
opportunities for vaccine development, and a crude vaccine
against CL has been widely used in parts of the Middle East.
Trials of a second-generation vaccine that includes three
Leishmania antigens are currently in progress.
Vector Control. Control of domestic and peridomestic sand-
fly vectors will probably continue as an additional benefit
accruing to programs against other insect vectors using indoor
residual spraying or insecticide-treated bednets. However, in
areas where dogs are among the main reservoir hosts, increased
use of insecticide-treated dog collars would merit further
appraisal. Such collars not only would reduce the likelihood of
new infections in dogs, but also could reduce the risk of trans-
mission from dogs to humans.
African Trypanosomiasis
Improved Diagnostics. Serological diagnosis is reliable for
verifying infection; however, most district hospitals or periph-
eral health units have neither the facilities nor the necessary
expertise to perform and read serological tests. In the past,
serological diagnosis, based on indirect fluorescent antibody
tests and ELISA, was restricted to central-level facilities or
specialized mobile teams. The card agglutination trypanosomi-
asis test has substantially simplified the use of serology but
requires specifically equipped health units with a cold chain.
Parasitological diagnosis, such as the miniature anion exchange
centrifugation test, is more expensive and complicated to use in
field surveys despite the development of a simplified sterile kit
version. Molecular diagnostics are not yet developed to a level
appropriate for widespread field use.
Treatment. Despite the availability of drugs free of charge
from WHO, treatment is hampered by the length of hospital-
ization required and by the toxicity of currently available drugs.
In addition, inability to use the same drug in the early and late
stages of the disease complicates the treatment protocol. The
existing late-stage drug, melarsoprol, is unsafe, its secondary
reactions are numerous, and the occurrence of a lethal
encephalopathic syndrome in 5 to 10 percent of treated cases
means that patients on melarsoprol must be hospitalized. A
new oral drug for the early stage, soon to be registered, must be
introduced in the field, which will take several years.
Drug resistance is well established in animal trypanosomes.
For T. congolense, T. vivax, and T. evansi, resistance to all
available drugs has been reported, along with trypanosome
populations with multiple drug resistance (Geerts and Holmes
1998). Much less information is available on human path-
ogenic trypanosomes. The resurgence of human African
trypanosomiasis in recent years has been accompanied by
increasing reports of treatment failure using melarsoprol. As
early as 1960, T.b. rhodesiense patients in Uganda were reported
to have relapsed after two or more courses of melarsoprol, and
in 1977, a 40 percent melarsoprol relapse rate was reported in
the DRC.
Relapses after treatment with early-stage drugs remain rare.
Whether relapses after melarsoprol treatment reflect parasite
drug resistance or host factors is unknown. Furthermore, even
though increasing rates of melarsoprol failure have been
observed in several countries, the magnitude and geographic
distribution of the problem have not been determined.
Analyses of existing data are complicated by the lack of a
standard treatment regimen and the range of clinical and
laboratory criteria used to define a relapse.
Vector Control. Even though available techniques to control
tsetse flies can be highly effective (Maudlin, Holmes, and Miles
2004), all are constrained by the difficulties of applying them
on a large enough scale for long enough to achieve sustainable
results. Insecticide spraying is efficient but is difficult to sustain
because of logistical constraints and high costs. Targets and
traps are effective, but their deployment is difficult to sustain
for long periods, and implementation through community
participation requires constant motivation and supervision to
remain effective. To address these problems, the African Union
has launched the Pan African Initiative (PATTEC), which
focuses on identifying regions where elimination of the tsetse
fly may be feasible using currently available techniques. This
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initiative is designed as part of a poverty reduction strategy that
aims at eliminating the problem of tsetseborne animal try-
panosomiasis, but in several areas it will also reduce the risk of
human infections.
SUMMARY 
For dengue, leishmaniasis, and African trypanosomiasis, the
longstanding problem is the lack of adequate specific treat-
ment. For dengue, no specific treatment is available. For the
leishmaniases and African trypanosomiases, specific treatment
has long depended on antiquated drugs that would be consid-
ered far too toxic for introduction under modern registration
systems. Even though progress is being made, especially in rela-
tion to the development of new oral drugs for leishmaniasis, in
purely pragmatic terms what is currently available will
probably represent almost the entire therapeutic arsenal for the
coming decades. Even without toxicological problems, the
development and registration of a new candidate drug will,
given current requirements, take at least a decade.
Although basic research will continue (table 23.2), the cur-
rent challenge is to make better use of what is already available.
Dengue can be prevented with available vector control tools
and strategies designed to reduce the risk of transmission. This
method requires a sustainable surveillance system capable of
providing early warning and predictions based on experience
of factors predisposing to new epidemic outbreaks. To a large
extent, it becomes a management exercise that accepts that
some dengue transmission will occur but aims at preempting
epidemic outbreaks rather than instigating emergency meas-
ures after an outbreak is in full crudescence. Moreover, because
preemptive measures and emergency responses are competing
strategies, analyses of their relative cost-effectiveness would be
appropriate.
Case finding and treatment for the leishmaniases and
African trypanosomiases depend on the effectiveness of the
diagnostic and treatment packages. Such packages are available,
and research is required into the most cost-effective means for
large-scale implementation. Again, the management exercise is
to accept that some transmission will occur but to be aware that
cases can be found and treated with minimal losses to healthy
life. As with dengue, predictive surveillance will help focus
attention on those areas where outbreaks seem most likely, and
rapid, accurate diagnostics are crucial both to avoid the waste
and danger of mistreatment and to minimize delays in admin-
istering the specific treatment required. But should such
approaches rely on health centers, on mobile teams, or on some
combination of the two? To what degree can the specialist diag-
nosis and treatment teams be integrated into more general
approaches to health care? And, most crucially, how is the epi-
demiological surveillance to be organized: disease and vector
notification, geographic information system mapping, analysis,
and prediction?
For the leishmaniases, vector control seems unlikely to
become a major component of disease control except where
sandfly distribution overlaps with that of other vectors or
where use of personal protection measures can be more widely
encouraged. For dengue, vector control is a major component,
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Table 23.2 Control Strategies, Major Challenges, and Research Needs of Each Disease
Disease Principal control strategy Major problems and challenges Major research needs
Dengue Interruption of transmission Lifestyles that provide abundant Vector control thresholds to interrupt
through vector control artificial larval habitats transmission
Patient management and Urban water infrastructure Behavioral changes conducive to
supportive treatment and management dengue prevention
Sustainable vector control Pathogenesis and disease prognosis
Early diagnosis and treatment Vaccine development
Vaccine development
Leishmaniasis Case detection and treatment Rapid field diagnosis Molecular-based field diagnostic kits
Deployment of oral drugs for treatment Effective, safe, oral drug treatments, 
Vaccine development including combination therapy
Diagnosis and treatment strategies
African Case detection and Rapid field diagnosis, including determination Molecular-based field diagnostic kits 
trypanosomiasis treatment of stage of infection Effective, safe, oral drug treatments
Interruption of transmission Safer drug treatment regimens Vector population genetics to determine
through vector control Sustainable large-scale vector control areas amenable to vector population elimination
Source: Authors.
but unless Aedes eradication appears again on the agenda, pre-
dicting the levels of control required in specific situations will
require much greater understanding of transmission dynamics.
Significant resources have been wasted on emergency dengue
vector control, which has subsequently been seen to have had
little more than a palliative effect, whereas sustained suppres-
sion of vector populations may require changes in urban water
management and in human behavior that exceed the usual
remit of health specialists.
For African trypanosomiasis, however, the prospects for
sustainable vector control are more promising. The vector’s low
reproductive rate, combined with its extreme sensitivity to
ultra-low doses of biodegradable insecticides, put tsetse flies
among the most promising candidates for large-scale elimina-
tion. Campaigns against tsetse flies during the past century
were invariably successful until they were discontinued and the
controlled areas became reinvaded. Thus, the operational issue
is to design large-scale international programs that can succes-
sively eliminate tsetse populations and prevent reinvasion of
controlled areas, as contemplated by the African Union’s Pan
African Initiative.
In essence, all three diseases face parallel needs involving
some marginal improvements to existing control techniques,
but, most important, they require a management exercise that
acknowledges the long-term need for surveillance, adequate
reporting, case finding, and treatment. The primary challenges
seem to reside less in the domain of new tools and more in the
deployment of what is already available.
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Helminth infections caused by soil-transmitted helminths
(STHs) and schistosomes are among the most prevalent afflic-
tions of humans who live in areas of poverty in the developing
world. The morbidity caused by STHs and schistosomes is most
commonly associated with infections of heavy intensity.
Approximately 300 million people with heavy helminth infec-
tions suffer from severe morbidity that results in more than
150,000 deaths annually (Crompton 1999; Montresor and oth-
ers 2002). In addition to their health effects, helminth infections
also impair physical and mental growth in childhood, thwart
educational advancement, and hinder economic development.
Because of the geographic overlap of these afflictions and their
impact on children and adolescents, the World Health
Organization (WHO); the World Bank; and other United
Nations agencies and bilaterals; and civil society are working to
integrate STH and schistosome control through a program of
periodic school-based, targeted anthelmintic drug treatments.
CAUSES AND CHARACTERISTICS 
OF HELMINTH INFECTIONS
Emphasis is placed on the four most common STH infections
and the three most common schistosome infections. Together,
these infections account for most of the global helminth dis-
ease burden.
Soil-Transmitted Helminths
The four most common STHs are roundworm (Ascaris lumbri-
coides), whipworm (Trichuris trichiura), and the anthropophilic
hookworms (Necator americanus and Ancylostoma duodenale).
Recent estimates suggest that A. lumbricoides infects 1.221 bil-
lion people, T. trichiura 795 million, and hookworms 740 million
(de Silva and others 2003) (table 24.1). The greatest numbers of
STH infections occur in the Americas, China and East Asia,
and Sub-Saharan Africa. Strongyloides stercoralis is also a com-
mon STH in some of these regions, although detailed informa-
tion on the prevalence of strongyloidiasis is lacking because of
the difficulties in diagnosing human infection. The life cycles of
Ascaris, Trichuris, and hookworm follow a general pattern. The
adult parasite stages inhabit the gastrointestinal tract (Ascaris
and hookworm in the small intestine; Trichuris in the colon),
reproduce sexually, and produce eggs, which are passed in
human feces and deposited in the external environment.
STH infections rarely cause death. Instead, the burden of
disease is related less to mortality than to the chronic and insid-
ious effects on the hosts’ health and nutritional status
(Stephenson, Latham, and Ottesen 2000; Stoltzfus and others
1997). Hookworms have long been recognized as an important
cause of intestinal blood loss leading to iron deficiency and pro-
tein malnutrition. The iron deficiency anemia that accompanies
moderate and heavy hookworm burdens is sometimes referred
to as hookworm disease (Hotez and others 2004). When host
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iron stores are depleted, the extent of iron deficiency anemia
is linearly related to the intensity of hookworm infection
(Stoltzfus and others 1997). Because of their underlying poor
iron status, children, women of reproductive age, and pregnant
women are frequently the ones most susceptible to developing
hookworm anemia (Brooker, Bethony, and Hotez 2004). Iron
deficiency anemia during pregnancy has been linked to adverse
maternal-fetal consequences, including prematurity, low birth-
weight, and impaired lactation (WHO 2002).
Chronic STH infections resulting from Ascaris, Trichuris,
and hookworm can dramatically affect physical and mental
development in children (WHO 2002). Studies have also
shown that the growth and physical fitness deficits caused by
chronic STH infections are sometimes reversible following
treatment with anthelmintic drugs (Stephenson, Latham, and
Ottesen 2000). The effects on growth are most pronounced in
children with the heaviest infections, but light infections may
also contribute to growth deficits if the nutritional status of the
community is poor (Stephenson, Latham, and Ottesen 2000).
Schistosomiasis
Five major species of parasitic trematodes of the family
Schistosomatidae—Schistosoma haematobium, S. intercalatum,
S. japonicum, S. mansoni, and S. mekongi—infect humans.
These parasites have a complex, indirect life cycle involving an
intermediate snail host. Disease is caused primarily by schisto-
some eggs, which are deposited by adult worms in the blood
vessels surrounding the bladder or intestines. Urinary schisto-
somiasis, in which the bladder is affected, is caused by infection
with S. haematobium, which occurs mainly in Africa. Intestinal
schistosomiasis results from infection with S. mansoni, which
occurs in the Middle East, South America, and Africa, and from
infection with S. japonicum, which occurs in parts of China
and the Philippines (Ross and others 2002). Two other schisto-
some species are known to cause intestinal schistosomiasis in
restricted geographical areas: S. intercalatum, found in Central
Africa, and S. mekongi, found in Cambodia and the Lao
People’s Democratic Republic. Schistosomiasis is estimated to
affect 187 million people worldwide (table 24.1).
A serious acute illness accompanied by fever and lym-
phadenopathy, known as Katayama Syndrome, can result from
heavy schistosome infections. Chronic disease is mostly due to
perforation of blood vessels and entrapment of eggs by host
tissues. The host’s reaction to entrapped eggs results in gran-
uloma formation. S. haematobium causes bladder wall
pathology, leading to ulcer formation, hematuria, and dysuria.
Granulomatous changes and ulcers of the bladder wall and
ureter can lead to bladder obstruction, dilatation, secondary
urinary tract infections and subsequent bladder calcification,
renal failure, lesions of the female and male genital tracts, and
hydronephrosis. S. haematobium is also associated with
increased risk of bladder cancer. The morbidity commonly
associated with S. mansoni infection includes lesions of the
liver, portal vein, and spleen, leading to periportal fibrosis,
portal hypertension, hepatosplenomegaly, splenomegaly, and
ascites. Schistosomiasis also causes chronic growth faltering
and can contribute to anemia (Ross and others 2002).
EPIDEMIOLOGY OF STH INFECTIONS
AND SCHISTOSOMIASIS
The most striking epidemiological features of human helminth
infections are aggregated distributions in human communities,
predisposition of individuals to heavy (or light) infection, rapid
reinfection following chemotherapy, and age-intensity profiles
that are typically convex (with the exception of hookworm).
For all the major human STH and schistosome infections
studied to date, worm burdens exhibit a highly aggregated
(overdispersed) distribution so that most individuals harbor
just a few worms in their intestines, although a few hosts har-
bor disproportionately large worm burdens (Anderson and
May 1991). As a rule, 20 percent of the host population harbors
approximately 80 percent of the worm population. This
overdispersion has many consequences, both with regard to the
population biology of the helminths and the public health con-
sequence for the host, because heavily infected individuals are
simultaneously at highest risk of disease and the major source
of environmental contamination. One feature that may help
explain overdispersion is that individuals tend to be predis-
posed to heavy (or light) infections. Predisposition has been
demonstrated for all four major STHs and the schistosomes.
The underlying cause of such predisposition remains poorly
understood. However, a combination of heterogeneity in
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Table 24.1 Global Prevalence and Distribution of Helminth
Infections
Helminth infections Total cases Major geographic areas 
STH infections 	 2 billion
Ascariasis 1.221 billion Sub-Saharan Africa, India,
China and East Asia
Trichuriasis 795 million Sub-Saharan Africa, India,
China and East Asia
Hookworm 740 million Sub-Saharan Africa, Americas,
China and East Asia
Schistosomiasis 187 million
S. haematobium 119 million Sub-Saharan Africa
S. mansoni 67 million Sub-Saharan Africa, Americas
S. japonicum 1 million China and East Asia
Source: de Silva and others 2003.
linked to morbidity, the age-intensity profiles provide a clearer
understanding of which populations are vulnerable to the
different helminths (figure 24.1). For A. lumbricoides and
T. trichiura infections, the age-intensity profiles are typically
convex in form, with the highest intensities in children 5 to
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exposure to infection or differences in susceptibility to infec-
tion and the ability to mount effective immunity (genetic and
nutritional factors) is likely to be important.
People of all ages rapidly reacquire infection following treat-
ment, but in schistosomiasis, older people reacquire infection
at slower rates than younger ones (Kabatereine and others
1999). The rate of reinfection is specific to certain species of
helminths and depends on the life expectancy of that species
(short-lived helminths reinfect more rapidly), on the intensity
of transmission within a given community, and on the treat-
ment efficacy and coverage. The basic reproductive rate (Ro)
describes the transmission potential of a parasite (and thus its
ability to reinfect the host). It defines the average number of
female offspring produced during the life span of the parasite
that survive to reproductive maturity in the absence of density
dependence. Ro is determined by parasite immigration and
death rates as well as by host density (and, in schistosomiasis,
also snail density). A parasite will fail to become established
unless Ro is greater than unity (Anderson and May 1991). Adult
worms usually survive between one and four years, whereas
eggs can sometimes remain viable for several more years in the
environment. Therefore, reinfection rates will remain high
until adults are removed with chemotherapy and until infective
stages, through time, become uninfective. In reality, density-
dependent processes regulate parasite populations; at endemic
equilibrium, the effective reproductive ratio equals unity (that
is, each female replaces herself). Control programs rely on
reducing the effective reproductive ratio long enough for the
parasite population to be driven to local elimination.
Theoretically, Ro provides useful insights, and it is helpful to
think of control programs attempting to break the transmis-
sion cycle by reducing Ro to less than unity. Therefore,
estimates can be made about how long and how many rounds
of chemotherapy are required to treat intestinal helminths. For
example, A. lumbricoides with an Ro of three and a life
expectancy of one year will need to be treated annually with
a drug that is 95 percent efficacious and with coverage of more
than 91 percent of the population. Where Ro is five—that is,
in areas where transmission is higher—treatment must be
given more frequently than once a year (Anderson and May
1991).
The age-dependent patterns of infection prevalence are gen-
erally similar among the major helminth species, exhibiting a
rise in childhood to a relatively stable asymptote in adulthood
(figure 24.1). Maximum prevalence of A. lumbricoides and
T. trichiura is usually attained before five years of age, and the
maximum prevalence of hookworm and schistosome infec-
tions is usually attained in adolescence or in early adulthood.
The nonlinear relationship between prevalence and intensity
has the consequence that the observed age-prevalence profiles
provide little indication of the underlying profiles of age inten-
sity (age in relation to worm burden). Because intensity is
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15 years of age (Bundy 1995). For schistosomiasis, a convex
pattern is also observed, with a similar peak but with a plateau
in adolescents and young adults 15 to 29 years of age
(Kabatereine and others 1999). In contrast, the age-intensity
profile for hookworm exhibits considerable variation, although
intensity typically increases with age until adulthood and then
plateaus (Brooker, Bethony, and Hotez 2004). In East Asia it is
also common to find the highest intensities among the elderly.
However, more generally, children and young adults are at
higher risk of both harboring higher levels of infection (thus
greater levels of morbidity) and becoming reinfected more
quickly. Both may occur at vital stages in a child’s intellectual
and physical development.
Risk Factors
Both host-specific and environmental factors have been identi-
fied that may affect the risk of acquiring or harboring heavy-
intensity helminth infections.
Genetics. No genes that control for human helminth infection
have yet been identified. However, recent genome scans have
identified a locus possibly responsible for controlling S. man-
soni infection intensity on chromosome 5q31-33 and loci
controlling A. lumbricoides intensity on chromosomes 1 and
13. There is also evidence for genetic control of pathology
attributable to S. mansoni, with linkage reported to a region
containing the gene for the interferon gamma receptor 1 sub-
unit (Quinnell 2003).
Behavior, Household Clustering, and Occupation. Specific
occupations, household clustering, and behaviors influence the
prevalence and intensity of helminth infections (Bethony and
others 2001), particularly for hookworm, in which the highest
intensities occur among adults (Brooker, Bethony, and Hotez
2004). Engagement in agricultural pursuits, for example,
remains a common denominator for hookworm infection.
Behavioral and occupational factors, through their effect on
water contact, interact with environmental factors to produce
variation in the epidemiology of schistosomiasis.
Poverty, Sanitation, and Urbanization. STH and schistoso-
miasis depend for transmission on environments contaminated
with egg-carrying feces. Consequently, helminths are intimately
associated with poverty, poor sanitation, and lack of clean
water. The provision of safe water and improved sanitation are
essential for the control of helminth infection. Although the
STH and schistosome infections are neglected diseases that
occur predominantly in rural areas, the social and environ-
mental conditions in many unplanned slums and squatter set-
tlements of developing countries are ideal for the persistence of
A. lumbricoides (Crompton and Savioli 1993). Schistosomiasis
transmission can also occur in urban areas.
Climate, Water, and Season. Adequate warmth and moisture
are key features for each of the STHs. Wetter areas exhibit
increased transmission, and in some endemic areas, both STH
and schistosome infections exhibit marked seasonality
(Brooker and Michael 2000). Recent use of geographical infor-
mation systems and remote sensing has identified the distribu-
tional limits of STH and schistosomes on the basis of temper-
ature and rainfall patterns (Brooker and Michael 2000). For
schistosomiasis, specific snail intermediate hosts prefer certain
types of aquatic environments. Construction of dams is known
to extend the range of snail habitats, thereby promoting the
reemergence of schistosomiasis.
BURDEN OF THE DISEASE
The revised estimates in 2003 (de Silva and others 2003) use the
methodology developed by Chan and others (1994) and build
on recent applications of geographical information systems to
derive updated atlases of helminth infections. To reflect recent
changes in the epidemiology of infection, de Silva and others
used data from only 1990 onward. These data confirm that
STH infections are the most prevalent infections of humans
and that a large proportion of the population in developing
countries is at risk. Of the 187 million cases of schistosomiasis
estimated to occur worldwide, most are caused by S. haemato-
bium in Sub-Saharan Africa (table 24.1).
WHO (2002) estimates that 27,000 people die annually
from STH infections and schistosomiasis (case fatality rate of
0.0014 percent). Many investigators, however, believe that this
figure is an underestimate. Crompton (1999) estimated that
155,000 deaths annually occur from these infections (case fatal-
ity rate of 0.08 percent), whereas Van der Werf and others
(2003), using the limited data available from Africa, estimated
the schistosomiasis mortality alone at 280,000 per year (case
fatality rate of 0.014 percent) because of nonfunctioning
kidneys (from S. haematobium) and hematemesis (from S.
mansoni). Therefore, the difference between estimates for
helminth-associated mortality is more than 10-fold.
Because it is uncommon for STHs and schistosomes to kill
their human host, citing mortality figures provides only a small
window on their health impact. Instead, measurements of dis-
ease burden using disability-adjusted life years (DALYs) and
similar tools portray a more accurate picture for helminthic
disease burden. WHO estimates the global burden of disease
from STH infections and schistosomiasis on the basis of the
enormous number of infected individuals, together with an
associated low disability weight (Van der Werf and others
2003). However, because an estimated 2 billion people are
infected with STHs and schistosomes, even minor adjustments
to the disability weights produce enormous variations in
DALYs or other measurements of disease burden. This helps to
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explain why, for instance, in 1990 the disease burden for the
STH infections and schistosomiasis was almost 18 million
DALYs, whereas the 2001 estimate was only 4.7 million DALYs.
In the intervening 11 years, the DALYs were as low as 2.6 mil-
lion. Such disparities are substantial when one considers that
the 1990 estimate ranks helminths close to major disease enti-
ties such as tuberculosis, measles, and malaria, whereas the
lowest estimate during the 1990s ranks helminth infections on
a par with gonorrhea, otitis media, and iodine deficiency. The
Disease Control Priorities Project helminth working group
has determined that the WHO global burden of disease
estimates are low because they do not incorporate the full clin-
ical spectrum of helminth-associated morbidity and chronic
disability, including anemia, chronic pain, diarrhea, exercise
intolerance, and undernutrition (King, Dickman, and Tisch
2005). However, for this chapter, the average disability weights
estimated by WHO are used throughout. Some of the specific
controversies are described below.
A. Lumbricoides and T. Trichiura infections 
Because the most significant physical and intellectual growth
disturbances occur as a consequence of moderate and heavy
worm burdens, the age-associated epidemiology of A.
lumbricoides and T. trichiura infections has focused attention
on infected school-age children in developing countries
(Bundy 1995). In a revised estimate of the probable number of
ascariasis infections worldwide and a better categorization of
the morbidity, de Silva, Chan, and Bundy (1997) indicated that
59 million of the 1.2 billion people infected (including 51 mil-
lion children less than 15 years of age) were at risk of faltering
growth, decreased physical fitness, or both as a result of infec-
tion. They estimated that about 1.5 million children would
never make up the deficit in growth, even if treated. In addition
to these chronic, insidious effects, they estimated that about
11.5 million individuals (almost all of them children) were at
risk of more acute clinical illness. Their figures also indicated
that at least 10,500 deaths annually were directly attributable to
one of the serious complications of ascariasis; children account
for more than 90 percent of those deaths. The actual threshold
at which A. lumbricoides and T. trichiura worm burdens result
in childhood morbidity is controversial because of the nonlin-
ear relationship between intensity and pathogenesis and the
difficulties of measuring and attributing morbidity in under-
served populations suffering from other underlying conditions
(Bundy 1995).
Hookworm Infection
Hookworm infection causes more DALYs lost than any other
helminthiasis with the exception of lymphatic filariasis. Even
these DALY measurements may still underestimate the true
disease burden of iron deficiency anemia and protein
malnutrition resulting from hookworm disease. Iron deficiency
anemia alone results in approximately 12 million DALYs lost
annually, making it the world’s most important nutrition prob-
lem. Data on the epidemiology of iron deficiency anemia in
East Africa and elsewhere point to the important contribution
of hookworms to this condition (Stoltzfus and others 1997). In
Tanzania, where hosts’ iron stores are often depleted, there is a
correlation between the number of adult hookworms in the
intestine and the amount of host blood loss (Stoltzfus and
others 1997). However, it is unclear whether current disability
weights effectively incorporate the full contribution of hook-
worm to severe iron deficiency anemia among iron-depleted
populations or whether they take host protein losses and
malnutrition into account. There is increasing interest in the
importance of hookworm anemia in preschool children, espe-
cially in Africa (Brooker, Bethony, and Hotez 2004), where
infants and preschool children are particularly vulnerable to the
developmental and behavioral deficits caused by iron deficien-
cy anemia (Stephenson, Latham, and Ottesen 2000). Closer
assessment of the impact of hookworm on another important
iron-deficient population—namely, women of reproductive
age—could also significantly increase current DALY estimates.
Approximately 44 million of these women harbor hookworms
(Bundy, Chan, and Savioli 1995). In addition, severe anemia in
pregnancy is associated with neonatal prematurity, reduced
birthweight, and impaired lactation (Christian, Khatry, and
West 2004).
Schistosomes
Scientists and public health workers disagree on the current
assessments of both morbidity and mortality attributable to
schistosomiasis. Several investigators have now initiated a
process to recalculate the burden of disease attributable to
schistosomiasis, focusing much more on the clinical course of
the different types of schistosomiasis and chronic sequelae
(King, Dickman, and Tisch 2005; Michaud, Gordon, and Reich
2003). Through a comprehensive literature review combined
with mathematical modeling, Van der Werf and others (2003)
estimate that urinary schistosomiasis in Africa results in
approximately18 million cases of bladder wall pathology and
20 million cases of hydronephrosis, and African intestinal
schistosomiasis results in approximately 8.5 million cases of
hepatomegaly. Mortality in Africa attributable to urinary and
intestinal schistosomiasis was extrapolated from these figures
using a limited number of studies reporting case fatality rates
for nonfunctioning kidney and hematemesis. From these
extrapolations, Fenwick and others (2003) conclude that in
Africa the mortality attributable to urinary schistosomiasis
could be as high as 150,000 per year, and the number dying as
a result of intestinal schistosomiasis could be as high as 130,000
per year.
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COST-EFFECTIVENESS ANALYSIS 
OF INTERVENTIONS
Classifying Interventions
The three major interventions are anthelmintic drug treat-
ment, sanitation, and health education.
Anthelmintic Drug Treatment. Anthelmintic drug treatment
(“deworming”) is aimed at reducing morbidity by decreasing
the worm burden. Repeated chemotherapy at regular intervals
(periodic deworming) in high-risk groups can ensure that
the levels of infection are kept below those associated with
morbidity (figure 24.2) and will frequently result in immediate
improvement in child health and development. Anthelmintic
drug treatment can prevent the development of irreversible
consequences of schistosomiasis in adulthood. For ascariasis
and trichuriasis, for which intensity peaks among school-age
children, frequent and periodic deworming may reduce
transmission over time. Obstacles that diminish the effective-
ness of periodic deworming are the low efficacy of single-dose
mebendazole and albendazole for the treatment of hookworm
and trichuriasis, respectively (Adams and others 2004; Albonico
and others 1994); high rates of posttreatment reinfection for
STHs in areas of high endemicity (Albonico and others 1995);
and diminished efficacy with frequent and repeated use
(Albonico and others 2003), possibly because of anthelmintic
resistance (see the section “Research and Development”).
Improved Sanitation. Improved sanitation is aimed at con-
trolling transmission by reducing soil and water contamina-
tion. Sanitation is the only definitive intervention to eliminate
STH infections, but to be effective it should cover a high per-
centage of the population. Therefore, because of the high costs
involved, implementing this strategy is difficult where
resources are limited (Asaolu and Ofoezie 2003). Moreover,
when used as the primary means of control, it can take years or
even decades for sanitation to be effective (Brooker, Bethony,
and Hotez 2004).
Health Education. Health education is aimed at reducing
transmission and reinfection by encouraging healthy behav-
iors. For STH infections and schistosomiasis, the aim is to
reduce contamination of soil and water by promoting the use
of latrines and hygienic behavior. Without a change in defeca-
tion habits, periodic deworming cannot attain a stable reduc-
tion in transmission. Health education can be provided simply
and economically and presents no contraindications or risks.
Furthermore, its benefits go beyond the control of helminth
infections. In this perspective, it is reasonable to include this
component in all helminth control programs.
Other Control Measures. In specific epidemiological condi-
tions, environmental or chemical control of snails can be useful
tools for reducing the transmission of schistosomiasis.
Research to develop new tools for control is in progress, includ-
ing vaccine development programs for hookworm infection
and schistosomiasis (see “Research and Development”).
Choosing Interventions
Periodic deworming stands out as the most cost-effective
means to reduce the morbidity of STH and schistosome
infections.
Periodic Anthelmintic Therapy. Periodic anthelmintic ther-
apy, or periodic deworming, represents the main measure in
areas where infections are intensely transmitted, resources for
disease control are limited, and funding for sanitation is lack-
ing. Drug treatment can be administered in the community
using different strategies:
• Universal treatment. The entire community is treated,
irrespective of age, sex, infection status, and other
characteristics.
• Targeted treatment. Treatment targets population groups,
which may be defined by age, sex, or other social character-
istics, irrespective of the infectious status.
• Selective treatment. Treatment targets individual-level appli-
cation of anthelmintic drugs, which is selected on the basis
of either diagnosis or a suspicion of current infection.
Recommended drugs for use in public health interventions
to control STH infection are the benzimidazole anthelmintics
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Figure 24.2 Predicted Effect on Ascaris and Trichuris Prevalence
Following Frequent and Periodic Dewormings with Benzimidazole
Anthelmintics 
(BZAs), albendazole (single dose: 400 mg, reduced to 200 mg for
children between 12 and 24 months), or mebendazole (single
dose: 500 mg), as well as levamisole or pyrantel pamoate (WHO
2002). Praziquantel (PZQ) (single dose: 40–60 mg/kg) is the
major drug used for the treatment of schistosomiasis. However,
therapy with oxamniquine has been the cornerstone for treat-
ment of S. mansoni infection in South American national
control programs over the past 20 years. The efficacy of oxam-
niquine and PZQ is comparable, although that of PZQ is slightly
better. The BZAs and PZQ are inexpensive; they have undergone
extensive safety testing and have been used by millions of indi-
viduals with only a few minor side effects. Drugs that do not
need dosage according to weight, such as BZAs (in school-age
children), are considered easier to use for population-based
interventions; however, the use of proxy indicators—for exam-
ple, substituting height for weight—has proved a successful
implementation strategy for PZQ (Hall and others 1999).
Distribution Strategy and Frequency of Treatment. The
selection of the distribution strategy and the frequency of
treatment is based on epidemiological data. The recommended
strategy for helminth control is a population-based approach,
in which individuals in targeted communities are treated irre-
spective of their infection status (WHO 2002). This strategy is
justified for several reasons, including the simplicity and safety
of delivering treatment. Individual diagnosis is difficult and
expensive and offers no safety benefit.
The intrinsic transmission potential of the parasite species
determines the frequency of treatment (see “Epidemiology of
STH Infections and Schistosomiasis,” earlier in this chapter). To
control morbidity in areas of intense transmission (prevalence
greater than 70 percent and more than 10 percent of moderate-
and heavy-intensity infection), WHO (2002) recommends
treatment two or three times a year for STH infections. In areas
with a lower intensity of transmission (prevalence between 40
and 60 percent and less than 10 percent of moderate- and
heavy-intensity infection), intervention once a year is recom-
mended (WHO 2002).
School-Age Children as a High-Risk Population. School-age
children typically have the highest intensity of worm infection
of any age group, and chronic infection negatively affects all
aspects of children’s health, nutrition, cognitive development,
learning, and educational access and achievement (World Bank
2003). Regular deworming can cost-effectively reverse and
prevent much of this morbidity. Furthermore, schools offer a
readily available, extensive, and sustained infrastructure with a
skilled workforce that is in close contact with the community.
With support from the local health system, teachers can deliver
the drugs safely. Teachers need only a few hours of training to
understand the rationale for deworming and to learn how to
give out the pills and keep a record of their distribution. School-
based deworming also has major externalities for untreated
children and the whole community. By reducing transmission
in the community of Ascaris and Trichuris infections, deworm-
ing substantially improves the health and school participation
of both treated and untreated children, both in treatment
schools and in neighboring schools (Bundy and others 1990;
Miguel and Kremer 2003).
These observations provided a basis for the adoption of res-
olution 54.19 at the 2001 World Health Assembly, which urged
member states to ensure access to essential drugs for STH and
schistosome infections in endemic areas for the treatment of
clinical cases and groups at high risk for morbidity (box 24.1).
To achieve this goal, WHO has developed a broad partnership
that promotes the incorporation of deworming into existing
institutions and programs, for both the education sectors and
the health sectors. The Partnership for Parasite Control was
launched in 2001 with the aim of mobilizing resources and
promoting synergy among public and private efforts for the
control of soil-transmitted helminths and schistosomiasis at
global and national levels. School-based deworming has its
full effect when delivered within an integrated school health
program that includes elements of the Focusing Resources on
Effective School Health (FRESH) framework.
Other At-Risk Populations. Not only school-age children can
benefit from treatment. Preschool children (one to five years
of age) are vulnerable to the developmental and behavioral
deficits caused by iron deficiency anemia, and recent analyses
by Brooker, Bethony, and Hotez (2004) indicate that hook-
worm is an important contributor to anemia in that age group
(see “Estimating Intervention Effectiveness”). Women of
reproductive age (15 to 49 years of age) are particularly sus-
ceptible to iron deficiency anemia because of iron loss during
menstruation and because of increased needs during
pregnancy (Bundy, Chan, and Savioli 1995). In certain
circumstances, male worker populations can also be at
increased risk (Guyatt 2000).
Estimating Intervention Effectiveness
The evidence base for the health and educational effect of
periodic deworming has accumulated significantly over the
past decade.
STH Infections. All the anthelmintic drugs mentioned above
substantially reduce the number of adult worms in the gastroin-
testinal tract. This effect is also reflected in reduced fecal egg
counts. In some cases, however, the efficacy of single-dose
mebendazole or albendazole on hookworm and Trichuris infec-
tions is low (Adams and others 2004;Albonico and others 1994).
Moreover, pyrantel pamoate has little effect on T. trichiura.
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Overall, however, anthelmintic treatment significantly improves
physical and cognitive outcomes in the following ways:
• Preschool children. Periodic distribution of anthelmintics
has a positive effect on motor and language development
and reduces malnutrition in very young children (Stoltzfus
and others 2004).
• School-age children. Treating school-age children has a
considerable effect on their nutritional status (Stoltzfus and
others 2004), anemia, physical fitness, appetite, growth
(Stephenson, Latham, and Ottesen 2000), and intellectual
development (Drake and others 2000).
• Women of reproductive age. Studies of pregnant women
conducted by Christian, Khatry, and West (2004) in Nepal
indicate that albendazole treatment improves maternal
hemoglobin as well as birth-weight and child survival.
Schistosomiasis. As with STH infections, anthelmintic
chemotherapy for schistosomiasis has an important effect on
child development, growth, and physical fitness (WHO 2002).
Richter (2003) recently summarized details of the effect of PZQ
on organ pathology. In S. haematobium infections, reversal of
urinary tract pathology can be seen six months after a cure. In
S. mansoni and S. japonicum infections, much of the intestinal
pathology regresses after chemotherapy. However, more than
one PZQ treatment is usually necessary to reverse hepatic
pathology, especially in areas of intense transmission. Early
intervention with PZQ is preferable to reverse organ pathology.
Intervention Costs
Several studies have evaluated the costs of school-based peri-
odic deworming in several different settings, whereas compara-
ble studies on other interventions are still lacking.
Periodic Deworming. The advantage of periodic deworming
lies in its simplicity (one tablet per child) and safety. Teachers
and other personnel without medical training can easily apply
the simple measures, which can be incorporated without diffi-
culty in existing health and nonhealth activities that reach the
high-risk group. Several organizations, including nongovern-
mental organizations, include an STH and schistosome
infection-control package within their routine activities and,
with very limited budgets, relieve the burden of helminth infec-
tions in the population covered. The costs of albendazole and
PZQ are available through the International Drug Price
Indicator Guide (http://www.msh.org). Delivery systems for
deworming have often depended on vertical programs, in
which mobile teams visit schools or communities to carry out
treatment (WHO 2002). Estimated costs for this approach are
outlined in table 24.2. For STH infections in Tanzania, Nigeria,
and Montserrat, the costs range from US$0.21 to US$0.51 per
treatment. However, by training teachers and other school offi-
cials to administer anthelmintic drugs, the system could
achieve low-cost delivery by “piggy-backing” on existing pro-
grams in the educational sector (WHO 2002). Specific exam-
ples of such programs conducted in Ghana and Tanzania are
summarized in the section “Implementation of Control
Strategies: Lessons of Experience,” later in this chapter. It was
found that delivery of school-based targeted anthelmintic
treatment could cost as little as US$0.03 per child, which may
be as low as one-tenth of the estimated costs for vertical deliv-
ery (WHO 2002). Thus, at current drug prices, the total cost
(drug plus delivery) of a single treatment with albendazole or
mebendazole may be as low as US$0.05, and that of a combined
treatment with PZQ may be as low as US$0.25 per child (WHO
2002).
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The 54th World Health Assembly
Box 24.1
The 54th World Health Assembly, which met in May 2001,
urged member states to ensure access to essential drugs for
schistosomiasis and STH infections in endemic areas
for the treatment of clinical cases and groups at high risk
for morbidity. The helminth infections of concern are the
major schistosomes and STHs outlined in the text. The
World Health Assembly determined that simple and sus-
tainable control measures can relieve a generally underes-
timated and unnecessary disease burden in high-
transmission areas. The following minimal targets, aimed
at reducing morbidity by 80 percent, can be achieved by all
countries in which such disease is endemic as an integral
part of the primary health care system: (a) access to ade-
quate diagnosis and essential anthelmintic drugs in all
health services in all endemic areas, even at peripheral lev-
els, for the treatment of symptomatic cases and of chil-
dren, women, and other groups at high risk of morbidity;
(b) regular administration of chemotherapy to at least
75 percent of all school-age children at risk for morbidity
by 2010; and (c) sustained, community-based efforts to
improve sanitation, clean water supplies, and health
education.
Source: WHO 2002.
Integrating drug distribution through the school system
rather than using mobile teams, along with a marked decline in
the price of BZAs and PZQ, has resulted in a 10-fold reduction
in delivery costs. However, those costs are artificially low
because they do not include the external costs for the coordi-
nating center responsible for supporting those approaches
(Guyatt 2003). It has been estimated, for instance, that mass
albendazole treatment of school-age children in Kenya could
cost more than US$3 million each year, equivalent to some
4 percent of current national public expenditure on health care
(Guyatt 2003). This analysis has not been evaluated against
actual operations, however, and current estimates from the
parasite control authorities in Kenya suggest that the actual cost
is likely to be far less. Large-scale chemotherapy programs for
helminth control continue to rely heavily on donor support,
suggesting that some affected countries may be unable to sup-
port the costs of deworming.
Monitoring of control programs is an important part of the
managerial process, and it should be carried out at minimum
cost so as not to divert resources from the intervention
(Brooker and others 2004). It is recommended that, at the
planning stage, approximately 5 to 10 percent of the program
budget be reserved for monitoring activities (Montresor and
others 2002).
Improved Sanitation. When sanitation improvements are
made alongside deworming, the results obtained last longer.
However, the investment needed to reach the level required to
interfere with STH transmission could be high. To correctly
evaluate the advantage of such investments, one must take into
account the consequences for other health indicators and for
economic development. An efficient sanitation infrastructure
removes the underlying cause of most poverty-related commu-
nicable diseases and can boost the economic development of a
country. The resources needed to improve hygienic standards
can be huge and require the cooperation of several sectors of
society (Asaolu and Ofoezie 2003). Currently, these are
qualitative judgments, and no cost-effectiveness analysis (CEA)
estimates exist for sanitation in this context.
Health Education and Communication. Measures to increase
the health awareness of the population are included as an
essential component of any population-based activity aimed at
controlling morbidity attributable to helminth infections.
However, the effectiveness of those activities in reducing trans-
mission of infection varies according to different reports. In
some cases, health education can decrease costs, increase levels
of knowledge, and decrease reinfection rates (Lansdown and
others 2002). Health education efforts can build trust and
engage communities, aspects that are crucial to the success of
public health initiatives. No CEA estimates exist for health
education in this context.
Linking Costs and Effects of Interventions
Interventions to reduce morbidity from helminth infections
fall into two categories: targeting the transmission mechanisms
and treating individuals directly. The former encompasses
improvements in infrastructure, including water supply and
sanitation, and health education. The latter entails the periodic
drug treatment of the population. Substantial improvements
through prevention may be a long-term outcome of economic
growth in general, because wealthier households have
improved sanitation facilities and practices, but those improve-
ments are not an option in the short term without large
investments in infrastructure. As shown in the previous sec-
tion, deworming options dominate on both effectiveness and
cost-effectiveness criteria. Costs continue to fall as drug costs
decrease. With better data and detailed mapping of disease
distribution within communities, targeting individuals at
high risk becomes more feasible, thus improving the cost-
effectiveness of control programs (Michaud, Gordon, and
Reich 2003).
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Table 24.2 Recent Examples of Delivery Costs for a Single Mass Treatment
Delivery cost per treatment
Strategy Drug Country US$ Percentage of total cost
Mobile team Albendazole Montserrat 0.51 67
Albendazole Bangladesh — 42
Levamisole Nigeria 0.32 81
PZQ Tanzania 0.21 24
School-based Albendazole Ghana 0.04 17
Albendazole Tanzania 0.03 13
Out-of-school children Arab Rep. of Egypt 0.16–0.21 40–47
Source: Guyatt 2003.
—  not available.
Evidence from existing programs that narrow the interven-
tion to school-age children (a high-risk group) shows that the
treatment costs of chemotherapy for helminth infections are
quite low—well below US$1 per school-age child. This finding
is in part due to the accessibility of the target group and the cost
savings of incorporating delivery into existing school and
health programs. Moreover, as discussed in the following
sections, the economic benefits of targeting this group may be
substantial. Still other targeted groups may also have low cost
per treatment when treatment is merged into existing
programs. For example, interventions through prenatal care
programs for pregnant women may be cost-effective. Likewise,
evidence on costs of treatment through existing integrated
management of infant and childhood illness (IMCI) programs
for small children and health campaigns (such as vaccination
and micronutrient programs) find low cost per case treated
(Montresor and others 2002).
Several factors can potentially alter the ranking of interven-
tions in regard to cost-effectiveness, although there are no
existing studies to evaluate this. Previous analysis may underes-
timate the effectiveness and overestimate the cost-benefit
ratios of mass treatment of school-age children if the
externalities of treatment are not considered (Miguel and
Kremer 2003). The cost-effectiveness of school-based deworm-
ing programs will change as the programs are extended to cover
children who are not enrolled in school. Such program exten-
sions are likely to have greater costs because they entail addi-
tional staff and outreach efforts per case treated. However, the
effectiveness of mass treatment of school-age children (both
enrolled and not enrolled) may be greater. Children who are
not enrolled in school come from households with lower
income levels. Lower income, which leads to poorer sanitation
conditions, is associated with greater incidence and intensity of
infections. Expanding mass treatment to children not enrolled
in school will result in treating populations that have higher
incidence and intensity, thus raising effectiveness (box 24.2).
Distributional and Equity Consequences
Interventions to control helminth infections can have equity
implications in several dimensions. Programs designed to tar-
get communities with high prevalence or high intensity of
helminth infection focus on areas with lower income, as
described in the sections on the causes, characteristics, and
epidemiology of such infections. Although no studies under-
take benefit-incidence analysis of public spending on such
health services, this targeting implies that state subsidies on
deworming services will be of most benefit to lower-income
groups. With the increasing availability of poverty maps,
empirical evaluation of the equity implications of deworming
will be feasible.
AVERTED, AVERTABLE, AND 
NONAVERTABLE BURDEN
In the short run, deworming can avert helminth infections. In
the long run, it is assumed that as income levels grow and
infrastructure improves, the number of infections averted by
reducing transmission will increase. However, given the slow
rate of poverty reduction in the 1990s for the poorest regions,
such as Sub-Saharan Africa, waiting for economic development
to lead to a reduction in infections is only, at best, a slow-paced
solution for the majority of the infected population. It is more
likely that most averted infections will depend on periodic
deworming. Thus, the question remains as to what portion of
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The High Cost-Effectiveness of Mass Treatment for Helminth Infection
Box 24.2
The combination of low-cost treatment and high preva-
lence rates suggests that the cost per DALY averted from
treating helminth infections will be quite low. Following
the consistent framework described in mass treatment of
school-age children for both STH infections and schistoso-
miasis proves to be extremely cost-effective. In fact, benefit-
cost ratios would be even higher if the analyses incorpo-
rated the additional benefits associated with externalities
for the untreated. For a population of 1 million people in
low- and middle-income countries, if treatment is limited
to school-age children treated 1.1 times per year with
albendazole and then reinfected, the cost per DALY averted
is estimated at US$3.41 for STH infections. That is, if
spending were capped at US$1 million, total DALYs would
be reduced by nearly 300,000. The estimate of cost per
DALY is higher for schistosomiasis relative to STH infec-
tions because of higher drug costs and lower disability
weights. Depending on whether generics or original for-
mulations are used, the cost per DALY averted ranges from
US$3.36 to US$6.92. However, in combination, treatment
with both albendazole and PZQ proves to be extremely cost
effective, in the range of US$8 to US$19 per DALY averted.
Source: Authors.
existing infections is potentially avertable through recom-
mended interventions and what portion is currently averted
with existing programs. For schistosomiasis, successful pro-
grams in several countries, including Brazil, China, and the
Arab Republic of Egypt, and the issues related to the sustain-
ability of these successes have been described (see
“Implementation of Control Strategies: Lessons of Experience”
later in this chapter). However, the number of averted schisto-
somiasis infections in Sub-Saharan Africa is likely to be small,
because few serious attempts at widespread control have been
made in recent years, and not much of the burden of STH and
schistosome infections is currently averted through private
treatment. In part, the low number of averted infections may
be due to the lack of information on the part of infected indi-
viduals, the insidious nature of the condition, and the lack of
drugs in the public or private health delivery system.
ECONOMIC BENEFITS OF INTERVENTION
The characteristics of helminth infections make a compelling
case for public sector intervention if based only on the evidence
related to the intervention’s effect on health. From an economic
perspective, the public sector has several reasons to become
involved in improving health outcomes.First,other benefits may
be gained, in addition to the benefit for the treated individual.
Second, some forms of intervention are almost pure public
goods; that is, no one can be excluded from using the goods or
services the interventions deliver, and the private sector is thus
unlikely to deliver them. Finally, preventive measures, such as
information on the value of washing hands,may not be delivered
through the private sector. The lack of knowledge about infec-
tions and subclinical symptoms may make individuals less like-
ly to seek treatment. In analyzing the gains of interventions for
worm control, one should account for the burden of helminth
infections, which extends well beyond the health impacts and
DALYs. The economic implications may be quite large.
The negative correlation between helminth infections and
income level is clearly demonstrated both within and between
countries (de Silva and others 2003). However, causality cannot
be inferred from this established relationship; poverty pro-
motes higher worm burdens, yet poor health induced by
helminths can lead to lower income. There may also be oppor-
tunity costs to uninfected household members residing with
infected persons. Few studies have been designed to evaluate,
either directly or indirectly, the magnitude of the effect of
deworming on economic productivity. The indirect evidence at
the micro level suggests that helminth infection has a signifi-
cant impact on adult productivity and, subsequently, on earn-
ings. More direct evidence for children shows that helminth
infection has long-term implications for educational attain-
ment and economic status.
Studies are increasingly documenting a causal impact of
adult health (broadly defined) on labor force participation,
wages, and productivity in developing countries (Thomas and
Strauss 1997). Moreover, helminth infection is known to affect
some of the health conditions related to productivity—namely,
iron deficiency anemia and wasting. Guyatt (2000) reviews
numerous studies relating these conditions to physical fitness
and productivity; Haas and Brownlie (2001) review studies on
the effect of iron supplementation on work. The studies gener-
ally show productivity gains linked to better health along the
various health dimensions studied. However, although some
evidence points to the indirect impact of STHs on income
earnings, these relationships have not been adequately studied,
either directly or indirectly.
More compelling links between helminth infection and eco-
nomic well-being may exist for children. The strong association
between worm burden and poor health outcomes for children
suggests that infections may affect school enrollment, atten-
dance, grade repetition, and grade attainment. In turn, the
potential impact on educational outcomes has implications
for the assessment of the economic benefits of intervention.
Numerous studies have demonstrated the benefits of schooling,
showing that the return on education is quite high. Increased
education is associated with, among other things, higher worker
productivity and generally higher productivity in nonmar-
ket production activities, including greater farmer efficiency
and productivity (Psacharopoulos and Patrinos 2002).
Although observational studies show that lower levels of
learning and schooling are linked to helminth infection (World
Bank 2003), establishing a causal relationship requires ade-
quately controlling for all unobserved or confounding factors.
Miguel and Kremer (2003) note that several methodological
issues hamper many existing randomized treatment-control
evaluations. First, externalities associated with interventions
can lead to underestimating impacts among the untreated pop-
ulation. Second, sample selection and attrition issues can affect
the validity of findings, although the direction of this effect
is ambiguous. Third, existing studies typically evaluate the
impact of deworming on cognitive skills, likely the culmination
of several years of health and education investments, as
assessed by tests administered to treated and untreated chil-
dren. Although studies find an effect on cognitive skills for
those with the heaviest worm burden, they do not focus on
other important education outcomes, which are likely to be
more affected in the short run by health improvements, such as
school enrollment and school attendance.
The study by Miguel and Kremer (2003) in Kenya attempts
to address those shortcomings through improved study design
and analytical methods. In addition to providing health gains,
deworming reduced total primary school absenteeism by at
least one-quarter in the first two years of the project. The gains
were largest for the youngest children, who suffered from more
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intense worm infections. Externalities would cause a substan-
tial underestimation of this effect. In terms of cost-effectiveness
as an educational intervention, deworming proved to be far
more effective at improving school attendance than other edu-
cational interventions implemented in a study in Kenya.
Deworming offers a high rate of return, increasing the net pres-
ent value of discounted wages by more than US$30 per treated
child compared with per treatment costs of under US$1. For
realistic estimates of returns to schooling, these results show in
general that the net present discounted value of lifetime earn-
ings is high compared with the costs of treatment even for
small gains in school participation (figure 24.3).
Bleakley (2003) examined the effect of a hookworm control
program undertaken about 1910 in the southern part of the
United States. Hookworm infection was estimated to cause a
23 percent drop in the probability of school attendance, and
children with greater exposure to the hookworm eradication
campaign were more likely to be literate. Moreover, the long-
term follow-up of affected cohorts showed that hookworm
infection in childhood led to significantly lower wages in
adulthood.
Helminth infections in preschool-age children can have con-
sequences for subsequent schooling, such as delaying primary
school enrollment and school attainment, thereby affecting
future labor market outcomes. Bobonis, Miguel, and Sharma
(2003) conducted a study of preschool-age children, using iron
supplementation and deworming drugs administered to chil-
dren two to six years of age. Preliminary results indicate that, in
addition to the weight gain associated with treatment, average
preschool participation rates increased sharply by 6.3 percent-
age points among assisted children older than two, reducing
preschool absenteeism by roughly one-fifth.
Beyond the current impacts on schooling and implications
for cognition, helminth infection in children can have long-
term implications for economic outcomes in adulthood
through its effect on physical growth. Height has been shown
to affect wage-earning capacity as well as participation in the
labor force for men and women (Thomas and Strauss 1997).
This relationship may be strongest in settings where infection
rates are highest—that is, low-income areas, where physical
endurance yields high returns in the labor market.
IMPLEMENTATION OF CONTROL STRATEGIES:
LESSONS OF EXPERIENCE 
Two case studies illustrate the profound health effects of peri-
odic deworming.
Case Study Number 1: Periodic Deworming 
in Ghana and Tanzania
The Partnership for Child Development (PCD) undertook an
evaluation of the use of schools in Ghana and Tanzania for the
delivery of health interventions, including research into the
processes, costs, and benefits (PCD 1999). The effort also
involved operations research and evaluation of programs with
regard to health and education outcomes and people’s percep-
tions of the programs (Hall and others 1999). The results
demonstrated the following:
• Simple interventions, such as deworming, have the
potential to improve children’s health and educational
achievement, especially for those worst affected and most
disadvantaged.
• The delivery of school-based health services is efficient and
cost-effective and is supported by the key stakeholders
involved. Implementers of the school health programs in the
education and health sectors and the community are posi-
tive regarding the teacher’s role in health provision, as long
as the health interventions are simple, safe, familiar, and
effective and are seen as responding to local needs.
• The provision of health services through schools need not
require long and complex training, nor significantly add to
the workload of teachers or administrators.
• Delivery through the existing education sector could occur
effectively without any additional infrastructure, as long as
the existing educational system is adequately functional.
The results of the evaluation of these programs also high-
lighted the need for deworming to be carried out in the context
of a wider framework of school health, which includes core
activities such as effective and nondiscriminatory school health
policies, provision of safe water and sanitation, and effective
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health education (http://www.freshschools.org and http://www.
schoolsandhealth.org).
Case Study Number 2: Schistosomiasis Control in Egypt 
In 1937, the prevalence of schistosomiasis in rural areas was
about 50 percent, almost every boy had blood in his urine by
the age of 12, and bladder cancer was the commonest cancer in
Egypt. Molluscicides, from copper sulfate to niclosamide, have
been used to try to kill the host snails, and drugs from antimony-
based compounds, through niridazole, metrifonate, and
PZQ, have been used to treat the millions of infected Egyptians.
Finally, after a 14-year control campaign using PZQ, the
prevalence of schistosomiasis has been reduced to below
10 percent. With infection intensities now low, the serious
health consequences of schistosomiasis have disappeared. The
program was started in 1988, when using loans from the
African Development Bank and the World Bank, Egypt invested
heavily in the purchase of PZQ, encouraging local production,
to control morbidity caused by schistosomiasis. Since the drug
was first made available in 1988, some 45 million doses have
been dispensed. A television campaign has encouraged people
to submit samples for diagnosis and to receive free treatment if
their diagnoses are positive. Since 1997, a mass chemotherapy
campaign was used to target populations in high-prevalence
villages and children in selected governorates where prevalence
was greater than 20 percent. In addition, molluscicides
have been applied in canals around high-prevalence villages.
The widespread use of PZQ has given dramatic results.
Morbidity, including hematuria, has almost disappeared, and
bladder cancer is on the decline.
RESEARCH AND DEVELOPMENT
Among the important tasks to be done to control helminth
infections are collection of better data on helminth disease
burden, research on the health and economic effects (and
safety) of periodic deworming, monitoring of the emergence of
anthelmintic drug resistance, and development of new tools to
supplement or complement existing control strategies.
Health and Economic Impact 
Overall, better estimates of disease burden are needed
(Michaud, Gordon, and Reich 2003), especially with respect to
obtaining a consistent and agreed-on estimate for the DALYs
attributed to helminth infections. In a systematic review of ran-
domized deworming trials, Dickson and others (2000) con-
clude that, although data support the effects of deworming on
weight gain, there are inconsistencies among trials and insuffi-
cient evidence as to whether such interventions improve cogni-
tive performance. Plausible mechanisms by which helminths
suppress growth in childhood and exert negative impacts on
intelligence, cognition, and school performance are largely
unstudied and unknown. In addition, some reports have ques-
tioned whether albendazole itself could adversely affect growth
(Forrester and others 1998). Those issues require clarification
as widespread deworming programs become more common.
The impact of helminths on populations other than
schoolchildren, including preschool-age children, women of
childbearing age, and adult workers, appears to be substantial.
However, those populations are understudied. Also unclear is
the impact of childhood STH and schistosome infections on
productivity in adulthood. The effect of chemotherapy on
many of the manifestations of schistosomiasis has not been
assessed systematically. It has been postulated that PZQ treat-
ment of schistosomiasis promotes partial immunity by destroy-
ing worms in the vasculature and releasing parasite antigens
(Colley and Secor 2004). In contrast, the frequent and periodic
treatment of STH infections (Albonico and others 1995) do not
appear to promote natural protective immunity.
The role of helminths and coinfections also warrants fur-
ther exploration. Some studies suggest that HIV-1 infection
may promote susceptibility to schistosomiasis (Secor, Karanja,
and Colley 2004), and human T-cell lymphotropic virus-1
(HTLV-1) infection may promote susceptibility to strongy-
loidiasis. In addition, emerging evidence indicates that STH
and schistosome infections may promote susceptibility to
other infectious agents, possibly including HIV/AIDS and
malaria (Fincham, Markus, and Adams 2003). This phenome-
non, if verified in an epidemiologic study, would further
increase helminth-associated DALY estimates.
Anthelmintic Drug Resistance and New Drug Development
A concern about the feasibility of sustainable control with
BZAs is the possible emergence of drug resistance among
human STHs. BZA resistance occurs because of the spread of
point mutations in nematode-tubulin alleles. This phenome-
non has already resulted in widespread BZA drug resistance
among STHs of ruminant livestock. There is still no direct evi-
dence for BZA resistance among human STHs, although such
resistance could account for an observed failure of mebenda-
zole for human hookworm in southern Mali, as well as a
diminished efficacy against hookworm in Zanzibar following
frequent and periodic use of mebendazole (Albonico and oth-
ers 2003). PZQ resistance must also be considered, especially as
it begins to be widely used in Sub-Saharan Africa (Hagan and
others 2004). Should PZQ resistance develop, there will be new
demands for antischistosomal drugs. Recently, the artemisins
have shown activity against schistosomulae and were successful
in protecting against S. japonicum in China (Hagan and others
2004).
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Anthelmintic Vaccines
The high rates of reinfection that can occur following treatment
with anthelmintic drugs and concern about emerging drug
resistance have prompted the search for alternative control tools.
For most helminth infections, reduction in adult worm burden
has been considered the “gold standard” for vaccine develop-
ment. For schistosomiasis, however, a vaccine that targets para-
site fecundity and egg viability, thereby reducing pathology and
transmission, would also represent an important breakthrough.
A 28-kDa glutathione S-transferase (GST) has shown promise
as a protective antigen for S. haematobium infection (Capron
and others 2005). The S. haematobium vaccine project based on
GST has successfully passed phase 1 testing; the research group,
which is based at the Pasteur Institute, is embarking on phase 2
clinical trials in Senegal and Niger. Additional schistosomiasis
vaccines are also undergoing early-stage development. Efforts
are also under way by the Human Hookworm Vaccine Initiative
to develop and test a first-generation recombinant hookworm
vaccine (Brooker and others 2005; Hotez, Bethony, and others
2005). The first vaccine manufactured under current good man-
ufacturing practices and tested for quality control and toxicity is
the Na-ASP-2 hookworm vaccine, which was developed from
research demonstrating human correlates of immunity and par-
tial protection data in vaccinated laboratory animals. Phase 1
human trials for evaluating the safety and immunogenicity of
the Na-ASP-2 hookworm vaccine are in progress. Additional
research is needed to determine how an anthelmintic vaccine
can be incorporated into existing control programs, as well how
it would be used for at-risk populations not currently targeted
for periodic deworming in schools.
CONCLUSIONS: PROMISES AND PITFALLS
Fulfilling the mandate of World Health Assembly resolution
54.19 will require the regular treatment of hundreds of millions
of children over decades. The obstacles in this undertaking are
formidable, and success will depend on the ability of countries
to identify or create reliable and sustained infrastructures for
this purpose. A focus on using preexisting school systems may
be key to achieving this goal. The treatment of schoolchildren
for A. lumbricoides, T. trichiura, and schistosome infections
achieves large externalities that reduce infection in other
vulnerable age groups. However, the different epidemiology of
hookworm raises concerns about the risks to preschool chil-
dren and women of reproductive age who remain untreated.
Providing regular treatment to these populations appears to be
a less cost-effective option, largely because of the absence of
a preexisting infrastructure. This situation presents a strong
argument for developing a hookworm vaccine that could be
used to protect these vulnerable groups. It has yet to be seen
whether the emergence of BZA drug resistance is a genuine
concern that could derail global deworming efforts in much the
same way that resistance to DDT and chloroquine has affected
the ambitions for global malaria control. It is possible that the
specific dynamics of helminth populations will provide suffi-
cient genetic flow to maintain susceptibility in much the same
way that insecticides remain the effective staple of global
agribusiness. Until new technologies become available,
anthelmintic chemotherapy for school-age children remains
the most practical and substantive means to control STH and
schistosome infections in the developing world.
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Acute respiratory infections (ARIs) are classified as upper res-
piratory tract infections (URIs) or lower respiratory tract infec-
tions (LRIs). The upper respiratory tract consists of the airways
from the nostrils to the vocal cords in the larynx, including the
paranasal sinuses and the middle ear. The lower respiratory
tract covers the continuation of the airways from the trachea
and bronchi to the bronchioles and the alveoli. ARIs are not
confined to the respiratory tract and have systemic effects
because of possible extension of infection or microbial toxins,
inflammation, and reduced lung function. Diphtheria, per-
tussis (whooping cough), and measles are vaccine-preventable
diseases that may have a respiratory tract component but also
affect other systems; they are discussed in chapter 20.
Except during the neonatal period, ARIs are the most com-
mon causes of both illness and mortality in children under five,
who average three to six episodes of ARIs annually regardless of
where they live or what their economic situation is (Kamath
and others 1969; Monto and Ullman 1974). However, the pro-
portion of mild to severe disease varies between high- and low-
income countries, and because of differences in specific etiolo-
gies and risk factors, the severity of LRIs in children under five
is worse in developing countries, resulting in a higher case-
fatality rate. Although medical care can to some extent mitigate
both severity and fatality, many severe LRIs do not respond to
therapy, largely because of the lack of highly effective antiviral
drugs. Some 10.8 million children die each year (Black, Morris,
and Bryce 2003). Estimates indicate that in 2000, 1.9 million of
them died because of ARIs, 70 percent of them in Africa and
Southeast Asia (Williams and others 2002). The World Health
Organization (WHO) estimates that 2 million children under
five die of pneumonia each year (Bryce and others 2005).
CAUSES OF ARIS AND THE BURDEN OF DISEASE
ARIs in children take a heavy toll on life, especially where med-
ical care is not available or is not sought.
Upper Respiratory Tract Infections
URIs are the most common infectious diseases. They include
rhinitis (common cold), sinusitis, ear infections, acute pharyn-
gitis or tonsillopharyngitis, epiglottitis, and laryngitis—of
which ear infections and pharyngitis cause the more severe
complications (deafness and acute rheumatic fever, respec-
tively). The vast majority of URIs have a viral etiology.
Rhinoviruses account for 25 to 30 percent of URIs; respiratory
syncytial viruses (RSVs), parainfluenza and influenza viruses,
human metapneumovirus, and adenoviruses for 25 to 35 per-
cent; corona viruses for 10 percent; and unidentified viruses for
the remainder (Denny 1995). Because most URIs are self-limit-
ing, their complications are more important than the infections.
Acute viral infections predispose children to bacterial infections
of the sinuses and middle ear (Berman 1995a), and aspiration
of infected secretions and cells can result in LRIs.
Acute Pharyngitis. Acute pharyngitis is caused by viruses in
more than 70 percent of cases in young children. Mild pharyn-
geal redness and swelling and tonsil enlargement are typical.
Streptococcal infection is rare in children under five and more
common in older children. In countries with crowded living
conditions and populations that may have a genetic predispo-
sition, poststreptococcal sequelae such as acute rheumatic fever
and carditis are common in school-age children but may also
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occur in those under five. Acute pharyngitis in conjunction
with the development of a membrane on the throat is nearly
always caused by Corynebacterium diphtheriae in developing
countries. However, with the almost universal vaccination of
infants with the DTP (diphtheria-tetanus-pertussis) vaccine,
diphtheria is rare.
Acute Ear Infection. Acute ear infection occurs with up to
30 percent of URIs. In developing countries with inadequate
medical care, it may lead to perforated eardrums and chronic
ear discharge in later childhood and ultimately to hearing
impairment or deafness (Berman 1995b). Chronic ear infection
following repeated episodes of acute ear infection is common in
developing countries, affecting 2 to 6 percent of school-age chil-
dren.The associated hearing loss may be disabling and may affect
learning. Repeated ear infections may lead to mastoiditis, which
in turn may spread infection to the meninges. Mastoiditis and
other complications of URIs account for nearly 5 percent of all
ARI deaths worldwide (Williams and others 2002).
Lower Respiratory Tract Infections
The common LRIs in children are pneumonia and bronchi-
olitis. The respiratory rate is a valuable clinical sign for diag-
nosing acute LRI in children who are coughing and breathing
rapidly. The presence of lower chest wall indrawing identifies
more severe disease (E. Mulholland and others 1992; Shann,
Hart, and Thomas 1984).
Currently, the most common causes of viral LRIs are RSVs.
They tend to be highly seasonal, unlike parainfluenza viruses,
the next most common cause of viral LRIs. The epidemiology
of influenza viruses in children in developing countries
deserves urgent investigation because safe and effective vac-
cines are available. Before the effective use of measles vaccine,
the measles virus was the most important viral cause of respi-
ratory tract–related morbidity and mortality in children in
developing countries.
Pneumonia. Both bacteria and viruses can cause pneumonia.
Bacterial pneumonia is often caused by Streptococcus pneumo-
niae (pneumococcus) or Haemophilus influenzae, mostly type b
(Hib), and occasionally by Staphylococcus aureus or other strep-
tococci. Just 8 to 12 of the many types of pneumococcus cause
most cases of bacterial pneumonia, although the specific types
may vary between adults and children and between geographic
locations. Other pathogens, such as Mycoplasma pneumoniae
and Chlamydia pneumoniae, cause atypical pneumonias. Their
role as a cause of severe disease in children under five in devel-
oping countries is unclear.
The burden of LRIs caused by Hib or S. pneumoniae is
difficult to determine because current techniques to establish
bacterial etiology lack sensitivity and specificity. The results of
pharyngeal cultures do not always reveal the pathogen that is
the cause of the LRI. Bacterial cultures of lung aspirate speci-
mens are often considered the gold standard, but they are not
practical for field application. Vuori-Holopainen and Peltola’s
(2001) review of several studies indicates that S. pneumoniae
and Hib account for 13 to 34 percent and 1.4 to 42.0 percent of
bacterial pneumonia, respectively, whereas studies by Adegbola
and others (1994), Shann, Gratten, and others (1984), and Wall
and others (1986) suggest that Hib accounts for 5 to 11 percent
of pneumonia cases.
Reduced levels of clinical or radiological pneumonia in clin-
ical trials of a nine-valent pneumococcal conjugate vaccine
provide an estimate of the vaccine-preventable disease burden
(valency indicates the number of serotypes against which the
vaccine provides protection; conjugate refers to conjugation of
polysaccharides to a protein backbone). In a study in The
Gambia, 37 percent of radiological pneumonia was prevented,
reflecting the amount of disease caused by S. pneumoniae, and
mortality was reduced by 16 percent (Cutts and others 2005).
Upper respiratory tract colonization with potentially patho-
genic organisms and aspiration of the contaminated secretions
have been implicated in the pathogenesis of bacterial pneumo-
nia in young children. Infection of the upper respiratory tract
with influenza virus or RSVs has been shown to increase the
binding of both H. influenzae (Jiang and others 1999) and
S. pneumoniae (Hament and others 2004; McCullers and
Bartmess 2003) to lining cells in the nasopharynx. This finding
may explain why increased rates of pneumococcal pneumonia
parallel influenza and RSV epidemics. A study in South Africa
showed that vaccination with a nine-valent pneumococcal con-
jugate vaccine reduced the incidence of virus-associated pneu-
monia causing hospitalization by 31 percent, suggesting that
pneumococcus plays an important role in the pathogenesis of
virus-associated pneumonia (Madhi, Petersen, Madhi, Wasas,
and others 2000).
Entry of bacteria from the gut with spread through the
bloodstream to the lungs has also been proposed for the patho-
genesis of Gram-negative organisms (Fiddian-Green and Baker
1991), but such bacteria are uncommon etiological agents of
pneumonia in immune-competent children. However, in
neonates and young infants, Gram-negative pneumonia is not
uncommon (Quiambao forthcoming).
Viruses are responsible for 40 to 50 percent of infection in
infants and children hospitalized for pneumonia in developing
countries (Hortal and others 1990; John and others 1991;
Tupasi and others 1990). Measles virus, RSVs, parainfluenza
viruses, influenza type A virus, and adenoviruses are the most
important causes of viral pneumonia. Differentiating between
viral and bacterial pneumonias radiographically is difficult,
partly because the lesions look similar and partly because bac-
terial superinfection occurs with influenza, measles, and RSV
infections (Ghafoor and others 1990).
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In developing countries, the case-fatality rate in children
with viral pneumonia ranges from 1.0 to 7.3 percent (John and
others 1991; Stensballe, Devasundaram, and Simoes 2003),
with bacterial pneumonia from 10 to 14 percent and with
mixed viral and bacterial infections from 16 to 18 percent
(Ghafoor and others 1990; Shann 1986).
Bronchiolitis. Bronchiolitis occurs predominantly in the first
year of life and with decreasing frequency in the second and
third years. The clinical features are rapid breathing and lower
chest wall indrawing, fever in one-third of cases, and wheezing
(Cherian and others 1990). Inflammatory obstruction of the
small airways, which leads to hyperinflation of the lungs, and
collapse of segments of the lung occur. Because the signs and
symptoms are also characteristic of pneumonia, health workers
may find differentiating between bronchiolitis and pneumonia
difficult. Two features that may help are a definition of the sea-
sonality of RSVs in the locality and the skill to detect wheezing.
RSVs are the main cause of bronchiolitis worldwide and can
cause up to 70 or 80 percent of LRIs during high season (Simoes
1999; Stensballe, Devasundaram, and Simoes 2003). The
recently discovered human metapneumovirus also causes bron-
chiolitis (Van den Hoogen and others 2001) that is indistin-
guishable from RSV disease. Other viruses that cause bronchi-
olitis include parainfluenza virus type 3 and influenza viruses.
Influenza. Even though influenza viruses usually cause URIs
in adults, they are increasingly being recognized as an impor-
tant cause of LRIs in children and perhaps the second most
important cause after RSVs of hospitalization of children with
an ARI (Neuzil and others 2002). Although influenza is consid-
ered infrequent in developing countries, its epidemiology
remains to be investigated thoroughly. The potential burden of
influenza as a cause of death in children is unknown. Influenza
virus type A may cause seasonal outbreaks, and type B may
cause sporadic infection. Recently, avian influenza virus has
caused infection, disease, and death in small numbers of indi-
viduals, including children, in a few Asian countries. Its poten-
tial for emergence in human outbreaks or a pandemic is
unknown, but it could have devastating consequences in devel-
oping countries (Peiris and others 2004) and could pose a
threat to health worldwide. New strains of type A viruses will
almost certainly arise through mutation, as occurred in the case
of the Asian and Hong Kong pandemics in the 1950s and
1960s.
HIV Infection and Pediatric LRIs
Worldwide, 3.2 million children are living with HIV/AIDS,
85 percent of them in Sub-Saharan Africa (UNAIDS 2002). In
southern Africa, HIV-related LRIs account for 30 to 40 percent
of pediatric admissions and have a case-fatality rate of 15 to
34 percent, much higher than the 5 to 10 percent for children
not infected with HIV (Bobat and others 1999; Madhi,
Petersen, Madhi, Khoosal, and others 2000; Nathoo and others
1993; Zwi, Pettifior, and Soderlund 1999). Pneumocystis jirove-
ci and cytomegalovirus are important opportunistic infections
in more than 50 percent of HIV-infected infants (Jeena,
Coovadia, and Chrystal 1996; Lucas and others 1996). Gram-
negative bacteria are also important in more than 70 percent of
HIV-infected malnourished children (Ikeogu, Wolf, and Mathe
1997). Patient studies have confirmed the frequent association
of these bacteria but added S. pneumoniae and S. aureus as
important pathogens (Gilks 1993; Goel and others 1999). The
first South African report on the overall burden of invasive
pneumococcal disease reported a 41.7-fold increase in HIV-
infected children compared with uninfected children (Farley
and others 1994).
INTERVENTIONS
Interventions to control ARIs can be divided into four basic
categories: immunization against specific pathogens, early
diagnosis and treatment of disease, improvements in nutrition,
and safer environments (John 1994). The first two fall within
the purview of the health system, whereas the last two fall
under public health and require multisectoral involvement.
Vaccinations
Widespread use of vaccines against measles, diphtheria, per-
tussis, Hib, pneumococcus, and influenza has the potential to
substantially reduce the incidence of ARIs in children in devel-
oping countries. The effects of measles, diphtheria, and pertus-
sis vaccines are discussed in chapter 20. The limited data on
influenza in developing countries do not permit detailed
analysis of the potential benefits of that vaccine. This chapter,
therefore, focuses on the potential effects of Hib and pneumo-
coccal vaccines on LRIs.
Hib Vaccine. Currently three Hib conjugate vaccines are avail-
able for use in infants and young children. The efficacy of Hib
vaccine in preventing invasive disease (mainly meningitis, but
also pneumonia),has been well documented in several studies in
industrialized countries (Black and others 1992; Booy and oth-
ers 1994; Eskola and others 1990; Fritzell and Plotkin 1992;
Heath 1998; Lagos and others 1996; Santosham and others
1991) and in one study in The Gambia (K. Mulholland and
others 1997). All studies showed protective efficacy greater than
90 percent against laboratory-confirmed invasive disease,
irrespective of the choice of vaccine. Consequently, all industri-
alized countries include Hib vaccine in their national immu-
nization programs, resulting in the virtual elimination of
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invasive Hib disease because of immunity in those vaccinated
and a herd effect in those not vaccinated. Available data from a
few developing countries show a similar herd effect (Adegbola
and others 1999; Wenger and others 1999).
The initial promise and consequent general perception was
that Hib vaccine was to protect against meningitis, but in devel-
oping countries the vaccine is likely to have a greater effect on
preventing LRIs. The easily measured effect is on invasive dis-
ease, including bacteraemic pneumonia. The vaccine probably
has an effect on nonbacteremic pneumonia, but this effect is
difficult to quantify because of the lack of an adequate method
for establishing bacterial etiology. In Bangladesh, Brazil, Chile,
and The Gambia, Hib vaccine has been associated with a reduc-
tion of 20 to 30 percent in those hospitalized with radiograph-
ically confirmed pneumonia (de Andrade and others 2004;
Levine and others 1999; K. Mulholland and others 1997; WHO
2004a). However, results of a large study in Lombok, Indonesia,
were inconclusive with regard to the effect of Hib vaccine on
pneumonia (Gessner and others 2005).
Pneumococcal Vaccines. Two kinds of vaccines are currently
available against pneumococci: a 23-valent polysaccharide vac-
cine (23-PSV), which is more appropriate for adults than chil-
dren, and a 7-valent protein-conjugated polysaccharide vaccine
(7-PCV). A 9-valent vaccine (9-PCV) has undergone clinical
trials in The Gambia and South Africa, and an 11-valent vac-
cine (11-PCV) is being tried in the Philippines.
Studies of the efficacy of the polysaccharide vaccine in
preventing ARIs or ear infection in children in industrialized
countries have shown conflicting results. Whereas some studies
of this vaccine show no significant efficacy (Douglas and Miles
1984; Sloyer, Ploussard, and Howie 1981), studies from Finland
show a generally protective effect against the serotypes
contained in a 14-PSV (Douglas and Miles 1984; Karma and
others 1980; Makela and others 1980). The efficacy was more
marked in children over two years of age than in younger chil-
dren. The only studies evaluating the effect of the polysaccha-
ride vaccine in children in developing countries are a series of
three trials conducted in Papua New Guinea (Douglas and
Miles 1984; Lehmann and others 1991; Riley and others 1981;
Riley, Lehmann, and Alpers 1991). The analysis of the pooled
data from these trials showed a 59 percent reduction in LRI
mortality in children under five at the time of the vaccination
and a 50 percent reduction in children under two. On the basis
of these and other studies, the investigators concluded that the
vaccine had an effect on severe pneumonia. The greater-than-
expected efficacy in these trials was attributed to the greater
contribution of the more immunogenic adult serotypes in
pneumonia in Papua New Guinea (Douglas and Miles 1984;
Riley, Lehmann, and Alpers 1991). On account of the poor
immunogenicity of the antigens in the 23-PSV against preva-
lent pediatric serotypes, attention is now directed at more
immunogenic conjugate vaccines (Mulholland 1998; Obaro
1998; Temple 1991).
The 7-PCV and 9-PCV have been evaluated for efficacy
against invasive pneumococcal disease in four trials, which
demonstrated a vaccine efficiency ranging from 71.0 to 97.4 per-
cent (58 to 65 percent for HIV-positive children, among whom
rates of pneumococcal disease are 40 times higher than in HIV-
negative children) (Black and others 2000; Cutts and others
2005; Klugman and others 2003; O’Brien and others 2003).
In the United States, the 7-PCV was included in routine vac-
cinations of infants and children under two in 2000. By 2001 the
incidence of all invasive pneumococcal disease in this age group
had declined by 69 percent and disease caused by the serotypes
included in the vaccine and related serotypes had declined by
78 percent (Whitney and others 2003). Similar reductions were
confirmed in a study in northern California (Black and others
2001). A slight increase in rates of invasive disease caused by
serotypes of pneumococcus not included in the vaccine was
observed, but it was not large enough to offset the substantial
reduction in disease brought about by the vaccine. The studies
also found a significant reduction in invasive pneumococcal
disease in unvaccinated older age groups, especially adults age
20 to 39 and age 65 and older, suggesting that giving the vaccine
to young children exerted a considerable herd effect in the com-
munity. Such an advantage is likely to occur even where the
prevalence of adult HIV disease is high and pneumococcal dis-
ease may be recurrent and life threatening.
The effect of the vaccine on pneumococcal pneumonia as
such is difficult to define given the problems of establishing the
bacterial etiology of pneumonia. Three studies have evaluated
the effect of the vaccine on radiographic pneumonia (irres-
pective of the etiological agent) and have shown a 20.5 to
37.0 percent reduction in radiographically confirmed pneumo-
nia (9.0 percent for HIV-positive individuals) (Black and others
2000; Cutts and others 2005; Klugman and others 2003).
Several field trials have evaluated the efficacy of PCV against
ear infection. Even though the vaccine resulted in a significant
reduction in culture-confirmed pneumococcal otitis, no net
reduction of ear infection was apparent among vaccinated chil-
dren, probably because of an increase in the rates of otitis
caused by types of pneumococci not covered by the vaccine,
H. influenzae and Moraxella catarrhalis (Eskola and others
2001; Kilpi and others 2003). However, a trial in northern
California showed that the vaccine had a protective effect
against frequent ear infection and reduced the need for tympa-
nostomy tube placement (Fireman and others 2003). Thus, a
vaccine for ear infection may be beneficial in developing coun-
tries with high rates of chronic otitis and conductive hearing
loss and should be evaluated by means of clinical trials.
The most striking public health benefit of a vaccine in
developing countries would be a demonstrable reduction in
mortality. Although the primary outcome in The Gambia trial
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was initially child mortality, it was changed to radiological
pneumonia. Nevertheless, the trial showed a 16 percent
(95 percent confidence level, 3 to 38) reduction in mortality.
This trial was conducted in a rural area in eastern Gambia
where access to round-the-clock curative care, including case
management, is difficult to provide. This trial demonstrates
that immunization delivered through outreach programs will
have substantial health and economic benefits in such popula-
tions. One additional study evaluating the effect of an 11-PCV
on radiological pneumonia is ongoing in the Philippines;
results are expected in the second half of 2005.
Case Management
The simplification and systematization of case management for
early diagnosis and treatment of ARIs have enabled significant
reductions in mortality in developing countries, where access to
pediatricians is limited. WHO clinical guidelines for ARI case
management (WHO 1991) use two key clinical signs: respiratory
rate, to distinguish children with pneumonia from those with-
out, and lower chest wall indrawing, to identify severe pneumo-
nia requiring referral and hospital admission. Children with
audible stridor when calm and at rest or such danger signs of
severe disease as inability to feed also require referral. Children
without these signs are classified as having an ARI but not pneu-
monia. Children showing only rapid breathing are treated for
pneumonia with outpatient antibiotic therapy. Children who
have a cough for more than 30 days are referred for further
assessment of tuberculosis and other chronic infections.
Pneumonia Diagnosis Based on Rapid Breathing. The initial
guidelines for detecting pneumonia based on rapid breathing
were developed in Papua New Guinea during the 1970s. In a
study of 200 consecutive pediatric outpatients and 50 consecu-
tive admissions (Shann, Hart, and Thomas 1984), 72 percent of
children with audible crackles in the lungs had a respiratory
rate of 50 or more breaths per minute, whereas only 19 percent
of children without crackles breathed at such a rapid rate.
Therefore, the initial WHO guidelines used a threshold of
50 breaths per minute, at or above which a child with a cough
was regarded as having pneumonia.
The major concern was the relatively low sensitivity of this
approach, which could miss 25 to 40 percent of cases of pneu-
monia. A study in Vellore, India, found that sensitivity could
be improved by lowering the threshold to 40 for children age 1
to 4, while keeping the 50 breaths per minute cutoff for infants
age 2 months through 11 months (Cherian and others 1988).
Subsequent studies showed that when these thresholds were
used, sensitivity improved from 62 to 79 percent in the
Philippines and from 65 to 77 percent in Swaziland, but at
the same time, the specificity fell from 92 to 77 percent in the
Philippines and 92 to 80 percent in Swaziland (Mulholland and
others 1992). On the basis of these and other data (Campbell,
Byass, and others 1989; Kolstad and others 1997; Perkins and
others 1997; Redd 1994; Simoes and others 1997; Weber and
others 1997), WHO recommends a respiratory rate cutoff of
50 breaths per minute for infants age 2 through 11 months and
40 breaths per minute for children age 12 months to 5 years.
Rapid breathing, as defined by WHO, detects about 85 per-
cent of children with pneumonia, and more than 80 percent of
children with potentially fatal pneumonia are probably suc-
cessfully identified and treated using the WHO diagnostic cri-
teria. Antibiotic treatment of children with rapid breathing has
been shown to reduce mortality (Sazawal and Black 2003). The
problem of the low specificity of the rapid breathing criterion
is that some 70 to 80 percent of children who may not need
antibiotics will receive them. Nevertheless, for primary care
workers for whom diagnostic simplicity is essential, rapid
breathing is clearly the most useful clinical sign.
Pneumonia Diagnosis Based on Chest Wall Indrawing.
Children are admitted to hospital with severe pneumonia when
health workers believe that oxygen or parenteral antibiotics
(antibiotics administered by other than oral means) are needed
or when they lack confidence in mothers’ ability to cope. The
rationale of parenteral antibiotics is to achieve higher levels of
antibiotics and to overcome concerns about the absorption of
oral drugs in ill children.
The Papua New Guinea study (Shann, Hart, and Thomas
1984) used chest wall indrawing as the main indicator of sever-
ity, but studies from different parts of the world show large dif-
ferences in the rates of indrawing because of variable defini-
tions. Restriction of the term to lower chest wall indrawing,
defined as inward movement of the bony structures of the chest
wall with inspiration, has provided a better indicator of the
severity of pneumonia and one that can be taught to health
workers. It is more specific than intercostal indrawing, which
frequently occurs in bronchiolitis.
In a study in The Gambia (Campbell, Byass, and others
1989), a cohort of 500 children from birth to four years old
was visited at home weekly for one year. During this time,
222 episodes of LRI (rapid breathing, any chest wall indrawing,
nasal flaring, wheezing, stridor, or danger signs) were referred
to the clinic. Chest indrawing was present in 62 percent of these
cases, many with intercostal indrawing. If all children with any
chest indrawing were hospitalized, the numbers would over-
whelm pediatric inpatient facilities.
Studies in the Philippines and Swaziland (E. Mulholland
and others 1992) found that lower chest wall indrawing was
more specific than intercostal indrawing for a diagnosis of
severe pneumonia requiring hospital admission. In the Vellore
study (Cherian and others 1988), lower chest wall indrawing
correctly predicted 79 percent of children with an LRI who
were hospitalized by a pediatrician.
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Antimicrobial Options for Oral Treatment of Pneumonia.
The choice of an antimicrobial drug for treatment is based on
the well-established finding that most childhood bacterial
pneumonias are caused by S. pneumoniae or H. influenzae. A
single injection of benzathine penicillin, although long last-
ing, does not provide adequate penicillin levels to eliminate
H. influenzae. WHO has technical documents to help assess the
relevant factors in selecting first- and second-line antimicro-
bials and comparisons of different antimicrobials in relation to
their antibacterial activity, treatment efficacy, and toxicity
(WHO 1990).
The emergence of antimicrobial resistance in S. pneumoniae
and H. influenzae is a serious concern. In some settings, in vitro
tests show that more than 50 percent of respiratory isolates of
both bacteria are resistant to co-trimoxazole, and penicillin
resistance to S. pneumoniae is gradually becoming a problem
worldwide.
In pneumonia, unlike in meningitis, in vitro resistance of
the pathogen does not always translate into treatment failure.
Reports from Spain and South Africa suggest that pneumonia
caused by penicillin-resistant S. pneumoniae can be successfully
treated with sufficiently high doses of penicillin. Amoxicillin is
concentrated in tissues and in macrophages, and drug levels are
directly correlated with oral dosages. Therefore, higher doses
than in the past—given twice a day—are now being used to
successfully treat ear infections caused by penicillin-resistant
S. pneumoniae. Amoxicillin is clearly better than penicillin for
such infections. The situation with co-trimoxazole is less clear
(Strauss and others 1998), and in the face of high rates of co-
trimoxazole resistance, amoxicillin may be superior for chil-
dren with severe pneumonia.
Intramuscular Antibiotics for Treatment of Severe
Pneumonia. Even though chloramphenicol is active against
both S. pneumoniae and H. influenzae, its oral absorption is
erratic in extremely sick children. Thus, the WHO guidelines
recommend giving intramuscular chloramphenicol at half the
daily dose before urgent referral of severe pneumonia cases. An
additional rationale is that extremely sick children may have
sepsis or meningitis that are difficult to rule out and must be
treated immediately. Although intravenous chloramphenicol is
superior to intramuscular chloramphenicol, the procedure can
delay urgently needed treatment and adds to its cost.
Investigators have questioned the adequacy and safety of
intramuscular chloramphenicol. Although early studies sug-
gested that adult blood levels after intramuscular administra-
tion were significantly less than those achieved after intra-
venous administration, the intramuscular route gained
wide acceptance following clinical reports that confirmed its
efficacy. Local complications of intramuscular chlorampheni-
col succinate are rare, unlike the earlier intramuscular prepara-
tions. Although concerns about aplastic anemia following
chloramphenicol are common, this complication is extremely
rare in young children. There is no evidence that intramuscu-
lar chloramphenicol succinate is more likely to produce side
effects than other forms and routes of chloramphenicol.
Hypoxemia Diagnosis Based on WHO Criteria. The ARI
case-management and integrated management of infant and
childhood illness (IMCI) strategies depend on accurate referral
of sick children to a hospital and correct inpatient manage-
ment of LRI with oxygen or antibiotics. Hypoxemia (deficiency
of oxygen in the blood) in children with LRI is a good predic-
tor of mortality, the case-fatality rate being 1.2 to 4.6 times
higher in hypoxemic LRI than nonhypoxemic LRI (Duke,
Mgone, and Frank 2001; Onyango and others 1993), and oxy-
gen reduces mortality. Thus, it is important to detect hypox-
emia as early as possible in children with LRI to avert death.
Although diagnoses of acute LRIs are achieved very easily by
recognizing tachypnoea, and although severe LRI is associated
with chest wall indrawing, the clinical recognition of hypox-
emia is more problematic. Different sets of clinical rules have
been studied to predict the presence of hypoxemia in children
with LRI (Cherian and others 1988; Onyango and others 1993;
Usen and others 1999). Although some clinical tools have a
high sensitivity for detecting hypoxemia, a good number of
hypoxemic children would still be missed using these criteria.
Pulse oximetry is the best tool to quickly detect hypoxemia in
sick children. However, pulse oximeters are expensive and have
recurring costs for replacing probes, for which reasons they are
not available in most district or even referral hospitals in devel-
oping countries.
Treatment Guidelines. Current recommendations are for co-
trimoxazole twice a day for five days for pneumonia and intra-
muscular penicillin or chloramphenicol for children with severe
pneumonia. The problems of increasing resistance to co-
trimoxazole and unnecessary referrals of children with any chest
wall indrawing have led to studies exploring alternatives to the
antibiotics currently used in ARI case management. One study
indicated that amoxicillin and co-trimoxazole are equally effec-
tive for nonsevere pneumonia (Catchup Study Group 2002),
though amoxicillin costs twice as much as co-trimoxazole. With
respect to the duration of antibiotic treatment, studies in
Bangladesh, India, and Indonesia indicate that three days of oral
co-trimoxazole or amoxicillin are as effective as five days of
either drug in children with nonsevere pneumonia (Agarwal
and others 2004; Kartasasmita 2003). In a multicenter study of
intramuscular penicillin versus oral amoxicillin in children with
severe pneumonia, Addo-Yobo and others (2004) find similar
cure rates. Because patients were treated with oxygen when
needed for hypoxemia and were switched to other antibiotics if
the treatment failed, this regimen is not appropriate for treating
severe pneumonia in an outpatient setting.
488 | Disease Control Priorities in Developing Countries | Eric A. F. Simoes, Thomas Cherian, Jeffrey Chow, and others
WHO recommends administering oxygen, if there is ample
supply, to children with signs and symptoms of severe pneu-
monia and, where supply is limited, to children with any of
the following signs: inability to feed and drink, cyanosis, res-
piratory rate greater than or equal to 70 breaths per minute,
or severe chest wall retractions (WHO 1993). Oxygen should
be administered at a rate of 0.5 liter per minute for children
younger than 2 months and 1 liter per minute for older chil-
dren. Because oxygen is expensive and supply is scarce, espe-
cially in remote rural areas in developing countries, WHO rec-
ommends simple clinical signs to detect and treat hypoxemia.
Despite those recommendations, a study of 21 first-level facil-
ities and district hospitals in seven developing countries found
that more than 50 percent of hospitalized children with LRI
were inappropriately treated with antibiotics or oxygen
(Nolan and others 2001)—and in several, oxygen was in short
supply. Clearly, providing oxygen to hypoxemic babies is
lifesaving, though no randomized trials have been done to
prove it.
Prevention and Treatment of Pneumonia in HIV-Positive
Children. Current recommendations of a WHO panel for
managing pneumonia in HIV-positive children and for pro-
phylaxis of Pneumocystis jiroveci are as follows (WHO 2003):
• Nonsevere pneumonia up to age 5 years. Oral co-trimoxazole
should remain the first-line antibiotic, but oral amoxicillin
should be used if it is affordable or if the child has been on
co-trimoxazole prophylaxis.
• Severe or very severe pneumonia. Normal WHO case-
management guidelines should be used for children up to
2 months old. For children from 2 to 11 months, injectable
antibiotics and therapy for Pneumocystis jiroveci pneu-
monia are recommended, as is starting Pneumocystis jirove-
ci pneumonia prophylaxis on recovery. For children age 12
to 59 months, the treatment consists of injectable antibi-
otics and therapy for Pneumocystis jiroveci pneumonia.
Pneumocystis jiroveci pneumonia prophylaxis should be
given for 15 months to children born to HIV-infected
mothers; however, this recommendation has seldom been
implemented.
COST-EFFECTIVENESS OF INTERVENTIONS
Pneumonia is responsible for about a fifth of the estimated
10.6 million deaths per year of children under five. Where pri-
mary health care is weak, reducing mortality through public
health measures is a high priority. As noted earlier, the available
interventions are primary prevention by vaccination and sec-
ondary prevention by early case detection and management.
The cost-effectiveness of Hib vaccines is discussed in chap-
ter 20. We did not attempt an analysis of the cost-effectiveness
of pneumococcal vaccines, because global and regional esti-
mates of the pneumococcal pneumonia burden are currently
being developed and will not be available until later in 2005. In
addition, current vaccine prices are relatively stable in devel-
oped countries, but the prices for low- and middle-income
countries are expected to be substantially lower when vaccines
are purchased through a global tender.
We evaluate case-management intervention strategies for
LRIs in children under five. Health workers who implement
case management diagnose LRIs on the basis of fast breathing,
lower chest wall indrawing, or selected danger signs in children
with respiratory symptoms. Because this method does not dis-
tinguish between pneumonia and bronchiolitis, nor between
bacterial and viral pneumonia, we group these conditions into
the general category of “clinical pneumonia” (Rudan and oth-
ers 2004). This approach assumes that a high proportion of
clinical pneumonia is of bacterial origin and that health work-
ers can considerably reduce case fatality through breathing rate
diagnosis and timely administration of antibiotics (Sazawal
and Black 2003). We calculated treatment costs by World Bank
region using standardized input costs provided by the volume
editors and costs published in the International Drug Price
Indicator Guide (Management Sciences for Health 2005) and
other literature (table 25.1). The analysis addresses four cate-
gories of case management, which are distinguished by the
severity of the infection and the point of treatment:
• nonsevere pneumonia treated by a community health
worker
• nonsevere pneumonia treated at a health facility
• severe pneumonia treated at a hospital
• very severe pneumonia treated at a hospital.
Information about these categories of case management and
their outcomes is drawn from a report on the methodology
and assumptions used to estimate the costs of scaling up select-
ed health interventions aimed at children (WHO and Child
Adolescent Health forthcoming). We assumed a total of three
follow-up visits for each patient treated by a community health
worker rather than the twice-daily follow-ups for 10 days rec-
ommended by the report. We also assumed that all severe
pneumonia patients receive an x-ray examination, rather than
just 20 percent as suggested by the report. Moreover, we
assumed a five-hour workday for a community health worker,
the minimum workday required for community health work-
ers under the Child Health and Survival initiative of the U.S.
Agency for International Development (Bhattacharyya and
others 2001).
Table 25.2 presents region-specific estimates of average
treatment costs per episode for the four case-management
strategies. Because we considered the prices of tradable com-
modities such as drugs and oxygen to be constant across
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regions, regional variations were due to differences in hospital
and health worker costs. Latin America and the Caribbean and
the Middle East and North Africa had the highest treatment
costs.
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Table 25.1 Inputs for Case Management of Pneumonia in Low- and Middle-Income Countries
Condition and intervention Cost per unit (2001 US$) Quantity Percentage of patients
Nonsevere pneumonia at the community level
Oral amoxicillin (15 mg/kg) 0.03/dose 3 doses/day for 3 days 100
Acetaminophen (100-mg tablet) 0.001/dose 6 doses 100
Community health worker houra 1.83/hour 1 initial 1-hour visit and 3 follow-up visits 100
Nonsevere pneumonia at the facility level
Oral amoxicillin (15 mg/kg) 0.03/dose 3 doses/day for 3 days 100
Acetaminophen (100-mg tablet) 0.001/dose 6 doses 100
Oral salbutamol (2-mg tablet) 0.003/dose 3 doses/day for 4 days 10
Outpatient health facility visita 1.72/visit 1 visit 100
Severe pneumonia at the hospital level
Oral amoxicillin (15 mg/kg) 0.03/dose 3 doses/day for 5 days 100
Nebulized salbutamol (2.5 mg) 0.13/dose 6 doses/day for 4 days 50
Injectable ampicillin (50 mg/kg) 0.21/dose 4 doses/day for 3 days 100
X-raya 9.21/test 1 test 100
Oxygen (1 liter/minute)b 20/day 3.5 days 50
Inpatient hospital carea 10.8/day 3 days 100
Very severe pneumonia at the hospital level
Oral amoxicillin (15 mg/kg) 0.03/dose 3 doses/day for 5 days 100
Nebulized salbutamol (2.5 mg) 0.13/dose 6 doses/day for 4 days 50
Injectable ampicillin (50 mg/kg) 0.21/dose 4 doses/day for 5 days 100
Injectable gentamicin (2.5 mg/kg) 0.14/dose 1 dose/day for 10 days 100
Oral prednisolone (1 mg/kg) 0.02/dose 1 dose/day for 3 days 5
X-raya 9.21/test 1 test 100
Oxygen (1 liter/minute)b 20/day 5 days 100
Inpatient hospital carea 10.8/day 5 days 100
Source: Management Sciences for Health 2005.
Note: We assumed that the average patient weighs 12.5 kilograms.
a. Provided by the volume editors. Input costs vary by region. 
b. Median costs obtained from Dobson 1991; Pederson and Nyrop 1991; Schneider 2001; WHO 1993.
Table 25.2 Average per Episode Treatment Costs of Case-Management Interventions for Acute Lower Respiratory Infection
(2001 US$)
Region Nonsevere, community level Nonsevere, facility level Severe, hospital level Very severe, hospital level
Low- and middle-income countries 8 2 82 172
East Asia and the Pacific 6 2 75 160
Latin America and the Caribbean 13 4 134 256
Middle East and North Africa 22 3 113 223
South Asia 5 2 66 148
Sub-Saharan Africa 7 2 64 145
Source: Authors’ calculations.
We calculated region-specific cost-effectiveness ratios
(CERs) for a model population of 1 million in each region, fol-
lowing the standardized guidelines for economic analyses (see
chapter 15 for details). Input variables included the treatment
costs detailed in tables 25.1 and 25.2, region-specific LRI
morbidity rates, adapted from Rudan and others (2004),
region-specific mortality rates and age structures provided by
the volume editors, and region-specific urban to rural popula-
tion ratios (World Bank 2002). The Europe and Central Asia
region was excluded from this analysis because of a lack of
incidence information. In the absence of region-specific infor-
mation, we assumed uniform intervention effectiveness rates.
Disability-adjusted life years are averted through reduced
duration of illness and decreased mortality with treatment. We
assumed an average illness duration of 8.5 days for those not
treated and of 6.0 days for those treated. We used a case-fatality
reduction of 36.0 percent on account of treatment (Sazawal
and Black 2003) and a diagnosis specificity of 78.5 percent for
patients diagnosed based on breath rate alone. The disability
weight cotemporaneous with infection was 0.28. We did not
consider disabilities caused by chronic sequelae of LRIs because
it is unclear whether childhood LRI causes long-term impaired
lung function or whether children who develop impaired lung
function are more prone to infection (von Mutius 2001).
Because a single year of these interventions yields only
cotemporaneous benefits—because effectively treated individ-
uals do not necessarily live to life expectancy given that they are
likely to be infected again the following year—we calculated the
cost-effectiveness of a five-year intervention. This time period
enabled us to consider the case in which an entire cohort of
newborns to four-year-olds avoids early childhood clinical
pneumonia mortality because of the intervention and receives
the benefit of living to life expectancy. Finally, this analysis con-
sidered only long-run marginal costs, which vary with the
number of individuals treated, and did not include the fixed
costs of initiating a program where none currently exists.
Table 25.3 presents the region-specific CERs of the four
case-management categories as well as the CER for providing
all four categories to a population of 1 million people. Among
all low- and middle-income countries, treatment of nonsevere
clinical pneumonia was more cost-effective at the facility level
than at the community level, and of all four case-management
categories, treatment of very severe clinical pneumonia at the
hospital level was the least cost-effective. Treatment of non-
severe clinical pneumonia at the facility level was more cost-
effective than treatment by a community health worker
because of the lower cost of a single visit to a health facility than
of multiple visits by a health worker. The CER of providing all
levels of treatment to all low- and middle-income countries
was estimated at US$398 per disability-adjusted life year.
Because we assumed that effectiveness rates were constant,
regional variations in the CER for each case-management cat-
egory were due only to variations in the intervention costs, and
the relative cost-effectiveness rankings for the strategies was the
same for all the regions. Variation in the CERs for providing all
categories of care was also due to region-specific urban to rural
population ratios. We assumed that all patients in urban areas
seek treatment at the facility level or higher, whereas 80 percent
of nonseverely ill patients in rural areas receive treatment at
the community level and the remainder seek treatment at the
facility level.
IMPLEMENTATION OF ARI CONTROL STRATEGIES:
LESSONS OF EXPERIENCE 
The lessons of ARI prevention and control strategies that have
been implemented by national programs include the vaccina-
tion and case-management strategies discussed below.
Vaccine Strategies
Hib vaccine was introduced into the routine infant immuniza-
tion schedule in North America and Western Europe in the
early 1990s. With the establishment of the Global Alliance for
Vaccines and Immunization (GAVI) and the Vaccine Fund,
progress is being made in introducing it in developing coun-
tries, although major hurdles remain. By 2002, only 84 of the
193 WHO member nations had introduced Hib vaccine. Five
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Table 25.3 CERs of Case-Management Interventions for Pneumonia 
(2001US$/disability-adjusted life year)
Nonsevere, Nonsevere, Severe, Very severe, Provision of all 
Region community level facility level hospital level hospital level four interventions
Low- and middle-income countries 208 50 2,916 6,144 398 
East Asia and the Pacific 439 91 6,511 13,945 900
Latin America and the Caribbean 547 424 14,719 28,106 1,941
Middle East and North Africa 733 180 6,810 13,438 1,060
South Asia 140 28 1,931 4,318 264
Sub-Saharan Africa 139 24 1,486 3,376 218
Source: Authors’ calculations.
countries have since been approved for support from GAVI for
Hib vaccine introduction in 2004–5.
The United States added 7-PCV to the infant immunization
program in 2000. Several other industrialized countries have
plans to introduce the vaccine into their national immuniza-
tion programs in 2005, whereas others recommend the use of
the vaccine only in selected high-risk groups. In some of these
last countries, the definition of high risk is quite broad and
includes a sizable proportion of all infants. The currently
licensed 7-PCV lacks certain serotypes important in developing
countries,but the 9-PCV and 11-PCV would cover almost 80 per-
cent of serotypes that cause serious disease worldwide.
Despite the success of Hib vaccine in industrial countries
and the generally appreciated importance of LRIs as a cause of
childhood mortality, as a result of a number of interlinked fac-
tors, uptake in developing countries has been slow. Sustained
use of the vaccine is threatened in a few of the countries that
have introduced the vaccine. First, the magnitude of disease
and death caused by Hib is not recognized in these countries,
partly because of their underuse of bacteriological diagnosis
(a result of the lack of facilities and resources). Second, because
the coverage achieved with traditional Expanded Program on
Immunization vaccines remains low in many countries, adding
more vaccines has not been identified as a priority. Third,
developing countries did not initiate efforts to establish the
utility of the vaccine until after the vaccine had been licensed
and used routinely for several years in industrialized countries.
Consequently, Hib vaccination has been perceived as an inter-
vention for rich countries. As a result of all these factors, actual
demand for the vaccine has remained low, even when support
has been available through GAVI and the Vaccine Fund.
In 2004, the GAVI board commissioned a Hib task force to
explore how best to support national efforts to make evidence-
based decisions about introducing the Hib vaccine. On the
basis of the task force’s recommendations, the GAVI board
approved establishment of the Hib Initiative to support those
countries wishing either to sustain established Hib vaccination
or to explore whether introducing Hib vaccine should be a
priority for their health systems. A consortium consisting of
the Johns Hopkins Bloomberg School of Public Health, the
London School of Hygiene and Tropical Medicine, the Centers
for Disease Control and Prevention, and the WHO has been
selected to lead this effort.
Case-Management Strategies 
Sazawal and Black’s (2003) meta-analysis of community-based
trials of the ARI case-management strategy includes 10 studies
that assessed its effects on mortality, 7 with a concurrent
control group. The meta-analysis found an all-cause mortality
reduction of 27 percent among neonates, 20 percent among
infants, and 24 percent among children age one to four. LRI-
specific mortality was reduced by 42, 36, and 36 percent,
respectively. These data clearly show that relatively simplified,
but standardized, ARI case management can have a significant
effect on mortality, not only from pneumonia, but also from
other causes in children from birth to age four. Currently, the
ARI case-management strategy has been incorporated into
the IMCI strategy, which is now implemented in more than
80 countries (see chapter 63).
Despite the huge loss of life to pneumonia each year, the
promise inherent in simplified case management has not been
successfully realized globally.One main reason is the underuse of
health facilities in countries or communities in which many chil-
dren die from ARIs. In Bangladesh, for example, 92 percent of
sick children are not taken to appropriate health facilities (WHO
2002). In Bolivia, 62 percent of children who died had not been
taken to a health care provider when ill (Aguilar and others
1998). In Guinea, 61 percent of sick children who died had not
been taken to a health care provider (Schumacher and others
2002). Schellenberg and others’ (2003) study in Tanzania shows
that children of poorer families are less likely to receive antibi-
otics for pneumonia than children of better-off families and that
only 41 percent of sick children are taken to a health facility.
Thus, studies consistently confirm that sick children, especially
from poor families, do not attend health facilities.
A number of countries have established large-scale, sustain-
able programs for treatment at the community level:
• The Gambia has a national program for community-level
management of pneumonia (WHO 2004b).
• In the Siaya district of Kenya, a nongovernmental organiza-
tion efficiently provides treatment by community health
workers for pneumonia and other childhood diseases
(WHO 2004b).
• In Honduras, ARI management has been incorporated in
the National Integrated Community Child Care Program,
whereby community volunteers conduct growth monitor-
ing, provide health education, and treat pneumonia and
diarrhea in more than 1,800 communities (WHO 2004b).
• In Bangladesh, the Bangladesh Rural Advancement
Committee and the government introduced an ARI control
program covering 10 subdistricts, using volunteer commu-
nity health workers. Each worker is responsible for treating
childhood pneumonia in some 100 to 120 households after
a three-day training program.
• In Nepal during 1986–89, a community-based program for
management of ARIs and diarrheal disease was tested in
two districts and showed substantial reductions in LRI
mortality (Pandey and others 1989, 1991). As a result, the
program was integrated into Nepal’s health services and is
being implemented in 17 of the country’s 75 districts by
female community health volunteers trained to detect and
treat pneumonia.
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• In Pakistan, the Lady Health Worker Program employs
approximately 70,000 women, who work in communities
providing education and management of childhood pneu-
monia to more than 30 million people (WHO 2004b).
RESEARCH AND DEVELOPMENT AGENDA
The research and development agenda outlined below summa-
rizes the priorities that have been established by advisory
groups to the Initiative for Vaccine Research (vaccine interven-
tion strategies) and the WHO Division of the Child and
Adolescent Health (case-management strategies).
Vaccine Intervention Strategies 
The GAVI task force on Hib immunization made a number of
recommendations that vary depending on the country.
Countries that have introduced Hib vaccine should focus on
documenting its effect and should use the data to inform
national authorities, development partners, and other agencies
involved in public health to ensure sustained support to such
vaccination programs. Countries eligible for GAVI support that
have not yet introduced Hib vaccines are often hindered by a
lack of local data and a lack of awareness of regional data. They
can address these issues through subregional meetings at which
country experts can pool data and review information from
other countries. In addition, most of the countries need to
carry out economic analyses that are based on a standardized
instrument. Finally, all countries that face a high Hib disease
burden need to develop laboratory facilities so that they can
establish the incidence of Hib meningitis at selected sites.
Countries in which the disease burden remains unclear may
have limited capacity to document the occurrence of Hib dis-
ease using protocols that are based on surveillance for menin-
gitis invasive disease. They will need to explore the possibilities
of using alternative methods for measuring disease burden,
including the use of vaccine-probe studies.
On the basis of experience with introducing Hib and hepa-
titis B vaccines, GAVI took a proactive approach and in 2003
established an initiative based at the Johns Hopkins School of
Public Health in Baltimore to implement an accelerated devel-
opment and introduction program for pneumococcal vaccines
(the PneumoADIP; see http://www.preventpneumonia.org).
The program’s intent is to establish and communicate the value
of pneumococcal vaccines and to support their delivery.
Establishing the value of the vaccine involves developing local
evidence about the burden of disease and the vaccines’ poten-
tial effect on public health. This effort can be accomplished
through enhanced disease surveillance and relevant clinical tri-
als in a selected number of lead countries. Once established, the
evidence base will be communicated to decision makers and
key opinion leaders to ensure that data-driven decisions are
made. Once the cost-effectiveness of routine vaccination is
established, delivery systems will have to be established, and
countries will need financial support so that the vaccines can be
introduced into their immunization programs. These activities
are being initiated before the launch of vaccine formulations
designed for use in developing countries, so as to inform capac-
ity planning, product availability, and pricing.
Case-Management Strategies
In 2003, WHO’s Division of Child and Adolescent Health con-
vened a meeting to review data and evidence from recent ARI
case-management studies and to suggest the following revisions
to case-management guidelines and future research priorities:
• Nonsevere pneumonia:
— Improve the specificity of clinical diagnostic criteria.
— Reassess WHO’s current recommended criteria for
detecting and managing treatment failure, given the
high rates of therapy failure.
— Reanalyze data from short-course therapy studies to
better identify determinants of treatment failure.
— Carry out placebo-controlled trials among children pre-
senting with wheezing and pneumonia in selected set-
tings that have a high prevalence of wheezing to deter-
mine whether such children need antibiotics.
• Severe pneumonia: In a randomized clinical trial in a con-
trolled environment, Addo-Yobo and others (2004) showed
that oral amoxicillin is as effective as parenteral penicillin or
ampicillin; however, the following actions need to be under-
taken before it can be recommended on a general basis:
— Analyze data on exclusions from the trial.
— Identify predictors that may help distinguish children
who require hospitalization and who subsequently
deteriorate.
— Reassess WHO’s current recommended treatment
failure criteria for severe pneumonia, given the overall
high rates of therapy failure.
— Conduct descriptive studies in a public health setting in
several centers worldwide, to evaluate the clinical out-
comes of oral amoxicillin in children age 2 to 59 months
who present with lower chest wall indrawing.
— Document the effectiveness of WHO’s treatment guide-
lines for managing children with pneumonia and HIV
infection.
• LRI deaths:
— To help develop more effective interventions to reduce
LRI mortality, study the epidemiology of LRI deaths in
various regions in detail, using routine and advanced
laboratory techniques.
• Oxygen therapy:
— Carry out studies to show the effectiveness of oxygen for
managing severe respiratory infections.
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— Collect baseline information about the availability and
delivery of oxygen and its use in hospital settings in low-
income countries.
— Explore the utility of pulse oximetry for optimizing oxy-
gen therapy in various clinical settings.
— Undertake studies to improve the specificity of clinical
signs in the overlapping signs and symptoms of malaria
and pneumonia.
— Study rapid diagnostic tests for malaria to assess their
effectiveness in differentiating between malaria and
pneumonia.
— Examine the effect of widespread use of co-
trimoxazole on sulfadoxine-pyrimethamine resistance
to Plasmodium falciparum.
• Etiology: Data on the etiology of pneumonia in children are
somewhat out of date, and new etiological studies are need-
ed that use modern technology to identify pathogens.
CONCLUSIONS: PROMISES AND PITFALLS 
The evidence clearly shows that the WHO case-management
approach and the wider use of available vaccines will reduce
ARI mortality among young children by half to two-thirds. The
systematic application of simplified case management alone,
the cost of which is low enough to be affordable by almost any
developing country, will reduce ARI mortality by at least one-
third. The urgent need is to translate this information into
actual implementation.
The case-management strategy has to be applied and
prospectively evaluated so that emerging problems of antimi-
crobial resistance, reduced efficacy of current treatment with
the recommended antimicrobials, or emergence of unexpected
pathogens can be detected early and remedial steps can be taken
rapidly. If community-level action by health workers is supple-
mented by the introduction of the IMCI strategy at all levels of
primary care, then both applying and evaluating this strategy
will be easier. Such synergy may also help in gathering infor-
mation that will help further fine-tune clinical signs, so that
even village health workers can better distinguish bronchiolitis
and wheezing from bacterial pneumonia. The criticism that the
case-management steps may result in overuse of antimicrobials
should be countered by documenting their current overuse and
incorrect use by doctors and other health workers. Although
there is a resurgent interest in basing interventions at the com-
munity level, our analysis suggests that doing so may not be
cost-effective. Indeed, ARI case management at the first-level
facility may still be the most cost-effective when coupled with
better care-seeking behavior interventions.
The international medical community is only beginning to
appreciate the potential benefits of Hib and pneumococcal vac-
cines. They are currently expensive compared with Expanded
Program on Immunization vaccines, but the price of Hib
vaccine may fall with the entry of more manufacturers into the
market in the next few years. Nevertheless, convincing evidence
of the vaccines’ cost-effectiveness is required to facilitate
national decisions on introducing the vaccine and using it sus-
tainedly. In low-income countries, positive cost-benefit and
cost-effectiveness ratios alone appear to be insufficient to
enable the introduction of these vaccines into national immu-
nization programs.
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The Millennium Declaration includes two goals directly rele-
vant to maternal and perinatal conditions: reducing child mor-
tality and improving maternal health. The fact that two out of
the eight Millennium Development Goals (MDGs) are exclu-
sively targeted at mothers and children is testament to the sig-
nificant proportion of the global burden of disease they suffer
and to the huge inequities within and between countries in the
magnitude of their burden. Achieving these goals is inextrica-
bly linked at the biological, intervention, and service delivery
levels (Bale and others 2003).
Maternal and child health services have long been seen as
inseparable partners, although over the past 20 years the rela-
tive emphasis within each, particularly at a policy level, has var-
ied (De Brouwere and Van Lerberghe 2001). The launch of the
Safe Motherhood Initiative in the late 1980s, for example,
brought heightened attention to maternal mortality, whereas
the International Conference on Population and Development
(ICPD) broadened the focus to reproductive health and, more
recently, to reproductive rights (Germain 2000). Those shifts
can be linked with international programmatic responses and
terminology—with the preventive emphasis of, for instance,
prenatal care being lowered as a priority relative to the treat-
ment focus of emergency obstetric care. For the child, inte-
grated management of childhood illnesses has brought
renewed emphasis to maintaining a balance between preventive
and curative care. The particular needs of the newborn, how-
ever, have only started to receive significant attention in the
past three or four years (Foege 2001).
Although health experts agree that the single clinical inter-
ventions needed to avert much of the burden of maternal and
perinatal death and disability are known, they also accept that
these interventions require a functioning health system to have
an effect at the population scale. Levels of maternal and peri-
natal mortality are thus regarded as sensitive indicators of the
entire health system (Goodburn and Campbell 2001), and they
can therefore be used to monitor progress in health gains more
generally. What is also clear is that maternal mortality and the
neonatal component of child mortality continue to represent
two of the most serious challenges to the attainment of the
MDGs, particularly in South Asia and Sub-Saharan Africa.
An estimated 210 million women become pregnant each
year, and close to 60 million of these pregnancies end with the
death of the mother (500,000) or the baby or as abortions.
This chapter focuses on the adverse events of pregnancy and
childbirth and on the intervention strategies to eliminate and
ameliorate this burden.
EPIDEMIOLOGY OF MATERNAL 
AND PERINATAL CONDITIONS
Much has been written about the lack of reliable data on
maternal and perinatal conditions in developing countries
(AbouZahr 2003; Graham 2002; Save the Children 2001). Weak
routine information systems, inadequate vital registration, and
reliance on periodic household surveys as the main source of
population-based data are all familiar obstacles to improving
public health in poor countries (Godlee and others 2004).
Recognizing the implications of these obstacles for prioritizing
health needs and interventions is important and is now
endorsed by a global movement toward evidence-based deci-
sion making for policy and practice (Evans and Stansfield 2003).
Chapter 26
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perinatal period can happen at any age, although it tends to
take place during the neonatal period (up to 28 days of life). By
contrast, perinatal deaths include both stillborn babies and
those who are born alive but die before the end of the seventh
day. Early neonatal deaths only include live births.
Nature and Characteristics 
Pregnancy and childbirth are not inherently pathological.
Maintaining an effective balance, however, between preserving
normality and ensuring a state of readiness to deal with abnor-
mality represents a fundamental challenge to health systems
and a tension in safe motherhood programming. Although this
balance between prevention and treatment is not peculiar to
maternal and perinatal conditions (or complications), the fol-
lowing additional characteristics are relevant to assessing the
burden as well as the effectiveness of interventions:
• The principle of “first, do no harm” has particular signifi-
cance in this area, because many preventive practices related
to pregnancy and childbirth can readily become harmful in
unskilled hands—for example, inappropriately early induc-
tion of labor or poor forceps technique. The iatrogenic bur-
den of maternal and perinatal conditions is rarely factored
into assessments of intervention effectiveness.
• The lives of two individuals, mother and baby, are poten-
tially at stake (Stoll and Measham 2001); however, interven-
tions will not necessarily benefit both equally, and indeed,
some will be in direct conflict.
• A large number of maternal and perinatal conditions pre-
sent clinically not as single entities but as complexes, such
as hemorrhage and sepsis or preterm delivery and birth
asphyxia. For the mother, the situation may be further com-
plicated by the role of underlying conditions, such as
HIV/AIDS underlying puerperal sepsis.
• The most extreme negative outcome, death of both the
mother and the baby, is highly concentrated around the
time of delivery, from the onset of labor or abortion to
48 hours postpartum or postabortion. Estimates indicate
that about two-thirds of maternal deaths occur within this
time window (AbouZahr 1998), and the proportion for
perinatal deaths appears to be even higher (Bale and others
2003). For the mother, however, a growing number of stud-
ies highlight the contribution of direct and indirect causes
of deaths, including violence, when a one-year postpartum
reference period is used (Etard, Kodio, and Traore 1999; Hoj
and others 2003).
• The initial clinical presentation of some conditions can be
severe, with rapid escalation to a life-threatening state, and
these conditions often require surgical intervention.
• A distinct clinical feature of some maternal conditions is
their unpredictability (AbouZahr 1998). This fact has had a
However, there has been much less appreciation of the conse-
quences for evaluations of effectiveness—and thus cost-
effectiveness—of the weaknesses in current outcomes measure-
ment and in routine data collection.Those weaknesses also affect
the monitoring of progress toward the MDGs. Initiatives for
improved health surveillance are thus urgently needed (CMH
2002). For the vast majority of the world’s population, the mag-
nitude of adverse maternal and perinatal outcomes is not known
reliably. It is impossible to determine whether many of the pat-
terns apparently observed, especially at a cause-specific level,
are real or are artifacts of the measurement process.
Definitions
The terms maternal and perinatal encompass a continuum of
health states—from the most positive (complete physical, men-
tal, and social well-being) to the most negative—and a huge
number of clinical conditions. This chapter focuses on eight
major conditions, hereafter referred to as the focus conditions,
which are estimated to account for about 75 percent of mater-
nal deaths and more than 60 percent of perinatal deaths. For
the mother, these conditions are hemorrhage, sepsis, hyperten-
sive disorders of pregnancy, obstructed labor, and unsafe abor-
tion. For the baby, they are low birthweight, birth asphyxia, and
infection (table 26.1).
We define maternal conditions as encompassing events
occurring from conception to 42 days postpartum (WHO
1992a). The chapters on women’s health, family planning, ado-
lescent health, and surgery address the longer-term sequelae of
pregnancy and childbirth; the preconception period; preg-
nancy at an early age; and specific interventions, such as repair
of obstetric fistulas. Within the period from conception to 42
days postpartum, two broad categories of conditions can be
distinguished: those arising specifically from pregnancy and
parturition (direct obstetric conditions), and those aggravated by
or aggravating to pregnancy (indirect obstetric conditions).
Because the latter conditions, such as malaria, HIV/AIDS, or
anemia, are not exclusive to pregnant or parturient women,
they are not dealt with here but in the relevant disease-specific
chapters.
Regarding perinatal conditions, we focus on those for which
interventions can be directed to the baby through the mother
during pregnancy or delivery. Our discussion is complemented
by the discussion in chapter 27, which concentrates on the
neonate, including special care of the small baby and emer-
gency care of the sick newborn.
Formal definitions of perinatal conditions tend to vary by
data source. Taken literally, they refer to conditions that arise in
the perinatal period (Murray and Lopez 1998), which are not
the same as events that occur in the perinatal period—that is,
from 28 weeks of gestation to the end of the seventh day of life.
For example, death resulting from conditions that arise in the
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Table 26.1 Maternal and Perinatal Focus Conditions and Risk Factors for These Conditions
Case Average duration
Definition or complications fatality ratea until death if Timing of Distal or Direct, Distal or Direct, 
Condition and sequelae (percent) condition fatal presentation proximate physiological proximate physiological
Maternal
Hemorrhage
Sepsis
Definition
Antepartum hemorrhage:
bleeding from the genital tract
during the last 3 months of
pregnancy
Primary postpartum hemorrhage:
excessive bleeding (more than
500 milliliters) from the genital
tract following delivery 
Definition 
Infection of the genital tract or
extragenital infections following
childbirth 
Not 
available
1.0b
1.3
12 hours 
2 hours 
6 days
28 weeks of gestation
up to delivery
Delivery to 24 hours
after delivery
Delivery to 6 weeks
postpartum
Risk factors for condition Risk factors for death from condition
Primigravidity
Grand multiparity
(greater than 4)
Fibroids
Anemia
Immunosuppression
Anemia
Sexually transmitted
infections
Inadequate prenatal
care
Placental abnormalities
(including placenta previa;
abruption; placenta
accreta, percreta, increta;
other adhesions)
Polyhydramnios
Multiple gestation
Previous third-stage
complication
Previous cesarean section
Preeclampsia, eclampsia
Intrauterine death
Hepatitis
Induced labor
Prolonged labor
Precipitate labor
Forceps delivery
Cesarean section
Chorioamnionitis
Disseminated intravascular
coagulation
Prolonged labor
Obstructed labor
Premature rupture of
membranes
Frequent pelvic
examinations
Intrauterine death
Foreign body insertion
(for example, herbs)
Episiotomy
Instrumental delivery
Remote location
Anemia
Coagulopathies
Delivery by
untrained personnel
Immunosuppression
Anemia
Lack of knowledge
about warning signs
Lack of postnatal
care
Cultural practices
Lack of blood
transfusion
Badly managed third
stage of labor
Delay or absence of
oxytocic treatment
Misdiagnosis
Inappropriate use of
antibiotics
Lack of access to
intravenous
antibiotics
(Continues on the following page.)
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Table 26.1 Continued
Case Average duration
Definition or complications fatality ratea until death if Timing of Distal or Direct, Distal or Direct, 
Condition and sequelae (percent) condition fatal presentation proximate physiological proximate physiological
Hypertensive
disorders of
pregnancy
Obstructed labor 
Unsafe abortion
Definition 
Raised blood pressure with
proteinuria 
Definition 
Labor in which progress is
arrested by mechanical factors
Definition 
Procedure for terminating an
unintended pregnancy carried
out by people lacking the
necessary skills or in an
environment that does not
conform to minimal medical
standards or both
1.7
0.7
0.3
2 days (eclampsia)
3 days
6 hours to 6 days
28 weeks of gestation
to 2 days postpartum
During labor
After first missed
period to 22 weeks of
gestation or fetal
weight of less than
500 grams 
Risk factors for condition Risk factors for death from condition
Extremes of maternal
age
Primigravidity
Genetic predisposition
Racial or geographical
predisposition
Diabetes and chronic
hypertension
Lack of prenatal care 
Malnutrition
Rickets in childhood
Bony deformity of
pelvis
Achondroplasia
Short stature
Primigravidity
Grand multiparity
Adolescent pregnancy
Unwanted pregnancy
Adolescence
Unmarried status
Absence of legal
abortion services
Lack of access to
contraception 
Lack of access to safe
abortion services
Sexually transmitted
infections
Cesarean section
Unhygienic delivery
conditions
Retained products of
conception
Multiple gestations
Molar pregnancy
Previous history of
pregnancy-induced
hypertension or chronic
hypertension
Cephalopelvic
disproportion
Malpresentation, position
Absence of aseptic
technique
Foreign body insertion
Poisoning from
abortifacients
Cultural practices
Lack of knowledge
Lack of prenatal
care
Lack of access to
cesarean delivery
Lack of access to
instrumental
delivery and
symphysiotomy
Scarred uterus
Inappropriate use
of oxytocin
Sociocultural
factors
Lack of access to
safe termination
services
Lack of access to
postabortion care
Appearance of
complications, such as
cardiovascular and
cerebral complications,
hemolysis, elevated
liver enzyme, low
platelets syndrome 
Disseminated
intravascular
coagulation
Eclampsia
Uterine rupture
Hemorrhage
Sepsis
Exhaustion,
dehydration
Perforated uterus
Poisoning from
abortifacients
Peritonitis
Septic shock
Acute renal failure
Hepatorenal failure
Bowel injury,
perforation
Hemorrhagic shock
Peritonitis
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Perinatal c 
Low birthweight (less
than 2,500 grams)d
Birth asphyxia
(excluding birth
trauma)
Complications or sequelae
Respiratory insufficiency in
preterm infants with lung
immaturity presenting as
respiratory distress syndrome
because of surfactant deficiency
Neonatal cerebral injury caused
by periventricular hemorrhage
mediated by perinatal stress
such as hypotension or trauma
Severe physiological jaundice of
preterm infant
Difficulties in establishing
spontaneous feeding and
inability to tolerate feeds
resulting from prematurity 
Failure of closure of the ductus
arteriosus, frequently seen in
preterm babies with lung disease
Hypoglycemia and other
metabolic disorders related to
prematurity
Complications or sequelae
Absent or depressed breathing
at birth
Neonatal encephalopathy:
clinically evident disturbance in
neurological behavior, commonly
with early neonatal seizures in
term babies, resulting from an
event causing hypoxia during
delivery
50
80
50
20
70
2
20
30
5 days
3 days
1–5 days 
1–14 days
3 days to months
7 days
20 minutes
3 days to life
Less than 24 hours
1–4 days
2–5 days
First day
3–14 days
Birth
Birth (5 minutes)
Birth to first 12 hours
Extremes of maternal
age
Race, ethnicity
Low socioeconomic
status
Unmarried status
Lack of education
Parity (0 or greater
than 4)
Smoking, alcohol use
Maternal malnutrition
Maternal diabetes or
hypertension
Genetic factors
Rubella, other viral
infection
Poor obstetric history
Diethylstilboestrol,
other toxic exposure
High altitude
Absent or inadequate
prenatal care
Drugs taken during
labor, including
anesthesia
Maternal diabetes
Maternal hypertension
Preeclampsia
Any other severe
illness
Multiple pregnancy
Short interpregnancy
interval
First or second trimester
bleeding
Placenta previa
Preeclampsia
Anemia
Hyperemesis
Isoimmunization
Fetal abnormalities
Cervical incompetence
Oligohydramnios or
polyhydramnios 
Prolonged or obstructed
labor
Abruptio placentae
Placental infarct,
insufficiency
Postmaturity
Prematurity or low
birthweight
Multiple pregnancies
Placenta previa or
separation
Cord prolapse
Lack of adequate
neonatal care
facility
Lack of knowledge
and understanding
Badly conducted
labor
Lack of fetal
monitoring 
Lack of partograph
Lack of neonatal
resuscitation
facilities
Birth asphyxia
Intraventricular
hemorrhage
Central nervous system
injury
Respiratory infection
Respiratory distress
syndrome
Necrotizing
enterocolitis
Cholestatic liver
disease
Other infections
Sudden infant death
syndrome
Neonatal coagulopathy
Central nervous system
injury
Neonatal
encephalopathy
(seizures and recurrent
apnea)
(Continues on the following page.)
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Table 26.1 Continued
Case Average duration
Definition or complications fatality ratea until death if Timing of Distal or Direct, Distal or Direct, 
Condition and sequelae (percent) condition fatal presentation proximate physiological proximate physiological
Infection Complications or sequelae
Neonatal sepsis of early onset
resulting from intrauterine or
intrapartum infection
Neonatal sepsis of late onset
resulting from nosocomial
infection or lack of immunity to
commensal bacteria 
Tetanus neonatorum, commonly
resulting from unhygienic cutting
of the cord or care of the cord
stump
Congenital syphilis resulting
from transplacental infection
with Treponema pallidum after
18 weeks gestation
HIV infection transmitted either
intrapartum or postpartum
30–40
15
80
30
5 days
5 days
3–7 days
5 days
First 3 days
After 3 days
3–14 days
Birth onward
Direct effects mainly
after neonatal period
Risk factors for condition Risk factors for death from condition
Lack of adequate
prenatal care
Maternal infection
Lack of maternal
immunization
Unhygienic cultural
practices
Premature rupture of
membranes
Preterm delivery
Birth asphyxia
Unhygienic delivery and
cord care
Congenital HIV
infection
Lack of adequate
neonatal care
Preterm delivery
Septic shock
Respiratory failure
Hepatorenal failure
Coagulopathies
Source: Maternal conditions: Chamberlain 1995; case fatality rates: AbouZahr 2003; mechanical factors of obstructed labor: WHO 1994; unsafe abortion: WHO 1992b; low birthweight: Bale and others 2003, Robertson 1993, Yasmin and others 2001; birth asphyxia: Bale and
others 2003, p. 324, Robertson 1993; infections: Robertson 1993; risk factors: Calder and Dunlop 1992, Murray and Lopez 1998.
a. Case fatality rates assume that no intensive care is available, because this is the norm in South Asia and Sub-Saharan Africa.
b. Case fatality for severe pph (blood loss ? 1000 ml).
c. Excludes stillbirths.
d. Includes preterm deliveries and small for gestational age. 
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profound effect on the prioritization of interventions in safe
motherhood, and it is an area in urgent need of further
research. The situation is confused by the alternative end-
points, such as death or disability, and by the extent to which
there are clear and predictable risk factors. Table 26.1 sum-
marizes some of these key characteristics as they relate to the
eight focus conditions.
Causes and Conceptual Frameworks
One of the most frequently quoted figures in safe motherhood
is that 88 to 98 percent of maternal deaths are avoidable with
moderate levels of health care (WHO 1986). This advocacy
statement simplifies the multiple pathways leading to death
and, thus, the multiple opportunities for primary and second-
ary prevention. In part, this simplicity is a further reflection of
the grouping together of clinical conditions that in reality are
distinctly different in terms of prevalence, case fatality, and
scope for intervention, such as eclampsia and puerperal sepsis
or congenital anomalies and birth asphyxia. The multiple end-
points and conditions, for both the mother and the fetus or
newborn, have implications for what is regarded as an
antecedent (a cause, a determinant, or a risk factor)1 and what
is regarded as a consequence (an outcome or a sequela).
A large number of conceptual frameworks depict path-
ways to adverse maternal and perinatal outcomes (Bale and
others 2003; McCarthy and Maine 1992). Several identify three
levels of contributory factors, which are also found in causal
models for general health outcomes (WHO 2002): (a) distal,
(b) proximal or intermediate, and (c) physiological or direct.
Table 26.1 highlights the risk factors for the focus maternal and
perinatal conditions. The distal determinants emphasize that
maternal and perinatal well-being is not just a medical issue.
Improvements throughout the health sector must be comple-
mented by attention to wider social, economic, and cultural
factors as well as to reproductive rights (CMH 2002). Many
conceptual frameworks also differentiate between the timing of
interventions: before pregnancy, during pregnancy, during
labor and delivery, or during the postpartum period. Similarly,
a further distinction can be made in terms of the timing of the
outcome, although from a programmatic perspective, such a
temporal focus may lead to fragmented care for women and
their babies.
Levels, Trends, and Differentials
The latest regional estimates of maternal mortality are for
2000–1 (table 26.2), with most of the figures for the developing
world produced by modeling (WHO 2004b). More than 99 per-
cent of annual maternal deaths occur in the developing world.
At a national level, the magnitude of the differential in terms of
lifetime risk is almost 500-fold between the highest figure for a
developing country (1 in 6) and the lowest estimate for a devel-
oped country (1 in 29,800) (WHO 2004b). This differential is
often cited as the largest discrepancy between the developing
and developed world of all public health statistics, reflecting
major differences both in obstetric risk, as measured by the
maternal mortality ratio, and in levels of fertility, as reflected in
the total fertility rate.
In terms of medical causes of maternal mortality, even
greater caution is needed regarding the reliability of any pat-
terns observed, because of their dependence on whether the
data are health service based or population based and on cod-
ing conventions. Figure 26.1a shows the percentage distribu-
tion among direct causes at a crude global level. Direct causes
account for about 80 percent of all maternal deaths, with indi-
rect causes responsible for the remainder. Of the direct causes,
hemorrhage is generally regarded as the most common and
may be underestimated, because health facilities are unaware of
many such deaths, given the short interval between onset and
death (see table 26.1). In terms of indirect causes, the pattern
varies enormously between different parts of the world,
primarily according to the prevalence of HIV/AIDS, malaria,
and tuberculosis.
The published data on severe maternal morbidity are
weaker still. A recent World Health Organization (WHO) sys-
tematic review indicates how prevalence figures vary hugely
according to the criteria used to identify cases (Say, Pattinson,
and Gulmezoglu 2004). Using disease-specific criteria, WHO
found that prevalence ranged from 0.80 to 8.23 percent. Using
organ system criteria, WHO found that the range was 0.38 to
1.09 percent. Finally, using management-based criteria, WHO
found that the range was 0.01 to 2.99 percent. Estimates sug-
gest that for every maternal death, at least 16 or 17 other
women suffer a life-threatening complication during preg-
nancy or childbirth (Gay and others 2003) and at least 30
women are left with long-term disabilities, such as an obstet-
ric fistula (UNFPA 2003). These estimates must be regarded as
crude approximations, most originating from small-scale
studies and most in urgent need of updating and verification.
Given the varying case fatality rates shown in table 26.1, the
fact that the distributional pattern for morbidity (fig-
ure 26.1b) does not completely mirror the one for mortality is
not surprising.
As concerns mortality in babies, an estimated 5.7 million
perinatal deaths occur each year, 47 percent as stillbirths and
53 percent in the first week of life (J. Zupan, personal commu-
nication, August 25, 2004). Many of those deaths are linked
directly with complications experienced by the mothers, and
several studies have shown that the survival prospects for a
baby whose mother dies are generally poor—less than 1 per-
cent in one study in Bangladesh (Koenig, Fauveau, and
Wojtyniak 1991). In 2004, neonatal deaths represented 36 per-
cent of all deaths of children under five in developing
countries, with about 1 million of these 3.94 million neonatal
deaths occurring in the first week of life (Jamison and others
2004). Table 26.3 presents modeled estimates for early neonatal
deaths in 2001. The data on the magnitude and patterns of still-
births remain particularly poor.
Given weak sources of information, the dearth of reliable
trends data is hardly surprising. At a global level, a major diffi-
culty arises from the need to use models to estimate maternal
mortality. As the basic methodology for the models has changed
over time, the data are not appropriate for trend assessment.
AbouZahr and Wardlaw (2001) provide patchy support for
downward trends in some parts of the world, mostly on the
basis of civil registration data and mostly restricted to countries
with maternal mortality ratios of less than 100 per 100,000 live
births—thus notably excluding South Asia and Sub-Saharan
Africa. Even where declines appear to have occurred, they did so
prior to 1990. Countries with sustained falls since then, such as
Argentina and China, cannot be regarded as representative of all
developing countries. Cause-specific trend data are extremely
rare, often gathered through small-scale hospital-based studies
or special inquiries (see, for example, Pattinson 2002). Recent
WHO (2004c) statistics on unsafe abortion show an apparent
decrease in incidence in all world regions, although the risk of
death remains high at 50 per 100,000 live births, and in parts of
Sub-Saharan Africa the risk is as high as 140 per 100,000 live
births (Rogo, Bohmer, and Ombaka 1999). These adverse
events, however, are often also the most seriously under-
reported, as elaborated further in chapter 57.
The availability of reliable trends data for perinatal mortali-
ty is even more problematic. A demand for population-based
estimates for newborn mortality is comparatively recent; thus,
there has been insufficient time to accumulate multiple data
points. Demographic and health surveys (DHSs) are a key
source for tracking trends in infant and child mortality. Several
DHSs now have data that can be disaggregated to show neona-
tal deaths, but only a few have information on stillbirths, and
the quality of that information is still being assessed.
Information from WHO suggests that early neonatal death rates
fell slightly, from 28 per 1,000 live births around 1980 to about
25 per 1,000 in 2000, for low- and middle-income countries,
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Table 26.2 Estimates of Maternal Mortality by Region, 2000–1
Range of uncertainty of
Maternal mortality Number of Estimated Lifetime risk maternal mortality
ratio (maternal maternal deaths number of of maternal ratio estimates Total
deaths per 100,000 as modeled maternal death (1 in Lower Upper fertility
Region live births), 2000 by WHO, 2000 deaths, 2001 number shown) estimate estimate rate
Central and Eastern 64 3,400 3,000 770 29 100 1.6
Europe, Commonwealth 
of Independent States, 
Baltic states, Europe, 
and Central Asia
East Asia and the 110 37,000 37,000 360 44 210 2.0
Pacific
Eastern and 980 123,000 — 15 490 1,500 5.5
Southern Africa 
Latin America and 190 22,000 16,000 160 110 280 2.6
the Caribbean
Middle East and 220 21,000 15,000 100 85 380 3.7
North Africa
South Asia 560 205,000 199,000 43 370 760 3.5
Sub-Saharan Africa 940 240,000 237,000 16 400 1,500 5.7
Western and  900 118,000 — 16 310 1,600 5.9
Central Africa
High-income countries 13 1,300 1,000 4,000 8 17 1.6
Low- and middle- 440 527,000 507,000 61 230 680 3.0
income countries
Low-income countries 890 236,000 — 17 410 1,400 5.4
World 400 529,000 508,000 74 210 620 2.7
Source: WHO 2004b, 2004d; UN 2002. 
—  not available.
Note: The regions are those used by the United Nations Children’s Fund. 
and the equivalent trend for stillbirths is suggested to be a drop
from 36 per 1,000 deliveries to 22 per 1,000 deliveries (J. Zupan,
personal communication, August 25, 2004).
Two types of differentials are particularly relevant: geo-
graphic (or regional) and socioeconomic. Table 26.2 indicates
the wide variation in the magnitude of maternal mortality
across regions, and a similar difference can be seen between
countries. In terms of absolute numbers of deaths, just 13
countries account for 70 percent of the global total (WHO
2004b).2 Caution is again needed, because the poorest coun-
tries also have the weakest information systems and, therefore,
have estimates derived solely from modeling. One regression
model (WHO 2004b), for example, uses independent variables,
such as the percentage of deliveries with health professionals
present and the proportion of deaths of women of reproduc-
tive age that are maternal deaths. Those variables are them-
selves subject to error and likely to be least reliable where
information systems are weakest. Geographic differences in
maternal mortality within countries are poorly documented,
although remote populations are often assumed to suffer the
highest levels because of poor access to emergency obstetric
care. Although this assumption seems logical, few reliable data
are available to confirm or refute it, and the possibility of high
levels of mortality in urban areas linked to unsafe abortion
(Thonneau and others 2002) makes the topic of geographic
differentials a priority for research.
Until recently, socioeconomic differentials in mortality have
tended to be inferred from utilization patterns for prenatal care
and health professionals at delivery. The DHSs continue to
provide the main data sources in this regard, for both interna-
tional and national analyses, and they demonstrate huge differ-
ences between wealth quintiles. A relevant recent development,
however, is the familial technique, which can be used to
examine socioeconomic differences in maternal mortality
using existing survey data (Graham and others 2004). Because
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Table 26.3 Early Neonatal Deaths by Gender and Cause, 2001
(thousands)
Worlda South Asia Sub-Saharan Africaa
Cause All Male Female All Male Female All Male Female
Perinatal conditionsb 2,522 1,400 1,123 1,086 596 489 573 332 241
Low birthweightc 1,301 710 591 757 406 351 243 141 102
Birth asphyxia 739 432 307 192 122 70 240 139 101
(including birth trauma)
Other perinatal conditionsd 482 258 225 137 68 68 90 52 38
Source: WHO 2004d.
a. Excludes the island of Mayotte.
b. Excludes stillbirths, congenital malformations, neonatal tetanus, congenital syphilis, acquired infections (respiratory and sepsis), and diarrhea.
c. Includes preterm deliveries and small for gestational age.
d. Includes all conditions originating in the perinatal period (P00–P96 codes in perinatal chapter of WHO 1992a), apart from low birthweight and asphyxia. 
Note: Nonobstetric (indirect) causes of death and morbidity, such as tuberculosis
and malaria, have been excluded.
Hemorrhage
28%
Sepsis
15%
Hypertensive
disorders
14%
a. Maternal mortality
Obstructed
labor
8%
Unsafe abortion
13%
Other maternal
22%
b. Maternal morbidity
Hemorrhage
18%
Sepsis
16%
Hypertensive
disorders
9%Obstructed
labor
9%
Unsafe abortion
26%
Other maternal
22%
Source: Mortality: WHO 2004d; Morbidity: Murray and Lopez 1998.
Figure 26.1 Medical Causes of Direct Maternal Mortality and
Morbidity (percentage distribution)
maternal health and health care are clearly associated with still-
births and early neonatal deaths, the same differentiating fac-
tors are likely to apply to perinatal outcomes. Indeed, data from
many DHSs show large gaps between rich and poor in relation
to neonatal mortality, with the greatest average disparity being
found in Latin American and the Caribbean (http://www.
worldbank.org/poverty/health/).
Attributable Burden 
The estimation of maternal and perinatal conditions as part of
international assessments of the burden of disease has long
been controversial, and much has been written about the prob-
lems and potential distortions of priorities (AbouZahr 1998;
Sadana 2001). Some of those criticisms relate to methods of
valuation based on disability-adjusted life years (DALYs), espe-
cially in relation to discounting and the omission of stillbirths,
and others to the inaccuracies and selectivity of the base data
on the incidence of complications, on case fatalities, and on
disabilities. Table 26.4 presents DALYs for South Asia and Sub-
Saharan Africa for the focus conditions for 2001. Those two
regions together account for 74 percent of the global burden of
maternal conditions and 64 percent of the global burden of
perinatal conditions.
The significance of the burden of maternal and perinatal
conditions is clear from two recent global assessments (CMH
2002; WHO 2002). The approaches the two initiatives adopted
have led to different conclusions about public health priorities.
The former focused on avoidable mortality resulting primarily
from direct obstetric conditions, whereas the latter considered
population risk assessments and highlighted the contribution
of indirect obstetric problems—especially micronutrient
deficiencies—and the role for preventive strategies. Clearly, the
choice between different measures of burden has a crucial
influence both on the strategic approach to achieving health
gains and on the prioritization of interventions.
INTERVENTIONS
Given the scope and nature of the burden of maternal and peri-
natal conditions, no quick fix is available and, thus, no single
intervention warrants exclusive attention. Rather, clusters or
packages of interventions need to be considered, and this
understanding has long been reflected in maternity services
throughout the world (Milne and others 2004). Even though
these clusters can be characterized or differentiated solely on
the basis of content—namely, the component interventions—
in practice, the health system or implementation context is also
a defining factor.
Levels and Types of Interventions
Box 26.1 presents one example of a comprehensive strategy for
safe motherhood. It illustrates the range of programmatic
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Table 26.4 DALYs for Perinatal and Maternal Conditions by Gender, Selected Regions, 2001
(thousands)
Worlda South Asia Sub-Saharan Africaa
Condition All Male Female All Male Female All Male Female
Maternal 26,789 n.a. 26,789 10,069 n.a. 10,069 9,743 n.a. 9,743
Hemorrhage 3,928 n.a. 3,928 1,718 n.a. 1,718 1,643 n.a. 1,643
Sepsis 5,348 n.a. 5,348 1,857 n.a. 1,857 1,843 n.a. 1,843
Hypertensive disorders of 1,895 n.a. 1,895 742 n.a. 742 842 n.a. 842
pregnancy
Obstructed labor 2,506 n.a. 2,506 1,185 n.a. 1,185 919 n.a. 919
Unsafe abortion 3,507 n.a. 3,507 1,467 n.a. 1,467 1,557 n.a. 1,557
Perinatalb 90,505 49,384 41,117 37,721 20,442 17,279 20,046 11,351 8,697
Low birthweightc 43,073 23,241 19,832 25,015 13,292 11,723 7,891 4,501 3,391
Birth asphyxia (including 31,972 17,945 14,025 8,283 4,957 3,326 9,256 5,195 4,062
birth trauma)
Other perinatal conditionsd 15,460 8,198 7,260 4,423 2,193 2,230 2,899 1,655 1,244
Source: WHO 2004d.
n.a.  not applicable.
a. Excludes the island of Mayotte.
b. Excludes stillbirths, congenital malformations, neonatal tetanus, congenital syphilis, acquired infections (respiratory and sepsis), and diarrhea.
c. Includes preterm deliveries and small for gestational age.
d. Includes all conditions originating in the perinatal period (P00–P96 codes in perinatal chapter of WHO 1992a) apart from low birthweight and asphyxia. 
issues raised by maternal and perinatal conditions:
• the scope for both primary and secondary prevention
• the difference between the individual receiving specific inter-
ventions (here, the mother) and the beneficiary (the baby)
• the multiple effects of single (component) interventions on
different outcomes
• the multiple benefits to the same outcome of different
interventions
• the short- and long-term time frames for interventions and
outcomes
• the balance between supply-side and demand-side
interventions
• the role for interventions outside the health sector.
Three main pathways are available for averting adverse out-
comes: preventing pregnancy, preventing complications, and
preventing death or disability from complications. The first
pathway is the only truly primary preventive strategy. It
requires intervention to avert the occurrence or mistiming of
pregnancy by means of effective family-planning methods, as
discussed in chapter 57. This preventive approach is relevant
for those women who are able to and wish to avoid or delay
pregnancy, but it has a limited role for those not in this posi-
tion, estimated at between 15 and 57 percent of women age 15
to 29 (WHO 2002). As concerns the primary prevention of
complications, comparatively limited reliable evidence is avail-
able on the true size of the avoidable fraction for many condi-
tions at a population level. The emphasis in this preventive
pathway is on maintaining normality and on managing mild
complications—and thus on good quality of care. Finally,
maternal death and disability may be avoided by effective,
timely, and appropriate clinical interventions, often referred to
as emergency obstetric care.
Given this complexity and the multiple approaches used to
address maternal and perinatal conditions, no perfect frame-
work for categorizing interventions exists. We, therefore, clus-
ter the alternative intervention pathways on the basis of the
following three parameters:
• level of care—home, primary, and secondary
• time period—pregnancy, labor and delivery, and
postpartum
• strategic approach—population-based versus personal
interventions.
Quality of Evidence
Pregnancy and childbirth have been the subjects of medical
investigation for centuries and, indeed, are among the oldest
clinical specialties.As a consequence, a substantial body of opin-
ion exists on the signs, symptoms, etiology, prognosis, natural
history, and management and treatment options for many
maternal and perinatal complications, particularly in developed
countries. Much of it can be regarded as conventional wisdom
acquired through practice. In contrast, a comparatively small
proportion of interventions can be regarded as based on evi-
dence, by contemporary scientific standards, and arrived at
through the conduct of robust research. Thus, in specification of
the content of intervention clusters, a built-in tension exists
between using the best available knowledge and using only evi-
dence that passes minimum quality criteria. Equally important
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Components of a Comprehensive Safe Motherhood Strategy
Box 26.1
The following are part of a comprehensive safe mother-
hood strategy:
• community education on safe motherhood and new-
born care
• evidence-based prenatal care and counseling
— nutritional advice 
— iron and folate supplements (multivitamins and
micronutrients) 
— iodization of edible oils and salt and vitamin A in
areas of endemic deficiency
— blood pressure screening
— screening and treatment for syphilis
— antiretrovirals, where voluntary counseling and
testing undertaken, and breastfeeding advice
— tetanus toxoid immunization
— treatment of urinary tract infections
• skilled assistance at delivery
• care of obstetric complications and emergencies
• postpartum care
• safe abortion and postabortion services
• family-planning information and services
• adolescent reproductive health education and services
Source: Dayaratna and others 2000.
is recognizing the fundamental distinction between knowing
what is effective at an individual case-management level, for
which an evidence base exists for maternal and perinatal condi-
tions, and demonstrating effectiveness at the aggregate levels of
composite strategies and entire countries or regions, for which
robust evidence is extremely limited (Graham 2002).
Population-Based Interventions
The primary aim of population-based interventions is to
reduce the risks leading to adverse outcomes at the population
level rather than at the individual level (WHO 2002).
Population-based interventions are essentially preventive and
seek to promote healthy behaviors, thereby reducing incidence
in the entire population. In the case of maternal and perinatal
conditions, such an approach could be adopted for two major
risk factors: lack of contraception and maternal undernutri-
tion. The grade of evidence for these population-based inter-
ventions is primarily level C for the former, but a mixture of A
and B for the latter.3
Fertility Behavior Change. Fertility behavior is ultimately the
primary exposure factor for both maternal and perinatal con-
ditions. Investigators have shown that the frequency (number
and spacing), the timing with regard to age, and the desirabil-
ity of pregnancy are associated with increased risks, although
some dispute remains about the effect of birth intervals.
Researchers have also investigated the influence of those factors
on perinatal conditions, finding clear associations with old or
young maternal age, short interpregnancy intervals, and high
or first birth order, with many of those variables also being
interrelated (Bale and others 2003).
Lack of effective use of contraception may result in
unwanted or mistimed pregnancies. Unintended pregnancies
are known to be associated with adverse maternal outcomes,
including unsafe abortion. Contraceptive behavior is clearly
determined by a host of socioeconomic, cultural, religious, and
medical factors (Hussain, Fikree, and Berendes 2000; Marston
and Cleland 2003; Mwageni, Ankomah, and Powell 2001),
which also have a bearing on intervention options. Most of the
options on the demand side focus on information, education,
and communication; those on the supply side focus on client-
friendly services. At a macro level, those intervention options
have been credited with the substantial increase in contracep-
tive use in developing countries over the past 40 years, which,
in turn, is seen as a contributor to the overall fall in the total
fertility rate from 6 to 3 (Cleland and Ali 2004). Nevertheless, a
significant unmet need for contraception persists in many
developing countries, with high levels of unsafe abortion as a
proxy indicator of that need.
As regards evidence of the effectiveness of family planning
in explicitly reducing maternal mortality or disability, no
primary sources are available, but there are a variety of mod-
eled estimates, such as Prata and others (2004), Walsh and oth-
ers (1993), and Winikoff and Sullivan (1987). Model estimates
vary enormously in terms of the size of the effect, depending
primarily on assumptions about the proportion of maternal
deaths caused by unsafe abortion. Investigators estimate the
potential gain from the avoidance of unintended or mistimed
pregnancies to be a 20 percent decrease in maternal deaths in
developing countries (Donnay 2000; Kurjak and Bekavac 2001;
UNICEF 1999).
Nutritional Interventions. Maternal undernutrition encom-
passes two main dimensions: underweight and micronutrient
deficiencies (principally iron and vitamin A). Unlike many of
the direct maternal complications, which are acute at onset and
of relatively short duration, these nutritional problems are
chronic and long term and, indeed, are intergenerational
(Tomkins 2001). The physiological mechanisms by which
undernutrition exerts an influence on outcomes in the mother
and baby are not entirely understood, but a large body of epi-
demiological evidence supports associations with, for example,
fetal growth or length of pregnancy (Villar and others 2002).
Those findings have originated mostly from populations with
either severe levels of undernutrition or significant cofactors,
such as malaria and other infections.
Considerable uncertainty surrounds the issue of timing
potential interventions, with conflicting opinions about mak-
ing targeted interventions during pregnancy; addressing
undernutrition among girl children or adolescents, and apply-
ing strategies for women of reproductive age, including peri-
conceptual women (Gay and others 2003; Rush 2000). Further
debate relates to the use of supplements versus food fortifica-
tion. A systematic review by Villar and others (2002) of ran-
domized controlled trials to prevent or treat adverse maternal
outcomes and preterm delivery concludes that limited evidence
supports large-scale interventions with multivitamins, miner-
als, or protein-energy supplementation, but that iron and folic
acid are effective against anemia. Rouse (2003) emphasizes the
potential cost-effectiveness of vitamin A or beta-carotene sup-
plementation in reducing maternal mortality if the findings of
West and others (1999) from Nepal are replicable elsewhere.
Personal Interventions
When we consider interventions directed at individuals rather
than whole populations, the need for a continuum of care for
mother and baby in terms of time (before and after delivery),
place (linking home and health services through an effective
referral chain), and person (the provider of care) is important.
A variety of conceptual frameworks emphasize this continuum
and the dangers of fragmentation. Care to prevent or treat
the vast majority of maternal and perinatal conditions can be
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provided at home, at the primary level (clinic or health center),
and at the secondary level (district hospital),4 with the district
or equivalent regarded as the essential planning unit for service
delivery (WHO 1994). This system is comparable to the 
“close-to-client” health system that the Commission on
Macroeconomics and Health (CMH 2002) has proposed,
whereby trained staff members other than doctors provide
much of the care, with an emphasis on primary prevention and
management of acute conditions.
Home-Based Care. Two topical interventions that fall into the
category of home-based care are (a) information, education,
and communication and birth preparedness and (b) male
involvement (for home-based newborn care, see chapter 27).
Evidence in this cluster of interventions falls predominantly
into the level C category.
Birth Preparedness Many descriptive studies indicate that
women, relatives, and other members of the community
frequently do not recognize danger signs in pregnancy, child-
birth, or the puerperium, and that lack of recognition can have
serious consequences for mother and baby (Gay and others
2003). Health education interventions at prenatal clinics
appear to be less successful at raising awareness and increasing
the use of emergency obstetric care than the use of pictorial
cards (Khanum and others 2000) or community education
(Bailey, Szaszdi, and Schieber 1995).
Birth preparedness includes planning for the place and the
attendant at delivery, as well as arranging for rapid transfer to a
health center or hospital, when needed, and sometimes identi-
fying a compatible blood donor in the case of hemorrhage
(Portela and Santarelli 2003). Initiatives to promote birth pre-
paredness can clearly be home or community based, but stud-
ies have emphasized the importance of linkages with prenatal
care so as to include appropriate recommendations for intra-
partum care (Shehu, Ikeh, and Kuna 1997). In circumstances in
which prenatal services are of poor quality or are underused,
traditional birth attendants or relatives are often the only
source of information; thus, initiatives need to reach those
individuals too.
Male Involvement Many studies have observed positive bene-
fits from the involvement of male partners in care-seeking
behavior related to pregnancy and delivery (Gay and others
2003). That involvement is now advocated as an essential
element of WHO’s Making Pregnancy Safer Initiative (WHO
2003). Models and mechanisms for achieving this involvement
have not been robustly evaluated, and considerable controversy
concerns those that are based on behavioral and social
cognitive theories that presume lack of knowledge as the
root problem (Portela and Santarelli 2003; Raju and Leonard
2000).
Primary-Level Care. Primary-level care is widely regarded as
the crucial entry point to maternity services—and also to care
before and after pregnancy. The focus here is essentially pre-
ventive, but with the capacity to detect problems, to manage
mild complications appropriately, and to stabilize and then
refer cases that require higher-level care. Although the name
used for primary care facilities varies from country to country,
we employ the commonly used term health center. In terms of
functionality in relation to maternal and perinatal care, the
health center should provide prenatal, delivery (including
management of complicated abortion), and postpartum care
(including family planning and postabortion counseling), as
well as care of the newborn.
The management of complicated cases is usually discussed
at two levels: basic emergency obstetric care (BEmOC) and
comprehensive emergency obstetric care (CEmOC), the dis-
tinction being made on the basis of the number of signal or
essential clinical functions performed.5 This distinction forms
the basis of a set of process indicators that the United Nations
(UN) has endorsed for program monitoring (UNFPA 2003).
The capacity of health centers to provide BEmOC depends on
the availability of supplies, drugs, infrastructure, and skilled
providers. Some of the signal functions may not always be per-
formed by midwives or nurses, sometimes because of the regu-
lation of roles by the government or professional bodies. For
this reason, a further distinction can be made between full
BEmOC, which comprises six functions, some of which may
require a doctor, and obstetric first aid, which includes two sig-
nal functions universally performed by midwives and nurses:
the administration of antibiotics or oxytocics, intravenously or
intramuscularly.
Routine Prenatal Care The literature available on routine pre-
natal care is extensive, and there is a long history of assessing the
component interventions (Hall, MacIntyre, and Porter 1985;
Rooney 1992). In safe motherhood programs, prenatal care
provides one of the rare examples of robust assessment of an
intervention package (Villar and others 2001). As Bale and oth-
ers (2003) note, even though many of the component clinical
interventions are effective in terms of perinatal outcomes
(Bergsjo and Villar 1997), reliable evidence of an effect on
maternal mortality in developing countries is not available
(McDonagh 1996). However, where early detection is followed
by appropriate treatment, prenatal care does seem to reduce
adverse outcomes from specific maternal conditions, including
hypertensive disorders of pregnancy, urinary tract infections,
and breech presentations (Carroli, Rooney, and Villar 2001;
Villar and Bergsjo 1997). Conversely, the limited effectiveness of
prenatal risk screening at a population level is now widely
acknowledged (Graham 1998). The poor predictive value of
many screening tools for maternal complications reinforces the
importance of access to emergency obstetric care for all women
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who develop a need for it and underlies calls for skilled atten-
dance at all deliveries. Many health experts, however, do accept
screening and treatment for syphilis and immunization with
tetanus toxoid as important prenatal interventions (Bale and
others 2003). Similarly, the prevention and treatment of anemia
and of malaria, with prophylaxis or bednets, are widely regarded
as essential elements of routine prenatal care. Nutritional sup-
plementation, however, remains more controversial.
Prenatal care has been assessed not only in terms of content,
but also in relation to alternative models of the number and
timing of visits (Munjanja, Lindmark, and Nystrom 1996).
Strong evidence exists on the cost-effectiveness of a targeted,
four-visit schedule (Villar and others 2001) that includes an
educational element on the recognition of danger signs and the
use of skilled attendance at delivery.
The principal sources of international data on levels, trends,
and differentials in prenatal care coverage are the DHSs. The
latest statistics show comparatively high coverage levels
when measured in terms of one or more visits—levels average
71 percent for Sub-Saharan Africa—but comparatively little
improvement between 1990 and 2000. Within countries, wide
socioeconomic differentials in uptake are apparent.
Delivery Care As indicated earlier, the risks of adverse out-
comes in mother and baby are usually highest during the intra-
partum period. Even though health experts have long appreci-
ated this fact, prioritization of this element of safe motherhood
is comparatively recent. Much has been written both on this
shift in emphasis and on the underlying rationale, as well as
on what skilled attendance at delivery should comprise (De
Brouwere and Van Lerberghe 2001). Investigators have sug-
gested a variety of conceptual models for defining content, with
varying degrees of emphasis on the attendant and on the
enabling environment (Bell and others 2003). All these models
recognize that skilled attendance encompasses both normal
and complicated deliveries, with the focus on the former and
on the management of mild complications at the primary level,
as is consistent with BEmOC, and with referral to CEmOC at
the secondary level when necessary.
Key unresolved issues at the primary level relate to the
skills and scope of work of the attendant, especially in relation
to being a multipurpose health worker, and to the potential
role of nonprofessionals, such as auxiliaries and trained
traditional birth attendants (Buttiens, Marchal, and De
Brouwere 2004). Work by Koblinsky and Campbell (2003) has
helped to inform this debate by proposing four basic models
of delivery care that vary according to configurations of place
of delivery and attendant. Evidence on the effectiveness of the
alternative models at a population level is lacking, and sup-
port for skilled attendance at delivery is, thus, based primari-
ly on historical and contemporary ecological analysis (De
Brouwere and Van Lerberghe 2001). Conversely, high-grade
evidence supports a number of clinical interventions, such as
active management of the third stage of labor, as well as essen-
tial newborn care.
Once again, the principal sources of data on levels and
trends in coverage of skilled attendants at delivery are the
DHSs. The data, however, are based on women’s self-reports of
who attended their deliveries, include only live births, and have
major definitional uncertainties. Some countries, for example,
use terms such as supervised deliveries and include as attendants
both auxiliaries and trained traditional birth attendants (see
Bell, Curtis, and Alayon 2003 for a critique of these data). A
global analysis of trends in deliveries by skilled attendants
showed wide variations in progress across different regions,
with the latest figures for Sub-Saharan Africa, Asia, and Latin
America and the Caribbean for 1990–2003 being 48, 59, and
82 percent, respectively (AbouZahr and Wardlaw 2001;
WHO 2004a). The proportion of deliveries with health profes-
sionals present (doctors, midwives, nurses) is one of the proxy
indicators for the MDG on maternal health (Graham and
Hussein 2004). It demonstrates not only major differentials
between countries, but also wide variation in uptake across
socioeconomic groups within countries (De Brouwere and Van
Lerberghe 2001). Although skilled attendants do not necessar-
ily operate only in fixed health facilities such as health centers,
the DHS data show low levels of professional attendance in the
community. Promoting skilled attendance is thus essentially
advocating for institutionalizing deliveries.
Postpartum Care Primary care services continue to neglect
the postpartum period despite significant morbidity among
mothers and babies during this time. Routine performance of
postnatal checks is not widespread, and most contacts with
services after delivery tend to focus on educational messages
on, for example, danger signs, breastfeeding, nutrition, and
lifestyle.
Postabortion Care One significant area of service delivery that
does not fit well with descriptive frameworks based on prena-
tal, intrapartum, and postpartum care is the management of
complicated abortions. Unsafe abortion accounts for a signifi-
cant proportion of the burden of maternal conditions, but it is
still treated as the poor relation in the debate on intervention
strategies (De Brouwere and Van Lerberghe 2001). In particu-
lar, with the prioritization in recent years of skilled attendance
at delivery, both the service base for and the provider of
postabortion care have become less well defined (Dayaratna
and others 2000). This crucial element of obstetric care falls
into BEmOC in the case of mild complications and CEmOC
for more serious cases, but whether it is regarded as part of
prenatal, delivery, or postnatal services appears to vary from
setting to setting. Moreover, postabortion care illustrates the
dangers of the fragmentation of broader reproductive health
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care, because primary prevention and counseling after treat-
ment for complications tend to fall within the remit of family-
planning services, whereas emergency care at the primary level
is usually provided as part of maternity services and at the sec-
ondary level may fall within obstetrics or gynecology services.
Secondary-Level Care. Secondary-level care is hospital-based
care, generally at the district level, including CEmOC. As a cen-
ter for referral, this level of care needs to be linked to the pri-
mary level through an effective chain of communications
(Murray and others 2001). The focus at the district hospital is
on secondary prevention, with the ability to manage the prin-
cipal maternal and perinatal conditions discussed earlier; thus,
district hospitals must be able to provide surgical interventions
and the requisite backup, such as blood banks (Kusiako,
Ronsmans, and Van der Paul 2000). In many countries,
however, the district hospital is also the local provider of pre-
ventive services, including prenatal and normal delivery care; as
such, it is responsible for attending to a wide mix of uncompli-
cated and complicated cases.
Although no high-grade evidence of the effectiveness of
CEmOC is available, many health experts agree that maternal
mortality cannot be significantly reduced in the absence of
such care (Bale and others 2003). The issue thus becomes one
of the cost-effectiveness of other strategies, given the presence
of CEmOC. The UN agencies have endorsed the threshold of
one CEmOC facility per 500,000 people. Data indicating the
attainment of this ratio—and, indeed, the percentage of met
need for CEmOC—are not widely available. Similarly, reliable
information on geographic or socioeconomic differentials in
access to CEmOC is extremely limited.
Policy Considerations and Approaches
The health of mothers and babies is a human right and needs
to be underpinned by policies and laws that increase access to
information and good-quality, affordable health services
(Germain 2000). A positive policy environment is crucial for
promoting maternal health and reducing the burden of mater-
nal and perinatal conditions. Such policy considerations need
to go beyond the health sector to include related issues, such as
transportation, nutrition, girls’ access to education, and gender
biases in the control of economic resources. Through a human
rights–based approach, programs can be fashioned to ensure
that every woman has the right to make informed decisions
about her own health and has access to quality services before,
during, and after childbirth (Freedman 2001).
The ICPD marked a dramatic shift not only by putting the
concepts of rights and choice center stage, but also by intro-
ducing the reproductive health paradigm. The first decade of
the ICPD plan of action was marked by major improvements
in policies related to maternal health in most of the 179
signatory countries. However, as observed at the ICPD  10
Conference, many promised changes remain at the level of pol-
icy pronouncement and have not yet been implemented. The
stagnation is most notable in relation to maternal mortality
and the HIV pandemic, especially in Sub-Saharan Africa. The
failure to fully implement the ICPD consensus can be attrib-
uted to lack of political will, inadequate funding for programs
to further reproductive health, and weak health systems. It is
too early to judge the effect of the MDG proclamation
(Johansson and Stewart 2002), although it could well suffer the
same fate unless special attention is given to maternal and child
health in the context of sectorwide approaches and Poverty
Reduction Strategy Papers (UNFPA 2003). Some suspect that
both these modalities may not give reproductive health the
focus and attention it requires, because competing needs may
crowd it out. Others argue, however, that sectorwide approaches
can be a boon for maternal health because they offer a more
effective platform for addressing ailing health systems
(Goodburn and Campbell 2001).
Whether at the national or international level, advocacy for
maternal and perinatal health should focus on the following
seven key message areas:
• magnitude of the problem 
• factors influencing maternal and perinatal outcomes
• functions of maternal health programs and which interven-
tions work
• consequences of not addressing maternal and perinatal
health
• costs of improving maternal and perinatal health
• responsibilities at each level of the health system and beyond
• policy and legal impediments to implementing comprehen-
sive safe motherhood and newborn health programs.
Major advocacy networks, such as the Partnership for Safe
Motherhood and Newborn Health, the White Ribbon Alliance,
and the Healthy Newborn Partnership, seek to promote mater-
nal and newborn health at the global level. Their purpose is to
create awareness by changing the language of discourse, build-
ing international political commitment, developing global
guidelines, and improving access to technical information for
providers and program managers.
COST-EFFECTIVENESS OF SELECTED
INTERVENTION PACKAGES
Cost-effectiveness analysis (CEA) faces several major chal-
lenges with respect to evaluating the prevention and treatment
of maternal and perinatal conditions. First is the sheer range of
conditions and potential interventions. The breadth of the
clinical area implies the need to make tough choices with
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respect to which packages of interventions to compare. A sec-
ond and related challenge is the lack both of reliable data on the
burden of conditions and of high-grade evidence on the effec-
tiveness and costs of packages. As a result, we can assess only
the relative cost-effectiveness of different packages of interven-
tions by means of modeling. Thus, the third set of challenges
is associated with modeling, which makes the analysis vulner-
able to all the usual criticisms of the modeling of cost-
effectiveness—in particular, uncertainty about the direction of
any bias introduced and the difficulty of establishing the valid-
ity of the model (Sheldon 1996). Finally, there are the related
issues of the appropriateness to maternal and perinatal condi-
tions of standard outcome measures used in the model—in
particular, DALYs, which exclude stillbirths and indirect mater-
nal conditions (AbouZahr 1999; De Brouwere and Van
Lerberghe 2001).
Selected Intervention Packages
For some of the reasons mentioned in the previous subsection,
researchers have made few attempts to model packages of inter-
ventions for maternal and perinatal conditions, and many of
those attempts do not specify content in sufficient detail to
replicate the package. Our approach is to define content by
beginning with a literature search of best practices in prevent-
ing and managing the focus maternal and perinatal conditions,
acknowledging that, by excluding conditions that impose a
lesser burden, we ignore interventions that might be highly
effective and cost-effective. We then grouped those interven-
tions that are considered effective and that are either being or
likely to be implemented on a substantial scale into packages of
care, bearing in mind previous CEA work, such as the WHO
mother-baby package (WHO 1994). Expert panels then
reviewed the component interventions and the packages and
assisted with identifying resource requirements. Given the
complementary CEA elsewhere in this volume on interventions
relevant to maternal and perinatal conditions such as family
planning, we focus on care during pregnancy, postpregnancy
care, and care immediately postdelivery—in other words, on
clusters or packages of interventions typically referred to as pre-
natal care, delivery or intrapartum care, and emergency obstetric
care. Table 26.5 outlines the content of those packages.
When one considers the intervention packages, contextual
factors are clearly crucial. Given the particularly high burden in
South Asia and Sub-Saharan Africa, we chose those two regions
as the specific health system scenarios for this chapter. Those
regions are also characterized by high levels of poverty and
encompass some of the most heavily indebted countries in the
world.
Comparison of Alternative Intervention Package Scenarios.
Following the approach of generalized CEA (Hutubessy and
others 2003), we evaluated intervention packages with respect
to a counterfactual (base scenario), varying the content and
coverage. We also performed sensitivity analyses to examine the
effects of changing the values of key variables for costs, effec-
tiveness, or both. Each intervention package scenario specifies
different dimensions of prenatal and intrapartum care provid-
ed at primary and secondary care facilities. As regards the
assumed pathways through which women with normal or
complicated pregnancies may or may not access care, the cru-
cial entry point in our model is prenatal care. That choice influ-
ences the detection and treatment of mild and severe compli-
cations during the antepartum period at both the primary and
the secondary levels, as well as the proportion of women deliv-
ering with a health professional present and with improved
access to emergency care for intrapartum or abortion-related
complications. In our CEA model, these effects are achieved
primarily through two types of interventions:
• improvements in the quality of care, incorporating the tech-
nical content or the proportion of women in receipt of the
care needed (that is, met need) 
• increases in the coverage of care—namely, the proportion of
women accessing care.
Routine prenatal care can be characterized in terms of
whether it is a basic or an enhanced package—in other words,
its technical content (table 26.5)—and by the percentage of
women accessing the package—in other words, its coverage.
Delivery at a primary-level health center is viewed as having a
single quality dimension in terms of content—namely, whether
BEmOC is available for women who develop mild complica-
tions, including complicated abortion (table 26.5). BEmOC is
assumed to require the presence of a doctor at the health cen-
ter; otherwise, only obstetric first aid is presumed to be avail-
able, covering just the two signal functions described earlier.
A percentage of women with severe complications who
access primary care will go on to secondary care. This percent-
age is assumed to be 20 or 50 percent of complicated cases
attending primary care. Our model makes no provision for
women who access secondary care directly in the event of a
serious complication, although it does allow for those who
were attending the hospital as their local provider of primary
care. Of those women who access the secondary care facility
from the primary level, a proportion will receive the CEmOC
that they need (assumed to vary between 50 and 90 percent of
complicated cases that reach secondary care). This figure
reflects such issues as staff skills and motivation and the avail-
ability of drugs and equipment. For the other quality-of-care
element—namely, the technical content of CEmOC—we
consider two levels: with (enhanced package) and without
(base package) selected interventions for high-risk babies
(table 26.5).
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Table 26.5 Care Packages at the Primary and Secondary Levels 
Level of care Base Enhanced 
and condition Content package package
Routine prenatal care Clinical examination, including for severe anemia, height and weight, blood pressure ? ?
at the primary levela Obstetric examination for gestational age estimation and uterine height, fetal heart, detection ? ?
of malpresentation and position, and referral
Gynecological examination ? ?
Urine test (multiple dipstick) ? ?
Laboratory tests: hemoglobin, blood type and rhesus status, syphilis and other symptomatic ? ?
testing for sexually transmitted diseases
Advice on emergencies, delivery, lactation, and contraception ? ?
Education about clean delivery, warning signs, and premature rupture of membranes ? ?
Iron and folic acid supplementation ? ?
Multivitamin supplementation — ?
Tetanus toxoid immunization ? ?
HIV voluntary testing and counseling — ?
Antimalarial chemoprophylaxis in endemic areas — ?
Screening and treatment for syphilis ? ?
Balanced protein-energy supplementation for all women — ?
Delivery care at the Clean delivery technique, clean cord cutting, clean delivery of baby and placenta ? ?
primary levelb Active management of the third stage of labor, including oxytocics ? ?
Episiotomy in appropriate cases ? ?
Recognition and first-line management of delivery complications (for example, obstructed labor, ? ?
early detection of cephalopelvic disproportion, malposition and malpresentation, previous 
cesarean delivery, postpartum hemorrhage, and preeclampsia or eclampsia) and referral
Intravenous fluid ? ?
Intravenous uterotonics, if bleeding occurs ? ?
Partograph ? ?
Essential newborn care ? ?
Intravenous antibiotics ? ?
Magnesium sulfate — ?
Forceps or vacuum extraction — ?
Manual removal of placenta — ?
Removal of retained products of conception — ?
Corticosteroids for preterm labor — ?
Antiretrovirals for prevention of mother-to-child transmission of HIV — ?
Antibiotics for premature rupture of membranes — ?
CEmOC package at the secondary level c
Postpartum hemorrhage Recognition of high-risk cases and arrangements for delivery in a facility ? ?
Grouping of blood ? ?
Iron and folate supplementation ? ?
Blood transfusion ? ?
Uterotonic drugs, oxytocics ? ?
Bimanual compression of uterus ? ?
Manual removal of placenta ? ?
Uterine packing or balloon tamponade ? ?
Fluid replacement ? ?
Hysterectomy ? ?
Removal of products of conception ? ?
Secondary postpartum hemorrhage management (antibiotics, uterotonics, removal of products ? ?
of conception, and fluid and blood replacement)
(Continues on the following page.)
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Antepartum hemorrhage Early detection of major placenta previa and abruption ? ?
Grouping and saving blood ? ?
Iron and folate supplementation ? ?
Cesarean section for major-degree placenta previa, abruption with a live baby ? ?
Blood and fluid replacement ? ?
Oxytocics ? ?
Sepsis Antibiotics for premature rupture of membranes, cesarean section ? ?
Fluid and blood transfusion ? ?
Intravenous antibiotics ? ?
Evacuation of products of conception ? ?
Drainage of abscess ? ?
Treatment of shock with fluids or blood, nitroglycerine ? ?
Pregnancy-induced Early detection and management of preeclampsia ? ?
hypertension Calcium supplementation in high-risk cases ? ?
Aspirin to prevent preeclampsia ? ?
Antioxidants to prevent preeclampsia ? ?
Intravenous magnesium sulfate ? ?
Antihypertensive drugs to reduce blood pressure ? ?
Immediate delivery if more than 36 weeks ? ?
Magnesium sulfate and antihypertensives for postpartum eclampsia ? ?
Obstructed labor Partograph ? ?
Cesarean section ? ?
Symphysiotomy ? ?
Destructive operation ? ?
Antibiotics ? ?
Fluid and blood transfusion ? ?
Hysterectomy ? ?
Abortion Evacuation of retained products of conception ? ?
Intravenous antibiotics ? ?
Fluid or blood transfusion ? ?
Postabortion contraceptive advice ? ?
Ectopic pregnancy Proof puncture (culdocentesis) — —
Laparotomy and salpingectomy — —
Blood transfusion (autotransfusion) ? ?
High-risk infant Forceps or vacuum extractiond ? ?
Corticosteroids for preterm labor — ?
Antiretrovirals for prevention of mother-to-child transmission of HIV — ?
Antibiotics for premature rupture of membranes — ?
Source: Authors.
—  not available.
a. The base package includes the four-visit schedule recommended by WHO (Villar and others 2001).
b. The base package includes the provision of obstetric first aid (intravenous or intramuscular antibiotics and oxytocics). The enhanced package includes the availability of a doctor, and thus the full range
of BEmOC (UNFPA 2003). In some settings, experienced midwives or clinical officers may perform all six BEmOC functions.
c. At the hospital level, prenatal or delivery care will also be provided for normal, uncomplicated cases and, thus, also includes all care listed in the first two panels of the table. 
d. Forceps or vacuum delivery can also be used for several other conditions, such as prolonged labor (not obstructed), fetal distress, preterm birth, aftercoming head of breech, and preeclampsia to speed
up delivery.
Table 26.5 Continued
Level of care Base Enhanced 
and condition Content package package
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The base case for our CEA model assumes the following:
• basic technical content for the prenatal care package
• prenatal care coverage for 50 percent of pregnancies 
• only obstetric first aid (two signal functions) available in
health centers 
• 20 percent of women with severe complications accessing
secondary care
• 50 percent of those severe cases receiving the CEmOC that
they need.
The different assumptions regarding quality of care and
coverage can be combined in many different ways, yielding a
large number of potential packages and a larger number of
potential comparisons between those and the base package.
However, not all possible scenarios are meaningful. For exam-
ple, because the base prenatal care package does not screen for
HIV, matching that package with enhanced delivery care that
provides antiretrovirals to reduce vertical transmission would
be inappropriate. We identified six packages for comparison
with the base case, representing a range of safe motherhood
strategies and focusing on prenatal and delivery care. Table 26.6
summarizes these alternatives and indicates their essential
characteristics from a safe motherhood perspective.
Resource Use and Costs
We adopted an ingredients approach (Creese and Parker 1994)
to identify resource use. For this type of bottom-up costing, we
prepared lists for primary- and secondary-level care facilities of
types of personnel, drugs, supplies (medical and nonmedical),
medical and surgical equipment relevant for the interventions,
and capital items (vehicles, buildings, building space). For most
of the scenarios, our identification of resources was based on
the WHO mother-baby package costing tool (WHO 1999), with
necessary modifications because of the content of care packages
indicated in table 26.5. We estimated the costs for clinical per-
sonnel on the basis of salaries for different grades according to
the guidelines provided by the volume editors for the two
selected regions. The time required by different staff members
for each care intervention and the changes in time and person-
nel because of varying content and coverage of packages were
informed by expert panel reviews, and we then calculated the
costs. We valued the other nontraded inputs using information
primarily provided by WHO-CHOICE (2004).
Cost-Effectiveness Ratios 
The CEA involves a number of fixed and variable assumptions
(see annex 26.A). The most important assumptions concern
the reducible burden of these conditions, the effectiveness of
the interventions, and the availability of appropriate human
resources. We have assumed that increases in care can be
achieved without major capital investments and that human
resources are not in short supply; therefore, more could be used
(with given wage rates) as required for increased activity and
enhanced coverage.
Table 26.7 summarizes the findings of the CEA in terms of
incremental cost-effectiveness ratios (ICERs) for the six pri-
mary comparisons between the base scenario and alternative
intervention packages for a population of 1 million. Table 26.8
gives details of total costs, deaths averted, life years saved, and
DALYs averted. Table 26.9 shows the findings of the sensitivity
analysis in terms of how the ICERs change when different
assumptions (see annex 26.A) are made with respect to effec-
tiveness, met need, and inpatient costs.
In interpreting the results, note that they are point esti-
mates. Even though they are based on the best information
currently available, all the inputs into the model are subject to
some degree of uncertainty. Without access to robust data on
individual costs and effects or without specifying distributions
for each variable, it is impossible to identify confidence limits
for the estimated ICERs. Thus, we do not know, for example,
whether the difference in the incremental cost per DALY
averted for Sub-Saharan Africa between increased coverage at
the primary level (US$92) and improved quality of CEmOC
(US$151) reflects a genuine difference in cost-effectiveness
or whether there are overlapping confidence intervals
(table 26.7).
With those important caveats in mind, at first sight the
results for South Asia and Sub-Saharan Africa appear quite dif-
ferent. For each intervention package, regardless of the specific
assumptions made, the cost per DALY averted is always lower
in Sub-Saharan Africa. The higher costs of care in Sub-Saharan
Africa (see annex 26.A) are thus more than compensated for by
the higher effectiveness, which is a result of the region’s greater
burden. However, some important similarities are apparent
between South Asia and Sub-Saharan Africa. Leaving aside
options 3b and 5b (the options without nutritional supple-
ments), the results for both regions show a consistent pattern.
Improvements in the overall quality of care, especially at the
primary level through the provision of BEmOC (option 3a),
together with increased overall coverage (option 5a), are the
most cost-effective intervention packages—and both include
nutritional supplements. They are followed by increased cover-
age at the primary level (option 2). Improved quality of
CEmOC (option 4) is the least cost-effective option. Removing
nutritional supplements from the packages makes relatively lit-
tle difference in Sub-Saharan Africa, slightly increasing cost-
effectiveness, but in South Asia, options 3b and 5b become less
cost-effective with the nutritional supplements removed. The
explanation lies in the ICERs of nutritional supplements as
such, which are US$48 or US$45 in South Asia and US$118 or
US$110 in Sub-Saharan Africa, depending on whether the
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Table 26.6 Comparisons Undertaken for CEA 
Primary level Secondary level
Abbreviated Quality of care: Quality of care: Quality of care: Safe 
description Option technical Percentage receiving technical motherhood Resource 
of package number Coverage content Coveragea care needed content Interpretation strategy implications
Routine maternity
care
Increased primary-
level coverage
Improved overall
quality of care
with nutritional
supplements
Improved overall
quality of care
without nutritional
supplements
Base
2 
3a
3b 
50 percent of
pregnant women
attend prenatal
care; 50 percent of
pregnant women
have professional
intrapartum careb
70 percent prenatal
care; 70 percent
delivery care
No change from
base
No change from
base
See first two
panels of
table 26.5
No change from
base
Enhanced prenatal
and delivery care
(BEmOC)
Enhanced prenatal
and delivery care
(BEmOC) without
BPS
20 percent of
complicated cases
at the primary
level referred to
the secondary
level
No change from
base
No change from
base 
No change from
base
50 percent of those
reaching the secondary
level receive the CEmOC
needed
No change from base
70 percent 
70 percent 
See table 26.5c
No change from
base
Enhanced CEmOC
(adds interventions
for high-risk babies)
Enhanced CEmOC
(adds interventions
for high-risk babies)
Basic package of
prenatal and
delivery care
Benefit from
increasing coverage 
Benefit from enhanc-
ing quality (content
and receipt of care
needed) at the primary
and secondary levels
As for 3a without BPS
Content of package
essentially the same
as WHO mother-baby
package, plus
magnesium sulfate
and active manage-
ment of labor
Information, educa-
tion, and communica-
tion for increasing
uptake of prenatal
and delivery care
Provision of BEmOC
at the primary level
As for 3a
Costs typical of
WHO mother-
baby package
Costs of informa-
tion, education,
and communica-
tion; increased
personnel; drugs 
Costs of doctors
and equipment at
the primary level,
training for
BEmOC and
CEmOC, costs of
BPS 
As for 3a without
costs of BPS
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Improved quality
of CEmOC 
Improved overall
quality of care and
coverage with
nutritional
supplements
Improved overall
quality of care and
coverage without
nutritional
supplements
4
5a 
5b 
No change from
base
70 percent prenatal
care; 70 percent
delivery care
70 percent prenatal
care; 70 percent
delivery care
No change
from base
Enhanced prenatal
and delivery care
(BEmOC) 
Enhanced prenatal
and delivery care
(BEmOC) without
BPS
No change
from base
50 percent 
50 percent 
80 percent 
90 percent 
90 percent 
No change
from base
Enhanced CEmOC
(adds interventions
for high-risk babies)
Enhanced CEmOC
(adds interventions
for high-risk babies)
Benefit from increased
percentage of women
with severe complica-
tions receiving the
CEmOC needed 
Benefit from improved
quality (technical con-
tent and percentage
receiving care needed)
and coverage at the
primary and secondary
levels
Benefit from improved
quality and coverage
at the primary and
secondary levels
without BPS
Improved quality
of CEmOC
Comprehensive
package: improved
coverage and content
with BPS
Improved coverage
and content without
BPS
Cost of additional
personnel time
and drugs
Costs of
providing and
running ambu-
lances, costs
of additional
personnel and
drugs, training
for BEmOC and
CEmOC, costs
of BPS
As for 5a without
the costs of BPS 
Source: Authors.
BPS  balanced protein-energy supplementation. 
a. Defined in terms of the percentage of complicated cases at the primary level referred to and reaching the secondary level.
b. Includes obstetric first aid for complicated cases, including abortion and postpartum complications.
c. The secondary level will also provide some prenatal and delivery care for normal cases, as defined in the first two panels of table 26.5 for the base package at the primary level.
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Table 26.7 ICERs per Million Population, South Asia and Sub-Saharan Africa
(U.S. dollars)
Incremental cost per Incremental cost per Incremental cost per  
death averted life-year saved DALY averted 
Option Alternative compared with South Sub-Saharan South Sub-Saharan South Sub-Saharan
number the base package Asia Africa Asia Africa Asia Africa
2 Increased primary-level coverage 6,129 3,337 217 119 148 92
3a Improved overall quality of care with 5,017 2,729 165 90 142 83
nutritional supplements
3b Improved overall quality of care 8,975 2,538 296 84 240 77
without nutritional supplements
4 Improved quality of CEmOC 10,532 5,089 372 195 255 151
5a Improved overall quality of care and 5,297 2,915 177 98 144 86
coverage with nutritional supplements
5b Improved overall quality of care and 7,944 2,865 269 96 203 84
coverage without nutritional supplements
Source: Authors’ calculations. 
Table 26.8 Costs and Effectiveness of Intervention Packages per Million Population, South Asia and Sub-Saharan Africa
Percentage 
Number Number of Number of of DALYs 
Option Total costs of deaths life years DALYs averted that 
number Intervention package (US$) averted saved averted are maternal
South Asia
1 Routine maternity care 408,976 79 2,240 3,273 50
2 Increased primary-level coverage 603,071 111 3,136 4,582 50
3a Improved overall quality of care with nutritional 829,505 163 4,793 6,225 26
supplements
3b Improved overall quality of care without nutritional 757,433 118 3,415 4,727 35
supplements
4 Improved quality of CEmOC 420,918 80 2,272 3,320 50
5a Improved overall quality of care and coverage with 1,287,354 245 7,201 9,354 26
nutritional supplements
5b Improved overall quality of care and coverage without 1,186,123 177 5,131 7,103 35
nutritional supplements
Sub-Saharan Africa
1 Routine maternity care 602,646 192 5,406 6,969 47
2 Increased primary-level coverage 859,027 269 7,568 9,757 47
3a Improved overall quality of care with nutritional 1,164,833 398 11,652 13,753 24
supplements
3b Improved overall quality of care without nutritional 1,049,209 368 10,733 12,770 26
supplements
4 Improved quality of CEmOC 617,724 195 5,483 7,069 47
5a Improved overall quality of care and coverage with 1,785,971 597 17,508 20,664 24
nutritional supplements
5b Improved overall quality of care and coverage 1,633,956 552 16,127 19,188 26
without nutritional supplements
Source: Authors’ calculations. 
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comparison is with or without increased coverage (options 5a
and 3a, respectively). This difference reflects the high burden
from low birthweight in South Asia and, thus, the gain from
nutritional supplements.
Comparing the content of the three most cost-effective
intervention packages (3a, 5a, and 2) suggests that much can be
achieved through improvements at the primary care level.
Improved quality in relation to managing complications—in
other words, the provision of BEmOC—and increases in cov-
erage (a combination of options 3a and 2) at the primary level
are likely to have even lower ICERs than those shown in
table 26.7. This finding is consistent with the Commission on
Macroeconomics and Health’s emphasis on close-to-client
services (CMH 2002), and it is highlighted further in chap-
ter 53. As noted earlier, given the importance of prompt
intervention in the event of obstetric complications, the effec-
tiveness of intervention packages that may reduce delays by
bringing services closer to communities is hardly surprising.
The benefits from option 2 were achieved essentially by
increasing prenatal care coverage from 50 to 70 percent,
because our model assumes that those women taking advan-
tage of professional delivery are those who have also had pre-
natal contact. Prenatal care is, thus, a crucial entry point to the
health system. Small changes in prenatal care coverage (20 per-
cent) lead to larger numbers of women also benefiting from the
rest of the care package in terms of obstetric first aid and
CEmOC.
This issue is important for safe motherhood and newborn
health, because the role of prenatal care has been subject
to intense debate about its benefits relative to resource use
(De Brouwere and Van Lerberghe 2001; Maine and Rosenfield
1999). Much of this discussion has focused on the lack of evi-
dence on the direct contribution of prenatal care to reducing
maternal mortality (McDonagh 1996; Rooney 1992), which, in
turn, is explained partly by the poor performance of at-risk
screening tools. However, differentiating the contribution to
the prevention of maternal deaths of the prenatal care compo-
nent alone is difficult. Ultimately, life-saving interventions
depend on the functioning of the entire health system, includ-
ing an effective referral network.
Our model also made assumptions about women’s willing-
ness and capacity to respond to referral to higher levels of care
in case of complications. This willingness and capacity depend
on many factors and are undoubtedly also driven by commu-
nities’ perceptions of quality of care. As noted earlier, coverage
rates of prenatal care are already high in many Sub-Saharan
African countries, but significant socioeconomic differentials
are apparent within countries. Our model does not address this
Table 26.9 Sensitivity Analysis Results, South Asia and Sub-Saharan Africa
(incremental cost per DALY averted, US$)
Effectiveness Met need Inpatient cost 
Best
assumption assumption assumption
Option number Alternative compared with base package estimate High Low High Low High Low
South Asia
2 Increased primary-level coverage 148 113 163 147 150 213 109 
3a Improved overall quality of care with nutritional supplements 142 100 163 143 144 142 143 
3b Improved overall quality of care without nutritional supplements 240 180 326 241 242 240 240
4 Improved quality of CEmOC 255 193 311 373 260 446 204 
5a Improved overall quality of care and coverage with nutritional 144 104 164 144 149 152 136
supplements
5b Improved overall quality of care and coverage without nutritional 203 153 250 203 210 227 189 
supplements
Sub-Saharan Africa
2 Increased primary-level coverage 92 70 104 91 93 191 84 
3a Improved overall quality of care with nutritional supplements 83 64 90 83 84 83 83
3b Improved overall quality of care without nutritional supplements 77 61 85 77 78 77 77
4 Improved quality of CEmOC 151 114 166 228 151 326 130 
5a Improved overall quality of care and coverage with nutritional 86 66 94 86 89 123 82 
supplements
5b Improved overall quality of care and coverage without nutritional 84 66 93 84 87 123 79 
supplements
Source: Authors’ calculations. 
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equity dimension but, given the recent work showing higher
risks of maternal death among the poorest groups (Graham
and others 2004), targeting disadvantaged women for improve-
ments in uptake might be worth considering (Gwatkin and
Deveshwar-Bahl 2002; De Brouwere and Van Lerberghe 2001).
Whereas option 2, increased primary-level coverage, relates
predominantly to the demand side of the health system
(Williams 1987), the most cost-effective packages (3a and 5a)
focus on the supply side, particularly at the health center level.
The latter packages are particularly relevant to the baby, includ-
ing screening of the HIV status of the mother and treatment
with antiretrovirals at the time of delivery to reduce the risk of
mother-to-child transmission, as well as provision of anti-
malarials. As a consequence, these options have a particularly
marked effect on the burden from perinatal conditions,
accounting for two-thirds to three-fourths of the total DALYs
averted (table 26.8). Note that these cost-effective options
include a doctor at the health center level to provide all six
BEmOC functions. In some situations, highly skilled midwives
will be able to act in this capacity, which would reduce costs
and further increase cost-effectiveness.
The most comprehensive packages in our model provide for
improved quality of care and coverage at both the primary and
the secondary levels (options 5a and 5b). Costing US$1.79 and
US$1.63 per capita, respectively, in Sub-Saharan Africa (as
calculated from the total costs of these packages shown in
table 26.8, and divided by the base of 1 million people), these
are also the most expensive packages. Not surprisingly, there-
fore, these two options avert much higher numbers of DALYs,
with the package that includes nutritional supplementation
averting nearly three times as many DALYs as the base package
(table 26.8). In CEA, generally the most comprehensive pack-
ages—that is, those that result in the greatest gain in quality
and coverage and, thus, cost the most—are often not cost-
effective, and yet our analysis found otherwise. This finding
may partly be explained by the linear assumptions about effec-
tiveness in the model and the assumption that the marginal
cost of care is constant. Such a finding also stresses both the
importance of a well-functioning health system (rather than an
excessive focus on one element) and the absence of any quick
fix. Moreover, we did not model these more comprehensive
options as perfect but unrealistic scenarios. We also still
allowed for 30 percent of pregnant women not attending pre-
natal care, 50 percent of severe complications at a primary level
not reaching CEmOC, and 10 percent of those reaching sec-
ondary care not receiving the emergency treatment they need.
Finally, a note of caution is warranted on the interpretation
of the CEA results. First, our model has necessarily used a num-
ber of assumptions for which data are extremely limited, and it
remains fairly crude, having been subject to only a limited sen-
sitivity analysis. Second, many comparisons are possible from
our model, but we have selected only six. Thus, we may not
have identified even more cost-effective intervention packages,
such as a combination of options 3a and 2.
ECONOMIC BENEFITS OF INTERVENTION 
A narrow definition of the economic benefits of safe mother-
hood interventions would focus primarily on the impact of
maternal mortality and morbidity on household investment
and consumption. Investment in this context refers not so
much to financial investment as to investment in improving
housing conditions, agricultural productivity, education, and
so on. The key elements to capture include the loss of produc-
tivity and the disruption of planned investment and consump-
tion. In addition to the loss of a woman’s own productivity,
consequent effects are likely on the productivity of other
household members—effects that may be particularly long
lived in the case of young children whose health and education
suffer because of their mother’s death. The household will also
be worse off because it will have diverted resources from pre-
ferred consumption and investment activities in response to
the health crisis. Thus, recognizing the dynamic consequences
of maternal death and disability and selecting an appropriate
time horizon for the analysis are important.
The potential benefits to individual households arising from
investments in safe motherhood are relatively clear, although
challenges in quantifying and valuing them remain. The bene-
fits may, however, be more widely spread in that improvements
in safe motherhood may reduce poverty, which in turn may
stimulate economic development. Increased economic develop-
ment may then feed back into further improvements in mater-
nal health, generating a virtuous cycle. The mechanisms where-
by changes in maternal health affect other parts of the economy
may be identified by a close examination of the influence of
maternal health on productivity and educational attainment.
A number of links may exist between safe motherhood and
the performance of the health care system; therefore, strategies
to improve safe motherhood may be a means of achieving
wider health service improvements (Goodburn and Campbell
2001). Jowett (2000, 213) notes that “to improve a facility’s
capacity to respond to obstetric emergencies, it is necessary to
have the skills and supplies to deal with trauma, give blood
transfusions and anesthesia, and have a functional operating
theatre.” Thus, initiatives in safe motherhood could be an entry
point for wider health sector reform and improvement.
LESSONS FOR IMPLEMENTATION
The findings from the CEA indicate potential health gains and
the reduced burden that may be achieved by implementing
selected packages of interventions. Such implementation
assumes, first, that decision makers accept the evidence and are
willing and able to act and, second, that an enabling health sys-
tem environment exists within which the requisite scale and
quality of care can be effectively delivered. These factors are not
peculiar to safe motherhood, but they undoubtedly help
explain the significant gap between evidence and action that
many argue is one of the main obstacles to progress (Godlee
and others 2004; Villar and others 2001). The gains from bridg-
ing this gap would be significant: the MDGs for child survival
and maternal health might become more than mere rhetoric
for poor regions if intervention packages of the scope and
nature described here were implemented. The most cost-
effective of the packages averted nearly 50 percent more direct
maternal deaths than the base package. This gain would be
encouraging, but the prospects for achieving it by 2015 are
weak (Johansson and Stewart 2002).
At the macro level, a supportive policy environment clearly
is crucial, as noted earlier. At the micro level, an enabling health
system implies a reduction in the disequilibrium between the
demand and supply sides (Williams 1987), with particular
attention to three interrelated issues: access, quality, and
finance. The CEA reported in this chapter emphasizes the
potential benefits to mother and baby of improved access to
care, particularly the importance of entry to the health system
through primary-level services. The increases in coverage could
be achieved by a variety of mechanisms but clearly require both
demand- and supply-side interventions.
On the supply side, this chapter has shown that improved
quality of care at both the primary and the secondary levels
encompassing technical, infrastructural, and human resource
dimensions (Pittrof, Campbell, and Filippi 2002) is a particu-
larly cost-effective option. The widespread call for all women to
deliver with skilled attendance immediately raises major ques-
tions about quality of care and capacity, because much of the
developing world faces an acute shortage, as well as an unequal
geographic distribution, of health professionals.
Our CEA assumes that redistributing human resources
within countries will accommodate the increased uptake of
care by women, although the most effective mechanisms for
achieving this goal, such as incentives, use of nonphysicians,
and increased private sector involvement, have not yet been
established (De Brouwere and Van Lerberghe 2001). What is
clear, however, is the importance of the interplay between sup-
ply and demand, with the supply of quality care stimulating
demand for care and vice versa. Quality care includes an effec-
tive referral system (Murray and others 2001) to ensure the
required match between the various levels of care different
women and their babies need at different times (De Brouwere
and Van Lerberghe 2001). Such systems require not only
financial resources to support transportation, communica-
tions, and feedback mechanisms, but also structured fee and
exemption strategies to reduce both inappropriate self-referral
to hospitals and financial barriers to access on the part of the
poor.
The financing of prenatal and delivery care services at an
adequate and sustainable level is a subject of much debate
and uncertainty, given the difficulty of distinguishing these
elements from broader health expenditure categories (De
Brouwere and Van Lerberghe 2001). Given the low level of
overall per capita expenditure on health in developing
countries—estimated at US$13 in 2002 for the poorest 49
countries (Bale and others 2003)—attaining our base interven-
tion package (costing approximately US$0.41 per capita in
South Asia and US$0.60 in Sub-Saharan Africa) does not
sound unrealistic at current resource levels (see table 26.8, and
divide by base population of 1 million people).
The effects of health sector reforms, particularly decentral-
ization of management and budget holding, appear to be mixed
in terms of increasing resource flows into maternity services,
with both apparent positive benefits, as in Bolivia (De Brouwere
and Van Lerberghe 2001), and negative effects through
the exacerbation of inequities (Russell and Gilson 1997).
Effective management decisions on finance, access, and quality
require information, an essential ingredient for stimulating
action. To allocate scarce resources where they are likely to
achieve the greatest gain, countries need information to assess
the burden of ill health, evaluate the performance of current
intervention strategies, identify the scope for improvement and
implement changes, and close the loop by evaluating effects and
cost-effectiveness (Lawn, McCarthy, and Ross 2001).
Even though the challenges that the poorest countries face
today clearly differ in many respects from those that developed
or transition countries experienced in the past, six historical
lessons provide particularly relevant insights. First, examples
abound of supportive policy contexts and individual champions
of progress in addressing maternal and newborn health, such
as those reported by De Brouwere and Van Lerberghe (2001).
Second, historical data on the uptake of prenatal care demon-
strate that community-based providers and advocates played a
crucial role. Third, the role of various professionals and profes-
sional bodies has not always been positive, particularly as
regards the “war” between advocates for home and institutional
deliveries (Koblinsky and Campbell 2003). Moreover, good his-
torical evidence indicates that excessive rates of forceps deliver-
ies and other interventions were significant contributors to
maternal mortality in countries such as the United Kingdom
and the United States (Buekens 2001). Fourth, primary-level
care depends on an effective referral system being in place to
maintain the confidence of both women and providers (Loudon
1997). Fifth, to reduce the burden of maternal and perinatal
conditions, the system of health care financing must facilitate
access for the poorest groups and guarantee service quality
(De Brouwere and Van Lerberghe 2001). Finally, the role of pop-
ulation-based information on births and maternal deaths was
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crucial in ensuring that actions were locally relevant (Sorenson
and others 1998), in demonstrating progress, and thus in stim-
ulating further action. This crucial role is particularly apparent
in the literature on several European countries in the past cen-
tury (Graham 2002; De Brouwere and Van Lerberghe 2001).
RESEARCH AND DEVELOPMENT NEEDS
The priorities for research and development arising from this
chapter need to be put in the context of wider requirements for
safe motherhood and newborn health that have been well artic-
ulated elsewhere (see, for example, Bale and others 2003). The
general heading under which the specific needs emerging from
this chapter can be grouped is evidence-based decision making,
which has five crucial requirements:
• recognizing the weakness of current approaches to allocat-
ing scarce health care resources in poor countries 
• making efforts to improve the scope and quality of data on
the burden from maternal and perinatal conditions 
• carrying out robust evaluation of the costs and effectiveness
of intervention strategies
• using reliable evidence to inform the decision-making
process 
• implementing prioritized strategies and robust, continuous
assessment of their performance.
Within those major areas, specific topics relevant to the CEA
undertaken here include the following:
• Ascertaining the burden of maternal and perinatal conditions.
Greater clarity and consensus are needed on the scope of this
important burden category and the implications of signifi-
cant current exclusions, such as indirect maternal conditions
and stillbirths. Practical assessment tools are needed to
enable meta-analysis and other modeling approaches to sys-
tematically factor in data constraints. Huge gaps in knowl-
edge exist with regard to the levels and consequences of
maternal morbidity (Say, Pattinson, and Gulmezoglu 2004),
the contribution of iatrogenic factors, the unpredictability of
maternal complications, and the levels of mortality. Most
of those gaps require significant developments in relation to
available measurement tools and in poor countries’ capacity
to use them as part of routine health surveillance. These
improvements not only are needed to inform future CEA but
also have wider implications for global health monitoring.
• Implementing change. In addition to evidence on the content
of intervention strategies, assessments of how to implement
changes are urgently needed. A limitation of our analysis is
that, even though the model may be a reasonable represen-
tation of the resource and health consequences of different
intervention packages, the way to achieve the required
change, such as a particular increase in the uptake of prena-
tal care, may not be known. Thus, the ICERs may be too low,
in that they do not fully capture the costs of the intervention.
• Estimating cost-effectiveness. More sophisticated economic
models need to be developed to facilitate the evaluation of a
wider range of safe motherhood strategies, particularly as
better primary evidence becomes available from other stud-
ies and initiatives using a variety of outcome measures
(Cairns, McNamee, and Hernandez 2003). Similarly, proba-
bilistic sensitivity analysis would be a valuable development
that would permit fuller exploration of the uncertainties
regarding the model’s parameters.
CONCLUSIONS
In 2001, maternal and perinatal conditions represented the sin-
gle largest contributor to the global burden of disease, at near-
ly 6 percent of total DALYs (Mathers and others 2004).
Reducing that burden is widely stated as a priority at both
national and international levels, but the track record of trans-
lating the rhetoric into action on a sufficiently large and equi-
table scale to make a difference at the population level remains
disappointing. The literature abounds with examples of this
disappointment (see, for example, Maine and Rosenfield 1999;
Weil and Fernandez 1999). Many reasons account for the lim-
ited progress, especially in the poorest regions of the world, and
researchers offer many interpretations of the bottlenecks. Lack
of evidence on the size of the burden and on the effectiveness
of alternative intervention strategies figures prominently in
these interpretations.
The modeling in this chapter is, therefore, based on imper-
fect knowledge and needs to be supplemented with data from
primary evaluations. The findings do, however, provide some
tentative insights into programmatic options that may repre-
sent the optimal use of resources in South Asia and Sub-
Saharan Africa. In this context, three issues deserve emphasis.
First, for intervention packages to achieve the degree of cost-
effectiveness shown here, improvements are needed across
health systems, and both the supply and the demand sides need
to be addressed. Second, crucial entry points to this system can
be achieved at the primary level, particularly through prenatal
care. The effect of increasing the volume of women in contact
with these services is likely to manifest itself in an increased
proportion of deliveries with skilled attendance and of deliveries
in which women obtain access to emergency obstetric care.
Finally, the quality of these services is crucial, and even with
only 50 percent uptake of care, benefits can still be achieved in
terms of overall DALYs averted and of reduced maternal and
perinatal mortality.
Initiatives to improve the quality of care, particularly at a
primary level, thus appear to be cost-effective options for the
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poorest regions of the world. Overall those findings appear to
lend support to a safe motherhood and newborn health
strategy that is close to the client and boosts community confi-
dence in health systems.
ANNEX 26.A: CEA MODEL ASSUMPTIONS 
We assumed that there are four primary-level health facilities
(health centers) and one secondary-level care facility (district
hospital) for every 500,000 people. We estimated the numbers
of pregnancies and births from the crude birth rate for each
region. We assumed that pregnant mothers attending for rou-
tine prenatal care are equally distributed between the five facil-
ities and that each facility provides similar routine prenatal and
delivery care. Routine prenatal care is assumed to comprise
four visits—except for mothers with complications, who make
six visits. Mothers with complications are referred to the dis-
trict hospital after their first visit if they cannot be treated at the
health center. We assumed that complications such as anemia
and sexually transmitted diseases are treated without referral to
secondary care, as are preeclampsia and incomplete abortion, if
a doctor is present at the facility. The average number of bed
days is assumed to be three days for normal deliveries and six
days for cesarean section and other complications. Table 26.A1
shows the U.S. dollar costs per inpatient bed day used in the
main analysis and in the sensitivity analysis.
We assumed the existence of excess capacity, so that an
increase in prenatal care coverage from 50 to 70 percent would
not require an increase in the number or capacity of existing
health care facilities, and the increased costs would mostly be
increases in variable costs. For increased coverage of prenatal
care, we assumed a need for increased expenditure on educa-
tion, information, and communication. Enhanced prenatal
care and comprehensive emergency obstetric care are assumed
to require additional expenditures on training, assumed to be
10 percent of total personnel costs. We assumed that the addi-
tional costs of basic emergency obstetric care compared with
obstetric first aid are largely due to providing doctors at each
health center. We also assumed that 8 percent of mothers
require cesarean section as a result of either maternal or
perinatal complications. About 2 percent of mothers are
assumed to require treatment for preterm delivery, and 1 per-
cent for premature rupture of membranes.
In practice, the proportion of women with serious complica-
tions receiving comprehensive emergency obstetric care varies
widely, from 3 percent in Cameroon to 75 percent in Sri Lanka
(Averting Maternal Death and Disability Working Group on
Indicators 2003). The scenarios considered in this chapter
assume that either 20 or 50 percent of women with serious com-
plications reach secondary care, and that 50, 70, 80, or 90 percent
of those women receive the elements of comprehensive emer-
gency obstetric care that they need, depending on which inter-
vention package is being considered. For the sensitivity analysis,
we used low values of 30, 50, 60, and 70 percent and high values
of 70, 80, 90, and 95 percent. We assumed that ambulances are
available, so that when the proportion of mothers with severe
complications reaching secondary care is increased, the addi-
tional costs are only the additional driver time and the increased
costs of running and maintaining the vehicle.
The prevalence and incidence of different maternal condi-
tions are taken from the WHO mother-baby package (WHO
1994). World Health Organization estimates of the burden of
different maternal and perinatal conditions (WHO 2004d)
have been applied to a population of 1 million, with a particu-
lar crude birth rate to generate an estimate of the potential
number of deaths that could be avoided, the years of life that
could be saved, and the DALYs that could be averted. The
assumptions regarding the effectiveness of the interventions
with respect to maternal and perinatal conditions were based
primarily on the WHO’s mother-baby package and a review of
the literature; they are shown in table 26.A2. We assumed that
each intervention has the same effect on the number of deaths,
years of life saved, and DALYs. The effectiveness of interven-
tions is assumed to be additive.
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Table 26.A1 Costs Per Inpatient Bed Day, South Asia and Sub-Saharan Africa
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South Asia Sub-Saharan Africa
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NOTES
1. Antecedent is here defined as a factor that changes the probability of
an adverse outcome or sequela, either positively (protecting) or, more usu-
ally, negatively (aggravating). A risk factor may be a leading contributor to
the global burden because of high prevalence in the population or because
of a large increase in the probability of adverse outcomes (WHO 2002).
2. Afghanistan, Angola, Bangladesh, China, the Democratic Republic
of Congo, Ethiopia, India, Indonesia, Kenya, Nigeria, Pakistan, Tanzania,
and Uganda.
3. We use a simple three-way distinction for levels of evidence. Level A
refers to evidence from randomized clinical trials or systematic overviews
of trials; level B relates to nonrandomized studies, often with multivariate
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analyses; and level C is assigned to case series, case studies, or expert
opinion.
4. This chapter does not deal with tertiary and specialist levels of care
or with rehabilitative care or care for chronic conditions.
5. The six functions of BEmOC are (a) administering antibiotics intra-
venously or intramuscularly, (b) administering oxytocics intravenously or
intramuscularly, (c) manually removing the placenta, (d) administering
anticonvulsants intravenously or intramuscularly, (e) carrying out instru-
mental delivery,and (f) removing retained products of conception.The two
additional functions in CEmOC are blood transfusion and cesarean sec-
tion. For a facility to be regarded as a BEmOC or CEmOC site, respectively,
it must perform all six or all eight functions regularly and must be assessed
every three to six months (UNFPA 2003).
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The second half of the 20th century witnessed impressive
reductions in the risk of under-five child mortality, which was
halved between 1960 and 1990. The greatest reduction was for
children after the first month of life, with relatively little
decrease in the neonatal period (the first 28 days of life).
Neonatal deaths, estimated at approximately 4 million annually,
now account for 38 percent of the world’s deaths of children
under five. The fourth Millennium Development Goal (MDG)
aspires to a global target, by 2015, of reducing the under-five
mortality rate by two-thirds, which implies approximately 30
deaths per 1,000 live births for children under five. Currently,
there are an estimated 30 deaths per 1,000 live births in the
neonatal period alone. Thus, the fourth MDG cannot be
achieved without substantial reduction in neonatal deaths
(Lawn, Cousens, and Zupan 2005).
Addressing neonatal mortality requires links within the
continuum of care from maternal health through pregnancy,
childbirth, and early neonatal care, and into child health pro-
grams. Such services can be delivered through a combination
of care at the family-community level, outreach, and clinical
care (figure 27.1). Yet neither child survival nor safe mother-
hood programs have adequately addressed newborn deaths.
The first week of life, when 75 percent of neonatal and 50 per-
cent of maternal deaths occur, is associated with low health
care coverage, particularly in poor communities. Investing in
maternal, neonatal, and child health (MNCH) services will
improve the survival of newborns and reduce stillbirths and
maternal and child deaths. The first weeks of life are also a
time of behavioral transition, representing an opportunity to
promote healthy behaviors that have benefit beyond the
neonatal period.
This chapter provides an overview of neonatal deaths, pre-
senting the epidemiology as a basis for program priorities and
summarizing the evidence for interventions within a health
systems framework, providing cost and impact estimates for
packages that are feasible for universal scale-up. The focus of
the chapter is restricted to interventions during the neonatal
period. The priority interventions identified here are largely
well known, yet global coverage is extremely low. The chapter
concludes with a discussion of implementation in country
programs with examples of scaling up, highlighting gaps in
knowledge.
NEONATAL DEATHS
One reason neonatal survival has received little attention rela-
tive to the huge number of deaths is the invisibility of those
deaths. Most deaths during the neonatal period occur at home
and are often unregistered even in transition countries
(Lumbiganon and others 1990). Social invisibility is linked to
an expectation of high mortality; many traditional societies do
not name newborns for up to six weeks. Data presented here are
derived from full-coverage vital registration for 72 countries,
which cover less than 4 percent of all neonatal deaths; demo-
graphic and health surveys, which cover 75 percent of global
neonatal deaths; and statistical modeling, for the 20 percent of
neonatal deaths in countries without data (WHO forthcom-
ing). Population-based data on neonatal morbidity or long-
term disability in low- and middle-income countries (LMICs)
are scarce. The World Health Organization (WHO) has
estimated that three conditions (birth asphyxia, prematurity,
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(60 per 1,000 live births), Mozambique (55 per 1,000 live
births), and Ethiopia (52 per 1,000 live births).
When Do Newborns Die?
Each year 3 million newborns die during their first seven days
of life, accounting for 75 percent of all neonatal deaths. At least
1 million babies die during their first 24 hours of life (Lawn,
Cousens, and Zupan 2005). If mortality rates during the first
five years of life are adjusted to rates per week, the risk in the
first week of life is massively higher than during any other time
of life: 24 per 1,000 in the first week compared with 3 per week
for the rest of the first month and only 0.12 per week after the
first year of life. Yet the first week is the very period in the con-
tinuum of care when services are most likely to be lacking, par-
ticularly in poor communities, where most deaths occur.
Time Trends in Neonatal Mortality
As shown in figure 27.2, the disparity in NMRs between LMICs
and high-income countries is increasing over time, especially
during the early neonatal period, which saw an almost 60 per-
cent reduction in high-income countries between 1983 and
and “other perinatal causes”), collectively termed perinatal
causes, contribute to 6.3 percent of global disability-adjusted
life years (WHO 2003a). Although these causes represent only
part of the neonatal burden, the WHO estimate is more than
triple that of HIV, yet receives remarkably little attention.
Where Do Newborns Die? 
Only 1 percent of neonatal deaths occur in high-income coun-
tries. These countries have average neonatal mortality rate
(NMR) of 4 per 1,000 live births, whereas in LMICs the aver-
age NMR is 33 per 1,000 live births, with a range of 2 to 70
(table 27.1). The highest number of neonatal deaths occur in
South Asia because of the large populations of this region. The
six countries with the highest numbers of neonatal deaths in
2000 include the populous nations of India (1.09 million
neonatal deaths annually), China (416,000), Pakistan
(298,000), Nigeria (247,000), Bangladesh (153,000), and
Ethiopia (147,000). Of the 20 countries with the highest
NMRs, 80 percent are in Sub-Saharan Africa. The highest rates
occur in countries there that have experienced recent civil
unrest, such as Liberia (65 per 1,000 live births), Sierra Leone
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2000, compared with about a 15 percent reduction in LMICs.
There has been no measurable decline in the regional average
NMR for sub-Saharan Africa. However some regions have
made significant progress in reducing NMRs, particularly Latin
America and the Western Pacific. Some low-income countries
such as Bangladesh, Indonesia, and Sri Lanka have achieved
NMR reductions of 40 to 50 percent. In South Asia and Sub-
Saharan Africa, the decline in late neonatal deaths was influ-
enced by the halving of neonatal tetanus deaths that occurred
during the 1990s as a result of increased tetanus toxoid protec-
tion and clean delivery practices. By 2000, two-thirds of LMICs
had eliminated neonatal tetanus and an additional 22 countries
were nearing this goal.
Historical data also show more rapid reductions in
postneonatal mortality, steady reductions in late neonatal
mortality, and slower reductions in early neonatal deaths. In
England, the NMR fell from more than 30 per 1,000 live births
in 1940 to 10 per 1,000 in 1975. This fall occurred before inten-
sive care, which was introduced only when the NMR had fallen
below 15 per 1,000. The greatest reduction of NMR coincided
with the introduction of free prenatal care, high coverage of
skilled childbirth care, and the availability of antibiotics.
Although the number of postneonatal and late neonatal deaths
is amenable to public health interventions (such as immuniza-
tion and improved hygiene and nutrition), larger reduction of
early neonatal deaths and of maternal deaths requires a system
that provides effective clinical care—particularly during child-
birth, which is more challenging.
Direct Causes of Neonatal Death 
Fewer than 3 percent of the world’s neonatal deaths occur in
countries that have vital registration data that are reliable
enough to use in cause-of-death analysis. Population-based
information in high-mortality settings often depends on
verbal autopsy tools of variable quality. The Child Health
Epidemiology Reference Group undertook an extensive exercise
to derive global estimates for program-relevant causes of neona-
tal death, including preterm birth, asphyxia, sepsis/pneumonia,
neonatal tetanus, diarrhea, and other causes, with the latter
including specific but less prevalent causes such as jaundice. For
low-mortality countries, vital registration data from 45 coun-
tries with full vital registration coverage (cumulative sample size
of 96,797) were included. For high-mortality countries, studies
were identified through extensive systematic searches, and a
meta-analysis was performed after applying inclusion criteria
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Table 27.1 NMRs and Neonatal Deaths by Region for 2000, and Variation in NMR by Income Quintile and by Region
Percentage of 
NMR per 1,000 deaths during the
live births Number (percentage) neonatal period
(range across Poorest Richest of neonatal deaths among children
Region countries) quintile quintile (thousands) under five
World 30 — — 3,998 (100) 38
High-income countries 4 (1–11) — — 42 (1) 63
Low- and middle-income countries 33 (2–70) — — 3,956 (99) 38
Region
Africa 44 ( 9–70) 48 34 1,128 (28) 24
Americas 12 ( 4–34) 35 18 195 (5) 48
Eastern Mediterranean 40 ( 4–63) 38 28 603 (15) 40
Europe 11 ( 2–38) — — 116 (3) 49
South Asia 38 (11–43) 50 28 1,442 (36) 50
Western Pacific 19 ( 1–40) 28 17 514 (13) 56
Source: Authors’ calculations, based on NMRs and under-five mortality, WHO and UNICEF estimates; NMR by income quintile based on analysis of demographic and health survey data for 50 countries,
1995–2002.
—  not available.
Median NMR by income 
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Figure 27.2 Trends in Early and Late Neonatal and Postneonatal
Mortality, by Country Income Levels
and using standard case definitions (56 studies, cumulative
sample size of 13,685). Models were developed to simultane-
ously estimate the seven selected causes of death by country
(Lawn, Cousens, and Wilczynska forthcoming).
Three causes of death—infections (pneumonia, diarrhea,
and tetanus) (36 percent), preterm birth (28 percent), and
asphyxia (23 percent)—account for the majority of neonatal
deaths. Causes of death vary between the early and late neona-
tal periods, with deaths caused by preterm birth, asphyxia, and
congenital defects occurring predominantly during the first
week of life and infection being the major cause of neonatal
deaths thereafter. Neonatal tetanus, a totally preventable condi-
tion, still accounts for more than a quarter of a million deaths,
even after the second global elimination deadline has passed.
Most neonatal tetanus deaths occur in 20 countries in South
Asia and Sub-Saharan Africa, all of which have very high
NMRs. Variation in causes of neonatal death is seen between
and within countries, closely associated with the NMR level.
Where the NMR is high (more than 45 per 1,000 live births),
more than half of neonatal deaths are due to infections; where
the NMR is low, prematurity and congenital abnormalities are
the major causes of death (Lawn, Cousens, and Zupan 2005).
Hence, information regarding the local epidemiology is impor-
tant in prioritizing interventions.
Indirect Causes of Neonatal Death
An estimated 20 million low birthweight (LBW) infants (that is,
weighing less than 2,500 grams), are born each year—
25 percent of them in South Asia (Blanc and Wardlow 2005).
Although globally only 16 percent of newborns have LBW, 60 to
80 percent of neonatal deaths occur in LBW infants (Lawn,
Cousens, and Wilczynska forthcoming). LBW is due to short
gestation (preterm birth), intrauterine growth restriction
(IUGR), or both. Globally, almost one-third of neonatal deaths
are directly attributable to preterm birth. In contrast, an analy-
sis of vital registration data for 45 countries and of five
population-based studies suggests that a maximum of 1 to
2 percent of neonatal deaths are directly attributable to IUGR
in full-term neonates (Lawn, Cousens, and Wilczynska forth-
coming). Prematurity and full-term IUGR are also indirect
causes or risk factors for neonatal deaths, particularly deaths
resulting from infection. The relative risk among preterm
infants is much higher than for full-term IUGR infants (Yasmin
and others 2001). Complex technology is not necessary to avoid
most deaths in moderately preterm newborns. Extra attention
to warmth and feeding and to prevention or early treatment of
infections is crucial (Lawn, McCarthy, and Ross 2001).
Maternal health and health care are important determinants
of neonatal survival. Neonatal outcomes are affected by female
health throughout the life cycle, from child, through adoles-
cence, and into pregnancy (Pojda and Kelley 2000). In general,
intrapartum risk factors are associated with greater increases in
risk of neonatal death than factors identified during pregnancy,
which are in turn associated with greater increases in risk
than prepregnancy factors (Lawn, Cousens, and Zupan 2005).
Obstructed labor and malpresentation present the highest risk
and require skilled intervention. The mother’s death substan-
tially increases the risk of death for her child. Greenwood and
others (1987) report that of mothers who died in labor (N  8),
all the babies died within one year.
Delays in access to care for severely ill young infants are com-
mon. Peterson and others (2004), in a study in Uganda, find that
almost 80 percent of the caregivers of severely ill young infants
did not comply with recommended referrals to a health facility.
The reason given in 90 percent of the cases was lack of money,
underscoring the need for pro-poor financing mechanisms and
promotion of community demand for care. This recalls the
“three delays” model for maternal deaths, which outlines delays
in recognition of illness and in access to care and provision of
care once at a health facility (Thaddeus and Maine 1994).
Poverty is the root cause of many maternal and neonatal
deaths, either because it increases the prevalence of risk factors
such as maternal infections or because it reduces access to care.
An analysis of 50 demographic and health surveys between
1995 and 2002 reveals that, within regions, the poorest quin-
tiles have an NMR that is, on average, 20 to 50 percent higher
than that for the highest income quintile (table 27.1).
Deliberate programmatic focus is required to ensure that care
reaches poor families.
Applying Lessons from Epidemiology to Programs
There are almost 4 million neonatal deaths annually. Given that
the proportion of child deaths that occur during the neonatal
period (currently 38 percent) will increase over time, the MDG
for child survival cannot be met without a significant reduction
in the NMR. Most neonatal deaths are in Sub-Saharan Africa
and South Asia and are due to preventable causes. Historical
data demonstrate that the NMR can be reduced to 15 per 1,000
without intensive care.
Priority should be given to two main gaps in the provision
of care. The first is the continuum of care by time. The period
through pregnancy and childbirth into infancy contains a gap
at childbirth and during the first week of life, when most
neonatal deaths—and also most maternal deaths—occur.
Addressing this gap will involve strengthening safe mother-
hood and child survival services and institutionalizing links at
the subnational, national, and global levels. The second gap
is between levels of care (figure 27.1)—particularly with the
family-community level, since poor and rural communities
account for the majority of neonatal and maternal deaths.
Approaches are needed to better link homes and health care,
supplying care closer to such communities, increasing demand
for skilled care, and empowering communities, including poor
communities, to make healthful decisions.
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INTERVENTIONS
We undertook literature searches and categorized interventions
by time period (during pregnancy, and intrapartum and post-
natal or neonatal periods) (table 27.2). We focus on interven-
tions delivered during the neonatal period that are likely to
reduce neonatal deaths, as opposed to those delivered during
the neonatal period that yield later benefits (for example,
prevention of mother to child transmission of HIV). Although
rigorous evaluation of evidence is vital, evidence is not available
for some well-established interventions. In the case of neonatal
resuscitation, for example, a randomized controlled trial is
impossible for ethical reasons, yet the intervention is a corner-
stone of neonatal care in high-income settings. Some impor-
tant practices, such as cleanliness, have undergone little rigor-
ous evaluation but are obviously beneficial (Bhutta and others
2005). On the basis of level of evidence and feasibility of imple-
mentation, we grouped interventions into three categories:
• Universally applicable interventions are selected on the basis
of mortality impact, cost, and feasibility. Some of these
interventions are feasible only after skilled care is available.
Other interventions are feasible immediately, even in the
absence of skilled care. A particular example is improved
family care practices. Interventions may apply to different
newborns as follows:
— essential newborn care for all babies at all levels
— extra newborn care for babies with specific risk factors,
such as LBW
— emergency newborn care for babies who are ill, particu-
larly those with infections.
• Additional interventions should apply where neonatal mor-
tality is lower and capacity is greater. These interventions are
more complex, requiring more skilled staff members and
additional commodities, and therefore cost more for less
reduction in mortality. Universal scaling up cannot be rec-
ommended at present, but these interventions become
important for further reduction of mortality and disabilities
after universal care packages are in place.
• Situational interventions are necessary because of locally
prevalent risk factors, such as HIV or malaria.
The packages of newborn care selected for universal scale-up
are summarized in table 27.3 and discussed in the following sub-
sections, starting with family-community interventions and fol-
lowed by essential, extra, and emergency newborn care
packages.
Family-Community Care of the Newborn 
Family care of the newborn is important for all newborns. It
includes promoting positive behaviors such as breastfeeding
and demand for health care throughout the neonatal period
and afterward (WHO 2003c). Cleanliness (for example, cord
care and hand washing), warmth provision, and exclusive
breastfeeding reduce neonatal illnesses, especially infection.
Implementation of this package will depend on the setting, the
coverage of facility delivery, and the availability of community
workers or other channels but is feasible even in poorly
developed health systems (Knippenberg and others 2005). The
role and value of the mother are central.
Although much has been written to describe traditional
newborn care practices, few studies assess behavior change. An
exception is the study by Meegan and others (2001) of the
Masai in Kenya, where behavioral messages about cord care
practices were associated with the virtual elimination of neona-
tal tetanus—with no increase in tetanus toxoid immunizations.
The Warmi Project in rural Bolivia demonstrated that raising
community awareness of maternal, fetal, and neonatal health
issues through women’s community groups increased family-
planning coverage, attendance at prenatal and postnatal
services, and the presence of trained traditional birth assistants
at childbirth, resulting in a 62 percent reduction of perinatal
mortality (O’Rourke, Howard-Grabman, and Seoane 1998). A
cluster randomized trial in rural Nepal, where 90 percent of
women deliver at home, also used female facilitators working
with women’s groups. Comparing the 12 intervention villages
with their paired villages showed a 30 percent reduction in the
NMR (mainly late NMRs) mediated through increased health
seeking and improved home behaviors (such as doubling the
rates of practices such as hand washing and use of clean deliv-
ery kits) and strengthening of the health system (Manandhar
and others 2004).
A family-community package promoting good home care
of the newborn—particularly cleanliness, warmth, and exclu-
sive breastfeeding—would have an expected reduction in the
NMR of 10 to 40 percent, varying with the baseline NMR and
the potential for accessing care. The effect might be greater if
the package successfully addressed harmful local practices. The
effect of early care seeking for illness will depend on the capac-
ity of the primary and referral health care levels to manage
neonatal illness. Thus, community-level interventions with no
supply-side strengthening will have only a limited effect. Many
questions remain about how best to work with families and
communities, given widely differing cultures and behaviors
and the varying capacities of existing community health work-
ers (Darmstadt and others 2005), and about the wider applica-
tion of demand subsidies.
Essential Newborn Care at the Time of Birth
WHO (2003d) defines essential newborn care as the care of the
newborn at birth, including cleaning, drying, and warming the
infant; initiating exclusive breastfeeding early; and caring for
the cord. Essential care of the newborn is necessary for all
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Table 27.2 Interventions to Reduce Fetal and Neonatal Mortality by Timing of Intervention and by Scalability of Intervention
Period
Prepregnancy
During pregnancy 
• Essential for all
pregnancies 
• Extra care for
those at risk of
complications
• Emergency for
those with 
complications (first
referral level and
above)
Birth 
• Essential
Interventions for universal coverage (priority
interventions for high-mortality settings)
Family planning [B]:
• delay age of first pregnancy to after 18
• space births by two to three years
• provide opportunity for women to reduce births
to their desired number and to avoid pregnancy
after age 45 
Prevention, identification, and management of
sexually transmitted diseases [A]
Micronutrient deficiency prevention strategies
• iodination of salt [B]
Four-visit prenatal care package, including
• two tetanus immunizations [A]
• iron and folate supplements [B]
• syphilis screening and treatment [A]
• identification and referral of multiple
pregnancy, abnormal lie, preeclampsia [B]
• birth planning and emergency preparedness [C]
• prenatal counseling and preparation for
breastfeeding [C]
Extra prenatal care (more frequent visits, more
skilled caregiver) if 
• multiple pregnancy or abnormal lie (breech or
transverse) [RF A]
• pregnancy-induced hypertension or 
preeclampsia [RF A]
• diabetes [RF A]
• severe anemia [RF A]
• previous fetal or neonatal death [RF A]
Management of emergencies, including
• preeclampsia or eclampsia [A]
• bleeding in pregnancy [A*]
• uterine infection [RF A]
Skilled care in labor, including
• monitoring progress of labor (partograph),
maternal and fetal well-being [A]
• infection control [A*]
Newborn resuscitation if required [A*]
Situational interventions (where
specific conditions are prevalent)
HIV prevalent:
• primary prevention strategies [B]
• voluntary counseling and testing
and option of antiretroviral 
therapy [A]
High prevalence of recessive
conditions (such as sickle cell disease)
or high rates of consanguineous
marriages: offer genetics counseling
[RF A]
HIV prevalent:
• primary prevention strategies [B]
• voluntary counseling and testing
and option of antiretroviral 
therapy [A]
Malaria endemic:
• intermittent presumptive treatment
monthly after 20 weeks [A]
• insecticide-treated bednets [B based
on effect on LBW, not on NMR]
Hookworm infestation prevalent: 
• presumptive treatment with
mebendazole [B] 
Iodine deficiency prevalent:
• iodine supplementation [B] 
Famine: 
• targeted food supplementation [B] 
Group B streptococcus prevalent: 
• screening and treatment [A] 
Mother HIV positive: 
• antiretroviral therapy [A] 
Additional interventions (where
the health care system has
additional capacity and the NMR
is lower; for example, transition
countries)
Rubella immunization either of girls
only or of all population if regular
coverage can be maintained at more
than 80 percent of the population [A]
Periconceptual or preconceptual
provision of folate [A]
Information counseling and support for 
• smoking [RF A]
• alcohol and drug abuse [RF A]
• women experiencing violence [RF A]
Identification and treatment of
bacteriuria [A]
Information counseling and support for 
• smoking cessation [RF A]
• alcohol and drug abuse [RF A]
• healthy diet and avoidance of
unhelpful dietary taboos [C]
• women experiencing violence [RF A]
External cephalic version for breech
presentation at 36 weeks [A]
Fetal growth monitoring [A]
In utero transfer of high-risk 
pregnancies [B]
Supportive companion in labor [A]
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• Extra care 
• Emergency 
Postnatal and 
newborn
• Essential
• Extra care
• Emergency
Extra care if 
• preterm (37 weeks) or prolonged (18 hours)
rupture of membranes or evidence of chorioam-
nionitis; give antibiotics to woman [A]
• failure to progress in labor including instrumen-
tal vaginal delivery (vacuum) if required [RF A]
Newborn resuscitation if required [A*]
Emergency obstetric care for acute intrapartum
emergencies: [A*]
• obstructed labor and fetal distress
• bleeding, infections, or eclampsia
Neonatal resuscitation if required [A*]
Essential newborn care for all newborns, 
including
• early and exclusive breastfeeding [B]
• warmth provision and avoidance of bathing
during first 24 hours [C]
• infection control, including cord care and
hygiene [B]
• postpartum vitamin A provided to mother [B]
• eye antimicrobial provided to prevent
ophthalmia [A]
• information and counseling for home care and
emergency preparedness [C]
Extra care for small babies (preterm or term
IUGR) and multiple births, severe congenital 
abnormalities:
• extra attention to warmth, feeding support, and
early identification and management of
complications [B]
• kangaroo mother care [A: morbidity not
mortality data]
• vitamin K injection [B] 
Emergency care providing specific and supportive
care according to evidence-based guidelines for
the following:
• severe infections [A]
• neonatal encephalopathy (following acute
intrapartum insult)
• severe jaundice or bleeding [A*]
• neonatal tetanus
Tocolytics in preterm labor and transfer
to higher-level care if available [A]
If preterm labor, then give prenatal
steroid injection to mother [A]
Trained breastfeeding counselors
undertaking home visits [A]
Vitamin K (cost-effective as 
prophylaxis for all babies in transition
countries) [B]
Routine newborn screening programs
for sickle cell disease, glucose 
6 phosphate dehydrogenase
deficiency [B] 
Provide special or intensive care for
preterm babies [A]
Provide special care for sick and small
babies using skilled nurses and a 
higher nurse-to-patient ratio [B]
Maternity waiting home if limited
access to emergency obstetric care,
high-risk condition identified, and
culturally acceptable [B]
Hepatitis B prevalent: 
• give hepatitis B immunization
early [A] 
Mother HIV positive: 
• provide counseling and support for
feeding choices [C] 
Mother with tuberculosis:
• keep baby with mother and give
izoniazid prophylaxis 
Mother with syphilis: 
• treat the baby even if asymptomatic
[A*]
Source: Authors, based on extensive literature review. References detailed on http://www.fic.nih.gov/dcpp/.
Note: A  rigorous meta-analysis or at least one good randomized controlled trial exists, RF A  evidence regarding risk is strong, B  well-conducted clinical studies exist but no randomized controlled
trial done, C  some descriptive evidence and expert committee consensus exists, A*  unethical to test rigorously and widely practiced as standard (for example, blood transfusion, neonatal resuscita-
tion). Bold text signifies priority packages or interventions considered in detail in this chapter.
Table 27.2 Continued
Additional interventions (where
the health care system has 
additional capacity and the NMR 
Interventions for universal coverage (priority is lower; for example, transition Situational interventions (where 
Period interventions for high-mortality settings) countries) specific conditions are prevalent)
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Table 27.3 Packages for Universal Scale-up of Newborn Care 
Intervention
package
Family-
community
care of the
newborn at
home after
birth
Essential
newborn care
at the time of
birth 
Neonatal
resuscitation 
Extra care of
small new-
borns
Emergency
care of ill
newborns 
Neonatal
packages
plus MCH
package 
Contents
Healthy home care practices
(exclusive breastfeeding,
warmth protection, clean
cord care, care seeking for
emergencies); if birth out-
side a facility, then clean
delivery kit.
Immediate drying, warmth,
early breastfeeding, hygiene
maintenance, and infection
prevention 
Resuscitation after birth if
required
Extra support for warmth
(kangaroo mother care),
feeding, and illness
identification and
management 
Management of ill infants,
especially those with
neonatal infections
Neonatal packages as
above, in addition to family
planning, prenatal care, and
comprehensive obstetric
care packages
Number of
target popula-
tion per year
(millions)
All newborn
infants:
World 130 
South Asia and
Sub-Saharan
Africa 63 
All newborn
infants:
World 130 
South Asia and
Sub-Saharan
Africa 63 
Newborns not
breathing at
birth:
World 6.5
South Asia and
Sub-Saharan
Africa 3.2 
LBW neonates:
World 20.0 
South Asia and
Sub-Saharan
Africa 10.7 
Neonates with
illnesses: 
World 13.0
South Asia and
Sub-Saharan
Africa 6.3
All newborn
infants:
World 130 
South Asia and
Sub-Saharan
Africa 63 
Implementation strategy
Women’s groups and
community health workers
doing postnatal visits, with
links to the formal health care
system, including support for
referral. If appropriate, extra
care of moderately small
babies at home and
community-based manage-
ment of acute respiratory
infections.
Skilled attendant, or if no
skilled attendant available,
some simple postnatal
practices are feasible at
home with other cadres
of workers.
Skilled attendant.
Facility-based care for
severely preterm babies.
Community-based care is
effective for moderately
preterm babies.
Facility-based care with
antibiotics and supportive
care. Community-based
management with oral
antibiotics for acute
respiratory infections.
Supply of care throughout
pregnancy, childbirth, and
postnatal period with
increased demand and
improved referral systems.
Sub-
Saharan
Africa
28
14
3
10
20
5
South
Asia
36
11
3
10
20
5
Reduction
in all-
cause
NMR
(percent)
10–40
20–30
10–25
20–40
20–50
—
Comments on evidence
Mortality reduction based
on studies in high NMR
settings with weak health
systems. Extra care of LBW
infants and community
management of acute
respiratory infections not
included in range shown.
Based on conservative
combining of single
interventions (for example,
breastfeeding) in the
package.
Limited studies, mainly from
lower NMR settings with
high percentage of asphyxia
deaths, so range from
studies was reduced.
Most studies are nonran-
domized controlled trials at
the community level in
settings with extremely high
LBW rates. Effect depends
on baseline NMR and LBW
rates.
Meta-analysis of effect on
the NMR of oral antibiotic
management of acute
respiratory infections in the
community in high-mortality
settings.
No study data identified.
Marginal budgeting for
bottlenecks tool suggests
58 percent in South Asia
and 71 percent in 
Sub-Saharan Africa. 
Source: Local data or Darmstadt and others 2005; Knippenberg and others 2005; Lawn, Cousens, and Zupan 2005.
Note: The range of reduction of all-cause NMRs given for each package is independent of the others; hence, the total is greater than 100 percent.
Estimated current
coverage (percent)
infants and is ideally provided by a skilled attendant, but in the
absence of skilled care, many of the tasks can be carried out at
home by alternative cadres of workers. WHO’s essential care
package includes resuscitation, which we consider separately
because the skill level required is more complex.
Clean care of the umbilical cord (clean blade and tie) is
important in reducing the incidence of neonatal tetanus and
umbilical sepsis, but evidence for topical treatment of the cord
remains unclear (Zupan and Garner 2000). Hand washing is
important at all levels of care. Hypothermia is an important
and preventable contributor to morbidity and mortality, espe-
cially in preterm babies. The so-called warm chain involves
ensuring that childbirth takes place in a warmed room, drying
the newborn, encouraging skin-to-skin contact between the
newborn and the mother, and avoiding bathing for at least
12 hours (Lawn, McCarthy, and Ross 2001). In hospitals in
LMICs, many newborns are hypothermic, and staff knowledge
and practices could be improved (Dragovich and others 1997).
The effects of exclusive breastfeeding have been intensively
studied, and the positive effect on infant mortality is unequiv-
ocal, although studies often do not specify the effect on neona-
tal mortality and morbidity. The WHO collaborative trial
found the risk of mortality in nonbreastfed neonates to be
2.5 to 7.0 times greater than for breastfed neonates (WHO
Collaborative Group 2000). The practice of keeping well babies
close to their mothers and allowing feeding on demand
increases breastfeeding rates, reducing both hypothermia and
nosocomial infections (WHO 1998b). Unfortunately, as exem-
plified by the low proportion of hospitals that are certified as
baby friendly, this practice is poorly implemented. Supportive
policy, such as the International Code of Marketing of
Breastmilk Substitutes, is also important at the national level.
The effect of essential newborn care has not been formally
tested as a package, although exclusive breastfeeding, cleanli-
ness, infection control measures, and hypothermia avoidance
all individually reduce neonatal mortality and morbidity.
Nevertheless, only 11 percent of babies in South Asia and
14 percent in Sub-Saharan Africa are exclusively breastfed to
three months. The Bellagio group estimated a 15 percent
reduction in the NMR through 99 percent coverage of exclusive
breastfeeding and an 11 percent impact reduction through
clean delivery (Jones and others 2003). Conservatively, an es-
sential newborn care package may result in a 10 to 25 percent
reduction in the NMR, but field trials of a combined package
are still required. No economic assessments were identified.
Newborn Resuscitation 
Approximately 5 to 10 percent of newborns do not breathe
spontaneously and require stimulation. About half of those
have difficulty initiating breathing, requiring resuscitation
(WHO 1998a). The major reasons for failure to breathe include
preterm birth and acute intrapartum events resulting in hyp-
oxic brain injury. Basic resuscitation using a self-inflating bag
and air is effective for the majority of these newborns, although
some may be too premature or have already experienced severe
hypoxic brain injury and die despite resuscitation.
Monitoring labor and providing effective obstetric care can
reduce the need for resuscitation (Dujardin, Sene, and Ndiaye
1992), but resuscitation may be required even with good
obstetric care. Therefore, every skilled attendant should be
competent in newborn resuscitation (box 27.1).
For most babies who do not breathe at birth, ventilation with
a self-inflating bag and mask is lifesaving, and the time to first
breath differs little between use of a self-inflating bag and mask
and use of endotracheal intubation. Evidence is growing that
most newborns can be successfully resuscitated without the use
of oxygen (Saugstad 2001), although a small proportion of
infants require such advanced resuscitation techniques as endo-
tracheal intubation, oxygen, chest compression, or drugs. Such
advanced resuscitation is appropriate only in institutions that
provide ventilation. In the 1980s, the high cost of a self-inflating
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Institutionalizing a Neonatal Resuscitation Program in a Chinese Province
Box 27.1
A hospital-based study from China reports baseline sur-
veillance of 1,722 newborns followed by a two-year
prospective assessment of 4,751 newborns, while institut-
ing standardized resuscitation guidelines. Previous tradi-
tional resuscitation involved infusing central stimulants
plus vitamin C and 50 percent glucose; wiping the baby
with alcohol; and pressing the philtrum. Health profes-
sionals recognized that asphyxia was the leading cause of
neonatal death and the second leading cause of infant
death nationally. They also recognized that child survival
goals could not be met unless asphyxia was addressed.
They developed and implemented an evidence-based
neonatal resuscitation program, training staff in using the
new guidelines. The early NMR fell significantly—by
66 percent, to 3.4 per 1,000.
Source: Zhu and others 1997.
bag and mask led to the development of a prototype mouth-
to-mask device operated by blowing expired air. A study by
Massawe and others (1996) in two teaching hospitals, one in
Tanzania and the other in India, found that resuscitators using
this device could maintain a maximum of only 20 breaths per
minute, one-third of the recommended rate. Low-cost (less
than US$5) versions of the bag and mask are now available, and
it is the recommended device for resuscitation.
Although small-scale studies show that nonprofessional
cadres can learn the technique of resuscitation (Bang and oth-
ers 1999; Kumar 1995), a significant effect on mortality has not
been demonstrated, and the feasibility of maintaining compe-
tency and the cost-effectiveness of training such cadres have yet
to be ascertained. If traditional birth assistants attend, say,
20 deliveries a year, they would encounter a baby requiring
resuscitation an average of only once a year, so the effect would
be lower, and the cost per life saved higher, compared with a
facility-based midwife who does 200 or more deliveries a year.
Thus, more research is required before home resuscitation by
traditional birth assistants can become a widespread policy. In
the meantime, it should be ensured that where skilled atten-
dants exist, they have the skills and equipment to perform
neonatal resuscitation.
Because a randomized controlled trial would be considered
unethical, the studies identified apply a before-and-after com-
parison. No cost assessments were identified. Achieving wider
coverage of resuscitation is a challenge, especially for the
47 percent of the world’s babies born at home.
Extra Care for Small Babies 
Because 60 to 80 percent of neonatal deaths occur in LBW
babies, targeting this group for additional preventive and early
curative care is a logical approach to mortality reduction.
Addressing deaths among severely preterm infants (fewer than
32 weeks of gestation) is more complex, but most preterm
infants are moderately preterm (33.0 to 36.9 weeks). Excess
mortality from acquired infections and other complications
can largely be prevented or managed without intensive care.
A number of community-based studies have undertaken
simplified identification of small babies and provided extra care
at home, especially feeding (including the use of a dropper or
cup feeding if required), warmth promotion, and cord cleanli-
ness. The reported NMR reductions range from 25 percent
(Pratinidhi and others 1986) to 42 percent (Daga and others
1988). Datta (1985) applied a comprehensive approach, includ-
ing weighing all babies and providing extra home support to
LBW infants through feeding counseling and early recognition
of and referral for illness, alongside strengthening of local
health systems. Compared with a control area, the NMR was
reduced by more than 30 percent, with the greatest reduction
among the group of 1,500- to 2,500-gram babies. In Bang and
others’ (1999) study, 90 percent of neonatal deaths were in LBW
infants, and all LBW babies were targeted for increased home
visits. Special sleeping bags were provided for warmth, and
support was given for breastfeeding and early treatment of pos-
sible infections. The NMR fell by 87 percent in the moderately
preterm group (35 to 37 weeks) (Bang and others 1999).
So-called kangaroo mother care involves continuous skin-
to-skin contact between mother and baby to provide thermal
stability and promote exclusive breastfeeding for clinically
stable preterm infants. The published evidence relates to facili-
ty-based care with or without kangaroo mother care after
discharge. Mortality impact data for kangaroo mother care are
lacking, but a review by Conde-Agudelo, Diaz-Rossello, and
Belizan (2000) that included three randomized controlled tri-
als found that serious morbidity was reduced by about 60 per-
cent at the six-month follow-up visit. Although cost has not
been formally evaluated, it must be considerably less than for
incubator care. The lack of assessments of kangaroo mother
care at community level is a research gap.
A few studies in health facilities in LMICs have reported
increased survival of LBW infants with improved care. One
from Papua New Guinea demonstrated a 56 percent reduction
in the NMR with the introduction of standards for care and of
basic technology (Duke, Willie, and Mgone 2000). Data from
Ghana showed a 28 percent reduction in mortality for LBW
infants with support for breastfeeding, attention to warmth,
and early management of infections and jaundice using stan-
dard protocols (Lawn, McCarthy, and Ross 2001).
The reported effect for extra care of LBW babies in the com-
munity varies between 20 and 40 percent, excluding Bang and
others’ (1999) study because additional interventions were
involved. Given the high LBW prevalence in these studies, the
effect may be less in other settings with a lower LBW preva-
lence. Data from facilities that do not offer intensive care
suggest a similar or slightly larger effect. Cost-effectiveness
assessments were not identified.
Emergency Care for Ill Newborns 
For many of the world’s 4 million neonatal deaths, the immedi-
ate cause is a neonatal illness presenting as an emergency either
soon after birth (such as complications of preterm birth and
asphyxia) or later (because of neonatal tetanus or community-
acquired infections). Other important but less prevalent
conditions include jaundice and hemorrhagic disease of the
newborn. Long-term disability follows many neonatal condi-
tions, but it is poorly documented. Many serious neonatal prob-
lems present with similar signs: inability to feed, breathing dif-
ficulty, and temperature instability. All those conditions have
high fatality rates, particularly neonatal tetanus (Institute of
Medicine 2003) and neonatal encephalopathy (Ellis and others
1999), and preventive interventions may be the most realistic
option in those conditions. Early phototherapy for jaundice
reduces both mortality and chronic disability subsequent to
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kernicteris and is feasible in facilities (WHO 2003b). We focus
on the clinical neonatal management of infection, which is the
most prevalent neonatal illness and the most feasible to scale up.
A meta-analysis of community-based trials of case manage-
ment of pneumonia in Africa and Asia yields a summary
estimate for NMR reduction of 27 percent (Sazawal and
Black 2003). The antibiotic regime used was mainly oral co-
trimoxazole, although two studies included injectable peni-
cillins. Bang and others’ (1999) study in rural India reports a
62 percent reduction in the NMR with a home-based package for
neonatal sepsis that included injectable gentamicin, although
this reduction may be related to a number of simultaneously
introduced interventions in addition to the gentamicin.
The effect of emergency care on neonatal sepsis can be
assumed to be similar to the range in Sazawal and Black’s (2003)
meta-analysis: 20 to 60 percent. Published cost data were not
identified apart from the Bang and others (1999) study, which
indicated a cost of US$5.30 per neonate treated. This cost esti-
mate includes the time of community health workers and the
cost of equipment and drugs, but not associated supervision or
system costs.
MARGINAL IMPACT AND COST OF SCALING UP
UNIVERSAL NEONATAL PACKAGES
Because newborn health depends on services in the continuum
of care for mother, newborn, and child, a vertical program
would be duplicative, expensive, and inappropriate (Tinker and
others 2005). Hence costing and impact estimates will be based
on marginal additions of neonatal-specific packages to existing
maternal and child health (MCH) services (table 27.4). This
scenario reflects the reality in many South Asian and Sub-
Saharan African contexts, where MCH services exist but do not
yet include newborn interventions. We will cost packages,
because packages are more cost-effective than single interven-
tions, and the emphasis is on the packages described for uni-
versal scale-up (table 27.3). The benefits take into account only
neonatal deaths averted, whereas many of the interventions will
also reduce maternal deaths, stillbirths, and childhood morbid-
ity and disability—and therefore the benefits underestimate
gains for both the fourth and the fifth MDGs.
Costing and impact simulations are provided using the
“marginal budgeting for bottlenecks” tool, a prioritization tool
developed by the United Nations Children’s Fund (UNICEF),
the World Bank, and WHO. The inputs for the analysis pre-
sented here are as follows:
• Baseline epidemiology uses NMRs from the latest demo-
graphic and health surveys by country or state and recent
local relevant demographic data, such as crude birth rates.
• Cause-specific neonatal mortality estimates by country are
from the Child Health Epidemiology Reference Group’s
neonatal estimates by country (Lawn, Cousens, and
Wilczynska forthcoming).
• Baseline coverage estimates for the neonatal packages pre-
sented in table 27.3 are taken from local data, if available
(for example, exclusive breastfeeding prevalence), or drawn
from coverage estimates in the Lancet newborn series
(Darmstadt and others 2005; Knippenberg and others 2005;
Lawn, Cousens, and Zupan 2005).
• Impact estimates for neonatal mortality are from the litera-
ture, as presented in this chapter. The range uses the 95 per-
cent confidence interval, rounded to the nearest 5 percent
where available (table 27.3). If the data were from an 
efficacy trial or a before-and-after trial, the range in the lit-
erature was reduced to reflect the expected effectiveness,
based on expert opinion. Cause-specific mortality was used
to allow combinations of effects across packages, and the
assumptions applied were aligned with those used in the
Lancet neonatal series (Darmstadt and others 2005)—
although the packages here differ, because this chapter is
restricted to the neonatal period. The assumptions for
cause-specific impact are detailed at http://www.fic.nih.
gov/dcpp. The effect for outcomes other than neonatal ones
was based on data in the marginal budgeting for bottlenecks
tool, primarily from the Lancet Bellagio series (Jones and
others 2003) and Cochrane reviews. Effects are combined in
a residual manner; for example, deaths averted by preventive
strategies are removed from the pool before curative
approaches are applied, and hence the total effect is less than
the sum of the effects. Years of life lost were calculated using
local average life expectancy discounted at 3 percent per
year. This measure equates to the fatal outcome component
of disability-adjusted life years, as described in chapter 15.
• Specific costs of adding the intervention packages are calcu-
lated on the basis of the cadre of worker, additional person-
nel time, in-service training, supervision, performance
incentives, travel and subsistence costs for referral care,
drugs, and equipment. Demand promotion and community
mobilization are included. The costs of time, training, and
incentives are based on national salary levels, using real
country data or World Bank databases. The costs of com-
modities are based on the UNICEF supply system
(http://www.supply.unicef.dk/Catalogue/). The cost of
strengthening health systems, including improving manage-
ment and logistics, constructing new facilities, and deploy-
ing and training new cadres of workers, is included in the
comprehensive MCH package.
Table 27.4 presents the estimated NMR effects and per
capita costs, in selected Indian states and Sub-Saharan African
countries, of strengthening health systems to increase coverage
with existing MCH packages (without neonatal care after
birth). It then presents the additional specific costs of including
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Table 27.4 Estimated Marginal Effect and Cost of Adding Neonatal Packages to Existing MCH Packages for Three Scenarios in Selected Indian States and 
Sub-Saharan African Countries
Additional cost per neonatal 
NMR reduction 2004–15 YLL averted for 20 percent 
(range of lower and upper efficacy, percent) Cost per capita (US$) increase in coverage for lower
Indiaa Sub-Saharan Africab Indiaa Sub-Saharan Africab and upper efficacy ranges (US$)
Package Scenario 1 Scenario 2 Scenario 1 Scenario 2 Scenario 1 Scenario 2 Scenario 1 Scenario 2 Indiaa Sub-Saharan Africab
MCH package (no 12–12 27–27 11–11 24–24 2.00 4.80 2.40 5.10 480 506
neonatal care after birth)c
Marginal impact or cost 
of adding neonatal packages 
to the MCH package
Family-community packaged 3–8 5–15 2–6 6–14 0.30 0.60 0.23 0.37 100–257 100–270
Clinical packagese 0–9 0–22 1–9 3–22 0.04 0.10 0.11 0.23 11–265 25–360
Total impact or cost with 13–26 27–58 11–23 24–46 2.40 5.50 2.80 5.70 244–516 282–583
combined MCH and (average 380) (average 432)
neonatal-specific packages
Source: Estimates by authors, using the “marginal budgeting for bottlenecks” tool as detailed in the text. 
YLL  years of life lost. YLL includes neonatal fatal outcomes only and is based on local life expectancy discounted at 3 percent per year.
Scenario 1: increasing coverage by 20 percent.
Scenario 2: meeting fourth MDG, necessitating about 45–60 percent NMR reduction, depending on the percentage of under-five mortality that is neonatal.
Note: No specific neonatal outreach package is shown, because this is in prenatal care as part of the MCH package or home postnatal visits in the family-community package
a. Five states in India are represented: Gujarat, Madhya Pradesh, Orissa, Rajasthan, and West Bengal.
b. Five countries in Sub-Saharan Africa are represented: Benin, Ethiopia, Madagascar, Mali, and Rwanda.
c. The MCH package consists of family planning, prenatal and obstetric care, and child health services (comprehensive integrated management of infant and childhood illness including prevention and community activities) and includes system strengthening costs.
d. Includes interventions listed in table 27.3 under family-community package plus extra care of moderately small babies at home and community-based management of acute respiratory infections.
e. Includes clinical care packages listed in table 27.3 (essential newborn care, neonatal resuscitation, extra care of small newborns, and emergency care of ill newborns). 
neonatal packages at the family-community level and in clini-
cal services and, finally, the combined costs for comprehensive
MNCH. Results are shown for two coverage scenarios:
• Scenario 1: increasing coverage of the interventions by
20 percent from the baseline
• Scenario 2: increasing coverage to the level required to meet
the fourth MDG, necessitating about a 45 to 60 percent
reduction in NMR, depending on the baseline percentage of
under-five mortality that is neonatal.
Table 27.4 shows that the addition of neonatal packages will
reduce neonatal deaths at an average cost of about US$0.50 per
capita per year for up to a 15 percent reduction in NMR at the
family-community level and about US$0.20 per capita for a 22
percent NMR reduction at the clinical care level. Although the
cost per capita is low for clinical care, the cost per case treated is
higher, and the lag time to scale up is longer. The family-
community neonatal package in India is estimated to cost
US$100 to US$257 per year of life saved (table 27.4), which cor-
responds to about US$2,800 to US$7,800 per death averted.That
is similar to the results of US$3,442 per neonatal death averted
or US$111 per life year saved in a community participatory
package in Nepal (US$4,397 and US$142, respectively, with
health system strengthening) (Manandhar and others 2004).
The comprehensive MNCH package (the MCH package
plus integrated neonatal packages) is more expensive than the
neonatal packages alone: US$2.40 to US$2.80 per capita and
per year for a 20 percent increase in coverage, and US$5.50 to
US$5.70 to achieve the mortality reduction necessary to meet
the fourth MDG (including the health system strengthening
and demand-side approaches required). However, the effect of
the MNCH packages on the NMR is more than double that of
the neonatal packages alone—for example, a reduction of up
to 58 percent in NMRs in Africa, compared with up to 22 per-
cent using interventions in the neonatal period only. This find-
ing emphasizes the advantages of a comprehensive approach
across the continuum of care. Hence, the average cost per year
of life saved is still low at US$380 (India) and US$432 (Sub-
Saharan Africa) for a 20 percent increase in coverage, includ-
ing costs of system strengthening. If the coverage of the MCH
plus neonatal packages were to reach 90 percent, those pack-
ages would avert up to 71 percent of neonatal deaths in the
African countries and up to 76 percent in the Indian states.
In settings where the current coverage of skilled care is low,
opportunities exist to start with family care and extra care of
LBW babies while building toward more challenging clinical
packages. Some clinical care packages—such as simple extra
care of the small baby or the provision of oral antibiotics for
pneumonia later in the neonatal period—can be adapted for
delivery through community health systems. Varying the
cadres of worker involved or the level of health system at which
the package is delivered may reduce the cost of the package,
but it also necessitates extra supervision and attention to links
with the formal health system. Box 27.2 describes the projected
effect and cost of various packages in Ethiopia for a 12-year
program to improve maternal and child survival targeted at
achieving the fourth MDG by 2015. Outreach services such as
prenatal care alone have an effect of about 10 percent on
NMRs, but when they are combined with a family package
using community health promoters, an additional 30 percent
reduction in the NMR is projected in Ethiopia.
Outreach and family care options are more feasible initially.
Yet if commitment toward moving to strengthen the clinical
care system is lacking, the potential reduction in NMRs
over time from those options is limited, and the cost per death
averted is higher. Although the estimated cost (averaged over
12 years, with gradually increasing amounts) is low, the input is
higher than the current government and donor health expendi-
ture of the countries examined. Thus, spending in India would
have to be doubled, and in some African countries probably
tripled. Considerable new funding is required at the national
and international levels, as well as more efficient allocation and
absorption of existing funds (Martines and others 2005).
IMPLEMENTATION
Effective interventions exist and are low cost, especially when
added to existing programs, but current coverage is low, espe-
cially for the poor, who have the highest mortality risk.
Approximately 53 percent of women worldwide deliver with a
skilled attendant: fewer than 30 percent in the poorest coun-
tries and more than 98 percent in the richest countries. In 
Sub-Saharan Africa, average coverage with skilled care has
increased at only 0.2 percent per year in the past decade;
without faster progress, coverage of skilled attendance will still
be less than 50 percent in 2015. Analysis in 50 low-income
countries showed that the richest 20 percent of women were,
on average, almost five times as likely to use a skilled attendant
as the poorest 20 percent (Knippenberg and others 2005).
Hence, coverage is low, progress is slow, and inequity is high.
Each country or decision-making unit starts with a different
epidemiology and varying coverage and capacity in its health
system. No single recipe for strengthening newborn care in
health systems is available. Scaling up MNCH care will involve
systematic steps to assess local situations and opportunities,
improve care within current constraints, and overcome supply
and demand constraints—especially for the poor. No country
or program can achieve multiple new interventions at once,
and scaling up human resources takes time. Therefore, phasing
approaches is essential not only to allow faster approaches to
reach the poor soon, but also to allow consistent strengthening
of the health system (Knippenberg and others 2005).
Newborn Survival | 543
Step 1: Assess the Situation and Advocate for Action
for Newborn Health 
Careful examination of local data is required (Lawn, McCarthy,
and Ross 2001). Newborn health should be included in general
health sector and public sector planning—for instance,
for education and transportation. When governments set
mortality reduction targets for children under five, they should
consider setting simultaneous targets for reducing NMRs
(Martines and others 2005). The level of participation—
involving multiple stakeholders, including women and com-
munities—and the political will to implement and finance such
plans are also crucial to success. Reaching every pregnant
woman and every newborn with effective care involves every-
one: the family and community provide home care and advo-
cate for access to preventive and curative care; the health system
supplies care during normal pregnancy, childbirth, and postna-
tal care, along with emergency obstetric and young infant care
services if required; and the government and global policy
makers provide supportive policy and resources, in particular
to ensure that there are enough health care providers, such as
midwives. National champions can be effective in promoting
progress. Global partnerships may also play a role in facilitating
broad national plans and promoting donor convergence in
implementation (Tinker and others 2005).
The government of Nepal recently held a series of stake-
holder meetings and developed a plan for a national newborn
health strategy. Representatives from such diverse backgrounds
as neonatology, safe motherhood programs, and community
mobilization efforts met over a five-month period to create an
operational plan for newborn care through 2017 (Khadka,
Moore, and Vikery 2003).
Step 2: Achieve Optimal Newborn Care within the
Constraints of the Current Health System
Because situations vary even within countries, data-driven pri-
oritization and good leadership are crucial to using resources
well (Lawn, McCarthy, and Ross 2001). Program areas related
to newborn health include safe motherhood, child survival,
immunization, family planning, and nutrition, along with
management of sexually transmitted diseases, prevention of
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Steps to Increase Coverage of Key MNCH Interventions in Ethiopia
Box 27.2
Ethiopia is one of the poorest countries in the world, with
gross national income of US$100 (in 2000), less than
half the average for Sub-Saharan Africa. Neonatal deaths
of some 135,000 a year account for 29 percent of child
deaths. According to a 2000 demographics and health sur-
vey, coverage of care is extremely low: only 6 percent of
women deliver with a skilled attendant present and only
8 percent receive postnatal care within 48 hours of deliv-
ery. The poor and those in rural areas have even lower cov-
erage. Health professionals are in short supply. At the same
time, obstetric services may be unused even when accessi-
ble because of issues of affordability and acceptability
(most health workers are male).
In 2004, the government and major stakeholders held a
national partnership conference to develop a national plan
for scaling up child survival interventions. The govern-
ment decided on a health extension package that would
deploy two female health extension workers to each kebele
(commune of 5,000 inhabitants). Those workers are
mainly responsible for MNCH interventions, such as
immunization, micronutrient supplementation, and fam-
ily planning, but they also have other public health and
some clinical responsibilities. In addition, one primary
school graduate per 50 families will be trained to promote
healthy family behaviors.
Estimates based on the marginal budgeting for bottle-
necks tool suggest that, during the first eight years, progres-
sive scaling up of the health extension and health promoters
packages, together with some upgrading of clinical services,
will cost an additional US$4 per person per year. That effort
could result in a 30 percent reduction in the NMR, attribut-
able mostly to improved behaviors, such as clean delivery
and exclusive breastfeeding, and to increased demand for
care. Increased coverage with family planning and tetanus
toxoid vaccination through the health extension package
accounts for about 10 percent of the NMR reduction. By the
end of the 12-year period, an additional 30 percent reduc-
tion in NMR is expected from strengthening clinical servic-
es.A comprehensive package of family-based, outreach, and
clinical services is projected to reduce the NMR by nearly
50 percent, associated with a 25 percent reduction in the
maternal mortality ratio—as compared with a less than
5 percent reduction in the maternal mortality ratio with
family and outreach care alone. The incremental annual
cost of almost US$10 per person is more than three times
current public spending on health of US$2.70.
Source: Knippenberg and others 2005.
maternal-child transmission of HIV, and prevention of malaria
during pregnancy. The reality is that such interventions have
not reached most women and children and that existing serv-
ices fail to coordinate along the continuum of care. This situa-
tion results in gaps in service and missed opportunities. In
Africa, for example, the regional average for prenatal care cov-
erage is 64 percent, yet coverage of tetanus toxoid immuniza-
tion is 42 percent (Knippenberg and others 2005). Syphilis
treatment is another opportunity that frequently is missed dur-
ing prenatal care (Gloyd, Chai, and Mercer 2001). Including the
newborn in transport and funding programs that currently
address only maternal emergencies may be of little marginal
cost for significant benefit. In India, where integrated manage-
ment of infant and childhood illness (IMCI) is being scaled up,
the marginal cost of adding selected neonatal conditions to the
clinical care component of IMCI is low, estimated at less than
US$0.10 per capita (box 27.3).
In many settings in South Asia and Sub-Saharan Africa, even
where midwives are in place they do not have the skills required
for newborn care. Competency-based training in neonatal
resuscitation is a rarity and must be incorporated into preser-
vice as well as in-service training (box 27.1). India’s National
Neonatology Forum identified birth asphyxia as a leading
cause of neonatal deaths and launched the Neonatal
Resuscitation Program, developing a course with standard
guidelines and certification of competency (Deorari and others
2001). Between 1990 and 1992, more than 12,000 physicians
and nurses were trained. The effect of the program was evalu-
ated in 14 teaching hospitals in India. Changes in resuscitation
practices were noted, and asphyxia-related mortality fell signif-
icantly. The prevalence of survivors with disabilities was not
assessed.
An alternative model of skill strengthening has been tested
in South Africa, where significant improvements in knowledge
and skills have been documented as a result of the Perinatal
Education Programme, a distance-run self-taught course
(Woods and Theron 1995). More than 30,000 midwives in
South Africa have passed the examinations, and the program’s
manuals are used in many undergraduate medical and nursing
schools.
Numerous publications have detailed suboptimal hospital
management of women in labor or newborns, variously
reported as contributing to 10 to 75 percent of all perinatal
deaths (Lawn and Darmstadt forthcoming). Thus, there is
scope for improving outcomes and client satisfaction in virtu-
ally all settings. For example, in much of Sub-Saharan Africa, a
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Adding Newborns to IMCI in India
Box 27.3
An estimated 1.1 million neonatal deaths occur annually
in India—approximately 28 percent of the world’s total.
Between 1960 and 1990, India achieved a 50 percent
reduction in infant mortality, but in the 1990s, the decline
in the infant mortality rate slowed, partially because of the
increasing proportion of infant deaths during the neona-
tal period. The government looked for ways to add to
existing programs and to increase coverage of services,
especially given that most neonatal deaths occur in the
first few days of life in home settings.
Two major adaptations have been made to the standard
IMCI approach:
• Integrated management of neonatal illness was intro-
duced into the global generic guidelines for IMCI, which
do not cover illness in the first week of life.
• Focus on outreach services and family care, taking the
program into communities to achieve higher coverage, is
being promoted through a variety of strategies, namely:
— three home visits in 10 days for normal weight
babies, with a further three in the subsequent three
weeks if the infant is LBW, to provide essential new-
born care, extra care of the LBW infant, and early
identification and referral for sepsis 
— improved coordination between auxiliary nurse-
midwives and community health workers to assist
with the integration of health and nutrition services
at household levels.
The marginal cost of adding N (for neonatal) into IMCI
in relation to clinical care is estimated at less than US$0.10
per person, given the existence of traditional IMCI pro-
grams. Training the health and nutrition workers (2 per
1,000 population) and providing home visits is estimated
to cost US$0.22 per person. In 2002, the government began
to test the integrated management package in 50 districts
of United Nations Children’s Fund areas of programming.
This initiative has prompted policy makers to scale up
implementation throughout the country during the
2005–10 phase of its Reproductive and Child Health
Program.
Source: Adapted from K. Suresh, M. Babille, and V. K. Paul, personal communication,
April 2004. 
significant proportion of women deliver in facilities that collect
data that could be used to identify achievable improvements in
care (box 27.4).
Step 3: Phase the Systematic Scaling-Up of Newborn Care
Although some resource-poor countries have succeeded in
building functional systems (box 27.5), the process, especially
for clinical care, takes time. Professional care during childbirth
and childhood illnesses is the ideal, but significant costs are
involved in increasing the numbers of professionals and
retaining them, especially in rural posts. Even maintaining cur-
rent staff presents challenges, given low pay and high frustra-
tion. To markedly increase coverage requires new commitment
now to a massive expansion in the number of midwives and to
innovative approaches to retain staff, especially in hard-to-
serve areas. Supply constraints must be systematically identi-
fied and targeted—notably, human resources, accessibility to
facilities, financial barriers, and supply of commodities and
drugs (Knippenberg and others 2005). Demand-side strategies
are also important, including consideration of subsidies for
preventive care or transport for emergency care.
In the meantime, most neonatal deaths continue to occur in
underserved and poor communities that will wait the longest
for access to skilled care. Each year, 60 million women deliver
without skilled care present. There is a moral imperative to
reach those women now. Feasible strategies to reduce NMRs
exist (for example, efforts to improve family behaviors, tetanus
toxoid immunization campaigns, and community-based man-
agement of acute respiratory infections) and have been demon-
strated in poorly developed health care systems. Interim strate-
gies are available, such as linking a group of traditional birth
attendants with skilled attendants (Koblinsky, Campbell, and
Heichelheim 1999) or medical assistants to perform cesarean
sections. Policy conflicts between skilled and community
approaches are not helpful. Both approaches are required. With
phased program planning, community services can be used
now while professional care is being strengthened. The com-
munity services can then promote demand for skilled care
(Knippenberg and others 2005).
Step 4: Monitor Coverage and Measure Effect and Cost
In most high-mortality countries, NMRs are measured only
intermittently (typically every five years through demographic
and health surveys). Tracking of coverage indicators, and espe-
cially equity of coverage, is important for managing program
decision making. Information is lacking, and the information
that is available is often not used to improve care. Governments
must be encouraged to report funding, coverage, and outcomes
related to national plans for maternal, neonatal, and child sur-
vival. Donors should also be accountable for reporting funding
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South Africa and the Perinatal Problem Identification Programme: Locally Owned Data for Decision Making
Box 27.4
Care for pregnant women and newborns in South Africa
ranges from unattended childbirth in rural mud huts to
advanced obstetric and intensive neonatal care. National
perinatal mortality is estimated at 40 per 1,000 live births,
with regional and racial disparities. During the 1990s,
growing awareness of the importance and preventability
of newborn deaths resulted in the development of the
Perinatal Problem Identification Programme. Under the
program, basic data are entered into a computer program
that calculates perinatal mortality, supporting the identifi-
cation of avoidable factors to aid the prioritization of
actions to address key problems. More than 44 sites across
the country use the Perinatal Problem Identification
Programme, covering almost 80,000 births annually, or
approximately 10 percent of deliveries, with 3,045 perina-
tal deaths (2000). Avoidable factors were identified in
83 percent of deaths, with half of these being patient
related, such as a delayed response to complications. A
further 14 percent of avoidable factors were administra-
tive and, in particular, were related to transportation and
lack of staff members. About 25 percent of the avoidable
factors involving health workers pertained to intrapartum
care, especially poor monitoring (not using the parto-
graph) and inadequate response to problems identified
during labor. Half of the cesarean sections were delayed by
an hour or more.
The program identified the following national priori-
ties to reduce perinatal deaths:
• reducing intrapartum asphyxia, especially in rural
areas—for instance, using maternity waiting homes and
addressing transport delays 
• improving intrapartum management by means of proto-
cols (partograph and effective monitoring), competency-
based training, and ongoing audit
• implementing syphilis screening and treatment more
effectively.
Source: Authors, based on data from Pattinson 2002.
flows and ensuring that commitments are kept (Martines and
others 2005).
RESEARCH PRIORITIES
The overwhelming priority in newborn health research
remains how to reach underserved populations. This effort
involves demonstrating the effect, cost, and scaling up process
for packages of interventions. The processes of adapting effec-
tive packages to different settings using various cadres of health
workers and of identifying indicators of successful implemen-
tation that are replicable are all basic to scaling up yet have been
little studied.Costing of newborn health interventions is a major
gap. Virtually no published examinations of the marginal
benefits and costs of adding neonatal interventions to exist-
ing programs aimed at safe motherhood, IMCI, HIV/AIDS,
malaria, and sexually transmitted diseases are available. A
demonstration of such synergies will help influence policy
makers to incorporate neonatal issues into these and other pro-
grams. Testing innovative approaches to protect poor families
from user costs is also important.
Given that preterm birth accounts for almost 30 percent of
neonatal deaths and contributes indirectly to many more
deaths, reducing the incidence of preterm birth and decreasing
deaths among preterm infants are important areas for study.
Low-tech extra care of small babies has the potential to reduce
deaths significantly, but the effectiveness of various home and
facility packages, including the potential of emollients for pre-
venting infections, needs to be tested. A large industry is devel-
oping high-tech devices for newborn care to address the 2 per-
cent of neonatal deaths in rich countries. Yet there is little
investment in the development and testing of low-cost, simple,
robust devices in the settings where most fetal and neonatal
deaths occur.
Understanding is lacking of the effects of maternal infec-
tions, particularly of synergies between HIV, malaria, and sex-
ually transmitted diseases (Ticconi and others 2003) as well as
the potential synergy between maternal infections and appar-
ent asphyxial injury to neonates (Peebles and Wyatt 2002).
Incidence and intervention data regarding neonatal mor-
bidity and disability at the population level are entirely lacking
in LMICs. Improved tools for assessing cause-specific mortali-
ty and morbidity outcomes are required to advance answers to
many of these questions (Lawn, Cousens, and Wilczynska
forthcoming).
CONCLUSIONS
Reductions in neonatal mortality are necessary to meet the
fourth MDG. High-impact, low-cost, feasible interventions are
available. They could avert approximately 70 percent of the
world’s 4 million neonatal deaths, according to analysis pre-
sented here, an estimate similar to the estimates in the Lancet
neonatal series (Darmstadt and others 2005). Large gains in
neonatal survival are linked to other health gains, such as
reduced childhood morbidity and disability, prevention of still-
births, and improved maternal survival, thus contributing also
to the achievement of the fifth MDG.
The success of some low-income countries is encouraging,
but in South Asia and Sub-Saharan Africa, coverage is generally
low, progress is slow, and inequity is high. While countries con-
tinue to move toward a more comprehensive health care sys-
tem, simpler approaches at family-community level and
through outreach services can save many lives now, even in the
poorest settings. Well-known interventions, such as neonatal
resuscitation and case management of infections, can be added
to other programs, particularly safe motherhood and IMCI
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Reducing Newborn Deaths Is Possible in Low-Income Countries
Box 27.5
Sri Lanka achieved neonatal mortality of 11 per 1,000 live
births in 2000 despite a low gross national product per
capita of US$800 and less than US$1.50 per capita per year
of health spending on maternal and neonatal health. In
1959, maternal and neonatal mortality were high, with an
NMR of 50 per 1,000 live births, and gross national prod-
uct per capita was US$290. Maternal and infant mortality
were halved by 1980 because skilled childbirth care was
scaled up and because prenatal, childbirth, and postnatal
and newborn care services were provided close to commu-
nities and without user charges. The period 1980–2000 saw
a further 50 percent reduction in the NMR without the use
of intensive care, apart from one unit in the capital.
Malaysia also followed a policy of rapid scale-up of the
coverage of skilled care at birth. It trained large numbers
of midwives and encouraged collaboration with tradition-
al birth attendants to promote a gradual transition to
skilled care over several decades. The NMR is now 6 per
1,000 live births, and 95 percent of women deliver with a
skilled attendant.
Source: Adapted from Koblinsky 2003.
programs, at low marginal cost. However, to reach the MDGs,
skilled care is required. Scaling up coverage to ensure profes-
sional midwives reach those in underserved areas will require
major new investment to generate and retain more skilled staff
members, along with the necessary supportive infrastructure.
This investment will involve increased spending, which—as
shown here—may double current national health expenditures
per capita in Asia and triple them in many African countries.
Even if poor countries spend more and spend better, outside
funding will be required.
Current investment in MNCH by most national govern-
ments and international donors is utterly inadequate compared
with investment in conditions that have higher profiles yet
lower mortality rates. The deaths of 10,000 newborns each day
are unconscionable when most could be saved now at relatively
low cost if the political will to do so existed.
ACKNOWLEDGMENTS
The following individuals are gratefully acknowledged for
reviewing this chapter: Gary Darmstadt, Affette Mccaw-Binns,
Barbara Stoll, and Anne Tinker. We thank Saving Newborn
Lives, especially Julia Ruben, for editing assistance.
Joy E. Lawn was supported by the Bill & Melinda Gates
Foundation through a grant to Save the Children/USA for the
Saving Newborn Lives initiative.
REFERENCES 
Bang, A. T., R. A. Bang, S. B. Baitule, M. H. Reddy, and M. D. Deshmukh.
1999. “Effect of Home-Based Neonatal Care and Management of
Sepsis on Neonatal Mortality: Field Trial in Rural India.” Lancet 354
(9194): 1955–61.
Bhutta, Z., G. L. Darmstadt, B. Hasan, and R. Haws. 2005. “Community-
Based Interventions for Improving Perinatal and Neonatal Outcomes
in Developing Countries: A Review of the Evidence.” Pediatrics 115 (2):
520–603.
Blanc, A., and T. Wardlow. 2005. “Monitoring Low Birth Weight: An
Evaluation of International Estimates and an Updated Estimation
Procedure.” Bulletin of the World Health Organization 83 (3): 178–85.
Conde-Agudelo, A., J. L. Diaz-Rossello, and J. M. Belizan. 2000. “Kangaroo
Mother Care to Reduce Morbidity and Mortality in Low Birthweight
Infants.” Cochrane Database of Systematic Reviews (2) CD00277
[PMID:].
Daga, S. R., A. S. Daga, S. Patole, S. Kadam, and Y. Mukadam. 1988. “Foot
Length Measurement from Foot Print for Identifying a Newborn at
Risk.” Journal of Tropical Pediatrics 34 (1): 16–19.
Darmstadt, G. L., Z. A. Bhutta, S. N. Cousens, T. Adam, L. de Bernis, and
N. Walker. 2005. “Evidence-Based, Cost-Effective Interventions That
Matter: How Many Newborns Can We Save and at What Cost?” Lancet
365 (9463): 977–88.
Datta, N. 1985. “A Study of Health Problems of Low Birth Weight Babies
in a Rural Community and the Feasibility of Intervention Package
Likely to Improve Their Health Status.” Ph.D. dissertation,
Postgraduate Institute of Medical Education and Research,
Chandrigarh, India.
Deorari, A. K., V. K. Paul, M. Singh, and D. Vidyasagar. 2001. “Impact of
Education and Training on Neonatal Resuscitation Practices in 14
Teaching Hospitals in India.”Annals of Tropical Paediatrics 21 (1): 29–33.
Dragovich, D., G. Tamburlini, A. Alisjahbana, R. Kambarami,
J. Karagulova, O. Lincetto, and others. 1997. “Thermal Control of the
Newborn: Knowledge and Practice of Health Professionals in Seven
Countries.” Acta Paediatrica 86 (6): 645–50.
Dujardin, B., H. Sene, and F. Ndiaye. 1992. “Value of the Alert and Action
Lines on the Partogram.” Lancet 339 (8805): 1336–38.
Duke, T., L. Willie, and J. M. Mgone. 2000. “The Effect of Introduction of
Minimal Standards of Neonatal Care on In-Hospital Mortality.” Papua
New Guinea Medical Journal 43 (1–2): 127–36.
Ellis, M., N. Manandhar, P. S. Shrestha, L. Shrestha, D. S. Manandhar, and
A. M. Costello. 1999. “Outcome at One Year of Neonatal
Encephalopathy in Kathmandu, Nepal.” Developmental Medicine and
Child Neurology 41 (10): 689–95.
Gloyd, S., S. Chai, and M. A. Mercer. 2001. “Antenatal Syphilis in Sub-
Saharan Africa: Missed Opportunities for Mortality Reduction.” Health
Policy and Planning 16 (1): 29–34.
Greenwood, A. M., B. M. Greenwood, A. K. Bradley, K. Williams, F. C.
Shenton, S. Tulloch, and others. 1987. “A Prospective Survey of the
Outcome of Pregnancy in a Rural Area of The Gambia.” Bulletin of the
World Health Organization 65 (5): 635–43.
Institute of Medicine. 2003. Improving Birth Outcomes: Meeting the
Challenge of the Developing World. Washington, DC: National Institutes
of Science.
Jamison, D. T., S. Shahid-Salles, J. S. Jamison, J. Lawn, and J. Zupan. 2006.
“Incorporating Deaths Near the Time of Birth into Estimates of the
Global Burden of Disease.” In Global Burden of Disease and Risk
Factors, eds. Alan Lopez, Colin Mathers, Majid Ezzati, Dean Jamison,
and Christopher Murray. New York: Oxford University Press.
Jones, G., R. W. Steketee, R. E. Black, Z. A Bhutta, and S. S. Morris. 2003.
“How Many Child Deaths Can We Prevent this Year?” Lancet 362
(9377): 65–71.
Khadka, N., J. Moore, and C. Vikery. 2003. “Nepal’s Neonatal Health
Strategy: A Policy Framework for Program Development.” In Shaping
Policy for Maternal and Neonatal Health: A Compendium of Case
Studies, ed. S. Crump, 47–52. Washington, DC: JHPIEGO.
http://www.mnh.jhpiego.org/resources/shapepolicy.asp.
Knippenberg, R., J. E. Lawn, G. L. Darmstadt, G. Bekyorian, H. Fogstadt,
N. Waleign, and V. Paul. 2005. “Systematically Scaling Up Newborn
Care in Countries.” Neonatal Series Paper 3. Lancet 365: 1087–98.
Koblinsky, M. A., ed. 2003. Reducing Maternal Mortality: Learning from
Bolivia, China, Egypt, Honduras, Indonesia, Jamaica, and Zimbabwe.
Washington, DC: World Bank. http://www-wds.worldbank.org/
servlet/WDSContentServer/WDSP/IB/2003/06/06/000094946_030528
0402518/Rendered/PDF/multi0page.pdf.
Koblinsky, M. A., O. Campbell, and J. Heichelheim. 1999. “Organizing
Delivery Care: What Works for Safe Motherhood?” Bulletin of the
World Health Organization 77 (5): 399–406.
Kumar, R. 1995. “Birth Asphyxia in a Rural Community of North India.”
Journal of Tropical Pediatrics 41 (1): 5–7.
Lawn, J. E., S. N. Cousens, and K. Wilczynska. Forthcoming. Estimating the
Cause of Death for 4 Million Neonates in the Year 2000.
Lawn, J. E., S. N. Cousens, and J. Zupan. 2005. “Four Million Neonatal
Deaths: When? Where? Why?” Neonatal Series Paper 1. Lancet 365
(9462): 891–900.
Lawn, J. E., and G. L. Darmstadt. Forthcoming. “A Review of Strategies to
Address Birth Asphyxia Especially for the Poor.” Journal of Perinatology
(Suppl.).
Lawn, J. E., B. McCarthy, and S. R. Ross. 2001. The Healthy Newborn: A
Reference Guide for Program Managers. Atlanta: Centers for Disease
548 | Disease Control Priorities in Developing Countries | Joy E. Lawn, Jelka Zupan, Geneviève Begkoyian, and others
Control and Prevention and CARE. http://www.cdc.gov/reproductive-
health/health_newborn.htm.
Lumbiganon, P., M. Panamonta, M. Laopaiboon, S. Pothinam, and
N. Patithat. 1990.“Why Are Thai Official Perinatal and Infant Mortality
Rates So Low?” International Journal of Epidemiology 19 (4): 997–1000.
Manandhar, D. S., D. Osrin, B. P. Shrestha, N. Mesko, J. Morrison, K. M.
Tumbahangphe, and others. 2004. “Effect of a Participatory
Intervention with Women’s Groups on Birth Outcomes in Nepal:
Cluster-Randomised Controlled Trial.” Lancet 364 (9438): 970–79.
Martines, J., V. K. Paul, Z. A. Bhutta, M. Koblinsky, A. Soucat, N. Walker,
and others. 2005. “Increasing Newborn Survival: A Call to Action.”
Lancet 365 (9465): 1189–97.
Massawe, A., C. Kilewo, S. Irani, R. J. Verma, A. B. Chakrapam, T. Ribbe,
and others. 1996. “Assessment of Mouth-to-Mask Ventilation in
Resuscitation of Asphyctic Newborn Babies: A Pilot Study.” Tropical
Medicine and International Health 1 (6): 865–73.
Mathers C. D., C. J. L. Murray, and A. D. Lopez. 2006. “The Burden of
Disease and Mortality by Condition: Data, Methods and Results for the
Year 2001.” In Global Burden of Disease and Risk Factors, eds. Alan
Lopez, Colin Mathers, Majid Ezzati, Dean Jamison, and Christopher
Murray. New York: Oxford University Press.
Meegan, M. E., R. M. Conroy, S. O. Lengeny, K. Renhault, and J. Nyangole.
2001. “Effect on Neonatal Tetanus Mortality after a Culturally-Based
Health Promotion Programme.” Lancet 358 (9284): 640–41.
O’Rourke, K., L. Howard-Grabman, and G. Seoane. 1998. “Impact of
Community Organization of Women on Perinatal Outcomes in Rural
Bolivia.” Revista Panamericana de Salud Pública 3: 9–14.
Pattinson, R. C., ed. 2002. Saving Babies 2001: Second Perinatal Care Survey
of South Africa. Pretoria: MRC Unit for Maternal and Infant Health
Care Strategies.
Peebles, D. M., and J. S. Wyatt. 2002.“Synergy between Antenatal Exposure
to Infection and Intrapartum Events in Causation of Perinatal Brain
Injury at Term.” British Journal of Obstetrics and Gynaecology 109 (7):
737–39.
Peterson, S., J. Nsungwa-Sabiiti, W. Were, X. Nsabagasani, G. Magumba,
J. Nambooze, and G. Mukasa. 2004.“Coping with Paediatric Referral—
Ugandan Parents’ Experience.” Lancet 363 (9425): 1955–56.
Pojda, J., and L. M. Kelley, eds. 2000. Low Birth Weight: Report of a Meeting
in Dhaka, Bangladesh, 14–17 June 1999. Nutrition Policy Paper 18.
Geneva: United Nations Subcommittee on Nutrition.
Pratinidhi, A., U. Shah, A. Shrotri, and N. Bodhani. 1986. “Risk-Approach
Strategy in Neonatal Care.” Bulletin of the World Health Organization
64: 291–97.
Saugstad, O. D. 2001.“Resuscitation of Newborn Infants with Room Air or
Oxygen.” Seminars in Neonatology 6 (3): 233–39.
Sazawal, S., and R. E. Black. 2003.“Effect of Pneumonia Case Management
on Mortality in Neonates, Infants, and Preschool Children: A 
Meta-analysis of Community-Based Trials.” Lancet Infectious Diseases
3 (9): 547–56.
Thaddeus, S., and D. Maine. 1994. “Too Far to Walk: Maternal Mortality in
Context.” Social Science and Medicine 38 (8): 1091–110.
Ticconi, C., M. Mapfumo, M. Dorrucci, N. Naha, E. Tarira, A. Pietropolli,
and others. 2003. “Effect of Maternal HIV and Malaria Infection on
Pregnancy and Perinatal Outcome in Zimbabwe.” Journal of Acquired
Immune Deficiency Syndrome 34 (3): 289–94.
Tinker A., P. ten Hoope-Bender, S. Azfar, F. Bustreo, and R. Bell. 2005. “A
Continuum of Care to Save Newborn Lives.”Lancet 365 (9462): 822–52.
WHO (World Health Organization). 1998a. Basic Newborn Resuscitation:
Practical Guide. WHO/RHT/MSM/98.1, 1–32. Geneva: WHO.
———. 1998b. Evidence for the Ten Steps to Successful Breastfeeding.
WHO/CHD/98.9, 1–118. Geneva: WHO.
———. 2003a. Global Burden of Disease, 2000. Version c. Geneva: WHO.
———. 2003b. Pregnancy, Childbirth, Postpartum, and Newborn Care: A
Guide for Essential Practice. Geneva: WHO.
———. 2003c. Working with Individuals, Families, and Communities.
Geneva: WHO.
———. Forthcoming. Neonatal and Perinatal Mortality, Estimates for
2000. Geneva: WHO.
WHO (World Health Organization) Collaborative Group. 2000. “Effect of
Breastfeeding on Infant and Child Mortality Due to Infectious
Diseases in Less Developed Countries: A Pooled Analysis.” Lancet 355:
451–55.
Woods, D. L., and G. B. Theron. 1995. “The Impact of the Perinatal
Education Programme on Cognitive Knowledge in Midwives.” South
African Medical Journal 85 (3): 150–53.
Yasmin, S., D. Osrin, E. Paul, and A. Costello. 2001. “Neonatal Mortality of
Low-Birth-Weight Infants in Bangladesh.” Bulletin of the World Health
Organization 79 (7): 608–14.
Zhu, X. Y., H. Q. Fang, S. P. Zeng, Y. M. Li, H. L. Lin, and S. Z. Shi. 1997.
“The Impact of the Neonatal Resuscitation Program Guidelines
(NRPG) on the Neonatal Mortality in a Hospital in Zhuhai, China.”
Singapore Medical Journal 38 (11): 485–87.
Zupan, J., and P. Garner. 2000. “Topical Umbilical Cord Care at
Birth.” Cochrane Database of Systematic Reviews (3) CD001057
[DOI:10.1002/14651858].
Newborn Survival | 549

551
Undernutrition and micronutrient deficiencies contribute sub-
stantially to the global burden of disease (Ezzati and others
2002). Impoverished communities experience high rates of
undernutrition and increased exposure to infectious diseases
caused by crowding and inadequate sanitation. Women of
reproductive age and children experience devastating health
consequences as a result of limited resources, cultural influ-
ences, and biological vulnerabilities. Undernutrition and infec-
tious diseases exist in a baleful synergy: undernutrition reduces
immunological capacity to defend against diseases, and dis-
eases deplete and deprive the body of essential nutrients.
Undernutrition and infectious diseases further exacerbate
poverty through lost wages, increased health care costs, and—
most insidiously—impaired intellectual development that can
significantly reduce earning potential. Health experts have
recently recognized the long-term effects of early undernutri-
tion and inadequate infant feeding for obesity and chronic dis-
eases, including diabetes and cardiovascular diseases. This
chapter summarizes the problems of undernutrition and vita-
min A, iron, zinc, and iodine deficiencies in young children and
current programmatic efforts to prevent and treat them.
NATURE, CAUSES, AND BURDEN 
OF UNDERNUTRITION
The following section describes the magnitude, distribution,
and etiology of growth faltering and specific micronutrient
deficiencies in young children.
Growth Faltering
Because nutritional inputs are necessary for children’s growth,
undernutrition is generally characterized by comparing the
weights or heights (or lengths) of children at a specific age and
sex with the distribution of observed weights or heights in a ref-
erence population of presumed healthy children of the same
age and sex and then calculating z-scores, that is, the difference
between a child’s weight or height and the median value at that
age and sex in the reference population, divided by the standard
deviation (SD) of the reference population. A child whose
height-for-age is less than 2 SD is considered stunted, because
the chances of the child’s height being normal are less than
3 percent. A child whose weight-for-age is less than 2 SD is
considered underweight, and one whose weight-for-height
is less than 2 SD is deemed wasted. Stunting results from
chronic undernutrition, which retards linear growth, whereas
wasting results from inadequate nutrition over a shorter peri-
od, and underweight encompasses both stunting and wasting.
Typically, growth faltering begins at about six months of age, as
children transition to foods that are often inadequate in quan-
tity and quality, and increased exposure to the environment
increases their likelihood of illness.
Although knowledge about the prevalence of stunting and
wasting is preferred, information about underweight is more
available globally. The high correlation between stunting and
underweight and the low prevalence of wasting mean that the
prevalence of underweight directly describes the magnitude of
the problem of growth faltering and stunting in young chil-
dren. About 130 million children under the age of five are
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Table 28.2 Estimated Deaths of Children Ages Birth through Four Attributable to Selected Nutritional Deficiencies by Region
(thousands)
Weight-for-age Vitamin A Iron deficiency Zinc
Region less than 1 SDa deficiency anemiab deficiency
East Asia and the Pacific 125 11 18 15
Eastern Europe and Central Asia 14 0 3 4
Latin America and the Caribbean 22 6 10 15
Middle East and North Africa 305 70 10 94
South Asia 870 157 66 252
Sub-Saharan Africa 1,334 383 21 400
High-income countries 0 0 6 0
Sources: Underweight: Fishman and others 2004; vitamin A: Rice, West, and Black 2004; iron: Stoltzfus, Mullany, and Black 2004; zinc: Caulfield and Black 2004.
a. In high-income countries, the percentage of children at each weight-for-age criterion are those expected in a healthy population. 
b. Considers only deaths directly attributable to iron deficiency anemia in children. Does not include perinatal deaths attributable to maternal iron deficiency anemia.
Table 28.1 Estimated Prevalence of Selected Nutritional Deficiencies in Children Ages Birth through Four, by Region
(percent)
Weight-for-age Iron 
Weight-for-age 2 SD through Vitamin A deficiency Zinc
Region less than 2 SD less than 1 SD deficiency anemia deficiency
East Asia and the Pacific 18 29 11 40 7
Eastern Europe and Central Asia 6 21 1 22 10
Latin America and the Caribbean 6 23 15 46 33
Middle East and North Africa 21 35 18 63 46
South Asia 46 44 40 76 79
Sub-Saharan Africa 32 38 32 60 50
High-income countries 2 14 0 7 5
Sources: Underweight: Fishman and others 2004; vitamin A: Rice, West, and Black 2004; iron: Stoltzfus, Mullany, and Black 2004; zinc: Caulfield and Black 2004.
the greatest total burden of disease (Fishman and others 2004).
Children whose weight-for-age is less than 1 SD are also at
increased risk of death, and undernutrition is responsible for 44
to 60 percent of the mortality caused by measles, malaria, pneu-
monia, and diarrhea. Overall, eliminating malnutrition would
prevent 53 percent of deaths in young children, with most of
those deaths occurring in South Asia and Sub-Saharan Africa
(table 28.2).
Morbidity attributable to undernutrition depends on the
nature of the illness. Susceptibility to a highly infectious disease
such as measles is unlikely to be affected by nutritional status:
all individuals are equally likely to become infected if they are
unvaccinated and naive. However, 5 to 16 percent of pneumo-
nia, diarrhea, and malaria morbidity is attributable to moder-
ate to severe underweight (Fishman and others 2004). As
table 28.3 shows, the number of disability-adjusted life years
(DALYs) attributable to undernutrition is high and, as with
mortality, is concentrated in South Asia and Sub-Saharan
Africa. The tremendous costs associated with the care and
treatment of childhood diseases that could be partially
underweight, with the highest prevalences in South Asia and
Sub-Saharan Africa (table 28.1). The prevalence of stunting,
underweight, and wasting is decreasing in most areas of the
world; however, in most of Africa, stunting is increasing.
Childhood malnutrition diminishes adult intellectual
ability and work capacity, causing economic hardships for
individuals and their families. Malnourished women tend to
deliver premature or small babies who are more likely to die or
suffer from suboptimal growth and development (Allen and
Gillespie 2001). Poor early nutrition leads to poor school readi-
ness and performance, resulting in fewer years of schooling,
reduced productivity, and earlier childbearing. Thus, poverty,
undernutrition, and ill-health are passed on from generation to
generation. Undernutrition impedes economic progress in all
developing countries.
Undernutrition raises the likelihood that a child will become
sick and will then die from the disease. Morbidity and mortality
are highest among those most severely malnourished; however,
given the high prevalence of mild to moderate underweight,
the mildly or moderately underweight individuals experience
prevented through improvements in child nutrition have not
been quantified.
Evidence is accumulating that early malnutrition increases
the risk of numerous chronic diseases later (Caballero 2001;
Gluckman and Hanson 2004). Associations of early undernu-
trition with diabetes, hypertension, renal disease, and cardio-
vascular disease mean that child undernutrition also leads to
high adult health care costs.
Vitamin A Deficiency
Vitamin A deficiency (VAD) is a common cause of preventable
blindness and a risk factor for increased severity of infectious
disease and mortality (Rice, West, and Black 2004). One of the
first symptoms of marginal VAD is night blindness. If VAD wors-
ens, additional symptoms of xerophthalmia arise, eventually
resulting in blindness. A child who becomes blind from VAD has
only a 50 percent chance of surviving the year. Even if children
survive, blindness severely diminishes their economic potential.
VAD may cause anemia in some regions, but it does not appear
to impair children’s growth (Ramakrishnan and others 2004).
Increased mortality is associated with VAD, most likely
because of the detrimental effects on the immune system,
which result in increased severity of illness (Sommer and West
1996). According to Rice, West, and Black (2004), VAD is
responsible for almost 630,000 deaths each year from infectious
disease (table 28.2), accounting for 20 to 24 percent of the mor-
tality from measles, diarrhea, and malaria (Rice, West, and
Black 2004). Attributable fractions are highest where VAD is
prevalent and mortality is high. Linking morbidity with VAD is
far more difficult. Vitamin A supplementation decreases the
severity of diarrhea and complications from measles, but in
some trials, supplementation has been associated with
increased lower respiratory infections.
VAD results from inadequate intakes of vitamin A because
of low intakes of animal foods; inadequate intakes of nonani-
mal sources of carotenoids that are converted to vitamin A; and
inadequate intakes of fat, which facilitates the absorption of
carotenoids. Dietary sources of preformed vitamin A include
liver, milk, and egg yolks. Dark green leafy vegetables such as
spinach, as well as yellow and orange noncitrus fruits (man-
goes, apricots, papayas) and vegetables (pumpkins, squash,
carrots), are common sources of carotenoids (vitamin A pre-
cursors), which are generally less bioavailable than preformed
vitamin A but tend to be more affordable.
Table 28.1 shows recent estimates of the prevalence of VAD
in young children (Rice, West, and Black 2004). Of those
affected, 250,000 to 500,000 each year will lose their sight as a
result. The overall prevalence of VAD is decreasing markedly
because of increased awareness of VAD as a public health
problem and increased measles immunization and vitamin A
supplementation or fortification programs. However, the
prevalence of VAD is increasing or is unknown in some regions
because of political instability, high rates of infectious disease,
and increasing poverty.
Iron Deficiency
More than 2 billion people, mostly women and young children,
are thought to be iron deficient (Stoltzfus and Dreyfuss 1998).
Iron is found in all plant foods but is more plentiful and
bioavailable in meat. Deficiency results from insufficient
absorption of iron or excess loss. Absorption is tightly regulated
in the intestines, depending on the iron status of the individual,
the type of iron, and other nutritional factors. Once iron is
absorbed, it is well conserved. Iron is depleted primarily
through blood loss, including from parasitic infections such as
schistosomiasis and hookworm.
Mainly found in hemoglobin, iron is essential for the bind-
ing and transport of oxygen, as well as for the regulation of cell
growth and differentiation (Beard 2001). Iron deficiency is the
primary cause of anemia, although vitamin A deficiency, folate
deficiency, malaria, and HIV also result in anemia. Iron defi-
ciency anemia is most prevalent in South Asia and Sub-Saharan
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Table 28.3 Estimated DALYs Lost by Children Ages Birth through Four Attributable to Selected Nutritional Deficiencies by Region
(thousands)
Weight-for-age Vitamin A Iron deficiency Zinc Iodine
Region less than 1 SD deficiency anemiaa deficiency deficiency
East Asia and the Pacific 5,777 994 241 1,004 66
Eastern Europe and Central Asia 489 1 66 149 409
Latin America and the Caribbean 725 218 109 587 83
Middle East and North Africa 10,308 2,403 109 3,290 381
South Asia 27,879 4,761 704 8,510 366
Sub-Saharan Africa 45,131 13,552 596 14,094 748
High-income countries 0 0 40 2 2
Sources: Underweight: Fishman and others 2004; vitamin A: Rice, West, and Black 2004; iron: Stoltzfus, Mullany, and Black 2004; zinc: Caulfield and Black 2004. 
a. Only considers DALYs directly attributable to iron deficiency anemia. Not included are DALYs due to perinatal deaths attributable to maternal iron deficiency anemia.
Africa, but it is not limited to developing countries (table 28.1).
Iron deficiency results in neurological impairment, which may
not be fully reversible (Grantham-McGregor and Ani 1999).
Finally, iron deficiency is known to decrease immune function,
but some investigators have also hypothesized that deficiency
protects against infectious disease or that iron supplementation
increases infectious disease (Caulfield, Richard, and Black
2004). Iron deficiency and anemia do not appear to contribute
to growth faltering (Ramakrishnan and others 2004).
Stoltzfus, Mullany, and Black (2004) find that iron deficiency
anemia was an underlying factor in 841,000 deaths per year
resulting from maternal and perinatal causes, and it directly
causes the deaths of 134,000 young children annually
(table 28.2). Worldwide, iron deficiency is a substantial contrib-
utor to DALY losses (table 28.3).
Iodine Deficiency
Iodine is necessary for the thyroid hormones that regulate
growth, development, and metabolism and is essential to pre-
vent goiter and cretinism. Inadequate intake can result in
impaired intellectual development and physical growth. A
range of impairments resulting from iodine deficiency are
referred to as iodine deficiency disorders (IDD) (Hetzel 1983)
and can include fetal loss, stillbirth, congenital anomalies, and
hearing impairment. The vast majority of deficient individuals
experience mild mental retardation. This decrease in mental
ability and work capacity may have significant economic con-
sequences. Iodine deficiency has not, however, been associated
with the incidence or severity of infectious disease, and studies
implicating deficiency as an underlying cause of mortality are
limited. Because of this, few child deaths can be attributed to
iodine deficiency, but the directly attributable DALY losses
remain considerable (table 28.3).
The prevalence of iodine deficiency is often estimated from
the prevalence of palpable goiter, but this method is not
sensitive to milder expressions of deficiency. Iodine deficiency
is thought to be a public health problem in a community if goi-
ter is detected in more than 5 percent of the school-age popu-
lation. A prevalence greater than 30 percent means that the
deficiency is severe. According to World Health Organization
(WHO) estimates, goiter rates among school-age children
exceed 5 percent in 130 countries, putting 2,225,000 people at
risk of IDD. A high prevalence of IDD occurs in Eastern Europe
and Central Asia, the Eastern Mediterranean and North Africa,
South Asia, and Sub-Saharan Africa (WHO 1999). Iodized salt
programs are decreasing iodine deficiency in many regions;
however, this reduction is offset by apparent increases in other
regions, where public health officials are now aware of the
problem because of increased surveillance.
Switzerland and the United States embarked on iodine forti-
fication programs in earnest in the early 1920s. Success resulted
in enthusiastic political and financial support for increased
global coverage, and control of IDD through salt iodation rep-
resents a great achievement in international public health.
Nevertheless, significant numbers of people remain at risk.
Zinc Deficiency
Zinc is ubiquitous within the body and is vital to protein syn-
thesis, cellular growth, and cellular differentiation. Studies in
children have demonstrated important roles for zinc in relation
to immune function, growth, and development (Brown and
others 2002; Shankar and Prasad 1998).
Zinc deficiency results from inadequate intakes and, to
some extent, increased losses. Only animal flesh, particularly
oysters and shellfish, is a good source of zinc, and fiber and
phytates inhibit absorption. Thus, as with iron deficiency,
populations consuming a primarily plant-based diet are sus-
ceptible. Deficiency can also result from losses during diar-
rheal illness.
Consensus is currently lacking on how to measure zinc
deficiency in individuals. The International Zinc Nutrition
Consultative Group recommended using serum or plasma zinc
concentrations to identify the risk of deficiency at the popula-
tion level. In addition, the group used information on
absorbable zinc in the food supplies of 176 countries to esti-
mate the proportion of each national population at risk of
inadequate intake (table 28.1). This information was used to
calculate the burden of disease (table 28.2) associated with zinc
deficiency in young children. Prevalence is not expected to
decrease unless the implementation of zinc-related interven-
tions increases substantially (Caulfield and Black 2004).
The health consequences of severe zinc deficiency have been
elucidated over the past 40 years, whereas the health risks of
mild to moderate deficiency have been described only recently.
Clinical presentations of severe deficiency include growth
retardation, impaired immune function, skin disorders, hypo-
gonadism, anorexia, and cognitive dysfunction. Mild to mod-
erate deficiency increases susceptibility to infection, and the
benefits of zinc supplementation on the immune system
are well documented (Shankar and Prasad 1998). Zinc can pre-
vent and palliate diarrhea and pneumonia (Zinc Investigators’
Collaborative Group and others 1999, 2000) and also may
reduce malaria morbidity in young children (Caulfield,
Richard, and Black 2004). Improvements in growth have been
demonstrated (Brown and others 2002), which may operate
directly or indirectly through increased immune function and
decreased infectious disease.
Zinc deficiency is estimated to be responsible for about
800,000 deaths annually from diarrhea, pneumonia, and
malaria in children under five (table 28.2). Sub-Saharan Africa,
the Eastern Mediterranean, and South Asia bear the heaviest
attributable burden of pneumonia and diarrhea, with Sub-
Saharan Africa accounting for nearly the entire attributable
malaria burden.
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INTERVENTIONS
Clearly, growth faltering and micronutrient deficiency disor-
ders are prevalent, have deleterious consequences for children’s
health and development, and are primary contributors to the
global burden of disease. Economic development is not the
only path to solving childhood undernutrition. Improvements
in family income may not translate into increased food intakes
because the income elasticity for caloric intake is relatively low.
The effects on micronutrient deficiencies might be greater if
the food sources of those nutrients (meat, seafood, eggs, forti-
fied food products) were more sensitive to income increases
and if children had access to those foods. Price subsidies may
reduce undernutrition in young children if targeted to foods
consumed by them; the potential contribution of price subsi-
dies to family nutrition is discussed elsewhere (see chapter 11).
This chapter focuses on specific public health measures that are
intended to address the problems directly. Progress has been
made in some areas, but the current magnitude of the prob-
lems and of the associated disease burden underscore the need
for more investment in nutritional interventions.
Growth Faltering and Childhood Stunting
Infants and young children falter in their growth because of
inadequate dietary intakes and recurrent infectious diseases,
which reduce appetite, increase metabolic requirements, and
increase nutrient loss. Even though this problem is understood,
progress to reduce malnutrition has been slow. Over time,
thinking on how to reduce growth faltering and childhood
stunting has shifted. Whereas previous efforts focused almost
exclusively on identifying and rehabilitating severely malnour-
ished children, current efforts emphasize prevention through
combined nutritional and disease prevention and treatment
interventions.
Initially, these efforts to prevent undernutrition focused on
diseases rather than on improved child feeding practices as
such. However, according to Becker, Black, and Brown (1991),
despite the devastating effects of illness on nutritional status,
improving dietary intakes is more effective than disease
prevention efforts in reducing undernutrition. Because of dra-
matic reductions in appetite during illness, efforts to improve
dietary intakes initially focused on maintaining energy intakes
despite anorexia and on increasing intakes during recupera-
tion, when appetite may be normal or high. More recent
interventions aim at feeding healthy children optimal diets,
which includes paying attention to dietary quality. Finally,
some have argued that, for nutritional advice to be effective, it
needs to be provided alongside growth monitoring and pro-
motion; however, it is increasingly recognized that messages
for prevention are largely universal and that integrated growth
monitoring and promotion are not the only model for service
delivery.
Promotion of Optimal Feeding of Infants and Young
Children. Much of the early focus on optimal feeding was on
breastfeeding, which should be immediate and exclusive until
six months of age. At that time nutritious and safe foods should
be added to a diet that is still based on breast milk until early in
the second year of life. A consensus has been reached that six
months is the recommended duration of exclusive breastfeed-
ing (WHO 2002) and that the total duration is a decision left to
the mother.
Multiple approaches exist to promote the initiation of
breastfeeding and to prolong exclusive breastfeeding—health
education; professional support; lay support; health sector
changes (for example, infant friendly hospitals); and media
campaigns—through health facilities and community pro-
grams. A recent Cochrane review estimates the potential effec-
tiveness of these approaches (Sikorski and others 2002).
Women who received any form of support for breastfeeding
were 22 percent less likely to stop exclusive breastfeeding, and
women who received lay support, in particular, were 34 percent
less likely to stop exclusive breastfeeding. Substantial evidence
indicates that interventions can be effective in prolonging
breastfeeding and exclusive breastfeeding and that operational
research is needed for program implementation and sustain-
ability. If such programs were fully successful, they would
reduce deaths in children under five by 13 percent (Jones and
others 2003).
Complementary feeding is the process of introducing other
foods and liquids into the child’s diet when breast milk alone
is no longer sufficient to meet nutritional requirements.
According to Brown, Dewey, and Allen (1998), complementary
feeding practices are suboptimal from several perspectives:
• Complementary foods are introduced too early or too late.
• Foods are served too infrequently or in insufficient amounts,
or their consistency or energy density is inappropriate.
• The micronutrient content of foods is inadequate to meet
the child’s needs, or other factors in the diet impair the
absorption of foods.
• Microbial contamination may occur.
In addition, because children often do not eat all the food
offered to them, interaction between the caregiver and the
child, along with other psychosocial aspects of care during
feeding, requires attention. The amount of complementary
food a child needs depends on breast milk intake. Guidelines
are available for determining energy and nutrient intakes from
complementary foods, given breast milk intakes (Dewey and
Brown 2003).
Several reviews of the multiple approaches to improving
infant and young child feeding practices are available (Allen
and Gillespie 2001; Caulfield, Huffman, and Piwoz 1999;
Dewey 2002; Hill, Kirkwood, and Edmond 2004; Swindale and
others 2004). Caulfield, Huffman, and Piwoz (1999) review
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16 programs in 14 countries to improve dietary intakes of
infants 6 to 12 months of age. The programs were designed to
promote exclusive breastfeeding and appropriate feeding dur-
ing illness up to age three, and the content and approaches
reflected current thinking regarding nutrition and behavior
change. The approaches employed included using the mass
media to reach both caregivers and the population as a whole
to change cultural norms about complementary feeding and
using one-on-one or small group interactions with community
health workers to provide individualized information and
support.
Most of the projects achieved good coverage (50 to 70 per-
cent), with rates varying depending on the communication
strategy. They resulted in large shifts in maternal knowledge
and attitudes and changes in infant feeding practices. In the few
programs assessing dietary intakes, intakes improved by 70 to
165 kilocalories per day. Differences in nutritional status at
12 months indicated weight-for-age and height-for-age gains
of 0.24 to 0.87 SD. Even with a 50 percent overestimation of the
effects, the effect of such programs could translate into tangible
reductions in malnutrition and attributable mortality. In addi-
tion, these calculations do not consider the cumulative reduc-
tion in malnutrition from programs that benefit children’s
growth into the second and third years of life. Jones and others
(2003) use the results of the analysis, along with knowledge of
the relationship between underweight and child mortality, to
estimate that programs to promote complementary feeding
could reduce by 6 percent the deaths of children under five in
developing countries.
Many programs provide supplemental food to participants
either to provide them an incentive for participating in other
activities (to offset time costs and increase consumer demand
for preventive services) or to rehabilitate severely malnourished
children. Although the latter approach is traditionally consid-
ered for supplemental food programs, the former approach is
more common. Indeed, India’s Integrated Child Development
Services Program, the world’s largest supplemental food pro-
gram, plans to shift from rehabilitation to the use of supple-
mental food as a “magnet” for providing other integrated child
development services (Kapil 2002). No consensus exists on
when or how to include supplemental food to reduce under-
nutrition, and inefficient targeting is frequently a key con-
straint to effectiveness. Swindale and others’ (2004) review of
the effectiveness of food-assisted child survival programs con-
cludes that such programs are reducing malnutrition by 2.0 to
2.5 percent per year.
Despite evidence of the effectiveness of nutritional interven-
tions in improving feeding practices and preventing undernu-
trition, few programs take a comprehensive approach toward
optimizing infant feeding, perhaps because of a lack of consen-
sus on the key components of a comprehensive strategy. In
2002, participants at a WHO consultation developed 10 guiding
principles for optimal feeding of the breastfed child (PAHO and
WHO 2003). These principles, outlined in box 28.1, build on
lessons from previous programmatic efforts such as those
reviewed here and provide a basis for designing comprehensive
programs to reduce malnutrition. The international public
health community faces the challenge of implementing and
evaluating these approaches.
Disease Control and Prevention. Interventions to prevent or
decrease malnutrition or infectious disease are expected to
decrease child mortality, and interventions that accomplish
both will have the greatest effect (Pelletier, Frongillo, and
Habicht 1993). This subsection considers the potential for dis-
ease control and prevention efforts to reduce undernutrition in
young children.
Malaria is responsible for a large portion of childhood mor-
tality in Sub-Saharan Africa. The effect of undernutrition on
susceptibility to malaria has been discussed at length elsewhere
(Caulfield, Richard, and Black 2004), but the nutritional defi-
ciencies resulting from malaria have been insufficiently
explored. Insecticide-treated bednets have been shown to pre-
vent clinical episodes of malaria and decrease the prevalence of
anemia in children (Lengeler 2003). Improvements in growth
have also been documented.
Water, sanitation, and hygiene interventions decrease child-
hood malnutrition primarily by preventing diarrheal disease
(Checkley and others 2004). Hand-washing interventions can
reduce the risk of diarrheal diseases by about 45 percent. Hand-
washing interventions can be included in water and sanitation
programs or can exist as a single intervention, and they are
both effective and cost-effective (Borghi and others 2002).
Vitamin A Deficiency
Even though the consequences of VAD had been defined by
1920, it was 1986 when vitamin A interventions were rigorously
studied in a large, controlled community trial (Sommer and
West 1996). A number of other community trials soon also
demonstrated a significant decrease in child mortality with
vitamin A supplementation (Beaton and others 1993).
Supplementation can alleviate acute VAD quickly, whereas
long-term strategies incorporate fortification and dietary
diversification.
Supplementation can be either a curative or a preventive
measure. If an individual presents with ocular symptoms of
VAD, supplementation is part of the usual standard of care.
Beyond the use of supplementation for symptoms that result
directly from deficiency, its use as part of the treatment regi-
men for measles or severe malnutrition can improve health
outcomes. In deficient areas, high-dose oral supplementation is
recommended every four to six months for children under five
and is highly efficacious in reducing ocular effects as well as
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mortality (Sommer and West 1996). A meta-analysis of con-
trolled trials in children demonstrated a 23 percent reduction
in mortality (Beaton and others 1993). High-dose vitamin A
supplements are considered safe for infants younger than
six months. Several studies suggest that giving vitamin A within
48 hours of birth reduces mortality in the first three months by
21 to 74 percent (D. Ross 2002).
A variety of foodstuffs have been fortified with vitamin A,
including oil, monosodium glutamate, butter, wheat flour,
sugar, and rice. Fortified white sugar has been successful in
reducing VAD prevalence in Central America. In El Salvador
and Guatemala, where fortified sugar is the primary source of
vitamin A, it accounts for approximately 30 percent of the rec-
ommended dietary intake (RDI). Fortification of monosodium
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Guiding Principles for Complementary Feeding of the Breastfed Child 
Box 28.1
1. Practice exclusive breastfeeding from birth to six
months of age and introduce complementary foods at
six months of age (180 days) while continuing to
breastfeed.
2. Continue frequent, on-demand breastfeeding until
two years of age or beyond.
3. Practice responsive feeding, applying the principles of
psychosocial care. Specifically, do the following:
• Feed infants directly and assist older children when
they feed themselves, being sensitive to their hunger
and satiety cues.
• Feed slowly and patiently; encourage children to
eat, but do not force them.
• Experiment with different food combinations,
tastes, textures, and methods of encouragement if
children refuse many foods.
• Minimize distractions during meals if the child
loses interest easily.
• Remember that feeding times are periods of learn-
ing and love, and talk to children during feeding,
including making eye contact.
4. Practice good hygiene and proper food handling:
• Wash hands before food preparation and eating
(both caregivers and children).
• Store foods safely and serve foods immediately after
preparation.
• Use clean utensils to prepare and serve food.
• Use clean cups and bowls when feeding children.
• Avoid the use of feeding bottles, which are difficult
to keep clean.
5. Start at six months of age with small amounts of food
and increase the quantity as the child gets older, while
maintaining frequent breastfeeding.According to aver-
age breast milk intakes in developing countries, infants’
needs from complementary foods are approximately
200 kilocalories per day at 6 to 8 months, 300 kilocalo-
ries per day at 9 to 11 months, and 550 kilocalories per
day at 12 to 23 months.
6. Increase food consistency and variety gradually as the
infant gets older, adapting to the infant’s requirements
and abilities. Infants can eat pureed, mashed, and
semisolid foods beginning at six months. By eight
months most infants can also eat finger foods—that is,
snacks that they can eat unaided. By 12 months, most
children can eat the same types of foods that the rest of
the family consumes, keeping in mind the need for
nutrient-dense foods. Avoid foods that cause choking.
7. Increase the frequency with which the child is fed
complementary foods as he or she gets older. The
appropriate number of feedings depends on the
energy density of local foods and the usual amounts
consumed at each feeding. For the average healthy,
breastfed infant, meals should be provided two or
three times a day at 6 to 8 months of age and three or
four times a day at 9 to 23 months of age, with addi-
tional snacks.
8. Feed a variety of foods to ensure that nutrient needs
are met. The child should eat meat, poultry, fish, or
eggs daily, or as often as possible. Vegetarian diets
cannot meet nutrient needs at this age unless nutrient
supplements or fortified products are used.
9. Use fortified complementary foods or vitamin and
mineral supplements for the infant, as needed. In some
populations, breastfeeding mothers may also need
vitamin and mineral supplements or fortified prod-
ucts for their own health and to ensure normal con-
centrations of certain nutrients in their breast milk.
10. Increase fluid intake during illness, including more
frequent breastfeeding, and encourage the child to eat
soft, varied, appetizing, favorite foods. After illness,
give food more often than usual, and encourage the
child to eat more.
Source: PAHO and WHO 2003. 
glutamate with vitamin A has been demonstrated to be biolog-
ically efficacious. Even though program implementation was
flawed by unacceptable cost, discoloration of the monosodium
glutamate, and packaging problems, indicators of VAD
declined significantly during periods of fortification in both
Indonesia and the Philippines (Dary and Mora 2002).
Vitamin A intakes can also be improved through dietary
diversification, either by educating communities about impor-
tant sources of vitamin A and beta-carotene that are available
in the local diet or by increasing economic prosperity so that
individuals have additional funds to spend on a wider variety
of food. Education alone has not been demonstrated to affect
the degree of VAD in a community, but it can be a powerful
tool when incorporated in a broader strategy that also includes
supplementation and fortification (Sommer and West 1996).
Iron Deficiency
Despite the public health community’s enduring interest in
preventing and treating iron deficiency anemia, little evidence
suggests that the problem has been reduced. Indeed, in some
regions the opposite may be true. From the 1970s to the 1980s,
the iron density of people’s diets decreased in every region
except the Near East and North Africa as iron-poor cereals dis-
placed legumes. During much of this period, iron deficiency
anemia increased in South Asia and Sub-Saharan Africa, where
the problem is most severe (Stoltzfus, Mullany, and Black
2004). Goals for reducing iron deficiency anemia were articu-
lated for the 1990s at the 1990 World Summit for Children, and
many countries adopted policies for providing supplementa-
tion for young children; however, few large programs have been
developed to eliminate the problem.
The explanations for this failure to act include doubts
among both scientific program planners and policy makers
about the causes and consequences of iron deficiency and
anemia; lack of political commitment; inadequate program
planning, including mobilization and training of health staff
members; insufficient community involvement; and, in partic-
ular, inherent difficulties with prolonged adherence to daily
supplementation (Stoltzfus, Mullany, and Black 2004). Despite
this bleak picture, guidelines for supplementation have been
formulated for children ages 6 to 24 months and for low birth-
weight infants beginning at 2 months (Stoltzfus and Dreyfuss
1998). Also, various scientific documents synthesize and com-
municate current knowledge about the consequences of iron
deficiency anemia and programming efforts.
Ample evidence indicates that iron deficiency is the principal
cause of anemia in children; that iron supplements are effica-
cious in preventing and treating iron deficiency anemia, increas-
ing hemoglobin concentrations by about 1 gram per deciliter on
average in controlled trials; and that supplements reduce severe
anemia even in malarious areas. The contribution of parasitic
infections such as malaria and hookworm to anemia does not
negate the usefulness of iron supplements; rather it underscores
the need for multiple inputs to prevent severe anemia, given the
risks of transfusion. Although current recommendations indi-
cate daily supplements, less frequent delivery, such as intermit-
tently or weekly, is commanding interest. Beaton and McCabe’s
(1999) meta-analysis concludes that both daily and weekly sup-
plementation are efficacious if adherence is good.
In many countries, iron fortification of foods is the principal
strategy for reducing iron deficiency and anemia. Fortified
foodstuffs include wheat and maize flours, noodles, sugar,
condiments, and complementary foods and milk for infants and
children. Efficacy studies indicate the potential of fortification
to increase iron intakes and reduce anemia, and effectiveness
trials in Chile (dry milk for infants), Ghana (complementary
food for young children), Guatemala (sugar), India (salt),
Mexico (fortified weaning food and dry milk), and República
Bolivariana de Venezuela (maize and wheat) have found
improvements in hemoglobin concentration or reductions in
anemia prevalence (Allen and Gillespie 2001; Rivera and others
2004). Nevertheless, few national iron fortification programs
have evaluation results that are without controversy. Yip and
Ramakrishnan (2002) argue that the strongest examples of the
potential for fortification are found in the Chilean program of
fortified dry milk for infants and in the U.S. program of iron-
fortified infant cereals. A randomized trial in Mexico of a
poverty alleviation program that distributes a complementary
food fortified with multiple micronutrients, including iron,
found positive effects on anemia rates (Rivera and others 2004).
Evaluations of newly implemented iron fortification programs
should gauge their contribution to anemia prevention.
Newer strategies, such as sprinkles (powders), spreads, or
foodlets (a hybrid of a food and a tablet), appear promising,
particularly for regions where the infrastructure will not sup-
port more traditional forms of fortification (Zlotkin and others
2003). Processed complementary foods and beverages offer
additional vehicles for reducing iron and other micronutrient
deficiencies and promoting well-being (Solon and others
2003). Implementing such strategies and documenting their
cost-effectiveness are important activities for the next few years.
In many settings, promoting iron-rich organ meats and ani-
mal products and undertaking other food-based strategies may
increase iron intakes and contribute to anemia reduction. Such
approaches have been promoted for many years, but research is
still needed to document their efficacy and effectiveness (Ruel
and Levin 2000).
Iodine Deficiency Disorders
Interventions to diminish iodine deficiency using either
supplementation or fortification are both efficacious and inex-
pensive, and WHO, the United Nations Children’s Fund, and
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the International Council for the Control of Iodine Deficiency
Disorders have pledged to eliminate iodine deficiency and the
spectrum of IDD.
For regions with severe endemic iodine deficiency, high-
dose iodine supplementation is indicated while longer-term
solutions are put into place. Iodized oil and iodide tablets are
the most common means of direct administration. Injections
of iodized oil have been used with much success to decrease
the prevalence of IDD and have been shown to be effective for
three to four years, depending on the dosage (Hetzel 1989).
Although injected oil is effective, it is also expensive, requires
trained personnel to administer, and carries the risk of infec-
tious disease transmission from contaminated needles.
Because of those drawbacks, researchers began exploring oral
administration as an alternative. Oral administration of
iodized oil in liquid and tablet form has been successful in the
long-term correction of clinical deficiency, and in Indonesia,
oral administration was associated with a reduction in infant
mortality (Cobra and others 1997).
Iodized or iodated salt is the primary strategy for correct-
ing iodine deficiency because of the nearly universal con-
sumption of salt regardless of socioeconomic status; the lack
of an effect on consistency, color, or taste from the addition
of iodine; and the limited number of producers in many
countries. Large-scale salt fortification has been highly suc-
cessful in many countries, and of the 130 countries with iodine
deficiency, 75 percent have laws mandating salt iodization. The
goal of universal salt iodization for consumption by both
humans and livestock in all countries with endemic iodine
deficiency was set at the 1990 World Summit for Children
(WHO, UNICEF, and ICCIDD 2001). Some populations do
not easily embrace salt iodization because of cultural prefer-
ences or because they have an ample supply of unprocessed
salt, so other means of fortification are needed. One promising
option is to add potassium iodate to irrigation water.
Zinc Deficiency
Although zinc deficiency is likely widespread and even mild
deficiency probably has significant health consequences, few
interventions have been developed to combat it in developing
countries. Possible interventions include supplementation,
fortification, and dietary diversification or modification. The
strong evidence that the use of zinc supplements given during
and for a short time after diarrhea improves the outcome of that
episode and prevents future episodes has led to the rec-
ommendation that zinc, along with increased fluids and contin-
ued feeding,be used to treat all episodes of acute diarrhea (WHO
and UNICEF 2004). Substantial efforts are under way to initiate
programs in developing countries. Prophylactic zinc supple-
mentation also improves growth and reduces diarrhea incidence
(International Zinc Nutrition Consultative Group 2004).
Fortification interventions include the traditional method
of adding zinc to a commercial food, consumer fortification
using sprinkles, and plant-breeding techniques. For example,
Mexico has introduced several large-scale programs, including
the fortification of maize and wheat flours and the distribution
of fortified complementary food and fortified milk to low-
income children (Rivera and Sepulveda 2003). Researchers are
investigating the possibility of home fortification of food using
sprinkles containing iron and zinc (Zlotkin and others 2003),
but further research is needed to determine whether sprinkles
are a viable option. Through plant breeding and genetic engi-
neering, staple crops may be made to contain more zinc or less
phytate, resulting in increased zinc bioavailability (Ruel and
Bouis 1998). Other dietary strategies target food preparation
techniques, such as fermentation of unrefined flour to increase
zinc bioavailability.
INTERVENTION COSTS AND 
COST-EFFECTIVENESS
Multiple strategies exist for preventing malnutrition in young
children in the short and long term. This section considers the
costs and cost-effectiveness of these interventions for prevent-
ing malnutrition or deaths attributable to each nutritional
problem. Table 28.4 presents a compendium of cost informa-
tion, including, where possible, the costs of preventing a child
death or saving a DALY.
Horton and others (1996) use data from Brazil, Honduras,
and Mexico to estimate the costs and cost-effectiveness of
hospital-based programs to promote breastfeeding. Using
standard costing methods, they examine the costs of breast-
feeding promotion activities in each program and the addi-
tional inputs, as well as the savings. Savings accrued from the
removal of infant formula where it was currently used. Using
data on infant feeding practices and morbidity and mortality
from Brazil, they estimated the costs of the programs per
birth, per diarrhea case averted, and per death averted. As
table 28.4 shows, the costs of such programs range from
US$0.30 to US$0.40 per child, and from US$100 to US$200 per
death averted, making them comparable in cost-effectiveness to
measles and rotavirus vaccination. Assuming that deaths would
otherwise have occurred around age one, and using average
Latin American life expectancy at that age, yields a cost per
DALY gained of only US$3 to US$7.
In many community-based strategies, multiple organiza-
tions work through a variety of communication channels to
promote exclusive breastfeeding. Two studies in Ghana and
Madagascar provide costs estimates for such programs
(Chee, Makinen, and Sakagawa 2002; Chee and others 2003).
The programs cost US$4 to US$16 per child, and given the
effect on mothers’ practices, the cost ranged from US$5 to
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Table 28.4 Costs and Cost-Effectiveness of Nutrition Interventions
Costs (US$)
Type of deficiency Per child or per Per death Per DALY
and intervention Source Year Country outcome averted gained
Underweight
Breastfeeding support
Breastfeeding promotion
Breastfeeding promotion 
Child survival program
with nutrition component
Nutrition programs
Less intensive
More intensive
Growth monitoring and 
counseling
Vitamin A deficiency
Capsule distribution
Fortification
Sugar
Other
Iron deficiency
Supplements
Fortification
Salt
Sugar
Cereal 
Iodine deficiency
Oil injection
Fortification
Water
Salt
Salt
Zinc deficiency
Supplements with oral 
rehydration salts  
Horton and others 1996
Ross, Loening, and 
Mbele 1987
Chee, Makinen, and 
Sakagawa 2002 
Chee and others 2003
J. Ross 1997; WHO 2002
Fiedler 2003 
Rassas, Hottor, and others 2004
Rassas, Nakamba, and others 2004
Fiedler 2000 
Fiedler and others 2000  
Institute of Medicine 1998; 
World Bank 1994 
Institute of Medicine 1998; World
Bank 1994 
World Bank 1994 
World Bank 1994
World Bank 1994
Institute of Medicine 1998; 
World Bank 1994
Robberstad and others 2004
1996
1987
2002
2003
1997
2003
2004
2004
2000
1994
1994
1994
1994
1994
2004
Brazil,
Honduras,
Mexico
Mali
Ghana
Madagascar
Across
programs
Honduras
Ghana
Zambia
Nepal
Guatemala
India
Guatemala
Peru
Zaire
Indonesia
Italy
India
n.a.
0.30–0.40 per birth;
0.65–1.10 per diarrhea case
averted
2–3 per child
16 per child; 5–58 per
adopter of exclusive 
breastfeeding
4.41 per child; 10–17 per
adopter of exclusive 
breastfeeding
76–101 per undernourished
child averted
2–5 per child
5–10 per child
4 per child; 20 per under-
nourished child averted
0.90 per child
1.23 per child
1.25 per child
0.17 per child
0.05–0.15 per child
3.17–5.30 per child
0.12 per child
0.20–1.00 per child
0.09 per child
2.75 per child
0.80 per child
1.25 per child
0.05 per child
0.02–0.05 per child
0.05 per child
0.47 per child
100–200
282
203a
—
1,200
240–320b
277
162
327
1,000 
—
—
—
2,000
—
—
—
1,000
—
2,100
3–7
11
7.80
—
41–43
8–11
11
6–7
11–12
33–35
—
—
—
66–70
—
—
—
34–36
—
73
—  Source did not include data from which to estimate deaths averted (and DALYs gained).
Note: Deaths prevented by promoting or supporting breastfeeding are assumed to occur around age one. Deaths prevented by other programs to reduce underweight and all programs to reduce micronu-
trient deficiency are assumed to occur between ages one and five. Authors’ estimates of costs per DALY (in parentheses) using region-specific life expectancies at ages one and five, reflect this range.
a. Assumes that all the DALY gains come from preventing deaths. 
b. Assumes that an undernourished child has a chance of 1 in 16 to 1 in 12 (6 to 8 percent) of dying before age five, the same as estimated for child survival programs. 
US$58 per adopter of exclusive breastfeeding. In Ghana, an
estimated 883 deaths were averted, yielding a program cost of
US$7.80 per DALY gained or US$203 per death prevented.
The range of costs within each program depended on the
baseline prevalence of the behavior, the population density,
and the characteristics of the implementing organizations
themselves. Programs will be more cost-effective when the
baseline prevalence is lower; the population density is higher;
and the organizations involved are focused, highly motivated,
and well organized.
Less information is available on the costs of community-
based nutrition programs to prevent growth faltering, to con-
trol morbidity, and to improve survival. The costs of a program
in Mali (Ross, Loening, and Mbele 1987), which included pro-
motion of breastfeeding, counseling, and education on optimal
child feeding; prevention of diarrheal disease; and growth
monitoring, were estimated to be US$282 per death averted
and US$11 per DALY gained. This estimate is consistent with
others that nutrition programs cost US$2 to US$10 per child,
depending on the intensity of nutrition counseling, including
Fiedler’s (2003) study of the Integrated Community Child Care
Program in Honduras, which had an estimated cost of US$4
per child. (For a fuller analysis of such programs, including
contextual and programmatic characteristics that affect out-
comes, see chapter 56.)
In the past five years, investigators have undertaken several
cost analyses of national programs to distribute vitamin A
capsules. Two reports from Ghana and Zambia are particularly
informative (Rassas, Hottor, and others 2004; Rassas,
Nakamba, and others 2004). As table 28.4 shows, such pro-
grams cost US$0.90 to US$1.23 per child, with the costs per
death averted ranging from US$162 to US$277. (Deaths from
micronutrient deficiencies are assumed to occur between ages
one and five, and estimates of cost per DALY ranging from
US$6 to US$11 reflect this range, as well as region-specific life
expectancies at those ages.) These costs are comparable with
estimates of a vitamin A program in Nepal that cost US$1.25
per child and US$327 per death averted (Fiedler 2000). Ching
and others (2000) examine the costs of incorporating vita-
min A capsule distribution into immunization campaigns in
50 countries in 1998 and 1999. Their analysis finds that the
total costs per death averted ranged from about US$150 to
US$600, with the incremental costs for vitamin A distribution
amounting to only about US$30 to US$150 per death averted.
The costs per death averted depended on the country setting,
the program’s coverage, the delivery of vitamin A (one or two
doses), and the underlying level of mortality. The incremental
cost per DALY gained could be as low as US$1 or as high as
US$6.
Fewer examples of vitamin A fortification programs are
available, with the only clear example being sugar fortification
in Central America. In 1994, estimates indicated that a pro-
gram in Guatemala cost US$0.17 per child, and US$1,000 per
death averted. Counting only the losses from mortality, the cost
of saving a DALY was US$33 to US$35. However, for each death
prevented, there were probably several cases of eye damage
prevented and of improved general health; thus, taking full
account of nonfatal effects would reduce the cost per DALY
somewhat.
Iron supplementation is more costly than distribution of
vitamin A capsules, as it involves a daily supplement over an
extended period. Estimates indicate that such programs cost
US$3.17 to US$5.30 per child. Numerous cost estimates are
available for iron fortification programs, because these pro-
grams have been the principal strategy to prevent and control
iron deficiency anemia. Such programs have traditionally cost
US$0.09 to US$1.00 per child, depending on the country and
the vehicle for fortification. These estimates are based on ele-
mental iron as the fortifier. Even though this is the cheapest
form available, critics have questioned the bioavailability of ele-
mental iron, and many researchers now advocate using other
forms of iron.
Iodine fortification programs cost little, about US$0.02 to
US$0.05 per child. Iodized oil injections are more costly at
US$0.80 to US$2.75 per beneficiary, but these programs may
be recommended for settings where people consume little
commercialized and easily fortified food.
Currently, no examples of zinc intervention programs are
available from which to estimate cost-effectiveness. However,
Robberstad and others’ (2004) simulation analysis examines
the potential costs and cost-effectiveness of providing zinc as
an adjunct to oral hydration salts in treating diarrhea in young
children. Providing zinc as part of case management carries an
estimated incremental cost of US$0.47 per treatment, ranging
from US$0.33 to US$0.62. Given the relationship between zinc
provision and mortality risk, this addition to current manage-
ment programs would cost, on average, US$2,100 per death
adverted and US$73 per DALY gained.
Despite the enormity of the nutritional problems, the
associated loss of DALYS, and the existence of programs to
combat malnutrition, surprisingly little data on the costs or
cost-effectiveness of nutritional programs are available. This
problem represents a serious gap in information for health
planning, implementation, and advocacy. Nonetheless, con-
siderable evidence indicates that when programs to promote
breastfeeding or child growth or to correct micronutrient defi-
ciencies are delivered to populations with a relatively high
prevalence of malnutrition, the cost per participating child is
usually so low that deaths can be averted at a cost per DALY
that is less than US$100, and often less than US$10, even in
regions with low life expectancy. Few health interventions are
comparably cost-effective.
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ECONOMIC BENEFITS OF INTERVENTION
The previous sections outlined the costs to society in terms of
deaths and disabilities resulting from growth faltering and
micronutrient malnutrition, as well as the costs and cost-
effectiveness of options for their alleviation and prevention;
however, DALYs do not capture the full range of potential
benefits to society from effective nutrition programs. For
example, even though the effect of iron deficiency on mental
retardation in children contributes to the attributable DALYs
(Stoltzfus, Mullany, and Black 2004), the negative effects of
iron deficiency on cognition that do not constitute retarda-
tion are not considered. Other effects of malnutrition on cog-
nitive and physical functioning that ultimately affect labor
productivity are also not considered, nor are other long-term
health consequences of child undernutrition. Finally, because
undernutrition increases the frequency and severity of dis-
ease, undernutrition is associated with considerable health
care costs, which are also not captured in burden estimates.
Malnutrition and Human Capital Formation
Researchers have studied cognitive function using global meas-
ures of development and intelligence, such as IQ, along with
school performance and more narrowly defined intellectual,
psychomotor, and behavioral skills. A large body of research
has examined whether undernutrition causes lasting cognitive
deficits in later life and whether potential deficits are amenable
to subsequent nutritional interventions. Acute malnutrition
is associated with negative neuroanatomical, emotional, and
behavioral effects on children’s development. After recovery,
results of behavioral and developmental tests generally
improve, but the long-term developmental implications
remain unclear. Many studies find IQ scores 8 to 18 points
lower in children who suffered from severe malnutrition
(Fishman and others 2004). Studies of chronic undernutrition
also report deficits in IQ and school performance with stunting
during early childhood. Evidence from nutritional interven-
tions among high-risk or undernourished children suggests
that early supplementary feeding (but no sooner than two years
of age) improves developmental scores during the intervention,
with some evidence of long-term benefits. For example, follow-
up of Guatemalan children exposed to prenatal and early 
postnatal supplementation demonstrated long-term cognitive
benefits even after adjusting for socioeconomic factors and
educational experience (Pollitt and others 1995). These results
argue strongly for preventing acute severe malnutrition and
generalized growth faltering that leads to stunting in children.
Nutritional interventions may preserve or improve cogni-
tive function through mechanisms other than preventing
growth faltering or acute malnutrition. For example, breast-
feeding confers some cognitive benefits. Anderson, Johnstone,
and Remley’s (1999) meta-analysis estimates gains of 3.5 IQ
points, adjusting for important covariates.
Iron deficiency has long been associated with developmental
delays, and iron supplementation studies have demonstrated
improvements in cognitive function. Whether the negative
effects of iron deficiency and anemia on development are
reversible remains controversial, which implies the need for
strong preventive measures. More research is needed to learn
about the effects of iron deficiency on development and to
develop measures for evaluating programs that provide iron.
Multiple lines of evidence indicate that zinc influences
development (Black 1998). Despite a clear biological role, epi-
demiological studies provide insufficient evidence to draw con-
clusions on the gain in human capital if zinc deficiency were
reduced through public health interventions. Research to
address this gap is under way.
The public health community has long recognized that
iodine deficiency is the most common cause of preventable
mental retardation. Even though the problem of maternal
iodine deficiency and cretinism in the offspring is well recog-
nized, evidence also suggests that deficiency in children is neg-
atively associated with cognitive abilities. Bleichrodt and Born’s
(1994) meta-analysis finds losses of 13.5 IQ points in those
with iodine deficiency. Some of these effects occur in the
absence of goiter, the hallmark of IDD. More research is needed
to fully understand the human consequences of milder forms
of iodine deficiency that are probably still prevalent in devel-
oping countries.
Malnutrition and Loss of Productivity
Abundant evidence demonstrates that both anemia and iron
deficiency decrease fitness and capacity for aerobic work by
decreasing oxygen transport and respiratory efficiency in mus-
cles. The consequences of iron deficiency are thus measurable
in terms of loss of economic productivity. Aguayo, Scott, and
Ross’s (2003) case study in Sierra Leone estimates that anemia
among women is associated with agricultural productivity
losses of US$19 million per year. For children, the economic
costs are not as clear, but those costs may be substantial depend-
ing on the children’s ages and the types of work they perform.
Growth faltering that leads to stunting in early childhood
translates into shortened adult stature. Adult height is related
not only to total food consumption but also to protein intake
(Jamison, Leslie, and Musgrove 2003), which reinforces the
importance of dietary quality. Multiple levels of evidence link
adult stature and worker productivity (Martorell 1996).
Haddad and Bouis (1991) estimate that a 1 percent decrease in
adult stature is associated with a 1.4 percent decrease in pro-
ductivity. Others find that a 1 percent increase in adult stature
is associated with a 2.0 to 2.4 percent increase in wages or earn-
ings. Other things being equal, current programs to prevent
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stunting in early childhood can deliver about a third to a half of
that 1 percent increase in adult stature. Thus, a lifetime of eco-
nomic loss results from a failure to prevent stunting in early
childhood and accompanying deficits in adult stature, and
strategies to reduce this tremendous loss are available.
In addition, the impacts of malnutrition on cognitive devel-
opment translate indirectly into deficits in productivity in
adulthood. Children who are malnourished are more likely to
start school late, to perform less well, and to stay in school for
a shorter time (Behrman, Alderman, and Hoddinott 2004).
Studies suggest that improvements in nutrition within the cur-
rent range of benefits of programs for young children can lead
to substantial increases in rates of school initiation and to more
years of schooling (Alderman, Hoddinott, and Kinsey 2003;
Alderman and others 2001; Behrman and others 2003). Both
years of schooling and school performance affect wages and eco-
nomic productivity. Alderman, Hoddinott, and Kinsey (2003)
calculate that the effects of malnutrition during early childhood,
with the accompanying effects on schooling, lead to a 12 percent
reduction in lifetime earnings in Zimbabwe. Current program-
ming could restore a significant proportion of those lost wages.
Resource Allocation
Malnutrition increases the likelihood that a child will be sick
and,when sick,will become seriously ill.Thus, resources must be
allocated to health care services to deal with the increased fre-
quency and severity of illness caused by undernutrition and
micronutrient deficiencies. To our knowledge, this increase in
likelihood and severity of illness has never been quantified, but
it is likely to be high, considering not only the costs of health care
infrastructure, but also the time costs and costs of lost wages
or schooling borne by the family for each episode of illness.
Furthermore, to the extent that undernutrition or micronutrient
deficiencies lead to deficits in cognitive development, resources
need to be allocated to special education, rehabilitation, and
vocational services. The costs associated with not providing such
services are ultimately paid in mortality and economic statistics.
Adult Disease and Disability
In the past 10 years, a growing literature has identified associa-
tions between small size at birth; early patterns of postnatal
growth; and adult conditions as diverse as diabetes, cardiovas-
cular disease, and schizophrenia. More research is needed to
provide evidence of causality for such associations and to
create the evidence base for attributing those effects to mal-
nutrition in burden-of-disease calculations. Given current
knowledge, health care budgets in developing countries will
likely be strained to deal with the burden of chronic diseases of
adulthood caused by the failure to prevent maternal and child
undernutrition.
PROGRAM IMPLEMENTATION: 
LESSONS OF EXPERIENCE
For decades, countries have implemented programs to alleviate
growth faltering and micronutrient deficiencies in children;
therefore, it is timely to consider what has been accomplished
and what can be learned from successes and failures. The task
is difficult, because nutrition programs are diverse, ranging
from the simple fortification of salt with iodine to multifaceted
programs to improve dietary intakes and prevent growth fal-
tering. Nonetheless, some general statements about the state of
programming in this area are possible.
Success in conceptualizing and implementing programs to
reduce growth faltering by combining disease control strategies
with the promotion of breastfeeding and optimal complemen-
tary feeding has been demonstrable. The focus has shifted away
from growth monitoring and promotion (counseling) strate-
gies to population-based assessment with more generalized
dissemination of key messages for behavior change. Available
data suggest high cost-effectiveness for such programs. Key
challenges involve scaling up and sustainability, as well as
strengthening of monitoring and evaluation systems. A gap in
this knowledge concerns optimal feeding in the presence of
HIV infection, and testing options and designing programs in
such settings are of the highest priority.
Iodine fortification has been a clear success over decades,
which underscores the need for continued and consistent fund-
ing and advocacy for such programs. Even when universal
access to iodine becomes a reality, policy and programmatic
supports will be necessary to maintain it.
The success of iodine fortification contrasts with other exam-
ples of fortification that have made slow and uneven progress.
Fortification of foodstuffs with vitamin A is limited geo-
graphically, and even though many countries have embarked on
iron fortification, these programs lag because of controversies
about the effectiveness of existing programs, the evaluation
methods used, and the lack of infrastructure for fortification in
some settings. Concerted efforts to address the controversies
and to provide evidence of the effectiveness of fortification in
controlling iron deficiency are under way. In addition, recogni-
tion that fortification should address multiple micronutrient
deficiencies, chiefly the B vitamins and zinc, has grown.
Programs to distribute vitamin A capsules twice a year are a
reality in many areas characterized by VAD. Jones and others
(2003) estimate that current coverage of supplementation for
children living in areas with VAD is 55 percent. In the past few
years, studies have provided solid data on the costs and cost-
effectiveness of such programs in diverse settings.
In contrast, despite concerns about the health and develop-
mental consequences of iron deficiency and anemia, few exam-
ples are available of even small-scale iron supplementation
programs for young children. Supply and adherence continue to
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constrain progress, with adherence depending on program
workers’ and families’ perceptions of benefits and their reluc-
tance to continue the long-term use in children of what are often
considered to be medicines. Similar constraints apply to pro-
grams to provide iron supplements to pregnant women, but
operational research has overcome many obstacles,and the hope
is that the lessons learned can inform the design and implemen-
tation of iron supplementation programs for young children.
Food-based strategies, particularly dietary diversification
and the promotion of specific food groups for preventing
micronutrient malnutrition, are less advanced than other pro-
grams. In part, this lack of advancement reflects the diverse
nature of the behaviors to be changed and of the available
options. Given this diversity and the fact that such strategies
are more setting specific than, for example, capsule distribu-
tion, the lack of summary estimates of effectiveness is not sur-
prising. Consensus is growing that improving dietary intakes
through agricultural innovations and dietary diversification
represents long-term answers to micronutrient malnutrition,
but progress is slow because of the urgency of alleviating defi-
ciencies in the short term. More research is needed to define the
policies that will promote these strategies.
Research over the past decade has articulated a strong
case for interventions to prevent zinc deficiency, with sup-
plementation and fortification identified as important
approaches. Experiences with zinc supplementation or forti-
fication programs are needed to provide estimates of costs
and cost-effectiveness. If the costs of providing zinc supple-
ments to young children are in line with those reported
earlier, then such programs would be highly cost-effective,
considering the prevalence and burden of disease associated
with zinc deficiency.
Child malnutrition results from multiple factors, and even
though each context has its own unique features, the etiology
has many more commonalities. Thus, for program planners
and policy makers intent on alleviating malnutrition to begin
designing and implementing programs in their particular set-
tings from scratch is strikingly inefficient. In the past decade,
this point has been recognized, and documents that articulate
processes for program implementation and evaluation have
mushroomed. These “road maps” permit policy makers and
program planners to capitalize rapidly on interest in address-
ing nutrition problems. The road maps also communicate a
sense of feasibility by streamlining the complex processes of
program design and evaluation. Thus, their use can reduce the
likelihood that programs will be diffuse (too many inputs),
will be culturally inappropriate, will have unrealistic expecta-
tions, and will have no possibility of sustainability and no
plans for process or impact evaluation.
Demonstrating that nutrition programs are effective is key
to translating scientific findings into policies and programs as
well as to ensuring the continuity and expansion of funding.
Despite decades of nutrition programs, with identifiable suc-
cesses, uncertainty about their effectiveness persists. The value
of publishing solid process and outcome evaluations in the
scientific literature in addition to project reports has only
recently been recognized and cannot be overstated. Whereas
outcome evaluations provide data on program effects, process
evaluations provide key information to maintain quality assur-
ance and to support the plausibility of key outcomes.
Consensus is growing on the need to evaluate a package of
services rather than use complex strategies to tease apart the
effects of specific program elements. Well-designed programs
with process evaluation efficiently provide this information.
Although following standard scientific approaches to estab-
lish program effectiveness has enabled progress in many
interventions, alternative designs can and should be used for
this purpose. Scientists traditionally argue that randomized
controlled trials are needed to establish causal evidence of
effectiveness and that multiple trials are needed in diverse set-
tings, perhaps followed by pooled or meta-analyses to provide
summary estimates. Others argue that designs that provide
plausible evidence of program effects or adequate information
to support continued funding should be recognized as valid by
funders and publishers in refereed journals and should be
implemented more broadly (Victora, Habicht, and Bryce 2004).
RESEARCH AND DEVELOPMENT AGENDA
Despite progress, much work remains unfinished. Other chap-
ters focus on research and development needs in relation to
packaging services, scaling up, and ensuring sustainability.
Here the focus is on research for strengthening the database for
policy making.
Gaps in knowledge remain with respect to recognized
strategies for intervention programs. Often information on
intervention efficacy exists, yet little scientific literature on pro-
gram effectiveness is available. Key gaps include the following:
• evaluation of the effectiveness of national iron fortification
programs to reduce iron deficiency anemia 
• implementation and evaluation of the effectiveness of iron
supplementation programs for young children 
• evaluation of the effect on child mortality of multifaceted
programs to reduce child undernutrition 
• evaluation of the effectiveness of programs based on the
new guiding principles for reducing undernutrition and
micronutrient malnutrition in young children 
• implementation and evaluation of the effectiveness of food-
based strategies to reduce micronutrient malnutrition 
• implementation and evaluation of the effectiveness of early
postnatal vitamin A supplementation to reduce infant
mortality.
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Costing studies should accompany the evaluations to allow
estimates of cost-effectiveness for decision making.
Because of the logistical difficulties in developing fortifica-
tion approaches in settings with little industry infrastructure,
alternative fortification approaches are needed, such as
micronutrient sprinkles or foodlets. In addition, operational
research is needed to develop, implement, and evaluate pro-
grams to improve zinc status. Never has so much evidence been
amassed on the consequences of a deficiency disorder without
programmatic application. The challenge now is to develop and
implement programs for preventing and treating zinc deficiency
and to evaluate their effectiveness for child growth, health, and
survival. The International Zinc Nutrition Consultative Group
(2004) has laid out a research agenda with these aims in mind.
CONCLUSIONS
Undernutrition is a major cause of death and disability in
young children. When ranked among other causes, growth fal-
tering and micronutrient deficiencies figure prominently, both
because they are prevalent and because their consequences are
devastating. Not included in the numbers, however, are the
losses of lifetime productivity associated with early malnutri-
tion and the resources that must be allocated to confront the
developmental and morbidity consequences of child malnutri-
tion, which last a lifetime.
Success has been achieved in preventing and controlling
iodine deficiency, and palpable progress has been made in the
past 20 years in correcting vitamin A deficiency and promoting
breastfeeding; however, for iron, articulated goals have not
been translated into programs, and the problem has remained
the same or worsened. Zinc deficiency is now recognized as an
important new challenge.
As shown here, solid evidence shows that nutrition pro-
grams can be effective at addressing nutritional problems in
young children. Increasingly available cost data, when com-
bined with outcome evaluations, demonstrate that nutritional
interventions rank favorably in terms of cost-effectiveness
when compared with competing interventions. The case that
further investment in nutrition interventions is warranted is
thus compelling.
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INTRODUCTION
Cancer imposes a major disease burden worldwide, with
considerable geographic variations in incidence; mortality;
survival; overall disease burden; causative environmental fac-
tors; and mix of prevention, detection, treatment, and palliative
programs that make up a country’s cancer control strategy.
Unless cancer prevention and screening interventions effec-
tively reduce the incidence of cancer, the number of new can-
cer cases will increase from an estimated 10 million cases in
2000 to 15 million in 2020, 9 million of which would be in devel-
oping countries. By 2050, the cancer burden could reach 24 mil-
lion cases per year worldwide, with 17 million cases occurring in
developing countries (Parkin, Bray, and Devesa 2001).
Researchers have made numerous efforts to quantify the
global burden of cancer and to estimate site-specific cancer
mortality and morbidity (see, for example, Ferlay and others
2004; Parkin, Bray, and Devesa 2001). A recent report from the
International Agency for Research on Cancer provides esti-
mates of cancer incidence for Africa by site and country (Parkin
and others 2003). In general, however, data on cancer incidence,
prevalence, and mortality are less complete and less accurate in
developing countries than in developed countries, because the
latter have more resources to invest in population-based cancer
registries and the infrastructure to maintain such registries.
Despite the limitations of current data for developing coun-
tries, the epidemiology of cancer in developing countries clearly
differs from that in developed countries in some important
respects. Developed countries often have relatively high rates
of lung, colorectal, breast, and prostate cancer because of the
earlier onset of the tobacco epidemic, the earlier exposure to
occupational carcinogens, and the Western diet and lifestyle in
such countries. In contrast, up to one-fourth of cancers in
developing countries are associated with chronic infections.
Liver cancer is often causally associated with infection by the
hepatitis B virus (HBV), cervical cancer is associated with infec-
tion by certain types of human papillomavirus (HPV), and
stomach cancer is associated with Helicobacter pylori infection.
This chapter focuses on interventions for controlling seven
cancers that impose a particularly heavy burden of disease on
developing countries: cervical cancer, liver cancer, stomach
cancer, esophageal cancer, lung cancer, colorectal cancer, and
breast cancer. In 2000, these seven types of cancer accounted
for approximately 60 percent of all newly diagnosed cancer
cases and cancer deaths in developing countries (Ferlay and
others 2001). Four of the seven cancers—cervical, liver, stom-
ach, and esophageal—have elevated incidence and mortality
rates in developing countries. The other three—lung, colorec-
tal, and breast—have lower incidence and mortality rates than
the other four cancers, but they nonetheless impose a heavy
disease burden and are increasing because of demographic and
industrial transitions. Pediatric cancers and HIV-related can-
cers, two topics that are of great importance and concern, are
beyond the scope of this chapter.
BURDEN OF CANCER IN DEVELOPING COUNTRIES
Data from Ferlay and others (2004) clearly illustrate the differ-
ing patterns of cancer incidence in developing and developed
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countries (figures 29.1 and 29.2). In developing countries, the
top five female cancers in rank order of incidence are breast,
cervical, stomach, lung, and colorectal cancer; however, cervical
cancer still accounts for more deaths than breast cancer in
developing countries. The top five male cancers are lung, stom-
ach, liver, esophageal, and colorectal cancer (figure 29.1). The
incidence of cancers of the lung and breast is relatively high in
both developed and developing countries. Colorectal cancer
accounts for a smaller share of the burden in developing coun-
tries than in developed countries, but cancer of the stomach
accounts for a higher share. Some cancers that are more
common in developing than in developed countries, including
stomach, liver, and cervical cancer, are related to the absence of
a well-developed public health infrastructure for the control of
cancer-causing infectious agents and contaminants, the lack
of basic preventive health care and screening services for much
of the population, and the poor-quality diets available to the
most economically disadvantaged members of society in many
developing countries. Cancer of the esophagus, also relatively
common in developing countries, may reflect, in part, the con-
sumption of traditional beverages at extremely high tempera-
tures. Some cancers that are increasingly common in develop-
ing countries, including lung, breast, and colorectal cancer, may
reflect the increasing Westernization of lifestyles, longer life
expectancy, and globalization of markets for tobacco products.
For some cancers, including esophageal, liver, lung, and
pancreatic cancer, survival rates vary little between developing
and developed countries (Sankaranarayanan, Black, and Parkin
1998). Currently available methods of early detection and
treatment have not been demonstrated to be effective for these
cancers, so primary prevention remains the most practical
intervention for control. For a second group of cancers, includ-
ing large bowel, breast, ovarian, and cervical cancer, proven
methods of early detection, diagnosis, and treatment are avail-
able that can, in principle, be delivered through district health
care facilities. For these cancers, survival rates vary both
between developing and developed countries as a whole and
between specific countries within each of these groups. For a
third group of cancers, including testicular cancer, leukemia,
and lymphoma, the variability in survival between developing
and developed countries is tremendous. Even though relatively
effective treatments are available for these cancers, they are
multimodal treatments that require a relatively high level of
medical resources, a good health care infrastructure, and a level
of sophisticated knowledge, which low- and middle-income
developing countries may not have.
Table 29.1 shows estimated cancer deaths and the estimated
disease burden in terms of disability-adjusted life years
(DALYs) lost as a result of various types of cancers in develop-
ing and developed countries and by region in 2001. As the table
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Male Female
Stomach
Breast
Liver
Cervix uteri
Esophagus
Colon and rectum
Oral cavity
Leukemia
Prostate
Non-Hodgkin’s lymphoma
Bladder
Brain, nervous system
Ovary
Pancreas
Larynx
Other pharynx
Thyroid
Nasopharynx
Kidney
Corpus uteri
Hodgkin’s lymphoma
Multiple myeloma
Melanoma of skin
Testis
6,000 4,000 2,000 0
Globocan 2002, IARC
Source: Ferlay and others 2004.
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Figure 29.1 Estimated Number of Cancer Cases of All Ages,
Developing Regions, 2002 
(hundreds)
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Figure 29.2 Number of Cancer Cases of All Ages, Developed
Regions, 2002
(hundreds)
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Table 29.1 Number of Cancer Deaths and DALYs Lost to Cancer, by World Bank Region and Country Income Level, 2001
East Asia and Europe and Latin America and Middle East and Sub-Saharan Low- and middle- High-income 
the Pacific Central Asia the Caribbean North Africa South Asia Africa income countries countries
Cancer site Deaths DALYs lost Deaths DALYs lost Deaths DALYs lost Deaths DALYs lost Deaths DALYs lost Deaths DALYs lost Deaths DALYs lost Deaths DALYs lost
Trachea, bronchus, 387,000 5,333,000 165,000 2,323,000 55,000 728,000 20,000 283,000 129,000 1,807,000 15,000 225,000 771,000 10,701,000 456,000 5,397,000
and lung cancers
Stomach cancer 442,000 6,134,000 101,000 1,376,000 57,000 735,000 18,000 252,000 45,000 629,000 33,000 487,000 696,000 9,616,000 146,000 1,628,000
Liver cancer 373,000 5,923,000 28,000 379,000 21,000 277,000 9,000 138,000 27,000 464,000 46,000 762,000 505,000 7,945,000 102,000 1,223,000
Esophageal cancer 232,000 3,217,000 21,000 288,000 16,000 215,000 5,000 72,000 80,000 1,116,000 24,000 343,000 380,000 5,252,000 58,000 702,000
Colorectal cancer 159,000 2,334,000 96,000 1,290,000 37,000 485,000 10,000 164,000 35,000 499,000 20,000 291,000 357,000 5,060,000 257,000 3,175,000
Breast cancer 93,000 1,730,000 63,000 1,058,000 37,000 642,000 14,000 273,000 76,000 1,246,000 34,000 574,000 317,000 5,527,000 155,000 2,509,000
Mouth and 66,000 1,064,000 27,000 426,000 14,000 204,000 5,000 78,000 140,000 2,020,000 19,000 284,000 271,000 4,078,000 41,000 576,000
oropharyngeal 
cancers
Cervix uteri cancer 47,000 805,000 19,000 356,000 26,000 494,000 5,000 93,000 83,000 1,423,000 38,000 627,000 218,000 3,799,000 17,000 319,000
Lymphomas and 42,000 753,000 23,000 375,000 24,000 383,000 12,000 232,000 82,000 1,401,000 34,000 622,000 216,000 3,770,000 115,000 1,362,000
multiple myeloma
Leukemia 76,000 1,652,000 27,000 462,000 22,000 444,000 14,000 307,000 38,000 851,000 14,000 245,000 190,000 3,965,000 73,000 919,000
Prostate cancer 16,000 164,000 25,000 283,000 37,000 340,000 6,000 64,000 21,000 210,000 40,000 416,000 145,000 1,479,000 119,000 1,212,000
Pancreatic cancer 37,000 544,000 35,000 481,000 20,000 248,000 4,000 55,000 13,000 176,000 8,000 117,000 117,000 1,621,000 110,000 1,232,000
Bladder cancer 30,000 348,000 24,000 300,000 9,000 100,000 15,000 214,000 30,000 408,000 10,000 133,000 117,000 1,504,000 59,000 670,000
Ovarian cancer 25,000 464,000 21,000 350,000 9,000 152,000 2,000 42,000 21,000 327,000 9,000 152,000 86,000 1,488,000 46,000 651,000
Corpus uteri cancer 8,000 175,000 17,000 349,000 12,000 254,000 1,000 22,000 4,000 66,000 3,000 41,000 44,000 908,000 27,000 586,000
Melanoma and 5,000 66,000 11,000 160,000 7,000 97,000 1,000 19,000 3,000 41,000 8,000 118,000 35,000 501,000 30,000 409,000
other skin cancers
Other malignant 104,000 1,640,000 123,000 1,901,000 82,000 1,263,000 26,000 440,000 26,000 1,444,000 55,000 844,000 490,000 7,538,000 257,000 3,316,000
neoplasms
Total (all malignant 2,142,000 32,346,000 826,000 12,157,000 485,000 7,061,000 167,000 2,748,000 853,000 14,128,000 410,000 6,281,000 4,955,000 74,752,000 2,068,000 25,886,000
neoplasms)
Source: Mathers and others 2006.
Note: For an explanation of how DALYs are computed, see chapter 15 of this volume.
shows, the seven types of cancer that are the focus of this
chapter account for seven of the first eight cancer sites ranked
by number of deaths in developing countries. Considerable
heterogeneity in the pattern of cancer burden across the six
regions is apparent, and additional heterogeneity is apparent
within these regions. Deaths from liver cancer are relatively
high in East Asia and the Pacific and in Sub-Saharan Africa,
probably because of the high prevalence of chronic HBV
infection and the lack of adequate resources for food storage
and preservation in those regions (Parkin and others 2003).
The number of deaths from colorectal and breast cancer, as a
proportion of all cancer deaths, is relatively high in Europe
and Central Asia and in Latin America and the Caribbean,
probably because those regions have increasingly adopted
more Western lifestyle patterns of reproductive behavior, diet,
and physical activity. The number of deaths from oral cancer
is particularly high in South Asia, where the use of betel quid is
common.
TYPES OF INTERVENTIONS FOR
CANCER CONTROL
The World Health Organization (WHO) emphasizes that,
when developing national strategies for controlling cancer,
countries should consider the following four broad approaches
(WHO 2002):
• Primary prevention. The goal of primary prevention is to
reduce or eliminate exposure to cancer-causing factors,
which include environmental carcinogens and lifestyle fac-
tors related to nutrition and physical activity. For the seven
cancers considered here, approaches to primary prevention
include immunization against, or treatment of, infectious
agents that cause certain cancers; use of tobacco control
programs; reduction of excessive alcohol consumption;
dietary intervention; and pharmacological intervention.
• Early detection and secondary prevention. The main objective
of early detection or secondary prevention through
population-based screening programs is detection at a stage
at which curative treatment is possible. Interventions for the
early detection of cancer can help reduce mortality from
cancer only if they are part of a wider cancer control strategy
that includes effective diagnostic follow-up procedures and
treatment (Anderson and others 2003). For cervical, col-
orectal, and breast cancer, effective methods of early detec-
tion and treatment are available, but their implementation
has been uneven (Sankaranarayanan, Black, and Parkin
1998).
• Diagnosis and treatment. The primary modalities of cancer
treatment are surgery, chemotherapy, and radiotherapy, and
these modalities may be used alone or in combination.
There is increasing emphasis worldwide on the develop-
ment of specialized cancer centers that apply evidence-
based multimodal therapies, including rehabilitation and
palliative care.
• Palliative care. The scope of palliative care has been
expanded in recent years to encompass the alleviation of
symptoms and treatment during all phases of disease—
from diagnosis to death—and to address matters related to
the psychological and quality-of-life aspects of disease, as
well as the physiological aspects. Furthermore, palliative
care has been expanded to include consideration for the
well-being of the patient’s family members as well as for
the patient (Singer and Bowman 2002).
The discussion in this chapter focuses primarily on health
service interventions for controlling the seven cancers that are
the subject of this chapter. Other chapters deal with broad pub-
lic health interventions involving the control of occupational
and environmental exposures; health education; policy inter-
ventions such as regulation, labeling, and taxation related to
tobacco consumption; diet; and physical activity.
COST-EFFECTIVENESS OF CANCER
CONTROL INTERVENTIONS 
There is a growing literature on the cost-effectiveness of inter-
ventions within each of the four categories above. In this sec-
tion, we review published studies of the cost-effectiveness of
health services–based cancer control interventions, and we
present new analyses of the cost-effectiveness of screening
interventions for cervical and breast cancer.
Primary Prevention
This subsection reviews studies of the effectiveness and cost-
effectiveness of several interventions for the primary preven-
tion of cancer.
Immunization against—or Treatment of—Infectious Agents
That Cause Certain Cancers. Infectious agents are causally
associated with three of the seven cancers that are the focus of
this chapter—liver cancer (HBV), cervical cancer (HPV infec-
tion), and stomach cancer (H. pylori infection)—so eliminat-
ing these agents through immunization or other means offers
hope for preventing such cancers.
The HBV vaccine was designed to prevent liver cancer and
is currently the only such vaccine in widespread use. Long-term
protection against acute and chronic infection has been
demonstrated with the HBV vaccine in a wide range of settings
(Coursaget and others 1994; Viviani and others 1999), and
recent data support a reduction in hepatocellular carcinoma
(Lee, Hsieh, and Ko 2003).
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Infection with specific high-risk types of HPV plays a key role
in causing cervical cancer. A double-blind placebo-controlled
trial of an HPV 16 vaccine reported encouraging efficacy results
in young female volunteers who had been fully vaccinated (three
doses of vaccine or placebo) over a 1.7-year follow-up period
(Koutsky and others 2002). In a more recent study, a bivalent
HPV 16/18 vaccine prevented approximately 95 percent of per-
sistent infections with HPV 16 and 18 (Harper and others 2004).
Several modeling studies have explored the potential bene-
fits of HPV vaccination at the population level (Goldie and
others 2003; Hughes, Garnett, and Koutsky 2002; Kulasingam
and Myers 2003) and have elucidated several priorities for
future research, including a better understanding of the hetero-
geneity of vaccine response and the effects of type-specific vac-
cination on other HPV types.
Hughes, Garnett, and Koutsky (2002) evaluate the potential
effectiveness of HPV vaccination using a dynamic transmission
model and find that, when both men and women were
vaccinated—assuming 90 percent coverage, 75 percent effec-
tiveness, and 10-year immunity—type-specific HPV prevalence
was reduced by 44 percent. When only women were vaccinated,
the reduction was 30 percent. The authors show that, if the vac-
cine targeted only certain types of high-risk HPV, cervical can-
cer incidence was not reduced proportionally because other
high-risk types of HPV progressed to invasive cancer.
Goldie and others (2003) assess the impact of a type-specific
HPV 16/18 vaccine calibrated to population-based data for
Costa Rica. They find that a vaccine that prevented 98 percent
of persistent HPV 16/18 was associated with an approximate
equivalent reduction in HPV 16/18–associated cancer and a
51 percent reduction in total cervical cancer. The effect on total
cancer was attenuated because of the competing risks associ-
ated with oncogenic types of HPV other than HPV 16/18.
Three studies have evaluated the potential cost-effectiveness
of HPV vaccination in countries with cervical cancer screening
programs (Goldie, Kohli, and others 2004; Kulasingam and
Myers 2003; Sanders and Taira 2003). In general, these studies
indicate that a program of HPV vaccination that permits a later
age of screening initiation and a less frequent screening inter-
val is likely to be a cost-effective use of health care resources in
developed countries.
In Fujian province, China, a region of high mortality attrib-
utable to stomach cancer, a recently completed randomized
controlled trial of H. pylori eradication with antibiotics pro-
vides some evidence that this approach may be effective in pre-
venting stomach cancer in the subgroup of H. pylori carriers
without precancerous lesions at the time of treatment (Wong
and others 2004). A recent randomized trial of H. pylori
eradication in Chiapas, Mexico, which used preneoplastic con-
ditions as surrogate markers for the development of gastric
cancer, found some evidence for the effectiveness of this treat-
ment (Ley and others 2004).
Several studies, most of them in developed countries, have
assessed the potential cost-effectiveness of screening individu-
als for infection with H. pylori and then eradicating H. pylori
with antibiotic therapy as a means of preventing the later
occurrence of stomach cancer. Roderick and others (2003)
examine the cost-effectiveness of an H. pylori screening pro-
gram conducted in the United Kingdom. Discounting costs
and benefits at 6 percent, they find that the cost-effectiveness
ratio for screening for H. pylori, initiated at age 40, is approxi-
mately US$28,000 per year of life saved (YLS). Optimal cost-
effectiveness was not achieved until the H. pylori screening
program had run for at least 40 years. Harris and others (1999)
estimate the cost-effectiveness ratio associated with one-time
screening for H. pylori at age 50 to be approximately
US$50,000 per YLS (in 1995 dollars, 3 percent discount rate)
when treatment for H. pylori infection results in a 15 percent
reduction in stomach cancer risk. Assuming a 30 percent
reduction, the figure was US$25,000 per YLS for the United
States, but only a few hundred dollars per YLS in Colombia,
which has a much higher rate of stomach cancer and lower
health care costs.
Tobacco and Alcohol Control Programs. Tobacco consump-
tion is the most important cause of lung and other cancers of
the respiratory system, as well as of esophageal cancer, and may
be a contributing factor for several other cancers. The most
effective national tobacco control programs combine health
promotion, education, and health service interventions
with policies. Policy instruments include regulating tobacco
advertising and promotion; enacting smoking bans in work-
places, restaurants, and public buildings and on public
transportation; and increasing excise taxes on tobacco products
(Fiore, Hatsukami, and Baker 2002; WHO 2002). Decreased
rates of smoking uptake by children and adolescents would
result in the greatest potential gain in life years. The WHO
Framework Convention on Tobacco Control (WHO 2003b)
summarizes tobacco control policies and programs related to
regulation, taxation, and education. Da Costa e Silva (2003)
shows prioritized treatment approaches for tobacco cessation,
based on countries’ levels of resources.
Excessive alcohol use accounts for 20 to 30 percent of liver
and esophageal cancer (WHO 2001b). Interventions to reduce
excessive consumption of alcohol have many principles in
common with tobacco control, including the effectiveness of
regulatory and taxation measures along with health promotion
and addiction treatment programs.
Dietary and Related Interventions. The dietary ingestion of
substances produced by the mold Aspergillus flavus, specifically
aflatoxin B1, is causally associated with hepatocellular carci-
noma. Exposure to aflatoxins may be synergistic with HBV
infection in the development of this cancer. Effective means are
available for preventing the contamination of grains and other
types of food with aflatoxin during the growth, harvest, stor-
age, and processing of such products (Kensler and others 2003;
Turner and others 2002). Furthermore, chlorophyllin supple-
ments have been found to reduce the carcinogenic properties of
aflatoxin. That finding provides additional evidence for current
dietary guidelines that meals should contain foods rich in
chlorophylls—for example, spinach and other green, leafy veg-
etables (Kensler and others 2003).
Among those infected with H. pylori, diet is thought to play
a critical role in the progression of superficial gastritis to
chronic atrophic gastritis. Prolonged consumption of foods
rich in salted, pickled, and smoked products increases the risk
of stomach cancer, and increased consumption of fresh fruit
and vegetables likely decreases the risk. Obesity is also a well-
established risk factor for several cancers (Vainio and Bianchini
2002b). For that reason, WHO recommends that governments
seeking to ensure compliance with nutritional objectives con-
duct appropriate school and public education campaigns on
diet and work with the food and agriculture sectors (WHO
2002).
Pharmacological Interventions. Chemoprevention is defined
as the reduction of the risk of cancer development through the
use of micronutrients or pharmaceuticals. Clinical trials among
high-risk individuals to establish the efficacy of chemopreven-
tion via micronutrients (for instance, carotenoids and
retinoids) and dietary fiber have been mainly negative (Alberts
and others 2000; ATBC 1994; Omenn and others 1996;
Schatzkin and others 2000). However, several ongoing clinical
studies are examining the potential cancer preventive effects
of calcium, vitamin D, folic acid, selenium, and vitamin E
(Christensen 2004).
Both case-control and cohort studies show a reduced risk
for colorectal cancer after prolonged use of aspirin (Vainio and
Morgan 1999). Additional evidence indicates that aspirin has
a preventive effect on several other types of cancer, including
hormone receptor–positive breast cancer (Terry and others
2004), but questions remain about the balance between the
clinical benefits and adverse side effects of long-term aspirin
therapy, including gastrointestinal bleeding and hemorrhagic
stroke (Imperiale 2003).
Some evidence suggests that the antiestrogen drug tamox-
ifen may reduce the risk of breast cancer (Gail and others
1999), but there is also conflicting evidence (Powles and others
1998; Veronesi and others 1998). The potential for primary
prevention using other selective estrogen receptor modulators
is a topic of current clinical research (Lippman, Lee, and
Sabichi 1998). Preliminary analyses indicate that the use of
tamoxifen to prevent breast cancer could be cost-effective in
the United States (T. Smith and Hillner 2000).
Early Detection and Secondary Prevention 
This subsection looks at studies of the effectiveness and cost-
effectiveness of several interventions for the early detection and
secondary prevention of cancer.
Screening for Liver Cancer. Screening methods for early
detection of liver cancer include serum assays for alpha-
fetoprotein and, potentially, ultrasound. A recently completed
randomized controlled trial of liver cancer screening in China
evaluated the use of two or six alpha-fetoprotein assays over a
period of four years among men age 30 to 69 with chronic HBV
(Chen and others 2003). Screening resulted in earlier diagnosis
of liver cancer, but because treatment for established liver
cancer is largely ineffective, screening did not reduce overall
mortality.
Randomized trials that include ultrasound screening for
liver cancer and that incorporate recent advances in antiviral
preventive treatment have yet to be conducted. Sarasin,
Giostra, and Hadengue’s (1996) model-based cost-effectiveness
analysis explores whether biannual screening of patients with
Child-Pugh class A cirrhosis, under a set of assumptions sys-
tematically favorable to screening, would be cost-effective. The
authors conclude that, even under best-case conditions, screen-
ing for liver cancer is not likely to be cost-effective.
Screening for Stomach Cancer. Mass screening programs for
the early detection of invasive stomach cancer using radiologi-
cal or endoscopic techniques have been widely implemented in
Japan, where incidence rates of stomach cancer are high.
Babazono and Hillman (1995) compare the cost-
effectiveness of three methods for the early detection of stom-
ach cancer in the context of mass screening programs in Japan:
indirect radiology (barium meal plus photofluoroscopy), direct
radiology, and endoscopy. When screening for stomach cancer
was started late in life, indirect radiology was the most cost-
effective screening method. This analysis supports an increase
in the recommended age for initiating screening for stomach
cancer from age 40 to 50.
Screening for Lung Cancer. Investigators have carried out sev-
eral cost-effectiveness analyses of the screening of high-risk
individuals, such as current and former smokers, for lung can-
cer using helical computed tomography (Chirikos and others
2002; Mahadevia and others 2003; Marshall and others 2001).
The results of these studies vary widely from quite favorable
(US$19,000 per YLS) to extremely unfavorable (more than
US$100,000 per YLS). The main reason for the wide variation
in these studies is different assumptions about the clinical
nature of early lung lesions detected by helical computed
tomography—specifically, whether a large proportion of these
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small lung nodules represents “pseudo-disease” that will never
progress to clinical lung cancer (Marcus and others 2000). The
National Lung Cancer Screening Trial, currently under way
(van Meerbeeck and Tournoy 2004), hopes to answer this
question. Until results from the trial are available, no definitive
statement can be made about the effectiveness or cost-
effectiveness of lung cancer screening.
Screening for Colorectal Cancer. Screening methods for early
detection of colorectal cancer include fecal occult blood testing,
sigmoidoscopy,barium enema,and colonoscopy.Several studies
of the cost-effectiveness of colorectal cancer screening in devel-
oped countries have been published (Pignone and others 2002).
Table 29.2 presents estimates of the cost-effectiveness of col-
orectal cancer screening in the United States. Cost-effectiveness
ratios for various modalities of colorectal cancer screening range
from almost US$6,000 to about US$40,000 perYLS. Using mod-
els closely linked to European trials of biennial fecal occult blood
testing to screen for colorectal cancer, Whynes and Nottingham
Faecal Occult Blood Screening Trial (2004) report favorable
cost-effectiveness ratios ranging from US$2,500 to US$4,000
per YLS. Studies of the cost-effectiveness of colorectal cancer
screening in developed countries consistently conclude that
such screening is cost-effective, but they do not totally agree on
the relative rankings of different colorectal screening strategies
(Pignone and others 2002).
Screening for Cervical Cancer. Cytology-based screening
using the Papanicolaou smear has been the main screening
method used for the secondary prevention of cervical cancer
worldwide. In many low-income countries, however, cytology
screening has proved difficult to sustain because of its reliance
on highly trained cytotechnologists; good-quality laboratories;
and infrastructure to support up to three visits for screening,
evaluation of cytologic abnormalities with colposcopy, and
treatment (Sankaranarayanan, Budukh, and Rajkumar 2001).
Two alternative screening approaches replace the Pap smear
with simple visual screening methods, such as visual inspection
after application of an acetic acid solution (VIA), or with HPV
DNA testing (Denny and others 2000; Sankaranarayanan and
others 1999; Schiffman and others 2000; Wright 2003; Wright
and others 2000; Zimbabwe Project 1999). These newer
options also eliminate colposcopy, potentially allowing screen-
ing and treatment to be performed during the same visit. In
middle-income countries where cytology screening is available
but cervical cancer mortality has not been reduced, key ques-
tions center around improving the quality of cytology-based
programs; such improvement includes having adequate col-
poscopy and biopsy facilities and accessible treatment
(Lazcano-Ponce and others 1999); making use of HPV DNA
testing technology in a cost-effective manner; and targeting the
appropriate age group for cervical cancer screening more accu-
rately. The vast majority of published cost-effectiveness analy-
ses of population-based cervical cancer screening performed
during 1980–2003 focused on high-income countries. (A list of
the 39 studies reviewed is available from the authors.) The
detailed results of each study are somewhat difficult to com-
pare. The types of costs included in each study varied substan-
tially (patient time costs and programmatic costs often were
omitted), studies frequently did not discount costs and benefits
or did not note the discount rate used, and sensitivity analyses
were not conducted consistently on all relevant variables.
Despite those limitations, several themes emerge. The
incremental cost-effectiveness of screening in the general pop-
ulation becomes increasingly less favorable as programs are
intensified by shortening the screening interval. For example,
Mandelblatt and others (2002) reported that for conventional
cytology and HPV testing, compared with cytology alone, the
incremental cost was more than US$300,000 when conducted
annually compared to US$15,400 per YLS when conducted
every 10 years. Maxwell and others (2002) reported that liquid-
based cytology and HPV testing for equivocal results cost
US$231,300 per YLS if conducted annually incremental to
14,300 per YLS if conducted every three years. Kim, Wright,
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Table 29.2 Estimates of the Cost-Effectiveness of Colorectal Cancer Screening Interventions, United States
(cost-effectiveness ratios expressed as 2000 US$/YLS)
Wagner and Frazier and Khandker and Sonnenberg, Delco, Vijan and 
Colorectal screening test others 1996 others 2000 others 2000 and Inadomi 2000 others 2001 
Annual fecal occult blood test 11,725 17,805 13,656 10,463 5,691
Flexible sigmoidoscopy every 5 years 12,477 15,630 12,804 39,359 19,058
Flexible sigmoidoscopy every 5 years 13,792 22,518 18,693 n.a. 17,942
and annual fecal occult blood test
Double-contrast barium enema every 5 years 11,168 21,712 25,624 n.a. n.a.
Colonoscopy every 10 years 10,933 21,889 22,012 11,840 9,038
Source: Pignone and others 2002.
n.a.  not applicable.
Note: All costs and life years are discounted at 3 percent, except in the study by Wagner and others (1996), who use a discount rate of 5 percent.
and Goldie (2002) reported similar results for this same strate-
gy (US$20,300 per YLS conducted every five years, US$59,600
per YLS every three years, and US$174,200 every two years).
The analyses, which included strategies that employed both fre-
quent screening and screening tests with higher sensitivity,
often found the cost-effectiveness of frequent screening to be
even less attractive. For example, Goldie, Kim, and Wright
(2004) reported annual screening with combined cytology and
HPV DNA testing in women over age 30 exceeded US$1 mil-
lion per YLS compared to every two years. Although many
analyses find that extending the age range to the very young,
the very old, or both can be less cost-effective, for certain
women in high-risk groups, including older, uninsured women
who have never been screened, screening for cervical cancer at
older ages can be cost-effective.
The analyses conducted in low-income countries focused
on assessing the cost-effectiveness of an expanded set of strate-
gies that included alternatives to conventional cytology. In
addition, these analyses—unlike those in developed regions—
often raised issues of feasibility, affordability, cultural context,
accessibility, and equity.
In one of the earliest stochastic modeling evaluations of cer-
vical cancer screening programs in developing regions,
Sherlaw-Johnson, Gallivan, and Jenkins (1997) explored the
effectiveness of cytology and HPV testing in the context of
infrequent screening. They reported that the most efficient use
of resources would be to concentrate cervical cancer screening
efforts on women age 30 to 59 at least once per lifetime,
because such blanket screening would reduce the incidence of
invasive cervical cancer by up to 30 percent.
In an analysis focused on cervical cancer control in
Vietnam, Suba and others (2001) reported that, because of the
low direct medical costs associated with Vietnam’s cervical
cytology program, such a program appeared to be attractive for
that country. They found that total costs to establish a nation-
wide Pap screening program based on five-year intervals aver-
aged less than US$148,000 annually during the 10 years the
authors assumed would be necessary to develop the program.
Assuming 70 percent participation in the program, the authors
found the cost-effectiveness ratio for cervical cytology screen-
ing, compared with no screening, to be US$725 per discounted
YLS.
Goldie and others (2001) assessed the cost-effectiveness of
several cervical cancer screening strategies in previously
unscreened 30-year-old South African women. Screening tests
included VIA, cytology, and HPV DNA testing. Strategies dif-
fered by the number of clinic visits required, frequency of
screening and individual’s age at the time of screening, and
response to a positive test result. The authors found that when
all strategies were considered to be equally available and were
compared incrementally, HPV DNA testing was always more
effective and less costly than cytology and generally more effec-
tive but more costly than VIA. They found that, in comparison
with no screening, a single lifetime VIA screen at age 35, cou-
pled with immediate treatment of women with positive results,
resulted in a cost saving of US$39 per YLS as compared with a
two-visit HPV, although programmatic costs were not consid-
ered. Using sensitivity analysis, the authors find the choice
between using HPV DNA testing or VIA depended on the rel-
ative costs and sensitivity of the two tests and on the percentage
of women lost to follow-up between the first and second visit.
Mandelblatt, Lawrence, Gaffikin, and others (2002) used a
simulation model to compare seven cervical cancer screening
techniques in Thailand. Comparing each strategy to the next
less expensive alternative, the authors found that VIA per-
formed at five-year intervals in women age 35 to 55, followed
by immediate treatment of abnormalities, was the least expen-
sive option and saved the greatest number of lives.
The Alliance for Cervical Cancer Prevention used primary
data from studies conducted in India, Kenya, Peru, South
Africa, and Thailand to develop a series of standardized,
country-specific cost-effectiveness analyses. The costs and ben-
efits associated with alternative strategies to reduce cervical
cancer mortality were estimated for these five countries with
different epidemiological profiles by integrating country-
specific data from each site and using a standardized set of
assumptions agreed on by an expert panel with experience in
each country (Goldie, Gaffikin, and others 2004). In all five
countries, lifetime cancer risk was reduced by approximately 25
to 35 percent with a single lifetime screen using either one-visit
VIA or two-visit HPV DNA testing targeted at women age 35
to 40. Risk was reduced by more than 50 percent if screening
was performed two or three times per lifetime. Although the
cost of screening differed considerably between the countries,
strategies were identified that, when performed two or three
times per lifetime, would be considered extremely cost-effective
depending on the individual country’s per capita gross domes-
tic product.
We conducted an exploratory analysis to evaluate the poten-
tial cost-effectiveness of cervical cancer screening strategies in
Brazil, Madagascar, and Zimbabwe using computer-based sim-
ulation models calibrated to age-specific cervical cancer inci-
dence and mortality in each country, along with published
data. We evaluated once-in-a-lifetime screening between age 35
and 40 with (a) one-visit VIA, with screening and treatment
conducted during the same visit; (b) two-visit HPV DNA
screening, with HPV DNA testing during the first visit followed
by treatment of screen-positive women during the second visit;
and (c) three-visit cervical cytology screening, with a cytology
sample obtained during the first visit, colposcopy for screen-
positive women conducted during the second visit, and treat-
ment provided during the third visit. We assumed that for the
one- and two-visit strategies, women who screened positive
and were eligible for cryotherapy were treated immediately, but
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those ineligible for cryotherapy were referred for colposcopy
and diagnostic workup.
We estimated direct medical costs using data from the liter-
ature and unit costs provided by the volume editors and WHO.
All costs for the analysis are presented in 2000 dollars. We esti-
mated patients’ time costs and direct nonmedical costs using
our own previous work and wage estimates based on World
Bank data on per capita gross national income (WHO n.d.) and
wage estimate regressions developed by the U.S. Department of
Commerce. Table 29.3 presents the results of our analysis.
Lifetime costs per individual screened are given in interna-
tional dollars. Cost-effectiveness ratios are provided in U.S. dol-
lars as well as international dollars to facilitate comparison to
other studies.The available data show that cervical cancer screen-
ing conducted once, twice, or three times in a lifetime can have a
significant effect on the lifetime risk of cervical cancer compared
with no screening. For countries with limited resources, screen-
ing efforts should target women age 35 or older; strategies should
focus on screening all women at least once in their lifetime before
increasing the frequency of screening; and countries should con-
sider alternative approaches to the conventional three-visit cer-
vical cytology screening techniques—for example, single-visit
VIA, followed by immediate treatment, or HPV DNA testing or
cervical cytology followed by treatment at a second visit. Note
that all screening tests may not be equally available in low-
resource settings and that certain screening tests may be selected
because of cultural preferences or for programmatic reasons.
Implementing cervical cancer screening programs on the basis of
VIA, HPV DNA testing, or cytology requires different types of
resources,and the relative availability of these resources in differ-
ent settings will affect the choice of strategy.
Screening for Breast Cancer. Methods for early detection of
breast cancer include screening by mammography, clinical
breast examination (CBE), and breast self-examination.
Screening by mammography, CBE, or both may decrease breast
cancer mortality, but uncertainty about the magnitude of the
benefit remains because the quality of the evidence varies and
results are inconsistent (Humphrey and others 2002). Recent
controlled studies of organized breast self-examination pro-
grams indicate that this approach is not effective (Semiglazov
and others 1999; Thomas and others 2002).
A randomized controlled trial of CBE screening for breast
cancer began in Manila in 1995, but the intervention was
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Table 29.3 Economic Outcomes of Once-in-a-Lifetime Cervical Cancer Screening Programs, Brazil, Madagascar,
and Zimbabwe
Category No screening One-visit VIA Two-visit HPV DNA testing Three-visit cytology
Brazil
Lifetime cost (international $) 68.41 75.08 77.43 121.12
Cost-effectiveness ratio (international $/YLS)* n.a. 113 155 1430
Cost-effectiveness ratio (US$/YLS) n.a. 54 118 572
Life expectancy gain per 1 million screened n.a. 59,100 58,200 36,900
Number of deaths averted per 1 million screened n.a. 10,399 10,235 6,411
Number of DALYs averted per 1 million screened n.a. 56,646 55,751 35,174
Madagascar
Lifetime cost (international $) 25.22 32.98 40.41 51.91
Cost-effectiveness ratio (international $/YLS)* n.a. 167 332 921
Cost-effectiveness ratio (US$/YLS) n.a. 52 162 368
Life expectancy gain per 1 million women screened n.a. 46,500 45,800 29,000
Number of deaths averted per 1 million women screened n.a. 8,815 8,676 5,438
Number of DALYs averted per 1 million women screened n.a. 42,424 41,754 26,352
Zimbabwe
Lifetime cost (international $) 31.10 39.69 44.81 61.93
Cost-effectiveness ratio (international $/YLS)* n.a. 140 227 803
Cost-effectiveness ratio (US$/YLS) n.a. 42 114 321
Life expectancy gain per 1 million screened n.a. 61,300 60,400 38,400
Number of deaths averted per 1 million screened n.a. 10,412 10,248 6,419
Number of DALYs averted per 1 million screened n.a. 53,770 52,921 33,472
Source: Authors’ calculations.
n.a.  not applicable.
*Converted from national currency, using purchasing power parity (PPP) exchange rates.
discontinued after the first round because compliance with
referral among women who were found to have a breast lump
was extremely low (21 percent) and attempts to improve com-
pliance failed. Analysis of the incidence of cancer cases in 1999
shows that the screening intervention succeeded in detecting
more localized breast tumors, but the low compliance with
referral and low yield of early cancers meant that the early
detection program could not succeed in preventing deaths
from breast cancer (International Agency for Research on
Cancer n.d.).
Numerous cost-effectiveness studies of breast cancer
screening programs have been conducted in developed coun-
tries (Vainio and Bianchini 2002a). Most cost-effectiveness
studies of mammography screening in Europe yield cost-
effectiveness ratios in the range of US$3,000 to US$10,000 per
YLS, whereas those in the United States yield far less favorable
cost-effectiveness ratios, ranging from US$20,000 to
US$100,000 per YLS (table 29.4).
To investigate the potential cost-effectiveness of CBE and
mammography for India, we used a microsimulation model of
breast cancer screening (van Oortmarssen and others 1990).
The model simulates individual life histories of disease states,
and consequences of screening are calculated by comparing the
histories with and without screening intervention for each
individual. For our purposes, we assumed a population of 1 mil-
lion Indian women with the age distribution of the country
in 2000 (United Nations Population Division 2003). We
assumed that the screening program would last for 25 years
and would have an attendance rate of 100 percent. We
expressed the effects of screening as the reduction in the num-
ber of deaths caused by breast cancer and the number of life
years gained because of the screening program. Costs and
effects were discounted at a rate of 3 percent.
We estimated the model’s parameters using data from Dutch
screening projects (Collette and others 1992; Vervoort and oth-
ers 2004). We used trial results to estimate the effectiveness of
mammography in reducing breast cancer mortality (de Koning
and others 1995). We based sensitivity estimates of CBE on data
from Rijnsburger and others (2004) and based alternative
(lower) estimates on data from Bobo, Lee, and Thames (2000)
and Rijnsburger and others (forthcoming). We calibrated the
model so that it would correctly predict the age-specific inci-
dence and mortality of breast cancer in India (Ferlay and
others 2001) and its stage distribution at clinical diagnosis
(Sankaranarayanan, Black, and Parkin 1998). Details of these
methods are available elsewhere (Lamberts and others 2004).
We calculated total costs by comparing the differential costs
of breast cancer screening, diagnosis, initial therapy, adjuvant
therapy, follow-up, and advanced disease in the case of screen-
ing versus no screening. We calculated component costs by
multiplying the estimated resource use by the estimated costs
per unit for each health care input. Reliable cost data for India
were limited, so we extrapolated estimates from Dutch unit
costs (Mulligan and others 2003). For the analysis discussed
above, we calculated costs based on a market-basket approach.
The overall incidence of breast cancer is lower in India than
in Western countries. The relationship between the incidence
of breast cancer and age also differs: in Western countries, the
incidence of breast cancer increases with age, whereas in India,
it decreases with age, beginning at age 50. Investigators have
generally attributed this finding to a cohort effect: breast can-
cer is more common among younger cohorts than older
cohorts. The stage at which breast cancer is diagnosed is much
less favorable in India than in Western countries.
Table 29.5 presents the results of our exploratory cost-
effectiveness analysis of various breast cancer screening pro-
grams involving CBE or mammography for a population of
1 million women in India. As the table shows, biennial CBE
from age 40 to 60 costs US$2.6 million, averts 358 breast can-
cer deaths, prevents the loss of 4,896 life years, and has a cost-
effectiveness ratio of US$522 per YLS in comparison with no
screening. Biennial CBE from age 50 to 70 is less favorable in
terms of cost-effectiveness: US$582 per YLS.
The cost-effectiveness ratios for biennial mammography
screening are not as favorable as those for biennial CBE screen-
ing. Annual CBE screening results in almost the same number
of life years saved as biennial mammography screening at
36 percent of the cost.
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Table 29.4 Estimates of the Cost-Effectiveness of Breast
Cancer Screening Every Two Years for Women in Selected
Developed Countries
Age of Cost-
women being effectiveness 
Country screened (years) ratio (US$/YLS)a
Australia (de Koning 2000) 50–69 7,680
France (de Koning 2000) 50–69 4,580
Germany (de Koning 2000) 50–69 8,880
Netherlands (de Koning 2000) 50–69 3,140
Norway (Norum 1999) 50–69 14,790
Spain (de Koning 2000) 50–69 6,590
Spain, Catalonia (de Koning 2000) 50–69 4,400
Spain, Navarra (de Koning 2000) 45–65 2,450
United Kingdom (de Koning 2000) 50–69 2,680
United Kingdom (northwest) 50–64 3,650
(de Koning 2000)
United States (M. Brown and 50–69 34,600
Fintor 1993) 
United States (Simpson and 50–64 20,611
Snyder 1991)
Source: M. Brown and Fintor 1993; de Koning 2000; Norum 1999; Simpson and Snyder 1991.
Note: The discount rate used was 5 percent.
a. Converted from euros to U.S. dollars, using the exchange rate €1  US$0.925.
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Table 29.5 Cost-Effectiveness Analysis of Various Breast Cancer Screening Programs Involving Either CBE or Mammography
for a Population of 1 Million Women, Compared with No Screening, India
Base model: CBE once Biennial Biennial One lifetime 
biennial CBE, Annual CBE, Biennial CBE, every 5 years, mammography, mammography, mammogram, 
Category ages 40–60 ages 40–60 ages 50–70 ages 40–60 ages 40–60 ages 50–70 age 50
Effectiveness
Number of screening 2,319,839 4,426,854 1,620,568 1,056,544 2,318,641 1,619,051 212,008
tests performed
Number of cancers 1,689 2,330 1,683 938 2,561 2,649 465
detected by screening
Number of deaths averted 358 528 313 184 599 557 105
Number of life years saved 4,896 7,242 3,464 2,462 7,955 6,180 1,422
Percentage reduction in 7.8 11.4 6.8 4.0 13.0 12.1 2.3 
mortality 
Number of screening tests 6,473 8,385 5,170 5,730 3,868 2,909 2,028
per death averted
Number of screening tests 474 611 468 429 291 262 149
per life year saved 
Number of screening tests 1,373 1,900 963 1,127 906 611 456
per cancer detected
Cost-effectiveness
Differential costs (2001 US$) 2,553,425 5,230,303 2,017,186 1,108,883 14,681,387 10,559,356 1,282,024
Cost per death prevented 7,125 9,907 6,435 6,014 24,493 18,970 12,262
(2001 US$) 
Cost per life year saved 522 722 582 450 1,846 1,709 902
(2001 US$) 
Source: Authors’ calculations. 
Note: The discount rate used was 3 percent.
Table 29.6 shows the results of our sensitivity analysis for the
exploratory cost-effectiveness analysis of breast cancer screening
in India. Cost-effectiveness ratios are lower when the incidence of
cancer is higher, as in Bombay. Cost-effectiveness ratios are 32
and 16 percent higher, respectively, with a lower sensitivity of
CBE and when the averted costs of palliative treatment are not
included. Using alternative approaches to estimate screening pro-
gram costs has a major effect, resulting in cost-effectiveness esti-
mates 6 to 11 times higher than the base case analysis. This result
underlines the need for economic studies that can obtain reliable
data from primary sources on the true resource costs of cancer
control interventions in developing countries. With data from
such studies, researchers would not have to continue to rely on
extrapolating cost estimates from data in developed countries.
These results depend critically on assumptions about the
efficacy of CBE, for which the evidence is limited, highlighting
the need for controlled studies of CBE in developing countries.
Our estimates indicate that the cost-effectiveness of screening
mammography in India compares favorably, in absolute terms,
with breast cancer screening in developed countries.
Nevertheless, screening mammography for breast cancer is
likely to be less cost-effective in a country such as India than
is screening for cervical cancer.
Cancer Treatment and Palliative Care 
Barnum and Greenberg (1993) used an indirect approach to
estimate the cost-effectiveness of initial cancer treatment in devel-
oping countries. They assumed that they could estimate the effec-
tiveness of initial cancer treatment by comparing cancer survival
in the United States for the period 1975–80 with the period
1940–45.The logic of such a comparison is that major advances in
cancer diagnosis, surgery, radiation, and chemotherapy occurred
during the intervening period, and thus survival in the 1940–45
period could be equated to outcomes expected to result from no
treatment or ineffective treatment. Barnum and Greenberg’s
results indicated a cost-effectiveness ratio of the following:
• US$1,300 to US$6,200 per YLS for initial treatment of the
more treatable cancers, that is, cervical, breast, oral cavity,
and colorectal cancer
• US$53,000 to US$163,000 per YLS for initial treatment of
the less treatable cancers, that is, liver, lung, stomach, and
esophageal cancer.
The following subsections review cost-effectiveness studies
performed on selected adjuvant or palliative cancer treatments
that have been studied extensively in controlled clinical trials.
Breast Cancer Treatment Interventions. The following para-
graphs review studies of the cost-effectiveness of adjuvant sys-
temic therapy for early-stage breast cancer and of radiation
therapy following mastectomy and chemotherapy to treat
node-positive breast cancer in premenopausal women.
T. Smith and Hillner (2000), relying on results from the
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG
1998), modeled the natural history of breast cancer in pre-
menopausal 45-year-old women in the United States who were
diagnosed with early-stage breast cancer and treated with
tamoxifen, chemotherapy, or both. Table 29.7 summarizes the
cost-effectiveness of various breast cancer treatments. Smith
and Hillner’s cost-effectiveness estimates for single-modality
systemic adjuvant therapy for breast cancer are about the same
order of magnitude as Barnum and Greenberg’s (1993) esti-
mates of cost-effectiveness for initial therapy of breast cancer
(about US$7,300 per YLS in 2000 dollars). Other studies
(Malin and others 2002; Norum 2000) have yielded cost-
effectiveness estimates for chemotherapy and hormonal therapy
two to three times more favorable than Smith and Hillner’s
estimates. The more favorable estimates are probably the result
of the investigators’ use of a discount rate of 3 percent instead
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Table 29.6 Sensitivity Analysis for Changes in Breast Cancer Incidence and Attendance Rate, CBE Sensitivity, No Palliative
Treatment, and Alternative Cost Estimates for a Population of 1 Million Women, Compared with No Screening, India
Base model: Incidence 
biennial CBE, of breast cancer, Attendance CBE No palliative
Category ages 40–60 Bombay rate, 70% sensitivitya treatment Method 1b Method 2c
Effectiveness
Number of screening 2,319,839 2,319,991 1,624,401 2,320,051 2,319,839 2,319,839 2,319,839
tests performed
Number of cancers 1,689 1,921 1,229 1,370 1,689 1,689 1,689
detected by screening
Number of deaths averted 358 405 255 286 358 358 358
Number of life years saved 4,896 5,400 3,483 3,893 4,896 4,896 4,896
Percentage reduction in mortality 7.8 6.9 5.5 6.2 7.8 7.8 7.8 
Number of screening tests 6,473 5,727 6,358 8,119 6,473 6,473 6,473
per death averted
Number of screening tests per 474 430 466 596 474 474 474
life year saved 
Number of screening tests per 1,373 1,208 1,322 1,693 1,373 1,373 1,373
cancer detected
Cost-effectiveness
Differential costs (2001 US$) 2,553,425 2,505,274 1,798,662 2,684,628 2,983,754 28,814,056 16,532,879
Cost per death prevented (2001 US$) 7,125 6,184 7,040 9,395 8,325 80,396 46,130
Cost per life year saved (2001 US$) 522 464 516 690 609 5,885 3,377
Source: Authors’ calculations.
Note: The discount rate used was 3 percent.
a. From Rijnsburger and others forthcoming.
b. Costs using 2001 prices in the Netherlands.
c. Costs using 2001 prices in the Netherlands multiplied by the ratio of gross domestic product shares spent on health care in India and the Netherlands, respectively.
Table 29.7 Cost-Effectiveness of Selected Breast Cancer Treatments for a Hypothetical Cohort of 45-Year-Old Premenopausal
Women with Early-Stage Breast Cancer, United States 
(cost in 2000 US$/quality-adjusted life year)
Node-negative, Node-negative, Node-positive, Node-positive, 
estrogen receptor– estrogen receptor– estrogen receptor– estrogen receptor–
Treatment positive negative positive negative
Tamoxifen 17,400 326,800 6,600 88,300
Chemotherapy 17,400 7,600 14,000 7,500
Tamoxifen and chemotherapy 50,400 131,600 22,600 123,200
Source: T. Smith and Hillner 1993.
Alternative cost 
estimation
of 5 percent and their assumption that the benefits of treat-
ment continue over a longer period of time.
Two U.S. studies (Lee and others 2002; Marks and others
1999) have estimated the cost-effectiveness ratio for radiation
therapy following mastectomy and chemotherapy for node-
positive breast cancer in premenopausal women to be in the
range of US$22,600 to US$43,000 per quality-adjusted life year
(adjusted to 2000 U.S. dollars, with a discount rate of 3 per-
cent). Results were sensitive to treatment costs, survival benefit,
and patient time costs.
The clinical trials of postmastectomy radiation on which the
two U.S. studies are based compared radiation following sur-
gery plus chemotherapy with surgery plus chemotherapy
alone. Love and others (2003), however, offer observational
evidence that radiation treatment may also extend survival
for Chinese and Vietnamese women when administered to
patients with one to three positive nodes following mastectomy
alone or mastectomy combined with oophorectomy and
tamoxifen. If these benefits were confirmed, postmastectomy
radiation might be cost-effective in developing countries,
where the cost of radiation treatment is lower than in most
developed countries.
Colorectal Cancer Treatment Interventions. As concerns col-
orectal cancer, investigators have carried out cost-effectiveness
studies on surgical techniques, adjuvant treatment, follow-up
monitoring for recurrence, and treatment of advanced disease
(van den Hout and others 2002). Brown, Nayfield, and Shibley
(1994) estimate that the cost-effectiveness of adjuvant
chemotherapy for stage three colon cancer ranges from
US$3,000 to US$7,000 per YLS (adjusted to 2000 U.S. dollars,
with a discount rate of 6 percent). R. Smith and others’ (1993)
study conducted in the Australian health care setting obtains
similar results in terms of cost per YLS but yields substantially
higher costs per quality-adjusted life year.
Dahlberg and others’ (2002) cost-effectiveness study, which
relies on cost and clinical outcome data from the Swedish
Rectal Cancer Trial (1997), demonstrates that rectal cancer
patients receiving preoperative radiation therapy had improved
cancer-specific and overall survival rates, as well as reduced
local rectal cancer recurrence rates. They estimate the overall
cost-effectiveness of preoperative radiation therapy for rectal
cancer patients to be US$3,654 per YLS (in 2001 U.S. dollars,
using a discount rate of 3 percent). In a sensitivity analysis,
which varied the rates of local rectal cancer recurrence and the
survival advantage with and without radiation treatment, cost-
effectiveness ratios for preoperative radiation therapy for
patients with rectal cancer ranged from US$908 to US$15,228
per YLS.
Cervical Cancer Treatment Interventions. Five recent phase 3
trials indicate that a new alternative therapy—cisplatin-based
chemoradiation—is more effective than standard therapy
using radiation alone in the treatment of advanced cervical
cancer (Rose and Lappas 2000). Using an economic model,
Rose and Lappas apply unit costs to resource allocation data
derived from the cisplatin-based chemoradiation arms of the
five randomized trials and examine the benefits in terms of
increased median survival time. Costs per YLS for cisplatin-
based chemoradiation regimens varied from US$2,384 to
US$28,770 on the basis of published survival and from US$308
to US$3,712 on the basis of estimated survival. Although
chemoradiation for advanced cervical cancer would probably
be considered cost-effective in most developed countries,
analyses that take local treatment settings into account are
needed to determine if this result also holds for developing
countries.
Palliative Care Interventions. The most basic approach to pal-
liative care for terminally ill cancer patients, especially in low-
resource settings, involves using inexpensive oral analgesics,
ranging from aspirin to opiates, depending on individual
patients’ needs. Unfortunately, sufficient supplies of opioid
drugs for use in palliative care are often not available in develop-
ing countries because of regulatory or pricing obstacles, igno-
rance, or false beliefs (for more information see http://www.
medsch.wisc.edu/painpolicy/index.htm and chapter 52).
Appropriate palliative care for cancer patients may involve
a variety of other treatment modalities, including antiemetic
drugs to relieve the side effects of chemotherapy, radiation to
effect temporary tumor regression, and physical therapy to
alleviate disability related to lymphedema following breast can-
cer surgery. Berthelot and others’ (2000) study combines infor-
mation from several clinical trials and Canadian treatment cost
information to perform cost-effectiveness analyses of different
ambulatory chemotherapy regimens used for patients with
metastatic non-small-cell lung cancer to palliate symptoms and
modestly improve survival. They report that vinblastine plus
cisplatin resulted in both better survival and lower health care
expenditures than best supportive care because it resulted in
fewer episodes of rehospitalization.
Van den Hout and others’ (2003) study examines the cost-
effectiveness of single-fraction versus multiple-fraction radio-
therapy for palliative treatment of cancer patients with painful
bone metastases. They find that overall medical and social costs
for single-fraction radiotherapy for palliative therapy—
US$1,144 per patient in medical costs and US$1,753 per
patient in total social costs—were lower than comparable costs
for multiple-fraction radiotherapy, despite the higher rate of
retreatment associated with single-fraction radiotherapy.
Whether those results are directly applicable to radiation
treatment in developing countries, where single-fraction radia-
tion treatment may be relatively less effective, is unknown.
Nonetheless, the results strongly suggest that single-fraction
Health Service Interventions for Cancer Control in Developing Countries | 581
radiotherapy may be an acceptable, if not preferred, choice of
palliative treatment in settings where resources for radiation
treatment are relatively scarce and the need for palliative treat-
ment is relatively high.
APPLICABILITY OF COST-EFFECTIVENESS
STUDIES FROM DEVELOPED TO
DEVELOPING COUNTRIES
Many of the cost-effectiveness studies of cancer control inter-
ventions (prevention, screening, and treatment) have been per-
formed in the context of high-income, developed countries;
thus, the question arises whether such studies are applicable to
health care delivery settings in developing countries. No simple
rule is available to indicate how the results of cost-effectiveness
studies in developed countries might translate to health care
delivery settings in developing countries, but disease incidence
and time horizon are major pertinent considerations in rela-
tion to cancer prevention and screening interventions. In rela-
tion to cancer treatment, other considerations have to be taken
into account.
Factors Affecting the Applicability of Cost-Effectiveness
Studies of Prevention and Screening 
Cost-effectiveness analyses of cancer prevention and screening
interventions are complex.Several parameters have a large influ-
ence on the results of these studies, including the following:
• age-specific cancer incidence 
• all-cause life expectancy and temporal trends of major
epidemics 
• population age structure 
• availability, effectiveness, and costs of cancer treatment
• health system costs of the prevention or screening
intervention.
As illustrated by the several examples described in this
chapter, those parameters are likely to vary widely between
developed and developing countries.
For example, age-specific cancer incidence in the absence of
a preventive or screening intervention can have a major influ-
ence on the potential cost-effectiveness of a cancer prevention
or screening intervention. Generally, the higher the back-
ground incidence of the cancer, the more cost-effective the can-
cer prevention or screening intervention will be. For that rea-
son, the relative cancer incidence patterns in developed and
developing countries for the cancer screening interventions
described earlier need to be considered.
Figure 29.3 shows age-specific cancer incidence patterns for
cervical and breast cancer for developed and developing
countries. As the figure shows, the incidence of cervical cancer
in developing countries is relatively high in comparison with
the incidence of these cancers in developed countries, whereas
the incidence of breast cancer is relatively low in developing
countries compared with that in developed countries. Given
the relatively high incidence of cervical cancer in developing
countries, interventions for cervical cancer prevention and
screening are likely to be more cost-effective in developing
countries rather than developed countries, compared with
interventions for breast cancer, all else being equal.
Factors Affecting the Applicability of Cost-Effectiveness
Studies of Treatment 
Many of the treatments for breast, colorectal, and lung cancer
that have been shown to be efficacious in controlled clinical tri-
als have been estimated to have cost-effectiveness ratios in the
range of a few thousand U.S. dollars to a few tens of thousands
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of U.S. dollars per YLS. This range is considered quite favorable
in developed countries but might be viewed as less favorable in
low- and middle-income countries that face stringent con-
straints on health care resources. Disease incidence and time
horizon do not loom as major considerations in the case of the
cost-effectiveness of cancer treatment, because the cost of
treatment applies only to those individuals already diagnosed
with cancer and considered eligible for a specific treatment, not
to a broader population considered to be at risk for developing
cancer.
Thus, in low-income, low-cost countries with high
mortality rates, because of the lack of primary treatment, the
provision of basic cancer treatment may be a cost-effective first
step toward cancer control, especially for highly treatable can-
cers with relatively low incidence in developing countries. For
example, using a generalized cost-effectiveness approach,
Ginsberg and others (2004) conclude that the provision of
basic treatment for colorectal cancer in low-income African
countries is likely to be a cost-effective first step toward cancer
control.
Nevertheless, issues of economies of scale and scope may be
associated with fixed investments in specialized medical equip-
ment and skilled human capital. The centralization and region-
alization of cancer treatment may be associated with a higher
technical quality of care and might also be associated with the
need to use these resources at economically efficient levels.
Some cost elements, such as local labor and the availability of
generic drugs since initial clinical trials were conducted, will
clearly be lower in the contemporary setting of developing
countries than in many of the cost-effectiveness studies
reviewed earlier.
Finally, developments in cancer treatment, especially in rela-
tion to chemotherapy, are extremely dynamic. For example, the
1999 WHO list of essential drugs for cancer therapy (Sikora
and others 1999; WHO 2003a), includes 5-fluorouracil as a pri-
ority one (essential) drug and irinotecan as a priority three
(palliative benefit only) drug for the treatment of colorectal
cancer. Just five years later, in many developed countries the
following drugs, in addition to irinotecan, have been added
to the basic regimen of 5-fluorouracil plus leucovorin for
the treatment of colorectal cancer: oxaliplatin, bevacizumab,
and cetuximab. Whereas 5-fluorouracil-based treatment of
metastatic colorectal cancer increased median survival from 8
to 12 months, the newer drugs increase median survival to 21
months or more, at a significantly increased economic cost.
In the United States, the drug cost of 5-fluorouracil-based
therapy ranges from US$63 to US$263 for the initial eight
weeks of therapy. Adding irinotecan or oxaliplatin increases the
drug cost to about US$10,000, and adding bevacizumab or
cetuximab adds another US$20,000 to US$30,000 to the cost of
initial treatment. If the latter drugs are used over the longer
term as envisioned, the average cost of supplying the drugs to a
single patient could approach US$300,000. Those estimates do
not consider the additional costs of chemotherapy preparation,
administration, and supervision and supportive care (Schrag
2004). The situation is similar for other common cancers.
Clearly, low- and middle-income countries cannot afford to
make the newest cancer drugs widely available to cancer
patients; however, this example illustrates the need for periodic
updating of available chemotherapy options along with evalu-
ations of the incremental costs and benefits associated with
them.
RESEARCH AGENDA
Knowledge about the feasibility, effectiveness, and cost-
effectiveness of cancer control interventions by health services
in developing countries is extremely limited, partly because of
the relative paucity of active research in this area. Work in the
area of descriptive epidemiology, especially work based on
cancer registry data, dominates the research literature on can-
cer in developing countries. A second body of literature con-
sists of comparative epidemiology and case-control studies
designed to assess the importance of various risk factors for
cancer.
Although information from such studies is an essential first
step for characterizing the nature and extent of the cancer bur-
den and for monitoring the ultimate effect of cancer control
interventions, it does not provide a sufficient knowledge base
for designing and implementing cancer control programs. For
progress to be made for developing countries, much more work
is needed in the following areas:
• Clinical evaluation studies of cancer control interventions in
developing countries. Clinical evaluation studies of preven-
tive, screening, and treatment interventions that are specifi-
cally tailored to the needs and conditions of developing
countries would be useful, including controlled clinical tri-
als where possible.
• Health services research in developing countries. Health serv-
ices research designed to characterize the amount, distribu-
tion, and organizational structure of health sector resources
in developing countries would be helpful, along with
research to fill the gaps between current resource endow-
ments and the amount of funding that would be needed to
implement the minimally acceptable level of effective cancer
control. In developing countries, shortages of the equipment
and personnel needed to administer radiotherapy for can-
cer, for example, have been well documented (Levin,
Meghzifene, and Tatsuzaki 2001). However, no systematic
analyses are available outside developed countries (Owen,
Coia, and Hanks 1997) that project radiotherapy resource
needs in terms of clinically effective applications of
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radiotherapy, both by cancer site and by the known effec-
tiveness of radiotherapy for primary treatment, adjuvant
therapy, and palliative care. Similarly, even though
researchers have carried out patterns of care studies that
characterize the dissemination of radiation, chemotherapy,
and hormonal therapy in many developed countries, com-
parable information for developing countries is generally
unavailable. Health services research studies could also con-
tribute important information about the current structure
and organization of primary, secondary, and tertiary care in
specific developing countries, with the ultimate aim of mod-
eling and implementing cancer control delivery systems that
either are integrated with or supplement existing care deliv-
ery systems. Studies of this type are needed to ensure that
there is a balance, for example, between resources devoted to
screening and those devoted to diagnostic follow-up and
treatment. The disappointing performance of cervical can-
cer screening programs in many developing countries has
been due in part to the lack of effective diagnostic follow-up
and treatment following screening.
• Country-specific economic evaluation studies. Country-
specific studies need to be done that assess resource require-
ments, economic costs, effectiveness, and ultimately cost-
effectiveness of cancer control interventions adapted or
tailored to the needs and requirements of low- and middle-
income settings. Heuristic extrapolation is a first analytical
step in this direction, but such studies can indicate only
whether more direct and realistic studies are needed.
• Studies of innovative health care information and communica-
tions technology. More research is needed to determine if tech-
nological advances, such as computerized image reading or
long-distance consultation by oncology specialists, facilitated
by telemedicine communications technology, might alter
the cost-effectiveness equation by raising quality, by lowering
costs, or both. For remote localities or small, low-income
developing countries, training and employing local expertise
or advanced equipment for every aspect of cancer control
may not be necessary if advanced communication and
information technology could be used to facilitate virtual
collaboration.
CONCLUSIONS
Our ability to draw any conclusions about the cost-effectiveness
of cancer control interventions for low- and middle-income
developing countries is limited, because most cost-effectiveness
studies in this area have been conducted in high-income, devel-
oped countries. Cancer control interventions that appear to be
cost-effective in high-income countries may not be cost-
effective in low-income countries, even when the lower cost of
providing health services is taken into account.
A useful way to draw inferences about the relative cross-
country affordability of interventions is to translate cost-
effectiveness ratios into percentage of per capita gross national
product (GNP) per YLS (WHO 2001a). Our preliminary
analysis of breast cancer screening in India, for example, sug-
gesting an absolute cost-effectiveness level for screening mam-
mography of about US$2,000 per YLS, compared with about
US$3,000 per YLS in the Netherlands. At about 10 percent per
capita GNP per YLS, screening mammography might be con-
sidered to be extremely cost-effective for the Netherlands. In
India, however, we found a CE estimate equal to 400 percent
per capita GNP per YLS suggesting that national policy makers
would be much less likely to consider screening mammography
as a viable intervention given India’s health care budget con-
straints. However, they might well consider a CBE breast can-
cer screening program, at about 200 percent per capita GNP
per YLS in India, to be moderately affordable if the program
were definitively established to be effective.
For middle-income developing countries that have cancer
incidence rates similar to those in high-income developed
countries, the results of cost-effectiveness analyses from the
developed countries may be more relevant, although further
analysis clearly is needed. The case study of cervical cancer con-
trol that was cited earlier suggests that for low-income coun-
tries tailored cancer control interventions may need to be
developed that would be both cost-effective and affordable.
However, that suggestion does not imply that low-tech
approaches should be uncritically embraced and assumed to be
cost-effective. Until recently, education campaigns to promote
breast self-examination were widely advocated as the low-tech
alternative to screening mammography for breast cancer con-
trol in low-income countries; however, the best current evi-
dence now indicates that such campaigns have no effect on
breast cancer mortality (Semiglazov and others 1999; Thomas
and others 2002).
In cancer treatment interventions, the cost-effectiveness of
initial surgical treatment for treatable cancers, such as breast,
cervical, and colorectal cancer, may be in the relatively favor-
able range of a few to several thousand dollars per YLS, which
indicates that such interventions are likely to be cost-effective
for middle-income countries and are possibly cost-effective for
low-income countries. Although cost-effectiveness ratios for
some of the approaches to adjuvant therapy that use conven-
tional radiation and drugs also fall within this relatively favor-
able range, others are in the range of tens of thousands of
dollars for each YLS. Thus, these forms of treatment would
likely be considered potentially cost-effective and affordable in
middle-income countries but not in low-income countries;
however, more detailed examinations of specific cost condi-
tions and available resource endowments for the delivery of
cancer treatment services are needed to confirm these prelimi-
nary impressions. As with the case of cervical cancer control,
584 | Disease Control Priorities in Developing Countries | Martin L. Brown, Sue J. Goldie, Gerrit Draisma, and others
treatment interventions that are tailored to the conditions of
low-income countries might be shown to be efficacious and
more economically attractive than treatment approaches that
are transported directly from developed countries; however,
research in this area is lacking.
Time Horizon and a Balanced Approach to Cancer
Control Programs 
The time horizon for cancer prevention and screening inter-
ventions is highly relevant to policy makers and health system
planners, yet reports on the cost-effectiveness of such interven-
tions often omit information about time horizons. For exam-
ple, interventions that involve cancer control agents that pre-
vent cancer cases that would have otherwise occurred many
years after the preventive action, such as HPV vaccination, have
a long time horizon. Similarly, the favorable cost-effectiveness
of preventive screening for stomach cancer is not apparent
until four decades following the initiation of the intervention.
In the case of the 25-year program of CBE in India analyzed
earlier, only about 10 percent of the benefits in terms of breast
cancer deaths prevented would have been realized after 10 years
of program operation. Decision makers must understand and
take these time horizons into account when interpreting and
acting on cost-effectiveness ratios; however, the long time hori-
zon for cancer prevention and screening interventions is, in
itself, not an argument against the application of such inter-
ventions. In some cases, countries that are more recent entrants
into the field of cancer control may be able to benefit from the
experience of developed countries and from the dynamic tech-
nical progress in this area to go directly to new innovations. For
example, they might be able to implement HPV testing right
away as the basis for cervical cancer screening, bypassing
cervical cytology. Achieving the optimal temporal balance in
comprehensive cancer control represents a daunting challenge
to planning, evaluation, and implementation.
Start Small, Scale Up Smart
Because the current understanding of the effectiveness, optimal
resource mix, and cost of many cancer control interventions is
incomplete and uncertain, especially in relation to low- and
middle-income countries, developing countries should start
small. By starting small, they can gain knowledge from pilot
programs that are well documented with regard to organiza-
tional and process factors; that are conducted in controlled set-
tings, if possible; and that are monitored for efficiency, per-
formance, and effectiveness. Thus, for example, new screening
or treatment programs can be initiated in focused geographical
areas or specific facilities with known and well-characterized
target populations, and their performance and outcomes can
be compared with matched control areas or facilities.
Developing countries should consider scaling up their regional
or national programs only after the pilot programs have been
shown to perform well.
Starting small also might entail applying an initial pilot
program to a limited age range that is estimated to yield the
most benefits per resource use or to a limited group of high-risk
individuals defined by various risk characteristics, such as first-
degree relatives of people with cancer. Indeed, various versions
of this approach have characterized the dissemination of many
cancer control interventions in developed countries. Organized
breast cancer screening programs in some European countries,
for example, were first implemented as pilot programs in spe-
cific regions and evaluated against control communities
(Fracheboud and others 2001; Olsson and others 2000; van der
Maas 2001), and regional and national programs were initially
limited to the age groups, screening procedures, and screening
frequencies estimated to be the most cost-effective. The pro-
grams were later extended, in terms of more intensive proce-
dures, more frequent screening intervals, and wider age groups,
after monitoring and analysis of initial program performance
indicated that the incremental cost-effectiveness of these exten-
sions would be favorable (Boer and others 1995; Shapiro and
others 1998). The United Kingdom has taken a similar approach
to colorectal cancer screening (Steele and others 2001).
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NATURE AND DISTRIBUTION OF DIABETES
Diabetes is a metabolic disease characterized by hyperglycemia
resulting from defects in insulin secretion, insulin action, or
both (American Diabetes Association 2004).
Classification of Diabetes 
Diabetes takes three major forms. Type 1 diabetes results from
destruction of the beta cells in the pancreas, leading to absolute
insulin deficiency. It usually occurs in children and young
adults and requires insulin treatment. Type 2 diabetes, which
accounts for approximately 85 to 95 percent of all diagnosed
cases, is usually characterized by insulin resistance in which
target tissues do not use insulin properly. A third type of dia-
betes, gestational diabetes, is first recognized during pregnancy.
Other rare types of diabetes include those caused by genetic
conditions (for example, maturity-onset diabetes of youths),
surgery, drug use, malnutrition, infections, and other illnesses.
The Burden of Diabetes
Diabetes affects persons of all ages and races. The disease
reduces both a person’s quality of life and life expectancy and
imposes a large economic burden on the health care system and
on families.
Secular Trend and Projections. In 2003, the worldwide
prevalence of diabetes was estimated at 5.1 percent among
people age 20 to 79 (table 30.1). The prevalence of diabetes
was higher in developed countries than in developing coun-
tries. In the developing world, the prevalence was highest in
Europe and Central Asia and lowest in Sub-Saharan Africa.
Some of these variations may reflect differences in the age
structures and level of urbanization of the various popula-
tions. By 2025, the worldwide prevalence is projected to be 6.3
percent, a 24 percent increase compared with 2003. The
largest increase in prevalence by 2025 is expected to be in East
Asia and the Pacific, and the smallest in Sub-Saharan Africa.
In terms of those affected, the biggest increase in the devel-
oping countries is projected to take place among adults of
working age.
In 2003, 194 million people worldwide ages 20 to 79 had
diabetes, and by 2025, this number is projected to increase to
333 million, a 72 percent increase (table 30.1). The developing
world accounted for 141 million people with diabetes (72.5 per-
cent of the world total) in 2003. During the same period, the
number of people with diabetes is projected to double in three
of the six developing regions: the Middle East and North Africa,
South Asia, and Sub-Saharan Africa.
Diabetes-Related Mortality and Disability. The death rate
of men with diabetes is 1.9 times the rate for men without
diabetes, and the rate for women with diabetes is 2.6 times
that for women without diabetes (W. L. Lee and others
2000). Premature mortality caused by diabetes results in an
estimated 12 to 14 years of life lost (Manuel and Schultz
2004; Narayan and others 2003). Cardiovascular disease
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(CVD) causes up to 65 percent of all deaths in developed
countries of people with diabetes (Geiss, Herman, and Smith
1995).
The World Health Organization (WHO) estimates that, in
2001, 959,000 deaths worldwide were caused by diabetes,
accounting for 1.6 percent of all deaths, and approximately
3 percent of all deaths caused by noncommunicable diseases.
More recent estimates by WHO suggest that the actual num-
ber may be triple this estimate and that about two-thirds of
these deaths occur in developing countries (WHO 2004).
Within the developing regions, most deaths caused by diabetes
occurred in East Asia and the Pacific and the fewest in Sub-
Saharan Africa (table 30.1).
Diabetes-related complications include microvascular dis-
eases (for example, retinopathy, blindness, nephropathy, and
kidney failure) and macrovascular diseases (coronary heart dis-
ease, stroke, peripheral vascular disease, and lower-extremity
amputation). Those complications result in disability. In the
United States, a much higher proportion of people with dia-
betes than of people without diabetes have physical limitations:
66 percent compared with 29 percent (Ryerson and others
2003). Disabilities are even more pronounced among older
people (Gregg and others 2000).
The World Health Organization estimated that, in 2001, dia-
betes resulted in 19,996,000 disability-adjusted life years
(DALYs) worldwide. More than 80 percent of the DALYs result-
ing from diabetes were in developing countries (table 30.1).
East Asia and the Pacific had the largest burden, and the Middle
East and North Africa had the smallest burden. DALYs result-
ing from diabetes increased by 250 percent worldwide from
1990 to 2001 and by 266 percent for low- and middle-income
countries (Mathers and others 2000).
Economic Burden of Diabetes
Diabetes imposes large economic burdens on national
health care systems and affects both national economies and
individuals and their families. Direct medical costs include
resources used to treat the disease. Indirect costs include lost
productivity caused by morbidity, disability, and premature
mortality. Intangible costs refer to the reduced quality of life for
people with diabetes brought about by stress, pain, and anxiety.
Direct Medical Costs. Good data on the direct medical costs
of diabetes are not available for most developing countries.
Extrapolation from developed countries suggests that, in 2003,
the direct costs of diabetes worldwide for people age 20 to 79
totaled at least US$129 billion and may have been as high as
US$241 billion (table 30.1). In the developing world, the costs
were highest in Latin America and the Caribbean and lowest in
Sub-Saharan Africa. The direct health care costs of diabetes
range from 2.5 to 15.0 percent of annual health care budgets,
depending on local prevalence and sophistication of the treat-
ments available (International Diabetes Federation 2003b).
Indirect and Intangible Costs. In developing countries, the
indirect costs of diabetes are at least as high, or even higher,
than the direct medical costs (Barcelo and others 2003).
Because the largest predicted rise in the number of people with
diabetes in the next three decades will be among those in the
economically productive ages of 20 to 64 (King, Aubert, and
Herman 1998), the future indirect costs of diabetes will be even
larger than they are now.
Diabetes lowers people’s quality of life in many ways,
including their physical and social functioning and their
perceived physical and mental well-being. With a value of
Table 30.1 Estimated Numbers of People Age 20 to 79 with Diabetes, Mortality, DALYs, and Direct Medical Costs Attributable to
Diabetes, by Regions
Direct medical costs,
Disability-Number of people Prevalence 2003 (US$ million)
Deaths, adjusted life(thousands) (percent)
Low High 2001 years, 2001
Region 2003 2025 2003 2025 estimate estimate (thousands) (thousands)
Developing countries 140,849 264,405 4.5 5.9 12,304 23,127 757 15,804
East Asia and the Pacific 31,363 60,762 2.6 3.9 1,368 2,656 234 4,930
Europe and Central Asia 25,764 33,141 7.6 9.0 2,884 5,336 51 1,375
Latin America and the Caribbean 19,026 36,064 6.0 7.8 4,592 8,676 163 2,775
Middle East and North Africa 10,792 23,391 6.4 7.9 2,347 4,340 31 843
South Asia 46,309 94,848 5.9 7.7 840 1,589 196 4,433
Sub-Saharan Africa 7,595 16,199 2.4 2.8 273 530 82 1,448
Developed countries 53,337 68,345 7.8 9.2 116,365 217,760 202 4,192
World 194,186 332,750 5.1 6.3 128,669 240,887 959 19,996
Source: Number of persons with diabetes, prevalence of diabetes, and direct medical costs of diabetes, International Diabetes Federation 2003b; all other information, WHO 2004.
1 representing the health-related quality of life without illness
and 0 representing death, people with type 2 diabetes had a
value of 0.77 in the population of the United Kingdom
prospective diabetes study (Clarke, Gray, and Holman 2002).
Risk Factors for Diabetes
Risk factors for diabetes vary by disease type.
Type 1 Diabetes. Type 1 diabetes is most likely a polygenic dis-
ease, and a number of potential environmental risk factors have
been implicated—including dietary factors; breastfeeding; initi-
ation of bovine milk; infectious agents (for example, enterovirus,
rotavirus, and rubella); chemicals; and toxins—but the results
have been inconclusive (Akerblom and Knip 1998).
Type 2 Diabetes. The risk for type 2 diabetes is higher in
monozygotic twins and people with a family history of diabetes
(Rich 1990). This finding strongly suggests that genetic deter-
minants play a role, but so far few genes have been associated
with type 2 diabetes.
Environmental factors include prenatal factors, obesity,
physical inactivity, and dietary and socioeconomic factors
(Qiao and others 2004). Exposure to diabetes in utero increases
the risk of developing type 2 diabetes in early adulthood
(Dabelea and others 2000). Disproportionate growth and low
birthweight increase the risk of developing diabetes and insulin
resistance. In the postnatal environment, breastfeeding protects
against the development of obesity, insulin resistance, and dia-
betes (Pettitt and others 1997; Young and others 2002).
The strongest and most consistent risk factors for diabetes
and insulin resistance among different populations are obesity
and weight gain (Haffner 1998): for each unit increase in body
mass index, the risk of diabetes increases by 12 percent (Ford,
Williamson, and Liu 1997). The distribution of fat around the
trunk region, or central obesity, is also a strong risk factor for
diabetes (Yajnik 2001). Diabetes risk may be reduced by increas-
ing physical activity. Conversely, a sedentary lifestyle and physi-
cal inactivity are associated with increased risks of developing
diabetes (Hu and others 2003). Some studies report a positive
relationship between dietary fat and diabetes, but specific types
of fats and carbohydrates may be more important than total fat
or carbohydrate intake. Polyunsaturated fats and long-chain
omega-3 fatty acids found in fish oils (Adler and others 1994)
may reduce the risk of diabetes, and saturated fats and trans
fatty acids may increase the risk of diabetes (Hu, van Dam, and
Liu 2001). Sugar-sweetened beverages are associated with an
increased risk of diabetes (Schulze and others 2004). High
intakes of dietary fiber and of vegetables may reduce the risk of
diabetes (Fung and others 2002; Stevens and others 2002).
Increased affluence and Westernization have been associated
with an increase in the prevalence of diabetes in many
indigenous populations and in developing economies (Rowley
and others 1997; Williams and others 2001). Conversely, in
developed countries, those in lower socioeconomic groups
have a higher risk of obesity and consequently of type 2 diabetes
(Everson and others 2002). Surrogates for socioeconomic sta-
tus, such as level of education attained and income (Paeratakul
and others 2002; Robbins and others 2001) are inversely asso-
ciated with diabetes in high-income countries.
INTERVENTIONS AND DELIVERY MODES
Interventions against diabetes include those for preventing the
disease, those for detecting the disease in its asymptomatic stage,
and those for managing the disease to reduce its complications.
Preventing Type 1 Diabetes 
Not enough scientific evidence is available to indicate that
type 1 diabetes can be prevented, although various interven-
tions have been explored. Examples of tested interventions
include eliminating or delaying exposure to bovine protein and
using insulin or nicotinamide for people at high risk of devel-
oping the disease.
Preventing Type 2 Diabetes 
Four major trials—in China, Finland, Sweden, and the United
States—have demonstrated that intensive lifestyle interventions
involving a combination of diet and physical activity can delay
or prevent diabetes among people at high risk (Eriksson and
Lindgarde 1991; Knowler and others 2002; Pan and others 1997;
Tuomilehto and others 2001). In the largest randomized, con-
trolled trial to date, the Diabetes Prevention Program (Knowler
and others 2002), the goals of the intensive lifestyle intervention
were weight loss of 7 percent of baseline bodyweight through
a low-calorie diet and moderate physical activity for at least
150 minutes per week. After 2.8 years of follow-up, the average
weight loss was 4.5 kilograms for those in the lifestyle interven-
tion group and less than 0.3 kilograms for those in the placebo
group. The lifestyle intervention reduced the incidence of dia-
betes by 58 percent.
Pharmacological studies of diabetes prevention have been
reviewed in detail elsewhere (Kanaya and Narayan 2003). In
summary, a variety of specific medications have been tested
(for example, metformin, acarbose, orlistat, troglitazone,
angiotensin-converting enzyme [ACE] inhibitors, statins,
estrogens, and progestins) and have been found to lower dia-
betes incidence, but the expense, side effects, and cumulative
years of drug intervention are practical concerns. Except for the
Diabetes Prevention Program (Knowler and others 2002), no
trial of medication intervention has directly compared the
effectiveness of a drug to that of lifestyle modification.
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Screening for People with Diabetes or Prediabetes
The benefits of early detection of type 2 diabetes through
screening are not clearly documented, nor is the choice of the
appropriate screening test established. Questionnaires used
alone tend to work poorly; biochemical tests alone or in com-
bination with assessment of risk factors are a better alternative
(Engelgau, Narayan, and Herman 2000).
Managing Diabetes 
High-quality evidence exists for the efficacy of several current
treatments in reducing morbidity and mortality in people with
diabetes. These interventions are summarized in table 30.2.
In addition, a review of previous studies (Norris,
Engelgau, and Narayan 2001) found positive effects for short
follow-up (less than six months) of self-management training
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Table 30.2 Effectiveness and Cost-Effectiveness of Interventions for Preventing and Treating Diabetes in Developed Countries 
Strategy
Preventing diabetes
• Lifestyle interventions for preventing
type 2 diabetes 
• Metformin for preventing type 2 diabetes
Screening for diabetes
• Screening for type 2 diabetes in general
population
Treating diabetes and its complications
• Glycemic control in people with HbA1c
greater than 9 percent 
• Glycemic control in people with HbA1c
greater than 8 percent 
• Blood pressure control in people whose
pressure is higher than 160/95 mmHg 
• Cholesterol control in people with total
cholesterol greater than 200 milligrams/
deciliter 
• Smoking cessation with recommended
guidelines
• Annual screening for microalbuminuria 
• Annual eye examinations
• Foot care in people with high risk of ulcers 
• Aspirin use
• ACE inhibitor use in all people with 
diabetes 
• Influenza vaccinations among the elderly
for type 2 diabetes 
• Preconception care for women of
reproductive age
Benefit
Reduction of 35–58 percent in incidence among
people at high risk
Reduction of 25–31 percent in incidence among
people at high risk
Reduction of 25 percent in microvascular 
disease 
Reduction of 30 percent in microvascular disease
per 1 percent drop in HbA1c 
Reduction of 30 percent in microvascular disease
per 1 percent drop in HbA1c 
Reduction of 35 percent in macrovascular and
microvascular disease per 10 mmHg drop in
blood pressure 
Reduction of 25–55 percent in coronary heart
diseases events; 43 percent fall in death rate 
16 percent quitting rate 
Reduction of 50 percent in nephropathy using
ACE inhibitors for identified cases
Reduction of 60 to 70 percent in serious
vision loss
Reduction of 50 to 60 percent in serious foot 
disease 
Reduction of 28 percent in myocardial infarctions,
reduction of 18 percent in cardiovascular disease
Reduction of 42 percent in nephropathy; 
22 percent drop in cardiovascular disease 
Reduction of 32 percent in hospitalizations;
64 percent drop in respiratory conditions and 
death 
Reduction of 30 percent in hospital charges and 
25 percent in hospital days
Quality of
evidencea
I
I
III
I
I
I
II-1
I
III
I
I
I
I
II-2
II-2
Cost-effectiveness ratio 
(US$/QALY)b
1,100 (Diabetes Prevention Program Research
Group forthcoming)
31,200 (Diabetes Prevention Program Research
Group forthcoming)
73,500 (CDC Diabetes Cost-Effectiveness Study
Group 1998)
Cost saving (CDC Diabetes Cost-Effectiveness
Study Group 1998)
34,400 (CDC Diabetes Cost-Effectiveness Study
Group 1998; Klonoff and Schwartz 2000)
Cost saving (CDC Diabetes Cost-Effectiveness
Study Group 1998)
63,200 (CDC Diabetes Cost-Effectiveness Study
Group 1998)
12,500 (CDC Diabetes Cost-Effectiveness Study
Group 1998)
47,400 (Klonoff and Schwartz 2000)
6,000 (Klonoff and Schwartz 2000; Vijan, Hofer,
and Hayward 2000)
Cost saving (Ragnarson and Apelqvist 2001)
Not available
8,800 (Golan, Birkmeyer, and Welch 1999)
3,100 (Sorensen and others 2004)
Cost saving (Klonoff and Schwartz 2000)
Source: Authors.
Note: mmHg  millimeters of mercury; QALY  quality-adjusted life year.
a. I indicates evidence from at least one randomized, controlled trial; II-1 indicates evidence from a well-designed, controlled trial without randomization; II-2 indicates evidence from cohort or case con-
trol studies; and III indicates opinions of respected authorities (U.S. Preventive Services Task Force 1996).
b. We adjusted cost-effectiveness ratios to 2002 U.S. dollars using the consumer price index for medical care. In cases in which multiple studies evaluated the cost-effectiveness of an intervention, we
report the median cost-effectiveness ratio.
on knowledge, frequency, and accuracy of self-monitoring of
blood glucose; self-reported dietary habits; and glycemic con-
trol. Effects on lipids, physical activity, weight, and blood
pressure varied.
COST-EFFECTIVENESS OF INTERVENTIONS
AND PRIORITIES 
Most of the interventions to prevent and treat diabetes and its
complications significantly affect the use of health services. The
limitations of clinical trials include their failure in most cases
to capture the entire intervention effect over a lifetime and to
include all segments of a population to whom the intervention
may apply. Evaluating the cost-effectiveness of interventions
often requires the use of computer simulation models, but data
availability, technical complexity, and resource needs present a
significant barrier to constructing such models for developing
countries. Furthermore, data on interventions are often avail-
able only from developed countries, and these data are often
extrapolated to developing countries.
Estimating the Cost-Effectiveness of Interventions
in Developing Countries
To assess the cost-effectiveness of interventions in developing
countries, we updated the results from Klonoff and Schwartz’s
(2000) comprehensive review by including studies that were
published up to 2003. Table 30.2 summarizes the cost-
effectiveness of interventions for the developed countries,
mainly in the United States. The results show that the cost-
effectiveness of interventions varies greatly—from cost saving
(an intervention is both more effective and less expensive than
the comparator) to US$73,500 per quality-adjusted life year
(QALY) gained.
We estimated the cost-effectiveness ratio of diabetes interven-
tions for the six developing regions shown in table 30.3. We
assumed that the effectiveness of these interventions, as
measured in QALYs, was the same as in developed countries but
that the cost of interventions and other diabetes care differed
between developed and developing countries and also among the
six developing regions. Using this assumption, we estimated
the cost-effectiveness ratio for a developing region as the cost-
effectiveness ratio in the developed country, mainly represented
by the United States, multiplied by the ratio of costs in the devel-
oping region to the cost in the developed countries, which we
calculated as follows. These cost-effectiveness ratios are based on
costs and benefits over a lifetime, except for preconception care
for women of reproductive age.
We estimated that the cost of intervention and other diabetes
care in the United States was 8.6 times the cost in Latin America
and the Caribbean. This cost ratio was an average of four cost
ratios—each weighted by its share (Barcelo and others 2003)—
for outpatient care, inpatient care, drugs and laboratory tests,
and treatment for diabetic complications. The cost ratio for each
cost component was calculated as the cost of medical services or
drugs in the United States divided by the cost of the same serv-
ices or drugs in Latin America and the Caribbean. U.S. data for
medical services and drugs for routine diabetes care, plus treat-
ment cost for diabetes complications, were obtained from a
1998 cost-effectiveness Markov model of the U.S. Centers for
Disease Control and Prevention (CDC). Data for laboratory
service were obtained from the 2001 Clinical Diagnostic
Laboratory Fee Schedule from the U.S. Centers for Medicare
Services (available from http://www.cms.gov). Data for Latin
America and the Caribbean were obtained from three coun-
tries—Argentina (Gagliardino and others 1993), Brazil (Health
Policy Division of the Brazilian Ministry of Health), and Mexico
(Villarreal-Rios and others 2000).
We applied Mulligan and others’ framework (2003) to esti-
mate the costs of intervention and diabetes care in each devel-
oping region. Assuming that cost estimates are available for one
of the regions, this framework allows the development of a rel-
ative cost index for health care services that can then be used to
obtain cost estimates for the other five regions. Using costs esti-
mated by Mulligan and others (2003), we first estimated three
health service indexes, including hospital bed days, outpatient
and inpatient services, and laboratory tests and procedures. We
then combined the three indexes into one overall index for dia-
betes care in accordance with the share of each component in
developing countries (Barcelo and others 2003). Finally, we
estimated the costs of intervention and diabetes care in the
other five developing regions by multiplying the cost of care in
the Latin America region by the overall regional relative cost
index.
Ranking Implementation Priorities
We assessed the implementation priority and feasibility of
interventions, as explained in table 30.3.
Level 1 Interventions. All three interventions in this category
are cost saving and are also feasible in terms of all four aspects
considered. The barrier to implementing these interventions
may be a short-term hike in intervention costs.
Glycemic control in a population with poor control (hemo-
globin A1c greater than 9 percent or another measure of
glucose control in situations where HbA1c tests may be unaf-
fordable) is cost saving because the reduction in medical care
costs associated with both short-term and long-term complica-
tions is greater than is the cost of intervention. Glycemic con-
trol for people with type 1 diabetes involves insulin use and, for
people with type 2 diabetes, depending on the stage and sever-
ity of the disease, consists of diet and physical activity, oral
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glucose-lowering agents, and insulin. Patient education is an
essential component of these interventions to encourage
patients to comply with medication regimes and to change to
and maintain healthy lifestyles.
Glucose is generally poorly controlled in people with both
type 1 and type 2 diabetes, mostly because of lack of access to
insulin and other diabetes supplies in developing countries.
For example, the mean HbA1c level for people with diabetes
in India was 8.9 percent in 1998 (Raheja and others 2001).
A survey conducted by the International Diabetes Federation
in 1997 (2003b) showed that no country in Africa had 100 per-
cent accessibility to insulin. Ensuring adequate access to
insulin should be an important priority for developing
countries.
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Table 30.3 Cost-Effectiveness of Interventions for Preventing and Treating Diabetes and Its Complications in Developing Regions
Cost/QALY (2001 US$)
East Asia Latin America Middle East
and Europe and and the and Sub-Saharan Implementing
Intervention the Pacific Central Asia Caribbean North Africa South Asia Africa Feasibilitya priorityb
Level 1
Glycemic control in Cost saving Cost saving Cost saving Cost saving Cost saving Cost saving ++++ 1
people with HbA1c  
higher than 9 percent
Blood pressure control in Cost saving Cost saving Cost saving Cost saving Cost saving Cost saving ++++ 1
people with pressure higher 
than 160/95 mmHg 
Foot care in people with Cost saving Cost saving Cost saving Cost saving Cost saving Cost saving ++++ 1
a high risk of ulcers
Level 2
Preconception care for women Cost saving Cost saving Cost saving Cost saving Cost saving Cost saving ++ 2
of reproductive age
Lifestyle interventions for 80 100 130 110 60 60 ++ 2
preventing type 2 diabetes
Influenza vaccinations among 220 290 360 310 180 160 ++++ 2
the elderly for type 2 diabetes
Annual eye examination 420 560 700 590 350 320 ++ 2
Smoking cessation 870 1,170 1,450 1,230 730 660 ++ 2
ACE inhibitor use for people 620 830 1,020 870 510 460 +++ 2
with diabetes 
Level 3
Metformin intervention for 2,180 2,930 3,630 3,080 1,820 1,640 ++ 3
preventing type 2 diabetes
Cholesterol control for people 4,420 5,940 7,350 6,240 3,680 3,330 +++ 3
with total cholesterol higher
than 200 milligrams/deciliter
Intensive glycemic control for 2,410 3,230 4,000 3,400 2,000 1,810 ++ 3
people with HbA1c higher 
than 8 percent
Screening for undiagnosed 5,140 6,910 8,550 7,260 4,280 3,870 ++ 3
diabetes
Annual screening for 3,310 4,450 5,510 4,680 2,760 2,500 ++ 3
microalbuminuria
Source: Authors.
a. Feasibility was assessed based on difficulty of reaching the intervention population (the capacity of the health care system to deliver an intervention to the targeted population), technical complexity
(the level of medical technologies or expertise needed for implementing an intervention), capital intensity (the amount of capital required for an intervention), and cultural acceptability (appropriateness
of an intervention in terms of social norms and/or religious beliefs). ++++ indicates feasible for all four aspects, +++ indicates feasible for three of the four, ++ indicates feasible for two of the four, and
+ indicates feasible for one of the four. 
b. Implementing priority was assessed by combining the cost-effectiveness of an intervention and its implementation feasibility; 1 represents the highest priority and 3 represents the lowest priority.
Blood pressure control for people with diabetes and hyper-
tension reduces the incidence of both microvascular and
macrovascular diseases. Major medication interventions
include an ACE inhibitor, thiazide diuretics, or a beta blocker.
Blood pressure control is cost saving mainly because of its large
health benefits and relatively low intervention costs. Even in the
United States, moderate blood pressure control costs less than
US$250 per patient per year. Because many blood pressure
medications are generic drugs, the costs are much lower in
developing countries. In addition, the prevalence of people
with poor control of blood pressure may be high in developing
countries. For example, in Latin America and the Caribbean,
60 percent of people with type 2 diabetes in 2000 had blood
pressure higher than 140/90 mmHg (Gagliardino, de la Hera
and Siri 2001).
Complications related to foot problems are common among
diabetics in developing countries. For example, in India,
43 percent of diabetes patients had foot-related complications
(Raheja and others 2001). Interventions for foot care are low
tech and require little capital. Interventions for foot care in
developing countries should include educational programs for
patients and professionals (for example, on foot hygiene, treat-
ment of calluses, awareness of functional infections, and care
for skin injuries); access to appropriate footwear; and multidis-
ciplinary clinics. All three interventions could be cost saving,
mainly because the cost of the interventions is low and the
interventions can reduce the risk of foot ulceration and ampu-
tation, which are costly. Applying these interventions for high-
risk patients, such as those with at least one previous foot ulcer
or amputation, would yield even larger savings (Klonoff and
Schwartz 2000).
Level 2 Interventions. The six interventions in this category
are either cost saving and not feasible in one or more aspects or
cost less than US$1,500 per QALY and are at least moderately
feasible. Thus, interventions in this category represent good
value for money but may present some difficulties in terms of
feasibility.
Preconception care among women of reproductive age
includes patient education and intensive glucose management.
This intervention reduces short-term hospital costs for both
mothers and infants and improves birth outcomes. However,
the intervention may not be feasible in some developing
countries because of the resources needed for the intervention
and the difficulty of reaching the target population.
The lifestyle intervention for preventing type 2 diabetes
costs US$60 to US$130 per QALY over a lifetime, depending
on the region. The potential population eligible for a lifestyle
intervention (those with impaired glucose tolerance or
impaired fasting glucose) is large in developing countries. The
International Diabetes Federation (2003b) estimates that the
prevalence of impaired glucose tolerance was at least as high as
the prevalence of diabetes in all regions. The expertise
required for the intervention, such as dietitians and exercise
physiologists, and the capacity of health care systems to han-
dle the large populations eligible for the intervention may
present a barrier to implementing the intervention in many
developing countries.
People with diabetes are at higher risk of complications
from influenza and pneumococcal infections than those
without diabetes. Influenza vaccinations are a relatively cost-
effective intervention, mainly because of the low intervention
cost. However, the level of adoption for the intervention would
depend on a country’s ability to deliver the intervention to the
targeted population.
The detection of proliferative diabetic retinopathy and mac-
ular edema by dilated eye examination followed by appropriate
laser photocoagulation therapy prevents blindness. Annual
screening and treatment programs for diabetic retinopathy cost
US$700 or less per QALY gained in developing countries. The
intervention is more cost-effective among older people, those
who require insulin (Klonoff and Schwartz 2000), or those with
poor glucose control (Vijan, Hofer, and Hayward 2000). In
addition, screening less frequently, such as every two years, may
be more cost-effective than screening every year (Vijan, Hofer,
and Hayward 2000). Eye complications among people with
diabetes are common in developing countries; for example,
39 percent of people with diabetes in India had eye-related com-
plications (Rajala and others 1998). Although laser treatment is
an effective intervention, such treatment may not be available in
many developing countries or may be extremely costly.
ACE inhibitors can lower the blood pressure of those with
hypertension and delay the onset or prevent further progres-
sion of renal disease for those with diabetes. Compared with
screening for microalbuminuria and treating only those who
have the condition, offering ACE inhibitors to all people with
diabetes was more cost-effective at less than US$1,020 per
QALY gained. This intervention was more cost-effective among
younger people and was sensitive to the cost of drug. Thus,
lowering the cost of the medication is a key factor for the suc-
cess of this intervention in developing countries.
Smoking cessation includes both counseling and using
medication such as a nicotine patch. Smoking cessation
appears to be the least cost-effective among the level 2 inter-
ventions. However, the benefits of smoking cessation may be
underestimated because our calculations only took the reduced
risk of CVD into account (Earnshaw and others 2002). Adding
the health benefits derived from preventing cancer and pul-
monary diseases would improve the cost-effectiveness of
smoking cessation. Considering the high prevalence of smok-
ing in developing countries, smoking cessation should be a
high-priority intervention, but the availability of the nicotine
patch may be a barrier to implementing this intervention in
developing countries.
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Level 3 Interventions. The five interventions included in this
category cost at least US$1,640 per QALY but could cost as
much as US$8,550 per QALY. Compared with the level 1 and 2
interventions, those in this category are also less feasible. In
general, depending on cost-effectiveness and feasibility, these
interventions may not always be justifiable for all people in
developing countries, given the limited health care resources.
However, these interventions may be reasonable for selected
subpopulation groups, such as those who can afford them.
Metformin therapy for preventing type 2 diabetes among
people at high risk, such as those with prediabetes, is feasible
because the drug is affordable in many developing countries;
however, the intervention may not be good value for money.
Cholesterol control intervention for people with diabetes falls
into the same category. The cost-effectiveness of both these
interventions would improve if the costs of the drug could be
lowered.
The aim of intensive glucose control is to lower the glucose
level of a person with diabetes to a level close to that of a per-
son without diabetes. Implementing this intervention is a lower
priority, mainly because of its relatively low cost-effectiveness
in the context of the limited health care resources in develop-
ing countries. Although the U.K. Prospective Diabetes Study
clearly demonstrates that lowering glucose levels can prevent or
delay long-term diabetes complications (UKPDS Group 1998),
the marginal return on very intensive glucose control in devel-
oping countries was relatively small.
Screening for undiagnosed diabetes is a low-priority inter-
vention mainly because of its relatively high cost per QALY.
However, screening for undiagnosed diabetes can be a worth-
while intervention for subpopulation groups, such as those that
have a high prevalence of undiagnosed diabetes. In the United
States, for example, screening for undiagnosed diabetes among
African Americans was estimated to be 10 times more cost-
effective than screening among other population groups (CDC
Diabetes Cost-Effectiveness Study Group 1998). In addition,
screening for undiagnosed diabetes may be a worthwhile inter-
vention for patients with risk factors for other chronic diseases,
such as hypertension, high lipid profiles, and prediabetes.
Annual screening for microalbuminuria was a low-priority
intervention because screening added costs with no significant
benefits. Treating all persons with diabetes with ACE inhibitors
was a better treatment option than screening for microalbu-
minuria and treating only those who have the condition.
Cost-Effectiveness of a Polypill to Prevent CVD
A meta-analysis estimated that a hypothetical polypill could
reduce the risk of CVD by 80 percent among all people over
55 or people with diabetes of any age (Wald and Law 2003).
This hypothetical pill is a combination of three half-dose
antihypertensive medications—aspirin, statin, and folic acid
(see also chapter 33). Currently, neither is it available for use,
nor have estimates of its benefits and adverse effects been con-
firmed in a formal, randomized, controlled trial. The idea is
thus still theoretical. The cost-effectiveness of this hypothetical
pill was, however, simulated using a computer model of people
with newly diagnosed diabetes in the United States (Sorensen
and others 2004), and the assessment found that a polypill
intervention would cost US$11,000 per QALY gained. The
intervention would be cost saving if such a pill cost US$1.28
or less per day. We estimated that the cost-effectiveness ratio of
the polypill ranged from US$560 to US$1,280 per QALY
gained for the six developing regions. This result was sensitive
to changes in the cost of the intervention, but the intervention
remained cost-effective within the most likely ranges of its cost
(Sorensen and others 2004). A barrier to this intervention, in
addition to the feasibility of producing such pill, is that its
benefits and side effects would still have to be established in a
randomized clinical trial.
Cost-Effectiveness of Diabetes Education
People with diabetes play a central role in managing their dis-
ease. Thus, diabetes education is an integral part of diabetes
care. The goal of diabetes education is to support the efforts
of people with diabetes to understand the nature of their
illness and its treatment; to identify emergency health prob-
lems at early, reversible stages; to adhere to self-care practices;
and to make necessary changes to their health habits
(International Diabetes Federation 2003b). Health providers
can deliver diabetes education programs in various settings.
Evaluating the effectiveness of health education is challenging
because of the difficulty of separating out its effect from that
of other interventions. Nevertheless, a review of literature
published in the United States suggests that self-management
diabetes education may be cost-effective (Klonoff and
Schwartz 2000).
Training in diabetes self-management reduces medical
costs for diabetes care in developing countries in the short
term. A multicenter intervention study in 10 Latin American
countries demonstrated that an education program could
reduce the cost of drugs by 62 percent (International Diabetes
Federation 2003b), and another program in Argentina found a
reduction in diabetes-related costs of 38 percent (Gagliardino
and Etchegoyen 2001). Because the costs of education pro-
grams are generally low, the intervention may be cost-effective.
Training patients to better manage their diabetes is also
feasible because of its low technical complexity, low capital
requirements, and cultural acceptability. Thus, diabetes educa-
tion should be a high-priority intervention for all developing
regions.
598 | Disease Control Priorities in Developing Countries | K. M. Venkat Narayan, Ping Zhang, Alka M. Kanaya, and others
LESSONS AND EXPERIENCE
A number of lessons can be learned from the experiences
in countries where the interventions described have been
implemented.
Prevention 
Data are sparse on community- or population-based strategies
for preventing diabetes along with other chronic diseases such
as CVD. Available studies on preventing type 2 diabetes have
used clinic-based approaches targeted at high-risk groups, and
researchers generally agree that type 2 diabetes can be prevent-
ed or its onset delayed. Putting these results into practice, how-
ever, is fraught with difficulties and unanswered questions,
such as the following:
• Who would benefit from diabetes prevention? 
• How can those who may benefit be identified? 
• What are the costs and cost-effectiveness of diabetes pre-
vention at a population level? 
• How should results be extrapolated from developed countries
to developing countries, whose priorities and approaches
may be different?
Treatment
The quality of diabetes care generally remains suboptimal
worldwide, regardless of a particular country’s level of devel-
opment, health care system, or population (Engelgau and oth-
ers 2003; Garfield and others 2003). The Costs of Diabetes in
Europe—Type 2 study, conducted in eight European countries,
found suboptimal diabetes care in each country (Liebl, Mata,
and Eschwege 2002). In the United States, population-based
surveys in the 1990s among adults age 18 to 75 with diabetes
found that only 63 percent of them had had a dilated eye exam-
ination and only 55 percent had had a foot examination with-
in the past year, 18 percent had poor glycemic control, 42 per-
cent had good cholesterol control, and 66 percent had a blood
pressure within the normal range (Saaddine and others 2002).
The Diabcare-Asia project was conducted in the late 1990s.
Results from India, Singapore, and Taiwan (China) found that
in 1998, 32 to 50 percent of the diabetic population had poor
glycemic control (equivalent to HbA1c  8 percent), 43 to
67 percent had high cholesterol (greater than 5.2 millimoles per
deciliter), and 47 to 54 percent had an abnormal level of triglyc-
eride (greater than 1.7 millimoles per deciliter) (W. R. Lee and
others 2001; Raheja and others 2001). Data from Latin America
and the Caribbean showed that 41 percent of people with type
1 diabetes and 57 percent of those with type 2 diabetes had
poor glucose control. Of those with type 2 diabetes, 56 percent
had hypertension, 53 percent had high cholesterol, and 45 per-
cent had abnormal triglycerides (Gagliardino, de la Hera, and
Siri 2001).
Quality of Diabetes Care 
Small, single-site studies indicate that several interventions to
improve quality of care at the patient, provider, or system lev-
els are promising (Narayan and others 2004). A systematic
review (Renders and others 2001) found that multifaceted pro-
fessional interventions may enhance providers’ performance in
managing diabetes care; that organizational interventions
involving regularly contacting and tracking patients by means
of computerized tracking systems or through nurses can also
improve diabetes management; that patient-oriented interven-
tions can improve patients’ outcomes; and that nurses can play
an important role in patient-oriented interventions by educat-
ing patients and facilitating patients’ adherence to treatment
regimes. (See also chapter 70.)
Interventions that could modify providers’ behavior include
education as part of more complex interventions that also
focus on systems and on the organization of practices—for
example, feedback on performance, reminder systems, consen-
sus development, and clinical practice guidelines. Potential
systemic interventions include the use of continuous quality
improvement techniques; feedback on performance; physician
incentives for quality; nurses to provide diabetes care (which is
typically provided by physicians); computerized reminder sys-
tems for providers, alone or in combination with a perform-
ance feedback program; patient-tracking or other reminder
systems to improve regular follow-up; dedicated blocks of time
set aside for diabetes patients in primary care practices; team
care; electronic medical record systems; and other methods,
such as telephone and mailing reminders, chart stickers, and
flow sheets to prompt both providers and patients.
Interventions that empower patients can be successful com-
ponents of diabetes programs. A systems-oriented approach
using manual or computerized systems that remind patients to
make follow-up appointments and that prompt staff members
to generate reminder cards for patients can improve compli-
ance with follow-up and enhance efficiency of office practices.
In addition, comprehensive implementation of multiple risk-
factor interventions in real-life settings has been shown to
reduce vascular events by more than 50 percent among people
with diabetes (Gaede and others 2003).
The Institute of Medicine Committee on Quality of Health
Care in America (2001) argues strongly that newer systems of
care and newer ways of thinking are needed to tackle complex
diseases such as diabetes. Furthermore, the model of the process
of change in a simple mechanical system is woefully inadequate
for dealing with the complex, interactive, and interconnected
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adaptive systems in which diabetes is prevented and treated.
Applied research, designed to encompass the system as a whole
and not simply its component parts, can enhance our under-
standing of complex health care dynamics for chronic diseases
(Fraser and Greenhalgh 2001; Plsek and Greenhalgh 2001).
RESEARCH AND DEVELOPMENT AGENDA 
The following subsections discuss the major issues for research
and development.
Prevention 
Well-designed community-based studies of primary preven-
tion for type 2 diabetes are needed, especially as part of multi-
factorial interventions, in developing countries. Research is also
needed into safer and cheaper drugs to prevent diabetes when
lifestyle intervention either is not feasible or has failed. In addi-
tion, we need to know the long-term effects of diabetes preven-
tion on CVD and other outcomes. More effective and cheaper
ways to prevent the major complications of diabetes are also
needed. Other areas also deserving of research include nonin-
vasive methods for monitoring blood glucose and more effec-
tive and efficient ways of screening for prediabetes, diabetes,
and early diabetes complications. Evidence of the benefits of
diabetes education on outcomes is lacking, and organized
research to assess effective components of diabetes education
and their impact on control of risk factors and long-term out-
comes should be a priority.
Epidemiological and Economics Research
Scant data are available on the future burden of diabetes and its
complications in developing countries. Data on trends in and
the effects of risk factors for diabetes in developing countries—
obesity; birthweight; physical inactivity; television viewing;
dietary factors; fast foods; socioeconomic factors; and effects of
urbanization, industrialization, globalization, and stress—are
also sparse. Low-cost ways to obtain such data in a standardized
manner may be worth considering. More data are also needed
on the costs of diabetes, the impact of the disease on quality of
life, and the cost-effectiveness of various interventions in the
context of developing countries (International Diabetes
Federation 2003a).
Health Systems and Operational Research
Greater emphasis on translation research is needed. Well-
designed and standardized studies of quality of care and out-
comes will help (TRIAD Study Group 2002). Research aimed at
understanding system-level complexity and finding ways to
deliver chronic disease care that takes such complexity into
account is also likely to yield profitable results (Institute of
Medicine Committee on Quality of Health Care in America
2001).Computer models suitable for assessing cost-effectiveness
and for forecasting the burden in developing countries are need-
ed. Operational research aimed at understanding the tradeoffs
and the best mix of resource allocation for diabetes and chronic
disease care in developing countries is also needed.
Basic Research 
Further strategic unraveling of the genetic basis of type 2 dia-
betes and gene-environment interactions may help explain the
diabetes epidemic and provide better understanding of the
pathophysiology of the disease. It may also may lead to better
prevention and treatment strategies. Understanding the role of
prenatal influences, especially in developing countries, may
offer productive opportunities for interventions. Because of the
increasing occurrence of type 2 diabetes in children, as well as
the role of obesity in accelerating the onset of type 1 diabetes,
further research into the typology and classification of diabetes
is vital. The rapid industrialization and economic development
being experienced by several developing countries may make
research into the role of socioeconomic factors, urban stress,
and lifestyle factors on the causation of diabetes productive.
CONCLUSIONS
A growing diabetes pandemic is unfolding with rapid increases
in the prevalence of type 2 diabetes. The direct health care costs
of diabetes worldwide amount to 2003 US$129 billion per year.
Estimates indicate that developing countries spend between
2.5 and 15.0 percent of their annual direct health budgets on
diabetes care, and families with diabetic members spend 15 to
25 percent of their incomes on diabetes care.
A whole array of effective interventions to prevent diabetes
and its complications is available, and we have attempted to
assess their potential cost-effectiveness in developing regions.
Using these estimations and a qualitative assessment of the fea-
sibility of implementation, we have prioritized available inter-
ventions into the following three categories:
• level 1—cost saving and highly feasible
• level 2—cost saving or cost less than US$1,500 per QALY
but pose some feasibility challenges 
• level 3—cost between US$1,640 and US$8,550 per QALY
and pose significant feasibility challenges.
Table 30.4 presents a summary of all major diabetes inter-
ventions, major health effects of the interventions, and level of
implementation priority.
In addition, we propose diabetes education as an essential
intervention. However, more organized research into the
precise components of diabetes education and its effect on
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Table 30.4 Key Cost-Effective Interventions for Preventing and Treating Diabetes and Its Complications
Intervention
Level 1a
• Glycemic control in people with
poor control
• Blood pressure control
• Foot care
Level 2b
• Preconception care for women
of reproductive age
• Lifestyle intervention to prevent
diabetes
• Influenza vaccination
• Detection and treatment of eye
diseases
• ACE inhibitors
• Smoking cessation
Level 3 c
• Metformin therapy for
preventing diabetes
• Intensive glucose control
• Lipid control 
• Screening for microalbuminuria
• Screening for undiagnosed
diabetes 
Essential background interventiond
Diabetes education
Other promising interventione
Polypill
Description
Insulin, oral glucose-lowering agents, diet
and exercise 
Blood pressure control medications
Patient and provider education, foot
examination, foot hygiene, and appropriate
footwear
Patient self-management 
Behavioral change, including diet and
physical activity, to reduce bodyweight 
Vaccination
Eye examination to screen for and treat eye
diseases
Angiotensin-converting enzyme medication
Physician counseling and nicotine
replacement therapy
Metformin medication
Insulin, oral glucose-lowering agents, 
or both
Cholesterol-lowering medication
Screening for microalbuminuria and treating
those who test positive
Screening for undiagnosed diabetes and
treating those who test positive 
Patient self-management 
Hypothetical pill combining low doses of
antihypertensive medication, aspirin, statin,
and folate
Applicable population
People with diabetes, all ages, HbA1c
greater than 9 percent
People with diabetes, hypertensive, 
all ages
People with diabetes, middle-aged 
or older 
Women with diabetes who plan to
become pregnant
People who are at high risk (for example,
prediabetes for type 2 diabetes)
Elderly people with diabetes
People with diabetes, middle-aged 
or older 
People with diabetes
People with diabetes, all ages, 
smokers
People who are at high risk 
(for example, prediabetes for 
type 2 diabetes) 
Diabetes, all ages, with HbA1c less
than 9 percent
Diabetes, all ages, with high
cholesterol
Diabetes, all ages
People who are at high risk for type 2
diabetes 
Diabetes, all ages
Diabetes, all ages
Major effect
Reduction in microvascular disease 
Reduction in macrovascular disease,
microvascular disease, and mortality
Reduction in serious foot diseases and
amputations
Reduction in HbA1c level and hospital
expenses of the mother and baby
Reduction in type 2 diabetes incidence
by 58 percent
Reduction in hospitalizations,
respiratory conditions, and mortality
Reduction in serious vision loss
Reduction in nephropathy,
cardiovascular disease, and death
Increase in quitting rate and reduction
in cardiovascular disease 
Reduction in type 2 diabetes incidence
by 33 percent
Reduction in microvascular disease
Reduction in cardiovascular disease
events and mortality 
Reduction in kidney diseases
Reduction in microvascular disease
Reduction in HbA1c level and better
compliance with lifestyle changes 
Reduction in cardiovascular disease 
Source: Authors.
a. Level 1 interventions are cost saving and highly feasible. 
b. Level 2 interventions are cost saving or cost less than US$1,500 per quality-adjusted life year but pose feasibility challenges.
c. Level 3 interventions cost between US$1,640 and US$8,550 per quality-adjusted life year and pose significant feasibility challenges. 
d. Diabetes education is the backbone on which many diabetes interventions depend, but empirical data on the effectiveness of diabetes education on outcomes and on the precise components of
diabetes education are still lacking.
e. An intervention that appears promising but needs further research to document its effectiveness and/or safety. The polypill is only a theoretical concept at this time and is not available for
implementation.
long-term outcomes is needed. We also propose that further
research be launched in relation to the novel and potentially
promising polypill.
Finally, this chapter suggests a number of interventions at
the level of the patient, provider, and system that could help
address the overall suboptimal quality of diabetes care; notes
the possible benefits of making important drugs available at
cheaper costs in developing countries; and suggests some
research priorities for developing regions.
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Mental disorders are diseases that affect cognition, emotion,
and behavioral control and substantially interfere both with the
ability of children to learn and with the ability of adults to
function in their families, at work, and in the broader society.
Mental disorders tend to begin early in life and often run a
chronic recurrent course. They are common in all countries
where their prevalence has been examined. Because of the
combination of high prevalence, early onset, persistence, and
impairment, mental disorders make a major contribution to
total disease burden. Although most of the burden attributable
to mental disorders is disability related, premature mortality,
especially from suicide, is not insignificant. Table 31.1 summa-
rizes discounted disability-adjusted life years (DALYs) for
selected psychiatric conditions in 2001.
Mental disorders have complex etiologies that involve inter-
actions among multiple genetic and nongenetic risk factors.
Gender is related to risk in many cases: males have higher rates
of attention deficit hyperactivity disorder, autism, and sub-
stance use disorders; females have higher rates of major depres-
sive disorder, most anxiety disorders, and eating disorders.
Biochemical and morphological abnormalities of the brain
associated with schizophrenia, autism, mood, and anxiety dis-
orders are being identified using approaches such as post-
mortem analysis and noninvasive neuroimaging. Major world-
wide efforts under way to identify risk-conferring genes for
mental disorders are proving challenging, but initial results are
promising. Identifying the gene or genes causing or creating
vulnerability for a disorder should help us understand what
goes wrong in the brain to produce mental illness and should
have a clinical effect by contributing to improved diagnostics
and therapeutics (Hyman 2000).
Twin studies make it clear that environmental risk factors
also play an important role in mental disorders; concordance for
disease among identical twins, although substantially higher
than among nonidentical twins, is still well below 100 percent
(Kendler and others 2003). However, as is the case for genetic
factors, investigation of environmental risk factors has proved
difficult. For schizophrenia, where nongenetic components of
risk may include obstetrical complications and season of birth
(Mortensen and others 1999), perhaps as a proxy for infections
early in life, research has been hampered by the modest proven
effect of the nongenetic risk factors identified to date. For
depression, anxiety, and substance use disorders, where envi-
ronmental risk factors are more robust, adverse circumstances
associated with risk, such as early childhood abuse, violence,
poverty, and stress (Patel and Kleinman 2003) correlate with
multiple disorders and could be affected by selection bias as well
as by bias associated with self-reporting. Generalizable, prospec-
tive cross-cultural studies are needed to delineate nongenetic
risk factors more clearly. Posttraumatic stress disorder (PTSD)
is the mental disorder for which clear environmental triggers are
best documented. Even here, though, enormous interindividual
variability occurs in the threshold of stress severity associated
with PTSD as well as in the evidence from twin studies of genetic
influences on stress reactivity in triggering PTSD.
The last half of the 20th century saw enormous progress in
the development of treatments for mental disorders. Beginning
in the early 1950s, effective psychotropic drugs were discovered
that treated the symptoms of schizophrenia, bipolar disorder,
major depression, anxiety disorders, obsessive-compulsive
disorder, attention deficit hyperactivity disorder, and others.
The safety and efficacy of antipsychotic, mood-stabilizing,
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antidepressant, anxiolytic, and stimulant drugs have been
established through a large number of randomized clinical
trials. Psychosocial treatments have been developed and tested
using modern methodologies. Brief, symptom-focused psy-
chotherapies such as cognitive-behavioral therapies have been
shown to be efficacious for panic disorder, phobias, obsessive-
compulsive disorder, and major depression.
There is, however, an important caveat about the current
knowledge base for treatment. As is the case for almost all of
medicine, randomized clinical trials have been performed
largely with highly selected populations in specialized research
settings in industrial countries. A need exists to subject existing
treatments to effectiveness trials in more representative popu-
lations and diverse settings, especially in developing countries.
That limitation notwithstanding, a substantial body of knowl-
edge exists to guide treatment. It is particularly unfortunate,
therefore, that timely diagnoses and the application of
research-based treatments significantly lag behind the state of
knowledge in industrial and developing countries alike. As a
result, substantial opportunities exist to decrease the enormous
burden attributable to mental disorders worldwide by closing
the gap between what we know and what we do.
Mental disorders are stigmatized in many countries and
cultures (Weiss and others 2001). Stigma has been facilitated
by the slow emergence of convincing scientific explanations for
the etiologies of mental disorders and by the mistaken belief
that symptoms are caused by a lack of will power or reflect some
moral taint. Recent scientific findings combined with educa-
tional efforts in some countries have begun to reduce the stigma
(Rahman and others 1998), but shame and fear associated with
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Table 31.1 Disease Burden of Selected Major Psychiatric Disorders, by World Bank Region
World Bank region
Sub-Saharan Latin America and Middle East and Europe and East Asia and High-income 
Africa the Caribbean North Africa Central Asia South Asia the Pacific countries World
Total population (millions) 668 526 310 477 1,388 1,851 929 6,159
Total disease burden 344,754 104,287 65,570 116,502 408,655 346,941 149,161 1,535,870
(thousands of DALYs)
Total neuropsychiatric 15,151 18,781 8,310 14,106 37,734 42,992 31,230 168,304
disease burden 
(thousands of DALYs)
Total burden (thousands of discounted DALYs per year)
Schizophrenia 1,146 1,078 696 778 2,896 3,934 1,115 11,643 
Bipolar disorder 1,204 883 567 668 2,237 3,118 1,056 9,733 
Depression 3,275 5,219 2,027 4,268 14,582 14,054 8,408 51,833 
Panic disorder 519 409 264 340 1,081 1,401 536 4,550
Total burden (DALYs per year per 1 million population)
Schizophrenia 1,716 2,049 2,247 1,630 2,087 2,126 1,201 1,894 
Bipolar disorder 1,803 1,678 1,830 1,400 1,612 1,685 1,137 1,583 
Depression 4,905 9,919 6,544 8,944 10,507 7,594 9,054 8,431 
Panic disorder 777 777 852 713 779 757 577 740 
Percentage of total disease burden
Schizophrenia 0.33 1.03 1.06 0.67 0.71 1.13 0.75 0.76 
Bipolar disorder 0.35 0.85 0.86 0.57 0.55 0.90 0.71 0.63 
Depression 0.95 5.00 3.09 3.66 3.57 4.05 5.64 3.37 
Panic disorder 0.15 0.39 0.40 0.29 0.26 0.40 0.36 0.30 
Percentage of neuropsychiatric disease burden
Schizophrenia 7.56 5.74 8.38 5.52 7.67 9.15 3.57 6.92 
Bipolar disorder 7.95 4.70 6.82 4.74 5.93 7.25 3.38 5.78 
Depression 21.62 27.79 24.39 30.26 38.64 32.69 26.92 30.80 
Panic disorder 3.43 2.18 3.18 2.41 2.86 3.26 1.72 2.70 
Source: WHO Global Burden of Disease 2001 estimates recalculated by World Bank region (http://www.fic.nih.gov/dcpp/gbd.html).
mental illness remain substantial obstacles to help seeking, to
diagnosis, and to treatment worldwide. The stigmatization of
mental illness has resulted in disparities, compared with other
illnesses, in the availability of care, in research, and in abuses of
the human rights of people with these disorders.
This chapter focuses on the attributable and avoidable
burden of four leading contributors to mental ill health globally:
schizophrenia and related nonaffective psychoses, bipolar
affective disorder (manic-depressive illness), major depressive
disorder, and panic disorder. The choice of these disorders is
determined not only by their contribution to disease burden,
but also by the availability of data for the cost-effectiveness
analyses. Even where such data are available, they are often from
industrial countries and extrapolation has been necessary. The
exclusion of other mental disorders, such as childhood disor-
ders, from analysis is not because the authors consider these dis-
orders unimportant but because of the paucity of data.Also, this
chapter does not specifically deal with the important issue of
suicide. A background paper on suicide in developing countries
has been developed as part of the Disease Control Priorities
Project (DCPP) and is available (Vijayakumar, Nagaraj, and
John 2004). The economic analysis presented in this chapter
uses the cost-effectiveness analysis methodology specifically
developed for the DCPP. The authors recognize that mental
disorders impose costs and burdens on families as well as
individuals that are not captured by the DALY. Treatment will
alleviate some of this burden in addition to alleviating symp-
toms and disability.
A description of the major clinical features, natural course,
epidemiology, burden, and treatment effectiveness for each
group of disorders is given in the next section. For diagnostic
criteria, readers are referred to The ICD-10 Classification of
Mental and Behavioral Disorders (ICD-10) (WHO 1992) or
Diagnostic and Statistical Manual of Mental Disorders (DSM-
IVTR) (American Psychiatric Association 2000). A discussion
follows of population-level costs and cost-effectiveness of inter-
ventions capable of reducing the current burden associated
with four disorders in different developing regions of the world
(tables 31.2–31.6), before moving to a discussion of key issues
and implications for mental health policy and improvement of
services in developing regions of the world.
SCHIZOPHRENIA AND NONAFFECTIVE
PSYCHOSES
Schizophrenia is a chronic disorder punctuated by episodes of
florid psychotic symptoms, such as hallucinations and delu-
sions. Hallucinations are sensory perceptions that occur in the
absence of appropriate stimuli. Hallucinations may occur in
any sensory modality but in schizophrenia are most commonly
auditory—for example, hearing voices or noises. Delusions are
fixed false beliefs that are not explained by the person’s culture
and that the patient holds despite all reasonable evidence to the
contrary.
Patients also exhibit negative symptoms—that is, deficits in
normal capacities, such as marked social deficits, impoverish-
ment of thought and speech, blunting of emotional responses,
and lack of motivation. Additionally, patients typically have
cognitive symptoms, such as disorganized or illogical thinking
and an inability to hold goal information in mind to make
decisions or plan actions.
Natural History and Course
Schizophrenia, as defined in current diagnostic manuals, is
almost certainly heterogeneous, but still does not comprise all
nonaffective psychoses (NAPs). In addition to schizophrenia,
NAPs include schizophreniform disorder,characterized by schiz-
ophrenia-like symptoms of inadequate duration to qualify as
schizophrenia. Because they cannot be readily disentangled in
community epidemiological surveys, schizophrenia and other
NAPs are considered together.Because of the data available,how-
ever, the cost-effectiveness analyses reported below are restricted
to schizophrenia. Despite likely etiological heterogeneity, schizo-
phrenia exhibits consistency in its symptom pattern across those
countries and cultures studied (Jablensky and others 1992).
Incidence studies show that onset of schizophrenia and
other NAPs is typically in middle to late adolescence for males
and late adolescence to early adulthood for females, although
later onsets are observed. Childhood-onset cases are quite rare
but particularly severe (Nicolson and Rapoport 1999). Often,
schizophrenia is first diagnosed with the occurrence of an acute
episode of florid psychotic symptoms. The first psychotic
episode is often preceded by prodromal symptoms such as social
withdrawal, irritability or dysphoria, increasing academic or
work-related difficulties, and increasing eccentricity. However,
such symptoms are not specific; studies of whether early diag-
nosis and intervention can improve outcomes are under way
(McGorry and others 2002).
The course of schizophrenia is typically one of acute exacer-
bations of severe psychotic symptoms, followed by full or par-
tial remission. Psychotic episodes may be followed by a full
remission after the first and occasionally other early episodes,
but over time, residual symptoms and disability typically con-
tinue between relapses (Robinson and others 1999). The time
between relapses is markedly extended by maintenance treat-
ment with antipsychotic drugs, generally at lower doses than
are needed to treat acute episodes. Cognitive and occupational
functioning tends to decline over the first years of the illness
and then to plateau at a level that is generally well below what
would have been expected for the individual. Residual impair-
ment, though, has substantial cross-cultural variation for
reasons that are not well understood. Schizophrenia has consis-
tently been found in epidemiological surveys to be highly
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comorbid, usually with anxiety disorders, mood disorders, and
substance use disorders (Kendler and others 1996).
Epidemiology and Burden
A great many studies of NAP incidence have been carried out in
clinical samples. In a review of these studies, Jablensky (2000)
found incidence estimates to be in the range of 0.002 to 0.011
percent per year for schizophrenia and 0.016 to 0.042 percent
per year for overall NAP. Those annual estimates can be multi-
plied by the number of birth cohorts at risk to yield an estimate
of lifetime risk in any one cohort. Assuming conservatively that
the main age range of risk is between ages 15 and 55, researchers
estimate lifetime risk is in the range of 0.08 to 0.44 percent for
schizophrenia and in the range of 0.64 to 1.68 percent for NAPs.
Lifetime prevalence estimates from community epidemio-
logical surveys of NAPs are quite consistent with those from
clinical studies, in the range of 0.3 to 1.6 percent (see, for exam-
ple, Hwu, Yeh, and Cheng 1989; Kendler and others 1996).
Although schizophrenia is a relatively uncommon disorder,
aggregate estimates of disease burden are high—around 2,000
DALYs lost per 1 million total population (table 31.1)—
because the condition is associated with early onset, long dura-
tion, and severe disability.
Interventions
A substantial body of evidence exists on the efficacy of various
treatments for schizophrenia and NAP and on the effectiveness
of various models of health care delivery for persons with these
disorders. This evidence comes primarily from industrial coun-
tries. The efficacy data show conclusively that antipsychotic
drugs reduce severity of the episodes, hasten resolution of
florid symptoms, and reduce duration of hospitalization.
Maintenance treatment with antipsychotic drugs prolongs the
period between relapses (Joy, Adams, and Lawrie 2001).
A second generation of antipsychotic medications (also
called atypical) is replacing older neuroleptic antipsychotic
drugs throughout the industrial world. In some clinical trials,
second-generation drugs show small advantages in efficacy
over first-generation drugs, but their widespread adoption
results from marked improvement in tolerability. Their relative
lack of side effects compared with first-generation drugs has
led to improved quality of life and improved treatment adher-
ence. Second-generation drugs are not without side effects,
however; for example, some are associated with substantial
weight gain and increased risk of diabetes. One drug, clozapine,
has greater efficacy than other antipsychotic drugs, but because
of a 1 percent risk of agranulocytosis, its use requires weekly
blood counts and is cumbersome and expensive.
Psychosocial interventions also play an important role in
managing schizophrenia (Bustillo and others 2001). Cognitive-
behavioral approaches to managing specific symptoms and
improving medication adherence, group therapy, and family
interventions all have demonstrated efficacy in improving
clinical outcomes. Community-based models of mental health
care delivery with case management and assertive outreach
programs have been shown in health systems of industrial
countries to be effective ways of managing schizophrenia in the
community, for example, by reducing the need for hospital
admissions. However, the applicability of these models to
developing countries, as is discussed later, is hard to estimate
because of differences in health system characteristics. Long-
term remission rates for schizophrenia in developing countries
appear to be significantly higher than those reported in indus-
trial countries (Harrison and others 2001), likely resulting from
such factors as strong family social support.
Despite their clear usefulness, current treatments do not
prevent schizophrenia, and no clear evidence demonstrates that
they induce full recovery or prevent premature mortality.
Instead, treatment reduces time in episode of florid psychosis
and increases time between episodes; thus treatment effects can
be understood in terms of improvements in disability. Reported
treatment effect sizes from meta-analyses in the literature, con-
verted into improvements in the average level of disability
(Andrews and others 2003; Sanderson and others 2004), show
improvements (compared with no treatment) of 18 to 19 per-
cent (antipsychotic drugs alone) and 30 to 31 percent (antipsy-
chotic drugs with adjunctive psychosocial treatment). Placed
on a disability scale of 0 to 1, where 0 equals no disability, an
“average” case of schizophrenia moves from a disability level of
0.63 (untreated weight from the Global Burden of Disease
study, Murray and Lopez 1996) to 0.43 to 0.54 (treated).
MOOD DISORDERS
The cardinal features of mood disorders are pervasive abnor-
malities in the predominant emotional state of the person, such
as depressed, elated, or irritable. In mood disorders, these core
emotional symptoms are accompanied by abnormalities in
physiology, such as changes in patterns of sleep, appetite, and
energy, and by changes in cognition and behavior. In develop-
ing countries, concurrent somatic symptoms are also com-
monly reported and may be the chief complaint. A generally
accepted subclassification of mood disorders distinguishes
unipolar depressive disorders from bipolar disorder (defined
by the occurrence of mania). This distinction is based on
symptoms, course of illness, patterns of familial transmission,
and treatment response.
Bipolar Disorder
Bipolar disorder is characterized by episodes of mania and
depression, often followed by relative periods of healthy mood
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(euthymia). Mixed states with symptoms of both mania and
depression also occur. Mania is typically characterized by
euphoria or irritability, a marked increase in energy, and a
decreased need for sleep. Individuals with mania often exhibit
intrusive, impulsive, and disinhibited behaviors. They may be
excessively involved in goal-directed behaviors characterized
by poor judgment; for example, a person might spend all
funds to which he or she has access and more. Self-esteem is
typically inflated, frequently reaching delusional proportions.
Speech is often rapid and difficult to interrupt. Individuals
with mania also may exhibit cognitive symptoms; patients can-
not stick to a topic and may jump rapidly from idea to idea,
making comprehension of their train of thought difficult.
Psychotic symptoms are common during manic episodes. The
depressive episodes of people with bipolar disorder are symp-
tomatically indistinguishable from those who have unipolar
depressions alone. Unlike anxiety and unipolar mood disor-
ders, which are more common in women, bipolar disorder has
an equal gender ratio of lifetime prevalence, although the ratio
of depressive-to-manic episodes is higher among bipolar
women than men.
Natural History and Course. Retrospective reports from com-
munity epidemiological surveys consistently show that bipolar
disorder has an early age of onset (in the late teens through mid-
20s). Onset in childhood is increasingly recognized, although
it remains controversial. Late onset is less common. The vast
majority of patients with bipolar disorder have recurrent
episodes of illness, both mania and depression. Classic descrip-
tions of bipolar disorder suggest recovery to baseline function-
ing between episodes, but many patients have residual symp-
toms that may cause significant impairment (Angst and Sellaro
2000). These states of mania, depression, and lesser (or absent)
symptoms are used in the intervention analysis below.
The rate of cycling between mania and depression varies
widely among individuals. One common pattern of illness is
for episodes initially to be separated by a relatively long period,
perhaps a year, and then to become more frequent with age. A
minority of patients with four or more cycles per year, termed
rapid cyclers, tend to be more disabled and less responsive to
existing treatments. Once cycles are established, most acute
episodes start without an identifiable precipitant; the best doc-
umented exception is that manic episodes may be initiated by
sleep deprivation, making a regular daily sleep schedule and
avoidance of shift work important in management (Frank,
Swartz, and Kupfer 2000).
Bipolar disorder has consistently been found in epidemio-
logical surveys to be highly comorbid with other psychiatric
disorders, especially anxiety and substance use disorders
(ten Have and others 2002). The extent of comorbidity is much
greater than for unipolar depressive disorders or anxiety
disorders. Some individuals with classic symptoms of bipolar
disorder also exhibit chronic psychotic symptoms superim-
posed on their mood syndrome. These individuals are said to
have schizoaffective disorder. Their prognosis tends to be less
favorable than for the usual bipolar patient, although somewhat
better than for individuals with schizophrenia. Schizoaffective
disorder may also be diagnosed when chronic psychotic symp-
toms are superimposed on unipolar depression. Individuals
with this combination of symptoms have outcomes similar to
patients with schizophrenia (Tsuang and Coryell 1993).
Epidemiology and Burden. Lifetime and 12-month preva-
lence estimates of bipolar disorder have been reported from a
number of community psychiatric epidemiological surveys.
Lifetime prevalence estimates are in the range 0.1 to 2.0 percent
(Vega and others 1998; Vicente and others 2002), with a
weighted mean across surveys of 0.7 percent. Prevalence esti-
mates for past-year episodes have a similarly wide range (0.1 to
1.3 percent) (Vega and others 1998) and a weighted mean of
0.5 percent. It is important to note that good evidence exists
suggesting that bipolar disorder has a wide subthreshold spec-
trum that includes people who are often seriously impaired
even though they do not meet full DSM or ICD criteria for the
disorder (Perugi and Akiskal 2002). This spectrum might
include as much as 5 percent of the general population. The
ratio of recent-to-lifetime prevalence of bipolar disorder in
community surveys is quite high (0.71), indicating that bipolar
disorder is persistent.
Epidemiological data show that bipolar disorder is associ-
ated with substantial impairments in both productive and
social roles (Das Gupta and Guest 2002). Epidemiological evi-
dence documents consistent delays in patients initially seeking
professional treatment (Olfson and others 1998), especially
among early-onset cases, as well as substantial undertreatment
of current cases. Each of these characteristics—chronic, recur-
rent course; significant impairments to functioning; modest
treatment rates—contributes to estimates of aggregate disease
burden that approach those for schizophrenia (1,200 to 1,800
DALYs lost per 1 million population, making up more than
5 percent of the burden attributable to neuropsychiatric disor-
ders as a whole—see table 31.1).
Interventions. Analyses of the primary treatment approaches
for bipolar disorder are based on the three health states that
characterize the disorder—mania, depression, and euthymia.
Robust evidence from controlled trials shows that antipsychot-
ic drugs and some benzodiazepines produce a relatively rapid
reduction in symptoms of a manic phase. Mood-stabilizing
drugs act more slowly, but they reduce the severity and dura-
tion of acute manic episodes. Maintenance treatment with two
mood-stabilizing drugs—lithium and valproic acid (adminis-
tered as sodium valproate)—has been shown to have
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significant, albeit partial, efficacy in reducing rates of both
manic and depressive relapses. The drawback of lithium is that
toxic levels are not much greater than therapeutic levels; thus,
serum-level monitoring is required.
For the cost-effectiveness analyses, lithium and valproic
acid, which have empirical data supporting their efficacy in
treating and preventing manic and depressive episodes, were
considered. Because evidence suggests that psychosocial
approaches enhance compliance with medication (Huxley,
Parikh, and Baldessarini 2000), adjuvant strategies also were
assessed. The primary treatment effect was a change in the
population-level disability associated with bipolar disorder (a
weighted average of time spent in a manic, depressed, or
euthymic phase of illness). Both an acute treatment effect—
calculated as the product of initial response and reduced
episode duration—and a prophylactic treatment effect were
ascribed to lithium and valproic acid, resulting in an estimated
improvement of close to 50 percent over the untreated com-
posite disability weight of 0.445 (Chisholm and others forth-
coming). This estimate then was adjusted for expected nonad-
herence to treatment in real-world clinical settings—slightly
lower for lithium than for valproic acid (Bowden and others
2000). A secondary effect of treatment—reduction of the case
fatality rate by two-thirds—was also ascribed to lithium,
though, because of an absence of current evidence, not to val-
proic acid (Goodwin and others 2003). This reduction was
derived through a change in the standardized mortality ratio
from 2.5 to 1.5, estimated on the basis of natural history stud-
ies reported for the prelithium era (for example, Astrup,
Fossum, and Holmboe 1959; Helgason 1964) to the postlithium
era (for example, Goodwin and others 2003).
Major Depressive Disorder
The core symptom of major depression is a disturbance of
mood; sadness is most typical, but anger, irritability, and loss of
interest in usual pursuits may predominate. Often the affected
person is unable to experience pleasure (anhedonia) and may
feel hopeless. In many countries of the developing world,
patients will not complain of such emotional symptoms, but
rather of physical symptoms, such as fatigue or multiple aches
and pains.
Typical physiological symptoms that occur across cultures
include sleep disturbance (most often insomnia with early
morning awakening, but occasionally excessive sleeping);
appetite disturbance (usually loss of appetite and weight loss,
but occasionally excessive eating); and decreased energy.
Behaviorally, some individuals with depression exhibit slowed
motor movements (psychomotor retardation), whereas others
may be agitated. Cognitive symptoms may include thoughts of
worthlessness and guilt, suicidal thoughts, difficulty concen-
trating, slow thinking, and poor memory. Psychotic symptoms
occur in a minority of cases.
Natural History and Course. Major depression is an episodic
disorder that generally begins early in life (median age of onset
in the mid to late 20s in community epidemiological surveys),
although new onsets can be observed across the lifespan.
Childhood onset is being increasingly recognized, although not
all childhood precursors of adult depression take the form of a
clear depressive disorder. Most individuals suffering from
a depressive episode will have a recurrence (Mueller and others
1999), with recurrence risk greater among those with early-
onset disease. Many individuals do not recover completely
from their acute episodes and have chronic milder depression
punctuated by acute exacerbations (Judd and others 1998). The
current term for chronic, milder depression lasting more than
two years is dysthymia. Although the symptoms of minor
depression are, by definition, less severe than those of a major
depressive episode, chronicity ultimately makes even this lesser
form of the illness very disabling in many cases (Judd, Schettler,
and Akiskal 2002). Depression has consistently been found in
epidemiological surveys to be highly comorbid with other
mental disorders, with roughly half the people who have a
history of depression also having a lifetime anxiety disorder.
Comorbidities of depression and anxiety disorders are genera-
lly strongest with generalized anxiety disorder and panic
disorder (Kessler and others 1996).
Epidemiology and Burden. Prevalence of nonbipolar depres-
sion has been estimated in a number of large-scale community
epidemiological surveys. Lifetime prevalence estimates of hav-
ing either major depressive disorder or dysthymia in these sur-
veys are in the range 4.2 to 17.0 percent (Andrade and others
2003; Bijl and others 1998), with a weighted mean of 12.1 per-
cent. Six- to 12-month prevalence estimates have a similarly
wide range (1.9 to 10.9 percent) (Andrade and others 2003;
Robins and Regier 1991), with a weighted mean of 5.8 percent.
These wide differences in prevalence likely represent the difficul-
ties inherent in self-reporting of conditions that are invariably
stigmatized across cultures.Prevalence estimates are consistently
highest in North America and lowest in Asia (with prevalence
estimates of major depressive disorders generally a good deal
higher than those of dysthymia).
Epidemiological data document consistent delays in
patients initially seeking professional treatment for depression,
especially among early-onset cases (Olfson and others 1998), as
well as substantial undertreatment. For example, World Mental
Health surveys in six Western European countries found that
only 36.6 percent of people with active nonbipolar depression
in the 12 months before the survey received any professional
treatment for this disorder during the subsequent year
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(ESEMeD/MHEDEA 2000 Investigators 2004). The situation is
even worse in developing countries, where the vast majority of
people with depression who seek help do so in general health
care settings and complain of nonspecific physical symptoms.
Such individuals receive a correct diagnosis in less than 
one-quarter of cases and typically are treated with medicines of
doubtful efficacy (Linden and others 1999).
Depression is consistently found in community surveys to
be associated with substantial impairments in both productive
and social roles (Wang, Simon, and Kessler 2003). As with
bipolar depression, but exacerbated by its high incidence, the
recurrent nature and disabling consequences of (unipolar)
depression mean that overall disease burden estimates are high
in all regions of the world (5,000 to 10,000 DALYs per 1 million
population, as much as 5 percent of the total burden of disease
from all causes; table 31.1). Depression is, in fact, ranked as the
fourth leading cause of disease burden globally and represents
the single largest contributor to nonfatal burden (Ustun and
others 2004).
Interventions. Efficacy has been demonstrated for several
classes of antidepressant drugs and for two psychosocial treat-
ments for depression (Paykel and Priest 1992). The older tri-
cyclic antidepressants (TCAs) and newer drugs, including the
selective serotonin reuptake inhibitors (SSRIs), have similar
efficacy. The newer drugs have milder side-effect profiles and
are consequently more likely to be tolerated at therapeutic
doses (Pereira and Patel 1999). SSRIs have not been widely used
in developing countries because of their higher cost, although
as the patent protection expires, this situation is likely to
change (Patel 1996). Of the psychosocial treatments with
demonstrated efficacy, the most widely accepted are cognitive-
behavioral approaches. Alone or in combination, drug and psy-
chosocial treatments speed recovery from acute episodes.
Maintenance treatment with drugs decreases relapse risk
(Geddes and others 2003). Some evidence suggests that a
course of psychotherapy may also delay relapses. Although
most of the clinical trials have been carried out in industrial
countries, at least three high-quality trials have demonstrated
the efficacy of antidepressants, group therapy, or both in devel-
oping countries (Araya and others 2003; Bolton and others
2003; Patel and others 2003).
For the cost-effectiveness analyses, depression was modeled
as an episodic disorder with a high rate of remission and
subsequent recurrence, and with excess mortality from suicide
(Chisholm and others 2004). None of the selected depression
interventions was accorded a reduction in case fatality, however,
owing to the lack of robust clinical evidence that antidepressants
or psychotherapy in themselves alter the relative risk of death by
suicide (Storosum and others 2001). The main modeled impact
of intervention targeted toward episodic treatment of a new
depressive episode was a reduction in the duration of time
depressed, equivalent to an increase in the remission rate (25 to
40 percent improvement over no treatment; Malt and others
1999; Solomon and others 1997). In addition, all interventions
were attributed a modest improvement in the level of disability
for an unremitted depressive episode (10 to 15 percent),
resulting from increased proportions of cases moving from
more to less severe health states. For the estimated 56 percent of
prevalent cases eligible for maintenance treatment (at least two
lifetime episodes), an additional effect of efficacious mainte-
nance treatment was incorporated into the analysis by reducing
the incidence of recurrent episodes by 50 percent (Geddes and
others 2003). Estimates of intervention effectiveness include the
positive change that would occur naturally and also incorporate
any placebo effect, which, in the treatment of depression, is not
inconsiderable (Andrews 2001).
ANXIETY DISORDERS
Anxiety disorders are a group of disorders that have as their
central feature the inability to regulate fear or worry. Although
anxiety in itself is likely to feature in the clinical presentation of
most patients, somatic complaints such as chest pain, palpita-
tions, respiratory difficulty, headaches, and the like are also
common, and these symptoms may be more common in
developing countries. A number of different types of anxiety
disorder exist, some of which are now briefly described.
The central feature of panic disorder is an unexpected panic
attack, which is a discrete period of intense fear accompanied
by physiologic symptoms such as a racing heart, shortness of
breath, sweating, or dizziness. The person may have an intense
fear of losing control or of dying. Panic disorder is diagnosed
when panic attacks are recurrent and give rise to anticipatory
anxiety about additional attacks. People with panic disorder
may progressively restrict their lives to avoid situations in
which panic attacks occur or situations from which it might be
difficult to escape should a panic attack occur. They common-
ly avoid crowds, traveling, bridges, and elevators, and ultimate-
ly some individuals may stop leaving home altogether.
Pervasive phobic avoidance is described as agoraphobia.
Generalized anxiety disorder is characterized by chronic
unrealistic and excessive worry. These symptoms are accompa-
nied by specific anxiety-related symptoms such as sympathetic
nervous system arousal, excessive vigilance, and motor tension.
Posttraumatic stress disorder follows serious trauma. It is
characterized by emotional numbness, punctuated by intrusive
reliving of the traumatic episode, generally initiated by envi-
ronmental cues that act as reminders of the trauma; by dis-
turbed sleep; and by hyperarousal, such as exaggerated startle
responses.
Social anxiety disorder (social phobia) is characterized by a
persistent fear of social situations or performance situations that
expose a person to potential scrutiny by others. The affected
person has intense fear that he or she will act in a way that will
be humiliating. Separating social anxiety disorder from
extremes of normal temperament, such as shyness, is difficult.
Nonetheless, social anxiety disorder can be quite disabling.
Simple phobias are extreme fear in the presence of discrete stim-
uli or cues, such as fear of heights.
The core features of obsessive-compulsive disorder are obses-
sions (intrusive, unwanted thoughts) and compulsions (per-
formance of highly ritualized behaviors intended to neutralize
the negative thoughts and emotions resulting from the obses-
sions). One symptom pattern might be repetitive hand washing
beyond the point of skin damage to neutralize fears of
contamination.
Natural History and Course 
The anxiety disorders differ in their age of onset, course of ill-
ness, and symptom triggers. One of these disorders, PTSD, is
dependent for its etiology on one or more powerfully negative
life events. Although the anxiety disorders are discussed as a
group, panic disorder is chosen because of the available data for
the purposes of the cost-effectiveness analysis.
Prevalence estimates of anxiety disorders based on commu-
nity epidemiological surveys vary widely, from a low of 2.2 per-
cent (Andrade and others 2003) to a high of 28.5 percent
(Kessler and others 1994), with a weighted mean across surveys
of 15.6 percent. Prevalence estimates for anxiety disorders in
the past 6 to 12 months have a similarly wide range (1.2 to
19.3 percent) (Andrade and others 2003; Kessler and others
1994), with a weighted mean of 9.4 percent. Despite wide
variation in overall prevalence, several clear relative prevalence
patterns can be seen across surveys. Specific phobia is generally
the most prevalent lifetime anxiety disorder, with social phobia
generally the second most prevalent lifetime anxiety disorder.
Panic disorder and obsessive-compulsive disorder are generally
the least prevalent.
These surveys also provide evidence about the persistence of
anxiety disorders, indirectly defined as the ratio of 6-month or
12-month to lifetime prevalence. This ratio averages approxi-
mately 60 percent for overall anxiety disorders, indicating a
high rate of persistence across the life course. The highest
persistence is generally found for social phobia, and the lowest
for agoraphobia. These estimates of high persistence are con-
sistent with results obtained from longitudinal studies of
patients (Yonkers and others 2003).
Anxiety disorders have consistently been found in epidemio-
logical surveys to be highly comorbid both among themselves
and with mood disorders (for example, de Graaf and others
2003). The vast majority of people with a history of one anxiety
disorder typically also have a second anxiety disorder, while
more than half the people with a history of either anxiety or
mood disorder typically have both types of disorder.
Retrospective reports from community surveys consistently
show that anxiety disorders have early average ages of onset.
An impressive cross-national consistency can be seen in these
patterns, with an estimated median age of onset of anxiety at
approximately 15.
Epidemiological surveys have also looked at the treatment
of anxiety disorders. As with depression, consistent evidence in
these surveys suggests that delays in initially seeking profes-
sional treatment for an anxiety disorder are widespread after
first onset (Olfson and others 1998). This finding is especially
true among early-onset cases. Epidemiological data also show
that only a minority of current cases receive any formal treat-
ment in Western countries, whereas treatment of anxiety disor-
ders is virtually nonexistent in many developing countries. The
most recently published surveys, the World Mental Health
surveys in six Western European countries, found that only
26.3 percent of people with an active anxiety disorder in the
12 months before the survey received any professional treat-
ment (ESEMeD/MHEDEA 2000 Investigators 2004).
Anxiety disorders have consistently been found to be associ-
ated with substantial impairments in both productive roles (for
example, work absenteeism, work performance, unemploy-
ment, and underemployment) and social roles (social isolation,
interpersonal tensions, and marital disruption, among others)
(see, for example, Kessler and Frank 1997). As noted earlier, for
the purposes of this chapter, one of the anxiety disorders—
panic disorder—has been chosen to describe interventions and
undertake cost-effectiveness analysis. Panic disorder is as dis-
abling as obsessive-compulsive disorder and PTSD, accounts
for about one-third of all seriously impairing anxiety disorders,
is one of the most common anxiety disorders presenting for
treatment, and imposes an estimated burden of 600 to 800
DALYs per 1 million population.
Good evidence exists that both drug and psychosocial
treatments are effective for managing anxiety disorders.
Antidepressant drugs (both older TCAs and SSRIs) have been
shown to be effective for the treatment of several anxiety disor-
ders, including panic disorder, reducing the duration and
intensity of the disorder. Although high-potency benzodi-
azepines are efficacious for panic disorder, these drugs carry a
risk of dependence and are not considered the first line of
treatment. Psychosocial treatments, especially cognitive-
behavioral therapy, are also effective in diminishing both panic
attacks and phobic avoidance.
Interventions for Panic Disorder
Although evidence-based interventions for panic disorder have
yet to be evaluated or made widely available in developing
612 | Disease Control Priorities in Developing Countries | Steven Hyman, Dan Chisholm, Ronald Kessler, and others
countries, the potential population-level impact of a number of
interventions—including older and newer antidepressants,
anxiolytic drugs (benzodiazepines), and psychosocial
treatments—was examined. Interventions reduce the severity
of panic attacks and improve the probability of making a full
recovery. Effect sizes for symptom improvement were drawn
from a meta-analysis of the long-term effects of intervention of
panic disorder (Bakker and others 1998) and converted into an
equivalent change in disability weight (Sanderson and others
2004). Concerning remission, a number of controlled and
naturalistic studies (for example, Faravelli, Paterniti, and
Scarpato 1995; Yonkers and others 2003) reveal a consistent
remission rate of 12 to 13 percent for pharmacological and
combination strategies—except for benzodiazepine use, for
which the evidence is that longer-term recovery is actually
worse than placebo (Katschnig and others 1995)—which repre-
sents a 62 percent improvement in efficacy over the untreated
remission rate (7.4 percent).
COST-EFFECTIVENESS METHODS AND RESULTS
This section estimates the burden attributed to schizophrenia,
bipolar disorder, depression, and panic disorder that could be
averted (through scaling up) by proven, efficacious treatments.
It is followed by calculations of the expected cost and cost-
effectiveness of such treatments. Analysis is conducted at the
level of six low- and middle-income geographical World Bank
regions.
Estimation of Population-Level Effectiveness of Treatments
In modeling the impact of mental health interventions, we
used a state-transition model (Lauer and others 2003) that
traces the development of a population, taking into account
births, deaths, and the disease in question. In addition to pop-
ulation size and structure, the model makes use of a number of
epidemiological parameters (incidence and prevalence, remis-
sion, and cause-specific and residual rates of mortality) and
assigns age- and gender-specific disability weights to both the
disease in question and the general population. The output of
the model is an estimate of the total healthy life years experi-
enced by the population over a lifetime period (100 years). The
model was run for a number of possible scenarios, including no
treatment at all (natural history), current treatment coverage,
and scaled-up coverage of current as well as potential new
interventions. For the treatment scenarios, an implementation
period of 10 years was used (thereafter, epidemiological rates
and health state valuations return to natural history levels). The
model derived the number of additional healthy years gained
(equivalent to DALYs averted) each year in the population
compared with the outcome for no treatment at all. DALYs
averted in future years were discounted at a rate of 3 percent
(reflecting a societal preference for health benefits to be realized
sooner), but no age-weighting was used.
Estimation of the baseline epidemiological situation that
would prevail without treatment used incidence and preva-
lence estimates from the Global Burden of Disease 2000 study
of the World Health Organization (WHO) (see online Global
Burden of Disease documentation for the four disorders at
http://www.who.int/evidence/bod). Current pharmacolog-
ical or psychosocial treatments do not exert a primary preven-
tive effect on the onset of the four conditions (although
some evidence exists that treating depression in parents may
reduce risk for offspring), indicating that currently observed
incidence rates coincide with those that would pertain under
no treatment. Prevention of recurrences of acute episodes (sec-
ondary prevention) has been demonstrated for maintenance
treatments for major depression and bipolar disorder.
Maintenance treatment with antipsychotic drugs decreases the
risk of recurrent acute episodes of schizophrenia. For each con-
dition, a range of treatment strategies was considered and
assessed, including older (and widely available) psychothera-
peutic drugs, newer pharmacotherapies, psychosocial treat-
ments, and combination treatments (see table 31.2 for a list of
interventions included).
Estimation of Population-Level Treatment Costs
Cost estimation followed the principles and procedures
described in chapter 7 for carrying out economic analyses of dis-
ease control priorities in developing countries. For depression
and panic disorder, treatment was assumed to occur in a pri-
mary care setting, whereas for schizophrenia and bipolar disor-
der, which often produce highly disruptive behaviors, both hos-
pital- and community-based outpatient service models were
derived and compared. Both program- and patient-level costs
were identified and estimated. Program-level costs included the
infrastructure and administrative support for implementing
mental health treatments, as well as training inputs (for exam-
ple, two to three days per trainee were estimated for training
primary care doctors and case managers in psychotropic med-
ication management). Patient-level resource inputs included
medication regimens (for example, fluoxetine, 20 milligrams
daily), laboratory tests (for example, lithium blood levels),
primary care visits (including any contacts with a case manager),
and hospital outpatient and inpatient care. Estimated patient-
level resource inputs for each of the four disorders were informed
by empirical economic evaluative studies (for example, Patel and
others 2003; Srinivasa Murthy and others 2005) as well as a multi-
national Delphi consensus study of resource use for psychiatric
disorders in seven developing countries (Ferri and others 2004).
Region-specific unit costs or prices were applied to all resource
inputs (see Mulligan and others 2003) to give an annual cost for
each case as well as for all cases at the specified level of treatment
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coverage. Costs incurred over the 10-year implementation peri-
od were discounted at 3 percent and expressed in U.S. dollars
(rather than international dollars, which attempt to adjust for
differences in purchasing power between countries).
Coverage
In each World Bank region, treatment costs and effects were
ascribed to the population in need, both at current levels
of intervention coverage and at a scaled-up, target level of
coverage (80 percent for schizophrenia, 50 percent for the other
conditions). Target coverage levels were predicated on the basis
of what could feasibly be achieved given existing rates of treat-
ment (Ferri and others 2004; Kohn and others 2004), as well as
on prerequisites for increased coverage, such as recognition of
common mental disorders in primary care. Estimation of cur-
rent regional levels of effective coverage is hampered by lack of
data; nevertheless, an attempt was made to approximate the
expected proportion of the diseased population receiving
evidence-based pharmacological and psychosocial treatments
(Ferri and others 2004; Kohn and others 2004), plus those in
contact with traditional healers (the effectiveness of which was
conservatively approximated by ascribing a placebo effect size
for each disorder).
Results
Tables 31.3 through 31.6 provide estimates of the population-
level effects (measured in DALYs averted), costs, and cost-
effectiveness of each intervention by world region for the four
types of psychiatric disorder considered in this chapter. A num-
ber of key findings emerge from this analysis.
Treatment Effectiveness. Results for schizophrenia and bipo-
lar disorder are similar (albeit at differing coverage levels), rang-
ing from less than 100 DALYs averted per 1 million population
under the current situation in Sub-Saharan Africa and South
Asia to 350 to 400 DALYs averted per 1 million population for
614 | Disease Control Priorities in Developing Countries | Steven Hyman, Dan Chisholm, Ronald Kessler, and others
Table 31.2 Interventions for Reducing the Burden of Major Psychiatric Disorders in Developing Countries
Disorder Intervention Example
Schizophrenia 
Treatment setting: hospital outpatient 
Treatment coverage (target): 80 percent
Bipolar affective disorder
Treatment setting: hospital outpatient 
Treatment coverage (target): 50 percent
Depression
Treatment setting: primary health care 
Treatment coverage (target): 50 percent
Panic disorder
Treatment setting: primary health care 
Treatment coverage (target): 50 percent
Older (neuroleptic) antipsychotic drug
Newer (atypical) antipsychotic drug
Older antipsychotic drug and psychosocial treatment
Newer antipsychotic drug and psychosocial treatment
Older mood-stabilizing drug
Newer mood-stabilizing drug
Older mood-stabilizing drug and psychosocial treatment
Newer mood-stabilizing drug and psychosocial treatment
Episodic treatment
Older TCA
Newer antidepressant drug (SSRI; generic)
Psychosocial treatment
Older antidepressant drug and psychosocial treatment
Newer antidepressant drug and psychosocial treatment
Maintenance treatment
Older antidepressant drug and psychosocial treatment
Newer antidepressant drug and psychosocial treatment
Benzodiazepines
Older TCA
Newer antidepressant drug (SSRI; generic)
Psychosocial treatment
Older antidepressant drug and psychosocial treatment
Newer antidepressant drug and psychosocial treatment
Haloperidol
Risperidone
Haloperidol plus family psychoeducation
Risperidone plus family psychoeducation
Lithium carbonate
Sodium valproate
Lithium plus family psychoeducation
Valproate plus family psychoeducation
Imipramine or amitriptyline
Fluoxetine
Group psychotherapy
Amitriptyline plus group psychotherapy
Fluoxetine plus group psychotherapy
Imipramine plus group psychotherapy
Fluoxetine plus group psychotherapy
Alprazolam
Amitriptyline
Fluoxetine
Cognitive therapy 
Amitriptyline plus cognitive therapy
Fluoxetine plus cognitive therapy
Source: Authors’ own estimates and recommendations.
Note: Interventions in bold are the most cost-effective treatments of choice.
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Table 31.3 Cost-Effectiveness Results: Schizophrenia
Model definition:
World Bank region
Treatment setting: (a) hospital-
based; (b) community-based Sub-Saharan Latin America Middle East and Europe and East Asia and
Treatment coverage: 80 percent Africa and the Caribbean North Africa Central Asia South Asia the Pacific
Total effect (DALYs averted per year per 1 million population)
Current situation 74 136 115 258 87 148
Older (neuroleptic) antipsychotic drug 149 219 214 254 177 231
Newer (atypical) antipsychotic drug 160 235 230 273 190 248
Older antipsychotic drug plus 254 373 364 353 300 392
psychosocial treatment
Newer antipsychotic drug plus 261 383 373 364 308 403
psychosocial treatment
Total cost (US$ million per year per 1 million population)
Current situation 0.42 2.07 1.31 3.13 0.51 1.11 
Hospital-based service model 
Older (neuroleptic) antipsychotic drug 0.60 3.09 2.40 2.24 0.74 1.18
Newer (atypical) antipsychotic drug 2.80 6.33 5.41 6.16 3.36 4.63 
Older antipsychotic drug plus 0.67 3.27 2.56 2.36 0.81 1.26 
psychosocial treatment
Newer antipsychotic drug plus 2.87 6.56 5.61 6.31 3.44 4.73
psychosocial treatment
Community-based service model
Older (neuroleptic) antipsychotic drug 0.40 1.58 1.42 1.17 0.44 0.66 
Newer (atypical) antipsychotic drug 2.59 4.85 4.45 5.11 3.07 4.12 
Older antipsychotic drug plus 0.47 1.81 1.61 1.32 0.52 0.75 
psychosocial treatment
Newer antipsychotic drug plus 2.67 5.09 4.66 5.28 3.16 4.22 
psychosocial treatment
Cost-effectiveness (US$ per DALY averted)
Current situation 5,695 15,192 11,400 12,134 5,900 7,533
Hospital-based service model
Older (neuroleptic) antipsychotic drug 4,047 14,123 11,205 8,793 4,164 5,120
Newer (atypical) antipsychotic drug 17,433 26,893 23,543 22,530 17,702 18,700
Older antipsychotic drug plus 2,623 8,781 7,040 6,685 2,693 3,212
psychosocial treatment
Newer antipsychotic drug plus 10,996 17,146 15,027 17,329 11,164 11,746
psychosocial treatment
Community-based service model
Older (neuroleptic) antipsychotic drug 2,668 7,230 6,618 4,595 2,499 2,855
Newer (atypical) antipsychotic drug 16,174 20,583 19,352 18,685 16,178 16,622
Older antipsychotic drug plus 1,839 4,847 4,431 3,745 1,743 1,917
psychosocial treatment
Newer antipsychotic drug plus 10,232 13,313 12,485 14,481 10,239 10,484
psychosocial treatment
Source: Authors’ own estimates.
Note: Intervention data in bold are the most cost-effective treatments of choice.
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Table 31.4 Cost-Effectiveness Results: Bipolar Disorder
Model definition:
World Bank region
Treatment setting: (a) hospital- 
based; (b) community-based Sub-Saharan Latin America Middle East and Europe and East Asia and
Treatment coverage: 50 percent Africa and the Caribbean North Africa Central Asia South Asia the Pacific
Total effect (DALYs averted per year per 1 million population)
Current situation 79 128 97 199 93 153
Older mood-stabilizing drug (lithium) 292 336 296 381 319 389
Newer mood-stabilizing drug 211 300 273 331 278 351
(valproate)
Older mood-stabilizing drug plus 312 365 322 413 346 422
psychosocial treatment
Newer mood-stabilizing drug plus 232 330 300 365 306 386
psychosocial treatment
Total cost (US$ million per year per 1 million population)
Current situation 0.31 1.22 0.74 1.27 0.42 0.67 
Hospital-based service model
Older mood-stabilizing drug (lithium) 0.61 2.77 1.92 2.03 0.82 1.30 
Newer mood-stabilizing drug 0.79 2.87 2.04 2.20 1.03 1.53 
(valproate)
Older mood-stabilizing drug plus 0.63 2.79 1.95 2.05 0.84 1.32 
psychosocial treatment
Newer mood-stabilizing drug plus 0.81 2.90 2.08 2.22 1.06 1.55 
psychosocial treatment
Community-based service model
Older mood-stabilizing drug (lithium) 0.46 1.78 1.20 1.37 0.59 0.93 
Newer mood-stabilizing drug 0.64 1.91 1.36 1.57 0.82 1.17 
(valproate)
Older mood-stabilizing drug plus 0.48 1.80 1.23 1.39 0.62 0.95 
psychosocial treatment
Newer mood-stabilizing drug plus 0.67 1.95 1.39 1.59 0.85 1.19 
psychosocial treatment
Cost-effectiveness (US$ per DALY averted)
Current situation 3,967 9,518 7,668 6,398 4,463 4,373
Hospital-based service model
Older mood-stabilizing drug (lithium) 2,091 8,246 6,478 5,341 2,553 3,348
Newer mood-stabilizing drug 3,727 9,579 7,501 6,648 3,709 4,358
(valproate)
Older mood-stabilizing drug plus 2,016 7,644 6,036 4,957 2,424 3,119
psychosocial treatment
Newer mood-stabilizing drug plus 3,480 8,800 6,937 6,100 3,459 4,016
psychosocial treatment
Community-based service model
Older mood-stabilizing drug (lithium) 1,587 5,295 4,068 3,608 1,862 2,394
Newer mood-stabilizing drug 3,057 6,386 4,971 4,727 2,943 3,338
(valproate)
Older mood-stabilizing drug plus 1,545 4,928 3,823 3,359 1,787 2,241
psychosocial treatment
Newer mood-stabilizing drug plus 2,874 5,908 4,645 4,359 2,765 3,092
psychosocial treatment
Source: Authors’ own estimates.
Note: Intervention data in bold are the most cost-effective treatments of choice.
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Table 31.5 Cost-Effectiveness Results: Depression
Model definition:
World Bank region
Treatment setting: primary 
health care Sub-Saharan Latin America Middle East and Europe and East Asia and
Treatment coverage: 50 percent Africa and the Caribbean North Africa Central Asia South Asia the Pacific
Total effect (DALYs averted per year per 1 million population)
Current situation 133 264 218 308 218 243
Episodic treatment: older 599 995 920 874 987 891
antidepressant drug (TCA)
Episodic treatment: newer 632 1,049 971 925 1,042 941
antidepressant drug (SSRI)
Episodic psychosocial treatment 624 1,036 958 936 1,028 927
Episodic psychosocial treatment 745 1,237 1,144 1,100 1,228 1,107
plus older antidepressant
Episodic psychosocial treatment 745 1,237 1,144 1,100 1,228 1,107
plus newer antidepressant
Maintenance psychosocial treatment 1,174 1,953 1,806 1,789 1,937 1,747
plus older antidepressant
Maintenance psychosocial treatment 1,174 1,953 1,806 1,789 1,937 1,747
plus newer antidepressant
Total cost (US$ million per year per 1 million population)
Current situation 0.36 0.90 0.63 0.74 0.56 0.67
Episodic treatment: older 0.30 1.28 0.96 0.81 0.47 0.47
antidepressant drug (TCA)
Episodic treatment: newer 0.66 1.86 1.47 1.39 1.04 0.99
antidepressant drug (SSRI)
Episodic psychosocial treatment 0.37 1.67 1.27 0.97 0.55 0.53
Episodic psychosocial treatment 0.50 1.96 1.53 1.21 0.77 0.72
plus older antidepressant
Episodic psychosocial treatment 0.90 2.60 2.10 1.85 1.40 1.29
plus newer antidepressant
Maintenance psychosocial treatment 0.96 3.44 2.77 2.19 1.45 1.38
plus older antidepressant
Maintenance psychosocial treatment 1.80 4.80 3.99 3.56 2.81 2.59
plus newer antidepressant
Cost-effectiveness (US$ per DALY averted)
Current situation 2,692 3,414 2,905 2,391 2,546 2,777
Episodic treatment: older 505 1,288 1,039 929 478 533
antidepressant drug (TCA)
Episodic treatment: newer 1,042 1,771 1,516 1,501 1,003 1,048
antidepressant drug (SSRI)
Episodic psychosocial treatment 592 1,611 1,330 1,035 537 570
Episodic psychosocial treatment 674 1,586 1,335 1,104 627 653
plus older antidepressant
Episodic psychosocial treatment 1,203 2,101 1,834 1,682 1,140 1,161
plus newer antidepressant
Maintenance psychosocial treatment 817 1,760 1,533 1,226 749 788
plus older antidepressant
Maintenance psychosocial treatment 1,535 2,459 2,211 1,990 1,449 1,481
plus newer antidepressant
Source: Authors’ own estimates.
Note: Intervention data in bold are the most cost-effective treatments of choice.
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Table 31.6 Cost-Effectiveness Results: Panic Disorder
Model definition:
World Bank region
Treatment setting: primary 
health care Sub-Saharan Latin America Middle East and Europe and East Asia and
Treatment coverage: 50 percent Africa and the Caribbean North Africa Central Asia South Asia the Pacific
Total effect (DALYs averted per year per 1 million population)
Current situation 49 94 64 88 57 90
Anxiolytic drug (benzodiazepine) 144 182 170 183 168 195
Older antidepressant drug (TCA) 232 290 272 290 269 312
Newer antidepressant drug (SSRI; 245 307 287 307 284 330
generic)
Psychosocial treatment 233 292 273 292 270 313
(cognitive-behavioral therapy)
Older antidepressant plus  262 329 308 329 304 353
psychosocial treatment
Newer antidepressant plus 276 346 324 346 320 372
psychosocial treatment
Total cost (US$ million per year per 1 million population)
Current situation 0.06 0.13 0.08 0.07 0.05 0.10
Anxiolytic drug (benzodiazepine) 0.10 0.20 0.15 0.15 0.10 0.12
Older antidepressant drug (TCA) 0.09 0.18 0.14 0.14 0.08 0.11
Newer antidepressant drug 0.15 0.27 0.21 0.23 0.16 0.20
(SSRI; generic)
Psychosocial treatment (cognitive- 0.11 0.27 0.21 0.17 0.09 0.11
behavioral therapy)
Older antidepressant plus 0.15 0.32 0.26 0.23 0.13 0.17
psychosocial treatment
Newer antidepressant plus 0.22 0.41 0.34 0.32 0.22 0.26
psychosocial treatment
Cost-effectiveness (US$ per DALY averted)
Current situation 1,192 1,378 1,208 824 948 1,109
Anxiolytic drug (benzodiazepine) 681 1,075 892 842 572 629
Older antidepressant drug (TCA) 369 619 508 474 305 339
Newer antidepressant drug (SSRI; 630 865 747 741 567 606
generic)
Psychosocial treatment (cognitive- 468 927 786 594 338 365
behavioral therapy)
Older antidepressant plus  556 977 844 685 443 474
psychosocial treatment
Newer antidepressant plus 788 1,188 1,050 918 671 709
psychosocial treatment
Source: Authors’ own estimates.
CBT  cognitive behavioral therapy
Note: Intervention data in bold are the most cost-effective treatments of choice.
combination drug and psychosocial interventions in Europe
and Central Asia and East Asia and the Pacific. Second-
generation (atypical) antipsychotic drugs were considered
slightly more effective than first-generation drugs (on the basis
of a modest intrinsic efficacy difference and differences in
tolerability and adherence); lithium was considered modestly
more effective as a mood-stabilizing drug than valproate (on the
basis of its additional positive effect on suicide rates). Adjuvant
psychosocial treatment in combination with pharmacotherapy
significantly added to expected population-level health gain.
With the exception of Europe and Central Asia, less than 10 per-
cent of the disease burden currently is being averted, whereas the
implementation of combined interventions at a scaled-up level
of coverage is expected to avert 14 to 22 percent of the burden of
schizophrenia (coverage level, 80 percent) and 17 to 29 percent
of the burden of bipolar disorder (coverage level, 50 percent).
For primary care treatment of common mental disorders,
including depression and panic disorder, current levels of effec-
tive coverage avert only 3 to 8 percent of the existing disease
burden, whereas scaling up of the most effective interventions
to a coverage level of 50 percent could be expected to avert
more than 20 percent of the burden of depression and up to
one-third of the burden of panic disorder. Considered at a pop-
ulation level, episodic treatments for depressive episodes did
not differ substantially within regions (averting 10 to15 percent
of current burden); more substantial health gain is expected
by providing maintenance treatment to individuals with recur-
rent depression (approximately 1,200 to 1,900 DALYs averted
per 1 million population; 18 to 23 percent of burden). Such an
approach has been found to reduce the risk of relapse by half.
Although the evidence to date from developing regions is mea-
ger, our results suggest that SSRIs such as fluoxetine, alone or in
combination with psychosocial treatment, are the most effec-
tive treatments for panic disorder, with health gains consider-
ably better than those estimated for benzodiazepine anxiolytic
drugs such as alprazolam.
Treatment Costs. Community-based service models for
schizophrenia and bipolar disorder were found to be apprecia-
bly less costly than hospital-based service models (for example,
interventions for bipolar disorder were 25 to 40 percent less
costly). The total cost per capita of community-based outpa-
tient treatment with first-generation antipsychotic or mood-
stabilizing drugs, including all patient-level resource needs as
well as infrastructural support, ranged from US$0.40 to
US$0.50 in Sub-Saharan Africa and South Asia to US$1.20 to
US$1.90 in Latin America and the Caribbean and in Europe
and Central Asia (equivalent patient costs per year, US$170 to
US$300 and US$300 to US$800, respectively). The cost per
capita for interventions using second-generation (atypical)
antipsychotic drugs still under patent is much higher (US$2.50
to US$5.00). By contrast, some of the newer antidepressant
drugs (SSRIs) are now off patent, and their use in treating
depression and panic disorder was accordingly costed at their
generic, nonbranded price. The patient-level cost of treating a
6-month episode of depression ranged from as little as US$30
(older antidepressants in Sub-Saharan Africa or South Asia) to
US$150 (newer antidepressants in combination with brief psy-
chotherapy in Latin America and the Caribbean). Total annual
costs for all incidents of depressive episodes receiving treat-
ment, including training and other program-level costs, were as
much as US$2 to US$5 per capita for a maintenance treatment
program using newer antidepressants, three times more costly
than episodic treatment with newer antidepressant drugs only.
Patient-level resource inputs for panic disorder interventions
cost US$50 to US$200 per case per year, and overall costs
including program costs of training and administration
amounted to US$0.10 to US$0.30 per capita.
Cost-Effectiveness. Compared with both the current situation
and the epidemiological situation of no treatment (natural his-
tory), the most cost-effective strategy for averting the burden of
psychosis and severe affective disorders in developing countries
is expected to be a combined intervention of first-generation
antipsychotic or mood-stabilizing drugs with adjuvant psy-
chosocial treatment delivered through a community-based
outpatient service model, with a cost-effectiveness ratio of
below US$2,000 in Sub-Saharan Africa and South Asia, rising
to US$5,000 in Latin America and the Caribbean (equivalent to
more than 500 DALYs averted per US$1 million expenditure in
Sub-Saharan Africa and South Asia and 200 DALYs averted in
Latin America and the Caribbean). Currently, the high acquisi-
tion price of second-generation antipsychotic drugs makes
their use in developing regions questionable on efficiency
grounds, although this situation can be expected to change as
these drugs come off patent. By contrast, evidence indicates
that the relatively modest additional cost of adjuvant psy-
chosocial treatment reaps significant health gains, thereby
making such a combined strategy for schizophrenia and
bipolar disorder treatment more cost-effective than pharma-
cotherapy alone.
For more common mental disorders treated in primary care
settings (depressive and anxiety disorders), the single most
cost-effective strategy is the scaled-up use of older antidepres-
sants (because of their lower cost but similar efficacy compared
with newer antidepressants). However, as the price margin
between older and generic newer antidepressants continues to
diminish, generic SSRIs—which have milder side effects and
are more likely to be taken at a therapeutic dose (Pereira and
Patel 1999)—can be expected to be at least as cost-effective
and, therefore, the pharmacological treatment of choice in the
future. Because depression is often a recurring condition,
proactive care management, including long-term maintenance
treatment with antidepressant drugs, represents a cost-effective
way of significantly reducing the enormous burden of depres-
sion that exists in developing regions now (400 to 1,300 DALYs
averted per US$1 million expenditure).
POLICY AND SERVICE IMPLICATIONS
Many attempts have been made during the past 50 years to
have mental health care placed higher on national and interna-
tional agendas. In 1974, a WHO Expert Committee on the
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Organization of Mental Health Services in Developing
Countries (WHO 1975) made the following recommendations:
• Develop a national mental health policy and create a unit
within the Health Ministry to implement it.
• Budget for workforce development, essential drug procure-
ment, infrastructure development, data collection, and
research.
• Decentralize service provision and integrate mental health
into primary health care.
• Train and supervise primary health care providers in mental
health using specialist mental health staff.
Thirty years later, international agencies, nongovernmental
organizations, and professional bodies continue to make those
exact recommendations. One reason for the lack of action in
mental health has been the paucity of information on the cost-
effectiveness of mental health interventions. Advocacy without
the necessary science can readily be ignored in countries with
massive health problems and meager resources. This chapter
aims to address this deficiency.
Symptoms of mental disorders are often attributed to other
illnesses, and mental disorders are often not considered health
problems (Jacob 2001). Many nonscientific explanations for
mental illness exist, and stigma exists to varying degrees every-
where (Weiss and others 2001) with widespread delays or fail-
ure to seek appropriate care (James and others 2002).
When care is sought, a hierarchy of interventions comes into
play, ranging from self-help, informal community support, tra-
ditional healers, primary health care, specialist community
mental health care, and psychiatric units in general hospitals to
specialist long-stay mental hospitals. The mix of interventions
depends on the availability of resources within a country or
region (Saxena and Maulik 2003). The more resource-
constrained the country or region is, the greater is the reliance
on self-help, informal community support (especially family-
based), and primary health care.
Traditional healers are often the first source individuals with
mental illness and their families turn to for professional assis-
tance (see, for example, Abiodun 1995). A recent review of com-
mon mental disorders among primary health clinics and tradi-
tional healers in urban Tanzania showed that the prevalence of
common mental disorders among those attending traditional
healers was double that of patients at primary health care centers
(Ngoma, Prince, and Mann 2003). Traditional healers are a het-
erogeneous group and include faith healers, spiritual healers,
religious healers, and practitioners of indigenous or alternative
systems of medicine. In some countries, they are part of the
informal health sector, but in other countries, traditional healers
charge for their services and should be considered part of the
private health care sector. Often, traditional healers have high
acceptability and are accessible; at times, traditional healers
work closely (and apparently effectively) with conventional
mental health services (Thara, Padmavati, and Srinivasan 2004).
Alternatively, animosity and competition can exist, and recent
examples of human rights violations by traditional healers
demonstrate the heterogeneity of this group of providers.
The formal diagnosis and treatment of mental disorders
occur in both primary and specialist health services. Examples
in nearly a dozen countries now show it is feasible and practi-
cable to treat common mental disorders in primary health care
settings (for example, Chisholm and others 2000; De Jong
1996; Mohit and others 1999). The challenge is to enhance sys-
tems of care by taking effective local models and disseminating
them throughout a country.
Concern has been expressed that the more sophisticated
psychotherapies used in mental health care are beyond the
human resources of developing countries. However, basic psy-
chological therapies can be effective, though there is some evi-
dence, at least for depression, that the newer drug therapies are
more cost-effective than psychological therapies (Patel and
others 2003). Psychoeducational family intervention has been
shown to be suitable for rehabilitation in schizophrenia in rural
China (Ran and others 2003) and to be cost-effective compared
with other standard treatment (Xiong and others 1994).
Evidence also shows that nurses can replace physicians as pri-
mary health care providers in certain circumstances without
loss of effectiveness (Climent and others 1978). Primary care
practitioners need support to develop skills and experience in
diagnosing and treating mental disorders: they need a sustain-
able supply of medicines, access to supervision, and incentives
to see patients with mental illness (Abas and others 2003).
Community approaches using low-cost, locally available
resources may improve treatment adherence and clinical out-
comes even in rural and underresourced settings (Chatterjee
and others 2003; Srinivasa Murthy and others 2005).
In most countries, acute inpatient beds are being moved
from mental hospitals into general or district hospitals.
Although this policy potentially improves accessibility and
increases the links with, and support provided to, primary
mental health care, concerns can be raised as to whether gen-
eral hospitals can adapt to provide adequate services to people
with severe mental disorders. However, such services have
been effectively established in a number of countries (see, for
example, Alem and others 1999; Kilonzo and Simmons 1998),
showing this form of service delivery to be feasible when it is
clinically indicated.
Nongovernmental organizations are important providers of
mental health care. An estimated 93 percent of African and
80 percent of Southeast Asian countries have nongovernmental
organizations in the mental health sector. They provide diverse
services—including advocacy, informal support, housing,
suicide prevention, substance misuse counseling, dementia
support, rehabilitation, research, and other programs—that
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complement, or in some cases substitute for, public and private
clinical services (Levkoff, Macarthur, and Bucknall 1995; Patel
and Thara 2003).
Services for children and adolescents, the majority of the
population in many developing countries, are even more defi-
cient than those for adults. Priority needs to be given to these
services (Rahman and others 2000). At the other end of the life
spectrum, many developing countries are facing aging popula-
tions with grossly underdeveloped aged care services (Levkoff,
Macarthur, and Bucknall 1995). The high level of civil conflict
and natural disasters requires attention to postconflict and
posttrauma mental health conditions. The prevalence of these
disorders is demonstrated by a recent study (Livanou, Basoglu,
and Kalendar 2002) showing that, of 1,000 survivors of the
August 1999 earthquake in Turkey, the incidence of PTSD was
63 percent and of depression was 42 percent.
Specialist mental health providers, especially mental hospi-
tals, tend to focus the services they provide on the lower-
prevalence, higher-disability disorders, such as schizophrenia
and bipolar disorder. Modern treatments, if available and used,
allow most patients to be treated effectively out of hospital.
Specifically, the use of antipsychotic and mood-stabilizing
drugs and the development of strategies for community-based
treatment have led to the closing of large numbers of psychi-
atric inpatient beds in many countries and their replacement
with community services and general hospital psychiatric units
(for example, Larrobla and Botega 2001).
However, in some countries, the majority of psychotic
patients remain in long-term inpatient facilities that engage in
custodial care, which is often of poor quality; moreover, basic
rights are often violated at such facilities (van Voren and
Whiteford 2000). Even if the quality of care is reasonable, acces-
sibility is a problem: these hospitals are often situated in urban
areas, but populations are largely rural and have limited trans-
portation (Saraceno and others 1995). Furthermore, the con-
centration of resources in these facilities can leave little for
other service components (Gallegos and Montero 1999). For
example, in Indonesia, 97 percent of the mental health budget
is spent on public mental hospitals (Trisnantoro 2002). For
many developing countries, the debate about the role of, or
problems with, mental hospitals is subsumed within a gross
deficiency of psychiatric beds of any kind.
The priority for virtually all countries is generating suffi-
cient resources for primary mental health care and deciding
how to expand and best use scarce specialist resources. The
quality of care is often very poor, and huge variations exist in
resource availability between countries (Saxena and Maulik
2003; WHO 2001). Very few countries have what could be con-
sidered an optimal mix of these services, and there are no uni-
versally accepted planning parameters. However, conceptual
models for developing national mental health policy and
guidelines for service planning exist that can be useful in
developing countries (Tansella and Thornicroft 1998;
Townsend and others 2004; WHO 2003).
CONCLUSION: PUBLIC SUPPORT FOR A 
COST-EFFECTIVE INTERVENTION PACKAGE 
In developing countries, much of the mental health care spend-
ing is reported to be out of pocket. Individuals purchase mod-
ern and traditional treatments if they can afford to do so.
Although a large private health sector exists in low-income
countries (Mills and others 2002), the quality and cost vary.
Although unregulated markets fail in health, they fail even
more in mental health. It is unlikely that a country will be able
to rely on an unregulated private sector to deliver services that
will reduce the burden of mental disorders.
In addition to being a large and growing component of dis-
ease burden, mental disorders meet virtually all the criteria by
which we determine the need for government involvement in
health care (Beeharry and others 2002). They affect the poor,
cause externalities, and inflict catastrophic costs; moreover, pri-
vate demand is inadequate. Indeed, the authors recognize that
the main measure of outcome used in this and other chapters—
the disability-adjusted life year—is limited to capturing change
in service user–level symptoms, disability, recovery, and case-
fatality. The DALY does not capture the positive change that
treatment may have on a number of other significant conse-
quences of mental disorders, including family burden (in par-
ticular, productive time and household resources given up in
the care of the sick family member) and lost productivity, at the
level of both the individual and the household (treatment accel-
erates return to paid work or usual household activities) and, by
implication, at the level of society in general. The evidence base
for these productivity increases, although modest in volume,
constitutes an important additional argument alongside “cost
per DALY” considerations for investing in mental health.
The total budgetary requirements and health consequences
of a cost-effective package of mental health care can begin to be
mapped out by selecting one intervention for each of the four
disorders considered in this chapter. Although the data avail-
able for this exercise have limitations and will need to be refined
with further research, table 31.7 summarizes the estimated
costs and effects of a package consisting of (a) outpatient-based
treatment of schizophrenia and bipolar disorder with first-gen-
eration antipsychotic or mood-stabilizing drugs and adjuvant
psychosocial treatment, (b) proactive care of depression in pri-
mary care with generic SSRIs (including maintenance treat-
ment of recurrent episodes), and (c) treatment of panic disor-
der in primary care with generic SSRIs. The estimated benefit of
such a package would be an annual reduction of 2,000 to 3,000
DALYs per 1 million population, at a cost of US$3 million to
US$9 million (that is, US$3 to US$4 per capita in Sub-Saharan
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Africa and South Asia, and US$7 to US$9 per capita in Latin
America and the Caribbean). Accordingly, for every US$1 mil-
lion invested in such a mental health care package, 350 to 700
healthy years of life would be gained over what would occur
without intervention.
At a country level, data such as those presented in this chap-
ter can be used to estimate the proportion of burden currently
averted, the proportion that can be averted with current knowl-
edge and optimal coverage, and the burden not able to be
averted with current knowledge. Such modeling has been done
for some countries (for example, Andrews and others 2004).
Although much remains to be learned about the etiology
and treatment of mental disorders, the potential clearly exists
for a considerable reduction in the burden caused by them.
For these gains to be made, the challenge is to overcome the
cultural, financial, and structural barriers that prevent people
from seeking and receiving treatment. We need to close the gap
between what we know and what we do in treating mental dis-
orders. We can alleviate the substantial burden of these disor-
ders and reverse or limit many of the devastating social and
economic impacts.
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Historically, policy makers and researchers have used mortality
statistics as the principal measure of the seriousness of diseases,
based on which countries and organizations have launched
disease control programs. Mortality statistics alone, however,
underestimate the suffering caused by diseases that may be non-
fatal but cause substantial disability. Many neurological and
psychiatric conditions belong in this category. The absence of
some neurological disorders from lists of leading causes of death
has contributed to their long-term neglect. When the relative
seriousness of diseases is assessed by time lived with disability
rather than by mortality, several neurological disorders appear
as leading causes of suffering worldwide.
World Health Organization data suggest that neurological
and psychiatric disorders are an important and growing cause
of morbidity. The magnitude and burden of mental, neuro-
logical, and behavioral disorders is huge, affecting more than
450 million people globally. According to the Global Burden
of Disease Report, 33 percent of years lived with disability and
13 percent of disability-adjusted life years (DALYs) are due to
neurological and psychiatric disorders, which account for four
out of the six leading causes of years lived with disability
(Mathers and others 2003).
Unfortunately, the burden of these disorders in developing
countries remains largely unrecognized. Moreover, the burden
imposed by such chronic neurological conditions in general
can be expected to be particularly devastating in poor popula-
tions. Primary manifestations of the impact on the poor—
including the loss of gainful employment, with the attendant
loss of family income; the requirement for caregiving, with
further potential loss of wages; the cost of medications; and the
need for other medical services—can be expected to be partic-
ularly devastating among those with limited resources. In addi-
tion to health costs, those suffering from these conditions are
also frequently victims of human rights violations, stigmatiza-
tion, and discrimination. Stigmatization and discrimination
further limit patients’ access to treatment. These disorders,
therefore, require special attention in developing countries.
This chapter addresses Alzheimer’s disease (AD) and other
dementias, epilepsy, Parkinson’s disease (PD), and acute
ischemic stroke. These conditions are current or emerging pub-
lic health problems in developing countries, as assessed by high
prevalence, large numbers of people who are untreated, and
availability of inexpensive but effective interventions that could
be applied on a large scale through primary care. Unfortu-
nately, reliable population-based data from developing coun-
tries on the epidemiology of these and other neurological
disorders are extremely limited. Some other important neuro-
logical conditions that cause high morbidity, such as headache,
are not covered because of difficulties in recommending
evidence-based interventions in developing countries.
ALZHEIMER’S DISEASE AND OTHER DEMENTIAS
Dementia is a deterioration of intellectual function and other
cognitive skills that is of sufficient severity to interfere with
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social or occupational functioning. Of the many diseases that
lead to dementia, AD is the most common cause worldwide
among people age 65 and older, followed by vascular dementia,
mixed dementia consisting of AD plus vascular dementia, and
dementia caused by general medical conditions. Although dis-
tinguishing AD from other causes of dementia is important,
particularly for treatment with acetylcholinesterase inhibitors,
the burden from all causes of dementia is similar. Although the
discussion in this chapter deals mostly with AD, the role of
treatable dementias in developing countries is important as it
can reduce the burden of caring in families.
Prevalence and Incidence Rate
More than 100 prevalence studies of AD and other dementias
have been reported throughout the world. The prevalence of
dementia has generally been found to double with every five-
year increase in age, from 3 percent at age 70 to 20 to 30 percent
at age 85 (Henderson and Jorm 2000). Studies in developing
countries have shown a prevalence of dementia ranging from
0.84 to 3.50 percent (Chandra and others 1998; Hendrie and
others 1995; Rajkumar, Kumar, and Thara 1997). Several stud-
ies have reported the incidence rate of AD and other dementias
in Europe and the United States (Jorm and Jolley 1998).
Compared with incidence rates in developed countries, very
low age-specific incidence rates of AD and other dementias
have been reported from developing countries (Chandra and
others 2001; Hendrie and others 2001).
A comparison of data from developed and developing coun-
tries raises several important questions. The reported differ-
ences in the prevalence of AD and other dementias across
countries could be due partly to methodological differences or
could be due to genuine differences caused by variations in diet,
education, life expectancy, sociocultural factors, and other risk
factors. The low incidence reported from Ballabgarh, India, and
Ibadan, Nigeria, raises the possibility of environmental factors
or gene-environment interactions in the causation of AD. At
the same time, multi-infarct dementia is more common than
primary degenerative dementia in China (Li and others 1991),
which also suggests variation in risk factors across countries.
Risk and Protective Factors and Survivorship
Three separate genes (APP, PS1, and PS2) are linked to early-
onset, familial AD. Another gene (APO E4) is a risk factor for
late-onset, nonfamilial cases (Henderson and Jorm 2000). Other
genes have been implicated but not confirmed in large studies.
Other risk factors reported in the literature include increasing
age, positive family history of dementia, female gender (but this
factor is controversial), lower level of education, several medical
conditions, and exposure to such environmental factors as
organic solvents and aluminum (Henderson and Jorm 2000).
Protective factors reported in the literature include a higher
level of education, a specific gene (APO E2), the intake of anti-
oxidants, and the use of some anti-inflammatory medications
(Henderson and Jorm 2000). The use of estrogen supplements
for women was believed to be a protective factor for AD
(Henderson 1997), but a recent study of women taking a com-
bination of estrogen and progesterone showed that these
women had twice the risk of developing dementia than women
taking a placebo (Shumaker and others 2003).
Studies from developed countries have reported median
survival after the onset of dementia symptoms ranging from
5.0 years to 9.3 years (Walsh, Welch, and Larson 1990). In devel-
oping countries, the reported median survival was 3.3 years for
all demented subjects and 2.7 years for those with AD (Chandra
and others 1998).
Burden of Disease
Burden of disease estimates of AD and other dementias include
vascular dementia, unspecified dementias, and other unclassi-
fied degenerative diseases of the nervous system. Mathers and
others (2003) estimate DALYs for all dementias as 17,108,000,
with the burden being almost twice as much for females
(11,016,000) as for males (6,092,000). Because dementia is a
disease of older ages, the burden from dementia is generally
greater in high-income countries, where life expectancy is
higher, diagnosis is better, and better treatment leads to
increased longevity. Note, however, the relatively high burden
in East Asia and the Pacific and South Asia relative to their level
of economic development (table 32.1).
The bulk of care for those with dementia in developing
countries is provided by the family at home, where the main
caregivers are spouses (36 percent) and children (42 percent)
(Prince 2000). Women in both developed and developing
countries are usually the main caregivers (Prince 2000). Studies
in developed countries indicate that caregivers’ psychological
well-being is a key factor in patients’ admission to nursing or
residential care (Levin, Moriarty, and Gorbach 1994).
In estimating the overall costs of care for dementia, one
must emphasize the value of reducing the burden on care-
givers. Caregiving can result in social isolation, psychological
stress, and high rates of depression (Buck and others 1997).
However, the methodology for estimating the costs of informal
care needs to be standardized.
Interventions
As of now, there is no cure for AD, but some measures can pro-
vide symptomatic relief to patients and caregivers.
Population-Based Interventions. No firm evidence indicates
that any form of population-based intervention can prevent
AD or that the progression of cognitive decline in old age can
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be halted or reduced. However, growing inferential evidence
suggests that reducing the risk of brain trauma in earlier life,
for example, by mandating seat belt and crash helmet use, may
help prevent dementia in later life (Gentleman, Graham and
Roberts 1993).
Personal Interventions. There is a reduction in brain levels of
the neurotransmitter acetylcholine in patients suffering from
AD. Drugs that inhibit acetylcholinesterase, the enzyme
responsible for metabolizing acetylcholine, cause an increase in
brain acetylcholine. Evidence from randomized trials has con-
firmed that, for patients with mild to moderate AD, cognitive
performance benefits, at least in the short term, from the use of
acetylcholinesterase inhibitors (Foster and others 1996).
Despite this benefit to patients, the practical benefits of treat-
ment with acetylcholinesterase inhibitors are mainly attributa-
ble to the lowered caregiver burden. The benefits of using
acetylcholinesterase inhibitors for other dementias have yet to
be proven.
The behavioral and psychological symptoms of dementia
are a major source of stress to family members providing care
to patients. Training family caregivers in behavioral manage-
ment techniques, including problem solving, memory training,
and reality orientation, has been shown to reduce the level of
agitation and anxiety in people with dementia (Brodaty and
Gresham 1989; Haupt, Karger, and Janner 2000). Use of low
doses of antipsychotic medications, which calm the patient and
reduce symptoms such as aggression and wandering, have been
shown to reduce caregiver stress, but these improvements have
not been quantified (Melzer and others 2004).
Interventions that have specifically targeted stress and
depression among caregivers and have shown positive results
include caregiver training, counseling and support for care-
givers, and cognitive and behavioral family interventions
(Marriott and others 2000). Limitations to the implementation
of such strategies include the need for training by specialists,
which makes these strategies less suitable for developing
countries. The challenge for developing countries is to develop
culturally appropriate interventions that can be delivered
within existing resources, such as supporting families in their
role as caregivers.
Treating underlying disease and risk factors for cardiovascu-
lar disease can help prevent future cerebrovascular disease that
could lead to multi-infarct dementia. Other conditions, such as
hypothyroidism or vitamin B12 deficiency, which could lead to
or aggravate dementia, are easily treatable, and the costs of
treatment are much lower than the costs of dementia care.
In Western countries, the model of care for patients with
moderate to severe dementia is based on skilled, long-term care
in institutions. However, such long-term care institutions do
not exist in developing countries, and if they were set up, they
would be extremely expensive and beyond the reach of most
patients and their families. Thus, the model of care in develop-
ing countries should be based on home care, along with pro-
viding training and support for family caregivers.
Interventions that should not be pursued include the use of
multiple medications, which can be detrimental in older age
groups, particularly unproven medications such as cerebral
activators and neurotropic agents. In addition, in many devel-
oping countries, dementia is still equated with “madness,” and
patients are sometimes taken to traditional healers. Community
education has a role to play in eliminating such practices.
EPILEPSY
Epilepsy is a common brain disorder characterized by two or
more unprovoked seizures. Seizures are discrete events caused
by transient, hypersynchronous, abnormal neuronal activity.
Seizures may occur in close temporal association with a variety
of acute medical and neurological diseases, such as acute
stroke, sepsis, or alcohol withdrawal. However, the vast major-
ity of seizures have no immediate identifiable cause.
Epilepsy can be broadly divided into three categories:
idiopathic epilepsy (for example primary generalized
childhood-onset absence epilepsy), which is thought to have a
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Table 32.1 Disability-Adjusted Life Years by Cause and Region, 2001
(thousands)
Global total Latin America Middle East Sub- High-
East Asia and Europe and and the and Saharan income 
Condition Both sexes Males Females the Pacific Central Asia Caribbean North Africa South Asia Africa countries
AD and other 17,108 6,092 11,016 4,110 1,612 1,215 292 1,955 450 7,468
dementias
Epilepsy 6,223 3,301 2,922 1,303 354 737 248 1,741 1,373 464
PD 2,325 1,124 1,202 435 228 90 81 303 100 1,086
Cerebrovascular 72,024 35,482 36,542 25,832 12,616 3,936 1,948 13,184 5,125 9,354
disease
Source: Mathers and others 2006.
genetic basis; secondary or symptomatic epilepsy, which is
caused by a known central nervous system injury or disorder,
such as infection, stroke, traumatic brain injury, or cerebral
dysgenesis; and cryptogenic epilepsy, for which there is no clear
evidence of an etiological factor. Idiopathic and cryptogenic
cases represent approximately 70 percent of epilepsy cases; the
remaining 30 percent are symptomatic (secondary).
Prevalence, Incidence Rate, Remission, and Mortality
The generally accepted estimate of the prevalence of active
epilepsy globally is in the range of 5 to 8 per 1,000 population,
but investigators from African and Latin American countries
report at least double the prevalence reported elsewhere
(Leonardi and Ustun 2002).
The incidence rate of epilepsy in developed countries
is approximately 43 per 100,000 (Kotsopoulos and others
2002). In developing countries, the incidence rate of epilepsy
is higher, with a median of 69 per 100,000 (Kotsopoulos and
others 2002).
Based on follow-up of patients under treatment by general
practitioners in the United Kingdom, Cockerell and others
(1997) report that after nine years 86 percent of epilepsy
patients had achieved a remission of three years, and 68 percent
had achieved a remission of five years. Thus, data from devel-
oped countries suggest a good outcome of seizure control in
most patients with treatment. In developing countries,
although many people with new onset seizures do not receive
treatment, some proportion of patients go into spontaneous
remission even without treatment (Mani and others 1993).
However, the actual remission rate in developing countries is
yet to be documented in population-based studies.
The risk of premature death in people with epilepsy is two
to three times higher than for the general population. In addi-
tion to sudden unexplained death, which occurs in up to 1 in
100 patients with severe refractory epilepsy, additional mortal-
ity results from accidents and suicide. However, the exact cause
of the increased risk is not known in most cases.
Risk Factors
A reported risk factor for idiopathic (presumed genetic)
epilepsy is family history of epilepsy. Reported risk factors for
symptomatic epilepsy include prenatal or perinatal causes
(obstetric complications, prematurity, low birthweight, neona-
tal asphyxia). Recent data suggest that the effect of obstetric
complications or neonatal asphyxia may have been overem-
phasized. Prematurity, low birthweight, and neonatal seizures
may be independent risk factors as well as markers of underly-
ing disease. Other causes include traumatic brain injuries, cen-
tral nervous system infections, cerebrovascular disease, brain
tumors, and neurodegenerative diseases. Developmental
disabilities are not a risk factor for epilepsy in themselves, but
they may be associated with seizure disorder (Casetta and
others 2002; Leone and others 2002).
Treatment Gap
Epilepsy affects about 50 million people worldwide, of whom
approximately 80 percent live in developing countries (WHO
2000). The difference between the number of people with
active epilepsy and the number who are being appropriately
treated in a given population at a given point in time is known
as the treatment gap. Meinardi and others (2001) estimate that
90 percent of people with epilepsy in developing countries are
inadequately treated. Possible reasons for the high treatment
gap include fear of stigmatization, cultural beliefs, lack of
knowledge about the medical nature of epilepsy, illiteracy, eco-
nomic issues, distance to health facilities, inadequate supply of
antiepileptic drugs (AEDs), and lack of prioritization by health
authorities (Wang and others 2003). Even in the developed
world, patients who live in isolated rural regions or inner-city
slums and those who are isolated from the majority because of
cultural factors may suffer a treatment gap.
Faith Healers
Many people with epilepsy seek treatment from faith healers, to
whom they pay large sums in cash or in kind for treatment with
no beneficial medical effects. Karaagac and others (1999) find
that in Silivri, Turkey, 65 percent of 49 people with epilepsy had
visited religious figures at the onset or during the course of the
disease. A study from rural India revealed that 44 percent of
children with epilepsy had sought help from traditional practi-
tioners, whereas approximately 33 percent had received help
from both qualified and traditional practitioners (Pal and oth-
ers 2002). Native Americans still seek traditional healing cere-
monies for epilepsy instead of—or in addition to—Western
medicine.
Patient Compliance
In a study in rural Thailand, only 57 percent of people with
epilepsy were 100 percent compliant with treatment, possibly
because of misunderstanding of the instructions (48 percent),
forgetfulness (16 percent), and economic limitations (13 per-
cent) (Asawavichienjinda, Sitthi-Amorn, and Tanyanont 2003).
To improve compliance in a rural African community, medical
personnel visited the community every 6 months and provided
a long-term supply of medications; this effort led to a sub-
stantial increase in compliance at 20 months (Kaiser and
others 1998). In India, Desai and others (1998) demonstrate
the dependency of compliance on access to free treatment.
Inadequate communication between doctors and patients
influences compliance negatively (Gopinath and others 2000).
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Burden of Disease
The burden of disease (BOD) estimates for epilepsy include
epilepsy and status epilepticus. Mathers and others (2003) esti-
mate the DALYs for epilepsy as 6,223,000, with slightly higher
rates for males (3,301,000) than for females (2,922,000). Many
risk factors for epilepsy are linked with a lower level of eco-
nomic development; thus, the burden is highest in South Asia
followed by Sub-Saharan Africa (table 32.1). A notable obser-
vation is the reportedly low burden in the Middle East and
North Africa, despite parts of that region being relatively
underdeveloped. Epilepsy imposes a large economic burden on
patients and their families. It also imposes a hidden burden
associated with stigmatization and discrimination against
patients and even their families in the community, workplace,
school, and home. Social isolation, emotional distress, depend-
ence on family, poor employment opportunities, and personal
injury add to the suffering of people with epilepsy.
Interventions
Currently, there are no preventive measures for idiopathic or
cryptogenic epilepsy; however, much can be done to prevent
secondary seizures.
Population-Based Interventions. Public health policies, such
as better perinatal care by well-trained birth attendants (partic-
ularly in rural areas) and strategies to control severe head
injuries (for example, by means of laws requiring motorcyclists
to wear helmets and prohibiting drunk driving), can modify
risk factors for epilepsy and thereby reduce the incidence and
prevalence of epilepsy. Policies to control neurocysticercosis
(for instance, building latrines in rural areas) can serve to pre-
vent such infections. Mass deworming for neurocysticercosis
has not been shown to be effective in the long term (Pal,
Carpio, and Sander 2000) but was effective in a campaign in
Ecuador (M. Cruz, personal communication, 2004).
Estimates indicate that 70 to 80 percent of people in devel-
oping countries live in rural and remote areas and have no easy
access to skilled medical care. Strategies that involve training
community-based health care providers who practice in these
communities to identify and manage patients with epilepsy
should be considered.
Policies are needed to ensure the continuous availability of
cheap and efficacious medications, such as phenobarbital, to
all epilepsy patients. Campaigns to educate communities
about the medical nature of epilepsy and to dispel myths and
misconceptions about epilepsy could reduce stigma against
epilepsy and thereby encourage patients to seek medical
treatment.
Personal Interventions. Researchers, primarily in high-
income countries, have tested (a) the efficacy of both older
AEDs (such as phenobarbital, phenytoin, carbamazepine, and
valproic acid) and newer AEDs (such as lamotrigine, oxcar-
bazepine, and topiramate) in controlling seizure frequency and
(b) the safety of these AEDs when prescribed alone or in com-
bination. Some, but not all, of the new AEDs may be better
tolerated in monotherapy and have fewer long-term adverse
effects than older AEDs. However, no study has shown any dif-
ference in efficacy between the older and newer medications
(Aldenkamp, De Krom, and Reijs 2003). Newer medications
are more expensive and, for people in most developing coun-
tries, are practically impossible to access. In some low-income
countries, however, even older AEDs are not available, and
when they are, their supply is irregular.
Newer AEDs are generally recommended as add-on or
adjunctive drugs for better seizure control in patients with
refractory epilepsy already on AEDs. The first AED will render
approximately 50 percent of patients seizure free. Approxi-
mately 20 to 40 percent of patients who do not respond to the
first AED will respond to the introduction of a second AED,
with a greater than 50 percent decrease in seizure frequency
(Schapel and others 1993).
The Global Campaign against Epilepsy, which is jointly
sponsored by the World Health Organization, International
League against Epilepsy, and International Bureau for Epilepsy,
advocates using phenobarbital to close the high treatment
gap in low-income countries. As a first step, all patients with
epilepsy should be given phenobarbital, so that the majority
of patients responsive to phenobarbital will be appro-
priately treated. In resource-poor countries, phenobarbital
can be provided for as little as US$5 to US$10 per year. Pheno-
barbital has extremely low abuse potential. Its side effects—
predominantly sedation, possible mild cognitive impairment,
and depression—have limited its use in industrial countries. In
developing countries, however, side effects are less important
than uncontrolled seizures, and they can be diminished by
using the lowest possible effective doses. Thus, phenobarbital
is the drug of choice for large-scale, community-based pro-
grams, particularly in rural and remote areas of developing
countries.
In recent years, some centers in both developed and devel-
oping countries have been performing surgery on cases of
refractory epilepsy, that is, on patients who do not respond to
any AEDs. Before centers can undertake such surgery, however,
they must have the requisite expertise, facilities, and equip-
ment, including a skilled neurosurgeon. Proper selection of
patients—for example, those with mesial temporal pathology
on MRI—is extremely important. A meta-analysis of studies of
people who underwent epilepsy surgery in developed countries
shows that 58 percent are seizure free and 10 to 15 percent have
reduced seizure frequency (Engel and others 2003). After sur-
gery, even if patients are seizure free, medication should be
continued for one to two years (Engel and others 2003).
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PARKINSON’S DISEASE
PD is characterized by bradykinesia, resting tremor, cogwheel
rigidity, postural reflex impairment, progressive course, and
good response to dopaminergic therapy. Other distinct forms
of parkinsonism include relatively rare genetic forms and the
less common neurodegenerations with multiple system
involvement or significant striatal lesions (for example, pro-
gressive supranuclear palsy or multiple system atrophy).
Parkinsonism secondary to external causes, such as manganese
poisoning or carbon monoxide poisoning, although now rare,
is referred to as secondary parkinsonism. Because the burden
of these diseases to the patient is similar to or greater than that
for PD and there is no evidence for addressing these disorders
separately, they will not be distinguished here.
Prevalence, Incidence Rate, and Mortality
Prevalence estimates vary widely across populations (Tanner
and Goldman 1996; Zhang and Roman 1993). Recent reports,
contrary to previous reports, suggest that the prevalence in
developing and developed countries may be similar (Marras
and Tanner 2002). Few incidence studies have been performed,
and none in developing countries. Van Den Eeden and others
(2003) report the incidence rate of PD in the United States as
approximately 13 per 100,000 person-years. Men are affected
more commonly than women (Tanner and Goldman 1996).
Lower PD incidence in African Americans—and by extension
Africans—has been suggested but is controversial (Van Den
Eeden and others 2003). Most mortality estimates available for
developed countries show about a twofold overall increased
mortality, independent of age, in those with PD (Berger and
others 2000).
Causes and Risk Factors
The cause of PD is unknown. A specific environmental risk
factor has not been identified. Pure genetic forms account for
10 to 15 percent of cases or fewer. Increasing age and male gen-
der are risk factors worldwide (Marras and Tanner 2002).
Exposure to toxins, head trauma, frequent infections, diets high
in animal fat, and midlife adiposity have been reported to
increase PD risk, but none do so consistently (Tanner and
Goldman 1996). The most consistent association is an inverse
association with cigarette smoking and caffeine consumption,
suggesting a protective effect (Ascherio and others 2001).
Burden of Disease
The BOD estimates for PD include Parkinson’s disease and sec-
ondary parkinsonism. Mathers and others (2003) estimate the
DALYs for PD as 2,325,000, with the burden being slightly
higher in females (1,202,000) than males (1,124,000). Though
male gender is a risk factor for PD, the higher burden in females
may reflect their longer life span. As PD is a disease of older
ages, the burden from PD is generally higher in high-income
countries, where life expectancy is higher, diagnosis is better,
and better treatment leads to increased longevity. However, the
burden is high in East Asia and the Pacific and South Asia rela-
tive to that in other regions (table 32.1).
The economic burden of PD includes direct costs, such as
for medication, physicians, hospitals, and chronic care facilities.
Estimated indirect costs resulting from the loss of labor of both
patients and caregivers typically exceed direct costs. The quality
of life of both patients and caregivers is adversely affected.
Interventions
Treatment of PD is based on symptomatic relief, except for pre-
venting secondary parkinsonism caused by neurotoxins.
Population-Based Interventions. No determinants of PD
amenable to population-based interventions have been
identified.
Personal Interventions. Specific curative or neuroprotective
treatments for PD have not been established. Interventions
are primarily directed at palliation of symptoms and include
pharmaceuticals, surgery, physical therapy, and—in some
countries—traditional medicines.
Levo-dopa (l-dopa), l-dopa/decarboxylase inhibitor is the
most widely used therapy for PD. It provides partial relief of all
PD symptoms. Despite its benefits, chronic side effects after
long-term use can cause significant morbidity.
Researchers in developing countries have studied the use of
traditional medicines for PD. Clinical trials have shown that the
seeds of Mucuna pruriens, which contain l-dopa, are a safe and
effective treatment for PD (Parkinson’s Disease Group 1995),
and in animal studies, they are two to three times more effec-
tive than synthetic l-dopa dose per dose (Hussain and Manyam
1997). This substance is available in ayurvedic formulations in
India at a much lower cost than that of synthetic antiparkin-
sonian drugs. Another traditional medicine is derived from
Banisteriopsis caapi, which tribal societies of the Amazonian
jungle use to make a potent hallucinogenic brew. It reportedly
showed dramatic positive effects on rigidity and akinesia in
15 patients with postencephalitic parkinsonism (Lewin and
Schuster 1929). A third traditional option is tai chi, a basic exer-
cise in traditional Chinese medicine that may help with some
of the motor deficits of PD.
Surgical treatment for PD by deep brain stimulation is gen-
erally recommended to address the loss of efficacy of dopami-
nergic drugs. For most patients, it is not effective independent
of drugs. Although a few will have dramatic improvement and
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may be able to reduce or stop drugs, this effect is generally tem-
porary. Criteria for selection of patients for deep brain stimula-
tion include those with advanced disease who are responsive to
l-dopa, not demented, and in good general health. Additional
considerations are the high cost of the equipment, the need
for trained personnel to program the device, and—in most
cases—the need for several visits to a medical center to pro-
gram the stimulator correctly, with periodic returns to adjust
the settings.
STROKE
Stroke, also known as cerebrovascular accident or brain attack, is
a syndrome caused by an interruption in the flow of blood to
part of the brain caused either by occlusion of a blood vessel
(ischemic stroke) or rupture of a blood vessel (hemorrhagic
stroke). The interruption in blood flow deprives the brain of
nutrients and oxygen, resulting in injury to cells in the affected
vascular territory of the brain. The occlusion of a blood vessel
can sometimes be temporary and present as a reversible neuro-
logical deficit, which is termed a transient ischemic attack. Even
though stroke is a clinical diagnosis, brain imaging is required
to distinguish ischemic stroke from hemorrhagic stroke. When
imaging is unavailable, clinical scores can be useful to identify
patients with intracerebral hemorrhage (Allen 1983; Poung-
varin, Viriyavejakul, and Komontri 1991).
Frequency of Types of Strokes, Prevalence, Incidence Rate,
Mortality, and Disability after Stroke
In most parts of the world, about 70 percent of strokes are due to
ischemia, 27 percent are due to hemorrhage, and 3 percent are
of unknown cause (Gunatilake, Jayasekera, and Premawardene
2001). Approximately 25 percent of all ischemic strokes are due
to cardioembolic causes, with the proportion being higher
among younger individuals. In some parts of the world—for
instance, China and Japan—hemorrhagic strokes account for a
greater proportion of all strokes, ranging from 17.1 to 39.4 per-
cent in China (Zhang and others 2003) to 38.7 percent in Japan
(Fukiyama and others 2000).
Comparable data do not exist for all parts of the world. Most
morbidity data from Southeast Asian countries, for example,
are hospital based and are, thus, likely to be underestimates,
because many stroke patients die before they are brought to the
hospital. Mortality data are also likely to be underestimates,
because verifying the cause of death is usually difficult.
In India, the prevalence of stroke has been estimated at
203 per 100,000 population older than 20 (Anand and others
2001). The male-to-female ratio was one to seven. In Taiwan,
China, the crude point prevalence was 592 per 100,000 (Huang,
Chiang, and Lee 1997).
He and others (1995) report the age-adjusted stroke
incidence of 117 per 100,000 population in China. The annual
incidence of stroke in China is reported to have increased in
both men and women, with an average annual percentage
change of 4.5 and 4.2 percent, respectively (Wang, Zhao, and
Wu 2001). In Japan, the age-adjusted annual incidence of stroke
was 105 per 100,000 (Fukiyama and others 2000). Wide varia-
tion within these countries and a high risk of death after the first
stroke in the first year in Japan have been reported. Investigators
believe that those observations are due to variations in the
prevalence of hypertension and the consequent larger propor-
tion of hemorrhagic stroke (Kiyohara and others 2003).
Walker and others (2000) report the yearly age-adjusted
mortality rate per 100,000 for age group 15 to 64 ranged from
35 to 65 in men and 27 to 88 in women in Tanzania. When
compared with the rates in England and Wales—11 for men
and 9 for women—these rates are extremely high. The authors
postulate that the high rates in Tanzania are due to untreated
hypertension. Many developed countries have experienced a
steep decline in stroke mortality in recent decades, but the rate
of decline has fallen substantially in recent years (Liu, Ikeda,
and Yamori 2001; Sarti and others 2000). Mortality from stroke
has increased in some Eastern European countries (Sarti and
others 2000).
Approximately 15 percent of patients die shortly after a
stroke. Of the remaining 85 percent, approximately 10 percent
recover almost completely, and 25 percent recover with minor
impairments (National Stroke Association 2002). Thus,
approximately 40 percent experience moderate to severe
impairments that require special rehabilitative care. About
10 percent will require care in a nursing home or other long-
term facility.
Risk Factors
Risk factors for stroke in general are similar to those for car-
diovascular disease. Moreover, risk factors for first stroke and
recurrence of stroke are also similar if they remain uncon-
trolled after the first attack (see chapter 33).
Increasing age, particularly after 55, is one of the most
important risk factors for stroke (Thorvaldsen and others
1995). Although stroke is more prevalent among men, stroke-
related fatality rates are higher among women (Goldstein and
others 2001). Hypertension is the most important modifiable
determinant of both first and recurrent stroke (Eastern Stroke
and Coronary Heart Disease Collaborative Research Group
1998). The association between blood pressure and stroke
in East Asian populations seems stronger than in Western
populations (Eastern Stroke and Coronary Heart Disease
Collaborative Research Group 1998). Other risk factors include
smoking, environmental exposure to tobacco smoke, dyslipi-
demia, atrial fibrillation, diabetes and impaired glucose
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tolerance, generalized and abdominal obesity, physical inactiv-
ity, excess alcohol consumption, increased homocysteine levels,
drug abuse, hemostatic factors, and existing cerebrovascular
disease (Goldstein and others 2001).
In developing countries, rheumatic heart disease leading to
embolic stroke is also a major cause. This risk factor is declin-
ing in importance with the control of rheumatic fever.
Dehydration in postpartum women can lead to a stroke, par-
ticularly in remote areas where deliveries are conducted at
home.
Burden of Disease
The BOD estimates for stroke include subarachnoid hemor-
rhage, intracerebral hemorrhage, cerebral infarction, and
sequelae of cerebrovascular disease. Mathers and others (2003)
estimate the DALYs for cerebrovascular disease as 72,024,000,
with the burden being almost similar for females (36,542,000)
and males (35,482,000). The burden is highest in East Asia and
the Pacific, followed by South Asia and by Europe and Central
Asia (table 32.1). The burden in Sub-Saharan Africa is higher
than in the Middle East and North Africa, which may suggest
an etiology for stroke other than atherosclerotic disease.
Health experts anticipate that the number of stroke cases
will increase, particularly in developing countries, because of
aging populations and increased exposure to major risk factors.
Corresponding to this increase in the number of stroke cases
will be an increase in the number of people with disabilities
surviving after stroke.
Interventions
Several intervention strategies are available for stroke, but only
a few can be applied in developing countries.
Population-Based Interventions. Public health policies to
address risk factors for stroke include tobacco and alcohol con-
trol, laws to provide labels showing the fat content of foods,
and public education about the harm caused by high-fat foods.
Public health programs to control rheumatic fever will reduce
rheumatic heart disease and the subsequent risk of embolic
strokes. Better training of birth attendants will reduce the risk
of peripartum hemorrhage, which leads to puerperal strokes.
Personal Interventions. Modification of adverse lifestyle and
major risk factors such as hypertension, diabetes, high lipid
levels, smoking, and alcohol abuse is beneficial both for pri-
mary prevention and recurrence of stroke. Some evidence indi-
cates that the decline in the incidence of stroke observed in
many countries is due to better management of hypertension
(MacWalter and Shirley 2002). Special consideration should be
given to the profile of risk factors in developing countries,
which include not only recognized risk factors in developed
countries but also locally relevant risk factors, such as rheu-
matic heart disease and puerperal stroke.
Treatment strategies for acute ischemic stroke include the
following:
• General management. Overall medical care of patients with
an acute stroke is important. Attention to complications
such as bronchoaspiration, fluid and electrolyte imbalance,
and control of blood sugar, as well as prevention of deep
vein thrombosis, is crucial. Experience in developed coun-
tries suggests that specialized stroke units provide the best
care for acute stroke patients (Smaha 2004), but in develop-
ing countries, particularly in rural areas, where hospital beds
are scarce and most patients are attended by general physi-
cians, such units are impractical.
• Platelet antiaggregants. Aspirin can prevent early stroke
recurrence if given during the acute phase of stroke (within
48 hours) (Chinese Acute Stroke Trial Collaborative Group
1997; International Stroke Trial Collaborative Group 1997).
The adverse effects of aspirin (cerebral hemorrhage and gas-
trointestinal complications) appear to be dose related, and
most agree that using a low dose of aspirin is prudent
(Antithrombotic Trialists’ Collaboration 2002). Since
aspirin can aggravate a hemorrhagic stroke, simple guide-
lines for the use of platelet antiaggregants should be devel-
oped and could be based on scales such as the Siriraj score
to rule out hemorrhage (Poungvarin, Viriyavejakul, and
Komontri 1991).
• Thrombolytic therapy. Tissue plasminogen activator and
recombinant tissue plasminogen activator (rt-PA) can be
used to halt a stroke by dissolving the blood clot that is
blocking blood flow to the brain (National Institute of
Neurological Disorders and Stroke rt-PA Stroke Study
Group 1995). Thrombolytic therapy can increase bleeding
and must be used only after careful patient screening, with a
CT scan of the brain within three hours of stroke symptom
onset, to exclude an intracranial bleed. It also requires
appropriately trained physicians to administer the medica-
tion. These prerequisites for the administration of throm-
bolytic agents restrict its use to selected centers in develop-
ing countries.
Strategies for prevention of recurrence of stroke apply
equally to individuals who have experienced a transient
ischemic attack and to those who have experienced a complete
stroke. These strategies include the following:
• Platelet antiaggregants. Aspirin therapy is effective in pre-
venting recurrence of stroke, with low daily doses being at
least as effective as higher daily doses (Antithrombotic
Trialists’ Collaboration 2002). When compared with aspirin,
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clopidogrel has a slight benefit among those who have had
a previous stroke, myocardial infarction, or symptomatic
peripheral arterial disease. Clopidogrel is an effective and
safe alternative for patients who do not tolerate aspirin.
Although clopidogrel may be slightly more effective than
aspirin, it is also more expensive. Antiplatelet combination
therapy using agents with different mechanisms of action,
such as the combination of extended release dipyridamole
and aspirin, has been shown to reduce the risk of stroke over
aspirin alone (Sacco, Sivenius, and Diener 2005). In con-
trast, combination therapy with aspirin and clopidogrel
offers no advantage over aspirin alone and also increases the
risk of hemorrhage (Diener and others 2004).
• Anticoagulant therapy. Anticoagulation with warfarin should
be considered in stroke patients with atrial fibrillation,
because of its clear efficacy in preventing embolic strokes,
provided that patients are appropriately monitored
(European Atrial Fibrillation Trial Study Group 1993;
Mohr and others 2001). Anticoagulant therapy also reduces
the risk of embolic stroke in patients with rheumatic heart
disease. However, anticoagulation can be hazardous in devel-
oping countries because of the lack of monitoring facilities.
• Surgical treatment. In patients with symptomatic carotid
disease with stenosis of 70 percent and in asymptomatic
patients with high-grade stenosis, carotid endarterectomy
has been shown to be more beneficial than medical
care alone (Asymptomatic Carotid Atherosclerosis Study
1995; Asymptomatic Carotid Surgery Trial Collaborative
Group 2004; North American Symptomatic Carotid
Endarterectomy Trial Collaborators 1991). However,
inappropriate selection of patients or high intraoperative
complications could obviate such benefits. Carotid angio-
plasty has been suggested as an alternative to carotid
endarterectomy in management of severe internal carotid
artery disease, but its advantages and disadvantages have yet
to be clearly established (Naylor, London, and Bell 1997).
Carotid endarterectomy for stroke prevention is available at
only a few centers in developing countries, which makes its
widespread use impractical.
The goal of rehabilitation after a stroke is to enable individ-
uals who have experienced a stroke to reach the highest feasible
level of independence as soon as possible. Successful rehabilita-
tion depends on the extent of brain damage, skill of the reha-
bilitation team, length of time before rehabilitation is started,
and support provided by caregivers. Because each stroke
patient has specific rehabilitation needs, customizing the
rehabilitation program is important. Rehabilitation therapies
include several complementary approaches:
• physical therapy, which helps stroke patients relearn simple
motor activities, such as walking
• occupational therapy, which helps patients relearn everyday
activities, such as eating and drinking
• speech therapy, which helps patients relearn language and
speaking skills
• counseling, which can help alleviate some of the mental and
emotional problems that result from stroke.
Comprehensive rehabilitation in a multidisciplinary stroke
unit reduces deaths, disability, and the need for long-term insti-
tutional care (Smaha 2004), but such facilities are extremely
limited in developing countries. Home-based rehabilitation
services can prevent long-term deterioration in activities of
daily living, although the absolute impact is relatively modest
(Outpatient Service Trialists 2002). However, in developing
countries, the vast majority of patients will be treated either at
home by a general physician or in a small community hospital
where no skilled rehabilitation therapist is available.
COST-EFFECTIVENESS OF INTERVENTIONS
IN DEVELOPING COUNTRIES
We determined incremental cost-effectiveness ratios (ICERs)
for selected interventions for each condition by calculating
total DALYs lost by a population because of the condition with
and without treatment and then dividing the difference by
the treatment cost. The disability weights used are presented
in table 32.2. All analyses in this section followed the volume
editors’ standardized guidelines for economic analysis, region-
specific age structures, and underlying mortality rates. We
converted nontradable inputs into U.S. dollars at the market
exchange rate. We assumed that the costs of tradable inputs
were internationally consistent, as were costs associated with
surgical treatments. Table 32.3 presents the costs of drugs and
medical services. No fixed costs were assumed; therefore, our
results are not linked with the extent of treatment coverage.
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Table 32.2 Disability Weights Used in ICER Analysis
AD and other Acute Recurrent
Weight dementias Epilepsy PD stroke stroke
Untreated 0.627 0.15 0.392a 0.278b 0.556
Treated 0.627c 0 0.316 0.235b n.a.d
Source: Mathers and others 2006.
n.a.  not applicable. 
a. Treatment for PD is assumed to be effective for a maximum of 10 years. We also assume that a
patient reverts to the untreated disability weight after 10 years.
b. Disability is assumed to last a maximum of 10 years; then we assume the patient recovers fully.
c. The patient is assumed to experience no benefit from treatment. Benefits are in the form of
reduced caregiver hours.
d. Treatment does not change the disability weight following a recurrent stroke; only the likelihood
of experiencing a second stroke is reduced.
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Table 32.3 Input Requirements for Interventions by Condition
Primary health care worker 
visits to patient in home or 
Visits to primary health care patient visits to see the worker Specialist care in 
doctor in outpatient department in outpatient department outpatient department Inpatient care
Patients using the Visits per Patients using the Visits per Patients using the Visits per Patients using the Length Annual drug 
Condition servicea (percent) year service (percent) year service (percent) year service (percent) of stay costs (US$) 
AD and other dementias
Acetylcholinesterase inhibitors 100 4 100 12 100 2 5 7 638
Antipsychotics 100 12 100 12 25 6 5 7 10
Epilepsy
Phenobarbital 100 2 100 6 10 2 1 3 1
Lamotrigineb 100 2 100 6 10 2 1 3 144
Surgery n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 2,600c
PD
Levodopa/carbidopa 100 3 100 6 100 2 1 5 71
Ayurvedic preparations 100 3 100 6 100 2 1 5 19
Deep brain stimulation n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 37,000
Stroke (acute attack)
Aspirin n.a. n.a. 100 1 100 1 100 14 3
Heparin n.a. n.a. 100 1 100 1 100 14 691
rt-PA n.a. n.a. 100 1 100 1 1 7 1,777d
Stroke (prevention of recurrence)
Aspirin 100 4 100 6 100 1 n.a. n.a. 3
Dipyridamole and aspirin 100 4 100 6 100 1 n.a. n.a. 64
Carotid endarterectomy n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 6,216
Source: Authors.
n.a.  not applicable.
a. Percentage of patients receiving the specified treatment. 
b. Nondrug treatment costs for lamotrigine are not included in the cost-effectiveness analyses because they are accounted for in the phenobarbital treatment costs. Lamotrigine is taken in addition to phenobarbital.
c. Epilepsy surgery also requires screening at a cost of US$600 per screened patient. Because only half of screened patients are eligible for surgery, the cost amounts to US$1,200 per treated patient.
d. This treatment requires testing for eligible patients. The costs of screening ineligible patients include all the same hospital and doctor costs as treatment, as well as 80 percent of the drug cost to account for the diagnostic CT.
AD and Other Dementias
We analyzed the use of acetylcholinesterase inhibitors in the
treatment of AD on the basis of the following assumptions:
first, only patients who were older than 60 at the time of onset
were considered; second, the treatment has no long-term
benefits—that is, it does not reduce patient disability and has
no effect on mortality.
We computed the benefits of reduced caregiver hours on the
basis of reports that the improvement in cognitive function in
AD patients associated with treatment using acetylcholines-
terase inhibitors was a 1.2 point change in the global assessment
scale for cognitive function, as measured by the Mini Mental
State Examination. A 1 point improvement in the score was
associated with a 0.56 hour per day reduction in caregiver
hours, or roughly 205 hours per year (Marin and others 2003).
The cost of using acetylcholinesterase inhibitors per hour of
caregiver time saved averaged US$13 across low- and middle-
income countries (LMICs) and was at least US$11 in specific
regions (the regions are the same as those in table 32.1). This
amount is substantially more than the wage rate in these
regions, which would generally not exceed US$1 to US$1.50
per hour, even for hired caregivers specifically trained to care
for AD patients. We, therefore, conclude that the use of acetyl-
cholinesterase inhibitors in developing countries is not efficient
from an economic perspective. Calculating the cost per DALY
averted for acetylcholinesterase inhibitors would not be mean-
ingful, because we assume no benefit to the patient. Finally, the
use of acetylcholinesterase inhibitors is uncommon in develop-
ing countries; therefore, reducing its use is not an important
concern.
Epilepsy
We analyzed the cost-effectiveness of phenobarbital in the
treatment of epilepsy, and the results are shown in table 32.4.
We assumed that phenobarbital was provided to all patients.
The cost of using phenobarbital per DALY gained in LMICs
was US$89. Table 32.4 shows that the benefits of phenobarbital
are large relative to its cost.
We did not look at other AEDs, such as phenytoin or carba-
mazepine, because the costs of those medications are much
greater than that of phenobarbital, but their effectiveness is
essentially the same (Aldenkamp, De Krom, and Reijs 2003).
Although their use may be justified for specific medical rea-
sons, phenobarbital is much more cost-effective.
We analyzed treatment options for patients who are refrac-
tory to treatment with phenobarbital. We assumed that such
cases were treated either with a combination of phenobarbital
and lamotrigine or with a combination of phenobarbital
and surgery. We used the cost for epilepsy surgery of US$2,600,
in accordance with a study from Colombia, and applied it to
all regions (Malmgren and others 1996; Tureczek, Fandino-
Franky, and Wieser 2000). We assumed that roughly half of
surgery recipients experience no more seizures and that the
remaining half continue to take phenobarbital despite under-
going surgery. Our evaluation of the surgical option included
the costs of diagnostic services and the costs associated with
screening patients who ultimately may not be eligible for sur-
gery. For patients in LMICs who are refractory to phenobarbi-
tal, the ICER of the add-on drug lamotrigine was US$3,000,
and the ICER of the surgical option plus phenobarbital was
US$3,100. The difference between phenobarbital and the other
two options was significant in all regions.
Among refractory epilepsy patients eligible for surgery
and according to postoperative outcome studies conducted
in developed countries, surgery may be of comparable cost-
effectiveness to treatment with a combination of phenobarbital
and lamotrigine. Because effectiveness data for developing
countries are not available, this calculation is based on cost esti-
mates from a study in Colombia and estimates of the effective-
ness of surgery from developed countries. If the surgical out-
come in developing countries were worse than in developed
countries, the cost-effectiveness of surgery would be lower.
Furthermore, we note a number of limitations to the use of
surgery in refractory epilepsy, particularly in developing coun-
tries, along with the lack of long-term follow-up data on the
outcome of surgery. We stress that the primary treatment of
epilepsy is with phenobarbital, and effective treatment of epi-
lepsy lies in more efficient use of this highly cost-effective med-
ication to close the treatment gap.
Parkinson’s Disease
We evaluated three interventions for PD: a combination of
l-dopa and carbidopa, traditional medicines such as the
ayurvedic treatment used in India, and deep brain stimulation.
We assumed that treatment for all three modalities was effec-
tive for 10 years from the onset of treatment. The ICERs in
LMICs for these three modalities were US$1500, US$750 and
US$31,000, respectively (table 32.4). On the basis of the cost of
medication and evidence from clinical trials of effectiveness
(Parkinson’s Disease Group 1995) and from animal studies
(Hussain and Manyam 1997), we found that ayurvedic treat-
ment was the most cost-effective option. The relatively favor-
able ICER for ayurvedic treatment is due to the extremely low
medication cost of this intervention. The relatively high ICER
for deep brain stimulation was largely attributable to the
extremely high cost of surgery. Table 32.4 shows DALYs gained
for US$1 million of health expenditure.
Stroke
We evaluated two sets of interventions for stroke: treatment of
acute stroke and prevention of secondary stroke. We assumed
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638 Table 32.4 Results from Cost-Effectiveness Analysis of Interventions for Alzheimer’s Disease, Epilepsy, Parkinson’s Disease, and Stroke, by World Bank Region
Low- and middle- East Asia and Europe and Latin America and Middle East and Sub-Saharan 
Condition income countries the Pacific Central Asia the Caribbean North Africa South Asia Africa
AD
Cost per care hour reduced using 11 11 12 13 12 11 11
acetylcholinesterase inhibitors (US$)
Epilepsy
Incremental costs of DALYs gained per year 
of treatment compared with no treatment (US$)
Phenobarbital 89 78 122 261 165 54 25
Phenobarbital and lamotrigine 2,994 3,306 2,945 4,301 3,344 2,872 1,490
Phenobarbital and surgery 3,060 3,411 3,049 3,477 2,904 3,097 1,788
Number of DALYs gained per US$1 million per year
Phenobarbital 11,262 12,799 8,185 3,828 6,072 18,581 39,632
Phenobarbital and lamotragine 334 302 340 232 299 348 671
Phenobarbital and surgery 327 293 328 288 344 323 559
PD
Incremental costs of DALYs gained per year of 
treatment compared with no treatment (US$)
Levodopa/carbidopa 1,512 1,398 1,760 2,254 1,944 1,311 1,281
Ayurvedic preparation 751 638 1,000 1,494 1,184 551 520
Levodopa/carbidopa and deep brain stimulation 31,114 26,941 29,310 29,444 30,770 31,347 34,069
Number of DALYs gained per US$1 million per year
Levodopa/carbidopa 662 715 568 444 514 763 781
Ayurvedic preparation 1,331 1,568 1,000 669 845 1,815 1,922
Levodopa/carbidopa and deep brain stimulation 32 37 34 34 32 32 29
N
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Stroke (treatment of acute attack)
Incremental costs of DALYs gained per year 
of treatment compared with no treatment (US$)
Aspirin 149 109 104 574 534 118 112
Heparin 2,675 2,185 1,318 4,952 5,443 2,967 2,940
rt-PA 1,278 1,169 648 2,158 2,516 1,630 1,623
Number of DALYs gained per US$1 million per year
Aspirin 6,691 9,209 9,633 1,742 1,873 8,463 8,942
Heparin 374 458 759 202 184 337 340
rt-PA 783 856 1,543 463 398 613 616
Stroke (prevention of recurrence)
Incremental costs of percent recurrence risk 
averted after 2 years of treatment (US$)
Aspirin 4 3 6 9 7 2 2
Dipyridamole and aspirin 5 5 6 8 7 4 4
Carotid endarterectomy 87 87 87 87 87 87 87
Incremental costs of DALYs gained per 2 years 
of treatment compared with no treatment (US$)
Aspirin 70 60 59 233 196 52 34
Dipyridamole and aspirin 93 95 63 194 186 96 69
Carotid endarterectomy 1,458 1,614 836 2,001 2,234 1,759 1,284
Number of DALYs gained per US$1 million 
per 2 years of treatment
Aspirin 14,313 16,569 16,866 4,285 5,093 19,348 29,373
Dipyridamole and aspirin 10,752 10,555 15,969 5,150 5,384 10,369 14,572
Carotid endarterectomy 686 620 1,197 500 448 568 779
Source: Authors.
that stroke sufferers have fully recovered 10 years after their last
stroke.
We evaluated aspirin, heparin, and rt-PA for the treatment
of acute stroke. The International Stroke Trial Collaborative
Group (1997) reports that, within 14 days of the onset of
stroke, mortality with heparin treatment is less than with a
placebo; however, after six months, mortality is actually greater
for patients treated with heparin than with a placebo—that is,
there is a negative cost per DALY gained if this effect is incor-
porated. The estimates presented here are based on the change
in the short-term mortality risk. For LMICs, the cost per DALY
averted using aspirin was US$150 (table 32.4). The equivalent
costs of interventions using rt-PA and heparin were US$1,300
and US$2,700, respectively. The costs of heparin are higher than
the costs of rt-PA, despite the expensive equipment required for
rt-PA, because of the lower effectiveness of heparin.
Table 32.4 presents DALYs averted for US$1 million of
health expenditure for the three treatments. The cost per DALY
gained using aspirin is a conservative estimate, because the use
of aspirin has additional benefits in terms of preventing a
recurrence of stroke.
Table 32.4 shows the costs of preventing a second stroke
within two years of the first stroke. For LMICs, aspirin was the
least expensive option at US$3.80 per single percentage point
decrease in the risk of a second stroke within two years of the
first. This rate translates to roughly US$70 per DALY gained
(table 32.4). Combining dipyridamole with aspirin, because of
higher cost, was slightly more expensive at roughly US$5.20 per
single percentage point decrease in recurrent stroke risk for a
single individual, or about US$93 per DALY. In contrast,
carotid endarterectomy was US$87 for an equivalent decrease
in individual recurrence risk or almost US$1,500 per DALY.
The aspirin monotherapy option for preventing a recurrence of
stroke was the most cost-effective approach only in South Asia
and Sub-Saharan Africa, largely because of the relatively low
costs of nontradable inputs, such as hospital and doctors’ fees,
in those regions. Low input costs of nontradables increase the
relative importance of drug costs in determining the most cost-
effective intervention; therefore, the cheaper drug, aspirin, was
most cost-effective. Table 32.4 shows that, though US$1 million
would be most effectively spent on aspirin alone in South Asia
and Sub-Saharan Africa, investment in aspirin and dipyri-
damole treatment would result in a greater DALY gain in the
other regions.
RECOMMENDATIONS
The use of acetylcholinesterase inhibitors for treating patients
with AD, as assessed by the number of caregiver hours saved,
suggests that this intervention is not cost-effective. This find-
ing, combined with the limited efficacy of acetylcholinesterase
inhibitors, suggests that they should not be widely used in
developing countries. Instead, giving low doses of antipsychotic
medication to patients with any form of dementia who also
have behavioral problems may be a better option for reducing
caregiver stress, although this possibility has not been system-
atically evaluated.
Phenobarbital is by far the most cost-effective intervention
for managing epilepsy and should be recommended for wide-
spread use in public health campaigns against epilepsy in
LMICs. For those patients who do not respond to phenobarbi-
tal, the addition of lamotrigine is advisable rather than surgery,
because of the resource-intensive evaluation and infrastructure
required for epilepsy surgery.
Indigenous systems of medicine, such as the ayurvedic med-
icines used in India, are much more cost-effective than Western
medications or surgical procedures for managing patients with
PD. Other countries may wish to test and standardize such
medications for their own use.
Aspirin is by far the most cost-effective intervention both for
treating acute stroke and for preventing a recurrence of stroke.
It is easily available in developing countries, even in rural areas.
RESEARCH AND DEVELOPMENT AGENDA
The populations of most developing countries are aging
rapidly. Many neurological disorders frequently occur in the
elderly, posing an emerging public health problem. As a result,
developing countries should begin or expand their research
and development agendas to address issues related to the pre-
vention, identification, and management of neurological
disorders. In the short term, they should focus on early identi-
fication, optimum treatment, and amelioration of distress and
handicaps and on reduction of the social and economic burden
on patients and their families. In the long term, they should
develop and implement strategies for primary prevention of
neurological disorders. Specific areas for research and develop-
ment include the following:
• Conducting population-based epidemiological studies in
developing countries. Population-based data from develop-
ing countries are insufficient, which limits evidence-based
planning. In addition, such data may also suggest important
hypotheses for research if they identify genuine differences
across regions (for example, the reported difference in the
incidence of AD in developed and developing countries). In
addition, the identification of risk or protective factors
would be useful in the primary prevention of such diseases.
• Enhancing existing health care delivery systems. In most
developing countries, approximately 70 to 80 percent of
patients live in rural areas, where medical care is frequently
provided by nonphysician health care providers or, at best,
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by a general physician. Limitations in the availability of
health care have resulted in a huge treatment gap for many
neurological disorders. For such situations, a simple model
for the management of neurological disorders by existing
community-based health care providers, trained to provide
such services, would be helpful. Research is needed on
optimum referral systems for more difficult cases that local
communities will accept and can afford. Strategies for home-
based care of patients need to be systematically evaluated.
• Developing cheaper and more efficacious medicines. Many
currently available medications have significant side effects
and are too expensive for many patients in developing coun-
tries. Newer medications need to be developed with lower
costs, fewer side effects, better efficacy, and less frequent
dose schedules.
• Promoting the use of indigenous systems of medicine. Many
people in developing countries use local indigenous medi-
cines. More research needs to be done on the pharmacolog-
ical properties of those medications (see chapter 69).
• Launching stigma removal campaigns. The stigmatization of
patients with neurological disorders and of their families is
still prevalent, particularly in rural and remote areas, and it
often prevents patients from seeking and obtaining appro-
priate medical care. Effective strategies to address this issue
need to be developed and implemented on a large scale.
MISSED OPPORTUNITIES
Many research studies have reported that the incidence of AD
is lower in developing countries than in Western countries.
Migration studies, such as those looking at the migration of
Africans to the United States, have shown a change in the risk
for AD within one or two generations. This finding suggests
that developing countries may have some protective factors that
rapidly change on migration to developed countries. Despite
this information being available for more than 25 years, no
systematic efforts have been made to identify these protective
factors. Given the rapid adaptation of Western lifestyles in
developing countries, identifying these factors is important
before the opportunity is permanently lost.
The successful use of phenobarbital for treating epilepsy was
first described in 1912. Not only is it effective for many types
of epilepsy, but it is also inexpensive. Nevertheless, despite its
availability for more than 90 years and its modest cost, the
treatment gap for epilepsy still exceeds 90 percent in many
developing countries.
Indigenous systems of medicine, such as for the treatment
of PD, have been used for centuries in developing countries.
However, their utility has not been fully exploited.
Despite evidence of the benefit of control of hypertension
in the primary prevention of stroke, most efforts in developing
countries are directed at treatment of stroke. This approach
not only is more expensive but also is less beneficial to the
patient.
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Cardiovascular disease (CVD) is the number one cause of
death worldwide (Mathers and others 2006; Murray and Lopez
1996; WHO 2002b). CVD covers a wide array of disorders,
including diseases of the cardiac muscle and of the vascular sys-
tem supplying the heart, brain, and other vital organs. This
chapter reviews the epidemiological transition that has made
CVD the world’s leading cause of death, assesses the status of
the transition by region, and indicates regional differences in
the burden of CVD. It also reviews the cost-effectiveness of var-
ious interventions directed at the most relevant causes of CVD
morbidity and mortality.
EPIDEMIOLOGY OF CVD
At the beginning of the 20th century, CVD was responsible for
less than 10 percent of all deaths worldwide, but by 2001 that
figure was 30 percent. About 80 percent of the global burden of
CVD death occurs in low- and middle-income countries.
Murray and Lopez (1996) predicted that CVD will be the lead-
ing cause of death and disability worldwide by 2020 mainly
because it will increase in low- and middle-income countries.
By 2001, CVD had become the leading cause of death in the
developing world, as it has been in the developed world since
the mid 1900s (Mathers and others 2006; WHO 2002a). Nearly
50 percent of all deaths in high-income countries and about 28
percent of deaths in low- and middle-income countries are the
result of CVD (Mathers and others 2006). Other causes of
death, such as injuries, respiratory infections, nutritional defi-
ciencies, and HIV/AIDS, collectively still play a predominant
role in certain regions, but even in those areas CVD is now a
significant cause of mortality.
Predominant Cardiovascular Diseases
This chapter focuses on the most common causes of CVD
morbidity and mortality:
• ischemic heart disease (IHD)
• stroke
• congestive heart failure (CHF).
These diseases account for at least 80 percent of the burden
of CVD in all income regions, which share many of the same
common risk factors; accordingly, similar interventions are
appropriate. A fourth manifestation, rheumatic heart disease
(RHD), which accounts for 3 percent of all disability-adjusted
life years (DALYs) lost as a result of CVD, does not contribute
significantly to the overall global burden of CVD. The burden
of RHD will likely continue to diminish, but it is still an impor-
tant inflammatory cause of heart disease in developing coun-
tries and accordingly is addressed in this chapter. We do not
address many other forms of CVD because of the scope of this
volume; the regional rather than global nature of some inflam-
matory diseases, such as Chagas disease; or the congenital
abnormalities or genetically based cardiomyopathies for which
prevention and treatment options remain limited.
Ischemic Heart Disease. IHD is the single largest cause of death
in the developed countries and is one of the main contributors
to the disease burden in developing countries. The two leading
manifestations of IHD are angina and acute myocardial infarc-
tion. In 2001, IHD was responsible for 7.3 million deaths and 58
million DALYs lost worldwide (WHO 2002b). Seventy-five per-
cent of global deaths and 82 percent of the total DALYs resulting
from IHD occurred in the low- and middle-income countries.
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Angina is the characteristic pain of IHD. It is caused by
atherosclerosis leading to stenosis (partial occlusion) of one or
more coronary arteries. Patients with chronic stable angina
have an average annual mortality of 2 percent or less. Acute
myocardial infarction (AMI) is the total occlusion of a major
coronary artery with a complete lack of oxygen and nutrients
leading to cardiac muscle necrosis. AMI is usually diagnosed
by changes in the electrocardiogram; by elevated serum
enzymes, such as creatine phosphokinase and troponin T or I;
and by pain similar to that of angina. Thirty-day mortality
after an AMI is high: even with best medical therapy it
remains at about 33 percent, with half the deaths occurring
before the individual reaches the hospital. Even in a hospital
with a coronary care unit where advanced care options are
available, mortality is still 7 percent. In a hospital without
such facilities or therapies, the mortality rate is closer to 30
percent. Even though mortality among patients who have
recovered from an AMI has declined in recent decades,
approximately 4 percent of patients who survive initial hospi-
talization die in the first year following the event (Antman
and others 2004).
Stroke. Stroke is caused by a disruption in the flow of blood to
part of the brain either because of the occlusion of a blood
vessel (ischemic stroke) or the rupture of a blood vessel (hem-
orrhagic stroke). Many of the same risk factors for IHD apply
to stroke; in addition, atrial fibrillation is an important risk fac-
tor for stroke. The annual risk of stroke in patients with non-
valvular atrial fibrillation is 3 to 5 percent, with 50 percent of
thromboembolic stroke being attributable to atrial fibrillation
(Wolf, Abbott, and Kannel 1991). Chapter 32 discusses the
diagnosis and management of the clinical syndromes in greater
detail.
Congestive Heart Failure. CHF is the end stage of many heart
diseases. It is characterized by abnormalities in myocardial func-
tion and neurohormonal regulation resulting in fatigue, fluid
retention, and reduced longevity. CHF is caused by pathological
processes that affect the heart; IHD and hypertension-related
heart disease are the most common etiologies. The risk of
developingCHFis twotimesmore inhypertensivemenandthree
times more in hypertensive women compared with those who are
normotensive. CHF is five times more common in those who
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Glossary
ACE inhibitors (angiotensin-converting enzyme
inhibitors): a group of antihypertensive drugs that exert
their influence through the renin-angiotensin-aldosterone
system.
Antiplatelets: drugs that interfere with the blood’s ability
to clot.
Atheroschlerosis: a chronic disease characterized by
thickening and hardening of the arterial walls.
Atrial fibrillation: an abnormal rhythm of the heart that
can result in an increased risk of stroke because of the for-
mation of emboli (blood clots) in the heart.
Beta-blockers: a group of drugs that decrease the heart
rate and force of contractions and lower blood pressure.
Cardiogenic shock: poor tissue perfusion resulting
from failure of the heart to pump an adequate amount of
blood.
Cardiomyopathy: a disorder of the muscle limiting the
heart’s function.
Chagas disease: a tropical American disease caused by a
parasitic infection. Chronic symptoms include cardiac
problems, such as an enlarged heart, altered heart rate or
rhythm, heart failure, or cardiac arrest.
Dyslipidemia: a condition marked by abnormal concen-
trations of lipids or lipoproteins in the blood.
Embolus: a blood clot that moves through the blood-
stream until it lodges in a narrowed vessel and blocks
circulation.
Endocarditis: inflammation of the lining of the heart and
its valves.
Hypertension: abnormally high arterial blood pressure.
Reperfusion: restoration of the flow of blood to a previ-
ously ischemic tissue or organ.
Statins: a group of drugs that inhibit the synthesis of cho-
lesterol and promote the production of low-density
lipoprotein (LDL)–binding receptors in the liver, resulting
in a decrease in the level of LDL and a smaller increase in
the level of high-density lipoprotein (HDL).
Thrombolysis: the breaking up of a blood clot.
Thrombus: a blood clot that forms inside a blood vessel or
cavity of the heart.
Transient ischemic attack: transient reduced blood flow
to the brain that produces strokelike symptoms but no
lasting damage.
have had an AMI than in those who have not. The prognosis for
those with established CHF is generally poor and worse than for
those with most malignancies (McMurray and Stewart 2000) or
AIDS, with a one-year mortality rate as high as 40 percent and a
five-year mortality between 26 and 75 percent.
The worldwide burden of CHF is substantial and continues
to rise. Throughout the developed world the prevalence is
about 2 to 3 percent, with an annual incidence rate of 0.1 to 0.2
percent (McMurray and Stewart 2000). However, the incidence
and prevalence of CHF rise dramatically with age. Prevalence is
27 per 1,000 population for those older than 65, compared with
0.7 per 1,000 for those younger than 50 (McKelvie 2003). CHF
occurs more frequently in men, and incidence and mortality
differ substantially according to gender and socioeconomic sta-
tus. CHF causes 53,000 deaths in the United States each year
and contributes to another 213,000, and the death rate attrib-
uted to CHF rose by 155 percent from 1979 to 2001 in the
United States (American Heart Association 2002). CHF is the
first-listed diagnosis in 1 million hospitalizations.
Rheumatic Heart Disease. RHD is the consequence of an
acute rheumatic fever (ARF)—that is, a poorly adapted
autoimmune response to group A -hemolytic streptococci. It
affects the connective tissue, mainly the joints and the heart
valves. The most serious complications are valvular stenosis,
regurgitation following the valvulitis, or both (Ephrem,
Abegaz, and Muhe 1990). RHD is also a predisposing factor for
infective endocarditis, a disease of younger adults, predomi-
nantly males (Koegelenberg and others 2003).
According to 2001 estimates, RHD accounts for 338,000
deaths per year worldwide, two-thirds of them in Southeast
Asia and the Western Pacific (WHO 2002b). About 12 million
people in developing countries, most of them children, suffer
from RHD (WHO 1995). Steer and others’ (2002) review of
developing countries suggests that RHD prevalence in children
is between 0.7 and 14 per 1,000, with the highest rates in Asia.
RHD and ARF are the most common causes of cardiac disease
among children in developing countries (Ephrem, Abegaz, and
Muhe 1990; Schneider and Bezabih 2001; Steer and others
2002) and account for almost 10 percent of sudden cardiac
deaths (Kaplan 1985).
Until the 1950s, ARF accounted for a substantial portion of
cardiovascular problems among schoolchildren in developed
countries, and even though it is now far less common, out-
breaks still occur (Carapetis, Currie, and Kaplan 1999),
suggesting that neither antibiotics nor other public health mea-
sures have been totally effective in controlling ARF.
The Epidemiological Transition
Over the past two centuries, the industrial and technological
revolutions have resulted in a dramatic shift in the causes of
illness and death. Before 1900, infectious diseases and malnu-
trition were the most common causes of death; however,
primarily because of improved nutrition and public health
measures, they have gradually been supplanted in most high-
income countries by CVD and cancer. As improvements con-
tinue to spread to developing countries, CVD mortality rates
are increasing.
Known as the epidemiological transition, this shift is highly
correlated with changes in personal and collective wealth (the
economic transition), social structure (the social transition),
and demographics (the demographic transition). Omran
(1971) provides an excellent model of the epidemiological
transition that divides it into three basic ages: pestilence and
famine, receding pandemics, and degenerative and human-
created diseases (table 33.1). Olshansky and Ault (1986) add a
fourth stage: delayed degenerative diseases.
The consistent pattern for most high-income countries going
through the epidemiological transition has been initially high
rates of stroke, mostly hemorrhagic. Only in the third phase,
with the presence of increased resources, but coupled with
increased diabetes and smoking rates and adverse lipid profiles,
do rates of IHD climb. This phase is also accompanied by better
control of severe hypertension, reducing the rates of hemor-
rhagic stroke, which is then replaced by ischemic stroke. Most
regions appear to be following this pattern and have a predomi-
nance of IHD. The two exceptions are East Asia and the Pacific
and Sub-Saharan Africa. The pattern in East Asia and the Pacific
is dominated by China and appears to be a result of China’s stage
in the transition but may also be following a pattern similar to
Japan’s—that is, dominated by more strokes and fewer IHD
deaths—whereas Sub-Saharan Africa is in an earlier phase of the
epidemiological transition.
Even though countries tend to enter these stages at different
times, the progression from one stage to the next tends to pro-
ceed in a predictable manner. The six World Bank regions are
at various phases of the epidemiological transition (table 33.1),
and where development has occurred, it has often been at a
more compressed rate than in the high-income countries.
Although rates of IHD and stroke fell 2 to 3 percent per year in
the high-income countries during the 1970s and 1980s, the rate
of decline has since slowed. Overweight and obesity are esca-
lating at an alarming pace, while rates of type 2 diabetes, hyper-
tension, and lipid abnormalities associated with obesity are on
the rise. This trend is not unique to the developed countries,
however. According to the World Health Organization, world-
wide more than 1 billion adults are overweight and 300 million
are clinically obese. Even more disturbing are increases in
childhood obesity that have led to large increases in diabetes
and hypertension. If these trends continue, age-adjusted CVD
mortality rates could increase in the high-income countries in
the coming years. These trends are discussed in greater detail in
chapter 45.
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Table 33.1 Stages of the Epidemiological Transition and Its Global Status, by Region
Percentage Percentage 
Life of deaths of the world’s 
expectancy attributable population 
Stage Description (years) Dominant form of CVD to CVD in this stage Regions affected
Pestilence and famine Predominance of 35 RHD, cardiomyopathy caused 5–10 11 Sub-Saharan Africa, parts of all regions excluding 
malnutrition and infectious diseases by infection and malnutrition high-income regions
Receding pandemics Improved nutrition and public 50 Rheumatic valvular disease, 15–35 38 South Asia, southern East Asia and the Pacific, 
health leads to increase in IHD, hemorrhagic stroke parts of Latin America and the Caribbean
chronic diseases, hypertension
Degenerative and Increased fat and caloric intake, 60 IHD, stroke (ischemic and 50 35 Europe and Central Asia, northern East Asia and 
human-created widespread tobacco use, chronic hemorrhagic) the Pacific, Latin America and the Caribbean, 
diseases disease deaths exceed mortality Middle East and North Africa, and urban parts of 
from infections and malnutrition most low-income regions (especially India)
Delayed degenerative CVD and cancer are leading 70 IHD, stroke (ischemic and 50 15 High-income countries, parts of Latin America and 
diseases causes of morbidity and mortality, hemorrhagic), CHF the Caribbean
prevention and treatment avoids 
death and delays onset; 
age-adjusted CVD declines
Source: Adapted from Olshanksy and Ault 1986; Omran 1971; WHO 2003b.
Risk Factors
The risk of developing CVD depends to a large extent on the
presence of several risk factors. The major risk factors for CVD
include tobacco use, high blood pressure, high blood glucose,
lipid abnormalities, obesity, and physical inactivity. The global
variations in CVD rates are related to temporal and regional
variations in these known risk factors. Discussions of the
strength of the associations of the various factors with CVD are
found elsewhere (chapters 30, 44, and 45). Although some risk
factors, such as age, ethnicity, and gender, obviously cannot be
modified, most of the risk is attributable to lifestyle and behav-
ioral patterns, which can be changed.
BURDEN OF DISEASE
CVD is the leading cause of death in all World Bank regions with
the exception of Sub-Saharan Africa (figure 33.1), where
HIV/AIDS has emerged as the leading cause of mortality
(Mathers and others 2006). Between 1990 and 2020, IHD is
anticipated to increase by 120 percent for women and 137 per-
cent for men in developing countries,compared with age-related
increases of 30 to 60 percent in developed countries (Leeder and
others 2004). Even though 80 percent of CVD deaths occur in
low- and middle-income countries, the death rates for most
regions are still below the rate for high-income countries, which
is 320 per 100,000 population annually. The marked exception is
Europe and Central Asia,which has a rate of 690 CVD deaths per
100,000 population.
Regional Burdens
The majority of the burden occurs in East Asia and the Pacific,
Europe and Central Asia, and South Asia because a large pro-
portion of the world’s population lives in East Asia and the
Pacific and South Asia and the incidence of IHD is high in
Europe and Central Asia.
East Asia and the Pacific. The status and character of the epi-
demiological transition across the region reflects the diversity of
economic circumstances in East Asia and the Pacific. Since the
1950s, life expectancy in China has nearly doubled from 37 years
to 71 years (WHO 2003b). Approximately 60 percent of the
population still lives outside urban centers, and as is the case in
most developing countries, rates of IHD, stroke, and hyperten-
sion are higher in urban centers. China appears to be straddling
the second and third stages of a Japanese-style epidemiological
transition, with CVD rates higher than 35 percent, though dom-
inated by stroke, not IHD. However, in urban China, the death
rate from IHD rose by 53 percent from 1988 to 1996.
Europe and Central Asia. The emerging market economies,
which consist of the former socialist states of Europe, are
largely in the third phase of the epidemiological transition. As
a group, they have the highest rates of CVD mortality in the
world, similar to those seen in the United States in the 1960s
when CVD was at its peak. Belarus, Croatia, Kazakhstan,
Romania, and Ukraine have seen significant increases in IHD
death rates (figure 33.2). In the Russian Federation, life
expectancy for men has dropped precipitously since 1986 from
71.6 years to about 59 years in 2004, in large part because of
CVD. In the Czech Republic, Hungary, Poland, and Slovenia,
age-adjusted CVD rates have been declining. Nevertheless,
CVD rates generally remain higher than in Western Europe.
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Figure 33.1 Major Causes of Death in Persons of All Ages in Low-
and Middle-Income Regions
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Figure 33.2 Percentage Change in Ischemic Heart Disease Death
Rates in People Age 35 to 74, 1988–98, Selected Countries
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Latin America and the Caribbean. In 2001, CVD accounted
for about 31 percent of all deaths in Latin America and the
Caribbean, but that figure is expected to rise to 38 percent by
2020 (Murray and Lopez 1996). In recent decades, average life
expectancy in Latin America and the Caribbean has risen from
51 to 71 years, and the quality of nutrition has improved steadily.
At the same time, the region has seen a switch from vegetables as
a source of protein to animal protein and an increase in fat
intake as a percentage of energy. As a whole, the region seems to
be in the third phase, but in South America, some areas are still
in the first phase of the transition.
Middle East and North Africa. Increasing economic wealth in
the Middle East and North Africa has been characteristically
accompanied by urbanization. The rate of CVD has been
increasing rapidly and is now the leading cause of death,
accounting for 25 to 45 percent of total deaths. Over the past
few decades, daily per capita fat consumption has increased in
most countries in the region, ranging from a 13.6 percent
increase in Sudan to a 143.3 percent increase in Saudi Arabia
(Musaiger 2002). IHD is the predominant cause of CVD, with
about three IHD deaths for every stroke death. RHD remains a
major cause of morbidity and mortality, but the number of
hospitalizations for RHD is declining rapidly.
South Asia. Some regions of India appear to be in the first
phase of the transition, whereas others are in the second or
even the third phase. Nonetheless, India is experiencing an
alarming increase in heart disease, which seems to be linked to
changes in lifestyle and diet, rapid urbanization, and possibly
an underlying genetic component. Diabetes is also a major
health issue. India has 31.6 million diabetics, and the number
is expected to reach 57.2 million by 2025 (Ghaffar, Reddy, and
Singhi 2004). The World Health Organization estimates that,
by 2010, 60 percent of the world’s cardiac patients will be in
India. About 50 percent of CVD-related deaths occur among
people younger than 70, compared with about 22 percent in the
West. Between 2000 and 2030, about 35 percent of all CVD
deaths in India will occur among those age 35 to 64, compared
with only 12 percent in the United States and 22 percent in
China (Leeder and others 2004).
Sub-Saharan Africa. In Sub-Saharan Africa, deaths attributa-
ble to CVD are projected to more than double in between the
years 1990 and 2020. Although HIV/AIDS is the leading over-
all cause of death in this region, CVD is the second-leading
killer and is the first among those over the age of 30. Stroke is
the dominant form, in keeping with patterns characteristic of
earlier phases of the epidemiological transition. With increas-
ing urbanization, levels of average daily physical activity are
falling and smoking rates are increasing. Hypertension has
emerged as a major public health concern, and hypertensive
disease accounts for the dominance of stroke (Bertrand 1999).
RHD and cardiomyopathies, the latter caused mostly by mal-
nutrition, various viral illnesses, and parasitic organisms, are
also important causes of CVD mortality and morbidity.
Social and Economic Impact
Leeder and others’ (2004) report highlights the economic
impact of cardiovascular diseases in developing economies,
which arises largely because working-age adults account for a
high proportion of the CVD burden. Conservative estimates in
Brazil, China, India, Mexico, and South Africa indicate that
each year at least 21 million years of future productive life are
lost because of CVD. In South Africa, for example, costs for the
direct treatment of CVD were equivalent to 2 to 3 percent of
gross domestic product, or roughly 25 percent of all health care
expenditures (Pestana and others 1996).
Current expenditures in developed countries are indicators
of possible future expenditure in developing countries. For
example, Hodgson and others (2001) estimated that in 2003
the direct and indirect costs of CVD in the United States would
amount to US$350 billion. They also estimated that in 1998
Americans spent US$109 billion on hypertension, equivalent to
about 13 percent of the health care budget. Studies are limited
but suggest that obesity-related diseases are responsible for 2
to 8 percent of all health care expenditures in developed
countries.
COST-EFFECTIVENESS OF INTERVENTIONS
CVD remains one of the most studied and written about sub-
jects in medicine. As a result, many interventions exist with
strong evidence for significant reductions in morbidity and
mortality associated with CVD.
Intervention Effectiveness by Disease
This chapter addresses those interventions believed to have the
largest effect because they result in large reductions in CVD
events, are inexpensive, or the prevalence or incidence of the dis-
eases to which they are directed is significant.The omission of an
intervention does not imply that it is not cost-effective but rather
that either it had an effect on a smaller percentage of people or
the chapter was unable to encompass all such interventions.
Acute Myocardial Infarction. Treatment of AMI involves
medical therapies that reduce myocardial oxygen demand and
fatal arrhythmias (beta-blockers), that restore blood flow by
inhibiting platelet aggregation (aspirin), or that dissolve
the thrombus occluding the arterial lumen (thrombolytics) or
an invasive intervention with cardiac catheterization and
angioplasty.
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Beta-blockers are used both during and after an AMI.
Benefits persist for at least 6 years and up to 15 years after the
first AMI. The second Thrombolysis in Myocardial Infarction
trial showed significant benefits when beta-blockers were used
within two hours of symptoms (Roberts and others 1991).
Aspirin, an antiplatelet agent, and thrombolytic agents, the
standard treatments for reopening the artery in AMI, have
demonstrated an additive effect in reducing mortality (GISSI
1986), with a benefit irrespective of age, sex, blood pressure,
heart rate, or previous history of AMI or diabetes (Fibrinolytic
Therapy Trialists’ Collaborative Group 1994). The benefits are
greater the closer the thrombolytics are given to the time of
onset, and the risk of bleeding is greater the later they are given.
The risk of adverse events following administration of throm-
bolytics is low during the first 24 hours; trials with throm-
bolytics show that the benefits are greatest when they are
administered less than 12 hours after an AMI and preferably
less than 6 hours (Antman and others 2004).
The invasive alternative to immediate medical reperfusion
of an occluded coronary artery is angioplasty or percutaneous
coronary intervention. Its superiority over thrombolysis in
developed countries remains a matter of debate. Issues that
remain important in relation to the choice of strategy are over-
all severity or location of the AMI and the time from symptom
onset to initiation of treatment. In patients presenting late or
with a high risk of mortality, such as those in cardiogenic
shock, percutaneous coronary intervention may be beneficial
(Hochman and others 1999). However, as with thrombolytic
agents, the benefits of percutaneous coronary intervention
diminish significantly with time between the onset of symp-
toms and the opening of the artery (De Luca and others 2004;
D. O. Williams 2004).
The invasive strategy requires a facility and individual physi-
cians who conduct enough of the procedures annually to
remain proficient. In the absence of these conditions, the
American Heart Association recommends that treatment focus
on thrombolytics (Antman and others 2004). Given either a
lack of facilities and operators for percutaneous interventions
or long distances to such facilities in many developing coun-
tries, we did not evaluate this procedure.
Long-Term Management of Existing Vascular Disease. The
management of individuals with chronic vascular disease con-
sists of invasive techniques, pharmacotherapy, lifestyle and
behavioral changes, and rehabilitative measures. It also involves
addressing such issues as adherence to treatment, regular follow-
ups to determine compliance and assess risk, and treatment of
comorbidities that are likely to have an impact on the progres-
sion of vascular disease (for instance, renal disease).
Invasive Interventions The three most common procedures
are coronary artery bypass graft (CABG), percutaneous trans-
luminal coronary angioplasty (PTCA), and PTCA with stents.
CABG is the placement of grafts, usually from the saphenous
vein or internal mammary artery, to bypass stenosed coronary
arteries while maintaining cerebral and peripheral circulation
by cardiopulmonary bypass. CABG is a major operative proce-
dure requiring appropriate surgical and anesthetic environ-
ments and has a perioperative mortality of 1 to 3 percent, with
later complication rates of 15 to 20 percent.
Almost 1 million CABGs per year are performed worldwide,
with about 519,000 interventions in the United States alone in
2000 (American Heart Association 2002). The main indication
for CABG is for those with left main coronary artery stenosis or
those with involvement of multiple coronary arteries with
reduced left ventricular function, particularly among diabetics.
The prevalence estimates of those with left main coronary
artery stenosis or involvement of three coronary arteries has
varied over time, but current estimates range from 7 to 20 per-
cent of survivors of myocardial infarction (Kuntz and others
1996; Rogers and others 1991; Topol, Holmes, and Rogers
1991) For these cases, investigators have shown that CABG is
more beneficial than medical treatment, both in terms of
symptoms and of mortality (Eagle and others 1999).
Both developed and developing countries are increasingly
using PTCA (Denbow and others 1997). The main indications
for its use are low-risk patients with single- or double-vessel
disease and poor response to medical treatment. The success
rate of PTCA is more than 95 percent; however, because it has
no mortality benefit when compared with medical therapy
or CABG, we did not evaluate new analyses of the cost-
effectiveness of this intervention, but instead provided infor-
mation from experience in developed countries. The addition
of stents to PTCA has lead to a decrease in restenosis rates and
readmissions to hospitals but shows no change in mortality
compared with medical therapy.
Pharmacological Interventions The pharmacological inter-
ventions either prevent thrombosis, as does aspirin, or target
the individual risk factors, as do the antihypertensives (diuret-
ics, beta-blockers, and ACE inhibitors) or statins targeting
cholesterol. Furthermore, these agents may possibly have addi-
tional properties of reducing the risk of fatal arrhythmias,
improving repair after AMI (remodeling), or stabilizing the
atherosclerotic plaque.
Overall, the long-term administration of antiplatelet agents
in those with vascular disease leads to a 25 percent reduction
in the risk of major vascular events: 33 percent for nonfatal
AMI, 25 percent for nonfatal stroke, and 16 percent for any
vascular death. The use of aspirin has produced similar
benefits in individuals with IHD or prior stroke. Antiplatelet
treatment in individuals with a previous AMI has been
shown to prevent 18 nonfatal myocardial infarctions, 5 nonfa-
tal strokes, and 14 vascular deaths for every 1,000 patients
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treated for two years (Antithrombotic Trialists’ Collaboration
2002).
The benefits of antiplatelet agents for those with vascular
disease far outweigh the risks. The risk of intracranial bleeding
increases by nearly 25 percent with the use of antiplatelet
agents, but in absolute terms this risk comes to only one or two
intracranial bleeds per 1,000 patients treated per year. The risk
of major extracranial bleeding, mostly gastrointestinal, also
increases by 60 percent, or one or two excess events per 1,000
patients per year.
The most established and commonly used agent is aspirin,
although other agents (for example, clopidogrel or ticlopidine)
with similar efficacy but much greater cost are available. Low
doses of aspirin—75 to 100 milligrams (mg) per day—are as
beneficial as higher doses.
Lowering LDL and elevating HDL cholesterol levels is one
of the cornerstones of treatment of cardiovascular disease,
and investigators have suggested that suboptimal levels of
cholesterol contribute to almost two-thirds of the global car-
diovascular risk (WHO 2002b). Although the usual target of
lipid-lowering therapy has been lowering total or LDL choles-
terol, medical experts are increasingly recognizing the impor-
tance of increasing HDL cholesterol and lowering triglyceride
levels, especially in high-risk individuals, such as those with
diabetes or metabolic syndrome, as well as in ethnic popula-
tions like Southeast Asians.
Recent evidence has demonstrated that the relationship
between cholesterol levels and vascular events is continuous
and occurs at much lower cholesterol thresholds than previ-
ously believed. The clinical trials have consistently demon-
strated a 25 to 30 percent reduction in the risk of cardiovascu-
lar morbidity and mortality. Furthermore, the evidence
suggests that more aggressive reductions in cholesterol have
higher benefits than mild or moderate reductions (Cannon and
others 2004; Knatterud and others 2000). No increased risk of
cancers appears to exist, as was previously believed, although a
small increase exists in the risk of inflammation of noncardiac
muscle (myopathy) (Pfeffer and others 2002).
As with cholesterol, the relationship between blood pressure
and vascular events is continuous and is discussed further in
chapter 45. Even patients with presumed “normal” blood pres-
sure and prior vascular disease benefit from lowering blood
pressure (Nissen and others 2004), confirming earlier evidence
that individuals with a history of AMI who have lower blood
pressure are less likely to have future vascular events.
Furthermore, investigators have established mortality and mor-
bidity benefits for several specific classes of drugs to reduce
blood pressure in patients with vascular disease, namely,
beta-blockers, calcium-channel blockers, and ACE inhibitors
(Fox 2003).
In patients with a prior history of stroke or transient
ischemic attack (transient occlusion of artery supplying the
brain), the long-term benefits of lowering blood pressure have
been clearly established. Lowering blood pressure reduces the
overall risk of future stroke by 28 percent and of other vascular
events and CHF by 26 percent in patients with a history of
stroke disease, irrespective of their hypertension status. The
benefits are even more pronounced for individuals with a his-
tory of hemorrhagic stroke. Larger reductions in blood pres-
sure confer greater benefits, and benefits are present across dif-
ferent age groups, genders, and ethnicities and with varying
comorbid status.
Beta-blockers are one of the cornerstones of long-term
treatment of individuals with IHD, especially those with a his-
tory of AMI. Long-term use of beta-blockers has been associ-
ated with 23 percent relative risk reduction in mortality
(Freemantle and others 1999), 25 percent relative risk reduc-
tion in nonfatal myocardial infarction, and 30 percent relative
risk reduction in sudden cardiac death (Yusuf and others
1985). The benefits are larger for those at highest risk of sus-
taining a vascular event in the future and are present across all
age groups and sexes. Furthermore, beta-blockers provide clear
benefits in patients with chronic stable angina, where they pro-
vide symptom relief as well as reductions in vascular events
(Heidenreich and others 1999).
ACE inhibitors have proved invaluable in preventing cardio-
vascular events and CHF in those with IHD. The extent to
which the benefits conferred by their use are caused by their
ability to lower blood pressure or by their other properties,
such as cardiac remodeling and neurohormonal modulation, is
not clear. Long-term use of ACE inhibitors in those with a his-
tory of myocardial infarction and in other individuals at high
risk of vascular disease reduces vascular mortality by 25 percent
and other nonfatal events, such as recurrent myocardial infarc-
tion, revascularization, hospitalization, progression or new
onset of CHF, and stroke (Teo and others 2002). In those with
asymptomatic or symptomatic left ventricular dysfunction
after myocardial infarction, ACE inhibitors reduce the risk of a
variety of vascular endpoints by 20 to 26 percent. Similarly, the
use of ACE inhibitors even in those with no evident left ven-
tricular dysfunction confers a 21 percent reduction in risk for
major coronary events (Dagenais and others 2001), 32 percent
for stroke (Bosch and others 2002), and 20 to 22 percent for
composite vascular outcomes (Fox 2003).
Nonpharmacological Interventions Cessation of smoking
and dietary modifications are important goals of secondary
prevention of CVD. Cardiac rehabilitation, including exercise,
is useful for a wide range of patients with IHD and reduces
future vascular events by about 15 percent. Exercise alone
reduces vascular mortality by 24 percent and vascular end-
points by 15 percent (Jolliffe and others 2000). Results of trials
for psychological interventions targeted at stress, depression,
low social support, and so on have been conflicting.
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Congestive Heart Failure. Diuretics are standard therapy for
CHF, with the loop and thiazide diuretics most commonly
used. Diuretics provide relief of symptoms more rapidly than
any other CHF medication because they are the only drugs
that can adequately control the fluid retention associated with
CHF. Using spironolactone, a neurohormonal antagonist,
together with a diuretic decreased the risk of mortality by 30
percent and of hospitalization by 35 percent, compared with
a placebo in patients with severely advanced heart failure
(Pitt and others 1999); however, this combination requires
intensive monitoring of electrolytes and testing to follow
patients and thus was not included in our cost-effectiveness
analyses.
Investigators have shown that ACE inhibitors reduce risks
related to a variety of endpoints, including mortality, hospital-
ization, major coronary events, deterioration of symptoms, and
progression from asymptomatic to symptomatic left ventricu-
lar dysfunction, by 25 to 33 percent. The benefit is conferred
irrespective of the etiology of systolic failure; begins soon after
the start of treatment; persists over the long term; and is inde-
pendent of age, sex, and baseline use of other medications.
Furthermore, the use of ACE inhibitors has proved to be highly
cost-effective in developed countries.
Beta-blockers improve symptoms, decrease hospitalization
and deterioration of heart function, and improve mortality.
They should be used even when the patient becomes asympto-
matic. Beta-blockers are beneficial at all stages of CHF, reduc-
ing the morbidity and mortality associated with CHF by 25 to
33 percent. Because most patients with CHF die of sudden car-
diac death, the protective effects of beta-blockers are probably
related to their antiarrhythmic properties.
Digitalis decreases hospitalization rates in individuals with
CHF but has no effect on vascular or total mortality (Digitalis
Investigation Group 1997). Given that it also has a narrow
therapeutic-toxic window and requires careful monitoring, its
role in standard treatment for CHF has diminished and has not
been included in our cost-effectiveness analyses.
Rheumatic Heart Disease. The management of patients
with ARF includes providing antistreptococcal treatment,
managing clinical manifestations, and screening children. In
the acute stage, all patients with ARF should be treated as if
they have a group A streptococcal infection—that is, with a 
10-day course of penicillin. Anti-inflammatory agents
provide symptomatic relief during ARF but do not prevent
RHD. Secondary prophylaxis prevents colonization of the
upper respiratory tract and consists of penicillin or sulfadiazine
for the first five years (and for life for patients with valvular
heart disease). Noncompliance is frequent, reaching rates
as high as one-third of patients (Bassili and others 2000).
Tertiary treatment entails surgery for valve replacement or
valvuloplasty.
Linking Costs and Effectiveness in Developing Countries
Few intervention trials have been carried out solely in develop-
ing countries, but investigators have extrapolated estimates of
cost-effectiveness ratios for the developing world in general
based on changes in key input prices (Goldman and others
1991); however, this process is limited by the fact that both the
underlying epidemiology and the costs can differ significantly
across and within countries and regions. Thus, our results
reflect models that used prices and epidemiological data for
World Bank regions where applicable. Intervention effects were,
however, based on systematic reviews of randomized trials or
meta-analyses in developed countries. Until intervention trials
are conducted in developing countries, this option remains the
best for evaluating the cost-effectiveness of various interven-
tions in the developing regions. In cases in which models for dis-
eases in selected regions were not developed, we present results
of cost-effectiveness analyses from high-income countries.
We used estimates of life expectancy for the model from
data supplied by the volume editors. The model includes only
the costs related to the intervention itself and to CVD events
and their sequelae. Costs include personnel salaries, health care
visits, diagnostic tests, and hospital stays as provided by the vol-
ume editors. Our analysis does not include indirect costs, such
as those arising from lost work time or family assistance. Drug
costs are from McFayden (2003). All are in U.S. dollars unless
otherwise specified. Disability weights were taken from
Mathers and others (2006).
Ischemic Heart Disease.
Acute Myocardial Infarction We evaluated four incremental
strategies for the treatment of AMI and compared them with
a strategy of no treatment as a base case. The four treatment
strategies were aspirin (162.5 mg per day for 30 days); aspirin
and atenolol (100 mg per day for 30 days); aspirin, atenolol, and
streptokinase (1.5 million units); and aspirin, atenolol, and tis-
sue plasminogen activator (100 mg accelerated regimen). Doses
for the aspirin and streptokinase were those used by the Second
International Study of Infarct Survival Collaborative Group
(ISIS-2 Collaborative Group 1988), the atenolol regimen was
that of the First International Study of Infarct Survival (ISIS-1
Collaborative Group 1986), and the tissue plasminogen activa-
tor dosing was that used in the Global Use of Strategies to Open
Occluded Coronary Arteries (GUSTO)–I trial (GUSTO
Investigators 1993). The relative risk of dying from AMI was
reduced for all patients receiving the medications. Patients
receiving the thrombolytics faced increased risks of major
bleeds and hemorrhagic strokes. Because the effectiveness of
streptokinase diminishes over time, we carried out two further
sensitivity analyses to compare its use for patients over and
under the age of 75 and for patients who receive the intervention
sooner or later than six hours after the onset of symptoms.
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Table 33.2 presents incremental cost-effectiveness ratios
(ICERs) for each therapy by region. The incremental cost per
DALY averted was less than US$25 for all six regions for the
aspirin and aspirin plus atenolol interventions; US$634 to
US$734 for aspirin, atenolol, and streptokinase; and slightly
less than US$16,000 for aspirin, atenolol, and tissue plasmino-
gen activator. Minor variations occurred between regions
because of small differences in follow-up care costs. The results
for an analysis that evaluated ICERs as cost per life year saved
showed no significant differences.
Table 33.3 displays the results of the secondary analysis for
streptokinase and tissue plasminogen activator. Giving the
streptokinase sooner than six hours following onset reduces the
incremental cost per DALY to less than US$440 compared with
more than US$1,300 if given after six hours. Similar effects are
seen when streptokinase is given to those under 75 compared
with those 75 years or older.
According to meta-analyses, nitroglycerin has a modest
effect on mortality in AMI: a 3 percent reduction. However,
given that it can have profound effects on blood pressure that
could limit the use of beta-blockers that confer more signifi-
cant benefits, its use should be limited to patients with ongoing
ischemic pain and systolic blood pressures greater than 90 mil-
limeters of mercury who do not have ongoing right ventricu-
lar infarction. When modeled, it had a reasonable cost-
effectiveness ratio of US$70 per life year saved, but we did not
include the analysis in the incremental analysis because of the
blood pressure effects of the multiple agents.
Secondary Prevention Four medical therapies—aspirin, beta-
blockers, statins, and ACE inhibitors—have been the mainstay
of treatment for those with IHD in the developed world. To
evaluate the best medical intervention, we used incremental
cost-effectiveness analysis to examine the 15 different possible
combinations of the four standard medical therapies. The four
therapies were 75 to 100 mg per day of aspirin, 100 mg per day
of atenolol, 10 mg per day of enalapril, and 40 mg per day of
lovastatin. In addition, CABG surgery provides an invasive
option that gives added mortality benefit when compared with
conventional medical therapy in patients with certain anatom-
ical obstructions in coronary circulation. Thus, we evaluated
CABG in addition to all four medications for those with left
main coronary artery disease or with three-vessel coronary
artery disease and reduced left ventricular function. Because
these therapies also have significant effects on the incidence of
stroke, we included the effect on DALYs and costs for stroke in
the analyses.
In addition to the mortality benefits demonstrated by trials
of the individual medications or surgery, they also resulted in
significant reductions in hospitalizations in developed coun-
tries. The cost savings from these reduced hospitalizations
make the cost-effectiveness of such interventions quite favor-
able in developed countries; however, given that hospital facil-
ities may not be available to most patients in many developing
regions, we undertook two separate analyses, one with hospital
costs and one without.
In a setting where hospitals are available, a combination of
aspirin and atenolol dominated no therapy and was cost saving
in all regions (table 33.2). The ICERs for the addition of
enalapril ranged from US$660 per DALY in Sub-Saharan Africa
to US$866 per DALY in Europe and Central Asia. The combi-
nation of all four medications ranged from US$1,720 per
DALY to US$2,026 per DALY. For CABG the costs per DALY
ranged from about US$24,000 to more than US$72,000.
Despite having similar benefits as aspirin and atenolol in rela-
tion to mortality, enalapril and lovastatin demonstrated higher
per DALY costs because of the added costs of monitoring renal
and liver function, respectively, as is required for these two
medications.
When we assumed that hospitals were not readily available
(table 33.2), no therapy combination was cost saving compared
with no therapy. The combination of aspirin and atenolol was
the next best strategy, with ICERs ranging from US$386 per
DALY in South Asia to US$545 per DALY in Latin America and
the Caribbean. The addition of enalapril increased the range of
ICERs to US$783 per DALY to US$1,111 per DALY, and the
addition of lovastatin increased them still further. CABG was
not evaluated because of the underlying assumption that hos-
pitals were not available.
Table 33.4 shows the number of events prevented with the
four-drug combination medical therapy compared with no
therapy and the additional number of events averted
with CABG compared with the four-drug combination. The
medical regimen alone would prevent some 2,000 CVD deaths,
about 4,000 myocardial infarctions, and approximately 200
strokes per million persons treated in each region. The use of
CABG in addition to the medical regimen would prevent an
additional 65–70 deaths, nearly 300 myocardial infarctions, and
up to 30 strokes per million population.
Congestive Heart Failure. The interventions examined for
CHF were the addition of the ACE inhibitor enalapril, the beta-
blocker metoprolol, or both to a baseline of diuretic treatment.
As for the IHD interventions, we performed separate analyses
for each assumption of whether or not hospital facilities would
be available. For the model of treatment for CHF assuming
hospitalization (table 33.2), the addition of enalapril is cost sav-
ing and the ICER for the addition of metoprolol ranges from
US$124 to US$219 per DALY depending on the region. When
the availability of hospitals is limited (table 33.2), the enalapril
plus diuretics strategy is no longer cost saving, but it costs only
US$31 per DALY or less, and the ICER for enalapril, metopro-
lol, and diuretics increases only to about US$275 per DALY.
These figures are probably underestimates of the cost per
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Table 33.2 ICERs for Treatment Compared with No Treatment, by Region
US$/DALY
ACE 
inhibitors 
and beta-
blockers 
for CHF 
ACE inhibitors compared with 
and beta-blockers baseline of
Medical therapy and for CHF compared diuretics, 
Medical therapy for Medical therapy and CABG for IHD CABG for IHD compared with baseline limited 
AMI compared with compared with baseline of no treatment, with baseline of no treatment, of diuretics, hospital 
baseline of no treatment hospital access limited hospital access hospital access access
ASA ASA, BB, ASA, BB, ASA, BB, ASA, BB, ASA, BB, ACEI, ACEI, 
Region ASA ASA, BB BB, SK TPA ASA, BB ACEI ACEI, Statin CABG ASA, BB ACEI Statin ACEI MET ACEI MET
East Asia and 13 15 672 15,867 Cost saving 781 1,914 33,846 461 942 2,220 Cost saving 189 27 274
the Pacific
Europe and 19 21 722 15,878 Cost saving 866 2,026 47,942 530 1,097 2,470 Cost saving 144 30 275
Central Asia
Latin America and 20 22 734 15,887 Cost saving 821 1,942 62,426 545 1,111 2,497 Cost saving 124 31 275
the Caribbean
Middle East and 17 20 715 15,893 Cost saving 672 1,686 72,345 527 996 2,305 Cost saving 128 29 275
North Africa
South Asia 9 11 638 15,860 Cost saving 715 1,819 24,040 386 828 2,034 Cost saving 219 25 273
Sub-Saharan 9 11 634 15,862 Cost saving 660 1,720 26,813 389 783 1,955 Cost saving 218 25 273
Africa
Source: Authors’ calculations.
ASA  aspirin, BB  atenolol, SK  streptokinase, TPA  tissue plasminogen activator, ACEI  enalapril, Statin  lovastatin, MET  metoprolol.
Note: The intervention in the first column of each set of strategies is compared with the baseline; each successive intervention for each set of strategies is compared with the intervention immediately to its left.
DALY, given some loss in the mortality benefit for the hospital-
ization that the model does not capture.
Rheumatic Heart Disease. For RHD, except in epidemics, sec-
ondary prevention is more effective than primary prevention.
Primary prevention by means of antibiotic treatment of strep-
tococcus infections of the pharynx is not highly cost-effective in
endemic situations, given that only 10 to 20 percent of such
infections are from streptococcus, less than 3 percent of these
will evolve into rheumatic fever, and only a proportion of these
continue on to RHD (Strasser 1985). The development of a
rapid antigen test for diagnosing group A streptococcal pharyn-
gitis may make primary prevention more cost-effective (Majeed
and others 1993). Similarly, in an epidemic in which the pro-
portion of infections from streptococcus is higher or the rate of
progression to rheumatic fever is higher, primary prevention
may be cost-effective. Secondary prevention using benzathine
penicillin injections is cost-saving according to Strasser (1985)
and should be considered for all developing countries with the
infrastructure to perform the required follow-up.
Cost-Effectiveness Analyses in High-Income Countries
Table 33.5 summarizes the results of cost-effectiveness analyses
for CVD interventions in high-income countries. These results
include analyses that are similar to ours. The differences are
that they reflect costs and treatment patterns in the high-
income countries studied, mostly the United States. Costs in
developing countries are roughly one-fifth of those in devel-
oped countries (but closer to one-third in Latin America and
approaching one-half in South Africa). However, where
patented drugs are involved and patent laws are enforced, the
costs may be much closer to U.S. levels.
Because the cost-effectiveness studies have been undertaken
largely in the United States, the results do not always readily
transfer to developing countries. In some U.S. studies, the
alternative procedure considered is medical management; such
facilities simply may not exist in developing countries.
Similarly, interventions that are cost saving in the United States
may not be cost saving in developing countries but may well be
cost-effective in terms of cost per DALY saved. Furthermore,
the cost-effectiveness analyses reflect morbidity and mortality
rates in developed countries.
Interventions that Kupersmith and others (1995) classify as
highly cost-effective in the United States (less than US$20,000
per life year saved or quality-adjusted life year saved) may be
cost-effective in many developing countries. Interventions that
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Table 33.3 Sensitivity Analyses: Effect of Time to Treatment
and Age on Use of Thrombolytics in AMI (All Regions
Combined)
SKa (US$/DALY) TPAa (US$/DALY)
Time to thrombolysis
6 hours 374–437 15,800
6–12 hours 1,300–1,440 15,700
Age at treatment
75 559–650 14,800
75 or older 1,260–1,350 21,000
Source: Authors’ calculations.
SK  streptokinase; TPA  tissue plasminogen activator.
a. In addition to aspirin and atenolol.
Table 33.4 Number of Deaths and CVD Events Prevented by the Use of a Four-Component Medical Regimen and CABG per
100,000 Myocardial Infarction Survivors over 10 Years, by Region
Number of events prevented with four-component Number of incremental events prevented with
medical regimen compared with no therapya CABG compared with medical therapy
IHD Stroke Myocardial Myocardial 
deaths deaths infarctions Strokes IHD deaths Stroke deaths infarctions Strokes 
Region averted averted prevented prevented averted averted prevented prevented
East Asia and 1,900 104 4,077 209 79 11 248 22
the Pacific
Europe and 1,990 89 3,964 179 83 1 294 7
Central Asia
Latin America and 1,913 83 4,040 118 62 4 258 18
the Caribbean
Middle East and 1,908 95 4,294 118 62 1 296 22
North Africa
South Asia 1,930 97 4,043 122 34 2 275 30
Sub-Saharan Africa 1,909 91 4,233 173 69 12 254 1
Source: Authors’ calculations.
a. Aspirin, atenolol, enalapril, and lovastatin.
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Table 33.5 Cost-Effectiveness Analyses for CVD Interventions in High-Income Countries
Intervention Alternative Cost-effectiveness Source
IHD
Lovastatin, 20 mg/day Diet Cost saving (males age 45–54); US$4,700/life year saved (females age 45–54) Goldman and others 1991a
Defibrillators in emergency vehicles No defibrillators US$47 to US$551/life year saved; up to US$2,600 in rural areas Jermyn 2000; Ornato and others 1988; 
Rowley, Garner, and Hampton 1990b
Propranolol for postmyocardial No beta-blockers US$2,400 for high-risk patients; US$23,400 for low-risk patients Goldman and others 1988 a
infarction (beta-blocker) 
CABG for left main disease Medical management US$2,700 to US$6,700/life year saved Weinstein and Stason 1982;b A. Williams 1985a
PTCA (men age 55 with Medical management US$6,400 to US$8,800/life year saved (US$28,000 to US$132,000 for Wong and others 1990b
severe angina) mild angina) 
Primary angioplasty No intervention after AMI US$12,000/quality-adjusted life year Parmley 1999 
Three-vessel CABG Medical management US$14,000/life year saved Weinstein and Stason 1982
Streptokinase (reperfusion), with No intervention after AMI US$15,000/quality-adjusted life year Parmley 1999
PTCA available 
Tissue plasminogen activator (AMI) Steptokinase US$33,500/life year saved Lorenzoni and others 1998 
Primary stenting, one-vessel, men PTCA US$32,000/life year saved Cohen and others 1993 
over age 55
Three-vessel CABG for severe angina PTCA US$41,000/life year saved Wong and others 1990b
Two-vessel CABG Medical management US$33,000 to US$90,000/life year saved Weinstein and Stason 1982; A. Williams 1985
Angiography for coronary artery disease CABG US$45,000/quality-adjusted life year Doubilet, McNeil, and Weinstein 1985a
Stroke
Anticoagulants (warfarin) for chronic Aspirin Warfarin dominates for high-risk patients; US$10,000/quality-adjusted life Gage, Cardinalli, and Owens 1998c
nonvascular atrial fibrillation year for medium-risk patients; US$462,000/quality-adjusted life year for 
low-risk patients 
Anticoagulants for mitral stenosis No anticoagulants US$5,500/quality-adjusted life year Eckman, Levine, and Pauker 1992c
and atrial fibrillation 
Carotid endarterectomy Aspirin US$5,100 to US$51,000/life year saved Kuntz and Kent 1996; Matchar, Pauk, and 
(symptomatic patients) Lipscomb 1996c
Cardiac transplant No transplant US$54,000/life year saved Evans 1986a
Arrhythmias
Implantable cardioverter-defibrillator Medical management US$28,000/life year saved King, Aubert, and Herman 1998; Kuppermann and
for cardiac arrest (long term) others 1990
RHD
Benzathine penicillin injections No injections Cost saving Strasser 1985 
Source: Authors.
Note: All costs have been converted to 2001 U.S. dollars. 
a. Surveyed in Kupersmith and others 1995.
b. Surveyed in Tengs and others 1995.
c. Surveyed in Holloway and others 1999. 
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Kupersmith and others (1995) classify as cost-effective in
the United States (US$20,000 to US$40,000 per life year saved
or quality-adjusted life year saved) are probably borderline
cost-effective for developing countries. Interventions that
Kupersmith and others (1995) classify as borderline, expensive,
or very expensive in the United States are unlikely to merit
public funding in developing countries.
Thus, medical interventions that are likely to be cost-
effective in developing countries include benzathine penicillin
injections as secondary prevention for those who have had
rheumatic fever (usually for five years); ACE inhibitors for
CHF; and various drugs (beta-blockers, off-patent statins) for
long-term care following a myocardial infarction, confirming
our earlier analyses. Other therapies that are probably cost-
effective but that we did not analyze include antithrombotic
agents (aspirin, heparin) to prevent venous thromboembolism;
anticoagulants for medium- and high-risk nonvalvular atrial
fibrillation (stroke); and anticoagulants for mitral stenosis and
atrial fibrillation (stroke).
Selected invasive interventions that might possibly be cost-
effective for CVD in certain developing countries include pace-
maker implants for atrioventricular heart block, primary
angioplasty for acute myocardial infarction, and reperfusion
with streptokinase. Of course, the ability to undertake these
interventions assumes a cost-effective infrastructure for diag-
nosis and referral and an adequate volume of cases. For exam-
ple, the American Heart Association recommends acute angio-
plasty in centers where the physician conducts at least 75 such
procedures each year and the hospital conducts at least 200 per
year. For stroke, carotid endarterectomy is potentially cost-
effective for symptomatic patients compared with aspirin
alone, again in an environment with an adequate volume of
cases. Cost-effectiveness is much lower for asymptomatic cases.
Interventions that rank as cost-effective for heart disease in
the U.S. context and that are borderline cost-effective in devel-
oping countries include implantable cardioverter-defibrillator
for cardiac arrest, primary stenting for single-vessel disease (the
study was for men over age 55), CABG for two-vessel disease,
and angiography for patients with a high probability of coro-
nary artery disease.
RESEARCH AND DEVELOPMENT
Even though most of the interventions currently available
appear to be expensive and complex for developing countries,
the demand for effective care for cardiovascular diseases will
exert major pressure on health systems in coming decades.
Increased use of these procedures is already documented in
China and India (Murray and Lopez 1994, 1997; Unger 1999).
In this context, cardiovascular research should be concentrated
in the fields of primary prevention, health services, clinical
guidelines, clinical research, and epidemiology.
Primary Prevention
Because the control of many cardiovascular risk factors is
strongly related to the legislative environment—for example,
that pertaining to tobacco use or nutrition—the design and
implementation of appropriate laws and regulations is likely to
increase in developing countries. However, any such initiatives
need to be monitored and systematically evaluated, especially
to estimate the magnitude of the reduction achieved.
Another area of research is the assessment of chemoprophy-
laxis in primary prevention. Multidrug combinations such
as the hypothetical “polypill” are likely to be the first practical
initiative of a long list of important innovations. Both the
efficacy and the effectiveness of new interventions in primary
prevention should be evaluated as a matter of urgency, because
no results of large-scale clinical trials in developing countries
are as yet available.
Health Services 
Capacity building—more specifically, education and training—
of health care workers in developing countries, is a major issue
for the future, along with critical evaluations of the perform-
ance of health workers. Such evaluations should compare vari-
ous capacity-building strategies; for instance, they could com-
pare the delivery of simplified regimens of care by community
health workers versus delivery of care by trained health profes-
sionals.
The dissemination of innovations deserves special attention
in a context of scarce resources (Berwick 2003). The transfer of
technologies to developing countries should be made on cost-
effectiveness criteria, which implies analysis conducted in the
specific situation of developing countries—for example, cost-
effectiveness for thrombolytics in a developing country might
be much worse than in the United States if getting to a hospi-
tal on time is a problem. Sensitivity analysis of the cost-
effectiveness of surgical and medical interventions in develop-
ing countries is also needed.
Furthermore, the appropriate incentives for technological
changes in health care should be investigated (McClellan and
Kessler 1999). This line of research includes analyses of the
pricing of technologies (including drugs) or of new designs for
services, such as point-of-care devices for use by community
health workers.
The long period of incubation of CVD opens up opportu-
nities for extensive screening based on preclinical signs and
biomarkers. However, strong lines of research are needed to
secure effective and safe screening programs and should
include opportunistic screening for places where visits to
health centers are limited.
Finally, all assessments made in relation to health services
research should take into account the costs related to scaling up
any procedure evaluated.
Clinical Guidelines
The diffusion of health technologies usually leads to a widen-
ing of the clinical indication beyond the evidence-based scope
of the intervention (PTCA is a classic example) (Dravik 1998),
corresponding to a decrease not only in the procedure’s
efficacy, but also in its effectiveness (Anderson and Lomas
1988; Blustein 1993). Several studies suggest that overuse and
underuse tend to coexist in the same community and that
even severe scarcity of resources does not protect against
overuse of cardiological interventions, at least among certain
segments of the population (Joorabchi 1979; Soumerai and
others 1997).
The consequences of such trends are more dramatic in
developing than developed countries. Therefore, the introduc-
tion of costly care should be accompanied by a corresponding
effort in relation to the provision of formal education to
providers and prescribers, complemented by the development
of clinical guidelines aimed at avoiding both the overuse and
the underuse of procedures.
Clinical guidelines are already numerous, but all have been
established in affluent countries. A new, specific effort should
be made in developing countries to address local issues, such as
problems related to the availability of procedures or drugs or to
accessibility of services, and the development and maintenance
of these guidelines should follow best available standards.
Clinical Research
In most situations, health care innovations should be intro-
duced as experimental interventions to permit proper moni-
toring and evaluation. These experiments do not have to
address the efficacy of the procedure (many innovations will
already have been tested), but rather issues pertaining to their
effectiveness and efficiency in the specific context of developing
countries.
Another reason for the experimental approach is the rapid-
ity with which the field of CVD is evolving. It is not reasonable,
at the local level, to wait until the publication of trial results and
meta-analyses, which often takes place years after changes have
occurred in everyday practice. For this reason, a new culture of
clinical research should be developed in which every innova-
tion should be taken as an opportunity for systematic experi-
mental evaluation.
Among various topics in clinical research, adherence
deserves special mention. On average, 50 percent of patients in
developed countries do not take their prescribed medicines
after one year, despite having full access to medicines. In devel-
oping countries, this poor adherence is made worse by poor
access to health services and drugs, to lack of education, and to
other factors (Bovet and others 2002; WHO 2003a). Options
for improving adherence should be designed and experimented
with.
Epidemiological Research
A basic task of epidemiological research is to assess geographic
and secular trends in the distribution of risk factors. Of special
relevance is the movement from regional to country levels and
the trend within a country. The impact of poor health status in
early life should be assessed from the impact of poor fetal
health to the consequence of multiple childhood infections on
the risk for CVD. Because of the scarce availability of resources,
the development and maintenance of health care should be
supported by a comprehensive information system. Simple,
affordable health information systems are preferable along the
lines of the framework developed by the World Health
Organization.
CONCLUSIONS: PITFALLS AND PROMISES
A global CVD epidemic is rapidly evolving, and the burden of
disease is shifting.Twice as many deaths from CVD now occur in
developing as in developed countries. The vast majority of CVD
can be attributed to conventional risk factors. Even in Sub-
Saharan Africa, high blood pressure, high cholesterol, extensive
tobacco and alcohol use, and low vegetable and fruit consump-
tion are already among the top risk factors for disease.Because of
the time lag associated with CVD risk factors, especially in chil-
dren, the full effect of exposure to these factors will be seen only
in the future. Information from more than 100 countries shows
that more 13- to 15-year-olds smoke than ever before, and stud-
ies show that obesity levels in children are increasing markedly in
countries as diverse as Brazil, China, India, and almost all island
states (Leeder and others 2004). Populationwide efforts now to
reduce risk factors through multiple economic and educational
policies and programs will reap savings later in medical and
other direct costs as well as indirectly in terms of improved qual-
ity of life and economic productivity.
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As a result of carrier protection against malaria, the inherited
hemoglobin disorders are the commonest diseases attributable
to single defective genes. Approximately 7 percent of the
world’s population is a carrier, and 300,000 to 500,000 babies
with severe forms of such disorders are born each year (WHO
1989). Although these disorders are most frequent in tropical
regions, they are now encountered in most countries because of
migrations of populations.
INTRODUCTION
If untreated, many of the inherited hemoglobin disorders result
in death during the first few years of life. Their effect on the
burden of disease has only recently been recognized, following
an epidemiological transition caused by improvements in
hygiene, nutrition, and control of infection that has reduced
childhood mortality. Babies with severe hemoglobin disorders
are now able to survive long enough to present for diagnosis
and treatment. The impact of these diseases is being felt
throughout the Indian subcontinent and much of Asia.
Although the situation will worsen in Sub-Saharan Africa as
it undergoes a similar transition, such diseases are already
responsible for a major health burden. International health
agencies and the governments of affected countries need to
understand the future extent of the problem and to develop
programs to control and manage these diseases.
Normal Hemoglobin
Hemoglobin (Hb), the pigment in the red blood cells that
transfers oxygen to the tissues, changes structure during
human development. In adults two components exist: a major
hemoglobin, Hb A, and a minor hemoglobin, Hb A2. The bulk
of the hemoglobin during later fetal life is Hb F. These hemo-
globins each consist of two pairs of unlike globin chains. The
adult hemoglobins and fetal hemoglobin have 
 chains com-
bined with  (Hb A, 
22),  (Hb A2, 
22), or  chains (Hb F,

22). Each of the different globin chains is controlled by dis-
tinct genes; two genes exist for the 
 and  chains and one for
each of the other chains. Their structure and the regions of the
genes that control the production of the different globin chains
have been determined (Steinberg and others 2001; Weatherall
and Clegg 2001b).
Spectrum of Inherited Hemoglobin Disorders 
Inherited hemoglobin disorders fall into two main groups: the
structural hemoglobin variants and the thalassemias, which are
caused by defective globin production. They all follow a reces-
sive form of inheritance. Those with a single defective globin
gene—carriers or heterozygotes—are symptomless. If two car-
riers marry, a one in four chance exists that each child they
produce will receive defective genes from each parent—that is,
they are homozygous for the particular disorder.
The structural variants result mostly from single amino acid
substitutions in the 
 or  chains. Often these are innocuous,
but in some cases they may alter the stability or functional
properties of the hemoglobin and lead to a clinical disorder.
They are designated by letters of the alphabet or by the place
names where the condition was first discovered. Even though
researchers have identified more than 700 structural hemoglo-
bin variants, only three (Hb S, Hb C, and Hb E) are widespread.
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The homozygous state for the sickle cell gene results in sickle
cell anemia, whereas the compound heterozygous state for the
sickle cell and Hb C genes results in Hb SC disease. Hb SC dis-
ease, although milder, also has important public health impli-
cations. Hb E, the commonest variant globally, is innocuous in
its heterozygous and homozygous states, but because it is syn-
thesized less effectively than Hb A, it interacts with  tha-
lassemia to produce an extremely common condition called Hb
E  thalassemia, which is becoming an increasingly important
health burden in many parts of Asia.
The thalassemias are classified according to the ineffectively
synthesized globin chains. From a public health viewpoint,
only the 
 and  thalassemias are sufficiently common to be
important.
Clinical Features 
The inherited hemoglobin disorders are characterized by an
extremely diverse series of clinical syndromes of varying
severity.
Sickle Cell Anemia and Related Disorders. The clinical fea-
tures of sickle cell disorders reflect the red blood cells’ propen-
sity to assume a sickle shape in deoxygenated blood, leading to
shortened red cell survival and a tendency to block small blood
vessels (Bunn 1997; Serjeant 1992). Even though patients may
adapt to their anemia, their illness is interspersed with acute
episodes, including: attacks of bone pain; sequestration of
blood into the lungs, liver, or spleen; or thrombosis of cerebral
vessels, which may cause a stroke. They are extremely prone to
infection, particularly during early childhood, and to a wide
range of chronic complications. For reasons not yet under-
stood, the severity of the disease varies extensively. Even in
populations in eastern Saudi Arabia and parts of India, which
have a high frequency of 
 thalassemia and an unusual ability
to produce Hb F in adult life, both of which, when inherited
with sickle cell disease, result in a milder form of the illness,
morbidity is still high.
Although little is known about mortality from “sickling”
disorders in developing countries, in Sub-Saharan Africa many
children die early because of these conditions (Akinyanju 2001;
Fleming and others 1979). Fleming and others, working in
rural Nigeria, found that even though more than 2 percent of
all newborns had sickle cell anemia, it was absent in the ado-
lescent and adult populations. At the same time, they found
that urban centers in Nigeria, where medical care was available,
had an increasing number of affected adults, and by the late
1970s, a significant improvement in survival had clearly fol-
lowed the introduction of antimalarial measures (Molineaux
and others 1979). Both in Jamaica and in the United States,
death appears to peak between one and three years of age, usu-
ally from infection. Recent U.S. data suggest that the median
age of adult death is 42 for men and 48 for women (Dover and
Platt 1998). Even though Hb SC disease is milder than sickle
cell anemia, it is associated with many complications, including
a higher frequency of proliferative retinopathy.
Thalassemias. The homozygous or compound heterozygous
states for  thalassemia also run a variable course, although
without transfusion, death usually occurs in the first few years
(Weatherall and Clegg 2001b). With adequate transfusions and
the administration of drugs to remove iron, children may
develop well and survive to adulthood. However, these drugs
are expensive, and even when they are available in poorer coun-
tries, many children receive inadequate dosages and die in
childhood or adolescence from iron overload. The situation is
further complicated because the common  thalassemias of
intermediate severity—notably Hb E  thalassemia—exhibit a
clinical spectrum ranging from transfusion-dependent disease
to a condition compatible with normal survival and growth
into adult life without treatment.
The 
 thalassemias are equally heterogeneous. The
extremely common milder forms (termed 
 thalassemias
because some 
 chains are produced) produce only a mild
hypochromic anemia in homozygotes. In contrast, the 
o tha-
lassemias, so called because of the absence of 
 chain synthesis,
result in stillbirth in their homozygous states following preg-
nancies with toxemic and postpartum complications. The
compound heterozygous states for 
 and 
o thalassemias
result in Hb H disease, which varies in severity and may be
transfusion dependent.
The thalassemias are extremely heterogeneous at the molec-
ular level: more than 200 different mutations of the  globin
genes have been found, and the 
 thalassemias are almost as
varied. Every severely affected population in the world has a
few common mutations unique to a particular region, together
with varying numbers of rare ones.
Population Genetics and Dynamics
The high gene frequencies for the hemoglobin disorders are
attributable to the effects of natural selection. Although
severely affected homozygotes would, in the absence of medical
interventions, have died early in life, asymptomatic heterozy-
gotes for Hb S, Hb C, and probably  thalassemia and Hb E, as
well as those with mild forms of 
 thalassemia, are more resist-
ant to severe malarial infection than normal persons. Hence, in
environments in which malaria was common, carriers were
protected and survived to have more children, and the gene fre-
quencies rose until they were balanced by loss of severely
affected homozygotes from the population. Although some
decline in frequency among immigrant populations may occur
because of lack of exposure to malaria and outbreeding, this
decline will occur over many generations, and even if malaria
were completely eradicated, an equally long time would pass
before any significant fall occurred in the global frequency.
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Changes resulting from variation in selection or in popula-
tion dynamics will, however, be small compared with the effect
of the demographic and epidemiological transitions that many
countries have recently undergone. For example, thalassemia
was not identified in Cyprus until 1944, when major improve-
ments in public health revealed that the disease was common. By
the early 1970s, estimates indicated that, in the absence of steps
to control the disease, in about 40 years approximately 78,000
units of blood would be required each year to treat all the
severely affected children, 40 percent of the population would be
carriers, and the cost to the health system would equal or exceed
the island’s health budget (Weatherall and Clegg 2001b).
Global Distribution and Frequency 
of the Hemoglobinopathies
Figures 34.1a and 34.1b show the global distributions of the
hemoglobinopathies. Table 34.1 shows approximate carrier fre-
quencies by region.
The gene for Hb S is distributed throughout Sub-Saharan
Africa, the Indian subcontinent, and the Middle East, where car-
rier frequencies range from 5 to 40 percent or more. Hb E
is found in the eastern half of the Indian subcontinent and
throughout Southeast Asia, where carrier rates may exceed
60 percent. Thalassemia is frequent in a broad band from the
Mediterranean basin and parts of Africa, throughout the Middle
East, the Indian subcontinent, Southeast Asia, and Melanesia
and into the Pacific islands. The 
 thalassemias occur right
across the tropical zone, reaching extremely high frequencies in
some populations, whereas the 
o thalassemias are restricted to
parts of SoutheastAsia and the Mediterranean basin (table 34.1).
Several World Health Organization (WHO) workshops
have attempted to estimate the global burden of the thal-
assemias and important structural hemoglobin variants
(Angastiniotis and Modell 1998; Weatherall and Clegg 2001b;
WHO 1989, 1994). There are perhaps 270 million carriers and
300,000 to 500,000 annual births of infants with sickle cell
Figure 34.1a Global Distribution of Hemoglobinopathies Hb E and Hb S
Hb E Hb S
Source: Weatherall and Clegg 2001b.
Note: Structural hemoglobin variants are Hb E (innocuous unless interacting with 
 or  thalassemia) and Hb S
(causing sickle-cell disease in the homozygous state).
anemia or serious forms of thalassemia. Southeast Asia, where
the thalassemias and Hb E predominate, is most severely affect-
ed. Sub-Saharan Africa has the second-highest burden, reflect-
ing the high incidence of Hb S. Weatherall and Clegg (2001b)
summarize information about the different thalassemia muta-
tions in those regions.
These data only approximate the problems for health care
services that the hemoglobin disorders will pose in the future.
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Figure 34.1b Global Distribution of Hemoglobinopathies 
 and  Thalassemias

 and  thalassemias
Source: Weatherall and Clegg 2001b.
Table 34.1 Carrier Frequencies for Common Hemoglobin Disorders, by World Health Organization Region, 2001 
(percent)
Region Hb S Hb C Hb E  thalassemia o thalassemia  thalassemia
Americas 1–20 0–10 0–20 0–3 0–5 0–40
Eastern Mediterranean 0–60 0–3 0–2 2–18 0–2 1–60
Europe 0–30 0–5 0–20 0–19 1–2 0–12
Southeast Asia 0–40 0 0–70 0–11 1–30 3–40
Sub-Saharan Africa 1–38 0–21 0 0–12 0 10–50
Western Pacific 0 0 0 0–13 0 2–60
Sources: Livingstone 1985; Weatherall and Clegg 2001a, 2001b. 
Note: Many of these data are derived from small population samples. 
Unfortunately, few of the data are based on micromapping
of incidence in different populations. Weatherall and Clegg’s
(2001b) review of studies in Indonesia, Sri Lanka, and Thailand
reveals the extent of variability of incidence within relatively
short geographic distances, suggesting that the number of
annual births of babies with  thalassemia major or Hb E 
thalassemia may be underestimated. Similarly, published data
for the annual births of babies with sickle cell anemia in India
and the Middle East are almost certainly too low, because esti-
mates based on gene frequency suggest that the figure may be
close to 100,000. The data in table 34.1 and figure 34.2, there-
fore, represent a minimal estimate of the future likely health
burden resulting from inherited hemoglobin disorders.
Furthermore, in many cases, the data are not based on pro-
jected increases in birth rates.
Because of these uncertainties, including how long coun-
tries will take to pass through the epidemiological transition,
assessing the burden that the disorders will impose on health
services is difficult. As more babies survive and present for
treatment, the population on long-term therapy will steadily
expand; the more effective the treatment, the greater the bur-
den will be on health services. For example, from 2005 to
2025, an estimated 100,000 cases of Hb E  thalassemia will
be added to the Thai population, and 20,000  thalassemia
homozygotes will be born each year in southern China
(Weatherall and Clegg 2001b). If these children all survive to
adulthood, they will account for a large proportion of health
service expenditure.
BURDEN OF DISEASE
WHO disease burden estimates do not include the incidence or
prevalence of the hemoglobin disorders, nor the deaths or
disability-adjusted life year (DALY) losses from sickle cell disease
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Figure 34.2 Approximate Annual Births of Babies with Sickle Cell Anemia and  Thalassemia 
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Source: Weatherall and Clegg 2001b.
Note: These figures give only a broad approximation of the numbers of new births with the hemoglobinopathies, based as they are in many
cases on data from single centers. Figures not identified as sickle cell represent births of babies with  thalassemia.
or thalassemia. Neither do they treat these disorders as risk
factors for anemia, infection, stroke, and other conditions or
estimate the prevalence (frequency) of the underlying genetic
factors. Thus, the estimates provided here are necessarily incom-
plete and speculative.
For severe  thalassemia, figure 34.2 suggests 43,100 births
per year, nearly all in low- and middle-income countries, where
affected babies are likely to die before reaching two years of age.
At least 41,500 deaths probably occur each year, or 0.3 percent of
all deaths of children under five. This estimate may be too low,
because it does not include the estimated 20,000 births per year
in China. Thus, the severe  thalassemias probably account for
50,000 to 100,000 deaths per year, or 0.5 to 0.9 percent of all
deaths of children under five in low- and middle-income coun-
tries. Each death accounts for 29.2 DALYs if it occurs before the
child reaches the age of one. Taken together, all the deaths con-
tribute 1.46 million to 2.92 million DALYs to the world burden.
Treated  thalassemia victims who survive to age 40 or older
contribute much less to the disease burden because they are
fewer and their residual disability weight is only 0.02 to 0.10
(chapter 15 provides an explanation of disability weights).
Living with poorly treated thalassemia has a weight equal to or
greater than 0.1. No global estimates of the number of treated
survivors are available, but estimates indicate that 500,000 may
exist in Thailand alone, of which perhaps 55,000 are transfu-
sion dependent with severe disabilities. Their total DALY loss,
including disability for those with milder Hb H disease, would
be only some 15,000 per year, trivial relative to the DALYs
resulting from premature mortality. Deaths by age 10 from
homozygous  thalassemia or by age 30 from Hb E  tha-
lassemia would add 53,600 DALYs in Thailand.

o thalassemia contributes to the burden of disease primar-
ily through stillbirths or deaths shortly following birth and sec-
ondarily through mothers’ disability during pregnancy. WHO
does not count stillbirths, and no data on affected births are
available except for an estimate of 1,250 per year in Thailand,
which adds 37,242 DALYs. Assuming that mothers suffer a dis-
ability weight of 0.3 during the last trimester would add only
100 DALYs. Every 1,000 homozygous 
o thalassemia pregnan-
cies contribute about 30,000 DALYs, but insufficient informa-
tion is available on incidence elsewhere to use the Thai estimate
to project global or regional levels.
For sickle cell disease, the burden is harder to estimate
because of the higher survival rate and the disability during
crises. Figure 34.2 shows an estimated 216,000 births per year
in Africa alone, but reliable data on survival are not available.
Early studies suggested a mortality rate greater than 80 percent
by age five, but more recent estimates indicate that the figure is
probably greater than 50 percent, with the improvement result-
ing from treatment and from control of the infections that
cause most early sickle cell deaths. Mortality of 50 to 80 percent
at ages one to five implies at least 21,600 to 34,500 deaths
per year and possibly as many as 173,000. These translate into
0.5 million to 4.5 million DALYs, accounting for less than
1 percent, but perhaps as much as 2 percent, of the burden for
children under five. Life expectancies and the extent of disabil-
ities among survivors in Africa are unknown, so the low DALY
number is no doubt underestimated.
Outside Africa, Weatherall and Clegg (2001b) estimate
60,000 sickle cell births per year concentrated in India and
the Middle East and among descendants of Africans in the
Americas. The actual figure may be as high as 100,000. Without
treatment, deaths peak in the first 2 years of life, and half of all
deaths occur in the first 20 years. If 25 percent of sufferers die
at age 1 and 25 percent at age 10, those deaths would contribute
almost 14,000 DALYs for every 1,000 births in a low- or middle-
income country. Including deaths after age 20 and disability
might double the estimate.
Survival elsewhere is greater than in Africa, because of lower
risks of infection and greater access to treatment. The United
Kingdom has about 10,000 survivors (Davies and others 2000),
and the United States has some 50,000 (Ashley-Koch, Yang, and
Olney 2000). No good estimates are available of the numbers or
age distribution of survivors in most of the rest of the world,
but Hambleton’s (2004b) cohort study in Jamaica shows how
treatment increased survival: 70 percent of those enrolled
starting in 1973 survived to age 20, as did 80 percent of those
enrolled three to six years later.
Of 1,000 babies born with sickle cell disease, Jamaican clinic
records and follow-up show how many would die at each age in
each year, allowing an estimate of the burden from premature
mortality (Hambleton 2004a). Table 34.2 presents those results:
560 deaths per year represent almost 14,000 DALYs. Deaths
after age 50 contribute less because they are fewer, and life
expectancy and DALYs per death decline with age. Thus, 18,000
to 22,000 DALYs per year for deaths at all ages is a reasonable
estimate of the mortality burden from 1,000 sickle cell births
per year at Jamaican levels of treatment coverage and effective-
ness. Applied to the estimated 60,000 to 100,000 births per year
outside Africa, this figure implies at least 1.08 to 2.20 million
DALYs, or 0.1 percent of the total burden in low- and middle-
income countries.
Three sources of disability also contribute to the burden: ane-
mia without painful crises or other complications; disability
from mild or severely painful crises; and other clinical events,
both acute and chronic (for example, leg ulcers and retinopathy).
For the first source, the disability weight is assumed to aver-
age 0.04. This source adds a constant 0.04 DALYs for every year
a sickle cell patient survives. The loss per year per 1,000 births
in Jamaica is multiplied by 2.5 for deaths during each five-year
interval (because deaths are assumed to occur at the midpoint
of the interval) and by 5.0 for survivors, who suffer disability
for the entire five years. This loss adds about 10 percent to the
loss from premature mortality.
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For the second source of disability, even mild crises should be
weighted considerably worse than background anemia, and
severe crises requiring hospitalization should be weighted worse
still: values of 0.2 and 0.5, respectively, are assumed. The num-
ber of crises and the share that are severe vary with age,with peak
severity at ages 21 to 45 for a mean disability weight of 0.35.
Because each crisis lasts only 7 to 10 days,or about 0.023 year, the
loss per 1,000 births in each five-year age group never exceeds 10
DALYs and makes no difference to the total burden.
The third source of disability may carry disability weights of
0.135 for a leg ulcer, 0.276 for stroke survivors, 0.279 for acute
chest syndrome, and 0.567 for retinopathy, but disability
weights for a number of other conditions are unknown. Even if
acute conditions last one month with an average disability
weight of 0.5, they add less than 10 DALYs in any five-year
interval. These conditions occur much less frequently than
painful crises, but chronic ones may last much longer, con-
tributing more or less to the burden than pain crises but adding
little to mortality losses. Table 34.2 therefore includes only the
estimated losses from background anemia and the frequencies,
but not the DALY losses, of painful crises and other events that
add negligibly to the burden.
CONTROL AND TREATMENT
With the exception of the few patients who can obtain a bone
marrow transplant, no cure exists for the inherited disorders of
hemoglobin. Even though research directed at their correction
by means of somatic cell gene therapy is ongoing, this technol-
ogy will probably not be generally applicable for some time, and
when it is developed, it may be extremely expensive. Thus, for
the moment, the major approaches to the control and manage-
ment of these diseases are population screening, genetic coun-
seling and prenatal diagnosis, and management of symptoms.
Prevention
Programs to reduce the number of seriously affected individu-
als follow two approaches. First, population screening and
counseling programs can be established to educate populations
about the risks of having children with similarly affected
partners. Data about the effectiveness of this approach are
extremely limited. In an early study in Greece, people’s knowl-
edge of their genetic makeup had no effect on marriage pat-
terns (Stamatoyannopoulos 1973); however, a recent study in
the Islamic Republic of Iran found that about 50 percent of
affected couples decided to separate, and births with severe 
thalassemia fell to about 30 percent of those expected (Samavat
and Modell 2004). The reasons for this remarkable discrepancy
require further investigation.
The second preventive approach also involves population
screening or screening in prenatal clinics. If women are found
to be carriers, their partners are screened, and following coun-
seling they are offered a prenatal diagnosis and termination of
Table 34.2 Burden of Sickle Cell Disease by Age Group, Assuming 1,000 Births per Year and Survival to Various Ages, Jamaica,
Starting in 1973
Age group (years)
Total or 
Category 0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 average
Number of survivors 876 834 807 777 727 680 627 564 491 440 682.3
Number of deaths 124 42 27 30 50 47 53 63 73 51 560
Death rate (percent/year) 2.61 0.98 0.66 0.75 1.32 1.33 1.61 2.10 2.73 2.17 1.63
Number of DALYs lost/death 28.90 28.59 27.77 26.84 25.82 24.69 23.43 22.00 20.39 18.58 24.70
Total DALY losses from deaths 3,584 1,201 750 805 1,291 1,161 1,242 1,386 1,488 948 13,856
Number of DALYs lost from 188 171 164 158 150 141 130 119 106 93 1,420
background (chronic) anemia
Total DALYs lost from deaths and 3,772 1,372 914 963 1,441 1,302 1,372 1,505 1,594 1,041 15,276
chronic anemia
Number of pain crises/year 242.7 381.0 383.8 584.4 866.7 600.5 523.6 473.4 309.6 182.2 4,548
Number of other acute clinical 77.5 22.2 182.2 281.9
events 
Number of other chronic clinical 49.8 14.8 12.8 10.9 88.3
events 
Source: Authors’ calculations based on Hambleton 2004a, 2004b. 
Note: The number of DALYs lost per death is calculated assuming all deaths occur at the midpoint of the age interval. Life expectancies by age are those for all low- and middle-income countries
together. The number of pain crises is the total during one year for all the individuals in an age group. Those who die during the interval are assumed to die in equal numbers at the midpoint of each of
the five years and, therefore, to suffer half as much disability from chronic anemia and half as many pain crises in that year as those of the same age who survive the year. Blanks in the table indicate
that clinical events are rare in the corresponding age groups and their numbers are not well recorded. The totals of acute and chronic  clinical events are therefore probably slight under-estimates.
affected fetuses. This method has been used widely in the
Mediterranean region and elsewhere, resulting in a major
reduction in newborns with serious forms of thalassemia (Cao,
Galanello, and Rosatelli 1998; Weatherall and Clegg 2001b).
Prenatal diagnosis programs are available in China, India, the
Islamic Republic of Iran, Lebanon, Pakistan, Singapore,
Thailand, the United Arab Emirates, the United States, and
many European countries; several other countries are estab-
lishing similar programs.
Because severe thalassemia is incompatible with survival
without regular blood transfusions, prenatal diagnosis is a logi-
cal approach where acceptable until more definitive treatments
become available. The situation with sickle cell anemia is differ-
ent. First, it is not uniformly fatal in early life, and morbidity and
mortality during this period can be controlled. Second, the clin-
ical course of the condition is unpredictable: some patients’
symptoms are relatively mild, whereas others develop life-
threatening complications. Hence, even though some countries
are practicing prenatal diagnosis, in others neither communities
nor doctors consider that it should be applied widely. This com-
plex issue would be clarified if the reasons for the phenotypic
variability of the sickling disorders were better defined.
Whether or not screening programs are backed up with an
offer of prenatal diagnosis, they require an intense period of
education of the population about the nature of inherited
hemoglobin disorders. This education requires input from
many sectors of society, including the media, public health
workers, local volunteer societies, and the medical community.
Programs of this type require careful planning as well as
availability of facilities for screening and counseling when the
program is initiated. Their development also requires prior dis-
cussion between the government, health care workers, and
members of the community—including religious leaders.
Treatment
The treatment of the hemoglobinopathies varies widely
depending on the disease. The severe forms of  thalassemia
require lifelong blood transfusions. The family of  thalassemia
intermediate diseases ranges from transfusion-dependent
forms to symptomless carrier traits. Hb E  thalassemia, the
commonest hemoglobinopathy in Asia, varies in severity from
forms that require regular or intermittent transfusions to
milder anemia that does not require lifelong transfusions
unless complications arise, particularly hypersplenism.
Weatherall and Clegg’s (2001b) review of studies in Asia
indicates that the medical community does not always appreci-
ate these subtleties and that many patients who receive regular
transfusions might well have survived without transfusions had
their early management been more effective.
Thus, those managing patients with severe forms of  tha-
lassemia must make absolutely sure in infancy that regular
transfusions are required. If so, babies and children require
transfusion at monthly intervals using washed red cells
rather than whole blood. In addition, blood must be screened
for hepatitis B and C, for HIV, and—in some countries—for
malaria. Because patients accumulate iron from transfusions,
they also require lifelong treatment with a chelating agent, the
most effective being desferrioxamine delivered subcutaneously
overnight using a pump. Oral chelating agents, which would
undoubtedly improve compliance, are available, but their
efficacy and safety have yet to be verified. Some children with the
major form of  thalassemia—and many with the intermediate
varieties—will at some point require splenectomy, to be pre-
ceded by appropriate vaccinations and followed by prophylactic
penicillin. They also require regular assessments of their iron
status by measurements of serum ferritin or, better, by hepatic
iron concentrations. Various complications occur, particularly
for those not adequately transfused, including endocrine defi-
ciencies, bone disease, and infection. Bloodborne infections,
particularly hepatitis C and HIV/AIDS, are an increasing haz-
ard. Most children with  thalassemia also require regular folate
supplementation and vitamin C with their chelation therapy.
The serious forms of 
 thalassemia, 
o thalassemia, cause
stillbirth late in pregnancy and several maternal complications.
Although some infants have been given exchange transfusion or
transfusion in the immediate neonatal period and survived, they
have gone on to a transfusion-dependent life. Because of the
increased risk of congenital malformations as a result of the
disease—and particularly because of maternal complications—
this course of action is not recommended, and this disease is an
important indication for prenatal diagnosis. Those who inherit

o thalassemia from one parent and 
 thalassemia from the
other have a moderately severe form called Hb H disease that
is usually compatible with a life independent of transfusions
except for periods of stress, such as infection. The 
 tha-
lassemias cause no clinical problems,either in their homozygous
or heterozygous states.
Patients with sickle cell anemia are at high risk from infec-
tion early in life; therefore, diagnosis as early as possible is vital.
Excellent evidence, at least in developed countries, indicates
that prophylactic penicillin significantly reduces early morbid-
ity and mortality.
Even though many children adapt well to their anemia,
many eventually develop sickle cell crises (Ballas 1998). The
most common form, the so-called painful crisis, is character-
ized by severe bone pain that often requires hospital admission
and treatment with analgesics, oxygen, and infection control.
More life-threatening crises, including stroke, marrow aplasia
associated with viral illness, and pulmonary crises with severe
hypoxia, require urgent hospital treatment. Regular Doppler
testing of the cerebral blood flow can anticipate neurological
complications that can be prevented by regular transfusions
(Adams and others 1998), which can be continued indefinitely.
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Because most aplastic crises result from human parvovirus
infection, the development of a vaccine would be a great
advantage. The other acute complication, splenic sequestration
causing rapid enlargement of the spleen, is associated with pro-
found anemia. It necessitates urgent hospital admission and
blood transfusion, plus sometimes splenectomy. A variety of
other complications require hospital treatment, including pri-
apism, aseptic necrosis of the femoral or humoral heads, renal
failure, and recurrent hematuria. At every age patients with
sickling disorders seem to be more prone to infection that often
requires hospital admission. In most sickling disorders, crises
are more frequent and anemia worsens during pregnancy. A
review of extensive clinical trials in the United States shows
that the long-term administration of hydroxyurea reduces
the frequency of crises and prolongs life in adult sufferers
(Weatherall 2003).
Although milder, Hb SC disease is clinically important, par-
ticularly because of the relatively high incidence of ocular
complications.
Requirements
Screening and diagnosis for the hemoglobin disorders requires
relatively simple laboratory techniques combined with a well-
organized program for their application in the community.
Screening and Carrier Detection. Unlike many genetic dis-
eases, carrier screening for the main hemoglobin disorders is
well established, accurate, and inexpensive. The initial screen-
ing for thalassemia usually measures the mean cell volume and
the mean cell hemoglobin. Thresholds below which the likeli-
hood of some form of thalassemia is great are well established.
The diagnosis of  thalassemia is confirmed by finding a raised
level of Hb A2 using high-performance liquid chromatography
(HPLC) or cheaper forms of chromatography or quantitative
hemoglobin electrophoresis. Ideally, the initial blood count
should use an electronic cell counter, and the Hb A2 should be
measured using HPLC. However, the equipment for HPLC
analysis is expensive, and the cost per sample is approximately
US$2. For this reason, several more economical approaches
have been developed (Fucharoen and others 2004). The initial
screening can be done using a single-tube osmotic fragility test,
which, even though it may result in a relatively high number
of false positive results, usually gives fewer false negatives.
Commercial kits for osmotic fragility testing have recently been
produced, and at least one variety has been validated in
Thailand. Further validation of this approach is required before
it can be recommended. Various cheaper methods for measur-
ing the Hb A2 level are available.
When the red cell indices suggest thalassemia or an osmotic
fragility test is positive but the Hb A2 level is normal, it is vital
to distinguish between iron deficiency and 
 thalassemia.
Several simple, cheap tests are available for diagnosing iron
deficiency, but 
 thalassemia presents more of a problem.
Screening tests will identify those heterozygous for 
o thal-
assemia or homozygous for 
 thalassemia but will miss most
cases of heterozygosity for 
 thalassemia. However, given the
restricted distribution of 
o thalassemia, these distinctions are
clinically important only in areas where 
o thalassemia is com-
mon. Further diagnosis of the 
 thalassemias requires DNA
analysis.
Several simple and cheap screening tests are available for sick-
ling disorders, but all of them require confirmation of the
genotype by hemoglobin electrophoresis. Neonatal screening
requires electrophoresis because the solubility test, which is used
widely for adult screening, is unreliable in the first months of life.
Throughout Asia, screening for Hb E is also necessary, either
with a one-tube dye test or by hemoglobin electrophoresis. The
Hb E trait is missed by measuring cell size or osmotic fragility.
Initial Diagnosis of More Severe Hemoglobinopathies. The
initial diagnosis of  thalassemia is usually clinical. It can
be confirmed by finding typical thalassemic changes of the
peripheral blood, together with an elevated level of Hb F. A
variety of cheap tests for measuring Hb F levels are available, or
HPLC analysis can be used. Hemoglobin electrophoresis or
HPLC is used to diagnose 
o thalassemia homozygotes and
children with Hb H disease.
Sickle cell anemia, Hb SC disease, or combinations of the
sickle cell gene with forms of  thalassemia can all be identified
by hemoglobin electrophoresis and can be confirmed by a fam-
ily study.
Further Analysis. More detailed confirmatory analysis,
including identification of the underlying mutation, is required
for the  thalassemias as a prerequisite for prenatal diagnosis.
A variety of approaches to mutation analysis based on the poly-
merase chain reaction, which amplifies particular regions of
DNA, are available, but because every population has a number
of less common mutations, a central reference laboratory in
each country must be able to sequence the  globin genes.
Rapid DNA-based techniques for identifying the different
deletion and nondeletion forms of 
 thalassemia are also avail-
able (Weatherall and Clegg 2001b).
Facilities and Organization. To provide an adequate labora-
tory service, each country with a high incidence of  thal-
assemia or sickle cell anemia (a carrier rate equal to or greater
than 1 to 2 percent) requires at least one central reference lab-
oratory to carry out accurate hemoglobin and DNA analyses.
Peripheral hospital laboratories with expertise in screening
tests and their quality control are also required.
General pediatricians, pediatricians with a special interest in
blood diseases, or pediatricians or other clinicians who devote
their entire time to the management of such diseases may care
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for children with severe hemoglobin disorders.A problem arises
for older patients, who must often change their doctors during
adolescence. There is a serious dearth of physicians trained to
care for older patients. Ideally, every country with a high inci-
dence of inherited hemoglobin disorders should have centers
specially designated for treating patients of all ages. Such centers
require outpatient transfusion facilities, space for parents to wait
while their children are being transfused, inpatient facilities, and
access to basic laboratory diagnostic services. Centers involved
in prenatal diagnosis require access to appropriate obstetric
services. The advantage of specialist centers is continuity of care.
Patients with chronic disease must have confidence in their
medical advisers. Such confidence can be achieved only if they
see the same staff over the entire course of their illness.
As concerns personnel, a WHO working group has recom-
mended one doctor, three nurses, one laboratory technician,
one counselor, and one administrative assistant for every 50 to
100 patients (WHO 1994). Overall, the workload is higher in
centers for thalassemia than for sickle cell anemia, largely
because of the lesser need for regular blood transfusions for
those with the latter condition. However, sickle cell anemia is
associated with more acute inpatient episodes per year.
The other major role of centers of this type is education,
including training other clinicians, medical students, coun-
selors, nurses, and others needed to provide information to
local communities.
A number of publications describe treatment protocols
to use in managing patients (Weatherall and Clegg 2001b;
WHO 1985, 1987, 1989, 1994). Treatments include the
following:
• Blood transfusion. Although regular transfusion is required
most frequently for managing the thalassemias, it is increas-
ingly being applied for the prophylaxis of serious complica-
tions of sickle cell anemia. Treatment centers need to
cooperate closely with national blood transfusion programs.
Washed or otherwise leukocyte-depleted blood should
always be used. Blood has to be screened for hepatitis B,
hepatitis C, HIV, and—in some populations—malarial
parasites. Blood requirements for patients with thalassemia
range from 500 to 1,500 liters per 100 patients per year,
depending on their age distribution.
• Iron chelation. Transfusion-dependent thalassemic patients
and patients with sickle cell anemia maintained on transfu-
sion for prophylactic purposes require 30 to 50 milligrams
per kilogram per day of desferrioxamine infused subcuta-
neously by pump. One pump is required per patient.
Regular assessment of body iron and assessment for com-
plications are essential.
• Immunization and other prophylactic measures. Every child
with sickle cell anemia should receive oral prophylactic
penicillin from the time of diagnosis. Some centers now
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routinely immunize patients with polyvalent pneumococ-
cal, meningococcal, and Haemophilus influenzae vac-
cines. However, the effectiveness of regimens of this type
has not been clearly established even for splenectomized
patients.
• Splenectomy. Each year, 2 to 3 percent of patients with severe
 thalassemia require splenectomy. When patients who have
received suboptimal treatment first receive standard treat-
ment, the proportion needing splenectomy can be much
higher—up to 30 percent in the first one or two years
(WHO 1994). Because of the spleen’s natural tendency to
atrophy, splenectomy is required only in patients with sickle
cell anemia who are having repeated splenic sequestration
episodes or who develop hypersplenism.
• Bone marrow transplantation. Given the continuing
improvement in results, bone marrow transplantation is
now a realistic option for patients with severe forms of 
thalassemia and sickle cell anemia who have histocompati-
ble related donors and, in particular, are relatively free of
complications, particularly chronic hepatitis and severe iron
loading (Giardini 1997). Marrow transplantation requires
specialized facilities and a trained staff, and the initial capital
expenditure is high, but it should be considered wherever
the serious hemoglobinopathies are a major problem if the
alternative is lifetime treatment.
• Prenatal diagnosis programs. If prenatal diagnosis programs
are part of an existing genetic and diagnosis service, fetal
sampling will involve only marginal costs. If they must be
set up from scratch, they require at least two obstetricians
trained in fetal medicine, access to ultrasound, and a spe-
cialist nurse. Disposable or reusable sampling equipment
is also required, together with suitable sterile facilities for
amniocentesis, facilities for termination of pregnancy in
the first or second trimesters, and access to experienced
bereavement counselors. Access to a laboratory able to carry
out mutation analysis is also required.
• Other treatments. Patients with hemoglobinopathies require
folate supplements. Those infected with hepatitis C require
treatment with antiviral agents. Those with endocrine dam-
age caused by iron loading may require hormone replace-
ment therapy.
In addition, centers for hemoglobin disorders require a
trained counselor or clinical psychologist to handle both
genetic and social issues. They should interact with local pub-
lic health organizations to disseminate information about
inherited hemoglobin diseases to schools and to the commu-
nity at large. Many countries have parent support groups. The
Thalassemia International Federation, an international body
run largely by parents and lay members, provides advice and
support for national parent associations and hemoglobinopa-
thy programs.
COSTS AND EFFECTIVENESS OF DIAGNOSIS
AND MANAGEMENT
Defining the full costs of treating patients with inherited disor-
ders of hemoglobin is difficult, and comparing them between
countries is even harder. The variables that confound such esti-
mates include different health care systems, varying methods of
obtaining donated blood, widely varying practices in screening
blood for pathogens, and differing costs of drugs and equip-
ment. WHO working parties and others have produced
approximate data (Alwan and Modell 1997; WHO 1985, 1987,
1989, 1994).
Thalassemias 
Information about the economic aspects of the thalassemias is
sparse, including the costs and effectiveness of different inter-
ventions, three of which are discussed here: screening and
counseling, treatment using transfusions and chelation, and
cure by means of bone marrow transplant.
Screening and Counseling. Screening and counseling are
cost-effective to the extent that they avert an affected birth or
ensure early and adequate treatment of an affected child.
Several studies, beginning with community screening pro-
grams in Montreal (Scriver and others 1984), have provided
strong evidence that screening and prenatal diagnosis are highly
effective in relation to control of the thalassemias. Alwan and
Modell (1997), Davies and others (2000), and Modell and
Kuliev (1991, 1993) provide detailed discussions of the issues
involved, together with estimates of the costs of screening and
counseling programs compared with the treatment of estab-
lished disease, and even though the estimates are based mainly
on studies in developed countries, the findings are probably
more generally applicable.
The effectiveness of prenatal diagnosis programs can be
quite high if more than 2 percent of the population is a carrier
and the public education programs that precede their establ-
ishment are well designed. In Europe, 80 to 90 percent of coun-
seled at-risk couples now request prenatal diagnosis, and a
rapid reduction in affected births has been observed. The thal-
assemia birth rate fell almost 100 percent between the late
1970s and the late 1980s in Cyprus and Sardinia and about
80 percent in mainland Greece and Italy (Modell and Kuliev
1991). Between 1974 and 1986, such births fell by 40 percent in
the United Kingdom (Modell and Kuliev 1991).
In terms of cost-effectiveness, terminating a pregnancy can-
not be compared with improving the health of a child carried
to term, but it is clearly cost saving compared with treatment.
Modell and Kuliev (1991) estimate the cost of replacement
(when a couple terminates an affected pregnancy and subse-
quently has a normal child) at only 30 percent of the annual
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cost of treatment, or 2 percent of the discounted lifetime cost.
Similarly, Scriver and others (1984) estimate the costs of pre-
venting an affected birth in Canada as less than annual treat-
ment costs and about 4 percent of lifetime costs.
Treatment. Investigators have made several estimates of the
costs of treating the  thalassemias. Approximate annual costs
of care in Thailand in 2003 were as follows (authors’ estimates
updated from unpublished Thai sources):
• homozygous  thalassemia: US$19.84 million for patients
in their first year of treatment and US$17.7 million per year
for patients in subsequent years of treatment 
• Hb E  thalassemia: US$100.3 million for patients in the
first year of treatment and US$92.4 million for patients in
subsequent years of treatment
• homozygous 
o thalassemia: US$727,000
• Hb H disease: US$7.49 million.
The life expectancy of a child in Thailand homozygous for
 thalassemia is only 10 years, reflecting an inability to provide
the bulk of patients with expensive chelating drugs. These costs
are therefore not fully comparable to those from more devel-
oped countries, where better care means that children live
longer. Han, Han, and Myint (1992) provide data for Myanmar
that are comparable to those for Thailand.
Table 34.3 shows the annual costs for a program in Toronto
that offers a high level of symptomatic care, and table 34.4
presents treatment costs for the eastern Mediterranean, taking
into account the increasing expenditure required as children
grow and require higher doses of maintenance drugs and more
units of blood each year. Despite the difficulties of making
comparisons, tables 34.3 and 34.4 indicate that the costs for
managing  thalassemia in the eastern Mediterranean are
roughly similar to those in Toronto, exclusive of transfusion,
and are therefore probably reasonable estimates of the costs of
managing thalassemias in developed countries.
Transfusion is required to keep a child with severe thal-
assemia alive beyond age one or two, but by itself prolongs life
only to age 10 to 15. The gain is the added 9 to 14 years lived
with disability weights of 0.1 to 0.5, implying 0.50 DALY gained
for the last years and 0.75 to 0.90 per year earlier. Table 34.4
shows the costs of transfusion at ages 7 to 11, and figures in
parentheses in the table show the costs at age 2 and for adults.
Costs and health gains run parallel, so it makes little difference
whether they are discounted when summed over an interval.
Table 34.5 shows discounted total costs and DALYs gained for
death at age 10 or 15 and using disability values of 0.1 and 0.25.
For both ages, the cost per DALY is about US$2,000 for low
disability and about US$3,000 for high disability for transfu-
sion only.
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Table 34.4 Costs of Treatment of Thalassemia for One Patient Age 7 to 11, Eastern Mediterranean
(2001 US$)
Category Minimum treatment Full treatment
Costs other than iron chelation
Day transfusion: hotel and nursing 375 375
12 transfusions/year 1,088 (600–1,575) 2,250 (1,390–3,150)
Investigations 135 (135–435) 278 (278–870)
Occasional costs (such as operations) 150 645
Staff salaries 300 620
Total if no desferrioxamine therapy 2,048 (1,560–2,835) n.a. n.a.
Desferrioxamine therapy (iron chelation) 3,080 (1,440–4,725) 6,165 (2,880–9,450)
Total with desferrioxamine therapy 5,128 (3,000–7,560) 10,333 (6,190–15,110)
Source: Alwan and Modell 1997.
Note: n.a.  not applicable. The figures in parentheses show the range of costs for a two-year-old and an adult; where no range is shown, the cost is independent of age. Both minimum and full
treatment include transfusion and chelation. Full treatment means more frequent transfusion and consultations, more laboratory work, and more surgery. 
Table 34.3 Annual Costs of Hemoglobinopathy per Outpatient, Excluding Transfusion, Toronto 
(2001 US$)
Thalassemia Sickle cell disease
Category Chelated Nonchelated Chelated Nonchelated
Clinic staff salaries 1,011.95 183.68 1,011.95 252.99
Clinic supplies 930.19 25.15 930.19 34.65
Medical and surgical outpatient unit 2,069.57 n.a. 2,069.57 n.a.
Consultations 92.58 88.39 92.58 11.94
Diagnostic tests 742.58 281.44 905.89 210.99
Laboratory costs 413.96 31.04 414.01 42.74
Laboratory costs (medical dayunit visits) 665.81 n.a. 665.81 n.a.
Total 5,926.64 609.70 6,090.00 553.31
Source: Estimated costs provided by Nancy Oliveri of the University of Toronto.
Note: n.a.  not applicable.
A thalassemic patient can be kept alive beyond adolescence,
possibly for a normal life span, if also chelated. This treatment
means added annual costs of about US$3,000, or about
US$6,000 (table 34.4) for full treatment, plus higher costs of
transfusion and other components. Besides prolonging life, full
treatment is assumed to reduce disability from 0.10 to 0.02 and
from 0.25 to 0.10. Table 34.5 also shows discounted incremen-
tal costs, DALY gains, and cost per DALY of full treatment com-
pared with those of minimal treatment. The incremental cost
per DALY is high up to age 15 because of the modest gain com-
pared with prolonging life with greater disability. From age 15,
the cost drops because the child would otherwise die. If a life
expectancy of 80 years is assumed, lifetime costs are some
US$9,000 to US$11,000 per DALY at a disability weight of 0.1
and roughly US$10,000 to US$12,000 at a disability weight
of 0.25.
Comparing full treatment to none, annual costs rise with
age from US$6,190 to US$15,110 (table 34.4). As table 34.5
shows, up to age 15, 10.8 to 11.8 discounted DALYs are gained
at a total cost of US$121,284 and a cost per DALY of approxi-
mately US$10,300 to US $11,200, comparable to lifetime incre-
mental costs. Beyond age 15, the cost per DALY is some
US$16,000 to US$17,000, and over the lifetime it is between
US$13,000 and US$15,000. Because costs and gains run
parallel—and also because of discounting—the lifetime cost
per DALY is not sensitive to age at death of 45 or older, so dif-
ferences in regional life expectancies do not matter.
These cost estimates come from the eastern Mediterranean.
In Thailand, the first-year costs are much higher than the
costs shown in table 34.5 and include the costs of delivering
the child and protecting it from infection. Thereafter, the cost
per year of treating the 6,250 survivors of each birth cohort
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with transfusion alone (assuming they live only 10 years)
drops, implying a cost per DALY of US$3,146 to US$3,776.
Half the 97,500 people with Hb E  thalassemia are assumed
to require treatment, leading to a cost per DALY of US$2,100
to US$2,500, consistent with costs in the eastern
Mediterranean. For chelated patients in Toronto, the estimate
of US$5,927 per year (table 34.3) implies a cost per DALY of
US$6,600 to US$8,000, considerably less than in the eastern
Mediterranean, but the costs do not include transfusion. Thus,
data from three different regions on the cost-effectiveness of
full therapy for victims of the common treatable forms of
thalassemia are roughly comparable.
De Silva and others’ (2000) study provides approximate
costs for treating thalassemia in Sri Lanka. If we assume that a
prevention program will probably not be developed in the near
future, the data suggest that management of the disease will
consume approximately 5 to 8 percent of the country’s health
budget based on 1999 figures. Those estimates have not been
used to derive cost-effectiveness results.
Bone Marrow Transplantation. Angelucci and Lucarelli
(2001) discuss the economic aspects of bone marrow trans-
plantation. The 1991 cost was US$73,250, excluding follow-up
but including the expense of setting up a program. This
amount is almost certainly cost saving compared with lifelong
transfusion and chelation, and it is also more cost-effective,
given the reduction in disability from curing the disease.
Sickle Cell Disease 
Extensive data on the costs of sickle cell anemia come from
Davis, Moore, and Gergen’s (1997) analysis in the United
States. An estimated 75,000 hospitalizations of both children
and adults occurred each year from 1989 through 1993. The
average cost of hospitalization in 1996 was estimated at
US$6,300, resulting in a total direct cost of US$575 million per
year. In this and subsequent studies, the bulk of hospitaliza-
tions was confined to a subset of about 10 percent of the total
patient population.
In the United States, specialized treatment centers provide a
cost-saving approach to the care of sickle cell anemia. Patients
enrolled in these centers used emergency rooms and inpatient
units significantly less frequently than those cared for in the
general hospital community, resulting in significantly lower
health care costs (Nietert, Silverstein, and Abboud 2002; Yang
and others 1995). Currently, only a small proportion of
patients are treated in centers of this kind, even in developed
countries. A pilot study in Benin found that the development
of a comprehensive clinical care program reduced the fre-
quency and severity of acute complications related to sickle cell
anemia (Rahimy and others 2003). The annual cost per family
using the program was US$40, and the annual cost for each
hospitalization was US$100.
Neonatal Screening and Prophylaxis. Extensive controlled
trials in several developed countries have demonstrated the
Table 34.5 Cost-Effectiveness of Treatment for Homozygous  and Transfusion-Dependent Hb E  Thalassemia
DALYs gained/patient Cost/DALY (US$)
Cost/patient Disability Disability Disability Disability 
Category (US$) weight  0.1 weight  0.25 weight  0.1 weight  0.25
Minimal treatment, transfusion only
Until death at age 10 17,368 6.96–7.60 6.00–6.39 2,285–2,495 2,718–2,896
Until death at age 15 23,840 10.25–10.81 7.52–7.87 2,206–2,325 3,029–3,170
Full treatment with chelation: incremental
compared with minimal treatment
Until age 15 60,467 1.03–3.80 0.55–2.03 15,912–58,706 29,787–109,940
Beyond age 15 to maximum age 80 132,901 17.25 16.35 7,704 8,129
Total lifetime 193,368 18.28–21.05 16.90–18.38 9,186–10,578 10,520–11,442
Full treatment with chelation: total
compared with no treatment
Until age 15 121,284 11.81 10.84 10,273 11,186
Beyond age 15 to maximum age 80 274,662 17.25 16.35 15,922 16,799
Total lifetime 395,946 29.06 27.19 13,625 14,578
Source: Authors’ calculations. All costs and DALYs gained are discounted at 3 percent annually, starting at birth.
Note: Differences in DALYs gained for a given age range and disability weight depend on how rapidly health is assumed to deteriorate in the years immediately preceding death.
life-saving effect of giving prophylactic penicillin from birth. A
randomized trial suggested that this approach would save sig-
nificantly more lives than starting prophylactic penicillin when
an infant presents with symptoms of the disease. Without
treatment, pneumococcal infection is the leading cause of death
before age five. Penicillin by monthly injection or daily oral dose
from about age four months to four years reduces bacteremia
by 83 to 86 percent (D. Bonds, personal communication,
September 28, 2004; Gill and others 1989, 1995; Panepinto and
others 2000). Prophylaxis also reduces the case-fatality rate
from infection from 27 to 18 percent.
Data from the United States show that neonatal screening
for sickle cell disease followed by the use of appropriate
prophylactic treatment prevents deaths (Tsevat and others
1991). With 16 percent of the U.S. population being African
American, without screening and treatment 13 deaths would
occur per million infants. Six of these deaths could be pre-
vented by targeting only African Americans, and two more
could be prevented by universal screening. Ignoring disability
and discounting at 3 percent, we find that targeted screening
costs US$6,709 per life year saved, or somewhat more per
DALY. At more than US$30,000 per life year saved, universal
screening would not be cost-effective compared with targeted
testing (Panepinto and others 2000).
Data from a Jamaican cohort of 315 children with sickle
cell disease allow for a similar cost-effectiveness analysis in a
middle-income country (Hambleton 2004a, 2004b). They sug-
gest that treatment averts seven to eight deaths, or that a newly
diagnosed child’s chances of dying before age four are reduced
by 2.4 percentage points. Because bacteremia becomes less fre-
quent with age, few cases occur—and little is known about the
mortality risk—after childhood.
In the Jamaican cohort, up to 2 percent of children take pro-
phylactic penicillin orally; the rest receive monthly injections
requiring 10 minutes of a nurse’s time. A clinician sees each
child for 20 minutes four to six times a year. Table 34.6 shows
the costs of personnel and penicillin. Other recurrent costs,
such as those for syringes, will be low in comparison. No
allowance is made for capital costs. The marginal cost of detect-
ing sickle cell disease in newborns who have already been
screened for other conditions such as phenylketonuria is only
about US$3.30 (D. Bonds, personal communication,
September 28, 2004). The cost of screening children who do
not have sickle cell disease depends on prevalence and is not
included in the estimates. It becomes unimportant as more of
the population is at risk.
On average, preventing a death costs about US$8,000 to
US$12,000 by means of injection and about US$5,000 more
when oral penicillin is used. Because death would typically
occur between one and two years of age, each death averted
saves 29 DALYs and costs about US$270 to US$400 per DALY.
Penicillin prophylaxis is probably more cost-effective than any
other intervention. It is standard practice in Jamaica and the
United States and can be recommended for middle-income
countries where the prevalence is high enough—in the general
population or in those of African origin—to justify screening.
Application to Other Countries. The limited data available
indicate that specialized treatment centers and neonatal screen-
ing programs are effective approaches toward the control of
sickle cell anemia. Although these conclusions should be valid
for developing countries, many uncertainties remain. In partic-
ular, data on the causes of infection in infants with sickle cell
disease in Africa are sparse. Because the spectrum of infection
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Table 34.6 Cost-Effectiveness of Penicillin Prophylaxis for Sickle Cell Disease Detected by Newborn Screening, Jamaica
Category Monthly injection Daily oral dose Total/1,000 children
Monthly cost of penicillin (J$) 22 250 26,560
Nurse’s time, 10 minutes/month (J$) 90 n.a. 88,200
Clinician’s time, 20 minutes 4–6 times/year (J$) 152.67–229.00 152.67–229.00 152,670–229,000
Total year 1, 8 treatments (J$) 2,117–2,728 3,221–3,832 2,140,000–2,750,000 
Total, each of years 2–4, 12 treatments (J$) 3,176–4,092 4,832–5,748 3,210,000–4,130,000 
Discounted total (discount rate of 3 percent), first 4 years 11,101–14,303 16,889–20,091 11,220,000–14,420,000 
Equivalent in U.S. dollarsa
US$1  J$49.8 223–287 339–407 220,000–290,000
US$1  J$59.8 186–239 282–336 190,000–240,000 
Number of deaths averted by prophylaxis 0.024/child 0.024/child 24 deaths
Costs per death averted (US$) 7,750–11,958 11,750–16,958 7,830–12,058
Costs per DALY gained (US$) 267–412 405–585 270–416
Source: Authors’ calculations based on data from Hambleton 2004a, 2004b. 
Note: n.a.  not applicable. The results are based on a cohort study of 315 cases.
a. Two exchange rates are shown because the exchange rate changed during the course of the study.
may be different, the value of penicillin prophylaxis in Africa is
unknown.
Laboratory diagnosis is well defined, is cheap, and does not
differ depending on the level of available technology. The
major uncertainty is whether the increasing indications for
prophylactic transfusion in developed countries will be mir-
rored in other populations.
Other Treatments. As indicated in the discussion of the bur-
den of disease, sickle cell patients suffer various clinical events
for which treatment may be life saving, such as transfusion for
aplastic crises. For painful crises, intervention (analgesics and
possibly hospitalization) is only palliative. Because of the lack
of information on costs and of consensus on the associated dis-
abilities with and without treatment, we have not assessed the
cost-effectiveness of any of these treatments.
OPTIONS FOR CONTROL AND MANAGEMENT 
OF INHERITED HEMOGLOBIN DISORDERS
Even though much more work is needed on both the scientific
and the economic aspects of the hemoglobinopathies, certain
issues are now clear. Until more definitive ways of treating
them are available, reliable knowledge exists on how they can
best be managed symptomatically. Furthermore, compelling
evidence suggests that population screening programs com-
bined with prenatal diagnosis can reduce the financial burden
these increasingly common diseases impose on health services.
Defining several options for their control and management is
therefore possible. These are based, with some modifications,
on Alwan and Modell (1997).
Severe  Thalassemias
This list provides most of the possible options for the control
and management of  thalassemia in developing countries.
• Option one: best possible patient care, together with retro-
spective genetic counseling after the first affected child is
diagnosed
• Option two: best possible patient care, together with retro-
spective genetic counseling and the option of prenatal diag-
nosis for subsequent pregnancies
• Option three: best possible patient care, together with retro-
spective genetic counseling and prospective (premarital)
carrier screening and counseling, but no prenatal diagnosis
• Option four: best possible patient care with premarital,
family-based, and population-based prospective carrier
screening and genetic counseling, but no prenatal diagnosis
• Option five: best possible patient care, premarital and prena-
tal prospective carrier screening and genetic counseling, and
the option of prenatal diagnosis
• Option six: based on option four or five but includes the
availability of a bone marrow transplant program.
Options one and two, though still commonly practiced in
many countries, offer little prospect of reducing the frequency
of serious forms of thalassemia. Overall, that reduction is
best achieved by option five, which combines maximum
possibilities for reducing the frequency of severe disease with
the best possible care for affected children. Although thal-
assemia births have fallen sharply in some developed countries,
the effect of prenatal screening is likely to be lower for the large
mainland populations of Asia if this policy is implemented,
which is why this option includes best-practice treatment.
Limited studies also suggest that families that undergo prenatal
diagnosis tend to settle at the population norm for the number
of children that they subsequently have and that their views on
their ability to have unaffected children are extremely positive.
For those countries or groups in which termination of preg-
nancy is unacceptable for religious or cultural reasons, option
four is recommended. Option six, which is possible only in
countries where bone marrow transplantation is available,
should be exploited by any country with a high frequency
of the disease, because it offers a potentially cost-effective
approach to managing some proportion of affected children.
For the extremely heterogeneous intermediate forms of
 thalassemia, notably Hb E  thalassemia, options three and
four would probably be best, at least until a better understand-
ing has been gained of the clinical heterogeneity of these
thalassemias.
 Thalassemias
Few options are available for the 
o thalassemias. Homozygous
babies with this condition are stillborn. However, because of
the serious maternal complications of carrying these babies,
this condition should be screened for prenatally, and affected
babies should be identified by prenatal diagnosis with a view to
terminating the pregnancy.
Hb H disease, the compound heterozygous state between 
+
and 
o thalassemia, is generally a relatively mild disorder that
simply requires careful follow-up and treatment of complica-
tions. Although some have suggested that screening and prena-
tal diagnosis may be relevant for the more severe forms, more
data are required to reach a conclusion.
Sickle Cell Disorders
These options for the management of the sickle cell disorders
are directed particularly at the populations of developing coun-
tries, although, overall, they are relevant to most countries:
• Option one: best possible patient care with the use of pro-
phylactic penicillin following diagnosis, together with retro-
spective genetic counseling 
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• Option two: best possible patient care, together with a
neonatal screening program and the use of penicillin for all
homozygous babies, together with retrospective screening
and counseling
• Option three: best possible patient care, together with
neonatal screening and the use of prophylactic penicillin
from birth for homozygotes, together with population
screening and prospective genetic counseling
• Option four: as for option three, plus the availability of pre-
natal diagnosis, bone marrow transplantation, or both.
Option three would be required to combine best manage-
ment with the possibility of reducing the frequency of the dis-
ease, although whether this option would have any effect by
altering the pattern of marriage is not clear. Whether prenatal
screening of mothers would be valuable is also not clear: it
would reduce the number of neonates who require screening,
but because the cost of screening for sickle cell trait is so small,
the issue is probably not important. Prenatal diagnosis can be
developed (option four), but this option does not seem to be a
high priority for sickling disorders in many developed coun-
tries, at least until more is known about the reasons for their
phenotypic heterogeneity. By contrast, demand is greater in
developing countries with limited facilities for the care of these
patients. Some developed countries are beginning to immunize
children with sickling disorders against infections with pneu-
mococcus, H. influenzae, and meningococcus, but in develop-
ing countries, this treatment would add enormously to the
burden of management programs. Clinical trials to test the effi-
cacy of prophylactic penicillin with or without these vaccine
regimens are urgently needed. Similarly, more information
about the pathogens that cause early deaths in developing
countries is required before the widespread use of prophylactic
penicillin can be recommended.
Bone Marrow Transplantation
Experience in developed countries indicates that bone marrow
transplantation may offer a cost-effective approach to manag-
ing a subset of patients with inherited disorders of hemoglobin
(Borgna-Pignatti 1985). In developing countries, if this service
is available at all, it is usually confined to the private sector or
to those who can pay the fees teaching hospitals require. Given
this context, defining the role of bone marrow transplantation
in the global control of these diseases is difficult.
International and National Support Groups 
Largely through the efforts of parents with affected children and
clinicians who have taken an interest in the hemoglobin disor-
ders, many countries have developed national thalassemia or
sickle cell anemia societies that provide support for parents,
workshops for doctors, and a variety of other important inputs.
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In the case of thalassemia, the Thalassemia International
Federation acts as an international coordinating body that helps
countries develop workshops for training in diagnosis and treat-
ment and organizes international meetings at which experts
from different countries share their research and clinical experi-
ences. In 1996, a group of doctors formed the Fédération des
Associations de Lutte contre la Drépanocytose en Afrique
(Federation of Associations to Control Sickle Cell Anemia in
Africa). The membership has grown to 13 Sub-Saharan coun-
tries. The federation represents a major initiative in relation to
regional training in both the diagnosis and the treatment of
sickle cell disease in Sub-Saharan Africa. Unfortunately, it has
been unable to raise sufficient funds to equip and run even a
modest secretariat. Considering the success of the Thalassemia
International Federation, particularly in countries with limited
facilities for managing the hemoglobin disorders, the lack of
support for this initiative in Africa is a clear indication of the
importance of educating nongovernmental organizations and
similar bodies about the increasing public health problems
resulting from the inherited hemoglobin disorders.
Ethical and Social Issues
The various options for controlling and managing the hemo-
globin disorders raise many ethical and social issues (see
Weatherall and Clegg 2001b for more details). These issues
arise most often in developing countries, where the level of
education is often low and understanding of genetic diseases is
limited. Serious genetic diseases such as thalassemia are associ-
ated with social problems such as patient stigmatization and
broken marriages because one partner blames the other for the
birth of an affected child. In countries where arranged mar-
riages are still common, screening programs for heterozygotes
may make it difficult for female carriers to find husbands. In
addition, cultural and religious objections about interfering
with nature arise when pregnancies are terminated because
children have serious genetic diseases. At the same time, if
governments perceive prenatal diagnosis and termination of
pregnancy to be a highly cost-effective way of controlling these
diseases, which they are, the danger arises that governments
will pressure women to undergo these procedures. Therefore,
before any programs are established, extensive discussions
between governments, the medical profession, and the com-
munity about how to control these diseases are vital.
FURTHER RESEARCH
Despite the progress made toward understanding the molecu-
lar pathology, pathophysiology, and management of the inher-
ited hemoglobin disorders, many gaps persist:
• First, much better data are required about their frequency
and distribution in many developing countries.
• Second, more information is required about the reasons,
both genetic and environmental, for the remarkable clinical
heterogeneity of these conditions.
• Third, much better criteria are required for the management
of the intermediate forms of thalassemia and of sickle cell
anemia.
• Fourth, much more work is required on the role of the envi-
ronment, a topic that has been badly neglected compared
with research on the genetics of these conditions.
• Finally, further studies are required on better methods for
their symptomatic management or a definitive cure.
One important approach toward progress in controlling
these diseases is further development of North-South partner-
ships (WHO 2002). Arrangements of this kind have been
extremely successful for thalassemia but have not evolved for
sickle cell anemia research. In both cases such partnerships
should evolve and lead to local South-South networks allow-
ing individual countries to share their expertise about these
increasingly important conditions.
Finally, a great deal more work needs to be carried out, par-
ticularly in developing countries, to investigate the economic
aspects of these diseases, in terms of both their overall health
burden and their control and management.
CONCLUSIONS
The inherited hemoglobin disorders are posing an increasing
global health problem, killing thousands of children because of
the inadequacy or unavailability of treatment. With appropri-
ate therapy, many children can survive and have an excellent
quality of life, despite requiring lifelong treatment. Even
though the full economic burden of managing these disorders
is currently unknown, in the case of thalassemia, screening
and prenatal diagnosis are cost-effective means of prevention.
Penicillin prophylaxis provides cost-effective protection from
infection for babies with sickle cell disease and should be stan-
dard practice wherever it is affordable.
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Adult respiratory diseases in the developing world are a major
burden in terms of morbidity and mortality and, particularly as
related to chronic respiratory disease, are of increasing concern
(Murray and Lopez 1996). For many years, the leading cause of
adult respiratory disease mortality has been tuberculosis, which
still kills far more people than it should, given the increased
efficacy of treatment and preventive regimens (see chapter 16).
However, the burden of other acute and chronic adult respira-
tory diseases, which is the focus of this chapter, has been rising
throughout the world. These diseases fall into four categories:
acute diseases, such as pneumonia and influenza; chronic
diseases, such as chronic obstructive pulmonary disease
(COPD) and asthma; occupational lung diseases, such as byssi-
nosis, asbestosis, and coal worker’s pneumoconiosis; and other
parenchymal lung diseases, such as immune-related lung
diseases. Lung cancer, tuberculosis, and AIDS-related lung dis-
eases are dealt with in chapters 29, 16, and 18, respectively.
ACUTE DISEASES: PNEUMONIA AND INFLUENZA
Obtaining figures on the incidence and burden of pneumonia
and influenza in adults throughout the developing world has
been surprisingly difficult. Much of the research and surveil-
lance has been directed toward the pediatric age group (see
chapter 25). In 2000, fatal lower respiratory infections, as a
class that represents serious pneumonia and influenza, were
reported as the cause of 120 deaths per million men and
76 deaths per million women worldwide for the 15 to 59 age
group (WHO 2000). For both sexes in this age group, this sta-
tistic represents approximately one-third of the deaths caused
by tuberculosis. However, for the age groups over 60, rates
of death from lower respiratory disease more than double
for each decade of life, whereas rates of death from tuber-
culosis remain relatively constant. Notably, acute respiratory
diseases—in addition to tuberculosis—remain major concerns
among adults with AIDS.
The diagnosis of pneumonia varies according to the patient’s
access to medical care. Often the diagnosis is made simply on
the basis of cough and fever. For patients with access to a hospi-
tal, the likelihood of obtaining a chest x-ray increases; generally
the infection is bacteriologically confirmed only in the most
sophisticated medical centers. The natural history of pneumo-
nia without antibiotic treatment varies with the etiologic agent
and the patient’s underlying comorbid conditions and age.
Mortality resulting from these lower respiratory diseases is
approximately 10-fold higher in people age 60 to 69 than in
people age 15 to 59 (WHO 2000). Comorbid conditions, mal-
nutrition, low socioeconomic status, and cigarette smoking
each play a role in increasing the incidence of disease and wors-
ening the prognosis, both with and without treatment.
From studies conducted in the developed world, it would be
reasonable to conclude that common antibiotics for pneumo-
nias that occur outside a hospital setting would effectively
reduce days lost from work and, in the absence of other morbid
conditions, mortality. The few studies in which sputum speci-
mens have been cultured suggest that Streptococcus pneumoniae
is found in between 40 and 50 percent of the cases. Gram-
negative organisms or mixed infections are often isolated, and
thus, the use of broad-spectrum antibiotics is warranted (Hooi,
Looi, and Ng 2001; Hui and others 1993; Lieberman and others
1996). As would be expected, increased use of antibiotics
has resulted in increased resistance to common antibiotics. In
addition, 10 to 15 percent of these cases may be tuberculosis
(Dolin, Raviglione, and Kochi 1994).
Chapter 35
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Scott and others (2000) suggested that, despite the similarity
of the mortality rates for hospital-treated pneumonia in devel-
oping and developed countries, there are important differences
in the age distributions. The median age at death among
Kenyan adults was 33 years, in contrast to more than 65 years
in more developed countries. Many patients in developing
countries present late in the course of the disease. Often they
die before an appropriate diagnostic workup can be completed,
thus leading to an underestimate of case-fatality rates.
Signs and symptoms of influenza can vary from trivial to
explosive. Although the disease is usually self-limiting, it can
result in both severe incapacity and, when not properly treated,
potentially fatal secondary pneumonia. Clearly, patients with
comorbid conditions, the very young, pregnant women, and
the elderly are at greater risk of suffering from complications
from influenza. Those criteria, along with the adequacy of sup-
ply, form the basis for choosing who should be considered for
vaccination each year. Because the symptoms of influenza can
be quite similar to those of bacterial pneumonia, influenza may
often be misdiagnosed as pneumonia. Generally, influenza is
more self-limiting than pneumonia, although the infectivity
and transmission of influenza from person to person can be
substantial. The current threat of H5N1 influenza has resulted
in increased human and avian surveillance and preparations
for a possible pandemic (box 35.1).
The recent 2003 outbreak of severe acute respiratory syn-
drome (SARS; see chapter 53) emphasizes the importance of
accurate and open surveillance and a coordinated response in
682 | Disease Control Priorities in Developing Countries | Frank E. Speizer, Susan Horton, Jane Batt, and others
H5N1 Influenza
Box 35.1
Clearly, of even greater concern is the potential for a new
influenza A pandemic, as occurred in 1918 and more
recently in 1958 and 1968, from a newly altered strain of
avian influenza. With each additional bird-to-human case,
modest genetic mutation or re-assortment increases the
chance for the avian virus to be altered to become estab-
lished and virulent in mammalian species. This may result
in the establishment of sustained transmission among
humans. While the pandemics of 1958 and 1968 were
together responsible for approximately 3 million deaths,
mostly in the very young, the elderly, and in those with co-
morbid conditions, the 1918 episode is believed to have
caused over 40 million deaths, mostly in the age group 15
to 35 years. This potential for greatly increased mortality
among such a robust population has fueled recent concern
(WHO 2005a).
This concern has become more immediate with the
identification of a sub-strain of influenza A, H5N1, first
identified in 1997 in Hong Kong when it jumped from
poultry to humans and killed six of 18 infected people.
Virtually all of the original cases were believed to have
been bird-to-human transmission. Since that time there
have been a few hundred serologically confirmed cases in
Cambodia, Indonesia, Thailand, and Vietnam, with high
case fatality but no sustained evidence of ongoing human-
to-human transmission (WHO 2005b).
The H5N1 strain is highly pathogenic among poultry.
During 2003–2004 it resulted in outbreaks in 8 countries
in Asia, with over 100 million birds dying from disease or
being culled. More recently, though an additional 150 mil-
lion birds have been culled, because much of the develop-
ing world’s poultry economy depends on rural backyard
sources, it is not clear how effective these control measures
have been. Although these efforts were thought to help
control the spread of the virus, permanent ecological
reservoirs appear to have become established in wild fowl
and domestic chickens over a relatively broad region of
Southeast Asia. WHO authorities have expressed concern
about the finding that migratory birds that are infected
with H5N1 but are relatively asymptomatic have spread
viable viruses over large regions with subsequent infection
in domestic poultry. Furthermore, more recently there has
been evidence of disease in wild and zoo mammals as well
as isolated cases of infection in domestic cats. Recent
reports from Vietnam include two cases in humans
infected through the consumption of uncooked duck
blood. Further investigation of possible person-to-person
transmission is underway. Recently, WHO (2005b) stated,
“The possible spread of H5N1 avian influenza to poultry
in additional countries cannot be ruled out. WHO recom-
mends heightened surveillance for outbreaks in poultry
and die-offs in migratory birds, and rapid introduction of
containment measures, as recommended by FAO and OIE.
Heightened vigilance for cases of respiratory disease in
persons with a history of exposure to infected poultry is
also recommended in countries with known poultry out-
breaks. The provision of clinical specimens and viruses,
from humans and animals, to WHO and OIE/FAO refer-
ence laboratories allows studies that contribute to the
assessment of pandemic risk and helps ensure that work
towards vaccine development stays on course.”
Humans have little natural immunity to the H5N1
viruses. Thus, in contrast to the usual influenza epidemics,
which affect the very young, elderly, and those with
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Table 35.1 Public Health Measures in the SARS Episode, 2003 
Procedure Comment
1. Isolation of patients Isolate rapidly after onset of symptoms.
2. Quarantine of contacts Usually at home, but separate from patients. When in contact with unexposed subjects, wear masks and avoid public
transportation and visits to crowded places.
3. Education Reduce delay between onset of symptoms and isolation. In endemic areas, get subject to monitor temperature daily. Use
fever hotlines, fever evaluation clinics. 
4. Thermal screening Monitor temperature of travelers from endemic areas (not proven effective).
5. Increased social distance Cancel mass gatherings. Close schools, theaters, public facilities. Require use of masks in public settings.
6. Disinfection Practice frequent hand washing. Use aerosol disinfectant agents.
7. Travel advisories Postpone unessential travel. Screen travelers at entry and exit (not proven effective). Distribute health notices to travelers.
Source: Data compiled and summarized from Bell 2004.
comorbid conditions, virtually the entire population in an
exposed community is at risk. In human cases of avian
influenza, following the initial respiratory infection,
mortality results from two distinct processes. One process
begins with relatively rapid onset of respiratory distress
from hypoxia associated with ARDS.a The alternative
process results from secondary bacterial infection with a
variety of organisms. In the documented H5N1 influenza
infections in humans, respiratory symptoms are most
prominent. However, in one case of encephalitis in a child
from Vietnam, H5N1 influenza virus was identified in
cerebrospinal fluid and fecal matter, and in throat and
serum samples. Isolates from several cases were resistant
to two commonly used antiviral medications (amantadine
and rimantadine), while two other antiviral medications
(oseltamivir and zanamivir) still appear to be effective.
There is no way to predict the outcome of these ongoing
events. What seems evident is that if human-to-human
transmission becomes established, a pandemic will follow.
Given the lack of natural immunity, there is considerable
concern that even if adequate vaccines were available, distri-
bution on a worldwide basis would be limited by economic
considerations as well as distribution problems in the devel-
oping world. Efforts are underway to identify the genetic
make-up of the strains of H5N1 that will yield the most
effective vaccines and to produce such vaccines in a cost-
effective manner. Testing H5N1 vaccines based on recently
identified viruses in normal healthy volunteers suggests the
immunologic response may be adequate, but several
months of production would be necessary to produce ade-
quate supplies for one region, let alone for worldwide distri-
bution. Stockpiles of effective antiviral medications are
being generated in some countries. In the interim, WHO
has encouraged the rapid reporting of cases and the estab-
lishment of procedures for better public health intervention
strategies before and during a pandemic (WHO 2005c).
Many countries have developed pandemic influenza pre-
paredness plans in anticipation of such an event.
Source: Authors.
a. ARDS is defined as Acute Respiratory Distress Syndrome resulting from multiple causes, the most likely in this situation being an immunological reaction to the virus.
controlling the spread of newly active influenza strains. The
potential for global spread and the occurrence of worldwide
epidemics of influenza (presumed to be transmitted to humans
from domesticated or wild animals and then through close
proximity to humans with symptomatic disease—generally to
caregivers) points out the importance of continued surveil-
lance for such episodes (Low and McGeer 2004). The lessons
learned from the SARS epidemic reinforce the importance of
proven traditional public health measures, such as finding and
isolating cases, quarantining close contacts, and improving
infection control practices (Bell 2004). Those methods, along
with several other, less traditional efforts, were presumed to be
part of the reason the epidemic was contained as promptly as it
was (see table 35.1). However, because of the high case-fatality
rate, the disease caused significant disruption throughout the
world.
Economic Impact of Influenza and Cost-Effectiveness
of Interventions in the Developed World
Influenza is common in developed countries. Annually, it
affects 10 to 20 percent of the U.S. population (Lee and others
2002); those affected experience on average a loss of 2.8
workdays per episode. Those over 65 years of age are more
susceptible to complications, increased costs of hospitaliza-
tion, and even death. The cost of outbreaks can be large. The
costs of the 1996–97 epidemic in Germany were estimated
at US$1,045 million, and the annual costs of outbreaks at
US$11 million to US$18 million (WHO 2002a).
For those over age 65, many countries encourage preventive
vaccinations annually, on the basis of studies suggesting that
vaccination (either opportunistic or in a campaign) is cost-
effective in elderly populations (for example, see the model of
Scuffham and West 2002). Given a good antigenic match, inac-
tivated influenza vaccines prevent laboratory-confirmed illness
in 70 to 90 percent of healthy adult vaccine recipients (WHO
2002a). Vaccination is less costly than chemoprophylaxis (with
ion-channel inhibitors such as amantadine and rimantadine,
or with neuraminidase inhibitors such as zanamivir and
oseltamivir) or early treatment with the same drugs. In both
the institutionalized and the healthy elderly, vaccination sub-
stantially reduces overall mortality from influenza (by 40 to
68 percent).
The cost-effectiveness of vaccination for healthy working-
age adults, taking into account workdays lost, is a matter of
debate. Demicheli and others (2000) concluded that the most
cost-effective option for healthy adults age 14 to 60 was to take
no action. However, these authors include only medical costs in
their calculations. Postma and others (2002) reviewed 11 stud-
ies. Only one shows cost savings on the basis of medical costs
alone, but nine of them implied cost savings from vaccination
if the value of lost work is included. Because of differences in
costs and health care usage patterns, data on cost savings in
developed countries cannot be helpfully extrapolated to devel-
oping countries.
Economic Impact of Influenza in the Developing World
In Hong Kong, China (where there is a milder year-round pat-
tern of infection, little influenza-related mortality, and low
reported work losses), a model suggested that vaccination was
not cost saving, even if targeted to the elderly (Fitzner and
others 2001). The only case for vaccination was if it controlled
the emergence of highly virulent strains and prevented trans-
mission to the rest of the world. According to the World Health
Organization (WHO), much less is known about the impact of
influenza in the developing world. However, in the tropics,
where viral transmission normally continues year-round,
influenza outbreaks tend to have high attack and case-fatality
rates. For example, during an influenza outbreak in
Madagascar in 2002, more than 27,000 cases were reported
within three months and 800 deaths occurred despite rapid
intervention. An investigation of this outbreak, coordinated by
WHO, found that health consequences were severe in poorly
nourished populations with limited access to adequate health
care (WHO 2002b). It is not possible to extrapolate the exact
annual burden of influenza in the tropics from data on such
occasional and severe outbreaks. Because many areas (for
example, Sub-Saharan Africa) do not have surveillance centers,
not enough is known at this point to make policy recommen-
dations. There are also no readily available estimates of the
cost-effectiveness of influenza vaccination in those environ-
ments. (For further discussion of the role of vaccination, see
chapter 20.)
CHRONIC RESPIRATORY DISEASES:
NATURE, CAUSES, AND BURDEN 
COPD and asthma have very different diagnoses and causes;
hence, they are discussed in separate sections. However, the
treatments for these different chronic respiratory diseases share
similarities, and that discussion is therefore combined. One of
the difficulties in defining COPD on a worldwide basis is that
three distinct levels are used, depending on the sophistication
of the health care system in the country where the patient is
being evaluated:
• Chronic bronchitis with and without obstruction, which may
be part of the COPD diagnosis, is defined by the presence of
chronic cough and phlegm for three months per year for
two or more years and is generally assessed by standardized
questionnaires.
• Obstructive airways disease is often assessed by reduced pul-
monary function as measured by simple spirometry and the
presence of a reduced ratio of the forced expiratory volume
in one second (FEV1) divided by the vital capacity (VC).
• For emphysema, which is also part of the syndrome of
COPD, pulmonary function (changes in lung volume and
reduced diffusion capacity), x-ray evidence of bullae forma-
tion, hyperinflation of the chest, and (with the use of high-
resolution CT scanning) the presence of characteristic
changes in lung architecture all may contribute to the
diagnosis.
What is apparent is that not all these diagnostic procedures
are applied equally, particularly in the developing world; thus,
COPD may be seriously underreported. The 1998 Workshop
Report by the WHO and the National Institutes of Health
(NIH) on “Global Strategy for the Diagnosis, Management,
and Prevention of COPD,” developed as part of the Global
Initiative for Chronic Obstructive Lung Disease (GOLD 2001),
uses an international standard for defining the level of obstruc-
tion from COPD. This strategy should improve worldwide
estimates. This standard definition will still require the use of
equipment that measures pulmonary function (Buist 2002).
Over the next several years, as the price and distribution of this
equipment becomes more favorable and as more groups
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undertake the training in its use and in the interpretation of
results from the tests, diagnostic uniformity will improve.
Unfortunately, as pointed out by Aït-Khaled, Enarson, and
Bousquet (2001), the applicability of these guidelines has not
been effectively tested in developing countries.
In adults, COPD dominates all other chronic respiratory
diseases in accounting for 2 percent to more than 10 percent
of lost disability-adjusted life years (DALYs) on a worldwide
basis. Its incidence increases dramatically with age (fig-
ures 35.1a and 35.1b). Of note, mortality from COPD is low
before age 45. Over age 45, death rates increase from 50 to 200
per 10,000 individuals and are consistent across age groups in
men and women, with the exception of death rates in women
over age 80, which exceed those in men in that age group
(figure 35.2).
Much of COPD in the developed world is related to cigarette
smoking, and there is no question that progression of the dis-
ease is related to the number of cigarettes smoked and the years
of smoking. Smoking cessation has been associated with
reduced mortality from COPD, presumably through a mecha-
nism that results in a modest improvement in pulmonary
function that appears to be related primarily to the extent of
chronic bronchitis and mucus hypersecretion (Scanlon and
others 2000; Speizer and others 1989). Within a few years of
stopping smoking, smokers’ rate of decline of pulmonary func-
tion (that is, FEV1) returns to the rate found in nonsmokers,
although little of the lost pulmonary function is regained
(Fletcher and others 1976). Similar effects are seen in the
developing world. However, because smoking is far less
prevalent in developing countries, especially among women,
other exposures are related to the development of disease (see
also chapter 46). One of the most important exposures, partic-
ularly for women, is to unvented coal-fired cooking stoves,
starting during childhood and continuing into adult life (see
chapter 42).
Because the interventions and treatments for COPD overlap
with those for asthma, they will be treated together.
The diagnosis of asthma has been debated for centuries.
Health care providers can generally agree on the diagnosis in
the individual patient who is wheezing and in whom other eti-
ologic factors are ruled out. They would also agree on the def-
inition of the disease as an inflammatory response in the
airways that results in variable and generally reversible airflow
obstruction with or without treatment. However, depending
on the training of health care providers, the nature of surveil-
lance, the characteristics of a given community, and the par-
ticular environment of the community, the accuracy of the
estimate of the prevalence of asthma in a community may vary
much more. The reported prevalence of the disease may be
based on no more than an answer to this question: “Has a
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Figure 35.2 COPD by Age and Sex, Worldwide
provider ever told you that you (or your child) has had
asthma?” The response to this question has been validated in a
number of studies. In contrast, the diagnosis may depend on
examination of the patient’s chest, physiological testing,
responsiveness to provocative stimuli to the airways, and
specific response to therapy. Thus, estimates of community
burden from asthma may depend on the threshold used in
making the diagnosis.
Despite variations in diagnostic criteria, worldwide esti-
mates of the asthma burden among adults have generally
come from surveys within selected communities. In contrast
to other adult respiratory diseases, the prevalence of asthma is
relatively low (figures 35.1a and 35.1b). In adults, the DALYs
for asthma are at a peak of about 2 percent of the total world-
wide in people age 15 to 29, and they decline in each older age
group. This pattern is also reflected in mortality rates, with the
highest rates occurring in young people and equal rates in
men and women about age 60. After age 60, reported rates of
death caused by asthma in men begin to exceed those in
women, and both become substantial. That shift reflects pri-
marily either increasingly questionable diagnostic accuracy or
misclassification of other obstructive respiratory diseases such
as COPD.
Economic Impact of Asthma and COPD 
in the Developed World
In the United Kingdom (where asthma rates are particularly
high), respiratory disease accounts for 6.5 percent of hospital
admissions. Fifteen percent of the working population report
work-limiting health problems caused by respiratory disease,
and 18.3 million workdays were lost to asthma problems in
1995–96 (Chung and others 2002).
In the Netherlands, annual costs associated with asthma
and COPD (direct and indirect) were estimated to exceed
US$500 million for a population of about 14 million (data for
the 1980s). Asthma or COPD was responsible for 3 percent of
absenteeism caused by illness, and asthma was also the main
reason for absence from school among children age 4 to 12
(Rutten–van Mölken and others 1992).
In the United States in the early 1990s, health care costs
attributable to respiratory disease were US$11 billion (about
2 percent of total health care costs), and an estimated 3 million
workdays and 10 million schooldays were lost to respiratory
disease (Stoloff, Poinsett-Holmes, and Dorinsky 2002).
Another survey (Weiss and Sullivan 2001) estimated the
costs of asthma in 1991 US dollars for four developed countries
(Australia, Sweden, the United Kingdom, and the United
States) and one state (New South Wales in Australia). Per
patient costs of asthma ranged from US$326 (Australia) to
US$1,315 (Sweden) annually, with direct costs accounting, in
most cases, for more than half of total costs.
Economic Impact of Asthma in the Developing World
Data for developing countries are much scarcer. For Estonia,
Kiivet and others (2001, cited in Lee and Weiss 2002) estimated
the direct annual costs of asthma to be US$104 per year per
asthma patient, equivalent to 1.4 percent of direct health care
costs. In Singapore, medical costs for asthma constitute 1.3 per-
cent of total health care costs (Chew, Goh, and Lee 1999, cited
in WHO 2001).
One study (Aït-Khaled, Enarson, and Bousquet 2001, cited
in Weiss and Sullivan 2001) found that asthma drugs cost
between 3.8 and 25 percent of the patient’s monthly income in
24 developing countries in Asia and Africa. K. R. Smith (2000)
estimates the burden of respiratory disease in India that is
attributable to indoor air pollution (only a fraction of all respi-
ratory disease) as 1.6 billion to 2 billion sick days per year. Of
that total, asthma is responsible for about one-third, acute res-
piratory infection is responsible for about one-third, and the
remainder is attributable to COPD, tuberculosis, and ischemic
heart disease. Asthma and COPD combined account for 44 per-
cent of the burden.
Cost Effectiveness of Interventions for COPD and Asthma
in Developed Countries 
Five recent overviews of the economics of chronic respiratory
disease, COPD, and asthma (Friedmann and Hilleman 2001;
Lee and Weiss 2002; Ruchlin and Dasbach 2001; Sullivan and
Weiss 2001; Weiss and Sullivan 2001), in addition to many indi-
vidual studies, focus on developed countries.1 Only a limited
number of studies use cost- or quality-adjusted life years
(QALYs) saved as the outcome (others use life years saved).
(Studies focusing on intermediate health outcomes and on cost
minimization are not discussed here.) In general, costs in
developing countries would be about 20 percent of those
reported here, according to detailed unit cost data by region
from WHO-CHOICE (Choosing Interventions That Are Cost-
Effective) and on comparisons of respiratory drug prices from
online pharmacies in the United States and from the
International Drug Price Indicator Guide (http://erc.msh.org).
The exceptions are interventions involving nondiscounted
drugs that are still under strictly enforced patents, for which the
costs in developing countries would be closer to those in the
United States. Table 35.2 summarizes the results.
Inhaled salbutamol (short-acting beta-2 agonist) is the first
line of treatment for both intermittent asthma (daytime symp-
toms less than once per week, nocturnal symptoms less than
twice per month, and normal spirometry between episodes)
and COPD (mild to severe) in both developed and developing
countries. This treatment became standard practice beginning
in the 1970s, so there are no cost-effectiveness studies of salbu-
tamol compared with placebo. This medical intervention is
likely the most cost-effective one, but it is still likely to cost
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some thousands of dollars per life year saved in the United
States.
The next line of treatment currently recommended for
developing countries is inhaled corticosteroids (for example,
beclomethasone) for mild to severe persistent asthma (disease
ranging from daytime symptoms greater than once per week,
nocturnal symptoms more than twice a month, and normal
spirometry between episodes to daily frequent symptoms asso-
ciated with severe obstruction) and inhaled ipratropium bro-
mide for COPD. Both first-generation corticosteroids and ipra-
tropium bromide are off patent. However, as pointed out by
Chan-Yeung and others (2004), the use of corticosteroids either
intermittently or chronically is commonly recommended in
developed countries, where the background level of tuberculo-
sis among patients is considerably lower. In developing coun-
tries with higher tuberculosis rates, corticosteroids must be
used with greater caution.
Inhaled steroids cost about US$13,900 per QALY for mild
to moderate asthma or when used in early treatment of
COPD. The cost per QALY is likely to be lower for severe asth-
ma, but ethical considerations render random controlled trials
unfeasible.
No cost-effectiveness study could be found for ipratropium
bromide compared with placebo. We estimate that the cost per
QALY saved would be between one-half and two-thirds of that
for a new-generation inhaled steroid such as fluticasone
propionate. This estimate, which is based on the relative cost
of the two drugs in the United States and assumes similar
effectiveness of the two drugs, would put the cost of ipratro-
pium bromide between US$6,700 and US$8,900 per QALY.
Most of the other interventions summarized in table 35.2
have a higher cost per QALY. For individuals who develop
COPD related to a severe deficiency in alpha-1 antitrypsin,
alpha-1 antitrypsin therapy is sometimes considered, at a cost
of between US$45,000 and US$215,000 per life year.2 The use
of long-acting beta-2 agonists and leukotriene modifiers is now
an accepted and integrated component of the treatment of
moderate to severe asthma in the developed world. However,
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Table 35.2 Cost-Effectiveness of Interventions for Asthma and COPD in 2001 
Reference Intervention Alternative Cost-effectiveness
Pharmacological
Authors’ estimates Inhaled ipratropium bromide Placebo US$6,700–US$8,900/QALY for moderate COPD
Paltiel and others 2001 Quick relieversa and inhaled Quick relievers only US$13,900/QALY in adults with mild to moderate
corticosteroids asthma: US$10,600 for moderate only
Van den Boom and others 2001 Inhaled corticosteroid Placebo US$13,400/QALY COPD treatment
(fluticasone propionate)
Akins and O’Malley 2000 A-1 antitrypsin augmentation therapy Standard careb US$14,400/QALY, severely deficient individuals
Hay and Robin 1991, A-1 antitrypsin augmentation therapy Standard careb US$45,000–US$215,000/life year, depends on age, 
in Ruchlin and Dasbach 2001 efficacy, and so forth
Education
Toevs, Kaplan, and Atkins 1984, Education and exercise program Exercise program only US$71,500/QALY
in Ruchlin and Dasbach 2001
Long-term oxygen
Authors’ estimate Home oxygen therapy for COPD No oxygen US$19,000/life year (US$26,700–US$38,000/QALY)
Mechanical ventilation
Schmidt and others 1983, in Mechanical ventilation Standard hospital carec US$6,400–US$23,600/life year (COPD, asthma, cardiac 
Rutten–van Mölken (excluding ventilation) patients) excluding physician costs
Anon and others 1999 in Mechanical ventilation in Standard hospital carec US$35,000–US$60,700/QALY
Ruchlin and Dasbach 2001 intensive care unit, asthma, (excluding ventilation)
and COPD patients
Surgery
Al and others 1998, in Lung transplant in end-stage disease No transplant US$464,000/QALY
Ruchlin and Dasbach 2001
Ramsey and others 1995, Lung transplant in those eligible No transplant US$238,200/QALY
in Ruchlin and Dasbach 2001 
a. Quick relievers refer to rapid-acting bronchodilators (for example, salbutamol) that act to relieve bronchoconstriction and accompanying acute symptoms of wheeze, chest tightness, and cough. 
b. Standard care includes medical management (ipratropium bromide, beta-2 agonist, steroid) and home oxygen as needed.
c. Standard care includes medical management and oxygen.
the cost savings for the developing world are difficult to
demonstrate because the endpoints of studies using those
drugs are often changes in spirometric testing, improved
quality-of-life measures, steroid-sparing effects, or altered
hospital admission rates.
Likewise, oral or intravenous steroids play a crucial role in
the treatment of acute exacerbations in both asthma and COPD,
but endpoint assessments in studies typically address decreases
in the duration of hospital stays and increases in the use of
emergency department facilities, which result in decreases in
health costs in the developed world. Oral steroids are inexpen-
sive, even by standards in developing countries, and in the short
term might appear to be cost-effective, but they are associated
with major medium- to long-term consequences and are not
recommended as standard therapy.
Educational programs tend to be cost saving in developed
countries, where uncontrolled exacerbations are extremely
costly in terms of hospital care (six such programs are surveyed
in Van Mölken and others 1992 and one in Ruchlin and
Dasbach 2001). Similarly, exercise rehabilitation programs (six
surveyed in Ruchlin and Dasbach 2001) can also be cost sav-
ing. WHO (2001) has commented on cost savings achieved by
education programs for asthma from four different U.S. stud-
ies. Only one of these studies addressed cost per well year,
which was estimated at US$71,500 in 2001 (Toevs, Kaplan, and
Atkins 1984, cited in Ruchlin and Dasbach 2001). However,
there are likely to be monetary savings from fewer workdays
lost, which are not factored into this analysis.
WHO (2001) surveyed one self-management training pro-
gram for chronic asthma in India (Ghosh and others 1998),
which resulted in improvements in health status, reduced use
of emergency departments and hospitals, and savings on health
costs. Sudre and others (1999) pointed out that studies of edu-
cation programs tend not to provide a good description of the
actual program content and that a more systematic description
of these interventions needs to be promoted to replicate best
practice.
Long-term oxygen therapy is a life-prolonging intervention
in advanced stages of COPD. Recent studies do not quantify the
cost per QALY but instead compare different methods of oxy-
gen delivery (cylinder or concentrator). These authors’ crude
estimate for long-term oxygen use is US$19,000 per life year
saved.3 If the quality-of-life scores of patients on long-term
oxygen were 0.8 or 0.6, the cost per QALY would be US$22,750
or US$31,700, respectively. (K. J. Smith and Pesce 1994, cited in
the Harvard Catalogue of Preference Scores, assign a median
score of 0.4 to quality of life for patients with severe COPD
with high supportive care needs and poor functional status.)
In hospitals, mechanical ventilation in the intensive care
unit has been estimated to cost US$35,000 to US$60,700 per
QALY in 2001 (Anon and others 1999, cited in Ruchlin and
Dasbach 2001). Studies suggest that noninvasive positive
pressure ventilation, where it is feasible, is less costly than inva-
sive mechanical ventilation for specific indications. Finally,
costs of lung transplants are at a level scarcely affordable even
in developed countries; Al and others (1998, cited in Ruchlin
and Dasbach 2001) estimated costs at US$464,000 per QALY,
and Ramsey and others (1995, cited in Ruchlin and Dasbach
2001) estimated costs at US$238,000 per QALY (in 2000 U.S.
dollars).
All those interventions compare unfavorably with the cost-
effectiveness of smoking prevention for preventing COPD
(discussed in chapter 46). Smoking prevention is one of the
most cost-effective health interventions that exists, and there is
a strong case for moving resources from expensive curative
interventions to that intervention. Likewise, prevention of
COPD by switching the cooking source from unventilated
stoves that burn biomass to either improved stoves or kerosene
stoves is more cost-effective than treatment (see chapter 42).
Cost-Effectiveness of Interventions for COPD and Asthma 
in Developing Countries
It is difficult to transfer the costs per QALY saved in developed
countries to developing countries. The cost of patented drugs
in developing countries should be the same as that in devel-
oped countries, whereas the costs of education and of the time
of medical personnel should be substantially lower (on the
order of 20 percent of U.S. levels). In practice, the costs of off-
patent drugs also vary considerably. Beclomethasone dipropi-
onate (one of the older, off-patent inhaled steroids) is available
for about US$15 per 200-dose inhaler in Canada in online
pharmacies but is quoted at US$1 to US$3 by agencies and
suppliers on the International Drug Price Indicator Guide
(http://erc.msh.org). A similar price difference exists for salbu-
tamol inhalers. Hence, the most cost-effective therapies in
developed countries (inhaled salbutamol and first-generation
corticosteroids for asthma and ipratropium bromide for
COPD) are also likely to be cost-effective in the wealthier devel-
oping countries—or more broadly if inexpensive drug supplies
are available. Those drugs are likely to be particularly cost-
effective for those with severe and moderately severe asthma or
COPD but less cost-effective for those with mild disease.
Recent practice suggests that a combination of long-acting beta
agonists and inhaled corticosteroids can control moderate to
severe disease more rapidly. However, to make this form of
therapy cost-effective, the patient needs to be reevaluated to
determine whether one or the other drug can be removed.
Because of cost considerations, that may not be feasible in the
developing world.
Once control has been obtained, education alone appears to
be ineffective when only respiratory outcomes are considered
(although education on the benefits of exercise has other health
benefits: see chapter 44 on lifestyles). However, education
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addressing the appropriate use of medication is extremely
important, particularly in developing countries, where timely
emergency care for severe exacerbations may not be readily
available. Although the cost of educational efforts would be
expected to be considerably lower in developing countries, this
area requires more systematic research.
Long-term oxygen is also an option for high-income house-
holds in middle-income developing countries. The costs are
likely to be lower than in developed countries. In Brazil the
monthly cost for supplemental home oxygen therapy is close
to US$150 (Sant’Anna and others 2003), compared with
US$400 per month paid by Medicare, which would bring the
cost-effectiveness to US$7,000 per life year by these authors’
crude estimates,or between US$8,750 and US$11,700 per QALY.
Publicly funded systems are unlikely to be able to pay this rate,
although private insurers and wealthy households might pay
because such therapy prolongs life.
The other interventions in table 35.2 are likely to be too
expensive for most developing countries to use at present.
OCCUPATIONAL LUNG DISEASE AND OTHER
RESPIRATORY DISEASES
Although occupational lung diseases are often considered dis-
eases of the industrial world, they are occurring with increased
frequency in the developing world, where guidelines for worker
safety are generally more lax or nonexistent. In addition,
because of increased migration from rural areas to more
urbanized centers and the transfer of major manufacturing
activities from the developed market economy countries to the
less developed countries, the number of employees with
potentially harmful occupational exposures has increased
exponentially in the past 30 years. The general discussion of
occupation-related diseases is reviewed in chapter 60. We focus
here on specific occupation-related lung diseases.
Occupational lung diseases are, for the most part, charac-
terized as related to particular occupational exposures and
generally fall into two broad pathophysiological types. One
type may result in pulmonary fibrosis, which is manifested by
restricted lung volume and decreased diffusion capacity on
pulmonary function testing and increased interstitial pul-
monary markings on chest x-ray. Certain occupational lung
diseases, such as silicosis, are complicated by a substantially
increased risk of tuberculosis, which contributes to the overall
burden of respiratory disease in the developing world. The
second pattern of occupational lung disease is that of obstruc-
tive airways disease, which may be reversible (occupational
asthma) or irreversible (chronic bronchitis with or without
obstruction or emphysema or COPD), in which the chest x-
ray often is negative and the diagnosis is dependent largely on
reported histories of exposures, symptoms, and pulmonary
function testing.
There are few reliable estimates of the global burden of
occupation-related respiratory diseases. Because of the lack of
systematic surveillance in most developing countries, the few
published estimates of occupation-related respiratory diseases
have relied on selected studies involving particular industries
that investigators have had unique opportunities to explore.
For example, Trapido and others (1996) conducted a survey in
a relatively small group of former mineworkers and found that
approximately 55 percent had pneumoconiosis with or without
tuberculosis. They estimated that about 25 percent of migrant
and former mineworkers in South African gold mines with
15 to 25 years of exposure had occupational lung diseases.
Loewenson (1999) pointed out the difficulties in making
assessments of occupational risk throughout the African coun-
tries and suggested a series of methodological issues that need
to be considered.
Leigh and others (1999) estimated the global burden of dis-
eases related to occupational factors at 4.2 million to 10.0 mil-
lion cases per year. If one subtracts the rates for established
market economy countries, the total burden for the rest of the
world is approximately 3.4 million to 9.1 million cases per year.
Using limited data and applying rates from individual nations
and regional groups of countries, the authors made an indirect
calculation for the expected number of cases of occupation-
related diseases globally. Figure 35.3 summarizes their esti-
mates for pneumoconiosis and other chronic respiratory dis-
eases by age and gender. Notably, these two categories of disease
account for approximately 30 percent of all occupational dis-
eases. The prevalence of these diseases increases with age and is
higher among men.
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Figure 35.3 Estimated Combined Pneumoconiosis and Other
Occupation-Related Chronic Respiratory Diseases
Asbestosis and asbestos-related cancers present a particular
problem in developing countries. Asbestosis can manifest both
as other interstitial lung disease, as described above, and as
obstructive airways disease. In addition, occupational expo-
sure is associated with the occurrence of lung cancer, and
according to studies in developed countries, the rate of occur-
rence is synergistically associated with smoking. Because the
cost of health care compensation in the developed world
exceeds the potential profit from mining and manufacturing
of asbestos products, much of the industry has moved to the
developing world.
LaDou (2004) has recently summarized the status of the
potential for reducing occupational exposure on a worldwide
basis and suggests that upward of 10 million lives will be lost if
the current lack of controls and continued increases in mining
and manufacturing are not changed. In 2000, more than 2 mil-
lion tons of asbestos products were produced, whereas 25 years
earlier the total production was 350,000 tons each year. Except
for the Russian Federation and Canada, virtually all the larger
producers are in the developing world, where the recognition
and reporting of health effects are less well established. The
likelihood of reversing this trend and developing an interna-
tional ban on asbestos use is small, particularly because it is the
nations that produce more asbestos products that are, in fact,
increasing consumption.
The economic burden of occupational lung diseases is sur-
prisingly difficult to document. Most developed countries and
some developing countries (for example, South Africa) have
legislation protecting workers from exposure and compensat-
ing those who have contracted chronic conditions. In the
United States, compensation payments from the Social Security
Administration and the Department of Labor for black lung
disease totaled US$1.6 billion in 1996 (NIOSH 1999). Data
exist on compensation for claims for various occupational lung
diseases for the United States and the European Union coun-
tries. However, claims data represent only a small fraction of
the true economic cost (for example, not all workers make
claims; compensation payments lag considerably). For the
United States, the annual costs of complying with the revised
respirator standards for 1993 were US$111 million for about
5 million workers needing to use a respirator (presumably
these costs of prevention were far lower than the economic cost
of unprotected work) (OSHA 1998). The primary treatment
for affected workers is to remove them from the inciting expo-
sures. (See chapter 60 for discussion of preventive strategies
that need to be considered to reduce the risk of occupational
disease.)
Some of the other major classes of adult respiratory diseases
are discussed in other chapters: tuberculosis, in chapter 16;
AIDS-related lung disease, in chapter 18; and lung cancer, in
chapter 29. Other diseases that have been studied, particularly
in the developed world, include the hypersensitivity or
immunologically related pulmonary diseases most often asso-
ciated with environmental exposures to specific inhaled anti-
gens or interstitial inflammation and fibrosis, often of
unknown origin. In the developing world, little systematic
work has been done on these diseases to assess incidence or
prevalence. These conditions probably occur considerably less
frequently than asthma and COPD. However, they are likely
to have a higher prevalence in developing countries than is
reported in the developed world simply because of the pre-
sumed associations with exposures to organic dusts and the
increased prevalence of malnutrition (see chapter 56), both of
which are likely to occur in more rural and less developed areas
of the world.
See chapters 16, 18, and 29 for interventions for tuberculo-
sis, AIDS-related lung disease, and lung cancer, respectively.
Managing immunologic and fibrotic respiratory diseases with
medication is extremely difficult and expensive. Therapeutic
trials often fail, presumably because the treatments are not
aimed at a particular antigen. The most effective way of manag-
ing these respiratory diseases is to reduce exposure to the
inciting agents, an approach that hinges on two strong prem-
ises, which are not always applicable in the developed world.
First, the disease must be recognized as related to a common
environmental contaminant encountered in an occupational or
avocational exposure—for example, exposure to thermophilic
actinomycetes in moldy hay or sugarcane results in farmer’s
lung, and exposure to bird feathers or droppings results in bird
fancier’s disease.Second,community resources must be directed
toward educating the public about the importance of limiting
exposure to these agents.
GENERAL APPROACH TO LOWERING RISK
OF ADULT RESPIRATORY DISEASE
Although interventions of various sorts are indicated for each
of the disease categories discussed, these interventions are often
costly and sometimes ineffective in lowering or preventing pre-
mature mortality. Thus, from an operational perspective, it is
important to consider preventive and therapeutic strategies that
will have greater societal effect than will the management of the
manifestations of diseases as they arise in individuals. This
approach applies to acute diseases (vaccination schemes to
reduce the burden of influenza, in contrast to individual man-
agement of community-acquired pneumonia) and chronic dis-
eases (smoking prevention and reduction programs, compared
with availability of routine asthma medication). Primary pre-
vention strategies should include efforts by multiple agencies of
government and the community coming together to establish
appropriate priorities for action. Four sources of exposure
stand out: tobacco smoke, indoor smoke, outdoor air pollu-
tants, and occupational exposure (see chapters 46, 42, 43,
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and 60, respectively). Of these, the most pressing and cost-
effective is a cohesive policy to control tobacco smoking.
In conjunction with the International Union against
Tuberculosis and Lung Disease (IUATLD) and selected univer-
sities and health institutions in various countries, WHO is
developing the Practical Approach to Lung Health (PAL, previ-
ously known as the Adult Lung Health Initiative). The program
is focused on improving primary care services, as well as appro-
priate referral to secondary health care facilities, for individuals
with tuberculosis, acute respiratory infections (especially pneu-
monia), asthma, and COPD. Four countries (Chile, Morocco,
Nepal, and South Africa) are serving as the pilot implementa-
tion sites (WHO 2003).
In Chile, where respiratory symptoms account for one-third
of primary health care visits, a respiratory disease program was
initiated in 2001 as part of ongoing efforts to strengthen pri-
mary health care. The pilot program was implemented in 15
centers. Standard formats are used to devise scores to deter-
mine follow-up for asthma and COPD. Sentinel centers are
used to provide epidemiologic information. Influenza immu-
nization coverage of the elderly and at-risk population has
reached 85 percent (WHO 2003).
In Morocco, survey work done before establishing a PAL
strategy showed that 31 percent of patients who consult
primary health care centers present with respiratory symp-
toms. Of those patients, 85 percent have acute respiratory
infections, 14 percent have chronic conditions, and 1 percent
have tuberculosis. In Mexico, an IUATLD study implementing
asthma control measures was shown to be cost-effective.
Control of asthma improved, and the majority of patients
experienced a decrease in the severity of asthma. The cost of
asthma management decreased because of lower costs for
emergency services and hospitalizations (WHO 2003).
FUTURE RESEARCH NEEDS
One of the difficulties in quantifying the burden of respiratory
diseases in adults is the inability to apply uniform methods of
diagnosis across economies in which sophisticated diagnostic
procedures are possible, let alone across less developed
economies. The problems relate in part to differences in the
language describing the same symptoms, levels of registration
of census and disease reporting, availability of diagnostic pro-
cedures, and reluctance to make accurate estimates because of
the cost of intervention strategies. Furthermore, unless controls
on cigarette smoking are initiated, little progress in stemming
the increasing burden of chronic respiratory diseases can be
expected.
There are still a number of unanswered questions related to
COPD, which remains the dominant respiratory disease in
adults. The developing world provides some unique opportu-
nities for research that go beyond the primary prevention that
would result from better smoking control policies. Because not
all smokers are at increased risk, the interaction of smoking
with nutritional status (including micronutrient status), with
genetic factors that determine susceptibility, and with respira-
tory infections may act as a precursor of susceptibility to envi-
ronmental (ambient or occupational) pollution and personal
(smoking) pollution. Similarly, the role of immunologic stim-
ulation or immunocompetence needs further exploration as it
relates to the development of asthma. Synergies between the
conditions discussed in this chapter and other infections (par-
ticularly tuberculosis, but possibly others) may be especially
important in the developing world. Finally, specific environ-
mental conditions—such as altitude, heat and cold stress, and
increased ambient pollution from rapid urbanization—and
their effects on asthma and COPD should be explored.
Acute respiratory infections, specifically bacterial pneumo-
nia, have not been addressed nearly as well for adults as they
have been for children. For example, simple data on the preva-
lence of infecting organisms, typical susceptibilities, the ability
to train ancillary workers in clinical diagnosis, and the correla-
tion of clinical assessment with verified disease would be help-
ful in establishing the feasibility of assessment and treatment at
home versus at a clinic or hospital, specifically in the develop-
ing world. Common etiologic agents in North America are
common elsewhere; therefore, treatment of disease would be
relatively inexpensive. Most community-acquired acute disease
responds relatively well. Certainly, penicillin should be recom-
mended as a first-line drug for community-acquired pneumo-
nia. Educating local healers on the importance of initiating
treatment earlier in the course of disease would translate into
savings with respect to decreased days of work lost and reduced
case-fatality rates. Follow-up monitoring and the development
of hospital-based bacteriologic testing should be expanded to
identify and control for the emergence of resistant bacterial
strains.
Studies of asthma in the developed world have been exten-
sive and of extremely high quality but are directed specifically
toward the health care structures in which they are tested.
Specific cost-effectiveness studies in the developing world
should be done to see, for example, whether a focus on disease
education and modification of risk factors in addition to med-
ications outweighs simple administration of medications (with
instructions on use). In the developed world, there is no ques-
tion that an approach that is multitiered and involves multiple
health care providers is the best, but we still do not have
concrete evidence of where monies are best spent in the devel-
oping world. Another possible fruitful area of research is on
education programs. Most of the literature relates to education
programs for specific entities (for example, “asthma triggers”)
and their costs in developed countries. Education programs
in developing countries that are multidimensional (smoking
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cessation, indoor air quality, vaccination) are likely to be rela-
tively inexpensive and cost-effective. Better methods of educat-
ing local healers through the use of demonstration projects
should be tested, as should more efficient distribution systems
to make relatively inexpensive medication available. General
increased awareness of the impact of symptoms on adults and
of the potential for earlier intervention in a disease should also
be explored and tested for their effects on reducing respiratory
disease burdens.
NOTES
1. The survey of the cost-effectiveness of interventions below is based
on a review of the University of York database (http://www.york.ac.uk/
inst/crd), combined with a Medline search (focusing mainly on data after
1996).
2. According to Hay and Robin (1991), cited in Ruchlin and Dasbach
(2001). Akins and O’Malley (2000) have a much lower estimate, which
probably does not include all the costs of screening and the like.
3. This estimate was calculated as follows: the MRC (1981) trials sug-
gest that over five years the mortality in a randomized trial for patients
with severe hypoxemia is 667 per 100,000 for those not treated with long-
term oxygen, compared with 548 per 100,000 for those treated with long-
term oxygen (reviewed in Crockett and others 2001). The cost per month
of home oxygen is taken as US$400 (based on U.S. Medicare reimburse-
ments in the early 1990s).
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CAUSES AND CHARACTERISTICS OF THE BURDEN
OF DISEASES 
Estimates of the global burden of disease indicate that diseases
of the kidney and urinary tract account for approximately
830,000 deaths and 18,467,000 disability-adjusted life years
annually, ranking them 12th among causes of death (1.4 per-
cent of all deaths) and 17th among causes of disability (1.0 per-
cent of all disability-adjusted life years). This ranking is similar
across World Bank regions (table 36.1).
Recent research suggests that the data shown in table 36.1
underestimate the global prevalence of kidney disease. Chronic
kidney disease (CKD) patients often suffer from cardiovascular
or cerebrovascular disease, and their deaths may be attributed
to either complication (Hostetter 2004). Altered kidney func-
tion is often found in patients with hypertensive and ischemic
heart disease, both of which are associated with increased car-
diovascular morbidity and mortality. Approximately 30 per-
cent of patients with diabetes have diabetic nephropathy, with
higher rates found in some ethnic groups (King, Aubert, and
Herman 1998). Table 36.2 shows that both genders are similarly
affected by kidney disease (Coresh and others 2003).
Generally, renal diseases progress to a final stage as end-
stage renal disease (ESRD) and function is substituted by renal
replacement therapy (RRT), hemodialysis, peritoneal dialysis,
or transplantation. National and international registries of
patients on RRT are useful for providing information on the
prevalence of renal diseases in a given country. Data combined
from different sources show that more than 1.5 million people
worldwide are on RRT, 80 percent of whom live in Japan,
Europe, and North America (Weening 2004).
The percentage of patients on regular dialysis varies across
countries as a consequence of the capacity of health care systems
to provide treatment. Europe is an example. Whereas in the
15 countries of the European Union (before 2004) the prevalence
rate of RRT was approximately 650 patients per 1 million people,
in Central and Eastern Europe it was only 160 patients per 1 mil-
lion people, reflecting differences in gross national product.
Much less is known about the prevalence of earlier stages of
CKD, when symptoms may be mild, ignored, or undiagnosed.
A lack of standardization of the stages of CKD has hampered
assessments of the burden of CKD. In an attempt to carry out
such an assessment, the National Center for Health Statistics of
the Centers for Disease Control and Prevention in the United
States conducted a survey from 1988 to 1994. The center ana-
lyzed a sample of 15,625 noninstitutionalized individuals
age 20 and older and defined five stages of renal dysfunction
according to estimates of renal function and urine albumin
level. Coresh and others (2003) found that the estimated preva-
lence of CKD in the United States is 11 percent of the adult
population, or 19.8 million people. Nationally representative
data on U.S. adults older than 20 show that 6.3 percent, or
11 million people, have stage 1 CKD, or kidney damage (pro-
teinuria) with normal kidney function (Glomerular Function
Rate (GFR) at least 90 milliliters per minute in 1.73 per meter
squared) or stage 2 CKD, that is, mildly reduced kidney func-
tion (60 to 89 ml/min/1.73 m2). Furthermore, 4.3 percent,
or 7.6 million people, exhibit stage 3 CKD, or moderately
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reduced kidney function (30 to 59 ml/min/1.73 m2), and 0.2
percent, or 400,000, have stage 4 CKD, or severely reduced kid-
ney function (15 to 29 ml/min/1.73 m2) (Coresh and others
2003; Coresh, Astor, and Sarnak 2004; National Kidney
Foundation 2002). A sizable proportion (360,000) of these
patients eventually progress toward ESRD (stage 5, or less than
15 ml/min/1.73 m2) and require RRT. Early detection of CKD
is, therefore, important to retard or arrest the loss of renal func-
tion. Late detection of CKD is a lost opportunity for making
lifestyle changes and initiating therapeutic measures.
CAUSES OF DISEASES OF THE KIDNEY
AND URINARY SYSTEM
Kidney disease leading to ESRD has many causes. The preva-
lence varies by country, region, ethnicity, gender, and age.
Genetic Diseases
Knowledge of inherited kidney disease has changed radically
with advances in molecular biology and gene-sequencing
technology. The characterization of inherited kidney diseases
has improved, and novel mutations leading to selective renal
defects have been described. Inherited kidney diseases are rare,
with the exception of autosomal dominant polycystic kidney
disease, the fourth most common cause of ESRD in developed
countries. This disease has a prevalence of 1 in 1,000 people
and affects approximately 10 million people worldwide
(Grantham 1997). Autosomal recessive polycystic kidney dis-
ease is less frequent, with an incidence of 1 in 40,000, but is an
important hereditary disease of childhood (Guay-Woodford,
Jafri, and Bernstein 2000). Many other inherited diseases can
lead to ESRD, but together they account for only a small per-
centage of all people with ESRD.
Glomerulonephritis
Glomerulonephritides are a group of kidney diseases that affect
the glomeruli. They fall into two major categories: glomeru-
lonephritis refers to an inflammation of the glomeruli and can
be primary or secondary, and glomerulosclerosis refers to scar-
ring of the glomeruli. Even though glomerulonephritis and
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Table 36.1 Contribution of Diseases of the Kidney and Urinary System to the Global Burden of Disease by Gender and Region
(thousands)
Disability-adjusted Years lived Years of
Gender and region Population Deaths life years with disability life lost
Females 3,056,384 397 8,008 2,546 5,450
Males 3,093,849 433 10,459 4,493 5,960
World 6,150,233 830 18,647 7,039 11,415
East Asia and the Pacific 1,850,775 233 5,400 1,858 3,530
Europe and Central Asia 447,180 53 1,417 623 793
Latin America and the Caribbean 526,138 70 1,667 779 888
Middle East and North Africa 309,762 57 1,283 460 823
South Asia 1,387,873 156 3,991 1,373 2,619
Sub-Saharan Africa 667,663 107 2,623 1,046 1,576
Source: Mathers and others 2006.
Table 36.2 Global Deaths Caused by Diseases of the Genitourinary System by Gender and Age
Age (years)
Gender Birth–4 5–14 15–29 30–44 45–59 60–69 70–79 80+
Male deaths
Number (thousands) 11 7 24 43 80 86 110 88
Percent 3 2 5 10 18 19 24 20
Female deaths
Number (thousands) 10 6 21 29 61 66 85 98
Percent 3 2 5 8 16 18 23 24
Source: WHO 2002.
glomerulosclerosis have different causes, both can lead to
ESRD. Glomerulonephritis ranks second after diabetes as the
foremost cause of ESRD in Europe. (Stengel and others 2003)
and is the second leading cause of ESRD in the United States,
according to the United States Renal Data System (http://www.
ifrr.net/). Approximately 20 to 35 percent of patients requiring
RRT have a glomerular disease.
Glomerular diseases are more prevalent and severe in tropi-
cal regions and low-income countries (Seedat 2003).A common
mode of presentation is the nephrotic syndrome, with the age of
onset at five to eight years. Estimates indicate that 2 to 3 percent
of medical admissions in tropical countries are caused by renal-
related complaints, most resulting from glomerulonephritis.
A number of kidney diseases that result from infectious dis-
eases, such as malaria, schistosomiasis, leprosy, filariasis, and
hepatitis B virus, are exclusive to the tropics. HIV/AIDS can be
complicated by several forms of kidney disease; however,
patient data are sparse (Seedat 2003).
Acute poststreptococcal nephritis following a throat or skin
infection caused by Group A streptococcus has almost disap-
peared in high-income countries because of improved hygiene
and treatment but remains an important glomerular disease in
India and Africa, where epidemics have been reported (Seedat
2003).
The eradication of endemic infections, along with improve-
ments in socioeconomic status, education, sanitation, and
access to treatment, is a crucial step toward decreasing the inci-
dence of glomerular diseases in developing countries.
Infections, Stones, and Obstructive Uropathy
Infections of the urinary tract are a common health problem
worldwide and can be categorized as either uncomplicated or
complicated. Uncomplicated infections include bladder infec-
tions such as cystitis, seen almost exclusively in young women
(Hooton 2000). Among sexually active women, the incidence
of cystitis is 0.5 episodes per person annually, and recurrence
develops in 27 to 44 percent of cases. Acute, uncomplicated
pyelonephritis, involving the kidney, is less frequent in women
than is cystitis. Males are less susceptible to acute, uncompli-
cated infections of the bladder or the kidney, with an incidence
of five to eight episodes per 10,000 men annually. Even though
uncomplicated urinary tract infections are considered benign,
they have significant medical and financial implications esti-
mated at approximately US$1.6 billion per year (Foxman 2003).
As for complicated urinary tract infections, hospitalization
results in almost 1 million such infections per year in the United
States. Bladder catheterization is the most important cause.
Developing countries exhibit a different pattern of urinary
tract infection. Obstructive or reflux nephropathy is often
attributed to urinary schistosomiasis (Barsoum 2003).
Worldwide, 200 million people are affected and an estimated
300 million are at risk. The disease causes lesions in the bladder
and predisposes those with the condition to secondary infec-
tions, bladder cancers, and chronic pyelonephritis.
Some 15 to 20 million people have tuberculosis (TB) world-
wide, of whom 8 million to 10 million are infectious.
Genitourinary TB is a common form of extrapulmonary TB
and is always secondary to the primary lesion, which usually
occurs in the lung (Pasternak and Rubin 1997). Lesions
referred to as ulcero-cavernous or miliary affect the kidneys. If
left untreated, such lesions may progress to kidney destruction.
Early recognition of and effective therapy for TB substantially
decrease the consequences in relation to kidney function.
In the industrial countries, kidney stones are a common
problem (Morton, Iliescu, and Wilson 2002), affecting 1 person
in 1,000 annually, and the incidence is increasing in tropical
developing countries (Robertson 2003). Factors such as age,
sex, and ethnic and geographic distribution determine preva-
lence. The peak age of onset is in the third decade, and preva-
lence increases with age until 70.
Although largely idiopathic, the following risk factors are
associated with stone disease: low urine volume, hyperurico-
suria, hyperoxaluria, hypomagnesuria, and hypocitraturia.
Diarrhea, malabsorption, low protein, low calcium, increased
consumption of oxalate-rich foods, and low fluid intake may
play a role in the genesis of stone disease. In developing coun-
tries, 30 percent of all pediatric urolithiasis cases occur as blad-
der stones in children. The formation of bladder stones in chil-
dren is caused by a poor diet high in cereal content and low in
animal protein, calcium, and phosphates.
Kidney stones can have different clinical presentations,
ranging from asymptomatic to large obstructing calculi in the
upper urinary tract that can severely impair renal function and
lead to ESRD. Although specific causes of kidney stones should
be treated appropriately, general treatment includes increased
fluid intake, limited daily salt intake, moderate animal protein
intake, and medical treatment with alkali and thiazides.
The Afro-Asian stone-forming belt stretches from Sudan,
the Arab Republic of Egypt, Saudi Arabia, the United Arab
Emirates, the Islamic Republic of Iran, Pakistan, India,
Myanmar, Thailand, and Indonesia to the Philippines. The dis-
ease affects all age groups from less than 1 year old to more
than 70, with a male to female ratio of 2 to 1. The prevalence of
calculi ranges from 4 to 20 percent (Hussain and others 1996).
Urolithiasis accounts for some 50 percent of the urological
workload and the bulk of urological emergencies. Patients may
present with major complications leading to eventual ESRD
and resulting in significant morbidity and mortality. In devel-
oped countries, only about 1 percent of patients are on dialysis
because of obstructive uropathy, whereas in developing coun-
tries such as Indonesia and Thailand, obstructive uropathy is
often the leading cause of ESRD, accounting for 20 percent or
more of patients on dialysis. The availability of appropriately
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trained medical and surgical personnel and of equipment
essential for treating stone disease promptly would reduce the
incidence of obstructive uropathy and ESRD. Cost analyses
indicate that the medical prevention of stones saves more than
US$2,000 per person annually (Parks and Coe 1996).
Benign Prostatic Hypertrophy 
Benign prostatic hypertrophy is a major cause of lower urinary
tract symptoms and leads to obstructive renal failure and
ESRD. By age 80, 80 percent of men have benign prostatic
hypertrophy. The World Health Organization quotes a mortal-
ity rate of 0.5 to 1.5 per 100,000 (La Vecchia, Levi, and Lucchini
1995). The actual incidence of benign prostatic hypertrophy is
difficult to assess because of the lack of epidemiological data. In
the developed world, the incidence varies between 0.24 and
10.90 per 1,000 annually from age 50 to 80, and the probabili-
ty of prostate surgery for benign prostatic hypertrophy ranges
from 1.4 to 6.0 percent (Oishi and others 1998).
Acute Renal Failure 
Acute renal failure refers to a sudden and usually temporary loss
of kidney function that may be so severe that RRT is needed
until kidney function recovers. Even though acute renal failure
can be a reversible condition, it carries a high mortality rate.
Acute renal failure is a prominent feature of major earthquakes,
where many suffer from crush syndrome accompanied by
severe dehydration and rapid release of muscle cell contents,
including potassium. Kidney function shuts down unless body
fluid and blood pressure are rapidly corrected and frequent
hemodialysis is available. Recent earthquake rescues in the
Islamic Republic of Iran and Turkey have demonstrated the
benefits of rapid hydration and dialysis (Sever and others 2001).
Diabetes
Diabetes is one of the most common noncommunicable dis-
eases (see chapter 30). With the serious complication of
nephropathy, diabetes has become the single most important
cause of ESRD in the United States and Europe, according to
Stengel and others (2003) and the United States Renal Data
System (http://www.ifrr.net/). Diabetes may account for one-
third of all ESRD cases.
Family-based studies and segregation analyses suggest that
inherited factors play a major role in people’s susceptibility to
diabetic renal complications (Seaquist and others 1989). In the
United States, the burden of ESRD is threefold to fivefold
greater among African Americans, Mexican Americans, and
Native Americans than other Americans, and Imperatore and
others (2000) find a 200 percent greater possibility of the occur-
rence of inherited diabetic nephropathy. A family history of
hypertension has also been associated with an increased risk of
diabetic nephropathy. When specific markers of risk are found,
high-risk individuals can be identified early and monitored for
the development of proteinuria and kidney dysfunction.
The earliest sign of diabetic nephropathy is the appearance
of small amounts of protein in the urine (proteinuria). As pro-
teinuria increases and blood pressure rises, kidney function
declines. The complete loss of kidney function occurs at differ-
ent rates among type 2 diabetes patients, but it eventually
occurs in 30 percent of proteinuria cases. The latter have a 
10-fold increased risk of dying from associated coronary artery
disease, which may obviate the progression of diabetic
nephropathy to ESRD. As therapies and interventions for coro-
nary artery disease improve, patients with type 2 diabetes may
survive long enough to develop kidney failure.
Hypertension
Hypertension and kidney disease are closely related. Most pri-
mary renal diseases eventually produce hypertension. Arterial
hypertension accelerates many forms of renal disease and has-
tens the progression to ESRD (Luke 1999). Recent studies have
firmly established the importance of continuous blood pres-
sure reduction to slow the progression of many forms of renal
injury, particularly glomerular disease (Agodoa and others
2001; Peterson and others 1995). Over the long term, damage
to the heart and cardiovascular system resulting from hyper-
tension represents the major cause of morbidity and mortality
among ESRD patients (Martinez-Maldonado 1998).
Before the development of effective antihypertensive agents,
40 percent of hypertensive patients developed kidney damage
and 18 percent developed renal insufficiency over time
(Johnson and Feehally 2000). Elevated serum creatinine devel-
ops in 10 to 20 percent of hypertensive patients, with African
Americans and Africans at particularly high risk. In 2 to 5 per-
cent of hypertensive patients, progression toward ESRD will
occur in 10 to 15 years. Despite the relatively low rate of pro-
gression, hypertension remains the most common cause of
ESRD after diabetes in the United States, is the foremost cause
of death in all developed countries, and is a likely primary
cause in developing countries given its high global prevalence
rate. Native Americans and Hispanic Americans are dispropor-
tionately affected relative to Caucasian Americans.
GLOBAL PERSPECTIVES IN RELATION TO RRT
Despite the lack of uniform data worldwide, the medical com-
munity is aware that the total number of patients requiring
RRT is growing in all high- and middle-income countries. In
the United States, for example, 360,000 people with ESRD
were on RRT in 2003, compared with 150,000 in 1994, and
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according to a recent forecast, by 2014 the figure will have
increased to 650,000 (Xue and others 2001). This increase rep-
resents a linear growth in new cases combined with longer sur-
vival by existing patients.
Levels in middle-income countries are lower, but rising. In
Eastern Europe between 1990 and 1996, following economic
changes, the number of hemodialysis and peritoneal dialysis
centers increased by 56 and 296 percent, respectively
(Rutkowski 2002), and the number of patients rose by 78 and
306 percent, respectively.
Overall, the incidence of ESRD is increasing worldwide at an
annual growth rate of 8.0 percent, far in excess of the annual
population growth rate of 1.3 percent.Nearly 1.6 million people,
or only 15 percent of those affected, are receiving RRT, 80 per-
cent of them in developed countries. The remaining 20 percent
are treated in more than 100 developing countries, whose pop-
ulations account for more than 50 percent of the world’s popu-
lation. A large proportion of people living in the poorest coun-
tries die of uremia because of a complete lack of RRT.
Risk Factors for Kidney Disease 
The identification of risk factors can prevent or limit disease
through lifestyle modifications or specific therapeutic inter-
ventions (Appel 2003; McClellan and Flanders 2003). For
example, familial predisposition for a disease, which is not
amenable to modification, can be used to identify high-risk
populations for future monitoring.
Low socioeconomic status and limited access to health care
are strong risk factors for kidney failure but account for only
part of the excess of ESRD among African Americans
(Perneger, Whelton, and Klag 1995), whereas racial and social
factors account for most ESRD incidence (Pugh and others
1988; Rostand 1992). Factors associated with the progression of
CKD include the following:
• unmodifiable variables
– old age
– gender
– genetics
– ethnicity
• risk factors susceptible to social and educational
interventions
– low birthweight
– smoking
– alcohol abuse
– illicit drug abuse
– analgesic abuse and exposure to toxic substance such as
lead
– sedentary lifestyle
• risk factors susceptible to pharmacological interventions
– hypertension
– dyslipidemia
– poor glycemic control in diabetic patients
– proteinuria
• biological markers
– hemoglobin
– insulin-resistant syndrome
– proteinuria
– serum creatinine.
Growing evidence suggests that fetal exposure to an abnor-
mal intrauterine environment leads to an increased risk of
chronic disease later in life. For example, children of diabetic
mothers are prone to obesity and diabetes at a young age, and
intrauterine growth retardation can lead to ischemic heart dis-
ease, diabetes, hypertension, and kidney disease. Disadvantaged
racial minorities in developed countries and the impoverished
in developing countries are at risk of intrauterine growth
retardation caused by malnutrition (Nelson 2001; Nelson,
Morgenstern, and Bennett 1998). Attention to maternal nutri-
tion and other factors that would reduce low birthweight and
impaired nephron development may have long-term implica-
tions for the development of CKD.
In low-income countries, poverty is associated with
increased exposure to infectious diseases that increase suscep-
tibility to CKD, including glomerulonephritis and parasitic dis-
eases. Obesity caused by a diet rich in saturated fats and high in
salt are risk factors for diabetic nephropathy and hypertensive
kidney disease. Change in dietary habits and physical activity
can reduce the overall incidence of diabetes (see chapter 44).
Smoking and excessive alcohol consumption increase the risk
of ESRD (McClellan and Flanders 2003), and analgesic abuse
and exposure to toxic substances such as lead may affect pro-
gressive renal insufficiency (Lin and others 2001).
Interventions to Delay CKD 
During the past 20 years, human and animal research has
developed our understanding of CKD and led to preventive
measures. The notion of renoprotection has resulted in a dual
approach to renal diseases based on effective and sustained
pharmacological control of blood pressure and reduction of
proteinuria. Lowering blood lipids, stopping smoking, and
maintaining tight glucose control for diabetes form part of the
multimodal protocol for managing renal patients monitored
by specific biological markers (Ruggenenti, Schieppati, and
Remuzzi 2001).
Abnormal urinary excretion of protein is strongly associated
with the progression of CKD in both diabetic and nondiabetic
renal diseases. Clinical studies have established that a reduction
in proteinuria is associated with a decreased rate of kidney func-
tion loss. A specific category of drugs that lower blood pres-
sure, the angiotensin-converting enzyme (ACE) inhibitors or
angiotensin receptor blockers, appear to be more effective than
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other antihypertensive drugs in slowing the progression of both
diabetic and nondiabetic CKDs (Brenner and Zagrobelny 2003).
The administration of an ACE inhibitor (or of an angiotensin
receptor blocker) is an important treatment for controlling
blood pressure and slowing the rate of progression of chronic
kidney failure. Other drugs to lower blood pressure are added as
necessary to achieve current targets of 120/80 to 130/80 mil-
limeters of mercury. Concurrent diuretic therapy is often neces-
sary in patients with renal insufficiency, because fluid overload
is an important determinant of hypertension in such cases.
Dyslipidemia accelerates atherosclerosis and may promote
the progression of renal disease. Careful control of the blood
glucose level in diabetic patients can be beneficial and may
limit other complications. Obesity has not been directly linked
to the progression of CKD but is an important risk factor for
diabetes and cardiovascular morbidity and mortality. Many
patients and health care professionals do not appreciate the
benefits of smoking cessation, an important measure in pro-
tecting the kidneys from progressive disease resulting from car-
diovascular disease (CVD). Additional elements of secondary
prevention measures include the treatment of anemia and of
abnormal calcium and phosphorus metabolism.
The International Society of Nephrology is developing a
program that can be implemented according to the specific
needs of a given developing country. The program has two
objectives: (a) to identify the prevalence of renal disease among
seemingly healthy subjects using a communitywide screening
program, especially among populations at risk, and (b) to ini-
tiate interventions to prevent the progression of renal disease
and affect both renal and CVD outcomes in subjects with or at
risk of developing renal disease based on the screening pro-
gram (Weening 2004). The Kidney Help Trust of Chennai,
India, has undertaken a screening program for a population of
25,000. All those who tested positive for high blood pressure,
diabetes, or both (about 15 percent) were further studied and
then treated with inexpensive antihypertensive and antidia-
betic drugs. The cost of the one-year program was Rs 300,000
(US$7,500) or a per capita cost of US$0.27, well within the lim-
its of the Indian government’s per capita annual health expen-
diture of US$7.67 (Mani 2003). A similar program in Bolivia
examined a population of 14,000 and also found that 15 per-
cent were hypertensive, diabetic, or both.
An extremely successful program of detection and treat-
ment of renal and cardiovascular diseases among Australian
Aborigines was conducted from 1995 to 2000. The ESRD rate
among Aborigines is 3 to 10 times that in developed countries.
Treatment consisted of long-acting ACE inhibitors to lower
blood pressure. After an average of 3.4 years of follow-up, the
incidence of ESRD was reduced by 63 percent and nonrenal
deaths were reduced by 50 percent. Hoy and others (2003) esti-
mate that this two-year program may have saved US$500,000
to US$2.7 million in avoided or delayed dialysis costs.
Trained staff members can carry out screening programs
inexpensively. Economic analysis, however, suggests that large-
scale programs should be restricted to screening and treating
only specific high-risk populations. Screening programs can be
implemented using simple, cheap, and reliable tests consisting
of measurements of bodyweight, blood pressure, blood glu-
cose, and creatinine. Screening includes testing urine for hemo-
globin, glucose, leukocytes, and protein (repeat tests may be
necessary on a spot urine sample); calculating albumin to
creatinine ratios; testing positive results for increased serum
creatinine and fasting glucose (or glycosylated hemoglobin A1c
test); and reassessing the urine protein excretion rate, a corner-
stone of kidney assessment. Resulting albumin to creatinine
ratio categories would indicate a scale of severity of glomerular
disease, with a cardiovascular risk score based on body mass
index, hypertension, fasting glucose level, microalbuminuria or
gross albuminuria, and serum creatinine. Patients with positive
markers for kidney disease would receive the best treatment
available at the screening center. Incorporating screening for
kidney disease within screening programs developed for CVD
and diabetes is important because proteinuria and renal dys-
function are early sensitive markers of vascular dysfunction
and CVD patients are at significantly higher risk of kidney dis-
ease than the general population.
Resultant medical treatment would focus on the use of ACE
inhibitors or angiotensin receptor blockers with a target blood
pressure of 120/80 to 130/80 millimeters of mercury. The
greater the level of proteinuria, the more treatment is required;
thus, the ACE inhibitor dose would be titrated up as proteinuria
levels increased. Diuretics and other antihypertensives would be
added to meet blood pressure targets. Efforts should be made to
obtain low-cost (off-patent) ACE inhibitors or other low-cost
antihypertensives. Such treatment should delay or stop the pro-
gression of kidney disease and reduce the risk of CVD. Other
preventive measures include serum glucose and lipid control
and low-dose aspirin if a risk of CVD exists (see chapter 44).
ECONOMIC BENEFITS OF INTERVENTION
An abundance of literature is available on the economics of
ESRD. In the industrial world, treatment is usually readily
available and is covered by government or private health insur-
ance. Previous restrictions—for example, treatment being lim-
ited to certain age groups—have been removed (Chugh and
Jha 1995). Dialysis treatment accounts for 0.7 to 1.8 percent of
health care budgets in European countries, even though dialy-
sis patients account for only 0.02 to 0.05 percent of the popu-
lation (Schiepatti, Perico, and Remuzzi 2003).
The most cost-effective option is prevention. Population
screening is not particularly cost-effective, given the low inci-
dence of ESRD—namely, 100 to 200 per million population
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worldwide (Kher 2002)—and given that testing is not highly
accurate. According to Kiberd and Jindal (1998), screening
costs around US$20 per test, but the positive predictive value
for a single test is only 0.3. Even repeat testing does not improve
predictive value dramatically. Screening strategies have, there-
fore, focused on specific populations at higher risk of ESRD
than the general population. Whereas only 2 to 5 percent of
more than 1 billion hypertensive patients will ultimately devel-
op nephropathy, approximately 30 percent of type 1 and type 2
diabetic patients will develop overt nephropathy (Satko and
Freedman 2001). The conclusion is that treating all diabetics in
developed countries with ACE inhibitors is a cost-saving strat-
egy. The modest outlay for ACE inhibitors, which amounts to
US$320 per year in the United States and is likely to come down
as more ACE inhibitor treatments come off patent, offsets the
much larger future costs of dialysis and transplant (Golan,
Birkmeyer, and Welch 1999; Kiberd and Jindal 1998).
We undertook a crude cost-effectiveness calculation for
treating diabetics in developing countries with ACE inhibitors
in those cases in which no treatment of ESRD is undertaken. If
we use Clark and others’ (2000) assumptions, 82 percent of
diabetic patients not using ACE inhibitors would survive for
11 years from the onset of macroproteinuria to ESRD, whereas
72 percent of those using ACE inhibitors would survive for
18 years from the onset of macroproteinuria to ESRD (the
annualized death rate for both groups is 1.8 percent). If we
make the gross assumption that all patients with ESRD in poor
developing countries die, this assumption suggests that, at a
discount rate of 3 percent and an annual cost for ACE
inhibitors of US$320, the cost per quality-adjusted life year
(QALY) saved would be about US$1,100 for treating diabetic
patients with macroproteinuria. Because of the lack of data,
these calculations apply survival rates in developed countries to
developing countries; thus, the rates are likely too high. Using
survival rates in developing countries would probably increase
the cost per QALY saved, but treatment with ACE inhibitors is
nevertheless likely to be an attractive investment (table 36.3).
Satko and Freedman (2001) suggest that screening first- and
second-degree relatives of ESRD patients may be cost-effective.
They cite one study that found 38 percent of first-degree rela-
tives of African-American patients with hypertensive ESRD
had some form of renal disease (Bergman and others 1996).
Satko and Freedman also cite a study by Freedman, Soucie and
McClellan (1997) revealing that in 4,365 incident ESRD
patients in the southeastern United States, 14 percent of white
patients and 23 percent of black patients had first- or second-
degree relatives with ESRD (the rates would probably have
been higher if subclinical nephropathy had been included).
Satko and Freedman (2001) recommend annual screening for
blood pressure, urinalysis, measurement of serum creatinine
and blood urea nitrogen concentration, and testing for diabetes
mellitus, when appropriate, for first- and second-degree
relatives of ESRD patients. They did not calculate any formal
cost-effectiveness results (table 36.3).
Kidney transplants are the most cost-effective intervention
for ESRD. Transplant costs in developed countries have
declined steadily from about US$60,000 in 1970 to about
US$10,000 currently (Winkelmayer and others 2002). In addi-
tion to facing transplant costs, patients face ongoing costs for
immunosuppressive drugs, which start at about US$3,000 per
year initially but can decline thereafter to US$300 per year
(Kher 2002). Kidney transplants are cheaper in India than in the
United States, ranging from US$1,500 in government hospitals
to as much as US$7,000 in private hospitals. Such costs, com-
bined with a higher quality of life than obtained with dialysis,
make renal transplantation the most cost-effective option (table
36.3). However, the availability of kidneys is a major limiting
factor. Developed countries tend to have well-organized organ
retrieval programs, and cadaveric donor transplants are more
common than they are in developing countries. Japan, with its
extremely low transplant rates, is an exception, perhaps because
of difficulties in obtaining permission for organ donation.
Developing countries have limited access to cadaveric donor
programs but better living donor programs. Unrelated living
donors are more common than in developed countries because
poverty increases the willingness of donors to offer kidneys in
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Table 36.3 Cost-Effectiveness of Selected Interventions for
Kidney Disease
Sources: aWinkelmayer and others 2002 (review); bauthors’ rough estimates; cSatko and Freedman
2001; dGolan, Birkmeyer, and Welch 1999; eKiberd and Jindal 1998.
Intervention
Center hemodialysisa
Home hemodialysisa
Kidney transplanta
ACE inhibitors for all
type 1 diabetics with
macroproteinuriab
Screening diabetic 
relatives of 
nephropathy patientsc
Treat all type 2 
diabetics with ACE
inhibitorsd
Treat all insulin-
dependent diabetics
with ACE inhibitorse
Alternative
No RRT
No RRT
No RRT
No RRT
No screening
Screening for 
microalbuminuria and
treating those who test
positive
Screening for 
microalbuminuria or
macroproteinuria and
treating those who test
positive
Outcome (2000 US$)
55,000–80,000/life year
79,000–114,000/QALY
33,000–50,000/life year
47,000–71,000/QALY
10,000/life year
11,000/QALY
1,100/QALY
Screening potentially
cost saving
Incremental cost-
effectiveness ratio is
7,500/QALY for treating
all type 2 diabetics
Treating all 
insulin-dependent 
diabetics dominates
under a plausible range
of parameters
exchange for payment. The Philippines recently restricted
donations to “emotionally related” donors, but that limitation
does not prevent abuses, such as men marrying women of the
appropriate blood type in the hope of obtaining a kidney.
Developing countries face particular transplantation prob-
lems, such as patients’ inability to continue paying for
immunosuppressive drugs and the transmission of hepatitis B
and C, malaria, and TB through organ transplant (Kher 2002).
Long-term hemodialysis was introduced in 1960 and is the
most costly treatment option at approximately US$60,000 per
year at a center and US$40,000 at home in developed countries.
It is most cost-effective if used as an interim measure before
kidney transplant. Peritoneal dialysis—for example, continu-
ous ambulatory peritoneal dialysis—was developed in the late
1970s and is less expensive—approximately US$20,000 per
year (Winkelmayer and others 2002). Most economies con-
tinue to rely on hemodialysis for dialysis patients, except for
those mandating that continuous ambulatory peritoneal
dialysis be the first choice—that is, Hong Kong (China),
Mexico, New Zealand, and the United Kingdom. Switching to
continuous ambulatory peritoneal dialysis has the potential of
reducing costs for developing countries, especially if they man-
ufacture the consumables domestically rather than importing
them. Nevertheless, dialysis remains costly and is not a viable
long-term solution in places where health budgets are limited.
More than 120 countries have dialysis programs (Moeller,
Gioberge, and Brown 2002). The following data from India
highlight the stark economics of dialysis (Kher 2002).
Government hospitals will provide hemodialysis only for acute
renal failure or pretransplant stabilization (Li and Chow 2001),
and with an incidence of 100 per million population, approxi-
mately 100,000 patients develop ESRD each year. Of the 10,000
who consult a nephrologist, RRT is initiated for 9,000. Of the
8,500 who begin hemodialysis, about 60 percent are lost to
follow-up within three months, probably because of the costs
involved. Few remain on dialysis after 24 months. Between 17
and 23 percent of those on dialysis for two to three months
receive transplants.
IMPLEMENTATION OF CONTROL STRATEGIES:
LESSONS OF EXPERIENCE
Measures for primary and secondary prevention of CKD are
now well documented and will eventually reduce the number
of patients requiring dialysis. Until recently, the focus has been
on RRT to save lives, and considerable efforts are being made to
improve the quality of dialysis. In the United States, guidelines
derived from the Kidney Disease Outcomes Quality Initiative
have added greatly to the quality of dialysis in terms of access
(graft or fistula), adequacy, treatment of anemia, treatment of
secondary hyperparathyroidism, and—more recently—greater
emphasis on CVD, all of which contribute to quality-of-life
outcomes, but at an increased cost (National Kidney
Foundation 2002).
The high mortality rate of dialysis approximates 10 percent
per year and has changed little over the past decade; however,
new approaches are emerging for dealing with CVD in RRT
facilities. More patients with kidney disease die before they get
to the point at which they need treatment for renal failure,
because early kidney disease is a major marker for CVD and
reinfarction, congestive heart failure, and stroke.
In middle-income countries such as Thailand and Turkey and
in middle-income countries in Latin America (Zatz, Romão, and
Noronha 2003), extensive dialysis facilities are available, as they
are in some low-income countries. For example, in 2003,
Pakistan had 110 centers with 2,400 patients on hemodialysis;
India had 100 centers with 6,000 patients mostly on hemodialy-
sis; and China had 75,000 patients on dialysis.Those figures show
that needs and markets for dialysis are expanding. However, in
poorer countries, such as Nicaragua and Tanzania, options for
RRT are limited because of the lack of equipment, trained
staff, and costly consumables. In addition, many low-income
countries lack health insurance to defray treatment expendi-
tures, keeping dialysis out of reach. In such countries—for
example, Nigeria—dialysis directed at preparation for renal
transplantation is the best policy. Recent findings concerning
primary prevention through lifestyle changes and secondary
prevention by means of pharmaceutical treatment should
eventually reduce, but not eliminate, the burden of ESRD.
The acknowledgment by the World Bank and the World
Health Organization that chronic conditions, particularly those
resulting from diabetes and hypertension, will increase to
become a leading cause of death by 2028 has intensified the need
for prevention and RRT programs. The need to increase aware-
ness, launch targeted screening and intervention studies, pro-
vide training for staff, maintain education for physicians in
kidney and urological disease, and assist centers for RRT is
urgent.
Developed nations have well-established nephrology and
urology centers attached to academic medical institutions and
regional public and private secondary and tertiary referral hos-
pitals. They have training programs to meet national require-
ments for health professionals—including renal physicians, pri-
mary care physicians, and nurses—specializing in kidney and
urological disorders. Their centers incorporate the results of
up-to-date research developments pertaining to kidney disease
and clinical applications of the latest advances in care and tech-
nology. Numerous publications arise from academic endeavors,
and a close association exists between health care delivery and
pharmaceutical industries. Each country and region has soci-
eties of nephrology and urology for adults and children.
Middle-income countries may have both public academic
centers and private hospitals that offer specialized equipment,
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such as lithotripters and imaging technology, and dialysis and
transplant programs. Although facilities and trained staff for
RRT are more limited than in developed countries, some devel-
oping countries, such as Turkey, have excellent facilities.
In lower-income countries, facilities and staff are in short
supply, and assistance is needed. Large countries, such as
China, India, and Pakistan, have kidney centers available but
have considerable unevenness in development of kidney cen-
ters and health care in general. Some lower-income countries
possess remarkable institutions; for instance, the Sindh
Institute of Urology and Transplantation in Karachi, Pakistan,
which is supported mainly by charitable donations, provides
every patient who presents with ESRD an opportunity for
accessing RRT. Overall, however, centers of excellence are
urgently needed in developing countries. All the “players,” from
governments and international organizations to societies and
foundations, need to be congregated in conjunction with
national institutions to focus on the continued advantages—
through treatment—that can be delivered to those developing
cardiovascular, diabetic, and kidney disease.
RESEARCH AND DEVELOPMENT AGENDA
Significant progress in knowledge about the geographic burden
of kidney and urological diseases has taken place during
the past three or four decades as a result of more accurate
registries. An international kidney disease data center, in
partnership with the World Bank and the World Health
Organization, is now required to progressively increase the
amount and quality of data collected worldwide.
Basic Knowledge of Kidney Disease
Recent research findings have advanced the understanding and
treatment of kidney disease. A continuing emphasis on under-
standing the basic mechanisms of glomerulonephritic, vas-
culitic, and autoimmune disease and the detailed mechanisms
of the progression of kidney disease to kidney failure is
required, as well as research into improved therapies. Well-
developed research centers are best equipped to deal with these
requirements, aided by national governments, charitable
organizations and foundations, international organizations,
and centers in the developing world.
Prevention of Kidney Failure
Prevention of acute and chronic kidney disease should be a
global priority. During the past decade, an array of clinical
trials has been directed at assessing the benefits of interven-
tional therapy, particularly the success of ACE inhibitors. Such
trials can play an important role in increasing knowledge and
improving the implementation of prevention of kidney disease
in developing countries. Training epidemiologists and physi-
cians to execute screening strategies and clinical trials in their
own settings is urgently needed. The cooperation of global
funding agencies and training centers; the consistent availabil-
ity of effective, inexpensive pharmaceuticals; and the assess-
ment of the efficacy and side effects of multiple drug therapy
must be coordinated. The priority is to make low-cost drugs
available, using as a model the recent process that allowed uni-
versal access to inexpensive antiretrovirals for HIV infection.
Renal Replacement Therapy
Successful RRT outcomes depend on reducing morbidity and
mortality among dialysis patients. RRT costs escalate in concert
with the rising costs of pharmaceuticals—for example, eryth-
ropoietin compounds to treat anemia and vitamin D metabo-
lites and calcimimetics to treat secondary hyperparathyroidism
and bone disease. Strategies that will result in less expensive
dialysis systems and pharmaceuticals are needed (Schieppati,
Perico, and Remuzzi 2003). Costs relating to renal transplanta-
tion have reached a steady state, but the lack of availability of
donor kidneys is a serious—and perhaps irresolvable—
limitation.
Establishment of Teaching and Research Centers
Most high-quality training and research centers for kidney and
urinary diseases are in the developed world, where training is
expensive. Important centers of clinical care have emerged in
countries such as Argentina, China, Mexico, South Africa,
Thailand, and Turkey. The ability to obtain high-quality train-
ing at the local level would be advantageous to developing
countries. For example, the International Society of
Nephrology has identified and supported a major clinical
training center in South Africa that plays a leading role in train-
ing nephrologists and urologists for South Africa and other
Sub-Saharan African countries to world standards at lower
costs than in developed countries and with increased retention
of local physicians. Such local centers should be a national pri-
ority in developing countries and should be closely linked to
international centers for cardiovascular and diabetic disease,
meeting approved international standards for training while
recognizing national differences in the pattern of kidney dis-
ease. Financial assistance is required to enhance the education
and training of health professionals, improve baseline infra-
structure, and initiate research studies directed at critical clini-
cal questions and at current and new knowledge relating to the
prevention of kidney disease. The centers should have excellent
data collection methods and a computer infrastructure that
would connect them to current knowledge and allow them to
communicate freely on a global scale. Major priority should be
given to developing leading centers in selected regions.
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Cost-Effectiveness of Treatment
More work is needed in the area of screening and treatment in
both developed and developing countries. Work on the cost-
effectiveness of screening and treating particular subpopula-
tions would be useful, as would the development of better pre-
dictive tests for microalbuminuria. In addition, cohort studies
of hypertensive and diabetic populations might help develop
better indicators that predict susceptibility to progression
toward nephropathy.
CONCLUSIONS: PROMISES AND PITFALLS
Kidney disease and kidney failure, especially as a complication
of type 2 diabetes mellitus and hypertension, are rising globally
and are rising faster in developing countries. Kidney failure
patients account for a small fraction of the disease burden but a
disproportionately high cost. CKD, along with all chronic dis-
eases, is placing long-term demands on health care. On a global
scale, RRT is rising sharply in terms of costs and is usually
unavailable in developing countries. Hemodialysis and peri-
toneal dialysis are life saving, but in the long term they require
coupling with newer, proven, interventional pharmacological
treatments that frequently delay or stop continuing progression
to ESRD. Advances in the past decade have proven that primary
and secondary prevention measures can now reduce the burden
of ESRD, and if they are not widely disseminated, the need for
RRT will increase along with the certainty that the requirements
of kidney disease patients cannot be met.
The following guidelines for diseases of the kidney and uri-
nary system are recommended:
• Expand surveillance of the prevalence of various kidney and
urological diseases in developing countries. Provide support
for further epidemiological studies in selected countries for
assessing the prevalence of kidney disease and interventions
to address it and for establishing an international kidney
disease data center.
• Promote public awareness in developing countries about
the nature and early signs of kidney disease along with
knowledge of prevention measures and therapies.
• Focus more attention on the increasing prevalence of dia-
betes and hypertension, and develop kidney disease pro-
grams in that context. Measures of kidney function and
protein excretion should be taken. The implementation of
primary and secondary prevention to reduce the prevalence
of ESRD should be expanded.
• Increase coordination and resources for efficient and timely
distribution of supplies and equipment, assessment of
patients, and frequent dialysis for acute renal failure patients
caused by crush injuries during such major disasters as
earthquakes. Countries in earthquake-prone regions should
develop emergency policies and practices and be linked with
the appropriate international agencies.
• Have the World Bank and the World Health Organization
establish a policy advisory group with relevant internation-
al groups, such as the International Society of Nephrology,
to address and advise national and regional health min-
istries on kidney and urological strategies as requested.
• Make major health and medical education programs avail-
able on an annual basis through existing societies and agen-
cies to train and update physicians, nurses, technicians, and
other relevant health professionals.
• Develop selected centers of excellence for education, train-
ing, clinical care, and prevention of kidney and urological
disease and clinical care of renal failure. At least 10 such cen-
ters should be developed in the next decade and located in
the countries of the former Soviet Union, Africa, Asia,
Eastern Europe, and Latin America. Funds should be
provided by international and national agencies and
national government organizations and be sustained for up
to 10 years.
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In assigning health priorities, skin diseases are sometimes
thought of, in planning terms, as small-time players in the
global league of illness compared with diseases that cause signif-
icant mortality, such as HIV/AIDS, community-acquired pneu-
monias, and tuberculosis. However, skin problems are generally
among the most common diseases seen in primary care settings
in tropical areas, and in some regions where transmissible dis-
eases such as tinea imbricata or onchocerciasis are endemic,
they become the dominant presentation. For instance, the
World Health Organization’s 2001 report (Mathers 2006) on
the global burden of disease indicated that skin diseases were
associated with mortality rates of 20,000 in Sub-Saharan Africa
in 2001. This burden was comparable to mortality rates attrib-
uted to meningitis, hepatitis B, obstructed labor, and rheumat-
ic heart disease in the same region. Using a comparative assess-
ment of disability-adjusted life years (DALYs) from the same
report, the World Health Organization recorded an estimated
total of 896,000 DALYs for the region in the same year, similar
to that attributed to gout, endocrine disease, panic disorders,
and war-related injuries. As noted later, those figures require
confirmation by more detailed studies, and their practical
application to health interventions needs to be tested.
Assessing the impact of skin disease on the quality of life in
comparison with that of chronic nondermatological diseases is
difficult; however, the study by Mallon and others (1999),
which was not carried out in a developing country, compares
the common skin disease acne with chronic disorders such as
asthma, diabetes, and arthritis and finds comparable deficits in
objective measurements of life quality. Skin disease related to
HIV, which may constitute an important component of the
skin disease burden in developing countries, particularly in
Sub-Saharan Africa, leads to a similar impact on life quality
compared with non-HIV-related skin problems, although the
use of antiretroviral therapy significantly improves quality of
life (Mirmirani and others 2002). Those findings indicate that
skin diseases have a significant impact on quality of life.
Although mortality rates are generally lower than for other
conditions, people’s needs for effective remedies for skin con-
ditions should be met for a number of important reasons.
• First, skin diseases are so common and patients present in
such large numbers in primary care settings that ignoring
them is not a viable option. Children, in particular, tend to
be affected, adding to the burden of disease among an
already vulnerable group.
• Second, morbidity is significant through disfigurement,
disability, or symptoms such as intractable itch, as is the
reduction in quality of life. For instance, the morbidity from
secondary cellulitis in lymphatic filariasis, which may lead
to progressive limb enlargement, is severe, and subsequent
immobility contributes to social isolation.
• Third, the relative economic cost to families of treating even
trivial skin complaints limits the uptake of therapies.
Generally, families must meet such costs from an over-
stretched household budget, and such expenses in turn
reduce the capacity to purchase such items as essential foods
(Hay and others 1994).
• Fourth, screening the skin for signs of disease is an impor-
tant strategy for a wide range of illnesses, such as leprosy, yet
a basic knowledge of the simple features of disease whose
presenting signs occur in the skin is often lacking at the
primary care level.
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A shortage of elementary skills in the management of skin
diseases is a further confounding problem. A number of stud-
ies assessing success in the management of skin diseases in pri-
mary care settings in the developing world find that treatment
failure rates of more than 80 percent are common (Figueroa
and others 1998; Hiletework 1998). An additional point, often
overlooked, is that skin diseases in the developing world are
often transmissible and contagious but are readily treatable
(Mahé, Thiam N’Diaye, and Bobin 1997).
A number of common diseases account for the vast majority
of the skin disease burden; therefore implementing effective
treatments targeted at those conditions results in significant
gains for both personal and public health. Even where eradica-
tion is impossible, control measures may be important in
reducing the burden of illness; yet few systematic attempts have
been made to validate control programs for skin diseases as
public health interventions.
PREVALENCE OF SKIN DISEASES 
Few studies aimed at estimating the prevalence of skin diseases
have been carried out in Western societies. However, Rea,
Newhouse, and Halil’s (1976) study in Lambeth, south
London, which used a questionnaire-based, population-
centered approach backed by random examination, reveals an
overall 52 percent prevalence of skin disease, of which the
investigators judged that just over half the cases required treat-
ment. Studies from developing countries have generally
adopted a more inclusive approach that uses systematic,
community-based surveys backed by examination. Published
figures for the prevalence of skin diseases in developing coun-
tries range from 20 to 80 percent.
In a study in western Ethiopia, between 47 and 53 percent of
the members of two rural communities claimed to have a skin
disease (Figueroa and others 1998), but when they were exam-
ined, 67 percent of those who denied having skin problems
were found to have treatable skin conditions, most of which
were infections. However, prevalence alone does not equate
with disease burden. For instance, most communities recognize
scabies as a problem because of its intractable itching and sec-
ondary infection, whereas they may ignore tinea capitis, which
is equally common among the same populations, because they
are aware that it follows a benign and asymptomatic course in
many patients.
Researchers agree about the main risk factors associated
with skin disease in developing countries, the most important
of which appears to be household overcrowding. In primary
schools in western Ethiopia, more than 80 percent of randomly
examined schoolchildren had at least one skin disease,
which was usually caused by one of four conditions: scabies,
pediculosis capitis, tinea capitis, or pyoderma (Figueroa and
others 1996). Those figures mirror work carried out elsewhere.
For instance, in Tanzania, in a survey of two village communi-
ties, Gibbs (1996) found that 27 percent of patients had a treat-
able skin disease, and once again, infections were the most
common diseases. Overcrowding was a major risk factor in that
survey. A similar community-based survey in Sumatra,
Indonesia, showed a 28 percent prevalence of skin disease (Saw
and others 2001). What seems to influence the overall preva-
lence and pattern of skin conditions in certain areas is the exis-
tence of a number of common contagious diseases, notably,
scabies and tinea capitis. Hot and humid climatic conditions
may also predispose populations to pyoderma, thereby affect-
ing the distribution of disease.
PATTERNS OF SKIN DISEASES
AT THE COMMUNITY LEVEL
A recent (unpublished) survey by the International
Foundation of Dermatology designed to provide information
about community patterns of skin disease in nine different
countries across the world—Australia (Northwest Territory),
Ethiopia, Indonesia, Mali, Mexico, Mozambique, Senegal,
Tanzania, and Thailand)—and poor regions in other tropical
environments from Mexico to Madagascar indicates that
the following were the main skin conditions at community
level:
• Scabies. Although scabies was often the commonest skin
disease, it was completely absent in some regions.
• Superficial mycoses. This group of infections was usually
reported as one of the three commonest diseases.
• Pyoderma. This disease was often, but not invariably, associ-
ated with scabies.
• Pediculosis. This disease was the subject of much variation
but is often overlooked in surveys. Firm, community-level
data on the prevalence of pediculosis are deficient; thus, this
disease is not discussed further in this chapter.
• Eczema or dermatitis. Although this disease was usually
unclassified, irritant dermatitis and chronic lichen simplex
were often cited.
• HIV-related skin disease. This disease was reported mainly in
Africa. The pruritic papular dermatitis of AIDS is a specific
problem.
• Pigmentary anomalies. Three different problems were cited:
hypopigmentation, often diagnosed as pityriasis alba, a form
of eczema; melasma; and dermatitis caused by cosmetic
bleaching agents (Mahé and others 2003).
• Acne. This disease was reported as an emerging and
common problem.
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These diseases are the same as those recorded in the litera-
ture described previously. Other skin conditions cited by dif-
ferent members of the group surveyed follow:
• Tropical ulcer. The incidence was highly variable, but tropi-
cal ulcer can account for a huge workload in primary care
centers in endemic areas.
• Nonfilarial lymphoedema. This condition was mainly con-
fined to Ethiopia.
• Onchodermatitis, filarial lymphoedema, endemic trepone-
matoses, Buruli ulcers, and leprosy. These conditions are dis-
cussed in detail elsewhere in this book, but note that they
often present with skin changes and symptoms.
According to World Bank (2002) figures for low-income
populations in 2000, the estimated numbers of individuals
infected with pyoderma and scabies, based on the highest
prevalence figures from community surveys in the developing
world, are 400 million and 600 million, respectively. Based on
the lowest prevalence figures, these estimated numbers are
40 million and 50 million, respectively. For tinea capitis, the
estimated number of cases based on the highest estimates of
prevalence for Sub-Saharan Africa alone is 78 million.
Overall, these data suggest that significant changes could be
made in reducing the burden of skin diseases by focusing on
the small group of conditions, particularly infections, that
account for the bulk of the community case load. This chapter
concentrates on those conditions for which such a strategy
could be implemented—namely, scabies, pyoderma, fungal
infections, tropical ulcers, HIV/AIDS-related dermatoses, and
pigmentary disorders.
EFFECTIVE THERAPIES
In considering the evidence for effective treatment, a subgroup
of the team (Bendeck, Chen, and McLeod) undertook a data
search to establish the evidence base for treatment of the com-
mon conditions. They carried out comprehensive searches of
the MEDLINE (1966–April 2003) and EMBASE (1980–April
2003) databases to identify therapeutic studies on scabies,
pyodermas, and superficial mycoses (but note that many of the
studies were performed in industrial countries). They used
foreign-language articles if an English abstract was provided.
Table 37.1 shows search terms for each of the skin diseases
common in the developing world and for treatment.
The team members reviewed study titles and abstracts to
select relevant articles and scrutinized the bibliographies of
selected articles to identify pertinent studies not captured in
the initial literature search. They defined admissible evidence as
primary therapeutic studies, based on clinical evaluation, of the
treatment of each disease.
SKIN DISEASES
Scabies
Scabies is a common ectoparasitic infestation caused by
Sarcoptes scabei, a human-specific mite that is highly prevalent
in some areas of the developing world. Scabies is transmitted by
direct contact. In industrial societies, it is usually seen in sexu-
ally active adults, although it may also appear in the form of
clusters of cases among the elderly in residential homes. Peaks
of infection in communities may be cyclical. The ease of trans-
mission appears to depend, in part, on the parasitic load, and
some patients, including the elderly, may have large numbers of
parasites present. By contrast, in healthy adults, the total para-
site load may be low, but they, nonetheless, may suffer from
highly itchy lesions. The organisms can also reach high densi-
ties in patients suffering from a severe depression of immuno-
logical responses, as in HIV infection. In this crusted or
Norwegian form of scabies, lesions may present with atypical
crusted lesions that itch little.
In developing countries, transmission commonly occurs in
young children and infants and their mothers and is related to
close contact, overcrowding, and shared sleeping areas. Sexual
contact is less important as a means of transmission. Scabies is
also a scourge of prisons in developing countries, where it is
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Table 37.1 Search Strategy for Therapies 
Search term for 
Disease Search term for disease treatment
Scabies [“scabies”] [“treatment of” or
“ivermectin” or
“permethrin” or
“Lindane” or
“malathion” or
“benzoyl benzoate” or
“crotamiton” or
“sulfur”]
Pyoderma or [“skin diseases, bacterial” or [“drug therapy” or 
bacterial skin “ecthyma” or “staphylococcal “prevention & control” 
infections skin infections” or “impetigo” or “therapy”]
or “pyoderma” or “folliculitis”]
Tinea capitis: [“tinea capitis”] [“drug therapy” or
“therapy” or
“prevention & control”] 
Tinea imbricata: [“tinea imbricata.mp”]
Tropical ulcer [“tropical ulcer$.ti”] or 
[“skin ulcer(explode)” and 
“tropic$.mp”]
Source: Authors.
Note: Terms in brackets are medical subject heading terms. If no standard medical subject
heading terms were available, databases were searched either using the title option (denoted
as “.ti”) or the keyword option (denoted as “.mp”). 
associated with overcrowding (Leppard and Naburi 2000). No
evidence exists that transfer is related to inadequate hygiene.
The most important complication of scabies is secondary
bacterial infection, usually caused by Group A streptococci.
Evidence from studies among the indigenous population of
northern Australia indicates that this infection is not always
benign and that persistent proteinuria is associated with past
scabies infestation, suggesting that nephritis related to second-
ary infection of scabies may cause long-lasting renal damage
(White, Hoy, and McCredie 2001).
The disease presents with itchy papules and sinuous linear
tracks in the skin that can be highly pruritic and particularly
troublesome at night. Often more than one member of a
household has the disease.
Treatment. The treatments used for scabies are mainly applied
topically. Treatment is not based on treating just affected
individuals, both because of the ease with which scabies
spreads and because symptoms may develop days or weeks
after infection. The advice given to patients always includes a
recommendation to treat the entire household with a similar
medication, a difficult problem when many people live in the
same dwelling. The treatments commonly available include
the following:
• Sulfur ointments. There are no controlled clinical studies of
the use of this cheap medication, which is usually made up
in an ointment base. Soap containing sulfur is available in
some areas. Anecdotally, sulfur ointment needs to be applied
for at least one week to the entire body. Irritation is a com-
mon side effect, and lower concentrations, such as 2.5 per-
cent, are applied to infants.
• Benzyl benzoate. A 10 to 25 percent benzyl benzoate emul-
sion is applied over the entire body and left on the skin for
up to 24 hours before washing off. Current recommenda-
tions suggest that one to three applications may be suffi-
cient, but consensus on the optimal treatment regimen
would be useful. Benzyl benzoate emulsion is an irritant and
can lead to secondary eczema in some patients.
• Gamma benzene hexachloride (Lindane). This product is
widely available and is used as a single application washed
off after 12 to 24 hours. Concerns have arisen about the
increasing risk of drug resistance and the absorption of the
drug through the skin. It is also not used in children because
of reports of neurotoxicity and fits. This product is not
available in many countries.
• Malathion (0.5 percent) in an aqueous base. The highly puri-
fied commercial forms are effective after a single applica-
tion, although a second is advised. No data are available on
the use of this preparation in developing countries.
• Crotamiton cream or monosulfiram 25 percent. These alter-
native therapies have highly variable efficacy rates.
• Permethrin 5 percent cream. This effective, nonirritant treat-
ment is usually administered as a cream applied all over the
body. A single application washed off after 8 to 12 hours is
used. The tubes are small, and adequate quantities should
be prescribed. This treatment is also the most costly of the
topical therapies.
Treatment failures in developing countries may be related
to the lack of a suitable place in many communities where
patients can apply treatment effectively over the entire body
from the neck down in privacy.
Oral ivermectin, which is an important drug in the treatment
of onchocerciasis, has also been used in patients with scabies,
particularly those with the crusted form or in places such as pris-
ons, where large numbers of infected individuals live in close
proximity. It has also been applied as a community-based treat-
ment and is reported to be effective as such (Hegazy and others
1999). It is not licensed for the treatment of scabies, and the lack
of safety data on the use of ivermectin in infants limits its use.
In addition, insufficient evaluations of its efficacy and cost-
effectiveness in developing countries have been carried out.
Evidence for Effective Therapies. The team identified 56 arti-
cles on therapies for scabies and found the following to be the
viable ones: oral and topical ivermectin, permethrin, gamma
benzene hexachloride, benzyl benzoate, crotamiton, malathion,
and topical sulfur. Table 37.2 summarizes the evidence for
ivermectin versus a placebo or permethrin and for topical
ivermectin, as well as for the less expensive topical sulfur.
Community-Based Treatments for Scabies. Few studies have
addressed the problem of community-administered treatments
for scabies, despite the argument that without a community
approach to therapy in many developing countries, the success-
ful management of scabies in areas where it affects more than
5 to 6 percent of the population is doomed to failure. Taplin
and others’ (1991) study of the use of 5 percent permethrin
cream in the San Blas Islands, Panama, confirms this view. A
three-year program of treatments backed by surveillance
reduced the prevalence of scabies from 33 percent to less than
1 percent; however, a three-week break in regular treatment was
followed by a rapid increase in prevalence to 3 percent. The
results of treatments involving the application of similar proto-
cols, but using other topical agents, are not available. Oral iver-
mectin lends itself to a community-based treatment approach
and has been used in this way (Hegazy and others 1999; Usha
and Gopalakrishnan Nair 2000), but insufficient follow-up data
are currently available to comment further on this approach.
Bacterial Skin Infections or Pyoderma
Bacterial skin infections or pyoderma are common in most
developing countries (Mahé, Thiam N’Diaye, and Bobin 1997).
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Generally these infections arise as primary infections of the
skin known as impetigo or as secondary infections of other
lesions such as scabies or insect bites. The usual bacterial causes
are Group A streptococci or Staphylococcus aureus. Bacterial
infections are common in communities. In many cases, no bac-
teriological confirmation is available from cultures, but surveys
show that Group A streptococci account for a substantial num-
ber of cases (Carapetis, Currie, and Kaplan 1999; Taplin and
others 1973), which is not often the case in similar infections
in temperate climates, where S. aureus dominates. This finding
carries implications for the selection of treatment options. The
reasons for this finding are not clear, although humidity and
heat are associated with increased risk of bacterial skin infec-
tion. In addition to these superficial infections, S. aureus also
causes folliculitis, or hair follicle infections and abscesses. Rarer
causes of skin infection in developing countries include
cutaneous diphtheria and anthrax, as well as necrotizing infec-
tion caused by Vibrio vulnificus.
Bacterial infection causes irritation and some discomfort. In
some cases, the infection penetrates deep down through the
epidermis, causing a necrotic ulcer—a condition known as
ecthyma. However, some evidence suggests that streptococcal
infection may cause additional long-term damage through the
development of prolonged proteinuria, as described earlier in
relation to scabies.
Treatment. Treatment with topical antibacterials, such as
fusidic acid or mupirocin, is expensive; thus, the use of cheap-
er agents, such as antiseptics, is an important option but one
that has been evaluated in only a few instances. Chlorhexidine
and povidone iodine have both been used, but potassium per-
manganate is also said to be clinically effective. Gentian violet
at concentrations of 0.5 to 1.0 percent is a cheap agent that is
widely used, with proven in vitro efficacy against agents com-
monly involved in pyoderma. Most of those compounds have
been used to prevent rather than to treat infections. The most
extensively evaluated topical preparations are fusidic acid oint-
ment and mupirocin, which are given daily for up to 10 days.
Those drugs are effective in eradicating bacterial infections but,
as noted, are not cheap options. Group A streptococci are still
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Table 37.2 Evidence of the Efficacy of Treatments for Scabies
Treatment and Number 
average wholesale of people 
price Strongest evidence in study Results Comments
Ivermectin oral Randomized clinical trial 55
US$5.20 (3 mg), given at (versus placebo)
200 g/kg, one or (Hegazy and others 1999)
two doses
Randomized clinical trial 85
(versus permethrin) (Taplin 
and others 1991)
Ivermectin (topical) Open-label, prospective, 32
single group (Macotela-Ruiz 
and Ramos 1996)
Sulfur compounds Open-label, nonrandomized, 102
(topical) prospective cohort (Usha and 
Ointment (480 grams) Gopalakrishnan Nair 2000)
US$2.32
Source: Authors.
g  microgram; kg  kilogram; mg  milligram; p  probability.
79.3 percent cure with single dose of
ivermectin 200 g/kg versus 16.0 percent
cure with placebo (p  0.001)
Single dose: 70.0 percent cure with
ivermectin 200 g/kg versus 97.8 percent
cure with permethrin 5 percent
Second dose (two-week interval): 
95.0 percent cure with ivermectin
200 g/kg (statistically equivalent cure
rates with ivermectin and permethrin
used as single dose/application)
100 percent cure rate with two doses of
ivermectin 1 percent solution at six weeks
(no statistics reported)
71 percent cure at four weeks using
sulfur, 5 percent in children younger than
12 months, and 10 percent in children
older than 12 months 
• Will treat concomitant strongy-
loidiasis and onchocerciasis
• Not approved for scabies by the
U.S. Food and Drug Administration
• Safety not established for children
under five and pregnant women
• A single application of permethrin
is superior to a single dose of
ivermectin, which suggests that
ivermectin may not be effective at
all stages in the life cycle of the
parasite
• Subjects treated with 1 percent
ivermectin in a solution of
propylene glycol at 400 g/kg
repeated once after one week
• Well tolerated
• Typically used as 5 percent to 
10 percent in petrolatum
• Messy and smelly
• Must be applied repetitively for
three nights 
• Mild local irritation may occur
sensitive to penicillin, which can be used for treatment, with
alternatives for staphylococcal infections being cloxacillin,
flucloxacillin, and erythromycin. Industrial countries largely
view methicillin resistance among staphylococci as a nosoco-
mial problem, yet it has now spread to the community, and
skin infections provide an ideal medium for the spread of
resistance, even in developing countries. S. aureus strains iso-
lated from skin sites, even in remote tropical areas, are now
resistant to beta-lactam penicillins and tetracyclines through
the spread of resistance genes. Tetracycline ointment is still
available in many rural pharmacies and is widely used to treat
superficial skin lesions, even though some bacterial infections
will be unresponsive. Topical neomycin and bacitracin are
widely available, are associated with identifiable levels of treat-
ment failure, and also carry a risk of sensitization or adverse
effects.
Evidence for Effective Treatment. The team reviewed 727
studies of therapies for pyoderma or bacterial skin infections.
These studies could be grouped into either prophylactic
regimens or therapeutic trials. For the prevention of pyoderma,
the studies surveyed included the following effective therapies:
chlorhexidine solution, hexachlorophene scrubbing, and
neomycin/polymyxin B-bacitracin (Neosporin) cream. For
the treatment of pyodermas, a number of studies reported
effective topical therapies, namely: povidone-iodine solution,
hydrogen peroxide cream, electrolyzed strong acid aqueous
solution, tea ointment, Soframycin ointment, honey, fusidic
acid cream, trimethoprim-polymyxin B sulfate cream, rifax-
imin cream, sulconazole cream, miconazole cream, neomycin/
polymyxin B-bacitracin (Neosporin) cream, terbinafine
cream, and mupirocin. Systemic agents cited were cephalexin,
erythromycin, penicillin, Augmentin, amoxicillin, sultami-
cillin, (di)cloxacillin, azithromycin, cefadroxil, cefpodoxime,
cefaclor, ceftizoxime, clindamycin, clarithromycin, tetracy-
cline, fluoroquinolones, and fusidic acid.
Table 37.3 presents the evidence for commonly used anti-
septics and some of the specific antibacterial agents. In prac-
tice, topical treatments such as chlorhexidine, povidone, and in
some cases neomycin or mupirocin will provide the most cost-
effective control measures. For extensive infection, cloxacillin
or erythromycin provides alternatives. However, current
evaluations are subject to some weaknesses, such as a lack of
large, comparative studies, particularly of the topical therapies,
including antiseptics, used in developing countries.
Community-applied measures for managing skin infections
have not been evaluated, but measures such as early treatment
of scabies or basic wound care of sores might provide
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Table 37.3 Evidence of the Efficacy of Topical Treatments for Pyoderma
Treatment, level of 
evidence, cost 
(manufacturer, Number of 
formulation, average people 
wholesale price) Evidence in study Results Commentsa
6.3 percent clinical pyoderma on
postdischarge in the chlorhexidine group;
24 percent in the nonchlorhexidine group
(no statistics reported)
Hospital A: 15.2 percent of group without
and 2.1 percent with chlorhexidine
prevented cord pyoderma; hospital B:
21.0 percent with ethanol and 1.0 percent
with chlorhexidine prevented pyoderma
(no statistics reported)
92 percent improvement with fusidic acid
and 88 percent with placebo
12/12 Betadine responded; 0/13 salicylic
acid responded
Chlorhexidine gluconate 
(4 percent) detergent solution
Level of evidence: VI 
Cost:
• Clay-Park
• Liquid, topical, 4 percent 
• 120 ml, US$7.01 
Povidone-iodine solution
(Betadine)
Level of evidence: II
Cost:
• Alpharma 
U.S. Pharmaceutical
Directory 
• Solution, topical product,
10 percent,
• 400 ml, US$5.46
Open-label, prospective
cohort (versus nothing)
(Taplin and others 1973)
Open-label, prospective
cohort (versus 70 per-
cent ethanol and versus
nothing) (Taplin and
others 1973)
Double-blind RCT
(fusidic acid cream plus
povidone iodine versus
placebo cream plus
povidone iodine)
(Seeberg and others
1984)
Open-label, prospective
cohort (versus salicylic
acid) (Linder 1978)
3,602
5,220
160
25
• Neonatal cord pyoderma
• Prophylaxis study
• Neonatal cord pyoderma
• Prophylaxis study
• Performed and reported at two
different hospitals
• Impetigo
• 14 percent of placebo group versus
4 percent in fusidic acid group may
have received antibiotics in weeks
2 and 4, potentially explaining the
lack of difference in efficacy
• Disinfection of chronic wounds of
lymphedematous patients
• Outcome measure and statistics
not clear
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Table 37.3 Continued
Treatment, level of 
evidence, cost 
(manufacturer, Number of 
formulation, average people 
wholesale price) Evidence in study Results Commentsa
100 percent of mupirocin patients versus
85 percent of placebo (difference not
significant)
85 percent of mupirocin versus 53 percent
vehicle-treated patients (p  0.007)
90 percent of erythromycin and 96 percent
for mupirocin (no statistics given); long-
term follow-up: 9 erythromycin versus
3 mupirocin patients developed new
lesions (p  0.05)
No significant difference in various
evaluations of clinical efficacy except
investigator’s global evaluation
(efficiency/safety performance) (p  0.01)
93 percent mupirocin versus 96 percent
erythromycin (no statistical difference)
Recurrence with erythromycin: 10 percent
of patients with S. aureus and 6 percent of
patients with S. pyogenes; recurrence with
mupirocin: none.
Potassium permanganate
Level of evidence: none
Cost:
• A-A Spectrum
• Crystal, NA
• 500 gm, US$16.10 
Mupirocin
Level of evidence: I
Summary: Efficacy supported
by two RCTs and several
comparison studies; some
concern about resistance
Cost:
• GlaxoSmithKline (GSK)
Pharmaceuticals 
• Ointment, TP, 2 percent
• 22 gm, US$41.36
Double-blind RCT 
(versus placebo vehicle)
(Koning and others
2002)
Double-blind, RCT 
(versus vehicle) 
(Daroczy 2002)
Open-label RCT (versus
oral erythromycin) 
(Eells and others 1986)
Open-label RCT (versus
oral erythromycin)
(Barton, Friedman,
and Portilla 1988;
Breneman 1990)
Investigator-blinded,
RCT (versus oral
erythromycin) 
(McLinn 1988)
52
106
97
60
75
• Impetigo/ecthyma
• Outcome: cure or improvement
• 38 in final evaluation; no ITT
• Secondarily infected dermatoses
with S. aureus or S. pyogenes
• Outcome: marked or moderate
improvement
• 92 in final evaluation; no ITT
• Impetigo contagiosa
• Outcome: cure or clinical
improvement
• Also looked at long-term (up to
one month) follow-up
• Impetigo
• Both articles present the same
research
• More adverse effects with
erythromycin
• Impetigo
• Also looked at bacterial
recurrences
• 53 patients clinically and bacterio-
logically assessable; no ITT
Source: Authors.
gm  gram; ITT  intent to treat; ml  milliliter; p  probability; RCT  randomized clinical trial; TP  topical product.
a. Comments include type of skin infection; indication of prophylaxis, otherwise therapeutic trial; ITT analysis; and other comments.
significant benefits. In this area, carefully designed pilot control
programs would provide extremely valuable data.
Fungal Infections
Fungal infections that affect the skin and adjacent structures
are common in all environments. They include infections such
as ringworm or dermatophytosis; superficial candidosis and
infections caused by lipophilic yeasts and Malassezia species;
and some other common causes of foot infection, such as
Scytalidium. The clinical and social impact of fungal infections
on individuals varies with local conditions. For instance, tinea
pedis is a treatable condition that causes cracking and inflam-
mation with itching between the toes. It is generally viewed as
a nuisance that only marginally affects the quality of life; how-
ever, under certain conditions its significance is far greater. For
example, fungal infections of the web spaces and toenails in
diabetics provide a portal of entry for S. aureus, an event closely
related to the development of serious foot complications in
patients with peripheral vascular disease and neuropathy.
Similarly, foot infections originally caused by dermatophytes
can develop into more serious disabling infections through sec-
ondary Gram-negative bacterial infection among certain occu-
pational groups in the tropics, such as workers in heavy indus-
try, the police, or the armed forces. Wearing heavy footwear is
a risk factor for the emergence of this problem.
Other infections, such as oropharyngeal candidosis, are
important complications of HIV. This commonest infectious
complication of AIDS is a potential early marker. Whereas in
many patients it may simply have nuisance value, in others it
has a more serious impact and leads to dysphagia and loss of
appetite. Malassezia infections such as pityriasis versicolor are
also common in the developing world and often occur in more
than 50 percent of the population; however, they are generally
asymptomatic but cause patches of depigmentation, and
patients seldom seek treatment.
Some fungal infections are extremely widely distributed or
common in defined endemic areas. They include tinea capitis
and tinea imbricata.
Tinea Capitis. Tinea capitis is a common, contagious disease
of childhood that can spread extensively in schools. It is caused
by dermatophyte fungi of the genera Trichophyton and
Microsporum (Elewski 2000). Infections can spread from child
to child (anthropophilic infections) or from animals to children
(zoophilic infections). Anthropophilic infections tend to be
endemic or epidemic, whereas the zoophilic forms occur spo-
radically. The commonest sources and causes of zoophilic
infections are cats and dogs (Microsporum canis), cattle and
camels (Trichophyton verrucosum), and rodents (T. mentagro-
phytes). The causes of the anthropophilic form of this infection
vary in different areas of the world. Although in areas of the
developing world this condition is endemic at high levels,
in many parts of Africa it is a common condition affecting
more than 30 percent of children in primary schools. The
main African species are M. audouinii, T. soudanense, and
T. violaceum. The last is also found in the Middle East and
India. T. tonsurans, the form of tinea capitis endemic in the
United States (Wilmington, Aly, and Frieden 1996) and in parts
of Europe, such as France and the United Kingdom (Hay and
others 1996), is extremely resistant to treatment. No evidence
indicates that this form has spread to Africa yet, although this
possibility exists.
Families of children with tinea capitis seldom present for
treatment. However, in a small proportion of individuals, tinea
capitis produces a highly inflammatory lesion with suppura-
tion on the scalp along with permanent scarring and local
hair loss. The numbers of infected individuals showing this
highly symptomatic change are not known with any accuracy,
but it is believed to occur in about 5 percent of cases, more
with T. tonsurans. This factor poses a dilemma in management,
because where the disease is common and endemic, a regular
source will always exist for new, severe, inflammatory infec-
tions in children. Therefore, addressing this issue by tackling
individual cases without addressing the reservoir, albeit illogi-
cal, may ultimately be the most practical approach.
The diagnosis of tinea capitis is difficult to make clinically
in mild cases because the main presenting signs are localized
patches of hair loss with fine scaling. In some children, the hair
loss is more diffuse. With the inflammatory forms, circum-
scribed patches of hair loss with erythema and pustulation also
occur, and the whole area is raised into a boggy mass. The only
way to confirm the diagnosis accurately is to take hair samples
for culture and microscopy, which is not possible in many areas
because they lack laboratory diagnostic facilities. One specific
form of tinea capitis, favus, is clinically recognizable and distinct,
because the scalp is covered with white plaques called scutula.
The infection is chronic and can develop into permanent, scar-
ring alopecia. Inhabitants of endemic areas often recognize favus
as a distinct condition that causes chronic illness, and as a result,
the uptake of consultation for treatment is higher.
Highly effective, topically applied treatments for tinea
capitis are unavailable, and even though simple remedies
such as benzoic acid compound (Whitfield’s ointment) may
lead to clinical improvements, relapse is almost universal.
Nevertheless, the use of topical therapies may limit the spread
of tinea capitis. Treatment depends on the use of oral therapies.
The most widely available of these is griseofulvin, which is
given to children in doses of 10 to 20 milligrams per kilogram
daily for a minimum of six weeks. Noncontrolled studies show
that a single dose of 1 gram of griseofulvin given under super-
vision can eradicate infection in more than 70 percent of indi-
viduals, but such regimens have not been adequately assessed
under trial conditions to determine their effect on community
levels of infection, nor are follow-up data available.
Recent years have seen the development of a number of
effective, new, oral antifungals, including terbinafine, itracona-
zole, and fluconazole. Terbinafine is a highly active agent that is
effective in the treatment of dermatophyte infections. It is given
in doses of 62.5 milligrams for those under 10 kilograms,
125 milligrams for those weighing 10 to 40 kilograms, and
250 milligrams for those over 40 kilograms. Evidence indicates
that it is effective after one week of therapy in T. violaceum and
T. tonsurans infections, but the best responses are seen when it
is used for four weeks. Unfortunately, at these doses it is less
effective for Microsporum infections, although some data sug-
gest that responses are significant if the doses are doubled. This
drug is, therefore, difficult to administer in standardized proto-
cols when the cause of infection is uncertain. Itraconazole is
also effective, but no suitable pediatric formulation is available
because it is marketed in a capsule form that is difficult to
administer to young children. Fluconazole is also effective,
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although comparative studies of its use are not available. All
three drugs are costly, and a community-based program that
uses them would be difficult to fund and implement.
The team found a total of 432 articles for the treatment of
tinea capitis. Table 37.4 presents key references for the oral
therapies, the mainstay of therapy. The effective treatments
included topical therapies (benzoic acid, bifonazole, selenium
sulfide, ketaconazole shampoo, and miconazole shampoo) as
well as systemic agents (griseofulvin, terbinafine, itraconazole,
fluconazole,and ketoconazole).The results of topical treatments
appear inferior to those of oral therapy, although they have not
been directly compared, and some of the topical agents were
applied to prevent transmission rather than to treat infection.
Attempts at community control of tinea capitis have been
devised but have not been monitored adequately. The methods
have been based on surveillance through culture and treatment
of all infected children. Culture-based diagnosis is difficult to
implement regularly in developing countries. The treatment
used for community therapy has been griseofulvin in conven-
tional daily or large single doses, but those approaches have not
been compared. In addition, control protocols usually advise
treating carriers with topically applied agents such as selenium
sulfide (which is relatively cheap) or a miconazole shampoo
(which is moderately priced). In practice, some “carriers” are
really patients with extremely localized and hard-to-detect
infections, and such patients will not respond to topical treat-
ment in the long term. A second problem is the absolute
reliance on laboratory confirmation of cultures to direct
treatment of carriers. Therefore, other strategies need to be
evaluated, such as reducing the community load, perhaps by
topical therapy or single-dose griseofulvin, to reduce the risk of
spread. An alternative would be to continue with the existing
practice of treating individual cases while recognizing that this
process ignores the community reservoir.
Tinea Imbricata (Tokelau Ringworm). In many parts of the
developing world, tinea imbricata is an exotic and unusual
infection, with isolated foci occurring in remote areas of
Brazil, India, Indonesia, Malaysia, Mexico, and the western
Pacific. However, in some specific locations, it is common and
endemic, reaching prevalence rates of more than 30 percent
in some communities in the western Pacific. For example,
extrapolating from a school survey in Goodenough Island,
Papua New Guinea, Hay and others (1984) estimate that more
than 7,000 people out of a population of about 20,000 were
infected.
The disease presents in the form of widespread scaling,
often arranged in concentric rings or with large sheets of
desquamation. The infection may develop early in life and
persist into old age without the development of effective
immunity. Tinea imbricata often affects wide areas of the body,
sparing only body folds and scalp skin. In those areas where it
is endemic, it can be a significant problem occupying much of
the time of health aid post staff.
Individual treatments have depended on the antifungals
described earlier, including griseofulvin. Terbinafine and itra-
conazole are highly effective, but their cost has constrained
their use. As table 37.5 shows, the relapse rates after itracona-
zole are also higher than after terbinafine (Budimulja and
others 1994). Topical agents such as benzoic acid compound
(Whitfield’s ointment) are helpful, but are seldom curative and
are difficult to apply over such large areas. Some patients may
be treated with locally derived treatments, such as the sipoma
paint used in Papua New Guinea, which contains salicylic acid,
brilliant green, and kerosene. Traditional treatments have also
been used, but never evaluated. The leaves of Cassia alata, for
instance, are widely used in the western Pacific.
The team found studies of the use of griseofulvin,
terbinafine, and itraconazole for tinea imbricata. Some studies
did mention sipoma paint and Cassia alata, but no studies
evaluating their efficacy have been performed. The team also
found case reports supporting the use of griseofulvin.
Different treatments for use on a community basis need to
be evaluated because the impact of this condition on local
health services in areas of high prevalence is heavy in terms of
both time and staff workload.
Tropical Ulcer
Tropical ulcer is a common condition found mainly in chil-
dren and teenagers in well-defined tropical regions. It usually
affects the lower limbs (Bulto, Maskel, and Fisseha 1993),
causing the sudden appearance of regular and deep ulceration.
It is mainly seen in Africa, India, and the western Pacific and
in parts of Indonesia and the Philippines. The disease is
caused by a combined infection of a number of different bac-
teria together with a fusiform bacterium, Fusobacterium
ulcerans, and an as yet unidentified spirochete. The disease is
associated with poor living conditions and exposure to water,
particularly flood or stagnant water and mud. In endemic
areas, it is a constant drain on resources. Morris and others’
(1989) study of aid posts in East Sepik province, Papua New
Guinea, shows that management of tropical ulcer was occupy-
ing a third of the posts’ time and almost half their health care
budgets.
The lesion usually starts with mild discomfort and overlying
hyperpigmentation on the skin that progresses rapidly over a
few days until the skin breaks down and sloughs, revealing an
underlying ulcer. The lesion is often clean on first presentation
and round with smooth edges. It generally starts on the lower
leg or ankle, and in about 10 percent of cases, it progresses to
become an irregular, enlarged, and chronic ulcer.
The condition heals well in most patients with simple
cleansing and treatment with penicillin; however, early grafting
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Table 37.4 Evidence of the Efficacy of Different Regimens for Tinea Capitis
Treatment, level of 
evidence, cost 
(manufacturer, Number of 
formulation, average people 
wholesale price) Evidence in study Results Comments
Mycological cure: 12/20 using benzoic acid
compound and 10/19 using miconazole
cream 
Prevalence dropped from 7.8 percent to
5.8 percent (p  0.05)
Effective treatment: 4650 (92 percent)
griseofulvin, 47/50 (94 percent) terbinafine,
4350 (86 percent) itraconazole, 4250
(84 percent) fluconazole (p  0.33)
60.7 percent responded well; 39.3 percent
returned less than eight months later;
10.7 percent had a recurrence later 
No statistically significant differences
(cure  67 percent in both groups);
however, graphical presentation of data
demonstrates a slightly higher proportion
of patients in terbinafine group achieved
“cure” earlier
Terbinafine for six weeks had a similar
efficacy to griseofulvin
Week 8: 76 percent griseofulvin and
72 percent terbinafine (not statistically
significant);
week 12: 44 percent griseofulvin and
76 percent terbinafine (p  0.05)
88 percent itraconazole versus 88 percent
griseofulvin
Benzoic acid compound
(Whitfield’s ointment)
Level of evidence: III
Cost: not found
Griseofulvin
Level of evidence: III
Cost:
• Pedinol, tablets, 125 mg,
US$63.00 for 100 tablets 
• Martec, tablets, 125 mg,
US$34.10 for 100 tablets 
Investigator-blinded RCT
(versus miconazole
cream) (Wilmington,
Aly, and Frieden 1996)
Observational study
(Hay and others 1996)
Multicenter, single-
blinded, RCT (versus
terbinafine, itracona-
zole, and fluconazole)
(Wright and Robertson
1986)
Single-cohort retrospec-
tive analysis (Schmeller,
Baumgartner, and
Dzikus 1997)
Multicenter, open-label,
RCT (four weeks
terbinafine versus eight
weeks griseofulvin)
(Gupta and others 2001)
Parallel-group, multi-
center, double-blind RCT
(versus terbinafine)
(Abdel-Rahman,
Nahata, and Powell
1997)
Double-blind RCT 
(versus terbinafine)
(Fuller and others 2001)
Double-blind RCT 
(versus itraconazole)
(Lipozencic and others
2002)
41
200
474
210
134
50
35
• Neither treatment is fully
efficacious
• Prevalence study of dermatophyto-
mycoses in rural schools 
• After institution of treatment by
12 trained community health
workers, only prevalence of tinea
capitis dropped significantly
• ITT analysis performed
• Griseofulvin for six weeks similar
in efficacy to terbinafine, itracona-
zole, and fluconazole for two to
three weeks
• Observation over a two-year period
• Conclusions: griseofulvin may be
ineffective in one-third or more
patients 
• 147 patients were evaluable; no ITT
• Four weeks of treatment with oral
terbinafine had a similar efficacy
to eight weeks of treatment with
griseofulvin
• Four oral terbinafine groups (6, 8,
10, or 12 weeks) compared with
12 weeks of griseofulvin
• ITT analysis performed
• Six weeks of terbinafine could
represent an alternative to
griseofulvin
• Outcome: cure rates at weeks 8
and 12
• Terbinafine is a good alternative
for less-frequent recurrences
• Tinea corporis and tinea capitis
evaluated together 
• Outcome measure: cure
• 34 patients evaluable for efficacy;
no ITT
• Two griseofulvin patients discon-
tinued therapy because of vomiting
• Itraconazole has the same efficacy
as griseofulvin and fewer side
effects
Source: Authors.
ITT  intention to treat; p  probability; RCT  randomized clinical trial.
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Table 37.5 Evidence of the Efficacy of Terbinafine for Tinea Imbricata
Treatment, level of 
evidence, cost 
(manufacturer, brand Number of 
name, formulation, people 
average wholesale price) Evidence in study Results Comments
Clinical and mycological cure rate: 
• 37/37 for terbinafine, 3135 for
itraconazole (p  0.05)
At week 17 follow-up, reinfection or
relapse:
• 637 (16 percent) evaluable terbinafine
patients
• 2431 (75 percent) evaluable
itraconazole patients (p  0.001)
Terbinafine
Level of evidence: II
Cost:
• Novartis
• Lamisil
• Tablets, 250 mg,
US$260.51 for 30 tablets
(AWP)
• Tablets, 250 mg,
US$868.16 for 100 tablets
(AWP)
• Cream, TP, 1 percent,
15 gm, US$32.61 (AWP)
• Cream, TP, 1 percent,
30 gm, US$58.40 (AWP)
Double-blind random-
ized clinical trial
(terbinafine versus
itraconazole) 
(Lopez-Gomez and
others 1994)
83 • Terbinafine has a slightly higher
cure rate and a lower reinfection
and relapse rate than itraconazole
• 72 patients eligible for follow-up 
Source: Authors.
AWP  average wholesale price; gm  gram; mg  milligram; p  probability.
may be necessary if healing is delayed. Treatment, therefore,
consists of early treatment with penicillin, a strategy that may
also fit with a syndromic approach to ulceration, because it will
also be effective for yaws. The alternative is oral metronidazole,
but no evidence of the comparative efficacy of these two
approaches is available.
In searching the literature for effective remedies for tropical
ulcer, the team found little evidence. The team did find studies
evaluating metronidazole and topical dressings, and several
articles mentioned the efficacy of penicillin and split skin graft-
ing, but no randomized controlled trials have been performed.
A single case report supports the use of co-trimoxazole. The
management strategy thereafter depends on keeping the
wound clean to allow appropriate healing using local antisepsis
and cleansing, such as potassium permanganate solution,
chlorhexidine, or even saline, and protecting the area from
further abrasion or secondary infection with sterile dressings.
Clinical experience suggests that if this regimen is not followed,
the risk of developing chronic leg ulceration is substantial.
No community strategies for preventing tropical ulcer are
known, although the process of infection suggests that simple,
hygienic measures to disinfect and clean the affected limb,
perhaps modified from those used in lymphatic filariasis,
might be effective as a simple preventive regimen. The possible
use of vaccines has been substantially researched for the animal
counterpart, sheep foot rot, which is caused by a similar com-
bination of organisms.
HIV-Related Skin Diseases
A wide range of skin conditions may develop as a consequence
of HIV infection, but most are beyond the scope of this
chapter. They include conditions that are a significant drain
on scarce resources. These include Kaposi’s sarcoma and toxic
epidermal necrolysis, a potentially life-threatening form of
skin failure that is often drug induced and requires the level of
care and attention that would be deployed for patients with
severe burns.
The commonest skin-related complication of HIV, particu-
larly in Africa, is the itchy papular eruption or papular pruritic
eruption of HIV. It presents with fiercely itchy multiple papules
on the face and upper trunk. It is of unknown etiology and
responds only to symptomatic treatment—for instance,
antipruritic preparations such as antihistamines—although
simple topical preparations, such as calamine or menthol
creams, may alleviate the itching. Recognizing this condition is
important, because it is seen only in HIV/AIDS cases and is
often mistakenly treated as acne. It does not respond to treat-
ments for acne.
Pigmentary Disorders
The development of pigmentary change is an important source
of concern in many communities (Taylor 1999). Disorders
associated with pigmentary changes are common and range
from hereditary defects such as albinism (Lookingbill,
Lookingbill, and Leppard 1995) to increased pigmentation, or
hyperpigmentation, associated with inflammatory skin lesions
such as acne. Albinism is a significant cause of life-threatening
skin cancer in the developing world.
For many of these conditions, no effective remedies are
available. For instance, hyperpigmentation secondary to
inflammation cannot be removed effectively, although it may
fade with time. Similarly, no effective cure exists for vitiligo, a
common disease involving loss of pigment, although experi-
mental treatments such as melanocyte grafting do produce
localized repigmentation. Therefore, advising patients of the
current comparative ineffectiveness of treatments for these
conditions is important. Preventing the use of therapies that do
not lead to effective outcomes should be an important part of
the strategy for treating skin diseases.
Some forms of increased pigmentation, such as melasma,
which is hyperpigmentation of the cheek and forehead areas
and is seen mainly in women, respond to the application of
hydroquinone derivatives. However, because such treatments
are often misused, they would not be used at the community
level and would be used only with advice from a trained prac-
titioner. Depigmenting creams, lotions, and emulsions are
widely available as cosmetic preparations in many local mar-
kets and shops, and in a study in Dakar, Senegal, more than
50 percent of women questioned stated that they were regularly
using bleaching creams ranging from hydroquinones to corti-
costeroids (Mahé and others 2003). Hydroquinones are poten-
tially damaging to the skin and with continuous use cause
patchy increased pigmentation and scarring of the facial skin.
Similarly, misuse of corticosteroids is associated with a range of
secondary effects from skin thinning to increased infection
rates. Warning people about the potential risks of depigment-
ing creams would be a useful health promotion strategy in
many communities.
Skin depigmentation is also a feature of leprosy. Thus,
teaching health care workers responsible for leprosy surveil-
lance to recognize skin patterns is a practical strategy of great
potential value in continuing progress toward eliminating this
disease.
ECONOMIC ASSESSMENTS AND SKIN DISEASES
IN DEVELOPING COUNTRIES
Apart from the studies mentioned here in relation to families’
costs for treating community-acquired skin diseases in
Mexico (Hay and others 1994) and costs to health posts of
managing tropical ulcer in Papua New Guinea (Morris and
others 1989), no published studies are available of the eco-
nomic burden of skin disease. An extensive literature search
did reveal some studies related to diseases that affect the skin
but discussed elsewhere in this work (Buruli ulcer and
onchocercal skin disease), as well as a paper on the direct
costs of treating scabies in Italy. These studies are shown in
table 37.6.
Examples of drug costs (tables 37.2 to 37.4) for tinea capitis,
scabies, and pyoderma can be estimated as follows:
• Treatment of a single case of scalp ringworm using griseo-
fulvin purchased from two differently priced U.S. sources to
achieve the published efficacy rates (table 37.4) with a con-
ventional therapeutic course of six weeks, assuming a daily
dose of 250 milligrams, would provide between 61 and
92 percent efficacy at a drug cost per individual of US$29 or
US$53, depending on the drug source. Alternatively, a single
supervised dose of 1 gram would cost US$1.40 or US$2.50.
With supervision of treatment, the total cost per cure using
daily treatment ranges from US$35 to US$88 per patient.
• Treatment of 100 people with scabies using sulfur ointment,
assuming 500 grams per individual, would cost US$58 or
US$0.58 per person. This regimen would provide a 71 per-
cent cure rate at three months and a cost per cure of $1.30
per patient.
• Treatment with povidone of an individual with pyoderma
would cost US$0.68, assuming that 400 milliliters would
treat eight people. This regimen would provide a cure rate of
88 percent at three months and a cost per cure of US$1.10
per patient.
These calculations have taken into account ideal community
treatment conditions, where the recurrence rate is negligible.
However, if such a community-based scheme is not effectively
developed, more than 50 percent of those with scabies are likely
to be reinfected. The figures are lower for tinea capitis (15 per-
cent) and pyoderma (10 percent). Table 37.7 shows the costs of
treating large populations.
Although little information is currently available, in partic-
ular about the effect of local pricing of medications on overall
effective treatment costs, the studies cited in this chapter indi-
cate that the financial burden of skin diseases within families
may well be significant and that producing a series of robust
analyses of the cost implications of both treatment and failure
to provide adequate management strategies for these common
conditions is critical.
The 1990 global burden of disease study estimated that
the disability weighting associated with skin disease was at
least 0.02. However, the disability weighting for severe scabies
(25 percent of cases) and patients with ecthyma (10 percent of
pyoderma cases) is 0.10. If we take skin cases with the lower
disability estimates—for example, mild to moderate scabies
and pyoderma—the cost per DALY gained would be about
US$1.00 to US$1.50 (table 37.7). For tinea capitis, the cost per
DALY gained using daily treatment would be considerably
higher, US$175 at the lower drug cost.
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Table 37.6 Literature Review on the Economic Impact of Skin Diseases 
Year of Study type and 
Disease Author research Country population Cost categories and indicators Results 
Buruli ulcer Asiedu 1998 Ghana
Onchocerciasis Workneh 1993 Ethiopia
(OSD)
Onchocerciasis Oladepo 1997 Nigeria
(OSD)
Onchocerciasis Benton 1998 Ethiopia, 
(OSD) Nigeria, 
and Sudan
Scabies Papini 1999 Italy
Source: Asiedu 1998; Workneh 1993; Oladepo 1997; Benton 1998; and Papini 1999.
OSD  onchocercal skin disease.
Retrospective study of
102 cases at a district
hospital in the Ashanti
region
Males age 18 to 54
working at a coffee
plantation with OSD
and without OSD
Matched pairs of male
farmers with OSD and
without OSD
Communities
Outbreaks in two
nursing homes
• Health care costs (inpatient
services including medicines,
surgery, laboratory) 
• Indirect costs (loss of produc-
tivity, food, miscellaneous)
• Days of leave
• Income
• Current cultivated farm size 
• Personal wealth 
• Educational impact
• Direct costs
• Indirect functional capacity
costs, for example, from
disability
• Health care costs (medical
consults, treatment, disinfesta-
tion procedures, laundry, extra
staffing, disposable materials)
• Total costs: US$783.27 per
patient
• Health care costs:
US$233.78 per patient
• Indirect costs: US$549.49
per patient
• Percentage of total health
care cost relative to district
budget: 40 percent
• Those with OSD had
significantly more days of
leave and less income than
controls
• Those with OSD had signi-
ficantly smaller farm sizes
and less personal wealth
• Children of OSD heads of
household had double the
risk of dropping out of
school 
• People with severe OSD
spend US$20 more per year
on health (15 percent of
their incomes) 
• People with severe OSD
spend longer time seeking
care
• US$151.17 per resident
Table 37.7 Cost of Cure and Impact on DALYs for the Three Most Common Skin Diseases, Using the Cheapest Effective
Treatments
Cost of cure Number of people cured 
Disease (US$/million population) for US$1 million Cost per DALY gained (US$) Comment
Tinea capitis 5,250,000 285,000 175 (assuming cost per drug of Estimated on the basis of a high-
US$29 for course of treatment) prevalence (15 percent) region 
such as Ethiopia 
Scabies 58,000 1,700,000 1.00–1.50 Estimated on the basis of a high-
prevalence (10 percent) region 
Pyoderma 55,000 900,000 1.00–1.50 Estimated on the basis of a high-
prevalence (5 percent) region.
Source: Authors.
The benefits of devising control measures for treatable skin
disease are also affected by the high prevalence figures for skin
diseases in low-income countries with total populations of
between 40 million and 600 million affected, depending on
variations in disease prevalence.
CURRENT STATUS OF COMMUNITY CONTROL
MEASURES IN DERMATOLOGY
Despite the logic of developing community-focused services
for dermatology, such services have seldom been achieved
(Hay, Andersson, and Estrada 1991). Perhaps the best current
example of a concerted, community-based approach is the
Regional Training Center for Dermatology in Moshi, Tanzania,
which focuses on developing a primary care skills base in
African countries for the care of patients with skin and sexu-
ally transmitted diseases (Kopf 1993). The program has now
trained more than 100 medical assistants and nurses, who were
placed in 15 different countries at the primary care level and
who, in many cases, play key roles in developing local health
programs. A key issue is that action proportional to the severity
of the problem is needed. For instance, one option would be to
help nonspecialized health workers significantly improve their
skills in managing common skin diseases. That option would
present a new challenge for the teaching of dermatology. Along
those lines, a recent initiative to effect change through a control
and education program in Mali targeted at pyoderma, scabies,
and tinea capitis is currently being evaluated. Early assessments
indicate that the teaching methods have been effective in instil-
ling recognition skills among primary care health workers. The
effect on community levels of skin diseases is not yet known.
Skin diseases remain a low priority for many health author-
ities, despite the large demand for services. Addressing the
potential for controlling skin problems by means of simple and
effective public health measures should be a realistic target for
alleviating a common and solvable source of ill health. An
effective plan, team, and basic dermatological formulary can do
much to improve matters (Estrada and others 2000). This
chapter outlines some of the challenges for such programs and
some of the deficiencies of current provision.
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The oral cavity is an essential part of the body and contributes
to total health and well-being. Recent research indicates that
poor oral health affects general health and that some systemic
diseases can affect oral health. A variety of diseases involve the
oral cavity; the two main oral diseases present worldwide and
lead to tooth destruction or tooth loss:
• dental caries, the disease that leads to cavities in the teeth
• periodontal disease, which leads to loosening of teeth.
Both diseases are preventable, and strong efforts have been
made to control them. Other diseases and conditions are much
less prevalent, yet serious, and sometimes even life threatening:
oral precancer and cancer, oral manifestations of HIV and
AIDS, noma, developmental disorders, and fluorosis of teeth.
DENTAL CARIES
Dental caries develops by the localized dissolution of the tooth
hard tissues, caused by acids that are produced by bacteria in
the biofilms (dental plaque) on the teeth and eventually lead to
“cavities.” The biofilm consists of microorganisms, including
the highly cariogenic mutans streptococci, and a matrix made
up mainly of extracellular polysaccharides. The destructive
acids are produced when fermentable carbohydrates (sugars)
reach these biofilms, each episode resulting in tooth damage
(attack). If this process does not occur frequently, then the nat-
ural capacity of the body (through saliva) to remineralize will
prevent formation of a cavity. Thus, the main risk factors
include presence of cariogenic biofilms and frequent consump-
tion of fermentable carbohydrates. Exposure to fluorides in
optimum concentrations reduces the risk, and normal saliva
flow and saliva protective systems are also important to coun-
teract the cariogenic factors.
Untreated caries can give rise to infection of the tooth pulp,
which can spread to the supporting tissues and the jaws, culmi-
nating in advanced disease conditions that are often painful. For
example, in Thailand, recent surveys of a sample of 12-year-old
children revealed that 53 percent had suffered from pain or dis-
comfort from teeth over the past year (Petersen and others
2001). The corresponding figures in China were 34 percent for
12-year-olds (Peng, Petersen, Fan, and others 1997) and 74 per-
cent for adults (Petersen, Peng, and Tai 1997).
Tooth decay is a public health problem worldwide.
According to the U.S. Surgeon General’s report (U.S. Public
Health Service 2000), dental caries is the single most common
chronic childhood disease in the United States. Epidemiological
data for almost 200 countries are available in the World Health
Organization (WHO) Country/Area Profile Programme
(CAPP) oral health database (http://www.whocollab.od.mah.
se/index.html) (see table 38.1 for examples). Caries prevalence
of permanent teeth is expressed by the decayed, missing, and
filled teeth (DMFT) index (calculated by counting the number
of DMFT of individuals and taking the mean for the group
examined). One indicator age group used for international
comparisons is 12-year-old children. The WHO oral health
goal was to achieve three DMFT or fewer among 12-year-olds
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Table 38.1 Mean DMFT and SiC Index of 12-Year-Olds for Some Countries, by Ascending Order of DMFT
Mean 
Country DMFT SiC Index Year Sample size Reference
Australia 0.8 2.4 1999 29,130 Armfield, Roberts-Thomson, and Spencer 2003
Nepal 0.8 2.5 2000 623 Data from WHO, courtesy P. E. Petersen 
Sweden 0.9 2.6 2001 71,896 Sundberg 2002
Jamaica 1.0 2.8 1995 362 Data from PAHO, courtesy E. D. Beltran and S. Estupinan-Day
China 1.0 3.0 1996 23,452 Data from WHO, courtesy P. E. Petersen
Senegal 1.2 2.8 1994 300 Sembene, Kane, and Bourgeois 1999
Sri Lanka 1.4 3.6 1994–95 2,003 Abayaratna and Krishnarasa 1997
England, U.K. (Northwest) 1.4 3.2 2000–1 12,029 Pitts and others 2002
United States 1.4 3.6 1988–91 176 Data from PAHO, courtesy E. D. Beltran and S. Estupinan-Day
Portugal 1.5 3.6 1999 800 Data from WHO, courtesy P. E. Petersen
Germany 1.7 4.1 1997 1,043 Micheelis and Reich 1999
Israel 1.7 4.1 2002 1,327 Courtesy S. P. Zusman, Division of Dental Health, Israel
South Africa 1.7 4.3 1988–89 1,571 van Wyk 1994
Greece (Northeastern 1.8 4.2 2001 2,217 Demertzi and Topitsoglou 2002 
province) (11-year-olds)
Scotland (U.K.) 1.8 4.3 1996–97 6,165 Data from K. Woods from the study Pitts, Evans, and Nugent 1998
France 2.0 4.7 1998 6,000 Hescot and Roland 2000
Thailand 2.4 4.9 2001 1,116 Data from WHO, courtesy P. E. Petersen
Mexico (state of Mexico) 2.5 5.0 1997 1,138 Irigoyen and Sanchez-Hinojosa 2000
Uruguay 2.5 5.3 1999 596 Sector Público 1999
Comoros 2.6 6.1 2000 142 Data from WHO, courtesy P. E. Petersen
Belarus 2.7 5.4 1999 2,537 Data from WHO, courtesy P. E. Petersen
Romania 2.7 5.8 2001 785 Data from WHO, courtesy P. E. Petersen
Nicaragua 2.8 5.7 1997 365 Data from PAHO, courtesy E. D. Beltran and S. Estupinan-Day
Greenland 3.5 7.0 2002 236 Data from WHO, courtesy P. E. Petersen
Latvia 3.8 7.1 1998 416 Data from WHO, courtesy P. E. Petersen
Poland 3.9 7.2 1997 1,732 Data from WHO, courtesy P. E. Petersen
Honduras 4.0 7.5 1997 307 Data from PAHO, courtesy E. D. Beltran and S. Estupinan-Day
Bolivia 4.7 8.8 1995 389 Data from PAHO, courtesy E. D. Beltran and S. Estupinan-Day
Slovak Republic 5.9 14.3 1998 1,589 Data from WHO, courtesy P. E. Petersen
Costa Rica 8.5 13.7 1988 1,349 Data from PAHO, courtesy E. D. Beltran and S. Estupinan-Day
Source: Authors.
PAHO  Pan American Health Organization; SiC  Significant caries.
level in populations with skewed distribution. The Significant
Caries (SiC) Index was proposed to bring attention to those
hidden high caries groups (Bratthall 2000). The SiC Index is cal-
culated by simply taking the mean DMFT of the one-third of the
group having the highest DMFT in a population (figure 38.1).
Table 38.1 shows several countries having fewer than three
mean DMFT but high SiC Index values, thus illustrating the
hidden caries burden for children (Nishi and others 2002).
Dental caries is found not only in children and young adults
but also in all age groups. The elderly, in particular those
with exposed tooth root surfaces, constitute a special risk
by 2000. According to the CAPP database, 70 percent of the
countries had achieved three DMFT or fewer by 2001, repre-
senting 85 percent of the world population. Several developing
economies, however, have reported a trend toward higher levels
of dental caries.
A detailed analysis of caries data for many countries, both
industrial and developing, shows skewed distributions of the
disease—that is, a proportion of a population of children show-
ing a high or very high number of caries and the rest showing a
low number of caries or none. Expressing caries prevalence as
mean DMFT may, therefore, not accurately describe the disease
population (Barmes 2000). A Swedish study reported DMFT
values of 21.4 and 24.4 for 50- and 70-year-olds, respectively,
indicating that nearly all teeth were affected in these age groups
(Hugoson and others 1995). Thomson (2004), reviewing longi-
tudinal studies of older adults (age 50+), found an incidence of
root surface caries varying from 29 to 59 percent and conclud-
ed that older people are a caries-active group, experiencing new
caries at a rate comparable to that of adolescents. With increas-
ing numbers of people becoming 50 years of age or older in
some developing countries, root surface caries may become a
significant problem.
When we consider the global epidemiology of dental caries,
the main patterns seem to be the following:
• Countries with low mean sugar consumption (less than
10 to 15 kilograms of sugar per person per year) generally
have low mean caries prevalence.
• Countries with high mean sugar consumption (more than
20 to 25 kilograms of sugar per person per year) and with-
out effective preventive programs generally have high mean
caries prevalence.
• Countries with high mean sugar consumption (more than
20 to 25 kilograms of sugar per person per year) using effec-
tive preventive programs have been able to reduce the caries
prevalence.
If we consider the prevalence of caries within a population,
the main patterns seem to be as follows:
• Disadvantaged or poor population groups have higher
dental caries experience than advantaged groups.
• Individuals with poor oral hygiene and frequent sugar
intake are at increased risk.
• Individuals not exposed to fluorides—for example, from
fluoridated water or toothpastes—are at increased risk of
caries.
• Persons with individual risk factors, such as reduced saliva
flow or exposed tooth root surfaces, or with certain general
diseases are also at increased risk of caries.
Caries Intervention Programs
Since the discovery of the caries-preventive effect of fluorides
in the 1930s, different forms of fluoride administration pro-
grams have been implemented, often with remarkable caries-
reducing effects. Fluoride has been added to different vehicles,
such as water, salt, toothpaste, and milk. Fluoride tablets and
fluoride mouth rinsing have been used among young children
and in schools, and more recently even among adults at high
caries risk (Petersen 1989, 1990). For individual use, fluoride
in high concentrations has been added to various forms of gels
and varnishes to be applied on the teeth. Furthermore, fluor-
ide in chewing gum is available in some countries. When a
group of international experts on cariology were asked in a
study to identify the main causes of the caries decline seen in
several Western countries during recent decades, practically
all the experts pointed to fluoride dentifrice as the most signif-
icant factor (Bratthall, Hänsel-Petersson, and Sundberg 1996).
According to WHO (1994), community water fluoridation
is safe and cost-effective in preventing dental caries in every
age group, benefiting all residents served by the community
water regardless of their social or economic status (Burt 2002;
Petersen and Lennon 2004; White, Antczak-Bouckoms, and
Weinstein 1989). Examples of countries with fluoridated water
supplies for significant parts of the populations are Argentina,
Brazil, Brunei Darussalam, Canada, Chile, Ireland, New
Zealand, the United Kingdom, and the United States. In many
developing countries, lack of community water supplies makes
water fluoridation impossible.
Effective fluoride toothpastes have been available for about
40 years (WHO 1994). They have been tested in numerous
studies, in particular in school-based programs. The most
commonly used concentrations are 1,000 or 1,500 parts per
million (ppm). Because most studies have been conducted in
developed countries, WHO launched a program testing a so-
called “affordable fluoridated toothpaste” in developing coun-
tries. In the West Kalimantan Province of Indonesia, a super-
vised school-based toothbrushing program was implemented
over a period of three years, resulting in a reduction of 12 to
40 percent of caries incidence in the study groups when com-
pared to control groups (Adyatmaka and others 1998).
Domestic salt fluoridation is another method of automatic
fluoridation. In the early 1950s, Switzerland and Austria
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Figure 38.1 DMFT for 331 12-Year-Olds, West Kalimantan, Indonesia 
introduced this approach by offering their populations fluori-
dated salt for the table and for cooking. The fluoride concen-
tration in the salt originally was 90 ppm and was later increased
to 250 ppm. Fluoridated salt is now available in several coun-
tries in Europe and in South and Central America. A compari-
son of caries data for Jamaica in 1984 (before salt fluoridation)
and 1995 (after salt fluoridation) showed a reduction of caries
experience of 69 percent, 84 percent, and 87 percent among 
15-, 12-, and 6-year-olds, respectively (Estupinan-Day and
others 2001).
Milk fluoridation projects are being conducted in several
countries, including Bulgaria, China, the Russian Federation,
Thailand, and the United Kingdom. In Bulgaria, a milk fluorida-
tion project resulted in a 79 percent lower DMFT in those chil-
dren who had participated in the full five years of the program
than in the control children (Pakhomov and others 1995).
Fluoride tablets and fluoride mouth-rinsing programs
under supervision in schools have been implemented in several
countries, including the Scandinavian countries, the United
Kingdom, and the United States. The requirement that teachers
and students be motivated has limited such approaches. In
recent years, many national fluoride programs have been
adjusted as the additional caries-reducing effects of topical
applications with daily use of fluoridated toothpaste have been
questioned (Petersen and Torres 1999).
Oral Health Education and Promotion Programs
The WHO Global Oral Health Programme has developed a
manual for integration of oral health with school health pro-
grams (WHO 2003). In many industrial countries, school health
education programs have included oral health, and researchers
have shown that children’s self-care capacity improved in regard
to regular toothbrushing with the use of fluoridated toothpaste
(Flanders 1987; Honkala, Kannas, and Rise 1990; Petersen and
Torres 1999; Sogaard and Holst 1988; Wang and others 1998).
Examples also exist from school oral health education in devel-
oping countries. Some programs have been organized within
the context of the WHO Health Promoting Schools Initiative. In
Madagascar, the evaluation of program outcomes has shown
remarkably good results in reducing dental caries risk, improv-
ing self-care capacity of children and mothers, and introducing
higher levels of dental knowledge and attitudes (Razanamihaja
and Petersen 1999). Other successful examples are available
from Tanzania (Petersen and others 2002; van Palenstein
Helderman and others 1997), Zimbabwe (Frencken and others
2001), and Namibia (Priwe 1998).
In China, principles from the WHO Health Promoting
Schools Initiative have been applied in certain provinces; posi-
tive effects of programs were obtained regarding health-related
knowledge and behavior, but the clinical outcome measures
were less evident (Petersen and others 2004; Tai and others
2001). The Chinese health authorities have emphasized pre-
ventive oral care and oral health education since the late 1980s.
The nationwide mass campaign “Love Teeth Day” has been
conducted annually since 1989, and the effective transmission
of oral health messages to the public has shown improved oral
health knowledge and behavior in children as well as in adults
(Peng, Petersen, Tai, and others 1997).
In addition, various dental organizations (Cohen 1990) and
private companies have developed and carried out successful
oral health programs worldwide. For example, toothpaste man-
ufacturers have donated toothpastes, toothbrushes, and educa-
tional material promoting oral health in several countries.
Effectiveness of the Oral Health Programs
In countries with systematic national oral disease prevention
programs, the total cumulative effect of these programs is
reflected in the epidemiological figures demonstrating caries
decline (table 38.2) and in the growing proportions of caries-
free individuals. However, singling out the effects of specific
activities or methods of programs is difficult because several
program components often operate simultaneously. For exam-
ple, in industrial countries, practically all individuals use fluor-
idated toothpaste, and removing this preventive measure from
a group of individuals just to evaluate the effect of another
fluoride program would be unethical. In addition, other factors
affect caries reduction, such as changing lifestyles, changing
patterns of sugar consumption, and improving living
conditions.
The current trend in clinical health care and public health is
to base recommendations on evidence derived from systematic
reviews of the literature and critical assessment of the quality of
results (U.S. Public Health Service 2000). The office of the U.S.
Surgeon General (U.S. Public Health Service 2000) and
the Swedish Council on Technology Assessment in Health Care
(SBU 2002) are examples of entities that have attempted to
determine the effectiveness in public health of evidence-based
approaches and technologies.
Oral Health in America, the U.S. Surgeon General’s report
(U.S. Public Health Service 2000), reviewed experiences from
the administration of fluorides. Primarily based on U.S.
studies, the report had these conclusions:
• Strong evidence exists supporting the effectiveness of water
fluoridation in preventing crown and root caries in children
and adults.
• Strong evidence exists of the effectiveness of the school-
based fluoride supplement (tablets) program. The program,
with motivated supervising personnel, such as teachers, is
recommended for children at high risk for caries.
• Evidence supports the effectiveness of school-based fluoride
(0.2 percent sodium fluoride) mouth-rinsing programs
conducted before 1985 (before the introduction of fluoride
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Table 38.2 Declining Caries Experience in Some Countries
DMFT in 
Country Year 12-year-olds Reference
African region
Côte d’Ivoire 1996 1.8 Guinan and others 1999
1993 2.6 Data from Oral Health Programme, WHO
Niger 1997 1.3 Petersen and Kaka 1999
1992 1.5 Data from Oral Health Programme, WHO 
1988 1.7 Woodward and Walker 1994
American region
Colombia 1998 2.3 Data from PAHO
1984 4.8 Woodward and Walker 1994
Costa Rica 1999 2.3 Data from PAHO
1996 4.8 Data from Ministry of Health
1993 4.9 Data from PAHO
Guyana 1995 1.3 Beltran-Aguilar, Estupinan-Day, and Baez 1999
1983 2.7 Woodward and Walker 1994
Haiti 2000 1.0 Data from PAHO
1994 2.2 Data from PAHO
Honduras 1997 3.7 Beltran-Aguilar, Estupinan-Day, and Baez 1999
1987 5.7 Beltran-Aguilar, Estupinan-Day, and Baez 1999
Jamaica 1995 1.1 Beltran-Aguilar, Estupinan-Day, and Baez 1999
1984 6.7 Beltran-Aguilar, Estupinan-Day, and Baez 1999
Nicaragua 1997 2.8 Beltran-Aguilar, Estupinan-Day, and Baez 1999
1983 6.9 Beltran-Aguilar, Estupinan-Day, and Baez 1999
Panama 1997 3.6 Beltran-Aguilar, Estupinan-Day, and Baez 1999
1989 4.2 Beltran-Aguilar, Estupinan-Day, and Baez 1999
United States 1992–94 1.28 NHANES III, Courtesy D. Bruce
1988–91 1.4 Beltran-Aguilar, Estupinan-Day, and Baez 1999
1986–87 1.8 Beltran-Aguilar, Estupinan-Day, and Baez 1999
Venezuela, R. B. de 1997 2.1 Beltran-Aguilar, Estupinan-Day, and Baez 1999
1986 3.6 Data from PAHO
Middle Eastern region
Saudi Arabia 1995 1.7 Data from Oral Health Programme, WHO 
1991 2.1 Data from Oral Health Programme, WHO 
United Arab Emirates 1995 1.6 Nithila and others 1998
1993 2.0 Data from Oral Health Programme, WHO 
European region
Belarus 2000 2.7 Leous and Petersen 2002
1994 3.8 Leous and Petersen 2002
Denmark 2002 0.9 Data from National Board of Health, Denmark
1995 1.2 Data from National Board of Health, Denmark 
1980 5.0 Data from National Board of Health, Denmark 
(Continues on the following page.)
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Table 38.2 Continued
DMFT in 
Country Year 12-year-olds Reference
France 1998 1.9 Hescot and Roland 2000
1993 2.1 Hescot and Roland 2000
1990 3.0 Hescot and Roland 2000
Hungary 1996 3.8 Szoke and Petersen 2000
1991 4.3 Szoke and Petersen 2000
1985 5.0 Szoke and Petersen 2000
Israel 2002 1.66 Data from Dr S. P. Zusman, Division of Dental Health, Israel 
1989 3.0 Zadik, Zusman, and Kelman 1992
Latvia 2000 3.9 Latvia, State Dentistry Centre 2000
1998 4.2 Latvia, State Dentistry Centre 2000
Norway 2000 1.5 Data from Norwegian Board of Health 
1992 2.2 von der Fehr 1994
1986 3.1 Haugejorden 1994
Poland 2000 3.8 Wierzbicka and others 2002
1991 5.1 Wierzbicka and others 2002
Portugal 1999 1.5 de Almeida and others 2003
1990 3.2 de Almeida and others 2003
1984 3.7 de Almeida and others 2003
Romania 2000 2.7 Petersen and Rusu 2002
1990 3.9 Petersen and others 1994
Sweden 2001 0.9 Sundberg 2002
1995 1.4 Sundberg 2002
1985 3.1 Sundberg 2002
United Kingdom 1996–97 1.1 Pitts, Evans, and Nugent 1998
1983 3.1 Downer 1994
Asian region
Bangladesh 2000 1.0 Ullah 2001
1981 1.5 Data from Oral Health Programme, WHO 
Sri Lanka 1994–95 1.4 Abayaratna and Krishnarasa 1997
1983–84 1.9 Sri Lanka, Ministry of Health 1985
Western Pacific region
Australia 1999 0.8 Armfield, Roberts-Thomson, and Spencer 2003
1990 1.4 Armfield, Roberts-Thomson, and Spencer 2003 
1980 3.6 Carr 1988
Hong Kong (China) 2001 0.8 Hong Kong, Department of Health 2003
1986 1.5 Lo, Evans, and Lind 1990
Japan 1999 2.4 Data from Ministry of Health and Welfare 
1993 3.6 Miyazaki and Morimoto 1996
1987 4.9 Miyazaki and Morimoto 1996
Malaysia 1997 1.6 Malaysia, Dental Services Division 1997
1988 2.4 Malaysia, Dental Services Division 1997
Source: Authors.
PAHO  Pan American Health Organization; NHANES III  Third U.S. National Health and Nutritional Examination Survey.
Note: Numbers in italics indicate that the country did not achieve the WHO global goal of fewer than three DMFT by 2000 but shows caries decline.
toothpastes) in preventing caries in children. The cost-
effectiveness of this intervention is reduced with the current
decline in prevalence of caries. It is recommended for use in
high-risk children consistently over a period of time.
• Strong evidence supports the effectiveness of sealants in
preventing pits and fissure caries. The report recommends
that the programs be limited to high-risk children and high-
risk teeth.
• Fluoride varnishes were not approved for use in the United
States until 1994; hence, investigations are ongoing of the
effectiveness of this intervention.
The Swedish Council on Technology Assessment in Health
Care (SBU 2002) applied strict criteria of evidence of effective-
ness; that is, the study had to be randomized and have a sample
representing the total population. For permanent teeth, a
three-year follow-up was necessary. The number of studies
meeting all the criteria was not very high. Here are some
conclusions of this review:
• Daily use of fluoridated toothpaste is an effective method
to reduce caries in permanent teeth among children and
adolescents. Daily, weekly, or biweekly fluoride mouth rins-
ing can reduce caries, but together with daily fluoride
toothpaste use, the additional effects are not strong.
• Daily fluoride mouth rinsing can reduce root surface caries
in the elderly, and professional application of fluoride
varnish twice a year has a caries-reducing effect in perma-
nent teeth among youth, as does the use of fluoridated
toothpaste.
• Fissure sealants have a caries-reducing effect.
According to the SBU report, it was difficult to interpret the
effect of programs aimed at reducing the intake of sugars or the
effect of so-called sugar substitutes. Systematic evaluation of
community preventive programs should be carried out in the
future, particularly to help identify appropriate alternatives for
developing countries.
ASPECTS OF TREATMENT OF CAVITIES
AND OF CARIES DISEASE
One has to differentiate between treatment of cavities and
treatment of the disease process resulting in cavities. The
normal treatment of a tooth with a cavity is a filling or, if the
cavity is large, a crown. Large cavities may involve “root-
fillings” or even extraction of the tooth. A variety of materials
are used globally: composites, amalgam, gold, porcelain, and
others. Options for replacing extracted teeth include removable
prostheses, fixed bridges, or implants. The more complex treat-
ments are costly, and no country has been able to afford to
introduce systems in which all dental costs are covered by
public funds. Moreover, a filling does not affect the disease
process causing the cavities. Treatment must be directed against
the causative factors (described earlier). For the individual case,
several options are available in addition to the various fluoride
programs mentioned: dietary counseling, sugar substitutes,
antimicrobial agents to reduce plaque and specific bacteria, and
the use of saliva-stimulating products.
In many developing countries, the lack of dental manpower
means that carious teeth remain untreated. The ratio of den-
tists to population is particularly unfavorable in the African
region compared with Western European countries. For
instance, according to CAPP, the ratio is 1 to 1.2 million in
Ethiopia, 1 to 225,000 in Mali, and 1 to 166,000 in Zambia,
against about 1 to 1,000 in Scandinavian countries and 1 to
2,100 in the United Kingdom (see http://www.whocollab.od.
mah.se/index.html). In India, the ratio is 1 to 27,000 in the
urban areas but 1 to 300,000 in the rural areas (Shah 2001).
Such ratios mean that neither dental caries disease nor the
cavities will receive proper attention.
After taking into consideration the high costs for dental
treatment and the lack of dentists, atraumatic restorative treat-
ment (ART) was introduced. This approach requires only hand
instruments rather than sophisticated electric dental drills, and
trained dental auxiliaries can deliver ART. The public dental
health services in South Africa adopted the approach as an
appropriate and economic means of providing basic restorative
care in certain communities. A randomized clinical trial con-
ducted in Tanzania showed no statistically significant differ-
ences between the retention of occlusal amalgam (74 percent)
and ART occlusal restorations (67 percent) after a six-year
follow-up (1992–98) (Mandari, Frencken, and Van’t Hof 2003).
A potentially affordable treatment procedure that could pre-
vent untreated carious teeth from being extracted, ART may
have relevance to some middle-income countries, although the
method is not realistic for most low-income countries, where
sustainability of such programs would be low.
PERIODONTAL DISEASES: CHRONIC GINGIVITIS
AND CHRONIC PERIODONTITIS
Gingivitis, the inflammation of gum tissue caused by bacteria
accumulating in the plaque along the gingival margin, pre-
cedes chronic periodontitis. The more destructive form of
periodontal disease, which breaks down the supporting tissues
of the teeth, progressively leading to loosening of teeth and
tooth loss, affects 10 to 15 percent of most adult populations
(Papapanou 1999). Cigarette smoking and diabetes mellitus
(with poorly controlled diabetes) are two major risk factors
associated with periodontal disease and appear markedly to
affect the initiation and progression of the disease (Genco
1996; Papapanou 1999).
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In recent years there has been a growing awareness of the
association between some systemic diseases and oral disease,
especially periodontal diseases. For example, a national study in
the United States found that the prevalence of diabetes mellitus
in patients with periodontitis was significantly greater
(twofold) than in nonperiodontal patients (Soskolne and
Klinger 2001). Periodontal disease may be considered one of
the complications of diabetes. Effective control of periodontal
infection in diabetics appears to reduce the levels of advanced
glycogen end-products in the serum.
Proper oral hygiene practices can prevent both gingivitis
and advanced periodontal disease. All intervention programs
leading to improved oral hygiene are instrumental in the
control of periodontal disease and will reduce risk of future
tooth loss. The school-based oral health educational programs
previously discussed are effective in preventing gingivitis, but
no community-based intervention program addresses peri-
odontal disease, especially among adults. Tobacco cessation
programs are also important in the prevention of periodontal
diseases. Treatment of periodontal diseases consists of plaque
removal, scaling, and sometimes surgery, plus motivation and
instruction in oral hygiene. Dental hygienists can perform parts
of the treatment program.
ORAL PRECANCER AND CANCER
The most frequent form of oral precancerous lesion, leuko-
plakia, appears as a white patch that cannot be rubbed off, typ-
ically in the buccal mucosa, lateral borders of the tongue, and
floor of the mouth. The prevalence of leukoplakia among those
15 years old and above ranged from 1.1 percent in Cambodia,
to 1.7 percent in Myanmar, to 3.6 percent in Sweden (Axell
1976; Ikeda and others 1995). Malignant transformation varies
in different populations; nearly 5 percent of lesions are found
to be malignant at first biopsy, and 5 percent develop into
malignancy at a later stage. Erythroplakias appear as red patches
and are less common but have a higher tendency (90 percent or
more) than leukoplakias to transform into malignancies
(Sudbo and Reith 2003).
Oral cancers affect about 300,000 people worldwide
annually (Ferlay and others 2001) and often develop from oral
precancerous lesions (Sudbo and Reith 2003). Early detection
of oral precancerous lesions, notably oral leukoplakia and
erythroplakia, could easily prevent the development of the
disfiguring disease oral cancer and premature death.
Tobacco use in any form (smoking or chewing) and exces-
sive alcohol consumption remain the primary risk factors in
the development of these precancerous lesions (“Early
Diagnosis and Prevention of Oral Cancer and Precancer” 1995;
Reichart 2001). Factors such as local irritation, Candida albi-
cans infection, and nutritional deficiencies are also associated
with the presence of leukoplakia.
Screening populations and routine examination in dental
and medical clinics for oral precancer and early cancer lesions
would reduce the mortality, morbidity, and cost of treatment
associated with oral cancers. Not all oral premalignancies
show malignant transformation, and detection of these
oral lesions by biopsies are straightforward, not requiring
sophisticated equipment. Tobacco cessation programs aimed
at younger and older age groups and control of excessive alco-
hol intake are definitely beneficial in the prevention of oral
cancer.
ORAL MANIFESTATIONS OF HIV/AIDS
The scarce epidemiological data available on oral manifesta-
tions of HIV in developing countries are difficult to interpret
because these studies are not standardized (Holmes and
Stephan 2002). In the study groups, the prevalence of oral
lesions in Africa ranged from 15 percent to more than 90 per-
cent of infected individuals; in India the prevalence was 72 per-
cent; and in Thailand it was 82 percent. Reviews are available
on the different studies performed on oral manifestations
of HIV and AIDS (Naidoo and Chikte 1999; Patton and
others 2002).
Candida infections, oral hairy leukoplakia, oral ulcers, and
Kaposi’s sarcoma are some of the common oral manifestations
of HIV and AIDS. Notably, Kaposi’s sarcomas were never
detected in the Asian populations studied in India, Singapore,
and Thailand but were seen in South African, Zambian, and
Zimbabwean studies (Arendorf and others 1998; Hodgson
1997; Holmes and Stephan 2002; Lim and others 2001;
Nittayananta and Chungpanich 1997; Ranganathan and others
2000). The presence of oral candidiasis and hairy leukoplakia
alone or at the same time in an apparently healthy individual
could be an early indicator of the undetected HIV infection
progressing to AIDS. Those signs may be used as indicators
during clinical examinations in developing countries where
technology for laboratory tests is not available or is too expen-
sive (Greenspan and Greenspan 2002; Holmes and Stephan
2002).
NOMA (CANCRUM ORIS)
Noma usually begins as a small ulcer of the gingiva and devel-
ops into a rapidly spreading gangrenous condition of the oral
and facial tissues. Seen mainly in debilitated and malnourished
children, it is disfiguring and deadly. The condition is reported
in developing countries in several regions of the world, partic-
ularly in Sub-Saharan Africa (Enwonwu, Falkler, and Idigbe
2000; Naidoo and Chikte 2000; Petersen 2003). Noma disap-
peared from the industrial world in the 20th century except
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during World War II. In contrast, risk factors such as poverty,
poor hygiene, and malnutrition, eventually in combination
with infectious diseases such as HIV and AIDS, may have
recently increased the prevalence of this disease in Sub-Saharan
Africa (Enwonwu 1995; Naidoo and Chikte 2000). Most
important, 90 percent of infected children die without having
received any care.
Although the specific etiologic factors for noma are not
known, poverty has been identified as the single most impor-
tant risk indicator. Accordingly, improving the overall socio-
economic conditions can prevent noma. Public health
approaches such as providing a high-protein diet, clean water,
and sanitation and preventing communicable diseases such
as diphtheria, dysentery, and tuberculosis would be needed
for effective prevention of noma in Africa. Prognosis of
noma is considerably better with timely administration of
antibiotics.
DEVELOPMENTAL DISORDERS
Developmental disorders involve teeth and the craniofacial
structures. A few of these disorders are congenital diseases of the
enamel or dentin; problems related to the number, size, or shape
of teeth; and craniofacial birth defects, such as cleft lip and
palate (CL/P). Among the most common congenital malforma-
tions seen in humans, cardiovascular malformation is ranked as
the first and CL/P as the second. Unilateral CL/P occurs six
times more frequently than the bilateral form. Females are more
prone to get cleft palates, whereas cleft lip or CL/P is most com-
mon in males (U.S. Public Health Service 2000).
The incidence of CL/P differs from 0.18 to 3.74 per 1,000
live births, the highest incidence being seen in Native
Americans at 3.74 per 1,000, closely followed by the Japanese at
3.36 per 1,000 live births. A fairly uniform incidence of 1 per
600 to 700 live births is reported among Europeans. Overall,
the incidence rates appear high among Asians (0.82 to 3.36 per
1,000 live births), intermediate in Caucasians (0.9 to 2.69 per
1,000 live births), and often very low in black Africans (0.18 to
1.67 per 1,000 live births) (Hewson and McNamara 2000;
Vanderas 1987; Wantia and Rettinger 2002).
The causes of CL/P are complex, involving multiple genetic
and environmental risk factors. Not all cases of CL/P are inher-
ited. A number of risk factors, such as folic acid deficiencies,
maternal smoking, and maternal age, have been implicated in
the formation of clefts (Wantia and Rettinger 2002).
Advanced surgery, specific prosthetic appliances, and ortho-
dontic treatment can improve the quality of life for those born
with clefts. However, such treatment is not accessible to chil-
dren of several developing countries. Tobacco cessation
programs aimed at pregnant mothers are essential in the pre-
vention of CL/P.
FLUOROSIS OF TEETH
Fluorosis of teeth develops during formation of teeth when
children are young. Drinking water having more than 1.5 ppm
of fluoride can give rise to enamel defects and discoloration of
teeth, leading to endemic fluorosis in the population. These
effects may vary from mild to severe. For example, in the Great
Rift Valley area of East Africa, the ground water has high levels
of fluoride, leading to high rates of dental fluorosis—nearly
90 percent in some parts of Kenya (Chibole 1987). Some indi-
viduals in developed countries can acquire fluorosis of teeth as
a result of the widespread use of different forms of fluorides in
the prevention of caries, though the degree of fluorosis often is
mild compared with endemic fluorosis.
Defluoridation of the central water supplies is possible
when naturally occurring fluoride is excessive in the drinking
water. However, most developing countries do not have central
water distribution systems, and the cost of defluoridation
equipment and its maintenance can be high. WHO encourages
effective and inexpensive methods that are useful for individual
households or community defluoridation of drinking water
(WHO 1994). Such methods exist, but a number of operational
problems have been identified, requiring further initiatives in
this field (Kloos and Haimanot 1999).
COMMON-RISK-FACTOR INTERVENTION
PROGRAMS
New research is pointing to associations between chronic oral
infections—particularly periodontitis—and heart and lung
diseases, stroke, osteoporosis, low birthweight, and premature
births in addition to diabetes. Such findings strengthen WHO
health promotion strategies that are based on the common-
risk-factor approach, which controls essential risk factors that
contribute to a large number of chronic diseases (Petersen
2003). Risk behaviors such as smoking; alcohol; diets rich in
fats and sugars and low in fiber, fruit, and vegetables; stress;
poor hygiene; and sedentary lifestyle are factors leading to such
major chronic diseases as cardiovascular diseases, cancers, dia-
betes, obesity, osteoporosis, dental caries, and periodontal dis-
ease. These principal risk factors for major chronic diseases are
often seen to cluster in the same individuals.
The WHO Global Oral Health Programme recommends the
common-risk-factors approach (Petersen 2003), which implies
development of integral activities in health promotion and
disease prevention, involving health education, community
empowerment, and legislative policy development. For exam-
ple, such programs could aim at reducing the caries levels
among preschool children and simultaneously improving gen-
eral health. Promoting the reduction of sugar consumption
would improve not only oral health but also general health
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through better quality of children’s diet. Some prevention
strategies for oral health, suitable for developing countries are
outlined in table 38.3.
RESEARCH AND FUTURE ACTIONS
Several promising actions against factors causing the two major
oral diseases, caries and periodontal disease, are ongoing:
attempts to control the formation of the biofilm with its
microflora are of high priority. One research line is to identify
pathogenic bacteria and try to replace them with genetically
modified, less pathogenic bacteria or to eradicate them
by antibiotics or antiseptics. Preventing dental caries by a vac-
cine is not a new idea, and efforts continue. Among other ideas
is the use of plantibodies (plant-derived therapeutic antibodies)
or genetically modified bacteria, releasing components targeting
pathogens. Functional foods, which include various elements in
food, may be another future option to control oral diseases.
Although pilot or small-scale studies seem promising, it will be
several years before such methods can possibly be of use in pop-
ulations because large clinical trials have not even started.
Saliva is believed to be usable as a diagnostic tool, providing
noninvasive assessment of a number of oral and systemic dis-
eases. Devices are being designed to identify in saliva various
bacteria and their virulence factors, drugs, metabolic products,
hormones, biomarkers for oral cancer, inflammatory media-
tors, and more. Future developments may result in other
affordable and effective devices.
Continuous attempts are being made to assess the sociobe-
havioral factors in oral health and the information on risk fac-
tors. Caries risk assessment models are tested also for the indi-
vidual cases. Through present knowledge, individuals in need
of targeted actions can be identified. Another strong trend is to
use evidence-based reviews. This type of research is, of course,
not restricted to oral health. Several reviews have already been
done, and a frequent conclusion is that the number of ran-
domized clinical trials is limited, in particular for common
clinical procedures. This trend will change as the quality of
future oral health research improves, but not all research prob-
lems can be solved by such studies. Community-based partic-
ipatory research is another approach that may be used to
improve oral health studies (O’Fallon and Dearry 2002).
Within the management of dental diseases—in particular,
caries—is the “minimally invasive dentistry” approach, which
promotes the concept that large restorations (crowns, bridges)
are not as necessary as believed. Risk assessment, preventive
measures, and improved dental materials with good adhesion
capacity are some of the several components in this approach.
Research in transfer of knowledge using the Internet or
other electronic media is another strongly expanding area,
from which developing countries should be able to benefit.
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Table 38.3 Prevention Strategies for Oral Health
Disease or condition Causes Actions needed and methods
Dental caries
Periodontal diseases
Oral precancer and cancer
Oral manifestations of HIV/AIDS
Noma (cancrum oris)
Developmental disorders
Fluorosis of teeth
High or frequent sugar consumption, plaque present,
highly cariogenic microorganisms, nonuse of fluorides,
reduced saliva flow, systemic diseases, and other
individual risk factors
Plaque present, pathogenic bacteria, influence of systemic
diseases, tobacco use
Tobacco and alcohol use; see chapter 29
See chapter 18
Probably bacterial in connection with severe
malnourishment
Various genetic or environmental causes such as
tobacco use 
Too high concentration of fluoride in drinking waters or
from other sources
Targeted actions against causative factors on community
and individual levels 
Health education toward self-care capacity, fluoride pro-
grams, sugar restriction, actions based on risk assessment
of individuals and groups
Improved oral hygiene, professional cleaning, antibiotics,
identification and treatment of systemic diseases 
Elimination of pockets if present and removal of local
dental irritants, such as rough fillings 
Tobacco cessation
Tobacco cessation; see chapter 29
See chapter 18. Special oral care
Antibiotics together with nutritional support; surgery
sometimes necessary
Tobacco cessation programs aimed at pregnant mothers 
Identification of water sources and reduction of fluoride or
recommendation of other water sources 
Source: Authors; partly based on Bratthall and Barmes 1993.
Note: This table is by no means complete. Many other oral diseases or conditions are important and need attention. The listed ones are of special relevance for developing countries.
COST-EFFECTIVENESS OF ORAL HEALTH CARE
Using the evidence available, the U.S. Surgeon General’s report
(U.S. Public Health Service 2000) and the report of the Swedish
Council on Technology Assessment in Health Care (SBU 2002;
see also Kallestal and others 2003) have attempted to determine
the cost-effectiveness of oral health intervention programs
from developed countries.
Among the findings in the U.S. report were the following:
• Water fluoridation costs about a dollar per person per year
for water serving most individuals in the United States.
Community water fluoridation is believed to be an effective
and cost-effective caries preventive method.
• Economic analyses of community dental sealant programs
suggest that they are cost-effective and may even provide
cost savings when used in high-risk populations.
The Swedish report (SBU 2002), reviewing original studies
on economic evaluation of caries prevention (a total of 17
selected from 1966 to 2003 MEDLINE and manual Internet
searches), commented that no conclusion could be drawn
owing to the low evidence values and contradictory results.
This comment prompted the group to present its own calcula-
tion for cost-effectiveness based on Swedish caries prevalence
and charges used in Swedish dental care. The group found that
the cost-effectiveness for fluoridated toothpaste is extremely
good (cost per prevented DMFT very low), which, of course, is
not surprising, given the significant caries-reducing results in
combination with low cost for society.
No clear correlation appears to exist between caries experi-
ence and health care investment for individual countries.
Some countries with the lowest health care expenditures have
values for caries experience (DMFT) that are similar to or
even lower than those countries having the highest expendi-
tures on health (figure 38.2). Those low-income countries
often have low per capita sugar consumption and, therefore,
do not need to install expensive measures for treatment or
prevention.
It may seem surprising that so few studies are available
regarding the cost-effectiveness of caries prevention, or of any
other oral disease. In a critical review article, Schwarz (1998)
analyzed the issue. He wrote, “Several decades after consider-
able improvements in the oral disease situation were docu-
mented in Scandinavia, doubts are still expressed about
whether preventive measures are cost-effective.” In addition, he
recommended that four elements be considered when a pre-
ventive effect was evaluated: the definition of prevention, the
practical perception of effective prevention, the appropriate-
ness of traditional cost-effectiveness analysis, and the time fac-
tor. He pointed out that “caries prevention is not uniformly
defined by the profession, that dental research is casting doubt
on the effectiveness of traditionally accepted preventive meas-
ures, that political pressures on health care are motivated by
economic pressures.” Finally, he stated that traditional cost-
benefit and cost-effectiveness analyses have not been able to
help the decision makers choose wisely and that the time per-
spective for the real effects of prevention lies beyond the inter-
ests of decision makers.
However, without proper prevention, the alternative strategy
is restorative dentistry—that is, to make fillings, crowns, and
dentures. Is this a feasible alternative for developing countries?
Yee and Sheiham (2003) give some examples: In Nepal, a sim-
ple amalgam filling would cost about US$4, which does not
include the many additional expenses for impoverished rural
families, who may have to travel by bus or walk for a day or two
to get to the clinic. The total expenses incurred, including den-
tal fees, meals, and lodging but not including lost wages, would
amount to US$12, an enormous sum considering the average
Nepalese’s earning of US$0.75 per day, and it is enough to buy
food for a month. Yee and Sheiham conclude that treating
caries with the traditional method of restorative dentistry is
beyond the financial capabilities of most low-income nations
because three-quarters of these countries do not even have suf-
ficient resources to finance an essential package of health care
services for their children. Yee and Sheiham (2003) estimate
that treating dental caries by the traditional amalgam restora-
tive dentistry in the permanent dentition of the child popula-
tion would cost about US$2,000 for 1,000 children of mixed
ages from 6 to 18 years, which would require financial
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resources beyond the capabilities of low-income nations.
Hence, they propose a public health and health promotion
approach to reduce caries burden instead of the restorative
approach.
Although several studies evaluating the effectiveness of
intervention and oral health promotion programs in develop-
ing countries are becoming available (Estupinan-Day and
others 2001; Pakhomov and others 1995; Petersen and others
2004), a definite need exists for further cost-effectiveness analy-
sis on such programs, which should be addressed in the future.
It would also be useful if studies were commenced on inter-
vention programs using the common-risk approach suggested
by WHO (Petersen 2003).
CONCLUSIONS 
Dental caries and periodontal diseases are the most known oral
diseases, but other conditions can strongly and negatively
influence the quality of life. Effective programs to reduce the
burden of oral diseases—in particular, caries—are available in
principle, but to run these programs in developing countries,
new approaches are needed. The WHO strategy of identifying
common risk factors seems promising for health promotion. In
broad terms, the most important challenges for oral health in
the 21st century relate to the transfer of knowledge and experi-
ences in preventive oral care to the poor and disadvantaged
population groups in both developing and developed
countries.
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This chapter examines the issue of unintentional injuries and
focuses on a selected number of cause-specific unintentional
injuries. Injuries have traditionally been defined as damage
to a person caused by an acute transfer of energy (mechanical,
thermal, electrical, chemical, or radiation) or by the sudden
absence of heat or oxygen. Unintentional injuries consist of
that subset of injuries for which there is no evidence of pre-
determined intent. The cause-specific unintentional injuries
examined here include those that the World Health
Organization (WHO) routinely analyzes and publishes data on
and that individually account for the greatest unintentional
injury burden in terms of mortality and disability-adjusted life
years (DALYs). These include road traffic injuries (RTIs), poi-
sonings, falls, burns, and drowning (figure 39.1).
BURDEN AND CAUSES OF UNINTENTIONAL
INJURIES 
This section provides a brief outline of the burden of uninten-
tional injuries and then reviews the available evidence about
known and potential causes of such injuries.
Burden of Unintentional Injuries
Worldwide, unintentional injuries accounted for more than
3.5 million deaths in 2001, or about 6 percent of all deaths and
66 percent of all injury deaths. Unintentional injuries were also
responsible for more than 113 million DALYs in 2001, or about
8 percent of all DALYs and some 70 percent of all injury
DALYs. More than 90 percent of unintentional injury deaths
occurred in low- and middle-income countries (LMICs),
accounting for around 7 percent of all deaths in those coun-
tries. Similarly, more than 90 percent of DALYs that were
attributed to unintentional injuries occurred in LMICs,
accounting for about 8 percent of all DALYs in those countries.
Injury death rates per 100,000 population were higher in
LMICs (62 per 100,000) than globally (57 per 100,000).
Males accounted for almost two-thirds of the deaths attrib-
uted to unintentional injuries in LMICs in 2001, with rates of
both injury death and DALY losses higher among males than
females (table 39.1). Compared with other age groups, young
people age 15 to 29 accounted for the largest proportion of
deaths from unintentional injuries in LMICs (figure 39.2).
RTIs accounted for the greatest burden of deaths from
unintentional injuries in LMICs in 2001, or about 34 percent
of the total burden, and the greatest burden of DALYs from
unintentional injuries in LMICs in 2001, accounting for
28 percent of the burden (figure 39.1). Whereas young people
age 15 to 29 years accounted for the highest proportion of all
unintentional injuries, those age 45 to 59 accounted for the
highest proportion of injuries from poisonings, while those
age 70 to 79 accounted for the highest proportion of injuries
from falls (figure 39.2).
Economic Burden of Unintentional Injuries. Estimates of the
burden of unintentional injuries as measured in terms of eco-
nomic costs are almost nonexistent. The best estimates avail-
able are for RTIs. Using road crash costs from 21 developed
and developing countries, the Transport Research Laboratory
Ltd. finds that the average annual cost of road crashes was
equivalent to about 1.0 percent of gross national product in
developing countries, 1.5 percent in transition countries, and
2.0 percent in highly motorized countries. The annual burden
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Table 39.1 Cause-Specific Death Rates and DALYs Lost
because of Unintentional Injuries, by Gender, Worldwide
and in LMICs, 2001
Global LMICs
Category Total Males Females Total Males Females
Deaths (per 100,000 population)
All unintentional 57 75 41 61 80 44
injuries
RTIs 19 28 11 20 30 11
Poisonings 6 7 4 6 8 5
Falls 6 8 5 6 8 5
Fires 5 4 6 6 4 7
Drowning 6 9 4 7 10 5
Other unintentional 15 19 11 16 20 11
injuries
DALY losses (per 1,000 population)
All unintentional 20 25 14 22 28 16
injuries
RTIs 6 8 3 6 9 4
Poisonings 1 2 1 1 2 1
Falls 2 3 2 3 3 2
Fires 2 1 2 2 2 2
Drowning 2 2 1 2 2 1
Other unintentional 7 9 5 8 10 6
injuries
Source: Authors. 
Note: All figures are rounded to the nearest 1,000.
of road crash costs is about US$518 billion globally and about
US$65 billion in LMICs, exceeding the total annual amount
these countries receive in development assistance (Jacobs,
Aeron-Thomas, and Astrop 2000).
Causes of Unintentional Injuries in LMICs
As in the case of most diseases, unintentional injuries are caused
by multiple factors. The traditional epidemiological paradigm
of host, vector, and environmental factors that in combination
contribute to the incidence of disease has been adapted and
applied in determining the causes of unintentional injury.
However, this paradigm has been extended to consider each
factor in relation to the time of the injury—that is, factors oper-
ating before, during, and after the injury that might be associ-
ated with both its incidence and its severity (Haddon 1968).
Although the matrix, called the Haddon matrix, was initially
developed to address the problem of RTIs only, it provides a
comprehensive framework in which researchers can consider
the multitude of factors that may play a role in the causal injury
pathway, as outlined in table 39.2.
In the past two decades, the evidence base for the identifica-
tion of risk factors for unintentional injuries in high-income
countries (HICs) has increased dramatically as the number
of injury researchers and research institutions has increased.
However, because of the paucity of injury researchers and
research institutions in LMICs, the evidence base for the iden-
tification of risk factors for unintentional injuries in these
countries is growing more slowly.
Although knowledge about risk factors for injuries in HICs
may also be relevant for LMICs, the material presented in the
following section focuses on information that has been
obtained from studies in LMICs. However, the section also
considers the extent to which information obtained from stud-
ies conducted in HICs may be relevant.
Risk Factors for Road Traffic Injuries. The increasing volume
of traffic is one of the main factors contributing to the increase in
RTIs in LMICs. Motorization rates rise with income (Kopits and
Cropper 2005), and a number of LMICs experiencing growth
have seen a corresponding increase in the number of motor vehi-
cles (Ghaffar and others 1999). In some LMICs, this growth has
been led by an increase in motorized two-wheeled vehicles, one
of the least safe forms of travel, which has resulted in concurrent
increases in related injuries (Zhang and others 2004).
The rapid growth in motor vehicles in many LMICs has not
been accompanied by improvements in facilities for these road
users or by facilities that respond to the continued predomi-
nance of nonmotorized traffic (Khayesi 2003).Many of the tech-
nical aspects of planning, highway design, traffic engineering,
and traffic management that are the hallmarks of transportation
systems in many HICs are absent in LMICs, which need to plan
for a level of heterogeneity in traffic that HICs do not encounter
(Tiwari 2000).
Studies undertaken primarily in HICs show a strong rela-
tionship between the increase in vehicle speeds and increased
risk of crash and injury, both for motor vehicle occupants and
for vulnerable road users, particularly pedestrians (European
Road Safety Action Program 2003). This relationship is likely to
be true for LMICs, and indeed, data obtained from routinely
collected police reports in a number of LMICs show that speed
is listed as the leading cause of road traffic crashes, accounting
for up to 50 percent of all crashes (Afukaar 2003; Odero,
Khayesi, and Heda 2003; Wang and others 2003).
Several case-control studies in HICs have confirmed the role
of alcohol in the increasing risk of road crashes (Peden and
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Table 39.2 The Haddon Matrix as Applied to Road Traffic Injuries 
Factors
Phase Nature of intervention Human Vehicles and equipment Environment
Precrash Crash prevention Information Roadworthiness Road design 
Attitudes Lighting Road layout
Impairment Braking Speed limits 
Police enforcement Handling Pedestrian facilities 
Speed management
Crash Injury prevention Use of restraints Occupant restraints Forgiving roadside (for
during crash Impairment Other safety devices example, crash barriers)
Crash-protective design
Postcrash Life sustaining First-aid skill Ease of access Rescue facilities
Access to medical personnel Fire risk Congestion
Source: Authors.
others 2004). Studies conducted in LMICs showed that drivers
had consumed alcohol in 33 to 69 percent of crashes in which
drivers were fatally injured and in 8 to 29 percent of crashes in
which drivers were not fatally injured (Odero and Zwi 1995).
Alcohol consumption by pedestrians also increases their risk of
injuries in HICs; moreover, in at least some LMICs, more than
50 percent of fatally injured pedestrians had consumed alcohol
(Peden and others 1996).
Other factors that increase the risks of road crashes in HICs
include fatigue, use of hand-held mobile telephones, and inad-
equate visibility of vulnerable road users (Peden and others
2004), all of which are equally likely to increase risks in LMICs.
Indeed, a recent case-control study from China shows that the
risks of a crash doubled with chronic sleepiness on the part of
the driver (G. F. Liu and others 2003), and surveys of commer-
cial and public road transport in a number of African countries
have shown that drivers often work long hours and go to work
exhausted (Mock, Amegashi, and Darteh 1999; Nafukho and
Khayesi 2002). Studies in Malaysia clearly show that motorcy-
clists who use daytime running lights have a crash risk about
10 to 29 percent lower than those who do not because of their
greater visibility (Radin Umar, Mackay, and Hills 1996).
Road- and vehicle-related factors may also increase the risk of
crash involvement. Specific factors related to road planning
include traffic passing through residential areas, conflicts
between pedestrians and vehicles, schools located on busy roads,
lack of median barriers to prevent dangerous passing on two-lane
roads,and lack of barriers to prevent pedestrian access onto high-
speed roads, although few studies have specifically examined the
risks associated with those factors (Ross and others 1991).
Although the severity of crash injuries is related to in-
vehicle crash protection, evidence indicates that many engi-
neering advances found in vehicles in HICs are not present in
vehicles in LMICs (Odero, Garner, and Zwi 1997). Perhaps one
of the most important factors contributing to injury severity
relates to crash protection for vulnerable road users. However,
few HICs, let alone LMICs, require the fronts of cars or buses
to be designed in a way that would protect vulnerable road
users (Mohan 2002).
A significant risk factor for increased severity of injuries of
users of motorized two-wheeled vehicles is riders’ failure to use
motorcycle helmets (B. Liu and others 2004). Studies in a num-
ber of Asian countries have shown that failure to use helmets,
use of nonstandard helmets, and use of improperly secured
helmets are not uncommon, even in countries with mandatory
helmet laws (Conrad and others 1996; Kulanthayan and others
2000). Failure to wear helmets is also a risk factor for increased
injury severity among bicyclists (Attewell, Glase, and
McFadden 2001). Although the failure to use seat belts is a sig-
nificant risk factor associated with injury severity among vehi-
cle occupants, many LMICs have no requirements for seat belts
to be fitted or used (Peden and others 2004).
Studies in HICs suggest that roadside hazards, such as
trees, poles, and road signs, may contribute to between 18 and
42 percent of road crashes and increase injury severity
(Kloeden and others 1998), although the extent to which this is
also true in LMICs has not been determined.
Risk Factors for Poisonings. The literature on poisonings in
LMICs includes comprehensive information about intentional
poisonings; significant information about occupation-related
poisonings, especially pesticide poisonings; and a growing
body of information about lead poisoning. Each of these types
of poisoning is covered elsewhere in this book. This chapter
focuses on risk factors for other types of poisoning in LMICs,
and, in particular, focuses on risk factors for poisonings in
young children.
The literature’s focus on risk factors for childhood poison-
ing probably reflects the fact that child poisoning victims are
seen more often than adults in most hospital settings (Ellis and
others 1994; Nhachi and Kasilo 1992). This fact is in stark con-
trast to the data presented earlier, which clearly show that mid-
dle-aged individuals sustain the vast majority of deaths and
DALYs from poisonings in LMICs. Those numbers no doubt
reflect the importance of work-related poisonings.
Young males consistently appear to be at higher risk of poi-
sonings than females (Ellis and others 1994; Fernando and
Fernando 1997; Soori 2001). The most common agents
involved in childhood poisonings are paraffin (or kerosene)
and other household chemicals; pesticides; and various plants
or animals, including snakes (Fernando and Fernando 1997).
Several case-control studies in LMICs indicate the impor-
tance of a number of sociodemographic risk factors, including
young parents, residential mobility, and limited adult supervi-
sion of children (Azizi, Zulkifli, and Kasim 1993; Soori 2001).
The studies also suggest that previous poisoning may be a risk
factor (Soori 2001). Another important factor seems to be stor-
age, including the number of storage containers used in the
residence; the use of nonstandard containers for storage (for
example, beverage bottles for storing kerosene); and the storage
of poisons at ground level (Azizi, Zulkifli, and Kasim 1993;
Chatsantiprapa, Chokkanapitak, and Pinpradit 2001; Soori
2001).
Risk Factors for Fall-Related Injuries. Risk factors for fall-
related injuries in older people are generally considered in
terms of risk factors for falling, risk factors associated with
the severity of the impact following the fall, and risks factors
associated with low levels of bone mineral density—insofar
as almost all fall-related injuries in older people involve bro-
ken bones. The risk factors associated with the latter two
categories are generally related to aspects of the aging process
and, as a consequence, are considered in more detail in
chapter 51.
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Analytical studies conducted in a variety of LMICs have
tended to show that risk factors for fall-related injuries, espe-
cially hip fractures, are consistent with the risk factors identi-
fied in HICs. Those risk factors include low bone density; poor
nutritional status and low body mass index; low calcium
intake; comorbid conditions, such as hypertension and dia-
betes; poor performance in activities of daily living; low levels
of engagement in physical activity; poor cognitive function;
poor perceived health status; poor vision; environmental fac-
tors affecting balance or gait; family history of hip fracture; and
alcohol consumption (Boonyaratavej and others 2001; Clark
and others 1998; Jitapunkul, Yuktananandana, and Parkpian
2001).
Some studies have identified other factors that may be more
relevant in the context of LMICs. For example, studies in
Thailand suggest that factors associated with poor socioeco-
nomic status may increase risk—for example, not having elec-
tricity in the house and living in Thai-style houses or huts
(Jitapunkul, Yuktananandana, and Parkpian 2001).
The literature specifically identifying risk factors for falls in
younger people in LMICs is sparse, but the information there is
indicates that such falls usually occur in and around the home,
with a significant proportion being associated with falls from
heights, including rooftops and trees (Adesunkanmi, Oseni,
and Badru 1999; Bangdiwala and Anzola-Perez 1990; Kozik and
others 1999; Raja, Vohra, and Ahmed 2001). However, falls
other than from heights predominate and are frequently related
to engagement in vigorous levels of physical activity.
Risk Factors for Burn-Related Injuries. Despite the focus of
WHO’s data on burn-related injuries sustained as a result of
fires, a number of country-specific surveys conducted in med-
ical facilities suggest that scalds from hot water may be equally
important or more important causes of burn-related injuries
(Chan and others 2002; Delgado and others 2002; Forjuoh,
Guyer, and Smith 1995; Rossi and others 1998). However, in
some countries, including China and particularly India, fire-
related injuries clearly outweigh scald-related injuries (Ahuja
and Bhattacharya 2002; Jie and Ren 1992).
Overall, women are at greater risk of fire-related burn
injuries than are men; however, data from population-based
and medical center surveys suggest that in some settings
(excluding India), males may be at greater risk of burns than are
females (Chan and others 2002; Zhu, Yang, and Meng 1988). In
many studies, burn-related injuries account for a much higher
proportion of injuries in young children compared with other
age groups (Jie and Ren 1992; E. H. Liu and others 1998).
Rural location appears to be a consistent risk factor for
burn-related injuries (Courtright, Haile, and Kohls 1993;
Zhu, Yang and Meng 1988), as is the home (Delgado and
others 2002; Forjuoh, Guyer, and Smith 1995; E. H. Liu and
others 1998).
Investigators have undertaken case-control studies aimed at
identifying risk and protective factors for burn-related injuries
in Africa, Asia, and South America, and all focus on identify-
ing risk factors for children. Environmental risk factors that
have been identified include lack of a water supply, storage of
a flammable substance in the home, cooking equipment in the
kitchen within reach of children, and housing that is located in
slums and congested areas. Persons with personal and socio-
economic risk factors included children who were not the first
born, who had a pregnant mother, whose mother recently was
dismissed from a job, who had recently moved, who had a pre-
existing impairment, whose sibling died from a burn or had
a history of burn, whose parents lacked alertness to burns,
whose clothing was made of synthetic fabrics, whose parents
were illiterate, and whose parents were of low economic status.
Protective factors included the presence of a living room,
better maternal education, and a history of previous injury
among males who lived in good environmental conditions
(Daisy and others 2001; Delgado and others 2002; Forjuoh
and others 1995; Werneck and Reichenheim 1997).
Risk Factors for Drowning. Most drowning incidents in
LMICs are not associated with recreation or leisure, as is com-
monly the case in HICs, but instead are associated with every-
day activities near bodies of water, including rivers, wells, and
buckets (Celis 1997; Hyder and others 2003; Kobusingye,
Guwatudde, and Lett 2001).
As noted earlier, men account for a higher proportion of
drowning incidents than women, and children age one to four
and young people appear to be at greatest risk, with drowning
accounting for a high proportion of injury-related deaths in
those age groups (Celis 1997; Kibel and others 1990; Kozik and
others 1999; Tan, Li, and Bu 1998). Some surveys also suggest
that older people may be at particularly high risk (Tan, Li, and
Bu 1998).
Descriptive surveys indicate that those living in rural areas
are at greater risk than those living in urban areas (Kobusingye,
Guwatudde, and Lett 2001), probably indicating greater expo-
sure to unprotected water surfaces. A number of studies find
that most adult drowning incidents appear to be associated
with positive blood alcohol tests (Carlini-Cotrim and da Matta
Chasin 2000; Celis 1997).
Case-control studies of drowning in young children have
identified both sociodemographic risk factors and risk factors
associated with proximity to bodies of water. Ahmed, Rahman,
and van Ginneken’s (1999) study in Bangladesh shows that the
risk of drowning increased with the age of the mother and
increased much more sharply the larger the number of children
in the family. Celis’s (1997) case-control study in Mexico finds
that the risk of drowning associated with having a well at home
was almost seven times that for children in homes without a
well.
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Table 39.3 Promising and Effective Interventions for Injuries in LMICs
Injury
RTIs
Promising interventions
Reducing motor vehicle traffic: efficient fuel taxes, changes in land-use policy, safety
impact assessment of transportation and land-use plans, provision of shorter and
safer routes, trip reduction measures
Making greater use of safer modes of transport
Minimizing exposure to high-risk scenarios: restricting access to different parts of the
road network, giving priority to higher occupancy vehicles or to vulnerable road users,
restricting the speed and engine performance of motorized two-wheelers, increasing
the legal age for operating a motorcycle, using graduated driver’s licensing systems
Safer roads
Safety awareness in planning road networks, safety features in road design, and
remedial action in high-risk crash sites: making provisions for slow-moving traffic and
vulnerable road users; providing passing lanes, median barriers, and street lighting
Traffic calming measures, such as speed bumps
Speed cameras
Safer vehicles
Improving the visibility of vehicles, including requiring automatic daytime
running lights
Incorporating crash protective design into vehicles, including installing seat belts
Mandating vehicle licensing and inspection
Safer people
Legislating strategies and increasing enforcement of, for example, speed limits,
alcohol-related limits, hours of driving for commercial drivers, seat belt use, bicycle
and motorcycle helmet use
Interventions shown to be effective in
LMICs (references)
Increasing the legal age of motorcyclists from
16 to 18 years (Norghani and others 1998)
Speed bumps in reducing pedestrian injuries
(Afukaar, Antwi, and Ofosu-Amaah 2003)
Daytime running lights on motorcycles (Radin
Umar, Mackay, and Hills 1996; Yuan 2000)
Increases in fines and suspension of driver’s
licenses (Poli de Figueiredo and others 2001)
Legislation and enforcement of motorcycle
helmets (Ichikawa, Chadbunchachai, and Marui
2003; Supramaniam, Belle, and Sung 1984).
INTERVENTIONS 
Interventions to prevent unintentional injuries have tradition-
ally been considered in terms of the three E’s—education,
enforcement, and engineering—and within the framework of
the Haddon matrix. That is, interventions are considered
in terms of preventing the occurrence of the injury, minimiz-
ing the severity of injury at the time of the injury, and mini-
mizing the severity of injury following the injury event.
Although randomized controlled trials are the gold standard
for assessing the effectiveness of injury interventions, such tri-
als are still relatively rare in relation to injuries, and in many
cases such trials may be impractical to implement. Studies
comparing the incidence of injury before and after the imple-
mentation of an intervention, sometimes with reference to a
control population in which the intervention has not been
introduced, more commonly provide the only evidence of
effectiveness. In some areas, findings from observational stud-
ies, such as case-control studies, provide the best available evi-
dence. However, randomized controlled trials are clearly not
needed for some interventions because their benefits are
obvious. Other interventions, particularly those that may have
modest but important benefits, may require rigorous evalua-
tion methods.
Evidence of the effectiveness of interventions in LMICs, as
opposed to HICs, is also relatively uncommon. Although the
proven efficacy of some interventions in HICs does not require
replication in LMICs—for example, the use of motorcycle
helmets—strategies that may be effective in increasing the rates
of helmet wearing in HICs may not necessarily be appropriate
in LMICs. Thus, WHO and others increasingly endorse
tailoring interventions found to be effective in HICs to LMICs,
followed by rigorous evaluation (Peden and others 2004).
Table 39.3 provides a summary of promising and recom-
mended interventions, as well as interventions that have
specifically been shown to be effective in LMICs.
Road Traffic Injuries
Many working to reduce RTIs use the “safer roads, safer vehi-
cles, safer people, and safer systems” motto. A recent augmenta-
tion of this motto derives from the recognition of the important
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Table 39.3 Continued
Interventions shown to be effective in 
Injury Promising interventions LMICs (references)
Poisonings
Fall-related injuries
Burn-related injuries
Drowning
Better storage, including positioning and nature of storage vessels
Use of child-resistant containers
Warning labels
First-aid education
Poison control centers
Older people
Muscle strengthening and balance retraining, individually prescribed
Tai chi group exercise
Home hazard assessment and modification for high-risk individuals
Multidisciplinary, multifactorial screening for health and environmental risk factors
Younger people
Multifaceted community programs of the Children Can’t Fly type
Fire-related injuries
Introducing programs to install smoke alarms
Separating cooking areas from living areas
Locating cooking surfaces at heights
Reducing the storage of flammable substances in households
Supervising children more effectively
Introducing, monitoring, and enforcing standards and codes for fire-resistant garments
Scald-related injuries
Separating cooking areas from play areas
Improving the design of cooking vessels
Fire- and scald-related injuries
Increasing awareness of burns prevention
Providing first-aid education
Limiting exposure to bodies of water close to dwellings, such as by fencing
Providing learn-to-swim programs
Providing education about risks for drowning
Increasing supervision and providing lifeguards at recreational facilities
Equipping boats with flotation devices and ensuring their use
Legislating and enforcing rules about the numbers of individuals carried on boats
Having trained and responsive coast guard services
Free distribution of child-resistant containers
(Krug and others 1994)
Source: Authors.
role of appropriate transport and land-use policies in managing
exposure to the risk of an RTI (Peden and others 2004).
Managing exposure to risk involves strategies aimed at
reducing motor vehicle traffic, encouraging the use of safer
modes of travel, and minimizing exposure to high-risk scenar-
ios, as outlined in greater detail in table 39.3. Evidence from
Malaysia shows that increasing the legal age of motorcyclists
from 16 to 18 has been beneficial (Norghani and others 1998),
but evidence of the effectiveness of many of the other strategies
is not yet available for LMICs.
Safer Roads. Intervention strategies focusing on safer roads
should incorporate safety awareness in planning road networks,
safety features in road design, and remedial action for high-risk
crash sites. HICs have adopted many of these strategies, and
though they have not been examined in rigorously controlled
studies, such strategies form the basis of best-practice guide-
lines and manuals now being used in LMICs (Ross and others
1991).
Traffic calming measures are among the strategies recom-
mended for incorporating safety features into road design.
Although evidence from randomized controlled trials is not
yet available (Bunn and others 2003), a before-and-after study
conducted in Ghana suggested that speed bumps were effective
in reducing traffic injuries, especially pedestrian injuries
(Afukaar, Antwi, and Ofosu-Amaah 2003). A recent summary
of research findings also suggests that automated speed
enforcement virtually eliminates speeding (ICF Consulting
Ltd. and Imperial College Centre for Transport Studies 2003).
Safer Vehicles. Strategies focusing on safer vehicles include
improving the visibility of vehicles, incorporating crash protec-
tive design into vehicles, and promoting further development
of “intelligent” vehicles. However, in LMICs, strategies that
simply ensure regular maintenance of older vehicles or removal
of vehicles in poor condition from the roads, as well as vehicle
licensing and inspection, have the potential to be cost-effective
(Peden and others 2004).
Meta-analyses of the effects of automatic daytime running
lights on cars consistently show that they reduce road crashes
(Elvik and Vaa 2004). Studies in both Malaysia and Singapore
show similar positive effects for daytime running lights on
motorcycles (Radin Umar, Mackay, and Hills 1996; Yuan 2000).
Although the fitting of seat belts—probably the most 
well-known and effective safer vehicle strategy—is covered by
technical standards worldwide and is mandatory in most coun-
tries, anecdotal evidence suggests that vehicles in many LMICs
lack functioning seat belts (Forjuoh 2003).
Safer People. Intervention strategies aimed at improving road
user behavior are increasingly focusing on the introduction
and enforcement of relevant legislation rather than on educa-
tional efforts. For example, Poli de Figueiredo and others’
(2001) research in Brazil indicates that increasing fines and
suspending drivers’ licenses immediately reduced RTIs and
deaths.
A large body of research, although little of it conducted in
LMICs, shows that setting and enforcing speed limits reduces
RTIs by up to 34 percent. It also shows that RTIs are reduced
in varying magnitudes by setting and enforcing legal blood
alcohol limits and minimum drinking-age laws, using alcohol
checkpoints, and running mass media campaigns aimed at
reducing drinking and driving (Peden and others 2004).
The introduction and enforcement of mandatory seat belt
and child restraint laws reduces occupant deaths and injuries
by up to 25 percent; however, such laws have not been intro-
duced in all LMICs (Peden and others 2004).
Both bicycle and motorcycle helmets reduce head injuries
among riders by up to 85 percent. Though education may be
effective in increasing helmet use, the effect is greater when
combined with legislation and enforcement, as demonstrated
in Malaysia and Thailand (Ichikawa, Chadbunchachai, and
Marui 2003; Supramaniam, Belle, and Sung 1984).
Poisonings
The prevention of unintentional poisonings includes consider-
ation of both occupational and nonoccupational poisonings;
however, chapter 60 provides a fuller discussion of effective
interventions in relation to work-related poisonings, so these
are not discussed here.
Suggested interventions to reduce exposure to nonoccupa-
tional poisonings include better storage of poisons in terms
of both the location and the nature of the storage vessels used.
Specific interventions include storing poisons outside the
home and above children’s head height and reducing the use
of secondhand household containers—for example soda
bottles—along with introducing and enforcing legislation to
prohibit the sale of poisons in such containers (Nhachi and
Kasilo 1994).
The efficacy of child-resistant containers in preventing access
to poisons has been demonstrated, and data from a controlled
before-and-after study in South Africa suggest that free distri-
bution of child-resistant containers is a highly effective means of
preventing poisoning in children (Krug and others 1994).
Fall-Related Injuries
Interventions proven effective for preventing falls by older peo-
ple in HICs include muscle strengthening and balance retrain-
ing that is individually prescribed at home by a trained health
professional; tai chi group exercise; home hazard assessment
and modification that is professionally prescribed for older
people with a history of falling; and multidisciplinary, multi-
factorial health and environmental risk factor screening and
intervention programs, both for community-dwelling older
people in general and for older people with known risk factors
(Chang and others 2004).
In relation to fall-related injuries among young children,
other than general recommendations about increased supervi-
sion of children and the importance of height reductions and
appropriate ground surfacing to prevent playground injuries,
only one intervention provides evidence of effectiveness that
may be relevant for LMICs. The Children Can’t Fly Program
has four major components, which include surveillance and
follow-up, media campaigns, community education, and the
provision of free, easily installed window guards to families
with young children living in high-risk areas (Spiegel and
Lindaman 1977). The program has been shown to be effective
in reducing falls in low-income areas.
Burn-Related Injuries
Evidence of the effectiveness of interventions to prevent fire-
related injuries is limited. A randomized controlled trial of a
smoke detector giveaway program in inner London was unable
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to show evidence of the program’s effectiveness on the incidence
of fires and fire-related injuries (DiGuiseppi and others 2002).
However, a more recent study suggests that installation pro-
grams may be more effective in increasing the use of these
alarms than giveaway programs alone (Harvey and others 2004).
Interventions that have been proposed but whose effective-
ness has not yet been proven include separating cooking areas
from living areas (including efforts to reduce the use of indoor
fires for cooking), ensuring that cooking surfaces are at heights,
reducing the storage of flammable substances in households,
and supervising young children more effectively (Forjuoh 2004).
The introduction, monitoring, and enforcement of standards
and codes for and the wearing of fire-retardant garments have
also been proposed (Bawa Bhalla, Kale, and Mohan 2000).
Evidence of the effectiveness of interventions to prevent
scald injuries is minimal but promising, although such inter-
ventions primarily focus on education, legislation, and enforce-
ment of efforts to regulate the temperature of water flowing
from household taps (Macarthur 2003).
Finally, interventions directed at increasing awareness of
burn prevention have been proposed, largely because of the
success of safe community interventions involving a multitude
of strategies (Ytterstad and Sogaard 1995).
Drowning
Evidence for the effectiveness of interventions to prevent
drowning is almost nonexistent. The only available data come
from case-control studies undertaken in HICs that suggest that
fencing domestic swimming pools reduces the risks of drown-
ing (Thompson and Rivara 2000). Extrapolation of those find-
ings to a low-income setting suggests that covering wells with
grills, fencing nearby lakes or riverbanks, and building flood
control embankments might be effective in reducing drowning.
COSTS, COST-EFFECTIVENESS, AND ECONOMIC
BENEFITS OF INTERVENTION 
Data on effective interventions for preventing unintentional
injuries in LMICs and on the economic costs of these injuries
are limited. As a result, published data on the costs, cost-
effectiveness, and economic benefits of interventions to prevent
unintentional injuries in LMICs are virtually nonexistent. The
economic evaluation of interventions and the measurement of
the economic costs of injuries therefore remain a high research
priority.
Some data are available from HICs on the costs and, in par-
ticular, the net economic benefits of interventions for RTIs.
Also, a body of evidence suggests that many of the interven-
tions designed to provide safer roads and vehicles, and to
improve driver behavior, have clear net economic benefits
(Peden and others 2004). Some data are also starting to emerge
from HICs with respect to the cost-effectiveness of fall-related
injury prevention programs for older people. However, data on
either the costs or the cost-effectiveness of interventions to pre-
vent poisonings, burns, or drownings are limited.
Cost-effectiveness studies done in HICs can only be sugges-
tive for LMICs, because the costs of property losses, disability,
and medical care are so vastly different. Furthermore, basic
efficacy is not always guaranteed when a control strategy that
worked in a modern city is exported to a poor LMIC village.
Consequently, the ability to extrapolate from high-income to
low-income countries is severely limited. Yet as middle-income
countries progress, they will begin to consider interventions
that have already been proven.
Despite the methodological challenges, we modeled the
cost-effectiveness of five potential interventions to prevent
unintentional injuries using information presented earlier on
known effective interventions in LMICs. In each case, the evi-
dence for effectiveness in an LMIC setting was strong. How-
ever, because so few interventions have been evaluated in
LMICs, we had to make certain assumptions to extrapolate
findings about costs and effectiveness in one LMIC setting to
other settings (for an outline of the assumptions associated
with this modeling, see Bishai and Hyder 2004). Our economic
analyses are highly generalized and indicative of what might be
achieved with the interventions considered.
For the analyses, we present all cost estimates in local cur-
rency converted to U.S. dollars (2001 exchange rates). We adopt
a societal perspective for each intervention, but if appropriate,
we comment on cost-effectiveness from a government perspec-
tive. The time horizon for each intervention is one year of sus-
taining the intervention. Costs are annualized so that a typical
year of operating the intervention is known. As with any inter-
vention, annual operating costs may fall as those involved learn
ways to carry out their tasks more efficiently. Each year of pro-
gram operation prevents an estimated number of deaths and
injuries. In each case, we present estimates of the raw numbers
of deaths and the undiscounted numbers of life years they rep-
resent. However, from an economic perspective, the life years
and DALYs of those who sustain nonfatal injuries count less
than the deaths. For comparability with other economic esti-
mates, and in accordance with the economic analysis guidelines
provided to authors, we discount estimates of DALYs using
both a 3 percent and a 6 percent discount rate. The 3 percent
discount rate is standard for economic evaluations in HICs;
however, a higher discount rate may be appropriate in LMICs.
Increased Penalties for Speeding and Other Effective Road
Safety Regulations
Poli de Figueiredo and others (2001) provide evidence from
Brazil on the effectiveness of an intervention to publicize and
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enforce traffic speed and other road safety regulations. This
intervention required three components—legislation to
impose stiffer penalties, media coverage of the new regime, and
better enforcement—and achieved a 25 percent reduction in
traffic fatalities between 1997 and 1998.
On the basis of a model of the costs of media coverage and
of better police enforcement, we estimate that implementing
such an intervention in a population of 1 million people might
range from as low US$8,100 in South Asia to US$196,000 in
LMICs in Europe and Central Asia (table 39.4). Those interven-
tion costs are incremental costs that assume that the population
already has 50 percent of the necessary police strength. We
define adequacy as one officer for every 5,000 vehicles and use
regional data on vehicles per 1 million people to estimate the
number of police officers and amount of equipment needed to
enforce traffic laws. The assumption is that after the interven-
tion the population will have enough officers to issue citations
to one-third of their beat’s 5,000 vehicles each year. This effort
would require them to write about 7 to 10 citations per work-
day. Using the estimates of traffic injury burdens in the regions
listed in the table and the potential to lower traffic deaths by
25 percent, as reported in the Brazilian study, we estimate
potential DALY reductions and cost per DALY averted (table
39.4; for details of the calculations see Bishai and Hyder 2004).
The cost estimates shown in table 39.4 do not include
potential cost offsets from savings derived by preventing
expenditures on medical care or vehicle repair. Including those
potential savings would lower the societal cost and enhance the
estimated cost-effectiveness. Those cost offsets will vary widely
by region. To demonstrate the importance of cost offsets, we
use data from Bangladesh, for which the Transport Research
Laboratory Ltd. (2003) has estimated the medical and property
costs of traffic crashes. On the basis of these estimates, we cal-
culate 1 fatality, 8 serious injuries, and 28 slight injuries occur
for every fatal crash in Bangladesh. Each serious injury is asso-
ciated with US$2,016 in costs for property, administration, lost
output, medical care, and pain and suffering, and each slight
injury incurs US$929 in similar costs (Bishai and Hyder 2004).
Thus, if we associate 1 prevented traffic fatality with preventing
8 serious injuries worth US$16,128 (8  US$2,016) and 28
slight injuries worth US$26,012 (28  US$929), then total
additional cost savings would amount to US$42,140.
If intervention costs in Bangladesh were close to the
US$8,105 shown in table 39.4 for South Asia, then the inter-
vention would save society more than it cost if it prevented only
one death and the expected proportion of nonfatal injuries. If
an enforcement intervention in Bangladesh were as effective
as the one documented in Brazil, it could lower fatalities by
25 percent. With 83 traffic fatalities per 1 million population,
the intervention could prevent 21 deaths and lead to net
savings of US$876,835—or (21  US$42,140)  US$8,105—
for every million population receiving this intervention.
Speed Bumps
A study in Ghana (Afukaar, Antwi and Ofosu-Amah 2003)
showed that road traffic fatalities fell by more than 50 percent
following the introduction of speed bumps. Because speed
bumps are usually most effective when installed at the most
hazardous junctions or near pedestrian crossings, planners
need to know which junctions are the most hazardous. We
assumed that half of a city’s crashes occur at junctions and that
cities have different numbers of treatable junctions. A few
junctions would have multiple fatalities per year, but most
would have one or zero fatalities per year. We assumed that the
number of fatalities per junction would be distributed as a
negative exponential to calculate how many junctions might
lack effective speed control modifications and could thereby
be targeted as those responsible for 10 percent or 25 percent of
a city’s preventable fatalities. Assuming a 10-year useful life for
a speed bump and using regionalized estimates of speed bump
construction costs, we modeled the annualized cost of con-
structing speed bumps at junctions responsible for 10 percent
or 25 percent of fatalities. As before, we lacked an evidence
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Table 39.4 Costs, DALYs, and Costs per DALY of an Intervention to Improve and Publicize Traffic Enforcement by Region 
(2001 US$)
Cost to intervene in a
Present value of annual DALYs averted Cost per DALY averted
population of 1,000,000 Discounted at Discounted at Discounted at Discounted at
Region for 1 yeara 3 percent per year 6 percent per year 3 percent per year 6 percent per year
East Asia and the Pacific 11,817 1,517 956 8 12
Europe and Central Asia 195,971 1,433 903 137 217
Latin American and the Caribbean 225,513 1,333 840 169 268
Middle East and North Africa 114,915 2,166 1,365 53 84
South Asia 8,105 1,528 963 5 8
Sub-Saharan Africa 24,518 2,003 1,370 12 18
Source: Authors’ calculations. 
a. Costs do not include cost offsets from prevented medical care and prevented vehicle repair. 
base from which to estimate cost offsets from prevented med-
ical care or vehicle repair and could not include those poten-
tial savings.
Table 39.5 presents the costs of DALYs saved and costs per
DALY saved by building speed bumps at the top 10 percent of
the most lethal junctions in a city of 1 million people. We
assumed the speed bumps could lower injuries by 50 percent,
as observed in the Ghana study. Given the low costs per DALY
averted and the typical high expenditures for medical care for
crash victims, we are confident that the medical savings to soci-
ety would more than offset the intervention’s costs, but we lack
the data to prepare complete estimates.
Bicycle Helmet Legislation and Enforcement
Thompson, Rivara, and Thompson’s (1989) case-control
study indicates that the effectiveness of a bicycle helmet for a
single rider is 85 percent. The effect on lives saved and DALYs
averted depends on how many people in a population ride
bicycles and the roadway environment for riders. Although
the degree of energy transferred to the brain in a crash and the
clinical efficacy of helmets may be the same worldwide, few
data are available on exposure and the bicycle crash burden in
LMICs. Thus, in modeling the effects of bicycle helmet legis-
lation, we were limited to assessing the case of the one coun-
try with adequate data on bicycle injury epidemiology: China.
In China, bicycle-related deaths kill 22 people per 1 million
population per year (Li and Baker 1997). Given estimates of
the annualized cost of helmet acquisition for all the bicyclists
in a Chinese population of 1 million and of the enforcement
costs of penalizing unhelmeted riders, we estimate that pro-
tecting bicyclists with helmets would cost US$265,000.
Assuming that China could convert from zero to 100 percent
adherence to helmet use, it could achieve an 85 percent reduc-
tion in head injuries from this intervention and would avert
2,478 DALYs at a 3 percent discount rate and 1,562 DALYs
at a 6 percent discount rate. Thus, the cost-effectiveness of
going from zero to 100 percent helmet use in China would be
US$107 (US$265,000/2,478) per DALY at a 3 percent discount
rate or US$170 (US$265,000/1,562) per DALY at a 6 percent
discount rate.
Motorcycle Helmet Legislation and Enforcement
As with bicycles, we have epidemiological data for China, where
motorcycle-related deaths kill 16 people per 1 million popula-
tion per year (Zhang and others 2004). We assume that a pop-
ulation of 1 million in China has 125,000 regular motorcyclists,
which will require the equivalent of half the time of a police
officer to cite 1 percent of them for helmet violations. At
Chinese salary levels, this effort would cost the equivalent of
US$7,500 per year. The helmets for this population would cost
US$250,000 at US$2 per year of helmet use. Thus, the total cost
of the intervention would be US$257,500. Assuming a mean
age of injury of 20 years and a disability weight of 0.4 for head
injury, we estimate the DALYs averted by motorcycle helmet
legislation as 589 at a 3 percent discount rate and 357 at a 6 per-
cent discount rate. This intervention therefore costs US$437
(US$257,500/589) per DALY based on a 3 percent discount rate
or US$721 (US$257,500/357) per DALY based on a 6 percent
discount rate.
Childproof Paraffin Containers
The use of childproof paraffin containers is relevant primarily in
Sub-Saharan Africa, where households use paraffin as a cooking
fuel and frequently store it in bottles previously used to store
beverages. Studies from South Africa have significantly
enhanced our understanding of the cost-effectiveness of distrib-
uting child-resistant containers. According to Krug and others’
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Table 39.5 Annualized Costs and DALYs of an Intervention to Build Speed Bumps for the Top 10 Percent of the Most Lethal
Junctions in a City of 1 Million, by Region 
Present value of annual 
Cost to intervene in DALYs averted (2001 US$) Cost per DALY averted (2001 US$)
population of 1,000,000 Discounted at Discounted at Discounted at Discounted at
Region for 1 yeara 3 percent per year 6 percent per year 3 percent per year 6 percent per year
East Asia and the Pacific 725 167 105 4.34 6.89
Europe and Central Asia 708 158 99 4.48 7.11
Latin American and the Caribbean 299 147 92 2.04 3.23
Middle East and North Africa 1,070 238 150 4.49 7.12
South Asia 324 168 106 1.93 3.06
Sub-Saharan Africa 498 220 151 2.26 3.30
Source: Authors’ calculations. 
a. Annual costs in local currency converted to US$ around 2001. Costs do not include cost offsets from prevented medical care and prevented vehicle repair. 
(1994) findings, a population of 1 million who used paraffin
regularly in South Africa experienced 1,040 poisonings a year.
After child-resistant containers were distributed, the incidence
dropped to 540, indicating that 500 poisonings per year had
been prevented. We therefore assume that (a) in a population of
1 million, child-resistant containers would need to be distrib-
uted to 200,000 households; (b) each child-resistant container
costs R 0.85 (US$0.33), including the costs of distribution; and
(c) total direct costs would be US$66,000 (200,000  US$0.33).
The average cost of treating a poisoned child in a South
African hospital was R 256.13 (US$100). Thus, indirect cost
savings would be US$50,000 (500  US$100), which would
partially offset the US$66,000 in direct costs, leading to a net
cost of US$16,000 to intervene. The mean age of children who
suffered poisoning in South Africa was 12 to 24 months.
Although no deaths were reported among children in the
South African study, the most common figure in the literature
is a 2 percent case fatality rate (Krug and others 1994), suggest-
ing that the prevention of 500 poisonings averted 10 deaths
among children around two years old. Life tables provided to
the authors for Sub-Saharan Africa show life expectancy at age
2 is 49 years; thus, the US$16,000 intervention could save
490 life years. Therefore, a rough estimate of the cost-effective-
ness of child-resistant containers as a way of preventing
paraffin poisoning in South Africa would be US$1,600
(US$16,000/10) per death averted.
Most survivors of paraffin poisoning do not suffer perma-
nent disability, and because we lack any objective means for
assigning disability weights to those who are disabled, we ne-
glect years lived with a disability in calculating DALYs. The
investment of US$16,000 thus results in 10 children surviving
for 49 more years. Undiscounted, this is 490 (10  49) life
years. The impact is 263 DALYs averted at a 3 percent discount
rate or 166 DALYs averted at a 6 percent discount rate. The
cost-effectiveness is US$61 (US$16,000/263) per DALY at a
3 percent discount rate or US$96 (US$16,000/166) per DALY
at a 6 percent discount rate.
Summary
Estimated costs per DALY from the interventions considered
here range from negative (that is, savings) to a few hundred
U.S. dollars per DALY. The order of magnitude of the costs per
DALY averted using these injury countermeasures suggests that
they could be categorized as highly cost-effective (Murray and
others 2000). Our estimates of intervention costs neglect the
potential savings from prevented medical spending but still
appear quite promising. Although our estimates provide some
indicative information about the economic properties of coun-
terinjury interventions, these findings point primarily to the
lack of information about the global economic burden of injury
that could enable more comprehensive estimates.
IMPLEMENTATION OF PREVENTION
AND CONTROL STRATEGIES 
Investments in the health sector to address specific problems are
a critical indicator of political commitment, sectoral efforts,
and priorities at the national and international levels. In some
cases, investments are so low that they provide a useful reference
point for assessing the returns on additional investments in the
future. Such a situation has been described as a null point in
health systems, and current expenditures on injury prevention
and control in LMICs approximate this concept (Murray and
others 2000).
This concept can be illustrated by considering investments
in preventing RTIs, which are responsible for the majority of
the burden of unintentional injuries and about which much
is known regarding effective interventions, even though such
interventions have not been examined in the context of rigor-
ously controlled studies in LMICs (see box 39.1).
Peden and others (2004) recognize that, despite the global
burden of RTIs, the levels of investment are pitifully small,
largely because of a lack of awareness of the scale of the prob-
lem and a lack of awareness that interventions can prevent and
reduce the levels of harm. As a consequence, the report directs
a number of recommendations at governments and communi-
ties in the hope that these recommendations will enable coun-
tries, particularly LMICs, to begin a sustainable process that
will eventually lead to the adaptation and implementation of
effective preventive strategies. The recommendations include
the following:
• Identify a lead government agency to guide the national
road safety effort.
• Assess the problems, policies, and institutional settings
relating to RTIs and the capacity for preventing RTIs in each
country.
• Prepare a national road safety strategy and plan of action.
• Allocate financial and human resources to address the
problem.
• Implement specific actions to prevent crashes, minimize
injuries and their consequences, and evaluate the effect of
those actions.
• Support the development of national capacity and interna-
tional cooperation.
Although few data are available to show the levels of invest-
ment in other areas of unintentional injury prevention, those
levels are no doubt considerably lower than for RTIs. With
increases in the proportions and numbers of older people in
many LMICs, the burden of fall-related injuries is likely to
increase significantly in the coming years. Recognition of the
changing demographics in countries such as China, Mexico,
and Thailand plus a growing body of evidence on effective
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interventions to prevent falls suggest that investments in this
area could lead to significant benefits. Similarly, increasing
recognition of the significance of the burden of drowning in
children is leading to growing awareness of the need to invest
in that area. However, the absence of any effective evidence-
based interventions may be a barrier to further investment,
suggesting that research into the burden of drowning must be
a priority.
Investment in prevention and control activities in other
areas of unintentional injuries is minimal in most LMICs, in
large part because the burden of those injuries is unrecognized
and because evidence of effective interventions is lacking.
Therefore, there is clearly a need to consider the development,
implementation, and evaluation of prevention strategies in
combination, so that effective interventions can be identified
and promulgated and so that ineffective interventions can be
identified and discarded.
RESEARCH AND DEVELOPMENT AGENDA 
The Global Forum for Health Research (2002) estimates that of
the US$73.5 billion spent on health research globally in 1998,
less than 10 percent was spent on addressing problems related
to 90 percent of the world’s population. Analyses revealed that
RTIs were a highly neglected area for investment compared
with the burden of disease RTIs represented as measured in
U.S. dollars per DALY. As a result, increasing the level of invest-
ment for research and development (R&D) on RTIs and other
injuries should be a focus of global advocacy efforts, and
investment is critical for promoting an R&D agenda on injuries
in LMICs.
Developing and prioritizing a global R&D agenda for unin-
tentional injuries, though, is challenging, and such an exercise
may be more useful at national or large subnational levels.
However, a number of issues requiring R&D are likely to be
common across a range of LMICs.
Epidemiological research to describe the existing burden,
causes, and distribution of unintentional injuries in LMICs
is still needed. Often the data are most limited for areas with
the greatest potential burden of injuries. Assessing the loss of
health and life from unintentional injuries—whom they affect,
how, and under what specific circumstances—is thus a
continuing research agenda for LMICs. Problems of underre-
porting and other biases in available data also need to be
addressed.
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Implementation: Case Study of RTIs
Box 39.1
Bishai and others (2003) quantify the magnitude of gov-
ernment investment in road safety and the extent of RTIs
in Pakistan and Uganda. They estimate that Pakistan spent
$0.07 per capita, or 0.015 percent of gross domestic prod-
uct (GDP) per capita, on road safety in 1998 and that
Uganda spent $0.09 per capita, or 0.02 percent of GDP per
capita. This type of evidence stands in stark contrast with
the high burden of RTIs in these countries.
These findings occur in the context of public expendi-
ture on health of 1.8 percent of GDP by Pakistan and
1.6 percent by Uganda (UNDP 1998). Per capita health
spending by households in Uganda was $7.70 in 1995/96,
and public spending on health at the district level was
$4.84 per capita in 1997/98 (Hutchinson 1999). Public
spending on road safety amounts to about 1 percent of
public spending on health in each country. It is equivalent
to 0.2 percent of military spending in Pakistan and
1.1 percent of Uganda’s military budget.
A review of road safety initiatives in Benin, Côte
d’Ivoire, Kenya, Tanzania, and Zimbabwe found similar
underinvestment in road safety and attributes this insuffi-
cient investment to conflicts between government min-
istries, inefficient civil services, and corruption rather than
to a lack of knowledge about possible road crash counter-
measures (Assum 1998).
RTIs have an inverted U-shaped relationship to eco-
nomic development—injuries rise early during develop-
ment, then plateau with investments in road safety, and
then fall as appropriate interventions succeed (van Beeck,
Borsboom, and Mackenbach 2000). This biphasic pattern
is known as a Kuznets curve. Attempts to estimate a
Kuznets curve for road fatalities suggest that the inflection
point at which fatalities begin to decline occurs at GDP per
capita in the range of $5,000 to $10,000 (Bishai and others,
forthcoming; Kopits and Cropper 2005). This relationship,
although based on historical records from HICs, has an
important lesson for LMICs: they do not need to experi-
ence massive death and disability from RTIs provided that
they undertake safety investments now. Waiting for overall
economic development before implementing specific
interventions will result in the needless loss of millions of
lives.
Note: All dollars in box 39.1 are 1998 international dollars.
The lack of intervention research in LMICs is a huge gap in
global health research. For the most part, no scientific trials
of injury interventions have been conducted in LMICs, and
existing and new interventions need to be modified, adapted,
and tested in those specific settings. Three broad domains
should be the foci of intervention research:
• R&D to enhance the efficiency of currently available effica-
cious interventions. For example, increasing the use of hel-
mets would prevent motorcycle injuries in East Asia.
• R&D to enhance the cost-effectiveness of interventions that
are currently not being implemented or that could be used
more widely. For example, seat belts and child restraints are
known effective interventions, and reducing the cost of such
interventions might enhance their wide-scale implementa-
tion in LMICs.
• R&D to develop new interventions for unintentional
injuries and to respond to that proportion of the burden
that is not currently being addressed. For example, child-
hood falls from rooftops in South Asia have been recognized
as an issue, but a locally derived intervention is currently
unavailable.
Although some might argue that intervention research
should be the priority in most LMICs, unless the basic under-
pinning research on the burden and determinants of uninten-
tional injuries has been undertaken, the political and financial
support for such research will not be forthcoming.
The dearth of economic and policy analysis of unintention-
al injuries in LMICs is an embarrassment for the global health
research community. A recent review of economic analysis of
road traffic interventions found a complete absence of any
detailed studies from the developing world (Waters, Hyder and
Phillips 2004). This gap in health systems research would need
to be addressed to develop and implement successful injury
prevention programs.
Defining a research agenda is necessary but is not by itself
sufficient to conduct research or to implement the results. Two
key conditions are required for moving forward: a critical mass
of people to conduct research and appropriate funds to support
R&D. Developing human resources for all aspects of injury pre-
vention and control in the developing world should be a high
priority. Individuals need to be trained and institutions sup-
ported and empowered to conduct quality scientific research in
their own countries and on issues relevant to their locations,
which would then be used within their countries. This
approach involves paying attention to the issue of strengthen-
ing the capacity for research, a major cross-cutting theme for
the health sector in the developing world.
Funding is and always will be a limiting factor for research;
however, the mismatch between the burden of injuries and
R&D investments can be corrected. Unintentional injuries are
a major health problem. They cause preventable loss of life and
health, and they have major economic implications. As a result,
R&D investments are a health and economic imperative for
developing countries and donor organizations.
CONCLUSIONS: PROMISES AND PITFALLS 
Unintentional injuries are an important contributor to global
death and disability burdens, especially in LMICs. However,
the significance of the burden is not matched by substantive
knowledge about risk factors or effective interventions in
LMICs. Nevertheless, the models outlined in this chapter indi-
cate that several interventions for preventing unintentional
injuries are highly cost-effective and in some cases could result
in significant cost savings.
Recent evidence shows that public efforts in injury control,
such as traffic safety, are poorly funded in developing countries
(Bishai and others 2003). The low expenditure compares unfa-
vorably with expenditure on other health conditions and with
expenditures in more developed nations, where government
efforts in relation to such issues as traffic safety are well funded.
Even adjusting for the 20-fold to 30-fold difference in gross
domestic product per capita between HICs and LMICs, the
investment disparities suggest that LMICs attach a low priority
to injury prevention.
Given the current low level of investment, initial invest-
ments in safety, if chosen with care, could turn out to be
extremely beneficial to public health and welfare. If, in the first
instance, investments were to be made only in the interventions
modeled here, then injury reductions would likely be signifi-
cant. The next step would be to modify other interventions that
have proven effective in HICs and to combine the introduction
of such interventions with evaluations of their effects. Policy
makers will be concerned that many of the cost-effective inter-
ventions are not low-cost interventions. They save many lives
but require an extensive upfront investment. Using cost-
effectiveness analyses of these interventions to document high
returns would encourage financing of these interventions and
widespread replication efforts.
Policy makers would be unwise to wait for advanced stages
of economic development to attend to the problem of road
safety or other unintentional injuries. Indeed, given the limited
but growing knowledge that low-cost, effective interventions
exist, for governments not to intervene would be unethical.
Even though institutional obstacles are formidable in develop-
ing countries, governments routinely overcome them to
address other perceived threats to public well-being—such as
crime, terrorism, and war—that disrupt fewer lives than unin-
tentional injuries. The real enigma is that such a profound loss
of life can take place each year in LMICs without an outcry that
would trigger sustained and effective political commitment by
governments and civil society.
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Violence kills more than 1.6 million people each year. The
impact of nonfatal violence cannot be quantified, but it is even
more pernicious given resultant disabilities and long-term
physical, psychological, economic, and social consequences.
The direct and indirect costs of violence are enormous.
Violence directly affects health care expenditures worldwide.
Indirectly, violence has a negative effect on national and local
economies—stunting economic development, increasing eco-
nomic inequality, eroding human and social capital, and
increasing law enforcement expenditures (Waters and others
2004).
The U.S.-based Centers for Disease Control and Prevention
identified violence as a leading public health problem in the
mid 1980s and early 1990s (Rosenberg 1985; Rosenberg and
Fenley 1991), as did the World Health Assembly in 1996
(Resolution WHA49.25). Contributing to the World Health
Organization (WHO) report on global violence and health,
Dahlberg and Krug (2002) divided violence into the following
categories:
• self-directed violence, or violence in which the perpetrator
is the victim (for example, suicide) 
• interpersonal violence, or violence inflicted by another indi-
vidual or a small group of individuals
• collective violence, or violence committed by larger groups,
such as states, organized political groups, militia groups, and
terrorist organizations.
This chapter focuses on interpersonal violence, which dis-
proportionately affects low- and middle-income countries
(LMICs).1 The WHO report on violence and health estimates
that more than 90 percent of all violence-related deaths occur in
LMIC countries (Dahlberg and Krug 2002). The estimated rate
of violent death in LMICs was 32.1 per 100,000 people in 2000,
compared with 14.4 per 100,000 in high-income countries.
This chapter is based on a public health approach to pre-
venting interpersonal violence. A public health approach has
three overriding characteristics: it applies scientific methodol-
ogy, emphasizes prevention, and encourages collaboration.
Applying a scientific methodology to a public health appro-
ach involves collecting and analyzing data to define the magni-
tude, scope, and characteristics of the problem, examining the
factors that increase or decrease the risk for violence, and iden-
tifying the factors that can be modified through interventions.
Interventions are designed, tested, and evaluated. Efficacious
and promising interventions are implemented, and their effects
and cost-effectiveness are evaluated. Ongoing monitoring of
intervention effects on risk factors and target problems builds
the database to allow quantitative assessment of successes and
clear identification of remaining needs.
Fundamentally, public health is focused on prevention of
harm caused by disease or violence. Although criminal justice
systems have traditionally focused on capturing perpetrators
of violence and punishing them for their actions (typically
through incarceration), the public health system attempts to
prevent violence from occurring and concentrates on identify-
ing ways to keep people from committing acts of violence.
Interventions may eliminate or reduce the underlying risk fac-
tors and shore up protective factors. Prevention strategies are
conceived and implemented with reference to the interaction
of risk factors among people at different stages of the life cycle
(Mercy and Hammond 1999; additional sources online).
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A public health approach must be collaborative, drawing
on contributions from different sectors and disciplines. Public
health analyses of violence aim to encourage integrated actions
by diverse sectors such as health, education, social services, and
justice. Each sector has a role to play, and collectively their
actions have the potential to reduce violence.
THE NATURE, BURDEN, AND CAUSES
OF INTERPERSONAL VIOLENCE
WHO (WHO Global Consultation on Violence and Health
1996, 2–3) defines violence as follows: “The intentional use of
physical force or power, threatened or actual, against oneself,
another person, or against a group or community that either
results in or has a high likelihood of resulting in injury, death,
psychological harm, mal-development, or deprivation.” This
definition emphasizes that, for the act to be classified as vio-
lence, a person or group must intend to use force or power
against another person. Thus, violence is distinguished from
unintended incidents that result in injury or harm.
The nature or mode of violence may be physical, sexual, or
psychological, or it may involve deprivation and neglect. Given
the difficulties of measuring deprivation and neglect, this chapter
concentrates on the physical, sexual, and psychological modes.
Acts of interpersonal violence are classified as family vio-
lence or community violence. Family violence is further cate-
gorized by victim: child, intimate partner, or elder. Child abuse,
as defined by WHO (1999, 15), is “physical and/or emotional
ill-treatment, sexual abuse, neglect or negligent treatment or
commercial or other exploitation, resulting in actual or poten-
tial harm to the child’s health, survival, development, or dignity
in the context of a relationship of responsibility, trust, or
power.” Behavior within an intimate relationship that causes
physical, psychological, or sexual harm is typically labeled inti-
mate partner violence or domestic violence. Elder abuse is mis-
treatment of older people, generally those older than age 60 or
65, in the home or in an institutional setting.
Community violence is categorized by two types of perpe-
trators: acquaintances and strangers. It includes sexual assault
by strangers and violence in institutional environments, such as
residential care facilities, jails, workplaces, and schools. Youth
violence, with perpetrators and victims typically 10 to 29 years
of age, is also a form of community violence.
Outcomes of Interpersonal Violence
Identifying the outcomes of interpersonal violence helps to
determine the magnitude of the problem.
Data. As noted earlier, a fundamental aspect of the public
health approach is the collection of accurate information, such
as demographic characteristics of victims and perpetrators,
weapon involvement, settings in which violence occurs, situa-
tional determinants, and nature and severity of resultant
injuries and other harm. Data sources include death certifi-
cates, vital statistics records, medical examiners’ reports, hospi-
tal and other medical records, police and judiciary records, and
self-reported information from victim surveys and special
studies. Multiple data sources, with their inherent strengths
and limitations, are essential.
The most widely encountered sources of information are
from the health and criminal justice sectors. Reliable data on
violent deaths are not routinely collected in most countries.
Where data collection systems are in place, coroner and mortu-
ary reports, death certificates, and vital statistics records usually
provide additional data about the victim. The health sector typ-
ically documents characteristics of the decedent and the cause,
location, circumstances, and time of death. The criminal justice
sector documents deaths or arrests resulting from interpersonal
violence, including sometimes recording information about the
relationship between the victim and the offender, the circum-
stances surrounding the violence, and the demographics of the
perpetrator.
Theoretically, health and criminal justice sector data include
information about nonfatal violence at all levels of severity,
including threats of violence and instances of psychological vio-
lence, deprivation, and neglect. In practice, however, only data
about violence-related injuries presenting at hospital emergency
departments are collected. Studies from a variety of coun-
tries show that for every victim reporting violence to the
police, at least two more present only at health agencies
(Houry and others 1999; Kruger and others 1998; Sutherland,
Sivarajasingam, and Shepherd 2002; additional sources online).
Victims of nonfatal violence treated by the health sector may
provide information about the perpetrator-victim relationship,
about the circumstances surrounding the attack, and about
contextual and developmental risk factors. However, the health
sector is frequently restricted in recording information about
perpetrators.
In LMICs, population-based surveys are a more useful
source of information about violence-related injuries at all
severity levels (Sethi, Habibula, and others 2004). Such surveys
have been conducted in Bangladesh (Rahman, Andersson, and
Svanstrom 1998); Colombia (Duque, Klevens, and Ramirez
2003); Iraq (Roberts and others 2004); Pakistan (Ghaffar 2001);
South Africa (Butchart, Kruger, and Lekoba 2000; additional
sources online); and Uganda (Kobusingye, Guwatudde, and
Lett 2001). Demographic and health surveys with questions
about violent victimization also collect information about the
relationship between violence and other health conditions, but
they can provide only limited insight into the perpetrators.
Hospital emergency departments have been used in some
postconflict settings to monitor weapons-related injuries
and evaluate the relative contributions of collective and
interpersonal violence to the caseload (Meddings and
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O’Connor 1999; Michael and others 1999). Some developing
countries, such as Bangladesh, Kenya, and Uganda, also use
violence and injury surveillance systems based in health facili-
ties to monitor hospitalizations resulting from violence and
other causes of injury (Kobusingye and Lett 2000; Odero and
Kibosia 1995; Rahman and others 2001). Where emergency
and forensic medical services are reasonably well developed
and where access to such services is equitable, violence and
injury surveillance tools have been integrated into hospital
emergency departments (Hasbrouck and others 2002; addi-
tional sources online), prenatal clinics (Dunkle and others
2004), forensic service centers for rape victims (Swart and oth-
ers 2000), and mortuaries (Butchart and others 2001). Those
efforts have proven effective in obtaining victim-based,
descriptive epidemiological information and insights into the
relationships between victims and perpetrators.
Deaths Resulting from Interpersonal Violence. Global bur-
den of disease estimates indicate that, in 2001, approximately
1.6 million people died as a result of violence. Of those deaths,
34 percent were due to interpersonal violence (table 40.1).
Rates and patterns of violent death vary by country and
region (figure 40.1). Homicide rates were highest in developing
countries in Sub-Saharan Africa and Latin America and the
Caribbean and lowest in East Asia, the western Pacific, and
some countries in northern Africa. Studies show a strong,
inverse relationship between homicide rates and both eco-
nomic development and economic equality (Butchart and
Engstrom 2002; Fajnzylber, Lederman, and Loayza 2000).
Poorer countries, especially those with large gaps between the
rich and the poor, tend to have higher rates of homicide than
wealthier countries.
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Table 40.1 Estimated Violence-Related Deaths, by Type
and Region, 2001
Rate Proportion
per 100,000 of total
Category Numbera populationb (percent)
Suicide 875,000 15.2 53.3
Homicide 557,000 9.3 34.0
War-related fatality 208,000 3.5 12.7
Total 1,640,000 28.0 100.0
LMICs 1,489,000 31.0 90.8
High-income countries 150,000 14.3 9.2
Source: Mathers and others 2006.
a. Rounded to the nearest thousand.
b. Age standardized.
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Figure 40.1 Homicide, Suicide, and War-Related Fatality Rates, by Region, 2001
Homicide rates differ markedly by age and sex (table 40.2).
Gender differences were least marked for children. For the 15 to
29 age group, male rates were nearly six times those for female
rates; for the remaining age groups, male rates were from two
to four times those for females. Female homicide rates doubled
after age 14 and gradually but steadily increased with age, and
male rates increased more than 14 times after age 14, peaked in
the 15 to 29 age group, and then gradually decreased with age.
Overall,homicides resulted in the deaths of 3.4 males per female.
Violence-Related Burden of Disease. The sum of years of
potential life lost because of premature mortality and years of
productive life lost because of disability is not a particularly
useful measure of the burden of violence. Disability-adjusted
life years rely, in part, on estimates of nonfatal events. In the
case of violence, those estimates are restricted to injuries and
physical disabilities, both markedly underreported. In addition,
given that psychological and other noninjury health conse-
quences of violence are substantial, failure to include them in
the measurement of disability-adjusted life years means that
estimates of the nonfatal burden of violence may be grossly
underestimated.
Violence-related morbidity can be analyzed as four distinct,
but often co-occurring, outcome clusters: injuries and disabili-
ties, mental health and behavioral consequences, reproductive
health consequences, and other health consequences.
Studies in a number of countries show that, for every homi-
cide among young people age 10 to 24, 20 to 40 other young
people receive hospital treatment for a violent injury (Mercy
and others 2002). Injuries range from minor, which can be self-
treated, to severe. Severe injuries are those that may require
resource-intensive emergency medical treatment and inpatient
care and may result in lifelong disabilities, such as amputations,
brain damage, or paraplegia. Few countries have information
systems for monitoring nonfatal violent injuries, and existing
systems typically record only data on violent injuries present-
ing at hospital emergency departments. Data from those sites
cannot be directly compared, given the marked differences
between and within countries in the availability and accessibil-
ity of emergency medical services.
The mental health consequences of violence are far reach-
ing. Child abuse has well-documented sequelae of psychiatric
disorders and suicidal behaviors (Runyan and others 2002).
Both short- and long-term sequelae have been demonstrated
(Mercy and others 2002, Heise and Garcia-Moreno 2002),
including depression, anxiety disorders, substance abuse disor-
ders, aggression, cognitive problems, sleep disorders, and post-
traumatic stress disorder. The severity and duration of those
consequences vary with the child’s age and the length of time
the child suffers the abuse, as well as the duration and intensi-
ty of the abuse, the child’s relationship to the abuser, and the
treatment received (Runyan and others 2002).
Intimate partner violence results in an increased incidence
of suicide and suicide attempts, as well as in depression, anxi-
ety, and phobias (Heise and Garcia-Moreno 2002). Additional
consequences include substance abuse, eating and sleep disor-
ders, poor self-esteem, posttraumatic stress disorder, psycho-
somatic disorders, and risky sexual behaviors. Sexual assault
results in consequences that can be long lasting and severe,
including posttraumatic stress disorder, depression, and con-
duct disorders, as well as sleep and eating disorders (Jewkes,
Sen, and Garcia-Moreno 2002).
According to Jewkes, Sen, and Garcia-Moreno (2002),
among adolescents and women age 12 to 45, the frequency of
pregnancy as a result of rape varies from 5 to 18 percent. In
addition, younger rape victims often have an increased rate of
later, unintended pregnancies. Rape frequently results in gyne-
cological problems, problems of sexual functioning, and sexu-
ally transmitted diseases, including HIV infection. HIV infec-
tion and the stigma it carries put both female and male victims
of sexual assault at increased risk of further violence. A similar
range of reproductive health consequences may also follow
intimate partner violence.
A strong, graded relationship exists between the breadth of
exposure to abuse or household dysfunction during childhood
and the presence of adult diseases, including ischemic heart
disease, cancer, chronic lung disease, skeletal fractures, and liver
disease (Felitti and others 1998). In developed countries, abuse
and other violent events of childhood have been associated
with a 4- to 12-fold increased risk for alcoholism, drug abuse,
depression, and suicide attempt; a 2- to 4-fold increased risk for
smoking, poor self-rated health, 50 or more sexual intercourse
partners, and sexually transmitted disease; and a 1.4- to 1.6-
fold increased risk for physical inactivity and severe obesity
(Anda and others 1999; Dietz and others 1999; Dube and
others 2001, 2002; Hillis and others 2000, 2001; Williamson
and others 2002). Similar exposures to violence in developing
countries may have different, yet equally wide-ranging, impacts
beyond direct physical and psychological injuries.
Data on Violence in Developing Countries
Studies documenting the human and economic toll of violence
in LMICs are strikingly scarce. In addition to disparate levels
of economic development, other differences between countries
strongly influence levels and patterns of interpersonal violence
and the toll that such violence takes on society. Countries with
weak governments and institutions are at considerably higher
risk for interpersonal violence than countries with developed
institutions, and countries at war are likewise at higher risk than
countries at peace. The same factors that lead to high levels of
interpersonal violence—lack of economic development; weak
social, political, and judicial institutions; social disturbances;
and warfare—also adversely affect nations’ ability to collect data
and to address the causes or consequences of this violence.
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Table 40.2 Estimated Global Homicide and Suicide Rates,
by Age Group, 2001
(number per 100,000 population) 
Homicides Suicides
Age Males Females Males Females
0–4 years 2.1 2.0 0.0 0.0
5–14 years 1.6 1.5 1.4 1.1
15–29 years 23.1 3.9 18.9 13.2
30–44 years 20.9 4.7 22.9 13.0
45–59 years 16.5 5.0 29.0 15.8
60 years 12.6 5.4 41.7 20.8
Total 14.3 3.7 17.7 10.7
Source: Mathers and others 2006.
Risk Factors for Understanding Violence
Risk factors for violence are conditions that increase the pos-
sibility of becoming a victim or perpetrator of violence. No
single factor explains why a person or group is at a high or low
risk of violence. Rather, violence is an outcome of a complex
interaction among many factors. This relationship is captured
in an ecological model that classifies risk factors for violence by
four levels: individual, relationship, community, and societal
(Dahlberg and Krug 2002). Although some risk factors may be
unique to a particular type of violence, the various types of
violence more commonly share a number of risk factors
(table 40.3).
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Table 40.3 Risk Factors for Becoming a Victim or Perpetrator of Violence
Level of the ecological model Risk factors
Individual 
(biological and personal history factors
that influence how individuals behave)
Relationship 
(with family members, friends, intimate
partners, peers)
Community 
(neighborhoods, schools, workplaces)
Societal 
(broad factors that reduce inhibitions
against violence)
Early developmental experience
Demographic characteristics (for example, age, education, family, or personal income)
Victim of child abuse and neglect
Psychological and personality disorders
Physical health and disabilities
Alcohol or substance abuse problems
History of violent behavior
Youth
Male
Gun ownership
Marital conflicts around gender roles and resources
Association with friends who engage in violent or delinquent behavior
Poor parenting practices
Parental conflict involving use of violence
Low socioeconomic status of household
High residential mobility
High unemployment
High population density
Social isolation
Proximity to drug trade
Inadequate victim care services
Poverty
Weak policies and programs in, for example, workplaces, schools, residential care facilities
Rapid social change
Economic inequality
Gender inequality
Policies that create and sustain or increase economic and social inequalities
Norms that give priority to parents’ rights over child welfare
Norms that entrench male dominance over women
Poverty
Weak economic safety nets
Poor rule of law
Poor criminal justice system that supports the use of excessive violence by police officers against citizens and
leaves perpetrators immune from prosecution
Social or cultural norms that support violence
Availability of means (for example, firearms)
Conflict or postconflict situation
Source: Krug and others 2002a.
ECONOMIC IMPACT OF VIOLENCE 
Violence exacts an extraordinary economic toll.
Costs of Violence
Estimates of the costs of violence vary broadly, with many of the
differences resulting from the inclusion or exclusion of different
categories. Cost categories can be broadly grouped into direct
costs, which result directly from acts of violence or attempts to
prevent them, and indirect costs, which include the opportunity
cost of time, lost productivity, and impaired quality of life.
Those and other methodological issues lead to differing
estimates of the costs of violence.2 Researchers have calculated
the value of a human life using lost wages, estimates of the
quality of life, wage premiums for risky jobs, willingness to pay
for safety measures, and individual behavior related to safety
measures. The value of human life used in U.S. studies ranges
from US$3.1 million to US$6.8 million (Fisher, Chestnut, and
Violette 1989; Viscusi 1993; additional sources online). The rate
used to discount future costs and benefits also varies, generally
from 2 to 10 percent.3
Fromm (2001) reviews a variety of sources and calculates an
aggregate total of US$94 billion in annual costs to the U.S.
economy resulting from child abuse, which is equal to 1 percent
of gross domestic product (GDP). The estimate includes direct
medical costs and related costs of legal services, policing, and
incarceration, as well as the value of indirect productivity
losses, psychological costs, and future criminality. Using sec-
ondary sources, Courtney (1999) calculates direct costs of
US$14 billion, including counseling and child welfare services,
resulting from child abuse in the United States.
The Centers for Disease Control and Prevention (CDC
2003) cite an estimated 5.3 million victimizations involving
intimate partner violence each year in the United States among
women 18 and older, resulting in nearly 2 million injuries.
More than 550,000 of those injuries require medical attention.
The costs of intimate partner violence, including medical care,
mental health care, and lost productivity, exceed US$5.8 billion
annually.
As a percentage of GDP, estimates of the costs of intimate
partner violence are considerably higher in LMICs than in
high-income countries. Morrison and Orlando (1999) calcu-
late the costs of domestic violence against women on the basis
of stratified random samples of women. Using only the lost
productive capacity of the women, they extrapolate total costs
of US$1.73 billion in Chile and US$32.7 million in Nicaragua.
In a subsequent publication, Buvinic and Morrison (1999) cal-
culate that the direct medical costs plus lost productivity are
equivalent to 2.0 percent of GDP in Chile and 1.6 percent of
GDP in Nicaragua.
Several studies have used the U.S. National Crime
Victimization Survey, an annual survey based on 100,000 inter-
views with crime victims, to estimate the incidence and calcu-
late the direct costs of sexual assault. For example, Miller,
Cohen, and Rossman (1993) calculate average psychological
costs of US$66,600 for each rape and total costs of US$85,000
for sexual assault resulting in physical injury. Psychological
costs, also referred to as “pain and suffering,” are considered
indirect costs. Because many studies do not include those types
of costs, cost estimates vary widely.
Violence at the workplace also extracts an economic toll, but
studies of its magnitude are not well developed and are ham-
pered by measurement difficulties and nonstandardized
methodologies. Biddle and Hartley (2002) study homicides in
the workplace in the United States and calculate an annual cost
of approximately US$970 million. An international report
commissioned by the International Labour Organization on
the costs of violence and stress in work environments estimates
that losses from stress and violence at work are equivalent to
1.0 to 3.5 percent of GDP over a range of countries (Hoel,
Sparks, and Cooper 2001). All those studies use a broad defini-
tion of workplace violence, including psychological violence
such as sexual harassment and bullying.
Violence committed by juveniles is particularly costly to
society. Miller’s (2001) analysis of violent crimes committed in
Pennsylvania in 1993 finds that juvenile violence accounted
for 24.7 percent of all violent crimes and 46.6 percent of total
victim costs from violent crime. Cohen (1988) calculates that
the total cost to society of a youth engaging in a life of crime
ranges from US$1.9 million to US$2.6 million.
Proximate Risk Factors
Alcohol, drugs, and guns contribute to the costs of interper-
sonal violence. According to estimates by the Children’s Safety
Network Economics and Insurance Resource Center (1997),
the cost of violent crime committed under the influence of
alcohol equaled US$33.3 million in 1995, or 8.3 percent of the
cost of all violent crime in the United States. The National
Crime Prevention Council (1999) estimates that the cost of all
drug-related crime, including productivity costs, amounts to
US$60 billion to US$100 billion annually in the United States,
with violent crime accounting for approximately 10 percent of
this figure.
Cook and Ludwig (2000) estimate that the annual costs of
gun violence in the United States are on the order of US$100 bil-
lion. Miller and Cohen (1997) calculate a significantly higher
estimate for the toll of gun-related violence in the United
States: US$155 billion (including psychological costs and the
value of quality of life). They also calculate that, on a per capita
basis, the cost of gun violence in Canada equals one-third of
the U.S. cost. Peden and van der Spuy’s (1998) study at the
Groote Schurr Hospital in Cape Town, South Africa, finds that
direct medical costs averaged R 30,628 (US$10,308) per gun-
shot victim.
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Effects on Public Finances
The public sector (and thus society in general) bears many of
the costs of interpersonal violence. Several studies (Klein and
others 1999; Payne and others 1993; additional sources online)
find that 56 to 80 percent of U.S. health care costs for stabbing
and gun injuries are either directly paid by public financing
or are not paid at all. In the latter case, government and society
absorb the costs in the form of uncompensated care financ-
ing and overall higher payment rates. In LMICs, society likely
also absorbs the costs of violence through direct public
expenditures and negative effects on investment and economic
growth.
INTERVENTIONS
The evidence base of ways to prevent violence is expanding
rapidly, but huge gaps remain in relation to effective strategies
for reducing the health burden associated with interpersonal
violence. The greatest strides have come in the areas of youth
violence and child abuse, and almost all the prevention knowl-
edge has been developed in high-income countries. Despite
those limitations, an understanding of the epidemiology and
etiology of violence and prevention provides important
insights into the spectrum of policies and interventions that
can be drawn on to prevent violence in LMICs.
Violence Prevention Strategies
The many commonalities among the various forms of violence
in relation to their epidemiology and etiology suggest that
common pathways to prevention may be available (Reza,
Mercy, and Krug 2001). A typology of prevention strategies is
useful in sorting through the complexities and commonalities
of this problem to identify the range of strategies that might
be incorporated into effective violence prevention plans. We
propose a typology of prevention based on two key dimen-
sions: the stages of human development and the ecological
model mentioned earlier.
The epidemiology of violence, including its onset, desis-
tance, and continuity, is closely related to the stages of human
development (Williams, Guerra, and Elliott 1997). Increasing
evidence points to the existence of discrete developmental
pathways to violent behavior (Loeber and others 1993; Tolan
and Gorman-Smith 1998; U.S. Department of Health and
Human Services 2001; additional sources online). Thus, inter-
vening at early developmental stages may reduce the likelihood
that violence is expressed during later developmental stages.
The ecological model is also an important dimension of the
typology, because violence is the product of multiple and over-
lapping levels of influence on behavior. The ecological model
assumes that violent behavior is influenced by social contexts
and the individual attributes brought to these contexts.
Intervention may therefore attempt to influence aspects or risk
factors at any or all of the model’s four levels (Dahlberg and
Krug 2002; Mercy and Hammond 1999).
Table 40.4 presents our typology of prevention strategies.
The examples presented are not exhaustive, nor have all the
strategies proven effective. Rather, they illustrate the breadth
of potential solutions and emphasize the need to consider
addressing the problem simultaneously at different stages of
human development and through different social contexts. In
many cases, an intervention might have an effect on multiple
forms of violence. At this time, data to prove or disprove the
effectiveness of most of these interventions are insufficient, and
in those cases in which sufficient data are available, they are
almost always from high-income countries.
Strategic Focuses for Prevention
A simple understanding of the approaches illustrated in table
40.4 is insufficient for developing a comprehensive violence
prevention strategy. A public health approach to violence pre-
vention concentrates on identifying ways to keep people from
committing violent acts. Interventions may eliminate or reduce
the underlying risk factors and shore up protective factors.
Interventions are typically classified in terms of three levels of
prevention: primary, secondary, and tertiary (Dahlberg and
Krug 2002).
Primary Prevention. Primary prevention interventions focus
on preventing violence before it occurs. The literature has given
rise to several strategic focuses for the primary prevention of
violence that are important considerations in violence preven-
tion planning. Some have been successfully implemented at the
community level in LMICs.
The cultural context plays an important role in violent
behavior. Cultural traditions are sometimes used to justify
such social practices as female genital mutilation and severe
physical punishment of children (Mercy and others 2003).
Conversely, cultural norms can be a source of protection
against violence, such as traditions that promote the equality
of women or respect for the elderly. Although evidence-based
approaches for changing cultural traditions as a violence pre-
vention strategy are not yet available, some countries have
adopted this strategy. In South Africa, the Soul City health
promotion campaign makes residents aware of the extent and
consequences of violence and encourages better parenting
through role models and improved communication among
family members. Evaluations have found shifts in attitudes
and social norms concerning intimate partner violence and
domestic relations. Willingness to change behavior and take
action to stop violence has increased in urban and rural areas
among both men and women (Krug and others 2002b,
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Table 40.4 Prevention Strategies, by Developmental Stage and Ecological Context
Developmental stage
Level of the Infant and toddler years Childhood Adolescence Adulthood
ecological model (age birth–3) (age 4–11) (age 12–19) (age 20)
Individual
Relationship
Community
• Reduction in unintended
pregnancies
• Access to prenatal and
postnatal services
• Treatment programs for
child witnesses of violence
and victims of maltreatment
to reduce consequences
• Home visitation servicesa
• Parenting traininga
• Therapeutic foster care
• Lead monitoring and toxin
removal
• Screening by health care
providers for maltreatment 
• Social development
traininga
• Preschool enrichment
programsa
• Drug-resistance educationb
• School-based programs to
prevent child maltreatment 
• Community-based
prevention of child sexual
abuse
• Gun safety training
• Parenting traininga
• Mentoring
• Partnership programs
between homes and
schools to promote parental
involvement
• Safe havens for children on
high-risk routes to and from
school
• After school programs to
extend adult supervision
• Recreational programs
• Social development
traininga
• Drug-resistance educationb
• Educational incentives for
at-risk, disadvantaged
studentsa
• Individual counselingb
• Supervised exposure to
prison and morgue (shock
or scare high-risk youthb)
• Residential programs in
psychiatric or correctional
institutionsb
• Academic enrichment
programs
• Gun safety training
• Boot campsb
• Waivers to try in adult
courtb
• School-based violence
prevention programsa
• Mentoringa
• Peer mediation and
counselingb
• Temporary foster care
programs for serious and
chronic delinquents
• Family therapya
• Recreational programs
• Multicomponent gang
prevention programsb
• Health care professionals
trained in identification and
referral of high-risk youth
and victims of sexual
violence
• Community policing
• Improvements in emergency
response, trauma care, and
access to health services
• Programs to buy back gunsb
• Metal detectors in schools
• Incentives for postsecondary
education or vocational
training
• Services for adults abused as
children
• Treatment for child and intimate
partner abuse offenders
• Waiting periods for firearm
purchases
• Owner liability for damage by
guns
• Programs to strengthen ties to
family 
• Programs to strengthen ties to
jobs
• Couples therapy
• Relationship education
• Adult recreation programs
• Shelters and crisis centers for
battered women and victims
of elder abuse
• Criminal justice reforms to
criminalize child maltreatment,
intimate partner violence, and
elder abuse 
• Mandatory arrest policies for
intimate partner violence
• Public shaming of intimate
partner violence offenders
• Services for identifying and
treating elder abuses
• Health care professional train-
ing in identification and refer-
ral of victims of elder abuse
and sexual violence
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Table 40.4 Continued
Developmental stage
Level of the Infant and toddler years Childhood Adolescence Adulthood
ecological model (age birth–3) (age 4–11) (age 12–19) (age 20)
Societal
• Community policing
• Emergency response and trauma care improvements
• Health care providers trained in the detection and reporting
of child maltreatment 
• Programs to buy back gunsb
• Promotion of safe storage of firearms and other lethal means
of inflicting violence
• Prevention and education campaigns to increase awareness
of child maltreatment 
• Child protection service programs
• Promote cultural norms to
value and protect life
• Promote strength-based
cognitive and socio-
emotional skills from birth
• Strengthen police and judicial systems
• Deconcentrate poverty
• Reduce income inequality
• Reduce violent content of
movies, television, video
games, and Internet sites
available to children
• Launch public information
campaigns to promote
pro-social norms
• Community policing
• Emergency response and trauma care improvements
• Programs to buy back gunsb
• Disruption of illegal gun markets
• Prohibition of firearm sales to high-risk purchasers 
• Mandatory sentences for gun use in crimes
• Coordinated community interventions for violence prevention
• Prevention and education campaigns to increase awareness of
youth violence, intimate partner violence, sexual violence, and
elder abuse
• Reduce violent content of
movies, television, video
games, and Internet sites
available to children
• Enforce laws prohibiting
illegal transfers of guns to
youths
• Strengthen police and judicial systems
• Promote safe storage of firearms
• Deconcentrate poverty
• Reduce income inequality
• Change cultural norms that support violence
and abuse of children and adults 
• Establish job creation
programs for the chronically
unemployed
Source: Authors.
a. These programs have been demonstrated to be effective in reducing violence or risk factors for violence.
b. These programs have been found to be ineffective in reducing violence.
box 9.1). In the Kapchorwa district of Uganda, a community
health program has enlisted the support of elders in adopting
alternative practices to female genital mutilation that are
consistent with their cultural traditions (United Nations
Population Fund 1998).
The lethality of interpersonal violence is affected by the
means people use to carry out this violence. Reducing access to
lethal means, such as firearms, may help minimize the health
consequences of violence. A wide variety of strategies have
been used to restrict access to firearms, such as mandating
waiting periods before purchase, promoting safe storage of
firearms, and limiting where firearms can and cannot be
carried. In the mid 1990s, Colombian officials in Bogotá and
Cali, noting that homicide rates increased during weekends fol-
lowing paydays, on national holidays, and near elections,
implemented a ban on carrying handguns during those times,
which resulted in a 13 to 14 percent reduction in homicide
rates (Villaveces and others 2000). In the Australian state of
Victoria, firearm-related suicides, assaults, and unintentional
deaths decreased following the 1988 implementation of legisla-
tion that required the registration of all firearms and strength-
ened licensing regulations; a mandatory waiting period was
added in 1996 (Ozanne-Smith and others 2004). However, the
evidence to determine whether such strategies are effective in
reducing firearm-related homicides is currently insufficient
(Hahn and others 2003), although several policies hold prom-
ise (Hemenway 2004; Ludwig and Cook 2003).
Inadequate parental involvement in children’s and adoles-
cents’ activities and lack of supervision are well-established risk
factors for youth violence (U.S. Department of Health and
Human Services 2001). Evidence indicates that a supportive
relationship with parents or other adults is protective against
antisocial behavior. Although not widely evaluated, some men-
toring programs that match high-risk youths with a positive
adult role model appear to be effective in reducing youth vio-
lence (Grossman and Garry 1997; Thornton and others 2002);
however, negative findings have also been reported for mentor-
ing, particularly when mentors receive little training and when
the relationships between adults and youths break down. The
design of mentoring programs varies considerably, and partic-
ipation by both mentors and youths can be uneven.
Programs that target those who influence children are more
effective than interventions that target all adults. For example,
preschool enrichment, home visitation, and parenting pro-
grams have been found to have both short- and long-term
effects on preventing violence (Farrington 2003; Mercy and
others 2002; Utting 2003; additional sources online). Early
intervention can help shape attitudes, knowledge, and behavior
of children at a time when they are more open to positive influ-
ences and can affect their behavior over their lifetime (Mercy
and others 1993).
Income inequality is a risk factor universally associated with
interpersonal and collective violence (Butchart and Engstrom
2002; Zwi, Garfield, and Loretti 2002; additional sources
online). Poverty itself does not appear to be consistently asso-
ciated with violence, but the juxtaposition of extreme poverty
with extreme wealth appears to be a key ingredient in recipes
for violence. Economic programs or policies that reduce or
minimize the effects of income inequality may be strategic in
violence prevention, although the evidence base for such inter-
ventions has not been established.
Secondary and Tertiary Prevention. Although an emphasis
on primary prevention is essential for reducing the health
burden associated with violence, secondary prevention pro-
grams and services are necessary for addressing the immediate
consequences of violent actions and behaviors, and tertiary
programs focus on long-term care. Efforts targeted at victims
of violence are extremely important for mitigating the physical
and psychological consequences of the various forms of
violence and abuse and for reducing victims’ risks for future
violence (National Center for Injury Prevention and
Control 2002).
Physicians and other health professionals are gatekeepers in
efforts to monitor, identify, treat, and intervene in cases of inter-
personal violence. As previously noted, more cases of interper-
sonal violence come to the attention of health care providers
than of police. The role of health care providers in prevention
efforts is neither widely understood nor embraced, and many
institutional and educational barriers limit their effectiveness
(Cohen, De Vos, and Newberger 1997). Programs to educate
health care providers are under way worldwide. Many hospital
emergency departments, doctors’ offices, and clinic settings use
screening programs to identify victims of intimate partner
violence, child abuse, or elder abuse, although the effectiveness
of those interventions in reducing subsequent violence is not
well understood (Heise and Garcia-Moreno 2002; Runyan and
others 2002; Wolf, Daichman, and Bennett 2002).
Therapeutic approaches have been implemented in many
parts of the world to reduce child abuse. Though some research
suggests that these interventions can improve the mental
health of victims, less information is available on other benefits
(Runyan and others 2002; additional sources online). One
approach to preventing child sexual abuse in the United States
challenges social norms by offering help to those at risk of
offending and by encouraging adults to watch for and act on
warnings of child sexual abuse before an offense is committed
(CDC 2001). Under such programs, individuals voluntarily
turn themselves in for treatment and thereby prevent potential
future violence.
The outcome of injury from interpersonal violence depends
not only on its severity, but also on the speed and appropriate-
ness of treatment (Committee on Trauma Research 1985).
Establishment of trauma systems designed to treat and manage
injured victims efficiently and effectively is an important factor
in reducing the health burden of violence. Research suggests
that reductions in criminal assaults resulting in death in the
United States are partly explained by the increased survival of
victims. Developments in medical technology and trauma
services may be reducing the number of interpersonal violence
fatalities (Harris and others 2002). Hospital emergency depart-
ments may also provide an opportunity to intervene with
victims who might otherwise seek revenge against their attack-
ers or victims who are at greater risk for revictimization
(Muelleman and others 1996).
COST-EFFECTIVENESS OF INTERVENTIONS
Studies show that implementing preventive interventions costs
less than dealing with the outcomes of violence, in some cases
by several orders of magnitude.
Examples of Cost-Saving Interventions
To date, most evaluations of preventive interventions measure
cost and effects in high-income countries. Although cost sav-
ings may not be comparable in LMICs, effects may be greater.
Legislation and Shelter for Abused Women. The 1994
Violence against Women Act in the United States has resulted
in an estimated net benefit of US$16.4 billion, including
US$14.8 billion in averted victims’ costs (Clark, Biddle, and
Martin 2002). This wide-ranging legislation introduced pro-
grams aimed at deterring crimes against women and providing
assistance to female victims of crimes. Interventions include
penalties for repeat offenders, use of sexual history in criminal
and civil cases, programs for victims of child abuse, safe homes
for women, confidentiality of the abused person’s address, and
pretrial detention in sex offense cases. Chanley, Chanley, and
Campbell’s (2001) analysis shows that providing shelters for
victims of domestic violence results in an estimated cost-
benefit ratio of 18.4 to 6.8.
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Parent Training and Home Visitation. Caldwell (1992) esti-
mates that the costs of child abuse and neglect in Michigan are
US$1 billion a year, including the costs of crimes committed by
the victims of child abuse later in life and the costs of their
incarceration. The study estimates that prevention costs,
including a home visitor program for every family and a com-
prehensive parent education program, are just one-nineteenth
of the cost of child abuse. Armstrong’s (1983) cost-benefit
analysis of a child abuse prevention program in Yeardon,
Pennsylvania, finds net savings of US$647,000 per year and a
cost-benefit ratio of 1.86.
Registering Firearms. Chapdelaine and Maurice (1996)
quantify the costs and benefits of a Canadian law that required
gun owners to register their firearms by January 1, 2001.
Implementing a universal licensing and registration system
cost approximately US$70 million (2001 U.S. dollars), includ-
ing a significant one-time expense, compared with annual
direct health care costs of gun-related violence of US$50 mil-
lion. When the indirect costs of gun violence are included, the
economic benefits of the law are much clearer. Miller (1995)
estimates the total costs of firearm-related injuries in Canada at
US$5.6 billion, including lost productivity and psychological
costs, equivalent to 1 percent of Canada’s GDP.
Youth Intervention. Greenwood and others (1996) compare
interventions to reduce youth crime in the United States and
find that providing high school students with incentives to
graduate, which costs US$14,100 per program participant, is the
most cost-effective intervention, resulting in an estimated 258
serious crimes prevented per US$1 million spent. Parent train-
ing prevents an estimated 157 serious crimes per US$1 million,
compared with 72 for delinquent supervision programs and 11
for home visits and day care. All those interventions (excluding
home visits) are more cost-effective than California’s “three
strikes” law, which incarcerates for life those individuals con-
victed of three serious crimes.
Need for LMIC Cost-Benefit Data
Though violence disproportionately affects LMICs, studies of
the economic effects of violence in those countries are scarce.
Comparisons with high-income countries are complicated by
the tendency to undervalue economic losses related to produc-
tivity in lower-income countries, because such losses are typi-
cally based on forgone wages and income. Thus, when the costs
of violent homicides are calculated, the estimates range from
US$15,319 per homicide in South Africa, to US$829,000 in
New Zealand, to more than US$2 million in the United States.
Given the existing methodological differences and widespread
gaps in the literature, systematic research into the costs of
violence and the costs versus benefits of prevention efforts is
urgently needed.
IMPLEMENTATION OF PREVENTION 
STRATEGIES
Promoting violence prevention involves encouraging and
supporting the development, implementation, and evaluation
of programs explicitly designed to stop the perpetration of
violence at local, regional, and national levels.
The 2003 World Health Assembly Resolution (WHA56.24)
on implementing the recommendations of the World Report on
Violence and Health (Krug and others 2002b; see also Butchart
and others 2004) advocates a five-point strategy.
Increasing Capacity for Collecting and Managing Data
Increased capacity for collecting health, criminal justice, and
social service sector data on violence and its consequences is
fundamental to building a sustained, high-level policy and
intervention programming response in LMICs. Population-
level data are needed to design and evaluate community-level
intervention trials. Health sector data can cover a larger and
often different subset of violence-related injuries than police
statistics and, with criminal justice and social service data, can
strengthen abilities to define the problem, identify causes and
risk factors, design appropriate interventions, and monitor the
interventions’ effectiveness.
Information systems play a large role in recent efforts to
address infectious diseases such as tuberculosis and HIV, allow-
ing better identification of high-risk populations and appro-
priate interventions. A similar role is imminent for violence
prevention. As previously stated, information systems must
integrate data from the criminal justice, labor, education, social
services, and health sectors and must be linked with systems
housed at multilateral agencies or regional joint initiatives.
Sharing information regionally allows countries to identify
opportunities for collaboration and to share best practices.
Support for Research
Supporting research on the causes, consequences, and preven-
tion of violence has proven effective in mobilizing prevention
responses in developing countries. In South Africa, the 1997
Essential National Health Research Conference identified
research for improved violence prevention and control as a top
priority, and in 2001, the Medical Research Council established
a program to give violence prevention research the same
priority as research into HIV/AIDS, tuberculosis, and malaria
(Jeenah and others 1997; Medical Research Council of South
Africa 2004). South Africa also has applied research data in
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various prevention contexts, including establishment of a
national violence and injury mortality surveillance system,
passage of firearms legislation, assessment of national and
municipal-level burden-of-disease estimates, and design of
prevention programs (Butchart and others 2001; Groenewald
and others 2003).
The currently limited evidence base and understanding
of the causes of all types of violence must be expanded
through planned, documented, evaluated, and shared research.
Some developing countries have opportunities to develop
and document prevention programs in special settings, such
as for refugees, orphans, nomadic, displaced, and homeless
populations.
Promoting Primary Prevention
An important first step in promoting primary prevention is
systematic documentation of existing prevention programs.
Records can include information on the types of violence and
risk factors addressed, target populations served, interventions
used, and any monitoring and measurement of the effects.
Such information can help make the programs more visible to
policy makers and development partners and can be used to
promote increased investment in programs that apply proven
and promising interventions.
WHO has outlined a methodology for systematic documen-
tation (Sethi, Marais, and others 2004, 22–33) and has initiated
a project to evaluate the feasibility and utility of such docu-
mentation in selected cities and provinces in Brazil, India,
Jamaica, Jordan, the former Yugoslav Republic of Macedonia,
Mozambique, the Russian Federation, and South Africa.
Strengthening Support Services for Victims
A situational analysis of the accessibility and organization of
emergency, acute, long-term, and rehabilitative services can
identify needs and help strengthen care and support services
for victims of violence. The establishment and adequate fund-
ing of first responder systems, such as police and ambulance
teams, may lower the costs of violence and contribute to pre-
vention. Maps showing hospitals and clinics with specialized
systems for treating victims of violence can help these first
responders. Ready access to legal resources empowers victims.
Mock and others (2004) offer guidelines for strengthening
victim care and support services.
Claramunt and Cortes’s (2003) assessment in Belize, Costa
Rica, El Salvador, Guatemala, Honduras, and Nicaragua estab-
lished baseline information that could be used to advocate for
strengthened medical and legal services for victims of sexual
violence. Their findings included a lack of adequate medical
and legal information systems, the insufficient training of
medical staff, and a lack of clear protocols for moving patients
through the system. Services in associated sectors—medical,
forensic, social, and legal—should be examined, because inte-
grated efforts can improve access to and value of services that
previously existed in isolation. Training of medical and legal
service providers in activities aimed at preventing violence may
also affect the success of long-term prevention; however, this
training strategy has not been extensively evaluated.
Developing Action Plans
A national plan of action for preventing interpersonal violence
and improving victim support and care is the blueprint that
provides a set of common goals, a shared time frame, a strategy
for coordinating activities, and a framework for evaluating the
different sectors involved. Such a plan is therefore central to
organizing national and community-level interventions that
involve more than one objective and that depend on input
from many different sectors. Strong political support from the
highest levels of government is important in aligning the vari-
ous players and ensuring that the plan is implemented and that
associated programs are maintained. Nongovernmental organ-
izations may provide support and continuity in countries
where programs may be interrupted because of unstable,
changing governments.
Collaboration among national governments and health-
related nongovernmental and multilateral organizations can
establish the importance of formally addressing violence
through public health approaches. Though legal and criminal
justice approaches provide a deterrent, experience in high-
income countries suggests that a proactive public health
approach can reduce the negative health, social, and economic
consequences of interpersonal violence.
CONCLUSIONS: PROMISES AND PITFALLS
Violence prevention may be seen as a luxury rather than a pub-
lic health priority in LMICs; however, the magnitude of the
problem and the associated health burden negate this view.
Resolutions on violence prevention passed by the World Health
Assembly and codified in the World Report on Violence and
Health and reports from the United Nations Crime Prevention
Council present frameworks for approaching violence preven-
tion. The first World Health Assembly resolution was cospon-
sored by a developing country, South Africa, and a developed
country, the United States. Both recognized the importance of
making violence prevention a global public health priority even
before evidence of effectiveness could be collected. Seven years
after the resolution, both developing and developed countries
applauded and adopted the World Report on Violence and
Health, signaling the beginning of an exciting new agenda for
public health.
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The public health model for violence prevention focuses on
primary prevention and intervention for victims and empha-
sizes the value of integrating efforts across sectors. However,
the model is weakened by a paucity of sustained interventions
and measured outcomes in LMICs.
Currently, the best approach may be to take small, incre-
mental steps, focusing on relatively discrete and easily imple-
mented interventions that address a prevalent problem. LMICs
should build on programs for which some evidence of effec-
tiveness exists in high-income countries and adopt a “learn as
you go” approach.
Many LMICs face the daunting challenges of the spreading
HIV/AIDS epidemic and ongoing intergroup conflict or war.
Those problems can destroy the infrastructure of civil society,
increase stress and economic hardship, and lead to increases in
suicide and interpersonal violence of all kinds—in both sexes
and at all ages. In prioritizing violence prevention efforts, policy
makers and health care professionals may mitigate some of the
secondary repercussions of these deadly factors.
A great deal of progress has been made in violence preven-
tion. There is strong reason to believe that the interventions
under way and the capacity to implement violence prevention
will make a difference. The lessons learned to date during the
public health community’s short experience with violence pre-
vention are consistent with the lessons from the community’s
much longer experience with the prevention of infectious and
chronic diseases. Violence can be prevented in LMICs if their
governments, their citizens, and the global community start
now, act wisely, and work together.
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NOTES
1. The World Bank (2004) classifies countries by annual gross national
income (2001 U.S. dollars) per capita as follows: low-income, US$735 or
less; lower-middle-income, US$736 to US$2,935; upper-middle-income,
US$2,936 to US$9,075; and high-income, US$9,076 or more.
2. Cost estimates have been converted to 2001 U.S. dollars to facilitate
comparisons.
3. Whenever possible, we have cited results calculated using a 3 percent
discount rate, as recommended by the U.S. Panel on Cost-Effectiveness in
Medicine (Gold, Siegel, and Weinstein 2001).
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Water supply in the context of this chapter includes the supply
of water for domestic purposes, excluding provision for irriga-
tion or livestock. Sanitation is used here in the narrow sense of
excreta disposal, excluding other environmental health inter-
ventions such as solid waste management and surface water
drainage.
The effect of these other measures on disease burden is
largely confined to urban areas and is considerably less than
that of water supply, sanitation, and hygiene promotion
(Cairncross and others 2003). More fundamentally, expendi-
ture on solid waste disposal and drainage is rarely seen as
forming part of a portfolio of investments in public health or
competing with public health investments. Rather, it is general-
ly perceived by decision makers as comparable with other
investments in municipal infrastructure and services, such as
roads or public transportation, which are not considered to be
public health interventions.
This chapter focuses on water supply, excreta disposal, and
hygiene promotion and considers the costs and benefits of each
in turn. Water supply and sanitation can be provided at various
levels of service, and those levels have implications for benefits.
Water supply and sanitation offer many benefits in addition to
improved health, and those benefits are considered in detail
because they have important implications for the share of the
cost that is attributable to the health sector. From the point of
view of their effect on burden of disease, the main health ben-
efit of water supply, sanitation, and hygiene is a reduction in
diarrheal disease, although the effects on other diseases are sub-
stantial. In the concluding sections, the percentage reductions
arrived at in the discussion throughout the chapter are used
together with data on existing levels of coverage to derive esti-
mates of the potential effects of water supply and excreta dis-
posal on the burden of disease, globally and by region, and with
cost data to derive cost-effectiveness estimates.
WATER SUPPLY 
What constitutes a perfectly satisfactory water supply to some
consumers leaves others, even in developing countries, consid-
ering themselves unserved. In much of rural Africa, a hand
pump 500 meters from the household is a luxury, but most res-
idents in urban Latin America would not consider themselves
served by a water supply unless they had a house connection.
In Asia, urban planners would consider a community served if
there were sufficient standposts on the street corner; however,
if the water only flows for a few hours per week, producing
lengthy nighttime queues, the residents may regard this situa-
tion as a lack of service and opt to buy water expensively from
itinerant vendors. As these examples illustrate, water supply is
not a single, well-defined intervention, such as immunization,
but can be provided at various levels of service with varying
benefits and differing costs.
Levels of Service and Their Costs
Many public health workers unfamiliar with the water sector
assume that the most important characteristic of a water sup-
ply is its improved quality. However, most of the benefit is
attributable to improved convenience of access to water in
Chapter 41
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quantity. Moreover, global statistics are not available on the
coverage and costs of provision of water in terms of its quality.
The Global Water Supply and Sanitation Assessment 2000 Report
(WHO and UNICEF 2000), the most recent compilation of
global statistics on water supply, changed the way that such
data are compiled, from the previous unreliable estimates by
provider agencies to consumers’ responses in population-based
surveys. The change required a departure from the old defini-
tion of reasonable access to safe water, because most consumers
cannot tell whether their water supply is safe. They can, how-
ever, state the type of technology involved, and that fact was
used to define a new indicator of improved water supply. In the
main, improved water supplies could be expected to provide
water of better quality and with greater convenience than tra-
ditional not improved sources. The report treated the following
technologies as improved: household connection, public stand-
pipe, borehole, protected (lined) dug well, protected spring,
and rainwater collection. Unprotected wells and springs, ven-
dors, and tanker-trucks were considered unimproved. Bottled
water was also considered unimproved because of concerns
about the quantity of water supplied, not because of concerns
over the water quality.
Reasonable access was defined as the availability of at least
20 liters per capita per day from a source within 1 kilometer of
the user’s dwelling. Within the broad category of those with
reasonable access to an improved water supply, two significantly
different levels of service can be distinguished:
• house connections 
• public or community sources.
In most settings, these subcategories correspond to very dif-
ferent levels of water consumption, different amounts of time
spent collecting water, and as discussed in later sections, differ-
ent health benefits.
The Global Water Supply and Sanitation Assessment 2000
Report also gives median construction costs per person served
for the various technologies in the three main regions of the
developing world. These costs are shown in figure 41.1.
However, local conditions, such as the size of the community to
be served and the presence of suitable aquifers, can cause
tremendous variations in the unit cost of water supply.
For a community of given size, there are no significant
returns to scale in the number of house connections made.
Most of the investment in major works must be made before
house connections can be offered, so that the marginal cost of
each connection is only a fraction of the total. For those and
other reasons, water supply is a natural monopoly requiring
“lumpy” investments, which makes the unit costs difficult to
calculate.
The cost of house connections may be representative in
Latin America and the Caribbean, where they are often pro-
vided in rural areas. In Asia and Africa, however, the reported
costs of house connections relate almost exclusively to urban
areas because such connections are only rarely provided in
smaller communities. The smaller size of rural communities
means that piped systems in general—and house connections
in particular—will tend to be more expensive per capita there
than in urban areas. An overall unit cost figure of US$150,
just above the highest of the three continental medians, is
therefore taken for house connections in the cost-effectiveness
calculations.
For public water points corresponding to improved water
supply, hydrogeological and other constraints mean that the
cheapest technology is not feasible in every community. A cost
figure of US$40 per capita is about the middle of the range
offered by different technologies (standpost, borehole, and
dug well) providing this level of service for each continent
(figure 41.1) and, therefore, seems reasonable for this level of
service, although it can be expected to vary between US$15 and
US$65 or more, depending on local conditions. The range of
costs reported by individual countries for the Global Water
Supply and Sanitation Assessment 2000 Report varied by more
than an order of magnitude.
In calculating the cost-effectiveness of investment in water
supplies, one must amortize these capital costs over an appro-
priate lifetime. Most major components of an urban water
supply system have a potential lifetime of 50 years or more, but
a prudent utility would aim to amortize them within about
20 years. A reasonable basis for calculation, for both urban and
rural supplies, is to allow an amount of 5 percent of the capital
cost as an annual straight-line amortization of the construction
cost of the water supply.
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Figure 41.1 Median Construction Cost of Water Supply Facilities for
Africa, Asia, and Latin America and the Caribbean
Construction costs do not represent the full cost of water
supplies. The Global Water Supply and Sanitation Assessment
2000 Report also gives median reported production costs per
cubic meter for urban (house connection) water supplies as
US$0.20 for Asia and US$0.30 for Africa and Latin America
and the Caribbean. If we assume a mean daily water consump-
tion of 100 liters per capita by those with household connec-
tions, those figures give annual per capita operation and main-
tenance costs of US$7.30 and US$10.95, respectively, or 8 to
10 percent of the capital cost of construction. In this chapter, a
generic figure of US$10 is used for the annual per capita oper-
ation and maintenance cost.
Reliable figures for the annual maintenance costs for rural
water supplies are harder to find, particularly because much of
the maintenance is carried out by the volunteer labor of villagers.
Arlosoroff and others (1987), after reviewing a wide range of
rural water supply projects in various countries, concluded that
with a centralized maintenance system, the annual per capita
cost of maintenance of a hand pump–based supply can range
from US$0.50 to US$2.00,while well-planned,community-level
maintenance can bring that figure down as low as US$0.05 per
capita per year. A nominal annual figure of US$1.00 per capita is
therefore used in this chapter. A similar figure can be applied to
urban public standposts, for which volunteer labor is less forth-
coming but transport costs are lower. This maintenance cost
represents 2.5 percent of the construction cost arrived at above.
The Time-Saving Benefit
Benefits to health are not normally foremost in the minds of
those provided with new water supplies. An exhaustive study of
the economics of rural water supply by the World Bank con-
cluded that “the most obvious benefit is that water is made
available closer to where rural households need it. . . . It is not
clear that rural populations think much about the relationship
between water and health” (Churchill and others 1987, 21–22).
The Value of Time. The saving in time and drudgery of carry-
ing water home from the source is substantial, and several rea-
sons exist to attribute a money value to it. The most powerful
argument for the money value of poor women’s time is that
households often pay others to deliver their water, or pay to col-
lect from nearby rather than from more distant sources that are
free of charge. Thompson and others (2001) found that, of
urban East African households lacking a piped supply, the pro-
portion paying for water had increased from 53 percent to
80 percent over 30 years. In a survey of 12 sites in 10 countries,
Zaroff and Okun (1984) found that households were spending
a median of over 20 percent of their income on the purchase of
water from vendors. The prices charged by vendors are typically
more than 10 times—and can be up to 50 times—the normal
tariff charged by the formal water supply utility.
Cairncross and Kinnear (1992) found that vendor prices
increased with the time required to collect the water, showing
that households pay more as the alternative of collecting water
themselves becomes more burdensome. If the amount paid to
the vendor for bringing the water is divided by the time saved
from collecting it, the implicit value that people ascribe to their
time can be calculated. Whittington, Mu, and Roche (1990),
working in rural Kenya, showed in this way that the implicit
value of the time saved was roughly US$0.38 per hour, very
close to the average imputed wage rate for such households of
US$0.35 per hour.
Because the poorest urban households typically spend more
than 90 percent of their household budget on food, the money
they spend on water is sacrificed from their food budget
(Cairncross and Kinnear 1992). The provision of water more
cheaply thus offers a substantial nutritional benefit to the
poorest.
Assessing the Time Saved. The cost of water collection in
rural areas is usually in time and effort rather than in money
paid to vendors. The saving in time and drudgery underlies
many social benefits. Given the relevance of the time-saving
benefit to water supply policy and the fact that the benefit is
usually uppermost in the mind of the consumer, it is remark-
able how few data have been collected on the amounts of time
spent collecting water.
Working in 334 study sites in Kenya, Tanzania, and Uganda,
Thompson and others (2001) found a mean distance from
rural unpiped households to their water sources of 622 meters.
In urban areas, the distance was only 204 meters, but queuing
at the tap meant that a water collection journey took almost
as long.
Feachem and others (1978) found in 10 villages of the
densely populated lowlands of Lesotho that the installation of
a water supply had saved the average adult woman 30 minutes
per day. In one-third of the villages, the saving per woman was
more than an hour a day. Lesotho has many springs, so that
time saving is likely to be on the low side compared with Africa
as a whole.
These time-saving benefits are confirmed by the Multi-
Indicator Cluster Surveys of the United Nations Children’s
Fund (UNICEF). A recent analysis of the responses in 23
African countries has produced a more representative account
of water collection journey times in that continent (G. Keast,
UNICEF, personal communication 2003). Nearly half the
households interviewed (44 percent) required a journey of
more than 30 minutes to collect water, implying that the
women in such households spent an hour or more each day in
water collection. At almost any reasonable level of service, most
of that time would be saved by an improved water supply.
In Asia, an Indian national survey for UNICEF found that
women spent an average of 2.2 hours per day collecting water
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from rural wells (Mukherjee 1990). A study in Sri Lanka, which
is generally considered to be well provided with water sources,
found that 10 percent of women had to travel more than 1 kilo-
meter to their nearest source (Mertens and others 1990).
Valuation of the Time-Saving Benefit. Putting a precise figure
on the money value of the time of poor people is a tricky task,
even for the most self-confident economist. In 1987, Churchill
and others took US$0.125 per hour as an illustrative but not
unrealistic figure. To take the same figure today could hardly be
described as extravagant. Assuming this valuation of an hour of
time—and that a water supply bestows a mean saving of only
15 minutes per person per day—yields a conservative estimate
of the value of the time-saving benefit of US$11.40 per year.
The data presented earlier indicate that, at least in Africa, the
true figure is nearer to double that amount, enough to justify
the full construction cost of a dug well or borehole supply in a
single year. In Latin America and the Caribbean, costs are
higher, and time savings may be less, but rural incomes are also
higher—and so, therefore, is the value of people’s time. Little
doubt exists that, in all three regions of the developing world,
the value of time saved is sufficient on its own to justify both
the investment costs (at any reasonable rate of amortization)
and the operation and maintenance costs of water supplies.
Even in settings where water vending is not common, con-
tingent valuation surveys have widely demonstrated a willing-
ness to pay for water supplies, particularly at the level of serv-
ice of house connections (World Bank Water Demand
Research Team 1993). In general, such measured willingness to
pay has exceeded the cost of providing the supplies, and pay-
ment to vendors often exceeds it by many times.
Policy Implications. Whether the consumers actually pay for
the full value of the time-saving benefit, it is what makes water
supplies popular and largely it is what motivates politicians to
invest in them. More than half the total annual investment in
water supply in the developing countries of Africa, Asia, and
Latin America and the Caribbean is from domestic sources
(WHO and UNICEF 2000). Most of the investment is from the
public sector. In general, investments in water supply—
whether by the governments of developing countries or by
external support agencies—do not come from health sector
budgets and are not compared with other health interventions
when investment decisions are made, even though health ben-
efits do arise from water supply improvements.
Water supply is thus a health-related intervention that
comes without cost to the budgets of the health sector.
Although it undoubtedly offers health benefits, it has a suffi-
cient economic and political rationale in other social benefits
associated with time saving. The health benefits are a positive
externality to this rationale. However, this fact does not mean
that the authorities responsible for public health should ignore
the water sector. The function of the health sector is one of reg-
ulation, advocacy, and provision of supplementary inputs, as
appropriate, to ensure that potential health benefits of water
supply are realized to the optimal extent.
For example, the regulatory role of the health sector in qual-
ity surveillance of drinking water is well known and widely
accepted. Substantial and largely unexploited additional poten-
tial is present in this role if quality is interpreted in the wider
sense of quality of service rendered by the water supply utility,
in terms not only of water quality but also of quantity, conti-
nuity, coverage, control of sanitary hazards, and cost. Those
other aspects, as will be argued in the following sections, are no
less important for health.
Where a regulatory role is not available to the health sector
or agencies concerned with public health, advocacy can be no
less cost-effective. For example, connection charges are a major
barrier to house connections for low-income groups. In many
cities of the developing world, the individual connection
charge is about a month’s basic wage. Advocacy of lower con-
nection charges, with the amount recovered from the monthly
water tariffs, can therefore help achieve an increase in the num-
ber of people who have house connections and who can bene-
fit from the corresponding health gain at no cost to the public
purse. Finally, the health sector can provide important comple-
mentary services, such as hygiene promotion and promotion of
low-cost sanitation to increase coverage; because of the nature
of such services, the water sector, with its focus on technology,
is ill-equipped to offer them.
The unit costs of such regulation and advocacy are minimal.
One example is the case of UNICEF’s participation over the
past 30 years in India’s rural water supply program. UNICEF’s
investment has represented no more than 1 percent of the total,
but its influence has played a central part in the evolution of the
technical and institutional model of the program that supplies
water to 1 in 10 members of the human race.
An example of the effectiveness of such measures is pro-
vided by the interventions of the Mexican Ministry of Health in
June 1991. Fostered by fear of the devastating effects of cholera,
these measures included the chlorination of water supplied for
human consumption and the prohibition of sewage irrigation
of fruit and vegetables. As a result, the incidence of diarrhea in
children under five years of age fell from 4.5 to 2.2 episodes per
child-year, and the corresponding mortality rate fell from 101.6
to 62.9 per 100,000 children (Gutiérrez and others 1996).
The current rate of annual investment per capita in water
supply and sanitation, including both national investment and
external aid funds, is reportedly US$2.25 in Asia, US$7.53 in
Africa, and US$8.87 in Latin America and the Caribbean
(WHO and UNICEF 2000). One percent of the water sector’s
investment would, therefore, be US$0.02 to US$0.10 per capita.
If each ministry of health in the developing world were to
invest such a sum in public health advocacy and regulation
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related to water supply, the sector’s performance, at least where
low-income groups are concerned, could be transformed. It is
hard to put a figure on the health effects of such investment,
but the Mexican example suggests that they would be substan-
tial. For the sake of cost-effectiveness estimation, such spending
is arbitrarily assumed to have the effect of ensuring improved
water supplies for an additional 10 percent of the population to
which it refers.
Direct Health Effects
The full list of water-related infections is large and varied, but
most are only marginally affected by water supply improve-
ments. The first effort to simplify the relationship between
water supplies and health in developing countries was made by
David Bradley (White, Bradley, and White 1972), who devel-
oped a classification of disease transmission routes in terms of
whether they were
• waterborne, in the strict sense in which the pathogen is
ingested in drinking water 
• water-washed—that is, favored by inadequate hygiene con-
ditions and practices and susceptible to control by improve-
ments in hygiene
• water-based, referring to transmission by means of an
aquatic invertebrate host
• water-related insect vector routes, involving an insect vector
that breeds in or near to water.
Whereas the prevention of waterborne disease transmission
requires improvements in water quality, water-washed trans-
mission is interrupted by improvements in the availability—
and hence the quantity—of water used for hygiene and the pur-
poses to which it is put. Water supply may affect water-based
transmission (for example, if it reduces the need for people to
enter schistosomiasis-infected water bodies) or water-related
insect vectors of disease (for example, if a more reliable supply
averts the need for the water-storage vessels in which dengue
vectors breed), though that will depend on the precise life cycle
of the parasite involved and the preferred breeding sites and
behavior of the vector.
Classification and Burden of Water-Related Diseases. Before
Bradley’s classification can be applied to diseases (rather
than transmission routes), it requires a small adjustment
(Cairncross and Feachem 1993) to allow for the fact that prac-
tically all potentially waterborne infections that are transmitted
by the feco-oral route can potentially be transmitted by other
means (contamination of fingers, food, fomites, field crops,
other fluids, flies, and so on) all of which are water-washed
routes. In addition to the feco-oral infections, a number of
infections of the skin and eyes can be considered water
washed but not waterborne. The final classification is shown in
table 41.1.
The classification can now be used to assess how the disease
burden prevented by water supply is distributed among disease
groups. Bradley himself did this, a time long before the
disability-adjusted life year (DALY) had been invented as a unit
of benefit measurement (White, Bradley, and White 1972, 191).
He used official statistics on the number of cases of each disease
diagnosed and treated by health services in East Africa and
combined them with notional percentages by which morbidity
and mortality caused by each condition could be expected to
fall if water supply were “excellent.”
Those notional reductions were based on subjective assess-
ments of the literature available at the time and were described
by their author as “little more than guesses,” but it is hard to
prove many of them seriously at fault, even today. A selection is
presented in table 41.2.
The result of these calculations was that the feco-oral disease
group accounted for 91 percent of the deaths preventable by
water supply, 50 percent of inpatient bed nights, and 33 percent
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Table 41.1 The Bradley Classification of Water-Related Infections
Transmission route Description Disease group Examples
Waterborne The pathogen is in water Feco-oral Diarrheas, dysenteries, 
that is ingested typhoid fever
Water-washed Person-to-person transmission Skin and eye Scabies, trachoma
(or water-scarce) because of a lack of water infections
for hygiene
Water-based Transmission via an aquatic Water-based Schistosomiasis, 
intermediate host (for example, guinea worm
a snail)
Water-related Transmission by insects that Water-related Dengue, malaria, 
insect vector breed in water or bite near insect vector trypanosomiasis
water
Source: Cairncross and Feachem 1993.
of outpatient consultations. Rosen and Vincent (2001) have
made a similar calculation for the whole of Africa in 1990 and
found that the feco-oral group accounted for 85 percent of the
preventable DALYs. When measured in terms of deaths or
DALYs, feco-oral infections account for the vast majority of the
impact, because of the high mortality caused by diarrheal dis-
eases among young children. Most deaths from diarrheal dis-
eases are of children younger than age five, and most of those
are among children younger than two. A child death averted is
worth 30 DALYs. Varley, Tarvid, and Chao (1998) have calcu-
lated that for diarrhea morbidity reduction to have the same
effect in DALYs as averting one such death, it would have to
prevent 115,000 child-days of diarrhea. After the diarrheal dis-
eases, the next most important category in terms of DALYs
(12 percent of the total) is the water-based group, primarily
schistosomiasis. The purely water-washed diseases, mainly skin
infections, represent a more conspicuous portion only when
compared in terms of the burden placed on health services by
inpatients or outpatients.
How representative is this African breakdown of the devel-
oping world as a whole? Diarrheal disease among poor com-
munities is cosmopolitan. A global review of studies of the inci-
dence of diarrhea morbidity could find no clear geographic or
climatic trend (Bern and others 1992), so the burden of disease
is no doubt similar around the developing world. The second
most important disease group is represented by schistosomia-
sis, which is absent from much of Asia and Latin America. The
relative importance of feco-oral disease is, therefore, likely to be
still greater in the poor communities of Asia and the Western
Hemisphere than it is in Africa.
Epidemiological Questions and Problems. The predominant
contribution of feco-oral diseases to the burden of disease
attributable to water supply raises an important question,
because this group can be transmitted by both waterborne and
water-washed routes. It is important for the water engineer to
know whether scarce funding should be spent on improved
water treatment and measures to protect water quality or
instead on providing a limitless supply of water at a high level
of access and convenience and encouraging its use for
improved hygiene practices. We need to know, that is, whether
the feco-oral infections endemic in poor communities are
mainly waterborne or mainly water washed.
Moreover, the fact that some diarrheal diseases are still
prevalent in communities with a high level of water supply serv-
ice indicates that water supply alone cannot completely prevent
these diseases. A further question then, is this: by how much do
water supply improvements reduce diarrheal diseases?
Numerous studies have sought to answer these questions,
but they are hard to answer rigorously, for several reasons. First,
it is almost impossible, ethically and politically, to randomize
the intervention. Where the intervention is an improvement in
the level of access to water, it cannot be blinded; no placebo
exists for a standpost. Where quasi-experimental studies have
been used—opportunistically exploiting an intervention
allocated by political or technical means—significant con-
founding has frequently been found (Briscoe, Feachem, and
Rahaman 1985).
Confounding has been especially intractable in studies in
which the allocation of facilities has been on a household basis,
so that the exposure groups are self-selected—for instance,
studies in which individual households that have chosen to
install a private tap are compared with others that have chosen
not to do so. The former households are likely to be wealthier,
better educated, and more conscious of hygiene than their
neighbors, so it would not be surprising if they were also more
likely do many other things that protect their families from
feco-oral disease. The more sophisticated studies have used
multivariate models to control for confounding, but where rel-
ative risks are low and the exposure groups are self-selected,
even those models do not guarantee that confounding is elim-
inated (Cairncross 1990).
A further difficulty arises from the fact that cases of feco-
oral disease in a given community cannot be considered inde-
pendent events, because such diseases are infectious. The sam-
ple size, it can be argued, is the number of such villages rather
than the number of individuals enrolled in the study. Yet a
number of important studies in the literature compare a single
intervention area with only one control area.
Other epidemiological weaknesses exist in the data. Blum
and Feachem (1983) reviewed 50 studies of the health effect of
water supply and sanitation projects and noted that every one
contained one or more of these basic errors of methodology. A
further weakness in the evidence for the effect of water supply
on diarrheal disease burden is that most of it relates to
diarrheal disease morbidity, and significant assumptions are
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Table 41.2 Percentage Reductions in Disease Rates
Assumed by Bradley 
Percentage reduction expected 
Diagnosis from excellent water supply
Most diarrhea and dysentery 50
Typhoid fever 80
Paratyphoid, other Salmonella 40
Trachoma 60
Scabies 80
Skin and subcutaneous infections 50
Urinary schistosomiasis 80
Intestinal schistosomiasis 40
Malaria 0
Source: White, Bradley, and White 1972.
needed to extrapolate such evidence to an effect on diarrheal
mortality.
Effect on Diarrheal Disease. Esrey and Habicht (1985) and
Esrey and others (1991) reviewed the same literature from a
different perspective. Though conscious of the methodological
shortcomings of most studies, they sought to assess the overall
reductions in diarrheal disease that water supply could be
expected to cause. They applied a number of criteria of epi-
demiological rigor and took the median reduction in morbidity
reported from each type of intervention. Their conclusions are
summarized in table 41.3.
For more than a decade, this review has remained the most
authoritative on the subject. However, the small reductions in
disease that it reports for water supply conceal an important
heterogeneity. Though these overall results are frequently
quoted, the following remark by Esrey and others (1991, 613)
has usually been overlooked:
In the studies reporting a health benefit, the water supply
was piped into or near the home, whereas in those studies
reporting no benefit, the improved water supplies were pro-
tected wells, tubewells, and standpipes.
In the studies in the two reviews by Esrey and Habicht
(1985) and Esrey and others (1991) in which the water supply
was provided in the home, the median reduction in diarrheal
disease is 49 percent (from 12 studies), and the reduction from
the two better studies is 63 percent. Those reductions are sev-
eral times greater than the overall median impacts in table 41.3.
The 63 percent figure will be used in the burden of disease cal-
culations that follow. In the two better studies, the members of
the comparison group were using not an unimproved water
supply, but a protected water source away from the home. The
reductions they found are, therefore, in addition to those
resulting from a public standpost level of service.
Some subsequent studies have confirmed this pattern. For
example, Bukenya and Nwokolo (1991) showed in Papua
New Guinea that use of a household tap was associated with
56 percent less diarrhea than use of public standposts provid-
ing water of good quality.
Conditions for Health Effect. Providing a public water point
appears to have little effect on health, even where the water pro-
vided is of good quality and replaces a traditional source that
was heavily contaminated with fecal material. By contrast,
moving the same tap from the street corner to the yard pro-
duces a substantial reduction in diarrheal morbidity. How is
this pattern to be understood?
The first step to an explanation is an understanding that
most endemic diarrheal disease is transmitted by water-washed
routes and is not waterborne. Although waterborne epidemics
of diarrheal diseases such as cholera and typhoid have been
notorious in the history of public health, the endemic pattern
of transmission seems to be different, particularly in poor com-
munities. Five types of evidence support this view:
• Negative health impact studies. As mentioned earlier, Esrey
and Habicht (1985) and Esrey and others (1991) cite a num-
ber of studies of the health impact of water supplies in
which water quality improvements have failed to have a sig-
nificant effect on diarrheal disease incidence.
• Food microbiology. Studies of the microbiology of foods in
developing countries—particularly the weaning foods fed
to children in the age group most susceptible to diarrheal
disease—have shown such food to be far more heavily con-
taminated with fecal bacteria than is drinking water
(Lanata 2003), even when the water has been stored in
open pots.
• Seasonality of diarrhea. In countries with a seasonal varia-
tion in temperature, bacterial diarrheas peak in the warmer
season, whereas viral diarrheas peak in the winter. This pat-
tern suggests that the bacterial pathogens show environ-
mental regrowth at some stage in their transmission route,
which means that they must have a nutritional substrate.
Water is, thus, a less likely vehicle than food.
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Table 41.3 Median Reductions in Diarrhea Morbidity Reported from Different Water Supply and Sanitation Interventions
Number of rigorous studies Median reduction in 
Intervention (object of from which morbidity diarrheal morbidity 
improvement) reductions could be calculated (percent)
Water quality only 4 15
Water quantity only 5 20
Water quantity and quality 2 17
Sanitation only 5 36
Water and sanitation 2 30
Hygiene promotion only 6 33
Source: Esrey and others 1991.
• Fly-control studies. Trials in rural Asia and Africa have
shown that fly control can reduce diarrheal disease inci-
dence by 23 percent (Chavasse and others 1999).
• Hand-washing studies. A recent systematic review of the
effect of hand washing with soap has shown that this simple
measure is associated with a reduction of 43 percent in diar-
rheal disease and 48 percent in diarrheas with the more life-
threatening etiologies (Curtis and Cairncross 2003).
Those five types of evidence suggest that domestic
hygiene—particularly food and hand hygiene—is the principal
determinant of endemic diarrheal disease rates and not drink-
ing water quality.
The second step is an understanding of how the level of
service and convenience of a water supply influence such
hygiene practices in the home. Taking the amount of water
used per capita as an indicator of hygiene changes, other things
being equal, one finds that providing a source of water closer to
the home—and therefore more convenient to use—has very
little effect on water consumption unless the old source was
more than 1 kilometer (30 minutes’ roundtrip journey) away
from the user’s dwelling (Feachem and others 1978).
However, water consumption doubles or triples when house
connections are provided (White, Bradley, and White 1972),
and reason exists to believe that much of the additional con-
sumption is used for hygiene purposes. For example, Curtis
and others (1995) found that provision of a yard tap nearly
doubled the odds of a mother washing her hands after cleaning
her child’s anus and more than doubled the odds that she
would wash any fecally soiled linen immediately.
In conclusion, water supplies are likely to have an effect on
diarrheal disease when they lead to hygiene behavior change—
that is, when the old source of water was more than 30 minutes’
roundtrip away or when house connections are provided.
By a happy coincidence, then, the health benefits of water
supply are most likely to be realized in exactly those cases in
which the time-saving benefit is greatest—when the old source
of water is farthest away, and when the new one is on the plot
of the individual household. Though water supplies offering
house connections are more expensive, the additional time
savings offered by this level of service mean that people are
willing to pay more for them. Moreover, collecting revenue
from households with private connections is far simpler than
collecting it from public taps because the sanction of discon-
nection can be used against households that default on pay-
ment of the tariff.
Calculating the burden of disease associated with inade-
quate water supply requires a figure for the reduction associ-
ated with the levels of service for which coverage statistics are
available. The following burden of disease calculations are
based on a reduction of 17 percent from an improved public
water supply (table 41.3) and of a further 63 percent from
house connections.
The effect of water supply improvements (and of hygiene
practices such as hand washing) on diarrhea mortality can be
expected to be at least as great as—and probably greater than—
their effect on morbidity for several reasons. A theoretical argu-
ment for this improvement pattern is given by Esrey, Feachem,
and Hughes (1985) in terms of infectious doses. Esrey and
others (1991) also reported a median reduction of 65 percent
in diarrhea mortality attributable to water supply, sanitation, or
both in three studies, compared with 22 percent from 49 stud-
ies of morbidity. The effect of hand washing on life-threatening
diarrheas—shigellosis, typhoid, cholera, and hospitalized
cases—is greater than that on diarrhea morbidity as a whole
(Curtis and Cairncross 2003). Finally, the two known direct
studies in the literature of the effect of house connections on
diarrhea mortality (“Serviço Especial da Saúde Pública,” an
unpublished study in Palmares, Pernambuco, Brazil, cited by
Wagner and Lanoix 1959; Victora and others 1988) found
reductions of 65 percent (relative to a public standpost) and
80 percent (relative to various communal sources, some
polluted), respectively.
Effect on Other Disease Categories. Water supplies have a
beneficial effect on a number of disease groups other than diar-
rhea, although the corresponding burden of disease is far less.
The median reductions in morbidity from other water-related
conditions, reported by Esrey and others (1990), are shown in
table 41.4.
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Table 41.4 Median Reductions in Morbidity Associated with Improved Water Supply and Sanitation: Conditions Other Than
Diarrhea, Related Most Closely to Water Supply
All studies Better studies
Median reduction Median reduction Range 
Disease Number of studies (percent) Number of studies (percent) (percent)
Dracunculiasis 7 76 2 78 75–81
Schistosomiasis 4 73 3 77 59–87
Trachoma 13 50 7 27 0–79
Source: Esrey and others 1990.
To be effective in controlling schistosomiasis, the water sup-
ply must be so convenient as to discourage water contact for
laundry and bathing. It is unlikely that this level of convenience
can be achieved without house connections.
Evidence suggests that water availability and hygiene can
produce substantial reductions in trachoma (Emerson and
others 2000). Because the reductions come from hygiene
improvements such as hand and face washing, they are also
likely to be greatest with house connections. Dracunculiasis is
affected by water quality, but the simplest improved water sup-
ply is adequate to prevent transmission.
Conflicting evidence exists about whether water supply or
improved water-washed hygiene affects the transmission of
intestinal helminths. On one hand, Henry (1981) found in an
intervention study in St. Lucia that piped water supplies were
associated with a 30 percent reduction in ascariasis among chil-
dren under age three over a two-year period. On the other hand,
Han and others (1988) showed in Burma that an intervention
to promote hand washing with soap had no effect on prevalence
or intensity of infection with Ascaris spp. However, the poten-
tial contribution of water supply to reducing the burden of dis-
ease through its effect on these other infections is relatively
minor when compared with its effect on diarrheal disease.
EXCRETA DISPOSAL 
In much the same way as with water supply, care is needed to
ensure that different people who talk about sanitation are refer-
ring to the same thing. When the WHO-UNICEF Joint
Monitoring Program was compiling the Global Water Supply
and Sanitation Assessment 2000 Report (WHO and UNICEF
2000), a major effort was needed to persuade some of the Latin
American partners that a pit latrine, considered a status symbol
in much of rural Africa, was an acceptable form of excreta dis-
posal. In some countries, even engineered sewerage systems are
considered unacceptable if not connected to a functioning
wastewater treatment plant.
Levels of Service, Technologies, and Their Costs
A wide range of technologies is used, particularly for settings in
which low-cost solutions are required, and this variation has
led some to inquire whether the different types of latrine might
confer differing health benefits. In the early 1980s, the World
Bank established a Technology Advisory Group for low-cost
sanitation, and this question was among those it was asked to
investigate. Using field studies and a thorough literature review,
the group concluded that all types of systems can be operated
hygienically, and that
The greatest determinants of the efficacy of alternative facil-
ities are, first, whether they are used by everyone all the
time, and second, whether they are adequately maintained.
. . . Pit latrines would, from the viewpoint of health rather
than convenience, approximate the same rating as a water-
borne sewerage system. (Feachem and others 1983, 49–50)
The group therefore judged it most appropriate not to dis-
tinguish between sanitation technologies and to consider all of
them as providing adequate access to sanitation as long as
they were private or shared (but not public) and hygienically
separated human excreta from human contact. This definition
was followed in the Global Water Supply and Sanitation
Assessment 2000 Report, which accepted only sewerage, septic
tanks with soakaways, pour-flush latrines, and pit latrines as
improved technologies. Service or bucket latrines and latrines
with an open pit were not accepted. The effect of technology
type on health benefit is discussed further in the sections
that follow.
Public latrines, however, do not provide an adequate solu-
tion to the excreta disposal needs of a community. Quite apart
from the notorious and widespread inadequacies in their
maintenance, they are not usually accessible at night or by the
elderly, by those with disabilities, or—if there is an entry
charge—by young children. Thus, some promiscuous defeca-
tion continues to be practiced, particularly by children, in
communities where public latrines are the only level of service
available.
Figure 41.2 shows the regional median construction costs
per capita of the various sanitation technologies found by the
Global Water Supply and Sanitation Assessment 2000 Report.
Although the simple, on-site systems tend to be cheaper than
systems such as sewerage and septic tanks, the difference is less
than might be expected. For example, a World Bank survey in
several developing countries found the mean cost of conven-
tional sewerage to be 10 times that for on-site systems such as
improved pit latrines and pour-flush toilets (Kalbermatten,
Julius, and Gunnerson 1982). It is likely that the off-site costs
of sewered systems and the cost of the additional water
needed for them to function have not been fully included in
national reports to the Global Water Supply and Sanitation
Assessment 2000 Report. For the purposes of calculating cost-
effectiveness, a construction cost of US$60 per capita seems
adequate for basic sanitation facilities (a household pit latrine,
ventilation-improved latrine, or a pour-flush toilet) in any
region of the developing world. Taking a relatively short life-
time of five years for a latrine and straight-line amortization
gives an annual cost of US$12 per capita per year. In such a
short lifetime, very little maintenance is normally required,
other than occasional cleaning; the cost of maintenance is,
therefore, considered to be included in the amortized annual
cost.
That said, it should be borne in mind that substantially
cheaper solutions are often feasible, such as the “15 taka latrine”
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(costing only US$0.27 per household) developed in Bangladesh,
which includes a pour-flush pan made of tin sheet and an odor-
and insect-proof seal made of flexible plastic pipe.
Social Benefits
Like water supply, sanitation offers a number of social benefits
in addition to direct health gains, which tend to feature more
prominently in the minds of the users. This outcome is illus-
trated by the responses given by a sample of householders in
rural Benin when asked to rate the importance they ascribed to
the various benefits of latrines on a scale of 1 to 4 (table 41.5).
Health-related benefits (shown bold in table 41.5) were rarely
mentioned spontaneously and generally rated among the less
important benefits.
With sanitation as with water supply, strong gender differ-
ences exist in the perception of the social benefits of sanitation.
For male heads of household in Benin as in other countries
around the world, enhanced social status figures highly among
the benefits of latrine ownership, whereas for women, security,
convenience, and aesthetic factors count for more. Women who
lack sanitation often risk sexual harassment on the way to and
from their defecation site. In some cultural settings, women are
constrained to go out for defecation and urination only during
the hours of darkness, effectively becoming prisoners of day-
light. Though no systematic study has been made of the health
implications of such practices, they are likely to include an
increased prevalence of urinary tract infections. The emancipa-
tion that a latrine bestows on such women cannot lightly be
dismissed.
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Table 41.5 Benefits of Latrine Ownership as Perceived by
320 Households in Rural Benin
(Average importance 
Benefit rating, scale 1–4)
Avoid discomforts of the bush 3.98
Gain prestige from visitors 3.96
Avoid dangers at night 3.86
Avoid snakes 3.85
Reduce flies in compound 3.81
Avoid risk of smelling or seeing 3.78
feces in bush
Protect my feces from enemies 3.71
Have more privacy to defecate 3.67
Keep my house or property clean 3.59
Feel safer 3.56
Save time 3.53
Make my house more comfortable 3.50
Reduce my family’s health 3.32
care expenses
Leave a legacy for my children 3.16
Have more privacy for household affairs 3.00
Make my life more modern 2.97
Feel royal 2.75
Make it easier to defecate 2.62
because of age or sickness
Be able to increase my tenants’ rent 1.17
For health (spontaneous mention) 1.27
Source: Jenkins 1999.
Figure 41.2 Median Construction Cost of Sanitation Technologies in Africa, Asia, and Latin America and
the Caribbean
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Willingness to Pay. The governments of developing countries
cannot afford to provide heavily subsidized sanitation to all—or
even to the majority—of their populations. The 2.6 billion peo-
ple in Africa, Asia, and Latin America who do have adequate
sanitation—53 percent of the population of those regions—
have paid most of the cost themselves. Even those of the urban
poor who do not have sanitation have expressed a willingness to
pay for its full cost—or at least the local cost (excluding major
interceptor sewers and treatment works, if required)—in a num-
ber of surveys, as long as credit is available on reasonable terms
to smooth the cash flow (Altaf 1994). With regard to the rural
poor, the success of well-conceived sanitation promotion pro-
grams in achieving coverage close to 100 percent, without a sub-
stantial subsidy, in some of the poorest rural communities in the
world (Allan 2003) shows that people are willing to pay for san-
itation if a suitable product is offered to them on suitable terms.
Why then do 2.4 billion people still lack sanitation? Several
factors constrain the expression of the existing demand.
The constraint most frequently mentioned by unserved
householders is cost, but this factor is usually more a perceived
constraint than an objective one, for several reasons. First, many
households are unaware of the true cost of latrines in their area,
or the lower-cost models are not offered because local suppliers
and artisans do not know about them or are attracted by the
greater margins to be made on the more expensive technolo-
gies. Second, the high cost of capital to the poor rules out their
borrowing the cost of a latrine, which to them would be a sub-
stantial investment. Third, they may be wary of investing in a
property that belongs to their landlord, lest it be used as an
excuse for a rent increase or even eviction. They may also feel,
with some reason, that it is for the landlord to make the invest-
ment, rather than themselves, and they may be waiting for the
landlord to do so. This belief has a similar effect to the common
misapprehension of citizens, often encouraged by politicians,
that the local government is responsible for sanitation and
will eventually come to their aid; in either case, the outcome is
inaction.
Other constraints include lack of ready access to necessary
techniques and skills or to specific building materials and
components. Where the skills exist locally, residents may lack
confidence in the quality of work and value for money offered
by the local artisans, or they may not know how to contact the
right artisans. In many urban areas, local building regulations
make low-cost sanitation technologies illegal.
Those constraints are compounded by the fragmentation of
governmental responsibility for sanitation. Often it is devolved
to local governments with little capacity to implement sanita-
tion improvements. At the national level, one ministry may be
responsible for sewerage and another for low-cost technolo-
gies; one may be responsible for construction, another for pro-
motion, and a third for enforcing building codes and planning
regulations.
Policy Implications. There are important externalities to
households’ investment in sanitation. Households are pro-
tected from their own feces by their sanitation facilities, but so,
too, are their neighbors, and this factor is probably more
important in epidemiological terms. If households are not fully
aware of the health benefit—or if much of it accrues to oth-
ers—a case exists for public intervention to increase coverage
because these externalities exist.
This public intervention need not be in the form of subsidy.
Strong arguments can be marshaled against a subsidy for low-
cost sanitation (Cairncross 2003a). Subsidy limits the number of
facilities that are built to the size of the subsidy budget; it encour-
ages the design and marketing of unaffordable sanitation sys-
tems; it frequently leads to capture by the better-off, who install
expensive toilets while the poor go without; and it distorts the
market, diverting the efforts of latrine builders who would
otherwise be seeking to meet the needs of low-income groups.
The intervention can be by regulation. National and local
governments have substantial regulatory powers that can be
used to increase sanitation coverage without significantly
increasing costs or public expenditure. For example, more than
90 percent of households in the town of Bobo Dioulasso,
Burkina Faso, have their own latrine (Traoré and others 1994) as
a direct result of the local administration’s practice in the past of
withdrawing rights of land tenure from owners who did not
build a latrine on their plot within a specified time.Another reg-
ulatory intervention is to enforce the obligation of landlords to
provide sanitation for their tenants.
An alternative strategy is to provide support to the market-
ing of sanitation. This strategy can be undertaken in a number
of ways that are not feasible for the existing producers, mainly
artisan builders and small component manufacturing work-
shops. Those interventions would aim principally at overcom-
ing the constraints to the expression of effective demand for
sanitation and could include the following:
• advertising and other forms of promotion 
• facilitation of building regulation approval 
• brokerage to put potential purchasers in touch with
providers 
• quality assurance and guarantee schemes 
• training in low-cost construction techniques and in
marketing 
• centralized production of essential components 
• provision of pit emptying and desludging services.
Promotion of improved hygiene practices, including appro-
priate use and maintenance of the sanitation facilities, is
another possible intervention by the public sector. All of those
measures will help increase sanitation coverage and health
benefits and are appropriate interventions for the health sector.
The costs of several of them are recoverable (after an initial
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launch period) as fees, so that public intervention need not
require public expenditure.
Costs of Promotion. The costs of promotion and administra-
tion found in two government-run rural sanitation programs
documented by the World Bank were US$16.80 (Zimbabwe)
and $20.00 (the Philippines) per latrine, respectively
(Cairncross 1992). Because these costs are largely fixed, the cost
per unit falls as the number of units built increases. Unit costs
will therefore be high in relatively unsuccessful programs.
Successful programs, on the other hand, often engender the
construction of more latrines than they can account for, which
also gives an upward bias to the promotional costs per unit
built. For example, for every latrine built by Lesotho’s rural
sanitation program in the late 1980s, four others were built
independently but as a result of its promotional activities.
More recently, successful sanitation programs managed by
nongovernmental organizations (NGOs) have documented
slightly lower unit costs for promotion. For example, the
Zimbabwean NGO AHEAD (Applied Health Education and
Development), working through district-level health staff and
a network of community health clubs, achieved the construc-
tion of 3,400 latrines in Makoni district within two years at a
total promotional cost of US$45,660, or US$13.43 per unit,
equivalent to US$2.24 per household member served
(Waterkeyn 2003). In Bangladesh, WaterAid and its partner, a
local NGO named VERC (Village Education Resource Centre),
have developed an approach that has successfully achieved 100
percent sanitation coverage and the elimination of open defe-
cation in more than 100 villages in six districts at a cost of US$8
per household, or US$1.50 per capita (Allan 2003). Both pro-
grams also promoted domestic hygiene practices in addition to
the construction and use of latrines. In Bangladesh, all (and in
Zimbabwe, most) of the costs of latrine construction were paid
by the population themselves.
The programs in Bangladesh and Zimbabwe were particu-
larly successful and well managed. The promotion cost is taken
as US$2.50 per capita for cost-effectiveness calculations, which
is slightly above the higher of the two, to allow for the imper-
fections of sanitation programs in the real world.
Direct Health Benefits
Evidence supports the claim that improved excreta disposal
helps prevent a number of diseases, including diarrhea, intes-
tinal worm parasites, and trachoma. Of these, the effect that
accounts for the largest burden of DALYs is that on diarrheal
disease.
Diarrheal Disease. The effect of sanitation on diarrhea mor-
bidity has already been mentioned. Table 41.3 shows the results
of Esrey and others’ (1991) review, attributing a median reduc-
tion in incidence of 36 percent to sanitation. Although this fig-
ure is the median of the five “better” studies, it must be inter-
preted with great care because almost all the known studies on
the health effects of sanitation are observational studies that
use self-selected exposure groups. Confounding by a sense of
hygiene is likely to be a significant problem in any such study.
From Brazil to Bangladesh, the owners of latrines have been
observed to behave more hygienically than their neighbors in
practices such as hand washing that are not affected by the
presence of a latrine (Hoque and others 1995—see table 41.6;
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Table 41.6 Factors Associated with Hand-Washing Behavior by 90 Women in Bangladesh
Hand-washing behavior 
Ratio of prevalences of observed after defecation
good practice (95 percent 
Associated factor Good Poor confidence interval)
Uses own sanitary latrine
Yes 22 11 1.73
No 22 35 (1.15–2.59)
Uses tubewell water exclusively
Yes 18 10 1.53
No 26 36 (1.03–2.29)
Owns agricultural land
Yes 36 24 2.25
No 8 22 (1.20–4.22)
Believes that washing hands prevents diseases
Yes 26 27 1.01
No 21 18 (0.66–1.55)
Source: Hoque and others 1995.
Strina and others 2003). It is thus impossible to prove, except
by an intervention study, that any health benefit associated with
latrine ownership is due to the latrine and not to the hygiene
habits of latrine owners.
The overall reduction in diarrhea from sanitation quoted by
Esrey and others (1991) likely disguises considerable hetero-
geneity in terms of the context rather than the type of sanita-
tion technology. For example, sanitation is likely to have a
greater effect on diarrheal disease in high-density urban areas,
where open defecation leads to gross fecal pollution of the
neighborhood, and less effect in rural communities, where all
but the youngest children use communal defecation sites some
distance away from their homes.
For example, Moraes and others (2003), working in urban
favelas in northeast Brazil, found that diarrhea incidence
among children in households with a toilet was half that in
households that did not have one. This comparison is likely to
be affected by confounding because the households with toilets
were a self-selected group. Comparison between communities
is less likely to be affected by confounding, but Moraes and oth-
ers found a greater reduction. The mean incidence of diarrhea
in young children in communities with sewers was only one-
third of that in the communities that, for administrative and
technical reasons, did not have sanitary drainage.
Thus, although the quality of the studies reviewed by Esrey
and others (1991) was in general poor and the range of reduc-
tions wide, little doubt exists that excreta disposal can be asso-
ciated with significant reductions in diarrhea morbidity.
Studies showing that proximity to open or overflowing sewers
(Moraes and others 2003), failure to dispose hygienically of
children’s stools (Traoré and others 1994), or the presence of
excreta on the ground in the household compound (Bukenya
and Nwokolo 1991) is a risk factor for fecal-oral infections pro-
vide supporting evidence for the likely effect of sanitation
infrastructure, particularly in urban settings, on diarrheal dis-
ease transmission.
In conclusion, there are some reasons, such as the likeli-
hood of confounding, to believe that Esrey and others’ (1991)
median reduction is an overestimate, but reasons exist also to
believe that the reductions measured were not as great as they
might have been had the provision of sanitation been
accompanied by hygiene promotion to ensure that the facili-
ties were fully and appropriately used (especially by young chil-
dren) and maintained. A systematic review of the effect of san-
itation on diarrheal disease is urgently required. Meanwhile,
and on balance, Esrey and others’ median reduction of 36 per-
cent in diarrhea incidence is the most authoritative estimate
available.
Interaction with Water Supply. The results of Esrey and oth-
ers’ (1991) review suggest that the effect of water supply and
sanitation combined is no greater than that of either on its
own. However, that conclusion is based on only two studies,
and the percentage reductions found in the individual studies
of each type of intervention exhibit a wide range. Reflection on
how in practice each of the two interventions interrupts the
transmission of fecal-oral pathogens would suggest that their
effects would be largely independent: whereas water supply
helps prevent contamination of drinking water, hands, and
food, excreta disposal helps prevent contamination of the
household yard and surroundings, including children’s play
areas. Esrey and others (1990) reported three other studies in
which sanitation and water supply had a greater effect together
than individually, but the reductions in diarrhea incidence in
those studies could not be calculated.
For the purpose of burden of disease calculations, therefore,
the effects of water supply and sanitation improvements on
diarrhea are considered here to be independent and additive,
which has the advantage of simplicity.
Effect on Other Disease Categories. The first evidence for the
health benefits of excreta disposal related not to its effect on
diarrheal disease but on intestinal helminths.
A prolonged series of in-depth studies from 1920 to 1930 by
researchers of the Rockefeller Foundation established beyond
doubt that promiscuous defecation, especially in the household
surroundings and particularly by children, played a major role
in the transmission of Ascaris spp., Trichuris spp., and hook-
worms in a range of settings from Panama to China and the
southeastern United States. By implication, the use of sanitary
toilets should interrupt transmission by that route.
However, more recent attempts to measure the reductions
in parasite prevalence or intensity attributable to improved
sanitation have often suffered from the same shortcomings as
the studies of their impact on diarrheal disease; many have
been cross-sectional studies and, therefore, subject to con-
founding.
Esrey and others (1991), in reviewing this literature, found
that water supply and sanitation reduced the prevalence of
ascariasis by a median of 28 percent (range 0 to 83 percent) and
of hookworm infection by 4 percent (0 to 100 percent). Those
reductions are likely caused by the sanitation rather than by the
water-supply improvements. Indeed, three of the nine positive
studies of ascariasis and three of the five positive studies of
hookworm involved sanitation alone. It is also likely that the
effect of excreta disposal on Trichuris infection is similar to that
on ascariasis (Henry 1981).
Much emphasis has been placed in recent years on
chemotherapy as a control intervention for intestinal
helminths, particularly the chemotherapy of schoolchildren.
However, that option is not always sustainable because the
children are quickly reinfected by the eggs and larvae that
remain in the environment. Sanitation, particularly school
sanitation, has been adopted by the major international donor
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agencies as an integral component of the FRESH (Focusing
Resources on Effective School Health) framework to ensure its
sustainability.
A study in Bangladesh (Mascie-Taylor and others 1999) sug-
gested that chemotherapy was more cost-effective (though less
effective) as a helminth control intervention than a health edu-
cation program that included the promotion of sanitation.
However, the health education program was excessively labor
intensive and, therefore, expensive; it involved the constant
deployment of six health educators and a supervisor in each
study area of only 550 households, resulting in a cost of
Tk 1600 (US$30) per household, compared with Tk 330
(US$6) per year for chemotherapy. That cost compares with
the total cost of US$8 per family for WaterAid’s successful “100
percent sanitation” approach in rural Bangladesh (Allan 2003).
Whereas the promotion of sanitation is a one-time cost, the
cost of chemotherapy is a recurrent annual expenditure.
Allowing for such a sanitation promotion initiative once every
five years—and using the chemotherapy costing of Mascie-
Taylor and others (1999)—sanitation promotion is more 
cost-effective against helminths in Bangladesh than is
chemotherapy. If the cost were apportioned between the effect
on diarrheal disease and the effect on helminths, sanitation
would be far more cost-effective than chemotherapy.
Sanitation can also help prevent trachoma. More than
70 percent of the incidence of this infection has been shown to
be caused by flies, mainly of the species Musca sorbens, which
breeds preferentially in scattered human feces. Pit latrines have
been shown to reduce the population of these flies by depriving
them of their breeding sites (Emerson and others 2004).
HYGIENE PROMOTION
To a greater degree than with water supply and sanitation, lam-
entably little reliable evidence exists on the cost or the effec-
tiveness of interventions to change hygiene behavior and still
less on the relative cost-effectiveness of different approaches to
the design of such interventions.
The Shortage of Evidence
With regard to effectiveness, Loevinsohn (1990) reviewed
health education interventions in developing countries and
applied four relatively modest criteria of scientific rigor to the
67 published studies he found:
• a description of the intervention in sufficient detail to allow
its replication
• an objective outcome measure, based either on health status
or on behavior change
• a control group and a sample size greater than two clusters
or 60 individuals
• a description of the target population (in terms of their level
of education and other factors) adequate to permit a judg-
ment of the relevance of the study to other contexts.
Only three studies were found to meet all four criteria. One
(Stanton and Clemens 1987) dealt with environmental hygiene
promotion and raises some doubts—although the hygiene
behavior of the intervention group was better than the control,
both were significantly worse than they had been before the
intervention.
A subsequent review of 31 studies (Cave and Curtis 1999)
found 5 more studies that could be considered methodologi-
cally sound, but none showed a clear effect on behavior. Of a
further 11 studies of “reasonable” rigor, only two showed a
major effect on behavior.
Shortcomings also exist in the cost data. Many costings are
based on budget forecasts and not on real expenditures. Even
when actual expenditures are used, major difficulties exist in
apportioning the overhead costs that make up a significant
proportion of the total. Health educators and the resources
they use (such as vehicles) are rarely dedicated exclusively to
health education. A further problem in the derivation of unit
costs is agreeing on the denominator, which can be the number
of people attending health education sessions, the number of
members in their households, or the number of people in the
target catchment area. For those reasons, different analysts are
likely to derive different unit costs from the same data; indeed,
the same authors have on occasion arrived at widely differing
unit cost figures from the same data.
Time adds a further dimension to this discussion. Do inter-
ventions to promote hygiene behavior change have to be
implemented continuously, or at least annually, if their effect is
to be sustained, or are such changes self-sustaining? 
Sustainability
We will take the last question first. Wilson and Chandler (1993)
returned after two years to a population in which a four-month
intervention to promote hand washing with soap had included
provision of free soap. They found that 79 percent of mothers,
the original target group, had continued the practice despite
the fact that they now had to buy the soap.
Further evidence of the sustainability of new hygiene
behaviors was found by Cairncross and Shordt (2003) in a col-
laborative study with partner organizations in six developing
countries in Africa and South Asia. Target populations of pre-
vious hygiene promotion projects were visited at 12-month
intervals, and various indicators of hygiene behavior were
assessed and compared. In four of the six countries, indicators
for populations in which the intervention had ended relatively
recently were also compared with those in areas where the last
intervention had ended several years previously. Those two
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types of comparison, with the various indicators assessed in
each country, allowed a total of 46 comparisons to be made.
Only in three such comparisons was there any indication of a
falling-off of hygiene with time since the intervention ended; in
one case, the falling-off was attributable to the deteriorating
condition of the latrines from wear and tear rather than to a
decline in compliance.
In some cases, new hygiene practices have become stronger
or more prevalent after the ending of external intervention to
promote them, as they become self-propagating and consoli-
dated in the community’s material culture (Allan 2003).
It is likely that hygiene promotion activities need to be
repeated from time to time—say, every five years—but are not
required on a continuous basis. It follows from this observation
that calculations of cost-effectiveness should take into account
the morbidity and mortality averted not only during the imple-
mentation of the intervention, but also for a number of years—
perhaps five—thereafter.
Costs
Cases in which the costs as well as the effectiveness of hygiene
promotion programs have been documented objectively are
few indeed. In the absence of suitable data, Varley, Tarvid, and
Chao (1998) calculated a costing for a typical program from
first principles, arriving at a cost of US$3 (range US$2 to US$3)
per household per year, or US$0.60 per capita.
One of the few cases in which data exist is a program in urban
Burkina Faso described by Borghi and others (2002). Their data
show that the total cost to the provider of the three-year inter-
vention was US$0.65 per capita, or US$4.54 per seven-person
household, after deducting the cost of the international research
component. Of this total, 63 percent is composed of adminis-
tration and undifferentiated start-up costs of the project. Most
of the remaining costs were accounted for in roughly equal
measure by house-to-house visits, discussions in health centers,
hygiene lessons in schools, and street theater presentations.
Additional costs were incurred by the 18.5 percent of house-
holds that complied, practicing improved hygiene as a result of
the program, amounting to US$8 per household per year.
More than 90 percent of that sum was the cost of soap for hand
washing.
However, on the basis of the observed increase in prevalence
of hand washing with soap, the intervention was estimated to
have averted sufficient diarrhea morbidity and mortality to
save US$2.80 per household per year (US$15 per compliant
household per year) in direct costs of medical care and indirect
costs attributable to lost productivity. Of this total, 93 percent
represented the lost future productivity associated with the
deaths of young children.
Waterkeyn (2003) provides an example from rural
Zimbabwe. In the two districts in which the Community
Health Clubs approach was examined, it was successful in
increasing the prevalence of hand washing with soap among
the club members by 6 percent and 37 percent, respectively, and
it was successful in reducing the prevalence of open defecation
by 29 percent and 98 percent, respectively. The marginal cost of
the intervention, which used existing health staff, was US$4.00
per club member, or an average of US$0.67 per member of an
affected household. Including the salaries of staff members
would roughly double the figure to about US$1.40 per capita.
Those figures can be compared with an estimate of US$5.00
per mother (in 1982 dollars) by Phillips and others (1987)
based on a review of several programs. Assuming that roughly
1 in 10 members of the population are mothers of young chil-
dren, this cost is equivalent to about US$0.50 per capita. For
cost-effectiveness analysis, a nominal cost of US$1.00 per cap-
ita is, therefore, taken because it is roughly the midpoint of the
range of recent estimates.
Effect on Diarrhea
Esrey and others (1991) found only six studies of the effect of
hygiene promotion interventions on diarrhea morbidity, with a
median reduction of 33 percent. A subsequent review by
Huttly, Morriss, and Pisani (1997) arrived at a similar result—
a median reduction of 35 percent.
The interventions promoting the single hygiene practice of
washing one’s hands with soap tended to achieve greater reduc-
tions in disease than those that promoted several different
behaviors. That finding was confirmed by a systematic review
of the literature on hand washing (Curtis and Cairncross
2003), which concluded that hand washing with soap—and
interventions to promote it—could reduce diarrhea morbidity
by 43 percent and life-threatening diarrhea by 48 percent.
Because the effect of diarrhea prevention in DALYs is mainly
attributable to the prevention of diarrhea deaths, the higher of
these two figures is more appropriate for calculating the effect
of hygiene promotion on the burden of disease.
It is not surprising that interventions advocating more
behavior changes should have less effect, because numerous
messages dilute one another in the minds of the target audi-
ence. Because some of the interventions in the systematic
review were planned without an adequate prior program of
formative research, it is possible that they could have had a still
greater effect if they were better conceived.
Effect on Respiratory Infections
Reasons exist to believe that hand washing with soap could be
a cost-effective intervention not only against diarrheal diseases,
but also for the prevention of acute respiratory infections
(ARIs). The intervention is plausible, given what is known
about the transmission routes of ARIs, and there is also
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epidemiological evidence, in that all six published studies of the
effect of hand washing on ARIs show a significant reduction
(Cairncross 2003b).
These two disease groups are the most important causes of
child mortality worldwide, and respiratory infections also
cause significant adult mortality, for which no alternative pre-
ventive intervention is yet available, field-tested, and ready for
implementation. A randomized, controlled trial of the efficacy
of hand-washing promotion on an ARI outcome is an urgent
priority for future research.
Interactions with Water Supply and Sanitation
It can be argued that there is little point in encouraging people
to wash their hands if they do not have access to water or to use
a latrine if they do not have one.
The argument has only limited validity where sanitation is
concerned; an important role for any hygiene promotion is to
promote sanitation itself. With regard to water, in the studies
reviewed by Curtis and Cairncross (2003), the reductions in
disease achieved by hand washing in settings with indoor
piped water supply were not significantly different from those
achieved elsewhere. Given that the rationale is ambivalent and
the evidence inconclusive, the simplest plausible assumption is
that the effects of water supply, sanitation, and hygiene pro-
motion on diarrhea are independent and additive to one
another.
EFFECT ON BURDEN OF DISEASE 
The effect of water supply, sanitation, and hygiene on the global
burden of disease can now be estimated, in two stages. First, the
evidence presented in this chapter is used to arrive at the reduc-
tions in diarrhea that are expected to result from the various
combinations and levels of service and that are assumed for the
calculation. Then, these figures are applied to the coverage lev-
els for individual countries and the burden of diarrheal disease
prevailing in the different regions of the world. Because such a
calculation has been done before by Prüss and others (2002)
from rather different premises, it was desirable to examine the
comparability of the results.
Assumptions: Reductions in Diarrheal Disease
In summary of the discussion of health effects in this chapter,
water supply, sanitation, and hygiene promotion are considered
to be associated, under typical conditions, with the reductions
in diarrheal disease morbidity shown in table 41.7. These
reductions are considered to be independent of one another,
so that the relative risks for several interventions can be
multiplied.
These assumptions can be compared as follows with the
assumptions underlying a previous calculation of the global
burden of disease from water, sanitation, and hygiene (Prüss
and others 2002; WHO 2002). For that calculation, the follow-
ing seven scenarios were considered:
VI. No improved water supply or basic sanitation
Va. Basic sanitation only
Vb. Improved water supply only
IV. Improved water supply and basic sanitation
III. Improved water supply and basic sanitation plus house
connection water supply, or improved hygiene or water
disinfected at point of use
II. “Regulated” water supply (presumably house connec-
tion) and full sanitation 
I. Ideal situation, corresponding to absence of disease
transmission through water, sanitation, and hygiene.
Scenario II is essentially the position prevailing in industri-
al countries. Leaving out scenarios I and III, which apply to
only a small proportion of the population, the following sce-
narios are broadly equivalent to the categories considered
earlier in this chapter:
VI. No improved water or sanitation
Va. Sanitation only
Vb. Improved water supply (public source)
IV. Both improved water supply and sanitation
II. House connection water supply, and sanitation.
In the Prüss model, the relative risks associated with transi-
tion from scenarios Va and Vb to VI are taken as 1.26 and 1.60,
respectively, comparable with the figures of 1.20 and 1.56 in
table 41.7. However, Prüss and others (2002) assume equal risks
in scenarios IV and Va, whereas a relative risk of 1.20 follows
from the assumption in this chapter that the effects of water
supply and sanitation are independent. The Prüss model
assumes a relative risk of 1.54 between scenarios III and IV,
corresponding to the diarrhea reduction of 35 percent from
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Table 41.7 Assumed Reductions in Diarrhea Attributable to
Water Supply, Sanitation, and Hygiene Promotion
Reduction in Corresponding 
Intervention diarrhea (percent) relative risk
Water supply
Public source 17 1.20
Additional, for house 63 2.70
connection
Excreta disposal 36 1.56
Hygiene promotion 48 1.92
Source: Authors.
hygiene promotion found by Huttly, Morriss, and Pisani
(1997). Scenario III is essentially a theoretical construct, and
between it and scenario II a further relative risk of 1.8 is
assumed (in what Prüss and others term their realistic
approach), on the basis of some recent trials of home disinfec-
tion of water, giving a total of 2.76 between scenarios IV and II.
The latter figure is close to the corresponding value of 2.70
implied by the assumptions made here, for different reasons.
Scenario I, like scenario III, is included not because it is preva-
lent in reality, but to illustrate a point. Its equivalent would
be the generalized and effective implementation of a well-
conceived hygiene promotion intervention. Because such
hygiene promotion has hardly ever been provided to whole
populations, it is similarly hypothetical. From that perspective,
the corresponding relative risks of 2.5 (Prüss and others 2002)
and 1.92 (table 41.7) are of a similar order of magnitude.
The similarity of the two sets of assumptions, based on
rather different premises, is illustrated in figure 41.3.
To allow for the uncertainty in their assumptions, Prüss and
others (2002) calculated the burden of disease attributable to
water supply, sanitation, and hygiene using two approaches.
The realistic approach used the assumptions described above
and shown in figure 41.3. The minimal approach assumed no
difference in risk between scenarios II and III. Given the ideal
and hypothetical nature of scenario I and the low probability of
intensive hygiene promotion being funded for a population
that already benefits from high levels of water supply and san-
itation provision, we consider the model on the right of figure
41.3 as optimistic and prefer to take for our more realistic
approach the less ambitious baseline of house connections and
full sanitation, which approximates the current position in
most of Western Europe and North America. This approach
responds to recent calls for “baselines and counterfactuals
which should include alternative, operationalizable policy/pro-
gram options (including the status quo)” (Ezzati 2003, 458). It
also has the advantage of providing an estimate of burden of
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1.26
2.50
2.76
(1.80) 
1.54 
1.00 
1.60
Prüss and others‘
model
I: Ideal—no
disease
transmission 
II: House
connection and
sanitation
III: Piped water
supply or other
improvement
IV: Improved water
and
basic sanitation 
Va: Basic
sanitation
Vb: Improved
water supply 
VI:
No water
supply or sanitation
1.201.56
(1.92)
2.70
1.20 
Present model 
House connection,
sanitation, and
hygiene promotion 
House
connection and
sanitation
Improved
water and basic
sanitation
Basic
sanitation
Improved
water supply
No water
supply or
sanitation
Source: Authors and Prüss and others 2002.
Note: The numbers show relative risk of diarrhea in upper relative to lower boxes. Relative risks in parentheses are set to 1.0 for the minimal version of the Prüss
model and for the realistic version of the present model.
Figure 41.3 Comparison of Assumptions Made by Prüss and others (2002) and in this chapter.
disease to which the industrial countries contribute only a
negligible amount.
Calculation of Burden of Disease 
Prüss and others (2002) worked with water and sanitation cov-
erage data for individual countries (WHO and UNICEF 2000)
to derive distributions of the population in each region
between five of the seven scenarios, as shown in table 41.8.
They then combined these figures with the relative risks in fig-
ure 41.3 and diarrhea incidence and case fatality rates from
Murray and Lopez (1996) to derive estimates of the number of
DALYs attributable to water supply, sanitation, and hygiene in
each region and mortality subregion. The results are shown, for
their realistic and minimal models, in the first two columns of
table 41.9. The realistic estimates are those presented in the
World Health Report 2002 (WHO 2002, 225).
Using the same spreadsheets but the relative risks on the
right of figure 41.3, we derive the results in the third and fourth
columns of table 41.9 for the optimistic and realistic versions of
the present model. The figures for the burden of disease attrib-
utable to deficient water supply, sanitation, and hygiene in the
industrial countries of Europe, North America, and the Pacific
are very different, but the global totals are remarkably similar.
It should be no surprise to find that the attributable burden
in the industrial (that is, low-mortality) countries of Europe,
North America, and the Pacific is zero or very close to zero. The
realistic model was deliberately designed to take as its baseline
the conditions prevailing in those countries. This finding does
not mean that no diarrheal disease in those countries can be
attributed to deficient water supply, sanitation, or hygiene;
rather, it means that the baseline there is the current condition,
because no realistic policy option is available to reduce the bur-
den of such disease in the immediate future.
Table 41.10 shows the two realistic assessments of DALYs
attributable to water supply, sanitation, and hygiene in terms of
percentages of the total DALYs in each region and subregion.
Again, the two estimates are close. The proportion of the total
disease burden attributable to water, sanitation, and hygiene
is greatest in the high-mortality countries of the Eastern
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Table 41.8 Distribution of the Population between Scenarios of Water Supply and Sanitation Provision 
(percent)
Region 
Scenario
(mortality in children and adults) II IV Va Vb VI
African
Child high, adult high 0 54 5 6 35
Child high, adult very high 0 42 10 9 38
American (Western Hemisphere) 
Child very low, adult very low 99.8 0 0 0 0.2
Child low, adult low 0 76 1 9 14
Child high, adult high 0 68 0 7 25
Eastern Mediterranean
Child low, adult low 0 83 5 8 4
Child high, adult high 0 66 0 16 18
European
Child very low, adult very low 100 0 0 0 0
Child low, adult low 0 79 8 1 12
Child low, adult high 0 94 5 0 1
Southeast Asian
Child low, adult low 0 70 3 7 19
Child high, adult high 0 35 0 53 12
Western Pacific
Child very low, adult very low 100 0 0 0 0
Child low, adult low 0 42 1 33 24
Source: Prüss and others 2002.
Mediterranean region, reaching 6 to 7 percent of the total. They
are followed by the high-mortality countries of Southeast Asia
and Africa, where the water and sanitation complex accounts
for 4 to 5 percent of the total. Globally, improvements in water
supply, sanitation, and hygiene could eliminate 3 to 4 percent
of the global burden of disease.
Cost-Effectiveness
The assumptions regarding effect on diarrheal disease are sum-
marized in table 41.7. Because the effect on diarrheal disease
accounts for the vast majority of the effect, no effort is made to
apportion the costs between their effectiveness in preventing
the other diseases affected by water supply, sanitation, and
hygiene. The costs derived in this chapter are summarized in
table 41.11.
The annual costs used for water supply included both the
amortized construction cost and operation and maintenance
costs. Given that investments in water supply and sanitation
are made largely by other sectors (and for other motives)
than health, an alternative cost-effectiveness estimate is made
that is based only on the costs of regulation, advocacy, and
promotion.
The other assumptions used to calculate the cost-
effectiveness of improved water supply—of house connections,
of sanitation, and of hygiene promotion—other than those set
out above, are as described by Varley, Tarvid, and Chao (1998).
The key parameters are as follows:
• proportion of population under age five: 17 percent
• diarrhea incidence: five cases per child under age five per
year
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Table 41.9 Distribution of DALYs Attributable to Diarrhea Caused by Poor Water Supply, Sanitation, and Hygiene by Subregion,
According to Various Assumptions 
(thousands)
Region (mortality in WHO 2002 Prüss 2002 Present model Present model 
children and adults) (realistic) (minimal) (optimistic) (realistic)
African
Child high, adult high 6,916 6,198 6,747 5,727
Child high, adult very high 11,720 10,473 11,402 9,678
American
Child very low, adult very low 61 61 49 1
Child low, adult low 1,290 1,143 1,232 1,009
Child high, adult high 756 673 725 613
Eastern Mediterranean
Child low, adult low 629 548 599 482
Child high, adult high 8,303 7,318 7,983 6,653
European
Child very low, adult very low 66 66 52 0
Child low, adult low 550 483 528 426
Child low, adult high 121 105 115 91
Southeast Asian
Child low, adult low 1,241 1,096 1,195 982
Child high, adult high 18,487 16,595 17,856 15,545
Western Pacific
Child very low, adult very low 27 27 21 0
Child low, adult low 3,991 3,574 3,619 3,303
Total, industrial countries 825 742 765 518
Total, developing countries 53,333 47,618 51,358 43,992
Global total 54,158 48,360 52,123 44,510
Source: See Acknowledgments.
• median age at onset of disease: 1 year
• average duration: 8 days
• case fatality rate: 0.5 percent
• coverage by oral rehydration therapy: 30 percent
• oral rehydration therapy reduction in case fatality rate:
50 percent
On this basis, we arrived at the cost-effectiveness values in
table 41.12.
All of these figures underestimate the cost-effectiveness of
investments in water and sanitation, for several reasons:
• The effects of these interventions on diseases other than
diarrhea have not been taken into account; they seem to be
relatively minor for water supply but may be substantial if
hand washing proves to affect ARI.
• Effects on diarrhea mortality, which account for 98 percent
of the DALYs, are likely to be greater than the reductions in
morbidity shown in table 41.7.
• The cost figures have generally been taken so as to be suffi-
cient for all contexts, whereas water supply and sanitation
can be implemented more cheaply in favorable settings—
such as where a convenient aquifer or reliable rainfall exists.
• Potential economies exist in combining the interventions;
for example, sanitation promotion can be combined with
hygiene promotion and water pipes laid with sewers.
• The current global initiative to promote hand washing,
involving commercial marketing expertise, may identify
more cost-effective approaches to hygiene promotion.
• If a sustainable low-cost sanitation industry can be devel-
oped, it will have an interest in promoting its own product.
As they stand, the cost-effectiveness values above, except for
house connections and construction of latrines, are well below
the US$150/DALY cutoff value proposed by the World Bank
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Table 41.10 DALYs Due to Diarrhea Attributable to Poor
Water Supply, Sanitation, and Hygiene by Subregion, as a
Percentage of Total DALYs
Region WHO 2002 Present model
(mortality in children and adults) (realistic) (realistic)
African
Child high, adult high 4.7 3.9
Child high, adult very high 5.6 4.6
American (Western Hemisphere)
Child very low, adult very low 0.1 0.0
Child low, adult low 1.6 1.2
Child high, adult high 4.3 3.5
Eastern Mediterranean
Child low, adult low 2.7 2.1
Child high, adult high 7.3 5.9
European
Child very low, adult very low 0.1 0.0
Child low, adult low 1.4 1.1
Child low, adult high 0.2 0.2
Southeast Asian
Child low, adult low 2.0 1.6
Child high, adult high 5.2 4.3
Western Pacific
Child very low, adult very low 0.2 0.0
Child low, adult low 1.7 1.4
Total, industrial countries 0.4 0.2
Total, developing countries 4.3 3.5
Global total 3.7 3.0
Source: See Acknowledgments.
Table 41.11 Costs Assumed for Cost-Effectiveness Calculations (US$ per capita)
Operation and 
Construction cost Amortization Amortized annual maintenance cost 
Intervention (US$ per capita) lifetime (years) cost (US$ per capita) (US$ per capita)
Water supply 
House connections 150.00 20 7.50 10.00
Hand pump or standpost 40.00 20 1.00 1.00
Water regulation and advocacy US$0.02 to US$0.10 per capita per year
Sanitation 60.00 5 12.00 n.a.
Sanitation promotion 2.50 5 0.50 n.a.
Hygiene promotion 1.00 5 0.20 n.a.
Source: Authors.
n.a.  not applicable.
(1993) as a criterion of cost-effectiveness. Allowing only for
the cost component that should fall to the health sector puts
them all well within this ceiling. For comparison, the cost-
effectiveness of promoting oral rehydration therapy, the
principal other measure available to prevent diarrhea mortali-
ty, has been estimated at US$23/DALY. The cost-effectiveness of
promoting sanitation and hygiene as derived above (US$11.15
and US$3.35, respectively, per DALY) compares favorably with
that figure.
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Access to modern energy sources has been described as a
“necessary, although not sufficient, requirement for economic
and social development” (IEA 2002). It is, therefore, of great
concern that almost half the world’s population still relies for
its everyday household energy needs on inefficient and highly
polluting solid fuels, mostly biomass (wood, animal dung, and
crop wastes) and coal.
The majority of households using solid fuels burn them in
open fires or simple stoves that release most of the smoke into
the home. The resulting indoor air pollution (IAP) is a major
threat to health, particularly for women and young children,
who may spend many hours close to the fire. Furthermore,
the reliance on solid fuels and inefficient stoves has other,
far-reaching consequences for health, the environment, and
economic development.
NATURE, CAUSES, AND BURDEN OF CONDITION 
About 3 billion people still rely on solid fuels, 2.4 billion on
biomass, and the rest on coal, mostly in China (IEA 2002;
Smith, Mehta, and Feuz 2004). There is marked regional varia-
tion in solid fuel use, from less than 20 percent in Europe and
Central Asia to 80 percent and more in Sub-Saharan Africa and
South Asia.
This issue is inextricably linked to poverty. It is the poor
who have to make do with solid fuels and inefficient stoves, and
many are trapped in this situation: the health and economic
consequences contribute to keeping them in poverty, and their
poverty stands as a barrier to change. Where socioeconomic
circumstances improve, households generally move up the
energy ladder, carrying out more activities with fuels and
appliances that are increasingly efficient, clean, convenient, and
more expensive. The pace of progress, however, is extremely
slow, and for the poorest people in Sub-Saharan Africa and
South Asia, there is little prospect of change.
Illustrated in figures 42.1 and 42.2 are findings for Malawi
and Peru, respectively, from Demographic and Health Surveys
(ORC Macro 2004). The examples are selected from available
national studies with data on main cooking fuel use to repre-
sent the situation in poor African and South American coun-
tries. The main rural and urban cooking fuels are illustrated in
figures 42.1a and 42.2a; the findings are then broken down
nationally by level of education of the principal respondent
(woman of childbearing age) in figures 42.1b and 42.2b, and in
urban areas by her level of education in figures 42.1c and 42.2c.
Biomass is predominantly, though not exclusively, a rural
fuel: indeed, in many poor African countries, biomass is the
main fuel for close to 100 percent of rural homes. Marked
socioeconomic differences (indicated by women’s education)
exist in both urban and rural areas. During the 1990s, use of
traditional fuels (biomass) in Sub-Saharan Africa increased as
a percentage of total energy use, although in most other parts
of the world the trend has generally been the reverse (World
Bank 2002).
In many poorer countries, the increase in total energy use
accompanying economic development has occurred mainly
through increased consumption of modern fuels by better-off
minorities. In Sub-Saharan Africa, however, the relative
increase in biomass use probably reflects population growth in
rural and poor urban areas against a background of weak (or
negative) national economic growth. Reliable data on trends in
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Figure 42.2 Patterns of Household Fuel Use in Peru, 2000Figure 42.1 Patterns of Household Fuel Use in Malawi, 2000 
household energy use are not available for most countries.
Information is available from India, where the percentage of
rural homes using firewood fell from 80 percent in 1993–94 to
75 percent in 1999–2000 (D’Sa and Narasimha Murthy 2004).
Nationally, liquid petroleum gas (LPG) use increased from 9 to
16 percent over the same period, with a change from 2 percent
to 5 percent in rural areas, and it is expected to reach 36 percent
nationally and 12 percent for rural homes by 2016.
International Energy Agency projections to 2030 show that,
although a reduction in residential biomass use is expected in
most developing countries, in Africa and South Asia the decline
will be small, and the population relying on biomass will
increase from 2.4 billion to 2.6 billion, with more than 50 per-
cent of residential energy consumption still derived from this
source(OECD and IEA 2004). The number of people without
access to electricity is expected to fall from 1.6 billion to 1.4 bil-
lion. Because electricity is used by poor households for lighting
and not as a cleaner substitute for cooking, electrification will
not, at least in the short to medium term, bring about
substantial reductions in IAP.
Levels of Pollution and Exposure
Biomass and coal smoke emit many health-damaging pollu-
tants, including particulate matter (PM),1 carbon monoxide
(CO), sulfur oxides, nitrogen oxides, aldehydes, benzene, and
polyaromatic compounds (Smith 1987). These pollutants
mainly affect the lungs by causing inflammation, reduced ciliary
clearance, and impaired immune response (Bruce, Perez-
Padilla, and Albalak 2000). Systemic effects also result, for
example, in reduced oxygen-carrying capacity of the blood
because of carbon monoxide, which may be a cause of intrauter-
ine growth retardation (Boy, Bruce, and Delgado 2002).
Evidence is emerging, thus far only from developed countries,
of the effects of particulates on cardiovascular disease (Pope
and others 2002, 2004).
Saksena, Thompson, and Smith (2004) have recently com-
piled data on several of the main pollutants associated with
various household fuels from studies of homes in a wide range
of developing countries. Concentrations of PM10, averaged
over 24-hour periods, were in the range 300 to 3,000 (or more)
micrograms per cubic meter (g/m3). Annual averages have
not been measured, but because these levels are experienced
almost every day of the year, the 24-hour concentrations can
be taken as a reasonable estimate. By comparison, the U.S.
Environmental Protection Agency’s annual air pollution stan-
dard for PM10 is 50 g/m
3, one to two orders of magnitude
lower than levels seen in many homes in developing countries.
During cooking, when women and very young children spend
most time in the kitchen and near the fire, much higher levels
of PM10 have been recorded—up to 30,000 g/m
3 or more.
With use of biomass, CO levels are generally not as high in
comparison, typically with 24-hour averages of up to 10 parts
per million (ppm), somewhat below the World Health
Organization (WHO) guideline level of 10 ppm for an eight-
hour period of exposure. Much higher levels of CO have been
recorded, however. For example, a 24-hour average of around
50 ppm was found in Kenyan Masai homes (Bruce and others
2002), and one Indian study reported carboxyhemoglobin lev-
els similar to those for active cigarette smokers (Behera, Dash,
and Malik 1988). The health effects of chronic exposure of
young children and pregnant women to levels of CO just
below current WHO guidelines have yet to be studied.
For additional information on levels of other pollutants in
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biomass and coal smoke, see Saksena, Thompson, and Smith
(2004).
Fewer studies of personal exposure have been done than of
area pollution, mainly because measurement of personal PM
typically requires wearing a pump, a cumbersome procedure.
CO can be measured more easily and has been used as a proxy:
time-weighted (for example, 24-hour average) CO correlates
well with PM if a single main biomass stove is used (Naeher
and others 2001). Time-activity and area pollution information
can also be combined to estimate personal exposure (Ezzati
and Kammen 2001). These various methods indicate that per-
sonal 24-hour PM10 exposures for cooks range from several
hundred g/m3 to more than 1,000 g/m3 (Ezzati and
Kammen 2001), with even higher exposures during cooking
(Smith 1989). Few studies have measured personal PM expo-
sures of very young children: one study in Guatemala found
levels a little lower than those of their mothers (Naeher,
Leaderer, and Smith 2000).
Health Impacts of IAP
A systematic review of the evidence for the impact of IAP on a
wide range of health outcomes has recently been carried out
(Smith, Mehta, and Feuz 2004; see table 42.1). This review
identified three main outcomes with sufficient evidence to
include in the burden-of-disease calculations and a range of
other outcomes with as yet insufficient evidence.
Studies for the key outcomes used in the burden-of-disease
calculations—acute lower respiratory infection (ALRI),
chronic obstructive pulmonary disease (COPD), and lung
cancer—had to be primary studies (not reviews or reanalyses),
written or abstracted in English (and for lung cancer, Chinese),
that reported an odds ratio and variance (or sufficient data to
estimate them) and provided some proxy for exposure to
indoor smoke from the use of solid fuels for cooking and heat-
ing purposes.
A limitation of almost all studies has been the lack of meas-
urement of pollution or exposure: instead, proxy measures
have been used, including the type of fuel or stove used, time
spent near the fire, and whether the child is carried on the
mother’s back during cooking. The studies do not, therefore,
provide data on the exposure-response relationship, although a
recent study from Kenya has gone some way to addressing this
omission (Ezzati and Kammen 2001).
In some countries, household fuels carry locally specific
risks. It has been estimated that more than 2 million people in
China suffer from skeletal fluorosis, in part resulting from use
of fluoride-rich coal (Ando and others 1998). Arsenic, another
contaminant of coal, is associated with an increased risk of
lung cancer in China (Finkelman, Belkin, and Zheng 1999).
There has been concern, however, that reducing smoke could
increase risk of vectorborne disease, including malaria. Some
studies have shown that biomass smoke can repel mosquitoes
and reduce biting rates (Palsson and Jaenson 1999; Paru and
others 1995; Vernede, van Meer, and Alpers 1994). Few studies
have examined the impact of smoke on malaria transmission:
one from southern Mexico found no protective effect of smoke
(adjusted odds ratio 1.06 [0.72–1.58]; Danis-Lozano and
others 1999), and another from The Gambia found that wood
smoke did not protect children in areas of moderate transmis-
sion (Snow and others 1987).
Method Used for Determining Attributable Disease Burden
Smith, Mehta, and Feuz (2004) have provided a full explana-
tion of the calculation of the disease burden associated with
IAP. Summarized here are the methods they used to estimate
the two most critical components of these calculations: the
number of people exposed and the relative risks.
Exposure. The absence of pollution or exposure measure-
ment in health studies required use of a binary classification:
the use or nonuse of solid fuels. The authors obtained esti-
mates of solid fuel use for 52 countries from a range of
sources, mostly household surveys, and statistical modeling
was used for countries with no data (the majority) (Smith,
Mehta, and Feuz 2004). They assumed, conservatively, that all
countries with a 1999 per capita gross national product (GNP)
greater than US$5,000 had made a complete transition either
to electricity or cleaner liquid and gaseous fuels or to fully
ventilated solid fuel devices. To account for differences in
exposure caused by variation in the quality of stoves, they
applied a ventilation factor (VF), set from 1 for no ventilation
to 0 for complete ventilation. In China, a VF of 0.25 was used
for child health outcomes and 0.5 for adult outcomes, reflect-
ing a period of higher exposure (to open fires) before the
widespread introduction of chimney stoves. Countries with a
1999 GNP per capita greater than US$5,000 were assigned a
VF of 0, and all other countries a value of 1, reflecting the very
low rates of use of clean fuels or effective ventilation tech-
nologies. The authors obtained the final point estimate for
exposure by multiplying the percentage of solid fuel use by the
VF. They arbitrarily assigned an uncertainty range of 5 per-
cent to the estimates.
Risk. Smith, Mehta, and Feuz (2004) carried out meta-
analyses for the three health outcomes with sufficient evidence
(table 42.2). They used fixed-effects models and sensitivity
analysis that took account of potential sources of heterogene-
ity, including the way in which exposure was defined and
whether adjustment had been made for confounders (Smith,
Mehta, and Feuz 2004).
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Table 42.1 Status of Evidence Linking Biomass Fuels and Coal with Child and Adult Health Outcomes 
Health outcome Age Status of evidence
Sufficient evidence for burden-of-disease calculation 
Acute lower respiratory infections Children  5 years
Chronic obstructive pulmonary disease Adult women
Lung cancer (coal exposure) Adult women
Chronic obstructive pulmonary disease Adult men
Lung cancer (coal exposure) Adult men
Not yet sufficient evidence for burden-of-disease calculation 
Lung cancer (biomass exposure) Adult women
Tuberculosis Adult
Asthma Child and adult
Cataracts Adult
Adverse pregnancy outcomes Perinatal
Cancer of upper aerodigestive tract Adult
Interstitial lung disease Adult
Ischemic heart disease Adult
Strong. Some 15–20 observational studies for each condition, from developing
countries. Evidence is consistent (significantly elevated risk in most though not all
studies); the effects are sizable, plausible, and supported by evidence from outdoor
air pollution and smoking.
Moderate-I. Smaller number of studies, but consistent and plausible. 
Moderate-II. Small number of studies, not all consistent (especially for asthma,
which may reflect variations in definitions and condition by age), but supported by
studies of outdoor air pollution, smoking, and laboratory animals.
Tentative. Adverse pregnancy outcomes include low birthweight and increased
perinatal mortality. One or a few studies at most for each of these conditions, not
all consistent, but some support from outdoor air pollution and passive-smoking
studies. 
Several studies from developed countries have shown increased risk for exposure
to outdoor air pollution at much lower levels than IAP levels seen in developing
countries. As yet, no studies from developing countries. 
Source: Smith, Mehta, and Feuz 2004.
The Burden of Disease from Solid Fuel Use
Information on the proportions exposed and risk of key disease
outcomes was combined with total burden-of-disease data to
obtain the population attributable fractions associated with
IAP (WHO 2002b). Globally, solid fuels were estimated to
account for 1.6 million excess deaths annually and 2.7 percent
of disability-adjusted life years (DALYs) lost, making them the
second most important environmental cause of disease, after
contaminated water, lack of sanitation, and poor hygiene
(table 42.3). Approximately 32 percent of this burden (DALYs)
occurs in Sub-Saharan Africa, 37 percent in South Asia, and
18 percent in East Asia and the Pacific. In developing countries
with high child and adult mortality, solid fuel use is the fourth
most important risk factor behind malnutrition, unsafe sex,
and lack of water and sanitation, and it is estimated to account
for 3.7 percent of DALYs lost (WHO 2002b).
Overall, there are more female deaths but similar numbers
of male and female DALYs (table 42.3b). The reason can be
found by looking further at the health outcomes. Deaths and
DALYs from ALRI in children under five years of age are
slightly greater for males (table 42.3c). Women experience
twice the DALYs and three times the deaths from COPD (male
smoking-attributable COPD deaths excluded). Far fewer cases
of lung cancer are attributable to IAP, but women experience
about three times the burden of men.
Table 42.3 also shows how the poorest regions of the world
carry by far the greatest burden, particularly for ALRI. More
than half of all the deaths and 83 percent of DALYs lost attrib-
utable to solid fuel use occur as a result of ALRI in children
under five years of age. In high-mortality areas, such as Sub-
Saharan Africa, these estimates indicate that approximately
30 percent of mortality and 40 percent of morbidity caused by
ALRI can be attributed to solid fuel use, as can well over half of
the deaths from COPD among women. Because they derive
from WHO risk assessments, these estimates include age
weights, such that years of life lost at very young or advanced
ages count less than years lost in the prime of adult life. Age
weighting makes little difference to the DALYs lost per death up
to age five; how much it affects the DALY cost of adult deaths
depends on the age distribution of deaths from COPD. Because
these are likely to occur at age 45 or beyond, the DALY losses are
underestimated compared with estimates without age weight-
ing that follow the usual practice in this volume.
Other Effects of Household Energy Use 
in Developing Countries
A number of other health impacts—for example, burns from
open fires—were not assessed because the burden-of-disease
assessment process allowed inclusion of only those health
effects resulting directly from pollution. Children are at risk of
burns and scalds, resulting from falling into open fires and
knocking over pots of hot liquid (Courtright, Haile, and Kohls
1993; Onuba and Udoidiok 1987). Modern fuels are not always
safe either, because children are also at risk of drinking
kerosene, which is often stored in soft drink bottles (Gupta and
others 1998; Reed and Conradie 1997; Yach 1994).
Families—mainly the women and children—can spend
many hours each week collecting biomass fuels, particularly
where environmental damage and overpopulation have made
them scarce. This time could be spent more productively on
child care and household or income-generating tasks. There are
also risks to health from carrying heavy loads and dangers from
mines, snake bites, and violence (Wickramasinghe 2001).
Inefficient stoves waste fuel, draining disposable income if fuel
is bought. Although women carry out most of the household
activities requiring fuels, they often have limited control over
how resources can be spent to change the situation (Clancy,
Skutsch, and Batchelor 2003). These conditions can combine
to restrict income generation from home-based activities that
require fuel energy (for example, processing and preparing
food for sale).
Homes that are heavily polluted and dark can hinder pro-
ductivity of householders, including children doing homework
and others engaged in home-based income-generating activities
such as handicrafts. In many poor homes, lighting is obtained
from the open fire and simple kerosene wick lamps, which pro-
vide poor light and add to pollution.
Solid fuel use has important environmental consequences.
Domestic use of solid fuels in high-density rural and urban
environments contributes to outdoor air pollution. Many low-
income urban populations rely on charcoal, the production of
which can place severe stress on forests. The use of wood as fuel
can contribute to deforestation, particularly where it is com-
bined with population pressure, poor forest management, and
clearance of land for agriculture and building timber. Damage
to forest cover can increase the distance traveled to obtain wood
and can result in the use of freshly cut (green) wood, dung, and
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Table 42.2 Summary of Relative Risk Estimates for Health
Outcomes Used in Burden-of-Disease Estimates
95 percent
Health Age and Number of Relative confidence
outcome sex group studies risk interval
ALRI Children  5 years 8 2.3 1.9–2.7
COPD Women  30 years 8 3.2 2.3–4.8
Men  30 yearsa 2 1.8 1.0–3.2
Lung cancer Women  30 years 9 1.9 1.1–3.5
(coal) Men  30 years 3 1.5 1.0–2.5
Sources: Smith, Mehta, and Feuz 2004.
a. Because of the limited quantity and quality of available evidence, the male COPD relative risk
and range have been fixed to include 1.0 (no effect) as the lower estimate.
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Table 42.3 Deaths and DALYs Lost Because of Solid Fuel Use
a. Overall 
Total 
Deaths DALYs burden 
World Bank region (thousands) (thousands) (percent)
East Asia and the Pacific 540 7,087 18.4
Europe and Central Asia 21 544 1.4
Latin America and the Caribbean 26 774 2.0
Middle East and North Africa 118 3,572 9.3
South Asia 522 14,237 36.9
Sub-Saharan Africa 392 12,318 32.0
World 1,619 38,532 100.0
b. All causes, by sex
Deaths (thousands) DALYs (thousands)
World Bank region Male Female All Male Female All
East Asia and the Pacific 152 388 540 3,028 4,060 7,087
Europe and Central Asia 9 13 21 251 293 544
Latin America and the Caribbean 12 14 26 368 405 774
Middle East and North Africa 57 61 118 1,849 1,724 3,572
South Asia 218 304 522 6,641 7,596 14,237
Sub-Saharan Africa 211 181 392 6,901 5,417 12,318
World 658 961 1,619 19,037 19,495 38,532
c. From ALRI (children under age five)
Deaths (thousands) DALYs (thousands)
World Bank region Male Female All Male Female All
East Asia and the Pacific 40 41 81 1,502 1,535 3,036
Europe and Central Asia 7 6 13 235 204 439
Latin America and the Caribbean 8 7 15 324 281 605
Middle East and North Africa 51 44 95 1,794 1,571 3,365
South Asia 177 178 355 6,228 6,278 12,506
Sub-Saharan Africa 198 153 351 6,777 5,191 11,967
World 481 429 910 16,860 15,058 31,918
d. From COPD (men and women 30 years and over)
Deaths (thousands) DALYs (thousands)
World Bank region Male Female All Male Female All
East Asia and the Pacific 105 338 443 1,461 2,430 3,891
Europe and Central Asia 2 7 9 16 89 104
Latin America and the Caribbean 4 7 11 44 125 168
Middle East and North Africa 6 17 23 55 153 208
South Asia 41 126 167 410 1,314 1,724
Sub-Saharan Africa 13 28 41 124 227 351
World 171 522 693 2,110 4,336 6,446
Source: Modified by authors to World Bank regions, from Smith, Mehta, and Feuz 2004. 
twigs, which are more polluting and less efficient. In some urban
communities, poverty and supply problems are resulting in the
use of plastic and other wastes for household fuel (IEA 2002).
Stoves with inefficient combustion produce relatively more
products of incomplete combustion, such as methane, which
have a markedly higher global-warming potential than carbon
dioxide (Smith, Uma, and others 2000). It has, therefore, been
argued that, although the energy use and greenhouse gas emis-
sions from homes in developing countries are small relative to
the emissions generated in industrial countries, cleaner and
more efficient energy systems could provide the double benefit
of reduced greenhouse gas emissions (with opportunities for
carbon trading) and improved health through reduced IAP
(Wang and Smith 1999).
The evidence available for assessing these effects, which
together could have a substantial influence on health and eco-
nomic development, is patchy at best. This area is important
for research (Larson and Rosen 2002).
INTERVENTIONS AND POLICY
The uses of energy in the home—for example, for cooking
and keeping warm and as a focus of social activities—have
important attributes that are specific to the locality, culture,
and individual households and are often associated with
established traditions and deeply held beliefs. Encouraging the
use of cleaner and more efficient energy technologies by pop-
ulations that are among the poorest in the world has not been
easy, but recent years have seen progress being made with
respect to suitable technology that meets the needs of house-
holds and with respect to the development of supportive
policy.
Poverty Reduction and the Millennium Development Goals
Given the close relationship between socioeconomic condi-
tions and solid fuel use, poverty reduction must be a key ele-
ment of policy to alleviate IAP. The United Nations
Millennium Development Goals set targets for poverty eradi-
cation, improvements in health and education, and environ-
mental protection; they represent the accepted framework for
the world community to achieve measurable progress (United
Nations Statistics Division 2003). Although reducing IAP
can contribute to achieving a number of these goals, it is par-
ticularly relevant to reducing child mortality (Goal 4) from
ALRI.
Goal 7, Target 9, aims at integrating sustainable develop-
ment into country policies and programs. The proportion of
population using solid fuels has been adopted as an indicator
for Target 9. Alleviating drudgery resulting from collecting fuel
and using inefficient stoves, together with the involvement of
women in implementing changes, can promote gender equality
and empower women (Goal 3). Household energy interven-
tions can also contribute to eradicating extreme poverty
(Goal 1) through health improvements, time saving, and better
environments for education and facilitating income generation
(WHO 2004a).
Interventions
Although the main focus of this chapter is IAP, the many other
ways in which household energy can affect health and develop-
ment emphasize why interventions should aim to achieve a
range of benefits, including the following:
• reduced levels of IAP and human exposure
• increased fuel efficiency
• reduced time spent collecting fuel and using inefficient
stoves
• reduced stress on the local environment 
• increased opportunities for income generation
• contribution to an overall improvement in the quality of the
home environment—in particular, the working environ-
ment and conditions for women.
Interventions for reducing IAP can be grouped under three
headings: those acting on the source of pollution, those improv-
ing the living environment (aspects of the home), and changes
to user behaviors (table 42.4).
It should not be assumed that an intervention that reduces
IAP will necessarily achieve other aims listed previously. For
example, in colder areas, an enclosed stove with a flue that
reduces IAP may reduce radiant heat and light, forcing house-
holds to use other fuels for those purposes. If not addressed
with households, such problems may well result in disappoint-
ing reductions in IAP exposure, poor acceptance of interven-
tions, and lack of motivation to maintain them.
Policy Instruments
Although a range of interventions is available, poor households
face many barriers to their adoption, and enabling policy is
needed (table 42.5). This area of practice is complex and evolv-
ing, often requiring solutions that are highly setting specific.
INTERVENTION COSTS AND EFFECTIVENESS
The cost-effectiveness analysis discussed in this chapter is based
on recent work by Mehta and Shahpar (2004). The key compo-
nents of this analysis are described here, with particular
emphasis on the underlying assumptions.
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Table 42.4 Interventions for Reducing Exposure to IAP
Source of pollution Living environment User behaviors
Improved cooking devices
• Improved biomass stoves without flues
• Improved stoves with flues attached
Alternative fuel-cooker combinations
• Briquettes and pellets
• Charcoal
• Kerosene
• Liquid petroleum gas 
• Biogas, producer gas
• Solar cookers (thermal)
• Other low-smoke fuels
• Electricity
Reduced need for the fire
• Insulated fireless cooker (haybox)
• Efficient housing design and construction
• Solar water heating
Improved ventilation
• Hoods, fireplaces, and chimneys built into the
structure of the house
• Windows and ventilation holes (such as in
roof), which may have cowls to assist
extraction
Kitchen design and placement of the stove
• Kitchen separate from house to reduce
exposure of family (less so for cook)
• Stove at waist height to reduce direct exposure
of cook leaning over fire
Reduced exposure through operation of source
• Fuel drying
• Using pot lids to conserve heat
• Properly maintaining stoves and chimneys and
other appliances
Reductions by avoiding smoke
• Keeping children away from smoke—for
example, in another room (if available and safe
to do so)
Source: Modified from Ballard-Tremeer and Mathee 2000. 
Table 42.5 Policy Instruments for Promoting Implementation of Effective Household Energy Interventions
Policy instruments Examples Applications
Information,
education, and
communication
Taxes and subsidies
Regulation and
legislation
Direct expenditures
Schools
Media
Community education
Tax on fuels and
appliances
Subsidy on fuels and
appliances
Air quality standards
Design standards for
appliances
Public program
provision of appliances
Learning about household energy, health, and development should be integrated in school curricula,
particularly in countries where these topics are a priority for health and economic development. This goal
can be achieved through programs such as the WHO Global School Health Initiative, which promotes
environmental health education, including education about IAP.
Local and national radio, television, and newspapers can be used to raise awareness and disseminate
information on technologies and opportunities to support implementation, such as promotions and microcredit.
These media can be directed at a range of audiences, including decision makers, professionals, and the public
where radio is widely used.
Opportunities such as adult literacy programs can be used to raise awareness and share experience of
interventions, and innovative methods can be used (for example theater). 
Reduced tax on fuels and appliances may promote development of distribution networks and uptake, and it
may be seen as efficient if there is evidence of health, education, and economic benefits.
General (for example, national) subsidies on fuels such as kerosene have been applied to promote use by poor
households. Subsidies have been found to be inefficient instruments, however, often benefiting the better off
rather than the poor. Time-limited subsidy on specific products (for example, clean fuel appliances, connection
to grid) may be a useful method for promoting initial uptake, generating demand, and thereby providing
market conditions for lower prices and more consistent quality.
Although some developing countries have air quality standards for urban air, none have them for indoor air in
settings where solid fuels are widely used. Routine monitoring and enforcement is not practical, but it may
be useful to set standards and targets linked to specific assessments. For more routine use, information from
censuses and surveys, such as fuel type, stove type, and venting for smoke, offers a practical alternative for
setting air quality standards for IAP in developing countries.
Design standards can be applied to safety (prevention of burns, gas leaks, and explosions); venting of
emissions; and efficiency. Although such standards may be difficult to enforce in an informal economy, they
could become valuable with wider-scale production.
Large-scale public provision of appliances, such as improved stoves or clean-fuel appliances, has generally
been found unsuitable. Some form of targeted provision or partial subsidy where households have made
informed choices and commit to cost sharing may be useful to stimulate demand and act in favor of equity. 
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Table 42.5 Continued
Policy instruments Examples Applications
Research and
development 
Funding of finance
schemes
Surveys 
Development and
evaluation of
interventions
Studies of health
effects
Research capacity
development
Experience has shown that credit is most likely to be made available and adopted for energy applications
that contribute directly to productive, income-generating activities (such as food processing for sale).
Meeting everyday cooking and space-heating needs is seen as a lower priority. Good opportunities may exist
where biomass fuel is purchased and where cost saving combines with other valued benefits, such as
increased prestige and cleaner kitchens. Support for such schemes, mainly in the form of raising awareness,
skills training in managing funds, and seed funding (the main source of funds being from users) may be 
cost-effective.
Surveys of fuel and appliance use, knowledge of risks to health, willingness to pay for interventions,
knowledge of and confidence in credit schemes, and the like are important for planning interventions.
Evaluation of interventions should be conducted in a range of settings, using harmonized methods, if
possible, that allow local flexibility but permit comparison with other types of interventions and other
locations. 
Stronger and better-quantified evidence of the effects on health of reducing IAP, which includes exposure
measurement, is required not only for key outcomes such as ALRI, but also for other health outcomes for
which evidence is currently tentative.
Capacity for carrying out a wide range of research—from national and local surveys, to monitoring and
evaluation of interventions, to more complex health studies—requires strengthening in those countries
where the problems associated with household energy and IAP are most pressing. 
Source: Authors.
Costs
Intervention costs have a number of components, the relative
importance of which will vary with the type of fuel and device
(box 42.1).
The level of costs incurred by consumers and others, includ-
ing government, depends not only on the type of intervention
but also on how it is delivered, supplied, and adopted.
Experience indicates that successful interventions are sustain-
able in local markets, implying that the consumer pays the
majority of initial and recurrent costs. The contributions of
the government, utilities, nongovernmental organizations
(NGOs), and the commercial sector will depend on many fac-
tors, including the type of intervention and fuel, location
(urban or rural), existing level of supply and distribution
Cost Components for Household Energy Interventions
Box 42.1
• Fuels, which vary from zero (in direct cash terms, though
not in opportunity cost) for collected biomass to a
U.S. dollar or so per week for kerosene and several
U.S. dollars per week for electricity (where used for
cooking).
• Stove appliances, which vary from zero for a simple
three-stone fire (stones arranged on the floor to sup-
port cooking pots, with the fire lit between the
stones), to US$50 (and in some cases more than
US$100) for a good-quality woodstove with a chim-
ney and up to several hundred U.S. dollars for a bio-
gas installation.
• Additional appliances—for example, an LPG storage
bottle has a moderately high initial cost but should last
for many years.
• Maintenance costs,which vary from zero for a three-stone
fire up to modest, but not negligible, costs of repairing
(and periodically replacing) woodstoves and chimneys.
Appliances for using kerosene, LPG, and electricity also
require maintenance and periodic replacement.
• Program costs, which apply to various aspects of
provision of energy services, particularly LPG and elec-
tricity, but may also include costs of, for example,
establishing more sustainable biomass reserves and
administrative costs.
Source: Authors.
networks, and support for credit (for example, seed funds and
fund capital) and targeted subsidies.
Some degree of market support may be required to stimu-
late demand and to encourage adoption by poor households,
particularly those using three-stone fires (and other simple
stoves) and collected biomass, because those methods do not
incur direct monetary costs. Some countries have applied sub-
sidies on fuels such as kerosene to assist poor families, but
general subsidies are now considered to be an inefficient instru-
ment for this purpose (von Schirnding and others 2002).
Targeted subsidy and small-scale credit may be more appropri-
ate ways of helping poor families acquire new household
energy technologies and can have low default rates. Experience
shows, however, that households are more likely to access cred-
it for directly productive (with regard to income) uses of
energy, rather than for everyday cooking and space-heating
needs. Because the latter are the most important sources of IAP,
more promotion of other benefits is needed, such as improved
family health; fuel cost savings; time saved by faster cooking
and reduced need for biomass; greater prestige; and cleaner
homes, clothes, and utensils. A number of these benefits may
result in reduced expenditure or increased income generation.
Box 42.2 illustrates how these various issues can influence the
decisions of a “typical” poor rural African household consider-
ing transition from gathered biomass to predominant use of a
commercial fuel (LPG).
Effectiveness
Most evidence available for assessing intervention effectiveness
deals with the effect on IAP levels and in some cases personal
exposure. No experimentally derived evidence is available,
however, on the effect of reducing IAP exposure on incidence
of ALRI or the course of COPD in adults. A randomized trial
of an improved chimney stove is currently under way in
Guatemala, focusing on ALRI in children up to 18 months of
age (Dooley 2003). A cohort study in Kenya by Ezzati and
Kammen (2001) describes significant exposure-response rela-
tionships for all acute respiratory infections—and for ALRI
specifically—associated with the use of traditional and
improved woodstoves and charcoal. However, those effect esti-
mates require confirmation because the study has small num-
bers of children (93 children under age five, living in 55 homes).
For the other major health outcome, lung cancer, Lan and
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Cost Issues in Switching to Cleaner Fuels for a “Typical” Poor Kenyan Family
Box 42.2
Ruth1 and her family live 3 kilometers from a small town
on the main road about one hour by bus from Kisumu.
They are subsistence farmers, with a small income from
selling vegetables, from irregular laboring work obtained
by her husband, and from making and selling handicrafts.
Ruth, a mother of five, cooks over a three-stone fire using
mostly wood, which she collects every other day from
plots up to two hours walking distance from home. She
spends 8 to 12 hours each week collecting wood. Ruth and
her family use about 2 liters of kerosene each week for
wick lamps and for cooking. They use dry cell batteries for
the radio; grid electricity runs nearby, but connection is
far too expensive. In all, the family spends an equivalent of
US$1 to US$2 per week on fuel and batteries.
Through her women’s group, Ruth hears that a few
families are using LPG, now available at a nearby petrol
station. The women say it is very quick and easy to use,
and it keeps pots, clothes, and walls clean. The women and
children seem to feel better, with less cough, runny eyes,
and headaches. But those families run small shops and
have been able to find the money to buy the gas bottle and
cooker.
She talks with her husband about LPG, and although
quite supportive, her husband thinks they cannot afford it.
They could spend a little more on fuel, but income is
irregular. Why abandon free fuel when they are so poor?
Ruth thinks she could earn more money from her handi-
crafts in the time she saves collecting wood. On balance,
they reckon they could probably afford the cost of the gas
if they could be sure of more regular income, but they do
not know where they could find the money to pay for the
cooker and bottle.
Ruth then learns about a revolving fund set up by her
women’s group with the help of an NGO. If she can make
small regular payments, she and her husband could get a
loan to buy the stove and gas bottle next year. But they
have never saved before, and what if they need money for
medicines or for the children at school? Will they be able
to keep saving each week to make sure they have enough
to refill the gas bottle when needed?
1. Not her real name.
Source: Authors.
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others (2002) reported adjusted hazard ratios of 0.59 (95 per-
cent confidence interval: 0.49 to 0.71) for men and 0.54 (0.44
to 0.65) for women using improved coal stoves compared with
traditional open coal fires in a 16-year retrospective cohort
study in rural China.
Measuring evidence on reductions in pollution and expo-
sure is nonetheless an important step in assessing effectiveness.
Summarized here are the main findings of studies that have
measured pollution levels in homes using traditional open
fires, various improved stoves, kerosene, and LPG (see also
Saksena, Thompson, and Smith 2004) and one that examined
the effect of rural electrification in South Africa (Rollin and
others 2004).
Effect of Improved Stoves. In East Africa, cheap improved
stoves without flues, burning either wood or charcoal, are pop-
ular. These wood-burning stoves can reduce kitchen pollution
by up to 50 percent, but levels still remain high (Ezzati,
Mbinda, and Kammen 2000). Charcoal emits much less PM
(but with a higher CO-to-PM ratio than wood), and stoves
such as the Kenyan jiko yield particulate levels in the region of
10 percent of those from wood fires.
In a number of Asian and Latin American countries,
improved stoves with flues have been promoted quite exten-
sively, although many such stoves are found to be in poor con-
dition after a few years. Some studies from India have shown
minimal or small reductions in PM (Ramakrishna 1988; Smith,
Aggarwal, and Dave 1983). Other studies, from Nepal, have
shown reductions of about two-thirds, although the very high
baseline levels mean that homes with stoves still recorded total
suspended particulate values of 1,000 to 3,000 g/m3 during
cooking (Pandey and others 1990; Reid, Smith, and Sherchand
1986). Results from Latin American countries are similar,
although the IAP levels are generally lower. Studies have shown
that plancha-type stoves (made of cement blocks, with a metal
plate and flue) reduce PM by 60 to 70 percent and by as much
as 90 percent when they are in good condition. Typical 24-hour
PM levels (PM10, PM3.5 [respirable], and PM2.5 have variously
been reported) with open fires of 1,000 to 2,000 g/m3 have
been reduced to 300 to 500 g/m3, and in some cases to less
than 100 g/m3 (Albalak and others 2001; Brauer and others
1996; Naeher, Leaderer, and Smith 2000). One study from
Mexico found little difference between homes with open fires
and with improved stoves (Riojas-Rodriguez and others 2001),
but the 16-hour levels of PM10 at about 300 g/m
3 with open
fires were relatively low.
Improved stoves with flues have so far had little success in
Sub-Saharan Africa, although recent work developing hoods
with flues for highly polluted Kenyan Masai homes reported
reductions in 24-hour mean respirable PM of 75 percent from
more than 4,300 g/m3 to about 1,000 g/m3 (Bruce and
others 2002).
Personal exposures were usually found to have been reduced
proportionately less than area pollution levels. For example, in
Kenya, where hoods with flues achieved a 75 percent reduction
in 24-hour mean kitchen PM3.5 and CO, the woman’s mean 
24-hour CO exposure was reduced by only 35 percent (Bruce
and others 2002). Similar results were found for child expo-
sures in a study of improved wood stoves in Guatemala (Bruce
and others 2004). We are aware of only one study that has used
direct measurement of personal particulate exposure in very
young children (Naeher, Leaderer, and Smith 2000). This study,
also in Guatemala, reported mean 10- to 12-hour (daytime)
PM2.5 levels for children under 15 months of age of 279 g/m
3
(SD of 19.5) for the open fire and 170 g/m3 (154) for the
plancha stoves, a 40 percent reduction.
Impact of Cleaner Fuels. Good evidence shows that kerosene
and LPG can deliver much lower levels of pollution, although it
is important to determine the extent to which the cleaner fuel
is substituting for biomass. For example, a study in rural
Guatemala comparing LPG with open fires and plancha chim-
ney stoves found that LPG-using households typically also used
an open fire for space heating and cooking with large pots. As a
result, the plancha stoves achieved the lowest pollution levels in
that setting (Albalak and others 2001). Still, a number of stud-
ies, mainly from India, show that introducing kerosene and
LPG dramatically reduces kitchen pollution, which perhaps
reflects different cooking requirements and less need for space
heating. In rural Tamil Nadu, two-hour (mealtime) kitchen res-
pirable PM levels of 76 g/m3 using kerosene and of 101 g/m3
using gas contrasted with levels of 1,500 to 2,000 g/m3 using
wood and animal dung (Parikh and others 2001). Personal
(cook) 24-hour exposure to respirable PM was 132 g/m3 with
the use of kerosene as opposed to 1,300 and 1,500 g/m3, respec-
tively, with the use of wood and dung (Balakrishnan and others
2002). Other studies confirm those findings, for example, with
the use of gas in Mexico (Saatkamp,Masera,and Kammen 2000).
Delivering electricity to rural homes requires extensive infra-
structure, and most poor people with access to electricity can
afford to use it only for lighting and running low-demand elec-
trical appliances. Without marked improvements in socioeco-
nomic conditions, electrification has little potential to bring
about substantial reductions in IAP. South Africa is one of the
few countries with a large rural population traditionally
dependent on biomass that has the resources for rural electrifi-
cation. An investigation of three rural villages with similar
socioeconomic characteristics, two not electrified and one elec-
trified, in the North West province found that 3.6 years (aver-
age) after connection to the grid, 44 percent of the electrified
homes had never used an electric cooker (Rollin and others
2004). Only 27 percent of electrified homes cooked primarily
with electricity; the remainder used a mix of electricity,
kerosene, and solid fuels. Despite the mixed fuel use, households
cooking with electricity had the lowest pollution levels. Overall,
homes in the electrified village had significantly lower 24-hour
mean respirable PM and CO levels and significantly lower mean
24-hour CO exposure for children under 18 months of age than
homes in the nonelectrified villages.
Effect of Other Interventions. Little systematic evaluation has
been made of other interventions listed in table 42.4.
Investigation of the potential of improving ventilation has,
overall, shown that although enlarging eaves can be quite effec-
tive (Bruce and others 2002), removing smoke generally
requires a well-functioning flue or chimney. Behavioral
changes are currently the subject of an intervention study in
South Africa (Barnes and others 2004a, 2004b).
Cost-Effectiveness Analysis
Although clean fuels can be expected to have a greater health
effect than improved stoves (even those with flues), clean fuels
may be too expensive and inaccessible for many poor commu-
nities over the short to medium term. Furthermore, even
though clean fuels may be the best longer-term goal, an inter-
mediate stage of improved biomass stoves may promote change
by raising awareness of benefits and thus creating demand by
improving health, saving time, and mitigating poverty. For
those reasons, this cost-effectiveness analysis (CEA) examines
both improved biomass stove and clean fuel options in the
following scenarios:
• access to improved stoves (stoves with flues that vent smoke
to the exterior), with coverage of 95 percent
• access to cleaner fuels (LPG or kerosene), with coverage of
95 percent
• part of the population with access to cleaner fuels (50 per-
cent) and part with improved stoves (45 percent).
In each case, the intervention is compared with the current
level of coverage of the respective technology or fuel.
Cost Assumptions. The assumptions for costs include pro-
gram costs, fixed costs (including stoves), and recurrent fuel
costs. Household costs for each region were drawn from the
most comprehensive estimates available in the literature (von
Schirnding and others 2002; Westoff and Germann 1995). For
LPG, costs include the initial price of a cooker and cylinder and
the recurrent refill costs. Assumed household annual costs, dis-
counted at 3 percent, range from US$1 to US$10 for improved
stoves and from US$3 to US$4 for kerosene or up to US$30 for
LPG. Recurrent costs of fuel were found to be the most signif-
icant cost for the cleaner fuel interventions. Wood fuel costs are
estimated at US$0.25 per week and assumed to be the same for
traditional and improved stoves.
Costs were estimated separately for cleaner fuel and
improved stove programs, using an “ingredients” approach
(Johns, Baltussen, and Hutubessy 2003) and a costing template
developed by WHO (2003). In summary, all the ingredients—
including administrative, training, and operational costs—
necessary to set up and maintain a given program must be added
up. For regional estimates, costs of all traded goods were in U.S.
dollars, whereas nontraded (local) costs were estimated in local
currency and converted to U.S. dollars using relevant exchange
rates. All costs were annualized using a 3 percent discount
rate. Costs for tradable goods are scaled, using region-specific
standardized price multipliers to reflect the increasing costs of
expanding coverage caused by higher transportation costs to
more remote areas (Johns, Baltussen, and Hutubessy 2003).
Price multipliers were not applied to improved stoves because
they tend to be manufactured locally with mainly local materials.
Program costs were found to make up a small proportion of the
overall intervention costs. Savings from averted health care costs
are not included; because many of these cases currently go
untreated, it can be argued that including treatment costs could
result in inflated cost-effectiveness ratios (CERs).
Effectiveness and Health Outcome Assumptions. For this
analysis, cleaner fuels are assumed to remove exposure com-
pletely, whereas improved stoves are assumed to reduce expo-
sure by 75 percent (ventilation factor of 0.25). The effect on
health of the exposure reduction will vary from region to
region, because it depends on current levels of exposure as well
as region-specific rates of morbidity and mortality. A number
of assumptions have been made about households in carrying
out analyses at the regional level. First, regional estimates of
household composition (numbers of people, by age group and
sex) and, hence, the effect of interventions on exposure and
health apply at the level of individual households. Second, the
age distribution of household members is similar in exposed
and nonexposed groups; for example, the number of children
per household is the same irrespective of household fuel use
and ventilation characteristics. That assumption is likely to be
conservative, since poorer, more polluted homes will typically
have higher fertility and more children under five; all other fac-
tors being equal, such households would therefore experience a
higher burden of disease from IAP exposure.
The health outcomes included are ALRI and COPD, because
they were responsible for nearly all of the 1.6 million deaths
attributable to IAP. The risk estimates used are those derived
from the meta-analyses, as summarized in table 42.2. Smoking
is an important confounding variable for COPD, particularly
with men, because they generally smoke more than women do
in developing countries. At present, information is sparse on the
independent effect of solid fuel use on COPD in the presence of
smoking. To avoid possible overestimation of the impact of IAP
on COPD, attributable fractions for COPD from solid fuel use
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were applied to disease burdens remaining after removal of
smoking-attributable burdens (Ezzati and Lopez 2004). Current
estimates of exposure are used in combination with estimates of
disease burden to obtain region-specific disease burdens for
exposed and unexposed populations. Regional patterns of dis-
ease for 2000 have been used, including incidence, mortality,
remission, duration, and case-fatality rate, obtained from WHO
(2004b). In contrast to the estimates of burden in table 42.3, no
age weighting has been used in the cost-effectiveness analysis.
Health impacts are discounted at 3 percent.
Implementation Period. The implementation period is
10 years, although effects have been evaluated over 100 years in
order to approximate the benefits for an entire population
cohort. Thus, health effects are calculated for a cohort with a
typical age structure for the population concerned that experi-
ences the intervention for 10 years. It is assumed that after
100 years, all of the cohort (including children born during the
10-year implementation period) will have died.
The implementation period has critical implications, partic-
ularly in situations in which it takes several years to establish an
intervention (for example, developing local markets for clean-
er fuel), in which there are high start-up costs, and in which
disease prevention is experienced in the distant future. This is
especially true for chronic health effects (for example, COPD)
that result from exposure over many years. If the intervention
is implemented and exposure reduced for only 10 years, the
disease burden is effectively deferred by 10 years, whereas
longer-term implementation would result in many more cases
being averted. For this analysis, using the 10-year intervention
scenario specified for the Disease Control Priorities Project-2,
incident cases are deferred by 10 years. For COPD, it is assumed
that reduced exposure results in a milder form of COPD,
accounted for by using a lower severity weighting.
Findings for Cost-Effectiveness Analysis. Findings from the
CEA are expressed, for the four intervention scenarios with dif-
fering coverage (50 percent, 80 percent, 95 percent), by region,
as (a) total healthy years gained in each region, (b) CERs in U.S.
dollars per healthy year gained, and (c) healthy years gained per
US$1 million (table 42.6). For all regions, the cleaner fuels yield
the greatest gain in healthy years, but improved stoves also have
a significant effect. The largest total population gains in healthy
years are in Sub-Saharan Africa and South Asia for all types of
interventions and in East Asia and the Pacific (mainly China)
for cleaner fuels.
In the two regions with the largest burden of disease attrib-
utable to solid fuel use (Sub-Saharan Africa and South Asia),
CERs are lowest (most favorable) for improved stoves,
although in both regions kerosene has CERs just over twice
those of improved stoves. In East Asia and the Pacific, kerosene
is most cost-effective, followed by improved stove and
clean fuel combinations and then by LPG (for coverage over
50 percent). In Latin America and the Caribbean, kerosene has
the most favorable CER, followed by kerosene in combination
with improved stoves. When the 50 percent and 80 percent cov-
erage scenarios are compared, large differences in the ratio are
seen in regions where coverage for that intervention is already
substantial, and there is much less health gain at lower levels of
coverage. Where no result is given, the specified coverage of the
intervention has already been reached.
Multivariate sensitivity analysis was conducted to assess the
effect of uncertainty in cost and effectiveness estimates. Costs
were assumed to vary with a standard deviation of 5 percent,
and effectiveness by the range of the confidence interval
around the relative risk for each health endpoint. Results for
Southeast Asia are shown in figure 42.3: the “clouds,” or uncer-
tainty regions, illustrate the range of possible point estimates
emerging from the sensitivity analysis. This example is repre-
sentative because other regions show essentially similar results.
Despite the uncertainty, the ranking of the interventions
remains the same (Mehta and Shahpar 2004).
Discussion. Results of this cost-effectiveness analysis indicate
that an improved biomass stove is the most cost-effective inter-
vention for South Asia and Sub-Saharan Africa, the two regions
with the highest solid fuel–related disease burden. This finding
is important given International Energy Agency projections to
2030, which indicate that biomass will remain the principal
household fuel for the poor in South Asia and Sub-Saharan
Africa and that actual numbers of users will increase over that
period (IEA 2002). Cleaner fuels (particularly kerosene) are the
most cost-effective options for East Asia and the Pacific, the
other region with a high burden of solid fuel–related disease.
Cleaner fuels, in particular LPG, appear relatively costly for
South Asia and Sub-Saharan Africa, but circumstances in indi-
vidual countries may vary considerably and in ways that make
this fuel much more cost-effective. Sudan, for example, has
abundant cheap supplies of LPG and favorable excise arrange-
ments for imported appliances, which would result in a lower
CER for LPG than in other countries in the region. Furthermore,
as will be discussed later, costs and benefits from the user’s per-
spective will differ markedly, depending on whether the starting
point is free fuel collection or purchased biomass fuel.
In interpreting the results, one should bear in mind the
assumptions underlying the CEA. Much of the evidence indi-
cates that, although improved biomass stoves may reduce
kitchen pollution by up to 75 percent, the reduction in exposure
of women and children is typically no more than 30 to 40 percent
(equivalent to VF of 0.6 to 0.7). Achievement of the 75 percent
reduction in exposure (VF  0.25) assumed for this analysis is
consistent only with well-designed and -maintained chimney
stoves that meet most of the cooking and heating energy needs
of the household and high population coverage (to avoid expo-
sure from neighbors and others). Those conditions may be
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Table 42.6 Intervention Scenarios for World Bank Regions
a. Healthy years gained
Sub- Latin America Middle East East Asia 
Coverage Saharan and the and North Europe and and the 
Intervention (percent) Africa Caribbean Africa Central Asia South Asia Pacific 
LPG 50 22,160,000 160,000 n.a. n.a. 44,810,000 2,560,000
80 60,370,000 4,670,000 15,570,000 1,330,000 149,300,000 228,710,000
95 75,630,000 11,260,000 22,510,000 4,810,000 184,940,000 568,640,000
Kerosene 50 22,160,000 160,000 n.a. n.a. 44,810,000 2,560,000
80 60,370,000 4,670,000 15,570,000 1,330,000 149,300,000 228,710,000
95 75,630,000 11,260,000 22,520,000 4,810,000 184,940,000 568,640,000
Improved stove 50 18,010,000 n.a. n.a. n.a. 48,880,000 1,120,000
80 40,270,000 1,380,000 6,630,000 n.a. 101,670,000 6,980,000
95 51,540,000 2,600,000 11,640,000 n.a. 128,380,000 32,760,000
Combined (with stove) LPG 69,250,000 8,650,000 19,540,000 3,230,000 170,340,000 427,350,000
Kerosene 69,250,000 8,650,000 19,540,000 3,230,000 170,340,000 427,350,000
b. Cost-effectiveness ratios (US$ per healthy year gained)
Sub- Latin America Middle East East Asia 
Coverage Saharan and the and North Europe and and the 
Intervention (percent) Africa Caribbean Africa Central Asia South Asia Pacific 
LPG 50 715 1,405 n.a. n.a. 542 1,695
80 518 783 756 1,221 312 115
95 518 814 762 1,321 314 100
Kerosene 50 84 631 n.a. n.a. 63 225
80 60 115 95 183 36 14
95 60 106 95 167 36 12
Improved stove 50 25 n.a. n.a. n.a. 15 297
80 21 947 457 n.a. 13 587
95 20 1,101 368 n.a. 13 327
Combined (with stove) LPG 295 761 606 1,375 177 83
Kerosene 45 296 220 507 26 25
c. Healthy years gained per US$1 million
Sub- Latin America Middle East East Asia 
Coverage Saharan and the and North Europe and and the 
Intervention (percent) Africa Caribbean Africa Central Asia South Asia Pacific 
LPG 50 1,400 710 n.a. n.a. 1,840 590
80 1,930 1,280 1,320 820 3,210 8,680
95 1,930 1,230 1,310 760 3,190 10,040
Kerosene 50 11,970 1,580 n.a. n.a. 16,000 4,440
80 16,600 8,690 10,500 5,470 27,850 72,840
95 16,620 9,470 10,560 6,000 27,680 85,840
Improved stove 50 39,640 n.a. n.a. n.a. 67,330 3,360
80 47,940 1,060 2,190 n.a. 74,750 1,700
95 49,510 910 2,720 n.a. 76,300 3,060
Combined (with stove) LPG 3,390 1,310 1,650 5,660 5,660 12,020
Kerosene 22,250 3,380 4,550 38,590 35,590 40,730
Source: Authors. 
n.a.  not applicable because the specified coverage of the intervention has already been reached.
achievable and should be the goal, but they are not currently
widespread. The relative cost-effectiveness advantage for
improved stoves over cleaner fuel reported here should there-
fore be viewed as relating more to what might be achievable
with good biomass stoves rather than to what is currently being
achieved. The assumption that kerosene and LPG are equally
clean and achieve zero exposure (VF = 0) presumes, at the very
least, the use of high-quality kerosene fuel and pressurized
burners. In many places, kerosene is of low quality, and the types
of kerosene stoves and lamps used result in poor combustion.
Cost comparisons for the various fuels also need careful
consideration. For example, the cost of solid fuel has been
assumed to be constant for traditional open fires and improved
stoves. As a general assumption this is reasonable, because the
efficiency of “improved” stoves varies, and some may even be
less fuel efficient than are open fires. However, new stove tech-
nology is markedly improving efficiency, and some designs
reduce daily fuel consumption by 40 percent or more, resulting
in savings of time (where fuel is collected) and money (where
fuel is bought) (Boy and others 2000).
Transition from biomass (collected free) or charcoal (typi-
cally paid for daily in small amounts) to LPG would almost
certainly require changes in saving and budgeting habits for a
poor household (see also box 42.2). Those changes may entail
arranging a loan to purchase the gas bottle and stove and saving
money for the relatively large, periodic outlay to refill the cylin-
der. Such changes are very likely to have other consequences
for the family that should not be overlooked. However, those
consequences are complex and difficult to allow for within the
current CEA framework. Empirical data are required on how
household budgets change with various interventions and
approaches to implementation.
The calculations have been undertaken for whole regions
and provide no indication of how CERs differ among countries
and specific communities. As local data on exposure, risk
factors, health outcomes, and intervention effectiveness
become available, similar analyses should be conducted at
national and subnational levels.
Averted treatment costs have not been included on the
grounds that most users of solid fuel are poor and have limited
access to health services; many do not seek medical care for ALRI
and even fewer do so for COPD.Inclusion of averted costs would
increase cost-effectiveness. However, efforts to raise awareness
about health risks and the importance of seeking care for ALRI
(and COPD), which should accompany an intervention pro-
gram, may increase care seeking and costs to the consumer. As
more complete information becomes available, future CEAs
should include treatment costs, with the option of allowing for
an increase in care seeking associated with the intervention.
Interpretation of the results of this CEA, particularly with
respect to comparisons with other types of intervention, needs
to acknowledge that, although public organizations and other
agencies will (or may) have some involvement in funding
intervention programs, most of the cost of market-based inter-
ventions will be borne by households and those involved in
production and marketing. Furthermore, it is hoped that, in
addition to reducing IAP, interventions (and the means of
accessing them) will have other positive effects, including on
household budgets, in creating opportunities for income gen-
eration and empowering women in decisions about how
energy is used. The promotion of market-based solutions
implies new opportunities for artisans and entrepreneurs, but
also the loss of traditional employment. The balance sheet for
interventions is therefore complex, is specific to the setting, and
will evolve as markets and enterprise develop.
Cost-Benefit Analysis
The CER gives cost per unit of health gained (healthy year)
based on reduced risk of specified disease outcomes (ALRI,
COPD). As discussed earlier, however, household energy inter-
ventions can affect a wide range of social, economic, and envi-
ronmental issues, with important implications for health and
development. In an economic analysis of water and sanitation
interventions, Hutton and Haller (2004) found that time saved
was the most important benefit. Those other effects cannot
easily be expressed in units of health gain. Cost-benefit analysis
(CBA) offers an alternative approach that may be better suited
to environmental health interventions, given that health argu-
ments alone will not motivate the multiple sectors involved in
financing and implementing household energy interventions.
All main benefits in CBA are expressed in a common unit of
monetary value and compared with costs in the cost-benefit
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Propane and LPG Kerosene Improved stoves
Combination: LPG and improved stoves
Combination: kerosene and improved stoves
Figure 42.3 Multivariate Sensitivity Analysis for Three Types of
Interventions and Combined Intervention Scenarios, Southeast Asia
Region
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Table 42.7 Possible Data Requirements for Quantifying Benefits
Impact category Variables or elements to identify
Direct benefits related to specific health outcomes
Expenditure and time for health care–seeking Health service use of those with diseases caused by IAP (number of cases, visits or days per case)
Health service use of those having accidents or injuries due to reasons related to fuel use:
Direct: burns, poisoning
Indirect: injuries in collecting fuel
Access features to get to health services (distance, mode of transport, time; average visits per case)
Other consumption related to health care–seeking
Time loss of seeking health care, both of the patient and of those accompanying patient
Other direct benefits in and around the home
Time gained owing to less illness and death Activities of those with diseases caused by IAP
Impact of disease on activities (time input, productivity)
Value of time of various occupations
Time saving of changed technology Reduced time spent collecting fuel
Reduced time spent cooking and on other tasks requiring fire or stove
Value of time of various occupations
Income-generating activities achieved through increased time 
Impact on household cleanliness and hygiene and need for cleaning
Change in household environment and production Effect of improved lighting on evening activities (education, production)
Effect of availability of electricity and other fuels on household production activities
Impact on ergonomics related to cooking
Consequences of process of acquiring new Increased confidence in capacity of the household to save for immediate or future needs
technology and related changes More involvement of women in decision making with respect to changes in household energy use and
related issues
Indirect benefits related to the environment
Local environment Impact of fuel scarcity on local environment, average fuel collection time
Increased risk of environmental effects (such as soil fertility) or disasters (such as flooding, landslides)
Global environment Contribution of local area to greenhouse gases
Source: Authors.
ratio (CBR). The assessment of costs in CBA would have many
assumptions and methods in common with CEA. The key dif-
ferences lie in the selection of effects for inclusion as benefits
and the methods for valuing them. In principle, there is no rea-
son all the full range of effects discussed earlier could not be
included (table 42.7), although in practice some, such as glob-
al climate effects, may be too uncertain. Where disadvantages of
interventions are identified, they should also be included.
Benefit valuation presents particular challenges: effects are
highly setting specific; evidence for some is limited, and their
effects poorly quantified; and valuation in monetary units of
benefits, such as lost working time averted for women, is diffi-
cult because women frequently are unpaid or work in informal
markets. As a result, methods of valuation based on human
capital may not be suitable, and alternative approaches such as
contingent valuation, in which communities are involved in
agreeing on market values for nontradable commodities, may
be preferable. A related issue is valuing benefits that relate to
sustainability and health, which would be experienced after
many years and by subsequent generations. Larson and Rosen
(2002) used a mix of valuation of statistical life and contingent
valuation methods to examine the CBRs for improved stoves
with respect to mortality (Guatemala, East Africa) and mor-
bidity (Pakistan), concluding that ratios appeared favorable.
Although they discuss other benefits, those benefits were not
included in their valuations. Their observation that the favor-
able CBRs are not reflected in the generally low adoption of
improved stoves led them to conclude that the information
required for assessing household demand correctly is not cur-
rently available.
IMPLEMENTATION OF CONTROL STRATEGIES:
LESSONS FROM EXPERIENCE
The past 30 to 40 years have seen many diverse programs on
household energy, from small-scale NGO- and community-led
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Key Features and Lessons from India’s National Stove Program
Box 42.3
The Indian National Programme of Improved Cookstoves
was established in 1983 with goals common to many such
initiatives:
• conserving fuel
• reducing smoke emissions in the cooking area and
improving health conditions
• reducing deforestation
• limiting the drudgery of women and children and
reducing cooking time
• improving employment opportunities for the rural
poor.
Although the Ministry of Non-Conventional Energy
Sources was responsible for planning, setting targets, and
approving stove designs, state-level agencies relayed this
information to local government agencies or NGOs. A
technical backup unit in each state trained rural women or
unemployed youths to become self-employed workers to
construct and install the stoves.
Between 1983 and 2000, the program distributed more
than 33 million improved stoves. Despite extensive gov-
ernment promotion efforts, improved stoves now account
for less than 7 percent of all stoves. Among those that have
been adopted, poor quality and lack of maintenance have
resulted in a life span of two years at most and typically
much less. Evaluation of the program identified four main
problems:
• Most states placed inadequate emphasis on commer-
cialization, now seen as crucial for effective and
sustainable uptake.
• Overall, there was insufficient interaction with users,
self-employed workers, and NGOs, so the designs did
not meet needs of households, and there was very poor
acceptance of user training.
• Quality control for installation and maintenance of the
stove and its appropriate use was lacking.
• High levels of subsidy (about 50 percent of the stove
cost) were found to reduce household motivation to
use and maintain the stove.
Some more successfully managed areas of the program
focused resources on technical assistance, research and
development, marketing, and information dissemination.
Recently, the government of India decentralized the pro-
gram and transferred all implementation responsibility to
state level. Since 2000, the program promotes only durable
cement stoves with chimneys that have a minimum life
span of five years. The introduction of these stoves will
make adhesion to technical specifications and quality con-
trol much easier.
Source: Authors, based on ESMAP and World Bank 2001.
initiatives to ambitious national programs, the largest of which
has been the installation of some 200 million improved stoves
in rural China. Although few have been subjected to rigorous
evaluation, an assessment has been made of the Indian national
stove program (box 42.3; ESMAP and World Bank 2001); the
Chinese national stove program (box 42.4; Sinton and others
2004; Smith and others 1993); and LPG promotion (box 42.5;
UNDP and ESMAP 2002). Experience with a number of smaller
initiatives has also been reported—for example, the ceramic
and metal stoves in East Africa, which have proved popular and
provided local employment (Njenga 2001), and improved
stove interventions in Guatemala (UNDP and ESMAP 2003).
Implementation of the Chinese national program differed
substantially from that in India. Although the Chinese rural
populations concerned are poor, they do have greater effective
purchasing power than the poor in many developing countries,
allowing development of a program with the majority of con-
sumers purchasing stoves at close to full cost (Smith and
others 1993). Among the key features of the Chinese program
reported to have contributed to its success are decentralization
of administration; a commercialization strategy that provided
subsidies to rural energy enterprise development and quality
control through the central production of critical components,
such as parts of the combustion chamber; and engagement of
local technical institutions in modifying national stove designs
to local needs. National-level stove competitions were held
among counties for contracts, ensuring local interest and
allowing the best-placed counties to proceed first; financial
payments were provided to counties only after completion of
an independent review of their achievements. No large flows
of funds came from the central government (in contrast, for
example, to India); local governments provided the major
financial contributions. As a result, delays and other problems
associated with transferring large amounts of money have been
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Household Effects of China’s National Improved Stove Program 
Box 42.4
In 2002, an independent multidisciplinary evaluation was
undertaken by a team of U.S. and Chinese researchers to
evaluate (a) implementation methods used to promote
improved stoves; (b) commercial stove production and
marketing organizations that were created; and (c) effects
of the program on households, including health, stove per-
formance, socioeconomic factors, and monitoring of
indoor air quality. The first two objectives were assessed
through a facility survey of 108 institutions at all levels. The
third objective was assessed through a household survey of
nearly 4,000 households in three provinces: Zheijang,
Hubei, and Shaanxi. Key findings were as follows:
• The household survey revealed highly diverse fuel
usage patterns: 28 and 34 different fuel combinations
were used in kitchens in winter and summer, respec-
tively. Most households owned at least one or more
coal and one or more biomass stoves. Of the biomass
stoves 77 percent, but only 38 percent of the coal stoves,
were classified as improved. On average, improved
stoves had a mean efficiency of 14 percent, which is
well below the program target of between 20 and 30 per-
cent, but above the mean efficiency of 9 percent for
traditional stoves.
• With respect to air quality (measured with PM4, the
“thoracic fraction” of particulate matter, and CO), coal
stoves showed significantly higher concentrations than
biomass stoves during the summer, but not during the
winter. Among households using biomass fuels (but
not among households using combinations of fuels
that included coal or LPG), improved stoves showed
significantly lower PM4 and CO concentrations than
traditional stoves.
• In both children and adults, coal use was associated with
higher levels of exposure (as measured by CO in exhaled
breath) and improved biomass stoves with lower levels.
Reported childhood asthma and adult respiratory dis-
ease were negatively associated with use of improved
stoves and good stove maintenance. These results
should, however, be treated as indicative because of
limited sample size.
Overall, several important conclusions emerge with
relevance to future improved stove programs:
• A wide range of combinations of different fuel and
stove types may limit the effect of an improved stove
program.
• Given the importance of space heating, making avail-
able an improved biomass stove for cooking may not be
a sufficient strategy to reduce IAP. Improved coal stoves
need to be promoted among rural Chinese households.
• Even among households using improved stoves, PM4
and CO levels were higher than Chinese national
indoor air standards, implying that a large fraction of
China’s rural population is still chronically exposed to
pollution levels substantially above those determined
by the Chinese government to harm human health.
Source: Authors, based on Sinton and others 2004.
avoided. The Chinese program succeeded in shifting norms:
most biomass stoves now available on the market have flues
and other technical features that classify them as improved.
Experience in the promotion of LPG has also been reported,
for example, from the Indian Deepam Scheme (ESMAP and
World Bank 2004; UNDP and ESMAP 2002) and from the LPG
Rural Energy Challenge (UNDP 2005). The latter initiative,
developed by UNDP and the World LPG Association in 2002,
is promoting the development of new, viable markets for LPG
in developing countries. Key elements include developing part-
nerships in countries; enabling regulatory environments that
facilitate LPG business development and product delivery;
reducing barriers, for example, by introducing smaller (more
affordable) gas bottles; and raising government and consumer
awareness of costs and benefits. McDade (2004) has recently
identified a number of key lessons emerging from experience
with the promotion of LPG markets (box 42.5).
Electrification has an important role in development (IEA
2002). Evidence from South Africa suggests that communities
with grid access experience lower IAP exposure (Rollin and
others 2004). Electricity is not expected to bring about large
reductions in IAP exposure in most low-income countries,
however, because most poor households can afford it only for
uses such as lighting and running entertainment appliances and
not for cooking and space heating. The International Energy
Agency has recently carried out a detailed review of electrifica-
tion, including the issues involved in supply and cost recovery
among poor (and especially rural) communities (IEA 2002).
The key lessons from experience with interventions to date
may be summarized as follows:
• Too often, intervention technologies have been developed
without adequate reference to users’ needs and, as a result,
have been poorly used and maintained or abandoned.
Consequently, it is important to involve users—particularly
women—in assessing needs and developing suitable
interventions.
• Sustainable adoption should also be promoted through
greater availability of a choice of appropriately priced inter-
ventions through local commercial outlets (artisans, shops,
markets). This situation will come about only if demand is
sufficient and if producers and distributors recognize this
demand.
• All too commonly, communities most at risk exhibit low
awareness, low demand, and poverty (often extreme
poverty). A combination of user involvement and market
approaches is needed, supported by the promotion and
availability of targeted subsidies or microcredit facilities or
both. The nature and extent of such financial support should
depend on the purchasing power of the community.
• Local initiatives such as those outlined above must be led by
national (and subnational) policy that acknowledges the
contributions of a range of actors (government, business,
NGOs, and so on) and sectors (energy, health, environment,
finance, and so on) and that results in coordinated action.
The instruments listed in table 42.5 should be considered
when developing national policy.
In a recent review of the situation in Guatemala, the United
Nations Development Programme and Energy Sector
Management Assistance Programme (UNDP and ESMAP
2003) found that, despite the almost total reliance of the rural
population on biomass, a marked lack of national policy, lead-
ership, and coordinated action existed in relation to household
energy. Countries need to develop mechanisms for action and
coordination in light of local needs, available institutional
capacity, and leadership potential.
THE RESEARCH AND DEVELOPMENT AGENDA 
WHO has, through a process involving multistakeholder meet-
ings and reviews, developed some consensus on research and
development priorities for household energy, IAP, and health
(see for example WHO 2002a). Effective coordination is a pre-
requisite because of the need for input from, and collaboration
between, many different organizations and “actors” that have
generally not previously worked in partnership on this issue.
One recent response to this need has been the establishment
of the Partnership for Clean Indoor Air, following the
Johannesburg World Summit on Sustainable Development in
2002 (EPA 2004; http://www.pciaonline.org/).
The evidence base on health effects requires further
strengthening, particularly to quantify the effect of a measured
reduction in IAP exposure on the risk of key outcomes (for
example, ALRI). A randomized controlled trial is currently
under way in Guatemala, focusing primarily on ALRI in chil-
dren up to 18 months of age (Dooley 2003); however, at least
one other such trial on another continent would be desirable.
Also required are observational studies for outcomes for
which few studies currently exist, including tuberculosis, low
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Key Lessons Learned in the Promotion of New Markets for LPG in Developing Countries 
Box 42.5
• LPG can be affordable outside of urban areas, where
wood fuel is currently purchased. On the other hand,
for many consumers who do not participate in the
monetized economy, it will be premature to promote
LPG markets.
• One-time subsidies on appliances could be a good use
of government (or other) resources.
• Microcredit initiatives should emphasize the cost-
saving and productive potential and should seek to
package both the gas (and appliances) and the
financing.
• Concerns about safe handling, cylinder refilling, and
transportation can be serious barriers to market
expansion. These issues need to be addressed by raising
awareness among consumers and strengthening regula-
tory environments.
• Appliances for a range of end uses required by con-
sumers must be available.
• Government leadership is essential, backed up by
policy that sets the basic parameters for successful mar-
ket expansion and avoids conflict between, for exam-
ple, subsidies on competing fuels that undermine
efforts to promote LPG markets.
• Specific initiatives, such as integrated energy centers (as
in Morocco and South Africa) offer an effective means
of developing markets in rural areas.
Source: Authors, based on McDade 2004.
birthweight and perinatal mortality, cataracts, asthma, and
cardiovascular disease. A small number of such studies are in
progress, but further effort is required, with perinatal outcomes
being a particular priority.
Despite limitations in the evidence on health effects, what is
known about the health, social, and economic consequences of
current patterns of household energy use in poor countries is
of sufficient concern to press ahead with an active program
of research and development regarding interventions. This
activity should address both the technology (and associated
knowledge and behavior) and the approaches taken for imple-
mentation. Although some development and innovation in
technology and fuels (for example, clean fuels derived from
biomass) are likely to be valuable, the single greatest challenge
is to promote wider access to—and adoption of—existing
knowledge and interventions. Projects and programs currently
in progress or being developed should be carefully evaluated
using quantitative and qualitative methods to assess a range of
effects. Work is currently under way to develop suitable meth-
ods and tools for this purpose (WHO 2005). Experience and
lessons learned need to be disseminated widely to ensure that
they reach governments, donors, researchers, NGOs, and com-
munities. As part of this effort, WHO is developing a resource
for countries that offers information on the effectiveness of
interventions as well as the enabling factors that facilitate long-
term, sustained adoption and use of suitable improved tech-
nologies in different settings (WHO 2004c).
Economic assessment, including cost-effectiveness analysis,
has a valuable part to play. Critical issues resulting from limited
evidence have been identified about estimations and assump-
tions for costs, exposure reductions, health effects, and averted
treatment costs, as well as the current inability to assess national
and subnational cost-effectiveness. CBA may be more suitable
for interventions in this and similar areas but will require better
description of environmental, social, and economic effects and
further development of valuation methods. New health studies
and broadly based evaluations of interventions should help fill
some of these gaps.
Determination of the macroeconomic costs to countries of
current household energy use and the potential gains resulting
from change to more efficient and cleaner options could sub-
stantially add to the case for action.
Monitoring progress requires the development and testing
of standard indicators for use in such policy documents as the
World Development Report and for routine application at
national and subnational levels. The Millennium Development
Goal Indicator on the proportion of the population using solid
fuels is a key starting point, and WHO, the reporting agency, is
working to broaden the monitoring of this indicator through
international surveys, such as demographic and health surveys
(ORC Macro 2004), the Multiple Indicator Cluster Survey
(UNICEF 2004), and the World Health Survey (WHO 2004d),
as well as through work on regional and national indica-
tors conducted under the Global Initiative on Children’s
Environmental Health Indicators (WHO 2004e). Future
reporting will need to be further refined by taking into account
differences in cooking practices (for example, type of stove and
cooking location), as well as in fuel use for lighting and heating.
Advocacy for stronger action, internationally and in coun-
tries, is required. Products and guidance for a range of audiences
should be prepared, with clear messages on the extent of the
problem, the population groups most affected, what works, and
what should be avoided. Tools such as the recently published
guidelines on estimating the national burden of disease from
solid fuels will help provide local evidence to argue for greater
attention and action (Desai, Mehta, and Smith 2004).
CONCLUSIONS 
IAP from solid fuel use is responsible for a large burden of dis-
ease among the world’s poorest and most vulnerable popula-
tions. Inefficient and polluting household energy systems hold
back development through resulting ill health, constraints on
women’s time and income generation, environmental impacts,
and other factors. Although there is a trend toward cleaner and
more efficient energy with increasing prosperity, little improve-
ment is in prospect for more than 2 billion of the world’s poor-
est people, particularly in South Asia and Sub-Saharan Africa.
The number of people relying on traditional biomass is
actually expected to increase until 2030.
Although the development of new energy technologies has
a part to play in addressing this problem, many effective inter-
ventions are already available. The single greatest challenge is
to dramatically increase the access of poor households to
cleaner and more efficient household energy systems. Much
valuable experience has been gained from successful—and
unsuccessful—programs in household energy over the past
three to four decades. Despite this experience, coherent,
evidence-based policy is lacking in most of the countries con-
cerned, where the lessons from experience now need to be
implemented. Implementation will require greater awareness
of the problem at international and national levels, provision
of support for national collaborative action, and a focus on
supporting appropriate, mainly market-based interventions.
Better information is crucial to this effort, including
stronger evidence of the health effects of IAP exposure; assess-
ment of the social, economic, and environmental benefits of
interventions; and indicators to monitor progress. Economic
analysis can help bring the case for action into policy, but it
needs to be applied at country level and to include a wider
range of benefits. Results from analysis at the regional level
show that interventions can be cost-effective, particularly
improved stoves, as long as these interventions can deliver sub-
stantial exposure reductions in practice. This conclusion, as
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well as its qualification, is important given the expectation that
biomass will remain the principal household fuel in many
developing countries for more than 20 years. The balance of
effort and resources put into promoting cleaner biomass inter-
ventions rather than cleaner fuels, or vice-versa, will be an
important policy issue for many countries and for the interna-
tional community (Smith 2002).
With a range of innovative projects and programs under
way in a number of countries and regions of the world, now is
an important time to focus attention and effort on achieving
the health, social, and economic gains that should result from
improvements in household energy systems in developing
countries.
NOTE
1. Particles are typically described according to the aerodynamic diam-
eter, and although the devices used to separate particles of a given size do
not yield a very sharp cutoff, this classification is functionally useful
because smaller particles are able to penetrate farther into the lungs. Total
suspended particles (TSP) include suspended particles of all sizes.
Commonly defined smaller particles include PM10 (up to 10 microns
diameter); respirable PM (includes all very small particles, about 50 per-
cent of those 4 microns in diameter, and none above 10 microns in diam-
eter); and PM2.5 (up to 2.5 microns in diameter).
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Environmental pollution has many facets, and the resultant
health risks include diseases in almost all organ systems. Thus,
a chapter on air and water pollution control links with chapters
on, for instance, diarrheal diseases (chapter 19), respiratory
diseases in children and adults (chapters 25 and 35), cancers
(chapter 29), neurological disorders (chapter 32), and cardio-
vascular disease (chapter 33), as well as with a number of chap-
ters dealing with health care issues.
NATURE, CAUSES, AND BURDEN OF AIR
AND WATER POLLUTION
Each pollutant has its own health risk profile, which makes
summarizing all relevant information into a short chapter dif-
ficult. Nevertheless, public health practitioners and decision
makers in developing countries need to be aware of the poten-
tial health risks caused by air and water pollution and to know
where to find the more detailed information required to handle
a specific situation. This chapter will not repeat the discussion
about indoor air pollution caused by biomass burning 
(chapter 42) and water pollution caused by poor sanitation at
the household level (chapter 41), but it will focus on the prob-
lems caused by air and water pollution at the community,
country, and global levels.
Estimates indicate that the proportion of the global burden
of disease associated with environmental pollution hazards
ranges from 23 percent (WHO 1997) to 30 percent (Smith,
Corvalan, and Kjellstrom 1999). These estimates include
infectious diseases related to drinking water, sanitation, and
food hygiene; respiratory diseases related to severe indoor air
pollution from biomass burning; and vectorborne diseases
with a major environmental component, such as malaria.
These three types of diseases each contribute approximately
6 percent to the updated estimate of the global burden of dis-
ease (WHO 2002).
As the World Health Organization (WHO) points out, out-
door air pollution contributes as much as 0.6 to 1.4 percent of
the burden of disease in developing regions, and other pollu-
tion, such as lead in water, air, and soil, may contribute 0.9 per-
cent (WHO 2002). These numbers may look small, but the
contribution from most risk factors other than the “top 10” is
within the 0.5 to 1.0 percent range (WHO 2002).
Because of space limitations, this chapter can give only
selected examples of air and water pollution health concerns.
Other information sources on environmental health include
Yassi and others (2001) and the Web sites of or major reference
works by WHO, the United Nations Environment Programme
(UNEP), Division of Technology, Industry, and Economics
(http://www.uneptie.org/); the International Labour Organi-
zation (ILO), the United Nations Industrial Development
Organization (UNIDO; http://www.unido.org/), and other rel-
evant agencies.
Table 43.1 indicates some of the industrial sectors that can
pose significant environmental and occupational health risks
to populations in developing countries. Clearly, disease control
measures for people working in or living around a smelter may
be quite different from those for people living near a tannery or
a brewery. For detailed information about industry-specific
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pollution control methods, see the Web sites of industry sector
organizations, relevant international trade union organiza-
tions, and the organizations listed above.
Air Pollution
Air pollutants are usually classified into suspended particulate
matter (PM) (dusts, fumes, mists, and smokes); gaseous pollu-
tants (gases and vapors); and odors.
Suspended PM can be categorized according to total sus-
pended particles: the finer fraction, PM10, which can reach the
alveoli, and the most hazardous, PM2.5 (median aerodynamic
diameters of less than 10.0 microns and 2.5 microns, respec-
tively). Much of the PM2.5 consists of secondary pollutants
created by the condensation of gaseous pollutants—for exam-
ple, sulfur dioxide (SO2) and nitrogen dioxide (NO2). Types of
suspended PM include diesel exhaust particles; coal fly ash;
wood smoke; mineral dusts, such as coal, asbestos, limestone,
and cement; metal dusts and fumes; acid mists (for example, sul-
furic acid); and pesticide mists.
Gaseous pollutants include sulfur compounds such as SO2
and sulfur trioxide; carbon monoxide; nitrogen compounds
such as nitric oxide, NO2, and ammonia; organic compounds
such as hydrocarbons; volatile organic compounds; polycyclic
aromatic hydrocarbons and halogen derivatives such as alde-
hydes; and odorous substances. Volatile organic compounds
are released from burning fuel (gasoline, oil, coal, wood,
charcoal, natural gas, and so on); solvents; paints; glues; and
other products commonly used at work or at home. Volatile
organic compounds include such chemicals as benzene,
toluene, methylene chloride, and methyl chloroform. Emis-
sions of nitrogen oxides and hydrocarbons react with sunlight
to eventually form another secondary pollutant, ozone, at
ground level. Ozone at this level creates health concerns, unlike
ozone in the upper atmosphere, which occurs naturally and
protects life by filtering out ultraviolet radiation from the sun.
Sources of Outdoor Air Pollution. Outdoor air pollution is
caused mainly by the combustion of petroleum products or
coal by motor vehicles, industry, and power stations. In some
countries, the combustion of wood or agricultural waste is
another major source. Pollution can also originate from indus-
trial processes that involve dust formation (for example, from
cement factories and metal smelters) or gas releases (for
instance, from chemicals production). Indoor sources also con-
tribute to outdoor air pollution, and in heavily populated areas,
the contribution from indoor sources can create extremely
high levels of outdoor air pollution.
Motor vehicles emit PM, nitric oxide and NO2 (together
referred to as NOx), carbon monoxide, organic compounds,
and lead. Lead is a gasoline additive that has been phased out in
industrial countries, but some developing countries still use
leaded gasoline. Mandating the use of lead-free gasoline is
an important intervention in relation to health. It eliminates
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Table 43.1 Selected Industrial Sectors and Their Contribution to Air and Water Pollution and to Workplace Hazards 
Industrial sector Air Water Workplacea
Base metal and iron ore mining PM Toxic metal sludge Silica
Cement manufacturing PM Sludge Silica
Coalmining and production PM, coal dust Sludge Coal dust, silica
Copper smelting Arsenic Arsenic Arsenic, cadmium
Electricity generation PM, SO2 Hot water SO2
Foundries PM Solvents Silica, solvents
Iron and steel smelting PM Sludge Carbon monoxide, nickel
Lead and zinc smelting PM, SO2, lead, cadmium, arsenic Lead, cadmium, arsenic PM, SO2, lead, cadmium, arsenic 
Meat processing and rendering Odor High biological oxygen demand Infections
Oil and gas development SO2, carcinogens Oil Hydrocarbons
Pesticide manufacturing Pesticides and toxic intermediates Pesticides and toxic intermediates Pesticides and toxic intermediates
Petrochemicals manufacturing SO2 Oil Hydrocarbons
Petroleum refining SO2 Sludge, hydrocarbons Hydrocarbons
Phosphate fertilizer plants PM Nutrients
Pulp and paper mills Odor High biological oxygen demand, mercury Chlorine
Tanning and leather finishing Odor Chromium, acids Chromium, acids
Textile manufacturing Toxic dyes
Source: World Bank 1999.
a. In all the cases, the workplaces are subject to risk of injury, noise, dust, and excessively hot or cold temperatures. 
vehicle-related lead pollution and permits the use of catalytic
converters, which reduce emissions of other pollutants.
Catastrophic emissions of organic chemicals, as occurred in
Bhopal, India, in 1984 (box 43.1), can also have major health
consequences (McGranahan and Murray 2003; WHO 1999).
Another type of air pollution that can have disastrous con-
sequences is radioactive pollution from a malfunctioning
nuclear power station, as occurred in Chernobyl in 1986
(WHO 1996). Radioactive isotopes emitted from the burning
reactor spread over large areas of what are now the countries of
Belarus, the Russian Federation, and Ukraine, causing thou-
sands of cases of thyroid cancer in children and threatening to
cause many cancer cases in later decades.
Exposure to Air Pollutants. The extent of the health effects of
air pollution depends on actual exposure. Total daily exposure
is determined by people’s time and activity patterns, and it
combines indoor and outdoor exposures. Young children and
elderly people may travel less during the day than working
adults, and their exposure may therefore be closely correlated
with air pollution levels in their homes. Children are particu-
larly vulnerable to environmental toxicants because of their
possibly greater relative exposure and the effects on their
growth and physiological development.
Meteorological factors, such as wind speed and direction,
are usually the strongest determinants of variations in air pol-
lution, along with topography and temperature inversions.
Therefore, weather reports can be a guide to likely air pollution
levels on a specific day.
Workplace air is another important source of air pollution
exposure (chapter 60). Resource extraction and processing
industries, which are common in developing countries, emit
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dust or hazardous fumes at the worksite (table 43.1). Such
industries include coalmining, mineral mining, quarrying, and
cement production. Developed countries have shifted much of
their hazardous production to developing countries (LaDou
1992). This shift creates jobs in the developing countries, but at
the price of exposure to air pollution resulting from outdated
technology. In addition, specific hazardous compounds, such
as asbestos, have been banned in developed countries (Kazan-
Allen 2004), but their use may still be common in developing
countries.
Impacts on Health. Epidemiological analysis is needed to
quantify the health impact in an exposed population. The
major pollutants emitted by combustion have all been associ-
ated with increased respiratory and cardiovascular morbidity
and mortality (Brunekreef and Holgate 2002). The most
famous disease outbreak of this type occurred in London in
1952 (U.K. Ministry of Health 1954), when 4,000 people died
prematurely in a single week because of severe air pollution,
followed by another 8,000 deaths during the next few months
(Bell and Davis 2001).
In the 1970s and 1980s, new statistical methods and
improved computer technology allowed investigators to study
mortality increases at much lower concentrations of pollutants.
A key question is the extent to which life has been shortened.
Early loss of life in elderly people, who would have died soon
regardless of the air pollution, has been labeled mortality dis-
placement, because it contributes little to the overall burden of
disease (McMichael and others 1998).
Long-term studies have documented the increased cardio-
vascular and respiratory mortality associated with exposure
to PM (Dockery and others 1993; Pope and others 1995).
The Bhopal Catastrophe
Box 43.1
The Bhopal plant, owned by the Union Carbide
Corporation, produced methyl isocyanate, an intermedi-
ate in the production of the insecticide carbaryl. On
December 2, 1984, a 150,000-gallon storage tank contain-
ing methyl isocyanate apparently became contaminated
with water, initiating a violent reaction and the release of
a cloud of toxic gas to which 200,000 people living near
the plant were exposed. Low wind speed and the high
vapor pressure of methyl isocyanate exacerbated the sever-
ity of toxic exposure, resulting in the immediate death of
at least 6,000 people.
The dominating nonlethal effects of this emission were
severe irritation of the eyes, lungs, and skin. Effects on
the nervous system and reproductive organs were also
reported. The reaction of methyl isocyanate with water
had a corrosive effect on the respiratory tract, which
resulted in extensive necrosis, bleeding, and edema.
Treatment was impeded by the unknown and disputed
composition of the gas cloud and a lack of knowledge
about its health effects and about antidotes.
Source: Dhara and Dhara 2002.
A 16-year follow-up of a cohort of 500,000 Americans living in
different cities found that the associations were strongest with
PM2.5 and also established an association with lung cancer
mortality (Pope and others 2002). Another approach is ecolog-
ical studies of small areas based on census data, air pollution
information, and health events data (Scoggins and others
2004), with adjustments for potential confounding factors,
including socioeconomic status. Such studies indicate that the
mortality increase for every 10 micrograms per cubic meter
(g per m3) of PM2.5 ranges from 4 to 8 percent for cities in
developed countries where average annual PM2.5 levels are 10
to 30 g/m3. Many urban areas of developing countries have
similar or greater levels of air pollution.
The major urban air pollutants can also give rise to signifi-
cant respiratory morbidity (WHO 2000). For instance, Romieu
and others (1996) report an exacerbation of asthma among
children in Mexico City, and Xu and Wang (1993) note an
increased risk of respiratory symptoms in middle-aged non-
smokers in Beijing.
In relation to the very young, Wang and others (1997) find
that PM exposure, SO2 exposure, or both increased the risk of
low birthweight in Beijing, and Pereira and others (1998) find
that air pollution increased intrauterine mortality in São Paulo.
Other effects of ambient air pollution are postneonatal
mortality and mortality caused by acute respiratory infections,
as well as effects on children’s lung function, cardiovascular and
respiratory hospital admissions in the elderly, and markers for
functional damage of the heart muscle (WHO 2000). Asthma
is another disease that researchers have linked to urban air pol-
lution (McConnell and others 2002; Rios and others 2004).
Ozone exposure as a trigger of asthma attacks is of particular
concern. The mechanism behind an air pollution and asthma
link is not fully known, but early childhood NO2 exposure may
be important (see, for example, Ponsonby and others 2000).
Leaded gasoline creates high lead exposure conditions in
urban areas, with a risk for lead poisoning, primarily in young
children. The main concern is effects on the brain from low-
level exposure leading to behavioral aberrations and reduced or
delayed development of intellectual or motoric ability (WHO
1995). Lead exposure has been implicated in hypertension in
adults, and this effect may be the most important for the lead
burden of disease at a population level (WHO 2002). Other
pollutants of concern are the carcinogenic volatile organic
compounds, which may be related to an increase in lung can-
cer, as reported by two recent epidemiological studies (Nyberg
and others 2000; Pope and others 2002).
Urban air pollution and lead exposure are two of the envi-
ronmental hazards that WHO (2002) assessed as part of its
burden-of-disease calculations for the World Health Report
2002. The report estimates that pollution by urban PM causes
as much as 5 percent of the global cases of lung cancer, 2 per-
cent of deaths from cardiovascular and respiratory conditions,
and 1 percent of respiratory infections, adding up to 7.9 mil-
lion disability-adjusted life years based on mortality only. This
burden of disease occurs primarily in developing countries,
with China and India contributing the most to the global bur-
den. Eastern Europe also has major air pollution problems, and
in some countries, air pollution accounts for 0.6 to 1.4 percent
of the total disability-adjusted life years from mortality.
The global burden of disease caused by lead exposure
includes subtle changes in learning ability and behavior and
other signs of central nervous system damage (Fewthrell,
Kaufmann, and Preuss 2003). WHO (2002) concludes that
0.4 percent of deaths and 0.9 percent (12.9 million) of all
disability-adjusted life years may be due to lead exposure.
Water Pollution
Chemical pollution of surface water can create health risks,
because such waterways are often used directly as drinking
water sources or connected with shallow wells used for drink-
ing water. In addition, waterways have important roles for
washing and cleaning, for fishing and fish farming, and for
recreation.
Another major source of drinking water is groundwater,
which often has low concentrations of pathogens because the
water is filtered during its transit through underground layers
of sand, clay, or rocks. However, toxic chemicals such as arsenic
and fluoride can be dissolved from the soil or rock layers into
groundwater. Direct contamination can also occur from badly
designed hazardous waste sites or from industrial sites. In the
United States in the 1980s, the government set in motion the
Superfund Program, a major investigation and cleanup pro-
gram to deal with such sites (U.S. Environmental Protection
Agency 2000).
Coastal pollution of seawater may give rise to health hazards
because of local contamination of fish or shellfish—for
instance, the mercury contamination of fish in the infamous
Minamata disease outbreak in Japan in 1956 (WHO 1976).
Seawater pollution with persistent chemicals, such as polychlo-
rinated biphenyls (PCBs) and dioxins, can also be a significant
health hazard even at extremely low concentrations (Yassi and
others 2001).
Sources of Chemical Water Pollution. Chemicals can enter
waterways from a point source or a nonpoint source. Point-
source pollution is due to discharges from a single source, such
as an industrial site. Nonpoint-source pollution involves many
small sources that combine to cause significant pollution. For
instance, the movement of rain or irrigation water over land
picks up pollutants such as fertilizers, herbicides, and insecti-
cides and carries them into rivers, lakes, reservoirs, coastal
waters, or groundwater. Another nonpoint source is storm-
water that collects on roads and eventually reaches rivers or
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lakes. Table 43.1 shows examples of point-source industrial
chemical pollution.
Paper and pulp mills consume large volumes of water and
discharge liquid and solid waste products into the environ-
ment. The liquid waste is usually high in biological oxygen
demand, suspended solids, and chlorinated organic com-
pounds such as dioxins (World Bank 1999). The storage and
transport of the resulting solid waste (wastewater treatment
sludge, lime sludge, and ash) may also contaminate surface
waters. Sugar mills are associated with effluent characterized by
biological oxygen demand and suspended solids, and the efflu-
ent is high in ammonium content. In addition, the sugarcane
rinse liquid may contain pesticide residues. Leather tanneries
produce a significant amount of solid waste, including hide,
hair, and sludge. The wastewater contains chromium, acids,
sulfides, and chlorides. Textile and dye industries emit a liquid
effluent that contains toxic residues from the cleaning of
equipment. Waste from petrochemical manufacturing plants
contains suspended solids, oils and grease, phenols, and ben-
zene. Solid waste generated by petrochemical processes con-
tains spent caustic and other hazardous chemicals implicated
in cancer.
Another major source of industrial water pollution is min-
ing. The grinding of ores and the subsequent processing with
water lead to discharges of fine silt with toxic metals into water-
ways unless proper precautions are taken, such as the use of
sedimentation ponds. Lead and zinc ores usually contain the
much more toxic cadmium as a minor component. If the cad-
mium is not retrieved, major water pollution can occur.
Mining was the source of most of the widespread cadmium
poisoning (Itai-Itai disease) in Japan in 1940–50 (Kjellstrom
1986).
Other metals, such as copper, nickel, and chromium, are
essential micronutrients, but in high levels these metals can be
harmful to health. Wastewater from mines or stainless steel
production can be a source of exposure to these metals. The
presence of copper in water can also be due to corrosion of
drinking water pipes. Soft water or low pH makes corrosion
more likely. High levels of copper may make water appear
bluish green and give it a metallic taste. Flushing the first water
out of the tap can minimize exposure to copper. The use of lead
pipes and plumbing fixtures may result in high levels of lead in
piped water.
Mercury can enter waterways from mining and industrial
premises. Incineration of medical waste containing broken
medical equipment is a source of environmental contamina-
tion with mercury. Metallic mercury is also easily transported
through the atmosphere because of its highly volatile nature.
Sulfate-reducing bacteria and certain other micro-organisms in
lake, river, or coastal underwater sediments can methylate
mercury, increasing its toxicity. Methylmercury accumulates
and concentrates in the food chain and can lead to serious
neurological disease or more subtle functional damage to the
nervous system (Murata and others 2004).
Runoff from farmland, in addition to carrying soil and sed-
iments that contribute to increased turbidity, also carries nutri-
ents such as nitrogen and phosphates, which are often added in
the form of animal manure or fertilizers. These chemicals cause
eutrophication (excessive nutrient levels in water), which in-
creases the growth of algae and plants in waterways, leading to
an increase in cyanobacteria (blue-green algae). The toxics
released during their decay are harmful to humans.
The use of nitrogen fertilizers can be a problem in areas
where agriculture is becoming increasingly intensified. These
fertilizers increase the concentration of nitrates in groundwa-
ter, leading to high nitrate levels in underground drinking
water sources, which can cause methemoglobinemia, the life-
threatening “blue baby” syndrome, in very young children,
which is a significant problem in parts of rural Eastern Europe
(Yassi and others 2001).
Some pesticides are applied directly on soil to kill pests in
the soil or on the ground. This practice can create seepage to
groundwater or runoff to surface waters. Some pesticides are
applied to plants by spraying from a distance—even from air-
planes. This practice can create spray drift when the wind car-
ries the materials to nearby waterways. Efforts to reduce the use
of the most toxic and long-lasting pesticides in industrial coun-
tries have largely been successful, but the rules for their use in
developing countries may be more permissive, and the rules of
application may not be known or enforced. Hence, health risks
from pesticide water pollution are higher in such countries
(WHO 1990).
Naturally occurring toxic chemicals can also contaminate
groundwater, such as the high metal concentrations in under-
ground water sources in mining areas. The most extensive
problem of this type is the arsenic contamination of ground-
water in Argentina, Bangladesh (box 43.2), Chile, China, India,
Mexico, Nepal, Taiwan (China), and parts of Eastern Europe
and the United States (WHO 2001). Fluoride is another
substance that may occur naturally at high concentrations in
parts of China, India, Sri Lanka, Africa, and the eastern
Mediterranean. Although fluoride helps prevent dental decay,
exposure to levels greater than 1.5 milligrams per liter in drink-
ing water can cause pitting of tooth enamel and deposits in
bones. Exposure to levels greater than 10 milligrams per liter
can cause crippling skeletal fluorosis (Smith 2003).
Water disinfection using chemicals is another source of
chemical contamination of water. Chlorination is currently the
most widely practiced and most cost-effective method of disin-
fecting large community water supplies. This success in disin-
fecting water supplies has contributed significantly to public
health by reducing the transmission of waterborne disease.
However, chlorine reacts with naturally occurring organic mat-
ter in water to form potentially toxic chemical compounds,
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known collectively as disinfection by-products (International
Agency for Research on Cancer 2004).
Exposure to Chemical Water Pollution. Drinking contami-
nated water is the most direct route of exposure to pollutants
in water. The actual exposure via drinking water depends on
the amount of water consumed, usually 2 to 3 liters per day for
an adult, with higher amounts for people living in hot areas or
people engaged in heavy physical work. Use of contaminated
water in food preparation can result in contaminated food,
because high cooking temperatures do not affect the toxicity of
most chemical contaminants.
Inhalation exposure to volatile compounds during hot
showers and skin exposure while bathing or using water for
recreation are also potential routes of exposure to water pollu-
tants. Toxic chemicals in water can affect unborn or young chil-
dren by crossing the placenta or being ingested through breast
milk.
Estimating actual exposure via water involves analyzing the
level of the contaminant in the water consumed and assessing
daily water intake (WHO 2003). Biological monitoring using
blood or urine samples can be a precise tool for measuring total
exposure from water, food, and air (Yassi and others 2001).
Health Effects. No published estimates are available of the
global burden of disease resulting from the overall effects of
chemical pollutants in water. The burden in specific local areas
may be large, as in the example cited in box 43.2 of arsenic in
drinking water in Bangladesh. Other examples of a high
local burden of disease are the nervous system diseases of
methylmercury poisoning (Minamata disease), the kidney and
bone diseases of chronic cadmium poisoning (Itai-Itai disease),
and the circulatory system diseases of nitrate exposure (methe-
moglobinemia) and lead exposure (anemia and hypertension).
Acute exposure to contaminants in drinking water can cause
irritation or inflammation of the eyes and nose, skin, and gas-
trointestinal system; however, the most important health
effects are due to chronic exposure (for example, liver toxicity)
to copper, arsenic, or chromium in drinking water. Excretion of
chemicals through the kidney targets the kidney for toxic
effects, as seen with chemicals such as cadmium, copper, mer-
cury, and chlorobenzene (WHO 2003).
Pesticides and other chemical contaminants that enter
waterways through agricultural runoff, stormwater drains, and
industrial discharges may persist in the environment for long
periods and be transported by water or air over long distances.
They may disrupt the function of the endocrine system, result-
ing in reproductive, developmental, and behavioral problems.
The endocrine disruptors can reduce fertility and increase the
occurrence of stillbirths, birth defects, and hormonally
dependent cancers such as breast, testicular, and prostate can-
cers. The effects on the developing nervous system can include
impaired mental and psychomotor development, as well as
cognitive impairment and behavior abnormalities (WHO and
International Programme on Chemical Safety 2002). Examples
of endocrine disruptors include organochlorines, PCBs,
alkylphenols, phytoestrogens (natural estrogens in plants), and
pharmaceuticals such as antibiotics and synthetic sex hor-
mones from contraceptives. Chemicals in drinking water can
also be carcinogenic. Disinfection by-products and arsenic
have been a particular concern (International Agency for
Research on Cancer 2004).
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Arsenic in Bangladesh
Box 43.2
The presence of arsenic in tube wells in Bangladesh
because of natural contamination from underground geo-
logical layers was first confirmed in 1993. Ironically, the
United Nations Children’s Fund had introduced the wells
in the 1960s and 1970s as a safe alternative to water con-
taminated with microbes, which contributed to a heavy
diarrheal disease burden. Estimates indicate that 28 mil-
lion to 35 million people of Bangladesh’s population of
130 million are exposed to arsenic levels exceeding
50 micrograms per liter, the prescribed limit for drinking
water in Bangladesh (Kinniburgh and Smedley 2001).
This number increases to 46 million to 57 million if the
WHO guideline level of 10 micrograms per liter is used.
The most common sign of arsenic poisoning in
Bangladesh is skin lesions characterized by hyperkeratosis
and melanosis. Other effects reported, but not epidemio-
logically confirmed, include cancer (particularly of the
skin, lungs, and bladder); liver damage; diabetes; hyper-
tension; and reproductive effects (spontaneous abortions
and stillbirths). Cancer and vascular effects are the domi-
nating effects in other arsenic-polluted areas (WHO
2001).
Source: Authors.
INTERVENTIONS 
The variety of hazardous pollutants that can occur in air or
water also leads to many different interventions. Interventions
pertaining to environmental hazards are often more sustain-
able if they address the driving forces behind the pollution at
the community level rather than attempt to deal with specific
exposures at the individual level. In addition, effective meth-
ods to prevent exposure to chemical hazards in the air or
water may not exist at the individual level, and the only feasi-
ble individual-level intervention may be treating cases of
illness.
Figure 43.1 shows five levels at which actions can be taken to
prevent the health effects of environmental hazards. Some
would label interventions at the driving force level as policy
instruments. These include legal restrictions on the use of a
toxic substance, such as banning the use of lead in gasoline, or
community-level policies, such as boosting public transporta-
tion and reducing individual use of motor vehicles.
Interventions to reduce pressures on environmental quality
include those that limit hazardous waste disposal by recycling
hazardous substances at their site of use or replacing them with
less hazardous materials. Interventions at the level of the state
of the environment would include air quality monitoring
linked to local actions to reduce pollution during especially
polluted periods (for example, banning vehicle use when pol-
lution levels reach predetermined thresholds). Interventions at
the exposure level include using household water filters to
reduce arsenic in drinking water as done in Bangladesh. Finally,
interventions at the effect level would include actions by health
services to protect or restore the health of people already show-
ing signs of an adverse effect.
Interventions to Reduce Air Pollution
Reducing air pollution exposure is largely a technical issue.
Technologies to reduce pollution at its source are plentiful, as
are technologies that reduce pollution by filtering it away from
the emission source (end-of-pipe solutions; see, for example,
Gwilliam, Kojima, and Johnson 2004). Getting these technolo-
gies applied in practice requires government or corporate
policies that guide technical decision making in the right
direction. Such policies could involve outright bans (such as
requiring lead-free gasoline or asbestos-free vehicle brake lin-
ings or building materials); guidance on desirable technologies
(for example, providing best-practice manuals); or economic
instruments that make using more polluting technologies more
expensive than using less polluting technologies (an example of
the polluter pays principle).
Examples of technologies to reduce air pollution include the
use of lead-free gasoline, which allows the use of catalytic con-
verters on vehicles’ exhaust systems. Such technologies signifi-
cantly reduce the emissions of several air pollutants from vehi-
cles (box 43.3). For trucks, buses, and an increasing number of
smaller vehicles that use diesel fuel, improving the quality of
the diesel itself by lowering its sulfur content is another way
to reduce air pollution at the source. More fuel-efficient
vehicles, such as hybrid gas-electric vehicles, are another way
forward. These vehicles can reduce gasoline consumption by
about 50 percent during city driving. Policies that reduce
“unnecessary” driving, or traffic demand management, can
also reduce air pollution in urban areas. A system of congestion
fees, in which drivers have to pay before entering central urban
areas, was introduced in Singapore, Oslo, and London and has
been effective in this respect.
Power plants and industrial plants that burn fossil fuels use
a variety of filtering methods to reduce particles and scrubbing
methods to reduce gases, although no effective method is cur-
rently available for the greenhouse gas carbon dioxide. High
chimneys dilute pollutants, but the combined input of pollu-
tants from a number of smokestacks can still lead to an over-
load of pollutants. An important example is acid rain, which is
caused by SO2 and NOx emissions that make water vapor in the
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Source: Kjellstrom and Corvalan 1995.
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Figure 43.1 Framework for Environmental Health Interventions
atmosphere acidic (WHO 2000). Large combined emissions
from industry and power stations in the eastern United States
drift north with the winds and cause damage to Canadian
ecosystems. In Europe, emissions from the industrial belt
across Belgium, Germany, and Poland drift north to Sweden
and have damaged many lakes there. The convergence of air
pollutants from many sources and the associated health effects
have also been documented in relation to the multiple fires in
Indonesia’s rain forest in 1997 (Brauer and Hisham-Hashim
1998); the brown cloud over large areas of Asia, which is mainly
related to coal burning; and a similar brown cloud over central
Europe in the summer, which is caused primarily by vehicle
emissions.
Managing air pollution interventions involves monitoring
air quality, which may focus on exceedances of air quality
guidelines in specific hotspots or on attempts to establish a spe-
cific population’s average exposure to pollution. Sophisticated
modeling in combination with monitoring has made it possi-
ble to start producing detailed estimates and maps of air pollu-
tion levels in key urban areas (World Bank 2004), thus provid-
ing a powerful tool for assessing current health impacts and
estimated changes in the health impacts brought about by
defined air pollution interventions.
Interventions to Reduce Water Pollution
Water pollution control requires action at all levels of the hier-
archical framework shown in figure 43.1. The ideal method to
abate diffuse chemical pollution of waterways is to minimize
or avoid the use of chemicals for industrial, agricultural, and
domestic purposes. Adapting practices such as organic farming
and integrated pest management could help protect waterways
(Scheierling 1995). Chemical contamination of waterways
from industrial emissions could be reduced by cleaner produc-
tion processes (UNEP 2002). Box 43.4 describes one project
aimed at effectively reducing pollution.
Other interventions include proper treatment of hazardous
waste and recycling of chemical containers and discarded prod-
ucts containing chemicals to reduce solid waste buildup and
leaching of toxic chemicals into waterways. A variety of techni-
cal solutions are available to filter out chemical waste from
industrial processes or otherwise render them harmless.
Changing the pH of wastewater or adding chemicals that floc-
culate the toxic chemicals so that they settle in sedimentation
ponds are common methods. The same principle can be used
at the individual household level. One example is the use of
iron chips to filter out arsenic from contaminated well water in
Bangladeshi households (Kinniburgh and Smedley 2001).
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Air Pollution Reduction in Mexico City
Box 43.3
Mexico City is one of the world’s largest megacities, with
nearly 20 million inhabitants. Local authorities have
acknowledged its air quality problems since the 1970s. The
emissions from several million motor vehicles and thou-
sands of industries created major concerns about health
effects. Annual average particulate matter (PM10) levels
of 50 to 100 g/m3 have been measured in the worst-
polluted central area and can be associated with annual
mortality excess of 15 to 30 percent. Even if only 20 per-
cent of the population were exposed to such high levels,
that exposure would account for 6,000 to 12,000 addi-
tional deaths per year. To tackle the problem, Mexico City
started air quality monitoring and health studies in the
1980s. High-risk groups were the 2.2 million children,
250,000 street vendors, and 250,000 commercial drivers.
After 20 years of policies and actions, interventions for
better health have borne fruit.
The first intervention was lead-free gasoline in 1990,
which enabled the government to require catalytic con-
verters on new cars, thus dramatically reducing carbon
monoxide, NOx, and hydrocarbon emissions. In 1997,
leaded gasoline was completely phased out. The annual
average concentration of lead in the air in the worst-
polluted area was reduced from 1.2 g/m3 in 1990 to less
than 0.1 g/m3 in 2000. Surveys of blood lead levels in
children showed reductions from 200 to 100 g/liter dur-
ing the same period, implying that the intervention had
protected thousands of children from lead poisoning.
Another key concern was SO2 emissions from industry
and diesel vehicles. Heavy fuel oil was phased out in the
mid 1990s, and the sulfur content of diesel was reduced. In
addition, power plants and some industry shifted to natu-
ral gas in the early 1990s. The result was a 90 percent
reduction of SO2 in ambient air in five years.
Air quality standards, emission standards for vehicles,
and other technical actions to reduce air emissions were
tightened during the 1990s, contributing to downward
trends of carbon monoxide, NOx, and ozone levels. Levels
of emissions were reduced by half at some sites, resulting
in an estimated reduction of 3,000 to 6,000 excess deaths.
Sources: Fernandez 2002; McMichael, Kjellstrom, and Smith 2001; WHO 2000.
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INTERVENTION COSTS AND 
COST-EFFECTIVENESS 
This chapter cannot follow the detailed format for the eco-
nomic analysis of different preventive interventions devised for
the disease-specific chapters, because the exposures, health
effects, and interventions are too varied and because of the
lack of overarching examples of economic assessments.
Nevertheless, it does present a few examples of the types of
analyses available.
Comparison of Interventions
A review of more than 1,000 reports on cost per life year saved
in the United States for 587 interventions in the environment
and other fields (table 43.2) evaluated costs from a societal per-
spective. The net costs included only direct costs and savings.
Indirect costs, such as forgone earnings, were excluded. Future
costs and life years saved were discounted at 5 percent per year.
Interventions with a cost per life year saved of less than or equal
to zero cost less to implement than the value of the lives saved.
Each of three categories of interventions (toxin control, fatal
injury reduction, and medicine) presented in table 43.2
includes several extremely cost-effective interventions.
The cost-effective interventions in the air pollution area
could be of value in developing countries as their industrial
and transportation pollution situations become similar to
the United States in the 1960s. The review by Tengs and
others (1995) does not report the extent to which the various
interventions were implemented in existing pollution control or
public health programs, and many of the most cost-effective
interventions are probably already in wide use. The review did
create a good deal of controversy in the United States, because
professionals and nongovernmental organizations active in the
environmental field accused the authors of overestimating
the costs and underestimating the benefits of controls over
chemicals (see, for example, U.S. Congress 1999).
Costs and Savings in Relation to Pollution Control
A number of publications review and discuss the evidence
on the costs and benefits of different pollution control 
interventions in industrial countries (see, for example, U.S.
Environmental Protection Agency 1999). For developing coun-
tries, specific data on this topic are found primarily in the 
so-called gray literature: government reports, consultant
reports, or reports by the international banks.
Air Pollution. Examples of cost-effectiveness analysis for
assessing air quality policy include studies carried out in
Jakarta, Kathmandu, Manila, and Mumbai under the World
Bank’s Urban Air Quality Management Strategy in Asia
(Grønskei and others 1996a, 1996b; Larssen and others 1996a,
1996b; Shah, Nagpal, and Brandon 1997). In each city, an emis-
sions inventory was established, and rudimentary dispersion
modeling was carried out. Various mitigation measures for
Water Pollution Control in India
Box 43.4
In 1993, the Demonstration in Small Industries for
Reducing Wastes Project was started in India with support
from the United Nations Industrial Development
Organization. International and local experts initiated
waste reduction audits in four pulp and paper plants, four
textile dyeing and finishing factories, and four pesticide
production units. The experts identified priority areas,
estimated the likely reduction in the pollutant load, and
came up with more than 500 pollution prevention
options. The 12 companies spent a total of US$300,000 to
implement pollution prevention options and saved US$3
million in raw materials and wastewater treatment costs.
The most impressive savings were in the pulp and paper
sector. For instance, the Ashoka Pulp and Paper Company
participated in the project with the dual objectives
of reducing production costs and complying with
environmental regulations in a cost-effective manner.
Pressure from the public to improve environmental
performance and the need to conserve water, especially
during the summer, added urgency to the project. The
company implemented 24 waste minimization options,
with 13 additional options under consideration, resulting
in net annual savings of about US$160,000. The payback
period for the implemented options was less than seven
months, and the annual savings will continue.
The project demonstrated that waste minimization can
cut pollution and business costs at the same time, espe-
cially when the environmental protection effort is directed
toward the production process itself rather than to end-
of-pipe treatment. The key to success lies in the sustained
involvement of local experts and committed factory
managers.
Source: United Nations 1997.
reducing PM10 and health impacts were examined in terms of
reductions in tons of PM10 emitted, cost of implementation,
time frame for implementation, and health benefits and their
associated cost savings. Some of the abatement measures that
have been implemented include introducing unleaded gaso-
line, tightening standards, introducing low-smoke lubricants
for two-stroke engine vehicles, implementing inspections of
vehicle exhaust emissions to address gross polluters, and reduc-
ing garbage burning.
Transportation policies and industrial development do not
usually have air quality considerations as their primary objec-
tive, but the World Bank has developed a method to take these
considerations into account. The costs of different air quality
improvement policies are explored in relation to a baseline
investment and the estimated health effects of air pollution. A
comparison will indicate the cost-effectiveness of each policy.
The World Bank has worked out this “overlay” approach in
some detail for the energy and forestry sectors in the analogous
case of greenhouse gas reduction strategies (World Bank 2004).
Water Pollution. The costs and benefits associated with inter-
ventions to remove chemical contaminants from water need to
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Table 43.2 Median Cost Per Life Year Saved, Selected Relatively Low-Cost Interventions 
(1993 U.S. dollars)
Intervention Cost per life year saved 
Toxin control
Control coal-fired power plant emissions through high chimneys and other means  0
Reduce lead in gasoline from 1.1 to 0.1 grams per gallon  0
Ban amitraz pesticide on apples  0
Introduce a chloroform emission standard at selected pulp mills  0
Control SO2 by desulfuring residual fuel oil  0
Initiate sedimentation, filtration, and chlorination of drinking water 4,200
Introduce radon remediation in homes with levels greater than 21.6 picocuries per liter 6,100
Ban asbestos in brake linings 29,000
Set arsenic emission standards at selected copper smelters 36,000
Fatal injury reduction 
Make motorcycle helmet laws mandatory  0
Install automatic seat belts in cars  0
Require bad drivers to attend driving improvement schools  0
Pass a law requiring smoke detectors in homes  0
Improve standards for concrete construction  0
Ban residential growth in tsunami-prone areas  0
Make seat belt use in cars mandatory 69
Install smoke detectors in airplane lavatories 30,000
Medicine 
Require all common types of early childhood vaccinations  0
Implement annual stool colon cancer screening for people age 55 and older  0
Introduce detoxification or methadone maintenance for heroin addicts  0
Screen newborns for phenylketonuria  0
Recommend cervical cancer screening every three years for women age 65 and older  0
Introduce universal prenatal care for expectant mothers  0
Vaccinate all citizens against influenza 140
Screen men age 45–54 for hypertension 5,200
Institute annual mammography and breast examinations for women age 40–64 17,000
Perform three-vessel coronary artery bypass surgery for severe angina 23,000
Source: Based on Tengs and others 1995.
Note: The fatal injury reduction and medicine categories are included for comparison purposes.
be assessed on a local or national basis to determine specific
needs, available resources, environmental conditions (includ-
ing climate), and sustainability. A developing country for which
substantial economic analysis of interventions has been carried
out is China (Dasgupta, Wang, and Wheeler 1997; Zhang and
others 1996).
Another country with major concerns about chemicals
(arsenic) in water is Bangladesh. The arsenic mitigation pro-
grams have applied various arsenic removal technologies, but
the costs and benefits are not well established. Bangladesh has
adopted a drinking water standard of 50 g/L (micrograms per
liter) for arsenic in drinking water. The cost of achieving the
lower WHO guideline value of 10 g/L would be significant.
An evaluation of the cost of lowering arsenic levels in drinking
water in the United States predicts that a reduction from 50 to
10 g/L would prevent a limited number of deaths from blad-
der and lung cancer at a cost of several million dollars per death
prevented (Frost and others 2002).
Alternative water supplies need to be considered when the
costs of improving existing water sources outweigh the bene-
fits. Harvesting rainwater may provide communities with safe
drinking water, free of chemicals and micro-organisms, but
contamination from roofs and storage tanks needs to be con-
sidered. Rainwater collection is relatively inexpensive.
ECONOMIC BENEFITS OF INTERVENTIONS 
One of the early examples of cost-benefit analysis for chemical
pollution control is the Japan Environment Agency’s (1991)
study of three Japanese classical pollution diseases: Yokkaichi
asthma, Minamata disease, and Itai-Itai disease (table 43.3).
This analysis was intended to highlight the economic aspects of
pollution control and to encourage governments in developing
countries to consider both the costs and the benefits of indus-
trial development. The calculations take into account the 20 or
30 years that have elapsed since the disease outbreaks occurred
and annualize the costs and benefits over a 30-year period. The
pollution damage costs are the actual payments for victims’
compensation and the cost of environmental remediation. The
compensation costs are based on court cases or government
decisions and can be seen as a valid representation of the eco-
nomic value of the health damage in each case. As table 43.3
shows, controlling the relevant pollutants would have cost far
less than paying for damage caused by the pollution.
A few studies have analyzed cost-benefit aspects of air pollu-
tion control in specific cities.Those analyses are based mainly on
modeling health impacts from exposure and relationships
between doses and responses. Voorhees and others (2001) find
that most studies that analyzed the situation in specific urban
areas used health impact assessment to estimate impacts avoided
by interventions. Investigators have used different methods for
valuing the economic benefits of health improvements, includ-
ing market valuation, stated preference methods, and revealed
preference methods. The choice of assumptions and inputs sub-
stantially affected the resulting cost and benefit valuations.
One of the few detailed studies of the costs and benefits of air
pollution control in a specific urban area (Voorhees and others
2000) used changing nitric oxide and NO2 emissions in Tokyo
during 1973–94 as a basis for the calculations. The study did not
use actual health improvement data but calculated likely health
improvements from estimated reductions in NO2 levels and
published dose-response curves. The health effects included
respiratory morbidity (as determined by hospital admissions
and medical expenses), and working days lost for sick adults,
and maternal working days lost in the case of a child’s illness.
The results indicated an average cost-benefit ratio of 1 to 6, with
a large range from a lower limit of 3 to 1 to an upper limit of 1
to 44. The estimated economic benefits of reductions in nitric
oxide and NO2 emissions between 1973 and 1994 were consid-
erable: US$6.78 billion for avoided medical costs, US$6.33 bil-
lion for avoided lost wages of sick adults, and US$0.83 billion
for avoided lost wages of mothers with sick children.
Blackman and others’ (2000) cost-benefit analysis of
four practical strategies for reducing PM10 emissions from
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Table 43.3 Comparison of Actual Pollution Damage Costs and the Pollution Control Costs That Would Have Prevented the
Damage, for Three Pollution-Related Disease Outbreaks, Japan 
(¥ millions, 1989 equivalents)
Pollution damage costs
Pollution Main Pollution Health Livelihood Environmental
disease pollutant control costs damage damage remediation Total 
Yokkaichi asthma SO2, air pollution 14,800 21,000 Not estimated Not estimated 21,000
(1,300)a
Minamata disease Mercury, water pollution 125 7,670 4,270 690 12,630
Itai-Itai disease Cadmium, water and soil pollution 600 740 880 890 2,510
Source: Japan Environment Agency 1991.
Note: US$1  ¥150.
a. Based on actual compensation payments to a fraction of the population. The larger figure is what it would have cost to compensate all those who were affected.
traditional brick kilns in Ciudad Juárez in Mexico suggests that,
given a wide range of modeling assumptions, the benefits of
three control strategies would be considerably higher than the
costs. Reduced mortality was by far the largest component of
benefits, accounting for more than 80 percent of the total.
Pandey and Nathwani (2003) applied cost-benefit analysis
to a pollution control program in Canada. Their study pro-
posed using the life quality index as a tool for quantifying the
level of public expenditure beyond which the use of resources
is not justified. The study estimated total pollution control
costs at US$2.5 billion per year against a monetary benefit of
US$7.5 billion per year, using 1996 as the base year for all
cost and benefit estimates. The benefit estimated in terms of
avoided mortality was about 1,800 deaths per year.
El-Fadel and Massoud’s (2000) study of urban areas in
Lebanon shows that the health benefits and economic benefits
of reducing PM concentration in the air can range from US$4.53
million to US$172.50 million per year using a willingness-to-pay
approach. In that study, the major monetized benefits resulted
from reduced mortality costs.
Aunan and others (1998) assessed the costs and benefits of
implementing an energy saving and air pollution control pro-
gram in Hungary. They based their monetary evaluation of
benefits on local monitoring and population data and took
exposure-response functions and valuation estimates from
Canadian, U.S., and European studies. The authors valued the
average total benefits of the interventions at US$1.56 billion
per year (with 1994 as the base year), with high and low bounds
at US$7.6, billion and US$0.4 billion, respectively. They esti-
mated the cost-benefit ratio at 1 to 3.4, given a total cost of
interventions of US$0.46 billion per year. Many of the benefits
resulted from reduced mortality in the elderly population and
from reduced asthma morbidity costs.
Misra (2002) examined the costs and benefits of water pol-
lution abatement for a cluster of 250 small-scale industries in
Gujarat, India. Misra’s assessment looked at command-and-
control, market-based solutions and at effluent treatment as
alternatives. In a cost-benefit analysis, Misra estimated the net
present social benefits from water pollution abatement at
the Nandesari Industrial Estate at Rs 0.550 billion at 1995–96
market prices using a 12 percent social discount rate. After
making corrections for the prices of foreign exchange,
unskilled labor, and investment, the figure rose to Rs 0.62 bil-
lion. It rose still further to about Rs 3.1 billion when distribu-
tional effects were taken into account.
IMPLEMENTATION OF CONTROL STRATEGIES:
LESSONS OF EXPERIENCE 
The foregoing examples demonstrate that interventions to
protect health that use chemical pollution control can have
an attractive cost-benefit ratio. The Japan Environment
Agency (1991) estimates the national economic impact of pol-
lution control legislation and associated interventions. During
the 1960s and early 1970s, when the government made many of
the major decisions about intensified pollution control inter-
ventions, Japan’s gross domestic product (GDP) per capita was
growing at an annual rate of about 10 percent, similar to that
of the rapidly industrializing countries in the early 21st century.
At that time, Japan’s economic policies aimed at eliminating
bottlenecks to high economic growth, and in the mid 1960s,
industry was spending less than ¥50 billion per year on pollu-
tion control equipment. By 1976, this spending had increased
to almost ¥1 trillion per year. The ¥5 trillion invested in pollu-
tion control between 1965 and 1975 accounted for about
0.9 percent of the increase in GDP per capita during this
period. The Japan Environment Agency concluded that the
stricter environmental protection legislation and associated
major investment in pollution control had little effect on the
overall economy, but that the resulting health benefits are likely
cumulative.
Air
The broadest analysis of the implementation of control strate-
gies for air pollution was conducted by the U.S. Environmental
Protection Agency in the late 1990s (Krupnick and
Morgenstern 2002). The analysis developed a hypothetical sce-
nario for 1970 to 1990, assuming that the real costs for pollu-
tion control during this period could be compared with the
benefits of reduced mortality and morbidity and avoided dam-
age to agricultural crops brought about by the reduction of
major air pollutant levels across the country during this period.
The study estimated reduced mortality from dose-response
relationships for the major air pollutants, assigning the cost of
each death at the value of statistical life and the cost of mor-
bidity in relation to estimated health service utilization. The
study used a variety of costing methods to reach the range of
likely present values presented in table 43.4. It assumed that the
reduction of air pollution resulted from the implementation of
the federal Clean Air Act of 1970 and associated state-level reg-
ulations and air pollution limits.
The analysis showed a dramatically high cost-benefit ratio
and inspired debate about the methodologies used and the
results. One major criticism was of the use of the value of
statistical life for each death potentially avoided by the
reduced air pollution. A recalculation using the life-years-lost
method reduced the benefits for deaths caused by PM from
US$16,632 billion to US$9,100 billion (Krupnick and
Morgenstern 2002). The recalculated figure is still well above
the fifth percentile estimate of benefits and does not under-
mine the positive cost-benefit ratio reported. Thus, if a devel-
oping country were to implement an appropriate control
strategy for urban air pollution, it might derive significant
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economic benefits over the subsequent decades. The country’s
level of economic development, local costs, and local benefit
valuations will be important for any cost-benefit assessment.
WHO’s (2000) air quality guidelines are among the documents
that provide advice on analytical approaches.
Water
We were unable to find an analysis for water similar to the
broad analysis presented for air, but the examples of water pol-
lution with mercury, cadmium, and arsenic described earlier
indicate the economic benefits that can be reaped from effec-
tive interventions against chemical water pollution. Since the
pollution disease outbreaks of mercury and cadmium poison-
ing in Japan, serious mercury pollution situations have been
identified in Brazil, China, and the Philippines, and serious
cadmium pollution has occurred in Cambodia, China, the Lao
People’s Democratic Republic, and Thailand. Arsenic in
groundwater is an ongoing, serious problem in Bangladesh,
India, and Nepal and a less serious problem in a number of
other countries.
WHO has analyzed control strategies for biological water
pollution and water and sanitation improvements in relation to
the Millennium Development Goals (Hutton and Haller 2004).
The analysis demonstrated the considerable benefits of water
and sanitation improvements: for every US$1 invested, the eco-
nomic return was in the range of US$5 to US$28 for a number
of intervention options. Careful analysis of the same type is
required for populations particularly vulnerable to chemical
water pollution to assess whether control of chemical pollution
can also yield significant benefits.
RESEARCH AND DEVELOPMENT AGENDA 
Even though a good deal of information is available about the
health risks of common air and water pollutants, further
research is needed to guide regulations and interventions. The
pollutants that were most common in developed countries in
the past are still major problems in developing countries; how-
ever, direct application of the experiences of developed coun-
tries may not be appropriate, because exposed populations in
developing countries may have a different burden of preexist-
ing diseases, malnutrition, and other factors related to poverty.
Research on specific vulnerabilities and on relevant dose-
response relationships for different levels of economic develop-
ment and for various geographic conditions would therefore
be valuable for assessing risks and targeting interventions. In
addition, global chemical exposure concerns, such as endocrine
disruptors in air, water, and food, require urgent research to
establish the need for interventions in both industrial and
developing countries.
An important research topic is to clearly describe and quan-
tify the long-term health effects of exposure to air pollution.
The existing literature indicates that long-term exposure may
have more adverse health effects than short-term exposure
and, hence, have higher cost implications. Another topic is to
assess the health issue pertaining to greenhouse gases and
climate change, which are related to the same sources as urban
air pollution (Intergovernmental Panel on Climate Change
2001). Research and policy analysis on how best to develop
interventions to reduce health risks related to climate change
need to be considered together with the analysis of other air
pollutants.
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Table 43.4 Present Value of Monetary Benefits and Costs Associated with Implementation of the U.S. Clean Air Act, 1970–90
(1990 US$ billions)
Present value, Present Present value, 
Category Pollutant 5th percentile value, mean 95th percentile
Mortality PM 2,369 16,632 40,957
Mortality Lead 121 1,339 3,910
Chronic bronchitis PM 409 3,313 10,401
IQ reduction Lead 271 399 551
Other morbidity Several 227 337 501
Soil damage PM 6 74 192
Visibility reduction PM 38 54 71
Agricultural damage Ozone 11 23 35
Total benefits All 3,452 22,171 56,618
Total costs All Not estimated 523 Not estimated
Net benefits (total benefits  total costs) All Not estimated 21,648 Not estimated
Source: Krupnick and Morgenstern 2002.
In addition, to improve analysis of the economic costs of
health impacts, better estimates are needed of the burden of
disease related to chemical air and water pollution at local,
national, and global levels. Cost-effectiveness analysis of air
and water pollution control measures in developing countries
needs to be supported by further research, as cost levels and
benefit valuations will vary from country to country, and
solutions that are valid in industrial countries may not work
as well in developing countries. Strategies for effective air and
water resource management should include research on the
potential side effects of an intervention, such as in
Bangladesh, where tube wells drilled to supply water turned
out to be contaminated with arsenic (see box 43.2). Research
is also needed that would link methodologies for assessing
adverse health effects with exposure and epidemiological stud-
ies in different settings to permit the development of more
precise forecasting of the health and economic benefits of
interventions.
The variety of health effects of urban air pollution and the
variety of sources create opportunities for ancillary effects that
need to be taken into account in economic cost-effectiveness
and cost-benefit analysis. These are the beneficial effects of
reducing air pollution on other health risks associated with the
sources of air pollution. For example, if the air pollution from
transportation emissions is reduced by actions that reduce the
use of private motor vehicles by, say, providing public trans-
portation, not only are carbon dioxide levels reduced; traffic
crash injuries, noise, and physical inactivity related to the
widespread use of motor vehicles also decline (Kjellstrom and
others 2003).
One of the key challenges for policies and actions is to find
ways to avoid a rapid buildup of urban air pollution in coun-
tries that do not yet have a major problem. The health sector
needs to be involved in assessing urban planning, the location
of industries, and the development of transportation systems
and needs to encourage those designing public transportation
and housing to ensure that new sources of air pollution are not
being built into cities.
Decades of economic and industrial growth have resulted in
lifestyles that increase the demands on water resources simul-
taneous with increases in water pollution levels. Conflicts
between household, industrial, and agricultural water use are
a common public health problem (UNESCO 2003). The
developing countries need to avoid the experiences of water
pollution and associated disease outbreaks in industrial coun-
tries. Strategies to ensure sufficient pollution control must
be identified at the same time as strategies to reduce water con-
sumption. High water use depletes supplies and increases
salinity in groundwater aquifers, particularly in coastal regions.
The impact of climate change must also be taken into consid-
eration (Vorosmarty and others 2000).
CONCLUSION: PROMISES AND PITFALLS
Evidence shows that a number of chemicals that may be
released into the air or water can cause adverse health effects.
The associated burden of disease can be substantial, and invest-
ment in research on health effects and interventions in specific
populations and exposure situations is important for the devel-
opment of control strategies. Pollution control is therefore an
important component of disease control, and health profes-
sionals and authorities need to develop partnerships with other
sectors to identify and implement priority interventions.
Developing countries face major water quantity and quality
challenges, compounded by the effects of rapid industrializa-
tion. Concerted actions are needed to safely manage the use of
toxic chemicals and to develop monitoring and regulatory
guidelines. Recycling and the use of biodegradable products
must be encouraged. Technologies to reduce air pollution at the
source are well established and should be used in all new indus-
trial development. Retrofitting of existing industries and power
plants is also worthwhile. The growing number of private
motor vehicles in developing countries brings certain benefits,
but alternative means of transportation, particularly in rapidly
growing urban areas, need to be considered at an early stage, as
the negative health and economic impacts of high concentra-
tions of motor vehicles are well established. The principles
and practices of sustainable development, coupled with local
research, will help contain or eliminate health risks resulting
from chemical pollution. International collaboration involving
both governmental and nongovernmental organizations can
guide this highly interdisciplinary and intersectoral area of
disease control.
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Coronary artery disease (CAD), ischemic stroke, diabetes, and
some specific cancers, which until recently were common only
in high-income countries, are now becoming the dominant
sources of morbidity and mortality worldwide (WHO 2002).
In addition, rates of cancers and cardiovascular disease (CVD)
among migrants from low-risk to high-risk countries almost
always increase dramatically. In traditional African societies,
for example, CAD is virtually nonexistent, but rates among
African Americans are similar to those among Caucasian
Americans. These striking changes in rates within countries
over time and among migrating populations indicate that the
primary determinants of these diseases are not genetic but
environmental factors, including diet and lifestyle. Thus, con-
siderable research has been aimed at identifying modifiable
determinants of chronic diseases.
Prospective epidemiological studies, some randomized pre-
vention trials, and many short-term studies of intermediate
endpoints such as blood pressure and lipids have revealed a
good deal about the specific dietary and lifestyle determinants
of major chronic diseases. Most of these studies have been con-
ducted in Western countries, in part because of the historical
importance of these diseases in the West, but also because they
have the most developed research infrastructure. A general
conclusion is that reducing identified, modifiable dietary and
lifestyle risk factors could prevent most cases of CAD, stroke,
diabetes, and many cancers among high-income populations
(Willett 2002). These findings are profoundly important,
because they indicate that these diseases are not inevitable con-
sequences of a modern society. Furthermore, low rates of these
diseases can be attained without drugs or expensive medical
facilities, an outcome that is not surprising, because their rates
have historically been extremely low in developing countries
with few medical facilities. However, preventing these diseases
will require changes in behaviors related to smoking, physical
activity, and diet; investments in education, food policies, and
urban physical infrastructure are needed to support and
encourage these changes (see box 44.1).
CHRONIC DISEASE PREVENTION
In this section, we briefly review dietary and lifestyle changes
that reduce the incidence of chronic disease. The potential
magnitude of benefit is also discussed.
Recommended Lifestyle Changes
Specific changes in diet and lifestyle and likely benefits are
summarized in table 44.1. These relationships and supporting
evidence are summarized here.
Avoid Tobacco Use. Avoidance of smoking by preventing
initiation or by cessation for those who already smoke is the
single most important way to prevent CVD and cancer (chap-
ter 46). Avoiding the use of smokeless tobacco will also prevent
a good deal of oral cancer.
Maintain a Healthy Weight. Obesity is increasing rapidly
worldwide (chapter 45). Even though obesity—a body mass
index (BMI) of 30 or greater—has received more attention
Chapter 44
Prevention of Chronic Disease by Means
of Diet and Lifestyle Changes
Walter C. Willett, Jeffrey P. Koplan, Rachel Nugent, Courtenay
Dusenbury, Pekka Puska, and Thomas A. Gaziano
than overweight, overweight (BMI of 25 to 30) is typically even
more prevalent and also confers elevated risks of many dis-
eases. For example, overweight people experience a two- to
threefold elevation in the risks of CAD and hypertension and a
more than tenfold increase in the risk of type 2 diabetes com-
pared with lean individuals (BMI less than 23) (Willett, Dietz,
and Colditz 1999). Both overweight and obese people also
experience elevated mortality from cancers of the colon, breast
(postmenopausal), kidney, endometrium, and other sites
(Calle and others 2003).
Many people with a BMI of less than 25 have gained sub-
stantial weight since they were young adults and are also at
increased risk of these diseases, even though they are not
technically overweight (Willett, Dietz, and Colditz 1999). For
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The Insulin Resistance Syndrome
Box 44.1
In recent years, researchers have recognized the insulin
resistance syndrome (also known as the metabolic syn-
drome) as a common contributing factor to the develop-
ment of diabetes, CAD, and some cancers. The syndrome
is characterized by increased waist circumference, low
HDL (high-density lipoprotein) cholesterol, high levels of
triglycerides, hypertension, and glucose intolerance. The
most direct causes are overweight and inactivity, but
dietary factors contribute. Genetic factors, which are
probably beneficial during periods of food shortages, also
play a role. Recent evidence indicates that the populations
of Asia, Latin America, and probably Africa are particu-
larly susceptible (Dickinson and others 2002; Harris and
others 1998).
Table 44.1 Convincing and Probable Relationships between Dietary and Lifestyle Factors and Chronic Diseases
Dietary and Type 2 Dental Birth Metabolic Sexual 
lifestyle factors CVD diabetes Cancer disease Fracture Cataract defects Obesity syndrome Depression dysfunction
Avoid smoking
Pursue physical activity
Avoid overweight
Diet
Consume healthy
types of fatsa
Eat plenty of fruits and 
vegetables
Replace refined grains 
with whole grains
Limit sugar intakeb
Limit excessive calories
Limit sodium intake
Source: Authors’ summary of a review by the WHO and FAO 2003; Bacon and others 2003; Fox 1999; IARC 2002. 
Note: Bold  convincing; Standard  probable relation; ↑  increase in risk; ↓  decrease in risk.
a. Replace trans and saturated fats with mono- and polyunsaturated fats, including a regular source of N-3 fatty acids.
b. Includes limiting sugar-based beverages.
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example, in rural China, where the average BMI was less than
21 for both men and women, F. B. Hu and others (2000) found
that the prevalence of hypertension was nearly five times
greater for those with a BMI of approximately 25 than for the
leanest people. Because many Asians are experiencing adverse
consequences of excess body fat with a BMI of less than 25, the
definition of overweight for Asia has recently been expanded to
include a BMI of 23 to 25 (WHO 2000). For most people,
unless obviously malnourished as an adolescent or young
adult, bodyweight should ideally not increase by more than 2
or 3 kilograms after age 20 to maintain optimal health (Willett,
Dietz, and Colditz 1999). Thus, a desirable weight for most
people should be within the BMI range of 18.5 to 25.0, and
preferably less than 23.
Additional valuable information can be obtained by meas-
uring waist circumference, which reflects abdominal fat accu-
mulation. In many studies, waist circumference is a strong
predictor of CAD, stroke, and type 2 diabetes, even after con-
trolling for BMI (Willett, Dietz, and Colditz 1999). A waist
circumference of approximately 100 centimeters for men and
88 centimeters for women has been used as the criterion for
the upper limit of the healthy range in the United States, but
for many people this extent of abdominal fat would be far
above optimal. Because abdominal circumference is easily
assessed, even where scales may not be available, further work
to develop locally appropriate criteria could be worthwhile. In
the meantime, increases of more than 5 centimeters can be
used as a basis for recommending changes in activity patterns
and diet.
Views about the causes of obesity and ways to prevent or
reduce it have been controversial. Diets low in fat and high in
carbohydrates were believed to limit caloric intake sponta-
neously and thus to control adiposity, but such diets have not
reduced bodyweight in trials that have lasted for a year or more
(Willett and Leibel 2002). Some researchers have suggested that
diets with a high energy density, referring to the amount of
energy per volume, offer an alternative explanation for the
observed increases in obesity (Swinburn and others 2004), but
long-term studies have not examined this theory. Sugar-
sweetened beverages contribute significantly to the overcon-
sumption of calories, in part because calories in fluid form
appear to be poorly regulated by the body (E. A. Bell, Roe, and
Rolls 2003). In children, an increase in soda consumption of
one serving per day was associated with an odds ratio of 1.6 for
incidence of obesity (Ludwig, Peterson, and Gortmaker 2001),
and in a randomized trial, replacement of a standard soda with
a zero-calorie diet soda was associated with significant weight
loss (Raben and others 2002). Reductions in dietary fiber and
increases in the dietary glycemic load (large amounts of rapidly
absorbed carbohydrates from refined starches and sugar) may
also contribute to obesity (Ebbeling and others 2003; Swinburn
and others 2004).
Aspects of the food supply unrelated to its macronutrient
composition are also likely to be contributing to the global rise
in obesity. Inexpensive food energy from refined grains, sugar,
and vegetable oils has become extremely plentiful in most
countries. Food manufacturers and suppliers use carefully
researched methods to make products based on these cheap
ingredients maximally convenient and attractive.
Maintain Daily Physical Activity and Limit Television
Watching. Contemporary life in developed nations has
markedly reduced people’s opportunities to expend energy,
whether in moving from place to place, in the work environ-
ment, or at home (Koplan and Dietz 1999). Dramatic
reductions in physical activity are also occurring in developing
countries because of urbanization, increased availability of
motorized transportation to replace walking and bicycle riding,
and mechanization of labor. However, regular physical activity
is a key element in weight control and prevention of obesity
(IARC 2002; Swinburn and others 2004). For example, among
middle-aged West African women, more walking was asso-
ciated with a three-unit lower BMI (Sobngwi, Gautier, and
Mbanya 2003), and in China, car owners are 80 percent more
likely to be obese (Hu 2002).
In addition to its key role in maintaining a healthy weight,
regular physical activity reduces the risk of CAD, stroke, type 2
diabetes, colon and breast cancer, osteoporotic fractures,
osteoarthritis, depression, and erectile dysfunction (table 44.1).
Important health benefits have even been associated with walk-
ing for half an hour per day, but greater reductions in risk are
seen with longer durations of physical activity and more
intense activity.
The number of hours of television watched per day is asso-
ciated with increased obesity rates among both children and
adults (Hernandez and others 1999; Ruangdaraganon and
others 2002) and with a higher risk of type 2 diabetes and gall-
stones (F. B. Hu and others 2001; Leitzmann and others 1999).
This association is likely attributable both to reduced physical
activity and to increased consumption of foods and beverages
high in calories, which are typically those promoted on televi-
sion. Decreases in television watching reduce weight
(Robinson 1999), and the American Academy of Pediatrics
recommends a maximum of two hours of television watching
per day.
Eat a Healthy Diet. Medical experts have long recognized the
effects of diet on the risk of CVD, but the relationship between
diet and many other conditions, including specific cancers, dia-
betes, cataracts, macular degeneration, cholelithiasis, renal
stones, dental disease, and birth defects, have been documented
more recently. The following list discusses six aspects of diet
for which strong evidence indicates important health implica-
tions (table 44.1). These goals are consistent with a detailed
2003 World Health Organization (WHO) report (WHO and
FAO 2003).
• Replace saturated and trans fats with unsaturated fats,
including sources of omega-3 fatty acids. Replacing saturated
fats with unsaturated fats will reduce the risk of CAD (F. B.
Hu and Willett 2002; Institute of Medicine 2002; WHO and
FAO 2003) by reducing serum low-density lipoprotein
(LDL) cholesterol. Also, polyunsaturated fats (including the
long-chain omega-3 fish oils and probably alpha-linoleic
acid, the primary plant omega-3 fatty acid) can prevent
ventricular arrhythmias and thereby reduce fatal CAD. In a
case-control study in Costa Rica, where fish intake was
extremely low, the risk of myocardial infarction was 80 per-
cent lower in those with the highest alpha-linoleic acid
intake (Baylin and others 2003). Intakes of omega-3 fatty
acids are suboptimal in many populations, particularly if
fish intake is low and the primary oils consumed are low in
omega-3 fatty acids (for example, partially hydrogenated
soybean, corn, sunflower, or palm oil). These findings
have major implications, because changes in the type of oil
used for food preparation are often quite feasible and not
expensive.
Trans fatty acids produced by the partial hydrogenation
of vegetable oils have uniquely adverse effects on blood
lipids (F. B. Hu and Willett 2002; Institute of Medicine
2002) and increase risks of CAD (F. B. Hu and Willett
2002); on a gram-for-gram basis, both the effects on blood
lipids and the relationship with CAD risk are considerably
more adverse than for saturated fat. In many developing
countries, trans fat consumption is high because partially
hydrogenated soybean oil is among the cheapest fats avail-
able. In South Asia, vegetable ghee, which has largely
replaced traditional ghee, contains approximately 50 per-
cent trans fatty acids (Ascherio and others 1996).
Independent of other risk factors, higher intakes of trans fat
and lower intakes of polyunsaturated fat increase risk of
type 2 diabetes (F. B. Hu, van Dam, and Liu 2001).
• Ensure generous consumption of fruits and vegetables and ade-
quate folic acid intake. Strong evidence indicates that high
intakes of fruits and vegetables will reduce the risk of CAD
and stroke (Conlin 1999). Some of this benefit is mediated
by higher intakes of potassium, but folic acid probably also
plays a role (F. B. Hu and Willett 2002). Supplementation
with folic acid reduces the risk of neural tube defect preg-
nancies. Substantial evidence also suggests that low folic
acid intake is associated with greater risk of colon—and
possibly breast—cancer and that use of multiple vitamins
containing folic acid reduces the risk of these cancers
(Giovannucci 2002). Findings relating folic acid intake to
CVD and some cancers have major implications for many
parts of the developing world. In many areas, consumption
of fruits and vegetables is low. For example, in northern
China, approximately half the adult population is deficient
in folic acid (Hao and others 2003).
• Consume cereal products in their whole-grain, high-fiber
form. Consuming grains in a whole-grain, high-fiber form
has double benefits. First, consumption of fiber from cereal
products has consistently been associated with lower risks of
CAD and type 2 diabetes (F. B. Hu, van Dam, and Liu 2001;
F. B. Hu and Willett 2002), which may be because of both
the fiber itself and the vitamins and minerals naturally pres-
ent in whole grains. High consumption of refined starches
exacerbates the metabolic syndrome and is associated with
higher risks of CAD (F. B. Hu and Willett 2002) and type 2
diabetes (F. B. Hu, van Dam, and Liu 2001). Second, higher
consumption of dietary fiber also appears to facilitate
weight control (Swinburn and others 2004) and helps pre-
vent constipation.
• Limit consumption of sugar and sugar-based beverages. Sugar
(free sugars refined from sugarcane or sugar beets and high-
fructose corn sweeteners) has no nutritional value except for
calories and, thus, has negative health implications for those
at risk of overweight. Furthermore, sugar contributes to the
dietary glycemic load, which exacerbates the metabolic syn-
drome and is related to the risk of diabetes and CAD (F. B.
Hu, van Dam, and Liu 2001; F. B. Hu and Willett 2002;
Schulze and others 2004). WHO has suggested an upper
limit of 10 percent of energy from sugar, but lower intakes
are usually desirable because of the adverse metabolic effects
and empty calories.
• Limit excessive caloric intake from any source. Given the
importance of obesity and overweight in the causation of
many chronic diseases, avoiding excessive consumption
of energy from any source is fundamentally important.
Because calories consumed as beverages are less well-
regulated than calories from solid food, limiting the con-
sumption of sugar-sweetened beverages is particularly
important.
• Limit sodium intake. The principle justification for limiting
sodium is its effect on blood pressure, a major risk factor
for stroke and coronary disease (chapter 33). WHO has
suggested an upper limit of 1.7 grams of sodium per day
(5 grams of salt per day) (WHO and FAO 2003).
Potential of Dietary and Lifestyle Factors to Prevent
Chronic Diseases
Several lines of evidence indicate that realistic modifications of
diet and lifestyle can prevent most CAD, stroke, diabetes, colon
cancer, and smoking-related cancers. Less progress has been
made in identifying practically modifiable causes of breast and
prostate cancers.
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One line of evidence is based on declines in CAD in coun-
tries that have implemented preventive programs. Rates of
CAD mortality have been cut in half in several high-income
countries, including Australia, the United Kingdom, and the
United States. The most dramatic example is that of Finland
(box 44.2).
Other evidence derives from randomized intervention
studies. These often have serious limitations for estimating the
potential magnitude of benefits, because typically only one or
a few factors are modified, durations are usually only a few
years, and noncompliance with lifestyle change is often sub-
stantial. Nevertheless, some examples are illustrative of the
potential benefit. In two randomized studies among adults
at high risk of type 2 diabetes, those assigned to a program
emphasizing dietary changes, weight loss, and physical activity
experienced only half the risk of incident diabetes (Knowler
and others 2002; Tuomilehto and others 2001). The Lyon
Heart Study, conducted among those with existing heart dis-
ease, found a Mediterranean-type diet high in omega-3 fatty
acids reduced recurrent infarction by 70 percent compared
with an American Heart Association diet (de Lorgeril and
others 1994).
A third approach is to estimate the percentage of disease
that is potentially preventable by reducing multiple behavioral
risk factors using prospective cohort studies. Among U.S.
adults, more than 90 percent of type 2 diabetes, 80 percent
of CAD, 70 percent of stroke, and 70 percent of colon cancer
are potentially preventable by a combination of nonsmoking,
avoidance of overweight, moderate physical activity, healthy
diet, and moderate alcohol consumption (Willett 2002).
Collectively, these findings indicate that the low rates of
these diseases suggested by international comparisons and time
trends are attainable by realistic, moderate changes that are
compatible with 21st-century lifestyles.
INTERVENTIONS
Interventions aimed at changing diet and lifestyle factors
include educating individuals, changing the environment,
modifying the food supply, undertaking community interven-
tions, and implementing economic policies. In most cases,
quantifying the effects of the intervention is difficult, because
behavioral changes may take many years and synergies are
potentially important but hard to estimate in formal studies.
Substantial nihilism often exists regarding the ability to
change populations’ diets or behaviors, but major changes are
possible over extended periods of time. For example, per
capita egg consumption in the United States decreased from
approximately 420 to 270 per year between 1940 and 1990
following recommendations for preventing CAD (though in
reality, the evidence for benefits was meager). Similarly, the
prevalence of smoking, despite its being a physically addictive
behavior, halved among men in the United States between
1965 and 2000. Because changing behaviors related to diet and
lifestyle require sustained efforts, long-term persistence is
needed. However, opportunities exist that do not require indi-
vidual behavior changes, and these can lead to more rapid
benefits.
Educational Interventions
Efforts to change diets, physical activity patterns, and other
aspects of lifestyle have traditionally attempted to educate indi-
viduals through schools, health care providers, worksites, and
general media. These efforts will continue to play an important
role, but they can be strongly reinforced by policy and environ-
mental changes.
School-Based Programs. School-based programs include the
roles of nutrition and physical activity in maintaining physical
Success in Finland
Box 44.2
Finland provides one of the best-documented examples
of a community intervention. In 1972, Finland had the
world’s highest CVD mortality rate. Planners examined
the policy and environmental factors contributing to CVD
and sought appropriate changes, such as increased avail-
ability of low-fat dairy products, antismoking legislation,
and improved school meals. They used the media; schools;
worksites; and spokespersons from sports, education, and
agriculture to educate residents. After five years, signifi-
cant improvements were documented in smoking, choles-
terol, and blood pressure. By 1992, CVD mortality rates
for men age 35 to 64 had dropped by 57 percent. The pro-
gram was so successful that it was expanded to include
other lifestyle-related diseases. Twenty years later, major
reductions in CVD risk-factor levels, morbidity, and mor-
tality were attributed to the project. Recent data show a
75 percent decrease in CVD mortality (Puska and others
1998).
and mental health (box 44.3). School food services should pro-
vide healthy meals, both because they directly affect health and
because they provide a special opportunity to teach by exam-
ple. In many countries, school-based physical education
remains a significant source of physical activity for young peo-
ple. In China, 72 percent of children age 6 to 18 engage in mod-
erate to vigorous physical activity for a median of 90 to 100 min-
utes per week (Tudor-Locke and others 2003). Maintaining
these programs should be a high priority because they have
likely contributed to the historically low rates of obesity in such
countries.
Worksite Interventions. Worksite interventions can effi-
ciently include a wide variety of health promotion activities
because workers spend a large portion of their waking hours
and eat a large percentage of their food there. Interventions can
include educating employees; screening them for behavioral
risk factors; offering incentive programs to walk, ride a bicycle,
or take public transportation to work; offering exercise
programs during breaks or after work; improving the physical
environment to promote activity; and providing healthier
foods in cafeterias (box 44.4). Worksite health promotion can
result in a positive return on investment through lower health
costs and fewer sick days.
Interventions by Health Care Providers. Controlled inter-
vention trials for smoking cessation and physical activity have
shown that physician counseling, especially when accompanied
by supporting written material, can be efficacious in modifying
behavior. Studies of dietary counseling by physicians indicate
that even brief messages about nutrition can influence behav-
ior and that the magnitude of the effect is related to the inten-
sity of the intervention (Pignone and others 2003). Identifying
patients who are overweight or obese, or who are gaining
weight but are not yet overweight, is an initial step in prevent-
ing and treating overweight. However, many physicians are not
well trained to measure and calculate BMI and identify weight
problems.
838 | Disease Control Priorities in Developing Countries | Walter C. Willett, Jeffrey P. Koplan, Rachel Nugent, and others
Live for Life®
Box 44.4
Johnson & Johnson introduced Live for Life in 1979 with
the goal of making its employees the healthiest in the
world (Bly, Jones, and Richardson 1986). In 1993, the
company integrated its health and wellness program with
its disability management, employee assistance, and occu-
pational medicine programs. Instead of using physicians
and nurses to treat symptoms, the combined program
sought to use a variety of health professionals to change
individual behavior and improve health status. Employees
were offered US$500 in benefit credits for participation.
The program included routine health risk assessment,
health promotion after recovery from a medical event, and
support when returning to work after a major illness. Even
though the intervention program had little effect on body-
weight, physical fitness did increase. By the end of the
third year, savings to the company were more than
US$400 per year per employee.
The Planet Health Program
Box 44.3
Planet Health, developed for middle school students, in
the United States, has an immediate goal of reducing tele-
vision viewing time with the long-range goal of prevent-
ing unhealthy weight gain (Gortmaker and others 1999).
Teachers incorporate messages about reducing television
watching, nutrition, and increasing fitness into mathe-
matics, social studies, science, and language arts lessons.
Fitness units and periodic “FitChecks” during physical
education complement the classroom lessons. Teacher
training, student self-assessment using graphs, and stu-
dent reflection about enjoyable activities that could
replace at least a portion of the time they spend watching
television are key elements. This program has reduced tel-
evision watching and weight in girls (Gortmaker and oth-
ers 1999). Because the program is integrated into existing
classes, its cost is minimal.
Transportation Policy and Environmental Design
Transportation policies and the design of urban environments
are fundamental determinants of physical activity and there-
fore influence the risks of obesity and other chronic diseases.
Countries can take a number of steps to make positive changes.
Limit the Role of Automobiles. In wealthy countries, the
automobile has strongly influenced the trend toward low-
density, automobile-based suburban developments, many built
without sidewalks. These sprawling settlements tend to have
few services within walking distance and are usually not linked
to public transporationt. Dependence on automobiles affects
physical activity, because those who use public transportation
tend to walk more. In a prospective study in eight provinces in
China, 14 percent of households acquired a car between 1889
and 1997, and the likelihood of men becoming obese during
the same period was twice as great in households that acquired
a car than in those that did not (A. C. Bell, Ge, and Popkin
2002).
National policies strongly influence automobile use and
dependency. In the United States, low taxes on gasoline, free
parking, and wide streets encourage car ownership: almost
92 percent of U.S. households own at least one car, and 59 per-
cent own two or more cars (Pucher and Dijkstra 2003). In
contrast, in most of Western Europe, narrow streets, limited
parking, and high gasoline prices make the costs of automobile
use almost double those in the United States (Pucher and
Dijkstra 2003). As a result, Europeans walk or bike more and
use their cars approximately 50 percent less than their
American counterparts. Investment in roads rather than in
public transportation creates a vicious cycle: poor public trans-
portation systems lead to more dependency on the automobile.
As car use grows, injuries and deaths associated with auto-
mobile accidents also grow. In China, the number of four-
wheeled vehicles increased from about 60,000 to more than
50 million between 1951 and 1999, and traffic fatalities
increased from about 6,000 to more than 413,000 (S. Y. Wang
and others 2003). Many innovative strategies have been
developed to discourage private automobile use and to
promote public transportation, walking, and bicycling (see
box 44.5). Singapore has long been in the lead in relation to
such efforts: a combination of limiting the number of licenses
issued, implementing a vehicle quota system, and introducing
a road pricing system has limited personal car ownership and
congestion throughout the country. Other nations and regions
are now enacting similar road pricing systems or congestion
taxes. For example, London’s congestion charging system levies
a fee of approximately US$8 per day for cars entering central
London. Since its inception in 2003, the charge has reduced
congestion in the city and is expected to channel funds back
into the city’s transportation facilities.
Unfortunately some countries, particularly China, have
taken a different approach to their future transportation needs.
Government initiatives that encourage families to buy automo-
biles include lowering taxes, simplifying registration proce-
dures, and allowing foreign financing. In Beijing alone, resi-
dents purchased 400,000 cars in 2003.
Promote Walking and Bicycle Riding. Walking or cycling for
transportation and leisure are effective and practical means of
engaging in physical activity and are still the most common
ways to travel in many developing countries. In Bangkok and
Manila, only 25 percent of travel is by car, motorcycle, or taxi,
compared with 75 percent by public transportation or walking
(Pendakur 2000). In Madras, India, only 8 percent of the pop-
ulation travels by private, motorized transportation; 22 per-
cent of people walk; 20 percent bike; and the rest use public
transportation (Pendakur 2000). In China, approximately
90 percent of the urban population walks or rides a bicycle to
work, shopping, or school each day (G. Hu and others 2002).
Walking or biking is more likely to be prevalent in smaller
cities—that is, those with 1 million to 5 million people—than
in larger ones.
Bicycle riding and walking are also important for children’s
health. Most American children do not walk or bike to school,
even when distances are short (box 44.6). In contrast, almost
Prevention of Chronic Disease by Means of Diet and Lifestyle Changes | 839
Reducing Automobile Use in Brazil
Box 44.5
Curitiba, Brazil, provides an example of the benefits of a
strategy that reduces automobile use and increases use of
public transportation. In 1965, city planners adopted a
master plan that promoted development along designated
corridors along with a bus system so efficient that it has
virtually eliminated the need for automobiles. Minibuses
are used to quickly and efficiently transport individuals
from residential neighborhoods to express bus lines. These
bus lines run almost every 90 seconds and can carry up to
270 passengers each. Compared with other Brazilian cities
of its size, Curitiba uses 30 percent less gasoline per capita,
and its air pollution is among the lowest in the nation.
90 percent of Chinese children under 12 walk or ride a bicycle
to school (Hu 2002).
In many areas, the shift toward private car use has not yet
begun and can perhaps be forestalled by policies that benefit
walkers and cyclists rather than drivers. Such policies include
implementing road designs that promote a safe and well-lit
environment for walking and cycling, including traffic-calming
measures to reduce automobile speeds.
Many Western European countries have taken steps to
increase safety for cyclists and walkers. In Germany and the
Netherlands, bike paths serve as travel routes, not just weekend
recreational destinations as they do in the United States. The
former countries have invested heavily in bike paths and have
also created extensive car-free areas in cities, with well-lit side-
walks, clearly marked crosswalks, and pedestrian islands that
have improved safety. Both countries have increased the num-
ber of bicycle-friendly streets (on which cars are permitted but
bicycles have the right of way) and have created systems to sep-
arate streams of traffic, including cars, pedestrians, and bicy-
cles. A meta-analysis of selected traffic-calming studies in many
countries reported reductions in traffic speed, accidents,
injuries, and fatalities and an increase in bicycle use and walk-
ing (Bunn and others 2003).
Design Cities and Towns to Promote Health. Handy and
others’ (2002) comprehensive assessment of recent research on
urban planning concludes that a combination of urban design,
land-use patterns, and transportation systems that promotes
walking and bicycling will help create active, healthier, and
more livable communities. In densely developed cities that
have been built around public transportation rather than away
from it, individuals are much more likely to take public transit,
walk, or bicycle than in other areas and to weigh less and be less
likely to suffer from hypertension (Ewing, Schieber, and Zegeer
2003; Lopez 2004; Saelens, Sallis, and Frank 2003).
Those living in walker-friendly neighborhoods also appear
to be more mentally healthy and are more likely to know their
neighbors, to be socially active, and to participate in the politi-
cal process (Leyden 2003). In contrast, urban sprawl has been
linked to decreases in mental health and social capital
(Frumkin 2002) as well as anger and frustration over long com-
mutes (Surface Transportation Policy Project 1999). Sprawl
adversely affects the elderly in particular because they are
unable to walk to places of interest and many cannot drive.
Such isolation does not promote good physical or mental
health.
The so-called smart growth movement has resulted from
concerns about urban sprawl and unsustainable development
and is encouraging governments worldwide to rethink how
they develop new areas and redevelop older suburbs and cities.
Smart growth principles include mixing land uses, using com-
pact building designs, including a range of transportation and
housing choices, building walker-friendly neighborhoods in
attractive communities with a distinctive sense of place, and
implementing a philosophy of directing development toward
existing communities and the preservation of open space
(Office of the Administrator 2001) (box 44.7).
The involvement of public health practitioners in trans-
portation planning and building design is becoming more
common. In Edinburgh, a health impact assessment conducted
on proposed options for transportation policy showed the
effects of specific choices on both affluent members of the
community and the poor. Its recommendations, now adopted,
included new spending on pedestrian safety, a citywide bicycle
network, more greenways and park-and-ride programs, and
more rail transportation or bus services. Priorities are to bene-
fit pedestrians first, cyclists second, public transportation users
third, freight and delivery people fourth, and car users last.
Establishing criteria for building design can also lead to
increases in physical activity. For example, increasing signage
promoting stair use, as well as the attractiveness of the facilities
themselves, encourages people to use the stairs (Boutelle and
others 2001) (box 44.8).
Improved Food Supply 
People’s diets can be enhanced by improving the food supply.
The usual position of the food industry is that it simply
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Walking and Cycling to School
Box 44.6
One of the most effective ways to promote walking and
cycling is through local schools. The Safe Routes to School
program (http://www.saferoutestoschools.org/), estab-
lished in Marin County, California, is a private-public
partnership that created a citywide map of safe biking and
walking routes and proposed solutions for problem areas.
The program also sponsors walk- and bike-to-school days,
frequent-rider contests, and other promotional events
(Staunton, Hubsmith, and Kallins 2003).
provides whatever consumers demand, but this argument is
misleading, because the industry spends more than US$12 bil-
lion annually to influence consumer choices just within the
United States and many times this amount globally. Much of
this sum goes to promote foods with adverse health effects, and
children are primary targets.
Improving Processing and Manufacturing. Altering the
manufacturing process can rapidly and effectively improve
diets because such action does not require the slow process of
behavioral change. One example is eliminating the partial
hydrogenation of vegetable oils, which destroys essential
omega-3 fatty acids and creates trans fatty acids. European
manufacturers have largely eliminated trans fatty acids from
their food supply by altering production methods.
Regulations can facilitate changes in manufacturing directly
or indirectly by providing an incentive for manufacturers to
change their processes. For example, in 2003, the U.S. Food and
Drug Administration announced that food manufacturers had
to include trans fatty acid content on the standard food label.
Following imposition of this requirement, several large food
companies said that they would reduce or eliminate trans fats,
and many more are planning to do so (U.S. Food and Drug
Administration 2003). In Mauritius, the government required
a change in the commonly used cooking oil from mostly palm
oil to soybean oil, which changed people’s fatty acid intake and
reduced their serum cholesterol levels (Uusitalo and others
1996). Changes in types of fat can often be almost invisible and
inexpensive. Omega-3 fatty acid intakes can be increased by
incorporating oils from rapeseed, mustard, or soybean into
manufactured foods, cooking oils sold for use at home, or both.
Selective breeding and genetic engineering provide alternative
ways to improve the healthfulness of oils by modifying their
fatty acid composition.
When the consumption of processed food is high, a reduc-
tion in salt consumption will usually require changes at the
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Enhancing Urban Life in the Republic of Korea
Box 44.7
In Seoul, the government is managing growth by creating
six satellite communities with high-rise residential build-
ings outside the city center. These communities are
intended to become new job-creation centers and to shift
the balance of employment away from one centralized
location to provide a more regional balance. Major
expressways are being removed to create parks, sidewalks,
and bikeways (http://www.itdp.org/STe/ste6/#seoul).
Promoting Physical Activity in Brazil
Box 44.8
One successful example of increasing activity is Agita São
Paulo, a multilevel physical activity initiative designed for
the 34 million citizens of Brazil’s São Paulo state (Matsudo
and others 2002). The program was launched in 1996 to
increase the public’s knowledge of the benefits of exercise
and expand participation in physical fitness activities by
encouraging people to do 30 minutes of moderate activity
at least five times a week. As elsewhere, program designers
perceived a lack of time as the major factor preventing
daily exercise. They chose three settings as places to pro-
mote activity: home (gardening, chores, avoidance of tele-
vision watching); transportation (walking, taking the
stairs); and leisure time (dancing). Agitol, a prescription
for exercise, was developed for physicians to dispense. Its
message is displayed on electricity bills and stickers, and it
is touted by radio stations and other media outlets.
After four years, 55.7 percent of those surveyed had
heard about Agita, 37 percent knew its purpose, and those
who knew of the program’s purpose were more likely to be
active. Agita appears to have played a role in increasing
activity in the region (Matsudo and others 2002). It is
closely linked to a national program to promote healthy
diets and active lifestyles by nutritional content labeling,
promotion of healthy diets in schools, communication of
guidelines for healthy eating, and encouragement of inno-
vative community-based initiatives (Coitinho, Monteiro,
and Popkin 2002).
manufacturing level, because processed food is a major salt
source. If the salt content of foods is reduced gradually, the
change is imperceptible to consumers. Coordination among
manufacturers or government regulation is needed; otherwise
producers whose foods are lower in salt may be placed at a dis-
advantage. Unfortunately, good examples are not available.
Another example of improved processing would be to reduce
the refining of grain products, which can be done in small,
almost invisible decrements.
Fortifying Food. Food fortification has eliminated iodine
deficiency, pellagra, and beriberi in much of the world. In
regions where iodine deficiency remains a serious problem,
fortification should be a high priority. Folic acid intake is sub-
optimal in many regions of both developing and developed
countries. Fortifying foods with folic acid is extremely inex-
pensive and could substantially reduce the rates of several
chronic diseases. Grain products—such as flour, rice, and
pasta—are usually the best foods to fortify, and in many coun-
tries, they are already being fortified with other B vitamins.
Since 1998, grain products in the United States have been
fortified with folic acid, which has almost eliminated folate
deficiency, and rates of neural tube defect pregnancies have
declined by about 19 percent (Honein and others 2001). Where
intakes of vitamins B12 and B6 are also low and contribute to
elevations of homocysteine, as among vegetarian populations
in India, simultaneous fortification of food with these vitamins
should be considered. The effects of fortification on reducing
CVD are not considered proven, but the potential benefits are
huge; therefore, intervention trials to evaluate the effects of
fortification should be a high priority.
Increasing the Availability and Reducing the Cost of Healthy
Foods. Policies regarding the production, importation, distri-
bution, and sale of specific foods can influence their cost and
availability. Policies may be directed at the focus of agricultur-
al research and the types of production promoted by extension
services. Policies often promote grains, dairy products, sugar,
and beef, whereas those that encourage the production and
consumption of fruits, vegetables, nuts, legumes, whole grains,
and healthy oils would tend to enhance rather than reduce
health.
Promoting Healthy Food Choices and Limiting Aggressive
Marketing to Children. Almost every national effort to
improve nutrition incorporates the promotion of healthy food
choices, such as fruits, vegetables, and legumes. Ideally, such
efforts are coordinated among government groups, retailers,
professional groups, and nonprofit organizations, and invest-
ment in such efforts should include the careful testing and
refining of social-marketing strategies.
Another strategy is to protect consumers from aggressive
marketing of unhealthy foods. Producers spend billions of dol-
lars a year encouraging children to consume foods that are
detrimental to their health. Manufacturers and fast-food chains
personify food products with cartoon characters; display food
brands on toys; and issue “educational” card games that subvert
children’s natural gift for play, story telling, and make believe.
The willingness to limit advertising depends on a country’s
political culture, but the public clearly distinguishes between
advertising aimed at adults and that targeted at children. For
example, in the United States, 46 percent of adults surveyed
supported restrictions on advertising to children (Blendon
2002). Restrictions can range from banning advertising to
children to limiting the types of products that advertisers may
promote to this audience.
Initiatives at the Community Level
Nations and regions can promote a variety of initiatives to
encourage greater physical activity and better nutrition. These
initiatives are likely to be most effective when they are multi-
faceted and coordinated and when they are developed with the
active involvement of individuals and organizations within
communities (Puska and others 1998).
Many countries are undertaking efforts to educate their
populations about healthy lifestyles. In the Islamic Republic of
Iran, the Isfahan Healthy Heart Program, a WHO collaborating
center for research and training for CVD control, prevention,
and rehabilitation for cardiac patients, has developed a com-
prehensive, integrated community intervention that involves
schools, worksites, health care facilities, food services, urban
planners, and the media. Physical activity is promoted by
creating safe routes for walking and bicycle riding and
by organizing recreational walking that involves entire families
(http://ihhp.mui.ac.ir).
South Africa’s Community Health Intervention Pro-
gramme, a partnership between an insurance company and an
academic institution, has created programs targeted to specific
age groups, including children and older adults. The program’s
twice-weekly classes have reduced blood pressure and increased
strength and balance (Lambert, Bohlmann, and Kolbe-
Alexander 2001) (box 44.9).
Singapore’s Fit and Trim Program uses a multidisciplinary
approach to increase physical activity and healthy diets among
schoolchildren. Between 1992 and 2000, the rate of obesity
declined by 13.1 to 16.6 percent for children age 11 to 12 and
15 to 16 (Toh, Cutter, and Chew 2002) (box 44.10 outlines the
national program for adults).
Economic Policies 
Economic policies can have important effects on behavior and
choices, and these policies have been particularly useful in
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reducing the prevalence of smoking (see chapter 46). Policies
that could influence diet and physical activity deserve careful
consideration because they are rarely neutral and often support
unhealthy behaviors. Consider the following examples:
• Subsidies can favor the consumption of less healthy foods,
such as sugar, refined grains, beef, and high-fat dairy prod-
ucts as opposed to fruits, vegetables, whole grains, nuts,
legumes, and fish. Poland provides a striking example of
how changes in subsidies can affect health (box 44.11).
Governments often subsidize foods indirectly by sheltering
them from sales taxes in the recognition that they are essen-
tial; however, this logic should not extend to foods with
adverse health effects, such as sugar-sweetened beverages
and those high in trans fats. Legislation can make this
distinction, providing a modest economic incentive for
healthier choices and at the same time conveying important
nutritional messages (see chapter 11).
• Use of individual automobiles is often subsidized by build-
ing and maintaining highways, providing inexpensive
parking, and imposing low taxes on petroleum products
that do not fully reflect their societal and environmental
costs. Increasing taxes on petroleum products and subsidiz-
ing public transportation could have an important effect on
choice of transportation modality, which as noted earlier,
has major effects on health.
• Walking, riding bicycles, and using public transportation
can be promoted by economic policies that, in addition
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A Comprehensive Intervention Approach in South Africa
Box 44.9
The Coronary Risk Factor Study in South Africa (Rossouw
and others 1993) tested community interventions at dif-
ferent levels of intensity in two communities with a third
control community. The target population was Caucasian
South Africans. Interventions included direct media cam-
paigns,public health messages delivered in a variety of ways,
and home mailings. Also included were community acti-
vities, such as fun walks, public meetings, involvement of
community-based organizations, free screening for blood
pressure, small-group personal interventions, and encour-
agement of food substitution in stores and restaurants. The
results showed an improvement in the community risk
factor profile for CAD in the intervention communities,
especially in relation to blood pressure, smoking, and over-
all risk. The results indicate no additional benefit of the
personal intervention for high-risk individuals beyond that
already offered by the mass media program. Estimated per
capita costs of the heavy intervention program were roughly
four times as much as for the mild intervention program
(US$22 per capita compared with US$5 per capita), and the
low-intervention community received almost the same
level of benefits as the high-intervention community.
The Singapore National Healthy Lifestyle Program
Box 44.10
Because CVD and cancer had become the major causes of
death in Singapore, the government adopted the National
Healthy Lifestyle Program in 1992 (Cutter, Tan, and Chew
2001). This coordinated, multisectoral approach involved
government ministries, health professionals, employers,
unions, and community organizations. The program
aimed at improving the social and physical environment so
as to promote healthy living. Healthy diets, regular physi-
cal exercise, and nonsmoking were emphasized. The pro-
gram used the mass media; legislative measures to discour-
age smoking; and widespread school, workplace, and com-
munity health promotion packages.
In a follow-up survey after six years, cigarette smoking
had decreased from 34 to 27 percent among men, the pro-
portion of adults who exercised regularly had increased
from 14 to 17 percent, and the prevalence of obesity was
stable. However, hypertension and high LDL cholesterol
levels had increased modestly. From 1991 to 1999, the age-
standardized incidence of myocardial infarction declined
from 98.2 to 83.0 per 100,000 residents (Mak and others
2003) and age-standardized mortality from CAD
decreased from 60.8 to 47.2 per 100,000 residents.
to providing better infrastructure, include discounts on
transportation fares, provide secure bicycle parking, and
reduce health insurance premiums.
COST-EFFECTIVENESS OF INTERVENTIONS
Only a few studies have described interventions for lifestyle
diseases in developing countries.
Modeling Likely Interventions 
Primary targets for reducing lifestyle diseases include changing
the fat composition of the diet, limiting sodium intake, and
engaging in regular physical activity.
Using available data, we calculated a range of estimates
under given assumptions for the cost-effectiveness of replacing
dietary saturated fat with monounsaturated fat, replacing
trans fat with polyunsaturated fat, and reducing salt intake. An
increase in moderate physical activity by three to five hours per
week is considered likely to lower the risk of many diseases, but
data to model the cost-effectiveness of this intervention are not
currently available. For further details of methods and assump-
tions underlying the analyses presented here, see the Web site
version of this book.
Reducing Saturated Fat Content. In the base case, assuming a
3 percent drop in cholesterol and a US$6 per person cost of the
intervention, averting one disability-adjusted life year (DALY)
would cost as little as US$1,865 in South Asia and as much as
US$4,012 in the Middle East and North Africa. The interven-
tion’s effectiveness could be increased by replacing part of the
saturated fat with polyunsaturated fat, which has additional
beneficial effects mediated by mechanisms other than LDL
cholesterol (see tables 44.2 and 44.3).
Replacing Dietary Trans Fat from Partial Hydrogenation
with Polyunsaturated Fat. We could not use the model for
saturated fat to estimate the effects of replacing trans fat with
polyunsaturated fat because only a small part of the benefit is
attributable to reducing LDL cholesterol (F. B. Hu and Willett
2002). Trans fats also adversely affect high-density lipoprotein
(HDL) cholesterol, triglycerides, endothelial function, and
inflammatory markers. In addition, increases in polyunsatu-
rated fat (assuming a mix of N-6 and omega-3 fatty acids) will
reduce LDL cholesterol, insulin resistance, and probably fatal
cardiac arrhythmias.
In calculations that are based only on the adverse effects on
LDL and HDL, replacing 2 percent of the energy from trans fat
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Poland: A Dramatic Decline in Heart Disease
Box 44.11
After Poland’s transition to a democratic government
in the early 1990s, the government removed large sub-
sidies for butter and lard, and consumption of nonhy-
drogenated vegetable fat increased rapidly (Zatonski,
McMichael, and Powles 1998). The ratio of dietary
polyunsaturated to saturated fat increased from 0.33
in 1990 to 0.56 in 1999, and during this period mor-
tality rates from CAD dropped by 28 percent (data
provided by W. Zatonski). Changes in smoking and in
the consumption of fruits and vegetables probably
played a minor role in this decrease (see figure).
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Notes: Squares represent data for Poland from 1990 to 1999. Circles are for deciles of
polyunsaturated fat to saturated fat and for risk of coronary heart disease in the Nurses’
Health Study (Hu 1999), which closely predict the observed changes in Poland.
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with polyunsaturated fat was estimated to reduce CAD by 7
to 8 percent (Grundy 1992; Willett and Ascherio 1994).
Epidemiological studies, which include the contributions of
the additional causal pathways, suggest a much greater reduc-
tion, from about 25 to 40 percent (F. B. Hu and others 1997;
Oomen and others 2001). Another likely benefit is a reduction
in the incidence of type 2 diabetes: estimates indicate that the
same 2 percent reduction would reduce incidence by 40 percent
(Salmeron and others 2001).
Because voluntary action by industry (as has nearly been
achieved in the Netherlands) or by regulation (as occurred in
Denmark) can eliminate partially hydrogenated fat from the
diet, this initiative does not require consumer education, and
the costs can be extremely low. In an analysis required before
implementing food labeling, the U.S. Food and Drug
Administration (2003) estimated that trans fat labeling would
be highly cost-effective. Even though the effect of labeling itself
was estimated to have only a modest effect on consumer
behavior, as noted earlier, it is having a major effect on manu-
facturers’ behavior.
The potential for reducing CVD rates by replacing trans fats
with polyunsaturated fats will depend on the diets of specific
populations. Whereas the intake of trans fat is low in China, it
is likely to be high in parts of India, Pakistan, and other Asian
countries because of the extraordinarily high content in com-
monly used cooking fats.
Table 44.2 presents the results of a cost-effectiveness analysis
assuming the two different estimates for CAD reduction: 7 per-
cent and 40 percent.We used costs of US$0.50 per adult per year,
which was the maximal cost in the U.S. Food and Drug
Administration analysis, and of US$6.00 per adult per year using
traditional health education approaches. The lower estimate—
or one even lower—is possible because trans fat can be elimi-
nated at the source rather than depending entirely on changes in
individual behavior. With the lower cost, the smaller effect esti-
mate leads to a cost-effectiveness ratio of between US$25 and
US$73 per DALY averted, depending on the region, and with the
higher-effect estimate, the intervention can be cost saving.
Reducing the Salt Content of Manufactured Foods through
Legislation and an Accompanying Education Campaign.
Table 44.2 shows the base-case cost-effectiveness of a legislated
reduction in salt content. The intervention appears to be rela-
tively cost-effective, with a cost per DALY averted of US$1,325
in South Asia to US$3,056 in the Middle East and North Africa.
Those regional variations are attributable to differing risk pro-
files across regions as well as to price differentials for the costs
of treating disease sequelae.
The actual blood pressure reduction from lower salt con-
sumption could vary from the base-case assumption, as could
the costs of the education campaign. Table 44.4 shows the
Prevention of Chronic Disease by Means of Diet and Lifestyle Changes | 845
Table 44.2 Incremental Cost-Effectiveness Ratios, Selected Interventions, by Region
(US$/DALY averted) 
Substituting 2 percent of energy from 
trans fat with polyunsaturated fat
Media campaign Reducing salt 
to reduce Intervention Intervention Intervention Intervention content by means 
saturated fat cost of cost of cost of cost of of legislation plus 
Region content US$0.50/adulta US$6.00/adult US$0.50/adulta US$6.00/adult public education
East Asia and the Pacific 2,769 73 1,583 Cost saving 227 2,056
Europe and Central Asia 2,929 65 1,670 Cost saving 228 2,170
Latin America and the Caribbean 3,297 40 1,865 Cost saving 225 2,476
Middle East and North Africa 4,012 25 2,259 Cost saving 252 3,056
South Asia 1,865 38 1,014 Cost saving 138 1,325
Sub-Saharan Africa 2,356 53 1,344 Cost saving 184 1,766
Source: Authors’ calculations.
a. Based on the U.S. Food and Drug Administration’s analysis of the costs of the intervention in the United States.
7 percent CAD reduction 40 percent CAD reduction
Table 44.3 Two-Way Sensitivity Analysis of the Costs of the
Intervention to Reduce Saturated Fat Content and of the
Relative Risk Reduction in CAD Events, South Asia
(US$/DALY averted)
Relative risk 
Cost per individualreduction in CAD 
events (percent) US$0.25 US$3.00 US$6.00a
10 Cost saving 318 680
5 Cost saving 680 1,403
4b Cost saving 911 1,865
1 258 3,572 7,188
Source: Authors’ calculations.
a. Threshold analysis reveals that at the base assumption of US$6 for the intervention, no level in
the range of assumed CAD reduction is cost saving. 
b. Threshold analysis reveals that at a cost below US$0.36 per individual and a 4 percent
reduction in CAD (base assumption), the intervention is cost saving.
results of lower costs of the education campaign and higher or
lower effects of the intervention on blood pressure. These
results may argue for initial efforts to focus on reductions in the
use of salt during the manufacturing process with no public
education campaign. The cost-effectiveness of such a change is
high and could be augmented with a public education cam-
paign only if needed to support the legislated change. At lower
implementation costs, the intervention is highly cost-effective,
even with half the assumed effect on blood pressure.
Adopting Physical Activity Interventions. Even though
health experts believe that physical activity interventions are
effective in reducing the risk of lifestyle diseases, no studies of
their cost-effectiveness are available from developing countries.
If people walk voluntarily (the model assumes no opportunity
cost), a net economic benefit would accrue to all segments of
the U.S. population. If we project the economic benefits to the
entire U.S. population and assume 25 percent compliance by
the sedentary population, the voluntary program would gener-
ate US$6.8 billion in savings (in 2001 U.S. dollars).
Aggregate Costs of Obesity and Unhealthy Lifestyles
A series of U.S. studies appears to confirm that the avoidable
costs of chronic diseases are substantial, although many devel-
oping countries have not yet experienced the full demands on
their health sectors resulting from these conditions. Colditz
(1999) estimates that obesity is responsible for 7 percent of all
U.S. direct health care costs and that inactivity is responsible for
an additional 2.4 percent of all health care costs. Indirect costs
associated with obesity and inactivity account for another
5 percent of health care costs. Pronk and others (1999) assess
the difference in health care costs between adult patients with
and without risk factors for noncommunicable diseases (phys-
ical activity, BMI, and smoking status) and find that a healthi-
er lifestyle of physical activity three times per week, a moderate
BMI, and nonsmoking status reduce health care costs by
49 percent compared with an unhealthy lifestyle.
Cost-Effectiveness of Community-Based Interventions
Populationwide and community-based interventions appear to
be cost-effective if they reach large populations, address high-
mortality and high-morbidity diseases, and are multipronged
and integrated efforts. The full costs of achieving changes in
behavior and policy are often complex and difficult to estimate.
Interventions may yield additional spinoff benefits. For
instance, decisions to reduce children’s television viewing could
easily improve school outcomes as well as reduce childhood
obesity. Similarly, increasing walking and bicycle riding for
transportation could reduce air pollution.
RESEARCH AND DEVELOPMENT PRIORITIES
A number of research and development priorities have been
identified:
• Conduct randomized trials of the use of folic acid and
alpha-linoleic acid to prevent CAD in developing countries.
These interventions cost little, and the potential benefits are
large and rapid.
• Develop prospective cohort studies of dietary and lifestyle
factors in developing and transition countries to refine the
understanding of risk factors in those contexts. To date,
almost all such studies have taken place in Europe and
North America.
• Develop surveillance systems for chronic diseases and for
major risk factors, such as obesity, in developing countries.
• Develop additional multifaceted, community-based
demonstration programs in developing countries to docu-
ment the feasibility of lifestyle changes and to learn more
about effective strategies.
• Conduct detailed cost-effectiveness analyses of various pre-
vention strategies to modify dietary and lifestyle factors.
RECOMMENDED PRIORITY INTERVENTIONS 
An overall objective is to develop comprehensive national and
local plans that take advantage of every opportunity to encour-
age and promote healthy eating and active living. These plans
would involve health care providers; worksites; schools; media;
urban planners; all levels of food production, processing, and
preparation; and governments. The goal is cultural change
in the direction of healthy living. An important element in
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Table 44.4 Two-Way Sensitivity Analysis of the Costs of the
Intervention to Reduce Salt Content and Its Effectiveness,
South Asia 
(US$/DALY averted)
Blood pressure Cost per individual
reduction (millimeters
of mercury) US$1a US$3 US$6
4 9 308 608
3 49 448 847
2b 129 727 1,326
1 368 1,565 2,761
Source: Authors’ calculations.
a. Threshold analysis reveals that at a cost of US$1 per individual, a blood pressure reduction
would have to be greater than 5 millimeters of mercury for the intervention to be cost saving. At
the base-case assumption of a cost of US$6 for the intervention, there is no cost saving threshold
level of reduction.
b. Threshold analysis reveals that at a cost of less than US$0.47 per individual the intervention is
cost-saving. 
cultural change is national leadership by individuals and by
professional organizations. Specific interventions will depend
on local physical and cultural conditions and should be based
on careful analysis of existing dietary and activity patterns and
their determinants; however, the following interventions can be
considered (specific interventions for control of smoking are
discussed elsewhere):
• Physical activity:
º Develop transportation policies and a physical environ-
ment to promote walking and riding bicycles. This inter-
vention includes constructing sidewalks and protected
bicycle paths and lanes that are attractive, safe, well-
lighted, and functional with regard to destinations.
º Adopt policies that promote livable, walker-friendly
communities that include parks and are centered around
access to public transportation.
º Encourage the use of public transportation and discour-
age overdependence on private automobiles.
º Promote the use of stairs. Building codes can require the
inclusion of accessible and attractive stairways.
• Healthy diets:
º Develop comprehensive school programs that integrate
nutrition into core curricula and healthy nutrition into
school food services. Regional or national standards to
promote healthy eating should be developed for school
food services. Programs should also aim at limiting
television watching, in part by promoting attractive
alternatives.
º Work with the agriculture sector and food industries to
replace unhealthy fats with healthy fats, including ade-
quate amounts of omega-3 fatty acids. This goal can be
achieved through a combination of education, regula-
tion, and incentives. Specific actions will depend on local
sources of fat and on regional production and distribu-
tion. For example, in areas where palm oil is dominant,
research could focus on developing strains that are lower
in saturated fat and higher in unsaturated fat through
selective breeding or genetic alteration. Labeling require-
ments or regulation can be used to discourage or elimi-
nate the use of partially hydrogenated vegetable oils and
to promote the use of nonhydrogenated unsaturated oils
instead.
º Require clear labeling of energy content for all packaged
foods, including fast food.
º Use tax policies to encourage the consumption of
healthier foods. For example, high-sugar sodas could be
fully taxed and not subsidized in the same way as health-
ier foods.
º Emphasize the production and consumption of healthy
food products in agriculture support and extension
programs.
º Implement folic acid fortification if folic acid intake is
low.
º Ensure that health providers regularly weigh both chil-
dren and adult patients, track their weights over time,
and provide counseling regarding diet and activity if
they are already overweight or if unhealthy weight gain is
occurring during adulthood. Those activities should be
integrated with programs that address undernutrition.
Health care providers should be encouraged to set a
good example by not smoking, by exercising regularly,
and by eating healthy diets.
º Promote healthy foods at worksite food services.
Worksites can also promote physical activity by provid-
ing financial incentives for using public transportation
or riding bicycles (and by not subsidizing automobiles
by providing free parking). Providing areas for exercise
during work breaks and showers may be useful.
º Set standards that restrict the promotion of foods high
in sugar, refined starch, and saturated and trans fats to
children on television and elsewhere.
º Set national standards for the amount of sodium in
processed foods.
• National campaigns:
º Invest in developing locally appropriate health messages
related to diet, physical activity, and weight control. This
effort is best done in cooperation with government agen-
cies, nongovernmental organizations, and professional
organizations so that consistent messages can be used on
television and radio; at health care settings, schools, and
worksites; and elsewhere. This effort should use the best
social-marketing techniques available, with messages
continuously evaluated for effectiveness.
º Develop a sustainable surveillance system that monitors
weight and height, physical activity, and key dietary
variables.
Implementation of the recommended policies to promote
health and well-being is often not straightforward because of
opposition by powerful and well-funded political and economic
forces, such as those involved in the tobacco, automobile, food,
and oil industries (Nestle 2002). The solutions will depend on a
country’s specific political landscape. However, experiences in
many countries indicate that alliances of public interest groups,
professional organizations, and motivated individuals can over-
come such powerful interests. Strategies should start with sound
science and can use a mix of mass media, lobbying efforts, and
lawsuits. Also, the food industry is far from monolithic, and ele-
ments can often be identified whose interests coincide with
health promotion, which can create valuable partnerships.As an
example, the willingness of some margarine manufacturers to
invest in developing products free of trans fatty acids greatly
helped the effort to reduce these fats, because these producers
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then became proponents for labeling the trans fat content of
foods. Protection of children can be a powerful lever because of
almost universal concern about their welfare and the recogni-
tion that they cannot be responsible for the long-term conse-
quences of their diet and lifestyle choices.
CONCLUSIONS
Many of the ongoing diet and lifestyle interventions in low-
and middle-income countries are relatively recent, and few
have documented reductions in the rates of major chronic dis-
eases. However, the successes of Finland, Singapore, and many
other high-income countries in reducing rates of CAD, stroke,
and smoking-related cancers strongly suggest that similar ben-
efits will emerge in the developing countries.
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High blood pressure, cholesterol, and bodyweight are responsi-
ble for a large and increasing proportion of the global burden of
disease. Although historically these risks have been regarded as
“Western,” their impact is now recognized as global: they are
already leading causes of disease in middle-income countries
and of emerging importance in low-income countries
(Ezzati and others 2004; WHO 2002). This chapter presents an
evidenced-based review of the impact of high blood pressure,
cholesterol, and bodyweight; the cost-effectiveness of relevant
interventions; and the economic benefits of interventions. The
chapter focuses on personal interventions—that is, those that
are mediated largely by interpersonal actions and take place at
the individual level. As such, the chapter should be considered
as complementary to chapter 44 on lifestyles, which addresses
populationwide interventions.
Prevention strategies have been broadly classified as indi-
vidual based (also known as high risk) or population based
(Rose 1985). The former typically involve screening to detect
individuals above a certain threshold level of an individual risk
factor—for example, people with hypertension—followed by
personal interventions for those individuals. In contrast, the
population-based approach aims at lowering mean risk-factor
levels and shifting the population distribution of exposure in
a favorable direction (Rose 1985). One example would be by
reducing salt content in manufactured foods, thereby lowering
blood pressure levels on a populationwide basis. Such an
approach has the potential to produce large and lasting changes
in disease incidence but requires substantial sociopolitical
investments.Another approach is an evolution of the individual-
based strategy in which treatments are targeted to those at high
absolute risk of cardiovascular disease (CVD) rather than those
with single risk-factor levels above traditional thresholds, such
as hypertension or obesity (Jackson and others 1993). Such an
approach appears to be highly cost-effective, with the potential
to substantially reduce CVD rates when combined with popu-
lationwide interventions (Murray and others 2003).
EPIDEMIOLOGY
Elevated blood pressure, cholesterol, and bodyweight are all
established risk factors for CVD and, in the case of body-
weight, for other diseases, such as diabetes, certain cancers,
and osteoarthritis. The associations between blood pressure
(Asia Pacific Cohort Studies Collaboration 1999, 2003a;
Prospective Studies Collaboration 2002); cholesterol (Asia
Pacific Cohort Studies Collaboration 2003b; Law, Wald, and
Thompson 1994; Prospective Studies Collaboration 1995);
and body mass index (BMI) (Asia Pacific Cohort Studies
Collaboration 2004; Willett and others 1995) and CVD are
direct and continuous from relatively low levels, indicating that
optimal levels are about 115/75 millimeters of mercury
(mmHg), 3.8 millimoles per liter (mmol/l), and 21 kilograms
per square meter (kg/m2), respectively (figure 45.1).
Although some studies suggest J- or U-shaped associations
(Calle and others 1999; Cruickshank 1994; D’Agostino and
others 1991; Farnett and others 1991; Field and others 2001; Iso
and others 1989; Kannel, D’Agostino, and Silbershatz 1997;
Stewart 1979; Troiano and others 1996), low levels of these risk
factors are unlikely to cause CVD. Rather, such associations
more likely reflect incipient disease, which itself produces
both a fall in risk-factor levels and an increase in CVD risk
(Alderman 1996; Flack and others 1995; MacMahon and others
1997; Manson, Willett, and Stampfer 1995; Neaton and
Wentworth 1992; Sleight 1997a, 1997b; Stevens and others
1998). No trial evidence points to a J-curve association for
blood pressure, despite including patients with below average
blood pressure (Hansson and others 1999; McMurray and
McInnes 1992; Pfeffer 1993; Staessen and others 1997).
The continuous associations between blood pressure, cho-
lesterol, and bodyweight and CVD demonstrate the lack of a
biological justification for current threshold levels, such as
those that define hypertension. Indeed, most of the disease
burden resulting from these three risk factors occurs in the
large majority of the population with nonoptimal levels but
without hypertension, hypercholesterolemia, or obesity. Hence,
this chapter avoids those terms and instead uses high blood
pressure, high cholesterol, and high bodyweight, defined as
nonoptimal levels of these risk factors (that is, over 115/75
mmHg, 3.8 mmol/l, or 21 kg/m2, respectively).
The strength of the proportional associations of these risk
factors with CVD is similar for most population subgroups.
Although they attenuate with age, they remain strong and
positive in the oldest age groups. Overall, in middle-aged
populations, a 10 mmHg lower systolic blood pressure (SBP) is
associated with a roughly 30 to 40 percent lower stroke risk
and 20 to 25 percent lower ischemic heart disease (IHD) risk, a
1 mmol/l lower cholesterol level is associated with about a 15
to 20 percent lower stroke risk and 20 to 25 percent lower
IHD risk, and a 2 kg/m2 lower BMI is associated with an 8 to
12 percent lower stroke and IHD risk and an approximately
20 to 30 percent lower diabetes risk.
BURDEN OF THE DISEASE, CONDITION, 
OR RISK FACTOR 
Epidemiological data on blood pressure, cholesterol, and body-
weight levels are predominantly available from developed
countries; however, evidence indicates that these risk factors
are important and increasing in many other countries. Surveys
in developing countries suggest increases in these risks occur
early in the path to industrialization (Bobak and others 1997;
Evans and others 2001; Suh 2001; Wu and others 1996). Good
evidence also documents risk-factor levels rising after people
migrate to more urbanized settings (Poulter and Sever 1994) in
Africa (Poulter 1999; Poulter, Khaw, and Sever 1988), China
(He, Klag, and others 1991; He, Tell, and others 1991), and the
Pacific islands (Joseph and others 1983; Salmond and others
1985; Salmond, Prior, and Wessen 1989). The World Health
Organization’s Global Burden of Disease study demonstrated
that CVD was a leading cause of death in many regions and
that most adults in developed and developing countries have
nonoptimal blood pressure, cholesterol, and bodyweight levels
(Ezzati and others 2004; WHO 2002). Indeed, even using
traditional cutoff points, these risk factors are prevalent: of 140
subgroups defined by age, sex, and region, 45 percent had a
mean SBP equal to or greater than 140 mmHg, 25 percent
had mean cholesterol levels over 5.5mmol/l, and 45 percent had
mean BMI levels of at least 25 kg/m2.
Health Burden
The Global Burden of Disease study assessed the burden attrib-
utable to nonoptimal levels of these risks (table 45.1) (Ezzati
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Figure 45.1 Continuous Risks of Blood Pressure, Cholesterol, and Body Mass and Coronary Heart Disease Risk
and others 2004; WHO 2002). The burden for blood pressure
was related to deaths and disability-adjusted life years (DALYs)
from IHD, stroke, hypertensive disease, and other CVD; end-
points for cholesterol included IHD and stroke; and endpoints
for BMI were IHD, stroke, hypertensive disease, diabetes,
certain cancers, and osteoarthritis. Globally, 7.1 million deaths
were attributed to high blood pressure in 2000, 4.4 million to
high cholesterol, and 2.6 million to high BMI. This burden was
shared approximately equally among the sexes. A large fraction
occurred in middle age, especially in developing countries, and
this factor, together with the frequently debilitating nature of
nonfatal CVD, accounted for a large number of DALYs.
More of the DALY burden was experienced in developing
countries than in developed countries, reflecting the large pop-
ulations in developing countries and their already high risk-
factor levels. In all regions, most CVD is attributable to the
combined effects of high blood pressure, cholesterol, and body-
weight levels (figure 45.2).
Table 45.2 shows the burden resulting from the overlapping
or multicausal etiology of diseases. Analyses of the combined
impact of these and other major cardiovascular risks indicate
that the joint contribution of established risks is responsible for
83 to 89 percent of the IHD burden and 70 to 76 percent of the
stroke burden worldwide (Ezzati and others 2003; Ezzati and
others 2004).
Financial Burden
The economic impact of high blood pressure, cholesterol, and
bodyweight levels can be estimated indirectly using the forego-
ing data—namely, that more than two-thirds of the CVD
burden can be attributed to those risks. In addition, more than
three-quarters of type 2 diabetes is caused by high bodyweight
(Ezzati and others 2004; WHO 2002). Hence the economic
impact of nonoptimal levels of those risks will be at least two-
thirds that due to CVD and diabetes. A recent report high-
lighted the economic impact of CVD in developing economies,
noting that a high proportion of the CVD burden occurs
among adults of working age (Leeder and others 2004). In
Brazil, China, India, Mexico, and South Africa, conservative
The Growing Burden of Risk from High Blood Pressure, Cholesterol, and Bodyweight | 853
Table 45.1 Global Burden of Disease Attributable to Nonoptimal Blood Pressure, Cholesterol, and BMI by Region, 2000
High-mortality Low-mortality Developed
Condition developing countriesa developing countriesb countriesc World total
Attributable deaths (thousands)
Blood pressure 1,969 2,205 2,966 7,140 (12.8%)
Cholesterol 1,405 849 2,161 4,415 (7.9%)
BMI 399 775 1,417 2,591 (4.6%)
Attributable DALYs (thousands)
Blood pressure 20,630 20,277 23,363 64,270 (4.4%)
Cholesterol 15,602 8,609 16,227 40,438 (2.8%)
BMI 6,408 11,115 15,892 33,415 (2.3%)
Sources: Ezzati and others 2004; WHO 2002b.
Note: The burden of disease estimated to be attributable to nonoptimal blood pressure (mean SBP  115 mmHg), cholesterol (mean  3.8 mmol/l), and body mass index (mean  21 kg/m2) in 2000.
A, B, C and D designations in specific notes below are as follows: A  very low child mortality and very low adult mortality; B  low child mortality and low adult mortality; C  low child mortality and
high adult mortality; D  high child mortality and high adult mortality; E  high child mortality and very high adult mortality.
a. The high-mortality developing countries include those in Africa, America D, the Eastern Mediterranean D, and Southeast Asia D.
b. The low-mortality developing countries include those in America B, Eastern Mediterranean B, Southeast Asia B, and the Western Pacific B.
c. The developed countries include those in America A, Europe, and the Western Pacific A. 
Source: Ezzati and others 2004; WHO 2002.
Note: Individual and joint contributions of high blood pressure, cholesterol, and body
weight to global cardiovascular burden are shown, with the size of each circle
proportional to the size of burden (as measured in DALYs) (WHO 2002). The percentages
indicate the attributable burden for each risk factor, and the overlap shows disease
caused by joint or mediated effects.
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Figure 45.2 Global CVD Burden Caused by High Blood Pressure,
Cholesterol, and Bodyweight
estimates indicated that at least 21 million years of future pro-
ductive life are lost because of CVD each year. Although no
detailed data exist on the direct economic burden of the indi-
vidual risk factors, the costs of CVD treatment in developing
countries are significant. In South Africa, for example, 2 to
3 percent of gross domestic product was devoted to the direct
treatment of CVD, or roughly 25 percent of all health care
expenditures (Pestana and others 1996). For many middle-
income countries, high body mass is already an important
cause of health inequities (Monteiro and others 2004).
Current expenditure in developed countries provides an
indication of possible future expenditure in developing coun-
tries. For example, estimated direct and indirect costs of CVD
in the United States were US$350 billion in 2003. In 1998,
US$109 billion was spent on hypertension, or about 13 percent
of the health care budget (Hodgson and Cai 2001). Studies are
limited but suggest that obesity-related diseases are responsible
for 2 to 8 percent of all health care expenditures in developed
countries. For example, in 1991, 2.5 percent of health care costs
in New Zealand were attributable to obesity (Swinburn and
others 1997), and in 1996, US$22 billion was attributed to obe-
sity-related CVD in the United States, equivalent to 17 percent
of CVD-related health expenditures (G.Wang and others 2002).
INTERVENTIONS 
Data on the choice of interventions for blood pressure, choles-
terol, and bodyweight and their effectiveness are now presented.
Choice and Classification of Interventions 
A variety of population-based and personal interventions
could potentially be used to address the risks associated with
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Table 45.2 Individual and Joint Contributions of Seven Selected Risk Factors to the Burden of CVD by Region
Percentage of the Population attributable fractions for individual Overall population 
Disease regional disease burden risk factors (percentages) attributable fraction (percent)
High-mortality developing countries
Stroke 1.6 High blood pressure (56), high cholesterol (18), 65–71
high BMI (7), low fruit and vegetable intake (12), 
physical inactivity (6), tobacco (7), alcohol (2)
IHD 3.0 High blood pressure (44), high cholesterol (54), 80–87
high BMI (11), low fruit and vegetable intake (33), 
physical inactivity (21), tobacco (8), alcohol (4)
Low-mortality developing countries
Stroke 4.7 High blood pressure (58), high cholesterol (13), 67–74
high BMI (11), low fruit and vegetable intake (10), 
physical inactivity (5), tobacco (8), alcohol (7)
IHD 3.2 High blood pressure (45), high cholesterol (48), 79–87
high BMI (22), low fruit and vegetable intake (31), 
physical inactivity (22), tobacco (8), alcohol (3)
Developed countries
Stroke 6.0 High blood pressure (72), high cholesterol (27), 81–86
high BMI (23), low fruit and vegetable intake (12), 
physical inactivity (9), tobacco (22), alcohol (0)
IHD 9.4 High blood pressure (58), high cholesterol (63), 89–93
high BMI (33), low fruit and vegetable intake (28), 
physical inactivity (22), tobacco (22), alcohol (0.2)
World
Stroke 3.1 High blood pressure (62), high cholesterol (18), 70–76
high BMI (13), low fruit and vegetable intake (11), 
physical inactivity (7), tobacco (12), alcohol (4)
IHD 4.0 High blood pressure (49), high cholesterol (56), 83–89
high BMI (21), low fruit and vegetable intake (31), 
physical inactivity (22), tobacco (12), alcohol (2)
Source: Ezzati and others 2003.
Note: See notes to table 45.1 for a breakdown of the regional groupings.
high blood pressure, cholesterol, and bodyweight. Of the per-
sonal interventions discussed in this section—lifestyle and
dietary, pharmacological, and surgical interventions—two
main strategies exist for choosing whom to treat: those above
certain threshold values of single risk-factor levels and those
above certain values of absolute cardiovascular (or global) risk,
which is determined by the levels of multiple factors.
Targeting treatments by levels of a single risk factor (such as
hypertension) does not effectively focus on overall risk of
developing CVD, which is mainly determined by the net effects
of other risk factors. For example, the predicted 10-year CVD
risk for someone with an SBP of 140/90 mmHg can vary from
5 to 50 percent depending on the number of concomitant risk
factors. The number of people who would need to be treated to
prevent an event can therefore vary by an order of magnitude,
even if they have the same blood pressure levels. Thus, a treat-
ment strategy based only on individual risk-factor levels is
likely to result in high-risk patients being undertreated and
many patients at relatively low risk being treated with little
absolute benefit, which is unlikely to be the best allocation of
scarce health care resources.
The absolute-risk strategy was developed in New Zealand
(Jackson and others 1993) and has been adopted extensively
elsewhere, for example, by the British Hypertension Society
(Ramsay and others 1999) and the Joint Task Force of European
and other Societies on Coronary Prevention (Wood and others
1998). The absolute CVD risk is estimated using risk assess-
ments such as the Framingham risk function (Anderson and
others 1991) or the Prospective Cardiovascular Munster Study
score (Assmann, Cullen, and Schulte 2002) on the basis of the
number and severity of CVD risk factors. Targeting treatments
at those at high absolute risk rather than those above arbitrary
thresholds ensures a favorable ratio of benefits to risks. It can be
expected to reduce events in the large proportion of people who
are, for example, nonhypertensive but who still have nonopti-
mal blood pressure (Rose 1981). Combinations of personal
interventions targeted at those at high absolute risk also have
the potential of being highly cost-effective.
The simplest indicator of high absolute risk is established
CVD, principally myocardial infarction, angina, stroke, or tran-
sient ischemic attack. For example, without preventive treat-
ment, people who have had a myocardial infarction face an
annual risk of death from coronary heart disease of about
5 percent (Law, Watt, and Wald 2002). That risk persists
indefinitely—probably for the rest of a person’s life—and
varies little with age or sex.
However, many individuals with no history of CVD are at
similar elevated risk for future CVD as a result of constellations
of elevated risks. Thus, the distinction between primary
and secondary prevention is somewhat artificial and could
lead to undertreatment of many high-risk individuals. While
recognizing that the distinction is somewhat arbitrary, this
chapter discusses the cost-effectiveness of efforts to manage
those without previous CVD, and chapter 33 reviews the man-
agement of those with known vascular disease. A unifying sys-
tem targeting treatments at those at highest risk, either with
CVD or multiple risk factors, is likely to be highly cost-effective
because more than 75 percent of events occur in the 5 to 10
percent of people with CVD or specific clusters of risk factors
(Haq and others 1999; Tosteson and others 1997).
The limitations of the individual-risk-factor approach,
together with increasing evidence that the thresholds do not
have any biological justification, have motivated the adoption
of strategies that take other risk factors into account. Although
the most complete way of doing so is using the absolute-risk
strategy outlined earlier, one intermediate strategy involves
lowering the thresholds of blood pressure or lipid levels at
which treatment is initiated if one or more additional CVD
risk factors, such as diabetes, are present (Chobanian and
others 2003).
Intervention Effectiveness
This section summarizes data on the effectiveness of popula-
tion-based interventions and personal interventions (lifestyle
and dietary interventions and pharmacological and surgical
interventions). The studies concerned have mainly been con-
ducted in developed countries.
Population-Based Interventions. Investigators have under-
taken a variety of population-based community intervention
studies, mostly in developed countries in the 1970s and 1980s
(for further details see chapter 44). These studies have tended
to be multifactorial projects testing whether comprehensive
community programs could produce favorable changes in such
risk factors as bodyweight, cholesterol, and blood pressure and
in CVD morbidity and mortality (Schooler and others 1997).
In general, they included a combination of populationwide
and individual interventions, including messages disseminated
through local associations, sports clubs, the media, and food
associations; healthy food options at restaurants and worksite
cafeterias; food labeling at supermarkets; face-to-face commu-
nication at meetings and distribution of educational materials;
smoking restrictions; and competitions to develop healthy
food. Except in Finland, the projects had mixed results,
although many demonstrated significant effects with respect to
individual components of the interventions. The limitations of
many of the projects include inability to detect small but
potentially important changes in risk factors, short duration of
intervention and follow-up, and issues with outcome measures.
Some have also suggested that those trials with less favorable
results may have lacked adequate community support and
public policy initiatives (Feinleib 1996; Mittelmark and others
1993; Schooler and others 1997; Susser 1995).
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A number of population-based interventions have also
taken place in developing countries, including the following:
• In China, the Tianjin Project showed a significant reduction
in sodium intake in men after three years of intervention,
and after five years, the prevalence rates of both hyperten-
sion and obesity decreased among 45- to 65-year-olds
(Schooler and others 1997).
• In Chile, the Mirame Project was a three-year intervention
program designed to provide and evaluate strategies to pro-
mote healthy lifestyles among schoolchildren and their fam-
ilies. Nissinen, Berrios, and Puska (2001) report a significant
positive effect on some risk factors for the intervention
schools.
• In Mauritius, government-led initiatives resulted in a
change in the composition of cooking oil from mostly palm
oil, which is high in saturated fatty acids, to wholly soybean
oil, which is high in unsaturated fatty acids. From 1987 to
1992, total cholesterol concentrations fell significantly, and
the estimated intake of saturated fatty acids decreased, with
much of this finding reportedly resulting from the change in
cooking oil (Uusitalo and others 1996).
An effective populationwide intervention draws together
different kinds of feasible activities that combined produce a
synergistic effect (Nissinen, Berrios, and Puska 2001; Puska
1999). Even though the projects and trials were undertaken in a
range of different communities and used a variety of methods
and interventions, several common themes emerge. Some of
the important elements of a successful program that enables
individuals to adopt healthier lifestyles include the following:
• clear responsibility for coordinating prevention efforts, with
credible agencies with good communication methods carry-
ing out long-term education programs
• intersectoral collaboration, with multiple messages sourced
from different organizations, including health sector enti-
ties, nonhealth government agencies, schools, workplaces,
religious organizations, and voluntary agencies
• collaboration with the food industry to ensure the availabil-
ity of reasonably priced healthier food options, with food
labeling that presents relevant information in a clear, reli-
able, and standardized format 
• realistic multiyear time frames.
Lifestyle and Dietary Personal Interventions. Many guide-
lines have concluded that lifestyle modifications, such as weight
loss, healthy diet (such as one rich in potassium and low in
sodium), physical activity, and moderate alcohol consumption
are effective in reducing blood pressure (see, for example,
Chobanian and others 2003). Trials indicate that a reduction of
salt intake lowers blood pressure, with larger blood pressure
reductions in the elderly and in those with higher initial blood
pressure levels (Law, Frost, and Wald 1991; Whelton and others
1998). An increase in daily fruit and vegetable intake may also
lower blood pressure, and when combined with an increase in
low-fat dairy products and a reduction in saturated and total
fat, may lower blood pressure even more (Appel and others
1997). Weight reduction lowers blood pressure in proportion
to the amount of weight lost (Whelton and others 1998), and
physical activity appears to lower blood pressure in a way that
may be independent of weight loss. High levels of alcohol
intake are associated with blood pressure elevation, which is
reversible by reducing intake (Kaplan 1995).
Dietary approaches to lowering total cholesterol and low-
density lipoprotein (LDL) cholesterol typically involve reduced
intake of dietary fats, particularly saturated fats. Evidence sug-
gests a dose-response relationship between saturated fatty acid
intake and LDL cholesterol levels (NCEP Expert Panel 2002).
Plant sterols and stanols have recently been incorporated into
foods such as margarine and can reduce LDL cholesterol
by about 10 percent; however, this approach is currently rela-
tively expensive (Law 2000). Dietary advice may also suggest
increasing the intake of viscous fiber—for instance, in the
form of cereal grains, fruits, and vegetables—because these
dietary sources may enhance the lowering of LDL cholesterol.
Maintaining bodyweight in the desirable range and engaging in
moderate physical activity complement these dietary strategies
(NCEP Expert Panel 2002).
Increases in obesity have been related to declines in energy
expenditure (for example, reductions in physical activity and
adoption of a more sedentary lifestyle) and a higher intake of
energy-dense but micronutrient-poor foods, such as most
processed foods (WHO 2003b).A variety of trials have recorded
beneficial health effects, with weight reduction achieved by a
combination of interventions (NHLBI Obesity Education
Initiative Expert Panel 1998). These interventions include
dietary counseling and therapy that involves a decrease in daily
caloric intake and a reduction in saturated fats and total fats.
An increase in physical activity is an important component of
weight-loss therapy. Behavioral strategies revolving around
self-monitoring of eating habits, stress management, problem
solving, and social support may also complement these
approaches. Overall, however, the effects of lifestyle modifica-
tions to reduce weight and maintain the weight loss are rela-
tively poor, with many reports finding that weight returns to
baseline levels after several years.
Pharmacological and Surgical Personal Interventions.
Randomized trials have shown that medications to lower blood
pressure effectively reduce the risk of stroke, IHD, and heart fail-
ure. Results from meta-analyses of more than 40 different trials
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published in 2003 included about 210,000 participants and
more than 8,000 stroke and 11,000 IHD events (Blood Pressure
Lowering Treatment Trialists’ Collaboration 2003; Fox and
EUROPA Investigators 2003; Law, Wald, and Rudnicka 2003;
Lawes and others 2004; Pepine and others 2003). The trials may
be broadly classified into three groups: (a) drug versus placebo
trials, (b) more intensive regimens to lower blood pressure ver-
sus less intensive regimens, and (c) drug versus drug trials.
The drug versus placebo trials achieved the greatest reduc-
tions in blood pressure, and a dose-response relationship was
apparent between blood pressure reduction and reduced risk of
stroke. Overall, the trials indicated that a 10 mmHg reduction
in SBP would result in a 32 percent reduction in stroke risk and
a 14 percent relative reduction in IHD risk. This finding is con-
sistent with the size of associations observed in cohort studies.
Clear evidence indicates that all the major drug classes have
similar effects on the risk of stroke and coronary heart disease
per mmHg reduction in blood pressure (Blood Pressure
Lowering Treatment Trialists’ Collaboration 2003; Lawes and
others 2004). The only clear evidence of clinically important,
class-specific effects are with agents that block the renin-
angiotensin system, which reduce diabetes incidence by about
one-quarter, and with calcium channel blockers, which reduce
heart failure less than other agents (although this result may be
partly caused by misclassification, because a known side effect
of calcium channel blockers is ankle edema, which is a diag-
nostic component of heart failure). Because all agents lower
blood pressure by about the same modest amount and because
their effects on blood pressure are additive (Law and others
2003), the key issue seems to be which combinations of two or
more drugs should be provided and how long-term adherence
can be maximized.
Over the past three decades, numerous trials have assessed
the effect of different cholesterol-lowering interventions (Law,
Wald, and Rudnicka 2003; Law, Wald, and Thompson 1994).
The placebo-controlled trials can be broadly classified into
those testing fibrates, statins, and other interventions (mostly
dietary interventions, but also some other interventions such as
resins and niacin). The statins are the most effective in lower-
ing total and LDL cholesterol, with reductions of more than
1 mmol/l in most trials. A good correlation has been found
between reduction in total cholesterol and relative risk reduc-
tion. This finding suggests, as for trials investigating blood
pressure lowering, that even though some drugs are more
effective in achieving greater reductions in risk factors, their
effect on disease outcomes is similar per unit reduction of
cholesterol. Overall, a 1 mmol/l reduction in total cholesterol is
associated with a 21 percent relative risk reduction in IHD and
a 17 percent reduction in risk of stroke. Again, this finding is
consistent with the epidemiology, with the proviso that the vast
majority of strokes in clinical trials were ischemic.
In clinical trials of statins, the relative risk reduction in car-
diovascular events is similar at all levels of baseline cholesterol,
extending to levels below 5 mmol/l total cholesterol, and is also
consistent among patients who are and are not taking concur-
rent blood pressure lowering and other medications (Heart
Protection Study Collaborative Group 2002). Similar findings
are observed with treatments to lower blood pressure (Progress
Collaborative Group 2001), indicating that these treatment
effects are independent. This finding is plausible, because they
act through different mechanisms and because observational
studies do not suggest a large interaction (Neaton and
Wentworth 1992).
The benefits of lowering blood pressure and cholesterol are
achieved surprisingly rapidly: for most outcomes,risk appears to
be fully reversed within 6 to 18 months of beginning treatment.
For example, individuals with cholesterol lowered in the past two
or more years are at approximately the same coronary heart dis-
ease risk as otherwise identical individuals whose cholesterol has
been at that level for decades (Law, Wald, and Thompson 1994).
Pharmacological agents for weight loss that have been sub-
ject to randomized controlled trials include dexfenfluramine,
sibutramine, orlistat, and phentermine/fenfluramine (although
the last has been withdrawn because of a reported association
between the drugs and valvular heart disease). Overall, trials
suggest only modest weight-loss effects, with an average net
weight loss of 1.5 kg after eight weeks and 2 to 3 kg after one
year (NHLBI Obesity Education Initiative Expert Panel 1998).
A systematic review of orlistat trials indicated a pooled net
weight loss of 1.2 kg at 12 weeks, 2.9 to 3.4 kg at one year, and
2.5 to 2.4 kg at two years (O’Meara and others 2001). Results of
a systematic review of trials assessing sibutramine were similar
(O’Meara and others 2002), with fewer data available on long-
term sustained weight loss.
Investigators have also undertaken several randomized con-
trolled trials to assess the effects of different surgical interven-
tions, generally in individuals with a BMI equal to or greater
than 35 or 40 kg/m2. Weight loss resulting from gastric bypass
varied from 50 to 100 kg six months to a year following surgery
(NHLBI Obesity Education Initiative Expert Panel 1998).
Overall, several trials suggest that surgery resulted in about
23 to 37 kg more weight loss than conventional treatment and
that this loss was maintained for eight years (Clegg and others
2002). Furthermore, gastric bypass surgery appears to be more
beneficial than gastroplasty or jejunoileal bypass.
In relation to compliance and adherence with pharmacolog-
ical therapy, population surveys have demonstrated that, even
in industrial countries, high blood pressure is either untreated
or inadequately controlled in about 70 to 75 percent of patients
and that adherence to medications among patients suffering
from chronic disease is only about 50 percent (WHO 2003a).
The extent of poor adherence is likely to be even greater in
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developing countries given the relative lack of health services
and inequities in access. Pharmacotherapy faces a variety of
potential barriers, including the symptomless nature of the
conditions, a lack of knowledge or denial of risk, the compli-
cated nature of drug regimens, the risk of side effects (real and
perceived), and the costs of treatment.
Health providers may use multiple strategies to increase
compliance and adherence. Patient-centered interventions
include involving individuals in the decision-making process;
providing individualized patient education and disease coun-
seling and adapting treatment to patients’ lifestyles; simplifying
dosing schedules; providing drug information leaflets, medica-
tion charts, and special reminder packaging for medications;
holding group sessions for education and family-oriented dis-
ease management therapies; and implementing automated
telephone assessment and self-care education calls with nurse
follow-up (Haynes and others 2003).
Strategies may also aim to increase physician adherence, and
interventions may include the use of guidelines, peer review
and audit, and prompts to remind physicians to review risks
and medications (Ebrahim 1998; NCEP Expert Panel 2002).
These strategies obviously do not address issues pertaining to
resources and access in poor countries.
Several trials and overviews have attempted to assess the
value of different interventions to improve compliance and
adherence; however, issues have arisen in connection with the
generalizability of the interventions, the low statistical power
in many trials, the lack of description of all parts of interven-
tions, and the assessment of complex interventions without
assessment of the separate effects of the intervention compo-
nents. Haynes and others’ (2003) systematic review concludes
that, overall, no single approach to improving adherence can be
recommended. Simpler treatment regimens can sometimes
improve adherence and treatment outcomes for both short-
and long-term treatments. Several complex strategies,
including combinations of more thorough patient instructions
and counseling, easier access to care, reminders, close follow-
up, supervised self-monitoring, family therapy, and rewards for
success can improve adherence and treatment outcomes in
some patients. However, even the most effective interventions
did not lead to large improvements in adherence or treatment
outcomes and were relatively resource intensive. By contrast,
Connor, Rafter, and Rodgers’s (2004) systematic review indi-
cates improved adherence and clinical outcomes with fixed-
dose combination treatment or unit-of-use packaging.
Few good, evidence-based strategies to improve obesity
management are currently available, although reminder
systems, brief training interventions, shared care, inpatient
care, and dietitian-led treatments may all be worth further
investigation (Harvey and others 2003). Thus, a clear need for
innovations still exists to help people follow medication
prescriptions as well as dietary and lifestyle advice.
COST-EFFECTIVENESS OF INTERVENTIONS
Costs include expenditures required to identify and treat risk
factors as well as expenditures for treating CVD when it is not
prevented. Where possible, this chapter deals with the separate
sources of costs for several reasons. First, the costs for identify-
ing those requiring treatment vary significantly by level of eco-
nomic development and by urban versus rural location. In
many situations in developing countries, such costs will make
most or all forms of screening beyond a determination of CVD
history unaffordable. Second, in some countries, such as India,
that are large producers of generic drugs, prices are reported to
be lower than in most other drug-producing or -importing
countries. Third, this approach allows researchers and policy
makers to understand the constituent costs so that they can
examine where cost reductions may be most beneficial. Fourth,
it clarifies what expenditures may be required as a result of
changes in decisions about the treatment of risk factors. Finally,
many people in developing countries do not have access to
hospitals for acute management of CVD events. Nonetheless,
increased expenditure on treating risk factors may lead to
significant reductions in the costs of treating subsequent CVD
events for many countries. Ultimately, the net effect is reflected
in cost-effectiveness analyses. Unless otherwise stated, costs are
in 2001 U.S. dollars.
The costs of personal interventions include the costs of
patient screening (identifying high-risk patients), drugs and
their acquisition, clinic visits, health care workers’ time, labora-
tory tests, and travel. Annual drug costs for medications to
lower blood pressure and cholesterol vary widely by country
and depend on whether generics are available and used. For
example, according to the International Drug Price Indicator
Guide (Management Sciences for Health 2004), annual costs in
2002 of generic 40 mg lovastatin ranged from US$14 in
Barbados to US$217 in Costa Rica, and on-patent statins can
cost almost a US$1,000 a year in the United States. Because
drug costs vary by up to two orders of magnitude across coun-
tries, results of cost-effectiveness analyses are particularly
sensitive to their input prices. Table 45.3 presents some 
sample prices. The costs of these medications have dropped
considerably in recent years, and now the annual costs for
hydrochlorothiazide (25 mg), atenolol (50 mg), and captopril
(50 mg), are US$2, US$4, and US$9, respectively (Management
Sciences for Health 2004). Statins will become increasingly
affordable as simvastatin joins lovastatin in coming off patent
(2006 in the United States and already off patent in Germany
and the United Kingdom).
The estimated number of visits to manage high blood pres-
sure and cholesterol, under traditional paradigms, ranges from
two to six per year at costs ranging from US$3 to US$20 per
visit across the six regions assessed, but note that generally
many fewer tests and less follow-up is required with a strategy
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based on absolute risk. Diagnostic testing for cholesterol in the
United States using a general laboratory is reimbursed at US$6
for total cholesterol, US$16 for a complete lipoprotein choles-
terol fractionation analysis, and US$6 for triglycerides (Xact
Medicare Services 2003). Point-of-care one-step enzymatic
strips that require only a few drops of blood from a finger
stick and that can process total cholesterol in minutes cost less
than US$3 per test (Greenland and others 1987). A basic
metabolic panel for those on diuretics or for measuring renal
function is US$12. The costs attributed to patient time and
travel for visits have not been estimated for many countries,
but they were recently estimated at US$12 to US$26 per visit
in the United States, depending on age and sex (Prosser and
others 2000).
A review of studies to date highlights several issues regard-
ing cost-effectiveness analyses, including the significant varia-
tions in terms of calculations of cost per life year saved. The two
most important aspects of the cost-effectiveness of any primary
intervention are the future risk for CVD of the population
treated and the costs of the medications.
Population-Based Interventions
Given the strong association between CVD and high blood
pressure, cholesterol, and body mass, most guidelines for those
risk factors begin by recommending lifestyle modifications.
Although these benefits can lead to changes in risk factors, their
effect on CVD events is not well documented. However, on the
basis of assumptions about cholesterol and blood pressure
reduction from population-based lifestyle education programs
and given the relatively low cost of the interventions—US$5 to
US$17 per person per year (Tosteson and others 1997)—the
cost-effectiveness of such programs may be reasonable.
However, the cost-effectiveness ratios of these interventions
were sensitive to the cost of the intervention as well as to the
expected reduction in the risk factor. For example, a commu-
nity intervention that expects a 4 percent reduction in total
serum cholesterol and costs US$5 per person annually targeted
would save more than US$2 billion over 25 years of the pro-
gram. When the North Karelia (Puska 1999) estimates were
used in a cost-effectiveness analysis in the United States
(Tosteson and others 1997), the cost-effectiveness ratios ranged
from being cost saving to US$88,000 (in 1985 U.S. dollars) per
life year saved, depending on the percentage reduction in cho-
lesterol (1 to 4 percent).
Personal Interventions to Lower Blood Pressure or
Cholesterol in Developed Countries
A common finding of cost-effectiveness analyses of primary
prevention of CVD by means of lowering blood pressure and
cholesterol is the wide variability in cost-effectiveness
ratios, depending on underlying risk, age, and costs of medica-
tions. For personal interventions using drug treatment for
lowering blood pressure and cholesterol levels, no single cost-
effectiveness analysis adequately summarizes experience in the
developed countries. Collectively, the studies evaluating
hypertension treatment in Australia, New Zealand, the United
States, and the Scandinavian countries suggest a range of cost-
effectiveness ratios from US$4,600 to more than US$100,000
per life year gained when applied to the entire adult population
without further risk stratification (Kupersmith and others
1995). Compared with the entire population, for those at high
risk with diastolic blood pressures over 105 mmHg and older
than 45, hypertension treatment can cost as little as a few hun-
dred dollars per life year gained or can even be cost saving
(Johannesson and others 1991).
Investigators have reported that primary prevention with
cholesterol-reducing medications is less attractive overall than
other interventions, such as hypertension treatment, from a
cost-effectiveness perspective, although once again this finding
is likely to differ considerably now that statins are off patent.
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Table 45.3 Annual Costs of Selected Cardiovascular Medications 
Medication United States (2002 US$)a Average international price (2002 US$) Projected polypillb
Beta-blocker 32–365 3–15 n.a.
Diuretic 6–37 1–3 n.a.
Statin 180–864 11–147 n.a.
Aspirin 2 1–6 n.a.
Angiotensin-converting 65–365 1–19 n.a.
enzyme inhibitor
Total 285–1,633 17–190 20–40
Sources: U.S. prices: Murray 2004; international prices: Management Sciences for Health 2004.
n.a.  not applicable. 
a. Based on average wholesale prices.
b. Based on a moderate increase from the sum of the lowest-cost generic components.
Reported cost-effectiveness ratios have ranged from US$10,000
to US$2 million per life year gained (Hay, Yu, and Ashraf 1999),
whereas dietary interventions for cholesterol reduction are more
favorable, with ratios of around US$2, 000 per quality-adjusted
life year (QALY) (Prosser and others 2000).For cholesterol treat-
ment, Prosser and others (2000) find cost-effectiveness ratios of
US$50,000 per QALY for on-patent statins among those at high-
est risk (high cholesterol levels and multiple risk factors) and up
to US$1.4 million per QALY among low-risk females when com-
pared with dietary strategy alone. The cost per life year gained in
the primary prevention trial of the West of Scotland Coronary
Prevention Study among high-risk individuals treated with
pravastatin was about US$30,000 (Caro and others 1997). Using
the same criteria, Downs and others (1998) find that the cost per
life year saved in the Air Force/Texas Coronary Atherosclerosis
Prevention Study cohort with average cholesterol levels was
more than US$100,000.In general,younger and older age groups
tend to have the least favorable cost-effectiveness ratios. For
younger groups, this finding probably reflects their overall lower
risk and the many years of treatment required before realizing a
benefit. For the elderly, high cost-effectiveness ratios may reflect
other competing causes of death and the delay of up two
years between treatment and benefit seen in most primary pre-
vention trials.
Personal Interventions to Lower Blood Pressure or
Cholesterol in Developing Countries
No trials of blood pressure, cholesterol, or body mass lowering
have been conducted solely in developing countries. As a result,
we have derived assessments of cost-effectiveness by extrapo-
lating from results in developed countries presented earlier.
Goldman and others (1991) report that a decline in the cost of
lovastatin by 40 percent, once generic, would result in a roughly
30 percent reduction in the cost-effectiveness ratio. However,
this finding does not take into account that both the underly-
ing epidemiology and the costs can be quite different across
and within countries and regions.
Murray and others (2003) compare 17 nonpersonal and per-
sonal health service interventions or combinations of interven-
tions in the 14 epidemiological subregions defined by the
World Health Organization (WHO) as part of its Choosing
Interventions That Are Cost-Effective (WHO-CHOICE) initia-
tive. The nonpersonal interventions included health education
through the mass media and legislative efforts to reduce salt
intake, improve blood pressure generally, and reduce cholesterol
and obesity levels. The personal interventions included treat-
ment with statins of those above two different cholesterol-level
thresholds (greater than 6.2 mmol/l or greater than 5.7 mmol/l),
treatment with beta-blockers and diuretics of those above two
different hypertension thresholds (greater than 160 mmHg or
greater than 140 mmHg), and treatment of individuals with
both hypertension and increased cholesterol with all three med-
ications. Finally, the effects of combination treatment with a
beta-blocker, diuretic, statin, and aspirin were modeled for four
groups defined on the basis of absolute risk (10-year probability
of a cardiovascular event of 5, 15, 25, or 35 percent).
Intervention effects were based on systematic reviews of
randomized trials or meta-analyses. Population health effects
caused by the interventions were based on stochastically simu-
lating populations on the basis of age, sex, and risk factor dis-
tribution of smoking, hypertension, cholesterol, BMI, and
smoking in the 14 subregions, both with and without the vari-
ous treatments to determine the effect. The effects of the inter-
vention were then translated into DALYs using a standard mul-
tistate modeling tool. Costs include both program-level costs
(media, training, and administration) and patient-level costs
(medicines, health care visits, diagnostic tests). All costs were
based on a standard ingredients approach and on regional esti-
mations. The costs of CVD events were not included.
The results are summarized in table 45.4. The incremental
cost-effectiveness ratios for the strategy assessing absolute risk
and using the triple combination of beta-blocker, statin, and
aspirin with or without the addition of health education and salt
legislation ranged from US$138 per DALY saved (absolute risk
greater than 35 percent) in the Africa E region to US$4,319 per
DALY saved (absolute risk greater than 5 percent) in the Latin
America and the Caribbean B region. These estimates are in
international or purchasing-power parity dollars (see chapter 15
for an explanation). Table 45.4 also shows the approximate
equivalent costs in U.S. dollars and explains the conversion
from the WHO-CHOICE estimates. The nonpersonal interven-
tions, including efforts to reduce salt intake in processed foods,
were less costly than the personal interventions. Personal
interventions based on treatment guidelines were cost-
effective; however, when the strategies for treating high choles-
terol or hypertension were compared with the absolute-risk
approach, they were not favorable and were dominated by the
latter, meaning that the absolute-risk approach of treating those
with a greater than 35 percent risk averted more DALYs and cost
less than either the blood pressure or cholesterol strategies. For
an example of a country-specific analysis, see box 45.1.
Several recent publications have suggested that combination
treatments of medications to lower blood pressure, statin,
aspirin, and perhaps other agents such as folate could more
than halve cardiovascular risk (Wald and Law 2003; WHO
2002; Yusuf 2002). This suggestion is especially relevant for
developing countries, given that suitable components are all
now off patent. Good evidence indicates that single-pill combi-
nations increase adherence to drug regimens (Connor, Rafter,
and Rodgers 2004) and reduce supply and transport costs. We
used a Markov model to evaluate the cost-effectiveness of such
a hypothetical pill or combination packaging of the individual
medications. We modeled the effect of a pill that included half
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of the standard doses of hydrochlorothiazide, atenolol, lisino-
pril, lovastatin, and aspirin on overall morbidity and mortality
in treating those without prior CVD. We did not include folate
because no randomized trials had shown that it reduced CVD
events at the time of the analysis. The assumptions of the rela-
tive risk reductions were based on those of Wald and Law
(2003). The strategies compared were for treating various high-
risk populations (absolute risk for CVD greater than 15, 25, and
35 percent over 10 years. We applied the model to a population
of 1 million adults over the age of 35, with the costs and bene-
fits seen from a societal perspective and with the intervention
run for 10 years. We calculated estimates for one representative
country from each region where demographic and risk factor
data existed. Unlike the WHO-CHOICE analysis, this analysis
separated use of the intervention according to those with and
without established CVD. Table 45.5 presents the results.
Table 45.6 shows the breakdown of events averted and costs
for India. Even though the absolute numbers differ for other
countries, the relative differences between the different groups
receiving the “polypill” compared with the groups not receiving
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Table 45.4 Comparison of the Cost-Effectiveness of Absolute Risk with Treatment According to Either Blood Pressure or Lipid
Targets Alone in Addition to Population-Based Strategies, Selected WHO Regions
Incremental cost-effectiveness 
ratio (cost/DALY saved)a
Region Strategy Risk (percent) International $ US$
Africa E Prevention (SL and/or HE) Dominatedb
Targeted risk factorsc Dominatedb
Absolute riskc (TRI) 35 138 42
25 778 295
15 1,445 639
Latin America and the Prevention (SL) 127 65
Caribbean B  Prevention (SL  HE) 145 74
Targeted risk factorsc Dominatedb
Absolute riskd (TRI  SL  HE) 35 286 178
25 1,598 1,058
15 2,391 1,664
5 4,319 3,075
Southeast Asia B  Prevention (SL) 70 18
Prevention (SL  HE) 127 32
Targeted risk factorsc Dominatedb
Absolute riskd (TRI  SL  HE) 35 301 133
25 1,197 578
15 2,094 1,120
5 3,952 2,233
Western Pacific B Prevention (SL) 97 18
Targeted risk factorsc Dominatedb
Absolute riskd (TRI  SL  HE) 35 1,124 423
25 1,278 564
15 2,092 1,042
5 4,028 2,135
Source: Murray and others 2003.
B  low child mortality and low adult mortality; E  high child mortality and very high adult mortality; HE  health education through the mass media to reduce cholesterol; SL  legislation to
decrease the salt content of processed foods, including appropriate labeling and enforcement; TRI  treatment with aspirin, beta-blockers, and a statin. 
a. Costs of prevention and nondrug costs for treatment according to absolute risk are converted at an estimated regional average ratio of exchange rate to purchasing-power parity rate; drug costs are
not converted, assuming drugs to be imported at world prices. The share of drug costs in total treatment cost, as a function of risk, is taken from the estimates for India in table 45.6 and assumed to be
the same for all regions. 
b. Dominated strategies were both less effective and more costly than comparator strategies. 
c. Treating SBP greater than 140 mmHg or 160 mmHg or total cholesterol greater than 5.7 mmol/l or 6.2 mmol/l (220 or 240 mg/dlL).
d. Risk refers to 10-year risk of CVD greater than or equal to the number listed.
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Example of Country-Specific Analysis: South Africa
Box 45.1
In another analysis, researchers (Gaziano 2001) compared
the approach based on absolute risk with blood pressure
guidelines in South Africa. The analysis used country-
specific epidemiology and, where available, applied local
cost data. The study compared six strategies for initiating
drug treatment—two different blood pressure levels
(160/95 mmHg and 140/90 mmHg) and four different
levels of absolute CVD risk over 10 years (40, 30, 20, and
15 percent)—to a strategy of no treatment. The method-
ology differed from the WHO-CHOICE study because of
the availability of local data. Data on diabetes prevalence
were included to further refine risk estimates. Also the
actual mix of medications was used to assess costs with
actual current drug-use patterns, which included the use
of some nongeneric medications.
The table displays the results. The four absolute-risk
strategies had the four lowest incremental cost-effectiveness
ratios.The strategy of initiating antihypertensive therapy for
those individuals with a predicted 10-year CVD risk greater
than 40 percent had an incremental cost-effectiveness ratio
of US$700 per QALY gained compared with no treatment.
The absolute risk of CVD greater than 30, 20, and 15 per-
cent had larger and increasing cost-effectiveness ratios.
Treatments based on the 1995 South African guidelines and
the Joint National Commission VI guidelines were both
more costly and resulted in fewer QALY gains than the 15
percent absolute-risk strategy and were therefore domi-
nated by the less costly absolute-risk treatment strategies.
Furthermore, the results showed that the cost-
effectiveness ratios were quite sensitive to the costs of
treatment for hypertension, especially medication costs.
Further analysis revealed a threshold point for an annual
treatment cost of US$53. Below this threshold, the 40 per-
cent absolute-risk strategy cost less and increased the
number of life years gained compared with the no pri-
mary prevention strategy and is therefore cost saving. In
South Africa, annual treatment with diuretics and beta-
blockers could be provided for less than US$40.
Table 45.5 Incremental Cost-Effectiveness Ratios of a Multidrug Regimen by World Bank Region Compared with a Baseline of
No Drug Treatment (2001 US$/DALY) 
Region 35 percent risk 25 percent risk 15 percent risk 5 percent risk
East Asia and the Pacific 830 1,440 2,320 3,820
Europe and Central Asia 940 1,450 1,960 3,620
Latin America and the Caribbean 920 1,470 2,420 3,740
Middle East and North Africa 720 1,290 2,190 4,030
South Asia 670 1,250 1,932 3,020
Sub-Saharan Africa 610 1,170 1,920 2,960
Source: Authors’ calculations.
Note: The regimen includes aspirin, a beta-blocker, a thiazide diuretic, an angiotensin-converting enzyme inhibitor, and a statin. The risk refers to a 10-year risk of CVD.
Incremental Cost-Effectiveness Ratios for Selected Hypertension Management Strategies over 10 Years, South Africa
Incremental cost-effectiveness ratioa
Treatment US$/QALY US$/life year savedb
No treatment n.a. n.a.
Absolute risk of CVD  40 percent 700 900
Absolute risk of CVD  30 percent 1,600 2,100
Absolute risk of CVD  20 percent 4,900 6,700
Absolute risk of CVD  15 percent 11,000 18,000
Target level 160/95 mmHg (1995 South African guidelines)c Dominatedd Dominatedd
Target level 140/90 mmHg (Joint National Commission VI guidelines) Dominatedd Dominatedd
Source: Gaziano and others 2005.
n.a.  not applicable.
a. Each strategy’s costs and effects are compared with those of the preceding less costly strategy. 
b. Total and incremental life years not shown. 
c. Compared with an absolute risk of CVD greater than 15 percent because the 1995 South African guidelines are dominated by the former.
d. A dominated strategy is one that is both more expensive and less effective than the preceding strategy to which it is compared.
it are similar for all countries. Although the total costs for treat-
ing lower-risk patients increase, so do the benefits, and the
overall incremental cost-effectiveness ratio remains relatively
favorable. The proportion of costs shifts away from those
attributable to hospital care when no primary prevention is ini-
tiated to costs attributable to ambulatory care and pharmaceu-
ticals when more lower-risk patients are treated.
Interventions to Reduce Bodyweight
No large-scale randomized trials of weight reduction as an iso-
lated intervention are available on which to base estimates of
the benefits of weight loss in lowering the risk of coronary
heart disease. Thus, costs per life year saved would have to be
modeled to project benefits. In one such analysis, a school-
based educational program to reduce obesity among middle
school students reported a cost of US$4,300 per QALY (L.
Wang and others 2003). However, this analysis assumed that
the weight loss would be maintained throughout adulthood,
but the high relapse rates found in weight reduction studies
do not bear out this assumption (Serdula and others 1999).
Further research is needed to evaluate the benefits of
weight reduction in relation to reducing CVD events and the
long-term sustainability of weight loss before reliable cost-
effectiveness estimates can be made.
Distributional and Equity Consequences
Failing to translate available evidence from industrial countries
about CVD prevention strategies into practicable solutions for
developing countries would have clear equity implications,
especially when CVD is a large and growing problem in devel-
oping countries and when safe and effective interventions that
were once extremely expensive are now available for a few cents
a day. Because access to cardiovascular health care in develop-
ing countries often depends on patients’ ability to pay, the poor
would stand to benefit the most from a low-cost intervention
such as a polypill.
Some see CVD as exclusively a disease of the affluent in
developing countries; however, in many developing coun-
tries, the transition of CVD to becoming a disease of the
poor has already begun—a transition already seen in devel-
oped countries around the world. A recent analysis of the
distribution of major cardiovascular risks by poverty levels
has shown that many cardiovascular risks already affect the
poor in the world’s poorest countries (Ezzati and others 2004;
WHO 2002). Combating the trend requires highly effective,
low-cost solutions relevant for most or all of those at risk in
developing countries, in contrast to the investments in high-
tech treatment interventions that have commonly occurred to
date.
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Table 45.6 Polypill Cost-Effectiveness Estimates for a Population of 1 Million Adults at Varying Levels of Risk for CVD Treated
for 10 Years in India
Absolute risk of a CVD event over 10 years
Comparison with  35  25  15  5 
Costs and effects no polypill percent percent percent percent
Total cost (2001 US$ millions) 23.5 34.5 51.4 92.2 205.2
Profile of total costs
Percentage attributable to inpatient stay 12.0 6.0 3.0 1.0 0.3
Percentage attributable to ambulatory care 0 29.0 40.0 49.0 54.0
Percentage attributable to labor 75.0 36.0 21.0 9.0 2.0
Percentage attributable to pharmaceuticals 0 23.0 31.0 38.0 42.0
Percentage attributable to laboratory expenses 12.0 6.0 3.0 1.0 0.0
Effectsa
Number of myocardial infarction cases averted n.a. 10,200 14,400 21,300 31,800
Number of stroke cases averted n.a. 5,200 7,000 12,400 19,600
Number of coronary heart disease deaths averted n.a. 10,500 13,500 19,600 25,900
Number of stroke deaths averted n.a. 5,900 7,500 10,500 14,200
Number of life years saved n.a. 39,000 51,000 67,000 98,000
Number of DALYs gained n.a. 41,000 57,000 86,000 134,000
Incremental cost-effectiveness (US$/DALY) n.a. 300 990 1,500 2,430
Source: Authors’ calculations.
n.a.  not applicable.
a. Each strategy compared with no polypill. 
ECONOMIC BENEFITS OF INTERVENTION
In the cost-effectiveness analyses, most of the gains are reported
in cost savings either from particular interventions, such as
decreased hospitalizations resulting from the improved combi-
nation therapy of the polypill, or from a more efficient means
of screening those at highest risk through an absolute-risk
approach. Those who do not die from the sequelae of poorly
controlled risk factors for CVD suffer from serious chronic ill-
ness, such as stroke and congestive heart failure. Those chronic
diseases can result in significant impairments, thereby prevent-
ing those affected from continuing to work and sometimes also
requiring the services of other family members, who them-
selves end up having to leave the workforce. Further losses
resulting from disability include the loss of wages for major
wage earners and their families and the state’s losses in terms of
disability compensation. Leeder and others (2004) estimate
that in 2000 the cost of CVD disability payments in South
Africa equaled US$70 million.
However, many other indirect economic gains or losses are
not included in the economic analysis, such as gains or losses in
productivity. Leeder and others (2004) report that, at current
CVD mortality rates, the potential productive years of life lost
(defined as those years between the ages of 35 and 64) will
nearly double by 2030. Those later adult working years are par-
ticularly important, given the many years of investment in skills
through formal education and experience that would be lost.
Preventing CVD would therefore improve the size and skills of
the workforce and would therefore aid economic development.
For those reasons, the Commission for Macroeconomics and
Health has recommended that any intervention that costs less
than triple a country’s per capita gross domestic product be
regarded as cost-effective (WHO 2001). Many of the combina-
tion cardiovascular preventive approaches outlined in this
chapter comfortably satisfy that criterion.
RESEARCH AND DEVELOPMENT AGENDA
The cost-effectiveness data reviewed in this chapter indicate that
the best use of resources for personal-level interventions for
preventing CVD mediated by high blood pressure, cholesterol,
and bodyweight would be combination medications targeted to
those at high absolute risk. This strategy represents a consider-
able departure from existing paradigms, such as hypertension
treatment. Research and development is therefore required in
several areas to develop, implement, and evaluate this strategy.
This research could include several themes as follows:
• Refine absolute risk-based treatment in developing country
settings:
º Evaluate optimal communications to the public and to
health professionals that explain the rationale for this
new paradigm and its advantages over traditional para-
digms, such as hypertension treatment. One barrier to
adopting preventive therapy based on absolute risk has
been its relative complexity compared with dichotomous
diagnosis-based strategies, such as hypertension–no
hypertension.
º Develop simple methods for predicting absolute risk
using straightforward, inexpensive, direct measures, such
as physical examination, clinical history, and on-site tests.
These methods would likely involve low-cost algorithms
completed by a multipurpose health care worker involv-
ing, for example, the collection of data on age, sex, tobacco
use, blood pressure, waist circumference, and urine
dipstick results. The development of different levels of
screening protocol may also be needed in certain settings.
º Calibrate existing algorithms for different disease rates
and cardiovascular profiles in developing countries.
º Develop treatment algorithms that can easily be adopted
in resource-poor settings by, for example, multipurpose
health care workers.
º Develop methods for predicting absolute risk on the
basis of the probability of lost healthy life years as well as
the probability of a clinical event. This strategy could
mean developing an index of healthy life years at risk
from a cardiovascular event in the next five years, which
would require taking case fatalities into consideration
and discounting. A major barrier to adopting a strategy
based on absolute risk has been the absence of a time-
based measure and, hence, the equal value placed on pre-
venting an event at a young and at an old age.
• Develop and evaluate combination treatments:
º Carry out new research on the ideal combinations for
different patient groups and populations at different
stages of the health transition. Local initiatives would be
needed to determine the ideal combination of medica-
tions based principally on cost, tolerability, and ability to
lower risk-factor levels. One default set of interventions
could be an angiotensin-converting enzyme inhibitor
(for example, enalapril or lisinopril); a diuretic (such as
hydrochlorothiazide or chlothalidone); a statin (for
instance, simvastatin or lovastatin); and low-dose
aspirin.
º Measure the potential costs and benefits of adding other
active agents, such as vitamins or diabetic medications.
º Quantify the extent of improved access, acceptability,
and tolerability for people with symptomatic vascular
disease who have established indications for those
medications.
º Evaluate the benefits and costs in developing countries
with large-scale clinical trials and demonstration
projects, both among patients who have established
indications (compared with usual care) and among those
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who do not have clear indications but are still at high risk
(compared with a placebo).
º Evaluate the advantages and disadvantages of a polypill
versus unit-of-use packs and other novel delivery
strategies.
• Investigate weight-loss initiatives:
º Develop strategies to improve the effectiveness of per-
sonal interventions to reduce bodyweight in developing
countries.
º Evaluate the use of gastric surgery for weight loss in the
extremely obese in selected settings.
• Assess technology:
º Screen which technologies should be transferred to devel-
oping countries on the basis of cost-effectiveness criteria.
º Design new technologies specifically for use by commu-
nity health workers (for example, point-of-care devices).
• Review public and personal health services:
º Carry out a critical evaluation of community health
workers versus trained health professionals in delivering
simplified screening and treatment regimens.
º Provide guideline assistance for CVD prevention and
management to regional and country-specific ministers
of health and policy makers.
º Support demonstration projects to determine the limita-
tions for managing chronic conditions in resource-poor
settings.
CONCLUSIONS
The analyses presented in this chapter indicate that providing
off-patent blood pressure and cholesterol-lowering medica-
tions targeted at those at high absolute risk seems to be a cost-
effective strategy. Currently available personal interventions to
prevent or reduce high BMI are likely to be much less cost-
effective.
An approach based on absolute risk will still involve choos-
ing some level below which people are not recommended for
personal treatments, which will leave some people at risk of
progression of vascular disease. This issue exists with current
paradigms and underscores the need for parallel improvements
in population-based prevention. The strategy based on
absolute risk must be regarded as complementary to popula-
tionwide initiatives that address the root causes of CVD—in
particular, the societal determinants that lead to high salt and
saturated fat in the diet in relation to high blood pressure and
cholesterol and high-energy diets coupled with decreasing
physical activity in relation to high bodyweight. Preventing and
reducing those risks in developing countries will reduce the
need for medication-based prevention strategies in the coming
decades.
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Cigarette smoking and other forms of tobacco use impose a
large and growing global public health burden. Worldwide,
tobacco use is estimated to kill about 5 million people annually,
accounting for 1 in every 5 male deaths and 1 in 20 female
deaths of those over age 30. On current smoking patterns,
annual tobacco deaths will rise to 10 million by 2030. The 21st
century is likely to see 1 billion tobacco deaths, most of them
in low-income countries. In contrast, the 20th century saw
100 million tobacco deaths, most of them in Western countries
and the former socialist economies.
Hundreds of millions of premature tobacco deaths could
be avoided if effective interventions were widely applied in 
low- and middle-income countries. Numerous studies from
high-income countries and a growing number from low- and
middle-income countries provide robust evidence that tobacco
tax increases, timely dissemination of information about the
health risks of smoking, restrictions on smoking in public and
workplaces, comprehensive bans on advertising and promo-
tion, and increased access to cessation therapies are effective in
reducing tobacco use and its consequences. Cessation by the
1.1 billion current smokers is central to meaningful reductions
in tobacco deaths over the next five decades. New analyses pre-
sented here find that higher tobacco taxes could prevent 3 mil-
lion tobacco deaths by 2030 among smokers alive today.
Reduced uptake of smoking by children would yield benefits
chiefly after 2050. Price and non-price interventions are, for the
most part, highly cost-effective.
This chapter begins with an overview of smoking trends and
tobacco’s health consequences, followed by a discussion of the
economic rationale for government intervention, with a focus
on the uniquely addictive properties of nicotine. A review of the
effectiveness of tobacco-control policies in reducing tobacco ini-
tiation and in increasing cessation follows. A cost-effectiveness
analysis of these interventions is provided. Finally, the con-
straints to implementing tobacco-control policies are discussed.
SMOKING TRENDS
Tobacco use, in both smoked and nonsmoked forms, is com-
mon worldwide. This chapter focuses on smoked tobacco,
chiefly cigarettes and bidis (tobacco hand rolled in the leaf of
another plant, temburi, which is popular in India and parts of
Southeast Asia), because smoked tobacco is more common—
accounting for about 65 to 85 percent of all tobacco produced
worldwide (WHO 1997)—and causes more disease and more
diverse types of disease than does oral tobacco use.
Prevalence
A systematic review of 139 studies on adult smoking prevalence
(Jha and others 2002) found that more than 1.1 billion people
worldwide smoke, with about 82 percent of smokers residing
in low- and middle-income countries. Table 46.1 provides an
update of these estimates for the population in 2000. Globally,
male smoking far exceeds female smoking, with a smaller gen-
der difference in high-income countries. Smoking prevalence is
highest in Europe and Central Asia, where 35 percent of all
adults are smokers.
While overall smoking prevalence continues to increase in
many low- and middle-income countries, many high-income
countries have witnessed decreases, most clearly in men. A
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study in 36 mostly Western countries, from early 1980 to the
mid 1990s, suggested that the decrease in smoking prevalence
observed among men was caused by the higher prevalence in
younger age groups of those who have never smoked. Among
women, there was little overall change in smoking prevalence
because the increasing prevalence of smokers in younger
cohorts counterbalanced increasing cessation in older age
groups (Molarius and others 2001).
Cessation
Ex-smoking rates are a good measure of cessation at a popula-
tion level. In some high-income countries, the prevalence rates
of ex-smokers have increased over the past two to three
decades. For example, in the United Kingdom, smoking preva-
lence among males over age 30 fell from 70 percent in the 1950s
to 30 percent in 2000; female smoking prevalence fell from 40
to 20 percent over the same period. Much of the decrease arose
from cessation. Today, two times as many ex-smokers as smok-
ers exist among those age 50 or over. Currently, 30 percent of
the U.K. male population is made up of former smokers (Peto
and others 2000). Polish male cessation rates have also
increased, partly because of control programs. One of every
four adult Polish males described himself as an ex-smoker
(Zatonski and Jha 2000). In contrast, the prevalence of male ex-
smokers in most developing countries is low: 10 percent in
Vietnam, 5 percent in India, and 2 percent in China (Jha and
others 2002). Even those low figures may be falsely elevated
because they include people who quit because either they were
too ill to continue or they had early symptoms of tobacco-
related illness (Martinson and others 2003).
HEALTH CONSEQUENCES OF SMOKING
The health consequences of smoking are often assumed to be
widely understood. In fact, ignorance of the magnitude of
tobacco hazards is widespread in terms of both individual
health and population policy. Thus, the salient aspects of
tobacco epidemiology are outlined in this section.
Key Messages for the Individual Smoker
More than 50 years of epidemiology on smoking-related dis-
eases have led to three key messages for individual smokers
worldwide (Doll and others 2004; Peto and others 2003).
• The eventual risk of death from smoking is high, with about
one-half to two-thirds of long-term smokers eventually
being killed by their addiction.
• These deaths involve a substantial number of life years for-
gone. About half of all tobacco deaths occur at ages 35 to 69,
resulting in the loss of about 20 to 25 years of life, compared
with the life expectancy of nonsmokers.
• Cessation works: those adults who quit before middle age
avoid almost all the excess hazards of continued smoking.
Worldwide, about 80 percent of deaths among the 2.7 bil-
lion adults over age 30 involve vascular, respiratory, or neoplas-
tic disease. Smoking is associated with an increase in the
frequency of many of these diseases, although important dif-
ferences exist between and across populations. The following
discussion focuses on the consequences of smoking on adult
mortality. Detailed epidemiological reviews of worldwide mor-
tality from smoking are found elsewhere (C. Gajalakshmi and
others 2000; V. Gajalakshmi and others 2003; Gupta and Mehta
2000; Liu and others 1998; Niu and others 1998; Peto and
others 1994).
Current Mortality and Disability from Smoking
Recent updates of indirect estimates of global tobacco mortality
(Ezzati and Lopez 2003; M. Ezzati, personal communication,
November 2004) indicate that in 2000, 5.0 million premature
deaths were caused by tobacco. About half (2.6 million) of
those deaths were in low-income countries. Males accounted
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Table 46.1 Estimated Smoking Prevalence (by Gender) and Number of Smokers, 15 Years of Age and Older, 2000
Smoking prevalence (percent) Total smokers
World Bank region Males Females Overall Millions Percentage of all smokers
East Asia and the Pacific 63 5 34 429 38
Europe and Central Asia 56 17 35 122 11
Latin America and the Caribbean 40 24 32 98 9
Middle East and North Africa 36 5 21 37 3
South Asia 32 6 20 178 15
Sub-Saharan Africa 29 8 18 56 6
Low- and middle-income economies 49 8 29 920 82
High-income economies 37 21 29 202 18
Source: Authors.
for 3.7 million deaths, or 72 percent of all tobacco deaths.
About 60 percent of male and 40 percent of female tobacco
deaths were of middle-aged persons (ages 35 to 69).
In high-income countries and former socialist economies,
the 1 million middle-aged male tobacco deaths were largely
composed of cardiovascular disease (0.45 million) and lung
cancer (0.21 million). In contrast, in low-income countries, the
leading causes of death among the 1.3 million male tobacco
deaths were cardiovascular disease (0.4 million), chronic
obstructive pulmonary disease (0.2 million), other respiratory
disease (chiefly tuberculosis, 0.2 million), and lung cancer
(0.18 million). The specific numbers of deaths from tobacco
and of total disability-adjusted life years (DALYs) by gender
and World Bank region are shown in table 46.2. Disability esti-
mates are not discussed here; however, disability is highly cor-
related with mortality in most settings.
Past and Future Trends in Mortality
In high-income and former socialist economies with more
complete and reliable mortality statistics, one can measure
the effects of increased smoking prevalence and subsequent
decreases that have been observed among large numbers of
adults. These changes are best documented by examining lung
cancer mortality rates among young adults because lung cancer
is not often misclassified with other causes of death at young
ages and it is almost entirely attributable to smoking.
Age-Standardized Lung Cancer Mortality Rates
Age-standardized male lung cancer rates at ages 35 to 44 per
100,000menintheUnitedKingdomhadfallenfrom18in1950to
4 by 2000. In contrast, comparable French male lung cancer rates
show the reverse pattern (Peto and others 2003; figure 46.1). In
France,the increase in smoking occurred some decades later than
in the United Kingdom,and declines in smoking began only after
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Table 46.2 Tobacco Mortality and Total DALYs by Gender, 2000 
(thousands)
Tobacco deaths Total DALYs
World Bank region Males Females Males Females
East Asia and the Pacific 829 274 13,116 4,128
Europe and Central Asia 754 161 12,407 2,686
Latin America and the Caribbean 177 97 2,789 1,613
Middle East and North Africa 97 28 1,676 554
South Asia 768 187 12,397 3,285
Sub-Saharan Africa 105 66 1,659 1,091
Low- and middle-income economies 2,730 813 44,044 13,357
High-income economies 929 548 12,304 6,866
World 3,659 1,361 56,347 20,222
Source: Ezzati and Lopez 2003; Mathers and others 2006. 
Note: The terms high-income and former socialist economies as used in the text correspond roughly to high-income and Europe and Central Asia regions using the World Bank classification. Low-income
countries corresponds roughly to East Asia and the Pacific, Latin America and the Caribbean, Middle East and North Africa, South Asia, and Sub-Saharan Africa.
1990. Similarly, a large increase in female lung cancer at young
ages was avoided in the United Kingdom, but female lung cancer
at young ages continues to rise in France.
Future increases in tobacco deaths worldwide are expected
to arise from increased smoking by males in developing coun-
tries and by women worldwide. Such increases are a product of
population growth and increased age-specific tobacco mortali-
ty rates, the latter relating to both smoking duration and the
amount of tobacco smoked. Peto and others (1994) have made
the following calculation: if the proportion of young people
taking up smoking continues to be about half of men and one-
tenth of young women, there will be about 30 million new
long-term smokers each year. As previously noted, epidemio-
logical studies in developed and developing countries suggest
that half of these smokers will eventually die from smoking.
However, if we conservatively assume that “only” about one-
third of smokers die as a result of smoking, then smoking will
eventually kill about 10 million people a year. Thus, for the
25-year period from 2000 to 2025, there would be about 150
million tobacco deaths, or about 6 million deaths per year on
average; from 2025 to 2050, there would be about 300 million
tobacco deaths, or about 12 million deaths per year.
Further estimations are more uncertain, but current smok-
ing trends and projected population growth indicate that from
2050 to 2100 there will be an additional 500 million tobacco
deaths. These projections for the next three to four decades are
comparable to retrospective and early prospective epidemiolog-
ical studies in China (Liu and others 1998; Niu and others 1998),
which suggest that annual tobacco deaths will rise to 1 million
before 2010 and to 2 million by 2025, when the young adult
smokers of today reach old age. Similarly, results from a large
retrospective study in India suggest that 1 million annual deaths
can be expected from male smokers by 2025 (V. Gajalakshmi
and others 2003). With other populations in Asia, Eastern
Europe, Latin America, the Middle East, and (less certainly)
Sub-Saharan Africa showing similar growth in population and
age-specific tobacco death rates, the estimate of some 450 mil-
lion tobacco deaths over the next five decades appears plausible.
Almost all of these deaths will be among current smokers.
Benefits of Cessation
Current tobacco mortality statistics reflect past smoking behav-
ior, given the long delay between the onset of smoking and
the development of disease. The prevention of a substantial
proportion of these tobacco deaths before 2050 requires adult
cessation. For example, halving the per capita adult consump-
tion of tobacco by 2020 (akin to the declines in adult smoking
in the United Kingdom) would avert about 180 million tobacco
deaths. Continuing to reduce the percentage of children who
start to smoke will prevent many deaths, but its main effect will
be on mortality rates in 2050 and beyond (figure 46.2; Jha and
Chaloupka 2000a; Peto and Lopez 2001).
Substantial evidence indicates that smoking cessation
reduces the risk of death from tobacco-related diseases. Among
doctors in the United Kingdom, those who quit smoking before
the onset of major disease avoided most of the excess hazards
of smoking (Doll and others 2004). The benefits of quitting
were largest in those who quit before middle age (between ages
25 and 34 years) but were still significant in those who quit later
(between ages 45 and 54 years).
Cessation before middle age avoids more than 90 percent
of the lung cancer risk attributable to tobacco, with quitters
possessing a pattern of survival similar to that of persons who
have never smoked. In the United Kingdom, among those
who stopped smoking, the risk of lung cancer fell steeply with
time since cessation. For men who stopped at ages 60, 50, 40,
and 30, the cumulative risks of lung cancer by age 75 were
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a. Mean of annual rates in component five-year age groups (35–39, 40–44). 
Figure 46.1 Changes in Lung Cancer Mortality at Age 35 to 44 in the United Kingdom and France, 1950–99
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Note: Peto and others (1994) estimate 60 million tobacco deaths between 1950 and 2000
in industrial countries. This figure estimates an additional 10 million tobacco deaths
between 1990 and 2000 in developing countries. The figure also assumes no tobacco
deaths before 1990 in developing countries and minimal tobacco deaths worldwide 
before 1950. Projections for deaths from 2000 to 2050 are based on Peto and Lopez (2001).
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Figure 46.2 Tobacco Deaths in the Next 50 Years under Current
Smoking Patterns
10 percent, 6 percent, 3 percent, and 2 percent, respectively
(Peto and others 2000; figure 46.3). These results have been
supported by a recent multicenter study of men in four
European countries; for men who quit smoking at age 40, the
study found that the excess lung cancer risk avoided was
85 percent, 91 percent, and 80 percent in the United Kingdom,
Germany, and Italy, respectively (Crispo and others 2004).
Smoking cessation is uncommon in most developing countries,
but some evidence exists that, among Chinese men, quitting
also reduces the risks of total and vascular mortality (Lam and
others 2002).
RATIONALE FOR GOVERNMENT INTERVENTION
In addition to the public health burden caused by tobacco,
an economic rationale exists for government to intervene to
reduce tobacco use:
• Consumers have inadequate information about the health
consequences of tobacco use (Jha and others 2000; Warner
and others 1995). Specifically, the decision to initiate smok-
ing is made primarily by youths, whose ability to make fully
informed, appropriately forward-looking decisions is
questioned by society in many different contexts (minimum
ages for drinking, driving, and voting, for instance). In
industrial countries, about 80 percent of adult smokers
begin smoking before age 20. Even if children and young
adults have information on future risks, they tend to dis-
count that future risk greatly.
• The addictive nature of tobacco is underappreciated and
poorly understood. Although general awareness of risks is
better in high-income countries, many people still underes-
timate tobacco’s danger relative to other health risks, and
many smokers fail to fully internalize these risks (Weinstein
1998).
• Smokers may impose costs on others from passive tobacco
smoke or, more controversially, from higher health care
costs (Lightwood and others 2000; Warner 2003).
The reader is referred to more detailed discussions on the
welfare economics of tobacco (Barnum 1994; Jha and others
2000; Peck and others 2000; Warner and others 1995; and
several background papers in the Disease Control Priorities
Project Working Paper Series). We discuss nicotine addiction
because this newer evidence has profound implications for
explaining smoking behavior and for devising control policies.
Nicotine Addiction 
Before the landmark 1988 U.S. Surgeon General’s report, which
suggested that cigarettes and other forms of tobacco are addic-
tive and that nicotine is the major agent in tobacco responsible
for addiction, the prevailing view was that tobacco use was
largely a voluntary behavior or personal choice (Koop 2003).
Since that time, clinicians, behavioral scientists, researchers,
and public health experts have increasingly recognized manu-
factured tobacco products as some of the most addictive and
deadly dependence-producing substances available. Although
numerous factors have been identified that can contribute to
the reinforcement of the smoking habit—for example, the syn-
ergistic and independent effects of other compounds in tobacco
smoke (such as tar and acetaldehyde) or the sensory and envi-
ronmental stimuli associated with smoking (such as tobacco
advertising)—little debate exists that nicotine is a significant
contributor to the development and maintenance of the smok-
ing habit (Markou and Henningfield 2003). In most aspects of
dependence, nicotine is on par with other powerfully addictive
drugs, such as heroin and cocaine. Newer evidence has con-
verged on the following key points.
Biological Aspects. Nicotine is a psychoactive drug that trig-
gers a cascade of neurobiological events in the reward areas of
the brain and throughout the body that can, in turn, act in con-
cert to reinforce tobacco use (Markou and Henningfield 2003).
Even a short-term exposure to nicotine has been shown to
induce long-lasting changes of the excitatory input into the
brain’s reward system, which may be an important early step in
the path to addiction (Laviolette and van der Kooy 2004).
Notably, in some experimental models, if nicotine’s neurobio-
logical effects are blocked pharmacologically, or if nicotine is
removed from cigarette smoke, smoking eventually ceases
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(Jarvis 2004). The overwhelming property of nicotine that
leads to its frequent use is the occurrence of nicotine with-
drawal, for which cigarette smoke provides rapid relief. Though
each individual differs greatly in his or her sensitivity to nico-
tine dependence, evidence suggests that most adults are sus-
ceptible to the biological effects of nicotine and tobacco
(Picciotto 2003).
Psychological Aspects. In addition to the unique neurobiolo-
gy of nicotine, the ready availability of tobacco influences the
uptake of smoking as well as the development and mainte-
nance of dependence. With illicit drugs, legal and social barri-
ers constantly test a user’s drive to consume the drug. In
contrast, a smoker is presented with nearly ubiquitous
opportunities and frequent cues to both purchase and use
tobacco because of mass marketing and promotion of tobacco
(Shiffman and West 2003). Young people, who are attracted
to many risk behaviors, such as fast driving or binge drinking,
do not “learn” from early smoking in the way that most young
people become safer drivers and moderate drinkers as adults
(Jha and others 2000; O’Malley, Bachman, and Johnston 1988).
Economics. The traditional economic formulation of costs
and benefits tends not to take into account the unique proper-
ties of addiction (see Chaloupka, Tauras, and Grossman 2000
for a review). Newer models have begun to incorporate factors
such as lack of information, regret, and addiction itself. One
key innovation by Gruber and Koszegi (2001, 2002) permits
smokers to be time inconsistent, meaning that, given prefer-
ences, smokers would make different decisions at different
points in time. This approach, now widely used within the new
field of behavioral economics, admits conflict between what
smokers would like for themselves today and what they would
like for themselves in the future.
Implications for Control Programs. These newer economic
models have several implications for control programs. First is
the need for much more aggressive tobacco taxation to deter
the development of tobacco smoking. Estimates suggest that,
in the United States, optimal taxation taking into account
smoking initiation and nicotine addiction would be at least
US$1 higher per pack (Gruber 2003; Gruber and Koszegi 2002;
Gruber and Mullainathan 2002). The second implication is
that the usual assumption that higher taxes reduce the welfare
or satisfaction of continuing smokers may not be true. Higher
taxes enhance welfare by acting like an external control device
over the time-inconsistent preferences of smokers, which
would reduce the likelihood of smoking initiation.
The third implication is that the overall economic benefits
of tobacco control, taking into account addiction, are likely to
be substantially positive. Earlier cost-benefit analyses have
shown that if even modest costs are assigned to uninformed
smoking choices, the net economic costs of tobacco are pro-
foundly negative (Barnum 1994; Peck and others 2000). While
some of the methods for such costing have been disputed,
newer economic evidence supports the idea that widespread
hazards of tobacco use lead to major economic costs. Jamison,
Lau, and Wang (2005) have outlined that male survival explains
income growth independent of changes in physical capital,
education, fertility, economic openness, and technical progress.
Thus, if adult male survival in the former socialist economies
of Europe had been that of high-income countries, annual
growth rates over the past three decades would have been about
1.4 percent rather than 1 percent, making 1990 per capita
income about 12 percent higher, or an absolute value of
US$140 billion. The chief determinant of the mortality gap
between the former socialist economies and high-income
countries from 1960 to 1990 is smoking (Peto and others 1994;
Zatonski and Jha 2000). More recent economic studies that
have put a value on “statistical life” suggest that smoking cessa-
tion generates huge benefits. For example, Murphy and Topel
(2003) find that in the United States, the value of reduced mor-
tality from all causes between 1970 and 1998 amounted to
US$2.6 trillion per year, or half of gross domestic product
(GDP) growth during the period. Fully US$1.1 trillion per year
arose from reduced heart disease, of which at least one-third
was from reduced smoking and saturated fat in diets (Cutler
and Kadiyala 2003; see chapter 15 for a fuller discussion on the
economic benefits of disease control).
INTERVENTIONS TO REDUCE DEMAND 
FOR TOBACCO
Numerous studies, mostly from high-income countries, have
examined the effect of interventions aimed at reducing the
demand for tobacco products on smoking and other kinds of
tobacco use. The small but growing number of studies from
low- and middle-income countries provide useful lessons
about differences in the effect of these interventions between
these countries and high-income countries. The following is a
review of the effect of price and non-price interventions in
reducing demand for smoking, including a discussion of each
intervention’s effect on initiation and cessation. A more com-
plete study of the effectiveness of various interventions is avail-
able elsewhere (Jha and Chaloupka 2000b).
Tobacco Taxation
Nearly all governments tax tobacco products. However, signifi-
cant differences exist across countries in levels of tobacco taxa-
tion. Some of these taxes are specific or per unit taxes; others
are expressed as a percentage of wholesale or retail prices (ad
valorem taxes). As illustrated in figure 46.4, taxes tend to be
absolutely higher and account for a greater share of the retail
price (two-thirds or more) in high-income countries. In 
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low- and middle-income countries, taxes are generally much
lower and account for less than half of the final price of ciga-
rettes. In the United States, federal and state excise taxes on cig-
arettes were one-third lower, in real terms, in 1995 than their
peak level of the mid 1960s. However, taxes rose sharply over the
next eight years and stood at US$1.12 per pack as of 2002.
Well over 100 studies from high-income countries clearly
demonstrate that increases in taxes on cigarettes and other
tobacco products lead to significant reductions in cigarette
smoking and other tobacco use (Chaloupka, Hu, and others
2000). These reductions reflect the combination of increased
smoking cessation, reduced relapse, lower smoking initiation,
and decreased consumption among continuing tobacco users.
Studies from Canada, the United Kingdom, the United
States, and many other high-income countries generally esti-
mate that the price elasticity of cigarette demand ranges from
0.25 to 0.50, indicating that a 10 percent increase in
cigarette prices will reduce overall cigarette smoking by 2.5 to
5.0 percent (Chaloupka, Hu, and others 2000; U.S. DHHS
2000). Estimates from a limited number of studies from low-
and middle-income countries suggest a greater price elasticity
of 0.8 in such countries. Recent studies using survey data
have concluded that half or more of the effect of price on over-
all cigarette demand results from reducing the number of cur-
rent smokers (CDC 1994; Wasserman and others 1991). Higher
taxes increase both the number of attempts at quitting smok-
ing and the success of those attempts (Tauras 1999; Tauras and
Chaloupka 2003). A study in the United States (Taurus 1999)
suggested that a 10 percent increase in price would result in 11
to 13 percent shorter smoking duration or a 3.4 percent higher
probability of cessation.
Many recent studies from the United States have used
individual-level data to explore differences in the price elastic-
ity of cigarette demand by age, with a particular emphasis on
youth and young adults (Chaloupka, Hu, and others 2000; U.S.
DHHS 2000). Given that most smoking behavior becomes
firmly established during teenage years and young adulthood,
interventions that are effective in preventing smoking initiation
and the transition to regular, addicted smoking will have sig-
nificant long-term public health benefits. Estimates from these
recent studies conclude that an inverse relationship exists
between price elasticity and age, with estimates for youth price
elasticity of demand up to three times those obtained for adults
(Gruber 2003; Ross, Chaloupka, and Wakefield 2001). Several
recent studies have begun to explore the differential effect of
cigarette prices on youth smoking uptake, concluding that
higher cigarette prices are particularly effective in preventing
young smokers from moving beyond experimentation into
regular, addicted smoking (Emery, White, and Pierce 2001;
Ross, Chaloupka, and Wakefield 2001).
In the United Kingdom and the United States, increases in
the price of cigarettes have had the greatest effect on smoking
among the lowest-income and least educated populations
(CDC 1994; Townsend, Roderick, and Cooper 1998).
Furthermore, it was estimated that smokers in U.S. households
below median income level are four times more responsive to
price increases than smokers in households above median
income level. In general, estimates of price elasticity for low-
and middle-income countries are about double those esti-
mated for high-income countries, implying that significant
increases in tobacco taxes in these countries would be effective
in reducing tobacco use.
Restrictions on Smoking
Over the past three decades, as the quantity and quality of
information about the health consequences of exposure to
passive smoking have increased, many governments, especially
in high-income countries, have enacted legislation restricting
smoking in a variety of public places and private worksites. In
addition, increased awareness of the consequences of passive
smoke exposure, particularly to children, has led many work-
places and households to adopt voluntary restrictions on
smoking. Although the intent of those restrictions is to reduce
nonsmokers’ exposure to passive tobacco smoke, the policies
also reduce smokers’ opportunities to smoke. Additional
reductions in smoking, especially among youths, will result
from the changes in social norms that are introduced by adopt-
ing these policies (U.S. DHHS 1994).
In Western populations, comprehensive restrictions on
cigarette smoking have been estimated to reduce population
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smoking rates by 5 to 15 percent (see review by Woolery, Asma,
and Sharp 2000) and can also lead to changes in social norms
regarding smoking behavior, especially among youths. As with
higher taxes, these restrictions reduce both the prevalence of
smoking and cigarette consumption among current smokers.
Smoking bans in workplaces generally reduce the quantity of
cigarettes smoked by 5 to 25 percent and reduce prevalence
rates by up to 20 percent (Levy, Friend, and Polishchuk 2001).
No-smoking policies were most effective when strong social
norms against smoking helped make smoking restrictions self-
enforcing.
Health Information and Counteradvertising
The 1962 report by the British Royal College of Physicians and
the 1964 U.S. Surgeon General’s Report were landmark tobacco-
control events in high-income countries. These publications
resulted in the first widespread press coverage of the scientific
links between smoking and lung cancer. The reports were fol-
lowed, in many countries, by policies requiring health warning
labels on tobacco products, which were later extended to
tobacco advertising.
Research from high-income countries indicates that these
initial reports and the publicity that followed about the health
consequences of smoking led to significant reductions in con-
sumption, with initial declines of between 4 and 9 percent and
longer-term cumulative declines of 15 to 30 percent (Kenkel
and Chen 2000; Townsend 1993). Efforts to disseminate infor-
mation about the risks of smoking and of other tobacco use in
low- and middle-income countries have led to similar declines
in tobacco use in those countries (Kenkel and Chen 2000). In
addition, mass media antismoking campaigns, in many cases
funded by earmarked tobacco taxes, have generated reductions
in cigarette smoking and other tobacco use (Kenkel and Chen
2000; Saffer 2000). Decreases in smoking prevalence were
largest in Western countries, where the public is constantly and
consistently reminded of the dangers of smoking by extensive
coverage of issues related to tobacco in the news media
(Molarius and others 2001).
In many low- and middle-income countries, a lack of aware-
ness continues to exist about the risks of mortality and disease
posed by smoking. For example, a national survey in China in
1996 found that 61 percent of smokers thought that tobacco
did them “little or no harm” (Chinese Academy of Preventive
Medicine 1997). In high-income countries, smokers are aware
of the risks, but a recent review of psychological studies found
that few smokers judge the size of these risks to be higher and
more established than do nonsmokers, and that smokers min-
imize the personal relevance of these risks (Weinstein 1998).
Bans on Advertising and Promotion
Cigarettes are among the most heavily advertised and pro-
moted products in the world. In 2002, cigarette companies
spent US$12.5 billion on advertising and promotion in the
United States alone, the highest spending level reported to date
(U.S. Federal Trade Commission 2004). Tobacco advertising
efforts worldwide include traditional forms of advertising on
television, radio, and billboards and in magazines and newspa-
pers as well as favorable product placement; price-related
promotions, such as coupons and multipack discounts; and
sponsorship of highly visible sporting and cultural events.
Numerous econometric studies, largely from the United
Kingdom and the United States, have explored the relationship
between cigarette advertising and promotional expenditure
and cigarette demand. In general, these studies have resulted in
mixed findings, with most studies concluding that advertising
has a small positive effect on demand (Chaloupka, Hu, and
others 2000; Townsend 1993). However, critics of these studies
note that econometric methods, which estimate the effect of a
marginal change in advertising expenditures on smoking, are
ill suited for studying the effect of advertising (Chaloupka,
Hu, and others 2000; U.S. Federal Trade Commission 2004;
Townsend 1993). Approaches used by other disciplines, includ-
ing survey research and experiments that assess reactions to
and recall of cigarette advertising, do support the hypothesis
that increases in cigarette advertising and promotion directly
and indirectly increase cigarette demand and smoking initia-
tion (U.S. DHHS 1994; U.K. Department of Health 1992).
These studies conclude that cigarette advertising is effective in
getting and retaining children’s attention, with the strength
of the association strongly correlated with current smoking
behavior, smoking initiation, and smoking intentions.
Comprehensive advertising and promotion bans on ciga-
rettes provide more direct evidence on the effect of advertising
these products (Saffer 2000). One study using data from
22 high-income countries for the period 1970 through 1992
provides strong evidence that comprehensive bans on cigarette
advertising and promotion led to significant reductions in cig-
arette smoking. The study predicts that a comprehensive set
of tobacco advertising bans in high-income countries could
reduce tobacco consumption by more than 6 percent, taking
into account price and non-price control interventions (Saffer
and Chaloupka 2000). However, the study concludes that par-
tial bans have little effect on smoking behavior, given that the
tobacco industry can shift its resources from banned media to
other media that are not banned.
Smoking Cessation Treatments 
Near-term reductions in smoking-related mortality depend
heavily on smoking cessation. Numerous behavioral smoking
cessation treatments are available, including self-help manuals,
community-based programs, and minimal or intensive clinical
interventions (U.S. DHHS 2000). In clinical settings,
pharmacological treatments, including nicotine replacement
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therapies (NRT) and bupropion, have become much more
widely available in recent years in high-income countries
through deregulation of some NRT from prescription to over-
the-counter status (Novotny and others 2000; U.S. DHHS
2000). The evidence is strong and consistent that pharmaco-
logical treatments significantly improve the likelihood of quit-
ting, with success rates two to three times those when pharma-
cological treatments are not used (Novotny and others 2000;
Raw, McNeill, and West 1999; U.S. DHHS 2000). The effective-
ness of all commercially available NRT seems to be largely
independent of the duration of therapy, the setting in which
the therapy is provided, regulatory status (over-the-counter
versus prescribed therapy), and the type of provider (Novotny
and others 2000). Over-the-counter NRT without physician
oversight have been used in many countries for a number of
years with good success.
Although NRT are successful in treating nicotine addic-
tion, the markets for NRT and other pharmacological thera-
pies are more highly regulated and less affordable than are
nicotine-containing tobacco products. Recent evidence indi-
cates that the demand for NRT is related to economic factors,
including price (Tauras and Chaloupka 2003). Policies that
decrease the cost of NRT and increase availability—such as
mandating private health insurance coverage of NRT, includ-
ing such coverage in public health insurance programs, and
subsidizing NRT for uninsured or underinsured individuals—
would likely lead to substantial increases in the use of these
products. Given the demonstrated efficacy of NRT in treating
smoking, these policies could generate significant increases in
smoking cessation.
INTERVENTIONS TO REDUCE 
THE SUPPLY OF TOBACCO
The key intervention on the supply side is the control of smug-
gling. Recent estimates suggest that 6 to 8 percent of cigarettes
consumed globally are smuggled (Merriman, Yurekli, and
Chaloupka 2000). Of note, the tobacco industry itself has an
economic incentive to smuggle, in part to increase market share
and decrease tax rates (Joossens and others 2000; Merriman,
Yurekli, and Chaloupka 2000). Although differences in taxes
and prices across countries create a motive for smuggling, a
recent analysis comparing the degree of corruption in individ-
ual countries with price and tax levels found that corruption
within countries is a stronger predictor of smuggling than is
price (Merriman, Yurekli, and Chaloupka 2000). Several gov-
ernments are adopting policies aimed at controlling smuggling.
In addition to harmonizing price differentials between coun-
tries, effective measures include prominent tax stamps and
warning labels in local languages, better methods for tracking
cigarettes through the distribution chain, aggressive enforce-
ment of antismuggling laws, and stronger penalties for those
caught violating these laws (Joossens and others 2000). Recent
analysis suggests that, even in the presence of smuggling,
tax increases will reduce consumption and increase revenue
(Merriman, Yurekli, and Chaloupka 2000).
In contrast to the effectiveness of demand-side interven-
tions, there is much less evidence that interventions aimed at
reducing the supply of tobacco products are as effective in
reducing cigarette smoking (Jha and Chaloupka 1999, 2000a).
The U.S. experience provides mixed evidence about the effec-
tiveness of limiting youth access to tobacco products in reduc-
ing youth tobacco use (U.S. DHHS 2000; Woolery, Asma, and
Sharp 2000). In addition, the effective implementation
and enforcement of these policies may require infrastructure
and resources that do not exist in many low- and middle-
income countries. A preliminary discussion is occurring in
Canada about reducing its number of retail outlets for tobacco
from the current 65,000. Neither the effect of such a move nor
its enforcement costs are well known. Crop substitution and
diversification programs are often proposed as a means of
reducing the supply of tobacco. However, little evidence exists
that such programs would significantly reduce the supply of
tobacco, given that the incentives for growing tobacco tend to
attract new farmers who would replace those who abandon
tobacco farming (Jacobs and others 2000). Similarly, direct
prohibition of tobacco production is not likely to be politically
feasible, effective, or economically optimal. Finally, although
trade liberalization has contributed to increases in tobacco use
(particularly in low- and middle-income countries), restric-
tions on trade in tobacco and tobacco products that violate
international trade agreements or draw retaliatory measures
(or both) may be more harmful (Taylor and others 2000).
EFFECTIVENESS AND COST-EFFECTIVENESS 
OF TOBACCO-CONTROL INTERVENTIONS
Using a static model of the cohort of smokers alive in 2000, we
estimate the number of deaths attributable to smoking over the
next few decades that could be averted by (a) price increases,
(b) NRT, and (c) a package of non-price interventions other
than NRT. Cost-effectiveness of these policy interventions was
calculated by weighing the approximate public sector costs
against the years of healthy life saved, measured in DALYs. The
details of an earlier version of this model have been published
previously (Ranson and others 2002).
Results of Model Projections
The following is an updated analysis, using higher price
increases and a greater effectiveness for NRT than did the
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original (Ranson and others 2002). This analysis is conservative
in its assumptions about effectiveness and generous in its
assumptions about the costs of tobacco control.
Potential Effect of Price Increases. With a price increase of
33 percent, the model predicts that 22 million to 65 million
smoking-attributable deaths will be averted worldwide, which
is approximately equivalent to 5 to 15 percent of all smoking-
attributable deaths expected among those who smoke in 2000
(see table 46.3). Low- and middle-income countries account
for about 90 percent of averted deaths. East Asia and the Pacific
alone will account for roughly 40 percent of averted deaths.
Total smoking-attributable deaths averted worldwide range
from 33 million to 92 million for a 50 percent price increase
and 46 million to 114 million for a 70 percent price increase. A
70 percent price increase would avert 10 to 26 percent of all
smoking-attributable deaths worldwide.
Of the tobacco-related deaths that would be averted by a
price increase, 80 percent would be male, reflecting the higher
overall prevalence of smoking in men. The greatest relative
effect of a price increase on deaths averted is among younger
cohorts. Note that these projections use conservative price
increases. In certain countries, such as Poland and South
Africa, recent tax increases have doubled the real price of ciga-
rettes (Guindon, Tobin, and Yach 2002).
Potential Effect of Nicotine Replacement Therapies.
Provision of NRT with an effectiveness of 1 percent is predicted
to result in the avoidance of about 3.5 million smoking-
attributable deaths (table 46.4). NRT of 5 percent effectiveness
would have about five times the effect. Again, low- and middle-
income countries would account for roughly 80 percent of
the averted deaths. The relative effect of NRT (of 2.5 percent
effectiveness) on deaths averted is 2 to 3 percent among indi-
viduals age 15 to 59 and lower among those age 60 and older
(results not shown).
Potential Effect of Non-price Interventions Other Than NRT.
A package of non-price interventions, other than NRT, that
decreases the prevalence of smoking by 2 percent is predicted
to prevent about 7 million smoking-attributable deaths (more
than 1.6 percent of all smoking-attributable deaths among
those who smoked in 2000; see table 46.4). A package of inter-
ventions that decreases the prevalence of smoking by 10 per-
cent would have an effect five times greater. Low- and middle-
income countries would account for approximately four-fifths
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Table 46.3 Reductions in Future Tobacco Deaths among Smokers Alive in 2000 from Price Increases of 10 Percent, 33 Percent,
50 Percent, and 70 Percent by World Bank Region
Reduction in number of deaths (millions)
Baseline 
10 percent 33 percent 50 percent 70 percent 
smoking-attributable 
price increase price increase price increase price increase
World Bank region deaths (millions) Low High Low High Low High Low High
East Asia and the Pacific 173 2.9 8.7 9.6 27.5 14.5 37.5 20.3 46.2
(percent) (1.7) (5.0) (5.5) (15.9) (8.4) (21.7) (11.7) (26.8)
Europe and Central Asia 51 0.9 2.6 2.8 8.1 4.3 11.2 6.0 13.8
(percent) (1.7) (5.1) (5.6) (16.0) (8.5) (22.0) (11.8) (27.2)
Latin America and the Caribbean 40 0.7 2.1 2.3 6.7 3.5 9.5 4.9 11.6
(percent) (1.8) (5.3) (5.8) (16.8) (8.8) (23.7) (12.3) (29.1)
Middle East and North Africa 13 0.2 0.7 0.8 2.2 1.2 3.1 1.6 3.8
(percent) (1.7) (5.2) (5.8) (16.6) (8.7) (23.2) (12.2) (28.5)
South Asia 62 0.9 2.6 2.9 8.5 4.4 12.5 6.2 16.0
(percent) (2.4) (8.6) (9.5) (27.7) (14.3) (40.6) (20.1) (52)
Sub-Saharan Africa 23 0.4 1.1 1.3 3.7 1.9 5.5 2.7 6.6
(percent) (1.6) (4.9) (5.4) (15.9) (8.2) (23.6) (11.5) (28.5)
Low- and middle-income countries 362 6.0 17.9 19.7 56.8 29.8 79.2 41.7 98.2
(percent) (1.6) (4.9) (5.4) (15.7) (8.2) (21.9) (11.5) (27.1)
High-income countries 81 0.6 2.6 2.1 8.5 3.2 12.2 4.5 16.2
(percent) (0.8) (3.2) (2.6) (10.6) (4.0) (15.1) (5.6) (20.0)
World 443 6.6 20.5 21.8 65.3 33.0 91.5 46.2 114.3
(percent) (1.5) (4.6) (4.9) (14.7) (7.5) (20.7) (10.4) (25.8)
Source: Authors’ calculations.
of quitters and averted deaths. The greatest relative effect of
non-price interventions on deaths averted would be among
younger cohorts.
Figure 46.5 summarizes the potential effect of a set of
independent tobacco-control interventions, using 33 and
70 percent price increases (using a high elasticity of 1.2 for
low- and middle-income regions and 0.8 for high-income
regions), a 5 percent effectiveness of NRT, and a 10 percent
reduction from non-price interventions other than NRT. In
this cohort of smokers alive in 2000, approximately 443 mil-
lion are expected to die in the next 50 years in the absence
of interventions. A substantial fraction of these tobacco
deaths are avoidable with interventions. Price increases have
the greatest effect on tobacco mortality, with the most
aggressive price increase of 70 percent having the potential
to avert almost one-quarter of all tobacco deaths. Even a
modest price increase of 33 percent could potentially
prevent 66 million tobacco deaths over the course of the
next 50 years. Although NRT and other non-price interven-
tions are less effective than price increases, they can still
avert a substantial number of tobacco deaths (18 million
and 35 million deaths, respectively). The greatest effect of
these tobacco-control interventions would occur after 2010,
but a substantial number of deaths could be avoided even
before then.
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Table 46.4 Reductions in Future Tobacco Deaths among Smokers Alive in 2000 from Price Increases of 33 Percent, Increased
NRT Use, and a Package of Non-price Measures by World Bank Region
Reduction in number of deaths (millions)
Baseline
Non-price intervention
smoking-attributable
33 percent price increase NRT effectiveness effectiveness 
World Bank region deaths (millions) Low elasticity High elasticity 1 percent 5 percent 2 percent 10 percent
East Asia and the Pacific 173 9.6 27.5 1.4 6.9 2.8 13.8
(percent) (5.5) (15.9) (0.8) (4.0) (1.6) (8.0)
Europe and Central Asia 51 2.8 8.1 0.4 2.1 0.8 4.1
(percent) (5.6) (16.0) (0.8) (4.0) (1.6) (8.1)
Latin America and the Caribbean 40 2.3 6.7 0.3 1.7 0.7 3.4
(percent) (5.8) (16.8) (0.8) (4.2) (1.7) (8.5)
Middle East and North Africa 13 0.8 2.2 0.11 0.6 0.2 1.1
(percent) (5.8) (16.6) (0.8) (4.2) (1.7) (8.4)
South Asia 62 2.9 8.5 0.4 2.2 0.9 4.3
(percent) (9.5) (27.7) (1.4) (7.2) (2.8) (13.9)
Sub-Saharan Africa 23 1.3 3.7 0.2 0.9 0.4 1.8
(percent) (5.4) (15.9) (0.8) (4.0) (1.6) (7.9)
Low- and middle-income countries 362 19.7 56.8 2.9 14.3 5.7 28.6
(percent) (5.4) (15.7) (0.8) (4.0) (1.6) (7.9)
High-income countries 81 2.1 8.5 0.6 3.1 1.2 6.1
(percent) (2.6) (10.6) (0.8) (3.8) (1.5) (7.6)
World 443 21.8 65.3 3.5 17.4 6.9 34.7
(percent) (4.9) (14.8) (0.8) (3.9) (1.6) (7.8)
Source: Authors.
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Figure 46.5 Potential Effect of Tax Increases, NRT, and Non-price
Interventions on Tobacco Mortality, 2000–50
Note that no attempt has been made in this analysis to
examine the effect of combining the various packages of inter-
ventions (for example, price increases with NRT, or NRT and
other non-price interventions). A number of studies have com-
pared the effect of price and non-price interventions; few
empirical attempts have been made to assess how these inter-
ventions might interact. Although price increases have been
found in this analysis to be the most cost-effective antismoking
intervention, policy makers should use both price and non-
price interventions to counter smoking. Non-price measures
may be required to affect the most heavily dependent smokers,
for whom medical and social support in stopping will be nec-
essary. Furthermore, these non-price measures may be effective
in increasing social acceptance and support of tobacco price
increases.
Cost-Effectiveness of Antismoking Interventions. In general,
price increases are found to be the most cost-effective anti-
smoking intervention. A 33 percent price increase (our base
case scenario) could be achieved for a cost of US$13 to US$195
per DALY saved globally, or US$3 to US$42 in low-income
countries and US$85 to US$1,773 in high-income countries.
Wider access to NRT could be achieved for between US$75 and
US$1,250 per DALY saved, depending on which assumptions
are used. Non-price interventions other than NRT could be
implemented for between US$233 and US$2,916 per DALY
saved (table 46.5). Thus, NRT and other non-price measures
are slightly less cost-effective than price increases but remain
cost-effective in many settings. The cost-effectiveness of NRT is
highly sensitive to the actual price of the NRT. NRT with a price
of US$25 have a cost-effectiveness of US$75 per DALY com-
pared with US$329 for an NRT price of US$150 (data not
shown).
For a given set of assumptions, the variation in the cost-
effectiveness of each intervention between low- and middle-
income regions is relatively small and sensitive to the discount
rate (data not shown). All three interventions are most cost-
effective in South Asia and Sub-Saharan Africa. The difference
between low- and middle-income countries and high-income
countries is more pronounced. For NRT, the cost per year of
healthy life gained is 3 to 10 times higher in high-income coun-
tries than elsewhere. For non-price interventions other than
NRT, the cost in high-income countries is 22 times higher, and
for price increases, almost 42 times higher. Of note, the esti-
mates of cost-effectiveness are given as wide ranges,which reflect
the range of assumptions used.
For price increases, the high-end estimates are roughly 25
times the low-end estimates, and this difference is consistent
among the regions. For NRT, the high-end estimates are 2.5 to
10 times the low-end estimates, varying among the regions. For
non-price interventions other than NRT, the high-end esti-
mates are 20 times the low-end estimates, and this difference is
consistent among the regions.
The cost-effectiveness results can be compared against exist-
ing studies only for high-income countries because of a lack
of studies situated elsewhere. Our estimates of deaths avoided
for a 10 percent price increase are conservative compared with
those of Moore (1996) and Warner (1986).
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Table 46.5 Range of Cost-Effectiveness Values for Price Increase, NRT, and Non-price Interventions, 2000 
(2002 U.S. dollars per DALY saved)
NRT with Non-price interventions 
33 percent price effectiveness of with effectiveness of 
Baseline
increase 1 to 5 percent 2 to 10 percent
smoking-attributable Low-end High-end Low-end High-end Low-end High-end 
World Bank region deaths (millions) estimate estimate estimate estimate estimate estimate
East Asia and the Pacific 173 2 30 65 864 40 498
Europe and Central Asia 51 3 42 45 633 55 685
Latin America and the Caribbean 40 6 85 53 812 109 1,361
Middle East and North Africa 13 6 89 47 750 115 1,432
South Asia 62 2 27 54 716 34 431
Sub-Saharan Africa 23 2 26 42 570 33 417
Low- and middle-income countries 362 3 42 55 761 54 674
High-income countries 81 85 1,773 175 3,781 1,166 14,572
World 443 13 195 75 1,250 233 2,916
Source: Authors.
COMPREHENSIVE TOBACCO-CONTROL
PROGRAMS 
In recent years, several governments, mostly in high-income
countries, have adopted comprehensive programs to reduce
tobacco use, often funded by earmarked tobacco tax revenues.
The programs generally have similar goals for reducing tobacco
use:
• preventing initiation among youths and young adults 
• promoting cessation among all smokers
• reducing exposure to passive tobacco smoke 
• identifying and eliminating disparities among population
subgroups (U.S. DHHS 1994).
Furthermore, the programs have one or more of four key
components: community interventions engaging a diverse set
of local organizations; countermarketing and health informa-
tion campaigns; program policies and regulations (such as
taxes, restrictions on smoking, bans on tobacco advertising,
and access to better cessation treatments); and surveillance and
evaluation of potential issues, such as smuggling (U.S. DHHS
1994). Programs have placed differing emphasis on these four
components, with substantial diversity among the types of
activities supported within each component. Disaggregating
current tobacco-control program spending reveals that the
greatest effect can be achieved through a focus on macro-level
changes, such as policy change. Recent analyses from the
United Kingdom and United States clearly indicate that these
comprehensive efforts have been successful in reducing tobacco
use and in improving public health (Farrelly, Pechacek, and
Chaloupka 2003; Townsend, Roderick, and Cooper 1998; U.S.
DHHS 1994). In California, for example, the state’s compre-
hensive tobacco-control program has produced a rate of
decline in tobacco use double that seen in the rest of the United
States.
The cost of implementing control programs is low.
Table 46.6 provides the estimated total costs of implementing
price and NRT interventions by World Bank region. Current
estimates of the costs of implementing a comprehensive
tobacco-control program range from US$2.50 to US$10 per
capita in the United States. The U.S. Centers for Disease
Control and Prevention recommends spending US$6 to US$16
per capita for a comprehensive tobacco-control program in the
United States (CDC 1999). Canadian spending on tobacco-
control programs was approximately US$1.70 per capita in
1996 (Pechmann, Dixon, and Layne 1998). At the highest rec-
ommended spending level (US$16 per capita) in the United
States, annual funding for a comprehensive tobacco program
would equal only 0.9 percent of U.S. public spending, per
capita, on health.
Evidence from the United States demonstrates that states
with the greatest prevalence of smoking have a greater marginal
effect with their tobacco-control spending, suggesting that the
potential gains from modest investments in comprehensive
tobacco-control measures are large. Each US$10 spent per
capita on tobacco control annually has resulted in a 55 percent
reduction (variation of 20 to 70 percent) in per capita cigarette
consumption (Tauras and others 2005). In the United States,
US$10 translates into 0.03 percent of per capita GDP in 2003.
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Table 46.6 Estimated Cost of Price Intervention and NRT Programs 
(2002 U.S. dollars)
Cost of NRT (US$25 to US$150) (millions)
To treat 1 percent of To treat 5 percent of 
Cost for price increase (millions) current smokers current smokers
Low-end estimate High-end estimate 
World Bank region GDP (billions) (0.02 percent GDP) (0.05 percent GDP) US$25 US$50 US$150 US$25 US$50 US$150
East Asia and the Pacific 1,802 360 901 1,079 2,158 6,474 5,395 10,791 32,372
Europe and Central Asia 1,136 227 568 318 635 1,906 1,588 3,176 9,529
Latin America and the Caribbean 1,673 335 836 250 500 1,500 1,250 2,500 7,499
Middle East and North Africa 694 139 347 84 169 506 422 843 2,530
South Asia 655 131 327 2,312 1,926 3,853 11,558 2,312 1,926
Sub-Saharan Africa 319 64 159 868 723 1,447 4,340 868 723
Low- and middle-income countries 6,279 1,256 3,138 4,911 6,111 15,686 24,553 20,490 54,579
High-income countries 25,992 5,198 12,996 3,034 2,529 10,114 15,172 3,034 2,529
World 32,271 6,454 16,134 7,945 8,640 25,800 39,725 23,524 57,108
Source: Authors.
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CONSTRAINTS TO EFFECTIVE 
TOBACCO-CONTROL POLICIES
Although substantial evidence exists concerning the effective-
ness of numerous policy interventions to reduce tobacco use,
the use of these interventions globally is uneven and limited
(see a more formal analysis in Chaloupka and others 2001).
World Bank data reveal that ample room exists to increase
tobacco taxes. In 1995, the average percentage of all govern-
ment revenue derived from tobacco tax was 0.63 percent.
Middle-income countries averaged 0.51 percent of govern-
ment revenue from tobacco taxes, while lower-income coun-
tries averaged only 0.42 percent. An increase in cigarette taxes
of 10 percent globally would raise cigarette tax revenues by
nearly 7 percent, with relatively larger increases in revenues
in high-income countries and smaller increases in revenues in
low- and middle-income countries (Sunley, Yurekli, and
Chaloupka 2000). Despite this evidence, price increases have
been underused. Guindon, Tobin, and Yach (2002) studied 80
countries and found that the real price of tobacco, adjusted for
purchasing power, fell in most developing countries from 1990
to 2000.
Why does so much variation exist in tobacco-control
policies? The political economy of tobacco control has been
inadequately studied. A few plausible areas of interest are out-
lined here. First, the recognition of tobacco as a major health
hazard appears to be the impetus for most of the tobacco-
control policies in many high-income countries. Some evi-
dence shows that improved national capacity and local needs
assessment could increase the likelihood that tobacco-control
measures will be adopted. For example, econometric analyses
in South Africa geared to local policy requirements substantially
increased the willingness of the government to implement
tobacco-control policies (Abedian and others 1998). Second,
tobacco-control budgets are only a fraction of what is required.
Funding is needed not so much to implement programs as to
fight off tobacco industry tactics and to build popular support
for control. Third, the most obvious constraint to tobacco
control is political opposition, which is difficult to quantify.
Opposition from the tobacco industry is well organized and
well funded (Pollock 1996).
A key tool for addressing political opposition is earmarking
tobacco taxes. Earmarking has been successfully used in several
countries, including Australia, Finland, Nepal, and Thailand.
Of the 48 countries currently in the World Health
Organization’s European region, 12 earmark taxes for tobacco
control and other public health measures. The average level of
allocation is less than 1 percent of total tax revenue (WHO
2002). Earmarking does introduce clear restrictions and ineffi-
ciencies on public finance, and for this reason alone most
macroeconomists do not favor earmarking, no matter how
worthy the cause. However, analysis suggests that the efficiency
or “dead-weight losses” from earmarking tobacco taxes are
minimal (Hu, Xu, and Keeler 1998). Furthermore, earmarking
tobacco taxes can be justified if governments use the funds to
benefit those who pay (the benefits principle), provide assured
funding for tobacco-control policies and programs, and secure
public support for new or higher tobacco taxes. Earmarked
taxes also have a political function in that they help concentrate
political winners of tobacco control and thus influence policy.
Earmarked funds that support broad health and social services
(such as other disease programs) broaden the political and civil
society support base for tobacco control. In Australia, broad
political support from the Ministries of Sports and Education
helped convince the Ministry of Finance that raising tobacco
taxes was possible. Indeed, after an earmarked tax was passed,
the Ministry of Finance went on to raise tobacco taxes further
without earmarking (Galbally 1997). Additionally, targeting
revenue from tobacco taxes to other health programs for the
poorest socioeconomic groups could produce double health
gains—reduced tobacco consumption combined with
increased access to and use of health services. In China, a
10 percent increase in cigarette taxes would decrease consump-
tion by 5 percent and would increase government revenue by
5 percent. The increased earnings could finance a package of
essential health services for one-third of China’s poorest
100 million citizens in 1990 (Saxenian and McGreevey 1996).
Finally, a key pillar in tobacco control that can help over-
come some of these constraints is the Framework Convention
on Tobacco Control (FCTC). The World Health Assembly
of the World Health Organization adopted the FCTC in
May 2003. It consists of a series of negotiated protocols within
a general framework. The first three protocols are negotiations
covering smuggling, advertising, and treatment of tobacco
addiction. Countries agreeing to the negotiated protocols are to
adopt appropriate legislation and, if necessary, implement the
appropriate measures. As of February 2005, 168 countries had
signed the FCTC, 57 had ratified it, and it had come into force
on February 27, 2005.
CONCLUSION
Worldwide, only two large and growing causes of death exist.
One is HIV-1 infection, and the other is tobacco. On current
consumption patterns, about 1 billion people in the 21st
century will be killed by their addiction to tobacco. Strong
evidence shows that tobacco tax increases, the dissemination
of information about health risks from smoking, restrictions
on smoking in public places and workplaces, comprehensive
bans on advertising and promotion, and increased access to
cessation therapies are effective both in reducing tobacco use
and in improving the health of populations. Despite this
evidence, these policies, especially higher taxes, have been
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applied aggressively only in a few high-income countries, cov-
ering a small proportion of the world’s smokers. Limited
implementation of effective tobacco control in developing
countries is due to political constraints as well as the lack of
awareness of the unique effectiveness and cost-effectiveness
of these interventions.
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This chapter provides an overview of epidemiology of alco-
hol use and health consequences as well as introducing cost-
effectiveness interventions to reduce alcohol-related harm.
EPIDEMIOLOGY OF ALCOHOL USE AND 
ALCOHOL-RELATED DISEASE CONDITIONS 
Alcoholic beverages and the problems they engender have
been familiar fixtures in human societies since the beginning
of recorded history. Because alcohol is causally related to
more than 60 International Classification of Diseases codes
(Rehm, Room, Graham, and others 2003), disease outcomes
are among the most important alcohol-related problems.
Depending on the pattern of consumption, alcohol is also
protective against diseases, most important among them,
coronary heart disease (Rehm, Sempos, and Trevisan 2003).
However, the net effect is negative, and 4 percent of the global
burden of disease is attributable to alcohol, or about as much
death and disability globally as is attributable to tobacco and
hypertension (Ezzati and others 2002; WHO 2002). Alcohol
thus constitutes a serious public health problem (Room,
Babor, and Rehm 2005). Evidence-based preventive measures
are available at both the individual and the population levels,
with alcohol taxes, restrictions on alcohol availability, and
drinking-and-driving countermeasures among the most
effective policy options (Babor and others 2003). This chapter
reviews the cost-effectiveness of different interventions in
developing regions of the world.
Dimensions of Alcohol Related to Disease
The relationship between alcohol consumption and health and
social outcomes is complex and multidimensional (Rehm and
others 2004). As figure 47.1 shows, alcohol consumption is
linked to acute and long-term health and social consequences
through three intermediate mechanisms—toxic and beneficial
biochemical effects, intoxication, and dependence (Babor and
others 2003; Rehm, Room, Graham, and others 2003)—as
follows:
• Toxic and beneficial biochemical effects. These effects of
alcohol consumption may influence chronic disease in
either beneficial or harmful ways. Accepted beneficial effects
include the influence of moderate drinking on coronary
heart disease through reduction of plaque deposits in arter-
ies, protection against blood clot formation, and promotion
of blood clot dissolution (Zakhari 1997). Examples of
harmful effects include increased risk for high blood pres-
sure and for liver damage (Rehm, Room, Graham, and
others 2003) and direct toxic effects on acinar cells trigger-
ing pancreatic damage (Apte, Wilson, and Korsten 1997) or
hormonal disturbances (Emanuele and Emanuele 1997).
These are just examples, because alcohol exposure is associ-
ated with a multitude of toxic effects on different organs.
• Intoxication. Alcohol intoxication is a powerful mediator for
acute health outcomes, such as accidental or intentional
injuries or deaths, although intoxication can also be impli-
cated in chronic health and social problems and in certain
forms of heart disease. The subjective feeling of intoxication
is mainly caused by the effects of alcohol on the central
nervous system, and these effects are felt and can be meas-
ured even at light to moderate consumption levels (Eckardt
and others 1998).
• Dependence. Alcohol dependence is a clinical disorder in its
own right, but it is also a powerful mechanism sustaining
alcohol consumption and mediating its impact on both
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chronic and acute physiological and social consequences of
alcohol (Drummond 1990). In the quantitative analyses
reported in this chapter, alcohol dependence—and alcohol-
use disorders (AUDs) in general—will be considered only as
a health outcome related to high-risk alcohol use.
This chapter, including the section on the cost-effectiveness
of interventions, focuses primarily on health consequences,
although later it briefly discusses the social consequences of
high-risk drinking and recommended interventions. The epi-
demiological calculations are taken from Ezzati and others’
(2002) comparative risk analysis (CRA) and the World Health
Organization (WHO) assessment of the global burden of dis-
ease (WHO 2002). (For further information, see Mathers and
others 2003; Rehm, Rehn, and others 2003; Rehm, Room,
Graham, and others 2003; Rehm, Room, Monteiro and others
2003; Rehm and others 2004). The CRA defines alcohol expo-
sure using two measures: the average volume of alcohol con-
sumption and patterns of drinking (figure 47.1). It then relates
these exposure measures to disease outcomes.
The average volume of consumption has been the conven-
tional measure of exposure in alcohol epidemiology (Bruun
and others 1975) and has been linked to many disease cate-
gories following the seminal work of English and others (1995;
see also Rehm, Room, Graham, and others 2003). Patterns of
drinking have been linked mainly to two categories of disease
outcome: acute effects of alcohol (such as accidental and inten-
tional injuries) and cardiovascular outcomes (mainly coronary
heart disease). The CRA defines patterns of drinking primarily
in terms of high-risk drinking occasions and also in terms of
drinking in public settings and the proportion of drinking that
occurs outside of meals (for further details, see Rehm and
others 2004).
Epidemiology of High-Risk Alcohol Use 
The intervention analyses presented in this chapter focus on
average high-risk drinking, although patterns of drinking were
also incorporated into the disease burden calculations. High-
risk drinking is defined in sex-specific terms as drinking
20 grams per day or more of pure alcohol on average for
females and 40 grams per day or more of pure alcohol on aver-
age for males (a bottle of table wine contains about 70 grams of
pure alcohol). This definition of high-risk drinking is fairly
standard in alcohol epidemiology and was first introduced by
English and others (1995) on the basis of Australian guidelines.
Originally, English and others (1995) used two categories: haz-
ardous drinking (defined as drinking between 20 and 40 grams
per day of pure alcohol on average for females and between 40
and 60 grams per day of pure alcohol for males) and harmful
drinking (defined as drinking 40 grams per day or more of pure
alcohol on average for females and 60 grams per day or more of
pure alcohol on average for males). These categories have been
used in almost every comprehensive meta-analysis on alcohol
and disease since 1995 (see Rehm, Room, Graham, and others
2003 for an overview). However, critics asserted that the terms
hazardous drinking and harmful drinking were not neutral;
thus, the CRA uses drinking categories II and III, referring to
the term high-risk drinking when both categories are consid-
ered together. High-risk drinking thresholds differ by sex
because the risk for chronic disease is related to lower volumes
of drinking for women than for men; thus, the thresholds for
high-risk drinking were set to reflect an approximately similar
risk of chronic disease.
Table 47.1 shows the distribution of high-risk drinking by
age and by World Bank region. The table excludes the Middle
East and North Africa because prevalence rates of high-risk
drinking are considerably lower than 1 percent and this situa-
tion is unlikely to change in the near future.
Calculating the burden of high-risk alcohol use that is
avertable by means of effective interventions requires additional
epidemiological data—in particular, rates of incidence to and
remission from high-risk alcohol use and the relative fatality of
high-risk alcohol users compared with non-high-risk alcohol
users. We derived remission rates from studies of natural
recovery from alcohol problems, which found an average of
10.9 years to remission (Sobell, Ellingstad, and Sobell 2000),
with an adjustment of plus 20 percent for older age groups and
minus 20 percent for younger age groups.We set the relative risk
of mortality for high-risk alcohol users age 15 to 44 at 2.5 and the
relativerisk forolderagegroupsat1.3 formenand1.4 forwomen
(Gmel, Gutjahr, and Rehm 2003; Rehm, Gutjahr, and Gmel
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Figure 47.1 Model of Alcohol Consumption, Intermediate Outcomes,
and Long-Term Consequences
2001). Using WHO disease-modeling software, we derived an
internally consistent epidemiological profile of current high-risk
alcohol use in each region, including specifications of incidence
and the relative risk of mortality,with currently observed rates of
prevalence, remission, and risk of mortality as inputs. A final
input parameter is the disability level for high-risk alcohol use,
which we estimated at 0.154 (where zero equals no disability);
this is a weighted average based on the severity breakdown of
high-risk drinkers from the CRA (80 percent category II, or
hazardous; 20 percent category III, or harmful). The preference
values for these health states of 0.11 and 0.33, respectively, are
derived from Stouthard, Essink-Bot, and Bonsel (2000).
Relationship between High-Risk Drinking and AUDs
Assessing the relationship between high-risk drinking and
AUDs is not a straightforward exercise. Even though high-risk
drinking over a long period entails the risk of AUDs, that all
people with AUDs are also high-risk drinkers does not auto-
matically follow. First, neither the definition of alcohol depend-
ence nor WHO’s (1993) definition of harmful use includes
actual consumption levels. An individual is considered depend-
ent if at least three of the following criteria apply:
• strong desire or compulsion to take the substance
• impaired control and physiological withdrawal if the sub-
stance is reduced or ceased
• tolerance to the effects of the substance
• preoccupation with use of the substance 
• persistent use despite clear evidence of harmful conse-
quences.
By contrast, harmful alcohol use is defined as a pattern of
use that is causing damage to physical or mental health. Thus,
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whereas many of these criteria are associated with high-risk
alcohol use, no strict classificatory rule indicates that people
with AUDs are a subcategory of high-risk drinkers.
Second, the prevalence of AUDs is often derived from sur-
veys, where the operationalization usually requires that three
symptoms be present in a lifetime and at least one of these cri-
teria be present within the past 12 months (see, for example,
Demyttenaere and others 2004, table 2). Thus individuals may
be categorized as alcohol dependent even if they are currently
abstaining from alcohol.
Third, qualitative studies across a wide range of cultures
have found that the criteria used for diagnosing AUDs often
have different meanings and implications in different cultural
settings (Room and others 1996; Schmidt and Room 1999). For
instance, in the United States over the past decade, the level of
reported AUDs increased despite decreases in high-risk drink-
ing (Grant and others 2004). This fact has been explained in
terms of changes in drinking norms and social attitudes during
a period when the United States has become a “drier” culture.
Thus, the measurement of AUDs is quite complex and cultur-
ally dependent. Moreover, AUDs are only one outcome of alco-
hol consumption and, in many parts of the world, not the most
important one. As a result, we decided to focus on high-risk
alcohol consumption rather than AUDs.
Relationship between Alcohol Use and 
Disease Categories
The exact procedures for quantifying the risk of disease attrib-
utable to alcohol are described in detail elsewhere (Rehm,
Room, Graham, and others 2003; Rehm and others 2004).
For most chronic disease categories, investigators have derived
alcohol-attributable fractions of disease by combining
Table 47.1 Prevalence of High-Risk Drinking by Gender, Age Group, and Region, 2000 
(percentage of the population)
Age group (years)
Region Gender 15–29 30–44 45–59 60–69 70
Europe and Central Asia Male 20.8 18.7 21.4 15.2 8.1
Female 11.2 10.4 11.5 7.9 5.7
Latin America and the Caribbean Male 9.7 11.1 10.6 7.9 3.4
Female 6.8 7.5 6.5 5.8 3.1
Sub-Saharan Africa Male 10.4 14.3 12.9 11.3 8.4
Female 3.1 4.7 5.1 3.2 2.2
East Asia and the Pacific Male 6.2 7.5 7.1 6.5 5.0
Female 0.3 0.2 0.1 0.1 0.0
South Asia Male 0.8 2.5 0.3 0.1 0.0
Female 1.2 0.4 0.4 0.0 0.0
High-income countries Male 18.0 17.9 16.2 10.9 7.6
Female 10.9 8.7 9.8 6.8 5.4
Source: Authors’ calculations based on Rehm, Rehn, and others 2003 and Rehm and others 2004.
Note: The criteria for high-risk drinking were set sex specific (for details see text).
prevalence and relative risk estimates based on meta-analyses
(Corrao and others 2000; English and others 1995; Gutjahr,
Gmel, and Rehm 2001; Ridolfo and Stevenson 2001; Single
and others 1996, 1999). For depression, we drew alcohol-
attributable fractions from mental health surveys, looking at
the rates of comorbidity and the order of onset of depression
and alcohol disorders. For coronary heart disease, we modeled
the interaction of average volumes and patterns of drinking
based on multilevel analyses that include temporal informa-
tion as covariates (Gmel, Rehm, and Frick 2003; Rehm and
others 2004). For the final estimates, we based alcohol-
attributable fractions on these multilevel results for all countries,
except for developed countries with relatively favorable drinking
patterns (Australia, Japan, and countries in North America and
Western Europe),which are not discussed here because the focus
is on developing countries. For injuries, we took a similar multi-
level approach to quantify the interaction of the average volume
of consumption and patterns of drinking in determining
alcohol-attributable fractions (Rehm and others 2004).
Thus the analysis includes the following major disease
categories:
• chronic disease 
º cancer (mouth and oropharyngeal, esophageal, liver,
female breast) 
º neuropsychiatric diseases (AUDs, unipolar major depres-
sion, epilepsy)
º diabetes
º cardiovascular diseases (hypertensive diseases, coronary
heart disease, stroke) 
º gastrointestinal diseases (cirrhosis of the liver) 
º conditions arising during the perinatal period (low
birthweight)
• injury 
º unintentional injury (motor vehicle accidents, drowning,
falls, poisonings, other unintentional injuries)
º intentional injury (self-inflicted injuries, homicide, other
intentional injuries).
We did not include other disease categories that are clearly
alcohol-related, such as fetal alcohol syndrome, because the
current analysis was based on the CRA and was, thus, limited
to the global burden-of-disease categories.
Social Determinants of Exposure and Risk 
Alcohol-specific risks to health are in part determined and
modified by social determinants. For example, Harrison and
Gardiner (1999) find that for men age 25 to 69 in England and
Wales in 1988–94, those in the lowest socioeconomic status
category, unskilled labor, had a 15-fold greater risk for alcohol-
related mortality than professionals in the highest category
had. These differences cannot be explained by the overall vol-
ume of drinking, which actually tended to be greater for those
in higher socioeconomic groups. Rather, the differences can be
explained by the fact that more of the drinking of those in
lower socioeconomic status categories is in high-risk patterns;
that is, depending on the use values for drinking in the culture,
poor drinkers may see little point in wasting resources on
drinking that is not to intoxication. Poorer drinkers are also
likely to be less protected physically and socially from possible
harm arising from drinking, such as injuries and chronic and
infectious diseases. Mäkelä (1999) finds that multiple dimen-
sions of socioeconomic status are required to capture all the
adverse interactions of socioeconomic status with alcohol-
related mortality.
A critical macroeconomic question is how a country’s level
of economic development is related to alcohol-related risks to
health. The impact of alcohol on disease and mortality may be
more potent in countries with greater poverty and nutritional
deficiencies (Isichei, Ikwuagu, and Egbuta 1993; Room and
others 2002, 119–30). However, most of the risk relationships
between alcohol and disease have been derived from studies in
established market economies, and the extent of systematic
research is currently insufficient to allow quantification of this
phenomenon. As a result, the estimated disease burden cited
here may be considered as a lower-bound estimate of the actual
alcohol-attributable disease burden in developing countries.
BURDEN OF DISEASE RELATED TO HIGH-RISK
ALCOHOL USE
In the following sections, the procedures to estimate alcohol-
related burden of disease are described, as well as the limita-
tions of the used approach.
Determining the Alcohol-Related Burden of Disease 
Table 47.2 breaks down alcohol-attributable disability-adjusted
life years (DALYs) by disease category and World Bank region
using a constant 3 percent per year discount rate, but with no
age weighting. Results differ from those of the CRA (Ezzati and
others 2002; Rehm and others 2004; WHO 2002) because of
the use of non-age-weighted DALYs.1
Determining the Burden of Disease Related to High-Risk
Alcohol Consumption 
In determining the burden of disease related to high-risk alco-
hol consumption, we first divided the burden of disease
between chronic and acute disease. For chronic disease, we
assume that almost the entire disease burden reported in the
CRA is associated with high-risk alcohol use. Indeed, the over-
all disease burden in the CRA is an underestimate, because
drinking up to 20 grams per day of pure alcohol by females and
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up to 40 grams per day of pure alcohol by males is globally
associated with a net beneficial effect in relation to chronic dis-
ease. However, this effect occurs mainly in countries with mod-
erate drinking patterns (Rehm, Sempos, and Trevisan 2003),
which tend to be high-income countries (Rehm, Rehn, and
others 2003). Although high-risk but regular drinking patterns
may also have some beneficial effects, such effects are not
important in countries with binge drinking patterns. (For the
association between alcohol and coronary heart disease, see
McKee and Britton 1998; Puddey and others 1999; Rehm,
Sempos, and Trevisan 2003; for consequences on modeling the
regional burden of disease, see Rehm and others 2004.)
For injuries, which are considered to be acute outcomes, we
started by separating out the proportion of injury not caused
by high-risk drinking, which we accomplished by assuming
that injuries are linearly related to per capita consumption
(Rehm and others 2004).2 This assumption is probably conser-
vative, because high-risk drinkers in countries with binge
drinking patterns are likely to have more frequent and intensive
drinking occasions, and the risk of injury usually rises
logarithmically with the amount of drinking on a specific occa-
sion (see, for example, National Highway Traffic Safety
Administration 1992). Following this initial calculation, we
could calculate the proportion of per capita consumption
related to high-risk drinking in each region, thereby determin-
ing the proportion of injury caused by high-risk drinking
(table 47.3). Together with our calculation of the chronic
disease burden attributable to high-risk alcohol use, this per-
centage enabled us to estimate the overall disease burden
attributable to high-risk alcohol use: whereas 3.6 percent of the
global burden was attributable to alcohol drinking generally,
2.8 percent was attributable to high-risk drinking.
Limitations of the CRA Approach
The CRA’s estimates of the global and regional alcohol-related
burden of disease are based on a number of assumptions, of
which the following are the most crucial:
• The estimates of per capita consumption and unrecorded
consumption for different countries do not contain sub-
stantial measurement error.
• The distribution of consumption as derived from surveys is
similar to actual distribution in the population.
• The relationships between alcohol and chronic disease
derived from meta-analyses of cohort and case-control
studies are stable among countries and regions.
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Table 47.2 Alcohol-Attributable DALYs by Disease Category and World Bank Region, 2001 
(thousands of DALYs)
Europe Latin America Middle East East Asia
and and the Sub-Saharan and North and the South High-income
Disease category Central Asia Caribbean Africa Africa Pacific Asia countries World
Chronic disease 
Maternal and perinatal 12 7 39 1 2 29 6 105
conditions
Cancer 526 296 635 25 2,820 189 1,103 5,594
Neuropsychiatric 2,159 3,315 1,035 89 4,726 1,444 4,752 17,600
Vascular 2,639 926 556 40 1,751 1,199 2,488 5,209
Other noncommunicable 1,175 739 504 27 997 306 1,153 5,126
diseases
Subtotal chronic disease 6,511 5,283 2,769 182 10,296 3,167 4,526 33,634
Injury
Unintentional 4,127 1,984 2,308 135 3,613 2,222 1,753 15,619
Intentional 1,822 1,872 1,074 9 927 567 571 6,755
Subtotal injury 5,949 3,856 3,382 144 4,540 2,789 2,324 22,374
Total DALYs attributable 12,460 9,139 6,151 326 14,836 5,956 6,850 56,008
to alcohol
Total DALYs from all diseases 116,502 104,287 344,754 65,570 346,225 408,655 149,161 1,535,871
Proportion of DALYs 10.7 8.8 1.8 0.5 4.3 1.5 4.6 3.6
attributable to alcohol (percent)
Source: Authors’ calculations based on Rehm and others 2004 and WHO 2002. 
Note: Negative DALYs can occur because certain patterns of alcohol have cardio-protective effects.
Some evidence indicates that per capita consumption can be
reliably estimated, and information on this indicator is avail-
able for the vast majority of countries (Rehm, Rehn, and oth-
ers 2003). With respect to survey information, reliability and
worldwide coverage are lower. However, because the overall
volume of consumption and, thus, the average volume per
capita are based on production and sales estimates, the measure
of the volume of drinking overall can be considered reliable.
These factors leave the stability of relationships between alco-
hol and chronic disease as the most crucial part of our esti-
mates. Some indications suggest that relative risks may not be
the same in developing countries as in developed countries (for
example, for tobacco and lung cancers, see Liu and others
1998). Thus, the CRA’s estimates may be biased, most likely
toward an overestimation of the impact of alcohol.
One additional problem pertains to the usual epidemiolog-
ical approach as applied to alcohol. Most information about
alcohol and chronic disease is derived from cohorts. Because
cohorts are frequently not representative of the population as a
whole, specific patterns of consumption such as binge drinking
are often not represented, and thus their influence cannot be
analyzed (Rehm, Gmel, and others 2003). Unfortunately, the
patterns most often missing are those that are the most detri-
mental with respect to health; thus, the impact of alcohol on
chronic diseases that are influenced by patterns of drinking
other than average volumes is underestimated.
INTERVENTIONS FOR REDUCING 
HIGH-RISK DRINKING
The next two sections estimate the burden of disease attributa-
ble to high-risk alcohol consumption that is currently being
averted or could be averted by a range of personal and nonper-
sonal intervention strategies and calculate the expected costs
and cost-effectiveness of such interventions. Methods and
analyses draw on Chisholm and others (2004), adjusted as nec-
essary to conform to the analytical standards of this volume,
including the specification of all costs in U.S. dollars rather
than international dollars.
Population Model
We determined intervention effectiveness using a state transi-
tion population model (Lauer and others 2003), which traces
the development of a regional population taking into account
births, deaths, and the specified risk factor—in this case, high-
risk alcohol use. In addition to population size and structure,
the population model uses a number of epidemiological
parameters (incidence and prevalence, remission, and cause-
specific and residual rates of mortality) and assigns age- and
gender-specific health state valuations to both the disease in
question and to the nondiseased population. The output of the
model is an estimate of the total healthy life years experienced
by the population over a lifetime period (100 years).
We ran the model for a number of possible scenarios,
including no intervention at all (natural history), current inter-
vention coverage, and scaled-up coverage of current and possi-
ble new interventions. For the intervention scenarios, we used
an implementation period of 10 years for an intervention pro-
gram (after which epidemiological rates return to their natural
history levels), from which we derived the number of addition-
al DALYs averted each year compared with the case for no
intervention at all. We discounted DALYs at 3 percent but did
not age weight them.
Effectiveness 
A number of interventions have been evaluated and shown
to be effective in reducing alcohol use, yet their level of
892 | Disease Control Priorities in Developing Countries | Jürgen Rehm, Dan Chisholm, Robin Room, and others
Table 47.3 DALYs Attributable to High-Risk Average Alcohol Consumption by Disease Category and Region, 2001 
(thousands of DALYs)
Europe and Latin America and Sub-Saharan East Asia and High-income 
Disease category Central Asia the Caribbean Africa the Pacific South Asia countries World
Total chronic disease 6,510 5,283 2,770 10,296 3,167 4,526 33,634
Total injury 3,149 1,500 1,693 1,532 514 1,092 9,207
Total DALYs attributable 9,659 6,783 4,463 11,828 3,681 5,618 42,841 
to high-risk alcohol 
consumption 
Total DALYs from 116,502 104,287 344,754 346,225 408,655 149,161 1,535,871
all diseases
Proportion of DALYs 8.3 6.5 1.3 3.4 0.9 3.8 2.8
attributable to high-risk 
alcohol consumption
Source: Authors’ calculations based on Rehm and others 2004 and WHO 2002. 
implementation remains low in all but a handful of countries
and their potential effect on population-level health has rarely
been assessed. By contrast, some interventions without clearly
established effects continue to be widely used, including, for
example, mass media public information campaigns and
school-based education aimed at reducing alcohol consump-
tion. Recent reviews of measures to reduce alcohol misuse have
assessed the quality of the evidence for four types of interven-
tions specifically aimed at reducing high-risk alcohol use
(Babor and others 2003; Ludbrook and others 2002):
• policy and legislative interventions, including taxation of
alcohol sales, laws on drunk driving, restrictions on retail
outlets, and controls on advertising
• measures to better enforce these interventions, such as ran-
dom breath testing of drivers
• mass media and other awareness campaigns 
• brief interventions with individual high-risk drinkers.
On the basis of these reviews, we included the following
strategies and intervention effects in our analysis: drinking-
and-driving legislation and random breath testing, taxation
of alcoholic beverages, reduced hours of sale in retail outlets,
and advertising bans (included as population-based interven-
tions) and so-called brief interventions (included as interven-
tions aimed at personal behavior). We considered including
one other intervention strategy—mass media or school-based
awareness campaigns—but omitted it in the final analysis on
the grounds that evidence for its effectiveness was weak, both in
terms of methodological quality and in terms of its effect on
consumption (as opposed to transfer of information or knowl-
edge alone) (Babor and others 2003; Edwards and others 1994;
Foxcroft and others 2003; Foxcroft, Lister-Sharp, and Lowe
1997; Ludbrook and others 2002).
Drunk-Driving Legislation and Random Breath Testing.
Drunk-driving laws and reinforcement policies, such as
random breath testing of drivers, influence fatal and nonfatal
traffic injuries among both high-risk alcohol users and other
members of the population, such as passengers and pedestri-
ans. We assessed two independent effects on alcohol-related
traffic injuries, but note that evidence for these effects comes
from the developed countries, where road infrastructures and
driving patterns may differ significantly from those in the
developing world. The first intervention was drunk-driving
laws, estimated to reduce traffic fatalities by 7 percent if widely
implemented across a region. The second was enforcement by
random breath testing, estimated to reduce fatalities by 6 to 10
percent in regions partially implementing such a strategy and
by 18 percent with wide implementation. The effect on non-
fatal injuries was estimated to be a reduction of 15 percent
(Peek-Asa 1999; Shults and others 2001). In each region, we
applied these estimated effects to the proportion of total deaths
and of years lived with a disability attributed to alcohol-related
traffic accidents (table 47.4).
Taxation on Alcoholic Beverages. Excise taxation on alcoholic
beverages primarily affects the incidence of drinking through
reduced consumption. Effects are measured in terms of price
elasticity, which relates the change in consumption to the size
of the price increase (table 47.5). We derived price elasticities,
adjusted downward by one-third to reflect possible reduced
price responsiveness among high-risk drinkers, with reference
to preferred type of alcoholic beverage (beer, wine, or spirits)
by region, built up from country-level data (WHO 2003b).
This downward adjustment of price elasticities for high-risk
drinkers is a conservative approach; most of the literature
found similar effects on high-risk and dependent drinkers as
on social users (Babor and others 2003; see also Farrell,
Manning, and Finch 2003).
Price elasticities ranged from 0.3 for the most preferred
beverage category to 1.5 for the least preferred (Babor and
others 2003; Levy and Ornstein 1983). For a beer-drinking
region where wine is the second-most preferred beverage type,
for example, elasticities were set as follows: beer 0.3, wine
1.0, distilled spirits 1.5. We performed sensitivity analysis
around these elasticities. We evaluated three rates of excise tax
on alcoholic beverages: the current rate of tax, a 25 percent
increase over the current rate, and a 50 percent increase over the
current rate. We adjusted estimated reductions in the incidence
of high-risk alcohol use by the observed or expected level of
unrecorded consumption resulting from illicit production and
smuggling (for instance, an estimated 35 percent of alcohol
consumption in Eastern Europe and Central Asia is unrecord-
ed, a proportion that was modeled to increase by 10 to 15 per-
cent with the tax increases). In regions with rates of unrecorded
consumption already greater than 50 percent (South Asia and
Sub-Saharan Africa), tax increases can actually have a regressive
impact on incidence if accompanied by a rise in the already high
level of unrecorded (and therefore untaxed) consumption.
Reduced Hours of Sale in Retail Outlets. Access to and avail-
ability of alcohol can be dramatically reduced by prohibition or
rationing, but implementing and sustaining such strategies
without adverse effects, such as black markets and poisonings
from home-produced alcohol, present considerable challenges.
A more modest strategy is to reduce the hours of sale of retail
outlets selling alcoholic beverages (for example, no sales for off-
premise consumption for a 24-hour period at the weekend),
which in Scandinavia has reduced consumption and alcohol-
related harm (Leppänen 1979; Nordlund 1984; Norström and
Skog 2003). On the basis of these studies, we modeled a mod-
est reduction of 1.5 to 3.0 percent in the incidence of high-risk
drinking and 1.5 to 4.0 percent in alcohol-related traffic
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fatalities, depending on the regional pattern of drinking, with
the largest effects in regions with the highest levels of high-risk
drinking occasions.
Advertising Bans. Public health specialists are becoming
increasingly interested in the effect of a comprehensive ban on
alcohol advertising, including advertising on television and
through radio and billboards. However, available evidence
from econometric studies suggests a modest effect on con-
sumption at best, even for a comprehensive ban, arguably
because of the continuing presence of other alcohol marketing
strategies, such as product placement or event sponsorship
(Grube and Agostinelli 2000; Saffer 2000; Saffer and Dave
2002). Here we consider the potential effects of a comprehen-
sive advertising ban (television, radio, and billboards) by mod-
eling a 2 to 4 percent reduction in the incidence of high-risk
alcohol use, depending on regional drinking patterns.
Brief Interventions. We modeled brief interventions (such as
physician advice provided in primary health care settings),
which involve a small number of education sessions and psy-
chosocial counseling, to influence the prevalence of high-risk
drinking by increasing remission and reducing disability.
Efficacy reviews of brief interventions reveal an estimated 13
to 34 percent net reduction in consumption among high-risk
drinkers (Higgins-Biddle and Babor 1996; Moyer and others
2002; Whitlock and others 2004), which, if applied to the total
population at risk, would reduce the overall prevalence of
high-risk drinking by 35 to 50 percent, equivalent to a 14 to
18 percent improvement in the rate of recovery over no treat-
ment at all. After taking into account adherence (70 percent)
and potential treatment coverage in the population (50 per-
cent of high-risk drinkers), however, we estimated remission
rates to be between 4.9 and 6.4 percent higher than natural
history rates.
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Table 47.4 Effectiveness of Drinking-and-Driving Legislation and Its Enforcement 
(per 100,000 population)
Effectiveness of 
Attributable fractions drinking-and-driving laws 
(per 100,000 deaths) and random breath testing
Deaths Reduced 
Deaths attributed to Reduced years lost due 
WHO attributed to alcohol-related deaths to disability 
World Bank region subregion Sex traffic accidentsa traffic accidentsa (per 100,000) (per 100,000)
Europe and Central Asia Europe B Male 1,473 657 141 77
Female 542 74 16 6
Europe C Male 2,197 1,396 299 193
Female 799 223 48 30
Latin America and Americas B Male 4,358 2,053 439 148
the Caribbean Female 1,514 220 47 12
Americas D Male 2,599 861 184 64
Female 1,093 101 22 6
Sub-Saharan Africa Africa D Male 2,159 417 89 43
Female 1,079 90 19 9
Africa E Male 2,075 803 172 107
Female 1,027 123 26 17
East Asia and the Pacific Southeast Asia B Male 7,809 1,993 427 164
Female 2,343 127 27 8
Western Pacific B Male 3,629 723 155 66
Female 1,790 157 34 12
South Asia Southeast Asia D Male 3,689 591 126 45
Female 1,451 53 11 3
Source: Deaths attributed to traffic accidents: WHO 2003a; deaths attributed to alcohol-related traffic accidents: Rehm and others 2004.
B  low child mortality, low adult mortality; C  low child mortality, high adult mortality; D  high child mortality, high adult mortality; E  high child mortality, very high adult mortality. 
a. Percentages for all age groups combined shown here. 
Table 47.5 Effect of Taxation on the Incidence of High-Risk Alcohol Use
Prevalence by preferred Rate of taxation
beverage (percent) by preferred beverage (percent) Price increases (percent)b
Elasticity Elasticity Elasticity Nonrecorded or Effect (percent)c
World Bank WHO Most Next Least Most Next Least 0.3, most 1.0, next 1.5, least untaxed consumption
region subregiona preferred preferred preferred preferred preferred preferred preferred preferred preferred (percent) Baseline Lowerd Uppere
Europe and Europe B 0.45 0.30 0.25 0.29 0.13 0.12 (current rate) 0.04 0.08 0.11 0.34 (current rate) 0.05 0.03 0.06
Central Asia (spirits) (beer) (wine) 0.36 0.16 0.15 (25 percent increase) 0.05 0.09 0.13 0.37 (10 percent increase) 0.05 0.04 0.07
0.44 0.20 0.18 (50 percent increase) 0.06 0.11 0.15 0.39 (15 percent increase) 0.06 0.04 0.08
Europe C 0.68 0.21 0.11 0.65 0.13 0.25 (current rate) 0.08 0.08 0.20 0.36 (current rate) 0.06 0.04 0.08
(spirits) (beer) (wine) 0.81 0.16 0.31 (25 percent increase) 0.09 0.09 0.24 0.40 (10 percent increase) 0.06 0.05 0.09
0.98 0.20 0.38 (50 percent increase) 0.10 0.11 0.27 0.42 (15 percent increase) 0.07 0.05 0.09
Latin America Americas B 0.53 0.30 0.17 0.16 0.49 0.22 (current rate) 0.03 0.22 0.18 0.29 (current rate) 0.08 0.06 0.10
and the Caribbean (beer) (spirits) (wine) 0.20 0.61 0.28 (25 percent increase) 0.03 0.25 0.22 0.32 (10 percent increase) 0.09 0.06 0.12
0.24 0.74 0.33 (50 percent increase) 0.04 0.28 0.25 0.34 (15 percent increase) 0.10 0.07 0.13
Americas D 0.58 0.39 0.03 0.26 0.21 0.25 (current rate) 0.04 0.12 0.20 0.22 (current rate) 0.06 0.04 0.08
(spirits) (beer) (wine) 0.33 0.26 0.31 (25 percent increase) 0.05 0.14 0.24 0.24 (10 percent increase) 0.07 0.05 0.09
0.39 0.32 0.38 (50 percent increase) 0.06 0.16 0.27 0.25 (15 percent increase) 0.08 0.05 0.10
Sub-Saharan Africa D 0.79 0.16 0.05 0.36 0.41 0.35 (current rate) 0.05 0.19 0.26 0.77 (current rate) 0.02 0.01 0.03
Africa (beer) (spirits) (wine) 0.45 0.51 0.44 (25 percent increase) 0.06 0.23 0.30 0.85 (10 percent increase) 0.01 0.01 0.02
0.54 0.62 0.53 (50 percent increase) 0.07 0.25 0.34 0.89 (15 percent increase) 0.01 0.01 0.02
Africa E 0.49 0.30 0.21 0.28 0.50 0.38 (current rate) 0.04 0.22 0.28 0.47 (current rate) 0.08 0.06 0.10
(beer) (spirits) (wine) 0.35 0.63 0.48 (25 percent increase) 0.05 0.26 0.32 0.52 (10 percent increase) 0.08 0.06 0.11
0.42 0.75 0.57 (50 percent increase) 0.06 0.29 0.36 0.55 (15 percent increase) 0.09 0.06 0.11
East Asia and Southeast 0.88 0.12 0.00 0.30 0.40 0.00 (current rate) 0.05 0.19 0.00 0.36 (current rate) 0.04 0.03 0.05
the Pacific Asia B (spirits) (beer) (wine) 0.38 0.50 0.00 (25 percent increase) 0.05 0.22 0.00 0.39 (10 percent increase) 0.05 0.03 0.06
0.45 0.60 0.00 (50 percent increase) 0.06 0.25 0.00 0.41 (15 percent increase) 0.05 0.03 0.07
Western 0.88 0.11 0.01 0.17 0.09 0.11 (current rate) 0.03 0.06 0.10 0.27 (current rate) 0.02 0.02 0.03
Pacific B (spirits) (beer) (wine) 0.21 0.11 0.14 (25 percent increase) 0.04 0.07 0.12 0.32 (10 percent increase) 0.03 0.02 0.04
0.26 0.14 0.17 (50 percent increase) 0.04 0.08 0.14 0.31 (15 percent increase) 0.03 0.02 0.04
South Asia Southeast 0.89 0.11 0.00 0.40 0.25 0.00 (current rate) 0.06 0.13 0.00 0.79 (current rate) 0.01 0.01 0.02
Asia D (spirits) (beer) (wine) 0.50 0.31 0.00 (25 percent increase) 0.07 0.16 0.00 0.87 (10 percent increase) 0.01 0.01 0.01
0.60 0.38 0.00 (50 percent increase) 0.08 0.18 0.00 0.91 (15 percent increase) 0.01 0.01 0.01
Source: WHO 2003b.
a. B  low child mortality, low adult mortality; C  low child mortality, high adult mortality; D  high child mortality, high adult mortality; E  high child mortality, very high adult mortality.
b. Price rise caused by tax  [percentage of tax/(1  percentage of tax)]  elasticity  2/3 (high-risk drinkers less responsive).
c. Effect  sum of (prevalence  price increase) for each beverage  (1  percentage of unrecorded consumption).
d. Lower-range elasticities  0.2, 0.7, 1.2.
e. Upper-range elasticities  0.4, 1.3, 2.0.
Costs
Costs covered in the analysis include program-level costs asso-
ciated with running the intervention (such as administration,
training, and media costs) and patient-level costs (such as costs
of primary care visits). Program-level costs include resource
inputs used in the production of an intervention at a level
above that of the patient or providing facility, such as central
planning, policy, and administration functions, as well as
resources devoted to preventive programs, such as the enforce-
ment of drunk-driving legislation by police officers (Johns and
others 2003). We derived estimated quantities of resources
required to implement each intervention for 10 years at the
national, provincial, and district levels with reference to the
region’s prevailing characteristics—for example, the stability
and efficiency of tax systems, the volume of traffic (for breath
testing), and the strength of antidrinking sentiment as indicated
by existing alcohol controls (advertising bans, restricted sales).
In this analysis, patient-level resource inputs used in the provi-
sion of a given health care intervention (for example, hospital
inpatient days, outpatient visits, medications, and laboratory
tests) are relevant only to brief interventions. We estimated an
average of four primary care visits per year for the intervention
itself, plus an additional 0.33 outpatient visits (20 percent 
1.67 visits) and 0.25 inpatient days (5 percent  5 days) (see,
for example, Fleming and others 2000). We applied these
patient-level resource inputs to the 50 percent of prevalent
high-risk alcohol users in receipt of brief advice in year 1 and
(because we model an enduring effect for 10 years) year 6 and
to the 50 percent of incident cases in years 2 to 5 and 7 to 10.
Note that, throughout, the costing does not include possible
offsetting revenues for the government, for instance, from
drunk-driving convictions and, in particular, from the rev-
enues likely to result from increased alcohol taxes.
Unit costs and prices of program- and patient-level resource
inputs include the salaries of central administrators; the capital
costs of vehicles, offices, and furniture; and the cost per outpa-
tient visit (see chapter 7 for an overview of the costing method-
ology, plus prices by World Bank region). All costs are
expressed in U.S. dollars for 2001 and are discounted at an
annual rate of 3 percent.
COST-EFFECTIVENESS OF INTERVENTIONS 
In the following section, we provide results relating to the
population-level health effects, costs, and cost-effectiveness of
the evidence-based interventions previously reviewed.
Population-Level Effects 
Except for random breath testing, two-thirds of the total pop-
ulation-level health gain from these interventions was among
males (the proportion for random breath testing rises to 80 to
90 percent because of the higher proportion of deaths and
injuries attributed to traffic accidents among men). A clear dif-
ference is also apparent between regions with relatively high
rates of high-risk alcohol use (that is, prevalence in the total
population greater than 5 percent) and regions with generally
low levels of high-risk drinking (that is, less than 2 percent).
As shown in table 47.6, in the three regions with a higher
prevalence of high-risk alcohol use—Europe and Central Asia,
Latin America and the Caribbean, and Sub-Saharan Africa—
the most effective interventions were taxation and brief physi-
cian advice to individual high-risk drinkers, with each averting
more than 500 DALYs per million population per year. The
remaining control strategies—random breath testing, reduced
access to alcoholic beverage retail outlets, and a comprehensive
advertising ban—mainly produced effects in the range of 200
to 400 DALYs averted per million population per year. In the
two regions with lower rates of high-risk drinking (particularly
among the female population), by contrast, the burden that is
avertable through taxation is very much reduced (10 to 100
DALYs averted per million population per year). In South Asia,
the most effective intervention is enforcement of drinking-
and-driving laws by means of random breath testing, because
of the higher rate of traffic-related injuries than elsewhere as
well as the low levels of high-risk drinking.
Population-Level Costs 
Table 47.7 summarizes the costs and cost-effectiveness of each
intervention and of two combination strategies by region. The
most costly interventions to implement in all regions were ran-
dom breath testing and brief physician advice in primary care.
The higher costs of brief advice stem from a combination of
patient-level costs in the provision of the intervention itself (an
average annual cost of US$7 to US$20 per treated case), plus
program costs associated with administration and training pri-
mary care providers (15 to 40 percent of total costs). Random
breath testing is also a relatively resource-intensive intervention
to implement because of the need for regular sobriety check-
points administered by law enforcement officers. Other inter-
ventions, including taxation, had a per capita cost in the range
US$0.02 to US$0.13, depending in part on the efficiency of the
tax collection system and the degree of antidrinking sentiment.
Population-Level Cost-Effectiveness 
Compared with doing nothing, taxation is the most cost-
effective population-level strategy in Europe and Central Asia,
Latin America and the Caribbean, and Sub-Saharan Africa, the
three regions with a relatively high prevalence of high-risk
drinking (table 47.7). At the current rate of tax, for example,
each DALY averted costs US$104 to US$225, equivalent to
4,435 to 9,633 DALYs averted per US$1 million expenditure.
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Advertising bans had a cost per unit of effect similar to that of
reduced access to sales outlets, US$134 to US$380, equivalent
to 2,631 to 7,442 averted DALYs per US$1 million dollars
expenditure, whereas random breath testing had the highest
estimated cost per DALY averted: US$973 to US$1,856 per
DALY, approximately 500 to 1,000 DALYs averted per US$1
million dollars expenditure. Brief physician advice provided in
primary care settings had an average cost-effectiveness in the
range of US$204 to US$502 per DALY averted, or close to 2,000
to 5,000 averted DALYs for every US$1 million expenditure.
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Table 47.6 Population-Level Effects of Interventions to Reduce High-Risk Alcohol Use by World Bank Region
Europe and Latin America East Asia
Coveragea Central and the Sub-Saharan and the
(percent) Asia Caribbean Africa Pacific South Asia
Burden of disease (DALYs/million population) 20,241 12,894 6,685 6,263 2,652
Total effect (DALYs averted/
million population/year)
Excise tax on alcoholic beverages 0.95 685 586 697 83 13
(current situation)
Excise tax on alcoholic beverages 0.95 756 654 724 96 10
(25 percent increase)
Excise tax on alcoholic beverages 0.95 828 719 764 109 8
(50 percent increase)
Reduced access to alcoholic beverage 0.95 441 287 386 203 32
retail outlets
Comprehensive advertising ban 0.95 395 243 406 226 20
on alcohol
Random breath testing of motor 0.80 284 307 197 181 125
vehicle drivers
Brief advice to heavy drinkers by 0.50 1,328 713 539 362 80
a primary care physician
Combination: highest tax  2,048 1,360 1,237 447 83
brief advice
Combination: highest tax  2,551 1,784 1,715 790 210
advertising ban  random breath 
testing  brief advice
Reduction in current burden (percent)
Excise tax on alcoholic beverages 0.95 0.03 0.05 0.10 0.01 0.01
(current situation)
Excise tax on alcoholic beverages 0.95 0.04 0.05 0.11 0.02 0.00
(25 percent increase)
Excise tax on alcoholic beverages 0.95 0.04 0.06 0.11 0.02 0.00
(50 percent increase)
Reduced access to alcoholic 0.95 0.02 0.02 0.06 0.03 0.01
beverage retail outlets 
Comprehensive advertising ban 0.95 0.02 0.02 0.06 0.04 0.01
on alcohol
Random breath testing of motor 0.80 0.01 0.02 0.03 0.03 0.05
vehicle drivers
Brief advice to heavy drinkers by 0.50 0.07 0.06 0.08 0.06 0.03
a primary care physician
Combination: highest tax  0.10 0.11 0.19 0.07 0.03
brief advice
Combination: highest tax  advertising 0.13 0.14 0.26 0.13 0.08
ban  random breath testing  brief advice
Source: Chisholm and others 2004.
a. Refers to the modeled percentage of all high-risk drinkers exposed to the intervention.
Starting from the current situation in these regions, the
most efficient strategies for reducing high-risk alcohol use
would be tax increases (additional gains are obtained at virtu-
ally no extra cost because the costs of tax administration and
enforcement remain relatively constant whatever the rate of
tax), followed by the introduction or escalation of comprehen-
sive advertising bans on alcohol products, reduced access to
retail outlets, and the provision of brief interventions such as
physician advice in primary care. Even a multifaceted strategy
made up of an increase in taxation plus full implementation of
the other interventions considered here has a favorable ratio of
costs to health benefits.
In East Asia and the Pacific and South Asia, the two regions
with lower rates of high-risk alcohol use, a comparison of
intervention costs and effects to a no-intervention scenario
reveals that current practice—namely, excise taxes on alcoholic
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Table 47.7 Costs and Cost-Effectiveness of Interventions to Reduce High-Risk Alcohol Use by World Bank Region
Total cost (US$ million/year/million population)
Excise tax on alcoholic beverages (current situation)
Excise tax on alcoholic beverages (25 percent increase)
Excise tax on alcoholic beverages (50 percent increase)
Reduced access to alcoholic beverage retail outlets 
Comprehensive advertising ban on alcohol
Random breath testing of motor vehicle drivers
Brief advice to heavy drinkers by a primary care physician
Combination: highest tax  brief advice
Combination: highest tax  advertising ban  random
breath testing  brief advice
Cost-effectiveness relative to no intervention 
(US$/DALY averted)
Excise tax on alcoholic beverages (current situation)
Excise tax on alcoholic beverages (25 percent increase)
Excise tax on alcoholic beverages (50 percent increase)
Reduced access to alcoholic beverage retail outlets 
Comprehensive advertising ban on alcohol
Random breath testing of motor vehicle drivers
Brief advice to heavy drinkers by a primary care physician
Combination: highest tax  brief advice
Combination: highest tax  advertising ban 
random breath testing  brief advice
DALYs averted/US$ million expenditure
Excise tax on alcoholic beverages (current situation)
Excise tax on alcoholic beverages (25 percent increase)
Excise tax on alcoholic beverages (50 percent increase)
Reduced access to alcoholic beverage retail outlets 
Comprehensive advertising ban on alcohol
Random breath testing of motor vehicle drivers
Brief advice to heavy drinkers by a primary care physician
Combination: highest tax  brief advice
Combination: highest tax  advertising ban  random
breath testing  brief advice
Coveragea
(percent)
0.95
0.95
0.95
0.95
0.95
0.80
0.50
0.95
0.95
0.95
0.95
0.95
0.80
0.50
0.95
0.95
0.95
0.95
0.95
0.80
0.50
Europe and
Central Asia
0.10
0.10
0.10
0.10
0.07
0.53
0.36
0.44
0.97
141
127
116
216
185
1,856
270
216
381
7,107
7,847
8,590
4,638
5,417
539
3,705
4,627
2,621
Latin America 
and the Caribbean
0.13
0.13
0.13
0.10
0.09
0.47
0.36
0.48
0.97
225
202
184
340
380
1,542
502
350
546
4,435
4,953
5,442
2,940
2,631
648
1,992
2,859
1,833
Sub-Saharan
Africa
0.07
0.07
0.07
0.06
0.05
0.19
0.11
0.18
0.39
104
100
95
152
134
973
204
143
229
9,633
10,007
10,553
6,580
7,442
1,027
4,891
7,016
4,364
East Asia and
the Pacific
0.04
0.04
0.04
0.03
0.03
0.18
0.08
0.12
0.30
516
447
394
146
123
984
224
269
383
1,937
2,239
2,536
6,856
8,139
1,016
4,460
3,718
2,612
South Asia
0.04
0.04
0.04
0.03
0.02
0.07
0.04
0.07
0.15
2,671
3,654
4,641
827
1,123
531
462
845
707
374
274
215
1,209
891
1,882
2,163
1,184
1,415
Source: Chisholm and others 2004.
a. Refers to the modeled percentage of all high-risk drinkers exposed to the intervention.
beverages—is not the most efficient response to the existing
burden of alcohol use. The reduced efficiency of taxation in
these lower-prevalence regions is related both to the distribu-
tion of the fixed costs of administering and enforcing alcohol
tax legislation across a smaller target population of drinkers
and to underlying drinking patterns: more than 85 percent of
all alcohol consumption falls into a single preferred drink cat-
egory, spirits, which therefore diminishes the scope for reduc-
ing the consumption of less preferred but more elastic cate-
gories of alcoholic beverages. In South Asia, targeted strategies
such as brief physician advice and random breath testing have
the lowest cost per DALY averted (around US$500), while tax-
ation policies are the most expensive at more than US$2,500
per DALY averted. In East Asia and the Pacific, the most cost-
effective interventions are brief physician advice, a comprehen-
sive ban on advertising, and reduced access to retail outlets
(below US$250 per DALY averted).
Implications and Limitations of Sectoral 
Cost-Effectiveness Analyses
This cost-effectiveness analysis offers a new approach to gener-
ating economic evidence that can inform public health policy
on alcohol in a wide range of cultural and epidemiological
settings (Chisholm and others 2004). Resulting estimates of
cost-effectiveness can inform policy makers not only by deter-
mining the efficiency of existing resource allocation and
practices, but also by identifying priorities for future alcohol
control strategies. Furthermore, use of a common methodology
enables comparison with cost per DALY estimates for other
risk factors or disease entities, which may constitute an impor-
tant argument when considering priorities for the allocation
of scarce health care resources. However, the application of a
broad sectoral approach using entire regions as the unit of
analysis clearly limits the approach’s use in specific country
contexts, where demographic or epidemiological characteris-
tics, as well as treatment costs and coverage, may not coincide
with estimates for the region as a whole. In addition, extrapo-
lation of the extent of intervention effects from relatively
information-rich countries to other sociocultural settings
lessens the precision of derived estimates of population-level
health gains.
Although an ongoing analytical step is to calibrate results
at the country level, the primary purpose and utility of the
sectoral approach is to identify interventions that are clearly
cost-effective as opposed to those that clearly do not seem to
offer good value for money. In this respect, the primary con-
clusion to be drawn from the analysis is that in regions with
high or moderate rates of high-risk alcohol use, a number of
intervention strategies can have a notable effect on population
health, including both individual-based interventions, such as
brief physician advice at the primary care level, as well as
population-wide measures, such as taxation of alcoholic bever-
ages. Of these, taxation has the most sizable and least resource-
intensive effect on reducing the avertable burden of high-risk
alcohol use. In regions where high-risk alcohol use represents
less of a public health burden, targeted approaches such as brief
physician advice as well as other intervention strategies that
restrict the supply or promotion of alcoholic beverages appear
to be the most cost-effective mechanisms, although greater
empirical support for the efficacy of these interventions in
these localities is clearly needed before considering their wide-
spread implementation.
Even though sectoral cost-effectiveness analysis pursues a
societal perspective, considerable challenges remain in relation
to the appropriate measurement of certain societal costs and
effects that fall outside the boundaries of the health system.
Therefore, this analysis has not been able to successfully cap-
ture potential reductions in workforce and household produc-
tivity losses among high-risk drinkers, nor does it incorporate
the economic costs associated with alcohol-related crime, vio-
lence, and harm reduction. It also does not value the time spent
by patients and informal caregivers in seeking or providing care
and support. Including these modest additional costs and sub-
stantial incremental effects is likely to improve the cost-
effectiveness ratios of all interventions, but to a variable and
currently unknown extent.
ECONOMIC BENEFITS OF INTERVENTIONS 
By design, estimates of the burden of alcohol do not include
most social harm and harm to people other than the drinker;
however, the burden of social problems from drinking can be
at least as significant as the health burden. The burden attrib-
utable to alcohol in the CRA estimates is actually a substantial
underestimate of the full harm alcohol imposes on human
welfare. The estimates reported earlier reflect primarily the
chronic disease and injury effects of drinking. Because the CRA
focused on disease and disability, the estimates were not
designed to take account of the social harm and problems that
are particular to alcohol and that result for the drinker and for
others as a consequence of a person’s drinking (Klingemann
and Gmel 2001). These problems are quite prevalent in many
populations (Room and others 2003) and are also affected by
the interventions listed earlier.
Some information on the relative burden of alcohol for
social services versus health services is available for a handful of
societies. In an estimate of the staffing and service costs attrib-
utable to alcohol in different service systems in Scotland for
fiscal year 2001/02, for instance, health services accounted for
only 21 percent of the estimated costs, whereas social services
accounted for 19 percent, and criminal justice and fire services
accounted for 60 percent (Catalyst Health Consultants 2001, 3).
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If those estimates are used as a rough gauge of the burden to
society, the illness and disability burden of alcohol may thus
constitute half or less of the total burden when social problems
are also taken into consideration.
Thus, policies that affect the levels of alcohol-related health
and social harm not only are a matter of intervening to save
people from the detrimental effects of their own behavior, but
also potentially have a broader effect on the health and well-
being of families and of associates of drinkers. This issue is
especially relevant for women: even though men predominate
among high-risk drinkers worldwide (Rehm and others 2004;
Room and others 2002), women bear much of the burden of
harm from others’ drinking, not only in such forms as domes-
tic violence, but also in such forms as diversion of family
resources from greater needs.
IMPLEMENTATION OF CONTROL STRATEGIES:
LESSONS OF EXPERIENCE 
The following paragraphs provide a few concrete examples of
interventions or policy changes that illustrate the actual imple-
mentation and effects of control strategies in developing soci-
eties (the examples are taken from Room and others 2002).
Tax Rate Reduction and the Resulting Disease 
Burden in Mauritius
Mauritius, an island nation in the Indian Ocean, has a popula-
tion of about 1 million. These people are of Indian, African,
European, and Chinese origin. By religious affiliation, 53 per-
cent are Hindu, 29 percent are Christian, and 17 percent are
Muslim. Tourism is the third-ranked industry in terms of hard
currency earnings. In June 1994, the government drastically
lowered customs duties on imported alcoholic beverages to
80 percent from rates that had ranged from 200 percent for
wine to 600 percent for whisky and other spirits (Abdool 1998).
The government made the change under pressure from the
hotel industry, which claimed that tourists were not purchasing
enough alcohol because of its high prices (Lee 2001). Other rea-
sons given for the change were to reduce unofficial imports
from abroad and to make better, more refined alcoholic bever-
ages available to the local population. Despite little evidence to
support the view, there were claims in the public discussion that
better-quality alcohol would result in fewer health problems.
The effects of the change were felt mainly by Mauritians
rather than tourists, as follows:
• Arrests for driving with blood alcohol over the legal limit
made primarily in connection with traffic crashes increased
by 23 percent between 1993 and 1997.
• Admissions of alcoholism cases to the island’s psychiatric
hospital shot up in 1994. The 1995 rate was more than twice
the 1993 rate, and the rate rose again slightly in 1996 and
1997. Medical specialists in Mauritius agree that patients
with alcohol problems account for an increasing portion
of admissions in general medical wards and now represent
between 40 and 50 percent of bed occupancy (Abdool
1998).
• Age-adjusted death rates per 100,000 population for chronic
liver disease and cirrhosis rose from 32.8 for males and
4.0 for females in 1993 to 42.7 for males and 5.3 for females
in 1996 (WHO 1999, 2000).
Even though available statistics are limited, the reduction in
alcohol import taxes clearly had a substantial negative effect on
the health of Mauritians. Thus, the government’s 1997 call for
control measures for alcohol—specifically, new permits for
licensed premises, increased excise duties on alcohol, and limi-
tations on bars’ opening hours—was not surprising. Alcohol
taxes were increased somewhat in the 1999/2000 budget (U.S.
Department of State 1999). However, an analysis by World
Bank staff that did not take health effects into account called
for further reductions in maximum tariff rates, identifying
Mauritius as having an antitrade bias on the basis of the struc-
ture of its alcohol and tobacco taxes (Hinkle and Herrou-
Aragon 2001).
Wallace and Bird (2003) suggest the following general prin-
ciples for setting and collecting alcohol taxes in the context of
developing societies from the perspective of revenue genera-
tion rather than public health (see also Tax Policy Chief
Directorate 2002):
• Countries around the world need revenues they can raise
relatively efficiently, but this need is probably more critical
in the case of developing nations. That said, alcohol taxes are
probably a good bet for future revenues.
• Excise taxes on alcohol should be set by alcohol content,
rather than as a percentage of the price.
• Tax rates should be logically defined so that alcoholic bever-
ages with similar alcohol content are treated similarly, with
stronger alcohol beverages taxed more heavily.
• Analyses of revenue-maximizing rates should be conducted
to determine a range of tax rates that is likely to maximize
government revenues.
• Tax systems should be designed to be as simple as possible
to allow for the maximum efficiency of tax administration.
Reduced Access through Locational Prohibition in Brazil
The second example involves the institution of a new control
on alcohol availability in an environment where it is likely to
be combined with driving. Although we have modeled the
effects of another, better studied availability control (namely,
closing on a weekend day), a wide variety of possible
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measures is available to control the time and place of alcohol
purchase or drinking (Babor and others 2003; Room and oth-
ers 2002). Even though in this case the particular control was
extremely limited in scope, it appears to have had measurable
effects.
Traffic deaths are an important source of mortality in Brazil,
amounting to 3.6 percent of overall mortality. The few available
studies suggest that alcohol plays a significant role in traffic
casualties. For instance, one study in São Paulo found positive
blood alcohol levels in 72 percent of pedestrian deaths and
32 percent of driver and passenger deaths of persons age 13 and
older (Carlini-Cotrim and Chasin 2000).
In 1985, motivated by concern about alcohol and impaired
driving and about the lax enforcement of drinking and driv-
ing laws, a conservative party politician from the state of São
Paulo introduced legislation to prohibit alcohol sales in com-
mercial facilities that had access to state highways. Even
though the bill passed in the legislature, its implementation
was delayed by the state’s alcohol producers and commercial
and industrial federations, which claimed that the law would
be a barrier to improved facilities for travelers, would encour-
age people to carry bottles in their cars, and would restrict
individual freedoms. Discussion in the press was also generally
unsympathetic. In August 1988, however, a new state gover-
nor from the same party implemented the law. At that time,
the press was slightly more supportive. Since then, the law has
been on the books, although site visits to restaurants and
snack bars along a state highway in 1997 suggested a low level
of compliance. In 1995, another legislator from the same
party proposed repealing the law on the grounds that no
studies proved that it lowered traffic accidents. The repeal
passed the legislature without significant public debate, but
the state governor vetoed it. Undaunted, the same legislator
then proposed a law to criminalize buying as well as selling
alcohol along state highways. That law passed but has not yet
been implemented.
A study by Carlini-Cotrim, Pinsky, and Serrano Barbosa
(1998) assesses the effects of the intervention. Finding data for
a controlled study comparing traffic casualties on state high-
ways with casualties on federal highways, which were unaffect-
ed by the law, proved impossible. The best data available were
on crashes and crashes resulting in injuries per 10,000 vehicles
traveling on three short highway systems administered by a pri-
vate agency. Linear regressions on those data for 1983–93
showed that the law had made a significant difference in the
number of accidents resulting in injuries on all three roads and
a significant difference in all accidents on two of the roads. A
separate analysis on estimated accidents and accidents with
injuries per 10,000 vehicles in two geographic areas of the state
did not show significant effects of the law. Overall, the analyses
do provide some support for the law having a beneficial effect
on the rate of traffic casualties.
Drunk-Driving Enforcement in South Africa
No published studies are available of the implementation of
random breath testing in a developing country. However, some
data are available on a campaign to increase drunk-driving
enforcement in South Africa, a strategy that has often shown
some effects, although weaker and less lasting than those of
random breath testing.
The minister of finance launched a short-term campaign,
ARRIVE ALIVE, for the period October 1997 to January 1998,
in response to the high rate of traffic fatalities and injuries. The
campaign’s main aim was to mobilize all available traffic polic-
ing, control, and education resources to reduce traffic accidents
on South African roads by at least 5 percent, especially in the
Western Cape, Gauteng, and KwaZulu Natal provinces, because
75 percent of all accidents occurred in those provinces. The
ARRIVE ALIVE campaign targeted, in turn, what were consid-
ered the three critical factors having the greatest impact on
injuries: failing to wear seat belts, drinking and driving, and
speeding. Unofficially, the campaign came to be called “belts,
booze, and bats out of hell.”
As many of the parties interested in road safety as possible
were involved, with funding drawn from a variety of govern-
ment and business sources. The campaign included a number
of components particularly relevant to alcohol use. New equip-
ment purchased by the provinces included alcohol screening
devices, alcohol evidentiary units, and so-called booze buses
(vehicles containing all the technology needed to check breath
and blood alcohol levels). Sentences were increased to under-
line the point that traffic violations are serious offenses, with a
three-month suspension of a driver’s license and an increased
maximum fine for a first conviction for drunk driving and with
license suspension for one to five years for second offenders.
Traffic supervisors underwent intensive training courses before
the start of the campaign.
Because the aim of the campaign included educating road
users, advertisements covering aspects of the campaign were
run on the radio, on television, and in movie theaters through-
out the country. Supplements were published in national and
provincial newspapers. Private companies, such as a supermar-
ket chain and an automobile manufacturer, also promoted
the campaign. A national transportation center, established to
collect and collate data from local and provincial authorities,
operated for 12 hours every day throughout the campaign.
Traffic authorities staffed an additional 80 roadside communi-
cations points, and at selected points on certain routes, road
signs were erected and updated to display the percentage of
speed limit and drinking-and-driving violations and the rate of
seat belt use in that area.
A total of 776 enforcement points were set up on 195 strate-
gic routes in the selected provinces. Posters, pamphlets, key
rings, and license decals were produced for distribution and
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display at roadblocks in the three provinces. Between October
1, 1997, and January 17, 1998, 6,674 notices of prosecution
were issued for alcohol-related traffic offenses, 83 percent of
which were issued in the intervention provinces.
Comparison studies showed a decrease in the drinking rate
of drivers in the three provinces, whereas the other six
provinces, as a group, showed an increase. KwaZulu Natal had
the lowest drinking rate of all drivers throughout the campaign
(3 to 7 percent), and the Western Cape had the most dramatic
decrease (from 12.0 to 9.3 percent in October). Except for in
Gauteng, the drinking rates for pedestrians decreased from
more than 15 percent to less than 7 percent. Overall, during the
months targeted, drinking-and-driving rates decreased by 2 to
4 percent, as measured by breath testing. The total number of
crashes decreased by 8 percent, and fatalities dropped by 9 per-
cent. The ratio of benefits to costs for the intervention was esti-
mated as 4 to 1, based on an investment in the campaign of
R50 million, or about US$4.4 million at 2002 rates (ARRIVE
ALIVE Campaign 2000).
Despite the potential inconvenience of roadblocks and other
enforcement activities, the public generally perceived the cam-
paign positively. The liquor retail and hospitality industries
complained about decreased sales, and tow truck operators
complained about reduced business.
Even though driver behavior improved during the focus
months, violations often increased after the focus was changed,
for example, from drunk driving to seat belt use. This finding
emphasizes the need for sustained enforcement as opposed to ad
hoc campaigns. (This example was summarized from ARRIVE
ALIVE Campaign 2000 and Cerff and Plüddemann 1998.)
Implementation of Brief Interventions in Several 
Developing Countries
In the first phase of the WHO Collaborative Project on
Identification and Management of Alcohol Related Problems
(Saunders and Aasland 1987), a screening measure suitable for
use in both developing and developed countries—the alcohol-
use disorders identification test—was developed to identify
people at risk for alcohol problems among those attending pri-
mary health care services. In the second phase, a multicenter
clinical trial of brief intervention procedures designed to
reduce the health risks associated with hazardous alcohol use
was carried out in primary health care settings in Australia,
Bulgaria, Costa Rica, Kenya, Mexico, Norway, the Soviet Union,
the United Kingdom, the United States, and Zimbabwe (Babor
and others 1994).
The project’s aims were to study the influence of simple
advice and brief counseling, to examine the moderating role of
reduced consumption on the prevention of alcohol-related
problems, and to evaluate the cross-national generalizability of
brief intervention techniques. The project’s hypothesis was
that the amount of change in alcohol consumption over a
nine-month period would be proportional to the intensity of
the intervention provided by a trained primary health care
professional. The results showed a significant effect of inter-
ventions on both consumption and intensity of drinking
among males, but the intensity of the intervention was not
related to the amount of change in drinking behavior; 5 min-
utes of simple advice turned out to be as effective as 20 min-
utes of brief counseling (Babor and Grant 1992). The female
sample was too small for the results to attain significance, and
the intervention did not significantly affect men’s frequency of
dependence symptoms, problems related to alcohol, or con-
cern expressed by others (WHO Brief Intervention Study
Group 1996).
The findings suggest that in a population of high-risk
drinkers, behavior change is more a function of motivational
factors and social influence than of the moderation skills and
social learning techniques that behavioral self-control training
packages typically use. Changes in drinking were not attribut-
able solely to the small number of patients who achieved an
abstinence goal, nor to the small number who gave up daily or
almost daily drinking. Rather, changes seem to have been dis-
tributed across a broad spectrum of the drinkers who reduced
their consumption by small, but clinically meaningful,
amounts.
RESEARCH AND DEVELOPMENT AGENDA
Research and development needs in the area of alcohol con-
sumption are large and multidimensional. The work reported
in this chapter represents best estimates from the available data,
some of which were developed to fill the needs of the analysis;
however, we cite few figures for the developing world for which
we can say that the underlying data are so good that they could
not usefully be improved. Nevertheless, more and better data
are available on alcohol than on many other health topics.
The health and social burdens of alcohol are clearly
extremely large in most developing societies. Thus, the most
urgent focus should be on development and evaluation proj-
ects to study the outcomes of various policy and program
interventions. The projects must necessarily be attuned to what
is politically feasible in a particular time and place. They are
likely to include natural experiment studies, where the research
tracks the effects of changes that governments undertake,
whether those changes are expected to increase or to decrease
the extent of alcohol problems. Where possible, the projects
should include experimental and quasi-experimental studies,
whereby the effects of a change at intervention sites are studied
in comparison to outcomes at control sites, with random
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assignment where possible. Costing data should be included to
permit cost-effectiveness analysis.
Also important are process studies—that is, research on
how policy makers decide on policy changes, how they
implement them, and what the reactions and sequelae are. For
example, deciding to introduce a new alcohol tax may be the
easiest part of an initiative, but actually implementing it in a
developing society with a great deal of unrecorded alcohol in
the informal market and with poorly guarded borders may be
much more difficult. Currently, no international mechanism or
nexus exists for developing and disseminating practical knowl-
edge about implementing effective alcohol control strategies
between developing countries.
At this time, nearly all studies of alcohol interventions come
from a limited range of developed countries. Extending knowl-
edge and experience in and between developing societies is
urgently needed.
A secondary need, but one that is also important, is to
extend the epidemiological database in developing societies on
levels and patterns of drinking and on the health and social
consequences of drinking. To this end, better estimation of
unrecorded alcohol consumption is needed. Which dimensions
of drinking patterns matter for what kinds of outcomes needs
to be studied in the context of different kinds of developing
societies. Studies of the effects that the interaction of drinking
levels and patterns with poverty and social exclusion have on
the extent of alcohol-related problems are also necessary.
Because most of our knowledge about the health effects of
drinking concerns mortality, studies of alcohol’s role in various
kinds of morbidity should be emphasized. Another area where
data are lacking is the social harm arising from drinking, for
which we cannot presently make the kinds of estimates that are
possible to make for harm to health. Developing and reaching
consensus on ways to measure the social harm caused by drink-
ing is a substantial agenda for both the developed and the
developing world.
Developing the epidemiological database can provide clues
to etiology to be pursued further by biomedical and social
researchers and, thus, offers hope for the development of new
treatments or preventive interventions. It can provide informa-
tion on the distribution of drinking patterns and problems in
subpopulations that can be used to guide targeting and pre-
vention and treatment priorities. However, from a short-term
policy perspective, the most important function of developing
the epidemiological database in a particular country may be
providing a base for creating political will for action. For exam-
ple, the development of devices to measure blood and breath
alcohol and the collection of data on drinking and driving that
they made possible were prerequisites for developing the polit-
ical will and support for implementing drinking-and-driving
countermeasures in industrial countries.
CONCLUSION 
The burden of disease attributable to alcohol in the developing
world is considerable, and the social harm not accounted for in
this analysis increases the costs. However, known interventions
can reduce the burden by up to 25 percent, depending on the
region of the world. Compared with other interventions in the
health care field, these interventions are quite cost-effective, but
given the nature of many of the interventions, caution is needed.
In particular, the following recommendations can be given:
• Interventions and research about their effectiveness are
based mostly on experiences from established market
economies; thus, the levels of effectiveness estimated in our
analysis should be treated as broad indications. Depending
on actual methods of implementation, individual interven-
tions could be more or less effective.
• Interventions should ideally be modeled on the basis of the
specific environment (that is, countries or provinces) and
on the harm distribution in the respective environment,
including social harm.
• General principles, such as restricting access to alcohol,
should be attuned to local cultures and traditions when
interventions are formulated.
• Population measures must take into account the complex
interplay of public opinion and balance the interests of dif-
ferent groups and stakeholders with conflicting values. One
of these stakeholders is, of course, the alcohol industry.
If policy makers keep these principles in mind, reducing the
alcohol-related health burden could be one of the most cost-
effective targets of population-level health programs in devel-
oping countries. This target is even more attractive because the
measures discussed will also reduce the alcohol-related social
burden, thereby further contributing to development.
NOTES
1. The global burden of disease attributable to alcohol is 4.0 percent
using age-weighted DALYs and 3.6 percent using non-age-weighted
DALYs. This difference can be explained by the many alcohol-attributable
outcomes occurring during adolescence and young adulthood, when age
weights are higher.
2. The CRA defined per capita consumption as average consumption of
pure alcohol per person 15 years old or older.
REFERENCES
Abdool, R. 1998. “Alcohol Policy and Problems in Mauritius.” Paper pre-
pared for the World Health Organization Alcohol Policy in Developing
Societies Project, World Health Organization, Geneva.
Apte, M. V., J. S. Wilson, and M. A. Korsten. 1997. “Alcohol-Related
Pancreatic Damage: Mechanisms and Treatment.” Alcohol Health and
Research World 21 (1): 13–20.
904 | Disease Control Priorities in Developing Countries | Jürgen Rehm, Dan Chisholm, Robin Room, and others
ARRIVE ALIVE Campaign. 2000. “ARRIVE ALIVE Safety Campaign.”
Pretoria: Department of Transport. http://www.transport.gov.za/
projects/arrive/presentation/slide41.htm.
Babor, T., F. Caetano, S. Casswell, G. Edwards, N. Giesbrecht, K. Graham,
and others. 2003. Alcohol: No Ordinary Commodity—A Consumer’s
Guide to Public Policy. Oxford, U.K.: Oxford University Press.
Babor, T. F., and M. Grant, eds. 1992. Project on Identification and
Management of Alcohol-Related Problems: Report on Phase II—A
Randomized Clinical Trial of Brief Interventions in Primary Health Care.
Geneva: World Health Organization, Program on Substance Abuse.
Babor, T. F., M. Grant, W. Acuda, F. H. Burns, C. Campillo, F. K. Del Boco,
and others. 1994. “Randomized Clinical Trial of Brief Interventions
in Primary Health Care: Summary of a WHO Project (with
Commentaries and a Response).” Addiction 89: 657–78.
Bruun, K., G. Edwards, M. Lumio, K. Mäkelä, L. Pan, R. E. Popham,
and others. 1975. Alcohol Control Policies in Public Health Perspective.
Helsinki: Finnish Foundation for Alcohol Studies.
Carlini-Cotrim, B., and A. A. da M. Chasin. 2000. “Blood Alcohol Content
and Death from Fatal Injury: A Study in the Metropolitan Area of São
Paulo, Brazil.” Journal of Psychoactive Drugs 32: 269–75.
Carlini-Cotrim, B., I. Pinsky, and M. T. Serrano Barbosa. 1998. Alcohol
Availability Restrictions in Developing Societies: The Case of São Paulo
Highways, Brazil. Report prepared for the WHO Alcohol Policy in
Developing Societies Project, World Health Organization, Geneva.
Catalyst Health Consultants. 2001. Alcohol Misuse in Scotland: Trends and
Costs—Final Report. Northwort, U.K.: Catalyst Health Consultants.
http://www.scotland.gov.uk/health/alcoholproblems/docs/trco.pdf.
Cerff, P., and A. Plüddemann. 1998. “Brief on the ARRIVE ALIVE
Campaign.” Prepared for the Alcohol Policy in Developing Societies
project. Cape Town, South Africa: Medical Research Council,
Urbanisation, and Health Research Programme.
Chisholm, D., J. Rehm, M. van Ommeren, and M. Monteiro. 2004.
“Reducing the Global Burden of Hazardous Alcohol Use: A
Comparative Cost-Effectiveness Analysis.” Journal of Studies on Alcohol
65 (6): 782–93.
Corrao, G., L. Rubbiati, V. Bagnardi, A. Zambon, and K. Poikolainen. 2000.
“Alcohol and Coronary Heart Disease: A Meta-Analysis.” Addiction 94
(10):1501–23.
Demyttenaere, K., R. Bruffaerts, J. Posada-Villa, I. Gasquet, V. Kovess, J. P.
Lepine, and others. 2004. “Prevalence, Severity, and Unmet Need for
Treatment of Mental Disorders in the World Health Organization
World Mental Health Surveys.” Journal of the American Medical
Association 291 (21): 2581–90.
Drummond, D. C. 1990. “The Relationship between Alcohol Dependence
and Alcohol-Related Problems in a Clinical Population.” British Journal
of Addiction 85 (3): 357–66.
Eckardt, M. J., S. E. File, G. L. Gessa, K. A. Grant, C. Guerri, P. L. Hoffman,
and others. 1998. “Effects of Moderate Alcohol Consumption in the
Central Nervous System.” Alcoholism: Clinical and Experimental
Research 22 (5): 998–1040.
Edwards, G., P. Anderson, T. F. Babor, S. Casswell, R. Ferrence, N.
Giesbrecht, and others. 1994. Alcohol Policy and the Public Good.
Oxford, U.K.: Oxford University Press.
Emanuele, N., and M. A. Emanuele. 1997.“The Endocrine System: Alcohol
Alters Critical Hormonal Balance.” Alcohol Health and Research World
21 (1): 53–64.
English, D. R., C. D. J. Holman, E. Milne, M. Winter, G. K. Hulse, G. Codde,
and others. 1995. The Quantification of Drug Caused Morbidity and
Morality in Australia. Canberra: Commonwealth Department of
Human Services and Health.
Ezzati, M., A. D. Lopez, A. Rodgers, S. Vander Horn, C. J. L. Murray, and
the Comparative Risk Assessment Collaborating Group. 2002.
“Selected Major Risk Factors and Global and Regional Burden of
Disease.” Lancet 360: 1347–60.
Farrell, S., W. G. Manning, and M. D. Finch. 2003. “Alcohol Dependence
and the Price of Alcoholic Beverages.” Journal of Health Economics
22 (1): 117–47.
Fleming, M. F., M. P. Mundt, M. T. French, L. B. Manwell, E. A. Stauffacher,
K. L. Barry, and others. 2000. “Benefit-Cost Analysis of Brief Physician
Advice with Problem Drinkers in Primary Care Settings.” Medical Care
38: 7–18.
Foxcroft, D. R., D. Ireland, D. J. Lister-Sharp, G. Lowe, and R. Breen. 2003.
“Longer-Term Primary Prevention for Alcohol Misuse in Young
People: A Systematic Review.” Addiction 98: 397–411.
Foxcroft, D. R., D. Lister-Sharp, and G. Lowe. 1997. “Alcohol Misuse
Prevention for Young People: A Systematic Review Reveals
Methodological Concerns and Lack of Reliable Evidence of
Effectiveness.” Addiction 92: 531–38.
Gmel, G., E. Gutjahr, and J. Rehm. 2003. “How Stable Is the Risk Curve
between Alcohol and All-Cause Mortality and What Factors Influence
the Shape? A Precision-Weighted Hierarchical Meta-Analysis.”
European Journal of Epidemiology 18 (7): 631–42.
Gmel, G., J. Rehm, and U. Frick. 2003. “Trinkmuster, Pro-Kopf-Konsum
von Alkohol und koronare Mortalität.” Sucht 49 (2): 95–104.
Grant, B. F., D. A. Dawson, F. S. Stinson, S. P. Chou, M. C. Dufour, R. P.
Pickering, and others. 2004. “The 12-Month Prevalence and Trends in
DSM-IV Alcohol Abuse and Dependence: United States, 1991–1992
and 2001–2002.” Drug and Alcohol Dependence 11 (3): 223–34.
Grube, J., and G. Agostinelli. 2000. Alcohol Advertising and Alcohol
Consumption: A Review of Recent Research. Berkeley, CA: Prevention
Research Center.
Gutjahr, E., G. Gmel, and J. Rehm. 2001. “Relation between Average
Alcohol Consumption and Disease: An Overview.” European Addiction
Research 7 (3): 117–27.
Harrison, L., and E. Gardiner. 1999. “Do the Rich Really Die Young?
Alcohol-Related Mortality and Social Class in Great Britain, 1988–94.”
Addiction 94: 1871–80.
Higgins-Biddle, J. C., and T. F. Babor. 1996. Reducing Risky Drinking.
Report prepared for the Robert Wood Johnson Foundation, University
of Connecticut Health Center, Farmington.
Hinkle, L. E., and A. Herrou-Aragon. 2001. “How Far Did Africa’s First
Generation Trade Reforms Go?” World Bank, Washington, DC.
http://www.uesiglo21.edu.ar/pdfs%20dpto%20economia/ES?002?
ECO.pdf.
Isichei, H. U., P. U. Ikwuagu, and J. O. Egbuta. 1993.“Pattern of Alcoholism
in Jos, Nigeria, and Castrop-Rauxel, West Germany: A Comparative
Study.” In Epidemiology and Control of Substance Use in Nigeria, ed. I. S.
Obot, 123–27. Jos, Nigeria: Centre for Research and Information on
Substance Abuse.
Johns, B., R. Baltussen, T. Adam, and R. Hutubessy. 2003. “Programme
Costs in the Economic Evaluation of Health Interventions.”
Cost-Effectiveness and Resource Allocation 1: 1. http://www
.resourceallocation.com.
Klingemann, H., and G. Gmel, eds. 2001. Mapping the Social Consequences
of Alcohol Consumption. Dordrecht, Netherlands: Kluwer Academic
Publishers.
Lauer, J. A., C. J. L. Murray, K. Roehrich, and H. Wirth. 2003. “PopMod: A
Longitudinal Population Model with Two Interacting Disease States.”
Cost Effectiveness and Resource Allocation 1: 6. http://www
.resourceallocation.com.
Lee, V. J. 2001. Tourism and Alcohol in the Developing World: Potential
Effects on Alcohol Policies and Local Drinking Problems. Stockholm:
Stockholm University, Centre for Social Research on Alcohol and
Drugs.
Leppänen, K. 1979. “Valtakunnallisen lauantaisulkemiskokoeilun vaiku-
tuksista alkoholijuomien myyntiin” (Effects of National Saturday
Closing Experiment on Alcohol Sales). Alkoholipolitikka 44: 20–21.
Levy, F., and S. I. Ornstein. 1983. “Price and Income Elasticities and the
Demand for Alcoholic Beverages.” In Recent Developments in
Alcoholism, ed. M. Galanter, 303–45. New York: Plenum.
Liu, B. Q., R. Peto, Z. M. Chen, J. Boreham, Y. P. Wu, J. Y. Li, and others.
1998. “Emerging Tobacco Hazards in China: 1. Retrospective
Proportional Mortality Study of One Million Deaths.” British Medical
Journal 317 (7170): 1411–22.
Ludbrook, A, C. Godfrey, L. Wyness, S. Parrot, S. Haw, M. Napper, and
others. 2002. “Effective and Cost-Effective Measures to Reduce Alcohol
Misuse in Scotland: A Literature Review.” Aberdeen, U.K.: Health
Economics Research Unit.
Mäkelä, P. 1999. “Alcohol-Related Mortality as a Function of Socio-
Economic Status.” Addiction 94: 867–86.
Mathers, C. D., C. Bernard, K. Moesgaard Iburg, M. Inoue, D. Ma Fat, K.
Shibuya, and others. 2003. “Global Burden of Disease in 2002: Data
Sources, Methods and Results.” Global Programme on Evidence
for Health Policy Discussion Paper 54, Geneva, World Health
Organization.
McKee, M., and A. Britton. 1998. “The Positive Relationship between
Alcohol and Heart Disease in Eastern Europe: Potential Physiological
Mechanisms.” Journal Royal Society Medicine 91: 402–7.
Moyer, A., J. W. Finney, C. E. Swearingen, and P. Vergun. 2002. “Brief
Interventions for Alcohol Problems: A Meta-Analytic Review of
Controlled Investigations in Treatment-Seeking and Non-Treatment-
Seeking Populations.” Addiction 97: 279–92.
National Highway Traffic Safety Administration. 1992. “Driving under the
Influence: A Report to Congress on Alcohol Limits.” Washington, DC:
U.S. Department of Transportation.
Nordlund, S. 1984. “Effekten av lørdagsstengningen ved Vinmonopolets
butikker” (Effects of Saturday Closing of the Wine/Liquor Monopoly
Outlets). Alkoholpolitik—Tidsskrift for Nordisk Alkoholforskning 1:
221–29.
Norström, T., and O. J. Skog. 2003. “Saturday Opening of Alcohol Retail
Shops in Sweden: An Impact Analysis.” Journal of Studies on Alcohol 64:
393–401.
Peek-Asa, C. 1999. “The Effect of Random Alcohol Screening in Reducing
Motor Vehicle Crash Injuries.” American Journal of Preventive Medicine
16 (1 Suppl.): 57–67.
Puddey, I. B., V. Rakic, S. B. Dimmitt, and L. J. Beilin. 1999. “Influence
of Drinking on Cardiovascular Disease and Cardiovascular Risk
Factors—A Review.” Addiction 94: 649–63.
Rehm, J., G. Gmel, C. T. Sempos, and M. Trevisan. 2003. “Alcohol-Related
Mortality and Morbidity.” Alcohol Research and Health 27 (1): 39–51.
Rehm, J., E. Gutjahr, and G. Gmel. 2001.“Alcohol and All-Cause Mortality:
A Pooled Analysis.” Contemporary Drug Problems 28: 337–61.
Rehm, J., N. Rehn, R. Room, M. Monteiro, G. Gmel, D. Jernigan, and U.
Frick. 2003. “The Global Distribution of Average Volume of Alcohol
Consumption and Patterns of Drinking.” European Addiction Research
9 (4): 147–56.
Rehm, J., R. Room, K. Graham, M. Monteiro, G. Gmel, and C. T. Sempos.
2003. “The Relationship of Average Volume of Alcohol Consumption
and Patterns of Drinking to Burden of Disease: An Overview.”
Addiction 98 (10): 1209–28.
Rehm, J., R. Room, M. Monteiro, G. Gmel, K. Graham, N. Rehn, and oth-
ers. 2003. “Alcohol as a Risk Factor for Global Burden of Disease.”
European Addiction Research 9 (4):157–64.
Rehm, J., R. Room, M. Monteiro, G. Gmel, K. Graham, T. Rehn, and oth-
ers. 2004. “Alcohol.” In Comparative Quantification of Health Risks:
Global and Regional Burden of Disease Due to Selected Major Risk
Factors, ed. M. Ezzati, A. D. Lopez, A. Rodgers, and C. J. L. Murray,
959–1108. Geneva: World Health Organization.
Rehm, J., C. T. Sempos, and M. Trevisan. 2003.“Average Volume of Alcohol
Consumption, Patterns of Drinking, and Risk of Coronary Heart
Disease: A Review.” Journal of Cardiovascular Risk 10 (1): 15–20.
Ridolfo, B., and C. Stevenson. 2001. The Quantification of Drug-Caused
Mortality and Morbidity in Australia 1998. Canberra: Australian
Institute of Health and Welfare.
Room, R., T. Babor, and J. Rehm. 2005. “Alcohol and Public Health: A
Review.” Lancet 365 (February 5): 519–30.
Room, R., K. Graham, J. Rehm, D. Jernigan, and M. Monteiro. 2003.
“Drinking and Its Burden in a Global Perspective: Policy Considerations
and Options.” European Addiction Research 9 (4): 165–75.
Room, R., A. Janca, L. A. Bennett, L. Schmidt, N. Sartorius, and others.
1996. “WHO Cross-Cultural Applicability Research on Diagnosis
and Assessment of Substance Use Disorders: An Overview of Methods
and Selected Results.” Addiction 91 (2): 199–220.
Room, R., D. Jernigan, B. Carlini-Marlatt, O. Gureje, K. Mäkelä, M.
Marshall, and others. 2002. Alcohol in Developing Societies: A Public
Health Approach. Helsinki: Finnish Foundation for Alcohol Studies.
Saffer, H. 2000. “Alcohol Consumption and Alcohol Advertising Bans.”
NBER Working Paper 7758, National Bureau of Economic Research,
Cambridge, MA.
Saffer, H., and D. Dave. 2002. “Alcohol Consumption and Alcohol
Advertising Bans.” Applied Economics 34 (11): 1325–34.
Saunders, J. B., and O. G. Aasland. 1987. WHO Collaborative Project on
Identification and Treatment of Persons with Harmful Alcohol
Consumption. WHO/MNH/DAT 86.3. Geneva: World Health
Organization.
Schmidt, L., and R. Room. 1999. “Cross-Cultural Applicability in
International Classifications and Research on Alcohol Dependence.”
Journal of Studies on Alcohol 60: 448–62.
Shults, R. A, R. W. Elder, D. A. Sleet, J. L. Nichols, M. O. Alao, V. G.
Carande-Kulis, and others. 2001. “Reviews of Evidence Regarding
Interventions to Reduce Alcohol-Impaired Driving.” American Journal
of Preventive Medicine 21 (Suppl. 4): 66–88.
Single, E., L. Robson, J. Rehm, and X. Xie. 1999. “Morbidity and Mortality
Attributable to Alcohol, Tobacco, and Illicit Drug Use in Canada.”
American Journal of Public Health 89 (3): 385–90.
Single, E., L. Robson, X. Xie, and J. Rehm. 1996. The Cost of Substance
Abuse in Canada. Ottawa: Canadian Centre on Substance Abuse.
Sobell, L. C., T. P. Ellingstad, and M. B. Sobell. 2000. “Natural Recovery
from Alcohol and Drug Problems: Methodological Review of the
Research with Suggestions for Future Directions.” Addiction 95:
749–64.
Stouthard, M. E., M. L. Essink-Bot, and G. L. Bonsel. 2000. “On Behalf of
the Dutch Disability Weights Group: Disability Weights for Diseases—
A Modified Protocol and Results for a Western European Region.”
European Journal of Public Health 10: 24–30.
Tax Policy Chief Directorate. 2002. The Taxation of Alcoholic Beverages in
South Africa and Its Impact on the Consumption Levels of Alcoholic
Beverages. Pretoria: National Treasury.
U.S. Department of State. 1999.“Mauritius: 1999–2000 Budget Increased.”
U.S. Department of State, Washington, DC. http://www.tradeport.org/
ts/countries/mauritius/mrr/mark0003.html.
Wallace, S., and R. Bird. 2003. “Taxing Alcohol in Africa: Reflections from
International Experience.” Paper presented at the South Africa
Conference on Excise Taxation, June 11–13, Gauteng, South Africa.
http://www.iticnet.org/030707-PRESENTATION_Bird.pdf.
Whitlock, E. P., M. R. Polen, C. A. Green, T. Orleans, and J. Klein. 2004.
“Behavioral Counseling Interventions in Primary Care to Reduce
Alcohol | 905
Risky/Harmful Alcohol Use by Adults: A Summary of the Evidence for
the U.S. Preventive Services Task Force.” Annals of Internal Medicine
140: 557–68.
WHO (World Health Organization). 1993. The ICD-10 Classification
of Mental and Behavioral Disorders: Diagnostic Criteria for Research.
Geneva: WHO.
———. 1999. Global Status Report on Alcohol. WHO/HSC/SAB/99.11.
Geneva: WHO, Substance Abuse Department.
———. 2000. 1997–1999 World Health Statistics Annual. Geneva: WHO.
http://www.who.int/whosis/.
———. 2002. World Health Report 2002: Reducing Risks, Promoting
Healthy Life. Geneva: WHO.
———. 2003a. “Burden of Disease Project.” WHO, Geneva. http://
www.who.int/evidence/bod.
———. 2003b. “WHO Global Alcohol Database.” WHO, Geneva.
http://www3.who.int/whosis/alcohol.
WHO Brief Intervention Study Group. 1996. “A Cross-National Trial of
Brief Interventions with High Risk Drinkers.” American Journal of
Public Health 86: 948–55.
Zakhari, S. 1997. “Alcohol and the Cardiovascular System: Molecular
Mechanisms for Beneficial and Harmful Action.” Alcohol Health and
Research World 21 (1): 21–29.
906 | Disease Control Priorities in Developing Countries | Jürgen Rehm, Dan Chisholm, Robin Room, and others
907
Illicit drugs are those banned by international drug control
treaties. They include cannabis products (for example, mari-
juana, hashish, and bhang); stimulant drugs (such as cocaine
and methamphetamine); so-called dance-party drugs (such as
3, 4-methylenedioxymethamphetamine, also known as ecstasy
or MDMA); and illicit opioids (for instance, heroin and
opium) and diverted pharmaceutical opioids (such as
buprenorphine, methadone, and morphine) (see annex 48.A).
Worldwide, 185 million people were estimated to have used
illicit drugs during 1998–2002 (UNODC 2004; UNODCCP
2002). Cannabis was the most widely used illicit drug, with
146.2 million users in 2002, or 3.7 percent of the global
population over age 15. The stimulant drugs were the next
most widely used illicit drugs: 29.6 million people worldwide
used amphetamines; 13.3 million used cocaine; and 8.3 million
used ecstasy. An estimated 15.3 million, or 0.4 percent of the
world population age 15 to 64, used illicit opioids; more than
half used heroin and the remainder used opium or diverted
pharmaceutical opioids. Illicit opioids continue to be the major
illicit drug problem in most regions of the world in terms of
impact on public health and public order (UNODC 2004).
Even though cannabis use accounts for about 80 percent of
illicit drug use worldwide, the mortality and morbidity attrib-
utable to its use are not well understood, even in developed
countries (W. Hall and Pacula 2003; Macleod and others 2004;
WHO Programme on Substance Abuse 1997). The same is true
of the morbidity and mortality attributable to cocaine and
amphetamine-type stimulants (Macleod and others 2004).
Dance-party drugs have been used for too short a time in most
developed societies to enable a good assessment of their poten-
tial for harm (Boot, McGregor, and Hall 2000; Macleod and
others 2004). The remainder of this chapter is concerned with
disease control priorities for illicit opioid dependence, because
dependent users account for most of the illicit opioids con-
sumed and experience most of the harm such dependence
causes (W. Hall, Degenhardt, and Lynskey 1999).
NATURE, CAUSES, AND HEALTH CONSEQUENCES
OF ILLICIT OPIOID USE 
Before considering interventions, we briefly summarize what is
known about the antecedents, causes, and health consequences
of illicit opioid use.
Antecedents of Heroin Use
Law enforcement efforts to reduce the availability of heroin
aim to increase its price, deter illicit drug use, and promote
social values that discourage heroin use (Fergusson, Horwood,
and Lynskey 1998; Hawkins, Catalano, and Miller 1992;
Newcomb and Bentler 1988). These gains may be at the cost of
increasing harm among the minority who use opioids despite
the prohibition—for example, by encouraging injecting use as
the most efficient way to use an expensive drug and increasing
needle sharing because clean injecting equipment is not freely
available (Rhodes and others 2003; Strathdee and others 2003).
Two aspects of the family environment are associated with
increased rates of both licit and illicit drug use in young people
in developed countries. The first is exposure to a disadvantaged
home environment, with parental conflict and poor discipline
and supervision; the second is exposure to parents’ and sib-
lings’ use of alcohol and other drugs (Hawkins, Catalano, and
Miller 1992). In developed countries, children who perform
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poorly in school because of impulsive or problem behavior and
those who are early users of alcohol and other drugs are most
likely to use illicit opioids (Fergusson, Horwood, and Swain-
Campbell 2002). Affiliation with drug-using peers is a risk fac-
tor for drug use that operates independently of individual and
family risk factors (Fergusson, Horwood, and Lynskey 1998;
Hawkins, Catalano, and Miller 1992).
Health Consequences of Heroin Use
The following sections describe the major health consequences
of heroin use. They include dependence, increased mortality
and morbidity attributable to drug overdoses, and bloodborne
viruses.
Heroin Dependence. In household surveys, 1 to 2 percent of
adults in Australia, the United States, and Europe report using
heroin at some time in their lives (Australian Institute of
Health and Welfare 1999; EMCDDA 2002; SAMHSA 2002).
The highest rates are typically among adults age 20 to 29. Self-
reported heroin use in population surveys probably underesti-
mates rates of use because heroin users are undersampled and
those who are sampled underreport their use (W. Hall, Lynskey,
and Degenhardt 1999).
In developed countries, one in four of those who report
heroin use become dependent on it (Anthony, Warner, and
Kessler 1994). People who are heroin dependent continue to
use heroin in the face of problems that they know (or believe)
to be caused by its use. These problems include being arrested
or imprisoned, having interpersonal and family problems,
catching infectious diseases, and suffering from drug over-
doses. Many heroin users who seek treatment have typically
been daily heroin injectors, although in Europe (EMCDDA
2002), North America (Office of National Drug Control Policy
2001), and parts of Asia, illicit opioid users also smoke or
“chase” the drug (inhale the fumes released when heroin is
heated) (UNODC 2004).
The American Psychiatric Association defines drug depend-
ence as “a cluster of cognitive, behavioral, and physiologic
symptoms indicating that the individual continues use of the
substance despite significant substance-related problems”
(American Psychiatric Association 1994, 176). In the fourth
edition of the association’s Diagnostic and Statistical Manual of
Mental Disorders (1994,), a diagnosis of substance dependence
requires that three or more of the following occur together:
At any time in the same 12-month period:
1. tolerance, as defined by either of the following:
a. need for markedly increased amounts of the substance
to achieve intoxication or desired effect
b. markedly diminished effect with continued use of the
same amount of the substance;
2. withdrawal, as manifested by either of the following:
a. the characteristic withdrawal syndrome for the
substance 
b. the same (or closely related) substance is taken to relieve
or avoid withdrawal symptoms;
3. the substance is often taken in larger amounts or over a
longer period than was intended;
4. there is a persistent desire or unsuccessful efforts to cut
down or control substance use;
5. a great deal of time is spent in activities necessary to obtain
the substance (e.g., visiting multiple doctors, driving long
distances), use the substance (e.g., chain smoking), or
recover from its effects;
6. important social, occupational, or recreational activities are
given up or reduced because of substance use;
7. the substance use is continued despite knowledge of having
a persistent or recurrent physical or psychological problem
that is likely to have been caused or exacerbated by the
substance.
Indirect estimation methods suggest that in Australia, the
United Kingdom, and the European Union fewer than 1 per-
cent of adults age 15 to 54 are heroin dependent (EMCDDA
2002; W. Hall and others 2000). Research in the United States
indicates that dependent heroin users who seek treatment or
who come to the attention of the legal system may use heroin
for decades (Goldstein and Herrera 1995; Hser, Anglin, and
Powers 1993), with periods of use punctuated by abstinence
(Bruneau and others 2004; Galai and others 2003), drug treat-
ment, and imprisonment (Gerstein and Harwood 1990). When
periods of abstinence are included, dependent heroin users use
heroin daily for 40 to 60 percent of the 20 years that they typi-
cally are addicts (Ball, Shaffer, and Nurco 1983; Maddux and
Desmond 1992).
Illicit opioid use increased in Asia, Europe, and Oceania
and, to a lesser extent, in Africa and South America in the
1990s, but it has stabilized or declined since 2000 (UNODC
2004). Most illicit opioid users (7.8 million) live in Asian coun-
tries that surround the major opium-producing countries,
Afghanistan and Myanmar. Europe accounts for about 25 per-
cent of illicit opioid use (4 million users or 0.8 percent of the
adult population age 15 to 64). Two-thirds of users are in
Eastern Europe, which reported large increases in illicit opioid
use during the second half of the 1990s (Atlani and others
2000; Hamers and Downs 2003; Kelly and Amirkhanian 2003;
Rhodes and others 1999; Uuskula and others 2002).
Illicit opioid use stabilized in much of Asia between 2000 and
2002 (UNODC 2004) as a result of decreased opium production
after the rapid expansion during the 1990s (Dorabjee and
Samson 2000; Reid and Crofts 2000). After 2000, India and
Pakistan reported stabilizing rates of illicit opioid use but
increased injection of pharmaceutical opiates (Ahmed and
others 2003; Dorabjee and Samson 2000; Strathdee and others
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2003). China has reported a steady rate of growth in illicit opiate
use in its southern and northern provinces (Beyrer 2003; Beyrer
and others 2000; Yu and others 1998) and a 15-fold increase in
the number of registered opioid addicts between 1990 and 2002,
bringing the total to about 1 million (UNODC 2004).
Oceania experienced a marked rise in heroin use in the late
1990s, largely driven by a dramatic increase in the availability of
heroin in Australia (Darke, Topp, and others 2002; W. Hall,
Degenhardt, and Lynskey 1999). In late 2000, an abrupt heroin
shortage resulted in a large reduction in fatal and nonfatal
overdoses (Day and others 2004; Degenhardt, Day, and Hall
2004).
Mortality, Morbidity, and Heroin Dependence. In developed
countries, dependent heroin users have an increased risk of
premature death from drug overdoses, violence, suicide,
and alcohol-related causes (Darke and Ross 2002; Goldstein
and Herrera 1995; Vlahov and others 2004). Heroin users
treated before the HIV epidemic were 13 times more likely to
die prematurely than their peers (Hulse and others 1999), with
opioid overdose the most frequent cause of death (W. Hall,
Degenhardt, and Lynskey 1999). In countries with a high
prevalence of HIV infection, AIDS is a major cause of prema-
ture death among drug users (EMCDDA 2002; UNAIDS and
WHO 2002). Fatal opioid overdose deaths increased in many
developed countries during the 1990s before declining after
2000 (UNODC 2004).
In parts of Asia, Eastern Europe, and the United States, the
sharing of contaminated injecting equipment accounts for a
substantial proportion of new HIV infections (EMCDDA
2002; UNAIDS and WHO 2002; UNODC 2004). Injecting
opioid use has been a major driver of HIV epidemics in China
(Yu and others 1998), Myanmar (Beyrer and others 2000), the
Russian Federation and former Soviet republics (Hamers and
Downs 2003), and Vietnam (Beyrer and others 2000; Hien
and others 2001).
The prevalence of infection with hepatitis B and C viruses
among injecting drug users is greater than 60 percent in
Australia (National Centre in HIV Epidemiology and Clinical
Research 1998), Canada (Fischer and others 2004), China
(Ruan and others 2004), the United States (Fuller and others
2004), and the European Union (EMCDDA 2002). Chronic
infection occurs in 75 percent of infections, and 3 to 11 percent
of chronic hepatitis C virus carriers develop liver cirrhosis
within 20 years (Hepatitis C Virus Projections Working Group
1998).
Heroin-related deaths primarily occur among young adults
and account for a large number of life years lost in developed
societies. In Australia in 1996, for example, such deaths
accounted for 2.2 percent of life years lost, with each death
accounting for 22 years of life lost (Mathers, Vos, and
Stephenson 1999). In Scotland and Spain, opiate-related deaths
account for 25 to 33 percent of deaths of young adult males
(EMCDDA 2002).
Economic Costs of Illicit Opioid Use. In Canada, Xie and
others (1996) calculate the costs of illicit drugs as 0.2 percent
of gross domestic product (GDP). In Australia, Collins and
Lapsley (1996) estimate the economic costs of illicit drug abuse
at 2 percent of GDP.
CONTRIBUTION OF OPIOID DEPENDENCE 
TO THE GLOBAL BURDEN OF DISEASE
Degenhardt, Hall, and others (2004) estimate the contribution
of illicit opioid dependence to the global burden of disease
using data on deaths caused by opioid and other drug over-
doses, suicides and accidents, and HIV/AIDS. When estimates
of morbidity attributable to illicit drug use were added in, illicit
opioid use accounted for 0.7 percent of global disability-
adjusted life years (DALYs) in 2000 (WHO 2003).
These estimates suggest that illicit opioid use is a significant
global cause of premature mortality and disability among
young adults. Even so, they probably underestimate the disease
burden attributable to illicit opioids, because they omit differ-
ences across subregions in the quality of data on causes of mor-
tality and estimates of mortality and morbidity attributable to
hepatitis and violence (Degenhardt, Hall, and others 2004).
INTERVENTIONS FOR ILLICIT OPIOID
DEPENDENCE
Methods adopted to control the problems arising from illicit
opioid dependence include source-country control; interdic-
tion of supply into end-use countries; enforcement by the
police force and the criminal justice system of legal prohibi-
tions on the supply, possession, and use of opioids; treatment
of those who are opioid dependent, both voluntarily and under
legal coercion from the criminal justice system; school-based
and mass media preventive educational programs; and regula-
tory policies restricting the prescription of opioids (Manski,
Pepper, and Petrie 2001).
Prevention of Heroin Use 
Countries use a variety of interventions in attempts to prevent
the initiation of use of illicit drugs such as cannabis (Manski,
Pepper, and Petrie 2001; Spooner and Hall 2002), in the belief
that early initiation of cannabis use leads to an increased
risk of using illicit opioids (Fergusson, Horwood, and 
Swain-Campbell 2002). These interventions include legal pro-
hibitions on the manufacture, sale, and use of opioid drugs
for nonmedical purposes; enforcement of these sanctions by
law enforcement officials by means of fines and imprisonment;
and enforcement of restrictions on medically prescribed opi-
oids to prevent their diversion (Manski, Pepper, and Petrie
2001). Preventive measures also include mass media and
school-based educational campaigns about the health risks of
opioid and other illicit drug use (Spooner and Hall 2002). It is
unclear how effective these interventions are in preventing
cannabis use and even less clear whether they reduce the initia-
tion of opioids (Caulkins and others 1999; Manski, Pepper, and
Petrie 2001).
The most popular interventions against illicit opioid use in
many developed societies have been the interdiction of drug
supply and the enforcement of legal sanctions against the pos-
session, use, and sale of opioid drugs (Manski, Pepper, and
Petrie 2001). As a consequence, imprisonment is the most com-
mon intervention to which many illicit opioid users have been
exposed (Gerstein and Harwood 1990). In Asia and Eastern
Europe, high rates of imprisonment of drug users have been a
factor in HIV transmission, because drug users engage in high-
risk injecting while imprisoned (Beyrer and others 2000).
Interventions to Reduce Heroin-Related Harm 
The most effective intervention to reduce bloodborne virus
infection arising from illicit injecting of opioids and other
drugs is the provision of clean injecting equipment to reduce
users’ risks of contracting or transmitting bloodborne viruses.
This intervention has been widely supported in most developed
countries, but it has been incompletely adopted in developing
countries that have problems with the concept of facilitating
the injection of illicit drugs (UNAIDS and WHO 2002). Vac-
cinations are available against hepatitis B but not hepatitis C.
These important interventions are covered in chapter 18.
A number of strategies can potentially reduce deaths from
opioid overdoses (Darke and Hall 2003; Sporer 2003). First,
injecting drug users can be educated about the dangers of com-
bining the use of opioids with alcohol and benzodiazepines
(McGregor and others 2001), both of which heighten the risk
of a fatal opioid overdose (Darke and Zador 1996; Warner-
Smith and others 2001). Heroin users also need to be discour-
aged from injecting in the streets or alone, thereby denying
themselves assistance in the event of an overdose. These inter-
ventions have yet to be evaluated.
A second strategy is to encourage drug users who witness
overdoses to seek medical assistance and to use simple resusci-
tation techniques until help arrives. A more controversial
option is to distribute the opioid antagonist naloxone to high-
risk heroin users (Darke and Hall 1997; Strang and others
1996). Neither of these interventions has been evaluated.
A third strategy is to provide supervised injecting facilities
in areas with high rates of injecting opioid use (Dolan and
others 2000; Kimber and others 2003). Supervised injecting
facilities have been introduced in Germany, the Netherlands,
and Switzerland (Dolan and others 2000; Kimber and others
2003), but their effect on overdose deaths has not been rigor-
ously evaluated to date. A supervised injecting facility was eval-
uated in Australia, but the evaluation was limited by the con-
current onset of a heroin shortage that resulted in a 40 percent
decline in overdose deaths (Kaldor and others 2003).
A fourth strategy is to increase methadone maintenance
among older, high-risk opioid-dependent people, because indi-
viduals enrolled in methadone maintenance treatment (MMT)
are substantially less likely to suffer from a fatal overdose
(Caplehorn and others 1994; Gearing and Schweitzer 1974;
Langendam and others 2001).
Treatment Interventions for Dependent Opioid Users
The range of treatment interventions includes voluntary pro-
grams such as detoxification, abstinence-oriented treatments,
and oral Methadone maintenance treatment, as well as invol-
untary options imposed by criminal justice systems.
Detoxification. Detoxification is supervised withdrawal from
a drug of dependence that attempts to minimize withdrawal
symptoms. It is not a treatment for heroin dependence; it
provides a respite from opioid use and may be a prelude to
abstinence-based treatment (Mattick and Hall 1996).
Naltrexone is a longer-acting opiate antagonist than nalox-
one; it can be used to accelerate the opioid withdrawal process.
Ultra-rapid opioid detoxification accelerates withdrawal by
giving the patient naltrexone under general anesthetic. There is
no evidence that accelerated withdrawal in itself reduces the
high rate of relapse to heroin use in the absence of further
treatment (W. Hall and Mattick 2000).
Abstinence-Oriented Treatments. Abstinence-oriented treat-
ments aim to achieve enduring abstinence from all opioid
drugs by providing some type of intervention after withdrawal
to reduce the high rate of relapse to opioids (Mattick and Hall
1996). The interventions may include social and psychological
support only or such support supplemented by pharmacologi-
cal methods.
Residential treatment in therapeutic communities and out-
patient drug counseling may entail encouraging patients to
become involved in self-help groups such as Narcotics
Anonymous. These approaches share a commitment to achiev-
ing abstinence from all opioids, using group and psychological
interventions to help dependent heroin users remain abstinent.
Therapeutic communities and drug counseling are usually pro-
vided through specialist addiction or mental health services.
The former are residential, and the latter are provided on an
outpatient basis.
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No randomized controlled trials of therapeutic communi-
ties or outpatient drug counseling have been carried out.
Observational studies in the United Kingdom (Gossop,
Marsden, and Stewart 1998; Gossop and others 1997) and the
United States (Hubbard and others 1989; Simpson and Sells
1982) have found that therapeutic communities and drug
counseling were less successful than MMT in attracting and
retaining dependent heroin users, but they substantially
reduced heroin use and crime among those who remained in
treatment for at least three months (Gerstein and Harwood
1990; Gossop, Marsden, and Stewart 1998; Gossop and others
1997). Some evidence indicated that therapeutic communities
may be more effective if they are used in combination with
legal coercion to ensure that heroin users are retained in treat-
ment long enough to benefit from it (Gerstein and Harwood
1990).
Recovering drug users run Narcotics Anonymous groups
using an adaptation of the 12-step philosophy of Alcoholics
Anonymous. Some individuals use these groups as their sole
form of support for abstinence, whereas for others these groups
complement therapeutic communities that are based on the
same principles. Such groups are usually not open to people
who are in opioid substitution treatment programs.
The most extensive research on self-help has been in the
treatment of alcohol dependence. Treated alcoholics who par-
ticipate in Alcoholics Anonymous groups have higher rates of
abstinence than those who do not (see, for example, Tonigan,
Connors, and Miller 2003; Tonigan, Toscova, and Miller 1996).
The good outcome in those who attend Alcoholics Anonymous
meetings may reflect the self-selection of motivated partici-
pants into self-help groups. Recent studies that have attempted
to control for this possibility using sophisticated statistical
methods have produced mixed results, with some showing the
persistence of an effect of self-help after correction (Tonigan,
Connors, and Miller 2003) while others do not (Fortney and
others 1998).
Shepard and others (forthcoming) evaluate the effect of self-
help participation on substance abuse 24 months after treat-
ment for members of a mixed population of substance abusers
treated at two treatment facilities in the United States, some of
whom had problems with heroin. They find that participation
in self-help groups was associated with longer abstinence from
all drugs. Correction for self-selection did not eliminate the
association in one treatment setting, but it made the results
much more equivocal in the other.
Oral Methadone Maintenance Treatment. This treatment
substitutes a long-acting, orally administered opioid for the
shorter-acting heroin, with the aim of stabilizing dependent
heroin users so that they are amenable to rehabilitation (Marsh
and others 1990; Ward, Hall, and Mattick 1998). When given in
high or blockade doses, methadone blocks the euphoric effects
of injected heroin, allowing the individual to take advantage of
psychotherapeutic and rehabilitative services.
Every one of the small number of randomized controlled
trials of MMT compared with placebo or no treatment has
produced positive results (W. Hall, Ward, and Mattick 1998;
Mattick and others 2003). Large observational studies show
that MMT decreases heroin use and criminal activity and
reduces HIV transmission while patients remain in treatment
(Gerstein and Harwood 1990; Simpson and Sells 1990; Ward,
Hall, and Mattick 1998). MMT is the best-supported form of
opioid maintenance treatment (Farre and others 2002; Marsch
1998; Mattick and others 2003).
Buprenorphine is a mixed agonist-antagonist that also
blocks the effects of heroin. When given in high doses, its
effects can last for up to three days, while its antagonist effects
substantially reduce overdose and abuse (Oliveto and Kosten
1997; Ward, Hall, and Mattick 1998). Meta-analyses have found
that buprenorphine is effective in the treatment of heroin
dependence (Mattick and others 2003) and is of equivalent effi-
cacy to MMT when delivered in primary health care and spe-
cialist treatment settings in Australia (Gibson and others 2003).
Bammer and others (2003) have proposed injectable heroin
maintenance as a way of attracting into treatment those heroin
users who are not interested in or have failed to respond to
MMT. This method has recently been evaluated in the
Netherlands (Central Committee on the Treatment of Heroin
Addicts 2002) and Switzerland (Perneger and others 1998;
Uchtenhagen, Gutzwiller, and Dobler-Mikola 1998). Perneger
and others (1998) report a randomized controlled trial of
injectable heroin maintenance in people who had failed at
MMT. Stabilizing and safely maintaining heroin addicts on
injectable heroin (self-administered on-site in a comprehensive
health and social service) proved feasible for six months and
substantially improved their health and social well-being. The
Swiss trials showed that it was possible to maintain opioid
addicts on injectable heroin for up to two years (Rehm and
others 2001; Uchtenhagen, Gutzwiller, and Dobler-Mikola
1998). A recent randomized controlled trial in the Netherlands
(Central Committee on the Treatment of Heroin Addicts 2002)
confirms the findings of Perneger and others (1998).
Criminal Justice Interventions for Dependent Illicit Opioid
Users. The most common intervention for illicit opioid
dependence in most developed societies is imprisonment
(EMCDDA 2003; Gerstein and Harwood 1990). Imprisonment
is not intended to be a health intervention. Nonetheless, it is an
ineffective way of reducing opioid dependence, when judged
by the high recidivism in longitudinal studies of dependent
heroin users (see, for example, Hser, Anglin, and Powers 1993;
Manski, Pepper, and Petrie 2001).
Legally coerced treatment is treatment that is legally forced
on those who have been charged with or convicted of an
offense to which their drug dependence has contributed
(W. Hall 1997). It is most often provided as an alternative to
imprisonment, under the threat of imprisonment if the person
fails to comply with the treatment (W. Hall 1997; Manski,
Pepper, and Petrie 2001; Spooner, Hall, and Mattick 2001). Its
major justification is that it is an effective way of treating
offenders’ drug dependence that reduces the likelihood of their
offending again (Gerstein and Harwood 1990). A consensus
view prepared for the World Health Organization (WHO)
(Porter, Arif, and Curran 1986) was that compulsory treatment
was legally and ethically justified only if the rights of the
individuals were protected by due process and if the treatment
provided was effective and humane.
Research into the effectiveness of legally coerced treatment
for opioid dependence has been limited to observational studies
(W. Hall 1997; Manski, Pepper, and Petrie 2001; Wild, Roberts,
and Cooper 2002). Anglin’s (1988) quasi-experimental studies
of the California Civil Addict Program provide the strongest
evidence of efficacy. These studies compared heroin-dependent
offenders who entered the program between 1962 and 1964
with a group of similar offenders who went through the crimi-
nal justice system during the same period. They found that com-
pulsory hospital treatment followed by close supervision in the
community substantially reduced heroin use and crime.
The effectiveness of less coercive forms of treatment has
been supported by analyses of the effectiveness of community-
based treatment provided while on probation or parole
(Hubbard and others 1989; Simpson and others 1986). These
studies showed that individuals who entered community-based
therapeutic communities and drug-free outpatient counseling
under legal pressure did as well as those who did so voluntarily
(Hubbard and others 1988; Simpson and Friend 1988). The
recent creation of specialized drug courts in the United States to
process those arrested for drug-related offenses awaits rigorous
evaluation (Belenko 2002; Manski, Pepper, and Petrie 2001).
Legally coerced MMT is also effective. The strongest
evidence comes from a study in which drug offenders were ran-
domly assigned to parole with and without community-based
MMT (Dole and others 1969). This study showed a greater
reduction in heroin use and lower rates of incarceration among
those enrolled in MMT in the year following their release from
prison. These findings are supported by observational studies
that found no major differences in response to MMT between
those who enrolled under legal coercion and those who did not
(Anglin, Brecht, and Maddahain 1989; Brecht, Anglin, and
Wang 1993; Hubbard and others 1988).
Economic Evaluations of Interventions for Illicit
Opioid Dependence
The few published economic evaluations of treatment inter-
ventions for illicit opioid dependence indicate varying levels of
cost-effectiveness.
Detoxification. The National Evaluation of Pharma-
cotherapies for Opioid Dependence Project in Australia con-
ducted a cost-effectiveness analysis of five interventions:
• naltrexone-induced rapid opioid detoxification under
anesthesia
• naltrexone-induced rapid opioid detoxification under
sedation 
• conventional inpatient detoxification 
• conventional outpatient detoxification 
• buprenorphine outpatient detoxification.
A successful outcome was defined as achieving abstinence
from heroin for one week (Mattick and others 2001).
Rapid detoxification under sedation was the most cost-
effective method of detoxification (US$2,355 for one week of
abstinence) and conventional outpatient detoxification the least
cost-effective (US$12,031). Rapid detoxification under anesthe-
sia achieved high rates of abstinence in the first week, but its
expense reduced its cost-effectiveness (Mattick and others
2001).
Doran and others (2003) compared the cost-effectiveness of
detoxification from heroin using buprenorphine in a specialist
Australian clinic and in a shared care setting. They conducted
a randomized controlled trial with 115 heroin-dependent
patients receiving a five-day treatment regime of buprenor-
phine. The specialist clinic was a community-based treatment
agency in Sydney. Shared care involved treatment by a general
practitioner, supplemented by weekend dispensing and some
counseling at the specialist clinic. They estimate that buprenor-
phine detoxification in the shared care setting was US$17 more
expensive per patient than the costs of treatment at the clinic
(US$236 per patient).
Drug-Free Treatment. The limited economic evaluations of
drug-free treatment have used data from observational studies
of treatment outcomes in samples of patients who have mixed
substance abuse problems that include opioids. For example,
Shepard, Larson, and Hoffmann (1999) calculate a range of
estimated costs for achieving an abstinent year in 408 patients
at two different treatment facilities in the United States. The
cost-effectiveness depended on the severity of the problem and
the intensiveness and cost of the intervention. For outpatients
with the least severe drug problems, the cost of an abstinent
year was US$7,000, whereas the same outcome in patients with
more severe problems who received long-term residential treat-
ment cost US$20,000.
Shepard and others (forthcoming) use these data to esti-
mate the cost-effectiveness of involvement in mutual self-
help groups, such as Alcoholics Anonymous and Narcotics
Anonymous, in sustaining abstinence for up to 24 months after
treatment. They find a positive association between self-help
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involvement and abstinence 12 and 24 months after treat-
ment. Applying statistical methods to correct for the effects of
self-selection into self-help, they find that in a Veterans
Administration hospital, the effects of self-help on abstinence
persisted after the statistical correction, but at the other site, the
results depended on the method of analysis that was used. They
estimate the cost of achieving an abstinent year by means of
self-help in the year following treatment at US$13,000, all of
that due to the costs that participants incurred in attending
a group.
Oral Opioid Maintenance Treatment. Goldschmidt’s (1976)
economic evaluation of MMT found that it was as effective
as a therapeutic community intervention and twice as cost-
effective. Cartwright’s (2000) review of the literature since 1976
identified a number of studies, all of which reported positive
benefit-cost ratios for MMT.
Gerstein, Harwood, and Suter’s (1994) California Drug and
Alcohol Treatment Assessment study is the most comprehen-
sive cost-benefit analysis carried out to date. The authors exam-
ine the effects of treatment—residential programs, outpatient
programs, and methadone programs—on alcohol and drug
use, criminal activity, health and health care utilization, and
source of income. For each treatment modality, they found that
the benefits during the first year of treatment significantly
exceeded the cost of delivering the care. The benefit-cost ratio
was 4.8 for residential treatment and 11.0 and 12.6 for outpa-
tients and discharged methadone participants, respectively.
Doran and others (2003) compared the cost-effectiveness
of buprenorphine and methadone treatment for opioid
dependence. In a randomized controlled trial, 405 subjects
were randomly assigned to each treatment at one of three
specialist outpatient drug treatment centers. The study found
that treatment with methadone was less expensive and more
effective than treatment with buprenorphine, but the differ-
ence in cost (US$143 per additional heroin-free day gained)
had a wide range of uncertainty around it (US$1,469 to
US$1,284).
The National Evaluation of Pharmacotherapies for Opioid
Dependence Project also provided a cost-effectiveness analysis
of methadone, buprenorphine, LAAM (levo-alpha-acetyl-
methadol), and naltrexone maintenance treatments (Mattick
and others 2001). The daily costs of these maintenance treat-
ments were similar for methadone and LAAM, but naltrexone
was slightly more expensive. Buprenorphine maintenance
treatment (BMT) was more expensive, but its cost-efficiency
could have been improved to make its cost similar to that for
the other treatments. MMT was the most cost-effective treat-
ment for opioid dependence because it achieved one of the
highest rates of retention in treatment among the four phar-
macotherapies examined. Naltrexone treatment was the least
cost-effective.
The costs of injectable heroin maintenance in the Dutch
study was between US$18,015 and US$23,243 per patient per
year (Bammer and others 2003). Most of the costs arose from
the supervision of heroin use and the security required to pre-
vent the diversion of heroin to the black market. Injectable
heroin maintenance needs to produce substantially greater
benefits for each participant than MMT to make it as cost-
effective as MMT.
Economic Modeling of the Cost-Effectiveness of Opioid
Maintenance Treatment. Barnett (1999), using data on the
efficacy of MMT in reducing mortality derived from
Gronbladh, Ohlund, and Gunne’s (1990) Swedish study and
U.S. cost data, estimated that MMT saved an additional year of
life at a cost of US$5,900. Barnett, Zaric, and Brandeau (2001),
using a similar approach, estimated that the use of buprenor-
phine by patients who would not use methadone would cost
less than US$45,000 per quality-adjusted life year. Overall,
however, they found that BMT was much less effective and
more costly than MMT. Zaric, Barnett, and Brandeau (2000)
assessed the economic benefits of using MMT to reduce HIV
transmission in heroin users. They found that for heroin users
living in a community with a high prevalence of HIV infection,
expanding MMT use produced an additional year of quality-
adjusted life at a cost of US$8,200.
Comparing the Cost-Effectiveness of Different Interventions
Comparative cost-effectiveness analyses of these interventions
face major obstacles because the small number of published
studies used different methods to cost interventions and differ-
ent endpoints to assess the outcome of treatment. The follow-
ing list, therefore, only ranks treatment interventions in the
approximate order of their cost-effectiveness. We believe that
estimates of their likely contribution to DALYs worldwide
would be too speculative.
• Detoxification. Buprenorphine and supervised naltrexone-
accelerated withdrawal delivered on an outpatient basis are
the most efficient and effective ways to achieve withdrawal
from opioids.
• Self-help groups. These groups provide the simplest form of
postwithdrawal support for enduring abstinence and are
also a low-cost intervention, because patients bear most of
the costs; however, they have a low rate of uptake, and their
effectiveness is only modest.
• Oral opioid agonist maintenance treatment. This form of
treatment is the most widely used intervention for illicit
opioid dependence in developed societies. It has a better
uptake than other interventions, and it is moderately effec-
tive under the usual delivery conditions.
• Drug-free residential treatment. This form of treatment has a
relatively low rate of treatment uptake and is costly because
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of its residential character and the need for intensive staff-
patient interaction. It is effective for the minority of people
who are retained in treatment long enough to benefit from
it (usually three months). Retention in treatment may be
improved if patients enter treatment under some form of
legal coercion.
• Naltrexone maintenance treatment. This form of treatment
has not been rigorously evaluated.
• Injectable opioid maintenance. This intervention is a more
expensive variant of agonist maintenance treatment that has
been used for patients with more severe cases of dependency
but for whom retention and treatment outcomes have been
good.
Calculation of the Averted, Avertable, 
and Unavertable Burden 
Assuming that the disease burden from opioid dependence is
potentially avertable, we used the following approach to esti-
mate the avoidable burden of opioid dependence. We initially
modeled the avertable burden using MMT and used this model
for BMT. The first step was to establish the base case for opioid
dependence using 2002 as the baseline year. We established the
model of the base case for opioid dependence for regions and
subregions according to WHO country classifications. We used
population estimates for each region for those age 15 to 59, the
age range in which heroin dependence is most prevalent. We
incorporated Degenhardt, Hall, and others’ (2004, table 13.1)
figures for the prevalence of opioid use by region, assuming
that the prevalence was 30 percent higher among male users
than female users.
We obtained population-attributable fractions related to
opioid dependence from the editors of this volume. We used
nine relevant WHO categories to estimate the burden of dis-
ease attributable to opioid dependence—namely HIV/AIDS,
drug-use disorders, road traffic accidents, poisonings, falls,
fires, drownings, other unintentional injuries, and self-inflicted
injuries.
We calculated the mortality rate for opioid deaths by divid-
ing the number of deaths by the estimated number of users. We
took estimates of years of life lost (YLLs) and years lived with
disability (YLDs), by gender, for each region from data
obtained from the editors of this volume. We then used those
estimates to calculate the DALYs for male users, female users,
and all users (YLL  YLD  DALY). We discounted the YLLs,
YLDs, and DALYs using a 3 percent discount rate.
The second step was to estimate the avertable burden by
treatment with methadone or buprenorphine. Using the popu-
lation and prevalence data, we assumed, in the first instance,
that 50 percent of those dependent on opioids entered treat-
ment. In the sensitivity analysis, we varied this proportion from
25 to 75 percent coverage. On the basis of Caplehorn and
others’ (1994) meta-analysis, we assumed that MMT reduced
mortality by 25 percent. In the sensitivity analysis, we varied
the reduction from 15 to 35 percent (using the confidence
intervals around the estimated reduction). We assumed that
the reduction in mortality associated with BMT was 20 per-
cent, which we varied in the sensitivity analysis from 10 to
30 percent. Finally, we assumed that those who were alive and
in treatment experienced a 25 percent reduction in disability,
consistent with the Dutch disability weights.
The third step was to estimate the burden for those not
treated. For those users not in treatment, we calculated DALYs
using the original mortality rates.
The fourth step was to estimate the total avertable burden
from treatment with methadone or buprenorphine by (a) adding
the results of the second and third steps, the revised DALYs for
those in treatment, and the residual for those not in treatment
and (b) subtracting those figures from the base case estimates.
The fifth step was to cost the interventions using data on
MMT and BMT from Doran and others (2003). They estimated
the cost of MMT at $A 1,415 and of BMT at $A 1,729 for six
months of treatment.We converted these estimates into U.S.dol-
lars and multiplied them by two to provide yearly estimates
of treatment costs of US$1,732 for MMT and US$2,117 for BMT.
We applied relative price weights for each region using the
Western Pacific as the reference case (1.00). We calculated the
relative price weights for each cost type using data provided by
the World Bank. The prices are a reflection of the public health
systems in each region, and as far as possible they reflect the
opportunity cost of health care resources in these regions.
Results. Our results are presented in table 48.1. We explored
various combinations of coverage and reductions in mortality
for MMT and BMT. For each intervention, as coverage and
reductions in mortality increased, the number of DALYs averted
increased. The wide discrepancies in DALYs averted within
regions primarily reflect differences in population-attributable
fractions for HIV/AIDS. Costs increased as a consequence of
increased coverage for both interventions, whereas results for
cost-effectiveness differ by both intervention and mortality.
The cost-effectiveness analysis suggests that for MMT (with
a coverage of 25, 50, or 75 percent and reductions in mortality of
35 percent) the cost in international dollars per DALY averted
ranges from a low of $128 in Africa, with high child and adult
mortality where the prevalence of illicit opioid dependence is
low (0.01 percent), to a high of $3,726 in Eastern Europe, with
low child and adult mortality where the prevalence of illicit
opioid dependence is high (0.55 percent). Across all the
regions, the average cost-effectiveness ratio for MMT (with 25,
50, and 75 percent coverage and 35 percent reduction in mor-
tality) is estimated at $2,236 per DALY averted.
Assessment. The results shown in table 48.1 provide a first
approximation of the potential avertable burden in DALYs if
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Table 48.1 Cost-Effectiveness Results
Total effect (DALYs averted per 1 million population)
Eastern
The Mediter- Southeast Western
Coverage Mortality 
Africa Americas ranean Europe Asia Pacific
Treatment (%) (%) AFR-D AFR-E AMR-A AMR-B AMR-D EMR-A EMR-D EUR-A EUR-B EUR-C SEAR-B SEAR-D WPR-A WPR-B
MMT 25 15 125 79 153 107 158 179 105 117 48 198 63 48 39 26
MMT 50 15 251 158 306 214 316 358 210 234 96 397 126 97 77 53
MMT 75 15 376 237 459 321 474 538 315 352 144 595 190 145 116 79
MMT 25 25 150 81 184 121 173 217 151 141 59 264 93 70 51 35
MMT 50 25 300 163 369 243 347 435 303 283 117 527 185 140 102 70
MMT 75 25 450 244 553 364 520 652 454 424 176 791 278 211 152 105
MMT 25 35 174 84 216 136 189 256 198 165 69 329 122 92 63 43
MMT 50 35 349 167 432 272 378 511 396 331 139 657 244 184 126 87
MMT 75 35 523 251 648 408 566 767 594 496 208 986 367 276 189 130
BMT 25 10 113 78 137 100 150 160 82 105 43 166 48 38 32 22
BMT 50 10 226 156 274 199 301 320 163 210 85 331 97 75 65 44
BMT 75 10 339 234 412 299 451 480 245 315 128 497 145 113 97 67
BMT 25 20 138 80 169 114 166 198 128 129 53 231 78 59 45 31
BMT 50 20 275 160 337 228 332 397 256 258 107 462 156 119 89 61
BMT 75 20 413 240 506 342 497 595 384 388 160 693 234 178 134 92
BMT 25 30 162 82 200 129 181 237 175 153 64 296 107 81 57 39
BMT 50 30 324 165 400 258 362 473 350 307 128 592 215 162 114 78
BMT 75 30 487 247 601 386 543 710 524 460 192 888 322 243 171 117
Total costs (US$ per 1 million population)
MMT 25 15, 25, 35 0.10 0.01 0.25 0.06 0.12 0.95 0.65 0.20 0.16 0.35 0.06 0.19 0.07 0.03
MMT 50 15, 25, 35 0.19 0.02 0.50 0.11 0.24 1.90 1.30 0.40 0.32 0.71 0.11 0.39 0.13 0.07
MMT 75 15, 25, 35 0.29 0.03 0.74 0.17 0.36 2.86 1.95 0.60 0.49 1.06 0.17 0.58 0.20 0.10
BMT 25 10, 20, 30 0.12 0.01 0.30 0.07 0.15 1.16 0.80 0.24 0.20 0.43 0.07 0.24 0.08 0.04
BMT 50 10, 20, 30 0.24 0.03 0.60 0.14 0.29 2.33 1.59 0.49 0.40 0.86 0.14 0.47 0.16 0.08
BMT 75 10, 20, 30 0.35 0.04 0.91 0.20 0.44 3.49 2.39 0.73 0.59 1.29 0.20 0.71 0.24 0.12
Cost-effectiveness (US$ per DALY averted)
MMT 25, 50, 75 15 768 136 1,618 520 755 5,315 6,213 1,711 3,379 1,782 875 3,984 1,716 1,284
MMT 25, 50, 75 25 643 132 1,342 458 688 4,381 4,300 1,419 2,764 1,341 597 2,749 1,301 974
MMT 25, 50, 75 35 552 128 1,146 408 632 3,726 3,288 1,212 2,339 1,074 453 2,099 1,048 784
BMT 25, 50, 75 10 1,041 168 2,204 682 969 7,269 9,764 2,329 4,646 2,606 1,396 6,277 2,493 1,867
BMT 25, 50, 75 20 855 164 1,793 595 880 5,869 6,210 1,895 3,716 1,869 867 3,975 1,809 1,354
BMT 25, 50, 75 30 726 159 1,510 527 805 4,921 4,553 1,598 3,096 1,458 629 2,909 1,419 1,062
DALYs averted per US$1 million spent
MMT 25, 50, 75 15 1,302 7,363 618 1,922 1,325 188 161 585 296 561 1,142 251 583 779
MMT 25, 50, 75 25 1,556 7,575 745 2,185 1,453 228 233 705 362 746 1,676 364 768 1,027
MMT 25, 50, 75 35 1,811 7,787 873 2,448 1,582 268 304 825 428 931 2,210 476 954 1,275
BMT 25, 50, 75 10 961 5,939 454 1,465 1,032 138 102 429 215 384 717 159 401 536
BMT 25, 50, 75 15 1,170 6,112 558 1,681 1,137 170 161 528 269 535 1,153 252 553 739
BMT 25, 50, 75 20 1,378 6,286 662 1,896 1,242 203 220 626 323 686 1,590 344 705 942
MMT and BMT were applied to 50 percent of the opioid-
dependent population in each region. Because the methods and
data used to estimate avertable DALYs are subject to certain
limitations, those results should be considered preliminary.
RELEVANCE TO DEVELOPING COUNTRIES
Much of the epidemiological research on illicit opioid depend-
ence, its disease burden, and its societal harm comes from
Australasia, Europe, and the United States. The major excep-
tion is research on the role of injecting drug use in HIV trans-
mission in developing countries (see, for example, Beyrer and
others 2000; Yu and others 1998). In addition, research on the
effectiveness and cost-effectiveness of interventions for illicit
opioid dependence has been conducted primarily in developed
countries (Ward, Hall, and Mattick 1998), with the exception of
studies of the effectiveness of methadone treatment in Hong
Kong, China (see, for instance, Newman and Whitehill 1979),
and in Thailand (Vanichseni and others 1991), both of which
showed comparable effectiveness to that found in developed
countries (W. Hall, Ward, and Mattick 1998).
Translating findings on interventions for opioid depend-
ence in developed countries into disease control priorities for
opioid dependence in developing countries presents three
major challenges. First, countries differ in the scale of illicit
opioid use and in the resulting disease burden. This variation
reflects the effects of differences in the prevalence of injecting
and noninjecting opioid users; the dependent opioid users’
access to treatment and health services for overdoses, blood-
borne viruses, and other complications of drug use; the access
to needle and syringe programs; the extent to which illicit
opioid use is concentrated in socially disadvantaged minority
groups; and the capacity of public health services to monitor
and respond to emerging infectious disease and drug-use epi-
demics. The burden is likely to be greatest in settings where the
primary route of administration is injecting and where public
and personal health services are poorly developed, as appears to
be the case in Asia and in Eastern Europe.
Second, societal wealth and health care infrastructure
affect the capacity of developing societies to treat illicit opioid
dependence.A country’s capacity to provide opioid substitution
treatment will be affected by the cost of oral opioid drugs, such
as methadone, LAAM, and buprenorphine, and the existence of
specialist drug treatment centers; trained medical, nursing, and
pharmacy staff; and a drug regulatory system, which are
required so as to deliver opioid substitution treatment safely
and effectively. Few developing countries possess this infra-
structure.However, examples exist of apparently successful drug
substitution programs, using such tools as sublingual buprenor-
phine, that have been conducted with minimal resources in
extremely poor settings (Crofts and others 1998).
Third, in societies with a sizable illicit opioid dependence
problem, cultural attitudes and beliefs will affect societal
responses, especially attitudes toward illicit opioid use and
dependence (Gerstein and Harwood 1990). A critical determi-
nant of the social response will be the relative dominance of
moral and medical understandings of drug dependence in gen-
eral and opioid dependence in particular. A moral model of
addiction sees addiction as largely a voluntary behavior, in
which case it is seen as an excuse for bad behavior that allows
drug users to continue to take drugs without assuming respon-
sibility for their conduct (Szasz 1985). In this view, drug users
who offend against the criminal code should be imprisoned
(Szasz 1985). This model is the dominant one in many devel-
oped societies, which imprison drug users at high rates without
any effect on the prevalence of drug abuse. Countries that
adopt punitive policies toward drug users are reluctant to
embrace harm reduction measures, such as needle and syringe
programs and opioid maintenance treatment (Ainsworth,
Beyrer, and Soucat 2003). A medical model of addiction, by
contrast, recognizes that dependent opioid users require spe-
cific treatment if the sufferer is to become and remain abstinent
(see, for example, Leshner 1997).
These competing views will affect the societal acceptability
of opioid maintenance and abstinence-oriented approaches to
the treatment of opioid dependence (Cohen 2003). Those who
have a moral view of addiction will tend to prefer drug-free and
self-help approaches toward treatment. Supporters of medical
models of addiction will favor some form of opioid substitu-
tion treatment and the provision of clean needles and syringes
to reduce the transmission of bloodborne viruses by injecting
opioid and other drug users. Stronger advocacy by interna-
tional organizations and agencies is needed for the adoption of
such harm reduction measures as needle and syringe programs
and agonist substitution programs.
RESEARCH AND DEVELOPMENT
Two main areas are important for research and development.
First, better estimates are needed of the prevalence of illicit opi-
oid dependence and prospective studies of the morbidity and
mortality that it causes in both developed and developing
countries. These estimates are especially needed in countries
where illicit opioid use is high because of their proximity to
source countries. Second, we need evaluations of the effective-
ness and cost-effectiveness of self-help, drug-free, and oral opi-
oid substitution treatment in developing countries. A priority
should be the identification of safe, innovative, and less expen-
sive ways of effectively delivering culturally acceptable forms of
opioid maintenance treatments in developing countries. This
effort may require experimentation with a range of substitute
opioids, such as buprenorphine, and cheaper options, such as
codeine and opium tincture.
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CONCLUSIONS: PROMISES AND PITFALLS
Illicit opioid use, especially injecting use, contributes to prema-
ture mortality and morbidity in many developed and develop-
ing societies. Fatal overdoses and HIV/AIDS resulting from the
sharing of dirty injecting equipment are major contributors
to mortality and morbidity, and the economic costs of illicit
opioid dependence are substantial. Illicit opioid dependence
generates substantial externalities that are not included in
burden-of-disease estimates, principally law enforcement costs
incurred in handling drug dealing and property crime.
The most popular interventions for illicit opioid depend-
ence in many developed societies have been law enforcement
efforts to interdict the drug supply and enforce legal sanctions
against the use of opioid drugs. One consequence of this strat-
egy has been that most illicit opioid users have been exposed
to the least effective intervention: imprisonment for drug or
property offenses. Prisons rarely take the opportunity to treat
dependence using opioid maintenance or to reduce the harm
caused by illicit opioid use by providing access to clean inject-
ing equipment.
In treatment settings, the most popular interventions have
been detoxification (which is not a treatment but a prelude to
treatment) and drug-free treatment (which is the least attrac-
tive and the least effective in retaining opioid-dependent peo-
ple in treatment). Opioid agonist maintenance treatment has
been ambivalently supported in many developed societies
despite its being the treatment for which there is the best evi-
dence of effectiveness, safety, and cost-effectiveness. The range
of opioid agonists available for maintenance treatment is
increasing. A number of developed countries have approved
the use of BMT, which the limited data suggest may be approx-
imately equivalent to MMT in efficacy and cost-effectiveness.
Opioid antagonists have a niche role in the treatment of opioid
dependence because of poor compliance and an increased
risk of overdose on return to heroin use. Their efficacy may
improve with the development of long-acting injectable forms
of the drug.
ANNEX 48.A: PREVALENCE OF USE, ADVERSE
HEALTH EFFECTS OF AND INTERVENTIONS
FOR CANNABIS, COCAINE, AMPHETAMINES,
AND MDMA USE AND DEPENDENCE 
Cannabis
Cannabis is the most widely used illicit drug globally, with
about 150 million users, or 3.7 percent of the world’s popula-
tion age 15 and older (UNODCCP 2003). Patterns of cannabis
use have been most extensively studied in Australia, Canada,
the United States, and Europe (W. Hall and Pacula 2003).
Europe generally has lower rates of use than Australia, Canada,
and the United States, with the highest rates in Denmark,
France and the United Kingdom (EMCDDA 2002; W. Hall and
Pacula 2003). The limited data from developing countries
suggest that, with some exceptions (for example, Jamaica and
South Africa), rates of cannabis use are lower in Africa, Asia,
the Caribbean, and South America than they are in Europe
and in English-speaking countries (W. Hall, Johnston, and
Donnelly 1999).
Surveys in the United States have found long waves of
cannabis use among young people since 1975. Cannabis use
increased during the 1970s to peak in 1979, before declining
steadily between 1980 and 1991. Use rose sharply in 1992 and
increased throughout the 1990s, before leveling off in the late
1990s (Johnston, O’Malley, and Bachman 1994a, 1994b). There
was also a rise in cannabis use during the early 1990s in
Australia, Canada, and some European countries (W. Hall and
Pacula 2003).
The natural history of cannabis use in the United States
typically begins in the mid to late teens and reaches its maxi-
mum in the early 20s before declining in the mid to late 20s.
Only a minority of young adults continue to use cannabis into
their 30s (Bachman and others 1997; Chen and Kandel 1995).
Getting married and having children substantially reduces rates
of cannabis use (Bachman and others 1997).
Cannibis use can have several adverse health effects, as dis-
cussed below.
Acute Effects of Cannabis Use. The most frequent unpleasant
effects of cannabis use are anxiety and panic reactions, which
most often occur in users who are unfamiliar with the drug’s
effects. Psychotic symptoms such as delusions and hallucina-
tions may be experienced following very high doses. There are
no cases of fatal cannabis poisoning in the medical literature,
and the fatal dose in humans is likely to exceed what recre-
ational users are able to ingest (W. Hall and Pacula 2003).
Cannabis intoxication impairs a wide range of cognitive and
behavioral functions that are involved in driving an automobile
or operating machinery (Beardsley and Kelly 1999; Jaffe 1985).
It has been difficult to determine whether these impairments
increase the risk of being involved in motor vehicle accidents
(Smiley 1999). Studies of the effect of cannabis on driving per-
formance on the road have found only modest impairments,
because cannabis-intoxicated drivers drive more slowly and
take fewer risks than drivers intoxicated by alcohol (Smiley
1999).
Cannabinoids are found in the blood of substantial propor-
tions of persons killed in motor vehicle accidents (Bates and
Blakely 1999; Chesher 1995; Walsh and Mann 1999), but these
findings have been difficult to evaluate because they have not
distinguished between past and recent cannabis use
(Ramaekers and others 2004). More recent research using bet-
ter indicators of recent cannabis use has found a dose-response
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relationship between cannabis and risk of motor vehicle
crashes (Ramaekers and others 2004). Cannabis used in com-
bination with alcohol substantially increases risk of accidents
(Bates and Blakely 1999; Ramaekers and others 2004).
Health Effects of Chronic Cannabis Use. Cannabis smoke is
a potential cause of cancer because it contains many of the
same carcinogenic substances as cigarette smoke (Marselos and
Karamanakos 1999). Cancers have been reported in the aerodi-
gestive tracts of young adults who were daily cannabis smokers
(W. Hall and MacPhee 2002), and a case-control study has
found an association between cannabis smoking and head and
neck cancer (Zhang and others 1999). A prospective cohort
study of 64,000 adults did not find any increase in rates of head
and neck or respiratory cancers (Sidney and others 1997).
Further studies are needed to clarify the issue.
Three studies of different types of cancer have reported
an association with maternal cannabis use during pregnancy
(W. Hall and MacPhee 2002). There have not been any increases
in the rates of these cancers that parallel increases in rates of
cannabis use (W. Hall and MacPhee 2002).
High doses of cannabinoids impair cell-mediated and
humoral immunity and reduce resistance to infection by
bacteria and viruses in rodents (Klein 1999). Cannabis smoke
impairs the functioning of alveolar macrophages, the first line
of the body’s immune defense system in the lungs. The doses
that produce these effects have been very high, and extrapola-
tion to the doses used by humans is complicated by the fact that
tolerance to these effects develops (Hollister 1992). There is as
yet no epidemiological evidence that rates of infectious disease
are higher among chronic heavy cannabis users. Several large
prospective studies of HIV-positive homosexual men have not
found that cannabis use makes it more likely that HIV-positive
men develop AIDS (W. Hall and Pacula 2003).
Chronic administration of tetrahydrocannabinol (THC)
disrupts male and female reproductive systems in animals,
reducing testosterone secretion and sperm production, motil-
ity, and viability in males and disrupting ovulation in females
(Brown and Dobs 2002). It is uncertain whether cannabis use
has these effects in humans because of the limited research on
human males and females (Murphy 1999).
The use of cannabis during pregnancy is associated with
smaller birthweight (English and others 1997; Fergusson,
Horwood, and Northstone 2002), but it does not appear to
increase the risk of birth defects (W. Hall and Pacula 2003). In
some studies, infants exposed to cannabis during pregnancy
show behavioral and developmental effects during the first few
months after birth; these effects are smaller than those seen
after tobacco use during pregnancy (Fried and Smith 2001).
The changes that cannabis smoking causes in heart rate
and blood pressure are unlikely to harm healthy young adults,
but they may harm patients with hypertension, cerebrovascular
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disease, and coronary atherosclerosis (Chesher and Hall 1999;
Sidney 2002). One controlled study suggests that cannabis use
can precipitate heart attacks in middle-aged cannabis users
who have atherosclerosis in the heart, brain, and peripheral
blood vessels (Mittleman and others 2001).
Regular cannabis smoking impairs the functioning of the
large airways and causes chronic bronchitis (Tashkin 1999;
Taylor and others 2002). Given that tobacco and cannabis
smoke contain similar carcinogenic substances, it is likely that
chronic cannabis smoking increases the risks of respiratory
cancer (Tashkin 1999).
Psychological Effects of Chronic Cannabis Use. Psychological
effects of chronic cannabis use can include a dependence
syndrome, cognitive effects, and psychotic disorders.
Dependence Syndrome A cannabis dependence syndrome
occurs in heavy chronic users of cannabis (American
Psychiatric Association 1994). Regular cannabis users develop
tolerance to THC. Some experience withdrawal symptoms on
cessation of use (Kouri and Pope 2000), and some report prob-
lems controlling their cannabis use (W. Hall and Pacula 2003).
The risk of dependence is about 1 in 10 among those who ever
use the drug, between 1 in 5 and 1 in 3 among those who use
cannabis more than a few times, and about 1 in 2 among daily
users (W. Hall and Pacula 2003).
Cognitive Effects Long-term daily cannabis use does not
severely impair cognitive function, but it may more subtly
impair memory, attention, and the ability to integrate complex
information (Solowij 1998; Solowij and others 2002). It remains
uncertain whether these effects are due to the cumulative effect
of regular cannabis use on cannabinoid receptors in the brain or
whether they are residual effects of THC that will disappear after
an extended period of abstinence (W. Hall and Pacula 2003).
Psychotic Disorders There is now good evidence that chronic
cannabis use may precipitate psychosis in vulnerable individu-
als (see, for example, Arseneault and others 2002; van Os and
others 2002; Zammit and others 2002). It is less likely that
cannabis use can cause psychosis de novo, because the inci-
dence of schizophrenia has either remained stable or declined
while cannabis use has increased among young adults
(Degenhardt, Hall, and Lynskey 2003).
Effects of Cannabis Use on Adolescents. Cannabis use has a
number of effects on adolescents.
Gateway Hypothesis Adolescents in developed societies typi-
cally use alcohol and tobacco before using cannabis, which in
turn, they use before using hallucinogens, amphetamines,
heroin, and cocaine (Kandel 2002). Generally, the earlier the
age of first use and the greater the involvement with any drug
in the sequence, the more likely a young person is to use the
next drug in the sequence (Kandel 2002). The role played by
cannabis in this sequence remains controversial (W. Hall and
Lynskey forthcoming; W. Hall and Pacula 2003).
The simplest hypothesis is that cannabis use has a pharma-
cological effect that increases the risk of using drugs later in the
sequence. Equally plausible hypotheses are that it is due to a
combination of (a) early recruitment into cannabis use of
nonconforming and deviant adolescents who are likely to use
alcohol, tobacco, and illicit drugs; (b) a shared genetic vulnera-
bility to dependence on alcohol, tobacco, and cannabis; and
(c) socialization of cannabis users within an illicit drug–using
subculture, which increases the opportunity, and encourage-
ment to use other illicit drugs (W. Hall and Pacula 2003).
Adolescent Psychosocial Outcomes Cannabis use is associated
with early withdrawal from high school, early family formation,
poor mental health, and involvement in drug-related crime. In
the case of each of these outcomes, the strong associations in
cross-sectional data are more modest when account is taken of
the fact that cannabis users show characteristics before they use
cannabis that predict these outcomes. For example, they have
lower academic aspirations and poorer school performance than
peers who do not use cannabis (Lynskey and Hall 2000; Macleod
and others 2004). Nonetheless, the evidence increasingly sug-
gests that regular cannabis use adds to the risk of these outcomes
in adolescents already at risk (W. Hall and Pacula 2003).
Interventions for Cannabis Dependence. Although many
dependent cannabis users may succeed in quitting without
professional help, some are unable to stop on their own and
will need assistance to do so. There has not been a great deal of
research on pharmacological treatments for cannabis depend-
ence, although a recent study trialed divalproex sodium with
promising results (Levin and others 2004). Limited research
exists on the effectiveness of different types of psychosocial
treatments for dependent cannabis use (Budney and others
2000; Copeland and others 2001; Stephens, Roffman, and
Simpson 1994). These approaches have involved short-term
cognitive behavioral treatments modeled on similar treatments
for alcohol dependence, usually given in three to six sessions on
an outpatient basis.
In all of these studies, rates of abstinence at the end of
treatment have been modest (20 to 40 percent), and subse-
quent high rates of relapse mean that rates of abstinence after
12 months have been very modest (Budney and Moore 2002).
Nonetheless, treatment does substantially reduce cannabis use
and problems. These outcomes are not very different from
those observed in the treatment for alcohol and other forms
of drug dependence (Budney and Moore 2002). Much more
research is needed before sensible advice can be given about the
best ways to achieve abstinence from cannabis.
Cocaine
After cannabis, cocaine is one of the most widely used illicit
drugs in developed and developing societies. Some 14 million
people were estimated to have used cocaine globally in 2003,
with demand for treatment second only to heroin (UNODCCP
2003). The highest rates of reported cocaine use—and the best
data on trends in cocaine use—come from the United States,
the world’s largest cocaine market. Rates of cocaine use in the
United States increased from the mid 1970s until 1985, when
5.7 million Americans age 12 and older reported using cocaine
in the preceding month. Rates of cocaine use in the preceding
month have declined steadily since 1985. In 2000, 11.2 percent
of Americans over age 12 reported that they had used cocaine
at some time in their lives, and 0.4 percent (800,000 people)
reported weekly cocaine use (SAMHSA 2001). Among young
U.S. adults age 18 to 25, lifetime prevalence was 14.9 percent in
2001, rising slightly to 15.4 percent in 2002 (SAMHSA 2003).
In 2002, annual prevalence figures from student surveys were
15 percent lower than 1998 figures and 60 percent lower than
1985 figures (UNODCCP 2003). A more recent study of U.S.
adults age 35 years found that 6 percent of men and 3 percent
of women had used cocaine within the preceding 12 months
(Merline and others 2004).
The reported prevalence of cocaine use in other developed
societies is much lower than that in the United States. In
Europe, for example, rates of lifetime cocaine use range from
0.5 percent to 5 percent (EMCDDA 2003), compared with
12.3 percent among American adults in 2001 (SAMHSA 2001).
Rates of cocaine use in Australia resemble those in Europe, with
4.3 percent of adults reporting lifetime use (Darke and others
2000).
The prevalence of cocaine use is likely to be lower in devel-
oping societies, but the poor quality of the available data makes
it difficult to be sure (UNDCP 1997). There probably has been
an increase in cocaine use in some developing countries in
recent years, but it is difficult to estimate the size of the increase
(United Nations Commission on Narcotic Drugs 2000). The
region with the highest rates of cocaine use among developing
societies is likely to be Central and South America. The botan-
ical source is indigenous to the region and has traditionally
been used by local populations. Moreover, several nations in
Central and South America have a history of production and
export to global markets. Recent reports indicate that cocaine
abuse is increasing in South America (UNODCCP 2003), and
a recent household survey on drug abuse in São Paulo, Brazil,
estimated cocaine prevalence at 2.1 percent (Galduroz and
others 2003).
Adverse Health Effects of Cocaine. Most cocaine use is infre-
quent; regular cocaine use (monthly or more frequently) can
be a major public health problem. Regular cocaine users who
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inject cocaine or smoke crack cocaine are especially likely to
develop dependence and to experience problems related to
their cocaine use (Platt 1997). In the United States, it has been
estimated that one in six of those who ever use cocaine become
dependent on the drug (Anthony, Warner, and Kessler 1994).
High rates of cocaine dependence are found among people
treated for alcohol and drug problems and among arrestees in
the United States (Anglin and Perrochet 1998).
In large doses, cocaine may be harmful in both cocaine-
naive and cocaine-tolerant individuals (Platt 1997; Vasica and
Tennant 2002). The vasoconstrictor effects of cocaine in large
doses place great strains on a number of the body’s physiolog-
ical systems (McCann and Ricaurte 2000). Effects on the car-
diovascular system can result in a range of difficulties, from
chest pain to fatal cardiac arrests (Lange and Hillis 2001).
Neurological problems include cerebral vascular accidents such
as strokes or seizures. Other effects of cocaine can include gas-
trointestinal problems such as vomiting, colitis, and bowel
infarction and respiratory problems such as asthma, respiratory
collapse, pulmonary edema, and bronchitis. Hyperthermia
may occur because of the increased metabolism, peripheral
vasoconstriction, and inability of the thalamus to control
body temperature (Crandall, Vongpatanasin, and Victor 2002).
Obstetric complications can include irregularities in placental
blood flow, premature labor, and low neonate birthweight
(Majewska 1996; Platt 1997; Vasica and Tennant 2002).
Adverse health effects from cocaine are potentially fatal and
can occur among healthy users irrespective of cocaine dose and
frequency of use (Lange and Hillis 2001; Vasica and Tennant
2002). Although the likelihood of health problems may
increase with dosage and frequency of use, there is wide indi-
vidual variation in reactions to cocaine and, therefore, no spe-
cific combination of conditions under which adverse health
effects can be predicted. There is no antidote to cocaine over-
dose as there is for an overdose of heroin (Platt 1997).
The impact of cocaine on mental health is also complex.
Although cocaine can produce feelings of pleasure, it may also
result in negative psychological symptoms such as anxiety,
depression, paranoia, hallucinations, and agitation (American
Psychiatric Association 1994). Regular cocaine users experience
high rates of psychiatric disorders. In the United States, regular
cocaine users report high rates of anxiety and affective disor-
ders (Gawin and Ellinwood 1988; Platt 1997). The repeated use
of large doses of cocaine can also produce a paranoid psychosis
(Majewska 1996; Manschreck and others 1988; Platt 1997; Satel
and Edell 1991). People who are acutely intoxicated by cocaine
can become violent, especially those who develop a paranoid
psychosis (Platt 1997).
Animal studies suggest that cocaine use may be neurotoxic
in large doses—that is, it can produce permanent changes in
the brain and neurotransmitter systems (Majewska 1996; Platt
1997). It is unclear whether use is also neurotoxic in humans.
Previous studies have documented a variety of neuropsycho-
logical effects of cocaine use, including deficits in memory and
problem solving (Beatty and others 1995; Hoff and others
1996; O’Malley and others 1992). More recently, a twin study
indicated that cocaine may lead to impaired attention and
motor skills up to one year after the conclusion of heavy use
(Toomey and others 2003).
The method by which cocaine is administered can result in
adverse health effects (Platt 1997). Snorting cocaine through
the nose can lead to rhinitis, damage to the nasal septum, and
loss of the sense of smell. Smoking cocaine can lead to respira-
tory problems, and injecting cocaine leads to the risks of infec-
tions and bloodborne viruses associated with all injecting drug
use.
Users who inject cocaine, either on its own or in combina-
tion with heroin (“speedballs”), inject much more frequently
than other injecting drug users and, as a consequence, engage
in more needle sharing, take more sexual risks, and have
higher rates of HIV infection (Chaisson and others 1989;
Schoenbaum and others 1989; van Beek, Dwyer, and Malcolm
2001). Associations between cocaine use and HIV risk-taking
have been reported in Europe (Torrens and others 1991),
Australia (Darke and others 1992), and the United States
(Chaisson and others 1989). Recent Australian research
has indicated that injecting cocaine users report more prob-
lems related to injecting drug use—such as vascular problems,
abscesses, and infections—than other injecting drug users
(Darke, Kaye, and Topp 2002).
The link between cocaine use and HIV risk is not restricted
to those who inject cocaine. Crack smoking has been linked to
higher levels of needle risk, sexual risk taking, and HIV infec-
tion (Chaisson and others 1989; Chirgwin and others 1991;
Desjalais and others 1992; Grella, Anglin, and Wugalter 1995).
Two mechanisms probably underlie the relationship between
cocaine use and HIV infection. First, the short half-life of
cocaine promotes a much higher frequency of injecting by
users than that seen in heroin injectors. Second, cocaine itself
disinhibits and stimulates users, encouraging them to take
greater risks with sexual activity and needle use (Darke and
others 2000).
Cocaine is associated with a risk of intentional injuries and
injuries in general. A recent review reported that 28.7 percent of
people with intentional injuries and 4.5 percent of injured driv-
ers tested positive for cocaine (Macdonald and others 2003).
Users are also at risk of death from an accidental overdose of
cocaine. A recent study of accidental deaths from drug overdose
in New York between 1990 and 1998 found that 70 percent of
deaths were caused by cocaine, often in combination with opi-
ates (Coffin and others 2003). The causes of cocaine-related
deaths are usually related to cardiovascular complications
(Vasica and Tennant 2002), but death may also be due to brain
hemorrhage, stroke, and kidney failure (Brands, Sproule, and
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Marshman 1998). Injection of cocaine is most likely to cause an
overdose, followed by smoking it, with intranasal use involving
the least risk (Pottieger and others 1992).
Much less is known about nonfatal cocaine overdose. A
study in Miami, Florida, found that 40 percent of users had
overdosed on cocaine at least once (Pottieger and others 1992).
More recently, a study in Brazil found that 20 percent of users
had experienced an overdose, with 50 percent knowing some-
one who had died from an overdose (Mesquita and others
2001). A study in Sydney, Australia, found that 17 percent of
injecting cocaine users and 6 percent of noninjecting cocaine
users had ever overdosed, with 9 percent and 3 percent, respec-
tively, overdosing in the preceding 12 months (Kaye and Darke
2003). Frequency of cocaine use, severity of dependence, and
route of administration did not predict an overdose, support-
ing the view that cocaine overdose is an unpredictable event.
Interventions for Cocaine Dependence. Efforts at interven-
tion have included pharmacological treatments as well as psy-
chotherapy and cognitive behavioral therapy.
Pharmacological Interventions Despite much research effort
there are no effective pharmacological treatments for cocaine
dependence (Kreek 1997; McCance 1997; Mendelson and
Mellon 1996; Nunes 1997; Silva de Lima and others 2002; van
den Brink and van Ree 2003). Attempts have been made to
develop longer-acting agonist drugs that act on the same
molecular targets as cocaine without producing its euphoric
effects (for example, methylphenidate) (Kreek 1997) or that
block its rewarding and euphoric effects (McCance 1997).
There has also been a search for drugs that indirectly change
the effects that cocaine has on the brain by acting on other
neurotransmitter systems, such as the serotonergic system
(for example, fluoxetine) (McCance 1997). None of these
approaches has produced an effective pharmacotherapy for
cocaine dependence (Lima and others 2003; Platt 1997; Soares
and others 2003).
Development of pharmacological therapies for cocaine
dependence and their evaluation is complicated by the multiple
interactive processes that may have contributed—for example,
coexisting substance abuse or mental health issues (Mendelson
and Mellon 1996). Many of the approaches to the treatment of
cocaine dependence have also been used in treating patients
with alcoholism and other substance abuse disorders.
A number of drugs have been used to treat cocaine based on
their relevance to the symptoms of cocaine dependence (Silva de
Lima and others 2002; van den Brink and van Ree 2003). The
frequency of depressive symptoms has led to the exploration of
the effectiveness of antidepressant drugs. Desipramine has been
used with mixed effectiveness for cocaine detoxification and the
maintenance of abstinence (Covi and others 1994; Gawin,
Kleber, and Byck 1989), but it appears to be most effective when
there is evidence of previous or consequent symptoms of
depression. Other antidepressants have been used with mixed
results: imipramine and trazodone have been found to have
more adverse effects than desipramine, and fluoxetine has not
been found to be effective (Mendelson and Mellon 1996). A
recent systematic review found no current evidence to support
the use of antidepressants in the treatment of cocaine depend-
ence (Lima and others 2003).
Dopamimetic drugs have also been used to treat cocaine
dependence; such treatments are based on the action of cocaine
to block reuptake of dopamine. Unfortunately, although some of
these drugs are relatively effective, they also result in quite
severe adverse effects (Mendelson and Mellon 1996). Current
evidence does not support the clinical use of dopamine ago-
nists for cocaine dependence (Soares and others 2003). Opioid
antagonists (for example, naltrexone) or opioid mixed agonist-
antagonists (such as buprenorphine) have been explored, on
the basis that cocaine dependence may be accompanied by
dependence on opiates. Although there have been problems
with compliance with naltrexone therapy (National Research
Council Committee on Clinical Evaluation of Narcotic
Antagonists 1978), buprenorphine has shown promising pre-
clinical and clinical trial results (Kosten, Kleber, and Morgan
1989). Other promising directions include cannabinoid recep-
tor antagonists and cortisol synthesis inhibitors (van den Brink
and van Ree 2003) and vaccination against the effects of
cocaine (Kantak 2003), but there is as yet no evidence on the
effectiveness of any of these interventions.
Acupuncture has also been used to treat cocaine depend-
ence. Auricular acupuncture is frequently used, but the small
number of trials that have been conducted have not provided
sufficient evidence of effectiveness (van den Brink and van Ree
2003).
Psychotherapy and Cognitive Behavioral Therapy The lack of
evidence for pharmacological therapy means that treatment
for cocaine dependence currently relies on cognitive behavior
therapies combined with contingency management strategies.
Unfortunately, psychosocial treatments for cocaine dependence
are also of limited effectiveness. Treatments such as therapeutic
communities, cognitive behavioral treatments, contingency
management, and 12 step–based self-help approaches benefit
cocaine-dependent people by reducing their rates of cocaine
use and improving their health and well-being, but rates of
relapse to cocaine use after treatment remain high (Platt 1997).
Mendelson and Mellon (1996) conclude that there are no
specific cognitive or behavioral interventions that are uniquely
effective in treating cocaine dependence. However, some success
has been demonstrated with incentive-based programs in which
rewards are provided for urine samples that are free of cocaine,
although there is doubt about whether results are sustained
(Roozen and others 2004). Such programs are generally more
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effective when the patient’s family and friends are involved
(Higgins and others 1994). Petry and others (2004) suggested
that contingency management was effective in reducing
cocaine use in a community-based treatment setting. They
found that the benefits of treatment depended on the magni-
tude of reward, with those earning up to US$240 obtaining bet-
ter results than those earning up to US$80. They suggested that
this form of intervention may work best for people with more
severe dependence on cocaine.
A multicenter investigation examining the efficacy of four
psychosocial treatments for cocaine-dependent patients con-
cluded that individual drug counseling in combination with
group drug counseling showed the most promise for effective
treatment of cocaine dependence over two forms of traditional
psychotherapy (Crits-Christoph and others 1999). Community
reinforcement involving an intensive, biopsychosocial, multi-
faceted approach to lifestyle change has shown positive effects
over four to six weeks and has the advantage of being tailored
to individual goals (Roozen and others 2004).
The few studies of the long-term effects of treatment have not
shown particularly encouraging results.A one-year follow-up of
the U.S. Drug Abuse Treatment Outcome Studies reported that
reductions in the use of cocaine in the year following treatment
were associated with longer duration of treatment, particularly
six months or more in long-term residential or outpatient treat-
ments (Hubbard, Craddock, and Anderson 2003). A five-year
national follow-up study of 45 U.S. treatment programs found
that only 33 percent of the sample had highly favorable out-
comes (Flynn and others 2003).
Amphetamines 
According to WHO, amphetamines and methamphetamines
are the most widely abused illicit drugs after cannabis, with an
estimated 35 million users worldwide (Rawson, Anglin, and
Ling 2002).
In Australia, the lifetime prevalence of amphetamine use is
between 6 and 8 percent in the general population, making
amphetamines the most commonly used illicit drug after
cannabis during that period (Makkai and McAllister 1998). In
1998, the lifetime prevalence of amphetamine use was highest
(25 percent) among male users age 20 to 29.
The use of amphetamines is generally less frequent than that
of opioids (Darke and Hall 1995; Darke, Kaye, and Ross 1999; W.
Hall, Bell, and Carless 1993; Hando, Topp, and Hall 1997;
Vincent and others 1998). This pattern is no doubt due to the
physical and psychological toll taken by regular amphetamine
use. Although such use is less frequent overall, however, there is
widespread bingeing on amphetamines, with frequent use over
several consecutive days, which may be followed by benzodi-
azepine use to “come down.” Polydrug use is particularly com-
mon among amphetamine users,who show a marked preference
for stimulant drugs such as hallucinogens and cocaine (Darke
and Hall 1995; Hando and Hall 1994; Vincent and others 1998).
Globally, Europe is the main center of amphetamine produc-
tion, particularly Belgium, the Netherlands, and Poland, with
production increasing in Eastern Europe (UNODCCP 2003).
Half of all Western European countries reported an increase in
amphetamine abuse in 2000, but in 2001 the figure fell to 33 per-
cent (UNODCCP 2003). Lifetime use of amphetamines is
reported to be between 0.5 percent and 6 percent among
European Union countries, with the exception of the United
Kingdom, where the figure is 11 percent. Denmark and Norway
also have relatively higher rates of use (EMCDDA 2003).
Adverse Health Effects of Amphetamine Use. Amphetamine
users who inject the drug are at high risk of bloodborne infec-
tions through needle sharing. Amphetamine users are as likely
as opioid users to share injection equipment (Darke, Ross,
Cohen, and others 1995; Darke, Ross, and Hall 1995; W. Hall,
Bell, and Carless 1993; Hando and Hall 1994; Kaye and Darke
2000; Loxley and Marsh 1991). In addition, the youth of
amphetamine users places them at risk of sexual transmission
of diseases such as HIV and hepatitis B virus (although not
hepatitis C). Primary amphetamine users have been demon-
strated to be a sexually active group, and small proportions
engage in paid sex to support their drug use (Darke, Ross,
Cohen, and others 1995; Hando and Hall 1994). Among gay
and bisexual men, amphetamines may be used to enhance sex-
ual encounters, which may lead to unprotected anal intercourse
and increased risk of HIV infection (Urbina and Jones 2004).
High-dose amphetamine use, especially by injection, can
result in a schizophreniform paranoid psychosis, associated
with loosening of associations, delusions, and hallucinations
(Gawin and Ellinwood 1988; Jaffe 1985). The psychosis could
be reproduced by the injection of large doses in addicts (Bell
1973) and by the repeated administration of large doses to nor-
mal volunteers (Angrist and others 1974).
High proportions of regular amphetamine injectors describe
symptoms of anxiety, panic attacks, paranoia, and depression.
The emergence of such symptoms is associated with injecting
the drugs, greater frequency of use, and dependence on amphet-
amines (W. Hall and others 1996; McKetin and Mattick 1997,
1998). Recent evidence also suggests that women may experi-
ence more emotional effects of amphetamine intoxication than
men and higher rates of anorexia nervosa than women without
amphetamine disorders (Holdcraft and Iacono 2004).
In sufficiently high doses, amphetamines can be lethal
(Derlet and others 1989). However, the risk is low compared
with the high risks of overdose associated with central nervous
system depressants such as heroin. Typically, amphetamine-
related deaths are associated with the effects of amphetamines
on the cardiovascular system—for example, cardiac failure and
cerebral vascular accidents (Mattick and Darke 1995).
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There is evidence that amphetamines are neurotoxic
(Robinson and Becker 1986). Evidence from animal studies
indicates that heavy amphetamine use results in dopaminergic
depletion (Ellison 1992; Fields and others 1991). The few stud-
ies of the neuropsychological effects of amphetamine abuse
report findings similar to those found with cocaine abuse.
Deficits in memory and attention have been attributed to
amphetamine use (McKetin and Mattick 1997, 1998). More
recently, a twin study indicated that amphetamine abuse might
lead to impaired attention and motor skills up to one year after
the conclusion of heavy use (Toomey and others 2003).
Interventions for Amphetamine Dependence. Treatment for
methamphetamine abuse has been a relatively recent develop-
ment and has generally been based on previous treatments for
cocaine abuse (Huber and others 1997). Cretzmeyer and oth-
ers (2003) reviewed treatments for methamphetamine abuse,
noting that there has been little research on the effectiveness
of drug treatment, probably because many amphetamine
users use multiple drugs. The combination of methampheta-
mine use with use of marijuana or other sedating drugs indi-
cates that effective treatments need to address the use of mul-
tiple drugs. A Cochrane Review concluded that evidence for
success in treatment of amphetamine dependence is very lim-
ited, with no pharmacological treatment demonstrated to be
effective (Srisurapanont, Jarusuraisin, and Kittirattanapaiboon
2003).
An early study explored the use of aversion therapy in a
multimodal treatment program using educational groups,
individual counseling, occasional family counseling, and after-
care planning. The intervention paired an aversive stimulus
(either chemical or electrical) with the act of using metham-
phetamines. Cocaine use was also treated in this way. After
12 months, 53 percent of patients were abstinent and the
researchers noted that their results were promising, despite a
number of limitations to the study (Frawley and Smith 1992).
An intervention combining imipramine, a tricyclic antide-
pressant, with intensive group counseling has been evaluated
with cocaine and methamphetamine abusers. Patients received
either a low or higher dose (as needed) of imipramine, as well
as intensive group counseling and access to medical and psy-
chiatric care. Those who received the higher dose stayed in
treatment longer, but the results did not support the use of
imipramine for methamphetamine abuse (Galloway and
others 1994).
The Matrix Program for methamphetamine and cocaine
abusers has also been evaluated. The Matrix Program uses a
cognitive behavioral approach with an emphasis on relapse
prevention (Huber and others 1997). The study evaluated the
effectiveness of three conditions: Matrix treatment alone,
Matrix treatment plus desipramine, and Matrix treatment plus
placebo (Shoptaw and others 1994). The researchers concluded
that those who received more Matrix treatment had better
abstinence rates than those who had less treatment but that
desipramine had no effect on treatment outcome.
J. Hall and others (1999) conducted an evaluation of the
effectiveness of the Iowa Case Management Project. The proj-
ect was designed to supplement interventions provided by a
drug abuse treatment agency and is a comprehensive social
work intervention, including outreach activities and provision
of limited emergency funds. The results of the evaluation
showed that comprehensive case management was effective in
improving employment status among amphetamine users sub-
sequent to treatment. There was an almost significant lower
incidence of depression among those who received the pro-
gram compared with controls. Drug use decreased significantly
for clients in both control and program conditions.
More recently, an Australian study evaluated the effective-
ness of brief cognitive-behavioral interventions among regular
users of amphetamines (Baker, Boggs, and Lewin 2001). The
researchers found a clinically significant reduction in daily
amphetamine use among the intervention groups compared
with controls and concluded that further studies of brief
cognitive-behavioral interventions are feasible and warranted.
Although some promising interventions have been identified
to assist methamphetamine abusers, no single treatment
option has yet been established as better than any other in a
randomized controlled trial (Cretzmeyer and others 2003).
Methylenedioxymethamphetamine
Methylenedioxymethamphetamine is more widely known
as ecstasy or MDMA. In Australia, the lifetime prevalence of
MDMA use increased from 1 percent of the population in 1988
to 4.6 percent (about one in 20 persons ) in 1998, with 2.3 per-
cent reporting MDMA use in the preceding 12 months (Topp
and others 1998). In 2001, 6.1 percent of Australians age 14
years or older reported lifetime use of MDMA, with 2.9 percent
reporting use within the preceding year (Degenhardt, Barker,
and Topp 2004). Rates of use are generally higher among males
than females (3.1 percent versus 1.5 percent). MDMA use in
the preceding 12 months is most common among those age
20 to 29 (5 percent of females and 12 percent of males) (Topp
and others 1998).
The availability of MDMA has also increased, as indicated by
the proportion of the population who have been offered MDMA
(from 4 percent in 1988 to 7 percent in 1991) (Makkai and
McAllister 1998), with 14 percent of those age 14 to 29 reporting
that they had been offered MDMA in the preceding year.
Research suggests that the pattern of MDMA use changed
during the 1990s (Topp and others 1998). Users of MDMA are
commencing use at a younger age, and they appear to be using
larger doses more frequently. The incidence of bingeing on
MDMA appears to have increased, as does the prevalence of the
parenteral use of this drug. The increase in the use of MDMA
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by injection has been noted among surveys of MDMA users
and of injecting drug users generally.
An examination of trends in the United States suggested
that, although the use of MDMA has increased over time, its
prevalence is significantly less than that of other drugs of abuse
(Yacoubian 2003b). A study of 14,520 U.S. college students
indicated 6 percent lifetime use of MDMA, 3 percent within the
preceding 12 months, and 1 percent within the preceding
30 days. Those who had used MDMA in the preceding
12 months were more likely to be white and a member of a fra-
ternity or sorority and to have used a range of other drugs
(Yacoubian 2003a). Rates of use are much higher in surveys of
club attendees. A recent U.S. survey found 86 percent reporting
lifetime use, 51 percent 30-day use, and 30 percent use within
the preceding 2 days (Yacoubian and others 2003).
Abuse of MDMA had showed signs of decreasing in Western
Europe but has recently shown signs of increase (UNODCCP
2003). Although MDMA use appears to be still diffusing, in
2003 only four countries (Ireland, the Netherlands, Spain, and
the United Kingdom) reported a rate of more than 3 percent
use among young adults in the preceding 12 months
(EMCDDA 2003). In the United States, use declined in 2002 for
the first time, but it increased in other regions, particularly the
Caribbean, parts of South America, Oceania, Southeast Asia,
the Near East, and southern Africa (UNODCCP 2003).
Lifetime experience of MDMA is reported to range from
0.5 percent to 5 percent in European Union countries, with use
more common in the Netherlands (EMCDDA 2003).
Population survey findings from New Zealand reported an
increase in the preceding-year use of MDMA from 1.5 percent
in 1998 to 3.4 percent in 2001. The increase was particularly
evident among young men age 20 to 24 (from 4.3 percent to
12.5 percent) (Wilkins and others 2003).
Adverse Health Effects of MDMA. Early studies of MDMA
use in Australia and the United States documented relatively
few problems associated with the drug’s use (Beck 1990; Beck
and Rosenbaum 1994; Downing 1986; Solowij, Hall, and
Lee 1992). A survey of 100 MDMA users (Solowij, Hall, and
Lee 1992) found that the most common adverse effects were
the side effects of acute use, such as appetite loss, dry mouth,
palpitations, and bruxism (teeth grinding). Among the few
heavy users in the study, only two reported feeling dependent
on the drug.
With a change in the pattern of MDMA use in Australia,
there has been an increase in the MDMA-related harms
reported (Topp and others 1998). Some of the acute physical
and psychological adverse effects that MDMA users have
attributed to the use of this drug include energy loss, irritabil-
ity, muscular aches, insomnia, and depression. More chronic
adverse effects were also reported, including weight loss,
depression, energy loss, insomnia, anxiety, and teeth problems.
A recent U.K. study of 430 regular users of MDMA reported
that 83 percent of participants reported low mood and 80 per-
cent experienced impaired concentration. Long-term effects
of MDMA included the development of tolerance to MDMA
(59 percent), impaired ability to concentrate (38 percent), and
depression (37 percent) (Verheyden and others 2003).
Physical symptoms that were perceived as being due to
MDMA use alone (Topp and others 1998) included an inability
to urinate, blurred vision, vomiting, numbness or tingling, loss
of sexual urge, and hot and cold flushes. As with amphetamines,
the use of MDMA to facilitate sexual encounters may lead to
risky sexual behavior and risk of sexually transmitted infections
such as HIV. Studies of gay and bisexual men have found an
association between MDMA use and high-risk sexual behavior
(Urbina and Jones 2004).
MDMA has been implicated in a growing number of deaths,
both in Australia and in other countries (Henry, Jeffreys, and
Dawling 1992; Solowij 1993; White, Bochner, and Irvine 1997).
Although the reasons for extreme reactions have yet to be
clearly determined, deaths have most often been attributed to
hyperthermia when MDMA was used at dance venues. A com-
bination of sustained exertion, high ambient temperatures, and
inadequate fluid replacement appears to compound the effect
of MDMA on thermoregulatory mechanisms, causing a rapid
and fatal rise in body temperature (Topp and others 1998).
Some deaths have been attributed to excessive water consump-
tion, which causes cerebral edema (Cook 1996; Matthai and
others 1996).
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Learning and developmental disabilities (LDDs) include func-
tional limitations that manifest in infancy or childhood as a
result of disorders of or injuries to the developing nervous
system (Institute of Medicine Committee on Nervous System
Disorders in Developing Countries 2001). These limitations
range from mild to severe and can affect cognition, mobility,
hearing, vision, speech, and behavior. The known causes of LDD
are numerous and include genetic factors, nutritional factors,
infections, toxic exposures, trauma, perinatal factors, and multi-
factorial conditions (table 49.1). Selected causes of LDD that are
not addressed in detail in this chapter are described in box 49.1.
Although information on the prevalence and impact of
disabilities in low- and middle-income countries (LMICs) is
scarce, five considerations support the conclusion that LDDs
are a public health priority in LMICs today:
• Prevalence. Although each individual cause is relatively rare,
taken together, LDD affects a large proportion of children. In
high-income countries, 10 to 20 percent of children have an
LDD (Benedict and Farel 2003). With improvements in child
survival in LMICs, it is not known whether the prevalence of
disabilities among children is increasing, as has been seen in
wealthier countries (Winter and others 2002), but the few
data available from LMICs suggest that the prevalence of
specific causes and types of LDD may be even higher than in
high-income countries. Examples include cognitive disabili-
ties associated with prenatal iodine deficiency, brain infec-
tions, and blindness associated with vitamin A deficiency
(Durkin 2002). The prevalence of childhood disabilities in
LMICs is not well established, but it is likely higher than in
high-income countries.
• Lifelong duration. By definition, LDDs have an early onset,
with the causes frequently occurring in the prenatal period.
These effects are typically lifelong,affecting learning and other
neurological functions, educational achievement, quality of
life, earning potential, and productivity across the life span.
• Costs. The extensive costs include the direct costs of acute
care, outpatient health care services, long-term care, rehabil-
itation, and special education, as well as the indirect costs of
morbidity and increased mortality (Waitzman, Romano, and
Scheffler 1994). Additionally, the costs and effects extend
beyond the individuals affected to include entire families.
Health, careers and employment of parents, family dispos-
able income, health and adaptation of siblings, and family
interaction are adversely affected when a family member has
an LDD (Stein and Jessop 2003). It is difficult to comprehend
the extent of these effects, just as it is difficult to measure
them and develop economic models that account for them.
• Education and work. As societies and economies become
increasingly information-oriented and dependent on edu-
cated and literate workers, the impact of disabilities affect-
ing cognition and learning becomes greater (Institute of
Medicine Committee on Nervous System Disorders in
Developing Countries 2001).
• Proven interventions. The prospects for preventing LDD and
for improving outcomes are considerable and can be
achieved, to some extent, by implementing interventions
that have been shown to be effective and cost-effective else-
where but that are not being implemented in LMICs.
This chapter provides an overview of the range of interven-
tions likely to improve child development and educational
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Table 49.1 Categories of Causes of LDD
Category Examples
Genetic
Chromosomal Down syndrome, chromosomal rearrangements
Segmental autosomal syndromes Prader-Willi syndrome, Angelman syndrome
Sex-linked, single gene Fragile X syndrome, Rett syndrome
Autosomal recessive Phenylketonuria, Tay–Sachs disease
Autosomal dominant Neurocutaneous syndromes, such as neurofibromatosis
Multifactorial 
Genetic and nutritional Neural tube defects
Nutritional
Prenatal: maternal iodine deficiency Developmental iodine deficiency disorder
Childhood: vitamin A deficiency Xerophthalmia, night blindness
Infections
Prenatal or perinatal Toxoplasmosis, rubella, cytomegalovirus, herpes, gonorrhea, syphilis, group B streptococcus, chlamydia,
trichomonas vaginalis, bacterial vaginosis, herpes simplex virus, HIV
Postnatal or childhood Encephalitis, meningitis, varicella, cerebral malaria, polio, trachoma, otitis media
Toxic exposures
Prenatal Alcohol, lead, mercury, antimicrobials (such as sulfonamides, isoniazid, ribavirin), anticonvulsants (such
as phenytoin, carbamazepine), and other drugs (such as accutane, thalidomide)
Postnatal or childhood Lead, mercury
Other maternal disorders
Thyroid disease Cerebral palsy
Other perinatal complications
Brain injuries associated with Cerebral palsy, cognitive disabilities, seizure disorders
premature birth, birth asphyxia
Injury
Traumatic brain injuries and other Cognitive, motor, speech, vision, hearing, seizure, and behavioral disabilities
disabling injuries from vehicle crashes, 
child abuse and neglect, falls, burns, 
warfare, and so forth
Poverty, economic disadvantage
Social and cognitive deprivation Mild mental retardation
Unknown LDD of unknown cause
outcomes for children in LMICs. Evidence of cost-effectiveness
is considered in some detail for three selected interventions. An
overview of other key risk factors and conditions that result in
LDD is provided. A research agenda is outlined for advancing
knowledge of how to prioritize cost-effective interventions and
how best to devote resources for the prevention of LDD in
LMICs.
LDD AND THE GLOBAL BURDEN OF DISEASE 
Estimates for disability-adjusted life years (DALYs) (Mathers
2006) are not available to convey the full range of LDDs or their
risk factors. Attempts have been made to estimate the DALYs
associated with specific causes of LDDs. For example, it is esti-
mated that 9.8 million DALYs, or nearly 1 percent of the global
burden of disease, are due to one relatively minor form of LDD,
namely, mild mental retardation (MR) caused by lead ingestion
from environmental sources (Fewtrell and others 2004). Since
only a small fraction—probably much less than 10 percent—of
LDD worldwide can be attributed to lead-induced mild MR,
this estimate suggests that LDD as a whole must account for a
large proportion, perhaps more than 10 percent of the global
burden of disease. Where DALY estimates are available, we use
them as a basis for economic analysis to estimate the costs of
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Interventions for the Prevention of Childhood Neurological Disabilities
Box 49.1
Attention Deficit Hyperactivity Disorder
Attention deficit hyperactivity disorder (ADHD) is the
most common neurological disorder in children in the
United States, with an estimated prevalence of 3 to 11 per-
cent. The prevalence is not known in LMICs, but as school-
ing increasingly becomes the norm, ADHD is likely to
become more obvious. The burden of ADHD in settings of
large class sizes will likely pose an increasing challenge. In
addition to its major impact on school performance,
ADHD affects family relationships and social competence,
with lasting consequences. Children with ADHD are also at
higher risk for injury, depression, and substance abuse.
Worldwide, with the growing use in school settings of stim-
ulants to control this chronic disorder, the impact on health
care costs is potentially huge. Although there are a paucity
of data on this topic, in one study, the cost of medicating
children for ADHD was close to an average of US$500 or
more per child per year, and this figure is considered a sub-
stantial underestimate (Chan, Zhan, and Homer 2002).
Autism Spectrum Disorders 
All autism spectrum disorders (ASDs) are characterized
by varying degrees of impairment in communication
skills and social interactions and in restricted, repetitive
patterns of behavior or interests. Although only 50 per-
cent of children in the United States with ASDs are diag-
nosed before six years of age, this group of disorders can
reliably be diagnosed by three years of age and in some
cases by as early as 18 months. ASDs range from a severe
form called autistic disorder to a milder form known as
Asperger syndrome. Prevalence studies of ASDs in Asia,
Europe, and North America estimate that 2 to 6 out of
every 1,000 children have an ASD. Screening instruments
using responses from children and parents are available.
Evidence indicates that early intervention (ideally in opti-
mal educational settings for at least two years during pre-
school) results in improved outcomes. Individuals with
ASDs generally respond well to highly structured, special-
ized programs. A variety of medications is used to treat
associated depression, anxiety, ADHD, seizures, and other
behavioral symptoms. Adults with severe ASDs require
intensive and constant supervision. Little information is
available regarding the parental and service costs of ASDs.
In a 2001 study in the United Kingdom, the lifetime cost
for a person with autistic disorder exceeded UK £12.4 mil-
lion, with most of the expense related to living support
and daily activities.
Infection
Numerous prenatal, perinatal, and postnatal infections
can damage the developing nervous system or sensory
pathways and cause long-term disabilities in children. The
relative contribution of these infections to the burden of
LDD is likely to vary by country. It will be influenced by
overall infant mortality, postneonatal contribution to
infant mortality, and regional difference in the distribu-
tion of the infections known to be associated with neuro-
logical sequelae during different periods in the early life
cycle. A few of the most important infections that may
result in LDD include the following:
• Congenital rubella (chapter 20). This disease is a major
global cause of preventable hearing impairment, blind-
ness, and intellectual disability. The incidence of con-
genital rubella syndrome has been variably set at 0.5 to
2.2 out of every 1,000 live births in LMICs during epi-
demics, which occur every four to seven years (Cutts
and others 1997). Though some LMICs have set elimi-
nation goals and vaccination has been noted to be cost-
effective, only 28 percent of LMICs routinely vaccinate
against rubella (Robertson and others 1997).
• HIV/AIDS infection (chapter 18). Neurological prob-
lems in HIV-infected children vary in different parts of
the world but may be as high as 40 to 50 percent (Bobat
and others 1998). The developmental trajectory of
infected children is confounded by maternal, social,
and biological risk factors during pregnancy and early
childhood. Maternal substance and drug abuse, more
common in HIV-infected women, have an independent
adverse effect on brain growth and neurodevelopmen-
tal outcome. Low birthweight and prematurity, pov-
erty, protein calorie malnutrition, and micronutrient
deficiencies—more frequently seen in HIV-infected
children and particularly in LMICs—may similarly
compromise early child development (Brouwers and
others 1996).
• Malaria (chapter 21). In Sub-Saharan Africa, malaria is
the leading cause of childhood mortality and morbidity.
Cerebral malaria is a well-known complication and
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(Continued )
Box 49.1
may result in neurological sequelae in survivors, con-
tributing significantly to the burden of LDD.
• Bacterial meningitis (chapter 20). This disease results
in long-term sequelae for many children, including
approximately 40 percent of children who survive
Haemophilus influenza meningitis, 50 percent who
survive pneumococcal meningitis, and 10 percent
who survive meningococcal meningitis. Cost-effective
immunization can prevent meningitis from all these
causes.
Alcohol 
Prenatal alcohol exposure resulting in fetal alcohol syn-
drome may be the most common single preventable cause
of MR worldwide (Viljoen 1999), but substantial chal-
lenges remain in diagnosing and preventing this disorder
(see chapter 47). In addition to growth retardation and
congenital heart disease, effects include ADHD, memory
deficits, and mood disorders. Adults continue to have
attention and social difficulties and higher rates of alcohol,
nicotine, and drug dependence. Children exposed to even
small amounts of alcohol (half a drink per day) in utero
have poor outcomes, suggesting that abstinence should be
recommended during conception and throughout preg-
nancy (Sokol, Delaney-Black, and Nordstrom 2003).
Although tools are available to help providers identify
women who consume alcohol, detection of maternal alco-
hol exposure is a challenge. The overall rate of fetal alco-
hol syndrome for LMICs has been placed at 1 to 4.8 out of
every 1,000 population (Sampson and others 1997) and is
higher among low socioeconomic populations and sub-
populations with particularly high alcohol intakes. If
individuals with the full spectrum of fetal alcohol
syndrome–related effects are included, this rate may be as
high as 1 in every 100 births. A prevalence rate of 40.5 to
46.4 out of every 1,000 children in South Africa, the high-
est rate worldwide, is attributable to particular historical
and social conditions (May and others 2000).
Public health measures to prevent prenatal alcohol
exposure have had limited success, and rates have not
changed over the past decade in the United States (Floyd
and Sidhu 2004). These measures include putting warning
labels on alcoholic beverages and broadcasting public
messages about alcohol dangers during pregnancy.
Improved outcomes might result from targeting the use of
screening tools for high-risk drinkers, who include women
in prisons, drug rehabilitation centers, hospital emergency
facilities, and sexually transmitted disease clinics (Sokol,
Delaney-Black, and Nordstrom 2003). Little is known
about the costs around the world. Annual costs for all indi-
viduals with fetal alcohol syndrome in the United States
during 1998 was estimated at US$4 billion, with lifetime
care per person, for individuals requiring such care, at
US$1.4 million (Lupton, Burd, and Harwood 2004).
Environmental Exposures 
Children are more susceptible to environmental factors,
including unsafe home environments, road traffic, and
chemicals (see chapters 42 and 43). Even in high-income
countries in Europe, mild MR resulting from lead expo-
sure accounted for 4.4 percent of DALYs among children
zero to four years of age. Legislative efforts are under way
to eliminate lead from gasoline and other environmental
sources of lead exposure in LMICs (Khan and Khan 1999;
Alliance to End Childhood Lead Poisoning 2002). In the 0
to 19 years age group, injuries from all causes accounted
for 19 percent of DALYs. The poor and vulnerable road
users—pedestrians, cyclists, and motorcyclists—bear the
greatest burden of road injuries. Nearly 25 percent of all
nonfatally injured victims requiring hospitalization sus-
tain a traumatic brain injury as a result of motor vehicle
crashes (Peden and others 2004). Although the effective-
ness of bicycle helmets for road safety is high, their use in
LMICs is low (Thompson, Rivara, and Thompson 1999).
Interventions aimed at reducing children’s exposure to
environmental factors and injuries could result in sub-
stantial gains. Targeted action by region, even within a
single country, is likely to prove most productive (Valent
and others 2004).
Nutritional Deficiency
Iodine deficiency from inadequate quantities of iodine in
soil, water, and food affects 13 percent of the world’s pop-
ulation, and an additional 30 percent are at risk (see chap-
ter 28). Maternal iodine deficiency during pregnancy may
result in an average loss of 15 IQ points in offspring, mak-
ing it a leading preventable cause of MR. Iodine deficiency
can be prevented with adequate consumption of iodized
salt, which is now consumed by about 70 percent of
households worldwide.
prevention of LDD. In this chapter, we estimated only costs of
the interventions for Down syndrome (DS), neural tube defects
(NTDs), and congenital hypothyroidism.
IMPAIRMENT, DISABILITY, AND PARTICIPATION
Quantifying the impacts of LDD and their preventive interven-
tions is complicated by the fact that these disorders can exist
and be measured at multiple levels, including three levels
distinguished by the World Health Organization (WHO) in
International Classification of Functioning, Disability, and
Health (WHO 2001):
• impairment, which refers to physiological or psychological
defects or abnormalities, such as failure of the neural tube to
close
• function or disability, which refers to the ability of an indi-
vidual to perform a task, such as walking, seeing, hearing,
learning language, and reading
• participation, which refers to the degree to which an indi-
vidual participates in school, employment, social role, and
recreational activities.
A given impairment may be associated with a range of func-
tional outcomes. Some but not all of these may be recognized
as disability. Disability is context specific and may vary from
culture to culture. For example, conditions such as dyslexia,
attention deficit and hyperactivity disorder (ADHD), and mild
MR may be especially disabling in school but not as noticeable
in nonacademic settings and environments where schooling is
optional. Environmental factors and social stigma may deter-
mine the participation of people with disabilities more than do
the functional deficits themselves. Some interventions may be
designed to enhance participation (for example, ramps, acces-
sible public toilets, inclusive education), whereas others may
target impairment and disability (for example, nutritional for-
tification, surgery, rehabilitation, special education, newborn
screening, and early treatment).
THREE LEVELS OF PREVENTION
Prevention of LDD involves primary, secondary, and tertiary
prevention activities:
• Primary prevention includes efforts to control the underly-
ing cause or condition that results in disability. Examples
include (a) maternal antiretroviral therapy to reduce the
risk of mother-to-child transmission of HIV and (b) fortifi-
cation of the food supply to prevent birth defects such as
spina bifida and iodine deficiency disorders.
• Secondary prevention aims at preventing an existing illness or
injury from progressing to long-term disability. Examples
include newborn screening for metabolic disorders followed
by dietary restrictions to prevent damage to the nervous sys-
tem and effective emergency medical care for head injury.
• Tertiary prevention refers to rehabilitation and special edu-
cational services to mitigate disability and improve func-
tional and participatory or social outcomes once disability
has occurred.
UNINTENDED CONSEQUENCES OF SUCCESSFUL
OR PARTIALLY SUCCESSFUL INTERVENTIONS
Interventions to reduce mortality and morbidity may be fol-
lowed by increases in the prevalence of LDD. Examples include
the following:
• Improved survival of very low birthweight infants at high
risk for LDD may cause the prevalence of disability in the
population to increase at the same time that it increases the
absolute number of survivors without disabilities.
• Rubella vaccination programs with less than optimal cover-
age will prevent infections in those vaccinated but leave
unvaccinated girls at risk for acquiring rubella infection dur-
ing their childbearing years (rather than during childhood,
as might be expected in the absence of a vaccination pro-
gram), thereby increasing the risk of congenital rubella
infection and disability in the population.
• Newborn screening and treatment for phenylketonuria in
infancy and childhood prevent MR, but phenylalanine
dietary restriction for women with phenylketonuria during
their childbearing years is essential to prevent prenatal neu-
rological damage and MR in their offspring.
OTHER FACTORS LEADING TO INCREASES
IN MEASURED PREVALENCE
Progress in the field of LDD may result in increases in the rec-
ognized prevalence of disability and in social and economic
costs, as in the following examples:
• Increased availability of services may increase the number of
children with recognized disabilities. Just as it is ethically
problematic to screen for disorders for which no services
can be offered, expansion of case finding becomes justified
and ethically demanded as services become available, with
the potential result of increasing the measured prevalence of
disability.
• As educational expectations and awareness of LDD increase,
the prevalence of recognized disability may increase.
In consideration of these trends and relationships between
public health advances and increases in disability, it may not be
realistic to expect short-term control of disability or cost sav-
ings following interventions that reduce mortality, even if those
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interventions have a net positive effect on public health. The
costs of disability and its prevention may increase initially in
the wake of interventions that successfully reduce mortality.
Figure 49.1 summarizes the causal pathways and potential
interventions for the prevention of LDD.
INTERVENTIONS IN LOW- AND 
MIDDLE-INCOME COUNTRIES
Numerous interventions are effective in preventing LDD.
Table 49.2 provides a summary of these interventions classified
on two axes. The horizontal axis distinguishes whether the
intervention would accomplish primary, secondary, or tertiary
prevention of disability. The vertical axis distinguishes four
levels of evidence for cost-effectiveness:
• evidence available for LMICs
• evidence available for high-income countries only
• evidence for cost-effectiveness not available, but cost-
effectiveness can be estimated from existing data
• evidence not available, but potential for benefits exists.
The literature indicates that the economic outcomes of a
given intervention may vary widely for two reasons:
• Variations exist across populations, even within the same
country, in the prevalence of the disorder, the cost of health
care, and the existing infrastructure available to implement
the intervention.
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Source: Authors.
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Figure 49.1 Causal Pathways for LDD
• Differences between studies exist in analytical methods
used, such as the willingness to pay versus the human
capital approach to valuation, and in cost categories, such as
whether to include parental time costs. Though these differ-
ences make cross-population comparisons difficult, the
overall evidence of cost-effectiveness is demonstrated by
repeated findings that the benefits of a particular interven-
tion outweigh the costs in a number of different settings.
Current evidence suggests that three interventions are cost
saving: folic acid fortification to prevent NTDs, prenatal
screening and selective pregnancy termination to prevent DS,
and neonatal screening and treatment for congenital hypothy-
roidism (CH).
Too little is known about the fourth type of intervention,
community-based rehabilitation, to evaluate it. There is a
paucity of knowledge and a history of failed interventions
for the prevention of premature birth and the disabilities
associated with premature birth.
Neural Tube Defects: Burden and Cost-Effectiveness 
of Folic Acid Fortification 
NTDs, which are the most common malformation of the cen-
tral nervous system, result from failure of the neural tube to
close during the first month of pregnancy. Anencephaly typi-
cally results in pregnancy loss, stillbirth, or neonatal death.
Spina bifida (open spine defect) is associated with a range of
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Table 49.2 Classification of Interventions to Prevent LDD 
Tertiary (rehabilitation or 
Primary (prevention of Secondary (prevention of prevention of further 
condition that can lead to disability once condition disability once disability 
disability) has occurred) has occurred)
Evidence for cost-effectiveness Food fortification (folic acid and iodinea)
available for LMICs Rubella vaccinea
Hemophilus vaccine
Removal of lead from paint and fuel
Vitamin A supplementation (vision)
Measles vaccine
Evidence for cost-effectiveness Prenatal screening for DS 
available for high-income and prevention of DS births 
countries only Newborn screening for metabolic 
disorders followed by interventions 
to prevent disability
Evidence for cost-effectiveness Malaria preventionb Early detection and care Special education
not available, but cost-effectiveness of neonatal jaundice Prosthetics
can be estimated from existing data Management of malaria Braille
Treatment for otitis media Sign language
Prevention and treatment of neonatal Occupational, physical, 
complications through emergency and speech therapies
obstetric and pediatric services Surgery
Eyeglasses Residential care
Hearing aids Assistive devices
Detection and treatment of maternal 
thyroid disorders
Evidence for cost-effectiveness Fetal alcoholism prevention Dehydration/diarrhea treatment Community-based 
not available, but potential for Trauma prevention (bicycle Postnatal combined cognitive rehabilitation
benefits exists helmets, burns) stimulation and nutritional intervention
Prevention of shaken baby Therapeutic stimulants for 
syndrome and child abuse treatment of ADHD
Note: Italicized text represents somewhat detailed consideration of cost-effectiveness included in this chapter.
a. Covered in chapter 56, but chapter emphasis is not on implications for preventing developmental disabilities.
b. Covered in detail in chapter 21.
functional deficits (requiring multiple surgical and rehabilita-
tive interventions), including paralysis of the lower extremities
and often primary enuresis and cognitive disabilities. Large
geographic variations in the prevalence of NTDs exist both
within and between countries. The burden of disease is highest
in South Asia and lowest in LMICs of Europe and Central Asia.
Similarly, deaths from NTDs are high in South Asia but lowest
in high-income countries. Estimates suggest that almost all
NTD disease burden is concentrated in the age group zero to
four years (Mathers 2006).
Folic Acid. Folate is a vitamin that occurs naturally in green
leafy vegetables, legumes, citrus, and other foods. Folic acid (FA)
is an easily absorbed synthetic form of folate that can be deliv-
ered as a dietary supplement or through FA fortification of flour
or other common staple foods. NTDs can be reduced by 70 per-
cent if women consume 400 g of FA daily around the time of
conception and until closure of the neural tube. At a population
level, either supplementation or fortification of the food supply
is necessary to ensure that 400 g of FA is consumed at the crit-
ical period of fetal development, as this dose is higher than can
reasonably be consumed by relying on naturally occurring
folate in foods. Fortification is much more likely than supple-
mentation to reach the population at risk because the benefit of
enhanced FA intake occurs early, typically before the pregnancy
is recognized. Fortification is of particular value to women who
may not receive prenatal care until the third trimester.
This section considers only evidence of cost-effectiveness of
FA fortification in LMICs with respect to the benefit of pre-
venting NTDs. Additional health benefits can be expected with
respect to stroke, heart disease, and cancer.
Cost-Effectiveness of Folic Acid Fortification A cost-benefit
analysis of grain fortification in the United States (Romano and
others 1995) included costs related to the addition of FA to
food, to annual testing and surveillance, to a one-time packag-
ing change, and to potential (though not substantiated) adverse
health effects associated with undiagnosed vitamin B12 defi-
ciency. Benefits included avoided costs of NTDs, such as mor-
tality costs (particularly for anencephaly) and costs of caring
for those with spina bifida. The benefits of fortification out-
weighed costs with cost-benefit ratios of 1 to 4.3 for low-level
fortification and 1 to 6.1 for high-level fortification.
Cost-effectiveness relative to status quo of FA fortification
depends on several factors:
• Costs of food fortification depend on the types and quanti-
ty of food that are fortified and the level of fortification.
• The proportion of the target population reached by the
fortified food is important since, in most LMICs, many peo-
ple consume food produced on their own farms or within
their villages.
• Grains from large mills are relatively cheap to fortify; more
resources are required to fortify grains milled in smaller
neighborhood mills.
• The amount of folate consumed by different populations in
the absence of fortification varies.
• Prevalence of NTDs varies across populations, and the cost-
effectiveness increases with prevalence.
Costs of food fortification may be lower in high-income
countries, where most people consume cereals processed in a
few large mills, equipment for fortification is likely to be in
place, and quality assurance is facilitated. In contrast, mills in
LMICs lack fortification equipment and capital, and running
costs are higher in the short run.
Costs of Food Fortification For optimal daily consumption,
the actual level of food fortification (defined as g of FA per
100 grams of the food item) should be adjusted for storage and
other losses so that a daily dose of 400 g is achieved. Food items
that should be fortified depend on specific dietary habits.
Staples such as rice and flour are obvious choices; salt, sugar,
bread, milk, and edible oils are promising candidates. There are
economies of scale in FA fortification.It can be and usually is car-
ried out in conjunction with other forms of fortification, such as
iron, iodine, and vitamin A fortification. Many food items are
already fortified in high-income countries. Other factors to be
considered in the choice of food for fortification are items that
are centrally processed and allow for quality control.Soy sauce in
China is an example: it is consumed on a daily basis by 70 percent
of the population and is prepared in a few large factories.
The recommended fortification level is thus 240 g per
100 grams of the staple food. This fortification rate is assumed
for all regional strata where the per capita staple consumption
per day is less than 300 grams. Wheat, rice, maize, or a combina-
tion of these foods is the staple in most countries. The
recommended level of FA fortification varies from 150 g to
240 g per 100 grams of cereal. So that women receive a daily
dose of 400 g, the target cereals for fortification should be those
for which daily per capita consumption is at least 200 grams. In
Sub-Saharan Africa,daily per capita cereal consumption exceeds
200 grams only if wheat, rice, and maize are considered together.
Quality assurance is done through analytic testing of forti-
fied products to confirm FA levels. Quality assurance costs in
the United States are estimated at US$0.64 cents per ton of for-
tified grain in quality assurance costs.
The costs of FA fortification include the cost of FA, setup,
and analytic testing. The analysis is done using two different
cost estimates: US$0.15 and US$0.50 per  ton of grain fortified.
The cost of FA determines the cost of premix added to the
flour. FA is almost never added alone; usually FA, iron, zinc,
and niacin are added in combination. The material cost of FA
alone is about US$0.10 to US$0.20 per metric ton of milled
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wheat. However, a more realistic cost for the premix (including
other supplements) is about US$0.50 per metric ton of milled
wheat. This higher estimate is conservative and does not
account for the health benefits from the other supplements.
Either way, the per capita costs are only a few cents in each
region. The low per capita cost in high-income countries of
US$0.009 assumes that 80 percent of the cereal supply is forti-
fied. In South Asia, where NTDs have the highest burden, the
per capita cost is estimated at US$0.067 (Bagriansky n.d.).
Benefits of Folic Acid Fortification The cost-effectiveness of FA
fortification in terms of its cost per DALY and per death averted
assumes that the fortification strategy will reduce the incidence
of NTDs by 50 percent. The costs are relatively high because of
the high cost of FA. Even a few cents per capita becomes expen-
sive if the per capita prevalence of NTD is very low.
Other Costs and Benefits The benefits of FA fortification
outweigh the costs. The benefits estimated here are conserva-
tive for three reasons:
• Strokes and coronary deaths are also prevented by FA forti-
fication and occur more frequently than NTDs.
• The percentage of NTDs that can be prevented by FA
fortification may be greater than 50 percent, because up to
70 percent of NTDs can be prevented by 400 g of pericon-
ceptional FA daily.
• These estimates do not take account of the costs of clinical
care and management for complications when NTDs are
not prevented.
Interventions to Prevent Disability Caused
by Down Syndrome 
Screening programs are critical public health interventions that
use universal or targeted screening tests to identify potential
causes or cases of LDD, including DS.
Prenatal and Neonatal Screening. Prenatal screening for
genetic abnormalities allows parents to determine whether to
continue with an affected pregnancy, whereas neonatal screen-
ing’s fundamental purpose is to improve the infant’s prognosis
through early diagnosis and treatment.
A number of LDDs have been screened for in high-income
countries since the 1960s, and researchers have conducted eco-
nomic evaluations of these screening programs, including those
for Tay-Sachs disease carriers, DS (Cusick and others 2003),
sickle cell disease (Panepinto and others 2000), phenylke-
tonuria (Lord and others 1999), and several other inborn errors
of metabolism (Insinga, Laessig, and Hoffman 2002).
Estimates for Prenatal Screening, Diagnosis, and Selective
Pregnancy Termination for Down Syndrome. DS is the most
common genetic cause of mental retardation. Identifying a
fetus with DS before birth and giving parents the option to ter-
minate the pregnancy early can help decrease the burden of the
disease on families and society. During counseling, parents may
receive information about the consequences of DS, which will
allow them to make an informed decision about the best care
for the newborn or about termination of the pregnancy.
Prenatal screening services provide an opportunity to pro-
foundly reduce the impact of MR. The cost-effectiveness of
prenatal screening for DS is based on two parameters: efficacy
(by assessing the false positive rate of screening procedures and
the number of fetal losses caused by screening) and financial
costs (costs of screening per DS pregnancy averted). On the
basis of the evidence, the best screening method is proposed,
and sensitivity of the parameters of interest to the LMIC is
tested. No formal comparisons are made between the costs of
screening and care for a person with DS. The purpose of this
analysis is to suggest the most cost-effective way of screening
that provides families with information about the health of the
child; it is not a cost-benefit analysis of whether a couple
should terminate a pregnancy.
Burden. DS is caused by trisomy of chromosome 21—an extra
chromosome rather than the usual diploid form—and is a
major cause of severe MR (IQ less than 50 with substantial
deficits in adaptive behavior). The incidence of DS is higher
than the birth prevalence because many fetuses are sponta-
neously miscarried and, in some cases, selectively terminated.
In the absence of prenatal screening and intervention, most
DS conceptions (71 percent) result in spontaneous abortion;
another 3 percent result in stillbirth, and 26 percent result in live
birth with subsequent LDD (Kline, Stein, and Susser 1989).
Because the incidence of DS cannot be determined without
doing surveillance of all conceptions, the frequency of DS is
typically measured in terms of prevalence per 1,000 live births
rather than in terms of incidence. Thus, the population preva-
lence of DS varies depending on the maternal age structure
(steep increase after age 35 years) as well as the availability and
use of prenatal diagnosis followed by selective termination.
Estimates from 10 LMICs range widely, from 0.1 out of every
1,000 live births in Indonesia to 4.4 out of every 1,000 live births
in Pakistan (Institute of Medicine 2003). Most studies, in both
high-income countries and LMICs, show DS birth prevalence
in the range of 1.0 to 1.6 out of every 1,000 births. The birth
prevalence of DS is likely higher in LMICs because of a higher
proportion of births among women over age 35 (11 to 15 per-
cent) relative to that in high-income countries (5 to 9 percent)
(Kline, Stein, and Susser 1989) and possibly because of differen-
tial access to prenatal screening for chromosomal abnormalities.
Life Expectancy and Quality of Life. Life expectancy for chil-
dren with DS is substantially lower than that of the general
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population. Congenital heart disease occurs in 40 to 60 percent
of children with DS and accounts for 30 to 35 percent of
deaths. Survival and life expectancy of children with DS have
increased dramatically: In a 1940–60 birth cohort in England,
only 50 percent of infants with DS survived beyond age two. By
comparison, in 1981–85, 90 percent survived beyond age five
(McGrother and Marshall 1990). Table 49.3 describes the esti-
mated total deaths caused by DS by region, as well as the esti-
mated total DALYs lost.
DS is always associated with cognitive impairment.
Disability can range from mild to profound, and most children
are affected moderately (IQ 40–55). Early intervention and
therapy can improve functional outcomes. Of children with DS,
60 to 80 percent have hearing loss, and approximately 70 per-
cent have ophthalmologic problems. As life expectancy of DS
individuals has increased, many grow to adulthood and face an
increased risk of early onset Alzheimer’s disease, cataracts, hear-
ing loss, hypothyroidism, and degenerative vascular disease.
Costs of Care. Based on 1988 data, the estimated incremental
lifetime economic costs of DS are US$410,000 per case or
US$647,709 in 2004 dollars (Waitzman, Romano, and Scheffler
1994). In another study, the estimate of per capita incremental
costs of DS, converted to 2004 dollars, include net medical costs
of US$168,567, developmental services costs of US$80,530,
special education costs of US$171,593, and total costs of
US$420,690 (Waitzman, Romano, and Scheffler 1994).
An estimate of lifetime costs per live born baby with DS—
including education, health, and lost productivity costs—
ranged from US$137,000 in 1990 to US$515,000 in 1993
(Gilbert and others 2001). Net savings using the annual pro-
gram of screening, diagnosis, and selective termination was
estimated to be US$885, with costs of US$446,000 per 10,000
pregnancies for a program that detects and prevents 9.7 DS
births per year and a lower bound estimate of US$137,000 of
potential lifetime costs per 9.7 births prevented.
The increased life span of individuals with DS and accompa-
nying age-associated morbidity impose heavy demands on
medical care and community services, as well as on sustained
support from family members. It is also important to note that
dollar costs of care for a DS child in LMICs would be much lower
than such costs in high-income countries because of lower
prices as well as lower treatment intensity. For example, in some
countries, congenital heart disease, which affects 40 to 60 per-
cent of DS children, cannot be treated effectively. This lack of
treatment will lower costs of care as well as life expectancy, and
cost estimates will vary for each individual area or region.
Cost-Effectiveness of Prenatal Screening, Diagnosis, and
Selective Pregnancy Termination. Prenatal screening can be
implemented to allow selective termination of DS pregnancies
and prevention of disability related to DS in the population.
This intervention raises ethical, social, and cultural concerns
for some individuals and populations that may preclude its
applicability.
A screening program incorporating maternal serum triple
screening in all pregnant women, regardless of maternal age,
yields an excellent DS detection rate and is associated with a low
false-positive rate (Wald and others 2003). DS pregnancies yield
lower levels of alpha-fetoprotein and unconjugated estriol but
have elevated levels of human chorionic gonadotropin com-
pared with other pregnancies. Ultrasound evaluation of the
fetus neck thickness improves screening sensitivity. It is also
useful when used in conjunction with serum screening (Wald
and others 2003). A positive screening result is followed by diag-
nosis using amniocentesis or chorionic villus sampling (CVS).
Although both diagnostic procedures are guided by ultra-
sound to reduce risk, they are invasive, are more expensive than
the screening procedure, and carry a small risk of miscarriage
of an unaffected pregnancy. Thus, only a select group screening
positive for possible trisomy 21 are offered the invasive diag-
nostic procedures. Amniocentesis, which involves the aspira-
tion of amniotic fluid, is performed between the 14th and 16th
weeks of pregnancy. CVS involves aspiration of villi and can be
performed between the 10th and 12th weeks of pregnancy.
Although CVS can be performed earlier in the pregnancy,
amniocentesis is easier to perform and is more widely used in
the second trimester. Following diagnostic confirmation of DS,
parents are provided with genetic counseling and the option of
terminating the pregnancy.
Although DS risk increases with maternal age, most births
occur in younger women and, therefore, two-thirds of all DS
births occur in younger mothers (Ross and Elias 1997). If pre-
natal diagnosis is available only for mothers 35 years or older,
only 33 percent of DS births will be detected. Studies demon-
strate that heavy reliance on maternal age to screen for DS may
not be desirable in LMICs. Maternal age factor is not so useful
in settings where early marriage and motherhood are the norm
and most DS pregnancies involve mothers younger than 35
(Gupta and others 2001). Therefore, maternal serum screening
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Table 49.3 Distribution of DALYs Lost to and Deaths Caused
by Down Syndrome, by World Bank Region, 2002
Region DALYs Deaths
East Asia and the Pacific 4,101,694 1,328
Europe and Central Asia 507,723 652
High income countries 199,215 2,113
Latin America and the Caribbean 214,346 1,979
Middle East and North Africa 347,898 1,311
South Asia 2,005,766 11,336
Sub-Saharan Africa 478,851 4,967
Source: Mathers and others 2006.
of all pregnant women is important in preventing DS births
and achieving cost-effectiveness (Wald and others 2003).
Procedure Costs Genetic screening and counseling services are
expensive. Even after initial high fixed costs to establish prena-
tal screening services, provision of high-quality services
requires staff training, equipment, and laboratory mainte-
nance. A recent report suggests establishing genetic screening
services when other public health interventions have reduced
the infant mortality rate to the range of 20 to 40 out of every
1,000 live births (Institute of Medicine 2003). Above this level,
other public health interventions may have greater benefits.
The breakdown of tasks is as follows:
• screening costs, which consist of laboratory expenses (con-
sumables and staff); informing women of results (by mail
if negative, by phone if positive); service costs (processing
results and monitoring the service); training in ultrasound
measurement of neck skin translucency; and overhead
expenses
• diagnostic costs, which comprise counseling before CVS or
amniocentesis, equipment and staff for these procedures,
laboratory expenses (consumables and staff), and overhead
expenses
• costs of termination of selected pregnancies, which include
surgical dilation, evacuation (11 to 13 weeks), or medical
termination with mifepristone (after 13 weeks).
We assume infrastructure exists for prenatal screening, diag-
nosis, and intervention. We use the following costs: triple serum
test, US$70; amniocentesis, US$1,200; genetic counseling,
US$100; and termination of pregnancy, US$2,000. These cost
estimates have been widely used in the literature (Cusick and
others 2003). However, the medical costs can be significantly
lower in LMICs and will also vary across and within countries.
Cost-Effectiveness and Efficacy We assume that 100 percent of
women attend a prenatal clinic between 10 and 14 weeks of ges-
tation and are offered tests in the first trimester,or between 15 and
19 weeks for the tests in the second trimester.We discuss the effect
of low uptake of prenatal care and its effect on cost-effectiveness
of prenatal screening programs in our sensitivity analysis.
In terms of economic considerations, it is desirable to bal-
ance the probability of the birth of a DS child with the risk of
procedure-related miscarriage. Sensitivity of prenatal screening
and the false-positive rates vary widely, depending on the
method used. The risk of procedure-related miscarriage can
vary from 0.04 to 0.8 percent (Nyberg and others 1998). We use
the conservative fetal loss rate of 0.9 percent (Gilbert and
others 2001) for both procedures.
Efficacy of prenatal screening is defined as the number of
unaffected fetuses lost due to prenatal testing per each DS birth
averted (Institute of Medicine 2003). The goal is to minimize
this ratio. The efficacy of prenatal screening varies with preva-
lence, and the primary determinant of variations in prevalence
of DS is the age structure of women giving birth. The preva-
lence of DS and the efficacy of prenatal screening increase with
the percentage of births to mothers over the age of 35. In this
analysis, a 90 percent rate of selective termination is used
(Waitzman, Romano, and Scheffler 1994). On this basis, the
number of fetal losses per DS birth avoided varies from 7.13
(for 1 in 10,000 prevalence) to 0.16 (for 44 in 10,000 preva-
lence). Therefore, in countries with low prevalence of DS, such
as Indonesia, more unaffected fetuses are lost than DS births
averted because of screening. In areas where the ratio of unaf-
fected fetal losses to DS births avoided is above 1, the efficacy of
screening for DS is questionable.
Because of higher loss rates for CVS, we use a 1.5 percent
fetal loss rate in our sensitivity analysis (Lippman and others
1992). Other costs not considered in this study are the psycho-
logical effects of a positive test on the parents, anxiety that may
persist from a false-positive test, and potential complications
resulting from pregnancy termination. Complications from
termination may vary (Stray-Pedersen and others 1991) and
may not be the same in LMICs, which should be taken into
account. The sensitivity rate for the triple serum test followed
by the amniocentesis is 62.3 percent in the clinical trials
(Vintzileos and others 2000), and the uptake of amniocentesis
is 90 percent for affected mothers and 80 percent for unaffected
mothers (Waitzman, Romano, and Scheffler 1994). We assume
the false-positive rate of 5 percent. The false-positive rate
affects the probability of losing an unaffected fetus as a result of
invasive testing that follows serum screening.
Financial cost-effectiveness is defined as the screening costs
per DS birth averted. It is presented in table 49.4. Cost-
effectiveness is the highest in countries with high birth preva-
lence of DS, given that women have access and receive prenatal
care. Costs of prenatal screening and termination per DS birth
averted vary from US$1,497,390 in Indonesia (for 1 in 10,000
prevalence) to US$37,185 in Pakistan (44 in 10,000 prevalence).
A similar relationship is seen between prevalence and cost per
DALY. In our analysis, we use costs data that are based on esti-
mates from developed countries. Because costs of care will vary
widely across and within countries, cost estimates should be
done for individual regions. Lower costs of care will reduce cost-
effectiveness of prenatal screening for DS. However, even after
the cost adjustment, it is unlikely that the benefits will complete-
ly go away, because of the large difference between a relatively
cheap screening program and high burden of disease of DS.
Sensitivity Analysis The results of the analysis above depend
on assumptions that may not hold in some LMICs. For exam-
ple, if many women accept screening but few decide to have an
amniocentesis, cost-effectiveness will be adversely affected. The
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public health benefits of screening for DS in socioeconomically
deprived areas are small because of low uptake of amniocente-
sis (Ford and others 1998). With lower uptake rates of amnio-
centesis, both efficacy and financial cost-effectiveness are
adversely affected as a result of low detection rates, and the
number of unaffected fetal losses decreases. It is also important
to note that, in some countries, many women may not have
access to prenatal care or may not seek prenatal care and pre-
natal testing. In such areas, programs that try to reduce DS
prevalence will have limited success, especially if a population
at greater risk of DS is not tested.
Cost-effectiveness is often measured per DS birth averted
since reduction in DS prevalence is the ultimate goal of prena-
tal testing. In many cultures, an abortion is not an acceptable
option. Acceptance of elective termination of pregnancy may
also vary across ethnicities and other subgroups within a given
country. A study in California found the uptake of termination
following the DS diagnosis varied from 47.5 percent for
Hispanics to 65.8 percent for whites and 70.8 percent for Asians
(Cunningham and Tompkinison 1999). If few families decide
to terminate pregnancy to avoid having a child with severe dis-
ability, cost-effectiveness per DS birth averted will be adversely
affected, and the screening program may fail to reduce the birth
prevalence of DS. If a large percentage of families are opposed
to induced abortion of fetal DS, the uptake of amniocentesis
also will be low.
Because fetal losses following CVS are often higher than
those for amniocentesis, efficacy analysis should be conducted
assuming a 1.5 percent fetal loss risk attributable to invasive
testing in the first trimester. With higher fetal losses, the efficacy
of the prenatal screening is adversely affected, although the
cost-effectiveness will not change.
In addition, assuming a higher false-positive rate of 8.3 per-
cent increases the number of invasive tests on unaffected moth-
ers and the number of unaffected fetal losses, thus adversely
affecting the efficacy of the prenatal testing (Vintzileos and
others 2000).
The analysis presented above is limited to an evaluation of
the cost-effectiveness of prenatal screening for DS only. Some
serum markers (for example, alpha-fetoprotein) will identify
other abnormalities, the benefits of which are not included in
this analysis.
Equity and Access The desirable policy is that women of sim-
ilar risk for DS have equal access to diagnostic tests. With lim-
ited access to prenatal care, the introduction of the screening
programs can have small public health effects. Although the
approach used in cost-effectiveness analysis is optimization of
societal net benefit, the policies to be recommended for the
prevention of disability must also consider individuals’ free-
dom in decision making at each step of the prenatal diagnosis.
Successful policies need to be based on cost-effectiveness
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Table 49.4 Financial Cost-Effectiveness and Efficacy of Prenatal Screening and Pregnancy Termination for the Prevention of
Down Syndrome Births 
DS births per
100,000 Cost per Cost per Cost of Cost per Fetal 
population DS 100,000 DS birth detection and DS birth losses per
Representative (birth births population detected DS births termination avoided US$ per Unaffected DS birth
country prevalence) detected (US$) (US$) prevented (US$) (US$) DALY fetal losses prevented
East Asia and the Pacific
Indonesia 10 5.61 7,546,188 1,345,851 5.05 7,556,281 1,497,390 14.88 36.0 7.13
Europe and Central Asia
Hungary 56 31.40 7,574,655 241,237 28.26 7,631,174 270,041 38.31 35.98 1.27
High-income countries
Canada 120.79 67.73 7,614,750 112,433 60.95 7,736,658 126,926 36.09 35.96 0.59
Latin America and the Caribbean
Argentina 160 89.71 7,639,014 85,150 80.74 7,800,496 96,612 22.50 35.94 0.45
Middle East and North Africa
Israel 100 56.07 7,601,884 135,579 50.46 7,702,810 152,643 22.14 35.96 0.71
South Asia
Pakistan 440 246.71 7,812,290 3,1666 222.04 8,256,364 37,185 4.12 35.84 0.16
Sub-Saharan Africa
South Africa 210 117.75 7,669,956 65,139 105.9 7,881,901 74,377 16.46 35.92 0.34
estimates that take into account the needs, sensitivities, and val-
ues of individuals and cultures (Institute of Medicine 2003).
Interventions to Prevent Disability Caused 
by Congenital Hypothyroidism
For CH, like DS, screening programs are critical public health
interventions.
Neonatal Screening in Low- and Middle-Income Countries.
When considering the costs and benefits associated with a CH
screening program, one must first have an estimate of how
prevalent CH is in the population so that the avoided costs
associated with disability can be calculated. It is important to
note that in high-income countries and in several middle-
income countries screening is usually done for a series of con-
ditions rather than for a single disorder. This fact is likely to
affect the cost. In several of these conditions, the treatment
includes dietary modification as well as costly prepared foods
and formulas. Policies in countries where this type of screening
occurs include labeling of food to alert potentially vulnerable
consumers.
Several studies have examined the prevalence of CH in spe-
cific populations, with substantially varying results. A review
of 13 studies reporting findings on CH prevalence identified
through individual screening programs found the lowest rate
to be 1 case of CH per over 6,000 screened in Thailand
(Wasant, Liammongkolkul, and Srisawat 1999). Contrasting
this is the highest rate reported: 1 case in 1,000 screened in
Pakistan (Lakhani and others 1989). Prevalence can vary not
only from one country to the next, but also within countries,
depending on different analyses or subpopulations within one
country. These variations demonstrate the need for identifying
the appropriate population in order to conduct economic eval-
uations of screening interventions.
According to three cost-benefit analyses of CH screening
(Layde, Von Allmen, and Oakley 1979; Barden and Kessel
1984), the benefits included savings from institutionalization,
special education, medical care, lost parent and child produc-
tivity, and slightly decreased life expectancy. The costs included
those of the screening program as well as the cost of treating
detected cases. Overall, CH screening programs are substantially
cost saving, with a cost-benefit ratio as high as 1 to 8.9 in high-
income countries (Dhondt and others 1991). Such savings have
not yet been evaluated in LMICs. Because the treatment is
inexpensive and highly effective, it is anticipated that CH
screening would also be substantially cost saving in LMICs.
Burden. Congenital hypothyroidism is a common cause of
MR that can be prevented by newborn screening and treat-
ment. By the end of the 1970s, neonatal screening programs
had been established in many regions of Canada, Europe,
Japan, and the United States. Thyroid hormone is required for
normal brain development, and little or no thyroid hormone in
the neonatal period results in damage to the nervous system.
Various causes of anatomical maldevelopment of the thyroid
gland are responsible for CH, and several genes have been
implicated. With biochemical newborn screening (best con-
ducted in centralized regional laboratories) using dried blood
spots and diagnosis in the first few weeks of life, MR is avoid-
able. Without appropriate treatment, two-thirds of patients
with CH have low IQ, and 30 percent experience severe or pro-
found cognitive disability (Beaulieu 1994). Even with appro-
priate treatment, some subtle intellectual impairment and
behavior deficits may still occur—the mean IQ may be approx-
imately 10 points lower than that of the general population
(Tillotson and others 1994). In the United States, infants are
screened as newborns and again at two to six weeks of age to
detect missed cases. For optimal outcomes, lifelong treatment
with thyroid hormone is required, with subsequent monitoring
and adjustments recommended every 3 to 12 months until
growth and puberty are complete. Many females born with CH
are now reaching childbearing age and require increased
dosages of thyroid hormone during pregnancy for optimal
neuropsychological outcome in their offspring.
Costs of Care. Estimated lifetime costs of care for the child
with CH include the following (Barden and Kessel 1984):
• Institutional care. At the time of the study, 15 percent of con-
genital hypothyroid individuals were institutionalized from
age 5 to 70.
• Foster care. About 25 percent of congenital hypothyroid
cases received foster care from age 5 to 20.
• Residential care. Such care was provided for 40 percent of
affected cases.
• Special education expenditures. Such expenses varied with
the level of MR (15 percent severe, 25 percent moderate, and
40 percent mild).
In 2004, estimated lifetime costs of CH care is US$191,000,
with a 6 percent discount rate. This estimate of the financial
costs of care for an affected person is fairly conservative; it does
not take into account lost productivity of the person with CH,
a potential loss of income attributable to the time inputs of the
family members who are taking care of the affected person, or
effects on quality of life.
Cost-Effectiveness of Neonatal Screening. Table 49.5 presents
cost-effectiveness analysis of neonatal screening for representa-
tive countries in the World Bank regions. Screening costs
include blood sample collection, laboratory costs, discounted
lifetime treatment cost, and costs of care for those missed
by the screening. Specimen collection and laboratory
costs (Barden and Kessel 1984; OTA 1988) constitute (in
2004 dollars) US$989,000 and US$969,000, respectively, per
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100,000 children tested. Lifetime discounted (at 6 percent)
treatment costs are US$6,292.64 in 2004 dollars (Barden and
Kessel 1984). Analysis of costs and benefits in table 49.5 shows
that, although screening for the population as a whole requires
considerable investment and infrastructure, the burden from
the disorder is high and treatment is cheap. Screening all new-
borns is beneficial compared with the high costs of lifelong care
for the affected individuals. Cost savings are positive for all rep-
resentative countries despite high variance in the prevalence of
CH. Even for a low birth prevalence estimate of 4 out of every
100,000 in Thailand (Wasant, Liammongkolkul, and Srisawat
1999), the cost savings would be US$106,326.
Effectiveness of the newborn screening in identifying the
affected infants depends on the ability of the screening pro-
gram to collect blood samples from all infants in the first week
and to perform tests in time to initiate treatment. This effort
may be difficult in some settings, where infants are born at
home or released on the first day after birth and do not have
contact with the health care system in the first month of their
lives (Sack, Feldman, and Kaiserman 1998). The wider the cov-
erage of the screening program, the higher will be the cost sav-
ings of screening. Also, follow-up screening for those infants
who test as false negative will increase sensitivity to 100 percent
and improve cost-effectiveness of the program.
In our cost-effectiveness analysis, we assumed the lifetime
care and treatment costs to be similar to those estimated for the
United States. However, medical costs may vary significantly
among and within countries. Such variation is unlikely to alter
the cost-effectiveness analysis, because the difference between
program and treatment expenditures and lifetime costs will
remain even after we scale the medical costs.
The analysis presented above is limited to an evaluation of
the cost-effectiveness of neonatal screening for CH. For mini-
mal extra cost, collected blood samples for CH can also be used
to identify other inherited disorders, including phenylke-
tonuria, maple syrup urine disease, and other inborn errors of
metabolism. Without the benefits of early detection and treat-
ment for these conditions, the result is severe MR.
Community-Based Rehabilitation
Community-based rehabilitation is a set of low-cost approaches
to providing rehabilitation services such as physical therapy,
occupational therapy, prosthetics, and assistive devices for
people with disabilities in developing countries. Such rehabili-
tation also aims to minimize stigmatization of people with dis-
abilities and to support inclusive education and integration of
people with disabilities into society. WHO and other organiza-
tions have actively promoted community-based models for
providing rehabilitation services—including services for chil-
dren with developmental disabilities—in resource-poor set-
tings (Institute of Medicine Committee on Nervous System
Disorders in Developing Countries 2001).
Although 80 percent or more of the world’s people with
disabilities live in developing countries, only 2 percent have
access to rehabilitation services (WHO Community-Based
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Table 49.5 Cost-Effectiveness of Neonatal Screening for Congenital Hypothyroidism by World Bank Region 
Program costs Cost per Cost 
CH births per CH for screening disability without Cost 
Representative 100,000 (birth births and treatment averted testing savings 
country prevalence) detected (US$) (US$) (US$) (US$)
East Asia and the Pacific
Thailand 23.94 22.74 2,236,661 98,366 4,342,987 2,106,326
Europe and Central Asia
Estonia 34.97 33.22 2,407,937 72,492 6,344,406 3,936,468
High-income countries
United States 25.00 23.75 2,253,200 94,872 4,536,250 2,283,050
Latin America and the Caribbean
Mexico 40.7 38.67 2,496,991 64,580 7,385,022 4,888,032
Middle East and North Africa
Saudi Arabia 36.25 34.43 2,427,813 70,509 6,576,658 4,148,845
South Asia
Pakistan 100.00 95.00 3,417,801 35,977 18,145,000 14,727,199
Sub-Saharan Africa
South Africa 24.13 22.93 2,239,768 97,686 4,379,292 2,139,524
Rehabilitation 1982). If families of people with disabilities are
taken into account, the number of people experiencing the
effects of disability is estimated to be up to 25 percent of
the world population. Community-based rehabilitation is
designed to expand access to rehabilitation services in poor and
rural areas by providing training in rehabilitation techniques to
individuals with disabilities, their family members, and others
in their communities. It also attempts to change negative atti-
tudes toward disability and to remove barriers in the physical
environment that prevent people with disabilities from fully
participating in society.
Costs. In the community-based rehabilitation model, com-
munity interventions are shifted from institutions and centers
to the homes and communities of people with disabilities and
are carried out largely by family members and volunteers. By
using volunteer workers and the existing infrastructure in the
communities, this form of rehabilitation minimizes costs of
delivering services and is assumed to be cost-effective relative
to the alternative institution-based rehabilitation (Institute
of Medicine Committee on Nervous System Disorders in
Developing Countries 2001; WHO Community-Based
Rehabilitation 1982; Lagerkvist 1992). Institutional care has
higher costs because it relies on paid staff, medical equipment,
building maintenance, and medical costs. Some advocate for
provision of institutional, center-based, medical, and commu-
nity-based approaches in a complementary fashion. In a
Zimbabwean community-based rehabilitation project two-
thirds of the patients were referred to hospitals or clinics
(Rottier and others 1993). Annual costs for training workshops
and salaries of rehabilitation workers amounted to US$60,000
to treat 1,614 individuals with disabilities.
Little information is available about the full costs of com-
munity-based rehabilitation and how they vary across disabili-
ties, age groups, and societies. The cost-effectiveness of such
rehabilitation or whether its costs are lower than alternative
rehabilitation models is unknown. It is usually implemented in
settings where no other rehabilitation models exist. The costs to
consumers in terms of their efforts, time, and money may be
substantial (Thomas and Thomas 1998). No formal estimates
are available of time costs and opportunity costs to family
members involved in community-based rehabilitation.
Meeting the needs of a family member with a disability may
prohibit or disrupt labor force participation of the caregiver
and reduce family income. This need for caregiving may espe-
cially affect women (Giacaman 2001). The effectiveness of
community-based rehabilitation in improving functional out-
comes for children with cerebral palsy in Bangladesh showed
no improvement, but researchers unexpectedly found a signif-
icant increase in reported stress and symptoms of depression in
the mothers of children in the community-based rehabilitation
intervention group (McConachie and others 2000).
Efficacy. Other attempts to evaluate community-based reha-
bilitation in different settings and for a range of outcomes
include one for preschool children with disabilities in rural
Guyana. The children showed significant improvement after six
months in the program, and noticeable improvements in the
attitudes of parents and others toward children with disabilities
were seen (O’Toole 1988). Community-based rehabilitation
programs in the Philippines and Zimbabwe found gains in
activities of daily living and communication as well as higher
rates of starting school and employment after six months in the
program (Lagerkvist 1992). Similarly, people with disabilities
participating in a community-based rehabilitation program in
Botswana showed high levels of independence in activities of
daily living; 20 percent of adults were working, and most
school-age children were attending class (Lundgren-Lindquist
and Nordholm 1996).
Some have questioned the efficacy of community-based
rehabilitation and its ability to expand access for people with
disabilities. Many people with disabilities do not patronize such
programs, and many who do try leave dissatisfied (Kassah 1998).
After initial diagnosis, only half of the identified individuals
with disabilities continued (Rottier and others 1993).
Community-based rehabilitation programs also face the diffi-
culty of working in diverse communities with unique cultural,
religious, economic, and social conditions, making it difficult for
a single model to meet the needs for rehabilitation services in
developing countries (Crishna 1999).
Prevention of Premature Birth
Premature birth—after 20 weeks but before 37 weeks—is a
powerful predictor of death and disability. Infants born before
28 weeks of gestation have a 50-fold increased risk of cerebral
palsy (Drummond and Colver 2002) and heightened risk of sen-
sory, cognitive, and educational impairment (Taylor and others
2004). The rate of preterm births in the United State has
increased steadily since 1990 (MacDorman and others 2002).
Survival of infants born before 34 weeks requires intensive and
expensive medical care (Gilbert, Nesbitt, and Danielsen 2003),
and the global survival rate differs depending on neonatal care
availability (Lorenz and others 2001). Infection or inflammation
of the placenta is common in preterm pregnancies (Goldenberg
and Culhane 2003), and many deaths attributed to asphyxia may
be caused by maternal, placental, or neonatal infection. The
cerebral palsy rate is significantly higher in premature infants
whose births are monitored electronically (Shy and others
1990).With the exception of magnesium sulfate administered to
women in preterm labor (Crowther and others 2003), no spe-
cific interventions result in decreased cerebral palsy among pre-
mature infants (Crowther and Henderson-Smart 2004).
Dietary supplements might decrease the frequency of low-
birthweight births and perhaps the frequency of marked
prematurity. In Bangladesh, where the rate of preterm labor
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was high, women who went into labor before term were older,
shorter, thinner, less educated, and more disadvantaged eco-
nomically, with closer spacing of births (Begum, Buckshe, and
Pande 2003). Deaths attributable to prematurity in LMICs are
seldom due to poor management and are largely related to
poor health facilities (Pattinson 2004).
Electronic Fetal Monitoring in Labor 
For decades most cerebral palsy and a major share of MR,
epilepsy, and learning and behavioral disorders of childhood
were considered to be due to deprivation of oxygen supply to
the fetus during birth. Recent research confirms that only a
minority of cerebral palsy cases, as well as associated MR and
seizures, are related to markers of birth asphyxia (Nelson and
Ellenberg 1986; Torfs and others 1990). Low Apgar scores, the
need for respiratory support, and neonatal seizures are more
commonly due to etiologies other than asphyxia, most notably
intrauterine exposure to infection (Wu and others 2003). So
that medical workers could recognize the onset of asphyxia and
“rescue” the fetus, continuous electronic fetal monitoring
(EFM) of the fetal heart rate during labor was introduced in
the 1970s. This intervention was disseminated before being
tested in randomized trials to compare continuous electronic
monitoring with intermittent observation by stethoscope (aus-
cultation). Since the introduction of EFM, fetal death in labor
has decreased, the cesarean section rate has quadrupled (Natale
and Dodman 2003), and the rate of cerebral palsy has
remained steady. Accordingly, EFM cannot be recommended
for use in LMICs. Intermittent auscultation with a stethoscope
appears to be the appropriate way to monitor fetal status
during labor.
RESEARCH AGENDA FOR PREVENTION OF
DISABILITIES IN LOW- AND MIDDLE-INCOME
COUNTRIES
Research needed as a basis for developing policies and inter-
ventions to prevent LDD in low- and middle-income countries
includes basic research, epidemiology, and evaluations of early
interventions, clinical treatments, prevention strategies, and
health services that are culturally appropriate and feasible.
Suggested research priorities include the following:
• etiology and prevention of adverse pregnancy outcomes
associated with LDD, such as low birthweight, preterm
birth, intrauterine growth retardation, and related factors
• community-based rehabilitation, including effectiveness,
cost-effectiveness, and social effects of different models for
providing rehabilitation services and special education to
children with LDD in LMICs
• methodological and prevalence studies to ensure that the
impacts of LDD are effectively measured by DALYs or other
international indicators
• cost-effectiveness of interventions to prevent specific nutri-
tional, infectious, genetic, and other causes of LDD
• impact on child development of multiple insults and risk
factors especially common in LMICs, such as neurotoxic
exposures, trauma, infectious disease or malnutrition,
poverty, maternal illiteracy, and other social factors 
• health services research related to access to prenatal care and
prenatal and newborn screening and evaluation of compo-
nents of the public health system that might impair or
enhance integration of services for patients with LDD
• prevalence of ADHD and a cost-benefit analysis of the use
of psychotropic medications
• prevalence and costs of autism spectrum disorders
• strategies to improve interventions for the prevention of
fetal alcohol syndrome and to develop effective intervention
programs for children affected by prenatal alcohol exposure 
• evaluation of criteria for newborn screening and effects of
new technology on measured incidence, costs, and system
effectiveness
• evaluation of financing of successful newborn screening and
treatment programs
• model systems of care for individuals diagnosed through
newborn screening from infancy to adulthood.
SUMMARY
Many potential interventions exist for the prevention of LDDs,
and relatively few are being implemented for the benefit of chil-
dren in LMICs. The following three interventions are effective
and cost-effective in preventing LDD:
• Folic acid fortification of the food supply can reduce the
occurrence of NTDs by 50 percent or more. This interven-
tion was found to be highly cost-effective in the United
States; however, in low-income countries, high capital and
running costs may compromise cost-effectiveness, at least in
the short run.
• Prenatal screening and selective pregnancy termination to
prevent DS are highly cost-effective under some conditions
but raise ethical, social, and cultural concerns that may
preclude their applicability in some LMICs. Screening is not
only expensive; it also has negative health outcomes: the
false-positive rates and the subsequent anxiety, a risk of
miscarriage of an unaffected pregnancy, and the resulting
potential complications from pregnancy termination.
Another concern is that, where access to prenatal care is lim-
ited, the potential for public health benefits of prenatal
screening will be small.
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• Neonatal screening and treatment for CH is highly cost-
effective in developed countries, where it provides a low-
cost strategy for preventing MR. For minimal extra cost, col-
lected blood samples from newborns can also be used to
identify and prevent the disabling effects of other inborn
errors of metabolism, such as phenylketonuria and maple
syrup urine disease. However, when only a part of the new-
born population is reached by screening, high costs will be
incurred to care for those missed by the screening, thereby
reducing the cost-benefit ratio.
For another type of intervention considered, community-
based rehabilitation, costs and benefits have not been quantified
sufficiently to allow evaluation. Such rehabilitation is designed
to expand access to services in poor and rural areas, to change
negative attitudes toward disability, to lower the costs of deliv-
ering services, and to enhance the participation of persons with
disabilities in society. The benefits of community-based reha-
bilitation may come at a high cost in terms of time and financial
resources of family members.
Another intervention, electronic fetal monitoring in labor,
has been shown to be unsuccessful in preventing childhood
neurological disability associated with premature birth: the risk
of cerebral palsy was significantly higher in infants delivered
using EFM. Consequently, this intervention is not recom-
mended for use during labor.
DALY estimates are not available to convey the full range of
LDDs or their risk factors. However, available data are consis-
tent with the possibility that these disabilities account for a
large proportion of the global burden of disease. Quantifying
the impacts of LDDs and their preventive interventions is com-
plicated by the fact that these disorders can exist at multiple
levels and that disability is context-specific, with impacts that
may vary across cultures. Several research priorities for
improving knowledge and developing policies and interven-
tions to prevent LDD in LMICs are suggested.
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Although the loss of vision and hearing has multiple causes,
and the burden of these diseases is complex, three major points
emerge from the outset:
• Impairments of the essential senses of vision and hearing
contribute to early demise and are important causes of mor-
bidity for individuals who are blind or deaf.
• Cost-effective interventions are available to address several
causes of these burdens now.
• The number of cost-effectiveness analyses of interventions
to preserve hearing or vision in developing countries is quite
limited.
Table 50.1 summarizes the conditions causing the sensory
deficits, the proposed interventions and sites of delivery, and
the cost and effectiveness of these interventions to the extent of
current knowledge. Earlier work by Evans and others (1996) in
Myanmar does not appear because the cost data are quite old
and because the cost-effectiveness data were in dollars per case
of blindness averted rather than dollars per disability-adjusted
life year (DALY) averted, which the latest information provides.
NATURE, CAUSES, AND EPIDEMIOLOGY
OF VISION LOSS
Table 50.2 provides definitions of visual impairment,
blindness, and low vision according to the International
Classification of Diseases, Injuries, and Causes of Death (WHO
1993). At this time, the World Health Organization (WHO) is
considering changing the classification in order to take into
account uncorrected refractive errors, but this change has not
yet been approved.
The major causes of adult-onset blindness are cataract
(47.8 percent), glaucoma (12.3 percent), macular degeneration
(8.7 percent), diabetic retinopathy (4.8 percent), trachoma
(3.6 percent), and onchocerciasis (0.8 percent). Uncorrected
refractive errors are also a major cause of morbidity related to
vision, but this type of disability is not included in the global
burden of disease by definition. It has been estimated to be on
the order of 15 percent of the total blind population and could
add 50 percent to the low-vision population. However, there
are no published data to do more than speculate.
The major causes of childhood vision loss have marked
regional variations. They include vitamin A deficiency (xeroph-
thalmia) and ophthalmia neonatorum in low-income coun-
tries, retinopathy of prematurity and hereditary conditions in
middle-income countries, and congenital cataract and glau-
coma everywhere. Table 50.3 shows the estimated number of
blind persons worldwide in 2002.
Vision loss is chronic and, almost invariably, without remis-
sion. The extent of morbidity is related to the level of alteration
of vision function. However, 80 percent of cases are avoidable,
either through treatment (cataract and refractive errors) or
through primary prevention (onchocerciasis, trachoma, glau-
coma, and diabetic retinopathy). Strictly speaking, blindness
attributable to glaucoma and diabetic retinopathy can be pre-
vented. However, prevention depends on the availability of a
simple, cheap, and efficacious diagnostic test and rigorous
treatment. These are not readily amenable to public health
programs even in the most technologically advanced countries,
especially in the case of glaucoma.
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Table 50.1 Cost and Effectiveness Data for Vision and Hearing Care Interventions 
Incremental cost-
Cost data effectiveness data
Condition Intervention (2004 US$) Effectiveness data (2004 US$/DALY averted)
Trachoma Trichiasis surgery 7.14 per village-based surgerya 77 percent cure rate over two yearsb 4–82c
Tetracycline — 51 percent cure rate in children at 9,600d
six months following treatmentd
Azithromycin — 88 percent cure rate in children at 4,100d
six months following treatmente
Cataract Extracapsular surgery — — 200 (low- and middle-
income countries); 2,400
(high-income countries)b
Onchocerciasis Ivermectin — — 40f
Source: Authors.
—  not available.
a. Frick, Keuffel, and Bowman 2001.
b. Baltussen, Sylla, and Mariotti 2004.
c. Baltussen and others (2005). Cost-effectiveness calculations are based on data from Frick and others (2001) for mass treatment of children only, not greater efficacy reported by Bowman and others
(2000) and Solomon and others (2004) for mass treatment of entire communities. The greater efficacy reported in mass treatment of entire communities may lead to better cost-effectiveness.
d. Bowman and others 2000.
e. Reacher and others 1992.
f. Waters, Rehwinkel, and Burnham 2004.
Table 50.2 Definitions of Visual Impairment Levels
Degree of Visual impairment 
impairment Definition categories
Low vision Visual acuity of less than 6/18 1 and 2
(Snellen 20/70) but equal to or 
better than 3/60 (20/400) 
in the better eye with best 
possible correction
Blindness Visual acuity of less than 3/60 3, 4, and 5
(20/400) or corresponding visual 
field loss of less than 
10 degrees in the better eye with 
best possible correction
Visual Blindness as well as low vision 1, 2, 3, 4, and 5
impairment
Source: Authors, based on current international definitions by WHO 1993. 
Table 50.3 Number of Blind Worldwide in 2002 from Various
Conditions 
Condition Number blind (millions)
Cataract 17.6
Glaucoma 4.5
Age-related macular degeneration 3.2
Corneal opacity 1.9
Diabetic retinopathy 1.8
Childhood blindness 1.4
Trachoma 1.3
Onchocerciasis 0.3
Other causes 4.8
Total 36.8
Sources: Pascolini and others 2004; Resnikoff and others 2004. 
Burden of Loss for Vision and Risk Factors
The risk factors for loss of vision are age, gender, poverty, and
poor access to health care. The overall prevalence of vision loss,
which mainly affects the population above age 40, is a function
of age. It is estimated that more than 82.2 percent of all blind
individuals are 50 or older. Increasing life expectancy results in
a growing number of cases of age-related blindness (for exam-
ple, cataract, glaucoma, macular degeneration). Among the 50
and older age group, cigarette smoking is a clear risk factor for
both cataract and macular degeneration. Childhood vision loss
represents approximately 4 percent of the total number of visu-
ally impaired. However, it is the second largest cause of “blind-
person years,” following cataract. Retinopathy of prematurity
(ROP) is an important cause in middle-income countries
(Gilbert and Foster 2001). Unfortunately, screening for ROP in
preterm infants, as well as the organization and provision of
low-vision services, is a tertiary-level function (requiring a well-
equipped clinic or hospital with the most modern facilities), and
no data on cost-effectiveness of interventions are available.
More disease-specific factors are poor hygiene, overcrowding,
ultraviolet radiation, diabetes mellitus, drugs, micronutrient
deficiency, heredity and ethnic background, and consanguinity.
Estimates of the global burden of visual impairment in 2002
were updated using the most recent available data on blindness
and low vision (Pascolini and others 2004). The global number
of people who are visually impaired is in excess of 161 million,
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Table 50.4 Global Burden of Visual Impairment, by Major Cause, 2002
Visual impairment
Blindness Low vision Percentage Percentage 
(thousands (thousands Thousands of total of total 
Condition of DALYs) of DALYs) of DALYs YLDs DALYs
Cataract 8,798 15,053 25,251 4.5 1.7
Glaucoma 1,202 2,442 3,866 0.7 0.3
Trachoma 1,403 772 2,329 0.4 0.2
Onchocerciasis 203 146 484 0.1 0.0
Other 4,657 8,814 14,191 2.5 1.0
Total 16,263 27,227 46,121 8.2 3.2
Source: Pascolini and others 2004; Resnikoff and others 2004.
YLDs  years of life lived with disability.
of whom 36.8 million are blind (Resnikoff and others 2004).
Because the international definition refers to the best-corrected
visual acuity (table 50.2), these figures actually underestimate
the magnitude of the global burden of the visual impairment,
especially in developing countries, where most of the refractive
errors are not corrected (Dandona and Dandona 2003; Fotouhi
and others 2004; Naidoo and others 2004). A WHO working
group has recommended the use of the more accurate “pre-
senting vision,” recognizing that many people do not have their
best-corrected vision. This recommendation is under review
and, if approved, would substantially increase the estimates of
the burden of disease attributable to impaired vision.
The number of women with visual impairment, as estimated
from the available studies, is higher than that of men, even after
adjustment for age. Female-to-male prevalence ratios indicate
that women are more likely to have a visual impairment than
men in every region of the world: the ratios from past studies
range between 1.5 to 1 and 2.2 to 1. (Resnikoff and others
2004). The major reported reason is women’s reduced access to
eye care services. Higher exposure to risk factors also con-
tributes in the case of trachoma. (Abou-Gareeb and others
2001; Nirmalan, Padmavathi, and Thulasiraj 2003).
Several population-based surveys reported higher risk of
mortality among people with visual impairment. Relative risk
of mortality among blind and low-vision people varied from
1.5 to 4.1 and from 1.1 to 1.6, respectively. In industrial coun-
tries, the relative risk of mortality varied from 1.6 to 2.0. The
effect may vary by gender (Lee and others 2002; Taylor and oth-
ers 1991). The link between visual impairment and mortality
remains poorly understood and cannot be attributed to known
associations with underlying disease.
The burden from visual impairment accounts for approxi-
mately 3 percent of the total global burden of disease and 9 per-
cent of total years lived with disability in 2001. Table 50.4 shows
the global burden by vision-related cause in DALYs. Globally,
half of the burden from visual impairment is due to cataract.
The burden of visual impairment is not distributed uni-
formly throughout the world; the least developed regions carry
the largest share, as shown by World Bank region in table 50.5.
Local and in-country variations, as well as regional variations,
are related to the following factors:
• Epidemiology of cause (for example, onchocerciasis,
trachoma).
Table 50.5 Global Burden of Visual Impairment, by World Bank Region, 2002 
(thousands of DALYs)
East Asia and Europe and Latin America and Middle East and
Condition the Pacific Central Asia the Caribbean North Africa South Asia Sub-Saharan Africa Worldwide
Cataract 6,141 239 956 934 10,259 5,369 23,898
Glaucoma 1,184 168 165 401 566 1,009 3,493
Trachoma 410 0 102 201 226 1,272 2,211
Onchocerciasis 0 0 1 23 0 458 482
Other 5,821 903 1,031 971 2,447 1,046 12,219
Total 13,556 1,310 2,255 2,530 13,458 9,154 42,303
Source: Pascolini and others 2004; calculated from Resnikoff and others 2004.
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• Socioeconomic patterns (poverty and socioeconomic depri-
vation), an essential element in most causes.
• Access to adequate eye care.Uneven access to good-quality eye
care (for example, for cataract, glaucoma, diabetic retinopa-
thy) results from such factors as distance, affordability, and
culture. Lack of resources is only part of the problem; existing
facilities are sometimes underused.
Interventions
Not all causes of visual impairment can be addressed using
public health types of interventions. Cataract, trachoma, child-
hood blindness, and onchocerciasis are discussed below.
Cataract. Surgery to remove the opacified lens is the only
effective treatment for cataracts. Neither diet nor medications
have been shown to stop cataract formation. There are several
possible approaches for the surgical extraction of cataracts.
Intracapsular cataract extraction using aphakic glasses is a
technique by which the whole lens is removed from the eye.
After surgery, special eyeglasses are provided to patients to
restore sight. A disadvantage of this intervention is the non-
compliance of people who need to wear glasses, which has been
found to be between 18 and 73 percent. Although this behavior
may be characterized as noncompliance, it must be said that
some programs do not provide glasses or provide aphakic
glasses of inferior quality. Also, replacing needed aphakic
glasses is impossible for some patients. It is also true that apha-
kic glasses cause tremendous distortions in vision, thus impair-
ing compliance.
In extracapsular cataract extraction with implantation of a
posterior chamber intraocular lens, the lens and the front por-
tion of the capsule are removed and then replaced with an arti-
ficial lens. Baltussen, Sylla, and Mariotti (2004) have evaluated
work on the cost-effectiveness of cataract surgery. That work
(done by WHO regions rather than by World Bank regions)
showed that both intracapsular and extracapsular surgeries are
cost-effective ways to reduce the impact of cataract blindness.
However, extracapsular surgery is both less costly and more
effective than intracapsular surgery and can therefore be con-
sidered the best choice for cataract control. Its cost-effective-
ness ratios are below US$200 per DALY averted in low- and
middle-income countries and below US$2,400 in high-income
countries.
Trachoma. WHO recommends an integrative approach to tra-
choma control through its SAFE strategy (surgery, antibiotics
to control the infection, facial cleanliness, and environmental
improvements). The facial cleanliness and environmental
improvements are preventive public health measures aimed at
reducing the incidence of infection. Antibiotic treatment, espe-
cially when given on a mass or community basis, is both pri-
mary prevention (reducing transmission in the community)
and secondary prevention (treating active infection to avoid
morbidity). Surgery is in fact tertiary prevention—that is,
repairing (and halting further) damage. The SAFE strategy has
not been subjected to a comprehensive economic evaluation,
but some cost-effectiveness information is available regarding
the antibiotic and surgery components.
The initial trachoma infection can be effectively treated with
antibiotics, either through mass treatment of all children below
10 years of age or through targeted treatment of infected chil-
dren and household members. A work by Baltussen and others
(2005) for trachoma-endemic areas in the world—similar to
studies of cataract control surgery—reveals that interventions
using antibiotics cost between US$4,000 and US$220,000 per
DALY averted for all regions studied. Targeted treatment with
antibiotics (be it on the basis of azithromycin or tetracycline) is
not cost-effective, and mass treatment of all children (not
entire communities) is cost-effective only when azithromycin is
donated. In Myanmar, tetracycline has been shown to be mod-
erately cost-effective (Evans and others 1996). Cost-effective-
ness studies are not available on mass treatment of entire com-
munities, the approach now most commonly in use with
donated azithromycin. Recent studies by Solomon and others
(2004) report a 70 percent fall in prevalence in an area in
Tanzania; moreover, the total community burden of ocular
Chlamydia trachomatis infection (measured by polymerase
chain reaction) fell to 8.7 percent of pretreatment levels at six
months after treatment. Additionally, Chidambaram and
others (2004) have demonstrated that, after mass azithromycin
treatment of a population in Ethiopia, an indirect protective
effect occurred among untreated children who resided in vil-
lages in which most individuals had been treated. As noted in
table 50.1, greater efficacy of azithromycin than that used to
calculate cost-effectiveness of mass treatment of children alone
may lead to better cost-effectiveness than shown in the table. To
date, if governments purchased the drug, mass distribution
would be excessively expensive from a societal perspective.
However, from the perspective of the governments of countries
in which azithromycin (donated by Pfizer Inc. through the
International Trachoma Initiative) is being distributed, mass
distribution appears to be relatively cost-effective.
Trichiasis scarring is amenable to surgical repair. To date, the
cost-effectiveness analyses that have been done suggest that
surgery is not particularly expensive per case of blindness pre-
vented, assuming that the eyelid correction prevents blindness
and that the individuals with operated trichiasis are not more
likely to be affected by other conditions (for example, dry eye)
that might lead to corneal opacification. Baltussen and others
(2005) suggest that trichiasis surgery—with cost-effectiveness
ranging between approximately US$4 and US$82 per DALY
averted across trachoma-endemic areas—would be even more
cost-effective than cataract surgery.
From these cost-effectiveness evaluations, one could con-
clude that it is best simply to correct lid damage attributable to
trachoma. Surgery (tertiary prevention) would then remain a
low but continuing cost. These evaluations do not, of course,
take into account the possibility of eliminating this blinding
disease. The implementation of the full SAFE strategy includes
primary, secondary, and tertiary prevention, and although
more costly at the outset, it could eliminate infection, pain, and
blindness (and the need and cost of lid surgery) into the future.
The WHO Alliance for the Global Elimination of Trachoma
(GET 2020) was established in 1997 to support the work of a
broad spectrum of collaborating international organizations,
nongovernmental development organizations, and founda-
tions in implementing the SAFE strategy. Kumaresan and
Mecaskey (2003) report that 10 countries have initiated tra-
choma elimination programs using donated azithromycin, and
many more programs are expected. They make the point that
the promise of elimination provides the justification for invest-
ing in trachoma control.
Childhood Blindness. In 1993, WHO estimated that as many
as 13.8 million children have some degree of eye damage
because of vitamin A deficiency; however, the number of chil-
dren with actual blindness is much lower—less than 500,000 in
1992. Recent WHO studies (Resnikoff and others 2004) include
vitamin A deficiency among causes of childhood blindness.
Cost-effectiveness studies of vitamin A supplementation, dis-
cussed in chapter 56, focus only on deaths averted unrelated to
blindness, but this public health intervention appears to be
cost-effective.
Onchocerciasis. Onchocerciasis, or “river blindness,” is
endemic in 28 countries in tropical Africa, where 99 percent of
infected people live. Isolated foci of infection also occur in
Latin America (six countries) and Yemen. Although it accounts
for only 0.8 percent of world blindness (Resnikoff and others
2004), the distribution of ivermectin, given at no cost by
Merck, has so far proved successful in drastically reducing this
cause of blindness. Additionally, patients suffer severe skin
lesions and pruritus, also remedied by the annual dosing with
ivermectin. Studies have shown that the cost per DALY averted
is as little as US$40 when adjusted for inflation (Waters,
Rehwinkel, and Burnham 2004).
During the past 25 years considerable progress has been
made by the Onchocerciasis Control Program in West Africa,
both through control of the black-fly vector (insecticide
spraying) and through the distribution of ivermectin. This
success, expressed in health, economic, and development
terms, was the motivating rationale for the launching in
December 1995 of a new program, the African Program for
Onchocerciasis Control. The objective is to create, by 2007,
sustainable community-directed distribution systems using
ivermectin. In Latin America, the Onchocerciasis Elimination
Program in the Americas is successfully using ivermectin dis-
tribution. A coordination group of nongovernmental organi-
zations is working closely with all three onchocerciasis control
programs and with national counterparts in virtually all
endemic countries. If present efforts in endemic countries are
successfully completed, the disease will be brought under con-
trol by 2010.
NATURE, CAUSES, AND EPIDEMIOLOGY
OF HEARING LOSS
In this chapter, the term hearing loss, used by itself, denotes any
or all levels of severity of hearing difficulty. These levels of
hearing impairment comprise mild (26–40 decibel hearing
level, dBHL), moderate (41–60 dBHL), severe (61–80 dBHL),
and profound (81 dBHL or greater). The term deafness denotes
profound hearing impairment (WHO 1991, 1997). Disabling
hearing impairment in adults is defined as “a permanent
unaided hearing threshold level for the better ear of 41 dB or
greater; for this purpose, the hearing threshold level is to be
taken as the better ear average hearing threshold level for the
four frequencies 0.5, 1, 2, and 4 kHz.” Disabling hearing
impairment in children under the age of 15 years is defined as
a permanent, unaided hearing threshold level for the better ear
of 31 dB or greater; for this purpose, the hearing threshold level
is to be taken as the better ear average hearing threshold level
for the four frequencies 0.5, 1, 2, and 4 kHz.
Mathers and others (2003) estimate that in 2002, 255 million
people worldwide had disabling hearing loss (moderate or
worse hearing loss in the better ear). Those 192 million people
with adult-onset loss (age 20 years and above) and 63 million
people with childhood-onset loss make up almost 4.1 percent of
the world’s population and just over 40 percent of all people
globally with hearing loss of any severity. The prevalence rates
of adult-onset hearing loss were estimated by subtracting the
prevalence rate for childhood onset (estimated in terms of
prevalence in ages around 15 to 19). Numbers with childhood-
onset hearing loss by cause have so far not been estimated sepa-
rately but are included among sequelae of other diseases (for
example, infectious diseases such as meningitis, otitis media,
congenital conditions). It has been estimated that at least
50 percent of the burden of hearing loss could be prevented by
primary, secondary, and tertiary preventive measures (Brobby
1989; WHO 1991).
Causes and Characteristics 
Hearing loss is grouped according to International Classi-
fication of Diseases and Related Health Problems, 10th revision,
version for 2003 (ICD-10) into conductive and sensorineural
loss and other hearing loss, ICD-10 codes 90–91 (WHO 2003).
The main causes are shown in table 50.6 according to the pro-
portion that these contribute to the total burden (WHO 1986).
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Chronic otitis media (COM, as in ICD-10 codes H65–H67)
includes chronic suppurative otitis media and otitis media with
effusion. These forms of otitis media, together with some other
middle ear diseases, such as perforation of the tympanic mem-
brane, cholesteatoma, and otosclerosis, are the major causes of
conductive hearing loss. In most WHO estimates of the burden
of otitis media, the data are not disaggregated into acute and
chronic otitis media.
Hearing loss is a chronic and often lifelong disability that,
depending on the severity and frequencies affected, can cause
profound damage to the development of speech, language, and
cognitive skills in children, especially if commencing prelin-
gually. That damage, in turn, affects the child’s progress in school
and, later, his or her ability to obtain, keep, and perform an occu-
pation. For all ages and for both sexes, it causes difficulties with
interpersonal communication and leads to significant individual
social problems, especially isolation and stigmatization.All these
difficulties are much magnified in developing countries, where
there are generally limited services, few trained staff members,
and little awareness about how to deal with these difficulties.
In addition to its individual effects, hearing loss substan-
tially affects social and economic development in communities
and countries. Ruben (2000), taking into account rehabilita-
tion, special education, and loss of employment, estimated the
cost to the U.S. economy in 1999 of communication disorders
(hearing, voice, speech, and language disorders) at between
US$176 billion and US$212 billion (2004 dollars; 2.5–3 percent
of the gross national product of the United States in that year).
Hearing loss accounted for about one-third of the prevalence
of these communication disorders.
Risk Factors
Occupations exposed to high levels of noise or ototoxic chemi-
cals are also at risk,and noise exposure potentiates chemical oto-
toxicity in some cases (Fechter 1995; Morata 1998). Certain
lifestyles (for example, use of personal stereos, noisy toys, fire-
crackers) and hobbies (for example, hunting) are also linked to
levels of noise exposure that can cause hearing loss (Berglund
and others 2000; Goelzer, Hansen, and Sehrndt 2001). Smoking
may be a risk factor for high-frequency hearing loss, adding to
the effect of noise (Mizoue, Miyamoto, and Shimizu 2003).
Other risk factors include poverty, poor access to health care,
poor hygiene, and overcrowding, all of which can lead to upper
respiratory tract infections, otitis media, and other infections
that may cause hearing loss, such as measles and meningitis.
Detailed risk factors and indicators have been developed for
neonates and infants (Joint Committee on Infant Hearing 2000);
these include conditions that should require admission to a
neonatal intensive care unit, stigmata of syndromes causing
hearing loss, positive family history, craniofacial anomalies, cer-
tain in utero and post-natal infections (cytomegalovirus,herpes,
rubella, syphilis, toxoplasmosis, meningitis), hyperbilirubine-
mia, conditions requiring prolonged mechanical ventilation or
oxygenation, persistent otitis media with effusion, and others.
Ototoxic medications, low birth-weight, and low Apgar
scores have also been cited as risk factors for neonates (Vohr and
others 2000). Offspring of consanguineous marriages have a
significantly higher incidence of autosomal recessive diseases,
including hearing impairment. Such diseases are an important
cause in communities where consanguinity is common (Shahin
and others 2002; Zakzouk 2000). Certain ethnic groups (First
Nations peoples such as Inuit and North American Indians, as
well as Australian Aboriginal people) appear to be at higher risk
of developing COM (WHO 1998).
Age, Geographic, and Gender Burdens
The prevalence of disabling hearing impairment that increases
markedly with age is mainly related to the effect of presbycusis.
The current shortage of data, particularly in developing coun-
tries, prevents accurate assessment of the global distribution of
the burden and causes.
Male-to-female ratios of age-standardized adult-onset
prevalence rates were found to be greater than 1 in most stud-
ies in all WHO regions (Mathers, Smith, and Concha 2005).
This finding may be related to occupational noise-induced
hearing loss, which differentially affects men.
Mortality
Barnett and Franks (1999) have found evidence that adults
with postlingual onset of deafness have higher mortality than
nondeaf adults. A 10-year longitudinal analysis of participants
(age 55 to 74 years) in the U.S. National Health and Nutrition
Examination Survey I found that, at baseline, hearing loss pre-
dicts mortality; relative risk  1.17 (Mui and others 1998).
Other studies have reported that the association disappears
after controlling for age, and in any case, any relationship that
may exist is too small to appear in published WHO estimates of
deaths by cause (WHO 2004a, annex table 2) and by years of
life lost, or YLLs (Mathers, Smith, and Concha 2005), in any
region. A small number of deaths (4,000 globally in 2002) are
recorded for otitis media (WHO 2004a), but these deaths are
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Table 50.6 Main Causes of Hearing Loss, by Proportion of
Total Burden
High proportion Moderate proportion Low proportion
Genetic causes Excessive noise Nutritionally related
Otitis media Ototoxic drugs and chemicals Trauma related
Presbycusis Prenatal and perinatal problems Menière’s disease
Infectious causes Tumors
Wax and foreign bodies Cerebrovascular disease
Source: WHO 1986. 
mainly due to infective complications and, hence, are not
directly caused by hearing loss.
Years Lived with Disability and DALYs 
Data on years of life lived with disability (YLDs) and DALYs are
available only for adult-onset hearing loss. The disease model
used, the assumptions and methods used for calculation, and
the disability weights are described elsewhere (Mathers, Smith,
and Concha 2005). Total global YLDs for adult-onset hearing
loss in 2001 are estimated to be 25.87 million, or 4.7 percent of
total YLDs attributable to all causes, which makes hearing loss
a leading cause of YLDs. Because YLLs are taken to be zero for
all regions, the DALY figures are identical to the YLD figures.
The most comprehensive data available are for all adult-onset
hearing loss (WHO 2004b; Mathers, Smith, and Concha 2003).
Fewer data on the burden are available at present for childhood
hearing loss and specific causes.
Interventions
Effective interventions include screening programs, education,
surgery, medications, and assistive devices.
Population-Based Interventions. Neonatal or early infant
hearing screening is important because early identification of
hearing loss (before 6 months of age, with early intervention)
is associated with significantly better language development
and may lead to better school and occupational performance
than that of children identified after 6 months with early inter-
vention (Keren and others 2002; Yoshinaga-Itano and others
1998). Implementation of neonatal hearing screening raises
from 20 to 80 percent the numbers of children with normal
development of language, compared with children whose hear-
ing loss is detected later (Yoshinaga-Itano and Gravel 2001).
Early identification of hearing impairment can reduce the
median age of identification of hearing impairment from
between 12 and 18 months to 6 months or less. Universal
neonatal hearing screening is highly sensitive, but depending
on the test method used, it may result in many false positives
(which may increase parental anxiety and lead to unnecessary
follow-up tests and interventions). It has a low positive predic-
tive value. Some screening protocols may decrease false-
positive rates (Kennedy and others 2000). Universal neonatal
hearing screening has been endorsed in developed countries
(Joint Committee on Infant Hearing 2000), although some
experts urge caution (Paradise 1999); however, it is expensive to
implement and, for most developing countries, is not yet an
option. Hearing screening targeted at high-risk neonates is
generally used in developing countries that do any type of
neonatal screening, but screening may fail to detect 50 percent
or more of cases of impairment (Lutman and Grandori 1999).
Neonatal screening programs will not detect the 10 to 20 per-
cent of cases of permanent childhood hearing impairment that
starts later in life and for which later surveillance is needed
(Grote 2000). No publications were found that have addressed
the DALY burden that might be avoided by implementing
neonatal hearing screening.
A recent WHO meeting of experts on noise-induced hearing
loss (WHO 1998) concluded that exposure to excessive noise is
the major avoidable cause of permanent hearing impairment
worldwide. They agreed that, in developing countries, occupa-
tional noise and urban environmental noise are increasing risk
factors for hearing impairment. Experts attending the meeting
recommended that all countries implement national programs
for prevention of noise-induced hearing loss, including effec-
tive hearing conservation. However, there are no published
reports yet on the effectiveness of such programs in developing
countries. The United States has produced a guide to hearing
conservation programs in the workplace (Franks, Stephenson,
and Merry 1996). It advises how to appraise programs by assess-
ing the completeness of their components and by evaluating
both the individual audiometric data for threshold shift and the
group data for variability compared with a nonexposed popu-
lation. Even in developed countries, there have been few, if any,
clinical trials and little convincing evidence of the efficacy of
occupational hearing conservation programs (Dobie 1995).
Personal Services. Chronic suppurative otitis media is one of
the most common causes of hearing impairment in developing
countries. Opportunities for prevention arise at all levels of
national health systems, particularly in the community and at
the primary level through primary ear and hearing care (PEHC)
(WHO 1998). Appropriate health promotion measures include
breastfeeding, immunization, adequate nutrition, personal
hygiene, improved housing, reduced overcrowding, and ade-
quate access to clean water. Primary health care workers can be
given appropriate training and basic equipment for early detec-
tion and management of chronic suppurative otitis media, but
the effectiveness and cost-effectiveness of this intervention in
developing countries has not yet been assessed.
Although WHO does not currently recommend treating
what is commonly called chronic middle ear infection with
antibiotics at the primary level (WHO 2000), evidence suggests
that antibiotics, especially topical quinolones, are more effec-
tive and cost-effective than ear toilet alone (Acuin, Smith, and
Mackenzie 2000). WHO is reviewing these recommendations
(WHO 2004b). New methods of delivery of effective but
expensive topical antibiotics may lower the cost in poor com-
munities, but treatment failure may be due to a high reinfec-
tion rate attributable to poor hygienic conditions. To be
effective as public health measures, interventions need to be
implemented on a large scale, with good coverage of the targeted
population (van Hasselt and van Kregten 2002). Ear surgery
plays an essential part in the prevention of further hearing
impairment and, sometimes, in the improvement of hearing.
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Services at the secondary level of intervention include pro-
vision of hearing aids in developing countries, which should
assign priority to children with moderate or severe hearing
loss, followed by adults (Arslan and Genovese 1996; WHO
2004c). However, even though globally about 6 million hearing
aids are dispensed annually (WHO 1999), there have been no
published randomized, controlled trials of the effectiveness of
hearing aids in reducing hearing disability in developing coun-
tries and few trials in developed countries.
A randomized trial of amplification in 194 U.S. veterans
showed significant improvements in communication, cogni-
tion, and social and emotional function, plus significant allevia-
tion of depression, with hearing aids compared with controls
(Mulrow and others 1990). No significant differences were
observed in clinical effectiveness and cost-effectiveness between
newer hearing aids that use digital signal processing and those
that do not—in particular, analog-based aids (Parving 2003;
Taylor, Paisley, and Davis 2001). Digital signal processing aids
are not affordable for most people in developing countries.
Over-the-counter hearing aids that can be purchased and used
without prior training are commonly available in some devel-
oping countries. Those aids were found not to meet the pre-
scription gain requirements of the majority of elderly clients
who usually purchased them (Cheng and McPherson 2000).
Learning to use a hearing aid and developing “hearing tac-
tics”are also important. Random assignment to a course for new
hearing aid users significantly reduced the handicap compared
with controls not assigned (Beynon,Thornton,and Poole 1997).
Lack of compliance in use is a substantial problem everywhere
among elderly and child users, including in developing coun-
tries (Furuta and Yoshino 1998; Sorri, Luotonen, and Laitakari
1984). Thus, measuring coverage without taking into account
actual usage is not enough to assess alleviation of the burden.
Cochlear implants are provided to children and adults with
severe and profound bilateral deafness on the basis that known
short-term outcomes in auditory receptive skills (Richter and
others 2002) will translate through various medium-term out-
comes into greater social independence and quality of life (the
social and quality outcomes have not yet been tested in a trial
or observational study) (Summerfield and Marshall 1999).
Cochlear implantation is beneficial in prelingually and postlin-
gually deaf children (Makhdoum, Snik, and van den Broek
1997) and, when accompanied by aural (re)habilitation, leads
to higher rates of mainstream placement in schools and lower
dependence on special education support services (Francis and
others 1999). Multichannel implants are superior to single-
channel implants (Cohen, Waltzman, and Fisher 1993) and are
more beneficial when implanted in young children (Richter
and others 2002). There has been no economic analysis of
cochlear implants in developing countries, and such interven-
tions are currently not a priority in most parts of the develop-
ing world (Berruecos 2000; WHO 2004c; Zeng 1995).
Intervention Cost and Cost-Effectiveness. All the data on the
costs and cost-effectiveness of interventions related to hearing
loss (including school-age screening, treatment of COM, surgi-
cal interventions, hearing aids, and cochlear implants) come
from developed countries. Although they can be summarized
quite readily, it is not clear whether and how they relate to the
costs that would be experienced in developing countries.
RESEARCH AND DEVELOPMENT AGENDA 
The public health research and development agenda for con-
trolling and reducing the burden of disease related to the loss
of sight and hearing should include the following:
• further population-based studies on the magnitude, causes,
and distribution of the burden
• economic analysis,especially on cost-effectiveness (for exam-
ple,cost-effectiveness of each of the components of the SAFE
strategy in trachoma control)
• research to develop eye and hearing care systems
• operational research on eye and hearing care delivery (par-
ticularly for cataract, diabetic retinopathy, and affordable
hearing aids in underserved areas)
• clinical and field trials on interventions: pneumococcal and
meningitis vaccines, treatment for chronic suppurative otitis
media, primary care of ears and hearing, and prevention of
noise damage.
Basic scientific research, particularly for age-related macular
degeneration, must move forward, as it is doing in the indus-
trial countries, where this disease constitutes a major burden
and where highly developed research establishments exist.
CONCLUSIONS: PROMISES AND PITFALLS
With what we now know about some of the cost-effective inter-
ventions cited above, we could make significant reductions in
the burden of disease related to loss of vision. Although wait-
ing for someone to have a condition and then remedying the
situation is not a particularly common “public health” recom-
mendation, given the costs of and knowledge of prevention
at this point, we can strongly recommend surgery both for
cataract (the primary option) and for trachoma (apparently a
better use of resources than mass treatment with antibiotics—
even if not acceptable on a humanitarian basis). For example,
clearing the backlog of cataract surgery globally could reduce
the DALYs associated with vision loss by more than half.
Hearing loss interventions have only begun to demonstrate
their potential effectiveness in developing countries, and no
cost work has been done in these settings. Furthermore,
although the means to reduce the burden of adult-onset
hearing loss are not as straightforward nor as easily applied,
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eliminating adult hearing loss would avoid slightly more YLDs
than eliminating the cataract surgery backlog. The data suggest
that these interventions (particularly cataract surgery) are rela-
tively cost-effective, but a lack of political will, a failure to rec-
ognize that steps can be taken now, insufficient capacity within
ministries of health to carry out the known beneficial interven-
tions, and, finally, a lack of equipment or funding for the pro-
grams still remain barriers to alleviating disabilities related to
vision and hearing loss.
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BURDEN OF MUSCULOSKELETAL DISEASE
Musculoskeletal conditions are the most common cause of
chronic disability around the world. The importance of muscu-
loskeletal conditions as a cause of mortality and morbidity has
been recognized by the designation of 2000–10 as the Bone and
Joint Decade (Hazes and Woolf 2000) by the United Nations,
World Health Organization (WHO),and more than 60 countries
around the world.WHO (2003,2004) has highlighted the burden
of musculoskeletal conditions. Estimates of the global burden of
these conditions have increased 25 percent over the past decade
(WHO 2000). Conditions considered under this rubric include
osteoarthritis (OA); inflammatory arthritis (rheumatoid arthri-
tis and the seronegative spondyloarthropathies); back pain; mus-
culoskeletal injuries, including sports injuries; crystal arthritis
(gout and calcium pyrophosphate disease), and metabolic bone
disease, principally osteoporosis (OP).
Back pain is extremely common in both industrial and
developing countries, with up to 50 percent of workers suffer-
ing an episode each year. Back pain causes 0.8 million disability-
adjusted life years (DALYs) each year and is a major cause of
absence from work and of correspondingly high economic
losses. Nearly 40 percent of back pain is due to occupational
risk factors, and many of these factors can be prevented with
the cooperation of labor, management, industrial engineers,
ergonomists, and health workers.
OA is increasing among the world’s aging populations and is
the sixth leading cause of years lost because of disability glob-
ally. It accounts for nearly 3 percent of the total global years lost
to disability, and 10 percent of men and 18 percent of women
over the age of 60 have OA. Table 51.1 provides an estimate of
the contribution of musculoskeletal conditions to the global
burden of disease, including a disaggregation by gender and
between the developed and developing world. The proportions
presented in the second and third panels are the most notewor-
thy data in table 51.1. First, the second panel shows that mus-
culoskeletal conditions account for approximately 1.7 and
2.4 percent of the burden of disease experienced by males and
females, respectively, or, across both genders, approximately
2 percent of the global burden of disease. The disaggregation by
developing and developed regions, however, shows that while
musculoskeletal conditions account for around 3.4 percent of
the total burden of disease in the developed world, they account
for 1.7 percent in the developing world. The data also show
that, of the set of musculoskeletal conditions, OA accounts for
the largest burden, approximately 52 percent of the total in
developing regions and 61 percent in developed regions.
Table 51.2 provides a further disaggregation of the estimated
burden of musculoskeletal conditions by developing region
and mortality stratum. Note that the burden of disease caused
by musculoskeletal conditions varies considerably by region:
in Africa, mortality stratum D, musculoskeletal conditions
account for less than 1 percent of the burden from all causes,
while in the Western Pacific, mortality stratum B, they account
for more than 3 percent of the total burden of disease. Similarly,
the relative importance of rheumatoid arthritis (RA) and OA
varies considerably by region. In the African regions, where the
prevalence of RA is low, only 12 percent of the burden created
by musculoskeletal diseases is due to RA; in the Americas, how-
ever, that proportion is approximately 24 to 27 percent.
Chapter 51
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Table 51.1 Estimated Burden of Musculoskeletal Diseases, by Gender and by Developed or Developing Regions, 2001
Developing Developed 
regions (both regions (both 
Total Males Females genders) genders)
Numbers of DALYs (thousands)
Rheumatoid arthritis 4,757 1,353 3,404 3,238 1,520
Osteoarthritis 16,372 6,621 9,750 11,049 5,323
Other musculoskeletal diseases 8,699 5,033 3,638 6,789 1,880
All musculoskeletal diseases 29,798 13,007 16,792 21,076 8,723
Percentage of total DALYs
Rheumatoid arthritis 0.32 0.18 0.49 0.27 0.59
Osteoarthritis 1.12 0.86 1.39 0.91 2.05
Other musculoskeletal diseases 0.59 0.65 0.52 0.56 0.73
All musculoskeletal diseases 2.03 1.69 2.40 1.74 3.37
Percentage of musculoskeletal DALYs
Rheumatoid arthritis 15.96 10.40 20.27 15.36 17.42
Osteoarthritis 54.94 50.91 58.07 52.43 61.02
Other musculoskeletal diseases 29.10 38.69 21.66 32.21 21.56
Source: Calculated from WHO (2004).
Note: Totals may not sum due to rounding.
Table 51.2 Estimated Burden of Musculoskeletal Conditions by Region and Mortality Stratum, Selected WHO Regions, 2001
Eastern Western
Africa Americas Southeast Asia Mediterranean Pacific
Condition D E B D B D B D B
Numbers DALYs (thousands)
Rheumatoid arthritis 127 141 532 83 117 855 99 218 1,065
Osteoarthritis 625 687 969 117 931 2,474 227 577 4,442
Other musculoskeletal diseases 285 316 677 107 516 1,756 159 408 2,590
All musculoskeletal diseases 1,037 1,144 2,178 307 1,564 5,085 485 1,203 8,097
Percentage of total DALYs
Rheumatoid arthritis 0.09 0.07 0.66 0.47 0.19 0.24 0.43 0.19 0.44
Osteoarthritis 0.42 0.33 1.19 0.67 1.52 0.69 0.99 0.51 1.84
Other musculoskeletal diseases 0.19 0.15 0.83 0.60 0.84 0.49 0.69 0.36 1.06
All musculoskeletal diseases 0.70 0.55 2.68 1.74 2.55 1.42 2.11 1.06 3.34
Percentage of musculoskeletal DALYs
Rheumatoid arthritis 12.28 12.29 24.45 27.23 7.50 16.82 20.38 18.11 13.19 
Osteoarthritis 60.27 60.10 44.49 38.50 59.51 48.66 46.90 47.97 54.99
Other musculoskeletal diseases 27.44 27.61 31.06 34.27 32.99 34.53 32.71 33.92 31.82
Source: Calculated from WHO (2004).
Notes: The letters in the column heads refer to mortality strata. B  low child and low adult mortality, D  high child and high adult mortality, E  high child and very high adult mortality. 
RA has a prevalence of 0.7 to 0.1 percent worldwide and
results in significant work disability and long-term treatment
costs. In addition, OP is increasing with the aging of popula-
tions: one in three people over the age of 50 suffers a fracture
because of OP. Back pain, OA, trauma, and RA account for
32,948,765 DALYs, or 2.15 percent of the global total for 2000.
A recent review of the prevalence of rheumatic disorders in
Sub-Saharan Africa suggests that the frequency of RA is
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increasing in East, Central, and South Africa but is rare in West
Africa (McGill and Oyoo 2002). Gout is also prevalent
throughout the continent, and the HIV epidemic has spawned
a variety of associated spondyloarthropathies among the aging
population. Countries such as Thailand are also recognizing an
increasing burden of disease caused by arthritis and trauma
(Jitapunkul and others 2003).
NATURE, CAUSES, AND EPIDEMIOLOGY
OF MUSCULOSKELETAL CONDITIONS
Osteoarthritis is the most common condition affecting human
joints and causes significant disability. The principal clinical
features are pain, which varies in severity and character, and
stiffness. Disability occurs as a result of pain, weakness, joint
instability, and reduced range of motion.
The following are the major forms of inflammatory
arthritis:
• rheumatoid arthritis
• seronegative spondyloarthropathies
— ankylosing spondylitis
— reactive arthritis
— enteropathic arthritis
— psoriatic arthritis
• juvenile chronic arthritis
— systemic
— pauciarticular
— polyarticular
• arthritis associated with systemic connective tissue diseases
— systemic lupus erythematosus
— progressive systemic sclerosis
— vasculitis
— polydermatomyositis
• crystal arthritis
— gout
— calcium pyrophosphate deposition disease
RA has a prevalence of between 1 and 3 percent in most
countries for which figures are available, but it may be slightly
less common in tropical countries. The exact etiology of RA is
unknown, but the evidence suggests an immune reaction, and
it presents as an inflammation affecting joints and other tissues.
Its clinical features can be divided into three groups: constitu-
tional, articular, and extra-articular. Constitutional features
involve tiredness, fatigue, weight loss, and fever, and articular
features involve principally the synovial joints, producing pain
and eventual deformity and disability.
The seronegative spondyloarthropathies are primarily
inflammatory arthropathies and share several common features,
including familial aggregation, asymmetric joint involvement,
and mucocutaneous lesions. These conditions may follow gas-
trointestinal or sexually acquired infections and can be associ-
ated with HIV. Gout and other forms of crystal arthritis tend to
present as an inflammatory response to the presence of uric acid
(gout) or various calcium crystals (chondrocalcinosis).
Much of the pain that produces complaints and reduced
function does not emanate from a frank arthropathy, but from
the soft tissues in or around a joint. When these pains are con-
fined to a particular area of the body’s surface, they can be
referred to as regional pain syndromes and may or may not be
related to injury or overuse. If these pains are more widespread
and are associated with specific tender points, the condition is
known as fibromyalgia. Fibromyalgia is well recognized in the
industrial world and has also been noted in China and Malaysia
and among Tamil Indians.
The major causes of infectious arthritis can be viral,
bacterial, fungal, or helminthic. Each can present as either a
polyarticular presentation or a monarthritis. Many of the
helminthic infections present with more generalized aches and
pains and involvement of muscle tissues as well as joints. All the
conditions have specific diagnostic features and treatments.
OP is characterized by low bone mass and deterioration in
the microarchitecture of the bone, which leads to fracture
after low or moderate trauma. The condition is defined by diag-
nostic criteria based on bone mineral density as follows: a bone
mineral density of more than 2.5 standard deviations below
the average bone mineral density of young adult women.
The clinical features of OP are primarily due to its major
outcome: fracture. The most important fractures occur in the
distal radius, vertebrae, or hip, often following minor trauma.
Vertebral fractures lead to loss of height, kyphosis, and back
pain. The incidence of fracture varies with country and with
type of fracture. Hip fractures are low in African countries but
high and increasingly reported in Australasia, Europe, and
North America. Fracture risk increases with age and is begin-
ning to have a significant impact on quality of life, mortality,
and health care costs in many countries.
Rickets is caused by a mineralization defect of newly formed
bone in the growing skeleton. This defect leads to an increase in
the amount of nonmineralized bone tissue (osteoid) and a
thinning of the growth plates. This condition produces bone
pain, bone deformation, swelling of the joints, and growth
retardation. Rickets is primarily caused by a lack of exposure to
sunshine because of climate, pollution, or overuse of clothing
or sunscreens. Rickets is relatively rare in industrial countries,
but it does occur as a consequence of dietary deficiency or
excess clothing.
Osteomalacia is the adult equivalent of rickets. It is similarly
characterized by an increase in osteoid tissue and causes bone
pain and fractures. It occurs primarily in the elderly in Europe
and North America because of a lack of exposure to sunshine
that is not compensated for by adequate vitamin D intake.
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PREVENTIVE STRATEGIES
Obesity brought about by increases in sedentary lifestyles and
changes in eating patterns is becoming a major problem world-
wide. Weight reduction has been demonstrated to reduce pain
and disability from OA of the knee and other forms of lower
limb arthropathy. In OA of the knee, weight reduction will not
only reduce pain and improve mobility, but it can put off the
time when surgical replacement of the weight-bearing joint is
necessary. Obesity can also be associated with back pain, and
weight reduction is an important factor in reducing the recur-
rence of episodes of back pain and in reducing long-term dis-
ability and chronic pain.
Smoking and excessive alcohol use are also associated with
OP. Adequate calcium intake (1,000 to 1,500 milligrams per
day) has been shown to maintain bone density and reduce the
risk of axial (vertebral) fractures. Smoking also increases the
risk of developing RA.
Weight reduction and diet are also important considera-
tions in the management of gout. Appropriate nutrition and
exercise underpin many of the preventive and treatment strate-
gies for musculoskeletal disease.
TREATMENTS
A range of treatment approaches is available to address the
multiple aspects of musculoskeletal disorders.
Symptomatic Treatments
Symptomatic treatments for musculoskeletal disease
principally involve pain reduction. Nonpharmacological treat-
ments such as massage, heat, and ice, and physiotherapeutic
techniques such as ultrasound may be useful in the short term.
Pure analgesic agents such as acetaminophen should be tried
initially; if no response occurs, compound analgesics or opioid
derivatives, including codeine, may be useful. The side effects of
the latter compounds are significant, particularly in the elderly,
with constipation and disorientation being the most common.
Table 51.4 shows the principal modalities of pain relief for
arthritis and soft tissue rheumatism. In many countries, com-
plementary medicines (traditional medicines) are also used
extensively, particularly for the management of pain. These
compounds remain unproven, and clinical studies to explore
their worth should be encouraged.
Recent years have seen the introduction of a number of
specific antiosteoarthritic agents, including glucosamine, chon-
droitin sulfate, soybean extract, and injectable hyaluronic acid
derivatives. Clinical trials have demonstrated that glucosamine
and chondroitin sulfate are beneficial in terms of pain reduc-
tion in patients with OA, but the effects are relatively small.
Table 51.3 Risk Factors for Musculoskeletal Disease 
Condition Genetic Environmental
Rheumatoid arthritis HLA DR
Seronegative HLA B27
spondyloarthropathy
Osteoarthritis Severe osteochondropathies Obesity
Lack of exercise
Soft tissue Occupation
Environment
Crystal arthritis Congenital (Lesch Nyhan) Obesity
Nutrition
Infectious Environment
Osteoporosis Lack of exercise
Nutrition
Metabolic bone disease Environment
Nutrition
Back pain Obesity
Occupation
Lack of exercise
Trauma Environment
Osteomalacia may also occur in countries with abundant sun-
shine where clothing prevents sun exposure. Osteomalacia is
commonly reported among migrants to Western Europe from
India and the Middle East.
Backpainaccounts for themajorityof musculoskeletaldisease
presentations to health professionals, and its lifetime prevalence
exceeds 80 percent in most industrial countries. Spinal disorder
refers to a wide range of specific and nonspecific musculoskeletal
disorders affecting the spinal column. These conditions include
congenital lesions such as scoliosis, infective problems such as
osteomyelitis and neoplastic disorder (myeloma or secondary
cancers), and trauma and referred back pain.
The majority of individuals with acute back pain will
improve significantly over a six-week period, although in many
cases the pain may recur. Early diagnosis and treatment, partic-
ularly of pain, by means of a modified exercise program will
reduce long-term morbidity and disability.
Musculoskeletal injuries are extremely common, whether in
the workplace or associated with sporting activities or with
daily living. Motor vehicle trauma, household accidents, and
occupational accidents occur frequently and are a major cause
of damage to the musculoskeletal system.
Table 51.3 shows the major genetic and environmental
risk factors for musculoskeletal diseases. Lack of exercise and
obesity are major contributors to soft tissue disorders, OA, and
back pain. Infectious forms of musculoskeletal disease depend
on the environment and on the types of organisms that are
prevalent.
Many cases of OA and soft-tissue rheumatism and most cases
of the inflammatory forms of arthritis will require an anti-
inflammatory drug as well as or instead of a pure analgesic. The
nonsteroidal anti-inflammatory drugs (NSAIDs) have been the
mainstay for treating arthritic conditions for nearly a century.
More recently, concern about the adverse gastrointestinal side
effects of NSAIDs led to the development of COX-1 (cyclo-
oxygenase-1) sparing agents. These agents have similar effects
on pain relief but a reduced incidence of gastrointestinal side
effects, although they may produce adverse events in the renal
and cardiovascular systems, such as hypertension, decreased
renal function, and increased stroke and heart attacks.
Rheumatoid Arthritis
The medical community now appreciates the importance of
early diagnosis and treatment of RA. All patients with RA
should be started on a specific antirheumatic drug on diagno-
sis. These drugs have been shown to be efficacious in random-
ized controlled trials (Gabriel, Coyle, and Moreland 2001), but
each has a quite different spectrum of adverse side effects. Even
with the new biologic agents, few patients with RA actually go
into complete remission, and disease activity continues despite
a reduction in endpoints, such as the number of painful and
swollen joints, function impairment, and pain. Most patients
with RA now receive combinations of antirheumatic drugs, the
most common being methotrexate, hydroxychloroquine, and
sulfasalazine. Corticosteroids are also used intermittently in
many cases. Patients with RA also need to receive information
about exercise programs and education on activities of daily
living so that they can make informed choices in relation to
their therapies.
Osteoporosis
A number of therapies are available for OP, including
calcitonin, calcium, bisphosphonates, hormone replacement
therapy (HRT), and selective estrogen receptor modifiers.
Clinical trial data support the use of HRT, bisphosphonates,
selective estrogen receptor modifiers, calcitonin, vitamin D and
calcium supplementation, and calcitriol in reducing fracture
rates in high-risk patients. Calcium and vitamin D supplemen-
tation are recommended to reduce hip fractures among the
elderly living in assisted living accommodations and nursing
homes. The recommended daily requirement for calcium
varies significantly between countries—for example, from
1,000 milligrams per day in the United States to less than
500 milligrams per day in India. Recommended levels of vita-
min D supplementation range from 500 to 1,000 international
units per day, particularly for at-risk aging females. In addition
to these pharmacological interventions, attention to risk factors
for falling is also important.
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Table 51.4 Treatment for Arthritis 
Specific Nonsteroidal Disease-modifying
antiosteoarthritis anti-inflammatory antirheumatic
Category Analgesics agents drugs drugs
Pharmacological Acetaminophen Glucosamine Nonspecific NSAIDs Chloroquine
treatments Compound analgesics Avocado extract Selective COX-1 sparing Hydroxychloroquine
Codeine Soybean agents Sulfasalazine
Opioid derivatives Chondroitin sulfate Gold
Diacerein D-penicillamine
Hyaluronic acid (injectable) Methotrexate
Azathioprine
Cyclophosphamide
Leflunomide
Cyclosporine A
Corticosteroids
Minocycline
Biologics:
Antitumor necrosis factor
Anti-interleukin-1 receptor antagonist
Nonpharmacological Massage n.a. n.a. n.a.
treatments Heat
Ice
Ultrasound
Source: Authors.
n.a.  not applicable
Surgical treatments vary, from the use of external splints for
fractures, to interventions such as arthroscopy, internal fixation
for complicated fractures, and insertion of prosthetic devices,
most commonly total hip and knee replacements. Biomaterials
are increasingly being used to repair bone or cartilage defects in
younger patients, particularly those with sporting or other
traumatic injuries.
Rehabilitation treatments include a range of activities, from
single discipline interventions such as physiotherapy to multi-
disciplinary programs, particularly for complex problems such
as back pain.
ECONOMIC ISSUES
An economic discussion of health policies designed to prevent,
treat, and manage musculoskeletal conditions in developing
countries is inherently difficult for a variety of reasons, but
primarily because of the lack of both epidemiological and 
cost-effectiveness data for most developing countries. Some
progress has been made by Symmons, Mathers, and Pfleger
(2004a, 2004b), who provide incidence estimates for OA and
RA from epidemiological data on prevalence and relative mor-
tality risks, although data from many areas are scant.
Perhaps a more important constraint on economic evalua-
tions in this field is the surprising number of interventions for
which trial data on efficacy are inadequate. Another issue, cur-
rently the target of a concerted effort to improve practice in the
field, is the lack of cross-study comparability of the results of
economic evaluations of interventions for OA, RA, and OP.
One of the most important variables is the choice of compara-
tor used to assess the cost-effectiveness of interventions.
The Outcome Measures in Rheumatology Clinical Trials
Economics Working Group, which was established in 1996, has
made some progress toward redressing this problem. In princi-
ple, the relevant comparator is generally the next-best alterna-
tive or alternatives to the intervention of interest. The choice of
comparator is especially important for cost-effectiveness analy-
sis, because cost-effectiveness is a relative, not an absolute, con-
cept; whether a particular intervention is considered efficient
depends on the efficiency of other interventions and on budget
constraints. This issue is a fundamental one, because a great
many health sector innovations involve new ways of producing
desirable effects with existing technology. The relevant
consideration in such cases is the additional benefits that the
innovation is expected to confer and the relative cost of
achieving those benefits. In such circumstances, the computa-
tion of incremental cost-effectiveness ratios (ICERs) on the
basis of a no-treatment alternative is of limited use, unless that
scenario is genuinely under consideration. Unfortunately, the
no-treatment (or, more accurately, the placebo treatment)
option is precisely the comparator that much of the literature
has used.
Another characteristic of economic evaluations in this field
is that they have been performed almost entirely for developed
countries. In the sections that follow, we discuss the steps we
have taken in an attempt to minimize the adverse consequences
of reliance on the literature for developed countries.
Nevertheless, the pragmatic approach that we have adopted is
subject to some important limitations and caveats.
Cost-effectiveness is a relative concept, in the sense that
cost-effectiveness ratios (CERs) are useful only for comparing
alternative ways of achieving a desired outcome—for instance,
improving the quality and length of life. Assertions that an
intervention is, in its own right, cost-effective are usually based
on the notion that a particular CER represents a cutoff between
those interventions that are efficient and those that are not.
Thresholds of this kind involve an assumption about the value
of life—for example, that a quality-adjusted life year (QALY) is
worth US$30,000. Nevertheless, the literature routinely uses
cost-effectiveness rules that are based on thresholds without
the theoretically necessary explicit consideration of implicit
budget constraints.
We have tried to avoid using a threshold type of approach in
relation to the discussion of cost-effectiveness. Instead, we
critically reviewed the cost-effectiveness literature in rheuma-
tology to provide an indication of the relative costs and
consequences of available interventions. In some cases, an
intervention appears to be inefficient because it costs more and
produces fewer benefits than a competing alternative or
because two interventions produce identical effects but one
costs less than the other. Nevertheless, we have provided a sum-
mary of our views—for ease of reference—as table 51.5. This
table summarizes our thoughts on the weight of the current
effectiveness and cost-effectiveness evidence and the likelihood
that developing countries might realistically consider each
intervention. For the reasons given above, though, we have
articulated the evidence in more detail in the text.
Cross-country differences in the epidemiology of conditions
of interest, the age structure of populations, and the access to
health care, along with differences in relative prices, are liable to
affect the cost-effectiveness of any given intervention. Some of
the substantive gaps between the developed and developing
worlds may compound the problem. For example, if the price
of labor relative to that of capital is consistently lower in the
developing countries, capital-intensive interventions may be
relatively less attractive than they are in the developed coun-
tries, especially if labor-intensive alternatives exist.
To improve comparability across the literature, we adjusted
reported CERs by converting them to 2001 U.S. dollar prices
(therefore, those we report generally differ from those the orig-
inal authors cite). Generally, we adjusted outcomes to U.S. dol-
lars for studies outside the United States that reported CERs
in local currencies using the official exchange rate in effect at
that time, but wherever such studies reported only U.S. dollar
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Table 51.5 Summary of the Economic Evaluation of Interventions for Musculoskeletal Conditions
Considered Generally 
cost-effective recommended 
Conditions and in developed for developing 
treatment options countries?a countries?b References Additional comments
Osteoporosis
Primary prevention
Physical activity
Calcium plus vitamin D
HRT
Raloxifene
Secondary prevention
Screening
Calcium and calcium plus vitamin D
HRT
Raloxifene
Calcitonin, alendronate, 
and biphosphonates
Fluoride
Alfacalcidol
Osteoarthritis
Primary prevention
Secondary prevention
Education program
Exercise program
Nonselective NSAIDs
Gastroprotective agents
Synovial fluid replacement
Tertiary interventions
Total hip arthroplasty
Knee replacement
Rheumatoid arthritis
Inpatient or outpatient
Telephone help line
Katzmarzyk Gledhill, and Shephard
2000; Geelhoed, Harris, and Prince
1994; Patrick and others 2001
Willis 2002
Geelhoed, Harris, and Prince 1994;
Armstrong and others 2001;
Kanis and others 2002
Armstrong and others 2001;
Kanis and others 2002
Norlund 1996
Kanis and others 2002
Fleurence, Torgerson, and Reid
2002; Kanis and others 2002
Kanis and others 2002
Coyle and others 2001; 
Kanis and others 2002
Kanis and others 2002
Kanis and others 2002
Lord and others 1999
Patrick and others 2001
McCabe and others 1998
Van Dieten and others 2000;
Gabriel, Campion, and O’Fallon
1994
Torrance and others 2002
Chang, Pellissier, and Hazen 1996
Segal and others 2004
Nordstrom and others 1996;
Hughes and others 2002
Based on consensus
Based on evidence
Differences in life expectancy
and incidence of OP will affect
age at which recommended
More randomized clinic trials
needed
Based on consensus
Different comparators, relative
price
With good communications and
low levels of access to medical
care
No
Yes
Yes
No
No
Yes
Yes
No
No
No
No
No evidence
No
No evidence
No for nabumetone
Yes, but several
qualifiers
Yes
Yes
Yes
No evidence
Yes
Yes (for low-cost
interventions)
Yes
—
No
No
Yes
Yes
No
No
No
No
Yes
Further research
needed
Low-cost programs
may be useful
No
—
—
—
Yes
(Continues on the following page.)
equivalents, we took these as given. Finally, we used the U.S.
Bureau of Labor Statistics consumer price index data for 2004
to inflate (deflate) the U.S. dollar CERs to 2001 prices. Thus,
unless otherwise stated, all price data are expressed in 2001 U.S.
dollars.
For clarity, we have classified cost-effectiveness results by
condition and also according to whether the intervention
constitutes a primary, secondary, or tertiary intervention. The
exception is RA, for which the management protocols are less
amenable to this type of abstraction. For RA, we found that cat-
egorizing the evidence according to a taxonomy that is problem
or intervention based was more useful.
Primary Interventions
This section reviews the evidence on the cost-effectiveness of
interventions designed to prevent the onset of OP. The works
surveyed analyzed interventions in healthy people, primarily
perimenopausal and postmenopausal women, with no estab-
lished history of OP.
Physical Activity. The prophylactic effects of physical activity
are generally well appreciated, and a large proportion of pre-
ventable disease is sometimes attributed to sedentary lifestyles.
Katzmarzyk, Gledhill, and Shephard (2000) estimate the rela-
tive risks for those who are inactive compared with those who
are physically active for a range of conditions, including OP.
Their results for Canada suggest mean OP relative risk factors
of 1.56 to 1.90 for sedentary versus active women, depending
on race, and indicate that the population-attributable fraction
of OP caused by inactivity was approximately 27 percent and
accounted for more than 16 percent of the direct economic
costs of physical inactivity.
The effectiveness and cost-effectiveness of programs
intended to encourage lifestyle changes are generally not well
established. Geelhoed, Harris, and Prince (1994) consider the
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Disease-modifying antirheumatic
drugs
Auranofin
Cyclosporine, azathioprine, 
D-penicillamine
Combination therapy
Biologics
Corticosteroids
Low back pain
Back schools
Massage
Early interventions
Ankylosing spondylitis
Spa exercise
Biologics
Thompson and others 1988
Anis and others 1996
Verhoeven and others 1998
—
Bae and others 2003
Van Tulder 2003
Furlan and others 2002
Gatchel and others 2003 
Van Tubergen and others 2002
—
Cost, monitoring, and adverse
events
Need trials in developing
countries, but current costs are
prohibitive
Side effects
Depends on labor market
conditions
Does not provide compelling
evidence
Unattractive because of their
high price
Not effective
Equal efficacy;
cyclosporine should
be used after
cheaper, more
effective drugs
Yes, in some
studies
No data 
Yes
No evidence
Little evidence
Yes
Yes, but ICERs
were sensitive to
indirect costs
No
No
No
Possibly
No
Possibly
No
Yes, if low cost
Yes
No
No
Source: Authors.
n.a.  not available.
a. Based on a cost-effectiveness threshold value of approximately US$30,000 or other favorable quantitative data on costs and benefits.
b. Based on authors’ judgment of generally favorable/unfavorable cost-effectiveness evidence. See text for precise cost-effectiveness (for example, cost per QALY) data.
Table 51.5 Continued
Considered Generally 
cost-effective recommended 
Conditions and in developed for developing 
treatment options countries?a countries?b References Additional comments
effect of an intervention in Australia involving exercise and
calcium supplements for healthy postmenopausal women to
prevent osteoporotic fractures. They find that the cost of the
intervention was US$96,119 per QALY; however, note that
the authors assumed no toxic effect of the lifestyle regimen on
diseases other than OP.
Calcium Plus Vitamin D. Willis (2002) analyzes the cost-
effectiveness of administering calcium plus vitamin D3to healthy
postmenopausal women in Sweden and demonstrates that this
intervention is a cost-saving one for 50-, 60-, and 70-year-old
women with a maternal family history of hip fracture and for 60-
and 70-year-old women with either a history of fragility fractures
or a smoking habit. In developing regions, calcium plus vitamin
D therapy may be a cost-effective or cost-saving intervention if
targeted at older, asymptomatic women with maternal histories
of hip and other fragility fractures—especially those who smoke.
A targeted strategy of this kind is likely to be the most cost-
effective in regions where environmental uptake of these ele-
ments is limited for dietary or other reasons.
Hormone Replacement Therapy. Geelhoed, Harris, and
Prince’s (1994) cost-effectiveness analysis of interventions in
a hypothetical cohort of 100,000 healthy postmenopausal
women includes several HRT strategies: (a) estrogen from age
50 for life, (b) estrogen from age 50 for 15 years, and (c) estro-
gen from age 65 for life. Compared with a no-therapy alterna-
tive, the cost per QALY was US$8,609 for strategy c, US$13,268
for strategy a, and US$30,183 for strategy b.
Armstrong and others (2001) compare HRT with a no-
therapy scenario in healthy postmenopausal women and exam-
ine how the risks of breast cancer and coronary heart disease
(CHD) might influence the cost-effectiveness of the interven-
tions over 5- and 10-year periods, as well as a lifetime interven-
tion of approximately 31 years. They report a relatively low cost
per QALY of US$2,238 to US$2,850 for women at a 10 to
15 percent risk of breast cancer. The cost-effectiveness of HRT
fell as the risk of breast cancer increased.
Both the base cases in these studies assume that HRT
reduces hip fracture rates, and Armstrong and others (2001)
also assume reductions in CHD. These constitute important
assumptions because, as Kanis and others (2002) point out,
data from randomized clinical trials (RCTs) support the
hypothesis of no effect of HRT on either appendicular fractures
or CHD. Thus, the ICERs reported by both the studies may
either understate or overstate the true cost per QALY produced
by using HRT as a primary prevention.
Raloxifene. Armstrong and others’ (2001) study also includes
a cost-effectiveness analysis of raloxifene use (compared with
HRT and no intervention) in healthy postmenopausal women.
Their results indicate that, by comparison with raloxifene, HRT
is a dominant long-term therapy for U.S. women at average risk
(in this case, a 10 percent lifetime risk) of breast cancer: the 5-
and 10-year period ICERs were US$37,620 and US$33, 472 per
QALY, respectively. For women at a 30 percent or higher risk of
breast cancer, the ICER for raloxifene versus HRT was less than
US$4,160, and decreased with risk.
Kanis and others (2002) argue that existing evidence on
raloxifene suggests that it has no significant effect on either
appendicular fractures or CHD. On the basis of the existing
cost-effectiveness evidence, the use of raloxifene as a prophy-
lactic intervention for OP in the developing regions has little to
recommend it.
Secondary Interventions
The following studies were concerned with interventions in
people with some indication of OP, either from a bone mineral
density assessment or a fracture. Some of the general studies
include Jönsson and others’ (1999) study based on Swedish epi-
demiological data. The authors consider two different levels of
intervention costs, those associated with HRT and those associ-
ated with HRT plus bisphosphonates, and find that the higher-
cost intervention (HRT plus bisphosphonates therapy) was
dominant for the 80-year-old group modeled. In the context of
developing countries, note both the relatively higher incidence
of osteoporotic fractures among 80-year-olds and the relatively
larger size of this demographic group in Sweden.
Screening. Norlund (1996) conducted a cost-benefit analysis
of fracture prevention in osteoporotic women age 50 to 54 in
Sweden, assuming 70 percent participation in the screening
program and an offer of HRT with 30 percent acceptance. The
study provides evidence of a negative net benefit, indicating
that the costs of a population screening program of this kind
exceed its benefits. Thus, population-based bone mineral den-
sity screening programs aimed at perimenopausal or post-
menopausal women are likely to be a poor use of health
resources in the developing world.
Calcium and Calcium Plus Vitamin D. Citing trial evidence,
Kanis and others (2002) assume that calcium supplements
alone reduce only vertebral fracture risks in women with estab-
lished OP. Assuming a compliance rate of 70 percent, the
authors find that the intervention’s cost per QALY for 50-, 60-,
70-, and 80-year-old cohorts were approximately US$64,995,
US$31,548, US$10,271, and US$10,527, respectively. They also
examine the cost-effectiveness of calcium plus vitamin D on
the basis of trial evidence that this combination also reduces
appendicular fractures. Assuming a 70 percent compliance
rate, they find that calcium plus vitamin D was cost saving in
80-year-olds and either cost saving or a low-cost intervention
(mean cost per QALY of US$584) in 70-year-olds. For 50- and
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60-year-olds, the mean costs per QALY were US$29,357 and
US$13,730, respectively. Thus, in developing regions, calcium
plus vitamin D therapy may be an attractive investment for
elderly women with established OP.
Hormone Replacement Therapy. Fleurence, Torgerson, and
Reid (2002) demonstrate an ICER of US$12,800 to US$19,700
for HRT for their Scottish sample. Kanis and others (2002) show
that while HRT was generally a dominant therapy for 80-year-
olds, with a cost per QALY of US$4,527, it was an expensive
therapy for 50-year-olds at a cost per QALY of US$42,940. These
results suggest that HRT is likely to be an attractive intervention
for established OP for some age groups in the developing
regions. Differences in life expectancy and the underlying inci-
dence of OP will, however, have a considerable bearing on the
age at which HRT interventions may be considered desirable in
each region.
Raloxifene. Kanis and others (2002) find that the cost per
QALY associated with raloxifene was approximately
US$835,622 in 50-year-olds, and although this cost generally fell
with age, it remains an expensive intervention. Raloxifene ther-
apy is not an attractive investment for the developing regions.
Calcitonin and Bisphosphonates. The cost-effectiveness evi-
dence on nasal calcitonin is unambiguous. It is a particularly
expensive intervention and represents an unattractive invest-
ment of health care resources even in wealthy developed coun-
tries. The most favorable cost-effectiveness results for nasal cal-
citonin come from a study by Coyle and others (2001), who
find that both calcitonin and alendronate reduced wrist, hip,
and vertebral fractures in postmenopausal women but that
etidronate had no such effect on hip and wrist fractures. The
ICERs for nasal calcitonin for 65-year-old women for five years
of therapy were US$34,166 per QALY compared with no ther-
apy and US$23,952 per QALY compared with etidronate. The
results of this study were sensitive to the underlying fracture
rate.
Kanis and others (2002, iv) also conclude that calcitonin is
“not cost-effective at any age largely because of its costs.”
Indeed, their estimates of costs per QALY for 70- and 80-year-
old women, the groups for which the intervention is most 
cost-effective, equate to approximately US$245,373 and
US$181,109, respectively. By contrast, both alendronate and
etidronate were dominating interventions for 80-year-olds. At
current prices, calcitonin therapy is not an attractive invest-
ment for the developing regions.
Fluoride. Kanis and others (2002) find that fluoride was gen-
erally a dominant intervention in women with established OP,
because it appears to decrease the risk of vertebral fracture but
to increase the risk of hip fracture, although the latter result is
statistically insignificant. When they assume that fluoride has
a neutral effect on hip fractures, the authors find that the cost
per QALY was in the acceptable range for interventions in
the United Kingdom—that is, less than US$46,684. Fluoride
is unlikely to be a desirable intervention for preventing OP in
developing countries.
Alfacalcidol. Kanis and others (2002) report wide confidence
intervals on the cost per QALY of an alfacalcidol intervention.
This result is largely due to substantial variation in the appar-
ent vertebral, hip, and humeral fracture risk available from
RCTs. Thus, alfacalcidol does not appear to be a good invest-
ment for developing economies; however, additional RCTs
are required to reduce the uncertainty regarding the cost-
effectiveness of this intervention.
COST-EFFECTIVENESS OF INTERVENTIONS
FOR OA
Primary Interventions
Despite clear evidence of an association of OA with obesity and
of a reduction in symptoms and progression of the disease with
weight reduction, no formal studies of the cost-effectiveness of
this intervention are available.
Secondary Interventions
Patient education programs, exercise programs, medications,
and synovial fluid replacement have demonstrated varying
levels of cost-effectiveness.
Education Programs. Lord and others (1999) evaluated the
cost-effectiveness of a nurse-led education program for
patients with OA of the knee in the United Kingdom, using
usual care as the comparator. They found that the costs for the
intervention group were greater than for the control group, but
that the outcomes for the two groups were not statistically
different.
The cost-effectiveness of education programs for OA
patients in the developing countries is unknown. Education
programs will be subject to diminishing returns, and their
marginal effectiveness may depend directly on the basic level
of education of those targeted. Though the scant evidence
presented here suggests that education programs may not be
cost-effective, further research on their effectiveness and cost-
effectiveness in developing countries is required.
Exercise Programs. Patrick and others (2001) analyzed the
cost-effectiveness of an aquatic exercise program for the man-
agement of OA and compare it with usual care. The study
involved a 20-week randomized trial of aquatic classes for 249
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adults age 55 to 75 with a confirmed diagnosis of OA. The
results were generally unfavorable. In many cases (24 percent of
the bootstrapped estimates), the exercise program was domi-
nated by usual care, and the 95 percent confidence interval
ranged from dominated to US$498,700 per QALY gained.
Evidence of the cost-effectiveness of exercise programs for
established OA is currently meager. Nevertheless, as part of a
diversified portfolio, low-cost exercise programs may still play
a useful role in the aging populations of developing regions and
confer some benefit on those with established OA, particularly
if they are associated with weight reduction.
Nonselective NSAIDs. In a U.K. study, McCabe and others
(1998) consider the cost-effectiveness of the use of five different
NSAIDs (nabumetone, diclofenac, ibuprofen, piroxicam, and
naproxen) in RA and OA. Taking the least and most expensive of
the five NSAIDs—namely, ibuprofen and nabumetone, which
were also at the high- and low-risk ends of the spectrum in terms
of adverse gastrointestinal events—the authors conclude that
nabumetone is not a cost-saving prescription.
Gastroprotective Agents. The most common side effects of
NSAIDs are gastrointestinal; therefore, evaluating therapies to
reduce these events is important. Van Dieten and others (2000)
review the literature on the cost-effectiveness of misoprostol in
reducing adverse gastrointestinal events in OA and RA patients
who take NSAIDs. Unfortunately, the reviewed studies evi-
dently reported CERs based on such nongeneralizable mea-
sures as cost per patient ratios. Nevertheless, van Dieten and
others (2000) argue that strong evidence exists that gastropro-
tection is cost-effective for OA and RA patients taking NSAID
therapy. This finding appears to be true in relation to several of
the reviewed studies, which produced estimates of cost savings
derived from prophylaxis. However, van Dieten and others’
(2000) study is at variance with that of Gabriel, Campion, and
O’Fallon (1994), who conclude that misoprostol was generally
dominant in that it provided no greater quality-of-life
improvement and cost more.
Synovial Fluid Replacement. In a Canadian study, Torrance
and others (2002) analyzed the cost-effectiveness of synovial
fluid replacement in a randomized, one-year, multicenter trial
of 255 patients with OA of the knee. Patients were randomized
to appropriate care with hylan G-F 20 or to appropriate care
without hylan G-F 20. The mean QALY gain in the intervention
group was 0.071, and the resulting ICER was US$5,233 per
QALY (with similar results from sensitivity analyses). However,
the relevant incremental comparators in developing regions are
likely to be quite different from those used by the foregoing
study. Also, the relative price of this product is likely to be
higher. Thus, we cannot find strong grounds for recommend-
ing that developing regions adopt this intervention.
Tertiary Interventions
Total joint replacement for arthritis is one of the most com-
monly performed and cost-effective operations in developed
countries. In developing countries, however, the availability of
this intervention is constrained by the availability of surgeons
able to perform the operation. If the surgical expertise is avail-
able, the cost-effectiveness of total joint replacement is likely to
be as good as in Australia, Europe, and North America.
Total Hip Arthroplasty. Chang, Pellissier, and Hazen (1996)
assess the cost-effectiveness of total hip arthroplasty in vari-
ous age groups compared with nonsurgical management. Their
analyses suggest that, in 60-year-old white women, total hip
arthroplasty is dominant compared with nonsurgical manage-
ment. For 85-year-old men, the cost per QALY is US$6,893.
Generally, their results suggest that, when total hip arthroplasty
is used as a treatment for OA of the hip with significant
functional limitation, it is cost-effective.
Knee Replacement. Segal and others (2004) review a number
of interventions for OA and suggest a cost per QALY of
US$5,407 for knee replacement in Australia.
COST-EFFECTIVENESS OF INTERVENTIONS
FOR RA
The result of a decade of vigorous debate about the appropri-
ate treatment strategies for RA appears to be a consensus that
patients with moderate or severe RA should be treated early
and aggressively, if possible, by combining several disease-
modifying antirheumatic drugs (DMARDs) (Maetzel and
others 2002).
The complex medical management of RA can involve the
use of a large number of agents, including NSAIDs, low-dose
corticosteroids, and a long list of DMARDs. The economic
literature for interventions in RA has, for good reason, tended
to focus on the cost-effectiveness of the alternatives that arise
when a particular management strategy fails. In that sense, the
intervention-based taxonomy used in earlier sections of this
chapter is a less helpful way to characterize some of the contri-
butions to this field. Thus, the subsections used in this part of
the chapter reflect at times a problem-based taxonomy and at
other times an intervention-based classification.
Treatment Modalities
One of the challenges common to the developing world is that
specialized medical expertise is often scarce. Thus, the consider-
ation of a variety of treatment modalities is worthwhile,
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especially those that involve labor substitution between special-
ist and nonspecialist categories. Unfortunately, relatively few
studies of this kind, let alone large randomized studies, are
available for RA.
In a nonrandomized study of 26 patients in Finland,
Nordstrom and others (1996) compare the costs of treating RA
patients either as inpatients or as outpatients. Even though the
authors find that the cost of treating patients as outpatients was
approximately one-sixth the cost of inpatient treatment, the
small sample size and possible bias associated with the non-
randomized design mean that the study’s results cannot be
generalized.
An interesting and possibly cost-effective strategy for man-
aging RA involves the use of a telephone help line staffed by
specialist nurses. Hughes and others (2002) examine the
costs and benefits of such an intervention in the United
Kingdom and conclude that it was cost saving. Their work was
based on a sample of 87 RA patients who used the telephone
help line in a given month. A large proportion of respondents
indicated that they used the help line in place of a visit to a gen-
eral practitioner, and on this basis, the authors computed that
the service produced a net saving.
The existing evidence on the effectiveness and cost-
effectiveness of a telephone help line for RA patients is based on
a relatively small sample. Nevertheless, this type of intervention
may be useful in developing regions with good communications
but low levels of access to medical care. This type of intervention
may be particularly worthy of consideration when direct access
to a medical practitioner is associated with large travel costs.
Disease-Modifying Antirheumatic Drugs
DMARDs include cyclosporine, azathioprine, D-penicillamine,
sulfasalazine, etanercept, hydroxychloroquine, methotrexate,
leflunomide, and gold compounds. Gabriel, Coyle, and
Moreland (2001) provide a comprehensive review of the effec-
tiveness and cost-effectiveness of DMARDs, including a com-
prehensive literature search in which they retrieved 30 articles
from 500 identified for possible relevance. Only six of those
papers included economic evaluations, and of those six, only
three included measures of both benefits and costs. Only one
of the articles used a nonclinical outcome measure (QALYs).
Thus, the cost-effectiveness evidence for the use of DMARDs
to treat patients with RA is generally scant.
The three full economic evaluations of DMARDs that
Gabriel, Coyle, and Moreland identified were studies of auran-
ofin (oral gold) (Thompson and others 1988), cyclosporine
(Anis and others 1996), and combined therapy (Verhoeven and
others 1998).
Auranofin. Thompson and others (1988) compare the cost-
effectiveness of auranofin with that of a placebo using data
from a six-month RCT of 311 patients with RA. The authors
report that the cost of auranofin was approximately US$692
greater than for the placebo treatment, but the lack of efficacy
of auranofin means that it is now rarely used in RA treatment.
Cyclosporine, Azathioprine, and D-penicillamine. In a
Canadian study, Anis and others (1996) conduct a cost-
effectiveness analysis of cyclosporine use in patients with RA
based on the results of a meta-analysis of five RCTs. Their
comparators included a placebo control, azathioprine, and D-
penicillamine and analyses based on societal costs or third-
party payer costs, but the ICERs were expressed as the cost per
patient per year improved, so the results are difficult to inter-
pret in the context of a general priority-setting exercise for
health expenditures. For the purposes of this chapter, perhaps
the study’s most useful result was that it found no statistically
significant differences between cyclosporine, azathioprine, and
D-penicillamine.
Given that the existing evidence on cyclosporine, azathio-
prine, and D-penicillamine indicates similar levels of efficacy,
cyclosporine should be used only after less expensive and more
effective therapies for the management of RA, including
azathioprine and D-penicillamine.
Combination Therapy. Verhoeven and others (1998) analyze
the use of combination therapy using data from the
Combinatietherapie Bij Reumatoide Artritis, or COBRA study,
conducted in Europe between 1993 and 1995. The study was a
56-week trial that involved treating an intervention group with
sulfasalazine, methotrexate, and prednisolone versus sul-
fasalazine alone as a control. Even though the authors conclude
that combined therapy is cost-effective, they qualify the results
by stating that the study was probably underpowered. Despite
the lack of good cost-effective data, the standard approach to
RA treatment is to use combination therapy with DMARDs
and to maintain corticosteroids at 7.5 milligrams per day or less
if possible.
Biologics. A number of trials have shown that the biologic
agents (tumor necrosis factor inhibitors and others) are the
most effective agents available for reducing inflammation in
RA. Their cost (US$10,000 to US$15,000 per patient per year);
mode of administration (intramuscular, subcutaneous, or by
intravenous infusion); and potential side effects (particularly
the reactivation of tuberculosis) preclude their use in develop-
ing countries. Until trials are carried out in developing envi-
ronments and are combined with robust cost-effectiveness
data, we cannot recommend their use.
Corticosteroids. Bae and others (2003) analyze the cost-
effectiveness of low-dose corticosteroids for the long-term
treatment of RA. They compare the results of corticosteroid
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treatment with treatment using any DMARDs plus a cortico-
steroid and with treatment using DMARDs and NSAIDs. Their
modeling includes a consideration of the rates of relevant side
effects of the treatments. They also look at NSAID-use scenarios
that included Proton Pump Inhibitor prophylaxis and the use of
COX-2–specific inhibitors rather than nonspecific NSAIDs.
The results generally showed that corticosteroids dominate
nonselective NSAIDs in terms of their cost-effectiveness. The
exceptions were when the adverse events rate for cortico-
steroids was assumed to be 1.5 times that of the base case and
when the comparators’ adverse events rates were assumed to
be 0.5 to 1.0 times the base case rate. In the latter case, the cost
per QALY was US$114,168, and in the former, NSAIDs were
dominant. The comparison of COX-2–specific inhibitors with
corticosteroids produced a higher-cost and higher-utility
outcome: the resulting incremental cost per QALY was
US$132,880.
The authors also produced useful age-specific estimates
of the cost-effectiveness of the two alternative treatment
approaches. Their ICERs show that corticosteroids dominate
for the management of 50- and 60-year-olds with RA. For 40-,
30-, and 20-year-olds, the ICERs were US$11,258, US$30,938,
and US$46,981, respectively.
The evidence suggests that a management strategy of
DMARDs plus low-dose corticosteroids is a less costly and
more effective strategy than DMARDs plus NSAIDs in older
age groups, largely because of the higher risks of adverse gas-
trointestinal events in those groups. For developing countries,
a relevant question to consider is the extent to which life
expectancy and risk factors for adverse gastrointestinal events
will differ from the age groups Bae and others (2003) studied.
Corticosteroid-induced OP is also a long-term risk, but for
women with RA starting corticosteroid therapy, watchful wait-
ing is recommended as preferable to screening, as long as the
steroid dose remains below 7 milligrams per day.
COST-EFFECTIVENESS OF INTERVENTIONS FOR
OTHER MUSCULOSKELETAL CONDITIONS
Low Back Pain
Low back pain is as common in developing countries as it is in
the developed world. Health professionals now generally agree
that conservative care for acute lower back pain is the initial
treatment of choice, unless there is structural evidence of
pathology that is amenable to surgical intervention (Gatchel
and others 2003). Evidence also indicates that programs that
incorporate some physical activity may reduce the costs of both
acute and chronic low back pain compared with those that do
not involve activity.
For economic evaluations, one of the important complicat-
ing factors associated with low back pain is that the
nonmeasurement of indirect costs may introduce substantial
bias into estimates of the cost-effectiveness of interventions.
This problem is potentially serious because, in some cases,
investigators have estimated the indirect costs of low back pain
at more than twice those of the direct medical costs (Bolten,
Kempel-Waibel, and Pforringer 1998).
Back Schools. Van Tulder and others (2003) review 15 RCTs of
back schools for patients with recurrent and chronic low back
pain, but they consider only three of these to be of high quality.
They conclude that the evidence is only moderate that back
schools have better short-term effects than other treatments for
chronic back pain. They also find some evidence that back
schools are more effective than placebos or waiting list controls
in occupational settings. However, the authors note that little is
currently known about the cost-effectiveness of back schools.
Thus, evidence is insufficient to provide a recommendation on
the probable cost-effectiveness of back schools for low back
pain in developing countries; however, early intervention,
education, and exercise programs should be encouraged.
Massage. Furlan and others (2002) examine the effectiveness
and cost-effectiveness of a variety of massage techniques for
nonspecific low back pain by comparing them with (a) sham or
placebo massage, (b) other medical treatments, or (c) no treat-
ment. The authors conclude that massage might be beneficial
for patients with subacute and chronic nonspecific low back
pain, especially when combined with exercises and education.
The evidence suggests that acupuncture massage is more
effective than classic massage, but this finding needs to be
confirmed.
Little is known about the cost-effectiveness of massage for
low back pain. On the basis of the existing evidence, in coun-
tries or regions in which massage—especially acupunctural
massage—is routinely available at low cost, the intervention
may be cost-effective. Where acupunctural interventions are
considered, the costs of bloodborne disease transmission must
also be weighed against the expected benefits of the interven-
tion. This consideration may be important in countries where
the prevalence of bloodborne viruses is high, particularly if
strict infection control measures are not routinely followed.
Early Interventions. The few studies of early intervention
programs to reduce the progression of acute low back pain to
chronic pain have tended to report considerable cost savings.
Gatchel and others (2003) published a prospective trial of early
interventions in individuals with acute low back pain and a
high risk of the pain progressing to chronicity. The authors
screened approximately 700 patients and designated them as
being at either low or high risk. The patients were then assigned
to early or nonintervention groups and followed for 12
months. The early intervention was generally conducted over a
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three-week period and involved an intensive, multidisciplinary
approach that included exercise classes, biofeedback and pain
management classes, group education sessions, case manager
and occupational therapist sessions, and interdisciplinary team
conferences.
The early intervention resulted in statistically significant dif-
ferences in return-to-work outcomes, number of health care
visits, and number of disability days caused by back pain. It also
resulted in a variety of pain surrogates. Furthermore, the mean
cost savings were approximately US$9,000 per patient. The
direct costs for the intervention group were approximately
US$2,500 higher than those for the intervention group, but this
finding was largely the result of the up-front costs of the inter-
vention program itself. The direct costs of health care visits and
pharmaceuticals were considerably lower for the intervention
group.
The evidence suggests that an intensive, multidisciplinary,
early intervention program is cost saving for individuals with
acute low back pain who are at high risk of having the pain
progress to chronicity; however, the cost savings associated with
this intervention are attributable to improved labor market out-
comes and earnings for injured individuals. The intervention
itself may increase costs in the short term, but it appears to be
associated with medium and long-term net benefits. Labor mar-
ket conditions, including wages, along with the age of low back
pain sufferers, may have an important bearing on the viability of
this type of intervention in developing countries.
Ankylosing Spondylitis
Although the direct costs associated with ankylosing spondyli-
tis are relatively low, its impact on indirect costs, including pain
and suffering, are substantial. To date, little work has been done
on the economics of interventions for ankylosing spondylitis.
Pharmaceutical interventions are currently typically limited to
NSAIDs and DMARDs such as methotrexate and sulfasalazine.
Van Tubergen and others (2002), however, analyze the cost-
effectiveness of a spa exercise intervention. The intervention
period was three weeks, and although the authors argue that
the cost-effectiveness of the intervention was favorable, they
also note that the ICERs were sensitive to variations in assump-
tions about indirect costs.
Although a spa exercise program is apparently beneficial
and may even be considered cost-effective for ankylosing
spondylitis sufferers in developed countries, the current cost-
effectiveness evidence does not provide a compelling case for
widespread adoption of the intervention in developing regions.
Patients, however, should be encouraged to exercise—
especially to swim. The cost-effectiveness of tumor necrosis
factor–inhibiting drugs is not yet evident for ankylosing
spondylitis, but the drugs are currently unattractive invest-
ments for developing countries because of their high price.
IMPLEMENTATION OF CONTROL STRATEGIES:
LESSONS OF EXPERIENCE
Given the increasing burden of musculoskeletal conditions
worldwide, addressing ways of preventing musculoskeletal
conditions is an important step. Few examples are available of
the implementation of strategies aimed specifically at prevent-
ing musculoskeletal conditions, but many recommendations
are aimed at modifying determinants that affect other aspects
of health in addition to musculoskeletal health. These recom-
mendations include ensuring adequate physical activity to
maintain physical fitness; maintaining an ideal body weight;
ensuring a balanced diet that meets the recommended daily
allowances for calcium and vitamin D; avoiding smoking;
balancing the use of alcohol and avoiding alcohol abuse; and
putting in place accident prevention programs to reduce mus-
culoskeletal injuries related to road traffic accidents, leisure
activities, and workplaces. Various programs involve changes in
the behavior of individuals and control of environmental haz-
ards (these programs are considered elsewhere in this volume).
Personal behavior changes can be achieved by education but
may require resources such as sports facilities. A safe environ-
ment will involve all sectors, and successful implementation
may require legislation. The benefits of these interventions on
musculoskeletal health are not quantified, but in any case they
are probably small. Physical activity and an ideal weight will
benefit the broadest range of musculoskeletal conditions.
Osteoarthritis
The strategy for managing OA is pain management with sim-
ple analgesics or NSAIDs, along with education to facilitate
self-management and rehabilitative programs to improve func-
tion, activities, and participation. These strategies include gen-
eral and specific exercise programs, devices such as walking
sticks, and environmental modifications. Joint replacement
surgery should be considered for end-stage joint damage.
Simple analgesics can be accessible over the counter or through
health clinics. Education and rehabilitative programs can also
be delivered through health clinics. Joint replacement surgery
requires resources in terms of physical facilities, financial
resources, and expertise. The cost-effectiveness of arthroplasty
is greatly affected by complications such as infection or failure
of the prosthesis, both of which are related to inadequate
resources.
Pain management should be available to those who have
disabling symptoms and is dependent on access to drugs and
education with respect to the benefits and risks. Access to
arthroplasty will be the greatest challenge, given the increasing
needs in the developing world brought about by aging popula-
tions and increases in other risk factors such as reduced physi-
cal activity and increasing obesity.
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Rheumatoid Arthritis
The greatest successes in recent years include advances in man-
aging RA and the ability to control disease activity; to prevent
tissue damage; and to improve function, activities, and
participation. Methotrexate is a readily accessible, effective
antirheumatic drug. Monitoring full blood count and liver
function is recommended, but the rarity of serious adverse
events may necessitate a review of this recommendation if the
costs and difficulties of monitoring would deny access to the
drug. Symptomatic therapy with NSAIDs and multidiscipli-
nary rehabilitation are also key components of the manage-
ment of RA. Central to this approach is ensuring early and
accurate diagnosis with long-term expert review, which
requires public awareness about arthritis and adequate compe-
tency and facilities in the community and in health clinics for
diagnosis and management. Education and rehabilitation can
also be delivered in these settings. Paramedical workers can be
trained to undertake much of this work. The problem is to
ensure adequate training and experience of health care workers
for a condition that affects 0.3 to 0.5 percent of adults in devel-
oping countries. Without treatment, the effects of RA can be
great, so effective management can yield significant gains. The
costs are relatively low, because paramedical workers can
deliver much of the care and because the drugs are not new and
are widely available.
Several established market economies have set up early
arthritis clinics, but running such clinics effectively may be
more difficult without a system to encourage and enable early
access to specialist care. The management of established RA is
usually undertaken by specialists in partnership with primary
care. Programs for managing RA are usually self-sustaining and
expandable because of the chronic incurable nature of the con-
dition and the general public’s gradual recognition of what can
be achieved.
Osteoporosis
The prevention of fractures related to OP is based on a “bone-
healthy” lifestyle of individuals who have adequate dietary
calcium, vitamin D, and weight-bearing exercise and who avoid
smoking and excessive alcohol consumption. Implementing
such measures requires raising public awareness and educating
primary care personnel. In addition, those at high risk of frac-
ture who would benefit from a specific intervention need to be
identified by the presence of risk factors, including low bone
density. The limitation to this approach is a lack of access to
bone densitometry, in which case the decision to treat may have
to be made on clinical grounds alone. The occurrence of low-
trauma fracture is a good indicator of OP and, in the presence
of other clinical risk factors, may be reason enough to treat. In
particular, multiple vertebral fractures are virtually diagnostic
of OP.
Various local programs aim at identifying and treating those
with OP. Their costs relate not only to diagnostic tests but also
to treatment. The cost of bisphosphonates is high compared
with the income levels in those countries likely to experience
the greatest increase in the burden of OP. The speed of benefits
of bisphosphonates is good, with clinical trials demonstrating
fracture risk reduction within 12 to 18 months. The role of
HRT is not clear at present, but because of the likely increased
risk of cardiovascular disease and strokes outweighing the ben-
efit of fracture prevention, it is not currently recommended for
preventing OP in unselected women. However, the benefit-risk
ratio will be favorable in those at increased risk of fracture and
low risk of cardiovascular disease, and the costs of HRT are
more feasible. Adherence to treatments for OP to prevent frac-
ture is poor because of the silent nature of their effect, and
patient education to modify expectations is important. The
effectiveness of any fracture prevention program depends on
adherence for as long as possible, given the long-term charac-
ter of the condition.
RESEARCH AND DEVELOPMENT 
Another important issue with musculoskeletal disease is the
development of a research agenda.
Size and Nature of the Burden of Disease
Uncertainty about the epidemiology of some musculoskeletal
conditions is still considerable, especially in developing coun-
tries (WHO 2003). Incidence estimates for OA and RA have
recently been generated from available epidemiological data on
prevalence, relative mortality risks, and so on, though for some
regions even these basic epidemiological data are scant (Africa,
Asia, and South America for RA and Africa, Eastern Europe,
and South America for OA). Additional primary measurement
is required to produce a more accurate picture of interregional
and intraregional epidemiological variations. This deficiency
limits estimates of the overall burdens of the various muscu-
loskeletal conditions and the extent to which they might be
reduced.
The studies of the Community-Oriented Program for
Control of Rheumatic Disease (COPCORD) (Darmawan and
others 1995) are, in part, meeting this need. The Bone and Joint
Monitor Project is also undertaking initiatives to standardize
data collection and reporting in epidemiological studies to
improve the collation and comparison of needed epidemiolog-
ical data. Global burden-of-disease data concentrate on specific
diagnoses, but a far greater burden that has yet to be estimated
relates to regional and generalized musculoskeletal problems
characterized by pain with disability. More research is neces-
sary in this area.
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Evaluation of Existing Interventions
Few reliable economic evaluations of available interventions
have been done. One reason is that a surprising number of
interventions have inadequate trial data or efficacy measures,
and many reasonably well-established interventions need to be
tested in trials against appropriate comparators. The hetero-
geneity of comparators used in different economic evaluations
and other methodological differences pose material risks to
comparisons of the costs and consequences of different
interventions for musculoskeletal conditions, and some stan-
dardization is needed.
Many studies have used only clinical outcomes and not life
years saved or QALYs as outcome measures. Positive steps are
being taken to correct the situation. The Outcome Measures
in Rheumatology Clinical Trials Economics Working Group
(Gabriel, Tugwell, and Drummond 2002) has made some
progress toward redressing this problem in the rheumatology
economics literature. Although work is not yet complete, this
concerted approach to standardization holds promise for the
literature.
Avertable Proportion of the Burden
New data are needed to estimate the burden that could be
averted by implementing the proposed strategies. Available
data are currently limited and relate predominantly to individ-
ual interventions in short-term clinical trials with outcomes
that do not enable reliable estimates of the avertable burden.
Interventions need to be evaluated, often in combination with
outcome measures that enable the burden on individuals and
society to be measured meaningfully and in more naturalistic
circumstances. Concordance cannot be assumed, in particular
for these largely chronic conditions, and it is influenced by
many personal and environmental factors. The impact of
musculoskeletal conditions is pervasive, underrecognized, and
underestimated. Therefore, data are needed not only on what is
theoretically avertable, but also on what is being averted and
the reasons for any disparities.
Resource Requirements
The implementation of strategies for preventing and control-
ling musculoskeletal conditions is multisectoral, and the
resource consequences of this need to be established. Different
models for the delivery of a strategy may have different
resource implications. These variations need to be explored to
ensure appropriate investment and provision of resources.
Likely Effectiveness of Interventions on Both Health and
Nonhealth Benefits
Musculoskeletal conditions are common and have a major
impact on individuals and society; however, they are inade-
quately treated, and the success of simple interventions is not
being achieved because of a lack of prioritization and
resources. Strategies for preventing musculoskeletal conditions
have a wide range of other health benefits; they need to be
jointly promoted, and the additional benefits need to be better
recognized. The various determinants of ill health—such as
lack of physical activity or obesity—that pose a risk to muscu-
loskeletal health need to be quantified along with their other
detrimental effects. The benefits and cost-effectiveness of mod-
ifying these determinants of health, with regard to preventing
or modifying the outcome of musculoskeletal conditions, need
to be quantified and compared with strategies that focus on
personal interventions.
Implementation
Improving musculoskeletal health requires implementing
strategies for preventing and controlling certain diseases and
environmental risk factors. Selected strategies must be in line
with local needs, priorities, and resources. Informed decision
making at the policy level requires data on the burden and the
avertable burden of musculoskeletal conditions, plus the costs
for particular populations by strategy. Changes in local demo-
graphics that are likely to increase the effect of musculoskeletal
conditions also need to be considered before developing plans
for implementation.
CONCLUSIONS: PROMISES AND PITFALLS
Musculoskeletal diseases are the most common cause of
chronic disability worldwide and will become increasingly
important as aging populations require relief from chronic pain
and disability. One of the characteristics of musculoskeletal
diseases is that they are not fatal and do not have the high
profile of other conditions, such as cancer and heart disease.
However, they are preventable in many cases, and simple inter-
ventions, such as maintaining ideal body weight and partici-
pating in an exercise program, may have a significant effect on
long-term morbidity. However, the field of musculoskeletal
disease is thwarted by a significant lack of epidemiological and
outcome data across a broad spectrum of geography, condi-
tion, and treatments.
The designation of 2000–10 as the Bone and Joint Decade
by the United Nations, WHO, and 60 countries will certainly
help raise the profile of these diseases in local communities. All
nations have a significant opportunity to embrace the decade,
to ensure that their populations understand the importance
of these diseases, and to encourage the training of a range of
health professionals to deal with this burgeoning epidemic.
Improving knowledge among health workers at all levels
about musculoskeletal conditions is important for early diag-
nosis and intervention, as is the provision of access to special-
ist services, such as orthopedic surgery. Simple programs that
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emphasize the importance of obesity and lack of exercise as
predictors of poor musculoskeletal outcomes are low cost,
but their implementation and their influence on health out-
comes need to be assessed in properly conducted studies.
Medications—particularly analgesic and anti-inflammatory
drugs for arthritis and pain and vitamin D and calcium sup-
plementation to prevent OP—need to be widely available.
Exciting advances in the treatment of inflammatory forms
of arthritis with biologics need to be evaluated from an eco-
nomic perspective, particularly in developing nations, where
the risk of exacerbating underlining infections such as tuber-
culosis is much higher than in developed countries. Currently,
biologic agents are not cost-effective in developing countries,
but they may be in the future. Access to hip and knee replace-
ments, probably the most cost-effective surgical intervention
available, is important but depends on the availability of a qual-
ified staff.
Musculoskeletal diseases will continue to present a challenge
to the health systems of both developing and developed
countries, but as we solve some of the issues related to commu-
nicable diseases, the hope is that more resources will become
available for tackling the burgeoning epidemic of noncommu-
nicable disease, including musculoskeletal conditions.
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The undertreatment of chronic pain is a global problem, espe-
cially for people in the final stages of cancer and, increasingly,
AIDS. The pain of dying is often severe, but it can be controlled
for most people by a simple and inexpensive intervention: oral
analgesic drugs, including morphine and other opioids.
Although it was long known that opioid drugs were essential
for the relief of moderate to severe pain, even in the 1980s the
amounts being used globally were so low that only a minority
of those dying could have had adequate pain relief. Since then
progress has been made, mainly in resource-rich countries,
widening the gap between rich and poor. The absence of opi-
oids in developing countries is not merely a problem of supply
or costs, however. This chapter lays out the institutional and
political barriers that restrict their availability in most low- and
middle-income countries.
BURDEN OF PAIN FROM CANCER AND AIDS
Pain is“an unpleasant sensory and emotional experience associ-
ated with either actual or potential tissue damage or described in
terms of such damage”(Task Force on Taxonomy 2004). Pain, in
its various manifestations, is the most common symptom lead-
ing patients to seek medical assistance (box 52.1).
Measurement of Pain
Pain is a subjective experience, but it can be described by
patients and assessed using validated questionnaires and scales
(Cleeland 1990). In categorical scales, the patient describes the
pain using specific words, for example, mild, moderate, severe,
or excruciating. With numerical scales, patients rate their pain
by choosing a number—for example, from 0 (no pain) to 10
(worst pain). Visual analog scales often take the form of a ruled
line, anchored on the left by the words no pain and on the right
by worst possible pain.
Pain measurement instruments have been validated in clin-
ical trials of analgesic therapies and subsequently used in
national and international surveys, repeatedly demonstrating
sensitivity and reliability for both cancer and AIDS patients.
These instruments include the Brief Pain Inventory (Bernabei
and others 1998; Cleeland and others 1996; Daut, Cleeland, and
Flanery 1983), the Memorial Pain Assessment Card (Fishman
and others 1987), the Memorial Symptom Assessment Scale
(Portenoy and others 1994), and the Edmonton Symptom
Assessment Scale (Chang, Hwang, and Feuerman 2000).
Effects of Pain
Pain dramatically affects quality of life. Patients with persistent
serious pain cease participating in social activities and may be
unable to work or care for their families (Daut, Cleeland, and
Flanery 1983). Psychological effects, including depression and
anxiety, increase with pain intensity (Rosenfeld and others 1996).
The suffering of an individual radiates throughout house-
holds, neighborhoods, and villages. Caregivers suffer distress,
anxiety, and depression. They may have to give up their own
employment to care for a dying relative. The loss of income of
the patient and the caregiver may dramatically lower the
family’s social status (Murray and others 2003).
Chapter 52
Pain Control for People with Cancer
and AIDS
Kathleen M. Foley, Judith L. Wagner, David E. Joranson, 
and Hellen Gelband
Pain in Patients with Cancer and AIDS
Several well-defined acute and chronic pain syndromes are asso-
ciated with cancer, with HIV/AIDS, and with their treatment
(Breitbart 2003; Foley 1979). In low-income countries, where
patients usually present late in the course of illness, pain from
the disease itself is more common than treatment-related pain.
Researchers consistently report that 60 to 90 percent of
patients with advanced cancer experience moderate to severe
pain, regardless of age and gender and whether ambulatory or
hospitalized (Cleeland and others 1988; Cleeland and others
1996; Daut and Cleeland 1982; Foley 1979, 1999; Stjernsward
and Clark 2003). The intensity, degree of pain relief, and effect
of pain vary according to the type of cancer, treatment, and
personal characteristics, but prevalence and severity of pain
usually increase with disease progression. No population-based
studies of AIDS-related pain have been published, but several
researchers report that up to 80 percent of patients in the last
phase of illness experience significant pain requiring analgesics
(Larue, Fontaine, and Colleau 1997; Schofferman and Brody
1990; Singer and others 1993).
Pain Days 
No standard metric has been developed to describe the pain
burden for people at the end of life. We have adopted a
transparent and direct measure—the pain day—defined as a
day of moderate or severe pain requiring an opioid drug for
relief. The elements that determine the number of cancer and
AIDS pain days in a population are the numbers dying from
each condition and the average prevalence and duration of
severe pain associated with dying.
Patterns of pain from specific cancers and from AIDS at
given stages appear to be similar everywhere. However, because
different cancers produce different symptoms, the mix of can-
cers in a country will influence the overall pattern and burden
of pain reflected in the total number of pain days.
About 2.1 million deaths from cancer and about 3 million
from AIDS occur annually in low- and middle-income countries
(LMICs) worldwide, and these numbers are increasing. Using
expertopinion,weestimate thatabout80percentof peopledying
from cancer and 50 percent of those dying from AIDS experience
moderate or severe pain, lasting for an average of 90 days.
INTERVENTIONS FOR PAIN RELIEF
The goal of pain control is not to cure disease, but to allow
patients to function as effectively as possible and to minimize
pain. Interventions for pain relief include drugs, radiotherapy,
and anesthetic, neurosurgical, psychological, and behavioral
approaches (see table 52.1). However, analgesic drugs are the
mainstay of treatment and the focus of this chapter. According
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Classification of Pain
Box 52.1
Pain is classified according to two main characteristics:
temporal and physiologic. Temporal categories are
• acute pain 
º characterized by a well-defined onset and self-
limited end
º allows clear description of location, character, and
timing
º shows signs of autonomic nervous system
hyperactivity—for example, tachycardia, hyperten-
sion, profuse sweating (diaphoresis), dilated pupils
(mydriasis), or pallor
• chronic or persistent pain
º long lasting, usually defined as at least three 
months
º characterized by a localization, character, and timing
that is often more vague than with acute pain
º characterized by adaptation of the autonomic nerv-
ous system, so signs of hyperactivity disappear
º results in significant changes in psychological, func-
tional, and social status.
Physiologic pain categories are
• somatic pain
º originates in ligaments, tendons, bones, blood ves-
sels, and nerves
º sharp or dull, but typically well localized and
intermittent 
• visceral pain
º originates in body organs and results from activa-
tion of nociceptive receptors and efferent nerves
º characterized by deep aching and cramping, often
referred to cutaneous sites 
• neuropathic pain
º results from direct injury to peripheral receptors,
nerves, or the central nervous system
º typically burning and dysesthetic (abnormal and
unpleasant), often in area of sensory loss.
Source: Authors.
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Table 52.1 Procedures Used to Control Specific Types of Cancer Pain
Type of procedure Most common indications
Anesthetic
Inhalation therapy with nitrous oxide Breakthrough pain, incidental pain in patients with diffuse, poorly controlled pain
Intravenous barbiturates (for example, sodium pentobarbital) Diffuse body pain and suffering inadequately controlled by systemic opioids
Local anesthetic by intravenous, subcutaneous, Neuropathic pain in any site with local application to the area of hyperesthesia or allodynia
or transdermal application
Trigger point injections Focal muscle pain
Nerve block
Peripheral Pain in discrete dermatomes in chest and abdomen or in distal extremities
Epidural Unilateral lumbar or sacral pain 
Midline perineal pain
Bilateral lumbosacral pain
Intrathecal Midline perineal pain
Bilateral lumbosacral pain
Autonomic
Stellate ganglion Reflex sympathetic dystrophy
Lumbar sympathetic Reflex sympathetic dystrophy of the lower extremities
Lumbosacral plexopathy
Vascular insufficiency of lower extremity
Celiac plexus Midabdominal pain from tumor infiltration
Intermittent or continuous epidural infusion with local anesthetics Unilateral and bilateral lumbosacral pain
Midline perineal pain
Neuropathic pain from the midthoracic region down
Intermittent or continuous epidural or intrathecal with Unilateral and bilateral pain below the midthoracic region; often 
local opioid analgesics combined with local anesthetics 
Intermittent or continuous intraventrical infusions Head and neck pain and upper chest
with opioid analgesics
Chemical hypophysectomy Diffuse bone pain
Neuroablative
Nerve root: rhizotomy Somatic and neuropathic pain from tumor infiltration of the cranial and intercostal nerves
Spinal cord: dorsal root entry zone lesion Unilateral neuropathic pain from brachial, intercostal, and lumbosacral plexopathy and 
postherpetic neuralgia
Spinal cord: cordotomy Unilateral pain below the waist; often combined with local neurolytic blocks in perineal and
bilateral lumbosacral plexopathy; may be performed bilaterally
Spinal cord: myelotomy Midline pain below the waist, but rarely used because it involves extensive surgery
Brain stem: mesencephalic tractomy Pain in the nasopharynx and trigeminal region
Thalamus: thalamotomy Unilateral neuropathic pain in the chest and lower extremity
Cortex: cingulotomy Useful through a stereotactic approach for diffuse pain
Pituitary: transsphenoidal hypophysectomy Bone metastases in endocrine-dependent tumors, breast, and prostate
Neurostimulatory 
Peripheral nerve: transcutaneous and percutaneous electrical Dysesthesias from tumor infiltration of nerve or trauma 
nerve stimulation
Spinal cord: dorsal column stimulation Of limited use in neuropathic pain in the chest, midline, and lower extremities
Thalamus: thalamic stimulation Of rare use in neuropathic pain in the chest, midline, or lower extremity
Radiotherapy
External beam Bone and brain metastases
Nerve and spinal cord compression
(Continues on the following page.)
to the World Health Organization (WHO), “A palliative care
programme cannot exist unless it is based on a rational nation-
al drug policy,” and this includes “regulations that allow ready
access of suffering patients to opioids” (WHO 2002, 87).
WHO Three-Step Analgesic Ladder and Its Effectiveness 
WHO has developed a “three-step analgesic ladder” (fig-
ure 52.1) for cancer pain and its treatment (WHO 1986),
which includes a strong opioid (morphine) (table 52.2). The
ladder is equally appropriate for patients with HIV/AIDS
(O’Neill, Selwyn, and Schietinger 2003).
The steps in the ladder represent increasing pain severity
and the drugs that should be used in each case:
• Step 1 is limited to nonopioids, including drugs that are
widely available (for example, acetaminophen, aspirin, or
nonsteroidal anti-inflammatory drugs, or NSAIDs).
• Step 2 describes moderate pain that requires a combination
of a nonopioid and opioid for relief.
• Step 3 is for pain requiring a strong opioid. No specific
dosages are recommended for opioid drugs because the
concept of a standard dose does not apply: effective doses of
oral morphine range from as little as 5 mg to more than
1,000 mg every four hours. Adjuvant drugs are also essential
to treat side effects of analgesics or to provide additive
analgesia (table 52.2).
Controlled field testing and clinical experience has demon-
strated that 70 to 90 percent of cancer patients can achieve pain
control using the ladder (Goudas, Carr, and Bloch 2001).
Although the ladder has not been validated in formal studies
for patients with AIDS, recent clinical reports describe its suc-
cessful application (Anand, Carmosino, and Glatt 1994;
Kimball and McCormick 1996; McCormack and others
1993; Newshan and Lefkowitz 2001; Newshan and Wainapel
1993; Schofferman and Brody 1990).
In an ideal world, a trained professional would prescribe pain
medication throughout the course of illness, in accordance with
the ladder. However, most patients self-medicate pain with anal-
gesics and traditional medicines that they buy over the counter
until they have late-stage disease and severe pain that can be
treated only with a strong opioid. That is when they are most
likely to seek formal medical care, which would start on step 3 of
the ladder. Unfortunately, the opioid they need is unlikely to be
unavailable in LMICs, even from health professionals.
Adequacy of and Barriers to Pain Control and Palliative Care
in Developing Countries
The adequacy of pain control in populations is not easily
measured. A useful and available surrogate is the per capita
consumption of morphine (Joranson 1993), a figure based on
mandatory annual reports by national governments to the
International Narcotics Control Board (INCB). Of the 27 mil-
lion grams of morphine used legally in 2002, 78 percent went
to six countries—Australia, Canada, France, Germany,
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Table 52.1 Continued
Type of procedure Most common indications
Physical 
Cutaneous stimulation (superficial heat, cold, massage) Dysesthesias from tumor infiltration of nerve or trauma
Transcutaneous electrical nerve stimulation Cutaneous nerve injury pain
Acupuncture For focal or diffuse pain syndrome
Bed rest Reduced movement–related pain syndrome
Psychological
Hypnosis Provides distraction and cognitive approach to reduce pain
Relaxation, imagery, biofeedback, distraction, reframing Provides distraction and cognitive approach to reduce pain
Patient education
Source: Breitbart 2003; Authors.
Pain persists
or increases
Nonopioid
Aspirin or
acetaminophen
± adjuvant drug
Step 1
Source: WHO 1990.
Pain persists
or increases
Opioid for mild to
moderate pain
Codeine
+ Nonopioid
Aspirin or
acetaminophen
± adjuvant drug
Step 2 
Opioid for moderate
to severe pain
Morphine 
+ Nonopioid
Aspirin or
acetaminophen
± adjuvant drug
Step 3
Figure 52.1 The Three-Step Analgesic Ladder
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Table 52.2 Basic Drug List for Cancer and AIDS Pain Relief: Analgesics and Adjuvant Drugs
Category Analgesics Basic drugs Alternatives
Nonopioids Acetylsalicylic acid (aspirin) Choline magnesium trisalicylate
Acetaminophen Diflunisal
Ibuprofen Naproxen
Indomethacin Diclofenac
Opioids for mild to moderate pain Codeine Dihydrocodeine
Hydrocodone
Tramadol
Opioids for moderate to severe pain Morphine Methadone
Hydromorphone
Oxycodone
Pethidine
Buprenorphine
Fentanyl
Opioid antagonists Naloxone Nalorphine
Adjuvant drugs for analgesia and symptom control
Antiemetics Prochlorperazine Metoclopramide
Ondansetron
Laxatives Senna Cisacodyl
Sodium docusate Bran
Mineral oil Dantron
Lactulose Sorbitol
Magnesium hydroxide
Antidiarrheal agents Loperamide Paregoric
Diphenoxylate hydrochloride and atropine sulfate
Antidepressants (adjuvant analgesics) Amitriptyline Imipramine
Paroxetine
Antipsychotic Haloperidol Thorazine
Anticonvulsants (adjuvant analgesics) Gabapentin Valproic acid
Carbamazepine
Corticosteroids Prednisone Prednisolone
Dexamethasone
Anxiolytics Diazepam Clonazepam
Lorazepam
Midazolam
Psychostimulants Methylphenidate Pemoline
Source: Foley, Aulino, and Stjernsward 2003. 
the United Kingdom, and the United States. The rest went to
the other 142 countries that reported. Morphine is largely
unavailable in Africa, the eastern Mediterranean, and Southeast
Asia (figure 52.2).
The major barriers to palliative care in LMICs are scarce
resources, lack of national policies or low priority for pain
relief, lack of awareness by health professionals and the public
that cancer and AIDS pain can be relieved, concern that medical
use of opioids will lead to drug abuse and addiction, and legal
restrictions on opioids. Medical, religious, gender, social, and
cultural factors also present barriers (see box 52.2). With AIDS,
social and self-stigmatization work against adequate care of any
kind. In addition, most of the emphasis in poor countries has
been on prevention and, more recently, on antiretroviral drugs.
In all cases, even less care is in place for children than for adults
(Joranson, Rajagopal, and Gilson 2002).
Legal Controls on Opioid Drugs
The Single Convention on Narcotic Drugs of 1961, amended by
the 1972 Protocol (United Nations 1961), is an international
treaty that aims both to prevent the illicit production of, traf-
ficking in, and use of narcotic drugs and to ensure their avail-
ability for medical and scientific needs. The INCB, established
in 1968 by the Single Convention, is the independent, quasi-
judicial organization that implements the Single Convention.
The Single Convention requires that all countries (even
nonsignatories) intending to make opioids available for
medical use estimate national opioid needs and report annually
on imports, exports, and distribution to the retail level. It also
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Living with and Dying from Cancer in Scotland and Kenya
Box 52.2
Physical suffering dominates the lives of people with
advanced cancer in rural Kenya. In contrast, the concerns
of cancer patients in Scotland, whose physical needs are
met, focus on the prospect of death. A recent study com-
pared these two groups.
The suffering in Kenya stems largely from poverty and
the high cost of basic health care. Hospital care is limited,
and patients feel happier at home. Families care for
patients without drugs or supplies or even the knowledge
of what to expect and how to help the patient. Patients are
concerned about the physical and financial burden on
their families. They are comforted and inspired by reli-
gious beliefs and by the support of their communities.
They accept their fate.
In Scotland, health care is free and of high quality.
Patients are able to get primary treatment for the cancer
and, when needed, palliative care. They are likely to be
angry about their illness rather than accepting, and many
feel isolated from family and friends. Although patients’
physical needs are met routinely, psychosocial needs are
met only for some.
Source: Murray and others 2003.
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Source: INCB 2003 and authors’ calculations. 
Figure 52.2 Global Morphine Consumption, by Country  (Per Capita, 2002)
sets out the following principles on which countries can
develop their own policies and regulations:
• Individuals must be authorized to dispense opioids by
virtue of their professional license or be specially licensed to
do so.
• Opioids may be transferred only between authorized parties.
• Opioids may be dispensed only with a medical prescription.
Many governments have imposed even tighter restrictions,
such as limiting the number of days for which an opioid pre-
scription can be written.
COSTS AND COST-EFFECTIVENESS 
This section describes the costs and benefits of providing oral
morphine and essential adjuvant drugs to terminally ill cancer
and AIDS patients who require it. It assumes the drugs are used
according to the WHO analgesic ladder. We recognize that
other analgesics can also contribute significantly to patients’
costs and pain relief, but at least some such drugs (acetamino-
phen, for example) are available relatively cheaply in most
places. Although not everyone has access to such drugs, we are
unaware of any data that could be used to estimate that pro-
portion. Costs are estimated for three countries at differing
income levels and with different patterns of cancer and AIDS
deaths: Chile, Romania, and Uganda (see box 52.3).
Costs Included in the Estimates 
The quantitative analysis presented here is restricted to the
costs, before such drugs reach the patient, of oral morphine
and the adjuvant drugs needed to treat its side effects. We men-
tion other costs associated with delivering oral morphine to
terminal AIDS and cancer patients later in this section, but for
reasons we discuss, we have not assigned dollar values to them.
Costs of Oral Morphine. The appropriate measure of drug
cost is the sum of costs to all payers—governments, insurers,
charities, and patients—for the drug itself, but that sum does
not include the costs of personnel to administer the drug or
otherwise care for the patient.
Oral morphine can be purchased in bulk powder or finished
form and administered as a tablet or liquid (De Lima and
others 2004; Rajagopal and Venkateswaran 2003). The cost to
the final payer is influenced by import taxes, if any; require-
ments to document the chain of custody of the product; costs
to local manufacturers of excipients, salts, diluents, and other
materials required to produce finished forms; and price
markups. The actual cost of oral morphine in LMICs is diffi-
cult to document because it is unavailable in so many places or
is manufactured for finished use at different points in the dis-
tribution chain. The price of a 30-day supply of immediate-
release oral morphine in 2003 ranged from US$10 in India to
US$254 in Argentina, among the few countries for which prices
were reported (De Lima and others 2004).
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Pain Control in Romania and Chile
Box 52.3
Palliative care has developed in Romania since the early
1990s, largely through the Romanian Association for
Palliative Care. Support has come predominantly from
U.K. charities and from the Open Society Institute.
Services are provided throughout the country by paid staff
and volunteers in 10 hospital-based inpatient services,
9 hospice home care teams, 2 day care services, and 1 pal-
liative care training center that provides services. Coverage
is still low: only 15 percent of cancer patients are treated
with opioid analgesics. Morphine is available (paid for by
the government) only for terminally ill cancer patients.
Prescription restrictions and extra authorization needed
for releasing morphine to each patient are still so burden-
some that patients may die before the paperwork is com-
pleted. The situation is improving gradually, however.
Palliative care has developed in Chile over the past
15 years, largely through nongovernmental organizations.
The Ministry of Health’s cancer program has also played
a role by including palliative care in its National Cancer
Control Program initiative and by moving to reform
drug laws. As a result, morphine consumption increased
from less than 5 kg in 1990 to 55 kg in 2000. Despite
these efforts, only a minority of patients have access to
oral morphine for chronic pain related to cancer or
AIDS. The remaining barriers include inadequately
trained clinicians, a lack of national standards and guide-
lines, cure-oriented cancer treatment policies, fear of
addiction on the part of both professionals and the pub-
lic, and a lack of resources to improve the health care
infrastructure.
Sources: International Observatory on End of Life Care 2005.
Morphine is likely to cost less where it is produced locally
and used in easy-to-reach, urban locations. Liquid prepara-
tions made by mixing morphine powder will cost less than
tablets. Even with these variations, if barriers to access to oral
morphine are removed, a total drug cost of 1 cent per mil-
ligram or less for immediate-release oral morphine should be
achievable for most countries. A realistic and conservative esti-
mate of the cost of oral morphine is 0.5 cent to 1.0 cent per mil-
ligram in the countries in our analysis.
The cost of morphine per patient depends on the number
of days that opioids are required and the average daily dose,
recognizing that the required dosage typically increases with
increasing pain nearer to death. An average daily dose in
palliative care programs in developing countries is roughly
60 to 75 mg per day, and patients require this dose for an
average of three months. (Merriman 2002; personal commu-
nication, L. De Lima, International Association for Hospice
and Palliative Care, June 2004; personal communication,
M. R. Rajagopal, Amrita Institute of Medical Sciences, Kochi,
Kerala, India, June 2004).
Using the inputs above, we estimate the cost of oral mor-
phine for a cancer or AIDS patient with severe pain near
the end of life at about 30 to 75 cents per day, or US$9.00 to
US$22.50 per month, which is needed for an average of three
months.
Costs of Other Necessary Drugs. Morphine’s most common
side effects are constipation, nausea, and (less frequently)
psychosis. Representative drugs to treat these conditions are
senna, a laxative, available to some government purchasers for
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Table 52.3 Background Data, Assumptions, and Results of Cost Analysis
Item Uganda Chile Romania
Economic, demographic, and health characteristics
Population, 2001 22,800,000 15,400,000 22,400,000
Gross national income per capita, 2001 (US$) 260 4,590 1,720
World Bank income designation Low Upper middle Lower middle
Percentage of the population living in rural areas 85 14 45
Number of cancer deaths, 2000 10,504 18,315 38,360
Number of AIDS deaths, 2001 84,000 220 350
Prevalence of cancer and AIDS deaths (per million population) 4,145 1,204 1,728
Morphine use per capita, 2001 (mg) 0.1 2.1 2.2
Total morphine use, 2001 (mg millions) 2.191 31.770 48.809
Assumptions and estimates used to determine the costs of oral morphine
Percentage of cancer patients requiring end-of-life care with oral morphine 80 80 80
Average number of days of oral morphine required for cancer patients 90 90 90
Average daily dose of oral morphine for cancer patients (mg) 60–75 60–75 60–75
Effectiveness of intervention, cancer (percentage of pain days averted per day of therapy) 80 80 80
Percentage of patients with cancer already receiving adequate end-of-life pain care 0.5 20.0 15.0
Percentage of AIDS patients requiring end-of-life care with oral morphine 50 50 50
Average number of days of oral morphine required for AIDS patients 90 90 90
Average daily dose of oral morphine for AIDS patients (mg) 60–75 60–75 60–75
Effectiveness of intervention, AIDS (percentage of pain days averted per day of therapy) 80 80 80
Percentage of patients with AIDS already receiving adequate end-of-life pain care 0.5 20.0 15.0
Average daily cost of related drugs for cancer and AIDS patients (US$) 0.18–0.33 0.18–0.33 0.18–0.33
Cost analysis results (all costs in 2002 US$)
Total incremental annual cost of oral morphine (US$ millions) 2.2–4.9 0.6–1.2 1.1–2.6
Incremental annual cost per capita (US$) 0.10–0.21 0.03–0.07 0.05–0.11
Incremental number of pain days per year avoided with use of oral morphine (millions) 3.6 0.9 1.9 
Incremental cost per person per day of pain avoided (US$) 0.60–1.35 0.60–1.35 0.60–1.35
Incremental cost per year of pain-free life added (US$) 216–420 216–420 216–420
Sources: Income and demographic data, World Bank 2003; cancer deaths, Ferlay and others 2001; AIDS deaths, UNAIDS and WHO 2002a, 2002b, 2002c; per capita morphine use, INCB 2003; authors’
calculations.
about 3 cents per day; prochlorperazine, an antiemetic, about
8 cents per day; and haloperidol, an antipsychotic, about 15
cents per day (Management Sciences for Health 2003). Retail
prices after markups would add 20 to 30 percent.
Under the assumptions of this analysis, oral morphine for all
dying cancer and AIDS patients would cost between 3 cents and
21 cents per capita per year (table 52.3) in Chile, Romania, and
Uganda. The cost per pain day avoided by oral morphine is the
same in all three countries, assuming that each country can
acquire and dispense morphine equally efficiently.
Cost-Effectiveness
The analysis indicates that the drug costs of oral morphine
come to about US$216 to US$420 per year of pain-free life
gained in the three sample countries. The next question is
whether the pain relief that could be achieved would be worth
the cost. We know that patients value pain-free days highly. A
day lived with the certainty of experiencing severe pain is of
very low value, perhaps even lower than death itself (Furlong
and others 2001; Le Gales and others 2002). Bryce and others
(2004) find that people are willing to give up several months of
healthy life for access to good end-of-life care. Patients in low-
income countries place as great or even greater value on pain
relief as patients in high-income countries (Cleeland and oth-
ers 1988; Murray and others 2003).
Costs Not Included in the Analysis
The analysis presented includes only the most basic costs—the
costs of oral opioids and associated drugs—that would be
incurred in a pain control program. Clearly, there are many
other costs, ranging from the costs of services at the individual
patient level to the costs of changing drug laws and policies at
the national level. The most significant additional costs are
discussed below.
Incremental Costs of Care Delivery. In addition to requiring
the drugs themselves, implementation of the three-step ladder
requires trained individuals to assess and monitor patients.
Where health care systems are well developed, the incremental
cost of adding oral morphine will be low. If it involved one
additional health center visit, the cost per patient would
increase by about US$8 in Chile, US$6 in Romania, and US$4
in Uganda, amounting to less than 1 cent per capita in all three
countries.
Where primary health care is weak, widespread access to
oral opioids depends on the development of new systems, such
as community- or hospital-based palliative care networks.
Clearly, allocating the full cost of upgrading the health care
system, or even the development of new palliative care pro-
grams, to oral morphine alone, would be inappropriate.
Other Costs. Security and recordkeeping related to stocking
and distributing opioids, required by the Single Convention,
entail additional fixed and ongoing costs. Because most hospi-
tals handle injectable opioids (for example, pethidine), these
costs would be less for hospital-based programs than for
community-based programs.
Professional training and education is required for all per-
sonnel involved in the use of opioids for dying patients, in part
to overcome fears and in part to ensure proper use. These costs
are likely to be highest where the health care system is most
deficient.
The costs of changing national policy toward opioids is sub-
stantial in terms of cost, time, expertise, and leadership (see, for
example,Pain and Policy Studies Group 2003 and 2004 and other
annual reports at http://www.medsch.wisc.edu/painpolicy/
publicat/annrepts.htm). The time expended is an opportunity
cost, but it may be amortized over a long time if the effort
succeeds.
Potential Cost Savings. In some circumstances, making oral
morphine available through a palliative care system could
actually save money—for example, if it enabled some termi-
nally ill patients who would otherwise be admitted to the hos-
pital for pain control to die at home, or if it shortened their
period of hospitalization. This outcome is more likely in places
with good medical infrastructure, but even in low-income
countries, patients in unbearable pain are often brought to
hospitals by distressed relatives who are willing go into debt
to ease the suffering.
IMPLEMENTATION OF STRATEGIES TO IMPROVE
PAIN CONTROL
Providing adequate oral morphine involves medical, political,
legal, and societal change. Model programs, such as Hospice
Uganda and efforts in India, have demonstrated the feasibility
of providing good palliative care, including oral morphine,
even for poor rural dwellers. WHO and the INCB have sup-
ported these efforts.
WHO Guidance on Palliative Care and Pain Relief
WHO has affirmed the need for palliative care and has defined
the elements of model programs in several reports. In 2002,
WHO’s executive board called for the integration of pain and
palliative care into national cancer control programs (box 52.4;
WHO 2002). The Joint United Nations Programme on
HIV/AIDS and the WHO AIDS Program consider pain and
palliative care to be essential and pain management to be inte-
gral to AIDS care (Foley, Aulino, and Stjernsward 2003).
WHO, in collaboration with the INCB and the WHO
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Collaborating Center (WHOCC), has developed guidelines for
national authorities to self-diagnose their regulatory systems
for problems that might lead to a lack of access to needed drugs
(WHO 2000). These organizations also sponsor national and
international workshops to help national authorities evaluate
their policies, develop action plans, implement policy change,
and evaluate outcomes. In addition to WHO and the INCB, a
number of programs and organizations are making resources
and expertise available to assist countries in various ways
(box 52.5).
Hospice Uganda. Hospice Uganda began in 1993 with an old
Land Rover, a grant to last three months, and a mandate to
become Africa’s model home-based hospice for dying cancer
and AIDS patients (Ramsay 2001). By July 2004, the original
Kampala location had served about 4,500 nearby patients.
Two additional sites—Mobile Hospice Mbarara and Little
Hospice Hoima—had served about 2,500 patients (Merriman
2004). Hospice Uganda’s influence has spread across Africa
through its reputation and the training programs it runs
(Merriman 2004).
At the beginning, morphine was largely unavailable, and the
law required that a physician prescribe it. Hospice Uganda’s
founder, Anne Merriman, convinced the government to amend
the law to allow specialist palliative care nurses and clinical offi-
cers to prescribe morphine (Merriman 2003). Now, morphine,
paid for by the government, is available for dying patients in
about 15 of Uganda’s 56 districts (Merriman 2003). In 1998,
Uganda became the first nation in Africa to list palliative care
as an essential clinical service.
The cost of treating a patient in Kampala and Mbarara is
about US$7 per week, including one home visit. For patients
who come to the hospice, the cost is about US$4 per week
(personal communication, A. Merriman, Hospice Uganda,
February 2003). Even at those prices, most patients cannot
afford even the medicines, which are subsidized by
contributions.
India. For decades, the only morphine available in India was
injectable and used for postoperative pain. The enactment of a
strict, national narcotics law caused morphine use to decline
even further, from a high of 573 kilograms in 1985 to 18 kilo-
grams in 1997, among the lowest per capita in the world. During
the period of declining use, international efforts to promote
pain control and palliative care programs began to reach India.
In 1992, pain relief and the availability of morphine were desig-
nated priorities in the National Cancer Control Programme
(Joranson, Rajagopal, and Gilson 2002; Rajagopal, Joranson,
and Gilson 2001; Rajagopal and Venkateswaran 2003).
The Ministry of Health convened national workshops from
1992 to 1994 to ascertain why morphine use continued to
decline. The following experience from a referral hospital,
recounted by a former narcotics commissioner of India, is
instructive:
the Institute has not been able to procure a single tablet [to]
date, primarily due to the stringent state laws and multiplicity
of licenses. After a lot of effort, the Institute had been able
to obtain the licenses in 1994 and had approached [a manufac-
turer] for a supply of tablets . . . [but] by the time the tablets
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WHO Pain Relief and Palliative Care Recommendations Based on Resource Level 
Box 52.4
WHO’s recommendations are as follows:
• Countries with low levels of resources should ensure
that minimum standards for pain relief and pallia-
tive care are progressively adopted at all levels of care
throughout the country. Countries also should
ensure that patient coverage is high through services
provided mainly by home-based care. Home-based
care is generally the best way to achieve good-quality
care and coverage in countries with strong family sup-
port and poor health care infrastructure. However,
many patients are cared for in large cancer hospitals,
and these institutions should have pain relief and
palliative care available to all patients.
• Countries with medium levels of resources should
ensure that minimum standards for pain relief and pal-
liative care are progressively adopted at all levels of care
and that, nationwide, coverage of patients is increasing
through services provided by health care workers and
home-based care.
• Countries with high levels of resources should ensure
that national pain relief and palliative care guidelines
are adopted by all levels of care and that, nationwide,
patient coverage is high through a variety of options,
including home-based care.
Source: WHO 2002.
could be arranged, the licenses had expired. The doctors at the
Institute and the associated pain clinic have stopped prescrib-
ing morphine tablets. (Joranson, Rajagopal, and Gilson 2002,
153).
In 1999, the INCB called on the government of India to take
measures to make morphine available for medical uses. In
1994, an initiative begun by the WHOCC, the Indian
Association of Palliative Care, and the Pain and Palliative Care
Society systematically studied the reasons for the lack of mor-
phine. In 1997, the WHOCC developed a proposal to reduce
the number of licenses and extend their period of validity, and
the following year all state governments were instructed to
adopt a model rule based on the proposal. Gradually, rules
have begun to change. By 2002, 7 of 28 states or territories had
adopted the model rule, but it has been implemented
successfully only in Kerala.
The success in Kerala can be attributed to three things:
(a) the state government simplified the licensing process and
stipulated that for oral morphine to be available from a center,
it must have at least one doctor with at least one month of
practical experience in palliative care; (b) the national drugs
controller exempted palliative care programs from needing a
drug license, thereby eliminating the need for a pharmacist;
and (c) a palliative care network was established, which consists
of about 50 small programs. Statewide, coverage has increased
to about 20 percent of those needing palliative care.
RECOMMENDATIONS FOR RESEARCH 
AND DEVELOPMENT
Policy makers and program implementers need practical tools
to improve pain control and palliative care. They need survey
instruments, guidance on how to effect policy and legal
changes, and palliative care models for resource-poor settings.
Many tools exist, but those could be made more accessible
through the use of toolkits, distance learning, Web sites, and so
on. Each country also should gather information to assess its
own capabilities and needs, such as the following:
• In relation to the national level:
º Study the incidence and prevalence of pain related to
major causes of illness and death using methodologies
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Selected Resources for Developing National Palliative Care Programs
Box 52.5
Resources available to countries include the following:
• The WHOCC for Policy and Communications in
Cancer Care at the University of Wisconsin serves as a
critical resource for palliative care education and coun-
try policy makers interested in assessing their opioid
drug regulations and developing strategies for change.
Its Web site links to WHO guidelines in several lan-
guages and provides articles and reports on efforts to
improve national policy and opioid availability in
Africa, Asia, Eastern Europe, and Latin America. See
http://www.medsch.wisc.edu/painpolicy/.
• The WHOCC publishes Cancer Pain Release every
quarter. The journal includes topical analysis of cur-
rent issues in cancer pain management and palliative
care and reviews recent international research and edu-
cational resources. See http://www.whocancerpain.
wisc.edu/.
• The Open Society Institute sponsored workshops in
cooperation with WHO’s Essential Drug and Cancer
units to bring together pain and palliative care experts
and drug policy makers from Central and Eastern
Europe and the former Soviet Union to develop strate-
gies for implementing regulatory change to improve
opioid availability. The Open Society Institute also sup-
ports the development of implementation strategies in
12 of these countries. That effort involves experts in
pain and palliative care, cancer, and AIDS and repre-
sentatives from ministries of health and financing and
health insurance programs. See http://www.soros.org/
initiatives/health/focus_areas/international.
• The Journal of Pain and Symptom Management has
published three special supplements over the past nine
years in association with the International Associa-
tion for the Study of Pain. The supplements describe
countries’ efforts to advance opioid availability and
palliative care. See http://www.elsevier.com/wps/find/
journaldescription.cws_home/505775/description#
description.
• The International Observatory on End of Life Care is a
clearinghouse on palliative care in resource-poor coun-
tries that is aimed particularly at policy makers. The
initial focus has been on Eastern and Central Europe,
but the intent is to cover all resource-poor countries.
See http://www.eolc-observatory.net/global_analysis/
index.htm.
Source: Authors.
adapted from developed countries (Breivik, Collett, and
Ventafridda forthcoming).
º Survey existing pain and palliative care programs to
identify national and local leaders in pain control
and palliative care and to catalog national guidelines and
standards for acute and chronic pain. For hospice and
palliative care services, assess the extent of available care,
service delivery models, national and local policies, and
professional and public knowledge about pain control
and palliative care.
º Assess national and local regulatory barriers to opioid
availability using WHO (2000) guidelines and needs
assessment protocols (Higginson 1997) to help countries
identify the patient-related, physician-related, and insti-
tutional issues that impede drug distribution.
º Study costs that affect opioid availability in several coun-
tries to document the costs of licensing, obtaining, stor-
ing, keeping records for, and dispensing opioid drugs.
º Study the costs of alternative delivery models for pain
control medications in LMICs.
º Assess the offsetting savings achievable by reducing hos-
pital days by means of better outpatient access to oral
morphine, to document potential savings in representa-
tive countries, which might help reduce barriers to
access.
• In relation to model programs:
º Construct an inventory of model programs for pain con-
trol and palliative care. Include their infrastructure and
personnel needs, their operating costs, and so on, in
easy-to-use formats such as toolkits and education and
training programs for policy makers and implementers.
Regularly add new information from ongoing and new
initiatives.
º Devise additional models, particularly for poor rural
communities, for providing palliative care and pain con-
trol practically, efficiently, and sustainably.
CONCLUSIONS
Unrelieved acute and chronic pain is a serious public health
problem worldwide, and 80 percent of cancer patients and
50 percent of AIDS patients experience severe pain during the
last months of life. Relief for these patients is possible only with
oral morphine or another opioid, but developing countries face
many barriers in this respect. Nevertheless, model pain and
palliative care programs have demonstrated the feasibility of
providing opioid treatment safely, effectively, and inexpen-
sively in resource-poor settings. To this end, national govern-
ments must resolve the legal and regulatory barriers to opioid
availability, but they need the expertise and support of the
global community to make pain relief a reality.
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Public health surveillance is the ongoing systematic collection,
analysis, and interpretation of data, closely integrated with the
timely dissemination of these data to those responsible for
preventing and controlling disease and injury (Thacker and
Berkelman 1988). Public health surveillance is a tool to esti-
mate the health status and behavior of the populations served
by ministries of health, ministries of finance, and donors.
Because surveillance can directly measure what is going on in
the population, it is useful both for measuring the need for
interventions and for directly measuring the effects of inter-
ventions. The purpose of surveillance is to empower decision
makers to lead and manage more effectively by providing
timely, useful evidence.
Increasingly, top managers in ministries of health and
finance in developing countries and donor agencies are recog-
nizing that data from effective surveillance systems are useful
for targeting resources and evaluating programs. The HIV and
severe acute respiratory syndrome (SARS) epidemics under-
scored the critical role of surveillance in protecting individual
nations and the global community. For example, in 2005, China
rapidly began to expand its surveillance and response capacity
through its Field Epidemiology Training Program (FETP);
Brazil and Argentina chose to use World Bank loans to develop
surveillance capacity; and the U.S. Agency for International
Development (USAID) redesigned its surveillance strategy to
focus on the use of data to improve public health interventions
(USAID 2005). Additionally, the guidelines for implementing
the 2004 draft revised International Health Regulations require
World Health Organization (WHO) member states to have
key persons and core capacities in surveillance (http://
www.who.int/csr/ihr/howtheywork/faq/en/#draft).
Just as decision makers require competent, motivated econ-
omists to provide quality technical analyses, they also need
competent staff members to provide scientifically valid surveil-
lance information and communicate the results as information
for action. Competent epidemiologists and surveillance staff
members are not a luxury in developing countries; they are a
necessity for rational planning, implementation, and interven-
tion (Narasimhan and others 2004).
DEFINITIONS AND BASIC CONCEPTS
In this chapter, we use the following definitions:
• Indicator: a measurable factor that allows decision makers
to estimate objectively the size of a health problem and
monitor the processes, the products, or the effects of an
intervention on the population (for example, the number
of new cases of diarrhea, the proportion of children fully
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immunized in a district, or the percentage of high school
students who report that they smoke at least one cigarette a
day).
• Active surveillance: a system employing staff members to
regularly contact heath care providers or the population to
seek information about health conditions. Active surveil-
lance provides the most accurate and timely information,
but it is also expensive.
• Passive surveillance: a system by which a health jurisdiction
receives reports submitted from hospitals, clinics, public
health units, or other sources. Passive surveillance is a rela-
tively inexpensive strategy to cover large areas, and it pro-
vides critical information for monitoring a community’s
health. However, because passive surveillance depends on
people in different institutions to provide data, data quality
and timeliness are difficult to control.
• Routine health information system: a passive system in which
regular reports about diseases and programs are completed
by public health staff members, hospitals, and clinics.
• Health information and management system: a passive sys-
tem by which routine reports about financial, logistic, and
other processes involved in the administration of the public
health and clinical systems can be used for surveillance.
• Categorical surveillance: an active or passive system that
focuses on one or more diseases or behaviors of interest to
an intervention program. These systems are useful for pro-
gram managers. However, they may be inefficient at the dis-
trict or local level, at which staff may need to fill out multi-
ple forms on the same patient (that is, the HIV program, the
tuberculosis program, the sexually transmitted infections
program, and the Routine Health Information System). At
higher levels, allocating the few competent surveillance
experts to one program may leave other programs under-
served, and reconciling the results of different systems to
establish the nation’s official estimates may be difficult.
• Integrated surveillance: a combination of active and passive
systems using a single infrastructure that gathers informa-
tion about multiple diseases or behaviors of interest to
several intervention programs (for example, a health
facility–based system may gather information on multiple
infectious diseases and injuries). Managers of disease-
specific programs may be evaluated on the results of the
integrated system and should be stakeholders. Even when an
integrated system is functioning well, program managers
may continue to maintain categorical systems to collect
additional disease-specific data and control the quality of
the information on which they are evaluated. This practice
may lead to duplication and inefficiency.
• Syndromic surveillance: an active or passive system that uses
case definitions that are based entirely on clinical features
without any clinical or laboratory diagnosis (for example,
collecting the number of cases of diarrhea rather than cases
of cholera, or “rash illness” rather than measles). Because
syndromic surveillance is inexpensive and is faster than sys-
tems that require laboratory confirmation, it is often the
first kind of surveillance begun in a developing country.
However, because of the lack of specificity (for example, a
“rash illness” could be anything from the relatively minor
rubella to devastating hemorrhagic fevers), reports require
more investigation from higher levels. Also an increase in
one disease causing a syndrome may mask an epidemic of
another (for example, rotavirus diarrhea decreases at the
same time cholera increases).
In the specialized area of surveillance for biologic terror-
ism, syndromic surveillance refers to active surveillance of
syndromes that may be caused by potential agents used by
biologic terrorists and sometimes refers to alternative meas-
ures such as increases in the use of over-the-counter drugs
or increases in calls to emergency departments.
• Behavioral risk factor surveillance system (BRFSS): an active
system of repeated surveys that measure behaviors that are
known to cause disease or injury (for example, tobacco or
alcohol use, unprotected sex, or lack of physical exercise).
Because the aim of many intervention program strategies is
to prevent disease by preventing unhealthy behavior, these
surveys provide a direct measure of their effect in the popu-
lation, often long before the anticipated health effects are
expected. These surveys are useful for providing timely
measures of program effectiveness for both communicable
and noncommunicable disease interventions.
OBJECTIVES OF SURVEILLANCE SYSTEMS
Public health surveillance provides the scientific and factual
database essential to informed decision making and appropriate
public health action. The key objective of surveillance is to pro-
vide information to guide interventions. The public health
objectives and actions needed to make successful interventions
determine the design and implementation of surveillance sys-
tems. For example, if the objective is to prevent the spread of
epidemics of acute infectious diseases, such as SARS, managers
need to intervene quickly to stop the spread of disease.
Therefore, they need a surveillance system that provides rapid
early warning information from clinics and laboratories. In
contrast, chronic diseases and health-related behaviors change
slowly. Managers typically monitor the effect of programs to
change risky behaviors such as tobacco smoking or chronic dis-
eases once a year or even less often. A surveillance system to
measure the population effects of a tuberculosis control pro-
gram might provide information only every one to five years—
for example, through a series of demographic and health sur-
veys. The principle is that different public health objectives and
the actions required to reach them require different information
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systems. The type of action that can be taken, when or how often
that action needs to be taken, what information is needed to
take or monitor the action, and when or how frequently the
information is needed should determine the type of surveil-
lance or health information system (box 53.1).
PRINCIPLES AND USES OF SURVEILLANCE
Foege, Hogan, and Newton (1976) state that “the reason for
collecting, analyzing, and disseminating information on a dis-
ease is to control that disease. Collection and analysis should
not be allowed to consume resources if action does not follow.”
The fundamental principle of public health surveillance is that
the surveillance should be designed and implemented to pro-
vide valid (true) information to decision makers in a timely
manner at the lowest possible cost. Because managers are
unlikely to need to make interventions to address small differ-
ences between areas, sacrificing precision makes sense to
improve timeliness and save resources that can be used for
public health interventions. The utility of surveillance data can
be viewed as immediate, annual, and archival, on the basis of
the public health actions that can be taken (table 53.1; Thacker
and Stroup 1998b).
ESTABLISHING AND MAINTAINING
A SURVEILLANCE SYSTEM
What is worth doing is worth doing right. Managers who
decide to use public health surveillance as a management tool
must recognize that they will need to commit political support
and human and financial resources. As with every health sys-
tem, competent, motivated health workers need to be found or
trained and provided with career paths and supervision. After
a manager decides to create a surveillance system, there are six
steps to establishing the system. Because the system must adapt
constantly to changes in the population and the physical
and social environment, these steps are linked continuously
(figure 53.1; Thacker and Stroup 1998a).
ANALYSIS AND DISSEMINATION
OF SURVEILLANCE DATA
Surveillance information is analyzed by time, place, and
person. Knowledgeable technical personnel should review data
regularly to ensure their validity and to identify information
Public Health Surveillance: A Tool for Targeting and Monitoring Interventions | 999
Different Objectives, Different Data, Different Systems
Box 53.1
Objective Action Data System
Detect epidemics Epidemic response Early warning information Active surveillance
Monitor intervention programs Program monitoring Program indicators Health information
Monitor impact of policy change Health policy Health indicators Health information
Monitor health system Resource allocation Administrative data Health information and 
management
Source: Nsubuga, Eseko, and others 2002.
Table 53.1 Utility of Surveillance Data 
Immediate detection of Epidemics
Newly emerging health problems
Changes in health practices
Changes in antibiotic resistance
Changes in distribution of population at risk for
disease
Periodic dissemination for Estimating magnitude of a health problem,
including cost
Assessing control activities
Setting research priorities
Determining risk factors for disease
Facilitating planning
Monitoring risk factors
Monitoring changes in health practices
Documenting distribution and spread of
disease and injury
Stored information for Describing natural history of diseases
Facilitating epidemiologic and laboratory
research
Validating use of preliminary data
Setting research priorities
Documenting distribution and spread of
disease and injury
Source: Adapted from Thacker and Stroup 1998b, 65.
of use to top managers. Simple tables and graphs are most
useful for summarizing and presenting data. Timely dissemi-
nation of data to those who make policy and implement
intervention programs is critical to the usefulness of surveil-
lance data.
The rapidly evolving field of public health informatics,
which deals with collection, classification, storage, retrieval,
analysis, and presentation of large amounts of health data,
offers the potential for truly integrated public health surveil-
lance based on data standardization, a communications infra-
structure, and policies on data access and sharing. Surveillance
will benefit by incorporating a systematic approach to stan-
dards for data content. For example, the U.S. Centers for
Disease Control and Prevention (CDC) has used standards-
based systems to support automatic electronic reporting of
diagnostic laboratory results of notifiable diseases, thereby
both increasing the number of cases reported and receiving
results more rapidly (Effler and others 1999). Use of data stan-
dards facilitates comparability of surveillance information
over time (for example, measurement of effect of program
interventions), across different surveillance approaches (for
example, facility-based reporting compared with sample sur-
veys), and across countries and regions. To be credible, a stan-
dard should be developed through an open, participatory
process, by an internationally recognized accredited standards-
development organization that is also capable of long-term
maintenance and evolution of the standard. Public health data
needs extend into multiple areas beyond clinical medicine (for
example, environmental toxins, unintentional injury, and food
safety).
One international standard computer program used in
many countries’ information systems is Epi Info, an epidemiol-
ogy surveillance and biostatistics program widely used around
the world for the analysis of surveillance data (http://www.cdc.
gov/epiinfo). CDC created, maintains, and distributes Epi Info
at no cost to users.
SURVEILLANCE AS A COMPONENT OF NATIONAL
PUBLIC HEALTH SYSTEMS 
WHO and the World Bank cite public health surveillance as an
essential function of a public health system (World Bank 2001).
When linked to policy and program units, surveillance infor-
mation improves the efficiency and effectiveness of health
services by targeting interventions and documenting their effect
on the population.
A critical challenge in the health sector in developing coun-
tries is to ensure quality and effectiveness of surveillance and
public health response in an environment of decentralization.
National-level program and surveillance system managers
may lose control of the quality and timeliness of locally col-
lected data. This situation can be avoided by training local
decision makers in how to use information to meet their
needs and negotiating with them over the core information
collected by each district local unit. National-level managers
or donors can also improve information quality by sponsor-
ing national surveillance scientific and quality assurance net-
works, linking funding to provision of adequate data, and
performing periodic surveys to confirm the results of local
reporting. If the responsibility for implementing programs is
devolved to local managers, then national-level managers need
only a few summary indicators, rather than the detailed infor-
mation they may be used to. District or local managers tend
to prefer integrated systems to minimize filling out redundant
forms.
Donors need surveillance data to target and evaluate their
investments. If they perceive weakness in the national system,
they may create parallel nongovernmental surveillance systems
to gather data directly to meet their needs. These systems
invariably pay workers more than government jobs do, so the
most competent people in the government system may leave to
work for the parallel system. Although this system meets
donors’ short-term needs, it invariably weakens government
systems. Parallel systems may weaken the very ministries that
they are meant to help and may not be sustainable after exter-
nal funding ends. Therefore, parallel systems are inherently
inequitable and should be used only as a last resort.
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Develop case definitions
Acquire tools and clearances for collection,
analysis, and dissemination
Implement surveillance system
Evaluate surveillance activities
Select appropriate personnel
Establish goals
Source: Adapted from Thacker and Stroup 1998a, 119. 
Figure 53.1 Elements in Establishing and
Maintaining a Surveillance System
SURVEILLANCE AS A TOOL TO IMPROVE
PUBLIC HEALTH
Managers need focused, timely, scientifically sound information
that provides evidence to make decisions on interventions for
improving the health of the population in their jurisdiction.
Simply collecting data and presenting them are not enough.
Using Surveillance Information for 
Evidence-Based Decisions 
A major gap in promoting effective surveillance lies between
the production of data and the ability to convert those data into
usable information and then initiate the appropriate public
health action. Surveillance and response can be described in
terms of a data generation hemisphere and a data use hemisphere
(USAID 2005). The data generation hemisphere is the tradi-
tional view of surveillance, whereas the data use hemisphere is
the public health response that begins with interpretation of
the data from the surveillance system (figure 53.2).
Substantial attention and the accompanying resources in
surveillance have been devoted to the prompt and complete
production of surveillance data. Although developing countries
experience weaknesses in both hemispheres, more attention is
needed to creating and strengthening the local capacity within
developing countries to identify and manage effective responses
to disease outbreaks and public health conditions of national
and international concern. In some disease-specific programs,
this capacity has to be imported through short-term expatriate
assistance. Even when local capacity is developed, it is often
specific to the disease program, making transfer of skills to
other areas problematic. The failure to develop this indigenous
capacity has limited the ability of developing countries to build
national surveillance systems that respond to both international
public health threats and local health concerns. This capability
is essential to the sustained development of countries.
Role of Field Epidemiologists in Providing Evidence
Developed countries have constructed their public health and
disease control strategies by using the principles of field epi-
demiology. Developing countries need to build and sustain
human capacity in field epidemiology. Strengthened field
epidemiologic capacity can serve a country in the following
specific areas:
• providing a response to acute problems
• providing the scientific basis for program and policy
decisions
• implementing disease surveillance systems
• supporting national health planning
• making resource allocation decisions
• allocating the human capacity base for national health
priorities.
Specific competencies that should be developed include, but
are not limited to, the ability to accomplish the following:
• design, implement, and evaluate surveillance for a health
event
• identify and assess an actual public health problem
• design and conduct a scientific investigation
• analyze and interpret data from an investigation
• recommend logical and practical public health actions after
the analysis and interpretation of data
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Figure 53.2 Surveillance and Response Conceptual Framework
• be proficient in all aspects of diseases of public health
importance (for example, HIV and AIDS, sexually transmit-
ted diseases, malaria, tuberculosis, and zoonoses).
These competencies need to be tailored to the various levels
of the health care system.
Since 1975, CDC and WHO have collaborated with more
than 30 countries to strengthen health systems and address
training needs for disease detection and response in a country-
specific, flexible, and sustainable manner. More than half of the
world’s population now lives in a country where surveillance,
investigation, and response are carried out by staff members
and trainees of FETPs and allied programs, which include
the Epidemic Intelligence Service in the United States, the
European Program for Intervention Epidemiology Training,
and Public Health Schools without Walls (PHSWOWs). These
programs generally function within central ministries of health
and may not be visible outside the public health system. It can
be argued that these programs provide most of the surveillance
of and response to emerging infections in the world, in addi-
tion to training most of the public health workers who manage
surveillance systems at the top level. FETPs are two-year courses
designed to provide a ministry with a motivated, professional
group of field epidemiologists with the expertise to respond to
managers’ needs for evidence, perform surveillance, respond to
outbreaks, and train and supervise technical personnel at other
levels (White and others 2001).
Other models have evolved. Guatemala’s marriage of its
FETP (part of a larger, Central American FETP) with the Data
for Decision Making program (Pappaioanou and others 2003)
exemplifies this successful local adaptation. Data for Decision
Making recruits health workers from the community and sub-
district levels to receive training in surveillance and outbreak
investigation in the context of their daily work. This training is
delivered as a series of linked workshops with practical field-
based projects, providing short-term service at the local levels.
The most promising graduates of the course are selected for
further training in an FETP. India, with its decentralized sys-
tem, complex cultural and population dynamics, and wide
variance in the sophistication of public health institutions,
provides another model for strengthening national surveil-
lance. The World Bank initiated the Integrated Disease
Surveillance Project, which develops the capacity of local and
midlevel surveillance workers in India. Additionally, FETP
graduates are recruited as the project’s surveillance officers at
the state level to coordinate the surveillance activities of the
hundreds of local health workers throughout the states.
SELECTED SURVEILLANCE STRATEGIES
Surveillance systems need to be designed and implemented to
meet top management’s needs for focused, reliable, timely
evidence gathered efficiently and presented effectively. Because
these needs differ, depending on management’s needs, a num-
ber of different strategies have been developed. Here are some
of the most useful.
Sentinel Surveillance
In a sentinel surveillance system,a prearranged sample of report-
ing sources agrees to report all cases of defined conditions,which
might indicate trends in the entire target population (Birkhead
and Maylahn 2000).When properly implemented, these systems
offer an effective method of using limited resources and enable
prompt and flexible monitoring and investigation of suspected
public health problems. Examples of sentinel surveillance are
networks of private practitioners reporting cases of influenza or
a laboratory-based sentinel system reporting cases of certain
bacterial infections among children. Sentinel surveillance is
excellent for detecting large public health problems,but it may be
insensitive to rare events, such as the early emergence of a new
disease, because these infections may emerge anywhere in the
population.
Periodic Population-Based Surveys 
Population-based surveys can be used for surveillance if they
are repeated on a regular basis (Thacker and Berkelman 1988).
Examples of population-based surveys in surveillance include
the BRFSS in the United States, HIV-prevalence surveys,
household surveys, and the demographic and health sur-
veys that many developing countries conduct every five years
(http://www.orcmacro.com). Population-based surveys require
careful attention to the methodology, particularly the use of
standard protocols, supervision of interviewers, comparable
sampling strategy, and standard questionnaires. These surveys
require a clear definition of the target population to which
the results can be generalized, and they need careful attention
to the sample size, based on efficiency and the epidemiologic
characteristics of the health condition under surveillance (for
example, rare conditions require substantial samples).
Supervising interviewers and maintaining high response rates
are critical to avoid bias. Because the surveys are repetitive, pop-
ulation changes (caused, for example, by mortality or mobility)
might bias results.
Laboratory-Based Surveillance 
The methods used for infectious disease surveillance form a
spectrum that evolves with the economic development of a
country. Foodborne disease (FBD) surveillance, for example,
is divided into four distinct levels of surveillance. Each level is
more complex and has greater capacity for controlling and
detecting disease, but it also depends on more resources and
infrastructure (figure 53.3).
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For FBD, surveillance for clinical syndromes is the most
common method of surveillance in the developing world.
Surveillance of FBD outbreaks that are investigated by public
health authorities is often a useful means of monitoring both
the safety of the food supply and the activities of the public
health system. Although both surveillance for clinical syn-
dromes and outbreak surveillance will remain important,
the future in FBD is in laboratory-based surveillance. If
microbiologic diagnosis is sought routinely for a sample of
patients with acute gastroenteritis, then surveillance based on
those diagnoses is possible. For enteric bacterial pathogens
such as Salmonella or Shigella, determining the serotype of the
strains in central reference laboratories allows more rapid and
complete identification of epidemics, which may otherwise
lead to preventable death and disability.
Laboratory-based surveillance systems require resources,
facilities, and training. A central public health reference labora-
tory is essential for quality assurance and quality control and
support. Such a laboratory-based system might begin with sys-
tematic referral of a sample of strains isolated at a sample of
sentinel clinics, plus those strains that are part of outbreaks. A
systematic sampling scheme provides better data than a more
haphazard attempt at universal reporting. Regular sharing of
information between the public health microbiology laborato-
ry and epidemiologists is critical for the information to be used
successfully.
The utility of serotyping as an international language
for Salmonella subtypes has led to its widespread adoption. In a
recent survey, 61 countries reported that they used Salmonella
serotyping for public health surveillance (Herikstad, Motarjemi,
and Tauxe 2002). A collaborative WHO program called
Global Salm-Surv promotes the use of Salmonella serotyping
internationally among countries that wish to upgrade their
national capacity for FBD surveillance (http://www.who.int/
salmsurv/en).
Molecular subtyping is now expanding the power of
laboratory-based surveillance to detect outbreaks in the back-
ground of sporadic cases by distinguishing the molecular
“fingerprint” of an outbreak strain. CDC maintains PulseNet,
an Internet-based network of all U.S. public health laboratories
that uses a standardized genotyping method called pulsed-
field-gel-electrophoresis (PFGE) as the basis for a national
database of PFGE subtypes (Swaminathan and others 2001).
Standardized subtyping protocols have now been developed for
seven pathogens, and next-generation, gene-based technologies
are under development for the future. Similar networks are
developing around the world, with PulseNet Europe and
PulseNet Canada already active and discussions rapidly
advancing for PulseNet Asia Pacific and PulseNet Latin
America. As with Salmonella serotyping itself, the global use of
standard genotyping will facilitate the detection of multiconti-
nent clusters.
Integrated Disease Surveillance and Response
The Integrated Disease Surveillance and Response (IDSR)
strategy, first developed in Africa, links epidemiologic and lab-
oratory data in communicable disease surveillance systems at
all levels of the health system, with emphasis on integrating
surveillance with response (WHO 1993, 1998). Districts
were identified as a focus for strengthening efforts in collecting
timely data, analyzing the collected data, and using the gener-
ated information for public health responses. The IDSR strategy
is based on core activities, including case-patient detection,
registration, and confirmation; reporting, analysis, use, and
feedback of data; and epidemic preparedness and response (for
example, outbreak investigations, contact tracing, and public
health interventions). Support functions include coordination,
supervision or performance evaluation, training, and resource
provision for infrastructure, including communication
(Nsubuga, Eseko, and others 2002).
Key steps in implementing the IDSR strategy include sensi-
tizing key health authorities and stakeholders; conducting situ-
ational analysis; preparing a strategic IDSR plan; identifying
and training a motivated, competent workforce; developing
national IDSR technical guidelines; implementing the plan;
and monitoring and evaluating implementation to improve
performance (WHO 2000b). Assessment of the existing
national surveillance and response activities provides baseline
data to measure progress; to identify and build consensus on
the national priority communicable diseases; to identify
surveillance gaps of the selected priority diseases; to document
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No formal
surveillancea
 Syndromic
surveillanceb
 Lab-based
surveillancec
 Integrated
food-chain
surveillanced
Outbreak detection can occur at all levels, but ability increases
along the spectrum
Source: Authors.
a. Without a formal surveillance, only large or unusual outbreaks can be detected.
b. Syndromic surveillance is based on groups of signs or symptoms indicative of a
common diagnosis, such as acute gastroenteritis. 
c. Laboratory-based surveillance relies on laboratory-confirmed pathogens, such as
Salmonella or Shigella. 
d. Integrated food-chain surveillance uses data from across the food chain. 
Figure 53.3 Spectrum of Case-Based Foodborne Disease
Surveillance
the strengths, weaknesses, and opportunities of the existing
systems; and to make appropriate recommendations. The
WHO Regional Office for Africa, collaborating with its part-
ners, has prepared tools and guidelines for implementation of
IDSR at the country level. Indicators to monitor the perform-
ance of the surveillance and response systems have been pre-
pared and field tested and are now in use in Africa.
Example: The Philippine National Epidemic 
Surveillance System
In the late 1980s, the Philippine Department of Health
(PDOH), relying on its integrated management information
system, detected less than one outbreak per year in a population
of more than 60 million people. In 1989, the PDOH designed
the National Epidemic Sentinel Surveillance System, a hospital-
based sentinel surveillance system that encompasses both the
flow of data and the personnel requirements needed to make
the surveillance system work effectively (table 53.2). After the
pilot study demonstrated promising results, the PDOH created
personnel positions and a supervisory structure for sentinel
physicians, nurses, and clerks in regional epidemiology and
surveillance units (RESUs) integrated into the public health
system. In 1995 alone, the system detected and formally inves-
tigated about 80 outbreaks, including 25 bacteriologically
confirmed outbreaks of typhoid and 5 of cholera. As the
Philippines developed HIV serological and behavioral risk
surveillance, the RESU staff conducted surveys in their com-
munities. By integrating surveillance functions that were based
on the skills of the workforce, PDOH was able to avoid the
duplications, inefficiencies, and sustainability problems of mul-
tiple vertical systems (White and McDonnell 2000).
Informal Networks as Critical Elements 
of Surveillance Systems 
WHO and other agencies frequently receive telephone calls or
informal reports about urgent health events.WHO publishes an
informal list of these“rumors,”which allows public health work-
ers to respond to health risks promptly rather than waiting for
formal reports (http://www.who.int/csr/don/en/). The gradu-
ates of FETPs, PHSWOWs, and similar programs that provide
competency-based on-the-job training in ministries of health
make up one of the most important informal networks.
FETPs and allied programs both train epidemiologists and
provide service to their ministries of health. For example, a stu-
dent in the Brazilian FETP was assigned to review routine data
on patients with leishmaniasis. She noted that some patients
had symptoms of heavy metal poisoning, and further study
indicated that a drug being used to treat leishmaniasis was con-
taminated with heavy metals. The drug was reformulated, and
the problem was resolved. When this study was presented at a
regional meeting of the Training Programs in Public Health
Interventions Network (a network of FETPs and allied training
programs), other countries banned the drug until it was refor-
mulated (CDC 2004a).
Large categorical surveillance systems are expensive, and
staff members might become complacent, especially if the
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Table 53.2 Steps in the Development of the Philippine National Epidemic Sentinel Surveillance System
Steps Data side Human capacity side
1. Identify the health problems thought to cause burden Consult top managers, donors, international agencies, and experts.
disease.
2. Determine who will make interventions. Involve users in design.
3. Determine information users’ need to make interventions. Involve users in design.
4. Decide how often decision makers need reports. Involve users in design.
5. Identify who collects, tabulates, and analyzes reports and Identify manager and staff to analyze, report, and enter data.
who disseminates information.
6. Design report. Involve users and staff in design.
7. Make table shells. Involve staff in design.
8. Design questionnaire. Involve staff in design.
9. Pilot questionnaire. Involve staff in implementation and evaluation.
10. Pilot data flow and analysis. Involve staff in implementation and evaluation.
11. Pilot system. Train staff in system and involve them in evaluation.
12. Run system. Involve staff in ongoing training and quality assurance monitoring.
13. Evaluate system: Was information used? Are data and Involve staff and users in design of external evaluation and in review of 
analysis of good quality? evaluator’s report.
Source: Adapted from White and McDonnell 2000, 311.
disease under surveillance is rare. For example, the polio sur-
veillance system for acute flaccid paralysis in the Western
Hemisphere detected no cases in July 2000. A trainee from the
FETP of the Dominican Republic, while investigating a case
of suspected poisoning in a child, documented the first out-
break of circulating vaccine-type poliovirus in the Western
Hemisphere since 1991. There were 13 confirmed cases in the
Dominican Republic and 8 cases in Haiti. Her investigation
led to national immunization days in both countries, which
raised immunization levels and stopped the outbreak (Kew
and others 2002).
THE ROLE OF SURVEILLANCE IN
MAJOR OUTBREAKS
It seems incredible that a disease as devastating as AIDS could
have spread silently to many countries over many years before
it was detected and before effective control measures were
implemented in the 1980s. In recent years, surveillance and
response systems at all levels have been more effective at iden-
tifying and preventing spread of infectious diseases.
Example: Surveillance and Global Response to SARS
An epidemic of severe pneumonia of unknown etiology was
detected in Guangdong province, China, in November 2002,
and control measures were instituted on the basis of the way
the disease spread from person to person. In February and
March 2003, the disease spread to Hong Kong (China) and
then to Vietnam, Singapore, Canada, and elsewhere (WHO
2003b). This new disease was named severe acute respiratory
syndrome, and a preliminary case definition was established on
the basis of initial epidemiologic investigations. A novel coro-
navirus (SARS-CoV) was identified as the causative agent in
March, and mapping of the full genome was completed in
April. This global pandemic ended in July 2003, as transmission
was interrupted in Taiwan (China), after more than 8,000
patients in 26 countries and five continents were affected and
774 deaths were confirmed (Peiris and others 2003).
WHO spearheaded the global effort to control this pan-
demic, working with national and subnational health workers.
In China, the FETP, which was initiated in October 2001 in the
China Center for Disease Control, mobilized all 20 of its
trainees, and they contributed substantially to the surveillance,
investigation, and control of the SARS outbreak, working with
local health officials (CDC 2003a). In Canada, which had the
most cases of SARS outside Asia, 8 of the 10 FETP residents
were involved in the SARS outbreak. They instituted surveil-
lance, conducted epidemiologic investigations, designed pre-
vention and control guidelines, responded to inquiries from
the media and the public, and planned and implemented
epidemiologic studies (http://www.phac-aspc.gc.ca/cfep-pcet/
outbreaks_e.html).
The success of this global effort to control the first new epi-
demic disease of the 21st century depended on a combination
of open collaboration among scientists and politicians of many
countries and the rapid and accurate communication of sur-
veillance data within and among countries. Rapid global spread
was recognized, and a global surveillance network was estab-
lished on the basis of an agreed-upon case definition that was
sufficiently specific to ensure effective reporting.
Public health surveillance is critical to recognizing new cases
of SARS and differentiating this disease from other causes of
severe respiratory illness, especially influenza (Heymann and
Rodier 2004). Ongoing research into sources in the environ-
ment as well as clinical, laboratory, and epidemiologic concerns
will improve surveillance for this critical public health prob-
lem. Notably, this highly contagious disease—for which there is
neither a vaccine nor a cure—was controlled by competent,
dedicated health workers with access to excellent communica-
tions. SARS presented a greater challenge than smallpox, for
which long incubation periods and vaccine facilitate control
(Mack 2005). Although it is reassuring that national, regional,
and global systems were effective in controlling SARS, there is
no reason to rest on our laurels. The only certainty is that there
will be more new challenges, very possibly including further
outbreaks of SARS.
Example: Avian Influenza in Thailand
The disastrous pandemic (worldwide epidemic) of influenza in
1918 is thought to have originated from epidemics in birds, as
were the influenza pandemics of 1957 and 1968 (Ungchusak
and others 2005). In early 2004, large epidemics of avian
influenza were recognized in birds in eight Asian countries; by
November, the disease had spread from birds to 44 humans,
73 percent of whom died (Ungchusak and others 2005). This
contagion sparked fears that the highly lethal avian virus might
be adapting to spread from person to person, which could
cause extensive health and economic damage around the
world. In Thailand, avian influenza was investigated by FETP
graduates and others in the Thai Ministry of Health in part-
nership with CDC. By applying field epidemiologic techniques
supported by laboratory studies, they detected that the virus
was being spread from human to human in a family. It is likely
that person-to-person transmission may have occurred in
other countries, where field epidemiology was not used.
The Thai example is important for achieving the following:
(a) raising global awareness of the potential of a global catas-
trophe early enough that plans can be made to avert or decrease
harm and (b) demonstrating that, as with SARS, the disease
could be controlled with proven field epidemiologic methods
supplemented by good communications, without vaccines,
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drugs, or a high-technology laboratory or surveillance system
(Mack 2005).
Example: Ebola in Uganda, the Role of the PHSWOW 
On October 8, 2000, a second-year student in the Ugandan
PHSWOW returned to Gulu district in northern Uganda for
his field project. He found a hospital jammed with patients
with high fevers, diarrhea, and bleeding. He diagnosed viral
hemorrhagic fever. He called the Ministry of Health in
Kampala, where that weekend a graduate of the PHSWOW was
in charge of taking calls about epidemics. She agreed with
his diagnosis and arranged for samples to be rushed to the
National Institute for Virology in South Africa, the nearest
WHO reference center for viral hemorrhagic fevers. When the
minister of health arrived at his office the next day, the gradu-
ate briefed him. Recognizing the gravity of the situation, the
minister sent the graduate to head the public health team sur-
veillance and control team in Gulu, and the student headed the
clinical team that established infection control in hospitals and
treated patients.
Laboratory tests quickly confirmed that the illness was
Ebola hemorrhagic fever, which usually kills more than 50 per-
cent of those infected (Heymann 2004). Public health surveil-
lance was difficult for several reasons. Because the disease was
severe and rapidly fatal, rural villagers feared that they might be
stigmatized if the government knew about cases in their area.
Some sought out traditional healers; others fled as soon as they
realized they had been exposed, which prompted outbreaks in
two other districts. Gulu was a politically unstable area, and
some villages were difficult to reach because of rebel or bandit
activity. The Ugandan government mobilized its military to
help with case finding and invited WHO, CDC, and other
international teams to assist. Patients with Ebola infection
require intense nursing and medical attention to control bleed-
ing, diarrhea, and fevers. Some patients bleed easily, and all
their secretions can be highly infectious. Hospitals in Gulu were
desperately short of supplies to control the spread of infection
from so many patients simultaneously. In spite of this situation,
Ugandan health workers selflessly cared for the sick. By
January 23, 2001, a total of 425 cases had occurred, the largest
Ebola outbreak recorded. Only 53 percent of the patients had
died, a proportion far less than the 88 percent reported in the
1976 Ebola outbreak in the Democratic Republic of Congo (for-
merly Zaire) and other previous epidemics (WHO Report of an
International Commission 1978). Sadly, 22 health care workers
were infected. Because the team from the Ugandan Ministry of
Health set up active surveillance nationwide, the other two
outbreaks, started when infected Gulu residents fled to distant
villages, were quickly detected and controlled. International
observers commented, “National notification and surveillance
efforts led to the rapid identification of these foci and to effec-
tive containment” (CDC 2001).
The Ugandan Ministry of Health invested in developing
competent, motivated health workers through the PHSWOW,
an active partnership with Makerere University, the Rockefeller
Foundation, CDC, and WHO. Both students and graduates
contributed to the ministry’s ability to rapidly identify and
control this dangerous epidemic. Because the minister had
timely evidence, he was able to notify other countries quickly
and to bring in international teams before the disease spread
further. Partially because of the lessons learned from this epi-
demic, Uganda has become one of the leading countries in
implementing the IDSR program.
SURVEILLANCE FOR SPECIFIC CONDITIONS
Surveillance systems are important tools for targeting, moni-
toring, and evaluating many health risks and interventions.
Because managers need a wide variety of information for spe-
cific interventions, systems have been developed and tested to
meet those needs.
Environmental Public Health Surveillance
Surveillance for environmental public health practice requires
the collection, analysis, and dissemination of data on hazards,
exposures, and health outcomes (figure 53.4; Thacker and
others 1996).
Health outcomes of relevance include death, disease,
injury, and disability. However, relating those outcomes to
specific environmental hazards and exposures is critical to
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Agent is a hazard
Agent is present in environment
Route of exposure exists
Agent produces adverse effect
Adverse effect becomes clinically apparent Outcomesurveillance
Exposure
surveillance
Hazard
surveillance
Source: Thacker and others 1996.
Agent reaches target tissue
Host is exposed to agent
Figure 53.4 The Process of Adverse Effects and the
Corresponding Surveillance 
environmental public health surveillance. Hazards include
toxic chemical agents, physical agents, biomechanical stressors,
and biologic agents that are located in air, water, soil, food, and
other environmental media. Exposure surveillance is the mon-
itoring of members of the population for the presence of an
environmental agent, its metabolites, or its clinically inappar-
ent (for example, subclinical or preclinical) effects.
Four challenges complicate environmental public health
surveillance. First, the ability to link specific environmental
causes to adverse outcomes is limited by our poor understand-
ing of disease processes, long lead times, inadequate measures
of exposure, and multiple potential causes of disease. Second,
data collected for other purposes rarely include sufficient infor-
mation to meet a case definition for a condition caused by
an environmental agent. Third, public alarm is often out of
proportion to the hazard of concern, and sentiment will often
influence public policy disproportionately to scientific infor-
mation. Fourth, biologic markers will become increasingly
critical elements of environmental exposure surveillance.
Obtaining data on exposure, which can include estimates
derived from hazard data through sophisticated modeling
or direct measurements of individual exposure obtained from
use of personal monitors (for example, passive air samplers),
is generally impractical in developing countries. Childhood
blood lead levels are the only biomonitoring data that are col-
lected routinely in several countries, either in national surveys
or from screening programs for children at high risk.
Health outcome surveillance as applied to environmental
public health is similar to traditional surveillance efforts. In the
United States, the focus is on surveillance for birth defects;
developmental disabilities (for example, cerebral palsy, autism,
and mental retardation); asthma and other chronic respiratory
diseases (for example, bronchitis and emphysema); cancer; and
neurological diseases (for example, Parkinson’s disease, multi-
ple sclerosis, and Alzheimer’s disease) (McGeehin, Qualters, and
Niskar 2004). Other nations have different sets of priority con-
ditions for surveillance. Disease registries, vital statistics data,
annual health surveys, and administrative data systems (for
example, hospital discharge data) are sources that have been
used for monitoring health conditions. The challenges men-
tioned previously have constrained our ability in all nations,
regardless of level of development, to establish and maintain
effective and comprehensive environmental public health sur-
veillance systems. As we invest in understanding the enlarging
threats in the global environment, we must overcome these
challenges and establish improved surveillance systems. The
health of the global community depends on this investment.
Injury Surveillance 
Injuries are a major public health problem and are among the
10 leading causes of death worldwide, killing an estimated
5 million persons each year and causing high rates of disability.
People from all economic groups are at risk for injuries, but
death rates caused by injury tend to be higher in developing
countries (Peden, McGee, and Sharma 2002). Injury surveil-
lance includes monitoring the incidence, causes, and circum-
stances of fatal and nonfatal injuries. Injuries are classified by the
intention of the act into two groups: unintentional injuries and
violence-related injuries.WHO (Holder, Peden, and Krug 2001)
and the Pan American Health Organization (Concha-Eastman
and Villveces 2001) have developed guidelines for establishing
injury surveillance systems in developing countries.
If the range of fatal and nonfatal injuries, as well as the risk
factors that can lead to injury, are to be fully captured, surveil-
lance systems need to be established in multiple settings. Fatal
injuries can be captured by using forensic or death certificate
data. A far greater number of injuries are nonfatal and can
be tracked through hospital- or primary care–based systems.
Systematic information on nonfatal injuries, including preva-
lence, incidence, and related risk behaviors can also be obtained
through ongoing population-based surveys.
Critical points should be addressed when planning an injury
surveillance system in a developing country. First, data sources
need to be clarified. In some developing countries, routine data
on injuries are not always captured in health information
systems. It is therefore necessary to consider other sources of
data—for example, law enforcement agencies, coroners, or
medical examiners. Next, the events and variables in an injury
surveillance system should be defined according to the objec-
tives of the system. Criteria such as the intentionality (violence-
related injuries versus unintentional injuries); the outcome
(fatal injuries versus nonfatal injuries); and the nature of
violence-related injuries (physical, sexual, psychological, depri-
vation, or neglect) should be considered when establishing the
system. Finally, case definitions and coding procedures should
be defined before implementing the system.
For example, the Nicaraguan Ministry of Health, in collab-
oration with CDC and the Pan American Health Organization,
began developing and implementing an injury surveillance
system in 2001 (Clavel-Arcas, Chacon, and Concha-Eastman
2004). The system, based on the medical facility emergency
department (ED), collects data on injuries in keeping with the
Injury Surveillance Guidelines established by WHO (Holder,
Peden, and Krug 2001). Under the system, a reportable case is
defined as a patient who died from or was treated for an injury
in the ED. Cases include patients with unintentional and vio-
lence-related injuries.
ED staff members identify cases and collect data in five
hospitals in Nicaragua. Information used to complete the
instrument is collected directly from the patients or their
representatives. An ED admission clerk collects basic demo-
graphic data on the patient’s arrival. ED medical staff members
(physicians and nurses) collect the remaining information
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(for example, location, mechanism of injury, nature, severity,
and circumstances surrounding the injury) during triage and
assessment.
The hospital epidemiologist collects data collection forms
daily from the ED, reviews the quality of data, and requests data
from the ED staff if the forms are incomplete. The statistician
reviews data daily. The country project coordinator also moni-
tors the quality of the data periodically. Using Epi Info 2002
programs developed specifically for this project, the project
coordinators analyze trends and identify potential risk factors
(Noe and others 2004). The information is used to produce
monthly reports for dissemination. Information is reported at
both the regional and the country levels.
Injury prevention programs in Nicaragua use surveillance
data to assess the need for new policies or programs and to
evaluate the effectiveness of existing policies and programs. For
example, the municipality of León is using the information
from the hospital to monitor the increase in suicide attempts
among youths abusing pesticides and to evaluate an intersec-
toral campaign to promote life that includes primary through
tertiary prevention strategies.
Surveillance for Biologic Terrorism 
Surveillance for biologic terrorism is conducted primarily for
outbreak detection and management. Surveillance must sup-
port early detection of an incident of biologic terrorism and its
characterization in the same manner as for the detection and
control of naturally occurring outbreaks of infectious diseases.
Early detection of outbreaks can be achieved by the following
(Buehler and others 2004):
• timely and complete receipt, review, and investigation of
disease case reports, including the prompt recognition and
reporting to or consultation with health departments by
physicians, health care facilities, and laboratories 
• improvement of the ability to recognize patterns indicative
of a possible outbreak early in its course (for example, by
using analytic tools that improve the predictive value of data
at an early stage of an outbreak or by lowering the threshold
for investigating possible outbreaks)
• receipt of new types of data (such as purchases of health
care products, absences from work or school, symptoms
presented to a health care provider, or orders for laboratory
tests) that can signify an outbreak earlier in its course.
Environmental detection systems for microbial pathogens
and toxins of concern for biologic terrorism might also be
categorized as new types of data early in the course of an out-
break, before infection (Meehan and others 2004). The primary
surveillance tools for event detection and management are
the traditional disease-reporting systems for notifiable diseases
discussed elsewhere in this chapter. These core surveillance
tools should be robust before new data types can be considered
for supplementing public health surveillance.
Syndromic surveillance is an investigational approach by
which health department staff members, assisted by automated
data acquisition and generation of statistical signals (comput-
erized algorithms), monitor disease indicators continually to
detect outbreaks of disease earlier and more completely than
might otherwise be possible with traditional reportable disease
methods (Buehler and others 2004).
CDC’s list of biologic terrorism agents and diseases can be
found at http://www.bt.cdc.gov and an updated list of refer-
ences dealing with syndromic surveillance is at http://www.cdc.
gov/epo/dphsi/syndromic/.
Complex Emergency Surveillance 
The key elements in planning a disaster surveillance system are
establishing objectives, developing case definitions, determin-
ing data sources, developing simple data collection instru-
ments, field testing the methods, developing and testing the
analysis strategy, developing a dissemination plan for the
report or results, and assessing the usefulness of the system.
The surveillance needs are different in the preimpact, impact,
and postimpact phases (Binder and Sanderson 1987).
The role of surveillance in disaster situations has included
the following broad framework of activities:
• predisaster activities (for example, hazard mapping, provi-
sion of guidelines, and training for medical and rescue
teams)
• continuous monitoring and surveillance for priority health
problems in affected populations (for example, in the post-
tsunami surveillance in Tamil Nadu, India, a one-page
instrument was used for 10 priority health conditions for
daily active surveillance in displaced populations at camps)
• prospective surveillance of affected populations focusing on
the natural history of exposure and health effects and long-
term effects of stress disorders among survivors.
Surveillance in Refugee Populations 
Support of relief efforts following national and global disasters
has been a relatively new application of epidemiologic practice
for the public health professionals. Nevertheless, since the ini-
tial CDC involvement with the United Nations in a large-scale
relief effort concerning approximately 20 million displaced
people affected by the 1967–70 civil war in Nigeria, CDC staff
members have participated in several assessments of the health
needs, damage, and nutrition in refugee populations resulting
from man-made and natural disasters. The more notable and
extended actions were conducted in the 1979–82 Khmer
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Thailand-Cambodia refugee-relief action, followed by long-
term public health surveillance of Somalian refugees
(1980–83), periodic but comprehensive health and nutritional
assessments of Afghan refugees in Pakistan (1980–2002), and
growth and nutritional assessments of internally displaced
populations—especially children—in the Democratic People’s
Republic of Korea (1990s) and southern Sudan. Although these
relief efforts occurred many years and many thousands of miles
apart, they shared several important characteristics:
• Large numbers of people were in fixed camps or on the
move searching for food and shelter. These needs were usu-
ally addressed by external aid agencies and many times
caused local environmental degradation (fuel, temporary
housing, water pollution, and so on).
• Refugees, after the initial phase, competed with indigenous
populations for scarce jobs, leading to social strife and
stress. Refugees were also exploited and suffered violence—
additional factors leading to stress and social maladjust-
ment.
• No administrative structure to provide and coordinate
assistance of the necessary magnitude existed before the
crisis, and thus, it had to be created after the fact.
• Assistance was complicated by the uncertainty associated
with military activity, crime, and hostile governments.
• Data that were relatively simple to gather and analyze
provided health workers and administrators information
needed to plan and monitor assistance and its impact.
• Close collaboration with other local and international
relief organizations (such as the United Nations High
Commissioner for Refugees, the International Red Cross,
the United Nations Children’s Fund, WHO, and USAID)
was essential to instituting and sustaining a meaningful sur-
veillance system for refugees that led to interventions.
The major goal of these activities is to identify and eliminate
preventable causes of morbidity and mortality. Planning
requires effective use of existing knowledge about characteris-
tic or predictable demographic patterns, easily applied health
indicators, and avoidable errors of omission or commission. As
in disasters, the principles of surveillance (data collection, data
analysis, response to data, and assessment of response) and
other public health techniques should be an integral part of
relief efforts. Retrospective evaluation of these efforts has also
proved useful (CDC 1983).
Chronic Disease Surveillance Systems
Development and evaluation of policies for health improve-
ment require a reliable assessment of the burden of disease and
injury, an inventory of the disposition of resources for health,
assessment of the policy environment, and information on the
cost effectiveness of interventions and strategies. In all these
areas, consideration of noncommunicable (mostly chronic)
conditions becomes critical. In 1999, noncommunicable
diseases were estimated to cause approximately 60 percent of
the deaths in the world and 43 percent of the global burden of
disease (WHO 2000a). WHO forecasts that by 2020 the burden
of disease from noncommunicable diseases for developing and
newly industrialized countries will have increased more than
60 percent (Murray and Lopez 1996).
Some developing countries have found it difficult to acquire
and analyze accurate mortality statistics regularly, let alone
morbidity and quality-of-life information. Ensuring develop-
ment, implementation, and widespread use of noncommuni-
cable disease data for better decisions on resource allocation is
critical to improving the quality of lives and promoting a more
equitable future for health within and between countries.
Hypertension, elevated blood cholesterol, tobacco use,
excessive alcohol consumption, obesity, and the multiple dis-
eases linked to these risk factors are a global public health prob-
lem. In one study, smoking, high blood pressure, and high
cholesterol alone explained approximately two-thirds to three-
fourths of heart attacks and strokes (Vartiainen and others
1995). Until recently, surveillance for risk factors was an activ-
ity commonly associated with developed countries (Holtzman
2003). However, recently WHO has increased attention to non-
communicable disease surveillance by developing tools and
working to achieve data comparability between countries
(WHO 2003c). Data on key health behaviors, obesity, hyper-
tension, lipids, and diabetes are collected inconsistently in
developing countries, especially in Africa. Data on tobacco use
are available through the Global Youth Tobacco Survey
(http://www.cdc.gov/tobacco/global).
Incidence data (the number and proportion of new cases in
a population) are limited in developing countries. However,
India’s National Cancer Registry program may serve as a notable
exception (http://icmr.nic.in/ncrp/cancer_regoverview.htm).
In 1981, the Indian Council of Medical Research, recognizing
that there was a lack of information on follow-up of cancer
patients to assess quality of care, instituted a cancer registry net-
work.The network provides data on the magnitude and patterns
of cancer in eight areas of India to enable studies of the histo-
logic features correlating with prognosis and association studies
(for example, whether a history of vasectomy is associated with
cancer of the prostate). Another important example relates to
the widespread use of folic acid in China and the resultant
reduction in incidence of birth defects (Kelly and others 1996;
Wald 2004).
Surveillance data have been critical in establishing the
importance of obesity as a public health priority in the United
States. Data for individual states provided by CDC’s BRFSS
have enabled individual health departments to document their
obesity epidemic (Sturm 2003). These data provide a measure
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of the effectiveness of interventions to meet the control
objectives. The BRFSS is a practical tool for developing and
middle-income countries, as Jordan demonstrated when it
implemented a BRFSS in 2002; the first survey documented
substantial levels of obesity, especially among women, com-
bined with low levels of physical activity (CDC 2003b).
ECONOMICS OF PUBLIC HEALTH 
SURVEILLANCE SYSTEMS 
The outbreak of SARS in 2003 demonstrates the far-reaching
economic impact of not having an effective global public
health surveillance system in place, with an estimated reduc-
tion in real gross domestic product of more than US$1.0 billion
in Canada (Darby 2003) and estimated income losses in the
range of US$12.3 billion to US$28.4 billion for East and
Southeast Asia as a whole (Fan 2003).
Public health surveillance is considered a global public good
(Zacher 1999), particularly when it is used for eradication of
such diseases as poliomyelitis. As eradication campaigns
decrease the number of cases, maintaining systems to find the
last few cases becomes more expensive. Often, the majority of
the costs for these systems fall on hard-pressed developing
countries. This factor raises questions of fairness and equity.
For example, as poliomyelitis becomes rare, it ceases to be a sig-
nificant risk to national populations, whereas other diseases,
such as malaria and diarrhea, typically are major causes of
morbidity and mortality. In such countries, it seems most fair
and efficient for the global community to finance eradication
campaigns, leaving national systems free to address the diseases
that most affect their populations. The negative impact of
globally mandated eradication surveillance systems can be
mediated or reversed by leveraging on the eradication pro-
gram’s infrastructure to gather surveillance data for diseases of
concern to local governments (Nsubuga, McDonnell, and
others 2002). A similar case can be made for influenza early
warning systems in countries that gather information that will
be used to create vaccines that will benefit other populations
but not their own. Equity demands that the countries that
benefit from such systems finance them.
Public health surveillance systems serve an essential func-
tion in preventing and controlling disease spread within and
across national borders. Although the private sector benefits,
it lacks the incentive to invest in public health surveillance
systems, and sovereign states depend on the contribution of
others (WHO 2002); this situation has important implications
for the financing of public health surveillance systems. Even
within national borders, the difficulty of quantifying the bene-
fits of surveillance systems for individual communities leads to
neglect by local authorities, providing the economic rationale
for funding by the national government. Developing countries
are reportedly the weak link in the global surveillance frame-
work, although they bear the greatest burden of disease, emerg-
ing and reemerging old pathogens, and drug-resistant
pathogens (U.S. GAO 2001). The greatest need for surveillance
systems is in these countries, but most lack both the resources
and the political will to build human capacity and finance the
systems (table 53.3). Resource constraints and intense pressure
to provide care and treatment services lead public health
authorities in the poorest countries to spend resources on
surveillance (U.S. GAO 2001). Because the costs and benefits
derive from surveillance systems spilling across national bor-
ders, donors should assist with capacity building in countries
that have been unable to invest the human and material
resources required.
An interesting and unresolved feature of these global public
goods—the solution to their adequate provision and supply
rests at local, national, and sometimes regional levels—has
prompted the international health community to advocate for
capacity building in developing countries rather than for con-
solidation of the fragmented systems at the global level (WHO
2002).
Standard tools of economic evaluation (Meltzer 2001) have
been used to compare the benefits and costs of several public
health interventions. The public good characteristics of surveil-
lance systems, with benefits that are not easy to quantify, make
the use of such tools difficult to implement in practice. However,
economic evaluation of laboratory surveillance systems to
detect specific disease-causing organisms have been undertaken
in the developed world by comparing benefits and costs now
and in the future (Elbasha, Fitzsimmons, and Meltzer 2000).
These evaluations have not been done in developing countries
and are needed. At best, an analysis of the benefits and costs of
existing or proposed surveillance systems is feasible. This analy-
sis requires an estimate of the cost of illness and answers the
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Table 53.3 Health Expenditures by National Income Level of
Countries, 2001
Government  expenditures Total expenditures 
on health as a on health as a 
percentage of gross percentage of gross
Income groupa domestic product domestic product
High income 6.30 10.74
Upper-middle income 3.68 6.41
Lower-middle income 2.58 5.63
Low income 1.22 4.78
Source: World Bank 2004.
a. All World Bank member economies with populations of more than 30,000 are classified into
income groups, divided according to 2003 gross national income per capita, calculated using the
World Bank Atlas method. The groups are low income, US$765 or less; lower-middle income,
US$766 to US$3,035; upper-middle income, US$3,036 to US$9,385; and high income, US$9,386 or
more.
question of how many cases of a particular disease need to be
prevented by the surveillance system to be exactly equal to the
expenditure on the system.
Given expenditures on specific health interventions or pro-
grams, one can, by using traditional econometric tools, apply
the data on health outcomes from the surveillance systems as
inputs to economic analysis. Surveillance also clearly leads to a
cost saving if it prevents the need for expenditure on treating
patients.
FUTURE OF SURVEILLANCE 
Public health agencies, ministries of finance, and international
donors and organizations need to transform surveillance from
dusty archives of laboriously collected after-the-fact statistics
to meaningful measures that provide accountability for local
health status or that deliver real-time early warnings for devas-
tating outbreaks. This future depends in part on developing
consensus on critical surveillance content and developing
commitment on the part of countries, funding partners, and
multilateral organizations to invest in surveillance system infra-
structure and to use surveillance data as the basis for decision
making. This vision of the future assumes a coherent, integrated
approach to surveillance systems that is based on matching the
surveillance objective with the right data source and modality
and on paying attention to country-specific circumstances
while maintaining global attention to data content needs.
Information technology and informatics can help in attain-
ing this vision. Specifically, technology can facilitate the collec-
tion, analysis, and use of surveillance data, if data standards are
developed and compatible systems are established. Data collec-
tion for surveillance would be an automatic by-product of any
electronic systems used to support clinical care. Under this sce-
nario, an automatic electronic message would be sent to the
responsible public health jurisdiction with information about
a health event (for example, death, disease, or injury), includ-
ing all relevant information from the electronic health record
about the patient, provider’s name, patient’s home address, risk
factors, previous immunizations, and treatments. Even before
this ideal capacity becomes widespread, technology such as cell
phone–based systems could accelerate collection of key data
(for example, occurrence of a viral hemorrhagic fever out-
break). The rapid penetration of cell phones in developing
countries might obviate the need for prohibitively expensive
landline-based systems. An accelerated system of wireless
Internet access might also transform the capacities to which a
local health post or a district health official might have access.
These systems should also be considered as means for collect-
ing information beyond traditional data. For example,
telemedicine access can permit views of a rash illness to be
shared with national or international medical specialists.
Analysis of surveillance data can also be transformed by
using available technology. Software that is Web-enabled,
together with the advances in geographic information system
software and global positioning devices, means that anyone
with Internet access can potentially apply the latest version of
software running on a distant server in the national capital to
local data to generate up-to-date maps and graphs describing
health status in that jurisdiction.
Use of surveillance data can also be transformed.
Sophisticated algorithms can be applied to data as it is collected
to determine when (and how) an alert should be sent to local,
national, or even international health officials to indicate a
need for immediate investigation. Increasingly sophisticated
visual display techniques and creation of custom channels with
data of particular relevance to groups of data users are just
some of the tools already being used to put public health con-
tent on the desktop of anyone with broadband, secure Internet
access.
Realization of this future vision does not require technology
beyond what is already feasible, but the following factors are
needed:
• the organizational and political will to develop and coordi-
nate the needed systems and standards that will enable those
systems
• appropriate attention to individual privacy and system
security 
• removal of the financial and logistical barriers to broadband
Internet access
• a strategic multisectoral approach to accelerating national
infrastructure among the poorest developing nations.
GLOBAL SURVEILLANCE NETWORKS 
Globally, infectious disease surveillance is implemented
through a loose network that links parts of national health care
systems with the media, health organizations, laboratories, and
institutions focusing on particular disease conditions. WHO
has described a “network of networks” (U.S. GAO 2001) that
links existing regional, national, and international networks of
laboratories and medical centers into a surveillance network
(figure 53.5).
Government centers of excellence (for example, CDC, the
French Pasteur Institutes, and FETPs) along with WHO coun-
try and regional offices also contribute to disease and health
condition reporting. Military networks, such as the U.S.
Department of Defense’s Global Emerging Infectious Disease
System, and Internet discussion sites, such as ProMed
(http://www.promedmail.org) and Epi-X (http://www.cdc.gov/
epix), also supplement the reporting networks. In 1997, WHO
started the Global Outbreak Alert and Response Network, and
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it was formally adopted by WHO member states in 2000. The
network has more than 120 partners around the world and
identifies and responds to more than 50 outbreaks in develop-
ing countries each year (Heymann and Rodier 2004).
The International Health Regulations are the only binding
international agreements on disease control. The regulations
provide a framework for preventing the international spread of
disease through effective national surveillance coupled with the
international coordination of response to public health emer-
gencies of global concern by using the guiding principle of
maximum protection, minimum restriction (WHO 2003a).
The current regulations apply only to cholera, plague, and yel-
low fever; they require WHO member states to notify WHO of
any cases of these diseases that occur in humans within their
territories and then give further notification when the territory
is free of infection. The regulations are being revised to include
the development of national core capacities and national focal
persons who have the competencies of graduates of FETPs and
allied training programs. Programs established to improve the
capacity of both epidemiologists and laboratorians to collect,
use, and interpret surveillance and outbreak data (for example,
the collaborative WHO program in foodborne diseases called
the WHO Global Salm-Surv) are also important components
in developing global surveillance networks.
RESEARCH AGENDA IN PUBLIC HEALTH
SURVEILLANCE
Developing nations share surveillance needs with the rest of the
world, yet they are challenged by economic limitations, weak
public health infrastructure, and the overwhelming challenges
of poverty and disease. As a result, countries in the developing
world often depend on the research efforts of others, or they
collaborate with others to conduct the research necessary for
their surveillance needs. Within individual countries, surveil-
lance systems are essential in measuring disease and injury bur-
den as a first step in establishing public health priorities that
lead to policies and programs.
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Source: U.S. GAO 2001.
a. UNHCR represents the United Nations High Commissioner for Refugees.
b. UNICEF represents the United Nations Children’s Fund.
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Figure 53.5 Global Infectious Disease Surveillance Frameworks
The major research question for surveillance is how to
develop and maintain a cadre of competent, motivated surveil-
lance and response workers in developing countries. Other
questions include how to design and maintain surveillance sys-
tems for these problems, especially morbidity systems for
chronic diseases. Standard methods can be used to evaluate
existing surveillance systems, which, in turn, will help define
surveillance needs (Romaguera, German, and Klaucke 2000).
Developing countries have used the IDSR strategy, which pro-
vides an efficient approach to data collection and analysis.
Unfortunately, the majority of developing countries have lim-
ited surveillance systems for noninfectious diseases; instead,
existing data systems (for example, vital records, motor vehicle
crash records, or insurance claims data) are potential sources of
surveillance data. In other settings, even these data sources are
scarce, and approaches such as verbal autopsies and recurrent
surveys might be alternatives (White and McDonnell 2000).
Surveillance for risk factors is another challenge, and
BRFSSs need to be validated and applied more widely in devel-
oping countries. Surveillance for injuries, environmental haz-
ards (such as traffic intersections that are associated with high
rates of injuries), and exposures to chemical or biological
agents is a key public health concern with few examples of
effective application anywhere in the developed or less devel-
oped parts of the world. Rigorous research is required in this
field (Thacker and others 1996).
The burgeoning use of electronic data systems and the
almost universal availability of the Internet provide a tremen-
dous opportunity for more timely and comprehensive surveil-
lance in all parts of the world. Yet in this rapidly emerging field,
critical needs exist, including the following:
• competent, motivated health workers
• data standards (Lober, Trigg, and Karras 2004) 
• global policies and practices for international surveillance 
• useful software (Dean 2000) 
• evaluation of the effectiveness of all these applications.
New approaches that must be evaluated by using standard
methods (Romaguera, German, and Klaucke 2000) include the
following:
• IDSR for infectious diseases
• syndromic surveillance (CDC 2004b) for terrorism and
emergency response 
• laboratory-based surveillance methods to enhance diagnos-
tic accuracy and increase timeliness of recognition of out-
breaks and interventions (Swaminathan and others 2001).
Many research questions remain about surveillance
methodology, including how to do the following:
• use data for forecasting or temporal and spatial analysis for
aberration detection
• conduct surveillance for multiple competing risk factors
that lead to a single condition (for example, smoking, cho-
lesterol, hypertension, and overweight for heart disease)
• conduct surveillance for the adverse effects of drugs
• interpret ecologic data relative to data collected on individ-
uals (Greenland 2004)
• measure cost-effectiveness of alternative approaches to sur-
veillance (for example, integrated compared with categori-
cal approaches)
• link data sources effectively (for example, hazard, exposure,
and outcome data for environmental diseases)
• build and sustain human infrastructure in developing
countries
• strengthen evidence-based decision-making cultures in min-
istries of health and finance.
CONCLUSION
Public health surveillance is an essential tool for ministries of
finance, ministries of health, and donors to effectively and
efficiently allocate resources and manage public health inter-
ventions. To be useful, public health surveillance must be
approached as a scientific enterprise, applying rigorous meth-
ods to address critical concerns in this public health practice
(Thacker, Berkelman, and Stroup 1989). Although the surveil-
lance needs in the developing world appear to differ from those
in the developed world, the basic problems are similar. In a time
when we are confronted with SARS and avian influenza, the
need to integrate global networks is undeniable, and research in
how these concerns are addressed is essential. Collaboration
among practitioners, researchers, nations, and international
organizations is necessary to address the global needs of public
health surveillance.
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This chapter focuses on the collection and management of
public health information, in contrast to clinical information,
which concerns individual patient care encounters. Even
when aggregated, clinical data are necessary, but not sufficient,
to inform efforts to improve the health of populations. While
substantial attention has been focused on these facility-based
clinical consultations and the health management information
system (HMIS) used to track the relevant data, we focus here
on the broader health information system (HIS) needed to
inform decisions at individual, facility, district, and national
levels. Considered here are the routine data collection systems
upon which program management, planning, monitoring,
and evaluation depend. Information needs for specific tasks,
such as for research or for program evaluation, are discussed
in the chapters on research (chapters 4 and 7). Other chapters
in this volume refer to information needs to enable disease
control or to evaluate programs and improve the delivery of
interventions. Those interested in these issues should also pay
special attention to chapter 53 and chapters 70–73. This
chapter bridges the global and the local issues; it makes the
case for strengthening the evidence base for action through
comprehensive health information systems that include cen-
sus, vital events, monitoring, public health surveillance,
resource tracking, facility-based service statistics, and house-
hold surveys.
INTRODUCTION
From infancy on, we receive information that gives form to our
thinking and problem solving. The method by which a phe-
nomenon is measured shapes societal perceptions of it and the
collective efforts to affect it. Likewise, the choices we make in
the collection and use of information for health will determine
our effectiveness in detecting problems, defining priorities,
identifying innovative solutions, and allocating resources for
improved health outcomes. Despite those fundamental reali-
ties, there has been little awareness to date of the ramifications
that greater information use can have for advancing health, and
even less attention has been given to systems needed to provide
timely, accurate, and relevant information.
An example of the formative power of information for pol-
icy change lies in the history of the United Nations’ Standard
System of National Accounts, created by Richard Stone more
than 50 years ago. The annual reporting of these accounts by
most countries shapes our impressions of the relative position
of nations, defines our views of the differential opportunities
offered to their citizens, and drives the content of national and
global political discourse (Jolly 2002). Another example is the
measurement of disability-adjusted life years (DALYs), which
has shaped priorities for investment in global health over the
past decade.
Chapter 54
Information to Improve Decision Making
for Health
Sally K. Stansfield, Julia Walsh, Ndola Prata, and Timothy Evans
The new source of power is not money in the hands of a few, but information in the hands of many. 
—John Naisbitt and Patricia Aburdene, Megatrends 2000 
However, data or information alone will not transform out-
comes. Data, which are simple measures of characteristics of
people and things, have little inherent meaning or value.
Analysis of the data enables the identification of patterns,
thereby creating information. Finally, the use of information to
generate recommendations, rules for action, and behavior
change signifies the creation of knowledge that is used to make
decisions and change human behavior.
Good decisions on effective policies, services, and behaviors
require timely, accurate, and relevant information. Health in-
formation is required for strategic planning and the setting of
priorities; clinical diagnosis and management of illness or
injury; quality assurance and quality improvement for health
services; detection and control of emerging and endemic dis-
ease; human resource management; procurement and manage-
ment of health commodities (including drugs, vaccines, and
diagnostics); regulation of toxic exposures; program evaluation;
research; and other types of policies and programs (Walsh and
Simonet 1995). Citizens require such information to choose
healthy behaviors, to demand effective policies and services, and
to hold their governments accountable for the allocation and
use of resources for health. Internationally, information is
required to meet transnational needs, such as for the detection
and control of consequences of epidemics and infectious dis-
eases, results-based management of development assistance
programs, and advocacy for increased financing for health.
Several recent trends further enhance the pressures to
deliver better health information. Global epidemics, such as of
severe acute respiratory syndrome (SARS) and “bird flu,” have
amply demonstrated the need and potential benefits of sensi-
tive and transparent systems for tracking health events.
Donors, including the Global Fund and the Global Alliance for
Vaccines and Immunization (GAVI), increasingly demand
performance measures and detailed evidence to justify new
requests for support. “Basket” funding and sectorwide ap-
proaches place further responsibilities on countries to define
their own priorities. Decentralization and devolution of budg-
etary controls have shifted much of this growing burden to
the periphery, requiring districts to provide local evidence as a
basis for decisions. Tracking progress toward the Millennium
Development Goals for health requires empowering countries
to measure key indicators and produce evidence-based strate-
gic plans to achieve and document that progress. Furthermore,
nearly every chapter in this volume cites the need for better
information, including through research dependent on a
health information system, to accelerate improvements in
health.1
Yet there is a striking disconnect between the need for infor-
mation and the ability to respond to that need. To collect,
collate, analyze, and communicate the necessary information
in a timely and understandable fashion requires organized
processes and procedures and a comprehensive HIS. However,
donor-driven and disease-specific initiatives have actually
undermined efforts to develop a comprehensive HIS by creat-
ing separate, parallel, and often duplicative systems to meet the
need for each funding source.
Health information and the systems for its supply are a pub-
lic good, meeting the defining criteria of being nonexcludable
(in that, once the information is in the public domain, it is dif-
ficult to withhold from users) and nonrival (in that consump-
tion of the information does not lessen its availability for use by
others).As a public good, the supply of health information is the
primary responsibility of governments: national governments
for information within these jurisdictions, and international
agencies and national governments together for international
comparative information and global summary data.
Harmonizing the data collection, standards, best practices,
and other elements of a national and global HIS has several
advantages. Standardization enables economies of scale for
training, hardware and software, and processes. Routine health
information is a summative good in that the collation of each
contribution produces a cumulative increase in the value of the
public good, strengthening the credibility and importance of
that information. Furthermore, standardization of systems
improves the reliability and comparability of information, both
within nations and across national and regional boundaries
(Cibulskis and Hiawalyer 2002).
SYSTEMS AND SUPPLY OF HEALTH INFORMATION 
To create an effective HIS, governments must finance the sys-
tem, create the necessary policy environment (for example,
through legislation and regulation), and develop systems and
services for the collection, collation, dissemination, and use of
health information. A substantial portion of the national health
information is fully within the control of government health
officials. However, information from the private health sector
and other parts of the government is also required. Table 54.1
lists some of the data required and their sources. A principal
challenge is the integration of these intra- and extrasectoral
functions into a single, comprehensive HIS.
Direct Expenditures for Health Information
As for most public goods, the production of health information
is mostly financed by government appropriation. Budget sup-
port for the HIS comes through both the ministry of health
and a national statistics office (NSO) in most countries. The
NSO is usually responsible for collecting information through
the national census and most household surveys. For the least
developed countries especially, bilateral and multilateral
donors are essential sources of finance, particularly for HIS
planning, infrastructure development, and training. In Africa,
it has been estimated that grants or loans from donors account
for between 20 and 70 percent of the financing for statistical
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systems overall. Revenue generated by selling statistical prod-
ucts and services accounts for 10 to 20 percent of the financing
for national statistical systems (Economic Commission for
Africa 2003). User fees or taxes for use of information products
and services can partially offset the costs of developing and
maintaining the information system. In many countries, taxes
and tariffs on computer equipment and government regulation
of communications and Internet use remain barriers to public
access to health information. Cost must not be a barrier to use
of health information for the public good.
Information Policy
Sound information systems require a legislative and regulatory
environment that encourages and supports effective HIS
development. At the global level, many efforts have been made
to establish international standards and policy frameworks for
statistical data (United Nations Statistical Commission 1994).
These policy frameworks are used to establish mandates for
collection of basic health data (such as a decennial census or
surveillance for reportable infectious diseases), to ensure the
independence of official statistical agencies, to reinforce pro-
fessional ethics, and to create norms for data quality and
dissemination.
Another key policy intervention, less tangible though equally
critical, is the creation of a culture of quality and transparency
in the management of health information. There should be pro-
tection from political interference and full empowerment of the
health statistics office to make public statements in response to
criticisms of reports and the underlying methods. Ethical prac-
tices for protecting privacy and confidentiality must be well
understood, and procedures should be in place to deal with
breaches in these standards. Accuracy and reliability should be
stated as expectations and ensured through periodic review of
data collection methods and through benchmarking with inter-
nationally credible definitions of indicators.A client orientation
should be instilled and users of data regularly consulted in
defining outputs and formats for the presentation of data.
Systems for Collection, Management, and Analysis 
Most developing countries have no comprehensive strategy for
information management, reflecting the fractal nature of
donor and national investments in these systems. Interventions
to improve the HIS in the least developed countries, often
donor driven, have often focused only on a specific subsystem,
primarily for health service statistics, and have neglected other
components of the HIS.
An effective HIS requires an overarching architecture that
defines the data elements, processes, and procedures for collec-
tion, collation, presentation, and use of information for deci-
sion making throughout the health sector (see box 54.1). This
information architecture promotes comparison and integra-
tion of data elements from a variety of subsystems. As O’Carroll
(2003) points out, such a comprehensive design enables phased
system development, reduces redundancy, increases efficiency,
and improves interoperability. Interoperability is critical to
ensuring, for example, that census data, vital statistics, and
health facility data can be integrated to generate rates, ratios,
cost-effectiveness estimates, and other information required to
compare options for health investment.
The Pan American Health Organization (PAHO) has led the
Regional Core Health Data Initiative “to facilitate speedy access
to basic information on the health situation in the countries of
the Region.” This initiative has involved an international con-
sultation and agreement on the priority data, collection meth-
ods, and indicators. The initiative has shown that it is possible
to create a regional database of essential, consistent, valid, stan-
dardized, timely, and regular information. PAHO has used the
information to set its priorities, whereas countries have applied
the results to design health programs and to allocate resources
to upgrade their information systems. In the future, the plan is
to expand the systems to subnational districts (PAHO 2004).
Other WHO regions, including the Asia Pacific, are institu-
ting similar initiatives with Web-based publication of core
health indicators.
Data Collection. No single mechanism for data collection is
adequate to meet the needs for public health decision making.
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Table 54.1 Health Information from Sources Outside
the Health Sector
Health information Responsible agency
Census and national surveys: National statistical office
Income and poverty distribution
Household expenditure for health
Coverage with health interventions
National expenditures for health, economic Ministry of finance
development indicators, and industrial 
production and distribution data
Employment data: Ministry of labor
Human resources for health
Occupational health information
Import data: Ministry of trade
Pharmaceuticals and vaccines
Capital equipment and health commodities
Food production and security information and Ministry of agriculture
nutritional status data
Military health service statistics Ministry of defense
Patterns of transportation injury (including Ministry of transportation
motor vehicle accidents)
Literacy rates and school health program Ministry of education
information
Source: Authors.
These needs can be met using a combination of the six key health
information subsystems: census, household surveys, public
health surveillance, vital events monitoring, health service sta-
tistics, and resource tracking. Surveys are conducted on a sam-
ple in order to limit costs,whereas the other subsystems are more
often designed to cover the entire population. In most develop-
ing countries, public health surveillance—except for certain dis-
ease-specific efforts—is conducted through passive reporting
from health facilities. Especially where utilization rates are low,
this facility-based surveillance may be considered a sample or
“sentinel”surveillance strategy.Vital events monitoring is, ideal-
ly,universal; however,many countries use a phased introduction
of vital events monitoring that makes it functionally a sentinel or
sample-based data collection effort during the transition to uni-
versal coverage.
A national census every 10 years is an irreplaceable compo-
nent of a national information system because it provides
denominator data for so many indicators and sampling frames
for subsequent sample surveys. The major costs of a census
come from activities to establish the census maps, enumerate
populations, enter data, and analyze the results. The carto-
graphic costs can often be shared with other government
departments, because the resulting updated maps can be
instrumental in carrying out other critical public functions.
Sample surveys of households are a mainstay of health infor-
mation collection in the developing world. They provide data
on service utilization; coverage of health interventions
(for example, immunization); morbidity (self-reported illness
or disability); pregnancy outcomes; mortality levels, differen-
tials, and trends; and causes of death (through associated verbal
autopsy; that is, expanded interviews in the case of death to
determine cause on the basis of signs and symptoms before
death).
Surveys are, almost without exception, funded externally in
the least developed countries and are not seen within the coun-
try as being part of a health information “system.” They are, in
fact, generally undertaken to compensate for the lack of infor-
mation available through routine systems (AbonZahr and
Boerma 2005). The investment in surveys has thereby enabled
donors and developing countries to sustain their neglect of the
development of comprehensive and sustainable national health
information systems. The United Nations Population and
Statistics Divisions and the European Statistical Office (EURO-
STAT) also support household survey work. Differences in
methodologies among these surveys are currently a barrier to
the comparison of results. The World Bank’s Managing for
Development Results Roundtable, held in Marrakech,
Morocco, in 2004, recommended harmonization of these sur-
veys to eliminate duplication.
Nonetheless, surveys offer an important source of informa-
tion that transcends most of the selection bias that is inherent
in service statistics. Especially in the least developed countries,
where vital events registration systems and census taking are
embryonic or nonexistent, surveys represent the only source
of unbiased information about demography, socioeconomic
status, coverage, morbidity, mortality, health expenditures, and
other characteristics of the population. Where substantial pro-
portions of the population use private health services, house-
hold surveys are particularly important. Even industrial coun-
tries rely on periodic community-based sample surveys for
immunization coverage, for health service utilization rates, and
for information on household health expenditures (Perrin,
Kalsbeek, and Scanlan 2004).
The World Health Organization (WHO) recommends using
periodic surveys to monitor coverage, such as for immunization
programs, especially in view of the shortcomings of service sta-
tistics for obtaining these measures (Murray and others 2003).
Some household surveys collect biological and clinical speci-
mens, such as blood, saliva, urine, and self-collected vaginal
swabs, or they check swabs for anemia, HIV, disease antibodies,
vitamin A, and other conditions. However, the performance
characteristics of most diagnostic technologies (for example,
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The Health Metrics Network: Harmonizing Investment in HIS Development
Box 54.1
Developing countries, multilateral agencies, bilateral
donors, and technical resource agencies have recently
come together to form a global Health Metrics Network
(HMN) that is designed to provide guidance for the
development of the HIS, both in meeting national infor-
mation needs and in producing the required indicators for
tracking progress toward global goals. The HMN will pro-
vide the first consensus technical framework for HIS
architecture and a plan for development of national health
information systems. This HMN Framework includes a
blueprint for iterative improvements in the HIS; descrip-
tions of core data collection subsystems (census, surveys,
vital events monitoring, service statistics, and resource
tracking); and procedures for management and dissemi-
nation of information.
Source: Authors.
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cost, ease of field use, sensitivity, and specificity) are designed
for clinical use and do not lend themselves readily to use in pop-
ulation surveys, especially in remote areas of developing coun-
tries. Moreover, the collection of diagnostic information along
with individual identifiers introduces complex ethical issues in
the notification of people with treatable conditions, the financ-
ing of any required treatments, and the use of the specimens for
other studies (Ties Boerma, Holt, and Black 2001).
Public health surveillance has been defined as the “ongoing
systematic collection, analysis, and interpretation of data on
specific health events affecting a population, closely integrated
with the timely dissemination of these data to those responsi-
ble for prevention and control” (Thacker and others 1996). In
developing countries, surveillance usually focuses primarily on
a set of notifiable diseases, mainly infectious, which health care
providers and laboratories are often required by law to report.
Some nations also track risk factors for important diseases,
injury events, adverse drug reactions, cancers, and pregnancy
outcomes. Surveillance may be intensified over a period of
years to enable targeting of special interventions for the control
or elimination of diseases such as polio, tetanus, or measles.
Active surveillance or screening of populations for target
diseases may also be used in specific circumstances, such as
during peak seasons for the disease or during natural disasters,
when the potential for epidemics may be high.
Most passive surveillance data, however, are incomplete.
Reliance on surveillance for reportable diseases diagnosed in
health facilities omits diseases diagnosed among those who go
to private providers or who are too poor to go to any health
facilities. Even in health facilities, reportable diseases are often
underrecognized or cannot be confirmed in laboratories that
have inadequate resources. Sentinel surveillance methods and
registries maintained in a few selected sites may be more repre-
sentative of the entire population and more cost-effective in
identifying and reporting the target diseases or health condi-
tions; however, an outbreak may go undetected in a geographic
area without a sentinel site. Special regional surveillance may
also be used where populations are vulnerable to special health
risks. The Vigisus project in Brazil, for example, has developed
a system of epidemiologic and environmental surveillance for
the prevention and control of disease among indigenous
populations in the Amazon region (http://www.br.undp.org/
propoor/BRA97028a.htm). Despite the methodological haz-
ards, public health surveillance is essential for both national
and global planning and preparedness, especially in view of the
risks of regional expansion (for example, of meningitis and
polio) or global spread of recent epidemics (for example, of
SARS and bird flu).
Vital events monitoring is the continuous, compulsory, and
(in most cases) universal civil registration of key vital events,
such as births, deaths (sometimes including fetal deaths), mar-
riages, divorces, and migrations. In many countries, vital events
monitoring systems function poorly and may be found only as
remnants of past colonial administrations. In 2003, 115 of 192
WHO member states reported mortality data with causes of
death, capturing about one-third of global deaths, or 18.6 mil-
lion deaths per year. In South Asia, only 60 percent of births are
registered (22.5 million), and in Africa, only 30 percent (17 mil-
lion). Alternatives to universal registration include the sample
registration systems used in China and India and the demo-
graphic surveillance sites in Tanzania. The International
Network of Field Sites with Continuous Demographic
Evaluation of Populations and Their Health in Developing
Countries (INDEPTH), an association of longitudinal vital and
health statistics surveillance sites in 17 countries, can provide
technical support and training for development and manage-
ment of these demographic surveillance sites (http://www.
indepth-network.org/). The UN Statistics Division has devel-
oped principles and recommendations for vital statistics
systems to guide countries in their development (http://
unstats.un.org/unsd/demographic/sources/civilreg/civilreg
methods.htm.)
Vital events monitoring systems may also be enhanced to
determine causes of death, whether those deaths occur within
health facilities or in the community. When deaths occur out-
side the health care system, a verbal autopsy, or structured inter-
view of the relatives of the deceased, can assist in determining
the cause of death. Verbal autopsies can, however, be used reli-
ably to diagnose only those few conditions that have character-
istic clinical signs or patterns of signs that can be recognized by
family members or by the health workers who review the inter-
view data. WHO is now developing standardized tools for
verbal autopsy that will enhance the sensitivity and specificity
of these instruments and permit comparisons over time and
across geographics.
Health service statistics are critical management tools for
both preventive and curative services. The statistics are col-
lected at each level: community outreach service points, pri-
mary care facilities, and district and regional referral hospitals.
Information from clients and providers documents the quantity
and quality of services and enables managers to detect and
solve problems in order to improve health outcomes and effi-
ciencies. This health information subsystem must be “flexible
and capable of adapting to local needs, while at the same time
allowing for standardization of health care quality assurance
indicators, and subsequent ability to measure and compare the
quality performance of health facilities nationwide” (Duran-
Arenas and others 1998). A principal barrier to improving serv-
ice quality in many health care facilities is the lack of reliable
systems for managing and retrieving individual patient
records.
Service statistics are especially powerful when they can be
compared with population-based measures from censuses and
surveys to estimate rates and ratios, such as disease incidence or
service coverage rates. Most service statistics subsystems track
data only from public sector providers and facilities. Future
improvements must implement systems and incentives to en-
sure reporting of service data from the private sector.
The resource-tracking subsystem must enable measurement
and management of human resources; facilities; commodities
(pharmaceuticals, vaccines, and other consumables); and
finances. Human resource tracking provides a mechanism for
licensing health service providers and accrediting health facili-
ties. Licensure and accreditation can be paired with incentives
to ensure service quality and private sector contributions to
achieving public health goals.
The national health account (NHA) framework provides
methods for measuring total national expenditures for health
from household, public, private, and donor sources. NHA data
document the sources of health financing, the amount spent
for services, the distribution of funds across services and inter-
ventions, and the distribution of health benefits from those
services and interventions. An NHA framework tracks the flow
of funds, for example, from the ministry of health to health
providers and government service programs or from house-
holds to pharmacies and private providers. These internation-
ally comparable data enable benchmarking of performance
among countries (Peters and others 2000).
Of the 68 countries that have implemented NHAs, only
one-third have used the framework more than once. However,
19 of 21 countries studied can report at least one instance in
which the NHA system has informed and shaped policies (De
and others 2003). For example, South Africa’s NHA analysis
documented a higher per capita health expenditure in the rich-
est districts, leading to intensified efforts to mitigate these
inequities (Abt Associates 2003).
Information and Communications Technologies. The rapid
evolution of information and communications technologies
(ICT) over the past 30 years has immense implications for the
potential speed, cost, and effectiveness of an HIS. But a “digital
divide” persists, with poor countries failing to benefit fully from
these ICT advances. Lack of access to reliable power sources,
absence of Internet connectivity, inability to procure computer
equipment and appropriate software, and inadequate technical
support are some of the barriers. African users account for only
1 percent of the world’s Internet traffic, 80 percent of which is
in South Africa (http://www3.sn.apc.org/africa). Although less
than 0.001 percent of the Internet use in Africa is among health
professionals, this usage is growing rapidly.
Internet access in health facilities can make the HIS more
effective and efficient by enabling instantaneous transmittal of
data to central locations. Internet access in facilities can also
speed data transmission and improve clinical outcomes by pro-
viding access to evidence-based decision support for clinical
care (Godlee and others 2004; McLellan 2001). Even in remote
areas where no telephone or cable access exists, satellite tech-
nology can provide access to e-mail. Several countries, such as
Bolivia and Peru, have successfully used satellite telephone
technologies to enable continuous Web-based updating of
health databases. Because the effectiveness of epidemic control
often depends on timely detection and reporting of outbreaks,
e-mail and telephone technologies have shown particular
promise for use in disease surveillance. In Peru, for example,
100 percent reporting was achieved and sustained within six
months of rollout of a pilot surveillance system using cellular
telephones (Lescano and others 2003). The system is to be
expanded to national coverage this year.
Although individual citizens will not soon have equal access
to ICT, these technologies can immediately be better used to
improve public health. Automation of data entry and analysis
can ease data capture, validation, analysis, and transmittal of
health information. District managers can generate reports
with tables and charts and transmit them to central levels,
which can then apply this knowledge to improve local manage-
ment. Special prompts and “exception reports” can alert man-
agers to unexpected findings that require double-checking or
immediate interventions (for example, outbreaks of infectious
disease, low immunization coverage, or other management
problems).
Use of free software, such as the U.S. Centers for Disease
Control and Prevention’s Epi Info, can lower costs, but often
these software packages require substantial adaptation to local
needs, along with additional training and technical support.
Acquisition of computer equipment should be viewed not as a
one-time capital expenditure but as a long-term commitment
to buy periodic upgrades, maintenance, and technical support.
Experience shows that purchase of inexpensive software and
computers, such as in the Eastern Cape Province of South
Africa, may actually increase overall costs when they require
early replacement with more adequate alternatives.
Geographic information system (GIS) technologies have
also been successfully used in districts in several countries to
enable mapping and visual representation of the geographic
distribution of risk factors, disease, and services. A desktop GIS
viewer and mapping software are available in several shareware
versions, including the WHO’s “Health Mapper,” so that maps
can be produced at little cost. Other potentially promising
technologies include electronic scanners and personal
digital assistants for data capture (http://www.healthnet.org)
and global positioning systems to facilitate the mapping
process.
The principal barriers to improved information systems,
however, are human, not technological. Substantial investment
in training and technical support must accompany the intro-
duction of any new technology. If the HIS is not functionally
solid, introducing ICT will likely only worsen existing
problems.
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Dissemination and Use of Health Information
Information is a means to the end of improving health, but the
availability of reliable information does not guarantee its use or
improved decision making. Because decisions are often driven
as much by politics as by evidence, it is critical to design infor-
mation systems to meet the needs of decision makers and to
create a culture of evidence that provides incentives and ac-
countability for evidence-based decision making. Extensive
dissemination promotes widespread use and accountability.
The many users of information include the following:
• health ministries at national, regional, and district levels
• researchers and evaluators
• legislative and policy analysts
• nongovernmental organizations and consumer organizations
• advocacy groups 
• private sector health providers and insurers
• communities, including groups of patients 
• journalists
• donors and international agencies concerned with health 
• individuals and families.
The literature on health information systems is replete with
complaints of the neglect of existing information, yet remark-
ably little is known regarding the effectiveness of interventions
to improve the use of information. The NHA experience (De
and others 2003) suggests that policy makers are most likely to
use information when it contributes to and informs a preferred
government direction, especially if that information is not
available to stakeholders outside the health ministry. But sys-
tems and dissemination patterns for information can be engi-
neered to ensure that clients, providers, and managers will seek
and use information to inform decisions. Standard procedures
can be developed to ensure analysis and use of data at the level
at which it is collected. Training of health workers can be
designed to include both basic and refresher training in the
analysis and interpretation of data that are relevant to each job.
Expectations of information use can be built into routine job
requirements, including use of evidence for planning, data
requirements for periodic reporting to supervisors, and use of
information during performance reviews. Groups of managers
can be convened across districts or regions for benchmarking,
in which each manager presents and compares performance
data and is rewarded for transparency and learning. These
practices will result only from intense training in analysis and
use. For example, Loevinsohn (1994) demonstrated that fewer
than half of midlevel managers were able to use the informa-
tion system even to identify best- and worst-performing dis-
tricts. Nonetheless, if managers use the information, and if
improved efficiency and coverage with interventions is the
result, the HIS becomes exceedingly cost-effective.
Information will “allow the public, their elected representa-
tives, or donors to determine whether they are obtaining value
for money” (Cibulskis and Hiawalyer 2002; see also Mackay
1998). Providing full access to the media will help to accelerate
expectations of evidence-based decision making and account-
ability. Civil society, including nongovernmental organizations,
should be the principal users of information to create and sustain
citizen demand for quality services. The Healthy Communities
Foundation’s “dashboard” of lead indicators of health system
performance exemplifies one promising example of the visual
display of data (http://whatcom.healthycities.org/demo/
aboutus.htm). Such dissemination and use of health informa-
tion has enhanced government accountability for improved
health in Papua New Guinea, where reports of local government
performance in improving health systems transformed election
results (G. Hiawalyer, personal communication).
BENEFITS, COSTS, AND COST-EFFECTIVENESS
OF IMPROVED INFORMATION
There is broad agreement that information—plus the knowl-
edge it enables—creates value. Yet it is challenging, indeed, to
quantify the added value of information. Information, after all,
is necessary but never sufficient to achieve improved outcomes.
Other resources—human, material, and financial—are
required for change. Nonetheless, it is possible to define the
interventions necessary to improve health information and to
draw on a few studies to estimate the cost and cost-effectiveness
of these investments.
Strengthening of Systems 
The steps involved in strengthening HIS include securing fund-
ing for a review of the current HIS and planning reforms and
then using that plan to secure funding for implementing the
reforms. The reforms depend on legislation and regulations
that delineate the requirements, incentives, and disincentives
for collecting the needed information. Finally, the review of the
current HIS includes a situational analysis and outline of a plan
that involves a comprehensive information architecture that is
linked to both national and international needs.
The HMN Framework includes assessment and planning
tools and HIS standards that will guide strengthening of sys-
tems. Full implementation will likely take at least 36 months,
and the effects on decision making and health outcomes will be
detectable only after approximately five years.
Benefits and Effectiveness of Improved Information
The value of health information can be characterized in terms
of cost savings; system efficiencies (for example, increased
coverage or quality of services); or improved health outcomes
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(for example, DALYs saved or improved health equity).
Information can also be used to increase overall resources for
health. Publications such as this volume, World Development
Report 1993: Investing in Health (World Bank 1993), and the
report of the Commission on Macroeconomics and Health
(2000), are important examples of evidence that has been used
to change health policies and increase resources for health.
The industrial world holds examples of the use of informa-
tion to make service provision more effective and efficient. A
quality improvement and evidence-based decision assistance
program for diabetes patients in the United States created a net
savings of US$510,133,2 primarily by averting hospitalizations
(Petrakos 1998). The U.S. Institute of Medicine estimates that a
computerized system for managing physician orders for med-
ications costing US$1 million to US$2 million could “pay for
itself in three to five years” and prevent injury to hundreds of
patients per year (Kohn, Corrigan, and Donaldson 2001).
There are also promising examples of the benefits and effec-
tiveness of improved information from developing countries.
Quality improvements driven by better information in Bolivia
resulted in a 300 percent increase in hospital utilization rates
(Pappaioanou and others 2003). In rural Mali, populations
enrolled in a community-based information system calculated
delivery costs for childhood immunization to be US$1.47 per
child, compared with US$2.79 per child among populations
not registered (Zayan, Berggren, and Doumbia 1992).
Better information can also improve efficiencies in the man-
agement of pharmaceutical resources. For example, imple-
menting a subnational information system in the Eastern Cape
province of South Africa led to improved access to pharmaceu-
ticals, with a 39 percent reduction in stockouts of essential
drugs. Such improvements undoubtedly lead to better health
outcomes, which may result in increased productivity and con-
sequently an increase in the growth rate of the gross domestic
product (Jamison, Sachs, and Wang 2001; Nordhaus 2002).
Costs of Improved Health Information
Few studies have documented the costs of an HIS. Kleinau
(2000) estimated the resource requirements for health service
statistics, the most expensive of the six subsystems. Using sim-
ilar assumptions, we have calculated updated costs.
This estimate includes only the public sector facilities, not
private sector reporting systems. Reporting from private
providers would likely include a more limited set of reported
data: diseases, vaccinations, possibly staffing, and minimal uti-
lization. Table 54.2 summarizes the total annual costs and per
capita costs of the six health information subsystems.
The costs of a facility-based services statistics subsystem of
the HIS (table 54.3) can be assumed in most developing coun-
tries to include routine public health surveillance, because
these data are obtained at health facilities when ill patients are
brought for treatment. The additional costs of program-specific
surveillance (for example, in support of polio eradication or
tetanus elimination programs) could be assumed with a
minor marginal investment in addition to facility-based and
community-based information systems, including for vital
events surveillance.
The calculated range for per capita annual costs of a com-
prehensive HIS—US$0.53 to US$2.99—compares closely to the
estimates from a country setting in which those data have been
obtained, including a low-resource country (Tanzania) with a
per capita cost of approximately US$0.50 (Rommelmann and
others 2004) and a high-resource country (Mexico) with a per
capita cost of approximately US$1.00. The Health Metrics
Network (HMN) Technical Task Force South Africa has also
estimated costs of the HIS at approximately US$26 million
(165 million rand) for a population of 43 million, yielding a per
capita cost of US$0.60. The highest range of the estimate would
apply in countries with higher salaries and a more comprehen-
sive HIS.
Estimations of the Cost-Effectiveness of Interventions
to Improve Health Information
The Tanzania Essential Health Interventions Program (TEHIP)
is perhaps the best source of evidence for the cost-effectiveness
of improved health information. The project was designed to
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Table 54.2 Cost of Essential HIS Subsystems
Total cost Per capita 
(US$ million) cost (US$)
Low High Low High 
HIS subsystem income income income income
Health service statistics 4.8 25.9 0.16 1.66
Public health surveillance 0 0 0 0
(included with health 
service statistics)
Census 7.5 30.0 0.25 1.0
Household surveys 0.6 1.0 0.02 0.03
Vital events surveillance 1.5 6.0 0.05 0.20
Resource tracking 1.5 3.0 0.05 0.10
Total 15.9 65.9 0.53 2.99
Source: Authors.
Note: Table is based on a population of 30 million. Household survey costs are based on the
experience of the demographic and health surveys during 2001–2003 (Macro International,
personal communication). Costs vary by sample size and by length of the survey instrument;
Macro International estimates, an average cost of US$100 per survey participant. A sample of
6,000 is assumed for the low-income setting, and a sample size of 10,000 is assumed for the
high-income setting. Cost estimates for vital events monitoring are based on demographic
surveillance sites. In the high-income setting, the annual costs are assumed to quadruple.
Resource-tracking costs are based on the experience of national health accounts (Abt Associates,
personal communication), and the Egyptian Budget Tracking system. Similar costs are estimated
for human resources and commodities.
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Table 54.3 Annual Costs of the Facility-Based Services Statistics Subsystem of an HIS
HIS cost Low-resource setting High-resource setting
Personnel
Primary care facility
First referral level
District hospital
Regional level 
National level
Subtotal (personnel)
Data collection instruments and supplies
Primary care facility
First referral level
District hospital
Regional 
National 
Subtotal (supplies)
Primary care facility
First referral level
District hospital
Regional level
National level
Subtotal (information technology)
Training cost
Total cost
Per capita cost
One person (salary US$4,514/year) spends 10 percent
of time at each of 6,000 facilities (US$2,708,400)
One person (salary US$4,514/year) spends 25 percent
of time at each of 1,000 facilities (US$1,128,500)
Two people (salary US$4,514/year each) spend
20 percent of time at each of 300 facilities
(US$541,680)
Three people (salary US$10,962/year each) spend
50 percent of time at each of 15 facilities
(US$246,645)
Six people (salary US$10,962/year each) spend
50 percent of time (US$32,886)
US$4,658,111
US$100/year
US$250/year
US$500/year
US$1,500/year
US$5,000/year
US$7,350
0
0
0
0
50 percent use of each of four computers with
software at US$1,100 (US$2,200)
US$2,200
US$180,000
US$4,847,661 
US$0.16 
Two people (salary US$10,351/year each) spend
20 percent of time at each of 6,000 facilities
(US$24,842,400)
Two people (salary US$10,351/year each) spend
75 percent of time at each of 1,000 facilities
(US$15,526,500)
Two people (salary US$10,351/year each) spend
100 percent of time at each of 300 facilities
(US$6,210,600)
Three people (salary US$25,134/year each) spend
100 percent of time at each of 15 facilities
(US$1,131,030)
Ten people (salary US$25,134/year each) spend
100 percent of time (US$251,340)
US$47,961,870
US$400/year
US$1,000/year
US$2,000/year
US$5,000/year
US$30,000/year
US$38,400
0
0
20 percent use of each of two computers with
software at US$1,100 at each of 300 facilities
(US$132,000) 
Two dedicated computers with software at US$1,100
at each of 15 facilities (US$33,000)
10 dedicated computers with software at US$1,100
(US$11,100)
US$176,100
US$1,730,000
US$49,906,370
US$1.66
Source: Authors.
Note: Based on a model country with a total population of 30 million.
test how evidence can be used to decentralize health sector
planning at the district level and to what extent evidence-based
priority setting would result in improved health outcomes. The
project budgeted for a marginal investment of US$2.00 per
capita for the information and for health interventions,
although only US$0.80 per capita was actually spent. The
slightly increased investment covered training in the use of the
information to set priorities and to better manage the most
cost-effective interventions. The information systems included
a district burden-of-disease intervention priority profile, dis-
trict health accounts, a district cost information system, and
district health service mapping. Management and technical
support strengthened the district and regional health sector
use of the information for management and administration.
Communities participated in the ownership and management
of health facilities. The cost-effectiveness estimates in this
Information technology: computers and software
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section are based solely on the declines in mortality of children
under five years of age, even though adult mortality also
decreased. To ensure a conservative estimate of the costs of the
HIS, we used a per capita cost of US$2.00—higher than the
actual investment for TEHIP and at the high end of the range
of costs for a comprehensive HIS estimated in table 54.2—
US$0.53 to US$2.99. All costs were ascribed to the information
system, because there were no improvements in the interven-
tions themselves. Expenditures and deaths before 2002 were
discounted by 3 percent annually (see box 54.2).
The demographic and epidemiologic data were taken from
the Rufiji district, where the most complete data were available.
The estimate of the number of children under age five (32,661)
is based on the 2002 census results. The Ministry of Health,
census, and Rufiji Demographic Surveillance System estimates
range from 31,000 to 36,000 children for 2003. Because of this
discrepancy, the decline in the total fertility rate, from 5 to 4.7
(5 percent), is taken into account in estimating the number of
children less than five years of age for 1999 to 2001. The prob-
ability of dying before five years of age declined by 15.6 percent,
and because of declining fertility, each year has 1.5 percent
The Tanzania Essential Health Interventions Program
Box 54.2
TEHIP is a partnership between Tanzania’s Ministry of
Health and the International Development Research
Centre. The project was established to determine the fea-
sibility of an evidence-based approach to health planning
at the district level. Testing the premise of the World
Bank’s (1993) World Development Report 1993: Investing in
Health, TEHIP enabled district health planners in two of
Tanzania’s 117 districts to collect and use burden-of-
disease and cost-effectiveness data to get the best value for
money from national investments in health. Interventions
included door-to-door collection of data and training or
technical support for managers in the analysis and use of
the data for decision making. TEHIP districts allocated
services to high-burden diseases, resulting in a tripling of
clinic utilization rates and increased treatment effective-
ness. With a per capita increase in spending of only
US$0.80, district health managers achieved a 47 percent
reduction in child mortality rates.
Table 54.4 The Effectiveness of Evidence-Based Resource Allocation in Improving Health
Probability
Number of of dying Mortality DALYs DALYs
children (birth to rate Total Deaths gained/ Total discounted 
Year  5 years 5 years) ( 5 years) deaths averted death DALYs at 3 percent
1999 31,000 135.5 34 1,054 — — — —
2000 31,500 119.0 25 791 263 41 10,850 11,511
2001 32,000 110.0 25 803 251 41 10,332 10,643
2002 32,661 114.0 26 853 202 41 8,303 8,304
Total DALYs gained 29,487 30,458
Source: Authors.
Note: 1999 is baseline year; therefore, no deaths were averted.
Table 54.5 Costs of Evidence-Based Resource Allocation for
Improving Health
Total cost at US$2 Discounted 
Year Population per capita (US$) cost (US$)
1998 186,809 373,618 420,510
1999 191,012 382,024 417,448
2000 196,515 393,030 416,966
2001 202,176 404,352 416,482
2002 208,000 416,000 416,000
Total costs 1,969,024 2,087,406
Source: Authors.
fewer children than the preceding year. DALYs saved from each
child death averted is estimated at 41.2. The resulting calcula-
tions of effectiveness are summarized in table 54.4.
The estimates of cost are based on population size projected
back from the 2002 census results, assuming an average annual
growth rate of 2.8 percent. Costs incurred in 1998 are included
because we assume that it takes at least two years (1998 to 2000)
of improving the HIS before health benefits accrue.
Source: Authors.
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Using these figures for effectiveness (table 54.4) and cost
(table 54.5), we find that the cost-effectiveness of the HIS that
results in improved evidence-based resource allocation and
child health may be conservatively estimated at US$68.50 per
DALY gained (US$2,087,406 to gain 30,457 DALYs). Even in
the poorest countries, this is well below the gross national
product (GNP) per capita benchmark for what is considered
worthwhile for government investment in health.
This analysis for the TEHIP project is based solely on child
deaths averted. But the improvement in health information
would also yield substantial benefits for adult populations. For
example, HIS-driven increases in coverage with hepatitis B vac-
cine have varied between 5 and 33 percent (Miller and McCann
2000). These increases in coverage with hepatitis B immuniza-
tion will result in incremental reductions in death and disability
among adults attributable to hepatitis B–induced cirrhosis and
liver cancer, thereby averting the loss of substantial numbers of
DALYs in low-income countries (World Bank 2002). Hepatitis B
vaccine is a cost-effective addition to an existing immunization
program, with a cost per death averted of US$11 to US$15
(US$193 to US$262 per DALY saved). But efficiency and cover-
age can be substantially improved with an additional invest-
ment in the HIS. The cost per DALY saved by incremental
investment in the HIS can be calculated using estimates of costs
of the HIS from table 54.2, plus the estimates of cost and deaths
averted because of immunization from Miller and McCann
(2000) for populations in all low-income countries (GNP per
capita less than US$997; World Bank 2002). Figure 54.1 shows
that, for the high-prevalence countries (Miller and McCann
2000), the investment in a comprehensive HIS is highly cost-
effective (US$159 to US$126 per DALY saved for low-cost set-
tings and US$757 to US$597 per DALY saved for high-cost
settings), even if the investment results in only minor increases
in immunization coverage. A similar analysis for countries with
a lower prevalence rate of hepatitis B demonstrates that the cost
per DALY saved is higher, but the investment in an HIS still
yields a savings of DALYs at a cost that is well below the GNP
per capita for the majority of the low-income countries.
These calculations of the cost-effectiveness of investments
in an HIS are highly conservative, because they consider health
benefits within a single population group (children, in the case
of TEHIP) or a single disease problem (hepatitis B). They
therefore underestimate the true cost-effectiveness of invest-
ment in an HIS, which can drive improvements in program
efficiency and effectiveness across a broader range of health
interventions.
FINANCING OF IMPROVED HEALTH 
INFORMATION
The annual per capita cost, estimated earlier, of US$0.53 to
US$2.99 for a comprehensive HIS, represents a substantial
portion of the current per capita health expenditure for many
developing countries. These figures include capital and recur-
rent costs, although they do not include the costs of any external
technical assistance. Because most countries have already made
a substantial investment in a HIS, the actual incremental costs to
improve the existing HIS likely are much less. Salaries, which
account for more than 90 percent of HIS costs, are expenditures
that are already being made in most settings, so the marginal
cost of HIS improvements would be primarily the initial devel-
opment costs of planning, training, technical assistance, and
information technology upgrades. Furthermore, the costs of
HIS improvements may be fully offset or even exceeded by the
savings from the resulting improvements in efficiencies in the
health care system.
Existing funding is adequate to strengthen systems substan-
tially in all low-income and lower-middle-income countries
primarily through the major international initiatives (Global
Fund to Fight AIDS, Tuberculosis, and Malaria; President’s
Emergency Plan for AIDS Relief; and Multi-country AIDS
Program of the World Bank). All these funders recommend
that 3 to 7 percent of grants and loans be allocated to monitor-
ing and evaluation. Several bilateral development agencies and
the multilateral development banks will provide financing for
HIS reform, including the U.S. Agency for International
Development (USAID) through the MEASURE (Monitoring
and Evaluation to Assess and Use Results) Project, which is
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Figure 54.1 Cost-Effectiveness of Health Information Systems: Cost
per DALY Saved Because of Increases in Coverage Attributable
to HIS
opment of the district-level HIS. The HMN will create an
alliance of countries committed to a parsimonious consensus
technical framework and encourage donors to cooperate with
and strengthen the HMN-sanctioned HIS architecture in
participating countries.
The predictors of success in developing and maintaining an
HIS are as follows:
• high-level commitment to HIS development and the linked
changes in management
• a champion of HIS reform who engages the stakeholders
and can work across sectors
• an information architecture that is simple, is structured to
drive decision making at the level that data are collected,
provides incentives and accountability for performance, and
links health information subsystems
• investment in training and increased status for the people
who manage the HIS.
RESEARCH AND DEVELOPMENT
An effective HIS delivers routine information that enables
informed policy making and management but also promotes
health research. Routine information systems may serve as a
research platform, but the HIS itself should also be a subject
of research. Research should drive the continual refinement of
HIS methods and tools, thereby ensuring expanding and well-
documented returns on our investments in health.
The instruments and methods of the HIS must be continu-
ally refined to improve its effectiveness and reduce its costs. For
the phased introduction of vital events monitoring, for exam-
ple, there is a pressing need for the development and validation
of methods for projecting subnational results to national rates
of birth and death. More research is needed to develop and test
new methods for rapid assessment in order to obtain timely
and affordable information to solve management problems. As
field-appropriate and cost-effective diagnostic technologies are
developed, research should be performed to document the util-
ity of obtaining biomarkers in household surveys.
Documenting improved outcomes and lower costs will pro-
vide evidence for policy makers on the effectiveness of HIS
investments. To better decide how to improve the HIS, decision
makers will need documentation of the costs and effects of
introducing ICT in support of the HIS. Existing and emerging
technologies should be tested for their cost and effectiveness in
assisting field-based data capture, instantaneous data transmis-
sion, GIS-based mapping of indicators, and compelling presen-
tation for decision making by policy makers, managers, and
other stakeholders. Research and development efforts are
needed to devise software—or preferably shareware—that is
specifically tailored to support the consensus technical frame-
work developed by the HMN.
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designed to improve and institutionalize the collection and use
of data for health policy development and program monitor-
ing. The HMN offers some financial assistance to countries that
are preparing for and planning HIS reform and will assist coun-
tries in negotiating financing packages that blend loan funding
with grants from bilateral donors to implement those reforms.
Several international agencies support strengthening sys-
tems for national statistics that extend beyond the health sec-
tor. STATCAP (Statistical Capacity Building), which is a new
lending program offered by the Partnership in Statistics for
Development in the 21st Century (PARIS21) through the
World Bank, supports the development of national statistical
systems. The separate Trust Fund for Statistical Capacity
Building offers smaller amounts of grant funding to prepare
the statistical master plan that is required for obtaining a
STATCAP loan. Although short-term project funding can often
be secured for system development, the resulting system and its
recurrent costs must be within the country’s capacity to sustain
it, both technically and financially.
IMPLEMENTATION OF CHANGE:
LESSONS OF EXPERIENCE
Underinvestment is the root cause of the nearly universal
weaknesses in the HIS in developing countries. This failure is
reflected in the poorly paid and undervalued HIS staff; in the
irregular and unreliable transmittal of data from the periphery;
in the underreporting of events, including births, deaths, and
morbidity; and in the failures to base planning and decision
making—at both the district and the central levels—on credi-
ble evidence (Azubuike and Ehiri 1999).
When the need for HIS improvement is identified, min-
istries of health should explicitly state the characteristics they
need in a reformed system and quantify the expected benefits.
A common mistake made in implementing HIS change is fail-
ing to recognize the associated need for change in management
processes and organizational culture. In contrast, recent HIS
reforms in Niger (Mock and others 1993) and Uganda
(Gladwin, Dixon, and Wilson 2003) have had unprecedented
success because they have been aligned with broader manage-
ment reforms and changes in organizational culture. Failure to
adjust management roles with HIS changes can constrain
effectiveness, such as when HIS managers are not given the
necessary increased status and authority to demand reports
and trigger corrective actions (Gladwin, Dixon, and Wilson
2003). Failure to invest adequately in training, especially in
skills for presentation and communication of results, may also
inhibit the use of health information. The demand from inter-
national organizations and global programs, such as the
Expanded Program on Immunization and Stop TB, for reports
on vast numbers of indicators has retarded the smooth devel-
Bailey and Pang (2004) point out the need for more research
in the developing world to better understand users’ informa-
tion needs. In fact, research is needed to better document the
entire information value chain, with special attention to
improving the identification of information needs, to over-
coming the natural disincentives to information sharing, and
to enabling better use of information for constructive change.
At present, there is still a need to improve the access to infor-
mation and knowledge in the developing world. However, the
future will bring the larger challenge of improving the man-
agement and use of information and the knowledge such infor-
mation can bring. Research in the HIS will be instrumental
in both accelerating equitable access to information and
improving the management and use of knowledge for
improved health.
CONCLUSIONS
More than ever before, it is in the mutual interest of the devel-
oping and industrial worlds to invest in strengthening systems
for collection and management of health information
(Stansfield 2005).
The trend toward “basket” funding for health and sector-
wide approaches makes the need for priority setting all the
more acute. Priority setting depends on accurate information.
The success of efforts to reduce poverty and health inequity
will depend on the existence of information systems to detect
those problems, facilitate the design of solutions, and track
progress toward eliminating the problems. Countries and
donors must, therefore, accelerate and harmonize their invest-
ments in information systems.
Within countries, the trend toward decentralization of
authority for management of health resources has led to fur-
ther challenges for the HIS, as well as to greater reliance on the
information it provides to inform decision making. It is clear
from the instructive failures of underresourced systems that the
accuracy and value of information reported to the national
level will depend on that information’s perceived value in the
periphery. Information is relevant only if it is used to solve a
local problem or if it helps to generate innovation that solves a
local problem (Bailey and Pang 2004). Therefore, the decen-
tralization of authority will be successful only with better infor-
mation systems to support decisions at the periphery, and
evidence-based decision making will be possible only if author-
ity can be devolved to the periphery. This decentralization,
along with increasing cooperation and collaboration across
sectors to improve health outcomes, makes it all the more
critical to present data in simpler ways that are understandable
and compelling to a broader and nontechnical audience.
Although historically neglected, investments in comprehen-
sive development of the HIS will clearly deliver good value for
money. Improvements in the HIS can accelerate broad
improvements in health if they are engineered to reflect, rein-
force, and even drive health sector reforms. Even more com-
pellingly, investments in the HIS can make health the “thin
edge of the wedge,” giving governments and politicians a posi-
tive experience with information sharing and overcoming the
natural disincentives to transparency and accountability. HIS
investments hold the promise, therefore, not only of trans-
forming public health, but also of accelerating progress toward
good governance in every sector.
NOTES
1. Sauerborn and Lippeveld (2000) have defined a health information
system as the “set of components and procedures organized with the objec-
tive of generating information that will improve health management
decisions at all levels of the health system.”
2. The dollar amounts given are quoted from the references and are not
adjusted for current dollar value.
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The control of infectious diseases is seriously threatened by the
steady increase in the number of micro-organisms that are resist-
ant to antimicrobial agents—often to a wide range of these
agents. Resistant infections lead to increased morbidity and pro-
longed hospital stays, as well as to prolonged periods during
which individuals are infectious and can spread their infections
to other individuals (Holmberg, Solomon, and Blake 1987;
Rubin and others 1999). The problem is particularly severe in
developing countries, where the burden of infectious diseases is
relatively greater and where patients with a resistant infection are
less likely to have access to or be able to afford expensive second-
line treatments, which typically have more complex regimens
than first-line drugs. Furthermore, the presence of exacerbating
factors, such as poor hygiene,unreliable water supplies,civil con-
flicts, and increased numbers of immunocompromised patients
attributable to the ongoing HIV epidemic, can further increase
the burden of antimicrobial resistance by facilitating the spread
of resistant pathogens. In this chapter, we discuss the causes and
burden of drug resistance and evaluate interventions that address
the resistance problem in developing countries.Although a num-
ber of the interventions we discuss are relevant to drug resistance
in HIV/AIDS and other forms of antiviral resistance, chapter 18
includes a more in-depth discussion of this subject.
RISK FACTORS
Drug Use in Humans
The evolution of drug resistance is facilitated by a number of fac-
tors, including increasing use of antibiotics and antimalarials;
insufficient controls on drug prescribing; inadequate
compliance with treatment regimens; poor dosing; lack of
infection control; increasing frequency and speed of travel,
which lead to the rapid spread of resistant organisms; and
insufficient incentives for patients, physicians, or even govern-
ments to care about increasing resistance. It is important to dis-
tinguish between risk factors for the emergence of resistance
(de novo resistance) and those for the spread of resistance (pri-
mary resistance).
The molecular basis of resistance may give a clue to the
likelihood of resistance emerging. If a single DNA base pair
mutation leads to the development of resistance, then its selec-
tion is likely to be widespread, especially if the biological fitness
cost of the mutation is low. De novo or acquired resistance
results in the appearance of a resistant strain in a single patient.
Subsequent transmission of such resistant strains from an infec-
tious case to other persons leads to disease that is drug resistant
from the outset, a phenomenon known as primary resistance
(IUATLD 1998). Independent, cumulative events result in mul-
tidrug-resistant bacteria or tuberculosis (MDR-TB). Both the
creation and the transmission of drug resistance contribute to
its prevalence in a given population. This mechanism also
holds true in the case of antimalarials; that is, resistance devel-
ops when malaria parasites encounter drug concentrations that
are strong enough to eradicate the susceptible parasite popula-
tion, but they fail to inhibit the multiplication of naturally
occurring resistant strains. Commonly used antimalarial drugs
are not mutagenic.
In the case of tuberculosis, spontaneous mutations leading
to drug resistance occur rarely in Mycobacterium tuberculosis,
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and multidrug regimens can prevent the emergence of clinical
drug resistance (Cohn, Middlebrook, and Russell 1959).
Resistance is thus an avertable phenomenon resulting from
inadequate treatment, which, in turn, is often the result of an
irregular drug supply, prescription of inappropriate regimens,
or poor adherence resulting from a lack of supervision. In the
case of malaria, the widespread misuse of chloroquine as pro-
phylaxis is believed to be an important factor in the emergence
and spread of resistance to this drug.
Despite conventional wisdom, the highest rates of antibiotic
resistance in the pneumococcus bacterium globally are not for
penicillins or macrolides, which usually require multiple DNA
mutations or the import of foreign genes, respectively, but for
sulfamethoxazole-trimethoprim, which can be selected from
among a population of susceptible pneumococci by a single
base change in the dihydrofolate reductase gene (Adrian and
Klugman 1997). The direct selection of resistance following
exposure of children carrying pneumococci has been shown in
a prospective study in Malawi to occur in 42 percent of children
exposed to sulfadoxine-pyremethamine for a week and in 38
percent of children a month after exposure to drug treatment
for malaria (Feikin and others 2000).
Evolutionary biology suggests that drug selection pressure is
an important factor in the emergence and spread of drug resist-
ance. Although the relationship between antimicrobial use and
drug resistance (in the pneumococcus, for example) is well
established in developed countries (Bronzwaer and others
2002), direct evidence to support this hypothesis is less forth-
coming in developing countries because of a lack of data on
antibiotic use. Resistance to antimicrobials is less likely to arise
in the poorest developing countries simply because of the lower
levels of antibiotic use associated with poorer socioeconomic
status. For instance, India—a large country with scant control
over antibiotic prescribing—has very low rates of resistance
among systemic isolates of pneumococci, at least in rural areas
(INCLEN 1999). These low rates exist despite wide antibiotic
availability, probably because extreme poverty limits the dura-
tion of antibiotic exposure for the treatment of acute pneumo-
coccal infections. Rising incomes and increased affordability of
antibiotics will likely change this low incidence of resistance;
the same may be true of quinolones, which are widely available
at relatively affordable prices, even in semirural and rural pop-
ulations. This trend may be responsible for the emergence of
nalidixic acid resistance to Shigella in Bangladesh and fluoro-
quinolone resistance to Salmonella typhi in India.
Recent evidence suggests that shorter courses of antibiotics
may select for less resistance in the pneumococcus compared
with longer courses (when patients comply with those courses)
(Schrag and others 2001). Very low levels of resistance have also
been found in isolated rural African communities (Mthwalo
and others 1998). This observation, however, should not lead
to complacency. Increased access to antibiotics in developing
countries, without controls on over-the-counter use, has led to
some of the highest rates of resistance in the world, as was seen
with penicillin resistance in Vietnam. Relatively wealthy coun-
tries such as the Republic of Korea and Japan also have lax con-
trol and even greater access to funds to purchase antibiotics
(Song and others 1999). Patterns of resistance differ by antimi-
crobial class, and resistance to several classes has been linked to
particular patterns of use in developing countries. Macrolide
use in children in China may be preferred to the use of beta-
lactams, which are known to be associated in rare instances
with serious anaphylactic reactions, and in Beijing and
Shanghai, the highest global rates of macrolide resistance are
encountered in nasopharyngeal isolates from children (Wang
and others 1998; Yang, Zhang, and McGee 2001). Tetracycline
use remains widespread in developing countries, and poor
African countries, such as the Central African Republic, may
have higher rates of resistance to tetracycline than to beta-
lactams or macrolides (Rowe and others 2000).
The relationship between compliance and resistance emer-
gence in the treatment of acute and largely self-limiting infec-
tions is less robust than in the case of chronic infections such as
tuberculosis (TB). It is likely that resistance selection occurs
more readily in the commensal flora (for example, the pneu-
mococcal flora of the nasopharynx) than among the organisms
causing the acute infection. Thus, shorter courses (and reduced
compliance) may reduce the selection of resistance in com-
mensal flora. In contrast, in TB, selection takes place in the
infecting pathogen, and poor compliance is associated with the
selection of resistant strains.
Antibiotic Use in Animals 
Many developed countries use antibiotics for veterinary uses,
both for improving feed efficiency and rate of weight gain
(subtherapeutic use) and for disease prevention and treatment
(therapeutic use) (Levy 1992). Although the extent of anti-
biotic use in animals in developing countries is unknown, one
study from Kenya reported that tetracyclines, sulfonamides,
and aminoglycosides were the most commonly used antimi-
crobials for veterinary purposes (Mitema and others 2001).
Over 90 percent of the antibiotics used were for therapeutic
purposes, and there was no evidence of use for growth
promotion.
There is strong evidence that the use of antibiotics in farm
animals promotes the development of drug-resistant bacteria
in animals (Aarestrup and others 2001). Because routes for the
movement of these resistant bacteria to humans are available,
there is sufficient circumstantial evidence that drug resistance
in bacteria associated with food animals can influence the level
of resistance in bacteria that cause human diseases (Wegener
and others 1999). Furthermore, mathematical models indicate
that the effect of subtherapeutic use on resistance in humans
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is greatest when resistance levels are undetectable (Smith and
others 2002). The appearance of drug-resistant strains of
Enterococcus faecium in broiler meat products at retail outlets
declined after the ban of antimicrobial growth promoters in
Denmark (Emborg and others 2003). Salmonella has been
recovered from chicken (35 percent), turkey (24 percent), and
pork (16 percent) samples obtained from area supermarkets in
Washington, D.C. (White and others 2001). There is evidence
that dissemination of tetracycline-resistance-encoding plas-
mids between aquaculture and humans has already occurred in
Europe (Rhodes and others 2000). The global nature of this
problem became apparent in 2001, when authorities in some
European countries found residues of chloramphenicol in tiger
shrimp imported from China, Indonesia, and Vietnam
(Holmstrom and others 2003).
Transmission of Resistant Pathogens
Once resistance has emerged in a population, it can spread
both geographically and between age groups. Unsafe drinking
water, unsanitary conditions, and poor infection control in
hospitals are risk factors for the transmission of all infections,
including resistant ones. The transmission of resistant strains
from children to adults has been suggested by anecdotal reports
as far back as the 1980s (Klugman and others 1986). That asso-
ciation is strongly supported by the role of conjugate pneumo-
coccal vaccine in reducing antimicrobial resistance among
adult pneumococcal bacteremic isolates in the United States
(Whitney and others 2003). The association of HIV infection
with pediatric serotypes and antimicrobial resistance in pneu-
mococci suggests the potential utility of this approach in
reducing the burden of antimicrobial resistance in pneumo-
cocci in developing countries where the burden of disease is
overwhelmingly associated with HIV infection in both children
(Madhi and others 2000) and adults (Jones and others 1998).
Disease Burden
Although no estimates of disease burden are currently available
that are specific to drug resistance, the contribution of drug
resistance to the burden of infectious diseases is believed to be
large. Resistance has emerged in malaria, HIV, TB, and other
bacterial infections that together constitute a significant pro-
portion of the burden of disease in developing countries.
An indication of the extent of the problem is provided by
the burden of diseases for which drug resistance is a problem
(table 55.1), as well as by the levels of drug resistance among
these pathogens (table 55.2 and figures 55.1 and 55.2).
Pneumococci. Surveillance of drug resistance in pneumococci
shows several general trends. The numbers of strains that are
fully susceptible to penicillin-G, once nearly universal in most of
the world, have declined by 30 to 50 percent in many countries
and by 75 percent in some, as resistant clones have spread widely
but irregularly throughout the world (Sa-Leao and others 2002).
At the same time, percentages resistant to macrolides and to
sulfamethoxazole-trimethoprim have increased, especially
where those drugs have been widely used, and resistance to
tetracycline or chloramphenicol has fluctuated widely. Linked
resistance to these drugs results in a growing percentage of
strains resistant to many or all of them. Resistance to fluoro-
quinolones is still rare but is beginning to be observed in many
places (Ho and others 2001; Quale and others 2002).
Certain Streptococcus pneumoniae clones have been widely
disseminated. A penicillin-, chloramphenicol-, and tetracy-
cline-resistant clone (and sometimes erythromycin) of Spanish
origin (Spain23F-1) has, since its original description, been iso-
lated in other parts of Europe, the United States, South and
Central America, South Africa, and East Asia (McGee and
others 2001). It is likely that this clone is even more widespread
and that the absence of reports from other areas reflects the
absence of molecular testing techniques needed to delineate
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Table 55.1 Estimated Burden of Disease in Disability-Adjusted Life Years, by Cause and Gender, 2001
Both sexes Males Females
DALYs Percentage DALYs Percentage DALYs Percentage 
Condition (Thousands) of total (Thousands) of total (Thousands) of total
Infectious and 359,377 24.5 184,997 24.1 174,380 24.9
parasitic diseases
Respiratory infections 94,037 6.4 49,591 6.5 44,446 6.4
Diarrheal diseases 62,451 4.3 31,633 4.1 30,818 4.4
Gonorrhea 3,320 0.2 1,437 0.2 1,883 0.3
Tuberculosis 36,040 2.5 22,629 2.9 13,411 1.9
Malaria 42,280 2.9 20,024 2.6 22,256 3.2
Source: WHO 2002b, annex table 3, 194. 
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Table 55.2 Prevalence of S. pneumoniae Not Susceptible to Three or More Drug Classes, Alexander Project 1998–2000
Percentage multiresistant defined as
Any three drug classes Any three drug classes Any five or more 
Region and country N excluding penicillin including penicillin Any four drug classes drug classes
Africa 540 14.3 24.8 13.5 3.3
Kenya 277 3.6 16.6 2.2 0.0
South Africa 263 25.5 33.5 25.5 6.8
Eastern Europe 1,109 10.1 11.7 6.0 1.0
Czech Rep. 275 0.7 1.1 0.4 0.0
Poland 453 13.0 15.2 6.4 1.1
Russian Fed. 161 10.6 12.4 3.7 1.2
Slovak Rep. 220 15.5 17.3 14.1 1.8
Western Europe 3,328 14.7 18.4 11.9 4.1
Austria 149 2.7 4.7 2.0 0.0
Belgium 230 13.9 15.7 7.0 2.6
France 444 35.6 49.1 34.9 11.7
Germany 321 4.7 5.9 1.6 0.0
Greece 431 18.6 19.5 13.9 2.1
Italy 304 19.7 22.4 9.9 1.0
Netherlands 185 0.0 1.1 0.0 0.0
Portugal 328 6.1 9.5 5.5 1.8
Ireland 54 9.3 14.8 9.3 1.9
Spain 295 27.8 32.9 25.4 15.3
Switzerland 349 5.7 7.7 4.9 2.3
United Kingdom 238 5.9 6.3 5.0 2.1
Far East 730 53.2 63.2 40.6 23.0
Hong Kong, China 193 76.2 79.3 70.5 60.1
Japan 404 48.3 63.1 29.2 6.4
Singapore 133 34.6 39.9 31.6 19.6
Middle East 314 11.2 18.2 10.5 4.1
Israel 148 8.8 12.2 8.8 2.0
Saudi Arabia 166 13.3 23.5 12.1 6.0
Latin America 2,861 13.3 20.1 12.1 1.9
Brazil 181 2.8 5.0 1.1 0.0
Mexico 248 21.0 31.1 20.2 3.2
United States 2,432 16.2 25.8 15.5 7.0
All isolates 8,882 17.5 23.7 14.6 5.9
Source: Jacobs and others 2003.
Note: Drug classes were defined as follows: -lactams (penicillin MIC 	 0.12 mg/L), macrolides (erythromycin MIC 	 0.5 mg/L), tetracyclines (doxycycline MIC 	 0.5 mg/L), 
phenicols (chloramphenicol MIC 	 8 mg/L), folate pathway inhibitors (co-trimoxazole MICs 	 1 mg/L based on trimethoprim component), and quinolones (ofloxacin MIC 	 8 mg/L).
clones, rather than an absence of the organisms themselves.
Other globally disseminated S. pneumoniae include specific
clones of serotypes 19F, 14, 19A, 9N, 9V, 3, and 6 (McGee and
others 2001). Spread of these pandemic clones has continued,
even in areas where successful interventions have reduced
selective pressure from antimicrobial use (Arason and others
2002). With increasing international travel, the potential of
these strains to spread to areas where resistance is uncommon
can no longer be considered remote.
Shigella. In many regions where Shigella, especially Shigella
dysenteriae, is prevalent and an important cause of infant
mortality, resistance first to sulfamethoxazole-trimethoprim,
then to ampicillin, and commonly to tetracycline and
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WHO has established 126 sentinel surveillance sites in 36 African countries that monitor the efficacy of locally used antimalarial drugs by following up patients in clinics. 
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Figure 55.1 Chloroquine Treatment Failure in Africa
Prevalence
 0.9%
1.0%–2.9%
3.0%–6.4%
	 6.5%
Source: WHO-IUATLD 2004.
Figure 55.2 Prevalence of MDR-TB among New TB Cases, 1994–2002
chloramphenicol has emerged and, over recent decades, spread
to half or more of the strains sampled. In the 1990s, resistance
has begun to emerge and spread to fluoroquinolones and third-
generation cephalosporins, which in many places are the last
effective oral drugs available (Ding and others 1999). In the
past two decades, emergence and spread of Shigella dysenteriae
type 1 resistant to sulfamethoxazole-trimethoprim, ampicillin,
tetracycline, chloramphenicol, and—increasingly—nalidixic
acid has reduced the effectiveness of these inexpensive and
widely available antimicrobials in the empiric management of
epidemic dysentery (Cunin and others 1999; Hoge and others
1995). The alternatives, ciprofloxacin and ceftriaxone, are rela-
tively expensive and not always available. As a consequence,
high fatality rates have been observed in a number of recent
dysentery outbreaks (Legros and others 1998). The emergence
of fluoroquinolone-resistant strains has quickly followed. The
unchecked spread of these pathogens could pose a major pub-
lic health challenge (Sarkar and others 1979).
Gonorrhea. Newly drug-resistant strains of gonococci tend to
spread rapidly because of their peculiar epidemiology and the
lack of control programs. Therefore, it is important to detect
microepidemics of such strains, but this need is rarely met. The
past half-century has witnessed the successive emergence and
spread of gonococcal strains resistant to each new drug that
becomes widely used to treat gonorrhea, including sulfon-
amides, penicillin, tetracycline, and sulfamethoxazole-
trimethoprim (Tapsall 2002). Within less than a decade, such
strains have commonly come to account for half or more of the
isolates in many regions. The recent emergence of resistance to
fluoroquinolones leaves only less available parenteral drugs,
such as spectinomycin or ceftriaxone, as the reliable therapy
(Ison and others 1998; Palmer, Leeming, and Turner 2001).
Tuberculosis. The emergence and spread of multidrug-resistant
tuberculosis, which is defined as combined resistance to isoni-
azid and rifampicin, threaten the control of TB globally (Kochi,
Vareldzis, and Styblo 1993). Patients infected with strains
resistant to multiple drugs are very difficult to cure (Espinal
and others 2000; Goble and others 1993), particularly if they
are HIV-infected or malnourished (Fischl and others 1992),
and alternative treatment is much more toxic and expensive
(Drobniewski and Balabanova 2002). A patient with MDR-TB
may remain infectious much longer than a patient with drug-
susceptible organisms. Among new cases, prevalence of resist-
ance to at least one TB drug ranges from 0 percent in some
Western European countries to 57.1 percent in Kazakhstan,
with a median of 10.2 percent. Multidrug resistance among
untreated patients ranged from 0 percent in eight countries to
10.0 to 14.2 percent in six others. In previously treated cases,
resistance to at least one drug ranged in different settings from
0 to 82.1 percent, with a median of 18.4 percent. Prevalence of
MDR-TB in previously treated cases ranged from 0 to 58.3 per-
cent, with a median of 7.0 percent (WHO 2004).
An estimated 273,000 (at a 95 percent confidence interval
[CI]; 185,000 to 414,000) new cases of MDR-TB occurred
worldwide in 2000. By simple extrapolation, 70 million people
could be latently infected with MDR-TB, and more than 1 mil-
lion active MDR-TB cases could remain among previously
treated patients. Despite its threatening potential, MDR-TB
is—and will probably remain—generally rare. Decades after
the introduction of TB drugs, the global prevalence of MDR-
TB in new patients remains less than 2 percent (Dye and
Espinal 2001). Old animal studies (Cohn and others 1954) and
recent analyses using molecular epidemiology (Garcia-Garcia
and others 2000) suggest that MDR-TB strains might be, on
average, less infectious. And unlike most other bacteria,
M. tuberculosis replicates rather slowly (low mutation rate) and
shares little if any genetic material. Thus, even in the absence of
widespread treatment of MDR-TB, its prevalence may not
necessarily explode (Kam and Yip 2001).
Malaria. Chloroquine-resistant strains of Plasmodium falci-
parum malaria appeared a half-century ago in Southeast Asia
and South America and spread across Africa, especially East
Africa, in the past quarter-century (Wellems and Plowe 2001).
The use of molecular markers testing indicates the wide
geographical reach of pfcrt polymorphism for chloroquine
resistance, and dhfr and dhps polymorphisms for sulfadoxine-
pyrimethamine. Current levels of treatment failure of
chloroquine are in figure 55.1. There is evidence that malaria
mortality, especially in children under the age of five, is rising as a
consequence of increasing resistance to chloroquine (Greenberg
and others 1989; Trape 2001). In response to increasing treat-
ment failure, many countries, including Malawi, South Africa,
and Tanzania, adopted sulfadoxine-pyrimethamine as first-line
treatment; however, resistance to this drug too is growing in
many parts of Africa. In Southeast Asia, the emergence of mul-
tidrug resistance to sulfadoxine-pyrimethamine and mefloquine
over the past decade and a half has prompted the use of combi-
nation treatments that include artemisinin (Wongsrichanalai
and others 2001).
ECONOMIC BURDEN
Although few estimates have been made of the economic
impact of drug resistance in developing countries, there is some
indication that this burden is substantial. Estimates for costs
associated with the loss of antibiotic effectiveness in outpatient
prescriptions in the United States range from US$378 million
to as high as US$18.6 billion (Elbasha 1999). A report by the
Office of Technology Assessment to the U.S. Congress estimated
the annual cost associated with antibiotic resistance in
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hospitals (attributable to five classes of hospital-acquired
infections from six antibiotic-resistant bacteria) to be at least
US$1.3 billion in 1992 dollars (Office of Technology
Assessment 1995). The U.S. Centers for Disease Control and
Prevention (CDC) estimated that the cost of all hospital-
acquired infections, including both antibiotic-resistant and
antibiotic-susceptible strains, was US$4.5 billion.
Patients infected with resistant strains are more likely to be
sicker, to be hospitalized for longer periods of time, and to die
of the infection (Carmeli and others 2002). Both the duration
of hospitalization and the attributable cost of treating
methicillin-resistant Staphylococcus aureus were found to be
nearly three time as large as those for a susceptible infection
(Abramson and Sexton 1999). One problem with estimating
the attributable morbidity and mortality that is caused by
resistant pathogens is that patients who are infected with resist-
ant strains are more likely to have been sicker in the first place.
Therefore, the ability to appropriately control for the underly-
ing severity of the illness that causes hospitalization is a
concern.
Another important cost of resistance comes from the need
to move to second-line treatments, which are often much more
expensive than the first-line treatment that is no longer effec-
tive. For instance, treating the roughly 300 million cases of
malaria with artemisinin-based combinations would involve
an excess burden of roughly US$200 million each year in drug
costs. Periodically changing first-line treatment may also involve
costs of assessing alternate treatment regimens, retraining
health care providers, and restocking health care facilities.
Though all these impose a significant economic burden, espe-
cially in poorer countries, they may be an inevitable conse-
quence of past drug use. A focus on the cost of resistance alone
may be misleading, because it is potentially possible to elimi-
nate drug resistance by not using any drugs. To appropriately
assess the net benefits of drug use, one must include the cost of
increased resistance and the benefits of antibiotic or antimalar-
ial use in treating infections and preventing their spread to
uninfected individuals.
INTERVENTIONS
In this section, we discuss interventions to address the chal-
lenge of drug resistance (table 55.3). Many interventions to
address the problem of resistance are the same as those that
reduce the burden of disease (these are discussed in detail in
the relevant disease-specific chapters in this volume). Reducing
disease diminishes the need for drug treatment and, therefore,
lowers the likelihood that resistant strains will emerge. Some
interventions, such as the use of drug combinations, reduce the
likelihood that resistance will emerge, whereas other interven-
tions, such as improvements in drug prescribing and patient
compliance with dosing, reduce the likelihood that a resistant
pathogen will survive and proliferate. Prolonging the effective
therapeutic life of existing drugs is not sufficient, however.
Increasing incentives for pharmaceutical firms to bring new
drugs to markets may also be called for.
Drug Treatment Strategies
The appropriate choice of drug treatment is an important step
in delaying the evolution of drug resistance. Drug combina-
tions that include drugs with different targets were first used
in the treatment of tuberculosis and have now become rou-
tine practice in the treatment of cancer and HIV/AIDS.
Combinations of artemisinin and its derivatives with other
antimalarials, notably mefloquine, have accelerated recoveries,
increased cure rates, and reduced transmissibility. In the
refugee camps on the western border of Thailand, where most
of the recent studies with artemisinin combinations have been
conducted, the use of combinations delayed the development
of resistance and reduced the incidence of disease (Nosten and
others 2000). The rationale behind drug combinations is that,
if resistance results from spontaneous genetic mutations, the
chance that a parasite will emerge that is simultaneously resist-
ant to two drugs with unrelated modes of action (that is, drug
targets) is the mathematical product of the individual parasite
mutation frequencies multiplied by the total number of para-
sites exposed to the drugs (White 1998, 1999). Combinations,
therefore, reduce enormously the probability that a resistant
mutant will arise. Sequential deployment of the drugs is much
less effective, because it does not exploit the multiplicative
reduction in selection risk.
In the context of antibiotics, combinations have typically
been used to broaden the spectrum of antimicrobial coverage
rather than to reduce the likelihood of the emergence of
resistance. With the development of new penicillins and
cephalosporins with broader spectra of activity a decade ago,
most serious infections have been treated with monotherapy.
The use of combination therapy to preserve new classes of
antibiotics from the emergence of resistance at a societal level
may be rational, but it has not been implemented because of
cost concerns and the potential for enhanced toxicity associ-
ated with the use of more agents than necessary to effect a cure
in an individual patient.
Other strategies include periodic withdrawal of a drug or
rotation between different drugs. These strategies depend on
the extent of the fitness cost of resistance1 and the extent of
multidrug resistance, which may vary with the specific combi-
nation of pathogen and drug. Withdrawal or drastic decline in
antimicrobial use is occasionally but not always accompanied
by the replacement of resistant strains with sensitive ones. The
effects of antimicrobial removal have best been assessed
for antibacterial drugs in northern Europe, where drug use is
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Table 55.3 Potential Nonclinical Interventions: Evidence from Developing Countries
Strategy Intervention Reference Description Study location
Treatment Combination therapy Nosten and others 2000 Use of an artesunate-mefloquine combination Thailand
strategies for malaria was found to reduce incidence of mefloquine 
resistance in Plasmodium falciparum malaria.
Cycling strategy Kublin and others 2003 Replacement of chloroquine with sulfadoxine- Malawi
pyrimethamine resulted in a decline in 
chloroquine-resistant strains over an eight-year 
period to levels that permit reintroduction of 
the drug.
Drug heterogeneity Bonhoeffer, Lipsitch, and Modeling studies demonstrated the superiority n.a.
Levin 1997; Laxminarayan and cost-effectiveness of policies involving 
and Weitzman 2002 use of different antibiotics on different patients 
compared with those using the same antibiotics 
on all patients.
Directly observed Balasubramanian, Oommen, Directly observed therapy reduced the Kerala, India
therapy short course and Samuel 2000 probability of treatment failure.
Dye and others 2002 Directly observed therapy for TB was 2.8 times South Africa
cheaper to deliver and between 2.4 and 4.2 times 
more effective than conventional treatment.
Reducing selection Training providers Bexell and others 1996 Continuing education seminars for paramedical Lusaka, Zambia
pressure prescribers resulted in patients being prescribed 
antibiotics less frequently at intervention centers 
(34 percent) compared with control centers (42 per-
cent). Drug choice and dosing were also improved.
Santoso, Suryawati, and One-on-one educational interventions and seminars Yogyakarta and 
Prawaitasari 1996 for medical and paramedical prescribers reduced Central Java 
antimicrobial prescription by 17 and 10 percent, provinces,
respectively (p  0.001). Indonesia
Training drug sellers Agyepong and others 2002 Training drug dispensers on patient communication Dangme West 
resulted in modest improvements in the proportion District, Ghana
of patients showing strict, full adherence to 
antimalarial regimen.
Treatment guidelines Qingjun and others 1998 Blister packages increased compliance with Hunan province, 
with education chloroquine therapy to 97 percent, from 83 percent China
in the control group.
Direct education of Helitzer-Allen and Introduction of a nonbitter antimalarial tablet and Malawi
patients others 1993 a new educational message were effective in 
improving antimalarial prophylaxis compliance 
among pregnant women by 57 to 91 percent.
Paredes and others 1996 Video, radio, and printed bulletins were used to Lima, Peru
educate women in an intervention community on 
the management of watery infantile diarrhea. The 
overuse of nonindicated medicines (antibiotics and 
antidiarrheals) dropped 11 percent in the intervention 
group and only 7 percent in the control group.
Reducing spread of Hand washing Kurlat and others 1998 Training of nursing staff in hand washing, handling of Argentina
resistance pathogens infants, and care of intravenous lines resulted in 
40 percent reduction in bacterimia rates.
Bednets (malaria) Maxwell and others 2002 Use of netting resulted in a 55 to 75 percent Tanzania
reduction in malaria morbidity and consequent 
conservation of antimalarial drug use.
Vaccination Klugman 2001 Pneumococcal vaccines target the serotypes most South Africa
commonly encountered clinically, which are more 
likely to be resistant to antimicrobials.
Source: Authors.
tightly regulated and susceptibility patterns are closely moni-
tored (Seppala and others 1997). A recent study demonstrated
that after chloroquine was replaced by sulfadoxine-
pyrimethamine in Malawi because of a loss of effectiveness
attributable to resistance, chloroquine-susceptible Plasmodium
falciparum strains appear to have returned (Kublin and others
2003). Though the results of this study offer promise for stop-
ping or reversing resistance trends, if antimicrobials are more
sparingly and less indiscriminately applied, little is known
about the rate at which the resistance to chloroquine may
reemerge with widespread use of this drug.
Rotating between two or more antibiotics has been proposed
to address the problem of nosocomial drug resistance in the
United States (Bergstrom, Lipsitch, and McGowan 2000;
McGowan 1986), even though there is not much supporting
empirical evidence to date. In one hospital-based study, switch-
ing from gentamicin to other aminoglycosides reduced resist-
ance to gentamicin. However, when gentamicin was reintro-
duced, resistance developed rapidly (Gerding 2000). Modeling
studies have indicated that a superior strategy may be to increase
antimicrobial heterogeneity so that different patients are treated
with drugs to which mechanisms of resistance are independent
(Bonhoeffer, Lipsitch, and Levin 1997; Laxminarayan and
Weitzman 2002).Although this may be difficult to implement in
many developing countries, the approach incorporates an evo-
lutionary perspective that may help deal with drug resistance.
Reducing Selection Pressure
Inappropriate antimicrobial use constitutes selective pressure
without a corresponding benefit to individual or public health.
(Eliminating all antibiotic use could, of course, eliminate the
problem of drug resistance, but this strategy is clearly undesir-
able.) This multifaceted problem arises from behaviors of
prescribers (not always physicians),dispensers (not always phar-
macists), and consumers (not always infected). An important
factor in overprescription is the issue of externalities; physicians,
patients, and pharmacists have few incentives to consider the
effects of their prescriptions or drug use on overall levels of
resistance and the burden imposed on the rest of society.
Physicians, both in private practice and in hospital settings, may
also derive income from drugs sold and may, therefore,prescribe
antibiotics more frequently than is desirable. In China, for
instance, many hospitals rely on selling drugs for the bulk of
their revenue (Hu and others 2001).Patient pressure demanding
a prescription is known to influence prescribing in developed
countries but could be less important in developing countries.
Interventions at the Provider Level
In this section, we discuss interventions directed at health care
providers and local retail pharmacies, such as education and
professional accountability.
Prescribing Patterns. Studies in developing countries have
shown that as much as a third of drug prescriptions, account-
ing for 20 to 50 percent of drug costs, are irrational and that
antimicrobials are among the most frequently prescribed med-
ications (Bosu and Ofori-Adjei 2000). Although altering pre-
scribing behavior is an important intervention to control drug
resistance, the widespread availability of drugs without a pre-
scription limits its effectiveness. The prescribing problem may
be worse among private practitioners than among public prac-
titioners (Siddiqi and others 2002). Continuing education for
practicing health workers is one type of intervention that has
been tested in several countries. In the United States, a decline
in antimicrobial prescribing in pediatric ambulatory care has
been attributed to educational programs directed at physicians
as well as the public (McCaig, Besser, and Hughes 2002). In
developing countries, successful educational programs for pre-
scribers have improved diagnostic quality, dispelled percep-
tions of patient pressure, reduced unjustified antimicrobial
prescription (Chuc and others 2002; Hadiyono and others
1996), and reduced polypharmacy (Hadiyono and others 1996)
among private as well as public providers, including nonphysi-
cians (Chakraborty, D’Souza, and Northrup 2000; Chuc and
others 2002). In general, these measurable outcomes were
improved by 5 to 20 percent by a single intervention—a modest
but significant change that is best combined with parallel inter-
ventions. Although cost-effectiveness was not a focus of the
studies, the resultant reduction in drug use would ultimately
result in cost savings. Important components of educational
interventions are long-term commitment and refresher
courses, and complementary interventions are also desirable
(le Grand, Hogerzeil, and Haaijer-Ruskamp 1999).
Prescription guidelines, essential drug lists, and formularies
are essential for defining policy and provide a useful framework
on which educational interventions can be based (Laing,
Hogerzeil, and Ross-Degnan 2001). The World Health
Organization (WHO) recommends standard treatment guide-
lines as one of several approaches for promoting rational drug
use. Also, guidelines proposed by pharmacy and therapeutics
committees or external advisers have been applied in developing
countries, with mixed results. Although standard treatment
guidelines reduced antibiotic use for respiratory infections by
50 percent in Fiji (le Grand, Hogerzeil, and Haaijer-Ruskamp
1999), they did not alter prescription patterns in a Ugandan
study and produced a detectable but insignificant effect in Sri
Lanka (Angunawela, Diwan, and Tomson 1991). In general,
follow-up was essential for success, and the use of standard
treatment guidelines was more effective with nonphysician
prescribers (le Grand, Hogerzeil, and Haaijer-Ruskamp 1999).
Education must form part of any treatment guideline interven-
tion, and evidence suggests that, if anything, educational
programs are more effective than simply formulating guidelines
(Laing, Hogerzeil, and Ross-Degnan 2001). Rigid guidelines
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such as preprinted order forms or prepackaged drug kits for the
management of community-acquired infections have been per-
ceived as excessively prescriptive and have not been successful
intervention tools (le Grand, Hogerzeil, and Haaijer-Ruskamp
1999). Devising incentives for compliance could potentially
lower the higher prescription rates among private providers,
where treatment guidelines by themselves are less likely to work.
Peer and supervisory monitoring increases professional
accountability, thereby promoting the application of knowl-
edge to practice. The requirement that antibiotic prescriptions
for inpatients be countersigned by an infectious disease con-
sultant was successful in reducing prescriptions by 50 percent,
with a resultant cost savings of about US$350,000 over two
years in a Panama hospital (Saez-Llorens and others 2000).
Such a program would have limited applicability in other
countries and settings where the number of trained medical
professionals is small. A supervisory program in Vietnam, with
medical equipment incentives, reduced the number of patients
for whom antibiotics were prescribed and increased the num-
ber who received a correct dose regimen (Chalker 2001).
Diagnostic Tests. Bacterial culture and susceptibility testing, a
necessary component of rational antimicrobial prescribing, is
uncommon in many developing countries (Okeke, Lamikanra,
and Edelman 1999). Furthermore, diagnostic tests to confirm or
refute infections are also commonly unavailable or unreliable, so
diagnoses are made largely on the strength of clinical signs and
symptoms (Berkley and others 2001). Laboratory tests are
expensive and routinely cost more than an empiric drug that
could be effective. In contrast, malaria dipsticks can be an inex-
pensive tool for case detection and may be cost-effective in low
transmission settings (Rimon and others 2003). Clinicians have
been known to use chemotherapy as a diagnostic tool: a cure
would confirm a diagnosis. Susceptibility testing of at least some
specimens will provide much-needed surveillance data to sup-
port empiric prescribing, although efforts should be made to
take into account spatial heterogeneity in resistance patterns.
Retail Pharmacies and Outlets. Drug distributors, including
not only pharmacists but also pharmacy attendants, patent
medicine stallkeepers, and itinerant drug sellers, often sell
drugs without prescription and are an important source of pri-
mary care for people in many developing countries (Igun 1994;
Indalo 1997). Patients in search of convenient and accessible
health care often seek treatment at drug retail premises. Many
drug sellers have not been formally trained in diagnosis and
prescription but often have financial incentive to perform those
tasks, with varying degrees of competence. Despite the poten-
tial loss of business to storekeepers, educational interventions
have been successful in increasing prescription requirement
demands and promoting referral advice, all steps in the right
direction (Chuc and others 2002). Models for delivering
educational interventions in developing countries vary but can
be broadly classified into focus group discussions (Hadiyono
and others 1996) and large seminars (Bexell and others 1996).
Both models have been found to be of comparable effective-
ness; however, applicability and cost are situation-specific
(Santoso, Suryawati, and Prawaitasari 1996).
Drug Quality. Ensuring drug quality is important, both to
benefit the individual patient and to ensure that a patient is not
subjected to suboptimal doses that would promote drug resist-
ance. The few studies that have been conducted indicate that
more than half of the antimicrobials marketed in developing
countries do not match their labels. Hence, even when pre-
scribers and consumers are using the drugs responsibly, thera-
peutic failure and subinhibitory levels of antimicrobials may
occur. Substandard drugs are those that are degraded as a result
of expiration or improper storage or that are counterfeit
(Okeke and Lamikanra 2001; Prazuck and others 2002; Taylor
and others 2001).
Interventions at the Patient Level
Improving communication between patients and providers
could improve adherence to prescribed antimalarial regimens
(Agyepong and others 2002). Compliance can also be positively
affected by packaging. Blister packages, when combined with
proper instruction about drug use, have been shown to pro-
duce modest increases in antimalarial compliance, particularly
for long-term regimens, such as with primaquine (Qingjun and
others 1998). Blister packages are also time-savers for primary
health care workers, potentially allowing them more time to
advise patients on drug use. However, the introduction of blis-
ter packages must be accompanied by clear directions to avoid
injury following ingestion of blister packages.
Reducing patient self-medication may also desirable,
although the effect on drug resistance remains to be precisely
quantified. Enforcement of prescription-only regulations for
most antimicrobials reduces self-medication in developed
countries (Carey and Cryan 2003; Goff, Koff, and Geiling
2002; Pechere 2001) and may be desirable in developing coun-
tries as well. However, such a strategy may be difficult to
implement in developing countries. There have been only rare
reports of reduction in antibiotic use following blanket
enforcement of prescription supply legislation in areas where
antibiotics are freely available (Bavestrello, Cabello, and
Casanova 2002). Opponents to enforcement demand a heavy
financial and political investment, implying that a black mar-
ket for medicines could emerge, particularly if the demand for
these drugs is not lowered (Bhutta and Balchin 1996; le Grand,
Hogerzeil, and Haaijer-Ruskamp 1999). The sale of antimicro-
bials is a lucrative business, even when illegal, because of high
demand.
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Educational interventions directed at consumers have been
proposed to reduce self-medication and increase compliance,
but evidence for the effectiveness of this strategy remains
inconclusive, largely because so few studies have been con-
ducted. Gonzalez Ochoa and others (1996) demonstrated that,
although refresher training for health personnel managing
acute respiratory infections reduced antibiotic prescribing by
9 to 19 percent in two intervention areas in Havana, no benefit
was seen from community education programs when used
alone or in conjunction with prescriber training. In contrast,
Denis (1998) was able to show that a poster had 5 percent effec-
tiveness alone and 20 percent effectiveness when used with a
video to promote appropriate use of quinine and tetracycline
regimens for malaria among Cambodian villagers. The best
method to deliver information about the consequences of
antibiotic resistance remains to be identified and will need to
be modified to suit different cultures (Marin and others 1995).
In the case of tuberculosis, first-line directly observed thera-
py (DOT) remains one of the most cost-effective of all public
health strategies (WHO 1994). The discovery that DOT can be
administered successfully as a short course (DOTS) has been
pivotal to successful implementation. Relatively simple, the
DOTS approach can improve patient compliance, cure the
vast majority of new TB patients, and prevent transmission of
the disease and the emergence of MDR-TB (Balasubramanian,
Oommen, and Samuel 2000; Dye and others 2002). Un-
fortunately, many countries have been slow to adopt and imple-
ment DOTS programs correctly, and only a minority of TB
patients worldwide are managed according to this protocol (Dye
and others 2002; Pungrassami and others 2002). Because many
patients either are treated outside the DOTS regimen or do not
adhere to the long-term chemotherapy necessary to eradicate
the causative organism, MDR-TB is likely to emerge and treat-
ment costs are likely to escalate to as high as 1,000 times the cost
of conventional treatment of drug-sensitive infection.
A DOTS program requires good laboratory support for case
identification and is highly employee intense, requiring health
workers to observe the ingestion of every dose of antimicro-
bials over several months. However, the potential economic
gains are immense because of the high costs of allowing the
continued spread of the disease and of managing resistant
patients and because of the benefit of reduced hospital admis-
sions (Dye and others 2003). Several studies have investigated
means for reducing the cost of conventional DOTS programs
without compromising effectiveness. Lwilla and others (2003)
demonstrated that both institutional and community-based
DOTS programs are effective, permitting cost-effective imple-
mentation in remote areas. Furthermore, although DOTS
involves supervised drug dosing, highly trained health workers
are not essential. Studies in South Africa, Haiti, and Thailand
have found that DOTS was effective when drug administration
was supervised by appropriately trained volunteers, including
storekeepers and former TB patients (Barker, Millard, and
Nthangeni 2002; Pungrassami and Chongsuvivatwong 2002).
Although DOTS was not designed to cure patients with
MDR-TB, it succeeds in 50 percent of cases (Espinal and others
2000). Controversy has emerged about the best approach
to MDR-TB in resource-constrained settings. Although some
experts assert that standard TB control prevents the emergence
of MDR-TB in a cost-effective way (Chaulet, Raviglione, and
Bustreo 1996) and that expensive treatment of MDR-TB would
divert scarce resources from struggling DOTS programs, others
argue that it is unethical to abandon MDR-TB patients and
maintain that, if untreated, MDR-TB strains will become dom-
inant, undermining tuberculosis control in future generations
(Farmer, Becerra, and Kim 1999). These arguments are of par-
ticular consequence for programs in poor countries.
Application of Antibiotics for Nonhumans
The use of antimicrobial agents in agriculture and aquaculture
can contribute to the spread of antimicrobial resistance in
humans, although the extent of this contribution has not been
precisely quantified. It is believed that agricultural antibiotic
use hastens the emergence of resistant pathogens in humans,
and antibiotic use in humans contributes to the spread of
resistance once it has emerged (Smith and others 2002). There
are no reliable estimates of the extent to which antibiotics are
being used for such nonhuman purposes even in developed
countries. In developing countries, one would expect use to
increase with rising incomes and greater industrialization of
agriculture and food production.
WHO has recommended that antimicrobials normally pre-
scribed for humans should no longer be used to promote
growth in animals (WHO 2000). Some countries in Europe,
including Denmark and Sweden, have already phased out such
use, and under the current plan, the European Union will ban
the use of antibiotics for growth promotion by 2006. Evidence
of the effect of a ban on antibiotic use in swine production is
available from Denmark. Although the ban significantly low-
ered the use of antibiotics in growth promotion and raised the
cost of swine production by less than 1 percent, the resulting
higher incidence of disease among swine increased the use of
antibiotics used for veterinary therapeutic purposes (Hayes
and Jensen 2003). A similar increase was noted in Sweden,
where antibiotic use in animals was banned in 1986; however,
this problem was temporary, and in the longer term, livestock
producers were able to move to an effective production system
with lower antibiotic use (Wierup 2001).
Containing the Spread of Resistant Micro-organisms
Although selection is a necessary component of the resistance
archetype, the dissemination of resistant organisms may have a
far greater effect on the current situation (Zaidi and others 2003).
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Interventions that block this dissemination have the added ben-
efit of improving health by interrupting disease transmission
and reducing the need for antibiotics in the first place. A case in
point is the reduction in drug-resistant Streptococcus pneumoni-
ae infections in the United States following the introduction of a
multivalent vaccine that protected against the serovars with
which resistance is commonly associated (Whitney and others
2003). By contrast, a drop in antibiotic use had no detectable
effect on resistance within a short period (Arason and others
2002). Because these types of interventions are easier to evaluate,
and in many cases are cheaper to implement (Coast and others
2002), they are likely to be of great value to public health in devel-
oping countries.
Interventions that interfere with the spread of many infec-
tious diseases will have a parallel effect on the dissemination of
resistant micro-organisms. Because the potential health bene-
fits are obvious, these types of interventions are likely to be
sustained (Wilson and Chandler 1993). A simple, cost-effective
example is hand washing, which could reduce diarrhea by
47 percent while also having beneficial effects on acute
respiratory tract and other community-acquired infections
(Curtis and Cairncross 2003) (see chapters 19 and 35).
Similarly, insecticide-impregnated bednets are another impor-
tant intervention for the control of malaria (see chapter 21).
The emergence, persistence, and intra- and interhospital
spread of multidrug-resistant organisms have all been facilitated
by inadequate infection control practices. Furthermore, the
emergence and spread of drug-resistant nosocomial pathogens
from hospitals to the community are also a concern, and a
history of hospitalization has been identified as a signifi-
cant risk factor for the acquisition of a resistant infection in
family members (OR 4.5, p  0.007) (Zaidi and others 2003).
Unfortunately, we lack good clinical trials that compare the
different approaches to infection control programs and their
ability to control antimicrobial resistance in hospitals and other
health care facilities (Duse and Smego 1999). It seems reason-
able to assume, however, that if the overall frequency of noso-
comial infections is decreased in a health care facility, then the
need for antimicrobial agents may be reduced. Furthermore,
well-structured and rational infection control strategies that
balance resources with the magnitude of the local problem
must surely play an important role in decreasing morbidity,
mortality, and costs (direct and indirect) to the patient, his or
her family, the hospital, and the health care sector in general.
Hospital-acquired infections rank among the most important
causes of death, either directly or indirectly, in the developing
world (Duse and Smego 1999; Ponce-de-Leon and Rangel-
Frausto 1993).
Global Coordination
Antimicrobial resistance is a global challenge that requires
urgent global action, not just across national boundaries but
also across the whole range of sectors involved. International
travel and trade, particularly of food products, have facilitated
the rapid globalization of resistance, and actions undertaken by
any single nation have consequences for other countries. Drug
resistance may threaten health gains made in other spheres of
public health. Thus, coinfection with antimicrobial-resistant
pathogens and HIV can lead to more rapid disease progression
and enhanced dissemination of resistant pathogens. The emer-
gence of antimicrobial resistance is considered a major threat
to the future security and political stability of some regions
(CIA 1999). Figure 55.3 shows the likely geography of the
emergence, spread, and evolution of chloroquine resistance.
Concerted international action is needed to contain antimi-
crobial resistance. Failure of individual countries to act to
contain resistance could lead to both national and interna-
tional consequences. For instance, the use of artemisinin as
monotherapy in any single country could potentially lead to
the rapid evolution of resistant strains, which could threaten
the use of this valuable drug in any other part of the world.
There is a considerable need for greater international col-
laboration on surveillance of antimicrobial resistance, both for
routine surveillance and as an early warning system for unusual
resistance events. Although existing laws at the international
level require reporting of some infectious diseases, they do not
include any systematic reporting of antimicrobial resistance.
Certain multiresistant pathogens, such as methicillin-resistant
S. aureus, are now notifiable at the national level in some coun-
tries, but the global nature of the resistance problem means
that national legal measures alone are not enough. At the same
time, the creation of new international duties would be under-
mined if they were not incorporated into national law (Fidler
1998).
To support such surveillance, the World Health Organi-
zation makes software (WHONET) available to enable clinical
laboratories to enter their drug susceptibility test results into
databases that can be analyzed for local management of resist-
ance. Those results can also be merged, creating, thus far,
approximately 80 national surveillance databases. Statutory
notification about pathogens with new resistance phenotypes is
under active discussion in several countries. Interpretation of
existing surveillance data is hampered by the multiplicity
of methods used to measure resistance and by the difficulties of
assessing the quality of the data. Enhanced laboratory capacity
is needed in many countries to provide effective diagnostic
services and resistance surveillance. Multicountry external
quality assurance schemes already exist but need to be extended
to cover more resource-poor nations. WHO has begun estab-
lishing international surveillance standards by issuing antimi-
crobial resistance surveillance standards (WHO 2002a), guide-
lines for the management of drug-resistant tuberculosis (WHO
1997), and protocols for detection of antimicrobial drug resist-
ance (WHO 1996). Monitoring the use of antimicrobial agents
1042 | Disease Control Priorities in Developing Countries | Ramanan Laxminarayan, Zulfiqar A. Bhutta, Adriano Duse, and others
is an important aspect of surveillance and needs to be strength-
ened internationally.
Coordinated surveillance for drug resistance to TB may be
a useful prototype to follow. By 2003, a global network of 20
supranational reference laboratories and five regional subnet-
works, known as the World Health Organization–International
Union against Tuberculosis and Lung Disease (WHO–
IUATLD) Global Project, was reporting data on representative
cases of TB from 62 countries. The network has monitored par-
ticipants’ laboratory testing methods and developed uniform
definitions, such as establishing clinical categories for new cases
and previously treated cases. The WHO–IUATLD Global
Project, which covers approximately 33 percent of the world’s
population and 28 percent of its reported cases of TB, and other
surveillance efforts reveal great variations from place to place in
the prevalence of resistance to antituberculosis drugs.
The WHO Global Strategy for Containment of Anti-
microbial Resistance (WHO 2001) recommends more than 60
interventions that can slow the emergence and reduce the spread
of resistance in diverse settings, and it provides a blueprint for
global coordinated action. A recent report by the Institute of
Medicine calls for such coordinated action at a global level to
subsidize artemisinin-based combination treatments for
malaria for deployment in developing countries to ensure that
combination treatments are available at the same or lower price
than monotherapies. The underlying rationale is that this
strategy would both save lives in the short term and delay the
emergence of resistance in the long term, thereby benefiting all
malarious countries (Arrow, Panosian, and Gelband 2004).
Encouraging the Development of New Drugs
The development of new products has not kept pace with the
problem of addressing microbial resistance to drugs that are
used to treat infections in human and veterinary medicine. In
the context of drug resistance, it is not sufficient to design poli-
cies that will encourage only the development of new drugs. It
is also important that such policies give pharmaceutical firms
(a) an incentive to invest in new classes of drugs, rather than
products that belong to existing drug classes and that are,
therefore, more likely to be rendered obsolete by resistance,
and (b) an incentive to care about drug resistance when mak-
ing decisions about how to market and sell their product. (See
chapter 6 for a discussion of product development not specific
to drug resistance.)
Current public and private investment in drugs, vaccines,
and other products to control major infectious diseases in
developing countries has recently been less than 2 percent of
total health research expenditures throughout the world. Of the
1,393 new chemical entities registered by Western health
authorities between 1975 and 1999, only 13 (less than 1 percent)
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Figure 55.3 Global Spread of Chloroquine-Resistant Strains of P. falciparum
were intended for the treatment of tropical diseases, and half of
those came from veterinary research.
Evidence suggests that in recent years, a steadily decreasing
proportion of pharmaceutical company profits has been
invested in antimicrobial research and development (R&D).
One reason given for this decline is increased development
costs, which result from more complex clinical trials, longer
development times, and the relative attractiveness of returns
from investing in drugs for chronic diseases, which must be
taken continuously rather than just for the duration of an infec-
tion. Efforts to reduce inappropriate antibiotic use may para-
doxically also reduce incentives for pharmaceutical firms to
invest in developing new products (Monnet and Sorensen
2001; Philipson and Mechoulan 2003). The related issue, of
using shorter treatment courses for many infections, may also
affect R&D incentives (Pichichero and Cohen 1997).
Encouraging research into antimicrobial agents that will be
used primarily in low-resource countries poses particular chal-
lenges, given the need for drug companies to make a profit.
Various incentives to the industry, including both push and
pull mechanisms, have been discussed (Kettler 2000). Push
mechanisms consist of incentives to offset R&D costs, such as
research grants, tax credits, public investment in applied 
research, cost-sharing between companies, and establishment
of local development facilities. Pull mechanisms are designed to
create a market, thereby improving the likelihood of a return
on investments. They could include an international purchase
fund for a new antimicrobial that meets specific criteria
(United Kingdom Government 2001), tax credits on sales, and
favorable patent policies, such as extension of patent terms or
market exclusivity on new products. Time-limited exclusivities
on new, clinically useful formulations might stimulate the
additional pharmaceutical and clinical studies that are needed
to support licensure. Better patent protection for new anti-
microbial agents in areas of the world where patent laws are not
enforced today would also help.
Patent policies to encourage investment in developing new
antibiotics should also take into consideration the effect of those
policies on incentives that would encourage pharmaceutical
firms to conserve the effectiveness of their products. If effective
patent lengths are too short, pharmaceutical companies will be
less likely to care about growing drug resistance to their product
and will be more interested in maximizing sales of their prod-
ucts during the period of patent production. Extending patent
lengths may not solve the problem, however. If different firms
make closely related antibiotics that have linked mechanisms of
action, no single firm may have an incentive to care about drug
resistance (Laxminarayan 2002). Increasing patent breadth, one
solution to this problem, would have the added advantage
of creating an incentive for firms to invest in developing new
classes of drugs rather than introducing drugs that are closely
related to existing products in modes of action.
IMPLEMENTATION OF STRATEGIES:
TWO LESSONS FROM EXPERIENCE
Integrated Management of Childhood Illness
The program on the integrated management of infant and
childhood illness (IMCI) was initiated by WHO, the United
Nations Children’s Fund, and other technical partners. The
program, which provides a framework for stepwise assessment
and management of sick children, has been successful in avert-
ing unnecessary antibiotic and antimalarial use and in reduc-
ing the cost of medications (Gove 1997). An underlying objec-
tive of IMCI is to detect, where present, conditions other than
those responsible for the primary complaint. The result is that
rational prescribing may actually increase, but because IMCI
guidelines reduce irrational prescribing, the net effect is a
reduction in drug use, including antimicrobials (Oluwole,
Mason, and Costello 2000). Drug costs associated with treating
children in Kenya were found to be reduced from an average of
44 cents per patient (U.S. currency) to between 16 and 39 cents
per patient when IMCI guidelines were followed (Boulanger,
Lee, and Odhacha 1999). A study that compared prescriptions
arising from standard and IMCI-guided consultation with a
health worker in Kaduna state, Nigeria, found a reduction in
polypharmacy when IMCI guidelines were used, from a medi-
an of five drugs down to two drugs, and an 80 percent reduc-
tion in the cost of all medicines (Wammanda, Ejembi, and
Iorliam 2003). This reduction represented savings of 93.4 and
68.6 percent for antibacterials and antimalarials, respectively,
although part of the savings could be attributed to the substi-
tution of tablets for more expensive syrup formulations.
The contribution of IMCI to promoting judicious drug use is
worth noting. A study that compared four districts of Kenya—
two districts that had IMCI programs (Morogoro and Rufiji)
and two that did not (Ulanga and Kilombero)—found that in
73 percent (95 percent CI; 65–80) of consultations studied in the
IMCI intervention districts, a child needing an oral antibiotic or
antimalarial was prescribed correctly, compared with 35 percent
(95 percent CI; 25–45) in the control districts (Armstrong
Schellenberg and others 2004). Also, in the IMCI districts,
86 percent (95 percent CI; 80–92) of children who did not need
antibiotics left the facility without an antibiotic, compared with
57 percent (95 percent CI; 48–66) in the control district.
Directly Observed Therapy
Strict compliance and cure verification make it possible to con-
duct directly observed therapy using shorter-term regimens
(the DOTS program). Outpatient treatment of a single TB case
in Pakistan, with complete compliance, was recently estimated
at US$164 and increased to US$310 when an institution-based
DOTS program was applied (Khan and others 2002). In
Beijing, the cost of saving one disability-adjusted life year
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(DALY) is 10 times higher when a DOTS TB program is not
used (Xu, Jin, and Zhang 2000). Recent expansion of DOTS
care in India has resulted in savings of about 0.2 million lives
and US$400 million in indirect costs (Khatri and Frieden
2002). Progress with DOTS in India was initially slow, but
following better implementation, recent findings suggest that
huge successes have been made in the past five years. The suc-
cesses can largely be attributed to improved management of
the program, area-specific appraisals, infrastructure, personnel,
and technical support as well as continuous supervision
(Khatri and Frieden 2002). This model is one that may apply in
other developing countries.
In New York city, individualized chemotherapy based on
drug susceptibility testing was nearly as effective in new
patients with MDR-TB as in those with drug-susceptible TB
(Telzak and others 1995), and the number of MDR-TB cases
decreased by more than 90 percent within the decade (Fujiwara
and others 1997). The relatively large number of MDR-TB
cases in high-income countries made second-line drugs more
available and affordable, and experience in the management of
MDR-TB grew considerably over the past decade (Mukherjee
and others 2004). Yet questions remained about which inter-
ventions had led to the city’s success. In 1999, WHO created a
working group on DOTS-plus to assess the feasibility and cost-
effectiveness of treating MDR-TB in low- and middle-income
countries (Espinal and others 1999). DOTS-plus has already
negotiated a 90 percent price reduction from the pharmaceuti-
cal industry (Gupta and others 2001), and experience from
Peru suggests feasibility and a mean cost of US$211 per DALY
gained (Suarez and others 2002).
AGENDA FOR ACTION
Although the evolution of resistance is a biological phenome-
non, it is influenced strongly by the behavior of physicians,
patients, and hospital administrators. In the language of eco-
nomics, drug resistance is an externality associated with the use
of antibiotics—a consequence not taken into consideration
by those who use antibiotics or antimalarials. From a public
policy perspective, there may be an economic case for societal
intervention, because patients, physicians, and nations acting
on self-interest alone may produce a higher degree of drug
resistance than is ideal for society as a whole. From a global
perspective, there is a case for international coordination to
ensure that the actions of any single country or region do not
increase the likelihood of emergence of resistance, which could
then spread to other parts of the world.
Rising incomes in the developing world are likely to encour-
age greater use of Western medicine and, consequently, greater
use of antibiotics. Moreover, the adoption of government-
sponsored or employer-sponsored insurance plans in many
parts of the developing world could further increase drug use.
Because developing countries will be less able to bear the costs
of increasing resistance, it is important that the patterns of
overuse and misuse observed in high-income countries not be
repeated. The right financial incentives must be in place for
both patients and physicians to face the full cost of using
antibiotics and antimalarials and to ensure that these drugs are
not overused.
Recommended Interventions
Sets of interventions specific to the diseases discussed in this
chapter are described below.
Pneumococci. A number of affordable interventions can be
considered. Data suggest that hand washing can interrupt not
only the spread of pathogens causing diarrhea but also the
transmission of nosocomial pathogens, and it can reduce respi-
ratory infection–related mortality and morbidity. The promo-
tion of a culture of hand washing requires access to clean,
sufficient water—an urgent goal. Patient education to reduce
demand for antibiotics for viral infections, and alteration of
perverse incentives for physicians to prescribe antibiotics exces-
sively are recommended. Pneumococcal conjugate vaccine has
been shown to reduce the burden of antibiotic-resistant invasive
disease, reduce transmission of resistant strains, and reduce
antibiotic use in vaccine recipients and their siblings. Strategies
for introducing this type of vaccine into the high-risk popula-
tions of developing countries are urgently needed. Better
diagnostics are a key to more appropriate and focused prescrib-
ing, but their application is likely to be delayed in poor
countries. The long-term effects of blanket recommendations
for antimicrobial prophylaxis among HIV-infected populations
must be closely monitored.
Shigella. Interventions must include improved strategies for
case definition, clinical recognition, and appropriate therapy of
dysentery. These strategies require a focus on educating physi-
cians and caregivers as well as restrictions on over-the-counter
availability of antibiotics in developing countries. Recent
strategies for reducing antimicrobial prescribing for diarrhea at
the community level also include coadministration of zinc with
oral rehydration therapy. This strategy has been shown to lead
to significant reduction in antimicrobial prescribing for diar-
rhea in Bangladesh and may be a useful adjunctive strategy
(Baqui and others 2002).
Tuberculosis. The top priority must be the expansion of DOTS
(Iseman, Cohn, and Sbarbaro 1993), which itself can prevent
the emergence of MDR-TB (Dye and others 2002). In individ-
ual countries or parts of countries, however, additional strate-
gies may be appropriate. Pablos-Méndez, Gowda, and Frieden
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(2002) have grouped countries according to the proportion of
TB patients completing treatment successfully and the level of
MDR-TB among previously untreated patients. The resulting
matrix provides a reasonable framework for deciding whether
to use second-line drugs in a national program. Countries with
treatment success of less than 70 percent should introduce or
improve the DOTS strategy as the top priority. In settings with
primary MDR-TB of less than 1.5 percent, treating MDR-TB is
not a public health priority, although individual cases could be
referred to clinical experts. The hotspots—those areas with pri-
mary MDR levels above 5 percent—are international public
health emergencies. Infection control practices must be empha-
sized in such settings. Intermediate situations are ideal for addi-
tional research comparing DOTS with various individualized
regimens against MDR-TB.
Malaria. With declining effectiveness of chloroquine and
rapidly emerging resistance to its replacement, sulfadoxine-
pyrimethamine, it is imperative that significant attention be
paid not just to the choice of an appropriate first-line treatment
for malaria, but also to strategies to prolong the effective ther-
apeutic life of the new treatment. WHO has recommended that
new artemisinin derivatives be used only in combinations with
other drugs. There is evidence that artemisinin has already
found its way into shops as monotherapy; discouraging the use
of this valuable drug in monotherapy through public subsidies
for combinations, by mandate, or through a combination of
measures is a necessary first step. Discouraging the use of
artemisinin as monotherapy is not sufficient, however. It is also
important to ensure that the partner drug in the combination
used with the artemisinin derivative is effective and, hence, able
to protect the artemisinin. Therefore, discouraging the use of
the partner drug as monotherapy, except in cases in which no
safe alternative exists, such as for sulfadoxine-pyrimethamine
in intermittent preventive treatment of malaria in pregnant
women, is an important step in ensuring the long-term sus-
tainability of malaria treatment. Training shopkeepers and
other purveyors of antimalarial treatments to recognize symp-
toms of malaria and to use diagnostics to detect malaria would
help reduce malaria treatment to instances for which it is
appropriate and would reduce the likelihood of the emergence
of resistance. Finally, steps to reduce the burden of malaria
through the use of insecticide-treated bednets and, in some
areas, residual household spraying would help reduce the need
for antimalarial treatment and thereby reduce treatment selec-
tion pressure.
Research Agenda
A description of a research agenda to explain the full range of
issues related to drug resistance is outside the scope of this
chapter and has been accomplished by other groups. Here, we
restrict our focus to the following five priorities:
• accounting for attributable morbidity and mortality and the
economic burden of drug resistance in the developing world
• measuring the cost-effectiveness of interventions to im-
prove prescribing and patient compliance
• researching incentives for firms to invest both in developing
new drugs and in maintaining the effectiveness of existing
drugs
• identifying socioeconomic, demographic, and cultural fac-
tors that determine antibiotic use and misuse and projecting
how antibiotic use will change in future years
• designing international coordinating mechanisms for sur-
veillance to report resistance outbreaks and coordinate
strategies for appropriate drug use, recognizing the global
nature of drug resistance.
CONCLUSION
Modern medicine rests on the bedrock of effective anti-
infective drugs. Unfortunately, the use of drugs creates selective
pressure for resistance to arise, and thus, the growth of resist-
ance may be an unavoidable consequence of our actions in
treating disease. It is, however, important for governments to
intervene to ensure that the effectiveness of our current arsenal
of anti-infectives is not depleted at an excessively rapid rate.
Given the potential for international spillovers of resistant
pathogens and the ability of actions taken in one region or
nation to affect other parts of the world where a disease is
prevalent, a strong case can be made for coordinated interna-
tional action—similar to another urgent global situation, the
depletion of the ozone layer and the subsequent Montreal
Protocol to phase out the use of chlorofluorocarbons—to
manage the evolution of resistance.
Some interventions that we recommend, such as more
restrictive prescribing policies and the use of combinations,
could, in the absence of subsidies from the state, place a burden
on the poorest patients. For instance, an overly restrictive policy
on drug sales at the retail level could harm those who have less
access to formal medical care and prescriptions. There may be
similar effects from mandating that antimalarial drugs be sold in
combinations that the poor cannot afford. Efforts to manage
resistance should not be balanced on the backs of the poor, how-
ever, because the rationale for these efforts is that society as a
whole gains from them. It is important that state subsidies be
used to ensure that interventions to manage for resistance do not
reduce patients’ access to effective and affordable drugs.
Huge gains in life expectancy have come from the introduc-
tion of effective drugs to treat infectious diseases. Our history
of treating infections successfully is brief, however, and dates
back only 50 or 60 years. Sustaining this ability in the long term
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requires a willingness to invest in interventions both to extend
the therapeutic life of existing drugs and to discover and
develop new ones. Some of these interventions, such as better
infection control, introduction of affordable vaccines, and
proper dosing, would benefit patients immediately; others,
such as using combination treatments for malaria and invest-
ing in new drugs, may not bear fruit in the near term. Without
a sustainable, long-term vision of coexistence with harmful
microbes and imaginative solutions to the problem of resist-
ance, our ability to control infectious diseases stands in peril.
NOTE
1. The fitness cost of resistance is an evolutionary disadvantage placed
on resistant pathogens. However, some argue that although most
resistance-determining mutations engender some fitness cost, these costs
are likely to be ameliorated by subsequent compensatory mutations.
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Rapid improvements in health and nutrition in developing
countries may be ascribed to specific, deliberate, health- and
nutrition-related interventions and to changes in the underly-
ing social, economic, and health environments. This chapter
is concerned with the contribution of specific interventions,
while recognizing that improved living standards in the long
run provide the essential basis for improved health.
Consideration of the environment as the context for interven-
tions is crucial in determining their initiation and in modifying
their effect, and it must be taken into account when assessing
this effect.
Undoubtedly much change has stemmed from scientific
advances, immunization being a prominent case. However, the
organizational aspects of health and nutrition protection are
equally critical. In the past several decades, people’s contact
with trained workers has been instrumental in improving
health in developing countries. This factor applies particularly
to poor people in poor countries but is relevant everywhere;
indeed, it is a reason that social services have essentially elimi-
nated almost all occurrences of child malnutrition in Europe
(where, when malnourished children are seen, it is caused by
neglect).
Community-based programs under many circumstances
provide this crucial contact. Their role is partly in improving
access to technology and resources, but it is also important in
fostering behavior change and, more generally, in supporting
caring practices (Engle, Bentley, and Pelto 2000; UNICEF
1990). Such programs may also play a part in mobilizing social
demand for services and in generating pressure for policy
change.
In community-based programs, workers—often volunteers
and part-time workers—interact with households to protect
their health and nutrition and to facilitate access to treatment
of sickness. Mothers and children are the primary focus, but
others in the household should participate. Commonly, people
go regularly to a central point in their community—for exam-
ple, for growth monitoring and promotion—or are visited at
home by a health and nutrition worker. The existence, training,
support, and supervision of the community worker—based in
the community or operating from a nearby health facility—are
indispensable features of these programs. Thus community
organizations are a key aspect of community-based health and
nutrition programs (CHNPs).
This chapter focuses on large-scale (national or state) pro-
grams. Although these programs are primarily initiated and
run at the local level, links with the national level and levels in
between are necessary. Both horizontal and vertical organiza-
tions are needed. Local organizations make action happen, but
they need input and resources, such as training, supervision,
and supplies, from more central levels.
The experience on which this chapter is based comes from a
considerable number of national and large-scale programs.
Most of these programs include both nutrition and health
activities, aimed particularly at the health and survival of
reproductive-age women and children. We draw on these expe-
riences as we try to put forward principles on which future pro-
grams can be based—programs that may have broader health
objectives for other population groups and diseases.
As of 2001, some 19 percent of global deaths were among
children—and 99 percent of all child deaths took place in 
low- and middle-income countries. The disability-adjusted life
years (DALYs) lost attributed to zero- to four-year-olds—plus
maternal and perinatal conditions, nutrition deficiencies, and
endocrine disorders—amount to 42 percent of the total disease
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burden (all ages, both sexes) from all causes for developing
regions. CHNPs address about 40 percent of the disease bur-
den. In terms of prevention, Mason, Musgrove, and Habicht
(2003) estimated that eliminating malnutrition would remove
one-third of the global disease burden. Comparative studies by
Ezzati, Lopez, and others (2002) and Ezzati, Vander Hoorn, and
others (2003) have reemphasized malnutrition as the predom-
inant risk factor and improvement of nutrition as playing
a potentially major role in reducing the burden. Clinical
deficiencies contribute directly to malnutrition, but even more,
malnutrition is a risk factor for infectious diseases (table 56.1).
Furthermore, changes in child malnutrition levels in develop-
ing countries are closely related to the countries’ mortality
trends (Pelletier and Frongillo 2003).
Dealing with women and children’s health and nutrition
addresses a substantial part of global health problems.
Moreover, the experience of community-based programs linked
to nutrition constitutes a significant part of the body of knowl-
edge on ways of improving it.A number of large-scale, sustained
health interventions, such as those described by Sanders and
Chopra (2004), use a mix of improved access to facilities and
community health workers. These interventions include the
Comprehensive Rural Health Project, Jamkhed, India; com-
munity health projects in Brazil (Ceará, Pelotas); and the work
of the Bangladesh Rural Advancement Committee (BRAC).
Table 56.2 describes the program experiences drawn on.
The evidence is clear that significant differences occur
between countries in the rates of change in health and nutri-
tional status. Figure 56.1 shows a comparison of Indonesia, the
Philippines, and Thailand. As is common, the indicator used is
underweight children, which is likely to reflect broader condi-
tions of health and survival. For Thailand, the figure shows the
now-well-known rapid improvement in the 1980s and 1990s.
For Indonesia, it shows slower but consistent improvement.
The Philippines had little progress until recently, and the start
of an improving trend coincided with increases in the number
of village health workers and implementation of high-coverage
interventions such as iodized salt and vitamin A supplementa-
tion (FNRI 2004). A crucial issue is how much of the improve-
ments was caused by interventions that could be replicated—
and within that issue is subsumed how much was because of
context, how much was programmatic, and what were the
interactions. The contrasts between these three countries are
instructive in part because they have several similar contextual
factors; for instance, the status of women is relatively good, and
social exclusion1 is not extensive (compare both of these in, for
example, South Asia). Thus programs may account for a signif-
icant part of the differences seen in improvement.
The benefits from CHNPs extend well beyond child nutri-
tion (which is used as a summary measure). These benefits
have not been quantified but would include improved educa-
bility (see chapter 49) and probably increased earning capacity
associated with it and with physical fitness.
WHAT IS KNOWN ABOUT EFFICACY
AND EFFECTIVENESS 
The efficacy of health and nutrition interventions in develop-
ing countries has been established for decades (for example,
Gwatkin, Wilcox, and Wray 1980). Prospective studies in sev-
eral settings showed that health interventions with or without
supplementary foods caused children to thrive and survive
better: studies in Narangwal, India (Kielmann and others 1978;
Taylor, Kielmann, and Parker 1978); by the Institute for
Nutrition for Central America and Panama (Delgado and
others 1982); in Jamaica (Waterlow 1992); and in The Gambia
(Whitehead, Rowland, and Cole 1976) are examples.2 These
studies showed the effect of interventions on growth and (usu-
ally) mortality but did not generally factor out the relative con-
tributions of health and nutrition. In fact, results from
Narangwal showed similar mortality effects from food or health
care; results from The Gambia indicated interaction such that
sick children did not grow even with adequate food intake
(appetite also playing an important role), and well children did
not grow with inadequate food intake (Gillespie and Mason
1991, annex 2).
By the early 1980s, the conclusion, based on data at the
experimental level (not from routine large-scale programs),
was that better health and better nutrition are both required for
child survival and development. This conclusion remains gen-
erally agreed on today; furthermore, concern exists that health
interventions may become less effective unless nutrition is con-
currently addressed (Measham and Chatterjee 1999; Pelletier
and Frongillo 2003). In their chapter on malnutrition in the
first edition of this book, Pinstrup-Andersen and colleagues
(1993) drew largely on efficacy findings, with an emphasis on
food supplementation. Those studies are not revisited here, but
we can continue to build on their conclusions.
The efficacy studies were followed by a number of national
or other large-scale programs in several countries. Some of
those were a direct follow-on; for example, the World Bank
Tamil Nadu Integrated Nutrition Program (TINP) followed the
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Table 56.1 Estimated Contributions to the Disease Burden in
Developing Countries
DALYs lost (percentage)
Factor Direct effect As risk factor Total
General malnutrition 1.0 14.0 15.0
Micronutrient deficiencies 9.0 8.5 17.5
Total 10.0 22.5 32.5
Source: Mason, Musgrove, and Habicht 2003, table 10.
Narangwal study, which was supported by the U.S. Agency for
International Development (USAID). A number of overviews
and analyses of these programs have been conducted—for
example, Allen and Gillespie (2001); Berg (1981, 1987);
Gillespie, Mason, and Martorell (1996; includes a summary of
overviews, 60); Gillespie, McLachlan, and Shrimpton (2003);
Jennings and others (1991); Mason (2000); Sanders (1999); and
Shrimpton (1989). These plus some newer examples provide
case studies for this chapter, and the sources for the case stud-
ies are included in table 56.2.
Underweight prevalences are improving at about 0.5 per-
centage points (ppts) per year except in Sub-Saharan Africa,
which is largely static (ACC/SCN 1989, 1992, 1996, 1998,
2004). Programs are needed to accelerate this trend. Cost data
from an earlier study (Gillespie and Mason 1991, 76), com-
bined with the estimated improvements from large-scale
programs, led to the assertion that “there seems to be some
convergence on around $5 to $10 per head (beneficiary) per
year being a workable, common level of expenditure in nutri-
tion programmes, though not generally including supplemen-
tary food costs . . . effective programmes, with these levels of
expenditure, seem to be associated with reducing underweight
prevalences by around 1–2 percentage points per year”
(Gillespie, Mason, and Martorell 1996, 69–70).
A further important consideration is that the effect is likely
to be nonlinearly related to the expenditure, showing the famil-
iar dose-response S-shaped curve. Thus, the first expenditures
produce little effect on the outcome, and one needs a minimum
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Table 56.2 Country Experiences in Community-Based Programs 
Country and program Program experience 
Africa
Tanzania: Iringa
Tanzania: Child Survival and
Development Program
Zimbabwe: Supplementary
Feeding Programme
Asia
Bangladesh: Bangladesh
Integrated Nutrition Program
and national
Bangladesh: Bangladesh Rural
Advancement Committee 
India: Integrated Child
Development Services 
India: Tamil Nadu Integrated
Nutrition Program
Indonesia
Philippines: national
Thailand
Americas
Costa Rica
Jamaica 
Nicaragua
Area program with UNICEF and WHO inputs, 1984–91. After rapid initial drop in child malnutrition, moderate steady
improvement. Program not sustained.
1985–95, World Bank support. Results similar to Iringa.
Wide-scale program following independence, 1980–90; infant mortality rate (IMR) dropped from 110 to 53 (1988). Not sustained.
BINP: area targeted covering 7 percent of population. Rapid improvement at start (1997); final evaluation not seen.
National: program coverage expanding from 2000 on. Substantial improvement in anemia and child underweight seen in
Bangladesh starting 1995.
Community-based health services with village health workers. Wide coverage since 1980s; particular focus on diarrhea.
Implemented since 1976. Village program with community health (anganwadi ) worker. Accelerated improvement reported in
some states.
Implemented 1980 to mid 1990s. Village program in Tamil Nadu with World Bank support; growth monitoring, supplementary
feeding, and so on. Substantial improvement in underweight reported.
Massive expansion of village programs 1975–90, covering all villages by 1990. Steady decrease in underweight during this
time. Program not sustained in 1990s; now planned to restart.
No wide CHNPs despite national decree in 1974. No significant improvement in child nutrition.
National program from late 1970s; 600,000 village health volunteers trained (1 percent of population). Rapid improvement
1980–90; for example, 36 percent to 13 percent underweight children.
Expanding rural health services from 1970s following malaria control. Rapid fall in IMR, 1965–80; in stunting, 1979–89.
Expanded health services with community health aides from mid 1970s. Rapid fall in underweight, 1985–89.
Community health movement, 1979–90, reduced IMR, eliminated polio; about 1 percent of population as village health volunteers.
Source: Authors, from data derived as follows: Tanzania—Gillespie and Mason 1991; Gillespie, Mason, and Martorell 1996; Jennings and others 1991, 117; Kavishe and Mushi 1993; Pelletier 1991;
Sanders 1999; Zimbabwe—Sanders 1999; Tagwireyi and Greiner 1994; Werner and Sanders 1997; Bangladesh—BINP and UNICEF 1999; BRAC 2004; Chowdhury 2003; INFS and Department of
Economics, University of Dhaka 1998; Mason and others 1999, 2001; Save the Children U.K. 2003; India—Administrative Staff College of India 1997; Mason and others 1999, 2001; Measham and
Chatterjee 1999; Reddy and others 1992; Shekar 1989; Indonesia—Berg 1987; Jennings and others 1991, 108; Rohde 1993; Soekirman and others 1992; the Philippines—Guillermo-Tuazon and Briones
1997; Heaver and Hunt 1995; Heaver and Mason 2000; Mason 2003; Thailand—Kachondam, Winichagoon, and Tontisirin 1992; Tontisirin and Winichagoon 1999; Winichagoon and others 1992; Costa
Rica—Horwitz 1987; Jennings and others 1991, 77–81; Muñoz and Scrimshaw 1995; Honduras—Fiedler 2003; Jamaica—ACC/SCN 1989, 1996; P. Samuda personal communication, 2004; Robinson per-
sonal communication, 2004; Nicaragua—Sanders 1985; Werner and Sanders 1997. 
input level of resource use before a worthwhile response is
achieved (Habicht, Mason, and Tabatabai 1984). This factor
generally applies to drawing inferences from cost-effectiveness
ratios, which often assume linearity. If the relation is S-shaped,
the implication is important: applying too few resources does
not simply solve the problem more slowly but does not solve it
at all and is a waste. Therefore, program intensity (resources
per person) is a critical measure.
Effective interventions must include a range of activities
relating to health and nutrition. They should be multifaceted,
not just for effectiveness but also for organizational efficiency.
The structure needed for community-based programs could
never make sense or be sustainably set up for single interventions
alone. One often-argued case (for example, by Save the Children
U.K. 2003) concerns children’s growth monitoring: evidently
growth monitoring in isolation from activities that improve chil-
dren’s growth is not going to achieve anything (or worse, con-
sidering the opportunity cost); however, weighing children and
charting their weight can be a useful part of broader programs
(for example, as growth monitoring and promotion).
COMMUNITY- AND FACILITY-BASED PROGRAMS 
Protecting and improving health, especially in poor communi-
ties, requires a combination of community- and facility-based
activities, with support from central levels of organization, as
well as some centrally run programs (for example, food fortifi-
cation). The place of these activities in a strategy is likely to
vary, depending on level of development (of infrastructure,
health services, and socioeconomic status) and on many local
factors. For the poorest societies, the first priorities are basic
preventive services, notably immunization, access to basic
drugs, and management of the most serious threats to health,
such as some access to emergency care. Moving up the devel-
opment scale, starting community-based activities may soon
become cost effective for prevention, referral, and management
of some diseases (notably diarrhea) when coverage of health
services is poor. Community-based programs continue to play
a key role until health services, education, income, and com-
munications have improved to the point that maternal and
child mortality has fallen substantially and malnutrition is
much reduced; at this intermediate development level, the
needs are less felt, and health services again take on a more
prominent role. In this scheme, the widely felt need for better
access to emergency obstetric services is problematic, requiring
a well-developed human and physical infrastructure, yet
arguably being one of the highest priorities.
Facility-based programs can be seen either as linking with
the community program (referrals, home visits from clinics,
and so forth) or as actually being part of the same enterprise. A
distinction is that community-based activities take place out-
side the health facility, in the home or at a community central
point, even if they may be supported by health personnel based
in health facilities. The local workers in community-based pro-
grams may be drawn from the community itself, may be home
visitors from a health center or clinic, or may sometimes be vol-
unteers supervised by these home visitors. Many community-
based programs come under the health sector, whatever the
exact arrangements with local health services. Regarding spe-
cific program components, we return to the relative role of
community programs and facilities later.
The integrated management of infant and childhood illness
(IMCI) program provides guidance mainly on the curative
health aspects and contains a number of nutrition activities
(for example, administration of vitamin A capsules). Links to
local health facilities are essential for the maintenance of the
community activities and for referral in cases of illness (see
chapter 63). As the IMCI training and implementation pro-
gresses, it should integrate directly with CHNPs (in fact,
become part of the same exercise), which will add treatment of
additional diseases. IMCI addresses diarrhea, acute respiratory
infection (ARI), malaria, nutrition, immunization, safe moth-
erhood, and essential drugs (WHO 1997). The 16 key practices
for child survival defined in the context of IMCI (Kelley and
Black 2001, S115) are exactly those to be promoted within
CHNPs, and most are already included (four are nutritional).
Decentralization should be considered in this context.
Although decentralized systems might be thought to be more
effective in supporting CHNPs, the evidence for this assump-
tion is scarce. Decentralization can reduce resources available at
the local level if it involves devolving responsibility without the
concomitant budgetary resources (Mills 1994). For example, in
Kenya, decentralization did not accompany devolving authority
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Figure 56.1 Comparison of Trends in Underweight Children in
Indonesia, the Philippines, and Thailand
for raising revenue locally. In other cases (for example, the
Philippines), decentralization has involved a shifting of
resources, but with priorities set in the local government units
by locally elected officials (municipal and city mayors), these
resources may be used for shorter-term priorities than under
previous, centrally decided, policies.
SUCCESS FACTORS
A number of useful concepts grew in the 1990s in relation to
effective community-based programs. The concept of success
factors helped sort out complex interactions: when numerous
possibilities exist, understanding the successful pathway to
effectiveness is more important than trying to disentangle what
did not work. Focusing on successful programs helps simplify
complexity and identify success factors, only some of which are
programmatic (directly under the influence of the intervention
itself); others are contextual.
The importance of context, within which programs are ini-
tiated and run, thus emerged as crucial, and priority factors
were proposed from studies of community-based programs in
Asia (Gillespie, Mason, and Martorell 1996, 67; Jonsson 1997).
Sanders (1999) described similar concepts under the headings
of community participation and political will. This distinction
and interplay between context and program factors is helpful in
identifying required supporting policies to improve the context
to make programs work. Details are in the later section titled
“Contextual Factors.”
An overall framework (figure 56.2) for causal links to child
survival and nutrition, put forward by the United Nations
Children’s Fund (UNICEF 1990), gave a basis for a common
language—even if the details might be questioned—revolving
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Figure 56.2 Conceptual Framework for the Causes of Malnutrition in Society
around food, health, and care as proximal causes to be addressed
through programs. Improving these factors attacks hunger, dis-
ease, and neglect, which are the converse of food, health, and
care. Basic causes are, like context, open to influence through
policy decisions and acting through directly influencing food,
health, and care and by modifying the effect of programs. Here
malnutrition is seen as the outcome of processes in society, and
direct interventions are seen as both shortcutting the needed
basic improvements in living conditions and being dependent
on these improvements in the long run for sustainability.
COMMUNITY-BASED PROGRAMS—WHAT
ARE THEY?
Community health and nutrition programs are often initiated
and run by the health sector, but sometimes a separate ministry
(for example, in India and Indonesia) or service (for example,
in Bangladesh) is set up. Attempts to use a national coordinat-
ing body appear to be less effective in leading to widespread
community programs; an example existed in the Philippines
until approximately 2000 (Heaver and Mason 2000). This inef-
fectiveness stems from the tendency of the coordinating body
not to have direct authority over fieldworkers or the budget to
create a national program with sufficient coverage and intensity
to have a measurable effect. In some other cases, the services
linked to poverty alleviation and social welfare programs can
play this role (for example, the Samurdhi program in Sri
Lanka). Involvement of the health services remains crucial,
sometimes as the operational agency responsible for the pro-
grams and certainly always for referral.
CHNPs have so far been much more relevant to communi-
cable diseases than to noncommunicable diseases in conditions
of poverty and where undernutrition is common. (An excep-
tion occurs if CHNPs help prevent intrauterine growth
retardation with later risks of noncommunicable diseases.)
However, in areas where diet-related chronic diseases are
developing in conditions of poverty (for example, much of
Latin America and the Caribbean) and obesity is rising rapidly,
the promotion of behavior change through counseling in
CHNPs may become increasingly important. Promoting
healthier diets requires access to outlets for fruit and vegetables,
often displaced by fast foods, which should be a concern of
community activities, as should lifestyle improvements such as
use of exercise and recreational facilities.
CHNPs often include activities well beyond direct preven-
tion and behavior change. As envisaged with primary health
care, water, sanitation, and other aspects of environmental
health are frequently included, as well as agricultural interven-
tions (for example, Zimbabwe in the 1980s). In Thailand, the
village programs are part of the “Basic Minimum Needs”
approach, which includes housing and environment, family
planning, community participation, and spiritual and ethical
development.
A diagram of the structure, derived from Thailand’s program
(figure 56.3), shows the relations between services that provide
supervision and contacts with the community (“facilitators”)
and with community workers, referred to as “mobilizers.”
The activities undertaken in CHNPs—the program
content—are familiar and are described here only briefly.
Program components, implemented by village workers or in
facilities, come under the following headings, which form a
menu, with the actual mix depending on local capabilities and
conditions (UNICEF 1998, 84; see chapter 24):
• Prenatal care includes checking weight gain in pregnancy,
prepregnancy weight, anemia, and blood pressure;
providing multiple micronutrient supplementation and
immunization (tetanus); counseling on diet, workload,
breastfeeding; and predicting and arranging for delivery.
• Women’s health and nutrition entails counseling on health
and nutrition and checkups, promoting improved status
and resource allocation in home and outside, promoting
improved access to health services, and often offering
family-planning services (these services may even be an
initiating factor for CHNPs, for example, in Indonesia).
• Breastfeeding includes providing knowledge on practices (ini-
tial, exclusive, continued); arranging mutual support; build-
ing confidence; preventing misinformation and undermin-
ing factors; facilitating time for breastfeeding; and providing
information along the lines of the infant formula code.
• Complementary feeding includes providing knowledge and
counseling (timing of introduction, type, energy density,
frequency, and so on); sometimes promoting village or
urban area production of weaning foods; sometimes
marketing inexpensive food; facilitating mother’s time allo-
cation; and promoting technology—storage, preservation,
hygiene methods (fermentation, even refrigerators).
• Growth monitoring and promotion requires equipment
(scales, charts, manuals); training and supervision; needs
training of weigher to interpret charts and counsel mother;
and a referral system for problems (for treatment, counsel-
ing, or other preventive intervention if growth is faltering).
Weighing at birth and monthly weighing should be
included, if possible, and adequate weight gain (rather than
achieved weight or any gain) should be used for guidance on
counseling or other intervention.
• Micronutrient supplementation should include vitamin A
for nonpregnant and pregnant women (low dose weekly,
preferably as part of multinutrients); for women within one
month of delivery (massive dose to protect infant through
breast milk); for infants and children (massive dose at nine
months immunization contact and thereafter every six
months and when medically indicated). It should also
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include vitamin A—daily or weekly, with immunization
campaigns, and so forth—and iron—daily or weekly for
women (especially during pregnancy) as well as for children
and adolescents. Iron is usually provided together with folic
acid and may also be provided as part of multiple micronu-
trient supplementation. Iodine is usually provided by forti-
fication and can be an infrequent (six-monthly) oral sup-
plement, if necessary, but it should be part of multiple
micronutrients for pregnancy.
• Micronutrient fortification is not usually included locally,
although it is an important central program, but local mon-
itoring is a coming opportunity, especially of iodized salt
testing kits.
• Supplementary feeding, using external supplies may some-
times be appropriate in emergencies and in conditions of
extreme poverty (for example, the Bangladesh Integrated
Nutrition Program, or BINP), providing 200 to 500 kilo-
calories per person per day, but otherwise it is to be avoided
as costly, with high opportunity cost, and not very effective;
moreover, it can distort programs, which come to be seen
largely as a source of free food.
• Supplementary feeding, using local supplies can be useful for
complementary feeding (weaning) if carefully organized
(which requires some resources). Village community pro-
duction and processing are useful, if feasible (for example,
in Zimbabwe), and the system can move to coupon method
(for example, in Thailand).
• Oral rehydration includes highly effective local preparations
for dehydration in acute diarrhea, as well as (or better than)
oral rehydration salts. These preparations require counsel-
ing of mothers and take a lot of parents’ time. Persistent
diarrhea requires other intervention, especially nutritional.
Care of children during sickness—especially continued
breastfeeding and other foods—needs to be stressed
(applies also to other illnesses).
• Immunization includes informing, referring, and facilitating.
• Deworming requires distribution and dosage supervision of
mebendazole every few months, a highly effective nutrition
intervention. Distribution methods are an issue.
The relative suitability of community- and facility-based
operations for the different components again depends on
local conditions, and these operations should be complemen-
tary. Community activities are essential for infant and child
feeding, other caring practices, environmental sanitation, and
the like. Facilities have a key role in immunization, prenatal
care, and—of course—referral for treatment. Growth monitor-
ing, micronutrient interventions, oral rehydration, and similar
activities may be focused in either. Because it has more regular
contact with clients, a community-based program may be
more effective in actually reaching mothers and children with
the component interventions than one that is facility based.
Box 56.1 compares two programs in Honduras that offered the
same content but differed in where the programs were based.
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Figure 56.3 General Structure for Community-Based Programs, Based on Thailand’s Program
PROGRAMMATIC FACTORS
Programmatic factors are considered first in terms of the char-
acteristics of the activities—their population coverage and tar-
geting, how much resources are applied per head (intensity),
and the technologies used. Then the needs for initiating and
sustaining these activities are discussed—the training needs,
supervision methods, and (importantly) incentives and remu-
neration for field workers.
Coverage, Targeting, Resource Intensity, and Technology
Even effective programs improve the health and nutrition only
of those they reach, so achieving as complete coverage as
possible of those at risk is a major determinant of the effect.
Although variations in the content of programs are seen in
different circumstances, most activities are common to most
programs. Variations in effect stem from factors such as cover-
age and adequacy of resources. How have CHNPs fared in
reaching large sections of the population with adequate
resources—and, indeed, what is the gap that would need to be
filled? The achievements of the 14 programs drawn on here as
case studies are summarized in table 56.3.
The programs expanded to include most of the communi-
ties within the areas targeted. The common evolution was to
target select areas and specific biological groups within those
areas—generally women and children—but not to give priority
to any great extent to poorer or less healthy communities.
Screening is sometimes done of individuals for admittance into
the programs (a form of targeting), based on nutritional status,
as in growth monitoring and promotion, as well as on a one-
time basis (for example, thin children in Zimbabwe). Recent
thinking suggests that because mortality risk, growth failure,
and morbidity are concentrated in children less than two or
three years of age, in contrast to an earlier focus on children
under five, these younger children should increasingly be a
focus of CHNPs. A common policy observed in practice, there-
fore, is to aim for complete coverage within the areas partici-
pating, adding new sites until the entire region is covered.
Relatively untargeted expansion to universal coverage may have
been at the expense of establishing adequate resources and
quality in the areas initially covered. In at least one case
(Thailand), having achieved broad coverage and reduced mal-
nutrition, the program became more targeted to areas in which
progress was lagging. The coverage figures in table 56.3,
although approximate, demonstrate considerable success in
initiating and implementing CHNPs on a large scale—usually
enough to have a substantial effect if the other factors needed
for success were met.
How complete a coverage of the population should one rec-
ommend? This factor relates to targeting, to the additional
resource requirements to reach the nonparticipants, and to
their level of risk. Usually risk is spread throughout the popu-
lation, although the extent varies considerably—at least a
doubling of indicators of risk is usually seen between better-
and worse-off areas or groups (for example, see Mason and
others 2001, figures 1.4–1.7, 1.10–1.13). The remoter areas—or
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Differential Effectiveness of Community- and Facility-Based Programs
Box 56.1
Effectiveness is more likely to be possible through
community-based programs because contact with care-
givers is typically more frequent and consistent. For ex-
ample, 83 percent of children enrolled in a community-
based growth monitoring and promotion program in
Honduras (Atención Integral a la Niñez Comunitaria, or
AIN-C) were weighed two or more times in a given
three-month period, whereas only 70 percent of children
were weighed with the same frequency in a facility-based
program. Workers visited 30 percent of mothers partici-
pating in the community program in their homes at least
once for follow-up when their children were sick, were
not growing, or had missed a weighing session.
Controlling for a range of maternal and socioeconomic
factors, researchers found that children 6 to 24 months of
age participating in the community-based program were
1.6 times more likely to be appropriately fed than were
children not enrolled in growth monitoring and promo-
tion. Children participating in the community program
also were more likely to have received vitamin A and iron
supplements than children participating in the facility-
based program. Results show that consistent participa-
tion in the community-based program was associated
with better weight for age. When a range of maternal and
socioeconomic factors were taken into account, children
participating fully in the community program were
435 grams heavier than children who were enrolled but
participated infrequently. In the facility-based program,
there was little difference in weight for children based on
levels of participation.
Source: Plowman and others 2002.
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Table 56.3 Characteristics of Selected Programs 
Country Coverage, targeting Resources, intensity
Africa
Tanzania: Iringa 
F: ()
Tanzania: Child Survival
and Development Program
F: 0
Zimbabwe: Supplementary
Feeding Programme
F: 
Asia
Bangladesh: BINP 
F: 
Bangladesh: BRAC
India: ICDS 
F: /
India: TINP
F: 
Indonesia
F: ()
Philippines: national
F: 0
Thailand: Primary Health
Care  Poverty Alleviation
Program  Basic Minimum
Needs 
F: ()
Population served  250,000 in 6 districts, 610
villages, 46,000 children, of which 33,700 par-
ticipated (73 percent). Targeting: children  5
years and women; no socioeconomic selection
of communities. Progressed from 168 to 610
villages 1984–88.
9 of 20 regions (population total approximately
12 million; 2 million children). Aimed for com-
plete coverage.
Population served: 56,000–96,000 with supple-
mentary feeding; up to 60 percent of all chil-
dren in community-based growth monitoring.
BINP: in 6 thanas, or subdistricts (7 percent of
population), children  2 years, 8 million preg-
nant and lactating women.
Health coverage 25 percent. Nutrition with
BINP, now expanding.
Children 0–6 years and pregnant and lactating
women, in 3,900 of 5,300 blocks, or subdis-
tricts; approximately 74 percent of population.
Coverage expanded without targeting except
by area.
Children 6–36 months, pregnant and lactating
women. Children with growth failure selected.
40 percent of blocks in Tamil Nadu; 20 percent
of children in 1990.
By 1990, 60,000 villages (of 65,000: 92 per-
cent) had posyandus (village health/nutrition
center). Women and young children.
Several programs, all targeted (for example, to
poorer areas), none with national coverage.
Expanded over about 5 years to cover 95 per-
cent of villages. 600,000 village health commu-
nicators (1 percent of population) trained;
60,000 village health volunteers.
US$8 to US$17/child/year (approximately US$30/child/year from total costs:
approximately US$6 million) 
2 village health workers/village  1,220 total; approximately 1:40 children 
[Volunteers]
US$2 to US$3/child/year 
[Volunteers]
External: US$3 million over 10 years 
For example, 1990, US$0.5 million, approximately US$0.50/child/year
(Approximately 1:10–200, based on numbers per project)
[Extension agents]
US$14 million/year; approximately US$18/child/year 
1 community worker per 1,000 population
Approximately 1:200 children
[Project supported]
1 community health volunteer per 300 households; 1 community nutrition
promoter per 200 households; community nutrition centers, 1:120 mothers and
children; supervision of community nutrition promoters by community nutrition
organizer, 1:10
Nonfood costs: approximately US$2/child/year.
1 community worker (anganwadi worker, or ANW) per 200 children; 
1 supervisor per 20 ANWs
[ANW paid, at low rate]
US$9/child/year, plus approximately US$3 on food. 
1 community nutrition worker per 300 children; 1 supervisor per 
10 community nutrition workers
[Project supported]
US$2–11/child/year, depending on supplemental food; Rohde (1993) gives
 US$1 recurrent.
Village workers (approximately 3 million total), 1 per 60 people, approximately
1 per 10 children; supervision 1 per 200.
[Volunteer]
US$0.40/child/year in targeted areas.
Village workers (barangay nutrition scholars) approximately 1:300 
[Low allowance given]
Ministry of Public Health; approximately US$11/head/year (1990)
1 village health communicator or volunteer per approximately 20 children;
1 supervision extension worker per 24 village health communicators and
volunteers
[Volunteer]
(Continues on the following page.)
groups that are hard to include for other reasons—may be
more expensive to reach. Clearly the calculations depend on
conditions and have to be made on a case-by-case basis. The
principle is obvious: only those areas and people included in
CHNPs are going to benefit; so wherever need exists, programs
are indicated. The implementation strategy, in theory, may
need to begin with the most urgent needs, although in practice,
programs may expand from the easier, more accessible areas;
this practice seems reasonable, provided that the expansion
really occurs and leads to equitable use of resources.
The program content is a mix of the components described
earlier, varying with local priorities. The most crucial difference
is whether extensive supplementary feeding is included. In
middle-income countries, supplementary feeding was less
prominent, often considered unnecessary, and because expen-
sive, perhaps counterproductive (for example, in Costa Rica;
Mata 1991). At the other extreme, such as for the Integrated
Child Development Services (ICDS) in India, food distribution
became the raison d’être of the program but, alone, was again
probably not worthwhile. For some of the intermediate cases,
supplementary food played a supporting role, with varying
results. Except in the very poorest societies, supplementary
feeding seems unlikely to be cost-effective.
The resources used for the programs found in table 56.3 can
be expressed per participant (referred to as intensity), as total
expenditures, and in terms of personnel; the latter figures may
be more generalizable. (The outcomes associated with these
resources are shown in table 56.5.) Data such as these have been
the basis for estimating that US$5 to US$10 per child per year
may be needed for effective programs. The dollar figures vary
from less than US$1 to more than US$20. Probably the low end
of this range (say, less than US$1 per child per year) does explain
low or doubtful effect. Both low coverage and low intensity
may explain the unchanged underweight prevalences in the
Philippines until 2000. Fund levels in Indonesia are unsure;
Rohde (1993) gave a figure of less than US$1, but others gave
higher estimates. Most would reckon the intensity in India too
low (Measham and Chatterjee 1999) at about US$2 per child
per year. Looked at otherwise, the intensity planned for external
funding (even if part of such funding is international costs) is in
the US$10 to US$20 range (Bangladesh, India—Tamil Nadu,
and Tanzania) and is the same as the estimate for Thailand. A
level of US$10 to US$20 per participant per year is probably
advisable for planning and sustaining effective programs.
The intensity measures of workers per mother-child and the
supervision ratios are relevant in assessing needs. The sug-
gested norms, originating from the Thai experience are 1:10–20
for both. Since then, it has emerged that the full-time equiva-
lence of community workers must be taken into account; the
Thai workers are local volunteers, probably devoting 10 to
20 percent of their time. In Honduras, Fiedler (2003) in a care-
ful cost study estimated that each volunteer spent 3.5 hours per
week (less than 10 percent of full-time equivalent, or FTE),
with a ratio of 1 volunteer to 8 children. The ratio of commu-
nity health and nutrition workers (CHNWs) to children may,
therefore, be as low as 1:200 for FTEs and as high as 1:8 or 1:10
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Table 56.3 Continued
Country Coverage, targeting Resources, intensity
Americas
Costa Rica
F:  to 0
Honduras
F: 0
Jamaica
F: 0
Nicaragua
F: 0
Expanded rural health program coverage 
19–67 percent (1974–89).
With community health volunteers, AIN-C
covers  50 percent of health areas (expanded
1991 on),  90 percent of children  2 years
in these; growth monitoring and home follow-
up, plus referral and treatment.
Community health aides (CHAs), waged, cover
most of country from health centers, with
home visiting.
Community health workers (brigadistas) with
“multiplier” approach, training others; 1980
approximately 1 percent trained; many more
for malaria control.
Rural health program: US$1.70/child/year
Food and Nutrition Program: US$12.50/child/year
2 health workers (full time) per 5,000 population; approximately 1:350 children
[Health worker]
Cost estimated as US$6/child/year
Volunteer teams 3:25 children, about 3.5 hours/volunteer/week
CHAs (full time) 1:500 households; approximately US$7/household/year 
[Health worker]
Volunteers, approximately 1:20 households
Source: See sources for table 56.2. 
F  role of supplementary feeding in the program; F:   mainly a feeding program, or primary role; F:   significant but not main role, often to selected children; F: ()  existed but relatively
minor; F: 0  none. 
Note: The status of community workers is given in brackets in the last column.
for part-time volunteers. In Jamaica, where the community
health aides work full time, the ratio is 1:500 households; in the
BRAC program in Bangladesh, it is 1:300, about half-time work
(afternoons) (Chowdhury 2003). (An indication of the status
of community workers is shown in brackets in the last column
of table 56.3.) In any event, these ratios provide some basis for
gauging the adequacy of personnel, and it seems that an effec-
tive ratio may be about 1:500 for community workers
employed full time and 1:10 or 1:20 for local volunteers work-
ing part time.
In reality, the ratios of community workers to children are
probably—not surprisingly—on the low side. Thailand, which
trained 600,000 village workers (1 percent of the population),
operated at about 1:20 for part-time volunteers, with similar
supervision ratios. The Indonesian program was similar (or
better) but had much less supervision. In contrast, the low
resourcing of the ICDS in India shows up in a ratio of 1:200
(for part-time anganwadi workers, or ANWs), and in the
Philippines, the ratio has until recently been 1:300 (for essen-
tially voluntary workers).
Increased application of technology can contribute to the
organization and running of community-based programs.
Technology can be applied easily to methods of assessment and
monitoring of children’s progress; improved weighing scales (or
in some circumstances, where rapid assessment in remote areas
is important, using arm circumference) can simplify anthro-
pometry. Modern computer technology for recordkeeping
could be much more widely used, freeing staff time for home
visits (for example, in Jamaica); e-mail, which is being rapidly
adopted, has great potential for transferring information, trou-
bleshooting, and consultation. Cell phone use is beginning
to transform communications even in the poorest countries,
where it is leapfrogging landline installation and use; as cover-
age expands, it will facilitate referral, for example, for emer-
gency obstetric care, the need for which may first be identified
by community workers. Coupled with improved transportation
and procedures to allow the use of such transportation in cases
of urgent need, modern communications can link communities
to centers with advanced knowledge for information exchange
and, by facilitating transportation when time is crucial, for
referral. Modern communications may also provide more effi-
cient ways of providing training, retraining, and supervision.
Application of current research and resulting technologies
can improve many of the other interventions discussed earlier.
In the micronutrient field, periodic supplementation (with
vitamin A in high doses) can be extended through community
programs, and fortified foods and micronutrient “sprinkles”
can be promoted (see chapter 28). The prospect of enabling
communities to test their salt for iodine content with simple
and cheap test kits is intriguing and has often been recom-
mended but has not yet been widely applied. Improved immu-
nization technology should continue to protect health, for
which CHNPs’ main role is to provide information and to
ensure that children are taken for immunization (either to reg-
ular clinics or for National Immmunization Days and the like).
Periodic deworming can be conducted by community pro-
grams (and hookworm vaccines currently under development
may soon contribute). Supporting the use of insecticide-treated
bednets could be fostered through CHNPs. By far the most
potentially important application of technology, certainly in
Sub-Saharan Africa, will be the unprecedented effort to provide
millions of people with antiretroviral therapy and associated
care and support, as discussed later.
Training, Supervision, Incentives, and Remuneration
Community-based health and nutrition programs typically
involve community workers, who may be entirely part-time
volunteers (for example, in Honduras and Thailand) or may
receive some remuneration financially or in kind (for example,
in India). Community workers may be part of the health sys-
tem, earning a wage and based in a local clinic (for example, in
Jamaica) or in the community itself (for example, in Costa
Rica); or they may be selected by and report to the community
(for example, in Tanzania and Thailand). Table 56.3 indicates
the status of community workers in the programs examined
here. The training, supervision, and incentives for community
workers are critical aspects of successful programs.
Inadequate training and supervisory support of community
workers are common weaknesses. Considerable attention was
given to training for the Iringa project (Tanzania), with village
health workers trained for up to six months. In the Tamil Nadu
Integrated Nutrition Program in India, community workers
received three months of training and participated in annual
refresher trainings. ICDS (India) initially trained the ANWs for
three months, with two annual refresher courses, but this
process declined. In Thailand, volunteers had two to five days
of initial training, with annual refresher courses; Indonesian
practice was similar. In Jamaica, where the community workers
are employees of the health system, two months of initial train-
ing is provided to recruits with significant prior educational
requirements. In Bangladesh, the BRAC community health vol-
unteers have four weeks of training. The quality of the training
has varied, poor training having been blamed for inadequate
implementation in cases such as ICDS in India (Measham and
Chatterjee 1999). Sanders (1985, 176–93) describes experiences
in the 1980s of village health workers (and barefoot doctors)
and their relation to the community.
Supervision of community workers is generally done by
employees who are commonly in the sector. Training of
supervisors (who often take on the role in addition to many
other tasks) for these purposes is highly variable and not always
adequate. Providing resources for visits to provide supervision
to community workers is a further constraint. Supervision
Community Health and Nutrition Programs | 1063
ratios in effective programs are about 1:20 (table 56.3, last col-
umn, when reported). Supervision and training of community
workers are closely linked; indeed, supervision (which must be
supportive rather than disciplinary) should include a substan-
tial element of on-the-job training.
Remuneration and incentives for sustaining motivation are
key issues in replicating the successful features of these pro-
grams, and the options vary with the culture. In Thailand, it is
argued that village volunteers consider the prestige associated
with the role of health worker preferable to getting a low wage.
In many cases, some right of access to health care is part of the
incentive. For the ICDS in India, in contrast, the ANW receives
a small financial remuneration, but the government (as else-
where) will not grant formal employment status (and attempts
to form unions have been strongly discouraged). Direct com-
parisons of the options of paid remuneration and voluntary
work are rare. One opportunity to study options for remuner-
ation is in the Philippines, where under a World Bank Early
Child Development project, the child development worker
receives a wage, which could be compared to near-volunteers at
the barangay (village) level.
When CHNWs are primarily voluntary, they are selected by
the community and report to community committees in some
form. CHNWs on government payrolls may come from the
communities and thus may be known to and identify with the
communities, but they may report to supervisors higher up in
the system. Both models can work, depending on the culture.
What probably works least well is when the community worker
is paid little and receives inadequate support and recognition
from the community or even comes from elsewhere.
Furthermore, as development progresses, reliance on volun-
teerism may become less useful.
For planning CHNPs in terms of community workers, the
total numbers and resource implications can be estimated as
follows. A full-time equivalent CHNW might visit 5 to 10
households per day, averaging a visit to each household roughly
every two months; a ratio of 1 CHNW to 200 households, there-
fore, seems to be in the range within which an effect in terms of
improving child health and nutrition is expected. Calculations
from salaries of community health aides (CHAs) in Jamaica
work out to US$7 per household per year, within the usual
range for expected effect. An important factor in regard to
financial resources, however, concerns the substantial cadre of
personnel who have training and job descriptions for commu-
nity work, are based in health centers, and for administrative
and financial reasons seldom leave the health facility. Moreover,
funds may not be released to allow travel to nearby villages. An
example is from Jamaica, where, because of clinic workloads,
CHAs spend time helping in clinics rather than on home visits;
in fact, technology could free staff time for community work
by automating tasks, such as record keeping, that detain the
CHAs. More effective deployment of existing personnel may
frequently be an option. Hiring additional personnel as com-
munity health workers would consume a significant proportion
of typical health budgets (at 1:200 households for FTEs, this
would amount to US$1 to US$2 per person per year, or about
20 percent of public health budgets in low-income countries).
A mix of redeployment of existing staff and new hiring from
budget reallocations should, nonetheless, be cost-effective.
Organization
Effective, respected, and socially inclusive organization at the
community level seems to have been a key feature of the suc-
cess in launching, expanding, and sustaining CHNPs. Most of
the successful CHNPs drew and built on established community
procedures; where they did not, effect and sustainability were
in doubt. In Thailand, the health services and the religious
organization at village level were important. The health services
themselves play a key role in Costa Rica, Honduras, and
Jamaica. In Indonesia, it was the community organizations
(and women’s groups) together with (initially) the family-
planning services. In Iringa, Tanzania, it was the local political
party structure, with substantial input from UNICEF. In
Zimbabwe, immediately after independence, it was the village
organizations that had fought the war, later helped by a con-
sortium of national and international nongovernmental
organizations (NGOs). The major part of the still-expanding
program in Bangladesh is run by BRAC, an NGO, and has built
on its links to the community for development, food security,
and educational activities, as well as for health. In contrast,
CHNPs that either failed to launch a wide program (for exam-
ple, in the Philippines) or had limited effect (in India, ICDS)
probably lacked some of these features. Inclusiveness is proba-
bly hard to achieve if not inherent.
Support from the central government is also crucial: CHNPs
need this support for training,supervision,wages,supplies, facil-
ities, and the like. Where such support becomes a regular gov-
ernment budget item, activities tend to become embedded and
are sustained, in contrast to where the support is from donors.
A further issue concerns maintaining the community pro-
gram’s preventive orientation. In Indonesia, for example,
according to Rohde (1993), the health services co-opted (and
medicalized) the posyandu (weighing post, or community
health and nutrition center) system by adding a diagnostic and
treatment module (in fact, a table in the meeting place). This
module attracted most of the attention, to the disadvantage of
the preventive aspects of the program. Thus, if the extension of
IMCI into the community means treatment (by trained but not
medically qualified people) in the community rather than
referral to facilities, treatment could become the main or even
sole focus, shifting attention from prevention. Some parallels
exist to the experience of ICDS in India, where, as noted earlier,
food became the raison d’être.
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CONTEXTUAL FACTORS
Community-based programs can work usefully, bringing
steady progress; whether they do depends on myriad factors
relating to the context. Three different concerns are (a) factors
affecting widespread initiation of CHNPs of potentially ade-
quate coverage, intensity, and content; (b) factors that lead to
sustainability; and (c) factors that allow activities to be effective
in improving health and nutrition—at best, when they, them-
selves, also contribute to a rapid transitional improvement, as
in Thailand, Costa Rica, and Jamaica.
Contextual factors may bring about improvements in health
and nutrition without any additional direct action—through
improving living conditions, education, and so forth. Often,
the changes caused by such nonprogrammatic factors are diffi-
cult to distinguish from program effects (current examples are
in Bangladesh and Vietnam, both showing rapid improvement
in nutrition). Moreover, the same factors (again, such as edu-
cation) may both produce endogenous change and increase the
effect of program activities.
Five contextual factors have been suggested as priorities (in
Asia; Mason and others 2001):
• women’s status and education
• lack of social exclusion
• community organization
• literacy
• political commitment.
Table 56.4 shows estimates of the positions of countries with
case study programs in regard to these factors. The levels of
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Table 56.4 Context in Which Selected CHNPs Start and Run
Level of 
Women’s Lack of health and Total minus 
Approximate status and social Community administrative Political political 
Country period educationa exclusion organization Literacy infrastructure commitment commitment Total
Tanzania
Iringa starts 1984–90 2 4 4 3 2 5 15 20
Iringa declines 1990– 2 4 2 3 2 2 13 15
Zimbabwe
Supplementary 1981–90 2 4 5 2 2 5 15 20
Feeding Programme 
starts
Supplementary 1990– 2 2 2 2 2 2 10 12
Feeding Programme 
declines
Bangladesh
BINP 1997– 1 3 2 2 3 3 11 14
India
ICDS 1975– 1 1 2 2 2 3 8 11
TINP 1980–9 2 2 3 3 3 4 13 17
Indonesia
UPGK starts 1975– 2 4 3 2 2 4 13 17
UPGK declines 1990– 2 4 2 2 3 2 13 15
Philippinesb 1974–2000 4 4 3 4 3 1 18 19
Thailand 1982– 4 3 4 4 3 4 18 22
Costa Rica 
RHP 1973– 4 4 4 3 4 4 19 23
Jamaica 1985– 4 4 3 4 4 4 19 23
Nicaragua 1979–90 3 2 3 3 3 4 14 18
Source: Authors.
a. Women’s status and education can be quantified by indicators such as adult literacy rates, females as percentage of males, and secondary school enrollment for girls.
b. Since 2000, the Philippines has begun a significantly improving trend, one factor being increased implementation of programs (CHNPs, as well as others, such as salt iodization); this increase is
caused in part by increased political commitment, both as new legislation and resource allocations.
Note: 0: worst; 5: best.
health and administrative infrastructure have been added. The
table also shows changes in these factors that may help explain
why the CHNPs declined in three cases.
Political commitment can lead to initiating community
programs and mobilizing resources. It may also respond to
emerging community mobilization, as seems to be the case
when programs start after political upheavals, as in Zimbabwe
and Nicaragua. Declining political commitment accounts for
loss of interest by the government in CHNPs; economic decline
undermining resource availability may cause a shift away from
financial support of CHNPs (for example, in Tanzania). In
table 56.4, estimates of levels of contextual factors are totaled
both without and including political commitment (last two
columns). The total without commitment may indicate how
favorable the context is if commitment is then made. Costa
Rica, Jamaica, and Thailand had a favorable context and, with
commitment, succeeded. The Philippines had comparable
favorable conditions—the position of women is generally
good, there is limited social division (exclusion), and so on.
However, the necessary commitment (of resources, in particu-
lar) was made only recently, with new legislation, adherence to
regulations (for example, iodized salt went from 25 to 65 per-
cent coverage), and increased resource allocation and assign-
ment of community workers. This new commitment may well
explain the recently resumed decrease in child malnutrition
(figure 56.2). In other examples—such as Indonesia and
Tanzania—the conditions were moderately favorable, and
while political support and finance existed, progress was made.
In Tanzania, financial crisis denied the programs sustained
support; in Indonesia and Zimbabwe, bureaucratization and
centralization of the political process, followed by political
turmoil, contributed to a similar outcome (Sanders 1993). The
situations in India and Bangladesh have not been very favor-
able. The position of women and social rifts, amounting to
exclusion, have probably inhibited effective programs, even
with political commitment. This context may now be changing
in Bangladesh, as seen in the activities of BRAC. Finally, this
analysis demonstrates the relation of decline in programs to
falling political commitment in Tanzania, Zimbabwe, and
Indonesia.
If this analysis approximates the truth, the forward-looking
policy implications may be important:
• First, investing initially in a favorable context makes sense
(as does possibly committing resources preferentially to
interventions in the more favorable contexts). Supporting
policies can address social constraints—such as improving
education for women—and (relatedly) seek to improve
human rights. In many cases, human rights may be of over-
riding importance for health: Farmer (2003) has made a
compelling case for rethinking health and human rights as a
prerequisite for progress and as a responsibility for those
working for health, especially of the poor and of the desti-
tute sick. This investment may be long term and difficult—
as in Kerala, India, for instance—but must be seen as
integral to the struggle for health (Sanders 1985).
Operationally, this commitment to human rights puts
greater responsibility on advocates and investors in health to
broaden the dialogue and scope for allocating resources and
to avoid committing resources regardless of the prospect of
success as influenced by the social and human rights con-
text. In health and nutrition, as in other areas, adjustment of
policies to support the success of interventions would be
pragmatic as well as the right thing to do.
• Second, even if the context is more favorable, genuine polit-
ical commitment is still essential. Excessive donor input may
inhibit this commitment. It is striking that Thailand had
to reject donor influence and make its internal decisions
before its programs became successful (Tontisirin and
Winichagoon 1999), Costa Rica had to fight and overcome
a medicalized approach (Muñoz and Scrimshaw 1995), and
Indonesia’s posyandu system was undermined when treat-
ment displaced prevention (Rohde 1993).
• Third, it is clear that severe economic stress, political pres-
sure, or both have caused unsustainability (Indonesia,
Nicaragua, Tanzania, and TINP).
• Fourth, if the context is unfavorable, it might be better to
work on improving the context than to commit resources to
programs that may not succeed—but, of course, success in
improving context itself depends on circumstances, notably
political commitment.
Considerations like these should contribute to identifying
supporting policies needed for programs to be effective and
modifications to interventions in particular conditions. For
example, it is often observed that a particular factor—say,
access to health services—is more strongly related to improve-
ment among the better off (for example, the educated)
population. This interaction of program with context leads to
identifying new needs—in this example, perhaps facilitating
access for the illiterate. In the longer run, resources or legisla-
tion (for example, to combat social exclusion or discrimination
against women) may be highlighted as prerequisites before a
program can be expected to work. Often failure to take account
of context when trying to transfer experiences from a pilot trial
(“scaling up”) may explain why efficacious interventions prove
ineffective in a larger population.
This analysis of contextual circumstances indicates that tar-
geting the poor may not always be cost-effective, and some
interventions may not be feasible in certain contexts. An exam-
ple is when the health infrastructure and services are almost
nonexistent; under those conditions, it can be argued that
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emergency treatment (especially for the diseases addressed by
IMCI) should be established and reliable resources put in place
first. A similar difficulty, often seen in food security, is that
most interventions may not work for the poorest of the poor.
For instance, supporting food (or cash crop) production in
low-potential areas may not be realistic; nonagricultural
employment may be better.
Thus, community-based programs work in a specific time
and place: programs may start, work for a time, and then evolve
or fade away. Even if they fade away, some useful effect may
be achieved: sustainability need not be forever. At the same
time, short project cycles (three years for many donors) can act
against sustained programs. Some compromise in donor poli-
cies to allow assurance of continuity for reasonable periods
(such as 10 years) could do a lot to increase the effectiveness of
donor support to CHNPs.
The essence of time and place is not fully understood.
Werner and Sanders (1997) give examples of favorable times,
as when the old order is changing (for example, after internal
conflict, as in Nicaragua and Zimbabwe) and when there is
renewed vigor and some new organization is in place. Another
generalization of a favorable context is when energy and inter-
connectedness exist in society. Thailand illustrates both: the
Thais needed to change the approach, moving away from
donor influence, in order to initiate the successful community
programs that helped transform health and nutrition
throughout the country, and that worked in part because of
cohesive features of Thai society (Tontisirin and Winichagoon
1999).
In these examples, programs that continued on a large
scale—either until the problem was largely resolved, as in Costa
Rica, Jamaica, and Thailand, or as it was expanding, as in BRAC
in Bangladesh or AIN-C (Atención Integral a la Niñez
Comunitaria) in Honduras—clearly had supportive context,
but their specific common features (and hence how they could
be replicated) are elusive. Perhaps one crucial condition for
success is that circumstances are such that people and commu-
nities begin to have the sense that they can take responsibility
for—and control of—their health and quality of life.
Responsibility comes with the emancipation of societies from
colonial or other repressive conditions and possibly when
grassroots attention becomes widespread, as it did in
Bangladesh through an NGO that identified with the people.
Evidence is growing that, among the poor in the United States,
this sense of control is directly related to better health and
reduced exposure to HIV and AIDS; Sampson, Raudenbusch,
and Earls (1997) call the concept collective efficacy. Cohen and
others (2000) show that health conditions improve when com-
munities themselves fix up their environment—the “broken
windows” theory. Such ideas may equally apply to poor com-
munities, especially urban ones, in developing countries too.
RESULTS
Indicators of progress in implementation—process indicators—
referring to coverage, intensity, and so on, are shown in table
56.3. As discussed earlier, most programs expanded population
coverage without much targeting. But usually the level of
resource application (intensity) was on the low side. More
research is needed on the contribution of CHNPs to health
process indicators, such as immunization coverage rates, as well
as to nonhealth activities, for instance, in agriculture and com-
munity development.
Impact evaluation, which refers to the net effects of inter-
ventions on changing health outcomes, is sorely lacking. The
efficacy of most of the component parts of CHNPs, when
resources are adequate and the problems are correctly identi-
fied, is established, but in routinely administered large-scale
programs, the changes in outcome that can be ascribed to pro-
gram actions are less known. Although controlled trials by def-
inition are not applicable, plausible evidence can be obtained by
careful attention to research design, measurement, and analysis
(Habicht, Victora, and Vaughan 1999). Some form of “with and
without” and “before and after” comparisons is needed; for
instance, such methods as staggered implementation, natural
experiments, and selection of comparison groups with some
statistical control can yield valuable information now lacking
and should be more widely attempted. In this context, it should
be noted that because of the timing and level of effort necessary
for the evaluation, the impact evaluation results (changes in
outcome ascribed to the program) may be more important for
policy decisions on future programs than for the program that
has been evaluated. Moreover, not all programs require detailed
evaluation. Thus, financial support for such policy-relevant
evaluations may come from budgets other than that of the pro-
gram to be evaluated. The evaluations should also be prospec-
tive as far as possible, so decisions on evaluation design and
finance are needed earlier rather than later.
Impact
For the examples used here, inferences were drawn from piec-
ing together results either from ad hoc surveys or from pro-
gram and administrative data; occasionally such inferences
were made from the comparison of baseline estimates with
midterm or final assessments, but the comparison groups, if
any, were imperfectly matched. Thus, the conclusions on
impact now put forward are tentative and based on judgments
from available information. Some of these conclusions were
drawn from trend assessments, details for which are in Mason
(2000, annex 5).
The most widely available indicators are mortality rates
(infant, child, and to a lesser extent, maternal; reliable data on
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age zero and cause-specific mortality rates are not usually
available from most developing countries); prevalences of
underweight in children from national surveys (often
supported by demographic and health surveys or UNICEF
Multi-Indicator Cluster Surveys); and indicators of health serv-
ices (notably immunization coverage rates). Estimates of mor-
bidity, even of the common diseases (such as diarrhea and
ARI), are not available systematically enough to judge trends in
relation to programs. Child underweight (or stunting) has a
particular value, because it measures an attribute of all children
(age and weight or height), rather than assessing a relatively
rare event, as in mortality estimates. Moreover, experience is
well established of how underweight prevalences behave as a
robust indicator, having a useful degree of responsiveness but
not being subject to wide fluctuations with transient events.
Under controlled conditions, improving health and nutri-
tion allows rapid catch-up in bodyweight and fast rates of
reduction in underweight prevalence (for example, Pinstrup-
Andersen and others 1993, 405). But in the real-world condi-
tions of CHNPs, the expected rate is slower. As examples,
Thailand maintained a reduction in underweight of about
2.9 ppts per year in the 1980s (see figure 56.1); the 22 projects
reviewed as reported by Jonsson (1997) ranged between about
1 and 3 ppts per year. A reduction rate of 2 ppts per year, sug-
gested earlier as an expectation from successful programs,
would lead to very significant improvement if achieved at
national levels: for South Asia, it would mean going from a
prevalence of underweight of about 60 percent in 1980 to
20 percent in 2000; for Africa, from 30 percent in 1990 to 10
percent in 2000.
Detecting this rate can be difficult with the noise of sam-
pling and nonsampling errors and with the common seasonal
changes, which can amount to 5 ppts fluctuations or more, cer-
tainly in Africa. The potential program-ascribed trend needs to
be separated from the underlying secular trend for the country,
roughly 0.5 ppts per year (from 1985 to 1995; ACC/SCN 1996).
Clearly the longer the program and the observing periods, the
easier it is to assess trends.
Where the data are detailed enough,an initial rapid fall is seen
in severe malnutrition—and probably in mortality,—followed
by a slower fall in mild to moderate malnutrition. The reasons
for the initial rapid fall are presumed to be immediate effects of
improved health care, immunization, and the use of oral rehy-
dration therapy. The outcomes estimated for the programs con-
sidered here concentrate on the sustained trend—after a year or
two of implementation—as summarized in table 56.5.
In Zimbabwe, from 1980 to 1988, the infant mortality rate
(IMR) fell from 110 to 53 per 1,000 live births, and severe mal-
nutrition fell from 17.7 to 1.3 percent. However, stunting fell
only in 1982–88, from 35.6 to 29 percent (1.1 ppts per year).
Tanzania shows a similar effect in Iringa, with severe and mod-
erate malnutrition falling much faster for the first two years.
Interestingly, the Child Survival and Development Projects
(supported by the World Bank, among others), which covered
a much larger population (but with less intensity than in
Iringa), appeared to show almost the same pattern as in Iringa:
a rapid initial fall (as much as 8 ppts per year, for one to two
years), continuing at 1 to 2 ppts per year.
In Costa Rica, the child mortality rate plummeted in the late
1960s, well before stunting fell in the 1970s (Saenz 1995, 129;
Vargas 1995, 111). A lag was seen in Thailand, where the child
mortality rate started to fall rapidly in 1977, and both severe
and moderate malnutrition appeared to start their fall in
1983–84. Both these improvements preceded the major growth
in gross national product, which began in 1987 (Kachondam,
Winichagoon, and Tontisirin 1992, tables 8 and 33). In analyz-
ing Indian experience, where the IMR has fallen faster than
child malnutrition, Measham and Chatterjee (1999) suggest
that further improvements in child survival may be con-
strained by the high rates of child malnutrition.
The sustained effects are generally of about an additional
1 ppt per year improvement (table 56.5). For Bangladesh (the
BINP), Tanzania, and Thailand, it is possible to distinguish
the sustained rate from the initial rapid fall. In Bangladesh, the
BINP started during a period of rapid improvement overall, so
extracting the underlying trend is especially important to give
a plausible view of the “with-project” rate: about 1.6 ppts per
year again seems a reasonable estimate. A similar extraction of
likely with-project changes allowing for underlying trends was
reported previously (Mason 2000, annex 5) for Tamil Nadu,
Andhra Pradesh (ICDS), and Orissa, indicating plausible
improvements for the first two states.
In sum, these results support the contention that after an
initial rapid fall, the sustained rates of improvement in child
underweight prevalence settle down to about an additional
reduction of 1 or 2 ppts per year. This conclusion is the same as
previously reached (Gillespie and Mason 1991), now supported
by some new results.
Cost-Effectiveness
Therefore, if we use prevalences of underweight children as the
basis for calculation, US$10 per child per year gives a reduction
of 2 ppts per year. If we are to translate this cost into an implied
effect on health and survival, underweight must be related to
the measure of disease burden, DALYs lost. Then the resources
needed per DALY saved—dollars per DALY—can be estimated.
A 32.5 percent reduction in the loss of DALYs is associated with
eliminating general plus micronutrient malnutrition as both
direct effects and risk factors (see table 56.1, discussed earlier);
as a first approximation, the average prevalence for developing
countries of 30 percent underweight can be applied. We can
calculate the associated DALYs gained from reducing malnutri-
tion at this rate (and assume that loss of DALYs from all
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Table 56.5 Outcomes and Resources in Selected Programs
Country Outcomes Resources
Africa
Tanzania: Iringa
Tanzania: Child Survival
and Development Program
Zimbabwe: Supplementary
Feeding Programme
Asia
Bangladesh: BINP 
Bangladesh: BRAC
India: ICDS
India: TINP
Indonesia
Philippines: national
Thailand
Americas
Costa Rica
Jamaica
Nicaragua
Underweight: 50 to 35 percent (1984–88)
Immunization: 50 to 90 percent
Rates in underweight: initial 2 years, 
8 ppts/year; first 4 years, 4.5 ppts/year;
sustained (years 2–7), 0.8 ppts/year
Underweight reduction rates similar to Iringa
Stunting: 35.6 to 29 percent (1982–88)
1.1 ppts/year
IMR: 1980–88: 110 to 53
BINP, first 6 thanas, initial effect (1997):
approximately 11 ppts/year; then (to
February 1999) approximately 1.6 ppts/year
additional 
Underlying (nonprogram) trend: national
approximately 1.7 ppts/year, program area
approximately 2.4 ppts/year
No program-specific data, but child under-
weight and anemia in women have substantial
falling trend in recent years.
Overall underweight prevalence declining only
slowly; some states reported faster, but link to
ICDS not shown.
1979–90: 1.4 ppts/year in TINP districts;
0.7 in non-TINP districts: increased improve-
ment of approximately 0.7 ppts/year (Reddy
and others 1992, 45). From other data,
increased improvement of 1.0 ppts/year.
Probably about 1 ppt/year; underlying trend
unknown
IMR: 1970, 1980, 1990: 118, 93, 61, respectively
No change found in underweight.
IMR: 1960, 1996: 77, 32, respectively
Approximately 2.9 ppts/year improvement in
child underweight. Breaks down to 1982–84:
7.8 ppts/year; 1985–90, 1.9 ppts/year.
IMR: 1970, 1980, 1990: 73, 55, 27, respectively
Stunting improved by approximately 
1–1.5 ppts/year (estimated from Muñoz
and Scrimshaw 1995, 111), 1979–89.
IMR: 1970, 1980, 1988; 62, 19, 16, respectively
1.9 ppts/year 1985–89
IMR: 1960, 1996: 58, 10, respectively
IMR fell from (at least) 92 to 80
US$8 to US$17/person/year (US$34/child/year from total costs);
2 village health workers/village  1,220 total;
Approximately 1:40 children
US$2 to US$3/child/year
External funds, approximately US$0.50/child/year
1 community worker per 1,000 population;
Approximately 1:200 children; US$14 million/year, approximately
US$18/child/year
Over all programs, US$196 million in 2003 (approximately US$8/household
over all households); health program covered 31 million people, over 20 percent
1 supervisor to 20 ANWs
US$7–12/child/year
US$2 to US$11/child/year, depending on supplementary food. Rohde (1993)
gives  US$1 recurrent.
Village workers (about 3 million total) 1:60 people; approximately 
1:10 children; supervision 1:200
Low coverage and intensity
Ministry of Public Health, approximately US$11/head/year (1990)
Village health communicator or volunteer approximately 1:20 children; supervi-
sion by extension workers: village health communicators and volunteers
approximately 1:24
Rural health program: US$1.7/child/year
Food and nutrition program: US$12.50/child/year 
2 health workers (full time)/5,000 population, approximately 1:350 children
Large numbers community health volunteers trained and supported
Source: See sources for table 56.2.
malnutrition comes down at this rate; CHNPs include some
attention to micronutrients). This reduction is then cumulated
through time (five years here) and assumes a linear relation
between cost, underweight reduction, and disease burden
avoided. The calculation also assumes a persistent effect of
reducing malnutrition.
Using these assumptions gives an estimate of US$200 to
US$250 per DALY saved in sustained programs. This estimate
does not include gains in DALYs from diseases that do not
show up as underweight, which must be substantial. Moreover,
if this calculation is applied just to the first rapid fall, typically
(in the three cases examined) about 8 ppts per year, the ratio
might fall by a factor of four, to US$50 to US$60 per DALY
saved (but start-up costs are higher too). The sustained figure
should be the more generalizable.
Many further provisos exist. Much of the effect here is on
a risk factor—malnutrition—reducing which, in turn, makes
other interventions more effective; hence, the comparison of
CHNPs with more direct interventions may not be valid. But
conversely (or perversely) improving nutrition could actually
reduce the cost-effectiveness of other interventions—such as
measles immunization—by reducing the mortality risk of chil-
dren who are not immunized.
FUTURE APPLICATIONS
The experience so far in CHNPs can be applied more broadly,
especially where community organizations can sustain support
for CHNWs. CHNPs have worked best so far in Asia and Latin
America. However, with the HIV/AIDS epidemic in Sub-
Saharan Africa needing high-priority attention, application of
CHNP experience to the HIV/AIDS crisis should be explored.
Extending CHNPs’ Coverage and Intensity
In a project sponsored by the Asian Development Bank (ADB)
and UNICEF that was aimed at identifying ways of investing in
improved child nutrition, Mason and others (1999, 2001) have
reviewed the extent of CHNPs in Asian countries. Resources
were estimated in terms of annual expenditures per child and of
ratios of population to community workers (“mobilizers”). The
project addressed the needs of eight countries (Bangladesh,
Cambodia, China, India, Pakistan, the Philippines, Sri Lanka,
and Vietnam), and previous experience in Indonesia and
Thailand provided additional guidance.
The population coverage of CHNPs was estimated as about
5 to 20 percent, except for India with the ICDS, which reports
about 70 percent coverage. The next indicators refer to estimates
within programs. The calculated intensity was commonly 200
children to 1 community worker (for example, Bangladesh,
India, Sri Lanka); ratios of up to 100:1 were reported in Pakistan
and Vietnam and up to 60:1 in the Philippines. Further research
has stressed the variation in time commitment of CHNWs in
different places—hence the need to convert to FTEs. The ratio
used as the norm, derived from experience in Thailand and
Indonesia, of about 1:20 is probably equivalent to 1:200 in FTEs.
In India, opinion has been that about a doubling of the ANW
numbers in the ratios is needed to get more effect (Measham and
Chatterjee 1999). From this perspective, these estimates indicate
that both coverage and intensity are low, although intensity may
be half that needed, whereas coverage (except in India) is far too
small. Supervision ratios are estimated as about 1:20 and higher.
Expanding the numbers of CHNWs also means increasing the
number of supervisors (usually from the health system), with
associated costs.
Calculations from scarce financial resource data show that
most government programs cost about US$1 per participant
child per year or less, whereas Bangladesh (BINP, with donor
support and in line with other donor-supported programs)
reached costs of US$15 to US$20 per child per year. By this cal-
culation, too, the resources per head, as well as the coverage,
were in most cases too low for widespread effect.
The estimates of coverage and intensity can be combined to
calculate the extent of current programs in relation to that
needed for full coverage at adequate intensity. The results based
on a 1:20 ratio of CHNW to children suggest that less than
1 percent of the need was currently available; at 1:200 (which
would cost more, because the CHNW would work full time)
perhaps 10 percent of the need would be covered. Either way, a
massive expansion would be called for if CHNPs were to be
used as a means for widely improving health (but still calling
for only about 20 percent of the public budget for health).
Expansion requires major resources, and not only financial
ones. Thailand trained 1 percent of the population as commu-
nity health workers (part time) and established an extensive
supervision and support structure, including retraining. The
estimates for the ADB-UNICEF project in financial terms were,
for Bangladesh, Cambodia, Pakistan, Sri Lanka, and Vietnam,
some US$190 million to US$280 million per year for improve-
ment of underweight by an additional 1.5 ppts per year (Mason
and others 2001, 64–68).
The Potential Role of CHNPs in Combating HIV and AIDS
in Sub-Saharan Africa 
Controlling the epidemic of HIV and AIDS in Sub-Saharan
Africa will take an unprecedented effort. As antiretroviral ther-
apy becomes available there will be new opportunities to turn
the tide. Supply of antiretroviral therapy drugs, although essen-
tial and the cutting edge of new programs, is only part of the
need. Food and income support, care for children (orphans
and others affected), counseling, support to promote and
sustain behavior change, and rehabilitation of people and
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communities are needed (see chapter 18). Many of these activ-
ities have precedents in the types of CHNPs run by community
health workers that are discussed here. What lessons are
transferable?
One concern is that CHNPs have a greater history of success
in developing countries outside Africa. Those within Africa seem
to have been sustained for limited periods, often linked to donor
interests. Reasons may have to do with lower levels of adminis-
trative infrastructure, different existing community organiza-
tion, and varying political commitment (see table 56.4). These
factors may now be weakened as the AIDS epidemic reduces the
numbers of qualified people and undermines community
organizations. It will be urgent to work on such contextual fac-
tors to create conditions in which community organizations can
be refurbished and built on.
Community organizations can work in Africa, as elsewhere,
when they have a real function with activities perceived as use-
ful to pursue and some resources (including mobilizing their
own) to use. Some transferable lessons are that such local
organizations are crucial; that in regard to supervision and
access to certain resources, they need to work with the govern-
ment structure—often through health system employees; and
that they need sustained resource support, much of which
must come from donors.
Treatment and rehabilitation of people with AIDS will be
home based in most cases and will depend substantially on
community support. Nutrition is an important component;
improved food intake is likely to enhance the effect of anti-
retroviral therapy, and when treatment progresses, nutrition
will help get sick people back on their feet and returned to a
productive life. A village health worker could play a key role in
this process. In much of Africa, HIV and AIDS affect many
communities, and in southern Africa, where HIV prevalences
reach 30 to 40 percent, almost all communities have chronically
sick adults. This fact means that most communities need pro-
grams: the problem is not highly concentrated. On the positive
side, the more developed and accessible communities are those
most affected by AIDS (Mason and others forthcoming;
UNICEF 2004), where establishing programs may be easier.
HIV and AIDS are affecting children both directly, as pediatric
AIDS, and indirectly, through the impoverishment and destitu-
tion of affected households. This effect is seen in worsening
child malnutrition. Here, too, support through CHNPs could
play a useful role.
The characteristics of CHNPs elsewhere—in terms of inten-
sity, training, supervision, and so forth—may provide some
guidance for establishing or extending them in Africa.
Mechanisms for identifying, supporting, and training village or
community health workers in this context can draw on experi-
ence with CHNPs; such issues as their identification in the
community and links with community and facility programs
will arise. A key issue will be the remuneration and incentives
for community workers, and this issue may need some research
and testing of different approaches. The activities of com-
munity workers in dealing with treatment (and prevention) of
HIV and AIDS have parallels to malnutrition and would prob-
ably include the following items:
• social support and facilitating access to resources (possibly
including food aid)
• counseling
• treatment and referral for opportunistic infections
• promoting rehabilitation to productive life (which may
benefit from improved nutrition) as antiretroviral therapy
progresses.
Schools too have an extremely important role in the fight
against HIV and AIDS and should be linked to, or part of,
CHNPs. Schools provide a refuge and a means of providing
help for orphans and vulnerable children, and they also provide
a crucial opportunity for preempting and combating high-risk
behavior.
RESEARCH NEEDS
The question of incentives, training, and support for commu-
nity workers urgently needs research, both from current expe-
rience and with prospective designs. The issues include the
following:
• What is the CHNW’s status, relative to the community or to
the government (or NGO) hierarchy?
• How are CHNWs selected and to whom do they report (for
example, community health committees, supervisors
employed in the health or other system)?
• What educational background and how much training and
retraining—and by what methods—are needed for
CHNWs?
• What ratios of CHNWs to households are effective (or most
cost-effective), both as part-time workers (volunteer or
otherwise) and as full-time employees?
• What supervision ratios work?
• What remuneration and incentives are effective?
• How can these efforts be financed?
Enough programs have been in operation for long enough
that researchers could base on them much of the needed
research on processes of implementation, launching new trials
only for processes for which sufficient information does not
exist. In contrast, impact evaluation requires new and prefer-
ably prospective studies.
A major gap in research is the application of community-
based programs to urban areas. Urban communities are
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conceived differently from the rural areas of most CHNPs,
organizations run along different lines, and so forth. Yet popu-
lation growth is in urban areas, and some problems, notably
HIV and AIDS, are worse there.
Finally, the cost-effectiveness analysis results given in an ear-
lier section are based on rather few and approximate results.
CHNPs may well provide a viable and cost-effective approach
under many circumstances in poor countries, and it may
be necessary to demonstrate this viability better and more
quantitatively for support to CHNPs to compete with more
traditional service delivery interventions. That, too, would
constitute worthwhile research.
NOTES
1. Social exclusion refers to the exclusion of groups from the main-
stream of public actions: lower castes in India, poorer groups in Pakistan,
many indigenous ethnic groups throughout Asia and the Americas, and
migrant workers in China and elsewhere; the result for public health is
that excluded people do not participate in programs even if they are
available.
2. Pinstrup-Andersen and others (1993) provide a more complete list.
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The use of modern contraception to prevent pregnancies is a
unique health intervention because, in many ways, it is not a
health intervention at all. In general, couples in sexual relation-
ships use contraception because, at the time the decision is
made, one or both members do not wish to conceive a child,
rather than because they wish to become healthier or to pre-
vent a risk to health. Governments also may have an interest in
promoting particular patterns of childbearing to meet social
and economic objectives. This is most often the case when
rapid population growth is seen as a drag on economic growth;
in contrast, however, governments in low-fertility countries
may promote pro-natalist policies to increase the labor supply.
Thus, the effectiveness of contraception has to be seen, first and
foremost, in terms of the effectiveness in permitting couples to
achieve their desired family size.
Although contraception is rarely used to improve health, it
does have health consequences. On the negative side, conse-
quences may include the potential health risks of hormonal
contraception or surgery. On the positive side, health may
benefit from fewer pregnancies, lower exposure to sexually
transmitted infections (STIs), and protection against ovarian
cancer through the use of some types of contraception. Some of
the consequences affect the users, some affect their sexual part-
ners, and some affect their children. Contraceptives affect a
user’s sexuality by changing menstrual patterns and, therefore,
particularly in some cultures, sexual activity. Also, by eliminat-
ing fear of unwanted pregnancy, contraceptives may enhance
the quality of sexual experience. Finally, condoms may decrease
sexual pleasure for men; true or not, this explanation is one of
the most commonly cited to account for why some men (or
couples) do not use condoms.
NATURE, CAUSES, AND BURDEN OF THE
CONDITIONS THAT CAN BE ADDRESSED 
Three rationales—each one involving controversy and touch-
ing on deeply held political and cultural perspectives—have
underlain policy and programmatic interest in contraception,
since the 1960s.
• The demographic rationale, typically framed around lower-
ing the rate of population growth to achieve broad 
economic, social, and environmental aims, was most promi-
nently applied in the 1960s and 1970s.
• The fertility rationale, which emerged in the 1980s, promoted
lower fertility under the assumption that smaller families
are better off in terms of economic and health conditions.
• The human rights rationale, which surfaced in 1994 at the
International Conference on Population and Development
in Cairo, served as a major force in the 1990s to focus atten-
tion on women’s rights to autonomy and empowerment in
childbearing and on female and male reproductive health.
The Cairo Programme of Action stressed the political and
cultural dimensions of contraception, including gender
issues.
Population Growth and Fertility
In part because of the demand for and availability of modern
contraception, the worldwide rate of annual population
growth has declined from just over 2 percent in the late 1960s
to 1.5 percent during 1980–2001. It is projected to decrease
to 1 percent during 2001–15. Although the growth rate has
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slowed, population growth in absolute terms is unprecedented.
World population increased from 2.5 billion people in 1950 to
6.3 billion in 2003 and is expected to rise to 7.1 billion by 2015
(UN 2003; World Bank 2003).
Fertility rates in developing countries have declined rapidly
in the past 50 years, from more than 6.0 children per woman in
the 1950s to about 2.8 children per woman today. Fertility rates
remain high, however, in the 49 least developed countries,
which had an average total fertility rate of 5.46 children per
woman during 1995–2000 (UN 2003).
Fertility levels and trends vary greatly between regions.
Fertility rates are lowest in low- and middle-income countries
in East Asia and the Pacific, at 2.1 children per woman.
Countries in Central Asia and Latin America and the
Caribbean also have relatively low total fertility rates, at 2.5 and
2.6 children per woman, respectively. The Middle East and
North Africa and South Asia follow, with average total fertility
rates of 3.4 and 3.3 children per woman in 2001, respectively.
Fertility rates are highest in Sub-Saharan Africa, at 5.2 children
per woman (World Bank 2003).1 Regional averages conceal
substantial variation among and within countries.
Because of a legacy of high fertility and corresponding
young population structures, population momentum ensures
that many developing countries will continue to grow at a rel-
atively high rate for many decades, even as fertility rates con-
tinue to decline. Population momentum alone will account for
almost three-fourths of the population growth in developing
countries in the next quarter-century. The largest growth at
present is in Asia and Sub-Saharan Africa. Total population
increase in these regions is now twice what it was in 1950. By
2015, population growth is expected to be substantially lower
in all regions except Sub-Saharan Africa.
Demand for Contraception
If a woman wishes to postpone or avoid childbearing and is not
using contraception (including use by her partners), she is said
to have an unmet need for contraception. The most com-
monly reported reasons for unmet need are lack of knowledge,
health concerns, and social disapproval (Casterline and Sinding
2000).
In 2003, an estimated 122.7 million women in developing
countries had an unmet need for contraception, including
105.2 million married women, 8.4 million unmarried women,
and 9.1 million women of all marital status in the states of the
former Soviet Union. This figure represents 17 percent of all
married women, a 2 percent decline from the late 1990s that is
due to increasing contraceptive use.
Overall, the highest unmet need is in Sub-Saharan Africa,
where 19.4 percent of all women have unmet need. About
13 percent of women in Asia, 10.6 percent of women in North
Africa and the Middle East, and 8.5 percent of women in Latin
America and the Caribbean and Central Asia have unmet need
for contraception. Whereas women in the other regions of the
world have an equally distributed unmet need for spacing and
limiting births, the majority of unmet need in Sub-Saharan
Africa is for spacing (Ross and Winfrey 2002). Unmet need is
highest in countries where growing numbers of women want
to avoid pregnancy but contraceptive prevalence is low. So, for
example, among developing countries for which data are avail-
able from USAID’s Demographic and Health Surveys, unmet
need is currently highest in Haiti, where it nears 40 percent of
all married women; it is more than 30 percent in Cambodia,
Nepal, Pakistan, Rwanda, Senegal, Togo, Uganda, and the
Republic of Yemen; and it is lowest, at less than 7 percent, in
Brazil, Colombia, and Vietnam.
Total Potential Demand for Contraception. A rough measure
of the total potential use of modern contraception in a country
can be estimated by combining the measure of unmet need
with the current proportion of women using contraception.
Brazil, Colombia, and Vietnam all have demand for contracep-
tion greater than 80 percent of currently married women. They
have satisfied most of this demand, with contraceptive preva-
lence rates above 75 percent, resulting in both low fertility rates
and low unmet need (Westoff 2001). In contrast, in most Sub-
Saharan African countries, the unmet need percentage exceeds
the percentage of women currently using contraception (see
table 57.1).
Health Consequences
Excess fertility is responsible for between 12 and 30 percent of
the maternal burden of disease (see table 57.2)2, although this
is clearly an underestimate of the present and future burden of
disease that can be prevented through investments in family
planning. These estimates include only the direct health bene-
fits of family planning for women by preventing unwanted
births, decreasing the number of abortions, and increasing the
length of birth intervals. Because of data limitations, these esti-
mates exclude the potential effect of family-planning programs
on children’s long-term nutritional status and education;
women’s status and the household economy; and public
savings from reduced fertility, AIDS, and other STIs through
condom promotion and prevention of mother-to-child trans-
mission (PMTCT). They also exclude the effect of such pro-
grams on environmentally related disease owing to population
growth. Last, the estimates do not consider the disabling effects
of unwanted pregnancies, despite the effect those pregnancies
or their termination under unsafe conditions can have on
women’s welfare and productivity.
Each year, 585,000 women die and more than 54 million
women suffer from diseases or complications caused by preg-
nancy and childbirth (WHO 1997).
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Risks Associated with Unwanted Pregnancies. Unwanted
pregnancies expose women to additional health risks by
increasing the number of lifetime pregnancies and deliveries.
Because the lifetime risk of maternal mortality is a function of
the number of pregnancies and the quality and utilization of
health care, reducing the number of pregnancies can lower
maternal mortality rates (Koenig and others 1988).
Ambivalence toward pregnancy also is associated with less early
and continuous prenatal care and lower use of professional
delivery care (Gage 1998; Joyce and Grossman 1990; Weller,
Eberstein, and Bailey 1987).
Many women who have unintended pregnancies turn to
induced abortion, both in countries where abortion is legal
and safe and in those where it is illegal and too often unsafe.
Contraception | 1077
Table 57.1 Total Potential Demand for Family Planning 
(percentage of currently married women)
Current Total 
Unmet contraceptive potential 
Country need use demand
East Asia and the Pacific
Cambodia 32.6 23.8 56.4
Indonesia 9.2 57.4 66.6
Philippines 18.8 47.8 66.6
Vietnam 6.9 75.3 82.2
Central Asian republics
Kazakhstan 8.7 66.1 74.8
Kyrgyz Republic 11.6 59.5 71.1
Turkmenistan 10.1 61.8 71.9
Uzbekistan 13.7 55.6 69.3
Latin America and the Caribbean
Argentina — — —
Belize — — —
Bolivia 26.1 48.3 74.4
Brazil 7.3 76.7 84.0
Colombia 6.2 76.9 83.1
Dominican Republic 11.8 69.5 81.3
Guatemala 23.1 38.2 61.3
Haiti 39.8 28.1 67.9
Nicaragua 14.7 60.3 75.0
Paraguay 15.0 48.4 63.4
Peru 10.2 68.9 79.1
Middle East and North Africa
Algeria — — —
Egypt, Arab Rep. of 11.2 56.1 67.3
Jordan 14.2 52.6 66.8
Morocco 16.1 50.3 66.4
Yemen, Rep. of 38.6 20.8 59.4
South Asia
Bangladesh 15.3 53.8 69.1
India 15.8 48.2 64.0
Nepal 31.4 28.5 59.9
Pakistan 31.8 11.8 43.6
Current Total 
Unmet contraceptive potential 
Country need use demand
Sub-Saharan Africa
Benin 25.7 16.4 42.1
Burkina Faso 25.8 11.9 37.7
Cameroon 19.7 19.3 39.0
Central African Rep. 16.2 14.8 31.0
Chad 9.7 4.1 13.8
Côte d’Ivoire 27.7 15.0 42.7
Eritrea 27.5 8.0 35.5
Ethiopia 23.1 5.9 29.0
Gabon 28.0 32.7 60.7
Ghana 23.0 22.0 45.0
Guinea 24.2 6.2 30.4
Kenya 23.9 39.0 62.9
Madagascar 25.6 19.4 45.0
Malawi 29.7 30.6 60.3
Mali 25.7 6.7 32.4
Mozambique 6.7 7.3 14.0
Namibia 21.9 28.9 50.8
Niger 16.6 8.2 24.8
Nigeria 17.5 15.3 32.8
Rwanda 35.6 13.2 48.8
Senegal 34.8 12.9 47.7
South Africa 15.0 56.3 71.3
Tanzania 21.8 25.4 47.2
Togo 32.3 23.5 55.8
Uganda 34.6 22.8 57.4
Zambia 26.5 25.9 52.4
Zimbabwe 12.9 53.5 66.4
Source: Demographic and Health Survey, various years.
—  not available.
Accurate measures of abortion are difficult to obtain in most
parts of the world. In countries where abortion is illegal, data
are lacking or incomplete, and even where it is legal, abortions
may be underreported because of societal attitudes (Bongaarts
1997; Henshaw, Singh, and Haas 1999). It is estimated that
about one-fourth of the 210 million pregnancies each year end
in abortion.
In 1995, approximately 35.5 million abortions were per-
formed in developing countries. The large majority of legal
abortions, 10.6 million, occurred in China. Most of the remain-
ing legal abortions took place in other parts of Asia (5.7 mil-
lion) and in the Caribbean (0.2 million). Developing countries,
which experienced an estimated 19 million illegal abortions in
1995, account for 95 percent of illegal abortions worldwide.
Nearly 10 million illegal abortions occurred in Asia, followed
by an estimated 5 million in Africa and 4 million in Latin
America. These figures mark a particularly large increase for
Africa, which was estimated to have only 1.5 million illegal
abortions in 1987 (Henshaw, Singh, and Haas 1999).
Unsafe abortion, typically associated with illegality, has
large impacts on both maternal mortality and maternal mor-
bidity. Each year, unsafe abortion is believed to account for
80,000 maternal deaths, or 13 percent of the burden of disease
in women of reproductive age (WHO 2002a). Deaths related
to unsafe abortions are estimated at 100 to 600 death per
100,000 abortions, compared with the mortality rate from
legal abortions of 0.6 deaths per 100,000 abortions (Salter,
Johnston, and Hengen 1997). Survivors of unsafe abortions
also experience consequences; unsafe abortion causes disabili-
ty in an additional 5 million women (WHO 2002a). Treatment
of complications from unsafe abortions constitutes a large
proportion of emergency gynecological hospital admissions
(Konje, Obisesan, and Ladipo 1992) and requires substantial
resources (Kinoti and others 1995; Salter, Johnston, and
Hengen 1997).
Legalizing abortion, improving the quality of abortion care,
and increasing access to safe abortion can have profound
impacts on the health consequences of abortion. When abor-
tion was illegal in Romania in 1988, complications from unsafe
abortion caused 86 percent of maternal deaths. After abortion
was legalized in 1989, the frequency of abortion persisted
because of contraceptive supply shortages, but the number of
maternal deaths fell by 50 percent (Hord and others 1991).
Risks Associated with Pregnancy and Birth. All pregnancies
and births involve some health risks to women, so prevent-
ing any pregnancy reduces women’s health risks. Higher mor-
tality and morbidity of women, infants, and children are
positively associated with the risk factors of giving birth when
a woman is too young or too old, the births are too close
together, there are too many births, or a woman has a preexist-
ing health condition. Births in most of these groups—women
who are older (over age 35), births that are spaced too closely
(24 months or less after the preceding birth), and births that
are higher order (fifth or higher)—are also more likely to be
reported as unintended, making their prevention doubly
important (Tsui, Wasserheit, and Haaga 1997).
An estimated 15 million women under age 20 give birth
each year. Women age 15 to 19 are twice as likely to die from
childbearing as women in their 20s, and women under age 17
are at even greater risk (Starrs 1997). Adolescent mothers are
more likely to suffer from obstetric complications if they lack
physical maturity or are malnourished (Aitken and Walls
1986). They are also less likely to receive adequate prenatal or
obstetric care, which may cause negative outcomes for them
and for their infants (McDevitt and others 1996). In many con-
texts, negative social consequences are profound, including loss
of school and employment opportunities.
Children born to adolescent mothers face a number of risks.
Research has demonstrated that infants of teenage mothers are
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Table 57.2 Maternal Burden of Disease Associated with Unwanted Fertility and Unsafe Abortions
Disability- Percentage 
Years lived adjusted of all 
Years of with life years maternal 
Region Deaths life lost disability (DALYs) DALYs
East Asia and the Pacific 3,637 107,795 380,255 420,030 17
Latin America and the Caribbean 6,323 190,544 298,390 429,399 30
Middle East and North Africa 8,428 244,461 256,742 395,368 12
South Asia 30,074 878,028 1,079,661 1,669,727 20
Sub-Saharan Africa 43,077 1,270,598 764,012 1,821,721 18
Sources: Adapted from WHO 2002a. Maternal morality related to unsafe abortions from WHO 1998. Percentage of infant disease preventable by family planning from Rutstein 2003. 
Notes: Because of data limitations, estimates are not available for Eastern Europe and Central Asia. Burden-of-disease estimates include a 3 percent discount rate without age weighting. WHO regions
are not identical to the World Bank Regions used here; however, a very close approximation was made by excluding WHO regions AMRO A, WPRO A, and EURO A. These estimates assume that 
90 percent of abortion-related disease burden is preventable by family planning and that the percentage of other preventable maternal disease is equal to the percentage of all births that are 
unwanted. 
more likely than those born to mothers in their 20s to die
before they reach their first birthday (Hobcraft 1992; McDevitt
and others 1996; Ross and Frankenberg 1993; Starrs 1997;
Sullivan, Rutstein, and Bicego 1994). Children of mothers
under age 20 may have a 20 to 30 percent higher risk of death
than children of older mothers (Hobcraft 1992; Sullivan,
Rutstein, and Bicego 1994). Infants of teenage mothers are also
at higher risk of being of low birthweight, small for gestational
age, or premature. Finally, adolescent women are less likely to
provide adequate care for their infants and children, because
they often lack the maturity, education, and resources to do so
(Geronimus 1987; Govindasamy and others 1993).
Women over age 35 face an increased risk of maternal mor-
tality. Mothers age 40 to 44, for example, are five times more
likely to die during pregnancy or childbirth than mothers in
their 20s (Royston and Lopez 1987). Mothers in their late 30s
and 40s may also face additional negative consequences,
because they may have preexisting health problems owing to
age or previous births.
As with children of adolescent mothers, children of women
over age 35 also suffer negative consequences. Children born to
mothers over age 40 are more likely than those born to younger
mothers to die before age 5 (Bicego and Ahad 1996; Sullivan,
Rutstein, and Bicego 1994). Older women are also more likely
to have stillbirths or to bear children with congenital abnor-
malities who may not survive childhood (Cnattingius and
others 1992; Fretts and Usher 1997).
Longer birth intervals reduce women’s risks of death and ill
health during pregnancy and childbirth. One study assessed the
effects of birth spacing in 450,000 women on the basis of hos-
pital records from 1985 to 1997 in 19 Latin American and
Caribbean countries. The study found that women who have
their babies 27 to 32 months after a preceding birth are more
than two times more likely to survive pregnancy and childbirth
than women who have short intervals of 9 to 14 months. Birth
intervals of 27 to 32 months are also associated with lower inci-
dence of third trimester bleeding, premature rupture of mem-
branes, anemia, and other negative outcomes (Conde-Agudelo
and Belizan 2000).
Recent research suggests that birth intervals of three to five
years provide even greater benefits than the two-year intervals
that were previously promoted. One study assessed the effect of
this longer birth interval in more than 430,000 pregnancies in
18 countries and found that children who are born three to five
years after the preceding birth are more likely to survive from
the perinatal period through age five. Children born at intervals
of three to five years are also 1.2 to 1.4 times less likely to be
malnourished or underweight or to experience stunting than
those born at intervals shorter than two years (Rutstein 2003).
Putting together a range of patchy data on the effect of fam-
ily planning on child mortality can yield estimates of the total
global impact, but those estimates are highly dependent on
assumptions and have varied widely. The World Bank (1993)
estimated that family-planning programs could prevent
between 20 and 40 percent of all infant deaths by preventing
mistimed and underspaced births. In a study of 25 countries,
Hobcraft (1994) estimated that if all birth intervals of less than
two years were prevented, child mortality levels would be
reduced by an average of 17 percent and up to one-third in
several countries. Rutstein (2003) found that birth spacing
of three to five years alone could prevent up to 46 percent of
infant mortality. Muhuri and Menken (1997) found that in
rural Bangladesh poor spacing and timing accounted for
25 percent of child mortality. Trussell and Pebley (1984) esti-
mated that spacing could decrease infant mortality by 10 per-
cent and child (age 1 to 5) mortality by 21 percent. Another
study found that, even in Latin America, which has lower child
mortality rates, spacing could reduce perinatal mortality by
14 percent (Conde-Agudelo and Belizan 2000).
In a study of 19 African countries, Rafalimanana and
Westoff (2001) found that median actual birth intervals in
every country were shorter than the preferred birth intervals
reported by women, reflecting the substantial unmet need for
birth spacing. Achieving preferred intervals would decrease
neonatal mortality by only 6 percent on average, and infant
mortality by a comparable amount, whereas removing all short
intervals would decrease both by 13 percent.
Women giving birth for the fourth or higher time are at
much higher risk of maternal complications and death.
Independent of a woman’s age, her risk of dying when giving
birth for the fourth or higher time is 1.5 to 3 times greater than
during a second or third birth (Winikoff and Sullivan 1987).
Women who have had at least three births are also more likely
to experience hemorrhage, uterine rupture or prolapse, or kid-
ney disease (Maymon and others 1998).
Children born to mothers who have had many births face
risks similar to those of children born to older mothers; they are
often the same women. Children born to mothers who have had
three or more births are more likely than those born to younger
mothers (those under age 20) to die before age 5 (Bicego and
Ahad 1996; Sullivan, Rutstein, and Bicego 1994). Women who
have had many births are also more likely to have stillbirths or to
bear children with congenital abnormalities who may not sur-
vive childhood (Cnattingius and others 1992; Fretts and Usher
1997). Children from larger families often receive lower levels of
education and health care than children from smaller families
because of competition for finite family resources (Blake 1981).
Women with preexisting health conditions often face greater
risks in pregnancy and childbirth. Pregnancy can aggravate
conditions such as high blood pressure, heart disease, malaria,
anemia, tuberculosis, hepatitis, and STIs, including HIV.
Indirect causes, including these preexisting conditions, ac-
count for an estimated 20 percent of maternal deaths each year
(WHO 1997).
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INTERVENTIONS
The “intervention” of contraception can be considered as the
method itself and as the means by which family-planning
clients obtain services (including counseling) and contracep-
tive commodities. Both the methods and the types of services
are diverse.
Contraceptive Methods 
Contraceptive methods can be classified as permanent and
long term—primarily for those women and couples who have
completed childbearing—or temporary—primarily for those
women and couples who wish to delay pregnancy.
Permanent and Long-Term Methods. Female sterilization, or
tubal ligation, used by about 187 million women worldwide
(WHO 2002a), is the most popular and effective contraceptive
available. The most effective types of female sterilization have a
10-year cumulative pregnancy rate of 7.5 per 1,000 procedures
(Peterson and others 1996).
Sterilization accounts for one-third of all contraceptive
practice. Because sterilization is considered a permanent form
of contraception, some women may regret their decision dur-
ing ensuing years. Some dissatisfaction with sterilization is
expected and is always observed among sterilized populations;
in most cases, the proportion of women regretting sterilization
falls below 10 percent. Regret is higher when sterilization was a
woman’s first and only contraceptive method, when a woman
was sterilized at or under age 30, or when a woman has fewer
than four living children (Loaiza 1995).
Between 40 million and 50 million men worldwide have
undergone a vasectomy, a figure representing 8 percent of the
world’s couples of reproductive age. This method comes in
fourth in contraceptive popularity, after female sterilization
(19 percent), the intrauterine device (IUD; 13 percent), and
oral contraceptives (“the pill”; 8 percent), and right ahead of
the male condom (4 percent; WHO 2002a). The method is as
effective as female sterilization (failure rate of less than 1 per-
cent) and much simpler and safer than tubal ligation.
The IUD is now used by 150 million women worldwide, or
about 13 percent of the world’s women of reproductive age,
because of its efficacy, safety, and convenience. After female
sterilization, it is the most popular method of contraception.
The 5-year life span of the IUD means fewer visits to health
providers and less expenditure of money, time, and effort.
IUDs prevent pregnancy through several mechanisms: they
alter sperm migrations, inhibit fertilization, and generate a
foreign-body reaction in the endometrium. Progestogen-
releasing IUDs cause changes in the amount and viscosity of
cervical fluid, altering sperm penetration. In a small percentage
of women, ovulation is inhibited in the first two years of use.
Failure rates for all copper-bearing IUDs are usually less than 1
per 100 women in the first year of use.
Temporary Methods. By far the most popular temporary con-
traceptive method is the oral contraceptive, commonly known
as “the pill,” which has a failure rate typical use of less than
10 percent over a year. Among 67 developing countries for
which survey data are available (not including China or India),
about 50 percent of married women who have ever used contra-
ception have used the pill at some point. The pill has been most
popular in Latin America; there, about 55 percent of all married
women have used the pill. In the Near East and North Africa,
about one-third of married women have used the pill, and in
Sub-Saharan Africa, about 15 percent have used it at some time
(Johns Hopkins Population Information Program 2000).
More than 20 million women use systemic contraceptives
containing only progestins. These contraceptives include
subdermal implants such as Norplant, injectable products,
IUDs, and vaginal rings. These products have high rates of con-
traceptive efficacy (0.3 to 1.0 percent failure rate over 12
months). Their long duration of action allows for a relatively
infrequent dose. Their main drawbacks are their tendencies to
cause highly irregular endometrial bleeding and amenorrhea.
Although altered bleeding does not have any ill health effects, it
does pose a problem for women in societies that bar or restrict
women from certain social and religious activities during men-
struation. The World Health Organization estimates that
between 10 and 30 percent of women abandon their progestin-
only methods for this reason (WHO 2002a).
Barrier methods, although less effective than hormonal
methods, IUDs, or sterilization, can offer effective contracep-
tion when used consistently and correctly. Barrier methods,
and particularly condoms, are the only type of contraception
that offers additional protection against STIs.
When used correctly during every act of sexual intercourse,
the male latex condom is effective against both unwanted preg-
nancy and HIV infection and other STIs. Typical use results in
pregnancy rates of 3 to 14 percent per year. If a condom breaks
or tears during intercourse, emergency contraception can be
used to reduce the risk of pregnancy.
The female condom, made of soft, pliable polyurethane and
prelubricated with a silicone-based substance, is inserted into
the vagina before sexual intercourse. The female condom is
slightly less effective than the male condom, with a failure rate
of 5 to 21 percent. Unlike the male condom, the female condom
can be inserted up to eight hours before intercourse. The
female condom adds to the arsenal of weapons in the fight
against STIs; offers women more control in sexual negotiations;
can be used in conjunction with the IUD, hormonal methods,
and sterilization; and has no special storage requirements.
The diaphragm, although not a popular method in develop-
ing countries, is being studied as a means of preventing not
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only pregnancy but also bacterial STIs. Results from those
randomized trials are pending.
Emergency Contraception. Since the mid 1960s, the use of
certain oral contraceptives has been shown to be effective in
preventing pregnancy. Two hormonal regimens have proved to
be both safe and effective for emergency contraception: com-
bined oral contraceptives and progestogen-only pills. Both
can be taken for up to 120 hours after unprotected intercourse.
Emergency contraception represents a second chance to prevent
an unwanted pregnancy after unprotected sex, and it is particu-
larly responsive to the needs of youths and of women who have
been coerced into intercourse.
Despite the demonstrated safety and efficacy of emergency
contraception, its acceptance by providers and the public,and its
inclusion on the WHO’s essential drug list, emergency contra-
ception is not widely available in many developing countries
(Langer and others 1999).
ORGANIZATION OF FAMILY-PLANNING
PROGRAMS
Because of the variety of users and methods of contraception,
a range of quite distinct ways to deliver needed goods and
services has been developed and tried over the past several
decades.Some programs are dedicated to providing only family-
planning services, often referred to as vertical programs; some
provide a range of reproductive and other health services,
loosely termed integrated programs; and some try to reach
current and potential clients through social marketing and
community-based distribution methods.
Vertical versus Integrated Service Delivery
The original large-scale family-planning programs in develop-
ing countries, many of which were launched on the basis of the
demographic rationale, tended to be organized around a verti-
cal structure with central management and logistics. Family-
planning workers based at fixed sites—whether run by
government agencies or by nongovernmental organizations
(NGOs)—were dedicated exclusively to providing informa-
tion, services, and contraceptive commodities related to family
planning. Funding, often from external donor agencies, was
earmarked for family-planning activities. In many instances,
the supervisory, budgeting, training, and logistics systems were
all separate from those of other health services. Some of the
largest vertical programs, such as the India program, promoted
sterilization on a large scale, sometimes provided through rudi-
mentary health facilities. Others, such as the Bangladesh pro-
gram, relied on the provision of information and commodities
through female outreach workers going house to house.
In the past two decades, increasing emphasis has been
placed on integrating family-planning programs into other
health services, particularly other types of reproductive health
services. Under this arrangement, family-planning services are
delivered in conjunction with routine primary care—a recog-
nition that women’s health needs are in no way confined to
contraception and that a broad range of reproductive and other
health services must be provided.
Social Marketing 
Social marketing refers to a variety of strategies using tradi-
tional commercial-marketing techniques to promote socially
beneficial behaviors, products, and services. In family planning,
social marketing has focused on making supplies of methods
of contraception widely available in existing commercial retail
outlets and on promoting these contraceptives to consumers
through mass media. In recent years, social-marketing pro-
grams have expanded their focus to behavior change and the
delivery of clinical services through social franchises.
In countries with low contraceptive prevalence, social-
marketing programs for contraceptives typically import
donated contraceptives and then repackage and promote them
with their own sales force. In higher-prevalence countries, pro-
grams may partner with commercial manufacturers to market
existing brands, often subsidizing promotion in exchange for
price guarantees. In the Dominican Republic, for instance, the
oral contraceptive manufacturer Schering agreed to cut the
price of its pills in half in exchange for advertising by a social-
marketing organization.
Most social-marketing programs for contraceptives distrib-
ute commodities through existing commercial outlets, such as
shops, pharmacies, and tobacco shops. Retailers make a small
profit, which increases their incentive to stock and promote the
products. Because such programs do not spend money build-
ing their own distribution network, they typically enjoy low
costs per output.
Social-marketing programs have achieved dramatic contra-
ceptive sales throughout the developing world, providing
contraception to about 10 million couples in 60 countries, in
addition to promoting a variety of other health products.
However, evidence from cross-national studies suggests that
social marketing’s effect on contraceptive use is driven less by
its brand sales—because users often switch brands—and more
by its promotional activity (Bulatao 2002).
INTERVENTION COST AND COST-EFFECTIVENESS
Synthesizing data on family-planning costs, outputs, and out-
comes to inform resource allocation has distinct challenges.
First, nearly all existing studies have estimated average—not
marginal—costs. The dearth of marginal cost data, general to
most of the cost-effectiveness studies presented in this volume,
severely weakens the ability to recommend interventions.
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Second, cost data based on units of output that cannot be
linked to health outcomes have limited use. Most studies on
effectiveness have not included costs, and most studies on costs
have not included effectiveness. In the family-planning litera-
ture, cost per output (such as the cost per couple-year of pro-
tection, or CYP) has often been called cost-effectiveness. Here,
we reserve the term cost-effectiveness for measures of cost per
unit of health impact (Gift, Haddix, and Corso 2003). Those
studies that have measured cost-effectiveness typically come
from mature programs, where both marginal costs and mar-
ginal effects are likely to be low.
Third, costs vary considerably according to the accounting
method used, the program setting and scale, the level of latent
demand among couples targeted, the method mix, the quality,
and the existing supply and service infrastructure (Dayaratna
and others 2000; Janowitz and Bratt 1992). Clinical costs are
particularly sensitive to setting, given the broad differences in
local salaries.
Finally, most evaluations of family planning estimate effects
within a single generation. However, averting a birth also averts
grandchildren, great-grandchildren, and so on. For economic
cost-benefit analyses, the multigenerational effects of a single
birth averted can be significant. However, this consideration
can be addressed through the use of an appropriate discount
rate.
Cost per Output 
The most common measure of output in family-planning pro-
grams is the CYP. Stover and others (1996) estimated the num-
ber of contraceptives of various methods needed to provide
1 CYP, given typical use: 15 cycles of pills, 120 condoms, 120
foaming tablets, or 4 three-month or 12 one-month injecta-
bles. An IUD provides 3.5 CYPs; male and female sterilization,
11 CYPs; and an individual trained in natural methods, 2 CYPs.
IUDs and voluntary sterilization have the lowest cost per
CYP, although they have a high up-front cost. Oral contracep-
tives are usually the least costly methods. Condoms and injecta-
bles are more expensive than the pill, and implants are often the
most expensive method per CYP. Mauldin and Miller (1994)
estimated that, based on the method mix in developing coun-
tries, the weighted average commodity cost of contraception
was US$1.55 per CYP.3
Commodity costs are relatively constant across programs,
although there is some variation owing to bulk procurement.
When program costs are added, costs vary considerably by the
program setting and mode of delivery. A review of programs in
Africa, for instance, found method costs per CYP could vary by
an order of magnitude, with the greatest variation in the cost of
condoms.
Barberis and Harvey (1997) found considerable variation in
costs per CYP by region and mode of service delivery in 14
developing countries. Across regions, costs per CYP were com-
parable in Asia, Latin America, and the Middle East, at US$4.00
to US$5.00. Costs were considerably greater in Africa, where
the average cost per CYP was US$14.00.
The least expensive mode of service delivery was clinical
provision of sterilization, with a weighted average cost of
US$2.34 per CYP. The second most economical mode was
social marketing of contraceptives, although those costs are
highly dependent on setting. In African countries, where such
programs were less developed, the costs were high—up to
US$19.00 per CYP. The weighted average cost of social market-
ing of contraceptives was US$3.00.
Costs of community-based distribution programs ranged
from US$4.85 to US$35.37 per CYP, with a weighted average of
US$12.55. Costs of clinic-based services, excluding steriliza-
tion, ranged from US$4.44 to US$16.65 per CYP, with a
weighted average of US$7.93. Clinic-based services supple-
mented with community-based distribution were the most
expensive mode of service delivery, ranging from US$4.44 to
US$19.38, with a weighted average of US$18.21. As noted
above, these estimates have typically not included costs to users
(see table 57.3).
Marginal Costs 
Knowles and Wagman (1991) found that unit costs decline as
the number of contraceptive users increases. Larger programs
enjoy an economy of scale in procurement; average costs
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Table 57.3 Weighted Average Program Costs per CYP, 
by Region and Mode of Delivery
(2001 U.S. dollars)
Region Mode of service delivery Cost per CYP
Africa Social marketing 15.95
Community-based distribution 20.32
Clinics 16.65
Clinics with community-based distribution 8.02
Asia Social marketing 2.59
Community-based distribution 6.50
Clinics 5.07
Clinics with community-based distribution 19.38
Latin America Social marketing 1.64
Community-based distribution 35.37
Clinics 6.40
Clinics with community-based distribution 6.47
Middle East Social marketing 3.82
Community-based distribution 4.85
Clinics 4.44
Clinics with community-based distribution 9.03
Source: Adapted from Barberis and Harvey 1997.
decrease as fixed costs from training and from information,
education, and communication (IEC) programs are distrib-
uted over more units; labor may be more efficiently used at
higher volumes; and larger programs may be further ahead on
the learning curve. However, as marginal costs diminish with
size, so may marginal returns in mature programs (Haaga and
Tsui 1995).
High rates of underutilization suggest marginal costs may be
close to zero for many clinics. Knowles and Wagman (1991) and
Janowitz and others (1996) found underutilization of clinical
capacity in Morocco and Bangladesh. In Morocco, more than
a third of all labor costs were spent waiting for patients. Foreit
and others (1992) found that administrative costs accounted
for 16 to 65 percent of fixed costs for a sample of clinics, whereas
capacity utilization ranged from only 32 to 76 percent.
One study of a community-based distribution project in
Bangladesh found that marginal costs represented 20 to 40 per-
cent of average costs and decreased with scale (Attanayake,
Fauveau, and Chakraborty 1993). In social-marketing pro-
grams, marginal costs are close to commodity costs less
revenue (Bulatao 1993). A weighted average of current com-
modity costs based on the existing method mix in developing
countries suggests a marginal cost of about US$1.55 per CYP
(Mauldin and Miller 1994).
Cost-Effectiveness Outside of Programs
The estimates of cost-effectiveness included here show only the
direct health benefits of family planning for women and chil-
dren from increasing birth intervals and reducing teenage preg-
nancies. As noted earlier, these estimates ignore important ben-
efits of family planning for the health of families. Because of
data limitations, most of these omissions cannot be corrected
here. Some are a general consequence of using the global
burden-of-disease framework, which takes disease, rather than
health interventions, as the starting point. This orientation
makes results less useful for the purpose of setting priorities in
health care, particularly for interventions, such as family plan-
ning, that affect a number of sequelae (Williams 1999).
Despite the abundance of cost-per-output data in family
planning, these data cannot be used to set priorities in health
funding because the protection offered by a unit of contracep-
tion is related to the behavior of a particular user. Several stud-
ies have sought to estimate a program’s impact on fertility as a
simple division of CYPs distributed in a population by the
mean birth interval in the population (Cakir, Fabricant, and
Kircalioglu 1996). However, such adjustments are not substi-
tutes for actual measures of impact.
A considerable literature has developed around the prob-
lems of using CYP as a measure of protection (for reviews, see
Fort 1996 and Shelton 1991). The typical calculation of CYPs
does not account for use-failure rates, wastage, and client char-
acteristics such as fecundity, coital frequency, use effectiveness,
or frequency of contraceptive use—one couple using condoms
all the time has a greater effect on fertility than two couples
using condoms half the time.
Most critically, even if CYP were an appropriate measure of
protection, CYPs do not account for method substitution. Many
clients who obtain contraceptives from a family-planning pro-
gram, at some program expense, were buying or would other-
wise have bought contraceptives from commercial providers or
would have relied on natural methods. Community-based dis-
tribution programs, for instance, may be more expensive per
CYP than social-marketing programs, but if such programs
reach more nonusers than social-marketing programs, they may
be more cost effective in preventing unwanted pregnancies.
Similarly, sterilization is the cheapest method per CYP, but in
many countries, it has a limited impact on fertility.
Three examples demonstrate the hazard of confusing out-
put, or even intermediate outcomes, with impact. Jensen (1996)
found that public providers in Indonesia, while more expensive
per CYP than private providers, had a greater effect on fertility
per unit output. Public programs may have reached more
nonusers. Janowitz and others (1992) found that a Honduran
social-marketing program distributed more than 40,000 CYPs
but had no net effect on contraceptive prevalence. Users substi-
tuted one contraceptive brand or method for another. Bertrand
and others (1986) found that a community-based distribution
program in then Zaire increased modern contraceptive preva-
lence without affecting total contraceptive prevalence. Modern
methods were substituted for traditional ones, such as pro-
longed lactation, periodic abstinence, or withdrawal. (Such
substitution can be an improvement when the traditional
method replaced is rhythm or withdrawal, but there is no more
protective contraception than postpartum abstinence.)
Cost-effectiveness analysis thus requires true estimates of
project effect—the difference between what happens in a pro-
ject’s presence and what happens in that project’s absence. A
number of studies have estimated effect, measuring births
averted, total or unwanted pregnancies averted, unsafe abor-
tions averted, maternal and child deaths averted, and measures
of health utility, such as the disability-adjusted life year (DALY).
As table 57.4 shows, costs vary significantly within regions.
In some regions, maximum and minimum costs differ by two
orders of magnitude. Our sensitivity analysis found that the
cost-effectiveness of programs was most sensitive (as a percent-
age of swing) to the existing level of unmet need for birth
spacing and limiting.
Costs per Births Averted. In a review, Pritchett (1994) found
that costs per birth averted ranged from US$37 in Jamaica,
the Philippines, and Thailand to US$415 in Nepal, with the
median value of 12 studies being US$82. Cochrane (1988)
estimated US$78 per averted birth in a cross-national analysis.
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Experimental studies in Bangladesh estimated the cost per
averted birth at US$95 (Attanayake, Fauveau, and Chakraborty
1993), US$281 (Pritchett 1994), US$293 (Balk and others
1988), and US$296 (Simmons, Balk, and Faiz 1991), varying by
the accounting method used. The Bangladesh experiment was
likely more expensive than other programs, as it involved a fre-
quent schedule of visitation for community-based distribution.
The model we developed for the Disease Control Priorities
Project produced costs between US$87 and US$163 per birth
averted, with costs lowest in Latin America and the Caribbean
and in the Middle East and North Africa.
Costs per Death Averted. Walsh and others (1993) estimated
that in a typical high-mortality country with a 20 percent con-
traceptive prevalence rate, family-planning programs cost
US$8,261 per maternal death averted and US$1,276 per peri-
natal infant death averted. In a setting with high mortality and
low contraceptive prevalence rates, offering family planning
alone was considerably more cost-effective in averting both
maternal and infant deaths than offering an integrated pro-
gram including prenatal care and birth attendant training. The
model developed for the Disease Control Priorities Project pro-
duced regional average costs between US$5,172 and US$34,564
per maternal death averted and between US$1,367 and
US$4,907 per infant death averted. Costs were lowest in South
Asia and Sub-Saharan Africa. Costs within regions varied by as
much as two orders of magnitude.
Stover (2003) estimated that by offering family-planning
services at PMTCT and voluntary counseling and testing sites in
countries with high HIV prevalence, child HIV infections could
be averted at a cost of US$489, and child deaths could be averted
at a cost of US$278 per event—well below the costs of averting
these events using traditional PMTCT services. In addition,
these family programs would avert orphans at a cost of US$278,
and maternal deaths at a cost of US$1,824 per event.
Costs per DALY. The 1993 report on world development
(World Bank 1993) estimated that family-planning programs
in low-income countries cost from US$40 to US$60 per DALY.
In the first edition of Disease Control Priorities in Develop-
ing Countries, Jamison (1993) estimated the costs of IEC or
behavior-change communication (BCC) programs promoting
condom use for family planning at between US$20 and
US$100 per DALY, depending on child and maternal mortality
rates.
Average costs for regions per YLL ranged from US$37 to
US$110. Costs per DALY and year of life lost (YLL) were lowest
in South Asia and Sub-Saharan Africa, whereas costs per year
lived with disability (YLD) were lowest in South Asia and in
East Asia and the Pacific. As with costs per death averted, costs
per DALY varied within regions by as much as two orders of
magnitude.
Family-planning programs that target HIV-positive women
to prevent mother-to-child transmission may be even more
cost-effective. According to an analysis of Stover’s (2003)
estimates, such programs cost about US$5 per DALY. In com-
parison, traditional PMTCT services, including antiretrovirals
and replacement feeding, cost US$37 per DALY, and nevirapine
regimens cost US$5 to US$12 per DALY (Marseille and others
1999; UNAIDS 1999). Kumar (2000) found that adding family-
planning and abortion services to PMTCT programs increased
their cost-effectiveness from US$124 per DALY for a short-
course antiretroviral drug regimen to US$93 per DALY for an
integrated strategy. Despite its cost-effectiveness, family plan-
ning is not currently included in most policies addressing
mother-to-child transmission of HIV.
Cost-Effectiveness within Programs 
Few studies compare the cost-effectiveness of program designs
and elements—for instance, between social marketing and
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Table 57.4 Average Costs per Benefit of Family Planning 
(2001 U.S. dollars)
Disability- Years Years 
Infant Maternal adjusted of life lived 
Births deaths deaths life years lost with 
Region averted averted averted saved averted disability
East Asia and the Pacific 163 4,907 12,880 60 110 103
Latin America and the Caribbean 87 2,316 34,564 53 66 187
Middle East and North Africa 97 1,989 18,917 49 55 209
South Asia 113 1,577 5,172 30 37 98
Sub-Saharan Africa 131 1,367 10,231 34 37 194
Source: Authors, based on a model by AGI and others (2000).
Note: The model used country-level data for 68 developing countries. Output costs were based on Population Action International estimates in 1994 of the public sector cost per user. Estimates are not
available for Eastern Europe and Central Asia.
community-based distribution, or between price subsidies and
promotional spending. Thus, although donors or government
ministers may have enough information to justify funding
family-planning programs, managers of such programs have
much less information to use in deciding how best to spend
money within their programs.
Program Inputs. Roughly half of program funds are spent
subsidizing price (Sanderson and Tan 1996), but there is little
evidence that price subsidies significantly affect contraceptive
use, even among the poor (Matheny 2004). In every demo-
graphic and health survey over the past decade, price has been
reported as a barrier to contraceptive use by fewer than 2 per-
cent of women with unmet need. Several studies suggest that
even the poorest urban users are typically willing to pay com-
mercial contraceptive prices—once they intend to contracept.
This finding is not entirely surprising, because the economic
costs of childbearing dwarf those of contraception (Pritchett
1994). Particularly if profits are reinvested in a program’s qual-
ity of services, higher prices may permit the provision of
amenities that attract more clients (Foreit and Levine 1993;
Litvack and Bodart 1993).
The most commonly reported barriers to contraceptive use
are lack of knowledge, health concerns, and social disapproval
(Casterline and Sinding 2000). It is likely, then, that the most
cost-effective inputs are those that address these barriers—by
increasing accurate knowledge about and social acceptance of
contraception, as well as by improving the quality of and access
to a variety of contraceptive methods.
Evidence suggests that quality has improved contraceptive
use for birth spacing in Tunisia (Cochrane and Guilkey 1995).
However, results are mixed in Peru (Mensch, Arends-Kuenning,
and Jain 1996) and the Philippines (DeGraff, Bilsborrow, and
Herrin 1993). Schultz (1994) found that, on average, improved
quality does not affect the contraceptive prevalence rate at the
national level.
Some improvements in quality require additional
resources—expanding facilities, adding equipment and staff,
and diversifying services. Quality improvements are necessary
to respond to ethical imperatives. Beyond the ethical ration-
ale, quality improvements can reduce the cost per unit of
output—improving the flow of clients and shifting service
delivery from physicians to paramedics. Improvements in qual-
ity can also increase utilization and allow higher prices to be
charged.
Unfortunately, the relative cost-effectiveness of investments
in these inputs has not been established. However, there is rea-
son to believe that, among all inputs, investments in IEC and
BCC activities are the most cost-effective—especially those that
encourage users to purchase contraceptives or services from the
private sector. Studies in many countries show that exposure to
IEC and BCC messages through television, radio, and print
increases the likelihood of contraceptive use (Dayaratna and
others 2000; Westoff and Bankole 1997). Social-marketing
programs appear to succeed in increasing contraceptive use
principally through their promotional activities (Bulatao
2002). IEC and BCC activities can also increase the efficiency of
clinic programs by increasing caseloads. Last, among all family-
planning activities, IEC and BCC activities may be the most
prone to market failure, providing a strong rationale for public
investment.
Integration. Integrating family planning with other reproduc-
tive health services was a major goal of the 1994 International
Conference on Population and Development. Although the
logic of integration is compelling, little research has been done
on the costs of integrated programs. In theory, integrated pro-
grams should be more efficient because they distribute joint
costs across more services. In clinics, integration should
increase cost-effectiveness if services such as Papanicolaou
smears, ultrasounds, pregnancy testing, abortions, and post-
abortion care are used to cross-subsidize less profitable contra-
ceptive services. Mitchell, Littlefield, and Gutter (1999) found
relatively low family-planning costs in two integrated clinics
and concluded that adding clients has a larger effect on costs in
a clinical setting than adding services does. Mancini, Stecklov,
and Stewart (2003), however, found that vertical programs that
focused exclusively on family planning offered contraceptive
supplies and services at a significantly lower cost per CYP than
integrated programs.
Delivering contraception services alongside abortion or
postabortion care can be cost-effective. Few clinics and hospi-
tals that treat women suffering from abortion complications
offer contraceptive counseling and services as part of their
postabortion care, yet these services are effective in increasing
contraceptive use. The key obstacle is finding support from
abortion providers—especially private providers, who may not
see profit potential in providing family planning. The same is
true of prenatal care. One study in Kenya showed that exposing
women to information about family planning during prenatal
care doubled the likelihood that they would use contraception
(Ndhlovu 1997). A study of 27 countries found that two-thirds
of women had an unmet need for contraception within one
year of their last childbirth (Ross and Winfrey 2001). In fact,
about one-third of all unmet need was among women post-
partum. This need could be satisfied with greater integration of
maternal and child health services and family planning, partic-
ularly during prenatal visits, delivery care, and six-week post-
partum visits.
Finally, integrating STI services with family planning can
help identify women with STIs who wish to avoid risky preg-
nancies and prevent fetal and neonatal complications.
Integrating STI services may also draw more men to family-
planning clinics.
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EQUITY: DISTRIBUTING THE BENEFITS
OF SUBSIDIES 
It is the poorest whose health and prosperity are most threat-
ened by unwanted pregnancies, and who are least able to pay
for family-planning services. Yet a significant portion of public
subsidies for family planning benefit the wealthy. This outcome
is in part a natural consequence of the demand for family plan-
ning. Wealthier couples typically want smaller families than
poorer couples. If subsidies follow demand rather than need,
they will concentrate among the wealthy. However, because
there is substantial unmet need for family planning among
poor couples, an efficient segmentation of the market would
have subsidized providers target poorer clients and unsubsi-
dized providers target wealthier clients.
In a study of 10 countries, Sine (2002) found that nonpoor
users obtained 45 percent of subsidized oral contraceptives and
56 percent of subsidized condoms supplied by governments
and nonprofit organizations. An analysis in Indonesia found
that only 16 percent of public subsidies for family planning
accrued to the poorest quartile. In the Philippines, 64 percent
of subsidies accrued to the richest half of households, whereas
17 percent accrued to the poorest quarter. In the Philippines,
the distribution of subsidies varied widely by contraceptive
method, with vasectomy subsidies concentrated among the
poor and condom subsidies concentrated among the middle
class (Haaga and Tsui 1995).
Behrman and Knowles (1998) found that the family-
planning program in Vietnam was only weakly pro-poor. The
main source of inefficiency stemmed from the greater use of
more heavily subsidized government providers, particularly
hospitals, by wealthier clients. One study in Bangladesh found
that, although family-planning workers had the largest effect
on the contraceptive behavior of uneducated women, the
workers—who typically come from the educated class—were
more likely to visit educated women (Arends-Kuenning 1997).
For similar reasons, clinics are often located in wealthier areas.
Whereas a significant share of wealthier users obtain subsi-
dized goods, a large share of poor users obtain goods from the
commercial sector. In a study of 12 countries, more than half of
even the poorest condom users purchased condoms from the
commercial sector in all countries but the Philippines (Foreit
1999). Sine (2002), in turn, found that 20 percent of poor and
near-poor users obtained their oral contraceptives from the
commercial sector, even in countries where free or subsidized
brands were available.
ECONOMIC BENEFITS OF INTERVENTION
Contraception or family planning can yield long-term eco-
nomic benefits through three main routes. One is reasonably
direct and easy to quantify; the others are more complex. First,
contraception can produce economic benefits by reducing
maternal mortality and morbidity and improving child
health—benefits that can be captured through estimates of
savings to the health system.
Second, contraception can have economic payoffs if it oc-
curs in a setting where high fertility is constraining economic
growth. Longstanding arguments in development economics
have centered on whether rapid population growth acts as a
drag on economic growth. Some camps argued that high fertil-
ity, in particular, would condemn a country to slow (or even
negative) per capita income growth. Others argued that the
negative effects would be mild and short lived, as households
adapt to existing resource constraints by reducing childbearing
and as technological changes, such as those that result in higher
agricultural yields, alter the productivity equation. By the late
1990s, however, a consensus emerged from examination of
more than 40 years of experience and data: rapid population
growth, in general, and high fertility, in particular, typically
lead to slower economic growth and higher levels of poverty
than would otherwise be realized (Birdsall and Sinding 2003).
Third, when contraception reduces the rate of population
growth, it can have multiple effects (economic and other) on the
environment. High fertility, coupled with rural-to-urban
migration, has led to rapid urban growth, often outpacing the
provision of clean water and sanitation. In an analysis of 42 cities
in Latin America, Asia, and Africa, Brockerhoff and Brennan
(1998) found that urban growth rates were positively correlated
with infant mortality rates, likely owing to crowding, a weaken-
ing of the public infrastructure, and increased air pollution.
Ambient air pollution is now emerging as a serious threat to
human health in virtually all the large cities in the world, respon-
sible for 1 percent of global deaths and DALYs (WHO 2002b).4
Population growth is also responsible for much of the
increase in carbon emissions that contribute to global climate
change. Although developing countries account for only
20 percent of carbon emissions today, some researchers have
estimated that these countries will account for 50 percent by
2050, given current rates of development (Bongaarts 1992).
Bongaarts estimated that population growth would account for
48 percent of the growth in carbon emissions in developing
countries between 1985 and 2100. Birdsall (1994) estimated
that realistic reductions in fertility could reduce emissions in
2050 by as much as 15 percent in developing countries; more
important, however, she estimated that by reducing fertility,
family-planning programs could reduce emissions more cost-
effectively than taxes on carbon emissions could. Similarly,
Brinkley, Potts, and Walsh (2003) found that family-planning
programs are likely more cost-effective than any emissions pol-
icy. (At the same time, it is important to note that the largest
per capita consumption of nonrenewable natural resources
occurs in the low-fertility settings of wealthy countries, where
policies promoting conservation are overdue.) 
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RESEARCH AND DEVELOPMENT AGENDA 
The agenda for research and development in the field of con-
traceptives and family planning is ample. It benefits from a
strong tradition of data- and research-driven policy and pro-
grammatic decisions. Priorities suggested below fall into the
realms of science, operations (or program), and policy.
On the scientific agenda, the top priority must be the devel-
opment of contraceptive products that protect women and
men against both pregnancy and HIV infection in ways that are
more acceptable from a user perspective than male or female
condoms. Two other high-priority topics are the development
of male contraceptives and of microbicides, a female-controlled
method that protects against both STIs (especially, HIV) and
unwanted pregnancy.
With respect to operations research, high-priority questions
include how to reach adolescents effectively and cost-effectively;
what to do in settings where progress has stalled (for example,
Bangladesh); and how to stimulate demand for family planning
in Sub-Saharan African countries, where the demand is rela-
tively low.
Another important and neglected topic is how to introduce
the sexual health dimension into contraceptive services. In gen-
eral, providers do not take into account sexuality and sexual
health during counseling or service delivery, in spite of the
mutual influence between sexual behavior and preferences and
contraception. On the one hand, women and couples’ sexual
activities strongly influence the adoption of contraception, and
the preference of these women and couples for a certain
method, in turn, influences its effective use and continuity. On
the other hand, particular characteristics of the different meth-
ods affect women’s and couples’ perceptions of their own sexu-
ality (Bruce 1987). In spite of these obvious links, neither the
family-planning literature nor family-planning services have yet
paid enough attention to the matter (Dixon-Mueller 1993).
On the policy research agenda, further research is required to
understand the relationship between fertility and other repro-
ductive health outcomes and economic outcomes at microeco-
nomic and macroeconomic levels. Such research includes, for
example, a careful analysis of how access to contraception may
affect women’s productivity, as well as human capital invest-
ments in the next generation. In addition, better understanding
of the distributional effect of family planning and other repro-
ductive health services would inform policies about how best to
target public resources.
NOTES
1. These are 2001 averages; country-by-country figures are 2000 and
earlier.
2. One problem in applying the burden-of-disease framework to fam-
ily planning is unique to interventions that affect the size of a population.
In most effectiveness analyses, one compares the state of the world with a
particular program to the state of the world without that program.
However, effectiveness analyses using disabilty-adjusted life years (DALYs)
are typically not conducted this way. The number of DALYs averted by
family planning is not the number of DALYs without a family-planning
program minus the total number of DALYs with a family-planning pro-
gram. Given the negative nature of DALYs as a measure, such an exercise
would lead to an absurd result. Nearly all lives have some number of
DALYs attached to them. These DALYs may be averted most cost-
effectively by preventing all births, reducing the burden of disease to zero.
To avoid this result, we cannot measure the effect of family planning by
comparison with a pure counterfactual. Rather, it is measured by ignoring
the DALYs that would have been attributed to contingent persons. By the
definition of DALYs, no individual can have any expectation of healthy life
until the moment of live birth. This, however, is not an ideal solution. Both
parents and health practitioners typically want to avoid perinatal deaths,
even if doing so means preventing the birth of an infant. This fact suggests
that one aim of health care is to prevent the ill health of contingent
persons—in which case we ought, at least in some circumstances, to meas-
ure the potential DALYs averted by preventing a birth.
3. All dollar amounts are expressed in 2001 U.S. dollars. In a few cases,
the year was not specified in the original source, and currency was con-
verted from the year of publication.
4. Because of data limitations, these DALYs include no morbidity.
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The paradigmatic shift in the past decade in our understanding
of the role of health and nutrition in school-age children has
fundamental implications for the design of effective programs.
Improving the health and nutrition of schoolchildren through
school-based programs is not a new concept. School health
programs are ubiquitous in high-income countries and most
middle-income countries. In low-income countries, these pro-
grams were a common feature of early, particularly colonial,
education systems, where they could be characterized as heavily
focused on clinical diagnosis and treatment and on elite
schools in urban centers. This situation is changing as new
policies and partnerships are being formulated to help ensure
that programs focus on promoting health and improving the
educational outcomes of children, as well as being socially pro-
gressive and specifically targeting the poor, girls, and other dis-
advantaged children. This evolution reflects five key changes
in our understanding of the role of these programs in child
development.
• First, ensuring good health at school age requires a life cycle
approach to intervention, starting in utero and continuing
throughout child development. In programmatic terms this
requirement implies a sequence of programs to promote
maternal and reproductive health, management of child-
hood illness, and early childhood care and development.
Promoting good health and nutrition before and during
school age is essential to effective growth and development.
• Second, operations research shows that the preexisting
infrastructure of the educational system can often offer a
more cost-effective route for delivery of simple health inter-
ventions and health promotion than can the health system.
Low-income countries typically have more teachers than
nurses and more schools than clinics, often by an order of
magnitude.
• Third, empirical evidence shows that good health and nutri-
tion are prerequisites for effective learning. This finding is
not simply the utopian aspiration for children to have
healthy bodies and healthy minds, but also the demonstra-
tion of a systemic link between specific physical insults and
specific cognitive and learning deficits, grounded in a new
multisectoral approach to research involving public health
and epidemiology, as well as cognitive and educational
psychology.
• Fourth, the provision of quality schools, textbooks, and
teachers can result in effective education only if the child is
present, ready, and able to learn. This perception has addi-
tional political momentum as countries and agencies seek to
achieve Education for All (EFA) by 2015 and address the
Millennium Development Goals of universal basic educa-
tion and gender equality in education access. If every girl
and boy is to be able to complete a basic education of good
quality, then ensuring that the poorest children, who suffer
the most malnutrition and ill health, are able to attend and
stay in school and to learn while there is essential.
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Figure 58.1 Age Distribution of Infection-Specific Morbidity
• Finally, education, including education that promotes posi-
tive health behaviors, contributes to the prevention of
HIV/AIDS—the greatest challenge for generations to come.
School health and nutrition programs that help children
complete their education and develop knowledge, practices,
and behaviors that protect them from HIV infection as they
mature have been described as a “social vaccine” against the
disease.
Because of the success of child survival programs, the num-
ber of children reaching school age (defined as 5 to 14 years of
age) is increasing and is estimated to be 1.2 billion children,
with 88 percent living in less developed countries (U.S. Census
Bureau 2002). As figure 58.1 illustrates, the pattern of disease is
age specific. A large body of evidence shows that these condi-
tions affect cognition, learning, and educational achievement
(see Jukes, Drake, and Bundy forthcoming; Pollitt 1990 for
reviews of this extensive literature).
This chapter focuses on the health, nutrition, and education
of the school-age child and on the programs that can be imple-
mented at school age to promote positive outcomes.
INFECTIOUS DISEASE AND SCHOOL-AGE
CHILDREN
A range of infectious diseases affect school-age children.
Helminth Infections
Between 25 and 35 percent of school-age children are esti-
mated to be infected with one or more of the major species of
worms (Bundy 1997; see also chapter 24). The most common
and important infections are caused by geohelminths (the
roundworm Ascaris, the whipworm Trichuris, and the two
species of hookworms Ancylostoma and Necator) and by the
schistosomes (Schistosoma spp.), which give rise to a wide range
of chronic but largely nonspecific symptoms. The most intense
worm infections and related illnesses occur at school age
(Partnership for Child Development 1998b, 1999) and account
for some 12 percent of the total disease burden and 20 percent
of the loss of disability-adjusted life years (DALYs) from com-
municable disease among schoolchildren (World Bank 1993).
Infected schoolchildren perform poorly in tests of cognitive
function; when they are treated, immediate educational and
cognitive benefits are apparent only for children with heavy
worm burdens or with concurrent nutritional deficits.
Treatment alone cannot reverse the cumulative effects of life-
long infection or compensate for years of missed learning, but
studies suggest that children are more ready to learn after treat-
ment for worm infections and may be able to catch up if this
learning potential is exploited effectively in the classroom
(Grigorenko and others forthcoming). In Kenya, treatment
reduced absenteeism by one-fourth, with the largest gains for
the youngest children who suffered the most ill health (Miguel
and Kremer 2004).
Malaria
Up to 5 percent of children infected with malaria early in life
have residual neurological sequelae (Snow 1999). In areas of
unstable transmission, malaria accounts for 10 to 20 percent of
all-cause mortality among school-age children (Bundy and
others 2000), and those who have suffered repeated attacks have
poorer cognitive abilities. In Kenya, primary school students
miss 11 percent of school days because of malaria, equivalent to
4 million to 10 million days per year (Brooker and others 2000).
Oral antimalarial treatment reduced school absenteeism by
50 percent in Ghana (Colbourne 1955); the use of insecticide-
treated bednets in Tanzania reduced malaria and increased
attendance (Shiff and others 1996). Girls in The Gambia were
more than twice as likely to enroll in primary school if they had
received malaria prophylaxis in early childhood (Jukes and
others submitted).
HIV/AIDS
Although school-age children have the lowest infection preva-
lence of any age group (figure 58.2), an estimated 3.8 million
children under 15 years of age have been infected with HIV and
more than two-thirds have died (UNAIDS 2002). Even unin-
fected children suffer physically, socially, and psychologically
through death or illness in their family (World Bank 2002). The
proportion of orphans, most of whom are of school age, has
risen from 2 to 15 percent in some African countries, with
Acute Respiratory Infection
Acute respiratory infection, the most common acute infection
in school-age children globally, is a significant cause of absen-
teeism. Research in industrial countries (Cohen and Smith
1996) finds that flu infection affects attention and reaction
time; colds primarily affect hand-eye coordination, as well as
reduce the ability to tolerate high levels of noise and other dis-
tractions common to the classroom.
MALNUTRITION, NONINFECTIOUS DISEASE,
AND HEALTH AND EDUCATION
Malnutrition and noninfectious disease also affect school-age
children.
Malnutrition
Stunting (low height for age) is a physical indicator of chronic
or long-term malnutrition, whereas underweight (low weight
for age) is an indicator of both chronic and acute malnutrition.
Both are common in school-age children (figure 58.3).
Girls who are better nourished are more attentive and more
involved during class, and boys have improved classroom
behavior and increased activity levels. One Z-score increase in
height for age is associated with an increase of 0.1 standard
deviation (SD) in tests of arithmetic and language. Stunted
children enroll in school later than other children. School food-
service programs have been successful in improving school
attendance.
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AIDS accounting for 50 percent of this increase. The number of
orphans is expected to reach more than 25 million by 2010.
School-age children with HIV infections have lower IQ
levels and poorer academic achievement, language, and visual
motor functioning. These deficits can be reduced or reversed
with antiretroviral therapy. The improvement is greater for
children of school age than for younger children.
6
Age (years)
1.0
2.0
0
3.0
Z-score
3.5
7 8 9 10 11 12 13 14 15 16 17 18
0.5
1.5
2.5
Source: Data from Partnership for Child Development 1998a.
Note: Z-scores of less than 2 indicate stunting.
Ghana Indonesia
Tanzania
India
Vietnam
Figure 58.3 Mean Z-Scores of Height-for-Age of Boys in Five
Countries 
1094 | Disease Control Priorities in Developing Countries | Donald A. P. Bundy, Sheldon Shaeffer, Matthew Jukes, and others
Short-Term Hunger
Hunger, which reduces ability to perform school tasks, is read-
ily reversed by feeding. Children age 11 to 13 years in Jamaica
improved their scores on arithmetic tests after one semester of
receiving breakfast at school because they attended more regu-
larly and studied more effectively (Simeon 1998). Missing
breakfast impairs performance to a greater extent for children
of poor nutritional status, who also benefit most from food
intervention (Pollitt, Cueto, and Jacoby 1998; Simeon and
Grantham McGregor 1989).
Micronutrient Deficiency
Micronutrient deficiencies may take several different forms,
each with negative impacts on children’s ability to perform well
in school.
Iron Deficiency. Iron deficiency, the most common form of
micronutrient deficiency in school-age children, is caused by
inadequate diet and infection, particularly by hookworm and
malaria (Hall, Drake, and Bundy 2001). More than half the
school-age children in low-income countries are estimated to
suffer from iron deficiency anemia (Partnership for Child
Development 2001). Children with iron deficiency score 1 to 3
SD worse on educational tests and are less likely to attend
school. Iron supplementation reduces these deficits.
Iodine Deficiency. Iodine deficiency affects an estimated
60 million school-age children; studies indicate prevalence
rates between 35 and 70 percent. Iodine deficiency is related to
lowered general cognitive abilities and tests scores. No conclu-
sive evidence shows that iodine supplementation improves
cognitive abilities in this age group (Huda, Grantham-
McGregor, and Tomkins 2001).
Vitamin A Deficiency. Vitamin A deficiency affects an esti-
mated 85 million school-age children. The deficiency, which
causes impaired immune function and increases risk of
mortality from infectious disease, is an important cause of
blindness. Recent studies suggest that this deficiency is also
a major public health problem in school-age children.
Multiple-micronutrient supplements have improved cogni-
tive function and short-term memory in schoolchildren and
have reduced absenteeism caused by diarrhea and respiratory
infections.
Obesity
An estimated 17.6 million children worldwide are overweight.
Obesity is associated with underperformance in education. In
low-income countries obesity is still rare, but the prevalence in
the children of many middle-income countries is similar to
that in the United States.
ESTIMATING THE BURDEN OF DISEASE
The cost per DALY of school health programs has been esti-
mated at US$20 to US$34, implying that the programs are at
least as cost-effective as many other public health “best buys”
(Bobadilla and others 1994). However, current methods of
estimating the burden for school-age children result in a signif-
icant underestimation of both the developmental conse-
quences of disease and malnutrition at school age and the over-
all benefits for health and development of school health and
nutrition programs.
There are two key reasons for this underestimation. The first
issue relates to time scales. Many serious diseases in adulthood,
including heart disease and carcinomas, are a consequence of
unhealthy practices established in early life. This later burden
can be substantially and cost-effectively averted by early inter-
vention, particularly by school-based life-skills programs. For
example, in the United States (Del Rosso and Marek 1996),
US$1 invested can avert US$18.80 spent on the later problems
caused by tobacco and US$5.70 on problems of drug and alco-
hol abuse. DALY estimates cannot capture these downstream
consequences of upstream intervention and instead attribute
the disease burden to the adult age group in which it appears.
This kind of estimate is particularly misleading in the case of
HIV/AIDS, for which prevention education at school age is
effective in averting later infection and disease (World Bank
2002), and in the case of estimates of intergenerational effects,
in which ensuring the health of an adolescent girl may help
secure the health of her baby born a few years later.
The second issue is illustrated by experience with helminth
infections. In 1990, the burden was first estimated at 18 million
DALYs, close to the value for tuberculosis, measles, and malaria.
This estimate reflected the ubiquity of infection and the long-
term consequences of cognitive impacts. In 2001, the estimate
was only 4.7 million DALYs (WHO 2003), and during the inter-
vening years one estimate put the value as low as 2.6 million.
This extraordinary variability is caused in part by different
emphases on the cognitive and health impacts and illustrates
how, for very common conditions, even minor changes in dis-
ability weight can affect the overall values. This variability also
reflects the importance of a sectoral perspective, because the
low estimates reflect a focus on health, whereas the higher
estimates include impact on educational achievement and
child development.
The scale of the burden of disease in terms of cognition is
illustrated by estimating the impact of stunting, anemia, and
helminths on the cognition of the estimated 562 million school-
age children in developing countries. According to typical
deficits in test scores attributable to these diseases, the total glob-
al loss of points ranges from 600 million to 1.8 billion IQ points,
an additional 15 million to 45 million cases of mental retarda-
tion (defined here as IQ less than 70), and a loss of between 200
million and 524 million years of primary schooling (Jukes,
Drake, and Bundy forthcoming). Although the precision of
these striking figures may be open to debate, they clearly show
that even minor cognitive deficits resulting from ubiquitous
conditions can result in an extraordinarily large scale of effect.
INTERVENTIONS
In light of the significant effects of ill health and malnutrition
on educational outcomes, the role of effective health promo-
tion and simple school-based programs to deliver low-cost
interventions becomes increasingly important (Bundy and
others 1992). Other chapters provide information on the
integrated management of childhood illness, early child devel-
opment, and adolescent health (see chapters 63, 27, and 59,
respectively). The focus here is on ill health and malnutrition at
school age and the role of the formal and nonformal education
sector in delivering interventions.
Developing a Programmatic Approach
The focus of school health and nutrition programs in low-
income countries has shifted significantly over the past two
decades away from a medical approach that favored elite
schools in urban centers and toward an approach that
improves health and nutrition for all children, particularly the
poor and disadvantaged. This change began in the 1980s, when
research showed not only that school health and nutrition pro-
grams were important contributors to health outcomes but
also that they were essential elements of efforts to improve edu-
cation access and completion, particularly for the poor.
In an effort to reconceptualize the relationship between
health and education, the United Nations Education, Scientific,
and Cultural Organization (UNESCO) hosted a series of work-
shops on this topic in the 1980s (Bundy 1989; Halloran, Bundy,
and Pollitt 1989) and supported one of the first authoritative
reviews of the area (Pollitt 1990). Similarly, the United Nations
Development Programme, in conjunction with the Rockefeller,
Edna McConnell Clark, and J. S. McDonnell Foundations sup-
ported the creation of the Partnership for Child Development
to strengthen the evidence base across the education and health
sectors and to support the dissemination of information
(Berkley and Jamison 1990; Bundy and Guyatt 1996). This par-
adigm shift coincided with the World Conference on Education
for All in Jomtien, Thailand, in 1990 and led to renewed efforts
by countries and agencies to develop more effective program-
matic approaches to school health and nutrition.
The United Nations Population Fund (UNFPA) has pio-
neered population and family life education (PopEd) as an
intrinsic part of school curricula. In 1994, the International
Conference on Population and Development placed specific
emphasis on school health, including reproductive and sexual
health. Efforts at country level have addressed PopEd both
within the school system and outside, and the concept has
evolved to include references to family life education, sex edu-
cation, HIV/AIDS awareness and prevention, and life-skills
programs. Today, approximately 84 countries have UNFPA-
supported school health programs.
In 1995, the World Health Organization (WHO) launched
its Global School Health Initiative to foster the development of
health-promoting schools (HPSs) (WHO 1996). The concept
started in Europe in the early 1990s, based on the Ottawa
Charter of Health Promotion (WHO 1986; European
Commission 1996), which recognized that health is created by
caring for oneself and others, by being able to make decisions
and have control over one’s life and circumstances, and by creat-
ing conditions that support health for all. WHO’s European
Regional Office, the Council of Europe, and the Commission of
the European Communities widely promoted the concept of
HPSs to foster healthy lifestyles and develop environments con-
ducive to health (European Commission, WHO Europe, and
Council of Europe 1996). Although definitions vary among
regions, countries, and schools, an HPS may be characterized as
one that is constantly strengthening its capacity as a healthy set-
ting for living, learning, and working. The initiative fosters the
development of HPSs by the following:
• consolidating research and expert opinion to describe the
nature and effectiveness of school health programs
• building capacity to advocate for the creation of HPSs and
to apply the components to priority health issues
• strengthening collaboration and national capacities to assess
the prevalence of important health-related behaviors and
conditions and to plan and implement policies and pro-
grams that improve health through schools 
• creating networks and alliances, including regional networks.
The key elements of how this approach is interpreted today
are listed in table 58.1.
In the mid 1990s, the United Nations Children’s Fund
(UNICEF) began promoting the Child-Friendly Schools
framework as a holistic way to promote children’s rights as
expressed in the Convention on the Rights of the Child
(UNICEF 1990) and children’s access to education as stated in
the World Declaration of Education for All (UNESCO 1990).
This approach included a gender-sensitive component, which
was further strengthened when girls’ education became the
first priority in UNICEF’s Medium Term Strategic Plan,
2002–5. Another key element is skills-based health education,
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including life skills, which has been promoted through
UNICEF with partner organizations as part of HPSs, child-
friendly schools, and the framework for Focusing Resources on
Effective School Health (FRESH). Research shows that this
approach is more effective than traditional strategies, which
tend to be didactic and to focus on scientific information
alone. In contrast, skills-based health education uses the expe-
riences of students as the starting point and explores the links
between knowledge, attitudes, and the interpersonal skills
required to promote health and learning (UNICEF, WHO,
World Bank, UNFPA, UNESCO 2003). The approach is inter-
active, activity based, and flexible so that it can be used to
address a range of health and social issues, including
HIV/AIDS, sanitation, drug use, violence and bullying, nutri-
tion, and cross-cutting issues such as gender and culture. Some
key elements of how the child-friendly schools approach is
interpreted currently, including its focus on healthy and pro-
tective learning environments, are listed in table 58.1.
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Focuses on the poorest and most
food-insecure communities.
Gives priority to girls and 
AIDS-affected children 
Serves as platform for essential
package approach that includes
water, sanitation, and
environmental measures
Supports learning through good
nutrition
Promotes access to education
Provides food 
Promotes and supports 
deworming
Promotes community and school
partnerships
Table 58.1 Characteristics of Agency-Specific School Health and Nutrition Programs, within the FRESH framework
FRESH Health-promoting Child-friendly Global school feeding
framework schools (WHO) schools (UNICEF) PopEd (UNFPA) campaign (World Food Program)
Policy
School
environment
Education
Services
Supportive
partnerships
Respects an individual’s 
well-being and dignity
Provides multiple opportunities
for success
Acknowledges good efforts and
intentions as well as personal
achievements
Is healthy 
Provides opportunities for 
physical education and
recreation
Provides skills-based health
education
Fosters health and learning
Provides school health services
Provides nutrition and food-
safety programs
Provides programs for counsel-
ing, social support, and mental
health promotion
Provides health promotion
programs for staff
Includes school and community
projects and outreach
Engages health and education
officials, teachers, teachers’
unions, students, parents, health
providers, and community
leaders in efforts to make the
school a healthy place
Respects and realizes the rights of
every child
Acts to ensure inclusion, respect,
and equality of opportunity for all
children
Is gender sensitive and girl friendly
Is flexible and responds to diversity
Sees and understands the whole
child in a broad context
Enhances teacher capacity, morale,
commitment, and status
Is healthy, safe, and secure
Is protective emotionally and
psychologically
Promotes quality learning outcomes
Provides education that is affordable
and accessible
Provides skills-based health
education, including life skills
relevant to children’s lives
Promotes physical health
Promotes mental health
Is child centered
Is family focused
Is community based
Creates a supportive and enabling
policy environment for reproductive
health and HIV prevention for
young people
Protects young people from early
and unwanted pregnancy, sexually
transmitted diseases, sexual
abuse, and violence
Strengthens HIV/AIDS and sexual
and reproductive health education
programs
Ensures access to youth-friendly
sexual and reproductive health
services
Targets young people in school
and out of school
Ensures active participation of
parents, youths, community
leaders, and organizations
Source: Summarized from World Bank Fresh Toolkit (2000), WHO (1996), and personal communications from Arlene Mitchell and Sheldon Shaeffer (May 2005).
Also during the 1990s, the World Bank Human Develop-
ment Network sought to support countries in implementing
school health and nutrition programs (Del Rosso and Marek
1996; World Bank 1993) and launched an International School
Health Initiative with the aim of raising awareness among deci-
sion makers in the education sector.
Thus, the 1990s were characterized by the creation of a
number of apparently separate programs to promote and sup-
port school health. However, analysis at the country level
revealed that although the various agency initiatives used
different “prisms” to view school health—public health for
WHO, quality education for UNESCO, and child rights for
UNICEF—the core activities for all the programmatic
approaches were essentially the same.
FRESH Framework
A major step forward in international coordination and cohe-
sion was achieved when the FRESH framework was launched
at the World Education Forum in Dakar in April 2000 (World
Bank FRESH Toolkit 2000). Among the early partners in this
effort were the Education Development Centre, Education
International, the Partnership for Child Development,
UNESCO, UNICEF, the World Food Programme (WFP),
WHO, and the World Bank. This partnership recognizes that
the goal of universal education cannot be achieved while the
health needs of children and adolescents remain unmet and
that a core group of cost-effective activities can and must be
implemented across the board to meet those needs and to
deliver on the promise of EFA.
The expanded commentary on the Dakar Framework for
Action reflects the recommendations of this partnership and
describes three ways in which health relates to EFA: as an input
and condition necessary for learning, as an outcome of effective
quality education, and as a sector that must collaborate with
education to achieve the goal of EFA. In the follow-up to the
Dakar Forum, UNESCO designated FRESH as an interagency
flagship program that will receive international support as a
strategy to achieve EFA.
The FRESH framework, which is based on good practice
recognized by all the partners, provides a consensus approach
for the effective implementation of health and nutrition
services within school health programs. The framework
proposes four core components that should be considered in
designing an effective school health and nutrition program
and suggests that the program will be most equitable and
cost-effective if all of these components are made available,
together, in all schools:
• Policy: health- and nutrition-related school policies that are
nondiscriminatory, protective, inclusive, and gender sensi-
tive and that promote the nutrition and physical and psy-
chosocial health of staff, teachers, and children
• School environment: access to safe water and provision of
separate sanitation facilities for girls, boys, and teachers 
• Education: skills-based education, including life skills, that
addresses health, nutrition, HIV/AIDS prevention, and
hygiene issues and that promotes positive behaviors
• Services: simple, safe, and familiar health and nutrition serv-
ices that can be delivered cost-effectively in schools (such as
deworming services, micronutrient supplements, and nutri-
tious snacks that counter hunger) and increased access to
youth-friendly clinics.
The FRESH framework further proposes that these four
core components can be implemented effectively only if they
are supported by strategic partnerships between the following
groups:
• health and education sectors, especially teachers and health
workers 
• schools and the community
• children and others responsible for implementation.
Adopting this framework does not imply that these core
components and strategies are the only important elements;
rather, implementing all of these in all schools would provide a
sound initial basis for any pro-poor school health program.
The common focus has encouraged concerted action by the
participating agencies. It has also provided a common plat-
form on which countries, agencies, donors, and civil society
can support all programs, including agency-specific programs
(table 58.1). Another important consequence of the FRESH
consensus framework has been to offer a common point of
entry for new efforts to improve health in schools, as illus-
trated by the three examples in box 58.1.
This consensus approach has increased significantly the
number of countries implementing school health reforms. The
simplicity of the approach, combined with the enhanced
resources available from donor coordination, has helped
ensure that these programs can go to scale. Annual external
support from the World Bank for these actions approaches
US$90 million, targeting some 100 million schoolchildren.
Common Interventions 
Table 58.2 lists some specific interventions commonly com-
bined within the school health intervention package, but it
should be recognized that not all of these interventions will be
needed or be appropriate for all locations. Some interventions
are synergistic: for example, worm infection will be addressed
by the provision of latrines, the promotion of hand washing,
relevant health and hygiene education, and deworming
services. Similarly, HIV/AIDS infection among youths will be
addressed by ensuring girls’ participation in school, offering
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skills-based health education (including life skills), offering
peer education, providing access to health clubs, and providing
access to treatment for sexually transmitted infections (STIs) at
clinics. It is also apparent that whereas some interventions
promote multiple outcomes—for example, skills-based health
education and life-skills development can help promote posi-
tive behaviors that prevent STIs and substance abuse—other
interventions may have a single focus, such as iron supplemen-
tation to avoid anemia.
Out-of-School Children
More than 100 million school-age children are out of school;
60 percent are girls (UNESCO 1993). School health programs
in Guinea and Madagascar have demonstrated that many of
these children will take advantage of simple services, such as
deworming, provided in schools (Del Rosso and Marek 1996);
the school acts essentially as a community center. It also has
been demonstrated that deworming programs in schools ben-
efit out-of-school children by reducing disease transmission in
the community as a whole (Bundy and others 1990).
Nevertheless, it is apparent that out-of-school children can-
not benefit from many of the important components of
school-based programs, such as skills-based health education
and life-skills development programs to prevent HIV/AIDS.
Reaching these children requires more flexible approaches that
combine the best of nonformal, informal, and community-
based approaches (see chapter 59).
COST-EFFECTIVENESS OF INTERVENTION
A key issue in addressing the costs of the new approach to
school health and nutrition programs is the significant savings
offered by using the school system infrastructure rather than
that of the health system as the key delivery mechanism. The
school system provides not only a preexisting mechanism, so
costs are at the margins, but also a system that aims at being
pervasive and socially progressive. Some important interven-
tions, especially in terms of health education, may be virtually
cost free; they require only policy changes that result in doing
things differently.
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Three Efforts to Improve Health in Schools
Box 58.1
The Multiagency Effort to Accelerate the Education
Sector Response to HIV/AIDS in Africa 
This effort, coordinated by a Working Group of the
UNAIDS Inter-Agency Task Team on HIV/AIDS and
Education, promotes the FRESH framework specifically
and helps education systems do the following:
• adopt policies that avoid HIV/AIDS discrimination
and stigmatization
• provide a safe and secure school environment
• provide skills-based health education, including life
skills, in schools to promote positive behaviors and
healthy lifestyles
• improve access to youth-friendly health services.
More than 36 countries and a similar number of agen-
cies, bilateral donors, and nongovernmental organiza-
tions have collaborated in this effort since November
2002.
The Global School Feeding Campaign of the WFP 
This campaign has gone beyond providing food aid to
develop a programmatic link between nutrition and educa-
tion. Working with partners, including national govern-
ments, parent-teacher and other community organizations,
UNICEF, WHO, the World Bank, UNESCO, and the Food
and Agriculture Organization, the campaign promotes the
following:
• policies that make food aid conditional on girls’ partic-
ipation in education 
• an essential package that includes school sanitation and
water and environmental improvement
• nutrition education that improves the quality of stu-
dents’ diets and HIV prevention education
• nutrition services that include food, deworming, and
alleviation of short-term hunger.
Some 70 countries have begun to implement these
principles and activities since 2002.
The Partnership for Parasite Control
Led by WHO and involving a broad range of development
partners, this initiative promotes public and private efforts
to include deworming in school health services, following a
resolution of the 54th World Health Assembly to provide by
2010 regular deworming treatment to 75 percent of school-
age children at risk (an estimated target population of 398
million). Of 41 target countries in Africa, 19 have begun
school-based deworming programs since 2001.
Source: Authors.
Annual costs of providing some common school-based
interventions to students are given in table 58.3. This table
illustrates two important points. First, some of the most widely
needed interventions can be provided at remarkably low cost.
Second, significant diversity exists in the cost of interventions,
which is affected by factors such as local capacity, location and
remoteness of communities, and community values and opin-
ions; hence, these factors must be borne in mind when identi-
fying a school health package. (See chapter 41 for details of the
costs of sanitation provision.)
Not illustrated in the table is the cost advantage of using the
existing school infrastructure for delivery. Estimates for deliv-
ery of simple interventions (such as anthelmintic pills or
micronutrient supplements) suggest that the teacher-delivery
approaches listed here may be one-tenth of the cost of the more
traditional mobile health teams and yet equally effective
(Guyatt 2003). As with all education innovations, however,
the additional cost of teacher orientation and training (in-
service as well as preservice) needs to be factored into the costs
of using the education system for delivery of health services.
ECONOMIC BENEFITS OF INTERVENTION
The most obvious benefit of school health interventions is
arguably through the economic returns of improved adult health
outcomes. Studies have increasingly documented a causal effect
of adult health (broadly defined) on labor force participation,
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Table 58.2 Common Interventions within a School Health Program
FRESH category Intervention Expected outcome
Policy
Environment
Education
Services
1. Child rights, avoidance of discrimination and stigmatization, gender
sensitive, child centered
2. Inclusion of pregnant girls and mothers in education
3. Enforcement of code of practice for teacher behavior zero tolerance policy
4. Collaboration between health and education sectors
1. Access to safe water
2. Hand washing
3. Provision of sanitation
4. Gender-separate sanitation
5. Garbage disposal
1. Curriculum addressing health, hygiene, and nutrition
2. Life-skills program
3. Peer education program
4. Health-promoting clubs
1. Deworming for intestinal worms and schistosomiasis
2. Prompt recognition and treatment of malaria
3. Insecticide-treated nets
4. Micronutrient supplements
5. Breakfast, snacks, and meals
6. First-aid kits
7. Referral to youth-friendly clinics
8. Counseling and psychosocial support
1. Inclusion of all children
2. Specific inclusion of girls
3. Avoidance of harassment and abuse
4. Effective implementation
1,2,3,5. Reduced infection
4. Reduced drop out of adolescent girls
1. Improved knowledge and skills to promote good
health, hygiene, and nutrition
2. Lifelong positive behaviors such as avoidance of
HIV/AIDS and substance abuse
3, 4. Reinforcement of positive behaviors
1. Reduction in worm infection
2. Reduction in impact of malaria
3. Reduction in incidence of malaria
4. Reduction in anemia and malnutrition
5. Avoidance of hunger
6. Management of injuries
7. Access to specific treatment
8. Mental health
Table 58.3 Annual per Capita Costs of School-Based Health
and Nutrition Interventions Delivered in Schools 
Condition Intervention Cost (US$)
Intestinal worms Albendazole or mebendazole 0.03–0.20
Schistosomiasis Praziquantel 0.20–0.71
Vitamin A deficiency Vitamin A supplementation 0.04
Iodine deficiency Iodine supplementation 0.30–0.40
Iron deficiency and anemia Iron folate supplementation 0.10
Refractive errors of vision Spectacles 2.50–3.50
Clinically diagnosed Physical examination 11.50
conditions
Undernutrition, hunger School feeding 21.60–151.20,
21.26–84.50a
Sources: Del Rosso and Marek 1996; Partnership for Child Development 1999; WHO 2000.
a. For South America and Africa, costs are standardized for 1,000 kilocalories for 180 days.
Source: Authors.
wages, and productivity in developing countries; Strauss and
Thomas (1995) present an overview of economic studies in this
area. For example, height has been shown to affect wage-earning
capacity as well as participation in the labor force for both
women and men (Haddad and Bouis 1991). The effect of health
on productivity and earnings may be strongest where low-cost
health interventions produce large effects on health, such as low-
income settings where physical endurance yields high returns in
the labor market. For a 1 percent increase in height, Thomas and
Strauss (1997) find a 7 percent increase in wages in Brazil com-
pared with a 1 percent increase in the United States.
However, the apparent benefits of school health and nutri-
tion programs will be underestimated when measured using
only mortality or health-related disability metrics because these
measures do not capture the impact of ill health on cognitive
development or educational outcomes. Evidence over the past
decade suggests these impacts have effect sizes in the range 0.25
to 0.4 SD and have implications for the child’s education and for
life beyond school, including future earning potential.We inves-
tigate those implications by considering the economic benefits
in terms of IQ and school attendance and by comparing school
health programs with traditional education interventions.
Economic Benefits of Long-Term Improvements in IQ
School health interventions can yield considerable economic
benefits through returns to wages and productivity if they
translate into improved cognitive functioning and IQ in adult-
hood.
For the United States, Zax and Rees (2002) estimate conser-
vatively that an increase in IQ of 1 SD is associated with an
increase in wages of more than 11 percent, falling to 6 percent
when controlling for other covariates. Similar estimates for the
relationship between IQ and earnings have been made for
Indonesia (Behrman and Deolalikar 1995) and Pakistan
(Alderman and others 1997) and in a review of developing
countries (Glewwe 2002). In South Africa, an increase of 1 SD
in literacy and numeracy scores was associated with a 35 percent
increase in wages (Moll 1998). Extrapolating these results, a 0.25
SD increase in IQ, which is a conservative estimate of the bene-
fit resulting from a school health intervention, would lead to an
increase in wages of from 5 to 10 percent.
Economic Benefit of Improved School Attendance
School health interventions can raise adult productivity not
only through higher levels of cognitive ability, but also through
their effect on school participation and years of schooling
attained. Healthier children are more likely to attend, and mod-
est improvements in examination scores can be associated with
continuation in schooling.
Malaria chemoprophylaxis given in early childhood in The
Gambia led to an increase of more than one year in primary
schooling. In preschool children in Delhi, iron supplementa-
tion was associated with an increase of 5.8 percent in rates of
participation at the preschool level (Bobonis, Miguel, and
Sharma 2004). In western Kenya, deworming treatment
improved primary school participation by 9.3 percent, with an
estimated 0.14 additional years of education per pupil treated
(Miguel and Kremer 2004). On the basis of crude estimates of
returns to schooling, an increase of 9.3 percent in participation
rates results in a return of US$44. Miguel and Kremer (2004)
conclude that these benefits still outweigh the costs even if
increased school participation leads to greater costs in teacher
compensation through the need for additional teachers. They
note that the benefit-cost ratio remains over 10 even if the rate
of return to an additional year of schooling is as low as 1.5 per-
cent. These results suggest that for realistic estimates of returns
to schooling, the net present discounted value of lifetime earn-
ings is likely to be high compared to the costs of treatment even
for small gains in school participation.1
In the absence of studies estimating the direct link between
school health interventions and school participation, the rela-
tionship can be estimated indirectly by considering the effect of
interventions on test scores and the implications that improved
test scores have for school participation. Improvements in cog-
nitive function can be converted into an equivalent number of
years of schooling. For example, Jukes and others (2002) found
that heavy schistosomiasis was (nonsignificantly) associated
with a decrease in arithmetic scores of 1.35 marks (0.25 SD).
An extra year of schooling was associated with an increase in
arithmetic scores of 2.24 marks (0.42 SD). Thus, the negative
effect of heavy schistosomiasis was equivalent to missing just
over half a year of schooling. The cognitive gains from an extra
year of schooling can also be estimated retrospectively: in a
study of adults in South Africa, each additional year of primary
schooling was associated with a 0.1 SD increase in cognitive test
scores (Moll 1998). According to these estimates, a typical
increase of 0.25 SD associated with school health and nutrition
programs is equivalent to an additional 2.5 years of schooling.
Liddell and Rae (2001) assessed the direct effect of test
scores on grade progression in Africa. Each additional SD
scored in first-grade exams resulted in children being 4.8 times
as likely to reach seventh grade without repeating a year of
schooling.2 According to these estimates, an increase of 0.25 SD
in examination scores, which is typically achieved by school
health and nutrition programs, will make children 1.48 times3
as likely to complete seventh grade, which implies that the extra
cumulative years of schooling attributable to the school health
intervention average 1.19 years per pupil. The previous esti-
mates for added years of schooling owing to school health
interventions range from seven months to two years. Increased
years of schooling are associated with, among other outcomes,
higher worker productivity and generally higher productivity
in nonmarket production activities, including greater farmer
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efficiency and productivity (Jamison and Lau 1982;
Psacharopoulos and Woodhall 1985; Strauss and Thomas
1995). Psacharopoulos and Patrinos (2002) summarize a wide
range of studies that focus on individual wage earnings. For
Sub-Saharan Africa, they find a 12 percent rate of return to one
additional year in school, compared with 10 percent for Asian
countries. These returns are very high, even allowing for a por-
tion of the return to years of schooling to be capturing ability
and factors other than schooling itself (Card 2001).
Education brings benefits beyond improved earnings. One
year of extra education for girls can lead to a reduction of from
5 to 10 percent in infant mortality (Schultz 1993). Five extra
years of education for women in Africa could reduce infant
mortality by up to 40 percent (Summers 1994).
Economic Benefits of Programs
The educational gains from school health and nutrition
programs should be considered in the context of alternative
educational inputs, such as improving teacher salaries and
qualifications, reducing class size, improving school facility
infrastructure, and providing instructional materials. Many
studies relate student outcomes to school characteristics, but
few of these studies provide information on the relative or
actual costs of the educational inputs. The costs, however, are
substantially greater than for the school health interventions
considered here. Despite the higher costs, the evidence from the
few randomized evaluations that have been conducted suggests
that the scale of effect of additional education inputs is typically
low (see discussion in Miguel and Kremer 2004). A review of
studies showed that instructional materials (such as additional
textbooks) had the highest productivity, raising student test
scores significantly more than other inputs for each dollar
spent. However, even these interventions have only a weak
effect. In a randomized experiment in Kenya, for example, pro-
viding textbooks had no effect on the bottom three quintiles of
students and raised test scores by only 0.2 SD for the upper two
quintiles. Relating these results to the findings in the previous
section and to the annual per pupil costs, school health inter-
ventions appear very cost-effective compared to the highest-
productivity, more traditional education inputs.
Recently, conditional cash-transfer programs have been
viewed as potentially very cost-effective methods to increase
school enrollment. These programs are generally large in scope,
representing a commitment of between 0.1 and 0.2 percent of
gross national income. The Progresa program in Mexico is
estimated to have increased enrollment by 3.4 percent and to
have increased schooling by 0.66 years, with an average cash
transfer (for grades 3 to 8) of about US$136 per child per
school year (assumed to be 180 days). Gains from a similar
program in Nicaragua were estimated at 0.45 years of school at
a cost of US$77 per year. If we compare these results with those
presented for school health and nutrition programs, the condi-
tional cash-transfer approach is, in both cases, apparently at the
lower end of effectiveness and the higher end of cost.
IMPLEMENTATION OF PROGRAMS AND LESSONS
FROM EXPERIENCE
The FRESH framework provides strategic guidance, but the
practical design of actual programs reflects differences in local
needs and capacity. Successful and equitable programs in low-
and middle-income countries are characterized by a focus on
school-based delivery, on a public health paradigm that mini-
mizes the need for clinical intervention and reliance on health
service facilities, and on participation of the public sector and
civil society locally.
Policy and Economic Issues in Defining Sectoral Roles
in Intervention
A negative correlation between income level and both ill health
and malnutrition is clearly demonstrated both in cross-country
comparisons and within countries (see de Silva and others
2003), partly because poverty promotes both disease and an
inadequate diet. Similarly, children who are not enrolled in
school come from households with lower income levels (Filmer
and Pritchett 2001).This fact suggests that school health services
that are pro-poor and specifically linked to efforts to achieve
universal participation in education will have a greater return.
Early school health programs, particularly in colonial Africa,
were intended to serve the minority of children who had access
to school in urban centers or elite boarding facilities. They relied
on specific infrastructures and services—such as mobile health
teams, school visits, school nurses, and in-school clinics—that
were additional to the normal range of health service provision.
This approach has proven difficult to make universally available,
even in middle-income countries. A school nurse program in
KwaZulu-Natal, for example, achieved inadequate coverage (18
percent of the target population) and little referral or follow-up
treatment of cases of ill health detected, despite a relatively high
investment of US$11.50 per student targeted per year (World
Bank FRESH Toolkit 2000). As shown in the following exam-
ples, using the FRESH framework approach reduces costs sig-
nificantly and enhances both coverage and outcomes.
An important element of the new approach to school health
is a focus on minimizing the need for clinical diagnosis. Mass
delivery of services, such as deworming and micronutrient sup-
plementation, is preferable on efficacy, economic, and equity
grounds to approaches that require diagnostic screening
(Warren and others 1993).
Sectoral Roles in Implementation
Table 58.4 gives examples from low- and middle-income
countries of how the four core components of FRESH are
being supported by different approaches. In about 85 percent
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Table 58.4 Nine Low- and Middle-Income Countries and How They Use FRESH
Program Country Outcomes (Costs
approach examples Policy Environment Health education Health services per child per year)
Public sector:
public sector–
supported and
–implemented
Parastatal support
for public sector
intervention 
Social fund: public
sector support for
community
intervention
Guinea,
Ghana, and
Tanzania
Madagascar
Tajikistan
In all three countries, the Ministry of Education (or in
Ghana, its executive body, the Ghana Education
Service) implements the program under the guidance
of the Ministry of Health, on the basis of a formal
policy agreement. In Tanzania, the Ministries of
Community Development and of Local Government
are also parties to the agreement. The existing in-
service teacher training and supply-line infrastruc-
tures are used to prepare teachers and supply the
necessary materials.
The Community Nutrition Programme provides train-
ing and support to the Ministry of Education on the
basis of a formally agreed-on health policy for the
education sector. In all schools in the 43 poorest
districts (44 percent of all districts), the program
prepares teachers and provides materials. In
addition, the program also provides Parent-Teacher
Associations (PTAs) with access to a social fund to
support construction of facilities. Each PTA can
request up to US$500, with a 20 percent community
contribution based on an annual parental contribution
of US$0.16.
The Ministry of Labor and Social Protection, with the
Ministries of Education and of Health, have devel-
oped a memorandum of understanding that sets out
health policies for the education sector. The program
channels resources through PTAs, which identify and
assist needy children. A training program, delivered
by NGOs, prepares PTA members to develop propos-
als of up to US$5,000 for their school to support
activities selected from a menu of items.
Separate sanitation facili-
ties for girls and boys in
all new schools; access to
potable water in all
schools.
Access to potable water
and hand-washing facili-
ties, in all schools; where
requested by PTAs,
construction of latrines,
wells, fences, and sports
facilities. 
Provision of sanitation
facilities, potable water,
and sports facilities.
Health, hygiene, and nutri-
tion education as part of the
formal curriculum.
A formal health education
curriculum, supported by
community information,
education, and
communication (IEC).
Training of teachers in
health promotion.
Deworming (for both schis-
tosomiasis and intestinal
worms) provided by teach-
ers twice a year; in Guinea,
this service is followed
by iron folate
supplementation. 
Twice-yearly deworming
and iron folate (for three
months) delivered by
teachers; test kits to
confirm iodization of local
sources of salt; where
requested by PTAs,
provision of food
preparation facilities.
Training of teachers to
provide first aid, micronu-
trients, and deworming;
provision of food prepara-
tion facilities.
In three years, in Guinea—
1.1 million students, in
Ghana—577 schools and
83,000 students (US$0.54), in
Tanzania—353 schools and
113,000 students (US$0.89).
In three years, 14,000 teach-
ers trained in 4,585 schools,
430,000 students (US$0.78
to US$1.08 per capita per
year).
The program targets the
100,000 neediest children in
all 200 schools in the six
poorest districts of Tajikistan
(US$1 per capita per year).
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Private sector:
community
payment for 
NGO-implemented
intervention
NGO implementa-
tion with financial
support from
public sector
Indonesia
Burkina Faso,
Malawi, and
the Philippines
The NGO Yayasan Kusuma Buana has a formal agree-
ment with the education department in Jakarta and
three other major cities to train teachers, perform
diagnostic tests, and provide medicines and materi-
als. The NGO offers Papanicolaou smear tests and
referral services to teachers. Unit costs are low
because parasite diagnosis involves mass screening
in a central laboratory (approximately 2,500 diag-
noses per day) and medicines are obtained at prefer-
ential rates from two commercial partners.
The international NGO Save the Children U.S.A.
implements school health and nutrition activities in
nonformal schools created with support from govern-
ment, local communities, and private donations.
Not included in program.
Separate sanitation facili-
ties for girls and boys and
access to potable water.
Nutrition and hygiene
education as part of the
curriculum.
Health, hygiene, and nutri-
tion education as part of the
curriculum supported by
extracurricular IEC activities
Stool examination by the
laboratory and deworming
by teachers as necessary
twice a year; iron folate
provided by teachers twice
a year (for three months).
Deworming and micronutri-
ent supplementation
(vitamin A and iron)
provided by teachers
annually.
The program has been in
existence for 17 years and
currently reaches 627
schools and 161,000 stu-
dents, at a cost to parents of
US$0.10 annually.
In three years, in Burkina
Faso, 42,000 students plus
nonenrolled children in 171
schools (US$2). In four years,
in Malawi, 122,000 children
in 181 schools (US$3). In four
years in the Philippines,
23,000 children in 53 schools
(US$6).
Source: Authors.
1104 | Disease Control Priorities in Developing Countries | Donald A. P. Bundy, Sheldon Shaeffer, Matthew Jukes, and others
of programs reviewed, school health and nutrition programs
are delivered and funded by the public education sector, with a
formal role for the health sector in design and supervision.
Although this public sector “mainstream” model has proven
the most popular approach, it is not the only successful one. In
some cases, the public sector has identified appropriate options
and developed operational manuals but then has used a social
fund to provide direct support to communities and has used
schools to select and implement the most relevant actions
locally, often with the assistance of nongovernmental organiza-
tions (NGOs). In other cases, services have been contracted out
by the public sector, and in some middle-income countries, the
move toward a demand-led approach has resulted in a private
sector service.
The private sector approach has proven sustainable over
nearly two decades in urban Indonesia but may require a tech-
nical infrastructure and local market base that are inappropri-
ate for predominantly rural low-income countries. The
approach is modeled on a program initiated in Japan in 1948,
which relied on private sector technicians, working independ-
ently at first but later formalized within the Japan Association
of Parasite Control, who conducted stool examinations and
then treated infected individuals for a per capita fee equivalent
to approximately US$0.74 in 2004. At its peak, the private
sector program conducted some 12 million examinations
annually, implying a turnover of nearly US$9 million at today’s
prices. The prevalence of roundworm infection fell from a
high of 73 percent in 1949 to less than 0.01 percent by 1985.
Although a private sector response is effective in some cir-
cumstances, overall the characteristics of school health and
nutrition programs make a compelling case for public sector
intervention. First, treatment externalities may create external
benefits to others in addition to the benefit for the treated
individual. This situation is clearly the case for communicable
disease interventions,especially against worm infection.Second,
some forms of intervention (such as vector control, health
education campaigns, epidemiological surveillance, and inter-
ventions that have strong externalities) are almost pure public
goods; that is, no one can be excluded from using the goods or
service they deliver,and thus the private sector is unlikely to com-
pete to deliver these goods. Finally, there is typically little private
demand for general preventive measures,such as information on
the value of washing hands. None of these factors is an argument
against a private sector role in service delivery, but they do
suggest that private sector demand is likely to be greater in
middle-income populations and where public sector actions
have created a demand.
Roles of Key Stakeholders in Implementation 
There are many ways to approach the delivery of school health,
but these diverse experiences suggest common features—in
particular, the consistency in the roles played by government
and nongovernmental agencies as well as other partners and
stakeholders (table 58.5). In nearly every case, the Ministry of
Education is the lead implementing agency, reflecting both the
goal of school health programs in improving educational
achievement and the fact that the education system provides
the most complete existing infrastructure for reaching school-
age children. However, the education sector must share this
responsibility with the Ministry of Health, particularly because
the latter has the ultimate responsibility for health of children.
It is also apparent that the program’s success depends on the
effective participation of numerous other stakeholders, includ-
ing civil society, and especially the beneficiaries and their par-
ents or guardians. The children and their families are the clients
of these programs, and their support for program implementa-
tion is critical to the program’s success.
Key Issues in Designing Effective Programs
The diverse experiences of school health programming suggest
some key elements that are common contributors to success in
many programs.
• Focus on education outcomes. Making explicit links among
school health programs and learning and education sector
priorities (especially EFA and gender equity) helps ensure
the commitment of the sector to program support and
implementation.
• Develop a formal, multisectoral policy. Education sector
actions in health require the explicit agreement of the health
sector. This potential tension can be resolved by defining
sectoral responsibilities at the outset; failure to enter into
dialogue has led, in Africa and Central Asia, to some health
sectors resisting teacher delivery of deworming drugs,
despite WHO recommendations.
• Initiate a process of wide dissemination and consultation.
Because there are multiple stakeholders, implementers,
enablers, and gatekeepers, a process of consultation is neces-
sary to establish ownership and to identify obstacles before
they constrain progress. The process should involve at least
community-based organizations, NGOs, faith-based organ-
izations, pupils, and teacher associations. In one country
in East Africa, lack of prior agreement on the content of
sexuality education delayed implementation for more than
three years.
• Use the existing infrastructure as much as possible. Building
on existing curriculum opportunities and the network of
formal and nonformal teachers will accelerate implementa-
tion and reduce costs. Programs that rely on the develop-
ment of new delivery systems—mobile school health teams,
a cadre of school nurses—take longer to establish and are
expensive and complicated to sustain and take to scale.
• Use simple, safe, and familiar health and nutrition interven-
tions. Success in rapidly reaching all schools depends on
stakeholder acceptance, which is more likely if the interven-
tions are already sanctioned by local and international agen-
cies and are already in common use by the community.
• Provide primary support from public resources. Compelling
arguments exist for public investment in school health pro-
grams: the contribution to economic growth, the high rate
of return, the large externalities, and the fact that the major-
ity of interventions are public goods.
• Be inclusive and innovative in identifying implementation
partners. Although public resources are crucial for school
health programs, contributions from outside the public sec-
tor can be vital. NGOs have proven effective in supporting
public sector programs through training and supervision,
particularly at local levels.Although market failure appears to
have largely precluded the private sector from effectively
implementing national programs in low-income countries,
examples of successful contributions do occur, particularly
in dense urban populations and in middle-income countries.
RESEARCH AND DEVELOPMENT AGENDA
Reliable evidence suggests that ill health and malnutrition
affect education access, participation, completion, and achieve-
ment, and that school-based health and nutrition programs
can provide a cost-effective and low-cost solution. This evi-
dence does not imply, however, that no uncertainties exist.
Cost-Effectiveness of School-Based HIV/AIDS Prevention
Substantial evidence suggests that skills-based health education,
including life-skills development programs, can promote posi-
tive behaviors and reduce the risks of exposure to HIV infection,
and that girls’ education programs have similar effects (Kirby
2002). Evidence also exists for a positive effect of completing
education on HIV prevalence (de Walque 2004; World Bank
2002). What is lacking is direct evidence about the contribution
that school-based prevention programs can make in reducing
the incidence of HIV infection, as well as evidence for the rela-
tive cost-effectiveness of such programs compared with existing
efforts to promote education completion and girls’ education.
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Table 58.5 Roles of Agencies, Partners, and Stakeholders in School Health and Nutrition Programs
Partner Roles Comments
Ministry of Education
Ministry of Health 
Other public sector agencies
(for example, Welfare, Social
Affairs, local government)
Private sector (for example,
health service, pharmaceuti-
cals, publications)
Civil society (for example,
NGOs, faith-based
organizations, PTAs) 
Teacher associations
Community (children,
teachers, parents)
Lead implementing agency
Lead financial resource
Education sector policy
Lead technical agency 
Health sector policy
Support for education and health systems
Fund holder
Specialist service delivery
Material provision
Training and supervision
Local resource provision
Definition of teachers’ roles
Partners in implementation
Definition of acceptability of curriculum and
teachers’ roles
Supplementation of resources 
Health and nutrition of schoolchildren is a priority for EFA.
Education policy defines school environment, curriculum, duties of teachers.
Education system has a pervasive infrastructure for reaching teachers and
school-age children.
Health of school-age children has lower priority than clinical services, infant
health.
Health policy defines role of teachers in service delivery, procurement of
health materials.
Ministries of local government are often fund holders for teachers and schools
and for clinics and health agents.
Ministries of Welfare and Social Affairs provide mechanisms for providing
social funds.
Sector has major role in drug procurement and training materials production.
Sector has specialist roles in health diagnostics.
At the local level, organizations serve as gatekeepers and fund holders and
may target implementation.
Organizations provide additional resource streams, particularly international
NGOs.
School health programs demand an expanded role for teachers.
Communities are gatekeepers for the content of health education (especially
moral and sexual content) and for the role of nonhealth agents (especially
teachers) in health service delivery; pupils are active participants in all aspects
of the process at the school level.
Communities supplement program finance at the margins.
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Cost-Effectiveness of Malaria Programs 
Malaria occurs commonly in schoolchildren, particularly in
areas of unstable transmission in Africa and Asia. It is a leading
source of mortality in this age group and adversely affects edu-
cation by reducing school attendance, cognition, learning, and
school performance. Current school-based approaches focus
on knowledge of the disease and the use of impregnated bed-
nets but do not address the need for treatment of affected chil-
dren. Yet presumptive treatment by teachers has been shown to
significantly reduce mortality (Pasha and others 2003), and
intermittent preventive treatment also shows considerable
promise (Brooker and others 2000). There is a need to confirm
the success of school-based treatment in different epidemio-
logical settings and to address questions about the cost and sus-
tainability of this approach.
Cost-Effectiveness of Targeting Food Aid 
The high prevalence of malnutrition in children continues to
be a major challenge for low-income countries. Providing food
to children at school is often seen as an important part of the
solution and is a major focus for food aid. However, the nutri-
tion literature suggests that ensuring good nutrition earlier in
life—certainly before 3 years of age, but perhaps earlier—is
essential to ensuring an appropriate development trajectory
throughout life (see chapter 27). Where food is limiting, it raises
the question whether the first target should be preschool rather
than school-age children. This debate has been blurred by
admixing the nutrition outcomes with broader social and edu-
cation issues. Clearly, providing a meal at school is socially
desirable and can offer education benefits for children who
otherwise would have to walk often long distances home to eat
or remain hungry. It is also clear that schools represent an
extensive and established network for providing nutrition
interventions to very large numbers of children at a low cost
per child. No comparable network exists to reach preschool
children. However, from a nutritional perspective, it remains
unclear whether ensuring good nutrition early in life has more
effect on subsequent development—including educational
achievement—than providing food at school age.
CONCLUSIONS 
The rationale for school-based health and nutrition programs
and the approach to their implementation have undergone a
paradigm shift over the past two decades.
The traditional perception of these programs as seeking to
improve the health of schoolchildren cannot be justified on the
basis of mortality or public health statistics alone. Instead, it is
increasingly recognized that a major—perhaps the major—
impact of ill health and malnutrition on this age group is that on
cognitive development, learning, and educational achievement.
In consequence, the clearest benefit of school health and nutri-
tion programs is measurable in terms of education outcomes
and their economic returns. The scale of benefit is significant:
school health and nutrition interventions can add four to six
points to IQ levels, 10 percent to participation in schooling, and
one to two years of education. This scale of benefit can add 8 to
12 percent to labor returns and provide a rate of return that
offers a strong argument for public sector investment.
Compelling evidence suggests that education qua education
can help protect individuals from HIV infection. Achieving EFA
goals and combining this outcome with school health programs
that help establish lifelong positive behaviors are now recognized
as essential to the multisectoral prevention response to
HIV/AIDS.
The scale of the education benefit and the role of education in
the fight against HIV/AIDS mean that school health and nutri-
tion programs are today seen as a priority for both the education
and the health sectors. This focus, in turn, has resulted in a shift
toward public health rather than clinical intervention and
toward school-based delivery rather than health system
approaches. These policy changes enhance cost-effectiveness
and social progressiveness, because delivery through the school
system is an order of magnitude less costly than using health sys-
tems and in low-income countries is better targeted to the poor.
These changes in emphases have coincided with significant
technical and political policy reform. Technical consensus
around the FRESH framework has encouraged countries and
agencies to develop programs around a common coordinating
principle, while the political imperative has been strengthened
by the recognition that school health and nutrition programs
are essential to achieving EFA and the Millennium Develop-
ment Goals and are at the center of the preventative response
to the HIV/AIDS pandemic.
Although much of this change has evolved over the past two
decades, significant acceleration has occurred since the World
Education Forum in 2000. Today, a majority of low-income
countries have recognized the need for school health and nutri-
tion programs and are seeking to implement them.
NOTES
1. These calculations assume the following: a return to an additional
year of school is 7 percent; wage gains are earned over 40 years in the
workforce, discounted at 5 percent per year with no wage growth; annual
wage earnings are US$400 per year, which is below the estimated agricul-
tural and nonagricultural annual wages for low-income countries (World
Bank 2003). The opportunity costs of the additional schooling (child
labor) have not been considered but are likely to be negligible.
2. These calculations assume that a pupil’s falling behind the equiva-
lent of one year in test scores has the same effect on earnings as losing
one year of schooling; that the advantage that third graders have over
second graders, for example, is the same as the advantage someone who
has studied for a total of three years has over someone who has studied
for two years; and that the impact of first-grade examination scores on
the probability of transition from one class to the next is the same at
each grade level.
3. If an increase of 1 SD in exam scores leads to children being 4.8 times
as likely to reach seventh grade, the increased likelihood of reaching sev-
enth grade because of a 0.25 SD increase can be calculated as EXP (0.25 
LN(4.8)).
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This chapter reviews the main direct causes of loss of productive
life years among adolescents and the range of interventions to
address these causes.It pays special attention to sexual and repro-
ductive health because adolescence is when important transi-
tions occur that can have a direct effect on young people’s health
as well as potential long-term consequences. In addition, a num-
ber of interventions have focused on this aspect of young peo-
ple’s behavior. The discussion centers on defined interventions
that have some relatively rigorous evaluation component. There
are some limitations to this chapter, however. First, it reviews
existing research and does not carry out new research; however,
it points to gaps in research and areas needing more work.
Second, the chapter uses a focused definition of health that
includes the most basic health outcomes (death, illness, timing of
transitions,or specific risky or protective behaviors that research
has attempted to measure). It does not attempt to cover aspects
that would be included in a broad definition of health and well-
being (for example, potential for growth, creativity, or participa-
tion) that are important but are poorly researched to date.
Finally, although the broader environment in which adolescents
live influences their behavior and responses to programs, this
chapter does not attempt to review that important group of fac-
tors or the broader set of programs that have a more indirect
effect on the health of young people (for example, school quality
or public health promotion activities at the societal level).
NATURE AND CAUSES OF THE BURDEN
OF DISEASE IN YOUNG PEOPLE
At first glance, adolescence appears to be a relatively healthy—
although not hazard-free—period of life, given the relatively
low mortality rates of young people.1 Nevertheless, adolescents
and young adults engage in a range of behaviors that can affect
the quality of their health and the probability of their survival in
the short term as well as affect their lifetime health and survival.
Health Challenges of Adolescents
If we look only at disability-adjusted life years (DALYs) for the
adolescent age group, adolescents appear to be relatively
healthy. Nonetheless, more than 33 percent of the disease bur-
den and almost 60 percent of premature deaths among adults
can be associated with behaviors or conditions that began or
occurred during adolescence—for example, tobacco and alco-
hol use, poor eating habits, sexual abuse, and risky sex (WHO
2002). Adolescence-related risk factors are a greater problem
in wealthier countries, largely because of the relatively greater
impact of smoking and diet-related risks in those countries,
though the prevalence of these risks is expanding rapidly in
many low- and middle-income countries (LMICs). Thus,
although adolescents are apparently healthy, they are practicing
unhealthy behaviors that will ultimately result in much death
and disability. This is an immense public health issue.
Therefore, focusing attention both on diseases experienced
during adolescence and on risk factors with their roots in ado-
lescence makes sense. Adolescent health efforts should empha-
size prevention because so much of the disease burden is pre-
ventable and because prevention is a particularly cost-effective
strategy in relation to adolescents, given the long duration over
which benefits will be reaped and adolescents’ greater openness
to change than adults.
Burden of Disease in Adolescence
The global burden-of-disease approach used to calculate DALYs
is an imperfect representation of the prevalence, morbidity, and
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mortality of conditions that adolescents face. DALYs fail to
capture fully the complexity of adolescent health concerns.
Nonetheless, no better comprehensive and comparative meas-
ure currently exists; thus, the discussion in this section will rely
primarily on available DALY data.
The World Health Organization (WHO), in 1999, commis-
sioned a special analysis of the burden of disease in adoles-
cence, which examined the 10 to 14 and the 15 to 19 age
groups. The study found that young people age 10 to 19, who
constitute 19 percent of the world’s population, account for
15 percent of the disease and injury burden worldwide. It also
found that more than 1 million people in that age group die
each year (WHO 1999). The top three causes of DALYs were
found to be unipolar major depression, transportation
accidents, and falls. The profile of disease burden was signifi-
cantly different for younger and older adolescents. In the 10 to
14 age group, injuries and communicable diseases were promi-
nent causes of DALYs. For the 15 to 19 age group, the disease
burden shifted to outcomes of sexual behaviors and mental
health.
Using 2002 data, WHO has made more detailed calcula-
tions of DALYs by sex for the 5 to 14 and 15 to 29 age groups
(table 59.1). These age ranges overlap adolescence and are,
thus, broadly indicative of the 10 to 19 age group. Notably,
table 59.1 shows large differences by sex in the pattern and level
of DALYs. These differences are important, because they relate
to the different needs of young women and young men for
interventions and services. Particular interventions also poten-
tially have different costs and benefits because of the different
proportions of females and males.
Worldwide, among young men age 15 to 29, injuries and
neuropsychiatric illnesses account for a high proportion of
DALYs (33 percent and 32 percent, respectively). By compari-
son, among young women age 15 to 29, injuries account for
14 percent of DALYs, and neuropsychiatric illnesses account
for about the same percentage of DALYs as among young men.
However, sexual and reproductive health conditions account
for 33 percent of young women’s DALYs, much higher than the
10 percent for young men. For both young men and young
women, all other communicable and noncommunicable
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Table 59.1 Worldwide Distribution of DALYs for Major Categories of Diseases and Conditions by Age Group and Sex, 2002
(percent)
Women Men
Category Age 5–14 Age 15–29 Age 5–14 Age 15–29
Sexual and reproductive causes 4.6 33.4 3.9 9.5
HIV/AIDS 3.8 11.9 3.7 8.6
Maternal conditions 0.4 16.3 0.0 0.0
Other sexual and reproductive conditions 0.4 5.2 0.2 0.9
Respiratory conditions 11.9 3.7 9.9 3.7
Cardiovascular conditions 2.2 2.9 2.0 3.3
Neuropsychiatric conditions 15.5 33.8 14.9 32.0
Unipolar depressive disorders 5.4 10.1 5.6 7.1
Bipolar disorders 0.6 4.1 0.7 4.2
Schizophrenia 0.7 4.4 2.3 4.2
Other mental health conditions 1.0 4.4 0.6 2.6
Alcohol use disorders 0.1 1.1 0.3 5.7
Drug use disorders 0.1 0.6 0.2 2.3
Other 7.6 9.1 5.2 5.9
Injuries 25.0 14.0 32.4 33.1
Unintentional, road traffic accidents 5.7 2.2 7.7 7.5
Unintentional, other 16.8 7.7 21.8 12.9
Intentional, self-inflicted 1.0 2.9 0.9 3.8
Intentional, not self-inflicted (war, violence) 1.5 1.2 2.0 8.9
Other communicable diseases 31.1 7.1 27.7 11.1
Tuberculosis 1.5 3.0 1.4 3.9
Other noncommunicable diseases 9.9 9.6 9.2 10.0
Total 100.2 104.5 100.0 102.7
Source: WHO 2004a.
diseases account for moderate proportions of DALYs (7 to
11 percent, depending on sex and disease group).
The disease burden among 5- to 14-year-olds is markedly
different from that for the 15- to 29-year-olds, and differences
between males and females are quite small. Communicable dis-
eases and respiratory illnesses account for much larger propor-
tions of DALYs for this age group compared with the 15 to
29 age group, whereas neuropsychiatric and sexual and repro-
ductive conditions account for much smaller proportions.
HIV/AIDS accounts for less than 4 percent of DALYs for both
males and females age 5 to 14.
Health Risk Behaviors among Adolescents
and Young People
Young people’s vulnerability to risky or unwanted sex and
other unhealthy behaviors is tied to a host of individual, family,
and community factors that influence their behavior and
that are closely related to their economic and educational
opportunities. Good health and other physical, moral, and
intellectual development outcomes are often mutually rein-
forcing. For example, healthy children do better in school.
Similarly, having more years of schooling provides essential
information and skills that are linked to more protective and
less risky behaviors.
Injuries. Violence and war account for more than a quarter
of injury-related deaths among young men age 15 to 29.
Adolescent boys and men in their 20s are an important part of
the military forces in all countries that have such forces. As
such, they are at high risk, particularly in areas where armed
conflict is occurring. The United Nations Children’s Fund esti-
mates that approximately 300,000 soldiers under the age of 18
are involved in armed conflicts worldwide (National Research
Council and Institute of Medicine 2005). Homicide is also an
important cause of death for young men, in particular, and it
is the leading cause of death for young men in some Latin
American countries (WHO 2001b). In addition, road accidents
account for significant proportions of injuries and deaths
among young people. Self-inflicted injuries, including suicide,
which are often related to mental illness, are also a major health
problem for young people, accounting for 4 percent of DALYs
in men age 15 to 29 and 3 percent of DALYs in women age 15
to 29.
Mental Health. Depression, schizophrenia, and other mental
illnesses are important causes of illness and death among
young men and women and account for a significant propor-
tion of DALYs for both men (18 percent) and women (23 per-
cent) age 15 to 29; for 5- to 14-year-olds, it is about 9 percent
for boys and 8 percent for girls. The relative importance of
mental illnesses is much greater in the high-income countries.
Smoking, Alcohol, and Drug Use. Most adult smokers world-
wide begin smoking in adolescence or earlier (World Bank
1999a). An estimated 15 percent of young men and 7 percent of
women age 13 to 15 are currently smoking cigarettes, according
to more than 100 surveys that have been conducted since 1999
by the Global Youth Tobacco Survey Program and carried out
under the auspices of WHO and the U.S. Centers for Disease
Control and Prevention (National Research Council and
Institute of Medicine 2005). Every day, worldwide, almost
100,000 young people start smoking, more than two-thirds of
them in LMICs (World Bank 1999a). Of the 300 million young
people smoking today, half will eventually die from tobacco use
(WHO 2001b). By 2030, tobacco is expected to be the single
biggest cause of death worldwide, accounting for about 10 mil-
lion deaths per year (World Bank 1999a).
Although discouraging young people from starting to
smoke and providing means for them to quit is extremely
important, deaths caused by tobacco tend to occur many years
later. Therefore, tobacco use as an underlying risk factor
accounts for very few DALYs in the 5 to 29 age group (WHO
2002). Alcohol and drug use account for 8 percent of all DALYs
for young men age 15 to 29 but for only 2 percent for young
women. Evidence indicates that young people are starting to
drink at earlier ages. Longitudinal studies have found that the
earlier young people start drinking, the more likely they are to
experience alcohol-related injuries and alcohol dependence
later in life (WHO 2001a).
Nutrition and Exercise. Nutritional deficiencies such as ane-
mia are widespread in both young men and women.
Worldwide, these conditions account for almost 5 percent of
DALYs among girls age 5 to 14 and almost 4 percent among
boys of the same age, with anemia being an important compo-
nent for both girls and boys. Although nutritional deficiencies
are relatively less important among 15- to 29-year-olds (just
over 1.0 percent among young men and about 1.5 percent
among women), anemia accounts for the bulk of these defi-
ciencies. Chronic undernutrition that causes stunting among
young people delays growth and physical maturation, increases
risks to pregnant mothers and their newborns, and decreases
the capacity to learn and to work (Behrman and others 2004;
Hoddinott and Quisumbing 2003). Malnutrition can take
other forms, some of which lead to being overweight or obese,
thereby increasing the risks for diseases such as diabetes. Such
forms of malnutrition are of increasing relevance in middle-
income countries such as Brazil, China, the Arab Republic of
Egypt, Mexico, and South Africa and at times coexist with
undernutrition (see, for example, Doak and others 2000).
Nutritional deficiencies increase the risks that girls and
young women face during pregnancy and childbirth (Delisle,
Chandra-Mouli, and de Benoist 2001), and evidence is emerg-
ing about the connection between poor maternal nutrition and
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greater risk of transmission of HIV from mothers to their
infants (Piwoz and Greble 2000).
Diet and lifestyle-related chronic diseases—many with their
roots in childhood and adolescence—are emerging as one of
the most important health problems in LMICs. Cardiovascular
diseases, which are responsible for 10 percent of DALYs lost in
LMICs, typically occur in middle age or later; however, risk fac-
tors are determined to a great extent by behaviors learned
during childhood and adolescence and continued into adult-
hood, such as dietary habits and smoking. Throughout the
world, these risks are starting to appear earlier. Physical activity
has decreased markedly in adolescence, particularly in girls, and
obesity has increased substantially (MacKay and Mensah 2004).
Sexual and Reproductive Behaviors. Worldwide, the majority
of young people initiate sexual activity during adolescence.
Significant proportions—in some regions and countries, the
majority—marry and become parents (table 59.2). Globally,
the age of onset of puberty has been decreasing progressively
for both boys and girls (National Research Council and
Institute of Medicine 2005). The age at first marriage has also
increased in most parts of the world over recent decades, except
in Latin America (Mensch, Singh, and Casterline 2003). The
decline in the age at puberty, combined with the general trend
toward later marriage, increases the period of time during
which adolescents may be sexually active before marriage and
may result in sexual initiation at an earlier age (National
Research Council and Institute of Medicine 2005).
Young women typically make the transition to marriage and
parenthood at an earlier age than young men, and early mar-
riage predisposes girls to HIV infection through unprotected
sex, because the partner, by virtue of age, has an elevated risk of
being HIV positive. In addition, marriage changes adolescent
girls’ support systems, thereby limiting their access to knowl-
edge about HIV/AIDS (Bruce and Clark 2003).
All these key transitions to adulthood bring with them the
potential for risks to health that may have both immediate and
longer-term effects. Among young women age 15 to 29, illnesses
related to pregnancy and childbearing account for 16 percent
of their DALYs. Some have unwanted pregnancies, and in
countries where abortion is legally restricted, unsafe abortion
is an important source of mortality and morbidity for young
women, with abortion complications accounting for almost
3 percent of DALYs worldwide among females age 15 to 29.
(WHO 2004c).
Even though adolescent childbearing has declined in recent
years, the proportion of young women who become mothers
during adolescence remains high in most LMICs, and very
early childbearing remains an issue in some regions (table 59.2).
Childbearing before age 16 also brings with it a high risk of
health consequences, both for the mother and for the newborn
(Save the Children U.S.A. 2004; WHO forthcoming-b).
In the most recent surveys carried out in LMICs, high pro-
portions of adolescents report that they have heard of contra-
ceptive methods; however, little is known about the quality and
accuracy of young people’s knowledge of contraception.
Moreover, substantial proportions of young women appear
to have an unmet need for contraception; they are not using
contraception even though they are sexually active and do not
want to have a child (CDC and ORC Macro 2003; Westoff and
Bankole 1995).
In addition to having a risk of early and unwanted preg-
nancy, adolescents are also at risk of acquiring sexually trans-
mitted infections (STIs), including HIV. HIV/AIDS accounts
for most of the sexual and reproductive health DALYs lost by
young men age 15 to 29 (almost 9 percent). Among young
women age 15 to 29, HIV/AIDS accounts for a higher propor-
tion of DALYs than for young men (almost 12 percent) because
of their higher levels of susceptibility. STIs and other sexual and
reproductive health disorders together account for just over
5 percent of young women’s DALYs, much more than among
young men. About half of all HIV infections occur in people
under age 25, and for biological, social, and economic reasons,
young women are disproportionately affected, especially in
Sub-Saharan Africa, where young women have twice the preva-
lence rate of young men (UNAIDS 2003).
Poverty and Adolescent Health
Poverty and inadequate health systems compound adolescents’
vulnerability to sickness and early death. At the same time,
poor health exacerbates poverty by disrupting and cutting
short school opportunities, by weakening or killing young
people in the prime of their working lives, or by placing heavy
financial and social burdens on families.
Poor adolescents bear a disproportionate burden of the
health problems in their age group. An analysis of data from
demographic and health surveys (Macro International
1990–98, unpublished raw data) indicates a strong association
between poverty and the health status of adolescents and
between poverty and adolescents’ use of health services. For
example, the poorest 20 percent of young women are between
1.7 and 4.0 times as likely to have an early birth as the richest
20 percent of young women. Similar disparities between rich
and poor adolescents are seen for indicators such as early mar-
riage, skilled attendance at birth, use of contraception, and
knowledge of HIV/AIDS transmission, and these disparities
tend to be greater for adolescents than for older women. For
example, surveys in 45 countries show that the poorest 20 per-
cent of women age 15 to 49 have a total fertility rate almost
double that of the richest 20 percent, whereas among adoles-
cents age 15 to 19, total fertility among the poorest 20 percent
is more than triple that of the richest 20 percent (Macro
International 1990–98, unpublished raw data).
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Table 59.2 Indicators of Sexual and Reproductive Behaviors among Adolescents and Youth by Gender and Age Group, Late
1990s to Early 2000s
a. Sexual Activity
Percentage of females age 20–24 who Percentage of males age 20–24 who 
became sexually active before age became sexually active before age
Region 15 18 20 15 18 20
East and Southern Africa 17 57 77 14 45 65
West and Central Africa 21 59 77 12 40 61
Caribbean and Central America 13 44 62 31 70 84
South America 9 41 61 31 73 87
Former Soviet Asia 1 20 53 — — —
Middle East — — — — — —
South and Southeast Asia — — — — — —
b. Marriage
Percentage of females age Percentage of males age 
20–24 who married before age 20–24 who married before age
Percentage of men age
Region 18 20 18 20 20–24 ever married
East and Southern Africa 37 55 14 28
West and Central Africa 45 60 12 27
Caribbean and Central America 35 53 22 38
South America 23 38 14 29
Former Soviet Asia 16 50 — 24
Middle East 23 40 — 17
South and Southeast Asia 42 60 — 41
c. Childbearing
Percentage of females age 20–24 Percentage of males who 
whohad a child before age ever fathered a child at age
Region 16 18 15–19 20–24
East and Southern Africa 9 27 2 24
West and Central Africa 13 31 2 13
Caribbean and Central America 7 22 2 27
South America 4 16 3 23
Former Soviet Asia 0 4 — —
Middle East 3 11 — —
South and Southeast Asia 9 24 — —
d. Contraceptive Use
Percentage of sexually active females Percentage of sexually active females 
age 15–19 using contraception age 20–24 using contraception
Region All Unmarried All Unmarried
East and Southern Africa 21 28 30 42
West and Central Africa 20 26 23 35
Caribbean and Central America 24 — 36 —
South America 28 38 33 59
Former Soviet Asia 25 — 43 —
Middle East — — — —
South and Southeast Asia — — — —
Source: National Research Council 2005. 
—  not available.
INTERVENTIONS
Improving the health of young people is complex and difficult,
arguably more so than for other age groups. Compared with
children, adolescents are less protected by their families and
communities and less amenable to simple solutions to their
health problems, many of which are behavior based. Compared
with adults, adolescents know less about how to stay healthy
and have fewer resources to prevent or treat health problems.
By contrast, their behaviors are less firmly entrenched, and they
are often involved in institutional activities, such as schools,
training programs, and the military, where programs with high
coverage can be sustained. The influences on young people’s
behaviors are becoming better understood (Blum and Mmari
2004; Pitts and others 2004), but even given what is known
about such influences, the challenge of designing interventions
to reinforce protective factors and mitigate risk factors remains.
Many of the factors associated with less risky health behaviors,
such as family connectedness and academic performance, go
far beyond the purview of health program managers.
Programs will have to seek multisectoral solutions that link
health sector interventions with other types of interventions
delivered through other sectors, either at the program level or
at the policy level. The difficulty in attributing improvements
in health outcomes among adolescents to interventions deliv-
ered in multiple settings or sectors reflects the challenges
involved. Programs aimed at young people are relatively new
and untested. Nevertheless, accumulated experience, backed by
an increasing body of research, has created international con-
sensus around a multi-intervention approach centered on the
following (WHO 1999):
• Young people need information and skills to make the right
decisions about behaviors that affect their health, such as
whether and when to have sex and whether to use tobacco.
• Young people need access to a broad range of health services
that give them the means to act on their knowledge, includ-
ing access to condoms.
• Young people need a social, legal, and regulatory environ-
ment that supports healthy behaviors and protects them
from harm.
Interventions to improve adolescent health have typically
reflected this consensus and are echoed in goals that have been
adopted internationally.
This section summarizes what is known about the effective-
ness of such interventions. Note that the health community’s
consideration of adolescent health has only occasionally advo-
cated attention to those health conditions that are of relatively
greater importance to the adolescent age group, at least as
measured by indicators such as DALYS. Much of the focus has
been on sexual and reproductive health and on risky behaviors
such as tobacco and drug abuse. The lack of age-specific data
and traditional reliance on mortality and morbidity statistics
contribute to the unbalanced attention. Another factor may be
that such behaviors tend to have longer-term health conse-
quences that are not reflected in standard DALY calculations.
An additional reason for the imbalance in adolescent data may
be the significant social impacts of sexual and reproductive
behavior (for example, the contribution of high fertility to
rapid population growth); the social and economic implica-
tions of large proportions of HIV-infected adolescents in many
countries; the mortality implications of initiating tobacco use
during adolescence; and the antisocial behavior associated with
substance abuse. Public health systems’ efforts to address health
problems associated with road safety, malaria, and mental
health have devoted inadequate attention to developing and
implementing programs that target adolescents.
Evidence on Sexual and Reproductive Health Interventions
Two recent reviews summarize research on the effectiveness of
adolescent sexual and reproductive health interventions.
Table 59.3 presents the results of the FOCUS on Young Adults
(2001) review. The FOCUS report looks at interventions in
LMICs and is based on relatively rigorous evaluations of 40
programs. The general findings from the FOCUS review, sup-
plemented by more recent research findings, are as follows:
• Almost all programs are effective in promoting positive knowl-
edge and attitudes. Almost all the rigorously evaluated pro-
grams that FOCUS reviewed improved knowledge of repro-
ductive health and selected attitudes.
• Most programs effectively influence behaviors. A majority of
programs significantly changed at least one important ado-
lescent behavior pertaining to reproductive health. Often,
however, programs tried and failed to improve many impor-
tant behaviors. Where research has found programs to be
effective in changing behaviors, such changes have typically
not been large.
• All six categories of interventions studied proved effective at
influencing reproductive behavior in at least one study. How-
ever, maintaining that certain models are more effective
than others is impossible because the period of observation
and the behaviors that were influenced varied by study.
Moreover, further replications in multiple settings are nec-
essary to provide a basis for identifying the key features or
elements of successful interventions.
• The evidence base is limited in a number of ways. Few studies
look at the effects on ultimate health outcomes, such as
pregnancy rates or rates of HIV infection. Furthermore,
many promising approaches have not been rigorously eval-
uated. Only a few studies assessed effects on the use of
health services, and none examined the effect of creating a
1114 | Disease Control Priorities in Developing Countries | Elizabeth Lule, James E. Rosen, Susheela Singh, and others
supportive environment on behaviors. Furthermore, much
of the available evidence from strong studies is for small-
scale programs that are carried out over short periods of
time, and little evidence is available on long-term effects on
behaviors (Speizer, Magnani, and Colvin 2003). A recent
study in Tanzania provides the first rigorous evidence that
the benefits of adolescent sexual and reproductive health
programs in low-income countries can last for at least three
years (AMREF, LSHTM, and NIMR 2003).
Kirby’s (2001) review covers roughly 70 rigorously evalu-
ated programs in Canada and the United States. The review
divides programs into three categories: (a) programs that focus
on sexual antecedents, such as sexuality and HIV education
and clinical programs; (b) programs that focus on nonsexual
antecedents; and (c) programs that incorporate both youth
development and reproductive health components. Kirby finds
that programs in all three categories proved effective in reduc-
ing sexual risk taking, pregnancy, and childbearing among
teens. In relation to youth development programs, Kirby finds
that a type of intervention known as service learning, in which
students work on community projects, had the strongest evi-
dence of effectiveness. By contrast, other types of youth devel-
opment programs were not effective in improving reproductive
health outcomes. Programs that incorporate both youth devel-
opment and reproductive health components were effective
over long periods.
In synthesizing U.S. and international data, Kirby (2003)
finds that programs are effective with different groups of ado-
lescents in different countries. Also, programs seem to be par-
ticularly effective for adolescents who are at especially high risk
of negative sexual and reproductive behaviors. In addition,
programs do not hasten or increase sexual activity—a common
criticism of opponents of adolescent programs. Of all the pro-
grams that have been rigorously evaluated, none has reported
a decrease in the age of sexual debut or an increase in sexual
activity among young people. A recent effort to review the evi-
dence on interventions for preventing HIV among young peo-
ple has made tentative conclusions about the effectiveness of
and subsequent support for wide-scale implementation (WHO
2004b).
On the basis of these international reviews, relatively strong
evidence of effectiveness on a range of outcomes has emerged
for the following interventions:
• Life-skills and health and sexuality education in schools. Well-
designed, well-implemented sexuality and reproductive
health education can provide young people with a solid foun-
dation of knowledge and skills to enable them to engage in
safe and responsible sexual behavior.
• Peer education. Peer education programs are especially
appropriate for young people who are not in school and for
hard-to-reach, at-risk subsets of the youth population,
including sex workers and street children.
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Table 59.3 Effectiveness of Adolescent Sexual and Reproductive Health Programs, LMICs
Number of programs showing significant impact/Total number of programs studied
Impact on key behaviors
Improved Reduced Increased Increased Improved at 
Number of knowledge Delayed number of contraceptive service least one
Type of program studiesa and attitudes sex partners use use behavior
All programs 40 33/36 6/17 6/10 18/23 4/9 23/30
School 21 17/19 4/11 3/6 6/10 1/3 9/14
Mass media 6 5/6 1/4 2/3 5/5 1/2 5/5
Community 4 4/4 1/1 — 4/4 — 4/4
Youth development (1) 1/1 — — 1/1 1/1 1/1
Peer education (3) 3/3 1/1 — 3/3 — 3/3
Workplace 4 4/4 — — 2/2 — 2/2
Health facility 4 2/2 — — 0/1 2/3 2/4
Youth-friendly services (3) 1/1 — — — 2/3 2/3
Youth center (1) 1/1 — — 0/1 — 0/1
Multicomponent 1 1/1 0/1 1/1 1/1 0/1 1/1
Sources: Multicomponent program: AMREF, LSHTM, and NIMR 2003; all other programs: FOCUS on Young Adults 2001.
—  not available.
a. Numbers of studies in parentheses are subsets.
• Mass media and community mobilization. Mass media and
community mobilization efforts that engage influential
adults, such as parents, teachers, community and religious
leaders, and music and sports stars, can help normalize pos-
itive adolescent behaviors and gender roles as well as direct
young people to appropriate health services.
• Youth development programs. Youth development programs
typically address a range of key adolescent needs, including
life skills, education, jobs, and psychosocial needs. U.S. pro-
grams with a voluntary community service component have
successfully improved key reproductive health behaviors,
but no evidence is available for developing countries.
• Clinical health services. Although some young people seek
care through the formal health system, many others are
deterred by the often judgmental attitudes of health work-
ers, particularly when seeking care and advice on matters
related to sexuality.
• Social marketing. This approach involves the use of public
health messages to promote healthy behaviors and the use of
condoms and other health products and services. Effective
programs bring products and services to places in the com-
munity that young people frequent, such as shops, kiosks,
and pharmacies.
• Workplace and private sector programs. Programs that reach
young people do so at their places of work and through pri-
vate channels, such as pharmacies and for-profit medical
services, where many young people prefer to seek care.
Many successful U.S. youth development programs have a
work component.
Evidence of Other Adolescent Health Interventions
Data on the effectiveness of other adolescent health interven-
tions are more scattered, partly because some issues have not
been recognized as adolescent-specific problems that require
youth-focused interventions.
Nutrition. Because anemia is a critical health problem in
many countries, many efforts have focused on improving the
iron intake of adult women. Interventions aimed at adolescent
girls have found that daily iron supplementation effectively
lowers anemia and iron deficiency (Elder 2002; MotherCare
2000). Obesity is rapidly becoming a serious health problem
among adolescents in many middle-income countries and is
often also associated with loss of self-esteem among adoles-
cents. A few studies show that preventing obesity is more suc-
cessful among adolescents than among adults (Delisle,
Chandra-Mouli, and de Benoist 2001).
Mass Deworming. In the Busia district of western Kenya, an
ongoing World Bank study is evaluating the effect on learning
outcomes of providing deworming treatment to all students in
a school. After two years, observed effects of deworming treat-
ment included fewer absences and lower dropout rates, but no
effect on test scores (World Bank 2002a). The treatment also
resulted in health and school participation benefits among
untreated children in the same schools, as well as in neighbor-
ing schools, suggesting that the deworming had positive
externalities.
Tobacco. Price increases are the most effective tool for reduc-
ing or deterring the use of tobacco products by young people.
Studies in the United States have shown that price increases
have a greater effect on tobacco use by young people than on
use by older age groups (University of Illinois at Chicago
Health Research and Policy Centers 2001). Other interventions
have also reduced tobacco use among young people, such as
comprehensive bans on all advertising, including bans on the
promotion of tobacco products and trademarks (World Bank
2002c). Programs that give young people the skills to resist peer
pressure and other social pressures to smoke have demonstrated
consistent and significant reductions or delays in adolescent
smoking. School-based programs are also more effective when
combined with communitywide supportive efforts. Informa-
tion campaigns that help young people see how the tobacco
industry tries to manipulate their behavior through advertising
have been highly effective in changing behavior and attitudes
toward smoking among young people in the United States
(American Legacy Foundation 2002).
Promising but Unproven Interventions
Many promising adolescent-focused interventions have not
yet been rigorously evaluated. These interventions include
programs aimed at providing young, newlywed couples with
reproductive health information and services (Alauddin and
MacLaren 1999); programs that combine livelihoods skills with
reproductive health information and services (Rosen 2001b);
voluntary counseling programs on and testing for HIV
(YouthNet 2002); actions aimed at changing social norms such
as gender roles (Horizons 2004); and interventions that address
the political and social context (WHO forthcoming-a). A few
studies of multipronged approaches are just becoming available
and have shown mixed results. Findings from a four-country
study found little or no effect of such an approach on key
reproductive health behaviors among adolescents (Frontiers,
Horizons, and YouthNet 2004). By contrast, a study in Tanzania
found that a multicomponent approach had a significant effect
on key reproductive health behaviors but no effect on health
outcomes (AMREF, LSHTM, and NIMR 2003).
Other possibly promising efforts include suicide prevention
programs, tuberculosis education linked with health education
(interpersonally or through the mass media), and malaria
treatment programs that focus on young people. Adequate
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evaluation is available on the efficacy of programs promoting
the use of seat belts and crash helmets through enforcement of
related laws and the support of intensive publicity and infor-
mation campaigns, as well as on the efficacy of programs pre-
venting alcohol use among adolescents. The evaluations are
sufficient for building confidence for investment, and they
serve as a basis for intervention design (National Research
Council and Institute of Medicine 2004; WHO 2004d).
COSTS AND COST-EFFECTIVENESS
OF INTERVENTIONS
Good cost studies of adolescent health programs in LMICs are
rare. The reported cost of such programs varies greatly depend-
ing on the country, type of intervention, target group, and
so on. For example, such programs cost between US$0.03 per
adolescent reached in a family life education radio program in
Kenya and US$71.00 per year per adolescent reached in a
school-based HIV prevention program in Zimbabwe. Of the
32 programs studied, 12 have a unit cost of less than US$10 per
year, and others have a unit cost of US$10 to US$25
(table 59.4). Cost estimates are available only for certain types
of interventions, with most of the estimates being for repro-
ductive health and HIV education programs. A few studies
have tried to measure cost per DALY of adolescent sexual and
reproductive health interventions; however, the estimates vary
widely. For example, in India, a youth-focused HIV prevention
program costs US$66.20 per DALY gained; in Honduras, the
cost of a voluntary counseling and testing program aimed at
youth is US$5,873 per DALY gained.
The estimates shown in table 59.4 should be interpreted
with great caution. Comparing costs across types of programs
and countries is difficult, but so is choosing comparable effec-
tiveness measures.3,4
ECONOMIC ANALYSIS
Economic analysis of adolescent health programs can pro-
vide important information on their value relative to other
interventions.
Economic Benefits of Interventions
The macro approach to measuring the economic benefits of
interventions is to define the benefits of investing in youth in
terms of the investments’ effect on economic growth, which
typically is measured in terms of growth in gross national
product per capita. Some research suggests that investments
in young people—whether in access to reproductive health
care, in education, or in other key facets of their lives—have
synergistic effects that promote overall economic development
(Birdsall, Kelley, and Sinding 2001). For example, shifts to
smaller family size and slower rates of population growth in
East Asia appear to have played a key role in the creation of an
educated workforce, the accumulation of household and gov-
ernment savings, the rise in wages, and the spectacular growth
of investment in manufacturing technology. The shift to
smaller families that is taking place in many countries will open
another window of opportunity as workers have proportion-
ately fewer old and young dependents to support.
If societies invest in health, education, and job creation, the
resulting economic gains will improve their overall quality of
life. Education, particularly for girls, is strongly related to
reproductive behavior. In most countries, girls who are edu-
cated are more likely to delay marriage and childbearing,
whereas girls with less education are more likely to become
mothers as adolescents. Unfortunately, the causal relationships
involved are not clear. Are girls more likely to get married when
they leave school, or do some girls prefer to terminate their
schooling and marry early? The difference is critical. In the first
case, the appropriate policy response would focus on improv-
ing schooling opportunities for girls. In the second case,
research would need to be done first to determine the underly-
ing reasons for girls’—and their parents’—preferences for early
marriage instead of additional schooling. The next step would
be to assess whether these reasons appear to reflect the girls’
(and society’s) best interests and, if not, to find interventions to
address the root causes of this preference.
The micro approach to measuring the economic benefits of
interventions is to build on microeconomic estimates of direct
productivity effects that can be measured in monetary terms.
For other effects that cannot readily be translated into monetary
terms, analysts can use the cost of the most cost-effective alter-
native to achieve the same effects. Knowles and Behrman
(2003a) use this approach to estimate the benefits of various
youth-focused investments, including in health. They summa-
rize the three types of effects: (a) those that can be directly valued
in monetary terms, (b) those that may require indirect valua-
tion, and (c) those that are particularly difficulty to monetize.
Table 59.5 presents examples of these effects.
Cost-Benefit Analysis 
Cost-benefit analysis is well suited to the economic analysis of
projects aimed at youth, in part because many investments in
young people yield multiple benefits, such as additional school-
ing and improved health. Finding any effectiveness measure
that adequately reflects the wide range of benefits obtained
from some types of investments in youth is difficult, but cost-
benefit analysis has the advantage of allowing comparisons
across a range of interventions that may vary considerably in
terms of type and effects.
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Table 59.4 Cost and Cost-Effectiveness of Adolescent Health Programs
Number Cost per 
Region and served Unit cost DALY
country Program type (name) per year (US$) Unit gained (US$) Source
Sexual and reproductive health interventions
Latin America
Brazil School-based HIV/AIDS prevention program — 0.70 Per condom — Antunes and others 1997
Honduras School-based reproductive health program — 10.44 Per targeted 1,323 World Bank 2002b 
to prevent HIV/AIDS adolescent
Honduras Social marketing of condoms to adolescents 904,612 10.20 Per targeted 3,292 World Bank 2002b 
adolescent
Honduras Symptomatic treatment of STIs — 48.97 Per adolescent 28,306 World Bank 2002b, as
treated cited in Knowles and
Behrman 2003b
Honduras Voluntary counseling and testing for youth 1,000 18.29 Per adolescent 5,873 World Bank 2002b, as 
undergoing cited in Knowles and 
voluntary counseling Behrman 2003b
and testing
Honduras Workplace information, education, and 1,000 20.88 Per worker 2,623.77 World Bank 2002b 
communication
Mexico Community peer educators 4,000 63.64 Per active user — Townsend and others 
of contraception 1987
per year 
Mexico Youth center 4,000 203.47 Per active user — Townsend and others 
of contraception 1987
per year
Peru School-based sexuality and HIV/AIDS 604 3.00 Per student reached — Caceres and others 1994 
prevention education
Europe and Central Asia
Hungary School-based HIV/AIDS prevention program 41,250 1.40 Per student — Soderlund and others 
per year 1993
Newly School-based HIV/AIDS prevention program — 1.33 Per student — Forrai, personal 
independent reached communication, 1992
states 
Asia
India Information, education, and communication — 1,324 Per HIV infection 66.20 World Bank 1999b 
programs targeted to youth averted
Sub-Saharan Africa
Africa School-based HIV/AIDS prevention program — 75–200 Average unit cost of — UNECA 2000
(primary teacher training and 
school); simple materials
121–241 
(secondary
school)
Africa School-based HIV/AIDS prevention program — 1.40–7.90 Per student reached — Watts and others 2000
Africa Peer education — 8.00–10.81 Per out of school — Kumaranayake and Watts 
adolescent reached 2001
Cameroon School-based HIV/AIDS prevention program 10,000 6.72 Per student reached — Kumaranayake and del 
Amo 1997
Kenya Radio program delivering family life 3,354,000 0.03 Per adolescent reached — Knowles and Behrman 
education (Youth Initiatives Project) 2003b
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Mozambique Community based “stepping stones” 500,000 0.30 Per person per year — World Bank 2003
approach (Action Aid)
Mozambique Voluntary counseling and testing, 11,726 18.40 Per person per year — World Bank 2003
peer education
Senegal Mulitpronged school, clinic, and — 68,215– Total intervention cost — RamaRao and Diop 2003
community interventions 111,714 over a two-year period 
South Africa Television show, mass media 6 million 0.38 Per person per year — World Bank 2003
campaign (Soul Buddyz)
South Africa Mass media campaign (LoveLife) — 20 million Annual budget — World Bank 2003
Tanzania Primary school peer education 2,850 1.37 Per person per year — World Bank 2003; Ross, 
(MEMA kwa Vijana) personal communication.
2003
Tanzania Secondary school peer education 16,250 24.12 Per person per year — World Bank 2003
(School Health Education Program) (over three years)
Uganda Outreach program for street children 5,000 18.50 Per person per year — World Bank 2003
(GOAL: Baaba Project)
Uganda Newsletters, radio show (Straight Talk) Nationwide 630,000 Amount spent in 2001 — World Bank 2003
program reaching 
all schools
Zambia Life skills for teachers and pupils — 0.16 Additional cost of — Knowles and Behrman 
(AIDS Action Program for Schools) one child-year of 2003b
AIDS education
Zambia School clubs, health clinics, peer 53,000 (over 2.26 Per person per year — World Bank 2003
education (Kafue Adolescent five years)
Reproductive Health Program)
Zimbabwe Secondary school clubs, income 35,200 (over 8.89 Per person per year — World Bank 2003
generation, peer education (Africare) two years)
Zimbabwe Secondary school clubs, counseling, 2,000 71.00 Per person per year — World Bank 2003
peer education (Midlands AIDS 
Service Organisation)
Other health interventions
LMICs Tax on tobacco products — — — 5–17 World Bank 1999a 
LMICs Iron supplementation for 13- to — 0.18 Per child per year — Knowles and Berhman 
15-year-olds 2003a
Source: Authors. 
—  not available.
Table 59.4 Continued
Number Cost per 
Region and served Unit cost DALY
country Program type (name) per year (US$) Unit gained (US$) Source
One of the few cost-benefit analyses specific to adolescent
health is Knowles and Behrman’s (2003a) study that examines
three interventions: a program to provide iron supplementa-
tion for secondary schoolchildren, a school-based program of
health education to prevent HIV/AIDS, and a tobacco tax. The
study estimates benefits and costs over a youth’s life cycle, dis-
counted back to the age of 18. The study uses direct estimates
of benefits that could be readily estimated in monetary terms
(such as gains in labor productivity) and indirect estimates of
other benefits, such as reduced fertility and improved health,
that could not be easily monetized. The latter were estimated as
the least cost of investments currently made to obtain the same
benefit; for example, the cost per birth averted in a family plan-
ning program was used to value reduced fertility. Table 59.6
summarizes the findings of these cost-benefit studies, together
with estimates of the benefit-cost ratios for selected other
youth-targeted interventions.
The examples of cost-benefit studies cited here and other
calculations of benefit-cost ratios show that health interven-
tions aimed at adolescents can be good public investments;
however, the results must be interpreted with some caution.
For example, the relatively low benefit-cost ratio of an HIV
prevention program in Honduras was for a program in a coun-
try where HIV incidence among young people is relatively low
(0.1 percent). Where the incidence is much higher, as in many
of the hardest hit countries in Africa (1 percent or more), this
ratio would be proportionately higher. In addition, in the
Honduran study, the benefits included were limited to the pre-
vention of HIV/AIDS and did not include other possible bene-
fits, such as increased education, reduced STIs other than HIV,
and reduced teen pregnancies and abortions. The Honduran
study also assumed that the effects of the intervention would
not continue beyond one year; however, if they were to continue
at the same level to age 29 (assuming that any decrease in the
effect of the intervention over time would be offset by increases
in the incidence of HIV infection with age), the benefit-cost
ratio would increase from 0.5 to 4.6. More than anything else,
Knowles and Behrman’s estimates demonstrate the sensitivity
of the benefit-cost ratios of investments in youth to wide vari-
ations in key assumptions, which may be equally plausible
because of the limited information available on the costs and
effects of many investments in youth.
Beyond the question of how sensitive such estimates are to the
underlying assumptions and the context, the basic question is
what guidance they provide for public policy. High benefit-cost
ratios certainly point to areas that merit further consideration for
possible policy interventions, but they do not indicate whether
using public resources for interventions has an efficiency ration-
ale, because they generally do not identify differences between
private and social benefit-cost ratios.If the purely private benefit-
cost ratios for an investment are high, then presumably
incentives to use private resources for this investment are high,
but an efficiency rationale for using public resources does not
exist unless the social benefit-cost ratio exceeds the private one
because of factors such as spillovers or market imperfections.
High benefit-cost ratios that do not distinguish between social
and private returns, therefore, call for further investigation.
Interventions may warrant the use of public resources on effi-
ciency grounds, but they also must answer that important
question of whether the benefits are social or private.
PROGRAM IMPLEMENTATION AND LESSONS
OF EXPERIENCE
Relatively few adolescent-focused programs have been tried on
a large scale. Sexual and reproductive health interventions and
suicide prevention are some of the few that have gone to scale,
and even in those areas, large-scale interventions are relatively
infrequent. The vast majority of interventions have been in rel-
atively small programs, often through nongovernmental
organizations.
Perhaps the main lesson learned from the experience to date
is an obvious one: programs to reach young people are not
1120 | Disease Control Priorities in Developing Countries | Elizabeth Lule, James E. Rosen, Susheela Singh, and others
Table 59.5 Types of Effects of Adolescent Health
Interventions Categorized According to Ease of Monetization
Type of effect Examples
Directly monetizable effects Enhanced labor productivity
of investments in youth Reduced underutilization of labor
Increased or decreased work effort
Expanded access to risk-pooling services
Reduced age at which children achieve 
a given level of schooling
Reduced cost of medical care
Indirectly monetizable broad Increased education
effects of investments in youth Averted teen pregnancy
Averted HIV infection
Averted tuberculosis infections
Improved health
Improved nutritional status
Delayed marriage
Averted abortion
Reduced tobacco use
Effects that are particularly Increased social capital
difficult to monetize Averted infertility
Averted social exclusion
Improved self-esteem
Enhanced national security (an effect of 
military training) 
Source: Adapted from Knowles and Behrman 2003a.
Table 59.6 Estimated Benefit-Cost Ratios, Selected
Investments in Youth 
Estimated Plausible 
benefit-cost range of 
ratio (assuming estimated 
3 percent annual benefit-cost 
Investment discount rate) ratio
Scholarship program (Colombia) 4.4 2.8–25.6
Adult basic education and 27.6 8.1–1,764.0
literacy program (Colombia)
School-based reproductive 0.5 0.1–4.6
health program to prevent 
HIV/AIDS (Honduras)
Iron supplementation 45.2 25.8–45.2
administered to 
secondary schoolchildren 
(hypothetical low-income 
country) 
Tobacco tax (hypothetical 20.2 7.0–38.6 
middle-income country) 
Source: Adapted from Knowles and Behrman 2003a.
simply programs for adults applied to a younger population;
they require different thinking and a different approach.
Determining Key Principles of Health Programming
for Adolescents
Experience to date suggests that effective, youth-focused efforts
share a set of common general principles. These principles
include the following:
• Recognize the diversity of the youth age group. A sexually
inexperienced 11-year-old has vastly different needs than
a married 20-year-old. Programs should apply different
strategies to reach youth, who vary by age, sex, employment,
schooling, and marital status.
• Involve young people.Policies and programs are more effective
when young people are involved in all aspects of their design,
implementation, and evaluation. Involvement must go
beyond tokenism and be genuine,meaningful,and sustained.
• Make health services appealing to youth. A key to rapidly
expanding young people’s access to health services is to
make them more youth friendly by using specially trained
health workers and by bolstering the privacy, confidentiality,
and accessibility of care.
• Address gender inequality. Gender inequalities expose young
girls to coerced sex, HIV infection, unwanted pregnancy,
and poor nutrition. Efforts should focus on changing the
factors that perpetuate gender inequalities.
• Address the needs of boys. Adolescence presents a unique
opportunity to help boys form positive notions of gender
relations and to raise their awareness of health issues. At the
same time, boys seem to be disproportionately exposed to a
number of adolescent health risks, including accidents and
injuries, suicide, tobacco use, substance abuse, and violence.
Program design should take into account the specific needs
of boys and young men as well as of girls and young women.
• Design comprehensive programs. Comprehensive programs
that provide information and services while addressing the
social and political context are more effective than narrowly
focused interventions.
• Consider all important benefits. Many adolescent health
interventions focus on only one benefit. For example, a
school-based sex education program may focus exclusively
on HIV prevention and may neglect other possible benefits
from the intervention, such as increased education, averted
teen pregnancy and abortions, and other averted STIs.
• Address the many nonhealth factors that influence adolescent
health. Linking school and livelihood opportunities to ado-
lescent health programs, at either the policy or program
level, is key to helping young people avoid risky behaviors.
• Address underlying risk and protective factors. Factors such as
feelings of self-efficacy, attitudes and behaviors of friends,
connectedness with parents and other influential adults, and
involvement in the community can either increase (risk fac-
tor) or decrease (protective factor) the chances that a young
person will engage in unhealthy behaviors.
Making a Difference on a Large Scale
Adolescent health programs are complex and may not be easy to
scale up because of technical, management, and political chal-
lenges. The following are examples of adolescent health pro-
grams that are national in scope. Unfortunately, little is known
about the costs and effectiveness of such large-scale efforts.
National Suicide Prevention Program in New Zealand.
Among industrial nations, New Zealand has one of the highest
suicide rates for both males and females age 15 to 24 (New
Zealand Ministry of Health 2002). In 1998, on the basis of inter-
national good practice, the government developed the National
Youth Suicide Prevention Strategy. This strategy, which includes
a component for the general population and one that focuses
on the indigenous Maori community, provides a framework for
understanding suicide prevention and signals the steps that
government agencies, communities, and service providers must
take to reduce suicide. Even though the national strategy has not
been in place long enough to adequately gauge its effects, in
1999, the first year following the adoption of the strategy, youth
suicide rates fell to their lowest levels since 1991.
Sexuality Education in Mongolia. Mongolia has implemented
a locally developed and tested sexuality education curriculum in
60 percent of schools nationwide. Current challenges include
increasing the number of hours allocated to sexuality education;
developing more and better written resources for adolescents,
including textbooks; developing materials that will help parents
communicate better with their children on sexuality; expanding
access to clinical services for adolescents through the public
health system; reaching out-of-school youths and the broader
community with sexuality education; and monitoring and eval-
uating the program regularly to assess its weaknesses and
strengths and how it could be improved (Gerdts 2002).
Addressing the Health Needs of Poor Youth
The following strategies, based on what is known about ser-
vices for poor people more generally and about the specific
needs of young people, show promise for meeting the needs of
poor youth:
• Targeting out-of-school youth. Out-of-school youth of a
given age are likely to be more marginalized than those who
are in school, and they are often those most in need of crit-
ical services, such as pregnancy prevention and prevention
of HIV/AIDS and other STIs. A number of countries,
including Paraguay, South Africa, and Zimbabwe, have
launched effective programs targeting out-of-school youth
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that combine the use of mass media, peer education, and
community-based efforts. For instance, the Arte y Parte
project targeted out-of-school youth in three cities in
Paraguay using a booklet about adolescent sexuality, street
drama, radio programming, newspaper columns, and dis-
tribution of promotional items (Magnani and others 2000).
• Focusing efforts on vulnerable youth. Young people who have
been orphaned or left vulnerable by AIDS typically rely first
on their extended families and communities for support.
Efforts to help vulnerable youth should strengthen those
safety nets. One example is the COPE program in Malawi,
where a nongovernmental organization–sponsored effort
works through existing government structures to help
orphans and other vulnerable children (Phiri, Foster, and
Nzima 2001).
• Tailoring subsidized programs to poor youth. Social market-
ing of reproductive health products and services—such as
contraceptives and condoms for pregnancy and disease pre-
vention or promotion of iron supplementation—often tar-
gets young consumers, but such efforts should ensure that
they reach the desired clients—namely, those who are poor
and less likely to be able to afford market prices. The Social
Marketing for Adolescent Sexual Health Project in four
African countries combined the use of mass media with
peer education to encourage young people to practice safer
sex, including condom use (Agha 2000).
Improving Health Systems to Meet Adolescents’
Health Needs
The shortcomings of health systems in LMICs are well known,
and adolescents in particular would benefit from the following
health system improvements:
• Strengthening human resource capacities. The poor quality of
the interaction with health workers is one of the main bar-
riers to adolescents’ use of health care in public sector facil-
ities. Through training, supervision, and other means,
health systems should encourage health workers to adopt a
more youth-friendly outlook. In addition, health systems
should integrate such training into the curricula of medical,
nursing, and nurse auxiliary schools.
• Involving the private sector. Many young people already seek
care from private doctors, nurses, and nurse-midwives or
from local pharmacies or other drug distribution outlets.
Along with encouraging private for-profit health providers
to serve youth, government policies should encourage
efforts to tap into the private sector as a source of health care
for adolescents by means of interventions such as social
marketing, contracted services, youth-focused social fran-
chising, and programs that serve young people at their place
of work. (Carranza 2003; LaVake and Rosen 2003; Rosen
2001a; Senderowitz and Stevens 2001).
• Strengthening the stewardship oversight function of govern-
ments. Governments have a key role to play in developing
supportive policies, both within the health sector and across
sectors; in contributing to cross-sectoral policies such as
national youth policies; and in providing input into policy
making in other sectors, especially education and labor.
Ideally, governments should have an overarching adolescent
health policy with specific reference to adolescent health
in policy documents for specific programs or diseases, such
as for AIDS, tuberculosis, malaria, sexual and reproductive
health, and population (WHO forthcoming-a; POLICY
Project and YouthNet forthcoming).
RESEARCH AND DEVELOPMENT AGENDA
The striking lack of good research and evaluation of adolescent
health interventions limits countries’ ability to address serious
health problems. At this juncture, research in the following
broad areas is critical:
• Refining estimates of DALYs for adolescents. Available DALY
information is inadequate to fully explore the burden of
disease for adolescent age groups. Future DALY estimates
should be made for five-year age groups in the 10 to 24 age
range.
• Documenting the effectiveness of current approaches. This
area includes better process evaluation to understand the
functioning of successful programs. Such evaluation neces-
sitates more rigorous research designs so that the effective-
ness of programs can be better documented, both in terms
of health outcomes and in terms of DALYs saved. Another
area in which more research could help is better documen-
tation of the nonhealth effects of adolescent health inter-
ventions. Greater investment is also needed to evaluate the
effects of health promotion strategies on reducing smoking,
including the smoke-free spaces prevalent in the Americas
and life-skills education.
• Testing new interventions. This area includes more research
on multicomponent programs and on new types of inter-
ventions. In relation to sexual and reproductive health, new
interventions include approaches such as providing anti-
retroviral therapy to HIV-infected youth and voluntary
counseling and testing for HIV, encouraging adolescents to
have fewer sexual partners, reducing the trafficking of young
people, preventing and addressing the health consequences
of early marriage, and reaching young married women with
information and services. Research must better inform
interventions so that they reach groups at particularly high
risk of poor health outcomes, such as child prostitutes, child
workers, refugees, AIDS orphans, and street children. More
research is also needed on a broad range of other adolescent
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health interventions, especially for those health problems
that are among the biggest killers and disablers of young
people: HIV/AIDS and mental illnesses for both males and
females, maternal conditions for females, and road accidents
for males. In addition, research is needed on programs that
attempt to influence gender roles and social norms and
investments designed to avert drug and alcohol abuse and to
improve mental health.
• Enhancing understanding of the risk and protective factors
influencing young people’s behavior. Even though our under-
standing of the major influences on youth behaviors has
come far, more refinement of such understanding is needed,
along with a better understanding of how to incorporate
such knowledge into the design of programs and policies.
• Improving cost and cost-benefit analysis. Good cost estimates
are rare, and more needs to be done to more fully estimate
the costs of the range of adolescent health interventions.
This effort means collecting more data on program costs
and more accurate data that include programs’ nonmone-
tary costs. Few full cost-benefit analyses of youth programs
exist, and more need to be done to improve evaluations of
the economic value of investments targeted at young people.
CONCLUSIONS
The health community has only recently recognized the impor-
tance of adolescent health problems. To address the unique
health problems associated with the adolescent years, policy
makers and the health community must expand the knowledge
base on effectiveness, costs, and economic benefits and pay
more attention to areas such as road safety, nutrition, mental
health, and malaria. Well-documented implementation experi-
ences from mostly small programs have produced a sound
body of knowledge about how programs function. These expe-
riences can provide the foundation for scaled-up efforts and
can help the health community improve health systems in ways
that will benefit adolescent health efforts.
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NOTES
1. The United Nations defines youth as those age 15 to 24. The World
Health Organization defines adolescence as age 10 through 19 and uses the
term young people to refer to those age 10 to 24.
2. Regional data cited from this report here and elsewhere in the chap-
ter are based on nationally representative surveys carried out between the
mid 1990s and 2001.
3. Knowles and Behrman (2003b) find that many cost estimates incor-
rectly treat income transfers as costs and frequently fail to include esti-
mates of administrative and distortionary costs (for example, the distor-
tionary cost of financing programs through taxes).
4. In cost-effectiveness analysis, as in cost-benefit analysis, estimates are
needed not only of what has actually happened, but also of what would
have happened in the absence of the program or intervention (that is, an
estimate of the counterfactual). There are no exceptions to this rule.
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Workers around the world—despite vast differences in their
physical, social, economic, and political environments—face
virtually the same kinds of workplace hazards. These hazards
are traditionally categorized into four broad types: chemical,
biological, physical, and psychosocial. What emerges from our
incomplete knowledge of their risk, however, is that the more
than 80 percent of the world’s workforce that resides in the
developing world disproportionately shares in the global bur-
den of occupational disease and injury. Several classic occupa-
tional diseases, such as silicosis and lead poisoning, that have
been substantially eliminated in industrial countries remain
endemic elsewhere in the world. Whether this high and pre-
ventable burden of ill health faced by workers in the develop-
ing world is the result of ignorance, inattention, or intent, com-
pelling evidence indicates that work-related health conditions
could be substantially reduced, often at modest cost.
NATURE AND CAUSES OF OCCUPATIONAL
HEALTH CONDITIONS IN THE DEVELOPING
WORLD
Despite country-to-country differences, some commonalities
exist within the workforce of the developing world that are
worth noting. Workforce distribution by economic sector is
different from that in the industrial world. Compared with
industrial countries, where single-digit percentages prevail—
for example, approximately 2 percent in the United
Kingdom—developing countries employ about 70 percent of
their economically active population in the agricultural sector
(World Bank 2003). For many of these workers, the distinction
between health at work and health at home is blurred, because
health in the workplace is integrated into all aspects of daily life
for these often subsistence agricultural workers. For example,
pesticide poisoning is a hazard faced by workers and their fam-
ilies and communities.
The informal workforce, which in industrial countries is
rarely larger than 10 percent of total employment, looms large
in developing countries. This workforce includes self-
employed, household-based unpaid labor (family members,
for example) and independent service workers such as street
vendors. In the developing world, employment in the informal
sector may reach 70 percent, with the contribution to the gross
domestic product (GDP) ranging from 10 to 60 percent
(ILO 2002).
Informal economy workers are often unprotected in the reg-
ulatory arena even in the industrial world. This circumstance
is exacerbated when the vulnerable employment status in the
developing world is coupled with problems of poverty and ill
health. Cottage-industry workers abound in the informal sec-
tor, and home-based work can fully blur distinctions between
occupational and other environmental hazards. Not uncom-
mon across the developing world are lead-poisoned adults who
manufacture batteries in crude facilities at home and their
lead-poisoned children, exposed to the lead while sleeping and
playing in the next room.
The migrant workforce, which is increasing worldwide, is
estimated to be 120 million (ILO 2000). In the industrial world,
immigrant workers often perform work deemed unattractive
(seasonal agricultural work in the United States, service sector
work in the United Kingdom), but the issues of a migrant
workforce in some parts of the developing world take on even
greater import. In southern Africa, for example, migrant min-
ing workers face the extraordinary burden of risk for the triad
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of silicosis, tuberculosis, and HIV/AIDS—diseases that are
inextricably linked to interactive determinants of workplace,
housing, and social and economic factors (Trapido and others
1996).
Workers in the developing world face different risks in the
health transition than do their counterparts in the industrial
world. They may be exposed to the combined and often syner-
gistic risks of both traditional and emerging hazards. Workers
may also face unregulated and unprotected exposures to
known hazards just as those same hazards—silica and asbestos,
for example—were faced decades ago by millions of workers in
the industrial world. A significant difference, though, is that
workers in the developing world are being exposed when wide-
spread knowledge is available about the risks and effective pre-
ventive measures (Kjellstrom and Rosenstock 1990). Even as
these workers are forced to replay history, despite the availabil-
ity of information and knowledge transfer unthinkable just a
generation ago, they face other hazards, including the produc-
tion, marketing, and importation of environmental hazards
such as cigarettes. In the instance of asbestos and tobacco, both
products are being aggressively marketed and exported by the
industrial world (especially asbestos from Canada and tobacco
from the United States) to the developing world.
A real example of hazards faced by developing workers in
what might be called the risk transition is that posed by dual
exposure to asbestos and cigarette smoke and risk for lung can-
cer. This example is especially troubling not only because the
risk is dauntingly high but also because exposures to both are
occurring with full knowledge of their individual and cumula-
tive effects. As shown in table 60.1, against a background of rel-
ative risk for lung cancer of 1 for a nonsmoking, nonasbestos-
exposed population, a working population with significant
asbestos exposure but no tobacco exposure may face a relative
risk of lung cancer of 5; a smoking population not exposed to
asbestos faces a relative risk of 10; and rather than these risks
being additive (that is, 15) the smoking, asbestos-exposed pop-
ulation has the extraordinary relative risk of lung cancer of 50.
Most important, in this well-recognized multiplicative-effect
scenario, if the smoking exposure alone were eliminated among
the asbestos-exposed workers, the overall risk of lung cancer
would be reduced by 90 percent; even if the smoking exposure
continued, elimination of the asbestos exposure would reduce
the overall risk by 80 percent. Those considerations are not the-
oretical but well supported by empirical data. In parts of China
and elsewhere in the developing world, asbestos exposure
abounds as cigarette smoking is rising. Effective intervention
strategies will be those based on a comprehensive approach to
the overall burden rather than those addressing the individual
burdens of specific exposures, recognizing that organizational
or institutional interventions (such as eliminating asbestos
from the workplace) are far more effective than those targeting
individual behaviors (such as smoking cessation).
GLOBAL BURDEN OF DISEASE FROM
OCCUPATIONAL HEALTH RISKS
The overall picture that emerges from all parts of the develop-
ing world is one of increased health and safety risks in all
occupations for which data are available.
Dramatic changes in the global labor force will occur as
globalization and population growth continue to affect the
global economy. For example, the labor force in Latin America
and the Caribbean is one of the fastest growing in the world,
with 217 million workers in 2000; the number of workers is
expected to reach 270 million in 2010 (PAHO 2002). The bur-
den of disease and injury attributable to workplace risks in the
formal and informal sectors is grave and will continue to rise.
Inadequate data and reporting systems make capturing the
effect of workplace risks problematic. Nonetheless, several
recent efforts by international bodies have shed some light on
the staggering burden, although in general attempts to derive
evidence-based estimates are likely to systematically and signif-
icantly underrepresent the extent of the problem.
The gravity of workplace risks is seen in the recent
International Labour Organization (ILO) estimate that among
the world’s 2.7 billion workers, at least 2 million deaths per year
are attributable to occupational diseases and injuries. The ILO
estimates for fatalities are the tip of the iceberg because data for
estimating nonfatal illness and injury are not available for most
of the globe. The ILO also notes that about 4 percent of the
GDP is lost because of work-related diseases and injuries
(Takala 2002).
A recent effort of the World Health Organization (WHO)
has provided insight into the global dimensions of several
selected occupational health risks. WHO included five occupa-
tional risk factors in its comparative risk assessment in a uni-
fied framework of 26 major health risk factors contributing to
the overall global burden of disease and injury (Ezzati and
others 2004; WHO 2002). The WHO comparative approach
used a common statistical model that allows a reader to com-
pare the contribution (attributable fraction) of several risk
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Table 60.1 Relationship between Asbestos, Smoking, and
Risk for Lung Cancer
Asbestos exposurea
Smokingb No Yes
No 1 5
Yes 10 50
Source: Kjellstrom and Rosenstock 1990.
a. If asbestos exposure eliminated, eliminate 80 percent lung cancers in asbestos workers.
b. If smoking eliminated, eliminate 90 percent lung cancers in asbestos workers.
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factors to a single outcome—lung cancer, for example.
Stringent requirements for consistency in describing risk fac-
tors limited the number of occupational risk factors that could
be included in the study. For all risk factors, it was necessary to
estimate an exposed population and exposure levels for 224
age, sex, and country groups in the 14 WHO geographic
regions of the world. Where possible, data could be extrapo-
lated to age, sex, and country groups for which data were not
available, based on similarities in demographic, socioeco-
nomic, or other relevant indicators. Because knowing the exist-
ing burden of disease and injury globally was necessary, the
only outcomes included were those for which WHO had rates
of disease or injury for all regions calculated by International
Classification of Disease (ICD) codes. Finally, estimates of the
risk factor–burden relationships by age, sex, and WHO subre-
gion were generated. Risk measures (relative risks or mortality
rates) for the health outcomes resulting from exposure to the
risk factors were determined primarily from studies published
in peer-reviewed journals. Adjustments were made to account
for differences in levels of exposure; exposure duration; and
age, sex, and subregion, as appropriate. The information about
each risk factor was entered into the WHO common model for
comparative analysis. The resulting burden was described as
the attributable fraction of disease or injury, using mortality
and disability-adjusted life years (DALYs) lost, with one DALY
being equal to the loss of one healthy life year—the common
currency measure that includes mortality and morbidity.
Because of the requirements for global data, only five occu-
pational risk factors could be described: risks for injuries, car-
cinogens, airborne particulates, ergonomic risks for back pain,
and noise. The exposed worker populations were estimated
using an approach based on the International Standard
Industrial Classification of All Economic Activities (ISIC), an
economic classification system of the United Nations that
organizes all economic activities by economic sectors and rele-
vant subgroupings (UN 2000). The ISIC system is used almost
universally by national and international statistical services to
categorize economic activity; therefore, it allows global com-
parisons. The ILO has developed economically active popula-
tion (EAP) estimates by applying economic activity rates, by
sex and by age group (older than age 15), to the population
estimates and projections of the United Nations (ILO 1996).
The EAP provides the most comprehensive global accounting
of people who may be exposed to occupational risks because it
includes people in paid employment, the self-employed, and
people who work to produce goods and services for their own
household consumption, both in the formal and in the infor-
mal sectors (ILO 2002). For the WHO comparative risk assess-
ment, the EAP was further divided into nine economic subsec-
tors (where people work) and seven occupational categories
(what type of work people do), on the basis of country-level
data for 31 countries (ILO 1995).
The absence of data in much of the developing world
limited the range of occupational risk factors that WHO could
measure, and the available data excluded children under age
15 who work. The WHO comparative risk assessment also
excluded important occupational risks for reproductive disor-
ders, dermatitis, infectious disease, coronary heart disease,
intentional injuries, musculoskeletal disorders of the upper
extremities, and most cancers. Psychosocial risk factors such as
workplace stress could not be studied, nor could pesticide,
heavy metal, or solvent exposures. The potential consequences
of omitting just pesticides from the global burden analysis can
be illustrated by the situation in Central America (PAHO
2002). The isthmus is primarily an agricultural and forested
area of .5 million square kilometers, of which 40 percent is
arable. Pesticide imports almost tripled from 15,000 metric
tons in 1992 to 41,000 in 1998, and 35 percent of the pesticides
were restricted in the exporting countries. In 2000, the subre-
gion imported some 1.5 kilograms of pesticides per inhabitant
per year, a quantity 2.5 times greater than the world average
estimated by WHO. Exposures in the formal and informal sec-
tors extend to the homes and families of the pesticide workers.
Although this situation is common in developing nations, the
WHO comparative risk assessment captured none of these
exposures.
The ILO and WHO data provide the most current, yet still
incomplete, picture of the overall problem of occupational
health risks. Nonetheless, with just the few occupational risk
factors studied in depth by WHO a picture emerges of the sig-
nificant effect of largely preventable conditions (Ezzati and
others 2004). WHO found that occupational injuries result in
about 312,000 deaths per year for the world’s 2.7 billion work-
ers; this figure contrasts to the approximately 6,000 deaths per
year caused by occupational injuries for the 150 million work-
ers in the United States. As in the industrial world, high injury
fatality rates in the developing world are clustered in certain
sectors, including agriculture, construction, and mining.
Using this metric, occupational injuries account for more than
10 million DALYs and 8 percent of unintentional injuries
worldwide.
The second occupational factor WHO analyzed was the
effect of exposure to workplace lung carcinogens (such as
asbestos, diesel exhaust, and silica) and leukemogens (such as
benzene, ionizing radiation, and ethylene oxide). WHO con-
cluded that occupational exposures account for about 9 per-
cent of all cancers of the lung, trachea, and bronchus and about
2 percent of all leukemias. Overall, about 102,000 deaths were
attributable to these two occupational cancers and about 1 mil-
lion DALYs.
Estimates of the global burden of chronic lung disease
demonstrate the significant contribution of occupational expo-
sures, which account for about 13 percent of all chronic
obstructive pulmonary disease (COPD) and about 11 percent
of asthma. In total, WHO found the annual worldwide burden
of work-related COPD to be about 318,000 deaths per year and
about 3.7 million DALYs. The occupational risk contribution
to the worldwide asthma burden was about 38,000 deaths and
about 1.6 million DALYs, reflecting the fact that a great deal of
asthma occurs at younger ages and is not fatal. WHO found
that 37 percent of all back pain worldwide is attributable to
work, resulting in an estimated 800,000 DALYs, a significant
loss of time from work, and a high economic loss. Worldwide,
16 percent of all hearing loss is attributable to workplace expo-
sures, resulting in 4.2 million DALYs.
WHO made a special risk analysis of hepatitis B, hepatitis C,
and HIV infections among health care workers caused by con-
taminated sharps, such as syringe needles, scalpels, and broken
glass (WHO 2002). This analysis illustrates the general prob-
lem of high risks existing in the small worker population hav-
ing exposure. WHO found that, among the 35 million health
workers worldwide, there were 3 million percutaneous expo-
sures to bloodborne pathogens in 2000. This finding is equiva-
lent to between 0.1 and 4.7 sharps injuries per year per health
worker. WHO concluded that of all the hepatitis B and hepati-
tis C present in health care workers, about 40 percent was
caused by sharps injuries, with wide regional variation. WHO
also found that between 1 and 12 percent of HIV infections in
health care workers was caused by sharps injuries. The com-
parative risk assessment by region and type of infection indi-
cates where special emphasis is needed (see figure 60.1).
Clearly, solutions exist to these problems, as shown by the
countries that have engaged in serious prevention efforts.
Proper needle handling and waste management, substitutions
for sharps, hepatitis B virus (HBV) immunization, postexpo-
sure prophylaxis, training, and legislative measures have been
successful. Beyond the personal and workplace consequences,
the potentially devastating societal impact of loss of this criti-
cal worker group can be anticipated if prevention measures are
not ensured in developing countries, where the proportion of
health care workers in the population is already small.
In total, the few occupational risk factors considered here
were responsible for about 800,000 deaths worldwide in 2000.
Not considered by WHO because of lack of global data are the
additional 1.2 million deaths that ILO estimated are attributa-
ble to work-related risks (Takala 2002). The leading occupa-
tional cause of death was unintentional injuries, followed by
COPD and lung cancer. Workers who developed outcomes
related to these occupational risk factors lost about 25 million
years of healthy life. Among the occupational factors analyzed
in this study, injuries, hearing loss, and COPD accounted for
about 80 percent of years of healthy life lost. Low back pain
and hearing do not directly produce premature mortality, but
they do result in substantial disability. This feature differenti-
ates these conditions from the others analyzed in the study.
Figure 60.2 provides summary results for the occupational risk
factors.
The WHO comparative risk assessment has accounted for
only about 800,000 (40 percent) of the 2 million deaths
estimated by ILO to occur each year because of occupational
illness and injury. Deaths attributable to a wide range of
occupational exposures could not be included because of the
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strict requirements for global data. Missing are deaths
attributable to asbestosis, silicosis, and other dust diseases;
infectious diseases; cardiovascular diseases; and violence.
Deaths attributable to workplace exposures to pesticides, heavy
metals, solvents, and other chemicals are not included.
Outcomes such as dermatitis, psychological disorders, and
upper-extremity musculoskeletal disorders that cause little
mortality but substantial disability are also not captured by the
WHO comparative risk analysis. Additionally, the consequences
of underreporting in existing systems and the dearth of record-
keeping systems in the developing nations lead to substantial
undercounting by both the ILO and WHO. Nonetheless, the
analyses provide important insights into the immense global
burden of disease and injury attributable to occupational risk
factors.
INTERVENTIONS
Strategies for controlling injury and occupational disease,
developed by industrial hygienists and others over many
decades in industrial countries, are as fully applicable in devel-
oping countries. The strategies include a hierarchy of controls
in the following decreasing order of preference: substituting
major hazards for less hazardous materials or processes; apply-
ing engineering controls to separate workers from hazards that
remain; using administrative controls to minimize contact
uncontrollable by engineering; and, as the last line of defense,
using personal protective equipment such as respirators and
protective garments. What differs in developing countries is the
context in which the paradigm must be applied. Options are
often sharply limited, and knowledge of them even more so;
economic and political factors may impede otherwise obvious
or desirable solutions; and the differing workplace context
may demand that attention be paid to certain problems and
concerns that would not be relevant in industrial countries in
temperate climates.
The following generic factors associated with work in devel-
oping countries may alter industrial hygiene practice and must
be considered in every effort to intervene to improve working
conditions and occupational health:
• Access to industrial hygiene consultation is limited; pro-
fessionals, sampling equipment, and laboratories are all in
short supply.
• Knowledge level about occupational health among man-
agers and workers is often limited.
• Markets for production materials as well as safety equip-
ment may be limited and may include more hazardous
materials or less effective protective equipment “dumped”
from industrial countries where they are no longer mar-
ketable (Hecker 1991; Ives 1985; Jeyaratnam 1990).
• Regional conflict, economic pressures, climatologic factors,
and lack of foreign exchange may make otherwise straight-
forward choices impractical.
• Supply of labor is often high, as is turnover, so economic
incentives for investment in health capital are lower than in
industrial countries.
Strategies for Improving Working Conditions
With these differences in context in mind, we now consider the
major types of intervention: international, national, workplace,
and individual.
International Interventions. The ILO–WHO Joint Com-
mittee on Occupational Health was formed in 1950 to provide
guidance to the ILO and WHO regarding international occu-
pational health issues. The committee meets periodically. At its
13th session, held in December 2003, the committee recom-
mended that WHO and ILO pursue the following priorities
(ILO and WHO 2003):
• Guide and support national occupational safety and health
programs. Such guidance and support includes providing
models for organizing at national or subnational levels;
providing basic occupational health services; promoting
management systems and tools, including control banding;
developing national profiles and indicators; assessing the
cost-effectiveness of interventions; and establishing effective
enforcement agencies.
• Enhance regional collaboration and coordination, including
the development and dissemination of models for coopera-
tion, such as the African Joint Effort.
• Coordinate and enhance information and educational pro-
grams and materials (for example, by developing a joint
Internet-based global portal) and statistics.
• Provide awareness-raising activities and instruments
through campaigns, events, and special days.
State or Government Interventions. The major role the gov-
ernment can play is to establish workplace rules and provide
a system of dissemination and enforcement. Evidence from
industrial countries is overwhelming that conditions are sub-
stantially improved when both a strong regulatory framework
and enforcement are achieved. An added benefit of govern-
ment, rather than private sector, control is to “level the playing
field”: all employers in an economic sector carry the same bur-
den. Conversely, improved health of the workforce, achieved by
developing strategies beyond the minimum required, could be
used to confer competitive advantages, a message to reluctant
employers that has been used in different parts of the world
with some success.
Regulatory decisions, such as the choice of exposure limits
or allowable practices, often stimulate the biggest discussion—
for example, the debate about dust levels to be allowed in South
African mines—but the larger issue for most countries is gar-
nering resources to ensure compliance, to attract adequately
trained personnel to conduct inspections, and to establish and
monitor laboratories to support regulatory efforts. The most
stringent exposure levels (often referred to as threshold limit
values, or TLVs) are useless if the offending hazard cannot be
routinely and accurately measured. Indeed, the South African
experience, despite the presence of excellent regulations, is not
encouraging in this regard (Joubert 2002).
Other forms of government intervention may indirectly
improve working conditions. Among these are workers’ com-
pensation regulations and stipulations that employers of cer-
tain sizes must engage professionals in health and safety (most
often nurses). Each of these interventions has the advantage of
stimulating certain behaviors and practices without requiring
the government to maintain the elaborate and technically com-
plex machinery required for direct monitoring of workplace
conditions.
Constraints on governmental regulatory and other inter-
ventions are many. Occupational and environmental regula-
tions are often perceived as burdensome costs that impede
investment and growth, perhaps creating what has been
referred to as “the race to the bottom,” in which threat of out-
migration of industry from one jurisdiction enhances reluc-
tance to regulate or enforce control strategies (Frumkin 1999).
Moreover, the costs to the government itself, notwithstanding
technical support from such agencies as the ILO, may be con-
siderable in terms of personnel and equipment, and occupa-
tional health has to compete with other public health priorities
for scarce resources. The result may be the promulgation of
minimal standards or emasculated enforcement of those that
already exist. The general impression of those working
throughout the developing world is that the level of regulation
and enforcement is woefully inadequate compared with that
in industrial countries. Detailed case examples from Brazil
(Bedrikow and others 1997); Kenya (Mbakaya and others
1999); Nigeria (Asuzu 1996); and Taiwan, China (Chen and
Huang 1997), underscore the ubiquity of this problem.
Workplace-Based Interventions. Issues beyond the economic
and legal ones impede application of the principles of indus-
trial hygiene. A primary factor is ignorance; many employers
may be uninformed about available controls and their value.
Insurance agencies, local safety groups, and—in some regions
of the world—trade unions may serve as facilitators of positive
influence. In general, however, such resources fall short of the
benefit of on-site industrial hygiene expertise that is lacking in
many regions of the world.
Economic factors often impede efforts to institute voluntary
controls. Materials used are frequently far cheaper than safer
substitutes, often precisely because these materials no longer
have markets in industrial countries that have banned or
restricted their use—for example, solvent mixtures containing
benzene and construction materials containing asbestos.
Similarly, equipment such as machines that are well guarded to
prevent injury or well baffled to limit noise may be prohibi-
tively expensive in a marketplace geared to “hand-me-downs”
compared with respirators or gloves. Unfortunately, even these
last lines of defense may be difficult to obtain or relatively
expensive unless local suppliers are available.
The single strategy for which no compelling economic dis-
incentive exists—training—may also be difficult. Through the
efforts of the ILO and numerous nongovernmental organiza-
tions and with widening access to the Internet, vast resources
have become available. Ample documentation from the indus-
trial and developing world indicates that even rudimentary
knowledge by supervisors and workers about risks and risk-
prevention measures is beneficial. Major impediments remain,
however, such as educational proficiency, language barriers,
and the applicability of training materials—often developed in
other contexts—to local situations. Thus, for example,
although the ILO has recently reported success with informa-
tion programs in rural Thailand (Kawakami and Kogi 2001),
a report from Ghana (Smith-Jackson and Essuman-Johnson
2002) suggests that workers and supervisors were unable to
correctly interpret four of the most common warning signs
used for hazard identification, despite having been trained in
their use. Worker training appears, on the whole, widely
underused.
Problems of infections in patients and health care workers
from reused needles and needlestick injuries have prompted
the international organizations to develop model interventions
that can be transferred elsewhere. WHO initiated Project
Focus: Ensuring Immunization Safety in Burkina Faso in July
2002 as a pilot project to use WHO materials in a focused effort
to address all issues related to injection and immunization
safety: availability of equipment and supplies (auto-disposable
syringes, safety boxes, incinerators); safe injection practices;
safe vaccine delivery; and safe waste management (WHO
2002). In 2000, WHO conducted a survey to assess the safety of
injections in a study group of a random sample of 80 health
centers. The situation was reassessed in June 2003 to evaluate
the use of safety boxes (which had been provided in a WHO
immunization campaign in Burkina Faso in 2001) and the
impact of Project Focus. Table 60.2 shows results of the
reassessment. Dramatic reductions were found in needle recap-
ping, needlestick injuries, and misuse of safety boxes.
Additionally, the number of clinics using safety boxes increased
from fewer than half to 86 percent.
Small enterprises present special challenges because they
lack resources and expertise to address health and safety prob-
lems. Thailand’s National Institute for the Improvement of
Working Conditions and Environment has used the ILO
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training approach called WISE (Work Improvement in Small
Enterprises) with some success. In one example, six enterprises
in the metal industry in Bangkok with between 15 and 115
workers participated in the WISE program, in which practical
workshops involved workers and management in deciding on
changes to be made in the workplaces. A wide range of inex-
pensive changes were put in place, and a booklet to illustrate
good practices for others was prepared (Krungkraiwong 2000).
Individual Interventions. The general principle that, for most
public health intervention, organization-level change is more
effective than strategies targeting the individual is even more
true when it comes to the workplace. With the exception of
self-employed workers, such as those in the informal sector and
subsistence farmers, occupational health and safety does not
lend itself readily to individual solutions, with the same factors
limiting employees more likely to limit individuals.
Improvement of Access to Health Care 
In a few developing countries, workers enjoy broad access to
high-quality health care. Chile, for example, has a system of
nonprofit employer mutual associations that provide advice on
reducing risks in workplaces and medical treatment and sick
pay for work-related illness and injury (Contreras and
Dummer 1997). In most countries, the role of on-site services
is generally limited to emergency services for an injury or acci-
dental overexposure and the conduct of medical surveillance
examinations for workers at risk for chronic conditions such as
noise-induced hearing loss, pneumoconiosis, or cancer.
In the developing world, access to health care is critical both
for work-related and other health issues. In many areas, espe-
cially remote or rural areas, on-site service may be the only
health care services available to workers and their families.
Moreover, the blurred distinction between “general health” and
“occupational health” in societies where people live and work
in the same community and environment, and where children
and spouses of workers may share common exposures and
adverse conditions with workers, serves to confer some advan-
tage to a more holistic approach to health services often best
provided at or near the workplace itself.
Control of Nonoccupational Exposures
In industrial countries, a sharp demarcation exists between
environmental risks associated with work and those associated
with home life. This differentiation is not the case in many
developing countries, especially at large, remote industrial
complexes and farms. Workers—with or without their
families—often cohabit with the workplace—and often with
many or all of its risks, including noise, chemicals, and biohaz-
ards. The most dramatic examples of this situation were the
industrial disasters at Chernobyl and Bhopal. It is not just in
disaster, however, that risk occurs. Pesticides, for example,
result in hundreds of thousands of cases of poisoning a year, a
high fraction from the misuse of farm chemicals for nonwork
applications, such as the appropriation of empty (but not
clean) drums for transporting water or other household goods,
a disturbingly common practice. In the industrial setting, car-
cinogens, neurotoxins, and other hazardous chemicals often
pollute homes, drinking supplies, and common areas for recre-
ation on a daily basis, adding to the exposure of workers and
placing nonworking family members at risk from what would
normally be seen as workplace hazards.
The remedy is often complex and beyond traditional indus-
trial hygiene practice. Housing, which in any event may be
substandard, needs to be modified to exclude the possibility
of contamination by effluent from farm or factory under any
foreseeable circumstances. Children and family members need
to be apprised of the hazards of all materials used for work and
prevented from even accidental access, a situation complicated
by the fact that children are themselves often inappropriately
engaged in the workplace. Food and water supplies need to be
secure and protected from cross-contamination, a particular
problem in the farm setting.
Surveillance and Reporting
Even in industrial countries, the strategies for recording any
aspect of workplace harm beyond acute injury has been an
issue; in most developing countries, even injury reports are
largely nonexistent. Still, broad agreement exists on the value of
statistical summaries of occurrences.
Unfortunately, a strong disincentive exists for such report-
ing unless it is required by law or by a parent company (as in
the case of some multinationals). If reporting is required, as in
the formal laws of many countries, successful implementation
calls for resources for systematic review, verification, and main-
tenance of the information. Even records whose limitations are
otherwise legion, such as workers’ compensation records or
regional reporting schemes, have proven highly advantageous
to control efforts in industrial countries. These, too, have a role
in developing countries, helping target even rudimentary and
limited control efforts.
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Table 60.2 Prevalence of Risk Factors and Injuries at
80 Observed Health Centers
(percent) 
Needle Needlestick Lack of Misuse of 
Year recapping injuries safety boxes safety boxes
2000 55 71 51 83
2003 17 32 14 18
Source: S. Khamassi, WHO Mediterranean Centre, personal communication 2003.
Capacity Building
Human capital in the form of professional capacity is critical to
improving working conditions. Professional capacity varies
greatly in developing nations but is higher where recognition of
the field is high and the need for professionals and for workplace
expertise is driven by occupational safety and health legislation
and enforcement. In Malaysia, for example, four decades of
rapid industrialization have included a series of legislative acts;
development of federal agencies; and inclusion of training at
various levels in occupational health in universities, the public
sector, and the private sector (Rampal, Aw, and Jefferelli 2002).
Key international events, such as joining the World Trade
Organization, encourage the development of an economic cul-
ture that better recognizes the value of safe workplaces.
Enforcement of national regulations, adoption of International
Standards Organization standards, and establishment of man-
agement systems lead to broadening of training for workers and
managers, although the scarcity of trained professionals is a
major obstacle to adequately implementing regulations and
policies and providing occupational health services (Christiani,
Tan, and Wang 2002; Wang, Cheng, and Guo 2002).
In countries with some capacity, the expertise tends to be
medical, rather than in other areas, such as industrial hygiene,
engineering, or ergonomics. In most countries, ministries of
health and of labor have jurisdiction over working conditions
but often have too few experts and inadequate coordination.
Moreover, the large percentage of work conducted in the infor-
mal sector presents a special challenge to these ministries.
Because globalization has brought the need for professionals in
occupational health to a crisis level, it is appropriate for inter-
national trade and development bodies to support national
and international capacity-building programs.
In 1970, when the United States enacted the Occupational
Safety and Health Act that established the National Institute for
Occupational Safety and Health (NIOSH), the country had
little professional capacity in that field. The new law charged
NIOSH with ensuring an adequate number of trained profes-
sionals and accomplished this task successfully by funding
graduate programs in U.S. universities. A follow-up 25 years
later found that 90 percent of NIOSH-supported trainees pur-
sued careers in the field, with more than 50 percent working in
private organizations and the balance in government and aca-
demia (U.S. DHHS 1996). Similar results could be achieved by
a determined, large-scale effort focused on assisting developing
countries in achieving adequate professional capacity.
Both infrastructure and programs are necessary to build
adequate capacity. In the international arena, a number of suc-
cessful coalitions exist that provide experienced institutions
and individuals. The WHO Global Network of Collaborating
Centers in Occupational Health is a strong international coali-
tion of 70 national, governmental, and academic centers of
occupational health that work together with WHO and ILO
headquarters and regional offices and three international non-
governmental organizations: the International Commission on
Occupational Health, the International Occupational Hygiene
Association, and the International Ergonomics Association
(Fingerhut and Kortum-Margot 2002). These partners, located
in approximately 40 countries, work together in 15 priority
areas within a 2001–2005 Work Plan. More than 300 projects
are under way, independently or jointly, to benefit workers in
developing and industrializing nations in about 15 priority
areas (WHO 2003).
Another strong regional coalition, coordinated with and
benefiting from the Global Network of Collaborating Centers,
is the WHO–ILO Joint Effort on Occupational Health and
Safety in Africa (WHO and ILO 2002b). This partnering
coalition—where centers outside Africa assist African
partners—includes individual occupational safety and health
professionals, employers, labor unions, and governmental and
academic institutions in all countries in Africa.
Enlarging small but successful existing programs is one
approach to capacity building. The U.S. National Institutes of
Health Fogarty International Center, NIOSH, and the National
Institute of Environmental Health Sciences sponsor a suc-
cessful program, International Training and Research in
Occupational and Environmental Health, which has developed
small but strong programs between U.S. universities and insti-
tutions in more than 30 developing nations (NIH 2003).
Capacity building requires high-quality educational op-
portunities. Advances in information technology over the past
decade are revolutionizing methods of education, and univer-
sities worldwide are developing large numbers of Internet-
based courses. Fostering access of students from developing
nations to these courses in leading universities is now feasible,
but a national or international program is needed to address
issues such as tuition, competition, intellectual property, and
degree requirements. This effort might be called Access to
Universities, following the model WHO program Access to
Biomedical Journals, through which WHO and the world’s
largest medical journal publishers have provided about 100
developing countries with Internet access to journals at no cost
or at deeply reduced rates (WHO 2001).
Professional associations have a long history of assisting in
capacity building through training, research, and conferences.
Recently, when the University of Witwatersrand in
Johannesburg developed the first Diploma Occupational
Hygiene program in South Africa, the country had too few
industrial hygienists to provide mentors for the field research
of the graduate students. The American Conference of
Governmental Industrial Hygienists responded to a request
of the International Occupational Hygiene Association, and
11 U.S. industrial hygienists volunteered to be occupational
hygiene field practitioner long-distance mentors for the
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incoming students during the 2003 course year. This approach
will continue until there are adequate industrial hygienists in
country to serve as mentors to future classes (WHO and ILO
2002a).
The U.K. Health and Safety Executive developed a model
program that provides clear solutions to chemical control
problems in workplaces. This Web-based, user-friendly prod-
uct was launched to enable small business owners in the United
Kingdom to use information from the suppliers of chemicals to
proceed through a series of simple steps to identify practical
control solutions that reduce worker exposures to levels that
present no danger to health (U.K. HSE 2002). This approach,
which eliminates the need to measure exposures and meets the
regulatory requirements of the United Kingdom, has immense
potential value for employers in developing nations, who could
devote scarce resources to controlling exposures rather than to
measuring exposures. The approach has gained momentum
through adoption by the International Program on Chemical
Safety and through formation of an international workgroup
to advance the approach in developing nations. To enable
global use of this approach, the ILO has translated the U.K.-
specific system into a product called the ILO Chemical Control
Banding Toolkit (ILO 2003).
ECONOMIC ASPECTS OF INTERVENTION
Measures to prevent occupational risks are not cost-free, and
where those costs ultimately come to rest affects the willingness
of employers to implement the preventive measures.
Who Bears the Costs of Preventive Measures?
In industrial countries, compelling economic incentives exist
for employers to control risks for injury and illness on the job,
especially those that result in demonstrable near-term lost
work or function. These include the high cost of medical care
(especially in the United States), the burden of workers’ com-
pensation payments, high replacement costs for the labor, risk
of litigation and liability, and negative business consequences
of adverse publicity. Although these factors may differ by coun-
try and sector, they are less likely in the developing world to
confer on employers a strong economic imperative for
prevention—labor is plentiful, its replacement cost is low,
and—most important—a high portion of the real cost of
injury and illness will not be borne by the employer. The statis-
tics in Latin America are staggering: although an estimated 2 to
4 percent of the GDP of the region is lost because of occupa-
tional fatalities alone, no evidence exists of private sector
investment to reduce the risk (Giuffrida, Iunes, and Savedoff
2002). Multinational companies appear to be an exception. For
many, the costs of injury and illness may accrue to the parent
country in terms of legal liability and adverse publicity, a lesson
well taught by Union Carbide’s experience in the aftermath of
the Bhopal disaster in 1984.
One approach to align economic incentives is to use regula-
tory and legal reform to shift the existing cost burden to those
in a position to remedy the situation—that is, to employers.
Increasing workers’ compensation benefits, especially those for
long-term effects and disabilities, is an example of such an
approach. Some evidence exists that, at least in southern Africa,
this approach does stimulate preventive behavior by employers.
An alternative is to critically reexamine the assumption that
employers do not harbor substantial underrecognized costs of
injury and illness even under the current situation, especially
in terms of indirect costs such as lowered productivity and
morale. Harari and his colleagues in Ecuador (Cullen and
Harari 1995) have been studying the effect of such exposures as
solvents and organophosphate pesticides on production levels.
They are attempting to make the case that relatively inexpen-
sive strategies for exposure control are economically advanta-
geous to employers.
Intervention Costs and Cost-Effectiveness
Workplace illness and injury produce personal suffering and
high economic costs. The ILO estimates that about 4 percent of
GDP worldwide is lost because of work-related diseases and
injuries (Takala 2002). The European Agency for Occupational
Safety and Health at Work (1998) indicates that the costs to
society in European countries ranged from 0.4 percent to
4 percent of gross national product.
Examining Industrial Countries. Identifying interventions
to successfully reduce or prevent workplace injuries and ill-
nesses will benefit society, employers, and workers. In 1996,
stakeholders in the United States identified intervention effec-
tiveness research as one of 21 priority areas in occupational
health research for the next decade (U.S. DHHS 1996). From
1996 to 2002, research conducted or funded by NIOSH to
develop and evaluate the effectiveness of solutions to prevent
work-related injury and illness has increased nearly sixfold,
from about US$5.5 million to US$33 million (U.S. DHHS
2003).
Research studies of workplace interventions often use sur-
rogate or implied measures for economic evaluation. For
example, economic benefit is assumed to occur following an
intervention if symptoms of illness or injury in a workforce
decrease while productivity remains constant. Intensive data-
entry workplaces are increasing rapidly in both industrial and
developing nations. Three studies of U.S. Internal Revenue
Service data-entry clerks by NIOSH found that short, strategi-
cally placed rest breaks of 5 to 15 minutes during the regular
daily schedule reliably reduced eyestrain, fatigue, and
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musculoskeletal discomfort for video-display terminal opera-
tors without decreasing productivity (Galinsky and others
1999, 2000). Similar benefits of improved comfort and reduced
stress from short rest breaks were observed among workers in
a meat-processing plant without affecting productivity
(Dababneh, Swanson, and Shell 2001).
Including economic costs of interventions is more difficult
but is an important measure to allow employers to make deci-
sions about interventions. A model intervention study,
“Evaluation of a Best Practices Back Injury Prevention
Program in Nursing Homes,” received the 2003 National
Occupational Research Agenda Partnering Award for Worker
Safety and Health (APHA 2003; Collins and others 2004).
Members of the partnership that carried out the intervention
study included a large nonprofit U.S. health care system that
owns nursing homes; manufacturers of lifting equipment;
researchers at Washington University, West Virginia University,
and NIOSH; and health care workers. The prevention program
combined measures to reduce back injury by identifying the
movements and postures that put nursing assistants at risk of
back strain, stress, and injury in lifting and moving residents.
Mechanical lifting devices for reducing those stresses and
strains were evaluated in the laboratory and then in the nurs-
ing homes. A best-practices training and lifting program was
put in place on the basis of researcher and employee input, and
rates for key measures of success were recorded for the three
years before the intervention and for the three years after the
intervention. The successful project reduced the frequency of
back injuries in six nursing homes by 57 percent, lowered
injury rates by 58 percent, and decreased workers’ compensa-
tion expenses by 71 percent. Box 60.1 illustrates the value of
evaluating costs of interventions in garment factories in
Central America.
Reducing Risk for Back Pain. The WHO summary of a variety
of cost-effectiveness studies for interventions addressing all
aspects of global health illustrated that the cost-effectiveness of
interventions in some areas of personal health has been well
studied but that environmental and occupational topics have
had relatively few studies. The WHO comparative risk assess-
ment concluded that about 37 percent of back pain globally is
attributable to occupational risk factors (WHO 2002). A cost-
effectiveness study of interventions to reduce occupational back
pain was also reported, using economic models developed to
calculate costs of interventions in three WHO geographic
regions that illustrate different levels of development.
Intervention studies were obtained from the published and
unpublished literature. All costs of running the interventions
were measured in international dollars (not exchange rate
dollars, as in the analysis reported later in this chapter) and
1136 | Disease Control Priorities in Developing Countries | Linda Rosenstock, Mark Cullen, and Marilyn Fingerhut
Use of a Toolkit to Determine Return on Investment in Central American Garment Factories
Box 60.1
The Regional Occupational Safety and Health Center
(Centro Regional de Seguridad y Salud Ocupacional)
Project in Central America developed an occupational
safety and health toolkit to enable managers and line
workers in garment factories to self-diagnose plant and
workstation hazards and to estimate the costs and benefits
of interventions (Amador and others 2003). Managers and
employees at more than 100 Central American garment
factories have been trained to use the toolkit. An in-depth
evaluation of the use of the toolkit in three garment facto-
ries, each employing between 700 and 1,000 workers, in
El Salvador, Guatemala, and Nicaragua found that within
one year the factories generated savings that were four to
eight times the costs of the interventions.
The overall investment by Confecciones La Palma in
2002 was US$6,360, and the savings attributed to that year
were US$27,242 from reduced injury, illness, and absen-
teeism and an increase in productive days (see table).
A CD-ROM version of the tool kit in Spanish and
English also contains the guide “How to Design and
Establish an Occupational Safety and Health Program in a
Garment Factory” and can be found on the NIOSH Web
site at http://www.cdc.gov/niosh.
Change in Illness and Injury Indicators in the First
Quarter of 2003 Compared with the First Quarter of 2002
at Confecciones La Palma
Indicator 2002 2003 Percent change
Number of accidents 63 36 40
Days of absenteeism 200 149 25
Sick days 822 426 48
Visits to factory clinic 2,716 2,163 20
Productive person-days Not given Not given 12
Source: Data provided by Confecciones La Palma.
Source: Amador and others 2003.
effectiveness was measured as age-weighted DALYs gained by
the intervention. The interventions for the prevention of back
pain were grouped into three major categories: worker training
(awareness education and hazardous job training); engineering
control (physical measures that control the exposure to the
hazard, including equipment that assists lifting, pushing, and
pulling); and the full ergonomics program (which includes both
of the previous interventions and implementation procedures).
As shown in figure 60.3, the analysis found that the most
effective intervention is the full ergonomics program, offering
a 74 percent reduction in back-pain incidence. Lesser benefits
are obtained by engineering control (56 percent reduction) and
training (20 percent reduction). The total costs of worker train-
ing are largely labor related, the costs of engineering control are
primarily capital costs, and the full ergonomics program costs
are equally shared between the two. Training was found to be
the most cost-effective intervention, as indicated by the lower
slopes of the lines from 0 to T, and was recommended as the
first choice when resources are scarce. However, the incremen-
tal cost-effectiveness ratios for the other options (indicated by
higher slopes of the lines) demonstrated that both engineering
control and the full ergonomics program are attractive alterna-
tives. Thus, even the full ergonomics programs were found to
be cost-effective in all three regions for their health effects
alone, without even considering the possible increase in pro-
ductivity that could be brought about by the interventions
(WHO 2002). Recalculating these results according to Disease
Control Priorities Project methods—using exchange rate
dollars and removing the age weights from DALYs (see chap-
ter 15)—would increase effectiveness somewhat because back
pain is more common at later ages and would reduce the
apparent costs in both Europe and Southeast Asia. It would
have little effect on costs in the high-income countries of the
Americas. The relative cost-effectiveness of the three interven-
tions would be unchanged in each region.
Reducing Risk for Silicosis. Silicosis is a disabling and often
fatal workplace lung disease caused by inhalation of silica dust.
The high-risk sectors of the economy include construction,
mining and mineral processing, foundries, and manufacturing
of pottery and glass. Large numbers of workers in both indus-
trial and developing nations are exposed. Box 60.2 illustrates
control of silica caused by grinding wheels in the agate cottage
industry in India. In the United States, more than 3.2 million
workers are exposed to silica dust, even though methods exist
to eliminate exposure (Harley and Vallyathan 1996).
A study was conducted to evaluate the cost-effectiveness of
alternative interventions to reduce silicosis in industrial and
developing nations (Lahiri and others 2005). The authors used
the limited published and unpublished data on costs of the var-
ious interventions and on the efficacy of exposure reduction.
To analyze the cost-effectiveness of each intervention in reduc-
ing disease incidence, they used models developed for WHO
(Murray and others 2000). The WHO DALY concept was used
to combine mortality and morbidity resulting from silicosis.
Two WHO regions were studied: the highly developed America
A region, represented by the United States and Canada; and the
developing Western Pacific B1 region, represented by China,
the Democratic People’s Republic of Korea, the Republic of
Korea, and Mongolia. Exposure estimates were taken from the
WHO comparative risk assessment study (Ezzati and others
2004).
The interventions included engineering control interven-
tions that protect many workers (use of the wet method—that
is, spraying a surface or wetting a blade to reduce dust; of local
exhaust ventilation; and of total plant ventilation) and worker
training plus personal protective equipment, an intervention
that protects the individual worker. The training involved four
types of personal protective equipment: comfort masks, dust
masks, full-face respirators, and half-face respirators. Lahiri
and others (2005) summarize the evidence of reduction in
exposure through the use of selected interventions from the lit-
erature. The difference in the health life years gained with and
without the intervention represented the effectiveness of the
intervention and was used as the denominator for the cost-
effectiveness ratio.
The engineering control interventions involve large capital
expenditures, whereas the implementation of personal protec-
tive equipment requires ongoing large equipment costs (filters
and cartridges) as well as labor costs for training the workers.
Costs of interventions vary from region to region, depending
on wage rates and raw material costs, but the costs of equip-
ment seem not to vary. The authors found the least expensive
alternative is training associated with use of a comfort mask.
However, that intervention has a relatively low efficacy of
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Figure 60.3 Cost-Effectiveness of Interventions for Lower Back Pain 
30 percent exposure reduction. Although the initial capital
expenditures are high for engineering controls, the annualized
costs based on a 10-year horizon are encouraging, with expo-
sure reduction of about 70 to 85 percent. The greatest exposure
reduction of 95 percent was achieved at the highest cost, with
training plus use of a full-face respirator, but an 80 percent
reduction was achieved at half this cost when training was
combined with a dust mask.
Table 60.3 shows that engineering controls in both
industrial and developing regions are the most cost-effective
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Economic Evaluation of an Engineering Control for Silica Dust in India
Box 60.2
The agate industry is a cottage industry concentrated in
residential settings in Khambhat and Dahegam, in the
state of Gujarat, India, where 15,000 grinders and 60,000
other workers, family members, and neighbors are
exposed to silica dust. The making of key chains, neck-
laces, and art pieces involves baking, chipping, grinding,
and polishing agate stones. The grinding-machine wheels
are driven at speeds of 1,440 rpm, generating large
amounts of dust containing respirable silica. The table
shows the extraordinary prevalence in the total exposed
populations (noted above) of silicosis and tuberculosis
caused by silica exposure.
(Bhagia, Ramnath, and Saiyed 2003). Economic analysis
was based on 600 dust control devices that could be
installed in the communities. The total costs include the
initial one-time cost of the devices (Rs 8,000, or approxi-
mately US$92); depreciation (10 percent per year); main-
tenance of machines (equivalent to the costs saved by
recycling the dust to be used in polishing); and the cost of
treating the diseases (about Rs 4,000, or approximately
US$184 per year per case). The gains included annual
income per avoided case of silicosis. Total savings per year
were estimated to be between Rs 23 million and Rs 29 mil-
lion (US$527,039 to US$664,528). The conclusion is that
installation of dust control devices in all the agate-
grinding units of Gujarat would reduce silicosis and
tuberculosis as well as yield financial and health benefits to
the workers, families, and the greater society that bears the
cost of illness.
Prevalence of Diseases in Agate-Dominated Areas of
Khambat and Dahegam
Silicosis Tuberculosisa
Category Percent Number Percent Number
Grinders 30 4,500 36 5,400
Nongrinding 8 4,800 16 9,600
workers, family, 
and neighbors
Source: Bhagia, Ramnath, and Saiyed 2003.
a. National tuberculosis prevalence in India of 4 percent and resulting cases have been
subtracted.
Table 60.3 Average Cost-Effectiveness Ratio
(US$/DALY gained)
America A region Western Pacific B1 region
Engineering control 105.89 109.35
Comfort mask 111.04 117.19
Dust mask 191.38 173.90
Half-face respirator 299.82 272.45
Full-face respirator 304.87 265.74
Source: Lahiri and others 2005.
The National Institute of Occupational Health in India
designed and distributed 10 dust control devices for the
grinding machines to employers, who generally employ 5
to 10 workers (see figure). The efficacy of the devices was
found to be 93 percent, and dust was greatly reduced Traditional Grinding Machine with Dust Control System
interventions, with expenditures of between US$105 and
US$109 per healthy year saved in the two regions. Although
exposure reductions with respect to each intervention type are
identical in both regions and the cost of interventions is some-
what higher in the America A region, it might seem perplexing
that the cost per unit of health gain is relatively lower in the
America A region than in the Western Pacific B1 region. The
reason for this result is that effectiveness (the denominator of
the average cost-effectiveness ratio) is represented by health
outcomes that are higher for this region because life expectancy
in the America A region is higher than in the Western Pacific B1
region. Therefore, lives saved through interventions in indus-
trial regions contribute more toward the healthy years gener-
ated by the model.
The study concluded that engineering controls are the most
cost-effective interventions in both regions and should be con-
sidered as the first choice in cases in which resources are scarce.
The results underestimate the health gains because other 
silica-related diseases such as tuberculosis and cancer are not
considered.
IMPLEMENTATION
The health of a country’s workforce, even more than the health
of the country’s overall population, is critical to its economic
and national security. No country has become a successful
economic power without sustained attention to the health of
workers, who create the successful economy. Responsibility for
the safety and health of workers lies with the government, the
employers, and the workers themselves. However, it is the gov-
ernmental framework, whether at a national or local level or
both, that is the linchpin on which other efforts rest.
Institutions and Programs
The potential to continually improve work-related health sta-
tus, as measured by morbidity and mortality data across multi-
ple economic sectors and across many countries, has been
compellingly demonstrated. Not surprisingly, because these
conditions are inherently preventable, what may be the lowest
achievable level of risk is debated in industrial countries. In the
United States, for example, occupational injury fatality rates
have been steadily declining, now approaching 3.8 per 100,000
workers, down from 7.5 just 20 years earlier (NIOSH 2000).
Key elements in improving worker health and safety, regard-
less of the level of development, include regulatory and
enforcement framework; worker, employer, and health profes-
sional education; surveillance and reporting systems; and dis-
semination and implementation of best practices. Often these
elements overlap in multifaceted approaches to addressing
complex and disparate work settings.
In the developing world, a patchwork of some of these
approaches has brought success: in Vietnam by reducing silico-
sis through industrial hygiene practices of wetting the process
and through surveillance (effective but much less so than pro-
tective equipment or, better yet, substitution of a safer prod-
uct), and in Nicaragua by efforts to reduce pesticide poisoning
through worker and health professional education and report-
ing systems. Even in highly developed countries, the continued
need for a responsive and broadly based framework, with gov-
ernment involvement at the center, is evident.
An example recently identified in the United States is the
comparison of injury indicators for workers across three
prominent sectors: construction, agriculture, and health care
(figure 60.4). Two decades of data demonstrate improving
nonfatal injury rates for construction and agricultural workers
(falling steadily from about 16 and 12 per 100 full-time work-
ers, respectively). This rate is in contrast to injury rates for
health care workers, which have risen by about one-third from
a starting point of about 10 per 100 workers (BLS 2002). Why
the difference? Although the reason is not fully delineated,
major efforts (including government regulation, research
investment and policy setting, education, and best-practice
efforts)—plus, in the case of construction workers, active trade
union involvement—in the two industrial sectors clearly
were under way in this time period. In contrast, in the health
care worker sector, no such national program existed in the
period, and industry pressures resulted in a number of poten-
tial workforce problems, such as increasing work demands on a
stressed and ill-prepared workforce.
Lessons Learned
As countries undergo rapid economic development, industrial-
ization, and the effects of globalization, leaders can examine
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Figure 60.4 Incidence Rates of Nonfatal Occupational Injuries (Total
Recordable Cases) by Selected Industry Sectors, 1980–2000
available occupational health system models as they develop
their national occupational health systems. The Republic of
Korea has experienced major economic and societal changes
since it emerged from the Korean War in the 1950s with a need
to establish occupational safety and health programs without
any historical experience. The system directed by the Industrial
Safety and Health Act of Korea is modeled after the specialist-
based system of Japan, which relies on medical screening and
specialists outside the workplace to deliver health and safety
services (Paek and Hisanaga 2002). Paek and Hisanaga note
that national traditions and culture strongly influence the
choice of system when developing countries examine models
from which to choose—for example, from the code-based sys-
tem of the United States, the performance-based system of the
United Kingdom, and the management system of the Nordic
countries.
Government involvement is necessary but not sufficient,
regardless of the level of development. Because national and
local legislation and policies create the framework within
which a society functions, international influence, assistance,
and requirements play a key role in encouraging developing
and industrializing nations to create appropriate laws and poli-
cies to support healthy workers. International trade, develop-
ment, and funding organizations have immense power, which
is not fully exercised to date, to influence countries on working
conditions. The large multinational trade agreements have also
failed to ensure that worker health and safety is adequately
addressed, and multinational corporations have generally not
transferred the safety and health systems of the industrial
world to developing nations. The consequences are grave, as
seen in the deaths of 2 million workers each year from occupa-
tional injuries and illness. Great power lies in these institutions
and trade agreements to produce direct changes in the health of
workers globally.
The ILO provides strong guidance internationally for indus-
trial and developing nations through its tripartite conventions
and recommendations. Each year the ministers of labor of all
member nations, employer representatives, and worker repre-
sentatives agree on policies in conventions, which the member
states are asked to ratify. The models provided by the ILO are
regularly used by some countries as they create their national
systems. Brazil, for example, has been a member country of the
ILO since 1919 and has ratified 75 ILO conventions. Set in place
by legislation in the 1970s, the Brazilian model for occupational
health services followed the ILO’s Recommendation 112 (1959)
as a paradigm (Dias, Mendes, and Schwartz 2002). Although
few countries ratify most conventions, more than 150 countries
have ratified Convention 182, which was passed in 1999 and
addresses the worst forms of child labor. A current critical need
is assistance to developing nations to meet the obligations
required by ratification. WHO sets international policies on
health, including worker health, at its annual meeting of health
ministers of all member nations. Both ILO and WHO regional
offices provide technical assistance and training. An unfortu-
nate gap exists, however, because often the national ministries
of labor relate to the ILO and the ministries of health to the
WHO. Because working people are influenced by the national
ministries of both labor and health, the international organiza-
tions have been advised to correct the situation (WHO and ILO
1995). A promising WHO/ILO Joint Effort on Occupational
Safety and Health in Africa has embraced partners across min-
istries and broadly within and outside Africa to work together
to assist countries, workers, and employers in the formal and
informal sectors (WHO and ILO 2002b).
Several coalitions of organizations have successfully assisted
developing countries to increase professional capacity and to
improve worker health and safety. A regional illustration is the
Association of Southeast Asian Nations Occupational Safety and
Health Network, which was established to promote regional
cooperation in training and research as well as harmonization of
standards in safety and health. The primary international coali-
tion is the WHO Global Network of Collaborating Centers in
Occupational Health, described previously. The U.S. Fogarty
International Training and Research Program in Occupational
and Environmental Health is another stable and experienced
network, consisting of U.S. universities working with universi-
ties in more than 30 developing nations to increase professional
capacity. Some of the institutions are also WHO Collaborating
Centers, and others are partners in Africa. The relationships
have provided opportunities for synergy and streamlining of
training and technical assistance (WHO and ILO 2002b).
Globalization has brought work-related hazards to develop-
ing countries lacking the infrastructure and professional capac-
ity to handle them adequately. It is incumbent on the national
and international bodies responsible for globalization to assist
the recipient nations. Organizations with proven track records
in occupational health could play key roles if international and
national laws provide the appropriate context and funding.
Globalization
Increased globalization has caused important changes for many
developing countries. Dias, Mendes, and Schwartz (2002) iden-
tify the series of developmental stages through which a country
passes: underdevelopment and poverty, industrial revolution
and accelerated economic development, internal adjustments
to strengthen national competitive power to enter globalized
markets, adjustments to foreign policy to integrate globalized
markets, and aims toward long-term sustainable human devel-
opment. These authors also analyze the positive and negative
effects on occupational health conditions in countries such as
Brazil, where crises and opportunities are experienced simulta-
neously. On the risk side, for example, free trade agreements
have intensified rapid industrialization and the export of
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industry and materials—many hazardous—to regions with
poor occupational infrastructure. These effects are likely
increasing risk and rates of injury and occupational disease.
Globalization has also engendered major occupational
health and safety development projects, most notably spon-
sored by Scandinavian governments (Partanen and others
1999). These initiatives have infused developing countries
with expertise, training programs, and equipment and have
provided much-needed (external) economic incentives for
adoption of change on national, regional, and local levels. The
major concern is sustainability, because the incentives are
external.
Globalization has resulted in a rapid increase in the number
of multinational companies operating outside industrial
countries. Indeed, this outcome was the underlying economic
intent of recent free trade agreements such as the North
American Free Trade Agreement (NAFTA). In general, these
companies bring with them a highly developed infrastructure
in occupational health practice from their base countries.
Unfortunately, although these model companies undoubtedly
upgrade the availability of high-quality services and training,
enhance workers’ awareness, and create pressure on other
industries in the region to conform, the pressure likely goes in
both directions. The competitive advantage of lowered invest-
ment in health and safety, as long as the labor markets are plen-
tiful and the direct costs to employers of illness and injury low,
results in strong pressure to minimize—or at least reduce—the
intensity and quality of services.
Even at their best, multinationals may inadvertently create
an occupational health and safety “caste system.” Many provide
extremely high levels of care and service for their international
managers and for technical support staff members, while offer-
ing local resources to indigenous workers. More broadly, occu-
pational clinics, industrial hygiene services, and the like are
often developed but available for the exclusive use of the multi-
nationals, creating communities inside which modern occupa-
tional health exists but outside which nothing changes except
the incorrect perception that progress has occurred. Often the
reverse of progress has actually occurred because the limited
numbers of trained physicians, occupational health nurses,
industrial hygienists, and safety professionals are siphoned off
to the higher-paying, more prestigious positions.
Free trade zones, established by treaties such as NAFTA, cre-
ate special considerations. Although the agreements offer the
potential to incorporate strong industrial world rules regarding
labor, environment, and health in underdeveloped zones, the
host countries often resist such changes, perceiving these rules
as trade restrictions. The final language regarding health and
safety in NAFTA, for example, is significantly less stringent
than rules in the United States. Moreover, some multinationals
resist even these rules, seeking broad economic relief as a foun-
dation of moving across the border (Frumkin 1999).
Nonetheless, globalization does offer potential solutions.
One is the link provided by international lending agencies such
as the World Bank and International Monetary Fund of health
and safety considerations to development loans. As a condi-
tion of receiving the development funds, control of health
and safety conditions could be mandated and enforced. A
second opportunity is voluntary initiatives, as were recently
developed in the Apparel Industry Partnership, wherein a con-
sortium of European and U.S. garment manufacturers agreed
to control labor and safety practices in their facilities in devel-
oping countries by joint consent.
Implications for Health System Development
Workers’ health and safety in most of the developing world
may fall under the jurisdictions of both the ministry of labor
and the ministry of health, with little collaboration and coordi-
nation between the two. The ministry of labor most commonly
is the governmental focus of any regulatory and enforcement
efforts, even though without requisite expertise and access to
follow-up care, it may mandate services falling squarely within
the traditional health system (for example, pulmonary func-
tion testing as ongoing screening for individual response to
exposure to pulmonary toxicants). Whatever the country-
specific organizational and structural constraints, the following
set of principles can be applied in providing health services to
workers:
• Coordination between occupational health services and over-
all health services. Occupational health services, consisting
of efforts to prevent work-related disease and disability as
well as to recognize and treat them once they occur, must
be coordinated with overall health services. The separation
between work-related and other health conditions, often
driven by regulatory and liability concerns, insurance, and
other external constructs (workers’ compensation system or
the disability system, for example), is not only clinically
challenging but inefficient in optimizing individual health
status. Although many work-related injuries and a few spe-
cific illnesses, such as asbestosis, can be readily pinpointed as
stemming from work alone, most health problems result
from multiple causes. This fact is as true in the developing
world as in the industrial one—whether it be cumulative
pesticide exposure from work and community sources, the
interaction of poverty and poor health status with chemical
work exposures, or the cumulative psychosocial stressors of
life both inside and outside work. A holistic approach to the
individual, recognizing the multisectoral, multiple determi-
nants of health on overall health status, should be the goal
in the provision of health services.
• Attribution of causality and access to health services. In parts
of the developing world, as in the industrial world, a phe-
nomenon exists wherein some threshold of causality (such
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as “more probably than not work related”) is the trigger to
workers’ compensation or other employer responsibility for
taking care of the illness or injury. All too often in this set-
ting, the incentive for the employer to disclaim responsibil-
ity leaves the worker, whatever the cause or causes of the
condition under question, falling through the cracks of
occupational health care and traditional health care.
Universal access to health care, unfortunately not available
in the United States or in much of the developing world, can
mitigate this problem.
• Health professional workforce expertise in occupational health.
As discussed in the section on capacity building, adequate
expertise does not exist in the developing world to address
traditional and emerging occupational health problems.
Occupational health services are multidisciplinary, including
nonmedical (industrial hygiene and engineering expertise,
for example) in addition to health (nursing and physician)
expertise. Without being prescriptive, health systems need
to ensure the existence of an adequately prepared workforce
(whether through broadly based training for all health per-
sonnel, training for occupational health specialists, or most
likely some combination of the two) if they are to grapple
even minimally successfully with reducing the human and
economic burden of work-related injuries and illnesses.
Unifying the three principles identified above is the need to
recognize that occupational health should be in the main-
stream of both health education (at the professional, employer,
and individual level) and health care. An argument against this
approach is the perception that doing so will result in an unten-
able burden on already underfunded health care. We suggest
that not so doing will create a greater burden, in both financial
and human terms.
RESEARCH AGENDA
Before 1996, there was no known national effort to identify and
promote an occupational health research agenda. That changed
with NIOSH taking the lead to launch the National
Occupational Research Agenda (NORA) (U.S. DHHS 1996).
Since then, a number of other countries in the industrial world
have launched similar efforts (for example, Italy, Sweden, and
the United Kingdom). Although all these efforts are relevant to
the developing world, the reality is that country-specific
research, even at the risk of reinventing the wheel, is often
needed to strengthen political will to effect policy. Moreover,
although traditional epidemiological etiologic research in
occupational health is not a priority or even feasible for much
of the developing world, research targeted at local conditions
and institutions is often what is most needed. Six areas are
identified, with appropriate modifications for local conditions,
as ongoing research priorities to address injury and disease
control strategies in the developing world. This research need
not be undertaken solely—and sometimes not even in part—
in the countries of concern, but rather is likely to be aided by
the capacity building derived from partnership between aca-
demic institutions and government agencies across countries of
different levels of development.
Public Health Systems Research
Although health services research has emerged as an important
area of inquiry in the health field in the industrial world over
the past few decades, scant attention has been paid to public
health systems research (Institute of Medicine 2003). Given
that occupational health sits at the interface between individual
and population health, this area of inquiry is particularly
germane to research in the field. This research would examine
the effectiveness of government systems working in coordina-
tion with other sectors (academic institutions, employers,
unions, voluntary agencies) in promoting occupational health
status.
Occupational Health Policy Research
Public policy to address improving occupational health in the
developing world should rest on a sound scientific base (that is,
be evidence based) and should be coupled with an under-
standing of the local and national frameworks for policy
(whether through legislative, regulatory, or other means).
Adequate research has not been undertaken to evaluate policy
development and implementation in public health in general
and occupational health specifically. As with the need for new
health systems research, this area of inquiry would undoubt-
edly benefit from partnerships among countries in the indus-
trial world and in the developing and industrializing world.
Intervention Effectiveness Research
Intervention effectiveness research, a cornerstone of the U.S.
NORA initiative, is critical to advancing occupational health in
the developing world. The absence of data in this chapter to
demonstrate cost-effectiveness of occupational health meas-
ures is indicative of the need for more such information to
target what will always be a demand for limited resources.
Recognizing the relative dearth of intervention effectiveness
research in countries with high research investments, this rec-
ommendation is made cautiously for countries with fewer
resources. However, it is assumed all too often that an accepted
intervention in a country with higher economic productivity
might not be viable in one with fewer resources. The research
agenda for the developing world in this arena needs to be tai-
lored to what is known and proven coupled with local and
national conditions and needs.
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Control Technology and Protective Equipment Research
Investigation of control technology and protective equipment,
another NORA priority, is critical for developing effective and
feasible control strategies in the developing world. Much of the
primary research in this category can be done in the industrial
world, but along with investments in intervention effectiveness
research, new technologies may still need to be tested in real
situations in developing countries. Simplified approaches to
management of chemicals suitable to the local work settings
have been developed in Indonesia and are being evaluated, and
the International Program for Chemical Safety is helping other
countries modify, implement, and evaluate the U.K. system,
which was originally designed for use by small enterprises in
the United Kingdom (ILO 2003).
Disease and Injury Research
Many questions of epidemiologic importance to improving the
health of all workers can best be answered in settings in the
developing world. This situation is not unique to occupational
health, but in the occupational health arena, it is important to
recognize that workers are often the first exposed and are
exposed to the highest levels of potential hazards (as compared
with their community counterparts). So, too, are levels of expo-
sure to many hazards far greater in the developing world than
elsewhere, and undertaking studies becomes efficient and fea-
sible in these settings that would prove difficult if not impossi-
ble in settings where exposures are lower and larger numbers of
study participants are needed to detect meaningful differences
in risk. Not surprisingly, then, sentinel studies of health effects
of interest to the industrial world have been undertaken in
other countries—for example, studies in Latin America identi-
fying the potential for acute pesticide intoxication to cause
chronic neurological effects (Rosenstock and others 1991).
Surveillance Research
Surveillance is a critical component of all effective occupational
health programs; thus, continuing research is needed into the
most effective ways to gather and interpret this information.
Surveillance systems are often limited at best in many develop-
ing countries, and evaluation research needs to be undertaken
to determine the benefits of investing in gathering both gener-
ic (absences from work, for example) and specific (blood lead
levels, for example) information on which to target public
health action.
CONCLUSIONS
The burden of occupational health problems is staggering in
both human and economic costs, and workers in the develop-
ing world bear this burden disproportionately. Moreover, the
most vulnerable—children and the poor—are also dispropor-
tionately at risk. Compounding this tragedy is that many effec-
tive and economically feasible interventions are available to
address these largely preventable health conditions.
Despite relatively little systemic data on cost and cost-
effectiveness, even this “tip of the iceberg” picture demonstrates
work-related conditions contributing significantly to overall
mortality and morbidity and demonstrates the overall societal
benefit of their prevention and treatment. Externalization of
costs by employers—to the society as a whole—often obscures
the actual overall benefit of a framework that relies on govern-
ment regulation and enforcement, education, and best prac-
tices. Effectively addressing these problems takes active involve-
ment from national and local government, employers, and
workers and their representatives. The challenges to reducing
the burden are heightened to the degree that public health and
health care delivery systems isolate occupational health from
the mainstream of health and health care.
Despite structural and political barriers to overcoming this
high burden of disease and injury, evidence exists of enormous
progress in the industrial world and of isolated progress in
parts of the developing world. Targeted future investments
in research and public health and health systems are critical
to ensuring that progress continues and is more equitably
distributed.
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Sudden-onset natural and technological disasters impose a
substantial health burden, either directly on the population or
indirectly on the capacity of the health services to address pri-
mary health care needs. The relationship between communica-
ble diseases and disasters merits special attention. This chapter
does not address epidemics of emerging or reemerging dis-
eases, chronic degradation of the environment, progressive cli-
matic change, or health problems associated with famine and
temporary settlements.
In line with the definition of health adopted in the constitu-
tion of the World Health Organization (WHO), the chapter
treats disasters as a health condition or risk, which, as any other
“disease,” should be the subject of epidemiological analysis,
systematic control, and prevention, rather than merely as an
emergency medicine or humanitarian matter. The chapter
stresses the interdependency between long-term sustainable
development and catastrophic events, leading to the conclusion
that neither can be addressed in isolation.
DISASTERS AS A PUBLIC HEALTH CONDITION
According to the International Federation of Red Cross and
Red Crescent Societies, internationally reported disasters in
2002 affected 608 million people worldwide and killed
24,532—well below the preceding decade’s annual average
mortality of 62,000 (IFRC 2003). Many more were affected by
myriad local disasters that escaped international notice.
Disaster has multiple and changing definitions. The essential
common element of those definitions is that disasters are
unusual public health events that overwhelm the coping capac-
ity of the affected community. This concept precludes the
universal adoption of a threshold number of casualties or vic-
tims. What would be a minor incident in a large country may
constitute a major disaster in a small isolated island state. Not
only are “quantitative definitions of disasters unworkably sim-
plistic” as noted by Alexander (1997, 289), but when based on
the economic toll or the number of deaths, they are also mis-
leading with regard to the immediate health needs of the
survivors or their long-term impact on the affected country.
Classification of Disasters
In the early 1970s, a series of well-publicized disasters (the civil
war and resulting famine in Biafra, the cyclone in Bangladesh,
and the earthquake in Peru) triggered the scientific interest of
the international public health community.
Disasters can be classified as natural disasters, technological
disasters, or complex emergencies. The latter include civil wars
and conflicts. These classifications are arbitrary and refer to the
immediate trigger—a natural phenomenon or hazard (biolog-
ical, geological, or climatic); a technologically originated prob-
lem; or a conflict. In reality, all disasters are complex events
stemming from the interaction of external phenomena and the
vulnerability of man and society.
The human responsibility in so-called natural disasters is
well acknowledged. The term natural disaster remains com-
monly used and should not be understood as denying a major
human responsibility for the consequences.
Disaster Terminology
The following definitions are adapted from those proposed by
the Secretariat of the International Strategy for Disaster
Reduction (ISDR), a United Nations (UN) body established to
sustain the efforts of the International Decade for Natural
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Disaster Reduction (UN/ISDR 2004) and the WHO World
Health Report 2002 (WHO 2002):
• Hazards are potentially damaging physical events, which
may cause loss of life, injury, or property damage. Each haz-
ard is characterized by its location, intensity, frequency, and
probability.
• Vulnerability is a set of conditions resulting from physical,
social, economic, and environmental factors that increase
the susceptibility of a community to the effects of hazards.
A strong coping capacity—that is, the combination of all the
strengths and resources available within a community—will
reduce its vulnerability.
• Risk is the probability of harmful consequences (health bur-
den) or economic losses resulting from the interactions
between natural or human-induced hazards and vulnerable
or capable conditions. In a simplified manner, risk is
expressed by the following function:
Risk  ƒ (Hazards  Vulnerability)
A public health approach to disaster risk management will
aim to decrease the vulnerability by adopting prevention and
mitigation measures to reduce the physical impact and to
increase the coping capacity and preparedness of the health
sector and community, in addition to providing traditional
emergency care (response) once the disaster has occurred.
Distribution and Risk Factors
Health and relative economic losses of natural disasters dispro-
portionately affect developing countries (Alexander 1997;
UN/ISDR 2004). More than 90 percent of natural disaster–
related deaths occur in developing countries. Even though the
economic losses are far greater in industrial countries, the per-
centage of losses in relation to gross national product (GNP) in
developing countries far exceeds that percentage in industrial
countries (figure 61.1).At an individual level,a sudden reduction
of US$5,000 from an annual income of US$50,000 is worrisome;
however, the ongoing loss of US$50 from a monthly income of
US$100 may be catastrophic.
For this reason, statistics of economic damage and mortality
alone are not true indicators of the effect of disasters on the
health and development of people and communities.
Disaster impact statistics show a global trend: more disasters
occur, but fewer people die; larger populations are affected, and
economic losses are increasing (IFRC 2000).
Geographic Distribution of Risk. Natural disasters do not
occur at random. Geological hazards (earthquakes and volcanic
eruptions) occur only along the fault lines between two tectonic
plates on land or on the ocean floor. However, the local popula-
tion often does not recognize the implications (the risks), as
shown in the December 2004 tsunami in the Indian Ocean.
Hydrometeorological hazards do not follow a well-
established distribution. Although the areas subject to seasonal
flood, drought, or tropical storms (cyclones, hurricanes, or
typhoons) are well known locally, global warming may possibly
redraw the map of climatic disasters. As the National Research
Council (1999, 34–35) notes, “This change is far from uniform.
A pattern of response ‘modes’ appears to be involved, in which
warming is concentrated in northern Asia . . . while large
regions of the northern Pacific and North Atlantic Oceans and
their neighboring shores have actually cooled.” El Niño–related
fluctuations in relation to the gross domestic product (GDP) of
Ecuador are shown in figure 61.2.
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Figure 61.2 Annual Growth of Gross Domestic Product and
Occurrence of Major Natural Disasters in Ecuador, 1980–2001
The risk of massive technological disasters, such as the cata-
strophic release of chemicals in Bhopal, India (methyl iso-
cyanate), in December 1984, is serious in countries with signif-
icant industry (WHO 1992, 1996). Very few countries are
immune to public health risks from hazardous chemical sub-
stances (from insecticides to industrial by-products) or dis-
carded radioactive material from therapeutic or diagnostic use.
Technological hazards increase rapidly with the unregulated
industrialization of developing countries and the globalization
of the chemical industry, suggesting that chemical emergencies
may become a major source of disasters in the 21st century.
Factors Affecting Vulnerability. Vulnerability to all types of
disasters—and to poverty—is linked to demographic growth,
rapid urbanization, settlement in unsafe areas, environmental
degradation, climate change, and unplanned development.
Age The importance of age as a factor of vulnerability can be
significant in situations where physical fitness is necessary for
survival. The higher fatality among children, elderly, or sick
adults following the 1970 tidal wave in Bangladesh (250,000
fatalities) and the 2004 tsunami in Asia (more than 180,000
dead or missing) illustrates this point.
Gender Reports on immediate morbidity and mortality
according to gender are not as conclusive. An Inter-American
Development Bank paper indicated that 54 percent of the
3,045 people who died as a result of Hurricane Mitch in
Nicaragua were male (IDB 1999). Stereotypes of gender vul-
nerability at the time of impact often do not apply. Depending
on the type of disaster, far more significant vulnerability factors
than gender or age are the time of day of the impact (and,
therefore, the occupational activity of each group) and the
structural vulnerability of housing, factories, and public build-
ings, including the location of the victims within the buildings.
Following disasters, increased vulnerability of women is com-
monly noted in temporary settlements, where violence and
sexual abuse are common. Specialized health care also may not
be available (Armenian and others 1997).
Poverty Economic vulnerability might play a much greater
role than age and gender. What has been noted regarding the
greater vulnerability of poor countries also holds true at the
community and family levels. Disasters predominantly affect
the poor. Poverty increases vulnerability because of the
unequal opportunity for healthy and safe environments, poor
education and risk awareness, and limited coping capacity. A
notable exception was the 2004 tsunami in Banda Aceh,
Indonesia, where the middle- and upper-class neighborhood
close to the shore was particularly affected.
A major example is the settlement of a large number of eco-
nomically disadvantaged populations in highly vulnerable
locations, particularly urban areas. Following Hurricane Mitch
in Tegucigalpa, Honduras, families that were relocated from
flooded areas to safer (but inconveniently remote) ground were
rapidly replaced by new illegal settlers. In 2003, families killed
by a landslide in Guatemala had been warned about their vul-
nerability but were unable to afford resettlement in safer (and
more costly) areas. Subsidies alone may not have prevented this
effect, given the overarching issue of land ownership by a few in
Central America.
Short-Term Health Burden
Losses fall under three categories, which may have both direct
and indirect components:
• lives and disabilities (both direct damage and an indirect
consequence)
• direct losses in infrastructure and supplies (direct impact)
• loss or disruption in the delivery of health care, both cura-
tive and preventive (indirect impact).
The immediate health burden is directly dependent on the
nature of the hazard. National health budgets of developing
countries are, in normal times, insufficient to meet the basic
health needs of the population. In the aftermath of a major dis-
aster, authorities need to meet extraordinary rehabilitation
demands with resources that often have been drained by the
emergency response (as distinct from the resources destroyed
by the event). Beyond the immediate response, decision mak-
ing in the allocation of resources among sectors is mostly influ-
enced by the magnitude of the economic losses rather than by
the health statistics (principally the disability-adjusted life year,
or DALY, losses) or social costs.
Earthquakes. As noted by Buist and Bernstein (1986), in the
past five centuries, earthquakes caused more than 5 million
deaths—20 times the number caused by volcanic eruptions. In
a matter of seconds or minutes, a large number of injuries
(most of which are not life-threatening) require immediate
medical care from health facilities, which are often unprepared,
damaged, or totally destroyed, as was the case in the earthquake
in Bam, Iran, in 2003. In the aftermath of that earthquake,
which resulted in 26,271 deaths, the entire health infrastructure
of the city was destroyed. All traumas were evacuated by air to
the 13 Iranian provinces long before the arrival of the first for-
eign mobile hospitals. Table 61.1 illustrates the accelerated pace
with which priorities evolve and overlap in the first week fol-
lowing an earthquake.
After a few weeks, national political solidarity and external
assistance wane, and the local budgetary resources are drained.
At the same time, health authorities face the overwhelming task
of providing services to a displaced population, rehabilitating
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health facilities, restoring normal services, strengthening com-
municable disease surveillance and control, and attending to
the long-term consequences, such as permanent disabilities,
mental health problems, and possibly long-term increases
in rates of heart disease and chronic disease morbidity
(Armenian, Melkonian, and Hovanesian 1998).
Tsunamis. Earthquakes on the ocean floor may cause cata-
strophic tidal waves (tsunamis) on faraway shores. Waves
caused by the seismic event crest at less than a meter in open
seas, but they are travel several hundred kilometers per hour, so
when they reach shallow waters, they can be 10 meters high.
Damage on the coast can be extensive. Usually, the number of
survivors presenting severe injuries is small in proportion to
the number of deaths.
Volcanic Eruptions. Volcanoes persist as a serious public
health concern, though they are often overlooked by authori-
ties and communities lulled by long periods of inactivity.
Eruptions are preceded by a period of volcanic activity, which
provides an opportunity for scientific monitoring, warning,
and timely evacuation.
Some issues, such as ash fall, lethal gases, lava flow, and pro-
jectiles, although of concern to the public, are of minimal
health significance: Ash fall causes a significant burden on
medical services but is unlikely to result in excess mortality
or significant permanent problems. However, ash fall affects
transportation, communications, water sources, treatment
plants, and reservoirs. Studies by Bernstein, Baxter, and Buist
(1986) following the 1980 eruption of Mount St. Helens
(United States) reviewed the transient, acute irritant effects of
volcanic ash and gases on the mucous membranes of the eyes
and upper respiratory tract as well as the exacerbation of
chronic lung diseases with heavy ash fall. Concentrations of
volcanic gases are rapidly diluted to nonlethal levels, which lead
to inconvenience but negligible morbidity for the general pub-
lic. Lava flows present little health risk because of their very
slow speed of progression. Mortality caused by ballistic projec-
tiles from a volcanic eruption is minimal.
Attention to these public concerns may distract the author-
ities from preparing for the greatest factors of mortality: the
pyroclastic flows (Mount Pelé in Martinique, in 1902, with
29,000 deaths) and lahars. Lahars are mud flows or mud and
ash flows caused by the rapid melting of a volcano’s snowcap,
as in Colombia in 1985 (23,000 deaths), or caused by heavy
rains on unstable accumulations of ash, as in the Philippines in
1991. Historically, pyroclastic explosions or lahars have caused
about 90 percent of the casualties from volcanic eruptions.
Potential contamination of water supplies by minerals from
ash; displacement of large populations for an undetermined
period of time (over five years in Montserrat, a small island in
the Caribbean); accompanying sanitation problems; and men-
tal health needs are of great public health significance (PAHO
2002a). Among the long-term problems, the risk of developing
silicate pneumoconiosis requires further investigation.1
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Table 61.1 Health Priorities Following Earthquakes 
Priority Time period Comments
Search and rescue 0 to 48 hours Returns are rapidly diminishing. Most effective work is done by local teams.
Trauma care 0 to 48 hours: initial lifesaving carea External assistance generally arrives too late for initial care. Traumas may 
48 hours to 6 months: secondary care include burns and crush syndrome, especially in urban areas. Paraplegics and
amputees require long-term care.
Routine medical emergencies and Resumes as soon as the need for acute Emergencies include earthquake-related cardiovascular emergencies and 
primary health care lifesaving care subsides (within 24 hours) premature births.
Attention to the dead Varies. Not a public health issue but a Priorities are identification and ritual burial.
social and political one
Disease surveillance Urgent—within 48 hours, unsubstantiated Surveillance is a sensitive public information and education issue. A simple, 
rumors of impending epidemics will be syndrome-based system is needed that will involve humanitarian 
circulating organizations.
Provision of safe water A predominant issue within 48 hours The challenge is to provide a sufficient quantity of reasonably safe water.
Temporary shelter 48 hours to several months Sanitation and provision of health services is a main issue. Accommodating 
families near their residence is preferable to setting up camps.
Provision of food 3 days to 6 weeks Food provision is a social or economic issue. Food stocks and agricultural 
output are not affected by earthquakes.
Psychosocial care 7 days to 6 months Mental health assistance is best provided by local personnel, if available.
Source: de Ville de Goyet 2001.
a. Following the earthquake in Mexico City in 1985 (10,000 deaths), bed occupancy rates did not exceed 95 percent despite the loss of 5,829 hospital beds.
Climatic Disasters. Many communities and health services
have learned to live with seasonal floods of moderate intensity.
Periodically, the magnitude of the phenomenon exceeds the
local coping capacity and overwhelms the resources of the
health systems. The health burden associated with seasonal
floods is well known locally: increased incidence of diarrheal
diseases, respiratory infections, dermatitis, and snake bites. The
actual risk of compromised water supplies depends on the level
of contamination of the community’s water supply before the
disaster, compared with contamination after the flooding.
Saline contamination is a long-term issue following sea surges
and tsunamis. Prolonged flooding endangers local agriculture
and occasionally requires food assistance on a large scale. The
primary factors of morbidity remain overcrowded living con-
ditions and poor water and sanitation in temporary settle-
ments and other areas where water and sanitation services have
deteriorated or are suspended.
Mortality and morbidity caused by tropical storms (hurri-
canes in the Atlantic Ocean and typhoons in the Pacific Ocean)
result from, in increasing order of importance, high winds,
heavy rainfall, and storm surge. When Hurricanes Mitch and
George hit the Caribbean in 1998, traumatic injuries (lacera-
tions or electrocution) caused by high winds of up to 150 miles
per hour were relatively few; deaths from extensive rainfall
(leading to flash floods and landslides) constituted the bulk of
the more than 13,000 fatalities (PAHO 1999). In the
Bangladesh delta, storm surges up to 6 meters traveled unim-
peded over hundreds of kilometers and claimed between
250,000 and 500,000 lives in 1970 and up to 140,000 lives dur-
ing five cyclones in the 1990s—primarily during one storm in
1991. Another cost is the need for specialized psychosocial
assistance to large numbers of the population who survive the
sustained violence of nature.
Cumulative mortality caused by small, undocumented
mudslides and rockslides from water-saturated, unstable slopes
probably approach the toll from well-known landslides
(earthquakes in Peru in 1970 and in El Salvador in 2001, and
the rains in Caracas, Venezuela, in 1999). Morbidity problems
are often minimal, as survivors in the path of the landslide
are few.
Impact on Communicable Diseases
Disasters related to natural events may affect the transmission
of preexisting infectious diseases. However, the imminent risk
of large outbreaks in the aftermath of natural disasters is over-
stated. Among the factors erroneously mentioned is the pres-
ence of corpses of victims, many buried beneath rubble. Dead
bodies from a predominantly healthy population do not pose a
risk of increased incidence of diseases (Morgan 2004).
Catastrophic incidence of infectious diseases seems to be con-
fined to famine and conflicts that have resulted in the total fail-
ure of the health system.
In the short term, an increased number of hospital visits and
admissions from common diarrheal diseases, acute respiratory
infections, dermatitis, and other causes should be expected fol-
lowing most disasters (Howard, Brillman, and Burkle 1996;
Malilay and others 1996). This increase may reflect duplicate
reporting (diarrhea cases were reported through both the
emergency and the routine surveillance systems in Maldives
after the 2004 tsunami), a temporary surge in surveillance, and
medical attention available to an otherwise underserved popu-
lation rather than representing a genuine change in the epi-
demiological situation.
In the medium term, heavy rainfalls may affect the trans-
mission of vectorborne diseases. Following an initial reduction
as mosquito-breeding sites wash away, residual waters may
contribute to an explosive rise in the vector reservoir. When
associated with a breakdown of normal control programs, this
rise in the vector reservoir may lead to epidemic recrudescence
of malaria or dengue. Retrospective studies (Bouma and Dye
1997; PAHO 1998; UN/ISDR 2004, 156) all confirm a direct
but delayed relationship between the intensity of rainfall
(regardless of the existence of flooding) caused by the El Niño
phenomenon and the incidence of malaria. Flooding has con-
tributed to local outbreaks of leptospirosis (in Brazil and
Jamaica, for example; PAHO 1982) and hepatitis A in Latin
America and Africa (WHO 1994).
In summary, what can be expected and prevented is a local
surge in problems that the health services are normally used to
handling.
Long-Term Impact and Economic Valuation
In addition to the delayed impact on transmission and control
of endemic diseases and the burden of disabilities (paraplegia,
amputation, burns, or chronic or delayed effects of chemical or
radiological exposure), the health sector bears a significant
share of the economic burden. Disasters must be seen in a sys-
temic (that is, intersectoral) manner: what affects the economy
will affect the health sector—and vice versa. After the emo-
tional response of the first few days, decision makers in a crisis
react primarily to political and economic realities, not to health
indicators. Economic valuation of the social burden—that is,
placing a monetary value on the cost—becomes a critical tool
as the various sectors compete for scarce resources. The health
sector, in particular, must learn how to use this tool in spite of
being absorbed by its immediate relief responsibilities.
Valuation of Disasters. The Economic Commission for Latin
America and the Caribbean (ECLAC) has developed over the
decades a methodology for the valuation of disasters (ECLAC
2003). This tool, intended for reconstruction, has also proved
its usefulness by developing historical records of major events,
particularly of the health burden expressed in economic terms.
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Valuation is made using all possible sources of information,
from georeferenced satellite mapping and remote sensing to
more conventional statistical data, direct observation, and sur-
veys, with a reliance on information gathered immediately after
the event. Economic valuation rests on the basic concepts of
direct damage and indirect losses.
Direct damage is defined as the material losses that occur
as an immediate consequence of a disaster.2 Direct damage is
measured first in physical terms. The physical loss includes
assets, capital, and material things that can be counted: hospi-
tal beds lost, equipment and medicines destroyed, damaged or
affected health service installations (number and type of instal-
lations, stocks of medicines, laboratory facilities, operating
rooms, and so on), and pipes and water plants destroyed.
The physical plant then is valued both in terms of dis-
counted present value and estimated replacement cost. Recon-
structing facilities with the same vulnerability and level of
service as before would be unacceptable; the affected health
infrastructure must be replaced by more resilient and efficient
installations to ensure better and sustainable service. This need
is most evident in developing countries where impacts tend to
be concentrated in those most at risk (the poor, marginalized,
and less resilient sectors of the population).
Indirect effects refer to production of goods and services that
will not occur as an outcome of the disaster, reduced income
associated with those activities not occurring, and increased
costs to provide those goods and services.
In the case of health services, indirect effects encompass
both the income losses associated with the diminished supply
of health care services and the increased costs of providing the
services following the disaster. Indirect effects are valued at
the current market value of goods or services not produced
and the costs associated with the necessary provision of servic-
es under emergency, disaster-related conditions. Both compo-
nents of the cost of illness—the cost of treatment and the cost
of lost opportunities (lost income and employment, loss of
time and productivity)—are sharply increased. The social bur-
den is heavier on the poorest, who are unable to adjust their
willingness to pay to absorb the additional expenses of alterna-
tive (private) providers of care.
The same approach applies to the economic valuation of
lives lost. Kirigia and others (2004) found a statistically signifi-
cant impact of disaster-related mortality on the GDP of African
countries. One single disaster death reduced the GDP per
capita by US$0.01828. Lost lives are given a higher economic
value in places where productivity is high.
Because economic valuation uses standard sectored proce-
dures that allow comparability of results, it can be used in the
decision-making process and for policy formulation since it
identifies sectors, geographical areas, and vulnerable groups
that are more severely affected economically. Over the years, a
number of conceptual improvements have been made to allow
for the measurement of aspects not included in national
accounting systems—to bring attention to environmental
losses as a cross-cutting issue; to highlight the contribution of
specific groups, namely women, as agents for change; and to
focus on the better management of both the emergency and the
reconstruction processes. It is also a valuable tool for prepared-
ness and mitigation of future damage.
Table 61.2 summarizes the valuations made by ECLAC over
the years for LatinAmerica and the Caribbean in terms of deaths,
affected populations, and economic losses (2003 values). Of
interest are the decrease in the number of deaths and the increase
in total damage (in particular, indirect damage) over time.
The distribution of direct and indirect damage in the health
sector also varies. According to ECLAC (2003), direct damage
between 1998 and 2003 in Latin America ranged from 44.6 per-
cent to 77.2 percent of total damage.
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Table 61.2 Impact of Disasters in Latin America and the Caribbean
Population Damage (2003 US$ millions)
Date Deaths Affected Total Direct Indirect
1972–80 38,042 4,229,260 9,376 5,420 3,956
1981–90 33,638 5,442,500 19,603 13,916 5,687
1991–2000 11,086 2,318,508 20,902 10,401 10,501
2001–2002 120 4,828,470 4,498 2,270 2,228
Total of major events 1972–2002 82,886 16,818,738 54,379 32,007 22,372
Overall estimate including small disastersa 103,608 21,023,422 67,974 40,009 27,965
Average per year 3,454 700,781 2,266 1,334 932
Source: ECLAC 2003.
a. The full image should include the recurrent small disasters that do not make the headlines but have a cumulative negative effect. Such disasters can be more pervasive and damaging to the develop-
ment process because their economic, social, psychological, and political effects are hardly perceived. An estimate of the average losses of small disasters would be at least 25 percent greater than
those of large disasters.
Specific Damage to the Health Infrastructure. Damage to
housing, schools, channels of communication, industry, and so
on contributes to the health burden. However, the following
analysis focuses on the health infrastructure (understood as
health care facilities, including hospitals, health centers, labora-
tories, and blood banks) and the drinking water and sanitation
infrastructure.
Damage to Hospitals and Health Installations Most data and
examples presented here come from Latin America and the
Caribbean because of the disaster reduction programs in the
health sectors of those regions. In the past two decades, damage
to approximately 260 hospitals and 2,600 health centers resulted
in interruption of services at a direct cost of US$1.2 billion. In
the 1985 earthquake in central Mexico, 5,829 beds were
destroyed or evacuated (PAHO 1985), at a direct cost of
US$550 million (ECLAC 1998). Hurricane Gilbert (1988)
damaged 24 of the 26 hospitals on Jamaica, and the El Salvador
earthquake (2001) resulted in the loss of 2,000 beds—40 per-
cent of the country’s hospital capacity (PAHO 2002b). The
health burden is not limited to the loss of medical care. The
control of communicable diseases and other public health pro-
grams suffer from loss of laboratory support and diagnostic
capabilities of hospitals. Further research on the actual impact
of these losses, in terms of DALYs, is essential.
A common misperception is that damage to critical health
facilities is promptly repaired. Experience shows that damaged
health infrastructure recovers at a slower pace than infrastruc-
ture in other service sectors, such as trade, roads, bridges,
telecommunications, and even housing. For example, as a result
of the earthquake that affected El Salvador in 1986, renovation
of the general hospital, the most sophisticated referral hospital
in the capital, was completed 15 years after the earthquake. The
only national pediatric facility was fully rehabilitated and
strengthened six years after the earthquake. Two years after the
earthquake of 2001 in El Salvador, several key hospitals still
remained vacated or services were transferred to unsuitable
temporary facilities. The factors are many: low priority assigned
to a nonproductive sector, the sector’s inexperience in develop-
ing comprehensive proposals for funding, conflicting attempts
to use the reconstruction process to influence the ongoing
reform and decentralization processes, the novelty of the engi-
neering and design issues for safe hospital construction, the
complicated negotiation process for loans, and the administra-
tive inexperience of the health sector in executing large invest-
ment projects. Indeed, few large health installations have been
built directly by developing countries in the past decades.
Damage to Water and Sewage Systems The primary goal of
water and sewage systems is to safeguard the public health of
the population. For that reason, these systems are considered
part of the health infrastructure.
The developmental burden is significant. In the past 30 years
in Latin America and the Caribbean alone, an estimated 400
urban water supply systems and 1,300 rural systems (in addition
to 25,000 wells and 120,000 latrines) were severely damaged, at
an estimated cost of almost US$1 billion—a major setback to
efforts to expand coverage and improve those services. In severe
flooding, the sudden interruption of these basic services coin-
cides with the direct effect on the transmission of waterborne or
vectorborne diseases. In the case of earthquakes, the number of
people who are adversely affected by water shortage may far
exceed those injured or suffering direct material loss.
As in the case of health care facilities, the rehabilitation of
public water systems is slow, particularly for community-
owned or community-operated rural systems, which may not
be repaired for decades. The foregoing demonstrates the need
for water authorities to harmonize their short-term objectives,
which are oriented almost exclusively to increasing the cover-
age of these services, with the long-term objective of reducing
vulnerability to extreme natural hazards.
INTERVENTIONS: FROM RESPONSE
TO PREVENTION 
The immediate lifesaving response time is much shorter than
humanitarian organizations recognize. In a matter of weeks, if
not days, the concerns of both the population and authorities
shift from search and rescue and trauma care to the rehabilita-
tion of infrastructure (temporary restoration of basic services
and reconstruction). In Banda Aceh, Indonesia, after the
December 2004 tsunami, victims were eager to return to nor-
malcy while external medical relief workers were still arriving in
large numbers.
Response and Rehabilitation
Immediate emergency response is provided under a highly polit-
ical and emotional climate. The public demands visible, albeit
perhaps unnecessary,measures at the expense of proven low-key
approaches. The international community, eager to demon-
strate its solidarity or to exercise its“right of humanitarian inter-
vention,”undertakes its own relief effort on the basis of the belief
that local health services are unwilling or unable to respond.
Donations of useless medical supplies and medicines and the
belated arrival of medical or fact-finding teams add to the stress
of local staff members who may be personally affected by the dis-
aster. The cultural disregard of the humanitarian community to
cost-effective approaches in times of disaster and the tendency to
base decisions on perceptions and myths rather than on facts
and lessons learned in past disasters contribute to making disas-
ter relief one of the least cost-effective health activities.
The responsibilities of the national or local health authori-
ties are significant.
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Assessment of the Health Situation. A country’s ministry of
health is expected to assess the health situation. To influence the
course of humanitarian response, this assessment must be rapid
and, therefore, simple; transparent in collaboration with the
main actors—nongovernmental organizations (NGOs) and
donors; and technically credible. The input of WHO, as the lead
agency in health matters, is most valuable. Confusion should be
avoided between assessing emergency needs and inventorying
or valuating the damage. In the first hours or days, relief actors
base their decision making on the ministry of health’s assess-
ment of what is required and, more importantly, what is not
required for emergency response. Later, the international
community will request detailed data, such as the number of
persons affected, buildings damaged, and monetary valuation.
Mass Casualties Treatment. Following natural disasters,
hospital capacity may be considerably reduced by actual dam-
age to the facility or, in the case of a seismic event, an often
unnecessary—but hard to reverse—evacuation. Triage of
patients is required in order to first treat those likely to benefit
most, rather than the terminally injured or those whose care can
be delayed. Lifesaving primary care takes place in the first six
hours (the golden rule of emergency medicine), making most of
the foreign field hospitals irrelevant for intensive acute care of
traumas (WHO and PAHO 2003). Effectiveness of immediate
care will depend on local preparedness before the disaster, not
on faraway resources.
Strengthened Surveillance, Prevention, and Control of
Communicable Diseases. Because the surveillance,prevention,
and control of communicable diseases are strengthened, the
anticipated massive outbreaks generally do not actually occur.
Traditional surveillance systems that are based on periodic
notification of diseases by the health services are inadequate in
a crisis situation. Early warning requires flexible and simple
syndrome-based monitoring in temporary settlements and
health centers, with information collected not only by the offi-
cial health services but also by the medical humanitarian
organizations. Systems that do not include consultation with
NGOs are unlikely to succeed.
Disease control programs in place before the disaster are the
fruit of local experience and external technical advice. In a dis-
aster situation, there is generally no need to resort to new and
expensive control measures. The key is to quickly resume,
strengthen, and better monitor the routine control programs.
No public health concerns justify the hurried disposal of
corpses through mass burial or unceremonious incineration.
This practice is socially and culturally damaging. In addition,
improvised mass immunization campaigns, especially by
external relief groups, should be discouraged in favor of oppor-
tunistically strengthening national routine immunization
coverage, especially in temporary settlements.
Environmental Health. Typical interventions in the aftermath
of disasters include strengthening the monitoring and surveil-
lance of water quality, vector control, excreta disposal, solid
waste management, health education, and food safety.
A first priority is water supply. It is often preferable to have
a large quantity of reasonably potable water than a smaller
amount of high-quality water (UNHCR 1998). Massive distri-
bution of water purification disinfectants can be effective if the
public is already familiar with their use and not confused by
the availability of many different brands and concentrations
of donated chemicals.
Health education and hygiene promotion efforts target pop-
ulations in shelters, temporary camps, collective kitchens, or
prepared food distribution centers.
The cost-effectiveness of the external relief effort could
often be increased by shifting resources from the overattended
medical response to the improvement of environmental health
in temporary settlements.
Transparent Management of Donations and Supplies. If
donations and supplies are managed transparently during the
emergency, the flow of assistance to the intended beneficiaries
will be improved. Unsolicited and often inappropriate medical
donations compete with valuable relief supplies for scarce
logistical resources. Good governance is critical, and effective
logistics cannot be improvised following a disaster. A human-
itarian supply management system developed by PAHO and
WHO successfully helped developing countries improve
transparency and accountability in managing humanitarian
supplies and donations (de Ville de Goyet, Acosta, and others
1996).
Coordination of the Humanitarian Health Effort. Coordina-
tion of the humanitarian health effort is essential to maximize
the benefit of the response effort and ensure its compatibility
with the public health development priorities of the affected
country. Effective coordination in the health sector must do the
following:
• Be comprehensive and include all external health actors.
• Be based on mutual respect rather than regulatory authority
alone. Dialogue and consultation are more effective than
enforcement.
• Benefit all parties, starting with the victims. It should aim to
support and facilitate the activities of other partners.
• Be evidence-based and transparent. Information is made to
be shared and used, not jealously guarded.
Coordination cannot be improvised in the aftermath of a
disaster. Preparedness before the occurrence of the hazard is
essential.
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Emergency Preparedness of the Health Sector
Effective response by national health authorities cannot be
impromptu. Ministries of health that neglected to invest in
capacity building before emergencies have generally experienced
serious difficulties in exercising their technical and political
leadership in the immediate aftermath of a disaster. Disaster
preparedness is primarily a matter of building institutional
capacity and human resources, not one of investing heavily in
advanced technology and equipment.
Building local coping capacity is one of the most cost-
effective ways to improve the quality of the national response
and the external interventions.
Disaster preparedness is not merely having a disaster plan
written by experts. It must involve the following:
• Identifying vulnerability to natural or other hazards. The
health sector should seek information and collaborate with
other sectors and institutions (civil protection, meteorology,
environment, geology) that have the primary responsibility
for collecting and analyzing this information.
• Building simple and realistic health scenarios of a possible
and probable occurrence. It is challenging enough to pre-
pare for a moderate-size disaster; building and sustaining a
culture of fear based on unrealistic worst-case scenarios may
serve the corporate interests of the disaster community but
not the interests of the public at large.
• Initiating a participative process among the main actors to
develop a basic plan that outlines the responsibilities of
each actor in the health sector (key departments of the
ministry of health, medical corps of the armed forces, pri-
vate sector, NGOs, UN agencies, and donors). What matters
is the process of identifying possible overlaps or gaps and
building a consensus—not the paper plan itself. Disasters
often present problems that are unforeseen in the most
detailed plans.
• Maintaining a close collaboration with these main actors. A
good coordinator is one who appreciates and adapts to the
strengths and weaknesses of other institutions. Stability is
essential. Changes of key emergency staff members during a
disaster situation or when a new administration or minister
take over have occasionally complicated the tasks.
• Sensitizing and training the first health responders and
managers to face the special challenges of responding to
disasters. Participation of external actors (UN agencies,
donors, or NGOs) in designing and implementing the train-
ing is critical. The incorporation of disaster management in
the academic curriculum of medical, nursing, and public
health schools should complement the on-the-job training
programs of the ministry of health, UN agencies, and
NGOs. Well-designed disaster management training pro-
grams will improve the management of daily medical emer-
gencies and accidents as well.
Prevention and Mitigation 
The slogan “prevention is better than cure” was invented by the
health sector. However, this sector has been slow to adopt the
concept of preventing deaths and injuries from disasters
through the mitigation (that is, reduction) of damage to its
own facilities. As is unfortunately often the case, political action
is often triggered only by a major disaster, such as the collapse
of Hospital Juarez in Mexico in the earthquake of 1985; in that
disaster 561 patients and employees died, (Poncelet 1997).
Evaluating the damage (the past vulnerability) helps establish
mitigation criteria for the future.
The level of protection required for each health installation
must be negotiated—from life protection, which prevents an
immediate structural collapse to permit the evacuation of peo-
ple; to investment protection, which minimized the economic
losses; to operational protection, which guarantees the sustain-
ability of services under any extreme circumstances. Though
a commercial or office building may be structurally designed
only to prevent loss of lives, key hospitals must remain opera-
tional during the times they are most needed.
Local engineering and architectural experts play a key role in
developing the knowledge, technical abilities, and cost-
effectiveness analysis to establish mitigation priorities.Technical
mitigation guidelines prepared at a global level (PAHO, WHO,
World Bank, and ProVention Consortium 2004) need to be
adapted to local culture, conditions, and resources.
Reducing the physical vulnerability of infrastructure
can take place on three different occasions (UN/ISDR 2004,
324):
• When reconstructing the infrastructure destroyed by a disaster.
At that time, risk awareness is high, political will is present,
and resources are available.
• When planning new infrastructure. Reducing vulnerability
is most cost-effective and politically acceptable when it is
included at the earliest planning and negotiation stage,
whether it involves a 1 to 2 percent additional cost for wind
resistance or a 4 to 6 percent additional cost for earthquake
resilience. Full resistance to any damage is prohibitively
expensive.
• Strengthening of existing facilities (retrofitting). This most
expensive measure has been adopted by several developing
countries (Chile, Colombia, Costa Rica, Mexico, Peru, and
others) to protect their most critical health facilities. In the
earthquake in Colombia in 1999, partial retrofitting of the
main hospital is credited for saving the installation. Costs
vary greatly (see table 61.3).
Mitigation of Damage to Hospitals. Mitigation does not
pretend to eliminate all possible damage from hazards but aims
to ensure the continuing operation of the health facility at a
level previously defined by the health authority. Hospitals
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should be subject to stricter norms than other less critical
facilities that are designed to prevent only total collapse and
loss of life.
Hospital mitigation interventions fall into three categories:
• Functional mitigation to ensure that the necessary support-
ing infrastructure services permit continuing operation:
water, electricity, road access, communications, and so
forth. Improving routine maintenance will facilitate opera-
tions under normal circumstances and in the event of
extreme hazards.
• Nonstructural mitigation to reduce losses and health injuries
from falling or moving objects. Measures include, for
instance, proper anchoring of equipment for earthquakes or
strong winds or the location of only noncritical services on
flood-prone floors.
• Structural mitigation to ensure the safety of the structure
itself (columns, beams, load-bearing walls).
Given the high economic, health, and political costs repre-
sented by the avoidable loss of critical health facilities, health
authorities and funding agencies should require that, in all new
health infrastructure projects, natural hazards be a decisive
factor for selecting the facility’s location and for formulating
the specifications at the earliest stage of the process.
Mitigation of Damage to Water Systems. Unlike hospitals,
water supply systems are geographically extensive and thus are
exposed to different types of hazards. The search for technical
solutions is more complex, given the diversity of the water
system’s components. Finally, in many countries, the health
authorities have no jurisdiction over the construction or oper-
ation of those services owned or administered by many local or
municipal agencies.
Even a short disruption of water services may have serious
and direct implications for the health of individuals, the oper-
ation of health services, and the community at large through its
impact on business. A probabilistic model studied the disrup-
tive potential of a water outage in the event of an earthquake
in Los Angeles county in the United States. As noted by the
authors, “water outage is more likely to be disruptive for busi-
nesses in some industries, such as health services, than for
others” (Chang and Chamberlin 2004, 89).
The health sector should, therefore, coordinate with the
institutions in charge of constructing, operating, and main-
taining water and sanitation services, both urban and rural, to
promote reduction of the vulnerability of existing systems. The
health sector should also ensure that health aspects and mitiga-
tion of damage be included in the regulatory framework and
operating procedures of water and sanitation services.
Protecting the water supply is feasible in developing
countries. The Costa Rican Institute of Aqueducts and
Sewage Systems reduced the vulnerability of one of the main
aqueducts of the country, the Orosi Aqueduct. Over 10 years,
Costa Rica invested almost US$1.5 million in studies and
reinforcements, an amount equivalent to 2.3 percent of the total
cost of the aqueduct. This investment would prevent a loss of
nearly US$7.3 million in direct damages alone (FEMICA 2003).
INTERVENTION COST, COST-EFFECTIVENESS,
AND ECONOMIC BENEFITS
The highly emotional and sensationalized climate of disaster
response has long prevented the adoption of a cost-
effectiveness approach in decision making. When survival of
both people and political institutions is threatened, perceptions
and visibility tend to prevail over facts and analysis, resulting in
a lack of evidence-based studies on costs and benefits.
The willingness to spend hundreds of thousand of dollars
per victim rescued from a collapsed building in a foreign coun-
try is a credit to the solidarity of the international community,
but it also presents an ethical issue when, once the attention has
shifted away, modest funding is unavailable for the mid-term
survival of tens of thousands of victims.
Cost-Effectiveness of Selected Humanitarian Interventions
Emergency health interventions are more costly and less effec-
tive than time-tested health activities. Improvisation and rush
inevitably come with a high price. The preferential use of
expatriate health professionals; the emergency procurement
and airlifting of food, water, and supplies that often are avail-
able locally or that remain in storage for long periods of time;
and the tendency to adopt dramatic measures contribute to
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Table 61.3 Retrofitting of Hospitals in Costa Rica
Duration of Cost of Percentage of total
Hospital Number of beds retrofitting (months) retrofitting (US$) value of the hospital
Hospital Mexico 600 31 2,350,000 7.8
Children’s Hospital 375 25 1,100,000 4.2
Hospital Monseñor Sanabria 289 34 1,270,000 7.5
Source: PAHO and WHO 2000.
making disaster relief one of the least cost-effective health
activities.
Search and Rescue. Few developing countries have established
the technical capacity to search for and attend to victims
trapped in confined spaces in the event of the collapse of mul-
tistory buildings. Industrial nations routinely dispatch search
and rescue (SAR) teams. Costs are high and effectiveness is
reduced by delayed arrival and quickly diminishing returns.
Following the 1988 earthquake in Armenia, in the former
Soviet Union, the U.S. SAR team extracted alive only two vic-
tims at a cost of over US$500,000. In Turkey in 1999, 98 per-
cent of the 50,000 people pulled alive from the rubble were sal-
vaged by relatives and neighbors. In Bam in 2003, the absence
of high-rise and reinforced concrete buildings ruled out the
need for specialized teams. Nevertheless, according to UN sta-
tistics, at least US$2.8 million was spent on SAR teams. An
alternative solution consists of investing these resources in
building the capacity of local or regional SAR teams—the only
ones able to be effective within hours—and training local
hospitals to dispatch their emergency medical services to the
disaster site.
Field Hospitals. The limited lifesaving usefulness of foreign
field hospitals has been discussed. Again, the lessons learned
from the Bam earthquake are clear. The international commu-
nity spent an estimated US$10.5 million to dispatch approxi-
mately 10 mobile hospitals,3 which arrived from two to five
days after the impact, long after the last casualty had been
evacuated to other Iranian provinces. This delay alone, hard to
reduce further, rules out any significant contribution to imme-
diate trauma care and led the hospitals to compete for routine
outpatient care with the teams of Iranian volunteers from
across the country. A few of the mobile hospitals, better pre-
pared to meet nontrauma needs and to stay much longer than
the usual two to three weeks, have been invaluable. No data are
available on the number of lives actually saved by mobile hos-
pitals (that is, lives that would not have been saved by local
means). Less understood are the negative effects of such hos-
pitals on local health services, which are often marginalized
and discredited for their lack of technology and sophistication
but which must cope once the external facility leaves.
The cost of mobilizing a mobile hospital for a few weeks
often exceeds US$1 million, funds that would be more pro-
ductive in the construction and equipping of a simple but
sturdy temporary facility. Such an approach was adopted by
the U.S. Army Southern Command in Wiwili, Nicaragua, in
the aftermath of Hurricane Mitch. In the case of Bam, Iran, the
cost of rebuilding the entire primary and secondary health
care facilities and teaching institutions was estimated by the
government of Iran to be US$10.75 million, an amount very
similar to that expended for the dispatch of field hospitals
from the international community. Guidelines for the use of
foreign field hospitals are available from WHO and PAHO
(2003).
In-Kind Donations. Unsolicited donations of inappropriate
medical supplies not only are of limited use, but often cause
serious logistic, economic, and political problems in the recip-
ient country. Warehousing those supplies and, in many
instances, building facilities (incinerators, for example) for the
safe disposal of pharmaceutical donations diverts humani-
tarian funds from more effective uses. Recipient countries col-
lectively share part of the responsibility by not clearly indicat-
ing what they do not want to receive and by not speaking out
once inappropriate items arrived.
Disease Prevention and Control. Postdisaster interventions
in surveillance and control of communicable diseases should
focus on strengthening existing programs. Benefits will outlive
the crisis. Improvised mass immunizations (instead of
improved sanitation and public awareness) and vector control
by aerial spraying or fogging (instead of breeding-site reduc-
tion or waste disposal) are just two examples of wasteful
managerial decisions.
Shelters. Tent cities should be a last resort. Family-size tents
may be expensive and do not last long. Establishing large set-
tlements is easy, but such settlements are difficult to sustain and
nearly impossible to terminate. They come with their own san-
itation problems and social shortcomings (lack of privacy, loss
of family identity, and loss of empowerment). Distributing
construction material (or, preferably, cash subsidies) is more
cost-effective and tailored to the needs and priorities of end
users.
Cash Assistance. Developed societies long ago abandoned the
distribution of in-kind relief goods and services to their
nationals in favor of direct financial assistance in the form of
subsidies, grants, or tax relief. The individual is free to deter-
mine actual priorities and to seek the most cost-effective source
of services (shelter, medical, food, or other). It is therefore sur-
prising that external assistance from these same countries
remains focused on the costly delivery of predetermined serv-
ices or commodities.
The most immediate lifesaving needs can be addressed only
locally with existing resources and capacity. No cash contribu-
tion will meet those immediate needs. Beyond the acute phase,
in many countries with market economies, most other services
and goods are easily procured by those with financial means,
suggesting that income availability is often the single limiting
factor in rehabilitation.
Undoubtedly, this approach would affect considerably the
type (and number) of humanitarian actors by transferring
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power and decision making to the local beneficiaries and
relying on local economic forces for delivery to the end user. It
may also bring its own set of problems (and abuses), though
perhaps that is a small cost, considering the economic and
social benefits of the most interested party—the victim—being
in charge.
Cost-Effectiveness of Prevention and Mitigation
The social benefits of making hospitals and water systems more
resilient to the effects of natural hazards are recognized but too
rarely applied. On the economic side, mitigation also increases
the investment capacity in the health sector by preventing
losses and the need for reconstruction (PAHO and UN/ISDR
1996; Bitrán 1996).
The most compelling case for the cost-effectiveness of
mitigation can be made during the planning phase for new
installations, when costs of additional structural safety are
minimal. Although the social benefits of prevention and risk
management are more evident in the health sector than in oth-
ers, further studies are needed to provide decision makers with
quantified parameters of the economic benefits brought about
by investment in risk management and disaster reduction.
PAHO and UN/ISDR (1996) studies indicate that such
increased investment fluctuates between 4 and 8 percent of a
hospital’s local construction cost.When the value of services lost
is added to the infrastructure loss, the additional investment is
reduced to between 2 and 4 percent of direct and indirect losses
observed. Even though this is a gross estimate that requires fur-
ther research in other regions and types of health facilities, the
figure is ratified by the estimated cost of reinforcement, which
fluctuates but averages between US$2,000 and US$5,000 per
bed, compared with the average cost of a new hospital bed of
between US$100,000 and US$150,000 (at 1996 prices).
Prevention of chemical and radiation accidents can be a
highly cost-effective expense that is normally absorbed by the
respective industries. Respect for existing norms in the use of
radiotherapy and diagnostic equipment and, once such equip-
ment is decommissioned, its proper disposal reduces DALYs
from accidents at a modest cost.
Mobilization of Resources
Funding for preparedness and response programs follows rules
and procedures that are distinct from those applicable to devel-
opment projects. Most donors maintain a specific office or
department for humanitarian affairs with a separate budget
line. Procedures are also streamlined for quick response to
unexpected situations. Processing a request takes a matter of
days in emergencies and takes months for preparedness or mit-
igation projects, but it can take years in typical development
projects negotiated with donors or financial institutions.
From a ministry of health point of view, competition for
disaster resources is with other sectors or humanitarian organ-
izations, not within the sector (as it would be, for instance, with
malaria or tuberculosis control projects).
Funding for Preparedness. “By strengthening our public
health planning for natural disasters and disease outbreaks, we
will be in a better position to care for our populations, regard-
less of the type of hazard that confronts our health depart-
ments” (Rottman 2003, 1). This message, addressed to the
public health community in the United States, is even more
pertinent for developing countries. Most humanitarian offices
in more developed countries allocate a modest but increasing
proportion of their funds for predisaster capacity building. The
capacity of the ministries of health to secure directly nonreim-
bursable funding depends on the following:
• The existence of an established disaster program within the
ministry, demonstrating a long-term commitment to health
disaster preparedness.
• An ongoing dialogue with local representatives of donors
and their prior involvement in disaster-related activities or
meetings of the health sector.
• A realistic projection of concrete activities, taking into con-
sideration the efforts of others, especially NGOs. One- or
two-year training or capacity-building projects are more
likely to be supported than those of longer duration that
have recurrent costs or involve the purchase of equipment
(radios, vehicles).
• The technical endorsement and support of WHO and other
UN agencies.
A multisectoral preparedness component is also increas-
ingly included in loans negotiated in the aftermath of disasters.
Intended to strengthen the capacity of the civil protection
agency, the funding is no substitute for local political commit-
ment to assume recurrent expenses, the only guarantee of
sustainability.
Resources for Emergency Response. The amount of external
resources available for response, financial or material, is influ-
enced by the type of hazard, geopolitical considerations, and
the number of deaths (rather than that of survivors in need of
assistance). Funding is channeled mostly through humanitar-
ian NGOs, the Red Cross system, or multilateral organizations,
rather than through national governments. Consequently, the
priority of the health authorities, rather than to seek direct con-
tributions to the ministry, should be to ensure that health needs
are properly identified and adequately covered by those agen-
cies benefiting from the donations. Ministries of health often
can obtain indirect financial support for their own activities
through UN projects.
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Concentrating on several key factors will improve the flow
of external resources toward health priorities:
• Issuing a rapid and reliable assessment of what is needed and
what is not needed for the emergency response, rather than
waiting for a detailed assessment of the physical damage.
• Focusing on tomorrow’s emergency health problems.
External response is unable to address today’s short-lived
problems.
• Keeping a long-term view. Funding for emergency response
is limited to a few months, whereas the health problems
caused by the disaster will stay much longer. Projects should
offer sustained benefits beyond their conclusion.
• Recognizing shortcomings in governance when in contact
with the many bilateral fact-finding or assessment missions
coming to the disaster site.
Funding for Reconstruction. Funding for reconstruction is
multisectoral and is often coordinated by an international
financing institution (global or regional), together with a con-
sortium of large donor countries. The health sector will com-
pete with other social priorities and the “productive” sectors in
an arena where the health burden (measured in DALYs) does
not carry the same weight as economic factors. Success will
depend on an exhaustive monetary valuation of the health
damage, rapid formulation of projects, political support from
the country’s highest authorities, and technical support and
endorsement of specialized UN agencies and larger NGOs.
Funding for Mitigation of Damage. Protecting the national
capital investment of the health sector is primarily the respon-
sibility of the country at risk. Development agencies or finan-
cial institutions may contribute only marginally to the actual
cost of retrofitting installations or improving the design of new
facilities.
Modest funding for pilot or demonstration prevention pro-
grams may be available from both the humanitarian and the
development sources of donor countries. Humanitarian offices
may support promotion of the concept, development of guide-
lines or studies on vulnerabilities, and training.
The health sector will benefit from close contacts with
financial institutions, the ministry of foreign affairs, and other
national ministries. Negotiations to ensure that new installa-
tions are able to withstand disasters must be initiated at the
earliest opportunity, and the corresponding additional costs
should be considered in the earliest stages of the project.
IMPLEMENTATION OF CONTROL STRATEGIES:
LESSONS OF EXPERIENCE AND CHALLENGES
FACED
All countries in Latin America and the Caribbean have estab-
lished programs and structures for disaster risk management
within their ministries of health. Some lessons can be learned
from this process:
• The occurrence of a major disaster in the country or its
neighbor is the initial catalyst for health authorities to rec-
ognize that disasters represent public health risks that must
be addressed in an institutionalized manner.
• Access to and support from the political level has deter-
mined the success or failure in coordinating the external and
domestic health response.
• A multihazard program covering the entire health sector is
most effective. Assigning responsibility for coordination
and management among different technical departments
according to the type of hazard (chemical or natural, for
instance) does not work.
• A risk management program should cut across departments
(medical care, epidemiology, water supply, sanitation, nutri-
tion, and so forth) of the ministry of health and become sec-
tor wide.
• The synergy between normal development, preparedness,
and disaster response activities should be recognized.
Poor development practices increase vulnerability, whereas
preparedness improves the attention to daily health
challenges. Programs narrowly focused on operational
response have generally failed.
In Asia, the Asian Disaster Preparedness Center also has
documented some interesting experiences (http://www.adpc.
ait.ac.th/).
THE RESEARCH AND DEVELOPMENT AGENDA
Disasters in any one country are relatively infrequent. In addition
to being a dangerous temptation for the authorities to postpone
preventive actions, this infrequency is an impediment for
research and institutional memory.On one hand,the humanitar-
ian culture tends to raise ethical questions on the role of observers
at a time when action at all costs is expected. On the other hand,
few health academicians wish to embark on projects when con-
trol groups and time for advance planning are unavailable.
Particularly encouraging are the increased numbers of pub-
lications and guidelines by UN organizations and NGOs and
the trend toward organizing workshops on lessons learned a
few months after a major disaster. These meetings of national
experts and officials together with representatives from exter-
nal actors are invaluable for identifying and sharing opera-
tional or institutional successes and failures for the collective
benefit of other countries at risk.
Epidemiological Research
Most of the DALYs attributable to disasters occur immediately
at the time of the disaster. Epidemiological research should,
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therefore, complement engineering studies to design better
facilities and preparedness measures. After the initial disaster,
basic questions need to be answered: How many secondary
deaths and disabilities can actually be prevented by improving
search and rescue and trauma care? How critical is the time fac-
tor in reducing DALY losses and assessing the effectiveness of
foreign SAR and field hospitals teams? How can researchers
objectively assess the risk of outbreak following disasters? In
particular, how can they better differentiate between cases
attributable to increased transmission and those resulting from
improved surveillance and medical attention provided to the
victims? What is needed are data to put to rest unquestioned
assumptions and clichés. The alternative is to continue to divert
scarce resources away from routine disease control programs
and toward costly measures of doubtful effectiveness.
Strategic Research
Research is required that will compare the effectiveness of pre-
paredness and response strategies and approaches:
• With respect to preparedness, how should researchers assess
the effectiveness of training and coordination versus that of
investing in hardware and stockpiles? For instance, will the
accreditation of hospitals based on their safety and readiness
improve their disaster performance?
• With respect to mitigation, how should limited funding for
retrofitting health facilities be allocated? Is nonstructural
mitigation a workable alternative in the absence of struc-
tural measures?
• With respect to response, what is the effect of international
assistance in terms of reductions in DALY losses that could
not be achieved locally? Is it contributing to strengthening the
capacity of the developing countries? What type of humani-
tarian assistance has proven to be development friendly?
• Finally, how should researchers measure the effectiveness
of preparedness or mitigation given the unpredictability of
disasters?
Economic Research
Humanitarian response is resistant to concepts of cost-
effectiveness. Economists should contribute to the comparative
study of the immediate and long-term effects of external inter-
ventions versus less costly alternatives such as relying on local
resources and building local capacity. A cost-benefit analysis of
international medical interventions prior to and during a
disaster situation is also overdue.
Economic assessment of the damage to the health sector
remains focused on physical losses and fails to sufficiently
consider the broader burden on a society caused by the loss of
health services over a sustained period. Refining the existing
methodology and developing quantitative indicators to esti-
mate those indirect costs should be a research priority.
CONCLUSIONS
Natural hazards are not likely to decrease in the foreseeable
future. Though geological events may occur independently of
any human control, available data suggest that mankind plays a
role in global climate. Technological hazards may also increase
rapidly as a result of the unregulated development of industries
in most countries and possibly the use of weapons-grade haz-
ardous substances against civilian populations. An increase in
the number of hazards should not mean that the resulting
health burden will also increase. A sustained effort is needed to
minimize risk, both by reducing vulnerability through preven-
tion and mitigation and by increasing capacity through pre-
paredness measures.
A Strategic Approach
The prime objective of a developing country is to develop.
Emergencies and disasters have proven to be major obstacles
and setbacks in the path toward sustainable development.
Conversely, the shortcomings in development programs and
institutions reduce the effectiveness of the health response in
times of crisis. Development and disaster risk management
cannot be addressed separately. Reducing risk is not a luxury
reserved for more developed societies; it is a necessity in coun-
tries with fragile economies and health systems. It is clearly a
public health priority.
Disasters, as any other public health problem, need to be
addressed on a long-term and institutionalized basis through
the establishment in the ministry of health of a program or
department for prevention, mitigation, preparedness, and
response for all types of disasters. Trends in Latin America sug-
gest that such an approach in the context of sustainable devel-
opment contributes to narrowing the gap in disaster-related
deaths and disabilities (as measured by DALYs) between indus-
trial and developing countries.
Disaster risk reduction is not merely a health issue. The eco-
nomic and political dimensions should not, however, be
allowed to overshadow the fundamental fact that disasters are,
above all, human tragedies incompatible with the definition of
health adopted by the WHO constitution. On one hand, the
health sector should adapt and use the methodology of eco-
nomic valuation of disaster impact as developed by ECLAC; on
the other hand, the financial world should also learn to give
equal consideration to the health burden (DALYs) in its deci-
sion making for development or reconstruction. For this to take
place, health and humanitarian actors need to dramatically
improve the availability of data.
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Disaster risk reduction is not the exclusive domain of a few
experts or officials. It is the collective responsibility of all disci-
plines and programs in the health sector, as well as a remark-
able tool or gateway for collaboration with other sectors. Alone,
the ministry of health cannot reduce the health burden or play
its coordinating role in the response.
Disaster risk reduction is unlikely to produce immediate
results. It requires sustained commitment over the years.
Learning from Errors 
Learning from past disasters is difficult. At a national level, the
relatively long periods between major disasters result in few
decision makers having prior disaster management experience.
At an international level, the frequent turnover of relief work-
ers ensures that many of the actors are relatively inexperienced
and susceptible to adopting myths and clichés, which are rarely
challenged by the media and the academic world. It is time for
an international initiative to identify the best practices, and it is
time for affected countries and scientists to point out the inad-
equacies of responses.
Humanitarian health interventions, as any other health
intervention, should be subject to cost-benefit reviews that
compare their benefits in terms of DALY loss reduction to
other alternatives, including a possible shift of international
emphasis from immediate medical response to preparedness or
rehabilitation projects.
Local health services are best situated to address the health
consequences of disasters. They should be better prepared to
do so. A formalized mechanism to transmit and share those les-
sons learned from past errors and to build the response capac-
ity is required in the health sector.
Finally, the greatest potential for saving lives is in reducing
the risks and the vulnerability through better infrastructure,
land-use management, public awareness, and training.
The challenge in risk reduction is to sustain public support
and political will in periods of calm. International organiza-
tions—WHO in particular—have a unique and critical role to
play as advocates for a long-term approach to disaster risk
management in the context of sustainable development.
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NOTES
1. In a nonnatural phenomenon, such as the attacks in New York on
September 11, 2001, a similar risk has been detected and is perceived as a
remnant potential long-term health risk similar to the effect of air con-
tamination from ash from volcanoes.
2. Evidently these direct losses are not easy to determine in long-
developing events (such as the ones associated with slow processes or
climatic variability), because over time there will be overlapping damage,
in contrast to the damage that occurs in sudden events such as hurricanes
or earthquakes.
3. Data came from reports of the UN Office of Coordinator for
Humanitarian Affairs (http://www.reliefweb.org), supplemented by
authors’ estimated costs for donors that did not report actual costs.
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Eradication of an infectious disease is an extraordinary goal. Its
possibility became apparent as soon as Edward Jenner demon-
strated an ability to provide immunity to smallpox. Writing in
1801, Jenner observed that, through broad application of vac-
cination, “it now becomes too manifest to admit of controversy
that the annihilation of the Small Pox, the most dreadful
scourge of the human species, must be the result of this prac-
tice” (Jenner 1801). Louis Pasteur claimed that it was “within
the power of man to eradicate infection from the earth” (Dubos
and Dubos 1953). And yet, by and large, public health has pro-
ceeded with more modest goals of local and regional disease
control. Notable successes have occurred. Indeed, some dis-
eases now thought of as “tropical” were previously endemic in
temperate climates. Systematic application of hygiene, sanita-
tion, environmental modification, vector control, and vaccines
have led, in many countries, to the interruption of transmission
of microbes causing such diseases as cholera, malaria, and
yellow fever.
Intensive efforts to eliminate breeding sites of the yellow
fever mosquito vector, Aedes aegypti, interrupted transmission
of this disease in Havana in 1901 and throughout Cuba soon
thereafter. Subsequently, yellow fever and malaria were able to
be controlled in Panama, thus permitting construction of the
Panama Canal. In 1915, the Rockefeller Foundation launched
an effort to eradicate the disease worldwide. Transmission
appeared to have ceased in the Americas by 1928, but then cases
reappeared, and by 1932, it became clear that a nonhuman
endemic focus was serving to reinfect areas otherwise free of
yellow fever. In the 1930s, F. L. Soper set out to eradicate the
Aedes aegypti vector from the Americas. By 1961, Soper reported
that he had largely succeeded except for the United States, where
the program received little support. By the 1980s, Aedes aegypti
had become reestablished in Central and South America.
In 1953, Brock Chisholm, the first director-general of the
World Health Organization (WHO), tried to persuade the
World Health Assembly (WHA) to undertake smallpox eradi-
cation, but a number of countries objected on the grounds that
eradication was not technically feasible. Instead, in 1955,
under the leadership of his successor, Marcolino Candau,
WHO began a global effort to eradicate malaria primarily by
means of household spraying of DDT. The relatively sophisti-
cated science of malaria control was abandoned in favor of this
simplistic technology (Jeffrey 1976). Despite an expenditure of
more than US$2 billion, the effort failed.
Even while the malaria eradication effort was under way, the
Soviet Union, in 1958, proposed to the WHA that smallpox be
eradicated. A resolution to this effect was offered in 1959 and
passed unanimously. However, the resolution provided little
international funding or support. Over the next seven years,
disease transmission was interrupted in some 30 countries in
Africa, Asia, and South America, but endemic smallpox per-
sisted in the Indian subcontinent, Indonesia, most of Sub-
Saharan Africa, and Brazil. WHO launched an intensified effort
in 1967 to eradicate the disease within a decade. This new
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We cannot refrain altogether from examining the roots of this controversy if only because the extreme views for and 
against eradication have exerted and are still exerting a . . . highly detrimental influence on public health practice.
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resolution included an annual budget of US$2.4 million, to be
paid according to the WHO scale of assessments. The resolu-
tion passed by the narrowest of margins, but a reinvigorated
effort was soon under way and paved the way for a historic
public health achievement (Henderson 1988). Following an
extraordinary worldwide effort, the last case of smallpox was
isolated in October 1977, and the disease was certified as being
eradicated in 1979, 170 years after Edward Jenner first dreamed
of that possibility. Understanding how and why smallpox
eradication succeeded is essential to the study of control and
eradication.
The smallpox success was inspirational, even though the
leaders of WHO’s smallpox eradication effort cautioned that,
among all the diseases that might be considered candidates for
eradication, smallpox was unique (Fenner and others 1988)
and that they foresaw no other disease as a candidate for eradi-
cation (Henderson 1982). At a meeting convened by the
Fogarty International Center of the National Institutes of
Health in 1980, scientists, public health officials, and policy
makers discussed the merits of eradicating other diseases, with
schistosomiasis, dracunculiasis, poliomyelitis, and measles
identified as possible candidates (Henderson 1998a). However,
no consensus was reached at that time on moving forward with
any of those diseases.
Poliomyelitis became the next principal target when mass
vaccination campaigns, proposed by Albert Sabin (1991),
proved remarkably successfully in Cuba and Brazil. In 1985,
an American Health Organization coordinated campaign was
launched to interrupt poliovirus transmission in the Americas
by 1991, and this effort succeeded. Some believed that global
eradication might be possible, although others were concerned
that the far less developed infrastructure of health, transporta-
tion, and communications services in many parts of Asia and
Africa would make it an unachievable task. In 1988, the WHA
adopted a resolution to eradicate polio, but at that time, a
longer-term strategy for ending polio vaccination was neither
formulated nor agreed on by the public health and scientific
community.
The WHA has adopted only one other resolution to eradi-
cate a disease—guinea worm, or dracunculiasis. The eradica-
tion of this disease can be achieved by applying simple tech-
nologies for providing water that is free of the vector copepod
and parasite and for treatment of patients with the disease. This
eradication program has made steady progress but has been
hampered in part by civil and political unrest and lack of pro-
gram priority because of low mortality and low incidence in
some remaining endemic areas. However, given the environ-
mental restriction of the parasite to rural tropical areas and its
relatively low transmissibility, eventual global eradication
seems within reach.
One other case—that of measles—is worth noting. A num-
ber of public health authorities have raised the possibility of
eradicating that disease. In the Americas, spurred on by the
success of regional cessation of transmission of wild poliovirus,
eventual consensus was reached to intensify measles control
efforts, primarily through surveillance and periodic pulse
application of measles vaccine in national campaigns. As a con-
sequence, transmission of measles virus was temporarily inter-
rupted in the Americas on several occasions but reestablished
again by importations (CDC 1998a). Although the U.S. Centers
for Disease Control and Prevention (CDC) and WHO have
advocated extending measles “elimination” through vaccina-
tion campaigns and second-dose opportunities to other
regions (Biellik and others 2002; CDC 1998a, 1998b, 1999a,
1999b, 2003d, 2004b, 2004d, 2004f), the intensive control
efforts required to break transmission of this highly infectious
agent make global eradication unlikely at this time.
DEFINITIONS
Yekutiel (1980, 5–8) provides an excellent treatise on the con-
cept of eradication, which includes a summary of the multiple
definitions that have been formulated (Andrews and Langmuir
1963; Cockburn 1961, 1963; Payne 1963a, 1963b; Spînu and
Biberi-Moroianu 1969). A conference devoted to eradication
held in Dahlem, Germany, in 1997 (Dowdle and Hopkins
1998) set out to provide precise definitions for control, elimina-
tion, eradication, and extinction in a biological, economic, and
political context (Dowdle 1998, 1999; Ottesen and others
1998); however, a number of eminent public health officials
(Cochi and others 1998; de Quadros 2001; Goodman and
others 1998b; Henderson 1998b; Salisbury 1998) challenged
these definitions at two subsequent meetings at the CDC
(Goodman and others 1998a, 1998b) and the U.S. Institute of
Medicine (Knobler, Lederberg, and Pray 2001).
Unfortunately, broadly accepted, standard definitions for
key concepts pertaining to disease control and eradication do
not exist in the literature. Making matters more confusing,
certain of the concepts have been given names that are part of
our everyday language and so are easily misinterpreted by non-
specialists as meaning something different from the meanings
understood by those who are preoccupied with eradication
programs. Most unfortunate is the all too casual use of the
words elimination and eradication to promote programs that
cannot reasonably be expected to achieve the promise implicit
in these words. Moreover, the two words themselves are com-
monly used interchangeably.
Control
Two concepts are central to this chapter: control and eradica-
tion. By control, we mean a public policy intervention that
restricts the circulation of an infectious agent beyond the level
that would result from spontaneous, individual behaviors to
protect against infection (Barrett 2004).
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Although control is a range rather then a level, a particular
level of control may be an aim of policy. Because every choice
entails consequences, choice of the “optimal” level of control
requires economic analysis. Optimal here is defined in relation
to the model that gives rise to the result. Control is local and so
needs to be looked at from the local perspective. Because one
country’s (or region’s) control may affect other countries
(regions), a global perspective exists as well. The level of con-
trol that is optimal for one country (region) may not be opti-
mal from the perspective of the world as a whole. Thus, a need
exists to distinguish between, say, a locally optimal level of con-
trol and one that is globally optimal.
Finally, control requires ongoing intervention. Sustaining a
given level of control requires an annual expenditure.
Eradication
Eradication differs from control in that it is global. The term
denotes the certified total absence of human cases, the absence
of a reservoir for the organism in nature, and absolute contain-
ment of any infectious source. Eradication permits control
interventions to stop or at least to be curtailed significantly.
Finally, eradication is binary. Control levels can vary, but a
disease is either certified as eradicated or not.
Every disease can be controlled, even if only by using simple
measures, such as quarantine. The ultimate achievement of
control is eradication. But not every disease that can be con-
trolled can be eradicated. Very few diseases, in fact, are poten-
tial candidates for eradication. The criteria for the feasibility for
eradication as a preference over control are discussed in the
section titled “Economic Considerations.”
Elimination
Control and eradication are the essential concepts, but two
other terms bear mention. The first is elimination. Some who
are concerned with eradication programs have explicitly
defined this term to denote the cessation of transmission of an
organism throughout a country or region. In contrast, eradica-
tion is defined as a global achievement. Like control, elimina-
tion is location-specific and would require ongoing interven-
tions to be sustained in order to prevent reemergence of the
disease from microbe importations.
Two problems exist with the term elimination. First, it has
been used to describe different phenomena, not just that
described in the definition given above. For example, some
public health officials have promoted programs aimed at “elim-
inating a disease as a public health threat,” which is interpreted
to mean reducing incidence to an “acceptable” level but not
necessarily to zero. This usage is very different from the one
outlined above and is almost certain to be misunderstood.
Second, the definition of the word elimination in common use,
as applied to disease control, is indistinguishable from eradica-
tion. The 1993 edition of the New Shorter Oxford English
Dictionary, for example, defines eliminate as to “remove, get rid
of, do away with, cause to exist no longer.” This same diction-
ary defines eradicate as “pull up or out by the roots, uproot,
remove or destroy completely, extirpate, get rid of.” This ambi-
guity invites misunderstanding among those not intimately
involved in an eradication effort. For purposes of clarity, we sel-
dom use the term elimination in this chapter and then only to
signify control measures sufficient to interrupt microbe trans-
mission in a specified area.
Extinction
Finally, the literature sometimes refers to extinction as a possi-
ble policy goal. In the context of infectious disease control, the
concept is problematic for two reasons. First, proving that an
organism has become extinct is impossible. To do so would
require demonstrating not only that the organism no longer
exists in nature but also that it no longer exists in any con-
trolled environment—a practical impossibility. Second, de
novo synthesis of viral agents from published genomes
(Cello, Paul, and Wimmer 2002) now put the concept in peril,
although much research remains to be done in this area.
Extinction, in the context of infectious diseases, may no longer
be irreversible.
Clearly, policy making will be improved by stating the goal
of any particular intervention in precise language.
FRAMEWORKS FOR ERADICATION
Numerous issues need to be considered in planning expanded
control measures that lead, possibly, to regional cessation of
transmission or global eradication of disease. These complex
issues will be further examined in the chapter.
Scientific Considerations
Scientific considerations include the nature of potential reser-
voirs for disease-causing microbes or their vectors, technolo-
gies available for interrupting disease transmission, changes in
host capabilities to deter infections and disease, and satis-
factory containment of organisms in laboratories.
Geographic and Environmental Controls. The limit of
endemicity for microbes and their associated diseases is deter-
mined in part by their ability to exist in nature outside the
human host. Both geographic and temporal variations deter-
mine the ecological niche of microbes, resulting in variable
annual incidence rates throughout the world. This niche limi-
tation is further extended to intermediary vectors and hosts in
complex biological systems. Natural environmental barriers
also may isolate the habitats of helminths. Infectious agents that
are not limited to an environmentally restricted intermediary
host or those that have longer latent periods, thereby allowing
translocation, may have a global pattern of distribution.
Examples include the highly transmissible viral agents such as
measles, rubella, influenza, and varicella. Although these agents
are not geographically constrained, their transmission patterns
are directly and indirectly influenced by seasonal environmen-
tal factors and population-based immunity.
Potential Reservoirs. A microbe and associated disease can
not be eradicated if the microbe is capable of persisting and
multiplying in a reservoir. Microbes that thrive in nonhuman
species may reemerge if control efforts cease, thus leaving
human populations susceptible. Similarly, if the infectiousness
of a human is long lived or could lead to potential recrudes-
cence, surveillance efforts would have to continue as long as the
last individual remained potentially capable of transmitting
infection, as would be the case with tuberculosis or hepatitis B
infection.
Transmissibility. The inherent rate of a microbe’s ability to
cause secondary infections is defined by an organism’s repro-
ductive rate in a fully susceptible (R0) and partially susceptible
(R) population. The reproductive rate of organisms that infect
individuals only once because of durable immunity is inversely
proportional to the average age of infection in an endemic
area. Agents that cause childhood infections, such as viral res-
piratory agents, are far more transmissible than helminths and
subsequently require more intensive control efforts to interrupt
transmission.
Natural Resistance to Reinfection. Many natural infections
induce long-lived immunity to reinfection. Although the most
commonly used vaccines have been available for fewer than
50 years—less than the lifetime of an individual—they, too, are
assumed to offer long-lasting immunity. Because eradication
depends on reducing susceptible populations in potentially
endemic areas, long-lived protection through immunization or
natural disease is important to successful programs.
Laboratory Containment. Laboratory specimens containing
the organism targeted for eradication could serve as reservoirs.
Considerable effort may be necessary to ensure their maximum
security. That these microbes may be inconspicuous in speci-
mens collected for other purposes poses special challenges.
This situation is especially true for the poliomyelitis virus,
which may be found in many stool specimens collected for
studies completely unrelated to current poliomyelitis eradica-
tion efforts.
Operational Considerations
Optimization of control requires a fundamental appreciation
of the biological systems that govern the ecology of microbes
and their intermediary and human hosts. The reproductive
rate, R, is influenced by many local factors, including popula-
tion density (of vectors, intermediary hosts, and humans) and
other environmentally determined conditions, all highly vari-
able throughout the world. For a disease to be controlled to
stop transmission, the intervention-altered reproductive rate
must be maintained below 1.0. At the same time, all reservoirs
of the responsible microbe must be controlled.
Three main components of possible eradication programs
are 
• surveillance, including environmental sampling where
appropriate and clinical testing
• interventions, including vaccination and chemotherapy or
chemoprophylaxis or both
• environmental controls and certification of eradication.
Each of these components must be undertaken at local,
community, national, regional, and global levels. Eradication
differs from control in that it is expected to be permanent.
Success depends on having adequate surveillance to identify
potentially infectious persons and on stopping transmission
before infection of a new cohort of susceptible persons arises
as a result of births, migration, or the waning effectiveness of
prophylactic measures.
Disease Surveillance. Effective surveillance requires a sensitive
system to detect the presence of microbes within the environ-
ment, intermediary hosts, and clinical cases. Surveillance and
response systems need to be more efficient than the rate of trans-
mission of the targeted agent.As eradication progresses, the sen-
sitivity of detection systems must be steadily enhanced to detect
all existing foci. Nonclinical or latent infections pose formidable
barriers to eradication efforts. Operationally, the need for near-
perfect sensitivity comes at the expense of lower specificity.
Thousands of skin lesions from suspected smallpox patients
were tested in reference laboratories during confirmation of
smallpox eradication, and tens of thousands of stool specimens
are being examined for poliovirus. Highly sensitive systems used
to detect measles cases in theAmericas began to identify a greater
proportion of rubella and parvovirus infections because of the
nonspecific surveillance of rash illness. Such findings are impor-
tant because the identification of other diseases that mimic the
targeted disease can lead to a misdirection of resources.
However, the ability to detect such similar clinical cases can serve
as a proxy measure for the adequacy of surveillance. For exam-
ple, identification of a minimum incidence of cases of acute flac-
cid paralysis that is not related to polio has served as an indicator
of adequate efforts of case finding for polio.
Interventions. Interventions to block transmission of the tar-
geted infectious agent should be easy to deploy and adaptable
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to diverse conditions, given the global goal of eradication. Cost
considerations and local acceptance of the required sacrifices
(both short and long term) are crucial for success.
Interventions may be designed for environmental control of
microbes, isolation (quarantine) of clinically infectious indi-
viduals to limit their contacts with susceptible persons, treat-
ment of clinical cases to limit the duration of infectiousness, or
reduction in the infected pool of individuals through immuno-
or chemoprophylaxis.
Certification. The last tool for eradication is a certification
process whereby independent, respected parties certify the
absence of disease transmission or the existence of any specific
microbe in an uncontrolled reservoir, including laboratories
(Breman and Arita 1980). Although certification can be
implemented on a regional basis, it must ultimately be done
globally. Certification is one of the greatest challenges in any
eradication effort, given the exceedingly great difficulty of ver-
ifying a negative finding in a reasonably short period of time.
When certification is completed, curtailment of control meas-
ures should be possible.
Strengthening control efforts sufficiently to achieve eradica-
tion is a difficult and expensive task. It requires that scaling up
of such efforts occur over a wide area—at the community,
national, regional, and global levels. Its efficacy depends heavily
on the adequacy of local financial and human resources, as well
as on a broad range of logistical factors.
Economic Considerations
Control and eradication programs have many economic
dimensions: private versus social net benefits, short-term ver-
sus long-term net benefits, and local versus international net
benefits. Such interventions also have implications for existing
public health programs.
Private versus Social Net Benefits. Individuals have private
incentives to protect themselves from disease—by means of
vaccination, for example. But when individuals protect
themselves—when they elect to be vaccinated—they offer a
measure of protection to others by helping limit the spread of
infection. In brief, the social benefit of vaccination is greater
than the private benefit alone. As more people become vacci-
nated, the marginal private and social benefit of vaccination—
that is, the benefit of vaccinating an additional susceptible
person—declines. The marginal private benefit is likely to fall
because, as more people are vaccinated, the probability of a sus-
ceptible person becoming infected falls. The marginal social
benefit is likely to fall for the same reason and for one other: as
more people become protected, the total number of susceptible
persons falls. The marginal social benefit of vaccination falls
sharply at the critical level of immunization—the level at which
herd immunity is conferred on all susceptible persons. When a
population is immunized to this level, a disease ceases to be
endemic, and imported infections cannot spark an epidemic.
This level is determined by the epidemiology of a disease,
but whether it pays to vaccinate to this level depends on the
economics, and the economics depend in turn on the social
costs and not only the social benefits of vaccination. These
costs consist of the direct costs of producing, distributing, and
administering a vaccine. The economics depend also on the
costs borne by the individuals who are vaccinated, such as those
incurred by individuals who experience vaccine complications.
The proportionate costs of reaching people who live in remote
areas and those who are at special risk, such as migrants and the
homeless, increase as the fraction of the population vaccinated
increases.
The economics of varying levels of disease control depend
on the relationship between the marginal social benefits and
the marginal social costs of vaccination. As vaccination levels
increase, the marginal social benefits of vaccination fall, where-
as the marginal social costs rise. Social welfare is maximized
where these two relations intersect, which might be called the
“optimal” level of vaccination—a level that may or may not
achieve cessation of transmission or eradication.
Short-Term versus Long-Term Net Benefits. Control pro-
grams require ongoing intervention. Sustaining a given level of
protection requires that, over time, a certain proportion of new
susceptible persons be vaccinated. Eradication differs from
control in being permanent. The economics of eradication
must therefore take account of long-term benefits as well as
short-term costs.
The long-term benefits of eradication consist of avoided
future infections and vaccination costs—a dividend. To calcu-
late this benefit, one projects future infection and vaccination
levels in the absence of eradication, attaches values to these,
and discounts them. If this sum exceeds the costs of eradica-
tion, then eradication enhances social well-being, and it there-
fore should be undertaken.
In deciding on the benefits of eradication, the cost of future
infections and vaccination should ideally be compared with the
best alternative to eradication: the level of optimal control
(Barrett and Hoel 2003).
The costs of eradication must also take into account ongo-
ing surveillance requirements, laboratory containment, and
perhaps the maintenance of stockpiles of vaccine in the chance
event of disease reemergence. From an economic perspective,
attractive candidates for eradication are those diseases that
some countries have themselves targeted for interruption of
transmission nationally or regionally.
Local versus International Net Benefits. Control differs from
eradication in another important way. Control refers to
location-specific interventions. Eradication, by contrast, is
global. In economic terms, eradication is a global public good.
No country can be excluded from the benefit of eradication,
and no country’s consumption of that benefit diminishes the
amounts available to other countries. Control, by contrast,
supplies only a local public good.
Eradication requires a global effort. A disease can be eradi-
cated only if microbe transmission ceases everywhere. This
spatial dimension to eradication is of fundamental importance
because no world government can implement an eradication
policy; the WHA can declare its support for eradication, but
WHO does not have the power to enforce the execution of a
national program in support of that goal. The outcome experi-
enced by any country depends not only on whether the coun-
try itself eliminates the disease within its borders but also on
whether all other countries do so. Indeed, eradication is a
weakest-link public good.
Whether eradication is achieved depends on the level of
control adopted by the country that undertakes the least
control. In practical terms, any country in which disease is
endemic can prevent eradication from being achieved. In 2004,
the global polio eradication initiative, after investing more than
US$3 billion and involving some 20 million volunteers over a
period of 16 years, was placed at risk of failure by the actions of
one local administration. In the Kano state of Nigeria, local
leaders claimed that the polio vaccine was tainted with the
AIDS virus and sterility drugs and declined to participate in a
national immunization day program. The European Union
then declined to pay for the national program in Nigeria,
believing the money would be wasted (Roberts 2004). One
consequence was the subsequent spread of polio to nine for-
merly polio-free countries. Concerted efforts by WHO later
persuaded local leaders in Nigeria to rejoin global efforts, but
special vaccination programs had to be launched over a popu-
lation area of more than 300 million persons. This situation
dramatically illustrated the vulnerabilities inherent in a
weakest-link public good.
What are the incentives for states to participate in an eradi-
cation effort? To begin, assume that countries are symmetric,
meaning that all countries have the same benefits and costs of
control. Assume as well that eradication is feasible. Four possi-
ble situations then exist (Barrett 2003):
• First, the global net benefit of eradication may be negative—
the cumulative programmatic costs outweigh the net pres-
ent value of the cumulative benefits. In this case, elimination
would also yield a negative net benefit to every country, and
so no country would eliminate the disease.
• Second, the global net benefit of eradication may be so large
that each country would choose to eliminate the disease
even if others did not. In this case, all countries would
eliminate the disease, and the disease would therefore be
eradicated. In these two cases, no need exists for an interna-
tional policy.
• Third, each country may have an incentive to eliminate a
disease only if all other countries have eliminated it. In this
case, achieving global eradication requires coordination.
Here a role exists for international policy, but all that is
required is for each country to be assured that all others will
eliminate the disease.
• Finally, and noting that the “last” country to eliminate a dis-
ease would get just a fraction of the global dividend from
eradication, under some circumstances no incentive may
exists for this country to eliminate the disease—even if all
other countries have done so and even if the entire world
would be better off if it did. This case is the most worrisome,
because implementation of the efficient outcome would
likely require enforcement.
All this hypothesizing assumes that countries are symmet-
ric, and of course they are not. Some countries gain less from
control and would gain less from eradication than others. Some
are unable to implement an elimination program, even if they
would very much like it to succeed. In these situations, achiev-
ing an eradication goal will require international financing and
technical assistance, with the countries that benefit most from
eradication compensating the other countries for the costs of
eradicating the disease. National and international reproach
are often expressed if a country lags in its eradication efforts.
International financing has been a key element in all eradica-
tion programs.
We have thus far looked at eradication from the perspective
of only the self-interests of states. But eradication also has
implications for development. In particular, eradication has
two advantages over control programs. The first is that the rich
countries may gain directly if the goal is achieved, giving them
a vested interest in ensuring that the goal is achieved. The sec-
ond is that eradication is permanent, making an investment in
eradication financially sustainable. This second advantage is
important because financial sustainability has proved to be a
key problem for disease control programs in developing coun-
tries (Kremer and Miguel 2004).
Vertical versus Horizontal Programs. Control and eradica-
tion programs cannot be viewed in isolation. All programs have
implications for the delivery of comprehensive primary care
services. An important question is whether targeted, or so-
called vertical, programs draw critical resources away from
other health care programs or whether they serve instead to
augment competence and capacity. The evidence is mixed.
Evidence suggests that disease-specific systems can serve
to expand polyvalent services (Aylward and others 1998).
Smallpox eradication, for example, gave many national govern-
ments the confidence to introduce the Expanded Program on
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Immunization, with the ability to deliver vaccines and
micronutrients in routine schedules and through national cam-
paigns. However, other evidence suggests that some vaccination
programs have adversely affected primary health services
(Steinglass 2001; Taylor, Cutts, and Taylor 1997) and may have
even increased costs. Implementation of international initia-
tives can also expose conflicts of priorities. The polio eradica-
tion initiative, for example, has successfully vaccinated children
in the poorest of countries against this disease, but in some
of these countries it has failed to timely include the co-
administration of measles and other common childhood vac-
cines, which would have had a much greater effect on child
mortality.
DISEASE-SPECIFIC CASE STUDIES 
In this section, we apply the reasoning developed previously to
provide an empirical analysis of the three most recent eradica-
tion programs—smallpox and the two ongoing programs,
poliomyelitis and dracunculiasis.
Smallpox
As noted before, smallpox eradication was achieved in October
1977, 11 years after the intensified program began. Following
implementation of a rigorous certification procedure, the
WHA declared smallpox eradicated in 1980.
Fenner and others (1988) have estimated the annual bene-
fits of smallpox eradication to developing and industrial coun-
tries (see table 62.1). These aggregate estimates, obtained by
prorating estimates of the benefits of eradication for India and
the United States to all developing and industrial countries,
respectively, suggest that developing countries benefited
more from smallpox eradication than industrial countries.
Qualitatively, a consistent picture emerges: smallpox eradica-
tion was not only an extraordinary investment for the world; it
was also an investment that benefited every country, rich and
poor alike.
When the eradication effort began, smallpox was no longer
endemic in most industrial countries. Nonetheless, these coun-
tries needed to maintain populationwide immunity under the
threat of possible imported cases from endemic countries.
They would gain from eradication not only through the cessa-
tion of vaccination and its associated costs but also by being
able to decrease the number of quarantine inspectors at ports
of entry and by averting costs of care related to the adverse
events from this live vaccine.
The still-endemic countries would also save vaccination
costs, although most were vaccinating only a comparatively
small proportion of their populations. The greater benefit to
them was the avoided cost of disease, including the extraordi-
nary death toll. A number of developing countries had
accorded smallpox prevention a high priority, as was evidenced
by the number that succeeded in interrupting transmission
without international assistance. This list includes China,
which was not a member of WHO at the time the eradication
effort commenced.
Indeed, and as shown in table 62.1, the still-endemic coun-
tries contributed an estimated two-thirds of the US$298 mil-
lion cost of eradication. International sources funded the
balance. If the latter cost is interpreted as the incremental cost
of achieving eradication, the benefit-cost ratio of global small-
pox eradication was over 450:1, a singularly high figure. Even
including the expenditure by endemic countries, the benefit of
eradication exceeded the cost by an unusually large amount.
Brilliant (1985) calculated the annual costs of the smallpox
eradication campaign for India to be about US$17 million per
year, including indirect costs (lost productivity caused by
adverse reactions to vaccination) and opportunity costs (health
workers being diverted from other programs). These costs were
only a fraction of the annual benefits of eradication to India,
which, by Brilliant’s calculations, were US$150 million. The
benefit estimates by Fenner and others (1988) are much larger,
and those of Ramaiah (1976) are smaller, but all three studies
draw the same (qualitative) conclusion: smallpox eradication
was a good investment for India. Basu, Jezˇek, and Ward (1979,
312) present estimates identical to those in Ramaiah (1976),
but without giving attribution.
Originally, India had decided to undertake a smallpox pro-
gram just one month after the WHA voted to eradicate the dis-
ease globally in 1959. The attempt failed, however, largely for
administrative reasons (Basu, Jezˇek, and Ward 1979; Brilliant
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Table 62.1 Benefits and Costs of Smallpox Eradication
(Millions of U.S. dollars)
Annual amount
Beneficiary
India 722
United States 150
All developing countries 1,070
All industrial countries 350
Total annual benefit 1,420
Expenditure
Total international, on eradication 98
Total national, by endemic countries 200
Combined total, on eradication 298
Benefit-cost ratio
International expenditure 483:1
Combined total expenditure 159:1
Source: Adapted from Fenner and others 1988.
1985; Fenner and others 1988). Essentially, India had an
economic incentive to control smallpox on its own (Brilliant
1985, 33) but lacked organizational capacity and an effective
strategy for achieving this goal. Note, however, that India had
other health priorities, including family planning. According to
Brilliant (1985, 33), “for India’s health planners, occupied then
by emergencies and competing political demands on scarce
resources, the long-term benefits from disease eradication were
not a great motivation. Health planners are sensitive to imme-
diate political realities, and the benefits of smallpox eradication
would be realized only at some future time when the $3 million
annual expenditures for smallpox could be applied to other
health problems. In the meantime, however, the cost of putting
so many scarce resources into one program rather than into
many health needs was high.”
Table 62.2 provides estimates of the benefits of smallpox
eradication to the United States. The total benefit of eradica-
tion to the United States is about the same order of magnitude
as India’s, but the breakdown is different. Whereas India
benefited mainly from avoided infections, the United States
benefited mainly from avoided vaccinations. By the time the
eradication program was launched, the United States had
already interrupted smallpox transmission, but vaccination
was costly, both in economic and human health terms (a small
number of people died every year from infections arising from
the live vaccine). Defending the nation from imported
infections imposed additional costs.
In health terms, smallpox eradication saved millions of lives;
in economic terms, it yielded a benefit many times greater than
the cost. Identifying another investment that has yielded com-
parable returns and has benefited every country is difficult.
One reason that the economics of smallpox eradication were so
favorable is that all countries had strong incentives to join in
the eradication of the disease. A huge organizational effort, but
only a relatively small incremental cost, was needed to achieve
eradication. The specter of global terrorism has recently caused
some countries to prepare themselves for a possible smallpox
attack by stockpiling vaccine. Although such actions reduce the
benefits of eradication, the economics remain favorable.
Smallpox, however, was a special case. Many attributes of
the disease and the vaccine favored eradication. The vaccine
was heat stable and required only a single dose to protect a per-
son for a period of at least 5 to 10 years. Vaccination was easily
performed and protected immediately on application. Every
individual who became infected exhibited a typical, easily rec-
ognized rash, thus permitting accurate surveillance without
recourse to laboratory diagnosis. The disease spread slowly so
that transmission could readily be stopped by isolating the
patient and vaccinating contacts within the area.
Poliomyelitis
The polio eradication program, launched by the WHA in 1988,
has made substantial progress (CDC 2003a, 2003b, 2003c,
2004a, 2004c, 2004e, 2004g, 2005). The incidence of paralytic
poliomyelitis in children fell by more than 99 percent, from an
estimated 1,000 cases per day worldwide in 1988 to fewer than
4 cases per day in 2003. The number of poliomyelitis-endemic
countries also fell, from 125 in 1988 to just 6 by 2003
(Afghanistan, the Arab Republic of Egypt, India, Niger, Nigeria,
and Pakistan). This laudable reduction was the result of
repetitive vaccination campaigns with easily administered oral
polio vaccine to whole regions, to nations, and to large sub-
populations.
During 2004, however, polio immunization activities in
northern Nigeria were halted for an extended period for fear
of tainted vaccines, and this permitted the development of epi-
demics extending throughout the country. The disease spread
as well to 10 other African countries and to Saudi Arabia,
Yemen, and Indonesia. Transmission has again been reestab-
lished in several African countries (Burkina Faso, Central
African Republic, Chad, Côte d’Ivoire, and Sudan). Heroic
efforts are being made to control these outbreaks by large-scale
immunization, but in countries such as these, where health
services are stressed and the health, communication, and trans-
portation infrastructures are weak, disease transmission is dif-
ficult to interrupt. Meanwhile, other countries throughout the
world that appear to be polio free are continuing their vaccina-
tion programs but finding it increasingly difficult to maintain
a momentum of interest, effort, and financing.
The difficulties of maintaining credible surveillance systems
throughout the developing countries were vividly demon-
strated by the discovery of polio in Sudan in May 2004, more
than three years after the last case had been reported (CDC
2005). In the interim, specimens from 75 to 90 percent of such
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Table 62.2 Benefits of Smallpox Eradication to the United
States, 1968
(Millions of U.S. dollars)
Amount
Direct costs for medical services
Vaccination 92.8
Treatment of complications 0.7
Indirect costs, loss of productivity
Work losses attributable to vaccination and reactions 41.7
Permanent disability attributable to complications 0.4
Premature death 0.1
Cost of international traffic surveillance and delays in 14.5
clearance of vessels
Total 150.2
Source: Sencer and Axnick 1973; see also Fenner and others 1988, table 31.2. 
cases were processed in the laboratory, and measures of
surveillance for acute flaccid paralysis cases were reported to
have been entirely satisfactory. At first, the Sudanese cases were
considered to have resulted from importations from Nigeria,
and, indeed, some cases were. However, from more detailed
laboratory studies, it was determined that type 1 wild virus
had been circulating undetected for more than three years and
type 3 virus for nearly five years.
Clearly, stopping the continuing transmission of wild
poliovirus is itself a formidable challenge, the success of which
is by no means certain. A problematic discovery since the glob-
al eradication program began was the finding that individuals
with particular immunologic disorders shed polio vaccine
virus for many months to years, thus serving as a reservoir for
this virus. The virus, in turn, can revert to a neurovirulent
form, which is capable of causing outbreaks of disease
(Bellmunt and others 1999). Such individuals may be wholly
without symptoms and impossible to identify except through
fecal cultures. Moreover, no treatment is known to stop them
from shedding virus. They pose an all but insurmountable
challenge to the current poliomyelitis eradication effort.
The program is further hampered by the tool that has pro-
vided so much success—oral poliovirus vaccine (OPV). In
resource-poor environments, poliomyelitis is best controlled
with the inexpensive, live, and easily administered oral vaccine.
The live vaccine is excreted and can infect other susceptible
contacts. The ability of OPV to immunize others indirectly
makes it an ideal vaccine for achieving high levels of
population-based immunity, especially in lower socioeconomic
populations that are the most difficult to reach. However, the
excreted virus occasionally reverts to a pathologic state, causing
not only cases but outbreaks of vaccine-associated paralytic
polio, which may not emerge until months or even years after
the vaccine has been administered (Kew and others 2004).
Unfortunately, the alternative inactivated polio vaccine (IPV) is
not immediately an option in many nations, not least because
global manufacturing capacity could not begin to meet
demand. Other problems include the current cost differential
between OPV and IPV, the increased difficulty of administer-
ing the vaccine by syringe and needle, and the need to achieve
higher coverage rates with IPV because it does not spread from
person to person as does OPV.
Tragically, if OPV use were discontinued, in the absence of
alternative immunity, polioviruses would likely circulate
silently (Eichner and Dietz 1996) and reemerge. Preliminary
results from a model presented by WHO indicate a greater than
60 percent chance of an outbreak within two years of the pos-
sible global cessation of OPV (WHO 2004) because of contin-
uous circulation of undetected live vaccine viruses that can
revert. Outbreaks have already been observed in several regions
where decreasing use of live vaccine has left pockets of suscep-
tible persons who eventually have been exposed to vaccine-
derived pathogenic viruses (Kew and others 2002). Such an
outbreak could occur with disastrous speed because the polio
virus is far more contagious than that of smallpox. In develop-
ing countries, virtually all cases of polio occurred among those
under five years of age, older persons having been protected by
the natural immunity of earlier infection. Within five years
after vaccination ceased, therefore, the population immunity
level in the developing countries would be no better than it was
before vaccination was introduced. With this is mind, it seems
questionable as to whether all health ministers could be per-
suaded to call for a country-wide cessation of poliomyelitis
vaccination itself, given the uncertainties of virus detection in
so many remote and inaccessible areas of the world.
By definition, eradication implies certifying cessation of
virus transmission and the absence of reservoirs so that control
interventions can cease. As noted earlier in this chapter, it is
only for this reason that eradication yields a dividend.
Although the interruption of wild poliomyelitis virus trans-
mission is theoretically feasible, the obstacles to achieving and
maintaining this goal are formidable. At this time, it is difficult
to foresee a future that does not envisage a continuing vaccina-
tion program, perhaps with IPV use in countries that can
afford the substantial additional costs entailed and with OPV
use in all other countries.
The polio eradication initiative, like that for smallpox, has
had to rely primarily on voluntary donations provided both to
WHO and bilaterally. Playing an especially important role have
been the Rotary International Foundation and the Bill &
Melinda Gates Foundation. From 1988 to 2004, more than
US$3 billion was spent on the effort (WHO 2003).
What are the economics of polio eradication? Bart, Foulds,
and Patriarca (1996) developed the first global cost-benefit
analysis of polio eradication, beginning with the costs incurred
since 1986, the year that the Pan American Health Organiza-
tion launched a regional eradication effort, and extending to
2040. They assumed that eradication would be achieved in
2005, using OPV, and that vaccination would cease after eradi-
cation had been certified. Benefits (like costs, discounted at
6 percent) reflect the avoided costs of acute care and avoided
vaccination costs after certification. Their analysis showed that
the initiative would break even by 2007 and yield a net benefit
to the world of more than US$13 billion by 2040—an encour-
aging result, but it was based on the assumption that all vacci-
nation would stop abruptly in 2005.
Khan and Ehreth (2003) developed a similar analysis but
provided regional detail. They estimated the costs and medical
costs avoided of polio immunization and eradication over the
period 1970 to 2050, assuming that vaccination could cease
after 2010. As table 62.3 shows, Khan and Ehreth estimated that
polio immunization and eradication would entail a negative
net cost overall, with Europe and the Americas saving the most
and with other regions incurring a positive net cost. Compared
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with other health interventions, this cost to developing
countries may still be comparatively cost-effective. However,
Khan and Ehreth comment that the cost per disability-adjusted
life year (DALY) saved is high for developing countries (see
table 62.3). As they explain (Khan and Ehreth 2003, 705), “This
implies that without the financial support from developed
countries of the world many developing countries would not
have opted for polio interventions for implementation. From
the developed countries’ point of view, providing support
for the polio program is not simply helping the poor and
the disadvantaged, it actually represents a good economic
investment.”
Unfortunately, both of these cost-benefit studies have
substantial limitations. First, both show that eradication is
economically attractive if one incorporates all costs and benefits
from the inception of this program. Because eradication has not
yet been achieved, this approach mixes retrospective evaluation
and prospective analysis (historical expenditures and benefits
are sunk and so are irrelevant to the current situation). Second,
benefits and costs are calculated in both studies relative to a
world without immunization. A better approach would be to
calculate the net benefits of eradication compared with the
alternative of an optimal control program. The choice is not
between doing nothing and eradication. It is between an
optimal level of control and eradication. Finally, both studies
assume that vaccination can cease in 2005 or 2010. As explained
previously, this possibility is highly unlikely.
A more recent analysis by Sangrujee, Cáceres, and Cochi
(2004) calculates the costs for 15 years following the goal of
certification of eradication in 2005 for three different scenarios:
continued use of OPV, OPV cessation with optional use of the
killed or inactivated polio vaccine, and OPV cessation with
universal IPV. Table 62.4 shows their results.
The respective cost to middle- and high-income countries is
the same for all three scenarios, reflecting the assumption that
the high-income countries will switch to IPV by 2005 and
middle-income countries will do so between 2006 and 2008.
The scenarios differ only for the low-income countries. In the
first scenario, these countries are expected to continue routine
immunization using OPV; in the second, immunization ceases
in 2011, followed by a system of surveillance and response. In
the third scenario, the low-income countries join the others in
switching to IPV between 2008 and 2010. Of these three sce-
narios, the second comes closest to the 2005 post-eradication
strategy now advocated by the polio eradication program
leadership.
Unfortunately, this analysis is also deficient. First, interrup-
tion of transmission will not occur before 2006, and certifica-
tion will take an additional three years. Hence, analysis of
post-eradication costs should begin in 2009 at the earliest, with
the costs of continuing immunization needing to be borne up
until that time. Second, the analysis assumes a capacity to sup-
ply IPV that exceeds current estimates. It is not obvious that this
scenario is feasible or, if it were, if the costs of scaling up pro-
duction are adequately reflected in the calculations. Third, and
most importantly, table 62.4 indicates that only low-income
countries would benefit from polio eradication over this 15-year
time scale—and yet the table does not include any estimate of
the risk these countries would bear of a possible outbreak.
Although this analysis suggests that the discontinued use of
OPV promises the greatest return to eradication, this assumes
that circulating vaccine-derived polioviruses could be con-
tained if and when they emerged. However, preparing for this
possibility would require a far more effective global surveil-
lance system than now exists, maintenance of a laboratory
infrastructure, and stockpiles of OPV. In addition, controlling
outbreaks with OPV without the risk of viruses reverting to
virulence will be exceedingly difficult in the setting of an accel-
erating proportion of immunologic-naive individuals. The use
of OPV in this scenario could very well cause poliomyelitis to
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Table 62.3 Net Costs of Polio Immunization and Eradication 
(Millions of U.S. dollars)
Medical care Immuni- Cost/DALY 
WHO region cost savings zation costs Net costs saved
Africa 1,100 3,942 2,842 442
Americas 76,900 25,460 51,440 4,983
Eastern 1,930 3,512 1,582 426
Mediterranean
Europe 38,250 17,249 21,001 2,780
Southeast Asia 1,270 6,519 5,249 1,041
Western Pacific 8,670 10,327 1,657 356
World 128,120 67,009 61,111 1,457
Source: Khan and Ehreth 2003.
Note: Cost savings, immunization costs, and net costs are present values for 2000 in millions of
U.S. dollars, calculated for the period 1970–2050 and discounted at 5 percent. These estimates
assume that immunization by OPV can cease after 2010.
Table 62.4 Postpolio Eradication Costs
(Millions of U.S. dollars)
Continue OPV Stop OPV Universal IPV
Low-income countries 1,364 487 4,418
Middle-income countries 12,196 12,196 12,196
High-income countries 6,409 6,409 6,409
Subtotal 19,969 19,092 23,023
Global response capacity 1,120 1,320 1,120
Total 21,089 20,412 24,143
Source: Sangrujee, Cáceres, and Cochi 2004.
Note: Costs are expressed in present value terms, calculated over the period 2005 to 2020, and
discounted at 3 percent.
again become endemic. In any case, the estimated cost of any of
the strategies exceeds $20 billion.
The economics of polio eradication are thus not as favorable
as concluded by either Bart, Foulds, and Patriarca (1996) or
Khan and Ehreth (2003). Both studies assume that vaccination
can cease without IPV being used as a substitute anywhere,
both exclude the costs of maintaining a response capacity, and
neither accounts for the real threat of reemergence. Sangrujee,
Cáceres, and Cochi (2004) take account of two of these consid-
erations, but their analysis calculates only the costs for 15 years,
ignoring both the risk of reemergence and the benefits of
eradication. Hence, each study provides only a partial glimpse
of the economics of polio eradication and does not adequately
address the fundamental difficulty (inability) of stopping
vaccination and maintaining eradication.
In conclusion, although the economics of polio eradication
may have been thought to be favorable by some (Aylward and
others 2003), they are far less favorable than were the econom-
ics of smallpox eradication, even assuming that polio vaccina-
tion could cease.
Dracunculiasis
Dracunculiasis, or guinea worm disease, is a nematode infec-
tion, which is controlled not by vaccination but by education of
the affected population, provision of nematode-free water
through wells or filtration, and treatment of cases. It is not a
global disease but found only in the rural areas of a few very
poor tropical countries. This last difference is especially impor-
tant from an economics perspective. It means that interna-
tional financing of a guinea worm eradication program needs
to rely more heavily on development assistance rather than on
the self-interest of donor countries.
Thus far, the eradication program has been successful in
reducing the number of cases of guinea worm 99 percent from
the 1986 level (Carter Center 2004). The geographic range of
the disease has also been reduced from 20 to just 12 countries.
Although this achievement is important, eradication remains
elusive many years beyond 1995, the year that the WHA set for
eradication in 1991 (Cairncross, Muller, and Zagaria 2002, 232).
Only one cost-benefit study of the guinea worm eradication
program has been published (Kim, Tandon, and Ruiz-Tiben
1997), and it is unfortunately flawed in a number of respects.
First, as indicated previously, eradication costs should be com-
pared with those associated with an alternative optimal control
program. Second, the cost-benefit analysis applies to the period
1987 to 1998 and thus is backward looking. The analysis can
reveal whether the money spent previously yielded a benefit in
excess of the cost (it did), but it cannot reveal whether eradica-
tion was worth pursuing at the time that this study was
undertaken. Finally, it takes no account of the investment
decision of eradication—the main reason for pursuing the
eradication goal in the first place.
This last omission is especially relevant to the study’s analy-
sis of the eradication program in Sudan. The study projected
that, by 1998, infections would cease everywhere except Sudan.
(Plainly, this prediction was wrong, although Sudan is the
largest problem for the program, mainly because of the ongo-
ing civil war, which has limited accessibility to endemic areas;
see Hopkins and others 2002.) It then calculates the net present
value of eliminating the disease there. The results are not
promising. They show that eradication is attractive only if the
disease can be eliminated in Sudan within five years. However,
this analysis ignores the dividend that eradication would earn
Sudan. It also disregards the most important feature of
eradication—that if the disease were certified to have been
eliminated from its last stronghold, it would yield a benefit to
all potentially vulnerable countries. Thus, the economics of
eliminating dracunculiasis from Sudan, if that is where the
disease makes its last stand, will be much more attractive than
suggested by this analysis.
CONCLUSIONS
Of the several attempts to eradicate diseases, all but one has
failed. Even the exception, smallpox, barely succeeded despite
the many factors favorable to eradication. Whether any eradi-
cation effort will ultimately succeed or fail cannot be known
with certainty at the time it is launched. Eradication entails
risk. Money spent on eradication may not ultimately pay a
dividend. Health risks may also exist. If eradication fails and
vaccination levels drop after the eradication goal is abandoned,
susceptible persons who were previously shielded from infec-
tion may become infected at a later age, when the disease can
cause greater harm. The risk also exists that, even if eradication
succeeds, the disease may be reintroduced by accidental or
deliberate release.
The reasons for potential failure of an eradication effort are
many. A nonhuman host may not be discovered until the num-
ber of infected humans drops to a very low level (as happened
with yellow fever). The tools of eradication may be vulnerable
to resistance (insecticides and drugs in the case of malaria).
Political problems and civil strife may prevent an eradication
program from being executed in critical areas where the disease
makes its last stand (a problem today for guinea worm).
Termination of vaccination may leave populations vulnerable
to microbe reintroduction from an unforeseen reservoir or
vaccine strain reversion (a risk now facing the poliomyelitis ini-
tiative). Another potential reason for failure is the inability
to raise the financial resources needed to complete programs
that extend beyond expected targets. All eradication programs
have experienced serious financial stringencies during the
course of their execution.
Most eradication programs to date have been launched
as visionary, far-reaching efforts but with vastly incomplete
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information. Basic epidemiological information and knowledge
of the effectiveness and operational constraints of interventions
and costs in different settings are often inadequate, and the
required monitoring, evaluation, training, and research compo-
nents of the program may be absent. If a program’s administra-
tors lack a careful, probing analysis of the epidemiology of the
various candidate diseases or of the technologies available, and
if their comprehension of the potential costs and who would
bear them is limited, a program is likely to founder, causing a
dispirited staff, confused beneficiaries, and donor fatigue and
ambivalence. It is crucial that the eradication methodologies
and assumptions in those regions of the world that would be
most likely to pose the most significant problems be tested and
addressed before launching an eradication program and that
evaluation and research continue during the program.
Proposals for disease eradication have seldom been brought
to the WHA with specific plans, costs, and uncertainties fully
laid out. Nor have the expected sources of fiscal support and
needed country support been addressed with specific commit-
ments requested of the members. The WHA has only a limited
deliberative capacity, and too much cannot be expected of its
members in session. However, designated special committees of
the WHA can and should be appointed, consisting of both
visionary eradicationists and field-experienced public health
and social science personnel. The WHA should take up the
question of eradication only after the subject has been thor-
oughly vetted and sufficiently large-scale pilot programs in the
most problematic areas have clarified that an adequate under-
standing of the epidemiology exists and that the appropriate
technologies are available.
In the past, members have not voted for a specific program
for which all the uncertainties have been laid out and the ben-
efits and costs associated with different outcomes have also
been calculated. Nor, with one exception, have they voted for a
resolution imposing responsibilities, including financing obli-
gations, on individual states. The next time a proposal to erad-
icate a disease is presented to the WHA, it should be compre-
hensive. It should demonstrate why the effort is worth taking,
even if the final outcome is uncertain; it should bind states,
morally if not legally, to fulfill the pledges needed to see the
program through to its completion; and it should prepare con-
tingencies should the eradication effort fail.
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NATURE, CAUSES, AND BURDEN 
OF CHILD MORTALITY
Every year, over 10 million children under five years of age die.
Most of those deaths are due to a small number of causes. In
the mid 1990s, it was estimated that 70 percent of all global
child deaths were due to five conditions: diarrhea, pneumonia,
malaria, measles, and malnutrition (Gove 1997; Tulloch 1999).
The World Health Organization (WHO) has since conducted a
comprehensive review of under-five deaths using additional
data and improved methods (Bryce and others 2005), and now
estimates that six causes accounted for 73 percent of these
deaths in 2000–2003: pneumonia (19 percent), diarrhea
(18 percent), malaria (8 percent), neonatal pneumonia or sepsis
(10 percent), preterm delivery (10 percent), and asphyxia at
birth (8 percent). Undernutrition is an underlying cause in at
least half of all under-five deaths. Few conditions, therefore,
account for a large proportion of all deaths.
These deaths are not randomly distributed.They tend to occur
in the poorest countries of the world, mostly in Sub-Saharan
Africa and South Asia (Black, Morris, and Bryce 2003), and with-
in any country they affect mostly the poorest families (Victora
and others 2003). Fortunately, cost-effective interventions are
available to prevent most of these deaths. Chapters 19, 21, 24–28,
and 56 in this volume, as well as the next section in this chapter,
describe these interventions in greater detail.Achieving universal
coverage with these interventions would likely prevent 60 percent
of those deaths (Jones and others 2003). Yet coverage levels for
nearly all of these interventions remain below 50 percent (Bryce
and others 2003), and children from the poorest families are least
likely to be reached (Victora and others 2003).
In addition, comorbidity is common. Among children who
die, a large proportion present with two or more diagnoses
(Black, Morris, and Bryce 2003). Comorbidity is also highly
prevalent at the community level and among children seeking
health care. Nutritional factors—including underweight,
micronutrient deficiencies, and inadequate infant feeding prac-
tices (see chapter 28)—play a major role in morbidity and
mortality, and yet these are often overlooked by practitioners.
Also, there are many missed opportunities for preventive inter-
ventions during outpatient visits—for example, immuniza-
tions and promotion of insecticide-treated mosquito nets.
POLICY SHIFT TO INTEGRATED MANAGEMENT
Until the mid 1990s, actions aimed at improving child health
were organized as vertical programs, each addressing a specific
disease or providing a given intervention or set of interventions
(Claeson and Waldman 2000). Typical examples of these pro-
grams are the Expanded Program on Immunizations (EPI),
Control of Diarrhoeal Diseases (CDD), acute respiratory infec-
tion (ARI) programs, malaria control programs, and nutrition
programs that include growth monitoring, breastfeeding pro-
motion and support, and micronutrient supplementation.
The need for an integrated approach to improve child health
became evident in the mid 1990s for a number of reasons.
From the perspective of epidemiology, a small number of
diseases accounted for a high proportion of deaths, and those
diseases were often present in the same children and had over-
lapping clinical signs. Integrated management was expected to
increase the probability that children would receive treatment
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for all major diseases and to decrease the possibility that chil-
dren would receive correct treatment for one disease and die
from another unrecognized illness. The important role played
by nutrition across these major diseases also suggested that an
integrated approach to case management was needed to ensure
that health workers addressed children’s nutritional needs
throughout the clinical encounter.
A second set of reasons for the policy shift to an integrated
approach was based on the need to promote managerial effi-
ciency. The vertical approach required countries to appoint
managers at national, provincial, and district levels to run each
program. It also led to separate training activities; for example,
health workers might be required to leave their posts on a num-
ber of occasions to be trained for the programs. Similar exam-
ples of duplication of effort were often found in supervision
and provision of essential drugs. There was a strong logical
basis for believing that integrating the management structure
of child health programs would lead to improved efficiency.
A third group of reasons for the shift to integrated case
management related to the need to improve the quality of case
management provided by health workers. Vertical programs
trained health workers to manage one disease at a time, and
decisions about how best to assess and treat those diseases, as
well as how to promote nutrition and educate caretakers, were
often left to individual health workers. An integrated set of
guidelines for managing sick children ensured that health
workers, including those with low levels of training, applied the
best available knowledge of case management systematically
and in correct sequence.
The realization that a few diseases were responsible for
most child deaths, that comorbidity was highly prevalent, that
effective interventions were available, and that there were
many missed opportunities for prevention led to the recogni-
tion that an integrated approach was needed. Thus, WHO and
United Nations Children’s Fund (UNICEF) launched the
Integrated Management of Childhood Illness (IMCI) strategy
in the mid 1990s (Tulloch 1999). Tanzania and Uganda began
implementing IMCI in 1996. By 2003, more than 100 coun-
tries had adopted the strategy (http://www.who.int/child-
adolescent-health).
INTERVENTIONS
A key aspect of IMCI was the integration of effective interven-
tions to improve child health and nutrition into a coordinated
strategy. IMCI has three components, each of which was meant
to be adapted at the country level according to local epidemiol-
ogy, health system characteristics, and culture.
Improving Health Worker Performance 
The first component of IMCI includes health worker training
and the reinforcement of correct performance. Training is based
on a set of adapted algorithms (Gove 1997) that guide health
workers through a process of assessing signs and symptoms,
classifying the illness according to treatment needs, and provid-
ing appropriate treatment and education to the child’s caregiver.
Figure 63.1 shows a general outline of the approach for children
age two months to five years (WHO and UNICEF 2001). Sick
children attending a first-level health facility are initially checked
for danger signs and for the main symptoms of the key IMCI dis-
eases: diarrhea, malaria, pneumonia, measles, and other severe
infections. Next, all children are assessed for malnutrition and
anemia, and vaccination status is verified. Children under two
years of age, as well as older children presenting low weight for
age, receive nutrition counseling. Other health problems related
by caretakers are then assessed, and children are classified
according to a color code: pink (immediate referral), yellow
(management in the outpatient facility), or green (home man-
agement). Separate case-management algorithms are available
for children under two months of age. IMCI health worker train-
ing emphasizes the integration of curative care with preventive
measures, including nutrition and vaccinations. A special train-
ing module addresses how to communicate effectively with
mothers. The training course was originally designed to last
11 days, including a large amount of hands-on experience.
Improving Health Systems
The second component of IMCI is aimed at providing support
for child health service delivery, including drug availability,
effective supervision, referral services, and health information
systems. Tools were developed for implementing specific
system-strengthening interventions, including a planning
guide for national and district managers, an integrated health
facility assessment tool, and a tool for improving referral level
care. In particular, several countries—beginning in Latin
America through the Pan American Health Organization
(PAHO) and more recently in Africa with WHO’s Regional
Office for Africa—made substantial efforts to improve the
management and availability of the specific drugs required for
IMCI (A. Bartlett, personal communication).
Improving Family and Community Practices 
The third component, known as community IMCI, focuses
on 12 key family practices relevant to child health and
development (see http://www.who.int/child-adolescent-
health/PREVENTION/12_key.htm). Community IMCI sup-
ports the development and implementation of community-
and household-based messages and interventions to increase
the proportions of children exposed to these practices. These
behaviors address breastfeeding, complementary feeding,
micronutrients, personal hygiene, immunizations, insecticide-
treated nets, mental and social development, continued feeding
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The Integrated Case Management Process 
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Source: WHO and UNICEF 2001.
Figure 63.1 Schematic Outline of IMCI Case Management for Children Age Two Months to Five Years
and increased fluids during illness, home treatment of infec-
tions, care-seeking practices, compliance with health worker
recommendations, and prenatal care.
This chapter addresses issues related to the integrated deliv-
ery of these interventions, most of which are covered in greater
detail in other chapters in this book. These include case man-
agement of ARI (chapter 25), diarrhea (chapter 19), malaria
(chapter 21), and malnutrition (chapter 28); community inter-
ventions to improve nutrition, including breastfeeding promo-
tion and complementary feeding (chapter 56); insecticide-
impregnated bednets (chapter 21); anthelmintic treatment
(chapter 24); vaccinations (chapter 20); and micronutrient
supplementation (chapter 28).
INTERVENTION COST AND COST-EFFECTIVENESS
One of the rationales for developing the IMCI strategy was the
belief that treating the sick child in an integrated manner, by
building on interventions that had already been shown to be
cost-effective, would result in gains in efficiency. Two types of
questions can be asked from an economic perspective. First, is
treating children on the basis of the IMCI strategy cost-effective?
Second, do the additional health benefits gained by switching
from routine practice to IMCI justify the additional costs
(if any)?
Only one publication has reported the cost-effectiveness of
the IMCI strategy as a whole. Using a modeling exercise, the
World Development Report 1993 identified IMCI as being able
to avert 14 percent of the global burden of disease in children
under age five in resource-poor countries at a cost of only
US$1.60 per capita per year, with a cost-effectiveness of US$30
to US$100 per disability-adjusted life year (DALY) averted. No
details of the methods used to derive those estimates are avail-
able (World Bank 1993). It is not clear if the costs are the addi-
tional costs of moving from current practice to IMCI or the costs
of undertaking care for children under age five using IMCI, nor
is it clear if the effectiveness is the additional effectiveness of
changing current practice or the total effect of the package.
Detailed studies of the cost-effectiveness of some of the com-
ponents of IMCI are available. For example, oral rehydration
therapy for diarrhea, case management for pneumonia, and
childhood vaccinations have been shown to be very cost-effective
when evaluated as separate interventions (see chapters 19, 25,
and 26). It is likely that the combination of different sets of
childhood interventions, as proposed by IMCI, would also be
cost-effective, although this depends on the relationship between
costs and effects when the interventions are undertaken at the
same time in the same population.
No published studies of the extent and nature of efficiency
gains through integration were found. WHO has recently
explored some of these gains for slightly different combina-
tions of childhood interventions in different parts of the world
(see http://www.who.int/evidence/cea). This research resulted
in estimates of the cost-effectiveness of single or combined
interventions compared with doing nothing or with incremen-
tal intervention or current practice. Because large-scale trials
on the effects of joint interventions have not yet been under-
taken, the joint effects were modeled using the effectiveness of
the individual interventions taken from systematic reviews.
The interventions included vitamin A and zinc fortification
and supplementation, oral rehydration therapy, case manage-
ment for pneumonia, and supplementary feeding and growth
monitoring. Costs and effects were estimated at various levels
of population coverage and in various combinations.
The results showed that a childhood package consisting of
vitamin A and zinc supplementation, oral rehydration therapy,
and case management of pneumonia was cost-effective com-
pared with doing nothing in most settings but that including
supplementary feeding and growth monitoring was not cost-
effective. Implementation of this combination at 50 percent
coverage was estimated to cost, in 2000 prices, approximately
US$4.10 per child (US$0.60 per capita) in poor African coun-
tries such as Tanzania. The cost-effectiveness was US$38 per
DALY averted. Costs increase faster than the increase in cover-
age. In Tanzania, it was estimated to cost an additional
US$12.10 per child under age five (US$1.80 per capita) to reach
95 percent coverage, with a resulting incremental cost-
effectiveness ratio of US$60 per DALY averted.
This study is important because it is one of the few that has
specifically explored the cost-effectiveness of undertaking com-
bined interventions in the same population, and the effect of
increasing coverage on costs. These absolutely critical questions
for policy makers considering different intervention strategies
are also critical to IMCI. However, the WHO study did not ana-
lyze the same interventions included in the IMCI package, nor
did it evaluate the effect of moving from current practice to
IMCI-based care.
Some information on the effect of moving from current
practice is available from two studies in Kenya and Nigeria.
Those studies compared the cost to the provider of traditional
prescribing patterns with the costs of pharmaceuticals that
would have resulted if the IMCI guidelines had been followed
strictly. In Nigeria, the traditional prescribing method was five
times more expensive: US$1.44 per child visit for pharmaceuti-
cals compared with US$0.29, using 1996 estimates
(Wammanda, Ejembi, and Iorliam 2003). In Kenya, also in
1996, the traditional method was almost three times costlier per
child visit if the low-cost combination of drugs was assumed
(US$0.44) and similar if the high-cost combination was
assumed (US$0.16) (Boulanger, Lee, and Odhacha 1999). In
Bangladesh, it was estimated that strict adherence to the IMCI
protocol could result in US$7 million in savings at the national
level simply from more rational use of drugs—almost 3 percent
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of the total health budget of the government of Bangladesh
(Khan, Ahmed, and Saha 2000; Khan, Saha, and Ahmed 2002).
These estimates were based on models and assumptions,
sometimes using evidence from separate systematic reviews
addressing the costs and effects of an intervention. It would be
valuable if information on relative cost-effectiveness of differ-
ent combinations of interventions at variable levels of coverage
could be derived from field studies rather than developed sole-
ly by modeling. Such an approach would allow the use of com-
parable methods and counterfactuals across the evaluation sites
to make the results more useful and generalizable to other
settings. In addition to answering questions related to the cost-
effectiveness of IMCI, it would clarify gains that can be obtained
from delivering interventions at the same time as part of an inte-
grated package rather than delivering them in a vertical manner.
This is one of the reasons the Multi-Country Evaluation of
IMCI Effectiveness, Cost, and Impact (MCE) was launched
(Bryce and others 2004). Five countries are currently participat-
ing in in-depth studies—Bangladesh (in 20 catchment areas),
Brazil (in 46 municipalities), Peru (in all 24 departments in the
country), Tanzania (in 4 districts), and Uganda (in 10 districts).
Seven other countries—Bolivia, Cambodia, Kazakhstan, the
Kyrgyz Republic, Morocco, Niger, and Zambia—were assessed
for the evaluation but could not be included, mostly because of
insufficient implementation of IMCI.
The overall objective of the MCE is to evaluate the actual
changes associated with IMCI as it is implemented in different
settings. All studies measured an identical set of indicators and,
with minor exceptions, used identical data collection tools
(Bryce and others 2004). The remainder of this section presents
the main findings from two MCE countries, Tanzania and
Brazil, for which evaluation results are currently available.
MCE in Tanzania
The MCE in Tanzania uses an observational design to compare
two districts where IMCI has been implemented since late 1997
(IMCI districts) with two districts where implementation
began in 2002 (comparison districts). The four districts had
reasonably well-functioning health services, comparable levels
of per capita health expenditure, high utilization rates of gov-
ernment health facilities, and high coverage of selected inter-
ventions (for example, EPI). Large numbers of governmental
and nongovernmental health actors were also active in the dis-
tricts, many of which were involved in health worker training
and community activities, although their coverage was patchy.
The two IMCI districts had engaged in activities designed to
strengthen district management skills; the districts also had
authority for priority setting and control over their health
budgets. These activities of national health sector reform had
not started in the comparison districts at the time of the study.
In the comparison districts, a high level of coverage of IMCI
training for health workers had been achieved, but there had
been no increase in the provision of under-five interventions at
the community level, as opposed to the facility level.
Cost data were collected for the start-up period of imple-
menting IMCI (from 1996 to 1997)—defined as the time from
the national decision to implement IMCI to the time when
IMCI started to be provided in health facilities—and for the
maintenance of child health services in both types of districts.
Costs were estimated from the societal perspective and were
collected from the national, district, hospital, health facility,
and household levels. Costs at all these levels were summed to
obtain the total cost to the district of providing care for chil-
dren under age five. So that comparison could be made across
districts, cost estimates were standardized to a hypothetical dis-
trict with a population of 50,000 children under age five. This
figure corresponds to a total population of around 300,000,
which is roughly the average district population for Tanzania.
Estimates of the additional cost to the district of implementing
IMCI were based on the difference in cost of under-five care
between the IMCI districts and the comparison districts,
which, at the time of the study, had not yet implemented IMCI
(Adam and others 2004b).
For 1999, the cost per child of caring for children under age
five in IMCI districts was US$11.19, 44 percent lower than in
the comparison districts (US$16.09) (Adam and others 2004b).
The lower cost per child in IMCI districts was due to lower hos-
pitalization and administrative costs at the district level. There
was no statistically significant difference in costs incurred to
treat children at primary care facilities and at the household
level (figure 63.2).
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Hospital costs were 2.5 times higher in the comparison dis-
tricts, not because of differences in the cost per under-five
admission, but because more children under age five were hos-
pitalized in those districts relative to IMCI districts (6 percent
in IMCI districts compared with 15 percent in comparison dis-
tricts; t–test: p  0.001). There are two possible explanations:
(a) improved quality of care and drug availability for children
under age five at IMCI primary facilities reduced the need for
referral and subsequent admission to hospitals, or (b) factors
other than IMCI, such as differences in quality or geographical
access to the hospitals in the different settings, meant that chil-
dren in non-IMCI districts were more likely to seek care at hos-
pitals. Given that IMCI training had only started one year
before data collection of hospital admissions, the second possi-
bility may have played a bigger role in this finding. Even if one
takes the most conservative assumption—that all the difference
was due to other factors—and excludes the hospital component
from the analysis, the total cost per under-five child in IMCI
districts was still lower than in comparison districts (6 percent).
The other important difference in costs between both types
of districts was found in costs incurred at the district level,
which were 50 percent higher in the comparison districts.
These costs were mainly linked to more frequent trips for drug
distribution and general purpose supervision in comparison
districts than in IMCI districts.
Similar costs of training were observed in both types of dis-
tricts during the study period. This finding was unexpected
given the emphasis of IMCI on training, but a wide variety of
training courses were performed in comparison districts for
preventive, curative, and administrative issues during the study
period. These courses included training for immunization, for
use of insecticide-treated bednets, and for use of district Health
Management Information System forms.
At the facility level, univariate comparison between IMCI
and comparison district health facilities showed a 16 percent
difference in the average cost per under-five visit (including
vaccination visits) at government health centers and dispen-
saries (US$1.40 and US$1.60 in IMCI and comparison districts,
respectively; t-test: p  0.5). The average number of visits per
child per year was 30 percent higher in the IMCI districts (3.28)
compared with comparison districts (2.49). Taken together, the
lower cost per visit but higher number of visits per child per
year in IMCI facilities resulted in similar overall costs per child
under age five for treatment in the two types of districts.
Multivariate regression analysis, however, led to a different con-
clusion. Taking into account differences in other determinants
across facilities, in particular the number of visits per facility,
the cost per visit was at least 30 percent lower in IMCI facilities
(t-test: p  0.001).
Sensitivity analysis showed the importance of hospitaliza-
tion costs in interpreting total district costs—the difference
between IMCI and comparison districts was not sensitive to
variation in the other parameters, only to the assumption
about rates of hospitalization. Therefore, if one assumes that
hospital admission rates were not related to IMCI, there is no
difference in the cost of under-five care in the two types of dis-
tricts. Otherwise, the costs in IMCI districts are lower than in
the comparison districts.
In the IMCI districts, IMCI was implemented concurrently
with measures designed to strengthen district management,
such as evidence-based planning and expenditure mapping
at district level (http://web.idrc.ca/en/ev-3170-201-1-DO_
TOPIC.html). In fact, it has been argued that the decision to
implement IMCI in the study districts was a result of the intro-
duction of the evidence-based planning. It is not possible to
separate the effects of IMCI from district-strengthening meas-
ures. The findings of the MCE study in Tanzania, therefore, can
be interpreted as the costs of IMCI in the presence of a strong
health system with adequate managerial capacity.
The US$11.20 cost per child of treating children under age
five using IMCI in Tanzania translates into a per capita cost of
US$1.70, compared with US$2.30 for routine care. This finding
is similar to previous per capita estimates of the cost of IMCI
in resource-poor countries (World Bank 1993). In addition, the
Tanzania evaluation had similar findings with respect to sav-
ings from drug costs to those expected based on previous stud-
ies (Khan, Saha, and Ahmed 2002; Wammanda, Ejembi, and
Iorliam 2003; World Bank 1993).
The effects of IMCI can be assessed in terms of changes in
intermediate outcomes, such as improved quality of care at
health facilities, or in terms of final outcomes, such as changes
in under-five mortality or DALYs averted. In the Tanzania eval-
uation, a health facility survey was carried out in 2000 to com-
pare the quality of case management and health systems sup-
port in IMCI and comparison districts. The results indicate
that children in IMCI facilities received better care than chil-
dren in comparison districts. Their health problems were more
thoroughly assessed, they were more likely to be diagnosed and
treated correctly as determined through a gold-standard reex-
amination, and the caretakers of the children were more likely
to receive appropriate counseling and reported higher levels of
knowledge about how to care for their sick children (Tanzania
IMCI Multi-Country Evaluation Health Facility Survey Study
Group 2004).
Estimating the effectiveness of IMCI training in improving
health workers’ performance required measuring the propor-
tion of children correctly managed in IMCI and comparison
facilities. Correct management is defined as the correct drug
being provided in the correct formulation (amount, times per
day, number of days) and the health worker explaining cor-
rectly to the caretaker how the drug should be administered at
home. Not prescribing an antibiotic or antidiarrheal drug for a
child who did not need one was also considered to be correct
performance. In Tanzania, 65 percent of children under age five
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presenting to the surveyed IMCI facilities were correctly man-
aged, compared with 16 percent in the comparison facilities.
When the information on costs and effectiveness are taken
together, the cost per child correctly managed is six times less
in IMCI districts (US$4.02) than in the comparison districts
(US$25.70) (Bryce and others forthcoming).
Some of the differences in costs might be due to factors
other than IMCI, so these ratios have to be interpreted with
care. What is clear, however, is that treating children using
IMCI in Tanzania was no more costly—and probably less
costly—than treating children using routine care. At the same
time, it resulted in higher quality of care. To the extent that this
higher quality of care leads to better health outcomes, IMCI is
cost-effective—it costs less (or at least no more) and results in
better outcomes (see box 63.1).
MCE in Brazil 
Brazil is another MCE site where IMCI is being implemented
in the context of an ambitious family health program (FHP),
which is supported by the Ministry of Health and the World
Bank and based at first-level government facilities. IMCI
implementation started in 1996 and is moving ahead in the
whole country, particularly in the northeast regions. IMCI
training is targeted at FHP team members.
The MCE in Brazil was carried out in four states, all in
northeast Brazil, the poorest area of the country. In total, 23
municipalities with both FHP and IMCI were compared with
matched municipalities with FHP but without IMCI. Early
results from one component of the evaluation—the time and
motion study—provide useful insights. After controlling for
possible confounding factors using regression analysis, the
evaluation found that IMCI-trained providers spent 1 minute
and 26 seconds longer per consultation with under-five chil-
dren than untrained providers did. The difference was much
greater when patient load was low but decreased as the number
of patients a provider saw per day increased. This finding sug-
gests that the system’s ability to absorb IMCI depends on cur-
rent capacity utilization. In terms of the assessment of quality
of care in the surveyed facilities, IMCI-trained health workers
were shown to provide significantly better care than those who
had not been trained (Amaral and others 2004; Gouws and
others 2004). (See “Lessons about Implementation Success
and Failure” later in this chapter for additional results on qual-
ity of care.)
These results are important for policy development relating
to child health. Where current caseloads are relatively low,
providers spend additional time to provide better child health
services, using IMCI as the basis of part of their current activi-
ties. In this study, the mean number of consultations per
provider per day was 34, and 95 percent of the providers had
caseloads of fewer than 50 patients per day. If this finding is
representative of the rest of Brazil, it would be possible to
introduce IMCI relatively easily throughout the country with-
out encountering capacity constraints in terms of provider
time. In areas with high patient loads, however, it would be
important to explore whether it is possible to maintain high
quality of care under IMCI in those areas and what the alter-
natives should be (Adam and others, forthcoming).
Summary of MCE Results 
The available results from the MCE so far show that costs
of child health care in Tanzania were comparable or lower in
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Impact of IMCI on Mortality and Nutrition in Tanzania
Box 63.1
Tanzania is the only MCE site where the evaluation has
been completed. Its design included a comparison of mor-
tality in four districts—two with and two without IMCI—
over the two-year period starting in mid 2000.
Demographic surveillance systems were used to compare
under-five mortality rates in areas of the IMCI and control
districts. Adjustments for age (zero to one and one to four
years) and rainfall were made using Poisson regression
models. During the IMCI phase-in period (July 1999 to
June 2000), under-five mortality levels were almost identi-
cal in IMCI and comparison districts, at about 27 deaths
per 1,000 child-years or approximately 120 deaths per
1,000 children between birth and the age of less than five
years. The quality of health care provided in the IMCI dis-
tricts was substantially higher than in the control districts
(see box 63.2). Over the following two years, mortality lev-
els became 13 percent lower in IMCI districts than in the
comparison areas, corresponding to a rate difference of
3.8 fewer deaths per 1,000 children per year. Stunting rates
also became significantly lower in the IMCI districts.
Contextual factors, such as mosquito net use, all favored
the comparison districts.
Source: Armstrong Schellenberg and others 2004.
districts with IMCI than with routine case management.
Quality of care was higher, and a 13 percent reduction in mor-
tality was also found in the IMCI districts in the study period.
This finding strongly suggests that IMCI is a cost-effective
intervention compared with routine care, as it costs less and is
more effective in saving children’s lives.
In Brazil, the MCE study also showed improved quality of
care for children under age five after health workers were trained
in IMCI. The results also showed that staff time constraints were
unlikely to limit the application of IMCI, because, in settings
with low caseloads, health workers could be expected to use the
available excess capacity to provide better care for children
under age five. Assuming that primary health facilities will
experience savings on drug costs similar to those observed in
Tanzania and previous modeling studies, one could also argue
that IMCI is a good value for money in the Brazilian setting.
Equity Issues
Some of the equity implications related to care seeking and
treatment have also been evaluated in the four rural districts
included in the IMCI evaluation in Tanzania (Schellenberg and
others 2003; Victora and others 2003). The MCE analysis found
no association between sex and any indicator of morbidity, care
seeking, case management, or compliance with treatment or
follow-up instructions, suggesting that mothers and health
workers treat boys and girls similarly (Schellenberg and others
2003). This finding is in accordance with that of Gwatkin and
others (2000). Similarly, there were no statistically significant
associations between socioeconomic status and reported
prevalence of fever, diarrhea, severe diarrhea, or pneumonia.
However, hospital admissions were almost half as common in
the lowest socioeconomic status quintile as in the highest 
(t-test: p  0.0093), suggesting that referral care is more readily
accessible to the wealthy.
Positive associations were observed between socioeconomic
status and care seeking from an appropriate provider (a quali-
fied health worker practicing allopathic medicine) for fever
without cough or diarrhea, for care seeking for episodes per-
ceived as severe, and for using an appropriate provider as the
first source of care. This finding is illustrated in figure 63.3,
which puts households into five wealth categories. The poorest
group was at least 25 percent less likely to have sought care than
the least poor. Among the children who sought care, antibiotic
use for probable pneumonia was less than half as common
among the poorest than among the least poor. Also, children in
the lowest socioeconomic group were half as likely to have been
given antimalarials as those in the highest category (t-test:
p  0.0001).
These findings suggest that, although the prevalence of dis-
ease (self-reported) does not differ by socioeconomic status,
care seeking and the probability of receiving appropriate care
vary markedly, even within an apparently homogeneous rural
population. This observation agrees with data on mortality and
nutritional status inequalities for Tanzania (Schellenberg and
others 2003). There is no evidence yet showing whether the
introduction of IMCI has reduced or increased this type of
inequality.
IMPLEMENTATION OF PROGRAMS:
LESSONS OF EXPERIENCE
The IMCI strategy was thoroughly evaluated from its onset.
Only two years after the first health worker training course took
place, the MCE was launched (Bryce and others 2004). MCE
researchers visited 12 countries and carried out in-depth stud-
ies in five of those. The MCE and the more recent Analytic
Review of IMCI (DFID and others 2003), which included vis-
its to six countries, provide the background for this section.
Institutions and Programs 
IMCI introduction was highly successful. As of December
2002, WHO’s global monitoring team reported that IMCI had
been introduced in 109 countries (see http://www.who.int/
child-adolescent-health/overview/child_health/map12_
02.jpg). Twelve countries were included in the introduction
phase, in which the strategy was officially endorsed, a national
IMCI coordination group was appointed, and key ministry
of health staff members were trained in the IMCI clinical
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guidelines. Another 50 countries were in the early implementa-
tion phase, which included development of a national plan,
selection of initial districts for implementation, adaptation of
the IMCI clinical guidelines and materials, training of course
facilitators, and planning at the district level. Finally, 47 coun-
tries were in the expansion phase, which included scaling up
IMCI activities in districts already covered and expanding to
cover additional districts (WHO and UNICEF 1999).
The fact that a country has adopted the IMCI strategy, how-
ever, does not mean that a high population coverage has been
reached. The best available estimates of IMCI coverage are pro-
vided by the percentage of health workers who underwent
IMCI training and are managing sick children. For example,
the Brazil MCE (Amaral and others 2004) has shown that
IMCI is being implemented in all 27 states, but in some
of those states only a few health professionals were trained. In
the three states selected for the evaluation because of report-
edly strong IMCI implementation, there was at least one IMCI-
trained health worker in 239 out of 443 municipalities
(54.0 percent), but only 23 municipalities (5.2 percent) had at
least 50 percent of health workers trained after three years. In
Peru, also a leading country in IMCI training, approximately 10
percent of all doctors and nurses providing child care were
trained after seven years of IMCI implementation (Huicho and
others 2005). Therefore, levels of training coverage in most
countries appear to be low.
Lessons about Implementation Success and Failure 
Both the MCE (Bryce and others 2004) and the Analytic
Review of IMCI that were carried out in 2002–3 (DFID and
others 2003) confirm that IMCI has been highly successful in
motivating managers and health workers. The training pro-
gram is highly regarded, and trainees are pleased with its logi-
cal, consistent approach to child health problems. Innovative
clinical skills, such as the use of palmar pallor to diagnose ane-
mia and the use of breathing rate for pneumonia, are often
praised. Nutritional counseling, an area in which most health
workers receive little formal training in school, is also greatly
appreciated. When asked about the limitations of IMCI, health
workers often mention the increased time required for a con-
sultation and the difficulty of following the IMCI guidelines
when there is a high patient load.
Several studies have shown that health workers trained in
IMCI do perform better than those not trained. Health facility
surveys carried out in Tanzania (Schellenberg and others
2003), Brazil (Amaral and others 2004), and Uganda show that
IMCI training substantially improves health worker perform-
ance in assessing and managing sick children, and in counsel-
ing their caretakers. Box 63.2 summarizes MCE findings on
antibiotic prescribing patterns, a critical area for managing sick
children (Gouws and others 2004).
Important constraints to IMCI implementation were also
identified through visits to 17 countries by the MCE and
Analytic Review teams. Using the framework developed by the
Commission on Macroeconomics and Health (Hanson and oth-
ers 2001), the teams described shortcomings in three areas: com-
munity and household issues, health service delivery issues, and
issues related to health sector policy and strategic management.
Community and Household Issues. Coverage levels for effec-
tive interventions to improve child survival are remarkably low
in most developing countries. A review of the 42 countries that
account for 90 percent of global child deaths showed that only
two out of nine key interventions reached more than half of all
children (Bryce and others 2003). This finding agrees with
Integrated Management of the Sick Child | 1185
Improving the Use of Antimicrobials through IMCI Case-Management: Findings from the MCE
Box 63.2
Antimicrobial drugs, including antibiotics and antimalari-
als, are an essential child survival intervention. Prompt and
correct provision of drugs to children under age five who
need them can save lives. Ensuring that these drugs are not
prescribed unnecessarily and that those who receive them
complete the full course can slow the development of
antimicrobial resistance. Analysis of data collected through
observation-based surveys at randomly selected first-level
health facilities in Brazil, Tanzania, and Uganda shows that
children receiving care from health workers trained in
IMCI are significantly more likely than those receiving care
from workers not yet trained in IMCI to receive correct pre-
scriptions for antimicrobial drugs, to receive the first dose
of the drug before leaving the health facility, to have their
caregivers advised on how to administer the drug, and to
have caregivers who are able to describe correctly how to
give the drug at home as they leave the health facility. IMCI
training is an effective intervention to improve the rational
use of antimicrobial drugs for sick children visiting first-
level health facilities in low- and middle-income countries.
Source: Gouws and others 2004.
those of the MCE, showing that the third component of
IMCI—improving family and community practices—was
poorly implemented. At the global level, UNICEF was primarily
in charge of developing this component (see http://www.
childinfo.org/eddb/imci/practices.htm), and at the country
level, UNICEF often acted through nongovernmental organi-
zations (NGOs). Coverage with these community-based pro-
grams tended to be patchy. In Peru (Huicho and others 2005)
and Tanzania, the districts that were selected for implementa-
tion of the community component were not the same as those
prioritized for health worker training, which were chosen by
the ministry of health with WHO support. This precluded any
possible synergy at the district level between improved quality
of care in health facilities and community interventions,
including those aimed at improving care seeking and compli-
ance with health workers’ advice.
All the countries that were visited, however, have a number
of programs and projects that deliver child survival interven-
tions at the community level. Many of these interventions are
part of the key IMCI family practices, but they are being deliv-
ered in an uncoordinated manner by national, international,
and nongovernmental organizations in limited geographical
areas. The low population coverage of these projects makes it
unlikely that they will ever result in a substantial effect on a
larger scale. The notable exceptions are the EPI programs,
which, despite some recent evidence of falling coverage (Bryce
and others 2003), still reach the vast majority of children in
developing countries.
On the basis of the experience obtained in these countries,
it appears that those key family practices that are most likely to
be synergistic with facility-based IMCI—improved care seek-
ing, home management of disease, and compliance with health
worker advice—are among those least likely to be supported by
existing programs. Existing programs seem to favor biological
interventions such as vaccines, micronutrient supplementa-
tion, and insecticide-treated materials.
The present criticism of community IMCI should not be
extrapolated to community-level child health interventions in
general, which can often be highly successful. These interven-
tions are covered in chapter 56.
Health Service Delivery Issues. Given the difficulties in
implementing the community component, IMCI was largely
restricted in nearly all countries to training health workers in
the improved management of care for young children. Even
there, some difficulties were apparent.
In countries such as Peru, Brazil, and Uganda, after an ini-
tial sharp increase in the number of health workers who were
trained, budgetary and other restrictions led to a decrease in
the number of training courses being offered. In Peru, about
10 percent of all eligible health workers in the public sector
were trained after seven years of implementation. At the
current rate of training, several decades will be needed before
full coverage is reached (Huicho and others 2005). Similar
results were observed in Uganda (J. Nsungwa-Sabiti, personal
communication).
Staff turnover is also a major problem. In Peru, between
1996 and 2001, 43 percent of IMCI-trained health workers had
already been rotated since their training (Huicho and others
2005). In Tanzania, where staffing patterns appear to be quite
stable in comparison with the situation in other countries,
23 percent of trained staff had moved within three years of
initial training (C. Mbuyia, personal communication).
Problems with turnover were also observed in Bolivia, Brazil,
and Niger. These health workers did not necessarily leave gov-
ernment employment, but high rotation means that IMCI may
not be continually delivered to the same target population over
time.
Another relevant issue mentioned in several countries was
that of low staff motivation, which was often associated with
low salary levels. In Uganda, the performance of health work-
ers fell dramatically in 2001 after the government discontinued
cost-sharing schemes that were used to supplement drug sup-
plies and health worker salaries at the facility level (Burnham
and others 2004). In Cambodia and Tanzania, salary levels are
so low that health workers need other sources of income to
maintain their families. Issues related to human resources are
addressed in greater detail in chapter 71.
Poor supervision was a major issue in all countries that
were visited. IMCI recommends regular supervisory visits that
should include systematic observation and feedback on case
management. In Peru, the average number of supervisory vis-
its was 0.19 per facility per year (Huicho and others 2005). In
Bangladesh, a baseline (pre-IMCI) health facility survey con-
ducted in 2000 found that none of the facilities in the study
area had received a supervisory visit, including observation of
case management, within the previous six months (S. E.
Arifeen, personal communication). Common reasons given by
health workers for erratic supervision activities are shortages of
vehicles, fuel, and staff members.
Problems with referral were also common. The Urgent
Referral category in figure 63.1 requires immediate referral to
a hospital. In several countries (Bangladesh, Cambodia, Niger,
Uganda, and Tanzania), it was reported that children in this
category are often not taken to a hospital because of distance or
lack of funds for travel and hospitalization-related expenses.
For example, in a Tanzania survey, only 5 of 13 children
who had been referred were actually taken to a hospital
(Schellenberg and others 2003). Also, in some countries hospi-
tal staff members who had not been trained in IMCI were
reluctant to admit children with danger signs identified
through the IMCI algorithm. This situation highlights the need
for reinforcing training of referral-level health workers using
IMCI guidelines.
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Another important limitation, observed in Bangladesh,
Cambodia, Niger, and Uganda, is the low use of public sector
health care for a variety of reasons (accessibility, official or
under-the-table user fees, perceived poor quality, lack of drugs,
and so on). For example, using Ministry of Health documents in
Niger, the authors estimated that the average annual number of
attendances by children under age five was 0.5. In Bangladesh,
only 8 percent of children who were ill were taken to a qualified
provider (S. E. Arifeen, personal communication). In the pres-
ence of such low utilization rates, it is unlikely that health work-
er training can have an effect on mortality rates, unless simulta-
neous community activities improve care-seeking practices.
Although equipment and vaccines that are needed for IMCI
delivery were available in most countries visited, availability of
drug supplies varied from country to country. Shortages were
reported in Cambodia and Zambia, and other countries, such
as Peru and Tanzania, reported that essential IMCI drugs were
mostly available.
Health Sector Policy and Strategic Management Issues.
Several of the problems described in the preceding section are
directly related to health sector issues. In addition, issues related
to higher-level policy and management may also represent con-
straints to successful IMCI implementation.
In some countries, IMCI was not fully institutionalized at
national or subnational levels. For example, a national coordi-
nator was not appointed or was appointed on a part-time basis.
In Peru, IMCI was implemented side by side with CDD and
ARI programs, which it was expected to replace, and in several
districts the ARI coordinator’s tasks were expanded to also
encompass IMCI. In several countries, IMCI activities did not
have a separate budget line, or they were not included in dis-
trict health plans, or neither. A report on the Analytic Review of
IMCI (DFID and others 2003, 39) states, “IMCI was generally
introduced as a strategy, not as a program. If this was not a bar-
rier in the pilot phase, it seemed to generate problems for rapid
scaling up. In five of the six Analytic Review countries, IMCI
focal persons did not have the rank or the responsibility of
previous disease specific program managers within their
Ministry of Health, and IMCI did not have a budget line and
a strong management structure.” The report also argued that
decentralization, as part of health sector reform, reduced man-
agerial capacity at the central level and had, at least in the short
term, a negative effect on IMCI implementation.
Conflict between IMCI guidelines and existing policies
and regulations was present in some countries, particularly
the former Soviet republics of Kazakhstan and the Kyrgyz
Republic, where policies for hospital admission—requiring, for
example, that all children with diarrhea be hospitalized—were
in conflict with IMCI guidelines. Another regrettable example
comes from Brazil, where both doctors and nurses were being
trained in IMCI until medical associations threatened legal
action to prevent nurses from being trained in using antibiotics
for life-threatening conditions. This obstruction succeeded
despite an MCE health facility survey that showed that IMCI-
trained nurses performed as well as doctors in managing sick
children (Amaral and others 2004). In Morocco, IMCI-trained
nurses are also unable to prescribe antibiotics because of cen-
tral regulations.
A particular challenge came to light when the MCE team
visited Cambodia and Niger and the Analytic Review team
visited Mali. These countries have high levels of under-five
mortality and thus the greatest need for IMCI. They also have
weak health systems and low utilization rates and are therefore
having difficulty implementing IMCI successfully. Just as for
individuals, the inverse care law—which suggests that those
who most need high quality care are the least likely to get it—
seems to also apply to countries (Hart 1971).
However, there is a possibility that IMCI (or other
approaches to managing sick children) might help strengthen
selected health system functions through specific approaches,
as the Analytic Review team observed in regard to drug and
commodity availability, service management, and health
worker motivation through IMCI in the Arab Republic of
Egypt (DFID and others 2003).
Implications for Health System Development 
The first component of IMCI, which involves training of health
care workers, has been implemented in many developing coun-
tries and has resulted in important improvements in the quali-
ty of care delivered to children in first-level facilities in limited
geographic areas. The potential population-level effect of IMCI
case-management training has not been realized, however, for
three reasons:
• Sufficient resources were not available for full
implementation.
• Few health systems in low-income countries are capable of
providing the policy, personnel, and managerial support
needed to expand and sustain high levels of IMCI training
coverage.
• At the time of this writing, not one country had succeeded
in mounting a behavior-change program capable of
improving care seeking, home management of illness, and
nutrition-related practices to coverage levels that will result
in population-level changes in service utilization or health
status.
One implication for health system development is that sup-
port should be continued and expanded for integrated case
management in first-level facilities as an essential component
of an effective child survival strategy. A second implication,
however, is that greatly expanded efforts must be directed
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simultaneously to the development of new and innovative
approaches to strengthening health systems and to reaching
families and communities with known and affordable child
survival interventions.
An important distinction can be made between interven-
tions and delivery strategies (Bryce and others 2003). The same
intervention (vitamin A capsules, perhaps) can be delivered
through different strategies—for example, to children attend-
ing health facilities, on National Immunization Days, or directly
at the household level through community networks. In spite
of its community component—which in most countries has
not been operational anyway—IMCI, as implemented to mid
2004, relies on health facilities as its key delivery strategy.
The first component of the IMCI strategy—a focus on
improving health worker skills—was innovative to the extent
that it provided clear technical guidelines and yet required
country-level adaptation. Similar levels of technical clarity and
country-level flexibility did not exist for the second and third
components of the IMCI strategy, which focused on improving
health systems to support IMCI and improving family and
community practices. Within these two components, the IMCI
strategy has been criticized for attempting to become a uniform
global strategy, with guidelines for implementation that do
not allow room for country-level modifications, especially the
incremental approaches to implementation needed by weak
health systems (Bryce and others 2003). The first component of
IMCI can serve as a model for the types of development work
that must now move forward in the health systems and family
practice areas; however, in these areas, key decisions about how
best to deliver interventions will need to be made at the country
level and below.
One example of progress is that WHO and its partners have
now developed a process for assessing country-level opportu-
nities and requirements for achieving population-level
behavior change in relation to key family practices and for
developing feasible and collaborative work plans for effectively
implementing child health activities at the community level (A.
Bartlett, personal communication).
As the MCE and Analytic Review have shown, IMCI
requires a functional health system with managerial capacity;
an ability to train health workers and to keep them on the
job; an efficient means of supplying drugs, vaccines, and equip-
ment; and the capacity to maintain regular supervisory activi-
ties. It also requires appropriate care-seeking practices, leading
to a reasonable level of health services utilization by children
under age five. In most countries, appropriate health services
utilization is unlikely to be achieved without strong family and
household-level interventions such as those promoted by com-
munity IMCI.
These problems, however, are not specific to IMCI; they
affect every other delivery strategy that relies heavily on health
facilities, including the predecessors of IMCI, namely the CDD
and ARI programs. In fact, at least in theory, the efficiency gains
represented by the integration promoted by IMCI should make
it easier for developing countries to implement as the key child
health strategy, so a return to vertical programs is not the
answer.
Given these difficulties, however, there may be a tempta-
tion to bypass health services altogether in the poorest coun-
tries by promoting the delivery of child health interventions
directly to families and households. There are successful
examples of such community delivery schemes—for example,
projects dispensing antimalarials (Pagnoni and others 1997;
Kidane and Morrow 2000) and antibiotics for pneumonia
(Sazawal and Black 1992). This approach may, in fact, be the
most viable short-term solution for countries with weak
health services, but it should not be forgotten that most suc-
cess stories represent small-scale pilot projects with strong
managerial backup. In countries with weak systems, the man-
agerial support for implementing and sustaining high-quality,
community-based interventions is also likely to be lacking, so
it may be naive to assume that such programs will have the
effects that health services have failed to deliver. Also, just as
first-level health facility care depends on referral services for
backup, community delivery schemes will require operational
first-level health facilities to handle complications and treat-
ment failures.
There is no substitute for strengthening health systems in
the poorest countries. In the long run, strengthening these sys-
tems will be the key intervention for reducing child mortality
as well as for promoting healthy growth and development.
Delivery strategies that reach communities either directly or
through other mechanisms are needed in the short term, but
the long-term goal of improving health services is paramount.
THE RESEARCH AND DEVELOPMENT AGENDA
This section starts by addressing health systems research issues
related to scaling up child health interventions effectively. Key
issues on the research agenda are how to make the best possi-
ble use of integrated case management in settings where health
systems are weak and how to design alternative delivery strate-
gies to improve child survival in such settings.
Specific issues relate to how to counteract the main con-
straints to scaling up IMCI that were described earlier in
“Implementation of Programs: Lessons of Experience.” For
example, research is needed in the following areas:
• how to increase utilization in the public sector (and the role
of user fees in this respect) 
• how to develop viable public sector–private sector
partnerships
• how to reduce staff turnover 
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• how to improve supervision and make it sustainable
• how to institutionalize IMCI case-management training
and supervision at the district level.
In addition, research is needed on how to strengthen health
systems and improve family and community practices for child
survival in ways that take into account and build on features of
the country context. These features include the epidemiologic
profile and the characteristics of the health system. Country-
level assessments and planning and support for longer-term
implementation are required to achieve high and equitable
coverage and population effect in different epidemiologic,
health system, and cultural settings (Bellagio Study Group on
Child Survival 2003). Innovative research is needed involving
country-level investigators and program staff members, with
international partnerships if required, to develop and evaluate
different combinations of health facility–based and household-
based delivery schemes. In particular, research should address
how to go to scale with interventions that have been proven
effective in pilot studies. From the costing perspective, research
should address the issue of how to estimate the cost of scaling
up using different scenarios of resource availability and
constraints.
Monitoring and evaluation are key components of the
required research. Tools must be developed for use at the dis-
trict and national levels, and capacity to use them must be
strengthened.
CONCLUSIONS: PROMISES AND PITFALLS
IMCI was introduced in the mid 1990s as an ambitious global
strategy that held many promises. Cost-effective vertical inter-
ventions against the main causes of under-five mortality in the
world were integrated into a single, facility-based health worker
training program. The program was accompanied by efforts to
improve health systems support for child health care and
to promote key family practices at the community level.
Integration was expected to further improve coverage levels
and the cost-effectiveness of child survival interventions rela-
tive to their delivery through separate vertical programs.
IMCI case-management training was repeatedly shown to
improve the quality of care delivered in first-level health facili-
ties, and the costing data reviewed above suggest that it can do so
at similar or lower costs than those of existing health services.
IMCI, therefore, is able to deliver better child health care at no
increase in costs.
Nevertheless, community IMCI interventions only reached
meager population coverage in the countries studied, and even
health worker training was never effectively scaled up in most
countries as a result of health system constraints. The major
effect on child survival that was initially expected as a result of
IMCI implementation has not yet materialized, and country
reports of the barriers to achieving and maintaining high cov-
erage levels suggest that effects will not be seen unless IMCI in
first-level facilities is buttressed by equally strong or stronger
efforts to develop health system capacity and reach families and
communities. In fact, progress in child survival in the late 1990s
and early 21st century has been slower than in earlier decades
(Bellagio Study Group on Child Survival 2003), and current
trends suggest that the Millennium Development Goals are
unlikely to be achieved for most countries unless major new
investments are made very soon.
The Tanzania results suggest that, in a setting where IMCI
was implemented in conjunction with health system strength-
ening and where utilization of health facilities is high, an effect
on mortality and nutritional status is likely. However, experi-
ence from other countries showed that reaching high and sus-
tained implementation was difficult.
Although IMCI has only partially lived up to initial expecta-
tions, it has many positive aspects that must be fostered. A
return to isolated vertical programs for child survival will not
solve the difficulties faced by scaling up IMCI effectively, and
integration should continue to be a key goal of child survival
strategies in the future. In fact, much of the frustration
associated with reported underperformance of IMCI arises
from the fact that sufficient resources—financial, human, and
organizational—were not planned for or available to support
its full implementation, either at national or at international
levels. The meager training coverage levels observed in most of
the MCE countries are clear evidence of insufficient imple-
mentation, and it is thus not surprising that coverage and effect
were also less than expected.
Renewed and expanded efforts to reduce child mortality
should build on the proven effectiveness of IMCI case manage-
ment in first-level facilities, but they also should incorporate
new knowledge. Country-specific planning is needed to reach
families and communities and to build on the existing health
system to achieve and sustain population-level coverage.
Countries with weak health systems will require creative
approaches to intervention delivery in the short term at the
same time that health systems are strengthened as a long-term
strategy. The poorest strata of the population are also the need-
iest in terms of health care and the hardest to reach. The chal-
lenge of improving equity is not unique to IMCI or to child
survival; it affects virtually every intervention and delivery
strategy. Unless equity considerations become a key part of pol-
icy making and of monitoring outcomes, interventions may
widen instead of narrow inequity gaps (Victora and others
2003).
A continuing challenge is how to raise and sustain the stand-
ing of child survival in the international agenda. The more than
10 million annual deaths of children under age five—more
than 20 deaths per minute—represent twice the number of
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deaths attributable to AIDS, malaria, and tuberculosis com-
bined (Black, Morris, and Bryce 2003). Putting child survival
back on the public health and development agenda is an essen-
tial developmental step in the process of refining country-level
and global child health strategies. Only through taking stock of
the lessons learned in early IMCI implementation can a flexi-
ble, integrated program be developed that will improve child
survival in particular and child health in general.
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Primary health care has always been a feature of health care
systems and—from a modern perspective—involves four inter-
related aspects: a set of activities, a level of care, a strategy for
organizing health care, and a philosophy that permeates health
care provision. At full stretch, then, the “primary health care
approach” can affect the configuration and focus of the entire
health system and extend to the development of communities
(Vuori 1985).
It is not always easy to see how information on the cost-
effectiveness of individual interventions—the focus of part 2
of this volume—contributes to the achievement of the wider
features of primary health care. Indeed, Starfield (1998) points
out that the importance of particular services or interventions
is overrated, in part because of limited appreciation of the
“essential and unique functions” of primary care. These func-
tions are mutually reinforcing and include first-contact care;
continuity in care (in Starfield’s words, “person-focused over
time”); comprehensiveness of available services; and coordina-
tion with specialized services and other levels of care. The
functions point to the centrality of how primary care is
organized and delivered, something with which the cost-
effectiveness approach has hitherto not been greatly
concerned. This chapter attempts to identify some of the com-
mon ground between the primary health care approach and
the cost-effectiveness approach. We propose that resource
constraints simultaneously require (a) the targeting of services
toward burdens of disease that are amenable to highly cost-
effective interventions and (b) the general strengthening of
the health system, particularly at the primary care and district
levels.
THE SCOPE OF GENERAL PRIMARY
CARE PRACTICE
General primary care can be defined as the immediate—and
often continuing—medical and health management of a child,
adult, or family when the patient first presents to the formal
health system. In low- and middle-income countries, such care
is often provided from publicly funded health posts and health
centers by nurses or other midlevel health workers, with med-
ical doctors expected to play a support, training, and referral
role.
Comprehensive versus Selective Care
The 1978 Alma Ata declaration on primary health care (WHO
and UNICEF 1978) was informed by a number of well-
described, small-scale health and development efforts in a
range of settings (Newell 1975; Tollman 1991). It focused
international health care efforts on low-cost, potentially high-
impact interventions, both medical and social, at both the
primary and community levels. In particular, the declaration
emphasized the importance of health promotion and commu-
nity development through, for example, the supply of water
and sanitation and the involvement of communities in decision
making.
Before long, the extent of resources and capacities needed to
implement such comprehensive activities led to the emergence
of the concept of “selective primary health care” (Walsh and
Warren 1979). This concept advocated a focus on a limited
number of priority conditions, such as children’s health and
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particular tropical diseases. Selective interventions, often cen-
trally planned, and managed and operated by a dedicated staff,
were intended as entry points into the health care system. Such
an approach, when fully operationalized as a “vertical pro-
gram,” proved especially useful in implementing control and
eradication campaigns and in dealing with epidemics following
natural disasters (Unger, de Paepe, and Green 2003; World
Bank 1994).
The selective approach attracted strong criticism for not
acknowledging that primary care practice needs to take
account of the range of conditions that present, many of
which—by definition—were excluded from the selective
agenda (World Bank 1993). In addition, administrators
responsible for vertical programs tended to have little contact
with local health officers and seldom coordinated well with
other vertical efforts, leading to duplication of training, super-
vision, and logistics management (Briggs, Capdegelle, and
Garner 2003). Other inefficiencies resulted from the need for
specialized personnel, which led to growing numbers of dedi-
cated staff members as well as excessive demand on service
users’ time if they needed multiple services. Verticalization can
also lead to competition between programs, favoring of some
conditions at the expense of others, weaknesses in continuity
of care, disruption of routine health services, and erosion of
country-level delivery capacity (Coker, Atun, and McKee 2004).
Concerns about the appropriateness of individual vertical
programs were matched at that time by concerns about the
continuing misallocation of resources toward expensive, cost-
ineffective care, culminating in the publication of Investing in
Health: World Development Report 1993 (World Bank 1993).
The report identified highly cost-effective interventions tar-
geted at the major causes of the prevailing burden of disease in
low- and middle-income settings. These interventions were
grouped into a “minimum package of health services,” which,
it was argued, governments and donors should prioritize for
funding (World Bank 1993). The delivery vehicle for most of
these services was the primary care system.
The definition and costing of intervention packages has
evolved over time, and this evolution is reflected in the World
Bank’s Better Health in Africa (1994), the World Health
Organization’s World Health Report 2000 (WHO 2000), and
the report of Working Group 5 of the Commission on
Macroeconomics and Health (Jha and Mills 2002). Although
some services have been added and others have been described
more specifically (partly informed by new research), the essen-
tial components of the package have remained remarkably con-
stant. Another World Health Organization (WHO) publication
(2002), World Health Report 2002, which focused solely on inter-
ventions against risk factors, corroborated several of the inter-
ventions in the package (Doherty and Govender 2004; see annex
64.A). Thus, a broad consensus appears to exist on the nucleus
of activities that is appropriate at the primary care level (see
table 64.1). In many ways, this consensus existed before the pub-
lication of Investing in Health (World Bank 1993), but econom-
ic evaluation has subjected conventional wisdom to empirical
validation and considerations of affordability; it has also scruti-
nized the components of particular interventions (frequency of
prenatal health care visits, for example). This evaluation has
served the purpose of providing a basis for consensus that is
more convincing to key constituencies, such as national treasur-
ies and donors. Consequently, several low- and middle-income
countries have delineated minimum or essential packages for
their own national contexts.
The notion of such packages is not without controversy,
however. Whereas some criticisms relate to methodological
issues—and hence to the advisability of generalizing the find-
ings of local studies and using them to establish priority serv-
ices on a global scale—others relate to the disease-oriented
basis of essential packages (Doherty and Govender 2004). The
authors of essential packages are not necessarily proponents of
verticalization (in some instances, they have argued strongly
for the cost-effectiveness that a horizontally well-integrated
service can achieve). However, the reality of activity by interna-
tional agencies, donors, and even governments means that, in
many instances, the implementation of narrowly defined pro-
grams continues to be favored (with HAART—highly active
antiretroviral therapy for the treatment of HIV/AIDS—having
the potential to follow suit). Continuing verticalization also
reflects the resource constraints faced by countries that are
unable to mount a comprehensive set of services and suggests
that services in developing countries are chronically under-
funded (Jha and Mills 2002).
The disease-based construction of packages may have rein-
forced this tendency to verticalization, as may have incentives
for program managers to monitor program activities in terms of
their effect on specific diseases. This factor accounts partly for
the suspicion that sometimes greets efforts at cost-effectiveness-
based planning, and it signals the need to continually promote
the effective integration of activities at the health facility level.
General Primary Care at a Key Interface
Although the primary care level constitutes the first point of
patient or family contact, it is also a critical base for extending
care to communities and vulnerable groups. These outreach
services may focus on individual preventive measures (such as
immunization, vitamin A, or oral rehydration therapy) or com-
munitywide health-promoting efforts (such as education on
child nutrition or adult diets and exercise; see chapter 56).
Increasingly, home-based care for chronic conditions, such as
HIV and AIDS and poststroke rehabilitation, can be expected to
feature in outreach services. These services depend substantially
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that links, on the one hand, ambulatory care with hospital and
specialty services and, on the other, individual clinical care with
community-wide or population-wide health, nutrition, and
family planning programs. Acting as the fulcrum of a compre-
hensive care and support system, development of general
primary care requires that local management teams plan serv-
ices for their defined catchment communities (Jha and Mills
2002)—recognizing that catchment populations can be more
difficult to define in urban (particularly high-density) settings.
Delineating the community for which a local health system is
responsible—and thereby making explicit the population
under the care of providers—makes it feasible to undertake
ongoing monitoring and evaluation of the performance of
local primary care services (quality of care and extent of cover-
age, for example) and contributes to the assessment of health
systems more broadly.
Given the pivotal position of general primary care, distin-
guishing sharply the cutoff between activities that occur at this
level and those that occur elsewhere is difficult. The balance of
services provided at the primary level rather than other health
service levels is, in fact, a moving target, affected by an array of
factors. For example, diagnostic and technological innovation
can influence substantially the level at which interventions are
delivered. In many middle-income countries, great potential
exists to move elements of surgical, psychiatric, and medical
care upstream to the primary care level, provided that the nec-
essary competencies, equipment, and technical or managerial
support exist. However, the converse also holds: no matter how
appropriate in theory, if service delivery is ineffective, the
downstream momentum to district and secondary hospital
levels (and into the private sector) is almost unstoppable, with
serious implications for the accessibility of care. In practice,
therefore, factors such as geographic and financial inaccessibil-
ity, limited resources, poor capacity, and erratic drug supply
and faulty equipment often mean that the services offered at
the primary care level are disappointingly limited in their
range, coverage, and effect.
“Fitting” of Interventions to the Health System
Recognition is growing that focusing simply on selecting cost-
effective interventions as the basis for services development
is inappropriate. Paying close attention to the qualities of the
delivery system that are required to support the introduction
of these interventions and, in time, provide support to their
scale-up is essential. The Multi-Country Evaluation of IMCI
Study Group (Bryce and others 2003, 159) highlights the
“importance of separating biological or behavioural interven-
tions from the delivery systems required to put them in place,
and the need to tailor delivery strategies to the stage of health-
system development.”
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Table 64.1 Selected Sets of Interventions Used in the Cost
Analysis of the Commission on Macroeconomics 
and Health, 2002 
Disease area Nature of interventions
Maternity-related Prenatal care
interventions Treatment of complications during pregnancy
Skilled birth attendance
Emergency obstetric care
Postpartum care (including family planning)
Childhood disease– Vaccinations (Bacillus Calmette-
related interventions Guérin, oral polio vaccine, diphtheria-
(immunization) pertussis-tetanus, measles, hepatitis B,
Haemophilus influenzae type B)
Childhood disease– Treatment of various conditions (acute 
related interventions respiratory infections, diarrhea, causes of fever, 
(treatment of childhood malnutrition, anemia), now increasingly 
illnesses) combined as integrated management of
childhood illness
Malaria prevention Insecticide-treated nets 
Residual indoor spraying
Malaria treatment Treatment for malaria
Tuberculosis treatment Directly observed short-course treatment for
smear-positive patients
Directly observed short-course treatment for
smear-negative patients
HIV/AIDS prevention Youth-focused interventions
Interventions working with sex workers and
clients
Condom social marketing and distribution
Workplace interventions
Strengthening of blood transfusion systems
Voluntary counseling and testing
Prevention of mother-to-child transmission
Mass media campaigns
Treatment for sexually transmitted infections
HIV/AIDS care Palliative care
Clinical management of opportunistic illnesses
Prevention of opportunistic illnesses
Home-based care
HIV/AIDS treatment Provision of highly active antiretroviral therapy 
Source: Jha and Mills 2002.
Note: Smoking cessation interventions, although considered a priority, were not included in this
cost analysis because it was assumed that they would be financed by tobacco taxes.
on community support and mechanisms for identifying, train-
ing, and supporting village or community health workers.
At the same time, primary care facilities mediate patient
access to hospital care, particularly at the district level. General
primary care, as a level of care, is thus located at a key interface
Thus, seeking and evaluating the goodness of fit between
interventions with the potential to be highly cost-effective and
the health system responsible for their effective delivery are
critical. A major challenge in focusing on the primary care level
is to establish the most effective combinations or clusters of
interventions that can target multiple conditions and risk fac-
tors affecting key community groups (children, women, and
older adults, for example) and that are appropriately adapted
to local epidemiologic, economic, and sociocultural contexts.
Clustering interventions appears to be a pragmatic approach
that achieves a degree of comprehensiveness while at the same
time acknowledging resource constraints. It also provides
opportunities to intensify training, improve the quality of care
provided, and assess community health impact (see chapter
63). If clusters, such as integrated management of infant and
childhood illness (IMCI) or reproductive health services, can
be fully integrated into health service planning, management,
and operations, the health system will be provided with some
focus while the shortcomings of vertical disease programs can
be potentially avoided. Thus, clustering may allow for broader
horizontal strengthening of local health system inputs. As
stated earlier, persistent efforts to achieve such integration are
essential, given that, as expressed by the Bellagio Study Group
on Child Survival (2003, 324), “in today’s environment of dis-
ease-specific initiatives, cross-disease planning, implementa-
tion, and monitoring are hard to establish and maintain.”
However, clustering does not entirely address concerns that
interventions based solely on cost-effectiveness assessments,
which seldom examine indirect and nonhealth benefits
(Doherty and Govender 2004), might deplete some of primary
care’s unique features, including responsiveness to the
expressed needs of local communities. Indeed, Gilson (2003,)
writes that “future analysis and policy development must
recognise that health systems are complex socio-political insti-
tutions and not merely delivery points for bio-medical inter-
ventions.” Community expectations of the services provided at
a health center or health post tend to be holistic and may well
depart from selected priority intervention categories. The
exclusion of services from clusters, or the exclusion of whole
clusters, can lead to inequity. Failure to manage this situation
adequately can undermine clients’ confidence in the public
health system and affect provider behavior negatively. WHO
(2000, 59) notes that providers “usually react to this . . . by
cross-subsidizing the excluded activities through the budget
received to pay for the defined benefit package; or by charging
extra for the additional services.”
These considerations need to be taken into account when
identifying clusters of interventions to be provided in local
contexts. Nonetheless, likely intervention clusters, with
potentially high goodness of fit at the primary care level, will
generally include IMCI; maternal and reproductive health serv-
ices; clinic and community-based management of tuberculosis,
HIV and AIDS, and sexually transmitted infections; malaria
management; management of hypertension, other cardiovas-
cular risk factors, and—increasingly—stroke and cardio-
vascular disease; and mental illness and substance abuse. In
all cases, a systematic approach must be taken to establish
explicit criteria, guidelines, or regulations regarding the appro-
priate treatment level (primary, secondary, and so on) for key
conditions and the interventions suitable for these conditions
at different levels of severity, according to a country’s stage
of health system development. Broadly categorizing countries
according to their income status and the general features of
their health system is too blunt an approach to allow the
detailed mapping of interventions to the health system capa-
bility that is required, and it fails to recognize the wide dispar-
ities in health system organization and effectiveness that exist
within national boundaries.
THE EFFECTIVENESS OF GENERAL PRIMARY CARE
Whereas it can be argued that highly cost-effective interven-
tions deserve to be implemented, no matter the level for
which they are designed, unique reasons exist for giving prior-
ity to those based at the primary level. As implied earlier, these
reasons relate to the extent of the burden of disease that is
potentially avertable through primary-level care (the health
effect), the welfare benefits that accrue to households spared
the experience of disease (the nonhealth effect), and the poten-
tial to provide widely accessible services (an equity effect based
on degree of need).
Unfortunately, although many small-scale projects and
assessments of single interventions have been able to measure
such effects (see part 2 of this volume), the empirical evidence
with regard to large-scale and routine primary care programs—
whether in industrial or low- and middle-income settings—is
scant (Doherty and Govender 2004; Starfield 1998). The key
problem is to demonstrate the causal link between provision of
general primary care services and positive health outcomes—
and especially to disentangle the influences of socioeconomic
conditions. This difficulty is compounded by other factors,
ranging from the complexity of the study design required to
convincingly evaluate routine programs (as opposed to field tri-
als) to the difficulties faced by health ministries in ensuring that
monies targeted at primary care are translated into the delivery
of quality health services.
Thus, we are able to comment only in broad terms on the
positive contributions of general primary care services, recog-
nizing that, although these contributions are potentially enor-
mous, the gains made by such services over the past two
decades have been mixed. Importantly, Almeida and others
(2001) caution against ascribing the failures of primary care to
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inherent weaknesses in the concept. In commenting on analy-
ses of the effectiveness of primary care, they point to “the
cataclysmic effect on public health systems in less-developed
countries of the global economic recession of the 1980s and the
application of policies stressing privatisation and decreased
public spending in that decade and the next; [this] resulted in
rising poverty and under-funding of health services in many
less-developed countries, to the point of near-collapse in the
poorest countries” (Almeida and others 2001,).
Health Effects
Investing in Health reported that in countries with moderate to
high mortality only a few conditions accounted for the major-
ity of the burden of ill health (World Bank 1993). Thus, in
1990, 55 percent of the global burden of disease was concen-
trated in children under 15, and 75 percent of this burden was
caused by 10 disease conditions or clusters (Bobadilla and oth-
ers 1994). Except for congenital malformations, all these causes
could be aligned with highly cost-effective interventions, many
of which are classic components of general primary care
(labeled the “clinical services” component of the package).
Indeed, almost all of the activities included in the “public
health” component of the package also involve some element of
individual service delivery in the primary care setting.
Together, it was estimated, these interventions could eliminate
21 to 28 percent of the burden of ill health in children.
With respect to adults, the World Bank (1993) found the
burden of disease to be less concentrated: here the 10 main
causes of disease and injury accounted for some 50 percent of
the burden.1 Most interventions against these problems were
found to be quite cost-effective, but their overall estimated
effect was moderate because they prevent or treat only part of
the problems. Such interventions could thus eliminate 10 to
18 percent of the adult disease burden.
These figures give some sense of the potential effect of inter-
ventions at the primary level when they are targeted at com-
mon, high-burden conditions in the population. Subsequent
work by the World Bank estimated that the primary care level
could potentially deal with up to 90 percent of health care
demands (World Bank 1994) and that only 10 percent of care
needs require the services and skills typically associated with
hospitals.
Shifting from estimates to empirical evidence, we find that
some studies have been able to demonstrate large-scale success
in the sphere of child health. For example, using data from a
national survey in Niger, Magnani and others (1996) showed
that children living in villages near health dispensaries were
32 percent less likely to die than children without access to
modern primary care services (differential access resulted from
the phased implementation of services, which produced a nat-
ural quasi-experiment). Drawing on earlier work, Ewbank
(1993,) concluded that the results of surveys in Zaire and
Liberia “suggest that child survival programmes in Africa can
reduce mortality substantially in populations living in different
environments at very different initial levels of child mortal-
ity. . . . In both countries, it appears that the programme
reduced mortality under age 5 by about 20% or more.” More
generally, many examples of successful health programs clearly
depend on the existence of a strong primary health care system
(see chapter 8).
Given the paucity of evidence from developing countries,
turning to the experience of high-income countries is useful,
although the configuration of primary care services in such set-
tings may be quite different. Following a detailed comparative
study of 11 industrial nations (which involved the method-
ologically complex—and at times controversial—assigning of
primary care and health system scores by country and then
associating these scores with a range of health status indicators
and total health care costs per capita), Starfield (1994,) con-
cluded that “countries with a stronger orientation to primary
care indeed are more likely to have better health levels and
lower costs.” Shi (1994,) found that, in the United States,
availability of primary care was “by far the most significant
variable related to better health status, correlating to lower
overall mortality, lower death rates due to diseases of the heart
and cancer, longer life expectancy, lower neonatal death rate,
and less frequent low birth weight.” Although working largely
at the level of health output rather than outcome, Blumenthal,
Mort, and Edwards (1995), in reviewing a number of studies in
the United States, found considerable evidence of the positive
effect of primary care services (see box 64.1). They argue that
the literature does not adequately address the issue of whether
primary care reduces the cost of providing care for underserved
populations, but they conclude that “a commitment to pri-
mary care should be made for its potential to improve the
satisfaction and health status of the American public, not for
its potential to save money” (Blumenthal, Mort, and Edwards
1995,).
Nonhealth Effects
Although most of the recent literature on primary care pack-
ages places value on primary care services because of their abil-
ity to reduce the burden of disease considerably and at low cost,
such services potentially bring other benefits to society. Among
the most striking may be the welfare benefits that accrue to
households as a result of the prevention of illness. Severe
disease can limit the ability of patients and caregivers to work,
leading to the consumption of household assets in the
purchasing of care. Russell (2003) found that such costs
amounted to just over 10 percent of household income in three
developing countries, a proportion that can have a catastroph-
ic impact on the sustainability of poor households. Through
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prevention and early treatment, geographically accessible and
financially affordable primary care services can reduce the neg-
ative economic consequences of ill health for households,
reduce absenteeism, and enhance children’s performance at
school.
Serving of Equity Goals
Primary care services have the advantage over hospital care of
tending to be more physically, financially, and culturally
accessible to local communities. Because of their staffing and
organization, they are less costly and more easily able to
provide comprehensive, integrated, personalized, and continu-
ous care (World Bank 1993). Because that part of the burden
of disease that is addressed by primary care services dispro-
portionately affects the poor, primary care services are theoret-
ically well placed to improve equity in health and health care.
Again, few data exist to demonstrate the equity effects of
primary care delivered on a large scale in middle- and low-
income countries. This gap is compounded by the fact that
cost-effectiveness analyses seldom take into account the costs
incurred by patients in seeking care (Doherty and Govender
2004).
However, in studies by Shi and Starfield (2000, 2001) exam-
ining income inequality and primary care in the United States,
a significant association between higher primary physician
supply and good health status was established, even in a context
of high income inequality: “The finding of a significant associ-
ation between primary care and self-rated health contributes to
the mounting evidence that specific aspects of health services
have an independent [of income levels] effect in improving
population health—in particular, the beneficial effects of
primary care” (Shi and Starfield 2000,). The authors suggest
that, at least within the particular settings studied, strengthen-
ing the primary care aspects of health services could mitigate
some of the adverse impacts that income inequality has on
individuals’ health status.
Primary-level services are also potentially responsive to
patients’ nonhealth needs. These include a need for the range
and quality of health services to meet community expectations
and a need for services to treat patients in a helpful and digni-
fied manner. In addition, primary-level facilities can act as
community resources (providing communal meeting places,
for example), and primary care services can contribute sup-
port to neighborhood sports and community development
activities. All in all, well-functioning primary-level services
represent the face of the health system and have the potential to
inspire trust in the system as a whole.
Another source of suspicion regarding the cost-effectiveness
approach is the fear that efficiency concerns will override these
positive features of primary care. Paalman and others (1998,)
note that “the fact that the most efficient interventions . . . tend
to specifically benefit the poor is more a result of coincidence
than of principle.” Indeed, the cost-effectiveness approach does
not intrinsically protect equity and could, for example, count
against the extension of services to populations living in
remote areas. Governments will, at times, need to make explicit
choices between serving equity goals and responding to
efficiency concerns when determining service priorities. This
tradeoff is easier to manage in wealthier countries, where
resources are less constrained.
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Evidence of the Effectiveness of Primary Care Services 
Box 64.1
The effectiveness of primary care services is illustrated as
follows:
1. Community-based interventions improve access to ser-
vices,reduce the use of emergency and outpatient depart-
ments at hospitals, increase the use of noninstitutional
ambulatory care, and reduce the use of hospital care
(especially with respect to preventable hospitalizations).
2. Primary care is associated with improved control of
routine illnesses that have serious consequences if
untreated.
3. The availability of primary care services is associated
with improvement in patients’ self-perceived health
status.
4. The longitudinal care afforded by primary care services
is independently associated with improved patient
satisfaction, reduced use of ancillary and laboratory
tests, improved patient compliance, shorter length of
stay, and improved recognition of patients’ behavioral
problems.
Source: Blumenthal, Mort, and Edwards (1995).
THE COST-EFFECTIVENESS OF PRIMARY
CARE INTERVENTIONS
Part 2 of this book details our best understanding of the cost-
effectiveness of many of the individual interventions that have
been clustered into “essential packages.” According to Investing
in Health, most of these interventions are highly cost-effective,
costing less than US$100 per disability-adjusted life year
(DALY) averted (see table 64.2; World Bank 1993).
Subsequent packages have expanded the Investing in Health
list somewhat, yet the primary-level interventions put forward
in 1993 remain among the most cost-effective available,
especially when combined with population-based interven-
tions (Commission on Health Research for Development 1990;
Jha and Mills 2002; WHO 2000). It is important to appreciate
that, because of the added costs of extending service delivery
to people living in more rural and peripheral areas, achieving
universal coverage would probably raise marginal costs
considerably above the average figures normally quoted.
Bobadilla and others (1994,) note that, in these instances, “the
relative importance of cost-effectiveness versus equity will then
determine whether to modify the package by leaving out some
interventions, providing mobile services rather than fixed
facilities, concentrating on public health rather than clinical
interventions for the high-cost population, or sacrificing some 
efficiency in order to preserve equity.” The need to redress
gender imbalances or respond to cultural preferences and other
factors, as well as the choice of interventions, also might affect
costs.
SCALING UP
Adequate delivery of services (and health care more broadly) at
the primary care level is, we believe, fundamental to effective
functioning of health systems. However, for the most part, pri-
mary care systems in low- and middle-income countries have
yet to receive the sustained attention and resources that their
importance warrants. Early efforts at primary care expansion
in the late 1970s and early 1980s were overtaken in many parts
of the developing world by economic crisis, sharp reductions
in public spending, political instability, and emerging disease.
Although essential packages based on cost-effectiveness criteria
have been criticized for their largely disease-oriented and verti-
cal approach, in most poor countries even these limited ver-
sions of general primary care remain incompletely applied and
largely unaffordable in relation to current per capita health care
expenditure. At the same time, renewed awareness of the cen-
trality of the primary level in responding to the consequences
of the HIV/AIDS epidemic or to rapidly rising cardiovascular
risk means that increasing demands will be placed on primary
care services. This section examines critical elements of any
strategy to scale up primary care efforts; a prerequisite, how-
ever, is an adequate understanding on the part of policy mak-
ers and planners of the position and role of primary care in the
national health system (Travis and others 2004).
Committing More Financial Resources 
In the mid 1980s, Drummond and Mills (1987) found the best
estimate of the cost of effective primary health care (including
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Table 64.2 Cost-Effectiveness of the Health Interventions
Included in the Investing in Health Minimum Package of
Health Services for Low- and Middle-Income Countries 
(2002 US$, 2001 prices)
Cost per DALY
Low-income Middle-income 
Interventions countries countries
Public health
Expanded program of immunization, 15–22 32–38
including vaccine against
hepatitis B and vitamin A
supplementation
School health program 25–32 48–54
Tobacco and alcohol control program 44–70 57–70
AIDS prevention program 4–6a 16–23a
Other public health interventions — —
(includes information, communication, 
and education on selected risk 
factors and health behaviors, plus 
vector control and disease 
surveillance)
Total 18 —
Clinical services
Chemotherapy against tuberculosis 4–6 6–9
Integrated management of the sick child 38–63 63–127
Family planning 25–38 127–190
Sexually transmitted disease treatment 1–4 13–19
Prenatal and delivery care 38–63 76–139
Limited care (includes treatment of 253–380 507–760
infection and minor trauma; for 
more complicated condition, 
includes diagnosis, advice, and 
pain relief, and treatment as 
resources permit)
Total — 168
Source: Bobadilla and others 1994; World Bank 1993.
Note: —  not available, presumably because the authors were not able to aggregate data to
country level.
a. Understates cost-effectiveness because the analysis examined the probability of transmission
to others in the first year only.
the recurrent and capital costs of basic and village-level health
services but not of water and sanitation) to be 2 percent of the
annual per capita gross national product (GNP). This amount,
they noted, is considerable, given that many governments in
developing countries do not spend even 2 percent of annual
per capita GNP on their entire health sector.
More recently, the Commission on Macroeconomics and
Health (CMH) estimated that an additional US$40 billion to
US$52 billion annual expenditure would be required by 2015
to scale up 49 priority health interventions—not all at the
primary care level—to reach high levels of coverage in 83
deserving countries (that is, countries with a GNP per capita
below US$1,200, plus all countries of Sub-Saharan Africa) (Jha
and Mills 2002). Apart from the recurrent and capital costs of
the interventions themselves, this estimate included manage-
ment costs generated at levels above “close-to-client” services,
expenditure to improve absorptive capacity, expenditure on
improvements in the quality of care, and 100 percent increases
in staff salaries to address the problems of staff recruitment and
retention. The inclusion of these costs accounts largely for the
greatly increased per capita estimates of the CMH package rel-
ative to earlier estimates by the World Bank (see table 64.3),
and probably provides a better estimate of what is needed,
given the enormous challenges facing primary care service
delivery.
The CMH has placed great emphasis on donor funding of
services to adequate levels (see chapter 12 for a more extensive
discussion of sources of financing). Other avenues of funding
include reprioritizing government budgets or recovering costs
through health insurance schemes and user fees, although these
all remain difficult options within low-income settings. In
particular the experience of user fee schemes, which prolifer-
ated in the 1990s, suggests that such schemes have negative
impacts on equity, especially at the primary care level, and
should be applied with great caution in poor communities
(Gilson 1998). Yet the fact remains that an injection of addi-
tional resources is clearly one prerequisite for the successful
scaling up of general primary care in the 21st century, backed
up by political commitment to the centrality of general pri-
mary care (and primary health care more broadly) as a funda-
mental strategy for tackling the highest-burden diseases and
their causes.
Developing Human Resources 
Although increased financial resources are imperative,
Kurowski and others (2003) emphasize that “human resource
availability is likely to determine the capacity to absorb addi-
tional financial resources and thus the pace of scaling up.”
These authors warn that human resource availability is likely to
be grossly insufficient to meet the scaling-up needs envisioned
by the CMH.
The skills and competencies necessary to deliver and sup-
port effective primary care are in some respects similar to
those required at other levels of the health system (see chap-
ter 71), but certain competencies warrant special emphasis at
the primary care level (see box 64.2). Above all, if local
services are to meet community health needs, leaders at the
primary care level will have to be freed from the constraints of
stifling, rule-bound bureaucracies and encouraged to develop
innovative and at times unorthodox responses to the demand-
ing challenges they face. As expressed in the World Health
Report 2000 (WHO 2000, 64), “a key challenge in health serv-
ice delivery is to balance the need for broad policy oversight
with sufficient flexibility so that managers and providers can
innovate and adapt polices to local needs and contexts in a
dynamic way.”
The creation of dynamic health teams at the primary level
is one of the greatest requirements for scaling up effective pri-
mary care. The role of community health workers in such
teams remains unresolved and bears further investigation. At
the same time, one of the most challenging constraints is to
overcome the loss of motivation and sense of resignation of
the great body of primary care workers who work in under-
staffed settings; who lack consistent, quality support; and who
have grown accustomed to a norm of inadequate service
delivery (Narasimhan and others 2004). As Hongoro and
Normand assert in chapter 71, the extent to which countries
can improve access to good quality primary care will depend
in large part on a “better matches of skills to needs . . . and
clearer understanding of how improved structures and incen-
tives will work.”
Harnessing Private Sector Resources
Private sector health care provision is widespread and growing.
It extends from local supply of drugs and equipment to fee-
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Table 64.3 Comparison of Per Capita Total Annual Health
Expenditure Required to Provide Minimum Packages
(2002 U.S.$, 2001 prices)
Low-income Middle-income
Report countries countries
Investing in Health 15 27
(World Bank 1993)
Better Health in Africa 16–20 —a
(World Bank 1994)
Commission on Macroeconomics Least Lower-middle 
and Health (Jha and Mills 2002) developed: 40 income: 39
Other low Upper-middle 
income: 36 income: 331b
Source: Doherty and Govender 2004.
a. Estimate not provided.
b. Higher figure because of range of services provided (beyond minimum package) and higher
input costs; applies to a small subgroup of countries. 
for-service and insurance-based medical care to the many
forms of traditional practice. Although general primary care in
most African, Asian, and Latin American settings is a major fea-
ture of publicly financed services that are provided by the pub-
lic sector, private providers clearly play a significant role in
many low- and middle-income countries with respect to the
provision of primary care services (Berman and Rose 1996;
Palmer and others 2003). Governments have thus viewed pri-
vate sector providers as contributing additional human and
related resources that can be deployed in the service of at least
a portion of the population (usually those with means, includ-
ing employees with access to reasonable health insurance cov-
erage). By alleviating the workloads faced by public providers,
private sector providers have allowed the public services to
focus more directly on poorer communities and patients with-
out means. Out-of-pocket payments, health insurance, and
donations (as opposed to government contracts) that fund pri-
vate sector services thus result in additional financing for the
health sector.
Patients often prefer the private sector for a number of rea-
sons. These reasons include geographic accessibility, conven-
ient opening hours, and more favorable staff attitudes, as well
as perceived better quality in terms of shorter waiting times,
greater privacy, higher standards of diagnosis, better (per-
ceived) treatment, and counseling (Doherty and Govender
2004). Although private providers are generally thought of in
relation to curative care, interest is growing in the role they
could play in meeting public health objectives, especially with
respect to the scaling up of primary care services (Palmer and
others 2003).
It is important that the potential contribution of private sec-
tor resources be optimized through appropriate use of public-
private partnership mechanisms, public sector contracts, and
government regulation. These mechanisms are generally easier
for not-for-profit providers to contemplate, because they have
often been instrumental in bringing primary care to poor com-
munities. Some nongovernmental organizations (NGOs) are
able to offer services that can fill notable gaps, home-based care
to HIV and AIDS sufferers being but one example.
The potential of for-profit providers to contribute to the
care of the poor is less obvious, especially given the incentives
to overservice that are inherent in the fee-for-service reim-
bursement system. Mills and others (2002) find that consumers
of private sector primary care are often unable to assess the
technical quality of services, tending to place more weight on
aspects of perceived quality, such as interpersonal skills of
providers and the comfort of the environment in which treat-
ment occurs, than on technical competence. Mills and others
(2002,) argue that the effectiveness of private services is by and
large rather low: “poor treatment practices have been reported
for diseases such as tuberculosis and sexually transmitted infec-
tions, with implications not only for the individuals treated but
also for disease transmission and the development of drug
resistance.”
Palmer and others (2003, 292) have reviewed a “new model
of private primary care provision” that has emerged in South
Africa. This innovation involves commercial companies pro-
viding “standardized primary care services at relatively low
cost” that are targeted at the low-income employed rather than
the very poor (Palmer and others 2003,). Regarding the grow-
ing popularity of these private clinics, the authors find that they
maintain excellent standards with respect to the quality of ser-
vices. The clinics also run at a cost per visit that is comparable
with public sector primary care clinics, demonstrating that the
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Important Skills and Competencies at the Primary Care Level
Box 64.2
The primary care level warrants the following important
skills and competencies:
• Ongoing monitoring of use of services with particular
reference to patient access and community coverage,
and program adjustment as indicated
• Continuous linking of general primary care services
with community outreach efforts in order to enhance
program effects in the defined catchment community
• Appropriate clinical skills for midlevel workers, espe-
cially in the absence of doctors, and practiced judg-
ment regarding timely referral to a hospital
• Responsiveness to community needs—whether or not
directly expressed—and heightened sensitivity to cul-
tural norms and local systems of leadership and
authority
• Facilitatory and responsive managerial styles by district
team leadership that support and encourage frontline
health workers.
Source: Authors. 
acceptability of services to users and low-cost service delivery
are not incompatible objectives.
Palmer and others (2003, 295) suggest that the increasing
popularity of these (affordable) private clinics may provide an
opportunity to encourage employed but low-income workers
(who historically have used public sector health services at lit-
tle or no charge) to make use of these clinic networks, which
would enable the public sector to better tend to its “role as reg-
ulator and providing services to the poorest.” Potentially, this
redirection of care could remove some of the burden on the
public sector, and the task of regulation might be made easier
by the strong hierarchical control exercised within these clinic
chains. To some extent, this shift has been the experience in Sri
Lanka, where government services have been designed with the
explicit assumption that certain forms of care will be provided
through the private sector (Rannan-Eliya 2001).
However, Palmer and others (2003) point out that the model
has potential drawbacks. The comprehensiveness and continu-
ity of services provided by these private clinics fall short of that
available in the public sector. Furthermore, how the behavior
of private clinics would change under a system of contractual
arrangements with the public sector is not clear. Whereas con-
tracting with the not-for-profit sector tends to accommodate
government objectives fairly easily (Gilson and others 1997),
the experience of contracting with the for-profit sector has had
mixed results. These and other concerns imply that, although
the for-profit sector is an important resource, arrangements for
the delivery of care through this sector should be developed
with caution. It also bears mention that, where public sector
systems are weak, private sector services gain ground to the
extent of unbalancing the public-private mix, with potentially
serious consequences for costs and continuity in patient care
and for coverage and equity more generally.
Setting Population Health and Clinical Care Priorities
Along with securing additional resources for primary care
delivery, country capacity to generate the information neces-
sary for setting and reviewing public health and clinical care
priorities must be strengthened as a fundamental measure
(Commission on Health Research for Development 1990). This
principle lies at the heart of influential pilot work—at times
referred to as community-oriented primary care—that emerged
in the first half of the 20th century and now underpins the
Tanzanian Essential Health Interventions Program (TEHIP),
1997–2004. TEHIP, through a research and development arm
tasked with devising practical tools for decentralized health
planning, has tested “how and to what extent evidence can
guide planning of the health sector at district level . . . [in order
to] improve technical and allocative efficiency with regard to
local choices for resource allocation and services offered” (de
Savigny and others 2002,).2 A dynamic process of using high-
quality local information, coupled with local problem solving,
planning, and ownership, was central to appropriate decision
making and consequent implementation.
Because local data on intervention costs and coverage are
generally not available to district planners and managers, local
cost-effectiveness analysis is difficult to incorporate into decen-
tralized priority setting. With TEHIP, priority setting was
driven more by the shares of the burden of disease that known
cost-effective interventions could address. New analytic tools
were devised that would help focus resource allocations on the
major “intervention-addressable” disease burdens; targeted
sets of cost-effective interventions were then applied—in place
of embarking on a disease-by-disease or detailed cost-
effectiveness approach (D. de Savigny, personal communica-
tion,). Available understanding on cost-effectiveness was used
to eliminate interventions known to be grossly cost-ineffective;
it was not used to prioritize or rank interventions generally
considered to be highly cost-effective.
TEHIP indicates that gross technical and allocative efficien-
cies are relatively easy to address when incremental funding is
available. As described by de Savigny and others (2002), the
net effect of decentralized funding, together with a mutually
reinforcing series of planning, management, and capacity-
development inputs, was a proportional and absolute increase
in resources for more efficient delivery of prioritized, cost-
effective interventions addressing the largest shares of the
preventable local burden of disease; an increase in the use of
government health services; and a decrease in mortality in
infants, children under five, adolescents, and adults. This effect
was achieved with relatively limited resources.
TEHIP and related experience make clear that delivery of
effective primary care requires a greatly stepped-up capacity to
provide an evidence base that is founded on current and evolv-
ing local disease and risk factor burdens, the performance of
local health services, client use of public as well as private and
traditional services, and (where appropriate) the costs of pro-
viding care. Effective use of such information can profoundly
enhance the ability of the health system to deliver on its core
service functions, target high-risk and vulnerable groups, assess
coverage in service provision, and gauge health effects.
Moreover, such information is vital to establishing the dimen-
sions of the local disease burden that should be managed at the
primary care level (Kahn and others 1999). As cogently stated
by the Bellagio Study Group on Child Survival (2003, 324),“the
capacity of countries to obtain and use information to support
child-health programmes will be a determining factor in
reducing child mortality.”
Developing a District Health System
Drawing from theory and experience in other branches of the
public sector (Mills and others 1990)—and often as part of
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wider public sector developments—the health sector intro-
duced decentralization widely in low- and middle-income
countries throughout the 1980s and 1990s (WHO 2000).
Positive justification for this method of delivering health care
and primary care in particular lay, first, in its intended benefits—
for patients and communities—through the provision of
context-appropriate services of steadily improving quality. This
service delivery was rightly seen as also conferring substantial
financial benefit on households. Second, decentralization was
expected to lead to the strengthening of local responsibility and
accountability, with growing authority of district management
teams over local cost centers. Third, it was presumed that the
more central management levels would invest in enhanced sup-
port systems, including management support, further training,
financial management and administration, laboratory services,
and drug supply systems (World Bank 1994).
In developing settings, few health systems did not decen-
tralize in some form or another over this period, and most
based services development on a so-called district (or subdis-
trict) health system model. Considerable effort was devoted to
achieving a balance between primary care service delivery and
referral to the first-level (or district) hospital. Incentives as well
as penalties were invoked to encourage first use of primary care
facilities.
Notwithstanding the theoretical appeal of health system
decentralization, numerous difficulties in implementation
were encountered, with the consequence that the performance
of decentralized, primary care–oriented systems and national-
level support to these systems have fallen way below expecta-
tions (Bellagio Study Group on Child Survival 2003). Although
various factors can account for this outcome—and although
these factors will differ according to local and regional
circumstances—common difficulties include inadequate or
insufficient primary care skills and competencies, which result
in poor-quality care; breakdown in referral systems for emer-
gencies and more complex cases (McCord and Chowdhury
2003; Snow and others 1994); delegation of responsibilities
without the concomitant delegation of authority, especially in
relation to budgeting; authoritarian or strictly hierarchical
managerial styles that are not conducive to local health services
support and development; and weak or absent measures to
develop workable cost-management systems appropriate to
different service levels.
These problems in achieving successful delivery need to be
addressed if decentralization is to achieve its intended benefits.
Again, greater appreciation of the role of decentralized systems
in the broader health care architecture, the support needed to
ensure their effectiveness, and the time required to build the
necessary capability are all necessary. As Bryce and others
(2003, 160) put it, “although research on interventions is plen-
tiful, little is known about the characteristics of delivery strate-
gies capable of achieving and maintaining high coverage for
specific interventions in various epidemiological, health
system, and cultural contexts.” From this perspective, a too-
narrow preoccupation with the cost-effectiveness of interven-
tions cannot but have shortcomings: “whatever package of
services is delivered, the resulting effectiveness and equity will
almost certainly depend on how the services are delivered, [in
other words] the strategy for organizing the care” (B. Starfield,
personal communication,).
Primary care is delivered through a system of facilities, equip-
ment, and personnel; tackling inefficiencies in the system may
have major positive benefits for quality of care, program cover-
age, and cost-effectiveness. In many settings a real opportunity
exists to increase the efficiency of general primary care teams by
giving attention to working conditions, ensuring functional
equipment, and maintaining a stable drug supply. Meaningful
step-ups in care, workable referral and communication systems,
gatekeeper functions where indicated, and effectively aligned
management and support are all needed. Achieving such effi-
ciencies should result in many more patients being assessed and
managed properly. Significant cost savings may accrue to the
health service (through patients being managed at the primary
care level rather than the first or specialist referral level) and to
patients, families, and households (through care being delivered
more rapidly and nearer to home).
Demanding Services: Relationships with Local Communities 
Among poor and vulnerable communities, the need for care is
demonstrably high, and the effectiveness of primary care serv-
ices is likely to substantially influence demand on the public
sector. In relation to infectious as well as noncommunicable
disease, outreach services have a major role to play in promot-
ing positive health and health-seeking behaviors and in
supporting community-level preventive and promotive efforts.
More generally, renewed efforts to enhance community rela-
tionships with primary care workers and the health system as a
whole—and to ensure that community voices actively and
appropriately bear on local service development and decision
making—can help bring clients and communities into con-
structive public health care partnerships.
A RESEARCH AND DEVELOPMENT AGENDA
FOR GENERAL PRIMARY CARE
Throughout this chapter, we have emphasized the challenges
and constraints to the effective delivery of general primary care
services. In this section, we single out a few areas that warrant
concerted research and development in the effort to establish a
high-functioning primary care platform to support the imple-
mentation of cost-effective interventions.
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Evolving Health Transitions
A critical consequence of fast-changing economic and social
conditions is the rapid transition in health profiles in essen-
tially all low- and middle-income settings. This shift has
already led or is leading to the coexistence of persisting infec-
tious disease; nutrition and reproductive health problems;
emerging noncommunicable disease and related risk factors
(such as hypertension, obesity, diabetes, stroke, and cardiovas-
cular disease); and a growing burden from accidents and inten-
tional injury. The challenge this transition poses to primary
care systems is considerable. For the most part, these systems
are oriented to maternal and child health and the management
of acute illness. An accelerating health transition will require
extending the reach and capacity of widely established primary
acute care systems (oriented to episodic care) to accommodate
the need for effective systems of chronic and long-term care
(including continuing, medium- to longer-term, patient or
client management and monitoring).
Introduction of Antiretroviral Therapy for HIV and AIDS
Many countries, particularly those in southern Africa and East
Africa, are moving to the rapid introduction and scale-up of
antiretroviral therapies for HIV and AIDS. Substantial and rap-
idly increasing financial investments are envisaged (indeed are
under way); a necessary accompaniment to such scale-up
should be improved drug supplies, strengthened laboratory
services, clinical training of primary care staff, and reassertion
of the importance of health service relationships with local
communities. Such measures—which can succeed only with
sustained public sector commitment—have the potential to
invigorate and motivate all facets of primary care delivery but,
equally, could undermine existing services. The challenge is
how to realize the positive potential of antiretroviral therapies
in meeting the needs of HIV and AIDS sufferers and their com-
munities, while ensuring a major contribution to strengthening
primary care provision more generally. In other words, the
challenge is to strengthen a particular service (HIV and AIDS
treatment and care) and primary care services simultane-
ously—through building more effective health teams, improv-
ing drug supplies, strengthening service monitoring and
evaluation, enhancing supervision and support systems,
extending service coverage, and so forth. Such systemwide
strengthening can be expected to greatly improve the technical
efficiency of key elements of the general primary care system.
Effective Support and Networking for Community 
and Home-Based Care 
Along with the reorientation of primary care systems to sup-
port chronic and long-term care are needs for “home-based”
care—taking place in rural households, urban residences, or
newer community-based facilities such as hospices. Although
home-based care of people living with AIDS is most promi-
nent, care and support for clients post-stroke or with other
forms of physical or mental disability are as important.
Primary care outreach services, working with community
health initiatives, NGOs, and communities, are well placed to
contribute expertise, training, and resources toward supporting
such efforts, which are growing rapidly in importance.
Research to Strengthen General Primary Care 
in the Public Sector
An abiding need exists for experimental and quasi-experimen-
tal evaluation of innovation in general primary care services
(whether delivered comprehensively or as clusters of interven-
tions), providing greater insight into the enabling and
constraining factors (which may be systemwide) and a more
robust understanding of the effects, costs, and cost-effectiveness
of modifications to these services in different settings. To
maximize the likelihood of success in efforts to scale up effec-
tive interventions or system innovations, such initiatives
should be carefully designed, implemented, and assessed in
partnership with senior health ministry officers (Berwick
2004). Such evaluations are required to assess new forms of
organizing primary care services (in particular, balancing per-
sisting acute needs with the growing need for chronic and long-
term care, or establishing the skills mix that is most effective in
particular settings); similarly, they are necessary when assessing
delivery of interventions—such as the cost-effectiveness of
multi-disease intervention clusters in different epidemiological
and social contexts, or the extent of uptake by vulnerable
groups (such as children or the elderly) or marginal popula-
tions. Operational research efforts are needed in a range of
spheres: to evaluate factors that facilitate or hinder effective
performance by service providers or to develop easily managed
monitoring systems to assist, for example, in assessments of
intervention coverage.
CONCLUSIONS
Clearly, a great many of the most cost-effective interventions
detailed in this volume depend on a high-functioning primary
care system for their effective implementation. This system
comprises the elements of the primary level of care (including
facilities, equipment, drugs, personnel, and associated manage-
ment support); their combination to form a competent deliv-
ery capability; and the services that are thereby delivered.
Because cost-effectiveness estimates are based on the presumed
effective delivery of primary care services, it can be argued that
1204 | Disease Control Priorities in Developing Countries | Stephen Tollman, Jane Doherty, and Jo-Ann Mulligan
General Primary Care | 1205
implicit in the estimates have been overly optimistic assump-
tions regarding key constituents (staff, drugs, equipment, mon-
itoring and evaluation, and so forth) of the primary care level
and their functioning. Great efforts to render such systems as
effective as possible, subject to the constraints of particular
environments, are therefore justified.
More generally, decisions on the best and most appropriate
sites for delivery of interventions are not always straightfor-
ward, will benefit from expert discussion, and will often be
context specific. Moreover, many interventions can be delivered
from multiple sites—although a hierarchy of preference will
usually exist, influenced by issues such as cost-effectiveness,
ease of service provision, need for monitoring, access, and cov-
erage. Careful review of the extensive range of interventions
presented in part 2 of this volume and their likely site of deliv-
ery reveals the following:
• The interfaces between (a) community and primary care
levels and (b) primary care and district levels are critical
sites that profoundly affect the effectiveness of service
delivery.
• No substitute exists for a well-functioning district health
system comprising community, primary care, and first-
referral (district) hospital levels. This organizational
and service unit is fundamental to effective health care
provision, and failure to recognize the interrelationship
between component levels has had high health costs and
resulted in great inefficiency.
The health and development cost of weak or inadequate
primary care systems to high-risk or vulnerable groups—and
to communities more generally—is demonstrably high.
However, effective general primary care that responds to the
rapid health transitions under way in all socioeconomic con-
texts offers the potential for major health and, hence, develop-
ment gains that provide good value for money and enhance
equity. Critical make-or-break points include upscaled finan-
cial investments paralleled by major and sustained investment
in human resources (principally the strengthening of local staff
capacity, the building up of key skill sets—including support-
ive management—and the encouragement of innovation in
services development); far greater attention to improving
delivery and service quality, monitoring service coverage,
improving access by vulnerable groups and taking account of
equity considerations in general; and establishment of a trust-
ing and constructive partnership with local communities.
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Annex 64.A Comparison of Proposed Basic Packages of Interventions 
Alma Ata Commission on
Declaration Investing in Better Health in World Health Macroeconomics and World Health
(WHO and Health (World Africa (World Report 2000  Health Working Group 5 Report 2002 
Intervention UNICEF 1978) Bank 1993) Bank 1994) (WHO 2000) (Jha and Mills 2002) (WHO 2002)a
Maternity-related interventions     
Prenatal care    
Treatment of complications during    
pregnancy
Skilled birth attendants    
Emergency obstetric care    
Postpartum care    
Family planning    
Nutrition: pregnant and lactating women 
Tetanus toxoid 
Childhood disease–related interventions    
(prevention)
Bacillus Calmette-Guérin     
Polio     
Diphtheria-pertussis-tetanus     
Measles     
Hepatitis B    
Haemophilus influenzae type B   
Vitamin A supplementation     
Iodine supplementation    
Zinc supplementation 
Anthelmintic treatment 
School health program (incorporating   
micronutrient supplementation, school 
meals, anthelmintic treatment, health 
education)
Childhood disease–related interventions   (as part   (as part 
(treatment) of IMCI) of IMCI)
Acute respiratory infections   
Diarrhea    
Causes of fever   
Malnutrition  (including  
nutrition and 
supplementary 
feeding)
Anemia  
Feeding and breastfeeding counseling 
Malaria prevention b   
Insecticide-treated nets  
Residual indoor spraying 
Malaria treatment b  
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Tuberculosis treatment b    
Directly observed treatment short course  
(DOTS) for smear-positive patients
DOTS for smear-negative patients 
HIV/AIDS prevention  (more limited   
than later 
packages?)
Youth-focused interventions 
Interventions working with sex  
workers and clients
Condom social marketing and 
distribution
Workplace interventions 
Strengthening of blood transfusions systems  
Voluntary counseling and testing  
Prevention of mother-to-child transmission 
Mass media campaigns  
Treatment for sexually transmitted infections    
HIV/AIDS care 
Palliative care  (see under 
limited care)
Clinical management of opportunistic illnesses  
Prevention of opportunistic illnesses 
Home-based care 
HIV/AIDS HAART provision 
Tobacco control program (taxes, legal action,   
information, nicotine replacement) 
Alcohol control program 
Other public health interventions (includes    (information, 
information, education, and communication education, and 
on selected risk factors and health communication)
behaviors, plus vector control and disease 
surveillance) 
Limited care (includes treatment of infection   
and minor trauma; for more complicated 
conditions includes diagnosis, advice, 
and pain relief, and treatment as 
resources permit) 
Noncommunicable diseases and injuries  
(selected early screening and prevention) 
Populationwide interventions to reduce 
the risks of cardiovascular disease (salt- 
and cholesterol-lowering strategies)
Water and sanitation    (disinfection at 
point of use)
Sources: Jha and Mills 2002; WHO 2000, 2002; WHO and UNICEF 1978; World Bank 1993, 1994.
HAART  highly active antiretroviral therapy for the treatment of HIV/AIDS; IMCI  integrated management of infant and childhood illness.
Note: A “” that appears in a shaded cell but not in the white cells beneath this area means that no details of the exact interventions were provided in the report.
a. Addressed only interventions against risk factors.
b. These and other disease prevention and control initiatives fell under a general item termed prevention and control of locally endemic diseases (HIV/AIDS was not an issue at the time).
Annex 64.A Continued
Alma Ata Commission on
Declaration Investing in Better Health in World Health Macroeconomics and World Health
(WHO and Health (World Africa (World Report 2000  Health Working Group 5 Report 2002 
Intervention UNICEF 1978) Bank 1993) Bank 1994) (WHO 2000) (Jha and Mills 2002) (WHO 2002)a
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NOTES
1. Bobadilla and others (1994) comment that separating interventions
according to age group is artificial because benefits may accrue in later life,
as in the case of hepatitis vaccine, and may improve well-being, such as
cognitive abilities. Adult interventions, such as HIV prevention and pre-
natal care, also benefit children.
2. TEHIP has functioned in a “high mortality” setting. Relevant evi-
dence is related to mortality levels and trends, including cause-specific mor-
tality, as well as to district-level financial allocations and changes over time.
REFERENCES
Almeida, C., P. Braveman, M. R. Gold, C. L. Szwarcwald, J. Mendes Ribeiro,
A. Miglionico, and others. 2001. “Methodological Concerns and
Recommendations on Policy Consequences of the World Health Report
2000.” Lancet 357: 1692–97.
Bellagio Study Group on Child Survival. 2003. “Knowledge into Action for
Child Survival.” Lancet 362 (9380): 323–27.
Berman, P., and L. Rose. 1996. “The Role of Private Providers in Maternal
and Child Health and Family Planning Services in Developing
Countries.” Health Policy and Planning 11 (2): 142–55.
Berwick, D. M. 2004. “Lessons from Developing Nations on Improving
Health Care.” British Medical Journal 328: 1124–29.
Blumenthal, D., E. Mort, and J. Edwards. 1995. “The Efficacy of Primary
Care for Vulnerable Population Groups.” Health Services Research 30
(1): 253–73.
Bobadilla, J. L., P. Cowley, P. Musgrove, and H. Saxenian. 1994. “Design,
Content, and Financing of an Essential National Package of
Health Services.” Bulletin of the World Health Organization 72 (4):
653–62.
Briggs, C. J., P. Capdegelle, and P. Garner. 2003. “Strategies for Integrating
Primary Health Services in Middle- and Low-Income Countries:
Effects on Performance, Costs and Patient Outcomes” (Cochrane
Review). In The Cochrane Library, Issue 4. Chichester, U.K.: John Wiley
and Sons.
Bryce, J., S. el Arifeen, G. Pariyo, C. F. Lanata, D. Gwatkin, J.-P. Habicht, and
the Multi-Country Evaluation of IMCI Study Group. 2003. “Reducing
Child Mortality: Can Public Health Deliver?” Lancet 362 (9378):
159–64.
Coker, R. J., R. A. Atun, and M. McKee. 2004.“Health-Care System Frailties
and Public Health Control of Communicable Disease on the European
Union’s New Eastern Border.” Lancet 363 (9418): 1389–92.
1208 | Disease Control Priorities in Developing Countries | Stephen Tollman, Jane Doherty, and Jo-Ann Mulligan
Commission on Health Research for Development. 1990. Health Research:
Essential Link to Equity in Development. New York: Oxford University
Press.
de Savigny, D., H. Kasale, C. Mbuya, G. Munna, L. Mgalula, A. Mzige, and
G. Reid. 2002.“Tanzania Essential Health Interventions Project: TEHIP
Interventions—An Overview.” Ministry of Health, Dar es Salaam,
Tanzania.
Doherty, J., and R. Govender. 2004. “The Cost-Effectiveness of Primary
Care Services in Developing Countries: A Review of the International
Literature.” Background paper for the Disease Control Priorities 
Project.
Drummond, M. F., and A. Mills. 1987. Cost Effectiveness of Primary Health
Care: A Review of Evidence. London: Commonwealth Secretariat.
Ewbank, D. C. 1993. “Impact of Health Programmes on Child Mortality in
Africa: Evidence from Zaire and Liberia.” International Journal of
Epidemiology 22 (Suppl. 5): S64–72.
Gilson, L. 1998. “The Lessons of User Fee Experience in Africa.” In
Sustainable Health Care Financing in Southern Africa, ed. A. Beattie,
J. Doherty, L. Gilson, E. Lambo, and P. Shaw,. Washington, DC: World
Bank.
———. 2003. “Trust and the Development of Health Care as a Social
Institution.” Social Science and Medicine 56: 1453–68.
Gilson, L., J. Adusei, D. Arhin, C. Hongoro, S. K. Mujinja. 1997. “Should
African Governments Contract Out Clinical Health Services to Church
Providers?” In Private Health Providers in Developing Countries: Serving
the Public Interest?, ed. S. Bennett, B. McPake, and A. Mills, 276–302.
London: Zed Press.
Jha, P., and A. Mills. 2002. “Improving Health Outcomes of the Poor: The
Report of Working Group 5 of the Commission on Macroeconomics
and Health.” Geneva: World Health Organization.
Kahn, K., S. M. Tollman, M. Garenne, and J. S. S. Gear. 1999. “Who Dies
from What? Establishing Cause of Death in South Africa’s Rural
Northeast.” Tropical Medicine and International Health 4: 433–41.
Kurowski, C., K. Wyss, S. Abdulla, N. Yemadji, and A. Mills. 2003. “Human
Resources for Health: Requirements and Availability in the Context of
Scaling Up Priority Interventions in Low-Income Countries.” Health
Economics and Financing Programme, London School of Hygiene and
Tropical Medicine, London.
Magnani, R. J., J. C. Rice, N. B. Mock, A. A. Abdoh, D. M. Mercer, and
K. Tankari. 1996. “The Impact of Primary Health Care Services on
Under-Five Mortality in Rural Niger.” International Journal of
Epidemiology 25 (3): 568–77.
McCord, C., and Q. Chowdhury. 2003. “A Cost Effective Small Hospital in
Bangladesh: What It Can Mean for Emergency Obstetric Care.”
International Journal of Gynecology and Obstetrics 81: 83–92.
Mills, A., R. Brugha, K. Hanson, and B. McPake. 2002.“What Can Be Done
about the Private Health Sector in Low-Income Countries?” Bulletin of
the World Health Organization 80: 325–30.
Mills, A., J. P. Vaughan, D. L. Smith, and I. Tabibzadeh. 1990. Health System
Decentralization: Concepts, Issues and Country Experience. Geneva:
World Health Organization.
Narasimhan, V., H. Brown, A. Pablos-Mendez, O. Adams, G. Dussault,
G. Elzinga, and others. 2004. “Responding to the Global Human
Resources Crisis.” Lancet 363 (9419): 1469–72.
Newell, K. 1975. “Health by the People.” World Health Organization,
Geneva.
Paalman, M., H. Bekedam, L. Hawken, and D. Nyheim. 1998. “A Critical
Review of Priority Setting in the Health Sector: The Methodology of
the 1993 World Development Report.” Health Policy and Planning 13
(1): 13–31.
Palmer, N., A. Mills, H. Wadee, L. Gilson, and H. Schneider. 2003. “A New
Face for Private Providers in Developing Countries: What Implications
for Public Health?” Bulletin of the World Health Organization 81 (4):
292–97.
Rannan-Eliya, R. P. 2001.“Strategies for Improving the Health of the Poor:
The Sri Lankan Experience.” Paper prepared for Health Systems
Resource Centre, Department for International Development. Health
Policy Programme, Institute of Policy Studies of Sri Lanka, Colombo.
Russell, F. 2003. “The Economic Burden of Illness for Households: A
Review of Cost of Illness and Coping Strategy Studies Focusing on
Malaria, Tuberculosis and HIV/AIDS.” Paper presented at the Disease
Control Priorities Project Workshop, Johannesburg, South Africa,
July 1–4.
Shi, L. 1994. “Primary Care, Specialty Care, and Life Chances.”
International Journal of Health Services 24 (3): 431–58.
Shi, L., and B. Starfield. 2000. “Primary Care, Income Inequality, and Self-
Rated Health in the United States: A Mixed-Level Analysis.”
International Journal of Health Services 30 (3): 541–55.
———. 2001. “The Effect of Primary Care Physician Supply and Income
Inequality on Mortality among Blacks and Whites in U.S. Metropolitan
Areas.” American Journal of Public Health 91 (8): 1246–50.
Snow, R. W., V. O. Mung’ala, D. Forster, and K. Marsh. 1994. “The Role of
the District Hospital in Child Survival at the Kenyan Coast.” African
Journal of Health Sciences 1 (2): 71–75.
Starfield, B. 1994. “Primary Care: Is It Essential?” Lancet 344: 1129–33.
———. 1998. Primary Care: Balancing Health Needs, Services, and
Technology. New York: Oxford University Press.
Tollman, S. M. 1991. “Community Oriented Primary Care: Origins,
Evolution, Applications.” Social Science and Medicine 32: 633–42.
Travis, P., S. Bennett, A. Haines, T. Pang, Z. Bhutta, A. A. Hyder, and oth-
ers. 2004. “Overcoming Health-Systems Constraints to Achieve the
Millennium Development Goals.” Lancet 364: 900–906.
Unger, J.-P., P. de Paepe, and A. Green. 2003. “A Code of Best Practice for
Disease Control Programmes to Avoid Damaging Health Care Services
in Developing Countries.” International Journal of Health Planning and
Management 18: S27–39.
Vuori, H. 1985. “The Role of Schools of Public Health in the Development
of Primary Health Care.” Health Policy 4: 221–30.
Walsh, J. A., and K. Warren. 1979. “Selective Primary Health Care: An
Interim Strategy for Disease Control in Developing Countries.” New
England Journal of Medicine 301: 967–74.
WHO (World Health Organization). 2000. The World Health Report 2000.
Health Systems: Improving Performance. Geneva: WHO.
———. 2002. The World Health Report 2002: Reducing Risks, Promoting
Healthy Life. Geneva: WHO.
WHO (World Health Organization) and UNICEF (United Nations
Children’s Fund). 1978. “Primary Health Care: A Joint Report by the
Director-General of the World Health Organization and the Executive
Director of the United Nations Children’s Fund.” WHO, Geneva.
World Bank. 1993. Investing in Health: World Development Report 1993.
New York: Oxford University Press.
———. 1994. Better Health in Africa: Experience and Lessons Learned.
Washington, DC: World Bank.
General Primary Care | 1209

1211
Health care comprises a continuum from home-based, self-
administered treatment to highly specialized intervention
dependent on professionals with many years of training and a
heavy capital investment. In principle, the role of the health
system planner is to balance the many separate components of
the system to optimize the magnitude and distribution of
health benefits, subject to a variety of constraints such as budg-
etary levels, geography, and human resources capacity. While
recognizing that other paradigms are possible and valid, we
generally adopt this optimization perspective in our discus-
sions because it combines broad social (including user) and
political dimensions with systematic economic principles when
decisions are made in a competitive, resource-constrained
environment. Following such logic, it should be possible to
define the place, purpose, and size of the district hospital sector
within a balanced system of care for any particular setting.
Although this view is theoretically appealing, the world of
real health systems that have evolved under different historical
and political pressures is somewhat different. This perspective
does, nevertheless, suggest some common principles involved
in defining the optimum balance of care even within groupings
as diverse as “developing countries.” Two further points are
worth considering:
• First, although the focus of this chapter is the district hospi-
tal, crucial links exist with many other aspects of the health
system. Choices made in relation to hospitals are likely to
affect the whole health system and vice versa. For example,
programs to improve peripheral clinic referrals of women
with high-risk pregnancies may result in a paradoxical
decline in the quality of care if critical human and other
resources are inadequate at the hospital level. Thus, the
picture of public district hospitals as underused, inefficient,
and providing poor quality care (Barnum and Kutzin 1993)
may reflect deficiencies in the entire health system as well as
at the hospital level.
• Second, optimizing the health system configuration is an
active, continuing process that must often proceed incre-
mentally, ideally tackling problems in order of priority. An
optimal balance is not likely to be achieved naturally
through neglect or reliance on market mechanisms.
Hospitals are major consumers of health budgets. However,
there is a paucity of good evidence—even in industrial
countries—on their effect (McKee and Healy 2002), whereas
the body of theory and opinion on their role is wide. This
chapter can serve as only an introduction to topics that
include, among others, the political and social value of hospi-
tals and their essential role in integrated health systems (Sachs
2001; Van Leberghe, de Bethune, and de Brouwere 1997; WHO
1999; World Bank 1993). The chapter first introduces basic
concepts relevant to district hospitals that may affect their role
and performance and a description of possible core services
(see figure 65.1). For discussions of the evidence justifying
inclusion of an intervention or process as a core service at this
level of care, the reader is referred to disease- and service-
specific chapters. Although recently attempts have been made
to refine definitions of performance (WHO 2000b), the term is
used in a general sense, referring to processes and outcomes
that contribute to improved levels and distribution of health.
The chapter then summarizes currently available economic
data on hospital care, focusing where possible on the district
level and acknowledging the difficulty in generalizing findings
from one setting to another. An illustration follows of some of
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the factors that threaten district hospitals’ performance, indi-
cating the broad range of influences to which they are subject.
Finally, possible strategies for improving performance are pro-
posed, focusing on cross-cutting interventions, and highlight
areas where current knowledge is inadequate and research is
urgently needed.
DEFINITIONS, BASIC CONCEPTS,
AND FRAMEWORK
The evolution of a hierarchical system of health care is readily
explained if one assumes the perspective of the provider,
although less obvious if one’s perspective is that of the com-
munity using the hospital or a government seeking to create
political capital. Concentrating skills and resources in one
place for conditions that are often relatively uncommon or
that cannot easily be treated closer to the home environment
is intuitively attractive. Such concentration also offers the
prospect of continued accumulation of experience and, thus,
skill and potentially benefits from system resources that may
serve a variety of needs.
What Is a District Hospital?
Health systems are often organized in a “hub-and-spoke”
arrangement, with a large district hospital (the hub) having
more and better-trained personnel and better equipment than
more peripheral clinics (the spokes). Although variations fre-
quently occur in practice (for example, a large district may have
several relatively similar hospitals), this simple model of service
provision is assumed throughout this chapter, with the district
hospital supplying first referral-level care for both outpatients
and inpatients. District hospitals also, in theory, may serve a
gatekeeping role for those patients with less common problems,
for whom skills and resources are most effectively concentrated
at even higher levels of care provided at a regional or national
level. Thus, from the perspective of provider efficiency,
economies of scale and economies of scope are important basic
concepts in considering district and referral hospital functions.
Such hierarchical health systems frequently overlap with
wider political and administrative hierarchies that are based on
geographically defined units. The district is, therefore, used in
this chapter as a generic term for an administrative unit often
comprising a population of 100,000 to 1 million people for
whom one tier of local government is typically responsible. The
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Figure 65.1 Conceptual Framework for Delivery of Health Services at the District Hospital
shared administrative boundaries and frequent proximity of
district hospitals to district political administrations often
result in the district hospital’s involvement in the much wider
tasks of district health management and public health. The per-
formance of these functions may be critical to the success of the
health system as a whole, but this role is easily forgotten.
Efficiency. Allocative efficiency deals with the desire to allo-
cate resources to secure the maximum health benefit from the
inputs available (Hensher 2001). Within this paradigm plan-
ners search for the balance between community care, primary
care, and facility-based care that results in the greatest health
benefit at the least cost. At the level of an individual hospital,
the issue of allocative efficiency arises when decisions must be
made to allocate resources to different services. In theory, cost-
effectiveness studies with a global health status outcome meas-
ure such as the disability-adjusted life year (DALY) should
inform debate on allocative efficiency, because such studies
provide a direct means of comparing alternative strategies.
Technical efficiency deals with the extent to which specific
institutions are getting the most out of the resources available.
For example, is a district hospital deploying its given resources
in the most effective manner to achieve the desired output?
Technical efficiency is often measured using partial indica-
tors such as cost per procedure. Interpreting such data often
requires great care, but most fundamentally it requires some
comparator, because a way of knowing the resources needed to
produce the desired output rarely exists. Thus, technical effi-
ciency is usually a relative term, and performance indicators—
carefully interpreted—can be used to identify best current
practice. New technology or a change in the availability or price
of resources may result in continual improvements in what is
achievable, so a process that was technically efficient can
become relatively inefficient over time. Data on technical effi-
ciency often provide the basis for benchmarking hospital serv-
ice providers and may identify poorly performing services for
targeted improvement strategies.
Economies of Scale and Scope and Hospital Size. A central
policy question is whether it is more efficient to concentrate
resources in a small number of large centers, where the planned
number of procedures can be high, or to have a greater num-
ber of smaller centers. The issue of economies of scale deter-
mines the most efficient size hospital. Where the average costs
of care can be shown to depend on hospital (or unit) size,
economies of scale exist (see figure 65.2). Recent evidence sug-
gests that, at least for industrial countries, large centers may
eventually suffer from diseconomies of scale, when the ineffi-
ciencies introduced in administering a very large facility begin
to outweigh any advantages (Posnett 2002). The potential for
diseconomies of scale in developing countries, where the mix-
ture of cases, the costs of inputs (particularly the relative costs
of staff salaries and technology), and the pattern of diseases
vary widely, has not been examined.
In discussing economies of scale, we must consider two fur-
ther issues. First, considerable evidence suggests that the ability
to specialize and the experience gained with high volumes of
patients can lead to better outcomes for physicians practicing
in larger hospitals. Second, although reducing the number (and
increasing the size) of hospitals may reduce health system costs
and improve outcomes, it may shift some costs to patients in
the form of increased travel time or even a reduction in the
ability to reach the hospital and secure care. Thus, excessive
concentration of hospital services may compromise health and
equity objectives, particularly in rural areas. The planner may
need to balance direct health system costs against the broader
population costs of securing access. In many circumstances,
this effort may give rise to an intermediate solution, such as
medium-sized hospitals, smaller local hospitals equipped to
deal with common procedures, or dispersed clinics staffed by
peripatetic specialist teams.
The hospital also offers the potential for improving effi-
ciency if different services use some of the same inputs.
Although the hospital might not be able to justify paying the
salary of a laboratory technician to perform hemoglobin meas-
ures and blood cross-matching only for the maternity unit, the
fact that such a person also contributes to the work of the sur-
gical, medical, and pediatric services makes that technician’s
presence more cost-effective. This laboratory service, therefore,
offers an economy of scope. The concentration of inputs, both
human and technological, evident at the district hospital offers
major opportunities for unit-cost reductions and, therefore,
economies of scope. Considering the mix of services provided
as hospitals are planned or augmented is important to antici-
pate or account for economies of scope.
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Figure 65.2 Theoretical Long-Term Average Cost Curve
Equity. Equity is a fundamental principle guiding most public
health systems. It can embrace concepts such as equality of pro-
vision or equality of access (for equal need), equality of benefit
from health services, or equality of outcome.Although often not
defined explicitly, many pro-poor policies, such as the Poverty
Reduction Strategy Papers that encompass health, are based on
some principle of equity. Loosely speaking, such policies aim to
reduce disparities in access or overall health status observed
between different sections of a population, most obviously the
differences between rich and poor sections of a community.
For health planners, however, equity principles pose some
hard challenges. For example, if an urban district has a public
hospital with adequate staff and resources providing a range of
acute services reasonably efficiently, should not every district
hospital provide the same range of services? In practice, ensur-
ing that a hospital in a poor, inaccessible rural district with a
highly dispersed, smaller population provides a similar level
and breadth of service may be difficult and considerably more
expensive. The result can be a hospital with apparently high
unit costs of treatment that, because of late presentation or
resource constraints, secures poorer outcomes. The central pol-
icy question is: To what extent is society prepared to see
resources deployed to address such equity concerns at the
expense of pure efficiency?
Issues of efficiency, economies of scale and scope, and equity
have contributed in part to the development of strategies defin-
ing an essential package of services that should be provided for
an entire population (Bobadilla and others 1994). These pack-
ages are often targeted at the most important causes of mortal-
ity and morbidity, so the inefficiencies in providing an equitable
service may be reduced. Nevertheless, the unit costs of reaching
disadvantaged populations are often likely to be higher than
average unit costs, and planners need to recognize this fact
when designing packages and set budgets accordingly.
What Essential Services Should a District Hospital Provide? 
The World Health Organization (WHO 1992) envisages that a
district hospital should be able to offer diagnostic, treatment,
care, counseling, and rehabilitation services provided by
predominantly generalist practitioners spanning the following
disciplines:
• family medicine and primary health care
• medicine
• obstetrics
• mental health
• eye care
• rehabilitation
• surgery (including trauma and orthopedics)
• pediatrics
• geriatrics.
Such hospitals will usually provide 24-hour care and be
integrated into the district health system at a wider level to pro-
vide or support a range of services:
• districtwide health information
• implementation of peripheral primary health care policies
• administrative and logistics support to primary health care
efforts
• communication with the community
• curative and chronic care for patients referred from periph-
eral units
• district laboratory services
• training and continuing medical education of health work-
ers and students
• links between health and other development agendas
• development of local solutions to local health problems.
This menu of recommended services at the district hospital
level does not represent a rigorous attempt to optimize the
health system configuration to maximize its cost-effectiveness.
Indeed, the logic of the earlier discussion is that the precise mix
of services provided should be informed by overall health sys-
tem design. Rather, the list represents what is perceived to be a
fair minimum level of health provision for all, based on accu-
mulated knowledge and experience of the common demands
for hospital care (the visible burden), the availability and
simplicity of interventions, the perceived effectiveness of inter-
ventions, and their acceptability in an environment con-
strained by limited information and limited availability of
human and financial resources (Van Leberghe, de Bethune, and
de Brouwere 1997).
An obvious logic supports the inclusion of many of these
core functions, sometimes supported by evidence of their
value. WHO’s Commission on Macroeconomics and Health
has attempted to define the services that small hospitals should
offer as part of the close-to-client package on the basis of
burden and likely cost-effectiveness (Sachs 2001). However,
although useful for suggesting service priorities, the report
considers primarily infectious diseases and maternal health. In
addition, it is not clear whether recommended services were
included on the basis of data on condition-specific burden and
intervention cost-effectiveness or of the potential effect of the
combined package of services considering potential economies
of scale and scope. Future studies should perhaps address more
clearly the issues of the incremental cost-effectiveness of new
or additional interventions at the district hospital level when
exploring the appropriateness of services.
Clinical Services
The initial drive to implement primary health care (PHC) left
district hospitals sidelined. They were often grouped with
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expensive tertiary units; were labeled high cost, inequitable,
and relatively ineffective; and were rarely protected by powerful
professional groups based in the tertiary centers. Their position
as an integral part of PHC was reestablished during the 1980s
(Canadian International Development Agency and the Aga
Khan Foundation 1981; WHO 1987). Currently the district
hospital is envisaged as the apex of the pyramid of primary
health care, most obviously in such programs as Safe
Motherhood and Integrated Management of Childhood
Illness. In programs such as Integrated Management of
Childhood Illness, the expected role of district hospital–level
care is explicit (WHO 2000a), with priority conditions reflect-
ing burden-of-disease estimates (Black, Morris, and Bryce
2003). Although the effectiveness of this approach has yet to be
established, evidence at the hospital level suggests that deliver-
ing a basic package of care may, in principle, cover the majori-
ty of admitted cases and improve service delivery (Ngoc Anh
and Tram 1995). However, without tackling current difficulties
at the hospital level, effectiveness cannot be assumed (see
“Information and Integration” later in this chapter).
Other basic approaches to delivery of services at the district
hospital level, such as triage of new outpatient attendees and a
basic package of neonatal care, also show promise (Duke,
Willie, and Mgone 2000; Robertson and Molyneux 2001).
Interventions such as the provision of basic trauma care can
effectively be offered only at this level of the health system (see
chapter 68), while in other areas (for example, chapters 26, 31,
and 67) hospital inpatient care should be considered together
with alternative means of delivering services if cost-
effectiveness is to be maximized. These examples all serve to
emphasize that close-to-client health services must be tightly
integrated with district hospital–level care and demonstrate
strong dependency on the referral system. Thus, cases too com-
plex or serious to be managed in the periphery are sent for care
where skills and resources are more highly concentrated, in the
expectation that health outcomes will be better. This attrac-
tively simple idea presupposes that the district hospital is able
to provide the care desired; although some evidence supports
the likely effectiveness of this approach (Van Leberghe and
Pangu 1988), clearly numerous potential obstacles exist along
this pathway (discussed in the later section “Factors Influencing
District Hospitals’ Performance”).
Additionally, although the focus has often been on district
hospitals as recipients of referrals, a much more dynamic rela-
tionship has been proposed (WHO 1987): for many PHC
activities such as immunization programs the district hospital
is both a provider of services and a coordinating center for
information and supplies. To permit early discharge, enhance
treatment compliance, and make home-based care possible—
all of which may improve cost-effectiveness—hospitals need to
play an active role in providing outreach services, supervision,
and support.
Cross-Cutting Services at the District Hospital
Some medical services provide support to a range of depart-
ments or users and are referred to as cross-cutting services.
Such services include those aimed at recuperation and rehabil-
itation (physiotherapy, occupational therapy, and so forth; see
chapter XX; laboratory services, and diagnostic imaging.
Whether and to what degree these services are provided may be
major determinants of the overall range of services that can be
offered, the fixed costs of providing care at district hospitals,
and their cost-effectiveness. Their provision should, therefore,
be planned as part of the portfolio of care to be offered, taking
into account expected use and estimates of the value added.
This strategy suggests a degree of flexibility that may conflict
with historical perspectives about what is important and “one
size fits all” national policies. Health information systems are
also a critical cross-cutting service; they are discussed in the
“Health Information Systems” section of this chapter.
It is worth noting here that the concentration in hospitals of
cross-cutting resources used by different activities often gives
rise to many accounting complications, such as allocating over-
head costs, which bedevil attempts to secure meaningful cost
comparisons across hospitals.
Wider Role in the District Health System
District hospitals often house the technical expertise and
professional authority essential for local implementation of
national policy, making them potentially key players in manag-
ing, monitoring, and supervising district health plans. They
should also act as advocates for plans that address local health
needs. This section examines this wider role of the district hospi-
tal, the value of which is often hard to quantify, but which may be
critical to the effectiveness of the local health system as a whole.
Integration with Other Local Health-Related Services. A dis-
trict hospital should, in most cases, be an integral part of a
wider district health system. Although not specifically dis-
cussed here, part of the broader remit is often to link up with
other governmental and nongovernmental actors in health and
health-related programs, which may include water and sanita-
tion, education, and social services. (A more specific discussion
can be found in WHO 1990.) Those important coordination
functions are hard to value in traditional examinations of cost
and cost-effectiveness but may be critical in sustaining a coor-
dinated health care approach, especially if greater autonomy is
devolved to district administrations.
Training. District hospitals often have a direct role in the pri-
mary training of health workers, particularly clinical assistants,
nurses, and health aides, as well as an ongoing role in providing
continuing medical education. Their role in building human
resources capacity among those actively participating in health
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care delivery and in ensuring that training and experience
reflect the real health needs of the community is potentially of
great value. Additionally, as the focal point of outreach for
many programs that aim to disseminate knowledge through
the cascade mechanism, district hospitals are often relied on to
transmit knowledge to more peripheral levels of care.
Supervision. Together with their training function, district
hospital staff members are often supposed to provide supervi-
sion and support to health workers at more peripheral levels of
care and to act as part of the regulatory mechanism, sometimes
in both the public and the private sectors.Although this function
is likely to be an important means of developing and refining the
referral system through two-way exchange of information and
of seeing that policy decisions are implemented, the ability of the
health staff to fulfill this function is often extremely limited.
Because resources are scarce, activities with the least tangible
benefit—such as supervision and monitoring—are frequently
abandoned, breaking important chains of communication.
Health Information Systems. Many national health informa-
tion systems rely on district hospitals to coordinate data col-
lection in the district. In theory, for a number of diseases the
district hospital may be the only source of information, for
example, for severe diseases such as neonatal tetanus, acute
flaccid paralysis, or operative deliveries. The district hospital is,
thus, a core data source supposedly providing burden-of-
disease data at greater resolution than is commonly available
and at a meaningful administrative level if action is required.
However, in many developing countries health information
systems are inadequate and inaccurate; staff members are not
equipped with the skills necessary to interpret data
(Loevinsohn 1993) and are often unaware of their local value,
thus depriving the local staff of essential planning and
monitoring tools. Introducing an information culture and the
necessary skills and infrastructure to support such a transition,
although of potentially enormous value, presents significant
challenges even for middle-income countries.
Formulating a Package of Services to Maximize 
Cost-Effectiveness
Interventions identified as being cost-effective in particular
service areas or necessary to preserve the integrity of an effec-
tive and equitable health system should be a part of a basic
package of services and responsibilities at the district hospital
level. However, the way in which these individual components
are combined and integrated is also critical. Factors, including
economies of scale and scope, whether gains or losses in effi-
ciency result from integration, and the influence of use and
resource availability, will all have a profound influence on
whether the district hospital itself is as cost-effective as the sum
of its parts suggests it should be.
ECONOMICS OF DISTRICT HOSPITALS:
A SUMMARY OF REPORTED EXPERIENCE
The previous sections outline the suggested functions and
extended role of a district hospital. Although some countries
have adopted the principle of essential packages of services and
defined detailed norms and standards for care at this level as
part of long-term health sector strategies, many countries lack
any specific hospital strategy (WHO 1994). Even where a well-
articulated strategy exists, decades of different political, social,
economic, and historical influences on health system develop-
ment result in great variability of district hospitals, both
between and within developing countries. Thus, some district
hospitals of 500 beds have a full complement of specialist con-
sultants and access to a wide range of diagnostic and therapeu-
tic services, while other hospitals of as few as 30 beds, but more
often 80 to 150 beds, are run almost entirely by medical assis-
tants and nurses, sometimes lack reliable power or water sup-
plies, and often offer few or no high-quality modern diagnostic
services. This variability makes it daunting to extrapolate find-
ings from one setting to another and may seriously undermine
the value of attempts to provide useful general descriptions of
hospitals. In particular, when interpreting calculated costs of
care at a national or individual level, we must remember several
critical points:
• Relevant data may often be missing or inadequately defined
at a country level.
• Because a number of accepted ways of calculating costs
exist, particularly at the level of individual interventions,
different methods are likely to lead to different estimates.
The particular design used to estimate costs should be con-
sidered when interpreting any results.
• In particular, a central feature of the hospital is that many of
its resources are used for more than one activity, so unit
cost estimates depend crucially on how the costs of these
resources are allocated among activities.
• The relative prices of inputs can vary substantially between
regions and countries.
• In the majority of cases, only the cost of care is reported
without reference to outcomes so that the cost per unit of
health benefit (however defined) is unknown.
• Calculated costs usually reflect the care offered; it may not
be the same as the care that is necessary, of an acceptable
quality, or most effective.
• Cost estimates cannot indicate the extent of unmet need or
other sources of inequity.
• The costs of care will depend to some extent on the severity
of illness of the patients and, for average costs per bed day,
on the variety and relative proportions of different illnesses
(the case mix). These areas are rarely commented on or
adjusted for.
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Levels of Provision of Hospital Care
Data on the levels of service provision for many developing
countries are crude. In the absence of any more meaningful
data, the number of beds is most often used as a (poor) substi-
tute. Bearing this weakness in mind, sources estimate the
average number of total hospital beds to be 1.3 per 1,000 pop-
ulation in developing countries (World Bank 2002), a figure
probably declining in many developing countries (Hensher and
others 1999), with varying estimates of the average number of
doctors from 0.5 per 1,000 population in low-income countries
generally (World Bank 2002) to 0.09 doctors per 1,000 popula-
tion in Sub-Saharan Africa (Peters and others 2000). These
estimates are considerably lower than the averages for beds
and doctors of 7.2 per 1,000 and 2.9 per 1,000, respectively, in
high-income countries (World Bank 2002). Although these
estimates provide some indication of the major disparities in
service provision between rich and poor countries, their value
is limited. Lack of information on the relative distribution of
beds and staff by geographic zone, or between district and
higher referral levels of care in a single country, and the fact
that bed and staff numbers are probably a poor reflection of
activity make these figures a poor substitute for data on patient
throughput and outcomes, statistics rarely available for district
hospitals. Furthermore, with the concentration on provision of
service, the demand for services may often be ignored. It is still
true in many countries that most deaths, presumably many
preventable, occur at home and that many chronic diseases are
inadequately treated. The need for hospital care is largely unde-
termined, but some have argued that the lack of provision of
district hospital care, in Sub-Saharan Africa at least, is a signif-
icant impediment to improving overall health status (Van
Leberghe, de Bethune, and de Brouwere 1997).
What Do District Hospitals Cost at a National Level?
Although it has been argued for some time that hospitals con-
sume too much of health sector budgets, thereby depriving pri-
mary care of adequate resources, it is surprisingly difficult to
identify how much hospitals cost in low- and middle-income
countries. Even where data exist on health expenditure, such
data are often at a highly aggregated national level and the
functions that are included (clean water and sanitation, for
example) are not always clear (World Bank 2002).
Furthermore, whether private or nongovernmental expendi-
ture, capital expenditure, or the value of noncash inputs—such
as donations of equipment or volunteers’ time—are included is
rarely apparent. Add to this ambiguity the nearly impossible
problem of separating what is spent at different levels of the
health or hospital system—for example, to distinguish between
district and referral hospitals—and it should be clear that we
currently have only a crude understanding of the costs of dis-
trict hospitals as a unit of service provision (Mills 1990a).
If just government health expenditure is considered, the
available data suggest that hospitals at every level taken together
consume 50 to 60 percent of recurrent national health budgets,
with the proportion appearing to increase as countries become
richer (Barnum and Kutzin 1993). If private expenditure on
health care (insurance and out of pocket) is included, the pro-
portion of total health expenditure consumed by all hospitals
falls to 30 to 50 percent of the total in developing countries
(excluding South America) (Mills 1990a). Whereas these figures
reflect total hospital sector expenditure, the limited data avail-
able suggest that district hospitals may receive less than 50 per-
cent of this total in many countries, consuming fewer resources
than secondary and tertiary referral facilities (Mills 1990a).
The Nongovernmental and Private Sectors
In many countries (especially in Africa) nongovernmental
institutions, often religious organizations, are major health
service providers, and private physicians are often as numerous
as those in the public sector. In Kenya, for instance, the number
of private and nongovernmental hospitals is equal to the num-
ber of public hospitals (Government of Kenya 2001), while in
Indonesia, 32 percent of hospital beds are private (Gani 1996).
This potentially important contribution to the hospital sector
may also be underrecognized, particularly in urban settings,
where multiple, small facilities may operate without registra-
tion, resulting in inaccurate local, regional, and national data
on levels of overall service provision. Although few data exist
on the effectiveness and quality of these hospitals, the belief is
widespread that they may be more efficient than public sector
hospitals. This belief is not necessarily borne out by the limited
data available (Bitran 1996), and concerns exist about the qual-
ity of care provided by private as well as public providers
(Brugha and Zwi 1998).
District Hospital Efficiency 
Data on hospital efficiency in developing countries are scant.
Considerable variability has been observed in the technical effi-
ciency with which surgical services were provided in a small
number of Indian hospitals, with differences in total salary
costs being the main explanatory variable (Purohit and Rai
1992). Also in India, some evidence has been provided that
nongovernmental hospitals may be more efficient, on average,
than public hospitals, although considerable variability existed
within both groups (Bhat, Verma, and Reuben 2001). In Kenya,
public hospitals were found to have an average inefficiency
level of 30 percent (that is, the same resources could have
achieved a 30 percent increase in output) with significant
contributing factors including shortage of appropriate
professional staff members, poor combinations of inputs
(resources), nonfunctioning theaters and laboratories, lack of
transportation, irregular distribution of drugs and supplies,
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and frequent breakdowns in medical equipment (Owino and
Korir 1997). All these data highlight the critical role of human
resources, often a hospital’s principal recurrent input cost (see
the next section). Underinvestment in or absence of staff or
inadequate flexibility in reallocating roles between different
health worker groups may prevent hospitals from functioning
efficiently (Hensher 2001).
What Are the Costs of Providing Care in District Hospitals? 
In a detailed review of actual hospital expenditure, Mills
(1990b) identified two input categories that together accounted
for two-thirds or more of recurrent expenditure in almost all
settings. Salaries varied between 20 and 80 percent and medical
supplies between 15 and 58 percent of reported hospital expen-
diture. These and other data also suggest that, in many coun-
tries, costs of referral hospital care are often more than double
the cost of equivalent care at district hospitals, although with-
out knowledge on case mix or illness severity such data are hard
to interpret (Barnum and Kutzin 1993; Mills 1990b). More
recent data collected from seven church-supported hospitals in
Tanzania also demonstrate considerable variability in the pro-
portion of costs attributable to salaries and supplies even within
a single organization in the same country (Flessa 1998). The
strong dependence of hospital costs on salaries particularly cau-
tions against generalizations across countries.
In the following analysis, all original U.S. dollar costs have
been adjusted to represent the U.S. dollar cost in 2004. The
Tanzanian nongovernmental hospital data indicate that the
average cost per inpatient day derived from 1995 reports
(including expenditure on maintenance and expatriate
salaries) would equate now to approximately US$3.60 (range
US$2.60 to US$6.00) in district hospitals (Flessa 1998).
However, if care had actually been provided according to the
standards defined by the provider (including recommended
staffing levels, building maintenance, and equipment), the esti-
mated cost per day would have risen to the equivalent of
US$11.60 (range US$9.20 to US$15.90) (Flessa 1998). This cost
compares with costs reported in Kenya in 1993–94 (Kirigia,
Fox-Rushby, and Mills 1998), adjusted to 2004 prices of actual
inpatient costs per day from two district hospitals of US$8.30
to US$10.10, and adjusted 1995 data from a district hospital in
Bangladesh of US$15.90 (McCord and Chowdury 2003). In a
middle-income country, South Africa, the cost per inpatient
day calculated between 1996 and 1998 and adjusted to 2004
prices in five district hospitals ranged from US$37.80 to
US$96.30 (Daviaud and others 2000). These data do not neces-
sarily reflect the cost of optimal care, and the Tanzanian study
demonstrates that even in externally supported hospitals actual
expenditure may be insufficient to provide good-quality care
and cover essential maintenance, resulting in steady deteriora-
tion of capital stock and worsening efficiency in the long term.
Data describing costs of treating some specific conditions in
district hospitals are summarized in table 65.1. Given the diffi-
culties in extrapolating data across contexts and the potentially
significant effect of exchange rate fluctuations, great caution
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Table 65.1 Costs of Delivering Care at the District Hospital Level 
Cost (original data
Country and year Item costed adjusted to 2004 US$) Comment
Kenya, 1993–94, two district
hospitals, research study
Zimbabwe, 1994–95, three district
hospitals,a research study
Zimbabwe, 1999, six provincial
hospitals, research study 
Uganda, modeling based on
1997–99 data factoring in program
expansion
Treatment of inpatient severe malaria
in children
Medical inpatient stay; HIV/AIDS
care
Severe malaria inpatient care;
Pulmonary tuberculosis inpatient
careb
Aspects of safe motherhood
delivered at hospitalc; actual and
recommended practices
US$41.50 to US$132.00 per case
treated
Non-HIV: US$49.20 to US$110.00
HIV: US$133.00 to US$217.00 per
inpatient stay
Severe malaria, mean costs per case
US$26.60 to US$49.90; tuberculosis,
median costs per case US$22.20 to
US$61.00
Eclampsia: actual US$63.40;
recommended US$127.00
Cesarean: actual US$53.20;
recommended US$57.80
Prenatal care: actual US$2.90;
recommended US$8.30
Step-down approach to allocate
all costs, including capital costs 
Bottom-up and step-down
approaches used, including 
capital costs 
Overhead costs purposefully
omitted; 1999 exchange rates
Attempt to estimate current pro-
gram costs and costs if program
implemented as recommended;
excludes facility costs
Sources: Kenya—Kirigia and others 1998; Zimbabwe 1994–95—Hansen and others 2000; Zimbabwe 1999—Hongoro and McPake 2003; Uganda—Weissman and others 1999.
Note: Shaded rows provide data from studies that did not include overhead or facility costs.
a. Only data from district hospitals are shown.
b. All hospitals had a median length of stay for tuberculosis cases of 10 days or less.
c. Only selected items are shown.
The District Hospital | 1219
Table 65.2 Estimate of the Effectiveness of a Kenyan District Hospital in Preventing Childhood Deaths in a Rural Community
with Good Access to the Hospital
Study site and population: Kenyan rural community with access to Population 51,183; 52 percent younger than age 15
basic primary health care services provided by five clinics, three private 
Surveillance period 1991–93
Service provider Kenyan Ministry of Health district hospital supplemented 
by research unit
Mortality rates:
Neonatal 31.5 per 1,000 live births
Infant 58.3 per 1,000 live births
Child 12.4 per 1,000 children ages one to four years
Observed number of admissions 2,223
Admission rate 45 per 1,000 children ages 1 to 59 months per year
Proportion of deaths occurring in the hospital:
Neonatal 28 percent
Ages 1 to 59 months 30 percent
Observed number of deaths 134
Expected number of deaths without inpatient care 349
based on expert estimates for case fatality rates
Lives saved 215
Estimated cost per life saveda US$104.40
Source: Snow and others 1994.
a. 2004 US$ equivalent, using admission cost data from Kirigia and others 1998. The estimated cost of the admissions in 2004 US$ would be 2,223  10.1  US$22,452.30. This expenditure prevented
215 deaths; average cost of life saved therefore  22,452.30/215  US$104.40.
should be used in interpreting these data, which, it should be
noted, derive in all cases from specific research rather than
routine sources.
Measuring the Effect and Cost-Effectiveness
of District Hospitals 
In the previous section, some limited data on the costs associ-
ated with provision of care at the district hospital were pre-
sented. What of a hospital’s cost-effectiveness? Ideally we would
like to know the aggregate health output of a hospital in terms
of improved health compared with a situation in which there is
no hospital. Such data do not exist, even from industrial coun-
tries, where the hospital has been the subject of intense aca-
demic study.
However, some attempts have been made to estimate the
effect of a hospital by comparing the observed outcome of ill-
ness treated with hospital care to consensus expert opinion on
the likely outcome of illness in the absence of hospital care.
Using this approach in Kenya, Snow and others (1994) esti-
mated that a well-functioning rural district hospital might
reduce all-cause child mortality by 44 percent in a population
with reasonable access to the hospital (see table 65.2).
Extending this approach, researchers in a small rural hospital in
Bangladesh calculated the benefit of hospital admission for
patients of all ages suffering from life-threatening conditions
using a slightly modified DALY (McCord and Chowdury 2003).
Over a three-month period, the total costs (including all staff,
capital, and hotel costs) of running the hospital were calculated
and divided by the estimated total number of DALYs gained
attributable to inpatient care over the same three months. The
authors report an average cost per DALY of approximately
US$11.00 in 1995, or US$13.30 in 2004 dollars (McCord and
Chowdury 2003; see table 65.3). This figure compares favorably
with costs per DALY of many primary care interventions
regarded as highly cost-effective (World Bank 1993). To what
extent these results depend on the quality of primary care, the
referral system, the inpatient care, the hospital administration,
and the commitment of health personnel working for a small
independent nongovernmental organization will remain
uncertain until more such data become available.
FACTORS INFLUENCING DISTRICT HOSPITALS’
PERFORMANCE
The overall macroeconomic policy framework, as illustrated
here with reference to financing mechanisms,may often be over-
looked as a considerable influence on hospital performance. For
the sake of simplicity, other factors (not exhaustively described
and illustrated in figure 65.1) are discussed as primarily affect-
ing the demand for hospital services or their supply and may
operate at both national and local levels. The way some of these
diverse factors affect people’s daily lives is illustrated in box 65.1.
What is clear is that failure to tackle these many challenges all too
often results in facilities that fail their communities.
Central Financing Mechanisms
Three broad methods of government financing of public
district hospitals are generally used: prospective with a fixed
budget, prospective with revenue depending on activity, and
retrospective in proportion to actual costs. The fixed budget is
widely used, often based on historical spending levels, with a
(frequently inadequate) provision for price changes. Such a sys-
tem clearly can secure good expenditure control and is admin-
istratively undemanding. However, it can often perpetuate
historical inequities and fail to respond to new demands and
priorities. Moreover, fixed budgets offer few incentives to max-
imize the effectiveness, quality, or quantity of care offered by
hospitals (Barnum, Kutzin, and Saxenian 1995).
Indeed, many budget systems continue to finance hospitals
through line-item budgets directly from the ministry of health
or finance. Such mechanisms allow central bureaucracies to
exert the maximum level of control over peripheral spending
with little or no capacity at peripheral levels for flexible use of
funds in response to local needs. Thus, centralized budget sys-
tems can contribute to technical inefficiency by preventing
local managers from optimizing the deployment of inputs. In
contrast, global fixed budgets provide for central control of
total spending but may permit increased independence when
allocating funds at a local level. Fixed budgets based on capita-
tion payments can be more sensitive to local needs than incre-
mental budgeting and can contribute toward equity objectives.
However, they demand technical skill and accurate data at the
central level, especially if capitation payments are adjusted for
differences in population health status or other needs.
Financing based on activity levels (such as the diagnosis-
related group methods in widespread use in high-income coun-
tries) are similarly demanding of central-level capacity and also
require considerable competence and probity at more periph-
eral levels of the administration. However, such financing might
be an essential prerequisite of insurance-based mechanisms. In
contrast to fixed budgets, it has the potential for encouraging
supplier-induced demand—the greater the hospital’s income,
the more services it provides. It produces some incentive to
reduce unit costs. Expenditure control may be difficult unless a
cap is put on the aggregate hospital sector budget.
Retrospective reimbursement of actual costs is a discredited
system of financing hospitals because it offers no incentive to
control costs or manage demand. In its favor, it may stimulate
higher-quality care. In practice, many health systems use a mix-
ture of all three payment mechanisms, with broadly fixed
budgets, sometimes adjusted for changes in demand, and some
element of retrospective reimbursement for unplanned activity.
In general, no one strategy is perfect. However, the considerable
demands on management for some schemes imply that a
global budget, ideally based on population needs, in conjunc-
tion with some form of quality-monitoring system may be the
most appropriate way forward for many developing countries
(Barnum, Kutzin, and Saxenian 1995).
Mechanisms permitting local income generation (cost
recovery, cost sharing, facility improvement funds, and local
taxes) may be superimposed on any of these schemes. Such
devices can help countries shift toward a local, more needs-
based allocation of financing and help promote accountability
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Table 65.3 Estimate of the Cost-Effectiveness of a Nongovernmental District Hospital in Rural Bangladesh 
Study site and population: Rural Bangladesh, with Population 160,000
community served by four peripheral clinics
Surveillance period July through October 1995
Service provider Independent nongovernmental organization
Major causes of death 74 percent under-five mortality attributable to perinatal deaths; maternal
mortality ratio high
Admissions analyzed 541 (33 percent obstetric/gynecological problems)
DALYs gained by hospital services:
Adult medical 177.0 life years; 6.5 disability years
Surgical 459.4 life years; 236.3 disability years
Pediatric 371.5 life years; 10.8 disability years
Obstetric/gynecological 897.5 life years; 125.4 disability years
Newborn (resulting from ob/gyn interventions) 1,024.3 life years
Total DALYs gained 3,308.7
Cost per DALY US$10.93 in 1995 ($13.30 in 2004 US$)
Source: McCord and Chowdury 2003.
by focusing local attention on the efficiency and quality of local
services. This flexibility presupposes that those empowered
with authority have the skills and freedom to make and execute
plans. The experience of such a decentralized policy on district
hospital or district health system performance is mixed, with a
lack of real transfer of authority reducing effectiveness in some
areas (Blas and Limbambala 2001), while more balanced and
carefully implemented mechanisms of decentralization may be
productive (Bossert and others 2003).
The specific effects of requiring out-of-pocket payments to
access health care are a matter of fierce debate. Although some
data suggest an improvement in allocative or technical efficien-
cy, other data do not (Arhin-Tenkorang 2000; Van der Geest
and others 2000). It has been suggested that an improved qual-
ity of service may overcome the cost barrier to access (Van der
Geest and others 2000). However, the likelihood that the poor
will be excluded from hospital care is a major concern. There is
also an increasing tendency to encourage district hospitals to
provide some beds with an enhanced level of professional
attention and hotel services (sometimes referred to as amenity
beds) as a means of generating profit; reports indicate that
the fees levied may not even cover the cost of the enhanced
service, let alone generate extra revenue with which to cross-
subsidize services for the poor (Flessa 1998; Suwandono and
others 2001).
Demand for Services
Patients’ demand for services may be influenced by a wide
variety of factors, many of which have little to do with the hos-
pitals themselves. Patients’ perceptions of the severity of their
illness, cultural beliefs, physical accessibility, and financial and
opportunity costs together with the performance of the periph-
eral health unit screening process all potentially limit the effec-
tiveness of the referral mechanism and thus the hospital (Font
and others 2002; Siddiqui and others 2001). Recent data high-
lighting the inability of many families to meet the financial
costs of hospital referral (Peterson and others 2004) and the
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Hospital Performance: Perspectives from a Sub-Saharan African Country
Box 65.1
Caretaker (C) and health worker (HW) experiences of
hospital care:
“When the doctor realized my child was breathless he
quickly called us into the office even though I was at the
back in the queue.” (C)
“The [nursing] sister came and talked to me and asked if I
had a problem, and I felt good and cared for.” (C)
“Things here have greatly improved; the ward is clean and
the treatment prompt. We are happy and hope that this
will continue.” (C)
“I admitted a patient in very poor condition with malaria
and anemia and I managed to remove blood for cross-
match and fix a line, start on oxygen, and get the doctor.
Blood was started quickly, and the child rapidly
improved.” (HW)
“I resuscitated a baby with severe asphyxia, and it success-
fully came up. The success was because I had attended a
course in basic life support skills for neonates.” (HW)
Caretaker and healthworker descriptions of referral to
hospital:
“If you do not have the money, you have to look for it first.
Sometimes you may even have to spend a day or two look-
ing for the money for the treatment. If you have coffee,
then you sell it before you go.” (C) (Peterson and others
2004).
“I spent a long time in MCH [Maternal and Child Health];
the doctor wanted money before he would see me, and I
did not have any.” (C)
“There is a lot of suffering when it comes to drugs because
they are usually not enough and most of the time the
mothers do not have money.” (C)
“I want to know everything about the illness; I asked the
nurses, but they refused to explain, so I got disheartened
from asking anyone.” (C)
“I had a patient with anemia and mild marasmus, and the
mother waited for three hours in the lab for an Hb only to
be turned away as she had no money. Then I went to get
the child some milk, and I was turned away as the store-
man said it was too late. The child had to wait until the
next day.” (HW)
“A child with severe LRTI [lower respiratory tract infec-
tion] was very dyspneic on admission. Only one cylinder
of oxygen was available, but we started giving it to the
child, and the condition improved. The condition became
worse when the oxygen ran out, and there was none left; he
started gasping and died.” (HW)
Source: English and others 2004a, unless otherwise noted.
potentially catastrophic consequences of severe illness (Xu and
others 2003) underscore the importance of financial barriers,
especially for the poor. Not only are there obvious implications
for health generally, but underusing service capacity also
reduces efficiency and increases the costs per case of hospital
care. Improving the efficiency and effect of a hospital may,
therefore, be best achieved by tackling factors that influence
demand—for example, providing emergency transport and
limiting out-of-pocket expenses. However, often a concern
exists that the provision of free high-quality services may itself
promote unnecessary demand—the so-called moral hazard. In
addition, the relative importance of demand factors may vary
considerably in different settings, for example, in urban and
rural areas, making universal rules unhelpful.
In the context of PHC, it is suggested that high demand for
services provided by hospitals rather than peripheral clinics,
driven by a perception that hospitals provide higher-quality
service and resulting in bypassing of the PHC level of care, is
inefficient. It has been proposed that hospitals be specifically
prevented from delivering PHC services (WHO 1990).
However, the view that patients who bypass PHC increase the
costs to the provider may not always be true (Siddiqui and oth-
ers 2001). Patients may also choose to bypass the district hos-
pital and proceed directly to referral hospitals, often increasing
the costs of care if the condition could have been treated in the
lower-level facility. The perceived quality of care at the district
level may be a major determinant of this behavior, with some
data suggesting that improved district services increase use
rates (Barnum and Kutzin 1993), potentially making district
hospitals more cost-effective but more costly.
The Supply of Services
A fundamental role of policy makers is to determine the geo-
graphical distribution of hospitals and the functions they
should undertake. These decisions are often severely circum-
scribed by topography, historical accident, and political imper-
atives, as well as by the level and quality of resources that are
available. Often, changes can be made only incrementally,
building on an existing structure of administration and capital
that may not be in any sense optimal.
Nevertheless, many of the factors determining the quality of
supply are theoretically under the influence of local manage-
ment personnel, who are in a potentially powerful position to
significantly affect a hospital’s function. Lack of resources, low
morale, inability to attract staff members to hardship areas,
poor training, and inadequate supervision among many other
factors may all conspire to prevent health workers from execut-
ing their duties effectively or even at all. Those factors may, in
turn, result in less demand for services from consumers, who
opt to avoid the hospital or go elsewhere for treatment. The
paradox resulting from this decline is that the hospital may
continue to operate within a fixed budget, thereby satisfying
finance ministries but having little or no effect on health. Long-
term underinvestment in facilities and skilled, motivated staff
may then condemn a health system to many years of under-
performance, given the time necessary to address these issues.
This is the fundamental reason for seeking to measure system
outputs and quality as well as costs.
On a regional or national scale, the actual distribution of
hospitals and personnel may work for or against effective serv-
ice delivery. For political reasons (to reward a community or to
honor a powerful politician, for instance), hospitals may be sit-
uated in areas that would not be chosen if purely rational plans
had been followed. Nongovernmental providers or philanthro-
pists may build or alter hospitals without regard to the overall
function of a health system or achieving either equity or effi-
ciency. Public, private, and nongovernmental hospitals may
compete for patients, potentially reducing efficiency in some
or all sectors. The crisis of inadequate personnel in low-
income countries, which limits the range, quality, and quantity
of services that can be offered, has been described
(Narasimhan and others 2004). However, imbalances in the
within-country distribution of staff members are less well
publicized and equally damaging. All the factors mentioned
and others are commonly encountered in health systems of
developing countries and are major barriers to implementing
potentially valuable interventions at an operational level
(Oliveira-Cruz, Hanson, and Mills 2001). New interventions
must therefore often be considered in the light of existing
(rather than optimal) levels of service provision and perform-
ance. Little literature is available on these public choice features
of decision making.
EFFECTING CHANGE WITH CROSS-CUTTING
INTERVENTIONS
So far this chapter has outlined concepts fundamental to
understanding the position, functions, and performance of the
district hospital and has presented some of the existing
(though limited) data on costs and cost-effectiveness.
Operating at the interface between primary care—aimed often
at the poor—and the more Western biotechnological model of
care at secondary and tertiary levels—often more accessible to
the better off—district hospitals are easy to ignore because they
lack any advocates for their role. However, optimizing their role
to maximize health benefits and promote equity does demand
the following:
• explicit policy decisions about the services that should be
offered at this level and about the balance between primary
care, district hospital care, and higher-level care services
provided
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• national strategies on the distribution of services that
encompass all providers
• commitment to provision and equitable distribution of
essential human resources and supplies
• systems for monitoring hospital performance in terms of
efficiency and quality and for intervention when perform-
ance is poor.
When a framework defining the district hospital is available,
interventions that might improve performance can be consid-
ered. The focus here is on cross-cutting interventions rather
than condition-specific or service area–specific interventions
described elsewhere. Cross-cutting interventions seem to be
rarely prioritized but have the ability to add value in many
areas and are perhaps critical when thinking of developing an
improved health system.
Human Resources
Key issues that affect district hospitals are the quantity and
quality of personnel and their range of skills. Staff members
should be appropriate to the tasks they are asked to perform.
This approach may mean continuing to use nursing or auxil-
iary staff members with more limited training in district hos-
pitals because they may be more cost-effective, running against
the tide of rising academic requirements often demanded by
professional associations (AED 2003). Similarly, devolving
some tasks to lower cadres of staff may be practical and much
more efficient—for example, training and licensing clinical
assistants to perform emergency surgery including cesarean
section. Such initiatives, too, may face opposition from power-
ful professional vested interests. Although some tasks may be
transferred downward, a problem often faced by district hospi-
tals is an absence of high-quality senior staff members or lead-
ers. Traditionally, running a district hospital has commanded
less respect and remuneration than work at a secondary or ter-
tiary facility and has been regarded as a stage to be moved
through as rapidly as possible. Arguably, the challenges to a
district hospital professional are at least as great as those of a
tertiary consultant specialist, and the development of appro-
priate skills-training programs, and parity of postgraduate
qualifications and pay, might help foster the development of a
professional group that improves performance and fills a much
needed advocacy role.
Improving Clinical Management
For more than a decade, industrial countries have increasingly
promoted the use of the best evidence in clinical management.
Clinical guidelines, means to implement them, feedback on
their use and value, clinical audit, and performance review
are all now the subject of considerable research, with some
evidence of benefit particularly when part of a broadly based
approach (Grol and Grimshaw 2003). District hospitals in
developing countries have largely missed out on this revolu-
tion, which may be of particular value in settings where care by
nonspecialists with little or no access to recent information is
the norm.
Information and Integration
Although much focus is given to technological development in
the fields of diagnosis, treatment, and imaging, relatively little
attention is paid to the potential for technology to change the
collection and use of information, despite the possibly major
effect on improving administrative and clinical management.
As at the primary care level, where many of the interventions
are currently available to achieve significant reductions in mor-
tality (Claesen and others 2003), many of the tools that could
be used to improve health are well known at the district hospi-
tal level. Making better use of these tools through more reliable
provision, better training, improved information collection,
on-the-spot analysis of data, and real-time use of the results for
service planning might be both possible and of considerable
benefit (Cibulskis and Hiawalyer 2002). Clearly, how a hospital
is performing as part of an integrated primary care system is
also vital. Local information on population health, on use and
referral patterns, and on success and the reasons underlying
successes and failures is invaluable if the hospital is to respond
to the particular needs of its locality.
Quality Improvement and Accreditation
Quality improvement is a generic technique adapted from
industry that involves a rolling approach to identifying prob-
lems, solving them, and assessing the results of change (see fig-
ure 65.3) and that has been institutionalized in hospital care in
many developed countries (DiPrete-Brown and others 1993).
An essential first step is defining standards for service provi-
sion, which can span all areas, including the technical content
of care, the physical environment in which care takes place, and
interpersonal relations between patients and health workers.
This approach is often linked to formal systems for external
assessment of hospitals’ performance and accreditation.
Accreditation may serve as a goal for participating hospitals, a
means of promoting positive competition, and a means of
identifying poorly performing institutions. Potential advan-
tages of such initiatives are empowerment of local service
providers to solve problems they feel are important and the
overall aim of working toward a systemwide standard of care.
However, although an obvious need exists for quality improve-
ment in hospitals in developing countries (English and others
2004b; Nolan and others 2000), few examples exist of hospital-
level interventions in industrial or developing countries that
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provide evidence of effect on major outcomes. One exception
is a broadly based quality improvement intervention targeting
maternal and child health in Peru that focused on the entire
system of care. This project was associated with a 25 percent
decrease in maternal deaths in program areas (see box 65.2
for details). However, the relatively poor progress of an
operational-level quality improvement and accreditation pro-
gram in Zambia’s hospitals highlights the significant problems
of intervening in countries with poorly functioning health sys-
tems that are severely constrained by lack of resources
(Bukonda and others 2002).
Hospital-Acquired Disease
Probably the most important infection in developing countries
that can be acquired as a result of hospital care is HIV, espe-
cially in Sub-Saharan Africa. Reuse of needles and blood trans-
fusion are the main sources of infection and also carry the risk
of hepatitis B and C and other viral infections important in
their own right. It has been estimated that effective measures to
improve blood safety in particular are a highly cost-effective
intervention at approximately US$8 or less per DALY (Creese
and others 2002).
Nosocomial infection, another major adverse consequence
of admission to hospital, is common in some settings in indus-
trial countries, contributing significantly to hospital costs.
Historically, relatively simple approaches to prevention have
proven reasonably effective with additional effect from dedi-
cated prevention services (Ayliffe and English 2003). The
potential effect of intervention in district hospitals in develop-
ing countries is largely unknown, although in China nosoco-
mial infection rates of between 8 and 13 percent have been
reported (Barnum and Kutzin 1993). Because overcrowding
and lack of basic resources, even water, are common in some
districts, the potential for simple cost-effective interventions to
prevent such infections seems high.
Other Managerial Initiatives
In high-income countries, numerous other initiatives are being
tested to promote improved efficiency and quality. They often
rely heavily on having in place appropriate institutional
arrangements, managerial capacity, and information systems,
so their feasibility for local implementation is highly dependent
on local circumstances. One of the most widely tested arrange-
ments within public national health systems has been the
experiment with internal markets, in which a range of public
hospitals compete for contracts from separate public service
purchasers, such as local governments. The split of purchaser
and provider of public services is recognized as a potentially
powerful instrument for securing efficiency improvements but
can be demanding in terms of managerial skills (Le Grand,
Mays, and Mulligan 1998).
A less direct way of introducing some form of competition
into the hospital market is to require hospitals to publish per-
formance reports that allow direct comparisons to be made
between hospitals.
An alternative to relying on indirect methods of influencing
behavior is to give physicians incentives or instructions to
deliver care in line with guidelines reflecting best practice. In the
United States, numerous experiments have been carried out
under the general banner of managed care (Glied 2000), and
other systems have attempted analogous approaches to hospital
regulation. At one extreme is the centralized U.K. system of per-
formance management, under which hospitals are given chal-
lenging and immediate targets and are rated according to meas-
ured outcomes (Smee 2002). At the other extreme is the system
of guided self-regulation practiced in the Netherlands, under
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Source: Adapted from Massoud and others (2001).
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Figure 65.3 Quality Improvement Process
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Prevention of Maternal and Child Deaths from Improvements in the Quality of Health Services:
An Example from Peru
Box 65.2
Recognizing the failure of previous training attempts to
improve the quality of health services, the Ministry of
Health, with support from the U.S. Agency for
International Development and the participation of local
institutions, developed an innovative program in Peru.
Aiming to reduce maternal and perinatal deaths, the pro-
gram expected to increase use of health services by
improving quality and by strengthening links between
the health services and their communities by working
with midwives and community health workers.
Multidisciplinary teams implemented a quality improve-
ment program in approximately 2,500 health facilities,
focusing on 
• standardizing care
• ensuring the availability at all times of essential sup-
plies and equipment
• making use of existing information systems and doing
small operational studies to generate data at the local
level to facilitate decision making
• promoting the participation of all personnel in a con-
certed and agreed-on plan of action 
• measuring patients’ satisfaction over time and address-
ing the causes of complaint.
Training activity mainly involved use of a participatory
problem-solving technique. In parallel, health networks in
each health region participated in a program to work with
1,143 midwives and 2,549 community health workers,
under the coordination of a health facility member who
was part of the multidisciplinary team.
Supervision and evaluation at each facility occurred
three and six months after training and before accredita-
tion visits. A tiered accreditation system was developed to
promote participation and provide an incentive for
improving quality. Results of each evaluation were pre-
sented to the Ministry of Health, which made accredita-
tion decisions through an independent institution to gen-
erate political support. Quality in five areas (correspon-
ding to the program aims) was assessed. Significant
improvements were observed in the proportion of indica-
tors achieved in all five aspects of quality evaluated (box
figure). An evaluation one year after the end of the pro-
gram found that performance had declined but remained
at 60 to 80 percent of the levels achieved at accreditation.
By the end of the three-year program (1996–99),
demand for health services had increased considerably, the
success itself creating managerial problems in many
instances. Motivation and satisfaction of patients and
health workers had also increased, and revenue collected
(through fee-for-service payment) at the facilities rose.
Maternal mortality in the regions included in the program
was 60 percent higher than in other regions at the start of
the intervention period and fell 25 percent after the inter-
vention, while no change was observed in the other health
regions. The inequitable distribution of maternal mortal-
ity was narrowed to a 20 percent excess in intervention
areas. A national demographic and health survey examin-
ing Peru between 1995 and 2000 found a significant over-
all reduction of maternal mortality, increases in prenatal
care coverage, and a higher proportion of deliveries in
health facilities or attended by health professionals.
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which hospitals are required to engage in quality improvement
but are given no prescription as to what format that effort might
take (Klazinga, Delnoij, and Kulu-Glasgow 2002).
THE FUTURE: RESEARCH AND
INFORMATION NEEDS
A few fundamental and urgent needs must be met as a prereq-
uisite to improving understanding of district hospitals in low-
and middle-income countries, although tackling these issues
may be far from simple:
• developing and accepting meaningful performance indica-
tors in conjunction with developing appropriate standards
of care
• collecting higher-quality routine data from district hospitals
• improving understanding of the costs and health conse-
quences of different, evidence-based, service provision
portfolios proposed for district hospitals and improving
understanding of the marginal benefits of incremental
additions and their implications for planning infrastructure
and estimating human resources and technology needs.
A solution to the first issue would perhaps pave the way for
and enhance the value of further focused research in a number
of areas.
Implications of a Changing Disease Spectrum 
In many middle-income and some low-income countries, the
demographic transition to noncommunicable diseases—
notably cardiovascular, smoking-related, and malignant dis-
eases—will have considerable implications for the hospital
sector. Thus, hospital costs likely will rise as older patients with
chronic diseases become an increasing proportion of inpa-
tients (Barnum and Kutzin 1993). In some cases, the relative
cost-effectiveness of hospital care will improve compared with
further expansion of primary or preventive services that incur
increasing marginal costs (Barnum and Kutzin 1993).
More immediately, in low-income countries in Africa, the
massive impact of the HIV pandemic is most easily seen in
the continent’s hospitals. Bed occupancy is rising, and hospi-
tal stays appear to be lengthening, as an increasing propor-
tion of hospital admissions, now over 50 percent in some
countries’ medical wards, have HIV-related disease (Mpundu
2000). Those diseases associated with HIV infection, notably
tuberculosis, and changing demands for care, such as the
need for palliation, may change not only the workload but
also the nature of the demands placed on the service. The
advent of antiretroviral therapy, which might ameliorate
some of these problems, will itself place great demands on the
hospital service provision mechanisms. With or without new
drugs, HIV will continue to tax both planners, who have to
respond to a rapid change in needs, and health care financ-
ing. Research that permits hospitals to tackle these new chal-
lenges and develop efficient and cost-effective strategies to
provide care for HIV-related disease while preventing a
decline in care standards for HIV-uninfected patients is a
high priority.
Accounting for Case Mix and Case Severity When
Measuring Hospital Performance 
Overall inpatient-fatality rates and case-fatality rates of differ-
ent common diseases are often included in district hospital
performance measures. These are crude measures unless some
adjustment is made for case mix when describing inpatient
fatality and for severity of illness when describing case fatality.
Alternatively, hospital outcomes should perhaps be replaced as
key indicators of performance by carefully chosen process indi-
cators, which are likely to be more generalizable tools of per-
formance monitoring that offer the advantage of specifically
identifying areas that require improvement (Lilford and others
2004).
Implications of Emerging and Existing Technologies 
Technology has had an enormous effect on the amount of
information available to clinicians and managers in industrial
countries, from new rapid diagnostic tests to automated stock-
checking and ordering procedures. A particularly exciting
potential in developing countries may be the ability to under-
take and interpret many diagnostic tests remotely, thereby
enabling district hospitals to operate without a skilled diagnos-
tic staff on site. It also seems probable that appropriately tar-
geted technology could have a major effect, not least in the
generation, communication, and analysis of hospital use, cost,
and outcome data, without which the health system cannot
identify and respond to needs.
Interventions That Improve Performance 
Interventions aimed at improving hospital administration and
clinical management at the district hospital level warrant inves-
tigation. For clinical management, interventions such as clini-
cal guidelines, supervision, and feedback; audit and continuing
professional development; quality improvement strategies and
accreditation; and improvements in referral and integration
with PHC may improve district hospital performance and be
relatively cost-effective. Such interventions deserve attention,
along with more traditional research aimed at optimizing treat-
ment of specific diseases.
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The appropriate allocation of resources to referral hospitals
within a national health system has long been a controversial
issue in health system planning in developing countries.
Consensus appears to be widespread that referral hospitals
consume an excessive share of health budgets and that their
contribution to improving health and welfare is low relative to
the expenditure on these facilities, but the literature does not
indicate what percentage of budgets should ideally be allocated
to referral hospitals. Presumably, except in the poorest coun-
tries, some referral facility is needed, but how much is required,
and how should the proportion allocated to referral facilities
vary with increasing levels of health expenditure and health
system sophistication?
One approach would be to review how much countries at
different levels of gross domestic product (GDP) currently
spend on referral hospitals. However, as explained later, the def-
inition of referral hospital varies widely; therefore, analyses of
national health accounts and studies of expenditure are rarely
comparable. Thus, although the chapter summarizes the litera-
ture on expenditure on referral hospitals, this evidence cannot
provide guidelines for policy makers.
A second approach might be to undertake a detailed analysis
of the role of referral hospitals in treating disease to derive their
contribution to total disability-adjusted life years (DALYs). A
simple analysis of the cost-effectiveness of specific interventions
offered by referral hospitals might allow the selection of those
interventions that are justified given their marginal cost per
DALY gained. Those interventions, multiplied by expected
demand, would then be aggregated to give a total optimal allo-
cation for referral hospital services. This approach is precisely
the one used for evaluating and prioritizing disease-specific
interventions throughout this volume. However, when this kind
of “pure” cost-effectiveness analysis is used to determine an
appropriate or optimal resource allocation for referral hospital
services, several problems arise. To begin with, hospitals have
complex economies of scope and scale. At the point when hos-
pitals offer a range of cost-effective interventions, the marginal
cost-effectiveness of additional interventions may be much
greater than would be the case if these other interventions were
evaluated in isolation. Yet a standard disease-specific analysis of
interventions would rarely be able to calculate the marginal
costs of referral hospital–based interventions. Similarly, impor-
tant and complex interdependencies exist between services and
specialties within referral hospitals that may be almost impossi-
ble to capture adequately using a cost-effectiveness analysis.
A further limitation to a cost per DALY approach arises
because referral hospitals produce multiple outputs, many of
which contribute so indirectly to DALYs that they cannot be
compared directly to individual health interventions, but
which are critical to the functioning of the health system. For
example, referral hospitals are arguably essential to the training
of doctors, particularly specialists. If a country can justify train-
ing its own doctors, then it must have a referral hospital. Yet the
value of this output in terms of DALYs probably cannot be cal-
culated. Indeed, many of the functions of a referral hospital
occur outside the hospital itself and involve enabling and facil-
itating the effective functioning of lower-level health services.
Although the referral hospital’s contribution may constitute
only a small fraction of the total cost of an intervention pro-
vided at a lower level of care (which may perhaps be viewed as
a fixed cost of the health system), the referral hospital’s role
may nevertheless be essential, thereby justifying a considerable
premium on its valuation above and beyond the cost per DALY
of the care directly provided within the hospital’s own walls.
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Finally, strong arguments can be made that cost-effective-
ness analysis fails to capture important dimensions of the indi-
vidual utility—and thus the social welfare—that accrues from
the provision of health services, especially those relating to
high-cost and low-frequency conditions.
We are, therefore, highly skeptical about the feasibility of
proposing a formulaic and purely quantitative response to the
question of how to achieve an appropriate allocation of
resources to the referral hospital level. Although perhaps unsat-
isfying for some readers, this chapter attempts instead to provide
an overview of the critical features of and challenges relating to
referral hospital care in developing countries and a guide to the
many issues that decision makers face in setting policy for this
level of care. We suggest that planners need to adopt a far more
qualitative and intuitive approach to deciding on the appropri-
ate allocation of resources for referral hospitals than for other
health care interventions. Such an approach is informed by a
more extensive listing of the roles of referral hospitals and their
direct and indirect benefits and costs to society.We acknowledge
that analysis of the value of referral hospitals is bedeviled by the
fact that, when judged empirically, they do not work as they are
supposed to. The chapter, therefore, considers the key problems
faced in the real environment in which referral hospitals operate
in poor countries before reviewing what needs to be done to
improve their functioning, drawing in particular on the authors’
knowledge of South Africa and the Caribbean.
DEFINITION AND CHARACTERISTICS
Any hospital, including a district hospital, will receive referrals
from lower levels of care. Indeed, referral can be defined as any
process in which health care providers at lower levels of the
health system, who lack the skills, the facilities, or both to man-
age a given clinical condition, seek the assistance of providers
who are better equipped or specially trained to guide them in
managing or to take over responsibility for a particular episode
of a clinical condition in a patient (Al-Mazrou, Al-Shehri, and
Rao 1990). Furthermore, higher-level hospitals in developing
countries do not treat only referred patients; tertiary hospitals
are frequently the first point of contact with health services for
many patients.
Differentiating referral hospitals from district hospitals,
therefore, requires consideration of the different resources used
by different levels of hospital. Such a differentiation will tend to
revolve around three features—the availability of increasingly
specialized personnel, of more sophisticated diagnostic tech-
nologies, and of more advanced therapeutic technologies—
that permit the diagnosis and treatment of increasingly com-
plex conditions.
This volume, including this chapter, uses a standard defini-
tion of hospital levels (Mulligan and others 2003). Table 66.1
presents some of the commonly used alternative terminology
for different levels of hospitals. Note that this chapter deals only
with general—that is, multispecialty—secondary and tertiary
hospitals. Specialized hospitals, such as psychiatric, substance
abuse, tuberculosis, infectious diseases, and rehabilitation hos-
pitals, clearly have important roles to play in a well-functioning
referral system. However, they are attended by specific features
and challenges, account for a relatively small share of overall
resources, and operate in a significantly different manner than
general hospitals do.
FUNCTIONS AND BENEFITS 
The functions of referral hospitals may broadly be categorized
into (a) the direct clinical services provided to individual
patients within the hospital and the community and (b) a set of
broader functions only indirectly related to patient care.
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Table 66.1 Definitions and Terms for Different Levels of Hospital
Disease Control Priorities Project: terminology and definitions Alternative terms commonly found in the literature
Primary-level hospital: few specialties—mainly internal medicine,
obstetrics and gynecology, pediatrics, and general surgery, or just general
practice; limited laboratory services available for general but not
specialized pathological analysis
Secondary-level hospital: highly differentiated by function with 5 to
10 clinical specialties; size ranges from 200 to 800 beds; often referred
to as a provincial hospital
Tertiary-level hospital: highly specialized staff and technical equipment—
for example, cardiology, intensive care unit, and specialized imaging
units; clinical services highly differentiated by function; could have
teaching activities; size ranges from 300 to 1,500 beds
District hospital
Rural hospital
Community hospital
General hospital
Regional hospital
Provincial hospital (or equivalent administrative area such as county) 
General hospital 
National hospital
Central hospital
Academic or teaching or university hospital
Source: Definitions from Mulligan and others 2003, 59.
Range of Clinical Services Provided 
The primary function of the referral hospital is to provide
complex clinical care to patients referred from lower levels;
however, no agreed international definition exists of which spe-
cific services should be provided in secondary or tertiary hos-
pitals in developing countries. The exact range of services
offered tends to vary substantially, even between tertiary hospi-
tals within the same country, as much because of historical
accident as deliberate design.
In South Africa, the National Department of Health is
attempting to improve the quality and accessibility of referral
hospital services through development plans that will try to
ensure that hospitals at each level move toward providing a
comprehensive set of clinical services (National Department of
Health, South Africa 2003). The department has developed a
target template of services (table 66.2) for regional (secondary)
hospitals, tertiary hospitals, and so-called national referral
services (which will be offered at only a small number of the
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Anesthetics —
Diagnostic radiology X-ray, CT scan, ultrasound, fluoroscopy
General medicine Echocardiography, stress electrocardiogram 
Specialist immunology nurse
Regional intensive care unit 
Diabetes, endocrine clinic
Gastroenterology, including endoscopy,
proctoscopy, sigmoidoscopy, colonoscopy
(with general surgery)
Geriatric care
Genetic nurse and counseling
Oncology palliation and basic care 
Neurology basic care
Spirometry and oximetry
Basic rheumatology
General surgery Regional burns service
24-hour trauma service, accident and
emergency
Mental health (psychiatry Acute inpatient and outpatient treatment
and psychology) Child and adolescent psychiatry
Electroconvulsive therapy 
Liaison psychiatry
Satellite clinics
Obstetrics and gynecology Emergency obstetrics and gynecology
Ultrasound, prenatal diagnosis
Kangaroo mother care 
Basic urogynecology
Orthopedic surgery General orthopedic surgery
24-hour trauma service, accident and
emergency
Pediatrics Neonatal low and high care
General pediatric medicine service
General pediatric surgery (general surgeon)
Rehabilitation center Physiotherapy, occupational therapy,
orthotics and prosthetics, speech therapy,
dietetics, podiatry
Acute rehabilitation team 
(Continues on the following page.)
Table 66.2 Target Service Configurations by Level of Referral Hospital, South Africa
Specialist services Components Specialist services Components 
available on site explicitly included available on site explicitly included
Regional (secondary) hospitals
Tertiary hospitals
Anesthetics —
Burns unit Specialized burns intensive care unit and
operating theater
Clinical pharmacology —
specialist
Critical care and intensive Full intensive care unit service
care unit
Dermatology Inpatient and ambulatory treatment
Diagnostic radiology X-ray, multislice CT scan, ultrasound,
fluoroscopy, mammography, color Doppler
ultrasound 
Ear, nose, and throat surgery —
Gastroenterology —
General medicine As regional plus:
Angiography
Coronary care
Echocardiography, stress electrocardiogram
Endoscopy, proctoscopy, sigmoidoscopy,
colonoscopy (with general surgery)
Genetic nurse and counseling
Oncology palliation and basic care 
General surgery Complex and high-acuity care
Infectious diseases —
Mental health (psychiatry Child and adolescent psychiatry, old-age 
and psychology) psychiatry, forensic psychiatry, substance
abuse treatment, liaison psychiatry,
treatment for eating disorders, inpatient
psychotherapy, social psychiatry, acute
psychotic (complicated) care, acute
nonpsychotic (complicated) care
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Neonatology Neonatal intensive care unit
Nephrology Tertiary dialysis and nephrology service
Obstetrics and gynecology As regional plus:
service Fetal and maternal medicine
Ophthalmology —
Orthopedic surgery Subspecialty orthopedics
Pediatric intensive care unit Full pediatric intensive care unit 
Pediatric medicine Specialist general pediatricians 
Pediatric surgery Specialist pediatric surgery service
Plastic and reconstructive —
surgery
Table 66.2 Continued
Specialist services Components Specialist services Components 
available on site explicitly included available on site explicitly included
Tertiary hospitals (continued)
Source: National Department of Health, South Africa 2003.
—  not available.
Rehabilitation center Physiotherapy, occupational therapy, orthotics
and prosthetics, speech therapy, dietetics,
podiatry, audiology
Acute rehabilitation team, including spinal beds
Stroke unit 
Respiratory medicine —
Trauma Tertiary major trauma center (protocol-based
transfer only, no walk-in accident and
emergency service)
Urology —
Vascular surgery —
largest tertiary hospitals). Although certainly not directly appli-
cable to all developing countries, the template does give a help-
ful picture of how services “build up” from one level of care to
another, and it can be used as a starting point for considering
the situation in different countries.
Clinical Services within the Community 
Referral hospitals may perform a number of functions that
provide population-level health benefits through direct
involvement in public health interventions. Responding to the
HIV/AIDS epidemic in Latin America and the Caribbean has
heightened awareness about the important role of the hospital
in reducing incidence and preventing disease outbreaks. For
example, hospitals scaled up services to prevent mother-to-
child transmission and initiated follow-up clinics for mothers
and babies. In Barbados, the main hospital scaled up voluntary
counseling and testing services to address the prevention of
horizontal transmission from mothers to their partners, with
positive outcomes. The program also served to increase access
to obstetric services at the primary health care level because of
the screening campaign initiated through the hospital’s preven-
tion of mother-to-child transmission program (Adomakoh,
St. John, and Kumar 2002).
National referral services
Cardiology Echocardiography, ultrasound, electrocardiog-
raphy, stress testing, Holter pacemaker
follow-up, catheterization laboratory,
electrophysiology, ablation
Cardiothoracic surgery —
Clinical immunology —
Cranio-maxillofacial surgery —
Critical care and intensive Additional intensive care unit capacity
care unit
Diagnostic radiology MRI
Endocrinology —
Genetics —
Geriatrics —
Hematology —
Medical and radiation —
oncology
Neurology —
Neurosurgery —
Nuclear medicine —
Obstetrics and gynecology Oncology
service Urogynecology
Reproductive medicine
Orthopedic surgery Orthopedic oncology
Pediatric cardiology —
Pediatric endocrinology —
Pediatric gastroenterology —
Pediatric hematology and —
oncology
Pediatric infectious diseases —
Pediatric intensive care unit Additional pediatric intensive care
unit capacity
Pediatric nephrology Dialysis and renal transplant
Pediatric neurology —
Pediatric respiratory medicine —
and allergology
Renal transplant Renal transplant unit
Rheumatology —
Urology —
Referral hospitals often prove to be a highly effective focal
point for disease-specific health promotion and education
activities. Bermuda’s diabetes education program serves all lev-
els of care and provides a strong link between the primary,
secondary, and tertiary health care levels. The program is cen-
tered in the main referral hospital and serves not only
diagnosed patients but also families at risk. Overall, hospitals in
the Caribbean are recognizing that central coordination of
public health programs within hospitals can provide benefits
by strengthening coordination with other services.
Valuing the Benefit of Clinical Services
Measuring the improvement in an individual’s health status
produced by the combined activities of a referral hospital,
whether for patient care in the hospital or for population-based
programs, would theoretically be possible, although practically
and methodologically demanding. To our knowledge, such an
effort has not been attempted at the referral hospital level,
though two studies have attempted to proxy the effect of
hospital interventions on health outcomes for small district
hospitals, focusing on survival only (McCord and Chowdhury
2003; Snow and others 1994). Both studies indicate that district
hospitals appear to have a significant positive effect on health
outcomes.
Large numbers of patients receive care in referral hospitals,
and most survive with their suffering alleviated, having gained
substantial benefit from the care they receive. Therefore, the
aggregate direct personal health benefits from referral hospital
care will almost certainly be high. The question of whether
referral hospital care is cost-effective relative to other interven-
tions delivered at lower levels of care is less easy to answer in
aggregate. By its nature, appropriate care in a referral hospital
will tend to require more complex input mixes and higher skill
levels and, hence, will be relatively expensive. Analysis of the
costs and cost-effectiveness of individual interventions offered
at different levels is tackled directly by the disease-specific
chapters in this volume.
Wider Activities and Functions
Aside from direct patient care, referral hospitals serve other
functions within the health system, some of which are offered
within the facility, such as teaching and research, while others
reach out to the lower levels of the health services, such as tech-
nical support and quality assurance.
Advice and Support to Lower Levels. The referral process
does not simply entail transferring a patient from a lower to a
higher level of care, nor does it end when a patient is dis-
charged from a referral hospital. An effective referral system
requires good communication and coordination between lev-
els of care and support from higher to lower levels to help
manage patients at the lowest level of care possible. Too often,
personnel in referral hospitals adopt an insular and inward-
looking perspective, focusing exclusively on the patients
directly under their care. However, referral hospitals should
offer significant support to personnel in lower-level facilities,
and specialist staff members should ideally spend a significant
portion of their time providing advice and support beyond
the walls of their own hospital, either in person or through
various modes of telecommunication. Even in poor countries,
a steady improvement in communications infrastructure
means that such support functions should become easier to
provide over time. Key dimensions of this support function
include the following:
• availability by telephone or e-mail to advise referring prac-
titioners on whether referral is required
• specialist advice to the patient’s local practitioner on post-
discharge care
• specialist advice on the long-term management of chronic
conditions
• specialist attendance at lower-level facilities to provide regu-
lar outreach clinics 
• provision of expert diagnosis or consultation through
telemedicine 
• coordination of discharge planning between levels of care
• coordination of the development of and training in the use
of shared care protocols and referral protocols
• provision of technology support by skilled technicians and
scientists.
Quality Assurance and Quality Improvement. Referral hos-
pitals can and do play a pivotal role in quality assurance and
improvement. The most important mechanism for quality
assurance and improvement is through the training that refer-
ral hospitals provide. The other key mechanism is through the
setting of standards for treatment. For example, experts at
referral hospitals should review evidence of effectiveness and
cost-effectiveness applicable to the local context, determine the
formularies to be used at each level of the health system, and
develop and amend treatment protocols. Referral hospitals can
improve the quality of peripheral services by giving advice,
offering on-site training, providing clinical services alongside
local practitioners, and monitoring the quality of the referrals
they receive.
Education and Training. Many tertiary referral hospitals in
developing countries are associated with universities and med-
ical schools and may, therefore, also be regarded as teaching hos-
pitals.Any country wishing to train its own doctors will need one
or more teaching hospitals. The number of doctors a country
needs will be influenced by its level of development, resources,
and personnel structure. Many will aim for a ratio of at least
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2 per 1,000 population, though most developing countries have
0.05 to 1.0 per 1,000 (Puzin 1996; WHOSIS 2004). If we
assume a 40-year working life and loss through brain drain or
other attrition of 25 percent, the number of doctors that must
be produced each year is between 16 and 67 per 1 million pop-
ulation, resulting in 0.5 to 2.0 doctors per 1,000 population
(box 66.1). A population of 40 million would, thus, need med-
ical schools able to graduate between 640 and 2,680 doctors per
year. Medical schools possess economies of scale, and although
some extremely small schools train 50 or so students a year,
agreement is widespread that a class size of about 150 to 200 is
optimal (see, for example, Harden and Davis 1998). A country
with fewer than 3 million population would really need to con-
sider whether training doctors locally is justified on economic
and other grounds, but for larger countries, the arguments for
training doctors locally are strong, and a teaching hospital
would, therefore, be required.
Basic generalist doctors should be trained in a range of facil-
ities across all levels of care, reflecting the facilities in which
they will work after graduation. Traditional approaches toward
medical education have been widely criticized by educational-
ists and health planners for being dominated by training in ter-
tiary settings by specialists. Not only is this setting inappropri-
ate, but typical content and clinical experience do not reflect
what the doctors will be doing or what they will need to know
after qualification. Nevertheless, the university teaching hospi-
tal cannot be omitted from the basic training of doctors. If stu-
dents and faculty were involved only in district-based services,
they would miss many important advances in biomedical
science and the care of complex problems (Husain 1996).
Moreover, doctors need to know enough about what the vari-
ous tertiary specialties do to be able to refer patients appropri-
ately and to make personal career choices.
The training of specialists, of course, depends far more on
the existence and proper functioning of referral hospitals.
Again, a particular country will need to decide how many spe-
cialists it needs in which specialties and whether it should send
its doctors abroad to specialize or train them internally. In
developed countries, 60 to 90 percent of doctors are specialists,
whereas in developing countries the range is wider (for exam-
ple, 76 percent of Indian doctors are specialists, 45 percent are
specialists in Tanzania, and 31 percent are specialists in
Morocco). A World Health Organization expert workshop
agreed on a figure of 50 percent (Puzin 1996). Therefore, a
country of 40 million would aim to train approximately 300 to
1,300 specialists per year. On average, such training lasts four
years. Thus, at any time the academic referral hospital system
would need to supply 1,200 to 5,200 residents. A guideline
many countries use requires a ratio of postgraduate specialist
supervision of not more than two residents per qualified spe-
cialist. This ratio can be used to get some idea of the referral
hospital capacity required to train specialists.
Although basic doctors could spend most of their training
time in primary care and district hospital facilities, with limited
exposure to tertiary care hospitals, the training of specialists—
as well as of other specialized allied staff members such as nurses
for intensive care or specialized psychiatry, physiotherapists
specializing in back injuries or burns, and pharmacists special-
izing in oncology—can take place only in referral hospitals.
In recent years, continuing medical education has grown in
importance as the need for professionals to continually update
their knowledge and acquire new skills has been more clearly
appreciated. The coordination and provision of appropriate
continuing medical education depends heavily on the specialists
and academics associated with referral and academic hospitals.
Management and Administration. Referral hospitals in many
developing countries play important roles in providing mana-
gerial and administrative support to other elements of the health
system. These roles may include managing laboratory services
on behalf of the whole health system; serving as the location for
drug and medical supply depots and distribution systems and
managing procurement systems; hosting and managing health
information systems, often including epidemiological surveil-
lance systems; managing centralized transport fleets; and, on
occasion, providing financial management, payroll, and human
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How Many Medical Students Should Be Trained Per 1 Million Population?
Box 66.1
In a steady state (that is, the number of doctors being
produced is equal to the number retiring from practice),
and if we assume that doctors practice, on average, for
40 years after qualifying, the total number practicing will
equal the number graduating in 1 year multiplied by
40 years. If a population of 1 million needs 1,000 doctors,
the number needing to be trained is 1,000/40  25 per
year. If 30 percent of doctors leave the country or leave
medical practice within 8 years of qualifying, then each
graduate, on average, contributes 30 years of service, and
1,000 practicing doctors (1,000/30)  33 must qualify
each year.
Source: Authors.
resource management services to other health units. Our intent
is not to consider whether such arrangements are “right” or
“wrong”—complex factors would have to be taken into account
in every individual circumstance—but to note that making
changes to the functioning of referral hospitals may have unin-
tended consequences. For example, moving referral hospitals
from funding based on a global budget to reimbursement sys-
tems based on patient activity may unintentionally cause hospi-
tals to cease to provide these wider support functions if explicit
alternative funding mechanisms are not established.
Research and Innovation. Referral hospitals tend to be where
most health research is undertaken. Whereas in developed
countries they may often be associated with the development of
new technologies, in developing countries they are more often
the site of research for the initial piloting and introduction of
new technologies developed elsewhere and for the evaluation
of their local suitability and field efficacy. Referral hospitals are
also the vehicle for disseminating such technologies through
the exposure of staff during training as well as through the role
that referral hospitals frequently play in continuing profes-
sional education.
Research activities are vital in attracting and retaining
specialist staff members who are required not just for the
treatment of complex patients, but also for the training of new
specialists. Research that is responsive to local conditions—that
is, local disease burdens and technology constraints—fills a
critical gap because researchers in developed countries and
pharmaceutical companies do not generally pursue such
research questions if they do not foresee sufficient returns to
their investments.
Valuing the Indirect Contribution to the Health System.
From the enumeration of the many roles of referral hospitals
and their indirect effect on health through their contribution
to the health system by way of supervision, administration,
training, research, and quality improvement, it is immediately
evident that these benefits cannot readily be translated into
DALYs or any other metric to be used in a relative cost-benefit
analysis.
Externalities and Intangible Benefits 
The previous sections reviewed the various functions of refer-
ral hospitals within the health system, all of which contributed
directly or indirectly to the health status of individuals. This
section addresses other ways in which referral hospitals con-
tribute to welfare and well-being, and comments on how they
complicate the issue of valuing the contribution of referral
hospitals in society.
Referral hospitals have a broader effect on overall societal
welfare than can be captured by measures of health outcomes.
Utility, or welfare, includes health as one of many important
outcomes, such as financial security, risk alleviation, and
psychological reassurance. However, as Hammer and Berman
(1995) note, health policy is typically conducted as if it has a
unidimensional objective—namely the maximization of health
(DALY) outcomes. Determining the appropriate resource allo-
cation to referral hospitals purely on the basis of the cost of
generating health (DALYs) may, therefore, seriously underesti-
mate the optimum level of resources, because such measures
will fail to capture the full welfare gains from the availability of
higher-level health services. An example will highlight the dif-
ference between valuing hospitals on the basis of their contri-
bution to health status alone compared with including wider
concepts of welfare in the valuation.
Renal failure leading to the need for dialysis is relatively rare,
and certainly rare in comparison to many other infectious and
chronic diseases in lower- or middle-income countries.
Treatment is lifesaving, but must continue indefinitely (involv-
ing visits two or three times every week) and is, therefore,
extremely expensive. In many cases, dialysis can be justified
only if it is linked to a renal transplant program, which termi-
nates the need for dialysis and frees the equipment for someone
else. The proportion of the total population who will benefit
from such a referral hospital program is small; therefore, the
DALYs generated are low, and the program would not rank
high among the priorities given a limited budget. However,
every member of the population is at risk of renal failure and,
if affected, would find that, in the absence of a publicly funded
program, he or she would either die or face extremely high
costs to secure treatment in the private sector or abroad.
Even in poor countries, patients’ price elasticity of demand
is low when faced with life-threatening illnesses, particularly
when treatment can change the outcome. Studies on poverty
have shown that a significant proportion of households that
have become poor did so as a result of serious illness, which
resulted in their liquidating assets to pay for health care (see, for
example, Liu, Rao, and Hsiao 2003). Thus, people seek the peace
of mind of knowing that they can obtain lifesaving treatment
should they need it without the risk of incurring catastrophic
costs of care. This additional welfare derives both from the
financial security of not having to spend more than people can
afford to save their lives and from the direct health benefits of
treatment itself. The utility from the former (financial security)
increases with the cost of the intervention required, whereas the
utility derived from the latter (direct health benefits) is unre-
lated to the cost of the intervention. Paradoxically, one could,
therefore, argue that the rarer a particular illness is—and the
more costly the intervention required—the greater will be the
welfare gain from public spending on that intervention.
This argument, of course, is likely to stand in direct contrast
to the conclusions drawn from prioritization based on cost-
effectiveness. For most individuals, willingness to pay is far less
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than the costs of the procedure to them; however, because the
whole population benefits from the security of knowing that
each individual would be entitled to referral hospital care
should he or she need it, in the aggregate the welfare value gen-
erated by public provision or funding may be many times
greater than the value of the DALYs generated directly for those
few patients who do receive treatment. This literature review
did not find evidence of studies on national willingness to pay
for referral hospital care in developing countries, but this area
could be of interest for future research.
In practice, too, the public—particularly an urban, middle-
income public—expects the government to provide care of last
resort for complex trauma or diseases, especially for natural
and man-made disasters. Thus, even though referral hospitals
may provide care to a small number of people, often with lim-
ited health benefits, politicians and the public alike may value
and prioritize them simply because they meet the public’s
expectations for what the government must provide. In addi-
tion, politicians and the public often regard a country’s ability
to provide the kind of complex, high-tech care offered in a
referral hospital as a measure of that country’s level of devel-
opment and sophistication, and it is a source of national pride.
Whether economically rational or not, this nonhealth benefit
appears to drive public choices to some extent.
Negative Impacts
The “negative” impact of referral hospitals is largely attributa-
ble to their potential to exert distortionary effects on the health
system by diverting resources from peripheral areas and from
lower levels of care (Fiedler, Schmidt, and Wight 1998; Filmer,
Hammer, and Pritchett 1997) for the following reasons:
• Tertiary hospitals and specialists have a high political and
public profile.
• Urban and political elites are more likely to use referral hos-
pitals than rural primary care facilities or district hospitals.
• Harmful competition with lower levels of care may result
from the maintenance of higher-level referral hospitals in
many poor countries, lowering use of the former.
• Referral hospitals can be entry points for the introduction
into the health system of inappropriate and unaffordable
technologies.
• Skilled personnel frequently find referral hospitals far more
attractive to work at than rural and district hospitals for
such reasons as preferences for a metropolitan location,
better hospital resources allowing for a more rewarding
professional experience, and better opportunities for pri-
vate practice (official or unofficial). However, given the
huge problem of global migration of health workers from
poor to rich countries (Bundred and Levitt 2000), one
could argue that well-functioning referral hospitals might
provide local health professionals with a good incentive to
remain at home, whereas the absence of referral hospitals
would increase the propensity of local professionals to
emigrate.
DETERMINANTS OF AN APPROPRIATE BALANCE
OF REFERRAL-LEVEL CARE
When one considers the ideal level of resources to be provided
for referral hospital care and the appropriate balance between
resources for referral hospitals and for other levels of the health
care system, no simple formula is available that can be applied
to different countries and contexts. However, certain key fac-
tors have an important influence on the need and demand for
referral-level care, the resources that may be available to the
health sector, and the ability of the health sector to provide ade-
quate and effective care in different settings.
General Determinants
Arguably the most important determinant of demand for and
ability to pay for referral hospital care is a society’s level of eco-
nomic development and wealth, captured (albeit imprecisely)
by measures of GDP per capita. Extensive international evi-
dence indicates that national health expenditure displays an
unambiguously positive income elasticity both across countries
and over time; that is, as a country gets richer, it spends rela-
tively more on health (see, for example, Getzen 2000; Schieber
1990). Studies in developed countries indicate that in the
United States, every 1 percent long-run increase in GDP leads
to a 1.6 percent increase in health expenditure, and in other
countries the increase is between 1.2 and 1.4 percent (Getzen
2000). Therefore, expecting developing countries to spend a
higher proportion of their GDP on health care as they become
wealthier seems to be reasonable. If the poorest countries were
to focus their limited resources on highly cost-effective inter-
ventions in primary health care, somewhat better-off countries
might be expected to spend progressively more on the referral
hospital level as resources became available.
An overlapping set of demographic and geographical factors
also plays an important role in determining the balance of
referral care—namely, population size, population density, ter-
rain, distances between main urban centers, and access.
Populations of some millions are required to justify a major
tertiary hospital with a full range of tertiary services. Small
countries with populations of less than 1 million will certainly
not be able to provide a full range of tertiary hospital services
because of the need to achieve minimum volumes to ensure
service viability and to attract a critical mass of specialized per-
sonnel. Countries with fewer than 100,000 inhabitants (gener-
ally island states) may find even secondary hospital services
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beyond their means and capabilities. Supranational referral,
reliance on larger neighbors, or regional collaboration may be
unavoidable for smaller countries, especially for tertiary care
provision, with the Caribbean and southern Africa providing
clear examples of many smaller states relying on referral facili-
ties in larger or wealthier neighbors. Within larger countries,
population density can complicate the planning of referral
services. Compact countries or regions with dense populations
can typically provide high levels of access to referral care at a
relatively small number of sites, whereas countries or regions
with more dispersed populations face more complex tradeoffs
regarding number of sites, volume thresholds, and transporta-
tion systems.
The other main influence on the appropriate balance of
referral services for a given country is its particular pattern
and burden of disease. Although referral-level services will
always be needed, as a society passes through epidemiologic
and demographic transitions, it is likely to require more of
those services typically found at referral hospitals. For example,
rapidly increasing rates of heart disease and cancers are typi-
cally encountered in industrializing nations and aging popula-
tions, and these are diseases whose effective management
requires access to the interventions, skills, and equipment that
will typically be concentrated at the referral hospital level.
Health System Determinants
A number of factors specific to the particular context of a
country’s health system will also influence the appropriate bal-
ance between referral hospitals and lower levels of care. These
factors are especially important in considering the appropriate-
ness of plans to change the balance of care between levels.
Broadly, they can be summarized as follows:
• capabilities of lower levels
• availability of specialized personnel
• training capacity, organization, and needs
• cultural issues, political issues, and traditions.
The first three factors are closely interrelated. If primary
health care and district hospital services are weak, cutting
resources for referral hospitals without destabilizing the system
will be more difficult. In such circumstances, rapid rebalancing
of resources is unlikely to be possible because careful efforts will
be required to develop lower-level services first, while still main-
taining the referral service.Where lower-level services are strong,
devoting relatively fewer resources to referral hospitals may well
be possible. However, even though an effective district health
system will be able to treat a large proportion of patients at lower
levels of care, it will also be better able to identify patients who
require referral for more complex care and, thus, may generate a
greater appropriate demand for referral hospital care.
Referral hospital services require a specialized staff to fulfill
their mission. If specialized personnel are not available in a
country, then attempting to develop referral hospitals on a
large scale will clearly be infeasible. However, many countries
arguably have too many specialized staff persons and too few
well-trained generalists. Where large numbers of specialists
exist, their presence will likely tend to draw resources dispro-
portionately toward the referral level and away from district
health systems. Wherever such imbalances exist, positive
changes will require a substantial training or retraining agenda.
The feasibility of such efforts is closely linked to the profes-
sional and social status of different professional groups and
subgroups—for example, whether medical specialists are
viewed as having a higher status than general practitioners—
and to the premium a society places on having access to
“advanced” medical care.
CURRENT BALANCE OF CARE IN PRACTICE
In this section, we summarize data on the current balance
between referral and lower levels of care. We first look at the
share of total health expenditure going to these different levels,
but given that referral care normally has much higher unit
costs, we recognize that the balance also needs to be viewed in
terms of volume of cases and access and equity.
Share of Health Expenditure
Different health systems categorize hospitals and services ren-
dered differently. Methodologies in national health accounts in
developing countries during the 1990s and early 2000s have
tended to use a simple, catch-all category of “hospitals” or“acute
hospitals” (for example, WHO 2002). Even high-income coun-
tries following the Organisation for Economic Co-operation
and Development’s system of health accounts provider classifi-
cation (OECD 2000, 136) distinguish only between “general”
hospitals and “mental health and substance abuse” and other
“specialty” hospitals in their national health accounts.
Consequently, making valid cross-country comparisons of
spending by levels of hospital care remains extremely difficult.
Mills (1990a) reviews published data on hospital expendi-
ture patterns in developing countries, and Barnum and Kutzin
(1993) provide a comprehensive survey of expenditure on hos-
pital services in a number of developing countries, drawing
their information largely from World Bank sector reviews.
These analyses remain the most authoritative assessment of the
proportion of public health expenditure absorbed by second-
ary and tertiary hospitals, even though their data represent only
a handful of countries at different points in time.
Overall, Mills (1990a) finds that hospitals in developing
countries appear to absorb from 30 to 50 percent of total
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health expenditure. Public hospitals of all types absorb some
50 to 60 percent of public health expenditure, and secondary
and tertiary hospitals absorb about 60 to 80 percent of public
hospital expenditure, with the remainder going to district hos-
pitals. Her results are broadly similar to those of Barnum and
Kutzin (1993, 26–33), who find that public hospitals at all lev-
els absorb a mean of approximately 60 percent of recurrent
public health expenditures. Across five countries (Belize,
Indonesia, Kenya, Zambia, and Zimbabwe), they find that
tertiary hospitals account for between 45 and 69 percent of
total public expenditure on hospitals. In South Africa, Thomas
and Muirhead (2000) find that tertiary hospitals account for
28 percent of hospital expenditure and 17 percent of total
public health expenditure, but when taken together with
regional referral hospitals, constitute 59 percent of hospital
expenditure.
Unit Costs of Care
One of the explanations for the high share of expenditure that
flows through higher-level referral hospitals is, of course, that
the unit costs of a referral hospital are necessarily higher
than the unit costs of a district hospital. This difference results
from the more complex case mix they treat, their more expen-
sive inputs, and the additional costs of their teaching functions
(Barnum and Kutzin 1993, 26). Mills (1990b) reports that her
analysis of available data indicated that secondary-level hospi-
tals were typically twice as expensive per bed day as district hos-
pitals and that tertiary hospitals were typically between twice
and five times as expensive per bed day as district hospitals.
Barnum and Kutzin (1993) find similar relationships between
unit costs by level of hospital in a variety of different countries.
This upward gradient in unit costs has also been found in
econometric studies of hospital costs (Adam, Evans, and
Murray 2003) and has been explicitly incorporated into the
regression-based unit cost estimates used in other chapters in
this volume.
Table 66.3 shows data on unit costs by level of care from
Mauritius and highlights a commonly encountered contradic-
tion of the preceding paragraph—namely, that costs appear
similar at all levels. This phenomenon is explained by average
bed occupancy in Mauritian district hospitals of around
45 percent in 1995, compared with average bed occupancies of
90 percent or more in tertiary hospitals. Thus, the high cost of
district hospital care in this case reflects not inputs, which are
much less extensive than in a tertiary hospital, but the effect of
low levels of utilization. Such a difference in utilization between
levels of hospital tends to be the norm in many developing
countries (Barnum and Kutzin 1993, 91–96). Note that the
regression-based unit costs of district hospitals used in the cost
analysis for this volume reflect an “optimized” bed occupancy
of 80 percent (Mulligan and others 2003, 29). This assumption
is entirely defensible from a long-run perspective, assuming
cost-minimizing behavior is necessary and appropriate. It does,
however, reflect quite a substantial shift from the levels of uti-
lization and productivity commonly seen in rural district hos-
pitals in most developing countries.
The use of a simple unit cost hides important cost differ-
ences between services and specialties within the same hospi-
tal, as demonstrated by the breakdown for Mauritian tertiary
hospitals in table 66.4. Differences in length of stay for differ-
ent specialties and conditions also obviously contribute to
radically different costs per admission or patient; however,
these differences should be captured by the condition
and procedure costs used in the disease chapters in this
volume.
Appropriateness of Utilization of Referral Hospitals
Perhaps the most frequent theme in the research literature on
referral hospitals in developing countries is the inappropriate
utilization of higher-level facilities and the apparent failure of
most referral systems in developing countries to function as
intended. Broadly speaking, hospitals of all levels, up to and
including national tertiary centers—especially in their outpa-
tients departments—are overwhelmed by patients who could
have been treated successfully at lower-level facilities, many of
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Table 66.3 Cost Per Bed Day in a Medical Ward by Level
of Hospital, Mauritius, 1995
(2001 U.S. dollars)
Level of hospital Cost 
District 17
Regional 21
Tertiary 20
Source: Murray and others 1996.
Table 66.4 Cost Per Bed Day for Selected Specialties,
Tertiary Hospitals, Mauritius, 1995
(2001 U.S. dollars)
Specialty Minimum Maximum
Medicine 16 20
Orthopedics 18 23
Pediatrics 29 43
Cardiothoracic surgery 36 39
Burns 37 37
Intensive care unit 106 120
Source: Murray and others 1996.
whom have self-referred, bypassing primary health care or dis-
trict hospitals in the process (Holdsworth, Garner, and
Harpham 1993; London and Bachmann 1997; Omaha and
others 1998; Sanders and others 2001).
Atkinson and others (1999) describe an extreme manifesta-
tion of this phenomenon, whereby the University Teaching
Hospital is actually the only public hospital in Lusaka.
Combined with the bypassing of primary health clinics in the
city, this situation results in the University Teaching Hospital’s
functioning primarily as a glorified health center and first-
contact provider for most of Lusaka’s population. The problem
of bypassing typically seems to be driven by a number of fac-
tors, including patients’ perception of superior quality of care
and resource availability at referral hospitals, which often may
be entirely well founded and rational (see, for example, London
and Bachmann 1997; Nolan and others 2001); the desire to
avoid delays in care if referral to a higher-level facility proves to
be necessary; and the fact that for many urban populations
a referral hospital may simply be the closest health facility.
Grodos and Tonglet (2002) argue that many countries’ failure
to develop an adequate urban equivalent of the district
health concept greatly exacerbates inappropriate utilization of
hospitals. The urban phenomenon of widespread bypassing
and self-referral is frequently accompanied by low rates of
formal referral from rural and outlying facilities (see, for
example, Nordberg, Holmberg, and Kiugu 1996; Omaha and
others 1998).
These problems have a number of negative impacts and con-
sequences. Simple conditions are unnecessarily treated in a
high-cost environment; outpatient departments are congested
by patients requiring primary care, thus causing long waiting
times; scarce staff time is diverted from specialized areas and
into inappropriate care; and more complex cases requiring spe-
cialized care are crowded out by more urgent but less technically
demanding cases that could be cared for at lower levels. The lat-
ter has been a particular concern in those countries with more
serious HIV/AIDS epidemics. As the number of patients falling
sick with AIDS increases rapidly, they start to occupy a signifi-
cant proportion of beds in hospitals at all levels (Gilks and others
1998), inevitably crowding out patients requiring other forms of
care.Although AIDS cases may well require hospitalization,only
a small proportion of cases require specialized or tertiary care.
Gilks and others (1998) find that this crowding-out effect may
fall over time as the health system adjusts to the pressures of
AIDS, but countries facing impending AIDS epidemics should
be prepared for its initial appearance.
Taken together, this complex of problems undermines the
effective delivery of both specialized care and appropriate pri-
mary health care. Specialized care is pushed to the back-
ground by the human wave of demand for primary care, while
hospitals unwittingly further undermine the credibility of the
primary health care system through one-sided competition
(Stefanini 1994), which reinforces the cycle and ensures
that primary health care facilities remain underused and
inefficient.
Access and Equity
By their nature, referral hospitals must be limited in number
and will inevitably be sited in major towns and cities. As a
result, a significant portion of the population, especially people
living in rural areas, will tend to live at some distance from the
nearest referral hospital. Studies of the accessibility of referral
hospital care in countries such as Ethiopia (Kloos 1990) and
Nigeria (Lyun 1983; Okafor 1983) have repeatedly confirmed
the existence of a steep distance-decay function, indicating
that—other things being equal—individuals with a given need
for a clinical service will be less likely to access that service the
farther away from the referral center they live.
Compounding the impact of distance, investigators find
that problems relating to the availability, regularity, and cost of
transportation to referral centers also affect service utilization
(Kloos 1990; Martey and others 1998). The same authors
indicate that prohibitive hospital fees are often a significant
barrier to utilization, especially among poorer patients. Other
important barriers included perceived lack of drugs and essen-
tial supplies, even at referral centers; negative staff attitudes;
and cultural and linguistic differences (for example, where the
staff at a referral center does not speak the language of a
patient from a remote area). As noted earlier, peripheral dis-
trict hospitals also tend to have low rates of referral. These bar-
riers, which all disproportionately affect rural patients, must
be contrasted with the phenomenon noted earlier of excessive
and inappropriate use of referral hospitals for primary care by
urban residents.
In addition to finding that public hospitals favor urban res-
idents over rural dwellers, a number of studies have indicated
that public hospitals in many poor countries disproportion-
ately benefit the better off, leading their authors to argue that
diverting public funds from hospitals and toward primary
health care would be pro-poor (see, for instance, Castro-Leal
and others 2000; Filmer, Hammer, and Pritchett 1997; Mahal
and others 2002). Other studies find this tendency in some
countries but not in others (Makinen and others 2000). By con-
trast, in Latin American countries, Barnum and Kutzin (1993)
find strong evidence that public hospitals are pro-poor in their
distributional effect. Even if referral hospital services are not
currently pro-poor, policy makers face two contradictory alter-
natives: either to retarget public funds toward primary health
care for the poor, hence greatly reducing or abandoning public
funding for referral hospitals, or to attempt to remove the bar-
riers that prevent the poor from using higher-level services,
which would probably require increased spending on all levels
of care.
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GETTING BETTER VALUE FOR MONEY FROM 
THE HOSPITAL SYSTEM
Although prescribing how resources should be allocated across
levels of care is hard, at least they should be efficiently
used, wherever they are spent within the hospital system. The
preceding analysis has highlighted how deficiencies at the lower
levels of the hospital system render referral hospitals less effi-
cient and how factors that affect access lead to skewed benefits
and inequity. Here we look more specifically at three areas for
improving the efficiency of the hospital system: interventions
within the referral hospital, the use of public-private partner-
ships, and strengthening of the referral chain.
Improving the Efficiency of Referral Hospitals
Although space does not permit a lengthy discussion of
approaches to improve efficiency in the context of referral
hospitals, this aspect is nonetheless important in planning and
system strengthening (for a more detailed discussion see
Barnum and Kutzin 1993; Hensher 2001; Walford and Grant
1998). In summary, the key areas on which planners and man-
agers should focus are as follows:
• reducing inappropriate outpatient and inpatient use of
referral 
• improving systems to allow early discharge from the
hospital 
• ensuring that bed occupancy rates can be maintained as
close as possible to optimal rates—namely, 85 percent for
referral hospitals 
• developing systems for booked outpatient appointments,
admissions, and procedures to permit better planning of
activity and staffing 
• undertaking as much activity as possible on an ambulatory
rather than an inpatient basis, supported by the use of
“step-down” beds and patient hotels 
• evaluating the staff skill mix and the potential for skill sub-
stitution, as well as efficient remuneration strategies, on a
continuous basis
• evaluating and improving processes and systems, including
cost-effective clinical guidelines for patient treatment, on a
continuous basis
• ensuring that new or replacement referral hospitals con-
form as much as possible to available evidence on
economies of scale—that is, that hospitals with fewer than
200 beds are likely to be scale inefficient and that disecon-
omies of scale are likely to become increasingly evident in
hospitals with more than 600 beds 
• adopting intelligent procurement processes and engaging in
effective negotiations with suppliers in relation to prices and
service levels
• ensuring effective ordering, stock control, and distribution
systems to minimize theft and wastage of key supplies 
• undertaking planned preventive maintenance and pro-
grammed replacement of equipment and buildings.
Can Public-Private Interactions Improve Efficiency?
In the context of this discussion, privately owned hospitals that
provide subsidized care to public patients, such as nongovern-
mental organization and mission hospitals, are regarded as
public hospitals. Private refers to for-profit hospitals that
are generally funded by paying patients and are minimally sub-
sidized. Few studies have been undertaken of how private
hospitals operate in developing countries (see, for example,
Muraleedharan 1999). Although the exact balance of and rela-
tionship between the public and private health sectors varies
greatly from country to country at all levels of the health sys-
tem, a common theme in almost all low- and middle-income
countries is that private hospitals do not follow the pyramidal
referral form that public hospital systems have adopted almost
universally. Most private health sectors do not clearly delineate
district, secondary, or tertiary hospitals. Different private hos-
pitals may offer different services and facilities on a more or less
idiosyncratic basis, with independent medical specialists prac-
ticing and admitting patients at various different hospitals.
In most systems, scope exists for both positive collaboration
and competition between public and private hospitals, espe-
cially for secondary and tertiary services. Competition between
public and private sectors obviously has the potential to be
beneficial by driving quality up and costs down, but it may also
have negative effects by encouraging a duplication of services
and resulting in the underutilization of fixed capital by creating
perverse incentives for physicians and patients and by compet-
ing with the public sector for scarce human resources. In some
settings, the private sector may be able to offer services that the
public purse cannot afford to provide, thus allowing patients
who could not afford private care some chance of accessing
sophisticated treatments through the government’s paying pri-
vate providers or by some pro bono provision of treatment for
poor patients.
In many countries, government hospitals are establishing
private wards as a vehicle for income generation. The fees for
such units are lower than those at private hospitals, offering
access to private facilities to patients who may not be able to
afford private hospitals. The link with academic medicine often
adds to the appeal of such facilities. However, as is the case in
South Africa, effectively only tertiary hospitals and a handful of
secondary hospitals are felt to be attractive enough to private
patients to offer genuine opportunities as preferred providers.
The mass of district and regional hospitals are unlikely to be
attractive to private patients; therefore, the positive spinoffs of
these initiatives may be limited in their scale and reach.
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Contracting out services to private providers, particularly
high-cost, low-volume services, may be an efficient way to offer
such services to public patients. For example, the government
of Barbados contracts out surplus demand for dialysis to a pri-
vate facility on the island. In some provinces of South Africa,
expensive imaging such as MRI has been contracted out to pri-
vate radiology practices. South Africa is also experimenting
with contracting out the management of some academic refer-
ral hospitals to a private hospital group that is assumed to have
greater management expertise and is free from certain public
sector constraints, such as salary scales for senior managers. It
is too early to judge the success of this arrangement, but in all
cases it is imperative that contracts be carefully regulated, mon-
itored, and enforced. For a comprehensive review of contract-
ing, see Bennet, McPake, and Mills (1997).
Particular problems may arise where the same doctors pro-
vide care in both public and private hospitals. Under fee-for-
service arrangements, physicians may focus on their more
lucrative private patients to the disadvantage of public hospi-
tal patients, refer patients with adequate insurance to their
private practices and private hospitals, and transfer patients
with expensive diseases or inadequate insurance to public
hospitals.
Improving the Functionality of Referral Systems
An ideal referral system would ensure that patients can receive
appropriate, high-quality care for their condition in the lowest-
cost and closest facility possible, given the resources available to
the health system, with seamless transfer of information and
responsibility as that patient is required to move up or down
the referral chain. Although few referral systems anywhere in
the world live up to this ideal fully, it does provide a target in
relation to improving the current situation. Improving the
effective functioning of referral systems broadly requires
progress in three areas: referral system design, facilitation of the
smooth transfer of patients and information between levels,
and what Walford and Grant (1998, 38) refer to as effective
“referral discipline.”
Improving referral system design must start with a detailed
attempt to assess which services should be provided at which
level of care, encompassing community- and home-based care,
primary health care, district hospitals, secondary hospitals, ter-
tiary hospitals, and specialized hospitals. Such an assessment
must take local circumstances into account, requires a signifi-
cant analytical and consultative effort by planners and clini-
cians if it is to be credible, and must explicitly be open to revi-
sion in light of practical experience. After such an exercise has
identified which services can appropriately be provided at each
level of care, adequate resources must be dedicated to strength-
ening lower levels of care to make them attractive and credible
in the eyes of patients. This effort will require significant
investment and funding to ensure the availability of appropri-
ate staff members and supervision, to ensure continuous drug
supplies, and to provide basic laboratory tests (Walford and
Grant 1998, 38). Given the pervasiveness of inappropriate use
of referral hospitals for primary health care problems by urban
residents, both urban and rural primary health care and district
health systems must be adequately strengthened. Financing
strategies that redistribute funds from urban to rural regions
may unwittingly hamper such strengthening of the referral sys-
tem by failing to allow for the development of appropriate
lower-level facilities for urban residents. This risk is especially
high when a country is pursuing a redistributive agenda against
a background of limited or zero overall growth in expenditure.
From a physical planning perspective, planners should con-
sider providing primary health care and district hospital walk-
in ambulatory services (emergency and general outpatients) in
a physically distinct facility sited immediately next to the refer-
ral hospital. This arrangement not only enables triage and fil-
tering of less severe cases (while proximity ensures that severe
emergency cases can be transferred rapidly) but also enables
rigorous enforcement of a referral-only policy within the refer-
ral hospital.
The development of effective patient transportation
arrangements is also critical, not only to ensure that patients
from remote areas have a fair chance of being successfully
referred to a center of excellence (bearing in mind that most
referral systems will almost certainly need to increase referral
rates from rural areas), but also to ensure that patients can be
discharged in a timely and well-planned fashion.
Perhaps more challenging is the concurrent need to align
the incentives of referral hospitals, district hospitals, and pri-
mary health care services. This goal may or may not be achiev-
able by means of an integrated management structure, but it
certainly requires a good deal of communication, collaborative
planning, and collaborative development of shared care proto-
cols, and senior personnel need to be given responsibility for
coordination and liaison across key interfaces of the referral
network. A single, global budget controlled by an authority that
is concerned with optimizing the cost-effectiveness of health
care delivery would seem to be a necessary condition to achieve
alignment across service levels; however, a consideration of
financing mechanisms is beyond the scope of this chapter.
At the patient level, a number of mechanisms to improve
referral discipline can be considered. In situations in which
eliminating nonreferred patients entirely from the referral hos-
pital is impossible, queuing systems should be redesigned to
separate referred patients from nonreferred patients so that
referrals can be fast-tracked. Explaining to nonreferred patients
why other patients are being fast-tracked past them is impor-
tant to encourage them to seek referral in future. Ideally, they
should be diverted to an on-site primary health care facility
where they can be treated more quickly than in the referral
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hospital. Another possibility may be to institute bypass fees for
nonreferred patients, charging them a penalty fee for failing to
use the referral system. Such a decision requires careful consid-
eration and planning. Credible lower-level care must be readily
available, and substantial efforts to communicate the new pol-
icy to the public will be required if this approach is to be seen
as fair. More broadly, intensive public communication and
education will be essential to inform the public how, where,
and when they should seek health care at different levels and to
build their confidence that lower-level facilities really will be
able to offer acceptable quality care when they need it.
CONCLUDING COMMENTS
This review of the available evidence indicates that referral hos-
pitals frequently do command a large share of health sector
resources and expenditure, yet no simple way exists of assessing
what an appropriate share would be. Strong referral hospitals
can distort priorities and undermine basic services, but they
also provide important health benefits to large numbers of
patients whom they treat successfully. Referral hospitals pro-
vide essential support to lower levels of the system, which can-
not function effectively without access to upward referral, and
they are frequently the most functional component of the
health system, paying greatest attention to quality of care.
Overall, we have argued that both national and international
policy makers should be cautious before demanding the reallo-
cation of resources away from referral hospitals and should be
still more cautious in allowing themselves to believe that such
a reallocation is likely to be achievable in practice. In particu-
lar, this chapter has made the case that a unidimensional focus
on cost-effectiveness analysis and cost per DALY gained will fail
to capture the importance of referral hospital services ade-
quately. In reality, in most developing countries, the scope for
reallocation of resources from referral hospitals to lower levels
of care is limited, and the managerial demands of achieving a
successful reallocation are great. Lower levels of care certainly
require strengthening, but this need is more likely to reflect
inadequate financing of the entire public health system than a
grossly excessive allocation to referral hospitals. Instead, refer-
ral hospitals should perhaps be seen as the capstone of the
referral pyramid: they should not be too heavy, but if they are
too light, the levels below them will lose cohesion. A restruc-
turing of referral hospital services is certainly called for to
improve appropriate referral and utilization, especially by
remote and rural populations; to transform the inappropriate
use of referral hospitals as primary health care providers; to
improve efficiency; and to provide much better outreach and
support to lower levels of care.
This restructuring should not be confused with wholesale
demolition. Undermining referral services will be far more
likely to undermine and destabilize the entire health system
than to liberate resources for primary health care. Clearly,
countries must critically evaluate their health priorities and
their balance of care and resources between levels, but they
should do so carefully and thoroughly, with a clear under-
standing of the analytical effort required to draw meaningful
conclusions, of the planning and managerial capacity that they
will require to bring about successful change, and of the long
time frames required to develop and implement robust plans
for major system changes.
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Countries with developing economies have not considered
surgical care to be a public health priority, yet surgically treat-
able conditions—such as cataracts (Javitt 1993); obstructed
labor (Neilson and others 2003); symptomatic hernias
(Olumide, Adedeji, and Adesola 1976; Rahman and Mungadi
2000); osteomyelitis (Bickler and Rode 2002; Hilton 2003);
otitis media (Smith and Hatcher 1992; Whitney and Pickering
2002); and a variety of inflammatory conditions—add a
chronic burden of ill health to populations. These acute and
chronic conditions take a serious human and economic toll
and at times lead to acute, life-threatening complications.
Inadequacies in the initial care of injured patients (Hyder
and Peden 2003; Jat and others 2004; Mock 2003; Mock and
others 1995); of women with obstructed labor; and of children
with treatable congenital anomalies, such as clubfoot (Ponseti
1999; Turco 1994) lead to preventable deaths or to chronic dis-
abilities that make productive employment impossible and
impose dependency on family members and society.
The role of surgery as a preventive strategy in public health
needs to be studied and measured far more extensively than is
currently the case. Another key reason for this study is that vir-
tually all countries are developing their economies, and as a
result, developing nations are increasingly facing a double
burden—that is, the infectious diseases that have historically
been so relevant and the conditions that emerge with economic
development (for example, trauma from motorcycle, truck,
and car accidents). The inclusion of a surgery chapter in this
book recognizes that surgical services may have a cost-effective
role in population-based health care. Recent studies (for
instance, McCord and Chowdhury 2003) show that basic hos-
pital service, which requires no sophisticated care, can be cost-
effective, with a cost per disability-adjusted life year (DALY)
that is much lower than might have been expected, and can be
on a par with other well-accepted preventive procedures, such
as immunization for measles and tetanus and home care for
lower respiratory infections (Armandola 2003; Dayan and
others 2004; Moalosi and others 2003; Ruff 1999).
We have identified four types of surgically significant inter-
ventions with a potential public health dimension: (a) the pro-
vision of competent, initial surgical care to injury victims, not
only to reduce preventable deaths but also to decrease the num-
ber of survivable injuries that result in personal dysfunction
and impose a significant burden on families and communities;
(b) the handling of obstetrical complications (obstructed labor,
hemorrhage); (c) the timely and competent surgical manage-
ment of a variety of abdominal and extra-abdominal emergent
and life-threatening conditions; and (d) the elective care of
simple surgical conditions such as hernias, clubfoot, cataract,
hydroceles, and otitis media.
NATURE, CAUSES, AND BURDEN 
OF SURGICAL CONDITIONS
Surgery is at the end of the spectrum of the classic curative
medical model and, as such, has not been routinely considered
as part of the traditional public health model. However, no
matter how successful prevention strategies are, surgical condi-
tions will always account for a significant portion of a popula-
tion’s disease burden, particularly in developing countries
where conservative treatment is not readily available, where the
incidence of trauma and obstetrical complications is high, and
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where there is a huge backlog of untreated surgical diseases
(Murray and Lopez 1996). Some surgical procedures can
certainly be perceived as forms of secondary or tertiary preven-
tion. Since the publication of the first edition of this book,
which did not have a chapter on surgery, the health care com-
munity has recognized that the surgical management of some
common conditions can indeed be a cost-effective intervention
(Javitt 1993; McCord and Chowdhury 2003). The purpose of
this chapter is to explore this hypothesis in more depth.
Methods for Determining Burden of Surgical Disease 
We have arbitrarily decided to define a surgical condition as
any condition that requires suture, incision, excision, manipu-
lation, or other invasive procedure that usually, but not always,
requires local, regional, or general anesthesia. We prefer this
definition for two main reasons, to one that would define
surgery as procedures performed by trained surgeons. First,
surgery does not have to be performed by qualified surgeons.
Indeed, in developing countries with few doctors, nondoctors
can be trained to perform several types of operations satisfac-
torily. Second, we believe that the concept of surgery should
include minor surgical procedures that nurses or general prac-
titioners could perform along with nonoperative management
of surgical diseases (for example, certain types of abdominal,
thoracic, or head trauma and burns and infections). Any defi-
nition of surgery will have limitations, as has ours, and those
limitations must be kept in mind when making interpretations,
extrapolations, or estimates. Our broad definition is compati-
ble with the concept of regionalized, coordinated, and interde-
pendent services provided at the community clinic level and at
the district and tertiary hospital levels. The most difficult task
we then face is trying to determine the burden of surgical con-
ditions as measured in DALYs. To our knowledge, this meas-
urement has never been attempted. What we provide here is a
starting point, with the understanding that the calculations will
change as data are developed.
Our methodology was based on data from the World
Health Report 2002: Reducing Risks, Promoting Healthy Life
(WHO 2002) and the global burden of disease study (Murray
and Lopez 1996). We began by listing all the conditions for
which surgery might be indicated into three groups, with group
I being communicable diseases, group II being noncommuni-
cable diseases, and group III being injuries. We then undertook
a comprehensive literature review for each condition to deter-
mine the proportion of the total burden of disease attributable
to it and the proportion of the burden that could be prevented
or treated by surgery. Essentially, we found no data of value
except maybe for cataracts (group II-F), for which a single
intervention (intraocular lens removal with or without
implant) is or should ultimately be indicated for nearly 100 per-
cent of patients (Dandona and others 1999; Javitt 1993).
The World Health Report 2002 attributes 8,269, of a total
1,467,257,000 DALYs, to cataracts (0.56 percent), and all those
DALYs are considered potentially surgical. Maternal conditions
(group I-C), perinatal conditions (group I-D), diabetes (group
II-C), intentional injuries (group III-B), and unintentional
injuries (group III-A), to name a few, are much broader cate-
gories of conditions for which the demarcation between the
surgical and nonsurgical burden is not as clear as for cataracts.
Faced with a near total lack of pertinent data, we decided
that the next best approach was to try to obtain consensus on a
“best educated guess” for the surgical burden of each condi-
tion. We developed a survey instrument that listed all the
possible surgical conditions (all potential surgical DALYs
representing the maximum imaginable DALYs that could con-
ceivably be surgical). We sent the questionnaire to 32 surgeons
in various parts of the world, asking them what was, in their
opinion, the proportion of each condition that would require
surgery, which we have referred to as estimated surgical DALYs
or the conservative minimum. For each of the 18 completed
questionnaires, we discarded the two lowest and two highest
values for each condition, leaving a sample of 14 surveys. The
lowest value of this sample was consistently chosen so as to err
systematically on the conservative side. Note that more than
90 percent of all retained values were within 10 percent of the
chosen value. We then applied this value to the DALY numbers
provided by the World Health Report 2002 for each category of
potentially surgical conditions.
Findings
Table 67.1 presents our estimates of the actual surgical burden
for each category of potential surgical conditions for the world
as a whole and by region. The table indicates that conditions
requiring surgery account for a significant proportion of
DALYs. Developing more refined, region-specific information
to help policy makers will require more detailed data on the
burden of surgical diseases (diseases requiring surgical treat-
ment) and on the cost-effectiveness of surgical therapy. To this
end, an extremely helpful step would be for international
surgical associations to regularly monitor the disease burden
attributable to surgical conditions throughout the world.
A few salient points about the burden of surgical diseases
can be made from data provided in table 67.1. We estimate very
conservatively that 11 percent of the world’s DALYs are
from conditions that are very likely to require surgery. Our esti-
mated figures are as high as 15 percent for Europe and as low
as 7 percent for Africa. Estimated surgical DALYs for the world
are 27 per 1,000 population. The estimated figure is about twice
as much for Africa (38 per 1,000) as for the Americas (21
per 1,000).
Table 67.2 summarizes the burden of common surgical con-
ditions based on World Health Report 2002 data. A more
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detailed look at these data allows us to make the following
observations:
• Injuries account for 63 million DALYs, or about 4 percent of
all DALYs and 38 percent of the world’s estimated surgical
DALYs.
• Surgical infections, including infected wounds, superficial
and deep abscesses, septic arthritis, and osteomyelitis,
undoubtedly account for a significant portion of surgical
DALYs, but the available data do not permit quantification.
• Surgical DALYs pertaining to acute abdominal conditions,
including appendicitis, intestinal obstruction, gastrointesti-
nal bleeding, hernias, and blunt or penetrating injuries also
cannot be calculated because of the lack of data.
• Approximately one-third of maternal conditions, including
hemorrhage, obstructed labor, and obstetrical fistulas, are
surgical, and these represent 10 million DALYs, or 0.7 per-
cent of all DALYs.
• Congenital anomalies refer to an ill-defined grouping of dis-
parate pathologies that includes congenital malformations
such as cleft lip and palate, hernias, anorectal malforma-
tions, and clubfoot. We estimate that some 50 percent of
congenital anomalies are surgical, representing about 14 mil-
lion DALYs, or 1 percent of all DALYs.
• Malignancies account for 31 million surgical DALYs, or
slightly more than 2 percent of all DALYs.
Table 67.3 breaks down the burden of common surgical
conditions by region, also showing rates per 1,000 population.
The absolute burden of injuries is highest in Southeast Asia,
followed by the Western Pacific and Africa. In terms of popula-
tion rates, whereas injuries account for 10 DALYs per 1,000
population for the world, the estimated figure is almost twice as
much for Africa (15 per 1,000) as for Europe (8 per 1,000).
Similarly, rates of obstetrical complications are far higher in
Africa than elsewhere, at 6 DALYs per 1,000 population. In
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Table 67.1 Estimated Surgical DALYs by Region
Estimated Estimated Estimated
surgical surgical DALYs surgical DALYs 
Total DALYs DALYs as a percentage per 1,000
Region (millions) (millions) of total DALYs population
World 1,468 164 11 27
Africa 358 25 7 38
Americas 145 18 12 21
Eastern Mediterranean 137 15 11 30
Europe 151 22 15 25
Southeast Asia 419 48 12 31
Western Pacific 258 37 15 22
Source: WHO 2002 and authors’ estimates.
Table 67.2 Burden of Common Surgical Conditions
Surgical DALYs
Estimated Estimated
surgical DALYs surgical DALYs
Estimated as a percentage per 1,000
Condition (millions)a Percentage of total DALYs population
Injuries 63 38 4.3 10
Malignancies 31 19 2.1 5
Congenital anomalies 14 9 1.0 2
Obstetrical complications 10 6 0.7 2
Cataracts and glaucoma 8 5 0.5 1
Perinatal conditions 7 4 0.5 1
Other 31 19 2.1 5
Source: WHO 2002 and authors’ estimates.
a. Estimated surgical DALYs refers to our conservative estimate of DALYs averted by surgical treatment in the most likely diseases for the most likely indications.
contrast, Europe has the highest rate of surgical DALYS related
to malignancies—9 per 1,000 population.
All these estimates are debatable. Work is needed to obtain
more valid, accurate, and reliable data, but in the meantime, we
believe that our results represent a conservative and acceptable
baseline estimate of the burden of surgical conditions against
which prospectively gathered data for given interventions can be
compared in order to assess the extent to which they address the
burden.In addition, the burden needs to be monitored over time.
Evidence suggests that the burden of intentional and uninten-
tional injuries is rising, particularly in Sub-Saharan Africa and
the Middle East. Some of the important contributing risk factors
include (a) aging populations; (b) increased access to and use of
mechanized vehicles and tools without commensurate improve-
ments in roads, traffic control systems, or capacity for trauma
care; and (c) persistent armed conflicts (Kaya and others 1999;
Krug, Sharma, and Lozano 2000; Meyer 1998; Mock and others
1995, 1999; Nantulya and Reich 2002; Peden and Hyder 2002).
INTERVENTIONS
Both population-based strategies and personal sevices pro-
vided in community clinic, district, and tertiary hospitals are
considered in this section.
Population-Based Strategies
Population-based approaches to the prevention of uninten-
tional and intentional injuries are discussed in the chapters on
those topics. A population-based approach to injury should
not, however, be limited to injury prevention. Patients may sur-
vive their primary injuries only to become chronically disabled
and a burden to their families and to society (Krug, Sharma,
and Lozano 2000; Mock and others 1999; Nantulya and Reich
2002; Peden and Hyder 2002). The incidence and severity of
the complications of survivable injury may be significantly
lessened by the provision of adequate surgical care during pre-
hospital care and initial hospitalization. No published data
from developing countries are available, however, either to
prove this plausible contention or to quantify the benefits of
adequate initial surgical treatment. A strategy to prevent
chronic disability arising from survivable injury requires well-
coordinated services for resuscitation, evacuation, and early
and expert operative management of the initial injury.
Many other surgical conditions that can be treated elec-
tively, such as hernias, hydroceles, and otitis media, are treated
when they present with complications requiring emergency
surgery. Thus, a pertinent question is whether treating such
conditions electively would be more cost-effective, but no reli-
able data are available to answer this question positively or
negatively.
Population-based strategies could also be applied to prevent
or treat some musculoskeletal conditions. For example, the
incidence of clubfoot is estimated at 1 or 2 per 1,000 live births,
but in developing countries these children are typically brought
in for orthopedic care when it is too late for effective nonsurgi-
cal conservative management (Ponseti 1999; Turco 1994).
Because we have no baseline data for the burden of clubfoot
and other musculoskeletal conditions, we are unable to
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Table 67.3 Estimated Surgical DALYs by Condition and Region
(DALYs in millions followed by DALYs per 1,000 population in parentheses)
Eastern Southeast Western
Condition Africa Americas Mediterranean Europe Asia Pacific
Injuries 10 7 6 7 20 13
(15) (8) (12) (8) (13) (8)
Obstetrical complications 4 1 1 3 1
(6) (1) (2) (0.5) (2) (1)
Cataracts and glaucoma 1 1 1 3 2
(2) (0.5) (2) (1) (2) (1)
Malignancies 2 4 1 8 6 10
(3) (5) (2) (9) (4) (6)
Perinatal conditions 2 1 1 3 1
(3) (1) (2) (0.5) (2) (1)
Congenital anomalies 2 2 2 1 4 3
(3) (2) (4) (1) (3) (2)
Other 4 3 3 5 9 7
(6) (4) (6) (6) (6) (4)
Source: WHO 2002 and authors’ estimates.
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quantify the DALYs that could be averted by comprehensive
surgical care.
The following sections describe the organization of surgical
services that we think would begin to provide coordinated sur-
gical care in developing countries. The provision of surgical
services in developing countries requires organizational struc-
ture and capacity at the level of community-based clinics,
district hospitals, and tertiary care hospitals. Our concept of
minimally adequate modules of surgical care is informed by
our personal experiences, the experiences of others, and a
recent World Health Organization report (WHO 2003). We
recognize that to accommodate local needs and reality on the
ground, any proposed plan to develop surgical services must be
flexible. Table 67.4 presents our estimates of the needs for
infrastructure, equipment and supplies, and workforce for the
three levels of surgical care: community clinic, district hospital,
and tertiary hospital.
Community Clinics
Table 67.4 shows resource and workforce requirements and
types of surgical services a community clinic could provide
for a population of around 20,000. We assume that surgical
services in community clinics would be provided at no cost to
patients. A cost-recovery system would be unlikely to succeed
everywhere but, if implemented, should be equitable, with pay-
ments adjusted to patients’ ability to pay. A mechanism for
accountability and monitoring should be established to avoid
the misuse of drugs and supplies. Simple patient records
should be maintained, including outcomes of treatment and
use of supplies. Even though the community clinic described
here is what we think it should be as opposed to what we know
it to be, our model may serve the needs of rural areas in devel-
oping countries and could provide a starting point for estimat-
ing costs.
District Hospitals
The next level of organization of surgical services is the district
hospital, which in addition to providing primary care for the
local population would also provide secondary-level surgical
services and serve as a referral center for a number of commu-
nity clinics in a defined region. In turn, the district hospital
would ideally refer patients requiring complex surgical care to
a tertiary-level hospital, but we recognize that such referral
cannot always be achieved in practice because of transporta-
tion limitations, economic constraints, and prevalent social
and cultural contexts. District hospitals vary in size from as
small as 10 to 20 beds to as large as 200 to 300 beds and vary in
their degree of sophistication in relation to diagnostic and ther-
apeutic capabilities. For this discussion, we have arbitrarily
chosen to focus on district hospitals with 100 beds or fewer.
Table 67.4 shows the infrastructure requirements for this
type of hospital. Patients requiring more complex imaging
studies and laboratory tests would be referred to the tertiary
hospital.
To the extent possible, all equipment and supplies
(table 67.4) should be standardized, and an efficient and reliable
system for maintenance and replacement should be ensured.
Operating room instruments and supplies should be available
to enable the performance of laparotomy, thoracotomy, obstet-
rical and gynecological procedures, treatment of extremity frac-
tures, skin grafting, and emergency burr hole of the skull. These
instruments should be available at least in duplicate. Table 67.4
also shows workforce needs and the types of surgical proce-
dures that may be performed in a district hospital.
The district hospital is assumed not only to serve as the
referral hospital for community clinics, but also to coordinate
the community clinics in its own region as a single operating
unit, assuming responsibility for wireless communication,
training the workforce, providing continuing medical educa-
tion, and monitoring the quality and outcome of care. It would
also provide primary care to its contiguous population.
Tertiary Hospitals
The tertiary hospital would function as the referral center for
all complex surgical care in a region, country, or group of
countries. Ideally, but depending on the country’s resource
constraints, it would provide the full range of care shown in
table 67.4. The tertiary hospital would also provide primary
surgical care for its local population and could take on the role
of a teaching hospital for doctors, nurses, and other health care
workers.
In the proposed organizational structure, the tertiary hospi-
tal is viewed as the top of a pyramid of surgical services, with
several district hospitals referring patients requiring complex
surgical care to the tertiary hospital. As such, it should also take
the primary responsibility for coordinating and collaborating
with all the district hospitals and community clinics in its
area of responsibility to ensure that surgical care is available
throughout the region and that well-functioning wireless com-
munication and ambulance systems are available. If a regional-
ized system of separate ambulance services is not available, the
tertiary hospital can provide the ambulance services required.
Specialists in the tertiary hospital should provide telephone
and electronic consultation for doctors and nurses in district
hospitals. The tertiary hospital should also coordinate and
monitor the quality of care in the region that serves as its refer-
ral base, undertake clinical outcome studies, and provide con-
tinuing medical education. In addition, it should be the main
teaching hospital for medical students, nurses, and technicians,
with the district hospitals and even the community clinics serv-
ing as clinical rotation sites for trainees. This organizational
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Table 67.4 Resource Requirements for Surgical Services and Surgical Procedures by Level of Care
Category of
requirement Community clinic 100-bed district hospital Tertiary hospital
Infrastructure
Equipment and
supplies
Human resourcesa
Weatherproof building (100 square
meters)
Storage space
Clean water supply
Power supply
Furniture 
Refrigerator
Blood pressure machine
Minor surgical trays
Sterile and burn dressings
Autoclave
Intravenous sets and solutions
Bandages and splints
Drugs: local anesthetics,
nonsteroidal anti-inflammatory
drugs, antibiotics, tetanus toxoid,
silver nitrate ointment, oxytocin,
magnesium sulfate
Wireless communication
equipment
Materials for recordkeeping 
Nurse or nurse equivalent
Skilled birth attendant
Orderly
Inpatient facility of 100 beds including several wards
and an isolation ward
Outpatient facility including an emergency room
Operating rooms (at least two: one clean, 
one contaminated) 
Labor and delivery rooms
Recovery room or intensive care unit
Blood bank
Pharmacy
Clinical laboratory
Radiology and ultrasonography suite
Anesthetic machines and inhalation gases
Monitors (electrocardiogram, blood pressure, pulse
oximetry)
Fully equipped operating room
Fully equipped delivery room
Fully equipped recovery room or intensive care unit
Respirators and oxygen supply
Blood products and intravenous fluids
Basic microbiology equipment
Pharmaceuticals (anesthetics, analgesics, antibiotics) 
Surgical materials (drapes, gowns, dressings, gloves)
and other consumables (disposable equipment and
devices)
Nurses (20)
Midwives (2–3)
Anesthetists (2–3)
Anesthesiologist (1)b
Primary care physicians (4)c
Obstetrician/gynecologist (1–2)
General surgeons (2)
Pharmacy assistants (2)
Pharmacist (1)b
Radiology technician (1)
Radiologist (1)
Physiotherapist (1)
A major facility providing:
• Full emergency services with advanced diagnostic
services;
• Inpatient wards for complex general medical and
surgical care
• Various types of specialty services
• Several delivery rooms and operating rooms
• One or more recovery rooms and intensive care
units
• Rehabilitation and occupational therapy facilities
All required equipment and supplies to undertake the
range of routine and complex services provided 
Nurses (50)
Midwives (5)
Anesthetists (5)
Anesthesiologists (3)
Primary care physicians (10)
Obstetricians/gynecologists (5)
General surgeons (5)
Orthopedic surgeon (1)
Pharmacy assistants (2)
Pharmacist (1)
Radiology technicians (5)
Radiologists (2)
Physiotherapists (5)
Neurosurgeon (1)b
Cardiac surgeonb
Reconstructive surgeonb
structure is ideally suited for the tertiary hospital to serve as the
backbone of community-based surgical education. The extent
to which this ideal function of a tertiary hospital can be imple-
mented will depend on the financial and other resources avail-
able to the country.
Coordinated Model System for Surgical Care 
The proposed system for surgical services requires the coordi-
nation and integration of the following:
• wireless communication
• continuing education programs
• regionalized supply system for equipment, essential drugs,
and surgical materials
• ambulance service
• uniform data collection system
• coordinated and ongoing monitoring of quality and out-
comes of care.
A wireless system of communication could render costly
wired systems unnecessary and could connect community clin-
ics, district hospitals, and tertiary hospitals in a dependable way
that facilitates consultation and referral. A Web-based system of
communication could be particularly important for mentoring
and for providing continuing medical education. The Web can
also be used to enhance contributions by volunteer surgeons,
anesthesiologists, surgical specialists, nurses, and technicians
from around the world. Associations such as the International
Surgical Association could develop a Web portal tied to national
surgical associations to ensure greater success in this regard.
A regionalized system for the purchase and delivery of
equipment and supplies is highly desirable. Such a system
could ensure that all equipment and supplies were standardized
and made available on demand in an efficient and predictable
manner.
Ground ambulance services are essential for patient transfer.
In some areas, collaboration with local taxi or bus services
might offer the needed support. In some more economically
advanced countries, tertiary hospitals might be able to provide
ambulance services using fixed-wing aircraft or helicopters.
If the proposed model for a surgical system is to be devel-
oped, systems for ongoing data acquisition and for evaluation
and monitoring should be built into the model. In this way, not
only could information be captured, but also the quality and
outcomes of care could be monitored on an ongoing basis.
COSTS AND COST-EFFECTIVENESS
OF INTERVENTIONS 
In today’s resource-constrained world, policy makers increas-
ingly need to be aware of the value of selective health care inter-
ventions. Cost-effectiveness analysis is one method that links
inputs (costs) with the resulting health care gains measured
along a common metric, usually using DALYs.
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Services provided Simple suturing and dressing of
wounds
Incision and drainage of abscesses
Care of simple burns
Control of hemorrhage
Splinting
Deliveries
Vacuum extraction and manual
vacuum aspiration
Emergency abdominal, thoracic, head injury
Uncomplicated general surgical operations for
hernias, anorectal conditions, and biliary tract disease
Surgical infection treatment and control
Obstetrical (including surgery for complications)
Simple orthopedic care: extremity fractures,
dislocations, and amputations
Burn care
Physiotherapy and occupational therapy
Education and training
Full emergency service
Management of all complex general surgery
Full range of services in orthopedics, trauma, urology,
otolaryngology, ophthalmology, and obstetrics and
gynecology
Basic (and, if resources permit, advanced)
neurosurgery and cardiovascular surgery
Intensive care services
Major burn service
Radiology services including CT and MRI imaging 
and angiography
Full service clinical laboratory
Physiotherapy
Occupational therapy
Training of doctors, nurses, and midwives
Source: Authors. 
a. Because of the variability in size and the complexity of services provided by tertiary hospitals, it is difficult to describe a standard tertiary hospital; the human resource needs given in the table
represent what we think are minimally adequate.
b. Desirable, but not absolutely necessary.
c. Can be a general internist, general practitioner, or general pediatrician.
Table 67.4 Continued
Category of
requirement Community clinic 100-bed district hospital Tertiary hospital
Even though an extensive body of literature examines the
cost-effectiveness of a range of nonsurgical interventions in
developing countries (Jha, Bangoura, and Ranson 1998), the
literature examining surgical interventions in these countries is
more sparse. Moreover, most of the available studies examine
surgical interventions for specific conditions (Marseille 1996;
Singh, Garner, and Floyd 2000). A common criticism of such
studies is that they do not fully capture the choices policy mak-
ers face in real life. For example, policy makers must often
choose between allocating resources for constructing several
community clinics or a single district hospital, both of which
provide a mix of surgical and nonsurgical services. Generally,
the surgical ward in a district hospital will provide care for a
wide range of conditions, such as trauma, childbirth, and
abdominal conditions. We assume that for policy makers,
knowing the cost-effectiveness of the surgical service, ward,
or clinic (as an intervention) is more useful than information
about the cost-effectiveness of each condition-specific surgical
intervention. Unfortunately, no literature exists that examines
the cost-effectiveness of a surgical service or ward. This section
attempts to fill that void with respect to district hospitals and
community clinics but not in relation to tertiary-level hospi-
tals, which vary in size, available resources, and role from
region to region, making it difficult to describe the cost-
effectiveness of a prototypical tertiary hospital.
Method for Estimating Costs and DALYs 
On the basis of the resource requirements listed in table 67.4,
we developed cost estimates for each of the six regions defined
by the World Bank. Table 67.5 details the assumptions and
table 67.6 provides the regional costs. We defined the standard
hospital in such a way as to facilitate comparisons across
regions, conceptualizing it as a 100-bed hospital with a male
ward and a female ward; two operating rooms; a recovery
room, an intensive care unit, or both; an x-ray unit and an
ultrasound machine; and a laboratory that can carry out basic
blood chemistry tests, examine urine, and cross-match blood.
This hospital also has an on-site laundry and kitchen and two
vehicles to serve as ambulances. The staff consists of 6 doctors
(4 primary care physicians, 1 obstetrician and gynecologist,
and 1 general surgeon); 20 nurses; 6 midwives; 2 physiothera-
pists; and 6 orderlies. The costs of an anesthetist and x-ray
technician have been included in the operating costs of the
operating rooms and radiology area, respectively. The model
assumes that the hospital averages 80 percent occupancy and
that two-thirds of inpatients will be surgical cases.1
We defined a standard community clinic (see table 67.4) as
a facility of 100 square meters serving a population of approx-
imately 20,000, staffed by a nurse or nurse-substitute, a skilled
birth attendant, and an orderly. Such a clinic treats approxi-
mately 4,000 surgical cases per year, with a surgical case being
defined as treatment of bruises, simple cuts requiring suturing,
foreign body removal, drainage of abscesses, basic burn treat-
ment, normal deliveries, and simple trauma.
As far as possible, we used standardized regional cost esti-
mates provided to the authors. When such information was
unavailable, we used our consensus judgment. Given the wide
variation in costs between and within regions, we conducted
sensitivity analyses to capture the range of possible outcomes.
When more than one source of cost estimates was available, the
mean of the estimates for that region were used as the best esti-
mate and a high-low range was noted. However, in many cases,
only a single cost estimate could be obtained, in which case the
data provide a point estimate,2 and we vary the cost estimate by
±20 percent to obtain a high-low range.
Our calculation of the number of DALYs averted was based
on the work of McCord and Chowdhury (2003), who calculate
the DALYs averted by a 50-bed hospital in Bangladesh, as
described in box 67.1. We adjusted this figure to reflect the bed
size of our standard district hospital. In the absence of region-
specific data, we applied this figure to all six regions after
making suitable adjustments. For the community clinic, we
estimated that such a clinic averts approximately 200 DALYs
per year as a result of surgical treatment, primarily from the
incision and drainage of abscesses and the preliminary treat-
ment of burns. Because these DALY estimates are based on a
single source, we vary the estimate by ±20 percent to obtain a
high-low range and apply these estimates across the six regions.
Results
Figure 67.1 presents the results of the cost per DALY averted cal-
culations for a district hospital and community clinic. The low
estimate represents the scenario in which the costs are the lowest
and the DALYs averted are the highest—that is, the best-case sce-
nario. In a similar vein, the high estimate is the worst-case sce-
nario: the costs are highest and the DALY averted is the lowest.
The best estimates for cost per surgical DALY averted at
a community health center (panel a of figure 67.1) hover in a
narrow range between US$212 and US$241. The cost per sur-
gical DALY gained at a district hospital is cheapest for Sub-
Saharan Africa at US$33 (range of US$19 to US$102) and most
expensive for Latin America and the Caribbean at US$94
(range of US$47 to US$164).
Standard economic costs can differ from costs actually
incurred in service delivery, both because in practice not all time
may need to be paid for (for example, hospitals may be able to
economize on staff because relatives help care for patients) and
because low-cost solutions may be found (for example, use of
paramedical staff members in place of professionals). Box 67.2
describes some of these strategies and compares the standard
economic cost presented above with the much lower financial
cost of a nongovernmental organization (NGO) hospital.
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Discussion
The data in figure 67.1, when compared with similar data for
other services presented in this book, indicate providing basic
surgical services is relatively cost-effective. Figure 67.1 also
indicates that, from a surgical perspective, the costs per DALY
averted at a community clinic tend to be higher than those
averted at a district hospital despite the lower costs of a com-
munity clinic. Although these observations may be taken as
evidence that surgical services are best provided at the district
hospital level, this goal may be impossible to put into practice.
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Table 67.5 Costing Assumptions for District Hospital and Community Clinic
Category Assumptions and comments
100-bed district hospital
Inpatient hospital bed days The estimate includes “hotel” costs (capital, salaries, overhead, building, equipment, and food) for a hospital running at
80 percent occupancy. Assumption: two-thirds of all cases seen are surgical and costs are adjusted accordingly. 
Operating rooms The estimate includes all operating room–related costs (surgeon, nurses, equipment, and so on). Assumption: the
operating room is running for 8 hours/day, 5 days/week, 52 weeks/year.
Laboratory Assumption: 16 new admissions/day, all of whom will require a laboratory test once during their hospital stay. Yearly
costs have been adjusted to reflect the percentage of surgical cases. 
X-ray Assumption: 16 new admissions/day, of whom half will undergo an x-ray examination once during their hospital stay.
Yearly costs have been adjusted to reflect the percentage of surgical cases.
Pharmacy Assumption: all admitted patients will use US$10 worth of drugs during their stay. Yearly costs have been adjusted to
reflect the percentage of surgical cases.
Blood transfusion Assumption: 400 units of blood transfused/year.
Ambulance The estimate includes 2 ambulances; 15 percent markup for freight, insurance, and distribution; US$500/year running
costs added; ambulance depreciated over 9 years. 
Staff
Nurses Assumption: nurses devote two-thirds of their time to surgical patients and costs have been adjusted accordingly.
Midwives Assumption: midwives devote 100 percent of their time to surgical patients. 
Doctors These are the four doctors whose costs have not been included in the operating room costs listed above. Because they
provide ward coverage, two-thirds of their costs are attributed to surgical patients.
Physiotherapists Assumption: physiotherapists devote two-thirds of their time to surgery patients.
Orderlies Assumption: six orderlies, each devoting two-thirds of their time to surgical activities.
Community clinic
Building costs The estimate includes costs of lighting and power. Assumption: building size is 100 square meters, 20-year straight-line
depreciation is used; 25 percent of costs are attributed to surgical patients.
Water supply Assumption: US$20 for water supply, of which 25 percent attributed to surgery.
Supplies The estimate includes surgical trays, sterile and burn dressings, intravenous sets and cannulas, bandages, splints, and
plaster of Paris for 4,000 patients. Assumption: local costs of US$5/patient.
Drugs The estimate includes local anesthetics, nonsteroidal anti-inflammatory drugs, tetanus toxoid, silver nitrate, and basic
antibiotics. Assumption: 4,000 patients, US$5/patient.
Furniture The estimate includes autoclave, surgical light, examination table, and beds. Assumption: total cost US$2,000, straight-
line depreciated for 10 years.
Refrigerator The estimate includes locally manufactured refrigerator, straight-line depreciated for 5 years; surgical cost attribution
only.
Wireless telephone Assumption: US$200 cost; 25 percent attributed to surgery.
Staff
Nurses and nurse-substitutes Assumption: nurses devote 25 percent of time to surgical duties and costs adjusted accordingly.
Skilled birth attendants Assumption: attendants devote 25 percent of time to surgical duties and costs adjusted accordingly.
Orderlies Assumption: orderlies devote 25 percent of time to surgical duties and costs adjusted accordingly.
Sources: Authors. 
Note: The figures for the district hospital should be viewed with particular caution. First, we used a single source of data for our assumptions. Had we used other data sources, the results could conceiv-
ably be different. Second, as a prototype we used a Sub-Saharan Africa district hospital that provides basic, low-tech surgical services. The provision of more sophisticated care can be expected to drive
up the costs of care significantly. 
The type of surgical care provided at the community clinic
level, though not resulting in a very large DALY gain, is
nevertheless important. It is inconceivable to think of a com-
munity clinic that does not have facilities for minor foreign
body removal, simple suturing of cuts and wounds, or splint-
ing of simple fractures. Furthermore, community clinics’ refer-
ral and primary treatment functions, which are hard to evalu-
ate separately from the delivery of final treatment, are critical
for many conditions, notably trauma.
Costs per surgical DALY averted at the district hospital
level seem to fall into three groups. Sub-Saharan Africa and
South Asia are the cheapest, with the best estimates of cost
per surgical DALY averted ranging between US$33 and
$US38; Europe and Central Asia, Middle East and North
Africa, and Latin America and the Caribbean seem to be the
most expensive, with the cost per surgical DALY averted rang-
ing between US$77 and US$94; and East Asia and the Pacific
falls in the middle. This finding indicates that, from the per-
spective of providing surgical care, a district hospital is an
exceptional “buy” in Sub-Saharan Africa and South Asia, both
areas with high disease burdens. Coupled with evidence that
district hospitals are comparatively underfunded compared
with national (tertiary) hospitals (Fiedler, Wight, and Schmidt
1999), a prima facie case exists for increasing support for
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Table 67.6 Annual Costs Attributable to Surgical Patients in a District Hospital and a Community Clinic, Best Estimates
(2001 U.S. dollars)
Latin America Middle East Sub-
East Asia and Europe and and and North Saharan
Category the Pacific Central Asia the Caribbean Africa South Asia Africa
100-bed district hospital
Inpatient hospital bed days 204,042 363,277 640,071 498,904 156,826 148,635
Operating rooms 778,752 1,130,688 1,163,136 896,064 526,656 419,328
Laboratory 34,304 44,403 45,251 37,619 27,058 23,974
X-ray 18,578 26,788 27,501 21,276 12,700 10,195
Pharmacy 38,544 38,544 38,544 38,544 38,544 38,544
Blood transfusion 7,572 8,548 8,632 7,892 6,872 6,572
Ambulance 7,389 7,389 7,389 7,389 7,389 7,389
Staff
Nurses 24,652 29,808 58,591 95,227 21,973 30,390
Midwives 11,100 13,422 26,382 42,870 9,894 13,680
Doctors 11,856 14,340 28,187 45,807 10,571 14,618
Physiotherapists 3,522 4,258 8,370 13,604 3,139 4,341
Orderlies 5,714 6,914 13,587 22,081 5,097 7,045
Total 1,146,026 1,688,380 2,065,641 1,727,277 826,718 874,551
Community clinic
Building costs 1,280 1,321 601 1,324 569 574
Water supply 5 5 5 5 5 5
Supplies 20,000 20,000 20,000 20,000 20,000 20,000
Drugs 20,000 20,000 20,000 20,000 20,000 20,000
Furniture 200 200 200 200 200 200
Refrigerator 10 10 10 10 10 10
Wireless telephone 50 50 50 50 50 50
Staff
Nurses and nurse-substitutes 667 807 1,585 2,577 595 822
Skilled birth attendants 667 807 1,585 2,577 595 822
Orderlies 361 437 858 1,394 322 445
Total 43,240 43,635 44,895 48,136 42,345 42,928
Sources: All district hospital costs and community clinic building and staff costs: DCPP guidelines; other community clinic costs: authors’ estimates.
district hospitals in developing countries. However, those pro-
viding such support have to be cognizant of realities on the
ground, especially political realities, because they have a sig-
nificant effect on the direction of change (Blas and
Limbambala 2001).
Data on the cost-effectiveness of surgical interventions for
specific conditions in developing countries are scarce. One
notable exception is for the surgical treatment of cataracts
(removal of the opaque lens with or without the insertion of an
intraocular implant). Blindness from cataracts is a significant
public health problem in many developing countries, and as
their populations age, estimates indicate that by 2020 more
than 40 million people will be blind or almost blind because of
cataracts (Brian and Taylor 2001). Box 67.3 describes a success-
ful program in India.
RESEARCH AND DEVELOPMENT AGENDA
The literature on surgical care in developing countries is so
meager that insufficient data are available to formulate an
agenda for research and development. Hence, of necessity, the
research that needs to be done is extremely basic, much of it
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Estimation of the DALYs Averted by a Small Hospital in a Developing Country
Box 67.1
The DALY estimates in this chapter are based on a report
from a 40-bed nongovernmental hospital in rural
Bangladesh in 1995 (McCord and Chowdhury 2003).
Obviously this experience was localized from one hospital,
in one country, at one time, but it is the only analysis avail-
able from such a hospital that estimates effectiveness using
DALYs or any other measure of the effect of a hospital on
the disease burden. The hope is that other similar studies
done in a variety of hospital situations will permit gener-
alizing with more confidence, but our personal experience
leads us to believe that the disease pattern presented to
small district hospitals in poor countries is remarkably
constant, especially for surgical conditions.
McCord and Chowdhury (2003) present the methods
for calculating DALYs in detail. They reviewed all dis-
charges and deaths every week for three months, con-
firmed the discharge diagnosis by means of a chart review,
and estimated the percentage chance that the hospital stay
had prevented death or disability. The review covered all
patients discharged, classifying them as medical, surgical,
obstetrical and gynecological, or pediatric. Of the dis-
charges, 62 percent were of surgical and obstetrical and
gynecological patients. Of the DALYs, 21 percent of those
averted were for surgical patients and 61 percent from
obstetrical and gynecological patients. Eighty-nine percent
of the estimated DALYs averted were generated by averting
premature death, and only 11 percent by preventing seri-
ous disability. Of the 192 surgical operations, 118 were
emergencies. Of 137 obstetrical patients, 81 had compli-
cated deliveries, complications of abortion, or ectopic
pregnancies.
Our estimates of the risk of death or serious disability
were based on tables McCord and Chowdhury created and
were necessarily arbitrary, but we believe they are
extremely conservative. For example
• If the chance of death or disability was less than 5 per-
cent, it was considered to be 0 percent. Because normal
out-of-hospital deliveries had less than a 5 percent
chance of death or disability, normal deliveries in the
hospital made no contribution to the estimated DALYs
averted.
• A cesarean section for obstructed labor was estimated
at 10 percent averted risk for the infant and 0 percent
for the mother.
• A cesarean for transverse lie was estimated at 90 per-
cent averted risk for the infant and 90 percent for the
mother.
• An appendectomy for nonruptured appendicitis was
estimated at 10 percent averted risk, because many
cases of appendicitis respond to antibiotics outside the
hospital setting.
• An appendectomy for a ruptured appendix with
generalized peritonitis was estimated at 90 percent
averted risk.
• An elective herniorrhaphy for a small hernia was
estimated at 0 percent averted risk.
• A herniorrhaphy for a large, disabling hernia was
estimated at 80 percent averted risk.
• A herniorrhaphy for a strangulated hernia that did not
reduce with conservative management was estimated at
80 percent averted risk.
Source: Authors.
information gathering. The following are some of the areas that
require investment in research and development:
• Estimates are needed of the burden of disease that requires
surgical intervention along with a determination of region-
specific DALYs that can be averted by means of surgical
intervention. We have applied the DALYs averted from a sin-
gle study in a developing country (McCord and Chowdhury
2003) to other regions, a procedure that negates regional dif-
ferences in disease incidence, health care–seeking behavior,
case mix, and clinical practice variations. In addition, the
calculation of DALYs averted should ideally be adjusted for
region-specific life expectancy and disability weights.
• Estimation of costs, both at a facility and regional level, is
needed, including reducing variability in estimation meth-
ods (Adam and Koopmanschap 2003). In addition, multiple
estimates of costs are needed. For example, Mulligan and
others (2003) derive their operating room costs from a sin-
gle study of ambulatory surgery in Colombia (Shephard and
others 1993). Even though they made adjustments to reflect
regional characteristics, further research is required to vali-
date their results, especially as they apply to different set-
tings in different countries.
• Better surgical data collection and analysis tools critical to
needs assessment should be designed.
• Development of appropriate surgical care models for all lev-
els of care based on local and regional characteristics and
surgical needs would be useful.
• Cost-effectiveness and cost-benefit analyses of health
systems implementation need to be determined, as do the
policy implications of creating the surgical care model
proposed in this chapter. The evaluation of surgery as a
prevention strategy in public health should include cost-
effectiveness analysis of adequate, prompt, initial surgical
treatment of injury to prevent chronic disability from poorly
diagnosed and treated survivable injuries and of elective
treatment of hernia, hydrocele, otitis media, cataract, and
clubfoot to prevent complications and disability.
• The surgical workforce in developing countries requires
more in-depth study to look at the mixes of workers needed,
the level of training required for the widely varying local sit-
uations of district hospitals, and the role for part-time sur-
gical talent. The thesis is that volunteer doctors, nurses, and
anesthesiologists who now contribute considerably to surgi-
cal care in developing countries in a relatively unstructured
fashion could do so more effectively and in a manner that
could help create sustainable local surgical workforces if a
well-coordinated system with extensive information and
communication support could be developed. This concept
merits in-depth study. If a well-planned, Web-coordinated,
global, highly integrated system could be developed, health
care volunteers around the world could be organized
strategically so as to deliver not only surgical care, but also
training of local surgical workforces. The emphasis on
training is crucial and would mitigate the complaints often
heard that surgical volunteers too often contribute to the
care of individual patients but fail to leave behind a
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Figure 67.1 Cost per Surgical DALY Averted for a Community Clinic
and a District Hospital
Low estimate High estimateBest estimate
Source: Authors’ calculations using costs in table 67.6 and methods for estimating
DALYs averted described in box 67.1.
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US dollars
Category NGO hospital (2001 US$) District Hospital in South Asia (2001 US$)
Inpatient bed days 110,936 156,826
Operating time 178,508 526,656
Laboratory 11,788 27,058
X-Ray 6,676 12,700
Pharmacy n.aa 38,544
Blood transfusion 3,858 6,872
Ambulance n.a.a 7,389
Staff n.a.b 50,673
Total 311,766 826,718
Source: NGO hospital: McCord and Chowdhury 2003; district hospital: table 67.6.
n.a.  not available.
a. Included in overhead, which is added to each cost center.
b. Included in total cost of ward and operating room.
mechanism for sustaining surgical care when they have left.
Those volunteers who come from the high-tech world of
modern surgery should realize that the latest technology is
often more of a burden and diversion than a help in poor
countries. Convincing demonstrations of how much can be
done without recourse to CT scans, ultrasound, and video-
assisted surgery could be the most useful contribution a vis-
itor could make.
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Surgical Cost in a Bare-Bones Hospital
Box 67.2
The estimated economic costs in this chapter assume
staffing and service levels generally derived from World
Health Organization recommendations for developing
countries (Mulligan and others 2003), but in many places,
surgical services are delivered in much simpler and less
expensive facilities. Independent project hospitals (NGO
hospitals) often operate on remarkably tight budgets.
Private hospitals, often set up in private houses by indi-
vidual surgeons, use locally trained staff with minimal
“hotel” service. Extremely poor countries operate hospi-
tals with a cost per patient per day of US$10 or less simply
because they cannot afford more. Such hospitals achieve
financial savings in several ways:
• Unpaid family members provide personal nursing care
and food, eliminating the need for a kitchen and many
trained nurses.
• Locally trained staff members substitute for profes-
sionally trained personnel.
• Many staff members have duplicate functions. In the
operating room the same person may work as surgical
assistant, scrub nurse, and orderly who cleans instru-
ments or transports patients.
• Day staff members cover night calls for emergencies.
• Specialized services are provided by general physicians
or technicians trained to do surgery or give anesthesia.
• Laboratory tests and x-rays are used sparingly. The only
laboratory procedure for an obstetrical patient could
be a hemoglobin determination.
• Only basic medicines are provided. More expensive or
complicated supplies are purchased outside the hospi-
tal by the family.
For one independent, nongovernmental hospital in
Bangladesh, we were able to obtain the actual financial cost
of all aspects of hospital operations during a three-month
period. These costs included salaries, supplies, hotel costs,
and depreciated cost of equipment and buildings, as well as
an overhead estimate to allocate a share of the total project
cost for administration, electricity, transportation, and
so on. Separating the surgical service costs for 3 months,
extrapolated to 12 months and a 100-bed hospital, we come
up with a much lower total cost than the low estimate in
this chapter for the economic costs of a model district hos-
pital, as shown in the table below. Part of the difference is
caused by differing cost definitions (financial versus eco-
nomic), but a good part is owing to the use of low-cost
approaches to the delivery of surgical care.
CONCLUSIONS
The inclusion of this chapter indicates the evolving apprecia-
tion that surgery has a role to play in public health strategies.
Previous concerns that surgery is a curative intervention
performed in expensive, high-tech hospitals precluded appreci-
ation of the potential role of surgery in public health. Public
health specialists now recognize not only that surgery has a
preventive role, but also that surgical treatment provided in
low-tech community hospitals is cost-effective. In addition, a
significant number of surgical procedures, including cesarean
sections and other abdominal operations, can be successfully
performed by surgical technicians (Jamisse and others 2004;
Pereira and others 1996).
Surgery has an important role as a public health strategy in
at least four areas:
• in the prevention of death and chronic disability in injured
patients by the provision of timely, expert, and complete ini-
tial surgical treatment
• in the timely surgical intervention in obstructed labor, in
pre- and postpartum hemorrhage, and in other obstetrical
complications
• in the provision of competent surgery to treat a wide range of
emergency abdominal and nonabdominal conditions
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Success Story: Cataract Surgery in India
Box 67.3
Prevention strategies aimed at known risk factors, such as
tobacco use and exposure to the sun, are unlikely to have
a significant effect on the need for surgical treatment of
cataracts in the foreseeable future (Ellwein and Kupfer
1995). The benefits of cataract surgery have been well doc-
umented in many developing countries.
In 1993–94, with a World Bank credit of US$118 mil-
lion, India expanded cataract surgery coverage to the dis-
advantaged with the goal of reducing the prevalence of
blindness. District blindness control societies were set up
and given the flexibility of financing different providers of
cataract surgery services to low-income groups at the dis-
trict level (Rose 1997). Mobile camps were a strategy
adopted for providing cheap and efficient cataract surgery
in rural districts. Because of these efforts, cataract surgery
nationally increased from 1.2 million surgeries in 1991–92
to 2.7 million in 1996–97. Singh, Garner, and Floyd (2000)
analyze the cost-effectiveness of publicly funded options
for delivering cataract surgery in Mysore, India, by assess-
ing outcomes in a systematic sample of patients operated
on in 1996–97. Patient satisfaction was 51 percent among
those operated on in government mobile camps, 82 per-
cent among those treated at the medical college hospital,
and 85 percent among those treated in nongovernmental
hospitals. Cost-effectiveness was US$97 per patient treated
for the mobile camps, US$176 for the state medical college
hospital, and US$54 for nongovernmental hospitals. Javitt
(1993) estimates the cost of cataract surgery in India at
less than US$25 per DALY averted.
As the World Health Organization (Brian and Taylor
2001) has stressed, successful and sustainable surgical
treatment of cataracts is linked to a spectrum of other
equally important activities, including ongoing training
of surgeons, nurses, and administrators; reliable and
affordable supply chains; and equipment purchase and
maintenance.
• in the surgical care of several elective conditions that have
a significant effect on the quality of life, such as cataract,
otitis media, clubfoot, hernias, and hydroceles.
Few published data are available to enable reliable estimates
of either the burden of surgical diseases or the cost-
effectiveness of surgical treatments in a region-specific manner
to help policy makers and voluntary groups. This area merits a
great deal of attention in relation to research and development.
Nevertheless, the clear conclusion is that surgery must be
considered a public health priority.
NOTES
1. This structure is based on the authors’ personal experiences of prac-
ticing in developing countries. We have defined surgical cases to include
deliveries and cesarean sections.
2. For example, operating room costs are based on the results of a sin-
gle study by Shepard and others (1993).
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INTRODUCTION
Emergency medical conditions typically occur through a sud-
den insult to the body or mind, often through injury, infection,
obstetric complications, or chemical imbalance; they may
occur as the result of persistent neglect of chronic conditions.
Emergency medical services (EMS) to treat these conditions
include rapid assessment, timely provision of appropriate
interventions, and prompt transportation to the nearest appro-
priate health facility by the best possible means to enhance
survival, control morbidity, and prevent disability (see
table 68.1). The goal of effective EMS is to provide emergency
medical care to all who need it. Advances in medical care and
technology in recent decades have expanded the parameters of
what had been the traditional domain of emergency services.
These services, no longer limited to actual in-hospital treat-
ment from arrival to stabilization, now include prehospital care
and transportation.
Despite the best efforts of primary care providers and public
health planners, not every emergency is preventable. Emergency
medical care is needed in diverse circumstances: prospective
patients range from rural farmers or fishers whose most com-
mon mode of transportation may be canoes or animal-drawn
carts, to factory workers living in densely populated urban
slums, to residents of high-income cities and suburbs. Actual
provision of emergency care may range from delivery using
trained emergency professionals to delivery by laypeople and
taxi drivers. Developing strategies to meet the range of needs
posed by such diverse circumstances will require innovation
and a reorientation of public health planning.
A number of misconceptions about emergency care are often
used as a rationale for giving it low priority in the health sector,
especially in low-income countries. These ideas include equat-
ing emergency care with ambulance transportation, neglecting
the role of the community and facility care provided,and assum-
ing that emergency departments and physicians are the only
acute care resources. Such a narrow view ignores the important
contributions of other disciplines, skills, and personnel. Perhaps
the most common misperception is that emergency medical
care is inherently expensive and requires high-technology
interventions as opposed to simple and effective strategies.
Emergency care, which may be delivered in crisis situations
with poor planning and ineffective use of resources, may be
inefficient. In many countries, few resources are set aside for
possible emergencies, and when situations that demand emer-
gency care arise, they precipitate hurried and costly resource
deployment. Efforts to improve emergency care, however, do
not necessarily increase costs. This chapter shows that
improved organization and planning for emergency care can
be done at a reasonable cost and lead to more appropriate use
of resources, improved care, and better outcomes (White,
Williams, and Greenberg 1996). This chapter does not address
nonacute conditions, even though emergency care is often the
only recourse for people with nonemergency conditions
because of the failure of these other components of the system
(see figure 68.1).
Chapter 68
Emergency Medical Services
Olive C. Kobusingye, Adnan A. Hyder, David Bishai, Manjul
Joshipura, Eduardo Romero Hicks, and Charles Mock
Definitions
The current literature is often inconsistent in the use and inter-
pretation of terminology. Accordingly, the specific terms used
in this chapter are defined as follows:
• Emergency care. Emergency medical care is that care deliv-
ered in the first few hours after the onset of an acute med-
ical or obstetric problem or the occurrence of an injury,
including care delivered inside a fixed facility.
• Paramedical personnel. Paramedical personnel refers to all
persons with medical training who are involved in the care
and transportation of patients in need of emergency med-
ical care. The length and quality of training vary, from highly
specialized personnel with capabilities for advanced life sup-
port to those with simple first-aid training and limited field
experience.
• Hospital. A hospital is a geographically fixed facility in which
personnel with some acceptable level of training deliver
emergency medical care. The distinctions between a clinic,
health center, and hospital are unclear, and the presence or
absence of a doctor is not a determining factor in this dis-
tinction. A range of facilities from small, basic units up to
tertiary care hospitals provides an increasing level of capa-
bility for emergency and other care.
• Triage. Triage is the screening of patients in the field or in
the receiving area of a fixed facility to determine their rela-
tive priority for treatment. Triage, which is usually necessary
in the occurrence of mass casualties, may be necessary
whenever a large number of patients requiring emergency
care present at the same time. It typically entails categoriz-
ing patients into three groups: those very unlikely to survive,
even with treatment; those whose conditions are minor and
who will recover without emergency care; and those with
potentially lethal conditions who are likely to survive if they
receive timely emergency care. Patients in the last category
form the highest priority for emergency care.
• Stabilization. A distinction is often made between initial
emergency care and stabilization on one hand and definitive
medical care on the other. Initial emergency care and stabi-
lization are usually considered the domain of mobile EMS;
lower levels of the health care system (for example, clinics
and smaller hospitals); and the emergency departments of
any fixed facility. Definitive care is usually considered the
domain of the hospital and of larger facilities and implies
the resolution of the condition needing treatment. However,
the distinction is somewhat arbitrary; a more accurate
approach is to view care as a continuum. Many of the ele-
ments of early care delivered in the course of emergency
treatment, whether in the field or in fixed facilities, can be
considered definitive (McCord and Chowdhury 2003;
McCord and others 2001).
Burden of Disease 
Investing in emergency medical care should become a priority.
Emergency medical systems address a diverse set of diseases
that span the spectrum of communicable infections, noncom-
municable conditions, obstetrics, and injuries. All of these
conditions may present to the EMS in their acute stages (for
example, diabetic hypoglycemia, septicemia, premature labor,
or asthma), or they are acute in their natural presentation
(for example, myocardial infarction, acute hemorrhage, or
injuries). Accordingly, defining the burden of disease addressed
by EMS can be problematic.
Malaria causes 300 to 500 million acute episodes worldwide
annually and results in an estimated 1 million deaths, mostly in
Sub-Saharan Africa. Effective emergency care can avert these
deaths, as well as those from acute respiratory and diarrheal
diseases in children and from noncommunicable diseases such
as diabetes, hypertension, and other cardiovascular diseases. In
addition to the acute presentation of chronic conditions, the
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Self-limiting episodes: treatment unnecessary
Treatable episodes: treatment delays
still tolerated well
Emergency
episodes:
treatment delays
jeopardize life or
human function
Source: Authors.
Figure 68.1 The Emergency Medical Care Pyramid
Table 68.1 Overview of Emergency Medical Services
Acute event On-site management Transportation Health facility care
Role of EMS Recognition Triage, stabilization, or both Safe and efficient transportation Prompt, appropriate, and quality care
Key issues Surveillance and Trained personnel, equipment Safe transportation, equipment, Personnel, equipment, 
identification referral system organization of services
Source: Authors.
lack of access to medical care and lack of sustained effective
treatment means that subacute episodes and flare-ups may be
life threatening. Early recognition can prevent the emergency
precipitated by infectious disease and many other medical con-
ditions or can limit the effects.
More than 500,000 maternal deaths occur each year; 95 per-
cent of these deaths are in low-income countries where emer-
gency care is often lacking. It is estimated that 15 percent of
all pregnant women experience a potentially life-threatening
condition and will need emergency care. Prenatal screening
methods alone may not be effective in reducing this risk ratio.
Although identifying risk factors for acute complications is
easy, identifying which of the at-risk women will actually
develop a life-threatening condition is not possible (Graham
1997). The only way to prevent the deaths is by ensuring access
to emergency obstetric care for all pregnant women.
Injuries were responsible for 21.7 percent of global deaths
and 31.1 percent of disability-adjusted life years (DALYs) lost
in 2001 (WHO 2002). Because both unintentional injuries
(chapter 39) and injuries caused by interpersonal violence
(chapter 40) are by definition acute events, nearly all require
emergency care (see table 68.2). In 2001, more than 80 percent
of all deaths attributable to injury were in low-income coun-
tries. Most injuries attributable to violence involve a predomi-
nantly young and productive population (WHO 2002) that is
resilient and can respond well to appropriate emergency care.
The conditions listed in table 68.2 represent 45 percent of
all deaths and 36 percent of the disease burden (including
disability) that occur in low-income countries. The numbers
represent a conservative estimate of the potential burden,
because they do not include all the conditions that could ben-
efit from emergency care and they do not include data from
high-income countries.
INTERVENTIONS FOR EMERGENCY CARE:
SYSTEMS, STRUCTURES, AND ORGANIZATION 
Emergency care must be appreciated as an entire system with
interdependent components. These components include pre-
hospital care, transportation, and hospital care. Each compo-
nent is important, but all of them must work together to make
a lasting effect on the health of a population. The organization
and operation of the prehospital care system will vary by coun-
try, but it should be linked to the local hospitals or facilities
where patients are taken. When prehospital transportation is
poor or absent, deaths occur that could have been prevented
even by inexpensive procedures (Mock and others 1998). For
example, the majority of maternal deaths may fall into this cat-
egory. Poor quality of care at the hospitals will lead to in-
hospital deaths and may eventually discourage communities
that might have the capacity to promptly transfer patients to
such facilities (Leigh and others 1997; Prevention of Maternal
Mortality Network 1995). Skilled and motivated personnel,
appropriate supplies, pharmaceuticals, equipment, coordina-
tion, and management oriented to the needs of the critically ill
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Table 68.2 Burden of Diseases Potentially Addressed by EMS in Low- and Middle-Income Countries 
(2001, all ages, both sexes)
Deaths DALYs DALY YLL YLD
Group Disease (thousands) (thousands) rates/1,000 population (thousands) (thousands)
I: Communicable Diarrheal diseases 1,777 58,697 11.25 50,883 7,835
Childhood clustera 1,362 43,131 8.26 40,506 2,624
Maternal conditions 507 26,383 5.05 13,363 13,020
Meningitis 169 5,475 1.05 4,343 1,131
Malaria 1,207 39,961 7.66 35,461 4,438
II: Chronic Diabetes 757 15,804 3.03 10,140 5,661
Hypertensive heart 760 9,969 1.91 9,077 888
Ischemic heart 5,699 71,882 13.77 67,925 3,921
Cerebrovascular 4,608 62,669 12.01 51,539 11,100
Asthma 205 11,514 2.21 3,799 7,714
III: Injuries Unintentional 3,214 113,235 21.70 73,140 40,104
Intentional 1,501 42,615 8.16 34,374 8,242
Total EMS related 21,766 501,335 96.06 394,550 106,678
Percentage of LMIC total 45 36 43 22
Source: Global Burden of Disease Project 2001.
YLL  years of life lost to premature mortality; YLD  years lived with disability; LMICs  low- and middle-income countries.
a. Pertussis, poliomyelitis, diphtheria, measles, and tetanus.
all contribute to make emergency care effective in reducing
death and disability.
Prehospital Care
Prehospital care encompasses the care provided from the com-
munity (scene of injury, home, school, or other location) until
the patient arrives at a formal health care facility capable of giv-
ing definitive care. This care should comprise basic and proven
strategies and the most appropriate personnel, equipment, and
supplies needed to assess, prioritize, and institute interventions
to minimize the probability of death or disability. Most effec-
tive strategies are basic and inexpensive, and the lack of high-
tech interventions should not deter efforts to provide good
care. Even where resources allow them, the more-invasive pro-
cedures performed by physicians in some prehospital settings,
such as intravenous access and fluid infusion or intubations, do
not appear to improve outcomes, and evidence suggests that
they may, in fact, be detrimental to outcomes (Liberman and
others 2003; Sampalis and others 1994, 1995, 1997).
Prehospital care should be simple, sustainable, and efficient.
Because resource availability varies greatly among and within
countries, different tiers of care are recognized. Where no for-
mal prehospital system exists, the first tier of prehospital care
may be composed of laypeople in the community who have
been taught basic techniques of first aid. Recruiting and train-
ing particularly motivated citizens who often confront emer-
gencies, such as drivers of public transportation, to function as
prehospital care providers can add to this resource.
The second tier comprises paramedical personnel who use
dedicated vehicles and equipment and are usually able to get to
patients and take them to hospitals within the shortest possible
time. This second tier may involve the performance of
advanced procedures, the administration of intravenous and
other medications by physician or nonphysician providers, or
both. This care is not always available in low-income countries;
few trained personnel and inadequate funding make round-
the-clock coverage impossible. Although providing advanced
life-saving measures in the prehospital environment may be
beneficial in some cases, these benefits may be negated if such
measures divert scarce resources from more basic interventions
that can benefit far larger numbers of patients (Hauswald and
Yeoh 1997). In most low- and middle-income countries of
Africa, Asia, and Latin America, high maternal and child mor-
tality are linked to inadequate emergency care, especially poor
access to quality hospital care. In these settings, it is imperative
that resources be integrated, instead of one system for injuries
and another for obstetric emergencies.
Personnel. Most of the world’s population does not have
access to formal prehospital care. No personnel are employed
for the sole purpose of dealing with medical emergencies
outside of hospitals, and no transportation is dedicated to the
task of getting patients in need of emergency care into hospi-
tals. There is a paucity of literature on the effect of first respon-
ders, except for one study that evaluated a program to train a
core group of paramedics, who then trained thousands of lay
first responders in northern Iraq and Cambodia. No data are
available on the effectiveness of lay responders compared with
the more trained paramedics.
The following discussion introduces a scenario in which the
observed mortality rate reduction could be achieved in a devel-
oping country’s health system by a small group of paramedics
working together with a large group of trained lay responders.
The scenario uses only emergencies caused by trauma, although
it is expected that both the paramedics and the lay first respon-
ders would also save lives from medical or obstetric emergen-
cies. Existing studies have not been large enough to document
these effects, and they are not included in the estimates of cost-
effectiveness.
Trained Lay Responders A case is made for training lay per-
sons able to recognize threatening conditions—whether
obstetric, traumatic, or medical. Cultural reasons may require
that those responding to obstetric emergencies be traditional
birth attendants or similar persons in the community. Husum
and colleagues demonstrated that lay people who are given
first-aid skills could effectively respond to emergencies in a
community with a high trauma burden (Husum, Gilbert, and
Wisborg 2003; Husum, Gilbert, Wisborg, and others 2003). In
Ghana, it was demonstrated that commercial taxi and minibus
drivers trained in first aid could provide effective prehospital
care (Mock and others 2002). Lay responders are likely to be
successful where the burden of injuries and other emergencies
is high. Attrition of both the responders and the skills is a con-
cern unless they are put to frequent use.
Paramedical Personnel In most middle-income countries and
some cities of low-income countries, trained paramedical
personnel render prehospital care (Mock and others 1998;
Tannebaum and others 2001). As for lay responders, coverage
varies by country. In most of Sub-Saharan Africa and Asia, para-
medical personnel and ambulances transfer patients between
health facilities and not from the scenes of injury or from homes
(Joshipura and others 2003). In middle-income countries,
though, they are a major component of existing emergency
medical systems (Arreola-Risa and others 2000; Mock 2002).
Their presence (coupled with vehicle ambulances) reduces the
interval between the recognition of an emergency and the
arrival at the hospital, and some evidence suggests that training
them in basic life-saving skills improves patient outcomes (Ali
and others 1997, 1998; Arreola-Risa and others 2000).
Effectiveness has also been demonstrated for well-placed
dispatch sites in urban populations, where the vehicles and
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personnel can be optimized. There is no evidence, however, for
the effectiveness of training prehospital care paramedical per-
sonnel in advanced life-saving skills (Sethi and others 2003).
Shorter prehospital times, in general, are considered an impor-
tant parameter of the quality of prehospital care. These times
have the following components:
• Notification time is the time elapsed from occurrence of
injury or recognition of severe illness until the EMS system
is notified.
• Response time is the time elapsed from notification until
arrival of an ambulance to the site of the ill or injured
person.
• Scene time is the time taken by prehospital providers from
arrival at until departure from the scene.
• Transport time is the time elapsed from leaving the scene
until arrival at the hospital or other treatment facility.
Notification time is influenced by the availability of telecom-
munications. Response time is influenced by the capabilities of
a dispatch center to handle emergency calls and especially by the
geographic distribution of sites of ambulance dispatch. The
greater in number and the more widely distributed the number
of ambulance stations are, the shorter the response times are.
Geographic distribution and associated response times can be
improved in some circumstances by using a tiered or layered
response system. This system requires having a relatively larger
number of basically trained and equipped first responders with
wider geographic distribution and a smaller number of centrally
located, more highly trained and equipped second responders.
This system allows the first responders to respond more rapidly,
with second responder involvement only if needed (Arreola-Risa
and others 1995).
Accordingly, paramedical personnel should be introduced
in large urban areas where they do not function at present and
should be stationed at dispatch sites with dedicated vehicles,
fast communications with the hospitals in the area, and links
with other emergency services such as the fire and police
departments. The communities served by the system should
have a well-known and rapid method of calling the paramed-
ical teams when an emergency arises. Because skills depreciate
with time, these personnel require refresher courses. Where
paramedical personnel already exist as part of the EMS, their
numbers and organization (location, training, deployment,
and monitoring) should be enhanced to improve response
times and, hence, patient outcomes, especially for cardiac and
obstetric emergencies. Availability of EMS for a given popula-
tion can be looked at either as number of units on duty or
number of sites of ambulance dispatch. They are usually closely
related, with one or two units per site, but not in systems
where a large number of units are on duty from one central
dispatch station.
The recommended ratio of one unit for 50,000 people sug-
gested by McSwain (1991) results in response times as low as
four to six minutes. The ratio does not distinguish between
basic life-support and advanced life-support capabilities.
Traffic congestion, poor maps, and poor road signs may all
increase this response time in cities with poor infrastructure. In
Monterrey, Mexico, one unit per 100,000 people manages an
average response time of 10 minutes. Hanoi, Vietnam, with one
unit for 3 million people, has an average response time of 30
minutes (Mock and others 1998).
Where paramedical services exist alongside lay responder
services, these two could be managed by the same organiza-
tional unit. The paramedical staff will be more successful in
urban areas, where distances between dispatch sites, commu-
nities served, and hospitals are short. Other enabling factors are
good telecommunications; rapid and dedicated transportation;
and coordinating capacity among the community, hospitals,
and other emergency services.
Intervention Cost and Effectiveness Training lay responders is
an intervention potentially available in low-income countries.
Projections for costs and effectiveness have been made based
on the following assumptions:
• Serving a population of 1 million requires 7,500 trainees.
Sensitivity analysis ranges from 5,000 to 10,000 trained lay
responders.
• Trained lay responders can be trained in half a day (St. John
Ambulance 1996).
• Training would have to be repeated every three years to
maintain efficacy.
• Annually, 2,500 laypeople would be trained on a rolling basis.
Using these assumptions (see annex 68.A for technical
details on costing guidelines) would require the following:
• 1,250 days of trainees’ time (0.5 days each) valued at salary
level 1
• 62.5 trainer days of time, with a ratio of 20 trainees per
trainer, valued at wages for salary level 3
• one training facility with a classroom (100 square meters)
valued at rent for basic space for 62.5 days
• 2,500 copies of photocopied curricula annually valued at
US$1 each.
The costs of providing trained paramedics can be estimated
using the following assumptions:
• Trained paramedic responders can be trained in 25 days
(St. John Ambulance 1996).
• Serving a population of 1 million requires 7,500 trainees.
Sensitivity analysis ranges from 100 to 200.
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• Training would have to be repeated every three years to
maintain efficacy.
• Annually, 50 paramedics would be trained.
As a result, the following would be required:
• 25  50  1,250 days of paramedic trainee time (salary
level 1)
• 125 trainer days, with a ratio of 10 trainees per trainer
valued at salary level 3
• one training facility offering a classroom (100 square
meters) valued at basic building values
• 50 photocopied curricula annually, valued at US$1 each 
• one paramedic kit with stethoscope, gloves, bandages, and
splint material for each trainee (kits would be renewed by
patient contributions).
The trainees would offer volunteer services after training.
We assume that volunteers are highly motivated individuals
who consider emergency medical service to their community
as the most rewarding use of their leisure time (Fiedler 2000).
The opportunity cost of their recurrent emergency service is
assumed to be zero. Communities or cultures that have a short-
age of individuals with an ethic of volunteer service may have
to devote funds toward maintaining incentives for “volunteer”
paramedics to serve. In such cases, this strategy may not be
cost-effective.
Table 68.3 shows the estimated costs of the lay first respon-
ders and paramedics intervention, drawing on the Disease
Control Priorities Project’s standardized input prices by region
for low, best, and high estimates.
Outcomes According to the World Health Organization
burden-of-disease estimates, the global incidence of trauma is
410 per 100,000 or 4,100 per million. Husum, Gilbert, and
Wisborg (2003) indicate that first-level responders and trained
paramedics can lower mortality in trauma by 9 percent; thus,
in 4,100 traumas, 370 lives can be saved. Dividing the sum of
the costs in table 68.3 by the 370 deaths averted provides a
rough estimate of costs per death averted. These costs per death
averted are divided by the regional life expectancy at age 20
(LE 20), with the assumption that the average age of trauma is
20, to give the cost per life year saved. LE 20 is roughly 50 years
in every region except Sub-Saharan Africa, where it is only 37
years. Shortages of equipment and supplies may reduce the
effectiveness of the prehospital personnel.
It is possible to offer more refined “regional” estimates of the
numbers of deaths averted by using local estimates of the bur-
den of injuries instead of the global estimate of 4,100 injuries
per million people. Yet given the uncertainty about regional
variation in the effectiveness of the intervention based on
administrative, infrastructure, and human resource capacity, it
would perhaps give a false impression that a firm and universal
basis exists to speculate quantitatively on the relative effective-
ness of the intervention in various regions. As a result, the
above estimates, as used in table 68.4, serve to inform global
dialogue rather than offer specific empirical numbers.
Equipment and Supplies. Equipment and supplies should
match the knowledge and skills of the personnel available to
use them. Even teams with the least resources should have the
following:
• protective wear, especially gloves and aprons
• a stretcher or the equivalent 
• pressure dressings (bandages—elastic, if possible—and
cotton or gauze dressings)
• splints—various sizes, made out of local materials
• radio, telephone, or other mode of rapid communication.
Annex 68.A provides a comprehensive list for better-
resourced communities. Intervention cost and effectiveness
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Table 68.3 Cost of Using Trained Lay First Responders Together with Trained Paramedics 
(local currency converted to 2001 U.S. dollars using exchange rates)
Region Low Best High
East Asia and the Pacific 27,539 48,050 75,232
Europe and Central Asia 30,209 52,339 79,605
Latin America and the Caribbean 32,777 74,589 110,453
Middle East and North Africa 33,050 104,585 261,935
South Asia 27,183 45,637 116,456
Sub-Saharan Africa 30,765 52,339 115,171
Unweighted average 30,254 62,923 126,475
Source: Authors.
Note: Cost of treating community of 1 million.
cannot be estimated because no studies are available on this
issue from low-income countries.
Traditional and Innovative Communications Systems.
Nowhere is the demand for efficient communication and rapid
transportation more critical than in emergency medical care.
The best teams equipped with state-of-the-art technology and
supplies will be wasted if they cannot be reached quickly or if
they have no contact with the hospitals where patients are to be
taken. Most of the world’s population lives in areas where there
is no telecommunications infrastructure, and this situation may
not change significantly in the near future. Innovation is needed
so that these populations can be enabled to access effective
emergency care interventions that already exist without waiting
for traditional telephone lines to get to their rural homes. Radio
communication is one solution in such settings. Equipping tra-
ditional birth attendants and remote health units with radio
receiver sets linked to local hospitals has been used to shorten
the response time and reduce maternal deaths (Samai and
Sengeh 1997). Cellular telephones may offer communities that
are remote from standard communications infrastructure an
opportunity to leap into a more modern and efficient mode.
Intervention Costs and Effectiveness There are no studies
from low-income countries on which to base intervention cost
and effectiveness estimates. The costs will depend on whether
the community adopts traditional communication or more
modern communication systems. If radio communication
were introduced, the purchase and maintenance of radio
receivers, supplies, and government licensing costs would need
to be estimated. If cellular telephones options were being
explored, then the purchase of telephones, plans, licenses, and
maintenance costs would need to be included. Where satellite
towers need to be installed, however, this cost will be much
higher than for all other components. Finally, if traditional
landline installation is being considered, the lines, equipment,
and telephone bills will need to be taken into account. The
health sector may be able to share the costs of such interven-
tions, especially traditional telephone lines, with other develop-
ment and infrastructure units of a national government.
Basic and Advanced Transportation Systems. Transporting a
patient from the location of the acute event to a hospital facil-
ity is a critical element of the prehospital component. Lack of
transportation is often a major barrier to accessing emergency
care (Lungu and others 2001; Samai and Sengeh 1997). In
devising a prehospital system of transportation, one should
consider locally available resources and the range of viable
alternatives for transportation. In some countries such trans-
portation may be part of a formal EMS system, whereas in
other cases it is entirely informal. For example, commercial
vehicles, the police, and relatives using private motorized or
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Table 68.4 Cost-Effectiveness of Combining Paramedics with Lay Responders
(local currency converted to 2001 U.S. dollars using exchange rates)
Region Low Best High
Cost per death averted with trained lay first responders together with volunteer paramedics
East Asia and the Pacific 74 130 203
Europe and Central Asia 82 141 215
Latin America and the Caribbean 89 202 299
Middle East and North Africa 89 283 708
South Asia 73 123 315
Sub-Saharan Africa 83 141 311
Unweighted average 82 170 342
Cost per life year saved with trained lay first responders together with volunteer paramedics
East Asia and the Pacific 3 5 8
Europe and Central Asia 3 5 8
Latin America and the Caribbean 3 8 11
Middle East and North Africa 3 11 27
South Asia 3 5 12
Sub-Saharan Africa 4 6 14
Unweighted average 3 7 13
Source: Authors.
Note: Cost of treating community of 1 million.
nonmotorized forms of transportation may bring seriously ill
and injured patients to medical facilities (Andrews,
Kobusingye, and Lett 1999; Joshipura and others 2003;
Kobusingye and others 2002). A bicycle ambulance in Malawi
set up to improve emergency obstetric care was actually used
more often for injuries and medical emergencies (Lungu and
others 2001).
Transportation should be accessible at short notice. A vehi-
cle with a stretcher is ideal, but almost any transportation that
will get a patient to a facility where definitive care can be
obtained is acceptable. Although a fully fitted and equipped
ambulance vehicle complete with trained paramedics delivers
better outcomes, ethical and equity considerations dictate that
before this vehicle is made available to an elite population in
the urban areas, basic transportation must be assured for all
who need emergency transportation and care.
In a city setting, a vehicle ambulance can make as many as
20 trips per day. On average this schedule will require salaries
for an administrator and two crews, each comprising a driver
and two paramedics or nurses, as well as expenses for commu-
nication, supplies, pharmaceuticals, and the costs of operating
the vehicle. A study of a decision to develop an EMS in Kuala
Lumpur (1.1 million people, 243 square kilometers) estimated
that the purchase and staffing of 48 ambulances at US$53,000
each per year would be required, totaling US$2.5 million per
year (Hauswald and Yeoh 1997). The authors noted that,
despite the paucity of ambulances, severely injured or ill
patients did get to a hospital with only minor delays by using
taxis, family transportation, or the police. Ambulances need
accurate maps, house numbers, and street or road signs, all of
which might not be in place in low-income cities. It was esti-
mated that ambulances were unable to locate patients in 20
percent of calls in Kuala Lumpur because of mapping and sign-
age problems (Hauswald and Yeoh 1997).
A study conducted in Turkey found that ambulance vehicle
costs were the leading component of capital costs (Altintas,
Bilir, and Tuleylioglu 1999). The cost per trip was US$163, and
the cost per patient transported was US$180.50, which the
authors thought were beyond the means of the private sector.
In state-run ambulance services in New Delhi, India, the cost
per trip was approximately US$40, yet one in three of the
ambulances served only to transport patients, with no para-
medic staff on board (India, Government of Delhi 2001).
The debates in high-income countries about helicopter
ambulances provide lessons for low-income countries. In some
cases, helicopter services have been discontinued because they
were not considered cost-effective (Hutton 1995). A study con-
ducted in the United States, which concluded that helicopters
were cost-effective, found that the cost per patient transported
was US$2,214 and that for every 100 flights there were six
survivors more than was predicted on the basis of injury severity
indices (Gearhart, Wuerz, and Localio 1997). Each additional
survivor cost an average of US$15,883, and the authors
acknowledged that the helicopter had to be used fully to spread
the high fixed costs across many patients and trips. A review of
civilian helicopter ambulance programs in the United States
concluded that the primary factor in the reduction of trauma
mortality was not the speed at which the patient was transported
but the administration of life-saving care by the helicopter med-
ical crew at the scene or at the outlying hospital (Moylan 1988).
In low-income countries, for the very few who benefit from such
a high-end intervention, there are likely to be thousands who
cannot access care even using the most basic means.
Intervention Costs and Effectiveness Costing transportation
systems requires the following assumptions:
• In an urban population, one ambulance unit can serve a
population of 30,000 people. Thus, 1 million people would
require 33 ambulance units (1 million/30,000).
• Each ambulance unit requires staffing of a rotation of six
paramedic-drivers and a seventh paramedic-driver to cover
vacation times and sick leaves.
• A supervisor oversees three ambulance units per year.
• A garage for the ambulance and communications equip-
ment would be 100 square meters but would entail rental of
office-style accommodations.
• A vehicle to be outfitted as an ambulance can be purchased
for as much as an off-road vehicle with a useful life of nine
years.
• The cost to modify the vehicle into a basic ambulance is
US$5,000 for a useful life of nine years.
• The ambulance will require fuel and maintenance based on
usage of 20,000 kilometers per year.
Given the preceding assumptions,
• The 231-member ambulance staff (33 ambulance units of
7 persons each) would be paid at salary level 2.
• The 10 administrators would be paid at salary level 2.
We ignore the additional burden on the health system from
additional visits. Quite possibly, hospital costs will rise as more
patients now get to the hospital with the help of ambulances. It
is also possible that patients currently arrive in less desperate
condition, so that the cost of care is lessened. No studies are
available on which to base cost estimates to address those issues.
Table 68.5 shows the estimated costs of the ambulance inter-
vention, drawing on the Disease Control Priorities Project’s
standardized input prices by region for low, best, and high
estimates.
Outcome Based on the World Health Organization’s 2001 bur-
den of disease estimates on epidemiology of trauma, ischemic
heart disease, and obstetric emergencies, we estimate that for
each 10,000 population there will be 9 deaths from trauma,1
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11 deaths from ischemic heart disease,2 and 2 deaths from
lethal obstetric emergencies.3 For modeling purposes, we con-
fine our attention to trauma, ischemic heart disease, and
obstetric cases. Although many possible lethal emergencies
may present, such as sepsis, malaria, snakebites, and asthma, by
confining attention to the major emergency conditions we
locate 2,200 (900  1,100 + 200) potentially savable lives in a
population of 1 million. The savings are outlined as follows:
• Savings from trauma reductions. Saving lives from trauma
depends on the quality of trauma care at the destination
facility. In one year for 1 million people, there will be 4,100
trauma cases and 900 trauma deaths. With rapid resuscita-
tion and oxygen available through use of ambulances, we
assume we can save 300 lives.
• Savings from myocardial infarction management. In one year
for 1 million people in low-income countries, 1,100 deaths
will typically result from myocardial infarction. Low-dose
aspirin provided to myocardial infarction victims lowers
mortality by 18 percent (Weisman and Graham 2002). In a
population without ambulance services, rapid aspirin
administration cannot be ensured; with EMS, aspirin use
can potentially be increased from about 0 percent to 100 per-
cent for heart myocardial infarction. Therefore, instead
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Table 68.5 Cost and Effectiveness of Ambulances 
(U.S. dollars)
Region Low Best High
Cost of treating community of 1 million with urban ambulances
East Asia and the Pacific 691,603 871,208 1,090,032
Europe and Central Asia 839,468 1,024,235 1,220,888
Latin America and the Caribbean 849,556 1,550,521 1,747,630
Middle East and North Africa 894,379 2,435,000 4,960,705
South Asia 676,111 803,361 1,973,093
Sub-Saharan Africa 781,568 951,906 1,905,417
Unweighted average 788,781 1,272,705 2,149,628
Cost per death averted of treating community of 1 million with urban ambulances
East Asia and the Pacific 988 1,245 1,557
Europe and Central Asia 1,199 1,463 1,744
Latin America and the Caribbean 1,214 2,215 2,497
Middle East and North Africa 1,278 3,479 7,087
South Asia 966 1,148 2,819
Sub-Saharan Africa 1,117 1,360 2,722
Unweighted average 1,127 1,818 3,071
Cost per life year saved of treating community of 1 million with urban ambulances
East Asia and the Pacific 50 63 79
Europe and Central Asia 62 75 90
Latin America and the Caribbean 61 111 126
Middle East and North Africa 65 176 359
South Asia 50 60 147
Sub-Saharan Africa 67 81 163
Unweighted average 59 95 161
Cost per death averted of treating community of 1 million with rural ambulances
East Asia and the Pacific 2,978 3,748 4,686
Europe and Central Asia 3,613 4,405 5,248
Latin America and the Caribbean 3,652 6,656 7,500
Middle East and North Africa 3,847 10,449 21,274
South Asia 2,911 3,457 8,470
Sub-Saharan Africa 3,361 4,092 8,178
Unweighted average 3,394 5,468 9,226
Source: Authors.
of 1,100 deaths, there will be 1,100  (1  0.18) deaths, sav-
ing 200 lives, but with only an average of five life years per
life saved.
• Savings from emergency obstetrics management. Obstetric
deaths for medically attended patients are approximately
100 times lower than for patients who do not receive med-
ical care. Accordingly, an ambulance system essentially saves
all of the obstetric emergencies from death; this saving
would amount to 200 deaths averted in the case described
previously. As a result, in the hypothetical population of
1 million people in low-income countries, 700 lives can be
saved by an ambulance system focusing on three causes
only: ischemic heart disease (200), obstetric (200), and
trauma (300).
The middle section of table 68.6 displays the cost per death
averted. To compute life years saved in the last section of the
table, we assume that the 500 deaths averted from obstetric
emergencies and trauma occur at age 20, but the 200 deaths
averted from ischemic heart disease save only five additional
life years per case. Regional life expectancy at age 20 years (esti-
mated) is used as before.
Costs for a Rural Ambulance Service The key difference deter-
mining higher costs for rural ambulances is that more ambu-
lance units are necessary to cover the population. We assume
that in rural areas one ambulance unit can cover a population of
10,000, although variation will occur, depending on population
density and geographical topography. On the basis of this
assumption, all of the cost estimates for rural ambulances are
essentially three times higher for a population of 1 million, as
are the costs per death averted and per life year gained. They are
assumed to have the same effectiveness as the urban services
because the increase in units aims at delivering the same quality
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Table 68.6 Summary of Cost and Effectiveness
(U.S. dollars)
Intervention
Trained lay first responders Staffed community Staffed community
Region and paramedic responders ambulance, urban ambulance, rural
Costs for a population of 1 million
East Asia and the Pacific 48,050 871,208 2,623,392
Europe and Central Asia 52,339 1,024,235 3,083,637
Latin America and the Caribbean 74,589 1,550,521 4,659,017
Middle East and North Africa 104,585 2,435,000 7,314,544
South Asia 45,637 803,361 2,419,607
Sub-Saharan Africa 52,339 951,906 2,864,062
Unweighted average 62,923 1,272,705 3,827,376
Cost per death averted for a population of 1 milliona
East Asia and the Pacific 130 1,245 3,748
Europe and Central Asia 141 1,463 4,405
Latin America and the Caribbean 202 2,215 6,656
Middle East and North Africa 283 3,479 10,449
South Asia 123 1,148 3,457
Sub-Saharan Africa 141 1,360 4,092
Unweighted average 170 1,818 5,468
Cost per life year gained for a population of 1 milliona
East Asia and the Pacific 5 63 190
Europe and Central Asia 5 75 227
Latin America and the Caribbean 8 111 335
Middle East and North Africa 11 176 530
South Asia 5 60 180
Sub-Saharan Africa 6 81 245
Unweighted average 7 94 284
Source: Authors.
a. Personnel consist of lay first responders together with paramedics.
of care as in the urban centers. This assumption may not hold
true if the quality of care at the receiving facilities is lower than
that in the urban areas.
Uncertainty of Estimates Substantial uncertainty remains
over the actual effectiveness of the interventions in emergency
medicine. The tables in this chapter should be approached with
due caution because ultimately the projections of the effective-
ness of interventions have been patched together from a hand-
ful of intervention trials whose success may or may not be
similar in other contexts. The projections include the following:
• Ambulance services can and do save lives by performing
field stabilization and by hastening the arrival of critical
patients when time makes a difference in the outcome.
• Only several dozen ambulance runs per year for a unit serv-
ing a population of 10,000 will actually have the potential to
save lives.
• Ambulance services are more cost-effective in denser popu-
lations and when roads are more passable, making trips
shorter.
• Training lay responders and paramedics can be relatively
cost-effective.
The financial support of an ambulance unit may rely on the
value perceived by the hundreds of patients who are comforted
by having rapid access to care or by knowing ambulances are
there if needed, even though their lives and health are not actu-
ally improved by ambulances.
Table 68.6 summarizes the best estimates of cost, cost per
death averted, and cost per life year.
Health Facility–Based Subsystem 
This subsystem refers to a level within the health care system
where appropriate definitive care is delivered. Formal health
facilities vary immensely between and within countries. In some
countries, this subsystem may be a regional hospital with spe-
cialists; in others, a district hospital with general practitioners or
nonspecialist doctors; and in still others, a health center with
competent nonphysician clinicians. In some low-income coun-
tries, some types of emergency medical care, for conditions such
as acute diarrhea or severe malaria, may be effectively delivered
at a health center staffed by nondoctor clinicians. However, such
a facility will be grossly inadequate for the management of a
severe multiple injury or obstructed labor. The triage process in
the prehospital subsystem should determine which patients
receive transportation to which facility, instead of merely trans-
portation to the nearest facility. Precious time and lives may be
lost when patients are taken to facilities where the desired defin-
itive care is not available.
Because the goal of an effective EMS is the provision of
emergency care to all who need it—universal emergency care—
the following section presents guidelines on the necessary
inputs at different levels. Two of the components in hospital
emergency care are discussed in more detail: (a) training and
(b) equipment and supplies. The first level of formal health
care is often staffed by nonphysician clinicians; the second level
is staffed by at least one physician and other trained health care
professionals; and the third is staffed by specialists in addition
to other health care professionals. Some middle-income coun-
tries have additional levels (major emergency care centers), and
some hospitals are specialized (chapters 65 and 66).
Training. Most in-service training for emergency care profes-
sionals working in hospitals is designed to address a particular
problem, such as severe injuries, emergency pediatrics, or
obstetric emergencies. Yet because of the resource constraints
of low-income countries, the same personnel will be confronted
with all these problems. Few courses in emergency care have
been rigorously evaluated (Black and Brocklehurst 2003; Sethi
and others 2003). The Advanced Trauma Life Support (ATLS)
course for doctors has resulted in improved patient outcomes
in some settings, although it may be too expensive for most
low-income countries and inappropriate in settings where doc-
tors do not see the majority of patients. In a tertiary hospital in
Trinidad and Tobago, injury mortality was reduced by 50 per-
cent following ATLS training (Ali and others 1993).
Life-saving obstetric skills training was found to contribute
to a reduction in maternal deaths. In Kebbi state in Nigeria, this
training led to a drop in case-fatality rates among women with
obstetric complications from 22 percent to 5 percent. Similar
trends were observed in other sites where the intervention was
implemented (Oyesola and others 1997; Prevention of Maternal
Mortality Network 1995). Emergency Triage Assessment and
Treatment has been used in many countries to improve pediatric
emergency care (WHO 2000). Other examples are Primary
Trauma Care, which is a trauma management course to train
doctors and other health workers in district hospitals and
remote locations (Wilkinson and Skinner 2000), and Advanced
Life Support in Obstetrics (see http://www.aafp.org/also). These
courses have been beneficial in standardizing protocol-based
emergency care, but their outcome evaluations are still awaited.
Low-income countries need to identify training models for their
versatile emergency care personnel, especially those working
at middle-level facilities, who respond to different types of
emergencies.
The costs of this intervention are not available in the litera-
ture and will require an estimation of trainer costs, space,
materials, and refresher courses.
Equipment and Supplies. A specimen list of resources for
emergency care required at different levels of facilities is
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provided in annex 68.A. This template is flexible, and countries
can customize it to suit local conditions, such as existing facility
levels and prevailing burden of emergency disease conditions.
Equipment and supplies at each level should match the knowl-
edge and skills of the personnel available to use them.
Systems Organization
Emergency care needs to be planned and implemented care-
fully. The various components that make up the EMS should be
linked to ensure that the entire system operates as a unit. A
coordinator should be responsible for monitoring and coordi-
nating all emergency medical care in the community or district
and should work with a committee to which the other compo-
nents send representation. A community representative should
be a key member of this committee.
Coordination costs are very important and should not be
overlooked in the development of a new EMS. Such costs
include the salary of the coordinator, an efficient telephone or
communication system, a vehicle, fuel, and a budget to organ-
ize meetings of stakeholders at least twice a year (Bazzoli,
Harmata, and Chan 1998; Nurok 2001).
Health Financing for Emergency Care
Emergency medical systems in low-income countries must be
pro-poor in their orientation, which requires explicit consider-
ation of how the poor interact with an EMS and how barriers
to acute care for the poor can be overcome. Issues of access to
an EMS become critical because the lack of money often keeps
people from using emergency services. Direct payment of costs
for transportation, medical treatment, and drugs makes lack of
money a major barrier to EMS for the poor in every country.
As a result, emergencies frequently cripple individuals and
families financially in poor communities, often for many years
in the future.
Financial protection for emergency health care is a necessity
in low-income countries and has not received adequate atten-
tion. The goal of such protection is to ensure that individuals
and families do not spiral down the pathway to abject poverty
as a result of interaction with the national health system. Such
financial protection may be achieved by a number of different
means, including community financing (Ande and others
1997; Desmet, Chowdhury, and Islam 1999; Macintyre and
Hotchkiss 1999). Community loan funds to cover transporta-
tion and other requirements for emergencies, especially for
obstetrics, have been explored with mixed results (Essien and
others 1997; Shehu, Ikeh, and Kuna 1997). Some experience
seems to indicate that these approaches can indeed overcome
several of the barriers to accessing emergency medical services
and should be explored further.
Documentation and Quality Assurance
Quality of care is critical to the interaction of the poor with the
EMS. Lack of funds, lower-paid jobs, social class distinctions,
ethnicity, and other affiliations make the already vulnerable
poor susceptible to receiving poor-quality care. For an EMS to
maintain and improve the care of patients, systematic docu-
mentation and periodic audits, or other processes to ensure
quality of care, need to be incorporated. Quality management
systems that are simple, are continuous, and allow for rapid
changes in the system need to be implemented.
Because of scarcity of resources, expensive machines and
elite specialists should not be advocated for the urban privi-
leged at the expense of the majority of the rural poor. The most
difficult decisions concern balancing funds invested in the
emergency care capacity of secondary and primary care centers
with support for referral and transportation networks to feed
tertiary care centers. These decisions are too variable and too
system specific to yield to a uniform policy prescription. Two
principles are advocated to inform these difficult decisions:
• Collect data on costs, capacities, and outcomes.
• Tighten the integration of the emergency care system to
improve function and lead to wiser decisions on where to
invest.
Legislative Instruments to Ensure Emergency Care
The issues discussed in the preceding sections supply the
rationale for countries to have specific legislation addressing
the provision of emergency care. This area requires major
cooperation between public health and law, which together
provide the legal framework for ensuring that all individuals
who deserve emergency care can receive it, irrespective of their
personal characteristics or their ability to pay. Having laws that
protect trained individuals and laypeople as they provide such
care is also important.
IMPLEMENTATION OF CONTROL STRATEGIES:
LESSONS OF EXPERIENCE 
A large proportion of trauma patients in developing countries
do not have access to formal emergency medical services.
Boxes 68.1 and 68.2 contain examples of interventions to pro-
vide appropriate emergency care in such countries.
THE RESEARCH AND DEVELOPMENT AGENDA 
The research and development priorities for emergency care
are challenging to define because emergency care is a neglected
area of research in low-income countries and the needs are
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first aid since taking the course. There was considerable
improvement in the provision of the components of
first aid in comparison to what was reported before the
course:
Component 
of first aid Before (percent) After (percent)
Crash scene management 7 35
Airway management 2 35
Bleeding control 4 42
Splint application 1 16
Triage 7 21
Conclusions: Even in the absence of a formal EMS,
improvements in the process of prehospital trauma care
are possible by building on existing, although informal,
prehospital transportation.
great. As a neglected topic, emergency care is part of the 
“10-90” gap of health research: less than 10 percent of global
research investments are for problems affecting 90 percent of
the world’s population (Global Forum 2000).
Approach to Research and Development for EMS 
The spectrum of research required is diverse and may be 
easily understood with the help of the schematic shown in 
figure 68.2. The rectangle is a schematic representation of the
totality of the global burden of disease that can be potentially
addressed by EMS (see “Burden of Disease”). A portion of this
potential burden is being addressed (or reduced) by those
existing interventions that have been implemented, defined by
box A. If the efficiency of current interventions were to be
enhanced and their coverage increased, then another portion of
the burden defined by box B could be addressed; this increase
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Improving Trauma Care in the Absence of a Formal Ambulance System 
Box 68.1
Background: The efficacy of a program that builds on the
existing, although informal, system of prehospital trans-
portation in Ghana was assessed. In Ghana, the majority
of injured persons are transported to the hospital by some
type of commercial vehicle, such as a taxi or bus.
Methods: A total of 335 commercial drivers were
trained using a six-hour basic first-aid course. The efficacy
of this course was assessed by comparing the process of
prehospital trauma care provided before and after the
course, as determined by self-reporting from the drivers.
The course was conducted with moderate amounts of
volunteer labor and gifts in kind, such as transportation to
the course. The actual cost of the course amounted to
US$3 per participant.
Results: Follow-up interviews were conducted on 71 of
the drivers a mean of 10.6 months after the course. In the
interviews, 61 percent indicated that they had provided
Source: Mock and others 2002.
Source: Authors.
Training for Emergency Care in India 
Box 68.2
The training of personnel working in emergency medical
services is crucial to the success of efficient delivery of
care. Evidence exists to support usefulness of life-support
training for emergency caregivers in low- and middle-
income countries. Courses such as the ATLS are available
and well established in some high- and middle-income
countries. In most low-income countries, such training is
not available, mainly because of prohibitive costs. The
three-day ATLS course costs on average US$700 per
trainee and is taught by six trainers to a group of 20
trainees at a time. The National Trauma Management
Course is an indigenous two-day course developed in
India by the Academy of Traumatology (India) with the
help of international peers. The curriculum takes into
account local conditions and capabilities. The cost is
US$50 per trainee, and the course is taught by local train-
ers to a group of 100 trainees at a time. Animal specimens
are used to teach life-saving procedures instead of expen-
sive commercially produced manikins. More than 2,000
health professionals have been trained in less than three
years. The course has now become a national training
standard for immediate trauma care in India.
in efficiency will require operations research, policy research,
and social science research. If existing interventions, which
have not been implemented because of their high costs, were
made more cost-effective, then another portion of the burden
defined by box C could be reduced. This process of making
interventions more cost-effective will require economic analy-
sis and clinical research in many instances. Finally, a portion of
the burden exists for which we do not have existing interven-
tions, defined by box D; it requires basic and clinical research to
develop and pilot interventions that can address other deter-
minants of the emergency care–related burden in the future.
This schematic representation is thus useful to demonstrate
two critical needs:
• essential research on emergency care in low-income
countries
• a diverse set of research studies and approaches to reduce
the burden that can be addressed by EMS.
Priority Setting for Research and Development
of Emergency Care
Setting priorities for research and development on EMS needs
to be a region-specific, if not country-specific, process. No cur-
rent list exists of global research and development priorities for
EMS, again reflecting the need for more attention and invest-
ments in this area. This chapter does not intend to prescribe a
list of issues or topics for global research and development
efforts, but rather to highlight the gap in global research and
development and to suggest possible issues and topics that may
be broadly relevant to low-income countries for these efforts in
the short to middle term.
A number of methods exist for setting research priorities
in the health sector, such as the Combined Approach Matrix
promoted by the Global Forum for Health Research (Global
Forum 2002) and the Essential National Health Research
process promoted by the Council for Health Research for
Development. Countries and regions can use these approaches
to help develop their research agenda for EMS.
The review of evidence available in the field of emergency
care as applicable to low-income countries reveals many gaps
in global knowledge. Following on the illustration of fig-
ure 68.2, there is a need to better understand the epidemiology
of those conditions that can be addressed by an EMS in a low-
income country and which interventions currently in place are
addressing them. We have little knowledge of how to enhance
the efficiency of these existing interventions and reduce their
costs. Most important, the lack of intervention trials done in
low-income countries creates a major research priority for the
field of EMS. Well-designed, locally appropriate interventions
that establish their effectiveness are urgently needed and
should include both interventions that may be available in
high-income countries and new ones. Economic analysis is
another area for major research input in the field of EMS,
where cost and cost-effectiveness information from low-
income countries is scant. These gaps only reflect the need for
a more systematic analysis of where research investments
should be directed in the next five years for EMS.
CONCLUSIONS: PROMISES AND PITFALLS
Emergency medical systems are a critical component of
national health systems in low-income countries. Governments
and ministries of health in low-income countries need to pay
specific attention to the development of EMS in their countries
and to ensure that the evolution of any EMS is both evidence
based and appropriate to their national needs. More important,
the context and implementation of EMS should help health
equity and not widen existing health disparities.
This chapter highlights not only the urgent need for more
attention to EMS in low-income countries but also points out
an opportunity for these countries in defining better EMS for
their needs. In promoting the systematic development of an
evidence-based EMS, low-income countries could help define
more effective and cost-effective emergency systems than cur-
rently exist in high-income countries. This opportunity should
not be lost as a result of political inattention or lack of funds;
the international and national stakeholders must move forward
to stem the preventable loss of life from the lack of an EMS.
Emergency care needs to be planned as an integral compo-
nent of public health systems in low-income countries. Too lit-
tle is known about the true extent of the need for emergency
care, the designs of EMS that would work well for different
communities and populations, and the costs and benefits of
delivering emergency care in low-income countries. These gaps
are a call for more investments in the research, development,
and implementation of EMS, especially in these countries.
Universal emergency care is consistent with the right to health
care because, by definition, emergency care is a matter of life
and death. Society should endeavor to ensure that prompt
appropriate care is available in critical moments when a delay
in care—or the delivery of inappropriate care—could mean
loss of lives.
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D: No emergency care interventions currently available to
address this burden
A: Currently implemented
emergency care
interventions that
are addressing this
burden
B: Existing emergency
care interventions
that are able to
address existing
burden if efficiency
enhanced 
C: Potential emergency
care interventions
that could address
this burden if they
were made cost-
effective
Figure 68.2 Schematic Illustration of the Burden of Disease
Potentially Addressed by EMS 
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Annex 68.A Essential Resources for the Delivery of Emergency Care in Hospitals
Major Regional District Primary
emergency emergency emergency emergency
care care care care
Resources center center center center
Organization and administration
Multidisciplinary emergency care team ✓ ✓
Maintenance of statistical data ✓ ✓ ✓
Resources
Immediate access to radiology or CT
and ultrasound scan facility on site ✓ ✓
Blood bank on site ✓
Access to blood bank ✓ ✓
Radiological technician on site 
24 hours a day ✓ ✓
Radiological services available promptly ✓
Clinical laboratory services
Laboratory services on site available 24 hours a day
(including, but not limited to, the following tests) ✓ ✓
Hemoglobin, glucose, gram stain, blood slide test ✓ ✓ ✓
Bacterial cultures ✓ ✓
Quality improvement
Evidence of quality improvement program in
accident and emergency department ✓ ✓ ✓
Monthly morbidity and mortality review ✓ ✓
Medical nursing audit and utilization review ✓ ✓
Personnel
Designated doctor in charge, member of the
emergency care team, with special competence in care
of critically ill and injured patients, present in the
emergency care unit 24 hours a day ✓ ✓
Designated doctor in charge, member of the emergency
care team, with special competence in care of critically
ill and injured patients, available on call ✓
Nursing personnel with special competence in the care
of the critically ill and injured patients, designated
member of the emergency care team, present in the
emergency unit 24 hours a day ✓ ✓ ✓
All personnel trained in airway, breathing,
and circulatory support techniques ✓ ✓ ✓ ✓
Equipment required for resuscitation per station shall include but not be limited to 
Bag valve resuscitator with reservoir ✓ ✓ ✓
Sphygmomanometer (blood pressure cuff) ✓ ✓ ✓
Cervical collars ✓ ✓ ✓ ✓
Chest decompression set ✓ ✓ ✓
(Continues on the following page.)
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Cut down set ✓ ✓ ✓
Delivery pack ✓ ✓ ✓ ✓
Diagnostic peritoneal lavage set open (1) ✓ ✓
Dressing trolley ✓ ✓ ✓ ✓
Drip stand ✓ ✓ ✓
Laryngoscope and blades (adult) ✓ ✓ ✓
Laryngoscope and blades (pediatric) ✓ ✓ ✓
McGills forceps (adult and pediatric) ✓ ✓ ✓
Ophthalmoscope ✓ ✓ ✓
Overhead x-ray gantry (full access to all beds) ✓
Portable ventilator capable of pediatric vent ✓
Resuscitation patient trolley ✓ ✓ ✓
Scissors to cut clothing ✓ ✓ ✓ ✓
Scoop stretcher (1) ✓ ✓ ✓ ✓
Spine board (1) ✓ ✓ ✓ ✓
Spot lamp (1) ✓ ✓
Sterile basic packs (2 per station) ✓ ✓ ✓
Stethoscope ✓ ✓ ✓ ✓
Suction apparatus ✓ ✓ ✓ ✓
Wheelchair (1) ✓ ✓ ✓ ✓
X-ray gowns (staff) ✓ ✓
X-ray viewing box ✓ ✓ ✓
Consumables (adult and pediatric)
Catheters (all sizes) ✓ ✓ ✓
Central lines ✓ ✓
Chest drains ✓ ✓ ✓
Diathermy ✓
Endotracheal tubes ✓ ✓ ✓
Eye protection for staff ✓ ✓ ✓ ✓
Gloves ✓ ✓ ✓ ✓
Humidification filters ✓ ✓ ✓
Intraosseous needles ✓ ✓
Intravenous cannulas, fluids, lines ✓ ✓ ✓
Introducers and endotracheal tubes (all sizes) ✓ ✓
Lumbar puncture set ✓ ✓ ✓
Annex 68.A Continued
Major Regional District Primary
emergency emergency emergency emergency
care care care care
Resources center center center center
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Malaria test kits ✓ ✓ ✓ ✓
Masks ✓ ✓ ✓ ✓
Medical waste disposal systems ✓ ✓ ✓ ✓
Nasal cannula ✓ ✓ ✓ ✓
Nasogastric tubes (all sizes) ✓ ✓ ✓ ✓
Nebulization masks ✓ ✓ ✓
Oropharyngeal airways ✓ ✓ ✓
Oxygen mask ✓ ✓ ✓ ✓
Suction catheters ✓ ✓ ✓ ✓
Syringes (assorted) ✓ ✓ ✓ ✓
Tracheotomy tubes ✓ ✓
Urine dipstick ✓
Wound care products ✓ ✓ ✓ ✓
Drugs shall include but not be limited to the following
Activated charcoal ✓ ✓ ✓ ✓
Adrenaline ✓ ✓
Flumazenil (or similar benzodiazepine) ✓ ✓ ✓
Antihistamine (such as diphenhidramine) ✓ ✓ ✓ ✓
Atropine ✓ ✓ ✓ ✓
Ciprofloxacin or equivalent ✓ ✓ ✓
Beta-2 antagonist (such as propranolol) ✓ ✓ ✓ ✓
Calcium chloride ✓ ✓ ✓ ✓
Calcium gluconate ✓ ✓ ✓ ✓
Dextrose, 50 percent ✓ ✓ ✓ ✓
Diazepam ✓ ✓ ✓
Dopamine ✓ ✓
Emetic (ipecac) ✓ ✓ ✓ ✓
Metronidazole IV ✓ ✓ ✓
Furosemide or equivalent ✓ ✓ ✓
Heparin, 1,000 g/ml ✓ ✓ ✓
Hydrocortisone ✓ ✓ ✓ ✓
Lidocaine IV ✓ ✓ ✓ ✓
Magnesium sulfate IV ✓ ✓ ✓
Midazolam ✓ ✓ ✓
Morphine ✓ ✓ ✓
Annex 68.A Continued
Major Regional District Primary
emergency emergency emergency emergency
care care care care
Resources center center center center
(Continues on the following page.)
NOTES
1. There are 4,715,000 trauma deaths in low- and middle-income
countries per population of 5,219,401,000; thus, there are 9.033 trauma
deaths per 10,000 people.
2. There are 5,699,000 ischemic heart disease deaths per 5,219,401,000
population; thus, there are 10.9 ischemic heart disease deaths per 10,000
people.
3. There are 2,000 to 4,000 births among 10,000 people based on crude
birth rates of 26 (South Asia), 39 (Sub-Saharan Africa), 22 (Latin
America), and 17 (East Asia). Maternal mortality runs at 1 per 1,000
people.
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Naloxone ✓ ✓ ✓
Nitroglycerin ✓ ✓ ✓ ✓
Crystalloids (such as normal saline) ✓ ✓ ✓ ✓
Phenytoin ✓ ✓ ✓
Polyvalent snake venom ✓ ✓
Potassium chloride ✓ ✓ ✓
Scoline (suxamethonium chloride) ✓ ✓
Sodium bicarbonate ✓ ✓ ✓ ✓
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Tetanus toxoid ✓ ✓ ✓ ✓
Vitamin K ✓ ✓ ✓ ✓
Note: Additional information on recommended drugs is available in the Model List of Essential Medicines (WHO 2002) and the WHO’s Complementary Model List.
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The objective of medicine is to address people’s unavoidable
needs for emotional and physical healing. The discipline has
evolved over millennia by drawing on the religious beliefs and
social structures of numerous indigenous peoples, by exploit-
ing natural products in their environments, and more recently
by developing and validating therapeutic and preventive
approaches using the scientific method. Public health and
medical practices have now advanced to a point at which
people can anticipate—and even feel entitled to—lives that
are longer and of better quality than ever before in human
history.
Yet despite the pervasiveness, power, and promise of con-
temporary medical science, large segments of humanity either
cannot access its benefits or choose not to do so. More than
80 percent of people in developing nations can barely afford
the most basic medical procedures, drugs, and vaccines. In the
industrial nations, a surprisingly large proportion of people
opt for practices and products for which proof as to their safety
and efficacy is modest at best, practices that in the aggregate are
known as complementary and alternative medicine (CAM) or as
traditional medicine (TM).
Much of this book considers the formidable challenges to
advancing human health through the further dispersion of
effective and economical medical practices. This chapter con-
siders both proven and unproven but popular CAM and TM
approaches and attempts to portray their current and potential
place in the overall practice of medicine.
With globalization, the pattern of disease in developing
countries is changing. Unlike in the past, when communica-
ble diseases dominated, now 50 percent of the health burden
in developing nations is due to noncommunicable diseases,
such as cardiovascular diseases, diabetes, hypertension,
depression, and use of tobacco and other addictive sub-
stances. Because lifestyle, diet, obesity, lack of exercise, and
stress are important contributing factors in the causation of
these noncommunicable diseases, CAM and TM approaches
to these factors in particular will be increasingly important
for the development of future health care strategies for the
developing world.
DEFINITIONS AND DOMAINS OF
COMPLEMENTARY AND ALTERNATIVE
MEDICINE AND TRADITIONAL MEDICINE
We refer to medical practices that evolved with indigenous
peoples and that they have introduced to other countries
through emigration as traditional medicine. We refer to
approaches that emerged primarily in Western, industrial
countries during the past two centuries as scientific or Western
medicine, although we acknowledge that not all Western
medicine is based on scientifically proven knowledge. The
terms complementary and alternative describe practices and
products that people choose as adjuncts to or as alternatives to
Western medical approaches. Increasingly, the terms CAM and
TM are being used interchangeably (Kaptchuk and Eisenberg
2001; Straus 2004).
Endless varieties of practices are scientifically unproven and
poorly accepted by medical authorities. For the sake of organ-
izing an agenda for research into these approaches, the
U.S. National Institutes of Health has grouped them into five
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somewhat overlapping domains (http://nccam.nih.gov/health/
whatiscam) as follows:
• Biologically based practices. These include use of a vast array
of vitamins and mineral supplements, natural products such
as chondroitin sulfate, which is derived from bovine or shark
cartilage; herbals, such as ginkgo biloba and echinacea;
and unconventional diets, such as the low-carbohydrate
approach to weight loss espoused by the late Robert Atkins.
• Manipulative and body-based approaches. These kinds of
approaches, which include massage, have been used
throughout history. In the 19th century, additional formal
manipulative disciplines emerged in the United States: chi-
ropractic medicine and osteopathic medicine. Both origi-
nated in an attempt to relieve structural forces on vertebrae
and spinal nerve roots that practitioners perceived as evok-
ing a panoply of illnesses beyond mere musculoskeletal pain.
• Mind-body medicine. Many ancient cultures assumed that
the mind exerts powerful influences on bodily functions and
vice versa. Attempts to reassert proper harmony between
these bodily systems led to the development of mind-body
medicine, an array of approaches that incorporate spiritual,
meditative, and relaxation techniques.
• Alternative medical systems. Whereas the ancient Greeks
postulated that health requires a balance of vital humors,
Asian cultures considered that health depends on the bal-
ance and flow of vital energies through the body. This latter
theory underlies the practice of acupuncture, for example,
which asserts that vital energy flow can be restored by
placing needles at critical body points.
• Energy medicine. This approach uses therapies that involve
the use of energy—either biofield- or bioelectromagnetic-
based interventions. An example of the former is Reiki ther-
apy, which aims to realign and strengthen healthful energies
through the intervention of energies radiating from the hands
of a master healer.
Alternative systems of medicine use elements from each of
these CAM and TM domains. For example, traditional Chinese
medicine incorporates acupuncture, herbal medicines, special
diets, and meditative exercises such as tai chi. Ayurveda in India
similarly uses the meditative exercises of yoga, purifying diets,
and natural products. In the West, homeopathic medicine and
naturopathic medicine each arose in the late 19th century as
reactions to the largely ineffectual and toxic conventional
approaches of the day: purging, bleeding, and treatments with
heavy metals such as mercury and arsenicals.
DEMOGRAPHY, USE, TOXICITY, AND EFFICACY 
The use of CAM and TM varies widely between and within coun-
tries.The World Health Organization (WHO) has published and
summarized numerous surveys of use (table 69.1). In developing
nations, TM is the sole source of health care for all but the privi-
leged few. By contrast, in affluent countries individuals select
CAM approaches according to their specific beliefs.For example,
as many as 60 percent of those living in France,Germany,and the
United Kingdom consume homeopathic or herbal products.
Only 1 to 2 percent of Americans use homeopathy,but 10 percent
of adults use herbal medicines, 8 percent visit chiropractors, and
1 to 2 percent undergo acupuncture every year (Ni, Simile, and
Hardy 2002). Use of CAM and TM among patients with chron-
ic, painful, debilitating, or fatal conditions, such as HIV/AIDS
and cancer, is far higher, ranging from 50 to 90 percent
(Richardson and Straus 2002).
There is remarkably little correlation between the use of
CAM and TM approaches and scientific evidence that they are
safe or effective. For many CAM and TM practices, the only
evidence of their safety and efficacy is embodied in folklore.
Beginning more than 1,500 years ago, data on the use of
thousands of natural products were assembled into impressive
monographs in China, India, and Korea, but these compendi-
ums—and similar texts from Arabic, Egyptian, Greek, and
Persian sources and their major European derivatives—are
merely catalogs of products and their use rather than formal
analyses of safety and efficacy.
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Table 69.1 Estimated Use of CAM and TM by Patients and
Practitioners Worldwide
Region or country Extent of use
Africa Used by 80 percent of the population for primary
health care
Australia Used by 49 percent of adults
China Accounts for 30 to 50 percent of total health care 
Fully integrated into the health system
95 percent of Chinese hospitals have TM units 
India Widely used
2,860 hospitals provide TM 
Indonesia Used by 40 percent of the entire population
Used by 70 percent of the rural population
Japan 72 percent of physicians practice TM
Thailand TM integrated into 1,120 health centers 
Vietnam Fully integrated into the health care system
30 percent of the population is treated with TM
Western countries CAM and TM not strongly integrated into the health
care system
France: at least 75 percent of the population has used
CAM at least once
Germany: 77 percent of pain clinics provide acupuncture
United States: 29 to 42 percent of population uses
CAM
Source: WHO 2002.
Many people who today choose herbal products in lieu of
prescription medications assume that because these products
are natural, they must be safe, even when the evidence for this
assertion is essentially anecdotal. Recent studies have shown
that herbals are highly variable in quality and composition,
with many marketed products containing little of the intended
ingredients and containing unintended contaminants, such as
heavy metals and prescription drugs. A few herbals are banned
outright in several countries. Comfrey and kava have been
associated with liver failure, aristolochia with genitourinary
cancer (De Smet 2002), and ephedra with heart attacks and
strokes (Shekelle and others 2003). More important, herbals
contain ingredients that can accelerate or inhibit the metabo-
lism of prescription drugs (table 69.2). The most notorious of
these is St. John’s wort, which affects the metabolism of nearly
50 percent of all prescription drugs (Markowitz and others
2003). The cumulative data on the pharmacological and poten-
tial adverse effects of herbal supplements now dictate that
patients discuss their use of supplements with knowledgeable
practitioners before initiating treatment.
As to evidence of the efficacy of CAM and TM approaches,
thousands of small studies and case series have been reported
over the past 50 years. Few were rigorous enough to be at all
compelling, but they are sufficient to generate hypotheses that
are now being tested in robust clinical trials. The existing body
of data already shows that some approaches are useless, that for
many the evidence is positive but weak, and that a few are
highly encouraging (table 69.3).
ECONOMICS OF COMPLEMENTARY AND
ALTERNATIVE MEDICINE AND TRADITIONAL
MEDICINE
Although social, medical, and cultural reasons may account for
why people in a given country prefer CAM and TM to conven-
tional (Western) medicine, economic forces are also at play.
This section describes the socioeconomic determinants of
seeking treatment from traditional healers and providers of
CAM; reviews the evidence on the cost-effectiveness of CAM
and TM; and discusses cost-effective approaches to regulating,
improving, and expanding the use of CAM and TM. Much of
this evidence is from industrial countries; few studies have been
conducted in or are applicable to low- and middle-income
countries. This caveat is important for two reasons. First, the
CAM and TM modalities discussed in this section may not be
used in many developing countries. Second, the limited data on
cost-effectiveness may not be applicable in the case of those
countries. Nevertheless, the data give a rough picture of the rel-
ative cost-effectiveness of a number of CAM and TM practices.
Economic Factors That Influence the Use of Complementary
and Alternative Medicine and Traditional Medicine 
Users of CAM and TM approaches choose health practices that
resonate with their beliefs about health (Astin 1998). Although
economic factors play a role in this choice, the underlying
incentives are not always predictable. For instance, a common
misconception is that patients opt for CAM and TM services
because they are cheaper alternatives to conventional medical
care. Even though there are certainly instances when the cost of
treatment using CAM or TM is much cheaper than the cost of
accessing a conventional medical service, several studies have
found that CAM and TM cost the same or more than conven-
tional treatments for the same conditions (see, for example,
Muela, Mushi, and Ribera 2000).
At least one study has shown that financial considerations
are rarely the primary factor in choosing a traditional healer,
ranking behind such reasons as confidence in the treatment,
ease of access, and convenience (Winston and Patel 1995). In
the United States, the average cost of a single visit to a Navajo
healer was US$388, and the average annual cost of using a
traditional healer represented roughly a fifth of the reported
annual income of respondents in a survey (Kim and Kwok
1998). The high cost of using a healer was cited as the most
common barrier to seeking care from this source. In Kenya, the
average charge per patient per visit to a TM practitioner was
K Sh 46 (US$4 in 1981), which was significantly greater than
the average charge per visit even in private health care facilities
(Mwabu, Ainsworth and Nyamete 1993). Finally, a survey in
Zimbabwe reported that the median cost of consulting an
herbalist was Z$23 per visit, compared with Z$1 for a govern-
ment clinic and Z$29 for a private doctor (Winston and Patel
1995). The same survey found that outcomes tended to be bet-
ter when patients went to government clinics (67.3 percent of
visits resulted in a good outcome) than when patients consulted
herbalists (50 percent of visits resulted in a good outcome).
TM is not always more expensive than conventional medi-
cine, however. Survey respondents in Ghana reported that the
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Table 69.2 Some Natural Products That May Alter Drug
Actions
Herbal product Class of drug
Ephedra (ma huang) Alpha and beta adrenergics
Garlic Anticoagulants; some HIV protease inhibitors
Ginkgo biloba extract Anticoagulants
Glucosamine Antidiabetics
Saw palmetto Androgens
St. John’s wort HIV protease inhibitors; some chemotherapy
drugs; cyclosporine A; birth control
Valerian Sedatives
Source: Niggemann and Gruber 2003.
cost of malaria treatment at a health clinic ranged from ¢1,900
to ¢3,000 (US$1.30 to US$2.00 in 1997), treatment at home
using drugs bought from pharmacies or health care workers
ranged between ¢200 and ¢1,000 (US$0.10 to US$0.70), and
treatment by an herbalist was virtually free (Ahorlu and others
1997).
Another common misconception is that the poor are more
likely to use TM. At least one study shows that this may not be
true. In Zimbabwe, the mean monthly income of households
visiting an herbalist, Z$877, was greater than the mean monthly
income of households using government clinics, Z$718
(Winston and Patel 1995).
Although some traditional healers charge more than con-
ventional practitioners, their fees may be negotiable, the
method of payment may be flexible (often on credit or in
exchange for labor), and payment may be contingent on out-
come. The availability of an outcome-contingent contract
favors TM over Western medicine when the disease condition
requires providers to both exert effort in curing patients and
induce patients to comply with their recommendations.
Nonetheless, this strategy may be difficult to apply to the larger
health care system.
Furthermore, patients tend to seek care from traditional
healers for conditions such as mental illness, impotence, and
chronic disorders, which they perceive as requiring greater
involvement by the extended family and kinship group.
Accordingly, the availability of financial support for seeking
treatments for these disorders is greater than it is for illnesses
such as malaria or diarrhea, for which patients more often seek
conventional treatment.
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Table 69.3 Levels of Evidence for the Efficacy of Selected CAM and TM Approaches
CAM or TM Study Level of 
approach Potential use outcome evidence Source
Artemisia annua Treating drug-resistant malaria Positive A van Agtmael, Eggelte, and van Boxtel 1999 
Black cohosh Controlling menopausal symptoms Mixed B Kronenberg and Fugh-Berman 2003
Cranberry Preventing urinary tract infection Positive B Jepson, Mihaljevic, and Craig 2000
Echinacea Preventing or treating viral colds Mixed B Barrett 2003; Taylor and others 2003
Garlic Lowering blood cholesterol Positive C Le Bars and others 1997
Ginkgo biloba Preventing or treating dementia Mixed B Kanowski and Hoerr 2003
extract
Ginseng Improving energy and immunity  Mixed C Richy and others 2003
against infection
Glucosamine Relieving osteoarthritis Positive A Reginster, Deroisy, and Rovalty 2001 
Hawthorn Improving cardiac function Mixed B Pittler, Schmidt, and Ernst 2003
Milk thistle Improving liver function Positive C Jacobs and others 2002
St. John’s wort Treating moderate to severe depression Negative A Hypericum Depression Trial Study Group 2002 
Treating mild depression Positive B Di Carlo and others 2001
Saw palmetto Relieving symptoms of benign prostatic hypertrophy Positive B Gerber and others 2001
Acupuncture Relieving arthritis pain Positive B Berman and others 1999
Relieving the pain of tooth extraction Positive B Lao and others 1995
Treating hypertension Mixed C Chiu, Chi, and Reid 1995
Relieving nausea from chemotherapy Positive A Shen and others 2000
Relieving addiction withdrawal Mixed B Margolin and others 2002
Treating asthma Negative B Linde, Jobst, and Panton 2000
Meditation Decreasing anxiety Positive B Speca and others 2000
Decreasing blood pressure Mixed B Schneider and others 1995
Biofeedback Preventing migraine Positive B Holroyd and Penzien 1990
Homeopathy Treating asthma Mixed B White and others 2003
Treating gastroenteritis Positive C Jacobs and others 2003 
Magnet therapy Treating plantar fasciitis Negative B Winemiller and others 2003
Chiropractic Treating lower back pain Positive B Cherkin and others 2003
Source: Authors. 
A  multiple high-quality, randomized, controlled trials; B  single high-quality trials or smaller, less rigorous trials; C  weaker clinical trials; Mixed  conflicting results among studies of similar quality.
Few published data are available on the financial costs of
TM in low- and middle-income countries. The data presented
here on the use of traditional healers are extracted from the
World Bank’s living standards surveys in Vietnam to provide
one nationally representative snapshot of the situation. Of
28,254 individuals in the sample, 10,033 had consulted a health
care provider in the four weeks preceding the survey. These
consultations included both home visits and visits to a
provider. Of the 10,033, 1,829 had been to a public provider,
1,431 to a private provider, 7,650 to a pharmacy, and 259 to a
traditional healer.1 The most common reasons for visiting a
traditional provider were headache, followed by cough and
fever. The per visit drug cost for consulting a traditional healer
was D 46, and the total cost per visit was D 51, compared with
drug costs of D 38 and total costs of D 41 for going to a private
clinic.
One commonly cited motivation for using CAM and TM is
that their use might lower the incidence and costs of side effects
associated with conventional treatments, but the published evi-
dence on this point remains mixed. There is some evidence that
CAM is used in addition to conventional treatments (Thomas
and others 1991), but CAM may also have the effect of displac-
ing conventional treatments. An outpatient survey found that,
of 246 patients who had been receiving conventional treatment
from the Royal London Homeopathic Hospital since the onset
of care, a third had halted their conventional treatment and
another third had reduced their intake of conventional med-
ication (van Haselen 2000).2 The extent to which homeopathic
treatment displaced conventional treatment varied by indica-
tion. The use of homeopathic treatment often replaced con-
ventional treatments in patients with skin and respiratory
infections; in patients with cancer, its use was purely comple-
mentary and therefore added to overall health care costs.
Thomas and others (1991) observe that patients who use
CAM and TM also commonly access conventional medical
care. In industrial countries, most CAM usage complements
conventional care, but this is also common in developing
nations. For instance, Mwabu (1986) provides evidence from
Kenya that patients are likely to use more than one type of
provider from the range of those available, such as government
facilities, mission clinics, private clinics, pharmacies, and tradi-
tional healers. Furthermore, the choice of provider depends on
patients’ illness, condition, socioeconomic status, and educa-
tion. If an initial visit to one kind of provider did not resolve
the disease satisfactorily, a follow-up visit was made to a differ-
ent kind of provider. Finally, the quality of care—including
efficiency of service and waiting time at government and pri-
vate clinics—is an important determinant of whether patients
choose to go to traditional healers. Most traditional healers sur-
veyed in a second study referred patients to Western practices
for treatment when necessary (Mwabu, Ainsworth, and
Nyamete 1993).
Economic Evidence
Although most studies tend to focus on a specific CAM or TM
practice, Sommer, Burgi, and Theiss (1999) looked more
broadly at whether the provision of CAM and TM services
through prepaid health plans or government insurance
reduces the overall costs of health care and found that it does
not. A possible reason is that few individuals who are offered
access to CAM use them, and those who do might access those
services in addition to, not in place of, more conventional
health services.
Studies that compare the cost-effectiveness of different
CAM and TM approaches using the same analytical framework
are rare. One such study in Peru looked at the costs and cost-
effectiveness of treatment using conventional medicine and
TM (EsSalud andOPS 2000). Complementary medical prac-
tices evaluated included acupuncture, homeopathy, tai chi,
meditation, reflexology, hydrotherapy, naturopathy, and mas-
sage. Patients were enrolled in either the Western medicine
group or the CAM group. Patients were not randomized
between the two treatment groups, but they were matched by
disease pathology and severity, age, and sex. Furthermore,
selected patients had completed at least one year in the health
system, as the investigators reasoned that this would enable
them to evaluate their follow-up. Overall, the investigators
found that complementary medicine was between 53 and
63 percent less expensive than conventional medicine for
achieving equivalent levels of effectiveness. Complementary
medicine was especially cost-effective for osteoarthritis, hyper-
tension, facial paralysis, and peptic ulcers.
The rest of this section looks at the economic evidence on
specific forms of CAM or TM.
Acupuncture. Lindall’s (1999) study finds that an acupunc-
ture referral for musculoskeletal conditions costs a mean of
US$422, roughly 60 percent less than the cost of referral to a
Western practitioner. However, this study was not randomized,
and patients had to have failed first-line drug treatment before
being offered the choice of second line-treatment, either with
acupuncture or with Western medicine.
Homeopathy. Evidence indicates that the cost of homeopathic
medication is lower than the average cost of allopathic prod-
ucts, which would be an economic factor in favor of its use if
homeopathy were proven to be effective. A study by the
National Health Service in the United Kingdom found that the
drug costs associated with homeopathy were lower than those
of allopathic practitioners (Swayne 1992). A four-year study of
100 patients that compared homeopathic drug costs with those
of conventional drugs found an average cost saving of US$96
during the study period for those using homeopathic drugs
(Jain 2003).3
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Ayurveda. A study that compared medical expenditures over a
four-year period for participants in a comprehensive program
of ayurvedic-based natural medicine (which included antioxi-
dant strategies, mind-body medicine, and other techniques)
with participants whose expenditures were covered through a
BlueCross BlueShield health insurance plan found that the
expenditures for the ayurvedic group were 50 percent lower per
person (Orme-Johnson and Herron 1997). However, the study
was not randomized and failed to control for the inclination of
only a subset of people to accept and remain compliant with
ayurvedic approaches.
Chiropractic. Some studies found that spinal manipulation is
less expensive than conventional treatments for episodes of
back pain. One nonrandomized study found that the cost of
chiropractic treatment over a five-year period, including both
provider costs and equipment costs (US$28,902), was 24 per-
cent less than the cost of Western pain therapy (US$38,029)
(Kumar, Malik, and Demeria 2002). Moreover, 15 percent of
patients in the chiropractic group were able to return to work,
compared with none in the control group.
However, other larger and better-controlled studies failed
to find a difference between chiropractic and physical therapy
in terms of either outcomes or costs (Cherkin and others
1998; Skargren and others 1997; Skargren, Carlsson, and
Oberg 1998). A study of adults with low back pain who were
randomly assigned to physical therapy or chiropractic manip-
ulation or were just given an educational booklet found no
significant differences in either the mean costs of care or the
outcomes between the physical therapy and chiropractic
groups (Cherkin and others 1998). Three-quarters of the par-
ticipants in these groups—who incurred costs of roughly
US$430 over the two-year period of the study—reported that
their outcome was either good or excellent, compared with a
third of those who were assigned booklets; however, the mean
cost of care for the booklet group was only US$153 for the
two-year period.
Mind-Body Treatments. Little evidence is available on the
cost-effectiveness of practices such as meditation and yoga, but
the cost of acquiring the skills required for these practices,as well
as the time costs of practicing them, are so low relative to con-
ventional medicine that evidence of their clinical effectiveness
might suffice to justify their use on economic grounds.Available
evidence from clinical studies suggests that mind-body treat-
ments can be cost-effective (Caudill and others 1991; Friedman
and others 1995; Hellman and others 1990; Sobel 1995).
Blumenthal and others (2002) find significant declines in coro-
nary events and in predicted costs of care for patients who were
assigned to a one-and-a-half-hour long weekly class on stress
management, relative to usual care for each of the first two years
of follow-up and after five years.
Beyond Cost-Effectiveness: Ancillary Benefits and Costs
of CAM and TM
Although cost-effectiveness is one guiding rationale for deter-
mining resource allocations for expanding (or restricting)
access to CAM and TM, additional societal benefits and costs,
such as effects on biodiversity, must also be considered. CAM
and TM could provide a rationale for conserving species, but
overharvesting of endangered species for medicinal purposes is
also a concern. According to WHO, 85 percent of the world’s
population (principally those in developing countries)
depends on plants for medicine, and 25 percent of prescription
drugs have an active ingredient derived from a flowering plant
(Cox 2001). The possible extinction of medicinal plants is of
concern not only to developing countries but also to industrial
countries, as in the cases of poaching of American ginseng and
overharvesting of native saw palmetto. Similarly, the reliance of
Chinese TM on tiger genitals, bear gallbladders, and black rhi-
noceros horns has played an important role in poaching and
threatens to wipe out these mega fauna.
Local knowledge and culture regarding the uses of medici-
nal plants may be important determinants of whether a certain
species will survive (Etkin 1998). In addition to the biodiversity
value of these saved species, scientists may be able to analyze
these plants for potential clinical application on a broader scale
than TM permits. Although preserving traditional knowledge
of healing practices helps preserve the culture and identity of
indigenous populations, CAM and TM may impose significant
costs. In such instances, promoting conventional treatments
that do not depend on endangered species may bring impor-
tant benefits to society.
EXPANDING THE BENEFICIAL USE OF
COMPLEMENTARY AND ALTERNATIVE MEDICINE
AND TRADITIONAL MEDICINE
Despite the uncertainty about the clinical efficacy and cost-
effectiveness of certain CAM and TM practices, expansion of
their use in instances in which moderate evidence of their effi-
cacy and good evidence of their safety exists could yield health,
social, and economic benefits. A number of surveys show that
local pharmacies are the primary source of treatment for many
ailments, especially in rural areas where government or private
clinics are less accessible. In these situations, improving the
quality of TM might serve as an effective substitute for allow-
ing the unregulated use of conventional medical treatments.
Training traditional healers is substantially less expensive than
training doctors or nurses. A study of 52 traditional healers
interviewed as part of a survey in Kenya estimated that the
average out-of-pocket (cash) costs of training to be a tradi-
tional healer were K Sh 418 (US$40 in 1981) (Mwabu,
Ainsworth, and Nyamete 1993).
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Traditional healers can also be recruited into a more broadly
based system for delivering public health; for example, with
additional training, traditional healers can serve as primary
health care workers (Hoff 1997) and provide advice on such
matters as sexually transmitted diseases and oral rehydration
therapy (Nations and de Souza 1997; Nations and others 1988;
Ndubani and Hojer 1999). In addition, permitting access to
CAM and TM within the context of the conventional health
care system would facilitate access to multiple health services at
one location.
Comprehensive policy on CAM and TM is lacking in most
countries, including the United States. According to the 1994
Dietary Supplement, Health, and Education Act, the U.S. Food
and Drug Administration cannot require proof that dietary
supplements and herbal products are safe and effective before
they are sold, although it is charged with requiring good man-
ufacturing practices. The quality of herbal products is not reg-
ulated, and herbal products typically differ from source to
source and from batch to batch in terms of their component
ingredients and respective amounts and in terms of whether
they contain contaminants. In the United States, no single
entity is responsible for all aspects of CAM and TM control,
education, information, and research, and no national, volun-
tary system of self-regulation exists. National nongovernmen-
tal organizations, such as the Accreditation Commission for
Acupuncture and Oriental Medicine, the American Board of
Medical Acupuncture, the Council of Chiropractic Education,
the Council of Homeopathic Education, and the Commission
on Massage Therapy Accreditation, accredit education in
some CAM and TM fields, but such accreditation bodies do
not exist in many developing countries. Nearly all countries
lack rigorous research training programs in CAM and TM.
A common misperception is that in the developing world
CAM and TM is used primarily by poorer, uneducated popu-
lations, while in industrial countries it is used more by affluent
and better-educated segments of the population (Eisenberg
and others 1998). In both settings, relatively little evidence
supports this view. Many investigators have failed to critically
assess the use of CAM and TM by minority and immigrant
populations in Western nations. In Africa, nearly 85 percent of
the population uses TM, often as the only way to obtain pri-
mary health care, and wealthier people in developing coun-
tries often use TM (WHO 2002). Investments in improving
the quality and consistency of TM could reduce the cost of
health care delivery, especially for chronic conditions such
arthritic pain and AIDS, where TM interventions may
improve patients’ sense of well-being, appetite, and energy. At
the same time, in the absence of resources to extend the public
health infrastructure, a network of certified CAM and TM
providers could provide the infrastructure for delivering
other care, such as immunizations and maternal-child health
programs.
Recognizing the redistributive nature of investment in TM
is important. Indigenous people will seek the help of tradi-
tional healers because of proximity, familiarity, and trust.
Investments in TM could therefore be used strategically to
increase access to conventional preventive and therapeutic
care. Including the traditional healer as part of the health care
team may thus be an important strategy both to attract
patients and to upgrade the skills and training of traditional
healers.
How equity is affected by the proportions in which different
condition-specific interventions are combined and how other
interventions (regulations, tax policy, managerial changes) are
likely to affect equity need to be studied. Given that the major-
ity of indigenous populations in developing countries use TM
for their primary health care, the availability, safety, and afford-
ability of TM, including herbal medicines, should be ensured as
a matter of equity. One way to do this is by supporting local
production of safe and effective herbals such as artemisia at
affordable prices. In addition, rigorous research on TM should
be supported. WHO is currently conducting collaborative
studies on herbal treatments for HIV/AIDS, malaria, sickle cell
anemia, and diabetes. Ineffective or unsafe herbal products
identified by such studies should be removed from use, while
those with proven efficacy and safety should be made available
for therapeutic use.
LESSONS LEARNED AND IMPLEMENTATION
The pervasiveness of different modalities of TM and CAM
varies greatly from country to country. For example, in China,
where traditional Chinese medicine is well integrated into the
health system, many different modalities may be used to treat a
given condition. In the United States, by contrast, CAM pro-
grams are slowly being integrated with conventional medicine.
Several medical schools have nascent CAM programs and have
integrated them into medical school curricula to differing
degrees. One of the more acclaimed programs of this kind
in the United States is that developed by Andrew Weil at
the University of Arizona Health Sciences Center. His
Integrative Medicine Fellowship Program trains physicians in
CAM and TM and strives to produce a new delivery model
whereby physicians, patients, and nurses form a healing team
for the care of the patient. However, this program needs to be
critically evaluated before its adoption by more institutions can
be urged.
Despite the complexity, diversity, and controversy
surrounding CAM/TM approaches, some notable success
stories reveal the influence of globalization, whereby
modalities discovered in the developing world have been
adopted in the West, with or without modifications, and vice
versa.
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Artemisinin 
Artemisinin is a recently developed, active metabolite of
artemisia, an herbal extract that has been used in China for
centuries to treat fever. Chinese scientists determined the active
ingredient of the herbal in the 1970s, and Western pharmaceu-
tical companies have developed several derivatives as drugs for
use against resistant Plasmodium malaria (Li and others 2000).
Randomized clinical trials have shown that one such drug,
dihydroartemisinin-piperaquine, is effective against drug-
resistant Plasmodium falciparum malaria (Hien and Dolecek
2004). Another artemisinin derivative, artesunate, was shown
to increase parasite clearance and reduce the gametocyte count
when added to existing drugs to combat malaria (Adjuik and
others 2004).
Acupuncture
Another CAM and TM modality that has considerable accept-
ance is acupuncture. Many pain management clinics, hospitals,
and academic centers in the West now provide acupuncture
services, and some insurance companies reimburse for
acupuncture services. Rigorous clinical trials have demonstra-
tive positive efficacy in two areas: (a) management of postop-
erative nausea and emesis (Shen and others 2000) and (b) ame-
lioration of the pain of chronic osteoarthritis (Ezzo and others
2001; Soeken 2004; Tukmachi and others 2004). Studies pro-
viding rational explanations of the mechanisms whereby
acupuncture might be achieving its effects complement the evi-
dence about its efficacy; for example, one mechanism of action
appears to involve opioid-dependent brain pathways. This kind
of two-step process—that is, initial demonstration of clinical
efficacy followed by scientific research into the mechanism of
action—is one way that CAM and TM will gain scientific
acceptance and integration into conventional medicine.
Chiropractic Medicine and Osteopathy 
Chiropractic medicine was invented in the American heartland
during the waning years of the 19th century. It uses spinal
manipulation to treat an array of conditions thought to arise
because of abnormal alignment of or stresses on vertebrae,
most often in patients with musculoskeletal complaints. Two
aspects of chiropractic medicine are success stories. First, even
though practitioners of conventional medicine ostracized prac-
titioners of chiropractic medicine in the late 19th century and
the first half of the 20th century, it has gradually evolved into a
viable healing discipline that is increasingly accepted by the
conventional medicine community. The evolution of chiro-
practic can be compared with that of osteopathy. Osteopathy
was developed in the United States in parallel with chiroprac-
tic, but the field elected to accommodate rather than reject allo-
pathic techniques.
The second success story is research showing that chiro-
practic manipulation for low back pain is superior to bed rest,
physical therapy, or provision of an educational booklet
(Cherkin and others 1998). Chiropractic manipulation has also
shown results comparable to those achieved with nonsteroidal,
anti-inflammatory drugs in alleviating back pain (Straus 2004).
Homeopathy
Homeopathy is a success in terms of its broad appeal and use,
not because of the strength of evidence supporting it. Indeed,
few conventional scientists and physicians find homeopathy to
be plausible. According to the “principle of similars” underly-
ing homeopathy, practitioners choose remedies that, when
given in high concentrations, produce symptoms similar to
those that the patient presents with. The substance is then put
in solution and serially diluted by as much as 1060, well beyond
the point defined by Avogadro’s number (at which a single
molecule of the original substance could remain in the solu-
tion). Homeopathy claims that the acts of serial diluting and
vigorous shaking imprint information into water so that
medicinal properties are retained even when no or few mole-
cules of the starting medicine are present.
As implausible as this claim may seem, homeopathy is used
worldwide with reported success (Jonas, Kaptchuk, and Linda
2003). Randomized controlled trials have suggested that it
might be effective for treating influenza (Vickers and Smith
2000), allergies (Taylor and others 2000), and postoperative
ileus (Barnes, Resch, and Ernst 1997). However, critics have
questioned the quality and analyses of these trials. Some have
questioned the validity of pooling data from trials of different
populations, interventions, and outcome measures, as several
reviews of homeopathy have done. Jonas, Kaptchuk, and Linda
(2003, 393) assert that “there is a lack of conclusive evidence
on the effectiveness of homeopathy for most conditions.
Homeopathy deserves an open-minded opportunity to
demonstrate its value by using evidence-based principles, but it
should not be substituted for proven therapies.”
Mind-Body Intervention
The work of David Spiegel at Stanford University on group
support for breast cancer patients excited wide interest in the
potential value of mind-body interventions (Spiegel and others
1989). The study was a randomized controlled trial with a 
10-year follow-up involving 86 women with metastasized
breast cancer. A one-year psychosocial intervention consisting
of weekly supportive group therapy with self-hypnosis for pain
showed that the mean survival time in the treated group was
37 months, compared with 19 months for the control group.
Moreover, Spiegel (1994) notes that appropriate psychotherapy
(both group and individual) not only reduced depression and
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anxiety and improved coping skills, but also saved money by
reducing the number of office visits, diagnostic tests, medical
procedures, and hospital admittances. Although Spiegel’s find-
ings have not been replicated, they do illustrate the potential
benefits of mind-body intervention and have led to studies of
possible mechanisms through which such interventions may
operate.
THE RESEARCH AND DEVELOPMENT AGENDA
The lack of product quality and consistency and the absence of
compelling data on the safety and efficacy of most CAM and
TM approaches present major challenges to any effort to opti-
mize the distribution of precious health resources. These diffi-
culties also pose opportunities for research. Other formidable
challenges include the variability in training, credentialing, and
licensing CAM and TM practitioners. Increasingly, efforts are
being made in several countries to regulate both products and
practitioners. Ultimately, stringent controls on training, prac-
tices, and products must be complemented by rigorous
research to ascertain which approaches are safe and effective—
and for which indications.
The global use and potential effect of CAM and TM
practices, the lack of adequate data validating their safety and
efficacy, and the existence of highly effective conventional alter-
natives for many of them dictate that resources should be
devoted to fuller characterization and standardization of CAM
and TM approaches. Investing precious resources in integrat-
ing such approaches further into health care infrastructures
can be justified only on the basis of compelling data. This point
leads to the question of what constitutes a rational agenda for
this work.
For resource-rich industrial nations, one model for CAM
and TM research is that being implemented by the National
Center for Complementary and Alternative Medicine
(NCCAM) of the U.S. National Institutes of Health (http://
nccam.nih.gov). In 2004, NCCAM planned to invest US$117
million in research and research training. It is supporting some
800 individual projects at present, including studies of the
composition of natural products and their pharmacological
effects, studies of the neurobiological mechanisms of acupunc-
ture and the placebo effect, and clinical trials with 30 to 30,000
participants. NCCAM now has a strategic plan for its interna-
tional programs that emphasizes research, training, and efforts
to learn about the rich, indigenous TM heritage. Australia,
through a government agency similar to NCCAM, is conduct-
ing research and training programs in collaboration with its
indigenous people. Although the scope of NCCAM’s research
agenda is larger than what most other nations could accom-
modate, its underlying philosophy should be universal. That is,
the standards for research into CAM and TM approaches
should be no different from those used in conventional bio-
medical research.
Both CAM and TM and biomedical practitioners need to
understand the strengths, limitations, and contributions of
their particular approaches so that they can work together in
ways that ensure the best possible care for their patients and the
achievement of their shared goals of improved individual and
public health. Once these issues have been addressed, countries
could devote additional resources to studying those CAM and
TM approaches that appear to be the most promising in rela-
tion to their most pressing public health problems. Some pri-
ority areas for CAM and TM research are widely applicable,
including studies of approaches to palliate chronic pain and
suffering, relieve depression, help release the grip of addictive
substances, and slow the progression of degenerative disorders
such as arthritis and dementia.
NOTES
1. Because some individuals had gone to more than one provider dur-
ing the four-week period, the total comes to more than 10,033.
2. The median duration of current treatment at the Royal London
Homeopathic Hospital was three years.
3. This study did not take into account the costs of physician time, the
costs of laboratory tests, or patients’ costs.
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Although the quantity rather than quality of health services has
been the focus historically in developing countries, ample evi-
dence suggests that quality of care (or the lack of it) must be at
the center of every discussion about better health. The follow-
ing examples are illustrative: In one study evaluating pediatric
care in Papua New Guinea, 69 percent of health center workers
reported that they checked for only two of the four examina-
tion criteria for pneumonia cases. Only 24 percent of these
workers were able to indicate correct treatment for malaria.
When clinical encounters were observed at aid posts, providers
met minimal examination criteria in only 1 percent of cases
(Beracochea and others 1995). In a study in Pakistan, only
56 percent of providers met an acceptable diagnostic standard
for viral diarrhea, and only 35 percent met the acceptable stan-
dard for treatment (Thaver and others 1998).
QUALITY DEFINITION AND POPULATION
FRAMEWORK
These deficiencies in quality of care represent neither the
failure of professional compassion nor necessarily a lack of
resources (Institute of Medicine 2001). Rather, they result from
gaps in knowledge, inappropriate applications of available
technology (Murray and Frenk 2000), or the inability of organ-
izations to change (Berwick 1989). Local health care systems
may have failed to align practitioner incentives and objectives,
to measure clinical practice, or to link quality improvement to
better health outcomes.
Increasing evidence, much of it developed since the mid
1990s, shows that quality can be improved rapidly. However, to
improve clinical practice—and thus quality of care—quality
must be defined and measured, and appropriate steps must be
taken (Silimper and others 2002). This chapter highlights
approaches to improving clinical practice and quality of care
that take place over months instead of years. Indeed, better
quality can improve health much more rapidly than can other
drivers of health, such as economic growth, educational
advancement, or new technology.
Definition and Framework
Health systems provide health actions—activities to improve
or maintain health. These actions take place in the context of
and are influenced by political, cultural, social, and institu-
tional factors (shown along the edges of figure 70.1).
Demographic and socioeconomic makeup, including genetics
and personal resources, affect the health status of individuals
seeking care. Access to the health care system is required to
obtain the care that maintains or improves health, but simple
access is not enough; the system’s capacities must be applied
skillfully. Thus, quality means optimizing material inputs
and practitioner skill to produce health. As the Institute of
Medicine defines it, quality is “the degree to which health
services for individuals and populations increase the likeli-
hood of desired health outcomes and are consistent with
current professional knowledge” (Institute of Medicine 2001,
244).
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Elements of Quality. Quality comprises three elements:
• Structure refers to stable, material characteristics (infra-
structure, tools, technology) and the resources of the organ-
izations that provide care and the financing of care (levels of
funding, staffing, payment schemes, incentives).
• Process is the interaction between caregivers and patients
during which structural inputs from the health care system
are transformed into health outcomes.
• Outcomes can be measured in terms of health status,
deaths, or disability-adjusted life years—a measure that
encompasses the morbidity and mortality of patients or
groups of patients. Outcomes also include patient satisfac-
tion or patient responsiveness to the health care system
(WHO 2000).
Structural measures are the easiest to obtain and most com-
monly used in studies of quality in developing countries. Many
evaluations have revealed shortages in medical staff, medica-
tions and other important supplies, and facilities, but material
measures of structure, perhaps surprisingly, are not causally
related to better health outcomes (Donabedian 1980). Although
higher technology or a more pleasant environment may be con-
ducive to better-quality care, the evidence indicates only a weak
link between such structural elements and better health out-
comes (Donabedian 1988). The notable exceptions are cases in
which physical improvements either increase access to primary
care in very poor settings or increase the volume of a clinical
procedure, such as cataract surgery, that is specifically linked to
better health outcomes (Javitt, Venkataswamy, and Sommer
1983). At best, however, structure is a blunt approximation of
process or outcomes; structural improvements by themselves
rarely improve the health of a population.
Process, by contrast, can be measured with every visit to a
provider. Measuring process is difficult, however, particularly
in developing countries. The private nature of the doctor-
patient consultation, a lack of measurement criteria, and the
absence of reliable measurement tools have limited the ability
to assess process (Peabody, Tozija, and others 2004). However,
new methods are being developed that can provide valid meas-
urements of clinical practice (Thaver and others 1998). In addi-
tion, evidence-based clinical studies have steadily revealed
which process measures lead to better health outcomes. This
combination of ubiquity, measurability, and linkage to health
outcomes makes the measurement of process the preferred way
to assess quality.
Although good outcomes are the objective of all health
actions, outcomes alone are not an efficient way to measure
quality for two reasons. The first is the quality conundrum. A
patient may receive poor-quality care but may recover fully, or
a patient may receive high-quality care for an illness such as
cerebral malaria and still not recover. Second, adverse health
outcomes are relatively rare and obviously do not occur with
every encounter.
The classic framework of structure-process-outcome is well
established. However, in recent years the concept of quality has
been expanded to include specific aims for improvement. For
example, the Institute of Medicine’s (2001) landmark report,
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Crossing the Quality Chasm, broadens the concept to include
other, more contextual elements to illuminate how process
changes can improve care. It focuses on six aims: patient safety,
effectiveness, patient centeredness, timeliness, efficiency, and
equity (see box 70.1).
Quality Assessment Perspectives. We can look at the Institute
of Medicine’s aims from two perspectives: patient perception,
and technical or professional assessment. Patients’ perceptions
of quality depend on their individual characteristics and affect
their compliance, follow-up decisions, and long-term lifestyle
changes (Zaslavsky and others 2000). Interpersonal relation-
ships, cultural appropriateness, and gender sensitivity—long
thought to be luxuries of wealthier countries—are also major
determinants of patient access and utilization in developing
countries. These findings have led to the inclusion of patient
satisfaction and patient responsiveness as outcome measures.
Technical assessment concerns whether providers meet nor-
mative standards for appropriateness of care or adherence to
explicit evidence-based criteria. Although patient perception or
satisfaction is important, researchers increasingly rely on objec-
tive, evidence-based quality criteria that can be more readily
linked to better health outcomes at both the individual and the
population levels.
Population-Level Considerations. Quality is typically
assessed through the interaction between individual doctors
and patients. However, emerging evidence shows that the
average quality of care given by groups of doctors and other
providers is an important determinant of overall community
health status. For example, in a cross-sectional analysis in the
former Yugoslav Republic of Macedonia, researchers found not
only that patients’ heath status was significantly higher in areas
where quality was higher but also that the overall self-reported
health status of those members of the general population who
had not recently received care was higher (Peabody, Tozija, and
others 2004).
Our quality-of-care framework supports these findings.
When process is improved among groups of providers,the aggre-
gate improvement in quality leads to better health outcomes for
the entire patient population. In addition, resources can be allo-
cated among clinical interventions based on actual effectiveness
and the overall impact of care on the population. For example,
cancer chemotherapy may be available and may prolong the lives
of cancer patients.However, it may result in fewer lives saved than
the expansion of coverage of directly observed treatment short-
course coverage for tuberculosis patients.
QUALITY OF CARE IN DEVELOPING COUNTRIES
The process of providing care in developing countries is often
poor and varies widely. A large body of evidence from indus-
trial countries consistently shows variations in process, and
these findings have transformed how quality of care is per-
ceived (McGlynn and others 2003). A 2002 study found that
physicians complied with evidence-based guidelines for at least
80 percent of patients in only 8 of 306 U.S. hospital regions
(Wennberg, Fisher, and Skinner 2002). It is important to note
that these variations appear to be independent of access to care
or cost of care: Neither greater supply nor higher spending
resulted in better care or better survival. Studies from develop-
ing countries show similar results. For example, care in tertiary
and teaching hospitals and care provided by specialists may be
better than care for the same cases in primary care facilities and
by generalists (Walker, Ashley, and Hayes 1988).
One explanation for variation and low-quality care in the
developing world is lack of resources. Limited data indicate,
however, that high-quality care can be provided even in environ-
ments with severely constrained resources. A study in Jamaica,
which used a cross-sectional analysis of government-run
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The Institute of Medicine’s Six Elements of Quality
Box 70.1
1. Patient safety. Are the risks of injury minimal for
patients in the health system? 
2. Effectiveness. Is the care provided scientifically sound
and neither underused nor overused?
3. Patient centeredness. Is patient care being provided in a
way that is respectful and responsive to a patient’s pref-
erences, needs, and values? Are patient values guiding
clinical decisions?
4. Timeliness. Are delays and waiting times minimized?
5. Efficiency. Is waste of equipment, supplies, ideas, and
energy minimized?
6. Equity. Is care consistent across gender, ethnic, geo-
graphic, and socioeconomic lines?
Source: Institute of Medicine 2001.
primary care clinics, showed that better process alone was linked
to significantly greater birthweight (Peabody, Gertler, and
Liebowitz 1998). A study in Indonesia attributed 60 percent of
all perinatal deaths to poor process and only 37 percent to eco-
nomic constraints (Supratikto and others 2002).
Cross-system or cross-national comparisons provide the
best examples of the great variation in clinical practice in devel-
oping countries. In one seven-country study, researchers
directly observing clinical practice found that 75 percent of
cases were not adequately diagnosed, treated, or monitored and
that inappropriate treatment with antibiotics, fluids, feeding,
or oxygen occurred in 61 percent of cases (Nolan and others
2001). Another study compared providers’ knowledge and
practice in California and FYR Macedonia, using vignettes to
adjust for case-mix severity. Although the quality of the overall
or aggregate process was lower in FYR Macedonia, a poor
country, the top 5 percent of Macedonian doctors performed as
well as or better than the average Californian doctor (Peabody,
Tozija, and others 2004).
In a study commissioned for this chapter, an international
team measured quality in five developing countries (China,
El Salvador, India, Mexico, and the Philippines), using the
same clinical vignettes at each site. The team evaluated the
process for common diseases according to international,
evidence-based criteria. Quality varied only slightly among
countries. The within-country range of quality of doctors was
10 times as great as the between-country range. Such wide
variation strongly suggests that efforts to improve health 
status must involve policies that change the quality of clinical
care.
POLICY INTERVENTIONS TO IMPROVE QUALITY
The success of quality improvement policies can be measured
by their ability to raise the average level of health and reduce
variation in quality. Two types of policies are intended to
improve quality and thus health outcomes:
• those that influence provider behavior by altering the struc-
tural conditions of organization and finance or that involve
the design and redesign of health care systems
• those that directly target provider behavior at the individual
or the group level.
Within each category, the evidence is examined to see the
effect of the policy on the health outcomes of populations.
Interventions Affecting Provider Practice by Changing 
Structural Conditions
Although structural components such as materials and staff
are not strongly linked to outcomes, other components of
structure—organization and finance—can influence process
by changing the socioeconomic, legal and administrative,
cultural, and information context of the health care system.
Legal Mandates, Accreditation, and Administrative Regula-
tions. Legal mandates, accreditation, and administrative regu-
lations affect quality by controlling entry into the practice of
health care. These policies include the licensing of profession-
als and facilities, their accreditation or certification to perform
certain procedures, and the formal delineation of functions
that various types of health workers can legally perform.
Although these policies assume that providers’ prior qualifica-
tions are good predictors of actual performance in health care
delivery, there is little evidence that such policies have a positive
effect on process or outcomes. They are more successful at bar-
ring unqualified persons from practicing than at ensuring
quality among those who are allowed to practice. A review of
health sector regulations in Tanzania and Zimbabwe, for exam-
ple, revealed that the regulations primarily control entry into
the market and ensure a minimum standard of quality
(Kumaranayake and others 2000).
Hospital accreditation, with its periodic reviews of health
facility performance standards, can potentially provide ongo-
ing regulatory pressure for improvement. To date, research has
not demonstrated that hospital accreditation programs are
linked to improvements in health outcomes. In a randomized
controlled trial of a hospital accreditation program in the
KwaZulu-Natal province of South Africa, researchers showed a
conclusive link between the implementation of the program
and improvements in the accreditation standard indicators.
However, they were unable to link those indicators to improve-
ments in health outcomes (Salmon and others 2003).
Malpractice Litigation to Enforce Legal Mandates To be
effective in promoting quality, malpractice litigation must rely
on adequate legal and judicial systems, which are deficient in
most developing countries. In India, one of the few developing
countries with the appropriate legal structure in place, inclu-
sion of the medical sector under the Consumer Protection Act
of 1986 allows victims to receive redress for negligent medical
practice. Although improvements have resulted, some argue
that the system needs greater involvement of professional
organizations to be effective (Bhat 1996).
Professional Oversight Peer review is as old as professional
societies. The power and the influence of such societies vary
widely among countries (Heaton 2000). Large provider organ-
izations, such as hospitals or public health institutions, often
routinely collect information on provider practices and patient
outcomes and use those data to guide, educate, supervise, dis-
cipline, or recognize providers. In the Philippines, public health
managers used a checklist of 20 observable behaviors against
which health workers in remote provinces were rated. The
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performance of providers in facilities where workers were
reviewed was significantly better than in comparable facilities
that did not adopt the reviews (Loevinsohn, Guerrero, and
Gregorio 1995). Others, however, assert that the “quality by
inspection” environment engendered by oversight leads to an
antagonistic relationship between workers and managers and
precludes cooperative problem solving and continuous
improvement (Berwick 1989). A qualitative study evaluating
supervisor-provider interactions in health care facilities in
Zimbabwe found that supervisors were adept at giving techni-
cal feedback but were not as proficient at making suggestions
for improvement or at working with providers and patients to
solve problems (Tavrow, Kim, and Malianga 2002).
National and Local Clinical Guidelines In many industrial
countries, evidence-based clinical guidelines are used to ensure
high-quality care, better health outcomes, and cost-effective
treatments. (Examples of institutions supporting this approach
are the U.K. National Institute for Clinical Excellence, the U.S.
Agency for Healthcare Research and Quality, and the Dutch
College of General Practitioners.) Guidelines are typically
developed for a clinical disease or symptom. They should be
derived from evidence-based criteria resulting from well-
designed clinical investigations or expert opinion. Because they
are derived from empirical studies, guidelines in developing
countries can, in principle, be identical to those in industrial
countries. When resource constraints limit transferability, diag-
nostic and treatment guidelines may have to be modified.
Technologies such as x-ray studies have gained widest accept-
ance in preventive and primary care services, such as integrated
management of childhood illness, where they serve both as
clinical standards and as educational guides. Including physi-
cians in the development and review of guidelines has proved
particularly effective in the challenging process of implement-
ing guidelines.
Sharing Information on Quality Improvement Technology.
Worldwide interest in quality has given rise to new professional
bodies, scientific publications, and institutions dedicated to
sharing ideas and innovations in quality improvement.
Organizations such as the Robert Wood Johnson Foundation,
the Nuffield Trust, and the Institute for Healthcare
Improvement cultivate ideas for improvement, bring people
and organizations together to learn from each other, and take
action to achieve results. Although the sharing of information
on quality health care practices has long been an established
part of provider education and training networks, the sharing
of information on successful systemwide policies for process
improvements could potentially accelerate the scale-up of
quality practice.
One organization active in developing countries is the
Council on Health Research for Development (COHRED),
which promotes, facilitates, and evaluates the Essential
National Health Research strategy in such countries as Benin,
the Arab Republic of Egypt, and Indonesia. COHRED aims to
develop a system of effective health research to improve health
services, including quality of care. The Quality Assurance proj-
ect funded by the U.S. Agency for International Development
has studied and shared information about quality in the devel-
oping world since 1990. Under the Quality Assurance project
umbrella, researchers have studied and implemented quality
measurement and improvement interventions and have used
these case studies to develop a library of tools and articles to
promote global quality improvement.
Public-Private Provision of Care. In most health care systems,
a professional regulatory framework governs the network of
civil servants delivering health care. These civil servants operate
alongside autonomous, self-governed, private providers—
independent for-profit physicians and health clinics and non-
profit nongovernmental organizations (NGOs). Two conclu-
sions arise from the often heated debate about the right balance
between public and private services. First, private practitioners
provide a significant amount of care in developing countries.
Second, though there is no one prescription for striking the
right public-private mix, in some cases the public regulatory
framework has led to private provision of higher-quality care.
The government of Senegal successfully contracted with
community-based groups for preventive nutrition services.
Eighteen months after nutrition services were implemented,
severe malnutrition disappeared among children age 6 to
11 months (Marek and others 1999). The success of the pro-
gram has led to its expansion nationwide.
Targeted Education and Professional Retraining. Continuing
medical education is a common approach to improving clini-
cal practice, but it neither changes clinical practice nor
advances health outcomes (Davis and others 1995). Newer
techniques—targeted education, case-based learning, and
interactive and multimodel teaching techniques—have had
some success. In Guatemala, distance education targeting diar-
rhea and cholera case management increased accurate assess-
ment and classification of diarrhea cases by 25 percent.
Rehydration did not improve, however, and improvements in
counseling were insignificant (Flores, Robles, and Burkhalter
2002). In Tanzania, training staff in the control of acute respi-
ratory infections of young children yielded reductions in
under-five mortality within two years (Mtango and Neuvians
1986).
Organizational Change. In recent years, organizational
change in the health care system has been shown to influence
quality of care and to further the six aims of the Institute of
Medicine by focusing on the continual design and redesign of
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systems. The emphasis is on developing organizational and
individual capabilities where they most profoundly affect the
process of care. Design and redesign interventions assume that
simply adding a new resource or a new process in isolation will
not improve care because better care is the product of many
processes working together. Although change interventions
have not been widely used in the developing world because
they require large investments to plan and implement, four
related models of organizational change have been successful in
changing provider practice in developing nations:
• Total Quality Management in health care Advances in
business management practices to continually design and
redesign systems for quality improvement have been effec-
tively adapted for health systems. In Total Quality Manage-
ment, also known as Continuous Quality Improvement,
teams use mutually reinforcing techniques in a cycle of plan-
ning, implementing, evaluating, and revising to improve the
quality of clinical and administrative processes. These tech-
niques include process mapping, statistical quality control,
and structured team activities. In rural Bihar, India, private
practitioners who treat sick children were provided with
standard case-management information, were given feed-
back on their performance, and were tracked and monitored
over time. This strategy produced significant improvements
in practitioners’ case-management skills (Chakraborty,
D’Souza, and Northrup 2000). In Malaysia, anesthesia safety
has been improved through the implementation of
consensus-based protocols that emphasize (a) communica-
tion among the operating, recovery, and ward team mem-
bers; (b) individual feedback; and (c) frequent monitoring
to identify areas for improvement (Tan 1999).
• Collaborative Improvement Model The early success of Total
Quality Management techniques has given rise to a related
model, the Collaborative Improvement Model. It addresses
broad and complex systemic processes within health care
systems and has facilitated the scale-up of quality improve-
ments.This model,designed to continuously improve organ-
izational and individual performance, comprises four ele-
ments: definition of an aim, measurement, innovation, and
testing to see whether the innovation meets the original aim.
This approach strikes a pragmatic balance between the need
for action and the need to be scientifically grounded. It has
been used with success in Peru and the Russian Federation. In
Peru, the collaborative improvement model was used by mul-
tidisciplinary teams in 41 clinics to design changes aimed at
achieving world-class tuberculosis care. The preliminary
results have led to impressive changes in the process of care,
but it is too early to determine whether they have been effec-
tive in improving quality (Berwick 2004).
• Plan-Do-Study-Act cycle The Plan-Do-Study-Act (PDSA)
cycle calls for action-oriented learning in quality improve-
ment. Team members using the PDSA model design a
quality-improvement intervention (plan), implement it on
a small scale (do), evaluate the results (study), and imple-
ment or alter the intervention accordingly (act). Often mul-
tiple PDSA cycles are necessary before the appropriate
improvement method can be identified. All improvement
techniques that involve the design and redesign of systems
use some form of the PDSA cycle. Successful scale-up of a
PDSA prototype is possible with careful leadership over-
sight. A team of investigators in Russia’s Tula province
developed a series of successful interventions for adults who
have poorly controlled hypertension. The interventions,
which were started in 20 clinics, were expanded to 500 clin-
ics within 18 months. The scale-up resulted in a sevenfold
increase in patients receiving hypertension management at
the primary care level and an 85 percent reduction in admis-
sions for hypertension. In Tver province, the same group
addressed problems related to prenatal care. They began
with 5 hospitals and scaled up to cover all 42 hospitals and
all maternity clinics in the province. The result was a 99 per-
cent reduction in newborns with hypothermia and a reduc-
tion in pregnancy-induced hypertension from 44 percent
to 6 percent (Berwick 2004). Although the experience of
researchers implementing interventions that are based on
system redesign in the developing world has been largely
positive, it is not clear whether the resources and leadership
exist to bring these interventions to scale through country
or regional policies. Further evidence is needed concerning
the real-world feasibility and cost-effectiveness of system
redesign.
• Internal enabling environment Creating the right environ-
ment for change involves leadership and leadership training,
clinicians empowered to make quality improvement deci-
sions, and resources for quality improvement planning
activities (Silimper and others 2002). The internal enabling
environment in Costa Rica promoted strong leadership that
led to the adoption of structural adjustment loans in the
early stages of health sector reforms. The loans were used to
maintain such public health programs as mother and child
nutrition, even though public spending dropped and prices
increased dramatically (Peabody 1996). An enabling envi-
ronment can also be created by teams of individuals, each
representing different stakeholder groups (physicians,
nurses, staff members, patients, and so forth) or simply by a
strong leader with an interest in teamwork and the resources
to support a discrete quality improvement function for team
members.
Interventions Directly Affecting Provider Practice
Practitioners are often forced to provide care in uncertain set-
tings. Technical limitations may reduce the ability to diagnose
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or predict outcomes, or they may have only probabilistic
knowledge about the efficacy of their proposed treatment for a
particular patient. The nature of clinical practice is often soli-
tary, and physicians have few available ways to gauge their clin-
ical acumen and skills. Performance-based feedback, however,
can reward high-quality care and increase knowledge about
appropriate actions. If the feedback mechanism is effective, it
can also serve as the basis for establishing systemwide incen-
tives for improving quality of care.
Training with Peer Review Feedback. In Mexico City, physi-
cian retraining on treatment of diarrhea, combined with the
concurrent creation of a peer-review structure, decreased the
use of antibiotics and increased the use of oral rehydration
therapy (ORT). These improvements continued to be seen in
a follow-up evaluation 18 months later (Gutierrez and others
1994). The approach has been effectively expanded to pre-
scribing practices for rhinopharyngitis among primary care
physicians, using an interactive training workshop and a man-
agerial peer-review committee (Perez-Cuevas and others
1996).
Performance-Based Remuneration. A potentially powerful
instrument for accelerating quality improvements involves
making payments directly to providers who meet quality stan-
dards that are based on process indicators associated with
favorable patient outcomes. Systems that tie performance to
remuneration use relatively small incentives—equivalent to
3 to 10 percent of the provider’s total compensation.
Performance-based remuneration has been successfully used
in the United States to compensate both private and public
providers (McBride, Neiman, and Johnson 2000).
Examples of performance-based incentives come from
developing countries too. The Nicaraguan Ministry of Health
has implemented a pilot program in six hospitals that offers an
incentive bonus (a maximum average of 17 percent of hospital
revenue) for facilities that achieve performance targets that
include quality measures (Jack 2003). In Haiti, a performance-
based payment scheme was set up for NGOs that provided
services to the population. The scheme resulted in all three par-
ticipating NGOs reaching target immunization coverage rates
(Eichler, Auxila, and Pollock 2001). Thus, payment for specified
and observable performance (in terms of provider effort, client
coverage, or health impact on the population) can be usefully
applied to NGOs and private providers.
The specific features of performance-based remuneration
are crucial. A study evaluating the South African government’s
experience in contracting with private organizations to operate
district hospitals found no cost savings—in fact, the govern-
ment was spending more than if it provided the services itself.
The contracting may have failed because remuneration was not
based on specific process or outcome measures. Instead, the
contractor’s obligation, the methods of monitoring perform-
ance, and the sanctions for nonperformance were only mini-
mally specified (Broomberg, Masobe, and Mills 1997).
High Volume of Care. Evidence exists that a high volume of
care by individuals or institutions leads to better health out-
comes (Habib and others 2004).Physician experience (learning)
and practice (repetition) lead to fewer complications, less
resource use, and better quality for a variety of procedures, such
as cataract surgery and laparoscopy (Brian and Taylor 2001).
More complex procedures, including endarterectomy, cancer
surgery,and coronary bypass surgery,have shown similar effects.
Volume effects leading to better health outcomes are not
confined to surgical procedures (Zgibor and Orchard 2004).
Facilities specializing in the care of chronic diseases such as dia-
betes, myocardial infarction, and heart failure are also associ-
ated with better outcomes. Debate exists over how much of the
volume effect is due to specialist care. The benefits of high-
volume care persist, however, even after controlling for referral
and case-mix biases. When carefully trained nonphysicians are
substituted for physicians, volume effects persist but can be
accomplished at significantly lower costs. In one study, nurse
practitioners and physician’s assistants were able to provide
high-quality care for common outpatient conditions such as
hypertension, diabetes, asthma, otitis media, pharyngitis, and
back pain at substantially lower costs than that of physicians
(Douglas and others 2004).
Performance-Based Professional Recognition. Providers
work in a community of peers in which professional status,
prestige, and recognition are often as valuable as material
rewards. Nonmonetary incentives, such as public recognition
or disclosure, administrative privileges, and awards from pro-
fessional organizations, can promote improvements in quality.
Uganda, for example, implemented the Yellow Star Program as
part of a broader health services improvement project. This
program evaluated health facilities on a quarterly basis, using
35 indicators of technical and interpersonal quality, and
awarded a large yellow star to facilities that scored 100 percent
in two consecutive quarters. The star was then prominently dis-
played outside the facility.
The Mexican Ministry of Health has implemented a strategy
that combines the accreditation and the training strategies
discussed earlier with nonmonetary incentives. The National
Crusade for Quality in Health Care introduces quality-oriented
incentives to health facilities and medical schools. It also
includes public recognition in an effort to encourage learning
and to change practice. The National Crusade has already gen-
erated measurable improvements in the responsiveness of
state-level health systems (Secretaría de Salud de Mexico 2003).
Both types of policies examined in this section are associ-
ated with better quality and better health outcomes—lower 
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premature mortality and avoidable morbidity, increased
patient satisfaction, and more health-seeking behaviors. When
effective, these policies result in increased coverage rates, better
prescribing patterns, and increased adherence to clinical guide-
lines. They can spell the difference between an individual’s
survival or death, between an individual benefiting from the
encounter with the health sector or being harmed by it, and
between an individual and society rising from poverty or sink-
ing deeper into it.
MEASURING QUALITY
Improving quality requires that we measure it accurately. The
successful outcomes discussed in the previous section rely on the
links between policy and changes in clinical practice. Such links,
however, can be created and demonstrated only when valid and
reliable measures of process are easily understood, inexpensive
to obtain, resistant to manipulation, and related to better health
outcomes.
Measuring Structure
Material measures of structure abound. Numerous facility-
based surveys in developing countries have cataloged capital
equipment and staffing levels, and financial reports track budg-
ets and expenditures (but rarely production costs). Facility
inventories of drugs and supplies are generally available; service
utilization figures are routinely reported to national-level
authorities. Such measurements, however, are often beside the
point. Even when material structural deficiencies are corrected,
they are not reliably linked to changes in health outcomes.
Measuring the organization and financing of health care is more
difficult. Although descriptions of the organization and financ-
ing of health systems exist, objective functional assessments of
systems (such as patient flows, the patient referral system, or
details of the relative pricing of services) are less often available.
Measuring Process
Technical advances have mitigated longstanding difficulties in
measuring process. Five approaches and their strengths and
weaknesses merit consideration: chart abstraction, direct
observation and recording of visits, administrative data, stan-
dardized patients, and clinical vignettes.
Chart Abstraction. Chart abstraction, or review of the med-
ical record, has long been used to measure technical quality.
Such familiar quality evaluations as clinical audits, physician
report cards, and profiles are based on chart abstraction. The
core strength of the medical record is that it is ubiquitous and
can generally be obtained after each encounter. Chart reviews,
however, suffer from problems of legibility when notes are
handwritten. Often they are generated for reasons other than
recording the actual events of the clinical visit (legal protection
or obtaining payments, for example) and thus lack crucial
clinical details. One prospective study showed that charts iden-
tified only 70 percent of items performed during the clinical
encounter (Luck and others 2000). In a related analysis, 6.4 per-
cent of the items recorded in the chart were false and had never
really occurred.
Where resources and infrastructure are sufficient, the elec-
tronic medical record (EMR) is becoming a priority for health
systems worldwide. EMR technology promotes uniformity, leg-
ibility, and communication, which can lead to guideline use
and reduce prescription errors. It also holds the promise of
managing populations rather than individuals by aggregating
patients into groups. However, the EMR has not always lived up
to its potential. In many countries, some impressive successes
have occurred—as have spectacular failures, costing billions of
dollars (McConnell 2004). The great heterogeneity in record-
keeping practices, problems with medical records (both paper
and electronic), and costs of trained medical abstractors have
led to a search for other reliable ways to measure quality.
Direct Observation and Recording of Visits. Direct observa-
tion and recording of visits is a commonly used approach in
developing countries (Nolan and others 2001). Ethically, the
provider and the patient must be informed of the observation
or recording, which introduces participation bias because
provider behavior may change as a result of being evaluated. In
addition, trained observers are costly, and variation between
observers is difficult to remedy.
Administrative Data. Administrative data, collected for pur-
poses of managing the delivery of care, are available in all but
the poorest settings. A data collection system, once established,
is ubiquitous and can provide information on charges and
many cost inputs. Administrative data, however, lack sufficient
clinical detail to be useful in evaluating process. In a 2003 study,
an incorrect diagnosis was recorded in the data 30 percent of
the time (although the diagnosis was made correctly). Overall,
these data reflected the actual clinical diagnosis only 57 percent
of the time (Peabody, Luck, Jain, and others 2004). As informa-
tion systems advance, accuracy problems may be mitigated,
although the lack of adequate clinical detail will continue to
limit the use of administrative data.
Standardized Patients. Standardized patients can be a gold
standard for process measurement (Luck and Peabody 2002).
Trained to simulate illness, standardized patients present them-
selves unannounced into a clinical setting to providers who
have previously given their consent to participate in the study.
At the conclusion of the visit, the standardized patient reports
on the technical and interpersonal elements of process.
Standardized patients are reliable over a range of conditions
and provide valid measurements that accurately capture
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variation in clinical practice among providers over time.
However, they are expensive and useful only for adult condi-
tions and only those conditions that can be simulated. Thus,
they are not practical for routinely evaluating quality.
Clinical Vignettes. Clinical vignettes were developed explicitly
for measuring quality within a group of providers and
evaluating quality at the population level. Vignettes are respon-
sive to variation in quality, and providers readily accept them if
they are given anonymously (Peabody, Luck, Glassman, and
others 2004). More than 20 vignettes have been used in 13
countries around the world. They can be administered on
paper, by computer, or over the Internet. Providers are typically
presented with several cases. When process is being measured
for many providers, each provider is presented with the same
case or set of cases, thus eliminating the need for case-mix
adjustment. The provider completing the vignette is asked to
take a history, do an examination, order the necessary tests,
make a diagnosis, and specify a treatment plan. The questions
are open ended and include interactive responses that simulate
the visit and evaluate the physician’s knowledge. In two sepa-
rate, prospective validation studies among randomly selected
providers, vignettes consistently demonstrated greater predic-
tive validity of process than did the abstracted medical record.
Vignettes have been validated against the gold standard of
standardized patient visits, and they reflect actual clinical prac-
tice, not just physicians’ knowledge. Vignettes have several
other advantages. Because exactly the same case can be given to
many providers, vignettes are useful for comparison studies.
They are also useful for pre- and postevaluations of policy
interventions designed to improve quality. Finally, they are
inexpensive to administer and straightforward to score, making
them particularly useful in developing countries.
ECONOMIC BENEFITS AND COSTS 
OF QUALITY CARE
Policy interventions can lead to higher-quality process of care
and can rapidly improve a population’s health outcomes, but is
quality improvement cost-effective? This section shows that it
is. We compare the economic benefits of better quality of care
at the individual and population levels with the costs of imple-
menting quality improvement interventions. We then discuss
why these interventions not only increase individual and social
welfare but also are cost-effective in the long run.
Individual Economic Benefits
Individuals benefit from better quality of care because they are
physically, emotionally, and mentally healthier. These benefits
can be quantified subjectively by self-report, objectively by
physiological assessments (such as blood pressure), and mone-
tarily by measuring income. Other things being equal, a healthy
individual generates more income than one who is often sick.
This benefit goes beyond the period of illness. Research on early
childhood development has shown that higher-quality prenatal
and postnatal care not only decreases mortality but also
improves subsequent school performance, which is critical to
future labor productivity (Van der Gaag 2000). The monetary
benefits of better individual health can be assessed by examining
the individuals’ expected income in the context of a life cycle
model. Expected income depends on the risk of death at various
points in time and the corresponding opportunities for educa-
tional attainment. This scenario can be simulated by improving
quality and then estimating how much the higher quality lowers
mortality and increases education attainment, both of which
increase an individual’s future income (see figure 70.2).
Social Macroeconomic Benefits
Societies that have healthier populations also have higher levels
of human capital and a greater capacity to generate wealth.
Higher quality of care for the individual increases society’s
human capital by reducing both the number of premature
deaths (thus increasing the labor force) and the amount of tem-
porary or permanent disability (thus improving worker pro-
ductivity). Providers and insurers also benefit from lower costs
by avoiding unnecessary or inappropriate care. Thus, society
benefits from both better health and lower public expenditures
for treatment, which can then be reallocated to other productive
uses. Interventions that improve quality have an especially high
social value when they have large positive externalities (for
instance, when better process reduces the incidence of a com-
municable disease). Sometimes, however, society benefits but
some stakeholders do not. For example, physicians who provide
better preventive care may experience less demand for their cur-
ative services and associated resources.
Several attempts have been made to estimate the correlation
between health outcomes and long-term economic growth.
The high prevalence of such diseases as malaria has been linked
in some studies to a slowing of economic growth by one to two
percentage points per year. These studies were severely limited
by the number of countries and by the many unobserved fac-
tors excluded from the models (Sachs 2001). These limitations
suggest another way to estimate the benefits of higher quality
on health outcomes and long-term economic growth. Because
diagnostic accuracy and treatment of malaria can be improved
with better-quality care, improving quality should increase
national income through reductions in mortality rates.
Indeed, cross-country data suggest that a one-year increase
in life expectancy is associated with an increase in the gross
domestic product (GDP) growth rate of 1 to 4 percentage points
(Bloom, Canning, and Sevilla 2001). Our own simulations show
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that quality improvements can result in as much as a 5 percent
annual reduction in child mortality rates, which can generate,
over 50 years, economic gains equivalent to 18 percent of cur-
rent GDP (see figure 70.3). Similar results would be obtained if
the effect of better quality on morbidity and disability were
simulated.
Economic Costs
Policies that improve the quality of care have both direct and
indirect costs. Direct costs relate to the human and physical
resources needed to implement the intervention. Indirect costs
come from more subtle changes, including alterations in the
quantity of health services provided, in provider demand for
various inputs (such as equipment and medication), in the
market prices of heath care, in government health budgets, and
ultimately in the macroeconomy. For interventions at the local
level, such as training doctors in a particular region, it is usually
sufficient to measure direct costs. Although the level of
detail required can be overwhelming when the interventions
are complex, the calculations are usually straightforward. The
costs of local interventions depend on local prices of such
inputs as labor, transportation, training kits, food, space rental,
and accommodations. The cost of training providers in the
appropriate treatment of childhood illnesses ranges from a
low of US$1 to a high of US$430 (Santoso, Suryawati, and
Prawaitasari 1996).
The direct and indirect costs of interventions at the central
or local government level are harder to quantify. Expanding
training programs to all public providers, enforcing standards
for private and public providers, changing payment sys-
tems, and developing policies to protect consumers against
malpractice are macro-level interventions that have direct
program-level costs. They affect the economy as a whole by
changing the allocation of public resources and the relative
prices of goods and services. Macroevaluations of health
policy interventions are seldom conducted, even though sys-
temwide interventions are likely to have the highest effect on
quality and health-related benefits.
Cost-Effectiveness of Improved Process
Two interventions that vividly illustrate the cost-effectiveness
of improvements in clinical practice and outcomes have been
chosen: detection and treatment of acute respiratory illnesses
and appropriate drug use and treatment for diarrhea.
Better Treatment of Pneumonia in Children. Part of the high
mortality from childhood pneumonia in the developing world
can be explained by poor-quality care, which is defined as the
inability either to accurately diagnose or to treat the disease.
Our prototype intervention has two cost components: the cost
of implementing an educational activity for providers and the
cost of treating nonsevere and severe childhood pneumonia.
The former component is based on a study and uses conserva-
tive high-end cost estimations (Kelley and others 2001); the
latter is the midpoint from another study (Stansfield and
Shepard 1990). The number of lives saved depends on the
effect of the intervention—that is, the change in the percent-
age of cases diagnosed and treated; the prevalence rate of both
types of pneumonia; the population covered by each provider;
the case-fatality ratio; and the effectiveness of the treatment.
Both the case-fatality ratio and the effectiveness ratio were
fixed at middle values suggested by earlier work (Stansfield
and Shepard 1990). For the other parameters, a large range of
variation was considered, producing 450 scenarios. Finally, six
impact levels were considered, which were based on two previ-
ous studies (Chakraborty, D’Souza, and Northrup 2000;
Mtango and Neuvians 1986).
The analysis showed that, under average conditions,
improving quality of care for conditions of acute respiratory
illness can be very cost-effective. When the baseline quality is
low and the disease prevalence is high, an intervention that
raises quality has a cost-effectiveness ratio of US$132 to
US$800 per life saved; if the policy intervention is ineffective or
the prevalence of pneumonia is low, the average cost of saving
a life could be more than US$2,000. When 60 percent of cases
are already appropriately diagnosed and treated, the cost-
effectiveness ratio rises to US$5,000 per life saved.1
Better Treatment of Diarrhea. Diarrhea remains one of the
leading causes of childhood morbidity and mortality in the
developing world. The diarrhea incidence rate among children
in resource-constrained countries can reach six to seven
episodes per year (Thapar and Sanderson 2004). ORT is the
accepted standard of care for acute diarrhea. Unfortunately, a
large proportion of cases are still treated with nonrehydration
medication, including antibiotics and antidiarrheals. Improved
diagnosis of dehydration and reduced use of unnecessary med-
ications, however, lead to better outcomes.
Various interventions can make sizable changes in the diag-
nostic and prescribing patterns of providers. Verbal case review,
combined with a package of additional intervention referred
to as INFECTOM (Information, Feedback, Contracting with
Providers to Adhere to Practice Guidelines, and Ongoing
Monitoring), increased the proportion of cases treated correctly
from 16 percent to 48 percent (Bloom, Canning, and Sevilla
2001). One study reports that small group, face-to-face inter-
ventions reduced antimicrobial prescriptions by 16 percent
and antidiarrheal prescriptions by 7 percent among a group
of providers treating acute diarrhea in Indonesia (Santoso,
Suryawati, and Prawaitasari 1996). The same study showed that
formal seminars reduced antimicrobial use by 10 percent and
antidiarrheal use by 7 percent. On the basis of these studies, an
average cost per intervention was used, ranging from US$25 to
US$125.
The savings from switching to a less costly treatment (instead
of antibiotics, for example) were subtracted from the direct
costs that are related to implementing the training activity.
Because other savings, such as those related to a lower use of
inpatient services, were ignored, the estimates are conservative.
Savings could be greater: Two years after an ORT unit was estab-
lished at the Kamuza Central Hospital in Malawi, 50 percent
fewer children with diarrhea were admitted to the pediatric
ward, and those admitted required 56 percent less intravenous
fluid for rehydration (Martines, Phillips, and Feachem 1990).
Again, the number of lives saved depends on the disease
prevalence; the effect of the policy on treatment quality; the
Improving the Quality of Care in Developing Countries | 1303
population covered by each provider; the average case-fatality
ratio, which was set at 6 per 1,000 on the basis of Snyder and
Merson (1982); and the effectiveness of the treatment. For the
latter parameter, reductions in mortality rates following ORT
treatment of 40 to 60 percent and reductions in effectiveness
ratios of 5 to 100 percent have been reported (Shepard, Brenzel,
and Nemeth 1986). Accordingly, the effectiveness ratio was set
at 80 percent. As before, alternative values for the other param-
eters were adopted, generating 450 scenarios.
Educational interventions to improve the quality of care for
treatment of diarrheal diseases are also highly cost-effective. In
general, the cost of saving a life through educational interven-
tions is less than US$500 and could be as low as US$14.
Scenarios with high cost per life saved (more than US$6,000)
are when prevalence rates are low or when implementation
costs for quality-related interventions are high.
Although the data available to estimate the costs and
benefits of health outcomes and process are limited, these
simulations, combined with published reports of successful
policy interventions, clearly show the cost-effectiveness of
interventions that improve health outcomes through better
quality of care. However, reliable measures of quality are neces-
sary to design and evaluate these interventions.
RESEARCH AGENDA ON QUALITY
Most of the issues discussed throughout this chapter represent
important topics for research. Establishing a research agenda
requires prioritizing both the type of research and the topics to
be studied. Quality-of-care research must also strike a balance
between relevance to decision making and excellence in scien-
tific rigor (Frenk 1992).
Observational studies are needed to document the extent
and correlates of quality at various levels: individual providers,
institutional providers, health care systems, and whole popula-
tions. Apart from offering much-needed basic descriptions
(especially in developing countries), these studies can test spe-
cific indicators of the dimensions of quality and can compare
the measurement approaches discussed earlier.
Intervention studies introduce planned changes into health
care settings and assess their consequences. It is fundamentally
important that intervention studies compare one provider
group or policy alternative with another. In addition, control
groups must be used so that any observed change can be
attributed to the intervention itself rather than to another
source of variation. The external validity of studies is often
undermined by the choice of highly specific sites, making it dif-
ficult to generalize the findings and to build a body of sound
evidence. If randomized trials cannot be conducted, the pre-
ferred option is quasi-experimental studies with clear control
groups and longitudinal designs (Peabody and others 1999).
Such studies should be complemented by cost-benefit and
cost-effectiveness analyses. Sometimes, in public health emer-
gencies, for example, control groups may not be practical or
ethical, in which case real-time operations research is an
acceptable substitute.
In the area of research topics, top priority should be given
to quality monitoring and assurance strategies to gain an
understanding of exactly what the health system is contribut-
ing to society and at what cost. Quantifying the associated
costs of different variants of quality monitoring and assurance
strategies should also be a high-priority item on the quality
research agenda. The second priority should be to increase the
evidence base regarding the effects on provider behavior of
public policies concerning quality of care and whether they
lead to better health outcomes. We need to learn more about
the long-term effects of different contracting and remunera-
tion policies on providers’ practices and the consequent
results of such policies for health outcomes. Finally, we need
to understand how contracting and remuneration policies
affect problems unique to the developing world, such as the
use of doctor substitutes and the migration of skilled
providers to wealthier countries.
CONCLUSION
Good quality means that providers are able to manage an indi-
vidual’s or a population’s health care by timely, skillful applica-
tion of medical technology in a culturally sensitive manner
within the available resource constraints. Eliminating poor
quality involves not only giving better care but also eliminating
underprovision of essential clinical services (systemwide
microscopy for diagnosing tuberculosis, for example); stopping
overuse of some care (prenatal ultrasonography or unnecessary
injections, for example); and ending misuse of unneeded serv-
ices (such as unnecessary hysterectomies or antibiotics for viral
infections). A sadly unique feature of quality is that poor qual-
ity can obviate all the implied benefits of good access and effec-
tive treatment. At its best, poor quality is wasteful—a tragedy in
severely resource-constrained health care systems. At its worst,
it causes actual harm.
Despite the urgency of improving health in developing
countries, quality of care has been largely ignored. Both
providers and patients agree this must change, but how can this
goal be reached? From the information marshaled for this
chapter, we can draw five conclusions:
• Better quality leads to better health outcomes in developing
countries.
• Process, the proximate determinant of health outcomes, can
be measured in valid and reliable ways, such as clinical
vignettes and electronic medical records.
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• Measured in the above ways, the process of care in develop-
ing countries is poor.
• The process of care can be improved in the short term.
• Policies affecting structural conditions, including the actual
process of care or the continual design and redesign of the
health care system, have been shown to be effective in devel-
oping countries.
We believe that two broad strategies would help to rapidly
improve health care quality in developing countries:
• encouraging explicit comparative research on outcomes and
process
• disseminating empirical findings on quality variation.
Encouraging Explicit Comparative Research on Outcomes
and Process
Comparisons highlighting different outcomes can be com-
pelling. For example, when 30-day mortality rates for coronary
artery bypass surgery at various facilities were disclosed in the
United States, care started to shift from many low-volume hos-
pitals to high-volume hospitals (Chassin 2002). In developing
countries, comparisons show that the insured are more likely
to have cesarean sections than are the uninsured (Barros and
others 1991). Although critics of comparative analysis are jus-
tified in saying that systems and populations vary, such criti-
cism misses an important point: Differences in outcome high-
light possibilities that help in the search for the underlying
causes of poor quality. Although poor quality may have many
causes, one of them is almost always poor clinical practice,
which can be remedied. We also favor a league or summary
table approach to making comparisons. In this approach, the
providers being compared agree on criteria before prospective
assessments are done. The data for the comparison should be
of the highest quality; the league tables themselves should
be easy to interpret; and the findings should be rapidly avail-
able (Devers, Pham, and Liu 2004). The league table itself
should be set up at the regional, national, and international
levels so that a variety of benchmarks are available.
Implementing quality comparisons will greatly facilitate the
process of policy evaluation and cost-benefit analysis and help
indicate directions for future research. Access to accurate, con-
sistent quality-of-care data will compel external funders, such
as the World Bank, to build quality assurance into their lending
and development programs. As major health programs such as
the Global Fund to Fight AIDS, Tuberculosis, and Malaria are
scaled up around the world, mechanisms to measure and
improve care quality will grow more important.
Disseminating Empirical Findings on Quality Variation
Public dissemination of information on quality, particularly in
low-literacy countries, does not seem to create the individual-
based choice market that many have envisaged. Instead, it
motivates managers and providers to undertake changes that
improve the delivery of care (Schneider and Lieberman 2001).
Outside pressure—perceived or real—appears to extend the
quality debate beyond traditional boundaries, allowing for
innovative collaborations and “out of the box” thinking
(Devers, Pham, and Liu 2004). Nongovernmental and private
organizations involved in health care delivery should also be
required to report basic quality measures, perhaps as a condi-
tion for funding, thus ensuring that similar pressure to improve
quality is exerted outside the public sector.
Public dissemination can create shock waves when poor
quality is “discovered,” leading to popular demand to increase
quality. For example, findings of widespread medical errors in
the United States, estimated to have resulted in as many as
98,000 deaths per year, launched the medical safety revolution
(Institue of Medicine 2001). Dissemination among physicians
and surgeons by means of report cards and ratings has been
effective at changing clinical practice. One advantage of dis-
semination among providers is that the results can be more
refined and technical than ratings meant for wider audiences.
Dissemination is the responsibility of public research and pub-
lic initiative. Because dissemination is inherently controversial,
it requires public financing—even more than other public
goods (Jamison, Frenk, and Knaul 1998).
Ultimately, improving quality is about value. In health care,
price is not a reliable proxy for quality and cannot be used as
a guide. Because patients and consumers cannot directly
observe quality, their ability to demand high-quality services is
limited, and they are often left to settle for a market that has
suboptimal equilibrium and poor quality of care. In addition,
providers often lack knowledge of optimal treatments and
technologies and thus are not aware of how they can produce
higher-quality care. Because the provider-patient interaction
is so private and personal, quality of care is hard to observe
and to measure. New measurement tools, however—such as
clinical vignettes and the electronic medical record—are being
developed and improved. As research links care with out-
comes and cost inputs, we can expect to have more accurate
and reliable data about clinical practice for use in making
quality assessments.
Investments in quality, however, must be judged critically as
well. When we invest in quality, an investment can be beneficial
but can come at a cost. So while quality goes up, value can go
up or down—or costs can go up while quality actually goes
down or stays the same, thus pushing the value of care down
and undermining other efforts to improve quality. Finally, as
we showed for acute respiratory illness and diarrhea, quality
can go up and costs go down, thus increasing overall value.
Examples of this optimal outcome must be actively sought out
and reported, because the success of a given investment cannot
be known in advance (Berwick 2004).
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Improving health status does not have to rely solely on
macroeconomic growth or other long-term development indi-
cators. Health outcomes can be rapidly improved in the short
term by ensuring the appropriateness of the circumstances
or setting under which the health care encounter occurs
(structural improvement) or by increasing the likelihood that
health care providers behave in ways most beneficial to
patients under the prevailing circumstances (process improve-
ment). However, this improvement will not occur sponta-
neously or routinely, despite the best intentions of beneficiar-
ies, providers, and governments. Quality improvement tools
and technologies and information on successful quality
improvement policies must be consistently shared among
developing countries to build local capacity. Funding and
incentives must also be consistent with high quality. Finally,
the political will to ensure that quality becomes a top priority
on the health reform agenda must be sustained.
NOTE
1. As a reference, if the average expected value of a life is close to
US$30,000, even the highest cost-effectiveness ratio found in the analysis
(US$12,000 per life saved), would imply a cost-benefit ratio below 50 per-
cent, assuming an initial average wage of US$1,000 growing at 2 percent
per year, a 5 percent discount rate, and unchanged mortality rates.
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Policy on human resources for health should support health
policy objectives and be a means for achieving policy goals. The
implication of such a focus is that health systems development
should start by identifying the tasks that must be carried out
and the skills needed to perform them. Meeting policy goals
depends on being able to recruit, train, and retain staff with the
necessary bundles of skills. Traditionally, skills are defined by
membership of a profession, especially medicine, nursing, mid-
wifery, and the allied health professions. Low- and middle-
income countries (LMICs), often from necessity, have widened
the range of health care workers to meet the service needs, with
some people trained in extremely basic skills and others receiv-
ing enhanced training, such as nurses trained in emergency
obstetrics. What is meant by a doctor or nurse also varies.
Even though structures and institutions vary widely, some
problems are common to most LMICs. First, persuading
doctors to work in remote rural areas is difficult, and they typ-
ically do not remain long in such posts. Second, emigration of
doctors and nurses is extensive. Third, it is common for doctors
to work in both the public and the private sectors (referred to
as dual practice), sometimes harming public services. Dual
practice may encourage doctors to skimp on their public health
efforts, to pilfer supplies, and to induce demand for their
private services (Bir and Eggleston 2003).
Many health sector human resource (HR) problems are
predictable from a simple labor market perspective, given the
combinations of incentives confronting health care workers
and the constraints policy makers face. Experience in LMICs
shows how problems have arisen and what policies have
succeeded.
Economics predicts that employers will employ workers as
long as the additional value of their services is at least as great
as the cost of employing them, and workers will work if the
rewards are of greater value than those accruing to other uses
of their time. If key professionals are in short supply, higher
salaries will be needed to attract them. Workers will invest in
training if they value higher future incomes and more interest-
ing work above the costs of income lost during training and of
fees paid for training programs. This chapter focuses on how
health systems might build and improve HR capacity.
Appropriate HR capacity is critical for the effective imple-
mentation of disease control interventions. Salaries account
for 50 to 80 percent of health sectors’ recurrent costs (Bach
2000). Table 71.1 shows the number of physicians and nurses
per 100,000 population in selected countries. The number of
health workers is related to the level of development because
of the tight resource constraints facing LMICs and because of
supply constraints, often exacerbated by migration of skilled
workers (Awases, Gbary, and Chatora 2003) and prevalence of
AIDS. In Africa, where the disease burden is high and increas-
ing rapidly, the number of health workers is particularly low.
Most African countries export health professionals to high-
income countries.
A study in six African countries showed that most health
workers intend to migrate for higher salaries. In Ghana, 70 per-
cent of 1995 medical graduates had emigrated by 1999 (Awase,
Gbary, and Chatora 2003). Pay differentials provide strong
incentives to migrate. For example, a junior doctor in the
United Kingdom averages a monthly salary of US$3,029 and a
registered nurse averages US$1,500, compared with US$300
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per month for a Ugandan medical officer and US$180 for a
registered nurse.
Scaling up service provision using current provision models
would require large increases in resources and could require a
change in strategy by development partners toward supporting
recurrent costs (Jha and Mills 2002). The labor market model
indicates that higher salaries would be needed to attract addi-
tional staff members, so funding would have to increase more
than in proportion to the number of staff members employed.
Many LMICs pay health workers on civil service scales,
which they control to contain overall government spending.
This practice further widens the gap between salaries for
professionals at home and abroad.
Although improved economic performance and increased
development assistance may allow some increases in health
spending, in most LMICs it is not plausible that such increases
would be sufficient to make the necessary skills available with-
out a range of strategies, including better regulation, stronger
incentives, and initiatives to make key skills available at lower
cost.
HEALTH CARE PROVISION AND ASSOCIATED
HUMAN RESOURCE NEEDS
Studies on developing services to meet the Millennium
Development Goals emphasize the importance of making
health workers with the appropriate skills available and moti-
vating them (Jha and Mills 2002). The problems include lack
of technical skills, low motivation, and poor support networks
(Kurowski and others 2003). This chapter, therefore, focuses
on HR planning, training and professional development,
incentives for workers to accept and stay in posts and to
deliver services, and alternatives to conventional professional
groups.
Incentives and Motivation
The labor market model outlined earlier provides a framework
for analyzing the role of incentives. A health worker will accept
a job if the benefits of doing so outweigh the opportunity cost.
Improving recruitment and retention requires either offering
higher rewards that make alternative employment less attrac-
tive or making qualifications less “portable”—that is, less likely
to be recognized in other countries. The development of new
health professions in many countries is a way of reducing the
portability of qualifications, thereby reducing the opportunity
cost of jobs at home. Another advantage is that training can be
more specific to local health system needs, but ensuring quality
and safety are important issues.
Health workers will choose to train and increase their skills
if the rewards of doing so exceed the cost. In general, the sup-
ply of skilled professionals rises as rewards increase, because
more will seek training, more will return to the workforce, and
fewer will move to other jobs or other countries. Because health
workers value both financial and nonfinancial rewards, they
will work for lower salaries if other job characteristics are
attractive.
The causes of health HR problems in developing countries
are complex, and attempts to address them must reflect this
complexity. Table 71.2 suggests a framework for exploring
links between factors at individual, organizational, and
health system levels. The framework is inspired by a systems
approach, which gives prominence to the roles of and rela-
tionships between different component parts in influencing
the whole.
The individual health worker level serves as a starting
point for exploring the determinants of health worker behav-
ior and performance (Kyaddondo and White 2003).
Performance here means productivity and quality of services.
Individuals respond to individual concerns through coping
strategies, such as informal and dual practices, with associated
consequences. There are multiple links between individual
health worker behavior and organizational and systemic
factors. Organizational and system arrangements define
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Table 71.1 Numbers of Physicians and Nurses, Selected
Countries and Country Groups, 1998
Physicians Nurses Physician-
per 100,000 per 100,000 nurse
Country population population ratio
Angola 5 100 0.05
Bangladesh 19 11 1.7
Boliviaa 29 14 2.1
Botswana 20 100 0.2
Brazil 136 44 3.1
Burkina Faso 3 20 0.15
Central African Republic 3 10 0.3
Equatorial Guinea 20 50 0.4
India 106 94 1.1
Nepal 4 5 0.8
Pakistan 57 34 1.7
Papua New Guinea 7 67 0.1
Perub 10 7 1.4
South Africa 20 100 0.2
Sri Lanka 37 103 0.4
Low-income countries 73 132 0.6
Middle-income countries 142 278 0.5
High-income countries 286 750 0.4
Global average 146 334 0.4
Global median 114 233 0.5
Sources: PAHO 2003; Support for Analysis and Research in Africa 2003.
a. 1999 data.
b. 1996 data.
the incentive context for health workers and influence both
organizational and individual performance.
Therefore, the configuration of the health system must
create incentives for appropriate supply and deployment of
health workers. HR development experts tend to focus more
on problems encountered in the lower tiers of this framework.
Political pressure for short-term solutions partly explains
why many countries do not address HR problems compre-
hensively. The wider context can also be important. Good
governance at the national level is necessary to make policy
interventions at the health system level or below effective.
Financial Incentives
Most of the comparatively scarce evidence on the relative
importance of financial and other incentives for health workers
at the individual level comes from developed countries. Two
findings emerge from recruitment and turnover studies. First,
at extremely low salaries, financial incentives are particularly
important (Normand and Thompson 2000). Second, at least
half of the variation in turnover can be attributed to financial
incentives (Gray and Phillips 1996). These findings leave con-
siderable scope for improving retention using organizational
changes, but such changes will be only partially successful if
much better financial rewards are available elsewhere.
International migration has increased as restrictions on
moves to high-income countries have been eased (Bach 2000).
Many developed countries have shortages of health profession-
als and actively recruit from low-income countries, thereby
raising the opportunity cost of remaining at home.
Health Care Systems’ Responses to Health Worker Issues
Health sector reforms have been widespread in recent years,
often with international support. These reforms tended to
focus more on structures and financing and less on resource
issues (Martineau and Buchan 2000). Other government
reforms aimed mainly at improving efficiency and reducing
the cost of government administration have often had large
effects on the health workforce (Adams and Hicks 2000;
Corkery 2000). Some changes have attempted to introduce
better incentives, such as performance-related pay and renew-
able contracts, and to remove underperformers and ghost
workers. Evidence on the effects of these reforms suggests that
more emphasis should have been placed on designing incen-
tives to improve performance and retention and on moving
further away from workforce quotas and norms. Using the
three levels of analysis, the following sections consider policies,
management, and incentives and how they can help match
skills to needs.
HEALTH CARE STAFF
Workforce planning should be dynamic and should link policy
goals to staff members’ skills and numbers and to performance-
enhancing incentives.
Workforce Planning to Meet Policy Goals
Several factors make workforce planning in health particularly
difficult, including changing needs as service models change,
long training time for some professions, and lack of direct gov-
ernment control over the number of professionals being
trained, for example, because of the growth of private medical
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Table 71.2 Framework for Diagnosing HR Issues 
in the Health Sector
Level Issue 
Individual health worker
Internal capacity
Remuneration 
Work environment 
Immediate environment
Distant environment
Productivity
Responses to organizational
and systemic constraints
Organizational level
Systemic level
Knowledge, skills, competencies, attitude
Salary and perquisites, payment methods 
See organizational-level issues
See systemic-level issues 
Outputs or outcomes per given unit of
time or per individual or group of
individuals
Low motivation, morale, productivity, and
quality of services
Informal practices, for example, unofficial
fees, dual practice, misuse of public
resources, and unethical practices
Emergence of unskilled informal
practitioners
Presence or absence of an appropriate
physical and operational context—that
is, availability of materials and facilities
to deliver services of acceptable quality,
workload management, and organiza-
tional norms and practices (organizational
culture, management and leadership
styles)
Organizational autonomy across key
strategic and functional issues
Level of bureaucracy and decentralization
in the health system, and funding and
regulatory arrangements 
Policy context—for example, pro-market
policies and diversification of the health
care market in the spirit of a public-
private mix
Socioeconomic and political context
Medico-legal policy and enforcement 
Source: Authors.
Note: This chapter uses a narrow definition of health system that considers socioeconomic and
political issues as part of a wider context.
schools, such as in Bangladesh, or because of people going
overseas for training (although Singapore has addressed this
problem by restricting the colleges that the government recog-
nizes for registering doctors). The greatest difficulty comes
from the unpredictable loss of skilled staff members to private
health sector jobs, jobs abroad, and jobs outside health. Thus,
a close link exists between HR planning and incentives and reg-
ulation. In Ghana, nurse training has often been the only avail-
able form of tertiary education for women, and many of those
who are trained do not practice.
A key to more rational workforce planning is better coordi-
nation between health planning and planning for training and
education. Powerful interest groups can oppose the expansion
of training. Training establishments often oppose change be-
cause it may disrupt existing arrangements and threaten current
staff members. The development of new professional groups
faces particular resistance from existing professional groups,
which, quite correctly, perceive the new groups as posing a threat
to their interests. For example, some dentists in South Africa
expressed concern over training of dental technicians who carry
out a wide range of preventive and restorative dentistry at lower
fees (Matomela 2004).
Models for HR needs are easy to devise, but determining
the appropriate model parameters is difficult. For example,
health planners must estimate the length of a nursing career—
potentially up to 45 years but often much less, especially if
nurses are willing to work outside nursing (Phillips and others
1994). Good data are needed on dropout rates from training.
HR sections of health ministries are usually poorly resourced,
have low status, and work with poor-quality data, and this
situation must be changed if planning is to improve.
Basic Skills Training and Continuing Skill Development
Whereas the quality of basic training of health professionals
varies widely in LMICs, the provision of continuing education
and development is almost universally inadequate. Hence, skill
levels of staff members fall over time. Evidence indicates that
good-quality continuing professional development is a positive
incentive and helps to retain staff members. Requirements to
undertake continuing education can be made a condition of
continued professional registration and can thereby provide
some guarantee of competence.
Good basic education includes development of both profes-
sional skills and learning skills. Basic training and continuing
development should be planned together. In many cases, the
large investment in basic training is lost because of lack of
maintenance, so that shifting some resources to updating and
renewing skills is efficient.
A further challenge is to align the content of training to the
skills professionals need. Many training programs in LMICs
provide skills oriented toward service needs in developed
countries, although there have been attempts to change this
balance. For example, more than 25 percent of Malawi’s
curriculum for medical students focuses on community health.
Given that any training program can cover only a portion of rel-
evant knowledge, focusing on locally relevant topics is increas-
ingly important. Educational reforms in many medical schools
in Africa and elsewhere are based on the community-based
educational model (Jinadu, Olofeitime, and Oribador 2002).
Numbers and Types of Health Professionals
Categories of workers result from combinations of previous
and current needs, national traditions, interest group pressures,
and historical accidents. Doctors, nurses, and some paramed-
ical professions have wide international recognition but vary
in definition. Professional traditions and professional bodies
bring some safeguards for quality and safety, and at best,
professionals champion the needs of patients. Membership of
a recognized profession can bring desirable independence from
management. However, internationally recognized qualifica-
tions make it easy for professionals to migrate to countries
offering higher incomes and better careers.
Most developing countries have new categories of staff that
do not match internationally recognized professions (Buchan
and Dal Poz 2003). Examples include nurses with extended
training and roles and people working at subnurse levels with
training of a few weeks to three years. Bangladesh has family
welfare visitors, health assistants, and medical assistants who
might elsewhere be classified as nurses or auxiliary nurses; in
Uganda, clinical officers have three years of training and work
as subdoctors; and nursing aids in Uganda have three months
of training. Training is for specific roles without the generic
training in conventional professions. Typically, such employees
are mobile nationally, but they do not transfer easily across
countries.
In the labor market model, employers want to employ staff
members if their contribution to service provision is of greater
value than the cost of their employment. Because those with
portable qualifications can work in other countries, salary lev-
els needed to retain workers reflect that possibility. Theory sug-
gests that staff members will develop new skills if such an
investment of their time and money produces significantly
increased salary or benefits. Many countries cannot fulfill their
requirements for health workers, but normally this difficulty
reflects salaries that are too low to attract staff. However, rais-
ing salaries may make employment of the full complement of
staff members unaffordable.
Staffing norms serve little useful role if the salaries needed
to fill the posts are unaffordable. Decisions about how many
people should be employed and in what capacities should be
based on the contributions those employees will make and the
costs of employing them. Staffing norms can be useful for
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planning, but they require careful analysis of affordability of
care, the skills needed, and the way to provide those skills most
efficiently. Several countries have of necessity turned to new
models of provision using staff skilled in the delivery of key
elements of high-priority services, such as immunization and
emergency obstetric care.
Safety and Effectiveness of New Health Professions
Research on the new professions is limited, and much of the
material is anecdotal (Buchan and Dal Poz 2003). A growing
literature from developed countries indicates that nurses can be
safe and effective in place of doctors in primary care (Venning
and others 2000). The fear is that the absence of a formal pro-
fession and the lack of internationally recognized training
could damage quality and safety. This issue is important, but
even if new professionals are less safe than doctors, they may be
much safer than the absence of a service such as emergency
obstetric care. In some countries, new professions play a major
part in the provision of services. A good example is Malawi,
where clinical officers with extensive training (but much less
than that of doctors) are a major resource, carrying out surgi-
cal procedures and administering anesthetics as well as provid-
ing medical care. In some countries, regulations govern such
extended roles (McAuliffe and Henry 1995).
Fenton, Whitty, and Reynolds’s (2003) study of emergency
cesarean sections carried out by clinical officers in Malawi
found that the overall maternal death rate was 1.3 percent,
which is high, but much lower than if services had not existed.
Perinatal deaths were 13.6 percent. None of the anesthetists was
medically qualified, but outcomes were better when these prac-
titioners had received anesthetics training (maternal deaths
were 0.9 percent compared with 2.4 percent). The researchers
found no significant difference in outcome between medically
qualified surgeons and those trained as clinical officers. Care
should be taken in interpreting the results of one study, but it
does suggest that well-trained clinical officers can safely substi-
tute for doctors in providing some important procedures.
Human Resource Policy and New Staff Groups
New staff groups are increasingly providing essential services in
LMICs. In Zimbabwe, a new cadre called primary health care
nurses, whose qualifications are lower than general nurses,
was introduced in 2003 to curb external migration by nurses
(Chimbari 2003). At the system level, such a development
requires regulation and standard setting; at the service provision
level, appropriate supervision and management is needed; and
at the individual level, incentives and training need to be con-
sidered. Employing fully qualified doctors and nurses might be
the safest option, but failing to provide services because of
staffing constraints is unlikely to be the next best option.
HEALTH WORKER INCENTIVES
The World Health Report 2000 defines incentives for health
workers as “all the rewards and punishments that providers face
as a consequence of the organizations in which they work, the
institutions under which they operate, and the specific inter-
ventions they provide” (WHO 2000, p. 61). Health workers face
a hierarchy of incentives or disincentives generated by the work
they do, the way they are paid, and the organizational and sys-
tem context in which they work. Incentives are generally
designed to accomplish the following:
• to encourage providers to furnish specific services
• to encourage cost containment 
• to support staff recruitment and retention
• to enhance the productivity and quality of services
• to allow for effective management.
Responses of providers to incentives depend on context and
on the stage of their career. Incentives that induce productivity
vary with experience, stage in a career path, and changes in
providers’ social responsibilities. Ideally, incentive structures
should recognize the evolutionary nature of work expectations.
Typically, incentives vary by type of employer: nongovern-
mental organization, public, or private. Public sector incentives
tend to be the weakest because resource constraints and
bureaucratic rules on civil servant employment constrain the
use of both financial and nonfinancial incentives.
Typology of Incentives
Extrinsic incentives can be individual and organizational, mon-
etary and nonmonetary (table 71.3). Discussions of provider
behavior in LMICs have focused mainly on financial incentives,
partly because of their low income levels compared with indus-
trial countries. The challenge is to establish an optimal mix of
financial and nonfinancial incentives that generate the desired
behavior of health workers.
Experience from vertical programs for priority diseases or
services—for example, poliomyelitis, malaria, family planning,
and sexually transmitted diseases—provide evidence about dif-
ferent incentives. Programs often offered staff members better
pay and incentive packages than those other public health
workers received (Beith and others 2001). The exact effects of
stronger incentives are unknown, but these programs generally
succeeded, as evidenced by the eradication of leprosy, the near
eradication of poliomyelitis in many countries, and the large
drop in average fertility in developing countries in the 1990s.
Successful vertical programs used combinations of incen-
tives, including better salaries, field and transportation
allowances, streamlined management, specialized training,
better facilities and material resources, and results-oriented
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management to support improved health worker productivity
and program performance. Goals were clearly specified, were
understood and shared by the staff, and were often linked to
incentives. The choice of vertical structures also reflects the
perceived difficulties of using existing health systems, with
their excessive bureaucracy, underfunding, and lack of capacity
to implement integrated disease control.
Vertical programs must eventually be reintegrated into the
system. The HIV/AIDS pandemic is a good example of a dis-
ease that might require targeted interventions until the capacity
of health systems in LMICs improves to a level that allows the
disease to be managed like other diseases. The success in inte-
grating vertical programs depends on the parallel development
of health system capacity, which depends in part on the align-
ment of health workers’ objectives with policy and with system
goals.
Aligning health worker and system objectives is difficult.
The aim is to have satisfied health workers who are motivated
to work harder (Hicks and Adams 2001). Evidence is limited,
but financial and nonfinancial incentives are mutually rein-
forcing, and changing the culture of the health system to make
goals more readily understood and shared can make financial
incentives more powerful. Such change in the organization of
health care can be politically sensitive because it can give health
sector workers advantages over other public employees.
Incentives may have conflicting effects. For example, decen-
tralization might create the autonomy needed for effective
management, but without transparent management and career
structures and job security, providers might view such a change
as a threat (Kyaddondo and White 2003). Getting the balance
right requires understanding the socioeconomic and political
circumstances and may be helped by using participatory
approaches to policy making and implementation.
Context
Context is defined here from an individual or an organizational
provider’s perspective. It constitutes what Adams and Hicks
(2000) refer to as external incentives—that is, methods used by
health systems to control the activities of health organizations
or funders.
The power of incentives depends on context. Health systems
in developing countries have varying cultural and economic
histories that shape providers’ expectations and responses to
incentives. Financial incentives are strong when health workers’
incomes are low, as in most developing countries. Nevertheless,
examples of strong nonfinancial incentives exist in countries
such as Thailand, where family ties and kinship affect health
workers’ decisions on where to work. Such nonfinancial incen-
tives affect the size of the financial incentives needed to change
where people choose to work.
History and experience determine a country’s working cul-
ture and norms. In developing countries, most health systems
are large bureaucracies whose management is driven centrally
by guidelines, standards, and reporting systems. Incentives
in such systems work against innovation, risk taking, and
improved efficiency. A possible approach is to introduce
changes that are based on the ideas of so-called new public
management. New public management replaces line manage-
ment with contracts or agreements between funders and policy
makers on the one hand and providers on the other. Providers
are given more managerial autonomy and are controlled by
means of contracts and regulation. This approach can more
easily embody new financial incentives, and autonomous
providers can develop cultures that are more innovating. Such
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Table 71.3 Typology of Incentives
Individual Organizational Environmental
incentives incentives incentives
Financial
Salary
Pensions
Illness, health, accident,
and life insurance
Travel and transport
allowances
Child care allowance
Rural location allowance
Heat allowance 
Retention and professional
allowances 
Subsidized meals,
clothing, and
accommodation
Nonfinancial
Vacation days
Flexible working hours
Access to training and
education
Sabbatical and study leave
Planned career breaks
Occupational health
Functional and 
professional autonomy
Technical support and
feedback systems
Transparent reward
systems
Valued by the organization
Internal 
Autonomy
Accountability
Market exposure
Financial responsibility
External
Governance
Public finance policy
Regulatory mechanisms
Amenities
Transportation
Job for spouse
School for children
Source: Adapted from Zurn 2003.
Note: These are mostly extrinsic incentives.
a radical change in managerial context can, in principle, make
other incentives easier to use.
Other dimensions of context are the regulatory framework
and its enforcement. Most developing countries have regula-
tions governing the activities of the health sector. These regula-
tions tend to be outdated or poorly enforced (Bloom, Han,
and Li 2001). The main reason for regulatory ineffectiveness is
low institutional capacity and widespread corruption. The
symptoms of regulatory failure are widespread informal activi-
ties, dual practice, malpractice and medical negligence, and the
presence of unqualified drug sellers (for example, in Bangladesh
and Tanzania) and practitioners (as in India) (Bhat 1996;
Killingsworth and others 1999; McPake and others 1999).
Where the regulatory system is dysfunctional, providers tend to
pursue their individual interests, often in private practice, to the
detriment of organizational and system performance. Effective
incentive systems that are based on performance require regula-
tion and governance structures that minimize the common
problems of patronage and corruption (Rasheed 1995).
Health system organization factors include governance and
the degree of decentralization. Links exist between working
culture and norms and the structural aspects of health system
organization. The locus of control and decision making play an
important part in health worker behavior. In theory, designing
incentive schemes that are responsive to health workers’
needs is much easier in a decentralized system. This theory is
based on the belief that subnational units are better placed to
make effective decisions on funding, regulating, and organizing
frontline activities than are centralized units. However, experi-
ence in developing countries shows that lack of capacity at
subnational levels has constrained decentralization, sometimes
leading to unintended effects such as wrong priorities (Bloom,
Han, and Li 2001). Any move toward decentralization requires
investment in new management skills and capacities.
Incentives in Practice
Many countries have attempted to reform their economies and
health sectors to improve general economic and health system
performance. For example, Cambodia, the Arab Republic of
Egypt, Uganda, and Zambia have attempted civil service reforms
(Corkery 2000). These reforms include attempts to reduce the
size of the civil service to lower costs and to improve productiv-
ity using incentives such as formal employment contracts and
performance-based pay and promotion. Such reforms have been
largely unsuccessful in developing countries because of the polit-
ical difficulties in reducing the size of the civil service. Structural
and organizational changes are typically unpopular with labor
unions, especially if union members perceive them as threaten-
ing their well-being. Experience also underscores the difficulties
of aligning system and organizational objectives with individual
providers’ objectives (Martineau and Buchan 2000).
The effect of incentives can be assessed in terms of their
objectives (Adams and Hicks 2000). Table 71.4 summarizes
incentive packages used in selected countries. The results shown
should be interpreted with caution, because of problems of
attribution and poor data. Adams and Hicks (2000) argue that
economic incentives in payment mechanisms for physicians
conform to economic logic, but little is known about the
response of other categories of health workers to such incentives.
Experience in Thailand illustrates the labor market model
outlined earlier. In general, public doctors prefer to practice in
urban areas, where conditions are usually more attractive and
opportunities for private practice are better. Thailand pays pub-
lic doctors who work in rural and remote areas significantly
more than those working in urban areas, and this incentive has
persuaded some to move (Wibulpolprasert and Pengpaiboon
2003). The government also added nonfinancial incentives, such
as changing physicians’ employment status from civil servants to
contracted public employees, providing housing, and intro-
ducing a system of peer review and recognition. These initiatives
were coupled with significant environmental changes, including
sustained rural development. In most developing countries,
providers in rural areas are paid less than those in cities, and it is
hard to recruit and retain health workers in rural areas.
China provides another example of how changes in the
environment—for example, the introduction of pro-market
policies—can change provider behavior, in this case from rely-
ing on government salaries alone to the use of “red packages”
(Bloom, Han, and Li 2001). These red packages were gifts that
were traditionally exchanged as an expression of mutual
appreciation, but they have now evolved into informal cash
payments from patients to health workers.
Health systems have a spectrum of workers with different
skills and expectations, and incentives for one group can have
negative effects on others (Adams and Hicks 2000). Policy
makers must strike a balance between competing interests of
professional groups and system goals. The unionization of
labor and the growth of professional associations or councils
can give health workers considerable bargaining power.
Solving one problem can create others. This situation often
occurs when governments respond to the grievances of the
most vocal professional groups, usually doctors, and neglect
other groups. This piecemeal approach has caused HR crises,
such as strikes and go-slows. Although health workers are nor-
mally somewhat motivated to pursue health policy goals, their
own interests can conflict with those goals. Providing higher
salaries to health workers, by increasing costs, can reduce access
to services by some social groups (Bloom, Han, and Li 2001).
Compensation
Provider payment systems transfer resources from payers (gov-
ernments, insurers, and patients) to providers (Maceira 1998)
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Table 71.4 Incentive Packages for Health Workers, Selected Countries
Complementary
Objectives Incentives measures Constraints Results
Recruiting and retaining staff
in the country
Recruiting and retaining staff
in rural areas
Pay competitive salaries
Include seniority awards in
pay scales 
Allow after-hours private
practice in public institutions
Tolerate informal payments
Provide higher salaries or
location allowances
(Wibulpolprasert and
Pengpaiboon 2003)
Base remuneration on
workload
Require service in defined
areas as condition of licens-
ing or specialty training
Provide opportunities for
government-sponsored
further education
Provide housing and good-
quality educational opportu-
nities for health workers’
families
Recruit trainees from rural
areas
Fiscal policies that increase
the after-tax marginal value
of salaries
Service standards and con-
trols to prevent reduced work
effort in the public system
Not applicable 
Decentralized administration
Freedom to allocate institu-
tional revenues or savings
from operational efficiency
to fund incentives
Improved infrastructure and
staff competence
Consistent application of
policies on transfers and
tenure
Adequate salary
Emphasis on public health
and family practice in
training curricula
Budget limitations
Low public service salaries
Policies to reduce salaries as
a share of operating costs
Work effort that may be con-
centrated in private practice,
leading to a deterioration of
quality in public practice
Informal charges that limit
access and may impede
reforms that involve formal
user fees and exemptions
Overall staff shortages
Budget limitations
Professional and lifestyle
disadvantages
Smaller potential for earn-
ings from private practice
than in urban areas
Conflicting financial incen-
tives (for example, loss of
housing allowance in
Bangladesh)
Risks posed by internal
conflicts and civil wars
(for example, Colombia
and Uganda) 
Loss of confidence if health
workers perceive the selec-
tion process as arbitrary
Providers’ concerns that a
temporary posting may
become indefinite 
Budget limitations
Traditionally, overrepresenta-
tion of urban area students
in student populations
Helped retain physicians in
Bahrain
Considered successful
in Bahrain 
In some countries, resulted
in deterioration of public
systems where providers
also engage in independent
private practice (McPake
and others 1999)
Resulted in widespread use
of informal payments in
Eastern and Central Europe,
Sub-Saharan Africa, and
some East Asian and Pacific
countries (Balabanova and
McKee 2003; Chakraborty
and others 2002; Thompson
and Witter 2000) 
Premium payments for
working in rural areas found
successful in Thailand 
(Wibulpolprasert and 
Pengpaiboon 2003)
Aided retention of profes-
sionals in Ghana and
Zimbabwe
(Chimbari 2003)
Found successful for nurses
but not doctors in Nepal
Found successful in Thailand 
and can be structured to provide financial incentives. Most
studies focus on payment mechanisms for doctors and their
effect on productivity, costs, and quality of services (Bitran and
Yip 1998). Table 71.5 summarizes common payment mecha-
nisms and the desired incentives. The evidence shows that the
operation of payment mechanisms is sensitive to the payment
structure and how it is implemented (Berman and others 1997;
Bitran and Yip 1998; Chomitz and others 1998).
Payment systems are more successful when built on existing
traditions and culture (that is, when they take into account gift
systems or, indeed, levels of corruption). It is normally best to
use a combination of payment methods. For instance, if there
is a shortage of public providers, they might be paid a basic
salary for normal working hours and fees for service for after-
hours work. This method creates incentives for providers to do
extra work and increase throughput, but providers may divert
patients to after-hours services, and the method’s feasibility
depends in part on monitoring and governance standards.
The challenge is to find payment combinations that motivate
providers to provide desired volume and quality of services
while containing costs.
Empirical Evidence on Payment Methods
Evidence of provider payment systems that have successfully
aligned system and provider incentives is still limited (Bitran
and Yip 1998). Interesting findings come from small-scale
experiments such as Cambodia’s New Deal (box 71.1). Health
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Enhancing the quality and
availability of primary care
Encouraging teaching and
research and reducing the
internal brain drain
Improving the quality of care
Provide training and promo-
tion opportunities for nurses
and medical auxiliaries
Train multifunctional health
workers
Mobilize women volunteers
from communities, traditional
birth assistants, and local
leaders
Pay health workers more if
they do not practice privately
Specify clinical guidelines in
provider contracts
License institutions and
professionals based on
defined standards
Pass laws requiring the
registration of drugs and
other potentially dangerous
substances 
Clear job descriptions and
criteria for promotion
None
Leadership role by profes-
sional organizations
Inclusion in the curricula of
medical schools 
Tradition of professional 
self-regulation
Acceptance of civil and legal
authority
Opposition by professional
associations to expanded
roles for multifunction health
workers in Nepal
Limited training capacity in
Uganda
Allowances perhaps uncom-
petitive with private practice
earnings
Vested interests of profes-
sional associations
Weak peer review systems
Low consumerism and weak
advocacy
Regulatory capture and a
culture of self-protection
Low capacity to enforce laws
and regulations
Resulted in successful
retraining of health
assistants and other health
workers in rural areas in
Nepal to make them eligible
for promotion
Resulted in regrading of
state-certified nurses to
state-registered nurses in
Zimbabwe (Chimbari 2003;
Pannarunothai, Boonpadung,
and Kittidilokkul 2001)
In Nepal, found successful in
basic medical sciences but
resulted in massive resigna-
tions in clinical departments
Uncommon incentive,
although a few countries (for
example, Thailand) do pay
professional allowances or
nonpractice allowances 
Uncommon in developing
countries
Some success recorded in
Cambodia’s contracting
experiment 
Reduced number of hospitals
and unqualified doctors in
Estonia
Resulted in limited success
according to evidence from
most developing countries
(Bhat 1996) 
Table 71.4 Continued
Complementary
Objectives Incentives measures Constraints Results
Source: Adapted from Adams and Hicks 2000. 
workers’ salaries were considered by many to be below the min-
imum required for a decent life, and workload is increasing
because of HIV/AIDS.
The Cambodian experiment attempted to align individual
health workers’ and system goals through performance-based
bonus payments and a set of internal regulations. Regulations
can alter the working and organizational culture in a way that
allows individual-based incentives to work. There were prob-
lems in enforcing penalties for violating regulations. Failure to
enforce regulations may lead providers to lose confidence in the
system. Countries with limited administrative and institutional
capacity should use simple payment mechanisms that are
enforceable within their capacity constraints (Barnum, Kutzin,
and Saxexian 1995). A lesson from the experiment is that the
context matters, and any strategy for offering incentives to
workers must be embedded in traditions and cultural practices.
In a competitive environment, contracts are a useful tool for
aligning health workers’ behavior with organizational and sys-
tem objectives. In the Cambodian example, contracts between
the purchaser and district-level facilities—and between district-
level facilities and management committees—were an attempt
to establish accountability structures that specify targeted activ-
ities. More interesting was the attempt to transfer some man-
agement risk and responsibilities to individual health workers
using subcontracts that permitted management committees to
monitor their activities and pay them accordingly, though
whether the contracts were well specified is not clear, and the
administrative and transaction costs are unknown. The use of
contracts requires management and monitoring capacity.
Introducing financial incentives for health workers is costly.
Policy makers in governments and development partners need
to ensure that adequate funding is available and sustainable.
Resources are also needed to improve working environments
and system capacities. Both financial incentives and other
incentives are important, but services are likely to improve only
if financial incentives are strengthened.
Group Incentives
Health workers typically work in teams. This system weakens
financial incentives because the efforts of individuals may have
little influence on overall performance. Indeed, individual
incentives can worsen team cooperation. For example, if pro-
motion is competitive and depends on measures of individual
productivity, this approach can be a disadvantage for those who
work for system goals in cooperative ways.
Designing effective group incentives is difficult. Paying
group bonuses for achieving a given level of output can work
only if individual team members feel adequately rewarded for
their efforts and if there is no perceived free-rider problem.
Most of the limited evidence on group incentives is for
developed countries and shows that much depends on the
production process and the organization of the teams (Ratto,
Propper, and Burgess 2002). Group financial incentives tend to
be weak, and using other approaches such as team building,
better sharing of information, and improved working condi-
tions is probably better.
Influence of System Capacities and Sustainability 
Issues on Incentives
The theoretical merits and demerits of different incentives are
well understood, but system capacities and financial con-
straints may limit their applicability. Few developing countries
have health systems that are capable of effectively implement-
ing and operating some of the payment systems shown in
table 71.5. The overall funding for the health sector may be
too low to pay providers more. Also, the skills and expertise
needed to design and implement contract- and case-based pay-
ment methods may be inadequate, and the country may lack
the information technology needed to capture relevant data to
support such contract- or case-based payment methods. Most
health workers in developing countries are civil servants, and
the particular needs of health workers may be lost in a general
public service. Some countries are considering delinking
health workers from public service commissions and setting up
independent health commissions to run the health sector. In
Zambia, however, delinking failed because of a lack of capacity
at both the national and the local levels to implement the nec-
essary HR changes (Martineau and Buchan 2000). Evidence
from Trinidad and Tobago suggests that insufficient govern-
ment commitment impeded the transfer of staff members
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Table 71.5 Major Payment Mechanisms
Payment mechanism Key incentives for providers
Fees for service Increase the number of cases seen
Increase service intensity
Provide more expensive services
Case payment (for example, Increase the number of cases seen
diagnosis-related groups) Decrease service intensity
Provide less expensive services
Daily charge Increase the number of bed days
through longer stays or more cases
Flat rate (bonus payment) Provide specific bonus services and
neglect other services
Capitation Attract more patients to register 
while minimizing the number of
contacts with each and minimizing
service intensity
Salary Reduce the number of patients and
the number of services provided
Global budget Reduce the number of patients and
the number of services provided
Source: Bennett, McPake, and Mills 1997.
from the public service, leading to disillusionment among
workers and effective opposition from unions (England 2000).
In countries with thriving private sectors, devising strong
incentives for public sector workers is difficult. For instance, in
Uganda, the private not-for-profit sector used to have better
working conditions and pay than the public sector and conse-
quently had better staffing levels. The government had to
increase public sector salaries significantly in the 1990s to
attract health workers back. The use of fees for service in the
private sector when public health workers are paid a salary is
likely to encourage private practice among public workers.
Thus, the effects of methods and levels of payments are influ-
enced by what is happening in the private sector.
Optimal Combination of Health Worker Compensation 
and Incentives
Although the optimal mix of provider compensation depends
on context and policy objectives, some general policy guidelines
on the design of payment methods to achieve organizational
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Cambodia’s New Deal Experiment: The First Year
Box 71.1
The New Deal experiment in Sotnikum district, Siem
Reap province, was launched in 2000 by the Ministry of
Health, Médicins Sans Frontiéres, and the United Nations
Children’s Fund. It is an example of a concerted attempt to
break the vicious circle of underpayment of health staff
members and underuse of public health services by tack-
ling the problem of low official income. The New Deal was
developed following wide consultations and consensus
building, and locally credible management structures were
established to monitor and enforce the new framework.
Staff motivation was a major problem among health
workers, as manifested by high levels of absenteeism from
work, low time input at work (an average of one to two
hours a day), and poor quality of services. Informal
charges, drug thefts, and dual practice by public health
workers were common, largely because of their low public
salaries: government staff received US$10 to US$12 per
month, compared with a minimum of US$100 required
for a basic standard of living. At the same time, because of
informal charges and extensive use of unregulated private
services, households spent more than US$30 per inhabi-
tant per year on health services, equivalent to 11 percent of
total household expenditure.
The New Deal was seen as a vehicle for improving
services by enhancing personal income, and its overall
objectives were (a) to improve access to quality health
care, (b) to build up the health system, and (c) to act as a
catalyst for changes in national health policy. The princi-
ple underlying the improvements in the personal income
of public health workers was that they would better com-
ply with internal regulations governing (a) job descrip-
tions and working hours; (b) payment of informal fees;
(c) misappropriation of drugs, materials, and funds; and
(d) diversion of patients to private practice.
The district (referral) hospital, health centers, and
operational office were each managed by an elected man-
agement committee, and individual contracts were signed
between staff members and management committees. The
contracts stipulated that a bonus would be paid in
exchange for strict adherence to internal regulations. The
benchmark bonus level was set at an average of US$60 to
US$90 per person per month. The management commit-
tee was responsible for enforcing the new framework of
accountability. Official fees were also introduced on the
assumption that the population would agree to pay for
better public service.
The district got its funding from government appropri-
ations, user fees, and external subsidies from various
sources; however, given the overall lack of funding avail-
able for the scheme, Médicins Sans Frontiéres and the
United Nations Children’s Fund had to provide an initial
injection of funds to support the bonus system.
At the hospital level, individuals signed contracts with
the management committees, and compliance with inter-
nal regulations improved. The staff was generally present,
fees were transparent, emergencies were attended at night,
patients received drugs, and informal payments were not
demanded. Use of health services increased significantly
after the arrangement had been introduced. The number
of documented violations was limited, though problems
were encountered in sanctioning penalties. Staff members
started receiving bonuses that gradually grew beyond the
negotiated maximum, creating a hospital debt crisis by
midyear, compounded by understaffing and underem-
ployment problems, which meant that most staff mem-
bers worked overtime. Nevertheless, the quality of services
improved significantly, and per capita family expenditures
on health fell 40 percent.
Source: Soeters and Griffiths 2003.
and system goals are available. Linking compensation to per-
formance makes intuitive sense, but care is needed in working
out the details. Health workers respond to both financial and
nonfinancial incentives, but the extent of the effect varies, and
the two can interact.
For new payment systems to work well, health workers
must be governed by effective managerial authority. Because
new payment systems aim to encourage particular behaviors
and hold providers accountable, clear responsibility must be
delineated within provider organizations. This delineation
may be easier to achieve if the management of providers has
some autonomy. Evidence from developing countries that
have attempted to introduce managerial autonomy and corpo-
ratization of health service institutions, such as public hospi-
tals and medical stores, indicates that delinking health workers
from government control is politically sensitive. Nevertheless,
such organizational or system changes are desirable if new
payment methods are to create the right incentives and
achieve the desired changes.
Part of the context for incentive systems is what type of dis-
ease control activities are best provided through markets or
hierarchies. Traditionally, the public sector has been domi-
nant. The economic arguments for government involvement
are well understood, but delivery of services within the frame-
work of government policy objectives can be by private (both
for-profit and not-for-profit) providers. Thus, the private sec-
tor is increasingly involved in the social marketing of condoms
and bednets, franchising, and contracting (Bennett, McPake,
and Mills 1997).
From an economic viewpoint the only issues are the cost,
quality, and sustainability of such arrangements. Emerging
evidence on private sector involvement in health services sug-
gests that the private sector is willing to participate in non-
clinical disease control activities if the incentive structure is
right. Private not-for-profit providers, such as hospitals and
clinics associated with churches, have traditionally comple-
mented government health care activities, especially in poor
and peripheral populations (Gilson and others 1997). In
recent years, Bangladesh has experimented with contracting
nongovernmental organizations to provide primary care serv-
ices in urban areas. Lessons from this experience are still
emerging and indicate that, despite many early mistakes,
this form of provision can be innovative and can help make
a break from bureaucratic traditions. Such contracting
depends on having contracting skills in both parties to the
contract. A good understanding of context and incentives is
also crucial.
In summary, incentive or payment packages should attempt
to link payment with individual or group performance and
should be assisted by supportive organizational and system
changes if the desired provider behavior is to be achieved. No
single best combination of payment methods exists.
ADVICE FOR GOVERNMENTS
Governments in developing countries face huge challenges in
strengthening their health systems, especially their HR capacity,
if cost-effective disease control interventions are to achieve
their desired results. Strengthening their systems will entail
developing self-sustaining systems for the supply, use, and
retention of health workers. The following considerations are
important in relation to putting effective policies and incentive
structures in place:
• Countries should explicitly link the planned number of each
category of staff members to health policy goals and set pri-
orities, taking overall resources into account when planning
HR needs.
• Countries should recognize that the salaries necessary to
recruit and retain staff members will depend on the oppor-
tunities such workers have for other employment within the
country and abroad, and planned numbers in each category
should be based on this reality.
• Countries should understand both that qualifications that
are recognized internationally are likely to attract higher
salaries and that such qualifications may only be partially
suited to the needs of essential health services in LMICs.
They should focus on developing the most important skills
by training new types of health workers, taking into account
evidence that use of such health workers can be safe when
properly trained. Many countries will be unable to prevent
the loss of professionals with portable qualifications, because
salaries offered will be far below those available elsewhere.
• Countries’ training policies should take into account the
decline in skills over time and the need to allocate scarce
resources between basic training and continuing staff
development.
• Countries should adapt and not imitate compensation and
incentive structures, given the evidence that effective incen-
tive structures depend on local conditions and traditions as
well as on universal principles.
• Policy makers should remember that the availability and
cost of suitably qualified human resources will affect feasi-
bility and cost-effectiveness of disease control interventions.
• When developing vertical disease control programs, program
managers must avoid introducing powerful incentives that
damage existing services by drawing away key personnel.
• Policy makers should identify potentially harmful, unin-
tended consequences when designing regulation and incen-
tive systems. For example, if doctors are allowed to practice
in both public and private services, the effects of private
practice on incentives in public practice tend to be negative
unless carefully monitored.
• Countries should recognize that the use of incentives to
improve performance normally requires good regulatory
frameworks and skilled managerial resources.
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RESEARCH AND DEVELOPMENT AGENDA
New staff categories are emerging in many LMICs, and these
workers are an important part of the workforce. Such staff cat-
egories are likely to increase, given migration and the high cost
of employing people with portable qualifications, but little
research is available on the appropriateness and safety of the
new sets of skills, and little is known about the range of new
professions, the content of and approach to training, the extent
of professional supervision, and the outcomes of treatment.
Sharing experience of such staff categories would be valuable.
Priorities, therefore, include a study to map the different new
staff groups in health systems in LMICs and to classify their
tasks, roles, and training, and studies to compare the outcomes
of conventional and new staff groups.
In addition to gaining a better understanding of the pat-
terns, roles, and performance of new staff groups, data are
needed on the length of time such workers remain in their
posts, the extent to which their new qualifications are portable,
and their migration patterns. Information is also lacking on
how best to provide professional supervision for these new staff
groups and how to encourage such employees to be profes-
sional in their work.
Limited evidence is available on the relationship of different
health care compensation methods to individual and organiza-
tional behavior in developing countries. The following are pos-
sible research areas (and some practical steps) that might help
fill information gaps and further understanding of the role of
health worker compensation and incentives in disease control
in developing countries:
• Databases. A useful step would be to set up HR databases
for developing countries as the Pan American Health
Organization has done for its region.
• Literature review. A review of unpublished materials on
countries’ experiences with using different payment and
compensation mechanisms at national or subnational levels
would also be useful. Failed experiments are seldom pub-
lished, but they provide useful lessons.
• HR supply. Traditional HR planning models are no longer
effective in handling health system dynamics in developing
countries. More research is required to develop HR models
in health that include the effects of HIV/AIDS, migration,
scaling-up of existing interventions, new technology, and
reforms. The underlying question should be how HR supply
mechanisms can meet health systems’ needs in terms of
numbers, knowledge, skills mix, and competencies.
• Demand and utilization. Getting the size of the health
workforce right is important in its own right, but that
alone is insufficient for improving health workers’ motiva-
tion and productivity. Research needs to focus on how to
improve the motivation and performance of health workers
in resource-constrained environments and on what is
needed to retain professionals in such settings. We know
little about how health care workers make decisions about a
range of incentives and disincentives generated by organiza-
tions and the systems in which they work. For example, what
does it take to convince doctors and nurses to work in rural
and remote parts of a country? To what extent are financial
and nonfinancial incentives important in attracting people
into training as health workers, deploying them to needy
areas, motivating them, and retaining them in the system?
To a significant extent, current problems in improving
access to care, in widening the range of effective services that
are provided, and in improving the quality of care depend on
better matches of skills to needs, better motivation of staff, and
clearer understanding of how improved structures and incen-
tives will work. Perhaps as important is that much of the debate
focuses on developments within traditional patterns of staffing
of services, but new patterns are increasingly emerging, and the
extent of evaluative research is inadequate for drawing strong
conclusions on how such developments can alleviate the con-
straints facing health systems. The development of incentive
systems should be coupled with the development of organiza-
tional and institutional capacity that supports sustainable HR
development in general.
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In 1988, the World Health Organization (WHO) reported that
30 percent of the world’s population, some 1.725 billion people,
lacked regular access to essential medicines. By 1999, the 15 per-
cent of the population who lived in high-income countries pur-
chased and consumed 90 percent of all medicines, by value
(WHO 2004f).Again as of 1999, a recent WHO report estimates
that 30 percent of the world’s population, including 47 percent
of Africans, 65 percent of people in India, 29 percent of people
in the Eastern Mediterranean, and 26 percent of Southeast
Asians (excluding those from India), had no access to essential
medicines (WHO 2004f). So although access has significantly
improved in a number of countries, a large fraction of the
world’s population still has no effective access to modern medi-
cines or vaccines. The majority of these people are either
extremely poor or are living in remote rural areas where the sup-
ply of drugs is limited or nonexistent—or both.
Many diseases can be effectively treated, managed, or pre-
vented with pharmaceuticals and vaccines. The WHO figure of
30 percent of the world’s population lacking access understates
the reality; even within countries with apparently good serv-
ices, some populations lack access. Similarly, immunization
coverage globally has remained static for more than a decade at
about 75 percent of children fully immunized, with about
27 million children born every year with no access to immu-
nization services. Some effective vaccines, such as hepatitis B
(HepB), are still not in routine use in many countries.
Medicines and vaccines are developed as a result of innova-
tion by researchers and pharmaceutical companies. The global
pharmaceutical market was worth more than US$400 billion
in 2004, and more than 80 percent of this market is in North
America, Europe, and Japan. Lipitor (atorvastatin), a
cholesterol-reducing drug and the world’s best-selling drug in
2002, had sales of US$8.6 billion, and growth was 20 percent
annually. Zocor (simvastatin), another cholesterol reducer and
the second-best seller, had sales of US$6.2 billion and was grow-
ing at 13 percent (IMS Global Learning Consortium 2003).
These figures contrast with the dearth of research on neglected
diseases prevalent in developing countries. For example, of the
1,325 new medicines launched between 1975 and 1997, only 11
were specifically for tropical diseases (Trouiller and others
2002). Médecins Sans Frontières (MSF) in 1999 initiated its
advocacy program, Drugs for Neglected Diseases, which has
highlighted this gap (http://www.accessmed-msf.org/).
Access to effective medicines and vaccines requires a com-
plex and coordinated system. It must encompass production
that ensures good quality, selection, procurement, and distri-
bution; correct prescription and dispensing and correct use by
patients; adequate financing; and effective monitoring of the
system. Multiple delivery systems involving public, private, and
nongovernmental organization (NGO) sectors frequently
coexist, and patients are very likely to use multiple systems to
access these products.
DRUG POLICIES
In any country, many stakeholders are interested in the national
policy on pharmaceuticals. In broad terms, they can be charac-
terized as producers, importers, distributors, prescribers,
finance providers, and consumers. Each has a different set of
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interests, which in some cases are contradictory and in other
cases congruent. To reconcile these disparate interests, many
countries have developed a national drug policy. Managers of
disease control programs need to be involved in these
discussions at an early stage to prevent policy decisions from
adversely affecting their programs. Any national drug policy
broadly relates to three key objectives: increasing access,
improving and ensuring quality, and ensuring rational pre-
scription and use by providers and patients.
The primary components of a drug policy are selection of
essential medicines; assurance of affordability, which includes
issues of pricing, taxation, generic competition, and policies
related to the Agreement on Trade-Related Aspects of
Intellectual Property Rights (WHO 2001a); financing options;
supply systems; regulation and quality assurance; rational use;
operational research and drug development; clinical research,
including clinical trials; human resource development for
pharmaceutical policy and program management; and moni-
toring and evaluation. WHO has developed manuals and has
provided technical support to countries to develop such
national policies (WHO 2001b, 2003a).
VACCINE POLICIES
Every country has a national vaccine policy, usually laid down
in a national health policy or through the establishment of
well-defined elements of such a policy. WHO defines global
frameworks and produces policy documents to advise develop-
ing countries (WHO 2002b). At the national level these guide-
lines may be adapted to fit national needs and capacities.
Standards and norms for vaccines are also set by WHO and are
generally adhered to worldwide (WHO 2003b).
WHO’s creation of the Expanded Program on Immunization
(EPI) in the 1970s established a policy for selection and use
of vaccines that the vast majority of developing countries
adopted. Only three vaccines—HepB, yellow fever (YF), and
Haemophilus influenzae type B (Hib)—have been added since
then, and the overall program directions remain largely intact.
In recent years, WHO has published a set of policy guide-
lines for vaccines not included in the global recommendations.
These position papers are regularly updated. Three guiding
principles provide the pillars for any national vaccine policy:
• Every eligible child must have equal access to nationally
adopted vaccines regardless of religion, caste, or economic
status.
• Vaccines require active government financial participation
to ensure that they are provided and used in adequate
quantities, thus ensuring the benefit of their considerable
externalities. For example, the benefits to society of an indi-
vidual’s being vaccinated are greater than those to the indi-
vidual, because vaccination prevents transmission. It can
also be argued that the elimination or eradication of a dis-
ease as a public health problem has public good characteris-
tics: the benefits of the absence of disease are available to
everyone, and all persons benefit at the same time.
Therefore, governments must take an active role in ensuring
that adequate vaccines of assured quality are available for
comprehensive immunization programs within the country.
The recent flu vaccine shortage and resulting rationing
problems in the United States have illustrated this principle
clearly.
• Countries should strive toward financial sustainability for
the national immunization program.
A vaccine policy normally has six specific objectives:
• To provide a coordinated approach to national vaccines and
equipment needs, including national vaccine production
where applicable
• To provide criteria for vaccine selection and introduction,
including burden-of-disease studies where relevant
• To develop a financial sustainability plan that ensures avail-
ability of vaccines in the longer term
• To define guidelines for private-public partnerships, includ-
ing vaccine research
• To define national research priorities
• To support the implementation of the national immuniza-
tion programs.
Policy setting is a continuous process that must keep up
with global developments and changing national needs.
Countries will normally formulate policies that are based on
the technical work of a national committee of experts, who
meet regularly under the auspices of the ministry of health.
Bilateral donors and the Global Alliance for Vaccines and
Immunization (GAVI) may influence policy setting, such as the
timing for introduction of new vaccines, where they contribute
significantly to the national immunization programs.
SELECTION OF DRUGS
Selection of a limited list of essential medicines that should
always be available is necessary both for supply officials who
work on procurement, storage, and distribution and for clini-
cians who aim to use medicines most effectively.
In 1977, WHO defined the first Model List of Essential
Drugs (WHO 1977); since then it has updated the list 14 times.
The latest list defines essential medicine as follows:
Essential medicines are those that satisfy the priority health
care needs of the population. They are selected with due regard
to public health relevance, evidence on efficacy and safety, and
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comparative cost effectiveness. Essential medicines are
intended to be available within the context of functioning
health systems at all times in adequate amounts, in the appro-
priate dosage forms, with assured quality and adequate infor-
mation, and at a price the individual and the community can
afford. The implementation of the concept of essential medi-
cines is intended to be flexible and adaptable to many different
situations; exactly which medicines are regarded as essential
remains a national responsibility.
In 2003, the WHO Expert Committee on Selection and Use
of Essential Medicines decided to define the criteria for core
and complementary lists, as follows:
The core list presents a list of minimum medicine needs for a
basic health care system, listing the most efficacious, safe, and
cost-effective medicine for priority conditions. Priority condi-
tions are selected on the basis of current and estimated future
public health relevance, and potential for safe and cost-effective
treatment.
The complementary list presents essential medicines for
priority diseases, for which specialized diagnostic or monitor-
ing facilities, or specialist medical care, or specialist training, or
all three are needed. In case of doubt, medicines may also be
listed as complementary because of their consistently higher
costs or less attractive cost effectiveness in a variety of settings
(WHO 2003d, 28).
At its 2002 meeting, the WHO Expert Committee changed
its attitude toward fixed-dose combinations (FDCs). The com-
mittee stated that most essential medicines should be formu-
lated as single compounds. Fixed dose combination products
are selected only when the combination has a proven advantage
over single compounds administered separately in therapeutic
effect, safety, adherence or in delaying the development of drug
resistance in malaria, tuberculosis and HIV/AIDS (WHO
2002c). This change reflected the interest in preventing the
development of resistance and in promoting adherence.
Although controversial, these FDC products will very likely be
the main form of treatment for AIDS, tuberculosis (TB), and
malaria.
The number of medicines on the WHO list has increased
over time. The 2003 WHO list has 320 drugs in 559 formula-
tions (Laing and others 2003). At country level, the essential
drugs list is used as a guide rather than as a template. A study
of 17 national lists of essential drugs showed that 68 percent
had fewer than 300 drugs. The number of drugs per list ranged
from 108 in Liberia to 389 in Karnataka state, India. Nine of the
drugs on the WHO list were not on any of the 17 national drug
lists in the study (Laing and others 2003).
At the first stage of identifying common diseases and com-
plaints, managers of disease control programs are in a strong
position to provide epidemiological information about the
incidence or prevalence of a condition. At the second stage, the
selection of treatments would ideally have already been under-
taken on the basis of available evidence or clinical trial data
from the country. The medicines identified within these guide-
lines would thus become the medicines on the essential
medicines list. This list would then serve as the basis for pro-
curement, storage, and distribution activities. The evidence-
based treatment guidelines would define treatment practices
and be the basis of training (including examinations and
licensing) and supervision.
SELECTION OF VACCINES 
Developing countries select vaccines used in national immu-
nization programs primarily on the basis of WHO policy
guidelines. Most countries have adhered strictly to the six
original vaccines—Bacillus Calmette-Guérin (BCG), oral
polio, diphtheria, pertussis, tetanus, and measles. On the
recommendation of the WHO Global Advisory Group on
Immunization, HepB vaccine was included in the global
guidelines in 1987, and YF vaccine was added in 1988; Hib
vaccine was added in 1994. These remain the only vaccines
recommended by the WHO for national use, and the recom-
mendation presupposes that a disease burden of public health
importance is present (see table 72.1).
A few vaccines, such as YF and Japanese encephalitis (JE),
have regional importance in accordance with the prevalence of
the disease. These vaccines are used in only a small number of
developing countries. WHO has not generally recommended
JE, although no evidence indicates that the disease burden of
Table 72.1 Current Vaccines Recommended by the World
Health Organization
Age
Vaccine Birth 6 weeks 10 weeks 14 weeks 9 months
BCG X
Oral polio Xa X X X
Diphtheria- X X X
tetanus-
pertussis
Hepatitis Bb X X X
Haemophilus X X X
influenzae type Bb
Yellow fever Xc
Measles Xd
Source: WHO 2002d, 88.
a. In endemic countries.
b. Only a few African countries have been able to introduce the vaccines to date.
c. In countries where yellow fever poses a risk.
d. In addition, a second opportunity to receive a dose of measles vaccine should be provided for
all children.
YF is greater than the JE disease burden. However, a safety issue
exists with mouse brain–derived vaccines such as JE.
Oral polio vaccine (OPV) is the vaccine of choice in devel-
oping countries, because it is easy to administer and the pro-
tective effect spreads to close contacts of vaccinees. It is suitable
for mass campaigns, so the vaccine is used in poliomyelitis
eradication programs. In 2005, the monovalent type 1 OPV, for
which seroconversion rates are substantially higher than for
trivalent OPV, has started to be used in areas where only type 1
wild poliovirus remains in circulation.
The selection of the original EPI vaccines was made on pro-
grammatic criteria rather than on considerations of disease
burden. The need for consistent and standardized regimens
determined the strategies selected by EPI. Adaptations over
time, as new vaccines came along and local needs changed,
were slow, and the uptake of newer vaccines remains a major
constraint in most developing countries, although support
provided through GAVI has improved the situation.
The term vaccine gap is used to describe the phenomenon
whereby children in developing countries receive at most eight
vaccines, if they are reached by immunization programs at all,
whereas children in industrial countries normally receive 10 to
12 antigens, depending on national schedules. Furthermore,
two vaccines in the routine schedule in the affluent world are
less reactogenic than those given in developing countries: acel-
lular pertussis vaccine (aP) and inactivated polio vaccine
(IPV). The combination measles-mumps-rubella (MMR) vac-
cine is normally given twice, offering long-term protection
against measles and rubella, important diseases in the develop-
ing world. The vaccine gap therefore consists mainly of three
vaccines—aP, IPV, and MMR.
The pneumococcal vaccine, which is currently used in some
countries, illustrates an additional aspect of the vaccine gap. Its
composition is directed against the most prevalent strains,
which cause otitis media in children. At the same time, millions
of children die in the developing world from pneumonia
caused by other strains of the bacteria, but no vaccine is cur-
rently available against those strains.
PROCUREMENT OF DRUGS
After the drugs have been selected, the next step is to decide
how much to order. Usually this decision is based in part on
past consumption, but it is also based on treatment guidelines
and morbidity patterns. Concentrating on larger quantities of
fewer drugs and dosage forms simplifies the process of order-
ing and reduces the chances of running out of stock. Ordering
tablets or capsules rather than syrups or injections saves a great
deal of money.
In 1997, when the second edition of Managing Drug Supply
was published (Quick and others 1997), four methods of
procurement were recommended under different circum-
stances. These methods were open tender, restricted tender
with performance monitoring, negotiated procurement, and
direct procurement. At that time, the World Bank was a major
funder, and many countries favored the use of open tender.
However, a major shift has taken place to restricted tender
based on prequalification and direct procurement from non-
profit suppliers. The World Bank has produced a number of
useful documents and resource materials that can be used for
national procurement activities (World Bank 2000).
Another method of procurement that has been more
widely used has been procurement from nonprofit suppliers,
such as the United Nations Children’s Fund (UNICEF) or
the International Dispensary Association (International
Dispensary Association 2004; UNICEF 2004). These organiza-
tions produce price lists twice yearly, and products can be
ordered directly. Management Sciences for Health (2004)
publishes an international drug price indicator guide annually
that reports these prices and other procurement prices.
Interestingly, the trend in drug prices generally has been down-
ward. Prices of some TB drugs fell by more than 90 percent
when procurement managers opened intensive negotiations
with suppliers. And since 2000, prices of many important first-
line antiretroviral drugs have fallen considerably. This trend is
attributable to “advocacy, corporate responsiveness, competi-
tion from generic manufacturers, sustained public pressure,
and the growing political attention paid to the AIDS epidemic.
In addition, originator companies began announcing discount
offers for the benefit of the poorest countries or those where
the HIV/AIDS prevalence is the highest” (WHO 2004d, 5). The
influence of economies of scale, in which unit costs have fallen
because of the increased consumption of needed pharmaceuti-
cals, might also have played a role.
Generic drugs obtained in bulk are almost always 10 or
more times less expensive than brand-name drugs. Bulk pur-
chase of generic drugs is the single best way to make a given
budget go farther to satisfy the drug needs of a population. For
price comparison, international prices (ex-factory, free-
on-board—that is, not including insurance, freight charges, or
taxes) are available online from Management Sciences for
Health (2004). Local prices must, of course, include trans-
portation and freight, as well as any applicable local taxes.
Organizations that procure drugs in bulk but then sell smaller
quantities, usually to nonprofit organizations, can help smaller
purchasers obtain the advantages of competitive tendering.
Examples include the International Dispensary Association,
which is based in the Netherlands, and the Copenhagen office
of UNICEF, which is able to supply drugs at very low cost to
government-supported institutions.
Recent studies have revealed just how much the local
component of drug costs can be, particularly in the private
sector. A survey of costs in nine countries found an average
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markup of 68.6 percent, with retail markups of 16 to 50 percent
comprising the largest single component in most cases. In
countries that charge a value added tax on drugs, the tax can
add 15 to 20 percent to the price of the drug (Levison and Laing
2003). Many of these cost elements are within the control of
national policy makers.
Finally, when considering a change of standard therapy,
managers of disease control programs need to take into
account the long lead time between ordering a particular drug
and having it arrive in the country ready for use—which can be
a year or more. Time will also be required to prepare, print, and
disseminate new guidelines, to train prescribers and dispensers,
and to dispose of drugs used in the older therapy (Williams,
Durrheim, and Shretta 2004).
PROCUREMENT OF VACCINES 
Countries can be grouped into three categories according to
the way they procure vaccines: procurement through United
Nations (UN) agencies, direct procurement, and local produc-
tion. Some countries procure their vaccines from a range of
sources and may cut across all three categories. Over the past 25
years, UNICEF has been the main bulk procurer of traditional
vaccines for most of the developing world, with the Pan
American Health Organization Revolving Fund for Vaccine
Procurement serving most Latin American countries. Because
the fund takes advantage of large volume purchasing, it obtains
prices comparable to those of UNICEF, which are available to
all participating countries—regardless of their income level or
size. The Gulf Cooperation Council also operates a purchasing
program for its member states. That program includes 43 dif-
ferent vaccines and sera.
Some countries, where governments take on an increasing
share of vaccine financing, purchase the vaccines directly from
the producers or their representatives. Unfortunately, procure-
ment is often being undertaken with little recognition that
stringent quality assurance procedures must be in place to
oversee the entire process. WHO is organizing workshops
specifically targeted at vaccine procurement and has developed
a vaccine procurement manual to guide such countries (WHO
2005a).
QUALITY ASSURANCE FOR PHARMACEUTICALS
AND VACCINES
In an ideal world, all products to be imported into a country
would be registered by a fully competent national drug regula-
tory authority to ensure quality. Unfortunately, this situation is
not always the case. A study of antimalarial samples from seven
African countries found that failures in ingredient content
ranging from 20 percent to 67 percent for chloroquine tablet
(CQT) and 5 percent to 38 percent for sulphadoxine/
pyrimethamine tablet (SPT) and dissolution failures ranging
from 5 percent to 29 percent for CQT, and 75 percent to 100 per-
cent for SPT (WHO 2003c). Good procurement practices of
both brand-name and generic drugs require that suppliers be
prequalified through the inspection of dossiers and factory
inspections for good manufacturing practice (GMP) and that
their performance be monitored.
Counterfeit medicines are a particularly difficult problem.
Counterfeit medicines “are deliberately and fraudulently misla-
beled with respect to identity and/or source. Counterfeiting can
apply to both branded and generic products, and counterfeit
medicines may include products with the correct ingredients
but fake packaging, with the wrong ingredients, without active
ingredients, or with insufficient active ingredients” (WHO
2005b, 1). In industrial countries, the newer brand-name med-
icines are counterfeited most often; Viagra is the frequent sub-
ject of counterfeiters. In poorer developing countries, the most
commonly used antimalarials, antibiotics, and now antiretrovi-
rals are the targets of the counterfeiters. The U.S. Food and
Drug Administration estimates that up to 25 percent of medi-
cines in developing countries are either counterfeit or other-
wise substandard and that earnings from counterfeit drugs
are more than US$32 billion per year (WHO 2005b).
THE WHO PREQUALIFICATION SCHEMES
Because undertaking prequalification tasks may be beyond the
capabilities of national authorities, WHO has, on behalf of all
UN agencies, started a prequalification scheme (WHO 2004d)
covering AIDS, TB, and artemisinin-containing malaria drugs.
The prequalification process is rigorous but efficient. WHO
provides a positive list of prequalified products and manufac-
turers that have applied for and received favorable product
assessments and manufacturing site inspections. Since January
2005, the Global Fund to Fight AIDS, Tuberculosis, and
Malaria has required recipients to use WHO-prequalified
products.
Ensuring quality is also an important aspect of any immu-
nization program. For countries receiving their vaccines
through UN agencies, WHO advises on the quality, efficacy,
and safety of vaccines on the market through a prequalification
of vaccines that entails the following steps: (a) reliance on a
fully functional national regulatory authority (NRA) in the
country of production and (b) verification of compliance with
specifications through a thorough process of independent
dossier reviews, testing of samples, site visits, ongoing moni-
toring of quality, and follow-up of complaints.
For a successful prequalification process, the NRA of the
country of production must be functional and empowered by
the government. A set of laws and structures must be in
place that guarantee the NRA’s authority and independence
and that the NRA exercises the following functions: licensing,
postmarketing surveillance, lot release, laboratory access, GMP
inspections, and evaluation of clinical performance. These
functions constitute the prerequisite for vaccines of assured
quality and are the focus in vaccine regulation.
LOCAL PRODUCTION OF PHARMACEUTICALS
Large-scale production of pharmaceuticals in the developing
world is limited to a few larger countries, most of which export
primarily to other developing countries.
Whether local production of pharmaceuticals should be
encouraged in low- and middle-income countries is a contro-
versial issue. During the 1980s and early 1990s, the United
Nations Industrial Development Organization encouraged the
establishment of national production facilities. Recently, the
World Bank and the executive board of WHO have reviewed
this issue (Kaplan and others 2003; WHO 2004a). The more
extensive World Bank report concluded:
In many parts of the world, there is no reason to produce med-
icines domestically, since it makes little economic sense. In the
local pharmaceutical manufacturing sector, local production is
often not reliable and, even if reliable, it does not necessarily
mean that medicine prices are reduced for the end user. If local
production is adopted by many countries, it may lead to less
access to medicines, since there are no economies of scale
in having a production facility in each country” (Kaplan and
others 2003).
Profit margins on bulk generic drugs are low so that public
production must be as efficient as private manufacturing. For
many countries, technical expertise, raw materials, quality stan-
dards, and production and laboratory equipment all need to be
imported, so foreign exchange savings may be small or nonex-
istent. Few developing countries have the capacity to produce
active ingredients for pharmaceutical manufacture. Industrial
investment to promote local manufacture of pharmaceuticals
in most, but not all, developing countries could be better used
to improve health infrastructure (Kaplan and others 2003).
In summary, a manager of a disease control program is
likely to obtain quality-assured products by procuring them
from prequalified suppliers at the lowest prices without con-
sidering whether the products are locally produced.
STORAGE AND DISTRIBUTION OF ESSENTIAL
DRUGS AND VACCINES
In the past, essential drugs, vaccines, and contraceptives were
for the most part distributed using separate logistics systems.
For vaccines and contraceptives, such systems were organized
vertically to some extent, and because they were concerned
with a far more limited range of products, the task was some-
what simpler.
A push has been made to integrate the distribution systems
for drugs, vaccines, and contraceptives, although in most places
separate systems are still operating, at least at the national level
and often down to provincial levels. Vian and Bates (2003)
noted a number of changes to the distribution systems in the
past few years. In many countries, health sector reform pro-
grams included efforts to reform central medical stores to allow
more autonomy and to introduce commercial incentives and
improved management methods. In some cases, this reform
has led to higher staff productivity, better performance, and
more enforcement of payment policies. However, disruption in
supply often occurs during central medical store transition
phases. Increased integration of commodities, including con-
traceptives and vaccines, has also been noted. In some cases, it
has decreased the amount and reliability of data collected on
logistics, creating problems for needs estimation and for track-
ing of consumption (Vian and Bates 2003).
Another trend is the increasing use of private transporters
and contracting out for transportation management; contract-
ing transport can generate cost savings and improve services.
Finally, a trend toward computerized systems exists, particu-
larly involving the use of donor-financed software for
improved management of logistics as well as a number of com-
prehensive assessment tools and indicator sets for evaluating
drug supply systems. But the proliferation of software systems,
with little coordination and not enough support and mainte-
nance of complex and fragile computer systems, can be coun-
terproductive, especially if paper-based systems that are
difficult to reintroduce upon failure of the computer system are
abandoned (Vian and Bates 2003).
Storage and Stocks Management
Drugs require secure storage in controlled climatic conditions
and a reliable method of stock rotation. The FEFO rule (first
expiry, first out) helps ensure that older stock is used up first.
Security is another major consideration: access to the store-
house must be carefully controlled so that theft and embezzle-
ment are minimized, and the persons who control access must
themselves be trustworthy. Proper storage conditions, includ-
ing minimizing exposure to heat, light, and humidity, are
important for some drugs, but most drugs have proved
remarkably resistant to poor conditions. Notable exceptions are
tetracycline products, which become toxic when exposed to
heat, and oxytocin and ergometrine, which lose their potency
when exposed to light and heat; all should  thus be stored in the
refrigerator. The same applies to insulin and, of course, most
vaccines. Correct FEFO stock rotation will ensure that expo-
sure to harsh conditions is minimized and that potency is
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preserved as much as possible. Ensuring good air circulation
and preventing direct water contact are most important.
Management of Donated Drugs 
Management of donated drugs is a major problem in some
areas, particularly if an emergency has precipitated an influx of
drug donations. The best strategy is to accept only invited
donations of drugs that the facility has specifically asked for
(WHO 1999a). Any drug that is neither vital nor essential, that
is not labeled clearly with its generic name, that is expired, that
is in a package that contains only a few days’ dosage, or that is
not on the national essential drugs list or on the facility’s for-
mulary should be discarded—and the pharmacist should feel
no guilt and fear no sanctions about disposing of such materi-
als. They take up space, require tracking like other drugs, and
present a risk of being accidentally dispensed to a patient and
causing the patient harm—a factor that must also be taken into
account. Proper disposal can be a problem. These drugs consti-
tute potential toxic waste, and they should be treated as such
and disposed of so that they cannot be retrieved and sold
(WHO 1999b).
Vaccine Management
Vaccines are delicate products that are destroyed if handled
incorrectly. Vaccine management involves the use and distribu-
tion of vaccines, from the manufacturers to the end users.
Aspects of vaccine management include inventory and fore-
casting, stock control, in-country distribution, storage and
handling, equipment replacement plans, procedures for the use
of the vaccine, monitoring of vaccine storage, transport man-
agement, and operational management.
Forecasting of vaccine needs is the first building block of an
adequate management system. In 2002, 22 of 82 countries sur-
veyed by UNICEF indicated that they had experienced a vac-
cine stockout. In addition to lack of resources, the main reasons
cited included poor or late forecasting.
In recent years, attention has focused on avoiding heat
exposure. The introduction of costly vaccines that are sensitive
to freezing has drawn attention to the need to protect vaccines
from excessive exposure to cold as well as heat. WHO guide-
lines for the international transport of vaccines now include
specific recommendations for each category of vaccine, includ-
ing freeze sensitivity. National cold stores are the next critical
level of the vaccine management system. A failure there—
where vaccines are received, stored, and distributed in bulk—
can result in extensive losses. The WHO-UNICEF Effective
Cold Store Management Initiative encourages countries to pro-
cure equipment and adopt management and training practices
that fully protect vaccines in national and intermediate vaccine
stores.
At the country level, emphasis is being put on the use of new
tools, such as the vaccine vial monitor. This heat-sensitive label
is a time-temperature indicator used to ensure that the vaccines
have not been damaged by excessive exposure to heat, to iden-
tify weaknesses in the cold chain, and to take vaccines beyond
the cold chain to children who have no access to fixed health
facilities.
Together with the increased use of vaccine vial monitors, the
gradual adoption of the multidose vial policy contributes to the
reduction of wastage. This policy of using opened multidose
vials of vaccine in subsequent immunization sessions applies to
all multidose vials of liquid vaccine containing thimerosal
(WHO 2000). The policy was formulated in 1996 but its adop-
tion remains limited.
PRESCRIPTION AND RATIONAL USE OF DRUGS
Rational drug use involves the correct drug being given to the
correct patient, for the correct indication, in the correct dosage,
by the correct route of administration, for the correct duration
of treatment. The dispenser must also correctly dispense and
label the drug and counsel the patient, and the patient must
take the drug correctly or comply with or adhere to treatment.
An error at any stage of this complex process can prevent the
drug from being effective. Usually, at least half of these errors
are attributable to the failure of patients to adhere to treatment,
but the other half of the errors occur before the patient actually
begins taking the drug. Few of the recommended treatments
for common diseases involve more than one or two drugs, yet
in actual practice, multiple drugs are often prescribed, even for
uncomplicated cases. Such overuse of drugs rapidly consumes
stocks, does not add to the quality of care (although patients
may believe that more drugs are better), and allows stockpiling
by patients.
The use of injections instead of equally effective oral prepa-
rations is also common. Not only are risks associated with the
injections themselves, but also the cost of these injections is far
greater than for the equivalent oral preparations. If all the pre-
scribers at a facility can agree on and adhere to standard treat-
ment guidelines that can be used as the basis for procurement
and storage, the problem of overprescription and stockouts can
gradually be eliminated. Uncertainties about dosages, particu-
larly pediatric dosages, can also be reduced by the use of stan-
dard guidelines by age or weight. Doctors often cite their mis-
trust or delay of laboratory results as a reason to “cover” the
patient for a variety of conditions. Dealing with laboratory effi-
ciency or accuracy issues may be a worthwhile way to improve
prescription practices that would also yield great benefits in
terms of quality of care. Regularly reviewing a sample of pre-
scriptions or case records and comparing treatments given to
the standard treatment guidelines is likely to have a dramatic
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effect on the improvement of treatment practices (Laing,
Hogerzeil, and Ross-Degnan 2001).
DISPENSING
Finally, the last step in the chain of the drug supply system is
delivery to the patient. Often, dispensing is done by untrained
staff members who know little about the drugs they are dis-
pensing and are unable to communicate effectively with the
patient. Anecdotal stories about patients receiving a handful of
white pills and throwing them on the ground are discouraging
to staff members but demonstrate that patients need explana-
tions about the drugs they are getting. Increasing the use of
dispensing materials—paper or plastic bags—may be worth-
while if it improves adherence to treatments. Brief training
courses for dispensers can substantially improve the quality of
dispensing.
Another major problem is the presence of dispensing doc-
tors. A number of studies in both developed and developing
countries have demonstrated that dispensing doctors prescribe
more by value and not according to national or accepted guide-
lines (Trap, Hansen, and Hogerzeil 2002). The higher number
of prescriptions is strongly associated with symptomatic treat-
ment (that is, a drug was prescribed for every symptom); gen-
eral overprescribing of antibiotics; overuse of injections; and
prescription of medicines with lower clinical value. From a pol-
icy and safety perspective, the functions of prescribing and dis-
pensing should be separated whenever possible (Nizami, Khan,
and Bhutta 1996).
ADHERENCE
Delivering the drug to the patient is not the end of the story:
the patient must adhere to the therapy. Failure to comply or
adhere will result in poorer health outcomes; it may compro-
mise the effectiveness of treatment, decrease the quality of life,
increase preventable disability, and lead to premature death. It
may also result in increased health care costs, more use of
emergency rooms, more and longer hospitalizations, and
potentially more use of intensive care units (Sabate 2003).
FINANCING ISSUES
The share of expenditures on health that goes to pharmaceuti-
cals is presented in table 72.2.
Asking patients to pay part or all of the cost of their drugs
can aid in holding down costs, reducing overuse, and replen-
ishing the funds for drugs in the system. Drugs are often
targeted for such fees because it is felt that patients will pay for
them if they have no other choice. A substantial literature now
exists on the advantages and disadvantages of user fees. On the
one hand, they do raise some revenue, but administrative costs
have often taken a large proportion of it. Their net contribution
has rarely exceeded 5 percent of a government’s recurrent
expenditure. On the other hand, they often accounted for as
high as 100 percent of nonsalary recurrent expenditures.
Moreover, where they have been retained at the facility level,
they have allowed for improvements in infrastructure and staff
income, as well as ensuring a more regular supply of drugs (Xu
and others forthcoming).
However, from a public health perspective, the disadvan-
tages are numerous. They are often applied inequitably, with
exemptions provided to richer people—such as government
workers, the military, and the police—while poorer people
must pay. But the main problem is that user fees discourage
some people, particularly the poor, from seeking care at all.
And among those who do seek care, the resulting costs can be
financially crippling, to the extent that households may sacri-
fice food, education, or other important purchases to pay for
drugs. Some are forced into poverty as a direct result of user
fees. A related issue of increasing importance with the advent of
effective antiretroviral therapy for AIDS is that user fees dis-
courage adherence to long-term treatment, resulting in treat-
ment failure, increased disease transmission, and the develop-
ment of drug resistance. Fees are, therefore, particularly
problematic for transmissible diseases.
On the basis of similar evidence, Creese (1997, 203) con-
cluded,“A range of policy options other than user fees exists for
dealing with situations of both under financing and rapid
growth in expenditure. As an instrument of health policy, user
fees have proved to be blunt and of limited success and to have
potentially serious side effects in terms of equity. They should
be prescribed only after alternative interventions have been
considered.” In this respect, WHO is now advocating that fees
should be minimized and that countries should be supported
in attempts to channel a high proportion of health expenses
through taxes or prepayment mechanisms such as forms of
insurance.
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Table 72.2 Measured World Pharmaceutical Spending, by
per Capita Income Clusters, 1990–2000
(percent)
Share of 
Share of expenditure
world total on health
Income group 1990 2000 1990 2000
High income 80.2 78.7 13.0 13.8
Middle income 17.1 18.8 22.5 24.8
Low income 2.7 2.4 20.8 19.2
Source: WHO 2004f.
Note: Income groups refer to World Bank classifications as of July 2000.
SUSTAINABLE FINANCING OF VACCINES
AND IMMUNIZATIONS 
Immunization is now generally accepted as representing one of
the “best buys” for the health sector that governments must
play a lead role in financing, but sustainable financing mecha-
nisms have been largely absent in poor countries (WHO
2004a). The cost of immunizing a child against the six basic
diseases hovers between US$15 and US$20 at current levels of
coverage, representing no more than US$0.50 per capita, and
on average 0.2 percent of the gross domestic product in most
low-income countries. These costs suggest that immunizations
are affordable for most developing countries from national
budgets. However, immunization programs account for only
5 to 10 percent of total government health expenditures in
many countries, which often rely heavily on donor funds.
Although the international community has recognized the
important reasons that financing of vaccines cannot be left to
individuals or households, donor support has often been quite
erratic. The result is volatile financing that is vulnerable to
shifts in donor priorities. In addition, recipient governments
recognize that donors are more likely to fund vaccines than
many other services, so they have taken the opportunity to
spend their own resources on activities that are important to
them but are less attractive to donors. This phenomenon can be
seen in the apparent mismatch between data on disease bur-
den, stated government priorities for health, and the allocation
of government funds.
The challenge facing governments in poor countries is how
best to finance vaccines, taking into account the variety of
other health problems and the possible sources of funds. More
funds could probably be raised from firms and households for
health in general, but user fees for immunization, as for drugs,
discourage people from seeking vaccination for their children.
However, helping countries move to a system in which more
prepayment exists for health services in general—either
through taxes or the various possible forms of health
insurance—would provide a pool of domestic funds that could
be used for vaccines. If these funds were raised progressively,
the rich could subsidize the poor.
A number of new issues relevant to immunization financing
have arisen recently, including the evolving nature of the world
market for vaccines, the growing divergence in vaccination
schedules between developed and developing countries, the
increasing diversity of products and presentations available to
countries, the emergence of developing country manufactur-
ers, and the importance of new global initiatives such as GAVI
and the Vaccine Fund. The Vaccine Fund focuses on helping
low-income countries introduce newer vaccines, such as HepB
and Hib, which are generally more expensive than the older
vaccines. In addition, the technology associated with the pro-
duction of new combination vaccines has increased prices, with
the cost per fully immunized child now reaching US$30 if
HepB and Hib are included. This increased cost adds to the
challenge. Governments in low-income countries and interna-
tional development partners need to develop long-term strate-
gies to ensure adequate financing for key health programs and
interventions, including vaccines.
Since GAVI and the Vaccine Fund were established, renewed
attention has been paid to financing issues as they relate to vac-
cine and immunization financing. GAVI has worked with
WHO and countries to consider how much it would require to
maintain existing levels of coverage after GAVI funding ends,
whereas among the prerequisites for countries to obtain assis-
tance from the Vaccine Fund is preparation of long-term
financing plans for immunization programs. However, most
low-income countries clearly will be unable to fund even a
minimum set of essential interventions in the short to medium
term without the assistance of international partners, thereby
increasing the need to develop the long-term financing strate-
gies described above. A mix of such strategies would include
raising additional domestic funds, ensuring that funds are used
effectively and efficiently, moving to greater reliance on pre-
payment mechanisms, and ensuring increased and stable flows
of external funds. Table 72.3 summarizes and compares some
recent trends in the financing of essential drugs, vaccines, and
contraceptives.
ISSUES FOR THE FUTURE
As the world’s population ages, health systems that formerly
focused primarily on infectious disease are being asked to
deliver new types of care, mostly for chronic illnesses and
increasingly for mental illness. By 2020, the major causes of the
burden of disease will shift from pneumonia, diarrhea, and
perinatal conditions to heart disease, mental illness (particu-
larly depression), and road traffic accidents. Tobacco will kill
more people than any other cause of disease, including HIV.
Unlike the United States and the countries of Western Europe,
China and India will face the challenges of an aging population
before they become high-income countries. Most health sys-
tems in the developing world are now prepared to deliver acute
care, particularly for infectious disease, rather than chronic
care. They are ill suited to long-term chronic care and follow-
up; in general they lack recordkeeping, demonstrate little devel-
opment of personal relationships with caregivers, and have
little provision for enhancing patient adherence with medica-
tion. In many situations, the irregular and intermittent supply
of medications for chronic disease means that the chronically
ill suffer many interruptions of their treatment. The changing
nature of health care will require changes in drug supply, which
are only beginning to become visible. The (perceived) differ-
ence between “good” and “bad” care is often the availability of
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drugs and supplies. Programs and funding agencies that are
planning improvements in health care—for example, increas-
ing coverage or case detection rates—often overlook the fact
that such improvements will increase drug needs and costs.
Drug Resistance
Although the burden of chronic and noninfectious disease is
increasing rapidly in the developing world, infectious diseases
still account for nearly half of deaths in low-income countries.
Most of these deaths are caused by six diseases: acute respira-
tory infections (mainly pneumonia), diarrheal disease, HIV
and AIDS, tuberculosis, malaria, and measles. Drug resistance
complicates the effective treatment for nearly all of these acute
infections. Furthermore, this trend is expected to accelerate in
the coming decades. In the treatment of HIV and AIDS, the
increase of retroviral drug resistance is becoming a serious
problem, especially in view of the limited number of treatment
regimens available to date.
Drug-resistant malaria is now widespread. Chloroquine—
once a cheap and reliable first-line treatment for malaria—is
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Table 72.3 Trends and Developments in Financing and Procurement of Essential Drugs, Vaccines, and Contraceptives
Commodity Trends and developments Implications for logistics
Essential drugs
.
Vaccines
Contraceptives
Use of loans and pooled or “basket” financing arrangements is
increasing, leading to increased government involvement in
procurement.
Procurement models adapted for health reforms such as
decentralization and privatization proliferate.
Countries are moving toward restrictive tender and prequalifica-
tion of suppliers.
Role of NGO suppliers continues in some countries as well as
role of international NGO suppliers.
User fees represent a major trend for essential drugs, with many
health facilities operating on a cash-and-carry basis.
Private sector role is increasing as it becomes more apparent
that public sector and NGO services cannot meet all needs.
Donor contributions have been decreasing starting in 1990s.
Government financing and procurement of vaccines is increas-
ing; a dependence on external resources persists.
Some shift in financing from grants to loans, and more use of
basket financing.
Use of pooled procurement mechanisms and revolving funds or
other international financial mechanisms, some based on
achievement of outcomes, is increasing.
New vaccines and vaccine combinations (new with old) are
supplied through GAVI.
Donor contributions have been flat or have decreased, starting
in 1990s.
Despite efforts to increase government contributions, there is
still a major dependence on external resources. 
Many governments continue to give contraceptives (as
compared with drugs) low priority for procurement with their
own funds.
Financing through loans and basket financing are increasing,
and governments are increasingly involved in procurement.
In the short term, procurement delays, shortages, emergency pro-
curement requests, higher prices, and greater waste will result
while governments develop internal capacity to procure. Also,
increasing government involvement can mean less predictable
results because of politics and governance issues.
Donors are more concerned about how procurement is done, trans-
lating into more technical assistance and emphasis on performance
benchmarking. Difficulties in evaluating procurement systems are
caused by a proliferation of models.
In the longer term, prequalification may shorten the procurement
cycle and lower costs. Similar effects from use of NGO suppliers
are possible. 
Fee systems can decrease demand unless mechanisms exist to
ensure service for those unable to pay.
Policy makers and managers will need to design and implement
programs that promote appropriate use of the private sector
Concerns are similar to those with essential drugs.
GAVI supplies may require logistics changes because of new
vaccines and injection equipment.
Pressure on governments to finance vaccine purchases may lead to
less government funding for EPI operating expenses and other
Ministry of Health programs.
Outcome-based support requires information systems resistant to
manipulation.
Concerns are similar to those with essential drugs.
Demand is created without supply keeping up.
Constraints of Mexico City policy (“global gag rule”) have limited
funding for contraceptives.
Source: Adapted from Vian and Bates 2003.
no longer effective in most countries. Newer drugs are signifi-
cantly more expensive. Most recently, the trend has been
toward multidrug combinations of products, and the addition
of more than one drug is often to “protect” the component
drugs from developing resistance as well as to improve the ther-
apeutic effect (WHO 2002a).
Drug resistance in tuberculosis control—in particular, mul-
tidrug resistance—is a growing problem. Multidrug-resistant
TB has now appeared around the world, and in many places
more than 20 percent of resistant new tuberculosis cases are
resistant to several drugs. Furthermore, the emergence of mul-
tidrug-resistant bacilli means that medication that once cost
US$20 must now be replaced with drugs that are significantly
more expensive and more difficult to use (WHO 2002a).
Another major concern is the use of antimicrobials in farming,
because about half of the antimicrobials produced each year
are used in farm animals. Some of the new resistant bacteria are
transmitted from food of animal origin or through direct con-
tact with farm animals. Some reports indicate that as much as
50 percent of human antimicrobial resistance is caused by
growth promoters in livestock, which are added to feed in sub-
therapeutic antibiotic doses (WHO 2002a).
HIV and AIDS
The HIV epidemic has had a tremendous impact on the phar-
maceutical supply situation. First, it has highlighted weaknesses
of drug supply and access around the world; the arrival of
highly active antiretroviral therapy for the treatment of
HIV/AIDS (HAART) means that HIV is to a large extent now
a treatable condition, yet treatment is not available to the
majority of those who suffer from HIV. Second, it has drawn
the world’s attention to the growing gap between rich and poor
in terms of pharmaceutical provision. Unlike many other
highly prevalent illnesses in the developing world, HIV and
AIDS are also of major concern in the wealthier countries, and
thus significant research has been undertaken and has yielded
effective new medications (HAART, in particular).
A recent WHO report highlights the issue of the affordabil-
ity of medications, pointing out that of the 23 countries that
are estimated to make up 80 percent of the 2003 global need for
HIV and AIDS treatment—estimated at about US$300 per
annum per patient—only 8 have pharmaceutical expenditure
levels above US$5 per capita, far short of the level of expendi-
ture needed (WHO 2004c). Prices have fallen dramatically;
WHO has continued to monitor the quality of AIDS drugs
available on the world market for sale in developing countries
and has removed substandard drugs from its list when neces-
sary (WHO 2004e). Many high-profile initiatives to solve this
problem have been started, most notably the WHO’s “3  5”
program; the Global Fund to Fight AIDS, Tuberculosis, and
Malaria; the Clinton Foundation’s efforts to lower prices for
HAART; and President George W. Bush’s Emergency Plan for
AIDS Relief. A number of issues are raised by the delivery of a
complex, lifelong, costly treatment to poorer communities,
especially in rural areas, one of which will be how to ensure
adequate adherence to treatment in different clinical settings,
ranging from district hospitals to health centers or even home
settings, for HAART delivery.
Aging and Chronic Diseases
One of the important results of the exercise to estimate the
global burden of disease was to highlight the growing impor-
tance of chronic disease, particularly in the developing world.
A large percentage of chronic illnesses are related to smoking
and lifestyle, and thus attempts to reduce smoking—or the
lethality of smoking—would have an important effect on the
need for medication for chronic disease.
Although many cancers are not yet curable, many are treat-
able with the goal either of slowing the spread or of palliating
the symptoms of the disease. As the burden of cancer increases,
palliative care, which involves the treatment of the symptoms
and especially the pain that accompanies most cancers, needs
to be given much higher priority. At present, the vast majority
of the millions of cancer patients in the developing world
receive totally inadequate pain control and suffer needless
agony, in part because of antiquated laws governing the use of
opioid analgesics (particularly morphine) and attitudes of
medical and nursing personnel toward pain control (as well as
attitudes of family members in some settings). The myths
about morphine need to be dispelled. When used appropri-
ately, especially in oral form, morphine does not lead to addic-
tion, tolerance, respiratory depression, cognitive impairment,
or premature death. In fact, people live longer when their pain
is controlled, and they can eat, sleep, and live normal lives
(Merriman and others 2002).
In countries where palliative care is fairly well developed
and available, the consumption of morphine per capita aver-
ages over 20 milligrams, but in most developing countries it is
negligible, and most of the needs for pain relief are unmet
(Joranson, Rajagopal, and Gilson 2002). The World Bank rec-
ognized the importance of alleviating pain, which it included in
its package of “essential clinical services” (World Bank 1993).
As the population ages, the ability of the health care system to
provide palliative care must grow along with it.
The trend toward more sedentary lifestyles and toward con-
sumption of diets with higher fat and sugar content is leading
to a steep increase in the burden of diabetes, with 150 percent
increases in prevalence predicted for many countries by 2030;
the absolute numbers will grow from 171 million in 2000 to
about 366 million in 2030. The greatest increases in diabetes
prevalence are predicted for the Middle East, Sub-Saharan
Africa, and India (Wild and others 2004). Most of these
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new cases will be type 2 and, thus, most will not be insulin
dependent, but they will require oral diabetic medications. For
those who do require insulin, given the current state of tech-
nology, the main barrier (other than cost) is the need for stor-
age of the insulin in a cold or cool location and for sterile injec-
tion equipment. In either case, to meet the predicted rise in
cases and to treat them with current drugs, a major expansion
of drug supply for diabetes must be anticipated. Many diabet-
ics currently do not receive adequate treatment. The pressure to
provide adequate treatment will increase as the population ages
and begins to demand treatment of its chronic afflictions—and
in that case the increase in demand for diabetes medications
would potentially be much more than 150 percent.
Another important finding of the global burden-of-disease
exercise was the high number of DALYs lost to mental illness,
depression in particular. In 2020, unipolar depression is pro-
jected to be the leading cause of morbidity and disability
among females worldwide and in developing countries.
Whereas in the industrial countries a pharmacological solution
is often used, this approach may not be feasible in the develop-
ing world, at least not at present price levels. Recent research in
the developing world has shown good results with weekly
group interpersonal therapy, without the use of antidepres-
sants. Trained laypersons ran the therapy sessions, not psy-
chiatrists or medical personnel (Bolton and others 2003).
VACCINE RESEARCH PRIORITIES
In the past two decades new advances in biotechnology have
resulted in the licensure of new vaccines, such as Hib, acellular
pertussis, HepB, and attenuated varicella. Research institutions
in the public sector have generated most of the basic scientific
breakthroughs, whereas the large pharmaceutical companies
have borne the cost for clinical development. Because such
development requires heavy investments that need to be
recouped from profits, new vaccines are expensive and there-
fore out of reach for poor populations.
Of all the vaccines currently under development, the three
most needed today are vaccines to prevent the three big
diseases—AIDS, TB, and malaria—which jointly account for
more than 5 million deaths per year, or about 50 percent of all
infectious disease deaths (see table 72.4). The total investment
in vaccine against these diseases is not impressive, and it will
probably take at least 5 to 10 years before a vaccine against any
of them is available.
GAVI has selected three vaccines for accelerated develop-
ment: meningococcal meningitis, rotavirus, and pneumococcal
vaccines. They have been selected because they are considered
close to licensure, or “near term.” Other important diseases are
considered neglected in terms of vaccine development, among
them shigella dysentery and dengue fever.
New diseases emerge and old ones reemerge, influencing
priorities in vaccine research. The severe acute respiratory syn-
drome (SARS) epidemic, the outbreak of avian influenza, and
the emergence of bioterrorism threats such as anthrax have led
to a new search for vaccines against these infections. The threat
of a pandemic of a reassorted influenza virus strain has recently
highlighted the need for much greater resources and attention
to be devoted to the development and distribution of effective
flu vaccines.
New Vaccine Technologies
Alternative routes of administration would improve program
safety, avoiding needle transmission of bloodborne pathogens.
The ability of nonprofessionals to administer vaccines would
also ease vaccine delivery strategies. New administration
routes, such as oral, nasal, and transcutaneous routes, are being
explored. An interesting project concentrates on the develop-
ment of a nasal measles vaccine that would greatly enhance the
feasibility of eliminating this disease by facilitating the admin-
istration during mass campaigns.
The concept of using plant-derived or edible vaccines
involves encoding protective antigens from pathogens into
transgenic plants. The plants are processed so that they can
deliver a uniform dose of vaccines. Human clinical trials have
been conducted with, for example, bananas and raw potatoes,
which have shown encouraging antibody responses. The
potential advantages of this technology could include ther-
mostability, low investment needs, multivalency, and oral
administration.
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Table 72.4 New Vaccines Needed
Priority Close to Vaccines for Other vaccines Vaccines for 
vaccines licensure vaccines neglected diseases of importance new threats
HIV, TB, malaria Meningococcus, Shigella, dengue, Human papilloma virus, SARS, anthrax, 
streptococcus Japanese encephalitis, respiratory syncytial virus, smallpox, pandemic 
pneumonia, rotavirus leishmaniasis, schistosomiasis, herpes simplex, enterotoxigenic, influenza
cholera Escherichia coli
Source: Authors. 
SARS  Severe acute respiratory syndrome.
New Immunization Technologies
Priority is given to new delivery technologies that will expand
access, improve safety, and cut the cost of immunization pro-
grams. They include the following technologies:
• The reuse of disposable syringes and needles is widespread
and contributes significantly to the transmission of hepati-
tis B and C and HIV. The autodisabled syringe prevents
reuse, and disposal in safety boxes reduces the risk to health
staff and the general public from contaminated syringes and
needles.
• Four different technologies are being explored to minimize
the risk of infection from accidental exposure to sharps: cor-
rosive disinfectants, thermoprocessing, needle destruction,
and plastic melting. However, none of these options will
soon be put into use in the field.
• Although the adoption of the multidose vial policy will
contribute to the reduction of wastage, the ultimate aim is
to provide all immunizations as monodose preparations.
Injection devices prefilled with a monodose increase quality
and safety at the point of use. UniJect is one such device that
has been tested with HepB and tetanus toxoid. Village health
workers or traditional birth attendants can use such devices.
Currently, the cost of the device and the need for additional
cold storage space when multidose presentation is ex-
changed for monodose pose obstacles to implementation.
• Needle-free injection devices deliver vaccine at high velocity
into the skin without penetration of a needle, reducing the
risk of transmission of bloodborne pathogens. Technologies
are being developed for both mono- and multidose presen-
tations. Available multidose injectors have not been found
safe, and new models are under development. However, reg-
ulatory obstacles and high cost have rendered the monodose
injector models that are currently available infeasible for
large-scale programs.
• Vaccine distribution and storage without a cold chain would
considerably simplify the delivery system, reduce cost, and
allow for an integrated supplies mechanism. Development
of vaccines that do not need a cold chain should be the high-
est priority for technology research. Sugar glass drying is
one such technology that has shown great promise. It can be
used to produce multivalent vaccines that are completely
heat stable except under extreme climatic conditions. The
high cost of regulation and licensing and the uncertainty
about market prospects in industrial countries have so far
impeded the development and use of this technology.
Obstacles to Vaccine Research
A host of obstacles confront vaccine research, the most impor-
tant being the low level of investment for vaccine development
when there are limited market prospects in the industrial
world. Only a limited number of research centers have the
capacity and experience required to conduct phase 2 and
especially phase 3 trials of new vaccines, and they are mainly
located in industrial countries. The capacity to conduct phase
3 trials in developing countries needs to be strengthened; the
current situation impedes further development of vaccines
needed in those countries.
Pilot lot production of vaccines is required for all phases of
clinical trials. The global capacity to produce pilot lots is, how-
ever, inadequate to meet demand. Close public-private part-
nerships are necessary to ensure that the production capacity is
available.
Manufacturers need markets to provide some assurance that
the development cost for new products can be recouped. Such
incentives require realistic forecasts of demands. Various mech-
anisms have recently been put in place to try to guarantee
future markets, most notably the Vaccine Fund.
Last, disease burden data are needed for both selections of
vaccines for national programs and for estimations of vaccine
requirements, including market projections. However, such
data are lacking in many countries and regions. Existing data
are especially weak for respiratory disease of both bacterial and
viral origin.
PRIORITIES FOR PHARMACEUTICAL RESEARCH
The WHO Priority Medicines Project, a recent exercise that
used evidence-based methods to outline the priorities for
public funding of pharmaceutical research, has recently been
published (WHO 2004b). It incorporated data from the
burden-of-disease rankings and from the Cochrane Database
of Systematic Reviews of data on clinical efficacy. It also incor-
porated the use of criteria of social justice, social solidarity, and
equity, so that neglected diseases and the needs of special
patient groups (the elderly, women, and children) were also
taken into account. The research identified 20 major diseases
that account for 60 percent of the total DALY burden both in
Europe and in the rest of the world—diseases that are common
to both groups included unipolar depression, ischemic heart
disease, cerebrovascular disease, chronic obstructive pul-
monary disease, and digestive diseases (excluding diarrheal
diseases).
The authors also mention the important contributions of
various cancers, lower respiratory tract infections, and diabetes
to the burden of disease, which is common to both developed
European countries and to the developing world (WHO
2004b). Smoking is clearly a major contributing risk factor, and
the authors caution that expenditure on pharmaceuticals for
smoking cessation must not divert resources from other efforts
to reduce smoking. The priority areas identified by this exercise
are presented in table 72.5.
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CONCLUSION
Ensuring that needed essential medicines and vaccines are
available is critical for the success of any disease control pro-
gram. A great deal is known about what works and what does
not work. Careful selection, procurement from prequalified
suppliers, proper storage and distribution using secure reliable
channels, and assurance of rational use and correct dispensing
are all critical components of any drug and vaccine supply
system. Ensuring that adequate funds are available to pay for
the procurement, distribution, and quality assurance of all
medicines and vaccines is equally critical. Depending on the
circumstances, either the public or the private sector or a com-
bination of both can efficiently deliver quality-assured
medicines and vaccines. The experience of a number of coun-
tries and programs has demonstrated that essential medicines
and vaccines can be reliably delivered to poor people using the
approaches described in this chapter.
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Financial resources alone are insufficient for individuals to
benefit from the opportunities presented by modern health
care systems. Some countries have achieved much better levels
of health than would be expected given their financial re-
sources (Mehotra 2000); many examples of poor-quality care
in countries at all levels of development reflect not only scarce
resources but also inadequate management of what resources
are available (see chapter 70).
Many inputs must come together at the appropriate time and
in the appropriate place to achieve maximum health gain. These
inputs include human resources (in particular, trained staff);
physical resources (such as pharmaceuticals and technology);
and intellectual resources (in the form of evidence and the abil-
ity to apply it appropriately). This congruence requires that the
production, distribution, and combination of these resources be
actively managed and that the relations among the various ele-
ments that contribute to health care be optimized.
The challenge of bringing these diverse inputs together is
becoming increasingly complex. Until the 1950s, providing
basic care at low cost to large populations was relatively
straightforward, given political will and sufficient resources.
Relatively few effective drugs were available; even fewer drugs
were effective in managing chronic disease. The available tech-
nology was limited to simple x-ray machines and chemistry
tests that required few skills to administer. Consequently, scal-
ing up the delivery of basic health care was relatively easy.
The situation in the former Soviet Union illustrates this
state of affairs. Beginning in the 1930s, the Soviet Union imple-
mented a vast system to provide basic health care where almost
none had existed. The very simple care available was sufficient
to produce significant reductions in maternal and childhood
mortality rates. What such a system could not do, however, was
respond effectively to the possibilities opened up by the explo-
sion in diagnostic and therapeutic knowledge that began in the
mid 1960s with the availability of new and easily tolerated
treatments for many common chronic disorders. As individu-
als became able to survive with their chronic diseases, they aged
and acquired other conditions, many of which could now be
treated effectively, constantly increasing the complexity of the
health care required. The inability to manage this increased
complexity resulted in persistently high mortality rates from
treatable conditions at a time when corresponding mortality
rates were falling in Western countries (Andreev and others
2003).
This situation has certain parallels with that faced by many
low- and middle-income countries today. Through a variety of
mechanisms, a political commitment to the health sector is
manifest in the increased availability of funding, such as
through the Global Fund for AIDS, Tuberculosis, and Malaria
(http://www.theglobalfund.org/en/). Much discussion has
focused on one of the elements of health care that these initia-
tives will support: the supply of drugs that target the microbi-
ological agents responsible for these three diseases. Yet
improved outcomes will be achieved only if such agents are
linked to the many other elements required to diagnose and
treat these patients. Most obviously, the supply of drugs such as
antiretroviral agents must be coupled with those used to treat
the opportunistic infections that exacerbate AIDS. Care for the
acute episode of illness should be linked to general support for
patients and family members as well as to activities designed to
prevent further spread of the disease. Furthermore, as drugs
to combat infections become more widely available, it is
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probable—unless highly developed prevention systems have
been put in place—that drug resistance will increase; this out-
come has been evidenced with tuberculosis in those parts of
the world where treatment has been available but poorly man-
aged, such as the former Soviet Union and Peru (Farmer,
Reichman, and Iseman 1999). The resulting resistant infections
are much more complicated and expensive to treat. The rise in
antibiotic resistance provides one of the most graphic examples
of the consequence of the failure to manage the delivery of
health care (see chapter 55).
Yet even where the financial resources and the political will
exist to deliver effective health care, many health care systems
contain numerous constraints to success (Hanson and others
2003):
• At the first level, that of the community or household, there
may be inadequate demand for services or physical, finan-
cial, or social obstacles to their use. This situation calls for
action to increase access and affordability, including health
care financing reforms (see chapter 12). It also requires poli-
cies to ensure that services are culturally appropriate, that
they address the particular needs of underserved popula-
tions, and that they provide dignity and privacy. Moreover,
services should be physically accessible, both in terms of dis-
tance from population settlements and in terms of their
construction—that is, facilities must be responsive to the
needs of persons with disabilities.
• At the second level, the delivery of health care, there may be
a shortage of resources, such as staff members, drugs, and
equipment. However, to bring these resources together
would require actions at the third level that anticipate future
needs, as well as actions that ensure that the needed drugs
and equipment are purchased at the best price possible, are
subject to appropriate quality controls, and are distributed
where needed.
• The third level includes health sector policy and strategic
management. Effective action may be constrained by weak
systems of management that are unable to take into account
the changing health needs of the population and the chang-
ing demands on health care providers. Management weak-
nesses include inadequate pharmaceutical regulation and
supply, ineffective training of health professionals, inability
to engage with civil society, and a failure to put in place
incentive systems to facilitate effective health care.
Constraints at this level may originate outside the country,
as governments are faced with demands by donors to follow
paths that either undermine their policy goals or remove the
flexibility needed to achieve them. Constraints acting at this
level also arise when policies in other areas affect the health
sector, such as when a weak, overly bureaucratic, and
unreformed civil service system implements obsolete regu-
lations; when there are inadequacies in infrastructure, such
as poor communication and transportation links; or when
there are weaknesses in the banking system.
• The fourth level refers to the environmental and contextual
constraints on effective policies. The delivery of effective
care may be affected by the physical environment, including
climate and population dispersion. However, an equally
important constraint is weak governance working within
unsupportive policy frameworks, which may be compro-
mised further by corruption, weak rule of law, political
instability, weak public accountability, and lack of a free
press. For example, de Soto (2000) has shown that, in many
middle-income countries, it is almost impossible even to
create a simple garment repair business because of a failure
of legislative reform, in particular a lack of clearly defined
property rights. As a result, much of the economic activity
in those countries is informal or even marginally illegal, a
response that is of particular concern in health care, given
the scope for unlicensed and incompetent providers to
endanger the public.
This framework underscores the importance of coordinat-
ing action at multiple levels. Health services can operate effec-
tively only if policies are in place at the community level to
ensure that those in need have access to services, and only if
policies are in place at higher levels to ensure that the resources
are available to provide those services.
This analysis of different levels demonstrates the impor-
tance of taking a systemwide approach to the management of
health services. However, because of limited space, this chapter
focuses primarily on the third level, that of strategic manage-
ment. It first examines the nature of management in general
and the specificities of management in the health system. It
then explores some issues that arise when managing health
services in different settings. It concludes with an exploration
of some of the strategies used in low- and middle-income
countries to optimize the delivery of care, using a framework
developed by Oliveira-Cruz, Hanson, and Mills (2003).
WHAT IS MANAGEMENT?
One of the earliest definitions of management was that of
French mining engineer Henri Fayol. Writing at the beginning
of the 20th century, he stated, “To manage is to forecast and
plan, to organise, to command, to coordinate, and to control”
(Fayol 1949). Put simply, managing is about assessing probable
future scenarios, deciding how best to respond to them, bring-
ing together the resources needed for that response, and deploy-
ing them as effectively as possible. Until relatively recently,
most management research was concerned with industrial
production, for which outputs could be measured relatively
easily. Relatively less attention was given to management of
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service industries in general and health care services in partic-
ular. As Shortell and Kaluzny (1983) noted, health care services
are different from many other organizations. Of course, many
of the specificities shown in box 73.1 are differences of degree,
with health services sharing many features with other service
organizations. Yet important differences exist.
Managing Health Care Services
During the 1970s, health care services in many countries faced
growing criticism for their perceived failure to articulate ex-
plicit goals or to develop the means to achieve them (Enthoven
1985; Griffiths 1984). This failure was contrasted with the per-
ceived success of the private sector, which was seen as more
capable of innovation and more responsive to demand.
These developments gave rise to what has been termed new
public management (Hood 1991), which is characterized by the
following:
• greater role for professional management in the public
sector
• closer scrutiny of the work of professionals, involving per-
formance measurement and target setting 
• link between resource allocation and measurable outputs 
• “unbundling” of previously integrated units, with contract-
ing for previously integrated services 
• shift to competition as a key to reducing costs and an
emphasis on a private-sector management style 
• careful use of resources to drive down the cost of labor and
other inputs, where possible.
Recognizing the many reasons for market failure in health
care (Arrow 1963), new public management builds on several
concepts that arise from new institutional economics. Included
in these is contestability (Baumol, Panzar, and Willig 1982), in
which the benefits that competition is thought to bring can
arise even when competition is absent, thus ensuring that the
barriers to market entry are sufficiently low to allow other
providers to emerge. User choice is given priority over most
other goals, including equity.
The enthusiasm for new public management was largely
ideological, reflecting the contemporary rejection of an
expanded role for the state; the extent to which this model was
actually able to achieve what was claimed for it remains highly
contested (Le Grand and Bartlett 1993; Stewart 1998). In par-
ticular, critics drew attention to the high transaction costs
involved (Evans 1997) and the lack of evidence that competi-
tion can actually bring about the intended improvements in
quality of care (Maynard 1998).
One feature of the new public management is its emphasis
on general management, with managers possessing skills and
expertise that can be applied to any sector. These managerial
attributes are considered to be of greater importance than tech-
nical or professional knowledge. As a consequence, in some
countries, the balance of power has begun to shift away from
health professionals and toward general managers. In many
places, the initial enthusiasm has given way to disillusionment
and subsequently to a more balanced view that, though the pre-
cise solution will reflect the particular circumstances of the
health care system, what is needed is a partnership between
these two groups.
In some countries, this development will mean that man-
agers must assume a greater role in relation to the delivery of
clinical care. Such an expanded role will extend from their
traditional responsibilities, such as financial controls, hotel
services, and payroll management, to active participation in
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Specificities of Health Care Organizations
Box 73.1
Health care services differ from many other organizations
in many ways:
• Defining and measuring outputs is difficult.
• The work involved is more variable and more complex
than in many other organizations.
• Much of the work is of an emergency nature and cannot
easily be deferred.
• The consequences of error can be severe.
• Activities by different groups of staff members are highly
interdependent, requiring a high level of coordination.
• The work involves a high degree of specialization.
• Workers are highly professional, with a primary loyalty
to the profession rather than to the organization.
• There is limited scope for effective organizational or
managerial control over clinicians, the group most
responsible for generating work and expenditure.
• Dual lines of responsibility often create problems of
coordination, accountability, and confusion of roles.
Source: Shortell and Kaluzny 1983.
setting and monitoring standards for care delivery, linked to a
responsibility for ensuring that the resources needed for care
delivery are available.
In other countries, this role may involve stepping back a
little. In an analysis of the British National Health Service, in
which the degree of managerial control over the delivery of
health care has proceeded further than in many other industrial
countries, Harrison and Pollitt (1994) note how clinical deci-
sion making is increasingly driven by diagnostic and treatment
protocols. Although often developed locally, working arrange-
ments are increasingly specified, with the introduction of
timetabled job plans for medical specialists and much greater
measurement of outcomes. Yet Harrison and Pollitt argue that
the growth of managerial control over professional activity is
likely to be constrained by the increasing involvement of pro-
fessionals in management, even if they do not fully adopt the
managerial agenda. A further constraint is the persisting ability
of professionals, because of their specialized knowledge, to
resist managerial control and the related unwillingness of lay
managers to extend their control into certain areas in which
they do not feel competent.
Managing for Improved Quality of Care
An increasing volume of research in industrial countries has
focused specifically on managerial and organizational responses
to evidence that health systems often deliver suboptimal care
(Institute of Medicine 2001). Quality of care is addressed in
more detail in chapter 70. However, some of the key messages
from this research are relevant here.
One message is that change must take place at all levels of
the system. In this context, Ferlie and Shortell (2001) identify
four such levels: the individual, the group or team, the organi-
zation, and the larger system or environment. They note the
growing evidence that strategies that focus on individuals alone
are unlikely to be successful, whereas those that are embedded
within broader organizational change are more likely to be
effective (Davis and others 1995). A second key message is the
importance of teamwork, with evidence that well-functioning,
multiprofessional teams provide better quality care (Aiken,
Sochalski, and Lake 1997). However, change may be inhibited
by barriers at the level of the organization, including lack of a
consistent focus on quality, inadequate information, lack of
physician involvement, and inadequate managerial support
(Shortell, Bennett, and Byck 1998).
MANAGING CLINICAL SERVICES 
IN DIFFERENT SETTINGS
Clinical services are provided in a variety of settings, from the
patient’s home to ambulatory care facilities and hospitals
providing inpatient care. They include those services that
involve direct contact between a patient and a health care pro-
fessional, as well as indirect contact, such as when a pathologist
provides a diagnosis on a biopsy or blood sample. Reflecting the
focus of much existing research, this section is structured in
terms of different settings of care: ambulatory care, hospitals,
and community care. Unfortunately, rather less research tran-
scends these often artificial and arbitrary divisions to look at the
more important issue of the patient’s journey through the health
care system, given that one of the greatest managerial challenges
facing those delivering clinical services is how to ensure that the
journey is efficiently navigated (McKee and Nolte 2004).
Furthermore, available research that focuses on health facilities
is often difficult to generalize because of the different meanings
attributed to common terms such as hospital, health center,
or more prosaically, hospital bed. For example, a major
teaching hospital in a capital city, such as the Kenyatta National
Hospital in Nairobi (http://www.kenyattanationalhospital.org/
services.html), which offers invasive cardiology, renal trans-
plants, and radiotherapy, is very different from a rural hospital
with perhaps 100 beds and a single operating theater that
provides only the most basic surgical and obstetric care.
Hospitals
Although hospitals are rarely the first places of contact between
patients and health systems, and although hospitals do not pro-
vide the greatest share of health care, it is appropriate to begin
with them because they often account for the largest share of
public health sector expenditure (OECD 2003). They are also
particularly difficult to manage for several reasons:
• One reason is the diversity of tasks that a hospital must
undertake (Healy and McKee 2002b). Many hospitals ful-
fill roles that go beyond the delivery of patient care to pro-
vide training and research, support to community-based
facilities, and even local employment or civic identity
symbols.
• A second reason is the blurring of boundaries between
hospitals and the rest of the health care system, which has
occurred as a result of the emergence of many innovative
models of care that cross the boundary between secondary
and either primary or social care. A related issue is the shift
taking place in many countries to managing patients
through a complex combination of short inpatient stays
and visits as an outpatient to specialist clinics and diagnos-
tic facilities (McKee and Healy 2001). This approach is
vastly more complicated to manage than the traditional
model in which patients were admitted to wards from
which they were taken to undergo investigations and treat-
ment at a time convenient for the specialist concerned, a
process managed by senior nurses. The new model requires
new health worker roles, which might be termed case
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managers. These case managers help patients to navigate
the system.
• A third reason is the contrast between the rapidly changing
demands on hospitals and the structural rigidities of hospi-
tals themselves (McKee and Healy 2000). The original justi-
fication for creating hospitals as institutions was the need
to concentrate equipment such as operating theaters, x-ray
machines, and laboratories, and expertise such as medical
specialists. Yet changes in the nature of health care are rais-
ing questions about how hospitals of the future should be
configured. Many laboratory functions are being replaced
by testing kits that can be used at the bedside, diagnostic
equipment such as ultrasound scanners is being used in pri-
mary care, and a new generation of primary care workers
are acquiring greatly augmented skills. In this rapidly chang-
ing environment, managers may be faced with aging hospi-
tal buildings that may lack sufficient electrical sockets for
the greatly increased amount of equipment now available,
or managers may have staff members with deeply ingrained
ways of working who pose a particularly acute managerial
problem.
These issues can be seen in the Kenyatta National Hospital
in Nairobi, where a new managerial approach was developed
but faced problems because of an unclear understanding of the
kind of services to be provided, weak managerial capacity, and
a lack of focus in targeting services (Collins and others 1999).
In Zambia, financial management and accountability improved
when the hiring of hospital staff was delinked from the national
civil service, yet the process has been derailed on a wider scale
because of trade unions’ resistance to the changes (Hanson and
others 2002).
Ambulatory Care
Ambulatory care, delivered on an outpatient basis, is the com-
monest form of contact between patients and health care
providers. Although it often receives relatively little attention
from policy makers compared with the more resource-
intensive inpatient hospital care, ambulatory care contributes
substantially to health care system performance (Berman
2000). Good management of ambulatory services is essential
because these services are often the entry and exit points for
consumers; however, these services can be difficult to manage
effectively (Waghorn and McKee 2000).
Effective coordination of ambulatory and inpatient services
is needed to ensure that patients are cared for in the most
appropriate settings, thereby reducing inefficiencies such as the
overuse of hospitals for nonemergency care. Such coordination
often involves developing shared protocols for referral and
management. In Benin and Guinea, for example, diagnostic
and treatment decision trees were developed collaboratively
with the local staff, leading to more efficient use of resources
(Levy-Bruhl and others 1997). In Zambia and Tanzania,
strengthening of management capacities in primary care facil-
ities through a team-based approach to decision making that
linked planning to budgeted action plans led to improved client
perceptions of facilities and to a marked increase in utilization
(Few and Harpham 2003). However, the challenges of manage-
ment in the ambulatory care sector are great in many countries;
this sector is often highly fragmented, with extensive and
largely unregulated private provision and few levers to exert
pressure for change.
Community and Social Care 
A particular challenge is how best to link long-term manage-
ment of medical conditions with community and social care in
those cases in which an effective response to health needs spans
the interface. Management of chronic physical or mental illness
in the elderly, for example, can fall under the responsibility of
home care and volunteer agencies, day centers, day hospitals,
rehabilitation hospitals, and long-term care institutions, as well
as community-based health teams (Bergman, Beland, and
Perrault 2002). A systematic review of community-based care
for elderly people in industrial countries concluded that such
schemes can favorably affect rates of institutionalization and
costs. However, comprehensive approaches involving program
restructuring are often necessary, and cost-effectiveness
depends on the characteristics of the health and social care sys-
tems. The review’s authors identified as a critical challenge the
expansion of those programs considered to be successful
(Johri, Beland, and Bergman 2003).
Low-income countries face particular obstacles because
they often lack effective alternatives to hospital care. As a result,
patients are frequently cared for by their families but with little
support, or they are consigned to large, poorly equipped, and
poorly staffed institutions. This situation has stimulated the
development of models of “community care,” in which health
care providers work with communities to deliver services. In
the area of mental health, for example, the World Health
Organization (WHO) has developed models of care that cover
a range of care settings, including community centers and out-
reach services and residential homes, backed up by access
to hospital outpatient and emergency care (WHO 2001).
Similarly, the complexities of caring for people with disabilities
in low-income countries have led to internationally developed
guidelines that advocate a shared role for heath care providers
and local communities (Helander 2000). Accordingly, effective
coordination of those services clearly depends in large part on
effective management. Shifting from hospital-focused care to
community care introduces many managerial challenges. One
element of an effective response should be to heighten the
autonomy of patients in managing their diseases, but this
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response requires attitudinal changes among providers, who
must commit to a real shift of power to patients, supported by
effective information systems and safeguards for vulnerable
patients (Litwin and Lightman 1996).
Health care systems are generally poor at addressing long-
term illnesses, especially when those illnesses require integrated
care spanning primary, secondary, and community providers
(McKee and Nolte 2004; WHO 2001). The often low status
accorded to these conditions in the hierarchy of priorities, cou-
pled with fragmentation between health and social sectors
(WHO 2002), will require greater commitment to managerial
reforms that can improve the delivery of appropriate services.
THE SPECIFICS: WHAT WORKS?
This section turns to those policies that are designed to
enhance the resources available to deliver health care and to
combine them in ways that optimize the potential benefits. It
looks, in turn, at the different elements required to deliver
effective care: human resources, physical resources, intellectual
resources, and the organizational or social resources that bind
them together. The section begins with the most important
resources for health care systems: the people who provide care.
Developing Human Resources
A key element in the delivery of effective health care is how to
provide staff members with the appropriate combination of
skills to do their jobs effectively.
Increasing Skills. In their review undertaken to inform the
Commission on Macroeconomics and Health, Oliveira-Cruz,
Hanson, and Mills (2003) identified 13 studies that assessed the
effects of training to enhance skills. Though the results were
mixed, training programs were overall more likely to have pos-
itive rather than negative effects. Several studies focused on
communication and counseling skills, which often lead to
improved client satisfaction. A study from Zambia showed that
training must be linked to other resources; although training
was associated with improved transmission of information,
there was no decline in the number of complaints from clients
who remained unhappy about long waits and short contact
time (Faxelid and others 1997).
Changing Skill Mix. The division of tasks among different
health care workers reflects many considerations, but evidence
about who would be best at doing these tasks is rarely
considered. There may be regulations restricting tasks to one
professional group, such as the right to prescribe, or there may
be cultural norms, which while unwritten have just as great an
effect. Underlying these factors is a set of issues that includes a
difference in the power of different professions, itself often a
reflection of gender relationships in society, with a predomi-
nantly male medical profession controlling a predominantly
female nursing profession. However, increasing evidence sug-
gests that traditional demarcations do not support the optimal
ways to provide care, and there is considerable scope for chang-
ing the mix of skills involved in delivering many aspects of
health care.
This topic has recently been reviewed systematically by
Sibbald, Shen, and McBride (2004), who have developed a tax-
onomy of the types of change in skill mixes that are possible
(table 73.1). Their review shows that many tasks undertaken by
one professional group can yield comparable and often better
results when performed by another group. In particular, they
show how nurse-led clinics often achieve better outcomes than
traditional doctor-led service (Connor, Wright, and Fegan
2002; Stromberg and others 2003; Vrijhoef, Diederiks, and
Spreeuwenberg 2000; Vrijhoef and others 2001, 2003).
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Table 73.1 A Taxonomy of Changes in Skill Mix in Health Care
Changing roles
Enhancement Increasing the depth of a job by extending the role or skills of a particular group of workers
Substitution Expanding the breadth of a job, in particular by working across professional divides or exchanging one type of worker for another
Delegation Moving a task down a traditional unidisciplinary ladder
Innovation Creating new jobs by introducing a new type of worker
Changing the interface between services
Transfer Moving the provision of a service from one health care setting to another (for example, substituting community for hospital care)
Relocation Shifting the venue from which a service is provided from one health care sector to another without changing the people who provide
it (for example, running a hospital clinic in a primary care facility)
Liaison Using specialists in one health care sector to educate and support staff members working in another (for example, hospital outreach
facilitators in primary care)
Source: Sibbald, Shen, and McBride 2004.
Although Sibbald, Shen, and McBride focus their review on
experience in industrial countries, by challenging many deeply
held beliefs they indicate what could be done in other settings
around the world, after taking into account local circumstances
such as the skills and expertise of those involved, as well as any
salient regulatory or training issues.
Strengthening Management
In their review of constraints to health service delivery,
Oliveira-Cruz, Hanson, and Mills (2003) identified 10 studies
that evaluated the effect of management strengthening. The
activities in those studies included the following:
• workshops for identifying and prioritizing managerial
programs
• introduction of regular planning and evaluation cycles 
• quality assurance methods 
• establishment of routine communication systems
• training activities.
They concluded that the results were generally positive, with
more rational use of funds; greater availability of funds as a
consequence of better planning; improved coordination and
integration of programs; improved methods of working; better
staff morale; enhanced data collection, reporting, and use; and
increased community participation. WHO has developed an
approach to strengthening management that has been success-
ful in a variety of settings (Cassels and Janovsky 1995).
It is important to identify where specific managerial skills
are lacking and to explore different ways of obtaining them,
whether through training, recruitment, or links with related
organizations. For example, improved financial management
in district health teams in Ghana was made possible by inte-
grating staff members from local government accounts offices
(Kanlisi 1991); a similar initiative was successful in The
Gambia (Conn, Jenkins, and Touray 1996). However, a word of
caution is required. Although a management strengthening
exercise undertaken in Tanzania was successful when imple-
mented at the local level, it failed when scaled up because the
same degree of involvement by the originating team was no
longer possible (Barnett and Ndeki 1992).
Managing Physical Resources
Managing infrastructure and other capital assets such as hospi-
tals and health centers requires investment planning in both
the short term (for example, maintenance) and the long term
(for example, new acquisitions). Historically, however, costs
associated with capital consumption and maintenance have not
been met through operating budgets, resulting in few incen-
tives for public sector health planners to efficiently manage
infrastructure or to respond to market demand and consumer
needs (England 2000; Preker, Harding, and Travis 2000).
Capital charging—requiring managers to explicitly account for
the value of physical assets out of funding allocation or con-
tract revenues—has been developed as a response, successfully
heightening public sector management of capital investments
in the United Kingdom and New Zealand (Heald and Scott
1996). Capital charging has been proposed as a strategy to
stimulate better capital management in developing countries as
well. For example, in Malaysia a corporatized hospital has been
required to reimburse invested capital through dividends, with
the Malaysian government recouping one-third of its original
investment within five years (Hussein and Al-Junid 2003).
Similarly, the Kenyatta National Hospital in Nairobi was
obliged to account for all accruals (for example, property and
depreciation) when it was given greater autonomy. Though
changes in accounting management have experienced some
shortcomings, improvements have been seen in financial trans-
parency, timeliness of reporting, donor satisfaction, and rev-
enue collection (Collins and others 1999).
Within the public sector, changes in line management have
facilitated the incorporation of more explicit infrastructure
concerns into the planning process. The central authority in
Hong Kong (China) has made capital acquisition decisions
jointly with hospitals during annual planning processes (Yip
and Hsiao 2003). The introduction of business planning to dis-
trict-level planning in Turkmenistan heightened accountability
for maintaining physical infrastructure: use of a global budget-
ing model (that is, increased autonomy in line management as
well as performance monitoring) led to reduced resource allo-
cation to personnel and a greater than fivefold increase in
maintenance expenditures (Ensor and Amannyazova 2000).
Explicitly managing capital investments in both the short and
the long term may facilitate efficient resource allocation.
Although capital charging is a relatively straightforward
technical solution, capital investment can be particularly sus-
ceptible to political derailment (Anell and Barnum 1998). In
the hospital sector, for instance, many transition economy
countries have had difficulty downsizing infrastructure
because those with decision rights to manage capital (that is,
local governments) are different from those who have incen-
tives to do so, such as hospital managers (Jakab and Preker
2003).
Strengthening Drug Procurement, Regulation, 
and Distribution
Managing pharmaceutical resources is crucial for ensuring
access to essential drugs and promoting their rational use
(Mossialos, Mrazek, and Walley 2004). WHO defines the goals
of rational use of drugs as delivering medications effectively—
appropriate to patients’ clinical needs and at dose levels and
durations appropriate to their individual requirements—and
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at an affordable cost (WHO 1985). The public sector plays a
key role in providing the framework for rational use of drugs
(Quick 1997) through measures ranging from drug regulation
to clinical practice guidelines.
National drug policies (NDPs) can be effective in regulating
private and public sector provision of essential medicines. The
Lao People’s Democratic Republic’s NDP has been important
in improving private pharmacy service quality (Stenson,
Tomson, and Syhakhang 1997). In Burkina Faso, an NDP has
enhanced the performance of rural pharmacies (Krause and
others 1998). At the local and facility levels, increasing
accountability can also lead to a more rational use of drugs. A
simulation exercise in Tunisia that required physicians to relate
pharmaceutical budgeting to involvement in the procurement
process improved prescribing practices by containing costs
while increasing the use of essential drugs (Garraoui, Le
Feuvre, and Ledoux 1999). Enhanced management informa-
tion systems, with corresponding supervision, monitoring, and
top-level support, have improved contraceptive management
in several countries (Kinzett and Bates 2000). The introduction
of standard treatment guidelines and formularies has reduced
overprescribing in several countries, and educational materials
for consumers in Cameroon increased compliance with antibi-
otic regimens (Nabiswa, Makokha, and Godfrey 1993).
A comprehensive review of interventions used in Sub-
Saharan Africa, where health systems are plagued by shortages
of supplies, high costs, large-scale use of proprietary drugs,
waste, and theft, provided considerable evidence to suggest
what works in those countries (Foster 1991). Successful inter-
ventions included the following:
• selection and precise quantification of drug needs—in
particular, the creation of essential drug lists 
• improved procurement, with greater use of generics, com-
petitive bidding, and international procurement agencies 
• improved storage and distribution, with better storage con-
ditions, inventory controls, security systems, and use of
prepacked kits.
At the same time, several factors constrain better manage-
ment of pharmaceuticals. Considerable resources are needed to
adequately monitor NDPs, and implementation can be difficult
(Petrova 2002). Furthermore, much of the pharmaceutical use
is outside the control of the public sector: two-thirds or more of
health problems are self-medicated. Though the public sector
may strive to inform consumers, patients’ nonadherence
remains high (Le Grand, Hogerzeil, and Haaijer-Ruskamp
1999). As in management of other inputs, political considera-
tions can thwart managerial responses. The Republic of Korea
decided to divide its prescribing and dispensing functions
precisely to address high levels of pharmaceutical overuse and
misuse, but it subsequently faced strikes and stiff opposition
from those same stakeholders (Kwon 2003). Management of
pharmaceuticals thus presents a complicated challenge, requir-
ing significant investment and flexible responses.
Using Intellectual Resources
The process of generating, disseminating, and using knowledge
is frequently imperfect. Pang and others (2003) have argued
that a well-functioning health care system must have in place
mechanisms that allow it to access and use research and the
products of research. They highlight the weaknesses of much of
the existing health care research, including fragmentation,
overspecialization, and damaging competition among re-
searchers, who are frequently isolated from other researchers
and from the policy-making community. Drawing on concepts
of the functions of a health system, they identify a series of four
roles for a health research system:
• stewardship, which includes defining and articulating a
vision for a national research system, identifying appropri-
ate priorities, and setting and monitoring ethical standards 
• financing, which includes obtaining research funds and allo-
cating them accountably
• creating and sustaining resources, which includes the physical
and human capacity to conduct, absorb, and use research 
• producing and using research, which includes generating
valid research outputs; translating research into formats that
inform health policy, practices, and public opinion; and
promoting the use of research to support innovation.
Such a system must be able to answer the many different
questions requiring research, from basic laboratory science,
such as new drug development, through health services
research, such as comparisons of the cost-effectiveness of dif-
ferent drug regimens, to organizational research, such as the
best way of delivering the most cost-effective drug regimen.
Although the majority of health systems and services research
continues to be undertaken in the industrial countries, a grow-
ing volume of research addresses the needs of low- and middle-
income countries, such as that by the participants in the
Effective Health Care Alliance Programme (EHCAP), an inter-
national research network that is undertaking systematic
research within the framework of the Cochrane Collaboration
(http://www.liv.ac.uk/lstm/ehcap/introduction.htm).
Establishing Relationships
The debate about the relative benefits of vertical (in which a
single disorder is tackled by a program managed across levels
from the Ministry of Health to the health care provider) and
horizontal (in which health care for a wide range of disorders
is delivered through a system that is integrated at each level)
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systems of health care delivery has been examined in detail in a
major review of relevant literature by Oliveira-Cruz, Kurowski,
and Mills (2003). They note how many activities lie on a con-
tinuum between the two extremes, with the Global Polio
Eradication Initiative more vertical than the Expanded
Programme on Immunization, which in turn is more vertical
than the integrated management of childhood illness
approach. They identify certain features that are often associ-
ated with vertical programs and that promote success: specific
objectives, clear work schedules, well-defined techniques, and
frequent supervision. They also identify characteristics that are
often associated with horizontal programs and that can ham-
per effectiveness: shortage of essential drugs, lack of adequate
staff training, intermittent supervision, and limited backup.
However, they note that horizontal programs have considerable
potential to deliver effective services if they are adequately
funded, staffed, and managed, largely because of their
economies of scale and scope.
To some extent, the approach is determined by the nature of
the program. Vertical programs are most effective when the
technology involved is very sophisticated or when it includes
procedures different from the usual tasks and thus requires spe-
cialist skills. Vertical programs may be more appropriate when
there is a need to rapidly achieve major reductions in the bur-
den of a disease, although this situation does not preclude
embedding the management of the program within existing
organizations. These programs are often a response to weak
management capacity in the existing system, although it is
argued that they can perpetuate this problem or even under-
mine what does exist, diverting the attention of staff members
from their usual tasks. Such programs often have a short time
horizon, either being absorbed into existing systems or brought
to an end. In part, their duration is linked to the source of their
funding, which is often from donors who themselves have a
short time horizon.
Integrating previously vertical programs into mainstream
systems can be successful, as with schistosomiasis programs in
Saudi Arabia (Ageel and Amin 1997) and Brazil (Coura Filho
and others 1992). However, a systematic review of integration
failed to identify consistent benefits, largely because of the very
limited extent of the evidence available and the context-specific
nature of this process (Briggs, Capdegelle, and Garner 2001).
The authors of that review concluded that the question facing
policy makers is not whether one approach is invariably better
than the other; rather, it is how best to build on the synergies
among them to maximize overall benefits. They note, for
example, how the many successes of the Malaria Eradication
Programme in the 1950s and 1960s were not sustained because
active case surveillance was not integrated into routine health
services (see also Bradley 1998).
Successful vertical programs are likely to involve community
participation, but not to the extent that there is overdependence
and subsequent attrition of volunteers. The programs’ develop-
ers will have learned lessons from other similar programs, in
relation to both organizational and technical issues. Where
several vertical programs coexist, the programs’ developers
should explore how they can share common elements.
Contracting for Services
The setting of contracts by public agencies to purchase health
care services is increasingly common in a number of low- and
middle-income countries. The theoretical case for contracting
out identifies potential advantages from combining public
finance with private provision. However, there may also be dif-
ficulties, such as ensuring that competition takes place among
potential contractors, that competition leads to efficiency, and
that contracts and the process of contracting are effectively
managed; consequently, these advantages may not always be
realized (McPake and Banda 1994).
Unfortunately, the question of whether the advantages out-
weigh the disadvantages has been the subject of relatively little
empirical study in low- and middle-income countries, and
what exists is often highly context specific. For example, in
Zimbabwe, a comparison of a hospital owned by a colliery,
from which services were purchased by the government, and a
nearby government hospital found that the colliery hospital
offered services of at least comparable quality at prices lower
than the unit costs of the government hospital after capital
costs were included (McPake and Hongoro 1995). However,
failure to establish policies on thresholds for use meant that
growth in expenditure on the colliery hospital was not con-
trolled. The authors argue that contracted facilities can achieve
powerful bargaining positions if there are no viable competi-
tors and the government does not retain the ability to offer an
alternative service. They also identify a need for specific skills to
manage contracts at all levels. Where a policy of contracting is
a response to crises arising from civil service retrenchment
and public expenditure cuts, these skills are unlikely to be
developed.
Another study examined the economic arguments for con-
tracting for district hospital care in South Africa, by using pri-
vate for-profit providers, and in Zimbabwe, by using non-
governmental (mission) providers (Mills, Hongoro, and
Broomberg 1997). In the South African setting, there were no
significant differences in quality among three contractor hospi-
tals and three government-run hospitals, but the contractor
hospitals provided care at significantly lower unit costs.
However, the overall cost to the government was similar for the
two options because of the additional cost of contracting, with
the efficiency gains captured almost entirely by the contractor.
In Zimbabwe, two district-designated mission hospitals deliv-
ered similar quality care at lower cost than did two government
hospitals. However, the contract between the government and
Strategic Management of Clinical Services | 1347
the missions was implicit, rather than explicit, and was of long
standing. As in the other Zimbabwean example, the authors
identified the importance of developing the government’s
capacity to design and negotiate contracts that allow the gov-
ernment to derive significant efficiency gains from contractual
arrangements.
Increasing Provider Autonomy 
A review of cross-country experiences with enhanced auton-
omy of hospitals found improvements in service delivery. The
most successful cases—in Hong Kong (China) and Tunisia—
applied private sector management techniques and training,
with appropriate performance assessment systems for staff. In
countries where reforms were considered less successful, man-
agers had been granted greater autonomy without suitable
performance-oriented incentives (New Zealand) or vice versa
(Indonesia) (Hawkins and Ham 2003). In the Kenyatta
National Hospital, greater autonomy led to the introduction of
performance appraisal linked to incentives, enabling the dis-
missal of poor performers and increased benefits and greater
responsibilities for good performers. This change was coupled
with clarification of clinical management roles. Comple-
menting increased salaries for staff nurses, these changes
helped improve the hospital’s strategic management, donor
accountability, and performance reporting (Collins and others
1999).
Implementing such management strategies in a coherent
fashion is not an easy task. Hospital governance in several
Eastern European countries, which has been transferred to
local governments to improve responsiveness, has included
measures such as performance-based payment mechanisms.
Performance did not improve as expected because of an
“inconsistent incentive environment”; rewards and sanctions
were not linked to performance. Important factors in that fail-
ure to improve were weak stewardship functions and an
absence of effective governance at the regional level, which
made it difficult to change the initial configuration of the hos-
pital system. Instead, increased hospital autonomy was used to
ensure the survival of the institution rather than to meet the
needs of the population. Thus, a continuing excess of capacity,
inefficiency, and poor responsiveness to patient expectations
remains (Healy and McKee 2002a). A review of experience with
programs that increased autonomy in Sub-Saharan Africa also
identified only modest success in achieving the stated goals
(McPake 1996).
Public or Private Provision?
Although there has been considerable enthusiasm for privatiz-
ing state facilities because of the supposed efficiency gains
achieved in the private sector, in reality the evidence is
somewhat mixed. Thus, a study of dispensaries run by the gov-
ernment and by nongovernmental organizations in Tanzania
found considerable variation in both sectors (Gilson 1995).
This finding was consistent with another study in Tanzania of
primary care providers in Dar es Salaam. In the latter, although
the quality of care offered by private providers was, on average,
better, much low-quality care was found in both types of facil-
ities (Kanji and others 1995). Considerable variation in
providers of both types, although with overall better quality
in the private sector, was also reported in a study in Senegal
(Bitran 1995). In summary, there is very little evidence to sup-
port the contention that private provision is better than public
provision, and what evidence exists indicates considerable vari-
ations in both.
Strategic Purchasing
The quest to deliver effective health care is a dynamic process,
adapting continually to changing health needs and the oppor-
tunities that arise that make it possible to respond in new and
better ways. However, health systems that have failed in the past
to respond to these changing circumstances face even greater
problems. The pace of change is constantly increasing, with fac-
tors such as greater population mobility contributing to the
reemergence of infectious diseases and with demographic
changes and lifestyle changes giving rise to a new burden of
chronic diseases.
Health care providers have faced difficulties in responding
to this challenge on their own. Although they may possess a
great deal of information about the patient sitting in front of
them and, on the basis of their training and accumulated expe-
rience, about what might be done to help that patient, health
care providers confront several important information gaps:
• First, they may know little about those who, despite being in
need of health care, do not seek help. These people will often
be the most disadvantaged in a society, with few means of
making their voices heard.
• Second, they may have inadequate knowledge about newly
emerging treatments or more effective ways of providing
those treatments, especially if the treatments involve creat-
ing multidisciplinary teams with new sets of skills, working
in ways outside their experience.
• Third, even if providers introduce changes, they may have
inadequate knowledge of whether such changes have been
effective.
These knowledge gaps provide the justification for action to
improve the delivery of health care at several levels above that
of the individual encounter between the patient and the health
professional. Strategic purchasing brings together a series of
interlinked activities: assessing health needs, using appropriate
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evidence to develop models of care that meet priority needs,
creating the appropriate combination of regulations and incen-
tives to implement those models, and then evaluating the
response and reassessing whether the need remains (Figure
73.1). All of these activities should take place within an overall
health strategy that takes into account the goals of a health care
system, such as those defined by WHO (2000), of increasing
health attainment, providing services responsive to the popula-
tion’s needs and expectations, and financing those services
equitably.
The development of a strategic purchasing function is com-
plicated, requiring high levels of information resources, both
on health needs and on effectiveness. Strategic purchasing
involves using technical and political skills, determining the
needs of the population, identifying evidence of the effective-
ness of different care packages, and setting priorities within
limited resources. The last of these components is arguably the
most difficult, given the high level of need and the scarcity of
resources in many places. This list of components highlights
why, in addition to having skills in financial and personnel
management, the effective health service manager needs at least
a working knowledge of clinical epidemiology and economic
evaluation.
Even in industrial countries, the strategic purchasing func-
tion is often poorly developed. Given its many interlinked com-
ponents and the problem of isolating any benefits from wider
changes in the health system, this function is very difficult to
evaluate. Nonetheless, it is included here as a model from
which concepts may be adopted in low- and middle-income
settings.
SUMMARY
Health systems worldwide face unprecedented challenges in
responding to the increasing complexity of health care. Systems
that were capable of providing basic care to populations for
whom diseases were either simple or complex but self-limiting
confront a fatal struggle to keep up with the increasing oppor-
tunities that modern science has provided. The challenge is
especially great for health systems in low- and middle-income
countries because the global community is no longer willing to
sit back while millions of people die from treatable diseases
such as malaria and tuberculosis and fail to receive life-
prolonging therapies for AIDS. As a consequence, some of the
resources, primarily pharmaceuticals, are being made available
to those who need them. However, the challenge that health
systems face is not simply a lack of money to purchase phar-
maceuticals; effective management systems are requisite as well
to create the infrastructure to identify those in need, establish
appropriate treatments, and ensure provision of these treat-
ments as long as necessary. Emerging challenges must be iden-
tified, and the necessary resources to deal with them must be
brought together and applied effectively.
Many countries have a clear need to invest in the develop-
ment of human resources. Although in many cases this invest-
ment will require new and wide-ranging human resource
strategies involving training, career progression, and retention,
there seems to be scope for rapid gains from some shorter
forms of training, particularly, in communications skills.
Although the evidence for the effectiveness of current models
of management strengthening is somewhat mixed, gains may
be realized by identifying and filling key gaps, such as those in
financial expertise. Changing the skill mix can do much to
match available skills to tasks.
Much also can be done to manage the capital stock better or,
in most cases, to manage it at all. For example, mechanisms
such as capital charging can focus greater management atten-
tion on this issue, although this will work only if sufficient
capacity can be focused. Important gains can be made from
better management of pharmaceuticals, an issue of increasing
importance because of the new funds made available for their
purchase.
Modern health care is based on the growth of knowledge,
and it is as important to manage intellectual resources as it is to
manage people and equipment. Doing so means investing in a
health research strategy that includes the generation, synthesis,
and adoption of knowledge.
Finally, it is necessary to bring these resources together opti-
mally, which raises issues of relationships between different
levels of the system, between the public and private sectors, and
between vertical and horizontal programs. Unfortunately,
despite the large amount of rhetoric on these often highly ide-
ological issues, there is surprisingly little research to inform
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Figure 73.1 A Framework for Strategic Purchasing 
policy. More than ever, the issue of context specificity
reemerges, leading once more to the answer “it depends.”
The delivery of optimal health care requires well-developed
managerial skills to apply methods that are appropriate for
the setting in which they are being applied. However, it also
requires governments to provide oversight of their health sys-
tems and to anticipate changes and give managers the tools
with which to respond to those changes.
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Age-standardized rate An age-standardized rate is a weighted
average of the age-specific rates, where the weights are the pro-
portions of a standard population in the corresponding age
groups (q.v.). The potential confounding effect of age is
removed when comparing age-standardized rates computed
using the same standard population.
Age weights Factor specifying the relative value of a year of
healthy life lived at different ages. The DALY can incorporate
non-uniform age weights which give less weight to years of life
lived in early childhood and at older ages (see Chapter 5).
AIDS: Acquired Immunodeficiency Syndrome Disease due to
infection with the human immunodeficiency virus (HIV).
BMI: Body mass index A measure of underweight and over-
weight calculated as weight (kg) divided by height squared
(m2).
Case Fatality Rate The proportion of cases of a disease or
injury that die as a result of their disease or injury over a
specified time period.
CHD: Coronary heart disease Synonymous with ischemic
heart disease (q.v.).
Childhood-cluster diseases GBD (q.v.) cause group including
the following vaccine-preventable diseases of childhood:pertussis,
poliomyelitis, diphtheria, measles and tetanus.
CODMOD: Cause of death model A statistical model for the
prediction of the broad distribution of causes of death based
on observed historical data on the relationships between cause
distributions, and overall levels of mortality and per-capita
income.
Comorbidity Presence of more than one disease or health
condition in an individual at a given time.
COPD: Chronic obstructive pulmonary disease Lung
diseases that persistently obstruct bronchial airflow. COPD
mainly involves two related diseases—chronic bronchitis
and emphysema. COPD is also called chronic obstructive lung
disease. Asthma is not included in COPD, as the obstruction to
bronchial airflow is usually reversible and between asthma
episodes the flow of air through the airways is usually good.
CVD: Cardiovascular disease Cardiovascular disease covers a
wide array of disorders, including diseases of the cardiac mus-
cle and of the vascular system supplying the heart, brain, and
other vital organs. The most common manifestations of CVD
are ischemic heart disease, congestive heart failure, and stroke.
CVD is used here as an abbreviation for cardiovascular disease,
not cerebrovascular disease (q.v.)
DALY: Disability Adjusted Life Year A measure of the gap in
healthy years of life lived by a population as compared with a
normative standard. More formally, DALYs are a time based
measure which adds together years of life lost due to premature
mortality with the equivalent number of years of life lived with
disability or illness.
DFLE: Disability-free life expectancy A form of HE (q.v.)
which gives a weight of 1 to states of health with no disability
above an explicit or implicit threshold and a weight of 0 to
states of health with any level of disability above that threshold.
DBP: Diastolic blood pressure
Demography The study of population size, growth and age
structure, and of the forces (fertility, mortality, migration) that
lead to population change.
Disability Restriction or lack of ability (resulting from an
impairment or health condition) to perform an activity in the
manner or within the range considered normal. Although the
word “disability” is widely used, the ICF (q.v.) uses this term
only as a broad umbrella term for capacity and performance in
activity/participation domains. The GBD (q.v.) used the term
disability, as in the DALY (q.v.), as a synonym for health states
(q.v.) less than full health (q.v.). Disability is also commonly
used to refer only to long-standing limitations in carrying out
activities of daily living.
Disability weight Measure of the relative valuations of a
health state on an interval scale. In the GBD (q.v.), health
state valuations lie between 0 (full health q.v.) and 1 (states
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equivalent to death). The disability weight quantifies judg-
ments about overall levels of health associated with different
health states (q.v.), not judgments on the relative values of lives
lived, persons, or of overall well-being, quality of life or utility.
The GBD disability weights are intended to reflect average
global valuations.
Discounting Process applied to costs, benefits, and outcomes
based on the concept that there is preference for money or
health in the present relative to the future.
DisMod An epidemiological disease model linking popula-
tions exposed to risk of disease with incident cases, prevalent
cases, case fatality and the duration of time lived with a disease
or injury, including its sequelae.
DSP Disease Surveillance Points System run by the Chinese
Centre for Disease Control and Prevention for the surveillance
of mortality and morbidity.
Epidemiological transition The process whereby major com-
municable diseases and conditions of poverty (e.g. malnutri-
tion) are progressively replaced by non-communicable diseases
such as cancers and CVD.
Epidemiology The study of the occurrence and causes of dis-
ease and injury in populations.
Full health Health state (q.v.) characterized by optimal levels
of functioning or capacity in all the important domains of
health, and freedom from any type of illness or disease. The
“optimal” levels of functioning are defined as those levels above
which further gains would not (in general) be regarded as
improvements in health. States of exceptional functioning
above these levels are thus considered to be talents or excep-
tional abilities, not higher states of health.
Garbage codes ICD codes (q.v.) for ill-defined or residual cat-
egories of major disease groups (e.g. cardiovascular diseases)
that do not provide meaningful information on underlying
disease or injury causes of death. Examples include ill-defined
primary site of cancer and atherosclerosis.
GBD: Global burden of disease A comprehensive demographic
and epidemiological framework to estimate health gaps (q.v.) for
an extensive set of disease and injury causes, and for major risk
factors, using all available mortality and health data and meth-
ods to ensure internal consistency and comparability of esti-
mates. In the first global burden of disease study, Murray and
Lopez estimated health gaps using DALYs (q.v.) for eight regions
of the world in 1990. This book presents updated estimates for
the year 2001 for the world and for World Bank regions.
Group I causes Major disease and injury cause group used in
GBD (q.v.). Includes communicable, maternal, perinatal
and nutritional conditions. These are causes which are
characteristically common in populations who have not yet
completed the epidemiological transition (q.v.).
Group II causes Major disease and injury cause group used in
GBD (q.v.). Comprises non-communicable diseases, including
malignant neoplasms, cardiovascular diseases, chronic respira-
tory diseases, digestive, musculoskeletal and genitourinary
conditions, as well as mental disorders and neurological
conditions.
Group III causes Major disease and injury cause group used
in GBD (q.v.). Includes unintentional and intentional injuries.
HALE: Health-adjusted life expectancy Any of a number of
summary measures which use explicit weights to combine
health expectancies for a set of discrete health states into a sin-
gle indicator of the expectation of equivalent years of good
health. Also referred to as ‘Healthy life expectancy’.
HE: Health expectancy Generic term for summary measures
of population health which estimate the expectation of years of
life lived in various health states.
Healthy life expectancy Synonym for HALE (q.v.) or Health-
adjusted life expectancy.
Health state Health state refers to an individual’s levels of
functioning within a set of health domains such as mobility,
cognition, pain, emotional functioning, self-care, etc. More
specifically, in terms of ICF (q.v.) concepts, health state is
defined as the capacities of an individual in all important
domains of health, where such domains may include domains
of body structure and function, and domains of activities/par-
ticipation. Health states do not include risk factors, diseases,
prognosis or the impact of health states on overall quality of
life, well-being or satisfaction.
Health status A general term referring to all aspects of the
health of individuals or populations. Usually understood to
include mortality risks, diseases, health states (q.v.), impair-
ments and disability. May also include some risk factors or
prognosis information.
High income Category in the World Bank income grouping of
countries used for countries with Gross National Income (GNI)
per capita of US$9,206 or more (exchange rate adjusted curren-
cies) in 2001. See Table 3A-3 for list of countries included.
HIV Acronym for the Human Immunodeficiency Virus, the
cause of AIDS (acquired immunodeficiency syndrome).
Ideal health Synonymous with full health (q.v.).
Incidence New cases of disease or injury occurring in a speci-
fied population in a given time period.
Incidence rate New cases of disease or injury occurring per
unit of population, per unit time.
ICD: International Statistical Classification of Diseases and
Related Health Problems A classification of diseases and
other causes of mortality prepared by the World Health
1354 | Glossary
Glossary | 1355
Organization since 1948, periodically revised as necessary. The
current tenth revision was issued in 1992 to come into effect on
1 January 1993. The ICD is a member of the WHO family of
international classifications.
ICF: International Classification of Functioning, Disability
and Health A classification of body structures and functions
(impairments) and activities/participation domains (perform-
ance and capacity). The ICF was endorsed by the WHO World
Health Assembly in 2001 as a successor to the 1980
International Classification of Impairment, Disability and
Handicap (ICIDH). The ICF is a member of the WHO family of
international classifications.
IHD: Ischemic heart disease Any of a number of heart condi-
tions in which heart muscle is damaged or works inefficiently
because of an absence or relative deficiency of its blood supply;
most often caused by atherosclerosis, it includes angina pec-
toris, acute myocardial infarction (heart attack), chronic
ischemic heart disease and sudden death. The term coronary
heart disease is synonymous with IHD.
Life expectancy The average number of years of life expected
to be lived by individuals who survive to a specific age. See also:
Period life expectancy.
Logit transformation A mathematical function that trans-
forms a variable such as probability of death into another func-
tional form, characterized by asymptotic values.
Low- and middle-income Category in the World Bank
income grouping of countries used for countries with Gross
National Income (GNI) per capita of less than US$9,206 in
2001 (exchange rate adjusted currencies). See Table 3A-3 for list
of countries included.
MONICA Study The MONICA (MONItoring CArdiovascular
disease) Study was an international research project coordinat-
ed by the World Health Organization from the mid-1980s to
the mid-1990s in which teams from 38 populations in 21 coun-
tries studied heart disease, stroke and risk factors in their
populations.
Neonatal period Persons under the age of 28 days are in the
neonatal period. The neonatal period is itself divided into the
early neonatal period, age less than 7 days, and the remaining
late neonatal period.
PAF: population attributable fraction Proportional reduc-
tion in disease or injury that would occur if population expo-
sure to a risk factor or group of risk factors were reduced to an
alternative distribution.
Perinatal deaths Includes stillbirths and neonatal deaths from
any cause, including tetanus and congenital malformations.
The perinatal period includes the period from 27 weeks of ges-
tation to 28 days of life.
Perinatal causes or conditions The cause category Perinatal
causes refers to the ICD cause group “Conditions arising in the
perinatal period”. Deaths from these causes (primarily low birth
weight and birth trauma/ asphyxia) may occur at any age, but
are largely confined to the perinatal period.
Period life expectancy A summary measure of a population’s
mortality that measures the expectation of years of life lived by
a fictitious birth cohort assuming that at each age the cohort
experiences the age-specific mortality rates observed in the real
population during a specified time period (such as a given cal-
endar year). See also: life expectancy.
Postneonatal period Persons between the age of 28 days and 1
year are in the postneonatal period.
Prevalence Actual number of cases of disease or injury present
in a population at any particular moment in time.
Probability of death The chance that an individual, alive at
age x, will be dead before his or her (x  n)th birthday, usually
written as nqx . 5q0 denotes the probability that a newborn
infant will die before his or her fifth birthday.
PTO: person trade-off A method for valuation of health states
that asks respondents to choose between hypothetical interven-
tions that offer health benefits to groups of individuals in dif-
ferent health states.
QALY: Quality-adjusted life year A measure of years of life
lived (or gained through an intervention) adjusted for quality
of life using health state preferences ranging between 0 (states
equivalent to death) through to 1 (full health). QALYs
were developed for the assessment of the cost-effectiveness of
interventions in health economics. QALYs gained and DALYs
averted through an intervention are calculated in very similar
ways, and the main differences relate to the interpretation of
the weights. Whereas the disability weights in the DALY
quantify loss of health, the corresponding QALY weights
are often interpreted in terms of well-being, quality of life,
or utility.
Risk Factor A risk factor is an attribute or exposure which is
causally associated with an increased probability of a disease
or injury.
RR: Relative risk Relative risk is a measure of the strength of
an association. It is calculated as a ratio of the risk of occur-
rence of a disease or death among two population groups, such
as those exposed to a risk factor and those not exposed.
SD: Standard deviation A measure of the dispersion or spread
of values of a variable (e.g. body weight) around a population
mean value.
Sensitivity analysis Systematic investigation of the effects on
estimates or outcomes of changes in data or parameter inputs
or assumptions.
Sequelae The medical conditions that can occur among peo-
ple who contract a disease or suffer an injury. The GBD (q.v.)
focuses on disabling sequelae of diseases and injuries; these
may remain present long after the initiating disease episode or
injury event.
Standard gamble (SG) A method for valuation of health states
based on the axioms of expected utility theory. The standard
gamble asks respondents to make choices that weigh improve-
ments in health against mortality risks.
Standard Population A population structure that is used to
provide a constant age or covariate distribution, so that the
age- and sex-specific rates within different populations can be
applied to it and can be compared without confounding by the
different age or covariate distributions of the populations.
STD: Sexually transmitted disease See: STI.
STI: Sexually transmitted infection An infection that can be
transferred from one person to another through sexual contact.
Among the sexually transmitted infections (STIs) are
HIV/AIDS, chlamydia, genital herpes, gonorrhea and syphilis.
The term “sexually transmitted infection (STI)” corresponds to
the older term “sexually transmitted disease (STD)”.
SMPH: Summary measures of population health Indicators
that summarize the health of a population into a single number.
SMPH combine information about mortality and population
health states.They may summarize either the average health level
or health inequality for a population. The two main classes of
summary measures are health expectancies (q.v.) and health gap
measures, of which the DALY (q.v.) is the best-known example.
Stillbirth Stillbirth refers to the birth of a dead fetus weighing
more than 1,000 grams up to 0.25 years (13 weeks) prior to the
expected time of birth (corresponding to 27 weeks of gesta-
tional age).
Stroke Stroke is defined as a condition that results in a disrup-
tion of blood flow to a region of the brain causing irreversible
“death” of brain tissue. There are two main types of stroke:
hemorrhagic and ischemic stroke. Stroke is the main cause of
mortality and burden for cerebrovascular disease (q.v.).
Sullivan’s method A method of calculating health expectan-
cies using data on the current prevalence of health states in a
population together with a period life table for the population.
Theoretical-minimum-risk exposure distribution The pop-
ulation distribution of exposure to a risk factor that would
result in the lowest population disease burden.
TTO: time trade-off A method for valuation of health states
that asks respondents to make hypothetical choices that weigh
improvements in health against reduced longevity.
Uncertainty analysis Estimation of range or distribution of
uncertainty in estimates based on an assessment of the uncer-
tainty or confidence intervals for all data and parameter inputs.
Uncertainty intervals should ideally include all sources of
uncertainty, including those arising from systematic biases and
measurement error. In contrast, generally reported confidence
intervals are based solely on the variation observed in sample
data.
Visual analogue scale A method for valuation of health states
in which respondents are asked to directly assess health levels
associated with different health states. Individuals place these
on a 0 to 1 scale representing a continuum from health states
considered equivalent to death through to full health (q.v.)
Verbal autopsy A method of inquiry to ascertain the likely
cause of death in populations where vital registration of deaths
is incomplete and unreliable. Relatives of the deceased are
interviewed about symptoms and signs experienced by the
deceased prior to death, from which a diagnosis of the proba-
ble cause of death is made.
Vital registration A system for the registration of vital events
in a population, including births and deaths, with medical cer-
tification of the cause of death according to the rules and pro-
cedures of the ICD.
YLD: Years Lived With Disability The component of the
DALY (q.v.) that measures lost years of healthy life through
living in health states of less than full health (q.v.).
YLL: Years of Life Lost The component of the DALY (q.v.) that
measures years of life lost due to premature mortality.
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costs and cost-effectiveness of
interventions, 1117, 1118–1119t
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1117, 1120t
health challenges of, 1109
health risk behaviors of, 1111–1112
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interventions, 1114–1117
lessons learned, 1120–1122
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1116–1117
research and development agenda,
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1112, 1113t, 1114–1116
sexually transmitted infections 
and, 1112
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water supply in, 771, 772, 773, 774, 776
WHO–ILO Joint Effort on Occupational
Health and Safety in Africa, 1134
yellow fever in, 396–397
Africa Measles Partnership, 404
African Americans
coronary artery disease of, 833
diabetes of, 598
African Programme for Onchocerciasis
Control (APOC), 168, 172, 437,
444, 957
African trypanosomiasis
burden of, 456
characteristics and transmission, 453–454
costs and cost-effectiveness of
interventions, 46, 459–460
economic impact of, 456
management and control strategies of,
458, 462–463
social impact of, 456
African Union, 462
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aging
arthritis and, 963
chronic diseases and, 107, 1333–1334
dementia and, 124
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other dementias
hearing loss and, 958
pregnancy of women over 40, 1079
shift of burden of disease due to, 1331
understanding biological basis of, 124
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Agreement on Trade-Related Aspects of
Intellectual Property Rights. See
TRIPS (Agreement on Trade-Related
Aspects of Intellectual Property
Rights)
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190, 220
agricultural runoff, 821
AIDS. See HIV/AIDS
AIDSVAX, 360b
air and water pollution, 817–832
See also indoor air pollution
air pollutants, 818–820
causes and burden of, 817–822
costs and cost-effectiveness of
interventions, 825–827, 826t
air pollution, 825–826
comparison of interventions, 825, 827t
water pollution, 826–827
economic benefits of interventions,
827–828
exposure to air pollutants, 819
exposure to chemical water pollution, 822
health impacts
air pollution, 819–820
water pollution, 822
industrial sectors contributing to, 818,
819t, 821
interventions, 823–824, 823f
air pollution, 823–824, 824b
water pollution, 824
lessons learned
air pollution, 828–829
water pollution, 829
research and development agenda,
829–830
sources of air pollution, 818–819
sources of chemical water pollution,
820–822
water pollutants, 820–822
albinism, 717–718
alcohol use and control, 887–906
addiction as clinical disorder, 887–888
adolescents and, 1111
advertising bans, 894
beneficial effects of moderate alcohol 
use, 887
costs and cost-effectiveness of
interventions, 49, 896–899, 898t
drowning and, 741
drunk driving and, 739–740, 893, 894t,
901–902
economic benefits of interventions,
899–900
epidemiology of, 887–890, 888f
fetal alcohol syndrome, 936b
high-risk drinking
burden of disease related to,
890–892, 891t
DALYs attributable to, 892t
epidemiology of, 888–889, 889t
interventions for reducing, 892–896
relationship to alcohol use 
disorders, 889
interpersonal violence and, 760
interventions
brief interventions, 894, 902
population-level effects and costs,
896–899, 897t
self-help, 911
kidney disease and, 699
lessons learned, 900–902
liver cancer and, 573
musculoskeletal disorders and, 966
relationship between alcohol use and 
disease categories, 889–890
research and development agenda,
902–903
sales hours and places of purchase,
regulation of, 893–894, 900–901
social determinants of exposure and 
risk, 890
taxation to discourage use, 218, 893,
895t, 900
Alcoholics Anonymous, 911
alfacalcidol, 972
allergies and homeopathy, 1288
Alma Ata Declaration on Primary Health
Care (1978), 88, 1193
alternative medicine. See complementary
and alternative medicine (CAM)
Alzheimer’s disease (AD) and other 
dementias, 124, 131, 627–629
See also neurological disorders
burden of, 628, 629t
cost-effectiveness of interventions in
developing countries, 637
interventions, 628–629
multi-infarct dementia, 628, 629
personal interventions, 629
population-based interventions,
628–629
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recommendations, 640
research and development agenda,
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survivorship, 628
women and, 201, 205–206
ambulances, 1267–1271, 1269t, 1270t
ambulatory care. See primary care
American Academy of Pediatrics 
recommendation on television
watching, 835
American Heart Association, 651, 658
American Psychiatric Association, 908
American trypanosomiasis. See Chagas 
disease
AMI. See acute myocardial infarction
amphetamines. See drug dependence
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in children, 553–554, 1094
costs and cost-effectiveness of
interventions, 561
developmental delays and, 562
helminth infections and, 467–468,
471, 553
interventions, 558
lack of data on interventions for, 563–564
in pregnant women with malaria, 420
in school-age children, 1094
ankylosing spondylitis, 976
anthrax, 107
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cost-effectiveness methods and results,
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generalized anxiety disorder, 611
interventions for panic disorder, 612–613
natural history and course, 612
obsessive-compulsive disorders, 612
phobias, 612
posttraumatic stress disorder (PTSD),
605, 610, 621
social anxiety disorder, 611
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427, 1043
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water supply and, 779
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as inexpensive intervention for CVD,
109, 123f
asthma. See chronic obstructive pulmonary
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attention deficit hyperactivity disorder
(ADHD), 935b
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dengue in, 452
detoxification methods in, 912
ecstasy (MDMA) use in, 924
heroin use in, 908, 909
illicit drug use in, 909, 922
interpersonal violence in, 763
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bacterial skin infections, 708, 709, 710–713,
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community-based programs in, 1067
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contracting for health care services in,
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development assistance and health 
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interpersonal violence in, 756, 757
leishmaniasis in, 452
leprosy in, 441
medical workers in, 1312
neonatal deaths in, 531, 533, 1079
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respiratory diseases of children in, 492
road traffic injuries in, 746
TB in, 291, 295
tidal wave in, 1149
BCG. See bacillus Calmette-Guérin
behavioral change interventions
successful programs, 175–177
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cardiovascular disease in, 649, 649t
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interpersonal violence in, 766
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excreta disposal in, 780
hemoglobinopathies in, 675
road traffic injuries in, 749b
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Better Health in Africa (World Bank), 1194
Bhopal catastrophe (India 1984), 819, 819b,
1133, 1149
bicycles. See transportation
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AIDS prevention efforts and, 254
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165, 240n5, 243, 244–245, 244t, 397
disease control priorities and, 111, 115
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partnerships, 147
Index | 1359
biologic terrorism
surveillance for, 998, 1008
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costs and cost-effectiveness of
interventions, 47, 613–619,
614–618t
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genomics and, 131
interventions, 609–610
natural history and course, 609
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bird flu. See avian influenza threat
blackfly control, 178, 435
blindness, 953–957
burden of, 954–956, 955t
cataract surgery, 956, 1258b
causes and epidemiology of,
953–957, 954t
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cost-effectiveness of interventions, 954t
definitions of visual impairment 
levels, 954t
interventions, 956–957
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blood-related disorders.
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HIV/AIDS and, 346–347
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African trypanosomiasis in, 458
HIV/AIDS in, 349, 360b
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1309–1310
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alcohol consumption regulation in,
900–901
breast cancer management in, 205
cardiovascular disease in, 650, 659
cervical cancer screening in, 576, 577t
Chagas disease in, 436, 438, 442
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cholesterol, and obesity in, 853–854
dengue in, 461
diarrheal diseases in, 374, 375, 376,
378, 778
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fluoridation of water in, 725
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to mothers, 187
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Effectiveness, Cost, and Impact
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physical activity initiative in, 841b
road traffic injuries in, 744, 745–746,
900–901
sexually transmitted infections in, 323
skin diseases in, 715
smallpox in, 1163
surveillance project in, 1021
transportation policy in, 839b
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treatment interventions for, 580–581
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African trypanosomiasis in, 458
drug policy in, 1346
health care worker safety for 
immunizations and injections 
in, 1132
hygiene promotion in, 785
malaria in, 421
sexually transmitted infections in, 325
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programs, 573
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cardiovascular disease (CVD), 15–16,
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burden of, 107, 649–650, 649f
as cause of death, 107
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heart failure (CHF)
costs and cost-effectiveness of
interventions, 47–48, 650–658,
655t, 656t, 657t, 858–863, 861t
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lung cancer, 574–575
metabolic disorders, 937
musculoskeletal disorders, 971
prenatal screening, 942–946, 944t, 948
sickle cell disease, 675–677
thalassemias, 673–675
secondary prevention
cancer, 572, 574–579
defined, 59
secondhand smoke, 875–876
self-help programs for substance abusers,
911, 913
self-targeting, 216
Senegal
contracting for health care services in,
188, 1297
HIV/AIDS in, 106, 358
mortality decline in, 10
skin diseases in, 708, 715
sensory deficits. See blindness; hearing loss
sentinel surveillance, 1002, 1021
severe acute respiratory syndrome.
See SARS
sex distinguished from gender, 196
sexual health, 1087
adolescents and, 1112, 1113t,
1114–1116
sexually transmitted infections (STIs),
311–330
adolescents and, 1112
antibiotic use for, 314, 322
bacterial STIs and their sequelae, 314–315
behavioral risk factors
associated with acquisition and 
transmission, 317
compensating behavior changes for,
317, 322
for exposure to infected sex partners,
316–317
burden of, 319–321
DALYs gained from prevention and
treatment, 319–320, 319t
impact of STIs on HIV, 320–321, 321t
circumcision as possible protection
against, 320, 322, 360b
coinfection with sexually transmitted
pathogens, 316
community-level interventions, 322–323
condom use for prevention, 312,
1080–1081
control strategies, 203, 323
scaling up of, 324–325
core groups and bridge populations,
313–314
costs and cost-effectiveness of interven-
tion, 323–324
determinants of costs, 323–324, 324t
demographic and social risk markers, 316
drug resistance and, 314, 1036
duration of infectiousness, 317, 322
effectiveness of interventions, 321–323
epidemiology and control, 313–314
epidemiology and management (since
1993), 312–313
gonorrhea, 314
group-level interventions, 322
HIV/AIDS and, 312, 314
See also HIV/AIDS
income and inequality, 318, 318t, 319f
individual-level interventions, 322
prevention of acquisition, 322
prevention of transmission, 322
research and development agenda,
325–326
societal determinants, 318
syndromic management, 313, 325
syphilis, 314
vaccines for, 322
viral STIs and their sequelae, 315
shigella, 371, 374, 378
See also diarrheal diseases
drug resistance and, 1034–1036, 1045
vaccine development needed for,
378, 383
sick leave from work, 221
sickle cell anemia and related diseases
See also hemoglobinopathies
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burden of, 667–669, 669t
clinical features of, 664
costs and cost-effectiveness of
interventions, 674t, 675–677, 676t
global distribution and frequency of,
665–667, 665f, 666t, 667f
interventions, 669–672, 677–678
neonatal screening and prophylaxis,
675–677
population genetics and dynamics,
664–665
Sierra Leone
development assistance for health to, 253
neonatal deaths in, 531
Significant Caries (SiC) Index, 724, 724t
silicosis. See occupational lung diseases
Sindh Instate of Urology and
Transplantation, 703
Singapore
Fit and Trim Program, 842
hemoglobinopathies in, 670
Kaposi’s sarcoma in, 730
National Healthy Lifestyle Program, 843b
road traffic injuries in, 744
transportation choices in, 839
Single Convention on Narcotic Drugs
(1961), 986
skin diseases, 707–721
See also leprosy
acne, 708
bacterial skin infections, 709, 710–713,
712–713t
Buruli ulcers, 709
current status of current community
control measures in dermatology, 720
economic assessments and diseases in
developing countries, 711–713t,
716–717t, 718–720, 719t
eczema or dermatitis, 708
effective therapies, 709, 709t
endemic treponematoses, 709
filarial lymphoedema, 709
fungal infections, 713–715
HIV-related, 707, 708, 709, 717
nonfilarial lymphoderma, 709
onchocerciasis and, 709
patterns at community level, 708–709
pediculosis, 708
pigmentary disorders of, 708, 717–718
prevalence of, 708
pyoderma, 708, 709, 710–713, 712–713t,
718, 719t
scabies, 708, 709–710, 711t, 719t
Tinea capitis, 714–715, 716t, 718, 719t
Tinea imbricata (Tokelau ringworm), 715,
717t
tropical ulcers, 709, 715, 717, 718
sleeping sickness. See African 
trypanosomiasis
smallpox eradication, 121, 165, 168, 172,
1163, 1169–1170, 1169t, 1170t
smoking. See tobacco use and control
smuggling of tobacco products, 877
soap subsidy, 217
social anxiety disorder, 611, 612
See also anxiety disorders
social epidemiology
research and development agenda, 109
social marketing
adolescents and, 1116, 1122
of contraceptives, 1081
Social Marketing for Adolescent Sexual
Health Project, 1122
social security reforms, 237–238, 237t
soda consumption and obesity, 835, 836
soil-transmitted helminth infections (STH
infections). See helminth infections
solidarity funds, 228
Somalia
African trypanosomiasis in, 458, 460
refugee populations and 
surveillance, 1009
somatic cell nuclear transfer, 130
South Africa
African trypanosomiasis in, 458, 460
cardiovascular disease in, 650, 656
cervical cancer screening in, 205
combination of high blood pressure,
cholesterol, and obesity in,
853–854, 862t
Community Health Intervention
Programme, 842
Coronary Risk Factor Study in, 843b
dental treatment in, 729
drunk-driving enforcement in, 901–902
excreta disposal in, 782
HIV/AIDS treatment in, 376
hospitals in, 1218, 1231, 1296, 1347
interpersonal violence in, 760, 761,
765–766
Kaposi’s sarcoma in, 730
kidney and urinary system diseases 
in, 703
malaria in, 420
outsourcing of health care services 
in, 93b
Perinatal Education Programme 
in, 545
Perinatal Problem Identification
Programme in, 546b
poisonings in, 747–748
primary care in, 1201
public view that public clinics dilute
drugs, 98
respiratory diseases of adults in, 691
sales tax exemptions on healthy foods 
in, 220
sexually transmitted infections in,
323, 325
tobacco-related legislation in, 168
South America. See Latin America and
Caribbean
South Asia
See also specific countries
alcohol consumption in, 898
breastfeeding in, 539
cardiovascular disease in, 649, 650, 652,
654, 655t, 656t
cost-effective interventions for, 50, 51t
neglected low-cost opportunities and
high-cost interventions in, 54–57t
dengue in, 454, 455, 457
development assistance for health 
to, 245
diet in, 836
epilepsy in, 631
food manufacture in, 845
hygiene promotion in, 784–785
leishmaniasis in, 455
malaria in, 414, 420
maternal and perinatal conditions in,
520t, 521t
mental disorders in, 614, 618, 619, 622
neonatal deaths in, 531
neurological diseases in, 628, 631
oral cancer in, 572
performance-based contracts with NGOs
in, 253
proposed guidelines for HIV/AIDS in,
348–349
road traffic injuries in, 746
strokes in, 634, 640
syphilis in, 314
tobacco use and control in, 880
vaccine-preventable diseases in, 397, 400,
402, 408
vital events registration in, 1021
women in, 195
Southeast Asia
See also specific countries
avian influenza in, 682b
ecstasy (MDMA) use in, 924
hemoglobinopathies in, 665, 666
mental disorders in, 620–621
rheumatic heart disease in, 647
strokes in, 633
Southern Cone Initiative on Chagas
disease, 167, 170, 177, 438
Spain
drug-related deaths in, 909
malaria in, 421
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Special Programme for Research and
Training in Tropical Diseases
(WHO), 114, 115, 145, 148t,
423, 446
spina bifida, 939–940
Sri Lanka
hemoglobinopathies in, 675
malaria in, 414, 418, 421
neonatal death reduction in, 533, 547b
prenatal care and childbirth in, 168,
169, 174
primary care in, 1202
water supply in, 774
STATCAP, 1028
statistics, use of, 121, 1021–1022
See also information systems
stem cell therapy, 130
sterilization, 1080, 1082
stewardship, 91–92, 1122, 1346, 1348
STH (soil-transmitted helminth) 
infections. See helminth infections
stillbirths. See child mortality
stomach cancer, 569, 570, 573, 574
stones and obstructive uropathy of
kidneys, 697–698
See also kidney and urinary system 
diseases
Stop TB Partnership, 182, 289
stoves, use of. See indoor air pollution
strategic management of clinical services,
1339–1352
strategic purchasing, 1348–1349, 1349f
Strategies for Enhancing Access to
Medicines Project, 92b
stroke, 633–635
See also cardiovascular disease (CVD);
neurological disorders
acute management and secondary 
prevention of, 48
burden of, 634
cost-effectiveness of interventions in
developing countries, 637, 639t, 640
frequency of types, prevalence, incidence
rates, mortality, and disability after
stroke, 633
interventions, 634–635, 635
ischemic hear disease (IHD) and, 646
personal interventions, 634–635
recommendations, 640
risk factors, 633–634
stunting, wasting, and micronutrient 
deficiency disorders, 551–567
adolescents and, 1111
causes and burden of, 551–554, 552t
community-based health interventions,
1068
costs and cost-effectiveness of
interventions, 559–561, 560t
DALYs lost due to in children under age
five, 552, 553t
deaths due to in children under age five,
552, 552t
economic benefits of interventions,
562–563
interventions, 555–559
iodine deficiency, 554, 558–559
iron deficiency, 553–554, 558
lessons learned, 563–564
research and development agenda,
564–565
school-age children and, 1093, 1093f
vitamin A deficiency, 553, 556–558
zinc deficiency, 554, 559
Sub-Saharan Africa
See also specific countries
African trypanosomiasis control in,
454, 456
breastfeeding in, 539
cardiovascular disease in, 647, 649, 650,
654, 655t, 656t
contraceptive use in, 1076, 1080
cost-effective interventions for, 50, 52t
neglected low-cost opportunities and
high-cost interventions in, 54–57t
diabetes in, 1333
diarrheal diseases in, 373
drug treatment in, 1346
epilepsy in, 631
guinea worm eradication in, 167, 169, 176
hemoglobinopathies in, 664, 665, 678
HIV/AIDS in, 106, 1070–1071
hospital-acquired diseases in, 1224
hospitals in, 1221b
indoor air pollution in, 803
influenza in, 684
interpersonal violence in, 757
iron deficiency in, 553–554
leishmaniasis in, 455
malaria in, 413, 414, 415, 417–418, 421,
423, 426, 935b
maternal and perinatal conditions in,
520t, 521t, 522
measles in, 396
mental disorders in, 614, 618, 619,
621–622
neonatal deaths in, 531, 533
neurological diseases in, 631
noma (Cancrum Oris) in, 730–731
poisonings in, 747–748
proposed guidelines for HIV/AIDS 
in, 349
provider autonomy in, 1348
school health programs in, 1101
skin diseases in, 707, 709
smallpox in, 1163
strokes in, 634
syphilis in, 314
TB in, 302
tobacco use and control in, 880
tsetse flies in, 454
vaccine-preventable diseases in, 395, 397,
399, 400, 402, 408
vaccines and drugs, access to, 1346
zinc deficiency in, 554
subsidies for health and health-related
products, 212–218, 212t, 213–214t
consumer subsidies, 212–218
diet, 843
food subsidies for young children, 555
producer subsidies, 218
substance abuse. See alcohol use and
control; drug dependence
Sudan
African trypanosomiasis in, 456, 460
guinea worm eradication in, 169
leishmaniasis in, 453, 459
polio in, 1170–1171
refugee populations and 
surveillance, 1009
suicide, 16, 607, 758
See also interpersonal violence
adolescents and, 1111, 1121
costs and cost-effectiveness of interven-
tions, 48
sulfadoxine-pyrimethamine, 45, 92
resistance to, 1032, 1036
sulfonamides, 122
surgery, 1245–1259
burden of surgical conditions, 1245–1248,
1247t
by condition and region, 1248t
methods of, 1246
for cancer, 580–581, 584
for cardiovascular disease, 651, 654, 658,
857–858
cataract surgery, 956
causes of surgical conditions, 1245–1248
community clinics and, 1249, 1253–1255,
1253t, 1254t, 1256f
coordinated model system for, 1251
costs and cost-effectiveness of
interventions, 49–50, 1251–1255,
1256, 1257b
cost assumptions, 1253t
method for estimating costs and
DALYs, 1252
at district hospitals, 5b, 27, 1249,
1253–1255, 1253t, 1254t, 1256f
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for epilepsy, 631, 637
for hearing improvement, 959
high volume of care and quality 
of, 1299
hip replacement surgery, 973
human resources and, 1256
interventions, 1248–1251
for kidney disease, 701–702
knee replacement surgery, 973
minimally invasive, 130–131
for musculoskeletal disorders, 968
for Parkinson’s disease, 632–633, 637
population-based interventions,
1248–1249
research and development agenda,
1255–1257
resource requirements for services and
level of care, 1250–1251t
SAFE strategy to combat trachoma.
See SAFE (surgery, antibiotics, face
washing, environmental change)
strategy to combat trachoma
single-shot surgical services, successful
programs involving, 174
at tertiary hospitals, 1249–1250
surveillance, 997–1015
active surveillance, defined, 998, 1021
analysis and dissemination of surveillance
data, 999–1000
avian influenza and, 1005–1006
as basis for evidence-based 
decisions, 1001
behavioral risk factor surveillance system,
defined, 998
biologic terrorism and, 998, 1008
categorical surveillance, defined, 998
chronic disease and, 1009–1010
disaster situations and, 1008, 1154
drug resistance and, 1042–1043
Ebola and, 1006
economics of, 1010–1011, 1010t
emergency surveillance, 1008
environmental public health surveillance,
1006–1007, 1006f
eradication of infectious diseases 
and, 1166
establishing and maintaining system for,
999, 1000b
field epidemiologists providing evidence,
1001–1002
future of, 1011
global surveillance networks, 1011–1012,
1012f
health information and management 
system, defined, 998
indicator, defined, 997
informal networks as elements of,
1004–1005
injury surveillance, 1007–1008
Integrated Disease Surveillance and
Response (IDSR), 1003–1004
integrated surveillance, defined, 998
laboratory-based surveillance,
1002–1003, 1003f
objectives of, 998–999, 999b
occupational health, 1133, 1143
as part of national public health
systems, 1000
passive surveillance, defined, 998, 1021
population-based surveys used
in, 1002
principles and uses of, 999, 999t, 1021
refugee populations and, 1008–1009
research agenda for, 1012–1013
routine health information system,
defined, 998
SARS and, 1005
sentinel surveillance, 1002, 1021
strategies for, 1002–1005
syndromic surveillance, defined,
998, 1008
as tool to improve public health,
1001–1002
training for, 117
SWaps (finance instruments), 234–235
Sweden
development assistance for health 
from, 244
diabetes and lifestyle changes in, 593
fluoridation programs in, 729
oral health programs in, 729, 733
oral precancer and cancer in, 730
Switzerland
iodine fortification program in, 554
salt fluoridation in, 725–726
synovial fluid replacement, 973
syphilis. See sexually transmitted 
infections (STIs)
T. vaginalis, 315
tacit knowledge, 110
Taiwan
arsenic contamination of water 
in, 821
strokes in, 633
universal coverage approach of, 237
tamoxifen, 574, 580
Tanzania
adolescents in, 1116
African trypanosomiasis in, 458
community-based programs in,
1066, 1068
deworming programs in, 478
DOTS development in, 111
drug shops, regulation in, 92b
HIV/AIDS in, 320, 331, 352
hospitals in, 1218
IMCI program in, 1181–1183, 1183b,
1184, 1184f, 1185b, 1186, 1187
kidney and urinary system diseases 
in, 702
leprosy in, 437
lymphatic filariasis in, 440
malaria in, 421, 425
malnutrition in, 1068
management of health care in,
1345, 1348
mental disorders in, 620
Multi-Country Evaluation of IMCI
Effectiveness, Cost, and Impact
(MCE) in, 1181–1183, 1183b
oral health and education program 
in, 726
primary care in, 1343, 1348
regulation of health care in, 1296
road traffic injuries in, 749b
sexually transmitted infections in,
320, 322
skin diseases in, 708, 720
strokes in, 633
training of medical staff on acute 
respiratory infections of children 
in, 1297
vital events registration in, 1021
water supply in, 773
Tanzania Essential Health Intervention
Program (TEHIP), 1024,
1026–1027, 1026b, 1202, 1208n2
targeting of interventions. See specific 
diseases and conditions
taxation
on alcohol, 218, 893, 895t
consumer taxes, 218–220, 219b
discouraging high-risk behaviors by, 177,
213–215t
on drugs, 1327
as method of revenue collection,
227, 229
producer taxes, 220
promoting health policies, 213–215t,
218–220
sales tax exemptions on healthy foods and
medicines, 220
on tobacco, 177, 218, 874–875, 875f,
879f, 882
on unhealthy foods, 219–220
TDR. See Special Programme for Research
and Training in Tropical Diseases
Index | 1393
technological progress and health gains,
10, 119–137
See also genomics
“appropriate technology” for developing
world, 111
array technology, 128
community health and nutrition 
programs and, 1063
cost-effective interventions and, 53
in developing countries, 133
dissemination of information on, 1297
high-technology hospital practice, 125,
1223, 1226
history of 20th century for science,
technology, and medicine, 120–126
immunization technologies, 1335
information and communication 
technologies (ICT), 1022
newborn care, 547
occupational health and, 1143
potential of information technology, 117
product development priorities, 139–155
vaccine technologies, 1334
teeth. See dental caries; oral and craniofacial
diseases and disorders
TEHIP. See Tanzania Essential Health
Intervention Program
television watching, 835, 838b
terrorism, 104b
attacks as disasters, 1161n1
biological, 107, 998, 1008
tertiary hospitals. See referral hospitals
tetanus. See diphtheria, pertussis, tetanus
Thailand
avian influenza in, 682b, 1005–1006
child mortality in, 1068
community-based programs in, 1059f,
1065, 1066, 1067
condom program in, 167, 170, 176
dengue in, 452, 455, 457, 459, 461
development assistance and health 
policy, 248b
drug dependence in, 916
epilepsy in, 630
fall-related injuries in, 748–749
hemoglobinopathies in, 668, 670, 673,
674–675
HIV/AIDS in, 13, 106, 167, 348b, 352
incentive pay to doctors in, 95, 95b
Kaposi’s sarcoma in, 730
kidney and urinary system diseases in,
697, 702, 703
medical workers in, 1315
milk fluoridation in, 726
nutrition investment in, 248b
occupational health in, 1132
oral and craniofacial diseases and 
disorders in, 723
road traffic injuries in, 744
sexual risk behaviors in, 312
sexually transmitted infections in, 323
skin diseases in, 708
tobacco taxes in, 882
vaccine-preventable diseases in, 406
water pollution in, 829
Thalassemia International Federation, 678
thalassemias, 127f
See also hemoglobinopathies
bone marrow transplantation, 675
burden of, 667–669
clinical features of, 664
control and treatment, 669–672
cost and effectiveness of diagnosis and
management, 673–675, 674t, 675t
global distribution and frequency of,
665–667, 666f, 666t, 667f
options for control and management 
of, 677
population genetics and dynamics,
664–665
screening and counseling, 673–675
Tinea capitis, 714–715, 716t, 718, 719t
See also skin diseases
Tinea imbricata (Tokelau ringworm),
715, 717t
See also skin diseases
tobacco-related deaths, 15f, 120, 869,
870–871, 871t, 872f, 878–880,
879t, 882
tobacco use and control, 869–885
adolescents and, 1111, 1116
advertising restrictions, 876
bans on smoking in public places,
875–876
cancer and, 573, 833, 871–872
cardiovascular disease and, 647, 652,
659, 833
cessation, 870, 872–873, 873f, 876–877
chronic diseases and, 833
cleft lip and palate and, 731
comprehensive control programs, 881
COPD and, 688, 690, 691–692
costs and cost-effectiveness of
interventions, 49, 877–880, 878t,
880t, 881t
deaths. See tobacco-related deaths
diabetes and, 597
health consequences of smoking,
870–873, 871t
interventions
government interventions, 873–874
reducing demand for tobacco, 874–877
reducing noncommunicable disease,
4b, 27
reducing supply of tobacco, 877
kidney disease and, 699, 700
musculoskeletal disorders and, 966
nicotine addiction, 873–874
nicotine replacement therapies,
876–877, 878
oral precancer and cancer and, 730
periodontal disease and, 729
price increases and, 878, 879, 882, 1116
respiratory diseases of adults, 685
smoking trends, 869–870, 870t
smuggling of tobacco products, 877
strokes and, 633, 634
taxation to discourage use, 177, 218,
874–875, 875f, 879f, 882
vision loss and, 954
warnings about, 168, 876
workers’ risk for asbestos and smoking
exposure, 1128, 1128t
Togo, malaria in, 421
total quality management in health 
care, 1298
tourism
dengue and, 455
leishmaniasis and, 453
malaria and, 426
tax rate reduction on alcohol in Mauritius
and, 900
trachoma
control program, 168, 170, 174, 178,
956–957
sanitation, prevention by, 784
water supply and, 779
Trade-Related Aspects of Intellectual
Property Rights. See TRIPS
(Agreement on Trade-Related
Aspects of Intellectual Property
Rights)
traditional medicine. See complementary
and alternative medicine (CAM)
traffic injuries, 16
adolescents and, 1111
alcohol consumption as cause of,
893, 894t
bicycle helmet legislation and 
enforcement, 747
burden of, 107
causes of, 739, 739t
costs and cost-effectiveness of
interventions, 48
economic burden of, 737, 739
implementation of prevention and 
control strategies, 748–749, 749b
interventions, 742–744, 742t
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motorcycle helmet legislation and
enforcement, 747
risk factors for, 739–740
safer roads and, 743–744
speed and safety regulations, 745–746, 746t
speed bumps, 746–747, 747t
training of medical personnel
alternative medicine and, 1286, 1287
changes needed in medical education for
global perspective, 134–135
for childbirth and newborn care, 545
community workers, 1063
continuing skill development, 1312, 1344
dissemination and use of health informa-
tion for, 1023
district hospitals’ role in, 1215–1216
epidemiologists, 1002
for hospital emergency workers,
1271, 1273b
nurses, 94
for occupational health, 1134–1135, 1142
professional retraining to improve quality
of care, 1297
for surgery, 1256–1257
for surveillance purposes, 117
traditional healers, 1286
transplant surgery, 130, 131
transportation
See also traffic injuries
automobile use, 839, 843
costs of unreliable systems, 187
for emergency medical services, 1264,
1267–1271
See also ambulances
intersectoral action for improvements 
in, 189
policy and environmental design,
839–840
walking and bicycle use, 839–840, 840b,
843–844
trauma care. See emergency medical services
Trichomonas vaginalis, 315
Trinidad and Tobago
health service agency reform in, 93,
1318–1319
TRIPS (Agreement on Trade-Related
Aspects of Intellectual Property
Rights), 150–152, 351, 1324
tropical diseases, 433–466
See also specific types
burden of, 436–438, 454–456
characteristics and transmission, 433–436,
451–454, 454t
costs and cost-effectiveness of
interventions, 442–445, 445t,
459–460
DALY estimates for, 437–438, 438t
interventions and effectiveness of, 45–46,
438–442, 460–463
kidney disease and, 697
management and control strategies of,
457–458, 463t
research needs and priorities, 115,
445–446, 446t
skin diseases, 709
See also skin diseases
tropical ulcers, 709, 715, 717, 718
See also skin diseases
tsetse flies, 453, 456, 458, 462, 464
tsunamis, 1150
tubal ligation, 1080
tuberculosis (TB), 289–309
alternative approaches to diagnosis and
treatment, 294–295
burden and trends, 291–292
averted and avertable burden, 302,
302f, 303f
children and, 293
complementary strategies, 304
cost-effectiveness of interventions,
40–43, 295–297, 296t, 297t,
301–303, 301b
managing endemic TB, 297–299, 298f
managing TB outbreaks, 299–301, 300f
cost per case prevented, 297–299
cost per death prevented and DALY
gained, 299
deaths due to in low- and middle-income
countries, 290–291
cost per death prevented and DALY
gained, 299
development assistance and, 244
diagnostics development for, 144,
145, 145t
DOTS strategy for treatment. See directly
observed therapy short course
(DOTS)
drug resistance and, 294, 304–305, 1036,
1045–1046
drugs for, 304, 1326
economic benefits of interventions,
302–303
HIV/AIDS and, 291, 292–293, 294, 301,
302, 304–305
impact and targets, 304
infection, disease, and death, 290–291
integrated management of, 295
interventions, 292–294
kidney and urinary system diseases 
and, 697
latent infection, treatment of, 292–293
MDGs and, 290, 305
outpatient and community-based 
treatment, 295
private sector treatment, 295
quality of care and treatment of, 27,
292–299
research and development agenda,
303–304
risk factors, 304
service delivery, 304
silicosis and, 689
successful programs in controlling, 94–95,
168–169, 174, 175
targeting poor in allocation of health
resources to fight, 5b
tobacco use and, 289, 304
vaccination, 292, 304
See also vaccine-preventable diseases
Turkey
ambulances in, 1268
condom program in, 216
epilepsy in, 630
kidney and urinary system diseases in,
698, 702, 703
leishmaniasis in, 459
mental disorders in, 621
universal coverage approach of, 237
typhoid, 775t, 776t, 777, 778
Uganda
African trypanosomiasis in, 454, 456, 460
Ebola in, 1006
government reform and health care 
delivery in, 91, 247, 1315
HIV/AIDS in, 13, 106, 320, 348b, 354, 358
Hospice Uganda, 990
IMCI program in, 1181, 1185b,
1186, 1187
interpersonal violence in, 756, 757, 763
malaria in, 418, 421
medical workers in, 94, 1312
primary care and removal of fees for
health services in, 97b
road traffic injuries in, 749b
sexually transmitted infections in,
312, 320
training of medical personnel in, 94
water supply in, 773
U.K. National Institute for Clinical
Excellence, 1297
UNAIDS. See United Nations Programme
on HIV/AIDS
UNESCO (United Nations Education,
Scientific, and Cultural
Organization), 1095
UNICEF. See United Nations Children’s
Fund
Index | 1395
unintentional injuries, 737–753
burden of, 737, 738f, 738t
burn-related injuries
indoor fires and, 797–799
interventions, 743t, 744–745
risk factors for, 741
causes of, 739–741, 739t
costs, cost-effectiveness, and economic
benefits of interventions, 745–748
driving injuries. See traffic injuries
drowning
interventions, 743t, 745
risk factors for, 741
economic burden of, 737, 739
fall-related injuries
interventions, 743t, 744, 748–749
risk factors for, 740–741
future challenges for, 750
implementation of prevention and 
control strategies, 748–749, 749b
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